<SEC-DOCUMENT>0001193125-26-177461.txt : 20260424
<SEC-HEADER>0001193125-26-177461.hdr.sgml : 20260424
<ACCEPTANCE-DATETIME>20260424163843
ACCESSION NUMBER:		0001193125-26-177461
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		38
FILED AS OF DATE:		20260424
DATE AS OF CHANGE:		20260424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rallybio Corp
		CENTRAL INDEX KEY:			0001739410
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				851083789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-294361
		FILM NUMBER:		26894930

	BUSINESS ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203- 859-3820

	MAIL ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rallybio Holdings, LLC
		DATE OF NAME CHANGE:	20180502
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d109079ds4a.htm
<DESCRIPTION>S-4/A NO. 1
<TEXT>
<HTML><HEAD>
<TITLE>S-4/A No. 1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on April&nbsp;24, 2026. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-294361</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>Amendment NO. 1 </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-4</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of
registrant as specified in its Charter) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</DIV></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">85-1083789</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>234 Church Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New Haven, CT 06510 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(203) <FONT
STYLE="white-space:nowrap">859-3820</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s
principal executive offices) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Stephen Uden, M.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Executive Officer
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Rallybio Corporation </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>234 Church
Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New Haven, CT 06510 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(203) <FONT
STYLE="white-space:nowrap">859-3820</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service)
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Zachary Blume, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Tyler Silvey, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ropes&nbsp;&amp; Gray
LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Prudential Tower</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>800 Boylston
Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Boston, MA 02199-3600</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">951-7000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Carlos Ramirez, Esq</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Rama Padmanabhan, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Lindsey O&#8217;Crump
Crow, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Charles S. Kim, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cooley
LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>10265 Science Center Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>San
Diego, CA 92121</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">550-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; line-height:8.75pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:8.75pt; font-size:8pt; font-family:ARIAL" ALIGN="center">As soon as practicable after the effectiveness of this registration statement and the satisfaction or waiver of all </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:8.75pt; font-size:8pt; font-family:ARIAL" ALIGN="center">other conditions under the Merger Agreement described herein. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.&#8194;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant
to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form
is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&#8194;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D.
filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a
smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; line-height:8.75pt; font-size:8pt; font-family:ARIAL"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant
shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall
become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#c21128"><B>The information in this preliminary proxy statement/prospectus is not complete and may be
changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy
these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#c21128">SUBJECT TO COMPLETION, DATED APRIL 24, 2026</FONT></P>  <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PROPOSED MERGER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>YOUR VOTE IS VERY IMPORTANT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the Stockholders of Rallybio Corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Corporation, a
Delaware corporation (&#8220;Rallybio&#8221;), and Candid Therapeutics, Inc., a Delaware corporation (&#8220;Candid&#8221;) have entered into an Agreement and Plan of Merger and Reorganization, dated March&nbsp;1, 2026 (the &#8220;Merger
Agreement&#8221;), pursuant to which, among other matters, Farmington Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Rallybio (&#8220;Merger Sub&#8221;), will merge with and into Candid, with Candid surviving as a wholly
owned subsidiary of Rallybio (such transaction, the &#8220;Merger&#8221;). In connection with the Merger, Rallybio will change its name to Candid Therapeutics, Inc. (together with its subsidiaries following the Merger, the &#8220;combined
company&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger will become effective at the time the Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware
or such other date and time as is agreed upon by Rallybio and Candid and specified in the Certificate of Merger in accordance with the General Corporation Law of the State of Delaware (&#8220;DGCL&#8221;) (such date, the &#8220;Closing Date,&#8221;
and such time, the &#8220;Effective Time&#8221;). At the Effective Time, (a)&nbsp;each outstanding share of Candid common stock, par value $0.0001 per share (&#8220;Candid Common Stock&#8221;), and each share of Candid preferred stock, par value
$0.0001 per share (&#8220;Candid Preferred Stock&#8221; and, together with the Candid Common Stock, &#8220;Candid Capital Stock&#8221;) (excluding shares held by Candid stockholders who have exercised and perfected appraisal rights, shares of Candid
Capital Stock held as treasury stock by Candid or held or owned by Rallybio, Merger Sub or any subsidiary of Rallybio or Candid, and any shares described in the following clause (b)) will be converted into the right to receive approximately 0.0716
shares of common stock of Rallybio, par value $0.0001 per share (&#8220;Rallybio Common Stock&#8221;), based on an assumed exchange ratio of 0.0716 (the &#8220;Exchange Ratio&#8221;), assuming a reverse stock split of Rallybio Common Stock at a
ratio of 1-for-2.5 to be implemented prior to the closing of the Merger (the &#8220;Closing&#8221;) as may be adjusted and as discussed in the accompanying proxy statement/prospectus, and which is further subject to certain adjustments as described
below, and (b)&nbsp;each share of Candid Common Stock issued in the Concurrent Financing (as defined and described in more detail below) will be converted into the right to receive a number of shares of Rallybio Common Stock calculated in accordance
with the exchange ratio formula set forth in the Merger Agreement (the &#8220;Concurrent Financing Exchange Ratio&#8221;), which is assumed to be 0.0716 and is subject to the same assumptions as the Exchange Ratio described above and below. Rallybio
will assume outstanding and unexercised options to purchase shares of Candid Common Stock, and in connection with the Merger such options will be converted into options to purchase shares of Rallybio Common Stock based on the Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of Rallybio Common Stock issued and outstanding at the time of the Merger will remain issued and outstanding, and, subject to the proposed reverse stock
split, will be unaffected by the Merger. In addition, on March&nbsp;1, 2026, Candid entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with certain investors, pursuant to which Candid has agreed to sell, and such
investors have agreed to purchase, shares of Candid Common Stock for an aggregate purchase price of $505.5&nbsp;million, immediately prior to the Effective Time of the Merger (such transaction, the &#8220;Concurrent Financing&#8221;). The closing of
the Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. The Concurrent Financing is more fully described in the section titled &#8220;<I>The Merger
Agreement&#8212;Subscription Agreement.</I>&#8221; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement,
immediately after the Closing, on a pro forma basis and based upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Candid (other
than investors in the Concurrent Financing) are expected to own approximately 57.55% of the combined company, <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Rallybio are expected to own approximately 3.65% of the combined
company and the investors in the Concurrent Financing are expected to own approximately 38.80% of the combined company (assuming proceeds from the Concurrent Financing of $505.5 million), in each case, calculated on a fully diluted basis, using the
treasury stock method, and subject to certain assumptions, including (i)&nbsp;a valuation for Rallybio of $47.5&nbsp;million (assuming Rallybio has net cash (&#8220;Rallybio Net Cash&#8221;) of $37.5&nbsp;million as of the Closing), (ii)&nbsp;a
fixed valuation for Candid of $750.0&nbsp;million, and (iii)&nbsp;the relative capitalization of Rallybio and Candid. The percentage of the combined company that each party&#8217;s equityholders will own following the Closing is subject to certain
adjustments (as described in more detail in the section titled &#8220;<I>The Merger Agreement&#8212;Merger Consideration and Exchange Ratio</I>&#8221;), including the amount of the final Rallybio Net Cash at the Closing. Rallybio Net Cash as
calculated under the Merger Agreement makes certain adjustments to the value of Rallybio&#8217;s Cash and Cash Equivalents (as defined in the Merger Agreement), and was equal to approximately $39.47&nbsp;million as of December 31, 2025. The
adjustments are described in the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; Based on its Cash and Cash Equivalents and other balance sheet line items as of December 31, 2025 and current
estimates of the other elements of Rallybio Net Cash (including projected adjustments to Rallybio&#8217;s Cash and Cash Equivalents), Rallybio calculates that it had Rallybio Net Cash of approximately $35.81 million as of April&nbsp;15, 2026.
Rallybio expects to continue to incur losses in future periods primarily related to the proposed Merger and, as a result, available Cash and Cash Equivalents will continue to decrease. For a description of the calculation of Rallybio Net Cash as set
forth in the Merger Agreement, please see the section titled &#8220;The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash.&#8221; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares of Rallybio Common Stock are currently listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the
symbol &#8220;RLYB.&#8221; Candid will file an initial listing application for the combined company with Nasdaq. After completion of the Merger, Rallybio will be renamed &#8220;Candid Therapeutics, Inc.&#8221;, and it is expected that the common
stock of the combined company will trade on Nasdaq under the symbol &#8220;CDRX.&#8221; On &#8195;&#8195;&#8195;&#8195;, 2026, the last trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of Rallybio
Common Stock was $&#8195;&#8195;&#8195;&#8195;&#8195; per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio stockholders are cordially invited to attend the 2026 annual meeting of Rallybio
stockholders (the &#8220;Rallybio annual meeting&#8221;). The Rallybio annual meeting is being held on &#8195;&#8195;&#8195;&#8195;&#8195;, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to
complete the Merger, the Concurrent Financing and related matters. The Rallybio annual meeting will be held entirely online. Rallybio stockholders will be able to attend and participate in the Rallybio annual meeting by registering at
www.virtualshareholdermeeting.com/RLYB2026 where they will be able to listen to the meeting live, submit questions and vote. At the Rallybio annual meeting, Rallybio will ask its stockholders to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Approve the issuance of shares of Rallybio Common Stock to the securityholders of Candid, pursuant to the terms of the
Merger Agreement, a copy of which is attached as <I>Annex A </I>to the accompanying proxy statement/prospectus, which will (a)&nbsp;represent more than 20% of the shares of Rallybio Common Stock outstanding immediately prior to the Merger and
(b)&nbsp;result in the change of control of Rallybio, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No.&nbsp;1&#8221;); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to effect a reverse stock
split of Rallybio&#8217;s issued and outstanding common stock at a ratio in the range from 1-for-2 to 1-for-3, inclusive, with the final ratio to be mutually agreed to by Rallybio and Candid, in the form attached as <I>Annex </I><I>I</I><I> </I>to
the accompanying proxy statement/prospectus (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal No.&nbsp;2&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to change the name of
Rallybio to &#8220;Candid Therapeutics, Inc.,&#8221; in the form attached as <I>Annex&nbsp;</I><I>J</I><I> </I>to the accompanying proxy statement/prospectus (the &#8220;Name Change Proposal&#8221; or &#8220;Proposal No.&nbsp;3&#8221;);
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to increase the number of
authorized shares of Rallybio Common Stock from 200,000,000 shares to 500,000,000 shares, in the form attached as <I>Annex </I><I>K</I><I> </I>to the accompanying proxy statement/prospectus (the &#8220;Authorized Share Proposal&#8221; or
&#8220;Proposal No.&nbsp;4&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Elect Helen M. Boudreau, Lucian Iancovici, and Christine A. Nash, as Class&nbsp;II directors, each for a three-year term
and until their successors are duly elected and qualified or until their earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal No.&nbsp;5&#8221;); provided that if the Merger is consummated, the
effect of the approval of the director nominees named in the Director Election Proposal will be limited because the composition of the Rallybio Board will be reconstituted upon completion of the Merger in accordance with the Merger Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Ratify the selection of Deloitte&nbsp;&amp; Touche LLP independent registered public accounting firm for Rallybio for
the fiscal year ending December&nbsp;31, 2026 (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal No.&nbsp;6&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Approve the 2026 Plan (as defined in the accompanying proxy statement/prospectus) in the form attached as
<I>Annex&nbsp;L</I> to the accompanying proxy statement/prospective, which will become effective on the date immediately following the consummation of the Merger and is contingent on the completion of the Merger (the &#8220;2026 Plan Proposal&#8221;
or &#8220;Proposal No.&nbsp;7&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Approve the 2026 ESPP (as defined in the accompanying proxy statement/prospectus) in the form attached as <I>Annex M</I>
to the accompanying proxy statement/prospective, which will become effective on the date immediately following the consummation of the Merger and is contingent on the completion of the Merger (the &#8220;2026 ESPP Proposal&#8221; or &#8220;Proposal
No.&nbsp;8&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Approve an adjournment of the Rallybio annual meeting, if necessary, to solicit additional proxies if there are not
sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Name Change Proposal and/or the Authorized Share Increase Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No.&nbsp;9&#8221;);
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Transact such other business as may properly come before the stockholders at the Rallybio annual meeting or any
adjournment or postponement thereof. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in the accompanying proxy statement/prospectus, certain Rallybio stockholders who in the aggregate owned
approximately 24.80% of the outstanding shares of Rallybio Common Stock as of March&nbsp;1, 2026, and certain Candid stockholders who in the aggregate owned approximately 66.14% of the outstanding shares of Candid Capital Stock as of March&nbsp;1,
2026, are parties to support agreements with Rallybio and Candid, respectively, whereby such stockholders have agreed to vote (i)&nbsp;in the case of Rallybio stockholders, in favor of the Merger and the other transactions and actions contemplated
by the Merger Agreement (collectively, the &#8220;Contemplated Transactions&#8221;), including (a)&nbsp;the Nasdaq Stock Issuance Proposal, (b)&nbsp;the Reverse Stock Split Proposal, (c)&nbsp;the Name Change Proposal, (d)&nbsp;the Authorized Share
Proposal, and (e)&nbsp;and the other transactions and actions contemplated by the Merger Agreement, including the Concurrent Financing and the Asset Dispositions (in each case, as defined in the Merger Agreement), and (ii)&nbsp;in the case of Candid
stockholders, in favor of adopting the Merger Agreement and approving the Merger and the other Contemplated Transactions, in each case, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form
<FONT STYLE="white-space:nowrap">S-4</FONT> of which the accompanying proxy statement/prospectus is a part, and pursuant to the Merger Agreement, Candid shall seek to obtain approval for the Merger Agreement and the Contemplated Transactions from
stockholders holding a sufficient number of shares of Candid Capital Stock to adopt and approve such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After careful consideration, each of
Rallybio&#8217;s board of directors (the &#8220;Rallybio Board&#8221;) and Candid&#8217;s board of directors (the &#8220;Candid Board&#8221;) have approved the Merger Agreement and the Contemplated Transactions and have determined that it is
advisable to consummate the Merger. The Rallybio Board has approved the proposals described in the accompanying proxy statement/prospectus and unanimously recommends that its stockholders vote &#8220;<B>FOR</B>&#8221; the proposals described in the
accompanying proxy statement/prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>More information about Rallybio, Candid, the Merger Agreement and Contemplated Transactions, and the foregoing
proposals is contained in the accompanying proxy statement/prospectus. Rallybio urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER
&#8220;<A HREF="#toc109079_3">RISK FACTORS</A>&#8221; BEGINNING ON PAGE 29 OF THE ACCOMPANYING PROXY STATEMENT/ PROSPECTUS. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio is excited about the
opportunities the Merger brings to Rallybio&#8217;s stockholders and thanks you for your consideration and continued support. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Stephen Uden, M.D.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>President and Chief Executive Officer</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Rallybio Corporation </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/prospectus. Any representation to the contrary is a criminal offense.</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>The accompanying proxy statement/prospectus is dated &#8195;&#8195;&#8195;&#8195;, 2026, and is first being mailed to Rallybio&#8217;s stockholders on or about
&#8195;&#8195;&#8195;&#8195;&#8195;, 2026. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>234 Church Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>New Haven, Connecticut
06510 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To
the stockholders of Rallybio Corporation: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On behalf of the Rallybio Board, we are pleased to deliver this proxy statement/prospectus for the proposed Merger
between Rallybio and Candid pursuant to which, among other matters, Merger Sub will merge with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio annual meeting will be held on &#8195;&#8195;&#8195;&#8195;&#8195;, unless postponed or adjourned to a later date. The Rallybio annual meeting will be held
entirely online. You will be able to attend and participate in the Rallybio annual meeting by registering at www.virtualshareholdermeeting.com/RLYB2026. Upon entry of your control number and other required information, you will receive further
instructions via email that provide you access to the Rallybio annual meeting and to vote and submit questions during the Rallybio annual meeting. The Rallybio annual meeting will be held for the following purposes, which are collectively referred
to as the &#8220;Proposals&#8221;: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To approve the issuance of shares of Rallybio Common Stock to the securityholders of Candid, pursuant to the terms of
the Merger Agreement, a copy of which is attached as <I>Annex </I><I>A</I><I> </I>to the accompanying proxy statement/prospectus, which will (a)&nbsp;represent more than 20% of the shares of Rallybio Common Stock outstanding immediately prior to the
Merger and (b)&nbsp;result in the change of control of Rallybio, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to effect a reverse stock
split of Rallybio&#8217;s issued and outstanding common stock at a ratio in the range from <FONT STYLE="white-space:nowrap">1-for-2</FONT> to 1-for-3, inclusive, with the final ratio to be mutually agreed to by Rallybio and Candid, in the form
attached as <I>Annex I</I> to the accompanying proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to change the name of
Rallybio to &#8220;Candid Therapeutics, Inc.,&#8221; in the form attached as <I>Annex </I><I>J </I>to the accompanying proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to increase the number of
authorized shares of Rallybio Common Stock from 200,000,000 shares to 500,000,000 shares, in the form attached as <I>Annex </I><I>K </I>to the accompanying proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To Elect Helen M. Boudreau, Lucian Iancovici, and Christine A. Nash, as Class&nbsp;II directors, each for a three-year
term and until their successors are duly elected and qualified or until their earlier death, resignation or removal; provided that if the Merger is consummated, the effect of the approval of the director nominees named in the Director Election
Proposal will be limited because the composition of the Rallybio Board will be reconstituted upon completion of the Merger in accordance with the Merger Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To ratify the selection of Deloitte as independent registered public accounting firm for Rallybio for the fiscal year
ending December&nbsp;31, 2026; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To approve the 2026 Plan (as defined in the accompanying proxy statement/prospectus) in the form attached as <I>Annex
L</I> to the accompanying proxy statement/prospective, which will become effective on the date immediately following the consummation of the Merger and is contingent on the completion of the Merger; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To approve the 2026 ESPP (as defined in the accompanying proxy statement/prospectus) in the form attached as <I>Annex
M</I> to the accompanying proxy statement/prospective, which will become effective on the date immediately following the consummation of the Merger and is contingent on the completion of the Merger; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To approve an adjournment of the Rallybio annual meeting, if necessary, to solicit additional proxies if there are not
sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Name Change Proposal and/or the Authorized Share Proposal; and </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To transact such other business as may properly come before the stockholders at the Rallybio annual meeting or any
adjournment or postponement thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board has fixed &#8195;&#8195;&#8195;&#8195;&#8195;, 2026 as the record date for the
determination of stockholders entitled to notice of, and to vote at, the Rallybio annual meeting and any adjournment or postponement thereof. Only holders of record of shares of Rallybio Common Stock at the close of business on the record date are
entitled to notice of, and to vote at, the Rallybio annual meeting. At the close of business on the record date, Rallybio had &#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;shares of Rallybio Common Stock outstanding and entitled to vote. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Your vote is important. The affirmative vote of a majority of the total votes cast by the holders of Rallybio Common Stock entitled to vote at the Rallybio annual
meeting, assuming a quorum is present, is required for the approval of Proposal Nos. 1, 2, 3, 6, 7 and 8. The affirmative vote of the holders of at least seventy-five percent of the outstanding shares of Rallybio Common Stock entitled to vote at the
Rallybio annual meeting is required for the approval of Proposal No.&nbsp;4. The votes cast for a nominee for director by holders of Rallybio Common Stock entitled to vote at the Rallybio annual meeting must exceed the votes cast against by such
holders for the election of directors pursuant to Proposal No.&nbsp;5, assuming a quorum is present. The affirmative vote of the holders of a majority of the shares of Rallybio Common Stock present in person (by virtual attendance) or represented by
proxy at the Rallybio annual meeting and entitled to vote on the matter is required for the approval of Proposal 9. Each of Proposal Nos. 1, 2 and 3 is a condition to completion of the Merger. The closing of the Concurrent Financing is conditioned
upon the satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. Therefore, the Merger and the Concurrent Financing cannot be consummated without the approval of Proposal Nos. 1, 2 and 3. The issuance of
Rallybio Common Stock in connection with the Merger and the change of control of Rallybio resulting from the Merger will not take place unless Proposal Nos. 1, 2 and 3 are approved by Rallybio stockholders and the reverse stock split is effected,
Rallybio&#8217;s name is changed to &#8220;Candid Therapeutics, Inc.&#8221; and the Merger is consummated. Proposal Nos. 4, 7 and. 8 are each conditioned on the consummation of the Merger. Therefore, if Proposal Nos. 1, 2 and 3 are not approved and
the Merger is not consummated, Proposal Nos. 4, 7 and 8 will each have no effect, even if one or more are approved by Rallybio stockholders.</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Even if you plan
to virtually attend the Rallybio annual meeting, Rallybio requests that you sign and return the enclosed proxy or vote by mail, by phone or online to ensure that your shares will be represented at the Rallybio annual meeting if you are unable to
virtually attend. You may change or revoke your proxy at any time before it is voted at the Rallybio annual meeting.</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>THE RALLYBIO BOARD HAS UNANIMOUSLY
DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, ADVISABLE AND IN THE BEST INTERESTS OF RALLYBIO AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE RALLYBIO BOARD UNANIMOUSLY RECOMMENDS THAT RALLYBIO
STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The proxy statement/prospectus and annual report to stockholders are available at </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By Order of the Rallybio Board of Directors, </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stephen Uden, M.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>President and Chief Executive Officer </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>&#8195;&#8195;&#8195;&#8195;,
2026 </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>REFERENCES TO ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This proxy statement/prospectus incorporates certain information about Rallybio that is not included in or delivered with this document. You may obtain this
information without charge through the Securities and Exchange Commission (&#8220;SEC&#8221;) website (www.sec.gov) or upon your oral or written request by<B> </B>sending a written request to: Rallybio Corporation, 234 Church Street, New Haven, CT
06510, Attention: Secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To ensure timely delivery of these documents, any request should be made no later than &#8195;&#8195;&#8195;&#8195;&#8195;, 2026,
which is five business days prior to the date of the Rallybio annual meeting, in order to receive them before the Rallybio annual meeting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For additional
details about where you can find information about Rallybio, please see the section titled &#8220;<I>Where You Can Find More Information</I>&#8221; beginning on page 422 of this proxy statement/prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_1">QUESTIONS AND ANSWERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_4">MARKET PRICE AND DIVIDEND INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_6">THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_7">THE MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_8">AGREEMENTS RELATED TO THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_9">RALLYBIO EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_10">RALLYBIO EXECUTIVE OFFICER AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_11">CANDID EXECUTIVE OFFICER AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_12">PROPOSAL NO. 1&#8212;THE NASDAQ STOCK ISSUANCE PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_13">PROPOSAL NO.2&#8212;THE REVERSE STOCK SPLIT PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_14">PROPOSAL NO.3&#8212;THE NAME CHANGE PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_14a">PROPOSAL NO.4&#8212;THE AUTHORIZED SHARE PROPOSAL </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_15">PROPOSAL NO.5&#8212;THE DIRECTOR ELECTION PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_16">PROPOSAL NO.6&#8212;THE AUDITOR RATIFICATION PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_17">REPORT OF THE AUDIT COMMITTEE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_18">PROPOSAL NO.7&#8212;THE 2026 PLAN PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_19">PROPOSAL NO.8&#8212;THE ESPP PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_20">PROPOSAL NO.9&#8212;THE ADJOURNMENT PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_21">RALLYBIO&#8217;S BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_22">CANDID&#8217;S BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_23">RALLYBIO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_24">CANDID&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_25">MANAGEMENT FOLLOWING THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_26">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED
COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_27">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_28">DESCRIPTION OF RALLYBIO CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_29">COMPARISON OF RIGHTS OF HOLDERS OF RALLYBIO CAPITAL STOCK AND CANDID CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_30">SECURITIES ACT RESTRICTIONS ON RESALE OF COMBINED COMPANY COMMON
STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_31">PRINCIPAL STOCKHOLDERS OF RALLYBIO</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_32">PRINCIPAL STOCKHOLDERS OF CANDID</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_33">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_34">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_35">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_36">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_37">STOCKHOLDER PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_38">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_45">ANNEX A&#8212;MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_46">ANNEX B&#8212;OPINION OF PUBCO FINANCIAL ADVISOR</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_47">ANNEX C&#8212;FORM OF PUBCO SUPPORT AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">C-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_48">ANNEX D&#8212;FORM OF COMPANY SUPPORT AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_49">ANNEX E&#8212;FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT>
AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">E-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_50">ANNEX F&#8212;FORM OF CVR AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_51">ANNEX G&#8212;FORM OF SUBSCRIPTION AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_52">ANNEX H&#8212;FORM OF REGISTRATION RIGHTS AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">H-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_53">ANNEX I&#8212;CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
 OF PUBCO TO PROVIDE FOR THE REVERSE STOCK SPLIT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">I-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_53a">ANNEX J&#8212;CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
 OF PUBCO TO PROVIDE FOR THE NAME CHANGE </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">J-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_54">ANNEX K&#8212;CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
 OF PUBCO TO PROVIDE FOR THE AUTHORIZED SHARE INCREASE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">K-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_55">ANNEX L&#8212;2026 EQUITY INCENTIVE PLAN</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">L-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_56">ANNEX M&#8212;2026 EMPLOYEE STOCK PURCHASE PLAN</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">M-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_57">ANNEX N&#8212;FORM OF PROXY CARD</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc109079_57a">ANNEX O&#8212;SECTION 262 OF THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE
 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">O-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_1"></A>QUESTIONS AND ANSWERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the
proposed reverse stock split described in Proposal No.&nbsp;2 of this proxy statement/prospectus. </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following section provides answers to frequently asked
questions about the Merger. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What is the Merger? </B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Rallybio, Merger Sub, and Candid entered into the Merger Agreement on March&nbsp;1, 2026. The Merger Agreement contains
the terms and conditions of the proposed merger transaction among Rallybio, Merger Sub and Candid. Under the Merger Agreement, Merger Sub will merge with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio. This
transaction is referred to as the Merger. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The Merger will become effective at the time the Certificate of Merger has been duly
filed with the Secretary of State of the State of Delaware or such other date and time as is agreed upon by Rallybio and Candid and specified in the Certificate of Merger in accordance with the DGCL. At the Effective Time, (a)&nbsp;each outstanding
share of Candid Common Stock and each share of Candid Preferred Stock (excluding shares held by Candid stockholders who have exercised and perfected appraisal rights as more fully described in the section titled &#8220;<I>The Merger&#8212;Appraisal
Rights</I>&#8221; of this proxy statement/prospectus, shares of Candid Capital Stock held as treasury stock by Candid or held or owned by Rallybio, Merger Sub or any subsidiary of Rallybio or Candid, and any shares described in the following clause
(b)) will be automatically converted solely into the right to receive a number of shares of Rallybio Common Stock equal to the Exchange Ratio, and (b)&nbsp;each share of Candid Common Stock issued in the Concurrent Financing, as more fully described
in the section titled &#8220;<I>Agreements Related to the Merger&#8212;Subscription Agreement</I>&#8221;of this proxy statement/prospectus, will be automatically converted solely into the right to receive a number of shares of Rallybio Common Stock
equal to the Concurrent Financing Exchange Ratio. Rallybio will assume outstanding and unexercised options to purchase shares of Candid Common Stock, and in connection with the Merger they will be converted into options to purchase shares of
Rallybio Common Stock based on The Exchange Ratio. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger
Agreement, upon the Closing, on a pro forma basis and based upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, pre-Merger equityholders of Candid (other than investors in the Concurrent Financing)
are expected to own approximately 57.55% of the combined company, pre-Merger equityholders of Rallybio are expected to own approximately 3.65% of the combined company and the investors in the Concurrent Financing are expected to own approximately
38.80% (assuming proceeds from the Concurrent Financing of $505.5 million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i)&nbsp;a valuation for Rallybio of $47.5
million (assuming Rallybio Net Cash of $37.5 million as of the Closing), (ii)&nbsp;a fixed valuation for Candid of $750.0 million, and (iii)&nbsp;the relative capitalization of Rallybio and Candid. The percentage of the combined company that each
party&#8217;s equityholders will own following the Closing is subject to certain adjustments (as described in more detail in the section titled &#8220;<I>The Merger Agreement&#8212;Merger Consideration and Exchange Ratio</I>&#8221;), including the
amount of the final Rallybio Net Cash at the Closing. Rallybio Net Cash as calculated under the Merger Agreement makes certain adjustments to the value of Rallybio&#8217;s Cash and Cash Equivalents (as defined in the Merger Agreement), and was equal
to approximately $39.47 million as of December 31, 2025. The adjustments are described in the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; Based on its Cash and Cash Equivalents and other
balance sheet line items as of December 31, 2025 and current estimates of the other elements of Rallybio Net Cash (including projected adjustments to Rallybio&#8217;s Cash and Cash Equivalents), Rallybio calculates that it had Rallybio Net Cash of
approximately $35.81 million as of April 15, 2026. Rallybio expects to continue to incur losses in future periods primarily related to the proposed Merger and, as a result, available Cash and Cash Equivalents will continue to decrease. For a
description of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">
calculation of Rallybio Net Cash as set forth in the Merger Agreement, please see the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash.</I>&#8221; </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Each share of Rallybio Common Stock issued and outstanding at the time of the Merger will remain issued and outstanding, and, subject to the
proposed reverse stock split, will be unaffected by the Merger. In addition, on March&nbsp;1, 2026, Candid entered into the Subscription Agreement with certain investors, pursuant to which Candid has agreed to sell, and such investors have agreed to
purchase, shares of Candid Common Stock for an aggregate purchase price of $505.5&nbsp;million immediately prior to the Effective Time. The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions
to the Closing as well as certain other conditions. The Concurrent Financing is more fully described in the section titled &#8220;<I>Agreements Related to the Merger&#8212;Subscription Agreement</I>&#8221; of this proxy statement/prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Why are the two companies proposing to merge? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Rallybio and Candid believe that combining the two companies will result in a substantially capitalized, clinical-stage
biotechnology company advancing a leading portfolio of <FONT STYLE="white-space:nowrap">T-cell</FONT> engager therapeutics for autoimmune diseases. For a more complete description of the reasons for the Merger, please see the sections titled
&#8220;<I>The Merger&#8212;Rallybio&#8217;s Reasons for the Merger</I>&#8221; and &#8220;<I>The Merger&#8212;Candid&#8217;s Reasons for the Merger</I>&#8221; of this proxy statement/prospectus. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Why am I receiving this proxy statement/prospectus? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">You are receiving this proxy statement/prospectus because you have been identified as a stockholder of Rallybio as of
the record date. This document serves as: </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a proxy statement of Rallybio used to solicit proxies for the Rallybio annual meeting to vote on the matters set forth
herein; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a prospectus of Rallybio used to offer shares of Rallybio Common Stock in exchange for shares of Candid Capital Stock in
the Merger. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What is the Concurrent Financing? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">On March&nbsp;1, 2026, Candid entered into the Subscription Agreement with certain accredited investors (the
&#8220;Investors&#8221;), pursuant to which Candid agreed to sell, and the Investors agreed to purchase, immediately prior to the Effective Time, shares of Candid Common Stock for an aggregate purchase price of $505.5&nbsp;million. This transaction
is referred to as the Concurrent Financing. Shares of Candid Common Stock issued pursuant to the Concurrent Financing will be converted into shares of Rallybio Common Stock in accordance with the Concurrent Financing Exchange Ratio in the Merger
Agreement. Candid and Rallybio have also agreed to enter into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investors at the closing of the Concurrent Financing. Pursuant to the Registration Rights
Agreement, the combined company will prepare and file a resale registration statement with the SEC within 30 calendar days following the closing of the Concurrent Financing. The combined company will use its commercially reasonable efforts to cause
such registration statement to become effective as promptly as practicable. Immediately after the Closing, under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, on a pro forma basis and based upon the
number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, the Investors are expected to own approximately 38.80% of the combined company, calculated on a fully diluted basis, using the treasury stock method and
subject to certain assumptions (as described in more detail in the section titled &#8220;<I>The Merger Agreement&#8212;Merger Consideration and Exchange Ratio</I>&#8221;). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What proposals will be voted on at the Rallybio annual meeting in connection with the Merger?
</B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Pursuant to the terms of the Merger Agreement, the following proposals must be approved by the Required Rallybio
Stockholder Vote (as defined in the Merger Agreement) at the Rallybio annual meeting in order for the Merger to close: </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Proposal No. 1</B>-<B>The Nasdaq Stock Issuance Proposal </B>to approve the issuance of shares of Rallybio Common Stock
to the securityholders of Candid, pursuant to the terms of the Merger Agreement, a copy of which is attached as <I>Annex A </I>to this proxy statement/prospectus, which will (a)&nbsp;represent more than 20%
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
of the shares of Rallybio Common Stock outstanding immediately prior to the Merger and (b)&nbsp;result in the change of control of Rallybio, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b),
respectively; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Proposal No. 2</B>-<B>The Reverse Stock Split Proposal </B>to approve an amendment to Rallybio&#8217;s amended and
restated certificate of incorporation to effect a reverse stock split of the issued and outstanding Rallybio Common Stock at a ratio in the range from 1-for-2 to 1-for-3, inclusive, with the final ratio to be mutually agreed to by Rallybio and
Candid, in the form attached as <I>Annex I </I>to this proxy statement/prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Proposal No. 3</B>-<B>The Name Change Proposal </B>to approve an amendment to Rallybio&#8217;s amended and restated
certificate of incorporation to change the name of Rallybio to &#8220;Candid Therapeutics, Inc.,&#8221; in the form attached as <I>Annex</I><I></I><I>&nbsp;J</I> to this proxy statement/prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Each of Proposal Nos. 1, 2 and 3 is a condition to the completion of the Merger. The closing of the Concurrent Financing is conditioned upon the
satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. The issuance of Rallybio Common Stock in connection with the Merger and the change of control of Rallybio resulting from the Merger will not take
place unless Proposal Nos. 1, 2 and 3 are approved by the required Rallybio stockholders, the reverse stock split is effected, Rallybio&#8217;s name is changed to &#8220;Candid Therapeutics, Inc.&#8221; and the Merger is consummated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">In addition to the requirement of obtaining the approval of the required Rallybio stockholders of Proposal Nos. 1, 2 and 3, the Closing is subject to
the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement. In the event of a waiver of a condition, the Rallybio Board will evaluate the materiality of any such waiver to determine whether amendment of this
proxy statement/prospectus and <FONT STYLE="white-space:nowrap">re-solicitation</FONT> of stockholder approval is necessary. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled
&#8220;<I>The Merger Agreement</I>&#8212;<I>Conditions to the Completion of the Merger</I>&#8221; of this proxy statement/prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The presence
of the holders of a majority of the shares of Rallybio Common Stock entitled to vote, present in person or represented by proxy, at the Rallybio annual meeting is necessary to constitute a quorum at the meeting for the Proposals. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What proposals are to be voted on at the Rallybio annual meeting, other than the Nasdaq Stock Issuance Proposal, the
Reverse Stock Split Proposal and the Name Change Proposal? </B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">At the Rallybio annual meeting, the holders of Rallybio Common Stock will also be asked to consider the following
proposals: </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Proposal No.</B><B></B><B>&nbsp;4 <FONT STYLE="white-space:nowrap">-The</FONT> Authorized Share Proposal</B> to approve
an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to increase the number of authorized shares of Rallybio Common Stock from 200,000,000 shares to 500,000,000 shares, in the form attached as
<I>Annex&nbsp;</I><I></I><I>K</I> to this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Proposal No. <FONT STYLE="white-space:nowrap">5-The</FONT> Director Election Proposal</B> to elect three Class&nbsp;II
directors to the Rallybio Board to hold office until the 2029 Rallybio annual meeting and until his or her respective successor has been duly elected and qualified, or until his or her earlier death, resignation or removal; provided that if the
Merger is consummated, the effect of the approval of the director nominees named in the Director Election Proposal will be limited because the composition of the Rallybio Board will be reconstituted upon completion of the Merger in accordance with
the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Proposal No. 6</B>-<B>The Auditor Ratification Proposal </B>to ratify the appointment of Deloitte&nbsp;&amp; Touche LLP
as Rallybio&#8217;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2026; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Proposal No. 7</B>-<B>The 2026 Plan Proposal </B>to approve the 2026 Plan in the form attached as <I>Annex&nbsp;L
</I>to this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Proposal No. 8</B>-<B>The 2026 ESPP Proposal </B>to approve the 2026 ESPP in the form attached as
<I>Annex&nbsp;</I><I>M</I><I> </I>to this proxy statement/prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Proposal No. 9</B>-<B>The Adjournment Proposal </B>to approve an adjournment of the Rallybio annual meeting, if
necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Name Change Proposal and/or the Authorized Share Proposal. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The approval of Proposals No.&nbsp;4, 5, 6, 7, 8 and 9 are not conditions to the Merger. Proposal
Nos. 4, 7 and 8 are each conditioned on the consummation of the Merger. Rallybio does not expect that any matter other than the Proposals will be brought before the Rallybio annual meeting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The presence of the holders of a majority of the shares of Rallybio Common Stock entitled to vote, present in person or represented by proxy, at the
Rallybio annual meeting is necessary to constitute a quorum at the meeting for the purpose of approving the Proposals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">As of the date of this proxy
statement/prospectus, the Rallybio Board does not know of any business to be presented at the Rallybio annual meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come
before the Rallybio annual meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What stockholder votes are required to approve the Proposals at the Rallybio annual meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">The affirmative vote of a majority of the total votes cast by the holders of Rallybio Common Stock entitled to vote at
the Rallybio annual meeting, assuming a quorum is present, is required for the approval of Proposal Nos. 1, 2, 3, 6, 7 and 8. The affirmative vote of the holders of at least seventy-five percent of the outstanding shares of Rallybio Common Stock
entitled to vote at the Rallybio annual meeting is required for the approval of Proposal No.&nbsp;4. The votes cast for a nominee for director by holders of Rallybio Common Stock entitled to vote at the Rallybio annual meeting must exceed the votes
cast against by such holders for the election of directors pursuant to Proposal No.&nbsp;5, assuming a quorum is present. The affirmative vote of a majority of shares of Rallybio Common Stock present in person (by virtual attendance) or represented
by proxy at the Rallybio annual meeting and entitled to vote on the matter is required for the approval of Proposal 9. Each of Proposal Nos. 1, 2 and 3 is a condition to completion of the Merger. The closing of the Concurrent Financing is
conditioned upon the satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. Therefore, the Merger and the Concurrent Financing cannot be consummated without the approval of Proposal Nos. 1, 2 and 3. The
issuance of Rallybio Common Stock in connection with the Merger and the change of control of Rallybio resulting from the Merger will not take place unless Proposal Nos. 1, 2 and 3 are approved by Rallybio stockholders, the reverse stock split is
effected, Rallybio&#8217;s name is changed to &#8220;Candid Therapeutics, Inc.&#8221; and the Merger is consummated. Proposal Nos. 4, 7 and 8 are each conditioned on the consummation of the Merger. Therefore, if Proposal Nos. 1, 2 and 3 are not
approved and the Merger is not consummated, Proposal Nos. 4, 7 and 8 will each have no effect, even if one or more are approved by Rallybio stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221;
votes, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be treated as shares present for the purpose of determining the presence of a quorum for
the transaction of business at the Rallybio annual meeting, but will not be counted as votes cast and will have no effect on the outcome of the vote for each of Proposals No. 1, 2, 3, 5, 6, 7, 8 and 9. Abstentions and broker non-votes will have the
same effect as votes &#8220;AGAINST&#8221; Proposal No. 4. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">As of &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, the directors and executive officers of
Rallybio owned or controlled &#8195;&#8195;&#8195;&#8195;&#8195; outstanding shares of Rallybio Common Stock entitled to vote at the Rallybio annual meeting. As of March&nbsp;1, 2026, the Rallybio stockholders that are party to a support agreement,
including the directors and executive officers of Rallybio, owned an aggregate number of shares of Rallybio Common Stock representing approximately 24.80% of the outstanding shares of Rallybio Common Stock. Each stockholder that entered into a
Rallybio support agreement has agreed to vote all shares of Rallybio Common Stock owned by him, her or it as of the record date (i)&nbsp;in favor of approving the Merger and the other transactions and actions contemplated by the Merger Agreement,
including the Nasdaq Stock Issuance Proposal, Reverse Stock Split Proposal, Name Change Proposal, the Authorized Share Increase Proposal, the Concurrent Financing and the Asset Dispositions (collectively, the &#8220;Contemplated
Transactions&#8221;), (ii)&nbsp;against any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii)&nbsp;against any acquisition proposal involving a third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Who is entitled to vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Only holders of record of Rallybio Common Stock at the close of business on the record date of
&#8195;&#8195;&#8195;&#8195;&#8195;, 2026, are entitled to notice of, and to vote at, the Rallybio annual meeting. At the close of business on the record date, there were &#8195;&#8195;&#8195;&#8195;&#8195; registered holders of record of Rallybio
Common Stock and there were &#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;shares of Rallybio Common Stock issued and outstanding. Each share of Rallybio Common Stock entitles the holder thereof to one vote on each matter submitted for stockholder
approval. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>As a Rallybio stockholder, how does the Rallybio Board recommend that I vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">After careful consideration, the Rallybio Board unanimously recommends that Rallybio stockholders vote
&#8220;<B>FOR</B>&#8221; each of the Proposals. </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Nasdaq Stock
Issuance Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Reverse Stock Split
Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Name Change
Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Authorized Share
Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; each of the director
nominees named in the Director Election Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Auditor
Ratification Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the 2026 Plan Proposal.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the 2026 ESPP Proposal.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Adjournment
Proposal, if necessary. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What are Rallybio contingent value rights? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Immediately prior to the Effective Time, Rallybio and the designated rights agent are expected to enter into a
Contingent Value Rights Agreement (the &#8220;Rallybio CVR Agreement&#8221;), pursuant to which holders of Rallybio Common Stock, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, restricted stock units and in the money stock options as
of the close of business on the last business day prior to the day on which the Effective Time occurs will receive one contingent value right (each, a &#8220;Rallybio CVR&#8221;) for each outstanding share of Rallybio Common Stock or share of
Rallybio Common Stock underlying such pre-funded warrant or equity award held by such equityholder on such date. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Pursuant to the
Rallybio CVR Agreement, each Rallybio CVR holder will be entitled to receive on a pro rata basis all of the net proceeds received, if any, by Rallybio as a result of payment of (i)&nbsp;any upfront, milestone, or royalty payments received under any
disposition agreement related to the Legacy Assets (as defined in the section titled &#8220;<I>Agreements Related to the Merger&#8212;Rallybio Contingent Value Rights Agreement&#8221;)</I>, and (ii)&nbsp;any cash proceeds received from Recursion
Pharmaceuticals, Inc. (&#8220;Recursion&#8221;) related to the earlier sale of Rallybio&#8217;s REV102 in July 2025. For a period of one year after the Closing, the combined company will use commercially reasonable efforts to effect the disposition
of the Legacy Assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The Rallybio CVR Payments (as defined in the section titled &#8220;<I>Agreements Related to the Merger&#8212;Rallybio
Contingent Value Rights Agreement</I>&#8221;), if any, will become payable to the designated rights agent for subsequent distribution to the Rallybio CVR holders. In the event that no such proceeds are received during the CVR Term (as defined in the
Rallybio CVR Agreement), holders of the Rallybio CVRs will not receive any payment pursuant to the Rallybio CVR Agreement. There can be no assurance that any Rallybio CVR holders will receive any Rallybio CVR Payments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The right to the contingent payments contemplated by the Rallybio CVR Agreement is a contractual
right only and is not transferable, except in the limited circumstances specified in the Rallybio CVR Agreement. The Rallybio CVRs are not evidenced by a certificate or any other instrument and are not registered with SEC. The Rallybio CVRs do not
have any voting or dividend rights and do not represent any equity or ownership interest in Rallybio or any of its respective affiliates. No interest will accrue on any amounts payable in respect of the Rallybio CVRs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What will Rallybio stockholders receive in the Merger? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Rallybio stockholders will continue to own and hold their existing shares of Rallybio Common Stock. Each share of
Rallybio Common Stock issued and outstanding at the time of the Merger will remain issued and outstanding, and, subject to the proposed reverse stock split, will be unaffected by the Merger. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Further, holders of Rallybio Common Stock, pre-funded warrants, restricted stock units and in the money stock options of record as of the close of
business on the last business day prior to the day on which the Effective Time occurs will receive one Rallybio CVR for each outstanding share of Rallybio Common Stock held by such stockholder or underlying such pre-funded warrant or equity award on
such date, as described in more detail in the section titled &#8220;<I>Agreements Related to the Merger&#8212;Rallybio Contingent Value Rights Agreement.</I>&#8221; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">For a more complete description of the treatment of Rallybio securities (as defined below) in the Merger, please see the sections titled &#8220;<I>The
Merger Agreement</I>&#8212;<I>Merger Consideration and Exchange Ratio</I>&#8221;<I></I>&nbsp;and &#8220;<I>Market Price and Dividend Information</I>&#8221; of this proxy statement/prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What will Candid securityholders receive in the Merger? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Candid stockholders will receive shares of Rallybio Common Stock, and Candid optionholders&#8217; outstanding and
unexercised options to purchase shares of Candid Common Stock as of immediately prior to the Effective Time will be assumed by Rallybio and will be converted into options to purchase shares of Rallybio Common Stock, with appropriate adjustments to
reflect the Exchange Ratio, as determined in accordance with the Merger Agreement. Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the Closing, on a pro forma basis and based upon
the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger and the Concurrent Financing, pre-Merger equityholders of Candid (other than investors in the Concurrent Financing) are expected to own approximately
57.55% of the combined company, pre-Merger equityholders of Rallybio are expected to own approximately 3.65% of the combined company and the investors in the Concurrent Financing are expected to own approximately 38.80% (assuming proceeds from the
Concurrent Financing of $505.5&nbsp;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i)&nbsp;a valuation for Rallybio of $47.5&nbsp;million (assuming
Rallybio Net Cash of $37.5&nbsp;million as of the Closing), (ii)&nbsp;a fixed valuation for Candid of $750.0&nbsp;million, and (iii)&nbsp;the relative capitalization of Rallybio and Candid. The percentage of the combined company that each
party&#8217;s equityholders will own following the Closing is subject to certain adjustments (as described in more detail in the section titled &#8220;<I>The Merger Agreement&nbsp;&#8212;Merger Consideration and Exchange Ratio</I>&#8221;), including
the amount of the final Rallybio Net Cash at the Closing. Rallybio Net Cash as calculated under the Merger Agreement makes certain adjustments to the value of Rallybio&#8217;s Cash and Cash Equivalents (as defined in the Merger Agreement), and was
equal to approximately $39.47 million as of December 31, 2025. The adjustments are described in the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; Based on its Cash and Cash Equivalents and
other balance sheet line items as of December 31, 2025 and current estimates of the other elements of Rallybio Net Cash (including projected adjustments to Rallybio&#8217;s Cash and Cash Equivalents), Rallybio calculates that it had Rallybio Net
Cash of approximately $35.81 million as of April 15, 2026. Rallybio expects to continue to incur losses in future periods primarily related to the proposed Merger and, as a result, available Cash and Cash Equivalents will continue to decrease. For a
description of the calculation of Rallybio Net Cash as set forth in the Merger Agreement, please see the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash.</I>&#8221; </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">For a more complete description of the treatment of Candid Common Stock and Candid stock options in the Merger, please see the sections titled
&#8220;<I>The Merger Agreement</I>&#8212;<I>Merger Consideration and Exchange Ratio</I>&#8221; of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">
this proxy statement/prospectus. For a description of the effect of the Concurrent Financing on Candid&#8217;s current securityholders, please see the sections titled &#8220;<I>Agreements Related
to the Merger</I>&#8212;<I>Subscription Agreement&#8221;</I> and &#8220;<I>Agreements Related to the Merger&#8212;Registration Rights Agreement</I>&#8221; of this proxy statement/prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Will the common stock of the combined company trade on an exchange? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Shares of Rallybio Common Stock are currently listed on Nasdaq under the symbol &#8220;RLYB.&#8221; Candid will file an
initial listing application for the common stock of the combined company with Nasdaq. At the Effective Time, Rallybio will be renamed &#8220;Candid Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade
on Nasdaq under the symbol &#8220;CDRX&#8221;; however, the parties may waive the closing condition in the Merger Agreement that the common stock of the combined company be approved for listing on Nasdaq prior to the Closing. For a description of
the effect of a waiver of the Nasdaq listing closing condition, please see the section titled &#8220;<I>Risk Factors&#8212;Risks Related to the Combined Company</I>&#8221; of this proxy statement/prospectus. On &#8195;&#8195;&#8195;&#8195;&#8195;,
2026, the last trading day before the date of this proxy statement/prospectus, the closing sale price of Rallybio Common Stock was $&#8195;&#8195;&#8195;&#8195;&#8195; per share. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Who will be the directors of the combined company following the Merger? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">The Merger Agreement provides that the parties will take all necessary action so that immediately after the Effective
Time, the board of directors of the combined company comprises seven members, with each member designated by Candid; provided, that the total number of directors to comprise the board of directors of the combined company immediately after the
Effective Time may be changed by Candid at any time prior to the Effective Time by written notice to Rallybio. Candid currently expects that immediately following the Effective Time, the combined company board of directors will consist of six
members comprising Candid&#8217;s current directors: Ken Song, M.D., Angie You, Ph.D., Dan Puckett, Michael Rome, Ph.D., Aaron Royston, M.D. and Jeffrey Tong, Ph.D. and one vacancy. For a more complete discussion of the expected members of the
combined company board of directors, please see the section titled &#8220;<I>Management Following the Merger</I>&#8221; of this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Who will be the executive officers of the combined company immediately following the Merger?
</B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">The Merger Agreement provides that the parties will take all necessary action so that immediately after the Effective
Time, the persons designated by Candid are appointed to the positions of officers of the combined company. Candid currently expects that the following individuals will serve as the executive officers of the combined company following the Merger:
</P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>TITLE</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ken Song, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>President and Chief Executive Officer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tim Lu, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief Medical Officer and Chief Scientific Officer</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arvind Kush</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief&nbsp;Financial&nbsp;Officer&nbsp;and&nbsp;Chief&nbsp;Business&nbsp;Officer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bernie Huyghe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief Technology Officer</I></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What risks should I consider in deciding whether to vote in favor of the Merger? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">You should carefully review the section titled &#8220;<I>Risk Factors</I>&#8221; of this proxy statement/prospectus and
the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company&#8217;s business will be subject, and risks and uncertainties to which each
of Rallybio and Candid, as independent companies, are subject. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>When do you expect the Merger to be consummated? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">The Merger is anticipated to close in <FONT STYLE="white-space:nowrap">mid-2026,</FONT> but the exact timing cannot be
predicted. For more information, please see the section titled &#8220;<I>The Merger Agreement</I>&#8212;<I>Conditions to the Completion of the Merger</I>&#8221; of this proxy statement/prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What are the material U.S. federal income tax consequences of the Merger to holders of Rallybio Common Stock?
</B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Rallybio stockholders will not sell, exchange or dispose of any shares of Rallybio Common Stock as a result of the
Merger. Thus, there will be no material U.S. federal income tax consequences to Rallybio stockholders as a result of the Merger. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What are the material U.S. federal income tax consequences of the issuance of the Rallybio CVRs, including any
distributions of Rallybio Common Stock under the Rallybio CVRs? </B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Although the U.S. federal income tax treatment of the Rallybio CVRs is uncertain and the matter is not free from doubt,
Rallybio intends to treat a holder&#8217;s receipt of the Rallybio CVRs as a distribution of property with respect to the holder&#8217;s existing shares of Rallybio Common Stock for U.S. federal income tax purposes. Please review the information in
the section titled &#8220;<I>Agreements Related to the Merger</I><I>&#8212;Rallybio Contingent</I><B><I> </I></B><I>Value Rights Agreement</I>&#8221; for a discussion of the material U.S. federal income tax consequences of the Rallybio CVRs to
holders of Rallybio Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What are the material U.S. federal income tax consequences of the reverse stock split to holders of Rallybio Common
Stock? </B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">A holder of Rallybio Common Stock should not recognize gain or loss upon the reverse stock split, except to the extent
such holder receives cash in lieu of a fractional share of Rallybio Common Stock, and subject to the discussion in the section titled &#8220;<I>Proposal No. 2&#8212;The Reverse Stock Split Proposal</I>.&#8221; Please review the information in the
section titled &#8220;<I>Proposal No. 2&#8212;The Reverse Stock Split Proposal&#8212;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</I>&#8221; for a more complete description of the material U.S. federal income tax
consequences of the reverse stock split to holders of Rallybio Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What do I need to do now? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Rallybio urges you to read this proxy statement/prospectus carefully, including the annexes and the documents
incorporated by reference, and to consider how the Merger affects you. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you are a Rallybio stockholder of record, as of the record date, you
may provide your proxy instructions in one of four different ways: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You can vote using the proxy card, simply complete, sign and date the accompanying proxy card and return it promptly in
the envelope provided. If you return your signed proxy card before the Rallybio annual meeting, Rallybio will vote your shares in accordance with the proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You can vote by proxy over the internet, follow the instructions provided on the proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You can vote by telephone by calling the toll-free number found on the proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You may attend the Rallybio annual meeting online and vote by registering at www.virtualshareholdermeeting.com/RLYB2026.
Upon entry of your control number and other required information, you will receive further instructions via email that provide you access to the Rallybio annual meeting and information on how to vote and submit questions during the Rallybio annual
meeting. Simply attending the Rallybio annual meeting will not, by itself, vote your shares or revoke your proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">We provide
internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet
access, such as usage charges from internet access providers and telephone companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">If you hold your shares in &#8220;street name&#8221; (as
described below), you may provide your proxy instructions by following the instructions on your vote instruction form provided by your broker, bank or other agent. Please provide your proxy instructions only once, unless you are revoking a
previously delivered proxy instruction, and as soon as possible so that your shares can be voted at the Rallybio annual meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent,
you should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from Rallybio. Simply complete and mail the voting instruction card to ensure that your vote is counted. To vote
at the Rallybio annual meeting, you may visit www.virtualshareholdermeeting.com/RLYB2026, press the &#8220;Attend Meeting&#8221; button and follow the instructions. You may be instructed to obtain a legal proxy from your broker, bank, or other
nominee and submit a copy in advance of the meeting. Further instructions will be provided to you via email. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Whether or not you plan to attend the
Rallybio annual meeting, Rallybio encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the Rallybio annual meeting, you may still attend the Rallybio annual meeting and vote. In such case, your
previously submitted proxy will be disregarded. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What happens if I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable?
</B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">If you are a Rallybio stockholder, the failure to return your proxy card or otherwise vote or provide proxy instructions
will reduce the aggregate number of votes required to approve each of the Proposals other than for Proposal No.&nbsp;4, which will have the same effect as a vote &#8220;AGAINST&#8221; such Proposal. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>May I attend the Rallybio annual meeting and vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Stockholders of record as of &#8195;&#8195;&#8195;&#8195;&#8195;, 2026 will be able to attend and participate in the
Rallybio annual meeting online by accessing www.virtualshareholdermeeting.com/RLYB2026. To join the Rallybio annual meeting, you will need to have your control number which is included on your proxy card. If your shares are held in &#8220;street
name,&#8221; you should contact your bank, broker or other nominee if you did not receive a control number. If your shares are held in &#8220;street name&#8221; you will also need to provide a legal proxy to vote during the meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Who counts the votes? </B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Broadridge Financial Solutions (&#8220;Broadridge&#8221;) has been engaged as Rallybio&#8217;s inspector of election. If
you are a stockholder of record, your executed proxy card is returned directly to Broadridge for tabulation. If you hold your shares through a broker, your broker returns one proxy card to Broadridge on behalf of all its clients.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>If my shares of Rallybio Common Stock are held in &#8220;street name&#8221; by my broker, will my broker vote my
shares for me? </B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">If you hold shares beneficially in street name and do not provide your broker or other agent with voting instructions,
your shares may constitute &#8220;broker <FONT STYLE="white-space:nowrap">non-votes.&#8221;</FONT> A &#8220;broker <FONT STYLE="white-space:nowrap">non-vote&#8221;</FONT> occurs when shares held by a broker or other agent are not voted with respect
to a particular proposal because the broker or other agent does not have or did not exercise discretionary authority to vote on the matter and has not received voting instructions from its clients. Matters for which the broker does not have
discretionary authority to vote are referred to as <FONT STYLE="white-space:nowrap">&#8220;non-routine&#8221;</FONT> matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Rallybio expects that Proposal Nos. 1, 2, 3, 4, 5, 7, 8 and 9 will be considered to be <FONT STYLE="white-space:nowrap">&#8220;non-routine&#8221;</FONT>
matters, and thus a Rallybio stockholder&#8217;s broker, bank or other agent may not vote shares on those Proposals in the absence of such holders&#8217; voting instructions. If a Rallybio stockholder does not instruct their broker how to vote with
respect to these Proposals, those votes will be counted as broker <FONT STYLE="white-space:nowrap">&#8220;non-votes,&#8221;</FONT> and will have no effect on the outcome of each Proposal other than Proposal No. 4, which will have the same effect as
a vote &#8220;AGAINST&#8221; such Proposal. Rallybio expects that Proposal No. 6 is considered to be a &#8220;routine&#8221; matter, and thus if a Rallybio stockholder does not return voting instructions to their broker, such holder&#8217;s shares
may be voted by his or her broker in its discretion. To make sure that your vote is counted, you should instruct your broker or other agent to vote your shares, following the procedures provided by your broker. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>What are broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and do they count for determining a quorum?
</B></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Generally, a &#8220;broker <FONT STYLE="white-space:nowrap">non-vote&#8221;</FONT> occurs when shares held by a broker
are not voted with respect to a particular proposal because the broker does not have or did not exercise discretionary authority to vote on the matter and has not received voting instructions from its clients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be treated as shares present for the
purpose of determining the presence of a quorum for the transaction of business at the Rallybio annual meeting, but will not be counted as votes cast and will have no effect on the outcome of the vote for each of Proposals No.&nbsp;1, 2, 3, 5, 6, 7,
8 and 9. Broker non-votes will have the same effect as votes &#8220;AGAINST&#8221; Proposal No.&nbsp;4. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>May I change my vote after I have submitted a proxy or provided proxy instructions? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Rallybio stockholders of record, unless such stockholder&#8217;s vote is subject to a support agreement, may change
their vote at any time before their proxy is voted at the Rallybio annual meeting in one of four ways: </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You may submit another properly completed proxy with a later date by mail or via the internet. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You can provide your proxy instructions via telephone at a later date. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You may send an instrument in writing revoking the proxy or another duly executed proxy bearing a later date to
Rallybio&#8217;s corporate secretary. Any written notice of revocation or subsequent proxy card must be received by the corporate secretary prior to the taking of the vote at the annual meeting. Such written notice of revocation or subsequent proxy
card should be sent to Rallybio&#8217;s Corporate Secretary at Rallybio Corporation, 234 Church Street, New Haven, CT 06510, Attention: Secretary. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You may attend the Rallybio annual meeting online and vote by registering
at<B></B>&nbsp;www.virtualshareholdermeeting.com/RLYB2026. Upon entry of your control number and other required information, you will receive further instructions via email that provide you access to the Rallybio annual meeting and information on
how to vote and submit questions during the Rallybio annual meeting. Simply attending the Rallybio annual meeting will not, by itself, vote your shares or revoke your proxy. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">All properly executed proxies that are not revoked will be voted at the Rallybio annual meeting and at any adjournments or postponements of the Rallybio
annual meeting in accordance with the instructions contained in the proxy. <B>If a holder of Rallybio Common Stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; all
of the Proposals in accordance with the recommendations of the Rallybio Board.</B> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">If a Rallybio stockholder who owns shares of Rallybio Common
Stock in &#8220;street name&#8221; has instructed a broker to vote its shares of Rallybio Common Stock, the stockholder must follow directions received from its broker to change those instructions. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Who is soliciting and paying for this proxy solicitation? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Rallybio and Candid are paying 40% and 60%, respectively, of the cost of (i)&nbsp;filing and printing of this proxy
statement/prospectus and any amendments and supplements hereto and paid to the financial printer or the SEC and (ii)&nbsp;the proxy solicitation firm engaged in connection with the Rallybio annual meeting. Arrangements will also be made with
brokerage firms and other custodians, nominees and fiduciaries who are record holders of Rallybio Common Stock for the forwarding of solicitation materials to the beneficial owners of Rallybio Common Stock. Rallybio will reimburse these brokers,
custodians, nominees and fiduciaries for the reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses they incur in connection with the forwarding of solicitation materials. Rallybio has
retained Georgeson LLC (&#8220;Georgeson&#8221;) to assist it in soliciting proxies using the means referred to above. Rallybio and Candid will pay the fees of Georgeson, which Rallybio expects to be approximately $40,000, plus reimbursement of
reasonable and customary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. In addition to solicitation by mail, the directors, officers, employees and agents of Rallybio may solicit proxies from
Rallybio stockholders by personal interview, telephone, email, fax or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Who can help answer my questions? </B></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">If you are a Rallybio stockholder and would like additional copies of this proxy statement/prospectus without charge or
if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact Rallybio&#8217;s proxy solicitor, Georgeson, at the following address, telephone number or email address:
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">51 West 52<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Street, 6<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>
Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">New York NY 10019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Call Toll Free: (866)
539-7406 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Email: rallybio@georgeson.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better
understand the Merger and the proposals being considered at the Rallybio annual meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy
statement/prospectus, and the documents incorporated by reference therein. For more information, please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 420 of this proxy statement/prospectus. Except where
specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.&nbsp;2 of this proxy statement/prospectus.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>The Companies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise
with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio&#8217;s lead program, RLYB116, is a differentiated complement component 5 (&#8220;C5&#8221;) inhibitor with the potential to
treat diseases of complement dysregulation. In addition, RLYB332, a long-acting <FONT STYLE="white-space:nowrap">matriptase-2</FONT> <FONT STYLE="white-space:nowrap">(&#8220;MTP-2&#8221;)</FONT> antibody for the treatment of diseases of iron
overload, is currently in preclinical development. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is a global clinical-stage biotechnology company focused on building the leading portfolio of TCE therapeutics to treat autoimmune diseases, which affect an
estimated 5-10% of the global population. Despite available treatments, many patients experience persistent disease activity, progressive organ damage, and lifelong dependence on immunosuppressive therapies that provide incomplete disease control
and cause significant adverse events. Cizutamig, which targets <FONT STYLE="white-space:nowrap">B-cell</FONT> maturation antigen (&#8220;BCMA&#8221;), is Candid&#8217;s lead clinical-stage TCE program and is advancing into global Phase&nbsp;2
studies in generalized myasthenia gravis (&#8220;gMG&#8221;) and systemic autoimmune rheumatic diseases-interstitial lung disease <FONT STYLE="white-space:nowrap">(&#8220;SARD-ILD&#8221;).</FONT> TCEs harness a patient&#8217;s own T cells to deplete
pathogenic <FONT STYLE="white-space:nowrap">B-cells,</FONT> with the potential to deliver either deep depletion of B-cells, which could provide durable disease remission (&#8220;immune reset&#8221;), or partial depletion of B-cells, which could
provide for controlled, sustained disease management (&#8220;immune dimming&#8221;). </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has built a diversified pipeline of four &#8220;TCE programs in
development targeting distinct <FONT STYLE="white-space:nowrap">B-cell</FONT> antigens&#8212;BCMA, CD20, and CD19. Candid&#8217;s most advanced clinical stage program, cizutamig, is a BCMA TCE in-licensed from EpimAb Biotherapeutics that is being
investigated in multiple Phase 1 dose-escalation trials in patients with gMG and systemic lupus erythematosus (&#8220;SLE&#8221;) as well as investigator-initiated trials (&#8220;IITs&#8221;) in SARD-ILD, systemic sclerosis (&#8220;SSc&#8221;), and
other diseases outside the United States. Biopsies obtained post treatment with cizutamig show deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion, including in plasma cells, bone marrow and lymph nodes. In Phase 1 dose escalation studies
in patients with gMG, Candid has seen clinical improvements with standardized physician and patient disease activity indices. In compassionate use via named patient use (&#8220;NPU&#8221;) studies in patients with
<FONT STYLE="white-space:nowrap">SARD-ILD,</FONT> Candid has seen improvements in lung function as measured by increases in force vital capacity (&#8220;FVC&#8221;). In patients with autoimmune disease treated with cizutamig, a favorable
tolerability profile has been observed, with low rates of adverse events related to cytokine release and no deaths or dose-limiting adverse events in Phase 1 dose escalation studies, compassionate use via NPU, and IITs. For information relating to
treatment-related serious adverse events, please see the section titled &#8220;<I>Candid&#8217;s Business&#8212;Cizutamig &#8211; A bispecific TCE Antibody Targeting BCMA-expressing B-cells and CD3-expressing T-cells&#8212;Safety profile of
cizutamig in autoimmune patients</I><I>.</I>&#8221; Candid plans to initiate global Phase&nbsp;2 clinical trials in gMG and <FONT STYLE="white-space:nowrap">SARD-ILD</FONT> by the middle of 2026, which are designed to evaluate whether the clinical
effects observed in earlier studies can be confirmed in larger, randomized, controlled settings. In gMG, Candid plans to conduct a head-to-head study comparing cizutamig to VYVGART<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a
neonatal Fc receptor (&#8220;FcRn&#8221;) antagonist therapy. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s second clinical-stage program, CND261, is a CD20 TCE in-licensed from Genor Biopharma that is
being investigated in Phase&nbsp;1 <FONT STYLE="white-space:nowrap">dose-escalation</FONT> studies in patients with rheumatoid arthritis (&#8220;RA&#8221;), SLE, as well as an IIT in ANCA-associated vasculitis outside the United States. CND261 was
engineered with the goal of achieving deeper B-cell depletion than approved <FONT STYLE="white-space:nowrap">CD20-targeted</FONT> monoclonal antibodies (&#8220;mAbs&#8221;) such as Rituxan<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or
GAZYVA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Lymph node biopsies post treatment with CND261 in patients with autoimmune disease shows deep depletion of CD20 positive <FONT STYLE="white-space:nowrap">B-cells.</FONT> In Phase 1
dose escalation studies, compassionate use via NPU, and IITs, Candid observed a favorable tolerability profile for patients with autoimmune disease treated with CND261 with low rates of adverse events related to cytokine release and no deaths or
dose-limiting adverse events. Beyond these two clinical programs, Candid has built a pipeline of next-generation trispecific TCEs, each designed to target two different antigens expressed on <FONT STYLE="white-space:nowrap">B-cells.</FONT> CND319 is
a TCE that targets CD19 and CD20 for <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion. In non-human primate studies, single doses of CND319 show deep tissue <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion with minimal cytokine
release. Candid expects to initiate first-in-human studies for CND319 in the middle of 2026. CND460 is a TCE that targets CD19 and BCMA and is currently undergoing IND-enabling studies with first-in-human trials planned for the first half of 2027.
CND460 is being developed in collaboration with a third-party development partner. Candid has the right to formally nominate CND460 as a development candidate upon the conclusion of those studies, which have not yet been completed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, Candid has not received approval from the FDA to initiate clinical trials in the United States and will require IND clearance prior to initiating any clinical
trials in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For more information on certain health complications that can result from B-cell depletion, including treatment with our drug
candidates, please see <I>&#8220;Risk Factors&#8212;Risks Related to Candid&#8212;Cizutamig&#8217;s mechanism of action results in deep and prolonged B-cell depletion, including memory B-cells, which may lead to hypogammaglobulinemia, loss of
vaccine-mediated immunity, and increased infection risk that could limit its clinical utility or require complex patient management strategies.&#8221;</I> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has built a portfolio of four TCE programs at various stages of development. Candid&#8217;s current pipeline is summarized in the table below. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00d17.jpg" ALT="LOGO" STYLE="width:6.30337in;height:2.70225in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s principal executive offices are located at 11622 El Camino Real, Suite 150, San Diego, CA 92130, and its telephone
number is (858) 247-0550. Candid&#8217;s website address is www.candidrx.com. Candid&#8217;s website is included as an inactive textual reference and the information contained on, or that can be accessed through, Candid&#8217;s website is not a part
of this proxy statement/prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Merger Sub </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Merger
Sub is a direct, wholly owned subsidiary of Rallybio and was formed solely for the purpose of carrying out the Merger. Merger Sub&#8217;s principal executive offices are located at 234 Church Street, New Haven, Connecticut 06510, and its telephone
number is (203) <FONT STYLE="white-space:nowrap">859-3820.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>The Merger </B>(see page 156) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;1, 2026, Rallybio, Merger Sub, and Candid entered into the Merger Agreement. Subject to the terms and conditions in the Merger Agreement, at the Effective
Time, Merger Sub will merge with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio. This transaction is referred to as the Merger. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger will become effective at the time the Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware or such other date and
time as is agreed upon by Rallybio and Candid and specified in the Certificate of Merger in accordance with the DGCL, subject to the satisfaction or waiver of certain conditions to the closing, including, among other things, approval by
Rallybio&#8217;s stockholders of the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal and the Name Change Proposal. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Exchange Ratio
and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the Closing, on a pro forma basis and based upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger,
pre-Merger equityholders of Candid (other than investors in the Concurrent Financing) are expected to own approximately 57.55% of the combined company, pre-Merger equityholders of Rallybio are expected to own approximately 3.65% of the combined
company and the investors in the Concurrent Financing are expected to own approximately 38.80% (assuming proceeds from the Concurrent Financing of $505.5 million), in each case, calculated on a fully diluted basis, using the treasury stock method,
and subject to certain assumptions, including (i)&nbsp;a valuation for Rallybio of $47.5&nbsp;million (assuming Rallybio Net Cash of $37.5 million as of the Closing), (ii)&nbsp;a fixed valuation for Candid of $750.0 million, and (iii)&nbsp;the
relative capitalization of Rallybio and Candid. The percentage of the combined company that each party&#8217;s equityholders will own following the Closing is subject to certain adjustments (as described in more detail in the section titled
&#8220;<I>The Merger Agreement&#8212;Merger Consideration and Exchange Ratio</I>&#8221;), including the amount of the final Rallybio Net Cash at the Closing. Rallybio Net Cash as calculated under the Merger Agreement makes certain adjustments to the
value of Rallybio&#8217;s Cash and Cash Equivalents (as defined in the Merger Agreement), and was equal to approximately $39.47&nbsp;million as of December&nbsp;31, 2025. The adjustments are described in the section titled &#8220;<I>The Merger
Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; Based on its Cash and Cash Equivalents and other balance sheet line items as of December&nbsp;31, 2025 and current estimates of the other elements of Rallybio Net Cash (including
projected adjustments to Rallybio&#8217;s Cash and Cash Equivalents), Rallybio calculates that it had Rallybio Net Cash of approximately $35.81&nbsp;million as of April 15, 2026. Rallybio expects to continue to incur losses in future periods
primarily related to the proposed Merger and, as a result, available Cash and Cash Equivalents will continue to decrease. For a description of the calculation of Rallybio Net Cash as set forth in the Merger Agreement, please see the section titled
&#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash.</I>&#8221; </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Rallybio&#8217;s Reasons for the Merger </B>(see page 166) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the course of its evaluation of the Merger, the Merger Agreement and the Contemplated Transactions, the Rallybio Board held numerous meetings, consulted with
Rallybio management, its legal counsel and its financial advisors and reviewed and assessed a significant amount of information and, in reaching its decision to approve the Merger, the Merger Agreement and the Contemplated Transactions, the Rallybio
Board considered various reasons for the Merger, as described later in this proxy statement/prospectus under the section titled &#8220;<I>The Merger&#8212;Rallybio&#8217;s Reasons for the Merger</I>.&#8221; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Candid&#8217;s Reasons for the Merger </B>(see page 169) </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the course of its
evaluation of the Merger, the Merger Agreement and the Contemplated Transactions, the Candid Board held meetings and conducted discussions, consulted with Candid senior management and legal </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
counsel, and considered a wide variety of factors and, in reaching its decision to approve the Merger, the Merger Agreement and the Contemplated Transactions, the Candid Board considered the
following factors: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Candid Board&#8217;s belief that, after reviewing various financing options to enhance stockholder value, the Merger
and Concurrent Financing represented the most favorable alternative reasonably available to Candid; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s prospects if it were to remain an independent privately held company, including its need to obtain
additional financing and the terms on which it would be able to obtain such financing, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cash resources of the combined company expected to be available upon the closing of the Concurrent Financing and
consummation of the Merger (including the ability to support Candid&#8217;s current and planned clinical trials and operations); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the access, as a public company, to a broader range of investors to support the development of Candid&#8217;s product
candidates than if Candid continued to operate as a privately held company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential to provide its current stockholders with greater liquidity by owning stock in a public company;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the expectation that substantially all of Candid&#8217;s employees, including its management, will serve in similar roles
at the combined company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms and conditions of the Merger Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the anticipated Nasdaq listing of the combined company&#8217;s common stock and the adoption of the name &#8220;Candid
Therapeutics, Inc.&#8221; for the combined company; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the likelihood that the Merger will be consummated on a timely basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For additional information, please see the section titled &#8220;<I>The Merger&#8212;Candid&#8217;s Reasons for the Merger</I>&#8221; of this proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recommendation of the Rallybio Board </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board has determined and believes that the issuance of shares of Rallybio Common Stock pursuant to the Merger
Agreement is fair to, advisable and in the best interests of Rallybio and its stockholders and has approved such issuance. The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Nasdaq Stock Issuance
Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board has determined and believes that it is fair to, advisable and in the best interests of Rallybio and its
stockholders to approve the amendment to Rallybio&#8217;s amended and restated certificate of incorporation to effect the reverse stock split, as described in this proxy statement/prospectus. The Rallybio Board unanimously recommends that Rallybio
stockholders vote &#8220;<B>FOR</B>&#8221; the Reverse Stock Split Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board has determined and believes that it is fair to, advisable and in the best interests of Rallybio and its
stockholders to approve the amendment to Rallybio&#8217;s amended and restated certificate of incorporation to change its name to &#8220;Candid Therapeutics, Inc.&#8221;, as described in this proxy statement/prospectus. The Rallybio Board
unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Name Change Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board has determined and believes that it is fair to, advisable and in the best interests of Rallybio and its
stockholders to approve the amendment to Rallybio&#8217;s amended and restated certificate of incorporation to increase the number of authorized shares of Rallybio Common Stock from 200,000,000 shares to 500,000,000 shares, as described in this
proxy statement/prospectus. The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Authorized Share Increase Proposal. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board has determined and believes that it is fair to, advisable and in the best interests of Rallybio and its
stockholders to elect each of Helen M. Boudreau, Lucian Iancovici, and Christine A. Nash, as Class&nbsp;II directors, each for a three-year term, as described in this proxy statement/prospectus; provided that if the Merger is consummated, the
approval of the Director Election </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
Proposal will only have an effect until the completion of the Merger because the composition of Rallybio&#8217;s board of directors will be reconstituted upon completion of the Merger, in
accordance with the Merger Agreement. The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; each of the director nominees named in the Director Election Proposal. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board has determined and believes that it is fair to, advisable and in the best interests of Rallybio and its
stockholders to ratify the selection of Deloitte as Rallybio&#8217;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2026, as described in this proxy statement/prospectus. The Rallybio Board unanimously
recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Auditor Ratification Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board has determined and believes that it is fair to, advisable and in the best interests of Rallybio and its
stockholders to approve the 2026 Plan. The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the 2026 Plan Proposal. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board has determined and believes that it is fair to, advisable and in the best interests of Rallybio and its
stockholders to approve the 2026 ESPP. The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the 2026 ESPP Proposal. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Rallybio Board has determined and believes that adjourning the Rallybio annual meeting, if necessary, to solicit
additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal the Reverse Stock Split Proposal, the Name Change Proposal and/or the Authorized Share Proposal is fair to, advisable and in the best interests of
Rallybio and its stockholders and has approved and adopted the proposal. The Rallybio Board unanimously recommends that Rallybio stockholders vote &#8220;<B>FOR</B>&#8221; the Adjournment Proposal, if necessary. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Interests of Rallybio&#8217;s Directors and Executive Officers in the Merger </B>(see page 177) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In considering the recommendation of the Rallybio Board with respect to issuing shares of Rallybio Common Stock in the Merger and other matters to be acted upon by the
Rallybio stockholders at the Rallybio annual meeting, the Rallybio stockholders should be aware that Rallybio&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Rallybio
stockholders generally. These interests include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Under the Merger Agreement, Rallybio&#8217;s directors and executive officers are entitled to continued indemnification,
expense advancements and insurance coverage. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">In connection with the Merger, each option to purchase Rallybio Common Stock, restricted stock unit with respect to
Rallybio Common Stock and performance-based stock unit with respect to Rallybio Common Stock held by Rallybio&#8217;s directors and executive officers as of the Effective Time will vest in full upon the Closing. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each Rallybio executive officer may be eligible to receive enhanced severance benefits pursuant to their respective
employment agreements with Rallybio in the event of a qualifying termination of employment following the Merger. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These interests are discussed in
more detail in the section titled &#8220;<I>The Merger-Interests of Rallybio&#8217;s Directors and Executive Officers in the Merger</I>&#8221; of this proxy statement/prospectus. The Rallybio Board was aware of these potential conflicts of interests
and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Rallybio stockholders approve the proposals to be presented to the Rallybio stockholders for consideration
at the Rallybio annual meeting as contemplated by this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Interests of Candid&#8217;s Directors and Executive Officers in the Merger
</B>(see page 181) </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In considering the recommendation of the Candid Board with respect to approving the Merger, Rallybio stockholders should be aware that
Candid&#8217;s directors and executive officers have interests in the Merger that </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
are different from, or in addition to, the interests of Candid stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the
extent material, are described below:<B> </B> </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">As of February&nbsp;28, 2026, the directors and executive officers of Candid as a group beneficially owned in the
aggregate approximately 7.1% of the outstanding shares of Candid Capital Stock. In addition, Dr.&nbsp;Song, his spouse and children are beneficiaries of the Song Beneficiary Trust U/T/A November&nbsp;6, 2024 (the &#8220;Song Beneficiary
Trust&#8221;), which is managed by an independent third-party trustee and which holds approximately 6.5% of the outstanding shares of Candid Capital Stock. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Under the terms of the Merger Agreement, each Candid stock option that is outstanding and unexercised immediately prior to
the Effective Time under Candid&#8217;s 2024 Equity Incentive Plan, as may be amended from time to time (the &#8220;Candid 2024 Plan&#8221;), whether or not vested, will be converted into and become an option to purchase shares of Rallybio Common
Stock at the Effective Time. Rallybio will assume the Candid 2024 Plan and all such Candid stock options in accordance with the terms of the Candid 2024 Plan and the terms of the stock option agreement by which such option is evidenced.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">As of February&nbsp;28, 2026, each of Dr.&nbsp;Song, Dr.&nbsp;Lu, Mr.&nbsp;Kush, Dr.&nbsp;Huyghe, Dr.&nbsp;You and
Mr.&nbsp;Puckett beneficially own Candid stock options to purchase 10,000,000, 1,200,000, 1,000,000, 500,000, 200,000 and 200,000 shares of Candid Common Stock, respectively, that will vest or begin vesting, if at all, upon or following a Liquidity
Event (as defined below), which will be satisfied in connection with the Contemplated Transactions. In addition, Mr.&nbsp;Puckett holds a Candid stock option to purchase 1,638,750 shares of Candid Common Stock that is subject to time-based vesting
conditions. All of these Candid stock options will be assumed by Rallybio and converted into options to purchase Rallybio Common Stock in accordance with the Merger Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s directors and executive officers are currently expected to become directors and executive officers of the
combined company following the Closing. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Under the Merger Agreement, Candid&#8217;s directors and executive officers are entitled to continued indemnification,
expense advancement and insurance coverage. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These interests are discussed in more detail in the section titled &#8220;<I>The
Merger&#8212;Interests of Candid&#8217;s Directors and Executive Officers in the Merger</I>&#8221; of this proxy statement/prospectus. The Candid Board was aware of these potential conflicts of interests and considered them, among other matters, in
reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Candid stockholders approve the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Opinion of Citizens JMP
Securities, LLC (</B>see page 171) </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio retained Citizens JMP Securities, LLC (&#8220;Citizens&#8221;) as a financial advisor in connection with the Merger.
The Rallybio Board selected Citizens to act as Rallybio&#8217;s financial advisor based on Citizens&#8217; qualifications, reputation, experience and expertise in the biopharmaceuticals industry, its knowledge of and involvement in recent
transactions in the biopharmaceutical industry, and its relationship and familiarity with Rallybio and its business. Citizens is an internationally recognized investment banking firm that has substantial experience in transactions similar to this
transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;1, 2026, Citizens delivered to the Rallybio Board its written opinion that, as of such date and based upon and subject to the various
assumptions made, and the qualifications and limitations upon the review undertaken by Citizens in preparing its opinion, the Exchange Ratio to be paid by Rallybio pursuant to the terms of the Merger Agreement is fair, from a financial point of
view, to Rallybio. The full text of the written opinion of Citizens, which describes the assumptions made and the qualifications and limitations upon the review undertaken by Citizens in preparing its opinion, is attached as Annex&nbsp;B to this
proxy statement/prospectus and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Citizens&#8217; financial advisory services and opinion were provided for the information
and assistance of the Rallybio Board (in their capacity as directors and not in any other capacity) in connection with and for </B></P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>
purposes of the Rallybio Board&#8217;s consideration of the Merger and the opinion of Citizens addressed only the fairness, from a financial point of view, as of the date thereof, to Rallybio of
the Exchange Ratio to be paid by Rallybio pursuant to the terms of the Merger Agreement. The opinion of Citizens did not address any other term or aspect of the Merger Agreement or the Merger and did not and does not constitute a recommendation to
any stockholder of Rallybio or Candid as to whether or how such holder should vote with respect to the Merger or otherwise act with respect to the Merger or any other matter. </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>The full text of the written opinion of Citizens should be read carefully in its entirety for a description of the assumptions made and qualifications and
limitations upon the review undertaken by Citizens in preparing its opinion. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>The Merger Agreement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Merger Consideration and Exchange Ratio </I></B>(see page 187) </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the
Effective Time, each outstanding share of Candid Capital Stock (excluding shares held by stockholders who have exercised and perfected appraisal rights, shares held as treasury stock by Candid or held or owned by Rallybio, Merger Sub or any
subsidiary of Rallybio or Candid, and shares issued in the Concurrent Financing) will be converted into the right to receive a number of shares of Rallybio Common Stock equal to the Exchange Ratio. Additionally, shares of Candid Capital Stock issued
in the Concurrent Financing will be converted solely into the right to receive a number of shares of Rallybio Common Stock equal to the Concurrent Financing Exchange Ratio, which is calculated by multiplying the total amount of Concurrent Financing
Merger Shares (as defined below) by the percentage of the proceeds resulting from the Concurrent Financing (&#8220;Concurrent Financing Proceeds&#8221;) (as defined below) represented by the applicable stockholder&#8217;s investment in the
Concurrent Financing, as set forth on the Allocation Certificate (as defined in the Merger Agreement). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No fractional shares of Rallybio Common Stock will be issued
in connection with the Merger, and any holder of Candid Capital Stock who would otherwise be entitled to receive a fraction of a share of Rallybio Common Stock (after aggregating all fractional shares of Rallybio Common Stock issuable to such
holder) will receive from Rallybio, in lieu of such fraction of a share: (i)&nbsp;one share of Rallybio Common Stock if the aggregate amount of fractional shares to which such holder would otherwise be entitled is equal to or exceeds 0.50; or
(ii)&nbsp;no shares of Rallybio Common Stock if such aggregate amount is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on an assumed Exchange Ratio of 0.0716, which assumes (i)&nbsp;a reverse stock split of Rallybio Common Stock of 1-for-2.5, to be implemented immediately prior to
the Closing, as may be adjusted, (ii) a valuation of Rallybio of $47.5 million (assuming Rallybio Net Cash at the Closing of $37.5&nbsp;million), (iii)&nbsp;a fixed valuation of Candid of $750.0 million (iv) the relative capitalization of Rallybio
and Candid, and (v) proceeds from the Concurrent Financing of $505.5&nbsp;million, Rallybio expects that it will issue approximately 62,246,687 shares of Rallybio Common Stock in the Merger, excluding any shares that may be subsequently issued in
connection with the exercise of Candid stock options assumed by Rallybio and assuming no stockholders of Candid exercise and perfect their appraisal rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Exchange Ratio and Concurrent Financing Exchange Ratio Formulas pursuant to which shares of Candid Capital Stock will be converted into shares of Rallybio Common Stock is derived based on (i)&nbsp;a Candid fixed valuation of $750.0&nbsp;million and
(ii)&nbsp;an initial Rallybio valuation of $47.5&nbsp;million, subject to certain adjustments based on Rallybio Net Cash at the Closing. The Rallybio valuation used to determine the Exchange Ratio will be increased or decreased on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-for-dollar</FONT></FONT> basis to reflect the amount by which Rallybio Net Cash at Closing is greater than or less than the Rallybio Target Net Cash (as defined in the Merger
Agreement) of $37.5&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately after the Closing, under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement,
on a pro forma basis and based upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, the <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Candid (other than
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
holders of shares issued in connection with the Concurrent Financing) are expected to own approximately 57.55% of the combined company, the <FONT STYLE="white-space:nowrap">pre-Merger</FONT>
equityholders of Rallybio are expected to own approximately 3.65% of the combined company, and the holders of shares issued in connection with the Concurrent Financing are expected to own approximately 38.80% of the combined company (assuming
proceeds from the Concurrent Financing of $505.5 million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i)&nbsp;a valuation for Rallybio of $47.5&nbsp;million
(assuming Rallybio Net Cash of $37.5&nbsp;million as of the Closing), (ii)&nbsp;a fixed valuation for Candid of $750.0&nbsp;million and (iii)&nbsp;the relative capitalization of Rallybio and Candid. The percentage of the combined company that each
party&#8217;s equityholders will own following the Closing is subject to certain adjustments. The Exchange Ratio and Concurrent Financing Exchange Ratio formulas assume an implied value of the combined company of approximately $1.303&nbsp;billion,
subject to certain adjustments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For more information about the Merger Consideration and Exchange Ratio, see the section titled &#8220;<I>The Merger
Agreement&#8212;Merger Consideration and Exchange Ratio</I>&#8221; of this proxy statement/prospectus. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of Rallybio Equity Awards </I></B>(see page
179) </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement provides that, prior to the Effective Time, Rallybio will take all actions necessary to provide that all Rallybio equity awards will be
fully vested as of the Effective Time and that all options to purchase Rallybio common stock will remain exercisable for no longer than 90 days following the termination of service of the holder of such option. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of Candid Stock Options </I></B>(see page 181) </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of
the Merger Agreement, each Candid stock option that is outstanding and unexercised immediately prior to the Effective Time under the Candid 2024 Plan, whether or not vested, will be converted into and become an option to purchase shares of Rallybio
Common Stock at the Effective Time. Rallybio will assume the Candid 2024 Plan and all such Candid stock options in accordance with the terms of the Candid 2024 Plan and the terms of the stock option agreement by which such Candid stock option is
evidenced. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conditions to the Completion of the Merger </I></B>(see page 191) </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The obligations of Rallybio and Candid to consummate the Merger are subject to the satisfaction or waiver, on or prior to the Effective Time, of the conditions set
forth in the section titled &#8220;<I>The Merger Agreement&#8212;Conditions to the Completion of the Merger</I>&#8221; below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Non-Solicitation </I></B>(see
page 196) </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Capitalized terms in this section are as defined in the section titled &#8220;<I>The Merger <FONT STYLE="white-space:nowrap">Agreement&#8212;Non-</FONT>
Solicitation.&#8221;</I> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio and its subsidiaries and their respective representatives are prohibited by the terms of the Merger Agreement, other than with
respect to any Asset Disposition, from, directly or indirectly, (i)&nbsp;soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any Acquisition Proposal or Acquisition
Inquiry or taking any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)&nbsp;furnishing any <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Rallybio or any of its
subsidiaries to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii)&nbsp;engaging in discussions (other than to inform any person of the existence of these prohibitions) or negotiations with any
person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv)&nbsp;approving, endorsing or recommending any Acquisition Proposal; (v)&nbsp;executing or entering into any letter of intent or any contract contemplating or otherwise
relating to any Acquisition Transaction (as defined below) (other than a confidentiality agreement permitted as described below); or (vi)&nbsp;publicly proposing to do any of the foregoing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding the foregoing, subject to compliance with the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> obligations set forth in the Merger Agreement,
and prior to obtaining the Required Rallybio Stockholder Vote, Rallybio and its subsidiaries may furnish <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Rallybio or any of its subsidiaries to, and enter into discussions or
negotiations with, any person in response to a bona fide Acquisition Proposal by such person, which the Rallybio Board has determined in good faith, after consultation with the Rallybio&#8217;s outside financial advisors
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A)&nbsp;none of Rallybio, any of its subsidiaries or any of their
respective representatives shall have breached the applicable <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions in the Merger Agreement of the Merger Agreement in any material respect, (B)&nbsp;the Rallybio Board concludes in
good faith based on the advice of outside legal counsel, that the failure to take such action would be inconsistent with the fiduciary duties of the Rallybio Board under applicable law; (C)&nbsp;Rallybio receives from such person an executed
confidentiality agreement containing provisions, in the aggregate, at least as favorable to Rallybio as those contained in the Mutual Confidential Disclosure Agreement, dated as of February 2, 2026, by and between Rallybio and Candid (the
&#8220;Confidentiality Agreement&#8221;); and (D)&nbsp;substantially contemporaneously with furnishing any such <FONT STYLE="white-space:nowrap">non-public</FONT> information to such person, Rallybio gives Candid notice of Rallybio&#8217;s intention
to furnish nonpublic information to, or enter into discussions with, such person and furnishes such <FONT STYLE="white-space:nowrap">non-public</FONT> information to Rallybio (to the extent such information has not been previously furnished by
Rallybio to Candid). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid and its subsidiaries and their respective representatives are prohibited by the terms of the Merger Agreement from, directly or
indirectly, (i)&nbsp;soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or taking any action that could reasonably be
expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)&nbsp;furnishing any <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Candid or any of its subsidiaries to any person in connection with or in response
to an Acquisition Proposal or Acquisition Inquiry; (iii)&nbsp;engaging in discussions (other than to inform any person of the existence of these prohibitions) or negotiations with any person with respect to any Acquisition Proposal or Acquisition
Inquiry; (iv)&nbsp;approving, endorsing or recommending any Acquisition Proposal; (v)&nbsp;executing or entering into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction; or (vi)&nbsp;publicly
proposing to do any of the foregoing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding the foregoing, subject to compliance with the <FONT STYLE="white-space:nowrap">non-solicitation</FONT>
obligations set forth in the Merger Agreement, and prior to obtaining the Required Candid Stockholder Vote (as defined in the Merger Agreement), Candid and its subsidiaries may solicit any Acquisition Proposal and furnish <FONT
STYLE="white-space:nowrap">non-public</FONT> information regarding Candid or any of its subsidiaries to, and enter into discussions or negotiations with, any person, including any person not making such Acquisition Proposal, following receipt of a
bona fide Acquisition Proposal by any person, which the Candid Board has determined in good faith, after consultation with the Candid&#8217;s outside financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a
Superior Offer if: (A)&nbsp;none of Candid, any of its subsidiaries or any of their respective representatives shall have breached the applicable <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions in the Merger Agreement in any
material respect, (B)&nbsp;the Candid Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would be inconsistent with the fiduciary duties of the Candid Board under applicable law; and
(C)&nbsp;Candid receives from such person an executed confidentiality agreement containing provisions, in the aggregate, at least as favorable to Candid as those contained in the Confidentiality Agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Termination and Termination Fees </I></B>(see page 205) </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of Candid or
Rallybio may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Merger Agreement is
terminated under certain circumstances, Rallybio will be required to pay Candid a termination fee of $1.425&nbsp;million, and if the Merger Agreement is terminated under certain other circumstances, Candid may be required to pay Rallybio a
termination fee of up to $50&nbsp;million, plus, in each case, up to a maximum of $500,000 in the reimbursement of reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses, which will
be credited against the payment of any termination fee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Support Agreements </I></B>(see page 210) </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution of the Merger Agreement, the executive officers and directors and certain other stockholders of Rallybio holding approximately 24.8% of
the outstanding Rallybio capital stock as of March 1, 2026 entered into support agreements in favor of Candid, providing among other things, that such officers, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
directors and stockholders (x)&nbsp;will vote all of their shares of Rallybio capital stock, among other things: (i)&nbsp;in favor of approving the Contemplated Transactions, including the
Rallybio Stockholder Matters (as defined in the Merger Agreement), the Authorized Share Increase Proposal and the other actions contemplated by the Merger Agreement, (ii)&nbsp;against any proposal made in opposition to, or in competition with, the
Merger Agreement or the Merger and (iii)&nbsp;against any acquisition proposal involving a third party and (y)&nbsp;will not solicit or negotiate alternative acquisition proposal or inquiries in their capacities as stockholders of Rallybio. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of Candid holding approximately 66.14% of the outstanding Candid
Capital Stock as of March 1, 2026 entered into the Candid Support Agreements in favor of Rallybio, providing among other things, that such executive officers, directors and stockholders (x)&nbsp;will vote all of their shares of Candid Capital Stock,
among other things: (i)&nbsp;in favor of adopting the Merger Agreement and approving the Merger, the other Contemplated Transactions, the Candid Stockholder Matters (as defined in the Merger Agreement) and the other actions contemplated by the
Merger Agreement, (ii)&nbsp;against any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii)&nbsp;against any acquisition proposal involving a third party and (y)&nbsp;will not solicit or negotiate
alternative acquisition proposal or inquiries in their capacities as stockholders of Candid. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements
</I></B>(see page 210) </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution of the Merger Agreement, the officers, directors, certain stockholders of Candid and who collectively hold
approximately 66.21% of the Candid Capital Stock as of March 1, 2026, entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, pursuant to which, subject to specified exceptions, such persons accepted certain restrictions on
transfers of the shares of Rallybio Common Stock beneficially held by such persons or such persons&#8217; family members (other than shares received as a result of the conversion of shares received in the Concurrent Financing) for the <FONT
STYLE="white-space:nowrap">180-day</FONT> period following the Effective Time. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Subscription Agreement and Registration Rights Agreement </I></B>(see page
210) </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution and delivery of the Merger Agreement, the Investors entered into the Subscription Agreement with Candid, pursuant to which
such Investors have agreed to purchase, immediately prior to the Merger, shares of Candid Common Stock representing an aggregate commitment of approximately $505.5&nbsp;million in the Concurrent Financing. The shares of Candid Common Stock that are
issued in the Concurrent Financing will be or will have the right to be, respectively, converted into shares of Rallybio Common Stock in the Merger. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio,
Candid and the Investors have also agreed to enter into the Registration Rights Agreement at the closing of the Concurrent Financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale
of certain shares of Candid Common Stock that are held by the Investors from time to time, including the shares of Rallybio Common Stock issued in exchange for shares of Candid Common Stock sold in the Concurrent Financing. We currently anticipate
that &#8195;&#8195;&#8195;&#8195; shares of Rallybio Common Stock will have registration rights pursuant to the Registration Rights Agreement following the Closing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of the conditions set forth in the Subscription Agreement and the satisfaction or
waiver of all conditions to the Closing set forth in the Merger Agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio Contingent Value Rights Agreement </I></B>(see page 212) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the Effective Time, Rallybio and the designated rights agent are expected to enter into the Rallybio CVR Agreement, pursuant to which holders of Rallybio
Common Stock, pre-funded warrants, restricted stock units and in the money stock options as of the close of business on the last business day prior to the day on which the Effective Time occurs will receive one Rallybio CVR for each outstanding
share, or share underlying such pre-funded warrant or equity award, held by such holder. Each Rallybio CVR holder will be entitled to receive on a pro rata basis all of the net proceeds received, if any, by Rallybio as a result of payment of
(i)&nbsp;any upfront, milestone, or royalty payments received under any disposition agreement related to the Legacy Assets, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and (ii)&nbsp;any cash proceeds received from Recursion related to the earlier sale of Rallybio&#8217;s REV102 in July 2025. For a period of one year after the Closing, the combined company will
use commercially reasonable efforts to effect the disposition of any remaining Legacy Assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Rallybio CVR Agreement, each Rallybio CVR holder will
be entitled to certain rights to receive 100% of the Rallybio CVR Payments actually received by Rallybio during an annual period (or portion thereof) beginning on the effective date of the Rallybio CVR Agreement and ending on December&nbsp;31 of any
given calendar year during the period beginning on the Closing and ending on December&nbsp;31, 2030 (each such annual period, a &#8220;CVR Payment Period&#8221;). Such proceeds are subject to certain permitted deductions, including for applicable
tax payments, certain expenses incurred by Rallybio or its affiliates, losses incurred or reasonably expected to be incurred by Rallybio or its affiliates due to thirdparty claims, demands, actions, or other proceedings relating to or in connection
with any disposition, any liabilities borne by Rallybio or any of its affiliates pursuant to contracts related to Legacy Assets and any amounts payable to the designated rights agent. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio CVR Payments, if any, will become payable to the designated rights agent for subsequent distribution to the Rallybio CVR holders. In the event that no such
proceeds are received during a CVR Payment Period, holders of the Rallybio CVRs will not receive any payment pursuant to the Rallybio CVR Agreement for such CVR Payment Period. There can be no assurance that any Rallybio CVR holders will receive any
Rallybio CVR Payments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The right to the contingent payments contemplated by the Rallybio CVR Agreement is a contractual right only and is not transferable, except
in the limited circumstances specified in the Rallybio CVR Agreement. The Rallybio CVRs are not evidenced by a certificate or any other instrument and are not registered with SEC. The Rallybio CVRs do not have any voting or dividend rights and do
not represent any equity or ownership interest in Rallybio or any of its respective affiliates. No interest will accrue on any amounts payable in respect of the Rallybio CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Management Following the Merger </B>(see page 181) </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective as of the
Closing, the combined company&#8217;s executive officers are expected to be the individuals designated by Candid, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>TITLE</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ken Song, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>President and Chief Executive Officer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tim Lu, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief Medical Officer and Chief Scientific Officer</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arvind Kush</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief Financial Officer and Chief Business Officer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bernie Huyghe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief Technology Officer</I></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Material U.S. Federal Income Tax Consequences of the Merger </B>(see page 183) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since the Rallybio stockholders will not sell, exchange or dispose of any shares of Rallybio Common Stock as a result of the Merger, there will be no material U.S.
federal income tax consequences to Rallybio stockholders as a result of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risk Factors </B>(see page 27) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Both Rallybio and Candid are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the
Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Risks Related to the
Merger </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Exchange Ratio will not be adjusted based on the market price of Rallybio Common Stock, so the consideration at the
Closing may have a greater or lesser value than at the time the Merger Agreement was signed; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If the conditions to the Closing are not met, the Merger may not occur; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger,
industry-wide changes and/or other causes; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Some executive officers and directors of Rallybio have interests in the Merger that are different from the stockholders of
Rallybio and that may influence them to support or approve the Merger without regard to the interests of the stockholders of Rallybio; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will
experience in connection with the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If the Merger is not completed, Rallybio&#8217;s stock price may decline significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio and Candid securityholders will have a reduced ownership and voting interest in, and will exercise less influence
over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Merger may not be completed on the terms or timeline currently contemplated, or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Lawsuits may be filed against Rallybio and the members of the Rallybio Board arising out of the proposed Merger, which may
delay or prevent the proposed Merger; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">During the pendency of the Merger Agreement, Rallybio and Candid may not be able to enter into a business combination with
another party at a favorable price due to specific restrictions in the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals for either of
Candid or Rallybio, including proposals that may be superior to the arrangements contemplated by the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Because the lack of a public market for the shares of Candid Capital Stock makes it difficult to evaluate the fairness of
the Merger, the stockholders of Candid may receive consideration in the Merger that is less than the fair market value of such Candid Capital Stock or Rallybio may pay more than the fair market value of such Candid Capital Stock;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The opinion delivered by Citizens to the Rallybio Board prior to the entry into the Merger Agreement does not reflect
changes in circumstances that may occur after the date thereof; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio or Candid may waive one or more of the conditions to the Merger without recirculation of this proxy
statement/prospectus or resoliciting stockholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Transfers of the combined company&#8217;s securities utilizing Rule 144 (&#8220;Rule 144&#8221;) of the Securities Act of
1933, as amended (the &#8220;Securities Act&#8221;) may be limited; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio&#8217;s winddown of its historical operations, the sale of assets, the suspension of development activities and
the proposed Merger, resulting in the conversion of Candid into a public company, will make Rallybio subject to the SEC requirements applicable to reporting shell company business combinations. As a result, the combined company will be subject to
more stringent reporting requirements, offering limitations and resale restrictions. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Risks Related to Rallybio </I></B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio has incurred significant losses since its inception and anticipates that, if it continues to progress the
development of its product candidates, it will continue to incur losses in the foreseeable future. Rallybio has not commercialized any products and has never generated revenue from the commercialization of any product. Rallybio is not currently
profitable, and may never achieve or sustain profitability; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If Rallybio continues to progress the development of its product candidates, it will require significant additional
capital to fund its operations. If Rallybio continues to progress the development of its product candidates and fails to obtain necessary financing, it may not be able to complete the development or commercialization of RLYB116 or any other product
candidate. Given Rallyiob&#8217;s limited resources and access to capital, Rallybio may decide to prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business;
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Raising additional capital may cause dilution to Rallybio&#8217;s stockholders, restrict its operations or require it to
relinquish rights to its intellectual property or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio&#8217;s failure to meet the listing standards of Nasdaq, could result in the delisting of its common stock.
Delisting could adversely affect the liquidity of Rallybio&#8217;s common stock and the market price of Rallybio&#8217;s common stock could decrease, and Rallybio&#8217;s ability to obtain sufficient additional capital to fund its operations and to
continue to operate as a going concern would be substantially impaired; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio is heavily dependent on the success of RLYB116, which is in early-stage clinical development. If Rallybio
continues to progress the development of its product candidates, and it is not able to develop, obtain marketing approval for, or successfully commercialize our product candidates, or if Rallybio experiences significant delays in doing so,
Rallybio&#8217;s business will be materially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Preclinical studies and clinical trials are expensive, time consuming and difficult to design and implement, and involve
uncertain outcomes. If Rallybio continues to progress the development of its product candidates, it may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of its product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Enrollment and retention of patients in rare disease clinical trials is an expensive and time-consuming process and could
be made more difficult or rendered impossible by multiple factors outside Rallybio&#8217;s control; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If Rallybio continues to progress the development of its product candidates, results of preclinical studies, clinical
trials or analyses that Rallybio may announce or publish from time to time, may not be indicative of results obtained in later trials, and any interim results Rallybio may publish could be different than final results; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If Rallybio continues to progress the development of its product candidates, any product candidates that Rallybio develops
or the administration thereof, may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety
warnings, or otherwise limit their sales; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The marketing approval processes of the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), the European Medicines
Agency (the &#8220;EMA&#8221;), and comparable foreign regulatory authorities, including the Medicines and Healthcare products Regulatory Agency in the United Kingdom (the &#8220;MHRA&#8221;), are lengthy, time-consuming, and inherently
unpredictable, and if Rallybio continues to progress the development of its product candidates, and is ultimately unable to obtain marketing approval for RLYB116 or any of Rallybio&#8217;s other product candidates, Rallybio&#8217;s business will be
substantially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio&#8217;s product candidates target rare diseases and conditions, and if Rallybio continues to progress the
development of its product candidates, the market opportunities for RLYB116 or any of Rallybio&#8217;s other product candidates, if approved, may be smaller than Rallybio anticipates. Rallybio must be able to successfully identify patients and
capture a significant market share to achieve profitability and growth; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio faces significant competition from biotechnology and pharmaceutical companies, and if Rallybio continues to
progress the development of its product candidates, Rallybio&#8217;s operating results will suffer if Rallybio fails to compete effectively; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If Rallybio continues to progress the development of its product candidates, it may pursue business development
transactions and collaborate with third parties for the development and commercialization of Rallybio product candidates. Rallybio may not succeed in identifying and acquiring businesses or assets,
<FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property rights or establishing and maintaining collaborations, which may significantly limit Rallybio&#8217;s ability to successfully develop and commercialize Rallybio&#8217;s other
product candidates, if at all, and these transactions could disrupt its business, cause dilution to its stockholders or reduce its financial resources; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If Rallybio is unable to obtain, maintain and enforce patent protection for its technology and product candidates, or if
the scope of the patent protection obtained is not sufficiently broad, Rallybio&#8217;s competitors could develop and commercialize technology and products similar or identical to Rallybio&#8217;s, and Rallybio&#8217;s ability to successfully
develop and commercialize its technology and product candidates may be adversely affected which may also impact the value of any potential CVR; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio equityholders may not receive any payment on the Rallybio CVRs and the Rallybio CVRs may otherwise expire
valueless; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The tax treatment of the CVRs is uncertain. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Risks Related to Candid </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid has a limited operating history, has not completed any clinical trials and has no drugs approved for commercial
sale, which may make it difficult for investors to evaluate Candid&#8217;s current business and predict its future success and viability; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid expects to incur significant losses for the foreseeable future and may never achieve or maintain profitability;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid will need to obtain substantial additional funding to complete the development and any commercialization of its
current and any future drug candidates, which may cause dilution to Candid&#8217;s stockholders. If Candid is unable to raise this capital when needed, it may be forced to delay, reduce or eliminate its research and development programs or other
operations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s approach to the development of drug candidates to treat autoimmune diseases is novel and unproven, and
Candid does not know whether it will be able to develop any drugs of commercial value, or if competing technological approaches will limit the commercial value of its drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid is early in its development efforts and only has two drug candidates, cizutamig and CND261, in early clinical
development. All of Candid&#8217;s other drug products, including CND319 and CND460, are in the preclinical or discovery stage. If Candid is unable to advance its drug candidates in clinical development, obtain regulatory approval and ultimately
commercialize its drug candidates, or experiences significant delays in doing so, Candid&#8217;s business will be materially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Clinical trials are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome. Any
difficulties or delays in the commencement or completion, or the termination or suspension, of Candid&#8217;s current or planned clinical trials could result in increased costs to Candid, delay or limit Candid&#8217;s ability to generate revenue or
adversely affect Candid&#8217;s commercial prospects; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s drug candidates have resulted in serious adverse events, including treatment-related serious adverse events
in oncology patients, and may in the future cause serious adverse events or undesirable side effects, or have other properties that may delay or prevent regulatory approval, cause Candid to suspend or discontinue clinical trials, limit the
commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if any; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Cizutamig&#8217;s mechanism of action results in deep and prolonged B-cell depletion, including memory <FONT
STYLE="white-space:nowrap">B-cells,</FONT> which may lead to hypogammaglobulinemia, loss of vaccine-mediated immunity, and increased infection risk that could limit its clinical utility or require complex patient management strategies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid has conducted, or plans to conduct, its initial clinical studies for cizutamig, CND261, and its other drug
candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case Candid&#8217;s development plans will be delayed, which could materially harm Candid&#8217;s business;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process subject to various
external factors beyond Candid&#8217;s control that may cause delays or complications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Since the number of patients that have been and will be dosed in Candid&#8217;s ongoing clinical trials is small, the
results from such clinical trials, once completed, may be less reliable than or may not be predictive of results achieved in larger clinical trials, which may hinder Candid&#8217;s efforts to obtain regulatory approval for its drug candidates;
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Results of any patient who receives Candid&#8217;s drug candidate in an IIT, compassionate use via NPU program or expanded
access program should not be viewed as representative of how the drug candidate will perform in Candid&#8217;s clinical trials and may not be able to be used to establish safety or efficacy for regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The affected populations for Candid&#8217;s drug candidates may be smaller than Candid or third parties currently project,
which may affect the addressable markets for Candid&#8217;s drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s success is dependent on its ability to successfully pursue business development, strategic partnerships and
investment opportunities as Candid matures. Candid is currently party to such arrangements, and may enter into additional collaboration and licensing arrangements in the future, and may not realize the benefits of such collaborations, alliances,
acquisitions or licensing arrangements. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid contracts with third parties for the manufacturing and supply of certain of its drug candidates for use in
preclinical testing and planned clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid faces significant competition from other biotechnology and pharmaceutical companies, and Candid&#8217;s operating
results will suffer if Candid fails to compete effectively; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">As a company with operations and business relationships outside of the United States, Candid&#8217;s business is subject
to economic, political, regulatory and other risks associated with international operations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid depends substantially on intellectual property rights granted under its agreements with Genor, EpimAb, and Wuxi
Biologics. If Candid loses its existing licenses or is unable to acquire or license additional proprietary rights from third parties, Candid may not be able to continue developing its drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid will need to expand its organization, and may experience challenges in managing this growth as it builds its
capabilities, which could disrupt its operations; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s future success depends on its ability to retain its key personnel and to attract, retain and motivate
qualified personnel. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Risks Related to the Combined Company </I></B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The combined company will need to raise substantial additional financing in the future to fund its operations, which may
not be available to it on favorable terms or at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Following the Merger, the combined company may be unable to successfully integrate the businesses of Rallybio and Candid
and realize some or all of the anticipated benefits of the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the
common stock may drop following the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The combined company will incur costs and demands upon management as a result of complying with the laws, rules and
regulations affecting public companies;</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If the assets subject to the Rallybio CVR Agreement are not disposed of in a timely manner, the combined company may have
to incur time and resources to wind down or dispose of such assets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Nasdaq may delist the combined company&#8217;s securities from trading on its exchange, which could limit investors&#8217;
ability to make transactions in its securities and subject the combined company to additional trading restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Provisions in the combined company&#8217;s amended and restated certificate of incorporation, the combined company&#8217;s
amended and restated bylaws and Delaware law may have anti-takeover effects that could discourage an acquisition of the combined company by others, even if an acquisition would be beneficial to the combined company&#8217;s stockholders, and may
prevent attempts by the combined company&#8217;s stockholders to replace or remove the combined company&#8217;s current management; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The combined company&#8217;s amended and restated certificate of incorporation will designate the state or federal courts
within the State of Delaware as the exclusive forum for certain types of actions and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
proceedings that may be initiated by the combined company&#8217;s stockholders, which could limit the combined company&#8217;s stockholders&#8217; ability to obtain a favorable judicial forum for
disputes with the combined company or its directors, officers or employees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio and Candid do not anticipate that the combined company will pay any cash dividends in the foreseeable future;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be
able to resell their shares of common stock for a profit, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the
combined company, its business or its market, its stock price and trading volume could decline; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The unaudited pro forma condensed combined financial statements included in this proxy statement/prospectus are presented
for illustrative purposes only and may not be an indication of the combined company&#8217;s financial condition or results of operations following the completion of the Merger; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If the combined company fails to maintain proper and effective internal controls, its ability to produce accurate
financial statements on a timely basis could be impaired; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to
successfully develop or commercialize its drug candidates or otherwise implement its business plan; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The combined company is expected to take advantage of reduced disclosure and governance requirements applicable to
emerging growth companies and smaller reporting companies, which could result in its common stock being less attractive to investors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Changes in tax laws may materially adversely affect the combined company&#8217;s business, prospects, financial condition
and operating results; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The combined company&#8217;s ability to use net operating loss carryforwards and other tax attributes may be limited,
including as a result of the Merger.</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These risks and other risks are discussed in greater detail under the section titled &#8220;<I>Risk
Factors</I>&#8221; of this proxy statement/prospectus. Rallybio and Candid both encourage you to read and consider all of these risks carefully. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Regulatory
Approvals </B>(see page 183) </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, Rallybio must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq
in connection with (i)&nbsp;the issuance of shares of Rallybio Common Stock to Candid stockholders in connection with the transactions contemplated by the Merger Agreement and the change of control resulting from the Merger and (ii)&nbsp;the filing
of this proxy statement/prospectus with the SEC. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Completion of the Merger is conditioned on the expiration or termination of any applicable waiting period (and
any extension thereof) under the HSR Act and the absence of any law or order restraining, enjoining, or otherwise prohibiting the consummation of the Merger. The HSR Act provides that certain transactions may not be completed until notification and
report forms are furnished to the U.S. Department of Justice (&#8220;DOJ&#8221;) and the U.S. Federal Trade Commission (&#8220;FTC&#8221;) and the HSR Act waiting period is terminated or expires. The applicable waiting period required under the HSR
Act expired at 11:59 p.m., Eastern Time, on April&nbsp;13, 2026. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Nasdaq Listing </B>(see page 183) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Merger Agreement, Rallybio has agreed to use commercially reasonable efforts, (i)&nbsp;to maintain its existing listing on Nasdaq until the Closing and
to obtain approval of the listing of the combined company on Nasdaq, (ii)&nbsp;to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Rallybio Common Stock
being issued in connection with the </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Merger and Contemplated Transactions, (iii)&nbsp;use commercially reasonable efforts to cause such shares to be approved for listing (subject to official notice of issuance) on the Nasdaq market
at or prior to the Effective Time, (iv)&nbsp;to effect the reverse stock split, and (v)&nbsp;to the extent required by Nasdaq Marketplace Rule 5110, to file an initial Nasdaq Listing Application for the Rallybio Common Stock on Nasdaq and to use
commercially reasonable efforts to cause such listing application to be conditionally approved prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Anticipated Accounting Treatment
</B>(see page 184) </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is expected be accounted for under accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) as
an <FONT STYLE="white-space:nowrap">in-substance</FONT> reverse recapitalization. For accounting purposes, Candid is expected to be considered the accounting acquirer. The treatment as an <FONT STYLE="white-space:nowrap">in-substance</FONT> reverse
recapitalization is based on the assessment that as a result of Rallybio&#8217;s discontinuation of its research and development activities and settlement of its other remaining operating assets and liabilities, immediately prior to the Closing,
Rallybio is expected to have nominal assets, apart from cash and cash equivalents and marketable securities. Under a reverse recapitalization, Candid is considered to effect a financing transaction in exchange for issuing equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Appraisal Rights </B>(see page 184) </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of Rallybio Common Stock are not
entitled to appraisal rights in connection with the Merger under the DGCL. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid stockholders are entitled to appraisal rights in connection with the Merger under
Section&nbsp;262 of the DGCL. See &#8220;<I>The Merger&#8212;Appraisal Rights</I>&#8221; elsewhere in this proxy statement/prospectus for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Comparison of Stockholder Rights </B>(see page 399) </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Both Rallybio and Candid
are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the DGCL. If the Merger is completed, Candid stockholders will become Rallybio
stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of combined company and the amended and restated certificate of incorporation of the combined company, as amended, as more fully described under the section
titled &#8220;<I>Comparison of Rights of Holders of Rallybio Capital Stock and Candid Capital Stock</I>&#8221; of this proxy statement/prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In
addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of Rallybio Common Stock. You
should also read and consider the other information in this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 424 of this proxy statement/prospectus for further information.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to the Merger </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Exchange Ratio will not be
adjusted based on the market price of Rallybio Common Stock, so the consideration at the Closing may have a greater or lesser value than at the time the Merger Agreement was signed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Exchange Ratio will not change based on changes in the trading price of Rallybio Common Stock. Therefore, if before the completion of the Merger, the market price
of Rallybio Common Stock increases from the market price on the date of the Merger Agreement, Candid stockholders could then receive merger consideration with substantially higher value for their shares of Candid common stock than the parties had
negotiated when they established the Exchange Ratio. The Merger Agreement does not include a price-based termination right. Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the
Closing, on a pro forma basis and based upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Candid (other than investors in the
Concurrent Financing) are expected to own approximately 57.55% of the combined company, pre-Merger equityholders of Rallybio are expected to own approximately 3.65% of the combined company and the investors in the Concurrent Financing are expected
to own approximately 38.80% (assuming proceeds from the Concurrent Financing of $505.5&nbsp;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i)&nbsp;a
valuation for Rallybio of $47.5&nbsp;million (assuming Rallybio Net Cash of $37.5&nbsp;million as of the Closing), (ii)&nbsp;a fixed valuation for Candid of $750.0&nbsp;million, and (iii)&nbsp;the relative capitalization of Rallybio and Candid. The
percentage of the combined company that each party&#8217;s equityholders will own following the Closing is subject to certain adjustments (as described in more detail in the section titled &#8220;<I>The Merger Agreement&#8212;Merger Consideration
and Exchange Ratio</I>&#8221;), including the amount of the final Rallybio Net Cash at the Closing. Rallybio Net Cash as calculated under the Merger Agreement makes certain adjustments to the value of Rallybio&#8217;s Cash and Cash Equivalents (as
defined in the Merger Agreement), and was equal to approximately $39.47&nbsp;million as of December&nbsp;31, 2025. The adjustments are described in the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net
Cash</I>.&#8221; Based on its Cash and Cash Equivalents and other balance sheet line items as of December&nbsp;31, 2025 and&nbsp;current estimates of the other elements of Rallybio Net Cash (including projected adjustments to Rallybio&#8217;s Cash
and Cash Equivalents), Rallybio calculates that it had Rallybio Net Cash of approximately $35.81&nbsp;million as of April&nbsp;15, 2026. Rallybio expects to continue to incur losses in future periods primarily related to the proposed Merger and,
as&nbsp;a&nbsp;result, available Cash and Cash Equivalents will continue to decrease. For a description of the calculation of Rallybio Net Cash as set forth in the Merger Agreement, please see the section titled &#8220;<I>The Merger
Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash.</I>&#8221; </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the conditions to the Closing are not met, the Merger may not occur.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if Proposal Nos. 1, 2 and 3 are approved by the stockholders of Rallybio, specified conditions must be satisfied or, to the extent permitted by
applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and each material condition to the completion of the Merger is described in the section titled &#8220;<I>The Merger Agreement&#8212;Conditions to
the Completion of the Merger</I>.&#8221; Rallybio and Candid cannot assure you that all of the conditions will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or will be delayed, and Rallybio and
Candid each may lose some or all the intended benefits of the Merger. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Merger may be completed even though a material adverse effect may result from the
announcement of the Merger, industry-wide changes and/or other causes. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, either Rallybio or Candid can refuse to complete the Merger if there is
a Rallybio Material Adverse Effect (as defined in the Merger Agreement) or a Candid Material Adverse Effect (as defined in the Merger Agreement), as applicable, between March&nbsp;1, 2026, the date of the Merger Agreement, and the Closing. However,
certain types of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
changes do not permit either party to refuse to complete the Merger, even if such change could be said to have a material adverse effect on Rallybio or Candid, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general business, political or economic conditions generally affecting the industry in which Rallybio or Candid operate,
including with respect to the imposition of, or adjustments to, tariffs or other trade restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or
other natural disasters, health emergencies, including pandemics and related or associated epidemics, disease outbreaks or quarantine restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in financial, banking or securities markets; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any change in the stock price or trading volume of Rallybio Common Stock (it being understood, however, that any effect
causing or contributing to any change in stock price or trading volume of Rallybio Common Stock may be taken into account in determining whether a material adverse effect with respect to Rallybio has occurred, unless such effects are otherwise
excepted from the definition of Rallybio Material Adverse Effect); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any failure by Rallybio to meet internal or analysts&#8217; expectations or projections or the results of operations of
Rallybio (it being understood, however, that any effect causing or contributing to the failure of Rallybio to meet internal or analysts&#8217; expectations or projections or the results of operations of Rallybio may be taken into account in
determining whether a material adverse effect with respect to Rallybio has occurred, unless such effects are otherwise excepted from the definition of Rallybio Material Adverse Effect); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any change in, or any compliance with or action taken for the purpose of complying with, any applicable law or GAAP (or
interpretations of ay applicable law or GAAP); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the announcement of the Merger Agreement or the pendency of the Contemplated Transactions; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the taking of any action required to be taken by the Merger Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a material adverse change occurs with respect to either party or both parties and Rallybio and Candid still complete the Merger, the stock price of the combined
company following the Closing may suffer and may reduce the value of the Merger to the stockholders of Rallybio, Candid or both. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Some executive officers and
directors of Rallybio have interests in the Merger that are different from the stockholders of Rallybio and that may influence them to support or approve the Merger without regard to the interests of the stockholders of Rallybio. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain executive officers and directors of Rallybio are parties to arrangements that provide them with interests in the Merger that are different from the stockholders
of Rallybio, including severance benefits, the acceleration of equity award vesting and continued indemnification. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Robert Hopfner, a current member of
Rallybio&#8217;s board, is affiliated with an investment fund participating in the concurrent financing. See &#8220;<I>The Merger&#8212;Interests of Rallybio&#8217;s Directors and Executive Officers in the Merger</I>&#8221; for more information.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board was aware of and considered these interests, among other matters, in reaching its determination (i)&nbsp;that the terms of the Merger Agreement
and the Merger and the other Contemplated Transactions are fair to, advisable and in the best interest of Rallybio and its stockholders, (ii)&nbsp;to approve and declare advisable the Merger Agreement and the Contemplated Transactions, including the
Merger and the issuance of shares of Rallybio Common Stock to the stockholders of Candid pursuant to the Merger Agreement and (iii)&nbsp;to recommend, upon the terms and subject to the terms and conditions set forth in the Merger Agreement, that the
stockholders of Rallybio vote to approve Nos. 1, 2 and 3. These interests, among other factors, may have influenced the directors and executive officers of Rallybio to support or approve the Merger. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For more information regarding the interests of Rallybio executive officers and directors in the Merger, see the section titled &#8220;<I>The Merger&#8212;Interests of
Rallybio&#8217;s Directors and Executive Officers in the Merger</I>.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they
will experience in connection with the Merger. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the combined company is unable to realize the full strategic and financial benefits currently anticipated
from the Merger, Rallybio stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able
to realize only part of the strategic and financial benefits currently anticipated from the Merger. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the Merger is not completed, Rallybio&#8217;s stock
price may decline significantly. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The market price of Rallybio Common Stock is subject to significant fluctuations. During the <FONT
STYLE="white-space:nowrap">12-month</FONT> period ended March&nbsp;1, 2026, the closing per share sales price of Rallybio Common Stock on Nasdaq ranged from a high of $7.54 on February&nbsp;27, 2026 to a low of $2.00 (after giving effect to
Rallybio&#8217;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-8</FONT></FONT> reverse stock split approved by Rallybio&#8217;s stockholders on January&nbsp;26, 2026 at a Special Meeting of Stockholders and effective as of
12:01 Eastern Time on February&nbsp;6, 2026) on April 8, 2025. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of Rallybio
Common Stock will likely be volatile based on whether stockholders and other investors believe that Rallybio can complete the Merger or otherwise raise additional capital to support Rallybio&#8217;s operations if the Merger is not consummated and
another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price of Rallybio Common Stock is exacerbated by low trading volume. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additional factors that may cause the market price of Rallybio Common Stock to fluctuate include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the entry into, or termination of, key agreements, including commercial partner agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof,
significant contracts, commercial relationships or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the loss of key employees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">future sales of its common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general and industry-specific economic conditions that may affect its research and development expenditures;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the failure to meet industry analyst expectations; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> fluctuations in financial
results. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating
performance of individual companies. These broad market fluctuations may also adversely affect the trading price of Rallybio Common Stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders
have often instituted class action securities litigation against such companies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio and Candid equityholders will have a reduced ownership and voting
interest in, and will exercise less influence over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of the Merger, the current stockholders of Rallybio and Candid will own a smaller percentage of the combined company than their ownership of their
respective companies prior to the Merger. Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the Closing, on a pro forma basis and based upon the number of shares of Rallybio Common
Stock expected to be issued in connection with the Merger, pre-Merger equityholders of Candid (other than investors in the Concurrent Financing) are expected to own approximately 57.55% of the combined company, pre-Merger equityholders of Rallybio
are expected to own approximately 3.65% of the combined company and the investors in the Concurrent Financing are expected to own approximately 38.80% (assuming proceeds from the Concurrent Financing of $505.5 million), in each case, calculated on a
fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i) a valuation for Rallybio of $47.5 million (assuming Rallybio Net Cash of $37.5 million as of the Closing), (ii) a fixed valuation for Candid of
$750.0 million, and (iii) the relative capitalization of Rallybio and Candid. The percentage of the combined company that each party&#8217;s equityholders will own following the Closing is subject to certain adjustments (as described in more detail
in the section titled &#8220;<I>The Merger Agreement&#8212;Merger Consideration and Exchange Ratio</I>&#8221;), including the amount of the final Rallybio Net Cash at the Closing. Rallybio Net Cash as calculated under the Merger Agreement makes
certain adjustments to the value of Rallybio&#8217;s Cash and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Cash Equivalents (as defined in the Merger Agreement), and was equal to approximately $39.47 million as of December&nbsp;31, 2025. The adjustments are described in the section titled
&#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; Based on its Cash and Cash Equivalents and other balance sheet line items as of December&nbsp;31, 2025 and current estimates of the other elements of Rallybio
Net Cash (including projected adjustments to Rallybio&#8217;s Cash and Cash Equivalents), Rallybio calculates that it had Rallybio Net Cash of approximately $35.81&nbsp;million as of April 15, 2026. Rallybio expects to continue to incur losses in
future periods primarily related to the proposed Merger and, as a result, available Cash and Cash Equivalents will continue to decrease. For a description of the calculation of Rallybio Net Cash as set forth in the Merger Agreement, please see the
section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash.</I>&#8221; </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Merger may not be completed on the terms or
timeline currently contemplated, or at all. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The consummation of the Merger is subject to numerous conditions, including (1)&nbsp;the effectiveness of the
registration statement of which this proxy statement/prospectus forms a part, (2)&nbsp;the approval by Rallybio&#8217;s stockholders of the Rallybio Stockholder Matters, (3)&nbsp;the approval by Candid&#8217;s stockholders of the Candid Stockholder
Matters, and (4)&nbsp;other customary closing conditions and there can be no assurance that the Merger will be consummated. See the section titled &#8220;<I>The Merger Agreement</I><I>&#8212;</I><I></I><I></I><I>Conditions to the Completion of the
Merger</I>.&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Merger is not completed for any reason, the price of Rallybio Common Stock may decline to the extent that the market price of Rallybio
Common Stock reflects or previously reflected positive market assumptions that the Merger would be completed and the related benefits would be realized. In addition, Rallybio and Candid have expended and will continue to expend significant
management time and resources and have incurred and will continue to incur significant expenses due to legal, advisory, printing and financial services fees related to the Merger. These expenses must be paid regardless of whether the Merger is
consummated. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lawsuits may be filed against Rallybio and the members of the Rallybio Board arising out of the proposed Merger, which may delay or prevent the
proposed Merger. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against Rallybio, the
Rallybio Board, Candid, the Candid Board and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and Rallybio may not be successful in defending against any such future claims.
Lawsuits that may be filed against Rallybio, the Rallybio Board, Candid, or the Candid Board could delay or prevent the Merger, divert the attention of Rallybio&#8217;s management and employees from Rallybio&#8217;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> business and otherwise adversely affect Rallybio&#8217;s financial condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>During the pendency of the
Merger Agreement, Rallybio and Candid may not be able to enter into a business combination with another party at a favorable price because of restrictions in the Merger Agreement, which could adversely affect their respective businesses.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Covenants in the Merger Agreement impede the ability of Rallybio and Candid to make acquisitions, subject to specified exceptions relating to fiduciary
duties, or complete other mergers, sales of assets or other business combinations pending completion of the Merger. As a result, if the Merger is not completed, the parties may be at a disadvantage to their competitors during that period. In
addition, while the Merger Agreement is in effect, each party is generally prohibited from soliciting, initiating, knowingly encouraging or entering into specified extraordinary transactions, such as a merger, sale of assets or other business
combination, with any third party, subject to specified exceptions, even if any such transaction could be favorable to such party&#8217;s stockholders or stockholders, as applicable. For a more complete description of the restrictions on pursuing
alternative transactions please see the section titled &#8220;<I>The Merger Agreement</I>.&#8221; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Certain provisions of the Merger Agreement may discourage
third parties from submitting competing proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
terms of the Merger Agreement prohibit each of Rallybio and Candid from soliciting competing proposals or cooperating with persons making unsolicited takeover proposals, except in certain limited circumstances. With respect to Rallybio, the Rallybio
Board may respond to an unsolicited competing proposal if it determines in good faith, after consultation with its outside financial advisor and outside legal counsel, that the unsolicited competing proposal constitutes, or is reasonably likely to
result in, a superior competing proposal and, after consultation with its outside legal counsel, that failure to take such action would be inconsistent with the fiduciary duties of the Rallybio Board. With respect to Candid, following receipt of a
bona fide acquisition proposal by any person that the Candid Board has determined constitutes, or is reasonably likely to result in, a superior offer, Candid may solicit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
acquisition proposals and furnish information to, and enter into discussions with, any person (including persons not making such proposal) if the Candid Board concludes in good faith, after
consultation with its outside legal counsel and financial advisor, that failure to take such action would be inconsistent with the fiduciary duties of the Candid Board. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In certain circumstances, and subject to compliance with the Merger Agreement, the Rallybio Board or the Candid Board may change its recommendation to its respective
stockholders if it determines such recommendation change is required to avoid a breach of its fiduciary duties. Additionally, subject to compliance with the procedures set forth in the Merger Agreement, including paying the applicable termination
fee, Candid may terminate the Merger Agreement in order to enter into an agreement with respect to a Superior Offer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon termination of the Merger Agreement in
certain circumstances, Candid may be required to pay to Rallybio a termination fee of (x) $50.0&nbsp;million, including (i)&nbsp;where the Candid Board changes or withdraws its recommendation in favor of the Merger or recommends to enter into an
alternative transaction, (ii)&nbsp;in certain circumstances where Candid enters into a Permitted Alternative Agreement (as defined in the Merger Agreement); or (iii)&nbsp;if (a) the Merger Agreement is terminated because Candid (1)&nbsp;fails to
obtain the requisite stockholder approval of the Merger Agreement and the transactions contemplated thereby or (2)&nbsp;breaches the Merger Agreement, (b)&nbsp;an alternative acquisition proposal was announced or disclosed prior to obtaining
Candid&#8217;s stockholder approval, and (c)&nbsp;within 12 months of the termination of the Merger Agreement, Candid enters into a definitive agreement with respect to an alternative transaction; or (y) $10.0&nbsp;million, if (i)&nbsp;the Merger
Agreement is terminated because the Merger has not been consummated by the End Date (as defined in the Merger Agreement), (ii) an alternative acquisition proposal was announced or disclosed prior to obtaining Candid&#8217;s stockholder approval, and
(iii)&nbsp;within 12 months of the termination of the Merger Agreement, Candid enters into a definitive agreement with respect to an alternative transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon
termination of the Merger Agreement in certain circumstances, a termination fee of $1.425&nbsp;million may be payable by Rallybio to Candid if (i)(a) the Merger Agreement is terminated because the Merger has not been consummated by the End Date (as
defined in the Merger Agreement) or Rallybio (1)&nbsp;fails to obtain the requisite stockholder approval of the Rallybio Stockholder Matters or (2)&nbsp;breaches the Merger Agreement, (b)&nbsp;an alternative acquisition proposal was announced or
disclosed prior to such termination, and (c)&nbsp;within 12 months of the termination of the Merger Agreement, Rallybio enters into a definitive agreement with respect to an alternative transaction, (ii)&nbsp;Rallybio fails to include its board
recommendation in this proxy statement/prospectus, or (iii)&nbsp;the Rallybio Board of directors changes or withdraws its recommendation in favor of the Merger or approves an alternative transaction, or willfully and intentionally breaches its <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> or certain other obligations under the Merger Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid and Rallybio have also each agreed to reimburse
the other party for up to $500,000 for third-party expenses, as applicable, if the Merger Agreement is terminated in certain circumstances. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These termination fees
and expense reimbursement provisions may discourage third parties from submitting competing proposals to Rallybio or Candid or their respective stockholders and may cause the Rallybio Board or the Candid Board, as the case may be, to be less
inclined to recommend a competing proposal. For more information regarding the potential termination fees, see the section titled &#8220;<I>The Merger Agreement-Termination and Termination Fees</I>.&#8221; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because the lack of a public market for the shares of Candid Capital Stock makes it difficult to evaluate the fairness of the Merger, the stockholders of Candid
may receive consideration in the Merger that is less than the fair market value of the shares of Candid Capital Stock or Rallybio may pay more than the fair market value of the Candid Capital Stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The outstanding shares of Candid Capital Stock are privately held and is not traded in any public market. The lack of a public market makes it extremely difficult to
determine the fair market value of the shares of Candid Capital Stock. Because the percentage of Rallybio equity to be issued to Candid stockholders was determined based on negotiations between the parties, it is possible that the value of the
Rallybio Common Stock to be received by Candid stockholders will be less than the fair market value of the shares of Candid Capital Stock, or Rallybio may pay more than the aggregate fair market value for the shares of Candid Capital Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The opinion delivered by Citizens to the Rallybio Board prior to the entry into the Merger Agreement does not
reflect changes in circumstances that may occur after the date thereof. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board has not obtained an updated opinion either as of the date of
this proxy statement/prospectus or as of any other date subsequent to the date of the opinion of Citizens, Rallybio&#8217;s financial advisor. Changes in circumstances, including without limitation the operations and prospects of Rallybio or Candid,
stock prices, general market and economic conditions and other factors, some or all of which may be beyond the control of Rallybio and Candid, are not reflected in the opinion of Citizens. The opinion of Citizens does not speak as of any date other
than the date thereof. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio or Candid may waive one or more of the conditions to the Merger without recirculation of this proxy statement/prospectus or
resoliciting stockholder approval. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Conditions to Rallybio&#8217;s or Candid&#8217;s obligations to complete the Merger may be waived, in whole or in part,
to the extent permitted by law, in certain circumstances unilaterally or by agreement of Rallybio and Candid. In the event of a waiver of a condition, the Rallybio Board will evaluate the materiality of any such waiver to determine whether amendment
of this proxy statement/prospectus and <FONT STYLE="white-space:nowrap">re-solicitation</FONT> of stockholder approval is necessary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that the Rallybio
Board, in its own reasonable discretion, determines any such waiver is not significant enough to require recirculation of this proxy statement/prospectus and <FONT STYLE="white-space:nowrap">re-solicitation</FONT> of its stockholders, it will have
the discretion to complete the Merger without seeking further stockholder approval, which decision may have a material adverse effect on the Rallybio stockholders. For example, if Rallybio and Candid agree to waive the requirement that the shares of
Rallybio Common Stock to be issued in the Merger have been approved for listing (subject to official notice of issuance) on Nasdaq as of the Closing, and their respective boards of directors elect to proceed with the Closing, Nasdaq may notify the
combined company of its determination to delist the combined company&#8217;s securities based upon the failure to satisfy the initial inclusion criteria in the Nasdaq application. The combined company may appeal the determination to a hearings panel
but such appeal will not stay the suspension and delisting action and Nasdaq may notify the combined company that its common stock will be immediately suspended from trading and delisted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in order to meet the initial listing requirements of Nasdaq or as otherwise determined in the discretion of the combined company board pursuant to the
terms of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements, the Rallybio Board or combined company board may release stockholders from their <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements and waive the requirement that such <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements be in full force and effect immediately following the Effective Time. Such release would increase the number of shares that may be sold in the public market immediately after the Merger and any
such sales could cause the combined company&#8217;s stock price to decline. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transfers of the combined company&#8217;s securities utilizing Rule 144 may be
limited. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A significant portion of the combined company&#8217;s securities will be restricted from immediate resale. Holders should be aware that transfers
of Rallybio&#8217;s securities pursuant to Rule 144 may be limited as Rule 144 is not available, subject to certain exceptions, for the resale of securities initially issued by shell companies (other than business combination related shell
companies) or issuers that have previously been a shell company. Rallybio&#8217;s winddown of its general and administrative operations that will not be needed after Closing and the proposed Merger (including the issuance of the Rallybio CVRs in
connection therewith) will make Rallybio subject to the SEC requirements applicable to reporting shell company business combinations. Rallybio anticipates that following the consummation of the Merger, the combined company will no longer be a shell
company. As a result, Rallybio anticipates that holders of restricted securities of the combined company, including affiliates of the combined company, will not be able to sell such securities pursuant to Rule 144 without registration until one year
after the combined company files Form 10 information with the SEC. For more information, see the section titled &#8220;<I>Securities Act Restrictions on Resale of Combined Company Common Stock</I>.&#8221; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio&#8217;s winddown of its historical operations, the sale of assets, the suspension of development activities and the proposed Merger, resulting in the
conversion of Candid into a public company, will make Rallybio subject to the SEC requirements applicable to reporting shell company business combinations. As a result, the combined company will be subject to more stringent reporting requirements,
offering limitations and resale restrictions. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to SEC guidance, the requirements applicable to reporting shell company business combinations apply
to any company that sells or otherwise disposes of its historical assets or operations in connection with or as part of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
plan to combine with a <FONT STYLE="white-space:nowrap">non-shell</FONT> private company in order to convert the private company into a public one. Rallybio has taken steps to winddown its
general and administrative operations that will not be needed after Closing and expects to issue the Rallybio CVRs in connection with the Closing and, as such, Rallybio&#8217;s plan to merge with Candid, resulting in the conversion of Candid into a
public company, will be subject to the SEC requirements applicable to reporting shell company business combinations, which are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the combined company will need to file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to report the
Form 10 type information (&#8220;Super <FONT STYLE="white-space:nowrap">8-K&#8221;)</FONT> after the Closing reflecting its status as an entity that is not a shell company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the combined company will not be eligible to use a Form <FONT STYLE="white-space:nowrap">S-3</FONT> until 12 full calendar
months after the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the combined company will need to wait at least 60 calendar days after the filing of the Super <FONT
STYLE="white-space:nowrap">8-K</FONT> to file a Form <FONT STYLE="white-space:nowrap">S-8</FONT> for any equity plans or awards, such as the 2026 Plan and the 2026 ESPP; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the combined company will be an &#8220;ineligible issuer&#8221; for three years following the Closing, which will prevent
the combined company from (i)&nbsp;incorporating by reference in its Form <FONT STYLE="white-space:nowrap">S-1</FONT> filings, (ii)&nbsp;using a free writing prospectus or (iii)&nbsp;taking advantage of the well-known seasoned issuer
(&#8220;WKSI&#8221;) status, even if otherwise eligible based on its public float; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">investors who (i)&nbsp;were affiliates of Candid at the time the Merger was submitted for the vote or consent of
Candid&#8217;s stockholders, (ii)&nbsp;receive securities of the combined company in the Merger and (iii)&nbsp;publicly offer or sell such securities will be deemed to be engaged in a distribution of such securities, and therefore would be
underwriters with respect to resales of those securities; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rule 144(i)(2) will limit the ability of holders of restricted securities, and any affiliates of the public company to
publicly resell Rule 145(c) securities per Rule&nbsp;145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities of the combined company per Rule&nbsp;144, until one year after the Form 10 information is filed with the
SEC. <FONT STYLE="white-space:nowrap">Non-affiliate</FONT> Rallybio stockholders prior to the Merger will not be subject to such restrictions on public resales of their shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing SEC requirements will increase the combined company&#8217;s time and cost of raising capital, offering stock under equity plans, and complying with
securities laws. Furthermore, such requirements will add burdensome restrictions on the resale of the combined company common stock by affiliates of Candid and any holders of &#8220;restricted&#8221; or &#8220;control&#8221; securities of the
combined company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For more information about the conditions to the completion of the Merger, see the section titled &#8220;<I>The Merger Agreement-Conditions to
the Completion of the Merger</I>.&#8221; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio equityholders may not receive any payment on the Rallybio CVRs and the Rallybio CVRs may otherwise expire
valueless. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The right of Rallybio equityholders to receive any future payment for or derive any value from the Rallybio CVRs will be contingent solely upon
(i)&nbsp;Rallybio&#8217;s and Candid&#8217;s (or the combined company&#8217;s) ability to monetize all or any part of the Legacy Assets pursuant to one or more disposition agreements entered into within the time period specified in the Rallybio CVR
Agreement, and the timing and amount of the consideration received thereunder and (ii)&nbsp;the receipt of cash proceeds from Recursion under the Membership Interest Purchase Agreement, dated July&nbsp;8, 2025, by and among Recursion
Pharmaceuticals, Inc., Exscientia Ventures I, Inc., Rallybio and Rallybio IPB, LLC (the &#8220;Membership Interest Purchase Agreement&#8221;). If Rallybio and/or Candid or the combined company (x)&nbsp;are not successful in entering into disposition
agreements related to the Legacy Assets (as defined below) or receiving payments thereunder, or if such payments are not sufficient to result in the payment of any Rallybio CVR Payments as a result of permitted deductions thereto and (y)&nbsp;do not
receive cash proceeds from Recursion pursuant to the Membership Interest Purchase Agreement, in each case within the time period specified in the Rallybio CVR Agreement, no payments will be made in respect of the Rallybio CVRs, and the Rallybio CVRs
will expire valueless. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the effective time, the combined company will have sole authority over whether and how to monetize the Legacy Assets (if at all),
and the combined company&#8217;s only obligations will be to carry out the obligations set forth in the Rallybio CVR Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, the Rallybio CVRs will be unsecured obligations of the combined company and all payments under the
Rallybio CVRs and all other obligations under the Rallybio CVR Agreement and the Rallybio CVRs and any rights or claims relating thereto will be subordinated in right of payment to the prior payment in full of all current or future senior
obligations of the combined company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The tax treatment of the CVRs is uncertain. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio intends to treat a holder&#8217;s receipt of the Rallybio CVRs as a distribution of property with respect to the holder&#8217;s existing shares of Rallybio
Common Stock for U.S. federal income tax purposes, which could be taxable to Rallybio stockholders without the corresponding receipt of cash. However, the U.S. federal income tax treatment of the Rallybio CVRs is uncertain. There is no legal
authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments under, the Rallybio CVRs, and there can be no assurance that the Internal Revenue Service (&#8220;IRS&#8221;) would not assert, or that a court would
not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the Rallybio CVRs. For more information regarding the U.S. federal income tax consequences of the CVRs, see the section titled
&#8220;<I>Agreements Related to the Merger&#8212;Rallybio Contingent Value Rights Agreement</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Rallybio </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Rallybio,</I>&#8221; the &#8220;<I>Company,</I>&#8221;
&#8220;<I>we,</I>&#8221; &#8220;<I>us,</I>&#8221; &#8220;<I>our</I>&#8221; <I>and other similar terms refer to Rallybio and its subsidiaries</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related
to Our Financial Position and Need for Additional Capital </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have incurred significant losses since our inception and anticipate that, if we continue to
progress the development of our product candidates, we will continue to incur losses in the foreseeable future. We have not commercialized any products and have never generated revenue from the commercialization of any product. We are not currently
profitable, and we may never achieve or sustain profitability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company with a limited operating history. As a result,
we are not profitable and we have incurred significant operating losses since inception, including net losses of $9.0&nbsp;million and $57.8&nbsp;million for the years ended December&nbsp;31, 2025 and 2024, respectively. Our loss for the year ended
December&nbsp;31, 2025 included a $23.0&nbsp;million gain in connection with the JV Sale (as defined below) in 2025. As of December&nbsp;31, 2025, we had an accumulated deficit of $302.0&nbsp;million. Investment in biopharmaceutical product
development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to gain regulatory approval and become commercially viable. Since inception, we have
devoted substantially all of our resources to raising capital, conducting discovery and research activities, acquiring product candidates, establishing and protecting our intellectual property, preparing for and conducting clinical trials, and
establishing arrangements with third parties for the manufacture of our product candidates. We do not have any product candidates approved for sale and have not generated any revenue from product sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product candidates, we expect to incur significant additional operating losses in the foreseeable future as we advance
our programs and operate our business. The costs of advancing product candidates through each clinical phase tend to increase substantially over the duration of the clinical development process. The total costs to advance a single product candidate
to marketing approval in even a single jurisdiction are substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses
or when, or if, we will be able to generate revenue from the commercialization of any product candidates or achieve or maintain profitability. Our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">plan for and conduct any future clinical trials for any of our product candidates, including the ongoing RLYB116
confirmatory clinical PK/PD trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek regulatory approvals for RLYB116 and any other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">advance our discovery and preclinical development activities for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hire additional clinical, scientific, and commercial personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">secure manufacturing sources and supply chain capacity sufficient to produce adequate clinical and commercial quantities
of our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish a sales, marketing, and distribution infrastructure to commercialize our products, if approved.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not know when or whether we will become profitable. Our ability to generate revenue and become profitable depends upon our ability to
successfully complete the development of our product candidates and to obtain the necessary regulatory approvals for their commercialization, which is subject to substantial additional risks and uncertainties, as described under
&#8220;&#8212;<I>Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval.</I>&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of our product candidates will
require additional preclinical and/or clinical development, regulatory approval in multiple jurisdictions, the securing of clinical and commercial manufacturing supply, the building of a commercial organization, and substantial investment before we
generate any revenue from product sales. As a result, If we continue to progress the development of our product candidates, we expect to continue to incur net losses and negative cash flows in the foreseeable future. These net losses and negative
cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to
generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through current or future collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not
achieve profitability. Even if we successfully commercialize RLYB116 or any of our other product candidates, we may continue to incur substantial research and development and other expenses to develop other current or future product candidates. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis or meet outside expectations for our profitability. Our failure to become and remain profitable would decrease the value of the
Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business, execute our business plan or continue our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product candidates, we will require significant additional capital to fund our operations. If we continue to
progress the development of our product candidates and fail to obtain necessary financing, we may not be able to complete the development or commercialization of RLYB116 or any other product candidate. Given our limited resources and access to
capital, we may decide to prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product candidates, we expect to spend significant amounts of capital to complete the development of, and if approved,
commercialize, one or more product candidates, including RLYB116. We are obligated to make certain payments under our agreements with Affibody, Sobi, and Kymab Limited (&#8220;Sanofi&#8221;), including milestone and royalty payments in connection
with achievement of certain development and commercial milestones as well as the sale of resulting products under such agreements. We may also spend significant capital to develop laboratory tests to identify patients for inclusion in our clinical
trials or who are likely to respond to our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product candidates, we believe that our existing
cash, cash equivalents and marketable securities as of December&nbsp;31, 2025, will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months beyond the date of the filing of this proxy
statement/prospectus. This estimate and our expectation to advance the preclinical and clinical development of RLYB116 and any other product candidates are based on assumptions that may prove to be wrong, or we may be subject to changing
circumstances. We could exhaust our available capital resources sooner than we expect. Our business is subject to numerous risks and uncertainties, and we may be unable to accurately estimate the actual amount of funds we will require for
development and commercialization of our product candidates. Our future capital requirements, both near and long-term, will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress, timing, costs and results of our clinical trials through all phases of development;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA, and other comparable foreign
regulatory authorities, including any regulatory designations allowing for priority review and any additional clinical trials required by the FDA, EMA or other comparable foreign regulatory authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the FDA, EMA and other comparable foreign regulatory authorities to accept our clinical trial designs,
as well as data from our completed and planned preclinical studies and clinical trials, as the basis for review and approval of RLYB116 and any other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost and timing of the manufacture and supply of <FONT STYLE="white-space:nowrap">non-clinical,</FONT> clinical and
commercial quantities of RLYB116 and our other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the identification, assessment, acquisition and/or development of additional research programs and additional product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of filing, prosecuting, and enforcing our patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third
parties against us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with potential clinical trial liability or product liability claims, including the costs associated
with obtaining insurance against such claims and with defending against such claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of making royalty, milestone or other payments under our current or any future
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to maintain our collaboration with AbCellera on favorable terms and establish new collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates or
technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product candidates, we will require significant additional capital, which we may raise through equity offerings, debt
financings, marketing and distribution arrangements, strategic alliances and licensing arrangements or other sources. Depending on our business performance, the economic climate and market conditions, we may be unable to raise additional funds when
needed on favorable terms, or at all. Furthermore, pursuant to Instruction I.B.6, a company with a public float of less than $75&nbsp;million measured at certain time periods may not issue securities under Registration Statements on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> in excess of <FONT STYLE="white-space:nowrap">one-third</FONT> of its public float in a <FONT STYLE="white-space:nowrap">12-month</FONT> period. For purposes of the prior sentence, &#8220;public float&#8221;
means the aggregate market value of a company&#8217;s shares held by <FONT STYLE="white-space:nowrap">non-affiliates.</FONT> We are subject to the limitations of Instruction I.B.6 which may limit the amount of funds we can raise using Registration
Statements on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> Moreover, uncertain geopolitical events, such as the war in Ukraine and conflict in Israel, and uncertain global economic conditions, including as a result of changes in tariffs and
other trade restrictions, have impacted the global economy, and a severe or prolonged economic downturn could result in a variety of challenges for our business, including disruptions in the financial markets, which could adversely impact our
ability to raise additional capital when needed or on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may need to significantly delay, scale back or discontinue the development of one or more of
our product candidates or the commercialization of any product that may be approved for marketing, or we could be forced to discontinue operations. In addition, attempting to secure additional financing may divert the time and attention of our
management from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and harm our product candidate development efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we have limited financial resources, we have focused and may continue to focus on a limited set of research programs and product candidates and for a limited
set of indications. We may forego or delay pursuit of opportunities with certain other product candidates or for other indications that could have greater commercial potential or a greater likelihood of success. Our capital allocation decisions may
cause us to fail to realize value from, or advance, viable commercial products or profitable market opportunities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause
dilution to our stockholders, restrict our operations or require us to relinquish rights to our intellectual property or product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue
to progress the development of our product candidates, until such time, if ever, as we generate significant revenue from product sales, we expect to finance our operations through the sale of equity, debt financings, collaborations, strategic
alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe
that we have sufficient funds for our current or future operating plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that we raise additional capital through the future sale of equity or convertible debt securities,
including sales of our common stock pursuant to the Sales Agreement with TD Securities (USA) LLC, each equityholder&#8217;s ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that
adversely affect their rights as a common stockholder. In addition, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends, and we may need to dedicate a substantial additional portion of any operating cash flows to the payment of principal and interest on such indebtedness. Any future indebtedness,
combined with our other financial obligations, could increase our vulnerability to adverse changes in general economic, industry and market conditions, limit our flexibility in planning for, or reacting to, changes in our business and the industry
and impose a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may be
required to relinquish valuable rights to our intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required
to delay, limit, reduce or terminate development or future commercialization efforts for one or more of our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have a limited operating
history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio
was founded in January 2018 and our operations to date have been limited primarily to research and development activities, and raising capital. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial,
obtain marketing approval, manufacture a commercial-scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, predictions about our future
success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we
continue to progress the development of our product candidates, we will eventually need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a
transition and, as a result, our business may be adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our quarterly and annual financial results may fluctuate, which makes our results
difficult to predict and may cause our results to fall short of expectations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our financial condition and operating results have varied in the past and
will continue to fluctuate from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> in the future due to
a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this proxy statement/prospectus: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in the level of expense related to any ongoing development of our product candidates or research pipeline;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays or failures in advancement of any existing or future product candidates into the clinic or in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the feasibility of developing, manufacturing and commercializing our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our relationships, and any associated exclusivity terms, with strategic collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make
or receive under existing or future arrangements, or the termination or modification of any such existing or future arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if we continue to progress the development of our product candidates, our operation in a net loss position in the
foreseeable future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if we continue to progress the development of our product candidates, our ability to consistently manufacture our product
candidates, including in sufficient quantities for clinical or commercial purposes; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our dependence on, and the need to attract and retain, key management and other personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic
investments or changes in business strategy; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential advantages that our competitors and potential competitors may have in developing and commercializing competing
products, securing funding for or obtaining the rights to critical intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if we continue to progress the development of our product candidates, regulatory developments affecting our product
candidates or those of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we continue to progress the development of our product candidates, and any of our product candidates receives
regulatory approval, the terms of such approval and market acceptance and demand for such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or disputes concerning patents or other proprietary rights, litigation matters and our ability to obtain and
maintain patent protection for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">business interruptions such as power outages, strikes, civil unrest, wars, acts of terrorism or natural disasters; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to use our net operating loss (&#8220;NOL&#8221;) and income tax credit carryforwards to offset income tax.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to these and other factors, the results of any of our prior quarterly or annual periods should not be relied upon as indications of our
future operating performance, and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a meaningful indication of our future performance. In any
particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to use our net operating loss and income tax credit carryforwards to offset future income tax liabilities may be subject to certain limitations.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred substantial NOLs during our history. To the extent that we continue to generate taxable losses, unused losses will carry forward and can
be used to offset future taxable income, if any, until such unused losses expire, if at all. NOLs generated in taxable years beginning after December&nbsp;31, 2017 are not subject to expiration. Federal NOLs generated in taxable years beginning
after December&nbsp;31, 2017 generally may not be carried back to prior taxable years. The deduction for NOLs arising in taxable years beginning after December&nbsp;31, 2017 is generally limited to 80% of current year taxable income. We also have
substantial federal and state research and development and other tax credit carryforwards. These tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, in general, under Sections 382 and
383 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and tax credit carryforwards to offset future taxable income.
Some of our historical NOLs may be subject to annual limitations on our ability to use them due to prior ownership changes. Additionally, the Merger may result in such an ownership change, and we may experience such ownership changes in the future
as a result of future transactions in our stock, some of which may be outside our control. If we undergo an ownership change, our ability to use our NOLs and income tax credit carryforwards could be further limited. For these reasons, we may not be
able to use a material portion of our NOLs or tax credit carryforwards, even if we attain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Discovery, Development, Clinical
Testing, Manufacturing, Marketing Approval and Commercialization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are heavily dependent on the success of RLYB116, which is in early-stage clinical
development. If we continue to progress the development of our product candidates, and are not able to develop, obtain marketing approval for, or successfully commercialize our product candidates, or if we experience significant delays in doing so,
our business will be materially harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead program, RLYB116, is in early-stage clinical development and we do not currently have any products that
generate revenues or any other sources of revenue. To date, we have invested a significant portion of our efforts and financial resources in the development of RLYB212 and RLYB116. If we continue to progress the development of our product
candidates, our future success is substantially dependent on our ability to successfully complete </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
preclinical and clinical development for, obtain marketing approval for, and successfully commercialize, RLYB116 and our other product candidates, which may never occur. None of our product
candidates are approved for commercial sale and we may never be able to develop a marketable product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining marketing approvals for the commercial sale
of our product candidates, we must demonstrate the safety and efficacy of our product candidates for use in each target indication through lengthy, complex and expensive preclinical studies and clinical trials. Failure can occur at any time during
the preclinical study and clinical trial processes. Because our product candidates are in an early stage of development, there is a high risk of failure, and we may never succeed in developing marketable products. If we continue to progress the
development of our product candidates, our ability to generate product revenue will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. Ongoing and future preclinical studies
and clinical trials of our product candidates may not show sufficient safety or efficacy or be of sufficient quality to obtain or maintain marketing approvals. For example, PK data from the Phase 2 clinical trial for RLYB212 demonstrated an
inability of the RLYB212 dose regimen to achieve predicted target concentrations, as well as the minimum target concentration required for efficacy. There can be no assurance that any of our product candidates, even if approved, will prove to be
commercially viable therapeutics. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB116 is designed for SC self-administration. The formulation or physical properties of RLYB116 may ultimately be determined to
be inadequate to support this route of administration. If SC administration is not feasible, then we may need to identify additional formulations or routes of administration, which could delay initiation of our future clinical trials or
commercialization and result in significant additional costs. Further, alternative formulations and routes of administration may be required to differentiate our product candidates from competitors and/or secure access to support successful
commercialization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product candidates, the success of our product candidates will depend on several factors,
including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful and timely initiation of preclinical studies, and successful and timely initiation of, enrollment in, and
completion of our clinical trials with results that support a finding of safety and effectiveness and an acceptable risk-benefit profile of our product candidates in the intended populations within the timeframes we have projected;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory grants of authorization to proceed under Investigational New Drug Applications (&#8220;INDs&#8221;) or CTAs
such that we can commence planned or future clinical trials of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to successfully utilize certain delivery systems, such as <FONT STYLE="white-space:nowrap">pre-filled</FONT>
syringes (&#8220;PFSs&#8221;), <FONT STYLE="white-space:nowrap">pen-injectors</FONT> and/or autoinjectors, for certain of our product candidates and to obtain marketing approval of any such drug/device combination product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome, timing, and cost of meeting regulatory requirements, including any post-marketing commitments, established by
the FDA, EMA and other comparable foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing commercially viable arrangements with third-party manufacturers for clinical and commercial supply;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing sales, marketing and distribution capabilities, whether alone or through a collaboration, to support
commercialization of our product candidates, if and when approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effectively differentiating and competing with other therapies approved and/or used for the same indications as our
product candidates, particularly RLYB116; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining third-party coverage and reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enforcing and defending intellectual property rights and claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintaining an acceptable safety profile of the product candidates following approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not successfully address one or more of these factors in a timely manner or at all, we could experience
significant delays or an inability to commercialize our product candidates, which would materially harm our business. Due to the uncertain and time-consuming clinical development and marketing approval process, we may not successfully develop any of
our product candidates and may choose to discontinue the development of any of our product candidates prior to receiving marketing approval. If we discontinue development of a product candidate, we will not receive anticipated revenues from that
product candidate and we may not receive any return on our investment in that product candidate. We may discontinue a product candidate for clinical reasons if it does not prove to be safe and effective for its targeted indications, or if such
product candidates do not achieve the necessary efficacy at tolerated doses required for patient benefit. For example, we discontinued RLYB212 development based on PK data from the Phase 2 clinical trial that demonstrated an inability of the RLYB212
dose regimen to achieve predicted target concentrations, as well as the minimum target concentration required for efficacy. In addition, there may be important facts about the safety, efficacy and risk versus benefit of our product candidates that
are not known to us at this time. Any unexpected safety events or our failure to generate sufficient data in our clinical trials to demonstrate efficacy may cause a product candidate to fail clinical development. Furthermore, even if that product
candidate meets its safety and efficacy endpoints, we may discontinue its development for various reasons, such as changes in the competitive environment or the standard of care and the prioritization of our resources. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. Supreme Court&#8217;s June 2024 decision in<I> Loper Bright Enterprises v. Raimondo</I> overturned the longstanding <I>Chevron</I> doctrine, under which courts
were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The <I>Loper</I> decision could result in additional legal challenges to regulations and guidance issued by federal agencies,
including the FDA, on which we rely. Any such legal challenges, if successful, could have a material impact on our business. Additionally, the <I>Loper</I> decision may result in increased regulatory uncertainty, inconsistent judicial
interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative action or as a result of legal challenges, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to
maintain regulatory compliance, our business could be materially harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical studies and clinical trials are expensive, time consuming and difficult
to design and implement, and involve uncertain outcomes. If we continue to progress the development of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of
our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining marketing approval from the FDA, EMA or other comparable regulatory authorities for the sale of our product
candidates, we must complete preclinical studies and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. To initiate clinical trials for any future product candidates, we must submit the results of preclinical
studies to the FDA, EMA or other comparable foreign regulatory authorities, along with other information, including information about CMC and our proposed clinical trial protocol, as part of an IND or similar regulatory filing that must be accepted
by the FDA, EMA or other applicable regulatory authorities before we may proceed with clinical development. In the event that regulators require us to complete additional preclinical studies or we are required to satisfy other regulator requests,
such as obtaining alignment on the device regulatory pathway for our FNAIT prevention program, the start of our clinical trials may be delayed or prevented. Even after we receive and incorporate guidance from these regulatory authorities, the FDA,
EMA or other regulatory authorities could (i)&nbsp;disagree that we have satisfied their requirements to commence our clinical trial, (ii)&nbsp;change their position on the acceptability of our data, trial design or the clinical endpoints selected,
which may require us to complete additional preclinical studies or clinical trials or (iii)&nbsp;impose stricter requirements for approval than we currently expect. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product candidates, we may experience events that could delay or prevent our ability to complete current clinical
trials or initiate and complete new trials, any of which may impact our product development timelines, result in increased costs, affect our ability to obtain marketing approval according to our plans, and delay commercialization of our product
candidates. These events include, but are not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities requiring us to submit additional data or imposing other
requirements before permitting us to commence a trial; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in receiving or denial by regulatory agencies of permission to proceed with our planned clinical trials or any
other clinical trials we may initiate, or placement of a clinical trial on hold; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">negative results from our <FONT STYLE="white-space:nowrap">non-clinical</FONT> trials or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">challenges, delays and cost involved in identifying, recruiting and retaining suitable participants and clinical trial
sites in sufficient numbers to participate in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in reaching an agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can
be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in obtaining an independent IRB approval at each site within the United States, or Independent Ethics Committee
(&#8220;IEC&#8221;) approval at sites outside the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays or problems in analyzing data, or the need for additional analysis or data or the need to enroll additional
patients; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure by us, our CROs, trial sites or investigators to adhere to clinical trial, regulatory, legal or contractual
requirements and perform trials in accordance with the FDA&#8217;s Good Clinical Practice (&#8220;GCP&#8221;) requirements and trial protocol; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inadequate quantity or quality of product candidate or other materials necessary to conduct clinical trials, for example
as a result of delays in defining and implementing the manufacturing process for materials used in clinical trials or for the manufacture of larger quantities or other delays or issues arising in the manufacturing of sufficient supply of finished
drug product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">lack of adequate funding to continue a clinical trial, including as a result of unanticipated costs or increases in costs
of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">occurrence of serious adverse events including unexpected serious adverse events, associated with the product candidate or
reports from <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical testing of our own or competing therapies that raise safety or efficacy concerns, or delays or failures in addressing patient safety concerns that arise during the course
of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in regulatory requirements and guidance that require changes to planned or ongoing preclinical and clinical
studies, or the conduct of additional studies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulties recruiting and retaining employees, consultants or contractors with the required level of expertise.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we could encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such
trials are being conducted, the FDA, EMA or other regulatory authorities, or recommended for termination by a Data and Safety Monitoring Board (&#8220;DSMB&#8221;) for such trial. Such authorities may impose a suspension or termination or recommend
an alteration to clinical trials due to several factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, the identification of safety issues or adverse side effects, failure to
demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, we rely and will rely on CROs and clinical
trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in the section titled
&#8220;&#8212;<I>Risks Related to Our Dependence on Third Parties</I>.&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Principal investigators for our clinical trials could serve as scientific advisors or
consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship
between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of a clinical trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site, and the
utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to
commence product sales and generate revenues. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our clinical trials could shorten any period during which we may have the
exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may
harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product candidates, results of
preclinical studies, clinical trials or analyses that we may announce or publish from time to time, may not be indicative of results obtained in later trials, and any interim results we may publish could be different than final results. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results of preclinical studies, clinical trials or analyses of the results from such trials, may not be predictive of the results of later clinical trials. Product
candidates in later clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and prior clinical trials or having shown promising results based on analyses of data from earlier
trials. Late-stage clinical trials may include a larger number of patients and could differ in other significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, patient population, efficacy endpoints,
dosing regimen and statistical design. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding earlier promising
results. In addition, conclusions based on promising data from analyses of clinical results, such as the prospective and post hoc analysis of results may be shown to be incorrect in subsequent clinical trials that have
<FONT STYLE="white-space:nowrap">pre-specified</FONT> end points or may not be considered adequate by regulatory authorities. We have completed Phase 1 clinical studies for RLYB116, however, even if we complete later clinical trials as planned, we
cannot be certain that their results will support the safety and efficacy requirements sufficient to obtain regulatory approval, and, as a result, our clinical development plans may be materially harmed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, interim, <FONT STYLE="white-space:nowrap">&#8220;top-line&#8221;</FONT> and preliminary data from our clinical trials that we announce or publish may change
as more patient data become available or as additional analyses are conducted. The data obtained in such clinical trials are subject to additional audit and verification procedures and following such procedures, such interim data could be materially
different from the final data. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Enrollment and retention of patients in rare disease clinical trials is an expensive and time-consuming process and could be
made more difficult or rendered impossible by multiple factors outside our control. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product candidates,
identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. We currently are conducting, and plan to conduct, clinical trials with our product candidates in rare disease indications,
which can make completion of such trial more difficult. The timely completion of clinical trials in accordance with their protocols depends, among other things, on the speed at which we can recruit eligible patients to participate in testing our
product candidates and our ability to enroll a sufficient number of patients who remain in the study until its conclusion. Clinical trial recruitment delays often result in increased costs, delays in advancing product development, delays in testing
the effectiveness of technologies, delays in obtaining marketing approval or termination of clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patient enrollment and retention in clinical trials
depends on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the design of the clinical trial, including the patient eligibility criteria defined in the protocol;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size and nature of the patient population required for analysis of the trial&#8217;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the existing body of safety and efficacy data with respect to the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the proximity of patients to clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in
relation to other available therapies, including any new drugs or medical devices that may be approved for the indications we are investigating; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">competing clinical trials being conducted by other companies or institutions, particularly for RLYB116;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">other factors we may not be able to control that may limit patients, principal investigators or staff, or clinical site
availability. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we may have difficulty identifying and enrolling patients for any planned clinical trials because the conditions for
which we plan to evaluate our current product candidates are rare diseases and we anticipate that there will be limited patient pools from which to draw for clinical trials. Further, because screening for many of these diseases is not widely
adopted, and because it can be difficult to diagnose these diseases in the absence of screening, we may have difficulty finding patients who are eligible to participate in our studies or trials. Our clinical trials for RLYB116 may compete with other
clinical trials for product candidates that are being tested for the same indications. This competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt
to enroll in a trial being conducted by one of our competitors. Furthermore, any negative results we may report in clinical trials of any of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical
trials of that same or a similar product candidate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Outside of the United States, our ability to initiate, enroll and complete a clinical trial successfully is
subject to numerous additional risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulty in establishing or managing relationships with CROs and physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">different standards for the conduct of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our inability to locate qualified local consultants, physicians and partners; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including
the regulation of pharmaceutical and biotechnology products and treatment. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not be able to initiate or continue clinical trials required by
the FDA, EMA or other regulatory authorities if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials. If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as
planned, we may need to delay, limit or terminate ongoing or planned clinical trials. Delays or failures in planned patient enrollment or retention may result in increased costs or program delays, which could have a harmful effect on our ability to
develop our product candidates or could render further development impossible. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product candidates, any
product candidates that we develop or the administration thereof, may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken
off the market, include safety warnings, or otherwise limit their sales. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adverse events or undesirable side effects caused by any product candidates we
develop could cause us or regulatory authorities or IRBs, IECs or DSMBs, where applicable, to interrupt, delay, or halt clinical trials and, if we seek approval of any such product candidate, could result in a more restrictive label, imposition of a
Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) program by the FDA or the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities. Additionally, the administration process or related
procedures associated with our product candidates also may cause adverse side effects. Even if we determine that serious adverse events are unrelated to study treatment, such occurrences could affect patient recruitment or the ability of enrolled
patients to complete the trial. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects. For example, complement inhibitors have, by design, immunosuppressive effects and, in some cases,
may be administered to patients with significantly compromised health. As a result, administration of RLYB116 could make patients more susceptible to infection. The chronic dosing of patients with RLYB116 could lead to an immune response that causes
adverse reactions or impairs the activity and/or efficacy of RLYB116. Patients may develop an allergic reaction to the drug and/or develop antibodies directed at RLYB116, or may require immunization with a meningococcal vaccine and prophylactic
antibiotics. An immune response that causes adverse reactions or impairs the activity of RLYB116 could cause a delay in or termination of our development plans. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some potential therapeutics that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further
development. In addition, side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential clinical trial or product liability claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Inadequate training or failures by clinical trial personnel in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Furthermore,
clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors may only be
uncovered when a significantly larger number of patients have been exposed to the drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or others later identify undesirable side effects caused by any
product candidate that we develop after the product is approved, several negative consequences could result, which could materially harm our business, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may suspend or withdraw approvals of such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may require additional warnings on the label, limit the approved use of such product candidate, or
otherwise restrict distribution or marketing such as through requiring adoption of a REMS program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be required to conduct additional clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of marketing approval based on
preclinical studies or early-stage clinical trials. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its
tolerability versus other therapies. Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations, and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The marketing approval processes of the FDA, EMA and comparable foreign regulatory authorities, including the MHRA, are lengthy, time-consuming and inherently
unpredictable, and if we continue to progress the development of our product candidates, and we are ultimately unable to obtain marketing approval for RLYB116 or any of our other product candidates, our business will be substantially harmed.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, we are not permitted to market a product candidate until we receive approval of a Biologics License Application (&#8220;BLA&#8221;)
or a New Drug Application (&#8220;NDA&#8221;) from the FDA. The process of obtaining BLA and NDA approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. Approval
policies or regulations may change, and the FDA and other regulatory authorities have substantial discretion in the approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. In addition, the
FDA may require post-approval clinical trials or studies as a condition of approval, which also may be costly. The FDA approval for a limited indication or approval with required warning language, such as a boxed warning, could significantly impact
our ability to successfully market our product candidates. The FDA also may require adoption of a REMS requiring prescriber training, post-market registries, or otherwise restricting the marketing and dissemination of these products. Certain of our
product candidates will rely on delivery systems, such as PFSs, <FONT STYLE="white-space:nowrap">pen-injectors</FONT> and/or autoinjectors, and may ultimately be regulated as a drug/device combination product. Although the FDA and similar foreign
regulatory agencies have systems in place for the review and approval of combination products, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the
product development and approval process. Despite the time and expense invested in the clinical development of product candidates, regulatory approval is never guaranteed for our product candidates. Assuming successful clinical development, we
intend to seek product approvals in countries outside the United States, including in Europe. As a result, we would be subject to regulation by the EMA, as well as the other regulatory agencies in these countries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Of the large number of drugs in development, only a small percentage successfully complete the marketing approval processes and are commercialized. This lengthy
approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain marketing approval to market our product candidates and we may be forced to abandon our development efforts for our product
candidate, which would significantly harm our business, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The time required to obtain approval by the FDA, EMA and other comparable foreign regulatory authorities is
unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change
during a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained marketing approval for any product candidate and it is possible that we will never obtain marketing approval for any product candidate.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate to the satisfaction of the FDA, EMA or other
comparable foreign regulatory authority, that such product candidates are safe and effective for their intended uses. Data obtained from preclinical studies and clinical trials are susceptible to varying interpretations, and regulatory authorities
may not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials, or marketing approval. Even if we believe the preclinical or clinical data for our product candidates are sufficient
to support approval, such data may not be considered sufficient to support approval by the FDA, EMA and other comparable regulatory authorities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to
progress the development of our product candidates, the FDA, EMA or other comparable foreign regulatory authority can delay, limit, or deny approval of RLYB116 or any of our other product candidates that we develop or require us to conduct
additional preclinical or clinical testing or abandon a program for many reasons, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to demonstrate to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities
that our product candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals
using drugs similar to our product candidates, or other products containing an active ingredient in our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance
required by the FDA, EMA or other comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety and efficacy
in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may not accept clinical data from trials which are
conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States or the applicable foreign jurisdiction; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to demonstrate that our product candidate&#8217;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the
submission of a BLA or NDA or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s disagreement regarding the formulation, the
labeling, and/or the specifications of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional time may be required to obtain regulatory approval for our product candidates because they are combination
products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve or find deficiencies with the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the policies, regulations, and guidelines of the FDA, EMA or other comparable foreign regulatory authorities regarding the
development, approval, and marketing of drugs and biologics may significantly change, including but not limited to, in the U.S., as a result of the 2025 change in presidential administration, which may render our clinical data insufficient for
approval or restrict us from marketing our product candidates in the manner in which we anticipate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never obtained marketing approval for a product candidate. If we continue to progress the development of our
product candidates, any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates target rare diseases and conditions, and if we continue to progress the development of our product candidates, the market opportunities for
RLYB116 or any of our other product candidates, if approved, may be smaller than we anticipate. We must be able to successfully identify patients and capture a significant market share to achieve profitability and growth. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates target rare diseases and conditions. With respect to RLYB116, we estimate that there are approximately 8,000 patients with immune PTR and up to
10,000 patients with refractory APS in the United States. Our projections of the number of eligible patients are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature,
population statistics and market research, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of eligible patients, and the number of patients may turn out to be lower than expected. Additionally, the
potentially addressable patient population for our current programs or future product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain
access to. For example, even if we obtain FDA approval for RLYB116, the drug may be approved for a target population that is more limited than what we currently anticipate. Furthermore, even if we obtain significant market share for any product
candidate, if approved, the potential target populations for our product candidates are for rare diseases, and we may never achieve profitability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, in many
cases there are either limited screening or diagnostic tests for the indications our product candidates are being developed to potentially treat. The lack of screening and diagnostic tests, coupled with the fact that there is frequently limited
awareness among certain health care providers concerning the rare diseases we may seek to treat, often means that a proper diagnosis can, and frequently does, take years to identify (or an appropriate diagnosis may never be made for certain
patients). As a result, even if one of our product candidates is approved for commercial sale, we may not be able to grow our revenues due to difficulty in identifying eligible patients. There can be no guarantee that any of our programs will be
effective at identifying patients that will benefit from our product candidates, and even if we can identify patients that our product candidates can help, the number of patients that our product candidates may ultimately treat may turn out to be
lower than we expect, they may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify, all of which may adversely affect our ability to grow and generate revenue and
adversely affect our results of operations and our business. In addition, even in instances where we are able to expand the number of patients being treated, the number may be offset by the number of patients that discontinue use of the applicable
product in a given period resulting in a net loss of patients and potentially decreased revenue. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face significant competition from biotechnology and
pharmaceutical companies, and if we continue to progress the development of our product candidates, our operating results will suffer if we fail to compete effectively. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our
ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If a product candidate we develop is approved, we will face intense competition. There are many public and private
biopharmaceutical companies, universities, government agencies and other research organizations actively engaged in the research and development of products that may be like our product candidates or address similar markets. Mergers and acquisitions
in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. In addition, the number of companies seeking to develop and commercialize products and therapies competing with our product candidates is likely to increase. However, we seek to build our portfolio with key
differentiating attributes to provide a competitive advantage in the markets we target. If we successfully develop and, if approved, commercialize RLYB116, this therapy may compete with anticoagulants such as Warfarin, or potentially be used in
conjunction, with currently marketed treatments and any new therapies that may become available in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product candidates, competition could render any product candidate
we develop obsolete, less competitive, or uneconomical. In addition, product candidates developed by our competitors may prove to be more safe or more effective than our product candidates. Our competitors may, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">have significantly greater name recognition and financial, manufacturing, marketing, product development, technical,
commercial infrastructure, and human resources than we do; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">more effectively recruit and retain qualified scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">more effectively establish clinical trial sites and patient registration; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to
administer, or have fewer or less severe side effects; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain quicker regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">better protect their patents and intellectual property or acquire technologies that are complementary to, or necessary
for, our programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">implement more effective approaches to sales, marketing, pricing, coverage, market access, and reimbursement; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">form more advantageous strategic alliances or collaborations. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not able to effectively compete for any of the foregoing reasons, our business will be materially harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Disruptions in the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key
leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which, if we continue to progress the development of our product candidates, could negatively impact our
business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times
at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would
adversely affect our business. For example, in recent years, including for 43 days beginning on October&nbsp;1, 2025 and for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory
agencies, such as the FDA, have had to furlough critical employees and stop critical activities. The Trump Administration has reduced the number of employees serving in government agencies, including the FDA. If a prolonged government shutdown
occurs, or if the U.S. government takes other personnel actions, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain marketing approval for a product candidate in the United States, we or our current or future collaborators may never obtain approval for or
commercialize the product candidate in any other jurisdiction, which would limit our ability to realize its full market potential. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market any
product in a particular jurisdiction, we or our current or future collaborators must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. Approval by the FDA in the United States does not ensure approval by comparable regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in
one jurisdiction may negatively impact our or our collaborators&#8217; ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory
approval in one country does not guarantee regulatory approval in any other country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Approval processes vary among countries and can involve additional product
testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and
time- consuming. Regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any
jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain
and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and we will be unable to realize the full market potential of any product we develop. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain marketing approval for any of our product candidates, we will still face extensive and ongoing regulatory requirements and obligations and
continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of the FDA and other regulatory authorities. These
requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with the FDA&#8217;s current cGMP requirements regarding the distribution of
samples to physicians and recordkeeping and Good Laboratory Practice (&#8220;GLP&#8221;) and GCP requirements for <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may also require costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. Additionally, the FDA closely
regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in a manner that is consistent with the provisions of the approved labeling. If we market our products for uses beyond
their approved indications or otherwise inconsistent with the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing by the FDA and other
federal and state enforcement agencies, including the DOJ. Violation of the FDCA and other statutes, including the False Claims Act, and equivalent legislation in other countries relating to the promotion and advertising of prescription products may
also lead to investigations or allegations of violations of federal and state and other countries&#8217; health care fraud and abuse laws and state consumer protection laws. Even if it is later determined we were not in violation of these laws, we
may be faced with negative publicity, incur significant expenses defending our actions and have to divert significant management resources from other matters. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including, but not limited
to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on manufacturing such products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions in the labeling or on the marketing of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to conduct post-marketing studies or additional post-marketing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issuance of warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal to approve pending applications or supplements to approved applications that we submit, or delays in such
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recalls or market withdrawals of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, restitution, or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspension or termination of ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions, consent decrees, or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we obtain FDA approval for RLYB116, safety risks not identified in our prior clinical trials may first appear after we obtain approval and commercialize RLYB116. Any
new post-marketing adverse events may significantly impact our ability to market the drugs and may require that we recall and discontinue commercialization of RLYB116. Furthermore, if any confirmatory post-marketing trial fails to confirm the
clinical profile or clinical benefits of RLYB116, the FDA may withdraw its approval, which would materially harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future
legislation or administrative or executive action, either in the United States or abroad. Further, the FDA&#8217;s, EMA&#8217;s and other comparable regulatory authorities&#8217; policies may change, and additional government regulations may be
enacted that could prevent, limit, or delay regulatory approval of a product candidate or increase the costs and regulatory burden of commercialization. If we are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business, prospects,
financial condition, and results of operations. Furthermore, <FONT STYLE="white-space:nowrap">non-compliance</FONT> by us or any collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, may also result in
significant financial penalties, which would adversely affect our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product candidates, we may seek
Fast Track designation, Breakthrough Therapy designation, or Priority Medicines (&#8220;PRIME&#8221;) program designation for our product candidates, but we might not receive any such designation, and even if we do, such designation may not actually
lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a drug is intended for the treatment of a serious or life-threatening condition,
and <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical data demonstrate the potential to address an unmet medical need for this condition, the product candidate may qualify for FDA Fast Track designation, for which sponsors must apply.
Sponsors of fast-track products may have more frequent interactions with the FDA, and, in some circumstances, the FDA may initiate review of sections of a fast track product&#8217;s application before the application is complete. We may submit an
application for Fast Track designation for RLYB116. The FDA has broad discretion whether to grant this designation, and we may not receive it. Moreover, even if we receive Fast Track designation, Fast Track designation does not ensure that we will
receive marketing approval and we may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it
believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product candidates, we also may seek a Breakthrough Therapy designation for some of our product candidates if future
results support such designation. A Breakthrough Therapy is defined as a drug (including biologic) that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that
the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Sponsors of products that have been designated as
breakthrough therapies are eligible to receive more intensive FDA guidance on establishing an efficient drug development program, an organization commitment involving senior managers, and may be eligible for rolling review. Drugs designated as
breakthrough therapies by the FDA may also be eligible for other expedited review programs, including accelerated approval and priority review, if supported by clinical data at the time the BLA or NDA is submitted to the FDA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that a product candidate meets the criteria for designation
as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation may not result in a faster development or regulatory review or
approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a Breakthrough Therapy, the FDA may later decide
that such product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
the European Union (&#8220;EU&#8221;) we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to
optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no
satisfactory method of treatment in the EU or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the EU and the applicant intends
to apply for an initial MA application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
public health interest and therapeutic innovation based on information that can substantiate the claims. The benefits of a PRIME designation include the appointment of a Committee for Medicinal
Products for Human Use (&#8220;CHMP&#8221;) rapporteur to provide continued support and help to build knowledge ahead of a MA application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for
accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and Health Technology Assessment
(&#8220;HTA&#8221;) advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to
conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product candidates, we may be unsuccessful in obtaining or may be unable to maintain the benefits associated
with orphan drug designation, including the potential for market exclusivity. If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as RLYB116 or any of our other
product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities in some jurisdictions, including the United States and the EU may designate drugs for relatively small patient populations as orphan drugs. Under
the U.S. Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United
States, or a patient population of more than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#8217;s Committee for
Orphan Medicinal Products evaluates, and the EC grants, an orphan drug designation principally to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10,000 persons in the EU. In addition, the product under consideration is indicated for a condition where there exists no satisfactory method of diagnosis, prevention or treatment authorized in the EU or, if
such method exists, that the medicinal product will be of significant benefit to those affected by that condition. We may seek orphan drug designation in the United States and the EU for certain of our product candidates but may be unsuccessful in
doing so. There can be no assurance that the FDA or the EMA&#8217;s Committee for Orphan Medicinal Products will consider orphan designation for any indication for which we apply or <FONT STYLE="white-space:nowrap">re-apply,</FONT> or that we will
be able to maintain such designation. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and
<FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the
product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug or biologic for the same orphan designation for that time period, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. In the United States, the exclusivity period is seven years. The
applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years in Europe if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market
exclusivity is no longer justified. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure
sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Similarly, in the EU, the market exclusivity can be broken if the holder of the MA for the original orphan medicinal product is unable to supply
sufficient quantities of the medicinal product. In addition, in both the United States and EU, if a different drug is subsequently approved for marketing for the same or a similar indication as any of our product candidates that receive marketing
approval, we may face increased competition and lose market share regardless of orphan drug exclusivity, which only protects against approval of the &#8220;same&#8221; drug for the same indication. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product candidates, we may seek accelerated approval by the FDA for one or more of our product candidates.
Accelerated approval by the FDA, even if granted for any of our product </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>
candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant
accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate
endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA requires that a sponsor of a product receiving accelerated approval perform a post-marketing confirmatory clinical
trial or trials. In addition, the FDA currently requires as a condition for accelerated approval the <FONT STYLE="white-space:nowrap">pre-submission</FONT> of promotional materials to FDA for review. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and
receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval.
Furthermore, if we decide to submit an application for accelerated approval there can be no assurance that such submission or application will be accepted or that the FDA will determine that the product candidate is eligible for or grant accelerated
approval. A failure to obtain any planned accelerated approval for our product candidates would result in a longer time period to commercialization of our product candidates, if approved, could increase the cost of development of our product
candidates and could harm our competitive position in the marketplace. If we receive accelerated approval for any of our product candidates, the FDA may withdraw accelerated approval if, among other things, a confirmatory trial required to verify
the predicted clinical benefit of the product fails to verify such benefit or if such trial is not conducted with due diligence. Withdrawal of any accelerated approval could substantially harm our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product candidates, the successful commercialization of any product candidate we develop will depend in part on
the extent to which regulatory authorities and private health insurers establish coverage and reimbursement. Failure to obtain or maintain coverage and reimbursement for our product candidates, if approved, could limit our ability to market those
products and decrease our or our ability to generate revenue. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any product candidate is approved for marketing, coverage and reimbursement for such
product by governmental healthcare programs, such as Medicare and Medicaid, private health insurers, and other third-party payors would be essential for most patients to be able to afford the prescription medication. Our ability to achieve
acceptable levels of coverage and reimbursement for products or procedures using our products will therefore have an effect on our ability to successfully commercialize any product candidates we develop. We cannot be sure that coverage and
reimbursement will be available for our product candidates, if and when such candidates obtain marketing approval, and any reimbursement that may become available may not be adequate and may be decreased or eliminated in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause third-party payors to limit both
coverage and the level of reimbursement for newly approved products and, as a result, such payors may not cover or provide adequate payment for any product we commercialize. We expect to experience pricing pressures in connection with the sale of
our product candidates due to the trend toward managed health care and additional legislative, administrative, or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and related
administration procedures, has become intense and new products face increasing challenges in entering the market successfully. Third-party payors are increasingly challenging the price and examining the cost-effectiveness of new products in addition
to their safety and efficacy. To obtain or maintain coverage and reimbursement for any product, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also need to provide discounts to purchasers to encourage purchasing of any approved product and rebates to third party payors to increase the possibility of
favorable coverage and adequate cost sharing thresholds for patients. We may be required to provide discounts or rebates on any approved product under government healthcare programs or to certain government and private purchasers in order to obtain
coverage under federal health care </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
programs such as Medicaid. Participation in such programs would require us to track and report certain drug prices. We may be subject to fines and other penalties if we fail to report such prices
accurately. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and
reimbursement for products can differ significantly from payor to payor, and one third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide similar coverage. Additionally, the process for
determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the price of such product or establishing the reimbursement rate that the payor will pay for the product once coverage is
approved. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance
that coverage and reimbursement will be obtained or will be consistent across payors. And, even if products are covered, third party payors may implement various mechanisms to control utilization (e.g., requiring prior approval for coverage for each
patient). Additionally, coverage and reimbursement for screening and diagnostic tests associated with any products would be assessed and determined separately. Furthermore, rules and regulations regarding reimbursement change frequently, in some
cases at short notice, and we believe that changes in these rules and regulations are likely. If coverage or reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product
candidates and may not be able to obtain a satisfactory financial return on our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also be subject to extensive governmental price controls
and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many
countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.
Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside of the United States, the reimbursement for products we commercialize may
be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the
development of our product candidates, even if a product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for
commercial success. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare
payors and the medical community. Various factors will influence whether our product candidates are accepted in the market if approved for commercial sale, including, but not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efficacy, safety and tolerability of our products, and potential advantages compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the clinical indications for which the product is approved, and product labeling or product insert requirements of the
FDA, EMA or other comparable foreign regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of treatment in relation to alternative treatments, including any similar treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability and access to screening and/or diagnostic tests; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of third-party coverage and reimbursement for any of our products that are approved and any screening
and/or diagnostic testing, as appropriate; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any restrictions on the use of our product together with other medications. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Market acceptance of our product candidates is heavily dependent on patients&#8217; and physicians&#8217; perceptions
that our product candidates are safe and effective treatments for their targeted indications and willingness to use screening and/or diagnostic tests to identify <FONT STYLE="white-space:nowrap">at-risk</FONT> target populations for our
therapeutics. The perceptions of any product are also influenced by perceptions of competitors&#8217; products that are in the same class or that have a similar mechanism of action. Because we expect sales of our product candidates, if approved, to
generate substantially all our revenues in the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If approved, our product candidates that are regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;) was enacted as part of the Affordable Care Act (&#8220;ACA&#8221;) to
establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of
a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, a reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will
not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. In addition, the approval of a biosimilar product may not be
made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still develop and receive approval of a
competing biologic, so long as their BLA does not rely on the reference product, sponsor&#8217;s data or submit the application as a biosimilar application. Any new policies or processes adopted by the FDA could have a material adverse effect on the
future commercial prospects for our biological products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that any of the product candidates we develop that is approved in the United States as a
biological product under a BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA
will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved,
will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace
and regulatory factors that are still developing. The approval of a biosimilar of our product candidates could have a material adverse impact on our business due to increased competition and pricing pressure. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product candidates, and are unable to establish sales, marketing and distribution capabilities either on our own
or in collaboration with third parties, we may not be successful in commercializing any product candidates we develop, if approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market and
successfully commercialize any product candidates we develop, if approved, we must build our sales and marketing capabilities or enter into collaborations with third parties for these services. We currently have no sales, marketing or distribution
capabilities and as a company have no experience in marketing products. If we commercialize any of our product candidates that may be approved ourselves, we will need to develop an <FONT STYLE="white-space:nowrap">in-house</FONT> marketing
organization and sales force across rare disease therapeutic areas, which will require significant expenditures, management resources, and time. There are significant expenses and risks involved with establishing our own sales and marketing
capabilities, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales leads and provide our sales and marketing team with adequate access to physicians who
may prescribe our products, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train, and
retrain marketing and sales personnel. Any failure or delay in the development of a product candidate that affects the expected timing of commercialization of the product candidate or results in the failure of the product candidate to be
commercialized could result in us having prematurely or unnecessarily incurred costly commercialization expenses. Our investment would be lost if we are unable to retain or reposition our sales and marketing personnel. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also enter into collaborations for the sales and marketing of our product candidates, if approved. To the extent that we depend on collaborators for sales and
marketing activities, any revenues we receive will depend upon the success of those collaborators&#8217; sales and marketing teams and the collaborators&#8217; prioritization of our products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and compliance with applicable regulatory requirements, and there can be no assurance that the collaborators&#8217; efforts will be successful. If we are unable to build our own sales and
marketing team or enter into a collaboration for the commercialization of product candidates we develop, if approved, we may be forced to delay the commercialization of our product candidates or reduce the scope of our sales or marketing activities,
which would have an adverse effect on our business, operating results and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Under the current presidential administration, we face uncertainty
regarding potential regulatory developments that may adversely affect our business if we continue to progress the development of our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been significant and wide-ranging changes in law, regulation and policy under the current Trump administration. Current and future adopt legislation,
regulation, or policy could adversely affect our business or creates a more challenging and costly environment to pursue the development and commercialization of our current or future product candidates. For example, the federal government,
including the FDA, may implement legislative, regulatory, or policy changes regarding the standards for approving biologic products that we may be unable to satisfy or regarding the marketing of approved biologics that may limit or prohibit the
advertising and promotion of our current or future product candidates, if approved. Additionally, the Trump administration has undertaken significant efforts to reduce the size and spending of the federal government, including at the FDA. A
significant reduction in the FDA&#8217;s workforce or the FDA&#8217;s budget or other disruptions at the FDA could impact the FDA&#8217;s ability to engage in routine regulatory and oversight activities and result in delays or limitations on our
ability to proceed with clinical development programs and obtain regulatory approvals. It is difficult to predict how executive actions that may be taken under the current Trump administration may affect the FDA&#8217;s ability to exercise its
regulatory authority. If such executive actions impose constraints on the FDA&#8217;s ability to engage in routine oversight and product review activities in the normal course, our business may be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Dependence on Third Parties </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to
progress the development of our product candidates, we may pursue business development transactions and collaborate with third parties for the development and commercialization of our product candidates. We may not succeed in identifying and
acquiring businesses or assets, <FONT STYLE="white-space:nowrap">in-licensing</FONT> or out-licensing intellectual property rights or establishing and maintaining collaborations, which may significantly limit our ability to successfully develop and
commercialize our product candidates, if at all, and these transactions could disrupt our business, cause dilution to our stockholders or reduce our financial resources. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired all rights to RLYB116 and RLYB114 from Sobi in 2019. We also obtained worldwide exclusive rights to RLYB332 from Sanofi in 2022. If we continue to progress
the development of our product candidates, we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> rights to product candidates, products or technologies, acquire other businesses or enter into collaborations with third parties. We may
not be able to enter into such transactions on favorable terms, or at all. Any such acquisitions, <FONT STYLE="white-space:nowrap">in-licenses</FONT> or collaborations may not strengthen our competitive position, and these transactions may be viewed
negatively by analysts, investors, customers, or other third parties with whom we have relationships. We may decide to incur debt in connection with an acquisition, or <FONT STYLE="white-space:nowrap">in-license</FONT> or issue our common stock or
other equity securities as consideration for the acquisition, which would reduce the percentage ownership of our existing stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We could incur losses
resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may not be able to successfully integrate the acquired personnel,
technologies, and operations into our existing business in an effective, timely, and <FONT STYLE="white-space:nowrap">non-disruptive</FONT> manner. Such transactions may also divert management attention from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> responsibilities, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or <FONT
STYLE="white-space:nowrap">in-licenses</FONT> or the effect that any such transactions might have on our operating results. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not realize the anticipated
benefits of any current or future collaboration, each of which involves or will involve numerous risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may shift its priorities and resources away from our product candidates due to a change in business
strategies, or a merger, acquisition, sale, or downsizing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may seek to renegotiate or terminate its relationship with us due to unsatisfactory clinical results,
manufacturing issues, a change in business strategy, a change of control or other reasons; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may cease development in therapeutic areas that are the subject of our collaboration;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may not devote sufficient capital or resources towards our product candidates, or may fail to comply with
applicable regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may change the success criteria for a product candidate, thereby delaying or ceasing development of such
candidate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a significant delay in initiation of certain development activities by a collaborator will also delay payment of
milestones tied to such activities, thereby impacting our ability to fund our own activities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator could develop a product that competes, either directly or indirectly, with our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator with commercialization obligations may not commit sufficient financial resources or personnel to the
marketing, distribution, or sale of a product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to
meet demand requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may terminate a strategic alliance; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a dispute may arise between us and a collaborator concerning the research, development, or commercialization of a product
candidate resulting in a delay in milestones or royalty payments or termination of the relationship and possibly resulting in costly litigation or arbitration, which may divert management&#8217;s attention and resources; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may use our products or technology in such a way as to invite litigation from a third-party.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or
commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we
are unable to establish and maintain collaborations on acceptable terms or to successfully transition away from terminated collaborations, we may have to delay or discontinue further development of one or more of our product candidates, undertake
development and commercialization activities at our own expense, or find alternative sources of capital, which would have a material adverse impact on our clinical development plans and business. If we fail to establish and maintain collaborations
related to our product candidates, we could bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise for which we
have not budgeted. This could negatively affect the development and commercialization of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may face significant competition in identifying
and acquiring businesses or assets, <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property rights and seeking appropriate collaboration partners for our product candidates, and the negotiation process may be time-consuming and
complex. In order for us to successfully partner our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and
other products or product candidates available for licensing from or in connection with collaborations with other companies. Our success in acquiring business or assets or in partnering with collaborators may depend on our history or perceived
capability of successful product development. Even if we are successful in our efforts to acquire businesses or assets, <FONT STYLE="white-space:nowrap">in-license</FONT> intellectual property rights or establish collaborations, we may not be
successful in developing such product candidates or technologies or able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our reliance on a central team consisting of a limited number of employees and third parties who provide various administrative, research and development, and
other services across our organization presents operational challenges that may adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had 14
full-time employees, upon whom we rely for various administrative, research and development, business development and other support services shared among our subsidiaries. The size of our centralized team may limit our ability to devote adequate
personnel, time, and resources to support the operations of all of our subsidiaries, including their research and development activities, the management of financial, accounting, and reporting matters, and the oversight of our third-party vendors
and partners. If our centralized team or our third-party vendors and partners performing such functions fail to provide adequate administrative, research and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
development, or other services across our entire organization, our business, financial condition, and results of operations could be harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Misconduct by
our employees and independent contractors, including principal investigators, CROs, consultants, vendors and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other
pharmaceutical functions and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate various laws, including: (i)&nbsp;the laws and regulations of the FDA, and other similar regulatory
authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii)&nbsp;manufacturing standards; (iii)&nbsp;data privacy, security, fraud and abuse and other healthcare laws and
regulations; or (iv)&nbsp;laws that require the reporting of true, complete and accurate financial information and data. Sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to
prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and
other business arrangements. Activities such as the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials, or illegal misappropriation of
drug product, could also result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are
subject to the risk that a person or government agency could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us or them and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in
Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of
our operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We currently rely and will rely on third parties for the manufacture of drug substance and drug product for our preclinical studies and
clinical trials and, if we continue to progress the development of our product candidates, expect to continue to do so for commercialization of any product candidates that we may develop that are approved for marketing. Our reliance on third parties
may increase the risk that we will not have sufficient quantities of such drug substance, product candidates, or any products that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could
delay, prevent, or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have limited personnel with experience in manufacturing, and we do not own
facilities for manufacturing RLYB116 or any other product candidate. Instead, we rely on and expect to continue to rely on contract manufacturers for the supply of cGMP-drug substance and drug product of RLYB116 and any other product candidates we
develop and, in the future, for commercial supply. Reliance on third parties may expose us to more risk than if we were to manufacture our product candidates ourselves. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be unable to establish necessary supply agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements
with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible breach of the manufacturing agreement by the third-party; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for
us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reliance on the third-party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related
reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible inability of third-party suppliers to supply and/or transport materials, components and products to us in a
timely manner as a result of disruptions to the global supply chain. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third-party manufacturers may fail to comply with cGMP regulations or similar regulatory requirements outside the
United States. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities
or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to
significant delays in the availability of our product candidates for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product
candidates. Moreover, our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal
of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business,
financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we provide oversight of manufacturing activities, we have limited ability to control the execution
of manufacturing activities by, and are or will be dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates by our CMOs. As a result, we are subject to the risk that our product candidates may have
manufacturing defects or fail to comply with regulatory requirements, which we have limited ability to prevent. CMOs may also have competing obligations that prevent them from manufacturing our product candidates in a timely manner. If a CMO cannot
successfully manufacture drug substance that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial
distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance, and qualified personnel, and we were not involved in developing our
CMOs&#8217; policies and procedures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The facilities and processes used to manufacture our product candidates are subject to inspection by the FDA, EMA and other
comparable foreign authorities. If the FDA, EMA or other comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds
deficiencies in the future, we may need to find alternative manufacturing facilities or conduct additional studies, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for, or
commercialize our product candidates, if approved. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or
otherwise inconvenient for us. Finding new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our
clinical trials and potential regulatory approval of our product candidates. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We have limited
ability to control the process or timing of the acquisition of these raw materials by our CMOs. Moreover, we currently do not have any agreements for the production of these raw materials. Supplies of raw materials could be interrupted from time to
time and we cannot be certain that alternative supplies could be obtained within a reasonable time frame, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product
candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost
effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of
the manufacture of our product candidates. Moreover, our product candidates utilize drug substances that are produced on a small scale, which could limit our ability to reach agreements with alternative suppliers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply
with and respect the intellectual property and proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes, misappropriates or otherwise violates the intellectual property or the
proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain
regulatory approval for, or commercialize our product candidates, if approved. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our collaborators also may breach their agreements with us or otherwise fail to
perform to our satisfaction, which could impact the development timeline of our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product
candidates, we will continue to rely on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If we fail to effectively oversee and manage these third parties, if they do not successfully carry out their
contractual duties, or if they perform in an unsatisfactory manner, it may harm our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely, and will continue to rely, on CROs, <FONT
STYLE="white-space:nowrap">CRO-contracted</FONT> vendors, and clinical trial sites to ensure the proper and timely conduct of our clinical trials. Our reliance on CROs for clinical development activities limits our control over these activities, but
we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and our CROs will be required to comply with the GLP requirements for our preclinical studies and GCP requirements for our clinical trials. Regulatory authorities
enforce GCP requirements through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we, or our CROs, fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed
unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements and may require a large number of patients. Our failure or any failure by our CROs, investigators, CMOs or other third parties to comply
with regulatory requirements or to recruit enough patients may delay ongoing or planned clinical trials or require us to repeat clinical trials, which would delay the regulatory approval process. Failure by us or by third parties we engage to comply
with regulatory requirements can also result in fines, adverse publicity, and civil and criminal sanctions. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and
regulations or healthcare privacy and security laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our CROs, vendors and clinical trial investigators are not our employees, and we do not control whether they
devote sufficient time and resources to our clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development
activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs and other third parties involved in our preclinical studies and clinical trials,
which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs and other third parties involved in our trials do not successfully carry out their contractual duties or
obligations, or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical
trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidates that we develop. As a result, our financial results and the commercial prospects for any
product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our relationship with any
CRO terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition,
there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with
our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Healthcare Laws and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to progress the development of our product candidates, enacted and future healthcare legislation may increase the difficulty and cost for us to
obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and other
jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes, and additional proposed changes, to the healthcare system that could affect our future results of operations. In particular,
there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of health care. As an earlier example with longstanding impact, in March 2010, the ACA was
enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. The ACA expanded health care coverage through a Medicaid eligibility expansion and the implementation of the individual mandate for health
insurance coverage. The ACA also imposed an annual fee payable on manufacturers of branded prescription drugs and biologic agents (other than those designated as orphan drugs) and implemented changes to the coverage and reimbursement of drug
products under government healthcare programs, including an expansion in the Medicaid drug rebate program, an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid drug rebate program, and the establishment of a new
Medicare Part D coverage gap discount program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beyond the ACA, there have been ongoing healthcare reform efforts, including efforts focused on drug pricing and
payment. For example, the Inflation Reduction Act (&#8220;IRA&#8221;) of 2022 includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D. These changes include caps on Medicare Part D <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, Medicare Part B and Part D drug price inflation rebates, a new Medicare Part D manufacturer discount drug program (replacing the ACA Medicare Part D
coverage gap discount program) and a drug price negotiation program for certain high spend Medicare Part B and D drugs (with negotiated prices for the first set of drugs taking effect in 2026). The IRA has had and will likely continue to have a
significant impact on the pharmaceutical industry. Additionally, changes to Medicaid effective in 2024 eliminated the Medicaid rebate cap. And changes to certain Medicare price reporting requirements for drugs beginning in 2026 will likely increase
the administrative and compliance burden for manufacturers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recently, drug pricing and payment has been subject to a number of reform initiatives. For example,
President Trump issued an Executive Order in April 2025 with multiple directives aimed at lowering drug prices, including refining the Medicare drug price negotiation program established by the IRA; accelerating competition for high-cost
prescription drugs by accelerating approval of generics and biosimilars and facilitating the process for <FONT STYLE="white-space:nowrap">re-classifying</FONT> prescription drugs as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> drugs; and increasing drug importation. In May 2025, President Trump issued another Executive Order that directed government agencies and officials to
identify most-favored nation pricing targets for prescription drugs (and looked to pharmaceutical manufacturers to make significant progress towards delivering target prices to patients); prevent foreign countries from disproportionately shifting
the cost of global pharmaceutical research and development to the United States; and facilitate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> purchasing programs for pharmaceutical manufacturers
to sell their products to patients at the most-favored-nation price. In the wake of the Executive Orders and related executive initiatives, a number of pharmaceutical manufacturers have announced <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> offerings with discounted prices and/or reached agreement with the federal government regarding pricing for drugs, including prices for Medicaid drugs and newly launched products. A website
sponsored by the federal government that is anticipated to offer pharmaceutical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> channels in the future has also been launched. Federal agencies are
developing new drug pricing pilot programs, such as a voluntary Medicaid initiative which would authorize the federal government to negotiate Medicaid supplemental rebates with participating manufacturers on behalf of state Medicaid programs, in
exchange for standardized coverage criteria for participating manufacturer drugs, and proposed Medicare Part B and D pilot models that, if finalized as proposed, would replace existing inflation-based Medicare rebates with rebates determined on the
basis of international prices, for drugs and patients subject to the model. Many of these reform initiatives would require additional legal and/or administrative action to implement and may be subject to legal challenge. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other federal healthcare reform efforts or actions may affect access to healthcare coverage or the funding of health care benefits, although the full impact of such
efforts or actions cannot be predicted. For example, the Congressional Budget Office has estimated that Medicaid provisions in the 2025 budget reconciliation legislation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
including restrictions in eligibility and funding for Medicaid, as well as changes to the healthcare marketplace such as the elimination of certain subsidies, will increase the number of
uninsured. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, measures designed to
encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Healthcare reform efforts have been and may continue to be subject to scrutiny, legal challenge and
subsequent amendment, creating further uncertainty. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other recent government actions may also affect prices or payments for prescription drugs. For example, the
Trump Administration&#8217;s recently announced tariff on branded or patented drugs may increase the cost of drug products that are imported from abroad or manufactured using products or materials imported from abroad. The timeline for
implementation of this tariff has not yet been finalized. As another example, the Budget Control Act, as amended, resulted in the imposition of reductions in Medicare (but not Medicaid) payments to providers in 2013 and will remain in effect through
2032 unless additional Congressional action is taken. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be
imposed on us could have an adverse impact on our results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Healthcare or other reform initiatives could affect demand for, or pricing of, any future
products if approved for sale. We cannot, however, predict the ultimate content, timing or effect of any federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business
and financial results. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have
instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other
jurisdiction. If we, or any third parties we may engage, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance,
our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we continue to
progress the development of our product candidates, our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others
will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business operations and current and future arrangements
with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain
the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws, some of which may apply only after our products
are approved for marketing, include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person
from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting,
receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and
Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. HIPAA which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits
executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such
products prior to approval or for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal laws that require pharmaceutical manufacturers to calculate, report and certify certain complex product
prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal Open Payments (or federal &#8220;sunshine&#8221; law), which requires pharmaceutical and medical device
companies to monitor and report certain financial interactions with certain healthcare providers to Centers for Medicare &amp; Medicare Services (&#8220;CMS&#8221;) for <FONT STYLE="white-space:nowrap">re-disclosure</FONT> to the public, as well as
ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities
that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring
pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or report information related to payments to health care providers, marketing
expenditures or drug prices; state and local laws requiring the registration of pharmaceutical sales representatives; state laws regulating the manufacture and distribution of biopharmaceutical products; and state laws governing privacy, security,
and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. laws and regulations prohibiting bribery and corruption, such as the U.S. Foreign Corrupt Practices Act
(&#8220;FCPA&#8221;), which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign
government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing
interactions with and payments to healthcare providers and laws governing the privacy and security of personal information, such as, where applicable, the General Data Protection Regulation (&#8220;GDPR&#8221;) which imposes obligations and
restrictions on the collection, use, and disclosure of personal data relating to individuals located in the EU and the European Economic Area (&#8220;EEA&#8221;) (including health data). See &#8220;&#8212;Our business operations may subject us to
data protection laws, including the GDPR, the United Kingdom (&#8220;UK&#8221;) GDPR, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) and other similar laws.&#8221; </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare and other laws and regulations will involve substantial
costs. Given the breadth of the laws and regulations and narrowness of any exceptions, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, regulatory authorities may possibly
conclude that our business practices may not comply with healthcare laws and regulations, including our consulting agreements and other relationships with healthcare providers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject
to actions including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, individual imprisonment,
contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Further, defending against
any such actions can be costly, time consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business operations may subject us to data protection laws, including the GDPR, the UK GDPR, the CCPA and other similar laws. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The GDPR and UK GDPR apply to companies established in the EEA and UK, respectively, as well as to companies that are not established in the EEA or UK, respectively,
and which collect and use personal data in relation to (i)&nbsp;offering goods or services to, or (ii)&nbsp;monitoring the behavior of, individuals located in the EEA or UK, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
If we conduct clinical trial programs in the EEA or UK (whether the trials are conducted directly by us or through a clinical vendor or collaborator), enter into research collaborations involving
the monitoring of individuals in the EEA or UK, or market our products to individuals in the EEA or UK, we will be subject to the GDPR or UK GDPR, as applicable, which place stringent operational requirements for processors and controllers of
personal data of individuals in the EEA and UK, respectively. If our or our collaborators&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR or UK GDPR requirements, we may be subject to litigation,
regulatory investigations, enforcement notices requiring us to change the way we use personal data, temporary or definitive bans on data processing, or fines of up to 20&nbsp;million Euros in the case of GDPR or &pound;17.5&nbsp;million in the case
of UK GDPR or, in each case, up to 4% of our total worldwide annual revenue of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, including class-action type litigation, negative publicity,
reputational harm and a potential loss of business and goodwill. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recent legal developments in Europe have created complexity and uncertainty regarding transfers of
personal data from the EEA and the UK to the United States. On July&nbsp;16, 2020, the Court of Justice of the European Union (&#8220;CJEU&#8221;) invalidated the <FONT STYLE="white-space:nowrap">EU-US</FONT> Privacy Shield Framework (the
&#8220;Privacy Shield&#8221;) under which personal data could be transferred from the EEA to US entities who had self-certified under the Privacy Shield scheme. This framework has been replaced by the
<FONT STYLE="white-space:nowrap">E.U.-U.S.</FONT> Data Privacy Framework, for which the EC adopted an adequacy decision in July 2023, and the UK Extension to the <FONT STYLE="white-space:nowrap">E.U.-U.S.</FONT> Data Privacy Framework, which took
effect in October 2023. While we do not currently rely upon these frameworks, we expect there to be legal challenges to this framework in the future, which could draw into question the legitimacy of other cross-border transfer mechanisms, including
the standard contractual clauses on which we rely to transfer personal data from the EEA and UK to the U.S. and other jurisdictions. On June&nbsp;4, 2021, the EC released two revised sets of standard contractual clauses for transfers of personal
data from the EEA to the U.S. and has indicated that it will release additional revised standard contractual clauses in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These recent developments may
require us to review and amend the legal mechanisms by which we make and/ or receive personal data transfers to/ in the United States. Other countries outside of the EEA and UK maintain different privacy laws that we are subject to which may further
increase our costs of compliance and expose us to greater legal risk. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are numerous U.S. federal and state laws and regulations related to the privacy and
security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information,
and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information.
Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. While we do not believe that we are
directly subject to HIPAA as either a &#8220;covered entity&#8221; or &#8220;business associate,&#8221; U.S. sites at which we conduct clinical trials are likely to be covered entities and thus must ensure that they obtain adequate patient
authorization or establish another basis under HIPAA to disclose a clinical trial subject&#8217;s individually identifiable health information to us and other entities participating in our clinical trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the CCPA imposes many obligations for the collection, processing, and sharing of personal information of California residents. The CCPA provides
for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Because we have not yet generated revenue and do not meet the CCPA&#8217;s other jurisdictional tests, we
do not yet meet the applicable threshold for the CCPA to apply to our business. If our business becomes subject to CCPA in the future, it could increase our compliance costs and potential liability. Similar laws have been proposed or passed in more
than half of the states in the U.S. and in the U.S. Congress. In addition, Washington state enacted the My Health, My Data Act, a health-focused consumer privacy law, which took effect in March 2024. This law imposes obligations related to the
collection and sharing of certain health-related information that is not subject to HIPAA and that does not fall within certain other exceptions in the law. Other states have enacted, or are in the process of enacting, similar health-focused
consumer privacy laws. Furthermore, all fifty U.S. states, the District of Columbia, Puerto Rico, and other U.S. territories have enacted data breach notification laws that require, among other things, notifications to state
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
governments and/or the affected individuals in the event of a data breach. Such laws differ from one another, and may impose significant compliance burden. Further, we may at times fail, or be
perceived to have failed, to have complied with such laws. This could result in significant consequences, which include, but are not limited to, the imposition of fines and penalties, government enforcement actions, investigations and other
proceedings, as well as additional reporting requirements and/or oversight. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also of note, in June 2024, the Protecting Americans&#8217; Data from Foreign
Adversaries Act of 2024 took effect. This law prohibits data brokers from making available certain personally identifiable sensitive data of U.S. individuals to &#8220;foreign adversary&#8221; countries, such as the People&#8217;s Republic of China
(&#8220;PRC&#8221;), and entities controlled by such countries. Additionally, in January 2025, the DOJ published a final rule implementing President Biden&#8217;s Executive Order 14117, &#8220;Preventing Access to Americans&#8217; Bulk Sensitive
Personal Data and United States Government-Related Data by Countries of Concern,&#8221; which became effective in April 2025. This final rule prohibits certain data brokerage transactions and transactions involving certain bulk human &#8216;omic
data, including human genomic data and biospecimens from which such data can be derived, with restricted jurisdictions, such as the PRC, and &#8220;covered persons&#8221; that have certain ties to such restricted jurisdictions. The final rule also
places restrictions on certain vendor, employment and investment agreements with such jurisdictions. These restrictions may affect our ability to engage in collaborations or license agreements with entities in restricted countries or with a nexus to
such countries going forward. As such, we will need to review periodically our operations in comparison to developments in such laws. Achieving and sustaining compliance with applicable international, federal and state privacy, security, and breach
reporting laws may prove time-consuming and costly. Failure to comply with any of these legal requirements could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or
stoppages in our business operations, including our clinical studies; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend
any claim or inquiry; adverse publicity; or revision or restructuring of our operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to environmental, health and safety laws and
regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release,
and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction,
laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including
liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future
environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to
obtain, maintain and enforce patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize similar or identical technology
and products, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success
depends in large part on our ability to obtain and maintain intellectual property, particularly patents, in the United States and other countries, with respect to any proprietary technology and product candidates we develop. If we are unable to
obtain or maintain patent protection of proprietary technology or product candidates by filing patent applications and/or <FONT STYLE="white-space:nowrap">in-licensing</FONT> related intellectual property in commercially relevant jurisdictions, our
business, financial condition, results of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent prosecution process is expensive, time-consuming and
complex, and we may not be able to identify, file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
timely manner. In some circumstances involving technology that we license from third parties, we do not have the sole right to control the preparation, filing and prosecution of patent
applications or to maintain, enforce and defend the <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents. Therefore, these <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and applications may not be prepared, filed, prosecuted,
maintained, defended and enforced in a manner consistent with the best interests of our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent rights of pharmaceutical and biotechnology companies
generally are highly uncertain, involve complex legal and factual questions and have been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has
emerged in the United States or in numerous foreign jurisdictions. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patent eligibility of certain inventions or discoveries relating to biotechnology.
These decisions conclude, among other things, that abstract ideas, natural phenomena and laws of nature are not themselves patent eligible subject matter. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Precisely what constitutes a law of nature or abstract idea is uncertain, and certain aspects of our technology could be considered ineligible for patenting under
applicable law. In addition, the scope of patent protection outside the United States is uncertain, and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European
patent law precludes the patentability of methods of treatment of the human body. With respect to both owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, we cannot predict whether the patent applications we and our
licensors are currently pursuing will issue as patents that protect our technology and product candidates, in whole or in part, in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from
competitors. Changes in either the patent laws or interpretation of the patent laws in the United States or other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights,
narrow the scope of our patent protection and, more generally, affect the value or narrow the scope of our patent rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Publications of discoveries in the
scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or, in some cases, are not published at all. Therefore,
neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the
future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights are uncertain. In addition, the scope of patent protection outside the United States is uncertain, and laws of foreign countries might not protect our rights to the same extent as the
laws of the United States or vice versa. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and
its scope can be reinterpreted after issuance. Even if our patent applications issue as patents, they might not issue in a form that will provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship,
scope, validity or enforceability, and our patents might be challenged in a variety of proceedings before courts or patent offices in the United States and abroad. Such challenges might result in loss of exclusivity or in patent claims being
narrowed, invalidated or held unenforceable, which could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology without payment to us, and/or limit the duration of the patent protection of our
technology and product candidates. If the breadth or strength of our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or
future product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For these reasons, our patent portfolio might not provide us with sufficient rights to exclude others from using or commercializing
technology and products similar or identical to our technology and product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with
various procedural requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United States Patent and Trademark Office (&#8220;USPTO&#8221;) and foreign patent offices have a number of procedural and documentary requirements that must be
complied with during the patent application and prosecution process. Periodic fees must be paid to the USPTO and foreign patent offices at several stages or annually over the lifetime of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
issued patents and pending patent applications. In certain circumstances, we might rely on our licensing partners to meet procedural, documentary, and fee requirements of the relevant patent
agency. With respect to our patents, we rely outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured, there are situations in which noncompliance can
result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we or our licensors fail to maintain current and future patents and patent applications
covering our product candidates, our competitors might be able to enter the market with similar or identical products or technology, which would have a material adverse effect on our business, financial condition, results of operations, and
prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the world. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is available, adequate judicial and governmental enforcement of such intellectual
property rights may be lacking. Consequently, third parties may attempt to develop and/or commercialize competitive products in foreign countries where we do not have any patent protection and/or where legal recourse may be limited. Further, we may
not be able to prevent third parties from importing products made using our inventions into the United States or other jurisdictions. This may have a significant commercial impact on our business operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate, and even if we do prevail, the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be
inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many countries, including India, China and
certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government
contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant
to our business, our competitive position may be impaired and our business, financial condition, results of operations, and prospects may be adversely affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes to patent laws in the United States and other jurisdictions could diminish the value of our patents, thereby impairing our ability to protect our
products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes in either the patent laws or interpretation of patent laws in the United States or other jurisdictions could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the maintenance, enforcement or defense of our issued patents, all of which could have a material adverse effect on our business. For example, in 2023, patent reform in the EU
created a unitary patent and established a Unified Patent Court (&#8220;UPC&#8221;). The unitary patent facilitates validation of a patent granted by the European Patent Office in the EU member states that participate in the unitary patent. The UPC
is a centralized body with jurisdiction over actions for preliminary injunctions, infringement, and revocation of patents granted by the European Patent Office. While the UPC has exclusive jurisdiction over unitary patents, patentees that do not
utilize the unitary patent for validation can opt existing or future patents out of the jurisdiction of the UPC. There are both risks and benefits associated with pursuing Unitary Patents and with submitting to the jurisdiction of the UPC in the
absence of a Unitary Patent. For example, because the UPC is a relatively new forum, little precedent exists, and the manner in which European patent law will be applied by the UPC is unpredictable, which presents potential risks to a patent&#8217;s
scope and enforceability. In addition, an unfavorable outcome before the UPC could result in a European patent being invalidated in all participating member states. In comparison, European patents that are not under the jurisdiction of the UPC must
be litigated separately in each member state, which causes patent challengers to incur additional costs and leaves open the possibility that a challenged patent could be affirmed in some member states, even if it is invalidated in others. From an
enforcement perspective, the ability to assert patents against infringers under the UPC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
system could have significant financial benefits for a patentee, due to the ability to litigate in a single forum, rather than in each individual member state. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, we do not have any unitary patents and we have opted out of UPC jurisdiction for our existing European patents. While we have and will continue to make <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> decisions about whether to pursue unitary patents or to elect the jurisdiction of the UPC, we cannot be certain that a more favorable outcome could be achieved if
the opposite decision were made. We also cannot be certain whether the legal precedent of the UPC will evolve in a manner that is more or less favorable to us than the precedent of individual member states in a given situation or for a given patent.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to legislative changes, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened
the rights of patent owners in certain situations. This combination of events has increased uncertainty with respect to the validity and enforceability of patents once obtained. Similarly, foreign courts have made, and will likely continue to make,
changes in how the patent laws in their respective jurisdictions are interpreted. Further, political changes in government leadership both within and outside of the U.S. could result in changes to national patent laws and regulations or
multi-country intellectual property treaties, which could impact patent enforcement in the U.S. and internationally. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by
U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to obtain licenses from third parties on commercially reasonable terms, our business could be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to our existing licensing agreements, it may be necessary for us to use the patented or proprietary technology of third parties to commercialize our
products, if approved, in which case we would be required to obtain a license from these third parties. The <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition of third-party intellectual property rights is a competitive area, and a
number of more established companies are also pursuing strategies to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may
have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to
us. These factors might mean fewer suitable licensing opportunities for us, as well as higher acquisition or licensing costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to obtain a
necessary license, the third parties owning such intellectual property rights could seek an injunction prohibiting our development and/or commercialization of the affected product candidates. Even if we are able to obtain a license, the terms may be
unfavorable; for example, it may require substantial licensing or royalty payments, or be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to obtain third-party intellectual property rights or to maintain our existing intellectual property rights, we may be required to expend significant
time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so,
we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with our obligations in our intellectual property licenses with third parties, or otherwise experience disruptions to our business
relationships with our licensors, we could lose intellectual property rights that are important to our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are party to license agreements that
impose upon us certain obligations, and we may enter into additional licensing and funding arrangements with third parties that may impose, among other things, diligence, development, and commercialization timelines, milestone and royalty payments,
and insurance If we fail to comply with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements, in which event we might be forced to cease developing,
manufacturing or marketing any product that is covered by these agreements or may face other penalties under such agreements, or our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
counterparties may require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Termination or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such
agreements may result in our loss of rights or our having to negotiate new or reinstated agreements with less favorable terms, which would impede, delay or prohibit the further development or commercialization of any product candidates that rely on
such agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disputes may arise regarding intellectual property that is or becomes subject to a licensing agreement, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of rights granted under the license agreement and other matters of contract interpretation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether and the extent to which our technology and processes infringe the intellectual property rights of the licensor
that are not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether our licensor or its licensor had the right to grant the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the
intellectual property rights without their authorization; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our involvement in the prosecution of licensed patents and our licensors&#8217; overall patent enforcement strategy;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amounts of royalties, milestones or other payments due under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sublicensing of patent and other rights under collaborative development relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The resolution of any contract disagreement that may arise could narrow the scope of our rights to the relevant intellectual property or technology, could increase our
financial or other obligations under the relevant agreement, or could result in loss of some or all rights under the license agreement. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain
our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates. Any of these outcomes could have a material adverse effect on our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite our efforts, our licensors or future licensors might conclude that we have materially
breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these <FONT
STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors could seek regulatory approval for and market products and technologies identical to
ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms
may not protect our competitive position for an adequate amount of time. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, if all maintenance fees are
timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it
affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for
the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are approved for use or commercialized. As a result, our patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours during periods when commercial exclusivity would be valuable to us. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we do not obtain a patent term extension for any product candidates we might develop, our business might be materially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the term of a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for a patent term extension
(&#8220;PTE&#8221;) of up to five years beyond the expiration date of the patent, as compensation for the patent term </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a PTE of up to five years beyond the
expiration date of the patent. The length of the PTE is related to the length of time the drug is under regulatory review, and cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. The patent term
of only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other
jurisdictions. While we expect to apply for PTE on patents covering our product candidates, there is no guarantee that such extensions will be granted and, even if granted, the length of such extensions. We may not be granted PTE either in the
United States or in any foreign country, even where that patent is eligible for PTE, if, for example, we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply
prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Furthermore, for licensed patents, we might not be able to control whether a petition to obtain a PTE is filed or obtained from the USPTO and/or foreign
patent office(s). If we are unable to obtain any PTE, or if the term of extension is less than we request, our business, financial condition, results of operations and prospects could be materially harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to seeking patents for some of our technology and product candidates, we seek to protect our trade secrets and other proprietary technology, in part, by
entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract research
organizations, contract manufacturers, consultants, advisors and other third parties. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies.
Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we cannot
guarantee that we have entered into confidentiality agreements with each party that may have or has had access to our trade secrets or proprietary technology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Over
time, our trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary information may be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel to and
from academic and industry scientific positions. Consequently, we may be unable to prevent others from exploiting that technology, which could affect our ability to expand in domestic and international markets. If any of our trade secrets were to be
disclosed to or independently developed by a competitor or other third-party, our competitive position would be materially and adversely harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also seek to
preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. These security measures may be breached, and we may
not have adequate remedies for any breach. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in
our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We might be unable to successfully register our trademarks and trade names, and/or to
establish name recognition based on our trademarks and trade names, which could result in substantial costs and diversion of resources, and could adversely impact our ability to compete effectively. In addition, our trademarks or trade names may be
challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using them. At times, competitors may adopt
trademarks or trade names similar to ours, impeding our ability to build brand identity, and possibly leading to market confusion. In addition, we could be subject to trademark or trade name infringement claims brought by owners of other registered
trademarks or trade names. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be
expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors and other third parties may infringe, misappropriate or otherwise violate our patents or other
intellectual property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property claims, which can be expensive and time-consuming. Any claims we assert against others could provoke
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
them to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property rights. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In a patent infringement proceeding, the perceived infringers could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In
patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are common. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of
novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or
made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
<FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings in the European
Patent Office. The outcomes of allegations of invalidity or unenforceability are unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing
partners were unaware during prosecution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An adverse result in any such proceeding could put our patents at risk of being invalidated or interpreted narrowly and
could put our patent applications at risk of not yielding an issued patent. A court may also refuse to enjoin a third-party from using the technology at issue, for example, on the basis that patents do not cover that technology. Furthermore, if the
breadth or strength of protection provided by our current or future patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or
future products or services. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our research programs and clinical trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO might be necessary to determine the priority of inventions
with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party
does not offer us a license on commercially reasonable terms or at all, or if a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our competitors gain access to the same technology. Our defense of interference or
derivation proceedings might fail and, even if successful, might result in substantial costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, because of the substantial amount of discovery required
in connection with intellectual property litigation and other proceedings, there is a risk that some of our confidential information or trade secrets could be disclosed during litigation. This could allow third parties to develop and commercialize
competing technologies and products, and have a material adverse impact on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be
subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We or our licensors may be subject to claims
that former employees, collaborators or other third parties have an interest in our patents, trade secrets or other intellectual property. For example, we may have inventorship or ownership disputes that arise from conflicting obligations of
employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our patents, trade secrets or other intellectual
property. If we or our licensors or collaborators fail in defending any such claims, we may be required to pay monetary damages and we may also lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual
property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a
material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third parties may allege that we are violating their
intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Numerous U.S. and foreign
issued patents and pending patent applications that are owned by third parties exist in the fields in which we are pursuing development candidates. We may not be aware of all such intellectual property
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
rights potentially relating to our technology and product candidates, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product
candidates do not infringe the intellectual property rights of third parties. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe,
misappropriate or otherwise violate any third-party&#8217;s intellectual property rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors may also assert that our product candidates infringe their
intellectual property rights as part of a business strategy to impede our successful entry into those markets. Adversarial proceedings might also be initiated by patent holding companies or other adverse patent owners who have no relevant product or
service revenue, and against whom our own patents might provide little or no deterrence or protection. The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of
success might be initiated and require significant resources and management attention to defend. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain
greater visibility as a public company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A court could hold that third-party patents are valid, enforceable and infringed by our product candidates or activities.
To successfully challenge the validity of a U.S. patent in federal court, we would need to overcome a presumption of validity, which is a high burden that requires clear and convincing evidence of invalidity. There is no assurance that a court would
invalidate the claims of any such U.S. patent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Parties making claims against us may obtain injunctive or other equitable relief that could block our ability to
commercialize our product candidates. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, indemnify customers,
collaborators or other third parties; seek new regulatory approvals; and/or redesign our infringing products, which may not be possible or practical. In addition, if we are found to infringe, misappropriate or otherwise violate a third-party&#8217;s
intellectual property rights, we may be required to obtain a license to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable
terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us. Further, a license
could require us to make substantial licensing and royalty payments. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims by third parties asserting that our employees, consultants
or contractors have wrongfully used or disclosed confidential information or trade secrets of such third parties, that we have misappropriated their intellectual property, or that they own what we regard as our own intellectual property.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our employees, consultants and contractors were previously employed or engaged by universities or other pharmaceutical or biotechnology companies.
Many of them executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and/or <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment or engagement. Although we try to
ensure that the individuals who work for us do not use the intellectual property rights, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may be subject to claims that we
or they have obtained, used, infringed, misappropriated, disclosed or otherwise violated the intellectual property rights of third parties. Any resulting litigation or the threat of litigation may adversely affect our ability to hire employees or
engage consultants and contractors. A loss of key personnel or their work product could hamper or prevent us from developing and commercializing products and product candidates, which could harm our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute
agreements assigning such intellectual property to us, we may be unsuccessful in obtaining such an agreement from each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with
them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could
have a material adverse effect on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail in prosecuting or defending any such claims,
we may be required to pay monetary damages, and we may also lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive position and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property litigation or other legal proceedings relating to intellectual property could cost
substantial resources. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur
significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements involving such proceedings, and if securities analysts or investors perceive these
results to be negative, it could have a substantial adverse effect on the price of our common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future
sales, marketing, or distribution activities. We may not have sufficient resources to conduct such litigation or proceedings adequately. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other
proceedings could compromise our ability to compete in the marketplace. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not
adequately protect our business or permit us to maintain a competitive advantage. For example: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we or our license partners or current or future collaborators might not have been the first to file patent applications
covering our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that our pending or future patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issued patents that we hold rights to may be held invalid or unenforceable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our competitors or other third parties might conduct research and development activities in countries where we do not have
patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that any of our pending patent applications, if issued, will include claims having a scope sufficient to
protect our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that any patents issued to us will provide a basis for an exclusive market for our commercially viable
product candidates or will provide us with any competitive advantages; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if
approved, before the relevant patents that we own or license expire; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may choose not to seek patent protection in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a <FONT STYLE="white-space:nowrap">third-party</FONT> may subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Employees, Managing Our Growth and Our Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are highly dependent on the expertise of the principal members of our management, scientific, and clinical teams. Our scientific and clinical development personnel
have extensive experience developing and implementing novel clinical trial designs and successfully conducting clinical trials in never-before treated patient populations. If we lose one or more of our executive officers or key employees, our
ability to execute our programs and implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited
number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these
additional key personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We may also experience competition for the hiring of scientific and clinical personnel from
universities and research institutions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our employees were previously employed by Alexion Pharmaceuticals, Inc. (now part of AstraZeneca), a potential
competitor. To the extent we employ or engage personnel from competitors, we may be subject to allegations that such individuals have been improperly solicited or have divulged proprietary or other confidential information, or that their former
employers own their research output. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our
research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to
us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If employees seek
alternate employment, we may have to increase reliance on external support to advance our operations. Any workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, and manufacturing personnel
who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing our product candidates in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business and operations would suffer in the event of system failures. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the implementation of security measures, our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from
computer viruses, unauthorized access, natural and manmade disasters (including hurricanes), terrorism, war, and telecommunication and electrical failures. While we do not believe that we have experienced any system failure or accident to date, if
such an event were to occur and cause interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs. For example, the loss of preclinical or clinical trial data from
completed, ongoing, or planned trials, or the loss of other proprietary data, could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We are aware that a third party accessed
the computer systems of one of our contractors and while we believe that such access did not result in loss of our proprietary data or disrupt our operations, we or our contractors may be subject to attacks in the future that could harm our
business. Likewise, we currently rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To
the extent that any disruption were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability, and the development of our product
candidates could be delayed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our proprietary or confidential information may be lost, or we may suffer security breaches. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of
personally identifiable information and other data relating to individuals. In the ordinary course of our business, we and third parties with which we have relationships will continue to collect and store sensitive data, including clinical trial
data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is
critical to our operations. Despite our and our collaborators&#8217; security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to employee error, technical
vulnerabilities, malfeasance, or other disruptions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Several proposed and enacted federal, state and international laws and regulations obligate companies to notify
individuals of security breaches involving personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors, or other organizations with which we have formed
strategic relationships. Although, to our knowledge, neither we nor any such third parties have experienced any material security breach, and even though we may have contractual protections with such third parties, any such breach could compromise
our or their networks and the information stored therein could be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
accessed, publicly disclosed, lost or stolen. Any such access, disclosure, notifications, <FONT STYLE="white-space:nowrap">follow-up</FONT> actions related to such a security breach or other loss
of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and significant costs, including regulatory penalties, fines, and legal expenses, and such an event could disrupt our
operations, cause us to incur remediation costs, damage our reputation, and cause a loss of confidence in us and our or such third parties&#8217; ability to conduct clinical trials, which could adversely affect our reputation and delay the clinical
development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>An active trading market for our common stock may not be sustained. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a market for our common stock is not sustained, it may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict
the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations may be below the expectations of public market analysts and investors, and, as a result of these and other factors, the
price of our common stock may fall. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our failure to meet the listing standards of the Nasdaq could result in the delisting of our common stock. Delisting
could adversely affect the liquidity of our common stock and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be
substantially impaired. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;24, 2025, we received a deficiency notice (the &#8220;Notice&#8221;), from the Listing Qualifications Staff (the
&#8220;Staff of Nasdaq&#8221;), notifying us that, for the prior 30 consecutive business days, the bid price of our common stock had closed below $1.00 per share, thereby failing to satisfy the minimum closing bid price requirement set forth in the
continued listing requirements of Nasdaq Listing Rule 5450(a)(1), (the &#8220;Bid Price Requirement&#8221;). The Notice had no immediate effect on the listing of our common stock on the Nasdaq Global Select Market. In accordance with Nasdaq Listing
Rule 5810(c)(3)(A), we had 180 calendar days, or until August&nbsp;25, 2025, (the &#8220;Compliance Date&#8221;), to regain compliance with the Bid Price Requirement by having shares of our common stock maintain a minimum closing bid price of at
least $1.00 per share for a minimum of 10 consecutive trading days before the Compliance Date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As we had not regained compliance with the Bid Price Requirement by
the Compliance Date, we filed an application to transfer the listing of our common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. On August&nbsp;26, 2025, we received approval from the Staff of Nasdaq to transfer the
listing of our common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, (the &#8220;Approval&#8221;). Our common stock was transferred to the Nasdaq Capital Market effective as of the opening of business on August&nbsp;29,
2025 and has continued to trade under the symbol &#8220;RLYB.&#8221; Nasdaq operates in substantially the same manner as the Nasdaq Global Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq&#8217;s
corporate governance requirements. As a result of the Approval, we were granted an additional <FONT STYLE="white-space:nowrap">180-day</FONT> grace period, or until February&nbsp;23, 2026, (the &#8220;Second Compliance Date&#8221;), to regain
compliance with the Bid Price Requirement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;26, 2026, our stockholders voted in favor of an amendment to our amended and restated certificate of
incorporation to effect a reverse stock split of our issued and outstanding common stock at a ratio ranging from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5</FONT></FONT> shares up to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-20</FONT></FONT> shares, which ratio would be selected by our board of directors. On January&nbsp;26, 2026, our board of directors approved a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-8</FONT></FONT> reverse stock split of our issued and outstanding common stock. On February&nbsp;6, 2026, we effected a reverse stock split at a ratio of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-8</FONT></FONT> shares. The primary goal of the reverse stock split was to increase the per share market price of our common stock to meet the Bid Price Requirement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;24, 2026, we were notified by the Staff of Nasdaq that the closing bid price of our common stock had been $1.00 per share or greater for at least 10
consecutive business days, from February&nbsp;6, 2026 to February&nbsp;23, 2026. Accordingly, we have regained compliance with the Bid Price Requirement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although
we regained compliance with the Bid Price Requirement following the reverse stock split, there can be no assurance that we will continue to meet the Bid Price Requirement, or any other Nasdaq continued listing requirements, in the future. If we fail
to meet any of these requirements, including the Bid Price Requirement, Nasdaq may again notify us that we have failed to meet the minimum listing requirements and initiate the delisting process. If our common stock were delisted from Nasdaq,
trading of our common stock could be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
conducted in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or on an electronic bulletin board established for unlisted securities
such as the Pink Sheets or the OTC Bulletin Board, but there can be no assurance that our common stock will be eligible for trading on such alternative exchange or market. Additionally, if our common stock were delisted from Nasdaq, the liquidity of
our common stock would be adversely affected, the market price of our common stock could decrease, our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially
impaired and transactions in our common stock could lose federal preemption of state securities laws. Furthermore, there could also be a further reduction in our coverage by securities analysts and the news media and broker-dealers may be deterred
from making a market in or otherwise seeking or generating interest in our common stock, which could cause the price of our common stock to decline further. Moreover, delisting may also negatively affect our collaborators&#8217;, vendors&#8217;,
suppliers&#8217; and employees&#8217; confidence in us and employee morale. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market price of our common stock may be volatile, which could result in
substantial losses for investors. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares of our common stock were offered in our IPO in July 2021 at a price of $104.00 per share and between the date of
our IPO and March&nbsp;6, 2026, the closing price per share of our common stock has ranged from as low as $2.00 to as high as $187.20. Some of the factors that may cause the market price of our common stock to fluctuate include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of existing or new competitive product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and results of preclinical studies for any product candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure or discontinuation of any of our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or
announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">commencement or termination of collaborations for our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of expenses related to any of our research programs or product candidates that we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the results of our efforts to develop additional product candidates or products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sales of our common stock by us, our insiders or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effects of public health crises, pandemics and epidemics; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general economic, industry, and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the other factors described in this &#8220;<I>Risk Factors</I>&#8221; section and elsewhere in this proxy
statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular,
has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and
industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation
has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If securities analysts stop publishing research or reports about our business or if they publish negative
evaluations of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our common stock is influenced in part on the research and reports
that industry or financial analysts publish about us or our business. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could
cause our stock price or trading volume to decline. Moreover, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares may be sold into the market, which could cause the market price of our common stock to decline
significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of a substantial number of shares of our common stock in the public market could occur at any
time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. As of March&nbsp;6, 2026, we have 5,289,675 shares of common
stock outstanding. All of these shares may be resold in the public market immediately, unless held by our affiliates who are subject to volume limitations under Rule 144. As of March&nbsp;6, 2026, we also have
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase up to an aggregate of 416,673 shares of common stock outstanding. We may not effect the exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, and a holder
will not be entitled to exercise any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with
its affiliates) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#8217;s election upon 61 days&#8217; notice to us
subject to the terms of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, provided that such percentage may in no event exceed 19.99%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, as
of December&nbsp;31, 2025, certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for
ourselves or other stockholders. On May&nbsp;9, 2023, we registered an aggregate of 1,543,950 shares of common stock held by holders with registration rights, for resale, pursuant to a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3.</FONT> In addition, we have entered into the Sales Agreement with TD Cowen to offer and sell shares of our common stock having an aggregate offering price of up to $100,000,000, from time to time, through an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offering program. We also registered an aggregate of 1,737,094 shares of common stock that we may issue under our equity compensation plans or that are issuable
upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that
they will be sold, in the public market, the market price of our common stock could decline. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Insiders have substantial influence over us, which could limit
your ability to affect the outcome of key transactions, including a change of control. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our directors and executive officers and their affiliates
beneficially own shares representing approximately 25% of our outstanding common stock as of March&nbsp;6, 2026. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring
stockholder approval, including the election of directors and approval of significant corporate transactions. The interests of these holders may not always coincide with our corporate interests or the interests of other stockholders, and they may
act in a manner with which you may not agree or that may not be in the best interests of our other stockholders. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the
market price of our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is
especially relevant for us because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. Because of the potential volatility of our stock price, we may become the target of securities
litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital
appreciation, if any, will be your sole source of gain. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid any cash dividends on our common stock. We currently anticipate that
we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, of our common stock will
be your sole source of gain on an investment in our common stock in the foreseeable future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an &#8220;emerging growth company,&#8221; and the reduced
disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an &#8220;emerging growth
company,&#8221; as defined in the JOBS Act and we may remain an emerging growth company (an &#8220;EGC&#8221;) until December&nbsp;31, 2026. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from
certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002 (&#8220;SOX Section&nbsp;404&#8221;), not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the
auditor&#8217;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding advisory vote on
executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to other public
companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common
stock, and our stock price may be more volatile. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying
with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended
transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised
standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period, or (ii)&nbsp;no longer qualify as an emerging growth company. Therefore, the reported results of
operations contained in our financial statements may not be directly comparable to those of other public companies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Provisions in our amended and restated
certificate of incorporation, our amended and restated bylaws and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent
attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated
bylaws and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might
otherwise receive a premium for your shares. Our amended and restated certificate of incorporation and bylaws include provisions that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder
approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">specify that special meetings of our stockholders can be called only by our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though
less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">specify that no stockholder is permitted to cumulate votes at any election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated
certificate of incorporation and amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These provisions, alone or together, could delay or prevent hostile takeovers and
changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section&nbsp;203 of the DGCL which prohibits a person who owns
in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or
combination is approved in a prescribed manner. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law
that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for
our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our amended and restated certificate of incorporation designates the state or federal courts within the State of Delaware as the exclusive
forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state or federal courts (as appropriate) within the
State of Delaware are exclusive forums for (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our
stockholders, (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, (4)&nbsp;action against us or any of our
directors or officers involving a claim or defense arising pursuant to the Exchange Act or the Securities Act, or (5)&nbsp;any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity
purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This exclusive forum
provision does not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter
jurisdiction. For instance, the provision does not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. This choice of
forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors,
officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings,
we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum
selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum provision. If
the federal forum provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The federal forum provision may also impose additional litigation costs on stockholders who assert that the provision is
not enforceable or invalid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General Risks </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A
variety of risks associated with operating internationally could materially adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business strategy includes potentially
expanding internationally. Doing business internationally involves several risks, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">multiple, conflicting, and changing laws and regulations, such as privacy regulations, tax laws, export and import
restrictions, economic sanctions laws and regulations, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional potentially relevant third-party patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">complexities and difficulties in obtaining protection and enforcing our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulties in staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient <FONT
STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limits in our ability to penetrate international markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and
regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of
disease, boycotts, tariffs, curtailment of trade, and other business restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain expenses, including, among others, expenses for travel, translation, and insurance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that
may fall within the purview of the FCPA its books and records provisions, or its anti-bribery provisions, as well as other applicable laws and regulations prohibiting bribery and corruption. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. federal income tax reform could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The rules dealing with U.S. federal, state, and local income taxation are constantly under review through the legislative process and by the IRS and the U.S. Treasury
Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future.
For example, the Tax Cuts and Jobs Act, (the &#8220;TCJA&#8221;), was enacted in 2017 and significantly reformed the Code. The TCJA, among other things, contains significant changes to corporate and individual taxation, some of which could adversely
impact an investment in our common stock. On March&nbsp;27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including temporary beneficial changes to the treatment of NOLs, interest deductibility limitations and payroll tax matters. There also may be technical corrections legislation or other
legislative changes proposed with respect to the TCJA and CARES Act, the effects of which cannot be predicted and may be adverse to us or our stockholders. Additionally, the IRA was enacted in August 2022. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Among other things, the IRA implemented a one percent (1%) excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic corporations,
and a corporate alternative minimum tax of fifteen percent (15%) on book income of certain large corporations. Future changes in tax laws could have a material adverse effect on our business, cash flows, financial condition or results of operations.
In particular, proposed tax legislation could result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government policy directly affecting our business or indirectly affecting us because of impacts on our
customers and suppliers. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">H.R. 1., also known as the One Big Beautiful Bill Act (the &#8220;OBBBA&#8221;), was enacted on July&nbsp;4, 2025.
The legislation includes several provisions that may impact the timing and magnitude of certain tax deductions. Key provisions include the permanent extension of several business tax benefits originally introduced under the TCJA. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential clinical trial or product liability lawsuits against us could cause us to incur substantial liabilities and, if we continue to progress the development
of our product candidates, could limit commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we continue to progress the development of our product
candidates, the use of any product candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of clinical trial and product liability claims. Clinical trial or product
liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits
based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, clinical trial or product
liability claims may result in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">impairment of our business reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of participants from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">significant costs to defend the litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">distraction of management&#8217;s attention from our primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to commercialize a product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">decreased market demand for any product; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">loss of revenue. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical trial and product liability insurance we currently carry, and any additional clinical trial and product liability insurance coverage we acquire in the
future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in
sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidate, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain
product liability insurance on commercially reasonable terms or in adequate amounts. A successful clinical trial or product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our
insurance coverage, could adversely affect our results of operation and business, including preventing or limiting the commercialization of any product candidates we develop. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unfavorable global economic conditions and geopolitical instability could adversely affect our business, financial condition or results of operations.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including changes in
tariffs and other trade restrictions. A severe or prolonged economic downturn, period of sustained increased inflation, tariffs and other trade restrictions or additional global financial crises, could result in a variety of risks to our business,
including weakened demand for our product candidates, if approved, or our ability to raise additional capital when needed on acceptable terms, if at all. For example, the global financial crisis caused extreme volatility and disruptions in the
capital and credit markets. Further, geopolitical instability outside the United States may also impact our operations or affect global markets, such as the invasion of Ukraine by Russia and the Israel-Hamas war. While we do not currently conduct
clinical trials in Ukraine, Russia, or the Middle East, we cannot be certain what the overall impact of these events will be on our business or on the business of any of our third-party partners, including our contract research organizations,
contract manufacturers or other partners. The impact of these events could also expand into other markets where we do business. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption. Any of the foregoing
could harm our business and we cannot anticipate all of the ways in which current geopolitical tensions, the economic climate and the financial market conditions could adversely impact our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have incurred, and will incur increased costs as a result of operating as a public company, and our
management will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company,
we have incurred, and particularly after we are no longer an &#8220;emerging growth company,&#8221; we will incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the
Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Capital Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and
maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other personnel in connection with our efforts to comply with the requirements of
being, a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and
will make some activities more time-consuming and costly. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are
often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in
continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to SOX
Section&nbsp;404, we are required to furnish a report by our management on our internal control over financial reporting with our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC. However, while we remain an emerging
growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404, we will need to
continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate,
validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to
conclude that our internal control over financial reporting is effective as required by SOX Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence
in the reliability of our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Candid </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Candid&#8217;s Limited Operating History, Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid has a limited operating history, has not completed any clinical trials and has no drugs approved for commercial sale, which may make it difficult for
investors to evaluate Candid&#8217;s current business and predict its future success and viability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is a clinical-stage biopharmaceutical company
with a limited operating history. Candid was incorporated in May 2024 and its operations to date have been limited to organizing and staffing the company, business planning, raising capital, licensing key intellectual property rights, conducting
research and development of its drug candidates with itself and with collaborators, scaling up drug candidate manufacturing, preparing for and conducting ongoing and planned preclinical studies and clinical trials, and providing general and
administrative support for these operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is developing four drug candidates, including cizutamig and CND261, which are in clinical development, and
CND319 and CND460, which are in preclinical development, each with respect to autoimmune diseases. Candid has not yet demonstrated an ability to successfully complete any clinical trial, obtain regulatory approvals, manufacture drugs at a commercial
scale, or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful drug commercialization. Consequently, this makes it difficult to evaluate the success of Candid&#8217;s business to date
and assess its future viability, and any predictions made about Candid&#8217;s future success or viability may not be accurate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid expects to incur
significant losses for the foreseeable future and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Investment in biopharmaceutical drug development is highly
speculative because it entails substantial upfront capital expenditures and the significant risk that drug candidates will fail to demonstrate adequate efficacy and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
an acceptable safety profile, gain regulatory approval or become commercially viable. For the year ended December&nbsp;31, 2025 and the period from May 1, 2024 (inception) to December 31, 2024,
Candid&#8217;s net loss was $92.2&nbsp;million and $174.3&nbsp;million, respectively. As of December&nbsp;31, 2025, Candid had an accumulated deficit of $266.5&nbsp;million. Substantially all of Candid&#8217;s operating losses have resulted from
expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid expects
to continue to incur significant expenses and additional operating losses for the foreseeable future as it seeks to advance its current and any future drug candidates through preclinical and clinical development, expand its research and development
activities, develop new drug candidates and advance any new drug candidates through preclinical and clinical development, complete clinical trials, seek regulatory approval and, if regulatory approval is received, commercialize its drug candidates.
Furthermore, the costs of advancing drug candidates into each succeeding clinical phase tend to increase substantially over time. The total costs to advance any of Candid&#8217;s drug candidates to regulatory approval in even a single jurisdiction
would be substantial. Because of the numerous risks and uncertainties associated with drug development, Candid is unable to accurately predict the timing or amount of increased expenses or when, or if, it will be able to generate any revenue from
the commercialization of any approved drugs or achieve or maintain profitability. Candid&#8217;s expenses will also increase substantially as it operates as a public company following the Merger and adds clinical, scientific, operational, financial
and management information systems and personnel, including personnel to support its drug development and planned future commercialization efforts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before Candid
generates any revenue from drug sales, each of its drug candidates will require additional preclinical and/or clinical development, potential regulatory approval in multiple jurisdictions, manufacturing, building of a commercial organization,
substantial investment and significant marketing efforts. Candid&#8217;s expenses could increase beyond expectations if Candid is required by the FDA, the EMA, or comparable foreign regulatory authorities to perform preclinical studies and clinical
trials in addition to those that Candid currently anticipates, and/or to modify any of its manufacturing processes or make other changes to its drug candidates or development programs. As a result, Candid expects to continue to incur net losses and
negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on Candid&#8217;s stockholders&#8217; equity and working capital. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As Candid continues to build its business, its financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a
variety of factors, many of which are beyond Candid&#8217;s control. For example, as Candid enters into multiple Phase 2 studies for its lead drug candidate, cizutamig, Candid anticipates a significant increase in expenses relative to its historical
expenses for preclinical and early stage clinical development activities. Accordingly, investors should not rely upon the results of any particular quarterly or annual period as indications of future operating performance. If Candid is unable to
develop and commercialize one or more of its drug candidates either alone or with collaborators, or if revenues from any drug candidate that receives regulatory approval are insufficient, Candid will not achieve profitability. Even if Candid does
achieve profitability, it may not be able to sustain or increase profitability. If Candid is unable to achieve and then maintain profitability, the value of its securities will be adversely affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid will need to obtain substantial additional funding to complete the development and any commercialization of its current and any future drug candidates,
which may cause dilution to Candid&#8217;s stockholders. If Candid is unable to raise this capital when needed, it may be forced to delay, reduce or eliminate its research and development programs or other operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The development of biopharmaceutical drug candidates is capital-intensive. Candid expects to spend substantial amounts to advance its drug candidates into clinical
development and to complete the clinical development of, seek regulatory approvals for and commercialize its drug candidates, if approved. Candid&#8217;s expenses are expected to increase substantially in connection with its ongoing and planned
development activities, particularly as it conducts its planned Phase 2 studies of cizutamig. In addition, as Candid&#8217;s drug candidates progress through development and toward commercialization, Candid will need to make milestone payments to
the licensors from whom it has <FONT STYLE="white-space:nowrap">in-licensed</FONT> its drug candidates. Candid will require additional capital beyond the proceeds of the Concurrent Financing, which it may raise through public or private equity or
debt financings or other capital sources, which may include strategic collaborations and other strategic arrangements with third parties, to enable Candid to complete the development and potential commercialization of its drug candidates or any
future new drug candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Furthermore, upon the Closing, Candid expects to incur additional costs associated with operating as a public company. Adequate additional financing may not be available to Candid on acceptable
terms, or at all. Candid&#8217;s failure to raise capital as and when needed would have a negative effect on its financial condition and its ability to pursue its business strategy. In addition, attempting to secure additional financing may divert
the time and attention of Candid&#8217;s management from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and harm its development efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, Candid&#8217;s cash and cash equivalents and short-term investments were $223.3&nbsp;million. Based on Candid&#8217;s planned use of the
net proceeds of the Concurrent Financing, Rallybio Net Cash and its current cash and cash equivalents, Candid estimates that its funds will be sufficient to enable Candid to fund its operating expenses and capital expenditure requirements through
2030. In particular, Candid expects that the net proceeds from the Concurrent Financing, Rallybio Net Cash and its existing cash and cash equivalents will allow Candid to fund the advancement of its drug candidates through multiple clinical
milestones, including the initiation and interim results of planned Phase 2 clinical studies for cizutamig in gMG and <FONT STYLE="white-space:nowrap">SARD-ILD,</FONT> and Phase 1 clinical trials for CND261, CND319 and CND460. This estimate is based
on assumptions that may prove to be wrong, and Candid could use its available capital resources sooner than currently expected. Changing circumstances could cause Candid to consume capital significantly faster than currently anticipated, and Candid
may need to spend more than currently expected because of circumstances beyond its control. Further, data generated from Candid&#8217;s Phase 1 clinical studies, investigator-initiated studies and/or compassionate use via NPU program for any of its
drug candidates may inform future clinical development, resulting in a reprioritization of resources toward new clinical indications to pursue and the initiation of additional clinical studies in support of any new potential indications. Because the
length of time and activities associated with successful development of Candid&#8217;s drug candidates are highly uncertain, Candid is unable to estimate the actual funds it will require for development and any marketing and commercialization
activities. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number, scope, rate of progress and costs of Candid&#8217;s planned clinical trials for cizutamig, CND261, CND319 and
CND460 and drug discovery and preclinical development activities for any future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and scope of clinical programs Candid decides to pursue, including the number of indications it decides to
pursue for a particular drug candidate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope and costs of manufacturing development for any of Candid&#8217;s current or future drug candidates, including
commercial manufacturing at scale, if any drug candidate receives marketing approval, including as a result of inflation or any supply chain issues; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with hiring additional personnel and consultants as Candid&#8217;s business grows, including
additional research and development personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost, timing and outcome of regulatory review of cizutamig, CND261, CND319 and CND460 and any future drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing Candid&#8217;s intellectual
property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of any milestone and royalty payments to Candid&#8217;s existing or future suppliers, collaborators or
licensors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with enhancing Candid&#8217;s operational systems and being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which Candid acquires or <FONT STYLE="white-space:nowrap">in-licenses</FONT> other drug candidates and
technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with commercializing cizutamig, CND261, CND319 and CND460 or any future drug candidates, if they
receive marketing approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Candid may seek additional capital due to favorable market conditions or strategic considerations, even
if Candid believes it has sufficient funds for its current or future operating plans. To the extent that Candid raises additional capital through the sale of equity or convertible debt securities, stockholder ownership interests will be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
diluted, and the terms of these securities may include liquidation or other preferences that adversely affect stockholder rights. Debt financing and equity financing, if available, may involve
agreements that include covenants limiting or restricting Candid&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Candid raises additional funds through
collaborations, strategic alliances or marketing, distribution, licensing or other similar arrangements with third parties, Candid may be required to relinquish valuable rights to its technologies, future revenue streams, research programs or drug
candidates or grant licenses on terms that may not be favorable to Candid. If Candid is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development
or future commercialization efforts or grant rights to develop and market cizutamig, CND261, CND319 and CND460, or any future drug candidates that Candid would otherwise prefer to develop and market itself. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to the Discovery and Development of Candid&#8217;s Drug Candidates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s approach to the development of drug candidates to treat autoimmune diseases is novel and unproven, and Candid does not know whether it will be able
to develop any drugs of commercial value, or if competing technological approaches will limit the commercial value of its drug candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s
success depends on its ability to develop, obtain regulatory approval for and commercialize its drug candidates, cizutamig, CND261, CND319 and CND460, which Candid believes represent relatively novel scientific approaches for the treatment of
autoimmune diseases. Specifically, the development of cizutamig and CND261 was historically focused on the development of therapies for cancer. To date, the FDA has not approved any TCE therapies for the treatment of autoimmune diseases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s initial belief that cizutamig, CND261, CND319 and CND460 may be developed as potential treatments for autoimmune diseases was based on Candid&#8217;s
interpretation of published third-party data evaluating autologous <FONT STYLE="white-space:nowrap">CAR-T</FONT> candidates within a limited autoimmune disease patient cohort, and using TCEs to treat autoimmune diseases, in which clinical
improvement following treatment were observed. To date, Candid has generated early clinical data in a mix of Phase 1 clinical studies and IITs, none of which have been completed, and through compassionate use via NPU treatment. Although Candid is
encouraged by the results observed to date, these studies are ongoing may not be representative of final data upon completion of the studies or in any planned or future clinical studies. In addition, data generated through IITs and compassionate use
via NPU, including any past clinical data developed for oncology indications, may prove to be less reliable than data obtained in a controlled clinical trial and Candid is unable to rely on this data to determine dosing, safety or therapeutic effect
in its trials given the different characteristics of the patient population and their disease burden of the oncology patients in past clinical trials. As a result, such findings should not be directly compared to Candid&#8217;s planned and future
clinical trials or the final results on its ongoing clinical trials, since there could be key differences, including patient population and clinical trial design. Moreover, the focus of Candid&#8217;s clinical development strategy includes
efficiently generating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical data across multiple autoimmune diseases and using this data to prioritize indication for further investment into mid to
later stage clinical trials. This broad development strategy may yield varying results across indications that may require Candid to reprioritize indication selection in the future. As an organization, Candid is early in its development efforts in
autoimmune diseases and may never succeed in demonstrating the safety, purity and potency, or efficacy for any of its drug candidates in clinical trials or in obtaining regulatory approval thereafter. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the biopharmaceutical industry is characterized by rapidly advancing technologies. Candid&#8217;s future success will depend in part on its ability to
maintain a competitive position with its scientific approach. If Candid fails to stay at the forefront of technological change in utilizing its approach to create and develop TCE bispecific antibodies, Candid may be unable to compete effectively.
Candid&#8217;s competitors may render Candid&#8217;s approach obsolete or limit the commercial value of its drugs by advances in existing technological approaches or the development of new or different approaches. By contrast, adverse developments
with respect to other companies that attempt to use a similar approach to Candid&#8217;s may adversely impact the actual or perceived value and potential of Candid&#8217;s drug candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of these events occur, Candid may be forced to delay, modify or abandon its development efforts for a drug candidate or program, which would have a material
adverse effect on Candid&#8217;s business and could potentially cause Candid to cease operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid is early in its development efforts and only has two drug candidates, cizutamig and CND261, in early
clinical development. All of Candid&#8217;s other drug products, including CND319 and CND460, are in the preclinical or discovery stage. If Candid is unable to advance its drug candidates in clinical development, obtain regulatory approval and
ultimately commercialize its drug candidates, or experiences significant delays in doing so, Candid&#8217;s business will be materially harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is
in the early stages of its clinical development for autoimmune indications and has two drug candidates, cizutamig and CND261, in early clinical development. Cizutamig is in multiple Phase 1 dose escalation trials in patients with gMG and SLE, as
well as IITs in <FONT STYLE="white-space:nowrap">SARD-ILD,</FONT> SSc and other diseases. In addition, based on early clinical data for cizutamig, Candid plans to advance cizutamig into multiple Phase 2 studies in gMG and <FONT
STYLE="white-space:nowrap">SARD-ILD</FONT> in the middle of 2026, prior to receipt of final Phase 1 clinical data in these indications. CND261 is in Phase 1 dose-escalation trials in patients with RA and SLE, as well as an IIT in ANCA-associated
vasculitis. Although Candid believes that its ongoing efforts with, and early clinical data for, cizutamig and CND261 support further evaluation in autoimmune diseases, Candid cannot predict, and there can be no assurance that, it will observe
positive results in its ongoing or planned trials. In addition, there is no assurance that Candid will realize any benefits from its plan to advance cizutamig into Phase 2 clinical development ahead of final Phase 1 clinical data. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s other drug candidates are still in the preclinical or discovery stages. Candid will need to submit IND applications to the FDA or comparable foreign
regulatory applications to applicable foreign regulatory authorities and receive allowance to proceed prior to initiating clinical trials for its drug candidates in the applicable jurisdiction and then progress these candidates through clinical
development. For example, to date, Candid has not received approval by the FDA to initiate clinical trials in the United States and will need IND clearance prior to initiating any of its planned clinical trials in the United States. Although Candid
has initiated clinical development activities in various geographies, including China, Europe and Australia, the acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or applicable
foreign authority in support of any regulatory applications or submissions may be subject to certain conditions or may not be accepted at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s
ability to generate product revenues, which Candid does not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of its current or future drug candidates. The success of
Candid&#8217;s current or future drug candidates will depend on several factors, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">allowance to proceed with clinical trials under INDs by the FDA or under similar regulatory submissions by applicable
foreign regulatory authorities for the conduct of clinical trials of Candid&#8217;s drug candidates and Candid&#8217;s proposed design of future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful enrollment in, and timely completion of, clinical trials with favorable results; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of preclinical studies with favorable results; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sufficiency of Candid&#8217;s financial and other resources to complete the necessary preclinical studies and clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">demonstrating the safety, purity and potency, or efficacy of Candid&#8217;s drug candidates to the satisfaction of the FDA
and other applicable foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the acceptance by the FDA and other regulatory authorities of data generated in geographies outside of the U.S. or such
other jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">receipt of regulatory approvals from applicable regulatory authorities, including BLAs from the FDA and approvals from
comparable foreign regulatory authorities, and maintaining such approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successfully developing subcutaneous or other formulations, if needed, of Candid&#8217;s drug candidates and advancing
them through clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">making arrangements with third-party manufacturers for the manufacture of Candid&#8217;s drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of Candid&#8217;s drugs, if and
when approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing and maintaining patent and trade secret protection or regulatory exclusivity for Candid&#8217;s drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acceptance of any drugs Candid develops and their benefits and uses, if and when approved, by patients, the medical
community and third-party payors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintaining an acceptable safety and efficacy profile of Candid&#8217;s drugs following approval; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">building and maintaining an organization of people who can successfully develop Candid&#8217;s drug candidates.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has not yet succeeded and may not succeed in demonstrating the safety, purity and potency, or efficacy, for any of its drug candidates in
clinical trials or in obtaining regulatory approval thereafter. Given Candid&#8217;s early stage of development, it will take several years before Candid can demonstrate the safety, purity and potency, or efficacy, of a drug candidate sufficient to
warrant regulatory approval, if Candid can do so at all. If Candid is unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize, its drug candidates, Candid may not be able to generate sufficient revenue to
continue its business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As an organization, Candid has never completed any clinical trials and may be unable to do so for any of its drug candidates.
</I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is early in its development efforts for its drug candidates, has never completed any clinical trials, and will need to successfully complete its
ongoing and planned Phase 1 trials and later-stage and pivotal clinical trials in order to obtain FDA or comparable foreign regulatory approval to market its drug candidates. Candid is conducting Phase 1 clinical trials for cizutamig and CND261, and
has plans to conduct multiple Phase 2 clinical trials for cizutamig. For some of these Phase 2 clinical trials, Candid is seeking IND clearance from the FDA and other foreign regulatory agencies. Candid plans to summarize findings from its emerging
data from Phase 1 studies, IITs and compassionate use via NPU studies, which were conducted in China, Europe and Australia, as the rationale for pursuing Phase 2 studies. There can be no assurance that the FDA or other foreign regulatory agencies
will agree that the data, including any data from ongoing Phase 1 clinical trials, submitted as part of Candid&#8217;s IND or other foreign regulatory filings support IND or other foreign regulatory clearance for autoimmune indications. For example,
the FDA has previously informed Candid that its Phase 1 oncology data for cizutamig would not support the IND filing and proposed Phase 1 clinical trial for cizutamig in autoimmune diseases without further preclinical testing due to potential
differences in <FONT STYLE="white-space:nowrap">T-cell</FONT> responses between oncology and autoimmune patients. Inability to obtain these clearances may hurt Candid&#8217;s ability to initiate and conduct these trials in a timely manner. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, Candid is planning to conduct its first Phase 1 clinical trials for CND319 and CND460; however, Candid must first receive regulatory clearance from the
FDA and other regulatory agencies, which may not occur on Candid&#8217;s expected timing or at all. There can be no assurance that the FDA or other foreign regulatory authorities will agree that the data submitted as part of Candid&#8217;s IND or
other foreign regulatory filings support IND or other foreign regulatory clearance for autoimmune indications. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has had limited interactions with the FDA
and other comparable foreign regulatory authorities and cannot be certain of the number of clinical trials Candid&#8217;s drug candidates will be required to undergo or the designs of such trials, or if such authorities will require additional
preclinical studies prior to clearing Candid&#8217;s INDs or other regulatory filings. As mentioned above, as a result of previous interactions with the FDA Candid has determined not to develop our product candidates within the U.S. at this time
given the FDA recommendation to additional preclinical studies and modifications to the study design. Although Candid believes the data generated globally in multiple autoimmune indications will be sufficient to enable clinical development in the
U.S. and clearance of an IND with the FDA, there can be no assurances as to what level of clinical data the FDA will require in order to clear an IND and begin a study in the U.S., or whether the FDA will require modifications to the study design
which could slow enrollment in the study globally. Consequently, Candid may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to submission and regulatory approval of any of its drug
candidates. Candid may require more time and incur greater costs than its competitors and may not succeed in obtaining regulatory approvals of its drug candidates. Failure to commence or complete, or delays in, Candid&#8217;s planned clinical trials
could prevent or delay Candid in submitting marketing applications, including BLAs, for and commercializing its drug candidates. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical trials are
expensive, time-consuming, difficult to design and implement, and have an uncertain outcome. Any difficulties or delays in the commencement or completion, or the termination or suspension, of Candid&#8217;s current or planned clinical trials could
result in increased costs to Candid, delay or limit Candid&#8217;s ability to generate revenue or adversely affect Candid&#8217;s commercial prospects. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining regulatory approvals for the commercial sale of any of its drug candidates, Candid must demonstrate
that its drug candidates are safe, pure and potent, or effective, for use in each intended indication and have an adequate risk versus benefit profile in their intended patient populations and for their intended use. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preclinical and clinical testing is complex, expensive, takes many years to complete, and is subject to uncertainty. Candid&#8217;s planned clinical trials may not be
conducted as planned or completed on schedule, if at all. Delays and failures can occur at any time during the clinical trial process. Candid cannot predict with any certainty whether or when it might complete a given clinical trial. Events that may
prevent successful or timely commencement, readouts, and completion of clinical trials and preclinical studies include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to obtain animals or materials to initiate and generate sufficient preclinical, toxicology or other in vivo or
in vitro data to support the initiation or continuation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in reaching agreement or consensus with the FDA, or other comparable foreign regulatory authorities as to the
design or implementation of Candid&#8217;s clinical trials, or failure to do so; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in or failure to obtain regulatory approval or allowance to commence a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in or failure to reach an agreement on acceptable terms with clinical trial sites or prospective contract research
organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in or failure to obtain institutional review board (&#8220;IRB&#8221;) approval or positive ethics committee
opinion at each clinical trial site; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to source any comparator drug in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> studies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">IRBs or ethics committees refusing to approve or provide a positive opinion, suspending or terminating the trial at an
investigational site, precluding enrollment of additional subjects, or withdrawing their approval or positive opinion of a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in or failure to identify and recruit suitable clinical investigators, or to recruit patients to participate in a
clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">patients choosing an alternative product for the indications for which Candid is developing its drug candidates, or
participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in or failure to have patients complete a clinical trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinical sites, CROs or other third parties deviating from trial protocol or dropping out of a trial;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the subcutaneous formulation of Candid&#8217;s drug candidates may yield different results in comparison to the
intravenous formulation, which could impact Candid&#8217;s clinical development, including trial enrollment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failures by Candid or its CROs to perform in accordance with the FDA&#8217;s GCP requirements, or applicable regulatory
requirements or guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure in addressing patient safety concerns that arise during the course of a trial, including occurrence of adverse
events associated with the drug candidate that are viewed to outweigh such drug candidate&#8217;s potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">lack of adequate funding to complete a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">selection of clinical endpoints that require prolonged periods of clinical observation or extended analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to add a sufficient number of clinical trial sites; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to manufacture sufficient quantities of drug candidate for use in clinical trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if Candid&#8217;s future clinical trials are completed as planned, their results may not support the safety, purity and potency, or effectiveness of Candid&#8217;s
drug candidates for their targeted indications or support continued clinical development of such drug candidates. For example, in clinical trials that are based on preclinical studies and early clinical trials, it is not uncommon to observe
unexpected results, and many drug candidates fail in clinical development despite very promising early results. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the
biopharmaceutical industry have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Furthermore, because Candid is developing its drug candidates across several indications, setbacks in
one indication may negatively impact its development in other indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, even if Candid&#8217;s ongoing and planned trials are successfully completed, the FDA or comparable
foreign regulatory authorities may not interpret the results as Candid does or may not accept data from clinical trials conducted outside such jurisdictions, and more trials could be required before Candid submits its drug candidates for approval,
if ever. To the extent that the results of Candid&#8217;s clinical trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, Candid may be required to expend significant resources,
which may not be available to Candid, to conduct additional trials in support of potential approval of its drug candidates. Furthermore, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may
also ultimately lead to the denial of regulatory approval of Candid&#8217;s drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other unforeseen events Candid may experience during, or as a result
of, clinical trials that could delay or prevent its ability to receive regulatory approval or commercialize its drug candidates or significantly increase the cost of such trials, include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid may experience changes in regulatory requirements or guidance, or receive feedback from regulatory authorities that
requires Candid to modify the design of its clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinical trials of Candid&#8217;s drug candidates may produce negative or inconclusive results, and Candid may decide, or
regulators may require Candid, to conduct additional clinical trials or abandon development programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of patients required for clinical trials of Candid&#8217;s drug candidates may be larger than Candid
anticipates, enrollment in these clinical trials may be slower than Candid anticipates or participants may drop out of these clinical trials at a higher rate than Candid anticipates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s third-party contractors, including its CROs, may fail to comply with protocol, legal and regulatory
requirements and scientific standards or fail to meet their contractual obligations to Candid in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid or its investigators might have to suspend or terminate clinical trials of its drug candidates for various reasons,
including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements, a finding that Candid&#8217;s drug candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are
being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">adverse events suffered by clinical trial participants, whether or not such adverse events are ultimately deemed to be
related to Candid&#8217;s drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of clinical trials of Candid&#8217;s drug candidates may be greater than anticipated and Candid may elect not to
cover the costs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA or other comparable foreign regulatory authorities may require Candid to monitor patients via hospitalization for
a certain period of time after dose administration of Candid&#8217;s drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the supply or quality of Candid&#8217;s drug candidates or other materials necessary to conduct clinical trials of its
drug candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulators may revise the requirements for approving Candid&#8217;s drug candidates, or such requirements may not be as
Candid anticipates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in
ways they view as advantageous to them but that are suboptimal for Candid. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Candid is required to conduct additional clinical trials or other
testing of its drug candidates beyond those that it currently contemplates, if Candid experiences delays in the commencement or completion of, or is unable to successfully complete clinical trials of its drug candidates or other testing, or if the
results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, the commercial prospects of Candid&#8217;s drug candidates could be harmed, and Candid&#8217;s ability to generate revenues from its
drug candidates may be delayed. In addition, if any of these risks were to materialize, Candid could: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">incur significant unplanned costs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">be delayed in obtaining regulatory approval for its drug candidates or not obtain regulatory approval at all;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain regulatory approval in some countries and not in others; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain regulatory approval with labeling that includes significant use or distribution restrictions or safety warnings,
including boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">be subject to additional post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">have the product removed from the market after obtaining regulatory approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these occurrences may harm Candid&#8217;s business, financial condition and results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s drug candidates have resulted in serious adverse events, including treatment-related serious adverse event in oncology patients, and may in the
future cause serious adverse events or undesirable side effects or have other properties that may delay or prevent regulatory approval, cause Candid to suspend or discontinue clinical trials, limit the commercial profile of an approved label, or
result in significant negative consequences following regulatory approval, if any. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has not yet completed any human clinical trials with its
drug candidates. Candid has initiated Phase 1 clinical trials and IITs for cizutamig and CND261, and intends to initiate future Phase 1 clinical studies and IITs for CND319 and CND460. Undesirable side effects that may be caused by Candid&#8217;s
drug candidates could cause Candid or regulatory authorities, the DSMBs for such trials, IRBs or ethics committees of the institutions in which such trials are being conducted to interrupt, delay, suspend or terminate clinical trials and could
result in a more restrictive label than anticipated or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities for any or all target indications. Results of Candid&#8217;s clinical trials could reveal a
high and unacceptable severity and prevalence of side effects or unexpected characteristics, and Candid may not be able to complete a clinical trial for cizutamig, CND261, CND319, CND460 or any of its future drug candidates on the timeline it
expects or at all. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While the data reported to date from the ongoing clinical evaluation for cizutamig and CND261 indicate that the drug candidates have been
generally well tolerated, there remains a risk of serious adverse events. For example, in a completed Phase 1 clinical trial in patients with multiple myeloma conducted prior to Candid&#8217;s in-licensing of cizutamig from EpimAb Biotherapeutics,
treatment-related serious adverse events of 5% incidence or higher were pneumonia and CRS, which were seen in 10% and 7.5% of patients, respectively. There were four treatment emergent deaths, but none were considered to be treatment-related.
Additionally, in Candid&#8217;s ongoing clinical development in autoimmune indications as of February 2, 2026, three treatment-related serious adverse events have been reported, including one case of pneumonia and two cases of COVID-19, all of which
resolved with treatment. It is possible that increased occurrences of adverse events and serious adverse events, including cytokine release syndrome (&#8220;CRS&#8221;), neurotoxicity or infections will occur in human subjects during ongoing and
planned clinical trials and the severity and rate of these events may not be acceptable in patients with autoimmune diseases. Any such findings could cause delays in completion or cancellation of clinical programs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure,
rare and severe side effects of Candid&#8217;s drug candidates or those of Candid&#8217;s competitors may only be uncovered when a significantly larger number of patients have been exposed to the drug candidate. For example, while Candid has
observed manageable tolerability profiles for cizutamig and CND261 based on early clinical data, such data is limited to a very small sample size and there can be no assurance that cizutamig, CND261 or any of Candid&#8217;s other drug candidates
will not cause more severe and/or serious side effects in a greater proportion of patients. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, while several TCEs have been approved for oncology
indications, Candid believes the FDA and comparable foreign regulatory authorities may apply a different risk-benefit threshold to Candid&#8217;s drug candidates pursuing autoimmune indications such that any potential harmful side effects that may
outweigh the benefits of such drug candidates would require Candid to cease clinical trials or abandon or limit its development of these drug candidates or would cause the FDA or comparable foreign regulatory authorities to deny marketing
applications for these drug candidates. Accordingly, the risks of negative impact from TCE antibody toxicities may therefore be higher for Candid&#8217;s autoimmune programs than for the oncology programs of others. Furthermore, to date, the FDA has
not approved any TCE therapies for commercialization in an autoimmune indication; and therefore, what the FDA may require to establish an acceptable safety profile is not yet known. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, further undesirable side effects, dose-limiting adverse events, or deaths in clinical trials with Candid&#8217;s drug candidates may cause the FDA or
comparable foreign regulatory authorities to place a clinical hold on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
associated clinical trials, to require additional studies, dose <FONT STYLE="white-space:nowrap">de-escalation,</FONT> or additional protocol amendments, or otherwise to delay or deny approval of
our drug candidates for any or all targeted indications. Treatment-related side effects could also affect site initiation, patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.
Even if serious adverse events are unrelated to study treatment, such occurrences could affect patient enrollment or the ability of enrolled patients to complete the clinical trial. In addition, these side effects may not be appropriately recognized
or managed by the treating medical staff. Candid expects to have to train medical personnel using its drug candidates to understand the side effect profiles for Candid&#8217;s clinical trials and upon commercialization of any of Candid&#8217;s drug
candidates, if approved. Inadequate training in recognizing or managing the potential side effects of Candid&#8217;s drug candidates could result in patient injury or death. Any of these occurrences may harm Candid&#8217;s business, financial
condition and prospects significantly. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cizutamig&#8217;s mechanism of action results in deep and prolonged <FONT STYLE="white-space:nowrap">B-cell</FONT>
depletion, including memory <FONT STYLE="white-space:nowrap">B-cells,</FONT> which may lead to hypogammaglobulinemia, loss of vaccine-mediated immunity, and increased infection risk that could limit its clinical utility or require complex patient
management strategies. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cizutamig is designed to achieve deep depletion of BCMA-expressing <FONT STYLE="white-space:nowrap">B-cells</FONT> and plasma
cells, which is central to its therapeutic mechanism in autoimmune diseases. However, this deep depletion extends beyond pathogenic <FONT STYLE="white-space:nowrap">B-cell</FONT> populations to include memory
<FONT STYLE="white-space:nowrap">B-cells</FONT> that are critical for maintaining protective immunity against infectious pathogens. Based on clinical experience to date, cizutamig treatment has resulted in prolonged
<FONT STYLE="white-space:nowrap">B-cell</FONT> depletion and hypogammaglobulinemia, with reduced levels of immunoglobulin G (&#8220;IgG&#8221;), IgA, and IgM observed in treated patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Hypogammaglobulinemia, defined as abnormally low levels of antibodies in the blood, occurred in 39% of autoimmune patients treated with cizutamig in Candid&#8217;s
clinical studies to date. While Candid has managed this complication through prophylactic administration of intravenous immunoglobulin (&#8220;IVIG&#8221;) therapy, hypogammaglobulinemia represents a significant safety concern that may: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Increase the risk of serious and opportunistic infections.</I> Patients with low immunoglobulin levels are at
heightened risk for bacterial, viral, and fungal infections, particularly infections of the respiratory tract and sinopulmonary system. In Candid&#8217;s clinical experience to date, Candid has observed infections including upper respiratory tract
infections (13% of patients) and three serious infectious adverse events (pneumonia and <FONT STYLE="white-space:nowrap">COVID-19),</FONT> all of which resolved with treatment. However, as Candid treats larger patient populations over longer
periods, Candid may observe more frequent or severe infections, including life-threatening opportunistic infections. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Result in loss of vaccine-mediated immunity.</I> Deep depletion of memory
<FONT STYLE="white-space:nowrap">B-cells</FONT> and plasma cells may eliminate antibodies generated from prior vaccinations, leaving patients vulnerable to vaccine-preventable diseases such as measles, mumps, rubella, varicella, tetanus, diphtheria,
pertussis, and other serious infections. Patients may lose protective antibody titers and require <FONT STYLE="white-space:nowrap">re-vaccination</FONT> after <FONT STYLE="white-space:nowrap">B-cell</FONT> reconstitution. However, the ability of
patients to mount adequate immune responses to <FONT STYLE="white-space:nowrap">re-vaccination</FONT> following deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion is uncertain and may be impaired, potentially leaving some patients without
adequate protection against vaccine-preventable diseases. This risk is exacerbated in areas with low vaccination rates or outbreaks of vaccine-preventable diseases. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Require complex and costly long-term management.</I> Managing hypogammaglobulinemia may require regular IVIG infusions,
which are expensive, time-consuming, require intravenous access, and carry their own risks including allergic reactions, hemolysis, thrombosis, and renal dysfunction. IVIG may need to be administered every <FONT STYLE="white-space:nowrap">3-4</FONT>
weeks for extended periods, potentially for many months or even years depending on the duration of <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion and immunoglobulin suppression. This requirement could significantly increase the overall
cost of treatment, reduce patient quality of life, and create practical barriers to therapy administration, particularly if patients must receive IVIG infusions at specialized treatment centers. Additionally, global IVIG supply constraints or
increased global supply costs could limit the availability of this supportive therapy, make it prohibitively costly or harm the commercial opportunity for Candid&#8217;s TCE therapies. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Limit the acceptable patient population.</I> Patients with <FONT STYLE="white-space:nowrap">pre-existing</FONT>
immunodeficiency, active infections, or other risk factors for serious infections may not be appropriate candidates for cizutamig therapy. This could substantially narrow the eligible patient population and limit the commercial potential of
cizutamig. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Create challenges in clinical trial design and execution.</I> The need to monitor and manage hypogammaglobulinemia and
its consequences may require more frequent patient monitoring, specialized laboratory assessments, and intensive supportive care infrastructure, which could slow enrollment, increase trial costs, and make it more difficult to conduct trials in
community practice settings. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, the duration and reversibility of <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion following
cizutamig treatment remain incompletely characterized. While Candid has observed <FONT STYLE="white-space:nowrap">B-cell</FONT> reconstitution in some patients beginning approximately four months after treatment, with returning <FONT
STYLE="white-space:nowrap">B-cells</FONT> displaying a na&iuml;ve phenotype, the timeline for full immune reconstitution and restoration of normal <FONT STYLE="white-space:nowrap">B-cell</FONT> function, including memory <FONT
STYLE="white-space:nowrap">B-cell</FONT> populations, may vary considerably among patients and could extend for many months or years. Prolonged <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion could result in extended periods of increased
infection risk and the need for ongoing immunoglobulin replacement therapy or other supportive measures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If regulatory authorities determine that the infection
risk or the complexity of managing hypogammaglobulinemia and loss of vaccine immunity outweighs the potential clinical benefit of cizutamig, they may: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refuse to approve cizutamig for marketing; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require additional clinical trials with more intensive safety monitoring; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approve cizutamig only with significant restrictions, such as a REMS or comparable foreign strategies, that could include
requirements for certification of healthcare facilities, prescriber training, patient enrollment in a registry, mandatory laboratory monitoring, or restricted distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require black box warnings or other labeling restrictions that could significantly limit physician willingness to
prescribe and patient willingness to accept treatment; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limit approved indications to only the most severe forms of autoimmune disease where the benefit-risk profile is most
favorable. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if cizutamig is approved, the infection risk and need for complex ongoing management may limit physician adoption, reduce patient
compliance, result in treatment discontinuations, and ultimately limit the commercial success of the product. Additionally, if serious or fatal infections occur in post-marketing use, regulatory authorities may require additional safety studies,
impose new restrictions, or in extreme cases, require withdrawal of the product from the market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The occurrence of serious infections or deaths attributable to
hypogammaglobulinemia or impaired immunity in Candid&#8217;s clinical trials or following any regulatory approval could also result in product liability claims, damage to Candid&#8217;s reputation, and negative impacts on Candid&#8217;s stock price
and business prospects. Any of these outcomes could materially and adversely affect Candid&#8217;s business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid has conducted, or plans to conduct, its initial clinical studies for cizutamig, CND261, and its other drug candidates outside of the United States.
However, the FDA and other foreign equivalents may not accept data from such trials, in which case Candid&#8217;s development plans will be delayed, which could materially harm Candid&#8217;s business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has conducted its initial clinical studies for cizutamig and CND261 in China, Europe and Australia, and plans to continue to conduct additional clinical studies
in China, Europe, Australia as well as other foreign geographies. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or applicable foreign authority may be subject to certain
conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of
foreign data alone unless (i)&nbsp;the data are applicable to the U.S. population and U.S. medical practice; (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii)&nbsp;the
data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an <FONT
STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application
for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory
authorities have similar approval requirements. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any applicable foreign
authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any applicable foreign authority does not accept such data, it would result in the need for additional trials, which could be
costly and time-consuming, and which may result in current or future drug candidates that Candid may develop not receiving approval for commercialization in the applicable jurisdiction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s global regulatory strategy relies on the FDA and other foreign regulatory authorities accepting its clinical data generated in China, Europe, Australia
and other foreign countries; however, there can be no assurance the FDA or applicable foreign authorities will accept data from any other clinical studies that Candid may conduct in such foreign countries and, even if such data is accepted as a
basis for the initiation of trials in the U.S. or such foreign countries, the FDA or such other foreign regulatory authorities may still require Candid to repeat or conduct additional clinical studies that would cause a delay in its timelines. If
the FDA or applicable foreign authorities do not accept any such data, Candid would likely be required to conduct additional Phase 1 or Phase 2 clinical studies, which would be costly and time consuming, and delay aspects of Candid&#8217;s
development plan, which could harm Candid&#8217;s business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Conducting clinical trials outside the United States exposes Candid to additional risks, including
risks associated with: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">foreign exchange fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">political and economic risks relevant to such foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cultural differences in medical practice and clinical research; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">diminished protection of intellectual property in some countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any such risks could materially and adversely affect Candid&#8217;s business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Enrollment and retention of patients in clinical trials is an expensive and time-consuming process subject to various external factors beyond Candid&#8217;s
control that may cause delays or complications. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The timely completion of clinical trials in accordance with their protocols depends, among other things, on
Candid&#8217;s ability to enroll a sufficient number of patients who remain in the trial until its conclusion. Clinical trial recruitment in autoimmune diseases has been challenging as several third-party drug candidates are being pursued for the
same autoimmune diseases and there is only a limited set of eligible patients for the given autoimmune diseases Candid is targeting. For example, Candid is aware of several active clinical trials evaluating drug candidates for the treatment of
myasthenia gravis, ILD, SLE, RA, IgA nephropathy (&#8220;IgAN&#8221;), among others, and many of the sponsors have highlighted challenges in patient recruitment. Candid may not be able to initiate or continue clinical trials for its drug candidates
if Candid is unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trials&#8217; conclusion as required by the FDA or other comparable foreign regulatory authorities. Candid may be required to
monitor patients via hospitalization for a certain period of time after dose administration of its drug candidates, which would negatively impact Candid&#8217;s ability to timely enroll patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The eligibility criteria of Candid&#8217;s clinical trials, once established, may further limit the pool of available trial participants. If the actual number of
patients with these diseases is smaller than Candid anticipates, Candid may encounter difficulties in enrolling patients in its clinical trials, thereby delaying or preventing development and approval of Candid&#8217;s drug candidates. Even once
enrolled, Candid may be unable to retain a sufficient number of patients to complete any of its trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid may experience difficulty in patient enrollment in
its clinical trials for a number of reasons. The enrollment of patients depends on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size and nature of the patient population required for analysis of the trial&#8217;s endpoints; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the proximity of patients to study sites; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the design of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the existing body of safety and efficacy data for the drug candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to recruit clinical trial investigators with appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug candidate being studied in
relation to other available therapies, including new drugs that may be approved for the indications Candid is investigating; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to obtain and maintain patient consents for participation in its clinical trials; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that patients enrolled in clinical trials will not remain in the trial through the completion of evaluation.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competing with numerous ongoing trials and established therapies poses a challenge in recruiting patients. Candid&#8217;s clinical trials may
also compete with other clinical trials of drug candidates that are in a similar immunotherapy area as Candid&#8217;s drug candidates, and this competition could reduce the number and types of patients available to Candid, because some patients who
might have opted to enroll in Candid&#8217;s trials may instead opt to enroll in a trial being conducted by one of Candid&#8217;s competitors. Additionally, for any future clinical trials for the treatment of other autoimmune diseases, the number of
qualified clinical investigators is limited, so Candid may conduct some of its clinical trials at the same clinical trial sites that some of Candid&#8217;s competitors use, which will reduce the number of patients who are available for
Candid&#8217;s clinical trials at such clinical trial site. Recent announcements of clinical trial plans by various immunotherapy companies targeting autoimmune diseases, including those Candid intends to treat, could intensify future competition
for investigators and patients. Failure to enroll a sufficient number of patients promptly could lead to delays or failure in completing Candid&#8217;s trials, hindering the development and commercialization of Candid&#8217;s drug candidates within
certain patient subgroups or altogether. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Since the number of patients that have been and will be dosed in Candid&#8217;s ongoing clinical trials is small,
the results from such clinical trials, once completed, may be less reliable than or may not be predictive of results achieved in larger clinical trials, which may hinder Candid&#8217;s efforts to obtain regulatory approval for its drug candidates.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preliminary results of clinical trials with smaller sample sizes can be disproportionately influenced by various biases associated with the conduct of
small clinical trials, such as the potential failure of the smaller sample size to accurately depict the characteristics of the broader patient population, which limits the ability to generalize the results across a broader community, thus making
the clinical trial results less reliable than clinical trials with a larger number of patients. As a result, there may be less certainty that such drug candidates would achieve a statistically significant effect in any future clinical trials. </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Candid is conducting numerous IITs and has generated data pursuant to compassionate use via NPU treatment. Such data is limited to a very small sample
size, but may still be relied upon by Candid to inform future clinical development and allocation of resources. If such IIT data is not indicative of data that would have been generated in a larger clinical trial, Candid&#8217;s assumptions in
support of its clinical development activities may prove to be inaccurate and the FDA or other comparable regulatory authorities may require Candid to conduct additional and larger clinical trials than Candid may plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Candid conducts any future clinical trials of its current and future drug candidates, Candid may not achieve a positive or statistically significant result or the
same level of statistical significance, if any, that Candid might have anticipated based on prior results. Such failure could hinder Candid&#8217;s efforts to obtain regulatory approval for its drug candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Results of any patient who receives Candid&#8217;s drug candidate in an IIT, compassionate use via NPU
program or expanded access program should not be viewed as representative of how the drug candidate will perform in Candid&#8217;s clinical trials and may not be able to be used to establish safety or efficacy for regulatory approval. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before seeking regulatory approval for any of its drug candidates, Candid must demonstrate statistically significant evidence of both safety and effectiveness in
well-controlled clinical trials. However, Candid does not control the design, administration or timing of IITs, compassionate use via NPU programs, and expanded access programs. Candid relies on investigators and physicians to ensure their
compliance with clinical and regulatory requirements when using Candid&#8217;s drug candidates for these trials. Failure to comply could expose Candid to liability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While IITs, compassionate use via NPU programs and expanded access programs may provide valuable insights, they are not a substitute for, or intended to replace,
Candid&#8217;s clinical trials and their results cannot be formally relied on or used to establish safety or efficacy for regulatory approval. In fact, they may identify concerns that could impact Candid&#8217;s findings or ongoing trials,
potentially delaying or jeopardizing regulatory approval from the FDA or other regulatory bodies. If results from IITs, compassionate use via NPU programs and expanded access programs are inconsistent with or differ from Candid&#8217;s sponsored
trials or raise concerns regarding Candid&#8217;s drug candidates, regulatory authorities may question Candid&#8217;s sponsored trial results and subject them to greater scrutiny than they otherwise would. This could result in the need for
additional clinical data, delaying clinical development and approval of Candid&#8217;s drug candidates. In addition, while IITs could be useful to inform Candid&#8217;s own clinical development efforts, there is no guarantee that Candid will be able
to use the data from these trials to form the basis for regulatory approval of its drug candidates. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, the patient population in such trials is at high
risk for serious adverse events. If these events are attributed to Candid&#8217;s drug candidates, it could negatively impact their safety profile, leading to delays or failure in obtaining regulatory approval or successfully commercializing
Candid&#8217;s drug candidates. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In summary, while IITs, compassionate use via NPU programs and expanded access programs offer valuable insights, they also pose
regulatory and operational challenges that could impact Candid&#8217;s ability to bring its drug candidates to market. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interim, topline and preliminary
data from Candid&#8217;s clinical trials or preclinical studies that Candid announces or publishes from time to time may not be predictive of future results and may change as more patient data become available and are subject to audit and
verification procedures, which could result in material changes to the final data. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, Candid may publicly disclose interim, topline or
preliminary data from its preclinical studies, clinical trials or planned clinical trials, which is based on a preliminary analysis of then-available data. The results and related findings and conclusions are subject to change following a more
comprehensive review of the data related to the particular study or trial. Candid also makes assumptions, estimations, calculations and conclusions as part of its analyses of data, and Candid may not have received or had the opportunity to fully and
carefully evaluate all data. As a result, the interim, topline or preliminary results that Candid reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data
have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data Candid previously
published. As a result, such data should be viewed with caution until the final data are available. Additionally, while Candid believes the early clinical trial results from the Phase 1 portions of the clinical trials for cizutamig and CND261 as
well as IITs and compassionate use via NPU are favorable, Candid may not see similar or favorable results in the future and Candid is unable to rely on any past clinical data developed for oncology indications or in IITs or compassionate use via NPU
to determine dosing, safety or therapeutic effect in its trials given the different characteristics of the patient population and their disease burden of the oncology patients in past clinical trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, Candid may also disclose interim data from its clinical trials. Interim data from clinical trials that Candid may subsequently complete are subject
to the risk that one or more of the reported clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, topline or preliminary data and final data could
significantly harm Candid&#8217;s business prospects. Further, disclosure of such data by Candid or by Candid&#8217;s competitors could result in volatility in the price of Candid Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, others, including regulatory authorities, may not accept or agree with Candid&#8217;s assumptions,
estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or product
and Candid in general. In addition, the information Candid chooses to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and investors or others may not agree with what Candid
determines is the material or otherwise appropriate information to include in its disclosure, and any information Candid determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities
or otherwise regarding a particular product, drug candidate or Candid&#8217;s business. If the interim, topline or preliminary data that Candid reports differ from actual results, or if others including comparable foreign regulatory authorities,
disagree with the conclusions reached, Candid&#8217;s ability to obtain approval for, and commercialize, its drug candidates may be harmed, which could harm Candid&#8217;s business, operating results, prospects or financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect Candid&#8217;s ability to obtain
regulatory approvals or commercialize these programs on a timely basis or at all. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before Candid can commence clinical trials for its drug candidates CND319
and CND460, Candid must complete extensive preclinical testing and studies that support its planned INDs in the United States and comparable applications outside the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid cannot be certain of the timely completion or outcome of its preclinical testing and studies and cannot predict if the FDA or comparable foreign regulatory
authorities will accept Candid&#8217;s proposed clinical programs or if the outcome of Candid&#8217;s preclinical testing and studies will ultimately support the further development of its programs. As a result, Candid may not submit INDs or similar
applications for its preclinical programs within its anticipated timelines, if at all, and submission of INDs or similar applications may not result in the FDA or comparable foreign regulatory authorities allowing clinical trials to begin. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and
novelty of the program, and often can be several years or more per program. Any delays in preclinical testing and studies conducted by Candid or potential future partners may cause Candid to incur additional operating expenses. The commencement and
rate of completion of preclinical studies for a drug candidate may be delayed by many factors, including, for example: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">dependence on third parties to conduct, supervise and monitor Candid&#8217;s planned preclinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in reaching a consensus with regulatory authorities on study design; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA (or comparable foreign regulatory authorities) not allowing Candid to rely on previous findings of safety and
efficacy for other similar but approved products and published scientific literature. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, because standards for <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> assessment are evolving and may change rapidly, even if Candid reaches an agreement with the FDA on a <FONT STYLE="white-space:nowrap">pre-IND</FONT> proposal, the FDA may not accept the IND submissions
as presented, in which case, the clinical trial timeline could be delayed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid may not identify or discover other drug candidates, may expend its limited
resources to pursue a particular drug candidate or a particular indication and may fail to capitalize on programs, drug candidates or indications that may present a greater commercial opportunity or for which there is a greater likelihood of
success. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s business depends upon its ability to identify, develop and commercialize drug candidates. Candid has explored and may continue to
explore strategic collaborations for the discovery of new drug candidates. Research programs to identify drug candidates require substantial technical, financial and human resources, whether or not any drug candidates are ultimately identified. In
addition, drug candidates against targets for different autoimmune diseases may require changes to Candid&#8217;s manufacturing processes, which may slow down development of or make it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
impossible to manufacture Candid&#8217;s drug candidates. Candid&#8217;s research programs may initially show promise in identifying potential drug candidates, yet fail to yield drug candidates
for clinical development for many reasons, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the research methodology or drug discovery approach used may not be successful in identifying potential drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">competitors may develop alternatives that render Candid&#8217;s drug candidates obsolete or less attractive;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid may choose to cease development if Candid determines that clinical results do not show promise;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">drug candidates Candid develops may nevertheless be covered by third parties&#8217; patents or other exclusive rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a drug candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be
effective or otherwise does not meet applicable regulatory criteria; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a drug candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because Candid has limited resources, Candid must choose to pursue and fund the development of specific types of treatment, and select certain
other therapies to test in combination with Candid&#8217;s drug candidates or treatment for a specific type of autoimmune disease. As a result, Candid may forgo or delay pursuit of opportunities with other programs, drug candidates or combinations
or for indications that could have had greater commercial potential. Candid&#8217;s resource allocation and other decisions may cause Candid to fail to identify and capitalize on viable potential programs, drug candidates or indications. In
addition, Candid&#8217;s estimates regarding the potential market for its drug candidates could be inaccurate. As a result, Candid&#8217;s spending on current and future programs, drug candidates or specific indications may not yield any
commercially viable drugs. For example, Candid is planning to initiate Phase 2 clinical trials of cizutamig in gMG and <FONT STYLE="white-space:nowrap">SARD-ILD</FONT> based on early clinical data from a small sample size and may prioritize an
indication that has less potential once final clinical data or clinical data from a larger sample size becomes available. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if Candid does not
accurately evaluate the commercial potential or target market for a particular indication or drug candidate, Candid may relinquish valuable rights to that drug candidate through collaborations, licenses, and other similar arrangements in cases in
which it would have been more advantageous for Candid to retain sole development and commercialization rights to such drug candidate. Alternatively, Candid may allocate internal resources to a drug candidate in a therapeutic area in which it would
have been more advantageous to enter into a partnering arrangement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of these events occur, Candid may be forced to abandon or delay its development efforts
with respect to a particular program, drug candidate or indication or fail to develop a potentially successful drug candidate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The affected populations for
Candid&#8217;s drug candidates may be smaller than Candid or third parties currently project, which may affect the addressable markets for Candid&#8217;s drug candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid selects the targets for development of its drug candidates based on a number of factors, including the estimated patient populations in which Candid believes
there is a meaningful addressable market opportunity. However, Candid&#8217;s projections of the number of people who have the diseases Candid is seeking to treat, as well as the subset of people with these diseases who have the potential to benefit
from treatment with Candid&#8217;s drug candidates, are estimates based on Candid&#8217;s knowledge and understanding of these diseases. The total addressable market opportunity for Candid&#8217;s drug candidates will ultimately depend upon a number
of factors, including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access, alternative therapies and product pricing and reimbursement.
Incidence and prevalence estimates are frequently based on information and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. The process Candid has used in developing an estimated
incidence and prevalence range for the indications Candid is targeting has involved collating limited data from multiple sources. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, the incidence and
prevalence estimates included in this proxy statement/prospectus should be viewed with caution. Further, the data and statistical information used in this proxy statement/prospectus, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
estimates derived from them, may differ from information and estimates made by Candid&#8217;s competitors or from current or future studies conducted by independent sources. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>International trade policies, including tariffs, sanctions and trade barriers may adversely affect Candid&#8217;s business, financial condition, results of
operations and prospects. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid operates in a global economy, which includes utilizing third-party suppliers in several countries outside the United
States. There is inherent risk, based on the complex relationships among the United States and the countries in which Candid conducts its business, that political, diplomatic and national security factors can lead to global trade restrictions and
changes in trade policies and export regulations that may adversely affect Candid&#8217;s business and operations. The current international trade and regulatory environment is subject to significant ongoing uncertainty including related legal
challenges. The U.S. government has recently announced substantial new tariffs affecting a wide range of products and jurisdictions and has indicated an intention to continue developing new trade policies, including with respect to the
pharmaceutical industry. In response, certain foreign governments have announced or implemented retaliatory tariffs and other protectionist measures. These developments have created a dynamic and unpredictable trade landscape, which may adversely
impact Candid&#8217;s business, results of operations, financial condition and prospects. The Bureau of Industry and Security, U.S. Department of Commerce, has initiated an investigation to determine whether pharmaceutical ingredients, including
finished drug product, manufactured outside the United States pose a national security risk and should be subject to additional tariffs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid does not own or
operate, and currently has no plans to establish, any manufacturing facilities. Candid currently relies, and expects to continue to rely, on third parties for the manufacture of its drug candidates for clinical testing, as well as for manufacture of
any products that Candid may commercialize, if approved. Currently, the drug substance and drug product are manufactured in China. Candid also relies on specialized laboratory equipment, supplies, materials and precursor compounds, all or part of
which Candid believes may be ultimately sourced from multiple countries outside the United States, to advance its research and development efforts. This dependence exposes Candid to geopolitical, trade, tariff, and sanctions risks, including actions
that could disrupt or restrict work with Chinese entities. Any supply disruption, delay or cost increase could materially delay our trials and increase program costs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Current or future tariffs will result in increased research and development expenses for Candid, including with respect to increased costs associated with manufacturing
drug substance and drug product. In addition, such tariffs will increase Candid&#8217;s supply chain complexity and could also potentially disrupt Candid&#8217;s existing supply chain. Unlike consumer goods, pharmaceuticals face unique regulatory
constraints that make rapid supply chain adjustments particularly difficult and costly. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to Candid&#8217;s development timelines. Increased
development costs and extended development timelines could place Candid at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence, negatively impacting
Candid&#8217;s ability to secure additional financing on favorable terms or at all. In addition, as Candid advances toward commercialization in the future, tariffs and trade restrictions could hinder Candid&#8217;s ability to establish
cost-effective production capabilities, negatively impacting Candid&#8217;s growth prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The complexity of announced or future tariffs may also increase the
risk that Candid or its suppliers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulations. Foreign governments may also adopt
<FONT STYLE="white-space:nowrap">non-tariff</FONT> measures, such as procurement preferences or informal disincentives to engage with, purchase from or invest in U.S. entities, which may limit Candid&#8217;s ability to compete internationally and
attract <FONT STYLE="white-space:nowrap">non-U.S.</FONT> investment, employees, customers and suppliers. Foreign governments may also take other retaliatory actions against U.S. entities, such as decreased intellectual property protection, increased
enforcement actions or delays in regulatory approvals, which may result in heightened international legal and operational risks. In addition, the United States and other governments have imposed and may continue to impose additional sanctions, such
as trade restrictions or trade barriers, which could restrict Candid from doing business directly or indirectly in or with certain countries or parties and may impose additional costs and complexity to Candid&#8217;s business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Trade disputes, tariffs, restrictions and resulting legal challenges and other political tensions between the United States and other countries may also exacerbate
unfavorable macroeconomic conditions including inflationary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns. The ultimate impact of current or future tariffs and trade restrictions and resulting
legal challenges remains uncertain and could materially and adversely affect Candid&#8217;s business, financial condition, and prospects. While Candid actively monitors these risks, any prolonged economic downturn, escalation in trade tensions, or
deterioration in international perception of U.S.-based companies could materially and adversely affect Candid&#8217;s business, ability to access the capital markets or other financing sources, results of operations, financial condition and
prospects. In addition, trade developments have and may continue to heighten the risks related to the other risk factors described elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid has <FONT STYLE="white-space:nowrap">in-licensed</FONT> the rights to cizutamig and CND261 in limited territories. Any adverse developments that occur
during any clinical trials or manufacturing conducted by third parties, including EpimAb or Genor, in other jurisdictions or other indications may affect Candid&#8217;s ability to obtain regulatory approval or commercialize its drug candidates.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has <FONT STYLE="white-space:nowrap">in-licensed</FONT> the right to develop, manufacture and commercialize cizutamig and CND261 everywhere in the
world except for Mainland China, Hong Kong, Macau and Taiwan (the &#8220;Licensed Territory&#8221;). EpimAb Biotherapeutics (&#8220;EpimAB&#8221;) and Genor Biopharma (&#8220;Genor&#8221;), over which Candid has limited control, have the right to
develop, manufacture and commercialize these drug candidates in geographies outside the Licensed Territory. If serious adverse events or other negative safety results are observed in any studies conducted by EpimAb, Genor or any third parties, such
results may negatively impact Candid&#8217;s programs in autoimmune diseases. For example, unfavorable safety results observed in third-party studies of Candid&#8217;s drug candidates could lead the FDA or other comparable foreign regulatory
authorities to suspend or impose restrictions on Candid&#8217;s clinical trials, and such events could ultimately result in the delay, limitation or denial of approval of these drug candidates or require Candid to conduct additional clinical trials
as a condition to regulatory approval, if any, which would increase Candid&#8217;s costs and time to market. If Candid receives FDA or foreign regulatory authority approval for any of its drug candidates and a new or serious safety issue is
identified in connection with clinical trials conducted by third parties, the FDA or other comparable foreign regulatory authority may withdraw or vary their approval, restrict Candid&#8217;s ability to market and sell its drugs or require
additional testing or evaluation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Disruptions to the operations of the FDA, the SEC, other U.S. governmental agencies or comparable foreign regulatory
authorities caused by funding shortages, leadership changes, staffing cuts or other staffing shortages, along with uncertainty regarding the potential for new initiatives, laws, regulations, policies and guidance affecting Candid&#8217;s drug
candidates or other aspects of Candid&#8217;s business, could materially and adversely affect Candid&#8217;s business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ability of the FDA or other
comparable foreign regulatory authorities to review and approve new products or take action with respect to other regulatory matters can be affected by a variety of factors, including government budget and funding levels, leadership changes, the
ability to hire and retain key personnel and accept payment of user fees, the availability of personnel and other resources, changes in statutes, regulations and policies that affect the FDA&#8217;s or comparable foreign regulatory
authorities&#8217; ability to perform routine functions, and other business disruptions. Average review times at the FDA and comparable foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of
the SEC and other government agencies on which Candid&#8217;s operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical
FDA, SEC and other government employees and stop critical activities. In addition, there have recently been terminations of large numbers of federal employees at various federal agencies, including the FDA. Changes and cuts in FDA staffing could
result in delays in the FDA&#8217;s responsiveness or in its ability to review IND submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion, or at all. A prolonged government
shutdown and/or employee terminations or resignations could significantly impact the ability of the FDA or other federal agencies to timely review and process Candid&#8217;s regulatory submissions, which could have a material adverse effect on
Candid&#8217;s business. Government shutdowns and/or employee terminations could also impact third parties with whom Candid works, such as clinical trial sites, which in turn could have a material impact on Candid&#8217;s business. Further, future
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
government shutdowns and/or employee terminations or resignations at the SEC could impact Candid&#8217;s ability to access the public markets and obtain necessary capital in order to properly
capitalize and continue Candid&#8217;s operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is substantial uncertainty as to whether and how the current administration will seek to modify or revise
the requirements and policies of the FDA and other regulatory agencies with jurisdiction over Candid&#8217;s drug candidates and any products for which Candid obtains approval. This uncertainty could present new challenges as Candid navigates
development and approval of its drug candidates. Some of these efforts have manifested to date in the form of personnel cuts and measures that could impact the FDA&#8217;s ability to hire and retain key personnel, which could result in delays or
limitations on Candid&#8217;s ability to obtain guidance from the FDA on its drug candidates in development and obtain the requisite regulatory approvals in the future. There is uncertainty as to whether Candid will be materially and negatively
impacted by governmental orders, regulations, policies or guidance, or disruptions to the normal operations of government agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to
Candid&#8217;s Reliance on Third Parties and Manufacturing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If third parties that Candid relies on to conduct preclinical studies and clinical trials do
not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Candid may not be able to obtain marketing approval for or commercialize its drug candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid does not independently conduct the majority of its preclinical studies and any of its clinical trials. Candid relies and plans to continue to rely on clinical
investigators, consultants, contract laboratories and other third parties, such as CROs, to conduct or otherwise support research and preclinical studies and clinical trials for its drug candidates. Candid relies heavily on these parties for
execution of preclinical studies and clinical trials for its drug candidates and controls only certain aspects of their activities. Nevertheless, Candid is responsible for ensuring that each of its preclinical studies and clinical trials is
conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and Candid&#8217;s reliance on CROs and other third parties will not relieve Candid of its regulatory responsibilities. For any
violations of laws and regulations during the conduct of Candid&#8217;s preclinical studies and clinical trials, Candid could be subject to untitled letters, warning letters or enforcement action that may include civil penalties up to and including
criminal prosecution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid and the third parties on which Candid relies for clinical trials are required to comply with regulations and requirements, including
GCP for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of
participating in clinical trials and that their rights are protected. These regulations are enforced by the FDA, the competent authorities of the EU Member States, and comparable foreign regulatory authorities for any drugs in clinical development.
The FDA and competent authorities of EU Member States enforce GCP requirements through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If Candid or these third parties fail to comply with applicable GCP, the
clinical data generated in Candid&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Candid to perform additional clinical trials before approving any marketing applications Candid
may submit. Candid cannot assure investors that, upon inspection, the FDA or comparable foreign regulatory authorities will determine that any of Candid&#8217;s future clinical trials will comply with GCP. In addition, Candid&#8217;s clinical trials
must be conducted with drug candidates produced under current Good Manufacturing Practice (&#8220;cGMP&#8221;) regulations. Candid&#8217;s failure or the failure of these third parties to comply with these regulations may require Candid to repeat
clinical trials, which would delay the regulatory approval process and could also subject Candid to enforcement action. Candid is also required to register certain ongoing clinical trials and provide certain information, including information
relating to the trial&#8217;s protocol, on a government-sponsored database, ClinicalTrials.gov, within specific timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Similar requirements and sanctions
may apply outside of the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although Candid intends to design the preclinical studies and clinical trials for its drug candidates, Candid will rely on
third parties to conduct its preclinical studies and clinical trials. As a result, many important aspects of Candid&#8217;s clinical development, including preclinical studies and clinical trial conduct and timing, will be outside of Candid&#8217;s
direct control. Candid&#8217;s reliance on third parties to conduct preclinical studies and future clinical trials will also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
result in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if Candid were relying entirely upon its own staff. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Communicating with CROs can also be challenging, potentially leading to mistakes, as well as difficulties in coordinating activities. Such CROs may: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">have staffing difficulties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fail to comply with contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">experience regulatory compliance issues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">undergo changes in priorities or become financially distressed; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">form relationships with other entities, some of which may be Candid&#8217;s competitors. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of the third parties with whom Candid contracts also have relationships with other commercial entities, including Candid&#8217;s competitors, for whom they may
also be conducting clinical trials or other activities, that could harm Candid&#8217;s competitive position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, principal investigators for Candid&#8217;s
preclinical studies and clinical trials may serve as scientific advisors or consultants to Candid from time to time and receive compensation in connection with such services. Under certain circumstances, Candid may be required to report some of
these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between Candid and a principal investigator has created a conflict of interest
or otherwise affected the interpretation of the trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated by the applicable preclinical studies or at the clinical trial site and the utility
of the preclinical studies and clinical trial itself may be jeopardized. This could result in a delay in approval, refusal to accept or rejection of Candid&#8217;s marketing applications by the FDA or comparable foreign regulatory authority, as the
case may be, and may ultimately lead to the denial of regulatory approval of Candid&#8217;s drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Candid&#8217;s CROs have the right to
terminate their agreements with Candid in the event of an uncured material breach and under other specified circumstances. If any of Candid&#8217;s relationships with these third parties terminate, Candid may not be able to enter into arrangements
with alternative third parties in a timely manner, on commercially reasonable terms, or at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is ultimately no guarantee that any of Candid&#8217;s CROs,
investigators or other third parties will devote adequate time and resources to such trials or studies, perform as contractually required or in a satisfactory manner or comply with regulatory requirements. If any of these third parties fails to meet
expected deadlines, fails to adhere to Candid&#8217;s clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, Candid may be unable to rely on clinical data collected by these third parties, may be required
to repeat, extend the duration of, or increase the size of any preclinical studies and clinical trials Candid conducts, or may result in the termination of its preclinical studies and clinical trials, all of which could significantly delay
commercialization, require significantly greater expenditures and harm Candid&#8217;s financial results and the commercial prospects for its drug candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s success is dependent on its ability to successfully pursue business development, strategic partnerships and investment opportunities as Candid
matures. Candid is currently party to such arrangements, and may enter into additional collaboration and licensing arrangements in the future, and may not realize the benefits of such collaborations, alliances, acquisitions or licensing
arrangements. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has entered into licensing and collaboration arrangements with EpimAb, Genor and Wuxi Biologics for the right to develop,
manufacture and commercialize cizutamig, CND261 and CND319, respectively, and may in the future form or seek strategic alliances or acquisitions, create joint ventures or enter into additional collaboration and licensing arrangements with third
parties that Candid believes will complement or augment its development and commercialization efforts with respect to its drug candidates that Candid may develop. Any of these relationships may require Candid to incur
<FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase its near and long-term expenditures, issue securities that dilute Candid&#8217;s existing stockholders or disrupt Candid&#8217;s management and business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development collaborations are subject to numerous risks, which may include the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators could fail to conduct trials on the timeline Candid expects or otherwise fail to support Candid&#8217;s
partnered trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with
Candid&#8217;s drugs or drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators could encounter safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues
or other problems with Candid&#8217;s partnered trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not properly enforce, maintain or defend Candid&#8217;s intellectual property rights or may use
Candid&#8217;s proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate Candid&#8217;s intellectual property or proprietary information or expose Candid to potential litigation, or other
intellectual property proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disputes may arise between a collaborator and Candid that cause the delay or termination of the research, development or
commercialization of the drug candidate, or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if a present or future collaborator of Candid were to be involved in a business combination, the continued pursuit and
emphasis on Candid&#8217;s product development or commercialization program under such collaboration could be delayed, diminished or terminated; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaboration agreements may restrict Candid&#8217;s right to independently pursue new drug candidates.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid faces significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether
Candid reaches a definitive agreement for other collaborations will depend, among other things, upon Candid&#8217;s assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the
proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of Candid&#8217;s clinical trials, the likelihood of approval by the FDA or comparable foreign
regulatory authorities, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to
Candid&#8217;s ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative drug
candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with Candid for Candid&#8217;s drug candidate. Further, Candid may not be successful in
its efforts to establish a strategic partnership or other alternative arrangements for future drug candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as
having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new collaborations or strategic partnership agreements related to any drug candidate Candid develops could delay the development and commercialization of
Candid&#8217;s drug candidates, which would harm Candid&#8217;s business prospects, financial condition and results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of these risks,
Candid may not be able to realize the benefit of its existing licensing agreements or any future collaborations or licensing agreements Candid may enter into. In addition, there have been a significant number of recent business combinations among
large pharmaceutical and biomedical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, Candid may not be able to negotiate collaborations on a timely
basis, on acceptable terms, or at all. If Candid is unable to do so, Candid may have to curtail the development of such drug candidate, reduce or delay one or more of its other development programs, delay the potential commercialization or reduce
the scope of any planned sales or marketing activities for such drug candidate, or increase its expenditures and undertake development, manufacturing or commercialization activities at its own expense. If Candid elects to increase its expenditures
to fund development, manufacturing or commercialization activities on its own, Candid may need to obtain additional capital, which may not be available to Candid on acceptable terms or at all. If Candid does not have sufficient funds, Candid may not
be able to further develop its drug discovery program or drug candidates or bring them to market and generate revenue. </P> <P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, Candid may sometimes collaborate with academic institutions to accelerate its preclinical research or
development under written agreements with these institutions. If collaborations occur, these institutions provide Candid with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration.
Regardless of such option, Candid may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to Candid. If Candid is unable to do so, the institution may offer the intellectual property rights to other
parties, potentially blocking Candid&#8217;s ability to pursue its program. If Candid is unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights Candid has, Candid
may have to abandon development of such program and Candid&#8217;s business and financial condition could suffer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s drugs require specific
constituents to work effectively and efficiently, and rights to those constituents are, and in the future may be, held by others. Candid may be unable to <FONT STYLE="white-space:nowrap">in-license</FONT> any rights from constituents, methods of
use, processes or other third-party intellectual property rights from third parties that Candid identifies. Candid may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which could harm Candid&#8217;s business. Even
if Candid is able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving Candid&#8217;s competitors access to the same technologies licensed to Candid. In that event, Candid may be required to expend
significant time and resources to develop or license replacement technology in order to establish or maintain Candid&#8217;s competitive position in the market. Any delays in entering into new collaborations or strategic partnership agreements
related to Candid&#8217;s drug candidates or its drug discovery capabilities could delay the development and commercialization of Candid&#8217;s drug candidates in certain geographies or limit Candid&#8217;s ability to discover and develop new drug
candidates, which could harm Candid&#8217;s business prospects, financial condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid contracts with third parties for the
manufacturing and supply of certain of its drug candidates for use in preclinical testing and planned clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid does not have any manufacturing facilities. Candid currently relies on contract and development manufacturing organizations (&#8220;CDMOs&#8221;) in China for
the manufacture and supply of its drug candidates for clinical testing. If any of Candid&#8217;s drug candidates are approved, Candid intends to continue to rely on CDMOs for commercial manufacture. Candid&#8217;s current reliance on CDMOs increases
the risk that Candid will not have sufficient quantities of its drug candidates or for any potential commercialization, or such quantities of its drug candidates at an acceptable cost or quality, which in each case could delay, prevent or impair
Candid&#8217;s development or potential commercialization efforts. Furthermore, in Candid&#8217;s clinical trials, Candid plans to evaluate differing dosing regimens using both intravenous and/or subcutaneous formulations of cizutamig, CND261,
CND319 and CND460. As such, Candid may require its drug candidates to be manufactured in high dose concentrations to facilitate the administration of the subcutaneous formulation. If Candid&#8217;s CDMOs are unable to manufacture such high dose
concentrations of Candid&#8217;s drug candidates, Candid could face delays in its planned clinical trials. Candid has started the process to locate an alternate CDMO elsewhere globally, but there is no guarantee that Candid can identify and engage
an alternate manufacturer in time so as not to disrupt Candid&#8217;s planned clinical trials on terms that are acceptable to Candid (including financial terms), or at all. Even if Candid is able to transfer its manufacturing process of its drug
candidates to another CDMO, establishing additional or replacement suppliers for supplies, and obtaining regulatory clearance or approvals that may result from adding or replacing suppliers, could take a substantial amount of time, result in
increased costs and impair Candid&#8217;s ability to produce its drugs, which would adversely impact Candid&#8217;s business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, all entities involved in the preparation of therapeutics for clinical trials or commercial sale, including Candid&#8217;s existing and future CDMOs for its
drug candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern, among
other things, manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational drugs and drugs approved for sale. Poor control of
production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of Candid&#8217;s drug candidates that may not be detectable in final product testing. Candid or its CDMOs must supply all
necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s Good Laboratory Practice regulations and cGMP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. The facilities and quality
systems of Candid&#8217;s third-party CDMOs must pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection for compliance with the applicable regulations as a condition to marketing approval of Candid&#8217;s drug candidates. Candid
does not control the manufacturing process of, and is completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of Candid&#8217;s drug candidates. If these third-party manufacturers cannot successfully
manufacture material that conforms to Candid&#8217;s specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or maintain regulatory approval for the use of
their manufacturing facilities in connection with Candid&#8217;s drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid, or Candid&#8217;s contract manufacturers, and any future collaborators
and their contract manufacturers could be subject to periodic unannounced inspections by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to monitor and ensure compliance with cGMP. Despite
Candid&#8217;s efforts to audit and verify regulatory compliance, Candid&#8217;s CDMOs may be found on regulatory inspection by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to be noncompliant
with cGMP regulations. Candid&#8217;s failure, or the failure of Candid&#8217;s CDMOs, to comply with applicable regulations could result in sanctions being imposed on Candid, including shutdown of the third-party vendor or invalidation of drug
product lots or processes, fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of drug candidates or drugs, operating restrictions and criminal prosecutions, any of
which could significantly and adversely affect supplies of Candid&#8217;s drugs, if approved, and significantly harm Candid&#8217;s business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that any of Candid&#8217;s manufacturers fails to comply with such requirements or to perform its obligations to Candid in relation to quality, timing or
otherwise, or if Candid&#8217;s supply of components or other materials becomes limited or interrupted for other reasons, Candid may be forced to manufacture the materials itself, for which Candid currently does not have the capabilities or
resources, or enter into an agreement with another third-party, which Candid may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of Candid&#8217;s manufacturers could require significant effort and
expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture Candid&#8217;s drug candidates may be unique or proprietary to the original manufacturer and Candid
may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. Further, analytical methods required for manufacturing may be difficult to transfer between CDMOs and the failure to properly
transfer or validate these methods may impact Candid&#8217;s development timelines. If Candid is required to or voluntarily changes manufacturers for any reason, Candid will be required to verify that the new manufacturer maintains facilities and
procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is equivalent to that produced in a prior facility. The delays associated with the verification of a new manufacturer and
equivalent product could negatively affect Candid&#8217;s ability to develop drug candidates in a timely manner or within budget. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain Chinese biotechnology
companies, CROs and contract development and manufacturing organizations may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could potentially impact services
available for Candid&#8217;s research and development or Candid&#8217;s ability to secure the materials it needs for its drug candidates. For example, on December&nbsp;18, 2025, President Trump signed the National Defense Authorization Act for
Fiscal Year 2026 into law, which includes the BIOSECURE Act. The BIOSECURE Act prohibits the U.S. government from procuring or obtaining biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern&#8221;
(&#8220;BCC&#8221;); entering into, extending, or renewing government contracts with an entity that directly or indirectly uses biotechnology equipment or services from a BCC in performance of that federal contract; and/or issuing grants or loans to
purchase, obtain, or use biotechnology equipment or services produced by a BCC.&nbsp;The BIOSECURE Act also prohibits U.S. government loan and grant recipients from using federal loan or grant money to enter into contracts with entities that use
equipment from BCCs in the performance of any federal prime contract or subcontract. Companies designated as a BCC include those that are identified on the U.S. Department of Defense&#8217;s annual List of Chinese Military Companies, also known as
the 1260H List. The U.S. government also has the ability to designate entities as BCCs through a separate designation process. There is a &#8220;safe harbor&#8221; provision providing that the restrictions do not apply to equipment or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
services that were formerly but are no longer provided by a BCC, as well as a &#8220;grandfathering&#8221; provision providing that the prohibitions shall not apply for a five-year period to
biotechnology equipment or services produced or provided under a contract or agreement entered into before the applicable effective date. Given the BIOSECURE Act, Candid may be restricted in its ability to work with certain Chinese biotechnology
companies to the extent Candid would contract with, or otherwise receive funding from, the U.S. government. Such counterparties may be subject to other U.S. legislation, sanctions, trade restrictions and other foreign regulatory requirements which
could increase the cost or reduce the supply of material available to Candid, delay the procurement or supply of such material or have an adverse effect on Candid&#8217;s ability to secure significant commitments from governments to purchase
Candid&#8217;s potential therapies. Such disruption could have adverse effects on the development of Candid&#8217;s drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Candid does not
have any long-term commitments or supply agreements with its CDMOs. Candid may be unable to establish any long-term supply agreements with CDMOs or to do so on acceptable terms or at all, which increases the risk of failing to timely obtain
sufficient quantities of its drug candidates or such quantities at an acceptable cost. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s or a third-party&#8217;s failure to execute on Candid&#8217;s
manufacturing requirements, do so on commercially reasonable terms and timelines and comply with cGMP requirements could adversely affect Candid&#8217;s business in a number of ways, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to meet Candid&#8217;s product specifications and quality requirements consistently; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an inability to initiate or continue preclinical studies or clinical trials of Candid&#8217;s drug candidates under
development; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delay in submitting regulatory applications, or receiving regulatory approvals, for Candid&#8217;s drug candidates, if at
all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">loss of the cooperation of future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subjecting third-party manufacturing facilities or Candid&#8217;s manufacturing facilities to additional inspections by
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to cease development or to recall batches of Candid&#8217;s drug candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in the event of approval to market and commercialize Candid&#8217;s drug candidates, an inability to meet commercial
demands for Candid&#8217;s product or any other future drug candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Candid does not have any long-term commitments or supply
agreements with any third-party manufacturers. Candid may be unable to establish any long-term supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of failing to timely obtain sufficient
quantities of Candid&#8217;s drug candidates or such quantities at an acceptable cost. Even if Candid is able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to manufacture Candid&#8217;s drug candidates according to Candid&#8217;s specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to manufacture Candid&#8217;s product according to Candid&#8217;s schedule or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">misappropriation of Candid&#8217;s proprietary information, including Candid&#8217;s trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for Candid.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any performance failure on the part of Candid&#8217;s existing or future manufacturers could delay clinical development or regulatory approval,
and any related remedial measures may be costly or time consuming to implement. Candid does not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of Candid&#8217;s
drug candidates. If Candid&#8217;s existing or future third-party manufacturers cannot perform as agreed, Candid may be required to replace such manufacturers and Candid may be unable to replace them on a timely basis or at all, which would have a
material adverse impact on Candid&#8217;s financial position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in methods of drug candidate manufacturing may result in additional costs or delays. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As Candid&#8217;s drug candidates progress through preclinical to late-stage clinical trials to regulatory approval and commercialization, it is common that various
aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize yield or manufacturing batch size, change drug product dosage form, minimize costs and achieve consistent quality and results. Such
changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause Candid&#8217;s drug candidates to perform differently, could impair Candid&#8217;s ability to utilize or interpret any existing data, and
affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or
more clinical trials, increase clinical trial costs, delay approval of Candid&#8217;s drug candidates and jeopardize Candid&#8217;s ability to commercialize its drug candidates and generate revenue. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If Candid&#8217;s third-party suppliers use hazardous, <FONT STYLE="white-space:nowrap">non-hazardous,</FONT> biological or other materials in a manner that
causes injury or violates applicable law, Candid may be liable for damages. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s research and development activities involve the controlled use
of potentially hazardous substances, including chemical and biological materials. Candid and its suppliers are subject to federal, state and local laws and regulations in the United States and by foreign governmental authorities governing the use,
manufacture, storage, handling and disposal of medical and hazardous materials. Although Candid believes that Candid and its suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed
standards, neither Candid nor its suppliers can completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, Candid may incur liability, or local, city,
state or federal authorities may curtail the use of these materials and interrupt Candid&#8217;s business operations. In the event of an accident, Candid could be held liable for damages or penalized with fines, and the liability could exceed
Candid&#8217;s resources. Candid does not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may
impair Candid&#8217;s research, development and production efforts, which could harm Candid&#8217;s business, prospects, financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Commercialization of Candid&#8217;s Drug Candidates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid faces significant competition from other biotechnology and pharmaceutical companies, and Candid&#8217;s operating results will suffer if Candid fails to
compete effectively. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biopharmaceutical industry in general, and the autoimmune field in particular, is characterized by rapidly advancing and changing
technologies, intense competition and a strong emphasis on intellectual property. Candid faces substantial and increasing competition from large and specialty biopharmaceutical companies, as well as public and private medical research institutions
and governmental agencies. A large number of companies are advancing development programs in autoimmune diseases, including myasthenia gravis and <FONT STYLE="white-space:nowrap">SARD-ILD.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s competition for <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion includes monoclonal antibodies (&#8220;mAbs&#8221;), bispecifics which include
TCEs, IgG degraders, and various forms of cell therapy from several pharmaceutical and biotechnology companies, including AbbVie Inc., Amgen, Argenx, Artiva Biotherapeutics, Inc., Biohaven Ltd., Bristol Myers Squibb Company, Cabaletta Bio, Inc.,
Cartesian Therapeutics, Inc, Cullinan Therapeutics, Inc., Dianthus Therapeutics, Inc., Fate Therapeutics, Inc., GSK plc, Immunovant, Inc., Johnson&nbsp;&amp; Johnson, Kyverna Therapuetics, Inc., Merck&nbsp;&amp; Co., Inc., Otsuka Pharmaceutical,
Ouro Medicines, Pfizer Inc., Roche Holding AG, among others. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s competitors will also include companies that are or will be developing other targeted
therapies, including small molecule or antibodies for the same indications that Candid is targeting. It is also possible that new competitors, including those developing similar drugs or alternatives to immunotherapy drug candidates, may emerge and
acquire significant market share. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of Candid&#8217;s current or potential competitors have significantly greater financial, technical and human resources, as
well as more expertise in research and development, manufacturing, preclinical testing, conducting clinical studies and trials and commercializing and marketing approved drugs. Mergers and acquisitions in the biopharmaceutical industry may result in
even greater resource concentration among a smaller number of competitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or
to <FONT STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make Candid&#8217;s drug candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in
efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, Candid&#8217;s competitors may succeed in obtaining patent protection, discovering, developing, receiving
regulatory and marketing approval for or commercializing drugs before Candid does, which would have an adverse impact on Candid&#8217;s business and results of operations. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large, established companies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid currently has no marketing and sales organization and
has no experience as a company in commercializing drugs, and may have to invest significant resources to develop these capabilities. If Candid is unable to establish marketing and sales capabilities or enter into agreements with third parties to
market and sell its drugs, Candid may not be able to generate product revenue. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has no internal sales, marketing or distribution capabilities, nor
has Candid commercialized a product. If any of Candid&#8217;s drug candidates ultimately receives regulatory approval, Candid must build a marketing and sales organization with technical expertise and supporting distribution capabilities to
commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment Candid&#8217;s own sales force and
distribution systems or in lieu of Candid&#8217;s own sales force and distribution systems. Candid has no prior experience as a company in the marketing, sale and distribution of biopharmaceutical drugs and there are significant risks involved in
building and managing a sales organization, including Candid&#8217;s ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a
geographically dispersed sales and marketing team. Any failure or delay in the development of Candid&#8217;s internal sales, marketing and distribution capabilities would adversely impact the commercialization of these drugs. Candid may not be able
to enter into collaborations or hire consultants or external service providers to assist Candid in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, Candid&#8217;s product revenues and Candid&#8217;s
profitability, if any, may be lower if Candid relies on third parties for these functions than if Candid were to market, sell and distribute any drugs that Candid develops itself. Candid will likely have little control over such third parties, and
any of them may fail to devote the necessary resources and attention to sell and market Candid&#8217;s drugs effectively. If Candid is not successful in commercializing its drugs, either on its own or through arrangements with one or more third
parties, Candid may not be able to generate any future product revenue and Candid would incur significant additional losses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Coverage and reimbursement may
be limited or unavailable in certain market segments for Candid&#8217;s drug candidates, which could make it difficult for Candid to sell its drug candidates, if approved, profitably. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Successful sales of Candid&#8217;s drug candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors, including
governmental healthcare programs, such as Medicare and Medicaid and comparable foreign programs, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any drug
candidates for which Candid obtains regulatory approval. In addition, because Candid&#8217;s drug candidates represent new approaches to the treatment of autoimmune disease, Candid cannot accurately estimate the potential revenue from its drug
candidates. For drugs administered under the supervision of a physician, obtaining coverage and adequate reimbursement may also be particularly difficult because of the higher prices often associated with such drugs. Patients who are provided
medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product
acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend
upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appropriate for the specific patient; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require Candid to
provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of its drugs. Even if Candid obtains coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve
Candid&#8217;s product for use in their facility or third-party payors may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients are unlikely to use Candid&#8217;s drug candidates unless coverage
is provided and reimbursement is adequate to cover a significant portion of the cost of Candid&#8217;s drug candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may
be reimbursed only for providing the treatment or procedure in which Candid&#8217;s product is used. Further, from time to time, the CMS revises the reimbursement systems used to reimburse healthcare providers, including the Medicare Physician Fee
Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government
healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors, and reduce the willingness of physicians to use Candid&#8217;s drug candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, no uniform policy of coverage and reimbursement for drugs exists among third-party payors. Therefore, coverage and reimbursement for drugs can
differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Additionally, any companion diagnostic test that
Candid develops will be required to obtain coverage and reimbursement separate and apart from the coverage and reimbursement Candid seeks for its drug candidates, if approved. Adequate third-party reimbursement may not be available to enable Candid
to maintain price levels sufficient to realize an appropriate return on its investment in product development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, the United States government and foreign
governments have continued implementing cost-containment measures. For example, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) imposes rebates on many Medicare Part B and Medicare Part D products to penalize price increases
that outpace inflation on an annual basis. HHS has also been empowered to negotiate the price of certain single-source biologics that have been on the market for at least 11 years covered under Medicare as part of the Medicare Drug Price Negotiation
Program. Each year up to 20 products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from
the Medicare program on a per unit basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid intends to seek approval to market its drug candidates in both the United States and in selected foreign
jurisdictions. If Candid obtains approval in one or more foreign jurisdictions for its drug candidates, Candid will be subject to rules and regulations in those jurisdictions. Outside the United States, reimbursement and healthcare payment systems
vary significantly by country, and many countries have instituted price ceilings on specific drugs and therapies. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these
countries, pricing negotiations with governmental authorities can take considerable time after obtaining regulatory approval of a drug candidate. The EU provides options for EU Member States to restrict the range of medicinal drugs for which their
national health insurance systems provide reimbursement and to control the prices of medicinal drugs for human use. An EU Member State may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by
the manufacturer or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Many EU Member States also periodically review their reimbursement procedures for
medicinal drugs, which could have an adverse impact on reimbursement status. Moreover, in order to obtain reimbursement for its drugs in some European countries, including some EU Member States, Candid may be required to compile additional data
comparing the cost-effectiveness of its drugs to other available therapies. This HTA of medicinal drugs is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the
larger markets. The HTA process is the procedure to assess the therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the
pricing and reimbursement status granted to these medicinal drugs by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies
between EU Member States. Since January&nbsp;12,&nbsp;2025, the clinical elements of HTA must be assessed via Joint Clinical Assessment at EU level&#8212;initially for all new oncology medicines and ATMPs, expanded to orphan medicines in&nbsp;2028,
and covering all remaining centrally authorized medicines from 2030. The downward pressure on healthcare costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new drugs. In addition, in some
countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a country. Even if a pharmaceutical product obtains a marketing authorization in the EU, there can be no
assurance that reimbursement for such product will be secured on a timely basis or at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The marketability of any drug candidates for which Candid receives
regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. Candid expects downward pressure on pharmaceutical pricing to continue. Further, coverage policies and
third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more drugs for which Candid receives regulatory approval, less favorable coverage policies and reimbursement rates may
be implemented in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Product liability lawsuits against Candid could cause Candid to incur substantial liabilities and could limit commercialization
of any drug candidate that Candid may develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of Candid&#8217;s drug candidates in clinical trials and the sale of any drugs for which Candid
obtains regulatory approval exposes Candid to the risk of product liability claims. Product liability claims might be brought against Candid by consumers, healthcare professionals, pharmaceutical companies or others selling or otherwise coming into
contact with Candid&#8217;s drugs. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If Candid cannot successfully defend against product liability claims, Candid could
incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">impairment of Candid&#8217;s business reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of participants from Candid&#8217;s clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">distraction of management&#8217;s attention from Candid&#8217;s primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to commercialize Candid&#8217;s drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">decreased demand for Candid&#8217;s drug candidates, if approved for commercial sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">loss of revenue. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The regulatory approval
process of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and even if Candid completes the necessary clinical trials, Candid cannot predict when, or if, it will obtain regulatory
approval for any of its drug candidates, and any such regulatory approval may be for a more narrow indication than Candid seeks. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research, testing,
manufacturing, labeling, storage, record-keeping, approval, selling, import, export, marketing, advertising, promotion, and distribution of drugs, including biologics, are subject to extensive regulation by the FDA and comparable foreign regulatory
authorities in and outside the United States. Prior to seeking approval to commercialize a drug candidate in the United States or abroad, Candid must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the
satisfaction of the FDA or comparable foreign regulatory authorities, that such drug candidates are safe, pure and potent, or effective, for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different
ways. Even if Candid believes available nonclinical or clinical data support the safety purity and potency, or efficacy, of its drug candidates, such data may not be sufficient to obtain approval from the FDA and comparable foreign regulatory
authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require Candid to conduct additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
preclinical studies or clinical trials for its drug candidates either prior to or post-approval, or may object to elements of Candid&#8217;s clinical development program. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is not permitted to market any biological drug product in the United States or outside the United States until Candid receives approval of a BLA from the FDA or
similar approvals from comparable foreign regulatory authorities. Candid has not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA and similar applications must include extensive preclinical
and clinical data and supporting information to establish the drug candidate&#8217;s safety, purity and potency, or effectiveness for each intended indication. The BLA and similar applications must also include significant information regarding the
chemistry, manufacturing and controls for the product, including with respect to chain of identity and chain of custody of the product. The process of obtaining such regulatory approval is expensive, often takes many years following the commencement
of clinical trials and can vary substantially based upon the type, complexity and novelty of the drug candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA and
comparable regulatory authorities have substantial discretion in the approval process, including the ability to delay, limit or deny approval of a drug candidate for many reasons. Despite the time and expense invested in clinical development of drug
candidates, regulatory approval of a drug candidate is never guaranteed. Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s drug candidates could fail to receive regulatory approval from the FDA or a comparable foreign regulatory authority for many reasons, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disagreement with the design or conduct of Candid&#8217;s clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to demonstrate to the satisfaction of regulatory authorities that Candid&#8217;s drug candidates are safe, pure
and potent, or effective for any proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">negative or ambiguous results from Candid&#8217;s clinical trials or results may not meet the level of statistical
significance or persuasiveness required by the FDA or comparable foreign regulatory agencies for approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">serious and unexpected drug-related side effects may be experienced by participants in Candid&#8217;s clinical trials or
by individuals using drugs similar to Candid&#8217;s drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full
population for which Candid seeks approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where
the standard of care is potentially different from that of their own country; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid may be unable to demonstrate that a drug candidate&#8217;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disagreement with Candid&#8217;s interpretation of data from preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the insufficiency of data collected from clinical trials of Candid&#8217;s drug candidates to support the submission and
filing of a BLA or other submission or to obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">such authorities may disagree with Candid regarding the formulation, labeling and/or the product specifications of
Candid&#8217;s drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">such authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers with
which Candid contracts for clinical and commercial supplies; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the approval policies or regulations that render Candid&#8217;s preclinical and clinical data insufficient for
approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This lengthy approval process as well as the unpredictability of future clinical trial results may result in Candid failing to obtain
regulatory approval to market its drug candidates, which would significantly harm Candid&#8217;s business, results of operations and prospects. The FDA or a comparable foreign regulatory authority may require more information, including additional
preclinical or clinical data to support approval, which may delay or prevent approval and Candid&#8217;s commercialization plans, or Candid may decide to abandon the development program. If Candid were to obtain approval, regulatory authorities may
approve any of Candid&#8217;s drug candidates for fewer or more limited indications than Candid requests (including failing to approve the most commercially promising indications), may grant approval contingent on the performance of costly
post-marketing clinical studies, or may approve a drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate. Even if Candid&#8217;s drug candidates meet
their safety and efficacy endpoints in clinical trials, such results may not enable Candid to obtain regulatory approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Candid may experience delays
or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. Accordingly, the
regulatory approval pathway for Candid&#8217;s drug candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU
Clinical Trials Regulation No.&nbsp;536/2014 (&#8220;CTR&#8221;), which was adopted in April 2014 and repeals the EU Clinical Trials Directive 2001/20 (&#8220;CTD&#8221;), became applicable on January&nbsp;31, 2022. The CTR foresaw a three-year
transition period that ended on January&nbsp;31, 2025. Since this date, all new or ongoing trials are subject to the provisions of the CTR. Compliance with the CTR requirements by Candid and its third-party service providers, such as CROs, may
impact Candid&#8217;s development plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, on December&nbsp;11, 2025, the European Commission, the Parliament and the European Council reached a
political agreement on a comprehensive overhaul of EU pharmaceutical legislation (the &#8220;Pharma Package&#8221;). The reform has been under negotiation since the European Commission submitted its proposal in April 2023. This
package&#8212;comprised of a new directive and regulation to replace existing legislation&#8212;aims to modernize the EU framework. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The political agreement is
still subject to formal approval by the European Parliament and Council. If approved in the form proposed, the Pharma Package will, among other changes, reduce the baseline market protection period by one year, with limited opportunities for
extensions; and expand the Bolar exemption. A decrease in market exclusivity opportunities for our product candidates in the EU, combined with the expanded Bolar exemption, could open them to generic or biosimilar competition earlier than under the
current regime, potentially impacting reimbursement status and the commercial prospects of our product candidates. The revisions may have a significant impact on the pharmaceutical industry and Candid&#8217;s business in the long term. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining regulatory approval of Candid&#8217;s drug candidates in one jurisdiction does not mean that Candid will be successful in obtaining
regulatory approval of its drug candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining and maintaining regulatory approval of Candid&#8217;s drug candidates in one
jurisdiction does not guarantee that Candid will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory
approval process in others. For example, even if the FDA grants regulatory approval of a drug candidate, comparable foreign regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the drug
candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or
clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a drug candidate must be approved for reimbursement before it
can be approved for sale in that jurisdiction. In some cases, the price that Candid intends to charge for its drugs is also subject to approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid may also
submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of drug candidates with which Candid must comply prior to marketing in those jurisdictions.
Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for Candid and could delay or prevent the introduction of Candid&#8217;s drugs in certain
countries. If Candid fails to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, Candid&#8217;s target market will be reduced and Candid&#8217;s ability to realize the full market
potential of its drug candidates will be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if Candid receives regulatory approval of its drug candidates, Candid will be subject to ongoing
regulatory obligations and continued regulatory review, which may result in significant additional expense and Candid may be subject to penalties if it fails to comply with regulatory requirements or experiences unanticipated problems with its drug
candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any regulatory approvals that Candid receives for its drug candidates will require surveillance to monitor the safety and efficacy of the drug
candidate. The FDA may also require a REMS in order to approve Candid&#8217;s drug candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves Candid&#8217;s drug candidates, the manufacturing processes, labeling, packaging, distribution,
adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for Candid&#8217;s drug candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and
other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that Candid conducts. As such, Candid and its CDMOs will be subject to continual review and inspections to assess
compliance with cGMP and adherence to commitments made in any BLA, other marketing applications and previous responses to inspectional observations. Accordingly, Candid and others with whom Candid works must continue to expend time, money and effort
in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA or comparable foreign regulatory authorities could require Candid to conduct another study to obtain additional safety or biomarker
information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, Candid will be required to comply with FDA and comparable foreign regulatory authorities&#8217; promotion and advertising rules, which
include, among others, standards for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the
product&#8217;s approved uses (known as <FONT STYLE="white-space:nowrap">&#8220;off-label</FONT> use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet
and social media. Although the FDA and comparable foreign regulatory authorities do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications
from companies or their sales forces with respect to <FONT STYLE="white-space:nowrap">off-label</FONT> uses of drugs for which marketing clearance has not been issued. Later discovery of previously unknown problems with Candid&#8217;s drug
candidates, including adverse events of unanticipated severity or frequency, or with Candid&#8217;s third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling
to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS or similar foreign program. Other potential consequences
include, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of Candid&#8217;s drug candidates, withdrawal of the product from the
market or voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, untitled letters, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal by the FDA or comparable foreign regulatory authority to approve pending applications or supplements to approved
applications submitted by Candid or suspension or revocation of license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention, or refusal to permit the import or export of Candid&#8217;s drug candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FDA and comparable foreign regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of Candid&#8217;s drug candidates. Candid cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or
abroad. If Candid is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Candid is not able to maintain regulatory compliance, Candid may lose any regulatory approval that it may have
obtained and may not achieve or sustain profitability. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s relationships with customers, physicians, other healthcare professionals and
third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, transparency laws, health information privacy and security laws and other healthcare laws and
regulations. If Candid </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>
or its employees, independent contractors, consultants, commercial partners and vendors violate these laws, Candid could face substantial penalties. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Healthcare professionals and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug
candidates for which Candid obtains marketing approval. Candid&#8217;s current and future arrangements with healthcare professionals, third-party payors, customers and others may expose Candid to broadly applicable fraud and abuse and other
healthcare laws and regulations. These laws may impact, among other things, Candid&#8217;s clinical research program, as well as Candid&#8217;s proposed and future sales, marketing and education programs. In particular, the promotion, sales and
marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing,
discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. Candid may also be subject to federal, state and foreign laws governing the privacy and security of identifiable patient information. The
U.S. healthcare laws and regulations that may affect Candid&#8217;s ability to operate include, but are not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully,
offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchasing, leasing, ordering or arranging for the purchase, lease, or order of any item or
service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. Although there are a number of statutory
exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that may be alleged to be intended to
induce prescribing, purchases or recommendations, including any payments of more than fair market value, may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a person or entity does not need to have actual
knowledge of this statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal civil and criminal false claims laws, including the federal civil False Claims Act (&#8220;FCA&#8221;) and civil
monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal government programs that are false
or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government, including federal healthcare programs. In addition, the government may assert that a claim including
items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Private individuals, commonly known as &#8220;whistleblowers,&#8221; can bring federal civil FCA qui
tam actions, on behalf of the government and such individuals and may share in amounts paid by the entity to the government in recovery or settlement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) which created new federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device, a material fact or making
any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and
their respective implementing regulations, which impose requirements on covered entities, including certain healthcare providers, health plans and healthcare clearinghouses, and their respective business associates that perform services for them
that involve creating, receiving maintaining or transmitting protected health information (&#8220;PHI&#8221;) and their subcontractors that use, disclose, access, or otherwise process PHI, relating to the privacy, security and transmission of
individually identifiable health information. Penalties for HIPAA violations can be significant. They vary greatly depending on the nature of violation, and could include civil monetary or criminal penalties. HIPAA also authorizes state attorneys
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create
a private right of action allowing individuals to sue Candid in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or
breach of PHI; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Physician Payments Sunshine Act and its implementing regulations require that certain manufacturers of drugs,
devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, annually report information to CMS related to certain payments or other
transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioners (physician assistants, nurse
practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the
physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also, many states have similar fraud and abuse statutes or regulations similar to the aforementioned federal laws
that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. In order to manufacture or distribute drugs commercially, Candid must comply with state laws that require the
registration of manufacturers and wholesale distributors of drug and biological drugs in a state, including, in certain states, manufacturers and distributors who ship drugs into the state even if such manufacturers or distributors have no place of
business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology
capable of tracking and tracing product as it moves through the distribution chain. Several states and local jurisdictions have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs and
comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, file periodic reports with the state, make periodic public disclosures on sales, marketing,
pricing, clinical trials and other activities and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology
companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid may also be subject to foreign equivalents of each of
the healthcare laws described above. For example, in the EU, interactions between pharmaceutical companies and healthcare professionals and healthcare organizations are also governed by strict laws, regulations, industry self-regulation codes of
conduct and physicians&#8217; codes of professional conduct both at the EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement,
purchase, supply, order or use of pharmaceutical drugs is prohibited in the EU. Relationships with healthcare professionals and associations are subject to stringent anti-gift statutes and anti-bribery laws, the scope of which differs across the EU.
Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the
breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of Candid&#8217;s business activities, including certain arrangements Candid has with physicians who are paid in the
form of stock or stock options for services provided to Candid, could be subject to challenge under one or more of such laws. If Candid or its employees, independent contractors, consultants, commercial partners and vendors violate these laws,
Candid may be subject to investigations, enforcement actions and/or significant penalties. If any such actions are instituted against Candid, and Candid is not successful in defending itself or asserting its rights, those actions could have a
significant impact on Candid&#8217;s business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and
other federal healthcare programs or comparable foreign programs, contractual damages, reputational harm, diminished profits and future earnings, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
additional reporting requirements and/or oversight if Candid becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment of Candid&#8217;s operations, any of which could adversely affect Candid&#8217;s ability to operate its business and its results of operations. In addition, the
approval and commercialization of any of Candid&#8217;s drug candidates outside the United States will also likely subject Candid to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid expects the drug candidates it develops will be regulated as biologics, and therefore they may be subject to competition sooner than anticipated.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The BPCIA was enacted as part of the Patient Protection Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act
(collectively, the &#8220;Affordable Care Act&#8221;), to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological drugs. The regulatory pathway establishes legal authority for the FDA to review and approve
biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until
12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is
uncertain when processes intended to implement BPCIA may be fully adopted by the FDA, any of these processes could have a material adverse effect on the future commercial prospects for Candid&#8217;s biological drugs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid believes that any drug candidate it develops that is approved in the United States as a biological product under a BLA, if any, should qualify for the <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject drug candidates to be
reference drugs for competing drugs, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference drugs in a way
that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> drugs is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, there is a special regime for biosimilars, or biological medicinal drugs that are similar to a reference medicinal product but that do not meet the
definition of a generic medicinal product. For such drugs, the results of appropriate preclinical or clinical trials must be provided in support of a Marketing Authorization Application (&#8220;MAA&#8221;). Guidelines from the EMA detail the type of
quantity of supplementary data to be provided for different types of biological product. In addition, the approval of a biologic product biosimilar to one of Candid&#8217;s drugs could have a material adverse impact on Candid&#8217;s business as it
may be significantly less costly to bring to market and may be priced significantly lower than Candid&#8217;s drugs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if Candid obtains regulatory
approval of its drug candidates, the drugs may not gain market acceptance among physicians, patients, hospitals, rheumatology clinics and others in the medical community. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of TCEs as a potential autoimmune disease treatment may not become broadly accepted by physicians, patients, hospitals, rheumatology clinics and others in the
medical community. Factors that will influence whether Candid&#8217;s drug candidates are accepted in the market include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the clinical indications for which Candid&#8217;s drug candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">physicians, hospitals, rheumatology clinics and patients considering Candid&#8217;s drug candidates as a safe and
effective treatment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential and perceived advantages of Candid&#8217;s drug candidates over alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the incidence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product labeling or product insert requirements of the FDA or comparable foreign regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of market introduction of Candid&#8217;s drug candidates as well as competitive drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s pricing and the availability of coverage and adequate reimbursement by third-party payors, including
government authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of coverage and adequate reimbursement by third-party payors, including government authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive
therapies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effectiveness of Candid&#8217;s sales and marketing efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Candid&#8217;s drug candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, rheumatology clinics or others in the
medical community, Candid will not be able to generate significant revenue. Even if Candid&#8217;s drugs achieve market acceptance, Candid may not be able to maintain that market acceptance over time if new drugs or technologies are introduced that
are more favorably received than Candid&#8217;s drugs, are more cost effective or render Candid&#8217;s drugs obsolete. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The advancement of healthcare reform
in the United States may negatively impact Candid&#8217;s ability to profitably sell its drug candidates, if approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third-party payors, whether domestic
or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes
to the healthcare system that could impact Candid&#8217;s ability to profitably sell its drug candidates, if approved. For example, in 2010 the Affordable Care Act was enacted. The Affordable Care Act and its implementing regulations substantially
changed the way healthcare is financed by both governmental and private insurers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since its enactment, there have been executive, judicial and political challenges
to certain aspects of the Affordable Care Act. For example, on July&nbsp;4, 2025, the OBBBA was signed into law, which narrowed access to Affordable Care Act marketplace exchange enrollment and declined to extend the Affordable Care Act enhanced
advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance. The OBBBA also is expected to reduce Medicaid spending and enrollment by
implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to further reduce
healthcare costs with alternatives to replace the expired Affordable Care Act subsidies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other legislative changes have been proposed and adopted since the
Affordable Care Act was enacted, including aggregate reductions to Medicare payments to providers, which went into effect beginning on April&nbsp;1, 2013 and due to subsequent legislative amendments to the statute will stay in effect through 2032,
unless additional Congressional action is taken. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The current administration is pursuing policies to reduce regulations and expenditures across government agencies
including at HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. For
example, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> platform (TrumpRx) U.S. patients and Medicaid programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other
developed nations, with additional mandates for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-patient</FONT></FONT> discounts and repatriation of foreign revenues. Other recent actions, for example, include
(1)&nbsp;directing agencies to reduce agency workforce and cut programs; (2)&nbsp;directing HHS and other agencies to lower prescription drug costs through a variety of initiatives; (3)&nbsp;imposing tariffs on imported pharmaceutical products; and
(4)&nbsp;as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to increase enforcement on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> pharmaceutical advertising. Additionally, the current administration recently called on Congress to enact &#8220;The Great Healthcare Plan,&#8221; to
codify and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand pharmaceutical drugs available for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> purchase, and enact restrictions on pharmacy benefit manager payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, potentially
impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks. In June 2024, the U.S. Supreme Court&#8217;s Loper Bright decision greatly reduced judicial deference to
regulatory agencies, which could increase successful legal challenges to federal regulations affecting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
our operations. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation
Program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control
pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation
from other countries and bulk purchasing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additional state and federal healthcare reform measures likely will be adopted in the future, any of which could impact
Candid&#8217;s operations. Candid&#8217;s revenue prospects could be affected by changes in healthcare spending and policy in the U.S. and abroad. Candid operates in a highly regulated industry and new laws, regulations or judicial decisions, or new
interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact Candid&#8217;s business, operations and financial
condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening
the availability of healthcare and containing or lowering the cost of healthcare. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of
healthcare and/or impose price controls may adversely affect Candid&#8217;s ability to generate revenue and achieve or maintain profitability. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The
advancement of healthcare reform globally may negatively impact Candid&#8217;s ability to profitably sell its drug candidates, if approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU,
similar developments may affect Candid&#8217;s ability to profitably commercialize its drug candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or Member State level
may result in significant additional requirements or obstacles that may increase Candid&#8217;s operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of
medicinal drugs, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement
of drugs in that context. In general, however, the healthcare budgetary constraints in most EU Member States have resulted in restrictions on the pricing and reimbursement of medicinal drugs by relevant health service providers. Coupled with
ever-increasing EU and national regulatory burdens on those wishing to develop and market drugs, this could prevent or delay marketing approval of Candid&#8217;s drug candidates, restrict or regulate post-approval activities and affect
Candid&#8217;s ability to commercialize its drug candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings
on specific drugs and therapies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;12, 2025, Regulation (EU) 2021/2282 on Health Technology Assessment (the &#8220;HTA Regulation&#8221;) entered
into application through a phased implementation. It is intended to increase cooperation among EU Member States in assessing clinical aspects of health technologies, including new medicinal products. The Regulation establishes a framework for joint
clinical assessments, joint scientific consultations, and the early identification of emerging health technologies. The Regulation permits EU Member States to use common tools, methodologies, and procedures and requires them to rely on <FONT
STYLE="white-space:nowrap">EU-level</FONT> joint clinical assessment reports for the clinical components of their national HTA evaluations. EU Member States, however, remain responsible for assessing
<FONT STYLE="white-space:nowrap">non-clinical</FONT> aspects, such as economic, ethical, and social considerations, and for making pricing and reimbursement decisions at the national level. Candid cannot predict the initiatives that may be adopted
in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the demand for Candid&#8217;s drug candidates, if Candid obtains regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to set a price that Candid believes is fair for its drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of taxes that Candid is required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of capital. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in
payments from private payors, which may adversely affect Candid&#8217;s future profitability. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid and the third parties with whom Candid works are subject
to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Candid&#8217;s actual or perceived failure to comply with such
obligations (or such failure by the third parties with whom Candid works) could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of Candid&#8217;s
business operations; reputational harm; loss of revenue or profits; and other adverse business consequences. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of business, Candid
collects, receives, stores, processes, generates, uses, transfers, discloses, makes accessible, protects, secures, disposes of, transmits, and shares (collectively, &#8220;processes&#8221;) personal data and other sensitive information, including
proprietary and confidential business data, trade secrets, intellectual property, clinical trial data, and sensitive third-party data (collectively, &#8220;sensitive information&#8221;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s data processing activities subject Candid to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry
standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the
United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section&nbsp;5 of the Federal Trade
Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by the HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health
information. Additionally, numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights
concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain data processing activities, such as targeted
advertising, profiling, and automated decision-making. The exercise of these rights may impact Candid&#8217;s business and ability to provide Candid&#8217;s products and services. Certain states also impose stricter requirements for processing
certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the CCPA, applies to personal data of consumers, business
representatives, and employees who are California residents, and requires businesses subject to the CCPA to provide specific disclosures in privacy notices and respond to requests of such individuals to exercise certain privacy rights. The CCPA and
other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials. Similar laws are being considered at the federal and local levels, and Candid expects more governmental bodies to pass similar laws in the
future. These developments further complicate compliance efforts and increase legal risk and compliance costs for Candid and the third parties upon whom Candid relies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the European Union&#8217;s
General Data Protection Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Law No.&nbsp;13,709/2018), and China&#8217;s Personal Information Protection Law
(&#8220;PIPL&#8221;) impose requirements for processing personal data. For example, the PIPL requires an organization that determines the processing purposes and means to provide sufficient notice and rely on an adequate legal basis when processing
personal data. In addition, the PIPL allows for fines to be assessed for noncompliance of up to RMB 50&nbsp;million, or 5% of the prior year&#8217;s total annual revenue. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s personnel and personnel of third parties with whom Candid works use generative artificial intelligence (&#8220;AI&#8221;) and/or automated machine
learning technologies to perform their work and the disclosure and use of personal data in AI technologies is subject to various privacy laws and other obligations. Governments have passed and are likely to pass additional laws and regulations
regulating AI and/or automated decision-making technologies. Candid&#8217;s use of this technology imposes additional compliance costs and noncompliance with our relevant obligations could lead to, among other things, regulatory investigations and
actions, as well as private claims. If Candid were unable to use AI and/or automated decision-making technologies, it could make Candid&#8217;s business less efficient and result in competitive disadvantages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Candid may be unable to transfer personal data from Europe, China and other jurisdictions to the United
States or other countries due to data localization requirements or limitations on cross-border data flows. Europe, China and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of data (including personal
data in certain instances) to other countries. In particular, the EEA and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. China has
established a cross-border data transfer regulatory framework that requires organizations to adopt an applicable transfer mechanism for the transfer if certain threshold is reached. Other jurisdictions (including the U.S.) have in the past and may
in the future adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are, for example, currently various mechanisms that may be used to transfer personal data from the EEA, the UK and
China to the United States in compliance with law, such as the EU&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework,
the UK extension thereto (which allows for transfers for relevant U.S.-based organizations who self-certify compliance and participate in the Framework) and China&#8217;s Standard Contract for the Cross-border Transfer of Personal Information, these
mechanisms are subject to legal challenges or contain practical enforcement uncertainties, and there is no assurance that Candid can satisfy or rely on these measures to lawfully transfer personal data to the United States or other jurisdictions. If
there were no lawful manner for Candid to transfer personal data from the EEA, the UK, China or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, Candid could face significant adverse
consequences, including the interruption or degradation of Candid&#8217;s operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased
exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our
business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some
European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. Additionally, the DOJ issued a rule
entitled the Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons, which places additional restriction on certain data transactions involving countries of concern (e.g., China,
Russia, Iran) and covered individuals persons (i.e., individuals and entities who are designated as such by the U.S. Attorney General or considered &#8220;foreign persons&#8221; and are majority owned by, organized under the laws of, a primary
resident in, or a contractor of, a covered person or country of concern, as applicable) that impacts certain business activities such as vendor engagements, sale or sharing of data, employment of certain individuals, and investor agreements.
Violations of the rule could lead to significant civil and criminal fines and penalties. The rule applies regardless of whether data is anonymized, <FONT STYLE="white-space:nowrap">key-coded,</FONT> pseudonymized,
<FONT STYLE="white-space:nowrap">de-identified</FONT> or encrypted, which presents particular challenges for companies like ours that operate in the clinical trial space and impacts the ability to transfer data in connection with certain
transactions or agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to data privacy and security laws, Candid is contractually subject to industry standards adopted by industry groups and is,
or may become, subject to such obligations in the future. Candid is also bound by contractual obligations related to data privacy and security, and its efforts to comply with such obligations may not be successful. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has in the past and may in the future publish privacy policies, marketing materials, and other statements concerning data privacy or security. Regulators are
increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, Candid may be subject to
investigation, enforcement actions by regulators or other adverse consequences. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obligations related to data privacy and security (and individuals&#8217; data
privacy expectations) are quickly changing, becoming increasingly stringent and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among
jurisdictions. Preparing for and complying with these obligations requires Candid to devote significant resources, which may necessitate changes to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Candid&#8217;s business, information technologies, systems, and practices and to those of any third parties that process personal data on Candid&#8217;s behalf. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid may at times fail (or be perceived to have failed) in its efforts to comply with its data privacy and security obligations, and despite Candid&#8217;s efforts,
Candid&#8217;s personnel or third parties with whom Candid works may fail to comply with such obligations, which could negatively impact Candid&#8217;s business operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Candid or the third parties with whom Candid works fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations,
Candid could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration
demands; additional reporting requirements and/or oversight; bans or restrictions on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration
demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for significant statutory damages. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these events could have a material adverse effect on Candid&#8217;s reputation, business, or financial condition, including but not limited to: interruptions or
stoppages in Candid&#8217;s business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize Candid&#8217;s drugs; expenditure of
time and resources to comply or defend any claim or inquiry; adverse publicity; or substantial changes to Candid&#8217;s business model or operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compliance with China&#8217;s Data Security Law, Cybersecurity Law, Personal Information Protection Law and any other future laws and regulations may entail
significant expenses and could affect Candid&#8217;s business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">China has implemented or will implement rules and is considering a number of additional
proposals relating to data privacy and security. China&#8217;s Data Security Law took effect in September 2021. The Data Security Law mandates the country to establish a data categorization and classification framework and entities processing
&#8220;important data&#8221; must comply with specific data protection obligations. In addition, the Data Security Law prohibits entities in China from transferring data stored in China to foreign law enforcement agencies or judicial authorities
without prior approval by the Chinese government. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to China&#8217;s Cybersecurity Law, which as enacted in November 2016, came into effect in June 2017,
and revised on October&nbsp;28, 2025 and effective on January&nbsp;1, 2026, network operators must follow the principles of legality, legitimacy and necessity when collecting and using personal information, publicly disclose the rules for personal
information collection and use, clearly state the purpose, method and scope of collecting and using personal information, and obtain the consent of the person whose information is collected and used. Network operators shall not collect personal
information unrelated to the services they provide. Network operators are not allowed to leak, tamper with, or damage the personal information they have collected, and are not allowed to provide personal information to others without the consent of
the person whose data has been collected. Network operators should take technical measures and other necessary measures to ensure the security of the personal information collected and used and prevent the leakage, damage and loss of such personal
information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;24, 2024, the State Council issued the Regulations on Network Data Security Management, which came into effect on January&nbsp;1,
2025. The Regulations on Network Data Security Management aim to implement the general requirements for data security management set forth in the Cybersecurity Law, the Data Security Law, and the PIPL. These regulations specify the compliance
requirements for data processing activities, personal information protection, &#8220;important data&#8221; security, cross-border data transfer and the obligations of online platform service providers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also, China enacted the PIPL, which became effective on November&nbsp;1, 2021. The PIPL creates a comprehensive data privacy and protection framework that applies both
to the processing of personal information in China and the processing activities conducted outside of China if such processing is for purposes of providing products and services to, or analyzing and evaluating the behavior of, individuals in China.
The PIPL also introduces data localization and cross-border data transfer restrictions, including requiring critical information infrastructure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
operators and personal information processing entities who process personal information meeting a volume threshold set by the Cyberspace Administration of China (&#8220;CAC&#8221;) to store in
China personal information generated or collected in China locally, and to pass a security assessment administered by the CAC for any export of such personal information. Lastly, the PIPL imposes significant fines for serious violations of up to RMB
50&nbsp;million or 5% of annual revenues from the prior year. For clinical trials conducted in China, Candid receives trial subject identification codes and clinical trial data from collaborating research institutions in clinical trial projects.
Candid cannot use such information to re-identify the specific identity of the trial subject. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, certain industry-specific Chinese laws and regulations
apply to the collection and processing of data in China and the transfer of data outside of China. China&#8217;s Regulations on the Administration of Human Genetic Resources (&#8220;HGR Regulation&#8221;), was promulgated by the State Council in May
2019 and came into effect in July 2019 and was then revised in March 2024 with revisions taking effect in May 2024. It stipulates that foreign organizations, individuals and the entities established or actually controlled by foreign organizations or
individuals are forbidden to collect, preserve and export China&#8217;s human genetic resources. Foreign organizations and the entities established or actually controlled by foreign organizations or individuals may only utilize and be provided with
China&#8217;s human genetic resources after satisfaction of all requirements under the HGR Regulation and other applicable laws, such as (i)&nbsp;China&#8217;s human genetic resources being utilized only in international cooperation with Chinese
scientific research institutions, universities, medical institutions and enterprises for scientific research and clinical trials after completion of requisite approval or filing formalities with competent governmental authorities, and
(ii)&nbsp;China&#8217;s human genetic resources information being provided after required filing and information backup procedures have been gone through. In May 2023, the Ministry of Science and Technology issued the Implementation Rules for the
Administrative Regulation on Human Genetic Resources, which came into effect on July&nbsp;1, 2023. These rules clarify key definitions under the HGR Regulation and provided detailed measures on the approval and filing process established under the
HGR Regulation. On October&nbsp;17, 2020, China enacted the Biosecurity Law, which became effective on April&nbsp;15, 2021, and latest amended on April&nbsp;26, 2024. The Biosecurity Law establishes a comprehensive framework governing the prevention
and control of outbreak of major newly-emerged infectious diseases, animal and plant epidemics, security of biotechnology research, development and application, biosafety management of pathogenic microbiology laboratories, security management of
human genetic resources and biological resources, prevention of the invasion of alien species and protection of biodiversity, countermeasures against microbial resistance and prevention of bioterrorism and threat of biological weapons. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While Candid intends to closely monitor the evolving laws and regulations in this area and take reasonable measures to mitigate compliance risks, Candid cannot
guarantee that its business and operations will not be adversely affected by Chinese laws and regulations related to data privacy and security. In addition, there remains uncertainties on the interpretation, application and enforcement of these
laws, rules and regulations and their scopes may continually change, through new legislation, amendments to existing legislation or changes in enforcement. Compliance with China&#8217;s data privacy and security laws, including without limitation,
the Cybersecurity Law, Data Security Law and the PIPL could significantly increase the cost to Candid of providing its service offerings, require significant changes to its operations or even prevent it from providing certain service offerings in
jurisdictions in which Candid currently operates or in which it may operate in the future. Despite Candid&#8217;s efforts to comply with applicable laws, regulations and other obligations relating to data privacy and security, it is possible that
Candid&#8217;s practices, offerings or platform could fail to meet all of the requirements. Any failure on Candid&#8217;s part to comply with such law or regulations or any other obligations relating to data privacy and security, or any compromise
of security that results in unauthorized access, use or disclosure of personal information or other data, or the perception or allegation that any of the foregoing types of failure or compromise has occurred, could damage Candid&#8217;s reputation,
discourage new and existing counterparties from contracting with Candid or result in investigations, fines, suspension or other penalties by Chinese government authorities and private claims or litigation, any of which could adversely affect
Candid&#8217;s business, financial condition and results of operations. Even if Candid&#8217;s practices are not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm its reputation and brand and adversely
affect its business, financial condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s business activities may be subject to the FCPA and similar anti-bribery
and anti-corruption laws of other countries in which Candid operates, as well as U.S. and certain foreign export controls, trade sanctions and import </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>
laws and regulations. Compliance with these legal requirements could limit Candid&#8217;s ability to compete in foreign markets and subject Candid to liability if Candid violates them.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Candid expands its operations outside of the United States, Candid must dedicate additional resources to comply with numerous laws and regulations in
each jurisdiction in which Candid plans to operate. Candid&#8217;s business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which Candid operates. The FCPA generally
prohibits companies and their employees and third-party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and
to devise and maintain an adequate system of internal accounting controls. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s business is heavily regulated and therefore involves significant
interaction with public officials, including officials of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees
would be considered foreign officials under the FCPA. Recently the SEC and DOJ have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of Candid&#8217;s employees,
agents or contractors, or those of Candid&#8217;s affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines,
criminal sanctions against Candid, its officers or its employees, disgorgement and other sanctions and remedial measures, and prohibitions on the conduct of Candid&#8217;s business. Any such violations could include prohibitions on Candid&#8217;s
ability to offer its product in one or more countries and could materially damage Candid&#8217;s reputation, its brand, its international activities, its ability to attract and retain employees and its business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Candid&#8217;s product and activities may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental
regulation of the import or export of Candid&#8217;s product, or Candid&#8217;s failure to obtain any required import or export authorization for its product, when applicable, could harm Candid&#8217;s international sales and adversely affect its
revenue. Compliance with applicable regulatory requirements regarding the export of Candid&#8217;s product may create delays in the introduction of Candid&#8217;s product in international markets or, in some cases, prevent the export of
Candid&#8217;s product to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain drugs and services to countries, governments and persons targeted by U.S. sanctions. If Candid fails
to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches
in the enforcement or scope of existing regulations, or in the countries, persons, or product targeted by such regulations, could result in decreased use of Candid&#8217;s product by, or in Candid&#8217;s decreased ability to export its product to,
existing or potential customers with international operations. Any decreased use of Candid&#8217;s product or limitation on Candid&#8217;s ability to export or sell access to its product would likely significantly harm Candid&#8217;s business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid is subject to various laws relating to foreign investment and the export of certain
technologies, and Candid&#8217;s failure to comply with these laws or adequately monitor the compliance of its suppliers and others Candid does business with could subject Candid to substantial fines, penalties and even injunctions, the imposition
of which on Candid could have a material adverse effect on the success of Candid&#8217;s business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is subject to U.S. laws that regulate foreign
investments in U.S. businesses and access by foreign persons to technology developed and produced in the United States. These laws include Section&nbsp;721 of the Defense Production Act of 1950, as amended by the Foreign Investment Risk Review
Modernization Act of 2018, and the regulations at 31 C.F.R. Parts 800 and 801, as amended, administered by the Committee on Foreign Investment in the United States; and the Export Control Reform Act of 2018, which is being implemented in part
through Commerce Department rulemakings to impose new export control restrictions on &#8220;emerging and foundational technologies&#8221; yet to be fully identified. Application of these laws, including as they are implemented through regulations
being developed, may negatively impact Candid&#8217;s business in various ways, including by restricting Candid&#8217;s access to capital and markets; limiting the collaborations Candid may pursue; regulating the export of Candid&#8217;s drugs,
services and technology from the United States and abroad; increasing Candid&#8217;s costs and the time necessary to obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
required authorizations and to ensure compliance; and threatening monetary fines and other penalties if Candid does not comply. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any failure to comply with Chinese regulations regarding the registration requirements for our employee equity incentive plans may subject us to fines and other
legal or administrative sanctions, which could adversely affect our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2012, the PRC
State Administration of Foreign Exchange (&#8220;SAFE&#8221;) promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies
(&#8220;Stock Option Rules&#8221;). In accordance with the Stock Option Rules and other relevant rules and regulations, Chinese citizens or <FONT STYLE="white-space:nowrap">non-Chinese</FONT> citizens residing in China for a continuous period of not
less than one year who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be a Chinese subsidiary of such
overseas listed company, and complete certain procedures. Candid and Candid&#8217;s employees who are Chinese citizens or who reside in China for a continuous period of not less than one year and who participate in Candid&#8217;s share incentive
plans will be subject to such regulation after the Closing. Candid plans to assist its employees to register their equity awards. However, any failure of Candid&#8217;s Chinese individual beneficial owners and holders of equity awards to comply with
the SAFE registration requirements may subject them to fines and legal sanctions and may limit the ability of Candid&#8217;s Chinese subsidiary to distribute dividends to Candid. Candid also faces regulatory uncertainties that could restrict its
ability to adopt additional incentive plans for its directors and employees under Chinese law. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As a company with operations and business relationships
outside of the United States, Candid&#8217;s business is subject to economic, political, regulatory and other risks associated with international operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s business is subject to risks associated with conducting business outside the United States, including its operations in China. Candid&#8217;s future
results could be harmed by a variety of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">economic weakness, including inflation, or political instability in particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">differing and changing regulatory requirements for drug development activities, clinical trials, registration, production,
distribution, packaging, labeling, storage and shipment, advertising, licensing and post-approval pharmacovigilance certification requirements and procedures, periodic renewal and reassessment processes, data privacy and security requirements and
compliance, environmental protection, health and safety; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limitations on access to clinical data or other results from foreign vendors or from certain foreign geographies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">communication, language or cultural barriers, including with respect to translations of preclinical studies or clinical
trial data or protocols; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such
jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potentially reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple
jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inquiries, investigations or other actions or proceedings by foreign regulatory authorities or judicial systems;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations and customs, tariffs and trade barriers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rates, including of the RMB, or restrictions
on the ability to obtain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange, including Candid&#8217;s ability to finance its PRC subsidiary; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment especially with respect to a
particular country&#8217;s treatment of or stance towards other countries; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by governments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">differing reimbursement regimes and price controls in certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">negative consequences from changes in tax laws; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variable tax treatment in different jurisdictions of options granted under our equity incentive plans;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulations restricting foreign investment or involving complex reporting or compliance requirements, particularly in the
PRC; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">business interruptions resulting from geopolitical actions, including war, military conflicts and terrorism, health
epidemics, or natural disasters including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Candid&#8217;s Intellectual Property
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid depends substantially on intellectual property rights granted under its agreements with Genor, EpimAb, and Wuxi Biologics. If Candid loses its
existing licenses or is unable to acquire or license additional proprietary rights from third parties, Candid may not be able to continue developing its drug candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is dependent on patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology that it owns and licenses from others. Candid depends
substantially on its agreements with Genor, EpimAb, and Wuxi Biologics, including the licenses granted thereunder. These licenses may be terminated upon certain conditions. Any termination of these licenses could result in the loss of significant
rights and could harm Candid&#8217;s ability to commercialize its drug candidates. In the future, Candid may also enter into additional license agreements that are material to the development of its drug candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid may also enter into additional agreements, including license agreements, with other parties in the future that impose diligence, development and
commercialization timelines, milestone payments, royalties, insurance and other obligations on Candid. Candid is also obligated to achieve certain development milestones with respect to licensed drugs in Candid&#8217;s fields of use within specified
time periods. If Candid fails to comply with its obligations to Genor, EpimAb, Wuxi Biologics or any of Candid&#8217;s other current or future collaborators, Candid&#8217;s counterparties may have the right to terminate these agreements, in which
event Candid might not be able to develop, manufacture or market any drug candidate that is covered by these agreements, which could adversely affect the value of the drug candidate being developed under any such agreement. Termination of these
agreements or reduction or elimination of Candid&#8217;s rights under these agreements may result in Candid having to negotiate new or reinstated agreements with less favorable terms, or cause Candid to lose its rights under these agreements,
including Candid&#8217;s rights to important intellectual property or technology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid may rely on third parties from whom it licenses proprietary technology to
file and prosecute patent applications and maintain patents and otherwise protect the intellectual property Candid licenses from them. Candid may have limited control over these activities or any other intellectual property that may be related to
Candid&#8217;s <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. In certain situations in Candid&#8217;s agreements with Genor, EpimAb and WuXi Biologics, Candid does not have the right to control patent prosecution, and
Candid cannot be certain that any action or inaction taken by Candid&#8217;s licensors will not have an adverse impact on Candid&#8217;s intellectual property rights. For example, Candid cannot be certain that such activities by these licensors will
be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. Additionally, under Candid&#8217;s agreements with Genor, EpimAb and WuXi Biologics, the
territories exclude China, Hong Kong, Taiwan, and Macau. As such, Candid has limited control over the patent prosecution in these jurisdictions, and Candid cannot be certain that the licensors will not make a statement or take a position that is
inconsistent with Candid&#8217;s patent prosecution strategy in the other jurisdictions. If this should happen in the excluded territories, this could negatively impact Candid&#8217;s patent prosecution strategies in the other jurisdictions. Candid
may have limited control over the manner in which its licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that may be licensed to Candid.
In addition, Candid may in the future <FONT STYLE="white-space:nowrap">co-own</FONT> some of its patent rights with other third parties. Candid may need the cooperation of any future <FONT STYLE="white-space:nowrap">co-owners</FONT> of its patent
rights in order to enforce such patent rights against third parties, and such cooperation may not be provided to Candid. It is also possible that Candid&#8217;s licensors&#8217; or <FONT STYLE="white-space:nowrap">co-owners&#8217;</FONT>
infringement proceedings or defense activities may be less vigorous than if Candid conducts them itself. Any of the foregoing could have a material adverse effect on Candid&#8217;s competitive position, business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more
established, or have greater resources than Candid, may also be pursuing strategies to license or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
acquire third-party intellectual property rights that Candid may consider necessary or attractive in order to commercialize its drug candidates. More established companies may have a competitive
advantage over Candid due to their larger size and cash resources or greater clinical development and commercialization capabilities. Candid may not be able to successfully complete such negotiations and ultimately acquire on commercially acceptable
terms the rights to the intellectual property surrounding the additional drug candidates that Candid may seek to acquire. Furthermore, Candid may be unable to <FONT STYLE="white-space:nowrap">in-license</FONT> on commercially acceptable terms any
compositions, methods of use, processes, or other third-party intellectual property rights from third parties, which Candid identifies as necessary for its drug candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If Candid is unable to obtain and maintain sufficient intellectual property protection for its drug candidates, or if the scope of the intellectual property
protection is not sufficiently broad, Candid&#8217;s competitors could develop and commercialize drugs similar or identical to Candid&#8217;s, and Candid&#8217;s ability to successfully commercialize its drugs may be adversely affected. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid relies, and will continue to rely, upon a combination of patents, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets and confidentiality agreements
to protect the intellectual property related to its drugs and technologies and to prevent third parties from copying and surpassing Candid&#8217;s achievements, thus eroding Candid&#8217;s competitive position in its market. Candid also relies on
protection afforded by <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights and proprietary technology of third parties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s
success depends in large part on its ability to obtain, maintain and enforce issued patents, trademarks and other intellectual property rights and proprietary technology in the United States and other countries for its drug candidates and their
uses, as well as Candid&#8217;s ability to operate without infringing the proprietary rights of others. Candid seeks to protect its proprietary position by filing patent applications in the United States and abroad related to its novel discoveries
and technologies that are important to its business. Candid&#8217;s pending and future patent applications may not result in patents being issued or provide assurance that issued patents will afford sufficient protection of Candid&#8217;s drug
candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive
technologies, drugs or drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining and enforcing patents is expensive and time-consuming, and Candid may not be able to file and prosecute all
necessary or desirable patent applications or maintain and/or enforce patents that may issue based on Candid&#8217;s patent applications, at a reasonable cost or in a timely manner. It is also possible that Candid will fail to identify patentable
aspects of its research and development results before it is too late to obtain patent protection. Although Candid may have the right to have some input in connection with such activities, Candid may not have the right to control the preparation,
filing, and prosecution of patent applications that are licensed to Candid by third parties in the future, or to control prosecution and maintenance of patents that Candid <FONT STYLE="white-space:nowrap">out-licenses</FONT> to third parties in the
future. Although Candid enters into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to patentable aspects of its research and development output, such as Candid&#8217;s employees,
corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby
jeopardizing Candid&#8217;s ability to seek patent protection. Consequently, Candid may not be able to prevent any third parties from using any of Candid&#8217;s technology that is in the public domain to compete with Candid&#8217;s technologies or
drug candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Composition of matter patents for biological and pharmaceutical drug candidates often provide a strong form of intellectual property protection
for those types of drugs, as such patents provide protection without regard to any method of use. Candid cannot be certain that the claims in Candid&#8217;s or its licensors&#8217; pending patent applications directed to composition of matter of
Candid&#8217;s drug candidates will be considered patentable by the USPTO or by patent offices in foreign countries, or that any claims that issue from Candid&#8217;s patent applications will be considered valid and enforceable by courts in the
United States or foreign countries. In addition, Candid cannot be certain that the claims of such patents, if granted, will be sufficiently broad to effectively prevent competitors from working around Candid&#8217;s claimed inventions by developing
an alternative formulation and thereby competing with Candid without infringing Candid&#8217;s patent rights. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making
and marketing a product that is identical to Candid&#8217;s product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for Candid&#8217;s targeted indications,
physicians may prescribe these drugs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">&#8220;off-label.&#8221;</FONT> Although <FONT STYLE="white-space:nowrap">off-label</FONT> prescriptions may infringe or contribute to the infringement of method
of use patents, the practice is common and such infringement is difficult to prevent or prosecute. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent position of biopharmaceutical companies generally is
highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including U.S. Supreme Court decisions, which have increased uncertainties as to the ability to
enforce patent rights in the future. In addition, the laws of foreign countries may not protect Candid&#8217;s rights to the same extent as the laws of the United States, or vice versa. European applications now have the option, upon grant of a
patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. This has been a significant change in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the
uncertainty of any litigation. During the first seven years of the UPC&#8217;s existence, a patent owner may opt its European patents out of the jurisdiction of the UPC. Candid may decide to opt out its future European patents from the UPC, but
doing so may preclude Candid from realizing the benefits of the UPC. Moreover, if Candid does not meet all of the formalities and requirements for <FONT STYLE="white-space:nowrap">opt-out</FONT> under the UPC, Candid&#8217;s future European patents
could remain under the jurisdiction of the UPC. The UPC will provide Candid&#8217;s competitors with a new forum to centrally revoke Candid&#8217;s European patents and allow for the possibility of a competitor to obtain a <FONT
STYLE="white-space:nowrap">pan-European</FONT> injunction. Such a loss of patent protection could have a material adverse impact on Candid&#8217;s business and its ability to commercialize its technology and drug candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of
Candid&#8217;s patent applications or those of any current or future licensors and the maintenance, enforcement or defense of Candid&#8217;s issued patents or those of any current or future licensors. For example, the United States and foreign
government actions related to the military conflict in Ukraine and Russia may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These
actions could result in abandonment or lapse of Candid&#8217;s patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on
Candid&#8217;s business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or
have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, Candid would not be able to prevent third parties from
practicing Candid&#8217;s inventions in Russia or from selling or importing drugs made using Candid&#8217;s inventions in and into Russia. Accordingly, Candid&#8217;s competitive position may be impaired, and Candid&#8217;s business, financial
condition, results of operations and prospects may be adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As noted above, Candid depends substantially on its agreements with Genor, EpimAb, and
WuXi Biologics, all of which are companies that are based in China. Any escalation in geopolitical tensions with China and the United States could have unpredictable consequences related to the ability to enforce the agreements and also the
enforceability of the associated intellectual property rights. Any inability to enforce these agreements or intellectual property rights could have a material adverse effect on Candid&#8217;s business. Additionally, unlike U.S. bankruptcy law which
grants safe harbor to <FONT STYLE="white-space:nowrap">non-debtor</FONT> licensees, Chinese bankruptcy law gives a court-appointed administrator authority to determine whether or not to continue to perform an agreement formed before the bankruptcy
application. As a result, a license agreement may be terminated by an administrator and thus result in termination of the license and loss of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">freedom-to-operate.</FONT></FONT> Candid
cannot be certain that it will not lose <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">freedom-to-operate</FONT></FONT> in the event Genor, EpimAb, and WuXi Biologics file for bankruptcy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that Candid or any of its potential future collaborators
will be successful in protecting Candid&#8217;s drug candidates by obtaining and defending patents. For example, Candid may not be aware of all third-party intellectual property rights potentially relating to Candid&#8217;s drug candidates or their
intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of Candid&#8217;s own patents and patent applications, as well as the impact of such third-party intellectual property upon
Candid&#8217;s freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, Candid cannot know with
certainty whether Candid was the first to make the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
inventions claimed in its patents or pending patent applications, or that Candid was the first to file for patent protection of such inventions. As a result, the issuance, inventorship, scope,
validity, enforceability and commercial value of Candid&#8217;s patent rights are highly uncertain. Candid&#8217;s pending patent applications may be challenged in patent offices in the United States and abroad. Even issued patents may later be
found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, Candid&#8217;s pending patent applications may be subject to third-party <FONT
STYLE="white-space:nowrap">pre-issuance</FONT> submissions of prior art to the USPTO or Candid&#8217;s issued patents may be subject to post-grant review proceedings, oppositions, derivations, reexaminations, or inter partes review proceedings, in
the United States or elsewhere, challenging Candid&#8217;s patent rights or the patent rights of others. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one or more of our owned or
licensed pending patent applications. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit Candid&#8217;s
ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of Candid&#8217;s technology and drugs. In addition, given the amount of time required for the
development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for Candid&#8217;s proprietary rights is
uncertain. Only limited protection may be available and may not adequately protect Candid&#8217;s rights or permit Candid to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to Candid&#8217;s
drug candidates or their uses could have a material adverse effect on Candid&#8217;s business, financial condition, results of operations and prospects. Such challenges also may result in substantial cost and require significant time from our
scientists and management, even if the eventual outcome is favorable to us. Any of the foregoing could adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the protection afforded by patents, Candid relies on trade secret protection and confidentiality agreements to protect proprietary <FONT
STYLE="white-space:nowrap">know-how</FONT> that is not patentable, processes for which patents are difficult to obtain and any other elements of Candid&#8217;s discovery and development processes that involve proprietary <FONT
STYLE="white-space:nowrap">know-how,</FONT> information or technology that are not covered by Candid&#8217;s patents. Candid may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent
filing. However, trade secret protection will not protect Candid from innovations that a competitor develops independently of Candid&#8217;s proprietary <FONT STYLE="white-space:nowrap">know-how.</FONT> If a competitor independently develops a
technology that Candid protects as a trade secret and files a patent application on that technology, then Candid may not be able to patent that technology in the future, may require a license from the competitor to use Candid&#8217;s own <FONT
STYLE="white-space:nowrap">know-how,</FONT> and if the license is not available on commercially-viable terms, then Candid may not be able to launch its product. Although Candid requires all of its employees to assign their inventions to Candid, and
requires all of its employees, consultants, advisors and any third parties who have access to Candid&#8217;s proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology to enter into confidentiality agreements, Candid
cannot be certain that its trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to Candid&#8217;s trade secrets or independently develop substantially equivalent
information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, Candid may encounter significant problems in
protecting and defending its intellectual property both in the United States and abroad. If Candid is unable to prevent unauthorized material disclosure of its intellectual property to third parties, Candid will not be able to establish or maintain
a competitive advantage in its market, and this scenario could materially adversely affect Candid&#8217;s business, financial condition and results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid cannot ensure that patent rights relating to inventions described and claimed in its pending patent applications will issue or that patents based on
Candid&#8217;s patent applications will not be challenged and rendered invalid and/or unenforceable. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent application process is subject to numerous
risks and uncertainties, and there can be no assurance that Candid or any of its potential future collaborators will be successful in protecting Candid&#8217;s drug candidates by obtaining and defending patents. Candid has pending Patent Cooperation
Treaty applications, and U.S. and foreign patent applications in its portfolio; however, Candid cannot predict: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if and when patents may issue based on Candid&#8217;s patent applications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of protection of any patent issuing based on Candid&#8217;s patent applications; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether the claims of any patent issuing based on Candid&#8217;s patent applications will provide protection against
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether or not third parties will find ways to invalidate or circumvent Candid&#8217;s patent rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether or not others will obtain patents claiming aspects similar to those covered by Candid&#8217;s patents and patent
applications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether Candid will need to initiate litigation or administrative proceedings to enforce and/or defend Candid&#8217;s
patent rights, which will be costly whether Candid wins or loses; and/or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether the patent applications that Candid owns or has <FONT STYLE="white-space:nowrap">in-licensed</FONT> will result in
issued patents with claims that cover Candid&#8217;s drug candidates or uses thereof in the United States or in other foreign countries. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid
cannot be certain that the claims in its pending patent applications directed to Candid&#8217;s drug candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. There can be no assurance that
any such patent applications will issue as granted patents. One aspect of the determination of patentability of Candid&#8217;s inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to
a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which Candid is not aware that may affect the patentability of Candid&#8217;s patent claims or, if issued, affect the validity or
enforceability of a patent claim. Even if the patents do issue based on Candid&#8217;s patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or
held unenforceable. Furthermore, even if they are unchallenged, patents in Candid&#8217;s portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around Candid&#8217;s claims. If the
breadth or strength of Candid&#8217;s intellectual property position with respect to its drug candidates is threatened, it could dissuade companies from collaborating with Candid to develop and threaten Candid&#8217;s ability to commercialize its
drug candidates. In the event of litigation or administrative proceedings, Candid cannot be certain that the claims in any of its issued patents will be considered valid by courts in the United States or foreign countries. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats to Candid&#8217;s competitive advantage. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of future protection afforded by Candid&#8217;s intellectual property rights is uncertain because intellectual property rights have limitations and may not
adequately protect Candid&#8217;s business or permit Candid to maintain its competitive advantage. For example: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may be able to make drug candidates that are similar to Candid&#8217;s but that are not covered by the claims of
the patents or patent applications that Candid owns or has exclusively licensed or the patent applications that Candid may file in the future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid or its licensors or collaborators might not have been the first to make the inventions covered by the patents or
patent applications that Candid owns or has exclusively licensed or the patent applications that Candid may file in the future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid or its licensors or collaborators might not have been the first to file patent applications covering certain
aspects of Candid&#8217;s inventions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may independently develop similar or alternative technologies or duplicate any of Candid&#8217;s technologies
without infringing Candid&#8217;s intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that noncompliance with the USPTO and foreign governmental patent agencies&#8217; requirements for a number
of procedural, documentary, fee payment and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that Candid&#8217;s pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issued patents that Candid owns or have exclusively licensed may be revoked, modified, or held invalid or unenforceable,
as a result of legal challenges by Candid&#8217;s competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s competitors might conduct research and development activities in countries where Candid does not have
patent rights and then use the information learned from such activities to develop competitive drugs for sale in Candid&#8217;s major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid cannot predict the scope of protection of any patent issuing based on Candid&#8217;s patent applications, including
whether the patent applications that Candid owns or has <FONT STYLE="white-space:nowrap">in-licensed</FONT> will result in issued patents with claims directed to Candid&#8217;s drug candidates or uses thereof in the United States or in other foreign
countries; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of
patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the claims of any patent issuing based on Candid&#8217;s patent applications may not provide protection against
competitors or any competitive advantages, or may be challenged by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if enforced, a court may not hold that Candid&#8217;s patents are valid, enforceable and infringed; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid may need to initiate litigation or administrative proceedings to enforce and/or defend Candid&#8217;s patent
rights, which will be costly whether Candid wins or loses; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid may choose not to file a patent application in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third-party may subsequently file a patent application covering such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid may fail to adequately protect and police its trademarks and trade secrets; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patents of others may have an adverse effect on Candid&#8217;s business, including if others obtain patents claiming
subject matter similar to or improving that covered by Candid&#8217;s patents and patent applications. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should any of these or similar events
occur, they could significantly harm Candid&#8217;s business, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid may not identify relevant third-party patents or
may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect Candid&#8217;s ability to develop and market its drugs. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid cannot guarantee that any of its patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of
relevant patents, are complete or thorough, nor can Candid be certain that it has identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of
Candid&#8217;s drug candidates in any jurisdiction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent
and the patent&#8217;s prosecution history. Candid&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, Candid may incorrectly determine that its drugs are not covered by a
third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Candid&#8217;s determination of the expiration date of any patent in the United States or abroad that Candid
considers relevant may be incorrect. Candid&#8217;s failure to identify and correctly interpret relevant patents may negatively impact Candid&#8217;s ability to develop and market its drugs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of
Candid&#8217;s rights to the relevant intellectual property or technology or increase Candid&#8217;s financial or other obligations to its licensors. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid currently depends, and will continue to depend, on its license agreements, including its agreements with Genor, EpimAb, and WuXi Biologics. Further development
and commercialization of Candid&#8217;s current or any future drug candidates may require Candid to enter into additional license or collaboration agreements. The agreements under which Candid currently licenses intellectual property or technology
from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what Candid believes to be the scope of
its rights to the relevant intellectual property or technology, or increase what Candid believes to be its financial or other obligations under the relevant agreement, either of which could have a material adverse effect on Candid&#8217;s business,
financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of Candid&#8217;s licenses or material relationships or any
<FONT STYLE="white-space:nowrap">in-licenses</FONT> upon which Candid&#8217;s licenses are based are terminated or breached, Candid may: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">lose its rights to develop and market its drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">lose patent protection for its drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">lose rights to important confidential <FONT STYLE="white-space:nowrap">know-how</FONT> for manufacturing its drugs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">experience significant delays in the development or commercialization of its drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">incur significant extra costs in order to develop, manufacture and commercialize its drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not be able to obtain any other licenses on acceptable terms, if at all; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">incur liability for damages. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These risks apply to any agreements that Candid may enter into in the future for its drugs or for any future drug candidates. If Candid experiences any of the
foregoing, it could have a material adverse effect on Candid&#8217;s business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>In the future,
Candid may need to obtain licenses of third-party technology that may not be available to Candid or are available only on commercially unreasonable terms, and which may cause Candid to operate its business in a more costly or otherwise adverse
manner that was not anticipated. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications
potentially relevant to Candid&#8217;s business. From time to time, in order to avoid infringing these third-party patents, Candid may be required to license technology from additional third parties to further develop or commercialize its drug
candidates. Should Candid be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell Candid&#8217;s drug candidates, such licenses may not be available to Candid on commercially
reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of Candid&#8217;s drug candidates could cause Candid to abandon any related efforts, which could seriously harm Candid&#8217;s
business and operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may
pursue strategies to license or acquire third-party intellectual property rights Candid may consider attractive or necessary. These established companies may have a competitive advantage over Candid due to their size, capital resources and greater
clinical development and commercialization capabilities. In addition, companies that perceive Candid to be a competitor may be unwilling to assign or license rights to Candid. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If Candid is sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay
Candid from developing or commercializing its drug candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s commercial success depends, in part, on its ability to develop, manufacture,
market and sell its drug candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that Candid has infringed or misappropriated their intellectual property. Litigation or other
legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in Candid&#8217;s favor, is likely to divert significant resources from
Candid&#8217;s core business, including distracting Candid&#8217;s technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim
proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of Candid Common Stock. Such litigation or proceedings could substantially
increase Candid&#8217;s operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Candid may not have sufficient financial or other resources to adequately conduct such
litigation or proceedings. Some of Candid&#8217;s competitors may be able to sustain the costs of such litigation or proceedings more effectively than Candid can because of their greater financial resources and more mature and developed intellectual
property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on Candid&#8217;s ability to compete in the marketplace. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and Candid may become party to, or threatened
with, litigation or other adversarial proceedings regarding intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
property rights with respect to its drug candidates. Candid cannot be certain that its drug candidates and other proprietary technologies Candid may develop will not infringe existing or future
patents owned by third parties. Third parties may assert infringement claims against Candid or its licensors based on existing or future intellectual property rights. Proving invalidity may be difficult. For example, in the United States, proving
invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If Candid or its licensors are found to infringe a third-party&#8217;s intellectual property rights, Candid
could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing candidate product or product. Alternatively, Candid may be required to obtain a license from such third-party in order to use the
infringing technology and continue developing, manufacturing or marketing the infringing candidate product or product. However, Candid may not be able to obtain any required license on commercially reasonable terms or at all. Even if Candid were
able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving Candid&#8217;s competitors access to the same technologies licensed to Candid. In addition, Candid could be found liable for monetary
damages, including treble damages and attorneys&#8217; fees if Candid is found to have willfully infringed a patent. A finding of infringement could prevent Candid from commercializing its investigational drugs or force Candid to cease some of its
business operations, which could materially harm Candid&#8217;s business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid or its licensors may not be aware of patents that have already been issued and
that a third-party, for example, a competitor in the fields in which Candid is developing its drug candidates, might assert are infringed by Candid&#8217;s current or future drug candidates, including claims to compositions, formulations, methods of
manufacture or methods of use or treatment that cover Candid&#8217;s drug candidates. It is also possible that patents owned by third parties of which Candid or its licensors are aware, but which Candid does not believe are relevant to its drug
candidates and other proprietary technologies Candid may develop, could be found to be infringed by Candid&#8217;s drug candidates. In addition, because patent applications can take many years to issue, there may be currently pending patent
applications that may later result in issued patents that Candid&#8217;s drug candidates may infringe. Candid&#8217;s competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial
investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with Candid&#8217;s ability to make, use and sell its
drug candidates. The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including Candid, which patents cover various types of drugs or methods of use.
The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If Candid were sued for patent infringement, Candid would need to demonstrate that its drug candidates, drugs or methods either do not
infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and Candid may not be able to do this. Proving invalidity may be difficult and there is no assurance that a court of competent jurisdiction
would invalidate the claims of any such U.S. patent. Even if Candid is successful in these proceedings, Candid may incur substantial costs and the time and attention of Candid&#8217;s management and scientific personnel could be diverted in pursuing
these proceedings, which could have a material adverse effect on Candid&#8217;s business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of Candid&#8217;s confidential information could be compromised by disclosure during litigation. In addition, Candid may not have sufficient resources to bring these actions to a successful conclusion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid may choose to challenge the enforceability or validity of claims in a third-party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an
<FONT STYLE="white-space:nowrap">ex-parte</FONT> <FONT STYLE="white-space:nowrap">re-exam,</FONT> inter partes review or post-grant review proceedings. These proceedings are expensive and may consume Candid&#8217;s time or other resources. Candid
may choose to challenge a third-party&#8217;s patent in patent opposition proceedings in the European Patent Office (&#8220;EPO&#8221;), or other foreign patent office. The costs of these opposition proceedings could be substantial and may consume
Candid&#8217;s time or other resources. If Candid fails to obtain a favorable result at the USPTO, EPO or other patent office then Candid may be exposed to litigation by a third-party alleging that the patent may be infringed by Candid&#8217;s drug
candidates or proprietary technologies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Candid is found to infringe a third-party&#8217;s intellectual property rights, Candid could be forced, including by
court order, to cease developing, manufacturing or commercializing the infringing drug candidate or product. Alternatively, Candid may be required to obtain a license from such third-party in order to use the infringing technology and continue
developing, manufacturing or marketing the infringing drug candidate. However, Candid may not be able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
obtain any required license on commercially reasonable terms or at all. Even if Candid were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby
giving Candid&#8217;s competitors access to the same technologies licensed to Candid. In addition, Candid could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if Candid is found to have willfully infringed a
patent. A finding of infringement could prevent Candid from commercializing its drug candidates or force Candid to cease some of its business operations, and could divert the time and attention of Candid&#8217;s technical personnel and management,
cause development delays, and/or require Candid to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be possible on a cost-effective basis, any of which could materially harm Candid&#8217;s business. In the
event of a successful claim of infringement against Candid, Candid may have to pay substantial monetary damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties and other fees, redesign Candid&#8217;s
infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that Candid has misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on Candid&#8217;s business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid may become involved in lawsuits to protect or enforce its patents or other
intellectual property, which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors or other third parties may infringe Candid&#8217;s patents,
trademarks or other intellectual property. To counter infringement or unauthorized use, Candid may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of Candid&#8217;s management and
scientific personnel. Candid&#8217;s pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims Candid asserts
against perceived infringers could provoke these parties to assert counterclaims against Candid alleging that Candid infringes their patents, in addition to counterclaims asserting that Candid&#8217;s patents are invalid or unenforceable, or both.
In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including
lack of novelty, obviousness, <FONT STYLE="white-space:nowrap">non-enablement</FONT> or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld
relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court
will decide that a patent of Candid&#8217;s is invalid or unenforceable, in whole or in part, and that Candid does not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such
patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that Candid does not have the right to stop the other party from using the invention at issue on the grounds that Candid&#8217;s patent claims do not cover the
invention, or decide that the other party&#8217;s use of Candid&#8217;s patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). An adverse outcome in a litigation or proceeding involving Candid&#8217;s
patents could limit Candid&#8217;s ability to assert its patents against those parties or other competitors and may curtail or preclude Candid&#8217;s ability to exclude third parties from making and selling similar or competitive drugs. Any of
these occurrences could adversely affect Candid&#8217;s competitive business position, business prospects and financial condition. Similarly, if Candid asserts trademark infringement claims, a court may determine that the marks Candid has asserted
are invalid or unenforceable, or that the party against whom Candid has asserted trademark infringement has superior rights to the marks in question. In this case, Candid could ultimately be forced to cease use of such trademarks. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if Candid establishes infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages,
which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Candid&#8217;s confidential information could be
compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it
could have a material adverse effect on the price of shares of Candid Common Stock. Moreover, Candid cannot assure you that it will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for
years before they are concluded. Even if Candid ultimately prevails in such claims, the monetary cost of such litigation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and the diversion of the attention of Candid&#8217;s management and scientific personnel could outweigh any benefit Candid receives as a result of the proceedings. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because of the expense and uncertainty of litigation, Candid may not be in a position to enforce its intellectual property rights against third parties.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the expense and uncertainty of litigation, Candid may conclude that even if a third-party is infringing Candid&#8217;s patents that may be
issued as a result of Candid&#8217;s pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of Candid or its
stockholders, or it may be otherwise impractical or undesirable to enforce Candid&#8217;s intellectual property against some third parties. Candid&#8217;s competitors or other third parties may be able to sustain the costs of complex patent
litigation or proceedings more effectively than Candid can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, Candid may decide that the more prudent course of action is to
simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. In addition, the uncertainties associated with litigation could compromise Candid&#8217;s ability to raise the
funds necessary to continue its preclinical studies, initiate and continue clinical trials, continue its internal research programs, <FONT STYLE="white-space:nowrap">in-license</FONT> needed technology or other drug candidates, or enter into
development partnerships that would help Candid bring its drug candidates to market. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid may be subject to claims that it has wrongfully hired an employee
from a competitor or that Candid&#8217;s employees, consultants or independent contractors have misappropriated or disclosed confidential information of third parties. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid may be subject to claims that its employees, consultants or advisors have misappropriated for Candid&#8217;s benefit or disclosed to Candid confidential
information of third parties. As is common in the pharmaceutical industry, in addition to its employees, in the future Candid may engage the services of consultants to assist Candid in the development of its drug candidates. Many of these potential
consultants, and many of Candid&#8217;s employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including Candid&#8217;s competitors or potential
competitors. Candid could in the future be subject to claims that Candid or its employees or consultants have inadvertently, or otherwise, misappropriated alleged trade secrets or other confidential information of former employers, clients or
competitors. To the extent that Candid&#8217;s employees, consultants or advisors use intellectual property rights or proprietary information owned by others in their work for Candid, disputes may arise as to the rights in any related or resulting <FONT
STYLE="white-space:nowrap">know-how</FONT> and inventions. Although Candid tries to ensure that its employees and consultants do not use the intellectual property, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade
secrets of others in their work for Candid, Candid may become subject to claims that Candid caused an employee to breach the terms of his or her <FONT STYLE="white-space:nowrap">non-competition</FONT> or
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, or that Candid or these individuals have, inadvertently, or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or
competitor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While Candid may litigate to defend itself against these claims, even if Candid is successful, litigation could result in substantial costs and could
be a distraction to management. If Candid&#8217;s defenses to these claims fail, in addition to requiring Candid to pay monetary damages, a court could prohibit Candid from using technologies or features that are essential to its drug candidates, if
such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect Candid&#8217;s reputation,
Candid&#8217;s ability to form strategic alliances or sublicense its rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on Candid&#8217;s business, results of
operations and financial condition. Even if Candid is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing Candid&#8217;s ability to
protect its drug candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with other biopharmaceutical companies, Candid&#8217;s success is heavily dependent on intellectual property,
particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or
interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish Candid&#8217;s ability to protect its inventions, obtain, maintain, and enforce its intellectual property rights and, more generally,
could affect the value of Candid&#8217;s intellectual property or narrow the scope of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Candid&#8217;s patents that issue in the future. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (&#8220;Leahy-Smith Act&#8221;),
signed into law on September&nbsp;16, 2011, could increase those uncertainties and costs surrounding the prosecution of Candid&#8217;s patent applications and the enforcement or defense of Candid&#8217;s issued patents. The Leahy-Smith Act includes
a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity
of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review,
inter partes review and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a
third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.
Accordingly, a third-party may attempt to use the USPTO procedures to invalidate Candid&#8217;s patent claims that would not have been invalidated if first challenged by the third-party as a defendant in a district court action. Thus, the
Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Candid&#8217;s patent applications and the enforcement or defense of Candid&#8217;s issued patents, all of which could have a material
adverse effect on Candid&#8217;s business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After March 2013, under the Leahy-Smith Act, the United States
transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was
the first to invent the claimed invention. A third-party that files a patent application with the USPTO after March 2013, but before Candid files an application covering the same invention, could therefore be awarded a patent covering an invention
of Candid&#8217;s even if Candid had made the invention before it was made by such third-party. This will require Candid to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the
United States and most other countries are confidential for a period of time after filing or until issuance, Candid cannot be certain that Candid or its licensors were the first to either (i)&nbsp;file any patent application related to
Candid&#8217;s drug candidates and other proprietary technologies Candid may develop or (ii)&nbsp;invent any of the inventions claimed in Candid&#8217;s or Candid&#8217;s licensor&#8217;s patents or patent applications. Even where Candid has a valid
and enforceable patent, Candid may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before Candid&#8217;s filing date or the other party benefits from a
compulsory license. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Candid&#8217;s patent applications and the enforcement or defense of Candid&#8217;s issued patents, all
of which could have a material adverse effect on Candid&#8217;s business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the patent
positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in
certain circumstances or weakening the rights of patent owners in certain situations. Candid cannot predict how decisions by the federal courts, the U.S. Congress or the USPTO may impact the value of Candid&#8217;s patent rights. For example, in the
2013 case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the Supreme Court of the United States held that certain claims to DNA molecules are not patentable. As another example, the Supreme Court of the United States held in Amgen v.
Sanofi (2023)&nbsp;that a functionally claimed genus of antibodies that bind and block the PCSK9 receptor was invalid for failing to comply with the enablement requirement of the Patent Act. In addition, the Federal Circuit issued a decision
involving the interaction of patent term adjustment (&#8220;PTA&#8221;), terminal disclaimers, and obvious-type double patenting. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT
STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken Candid&#8217;s ability to obtain new patents or to enforce its existing patents
and patents that Candid might obtain in the future. While Candid does not believe that any of the patents or patents that issue from pending patent applications that are owned or licensed by Candid will be found invalid based on these decisions,
Candid cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of Candid&#8217;s patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third
parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent.
If Candid is, or Candid&#8217;s licensor is, forced to grant a license to third parties with respect to any patents relevant to Candid&#8217;s business, Candid&#8217;s competitive position may be impaired, and Candid&#8217;s business, financial
condition, results of operations and prospects may be adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with various
procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and Candid&#8217;s patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these
requirements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications are due to be
paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could
result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to
properly legalize and submit formal documents. If Candid fails to maintain the patents and patent applications covering its drug candidates, Candid&#8217;s competitive position would be adversely affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid may rely on trade secret and proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> which can be difficult to trace and enforce and, if Candid is
unable to protect the confidentiality of its trade secrets, Candid&#8217;s business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to seeking
patents for some of its technology and drug candidates, Candid may also rely on trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain its competitive position.
Elements of Candid&#8217;s drug candidates, including processes for their preparation and manufacture, may involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents, and thus for
these aspects Candid may consider trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to be its primary intellectual property. Any disclosure, either intentional or unintentional, by Candid&#8217;s employees, the employees of third
parties with whom Candid Capital Stock its facilities or third-party consultants and vendors that Candid engages to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity
breach) of Candid&#8217;s trade secrets or proprietary information could enable competitors to duplicate or surpass Candid&#8217;s technological achievements, thus eroding Candid&#8217;s competitive position in its market. Because Candid expects to
rely on third parties in the development and manufacture of its drug candidates, Candid must, at times, share trade secrets with them. Candid&#8217;s reliance on third parties requires Candid to share its trade secrets, which increases the
possibility that a competitor will discover them or that Candid&#8217;s trade secrets will be misappropriated or disclosed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Trade secrets and <FONT
STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. Candid requires its employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to Candid any inventions generated
in the course of their employment. Candid and any third parties with whom Candid Capital Stock facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party&#8217;s property, trade
secrets, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> and information. Candid further seeks to protect its trade secrets, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> and information in part, by entering into
confidentiality agreements with parties who are given access to them, such as Candid&#8217;s corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors and other third parties. With Candid&#8217;s consultants,
contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Candid cannot guarantee that it has entered into such agreements with each party that may have or has had access to
Candid&#8217;s trade secrets or proprietary technology and processes. Candid cannot be certain that its trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to
Candid&#8217;s trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose Candid&#8217;s proprietary information, including its trade
secrets, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and Candid may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets to the same extent or in the same manner as the laws of the United States. Candid
may need to share its proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by
private parties or foreign actors, and those affiliated with or controlled by state actors. Further, if any of Candid&#8217;s trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, Candid would
have no right to prevent them from using that technology or information to compete with Candid. If any of Candid&#8217;s trade secrets were to be disclosed to or independently developed by a competitor or other third-party, Candid&#8217;s
competitive position would be harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid may become subject to claims challenging the inventorship or ownership of its patents and other intellectual
property. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid may be subject to claims that former employees, collaborators or other third parties have an interest in Candid&#8217;s patents or other
intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may
arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of
third parties involved in developing Candid&#8217;s drug candidates or as a result of questions regarding <FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be necessary to resolve these and other
claims challenging inventorship and/or ownership. Alternatively, or additionally, Candid may enter into agreements to clarify the scope of its rights in such intellectual property. If Candid fails in defending any such claims, in addition to paying
monetary damages, Candid may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Candid&#8217;s business. Even if Candid
is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s
current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that Candid&#8217;s licensors are not the sole and exclusive owners of the patents Candid has <FONT
STYLE="white-space:nowrap">in-licensed.</FONT> The U.S. federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable,
irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with <FONT STYLE="white-space:nowrap">&#8220;march-in</FONT> rights.&#8221; <FONT
STYLE="white-space:nowrap">March-in</FONT> rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a
&#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. If, in the future, Candid <FONT STYLE="white-space:nowrap">co-owns</FONT> or licenses in technology which is
critical to Candid&#8217;s business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, Candid&#8217;s ability to enforce or otherwise exploit patents covering such technology may be adversely affected. If other
third parties have ownership rights or other rights to Candid&#8217;s <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to Candid&#8217;s competitors, and Candid&#8217;s competitors could market
competing drugs and technology. This could have a material adverse effect on Candid&#8217;s competitive position, business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, while it is Candid&#8217;s policy to require its employees and contractors who may be involved in the conception or development of intellectual property to
execute agreements assigning such intellectual property to Candid, Candid may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that Candid regards as its own. The assignment of
intellectual property rights may not be self-executing, or the assignment agreements may be breached, and Candid may be forced to bring claims against third parties, or defend claims that they may bring against Candid, to determine the ownership of
what Candid regards as its intellectual property. Such claims could have a material adverse effect on Candid&#8217;s business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect Candid&#8217;s competitive position on its drug candidates for an
adequate amount of time. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a
patent is generally 20 years after its first effective filing date excluding U.S. provisional patent applications. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such
candidates might expire before or shortly after such drug candidates are commercialized. Even if patents covering Candid&#8217;s drug candidates are obtained, once the patent life has expired for a product, Candid may be open to competition from
biosimilar or generic drugs. As a result, Candid&#8217;s patent portfolio may not provide Candid with sufficient rights to exclude others from commercializing drug candidates similar or identical to Candid&#8217;s. Upon issuance in the United
States, the term of a patent can be increased by patent term adjustment, which is based on certain delays caused by the USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent
prosecution. Candid may also be required to disclaim a portion of patent term in order to overcome double patenting rejections from the patent office, thus potentially shortening Candid&#8217;s exclusivity period. The term of a U.S. patent may also
be shortened if the patent is terminally disclaimed over an earlier-filed patent. A PTE based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be
extended only once, for a single product. Moreover, the scope of protection during the period of the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous PTEs in
foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, Candid may not receive an extension if Candid fails to exercise due diligence during the testing phase or
regulatory review process, applies within applicable deadlines, fails to apply prior to the expiration of relevant patents or otherwise fails to satisfy applicable requirements. If Candid is unable to obtain PTE or restoration, or the term of any
such extension is less than Candid requests, the period during which Candid will have the right to exclusively market its product will be shortened and Candid&#8217;s competitors may obtain approval of competing drugs following Candid&#8217;s patent
expiration and may take advantage of Candid&#8217;s investment in development and clinical trials by referencing Candid&#8217;s clinical and preclinical data to launch their product earlier than might otherwise be the case, and Candid&#8217;s
revenue could be reduced, possibly materially. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If Candid&#8217;s trademarks and trade names are not adequately protected, then Candid may not be able to
build name recognition in its markets of interest and Candid&#8217;s business may be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s current or future trademarks or
trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. Candid may not be able to protect its rights to these trademarks and trade names or may be forced to stop using
these names, which Candid needs for name recognition by potential partners or customers in its markets of interest. During trademark registration proceedings, Candid may receive rejections of its applications by the USPTO or in other foreign
jurisdictions. Although Candid would be given an opportunity to respond to those rejections, Candid may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are
given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against Candid&#8217;s trademarks, and Candid&#8217;s trademarks may not survive such
proceedings. If Candid is unable to establish name recognition based on its trademarks and trade names, Candid may not be able to compete effectively, and Candid&#8217;s business may be adversely affected. Candid may license its trademarks and trade
names to third parties, such as distributors. Although these license agreements may provide guidelines for how Candid&#8217;s trademarks and trade names may be used, a breach of these agreements or misuse of Candid&#8217;s trademarks and trade names
by Candid&#8217;s licensees may jeopardize Candid&#8217;s rights in or diminish the goodwill associated with Candid&#8217;s trademarks and trade names. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover,
any name Candid has proposed to use with its drug candidate in the United States must be approved by the FDA, regardless of whether Candid has registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA
typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of Candid&#8217;s proposed
proprietary product names, Candid may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties
and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to
Candid&#8217;s, thereby impeding Candid&#8217;s ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered
trademarks or trademarks that incorporate variations of Candid&#8217;s registered or unregistered trademarks or trade names. If Candid asserts trademark infringement claims, a court may determine that the marks Candid has asserted are invalid or
unenforceable, or that the party against whom Candid has asserted trademark infringement has superior rights to the marks in question. In this case, Candid could ultimately be forced to cease use of such trademarks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Candid&#8217;s Industry and Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid will
need to expand its organization, and may experience challenges in managing this growth as it builds its capabilities, which could disrupt its operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, Candid had 48 full-time employees. Candid will need to expand its organization, and may have difficulty identifying, hiring and
integrating new personnel. Future growth would impose significant additional responsibilities on Candid&#8217;s management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors.
Also, Candid&#8217;s management may need to divert a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a substantial amount of time to
managing these growth activities. Candid may not be able to effectively manage the expansion of its operations, which may result in weaknesses in its infrastructure, give rise to operational mistakes, loss of business opportunities, loss of
employees and reduced productivity among remaining employees. Candid&#8217;s expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of drug candidates. If
Candid&#8217;s management is unable to effectively manage its growth, Candid&#8217;s expenses may increase more than expected, Candid&#8217;s ability to generate and/or grow revenues could be reduced, and Candid may not be able to implement its
business strategy. Candid&#8217;s future financial performance and its ability to commercialize its drug candidates and compete effectively will depend, in part, on Candid&#8217;s ability to effectively manage any future growth. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s future success depends on its ability to retain its key personnel and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s industry has experienced a high rate of turnover of management personnel in recent years. Candid is highly dependent on its executive officers, as well
as the other members of its current and future management, scientific and clinical teams. Although Candid has formal employment agreements with its executive officers, these agreements do not prevent them from terminating their employment with
Candid at any time. Certain of Candid&#8217;s executive officers are also eligible to receive severance benefits upon certain qualifying terminations of employment pursuant to their agreements. Additional details regarding these arrangements can be
found in the sections titled &#8220;<I>Candid Executive Officer and Director Compensation&#8212;Employment Arrangements with Candid&#8217;s Named Executive Officers</I>&#8221; and &#8220;<I>Candid Executive Officer and Director
Compensation</I><I>&#8212;Potential Payments upon Termination or Change in Control.</I>&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Candid loses one or more of its executive officers or key
employees, Candid&#8217;s ability to implement its business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited
number of individuals in Candid&#8217;s industry with the breadth of highly specialized skills and experience required to develop, gain regulatory approval of, and commercialize Candid&#8217;s drug candidates successfully. Competition to hire from
this limited pool is intense, and Candid may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous biopharmaceutical and biotechnology companies for similar personnel.
Candid also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, Candid relies on consultants and advisors, including scientific and clinical advisors, to assist Candid
in formulating its research and development and commercialization strategy. Candid&#8217;s consultants and advisors may be engaged by entities other than Candid and may have commitments under consulting or advisory contracts with other entities that
may limit their availability to Candid. If Candid is unable to continue to attract and retain high quality personnel, Candid&#8217;s ability to advance the clinical development of and commercialize drug candidates will be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s operating results may fluctuate significantly, which makes Candid&#8217;s future operating
results difficult to predict and could cause Candid&#8217;s operating results to fall below expectations or any guidance Candid may provide. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s
quarterly and annual operating results may fluctuate significantly, which makes it difficult for Candid to predict its future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of Candid&#8217;s
control, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and cost of, and level of investment in, research, development, regulatory approval, and commercialization
activities relating to any of Candid&#8217;s current or future drug candidates, which may change from time to time, including the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to enroll patients in clinical trials and the timing of enrollment; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and success or failure of preclinical studies or clinical trials for any of Candid&#8217;s current or future
drug candidates or competing drug candidates, or any other change in the competitive landscape of Candid&#8217;s industry, including consolidation among Candid&#8217;s competitors or partners; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">coverage and reimbursement policies with respect to any of Candid&#8217;s current or future drug candidates, if approved,
and potential future drugs that compete with Candid&#8217;s drugs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of manufacturing any of Candid&#8217;s current or future drug candidates, which may vary depending on the
quantity of production and the terms of Candid&#8217;s agreements with third-party manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expenditures that Candid may incur to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> develop, or
commercialize additional drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of demand for any approved drugs, which may vary significantly and be difficult to predict;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to commercialize any of its current or future drug candidates, if approved, inside and outside of
the United States, either independently or working with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to establish and maintain collaborations, licensing or other arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential unforeseen business disruptions that increase Candid&#8217;s costs or expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">future accounting pronouncements or changes in Candid&#8217;s accounting policies; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and amount of any milestone, royalty or other payments payable by Candid or due to Candid under any
collaboration, licensing or other similar agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The cumulative effects of these factors could result in large fluctuations and
unpredictability in Candid&#8217;s quarterly and annual operating results. As a result, comparing Candid&#8217;s operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be
meaningful. Investors should not rely on Candid&#8217;s past results as an indication of Candid&#8217;s future performance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This variability and unpredictability
could also result in Candid failing to meet the expectations of industry or financial analysts or investors for any period. If Candid&#8217;s revenue or operating results fall below the expectations of analysts or investors or below any forecasts
Candid may provide to the market, or if the forecasts Candid provides to the market are below the expectations of analysts or investors, the price of Candid Common Stock could decline substantially. Such a stock price decline could occur even when
Candid has met any previously publicly stated revenue or earnings guidance Candid may provide. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If Candid&#8217;s information technology systems or those of
third parties with whom Candid works, or Candid&#8217;s data, are or were compromised, Candid could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines
and penalties; disruptions of Candid&#8217;s business operations; reputational harm; loss of revenue or profits; and other adverse consequences. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the
ordinary course of its business, Candid and the third parties with whom Candid works process sensitive information, and, as a result, Candid and the third parties with whom Candid works face a variety of evolving threats which could cause security
incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud, natural disasters, telecommunications issues and other similar activities threaten the confidentiality, integrity, and availability of Candid&#8217;s sensitive
information and information technology systems, and those of the third parties with whom Candid works. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and certain of these threats come from a variety of
sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation
nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, Candid and the third parties with whom Candid works may be vulnerable to a heightened risk
of these attacks, including retaliatory cyber-attacks, that could materially disrupt Candid&#8217;s systems and operations, supply chain, and ability to conduct its business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid and the third parties with whom Candid works are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including
through those that may be increasingly more difficult to identify such as deep fakes and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server
malfunctions, software or hardware failures, loss or theft of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by AI, and other similar threats. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in Candid&#8217;s operations, ability to conduct
its business, loss of sensitive information and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but Candid may be unwilling or unable to make such payments due to, for
example, applicable laws or regulations prohibiting such payments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It may be difficult and/or costly to prevent, detect, investigate, mitigate, contain, and
remediate a security incident. Candid&#8217;s efforts to do so may not be successful. Actions taken by Candid or the third parties with whom Candid works to detect, investigate, mitigate, contain, and remediate a security incident could result in
outages, data losses, and disruptions of Candid&#8217;s business. Threat actors may also gain access to other networks and systems after a compromise of Candid&#8217;s networks and systems. For example, threat actors may use an initial compromise of
one part of Candid&#8217;s environment (or that of third parties with whom Candid works) to gain access to other parts of Candid&#8217;s environment, or leverage a compromise of the relevant networks or systems to gain access to the networks or
systems of third parties with whom Candid works, such as through phishing or supply chain attacks. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Remote work has increased risks to Candid&#8217;s information
technology systems and data, as more of Candid&#8217;s employees utilize network connections, computers and devices outside Candid&#8217;s premises or network, including working at home, while in transit and in public locations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future or past business transactions (such as acquisitions or integrations) expose Candid to additional cybersecurity risks and vulnerabilities, as Candid&#8217;s
systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, Candid may discover security issues that were not found during due diligence of such acquired or
integrated entities, and it may be difficult to integrate companies into Candid&#8217;s information technology environment and security program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid relies on
third parties to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee
email, content delivery, and other functions. Candid&#8217;s ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If the third
parties with whom Candid works experience a security incident or other interruption, Candid could experience adverse consequences. While Candid may be entitled to damages if the third parties with whom Candid works fail to satisfy their privacy or
security-related obligations to Candid, any award may be insufficient to cover Candid&#8217;s damages, or Candid may be unable to recover such award. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition,
supply-chain attacks have increased in frequency and severity, and Candid cannot guarantee that third parties&#8217; infrastructure in Candid&#8217;s supply chain or that of the third parties with whom Candid works have not been compromised. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While Candid has implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Candid
takes steps designed to detect, mitigate, and remediate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
vulnerabilities in its information systems (such as Candid&#8217;s hardware and/or software, including that of third parties with whom Candid works). Candid has not and may not in the future,
however, detect and remediate all such vulnerabilities including on a timely basis. Further, Candid has and may in the future experience delays in deploying remedial measures and patches designed to address identified vulnerabilities.
Vulnerabilities could be exploited and result in a security incident. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of the previously identified or similar threats have in the past and may in the future
could cause a security incident or other interruption that has in the past and may in the future result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to
Candid&#8217;s sensitive information or Candid&#8217;s information technology systems, or those of the third parties with whom Candid works. For example, Candid is aware of an event where a vendor&#8217;s information systems were compromised,
allowing hackers to intercept the vendor&#8217;s emails and impersonate the vendor in communication with Candid. A security incident or other interruption could disrupt Candid&#8217;s ability (and that of third parties with whom Candid works) to
conduct its business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has in the past and may in the future expend resources or modify its business activities (including its clinical trial activities) to
try to protect against security incidents. Certain data privacy and security obligations require Candid to implement and maintain specific security measures or industry-standard or reasonable security measures to protect Candid&#8217;s information
technology systems and sensitive information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Applicable data privacy and security obligations may require Candid, or Candid may voluntarily choose, to notify
relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related
actions are costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Candid (or a third party
with whom Candid works) experiences a security incident or is perceived to have experienced a security incident, Candid may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties,
audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity;
reputational harm; monetary fund diversions; diversion of management attention; interruptions in Candid&#8217;s operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may
negatively impact Candid&#8217;s ability to grow and operate its business. For example, the loss of data from clinical trials or similar activities could result in significant delays in our regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s contracts may not contain limitations of liability, and even where they do, there can be no assurance that
limitations of liability in Candid&#8217;s contracts are sufficient to protect Candid from liabilities, damages, or claims related to Candid&#8217;s data privacy and security obligations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid cannot be sure that any insurance coverage will be adequate or sufficient to protect Candid from or to mitigate liabilities arising out of Candid&#8217;s privacy
and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about Candid from public sources, data brokers, or
other means that reveals competitively sensitive details about Candid&#8217;s organization and could be used to undermine Candid&#8217;s competitive advantage or market position. Additionally, sensitive information of Candid could be leaked,
disclosed, or revealed as a result of or in connection with Candid&#8217;s employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s business could be affected by litigation, government investigations, and enforcement actions. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid currently operates in a number of jurisdictions in a highly regulated industry, and could be subject to litigation, government investigation and enforcement
actions on a variety of matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, environmental, whistleblower, false claims, data privacy and security, anti-kickback,
anti-bribery, securities, commercial, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
employment and other claims and legal proceedings that may arise from conducting Candid&#8217;s business. Any determination that Candid&#8217;s operations or activities are not in compliance with
existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief and/or other sanctions against Candid, and remediation of any such findings could have
an adverse effect on Candid&#8217;s business operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Legal proceedings, government investigations and enforcement actions can be expensive and time-consuming.
An adverse outcome resulting from any such proceedings, investigations or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs, healthcare debarment, injunctive relief,
product recalls, reputational damage and modifications of Candid&#8217;s business practices, which could have a material adverse effect on Candid&#8217;s business and results of operations. Even if such a proceeding, investigation, or enforcement
action is ultimately decided in Candid&#8217;s favor, the investigation and defense thereof could require substantial financial and management resources. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s employees and independent contractors, including consultants, vendors and any third parties Candid may engage in connection with development and
commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm Candid&#8217;s business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Misconduct by Candid&#8217;s employees and independent contractors, including consultants, vendors and any third parties Candid may engage in connection with
development and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate: (1)&nbsp;the laws and regulations of the FDA, the EU, EU Member States and comparable foreign regulatory
authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (2)&nbsp;manufacturing standards; (3)&nbsp;data privacy and security laws, and fraud and abuse and other healthcare laws and
regulations; or (4)&nbsp;other laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and
regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer
incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical
studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to Candid&#8217;s reputation. It is not always possible to identify and deter misconduct by employees and other
third parties, and the precautions Candid takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Candid from governmental investigations or other actions or lawsuits
stemming from a failure to comply with such laws or regulations. Additionally, Candid is subject to the risk that a person or government could allege fraud or other misconduct, even if none occurred. If any such actions are instituted against
Candid, and Candid is not successful in defending itself or asserting its rights, those actions could have a significant impact on Candid&#8217;s business and results of operations, including the imposition of significant civil, criminal and
administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting
obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of Candid&#8217;s operations.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in tax laws or regulations that are applied adversely to Candid or its customers may have a material adverse effect on Candid&#8217;s business, cash
flow, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">New U.S. federal, state or foreign income, sales, use, VAT, or other tax laws, statutes, rules,
regulations or ordinances could be enacted at any time, which could adversely affect Candid&#8217;s business operations, cash flows and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be
interpreted, changed, modified or applied adversely to Candid. For example, legislation informally titled the TCJA, the CARES Act, the IRA, and the OBBBA enacted many significant changes to U.S. tax laws. Future guidance from the IRS and other tax
authorities with respect to such legislation may affect Candid, and certain aspects of such legislation could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
conform to such legislation or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to Candid&#8217;s operations, the
taxation of foreign earnings and the deductibility of expenses or future reform legislation could have a material impact on the value of Candid&#8217;s deferred tax assets, could result in significant <FONT STYLE="white-space:nowrap">one-time</FONT>
charges and could increase Candid&#8217;s future tax expense. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s ability to use its net operating loss carryforwards and certain other tax
attributes may be limited. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, Candid had federal and state NOL carryforwards of approximately $24.9&nbsp;million and
$53.7&nbsp;million, respectively. Candid&#8217;s federal NOL carryforwards may be carried forward indefinitely but are limited to 80% of taxable income in such taxable year. It is uncertain if and to what extent various states will conform to
federal law. There also may be periods during which the use of state NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Sections 382 and 383 of the Code, and corresponding provisions of state and local law, if a corporation undergoes an &#8220;ownership change,&#8221; which
generally is defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and certain other tax
attributes to offset its post-change income or taxes may be limited. Candid may have experienced ownership changes in the past, and Candid may experience ownership changes as a result of subsequent shifts in Candid&#8217;s stock ownership (including
as a result of the Merger), some of which may be outside of Candid&#8217;s control. If Candid&#8217;s ability to use its NOL carryforwards and certain other tax attributes is materially limited by any ownership change, it could harm Candid&#8217;s
future results of operations by effectively increasing Candid&#8217;s future tax obligations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Investors&#8217; expectations of Candid&#8217;s performance
relating to environmental, social and governance factors may impose additional costs and expose Candid to new risks. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is an increasing focus from
certain investors, employees and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance factors. Some investors may use these factors to guide their investment strategies and, in some
cases, may choose not to invest in Candid if they believe Candid&#8217;s policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing
investor demand for measurement of corporate responsibility performance. The criteria by which companies&#8217; corporate responsibility practices are assessed may change, which could result in greater expectations of Candid and cause Candid to
undertake costly initiatives to satisfy such new criteria. If Candid elects not to or is unable to satisfy such new criteria, investors may conclude that Candid&#8217;s policies with respect to corporate responsibility are inadequate. Candid may
face reputational damage in the event that Candid&#8217;s corporate responsibility procedures or standards do not meet the standards set by various constituencies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, if Candid&#8217;s competitors&#8217; corporate responsibility performance is perceived to be greater than Candid&#8217;s, potential or current investors
may elect to invest with Candid&#8217;s competitors instead. In addition, in the event that Candid communicates certain initiatives and goals regarding environmental, social and governance matters, Candid could fail, or be perceived to fail, in its
achievement of such initiatives or goals, or Candid could be criticized for the scope of such initiatives or goals. If Candid fails to satisfy the expectations of investors, employees and other stakeholders or Candid&#8217;s initiatives are not
executed as planned, Candid&#8217;s reputation and financial results could be materially and adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid&#8217;s business is subject to risks
arising from pandemic and epidemic diseases. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> worldwide pandemic presented substantial public health
and economic challenges and affected Candid&#8217;s employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. Any future pandemic or epidemic
disease outbreaks could disrupt the supply chain and the manufacture or shipment of Candid&#8217;s drug candidates for use in its clinical trials and research and preclinical studies and, delay, limit or prevent Candid&#8217;s employees and CROs
from continuing research and development activities, impede Candid&#8217;s clinical trial initiation and recruitment and the ability of patients to continue in clinical trials, alter the results of the clinical trial due to disease progression in
participants, impede testing, monitoring, data collection and analysis and other related activities, any of which could delay Candid&#8217;s preclinical studies and clinical trials and increase Candid&#8217;s development costs, and have a material
adverse effect on Candid&#8217;s business, financial condition and results of operations. Any future pandemic or epidemic disease outbreak could also potentially further affect the business of the FDA or other comparable foreign regulatory
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
authorities, which could result in delays in meetings related to Candid&#8217;s planned clinical trials, as well as have an adverse impact on global economic conditions, which could have an
adverse effect on Candid&#8217;s business and financial condition, including impairing Candid&#8217;s ability to raise capital when needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to the
Combined Company </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>In determining whether you should approve the proposals contained in this proxy statement/prospectus, you should carefully read the
following risk factors in addition to the risks described above.</I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The combined company will need to raise substantial additional financing in the future to
fund its operations, which may not be available to it on favorable terms or at all. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company will require substantial additional funds to
advance its drug candidates into clinical development and to complete the clinical development of, seek regulatory approvals for and commercialize its drug candidates, if approved. The combined company&#8217;s future capital requirements will depend
upon a number of factors, including: the number, scope, rate of progress and costs of the combined company&#8217;s planned clinical trials for cizutamig, CND261, CND319 and CND460 and drug discovery and preclinical development activities for any
future drug candidates; the number and scope of clinical programs the combined company decides to pursue, including the number of indications it decides to pursue for a particular drug candidate; the scope and costs of manufacturing development for
any of the combined company&#8217;s current or future drug candidates, including commercial manufacturing at scale, if any drug candidate receives marketing approval, including as a result of inflation or any supply chain issues; the costs
associated with hiring additional personnel and consultants as the combined company&#8217;s business grows, including additional research and development personnel; the cost, timing and outcome of regulatory review of cizutamig, CND261, CND319 and
CND460 and any future drug candidates; the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing the combined company&#8217;s intellectual property rights and defending intellectual property-related claims; the
terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; the timing of any milestone and royalty payments to the combined company&#8217;s existing or future suppliers, collaborators or licensors; the
costs associated with enhancing the combined company&#8217;s operational systems and public reporting and compliance requirements; the extent to which the combined company acquires or <FONT STYLE="white-space:nowrap">in-licenses</FONT> other drug
candidates and technologies; and the costs associated with commercializing cizutamig, CND261, CND319 and CND460 or any future drug candidates, if they receive marketing approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Raising additional capital may be costly or difficult to obtain and could significantly dilute stockholders&#8217; ownership interests or inhibit the combined
company&#8217;s ability to achieve its business objectives. If the combined company raises additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely the
rights of its common stockholders. Further, to the extent that the combined company raises additional capital through the sale of common stock or securities convertible or exchangeable into common stock, its stockholder&#8217;s ownership interest in
the combined company will be diluted. In addition, any debt financing may subject the combined company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. If the combined company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the combined
company may have to relinquish certain valuable intellectual property or other rights to its drug candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the combined
company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the combined company or its stockholders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Following the Merger, the combined company may be unable to successfully integrate the businesses of Rallybio and Candid and realize some or all of the
anticipated benefits of the Merger. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger involves the combination of two companies which currently operate as independent companies. Following the
Merger, the combined company will be required to devote significant management attention and resources to integrating its business practices and operations. The combined company may fail to realize some or all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of the anticipated benefits of the Merger if the integration process takes longer than expected or is more costly than expected. Potential difficulties the combined company may encounter in the
integration process include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inability to successfully combine the businesses of Rallybio and Candid in a manner that permits the combined company
to achieve the anticipated benefits from the Merger, which would result in the anticipated benefits of the Merger not being realized partly or wholly in the time frame currently anticipated or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">creation of uniform standards, controls, procedures, policies and information systems; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the
Merger. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Rallybio and Candid have operated and, until the completion of the Merger, will continue to operate, independently. It is
possible that the integration process also could result in the diversion of each company&#8217;s management&#8217;s attention, the disruption or interruption of, or the loss of momentum in, each company&#8217;s ongoing businesses or inconsistencies
in standards, controls, procedures and policies, any of which could adversely affect the combined company&#8217;s ability to maintain its business relationships or the ability to achieve the anticipated benefits of the merger, or could otherwise
adversely affect the business and financial results of the combined company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market price of the combined company&#8217;s common stock is expected to be
volatile, and the market price of the common stock may drop following the Merger.</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The market price of the combined company&#8217;s common stock following
the Merger could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the
market price of the combined company&#8217;s common stock to fluctuate include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability of the combined company to obtain regulatory approvals for its drug candidates, and delays or failures to
obtain such approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure of any of the combined company&#8217;s drug candidates, if approved, to achieve commercial success;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure by the combined company to maintain its existing third-party license and supply agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure by the combined company or its licensors to prosecute, maintain, or enforce its intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in laws or regulations applicable to the combined company&#8217;s drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any inability to obtain adequate supply of the combined company&#8217;s drug candidates or the inability to do so at
acceptable prices; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">adverse regulatory authority decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">introduction of new products, services or technologies by the combined company&#8217;s competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to meet or exceed financial and development projections the combined company may provide to the public;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to meet or exceed the financial and development projections of the investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined
company or its competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined
company&#8217;s ability to obtain patent protection for its technologies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additions or departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if
they issue an adverse or misleading opinion regarding its business and stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general market or macroeconomic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sales of its common stock by the combined company or its stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">trading volume of the combined company&#8217;s common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to maintain compliance with the listing requirements of Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof,
significant contracts, commercial relationships or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">adverse publicity generally, including with respect to other products and potential products in such markets;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the introduction of technological innovations or new therapies that compete with potential products of the combined
company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the structure of health care payment systems; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> fluctuations in the
combined company&#8217;s financial results. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, the stock markets in general have experienced substantial volatility that has often been
unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation
against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm the combined company&#8217;s profitability and reputation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, a decrease in the stock price of the combined company may cause the combined company&#8217;s common stock to no longer satisfy the continued listing
standards of Nasdaq. If the combined company is not able to maintain the requirements for listing on Nasdaq, it could be delisted, which could have a materially adverse effect on its ability to raise additional funds as well as the price and
liquidity of its common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The combined company will incur costs and demands upon management as a result of complying with the laws, rules and
regulations affecting public companies.</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company will incur significant legal, accounting and other expenses that Candid did not incur as a
private company, including costs associated with public company reporting requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company will also incur costs associated with corporate
governance requirements, including requirements under the laws, rules and regulations of the SEC as well as the Nasdaq rules. These laws, rules and regulations are expected to increase the combined company&#8217;s legal and financial compliance
costs and to make some activities more time consuming and costly. These laws, rules and regulations also may make it difficult and expensive for the combined company to obtain directors&#8217; and officers&#8217; liability insurance. As a result, it
may be more difficult for the combined company to attract and retain qualified individuals to serve on the combined company board of directors or as executive officers of the combined company, which may adversely affect investor confidence in the
combined company and could cause the combined company&#8217;s business or stock price to suffer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the assets subject to the Rallybio CVR Agreement are not
disposed of in a timely manner, the combined company may have to incur time and resources to wind down or dispose of such assets. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the
Merger, holders of Rallybio Common Stock, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, restricted stock units and in the money stock options as of the close of business on the last business day prior to the Effective Time will
receive one Rallybio CVR for each outstanding share of Rallybio Common Stock, or share underlying an equity award of Rallybio Common Stock, held. Each Rallybio CVR will entitle the holder thereof to certain payments in respect of certain Legacy
Assets. Please see the section titled &#8220;<I>Agreements Related to the Merger&#8212;Rallybio Contingent Value Rights Agreement</I>.&#8221; If Rallybio does not enter into disposition agreements related to such Legacy Assets prior to the Closing,
the combined company may need to allocate time and resources to wind down or dispose of such assets. In addition, certain proceeds from such disposition agreements entered into prior to or following the Closing, will be distributed to the holders of
the Rallybio CVRs, pursuant to the Rallybio CVR Agreement. As a result, the combined company&#8217;s stockholders may receive no or limited benefits from any time or resources allocated to such Legacy Assets and such activities may be a distraction
to the combined company&#8217;s management and employees. As a result, the combined company&#8217;s operations and financial condition may be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nasdaq may delist the combined company&#8217;s securities from trading on its exchange, which could limit
investors&#8217; ability to make transactions in its securities and subject the combined company to additional trading restrictions. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently,
Rallybio&#8217;s common stock is publicly traded on Nasdaq. In connection with the proposed Merger, Candid will file an initial listing application with Nasdaq pursuant to Nasdaq&#8217;s &#8220;reverse merger&#8221; rules. The combined company will
be required to meet the initial listing requirements for its securities to be listed on Nasdaq. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the combined company fails to meet the Nasdaq listing
requirements and their respective boards choose to close the Merger without Nasdaq&#8217;s approval, then Nasdaq may notify the combined company of its determination to delist the company&#8217;s securities based upon the failure to satisfy the
criteria in the Nasdaq application. For more information, refer to the section titled &#8220;<I>Risk Factors&#8212;Risks Related to the Merger&#8212;Rallybio or Candid may waive one or more of the conditions to the Merger without recirculation of
this proxy statement/prospectus or resoliciting stockholder approval.</I>&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot assure you that the combined company will be able to meet those initial
listing requirements. Even if the combined company&#8217;s securities are so listed, the combined company may be unable to maintain the listing of its securities in the future. In order to continue listing its securities on Nasdaq following the
proposed Merger, the combined company will be required to maintain certain financial, distribution and stock price levels. If Nasdaq delists the combined company&#8217;s securities from trading on its exchange at the Closing (or thereafter) and the
combined company is not able to list its securities on another national securities exchange or regain compliance with Nasdaq, the combined company&#8217;s securities could be quoted on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market. If this were to occur, the combined company could face significant material adverse consequences, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a limited availability of market quotations for its securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced liquidity for its securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a determination that the combined company&#8217;s common stock is a &#8220;penny stock&#8221; which will require brokers
trading in the combined company&#8217;s common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a limited amount of news and analyst coverage; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a decreased ability to issue additional securities or obtain additional financing in the future. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts states from regulating the sale of certain securities, which
are referred to as &#8220;covered securities.&#8221; Since the Rallybio Common Stock is listed on Nasdaq, they are covered securities. Although states are preempted from regulating the sale of covered securities, the federal statute does allow
states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then states can regulate or bar the sale of covered securities in a particular case. If Rallybio was no longer listed on Nasdaq, its
securities would not be covered securities and it would be subject to regulation in each state in which it offers its securities, including in connection with the Merger. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Provisions in the combined company&#8217;s amended and restated certificate of incorporation, the combined company&#8217;s amended and restated bylaws and
Delaware law may have anti-takeover effects that could discourage an acquisition of the combined company by others, even if an acquisition would be beneficial to the combined company&#8217;s stockholders, and may prevent attempts by the combined
company&#8217;s stockholders to replace or remove the combined company&#8217;s current management. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amended and restated certificate of incorporation
and amended and restated bylaws of the combined company will be the amended and restated certificate of incorporation and amended and restated bylaws of Rallybio, which, along with Delaware law will contain provisions that may have the effect of
discouraging, delaying or preventing a change in control of the combined company or changes in the combined company&#8217;s management that stockholders may consider favorable, including transactions in which the combined company&#8217;s
stockholders might otherwise receive a premium for their shares. The combined company&#8217;s amended and restated certificate of incorporation and bylaws will include provisions that: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">authorize &#8220;blank check&#8221; preferred stock, which could be issued by the combined company&#8217;s board of
directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to the combined company&#8217;s common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">specify that special meetings of the combined company&#8217;s stockholders can be called only by the combined
company&#8217;s board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of the combined
company&#8217;s stockholders, including proposed nominations of persons for election to the combined company&#8217;s board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that vacancies on the combined company&#8217;s board of directors may be filled only by a majority of directors
then in office, even though less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that the combined company&#8217;s directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">specify that no stockholder is permitted to cumulate votes at any election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expressly authorize the combined company&#8217;s board of directors to modify, alter or repeal the combined
company&#8217;s amended and restated bylaws; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require supermajority votes of the holders of the combined company&#8217;s common stock to amend specified provisions of
the combined company&#8217;s amended and restated certificate of incorporation and amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These provisions, alone or
together, could delay or prevent hostile takeovers and changes in control or changes in the combined company&#8217;s management. These provisions could also limit the price that investors might be willing to pay in the future for shares of the
combined company&#8217;s common stock, thereby depressing the market price of the combined company&#8217;s common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, because the combined company
will be incorporated in the State of Delaware, the combined company will be governed by the provisions of Section 203 of the General DGCL which will prohibit a person who owns in excess of 15% of the combined company&#8217;s outstanding voting stock
from merging or combining with the combined company for a period of three years after the date of the transaction in which the person acquired in excess of 15% of the combined company&#8217;s outstanding voting stock, unless the merger or
combination is approved in a prescribed manner. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any provision of the combined company&#8217;s amended and restated certificate of incorporation, amended and
restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for the combined company&#8217;s stockholders to receive a premium for their shares of our common stock, and could also
affect the price that some investors are willing to pay for the combined company&#8217;s common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The combined company&#8217;s amended and restated
certificate of incorporation will designate the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by the combined company&#8217;s stockholders, which could
limit the combined company&#8217;s stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the combined company or its directors, officers or employees. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company&#8217;s amended and restated certificate of incorporation, which will be Rallybio&#8217;s amended and restated certificate of incorporation, will
provide that, subject to limited exceptions, the state or federal courts (as appropriate) within the State of Delaware will be exclusive forums for (1) any derivative action or proceeding brought on the combined company&#8217;s behalf, (2) any
action asserting a claim of breach of a fiduciary duty owed by any of the combined company&#8217;s directors, officers or other employees to the combined company or its stockholders, (3) any action asserting a claim against the combined company
arising pursuant to any provision of the DGCL, the combined company&#8217;s amended and restated certificate of incorporation or the combined company&#8217;s amended and restated bylaws, (4) action against the combined company or any of its
directors or officers involving a claim or defense arising pursuant to the Exchange Act or the Securities Act, or (5) any other action asserting a claim against the combined company that is governed by the internal affairs doctrine. Any person or
entity purchasing or otherwise acquiring any interest in shares of the combined company&#8217;s capital stock shall be deemed to have notice of and to have consented to the provisions of the combined company&#8217;s amended and restated certificate
of incorporation described above. This exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of
Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision will not apply to actions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. This choice of forum provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the combined company or its directors, officers or other employees, which may discourage such lawsuits against the combined
company and its directors, officers and employees. Alternatively, if a court were to find these provisions of the combined company&#8217;s amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more
of the specified types of actions or proceedings, the combined company may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect the combined company&#8217;s business and financial
condition. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware
law, there is uncertainty as to whether other courts will enforce the combined company&#8217;s federal forum provision. If the federal forum provision is found to be unenforceable, the combined company may incur additional costs associated with
resolving such matters. The federal forum provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio and Candid do not anticipate that the combined company will pay any cash dividends in the foreseeable future.</I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The current expectation is that the combined company will retain its future earnings, if any, to fund the development and growth of the combined company&#8217;s
business. As a result, capital appreciation, if any, of the common stock of the combined company will be its stockholders&#8217; sole source of gain, if any, for the foreseeable future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock
for a profit, if at all.</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the Merger, there had been no public market for Candid&#8217;s common stock. An active trading market for the combined
company&#8217;s shares of common stock may never develop or be sustained. If an active market for its common stock does not develop or is not sustained, it may be difficult for its stockholders to sell their shares at an attractive price or at all.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline.</I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If existing stockholders of Rallybio and Candid sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public
market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, including upon the expiration or release of <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions pursuant to the terms of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements, the trading price of the common stock of the combined company could decline. Neither Rallybio nor Candid is able to predict the effect that sales may have on the prevailing market price of the
combined company&#8217;s common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the
combined company, its business or its market, its stock price and trading volume could decline.</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for the combined company&#8217;s common
stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect not to provide research coverage of the combined company&#8217;s common stock after the
completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts, or
the content and opinions included in their reports. The price of the combined company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more
equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The unaudited pro forma condensed combined financial statements included in this proxy statement/prospectus are presented for illustrative purposes only and may
not be an indication of the combined company&#8217;s financial condition or results of operations following the completion of the Merger.</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro
forma condensed combined financial statements contained in this proxy statement/prospectus are presented for illustrative purposes only and may not be an indication of the combined company&#8217;s financial condition or results of operations
following the Merger for several reasons. The unaudited pro forma condensed combined financial statements have been derived from the historical audited financial statements of Rallybio and Candid for the year ended December&nbsp;31, 2025 and certain
adjustments and assumptions have been made regarding the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
combined company after giving effect to the Merger. The information upon which these adjustments and assumptions have been made is preliminary, and these kinds of adjustments and assumptions are
difficult to make with accuracy. Moreover, the unaudited pro forma condensed combined financial statements do not reflect all costs that are expected to be incurred by the combined company in connection with the Merger. For example, the impact of
any incremental costs incurred in integrating the two companies is not reflected in the unaudited pro forma condensed combined financial statements. As a result, the actual financial condition of the combined company following the Merger may not be
consistent with, or evident from, these unaudited pro forma condensed combined financial statements. The assumptions used in preparing the unaudited pro forma condensed combined financial statements may not prove to be accurate, and other factors
may affect the combined company&#8217;s financial condition following the Merger. For more information, please see the section titled &#8220;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>&#8221; in this proxy
statement/prospectus. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the combined company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements
on a timely basis could be impaired.</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the
rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and internal control over financial reporting. The combined company must perform
system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. As a private company, Candid has never been required to test its internal controls within a specified period. This will require
that the combined company incur substantial professional fees and internal costs to expand its accounting and finance functions and that it expends significant management efforts. The combined company may experience difficulty in meeting these
reporting requirements in a timely manner. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company may discover weaknesses in its system of internal financial and accounting controls and procedures
that could result in a material misstatement of its financial statements. The combined company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and
operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that
misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the combined company is not able to
comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, or if it is unable to maintain proper and effective internal controls, the combined company may not be able to produce timely and accurate financial statements. If that were
to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its
drug candidates or otherwise implement its business plan. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company&#8217;s ability to compete in the highly competitive pharmaceuticals
industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The combined company will be highly dependent on its management and scientific personnel. The
loss of the services of any of these individuals could impede, delay, or prevent the successful development of the combined company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its drug candidates or <FONT
STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the combined company loses the services of any of these individuals, it might not be
able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The combined company might not be able to attract or retain qualified management and other key personnel in the future due to the intense
competition for qualified personnel among biotechnology, pharmaceutical and other businesses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The combined company is expected to take advantage of reduced
disclosure and governance requirements applicable to smaller reporting companies and emerging growth companies, which could result in its common stock being less attractive to investors.</I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the Merger, the combined company is expected to continue to be eligible to use the reduced disclosure requirements appliable to smaller reporting companies
until the next determination date, in accordance with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
rules of the SEC. In addition, the combined company is expected to be an emerging growth company until the earlier of (i)&nbsp;the last day of the fiscal year in which the combined company has
total annual gross revenues of $1.235&nbsp;billion or more; (ii)&nbsp;December&nbsp;31, 2026; (iii) the date on which the combined company has issued more than $1&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the
date on which the combined company is deemed to be a large accelerated filer under the rules of the SEC, which means the market value of the combined company&#8217;s common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
exceeds $700&nbsp;million as of the last business day of the combined company&#8217;s second fiscal quarter.&nbsp;As an emerging growth company and/or smaller reporting company, the combined company will be able to take advantage of reduced
disclosure requirements, such as simplified executive compensation disclosures and reduced financial statement disclosure requirements in its SEC filings. Decreased disclosures in the combined company&#8217;s SEC filings due to its status as an
emerging growth company and/or smaller reporting company may make it harder for investors to analyze its results of operations and financial prospects. Rallybio and Candid cannot predict if investors will find the combined company&#8217;s common
stock less attractive if it relies on these exemptions. If some investors find its common stock less attractive as a result, there may be a less active trading market for its common stock and its stock price may be more volatile. The combined
company may take advantage of the reporting exemptions applicable to a smaller reporting company until it is no longer a smaller reporting company, which status would end once it has a public float greater than $250&nbsp;million as of the last
business day of the combined company&#8217;s second fiscal quarter. In that event, the combined company could still be a smaller reporting company if its annual revenues were below $100&nbsp;million and it has a public float of less than
$700&nbsp;million as of the last business day of the combined company&#8217;s second fiscal quarter. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in tax laws may materially adversely affect the
combined company&#8217;s business, prospects, financial condition and operating results. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">New tax laws, statutes, rules, regulations or ordinances could be
enacted at any time, which could adversely affect the combined company&#8217;s business, prospects, financial condition and operating results. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed,
modified or applied adversely to the combined company. For example, the TCJA, the CARES Act, the IRA, and the OBBBA enacted many significant changes to the U.S. tax laws. Future guidance from the IRS and other tax authorities with respect to such
legislation may affect the combined company, and certain aspects of such legislation could be repealed or modified in future legislation. Such tax law changes could have a material adverse impact on the combined company. In addition, it is uncertain
if and to what extent various states will conform to newly enacted federal tax legislation. While it is too early to assess the overall impact of these changes, as these and other tax laws and related regulations are revised, enacted, and
implemented, the combined company&#8217;s financial condition, results of operations, and cash flows could be materially adversely impacted. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The combined
company&#8217;s ability to use net operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger.</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of
Rallybio and Candid has incurred losses during its history, and the combined company does not expect to become profitable in the near future and may never achieve profitability. To the extent that the combined company continues to generate taxable
losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, if at all. As of December&nbsp;31, 2025, Rallybio had U.S. federal NOL carryforwards and state NOL carryforwards of
$183.3&nbsp;million and $181.6&nbsp;million, respectively, and Candid had U.S. federal and state NOL carryforwards of approximately $24.9&nbsp;million and $53.7&nbsp;million, respectively. Under current law, U.S. federal NOL carryforwards generated
in taxable periods beginning after December&nbsp;31, 2017, may be carried forward indefinitely, but the deductibility of such NOL carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to
federal law. In addition, under Sections 382 and 383 of the Code, federal NOL carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership
change&#8221; pursuant to Section&nbsp;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest
ownership percentage within a rolling three-year period. The combined company&#8217;s ability to utilize its NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership
changes, including potential changes in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If the combined company earns taxable income, such limitations could result in increased future income tax
liability to the combined company, and the combined company&#8217;s future cash flows could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_4"></A>MARKET PRICE AND DIVIDEND INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Common Stock is currently listed on Nasdaq under the symbol &#8220;RLYB.&#8221; The closing price of the Rallybio Common Stock on February&nbsp;27, 2026, the
last day of trading prior to the announcement of the Merger, as reported on Nasdaq, was $7.54 per share. The closing price of the Rallybio Common Stock on &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, the last practicable date before the date of this
proxy statement/prospectus, as reported on Nasdaq, was $&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;per share. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because the market price of the Rallybio Common Stock
is subject to fluctuation, the market value of the shares of the Rallybio Common Stock that the Candid stockholders will be entitled to receive in the Merger may increase or decrease. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is a private company and shares of Candid Capital Stock are not publicly traded. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming approval of Proposal Nos. 1, 2 and 3 and the Closing, following the consummation of the Merger, the Rallybio Common Stock will trade on The Nasdaq Capital
Market under Rallybio&#8217;s new name, &#8220;Candid Therapeutics, Inc.&#8221; and new trading symbol &#8220;CDRX&#8221;. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
&#8195;&#8195;&#8195;&#8195;&#8195;, 2026, the record date for the Rallybio annual meeting, there were approximately &#8195;&#8195;&#8195;&#8195;&#8195;registered holders of record of Rallybio Common Stock. As of &#8195;&#8195;&#8195;&#8195;&#8195;,
2026, Candid had &#8195;&#8195;&#8195;&#8195;&#8195;holders of record of Candid Common Stock and &#8195;&#8195;&#8195;&#8195;&#8195;holders of record of Candid Preferred Stock. For detailed information regarding the beneficial ownership of certain
Rallybio stockholders and Candid stockholders, see the sections of this proxy statement/prospectus titled &#8220;<I>Principal Stockholders of Rallybio</I>&#8221; and &#8220;<I>Principal Stockholders of Candid.</I>&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dividends </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio has never declared or paid any cash dividends on
Rallybio Common Stock and does not anticipate paying cash dividends on Rallybio Common Stock for the foreseeable future. Any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined company&#8217;s
then-current board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other
factors the then-current board of directors deems relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has never paid or declared any cash dividends on Candid Capital Stock, does not anticipate
paying any cash dividends on the Candid Capital Stock in the foreseeable future, and intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to pay dividends will
be at the discretion of the Candid Board and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable laws and other factors
the Candid Board deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This proxy statement/prospectus contains or incorporates statements that constitute forward-looking statements within the meaning of the federal securities laws in
relation to Rallybio, Candid, the Merger and the other proposed transactions contemplated thereby. Any express or implied statements that do not relate to historical or current facts or matters are forward-looking statements. In addition, any
statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;forecasts,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or
other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential
effects. There can be no assurance that future developments affecting Rallybio, Candid or the proposed transaction will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are
beyond Rallybio&#8217;s or Candid&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. In addition to other factors and
matters contained in or incorporated by reference in this document, Rallybio believes the following factors could cause actual results to differ materially from those discussed in the forward-looking statements: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that the conditions to the closing of the transaction are not satisfied, including the failure to timely obtain
stockholder approval for the Merger Agreement and the transactions contemplated thereby, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio&#8217;s and Candid&#8217;s ability to meet expectations regarding the timing and completion of the Merger;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that the Concurrent Financing is not completed in a timely manner or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">uncertainties as to the timing of the consummation of the Merger and the ability of each of Rallybio and Candid to
consummate the Merger and the other Contemplated Transactions, including the Concurrent Financing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">risks related to Rallybio&#8217;s continued listing on the Nasdaq Capital Market until Closing and the ability for the
combined company to list on Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expectations regarding the strategies, prospects, plans, expectations and objectives of management of Candid for future
operations of the combined company following the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability of the combined company to recognize the benefits that may be derived from the Merger, including the
commercial or market opportunity of the drug candidates of Candid and the combined company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possibility that Rallybio CVR holders may never receive any proceeds pursuant to the Rallybio CVR Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that as a result of adjustments to the Exchange Ratio, Rallybio stockholders and Candid stockholders could own
more or less of the combined company than is currently anticipated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">risks related to the market price of Rallybio Common Stock relative to the value suggested by the Exchange Ratio;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">risks related to Rallybio&#8217;s and Candid&#8217;s ability to correctly estimate their respective operating expenses and
expenses associated with the transaction, uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon Closing and other events and unanticipated spending and costs that could
reduce the combined company&#8217;s cash resources; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the
Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the fact that under the terms of the Merger Agreement, Rallybio and Candid are restrained from soliciting other
acquisition proposals during the pendency of the Merger, except in certain circumstances; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effect of the announcement or pendency of the Merger on Rallybio&#8217;s or Candid&#8217;s business relationships,
operating results and business generally, including disruption of Rallybio&#8217;s and Candid&#8217;s management&#8217;s </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
attention from ongoing business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that the Merger Agreement may be terminated in circumstances that require Rallybio or Candid to pay a termination
fee; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome of any legal proceedings that may be instituted against Rallybio, Candid or any of their respective directors
or officers related to the Merger Agreement or the transactions contemplated thereby; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability of Candid to maintain and protect its intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">competitive responses to the Merger; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">legislative, regulatory, political and economic developments beyond the parties&#8217; control; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio&#8217;s public securities&#8217; potential liquidity and trading; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, timing and success of clinical trials for cizutamig, CND261, CND319, CND460 and any future drug candidates
of Candid and unexpected costs that may result therefrom; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">risks related to the failure to realize any value from drug candidates and preclinical programs being developed and
anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing drug candidates to market; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">success in recruiting and retaining, or changes required in, Candid&#8217;s officers, key employees or directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory actions with respect to cizutamig, CND261, CND319, CND460 or any future drug candidates of Candid or its
competitors&#8217; products and drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to manufacture cizutamig, CND261, CND319, CND460 and any future drug candidates in conformity with
the FDA&#8217;s requirements and to scale up manufacturing of its drug candidates to commercial scale, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s reliance on third-party CDMOs to manufacture and supply cizutamig, CND261, CND319, CND460 and any future
drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that Candid may not be able to establish collaborations on commercially reasonable terms or realize the
anticipated benefits of any collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to successfully commercialize cizutamig, CND261, CND319, CND460 and any future drug candidates, if
approved, the rate and degree of market acceptance of cizutamig, CND261, CND319, CND460 and any future drug candidates and the favorability of pricing regulations, reimbursement practices from third-party payors or healthcare reform initiatives in
the United States and abroad; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s ability to successfully identify and validate new drug candidates or additional indications for cizutamig,
CND261, CND319 or CND460; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk of lawsuits related to cizutamig, CND261, CND319, CND460 or any future drug candidates of Candid;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that Candid, or its CROs, CDMOs, service providers, current and potential future partners or other third parties
upon which it relies, could experience a security incident, system disruption or failure, data loss, cyberattack, or similar event that could compromise the confidentiality, integrity and availability of systems and data; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sufficiency of Candid&#8217;s internal controls and procedures and its ability to remediate any material weaknesses;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments and projections relating to Candid&#8217;s competitors, its industry or the market opportunities for
cizutamig, CND261, CND319, CND460 or any future drug candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">economic, regulatory, political, geopolitical (including military conflicts and threatened hostilities), environmental and
public health developments in the United States and foreign countries. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should one or more of these risks or uncertainties materialize, or should
any of Rallybio&#8217;s or Candid&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that Rallybio considers immaterial or which
are unknown. You are urged to carefully review the disclosures Rallybio and Candid make concerning these risks and other factors that may affect Rallybio&#8217;s and Candid&#8217;s business and operating results under the section titled
&#8220;<I>Risk Factors</I>&#8221; of this proxy statement/prospectus. Additional factors that could cause actual results to differ materially from those expressed in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the forward-looking statements are discussed in reports filed with the SEC by Rallybio. Please see the section titled &#8220;<I>Where You Can Find More Information</I>&#8221; of this proxy
statement/prospectus. There can be no assurance that the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the Merger will be realized. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of Rallybio, Candid or the combined company could differ
materially from the forward-looking statements. Any public statements or disclosures by Rallybio and Candid following this proxy statement/prospectus that modify or impact any of the forward-looking statements contained in this proxy
statement/prospectus will be deemed to modify or supersede such statements in this proxy statement/prospectus. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document.
Rallybio and Candid do not intend, and undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, unless required by law
to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_6"></A>THE MERGER </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Background of the Merger </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following chronology summarizes the
material meetings and events that led to the execution of the Merger Agreement. </I><I>It</I><I> does not purport to catalog every discussion or interaction among the Rallybio Board, members of Rallybio&#8217;s senior management or Rallybio&#8217;s
advisors or other parties and their respective financial advisors, legal advisors, affiliates or other representatives.</I> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In an effort to enhance stockholder
value, the Rallybio Board, together with senior management, regularly reviews and discusses Rallybio&#8217;s near and long-term operating and strategic priorities. Among other things, these reviews and discussions have focused on the opportunities
and risks associated with Rallybio&#8217;s development programs and financial condition, as well as its strategic relationships and potential long-term strategic options. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since inception, Rallybio&#8217;s mission has been to develop and commercialize life-transforming therapies for patients with severe and rare
diseases.&nbsp;Rallybio&nbsp;built a broad pipeline with product candidates aimed at addressing diseases with unmet medical need in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2025, Rallybio and Recursion, which each owned one-half of the membership interests of RE Ventures I, LLC (&#8220;REV-I&#8221;), a joint venture developing a
product candidate for the treatment of patients with hypophosphatasia, began discussing potential transactions between the parties. After extensive discussion, the parties agreed to pursue a sale by Rallybio of its interests in REV-I to Recursion
(the &#8220;JV Sale&#8221;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 24, 2025, Nasdaq notified Rallybio that Rallybio was not in compliance with Nasdaq&#8217;s listing rules because the
closing bid price of Rallybio&#8217;s common stock had been below $1.00 per share for 30 consecutive business days. Nasdaq noted that Rallybio had until August 25, 2025 to cure the deficiency and regain compliance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On April 8, 2025, Rallybio announced that it had discontinued its lead clinical program, RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia,
based on pharmacokinetic data from its Phase 2 clinical trial. Rallybio announced that it would focus on advancing RLYB116, a once-weekly small volume C5 inhibitor for the treatment of complement-driven diseases, as well as its other emerging
preclinical programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After Rallybio&#8217;s April 8, 2025 announcement, representatives of Party A, a healthcare focused investment fund, contacted Rallybio to
propose a potential transaction pursuant to which Rallybio would acquire a recently formed company owned primarily by Party A and the parties would concurrently complete a private placement financing to fund the combined business. Rallybio and Party
A had entered into a mutual confidentiality agreement that did not include a standstill in connection with prior discussions about a potential investment by in Rallybio by Party A. Rallybio management and Party A held multiple meetings in April 2025
to discuss each company&#8217;s product candidates and the proposed structure, including a potential reverse merger or asset purchase, and terms of the transaction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On April 15, 2025, Rallybio received a proposal to acquire Rallybio for approximately $1 per share from a third party (the &#8220;April 2025 Proposal&#8221;), which
amount valued Rallybio at less than the amount of cash and cash equivalents held by Rallybio on such date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On May 2, 2025, the Rallybio Board held a meeting
attended by members of management. During the meeting, the Rallybio Board discussed a proposed workforce reduction to streamline operations following the discontinuation of the RLYB212 program and to reduce Rallybio&#8217;s cash burn rate. The
Rallybio Board considered the terms of the workforce reduction and impact on Rallybio&#8217;s operations and, following discussion, approved the separation of approximately 40% of Rallybio&#8217;s employees. The Rallybio Board then discussed
Rallybio&#8217;s depressed market value and its past and current challenges to obtain financing, particularly in light of difficult market conditions for the biotechnology industry. It also considered the ongoing discussions with Party A, the
potential JV Sale and other recent interactions with third parties regarding strategic transactions and financings, including discussions with privately held companies about potential reverse mergers and opportunities to monetize RLYB116. The
Rallybio Board also reviewed the April 2025 Proposal and, following discussion, concluded that the proposal did not properly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
value Rallybio&#8217;s existing programs and it was not in the best interests of Rallybio&#8217;s stockholders to pursue the April 2025 Proposal at that time. The Rallybio Board then directed
management to continue discussions with Party A and other third parties about potential business combination transactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On May 13, 2025, the Rallybio Board held
a meeting attended by representatives of management and Rallybio&#8217;s financial and legal advisors at Evercore Group L.L.C. (&#8220;Evercore&#8221;) and Ropes &amp; Gray LLP (&#8220;Ropes &amp; Gray&#8221;), respectively. During the meeting,
management presented about the development plans, timelines and costs for Rallybio&#8217;s product candidates and provided an overview of certain business development matters, including the JV Sale, discussions with Party A, and potential
collaboration partners for RLYB116. A representative of Ropes &amp; Gray reviewed director fiduciary duties, including in connection with the potential business development options being considered. Representatives of Evercore then reviewed biotech
market trends and financing challenges, certain potential strategic alternatives available to Rallybio, including a sale of Rallybio, a reverse merger, selling certain assets, remaining a standalone independent company or winding down, and a
potential process to evaluate the various alternatives and prospective counterparties. The Rallybio Board asked questions of management and Rallybio&#8217;s advisors and discussed parties that should be contacted about potential transactions, based
on recommendations from management and the advisors, as well as the Rallybio Board&#8217;s experience in the biotech sector. Following discussion, the Rallybio Board directed management to continue discussions with Party A and Recursion, as well as
to initiate a confidential process to explore strategic alternatives, including a reverse merger or sale of Rallybio. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On May 21, 2025, the Rallybio Board held a
meeting attended by representatives of management and Evercore. Management presented a proposal from Party A for a reverse merger, which ascribed a value of $25 million to Rallybio, which would result in Rallybio&#8217;s stockholders owning 15% of
the combined company following the proposed merger but without accounting for a concurrent equity financing that was contemplated to raise between $50-65 million. The Rallybio Board discussed, among other things, precedent transactions; the value
being ascribed by Party A to Rallybio&#8217;s current programs, management team and public listing; the viability of Party A&#8217;s product candidate and development plans; the financing requirements of the combined company; and potential
contingent value rights to be issued to Rallybio&#8217;s stockholders to deliver value based on the development or divestiture of Rallybio&#8217;s current programs. Following discussion, the Rallybio Board directed management to deliver a
counterproposal to Party A and continue discussions. Representatives of Evercore then described potential timelines and approaches for outreach to third parties to evaluate other potential strategic alternatives. Following the discussion, the
Rallybio Board directed representatives of Evercore to commence outreach to parties as previously discussed with the Rallybio Board at its meeting on May 13, 2025 to solicit proposals for a potential reverse merger with, or acquisition of, Rallybio.
The Rallybio Board also agreed to hold regular meetings to receive updates about the strategic process and to provide guidance to management and the advisors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
May 22, 2025, Rallybio provided a proposal to Party A that ascribed a value of $55 million to Rallybio, which would result in Rallybio&#8217;s stockholders owning 35% of the combined company following the proposed merger but without accounting for
the proposed concurrent financing that Rallybio proposed to be $60 million. In addition, Rallybio&#8217;s stockholders would receive contingent value rights that would entitle them to a pro rata share of proceeds from any divestiture of
Rallybio&#8217;s legacy assets. Party A delivered a response on May 26, 2025 that ascribed a value of $41 million to Rallybio, which would result in Rallybio&#8217;s stockholders owning 30% of the combined company following the proposed merger but
prior to a concurrent financing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June 2, 2025 and June 4, 2025, the Rallybio Board held meetings attended by representatives of management and Evercore.
Management provided updates on discussions with Party A, including Rallybio&#8217;s and Party A&#8217;s recent proposals, and also shared their perspectives on valuation of Rallybio. Representatives of Evercore noted that it had commenced outreach
to potential counterparties regarding a potential reverse merger or acquisition, and the representatives provided feedback about initial engagement with third parties. Following discussion, the Rallybio Board directed management to continue
negotiations with Party A and representatives of Evercore to continue its outreach. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June 18, 2025, the Rallybio Board held a meeting attended by representatives
of management and Evercore. Rallybio management noted that Rallybio and Party A had agreed on the material economic terms of a potential reverse merger transaction, including that Rallybio&#8217;s stockholders would own between 19.5-22.5% of the
combined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
company after completing the proposed merger and concurrent financing, and that Rallybio&#8217;s stockholders would receive contingent value rights that would entitle them to proceeds from the
divestiture of any Rallybio assets. The Rallybio Board and management discussed next steps for the proposed transaction, including outreach to potential investors for the concurrent financing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June 25, 2025, the Rallybio Board held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management provided an update on
discussions with Recursion, as well as the anticipated economics and documentation for the JV Sale. Representatives of Evercore then provided an update on its outreach to third parties, noting that, at the direction of the Rallybio Board, it had
initially contacted 16 privately held companies and healthcare-focused investment funds to gauge interest in a potential reverse merger, held calls with 12 of such companies and funds and delivered process letters to 10 of such potential
counterparties, requesting bids by June 24, 2025. To date, three companies had submitted written proposals and one more was expected. Representatives of Evercore then provided a summary of such proposals and noted that it had contacted 17 strategic
parties to inquire about their interest in acquiring Rallybio. Evercore held initial calls with 14 of such potential strategic parties and delivered process letters requesting bids by July 1, 2025. Rallybio granted access to a data room containing
non-public information to six parties, each of which had previously signed a confidentiality agreement that either did not include a standstill or included a standstill that permitted the counterparty to request a waiver. No party had yet delivered
a written proposal to acquire Rallybio in response to the outreach. The Rallybio Board asked questions about the proposals and discussed the proposed terms and process to evaluate each of the bids. The Rallybio Board directed the representatives of
Evercore to continue its discussions with interested parties and directed management to conduct due diligence on the counterparties and their current programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
July 8, 2025, Rallybio entered into an agreement for the JV Sale (the &#8220;ENPP1 Purchase Agreement&#8221;), which provided that Rallybio would receive as upfront consideration shares of Recursion&#8217;s common stock and additional payments of
Recursion stock and cash upon achievement of certain development and clinical milestones, as well as low single digit royalties on annual net sales of certain products developed and sold by REV-I. The consideration from the transaction was expected
to extend Rallybio&#8217;s anticipated cash runway into at least the middle of 2027. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July 9, 2025, the Rallybio Board held a meeting attended by representatives
of management, Evercore and Ropes &amp; Gray. Management provided an update on strategic alternatives, noting that it was continuing discussions with a few parties that expressed interest in acquiring RLYB116 and a few potential reverse merger
counterparties. Management also noted that it was conducting diligence about the scientific and commercial viability of the programs being developed by the reverse merger counterparties. Representatives of Evercore stated that no parties had
submitted a proposal to acquire Rallybio. However, one party had submitted a proposal to acquire RLYB116 for $11 million upfront, and two other parties had indicated they would submit proposals to acquire RLYB116. Representatives of Evercore also
noted that Rallybio had received, in addition to the existing proposal from Party A, proposals from five parties contemplating a reverse merger. Representatives of Evercore summarized the terms of each proposal and discussed recent management
presentations with two potential reverse merger counterparties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July 16, July 23 and July 30, 2025, the Rallybio Board held meetings attended by representatives
of management, Evercore and Ropes &amp; Gray. During each meeting, management provided updates on discussions with, and diligence of, counterparties regarding each strategic alternative being evaluated by the Rallybio Board. Management also provided
an overview of its work with Party A to prepare a presentation for investors about the potential opportunity, which could be used to market the potential concurrent offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July 28, 2025, Rallybio entered into an engagement letter with Evercore related to its services and advice in connection with potential transactions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August 5, 2025, the placement agents for a potential offering that would occur concurrently with a reverse merger transaction with Party A held an organizational
call with Rallybio management and legal counsel to discuss the terms, process and documentation for such an offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August 6, the Rallybio Board held a
meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management summarized the strategic alternatives being considered by Rallybio and recommended that Rallybio cease discussions with counterparties about a potential
sale of RLYB116, because the current proposals did </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
not adequately value the asset and the value should increase after additional clinical data became available later in 2025. Representatives of Evercore then summarized the terms of the proposed
reverse merger transactions being evaluated by the Rallybio Board, including the counterparties&#8217; existing programs, the anticipated ownership of Rallybio&#8217;s stockholders in the combined companies and future financing requirements.
Representatives of management and Evercore responded to questions from the Rallybio Board and, after discussion, the Rallybio Board determined not to pursue a sale of RLYB116 at that time, to continue discussions with Party A and to proceed with
marketing for a financing transaction that would close concurrently with that transaction. The Rallybio Board also directed management to continue discussions with two other parties that had proposed a reverse merger in case the transaction with
Party A did not proceed. The Rallybio Board considered these proposed reverse mergers as less favorable options for Rallybio stockholders than a transaction with Party A for, among other reasons, the proposed valuation of the counterparties and the
prospects of the counterparties&#8217; existing programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August 11, 2025, representatives of Rallybio and Party A and each of their legal advisors held a
meeting to discuss the structure of a potential reverse merger transaction, the potential equity consideration to be issued by Rallybio, the possibility of Rallybio&#8217;s stockholders receiving contingent value rights that would entitle them to a
pro rata share of consideration received upon the divestiture of Rallybio&#8217;s legacy assets and other related issues. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August 20, 2025, the Rallybio Board
held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management explained that Party A had recently indicated it would commit meaningfully less to the proposed financing than management had previously expected, so
completing a financing of $60 million would be challenging. As a result, management recommended proposing modified terms to Party A pursuant to which the parties would seek to raise only $40 million through a concurrent financing and
Rallybio&#8217;s stockholders would not receive a contingent value right so any proceeds from asset dispositions or paid to Rallybio under the ENPP1 Purchase Agreement would be retained by the combined company to fund its operations, which would
result in Rallybio&#8217;s stockholders retaining a larger percentage of the combined business&#8217;s equity. Representatives of Evercore reviewed potential execution risk for the financing given Party A&#8217;s position. The Rallybio Board
discussed their views of management&#8217;s proposal. Following discussion, the Rallybio Board asked a director to contact Party A to discuss the reasons for Party A&#8217;s reduced commitment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August 29, 2025, the Rallybio Board held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management summarized the status of
discussions with Party A, including Party A&#8217;s continued unwillingness to increase the size of its commitment in the proposed financing, which Party A had confirmed to a Rallybio director. Management then outlined modified terms it recommended
proposing to Party A, which would value Rallybio at $75 million, inclusive of its cash and cash equivalents, and which would not include any contingent value right for Rallybio&#8217;s stockholders. As a result, Rallybio&#8217;s stockholders would
own approximately 45.5% of the combined company after closing the merger and concurrent financing. Management also provided an overview of other alternatives, including proposed reverse mergers, continuing to operate as a standalone company and
liquidating Rallybio to return cash to stockholders. The Rallybio Board discussed the alternatives presented by management and, after discussion, directed management to deliver its recommended proposal to Party A, which management did following the
meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September 10, 2025, Party A delivered an updated proposal to Rallybio that ascribed a value of $62 million to Rallybio, assuming that Rallybio had
$53.6 million in cash and cash equivalents at the closing and a $40 million concurrent financing. Rallybio&#8217;s stockholders would receive a contingent value right that would entitle them to a pro rata portion of any consideration received upon a
divestiture of RLYB116. Based on these terms, following the transaction and related financing, Rallybio&#8217;s stockholders would hold 37.8% of the equity of the combined company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September 15, 2025, Party B, a privately held, clinical stage biotech company that had a lead investor that was also invested in Rallybio and a director who also
served on the Rallybio Board, submitted a written proposal to Rallybio. Party B had not received any non-public information prior to submitting its proposal, but had entered into a mutual confidentiality agreement with Rallybio that did not include
a standstill in anticipation of discussion potential strategic alternatives. Party B&#8217;s proposal ascribed a value of $50 million to Rallybio, which assumed that Rallybio had $40 million in cash and cash equivalents at the closing. The proposal
also contemplated that Rallybio&#8217;s valuation would be increased dollar-for-dollar for any cash proceeds it received from a sale of the RLYB116 assets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
prior to the closing, which proceeds Party B estimated could be up to $25 million. It also proposed that the parties would raise $45 million in connection with the transaction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September 24, 2025, the Rallybio Board held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management provided an update on
discussions with potential counterparties to potential strategic transactions, noting that Rallybio had recently received written proposals for a reverse merger from Party B, noting the related party nature of the proposed transaction, and a reverse
merger from Party C, a privately held biotech company that had submitted a new drug application to the FDA for its lead product candidate, as well as a verbal indication of interest for a reverse merger from a newly formed consolidation vehicle.
Management noted that Party C&#8217;s proposal ascribed the same value to Rallybio as Party B&#8217;s current proposal. Representatives from Evercore summarized the non-binding proposals currently in effect from Party A, Party B and Party C among
others and responded to questions about the financing in connection with each of the proposed transactions. The representatives of Evercore also responded to questions from the Rallybio Board about certain of the opportunities under consideration
and the timing of discussions with potential PIPE investors. Following discussion, the Rallybio Board determined to continue engaging with Party A and to seek investors to participate in the concurrent financing, and to initiate discussions with
Party B and Party C based on their recent proposals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October 7, 2025, the Rallybio Board held a meeting attended by representatives of management, Evercore and
Ropes &amp; Gray. Management provided a brief update on discussions with Party A and other parties that had proposed a reverse merger, including Party B and Party C. They also summarized recent interactions about potential partnering opportunities
for RLYB116, although most counterparties indicated they would like to see data from the ongoing trial before engaging further. A representative of Evercore then summarized the reverse merger proposals currently available for Rallybio, including
those with Party A, Party B and Party C, as well as each counterparty&#8217;s product pipelines, commercial opportunities and competitive landscape. The Rallybio Board discussed the scientific and commercial prospects of each potential
counterparty&#8217;s product candidates and valuation each counterparty ascribed to itself in their proposals. Following discussion, the Rallybio Board determined to continue discussions about potential reverse mergers, but agreed that it would
discontinue discussions with Party A if a co-lead investor in the concurrent financing was not identified promptly. The Rallybio director who served on the board of Party B then reminded the Rallybio Board of his role at Party B and that the
investment fund with which he worked had a significant investment in Party B, and stated that he would recuse himself from future discussions among the Rallybio Board about strategic alternatives, so long as a transaction with Party B remained an
option. The director did not attend any portion of a Rallybio Board meeting during which strategic alternatives were discussed until the Rallybio Board&#8217;s meeting on February 12, 2026, other than as noted below during the Rallybio Board&#8217;s
meeting on December 5, 2025. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October 24, 2025, the Rallybio Board held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray.
Management summarized the status of Rallybio&#8217;s work with Party A and Party B, including discussions with institutional investors about a financing related to the transaction with Party A and diligence regarding the science and commercial
opportunity for Party B&#8217;s lead product candidate. Management also summarized the terms proposed by Party B for a potential transaction on September 15, 2025. The Rallybio Board and management discussed the commercial opportunity for Party
B&#8217;s lead product, anticipated future financing needs and potential risks of Party B achieving its projections, including adverse data, safety issues and competition, as well as the commercial opportunity for Party C. The Rallybio Board and
management also discussed RLYB116 and the potential impact on Rallybio&#8217;s valuation of positive data from its ongoing trial. Following discussion, the Rallybio Board determined to cease discussions with Party A based on recent discussions with
potential investors and lack of progress towards a transaction, to deliver a revised term sheet to Party B and continue discussions about the business with representatives of Party B and to, in parallel, continue discussions with Party C, although
the Rallybio Board expressed its view that, due to Party C&#8217;s commercial prospects and proposed valuation, the proposed reverse merger with Party C was less advantageous to Rallybio stockholders than the proposed reverse merger with Party B.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October 27, 2025, the Rallybio Board held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management and certain directors
summarized recent discussions they had with representatives of Party B, noting that Party B remained interested in a potential reverse merger transaction with Rallybio, but was also considering other alternatives. Management proposed terms for a
counterproposal to Party B, and, following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
discussion, the Rallybio Board directed management to deliver the counterproposal as soon as possible. Management and the directors discussed how to accelerate the process with Party B and ensure
that Rallybio&#8217;s stockholders received the most value possible in the transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October 28, 2025, Rallybio delivered a term sheet to Party B that
ascribed a value to Party B of $175 million and Rallybio of $59 million, which reflected the value of Rallybio&#8217;s cash and cash equivalents but not RLYB116, and which would result in Rallybio&#8217;s stockholders owning 25.2% of the combined
company after the closing of the merger, but without accounting for a concurrent $45 million financing. The term sheet also provided that Rallybio&#8217;s stockholders would receive contingent value rights that would entitle them to a pro rata
portion of proceeds received upon the divestiture of Rallybio&#8217;s legacy assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 7, 2025, the Rallybio Board held a meeting attended by
representatives of management, Evercore and Ropes &amp; Gray. Management provided an update on the status of discussions with Party B, including Party B&#8217;s indication that it would like to continue to develop RLYB116 post-closing, rather than
divest the asset, and that a portion of the anticipated financing would be required to fund Party B&#8217;s operations prior to closing. The Rallybio Board discussed the strategy for negotiating the exchange ratio and RLYB116&#8217;s valuation. The
Rallybio Board directed management to continue discussions with Party B and also discussed whether to form a special committee to help manage negotiations with Party B and potential other alternative counterparties. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 9, 2025, the Rallybio Board executed a unanimous written consent forming a special transaction committee (the &#8220;Transaction Committee&#8221;) comprised
of Ms. Nash, Dr. Liu and Mr. Hunt to review, evaluate and negotiate possible strategic transactions. Each of the members was deemed independent under Nasdaq&#8217;s listing rules and did not have any conflicts with any counterparty Rallybio was
evaluating or expected to evaluate in connection with the strategic process. The Transaction Committee was delegated authority to propose and negotiate the price, structure, terms and conditions of possible transactions, but the Rallybio Board
retained authority to approve any proposed transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 11, 2025, the Transaction Committee held a meeting attended by representatives of management
and Ropes &amp; Gray. Management summarized recent discussions with the Chief Executive Officer of Party B, including about the value to be ascribed to Rallybio and RLYB116, which Party B would reflect in a written term sheet, and also noted that
Rallybio&#8217;s diligence of Party B was substantially complete, other than a review of financial information that had not yet been provided. Management and the Transaction Committee discussed the strategy and timing to finalize terms with Party B
and the Transaction Committee directed the representative of Ropes &amp; Gray to speak with Party B&#8217;s legal counsel about the structure of the potential transaction and related issues. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 14, 2025, Party B delivered a written counterproposal to Rallybio that ascribed a value of $200 million to Party B and $72.5 million to Rallybio, which
reflected the value of Rallybio&#8217;s cash and cash equivalents and valued RLYB116 at $12.5 million. Based on these terms, Rallybio&#8217;s stockholders would own 26.6% of the combined company after the closing of the merger and a concurrent $45
million financing. The term sheet noted that the proposed value of RLYB116 remained subject to diligence and $5 million of the proposed valuation was contingent on Rallybio having at least $37.5 million of net cash at the closing. It also proposed a
45-day exclusivity period during which the parties would be expected to negotiate a definitive documentation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 17, 2025, representatives of Ropes &amp;
Gray and Party B&#8217;s counsel held a call to discuss the structure of the proposed transaction between Rallybio and Party B, whether Rallybio&#8217;s stockholders could receive contingent value rights in connection with the transaction, and the
potential timeline for the transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 17, 2025, the Transaction Committee held a meeting attended by representatives of management, Evercore and
Ropes &amp; Gray. A representative of Ropes &amp; Gray described his conversation with Party B&#8217;s counsel earlier in the day and management summarized the key terms of the term sheet delivered by Party B, including the proposed transaction
structure, value ascribed to the parties, the definition of net cash, Party B&#8217;s financials and governance matters. Following discussion, the Transaction Committee directed management to return an updated term sheet to Party B that, among other
things, provided for a simultaneous sign-and-close structure and to increase the value ascribed to Rallybio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 18, 2025, Rallybio returned a draft term sheet to Party B as requested by the Transaction Committee,
which contemplated a simultaneous sign-and-close structure, ascribed a value of $77.5 million to Rallybio, with RLYB116 being valued at $5 million more than in the most recent Party B proposal, and certain modifications to the definition of net cash
used for determining the exchange ratio. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 21, 2025, Party B returned a further revised draft term sheet, which proposed a $75 million valuation for
Rallybio and certain modifications to the net cash definition, as well as other adjustments to reflect the simultaneous sign-and-close structure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 22,
2025, the Transaction Committee held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management summarized recent interactions with Party B and the current term sheet. The Transaction Committee and management
discussed certain financial information of Party B that Rallybio would need to review and certain other diligence matters. Representatives of Evercore and Ropes &amp; Gray discussed considerations about the proposed sign-and-close structure,
including timing, regulatory and litigation risks, as well as potential financing implications. The Transaction Committee directed management to continue negotiating the term sheet and to complete diligence on Party B as soon as possible. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November 25, 2025, the Rallybio Board held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management provided an update on the
status of discussions with Party B and terms reflected in Party B&#8217;s most recent proposal, as well as an overview of Party B&#8217;s lead asset, and Party B&#8217;s future financing requirements. Management then provided an update on the
positive data received to date in Rallybio&#8217;s RLYB116 confirmatory trial, and discussed the current development plan for RLYB116, Rallybio&#8217;s cash runway, potential partnering opportunities for RLYB116 and potential market reaction to the
data. Management responded to questions from the Rallybio Board and directors discussed RLYB116 and the opportunity with Party B. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December 3, 2025, the Rallybio
Board held a meeting attended by representatives of Evercore and Ropes &amp; Gray. Representatives of Evercore summarized certain features of the proposed transaction with Party B, including, that the combined company would have a stockholder that
owned more than 50% of the combined company&#8217;s equity on a fully-diluted basis, that the contemplated concurrent financing would not be marketed to new investors and that the combined company would likely need to raise additional funds by
mid-2027 based on Party B&#8217;s management&#8217;s current plan. The members of the Transaction Committee then provided an update on discussions with Party B and their perspectives about whether a transaction with Party B remained in the best
interests of stockholders at that time given its potential risks and benefits. The members of the Transaction Committee responded to questions and the directors discussed their perspectives on the options available to Rallybio noting the prospects
of Rallybio&#8217;s and Party B&#8217;s respective assets, the competitive landscape for the indications targeted by each company, financing challenges and the cash runway of Rallybio on a standalone basis and of the combined company. Following
discussion, it was the consensus of the Rallybio Board that it was a viable option for Rallybio to remain independent, but that the Rallybio Board also wanted to meet with management to assess the best path for stockholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December 5, 2025, the Rallybio Board held a meeting attended by representatives of management and Ropes &amp; Gray. At the request of the Rallybio Board, management
outlined its strategy for developing RLYB116 and managing the business if Rallybio remained independent, including headcount requirements and potential partnering opportunities. Management responded to questions from the Rallybio Board and then
departed the meeting. The Rallybio Board then invited the Rallybio director who also serves as a director of Party B to join the meeting and share his views regarding Party B and the opportunities presented by a combined company. He also responded
to questions from the Rallybio Board and then departed the meeting. Following the Party B director&#8217;s departure, the Rallybio Board discussed the two alternatives, including management&#8217;s plan for RLYB116, the risks presented by remaining
independent and combining with Party B and the potential benefits of each option. Following discussion, the Rallybio Board determined to request that Party B reduce its valuation to $150 million, which the Rallybio Board believes is more reflective
of its actual value, but if Party B declines Rallybio will proceed as a standalone company. Following the meeting, a director communicated the proposed change to a representative of Party B. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December 8, 2025, Party B delivered an updated term sheet that contemplated a $135 million valuation for Party B plus a new $15 million post-closing equity pool that
would be used to compensate Party B employees. It also contemplated that Party B&#8217;s valuation would be reduced if it had net liabilities above a certain threshold at closing and proposed a termination fee of $2.5 million payable by Rallybio if
negotiations were abandoned by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Rallybio prior to closing or if Rallybio sought to amend any terms in the term sheet. Following receipt, the Transaction Committee evaluated the term sheet and, after discussion, determined that
it would recommend that the Rallybio Board agree to the term sheet, so long as Party B agreed to remove the termination fee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December 10, 2025, the Rallybio
Board held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Members of the Transaction Committee presented the draft term sheet from Party B noting that Party B had agreed to lower its valuation to $150 million, as
previously requested by the Rallybio Board, which amount included $15 million of new equity awards that would be granted to Party B&#8217;s executives, and had agreed to remove the proposed termination fee from the term sheet. The Transaction
Committee noted that it recommended that the Rallybio Board approve the term sheet. A representative of Ropes &amp; Gray then provided a reminder about the Rallybio Board&#8217;s fiduciary duties. Representatives of management and Evercore responded
to questions from the Rallybio Board and, after extensive discussion of the alternatives, the Rallybio Board determined to pursue a transaction with Party B and directed management to finalize the term sheet. The term sheet with Party B was executed
later that day. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Between December 10, 2025 and early January 2026, Rallybio, Party B and their legal advisors engaged in negotiations regarding, and exchanged
drafts of, the proposed merger agreement and disclosure schedules, and other ancillary documents. The parties also discussed the terms of documents and messaging related to the anticipated concurrent financing and regulatory and exchange listing
matters related to the transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January 2, 2026, Rallybio filed a definitive proxy statement related to a special meeting of Rallybio&#8217;s stockholders
to consider a reverse split of the Rallybio Common Stock in order to regain compliance with the minimum bid requirements for continued listing on the Nasdaq Capital Market. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Later on January 2, 2026, the Transaction Committee held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management provided an
update about negotiations with Party B, including the status of documentation. Representatives of management then reviewed the full data received from Rallybio&#8217;s recently completed confirmatory study of RLYB116, noting that the study
established that RLYB116 provides rapid, complete and sustained inhibition of terminal complement, and that its safety profile was significantly improved from earlier material and showed that RLYB116 has the potential to support a convenient dosing
regimen. They suggested that the value of RLYB116 had likely increased due to the quality of the data and that it may be worth evaluating whether the terms of the Party B deal still appropriately reflect Rallybio&#8217;s value. Representatives of
Evercore then noted that they had received inbound interest from investors awaiting the data and discussed the timing and process for conducting a financing for Rallybio (the &#8220;RLYB116 PIPE&#8221;) if Party B waived the exclusivity
restrictions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January 6, 2026, the Rallybio Board and Transaction Committee each held a meeting attended by representatives of management, Evercore and Ropes
&amp; Gray. Management provided an update on discussions with Party B, presented the RLYB116 data to the Rallybio Board and responded to questions about each. Representatives of Evercore then reviewed a potential RLYB116 PIPE and the potential
timeline and process for conducting the RLYB116 PIPE. The Rallybio Board discussed the RLYB116 PIPE and determined that it would like to proceed, and directed the Transaction Committee and management to seek a waiver of Rallybio&#8217;s exclusivity
obligations to Party B and to offer to present the RLYB116 data to Party B. Later in the day, the Transaction Committee further discussed the size and potential process to pursue the RLYB116 PIPE and discussed the strategy for addressing with Party
B. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January 8, 2026, certain members of the Transaction Committee spoke with representatives of Party B to offer Party B the opportunity to receive the RLYB116
data and to request a waiver of Rallybio&#8217;s exclusivity obligations to facilitate the RLYB116 PIPE process. Dr. Uden later presented the data to representatives of Party B, although Party B did not agree to waive the exclusivity obligations.
Finally, the Transaction Committee held a meeting attended by representatives of management and Ropes &amp; Gray. The members of the Transaction Committee discussed Party B&#8217;s reaction to the waiver request and strategy for future
correspondence with Party B, as well as potential legal considerations, and correspondence with the Rallybio Board about recent discussions with Party B and anticipated developments on the transaction with Party B. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Between January 8, 2026 and January 13, 2026, members of the Transaction Committee and management spoke with
representatives of Party B and, on January 13, 2026, Party B agreed to release Rallybio from its exclusivity obligations under the term sheet in order to pursue the RLYB116 PIPE. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following Party B&#8217;s release, Rallybio and its advisors began preparing to conduct a confidential marketing process in connection with the RLYB116 PIPE and, on
January 22, 2026, engaged placement agents to use best efforts to assist Rallybio with the offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January 26, 2026, Rallybio held a special meeting of
stockholders at which the stockholders approved an amendment to the Rallybio&#8217;s amended and restated certificate of incorporation to effect a reverse split at a ratio to be selected by the Rallybio Board. Later on January 26, 2026, the Rallybio
Board approved a reverse split at a ratio of 1-for-8 shares of Rallybio Common Stock and Rallybio then filed a certificate of&nbsp;amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of
Delaware to effect the reverse stock split effective at 12:01 a.m., Eastern Time, on February 6, 2026.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January 28, 2026, the Transaction Committee held a meeting
attended by representatives of management, Evercore and Ropes &amp; Gray. Representatives of Evercore provided an update on the marketing process for the RLYB116 PIPE, noting they had reached out to 15 healthcare-focused investors, 14 of which
elected to discuss the potential offering. The RLYB116 data had been well received by investors, but none had yet committed to participate in the RLYB116 PIPE. The Transaction Committee asked questions and discussed timing for the offering and
agreed to wait until after it had more feedback from investors before updating the full Rallybio Board. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January 30, 2026, the Transaction Committee held a brief
meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management provided an update on the RLYB116 PIPE, noting that most investors had passed on the opportunity so it was unlikely an offering could proceed, but that
there were a couple investors still reviewing information. The Transaction Committee asked questions about investors&#8217; responses and agreed to inform the Rallybio Board of the outcome of the marketing effort and to discuss with the Rallybio
Board the messaging about reengaging with Party B on a reverse merger. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 2, 2026, the Rallybio Board held a meeting attended by representatives of
management, Evercore and Ropes &amp; Gray. Management began with an update on the marketing effort for the RLYB116 PIPE, noting that of the 16 investors contacted about participating, only two were continuing to evaluate the opportunity, so it was
unlikely Rallybio could complete a financing at that time. The Rallybio Board then discussed reengaging with Party B and potentially reaching out to other third parties now that exclusivity with Party B had lapsed. Robert Hopfner, a director of
Rallybio, mentioned that a representative of Wedbush Securities Inc (&#8220;Wedbush&#8221;), a financial advisor to Candid, had contacted him to inquire whether Rallybio might consider a reverse merger with Candid and Jonathan Lieber,
Rallybio&#8217;s Chief Financial Officer, noted that a representative of Wedbush had also put him in touch with Candid to potentially discuss a reverse merger. Following discussion, the Rallybio Board requested a director to contact a representative
of Party B to relay that Rallybio was unlikely to pursue the RLYB116 PIPE and was committed to pursuing a transaction with Party B. It also directed management to engage with Candid. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the meeting on February 2, 2026, a member of the Rallybio Board called a representative of Party B to explain that Rallybio was unlikely to proceed with the
RLYB116 PIPE and, therefore, would be willing to re-open discussions with Party B. The representative of Party B noted that Party B had entered into exclusive negotiations with a third-party and would not be able to discuss a transaction with
Rallybio at that time. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also on February 2, 2026, Rallybio entered into a mutual confidentiality agreement with Candid that did not include a standstill to
facilitate discussions about a potential reverse merger transaction. Later that day, Candid delivered a draft term sheet that ascribed a value of $8 million to Rallybio, which assumed that Rallybio would distribute all excess cash to its
stockholders prior to the closing of a transaction and divest its legacy assets, and a valuation of $750 million. Based on these terms, Rallybio&#8217;s stockholders would own less than 1% of the equity of the combined company following closing of
the proposed merger and a contemplated concurrent $200 million financing. The term sheet also provided that the equity to be issued to Candid stockholders would be registered on a Form S-4 prior to closing; would require Rallybio&#8217;s
stockholders to vote on the transaction unless the merger agreement was terminated prior to the stockholder meeting; permitted Candid to consider and terminate the merger agreement to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
accept a superior proposal subject to certain conditions; and provided that the parties would agree to negotiate exclusively (in the case of Candid, with respect to a reverse merger transaction)
for 30 days. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 3 and 4, 2026, representatives of Evercore held calls with Party C&#8217;s financial advisor to inquire about Party C&#8217;s interest in
re-engaging in reverse merger discussions with Rallybio and discussed the process for submitting a new proposal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 4, 2026, the Rallybio Board held a
meeting attended by representatives of management, Evercore and Ropes &amp; Gray. The Rallybio Board discussed Party B&#8217;s response, noting that it was uncertain if Party B would consummate an alternative transaction during its exclusivity
period, so Rallybio should not wait to pursue alternatives. Management then summarized recent interactions with Candid, noting that the parties had entered into a confidentiality agreement and Candid had delivered a non-binding term sheet, which
management summarized. The Rallybio Board discussed Candid and its proposal, including terms for a response to Candid&#8217;s initial proposal and directed management to deliver a counterproposal to Candid. The Rallybio Board also discussed
potential renewed interest in a reverse merger from Party C, which was simultaneously pursuing reverse merger transactions and an initial public offering. The Rallybio Board, management and the advisors discussed how to proceed with Candid, Party C
and other alternative options, including requesting Party C to deliver a refreshed written proposal. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 5, 2026, representatives of Evercore held
separate calls with Candid&#8217;s Chief Financial Officer and Wedbush to discuss Candid&#8217;s expectations and the process to pursue a reverse merger between Rallybio and Candid. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 9, 2026, Rallybio returned a draft term sheet to Candid, which accepted the $750 million valuation for Candid proposed in Candid&#8217;s February 2, 2026
draft term sheet and provided for, among other things, a $47.5&nbsp;million valuation for Rallybio, which assumed that Rallybio would have $37.5 million of net cash at the closing, that Rallybio&#8217;s stockholders would own approximately 4.76% of
the combined company&#8217;s equity following the closing of the merger and a contemplated concurrent $200 million financing, and that Rallybio&#8217;s stockholders would receive contingent value rights that would entitle them to receive a pro rata
portion of any proceeds from a divestiture of Rallybio&#8217;s legacy assets and any proceeds received from Recursion as a result of Rallybio&#8217;s prior sale of its interests in REV-I. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 9, 2026, Party C delivered a revised non-binding proposal for a reverse merger transaction with Rallybio that ascribed a $46 million valuation to Rallybio,
which assumed that Rallybio would have $36 million of net cash at the closing and that Rallybio&#8217;s stockholders would own approximately 7.72% of the combined company&#8217;s equity following the closing of the merger and a contemplated $100
million concurrent financing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 10, 2026, a representative of Evercore held a call with Candid&#8217;s Chief Financial Officer to discuss the terms of
the proposed reverse merger, including the treatment of Rallybio&#8217;s cash and the pro forma ownership of Rallybio&#8217;s stockholders in the combined company. Additionally, Candid returned an updated draft term sheet to Rallybio with updates
made to Rallybio&#8217;s net cash definition regarding expenses associated with the divestiture or disposition of Rallybio&#8217;s legacy assets. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Between
February&nbsp;10, 2026 and February 12, 2026, three Rallybio directors, Dr. Hopfner, Hui Liu and Martin Mackay, held separate calls with Dr.&nbsp;Song to discuss Candid&#8217;s management team, product pipeline, anticipated corporate milestones and
financing plans. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 12, 2026, the Rallybio Board held a meeting attended by representatives of management, Evercore and Ropes &amp; Gray. Management
confirmed that the remaining investors who had been evaluating the RLYB116 PIPE had withdrawn from the process, so Rallybio would no longer pursue a separate financing. They explained that Rallybio now had a few merger proposals to consider,
including from Candid, Party B, which may not continue to engage after its exclusivity period, and Party C. Management also described the development pipeline for each company, noting that the FDA had recently granted marketing authorization for
Party C&#8217;s lead product. Representatives of Evercore then summarized the terms of the three proposals, highlighting that the value ascribed to Rallybio&#8217;s cash and exchange listing was substantially similar in each proposal and noting the
anticipated ownership of Rallybio&#8217;s stockholders in the combined companies, the potential financing requirements proposed or required by each proposal based on assumptions provided by management of such potential counterparty and potential
risks </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
associated with each transaction. Party B had proposed a simultaneous sign-and-close structure, while the proposals from Candid and Party C required Rallybio to register the shares to be issued
and to have a meeting of stockholders to approve the issuance of the shares between signing and closing. Each of the directors then provided their perspectives about the alternatives, focusing on each company&#8217;s scientific and commercial
potential, the future financing obligations of each, anticipated timing to sign and closing, and potential post-closing trading dynamics. Following discussion, the Rallybio Board concluded that the Candid proposal was the best available alternative
for Rallybio&#8217;s stockholders, due to the prospects of its product pipeline, strength of its management team, ability to complete the proposed concurrent financing and anticipated cash runway for the combined business, and directed management to
deliver a non-binding term sheet to Candid for execution and proceed to legal and business diligence and negotiation of definitive documents as soon as possible. The Rallybio Board acknowledged that due to the exclusivity provisions of the term
sheet with Candid, Rallybio would no longer be able to pursue a potential transaction with either of Party B or Party C. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the meeting, on February 12,
2026, a representative of Evercore spoke with each of Candid&#8217;s Chief Financial Officer and a representative of Wedbush separately to convey that Rallybio intended to announce the results of its recently completed RLYB116 Phase 1 trial on
February 17, 2026, and that Rallybio intended to send an updated term sheet to Candid later that same day. Subsequently on February 12, Rallybio returned a further revised term sheet draft to Candid that provided that, among other things,
Rallybio&#8217;s stockholders would receive a contingent value right that would entitle them to 100% of the net proceeds received by the combined company upon any divestiture of Rallybio&#8217;s legacy assets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 13, 2026, Rallybio and Candid signed the form of non-binding term sheet delivered by Rallybio on February 12. The parties promptly commenced legal and
business diligence and representatives of Ropes &amp; Gray and Cooley LLP, counsel to Candid (&#8220;Cooley&#8221;), discussed process and documentation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Between
February 14 and February 27, 2026, Rallybio, Candid and their legal and financial advisors engaged in extensive negotiations regarding, and exchanged multiple drafts of, the proposed merger agreement and disclosure schedules for each of Rallybio and
Candid, the contingent value rights agreement, and forms of support agreements and a lock-up agreement. The parties also negotiated the terms of documents related to the Concurrent Financing with the placement agents for such financing and their
legal counsel. The negotiation of the merger agreement focused on, among other things, the following key terms: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the calculation of Rallybio&#8217;s net cash, including the treatment of certain liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the non-solicitation provisions, and specified exceptions, applicable to each party, including a proposal to permit Candid
to solicit alternative acquisition proposals from third parties for 30 days following Candid&#8217;s receipt of any superior offer (and associated tolling of Candid&#8217;s obligation to deliver its stockholder written consent within seven business
days of the effectiveness of the Form S-4 to be filed in connection with the proposed transactions), as well as a carve-out that would have permitted Candid to pursue certain strategic transactions without restriction. Following negotiation, Candid
agreed to a more limited &#8220;fiduciary out&#8221; exception that would permit Candid to respond to unsolicited bona fide acquisition proposals that constituted, or were reasonably likely to lead to, a superior offer, which exception would not
toll Candid&#8217;s obligation to deliver the written consent executed by each Candid required signatory within seven business days of the date of the effectiveness of the Form S-4; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the triggers for, and amounts payable upon, termination of the agreement. After extensive negotiation, the parties agreed
to a termination fee of $50 million payable by Candid in certain termination scenarios involving Candid entering into an alternative acquisition, with a reduced fee of $10 million payable by Candid for a termination under certain circumstances
following the expiration of the end date, and a termination fee of $1.425 payable by Rallybio in specified circumstances; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain of the interim operating covenants, the closing conditions, and the representations and warranties made by each
party. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the contingent value rights agreement, the parties negotiated, among other things, the following key terms: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inclusion of and threshold for any level of efforts required to divest Rallybio&#8217;s assets, </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the duration after the closing date of the Merger that such efforts obligations would last, which the parties finally
agreed to be one year; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the end date of the combined company&#8217;s obligations to make CVR payments to the CVR holders, which the parties agreed
to be December 31, 2030. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 17, 2026, Rallybio announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic
clinical trial evaluating RLYB116. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 18, 2026, the placement agents for the Concurrent Financing began marketing the offering to potential investors on a
confidential basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 21, 2026, Mr. Lieber discussed the potential transaction with Citizens, any potential conflicts that Citizens may have, and asked
that, if requested by the Rallybio Board, Citizens provide the Rallybio Board an opinion about the fairness, from a financial point of view, of the Exchange Ratio. Representatives of Citizens agreed to complete the work necessary to determine if it
would be able to deliver its opinion and provided diligence information requested by Citizens to complete its work. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 24, 2026, Nasdaq notified Rallybio
that it had regained compliance with the minimum bid requirements for continued listing on the Nasdaq Capital Market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February 27, 2026, Rallybio, Candid and
their legal advisors exchanged advanced drafts of the proposed merger agreement prior to the Rallybio Board&#8217;s consideration and approval of the Contemplated Transactions. Among other final key terms negotiated between the parties were the
circumstances in which Candid could solicit alternative proposals from third parties and the amount of the termination fee payable by Candid in connection with the termination of the merger agreement under certain circumstances, as outlined in
further detail above. Rallybio also entered into an engagement letter with Citizens in advance of the Rallybio Board&#8217;s meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also on February 27, 2026,
Evercore delivered a material relationships disclosure letter to Rallybio. Later on February&nbsp;27, 2026, the Rallybio Board met with members of Rallybio&#8217;s management and representatives of Citizens, Evercore and Ropes &amp; Gray. At the
meeting, a representative of Ropes &amp; Gray reviewed the Rallybio directors&#8217; fiduciary duties and the terms and conditions of the transaction documents, including the structure, closing conditions, antitrust covenant, interim operating
covenants, representations and warranties, non-solicitation covenants, and termination rights and fees. A director noted that the investment fund for which he works intended to invest in the Concurrent Financing and the other members of the Rallybio
Board determined that such investment would not impair the director&#8217;s independent judgment, so he should not be required to recuse himself. Citizens, after confirming to the Rallybio Board that it had no conflicts related to the proposed
transaction, then reviewed its financial analysis of the Exchange Ratio and delivered to the Rallybio Board its oral opinion, confirmed by delivery of a written opinion dated March 1, 2026, to the effect that, as of such date and based upon and
subject to the assumptions made, procedures followed, matters considered and limitations on the review undertaken by Citizens in preparing its opinion, the Exchange Ratio to be paid by Rallybio is fair, from a financial point of view, to Rallybio,
as more fully described below in the section titled <I>&#8220;&#8212;Opinion of Citizens JMP Securities, LLC (Rallybio&#8217;s Financial Advisor)</I>.&#8221; Following discussions about the proposed transaction with Candid, including the potential
merits and considerations for and against proceeding with it described further in the section titled <I>&#8220;&#8212;Rallybio&#8217;s Reasons for the Merger</I>,&#8221; the Rallybio Board unanimously (i) determined that the terms of the Merger
Agreement, the Merger and the other Contemplated Transactions are fair to, advisable and in the best interests of Rallybio and its stockholders, (ii) approved and declared advisable the Merger Agreement and the Contemplated Transactions, including
the Merger and the issuance of shares of Rallybio Common Stock to the stockholders of Candid pursuant to the terms of the Merger Agreement, and (iii) determined to recommend, upon the terms and subject to the conditions set forth in the Merger
Agreement, that Rallybio&#8217;s stockholders vote to approve the Rallybio Stockholder Matters. The Rallybio Board also approved or ratified certain other actions to be taken by Rallybio in connection with the Contemplated Transactions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March 1, 2026, the parties executed the Merger Agreement, the support agreements, the Lock-Up Agreements and the Subscription Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On the morning of March 2, 2026, Rallybio and Candid issued a joint press release announcing the Contemplated
Transactions. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On April&nbsp;17, 2026, members of the Candid management team notified members of the Rallybio management team that Candid received an
unsolicited proposal to acquire Candid. On April&nbsp;19, 2026, Candid notified Rallybio that the Candid Board determined that such proposal constitutes, or is reasonably likely to result in, a Superior Offer (as defined in the Merger Agreement). As
of April&nbsp;24, 2026, Candid has not notified Rallybio that the Candid Board has made or intends to make a Candid Board Adverse Recommendation Change, and the Merger Agreement remains in full force and effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rallybio&#8217;s Reasons for the Merger </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the course of its evaluation of
the Merger, the Merger Agreement and the Contemplated Transactions, the Rallybio Board held numerous meetings, consulted with Rallybio management, its legal counsel and its financial advisors and reviewed and assessed a significant amount of
information and, in reaching its decision to approve the Merger, the Merger Agreement and the Contemplated Transactions, the Rallybio Board considered the following factors, among others and not necessarily presented in any order of relative
importance: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio&#8217;s business, financial performance (both past and prospective) and its financial condition, results of
operations (both past and prospective), market capitalization and the need for future capital, business and strategic objectives, as well as the risks of accomplishing those objectives, including if Rallybio were to remain an independent company;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible alternatives to the Merger available to Rallybio, the range of possible benefits and risks to the Rallybio
stockholders of those alternatives and the timing and the likelihood of accomplishing the goal of any of such alternatives, and the Rallybio Board&#8217;s assessment that the Merger presented a superior opportunity for Rallybio&#8217;s stockholders
to any such alternatives; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio Board&#8217;s assessment of potential candidates for a strategic transaction, and in particular, the Rallybio
Board&#8217;s view that Candid was the most attractive and promising candidate and the Rallybio Board&#8217;s belief that the Merger would create more value for Rallybio&#8217;s stockholders than any of the other proposals that the Rallybio Board
had received or Rallybio could create as a standalone company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the process undertaken by the Rallybio Board in pursuit of a strategic transaction, including the proposed Merger, in each
case considering the current market dynamics; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic
transaction with Rallybio based on the business, scientific, regulatory, intellectual property, financial, accounting and legal due diligence conducted by the Rallybio management and Rallybio&#8217;s advisors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio Board&#8217;s belief, based in part on the clinical and scientific diligence process conducted by
Rallybio&#8217;s management and reviewed with the Rallybio Board, that Candid&#8217;s product candidates present a market opportunity with the potential to create meaningful value for the stockholders of the combined company and an opportunity for
Rallybio&#8217;s stockholders to participate in the future potential growth of the combined company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential for Rallybio&#8217;s equityholders to receive certain cash payments following the Closing pursuant to the
Rallybio CVR Agreement, which the Rallybio Board believed preserves for Rallybio&#8217;s existing equityholders the potential value from a sale or other disposition of Legacy Assets (as defined below) and obligates the combined company to use
commercially reasonable efforts following the Closing to pursue a disposition of such assets if Rallybio has not completed such a disposition prior to the Closing; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio&#8217;s current market capitalization and the potential dilution from any financings required to support its
plans and objectives were it to remain an independent company, as well as well as the uncertainty regarding the availability of such financing on terms acceptable to Rallybio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">financial market conditions at the time of the signing of the Merger Agreement, including market prices, volatility and
trading information with respect to Rallybio Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the financial analysis presented by Citizens to the Rallybio Board on March&nbsp;1, 2026 and Citizens&#8217; opinion,
dated March&nbsp;1, 2026, to the Rallybio Board that, as of such date and based upon and subject to the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
qualifications, limitations, assumptions and other matters set forth therein, the Exchange Ratio was fair, from a financial point of view, to Rallybio (as more fully described in the section
titled &#8220;<I>The Merger&#8212;Opinion of Rallybio&#8217;s Financial Advisor</I>&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the strength of the balance sheet of the combined organization, which includes Rallybio&#8217;s anticipated Rallybio Net
Cash at Closing of approximately $37.5&nbsp;million, plus the aggregate commitment represented in the Concurrent Financing of approximately $505.5&nbsp;million; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio Board&#8217;s belief that the terms of the Merger Agreement and the related agreements, including the
parties&#8217; respective representations, warranties and covenants, the conditions to their respective obligations to close the Merger and the termination rights of the parties, are reasonable under the circumstances, including:
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the belief that, as a result of <FONT STYLE="white-space:nowrap">arm&#8217;s-length</FONT> negotiations with Candid,
Rallybio and its representatives negotiated the most favorable Exchange Ratio to which Candid was willing to agree, and that the other terms of the Merger Agreement include the most favorable terms to Rallybio in the aggregate to which Candid was
willing to agree; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the calculation of the Exchange Ratio, Rallybio Net Cash at the Closing and the estimated number of shares of Rallybio
Common Stock to be issued in the Merger, and the fact that the relative valuation of Rallybio, and thus the relative percentage ownership of Rallybio&#8217;s stockholders immediately following the Closing, is subject to change based on the amount of
Rallybio Net Cash at the Closing; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and customary nature of the conditions to Rallybio&#8217;s and Candid&#8217;s respective obligations to
complete the Merger and the likelihood that the Merger will be completed on a timely basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability of Rallybio under the Merger Agreement to consider unsolicited acquisition proposals under certain
circumstances and for the Rallybio Board to potentially change its recommendation in favor of such a proposal should Rallybio determine such proposal to constitute, or be reasonably likely to result in, a superior offer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the belief by the Rallybio Board of the reasonableness of the potential termination fee of $1.425&nbsp;million and related
reimbursement of certain transaction expenses of up to $500,000, payable by Rallybio if the Merger Agreement is terminated in certain circumstances; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the belief by the Rallybio Board of the reasonableness of the potential termination fee of either $50&nbsp;million or
$10&nbsp;million payable by Candid, depending on the circumstances of the termination, and related reimbursement of certain transaction expenses of up to $500,000, which could become payable if the Merger Agreement is terminated in certain
circumstances, which the Rallybio Board believed would provide deterrence for competing acquisition proposals and provide Rallybio with compensation for the time, expense and disruption associated with negotiating the transaction if the Merger is
not completed under such specified circumstances; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements, pursuant to which certain executive officers, directors
and stockholders of Candid have agreed not to transfer their shares of common stock of the combined company for the <FONT STYLE="white-space:nowrap">180-day</FONT> period after the effective time of the Merger; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Candid support agreements, pursuant to which certain stockholders of Candid, solely in their capacities as
stockholders, have agreed, to execute a written consent or vote all of their shares of Candid Capital Stock in favor of the Merger and against any alternative acquisition proposals, and the fact that stockholders holding the necessary votes to adopt
the Merger Agreement and approve the Merger have entered into Candid support agreements; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio support agreements, pursuant to which certain stockholders of Rallybio, solely in their capacities as
stockholders, have agreed, to vote all of their shares of Rallybio Common Stock in favor of the Proposals and against any alternative acquisition proposals. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the course of its deliberations, the Rallybio Board also considered, among other things, a variety of risks and other countervailing factors related to entering into
the Merger, the Merger Agreement and the Contemplated Transactions, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possibility that the Merger will not be consummated in a timely manner or at all; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential adverse effect of the public announcement of the Merger on Rallybio&#8217;s business, including potential
volatility of the trading price of Rallybio Common Stock following the announcement of the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possibility that any Legacy Assets remaining after the Closing will not be monetized and the consequential potential
that Rallybio equityholders will not receive any consideration under the Rallybio CVRs and the Rallybio CVRs may otherwise expire valueless; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possibility that Candid will not be able to complete the Concurrent Financing on the terms or amounts contemplated or
at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the fact that certain provisions of the Merger Agreement could have the effect of discouraging competing proposals
involving Rallybio, including the restrictions on Rallybio&#8217;s ability to solicit alternative acquisition proposals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the fact that under certain circumstances Rallybio may be required to pay to Candid a termination fee of
$1.425&nbsp;million and/or an expense reimbursement of up to $500,000, and the potential effects of such termination fee and/or expense reimbursement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the provisions of the Merger Agreement that permit the Candid Board, subject to specified conditions, to consider and
engage with third parties regarding alternative acquisition proposals and to change its recommendation if the Candid Board determines that such proposal constitutes, or is reasonably likely to result in, a superior offer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the strategic direction of the combined company following the completion of the Merger, which will be determined by the
combined company&#8217;s board, which will not include a representative of the current Rallybio Board, and the combined company&#8217;s management, which is not expected to include any current Rallybio officers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the early-stage nature of Candid&#8217;s drug candidates and the risks and uncertainties associated with development and
commercialization of Candid&#8217;s drug candidates, including that such drug candidates may not generate acceptable clinical data in the future or be successfully developed into products that are marketed and sold, as well as other scientific,
technical and regulatory risks and uncertainties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the substantial fees and expenses incurred or that may be incurred by Rallybio or the combined company associated with
completing the Merger, including the costs associated with any potential transaction related litigation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possibility of disruptive stockholder demands or litigation following announcement of the Merger;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that the Merger may not be completed despite the parties&#8217; efforts or that the Closing may be unduly delayed
and the effects on Rallybio as a standalone company because of such failure or delay, including that a more limited range of alternative strategic transactions may be available to Rallybio in such an event and that Rallybio may experience additional
significant challenges associated with its need to raise additional capital through the public or private sale of equity securities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the fact that under certain circumstances, Rallybio will not be entitled to receive a termination fee from Candid even in
the event that the Merger is not consummated as a result of circumstances which are not under Rallybio&#8217;s control; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the dilution to the existing stockholders of Rallybio upon the consummation of the Merger; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possibility that Rallybio Net Cash, as more fully described below under the caption &#8220;<I>The Merger
Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>&#8221; in this proxy statement/prospectus, may be lower at the determination time than currently anticipated, which would reduce the relative percentage ownership of Rallybio&#8217;s
existing equityholders in the combined company; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the various other risks associated with the combined company and the Merger, including those described in the section
entitled &#8220;<I>Risk Factors</I>&#8221; in this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In light of the variety of factors considered in connection with
its evaluation of the Merger and the complexity of these matters, the Rallybio Board did not find it useful or practicable to and did not attempt to, quantify, assign or rank any relative or specific weights to the various factors that it considered
in reaching its determination that the Merger, the Merger Agreement and the Contemplated Transactions are advisable and in best interests of Rallybio and Rallybio&#8217;s stockholders. In addition, the Rallybio Board did not undertake to make any
specific determination as to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
whether any particular factor, or any aspect of any particular factor, was favorable or unfavorable to the ultimate determination of the Rallybio Board, but rather the Rallybio Board conducted an
overall analysis of the factors described above, including discussions with and questioning of Rallybio management and representatives of the Rallybio&#8217;s legal and financial advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Candid&#8217;s Reasons for the Merger </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion sets forth
material factors considered by the Candid Board in reaching its determination to approve the terms and authorize the execution of the Merger Agreement for the purpose of implementing the Merger and to approve the Concurrent Financing; however, it
may not include all of the factors considered by the Candid Board. In light of the number and wide variety of factors considered in connection with its evaluation of the Merger Agreement and the Concurrent Financing, the Candid Board did not
consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors it considered in reaching its determination. The Candid Board viewed its position and determinations as being based on all of
the information available and the factors presented to and considered by it. In addition, individual directors may have given different weight to different factors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the course of reaching its decision to approve the Merger and the Concurrent Financing, the Candid Board held meetings and conducted discussions, consulted with
Candid&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors in connection with its evaluation of the Merger Agreement and Concurrent Financing. Ultimately, the Candid Board concluded that a merger
with Rallybio, together with the Concurrent Financing, was the best option to access the liquidity and capital-raising opportunities of the public markets and obtain capital to support the advancement of Candid&#8217;s pipeline and the operations of
the combined company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additional factors the Candid Board considered included, among others, the following (which factors are not necessarily presented in any
order of relative importance): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the historical and current information concerning Candid&#8217;s business, including its financial performance and
condition, operations, management, competitive position and preclinical and clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s prospects if it were to remain an independent privately held company, including its need to obtain
additional financing and the terms on which it would be able to obtain such financing, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Concurrent Financing will generate substantial capital resources to fund the combined company through 2030;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential benefits from increased public awareness of Candid and its pipeline; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Candid Board&#8217;s belief that, after reviewing various financing options to enhance stockholder value, the Merger
and Concurrent Financing represented the most favorable alternative reasonably available to Candid; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cash resources of the combined company expected to be available upon the closing of the Concurrent Financing and
consummation of the Merger (including the ability to support Candid&#8217;s current and planned clinical trials and operations through 2030); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio Net Cash that would be available to the combined company after the Merger; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the access, as a public company, to a broader range of investors to support the development of Candid&#8217;s drug
candidates than if Candid continued to operate as a privately held company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential to provide its current stockholders with greater liquidity by owning stock in a public company;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the expectation that the Merger with Rallybio, together with the funding committed in the Concurrent Financing, would be a
higher probability and more efficient means to access capital than other potential options considered, including an IPO; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the expectation that substantially all of Candid&#8217;s employees, including its management, will serve in similar roles
at the combined company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Candid Board&#8217;s fiduciary duties to Candid stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms and conditions of the Merger Agreement, including, without limitation, the following: </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the determination that the expected relative percentage ownership of Rallybio equityholders and Candid equityholders in
the combined company was appropriate, based on Candid&#8217;s Board&#8217;s judgment and assessment of the approximate valuations of Rallybio (including the value the Rallybio Net Cash is
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
expected to provide to the combined company) and Candid (including the value of the amount of proceeds from the Concurrent Financing); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the expectation that the Merger will be treated as a reorganization for U.S. federal income tax purposes, with the result
that the Candid stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes with respect to the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rights of the Candid Board under the Merger Agreement to consider certain unsolicited acquisition proposals, and,
subject to specified conditions, to change its recommendation to approve the Merger and enter into a permitted alternative acquisition transaction, under certain circumstances should the Candid Board determine such acquisition proposal constitutes,
or is reasonably likely to result in, a superior offer; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the fact that Candid is permitted, subject to certain conditions, to engage with third parties and evaluate alternative
acquisition proposals that may arise following receipt of a bona fide acquisition proposal that the Candid Board determines constitutes, or is reasonably likely to result in, a superior offer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the limited number and nature of the conditions of Rallybio&#8217;s obligation to consummate the Merger;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the conditions to Candid&#8217;s obligation to consummate the Merger that Rallybio&#8217;s net cash at Closing must be at
least $0 and that Rallybio&#8217;s cash and cash equivalents at Closing must be at least $1.0 million; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the conclusion of the Candid Board that the potential termination fees payable by each of Rallybio or Candid to the other
party (which the Candid Board evaluated together with the other deal protection provisions in the Merger Agreement), and the specific circumstances when such fees may be payable, were appropriate in light of the circumstances of the transaction,
including the Candid Board&#8217;s continued ability, subject to specified conditions, to consider and respond to alternative acquisition proposals and enter into a permitted alternative acquisition transaction; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and
covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the fact that shares of Rallybio Common Stock issued to Candid stockholders will be registered on a Form <FONT
STYLE="white-space:nowrap">S-4</FONT> registration statement and will become freely tradable for Candid stockholders who are not affiliates of Candid and who are not parties to the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the support agreements, pursuant to which certain directors, officers and stockholders of Rallybio and Candid,
respectively, have agreed, solely in their capacity as stockholders of Rallybio and Candid, respectively, to vote all of their shares of Rallybio Common Stock or Candid Capital Stock, respectively, in favor of the adoption and approval of the Merger
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the anticipated Nasdaq listing of the combined company&#8217;s common stock and the adoption of the name &#8220;Candid
Therapeutics, Inc.&#8221; for the combined company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of appraisal rights under Section&nbsp;262 of the DGCL, which permits holders of Candid Capital Stock who
properly exercise such rights to seek judicial determination of the fair value of their shares of Candid Capital Stock ; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the likelihood that the Merger will be consummated on a timely basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Candid Board also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger
Agreement, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that the potential benefits of the Merger may not be realized; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that the Merger might not be consummated in a timely manner or at all, including as a result of the failure of
Rallybio to obtain the required Rallybio stockholder vote, and the potential adverse effect on the reputation of Candid and its ability to obtain future financing if the Merger and Concurrent Financing are not completed; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that future sales of common stock by existing Rallybio stockholders may cause the price of Rallybio Common Stock
to fall, thus reducing the value of Rallybio Common Stock received by Candid stockholders in the Merger; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size of the termination fees payable by Candid to Rallybio upon the occurrence of certain events, and the potential
effect of such termination fees in deterring potential acquirers from proposing an alternative transaction that may be more advantageous to Candid stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Exchange Ratio used to establish the number of shares of Rallybio Common Stock to be issued to Candid stockholders in
the Merger is fixed, except for adjustments due to Rallybio&#8217;s Net Cash, the amount of proceeds received by Candid in the Concurrent Financing and changes in the parties&#8217; outstanding capital stock at Closing, and thus the relative
percentage ownership of Rallybio stockholders and Candid stockholders in the combined company immediately following the consummation of the Merger is similarly fixed; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possibility that Rallybio could under certain circumstances consider unsolicited acquisition proposals the Rallybio
Board deems to be superior to the Merger Agreement or change its recommendation to approve the Merger Agreement upon certain events; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the expenses incurred and anticipated to be incurred in connection with the Merger and related administrative costs
associated with combining the organizations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the additional costs and compliance obligations Candid will incur that are associated with operating as a public company
following the consummation of the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the fact that Rallybio&#8217;s representations and warranties in the Merger Agreement do not survive the Closing, and the
potential risk of liabilities that may arise after the Closing; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">various other risks associated with the combined company and the Merger, including the risks described in the section
titled &#8220;<I>Risk Factors</I>&#8221; of this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing information is not intended to be exhaustive, but is
believed to include a summary of all of the material factors considered by the Candid Board in its consideration of the Merger Agreement, the Concurrent Financing, and the various transactions contemplated thereby. After conducting an overall
analysis of these and other factors, including thorough extensive discussions with Candid&#8217;s senior management and outside advisors, the Candid Board concluded that the benefits, advantages and opportunities of a potential transaction
outweighed the uncertainties and risks described above. Based on this overall analysis of the factors described above, the Candid Board unanimously approved the Merger Agreement, the Merger, the Concurrent Financing and the other transactions
contemplated by the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion of Citizens JMP Securities, LLC (Rallybio&#8217;s Financial Advisor) </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Introduction </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio retained Citizens as a financial advisor in
connection with the Merger. In connection with this engagement, the Rallybio Board requested that Citizens evaluate the fairness, from a financial point of view, to Rallybio of the Exchange Ratio to be paid by Rallybio pursuant to the terms of the
Merger Agreement. On March&nbsp;1, 2026, Citizens delivered to the Rallybio Board its written opinion that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken
by Citizens in preparing its opinion, the Exchange Ratio to be paid by Rallybio pursuant to the terms of the Merger Agreement is fair, from a financial point of view, to Rallybio. The full text of the written opinion of Citizens, which describes the
assumptions made and the qualifications and limitations upon the review undertaken by Citizens in preparing its opinion, is attached as Annex B to this proxy statement / prospectus and is incorporated herein by reference. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The summary of the written opinion of Citizens set forth below is qualified in its entirety by the full text of the written opinion attached hereto as Annex B.
Citizens&#8217; financial advisory services and opinion were provided for the information and assistance of the Rallybio Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of the Rallybio
Board&#8217;s consideration of the Merger, and the opinion of Citizens addressed only the fairness, from a financial point of view, as of the date thereof, to Rallybio of the Exchange Ratio to be paid by Rallybio pursuant to the terms of the Merger
Agreement. The opinion of Citizens did not address any other term or aspect of the Merger Agreement or the Merger and did not and does not constitute a recommendation to any stockholder of Rallybio or Candid as to whether or how such stockholder
should vote with respect to the Merger or otherwise act with respect to the Merger or any other matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The full text of the written opinion of Citizens should be read carefully in its entirety for a description of the
assumptions made and the qualifications and limitations upon the review undertaken by Citizens in preparing its opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with rendering the opinion
described above and performing its related financial analyses, Citizens reviewed, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain publicly available financial statements and certain other business and financial information relating to Rallybio;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the historical trading prices and trading activity for Rallybio Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain financial and operating data concerning Candid prepared by the management of Candid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly available market capitalization data regarding companies in the biotechnology industry that Citizens believed to
be comparable in certain respects to Candid, and publicly available financial terms of certain initial public offerings involving companies in the biotechnology industry that Citizens believed to be comparable in certain respects to Candid; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Merger Agreement draft, dated February&nbsp;27, 2026, and certain related documents. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens also participated in discussions with members of the senior management of Rallybio and Candid and their respective advisors and representatives. Citizens also
performed such other analysis and considered such other factors as Citizens deemed appropriate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens assumed and relied, without independent verification, upon
the accuracy and completeness of all information and data that was publicly available or furnished to or otherwise reviewed by or discussed with Citizens and relied upon the assurance of the management of Rallybio and Candid that they are not aware
of any facts or circumstances that would make such information inaccurate or misleading. The Rallybio Board was aware that neither Rallybio&#8217;s nor Candid&#8217;s management provided Citizens with, and Citizens did not otherwise have access to,
financial forecasts regarding Rallybio&#8217;s or Candid&#8217;s business. Accordingly, Citizens did not perform a discounted cash flow analysis with respect to Rallybio or Candid. In addition, with Rallybio&#8217;s consent, Citizens did not make
any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> or otherwise) of Rallybio or Candid, nor was Citizens furnished with any such evaluation
or appraisal, and Citizens was not asked to conduct, and did not conduct, a physical inspection of the properties or assets of Rallybio or Candid. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens was
advised that, given that Rallybio&#8217;s assets and liabilities are comprised of cash (net of liabilities) and the Legacy Assets (which currently are contemplated to be disposed) and that Rallybio is not expected to have any continuing business
operations on a standalone basis other than those incidental to Rallybio&#8217;s status as a publicly traded company, the management of Rallybio has not prepared financial forecasts relating to Rallybio. Accordingly, Citizens did not perform a
financial analysis of Rallybio, the Legacy Assets or the Rallybio CVRs, and did not ascribe any value to the Legacy Assets or the Rallybio CVRs. Citizens assumed the equity value of Rallybio to be $10.0&nbsp;million, and Rallybio Net Cash at Closing
to be $37.5 million, in each case as directed by the Rallybio Board. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens assumed that the representations and warranties of each party contained in the Merger
Agreement are true and correct, that each party will perform all of the covenants and agreements required to be performed by it under the Merger Agreement and that all conditions to the consummation of the Merger will be satisfied without waiver
thereof. Citizens assumed that the final form of the Merger Agreement will not vary materially from the last draft Merger Agreement reviewed by it and that the Merger will be consummated substantially on the terms described therein, without any
amendment or waiver of material terms or conditions. Citizens also assumed that all necessary governmental, regulatory and other consents and approvals contemplated by the Merger Agreement will be obtained and that in the course of obtaining those
consents and approvals no costs or restrictions will be imposed or waivers made that would have an adverse effect on the contemplated benefits of the Merger. Citizens relied on the assessments of Candid&#8217;s management as to, among other things,
Candid&#8217;s product pipeline, future products, technology and intellectual property, including the viability of and risks associated therewith. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens is not
a legal, tax or regulatory advisor and relied upon, without independent verification, the assessment of Rallybio and Candid and their legal, tax or regulatory advisors with respect to legal, tax or regulatory matters. Citizens is not in the business
of appraising tangible assets and did not make any independent valuation or appraisal of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
or all of the assets or liabilities (including any contingent, derivative or <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> assets or liabilities) of Rallybio or Candid, nor was it
furnished with any such valuations or appraisals. In addition, Citizens did not evaluate the solvency of any party to the Merger Agreement under any state or federal laws relating to bankruptcy, insolvency or similar matters. Citizens&#8217; opinion
is necessarily based on financial, economic, market and other conditions as in effect on, and the information made available to Citizens as of, the date thereof. Events occurring after such date may affect such opinion and the assumptions used in
preparing it, and Citizens did not and does not assume any obligation to update, revise or reaffirm such opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens was not requested to consider, and
Citizens&#8217; opinion did not address, Rallybio&#8217;s underlying business decision to enter into the Merger Agreement and pursue the Merger, or the relative merits of the Merger as compared to any alternative business strategies that might exist
for Rallybio or the effect of any other transaction in which Rallybio might engage. Citizens was not requested to consider, and its opinion did not and does not address, the <FONT STYLE="white-space:nowrap">non-financial</FONT> terms of the Merger
Agreement or the Merger, including, without limitation, the structure or form of the Merger, nor was Citizens asked to address the terms of any related transactions to be entered into by the parties, including, without limitation, the Rallybio CVRs
and the Concurrent Financing, or the fairness of the Merger or any other term or aspect of the Merger to, or any consideration to be received in connection therewith by, or the impact of the Merger on, the holders of any class of securities,
creditors or other constituencies of Rallybio or any other party. Citizens&#8217; opinion was limited to and addressed only the fairness, from a financial point of view, as of the date thereof, to Rallybio of the Exchange Ratio to be paid by
Rallybio pursuant to the terms of the Merger Agreement. Furthermore, Citizens expressed no opinion with respect to the amount or nature of any compensation to be paid to any officers, directors or employees of any party to the Merger, or any class
of such persons, relative to the Merger Consideration or otherwise, or with respect to the fairness of any such compensation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens&#8217; opinion was given at
the request of, and is intended for the benefit and use of, the Rallybio Board in connection with its consideration of the Merger, and it is not intended to be and does not constitute a recommendation to any equityholder of Rallybio as to how such
equityholder should vote or act on any matter relating to the Merger. Citizens&#8217; opinion was authorized by its fairness opinion review committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary
of Financial Analysis </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of the material financial analyses prepared by Citizens and reviewed with the Rallybio Board in connection
with its opinion, which was delivered to the Rallybio Board on March&nbsp;1, 2026. The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the opinion of,
Citizens, nor does the order of the analyses described below represent the relative importance or weight given to those analyses by Citizens. The preparation of a fairness opinion is a complex analytical process involving various determinations as
to the most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances and, therefore, a fairness opinion is not readily susceptible to summary description. In arriving at its opinion,
Citizens did not draw, in isolation, conclusions from or with regard to any factor or analysis that it considered. Accordingly, Citizens believes that its analyses must be considered as a whole and that selecting portions of such analyses and
factors without considering all analyses and factors, could create a misleading or incomplete view of the processes underlying Citizens&#8217; financial analyses and its opinion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Analyses relating to the value of Candid do not purport to be appraisals or reflect the prices at which Candid may actually be sold. Accordingly, the assumptions and
estimates used in, and the results derived from, the financial analyses are inherently subject to substantial uncertainty. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on
market data as it existed on or before February&nbsp;27, 2026, and is not necessarily indicative of current market conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens&#8217; financial analyses
and opinion were only one of many factors taken into consideration by the Rallybio Board in its evaluation of the Merger, as described under &#8220;<I>The Merger&#8212;Rallybio&#8217;s Reasons for the Merger</I>.&#8221; Consequently, the analyses
described below should not be viewed as determinative of the views of the Rallybio Board or management of Rallybio with respect to the Exchange Ratio or as to whether the Rallybio Board would have been willing to determine that a different Exchange
Ratio was fair. The Exchange Ratio, as well as the type of consideration payable in the Merger, was determined through <FONT STYLE="white-space:nowrap">arm&#8217;s-length</FONT> negotiations between Rallybio and Candid
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and was approved by the Rallybio Board. Citizens did not recommend any specific Exchange Ratio or other financial terms to Rallybio or the Rallybio Board or that any specific Exchange Ratio or
other financial terms constituted the only appropriate consideration for the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In preparing its analysis, Citizens took into account that the Exchange Ratio
is calculated in part by attributing equity value to Rallybio, which it assumed to be $10.0&nbsp;million, and by Rallybio Net Cash at Closing, which it assumed to be $37.5&nbsp;million, in each case as directed by Rallybio&#8217;s board of
directors. Further, Citizens was advised that the Legacy Assets are contemplated to be disposed for the benefit of holders of Rallybio Common Stock prior to the consummation of the Merger, who will receive contingent value rights relating to the net
proceeds received from any disposition or commercialization thereof occurring within a specified disposition period, and that Rallybio is not expected to have any continuing business operations on a standalone basis other than those incidental to
Rallybio&#8217;s status as a publicly traded company. Therefore, Citizens did not ascribe any value to the Legacy Assets or the Rallybio CVRs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As the Rallybio
Board was aware, neither Rallybio&#8217;s nor Candid&#8217;s management provided Citizens with, and Citizens did not otherwise have access to, financial forecasts regarding Rallybio&#8217;s or Candid&#8217;s businesses. Accordingly, Citizens did not
perform discounted cash flow analyses with respect to Rallybio or Candid. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid Valuation Analysis&#8212;Selected Biopharma Public Companies </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens reviewed publicly available information relating to the market capitalization of U.S.-listed, publicly-traded biopharmaceutical companies whose lead product
was in Phase 1b/2 through Phase 3 of clinical development, focused on immunology&nbsp;&amp; inflammation indications. The companies meeting these criteria were: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EQUITY</B><br><B>VALUE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ENTERPRISE</B><br><B>VALUE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>LEAD ASSET</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>INDICATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STAGE</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Immunovant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">IMVT-1402</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Graves&#8217;&nbsp;Disease</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase&nbsp;2b</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Apogee Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ZUMILOKIBART</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Atopic Dermatitis</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Spyre Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SPY001</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ulcerative Colitis</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dianthus Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2,611</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2,087</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Claseprubart</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Generalized&nbsp;Myasthenia Gravis</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nektar Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Rezpegaldesleukin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Atopic Dermatitis</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2b</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nurix Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Bexobrutideg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Autoimmune Cytopenias</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase&nbsp;1b/2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Celldex Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2,073</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1,493</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Barzolvolimab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chronic Spontaneous Urticaria</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Zura Bio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tibulizumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Hidradenitis Suppurativa</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Avalo Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">AVTX-009</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Hidradenitis Suppurativa</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens noted that although such companies had certain financial and operating characteristics that could be considered similar to those of Candid, none of the
companies had the same management, <FONT STYLE="white-space:nowrap">make-up,</FONT> technology, size or mix of businesses as Candid and, accordingly, there were inherent limitations on the applicability of such companies to the valuation analysis of
Candid. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens calculated the aggregate enterprise value of each of these companies based upon the closing price of the common stock of each such company on
February&nbsp;26, 2026 and the fully-diluted number of shares outstanding, using the treasury stock method. Citizens then added Candid&#8217;s estimated net cash of $216&nbsp;million and applied a 25% illiquidity discount to reach an adjusted equity
value for Candid of between $1,198&nbsp;million and $2,553&nbsp;million at the 25<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> percentiles, respectively, of the valuation of
comparable publicly traded companies, which implied an exchange ratio of between 0.2845x and 0.6032x at such respective percentiles, as compared to the assumed exchange ratio of 0.1791x (which does not give effect to the reverse stock split). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results of this analysis are summarized as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ENTERPRISE<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADJ.&nbsp;EQUITY<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADJUSTED<BR>EQUITY&nbsp;VALUE<BR>W/25%<BR>ILLIQUIDITY<BR>DISCOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">25th Percentile</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">75th Percentile</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid Valuation Analysis&#8212;Selected Biopharma Initial Public Offerings </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens reviewed publicly available information relating to the U.S.-listed initial public offerings completed since January&nbsp;1, 2021 for biopharmaceutical
companies whose lead product at the time of its IPO was in Phase 1 through Phase 2b/3 of clinical development, focused on immunology&nbsp;&amp; inflammation indications. These initial public offerings are listed below: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEAD ASSET (AT IPO)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">PRE-MONEY</FONT></B><br><B>EQUITY&nbsp;VALUE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">PRE-MONEY</FONT></B><br><B>ENTERPRISE<BR>VALUE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>IPO DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NAME</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>INDICATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>STAGE</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">AgomAb Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/05/26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ontunisertib</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Crohn&#8217;s&nbsp;Disease</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase&nbsp;2a</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Upstream Bio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/10/24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Verekitug</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Severe Asthma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Alumis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/27/24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">ESK-001</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Plaque Psoriasis</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Acelyrin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">05/04/23</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Izokibep</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Hidradenitis Suppurativa</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Phase&nbsp;2b/3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Third Harmonic Bio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/14/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">THB001</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chronic Urticaria</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Connect Biopharma Holdings</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/18/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">CBP-201</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Atopic Dermatitis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Phase 2b</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prometheus Biosciences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/11/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">PRA023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ulcerative Colitis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Phase 1a</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens noted that although such companies had certain financial and operating characteristics that could be considered similar to those of Candid, none of the
companies had the same management <FONT STYLE="white-space:nowrap">make-up,</FONT> technology, size or mix of businesses as Candid and, accordingly, there were inherent limitations on the applicability of such companies to the valuation analysis of
Candid. Citizens also noted that market conditions have varied over the precedent time periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens calculated a
<FONT STYLE="white-space:nowrap">pre-money</FONT> enterprise valuation for these companies and added Candid&#8217;s estimated net cash of $216&nbsp;million to reach an adjusted <FONT STYLE="white-space:nowrap">pre-money</FONT> equity value for
Candid of between $658&nbsp;million and $801&nbsp;million at the 25<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> percentiles, respectively, of the valuation of comparable IPO
transactions, which implied an exchange ratio of between 0.1575x and 0.1912x at such respective percentiles, as compared to the assumed exchange ratio of 0.1791x (which does not give effect to the reverse stock split). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results of this analysis are summarized as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">PRE-MONEY</FONT></B><br><B>ENTERPRISE<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">ADJ.&nbsp;PRE-MONEY</FONT></B><br><B>EQUITY VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>25th Percentile</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>442</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>658</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>75th Percentile</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>801</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid Valuation Analysis&#8212;Selected Biopharma Initial Public Offering
<FONT STYLE="white-space:nowrap">Step-Ups</FONT> </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens reviewed publicly available information relating to
<FONT STYLE="white-space:nowrap">step-up</FONT> multiples for U.S.-listed initial public offerings since 2021 for biopharmaceutical companies whose lead product at the time of its IPO was in Phase 1 through Phase 2b/3 of clinical development,
focused on immunology&nbsp;&amp; inflammation indications. The <FONT STYLE="white-space:nowrap">step-up</FONT> multiple was derived by dividing the IPO price per share by the price per share of the last financing round prior to IPO. These initial
public offerings are listed below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEAD ASSET (AT IPO)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">PRE-MONEY</FONT></B><br><B>EQUITY<BR>VALUE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">STEP-UP</FONT><BR>MULTIPLE</B><br><B>TO IPO</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>IPO DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NAME</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>INDICATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>STAGE</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">AgomAb Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/05/26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ontunisertib</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Crohn&#8217;s Disease</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2a</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Upstream Bio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/10/24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Verekitug</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Severe Asthma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Alumis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/27/24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">ESK-001</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Plaque Psoriasis</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Acelyrin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">05/04/23</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Izokibep</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hidradenitis Suppurativa</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Phase&nbsp;2b/3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1.5x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Third Harmonic Bio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">09/14/22</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">THB001</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chronic Urticaria</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1.0x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Connect Biopharma Holdings</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/18/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">CBP-201</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Atopic Dermatitis</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phase 2b</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prometheus Biosciences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/11/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PRA023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ulcerative Colitis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Phase 1a</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens noted that, although such companies had certain financial and operating characteristics that could be considered similar to those of Candid, none of the
companies had the same management <FONT STYLE="white-space:nowrap">make-up,</FONT> technology, size or mix of businesses as Candid and, accordingly, there were inherent limitations on the applicability of such companies to the valuation analysis of
Candid. Citizens also noted that market conditions have varied over the precedent time periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens calculated the
<FONT STYLE="white-space:nowrap">step-up</FONT> multiple of each of these companies and applied these multiples to Candid&#8217;s Series B valuation of $650&nbsp;million to arrive at an adjusted <FONT STYLE="white-space:nowrap">pre-money</FONT>
valuation range for Candid of between $683&nbsp;million and $1,203&nbsp;million at the 25<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> percentiles, respectively, of the
valuation of comparable <FONT STYLE="white-space:nowrap">step-up</FONT> transactions, which implied an exchange ratio of between 0.1632x and 0.2855x at such respective percentiles, as compared to the assumed exchange ratio of 0.1791x (which does not
give effect to the reverse stock split). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results of this analysis are summarized as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">STEP-UP</FONT><BR>MULTIPLE</B><br><B>TO IPO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>IMPLIED<BR>CANDID</B><br><B><FONT STYLE="white-space:nowrap">PRE-MONEY</FONT><BR>VALUATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>25th Percentile</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.1x</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>683</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>75th Percentile</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.9x</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens, as part of its investment banking business, is
customarily engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, negotiated underwritings, competitive biddings, secondary distributions of securities, private placements and valuations for estate,
corporate and other purposes.&#8195; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Citizens did not have a material relationship with, or otherwise receive fees from, Rallybio or Candid during the two years
preceding the date of its opinion, other than its provision of ordinary course equity research coverage of Rallybio. Consistent with applicable legal and regulatory requirements, Citizens has adopted policies and procedures to establish and maintain
the independence of its research department and personnel. As a result, Citizens&#8217; research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Rallybio or the Merger that
differ from the views of its investment banking personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of its trading, brokerage, investment management and financing activities, Citizens may at any
time hold long or short positions, and may trade or otherwise effect transactions, for its own account or the accounts of customers, in debt or equity securities of parties to the Merger or other companies or any currency that may be involved in the
Merger. In the future, Citizens may maintain other relationships with, and provide advisory and other services to the Candid, Rallybio and their respective affiliates, and may receive fees for providing such services. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board selected Citizens to act as Rallybio&#8217;s financial advisor based on Citizens&#8217; qualifications, reputation, experience and expertise in the
biopharmaceuticals industry, its knowledge of and involvement in recent transactions in the biopharmaceutical industry, and its relationship and familiarity with Rallybio and its business. Citizens is an internationally recognized investment banking
firm that has substantial experience in transactions similar to this transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with Citizens&#8217; services as a financial advisor to Rallybio,
Rallybio has agreed to pay Citizens a fee of $750,000, which became payable upon the rendering by Citizens of its opinion on March&nbsp;1, 2026. In addition, Rallybio agreed to reimburse certain of Citizens&#8217; expenses arising, and to indemnify
Citizens against certain liabilities that may arise, out of Citizens&#8217; engagement. The terms of the fee arrangements between Citizens and Rallybio, which are customary in transactions of this nature, were negotiated at <FONT
STYLE="white-space:nowrap">arm&#8217;s-length</FONT> between Citizens and Rallybio, and the Rallybio Board was aware of these arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Certain Disclosures
Regarding Evercore Group L.L.C. (Rallybio&#8217;s Financial Advisor) </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Evercore has acted as financial advisor to the Rallybio Board in connection with the
Merger. Pursuant to the terms of Evercore&#8217;s engagement letter with Rallybio, Rallybio has agreed to pay Evercore a fee for its services in the amount of approximately $2.25 million, which will be payable contingent upon the consummation of the
Merger. Rallybio has also agreed to reimburse Evercore&#8217;s expenses and to indemnify Evercore against certain liabilities arising out of the engagement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During
the two-year period ending on February 19, 2026, Evercore and its affiliates have not been engaged to provide financial advisory or other services to Rallybio and have not received any compensation from Rallybio during such period.&nbsp;In addition,
during the two-year period ending on February 19, 2026, Evercore and its affiliates have not been engaged to provide financial advisory or other services to Candid and have not received any compensation from Candid during such period.&nbsp;Evercore
may provide financial advisory or other services to Rallybio and Candid in the future, and in connection with any such services Evercore may receive compensation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Evercore and its affiliates engage in&nbsp;a wide range of activities for their own accounts and the accounts of customers, including corporate finance, mergers and
acquisitions, equity sales, trading and research, private equity, placement agent, asset management and related activities.&nbsp;In connection with these businesses or otherwise, Evercore its affiliates and/or their respective employees, as well as
investment funds in which any of them may have a financial interest, may at any time, directly or indirectly, hold long or short positions and may trade or otherwise effect transactions for their own accounts or the accounts of customers, in debt or
equity securities, senior loans and/or derivative products or other financial instruments of or relating to Rallybio, Candid, potential parties to the Merger and/or any of their respective affiliates or persons that are competitors, customers or
suppliers of Rallybio or Candid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Interests of Rallybio&#8217;s Directors and Executive Officers in the Merger </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In considering the recommendation of the Rallybio Board with respect to issuing shares of Rallybio Common Stock in the Merger and other matters to be acted upon by the
Rallybio stockholders at the Rallybio annual meeting, the Rallybio stockholders should be aware that Rallybio&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Rallybio
stockholders generally. The Rallybio Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Rallybio
stockholders approve the proposals to be presented to the Rallybio stockholders for consideration at the Rallybio annual meeting as contemplated by this proxy statement/prospectus. These interests include the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Under the Merger Agreement, Rallybio&#8217;s directors and executive officers are entitled to continued indemnification,
expense advancements and insurance coverage; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">In connection with the Merger, each option to purchase Rallybio Common Stock, restricted stock unit with respect to
Rallybio Common Stock and performance-based stock unit with respect to Rallybio Common Stock held by Rallybio&#8217;s directors and executive officers as of the Effective Time will vest in full upon the Closing; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each Rallybio executive officer may be eligible to receive enhanced severance benefits pursuant to their respective
employment agreements with Rallybio in the event of a qualifying termination of employment following the Merger. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These interests are discussed in
more detail below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of Shares of Rallybio Common Stock </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of Rallybio Common Stock issued and outstanding at the time of the Merger will remain issued and outstanding, and, subject to the proposed reverse stock
split, will be unaffected by the Merger. Rallybio&#8217;s directors and executive officers will continue to hold their existing shares of Rallybio Common Stock following the consummation of the Merger. In addition, holders of Rallybio Common Stock
as of the close of business on the last business day prior to the day on which the Effective Time occurs will receive one Rallybio CVR for each outstanding share of Rallybio Common Stock held by such holder on such date (as described in more detail
in the section titled &#8220;<I>Agreements Related to the Merger&#8212;Rallybio Contingent Value Rights Agreement</I>&#8221;). For more information regarding the beneficial ownership of Rallybio Common Stock by Rallybio&#8217;s directors and
executive officers, see the section titled &#8220;<I>Principal</I> <I>Stockholders of Rallybio</I>&#8221; of this proxy statement/prospectus. As of March&nbsp;6, 2026, the directors and executive officers of Rallybio and their affiliates
beneficially owned, in the aggregate, approximately 31.1% of the outstanding shares of Rallybio Common Stock (including shares issuable upon exercise of stock options exercisable within 60 days of such date). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth, for each Rallybio director and executive officer, the number of shares of Rallybio Common Stock beneficially owned as of March&nbsp;6,
2026, as well as the number of shares of Rallybio Common Stock held directly (excluding shares issuable upon exercise of stock options exercisable within 60 days of such date and shares held through affiliated investment funds): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;OF&nbsp;COMMON<BR>STOCK&nbsp;BENEFICIALLY<BR>OWNED<BR>(#)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;OF&nbsp;COMMON&nbsp;STOCK<BR>HELD DIRECTLY<BR>(EXCLUDING OPTIONS)<BR>(#)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Jonathan I. Lieber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Martin Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Wendy Chung</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Robert Hopfner, R.Ph., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">317,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Ronald M. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">437,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Hui Liu, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Christine A. Nash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">All directors and executive officers as a group (12 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,275,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes shares of Rallybio Common Stock issuable upon the exercise of stock options exercisable within 60 days of March&nbsp;6, 2026, and, in the case of Dr.&nbsp;Hopfner and Mr.&nbsp;Hunt, shares held through
affiliated investment funds (Pivotal bioVenture Partners and New Leaf Venture Partners, respectively). See &#8220;<I>Principal Stockholders of Rallybio</I>&#8221; for additional information regarding beneficial ownership. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents shares of Rallybio Common Stock held directly, excluding shares issuable upon exercise of stock options exercisable within 60 days and shares held through affiliated investment funds. No restricted stock
units are included in the table above. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of Rallybio Equity Awards </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Merger Agreement, before the Effective Time, Rallybio is required to take all actions necessary to provide that all Rallybio Stock Awards (as defined in
the Merger Agreement, which includes all outstanding options to purchase Rallybio Common Stock, restricted stock units and performance-based restricted stock units granted under the Rallybio Corporation 2021 Equity Incentive Plan (the &#8220;2021
Plan&#8221;)) shall be fully vested as of the Effective Time and that no option to purchase Rallybio Common Stock shall be exercised later than 90&nbsp;days following the termination of service of the holder of such option. As a result, all unvested
stock options, restricted stock units and performance-based restricted stock units held by Rallybio&#8217;s directors and executive officers will become fully vested as of the Effective Time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth, for each Rallybio director and executive officer, the number of unvested stock options, restricted stock units and performance-based
restricted stock units outstanding as of March&nbsp;6, 2026, and the estimated intrinsic value of accelerated vesting upon the Closing, calculated based on a per share price of $10.91 (the closing price of Rallybio Common Stock on the Nasdaq Capital
Market on March&nbsp;6, 2026). As of March&nbsp;6, 2026, the unvested stock options held by Rallybio&#8217;s executive officers had exercise prices ranging from $6.08 to $54.48 per share. Of these, only the unvested stock options with an exercise
price of $6.08 per share (granted February&nbsp;14, 2025) had an exercise price that was less than the closing price of Rallybio Common Stock on such date. All other unvested stock options held by the executive officers had exercise prices in excess
of the $10.91 per share closing price and accordingly had no intrinsic value. The actual amounts payable in respect of Rallybio Stock Awards held by directors and executive officers of Rallybio will depend on the number of shares of Rallybio Common
Stock subject to Rallybio Stock Awards held by such persons as of the Effective Time, which may differ from the amounts set forth in the table below. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UNVESTED&nbsp;STOCK<BR>OPTIONS<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UNVESTED<BR>RESTRICTED STOCK<BR>UNITS OR<BR><FONT STYLE="white-space:nowrap">PERFORMANCE-BASED</FONT><BR>RESTRICTED STOCK<BR>UNITS</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ESTIMATED&nbsp;VALUE&nbsp;OF<BR>ACCELERATED<BR>VESTING<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Jonathan I. Lieber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Martin Mackay, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Wendy Chung</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Robert Hopfner, R.Ph., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Ronald M. Hunt<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Hui Liu, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Christine A. Nash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated value of accelerated vesting represents the aggregate intrinsic value of unvested stock options (i.e., the excess, if any, of $10.91 per share over the per share exercise price, multiplied by the number of
unvested shares underlying such option) and the aggregate value of unvested restricted stock units (&#8220;RSUs&#8221;) or performance-based restricted stock units (&#8220;PSUs&#8221;) (i.e., $10.91 per share multiplied by the number of unvested
RSUs or PSUs). As of March&nbsp;6, 2026, the unvested stock options held by the named executive officers (Drs. Uden and Ryder and Mr.&nbsp;Lieber) had exercise prices ranging from $6.08 to $54.48 per share. Of these, only the stock options granted
on February&nbsp;14, 2025 with an exercise price of $6.08 per share were in the money, with an intrinsic value of $4.83 per share ($10.91 minus $6.08). All other unvested stock options held by the named executive officers had exercise prices in
excess of the $10.91 per share closing price and accordingly had no intrinsic value. Mr.&nbsp;Lieber&#8217;s January 2025 PSU grant of 15,000 shares was cancelled during fiscal year 2025 and accordingly is not reflected in this table. The May 2025
director options, the February 2026 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-lieu-of-cash</FONT></FONT></FONT> options, and the options held by the named executive officers with a $6.08
exercise price were the only <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> unvested options as of March&nbsp;6, 2026. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 2,500 unvested PSUs granted to Mr.&nbsp;Lieber on February&nbsp;18, 2026. See &#8220;Mr.&nbsp;Lieber&#8217;s PSU Awards&#8221; below for additional information. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 18,055 shares underlying an option granted on February&nbsp;18, 2026 in lieu of Dr.&nbsp;Mackay&#8217;s 2026 annual cash retainer of $65,000. These options vest in 11 equal monthly installments on the last day
of each remaining month of calendar year 2026 and have an exercise price of $4.45 per share, which was below the $10.91 per share closing price on March&nbsp;6, 2026. As of March&nbsp;6, 2026, one of the 11 installments had vested (approximately
1,641 shares), and the remaining approximately 16,414 shares were unvested with an aggregate intrinsic value of approximately $106,034 (16,414 shares &times; $6.46 per share). </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 14,305 shares underlying an option granted on February&nbsp;18, 2026 in lieu of Mr.&nbsp;Hunt&#8217;s 2026 annual cash retainer of $51,500. These options vest in 11 equal monthly installments on the last day of
each remaining month of calendar year 2026 and have an exercise price of $4.45 per share, which was below the $10.91 per share closing price on March&nbsp;6, 2026. As of March&nbsp;6, 2026, one of the 11 installments had vested (approximately 1,300
shares), and the remaining approximately 13,005 shares were unvested with an aggregate intrinsic value of approximately $84,012 (13,005 shares &times; $6.46 per share). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendments to Employment Agreements </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Merger,
on March&nbsp;1, 2026, Rallybio and each of Dr.&nbsp;Uden, Mr.&nbsp;Lieber, and Dr.&nbsp;Ryder entered into amendments to their respective employment agreements to clarify that the Merger will constitute a &#8220;change in control&#8221; for
purposes of each executive&#8217;s employment agreement. As a result, if any of these executive officers experiences a qualifying termination of employment (i.e., termination without cause or resignation for good reason) within the <FONT
STYLE="white-space:nowrap">12-month</FONT> period following the Closing, the executive will be entitled to receive enhanced <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> severance benefits,
including: (i)&nbsp;an amount equal to 1.5 times the sum of the executive&#8217;s annual base salary and target annual bonus, payable over 18 months; (ii)&nbsp;any earned but unpaid annual bonus with respect to the calendar year ending on or
preceding the date of termination; (iii)&nbsp;payment of COBRA premiums for up to 18&nbsp;months; and (iv)&nbsp;in the case of Mr.&nbsp;Lieber and Dr.&nbsp;Ryder, full vesting of any outstanding and unvested equity awards that are subject solely to
time-based vesting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to Dr.&nbsp;Uden, his second amended and restated employment agreement provides that any outstanding and unvested time-based
equity awards held by him as of a change in control will vest in full upon the consummation of the change in control, subject to his continued employment through the date of such change in control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For a full description of the terms of the employment agreement with Dr.&nbsp;Ryder (the &#8220;Ryder Employment Agreement&#8221;), including Dr.&nbsp;Ryder&#8217;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-change-in-control</FONT></FONT></FONT> severance benefits and restrictive covenants, see &#8220;<I>Rallybio Executive Officer and Director
Compensation&#8212;Narrative Disclosure to Summary Compensation Table&#8212;Severance upon termination of employment; change in control; restrictive covenants</I>&#8221; of this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dr.&nbsp;Mackay&#8217;s Consulting Agreement </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under
Dr.&nbsp;Mackay&#8217;s consulting agreement with Rallybio and Rallybio, LLC, effective January&nbsp;1, 2025, Dr.&nbsp;Mackay provides consulting services to the Rallybio for a fee of $18,750 per month ($225,000 on an annualized basis). In the event
of a Change in Control (as defined in the consulting agreement), Dr.&nbsp;Mackay&#8217;s outstanding time-based equity awards that were outstanding as of December&nbsp;31, 2024 will vest in full upon the consummation of the Change in Control,
subject to Dr.&nbsp;Mackay&#8217;s continued service relationship with Rallybio through the date of such Change in Control. Because the Merger Agreement requires Rallybio to take all actions necessary to provide that all Rallybio Stock Awards shall
be fully vested as of the Effective Time, all of Dr.&nbsp;Mackay&#8217;s outstanding equity awards will become fully vested as of the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Mr.&nbsp;Lieber&#8217;s PSU Award </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;29, 2025,
Mr.&nbsp;Lieber was granted 15,000 PSUs under the 2021 Plan. The January 2025 PSUs were subsequently cancelled during fiscal year 2025 and were not outstanding as of December&nbsp;31, 2025. On February&nbsp;18, 2026, Mr.&nbsp;Lieber was granted
5,000 PSUs, of which 2,500 vested on the date of grant (with 789 shares sold on February&nbsp;23, 2026 at $5.06 per share to cover applicable withholding taxes, resulting in a net issuance of 1,711 shares) and the remaining 2,500 PSUs will vest on
the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of a Change in Control, provided that a Change in Control is consummated on or before December&nbsp;31, 2026.The Merger will constitute a Change in Control for purposes of the PSUs.
Because the Merger Agreement requires Rallybio to take all actions necessary to provide that all Rallybio Stock Awards shall be fully vested as of the Effective Time, the PSUs will vest as of the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Interests of Candid&#8217;s Directors and Executive Officers in the Merger </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In considering the recommendation of the Candid Board with respect to approving the Merger, Rallybio stockholders should be aware that Candid&#8217;s directors and
executive officers have interests in the Merger that are different from, or in addition to, the interests of Candid&#8217;s stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests,
to the extent material, are described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Candid Board was aware of these potential conflicts of interest and considered them, among other matters, in
reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Candid stockholders approve the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Ownership Interests
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of February&nbsp;28, 2026, the directors and executive officers of Candid as a group beneficially owned in the aggregate approximately 7.1% of the
outstanding shares of Candid Capital Stock. In addition, Dr.&nbsp;Song, his spouse and children are beneficiaries of the Song Beneficiary Trust, which is managed by an independent third-party trustee and which holds approximately 6.5% of the
outstanding shares of Candid Capital Stock. In addition, each of Candid&#8217;s director and executive officers or their respective affiliates who beneficially own any shares of Candid Capital Stock also entered into a support agreement in
connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<I>Agreements Related to the Merger&#8212;Support Agreements.</I>&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of Candid Stock Options </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the Merger
Agreement, each Candid stock option that is outstanding and unexercised immediately prior to the Effective Time under the Candid 2024 Plan, whether or not vested, will be converted into and become an option to purchase shares of Rallybio Common
Stock at the Effective Time. Rallybio will assume the Candid 2024 Plan and all such Candid stock options in accordance with the terms of the Candid 2024 Plan and the terms of the stock option agreement by which such option is evidenced. See the
section titled &#8220;<I>The Merger Agreement&#8212;Treatment of Candid Stock Options.</I>&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of February&nbsp;28, 2026, each of Dr.&nbsp;Song, Dr.&nbsp;Lu,
Mr.&nbsp;Kush, Dr.&nbsp;Huyghe, Dr.&nbsp;You and Mr.&nbsp;Puckett beneficially own Candid stock options to purchase 10,000,000, 1,200,000, 1,000,000, 500,000, 200,000 and 200,000 shares of Candid Common Stock, respectively, that will vest or begin
vesting, if at all, upon or following a Liquidity Event (as defined below), which will be satisfied in connection with the Contemplated Transactions. In addition, Mr.&nbsp;Puckett holds a Candid stock option to purchase 1,638,750 shares of Candid
Common Stock that is subject to time-based vesting conditions. All of these Candid stock options will be assumed by Rallybio and converted into options to purchase Rallybio Common Stock in accordance with the Merger Agreement. See the sections
titled &#8220;<I>Candid Executive Officer and Director Compensation&#8212;Equity-Based Incentive Awards</I>&#8221; and &#8220;<I>Candid Executive Officer and Director Compensation&#8212;Director Compensation.</I>&#8221; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Management Following the Merger </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in the section
captioned &#8220;<I>Management Following the Merger</I>&#8221;, Candid&#8217;s executive officers and directors are currently expected to become the executive officers and directors of the combined company. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indemnification and Insurance </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For a discussion of the
indemnification and insurance provisions related to Candid&#8217;s executive officers and directors under the Merger Agreement, please see the sections titled &#8220;<I>The Merger Agreement&#8212;Other Agreements&#8212;Director Indemnification and
Insurance</I>&#8221; and &#8220;<I>Certain Relationships and Related Party Transactions of the Combined Company&#8212;Candid Related Party Transactions&#8212;Indemnification Agreements.</I>&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers of the Combined Company Following the Merger </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective as of the Closing, the combined company&#8217;s executive officers are expected to be the individuals designated by Candid. Candid currently expects that the
following individuals will serve as the executive officers of the combined company following the Merger: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>TITLE</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ken Song, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>President and Chief Executive Officer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tim Lu, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief Medical Officer and Chief Scientific Officer</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arvind Kush</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief&nbsp;Financial&nbsp;Officer&nbsp;and&nbsp;Chief&nbsp;Business&nbsp;Officer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bernie Huyghe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief Technology Officer</I></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Merger Consideration </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the Effective Time, each share of Candid Capital
Stock outstanding immediately prior thereto (excluding shares held by stockholders who have exercised and perfected appraisal rights, shares held as treasury stock by Candid or held or owned by Rallybio, Merger Sub or any subsidiary of Rallybio or
Candid and shares issued in the Concurrent Financing), will be converted into the right to receive a number of shares of Rallybio Common Stock equal to the Exchange Ratio. Additionally, the Candid Common Stock issued in the Concurrent Financing will
be converted solely into the right to receive a number of shares of Rallybio Common Stock equal to the Concurrent Financing Exchange Ratio, which is calculated by multiplying the total amount of Concurrent Financing Merger Shares by the percentage
of the Concurrent Financing Proceeds represented by the applicable stockholder&#8217;s investment in the Concurrent Financing, in each case as set forth on the Allocation Certificate. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No fractional shares of Rallybio Common Stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued.
Any holder of Candid Capital Stock who would otherwise be entitled to receive a fraction of a share of Rallybio Common Stock (after aggregating all fractional shares of Rallybio Common Stock issuable to such holder) will receive from Rallybio, in
lieu of such fraction of a share: (i)&nbsp;one share of Rallybio Common Stock if the aggregate amount of fractional shares of Rallybio Common Stock such holder of Candid Capital Stock would otherwise be entitled to is equal to or exceeds 0.50; or
(ii)&nbsp;no shares of Rallybio Common Stock if the aggregate amount of fractional shares of Rallybio Common Stock such holder of Candid Capital Stock would otherwise be entitled to is less than 0.50, with no cash being paid for any fractional share
eliminated by such rounding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Treatment of Candid Stock Options </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under
the terms of the Merger Agreement, each Candid stock option that is outstanding and unexercised immediately prior to the Effective Time under the Candid 2024 Plan, whether or not vested, will be converted into and become an option to purchase shares
of Rallybio Common Stock at the Effective Time. Rallybio will assume the Candid 2024 Plan and all such Candid stock options in accordance with the terms of the Candid 2024 Plan and the terms of the stock option agreement by which such option is
evidenced. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, from and after the Effective Time: (i)&nbsp;each outstanding Candid stock option assumed by Rallybio may be exercised solely for shares of
Rallybio Common Stock; (ii)&nbsp;the number of shares of Rallybio Common Stock subject to each outstanding Candid stock option assumed by Rallybio will be determined by multiplying (A)&nbsp;the number of shares of Candid Common Stock that were
subject to such Candid stock option, by (B)&nbsp;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Rallybio Common Stock; (iii)&nbsp;the per share exercise price for the Rallybio Common Stock
issuable upon exercise of each Candid stock option assumed by Rallybio will be determined by dividing (A)&nbsp;the per share exercise price of such Candid stock option, by (B)&nbsp;the Exchange Ratio and rounding the resulting exercise price up to
the nearest whole cent; and (iv)&nbsp;any restriction on the exercise of any Candid stock option assumed by Rallybio will continue in full force and effect and the term, exercisability, vesting schedule and any other provisions of such Candid stock
option will otherwise remain unchanged; provided, however, that the Rallybio Board or a committee thereof will succeed to the authority and responsibility of the Candid Board or any committee thereof with respect to each Candid stock option assumed
by Rallybio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Effective Time of the Merger </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger will be completed on the second business day after all of the conditions to the Closing are satisfied or waived, including the approval of the stockholders
of Rallybio, unless earlier terminated in accordance with the terms of the Merger Agreement. For more information on termination rights, see the section titled &#8220;<I>The Merger Agreement</I><I>&#8212;Termination and Termination Fees.</I>&#8221;
The Merger is anticipated to occur after the Rallybio annual meeting. Neither Rallybio nor Candid can predict the exact timing of the consummation of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulatory Approvals </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, Rallybio must comply with
applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with (i)&nbsp;the issuance of shares of Rallybio Common Stock to Candid stockholders in connection with the transactions contemplated by the Merger
Agreement and the change of control resulting from the Merger and (ii)&nbsp;the filing of this proxy statement/prospectus with the SEC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is subject to
the requirements of the HSR Act and the related rules and regulations, which provide that certain transactions may not be completed until notification and report forms have been furnished to the DOJ and the FTC and until certain waiting periods have
been terminated or have expired. The HSR Act requires Rallybio and Candid to observe a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-calendar-day</FONT></FONT> waiting period after the submission of their respective HSR
notification and report forms before consummating the Merger. The waiting period may be shortened if the reviewing agency grants &#8220;early termination&#8221; of the waiting period or lengthened if the acquiring person (here Rallybio) voluntarily
withdraws and refiles to allow a second <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-calendar-day</FONT></FONT> waiting period, or if the reviewing agency issues a request for additional information or documentary material (a
&#8220;Second Request&#8221;) prior to the expiration of the initial waiting period, the parties must observe a second <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-calendar-day</FONT></FONT> waiting period, which begins to
run only after each of the parties has substantially complied with the Second Request. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The applicable waiting period required under the HSR Act expired at
11:59 p.m., Eastern Time, on April&nbsp;13, 2026. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Material U.S. Federal Income Tax Consequences of the Merger </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio stockholders will not sell, exchange or dispose of any shares of Rallybio Common Stock as a result of the Merger. Thus, there will be no material U.S. federal
income tax consequences to Rallybio stockholders as a result of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nasdaq Stock Market Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Common Stock is currently listed on Nasdaq under the symbol &#8220;RLYB.&#8221; Pursuant to the Merger Agreement, Rallybio has agreed to (a)&nbsp;use
commercially reasonable efforts to maintain its existing listing on Nasdaq until the Closing, (b)(i) to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of
Rallybio Common Stock being issued in the Merger, and (ii)&nbsp;use commercially reasonable efforts to cause such shares to be approved for listing (subject to official notice of issuance) on the Nasdaq market at or prior to the Effective Time, and
(c)&nbsp;to the extent required by Nasdaq Marketplace Rule 5110, to file an initial Nasdaq Listing Application for the Rallybio Common Stock on Nasdaq and to use commercially reasonable efforts to cause such listing application to be conditionally
approved prior to the Effective Time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each party will reasonably promptly inform the other party of all verbal or written communications between Nasdaq and such
party or its representatives. Each party will cooperate with the other party as reasonably requested with respect to the Nasdaq listing application and promptly furnish to such party all information concerning itself, its members and its
stockholders that may be reasonably requested in connection with any action contemplated by the foregoing paragraph. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Nasdaq listing application is accepted,
Rallybio anticipates that the common stock of the combined company will be listed on Nasdaq following the Closing under the trading symbol &#8220;CDRX.&#8221; In order for the Nasdaq listing application to be accepted, among other requirements, the
combined company must maintain a bid price of $4.00&nbsp;or higher for a certain period of time following the proposed reverse stock split. As of &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, the bid price of Rallybio Common Stock was
$&#8195;&#8195;&#8195;&#8195;&#8195;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anticipated Accounting Treatment </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is expected be accounted for under GAAP as an <FONT STYLE="white-space:nowrap">in-substance</FONT> reverse recapitalization. For accounting purposes, Candid
is expected to be considered the accounting acquirer. The treatment as an <FONT STYLE="white-space:nowrap">in-substance</FONT> reverse recapitalization is based on the assessment that as a result of Rallybio&#8217;s discontinuation of its research
and development activities and settlement of its other remaining operating assets and liabilities, immediately prior to the Closing, Rallybio is expected to have nominal assets, apart from cash and cash equivalents and marketable securities. Under a
reverse recapitalization, Candid is considered to effect a financing transaction in exchange for issuing equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Appraisal Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the DGCL, Rallybio stockholders are not entitled to
appraisal rights in connection with the Merger. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid
stockholders are entitled to appraisal rights in connection with the Merger under Section&nbsp;262 of the DGCL. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The discussion below is not a complete summary
regarding Candid stockholders&#8217; appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as Annex O. Stockholders intending to exercise
appraisal rights should carefully review Annex O. Failure to follow precisely any of the statutory procedures set forth in&nbsp;Annex O may result in a termination or waiver of these rights. This summary does not constitute legal or other advice,
nor does it constitute a recommendation that Candid stockholders exercise their appraisal rights under Delaware law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Section&nbsp;262, where a merger is
adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&nbsp;228 of the DGCL, either the constituent corporation before the effective date of such merger or the surviving corporation, within 10&nbsp;days
after the effective date of such merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such merger, the effective date of such merger and that appraisal rights are available. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Merger is completed, within 10&nbsp;days after the effective date of the Merger, Candid will notify its stockholders that the Merger has been approved, the
effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger. Holders of shares of Candid Capital Stock who desire to exercise their appraisal rights must deliver a written demand for
appraisal to Candid within 20&nbsp;days after the date of the giving of that notice, and that stockholder must not have delivered a written consent approving the Merger. A demand for appraisal must reasonably inform Candid of the identity of the
stockholder and that such stockholder intends thereby to demand appraisal of the shares of Candid Capital Stock held by such stockholder. Failure to deliver a written consent approving the Merger will not in and of itself constitute a written demand
for appraisal satisfying the requirements of Section&nbsp;262. All demands for appraisal should be addressed to Candid, 11622 El Camino Real, Suite 150, San Diego, CA 92130, Attention: Jeff Woodley, Email: legal@candidrx.com, and should be executed
by, or on behalf of, the record holder of shares of Candid Capital Stock. ALL DEMANDS MUST BE RECEIVED BY CANDID WITHIN 20 DAYS AFTER THE DATE CANDID GIVES A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE
DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a Candid stockholder fails to deliver a written
demand for appraisal within the time period specified above, such stockholder will be entitled to receive the merger consideration for his, her or its shares of Candid Capital Stock as provided for in the Merger Agreement, but such stockholder will
have no appraisal rights with respect to his, her or its shares of Candid Capital Stock. To be effective, a demand for appraisal by a holder of shares of Candid Capital Stock must be made by, or in the name of, the registered stockholder, fully and
correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Candid. The beneficial owner must, in these
cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a
demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the
demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a
broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that
case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the
stockholder must continuously hold the shares of record from the date of making the demand through the Effective Time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a stockholder holds its shares of Candid
Capital Stock in a brokerage account or in other custodian form and such stockholder wishes to exercise appraisal rights, such stockholder should consult with his, her or its bank, broker or other custodian to determine the appropriate procedures
for the making of a demand for appraisal by the custodian. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At any time within 60&nbsp;days after the Effective Time, any stockholder who has demanded an appraisal,
but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to Candid. If,
following a demand for appraisal, such stockholder withdrawn his, her or its demand for appraisal in accordance with Section&nbsp;262, such stockholder will have the right to receive the merger consideration for his, her or its shares of Candid
Capital Stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Within 120&nbsp;days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with
Section&nbsp;262 will, upon written request to the combined company, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal
rights have been received and the aggregate number of holders of these shares. This written statement will be given to the requesting stockholder within 10&nbsp;days after the stockholder&#8217;s written request is received by the combined company
or within 10&nbsp;days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120&nbsp;days after the effective date of the Merger, either the combined company or any stockholder who has delivered a demand
for appraisal in accordance with Section&nbsp;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a stockholder,
service of a copy of the petition must be made upon the combined company. The combined company has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and Candid, which is expected to be
the combined company, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written
demand for appraisal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the combined company, the surviving
corporation will then be obligated, within 20&nbsp;days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded
an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the combined company. After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is
empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&nbsp;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the
stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction,
the Delaware Court of Chancery may dismiss the proceedings as to that stockholder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After determination of the stockholders entitled to appraisal of their shares,
the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a
fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding,
if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
representing those shares. At any time before the entry of judgment in the proceedings, the combined company may pay to each stockholder entitled to appraisal an amount in cash, in which case
interest shall accrue thereafter only upon the sum of (i)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii)&nbsp;interest
theretofore accrued, unless paid at that time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining fair value, and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required
to take into account all relevant factors. In<I>&nbsp;Weinberger v. UOP, Inc.</I>, the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by
any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors
involving the value of a company.&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the
accomplishment or expectation of the merger.&#8221; In<I>&nbsp;Cede</I><I></I><I>&nbsp;&amp; Co. v. Technicolor, Inc.</I>, the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of
value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In<I>&nbsp;Weinberger</I>, the Delaware Supreme Court construed Section&nbsp;262 to mean that &#8220;elements of future
value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid stockholders should be aware that the fair value of their shares as determined under Section&nbsp;262 could be more than, the same as, or less than the value
that such stockholders are entitled to receive under the terms of the Merger Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Costs of the appraisal proceeding may be imposed upon the combined company
and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of
the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro&nbsp;rata against the value of all shares
entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the Effective Time, be entitled to vote shares subject to that demand
for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the Effective Time; however, if no petition for appraisal is filed within
120&nbsp;days after the Effective Time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60&nbsp;days after the Effective Time, then the right of that
stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his, her or its Candid Capital Stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more
than 60&nbsp;days after the Effective Time may only be made with the written approval of the combined company. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure to follow the steps required by Section&nbsp;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of
Section&nbsp;262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_7"></A>THE MERGER AGREEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached as Annex A to this proxy statement/prospectus
and is incorporated by reference. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about Rallybio, Candid or
Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and
the&nbsp;terms&nbsp;and conditions of the Merger Agreement. Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Merger Agreement, except that references to Candid herein shall refer to
&#8220;the Company&#8221; in the Merger Agreement and references to Rallybio herein shall refer to &#8220;Parent&#8221; in the Merger Agreement.</I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The Merger
Agreement contains representations and warranties that Rallybio and Merger Sub, on the one hand, and Candid, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the
other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if such statements made in the representations and warranties prove to be incorrect. In addition,
the assertions made in the representations and warranties are qualified by the information in confidential disclosure schedules exchanged by the parties in connection with the signing of the Merger Agreement. While Rallybio and Candid do not believe
that these disclosure schedules contain information required to be publicly disclosed under applicable securities laws, other than information that has already been so disclosed, the disclosure schedules contain information that modifies, qualifies
and creates exceptions to the representations and warranties set forth in the Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Rallybio, Candid or
Merger Sub, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Rallybio and Merger Sub on the one hand, and Candid on the other hand, and may be modified by the additional information in the
disclosure schedules. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Structure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Merger Agreement, Merger
Sub, a wholly owned subsidiary of Rallybio formed in connection with the Merger, will merge with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio. Substantially concurrently with the completion of the Merger, Rallybio
will be renamed &#8220;Candid Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;CDRX.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Completion and Effectiveness of the Merger </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger will be completed on
the second business day after all of the conditions to the Closing are satisfied or waived, including the approval of the stockholders of Rallybio, unless earlier terminated in accordance with the terms of the Merger Agreement. For more information
on termination rights, see the section titled &#8220;<I>The Merger Agreement</I><I></I><I></I><I>&#8212;</I><I>Termination and Termination Fees.</I>&#8221; The Merger is anticipated to occur after the Rallybio annual meeting. Rallybio and Candid
cannot predict the exact timing of the Closing because it is subject to various conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Merger Consideration and Exchange Ratio </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Merger Consideration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the Effective Time, each share of Candid
Capital Stock outstanding immediately prior to the Effective Time (excluding shares held by stockholders who have exercised and perfected appraisal rights, shares held as treasury stock by Candid or held or owned by Rallybio, Merger Sub or any
subsidiary of Rallybio or Candid and shares issued in the Concurrent Financing), will be converted into the right to receive a number of shares of Rallybio Common Stock equal to the Exchange Ratio. Additionally, the Candid Capital Stock issued in
the Concurrent Financing shall be converted solely into the right to receive a number of shares of Rallybio Common Stock equal to the total amount of Concurrent Financing Merger Shares <I>multiplied</I> by the percentage of the Concurrent Financing
Proceeds represented by the applicable stockholder&#8217;s investment in the Concurrent Financing, in each case as set forth on the Allocation Certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No fractional shares of Rallybio Common Stock will be issued in connection with the Merger, and no certificates or
scrip for any such fractional shares will be issued. Any holder of Candid Capital Stock who would otherwise be entitled to receive a fraction of a share of Rallybio Common Stock (after aggregating all fractional shares of Rallybio Common Stock
issuable to such holder) shall receive from Rallybio, in lieu of such fraction of a share: (i)&nbsp;one share of Rallybio Common Stock if the aggregate amount of fractional shares of Rallybio Common Stock such holder of Candid Capital Stock would
otherwise be entitled to is equal to or exceeds 0.50; or (ii)&nbsp;no shares of Rallybio Common Stock if the aggregate amount of fractional shares of Rallybio Common Stock such holder of Candid Capital Stock would otherwise be entitled to is less
than 0.50, with no cash being paid for any fractional share eliminated by such rounding. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exchange Ratio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Exchange Ratio formula pursuant to which shares of Candid Capital Stock will be converted into shares of Rallybio Common Stock is derived based on (i)&nbsp;a Candid
fixed valuation of $750.0&nbsp;million and (ii)&nbsp;an initial Rallybio valuation of $47.5&nbsp;million, subject to certain adjustments based on Rallybio Net Cash at Closing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio valuation used to determine the Exchange Ratio will be increased or decreased on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-for-dollar</FONT></FONT> basis to reflect the amount by which Rallybio Net Cash at the Closing is greater than or less than $37.5&nbsp;million, or the Rallybio Target Net Cash
(as defined below). Accordingly, if Rallybio Net Cash at Closing is greater than $37.5&nbsp;million, the Rallybio valuation used to calculate the Exchange Ratio will be increased by the amount of such excess, and if Rallybio Net Cash at Closing is
less than $37.5&nbsp;million, the Rallybio valuation used to calculate the Exchange Ratio will be decreased by the amount of such shortfall. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately after the
Closing, under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, on a pro forma basis and based upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, the <FONT
STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Candid (other than holders of shares issued in the Concurrent Financing) are expected to own approximately 57.55% of the combined company, the
<FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Rallybio are expected to own approximately 3.65% of the combined company, and the holders of shares issued in connection with the Concurrent Financing are expected to own
approximately 38.80% of the combined company (assuming proceeds from the Concurrent Financing of $505.5 million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions further
described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected post-Merger equity ownership split percentages are based on the assumed Exchange Ratio and assumed Concurrent Financing Exchange
Ratio of 0.0716 for the Candid Capital Stock held by <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Candid and are subject to adjustments based on the final Exchange Ratio, final Concurrent Financing Exchange Ratio and final
amount of converted shares. The assumed Exchange Ratio and Concurrent Financing Exchange Ratio were calculated assuming, among other things, (i)&nbsp;a reverse stock split of Rallybio Common Stock at a ratio of 1-for-2.5, to be implemented
immediately prior to the Closing, as may be further adjusted, (ii)&nbsp;valuation of Rallybio of $47.5&nbsp;million (assuming Rallybio Net Cash at Closing of $37.5&nbsp;million), (iii)&nbsp;a fixed valuation of Candid of $750.0 million,
(iv)&nbsp;proceeds from the Concurrent Financing of $505.5&nbsp;million, and (v)&nbsp;the relative capitalization of Rallybio and Candid. Such assumed Exchange Ratio and Concurrent Financing Exchange Ratio are subject to certain adjustments,
including based on the amount of Rallybio Net Cash at Closing and the final ratio for the reverse stock split of Rallybio Common Stock. The Exchange Ratio and assumed Concurrent Financing Exchange Ratio formulas assumes an implied value of the
combined company of approximately $1.303&nbsp;billion, subject to certain adjustments. There can be no assurance that these assumptions will be accurate at the Closing when the final Exchange Ratio and Concurrent Financing Exchange Ratio are
determined. For more information on the Concurrent Financing, please see the section titled &#8220;<I>Agreements Related to the Merger&#8212;Subscription Agreement</I>&#8221; of this proxy statement/prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The &#8220;Exchange Ratio&#8221; for <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Candid (excluding shares issued in connection with the
Concurrent Financing) means the following ratio (rounded to four decimal places): the quotient obtained by <I>dividing</I> (a)&nbsp;the Candid Merger Shares <I>by</I> (b)&nbsp;the Candid Outstanding Shares, and the &#8220;Concurrent Financing
Exchange Ratio&#8221; for holders of shares issued in connection with the Concurrent Financing is calculated by <I>multiplying </I>the total </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
amount of Concurrent Financing Merger Shares <I>by </I>the percentage of the Concurrent Financing Proceeds represented by the applicable stockholder&#8217;s investment in the Concurrent
Financing, in each case, as set forth in the Allocation Certificate, for each of the foregoing, in which: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Aggregate Valuation&#8221; means the sum of (i)&nbsp;the Candid Valuation, plus (ii)&nbsp;the Rallybio Valuation
plus (iii)&nbsp;the Concurrent Financing Proceeds. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Candid Allocation Percentage&#8221; means the Candid Valuation <I>divided</I> <I>by</I> the Aggregate Valuation.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Candid Merger Shares&#8221; the product determined by <I>multiplying</I> (a)&nbsp;the Post-Closing Rallybio Shares
by (b)&nbsp;the Candid Allocation Percentage. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Candid Valuation&#8221; means $750,000,000. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Candid Outstanding Shares&#8221; means the total number of shares of Candid Capital Stock outstanding immediately
prior to the Effective Time (excluding any shares of Candid Common Stock issued in the Concurrent Financing), expressed on a <FONT STYLE="white-space:nowrap">fully-diluted</FONT> and <FONT STYLE="white-space:nowrap">as-converted</FONT> to Candid
Common Stock basis and using the treasury stock method, but assuming, without limitation or duplication, (i)&nbsp;the exercise of all Candid stock options outstanding as of immediately prior to the Effective Time, and (ii)&nbsp;the issuance of
shares of Candid Capital Stock in respect of all other outstanding options, restricted stock awards, restricted stock units, warrants or rights to receive such shares, whether conditional or unconditional and including any outstanding options,
warrants, restricted stock awards, restricted stock units or rights triggered by or associated with the consummation of the Merger (but excluding any shares of Candid Capital Stock reserved for issuance other than with respect to outstanding Candid
stock options as of immediately prior to the Effective Time). </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Concurrent Financing Allocation Percentage&#8221; means the quotient (rounded to four decimal places) determined by
<I>dividing</I> (A)&nbsp;the Concurrent Financing Proceeds <I>by</I> (B)&nbsp;the Aggregate Valuation. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Concurrent Financing Merger Shares&#8221; means, subject to Section&nbsp;1.5(f) of the Merger Agreement, the
product determined by <I>multiplying</I> (i)&nbsp;the Post-Closing Rallybio Shares <I>by </I>(ii)&nbsp;the Concurrent Financing Allocation Percentage. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Rallybio Allocation Percentage&#8221; means the Rallybio Valuation divided by the Aggregate Valuation.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Rallybio Equity Value&#8221; means $10,000,000. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Rallybio Outstanding Shares&#8221; means, subject to Section&nbsp;1.5(f) of the Merger Agreement (which addresses,
among other things, the possibility to effect the reverse stock split) and the immediately following sentence, the total number of shares of Rallybio Common Stock outstanding immediately prior to the Effective Time, expressed on a <FONT
STYLE="white-space:nowrap">fully-diluted</FONT> basis and using the treasury stock method (and shall include, for the avoidance of doubt, all In the Money Rallybio Options), but assuming, without limitation or duplication, the issuance of shares of
Rallybio Common Stock in respect of all Rallybio Stock Awards, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, and other outstanding options, warrants or rights to receive such shares, in each case, outstanding as of immediately prior
to the Effective Time (assuming cashless exercise), whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or associated with the consummation of the Merger (but excluding any shares of Rallybio
Common Stock reserved for issuance other than with respect to outstanding Rallybio Stock Awards as of immediately prior to the Effective Time and as set forth above). For the avoidance of doubt, no Out of the Money Rallybio Options shall be included
in the total number of shares of Rallybio Common Stock outstanding for purposes of determining the Rallybio Outstanding Shares. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Rallybio Target Net Cash&#8221; means $37,500,000. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Rallybio Valuation&#8221; means (i)&nbsp;if Rallybio Net Cash is greater than Rallybio Target Net Cash, the sum of
(w)&nbsp;Rallybio Equity Value plus (x)&nbsp;Rallybio Target Net Cash plus (y)&nbsp;the amount by which Rallybio Net Cash exceeds Rallybio Target Net Cash, (ii)&nbsp;if Rallybio Net Cash is equal to Rallybio Target Net Cash, the sum of
(x)&nbsp;Rallybio Equity Value plus (y)&nbsp;Rallybio Target Net Cash, or (iii)&nbsp;if Rallybio Net Cash is less than Rallybio Target Net Cash, the sum of (w)&nbsp;Rallybio Equity Value plus (x)&nbsp;Rallybio Target Net Cash minus (y)&nbsp;the
amount by which Rallybio Target Net Cash exceeds Rallybio Net Cash. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;Post-Closing Rallybio Shares&#8221; means the quotient obtained <I>by dividing</I> the Rallybio Outstanding Shares
by the Rallybio Allocation Percentage. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Calculation of Rallybio Net Cash </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Merger Agreement, &#8220;Rallybio Net Cash&#8221; means, without duplication, (a)&nbsp;Rallybio&#8217;s cash, currency, and cash equivalents as determined in
accordance with GAAP, <I>minus</I> (b)&nbsp;Rallybio&#8217;s accounts payable, accrued expenses (including Rallybio&#8217;s unpaid transaction expenses, the costs of any tail policy associated with any directors&#8217; and officers&#8217; insurance
policy to be bound at the Closing, lease termination costs, notice payments, fines or other payments to be made by Rallybio in order to terminate any existing agreements to which Rallybio is a party, and any other estimated expenses associated with
the wind-down of Rallybio&#8217;s prior research and development activities at or after the Closing, actual and estimated costs and expenses incurred in connection with the disposition of the Legacy Assets and other bona fide current and long-term
liabilities (with any such liabilities, to the extent not required to be set forth in a balance sheet prepared in accordance with GAAP, to be resolved by Rallybio and Candid in good faith), and 40% of all fees and expenses incurred in relation to
(i) the printing and filing of this registration statement and proxy statement/prospectus and any amendments and supplements hereto, and (ii) the proxy solicitation firm engaged in connection with Rallybio&#8217;s stockholders&#8217; meeting),
<I>minus</I> (c)&nbsp;any severance or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> or payments (including associated payroll taxes) that become payable by Rallybio to any director, officer,
employee or consultant of Rallybio or any of its subsidiaries or other person in connection with the consummation of the Merger and related transactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The final
determination of Rallybio Net Cash at Closing is subject to numerous factors, many of which are outside of Rallybio&#8217;s control. If Rallybio and Candid cannot agree on the amount of Rallybio Net Cash, the amount of Rallybio Net Cash will be
determined by an independent auditor of recognized national standing jointly selected by Rallybio and Candid as set forth in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Treatment of
Candid Stock Options </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the Merger Agreement, each Candid stock option that is outstanding and unexercised immediately prior to the Effective
Time under the Candid 2024 Plan, whether or not vested, will be converted into and become an option to purchase shares of Rallybio Common Stock at the Effective Time. Rallybio will assume the Candid 2024 Plan and all such Candid stock options in
accordance with the terms of the Candid 2024 Plan and the terms of the stock option agreement by which such option is evidenced. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, from and after the
Effective Time: (i)&nbsp;each outstanding Candid stock option assumed by Rallybio may be exercised solely for shares of Rallybio Common Stock; (ii)&nbsp;the number of shares of Rallybio Common Stock subject to each outstanding Candid stock option
assumed by Rallybio will be determined by multiplying (A)&nbsp;the number of shares of Candid Common Stock that were subject to such Candid stock option, as in effect immediately prior to the Effective Time, by (B)&nbsp;the Exchange Ratio, and
rounding the resulting number down to the nearest whole number of shares of Rallybio Common Stock; (iii)&nbsp;the per share exercise price for the Rallybio Common Stock issuable upon exercise of each Candid stock option assumed by Rallybio will be
determined by dividing (A)&nbsp;the per share exercise price of such Candid stock option, as in effect immediately prior to the Effective Time, by (B)&nbsp;the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent;
and (iv)&nbsp;any restriction on the exercise of any Candid stock option assumed by Rallybio will continue in full force and effect and the term, exercisability, vesting schedule and any other provisions of such Candid stock option will otherwise
remain unchanged; provided, however, that the Rallybio Board or a committee thereof will succeed to the authority and responsibility of the Candid Board or any committee thereof with respect to each Candid stock option assumed by Rallybio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directors and Executive Officers of the Combined Company Following the Merger </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement provides that the parties will take all necessary action so that immediately after the Effective Time, the board of directors of the combined
company comprises seven members, with each member designated by Candid; provided, that the total number of directors to comprise the board of directors of the combined company immediately after the Effective Time may be changed by Candid at any time
prior to the Effective Time by written notice to Rallybio. The parties currently anticipate that Ken Song, M.D., President and Chief Executive Officer of Candid, will serve as the President and Chief Executive Officer of the combined company; Tim
Lu, M.D., Ph.D., Chief Medical Officer and Chief Scientific Officer of Candid, will serve as Chief Medical Officer and Chief Scientific Officer of the combined company; Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid, will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
serve as Chief Financial Officer and Chief Business Officer of the combined company; and Bernie Huyghe, Ph.D., Chief Technology Officer of Candid, will serve as Chief Technology Officer of the
combined company. For more information about the directors and executive officers of the combined company following the Merger, please see the section titled &#8220;<I>Management Following the Merger.</I>&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conditions to the Completion of the Merger </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The obligations of each party to
consummate the Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties of the following conditions: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">there must not have been any temporary restraining order, preliminary or permanent injunction or other order preventing
the consummation of the Contemplated Transactions issued by any court of competent jurisdiction or other governmental body of competent jurisdiction and that remains in effect, and no law may have made the consummation of the Contemplated
Transactions illegal; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio stockholders must have approved (i)&nbsp;the issuance of Rallybio Common Stock or other securities of
Rallybio that (a)&nbsp;represent (or are convertible into) more than 20% of the shares of Rallybio Common Stock outstanding immediately prior to the Merger to the holders of Candid Capital Stock and Candid stock options in connection with the
Contemplated Transactions pursuant to the Nasdaq rules and (b)&nbsp;result in the change of control of Rallybio resulting from the Merger, in each case pursuant to the Nasdaq rules, (ii)&nbsp;the amendment to Rallybio&#8217;s amended and restated
certificate of incorporation to (a)&nbsp;change the name of Rallybio to &#8220;Candid Therapeutics, Inc.&#8221;, (b)&nbsp;effect the reverse stock split and (c)&nbsp;subject to approval of the Authorized Share Increase Proposal, effect the
Authorized Share Increase. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid must have obtained the affirmative vote (or delivered an action by written consent) of the holders of a majority of
the outstanding shares of (i)&nbsp;Candid Preferred Stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Candid Common Stock basis (which majority shall include (A)&nbsp;the holders of a majority of
the outstanding shares of Candid Series B Preferred Stock, exclusively and as a separate class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Candid Common Stock basis and (B)&nbsp;the holders of a majority of the outstanding shares
of Candid Series A Preferred Stock, together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Candid Common Stock basis), (ii) Candid Common Stock, voting together as a single class, and (iii)&nbsp;Candid Capital
Stock, voting as a single class on an as converted to Candid Common Stock basis (collectively, the Required Candid Stockholder Vote): (a) adopting and approving the Merger Agreement and the Contemplated Transactions, (b)&nbsp;acknowledging that the
approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares of Candid Capital Stock pursuant to Section&nbsp;262 of the DGCL, a true and correct copy of which will be attached thereto,
and that such stockholder has received and read a copy of Section&nbsp;262 of the DGCL, and (c)&nbsp;acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares of Candid Capital Stock in
connection with the Merger and thereby waives any rights to receive payment of the fair value of its shares of Candid Capital Stock under the DGCL, and such Required Candid Stockholder Vote must remain in full force and effect and must not have been
revoked; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio charter amendment must have been duly filed with the Secretary of State of the State of Delaware;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the existing shares of Rallybio Common Stock must have been continually listed on Nasdaq as of and from the date of the
Merger Agreement through the Closing Date and the shares of Rallybio Common Stock to be issued in the Merger pursuant to the Merger Agreement must have been approved for listing (subject to official notice of issuance) on Nasdaq as of the Closing;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Subscription Agreement must have been in full force and effect and cash proceeds of not less than $200 million shall
have been received by Candid, or will be received by Candid substantially simultaneously with the Closing, in connection with the consummation of the transactions contemplated by the Subscription Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">this registration statement must have become effective in accordance with the Securities Act and must not be subject to
any stop order or proceeding (or threatened proceeding by the SEC) seeking a stop order with respect to this registration statement that has not been withdrawn; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio Net Cash must have been finally determined in accordance with the Merger Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all waiting periods (and extensions thereof) applicable to the Merger under the HSR Act must have expired or otherwise
been terminated, which occurred at 11:59&nbsp;p.m., Eastern Time, on April&nbsp;13, 2026. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the obligation of Rallybio and Merger
Sub to consummate the Merger is further subject to the satisfaction or waiver of the following conditions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the representations and warranties of Candid set forth in the Merger Agreement under clause (y)&nbsp;of Section&nbsp;2.8
(i.e., the absence of any Candid Material Adverse Effect between September&nbsp;30, 2025 and the date of the Merger Agreement) must have been true and correct in all respects as of the date of the Merger Agreement and must be true and correct as of
the Closing Date with the same force and effect as if made on and as of such date; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the representations and warranties of Candid set forth in the Merger Agreement under Sections 2.1(a) (<I>Organization,
Standing and Power</I>), 2.2 (<I>Capital Stock</I>), 2.3 (<I>Subsidiaries</I>), 2.4 (<I>Authority</I>) and 2.24 (<I>Brokers</I>) must have been true and correct in all material respects as of the date of the Merger Agreement and must be true and
correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case
such representations and warranties must have been true and correct in all material respects as of such date); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all other representations and warranties of Candid set forth in the Merger Agreement must have been true and correct as of
the date of the Merger Agreement and must be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date, except (a)&nbsp;in each case, or in the aggregate, where the failure to be so true
and correct would not reasonably be expected to have an Candid Material Adverse Effect (as defined below) (without giving effect to any references therein to any Candid Material Adverse Effect or other materiality qualifications) or (b)&nbsp;for
those representations and warranties which address matters only as of a particular date (which representations must have been true and correct, subject to the qualifications set forth in the preceding clause (a), as of such particular date);
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid must have performed or complied with in all material respects all agreements and covenants required to be performed
or complied with by it under the Merger Agreement at or prior to the Effective Time; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio must have received from Candid (i)&nbsp;an officer&#8217;s certificate certifying (x)&nbsp;that certain
conditions set forth in the Merger Agreement have been duly satisfied and (y)&nbsp;that the information set forth in an allocation certificate delivered by Candid containing information regarding Candid&#8217;s capitalization is true and accurate in
all respects; and (ii)&nbsp;a copy of such allocation certificate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio must have received (i)&nbsp;an original signed statement from Candid that Candid is not, and has not been at any
time during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code, a &#8220;United States real property holding corporation,&#8221; as defined in Section&nbsp;897(c)(2) of the Code, conforming to the requirements of Treasury
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1445-2(c)(3)</FONT> and <FONT STYLE="white-space:nowrap">1.897-2(h),</FONT> and (ii)&nbsp;an original signed notice from Candid to be delivered to the IRS in accordance with the provisions
of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h)(2),</FONT> together with written authorization for Rallybio to deliver such notice to the IRS on behalf of Candid following the Closing, each dated as of the Closing
Date, duly executed by an authorized officer of Candid, and in form and substance reasonably acceptable to Rallybio; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">since the date of the Merger Agreement, there must not have occurred and be continuing any Effect that, considered
together with all other Effects, has or would reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Candid, taken as a whole (a &#8220;Candid
Material Adverse Effect&#8221;); <I>provided</I>, <I>however</I>, that any effects arising or resulting from the following will not be taken into account in determining whether there has been a Candid Material Adverse Effect: (a)&nbsp;general
business, political, or economic conditions generally affecting the industry in which Candid operates, including with respect to the imposition of, or adjustments to, tariffs or other trade restrictions; (b)&nbsp;acts of war, the outbreak or
escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics and related or associated epidemics, disease outbreaks or quarantine restrictions;
(c)&nbsp;changes in financial, banking or securities markets; (d)&nbsp;any change in, or any compliance with or action taken for the purpose of complying with, any law or GAAP (or interpretations of any law or GAAP); (e)&nbsp;the announcement of the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
Merger Agreement or the pendency of the Contemplated Transactions; (f)&nbsp;resulting from the taking of any action expressly required to be taken by the Merger Agreement; or (g)&nbsp;continued
losses from operations or decreases in cash balances of Candid; except, with respect to clauses&nbsp;(a) through (d), to the extent such Effect disproportionately affects Candid, taken as a whole, relative to other similarly situated companies in
the industries in which Candid operates, in which case, such Effect shall be taken into account to the extent of such disproportionate effect on Candid; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain of Candid&#8217;s investor agreements must have been terminated (or will be terminated as of the Closing); and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio must have received duly executed copies of the required <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreements from certain stockholders of Candid and each executive officer and director of Candid who is elected or appointed, as applicable, as an executive officer or director of Rallybio as of immediately following the Closing, each of which must
be in full force and effect as of the Closing. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the obligation of Candid to consummate the Merger is further subject to the
satisfaction or waiver of the following conditions: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the representations and warranties of Rallybio set forth in the Merger Agreement under clause (y)&nbsp;of Section&nbsp;3.8
(i.e., the absence of any Rallybio Material Adverse Effect between September&nbsp;30, 2025 and the date of the Merger Agreement) must have been true and correct in all respects as of the date of the Merger Agreement and must be true and correct as
of the Closing Date with the same force and effect as if made on and as of such date; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the representations and warranties of Rallybio set forth in the Merger Agreement under Sections&nbsp;3.1(a)
(<I>Organization, Standing and Power</I>), 3.2(a) and (b) (<I>Capital Stock</I>), 3.4 (<I>Authority</I>) and 3.22 (<I>Brokers</I>) must have been true and correct in all material respects as of the date of the Merger Agreement and must be true and
correct in all material respects on and as of the Closing with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such
representations and warranties must have been true and correct in all material respects as of such date). </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">All other representations and warranties of Rallybio set forth in the Merger Agreement must have been true and correct as
of the date of the Merger Agreement and must be true and correct on and as of the Closing with the same force and effect as if made on and as of the Closing Date, except (a)&nbsp;in each case, or in the aggregate, where the failure to be so true and
correct would not reasonably be expected to have an Rallybio Material Adverse Effect (as defined below) (without giving effect to any references therein to any Rallybio Material Adverse Effect or other materiality qualifications) or (b)&nbsp;for
those representations and warranties which address matters only as of a particular date (which representations must have been true and correct, subject to the qualifications set forth in the preceding clause (a), as of such particular date);
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio and Merger Sub must have performed or complied with in all material respects all of their agreements and
covenants required to be performed or complied with by each of them under the Merger Agreement at or prior to the Effective Time; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid must have received from Rallybio (i)&nbsp;an officer&#8217;s certificate confirming that certain conditions of the
Merger Agreement have been duly satisfied; (ii)&nbsp;a certificate containing information regarding Rallybio&#8217;s capitalization; (iii)&nbsp;the Rallybio closing financial certificate certifying Rallybio Net Cash as of the Anticipated Closing
Date (as defined in the Merger Agreement), a draft of which must have been provided at least five business days prior to Closing, which certificate will be accompanied by such supporting documentation, information and calculations as are reasonably
requested by Candid to verify and determine the information contained therein; (iv)&nbsp;and a written resignation executed by the directors of Rallybio who will not continue as directors of Rallybio after the Closing; and (v)&nbsp;the executed CVR
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">since the date of the Merger Agreement, there must not have occurred and be continuing any effect that, considered
together with all other effects, has or would reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Rallybio or its subsidiaries, taken as a
whole (a &#8220;Rallybio Material Adverse Effect&#8221;); provided, however, that any effects arising or resulting from the following will not be taken into account in determining whether
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
there has been a Rallybio Material Adverse Effect: (a)&nbsp;general business, political or economic conditions generally affecting the industry in which Rallybio or any of its subsidiaries
operate, including with respect to the imposition of, or adjustments to, tariffs or other trade restrictions; (b)&nbsp;acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other
natural disasters, health emergencies, including pandemics and related or associated epidemics, disease outbreaks or quarantine restrictions; (c)&nbsp;changes in financial, banking or securities markets; (d)&nbsp;any change in, or any compliance
with or action taken for the purpose of complying with, any law or GAAP (or interpretations of any law or GAAP); (e) any change in the stock price or trading volume of Rallybio Common Stock (it being understood, however, that any Effect causing or
contributing to any change in stock price or trading volume of Rallybio Common Stock may be taken into account in determining whether a Rallybio Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition);
(f) the failure of Rallybio to meet internal or analysts&#8217; expectations or projections or the results of operations of Rallybio (it being understood, however, that any Effect causing or contributing to the failure of Rallybio to meet internal
or analysts&#8217; expectations or projections or the results of operations of Rallybio may be taken into account in determining whether a Rallybio Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this
definition); (g) any changes in or affecting clinical trial programs or studies conducted by or on behalf of Rallybio or its subsidiaries, including any adverse data, event or outcome arising out of or related to any such programs or studies;
(h)&nbsp;the announcement of the Merger Agreement or the pendency of the Contemplated Transactions; (i)&nbsp;the Asset Dispositions; (j)&nbsp;any reduction in the amount of Rallybio&#8217;s cash and cash equivalents as a result of expenditures made
by Rallybio related to wind down activities of Rallybio associated with the termination of its research and development activities (including the termination of ongoing contractual obligations relating to Rallybio current products or product
candidates); or (k)&nbsp;the taking of any action expressly required to be taken by the Merger Agreement; except, with respect to clauses (a)&nbsp;through (d), to the extent disproportionately affecting Rallybio and its subsidiaries, taken as a
whole, relative to other similarly situated companies in the industries in which Rallybio and its subsidiaries operate, in which case, such Effect will be taken into account to the extent of such disproportionate effect on Rallybio and its
subsidiaries; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rallybio Net Cash at Closing (as determined in accordance with the Merger Agreement) must have been greater than or equal
to $0, and Rallybio&#8217;s cash and cash equivalents as of the Closing Date (as determined in accordance with the Merger Agreement) must be greater than or equal to $1.0&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Asset Dispositions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to Closing, Rallybio will use reasonable best
efforts to sell, transfer, license, assign or otherwise divest its intellectual property and other assets and technology in existence on the date of the Merger Agreement (the &#8220;Potentially Transferrable Assets&#8221;) to one or more third
parties in one or a series of transactions immediately following the Closing (the &#8220;Asset Dispositions&#8221;). Rallybio may, in contemplation of the Asset Dispositions, (a)&nbsp;establish one or more subsidiaries to hold the Potentially
Transferable Assets, (b)&nbsp;transfer to any such subsidiary any or all of the Potentially Transferable Assets and the liabilities and obligations related thereto and (c)&nbsp;take such other steps that are reasonably necessary to prepare for the
Asset Dispositions. If Rallybio transfers the Potentially Transferable Assets to one or more subsidiaries, the subsidiaries shall be subject to the same terms as Rallybio. Notwithstanding the foregoing, any such Asset Disposition shall require, to
the extent consistent with applicable laws, the prior written consent of Candid (not to be unreasonably withheld, conditioned or delayed) if such Asset Disposition would create any <FONT STYLE="white-space:nowrap">post-disposition</FONT> liabilities
or indemnity obligations for Rallybio following the Closing; <I>provided</I>, <I>however</I>, that the prior written consent of Candid shall not be required in connection with any Asset Disposition if Rallybio agrees that the maximum aggregate
dollar value of any post-disposition liabilities or indemnity obligation shall be considered as a reduction to Rallybio Net Cash as set forth in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Representations and Warranties </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement contains customary
representations and warranties of the parties. Candid represents and warrants to the following matters: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Organization, Standing and Power </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Capital Stock </P></TD></TR></TABLE> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Subsidiaries </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Authority </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No Conflict; Consents and Approvals </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Financial Statements </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No Undisclosed Liabilities </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Absence of Certain Changes or Events </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Litigation </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Compliance with Laws </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Health Care Regulatory Matters </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Benefit Plans </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Labor and Employment Matters </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Environmental Matters </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Taxes </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Contracts </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Insurance </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Properties </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Intellectual Property </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">State Takeover Statues </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No Rights Plan </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Related Party Transactions </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Certain Payments </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Brokers </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Concurrent Financing Compliance </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No Other Representations or Warranties </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio and Merger Sub represent and warrant to the following matters: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Organization, Standing and Power </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Capital Stock </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Subsidiaries </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Authority </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No Conflict; Consents and Approvals </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">SEC Reports; Financial Statements </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No Undisclosed Liabilities </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Absence of Certain Changes or Events </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Litigation </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Compliance with Laws </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Health Care Regulatory Matters </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Benefit Plans </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Labor and Employment Matters </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Environmental Matters </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Taxes </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Contracts </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Insurance </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Properties </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Intellectual Property </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Related Party Transactions </P></TD></TR></TABLE> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Certain Payments </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Brokers </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Opinion of Financial Advisor&#8195; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Merger Sub&#8195; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">State Takeover Statues </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No Other Representations or Warranties&#8195; </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The representations and warranties of Candid, Rallybio and Merger Sub contained in the Merger Agreement or any certificate or instrument delivered pursuant to the
Merger Agreement will terminate at the Effective Time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Capitalized terms in this section are as defined in the section titled &#8220;<I>The Merger
<FONT STYLE="white-space:nowrap">Agreement&#8212;Non-Solicitation</FONT></I>.&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT>
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio and its subsidiaries and their respective representatives are prohibited by the terms of the Merger Agreement, other than with respect to any
Asset Disposition, from, directly or indirectly, (i)&nbsp;soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any Acquisition Proposal (as defined below) or Acquisition
Inquiry (as defined below) or taking any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)&nbsp;furnishing any <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Rallybio
or any of its subsidiaries to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii)&nbsp;engaging in discussions (other than to inform any person of the existence of these prohibitions) or negotiations
with any person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv)&nbsp;approving, endorsing or recommending any Acquisition Proposal; (v)&nbsp;executing or entering into any letter of intent or any contract contemplating or
otherwise relating to any Acquisition Transaction (as defined below) (other than a confidentiality agreement permitted as described below); or (vi)&nbsp;publicly proposing to do any of the foregoing; <I>provided, however, </I>that, notwithstanding
the foregoing, subject to compliance with the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> obligations set forth in Section&nbsp;4.4 of the Merger Agreement, and prior to obtaining the Required Rallybio Stockholder Vote, Rallybio and its
subsidiaries may furnish <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Rallybio or any of its subsidiaries to, and enter into discussions or negotiations with, any person in response to a bona fide Acquisition Proposal by
such person, which the Rallybio Board has determined in good faith, after consultation with the Rallybio&#8217;s outside financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not
withdrawn) if: (A)&nbsp;none of Rallybio, any of its subsidiaries or any of their respective representatives shall have breached Section&nbsp;4.4 of the Merger Agreement in any material respect, (B)&nbsp;the Rallybio Board concludes in good faith
based on the advice of outside legal counsel, that the failure to take such action would be inconsistent with the fiduciary duties of the Rallybio Board under applicable law; (C)&nbsp;Rallybio receives from such person an executed confidentiality
agreement containing provisions, in the aggregate, at least as favorable to Rallybio as those contained in the Confidentiality Agreement; and (D)&nbsp;substantially contemporaneously with furnishing any such
<FONT STYLE="white-space:nowrap">non-public</FONT> information to such person, Rallybio gives Candid notice of Rallybio&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such person and furnishes such <FONT
STYLE="white-space:nowrap">non-public</FONT> information to Rallybio (to the extent such information has not been previously furnished by Rallybio to Candid). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If
Rallybio, any of its subsidiaries or any of their respective representatives, receives an Acquisition Proposal or Acquisition Inquiry during the period following the date of the Merger Agreement through the Closing, then Rallybio will promptly (and
in no event later than one business day after Rallybio becomes aware of such Acquisition Proposal or Acquisition Inquiry)&nbsp;(i) advise Candid orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the
person making or submitting such Acquisition Proposal or Acquisition Inquiry), (ii) in the case of a written Acquisition Proposal or Acquisition Inquiry, furnish any written documentation and correspondence to or from Rallybio or any of its
subsidiaries or any of their respective representatives, including any subsequent modifications or amendments, and (iii)&nbsp;in the case of an oral Acquisition Proposal or Acquisition Inquiry, provide a written summary of the terms thereof.
Rallybio will keep Candid reasonably and promptly informed with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification, amendment or proposed material modification thereto
(including any revision in the amount, form or mix of consideration) and of all verbal or written communications related thereto, together with copies of new written </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
documentation and correspondence to or from Rallybio, any of its subsidiaries or any of their respective representatives as well as written summaries of any material oral communications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the terms of the Merger Agreement, Rallybio agreed to immediately cease and cause to be terminated any existing discussions, negotiations and communications
with any person relating to any Acquisition Proposal or Acquisition Inquiry (other than any Asset Dispositions) as of the date of the Merger Agreement, immediately terminate access to any <FONT STYLE="white-space:nowrap">non-public</FONT>
information provided to such person via an electronic or physical data room and within three business days after the date of the Merger Agreement, request the destruction or return of any of such party&#8217;s nonpublic information provided to such
person as soon as practicable after the date of the Merger Agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid and its subsidiaries and their respective representatives are prohibited by the terms of the Merger Agreement from, directly or indirectly, (i)&nbsp;soliciting,
initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any Acquisition Proposal (as defined below) or Acquisition Inquiry (as defined below) or taking any action that could reasonably
be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)&nbsp;furnishing any <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Candid or any of its subsidiaries to any person in connection with or in
response to an Acquisition Proposal or Acquisition Inquiry; (iii)&nbsp;engaging in discussions (other than to inform any person of the existence of these prohibitions) or negotiations with any person with respect to any Acquisition Proposal or
Acquisition Inquiry; (iv)&nbsp;approving, endorsing or recommending any Acquisition Proposal; (v)&nbsp;executing or entering into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction; or
(vi)&nbsp;publicly proposing to do any of the foregoing; <I>provided, however, </I>that, notwithstanding the foregoing, subject to compliance with the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> obligations set forth in Section&nbsp;4.5
of the Merger Agreement, and prior to obtaining the Required Candid Stockholder Vote, Candid and its subsidiaries may solicit any Acquisition Proposal and furnish <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Candid or any
of its subsidiaries to, and enter into discussions or negotiations with, any person, including any person not making such Acquisition Proposal, following receipt of a bona fide Acquisition Proposal by any person, which the Candid Board has
determined in good faith, after consultation with the Candid&#8217;s outside financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer if: (A)&nbsp;none of Candid, any of its subsidiaries or
any of their respective Representatives shall have breached Section&nbsp;4.5 of the Merger Agreement in any material respect, (B)&nbsp;the Candid Board concludes in good faith based on the advice of outside legal counsel, that the failure to take
such action would be inconsistent with the fiduciary duties of the Candid Board under applicable law; and (C)&nbsp;Candid receives from such person an executed confidentiality agreement containing provisions, in the aggregate, at least as favorable
to Candid as those contained in the Confidentiality Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Candid, any of its subsidiaries or any of their respective representatives, receives an
Acquisition Proposal during the period following the date of the Merger Agreement through the Closing, then Candid will promptly (and in no event later than one business day after Candid becomes aware of such Acquisition Proposal)&nbsp;(i) advise
Rallybio orally and in writing of such Acquisition Proposal (including the identity of the person making or submitting such Acquisition Proposal), (ii) in the case of a written Acquisition Proposal, furnish any written documentation and
correspondence to or from Candid, any of its subsidiaries or any of their respective representatives, including any subsequent modifications or amendments, and (iii)&nbsp;in the case of an oral Acquisition Proposal, provide a written summary of the
terms thereof. Candid will keep Rallybio reasonably and promptly informed with respect to the status and material terms of any such Acquisition Proposal and any material modification, amendment or proposed material modification thereto (including
any revision in the amount, form or mix of consideration) and of all verbal or written communications related thereto, together with copies of new written documentation and correspondence to or from Candid or any of its subsidiaries or any of their
respective representatives as well as written summaries of any material oral communications). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the terms of the Merger Agreement, Candid agreed to
immediately cease any existing discussions, negotiations and communications with any person that relate to any Acquisition Proposal or Acquisition Inquiry that has not already been terminated as of the date of the Merger Agreement, immediately
terminate access to any <FONT STYLE="white-space:nowrap">non-public</FONT> information of Candid provided to such person via an electronic or physical data room. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#8220;Acquisition Inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of
interest or request for information made or submitted by Candid or any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
affiliates, on the one hand, or Rallybio or any of its affiliates, on the other hand, to the other party) that could reasonably be expected to lead to an Acquisition Proposal; <I>provided,
however</I>, that the term &#8220;Acquisition Inquiry&#8221; shall not include the Merger or the other Contemplated Transactions or any transactions related to the Asset Dispositions or Concurrent Financing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#8220;Acquisition Proposal&#8221; means, with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by
or on behalf of Candid or any of its affiliates, on the one hand, or by or on behalf of Rallybio or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to any Acquisition Transaction with such party,
other than the Asset Dispositions and the Concurrent Financing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions
(other than the Asset Dispositions and the Concurrent Financing) involving: any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender
offer, exchange offer or other similar transaction: (i)&nbsp;in which a party is a constituent entity; (ii)&nbsp;in which a person or &#8220;group&#8221; (as defined in the Exchange Act) of persons directly or indirectly acquires beneficial or
record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a party or any of its subsidiaries; or (iii)&nbsp;in which a party or any of its subsidiaries issues securities representing
more than 20% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries; or (y)&nbsp;any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that
constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a party and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#8220;Superior Offer&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being
treated as references to greater than 50% for these purposes) that: (a)&nbsp;was not obtained or made as a result of a breach of (or in violation of) the Merger Agreement; and (b)&nbsp;is on terms and conditions that the Rallybio Board or Candid
Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by Candid or Rallybio, as applicable, to
amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and outside financial advisors, are more favorable, from a financial point of view, to Rallybio&#8217;s stockholders or Candid&#8217;s stockholders,
as applicable, than the terms of the Contemplated Transactions and is not subject to any financing condition (and if financing is required, such financing is then fully committed to the third party). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rallybio Stockholder Meeting </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Promptly after the registration statement has
been declared effective by the SEC under the Securities Act, Rallybio will take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of Rallybio Common Stock for the purpose of seeking approval of:
(i)&nbsp;the issuance of Rallybio Common Stock or other securities of Rallybio that represent (or are convertible into) more than 20% of the shares of Rallybio Common Stock outstanding immediately prior to the Merger to the holders of Candid Capital
Stock and Candid stock options in connection with the Contemplated Transactions and the change of control of Rallybio resulting from the Contemplated Transactions, in each case pursuant to the Nasdaq rules, (ii)&nbsp;the approval of the Rallybio
charter amendment to (A)&nbsp;change the name of Rallybio to &#8220;Candid Therapeutics, Inc.,&#8221; (B) effect the reverse stock split (the matters contemplated by foregoing clauses (i)&nbsp;and (ii), (the &#8220;Rallybio Stockholder
Matters&#8221;)) and (iii)&nbsp;effect an increase of the number of authorized shares of Rallybio Common Stock to a number determined by Candid (the &#8220;Authorized Share Increase Proposal&#8221;), (iv) the combined company&#8217;s 2026 Equity
Incentive Plan, (v)&nbsp;the combined company&#8217;s 2026 Employee Stock Purchase Plan and (vi)&nbsp;any other proposals the parties deem necessary to consummate the Contemplated Transactions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio stockholders&#8217; meeting will be held as promptly as practicable after the registration statement is declared effective under the Securities Act and, in
any event, no later than forty-five calendar days after the effective date of the registration statement. Rallybio will take reasonable measures to ensure that all proxies solicited in connection with the Rallybio stockholders&#8217; meeting are
solicited in compliance with all applicable laws. If, on or before the date of the Rallybio stockholders&#8217; meeting, Rallybio reasonably believes that it (i)&nbsp;will not receive proxies sufficient to obtain the required approvals of the
Required Rallybio Closing Stockholder Matters (the &#8220;Required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Rallybio Stockholder Vote&#8221;) or the approval of the Authorized Share Increase Proposal, whether or not a quorum would be present or (ii)&nbsp;will not have sufficient shares of Rallybio
Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Rallybio stockholders&#8217; meeting, Rallybio may postpone or adjourn, or make one or more successive postponements or
adjournments of, the Rallybio stockholders&#8217; meeting as long as the date of the Rallybio stockholders&#8217; meeting is not postponed or adjourned more than an aggregate of thirty calendar days in connection with any postponements or
adjournments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio agreed that, subject to certain exceptions in the Merger Agreement: (i)&nbsp;the Rallybio Board will recommend that the holders of Rallybio
Common Stock vote to approve the Rallybio Stockholder Matters, the Authorized Share Increase Proposal, and the Equity Plan Proposals will use commercially reasonable efforts to solicit such approval within the timeframe set forth above,
(ii)&nbsp;this proxy statement/prospectus will include a statement to the effect that the Rallybio Board recommends that Rallybio&#8217;s stockholders vote to approve the Rallybio Stockholder Matters, the Authorized Share Increase Proposal, and the
Equity Plan Proposals (the recommendation of the Rallybio Board with respect to the Rallybio Stockholder Matters being referred to as the &#8220;Rallybio Board Recommendation&#8221;); (iii) the Rallybio Board Recommendation will not be withheld,
amended, withdrawn or modified (and the Rallybio Board will not publicly propose to withhold, amend, withdraw or modify the Rallybio Board Recommendation), and no resolution by the Rallybio Board or any committee thereof to withdraw or modify the
Rallybio Board Recommendation or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed; and (iv)&nbsp;the Rallybio Board will not publicly announce an intention or
resolution to effect any of the foregoing (the actions set forth in the foregoing clause (iii), collectively, a &#8220;Rallybio Board Adverse Recommendation Change&#8221;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The terms of the Merger Agreement provide that, subject to the limitations set forth in the Merger Agreement, if at any time prior to the approval of the Rallybio
Stockholder Matters at the Rallybio stockholder meeting by the Required Rallybio Stockholder Vote, Rallybio receives a <I>bona fide</I> Acquisition Proposal (which did not arise out of a material breach of the
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions of the Merger Agreement) from any person that has not been withdrawn and after consultation with outside legal counsel, the Rallybio Board determines, in good faith, that such
Acquisition Proposal is a Superior Offer, the Rallybio Board may make a Rallybio Board Adverse Recommendation Change if and only if: (A)&nbsp;the Rallybio Board determines in good faith, after consultation with Rallybio&#8217;s outside legal counsel
and financial advisor, that the failure to do so would be inconsistent with the fiduciary duties of the Rallybio Board to Rallybio&#8217;s stockholders under applicable law; (B)&nbsp;Rallybio has given Candid prior written notice of its intention to
consider making a Rallybio Board Adverse Recommendation Change at least four business days prior to making any such Rallybio Board Adverse Recommendation Change (a &#8220;Rallybio Determination Notice,&#8221; and such period, the &#8220;Rallybio
Notice Period&#8221;) (which notice will not constitute a Rallybio Board Adverse Recommendation Change); and (C)(1) Rallybio provided to Candid a description in reasonable detail of the reasons for such Rallybio Board Adverse Recommendation Change
(as defined in the Merger Agreement), the identity of the party making the Acquisition Proposal, a summary of the material terms and conditions of the Acquisition Proposal and written copies of any relevant proposed transaction documents (including
with respect to financing arrangements) in accordance with the Merger Agreement, (2)&nbsp;Rallybio has given Candid the three business days after a Rallybio Determination Notice to propose revisions to the terms of the Merger Agreement or make
another proposal and has made its representatives reasonably available to negotiate in good faith with Candid (to the extent Candid desires to negotiate) with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after
considering the results of any such negotiations and giving effect to the proposals made by Candid, if any, after consultation with outside legal counsel, the Rallybio Board determines, in good faith, that such Acquisition Proposal is a Superior
Offer and that the failure to make the Rallybio Board Adverse Recommendation Change would be inconsistent with the fiduciary duties of the Rallybio Board to Rallybio&#8217;s stockholders under applicable law; provided that during any Rallybio Notice
Period, Candid shall be entitled to deliver to Rallybio one or more counterproposals to such Acquisition Proposal and Rallybio will, and will cause its representatives to, negotiate with Candid in good faith (to the extent Candid desires to
negotiate) to enable Candid to propose in writing an offer binding on Candid to effect such adjustments to the terms and conditions of the Merger Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer. The
provisions of the Merger Agreement described in this paragraph also apply to any material change to the facts and circumstances relating to such Acquisition Proposal or any amendment to such Acquisition Proposal (including any revision in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
amount, form or mix of consideration), and require a new Rallybio Determination Notice and Rallybio will be required to provide Candid with notice of such material change or amendment, except
that the references to four business days will be deemed to be two business days. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The terms of the Merger Agreement also provide that, other than in connection
with an Acquisition Proposal, the Rallybio Board may make a Rallybio Board Adverse Recommendation Change in response to a Rallybio Change in Circumstance (as defined below), if and only if: (A)&nbsp;the Rallybio Board determines in good faith, after
consultation with the Rallybio&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary duties of the Rallybio Board to Rallybio&#8217;s stockholders under applicable law; (B)&nbsp;Rallybio has given Candid a
Rallybio Determination Notice at least four business days prior to making any such Rallybio Board Adverse Recommendation Change; and (C)&nbsp;(1) Rallybio has specified the Rallybio Change in Circumstance in reasonable detail, including the material
facts and circumstances related to the applicable Rallybio Change in Circumstance, (2)&nbsp;Rallybio has given Candid three business days after the Rallybio Determination Notice to propose revisions to the terms of the Merger Agreement or make
another proposal, and has made its representatives reasonably available to negotiate in good faith with Candid (to the extent Candid desires to do so) with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering
the results of any such negotiations and giving effect to the proposals made by Candid, if any, after consultation with outside legal counsel, the Rallybio Board determines, in good faith, that the failure to make the Rallybio Board Adverse
Recommendation Change in response to such Rallybio Change in Circumstance would be inconsistent with the fiduciary duties of the Rallybio Board to Rallybio&#8217;s stockholders under applicable law. The provisions of the Merger Agreement described
in this paragraph also apply to any material change to the facts and circumstances relating to such Rallybio Change in Circumstance and require a new Rallybio Determination Notice and Rallybio will be required to provide Candid with notice of such
material change, except that the references to four business days will be deemed to be two business days. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#8220;Rallybio Change in Circumstance&#8221; means a
change in circumstances (other than any such event, development or change to the extent related to (A)&nbsp;any Acquisition Proposal, Acquisition Inquiry or the consequences thereof, or (B)&nbsp;the fact, in and of itself, that Rallybio meets or
exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of Rallybio or any of its subsidiaries that occurs or arises after the
date of the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Candid Stockholder Action by Written Consent </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement contemplates that promptly after this registration statement is declared effective under the Securities Act, and in any event no later than three
business days thereafter, Candid will prepare, with the cooperation of Rallybio, and cause to be delivered to its stockholders an information statement to solicit the approval by written consent from the Candid Signatories, including Candid&#8217;s
stockholders sufficient for the Required Candid Stockholder Vote in lieu of a meeting pursuant to Section&nbsp;228 of the DGCL, for purposes of approving the Candid Stockholder Matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid agreed that: (i)&nbsp;the Candid Board will recommend that the Candid stockholders vote to approve the Candid Stockholder Matters and will use reasonable best
efforts to solicit such approval from Candid&#8217;s stockholders within the timeframe set forth above (the recommendation of the Candid Board that Candid&#8217;s stockholders vote to adopt and approve the Candid Stockholder Matters being referred
to as the &#8220;Candid Board Recommendation&#8221;); and (ii)&nbsp;the Candid Board Recommendation will not be withdrawn or modified (and the Candid Board will not publicly propose to withdraw or modify the Candid Board Recommendation), and no
resolution by the Candid Board or any committee thereof to withdraw or modify the Candid Board Recommendation or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal will be adopted or proposed
(the actions set forth in the foregoing clause (ii), if taken, constituting, in each case, a &#8220;Candid Board Adverse Recommendation Change&#8221;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding the foregoing, if at any time prior to the approval of Candid Stockholder Matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If Candid has received a bona fide Acquisition Proposal (which Acquisition Proposal did not arise out of a material breach
of Section&nbsp;4.5 of the Merger Agreement) from any person that has not been withdrawn and after consultation with outside legal counsel, Candid Board shall have determined, in good faith, that such
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
Acquisition Proposal is a Superior Offer, Candid Board may make a Candid Board Adverse Recommendation Change if and only if: (A)&nbsp;Candid Board determines in good faith, after consultation
with Candid&#8217;s outside legal counsel and financial advisor, that the failure to do so would be inconsistent with the fiduciary duties of Candid Board to Candid&#8217;s stockholders under applicable law; (B)&nbsp;Candid shall have given Rallybio
prior written notice of its intention to consider making a Candid Board Adverse Recommendation Change at least four Business Days prior to making any such Candid Board Adverse Recommendation Change (a &#8220;Candid Determination Notice&#8221;; and
such period the &#8220;Candid Notice Period&#8221;) (which notice shall not constitute a Candid Board Adverse Recommendation Change); and (C) (1)&nbsp;Candid shall have provided to Rallybio a description in reasonable detail of the reasons for such
Candid Board Adverse Recommendation Change the identity of the party making the Acquisition Proposal, a summary of the material terms and conditions of the Acquisition Proposal and written copies of any relevant proposed transaction documents
(including with respect to financing arrangements), in accordance with Section&nbsp;4.5(b), (2)&nbsp;Candid shall have given Rallybio the three business days after Candid Determination Notice to propose revisions to the terms of the Merger Agreement
or make another proposal and shall have made its representatives reasonably available to negotiate in good faith with Rallybio (to the extent Rallybio desires to negotiate) with respect to such proposed revisions or other proposal, if any, and
(3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals made by Rallybio, if any, after consultation with outside legal counsel, Candid Board shall have determined, in good faith, that such Acquisition
Proposal is a Superior Offer and that the failure to make Candid Board Adverse Recommendation Change would be inconsistent with the fiduciary duties of Candid Board to Candid&#8217;s stockholders under applicable law; provided during any Candid
Notice Period, Rallybio shall be entitled to deliver to Candid one or more counterproposals to such Acquisition Proposal and Candid will, and cause its representatives to, negotiate with Rallybio in good faith (to the extent Rallybio desires to
negotiate) to enable Rallybio to propose in writing an offer binding on Rallybio to effect such adjustments to the terms and conditions of the Merger Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer. For
the avoidance of doubt, the provisions of this Section&nbsp;5.2(e)(i) shall also apply to any material change to the facts and circumstances relating to such Acquisition Proposal or any amendment to such Acquisition Proposal (including any revision
in the amount, form or mix of consideration), and require a new Candid Determination Notice and Candid shall be required to provide Rallybio with notice of such material change or amendment, except that the references to four business days shall be
deemed to be two business days. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Other than in connection with an Acquisition Proposal, Candid Board may make a Candid Board Adverse Recommendation Change
in response to a Candid Change in Circumstance, if and only if: (A)&nbsp;Candid Board determines in good faith, after consultation with Candid&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary duties
of Candid Board to Candid&#8217;s stockholders under applicable law; (B)&nbsp;Candid shall have given Rallybio a Candid Determination Notice at least four business days prior to making any such Candid Board Adverse Recommendation Change; and (C)
(1)&nbsp;Candid shall have specified Candid Change in Circumstance in reasonable detail, including the material facts and circumstances related to the applicable Candid Change in Circumstance, (2)&nbsp;Candid shall have given Rallybio the three
business days after Candid Determination Notice to propose revisions to the terms of the Merger Agreement or make another proposal, and shall have made its representatives reasonably available to negotiate in good faith with Rallybio (to the extent
Rallybio desires to do so) with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals made by Rallybio, if any, after consultation with
outside legal counsel, Candid Board shall have determined, in good faith, that the failure to make Candid Board Adverse Recommendation Change in response to such Candid Change in Circumstance would be inconsistent with the fiduciary duties of Candid
Board to Candid&#8217;s stockholders under applicable law. For the avoidance of doubt, the provisions of this 5.2(e)(ii) shall also apply to any material change to the facts and circumstances relating to such Candid Change in Circumstance, and
require a new Candid Determination Notice and Candid shall be required to provide Rallybio with notice of such material change, except that the references to four business days shall be deemed to be two Business Days. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless the Merger Agreement is otherwise terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1</U> of the Merger Agreement, Candid&#8217;s obligation to solicit the
consent of its stockholders to sign Candid Stockholder Written Consent shall not be limited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or by any Candid Board Adverse Recommendation Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Appraisal Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the DGCL, Rallybio stockholders are not entitled to
appraisal rights in connection with the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid stockholders are entitled to statutory appraisal rights in connection with the Merger under Section&nbsp;262
of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Covenants; Operation of Business Pending the Merger </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operation of Rallybio&#8217;s Business </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the period from the
date of the Merger Agreement and continuing until the earlier of the termination of the Merger Agreement or the Effective Time, except (i)&nbsp;as set forth in Rallybio&#8217;s disclosure schedule, (ii)&nbsp;expressly permitted or required in
accordance with the Merger Agreement including in connection with the Asset Dispositions, (iii)&nbsp;as required by applicable law, or (iv)&nbsp;as may be consented to in writing by Candid (not be unreasonably withheld, conditioned or delayed), each
of Rallybio and its subsidiaries has agreed to (A)&nbsp;conduct its business and operations in the ordinary course of business (which includes actions required to effect the Asset Dispositions or effect the winding down of Rallybio&#8217;s <FONT
STYLE="white-space:nowrap">pre-clinical,</FONT> CMC and clinical activities) and in compliance in all material respects with all applicable laws and the requirements of all of its material contracts and (B)&nbsp;continue to pay material outstanding
accounts payable and other material current liabilities (including payroll) in the ordinary course of business, and will not: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital
stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except repurchases from terminated employees, directors or consultants of Rallybio or in connection with the payment of the exercise price and/or
withholding taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under any Rallybio equity incentive plan in accordance with the terms of such award in effect on the date of the Merger Agreement);
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to:
(A)&nbsp;any capital stock or other security of Rallybio or any of its subsidiaries (except for Rallybio Common Stock issued upon the valid exercise or settlement of Rallybio Stock Awards); (B) any option, warrant or right to acquire any capital
stock or any other security; or (C)&nbsp;any instrument convertible into or exchangeable for any capital stock or other security of Rallybio or any of its subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">amend the terms of any outstanding Rallybio options; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">except as required to give effect to anything in contemplation of Closing, amend any of its or its subsidiaries&#8217;
certificate of incorporation and bylaws (or comparable organizational documents), or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock
split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">form any subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture
with any other entity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">(A) lend money to any person (except for the advancement of reasonable and customary expenses to employees, directors and
consultants in the Ordinary Course of Business), (B) incur or guarantee any indebtedness for borrowed money, (C)&nbsp;guarantee any debt securities of others, (D)&nbsp;other than the incurrence or payment of Transaction Expenses (as defined in
&#8220;<I>The Merger Agreement&#8212;Other Agreements&#8212;Fees and</I> <I>Expenses</I>&#8221;), make any capital expenditure in excess of $50,000, or (E)&nbsp;forgive any loans to any persons, including Rallybio&#8217;s employees, officers,
directors or affiliates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">other than as required by applicable law or the terms of any Rallybio benefit plan as in effect on the date of the Merger
Agreement: (A)&nbsp;adopt, terminate, establish or enter into any Rallybio benefit plan; (B)&nbsp;cause or permit any Rallybio benefit plan to be amended; (C)&nbsp;pay any bonus or make any profit-sharing or similar payment to, or increase the
amount of the wages, salary, fringe benefits, commissions, bonus, or other compensation or benefits payable to any of its directors, officers, consultants, independent contractors or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
employees; (D)&nbsp;hire any officer, employee, consultant or independent contractor; (E)&nbsp;modify the terms of any severance, retention or change of control benefits offered to any current,
former or new employees, directors or consultants (other than acceleration of the Rallybio Stock Awards as contemplated by the Merger Agreement); or (F)&nbsp;grant any new, or modify any existing, severance, retention benefits, change in control
award, or similar compensation or benefit to any person; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recognize any labor union or labor organization; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its material assets or properties, or
grant any encumbrance with respect to such material assets or properties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, assign, transfer, license, sublicense or otherwise dispose of any Rallybio owned intellectual property or any
Rallybio <FONT STYLE="white-space:nowrap">in-bound</FONT> license; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">make, change or revoke any material tax election, fail to pay any income or other material tax as such tax becomes due and
payable (taking into account extensions of time to file any tax return granted in the Ordinary Course of Business of not more than seven months), file any amendment making any material change to any tax return, settle or compromise any income or
other material tax liability or submit any voluntary disclosure application, enter into any tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the ordinary
course of business the principal subject matter of which is not taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material taxes (other than pursuant to an
extension of time to file any tax return granted in the ordinary course of business of not more than seven months), or adopt or change any material accounting method in respect of taxes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into, materially amend or terminate any Rallybio material contract or contract that would be deemed a Rallybio
material contract if entered into prior to the date of the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">other than as required by law or GAAP, take any action to change accounting policies or procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate or settle any legal proceeding; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">(A) fail to maintain any material insurance policies in full force and effect prior to the renewal period of any such
material insurance policies or (B)&nbsp;fail to exercise renewal rights for any such material insurance policies following the applicable expiration or acquire substantially similar insurance policies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into or amend a contract that would reasonably be expected to prevent or materially impede, interfere with, hinder
or delay the consummation of the Contemplated Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into a new line of business or start to conduct a line of business; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">agree, resolve or commit to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operation of Candid&#8217;s Business </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the period from the date
of the Merger Agreement and continuing until the earlier of the termination of the Merger Agreement or the Effective Time, except (i)&nbsp;as set forth in Candid&#8217;s disclosure schedule, (ii)&nbsp;expressly permitted or required in accordance
with the Merger Agreement including in connection with the Concurrent Financing, (iii)&nbsp;as required by applicable law, or (iv)&nbsp;as may be consented to in writing by Rallybio (not to be unreasonably withheld, conditioned or delayed), Candid
has agreed to (A)&nbsp;conduct its business and operations in the ordinary course of business and in compliance in all material respects with all applicable laws and the requirements of all of its material contracts and (B)&nbsp;continue to pay
material outstanding accounts payable and other material current liabilities (including payroll) in the ordinary course of business, and will not, nor shall it cause or permit any of its subsidiaries to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital
stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except repurchases from terminated employees, directors or consultants of Candid or in connection with the payment of the exercise price or
withholding taxes incurred upon the exercise, settlement or vesting of any award granted under the Candid 2024 Plan in accordance with the terms of such award in effect on the date of the Merger Agreement); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to:
(A)&nbsp;any capital stock or other security of Candid or any of its subsidiaries (except for shares of Candid Common Stock issued upon the valid exercise of Candid stock options); (B) any option, warrant or right to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
acquire any capital stock or any other security other than stock options or restricted stock unit awards granted to employees and service providers in the ordinary course of business which are
included in the calculation of the Candid Outstanding Shares; or (C)&nbsp;any instrument convertible into or exchangeable for any capital stock or other security of Candid or any of its subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">except as required to give effect to anything in contemplation of the Closing (including in connection with the Concurrent
Financing), amend any of its or its subsidiaries organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or
similar transaction except, for the avoidance of doubt, in connection with the Contemplated Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">form any subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture
with any other entity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">(A) lend money to any person (except for the advancement of reasonable and customary expenses to employees and directors
in the ordinary course of business), (B) incur or guarantee any indebtedness for borrowed money, (C)&nbsp;guarantee any debt securities of others, (D)&nbsp;other than the incurrence or payment of Transaction Expenses (as defined in &#8220;<I>The
Merger Agreement&#8212;Other Agreements&#8212;Fees and</I> <I>Expenses</I>&#8221;), make any capital expenditures in excess of $1.5 million of the budgeted capital expenditure amounts set forth in Candid&#8217;s operating budget delivered to
Rallybio on the date of the Merger Agreement (the &#8220;Candid Budget&#8221;), or (E)&nbsp;forgive any loans to any persons, including Candid&#8217;s employees, officers, directors or affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recognize any labor union or labor organization; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its material assets or properties, or
grant any encumbrance with respect to such material assets or properties, except in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">dispose of any of its material assets or properties, except in the ordinary course of business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, assign, transfer, license, sublicense or otherwise dispose of any material Candid Owned intellectual property or any
material Candid licensed intellectual property, in each case (other than pursuant to <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses in the ordinary course of business, the abandonment and refiling of patent applications or <FONT
STYLE="white-space:nowrap">co-commercialization</FONT> or partnership transaction), in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">make, change or revoke any material tax election, fail to pay any income or other material tax as such tax becomes due and
payable (taking in account extensions of time to file any tax return granted in the ordinary course of business of not more than seven months), file any amendment making any material change to any tax return, settle or compromise any income or other
material tax liability or submit any voluntary disclosure application, enter into any tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the ordinary course
of business the principal subject matter of which is not taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material taxes (other than pursuant to an
extension of time to file any tax return granted in the ordinary course of business of not more than seven months), or adopt or change any material accounting method in respect of taxes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into, materially amend or terminate any Candid material contract or contract that would be deemed a Candid material
contract if entered into prior to the date of the Merger Agreement (except in the ordinary course of business); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">except as otherwise consistent with in the Candid Budget and the incurrence or payment of any Transaction Expenses or
other costs or expenses arising as a result of the Merger Agreement and the Contemplated Transactions (as defined in &#8220;<I>The Merger Agreement&#8212;Other Agreements&#8212;Fees and</I> <I>Expenses</I>&#8221;), make any expenditures or discharge
or satisfy any liabilities, in each case, in amounts that exceed the aggregate amount of the Candid Budget by $1.5&nbsp;million; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">other than as required by law or GAAP, take any action to change accounting policies or procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate or settle any legal proceeding; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">(A) fail to maintain any material insurance policies in full force and effect prior to the renewal period of any such
material insurance policies or (B)&nbsp;fail to use commercially reasonable efforts to renew any such material insurance policies following the applicable expiration or acquire substantially similar insurance policies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into or amend a contract that would reasonably be expected to prevent or materially impede, interfere with, hinder
or delay the consummation of the Contemplated Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into a new line of business or start to conduct a line of business; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">agree, resolve or commit to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Termination and Termination Fees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Termination of the Merger Agreement
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement may be terminated prior to the Effective Time (whether before or after the required stockholder approvals to consummate the Merger
have been obtained, unless otherwise specified below), subject to certain exceptions described more fully in the Merger Agreement: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by mutual written consent of Rallybio and Candid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by either Rallybio or Candid if the Contemplated Transactions have not been consummated by September&nbsp;1, 2026
(subject to any extension as provided in this paragraph, the &#8220;End Date&#8221;); provided, however, that the right to terminate the Merger Agreement under this paragraph will not be available to Candid, on the one hand, or Rallybio, on the
other hand, if such party&#8217;s action or failure to act has been a principal cause of the failure of the Contemplated Transactions to occur on or before the End Date and such action or failure to act constitutes a breach of the Merger Agreement;
provided, further, that either party will be entitled to extend the End Date for an additional sixty calendar days in the event that, by the date which is 30 calendar days prior to September 1, 2026, (i) the SEC has not declared the registration
statement or (ii)&nbsp;the waiting periods (and extensions thereof) applicable to the Merger under the HSR Act have not expired or otherwise been terminated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by either Rallybio or Candid if a court of competent jurisdiction or other governmental body has issued a final and <FONT
STYLE="white-space:nowrap">non-appealable</FONT> order, decree or ruling, or has taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by Rallybio if the Candid written consent executed by each Candid required signatory has not been obtained within seven
business days of the date of the registration statement is declared effective (subject to Candid&#8217;s rights and obligations with respect to the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions set forth in Section&nbsp;4.5 of
the Merger Agreement); provided, however, that once the Candid written consent has been obtained, Rallybio may not terminate the Merger Agreement pursuant to this paragraph; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by either Rallybio or Candid if (i)&nbsp;the Rallybio stockholders&#8217; meeting (including any adjournments and
postponements thereof) was held and completed and Rallybio&#8217;s stockholders shall have taken a final vote on the Rallybio Stockholder Matters and (ii)&nbsp;the Rallybio Stockholder Matters were not approved by the Required Rallybio Stockholder
Vote; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by Candid (at any time prior to the approval of the Rallybio Stockholder Matters by the Required Rallybio Stockholder
Vote) if any of the following circumstances has occurred: (a)&nbsp;Rallybio has failed to include in the Proxy Statement the Rallybio Board Recommendation or the Rallybio Board has changed its recommendation; (b)&nbsp;the Rallybio Board or any
committee thereof has publicly approved, endorsed or recommended any Acquisition Proposal; (c)&nbsp;following the date of the Merger Agreement, has entered into a contract relating to any Acquisition Proposal (other than a permitted confidentiality
agreement) in violation of the terms of the Merger Agreement; (d)&nbsp;Rallybio&#8217;s willful and intentional breach of its <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenants contained in the Merger Agreement; or (e)&nbsp;the
Rallybio Board&#8217;s failure to publicly reaffirm its recommendation within ten Business Days of Candid&#8217;s request in writing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by Rallybio (at any time prior to the completion of the Required Candid Stockholder Vote) if any of the following
circumstances has occurred: (a)&nbsp;the Candid Board has withdrawn or modified (or has publicly proposed or resolved to withdraw or modify) its recommendation; (b)&nbsp;Candid Board or any committee thereof has adopted or approved, or publicly
endorsed or recommended, any Acquisition Proposal; or (c)&nbsp;following the date of the Merger Agreement, Candid has entered into a contract relating to any Acquisition Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by Candid (at any time prior to the approval of the Rallybio Stockholder Matters by the Required Rallybio Stockholder
Vote and subject to Candid&#8217;s compliance in all material respects with all of Candid&#8217;s obligations </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
with respect to Rallybio&#8217;s match rights as set forth in Section&nbsp;5.2(e)(i) of the Merger Agreement) concurrently with entering into a Permitted Alternative Agreement and having paid to
Rallybio the Rallybio Termination Fee; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by Candid, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement by
Rallybio or Merger Sub or if any representation or warranty of Rallybio or Merger Sub has become inaccurate, in either case, such that certain closing conditions set forth in the Merger Agreement would not be satisfied as of the time of such breach
or as of the time such representation or warranty has become inaccurate; provided that Candid is not then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement, subject to certain rights to cure as set
forth in the Merger Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by Rallybio, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement by
Candid or if any representation or warranty of Candid has become inaccurate, in either case, such that certain closing conditions set forth in the Merger Agreement would not be satisfied as of the time of such breach or as of the time such
representation or warranty has become inaccurate; provided that neither Rallybio nor Merger Sub is then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement, subject to certain rights to cure as set
forth in the Merger Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The party desiring to terminate the Merger Agreement will give the other party written notice of such termination,
specifying the provisions of the Merger Agreement pursuant to which such termination is made and the basis therefor described in reasonable detail. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Termination Fees Payable by Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio must pay Candid a <FONT
STYLE="white-space:nowrap">one-time</FONT> nonrefundable termination fee of $1.425&nbsp;million if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">(i) the Merger Agreement is terminated pursuant to clause (b), (e) or (i)&nbsp;above, (ii) an Acquisition Proposal with
respect to Rallybio has been publicly announced, disclosed or otherwise communicated to Rallybio or the Rallybio Board at any time after the date of the Merger Agreement but prior to the termination of the Merger Agreement (which termination has not
been withdrawn) and (iii)&nbsp;within twelve months after the date of such termination, Rallybio enters into a definitive agreement with respect to a subsequent transaction or consummates a Subsequent Transaction in respect of such Acquisition
Proposal or in respect of any other Acquisition Proposal; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Merger Agreement is terminated by Candid pursuant to clause (f)&nbsp;above (or at the time the Merger Agreement is
terminated, Candid has the right to terminate the Merger Agreement pursuant to clause (f)&nbsp;above). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL">A &#8220;Subsequent
Transaction&#8221; is any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to greater than 50% for such purpose). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Merger Agreement is terminated pursuant to clauses (e), (f) or (i)&nbsp;above or in the event of the failure of Candid to consummate the transactions to be
contemplated at the Closing solely as a result of a Rallybio Material Adverse Effect (provided, that at such time all other conditions precedent to Rallybio&#8217;s obligation to close set forth in the Merger Agreement have been satisfied by Candid,
are capable of being satisfied by Candid or have been waived by Rallybio), then Rallybio will also reimburse Candid for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses
incurred by Candid in connection with the Merger Agreement and the Contemplated Transactions, up to a maximum of $500,000, by wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds within ten business days following the date on
which Candid submits to Rallybio true and correct copies of reasonable documentation supporting such expenses; provided, however, that such expenses shall not include any amounts for financial advisors to Candid except for reasonably documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses otherwise reimbursable by Candid to such financial advisors pursuant to the terms of Candid&#8217;s engagement letter or similar arrangement with such
financial advisors. To the extent any such expenses are paid, such amounts will be credited against any termination fee that becomes payable by Rallybio to Candid thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Termination Fees Payable by Candid </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid must pay Rallybio a <FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable termination fee of $50&nbsp;million if: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">(i) the Merger Agreement is terminated by Rallybio pursuant to clause (d), (i) or (j)&nbsp;above, (ii) an Acquisition
Proposal with respect to Candid has been publicly announced, disclosed or otherwise communicated to Candid or the Candid Board at any time after the date of the Merger Agreement but prior to obtaining the Required Candid Stockholder Vote (which
termination shall not have been withdrawn, (A)&nbsp;in the case of a termination pursuant to clause (b)&nbsp;or (j), at the time the Required Candid Stockholder Vote is obtained and (B)&nbsp;in the case of a termination pursuant to clause (d), at
the time of such termination), and (iii)&nbsp;within twelve months after the date of such termination, Candid enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction in respect of such
Acquisition Proposal or in respect of any other Acquisition Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Merger Agreement is terminated by Rallybio pursuant to clause (g)&nbsp;above (or at the time the Merger Agreement is
terminated, Rallybio has the right to terminate the Merger Agreement pursuant to clause (g)&nbsp;above); or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Merger Agreement is terminated pursuant to clause (h). </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, Candid must pay Rallybio a <FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable termination fee of $10&nbsp;million if (i)&nbsp;the Merger
Agreement is terminated by Rallybio pursuant to clause (b)&nbsp;above, (ii) an Acquisition Proposal with respect to Candid has been publicly announced, disclosed or otherwise communicated to Candid or the Candid Board at any time after the date of
the Merger Agreement but prior to obtaining the Required Candid Stockholder Vote (which termination shall not have been withdrawn at the time the Required Candid Stockholder Vote is obtained), and (iii)&nbsp;within twelve months after the date of
such termination, Candid enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction in respect of such Acquisition Proposal or in respect of any other Acquisition Proposal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Merger Agreement is terminated pursuant to clauses (d), (g) or (j)&nbsp;above or in the event of the failure of Rallybio to consummate the transactions to be
consummated to the Closing solely as a result of an Candid Material Adverse Effect (provided, that at such time all other conditions precedent to Candid&#8217;s obligation to close set forth in the Merger Agreement have been satisfied by Rallybio,
are capable of being satisfied by Rallybio or have been waived by Candid), then Candid will reimburse Rallybio for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses
incurred by Rallybio in connection with the Merger Agreement and the Contemplated Transactions, up to a maximum of $500,000, by wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds within ten business days following the date on
which Rallybio submits to Candid true and correct copies of reasonable documentation supporting such expenses; provided, however, that such expenses shall not include any amounts for financial advisors to Rallybio except for reasonably documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses otherwise reimbursable by Rallybio to such financial advisors pursuant to the terms of Rallybio&#8217;s engagement letter or similar arrangement with
such financial advisors. To the extent any such expenses are paid, such amounts will be credited against any termination fee that becomes payable by Candid to Rallybio thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director Indemnification and Insurance </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement provides that, subject to certain limitations as set forth in the Merger Agreement, from the Effective Time through the sixth anniversary of the
date on which the Effective Time occurs, Rallybio and the surviving company will indemnify each person who is, has been at any time prior to the date of the Merger Agreement, or who becomes prior to the Effective Time, a director, officer, fiduciary
or agent of Rallybio or any of its subsidiaries or Candid, in each case, to the fullest extent permitted by such party&#8217;s organizational documents or pursuant to indemnification agreements made available to Candid. Each such person will be
entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation; <I>provided</I> that any such person to whom expenses are advanced provides an undertaking to Rallybio, to the extent then
required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </P> <P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement also provides that the provisions relating to the indemnification, advancement of expenses and
exculpation of present and former directors and officers of Rallybio or any of its subsidiaries set forth in the organizational documents of Rallybio or any of its subsidiaries will not be amended, modified or repealed for a period of six years from
the Effective Time in any manner that would adversely affect the rights of individuals who, at or prior to the Effective Time, were officers or directors of Rallybio or any of its subsidiaries, unless required by applicable law. After the Closing,
the organizational documents of the surviving corporation will contain provisions no less favorable with respect to the provisions relating to the indemnification, advancement of expenses and exculpation of present and former directors and officers
presently set forth in Candid&#8217;s organizational documents as of the date of the Merger Agreement. Rallybio has agreed to purchase a six year &#8220;tail policy&#8221; for the <FONT STYLE="white-space:nowrap">non-cancellable</FONT> extension of
Rallybio&#8217;s existing directors&#8217; and officers&#8217; liability insurance policies and Rallybio&#8217;s and any of its subsidiaries&#8217; existing directors&#8217; and officers&#8217; insurance policies and Rallybio&#8217;s existing
fiduciary liability insurance policies (if any), in each case, for a claims reporting or discovery period of at least six years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective
Time. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulatory Approvals </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement provides that,
subject to certain limitations set forth in the Merger Agreement, Rallybio and Candid must: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as promptly as practicable, but in any event within ten Business Days following the date of the Merger Agreement, make
or cause to be made any filings required by each of them or any of their respective Affiliates under the HSR Act and (ii)&nbsp;use reasonable best efforts to file or otherwise submit, all applications, notices, reports and other documents reasonably
required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such
governmental authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such governmental body; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">consult and cooperate with one another, and consider in good faith the views of one another, in connection with, and
provide to the other in advance (to the extent legally permissible), any analyses, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by or on behalf of any party hereto in connection with proceedings under or
relating to the antitrust laws, as further specified in the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">bear its own expenses and costs incurred in connection with any filings and submissions pursuant to antitrust laws,
except that Candid has agreed to pay all fees related to any filing made pursuant to the HSR Act; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">in the event that any Legal Proceeding is instituted (or threatened to be instituted) by a governmental body challenging
the Merger, each of Rallybio, Merger Sub and Candid will cooperate in all respects with each other and use reasonable best efforts to contest and resist any such Legal Proceeding and to have vacated, lifted, reversed or overturned any decree,
judgment, injunction or other order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation of the Merger; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">cause its subsidiaries and affiliates not to, acquire or agree to acquire any rights, interests, assets, business,
person or division thereof (whether through acquisition, license, joint venture, collaboration or otherwise), or take any other actions, if such acquisition or action would reasonably be expected to (i)&nbsp;prevent, materially delay, or adversely
affect in any material respect the ability of the parties to consummate the any of the Contemplated Transactions, or (ii)&nbsp;result in any party being required to obtain any clearance, consent, approval, waiver, waiting period expiration or
termination, <FONT STYLE="white-space:nowrap">non-action</FONT> or other authorization under any Laws with respect to any of the Contemplated Transactions. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Listing </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Common Stock currently is listed on Nasdaq under
the symbol &#8220;RLYB.&#8221; Rallybio has agreed to use commercially reasonable efforts (i)&nbsp;to maintain its existing listing on Nasdaq until the Closing Date and obtain approval of the listing of the combined company on Nasdaq,
(ii)&nbsp;without derogating from the requirements of the foregoing clause (i)&nbsp;and to the extent required by the rules and regulations of Nasdaq, to prepare and submit to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Nasdaq a notification form for the listing of the shares of Rallybio Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for
listing (subject to official notice of issuance), (iii) to effect the reverse stock split and (iv)&nbsp;to the extent required by Nasdaq Marketplace Rule 5110, to file an initial listing application for the Rallybio Common Stock on Nasdaq (the
&#8220;Nasdaq Listing Application&#8221;) and to cause such listing application to be conditionally approved prior to the Effective Time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The parties will use
commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations and will reasonably promptly inform the other party of all verbal or written communications between Nasdaq and such party or its
representatives. Candid will cooperate with Rallybio as reasonably requested by Rallybio with respect to the Nasdaq Listing Application and promptly furnish to Rallybio all information concerning Candid and its stockholders that may be required or
reasonably requested in connection with any action contemplated by the foregoing paragraph. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid Financial Statements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid agreed to (i)&nbsp;furnish to Rallybio audited financial statements for the fiscal year ended 2025 for inclusion in the Proxy Statement and the registration
statement and (ii)&nbsp;use commercially reasonable efforts to, no later than May&nbsp;14, 2026, furnish to Rallybio unaudited interim financial statements for each interim period completed prior to the Closing that would be required to be included
in the registration statement or any periodic report due prior to the Closing if Candid were subject to the periodic reporting requirements under the Securities Act or the Exchange Act, each of which will be prepared in accordance with GAAP as
applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on that basis will present fairly, in all material respects, the consolidated financial position and the results of operations,
changes in stockholders&#8217; equity, and cash flows of Candid as of the dates of and for the periods referred to therein. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fees and Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Merger Agreement, all the Transaction Expenses (as defined below), except as described above in the section titled &#8220;<I>The Merger
Agreement&#8212;Termination and Termination Fees</I>&#8221; of this proxy statement/prospectus, shall be paid by the party incurring such expenses, whether or not the Merger is consummated; provided, that Candid shall bear 60% of all fees and
expenses incurred in relation to (i)&nbsp;the printing and filing with the SEC of this registration statement and any amendments and supplements thereto and paid to a financial printer or the SEC, and (ii)&nbsp;the proxy solicitation firm engaged in
connection with the Rallybio stockholder meeting. Notwithstanding the foregoing, in connection with a disagreement regarding Rallybio Net Cash, the fees and expenses of the Accounting Firm shall be allocated between Rallybio and Candid in the same
proportion that the amount unsuccessfully disputed by such party bears to the total disputed amount of Rallybio Net Cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#8220;Transaction Expenses&#8221; means,
with respect to each party, all fees and expenses incurred by such party at or prior to the Effective Time in connection with the Contemplated Transactions and the Merger Agreement, including (a)&nbsp;any fees and expenses of legal counsel and
accountants and the maximum amount of fees and expenses payable to financial advisors, investment bankers, brokers, consultants, and other advisors of such party; (b)&nbsp;fees paid to the SEC in connection with filing the registration statement,
the Proxy Statement, and any amendments and supplements thereto, with the SEC; (c)&nbsp;any fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and registration statement and any amendments and
supplements thereto; (d)&nbsp;any fees and expenses payable to Nasdaq; and (e)&nbsp;any fees and expenses of the Rights Agent and the Exchange Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Amendment
of Merger Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement may be amended by the parties at any time with the written approval of Candid, Merger Sub and Rallybio, except that
after the Merger Agreement has been adopted and approved by a party&#8217;s stockholders, no amendment which by law requires further approval by the stockholders of that party will be made without such further stockholder approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_8"></A>AGREEMENTS RELATED TO THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Support Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution of the Merger Agreement,
the executive officers and directors and certain other stockholders of Rallybio holding approximately 24.8% of the outstanding Rallybio capital stock as of March&nbsp;1, 2026 entered into the Rallybio support agreements in favor of Candid, providing
among other things, that such officers, directors and stockholders (x)&nbsp;will vote all of their shares of Rallybio capital stock, among other things: (i)&nbsp;in favor of approving the Contemplated Transactions, including the Rallybio Stockholder
Matters, the Authorized Share Increase Proposal and the other actions contemplated by the Merger Agreement, (ii)&nbsp;against any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii)&nbsp;against any
acquisition proposal involving a third party and (y)&nbsp;will not solicit or negotiate alternative acquisition proposal or inquiries in their capacities as stockholders of Rallybio. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of Candid holding approximately 66.14% of the outstanding Candid
Capital Stock as of March&nbsp;1, 2026 entered into the Candid support agreements in favor of Rallybio, providing among other things, that such executive officers, directors and stockholders (x)&nbsp;will vote all of their shares of Candid Capital
Stock, among other things: (i)&nbsp;in favor of adopting the Merger Agreement and approving the Merger, the other Contemplated Transactions, the Candid Stockholder Matters (as defined in the Merger Agreement) and the other actions contemplated by
the Merger Agreement, (ii)&nbsp;against any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii)&nbsp;against any acquisition proposal involving a third party and (y)&nbsp;will not solicit or negotiate
alternative acquisition proposal or inquiries in their capacities as stockholders of Candid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up&nbsp;Agreements</FONT>
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution of the Merger Agreement, certain executive officers, directors and stockholders of Candid holding approximately 66.21% of the
outstanding shares of Candid Capital Stock as of March&nbsp;1, 2026 entered into&nbsp;the <FONT STYLE="white-space:nowrap">Lock-Up&nbsp;Agreements,</FONT> pursuant to which, subject to specified exceptions, such persons accepted certain restrictions
on transfers of the shares of Rallybio Common Stock beneficially held by such persons or such persons&#8217; family members (other than shares received as a result of the conversion of shares received in the Concurrent Financing) for <FONT
STYLE="white-space:nowrap">the&nbsp;180-day&nbsp;period</FONT> following the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Subscription Agreement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution and delivery of the Merger Agreement, certain new and existing investors of Candid entered into the Subscription Agreement with Candid,
pursuant to which such investors have agreed to purchase, immediately prior to the Merger, shares of Candid Common Stock representing an aggregate commitment of approximately $505.5&nbsp;million in the Concurrent Financing. Under the Subscription
Agreement, the number of shares of Candid Common Stock shall be determined at a purchase price per share equal to (i)&nbsp;a fixed valuation for Candid equal to approximately $750.0&nbsp;million, (ii)&nbsp;divided by the number of shares of Candid
Common Stock outstanding immediately prior to the Effective Time (excluding the securities being issued under the Subscription Agreement). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares of Candid
Common Stock that are issued in the Concurrent Financing will be or will have the right to be, respectively, converted into shares of Rallybio Common Stock in the Merger. Accordingly, by approving Proposal No.&nbsp;1 relating to the Merger, Rallybio
stockholders will also be approving the issuance of shares of Rallybio Common Stock to be issued in exchange for all shares of Candid Common Stock that are sold in the Concurrent Financing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Subscription Agreement contains customary representations and warranties of Candid and also contains customary representations and warranties of the purchaser
parties thereto. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each purchaser&#8217;s obligation to purchase shares of Candid Common Stock from Candid pursuant to the Subscription Agreement is subject to the
satisfaction or waiver of certain conditions, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s representations and warranties in the Subscription Agreement being true and correct in all respects as of
the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date for the Concurrent Financing, subject to certain exceptions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid having performed and complied in all material respects with the obligations and conditions required to be performed
or complied with by it; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the issuance of a compliance certificate by an authorized officer of Candid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all consents, permits, approvals, qualifications, registrations and waivers necessary for the consummation of the purchase
and sale of the securities under the Subscription Agreement having been obtained and in full force and effect; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the issuance of a secretary&#8217;s certificate by the secretary of Candid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the satisfaction or waiver of all conditions to the Closing set forth in the Merger Agreement (other than the condition
regarding the Concurrent Financing and other than those conditions which, by their nature, are to be satisfied at the Closing of the transactions contemplated by the Merger), the Closing being set to occur substantially concurrently with the closing
of the Concurrent Financing, and the Merger Agreement not having been amended, modified or waived in a manner that would reasonably be expected to materially and adversely affect the benefits that the purchasers would reasonably expect to receive
pursuant to the Subscription Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no injunction having been issued prohibiting the consummation of the Concurrent Financing; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid having delivered the Registration Rights Agreement required by the Subscription Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the registration statement of which this proxy statement/prospectus forms a part shall have become effective under the
Securities Act, no&nbsp;stop order shall be suspending the effectiveness of the registration statement of which this proxy statement/prospectus forms a part and no proceeding for that purpose shall have been initiated or threatened in writing by the
SEC; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Nasdaq Listing Application shall have been approved by Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no material adverse effect shall have occurred that is continuing, since the date of the Subscription Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid having received at Closing aggregate proceeds from the purchase of securities pursuant to the Subscription
Agreement of not less than $450.0&nbsp;million; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an opinion from Candid counsel, dated as of the Closing. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s obligation to sell shares of Candid Common Stock to each purchaser pursuant to the Subscription Agreement is subject to the satisfaction or waiver of
certain conditions, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the representations and warranties made by the purchasers being true and correct as of the effective date of the
Subscription Agreement and true and correct in all material respects as of the closing date of the Concurrent Financing, subject to certain exceptions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each purchaser having performed and complied with all obligations and conditions required to be performed or complied with
by each purchaser; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each purchaser having obtained all registrations, qualifications, permits and approvals, if any, required under applicable
securities laws; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the satisfaction or waiver of all conditions to the Closing set forth in the Merger Agreement (other than the condition
regarding the Concurrent Financing and other than those conditions which, by their nature, are to be satisfied at the Closing of the transactions contemplated by the Merger) and the Closing being set to occur substantially concurrently with the
closing of the Concurrent Financing, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid having received payment in full from each purchaser as required by the Subscription Agreement, subject to certain
exceptions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no injunction having been issued prohibiting the consummation of the Concurrent Financing. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Subscription Agreement may be changed, waived, amended or modified only by a written instrument executed by Candid and the purchasers holding, or having the right
to purchase at the closing of the Concurrent Financing, a majority of the shares purchased or to be purchased in the Concurrent Financing, which must include each purchaser who has purchased or committed to purchase at least $25.0&nbsp;million of
shares of Candid Common Stock (the &#8220;Purchaser Majority&#8221;), subject to certain exceptions. The Subscription Agreement may be terminated upon the earlier to occur of (i)&nbsp;such date and time that the Merger Agreement is terminated in
accordance with its terms, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
(ii)&nbsp;upon the mutual written agreement of Candid and an applicable purchaser (provided such termination will not otherwise apply to other purchasers), (iii) by Candid, if on the closing date
of the Concurrent Financing, any of the closing conditions of the purchasers have not been satisfied or waived, and, as a result thereof, the transactions contemplated by the Subscription Agreement are not consummated, (iv)&nbsp;by a purchasers, if
on the closing date of the Concurrent Financing, any of the closing conditions of Candid have not been satisfied or waived, and, as a result thereof, the transactions contemplated by the Subscription Agreement are not consummated and (v)&nbsp;if the
closing of the Concurrent Financing has not occurred by September&nbsp;1, 2026 (or November&nbsp;1, 2026 if the End Date is automatically extended pursuant to the terms of the Merger Agreement). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing description of the Subscription Agreement does not purport to be complete and is qualified in its entirety by the full text of the form of Subscription
Agreement, which is attached hereto as<I>&nbsp;Annex </I><I>G</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights Agreement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Subscription Agreement contemplates Rallybio, Candid and the purchasers participating in the Concurrent Financing entering into the Registration Rights Agreement at
the closing of the Concurrent Financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of Candid Common Stock that are held by the purchasers participating in the
Concurrent Financing from time to time, including certain shares of Rallybio Common Stock issued in exchange for shares of Candid Common Stock sold in the Concurrent Financing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Registration Rights Agreement, the combined company will agree to prepare and file a resale registration statement covering the resale of certain shares
of Rallybio Common Stock within 30 calendar days of the Closing pursuant to Rule&nbsp;415 and to use its commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the earlier of
(a)&nbsp;the date that all registrable securities covered by such registration statement (i)&nbsp;have been sold thereunder or pursuant to Rule&nbsp;144, or (ii)&nbsp;may be sold without volume or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule&nbsp;144 and without the requirement for the combined company to be in compliance with the current public information requirement under Rule&nbsp;144, and
(b)&nbsp;five&nbsp;years after the date of the Registration Rights Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Registration Rights Agreement also provides that the combined company will pay
certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities. The form of Registration Rights Agreement is filed as Annex&nbsp;H to the registration statement of which this proxy
statement/prospectus is a part, and the foregoing description of the Registration Rights Agreement is qualified in its entirety by reference thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rallybio
Contingent Value Rights Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the Effective Time, Rallybio and the designated rights agent are expected to enter into the Rayllybio CVR Agreement,
pursuant to which holders of Rallybio Common Stock, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, restricted stock units and in the money stock options as of the close of business on the last business day prior to the day on which the
Effective Time occurs will receive one Rallybio CVR for each outstanding share, or share underlying such pre-funded warrants or equity award, held by such holder. Each Rallybio CVR holder will be entitled to receive on a pro rata basis all of the
proceeds received, if any, by Rallybio as a result of payment of (i)&nbsp;any upfront, milestone, or royalty payments received under any disposition agreement related to the Legacy Assets (as defined below), and (ii)&nbsp;any cash proceeds received
from Recursion related to the earlier sale of Rallybio&#8217;s REV102 in July 2025, in each case, net of certain permitted deductions as set forth in the Rallybio CVR Agreement (collectively, the &#8220;Net Proceeds&#8221;). For a period of one year
after the Closing, the combined company will use commercially reasonable efforts to effect the disposition of the Legacy Assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#8220;Legacy Assets&#8221; means
Rallybio&#8217;s rights, assets, technology and intellectual property that were in existence immediately prior to the execution of the Merger Agreement and were used or generated prior to such execution in one or more of Rallybio&#8217;s research
and development programs. For clarity, the Legacy Assets shall not include any asset, technology or intellectual property owned or controlled by Candid or its subsidiaries prior to the Closing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Rallybio CVR Agreement, each Rallybio CVR holder will be entitled to certain rights to receive a cash payment equal to such holder&#8217;s pro rate
share of 100% of the Net Proceeds actually received by Rallybio during an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
annual period (or portion thereof) beginning on the effective date of the Rallybio CVR Agreement and ending on December&nbsp;31 of any given calendar year (a &#8220;Rallybio CVR Payment&#8221;)
during the period beginning on the Closing and ending on December&nbsp;31, 2030 (each such annual period, a &#8220;CVR Payment Period&#8221;). Such proceeds are subject to certain permitted deductions, including for applicable tax payments, certain
expenses incurred by Rallybio or its affiliates, losses incurred or reasonably expected to be incurred by Rallybio or its affiliates due to third-party claims, demands, actions, or other proceedings relating to or in connection with any disposition,
any liabilities borne by Rallybio or any of its affiliates pursuant to contracts related to Legacy Assets and any amounts payable to the designated rights agent. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio CVR Payments, if any, will become payable to the designated rights agent for subsequent distribution to the Rallybio CVR holders. In the event that no such
proceeds are received during a CVR Payment Period, holders of the Rallybio CVRs will not receive any payment pursuant to the Rallybio CVR Agreement for such CVR Payment Period. There can be no assurance that any Rallybio CVR holders will receive any
Rallybio CVR Payments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The right to the contingent payments contemplated by the Rallybio CVR Agreement is a contractual right only and is not transferable, except
in the limited circumstances specified in the Rallybio CVR Agreement. The Rallybio CVRs are not evidenced by a certificate or any other instrument and are not registered with SEC. The Rallybio CVRs do not have any voting or dividend rights and do
not represent any equity or ownership interest in Rallybio or any of its respective affiliates. No interest will accrue on any amounts payable in respect of the Rallybio CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Material U.S. Federal Income Tax Consequences of the Rallybio CVRs to holders of Rallybio Common Stock. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a discussion of the material U.S. federal income tax consequences of the issuance of the Rallybio CVRs and payments (if any) thereon to U.S. holders of
Rallybio Common Stock. This discussion does not purport to be a complete analysis of all potential tax consequences and is based upon current provisions of the Code, existing Treasury regulations, judicial decisions and published rulings and
administrative pronouncements of the IRS, all in effect as of the date hereof and all of which are subject to differing interpretations or change. Any such change or differing interpretation, which may be retroactive, could alter the tax
consequences to holders of Rallybio Common Stock as described in this summary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion does not address all U.S. federal income tax consequences relevant
to U.S. holders of Rallybio Common Stock. In addition, it does not address consequences relevant to holders of Rallybio Common Stock that are subject to particular U.S. or non-U.S. tax rules, including, without limitation, to holders of Rallybio
Common Stock that are: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who do not hold their Rallybio Common Stock as a &#8220;capital asset&#8221; within the meaning of Section 1221 of
the Code; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">real estate investment trusts; regulated investment companies; tax-exempt organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">pass-through entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and
limited liability companies (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subject to the alternative minimum tax provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold their shares as part of a hedge, wash sale, synthetic security, conversion transaction or other
integrated transaction; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">traders in securities who elect to apply a mark-to-market method of accounting; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold shares of Rallybio Common Stock that may constitute &#8220;qualified small business stock&#8221; under
Section 1202 of the Code or as &#8220;Section 1244 stock&#8221; for purposes of Section 1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who acquired their shares of Rallybio stock in a transaction subject to the gain rollover provisions of Section
1045 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to Rallybio stock
being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons deemed to sell Rallybio Common Stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who acquired their shares of Rallybio Common Stock pursuant to the exercise of options or otherwise as
compensation or through a tax-qualified retirement plan or through the exercise of a warrant or conversion rights under convertible instruments; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expatriates or former citizens or long-term residents of the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I></I>U.S. Holders of Rallybio Common Stock subject to particular U.S. or non-U.S. tax rules, including those that are described in the preceding paragraph, are urged
to consult their own tax advisors regarding the consequences to them of Rallybio CVRs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If an entity that is treated as a partnership for U.S. federal income tax
purposes (or any other pass-through entity) holds Rallybio Common Stock, the U.S. federal income tax treatment of a partner in the partnership or other pass-through entity will generally depend upon the status of the partner, the activities of the
partnership or other pass-through entity and certain determinations made at the partner level. If you are a partner of a partnership or other pass-through entity holding Rallybio Common Stock, you should consult your tax advisors regarding the tax
consequences of the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR
SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE CVRS ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Definition of &#8220;U.S. Holder&#8221; </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this
discussion, a &#8220;U.S. holder&#8221; is a beneficial owner of Rallybio Common Stock that is, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation or any other entity taxable as a corporation created or organized in or under the laws of the United States,
any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust if either (i)&nbsp;a court within the United States is able to exercise primary supervision over the
administration of such trust, and one or more United States persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) is authorized or has the authority to control all substantial decisions of such trust, or (ii)&nbsp;the trust was in
existence on August&nbsp;20, 1996 and has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax Treatment of the Rallybio CVRs and the Proposed Reverse Stock Split </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although the matter is not free from doubt, Rallybio intends to treat the issuance of the CVRs (together with any payments on the CVRs) and the proposed Reverse Stock
Split as separate transactions for U.S. federal income tax purposes, and the following discussion (except as discussed below under &#8220;&#8212;<I>Alternative Treatment of the CVRs and the Reverse Stock Split as a Single
Recapitalization</I>&#8221;) assumes this treatment will be respected. The IRS could challenge this position, however. Rallybio urges you to consult your tax advisor with respect to whether the issuance of the CVRs (and any payments on the CVRs), on
the one hand, and the proposed Reverse Stock Split, on the other, constitute separate transactions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax Treatment of the CVRs to U.S. holders of Rallybio Common
Stock </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no authority directly on point addressing whether contingent value rights with characteristics similar to the CVRs should be treated for federal
income tax purposes as a distribution of property with respect to Rallybio Common Stock, an &#8220;open transaction,&#8221; or in some other manner, and such questions are inherently factual in nature. Accordingly, holders are urged to consult with
their tax advisors regarding this issue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio intends to report the issuance of the CVRs as a distribution of property with respect to its stock consistent
with &#8220;closed transaction&#8221; treatment. Rallybio&#8217;s views and actions (and the fair market value figure ascribed to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
CVRs) are not dispositive with respect to the tax treatment or fair market value of the CVRs and are not binding on the IRS as to a U.S. holder&#8217;s tax treatment of the receipt of CVRs or the
fair market value of the CVRs. The IRS and Treasury Department have expressly stated in Treasury Regulations that only in &#8220;rare and extraordinary cases&#8221; is the value of property so uncertain that &#8220;open transaction&#8221; treatment
is available. Here, Rallybio has determined that the value of the CVRs on the Closing Date can be reasonably ascertained and, as a result, Rallybio intends to report the issuance of the CVRs as a distribution of property with respect to its stock
consistent with &#8220;closed transaction&#8221; treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following sections discuss the U.S. federal income tax consequences of the CVRs if treated as a
closed transaction or, alternatively, as an open transaction. It is also possible that the issuance of the CVRs could be treated as one or more &#8220;debt instruments&#8221; or as a distribution of equity. Rallybio U.S. holders are urged to consult
their tax advisors regarding the tax consequences to them of the receipt of CVRs and payments on the CVRs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Closed Transaction Treatment.</I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If treated as a closed transaction, each Rallybio U.S. holder will be treated as receiving a distribution in an amount equal to the fair market value of the CVR issued
to such Rallybio U.S. holder on the date of the issuance. This distribution generally should be treated first as a taxable dividend to the extent of the Rallybio U.S. holder&#8217;s&nbsp;<I>pro rata&nbsp;</I>share of Rallybio&#8217;s current or
accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as a non-taxable&nbsp;return of capital to the extent of the Rallybio U.S. holder&#8217;s basis in its Rallybio Common Stock, and finally as capital gain
from the sale or exchange of Rallybio Common Stock with respect to any remaining value. Rallybio U.S. holders will receive a Form 1099-DIV&nbsp;notifying them of the portion of the CVR value that is reported by Rallybio as a dividend for U.S.
federal income tax purposes. Although Rallybio will estimate the value of the CVRs for purposes of reporting on Form 1099-DIV&nbsp;to Rallybio U.S. holders, the value of the CVRs is uncertain and the IRS or a court could determine that the value of
the CVRs at the time of issuance was higher. In such case, the Rallybio U.S. holders could be treated as having additional income or gain upon receipt of the CVRs as described above. A Rallybio U.S. holder&#8217;s initial tax basis in such
holder&#8217;s CVR should equal the fair market value of such CVR on the date of their issuance. The holding period of such CVR should begin on the date of issuance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The treatment of future payments received by a Rallybio U.S. holder on a CVR is uncertain. It is possible that payments received with respect to a CVR up to the amount
of the Rallybio U.S. holder&#8217;s adjusted tax basis in the CVR, may be treated as a non-taxable&nbsp;return of a Rallybio U.S. holder&#8217;s adjusted tax basis in the CVR, with any amount received in excess of such basis treated as gain from the
disposition of the CVR. Rallybio intends to treat any payment made in respect of a CVR in a manner consistent with the foregoing, but Rallybio&#8217;s position is not dispositive with respect to the tax treatment of such payments and is not binding
on the IRS. Assuming that this method of reporting is correct, the gain will be long-term&nbsp;capital gain if the Rallybio U.S. holder has held the CVR for more than one year at the time of such payment. Payments with respect to a CVR could
alternatively be treated as ordinary income. Rallybio U.S. holders are urged to consult their tax advisors regarding the characterization of payments received with respect to the CVRs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Open Transaction Treatment.</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the issuance of the CVRs is treated as an
open transaction, (because, for example, the value of the CVRs on the closing date cannot be &#8220;reasonably ascertained&#8221;), a Rallybio U.S. holder should not immediately take the CVRs into account in determining whether such holder must
recognize income, if any, on the receipt of the CVRs and such holder would take no tax basis in the CVRs. Rather, the Rallybio U.S. holder&#8217;s U.S. federal income tax consequences would be determined at the time future payments, if any, with
respect to the CVRs are received or deemed received, based on whether the CVRs are treated as a distribution of property or of equity, in accordance with the Rallybio U.S. holder&#8217;s regular method of accounting. As discussed above, Rallybio
does not intend to report the issuance of the CVRs as an open transaction and the IRS may disagree with any Rallybio U.S. holder reporting the CVR issuance as an open transaction. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Alternative Treatment of the CVRs and the Proposed Reverse Stock Split as a Single Recapitalization </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding Rallybio&#8217;s position that the CVRs and the proposed Reverse Stock Split are appropriately treated as separate transactions, it is possible that the
IRS or a court could determine that the issuance of the CVRs (and/or any payments thereon) and the proposed Reverse Stock Split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes with the CVRs constituting
taxable &#8220;boot&#8221; received in such recapitalization exchange. In such case, the tax consequences of the CVRs and the proposed Reverse Stock Split would differ from those described above, including the timing and character of income, which
would depend in part on many of the same considerations described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_9"></A>RALLYBIO EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Rallybio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Rallybio and its subsidiaries. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table identifies our executive officers, and sets forth their current positions at Rallybio Corporation, and their ages as of March 6, 2026. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>POSITION</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer; Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jonathan I. Lieber, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer and Treasurer</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should refer to &#8220;<I>Proposal No. 5&#8212;The Director Election Proposal</I>&#8221; for information about our Chief Executive Officer, Stephen Uden, M.D.
Biographical information for our other executive officers, as of March&nbsp;6, 2026, is set forth below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Jonathan I. Lieber, M.B.A., </I></B>has been Chief
Financial Officer and Treasurer of Rallybio since February 2023. Previously, Mr.&nbsp;Lieber, served as the Chief Financial Officer of Applied Genetic Technologies Corporation, a publicly-traded clinical-stage biotechnology company, from September
2021 until November 2022. From December 2018 until September 2021, Mr.&nbsp;Lieber was a Managing Director at Danforth Advisors, a firm providing strategic and operational finance and accounting for life science companies. From July 2015 until
December 2018, Mr.&nbsp;Lieber served as Chief Financial Officer of Histogenics Corporation, a publicly traded cell therapy company. Mr.&nbsp;Lieber also served as the Chief Financial Officer of Metamark Genetics, Inc., Repligen Corporation,
Xcellerex, Inc., and Altus Pharmaceuticals. Mr.&nbsp;Lieber began his career in healthcare as an investment banker at Salomon Brothers / Salomon Smith Barney and SG Cowen. He has been a member of the board of directors of Decoy Therapeutics, Inc.
(Nasdaq: DCOY) since June 2020, Mindwalk Holdings Corp. (Nasdaq: HYFT) since July 2025 and Zola Pharmaceuticals (private) since February 2024. Mr.&nbsp;Lieber received a B.S. in business administration and finance from Boston University and an
M.B.A. in finance from New York University&#8217;s Leonard N. Stern School of Business. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Independence </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the rules of the Nasdaq Stock Market, independent directors must comprise a majority of a listed company&#8217;s board of directors. In addition, the rules of the
Nasdaq Stock Market require that, subject to specified exceptions, each member of a listed company&#8217;s audit and compensation committees be independent and that director nominees be selected or recommended for the board&#8217;s selection by
independent directors constituting a majority of the independent directors or by a nominating and corporate governance committee comprised solely of independent directors. Under the rules of the Nasdaq Stock Market, a director will only qualify as
&#8220;independent&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and
that such person is &#8220;independent&#8221; as defined under Nasdaq Stock Market and the rules under the Exchange Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Audit committee members must also satisfy
the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit
committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory
fee from the listed company or any of its subsidiaries or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based upon information
requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board has determined that each of our directors, with the exception of Drs. Mackay and Uden, is an
&#8220;independent director&#8221; as defined under applicable rules of the Nasdaq Stock Market. In addition, all members of our audit committee satisfy the independence criteria set forth in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and all members of our Compensation Committee satisfy the independence criteria set forth in Rule <FONT
STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act and are <FONT STYLE="white-space:nowrap">&#8220;non-employee</FONT> directors&#8221; as defined in <FONT STYLE="white-space:nowrap">Section&nbsp;16b-3</FONT> of the Exchange Act, and all
members of the Nominating and Corporate Governance Committee are &#8220;independent&#8221; as defined under the applicable listing standards of Nasdaq. In making such determination, our Board considered the relationships that each such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director has with our Company and all other facts and circumstances that our Board deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director. Dr.&nbsp;Mackay is not independent under these rules because he is a former employee of the Company and is party to a consulting agreement with the Company. Dr.&nbsp;Uden is not an
independent director under these rules because he is an employee of Rallybio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Meetings and Attendance </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board held 22 meetings during the year ended December&nbsp;31, 2025. Each of the directors attended at least seventy-five percent (75%) of the meetings of
the Rallybio Board and the committees of the Rallybio Board on which he or she served during the year ended December&nbsp;31, 2025 (in each case, which were held during the period for which he or she was a director and/or a member of the applicable
committee and excluding any meetings in which a director was an interested party). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we do not have a formal policy regarding director attendance at the annual
meeting of stockholders, we expect our Rallybio Board members to prepare for, attend and participate in all Rallybio Board and applicable committee meetings, including by means of remote communication. All members of the Rallybio Board attended the
2025 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board of Directors Leadership Structure </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Dr.&nbsp;Mackay serves as Chairman of the Rallybio Board. From August&nbsp;1, 2023 until December&nbsp;31, 2024, Dr.&nbsp;Mackay served as Executive Chairman, and prior
to August&nbsp;1, 2023 served as Chief Executive Officer and Chairman. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2023, the independent directors designated a Lead Director, which is a role that
is similar to the role of an independent Chairman. Ms.&nbsp;Soteropoulos has served as Lead Director since December 2023. As set forth in Rallybio&#8217;s Corporate Governance Guidelines, the Lead Director presides at meetings of the Board at which
the Chairman, who is not currently independent, is not present, including executive sessions of our independent directors, serves as an independent point of contact for stockholders, and has other duties described in Rallybio&#8217;s Corporate
Governance Guidelines, which are available on our website. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The independent members of the Rallybio Board have periodically reviewed the Rallybio Board&#8217;s
leadership structure and have determined that Rallybio and its stockholders are well served with this structure. Dr.&nbsp;Mackay&#8217;s former service as chief executive officer provides him with valuable insights into the Company&#8217;s programs,
operations, strategy and culture. In addition, Dr.&nbsp;Mackay serves on the board of directors of three public companies, and his corporate governance experience is incorporated into his leadership of the Rallybio Board. The Rallybio Board believes
that it is in the best interests of Rallybio for the Rallybio Board to make a determination regarding whether or not to separate the roles of any chairperson and the Chief Executive Officer based on the then-current circumstances. Dr.&nbsp;Mackay
has not served as Chief Executive Officer since August 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board has a standing Audit, Compensation and Nominating and Corporate Governance Committee. Each of our audit committee, Compensation Committee and
Nominating and Corporate Governance Committee is comprised solely of independent directors, and is described more fully below. Each committee operates pursuant to a written charter and each reviews and assesses the adequacy of its charter
periodically. The charters for each committee are all available on our website (www.rallybio.com) under the &#8220;Investors&#8221; section. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee is composed of Helen M. Boudreau, M.B.A., Robert Hopfner, R.Ph., Ph.D., M.B.A., Ronald Hunt, M.B.A., and Hui Liu, Ph.D., M.B.A., with
Ms.&nbsp;Boudreau serving as Chair of the committee. The Rallybio Board has determined that each member of the audit committee meets the independence requirements of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act and the
applicable listing standards of Nasdaq. The Rallybio Board has determined that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Ms.&nbsp;Boudreau is an &#8220;audit committee financial expert&#8221; within the meaning of the SEC, regulations and applicable listing standards of Nasdaq. The audit committee&#8217;s
responsibilities include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appointing, approving the compensation of, and evaluating the qualifications, performance and independence of, our
independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the work of our independent registered public accounting firm, including through the receipt and consideration
of reports from such firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and permitted
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures, including earnings releases; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discussing with our independent registered public accounting firm critical audit matters and related disclosures;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and our independent registered public accounting firm any material issues
regarding accounting principles and financial statement presentations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing disclosures about any significant deficiencies or material weaknesses in our internal controls, including
disclosures in our annual and quarterly reports; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">coordinating The Rallybio Board&#8217;s oversight of our internal control over financial reporting, disclosure controls
and procedures, code of business conduct and ethics, procedures for complaints and legal and regulatory matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discussing our risk management policies with management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing policies regarding hiring employees from our independent registered public accounting firm and procedures for
the receipt and retention of accounting related complaints and concerns; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">meeting independently with our independent registered public accounting firm and management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving any related person transactions, in accordance with Company policy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing our guidelines and policies governing risk assessment and risk management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the integrity of our information technology systems, process and data; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing the audit committee report required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the audit committee&#8217;s charter; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, at least annually, an evaluation of the performance of the audit committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2025, the audit committee met 4 times. The report of the audit committee is included in this proxy statement/prospectus under
&#8220;<I>Audit Committee Report</I>.&#8221; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Nominating and Corporate Governance Committee is composed of Wendy K. Chung, M.D., Ph.D., Robert Hopfner, R.Ph., Ph.D., M.B.A., Ronald Hunt, M.B.A. and Christine
Nash, M.B.A., with Ms.&nbsp;Nash serving as Chair of the committee. The Rallybio Board has determined that each member of the Nominating and Corporate Governance Committee is &#8220;independent&#8221; as defined under the applicable listing
standards of Nasdaq. The Nominating and Corporate Governance Committee&#8217;s responsibilities include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying individuals qualified to become members of the Rallybio Board consistent with criteria approved by the board
and receiving nominations for such qualified individuals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to the Rallybio Board the persons to be nominated for election as directors and to each committee of the
Rallybio Board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">considering and, if appropriate, establishing a policy under which our stockholders may recommend a candidate to the
Nominating and Corporate Governance Committee for consideration for nomination as a director; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and recommending committee slates on an annual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to the Rallybio Board qualified candidates to fill vacancies on the Rallybio Board; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing and recommending to the Rallybio Board a set of corporate governance principles applicable to us and reviewing
the principles on at least an annual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to the Rallybio Board with respect to our board leadership structure and board
committee structure; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing our policies and program with respect to significant issues of corporate public responsibility;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">making recommendations to the Rallybio Board processes for annual evaluations of the performance of our Board and
committees of the Rallybio Board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the process for annual evaluations of our Board and committees of the Rallybio Board; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and reporting to the Rallybio Board any actual or potential conflicts of interest of members of the Rallybio
Board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">providing new director orientation and continuing education for existing directors on a periodic basis;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing plans for director succession; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the Nominating and Corporate Governance Committee&#8217;s
charter; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and overseeing Rallybio&#8217;s initiatives regarding environmental, social and governance matters, including
related risks and opportunities, and Rallybio&#8217;s public disclosure with respect to such matters; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, on an annual basis, an evaluation of the performance of the Nominating and Corporate Governance Committee.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Nominating and Corporate Governance Committee is responsible for developing and recommending to our Board criteria for membership on the
Board. During the year ended December&nbsp;31, 2025, the Nominating and Corporate Governance Committee met one time. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Compensation Committee is composed of Lucian Iancovici, M.D., Christine A. Nash, M.B.A. and Paula Soteropoulos, with Ms.&nbsp;Soteropoulos serving as Chair of the
committee. Our Board has determined that each member of the Compensation Committee is &#8220;independent&#8221; as defined under the applicable listing standards of Nasdaq and meets the independence criteria set forth in Rule <FONT
STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. The Compensation Committee&#8217;s responsibilities include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing our overall management compensation strategy, including base salary, incentive compensation and equity-based
grants; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving corporate goals and objectives relevant to the compensation of our chief executive officer and
other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to the Rallybio Board the compensation of our chief executive officer and other executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to the Rallybio Board with respect to
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and administering our cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, considering and selecting, to the extent determined to be advisable, a peer group of appropriate companies for
purposes of benchmarking and analysis of compensation for our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to the Rallybio Board any stock ownership guidelines for our executive officers and <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">retaining, appointing or obtaining advice of a compensation consultant, legal counsel or other advisor and determining the
compensation and independence of such consultant or advisor; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing, if required, the compensation committee report on executive compensation for inclusion in our annual report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our annual proxy statement in accordance with SEC proxy and disclosure rules; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">monitoring our compliance with the requirements of Sarbanes-Oxley relating to loans to directors and officers;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing our compliance with applicable SEC rules regarding stockholder approval of certain executive compensation
matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving all employment contracts and other compensation, severance and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">change-in-control</FONT></FONT> arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing and periodically reviewing policies and procedures with respect to perquisites as they relate to our
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing the risks associated with our compensation policies and practices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing and presenting to the Rallybio Board management&#8217;s plans for succession to senior management positions
based on guidelines developed and recommended by the Compensation Committee to the full Board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing Rallybio&#8217;s strategies, initiatives and programs with respect to Rallybio&#8217;s management of human
capital resources; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the Compensation Committee&#8217;s charter; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, on an annual basis, an evaluation of the performance of the Compensation Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to its charter, the Compensation Committee has the authority to delegate any of its responsibilities to subcommittees and has the authority to delegate to the
Chief Executive Officer the determination of compensation to employees other than executive officers under approved compensation programs to the maximum extent permitted by applicable law. During the year ended December&nbsp;31, 2025, the
Compensation Committee met five times. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Consultant </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Compensation Committee has engaged Pearl Meyer&nbsp;&amp; Partners, LLC (&#8220;Pearl Meyer&#8221;), as its independent compensation consultant. Pearl Meyer provides analysis and recommendations to the Compensation Committee regarding: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">trends and emerging topics with respect to executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">compensation programs for our executive officers, directors and employees; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">stock utilization and related metrics. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When requested, Pearl Meyer consultants attend meetings of the Compensation Committee, including executive sessions in which executive compensation-related matters are
discussed without the presence of management. Pearl Meyer reports to the Compensation Committee and not to management, although Pearl Meyer meets with management for purposes of gathering information for its analyses and recommendations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining to engage Pearl Meyer, the Compensation Committee considered the independence of Pearl Meyer, taking into consideration relevant factors, including the
absence of other services provided to the Company by Pearl Meyer, the amount of fees the Company paid to Pearl Meyer as a percentage of Pearl Meyer&#8217;s total revenue, the policies and procedures of Pearl Meyer that are designed to prevent
conflicts of interest, any business or personal relationship of the individual compensation advisors employed by Pearl Meyer with any executive officer of the Company, any business or personal relationship the individual compensation advisors
employed by Pearl Meyer have with any member of the Compensation Committee, and any stock of the Company owned by Pearl Meyer or the individual compensation advisors employed by Pearl Meyer. The Compensation Committee has determined, based on its
analysis and in light of all relevant factors, including the factors listed above, that the work of Pearl Meyer and the individual compensation advisors employed by Pearl Meyer as compensation consultants to the Compensation Committee has not
created any conflicts of interest, and that Pearl Meyer is independent pursuant to the independence standards set forth in the Nasdaq listing standards promulgated pursuant to Section&nbsp;10C of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted a Code of Business
Conduct and Ethics for our directors, officers and employees, including our Chief Executive Officer and President and our Chief Financial Officer. A copy of our Code of Business Conduct and Ethics may be accessed free of charge by visiting our
website at www.rallybio.com and going to the &#8220;Governance&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
tab under the &#8220;Investors&#8221; section, or by requesting a copy in writing from our Secretary at our New Haven, Connecticut office. We intend to post on our website any amendment to, or
waiver under, a provision of the Code of Business Conduct and Ethics that applies to our directors and certain of our executive officers within four business days following the date of such amendment or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Environmental, Social and Governance </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We endeavor to develop and
continuously execute on a scalable strategy that enables the Company to foster its culture and values, create positive social and environmental outcomes, and enhance our business. The Nominating and Corporate Governance Committee has been delegated
oversight for such activities by the Rallybio Board. The Company seeks to integrate such considerations into its business in a manner that enhances long-term performance and value for stakeholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_10"></A>RALLYBIO EXECUTIVE OFFICER AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Rallybio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Rallybio and its subsidiaries.</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Compensation</B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s named executive officers for the year ended December&nbsp;31, 2025 are: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Stephen Uden, M.D., Chief Executive Officer and President; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Jonathan I. Lieber, M.B.A., Chief Financial Officer and Treasurer; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Steven Ryder, M.D., Former Chief Medical Officer.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>
</P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Ryder&#8217;s employment with the Company terminated on March 31, 2026. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2025 Summary Compensation
Table </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the compensation awarded to, earned by or paid to each of our named executive officers for the fiscal years ended
December&nbsp;31, 2025 and December&nbsp;31, 2024. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME&nbsp;AND&nbsp;PRINCIPAL POSITION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SALARY($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK<BR>AWARDS</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>AWARDS<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-EQUITY</FONT><BR>INCENTIVE<BR>COMPENSATION<BR>PLAN<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">590,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,156,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,127,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jonathan I. Lieber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">478,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,688</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"></SUP><I>Chief Financial Officer and Treasurer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">478,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">865,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Former Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">911,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in the &#8220;Option Awards&#8221; column represent the aggregate grant date fair value of options to purchase shares of Rallybio Common Stock granted to our named executive officers in fiscal years
2025 and 2024 computed in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. The assumptions used to value the options for this purpose are set forth in Note&nbsp;7 to our consolidated financial statements included
elsewhere in this proxy statement/prospectus. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in the &#8220;Stock Awards&#8221; column represents the grant date fair value of the performance-based stock units granted in 2025, based on the probable outcome of the performance conditions at grant.
The grant date fair value of the award, assuming all performance conditions were satisfied at the maximum level is $104,688. This award was subsequently cancelled and was not outstanding on December&nbsp;31, 2025. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in the &#8220;Nonequity Incentive Plan Compensation&#8221; column represent annual bonuses earned with respect to fiscal years 2025 and 2024 under our annual bonus program as described below under
&#8220;Annual incentive bonuses.&#8221; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in the &#8220;All Other Compensation&#8221; column for fiscal years 2025 and 2024 reflect 401(k) plan matching contributions, described below under &#8220;Employee and retirement benefits.&#8221;
</TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overview </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Compensation Committee of our Board
of Directors is responsible for determining the compensation of named executive officers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Compensation Committee has engaged Pearl Meyer, an independent
compensation consulting firm, to assist it in evaluating the Company&#8217;s executive and director compensation practices, including program design, identification of an appropriate peer group for compensation comparison purposes and providing pay
benchmarking data. The Compensation Committee has assessed the independence of Pearl Meyer from management and, on the basis of that assessment and taking into consideration the independence factors that are required to be considered under
applicable stock exchange rules, determined that no relationships exist that would create a conflict of interest or that would compromise Pearl Meyer&#8217;s independence. </P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreements with our named executive officers </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2023, Dr.&nbsp;Uden entered into a second amended and restated employment agreement with the Company and our operating company subsidiary, Rallybio, LLC,
which sets forth the terms and conditions of Dr.&nbsp;Uden&#8217;s continued employment with us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the time of his commencement of employment, Mr.&nbsp;Lieber
entered into an employment agreement with the Company and Rallybio, LLC, which sets forth the terms and conditions of Mr.&nbsp;Lieber&#8217;s employment with us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;25, 2025, we entered into an employment agreement with Dr.&nbsp;Ryder. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The material terms of the agreements are described below. The terms &#8220;cause,&#8221; &#8220;good reason&#8221; and &#8220;change in control&#8221; referred to below
are defined in the respective named executive officer&#8217;s agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The employment agreements for Dr.&nbsp;Uden, Mr.&nbsp;Lieber and Dr.&nbsp;Ryder provide
for an initial annual base salary, subject to review for increase by our Board of Directors or the Compensation Committee. Each employment agreement also provides for a target annual bonus as a percentage of annual base salary, with the actual
amount of the bonus payable based upon the achievement of performance goals as determined by our Board of Directors or the Compensation Committee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Base
Salaries </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective January&nbsp;1, 2025, the annual base salary of Dr.&nbsp;Uden was increased from $551,200 to $590,000. The Compensation Committee
reviewed pay benchmarking data for the Company&#8217;s peer group and for the position of Chief Executive Officer and President held by Dr.&nbsp;Uden, and recommended, and the Board of Directors approved, Dr.&nbsp;Uden&#8217;s 2025 base salary of
$590,000. The annual base salaries of Mr.&nbsp;Lieber and Dr.&nbsp;Ryder remained unchanged at $478,400 and $531,227, respectively, for fiscal year 2025. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Annual incentive bonuses </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to fiscal year 2025, each of
our named executive officers was eligible to receive an annual bonus. For fiscal year 2025, the target bonus amount for Dr.&nbsp;Uden was 55% of his annual base salary. For fiscal year 2025, the target bonus amount for each of Mr.&nbsp;Lieber and
Dr.&nbsp;Ryder was 40% of the named executive officer&#8217;s annual base salary. Annual bonuses for fiscal year 2025 for our named executive officers were based on the attainment of <FONT STYLE="white-space:nowrap">pre-established</FONT> corporate
objectives as determined by the Compensation Committee and the Board of Directors. Following the end of fiscal year 2025, the Compensation Committee and the Board of Directors reviewed the Company&#8217;s performance against these goals and
determined that the performance goals for the named executive officers were achieved at 80% of target for Dr.&nbsp;Uden and Mr.&nbsp;Lieber and 95% of target for Dr.&nbsp;Ryder. Dr.&nbsp;Uden earned a bonus of $259,600, Mr.&nbsp;Lieber earned a
bonus of $153,088 and Dr.&nbsp;Ryder earned a bonus of $201,866. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Severance upon termination of employment; change in control; restrictive covenants
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Employment Agreements for Dr.</I><I></I><I>&nbsp;Uden and Mr.</I><I></I><I>&nbsp;Lieber</I>. Each of Dr.&nbsp;Uden and Mr.&nbsp;Lieber is entitled to
severance payments and benefits in connection with certain qualifying terminations of employment under his respective employment agreement. In connection with the Merger, on March&nbsp;1, 2026, each of Dr.&nbsp;Uden and Mr.&nbsp;Lieber entered into
an amendment to his respective employment agreement to clarify that the Merger will constitute a &#8220;change in control&#8221; for purposes of each executive&#8217;s employment agreement. As a result, the enhanced <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">change-in-control</FONT></FONT> severance benefits described below will become payable in the event of a qualifying termination following the Closing. If the executive officer&#8217;s employment is terminated by us without
cause, or by him for good reason, or as a result of our <FONT STYLE="white-space:nowrap">non-extension</FONT> of the employment term, he will be entitled to receive (i)&nbsp;any earned and payable, but unpaid, prior year annual bonus (or current
year bonus if the termination occurs on the last day of the calendar year), (ii) continued payment of his annual base salary for a period of 12 months following termination and (iii)&nbsp;subject to his timely election of COBRA coverage, payment of
a monthly amount equal to the monthly health premiums paid by us on behalf of the executive officer and his eligible dependents immediately prior to termination for 12 months following termination (or, if earlier, until such time as the executive
officer ceases to be eligible for COBRA coverage or obtains health coverage from another employer). If the executive officer&#8217;s employment is terminated by reason of his death or disability, he will be entitled to receive (i)&nbsp;any earned
and payable, but unpaid, prior year annual bonus (or current year bonus if the termination occurs on the last day of the calendar year) and (ii)&nbsp;continued payment of his annual base salary for a period of six months following termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the executive officer&#8217;s employment is terminated by us without cause or by him for good reason, or as a
result of our <FONT STYLE="white-space:nowrap">non-extension</FONT> of the employment term, in each case within the <FONT STYLE="white-space:nowrap">12-month</FONT> period following a change in control, which includes the Merger, in lieu of the
severance payments and benefits described above, he will be entitled to receive (i)&nbsp;any earned and payable, but unpaid, prior year annual bonus (or current year bonus if the termination occurs on the last day of the calendar year), (ii) an
amount equal to 1.5 times the sum of the executive officer&#8217;s annual base salary and target annual bonus, payable over 18 months following termination, (iii)&nbsp;subject to his timely election of COBRA coverage, payment of a monthly amount
equal to the monthly health premiums paid by us on behalf of the executive officer and his eligible dependents immediately prior to termination for 18 months following termination (or, if earlier, until such time as the executive officer ceases to
be eligible for COBRA coverage or obtains health coverage from another employer), and (iv)&nbsp;in the case of Mr.&nbsp;Lieber, full vesting of any outstanding and unvested equity awards, the vesting of which is based only on the passage of time,
held by Mr.&nbsp;Lieber as of the date of termination. With respect to Dr.&nbsp;Uden, under his second amended and restated employment agreement, any outstanding and unvested equity awards, the vesting of which is based only on the passage of time,
held by him as of a change in control will vest in full upon the consummation of the change in control, subject to Dr.&nbsp;Uden&#8217;s continued employment with us through the date of such change in control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March 1, 2026, we and Dr. Uden and Mr. Lieber entered into amendments to their respective employment agreements to clarify that the Merger will constitute a
&#8220;change in control&#8221; for purposes of the agreement. As a result, the enhanced change-in-control severance benefits described above will be triggered in the event of a qualifying termination following the closing of the Merger. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Employment Agreement for Dr. Ryder</I>. On June 25, 2025, we entered into an employment agreement with Dr.&nbsp;Ryder, pursuant to which Dr. Ryder served as our
Chief Medical Officer at an initial annual base salary of $531,227 and was eligible to receive an annual target bonus of up to 40% of his base salary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Dr.
Ryder&#8217;s employment agreement, if Dr. Ryder&#8217;s employment was terminated by us without cause or by him for good reason, he was entitled to receive (i) any earned but unpaid annual bonus for a calendar year ending on or preceding the date
of termination, (ii) continued payment of his annual base salary for a period of 12&nbsp;months following termination, and (iii) subject to his timely election of COBRA coverage, payment of a monthly amount equal to the monthly health premiums paid
by us on behalf of Dr. Ryder and his eligible dependents for 12&nbsp;months following termination (or, if earlier, until such time as Dr. Ryder ceases to be eligible for COBRA coverage or obtains health coverage from another employer). If Dr.
Ryder&#8217;s employment was terminated by us without cause or by him for good reason, in each case within the 12-month period following a change in control, which includes the Merger, in lieu of the severance payments and benefits described above,
he would be entitled to receive (i) any earned but unpaid prior year annual bonus, (ii) an amount equal to 1.5 times the sum of his annual base salary and target annual bonus, payable over 18 months following termination, (iii) subject to his timely
election of COBRA coverage, payment of a monthly amount equal to the monthly health premiums paid by us on behalf of Dr. Ryder and his eligible dependents for 18 months following termination (or, if earlier, until such time as Dr. Ryder ceases to be
eligible for COBRA coverage or obtains health coverage from another employer), and (iv) full vesting of any outstanding and unvested equity awards, the vesting of which is based only on the passage of time, held by Dr.&nbsp;Ryder as of the date of
termination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March 1, 2026, we and Dr. Ryder entered into an amendment to his employment agreement to clarify that the Merger will constitute a &#8220;change in
control&#8221; for purposes of the agreement. As a result, the enhanced change-in-control severance benefits described above will be triggered in the event of a qualifying termination following the Closing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with Dr. Ryder&#8217;s separation on March 31, 2026, we and Dr. Ryder entered into a separation agreement pursuant to which, among other things, Dr. Ryder
will receive the severance payments and benefits to which he is entitled under his employment agreement upon a termination without cause or for good reason and, upon Closing, will receive the enhanced severance payments due to him in the event of a
qualifying termination in connection with a change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Severance Subject to Release of Claims</I>. Our obligation to provide a named executive officer with severance
payments and other benefits under his respective employment agreement is conditioned on the executive officer signing a release of claims in favor of us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restrictive Covenants</I>. Under their respective employment agreements, each of the named executive officers has agreed not to compete with us during his employment
and for one year following his termination of employment or solicit our customers, employees, representatives, agents, vendors, joint venturers or licensors during his employment and for one year following his termination of employment. In addition,
each named executive officer has agreed to a perpetual <FONT STYLE="white-space:nowrap">non-disparagement</FONT> covenant. Each of the named executive officers is also party to a Confidential Information and Invention Assignment Agreement under
which each named executive officer has agreed to a perpetual confidentiality covenant and an assignment of intellectual property covenant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT
STYLE="white-space:nowrap">Better-of</FONT> Provision.</I> The employment agreements with each of the named executive officers also contain a Section&nbsp;280G &#8220;better of&#8221; cutback provision, pursuant to which any payments or benefits
that would constitute &#8220;parachute payments&#8221; within the meaning of Section&nbsp;280G of the Code will be reduced to the extent necessary to avoid the imposition of the excise tax under Section&nbsp;4999 of the Code, but only if such
reduction would result in a greater <FONT STYLE="white-space:nowrap">after-tax</FONT> benefit to the named executive officer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Employee and retirement
benefits </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently provide broad-based health and welfare benefits that are available to all of our employees, including our named executive officers,
including health, life and AD&amp;D, disability, vision and dental insurance. We maintain a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan (&#8220;401(k) Plan&#8221;), for our full-time employees, including our named executive
officers. The 401(k) Plan provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer eligible compensation subject to applicable annual limits provided for in the
Internal Revenue Code (the &#8220;Code&#8221;). We make matching contributions into the 401(k) Plan on behalf of participants, equal to up to 3% of eligible compensation. Employees&#8217; <FONT STYLE="white-space:nowrap">pre-tax</FONT> contributions
are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. Employees are immediately and fully vested in their contributions. Our 401(k)
Plan is intended to be qualified under Section&nbsp;401(a) of the Code with our 401(k) Plan&#8217;s related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement
plan, contributions to our 401(k) Plan and earnings on those contributions are not taxable to the employees until distributed from our 401(k) Plan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Insider
Trading Policy </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company adopted an insider trading policy in connection with the Company&#8217;s initial public offering in August 2021. The insider
trading policy prohibits our officers, directors, and employees from purchasing or selling the Company&#8217;s securities while in possession of material, nonpublic information, prohibits any hedging, short sales or pledging transactions with
respect to the Company&#8217;s securities by directors, officers and all employees, and includes requirements regarding Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans. In addition, it is the Company&#8217;s policy to comply with all
applicable securities laws when transacting in its own securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clawback </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the requirements of the Dodd-Frank Act, SEC rules and Nasdaq listing standards, we maintain a clawback policy that requires recoupment of
erroneously-awarded incentive compensation received by current or former executive officers in the event we are required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under applicable
securities laws. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Equity compensation </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In fiscal year 2025,
Dr.&nbsp;Uden was granted an option to purchase 56,711 shares of our common stock under the 2021 Plan, which vests in 48 equal monthly installments over four years, with a grant date fair value of $298,988. Mr.&nbsp;Lieber and Dr.&nbsp;Ryder were
each granted an option to purchase 22,499 shares of our common stock under the 2021 Plan, which vests in 48 equal monthly installments over four years, with a grant date fair value of $118,620 each. Each of these options was granted on
February&nbsp;14, 2025 with a per share exercise price of $6.08, the closing price of a share of our common stock on the date of grant (as adjusted for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-8</FONT></FONT>
reverse stock split effective February&nbsp;6, 2026). In each case, vesting is generally subject to the named executive officer&#8217;s continued employment with us through the applicable vesting date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;29, 2025, Mr.&nbsp;Lieber was granted 15,000 performance-based restricted stock units
(&#8220;PSUs&#8221;) under the 2021 Plan. The January 2025 PSUs were subsequently cancelled during fiscal year 2025 and were not outstanding as of December&nbsp;31, 2025. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;18, 2026, Mr.&nbsp;Lieber was granted 5,000 PSUs under the 2021 Plan. Of the 5,000 PSUs, 2,500 vested on the date of grant. The remaining 2,500 PSUs
(the &#8220;CIC PSUs&#8221;) will vest on the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of a Change in Control, which includes the Merger, but only if a Change in Control is consummated on or before December&nbsp;31, 2026,
subject to Mr.&nbsp;Lieber&#8217;s continued employment with the Company from the date of grant through the vesting date. If a Change in Control has not occurred on or before December&nbsp;31, 2026, the CIC PSUs will be automatically forfeited for
no consideration. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Compensation Committee generally grants options annually to executives and seeks to make such grants on or around the same date each year.
Throughout the year, equity awards may be made to new hires or in connection with promotions or other changes in employment, or, as in the case of the February 2026 PSU grant, in connection with a pending transaction. The Compensation Committee does
not grant equity-based awards in anticipation of the release of material nonpublic information and does not time the disclosure of material nonpublic information for purposes of affecting the value of executive compensation. In addition, during
2025, we did not grant options to any named executive officer during the four business days prior to or the one business day following the filing of a periodic report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> or the filing or furnishing of a Form <FONT STYLE="white-space:nowrap">8-K</FONT> that discloses material nonpublic information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Outstanding Equity Awards at Fiscal 2025 <FONT STYLE="white-space:nowrap">Year-End</FONT> </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information regarding outstanding equity awards held by our named executive officers as of the end of fiscal year 2025 (as adjusted for
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-8</FONT></FONT> reverse stock split effective February&nbsp;6, 2026): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS<BR>(#)<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS<BR>(#)<BR>UNEXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXERCISE<BR>PRICE<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXPIRATION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/28/2031</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/7/2032</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,798</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2033</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,615</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2034</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,890</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/14/2035</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jonathan I. Lieber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2033</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,119</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2034</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,809</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/14/2035</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/28/2031</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/7/2032</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,331</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2033</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,119</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2034</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,809</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/14/2035</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each stock option vests in 48 equal monthly installments over four years from the date of grant, generally subject to the named executive officer&#8217;s continued employment with the Company through each applicable
vesting date. See &#8220;Severance upon termination of employment; change in control; restrictive covenants.&#8221; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an option to purchase 20,000 shares of our common stock, granted on July&nbsp;28, 2021, which vested as to 25% of the underlying shares on July&nbsp;28, 2022. The remaining 75% of the underlying shares vest
in 36 equal monthly installments thereafter, generally subject to the named executive officer&#8217;s continued employment or service with us through the applicable vesting date. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an option to purchase 7,750 shares of our common stock, granted on February&nbsp;7, 2022, which vests in 48 equal monthly installments, generally subject to the named executive officer&#8217;s continued
employment or service with us through the applicable vesting date. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an option to purchase 26,750 shares of our common stock, granted on February&nbsp;6, 2023, which vests in 48 equal monthly installments, generally subject to the named executive officer&#8217;s continued
employment or service with us through the applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an option to purchase 26,999 shares of our common stock, granted on February&nbsp;15, 2024, which vests in 48 equal monthly installments, generally subject to the named executive officer&#8217;s continued
employment or service with us through the applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an option to purchase 56,711 shares of our common stock, granted on February&nbsp;14, 2025, which vests in 48 equal monthly installments, generally subject to the named executive officer&#8217;s continued
employment or service with us through the applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an option to purchase 29,999 shares of our common stock, granted on February&nbsp;1, 2023, which vested as to 25% of the underlying shares of common stock on February&nbsp;1, 2024 and vests as to the
remaining 75% of the underlying shares of common stock in 36 equal monthly installments thereafter, generally subject to the named executive officer&#8217;s continued employment with us through the applicable vesting date. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an option to purchase 14,999 shares of our common stock, granted on February&nbsp;15, 2024, which vests in 48 equal monthly installments, generally subject to the named executive officer&#8217;s continued
employment with us through the applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an option to purchase 22,499 shares of our common stock, granted on February&nbsp;14, 2025, which vests in 48 equal monthly installments, generally subject to the named executive officer&#8217;s continued
employment with us through the applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an option to purchase 14,874 shares of our common stock, granted on February 6, 2023, which vests in 48 equal monthly installments, generally subject to the named executive officer&#8217;s continued
employment or service with us through the applicable vesting date. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the compensation awarded to, earned by or paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the fiscal
year ended December&nbsp;31, 2025. Dr.&nbsp;Uden did not receive compensation for his service as a director in 2025. His compensation for 2025 is included in the Summary Compensation Table above. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FEES&nbsp;EARNED<BR>OR&nbsp;PAID&nbsp;IN&nbsp;CASH<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>AWARDS<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,228</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Wendy Chung, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,228</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Robert Hopfner, R.Ph., Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,228</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald Hunt, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,228</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Hui Liu Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,228</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Christine A. Nash, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,228</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,228</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,228</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent cash fees earned in fiscal year 2025, including amounts that certain <FONT STYLE="white-space:nowrap">non-employee</FONT> directors elected to receive in the form of an
option to purchase shares of our common stock as noted by footnote 4. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors may elect to receive their annual cash retainer in the form of an option to purchase shares of our common stock,
which vests in 12 equal monthly installments on the last day of each month during such calendar year, subject to the director&#8217;s continued service on our Board of Directors. The grant date of these <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-lieu-of-cash</FONT></FONT></FONT> options was January&nbsp;2, 2025 and the number of options granted to each <FONT STYLE="white-space:nowrap">non-employee</FONT> director was based on
their annual fees to be earned and the grant date fair value of the option to purchase shares of common stock computed in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. The assumptions used to value the options
for this purpose are set forth in Note&nbsp;7 to our consolidated financial statements included elsewhere in this proxy statement/prospectus. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the grant date fair value of options to purchase shares of our common stock granted to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in May 2025,
computed in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. The assumptions used to value the options for this purpose are set forth in Note 7 to our consolidated financial statements included elsewhere in this
proxy statement/prospectus. As of December&nbsp;31, 2025, the following <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held the following number of option awards: Ms.&nbsp;Boudreau&#8212;10,920; Dr.&nbsp;Chung&#8212;11,713;
Dr.&nbsp;Hopfner&#8212;20,896; Mr.&nbsp;Hunt&#8212;25,920; Dr.&nbsp;Liu&#8212;20,961; Ms.&nbsp;Nash&#8212;11,200; Dr.&nbsp;Mackay&#8212;96,668; and Ms.&nbsp;Soteropoulos&#8212;11,591. Dr.&nbsp;Iancovici did not hold any stock options as of
December&nbsp;31, 2025. As of December&nbsp;31, 2025, none of the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held unvested restricted stock awards. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">non-employee</FONT> director elected to receive his or her annual cash retainer in the form of an option to purchase shares of our common stock. The terms of the option to purchase
shares of our common stock are described below under &#8220;Director compensation policy&#8221;. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents the grant date fair value of the annual stock option grant to purchase 3,562&nbsp;shares of our common stock under the 2021&nbsp;Plan, granted on May&nbsp;13, 2025 at a per share exercise price of $2.38. The
annual option vests in full on the earlier of the first anniversary of the date of grant or the next annual meeting of our stockholders, subject to the director&#8217;s continued service on the Board of Directors through the vesting date.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Iancovici declined to accept a stock option grant or a cash retainer in respect of his service as a director in 2025. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents consulting fees paid to Dr.&nbsp;Mackay pursuant to his consulting agreement with the Company and Rallybio, LLC, effective January&nbsp;1, 2025, at a rate of $18,750 per month ($225,000 for the full year).
</TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director compensation policy </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Board of
Directors adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy for members of our Board of Directors. In December 2024, the Board of Directors updated the <FONT STYLE="white-space:nowrap">non-employee</FONT>
director compensation policy for compensation payable in 2025. Under the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy applicable to 2025 director compensation to the extent not updated as described below, our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors were and are compensated as follows: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each <FONT STYLE="white-space:nowrap">non-employee</FONT> director receives an annual cash fee of $40,000 ($65,000 for the
chair of our Board of Directors and $63,500 for the lead director, if applicable); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is a member of the Audit Committee receives an
additional annual cash fee of $7,500 ($15,000 for the Audit Committee chair); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is a member of the Compensation Committee receives
an additional annual cash fee of $6,000 ($12,000 for the Compensation Committee chair); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is a member of the Nominating and Corporate
Governance Committee receives an additional annual cash fee of $4,000 ($8,000 for the Nominating and Corporate Governance Committee chair). </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will annually be granted an option to purchase
3,562&nbsp;shares (as adjusted for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-8</FONT></FONT> reverse stock split effective February&nbsp;6, 2026) of our common stock under the 2021 Plan on the date of the first
meeting of our Board of Directors held after the annual meeting of our stockholders, prorated for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors initially elected or appointed to our Board of Directors during the 12 months preceding
the grant date to reflect the number of months of service during such <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to January
1st of any year, a <FONT STYLE="white-space:nowrap">non-employee</FONT> director may elect to receive his or her annual cash retainer in the form of an option to purchase shares of our common stock, which is expected to vest in 12 equal monthly
installments, on the last day of each month during such calendar year, subject to the director&#8217;s continued service on our Board of Directors through each applicable vesting date. Four of our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors made such an election with respect to their 2025 cash retainers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The stock options granted to our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors will have a per share exercise price equal to the closing price of a share of our common stock on the date of grant (or the immediately preceding date on which a closing price was reported if there is no closing price on the date of grant)
and will expire not later than ten years after the date of grant. The stock option granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director upon the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#8217;s initial
election or appointment to our Board of Directors will vest in three equal annual installments, subject to the director&#8217;s continued service on our Board of Directors through each applicable vesting date. The annual stock options granted to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors will vest in full on the earlier of the first anniversary of the date of grant or the next annual meeting of our stockholders, subject to the director&#8217;s continued service on our
Board of Directors through the vesting date. Upon a change in control (as defined in the 2021 Plan (or as such term or similar term is defined in any successor plan)), each initial stock option and each annual stock option that is then outstanding
will vest in full, subject to the director&#8217;s continued service on our Board of Directors through such change in control. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All cash fees will be paid
quarterly, in arrears, or upon the earlier resignation or removal of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director. The amount of each payment will be prorated for any portion of a calendar quarter that a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director is not serving on our Board of Directors, based on the number of calendar days served by such <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director is entitled to reimbursement for reasonable travel and other expenses incurred in connection with
attending meetings of our Board of Directors and any committee on which he or she serves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Compensation Committee reviews and makes recommendations to our Board of Directors regarding the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation arrangements, and the Board of Directors reviews and approves <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation. The Compensation Committee considers
information regarding director compensation paid at peer companies, including an evaluation of such compensation practices by the Compensation Committee&#8217;s compensation consultant. In December 2025 following a recommendation from the
Compensation Committee, the Board of Directors did not make any changes to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, applicable to 2026 director compensation, except the annual option to purchase shares
of our common stock was increased from an option to purchase 3,562&nbsp;shares of our common stock to an option to purchase 3,750&nbsp;shares of our common stock (in each case, as adjusted for the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-8</FONT></FONT> reverse stock split effective February&nbsp;6, 2026). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_11"></A>CANDID EXECUTIVE OFFICER AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This section provides an overview of Candid&#8217;s executive compensation programs as they relate to the executive officers named below who are expected to become
executive officers of the combined company (&#8220;named executive officers&#8221;), including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. For the year
ended December&nbsp;31, 2025, Candid&#8217;s named executive officers were: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Ken Song, M.D., Candid&#8217;s President and Chief Executive Officer and Chairman of the Board of Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Tim Lu, M.D., Ph.D., Candid&#8217;s Chief Medical Officer and Chief Scientific Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Arvind Kush, Candid&#8217;s Chief Financial Officer and Chief Business Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2025 Summary Compensation Table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information
regarding compensation earned with respect to the years ended December&nbsp;31, 2025 and 2024 by Candid&#8217;s named executive officers. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME AND PRINCIPAL POSITION</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SALARY&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK<BR>AWARDS<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>AWARDS<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-EQUITY</FONT><BR>INCENTIVE&nbsp;
PLAN<BR>COMPENSATION<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Ken Song, M.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">550,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,407,326</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">302,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,259,826</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>President and Chief<BR>Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5,493,018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">138,630</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5,906,648</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Tim Lu, M.D., Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">288,879</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">287,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,076,379</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Medical Officer and<BR>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">222,222</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">659,162</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">111,644</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">993,028</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Arvind Kush</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">425,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">240,733</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">170,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">835,733</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Financial Officer and<BR>Chief Business Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">181,510</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">549,302</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">72,658</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">803,470</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amounts reflect the aggregate grant date fair value of the stock awards and option awards granted during the applicable year computed in accordance with Financial Accounting Standards Board, Accounting Standards
Codification Topic 718,<I> Compensation&#8212;Stock Compensation</I> (&#8220;FASB ASC 718&#8221;). Assumptions used in the calculation of the grant date fair value of each stock award and option award granted are described in Note 8 to
Candid&#8217;s audited consolidated financial statements and notes appearing elsewhere in this proxy statement/prospectus. These amounts do not reflect the actual economic value that may be realized by Candid&#8217;s named executive officers upon
the vesting of the stock awards or option awards, the exercise of the option awards, or any subsequent sale of common stock underlying such stock awards or option awards. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents a grant of a restricted stock award in the applicable year. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amounts for 2025 reflect the grant date fair value of the Replacement Options (as defined below) and the amounts for 2024 reflect the grant date fair value of the Cancelled Options (as defined below). The Cancelled
Options were performance-based options that were not probable of vesting at the date the Replacement Options were issued, and, as a result, the grant date fair value of the Replacement Options replaced the grant date fair value of the Cancelled
Options. See &#8220;<I>&#8212;Equity-Based Incentive Awards</I>&#8221; below for more information. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amounts represent the annual cash performance bonus earned in the applicable year. Please see the description of bonus compensation under &#8220;<I>&#8212;Bonus Opportunity</I>&#8221; below. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative to the Summary Compensation Table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Annual Base Salary
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The base salary of Candid&#8217;s named executive officers is generally determined and approved by the Candid Board in connection with the commencement of
employment of the named executive officer and may be adjusted from time to time thereafter as the Candid Board determines appropriate. The 2025 annual base salaries for Dr.&nbsp;Song, Dr.&nbsp;Lu and Mr.&nbsp;Kush were $550,000, $500,000 and
$425,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Bonus Opportunity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to base salaries, each of Candid&#8217;s named executive officers is eligible to earn annual cash bonuses, which are designed to provide appropriate
incentives to Candid&#8217;s named executive officers to achieve defined annual corporate goals and to reward Candid&#8217;s named executive officers for individual achievements towards these goals. The annual bonus awarded to each named executive
officer may be based in part on the extent to which Candid achieves corporate goals. At the end of the year, the Candid Board reviews Candid&#8217;s performance against each corporate goal and considers the extent to which Candid achieved each of
its corporate goals. The Candid board of directors also generally considers each named executive officer&#8217;s individual contributions toward reaching these goals. The bonus amounts vary from year to year based on corporate performance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For 2025, each of Dr.&nbsp;Song. Dr.&nbsp;Lu and Mr.&nbsp;Kush was eligible for a target bonus equal to 50%, 50% and 40% of their base salary, respectively. In December
2025, the Candid Board determined that Candid achieved 110% of its 2025 corporate goals and approved payment of an aggregate amount equivalent to 110% of each named executive officer&#8217;s 2025 target bonus which was allocated among employees at a
range of 100% to 120% of their target bonus at management&#8217;s discretion. As a result, Dr.&nbsp;Song received a cash bonus of $302,500, Dr.&nbsp;Lu received a cash bonus of $287,500, and Mr.&nbsp;Kush received a cash bonus of $170,000,
representing bonus achievement of 110%, 115% and 100%, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Equity-Based Incentive Awards </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s equity-based incentive awards are designed to align Candid&#8217;s named executive officers&#8217; interests with those of its stockholders and to retain
and incentivize Candid&#8217;s named executive officers over the long-term. To date, Candid has used stock option grants, restricted stock awards and sales of restricted stock for this purpose because it believes they are an effective means by which
to align the long-term interests of its executive officers with those of its stockholders. Each stock option award and restricted stock award was granted under the Candid 2024 and, prior to the adoption of the Candid 2024 Plan, restricted stock was
sold pursuant to common stock purchase agreements, as described below in the Outstanding Equity Awards at Fiscal Year End table below. The terms of the Candid 2024 Plan are described below under the subsection titled &#8220;<I>&#8212;Equity
Incentive Plan.</I>&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">the Candid Board or an authorized committee thereof is responsible for approving equity grants. Vesting of equity awards is generally
tied to continuous service with Candid and serves as an additional retention measure. Candid&#8217;s named executive officers generally are awarded an initial new hire grant upon commencement of employment. Additional grants may occur periodically
in order to specifically incentivize Candid&#8217;s named executive officers with respect to achieving certain corporate goals or to reward Candid&#8217;s named executive officers for exceptional performance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2025, the Candid board of directors cancelled option awards to purchase (i) 10,000,000 shares of Candid Common Stock held by Dr.&nbsp;Song&#8217;s trust, The
Song Family Trust Dated October&nbsp;14, 2016 (the &#8220;Song Family Trust&#8221;), (ii) 1,200,000 shares of Candid Common Stock granted to Dr.&nbsp;Lu and (iii) 1,000,000 shares of Candid Common Stock granted to Mr.&nbsp;Kush (collectively, the
&#8220;Cancelled Options&#8221;). The Cancelled Options were originally granted in November 2024 with an exercise price of $0.70 per share and vested, if at all, upon an IPO liquidity-event based performance condition, subject to the grantee&#8217;s
Continuous Service (as defined in the Candid 2024 Plan) with Candid as of such date. In May 2025, the Candid Board approved replacement option awards to purchase (i) 10,000,000 shares of Candid Common Stock to Dr.&nbsp;Song&#8217;s trust, the Song
Family Trust, (ii)&nbsp;1,200,000 shares of Candid Common Stock to Dr.&nbsp;Lu and (iii)&nbsp;1,000,000 shares of Candid Common Stock to Mr.&nbsp;Kush (collectively, the &#8220;Replacement Options&#8221;). The Replacement Options have an exercise
price of $0.35 per share and vest as follows: (a)&nbsp;in the event the there is a liquidity event that is a change of control that meets certain requirements (the &#8220;CIC Liquidity Event&#8221;), then 100% of the total shares will vest
immediately prior to and contingent upon the closing of such transaction and (b)&nbsp;in the event there is a liquidity event that meets certain public listing requirements (the &#8220;Public Listing Liquidity Event&#8221; and, together with the CIC
Liquidity Event, a &#8220;Liquidity Event&#8221;), then 12/48<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the total shares will vest on the one year anniversary of the date of the Public Listing Liquidity Event, and 1/48<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> of the total shares will vest each month thereafter on the same day of the month as the vesting commencement date (or if there is no corresponding day, on the last day of the month), subject to the
grantee&#8217;s Continuous Service with Candid as of each such date and subject to the occurrence of such Public Listing Liquidity Event on or before December&nbsp;31, 2026. Upon the Closing Date, the Replacement Options will begin vesting in
accordance with subsection (b). For more information see the Outstanding Equity Awards at Fiscal Year End table below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Employment Arrangements with Candid&#8217;s Named Executive Officers </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dr.</I><I></I><I>&nbsp;Song.</I> In July 2024, Candid entered into an offer letter with Dr.&nbsp;Song, which governs the terms of his employment with Candid.
Pursuant to his offer letter, Dr.&nbsp;Song is entitled to an annual base salary of $550,000, and is eligible to receive an annual target bonus of up to 50% of his annual base salary, payable based on the achievement of individual or corporate
performance goals as determined by the Candid board of directors. Dr.&nbsp;Song is also eligible for standard benefits such as paid time off, reimbursement of business expenses, and participation in employee benefit plans and programs.
Dr.&nbsp;Song&#8217;s employment is at will. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dr.</I><I></I><I>&nbsp;Lu.</I> In July 2024, Candid entered into an offer letter with Dr.&nbsp;Lu, which governs
the terms of his employment with Candid. Pursuant to his offer letter, Dr.&nbsp;Lu is entitled to an annual base salary of $500,000, and is eligible to receive an annual target bonus of up to 50% of his annual base salary, payable based on the
achievement of individual or corporate performance goals as determined by the Candid board of directors. Dr.&nbsp;Lu is also eligible for standard benefits such as paid time off, reimbursement of business expenses, and participation in employee
benefit plans and programs. Dr.&nbsp;Lu&#8217;s employment is at will. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Mr.</I><I></I><I>&nbsp;Kush.</I> In July 2024, Candid entered into an offer letter with
Mr.&nbsp;Kush, which governs the terms of this employment with Candid. Pursuant to his offer letter, Mr.&nbsp;Kush is entitled to an annual base salary of $425,000, and is eligible to receive an annual target bonus of up to 40% of his annual base
salary, payable based on the achievement of individual or corporate performance goals as determined by the Candid board of directors. Mr.&nbsp;Kush is also eligible for standard benefits such as paid time off, reimbursement of business expenses, and
participation in employee benefit plans and programs. Mr.&nbsp;Kush&#8217;s employment is at will. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential Payments Upon Termination or Change in Control
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regardless of the manner in which a named executive officer&#8217;s service terminates, each named executive officer is entitled to receive amounts earned
during his term of service, including unpaid salary and unused vacation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, each of Candid&#8217;s named executive officers&#8217; equity awards is
subject to the terms of (i)&nbsp;the Candid 2024 Plan and award agreement thereunder or (ii)&nbsp;the relevant common stock purchase agreement, as applicable. A description of the termination and change in control provisions in the Candid 2024 Plan
and awards granted thereunder is provided in the subsection titled &#8220;<I>&#8212;Equity Incentive Plan</I>&#8221; below, and a description of the vesting provisions of each equity award held by Candid&#8217;s named executive officers which is
outstanding and unvested as of December&nbsp;31, 2025 is provided the Outstanding Equity Awards at Fiscal Year End table below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the common stock purchase
agreements with the Song Family Trust and Dr.&nbsp;Song and Mr.&nbsp;Kush, if within one month before or 12 months following a change in control, such named executive officer&#8217;s employment or service to Candid is involuntarily terminated by
Candid without cause, or such named executive officer resigns for good reason, and in either case other than as a result of death or disability, and provided such termination constitutes a &#8220;separation from service&#8221; within the meaning of
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h),</FONT> the repurchase option with respect to such restricted shares of Candid Common Stock will lapse as to 100% of any unvested shares and such unvested shares will
immediately become fully vested. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of the common stock purchase agreements: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;change in control&#8221; generally has the same meaning given to such term in the Candid 2024 Plan, as described
below; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;cause&#8221; means any of the following: (i)&nbsp;commission of any felony or any crime involving moral turpitude
or dishonesty, (ii)&nbsp;participation in a fraud or act of dishonesty against Candid, (iii)&nbsp;willful and material breach of duties that has not been cured within 30 days after written notice from the Candid board of directors of such breach,
(iv)&nbsp;intentional and material damage to Candid&#8217;s property, or (v)&nbsp;material breach of such named executive officer&#8217;s employee confidential information and inventions assignment agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#8220;good reason&#8221; means any of the following actions taken by Candid or a successor corporation or entity without
the named executive officer&#8217;s consent (unless such action is taken in response to conduct by such named executive officer that constitutes cause): (i) material reduction of such named executive officer&#8217;s base compensation, other than a
reduction that applies generally to all executives and does not exceed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
10%; (ii) material reduction in such named executive officer&#8217;s authority, duties or responsibilities, provided that a change in job position (including a change in title) will not be deemed
a &#8220;material reduction&#8221; unless such named executive officer&#8217;s new authority, duties or responsibilities are materially reduced from the prior authority, duties or responsibilities; (iii)&nbsp;failure or refusal of a successor to
Candid to materially assume Candid&#8217;s obligations under the agreement; or (iv)&nbsp;relocation of such named executive officer&#8217;s principal place of employment that results in an increase in such named executive officer&#8217;s <FONT
STYLE="white-space:nowrap">one-way</FONT> driving distance by more than 50 miles from such named executive officer&#8217;s then current principal residence; provided that if such named executive officer works remotely during any period in which such
named executive officer&#8217;s regular principal place of employment at a Candid office is closed, then neither such named executive officer&#8217;s relocation to remote work or back to the office from remote work will be considered a relocation of
such named executive officer&#8217;s principal place of employment with Candid for purposes of this definition. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the Merger, Candid
anticipates that the combined company board of directors will adopt a Severance and Change in Control Plan (the &#8220;Severance Plan&#8221;), which each of Candid&#8217;s named executive officers will become eligible to receive certain benefits
under the terms of the Severance Plan. Following its effectiveness, the terms of the Severance Plan will supersede the change in control benefits set forth in the common stock purchase agreements with the Song Family Trust and Dr.&nbsp;Song and
Mr.&nbsp;Kush. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at Fiscal Year End </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
following table sets forth certain information regarding equity awards granted to Candid&#8217;s named executive officers that remain outstanding as of December&nbsp;31, 2025. In addition, awards may vest on an accelerated basis under certain
circumstances, as described above under &#8220;&#8212;<I>Potential Payments upon Termination or Change in Control</I>.&#8221; </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:6.5pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>GRANT</B><br><B>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>VESTING<BR>COMMENCEMENT<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>UNEXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EQUITY<BR>INCENTIVE<BR>PLAN<BR>AWARDS:<BR>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>UNEARNED<BR>OPTIONS (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXERCISE<BR>PRICE<BR>PER<BR>SHARE<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXPIRATION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES OR<BR>UNITS OF<BR>STOCK THAT<BR>HAVE NOT<BR>VESTED (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARKET<BR>VALUE OF<BR>SHARES OF<BR>UNITS OF<BR>STOCK THAT<BR>HAVE NOT<BR>VESTED<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EQUITY<BR>INCENTIVE<BR>PLAN<BR>AWARDS:<BR>NUMBER<BR>OF<BR>UNEARNED<BR>SHARES,<BR>UNITS OR<BR>OTHER<BR>RIGHTS<BR>THAT HAVE<BR>NOT<BR>VESTED (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EQUITY<BR>INCENTIVE<BR>PLAN<BR>AWARDS:<BR>MARKET<BR>OR<BR>PAYOUT<BR>VALUE OF<BR>UNEARNED<BR>SHARES,<BR>UNITS OR<BR>OTHER<BR>RIGHTS<BR>THAT
HAVE<BR>NOT<BR>VESTED ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Ken&nbsp;Song,&nbsp;M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/1/2024<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/1/2024<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,973,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,390,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/5/2025<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/4/2035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Tim&nbsp;Lu, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/1/2024<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/1/2024<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,978,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,221,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/5/2025<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/4/2035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Arvind Kush</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/1/2024<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/1/2024<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,127,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/5/2025<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/4/2035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In connection with the named executive officer&#8217;s services to Candid, Candid issued and sold shares of Candid Common Stock to Mr.&nbsp;Kush and the Song Family Trust pursuant to common stock purchase agreements at
a purchase price of $0.0000018&nbsp;per share. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the equity awards were granted under the Candid 2024 Plan. All of the option awards were granted with a per share exercise price equal to the fair value of one share of Candid Common Stock on the date of grant,
as determined in good faith by the Candid Board. Dr. Lu paid $0.0000018&nbsp;per share for the shares of Candid Common Stock underlying his restricted stock award. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares of Candid Common Stock are subject to a repurchase option such that 12/48th of the shares issued and sold to the named executive officer vested and were released from the repurchase option on the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date, and 1/48<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the unvested shares vest and are released from the repurchase option on a monthly basis
thereafter, subject to the named executive officer&#8217;s Continuous Service to Candid as of the date of such release. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The vesting commencement date is the Closing Date. The options will vest as follows: 12/48th of the total shares will vest on the one year anniversary of the date of the Public Listing Liquidity Event, and 1/48th of the
total shares will vest each month thereafter on the same day of the month as the vesting commencement date (or if there is no corresponding day, on the last day of the month), subject to grantee&#8217;s Continuous Service with Candid as of each such
date and subject to the occurrence of the Closing on or before December&nbsp;31, 2026. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amount is calculated using a value of $0.37 per share, which is the fair value Candid used for financial reporting purposes as of such date. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid does not maintain nonqualified defined contribution plans or other nonqualified deferred compensation plans. The Candid Board may elect to provide its officers
and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in its best interests. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Perquisites, Health, Welfare and Retirement Benefits </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of
Candid&#8217;s named executive officers are eligible to participate in Candid&#8217;s employee benefit plans, including its medical, dental, vision, life, long term disability and accidental death and dismemberment insurance plans, in each case on
the same basis as all of Candid&#8217;s other employees. In addition, Candid provides the opportunity to participate in a 401(k) plan to its employees, including each of Candid&#8217;s named executive officers, as discussed in the subsection below
titled &#8220;&#8212;<I>401(k) plan</I>.&#8221; Candid generally does not provide perquisites or personal benefits to its executive officers, except in limited circumstances. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>401(k) plan </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s named executive officers are eligible to
participate in a defined contribution retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a <FONT STYLE="white-space:nowrap">tax-advantaged</FONT> basis. Eligible employees may defer eligible
compensation on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">after-tax</FONT> (&#8220;Roth&#8221;) basis, up to the statutorily prescribed annual limits on contributions under the Code. Individual&#8217;s
contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. The 401(k) plan is intended to be qualified under
Section&nbsp;401(a) of the Code with the 401(k) plan&#8217;s related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, contributions to the 401(k) plan
(except for Roth contributions) and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan. Candid may elect, at its discretion, to make matching employee contributions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clawback Policy </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the Merger, Candid expects the combined
company to adopt a new compensation recovery policy that is compliant with the Nasdaq Listing Rules, as required by the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act (&#8220;Dodd-Frank Act&#8221;). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Equity Incentive Plan </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid believes that its ability to grant
equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of its employees, consultants and directors with the financial interests of its stockholders. In addition, Candid believes that its
ability to grant equity-based awards helps Candid to attract, retain and motivate employees, consultants and directors, and encourages them to devote their best efforts to Candid&#8217;s business and financial success. The principal features of the
Candid 2024 Plan are summarized below. This summary is qualified in its entirety by reference to the actual text of the Candid 2024 Plan, which is filed as an exhibit to this proxy statement/prospectus. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid 2024 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Candid Board adopted and
Candid stockholders approved the Candid Therapeutics, Inc. 2024 Equity Incentive Plan (the &#8220;Candid 2024 Plan&#8221;) in May 2024. Candid most recently amended the Candid 2024 Plan in August 2024. The Candid 2024 Plan and each option thereunder
was assumed by Rallybio in connection with the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Share reserve</I>. Subject to certain capitalization adjustments, the aggregate number of shares of
Candid Common Stock that may be issued pursuant to awards under the Candid 2024 Plan is 60,711,153 shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Awards</I>. The Candid 2024 Plan permits the grant of
ISOs, NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock-based awards. ISOs may be granted only to Candid employees and to any of Candid&#8217;s parent or subsidiary corporations&#8217; employees.
All other awards may be granted to employees, directors and consultants of Candid and to any of Candid&#8217;s parent or subsidiary corporations&#8217; employees or consultants. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Administration</I>. The Candid Board or, if delegated by the Candid Board, a committee or one or more persons or bodies administers Candid 2024 Plan. Subject to the
terms of the Candid 2024 Plan, the administrator has the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
power to, among other things, select the persons to whom awards may be granted, determine the type of award to be granted to any person, determine the number and type of shares to be covered by
each award, establish the terms and conditions of each award agreement, determine whether and under what circumstances an option may be exercised without a payment of cash, and determine whether and to what extent and under what circumstances shares
and other amounts payable with respect to an award may be deferred either automatically or at the election of the participant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock options</I>. ISOs and NSOs
are granted pursuant to stock option agreements adopted by the administrator. The administrator determines the exercise price for a stock option, provided that the exercise price of a stock option generally cannot be less than 100% of the fair
market value of Candid Common Stock on the date of grant. Options granted under the Candid 2024 Plan vest at the rate specified by the administrator. The administrator determines the term of stock options granted under the Candid 2024 Plan, up to a
maximum of 10 years. Unless the terms of an optionholder&#8217;s stock option agreement provide otherwise, if an optionholder&#8217;s service relationship with Candid, or any of Candid&#8217;s affiliates, ceases for any reason other than disability,
death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. The option term may be extended in the event that the exercise of the option following such a termination of
service is prohibited by applicable securities laws or Candid&#8217;s insider trading policy. If an optionholder&#8217;s service relationship with Candid or any of Candid&#8217;s affiliates ceases due to disability or death, or an optionholder dies
within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a
termination for cause, options generally terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term. Acceptable consideration for the purchase of Candid Common
Stock issued upon the exercise of a stock option will be determined by the administrator and may include (1) cash, check, bank draft, electronic funds transfer or money order, (2) a broker-assisted cashless exercise, (3) the tender of shares of
Candid Common Stock previously owned by the optionholder, (4) a net exercise of the option if it is an NSO, (5) deferred payment or a similar arrangement with the optionholder and (6) other legal consideration approved by the administrator. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax limitations on incentive stock options</I>. The aggregate fair market value, determined at the time of grant, of Candid Common Stock with respect to ISOs that
are exercisable for the first time by an optionholder during any calendar year under all of Candid&#8217;s stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be
granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of Candid&#8217;s total combined voting power or </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">that
of any of Candid&#8217;s affiliates unless (1) the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2) the term of the ISO does not exceed five years from the date of grant.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted stock awards</I>. Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the administrator. Restricted stock
awards may be granted in consideration for (1) cash, check, bank draft or money order, (2) services rendered to Candid or Candid&#8217;s affiliates or (3) any other form of legal consideration approved by the administrator. Candid Common Stock
acquired under a restricted stock award may, but need not, be subject to a share repurchase option in Candid&#8217;s favor in accordance with a vesting schedule to be determined by the administrator. A restricted stock award may be transferred only
upon such terms and conditions as set by the administrator. Except as otherwise provided in the applicable award agreement, restricted stock awards that have not vested may be forfeited or repurchased by Candid upon the participant&#8217;s cessation
of continuous service for any reason. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to capital structure</I>. In the event there is a specified type of change in Candid&#8217;s capital structure,
such as a stock dividend, stock split or reverse stock split, appropriate adjustments will be made to (1) the number of shares available for issuance under the Candid 2024 Plan, (2) the number of shares covered by and, as applicable, the exercise
price of each outstanding award granted under the Candid 2024 Plan and (3) the number of shares that may be issued as ISOs under the Candid 2024 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Corporate
transactions</I>. In the event of a &#8220;corporate transaction&#8221; (as defined in the Candid 2024 Plan), the Candid Board generally may take one or more of the following actions with respect to outstanding awards: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">arrange for the surviving or acquiring corporation (or such corporation&#8217;s parent) to assume or continue such awards,
or to substitute a similar stock award for such outstanding awards; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cancel any or all vested and/or unvested awards in exchange for cash or other consideration, at the discretion of the
Candid Board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">accelerate the vesting of stock awards in whole or in part; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cancel any or all unvested awards without payment of any consideration; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">arrange for the lapse of any reacquisition or repurchase rights in Candid&#8217;s favor with respect to a stock award,
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">arrange for the assignment of any such rights to the surviving or acquiring corporation (or such corporation&#8217;s
parent); or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">make a payment equal to the excess, if any, of (A) the value of the property the participant would have received upon
exercise of the award immediately prior to the effective time of a corporate transaction, over (B) any exercise price payable in connection with such exercise. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Candid Board need not take the same action or actions with respect to all stock awards or portions thereof or with respect to all participants or with respect to
the vested or unvested portion of such stock awards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, a stock award may provide for additional acceleration of vesting and exercisability upon or
following a &#8220;change in control&#8221; (as defined in the Candid 2024 Plan) as may be provided in the award agreement evidencing such stock award or in any other written agreement with the holder thereof. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan amendment or termination</I>. The Candid Board may amend, modify or terminate the Candid 2024 Plan at any time. Unless terminated sooner by the Candid Board,
the Candid 2024 Plan will automatically terminate on the day before the tenth anniversary of the earlier of (1) the date the Candid 2024 Plan was approved by the Candid Board or (2) the date the Candid 2024 Plan was approved by Candid&#8217;s
stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Historically, Candid has not paid cash compensation to any of its <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on the Candid Board. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth in summary form information concerning the compensation that Candid paid or awarded during the year ended December&nbsp;31, 2025 to each
of Candid&#8217;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FEES&nbsp;EARNED<BR>OR&nbsp;PAID&nbsp;IN&nbsp;CASH<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK<BR>AWARDS<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>AWARDS<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dan Puckett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Michael Rome, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Aaron Royston, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Angie You, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amounts reflect the aggregate grant date fair value of the option awards granted during the year ended December&nbsp;31, 2025 computed in accordance with FASB ASC 718. Assumptions used in the calculation of the grant
date fair value of each option award granted are described in Note 8 to Candid&#8217;s audited consolidated financial statements and notes appearing elsewhere in this proxy statement/prospectus. These amounts do not reflect the actual economic value
that may be realized by Candid&#8217;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors upon the vesting of the option awards, the exercise of the option awards, or any subsequent sale of common stock underlying such option awards.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2025, the aggregate number of shares of Candid Common Stock and shares of Candid Common Stock underlying outstanding options to purchase shares of Candid Common Stock held by <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors was as follows: (i) Candid stock options to purchase 1,838,750 shares of Candid Common Stock held by Mr. Puckett and (ii) 1,638,750 shares of Candid Common Stock and Candid stock options to
purchase 200,000 shares of Candid Common Stock held by Dr. You. None of Candid&#8217;s other <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held shares of Candid Common Stock or options to purchase shares of Candid Common Stock as of
December&nbsp;31, 2025. </TD></TR></TABLE> <P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Outstanding equity awards held by Candid&#8217;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are
subject to the terms of the Candid 2024 Plan, as described above under &#8220;&#8212;<I>Equity Incentive Plan&#8212;Candid 2024 Equity Incentive Plan</I>.&#8221; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2025, the Candid board of directors cancelled option awards to purchase 200,000 shares of Candid Common Stock granted to each of Mr.&nbsp;Puckett and
Dr.&nbsp;You (collectively, the &#8220;Director Cancelled Options&#8221;). The Director Cancelled Options were originally granted in November 2024 with an exercise price of $0.70 per share and vested, if at all, upon an IPO liquidity-event based
performance condition, subject to the grantee&#8217;s Continuous Service with Candid as of such date. In May 2025, the Candid Board approved replacement option awards to purchase 200,000 shares of Candid Common Stock to each of Mr.&nbsp;Puckett and
Dr.&nbsp;You (collectively, the &#8220;Director Replacement Options&#8221;). The Director Replacement Options have an exercise price of $0.35 per share and vest as follows: (a)&nbsp;in the event of a CIC Liquidity Event, then 100% of the total
shares will vest immediately prior to and contingent upon the closing of such CIC Liquidity Event and (b)&nbsp;in the event of a Public Listing Liquidity Event, then 12/48<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the total shares
will vest on the one year anniversary of the date of the Public Listing Liquidity Event, and 1/48<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the total shares will vest each month thereafter on the same day of the month as the vesting
commencement date (or if there is no corresponding day, on the last day of the month), subject to the grantee&#8217;s Continuous Service with Candid as of each such date and subject to the occurrence of such Public Listing Liquidity Event on or
before December&nbsp;31, 2026. Upon the Closing Date, the Director Replacement Options will begin vesting in accordance with subsection&nbsp;(b). For more information with respect to the vesting terms see the Replacement Options described above.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has reimbursed and will continue to reimburse all of its <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their travel, lodging and other
reasonable expenses incurred in attending meetings of the Candid Board and committees of the Candid Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director Compensation Policy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the Merger, Candid intends to adopt a new <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation
policy on terms to be determined by the combined company&#8217;s board of directors. Under the <FONT STYLE="white-space:nowrap">non-employee</FONT> director policy, the combined company&#8217;s <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors will be eligible to receive compensation for service on the combined company&#8217;s board of directors and committees of combined company&#8217;s board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_12"></A>PROPOSAL NO. 1&#8212;THE NASDAQ STOCK ISSUANCE PROPOSAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the Rallybio annual meeting, Rallybio stockholders will be asked
to approve the issuance of shares of Rallybio Common Stock to (i)&nbsp;the securityholders of Candid, pursuant to the terms of the Merger Agreement, and (ii)&nbsp;certain investors in the Concurrent Financing, pursuant to the terms of the
subscription agreement, which will (a)&nbsp;represent more than 20% of the shares of Rallybio Common Stock outstanding immediately prior to the Merger and (b)&nbsp;result in the change of control of Rallybio, pursuant to Nasdaq Listing Rules 5635(a)
and 5635(b), respectively. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the Closing, on
a pro forma basis and based upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, pre-Merger equityholders of Candid (other than investors in the Concurrent Financing) are expected to own
approximately 57.55% of the combined company, pre-Merger equityholders of Rallybio are expected to own approximately 3.65% of the combined company and the investors in the Concurrent Financing are expected to own approximately 38.80% of the combined
company (assuming proceeds from the Concurrent Financing of $505.5&nbsp;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i)&nbsp;a valuation for Rallybio of
$47.5&nbsp;million (assuming Rallybio Net Cash of $37.5&nbsp;million as of the Closing), (ii)&nbsp;a fixed valuation for Candid of $750.0&nbsp;million, and (iii)&nbsp;the relative capitalization of Rallybio and Candid. The percentage of the combined
company that each party&#8217;s equityholders will own following the Closing is subject to certain adjustments (as described in more detail in the section titled &#8220;<I>The Merger Agreement&#8212;Merger Consideration and Exchange
Ratio</I>&#8221;), including the amount of the final Rallybio Net Cash at the Closing. Rallybio Net Cash as calculated under the Merger Agreement makes certain adjustments to the value of Rallybio&#8217;s Cash and Cash Equivalents (as defined in the
Merger Agreement), and was equal to approximately $39.47&nbsp;million as of December&nbsp;31, 2025. The adjustments are described in the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; Based
on its Cash and Cash Equivalents and other balance sheet line items as of December&nbsp;31, 2025 and current estimates of the other elements of Rallybio Net Cash (including projected adjustments to Rallybio&#8217;s Cash and Cash Equivalents),
Rallybio calculates that it had Rallybio Net Cash of approximately $35.81&nbsp;million as of April&nbsp;15, 2026. Rallybio expects to continue to incur losses in future periods primarily related to the proposed Merger and, as a result, available
Cash and Cash Equivalents will continue to decrease. For a description of the calculation of Rallybio Net Cash as set forth in the Merger Agreement, please see the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s
Net Cash.</I>&#8221; </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The terms of, reasons for and other aspects of the Merger Agreement, the Merger and the issuance of Rallybio Common Stock in the Merger
are described in detail in the other sections in this proxy statement/prospectus. A copy of the Merger Agreement is attached as <I>Annex </I><I></I><I>A </I>to this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Reason for the Proposal </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Nasdaq Listing Rule 5635(a)(1), a company
listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in
excess of 20% of the number of shares of common stock then outstanding. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&nbsp;5635(a)(1), Rallybio must obtain the approval of Rallybio stockholders for the issuance of these shares
of common stock in the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Nasdaq Listing Rule 5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of
stock that will result in a &#8220;change of control&#8221; of the listed company. Nasdaq has determined that the Merger constitutes a &#8220;change of control&#8221; of the listed company. Accordingly, in order to ensure compliance with Nasdaq
Listing Rule 5635(b), Rallybio must obtain the approval of Rallybio stockholders of the change of control of Rallybio resulting from the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Required Vote
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The affirmative vote of a majority of the total votes cast by the holders of Rallybio Common Stock entitled to vote at the Rallybio annual meeting, assuming a
quorum is present, is required to approve the Nasdaq Stock Issuance Proposal. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> (if any) will have no effect on the outcome of the vote on the Nasdaq Stock Issuance Proposal.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal (or the waiver thereof in
accordance with the terms of the Merger Agreement). Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be
effected. The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. Therefore, the Concurrent Financing cannot be consummated without the
approval of the Nasdaq Stock Issuance Proposal (or the waiver thereof). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of Rallybio&#8217;s stockholders have agreed to vote any shares of Rallybio Common
Stock owned by them in favor of the Contemplated Transactions including: (a)&nbsp;the Nasdaq Stock Issuance Proposal, (b)&nbsp;the Reverse Stock Split Proposal, (c)&nbsp;the Name Change Proposal, (d)&nbsp;the Authorized Share Proposal, and
(e)&nbsp;the other actions contemplated by the Merger Agreement, against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and against any alternative acquisition
proposals. See &#8220;<I>Agreements Related to the Merger&#8212;Support Agreements</I>&#8221; for more information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise instructed, it is the
intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<B>FOR</B>&#8221; the approval of the Nasdaq Stock Issuance Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE RALLYBIO BOARD UNANIMOUSLY RECOMMENDS A VOTE &#8220;FOR&#8221; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE NASDAQ STOCK ISSUANCE PROPOSAL </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_13"></A>PROPOSAL NO. 2&#8212;THE REVERSE STOCK SPLIT PROPOSAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the Rallybio annual meeting, Rallybio stockholders will be asked
to approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation that will implement a reverse stock split of the issued and outstanding shares of Rallybio Common Stock at a ratio in the range between 1-for-2 to 1-for-3
inclusive, with the final ratio to be mutually agreed to by Rallybio and Candid, for the purposes of maintaining compliance with Nasdaq listing standards or for the combined company to meet the initial listing standards of Nasdaq or otherwise if
deemed advisable by Candid. Upon the effectiveness of such amendment to Rallybio&#8217;s amended and restated certificate of incorporation to effect the reverse stock split (the &#8220;reverse stock split effective time&#8221;), the issued and
outstanding shares of Rallybio Common Stock immediately prior to the reverse stock split effective time will be reclassified into a smaller number of shares such that a Rallybio stockholder will own a ratio ranging from one new share of Rallybio
Common Stock for every 2 to 3 shares of issued common stock held by such stockholder immediately prior to the reverse stock split effective time, as specified. Based upon the reverse stock split ratio selected by Rallybio and Candid, proportionate
adjustments will be made to the per share exercise price, and/or the number of shares issuable upon the exercise or vesting of all then outstanding Rallybio stock options, which will result in a proportional decrease in the number of shares of
Rallybio Common Stock reserved for issuance upon exercise or vesting of such stock options, and a proportional increase in the exercise price of all such stock options. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The proposed form of certificate of amendment to Rallybio&#8217;s amended and restated certificate of incorporation, a copy of which is attached as <I>Annex
</I><I></I><I>I </I>to this proxy statement/prospectus, will affect the reverse stock split but <B><I>will not </I></B>change the number of authorized shares of Rallybio Common Stock, or the par value of Rallybio Common Stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board may determine to effect the reverse stock split, if it is approved by the stockholders, even if the other proposals to be acted upon at the meeting
are not approved, including the Nasdaq Stock Issuance Proposal. In addition, notwithstanding approval of this proposal by Rallybio stockholders, the Rallybio Board may, in its sole discretion, abandon the proposed amendment and determine prior to
the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the reverse stock split, as permitted under Section&nbsp;242(c) of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Reasons for the Proposal </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board approved the proposal approving
the amendment to Rallybio&#8217;s amended and restated certificate of incorporation effecting the reverse stock split for the following reasons: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio Board believes effecting the reverse stock split will result in an increase in the minimum bid price of
Rallybio Common Stock, thereby increasing the ability of the combined company to satisfy the Nasdaq initial listing requirements for the combined company common stock and reducing the risk of a delisting of Rallybio Common Stock from Nasdaq in the
future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio Board believes a higher stock price may help generate investor interest in Rallybio and ultimately the
combined company and help Rallybio attract and retain employees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio Board believes a higher stock price may increase trading volume in Rallybio Common Stock and facilitate
future financings by the combined company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio Board believes that the resulting increase in the number of authorized and unissued shares available for
future issuance will facilitate the issuance of shares to the stockholders of Candid pursuant to the Merger Agreement, as described in the Nasdaq Stock Issuance Proposal, and ultimately the consummation of the Merger, and the issuance of shares to
the investors in the Concurrent Financing pursuant to the Subscription Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Rallybio Board believes that a range of reverse stock split ratios provides it with the most flexibility to achieve
the desired results of the reverse stock split. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Requirements for Listing on Nasdaq </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Common Stock is listed on Nasdaq under the symbol &#8220;RLYB.&#8221; Candid will file an initial listing application pursuant to the terms of the Merger
Agreement for the combined company with Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the Nasdaq rules, an issuer must, in a case such as this, apply for initial inclusion following a
transaction whereby the issuer combines with a <FONT STYLE="white-space:nowrap">non-Nasdaq</FONT> entity, resulting in a change of control of the issuer and potentially allowing the <FONT STYLE="white-space:nowrap">non-Nasdaq</FONT> entity to obtain
a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require Rallybio to have, among other things, a $4.00 per share minimum bid price for a certain number of trading days preceding the Closing. Therefore, the reverse stock split may
be necessary in order to consummate the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, it is a condition to the Closing that the shares of Rallybio Common Stock to be issued in the Merger
pursuant to the Merger Agreement having been approved for listing on Nasdaq. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">One of the effects of the reverse stock split will be to effectively increase the
proportion of authorized shares which are unissued relative to those which are issued. This could result in Rallybio&#8217;s management being able to issue more shares without further stockholder approval. The reverse stock split will not affect the
number of authorized shares of Rallybio capital stock, which will continue to be authorized pursuant to Rallybio&#8217;s amended and restated certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Potential Increased Investor Interest </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The closing price of the Rallybio
Common Stock on &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, as reported on Nasdaq, was $&#8195;&#8195;&#8195;&#8195;&#8195; per share. An investment in Rallybio Common Stock may not appeal to brokerage firms that are reluctant to recommend lower
priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many
brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, the Rallybio Board believes that most investment funds are reluctant to invest in lower priced stocks. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of Rallybio Common
Stock at the levels expected or at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio cannot predict whether the reverse stock split will increase the market price for Rallybio Common Stock. The
history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the market price per share of Rallybio Common Stock after the reverse stock split will rise in proportion to the reduction
in the number of shares of Rallybio Common Stock outstanding before the reverse stock split; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower
priced stocks; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the reverse stock split will result in a per share price that will increase the ability of Rallybio to attract and retain
employees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for
continued listing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the reverse stock split will or increase trading volume in Rallybio Common Stock and facilitate future financings by the
combined company; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the market price per share will achieve and maintain the $4.00 minimum bid price requirement for a sufficient period of
time for the combined company&#8217;s common stock to be approved for listing by Nasdaq. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The market price of Rallybio Common Stock will also be
based on the performance of Rallybio, and after the Merger, on the performance of the combined company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price
of Rallybio Common Stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of Rallybio may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity
of Rallybio Common Stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Principal Effects of the Reverse Stock Split </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The reverse stock split will be realized simultaneously for all shares of Rallybio Common Stock and Rallybio options outstanding immediately prior to the reverse stock
split effective time. The reverse stock split will affect all holders of shares of Rallybio Common Stock outstanding immediately prior to the reverse stock split effective time uniformly and each such stockholder will hold the same percentage of
Rallybio Common Stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for immaterial adjustments that may result from the treatment of fractional shares as
described below. The reverse stock split will not change the par value of Rallybio Common Stock or preferred stock and will not reduce the number of authorized shares of Rallybio Common Stock or preferred stock. Rallybio Common Stock issued pursuant
to the reverse stock split will remain fully paid and nonassessable. The reverse stock split will not affect Rallybio continuing to be subject to the periodic reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Rallybio stockholders approve the amendment to Rallybio&#8217;s amended and restated certificate of incorporation effecting the reverse stock split, and if the
Rallybio Board still believes that a reverse stock split is in the best interests of Rallybio and its stockholders, Rallybio will file the certificate of amendment to Rallybio&#8217;s amended and restated certificate of incorporation with the
Secretary of State of the State of Delaware at such time as the Rallybio Board has determined to be the appropriate reverse stock split effective time. The Rallybio Board may delay effecting the reverse stock split without resoliciting stockholder
approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beginning at the reverse stock split effective time, each stock certificate representing <FONT STYLE="white-space:nowrap">pre-split</FONT> shares will be
deemed for all corporate purposes to evidence ownership of post-split shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Beneficial Owners of Common Stock</I>. Upon the implementation of the reverse
stock split, Rallybio intends to treat shares held by stockholders in &#8220;street name&#8221; (i.e., through a bank, broker, custodian or other nominee), in the same manner as registered stockholders whose shares are registered in their names.
Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding Rallybio Common Stock in street name. However, these banks, brokers, custodians or other nominees may have
different procedures than registered stockholders for processing the reverse stock split and making payment for fractional shares. If a stockholder holds shares of Rallybio Common Stock with a bank, broker, custodian or other nominee and has any
questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Registered Holders of Common Stock in
Book-Entry Form</I>. Rallybio&#8217;s registered holders of common stock hold their shares electronically in book-entry form with Rallybio&#8217;s transfer agent, Computershare Trust Company, N.A. These stockholders do not hold physical stock
certificates evidencing their ownership of Rallybio Common Stock. However, they are provided with a statement reflecting the number of shares of Rallybio Common Stock registered in their accounts. No action needs to be taken to receive post-reverse
stock split shares or payment in lieu of fractional shares, if applicable. If a stockholder is entitled to post-reverse stock split shares, a transaction statement will automatically be sent to the stockholder&#8217;s address of record indicating
the number of shares of Rallybio Common Stock held following the reverse stock split. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fractional Shares </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares
because they hold a number of <FONT STYLE="white-space:nowrap">pre-split</FONT> shares not evenly divisible by the number of <FONT STYLE="white-space:nowrap">pre-split</FONT> shares for which each post-split share is to be reclassified, will be
entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing price of the common stock on Nasdaq on the date of the filing of the certificate of amendment
to Rallybio&#8217;s amended and restated certificate of incorporation effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder will be aggregated (thus resulting in no more than one fractional share
per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where Rallybio is domiciled and where the
funds will be deposited, sums due for fractional interests that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by Rallybio or the
exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Potential Anti-Takeover Effect </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although the increased proportion of
unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the
Rallybio Board or contemplating a tender offer or other transaction for the combination of Rallybio with another company, the Reverse Stock Split Proposal is not being proposed in response to any effort of which Rallybio is aware to accumulate
shares of Rallybio Common Stock or obtain control of Rallybio, other than in connection with the Merger and the Concurrent Financing, nor is it part of a plan by management to recommend a similar amendment to the Rallybio Board and stockholders.
Other than the proposals being submitted to the Rallybio stockholders for their consideration at the Rallybio annual meeting, the Rallybio Board does not currently contemplate recommending the adoption of any other actions that could be construed to
affect the ability of third parties to take over or change control of Rallybio. For more information, please see the section titled &#8220;<I>Risk Factors&#8212;Risks Related to the Combined Company</I>&#8221; of this proxy statement/prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Material U.S. Federal Income Tax Consequences of the Reverse Stock Split </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a discussion of the material U.S. federal income tax consequences of the reverse stock split that are applicable to U.S. holders (which, for purposes
of this discussion, has the same meaning as in &#8220;<I>Material U.S. Federal Income Tax Consequences of the Rallybio CVRs to holders of Rallybio Common Stock</I>&#8221;) of Rallybio Common Stock. This discussion does not purport to be a complete
analysis of all potential tax consequences and is based upon current provisions of the Code, existing Treasury regulations, judicial decisions and published rulings and administrative pronouncements of the IRS, all in effect as of the date hereof
and all of which are subject to differing interpretations or change. Any such change or differing interpretation, which may be retroactive, could alter the tax consequences to holders of Rallybio Common Stock as described in this summary. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion assumes that any cash distributed pursuant to a cash dividend will be treated for U.S. federal income tax purposes as separate and distinct from the
reverse stock split. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, this discussion does not address all U.S. federal income tax consequences relevant to holders of Rallybio Common Stock. In
addition, it does not address consequences relevant to holders of Rallybio Common Stock that are subject to particular U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax rules, including, without limitation, to holders of Rallybio Common
Stock that are: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who do not hold their Rallybio Common Stock as a &#8220;capital asset&#8221; within the meaning of
Section&nbsp;1221 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">real estate investment trusts; regulated investment companies; <FONT STYLE="white-space:nowrap">tax-exempt</FONT>
organizations or governmental organizations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">pass-through entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and
limited liability companies (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subject to the alternative minimum tax provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold their shares as part of a hedge, wash sale, synthetic security, conversion transaction or other
integrated transaction; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">traders in securities who elect to apply a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold shares of Rallybio Common Stock that may constitute &#8220;qualified small business stock&#8221; under
Section&nbsp;1202 of the Code or as &#8220;Section&nbsp;1244 stock&#8221; for purposes of Section&nbsp;1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who acquired their shares of Rallybio stock in a transaction subject to the gain rollover provisions of
Section&nbsp;1045 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to Rallybio stock
being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons deemed to sell Rallybio Common Stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who acquired their shares of Rallybio Common Stock pursuant to the exercise of options or otherwise as
compensation or through a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expatriates or former citizens or long-term residents of the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of Rallybio Common Stock subject to particular U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax rules, including those that are described in the
preceding paragraph, are urged to consult their own tax advisors regarding the consequences to them of the reverse stock split. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If an entity that is treated as a
partnership for U.S. federal income tax purposes (or any other pass-through entity) holds Rallybio stock, the U.S. federal income tax treatment of a partner in the partnership or other pass-through entity will generally depend upon the status of the
partner, the activities of the partnership or other pass-through entity and certain determinations made at the partner level. If you are a partner of a partnership or other pass-through entity holding Rallybio Common Stock, you should consult your
tax advisors regarding the tax consequences of the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the following discussion does not address (a)&nbsp;any tax consequences of transactions
effectuated before, after or at the same time as the reverse stock split, whether or not they are in connection with the reverse stock split, except as specifically provided below; (b)&nbsp;the tax consequences of the reverse stock split under
state, local and foreign tax laws; (c)&nbsp;any U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences of the reverse stock split, including estate, gift or other tax consequences; or (d)&nbsp;the Medicare contribution tax
on net investment income. No ruling from the IRS has been or will be requested in connection with the reverse stock split. Rallybio stockholders should be aware that the IRS could adopt a position contrary to that set forth in this discussion and
which could be sustained by a court. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR
PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR
UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Tax Consequences of the Reverse Stock Split </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The proposed reverse stock split should constitute a &#8220;recapitalization&#8221; for U.S. federal income tax purposes pursuant to Section&nbsp;368(a)(1)(E) of the
Code. As a result, a U.S. holder should not recognize gain or loss upon the proposed reverse stock split, except with respect to cash received in lieu of a fractional share of Rallybio Common Stock, as discussed below. A U.S. holder&#8217;s
aggregate adjusted tax basis in the shares of Rallybio Common Stock received pursuant to the proposed reverse stock split should equal the aggregate adjusted tax basis of the shares of the Rallybio Common Stock surrendered (excluding any portion of
such basis that is allocated to any fractional share of Rallybio Common Stock), and such U.S. holder&#8217;s holding period in the shares of Rallybio Common Stock received should include the holding period in the shares of Rallybio Common Stock
surrendered. U.S. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Rallybio Common Stock surrendered to the shares of Rallybio Common Stock received in a recapitalization pursuant to the
proposed reverse stock split. U.S. holders of shares of Rallybio Common Stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares. It is
possible that the IRS or a court could determine that the issuance of the Rallybio CVRs (and/or any payments thereon) and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes with
the Rallybio CVRs constituting taxable &#8220;boot&#8221; received in such recapitalization exchange. In such case, the tax consequences of the Rallybio CVRs and the proposed reverse stock split would differ from those described above, including
with respect to the timing and character of income. </P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash in Lieu of Fractional Shares </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A U.S. holder that receives cash in lieu of a fractional share of Rallybio Common Stock pursuant to the proposed reverse stock split should recognize capital gain or
loss in an amount equal to the difference between the amount of cash received and the U.S. holder&#8217;s tax basis in the shares of Rallybio Common Stock surrendered that is allocated to such fractional share of Rallybio Common Stock. Such capital
gain or loss should be long-term capital gain or loss if the U.S. holder&#8217;s holding period for Rallybio Common Stock surrendered exceeded one year at the reverse stock split effective time. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Information Reporting and Backup Withholding </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments of cash made
in lieu of a fractional share of Rallybio Common Stock may, under certain circumstances, be subject to information reporting and backup withholding. To avoid backup withholding, each holder of Rallybio Common Stock that does not otherwise establish
an exemption should furnish its taxpayer identification number and comply with the applicable certification procedures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional
tax. Any amounts withheld will be allowed as a credit against the holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. Holders of Rallybio Common
Stock should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Required Vote </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The affirmative vote of a majority of the total votes cast by
the holders of Rallybio Common Stock entitled to vote at the Rallybio annual meeting, assuming a quorum is present, is required to approve the Reverse Stock Split Proposal Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> (if
any) will have no effect on the outcome of the vote on the Reverse Stock Split Proposal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is conditioned upon the approval of the Reverse Stock Split
Proposal (or the waiver thereof in accordance with the terms of the Merger Agreement). If the Merger is not consummated for any reason, the actions contemplated by the Reverse Stock Split Proposal may still be effected if the Reverse Stock Split
Proposal is approved. The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. Therefore, the Concurrent Financing cannot be consummated
without the approval of the Reverse Stock Split Proposal (or the waiver thereof). Rallybio may still elect to proceed with the reverse stock split if the Reverse Stock Split Proposal is approved by Rallybio stockholders even if Proposal No.&nbsp;1
is not approved, or even if approved, the Merger is not consummated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of Rallybio&#8217;s stockholders have agreed to vote any shares of common stock owned
by them in favor of the Contemplated Transactions including (a)&nbsp;the Nasdaq Stock Issuance Proposal, (b)&nbsp;the Reverse Stock Split Proposal, (c)&nbsp;the Name Change Proposal, (d)&nbsp;the Authorized Share Proposal, and (e)&nbsp;the other
actions contemplated by the Merger Agreement, against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and against any alternative acquisition proposals. See
&#8220;<I>Agreements Related to the Merger&#8212;Support Agreements</I>&#8221; for more information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise instructed, it is the intention of the
persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<B>FOR</B>&#8221; the approval of the Reverse Stock Split Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE RALLYBIO BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE REVERSE STOCK SPLIT PROPOSAL </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_14"></A>PROPOSAL NO. 3&#8212;THE NAME CHANGE PROPOSAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the Rallybio annual meeting, Rallybio stockholders will be asked
to approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to effect the name change of &#8220;Rallybio Corporation&#8221; to &#8220;Candid Therapeutics, Inc.&#8221; effective only upon the completion of the
Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The proposed form of certificate of amendment to Rallybio&#8217;s amended and restated certificate of incorporation, a copy of which is attached as Annex J
to this proxy statement/prospectus, will affect the name change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Effects of the Name Change Amendment </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Rallybio stockholders approve the amendment to Rallybio&#8217;s certificate of incorporation effecting the name change, Rallybio will file the certificate of
amendment to Rallybio&#8217;s amended and restated certificate of incorporation with the Secretary of State of the State of Delaware upon the completion of the Merger. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the Name Change Amendment and resulting change of the Rallybio&#8217;s corporate name, the common stock of the combined company will trade on Nasdaq under the
symbol &#8220;CDRX.&#8221; Stockholders will not experience any change in their rights as a stockholder as a result of this amendment to the Rallybio charter. Stockholders will not be required to submit their stock certificates for exchange as a
result of this proposed name change. Following the effective date of the name change, all new stock certificates issued by us will use our new name. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Required
Vote </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The affirmative vote of a majority of the votes properly cast for and against by the holders of Rallybio Common Stock entitled to vote on at the Rallybio
annual meeting is required to approve the Name Change Proposal. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> (if any) will have no effect on the outcome of the vote on the Name Change Proposal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is conditioned upon the approval of the Name Change Proposal (or the waiver thereof in accordance with the terms of the Merger Agreement). Notwithstanding
the approval of the Name Change Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Name Change Proposal will not be effected. The closing of the Concurrent Financing is conditioned upon the satisfaction or
waiver of each of the conditions to the Closing as well as certain other conditions. Therefore, the Concurrent Financing cannot be consummated without the approval of the Name Change Proposal (or the waiver thereof). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of Rallybio&#8217;s stockholders and Candid&#8217;s equityholders have agreed to vote any shares of common stock owned by them in favor of the Contemplated
Transactions including: (a)&nbsp;the Nasdaq Stock Issuance Proposal, (b)&nbsp;the Reverse Stock Split Proposal, (c)&nbsp;the Name Change Proposal, (d)&nbsp;the Authorized Share Proposal, and (e)&nbsp;the other actions contemplated by the Merger
Agreement, against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and against any alternative acquisition proposals. See &#8220;<I>Agreements Related to the
Merger&#8212;Support Agreements</I>&#8221;<I> </I>for more information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise instructed, it is the intention of the persons named in the accompanying
proxy card to vote shares represented by properly executed proxy cards &#8220;<B>FOR</B>&#8221; the approval of the Name Change Proposal. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE
BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE NAME CHANGE PROPOSAL </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_14a"></A>PROPOSAL NO. 4&#8212;THE AUTHORIZED SHARE PROPOSAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board has determined that it is advisable to increase
the authorized number of shares of Rallybio Common Stock from 200,000,000 shares to 500,000,000&nbsp;shares, and has voted to recommend that the stockholders adopt an amendment to Rallybio&#8217;s amended and restated certificate of incorporation
effecting the proposed increase. The full text of the proposed amendment to Rallybio&#8217;s amended and restated certificate of incorporation is attached to this proxy statement as <I>Annex </I><I>K</I><I></I>. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of February&nbsp;27, 2026, and assuming a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-2.5</FONT></FONT> reverse stock split of Rallybio
Common Stock of Rallybio Common Stock to be implemented immediately prior to the Closing and upon the approval of the Reverse Stock Split Proposal, 2,115,870 shares of Rallybio Common Stock were issued and outstanding (excluding treasury shares) and
approximately an additional 545,476 shares of Rallybio Common Stock were reserved for issuance upon the settlement or exercise of outstanding equity awards and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and a total of approximately
273,988 shares of Rallybio Common Stock were available for future issuance under Rallybio&#8217;s existing equity plans. Additionally, Rallybio expects that it will issue 62,246,687&nbsp;shares of Rallybio Common Stock in the Merger, assuming a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-2.5</FONT></FONT> reverse stock split of Rallybio Common Stock of Rallybio Common Stock to be implemented prior to the consummation of the Merger as may be adjusted and as discussed
in this proxy statement/prospectus and based on the assumed Exchange Ratio, excluding any shares that may be issued in connection with the exercise of options assumed by Rallybio. Following the issuance of the shares of Rallybio Common Stock in the
Merger and upon the approval of the 2026 Plan Proposal and the 2026 ESPP Proposal, a total of approximately 13,478,389 shares of Rallybio Common Stock is expected to be available for future issuance assuming the approval of this Proposal No.&nbsp;4.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board believes it continues to be in Rallybio&#8217;s best interest to have sufficient additional authorized but unissued shares of Rallybio Common
Stock available in order to provide flexibility for corporate action and strategic transactions in the future. Management believes that the availability of additional authorized shares for issuance from time to time in the Rallybio Board&#8217;s
discretion in connection with future financings, investment opportunities, stock splits or dividends or for other corporate purposes is desirable in order to avoid repeated separate amendments to Rallybio&#8217;s amended and restated certificate of
incorporation and the delay and expense incurred in holding special meetings of the stockholders to approve such amendments. Rallybio currently has no specific understandings, arrangements or agreements with respect to any future acquisitions that
would require Rallybio to issue a material amount of new shares of Rallybio Common Stock. However, the Rallybio Board believes that the currently available unissued shares do not provide sufficient flexibility for corporate action in the future.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio will not solicit further authorization by vote of the stockholders for the issuance of the additional shares of Rallybio Common Stock proposed to be
authorized, except as required by law, regulatory authorities or rules of Nasdaq or any other stock exchange on which the Rallybio Common Stock may then be listed. The issuance of additional shares of Rallybio Common Stock could have the effect of
diluting existing stockholder earnings per share, book value per share and voting power. Rallybio stockholders do not have any preemptive right to purchase or subscribe for any part of any new or additional issuance of Rallybio&#8217;s securities.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the corporate purposes mentioned above, an increase in the authorized number shares of Rallybio Common Stock may make it more difficult to, or
discourage an attempt to, obtain control of Rallybio by means of a takeover bid that the Rallybio Board determines is not in the best interest of Rallybio and its stockholders. However, the Rallybio Board does not intend or view the proposed
increase in the number of authorized shares of Rallybio Common Stock as an anti-takeover measure and is not aware of any attempt or plan to obtain control of Rallybio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Required Vote </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The affirmative vote of the holders of at least seventy-five
percent of the outstanding shares of Rallybio Common Stock entitled to vote at the Rallybio annual meeting is required to approve the Name Change Proposal. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> (if any) will have
the same effect as a vote &#8220;AGAINST&#8221; the Authorized Share Proposal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is <B><U>not</U></B> conditioned upon the approval of the Authorized
Share Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of Rallybio&#8217;s stockholders and Candid&#8217;s equityholders have agreed to vote any shares of common
stock owned by them in favor of the Contemplated Transactions including: (a) the Nasdaq Stock Issuance Proposal, (b) the Reverse Stock Split Proposal, (c) the Name Change Proposal, (d) the Authorized Share Proposal, and (e) the other actions
contemplated by the Merger Agreement, against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and against any alternative acquisition proposals. See &#8220;<I>Agreements
Related to the Merger&#8212;Support Agreements</I>&#8221; for more information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise instructed, it is the intention of the persons named in the
accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<B>FOR</B>&#8221; the approval of the Authorized Share Proposal. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE AUTHORIZED SHARE PROPOSAL </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_15"></A>PROPOSAL NO. 5&#8212;THE DIRECTOR ELECTION PROPOSAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the Rallybio&#8217;s certificate of
incorporation and bylaws, the Rallybio Board is divided into three classes. The members of each class are elected to serve a three-year term with the term of office of each class ending in successive years. Helen Boudreau, M.B.A., Lucian Iancovici,
M.D. and Christine A. Nash, M.B.A. are the Class&nbsp;II directors whose terms expire at Rallybio&#8217;s 2026 annual meeting of stockholders. Helen Boudreau, M.B.A., Lucian Iancovici, M.D. and Christine A. Nash, M.B.A. have been nominated for and
have agreed to stand for <FONT STYLE="white-space:nowrap">re-election</FONT> to the Rallybio Board to serve as a Class&nbsp;II director of Rallybio for three years and until their successors are duly elected and qualified or until their earlier
death, resignation or removal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is intended that, unless you give contrary instructions, shares represented by proxies will be voted for the election of each of
the nominees listed above. Rallybio has no reason to believe that any nominee will be unable to serve. In the event that either or both nominees are unexpectedly not available to serve, proxies may be voted for another person nominated as a
substitute by the Rallybio Board, or the Rallybio Board may reduce the number of directors to be elected at the annual meeting. Information relating to each nominee for election as director and for each continuing director, including his or her
period of service as a director of Rallybio, principal occupation and other biographical material is shown earlier in this proxy statement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio stockholders
should understand, however, that if the Merger is consummated, the effect of the approval of the director nominees named in the Director Election Proposal will be limited because the composition of the Rallybio Board will be reconstituted upon
completion of the Merger in accordance with the Merger Agreement. Immediately following the Merger, the combined company&#8217;s board of directors will be designated by Candid. All of Rallybio&#8217;s current directors are expected to resign from
their positions as directors of Rallybio, effective as of the Effective Time. For more information, see the section titled &#8220;<I>Management Following the Merger</I>.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nominees for Election as Class&nbsp;II Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table
identifies Rallybio&#8217;s director nominees and sets forth their principal occupation and business experience during the last five years and their ages as of March&nbsp;6, 2026. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="56%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DIRECTOR</B><br><B>SINCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>POSITION AND CLASS</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director (Class II); Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Helen Boudreau, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director (Class II)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director (Class II)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Christine A. Nash, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director (Class II)</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stephen Uden, M.D.,</I></B> is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of, and has been Chief Executive Officer and President, and a director of,
Rallybio since August 2023. From January 2018 until August 2023, Dr.&nbsp;Uden served as President, Chief Operating Officer and Chief Scientific Officer of Rallybio. Previously, Dr.&nbsp;Uden served as Senior Vice President, Research at Alexion from
June 2014 to October 2017. Prior to Alexion, Dr.&nbsp;Uden served in various leadership roles in the research organizations of Novartis (Japan), Wyeth (Japan), Neurogen and Pfizer. Dr.&nbsp;Uden received a BSc in biochemistry and an M.B., B.S. in
medicine from the University of London. We believe Dr.&nbsp;Uden is qualified to serve on Rallybio&#8217;s Board because of his executive management experience and research and scientific expertise at global pharmaceutical and biotechnology
companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Helen M. Boudreau, M.B.A.,</I></B> has served as a member of Rallybio&#8217;s Board since September 2020. Since 2020, she has been Managing
Director of Estuary Ventures LLC, providing board and advisory services. Previously, she served as Chief Financial Officer from July 2017 to June 2018 and as a board member from February 2016 to July 2017 of Proteostasis Therapeutics, Inc. From
October 2014 to June 2017, Ms.&nbsp;Boudreau served as Chief Financial Officer of FORMA Therapeutics, Inc., and from September 2008 to September 2014, Ms.&nbsp;Boudreau served in senior finance roles at Novartis AG, including Chief Financial Officer
Novartis Corporation US and Chief Financial Officer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Global Oncology. Prior to Novartis, Ms.&nbsp;Boudreau served in roles of increasing responsibility in strategy and finance at Pfizer from April 1999 to September 2008, including Vice President
Finance Customer Business Unit and Commercial Operations and Vice President Finance, Pfizer Global Research and Development. Earlier in her career, Ms.&nbsp;Boudreau worked at PepsiCo Inc. and YUM! Brands, Inc., McKinsey&nbsp;&amp; Company and Bank
of America Corporation. Ms.&nbsp;Boudreau currently serves as a board member of Shattuck Labs Inc. Ms.&nbsp;Boudreau previously served on the board of directors of Premier, Inc., Cara Therapeutics, Inc., Evaxion Biotech A/S, Proteostasis
Therapeutics, Inc. and Reunion Neuroscience Inc. Ms.&nbsp;Boudreau earned a B.A. in Economics from the University of Maryland, where she graduated summa cum laude, and an M.B.A. from the Darden Graduate School of Business at the University of
Virginia. Ms.&nbsp;Boudreau is Directorship Certified<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by the National Association of Corporate Directors (&#8220;NACD&#8221;) and earned the CERT Certificate in Cybersecurity Oversight from
Carnegie Mellon University Software Engineering Institute and NACD. We believe Ms.&nbsp;Boudreau is qualified to serve on Rallybio&#8217;s Board because of her financial expertise and extensive experience as an executive and director with
biotechnology companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lucian Iancovici, M.D.,</I></B> has served as a member of Rallybio&#8217;s Board since May 2020. Dr.&nbsp;Iancovici is currently a
Partner of TPG, a global alternative asset manager, where he has worked since January 2018. From September 2012 to October 2017, Dr.&nbsp;Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health
technologies. From January 2015 to October 2017, Dr.&nbsp;Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr.&nbsp;Iancovici was an associate at
McKinsey&nbsp;&amp; Company. Dr.&nbsp;Iancovici currently serves on the board of directors of Sionna Therapeutics, Inc. and on the boards of directors of several private companies. He is a board-certified internal medicine doctor who trained at
Columbia University Medical Center in New York prior to joining McKinsey&nbsp;&amp; Company. Dr.&nbsp;Iancovici received his B.A. in economics and an M.D., both from Tufts University. We believe that Dr.&nbsp;Iancovici is qualified to serve on
Rallybio&#8217;s Board because of his extensive experience in the venture capital industry, and his medical and scientific background and training. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Christine
A. Nash, M.B.A.,</I></B> has served as a member of Rallybio&#8217;s Board since April 2022. Since April 2018, Ms.&nbsp;Nash has been a principal at Chatiemac Consulting, LLC, a firm that provides strategic and commercial planning guidance to
biotechnology companies and investors focused on the development of medications for rare diseases. From September 2021 until September 2022, Ms.&nbsp;Nash served as Board Chair and senior advisor to the President and Chief Executive Officer of The
CM Group, an integrated healthcare agency focused on providing scientific and commercialization strategies and services to life sciences companies, where she also served as a member of the board of directors from August 2019 until September 2022.
From 2007 to 2015, Ms.&nbsp;Nash held positions of increasing responsibility at Hyperion Therapeutics, Inc., including as Senior Vice President and Chief Commercial Officer since May 2012. Prior to Hyperion, from 2004 to 2007, Ms.&nbsp;Nash held
various positions of increasing responsibility within the commercial organization at CoTherix, Inc. Ms.&nbsp;Nash&#8217;s previous experience includes business development and product planning and management roles with Genesoft Pharmaceuticals Inc.,
Oncology Therapeutics Network, Eli Lilly and Company, and Imana, Inc. Ms.&nbsp;Nash holds an M.B.A and a B.A. with Honors in Public Policy, both from Stanford University. We believe that Ms.&nbsp;Nash is qualified to serve on Rallybio&#8217;s Board
because of her extensive operational and business experience in the pharmaceutical and biotechnology industries, including executive leadership, and her experience overseeing commercial organizations and product launches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Required Vote </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s bylaws provide for a majority voting
standard for the election of directors in uncontested elections, which provides that to be elected, a director nominee must receive a greater number of votes FOR his or her election than votes AGAINST his or her election. The number of votes cast
with respect to that director&#8217;s election excludes abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> with respect to that director&#8217;s election. In contested elections where the number of director nominees exceeds the
number of directors to be elected, the voting standard will be a plurality of the shares present virtually in person or by proxy and entitled to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger
is <B><U>not</U></B><B></B>&nbsp;conditioned upon the approval of the Director Election Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise instructed, it is the intention of the persons
named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<B>FOR</B>&#8221; the approval of the Director Election Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE RALLYBIO BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; EACH OF THE DIRECTOR
NOMINEES NAMED IN THE DIRECTOR ELECTION PROPOSAL </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directors Continuing in Office </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table identifies Rallybio&#8217;s continuing directors and sets forth their principal occupation and business experience during the last five years and
their ages as of March 6, 2026. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DIRECTOR</B><br><B>SINCE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>POSITION AND CLASS</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">69</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman&nbsp;(Class&nbsp;I)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">58</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director (Class I)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Wendy K. Chung M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director (Class III)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Robert Hopfner, R.Ph., Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director (Class III)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald Hunt, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">61</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director (Class III)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Hui Liu, Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director (Class III)</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Class&nbsp;I Directors (Term Expires at 2028 Annual Meeting) </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Martin W. Mackay, Ph.D.,</I></B> is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Rallybio and Chairman of Rallybio&#8217;s Board. From January 2018
until August 2023, Dr.&nbsp;Mackay served as Chief Executive Officer and Chairman of the Board of Directors of Rallybio, and from August 2023 until December 2024 he served as Executive Chairman. From March 2013 to December 2017, Dr.&nbsp;Mackay
served as the Executive Vice President and Global Head of Research&nbsp;&amp; Development at Alexion Pharmaceuticals, Inc., and from July 2010 to January 2013, Dr.&nbsp;Mackay served as the President of Research&nbsp;&amp; Development at AstraZeneca
PLC. Prior to AstraZeneca, Dr.&nbsp;Mackay worked at Pfizer for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr.&nbsp;Mackay currently serves on the board of
directors of Charles River Laboratories International, Inc. and Sail Biomedicines. He previously served as a director of 5AM Acquisition Co. from October 2020 until April 2022. Dr. Mackay served on the board of Novo Nordisk from 2018 through 2025,
and on the board of SpringWorks Therapeutics through its acquisition by Merck KGaA in 2025. Dr.&nbsp;Mackay received a BSc First Class&nbsp;in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the University of
Edinburgh. We believe Dr.&nbsp;Mackay is qualified to serve on Rallybio&#8217;s Board because of his extensive experience serving on other boards and leading research and development organizations at both global pharmaceutical and biotechnology
companies, which provides Rallybio&#8217;s Board with a valuable combination of expertise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Paula Soteropoulos </I></B>has served as a member of
Rallybio&#8217;s Board since October 2020. Ms.&nbsp;Soteropoulos currently serves as Chairman of Ensoma, a private venture-backed company, serves on the board of directors of Metri Bio and Dianthus Therapeutics, Inc. She previously served as Chief
Executive Officer and President of Akcea Therapeutics, Inc. a biopharmaceutical company, where she was also a member of the board of directors. Prior to Akcea, Ms.&nbsp;Soteropoulos served as Senior Vice President and General Manager,
Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc., and prior to Moderna, she served in various roles of increasing responsibility at Genzyme Corporation, including as Vice President and General Manager, Cardiovascular,
Rare Diseases. Ms.&nbsp;Soteropoulos served for 11 years on the board of directors of uniQure N.V. Ms.&nbsp;Soteropoulos also serves on advisory boards of Chiesi USA and Kyowa Kirin North America. Ms.&nbsp;Soteropoulos earned both a B.S. in chemical
and biochemical engineering and an M.S. in chemical and biochemical engineering from Tufts University, and holds an executive management certificate from the Darden Graduate School of Business at the University of Virginia. Ms.&nbsp;Soteropoulos
serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University. We believe Ms.&nbsp;Soteropoulos is qualified to serve on Rallybio&#8217;s Board because of her extensive experience in the biotechnology
industry, her executive leadership experience and her service on the board of directors of other public and private biopharmaceutical companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Class&nbsp;III Directors (Term Expires at 2027 Annual Meeting) </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Wendy K. Chung M.D., Ph.D.,</I></B> has served as a member of Rallybio&#8217;s Board since August 2022. Dr.&nbsp;Chung is an American Board of Medical Genetics
certified clinical and molecular geneticist. Since July 2023, Dr.&nbsp;Chung has served as the Chair of the Department of Pediatrics at Boston Children&#8217;s Hospital and on the faculty of Harvard Medical School. From February 2014 until July
2023, she led the Precision Medicine Resource in the Irving Institute at Columbia University. From July 2017 until July 2023, Dr.&nbsp;Chung was the Kennedy Family Professor of Pediatrics and Medicine at Columbia University, and had been on the
faculty of Columbia University since 2002. Dr.&nbsp;Chung received her B.A. in Biochemistry from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. in Genetics from The Rockefeller University. We believe that
Dr.&nbsp;Chung is qualified to serve on Rallybio&#8217;s Board because of her extensive experience in medicine and research, and her service on other boards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Robert Hopfner, R.Ph., Ph.D., M.B.A.,</I></B> has served as a member of Rallybio&#8217;s Board since March 2020. Since October 2017, Dr.&nbsp;Hopfner has served
as a Managing Partner at Pivotal bioVenture Partners LLC, a venture capital firm. Prior to Pivotal, Dr.&nbsp;Hopfner served as a Principal at Bay City Capital LLC, a venture capital firm, from June 2007 to October 2009 and as a Managing Director and
Partner from October 2009 to September 2017. Dr.&nbsp;Hopfner currently serves as a board member of Evommune, Inc., and on the boards of directors of a number of private life sciences companies. Dr.&nbsp;Hopfner previously served on the board of
directors of Vaxcyte, Inc., Oculis Holding AG and Inozyme Pharma Inc. Dr.&nbsp;Hopfner received a B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago. We believe
Dr.&nbsp;Hopfner is qualified to serve on Rallybio&#8217;s Board because of his experience in advising public and private life sciences companies, as well as his research in the pharmaceutical field. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ronald Hunt, M.B.A.,</I></B> has served as a member of Rallybio&#8217;s Board since 2018. Since 2005, Mr.&nbsp;Hunt has served as a Managing Director and Member
of New Leaf Venture Partners, L.L.C., a venture capital firm. Previously, Mr.&nbsp;Hunt served at the Sprout Group, a venture capital firm and was a consultant with consulting firms Coopers&nbsp;&amp; Lybrand Consulting and The Health Care Group,
Inc. Mr.&nbsp;Hunt worked earlier in his career in various sales and marketing positions at Johnson&nbsp;&amp; Johnson and SmithKline Beecham Pharmaceuticals PLC. Mr.&nbsp;Hunt currently serves as a director of Iterum Therapeutics, Ltd., a
clinical-stage company, and on the boards of a number of private pharmaceutical and healthcare companies. Mr.&nbsp;Hunt previously served on the board of directors of Harpoon Therapeutics, Inc. Mr.&nbsp;Hunt received a B.S. from Cornell University
and an M.B.A. from the Wharton School of the University of Pennsylvania. We believe Mr.&nbsp;Hunt is qualified to serve on Rallybio&#8217;s Board because of his investment experience, his experience in the pharmaceutical industry and service on the
board of directors of other public and private biopharmaceutical and biotechnology companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hui Liu, Ph.D., M.B.A.,</I></B> as served as a member of
Rallybio&#8217;s Board since April 2022. Dr Liu has been the Chief Executive Officer and board member of Olethros B.V. since August 2025. Dr. Liu has also been Chief Operating and Business Officer of Gyes B.V. since August 2025. Until July 2024,
Dr.&nbsp;Liu was Chief Business Officer since December 2015 and Head of Merus U.S. since October 2018 of Merus N.V., a clinical-stage oncology company. From 2013 to 2015, Dr.&nbsp;Liu served as Vice President and Global Head, Business
Development&nbsp;&amp; Licensing, Oncology, and from 2009 to 2012 as Vice President and Global Head, Business Development&nbsp;&amp; Licensing, Vaccines&nbsp;&amp; Diagnostics, at Novartis AG. Prior to Novartis, Dr.&nbsp;Liu held positions of
increasing responsibility in business development at Pfizer from 2004 to 2009 and in the R&amp;D organization at Pfizer and its predecessor company Warner-Lambert from 1997 to 2001. From 2001 to 2004, Dr.&nbsp;Liu was an investment banker at Goldman
Sachs and Citigroup. Dr.&nbsp;Liu received a Ph.D. in molecular biology and an M.B.A. in finance from the University of Michigan and a B.S. in biology from Peking University. We believe that Dr.&nbsp;Liu is qualified to serve on Rallybio&#8217;s
Board because of his extensive operational and business experience in the pharmaceutical and biotechnology industries, including executive leadership, and his transactional experience. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_16"></A>PROPOSAL NO. 6&#8212;THE AUDITOR RATIFICATION PROPOSAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s stockholders are being asked to ratify the
selection by the audit committee of the Rallybio Board (the &#8220;audit committee&#8221;) of Deloitte as Rallybio&#8217;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2026. Deloitte has served as
Rallybio&#8217;s independent registered public accounting firm since 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The audit committee annually reviews the independent registered public accounting
firm&#8217;s independence, including reviewing all relationships between the independent registered public accounting firm and us and any disclosed relationships or services that may impact the objectivity and independence of the independent
registered public accounting firm, and the independent registered public accounting firm&#8217;s performance. Although ratification is not required by Rallybio&#8217;s bylaws or otherwise, the Rallybio Board is submitting the selection of Deloitte
to Rallybio&#8217;s stockholders for ratification as a matter of good corporate practice. If the selection is not ratified, the audit committee will consider whether it is appropriate to select another independent registered public accounting firm.
Even if the selection is ratified, the audit committee in its discretion may select a different registered public accounting firm at any time during the year if the committee determines that such a change would be in the best interests of Rallybio
and its stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A representative of Deloitte is expected to be present at the Rallybio annual meeting and will have an opportunity to make a statement if he
or she desires to do so and to respond to appropriate questions from Rallybio&#8217;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policy on Audit Committee
<FONT STYLE="white-space:nowrap">Pre-Approval</FONT> of Audit and Permissible <FONT STYLE="white-space:nowrap">Non-Audit</FONT> Services of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The audit committee <FONT STYLE="white-space:nowrap">pre-approves</FONT> all auditing services, internal control related services and permitted <FONT
STYLE="white-space:nowrap">non-audit</FONT> services (including the fees and terms thereof) to be performed by Deloitte, subject to the<I> de minimis</I> exception for <FONT STYLE="white-space:nowrap">non-audit</FONT> services that are approved by
the audit committee prior to the completion of an audit. The audit committee may delegate <FONT STYLE="white-space:nowrap">pre-approval</FONT> authority to one or more members of the audit committee consistent with applicable law and listing
standards, provided that the decisions of such audit committee member or members must be presented to the full audit committee at its next scheduled meeting. The audit committee is responsible for the audit fee negotiations associated with the
retention of Deloitte. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Principal Accountant Fees and Services </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio
regularly reviews the services and fees of its independent registered public accounting firm. These services and fees are also reviewed by the audit committee on an annual basis. The aggregate fees billed for the fiscal years ended December&nbsp;31,
2025 and 2024 for each of the following categories of services are as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FISCAL YEAR ENDED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>FEE CATEGORY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Audit Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">764,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">832,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Audit-Related Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tax Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All Other Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">767,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">836,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Audit Fees.</I> Audit fees for the fiscal years ended 2025 and 2024 consist of fees billed for professional services provided in connection with the audit of our
annual financial statements, the review of our quarterly financial statements, and audit services that are normally provided by an independent registered public accounting firm in connection with regulatory filings and were $764,105 and $832,578,
respectively. The audit fees for the fiscal year ended December&nbsp;31, 2025 includes fees for professional services provided in connection with our Form S-8 registration statement filed in May 2025, including comfort letters, consents and review
of documents filed with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
SEC, which totaled approximately $65,000. The audit fees for the fiscal year ended December&nbsp;31, 2024 includes fees for professional services provided in connection with our Form <FONT
STYLE="white-space:nowrap">S-8</FONT> registration statement filed in March 2024, Rallybio&#8217;s Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement filed in May 2024, including comfort letters, consents and review of documents
filed with the SEC, which totaled approximately $100,000. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax Fees.</I> There were no tax fees for the fiscal year ended 2025 and 2024. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>All Other Fees.</I> All other fees represent payment for access to Deloitte&nbsp;&amp; Touche LLP online software tools. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Audit Committee <FONT STYLE="white-space:nowrap">pre-approved</FONT> all services performed since the <FONT STYLE="white-space:nowrap">pre-approval</FONT> policy
was adopted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Required Vote </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The affirmative vote of a majority of the
votes properly cast for and against by the holders of Rallybio Common Stock entitled to vote on at the Rallybio annual meeting is required to approve the Auditor Ratification Proposal. Abstentions and broker non-votes (if any) will have no effect on
the outcome of the vote on the Auditor Ratification Proposal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is <B>not </B>conditioned upon the approval of the Auditor Ratification Proposal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards
&#8220;<B>FOR</B>&#8221; the approval of the Auditor Ratification Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE RALLYBIO BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
&#8220;FOR&#8221; THE AUDITOR RATIFICATION PROPOSAL. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_17"></A>REPORT OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The information contained in this report shall not be deemed to be &#8220;soliciting material&#8221; or &#8220;filed&#8221; or incorporated by reference in future
filings with the SEC, or subject to the liabilities of Section&nbsp;18 of the Exchange Act, except to the extent that Rallybio specifically incorporates it by reference into a document filed under the Securities Act or the Exchange Act. </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We operate in accordance with a written charter adopted by our Board of Directors and reviewed annually by the audit committee. We are responsible for overseeing the
quality and integrity of Rallybio&#8217;s accounting, auditing and financial reporting practices. In accordance with the rules of the SEC and Nasdaq, the audit committee is composed entirely of members who are independent, as defined by the listing
standards of Nasdaq and Rallybio&#8217;s Corporate Governance Guidelines. Further, the Rallybio Board has determined that one of our members (Ms.&nbsp;Boudreau) is an audit committee financial expert as defined by the rules of the SEC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We met 4 times during the fiscal year 2025 with Rallybio&#8217;s management and Deloitte&nbsp;&amp; Touche LLP (&#8220;Deloitte&#8221;), Rallybio&#8217;s independent
registered public accounting firm, including, but not limited to, meetings held to review and discuss the annual audited and quarterly financial statements and Rallybio&#8217;s earnings press releases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that we fully discharged our oversight responsibilities as described in our charter, including with respect to the audit process. We reviewed and discussed
our audited financial statements for the fiscal year ended December&nbsp;31, 2025, with management and Deloitte. Management has the responsibility for the preparation of Rallybio&#8217;s financial statements, and Deloitte has the responsibility for
the audit of those statements. We discussed with Deloitte the matters required to be discussed by Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;), Auditing Standard No.1301 and the SEC. We received the written disclosures and the
letter from Deloitte pursuant to Rule 3526, Communication with Audit Committees Concerning Independence, of the PCAOB, concerning any relationships between Deloitte and Rallybio and the potential effects of any disclosed relationships on
Deloitte&#8217;s independence, and discussed with Deloitte its independence. We reviewed with Deloitte their audit plans, audit scope, identification of audit risks and their audit efforts, and discussed and reviewed the results of Deloitte&#8217;s
examination of Rallybio&#8217;s financial statements both with and without management. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We considered any fees paid to Deloitte for the provision of <FONT
STYLE="white-space:nowrap">non-audit</FONT> related services and do not believe that these fees compromise Deloitte&#8217;s independence in performing the audit. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on these reviews and discussions with management and Deloitte, we approved the inclusion of Rallybio Corporation&#8217;s audited financial statements in its
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2025 for filing with the SEC. We also have selected Deloitte as the independent registered public accounting firm for the fiscal year
ending December&nbsp;31, 2026, subject to ratification by Rallybio Corporation&#8217;s stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Members of the Rallybio Audit Committee </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Helen M. Boudreau, M.B.A, Chair </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Robert Hopfner,
R.Ph., Ph.D., M.B.A. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Ronald Hunt, M.B.A. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Hui
Liu, Ph.D., M.B.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_18"></A>PROPOSAL NO. 7&#8212;THE 2026 PLAN PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unless otherwise indicated or the context otherwise requires, references in this section to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
&#8220;us,&#8221; or similar terms refer to the combined company and its subsidiaries following the Merger. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio stockholders are also being asked to consider and vote upon the 2026 Plan Proposal to approve the combined company&#8217;s 2026 Equity Incentive Plan (the
&#8220;2026 Plan&#8221;). The Rallybio Board initially approved the 2026 Plan on March&nbsp;16, 2026, subject to Rallybio stockholder approval. If the Rallybio stockholders approve the 2026 Plan, the parties have agreed under the terms of the Merger
Agreement that the 2026 Plan will become effective on the date immediately following the consummation of the Merger. If the 2026 Plan is not approved by the Rallybio stockholders, it will not become effective and no awards will be granted
thereunder. The 2026 Plan is described in more detail below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The summary is qualified in its entirety by reference to the text of the 2026 Plan, a copy of which is
attached as Annex L to this proxy statement/prospectus. Rallybio stockholders should refer to the 2026 Plan for more complete and detailed information about the terms and conditions of the 2026 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2026 Equity Incentive Plan </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2026 Plan will be the successor to and
continuation of the Rallybio Corporation 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). Once the 2026 Plan becomes effective, no further grants will be made under the 2021 Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Eligibility.</I><I></I> Any individual who is an employee of us or any of our affiliates, or any person who provides services to us or our affiliates, including
members of our board of directors, is eligible to receive awards under the 2026 Plan at the discretion of the plan administrator. If the 2026 Plan Proposal is approved by the Rallybio stockholders, all of our nonemployee directors (presently
expected to be six individuals), all &#8195;&#8195;&#8195; of employees, and &#8195;&#8195;&#8195; consultants (as of &#8195;&#8195;&#8195;) expected to continue with us after the Merger will be eligible to receive awards following the consummation
of the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Types of Awards</I>. The 2026 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;) to employees, including employees of
any parent or subsidiary, and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees,
directors, and consultants, including employees and consultants of our affiliates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized Shares</I>.&nbsp;If the request to approve the 2026 Plan is
approved by Rallybio&#8217;s stockholders, a number of shares of our common stock will be available for grant under the 2026 Plan equal to (a)&nbsp;the product of (i)&nbsp;fifteen percent (15%), multiplied by (ii)&nbsp;the total number of shares of
our common stock outstanding plus all shares of our common stock issuable upon conversion or exercise of outstanding securities and rights, including (without limitation) preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT>
basis, equity awards, warrants (including <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), and any convertible indebtedness or similar instruments, whether or not then vested or exercisable, determined on the effective date of the 2026
Plan, subject to adjustment for specified changes in our capitalization (the &#8220;Share Reserve&#8221;), plus (b)&nbsp;up to the number of shares of our common stock subject to outstanding stock awards granted under the 2021 Plan that, on or after
the 2026 Plan becomes effective, expire or otherwise terminate prior to exercise or settlement; are not issued because the stock award is settled in cash; are forfeited or repurchased because of the failure to vest; or are reacquired or withheld to
satisfy a tax withholding obligation or the purchase or exercise price if any, as such shares becomes available from time to time. Shares issued in connection with a merger or acquisition as permitted by applicable stock exchange listing rules,
including Nasdaq Listing Rule 5635(c), will not reduce the number of shares available for issuance under the 2026 Plan. Accordingly, any Candid stock options that are converted into our common stock as part of the Merger are not counted against the
foregoing equity pool established by the 2026 Plan.&nbsp;In addition, the number of shares of our common stock reserved for issuance under the 2026 Plan will automatically increase on January&nbsp;1 of each calendar year, starting on January&nbsp;1,
2027 through January&nbsp;1, 2036, in an amount equal to 5% of the total number of shares of our common stock outstanding plus all shares of our common stock issuable upon conversion or exercise of outstanding securities and rights, including
(without limitation) preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, equity awards, warrants (including <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), and any convertible indebtedness or similar
instruments, whether or not then vested or exercisable, on December&nbsp;31 of the preceding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
year, or a lesser number of shares determined by our board of directors. The maximum number of shares of our common stock that may be issued on the exercise of ISOs under the 2026 Plan is equal
to three multiplied by the Share Reserve. As of &#8195;&#8195;&#8195;&#8195;, the record date for the Rallybio annual meeting, the closing price of Rallybio Common Stock as reported on Nasdaq was $&#8195;&#8195; per share. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares subject to stock awards granted under the 2026 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares,
do not reduce the number of shares available for issuance under the 2026 Plan. Additionally, shares become available for future grant under the 2026 Plan if they were issued stock awards under the 2026 Plan and we repurchase them or they are
forfeited because of a failure to meet a contingency or condition required for the vesting of such shares, or if such shares are used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan</I><I></I><I>&nbsp;Administration</I>. Our board of directors, or a duly authorized committee of our board of directors, will administer the 2026 Plan. Our
board of directors may delegate concurrent authority to administer the 2026 Plan to our compensation committee under the terms of our compensation committee&#8217;s charter. We sometimes refer to our board of directors, or the applicable committee
with the power to administer our equity incentive plans, as the administrator. The administrator may also delegate to one or more persons or bodies the authority to (i)&nbsp;designate employees (other than officers) to receive specified awards, and
(ii)&nbsp;determine the number of shares subject to such awards. Such persons or bodies may not grant a stock award to themselves and neither our board nor any committee may delegate authority to any person or body (who is not a member of our board
or such body that is not comprised solely of members of our board) the authority to determine the fair market value of our common stock for purposes of the 2026 Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The administrator has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike price of awards, if any, the number of
shares subject to each award, the fair market value of a share of common stock, the vesting schedule applicable to the awards, together with any vesting acceleration, and the form of consideration, if any, payable upon exercise or settlement of the
award and the terms of the award agreements for use under the 2026 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, subject to the terms of the 2026 Plan, the administrator also has the power
to modify outstanding awards under the 2026 Plan, including the authority to reprice any outstanding option or stock appreciation right, cancel and <FONT STYLE="white-space:nowrap">re-grant</FONT> any outstanding option or stock appreciation right
in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any materially adversely affected participant. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Options</I>. ISOs and NSOs are granted under stock option agreements adopted by the administrator. The administrator determines the exercise price for stock
options, within the terms and conditions of the 2026 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2026 Plan
vest at the rate specified in the stock option agreement as determined by the administrator. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax Limitations on ISOs</I>. The aggregate fair market value,
determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that
exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates
unless (i)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&nbsp;the option is not exercisable after the expiration of five&nbsp;years from the date of grant.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Unit Awards</I>. Restricted stock&nbsp;units are granted under restricted stock unit award agreements adopted by the administrator. Restricted
stock&nbsp;units may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit may be settled by cash, delivery of stock, a
combination of cash and stock as deemed appropriate by the administrator, or in any other form of consideration set forth in the restricted stock unit agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a
restricted stock unit. Except as otherwise provided in the applicable award agreement, restricted stock&nbsp;units that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Awards</I>. Restricted stock awards are granted under restricted stock award agreements adopted
by the administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible
under applicable law. The administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of
the shares of our common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Appreciation Rights</I>. Stock appreciation rights are granted under stock appreciation grant agreements adopted by the administrator. The administrator
determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. A stock appreciation right granted under the 2026 Plan vests at
the rate specified in the stock appreciation right agreement as determined by the administrator. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Performance Awards</I>. The 2026 Plan permits the grant of
performance-based stock and cash awards. The administrator may structure awards so that the shares of our stock, cash, or other property will be issued or paid only following the achievement of certain
<FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. The performance criteria that will be used to establish such performance goals may be based on any one of, or combination of, the
following as determined by the administrator: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return;
return on equity or average stockholder&#8217;s equity; return on assets, investment, or capital employed; share price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; <FONT
STYLE="white-space:nowrap">pre-tax</FONT> profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added
(or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholder&#8217;s equity; capital expenditures; debt levels; operating profit or net operating profit;
workforce diversity; growth of net income or operating income; billings; financing; regulatory milestones; stockholder liquidity; corporate governance and compliance; intellectual property; personnel matters; progress of internal research; progress
of partnered programs; partner satisfaction; budget management; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; investor relations, analysts and communication; implementation or
completion of projects or processes; employee retention; number of users, including unique users; strategic partnerships or transactions (including <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
<FONT STYLE="white-space:nowrap">out-licensing</FONT> of intellectual property); establishing relationships with respect to the marketing, distribution and sale of the Company&#8217;s products, if approved; supply chain achievements; <FONT
STYLE="white-space:nowrap">co-development,</FONT> <FONT STYLE="white-space:nowrap">co-marketing,</FONT> profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other
measures of performance selected by the administrator. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The performance goals may be based on a company-wide basis, with respect to one or more business&nbsp;units,
divisions, affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i)&nbsp;in the award
agreement at the time the award is granted or (ii)&nbsp;in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of
performance goals as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude
the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles;
(6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture;
(8)&nbsp;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based
compensation and the award of bonuses under our bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and
(11)&nbsp;to exclude the goodwill and intangible asset </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
impairment charges that are required to be recorded under generally accepted accounting principles. In addition, we retain the discretion to reduce or eliminate the compensation or economic
benefit due upon attainment of the goals. The performance goals may differ from participant to participant and from award to award. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Stock Awards</I>. The
administrator may grant other awards based in whole or in part by reference to our common stock. The administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit</I>. The aggregate value of all compensation granted or paid to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director with respect to any calendar year, including stock awards granted and cash fees paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed $750,000 in
total value, or in the event such <FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to the board during such calendar year, $1,000,000 in total value (in each case, calculating the value of any such stock
awards based on the grant date fair value of such stock awards for financial reporting purposes). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to Capital Structure</I>. In the event there is a
specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (i)&nbsp;the class and maximum number of shares reserved for issuance under the 2026 Plan,
(ii)&nbsp;the class and maximum number of shares by which the Share Reserve may increase automatically each year, (iii)&nbsp;the class and maximum number of shares that may be issued on the exercise of ISOs, and (iv)&nbsp;the class and number of
shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Corporate Transactions</I>. The following applies to
stock awards under the 2026 Plan in the event of a corporate transaction, unless otherwise provided in a participant&#8217;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by
the administrator at the time of grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of a corporate transaction, any stock awards outstanding under the 2026 Plan may be assumed, continued or
substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or
acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective
time of the transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full to a date prior to the effective time of the transaction (contingent upon the effectiveness of the
transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent
upon the effectiveness of the transaction). With respect to performance awards with multiple vesting levels depending on performance level, unless otherwise provided by an award agreement or by the administrator, the award will accelerate at 100% of
target. If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then with respect to any such stock awards that are held by persons other than current participants, such awards
will terminate if not exercised (if applicable) prior to the effective time of the transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised
notwithstanding the transaction. The administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to take the same actions with respect to all participants. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event a stock award will terminate if not exercised prior to the effective time of a transaction, the administrator may provide, in its sole discretion, that the
holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&nbsp;the value of the property the participant would have received upon the exercise of the stock award over
(ii)&nbsp;any exercise price payable by such holder in connection with such exercise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the 2026 Plan, a corporate transaction is defined to include the
consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: (i)&nbsp;a sale or disposition of all or substantially all of our assets; (ii)&nbsp;a sale or disposition of more than 50% of
our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction where we do not survive the transaction; and (iv)&nbsp;a merger or consolidation where </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
we do survive the transaction but the shares of our common stock outstanding before such transaction are converted or exchanged into other property by virtue of the transaction, unless otherwise
provided in an award agreement or other written agreement between us and the award holder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Change in Control</I>. In the event of a change in control, as
defined under the 2026 Plan, awards granted under the 2026 Plan will not receive automatic acceleration of vesting and exercisability, although this treatment may be provided for in an award agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the 2026 Plan, a change in control is defined to include: (i)&nbsp;the acquisition by any person or company of more than 50% of the combined voting power of our
then outstanding stock; (ii)&nbsp;a consummated merger, consolidation or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving
entity (or the parent of the surviving entity); (iii)&nbsp;a consummated sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is
owned by our stockholders; and (iv)&nbsp;an unapproved change in the majority of the board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transferability</I>. A participant may not transfer
stock awards under the 2026 Plan other than by will, the laws of descent and distribution, or as otherwise provided under the 2026 Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan</I><I></I><I>&nbsp;Amendment or Termination</I>. Our board of directors has the authority to amend, suspend, or terminate the 2026 Plan, provided that such
action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary
of the date our board of directors adopted the 2026 Plan. No stock awards may be granted under the 2026 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clawback Policy.</I> All awards granted under the 2026 Plan will be subject to recoupment in accordance with any clawback policy that the combined company is
required to adopt pursuant to the listing standards of any national securities exchange or association on which the combined company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer
Protection Act or other applicable law, and any clawback policy that the combined company otherwise adopts, to the extent applicable and permissible under applicable law. In addition, the board of directors may impose such other clawback, recovery
or recoupment provisions in an award agreement as the board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of common stock or other cash or property upon the
occurrence of cause. No recovery of compensation under such a clawback policy will be an event giving rise to a participant&#8217;s right to voluntarily terminate employment upon a &#8220;resignation for good reason,&#8221; or for a
&#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the combined company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Federal Income Tax Consequences
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of the principal U.S. federal income tax consequences to participants and the combined company with respect to participation in the
2026 Plan, which will not become effective until the date immediately following the consummation of the Merger. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign jurisdiction in
which a participant may reside. The information is based upon current U.S. federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any participant may depend on his or her particular
situation, each participant should consult the participant&#8217;s tax adviser regarding the federal, state, local and other tax consequences of the grant or exercise of an award or the disposition of stock acquired under the 2026 Plan. The 2026
Plan is not qualified under the provisions of Section&nbsp;401(a) of the Code and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974, as amended. The combined company&#8217;s ability to realize the benefit
of any tax deductions described below depends on the combined company&#8217;s generation of taxable income as well as the requirement of reasonableness and the satisfaction of the combined company&#8217;s tax reporting obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax Consequences to the Participants </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Nonstatutory Stock
Options</I>.&nbsp;Generally, there is no taxation upon the grant of a nonstatutory stock option. Upon exercise, a participant will recognize ordinary income equal to the excess, if any, of the fair market value of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
underlying stock on the date of exercise of the stock option over the exercise price. If the participant is employed by the combined company or one of its affiliates, that income will be subject
to withholding taxes. The participant&#8217;s tax basis in those shares will be equal to their fair market value on the date of exercise of the stock option, and the participant&#8217;s capital gain holding period for those shares will begin on the
day after they are transferred to the participant. Subject to the requirement of reasonableness, the deduction limits under Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation, the combined company will generally be
entitled to a tax deduction equal to the taxable ordinary income realized by the participant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Incentive Stock Options.</I>&nbsp;The 2026 Plan provides for the
grant of stock options that are intended to qualify as &#8220;incentive stock options,&#8221; as defined in Section&nbsp;422 of the Code. Under the Code, a participant generally is not subject to ordinary income tax upon the grant or exercise of an
ISO. If the participant holds a share received upon exercise of an ISO for more than two years from the date the stock option was granted and more than one year from the date the stock option was exercised, which is referred to as the required
holding period, the difference, if any, between the amount realized on a sale or other taxable disposition of that share and the participant&#8217;s tax basis in that share will be long-term capital gain or loss. If, however, a participant disposes
of a share acquired upon exercise of an ISO before the end of the required holding period, which is referred to as a disqualifying disposition, the participant generally will recognize ordinary income in the year of the disqualifying disposition
equal to the excess, if any, of the fair market value of the share on the date of exercise of the stock option over the exercise price. However, if the sales proceeds are less than the fair market value of the share on the date of exercise of the
stock option, the amount of ordinary income recognized by the participant will not exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds the fair market value of the share on the date of
exercise of the stock option, that excess will be short-term or long-term capital gain, depending on whether the holding period for the share exceeds one year. For purposes of the alternative minimum tax, the amount by which the fair market value of
a share of stock acquired upon exercise of an ISO exceeds the exercise price of the stock option generally will be an adjustment included in the participant&#8217;s alternative minimum taxable income for the year in which the stock option is
exercised. If, however, there is a disqualifying disposition of the share in the year in which the stock option is exercised, there will be no adjustment for alternative minimum tax purposes with respect to that share. In computing alternative
minimum taxable income, the tax basis of a share acquired upon exercise of an ISO is increased by the amount of the adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the stock option is
exercised. The combined company is not allowed a tax deduction with respect to the grant or exercise of an ISO or the disposition of a share acquired upon exercise of an ISO after the required holding period. If there is a disqualifying disposition
of a share, however, the combined company will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant, subject to the requirement of reasonableness, the deduction limits under Section&nbsp;162(m) of
the Code and provided that either the employee includes that amount in income or the combined company timely satisfies its reporting requirements with respect to that amount. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Awards.</I>&nbsp;Generally, the recipient of a restricted stock award will recognize ordinary income at the time the stock is received equal to the
excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the stock is subject to restrictions constituting a substantial risk of forfeiture when it is received (for
example, if the employee is required to work for a period of time in order to have the right to transfer or sell the stock), the recipient generally will not recognize income until the restrictions constituting a substantial risk of forfeiture
lapse, at which time the recipient will recognize ordinary income equal to the excess, if any, of the fair market value of the stock on the date it becomes vested over any amount paid by the recipient in exchange for the stock. A recipient may,
however, file an election with the IRS, within 30 days following the date of grant, to recognize ordinary income, as of the date of grant, equal to the excess, if any, of the fair market value of the stock on the date the award is granted over any
amount paid by the recipient for the stock. The recipient&#8217;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from a restricted stock award will be the amount paid for such shares plus any ordinary
income recognized either when the stock is received or when the restrictions constituting a substantial risk of forfeiture lapse. Subject to the requirement of reasonableness, the deduction limits under Section&nbsp;162(m) of the Code and the
satisfaction of a tax reporting obligation, the combined company will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Unit Awards.</I>&nbsp;Generally, the recipient of a restricted stock unit award will generally
recognize ordinary income at the time the stock is delivered equal to the excess, if any, of (i)&nbsp;the fair market value of the stock received over any amount paid by the recipient in exchange for the stock or (ii)&nbsp;the amount of cash paid to
the participant. The recipient&#8217;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from a restricted stock unit award will be the amount paid for such shares plus any ordinary income recognized when
the stock is delivered, and the participant&#8217;s capital gain holding period for those shares will begin on the day after they are transferred to the participant. Subject to the requirement of reasonableness, the deduction limits under
Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation, the combined company will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock unit award.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Appreciation Rights.</I>&nbsp;Generally, the recipient of a stock appreciation right will recognize ordinary income equal to the fair market value of the
stock or cash received upon such exercise. Subject to the requirement of reasonableness, the deduction limits under Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation, the combined company will generally be entitled
to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock appreciation right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax Consequences to the Combined Company
</I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Compensation of Covered Employees.</I>&nbsp;The ability of the combined company to obtain a deduction for amounts paid under the 2026 Plan could be limited
by Section&nbsp;162(m) of the Code. Section&nbsp;162(m) of the Code limits the combined company&#8217;s ability to deduct compensation, for U.S. federal income tax purposes, paid during any year to a &#8220;covered employee&#8221; (within the
meaning of Section&nbsp;162(m) of the Code) in excess of $1&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Golden Parachute Payments</I>. The ability of the combined company (or the ability of
one of its subsidiaries) to obtain a deduction for future payments under the 2026 Plan could also be limited by the golden parachute rules of Section&nbsp;280G of the Code, which prevent the deductibility of certain &#8220;excess parachute
payments&#8221; made in connection with a change in control of an employer-corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>New Plan Benefits </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The awards, if any, that will be made to eligible persons under the 2026 Plan are subject to the discretion of the combined company&#8217;s board of directors.
Therefore, Rallybio cannot currently determine the benefits or number of shares subject to awards that may be granted in the future nor may it determine the amounts that would have been granted in the last completed fiscal year if the 2026 Plan had
been in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration with the SEC </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the 2026 Plan is approved
by Rallybio&#8217;s stockholders and becomes effective, the combined company intends to file a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> registering the shares reserved for issuance under the 2026 Plan as soon
as reasonably practicable after the combined company becomes eligible to use such form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Required Vote </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The affirmative vote of a majority of the total votes cast by the holders of Rallybio Common Stock entitled to vote at the Rallybio annual meeting, assuming a quorum is
present, is required to approve the 2026 Plan Proposal. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be treated as shares present for purposes of determining the presence of a quorum for the transaction of business
at the Rallybio annual meeting, but will not be counted as votes cast and will have no effect on the outcome of the vote on the 2026 Plan Proposal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2026 Plan
Proposal is conditioned on the consummation of the Merger. If the Merger is not consummated, the 2026 Plan Proposal will have no effect, even if approved by Rallybio&#8217;s stockholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is <B><U>not</U></B> conditioned upon the approval of the 2026 Plan Proposal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards
&#8220;FOR&#8221; the approval of the 2026 Plan Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE RALLYBIO BOARD UNANIMOUSLY RECOMMENDS THAT YOU </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>VOTE &#8220;FOR&#8221; THE 2026 PLAN PROPOSAL </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_19"></A>PROPOSAL NO. 8&#8212;THE 2026 ESPP PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unless otherwise indicated or the context otherwise requires, references in this section to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
&#8220;us,&#8221; or similar terms refer to the combined company and its subsidiaries following the Merger. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio stockholders are also being asked to consider and vote upon the 2026 ESPP Proposal to approve the combined company&#8217;s 2026 Employee Stock Purchase Plan
(the &#8220;2026 ESPP&#8221;). The Rallybio Board initially approved the 2026 Plan on March 16, 2026, subject to Rallybio stockholder approval. If the Rallybio stockholders approve the 2026 ESPP Proposal, the parties have agreed under the terms of
the Merger Agreement that the 2026 ESPP will become effective on the date immediately following the consummation of the Merger. If the 2026 ESPP is not approved by the Rallybio stockholders, it will not become effective. The 2026 ESPP is described
in more detail below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The summary is qualified in its entirety by reference to the text of the 2026 ESPP, a copy of which is attached
as<I>&nbsp;Annex</I><I></I><I>&nbsp;</I><I>M</I>&nbsp;to this proxy statement/prospectus. Rallybio stockholders should refer to the 2026 ESPP for a more complete and detailed information about the terms and conditions of the 2026 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2026 Employee Stock Purchase Plan </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The purpose of the 2026 ESPP is to secure
and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. Our 2026 ESPP will include two components.
One component will be designed to allow eligible U.S. employees to purchase our common stock in a manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Code. The other component will permit the grant of purchase rights
that do not qualify for such favorable tax treatment in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws. The
2026 ESPP will serve as the <FONT STYLE="white-space:nowrap">go-forward</FONT> employee stock purchase plan for the combined company, and the combined company expects to commence offerings under the 2026 ESPP following the current offering period
under the Rallybio Corporation 2021 Employee Stock Purchase Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Eligibility.</I><I> </I>Our employees and the employees of any of our designated affiliates,
will be eligible to participate in the 2026 ESPP, provided they may have to satisfy one or more of the following service requirements before participating in the 2026 ESPP, as determined by the administrator: (1)&nbsp;customary employment with us or
one of our affiliates for more than 20 hours per week and more than five&nbsp;months per calendar year or (2)&nbsp;continuous employment with us or one of our affiliates for a minimum period of time, not to exceed two&nbsp;years, prior to the first
date of an offering. In addition, our board of directors may also exclude from participation in the 2026 ESPP or any offering, employees who are &#8220;highly compensated employees&#8221; (within the meaning of Section&nbsp;423(b)(4)(D) of the Code)
or a subset of such highly compensated employees. If this 2026 ESPP Proposal is approved by the Rallybio stockholders, all &#8195;&#8195;&#8195; of our employees and our related corporations (as of &#8195;&#8195;&#8195;) will be eligible to
participate in the 2026 ESPP following the consummation of the Merger. An employee may not be granted rights to purchase stock under the 423 Component of the 2026 ESPP (a)&nbsp;if such employee immediately after the grant would own stock (including
stock issuable upon exercise of all such employee&#8217;s purchase rights) possessing 5% or more of the total combined voting power or value of all classes of our common stock or (b)&nbsp;to the extent that such rights would accrue at a rate that
exceeds $25,000 worth of our common stock for each calendar year that the rights remain outstanding. Our board of directors may approve different eligibility rules for the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Share Reserve</I>. The 2026 ESPP authorizes the issuance of shares of our common stock under purchase rights granted to our employees or to employees of any of our
designated affiliates. Following the consummation of the Merger, the maximum number of shares of our common stock that may be issued under the 2026 ESPP will not exceed the number of shares of our common stock equal to 1% of the total number of
shares of our common stock outstanding plus all shares of our common stock issuable upon conversion or exercise of outstanding securities and rights, including (without limitation) preferred stock on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, equity awards, warrants (including <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), and any convertible indebtedness or similar instruments, whether or not then vested or
exercisable, determined on the effective date of the 2026 ESPP, subject to adjustment for specified changes in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
capitalization (the &#8220;Initial Share Reserve&#8221;). Additionally, the number of shares of our common stock reserved for issuance will automatically increase on January&nbsp;1 of each
calendar year, beginning on January&nbsp;1, 2027 (assuming the 2026 ESPP becomes effective in 2026) through January&nbsp;1, 2036, by the lesser of (i) 1% of the total number of shares of our common stock outstanding plus all shares of our common
stock issuable upon conversion or exercise of outstanding securities and rights, including (without limitation) preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, equity awards, warrants (including <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants), and any convertible indebtedness or similar instruments, whether or not then vested or exercisable, on December&nbsp;31 of the preceding calendar year, and (ii)&nbsp;a number of shares equal to
three times the Initial Share Reserve; provided that before the date of any such increase, our board of directors may determine that such increase will be less than the amount set forth in clauses (i)&nbsp;and (ii). As of
&#8195;&#8195;&#8195;&#8195;, the record date for the Rallybio annual meeting, the closing price of Rallybio Common Stock as reported on Nasdaq was $&#8195;&#8195; per share. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Administration</I>. Our board of directors, or a duly authorized committee thereof, will administer our 2026 ESPP. Our board may delegate concurrent authority to
administer the 2026 ESPP to our compensation committee under the terms of the compensation committee&#8217;s charter. The 2026 ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase
shares of our common stock on specified dates during such offerings. Under the 2026 ESPP, we may specify offerings with durations of not more than 27&nbsp;months and may specify shorter purchase periods within each offering. Each offering will have
one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering under the 2026 ESPP may be terminated under certain circumstances. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Payroll Deductions</I>. Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, will be eligible to
participate in the 2026 ESPP and to contribute, normally through payroll deductions, up to a maximum percentage of their earnings (as defined in the 2026 ESPP) or up to a set dollar amount for the purchase of our common stock under the 2026 ESPP.
Unless otherwise determined by our board of directors, common stock will be purchased for the accounts of employees participating in the 2026 ESPP at a price per share that is at least the lesser of (i)&nbsp;85% of the fair market value of a share
of our common stock on the first date of an offering; or (ii)&nbsp;85% of the fair market value of a share of our common stock on the date of purchase. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Limitations</I>. Employees may have to satisfy one or more of the following service requirements before participating in the 2026 ESPP, as determined by our board of
directors, including: (i)&nbsp;customary employment with us or one of our affiliates for more than 20 hours per week and more than five&nbsp;months per calendar year; or (ii)&nbsp;continuous employment with us or one of our affiliates for a minimum
period of time (not to exceed two&nbsp;years). No employee may purchase shares under the 2026 ESPP at a rate in excess of $25,000 worth of our common stock based on the fair market value per share of our common stock at the beginning of an offering
for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the 2026 ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our
outstanding capital stock measured by vote or value under Section&nbsp;424(d) of the Code. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to Capital Structure</I>. In the event that there occurs a
change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating
dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, the board of directors will make appropriate adjustments to: (i)&nbsp;the number of shares reserved under the 2026 ESPP; (ii)&nbsp;the
maximum number of shares by which the share reserve may increase automatically each year; (iii)&nbsp;the number of shares and purchase price of all outstanding purchase rights; and (iv)&nbsp;the number of shares that are subject to purchase limits
under ongoing offerings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Corporate Transactions</I>. In the event of certain significant corporate transactions, including the consummation, in a single
transaction or in a series of related transactions, of any one or more of the following events: (i)&nbsp;a sale of all or substantially all of our assets; (ii)&nbsp;a sale or disposition of more than 50% of our outstanding securities; (iii)&nbsp;a
merger or consolidation where we do not survive the transaction; and (iv)&nbsp;a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or
exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our stock under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the 2026 ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to
assume, continue, or substitute for such purchase rights, then the participants&#8217; accumulated payroll contributions will be used to purchase shares of our common stock within ten business days (or such other period specified by the board of
directors) before such corporate transaction, and such purchase rights will terminate immediately after such purchase. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2026 ESPP Amendment or Termination</I>.
Our board of directors has the authority to amend or terminate our 2026 ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#8217;s consent.
We will obtain stockholder approval of any amendment to our 2026 ESPP as required by applicable law or listing requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Federal Income Tax
Consequences </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of the principal U.S. federal income tax consequences to participants and the combined company with respect to
participation in the 2026 ESPP. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The information is based upon current U.S. federal
income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any participant may depend on his or her particular situation, each participant should consult the participant&#8217;s tax adviser regarding
the federal, state, local, and other tax consequences of the grant or exercise of a purchase right or the sale or other disposition of the combined company&#8217;s common stock acquired under the 2026 ESPP. The 2026 ESPP is not qualified under the
provisions of Section&nbsp;401(a) of the Code and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax Consequences to Participants </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>423 Component of the 2026 ESPP.
</I>Rights granted under the 423 Component of the 2026 ESPP are intended to qualify for favorable U.S. federal income tax treatment associated with rights granted under an employee stock purchase plan which qualifies under the provisions of
Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A participant will be taxed on amounts withheld for the purchase of shares of the combined company&#8217;s common stock as if such
amounts were actually received. Otherwise, no income will be taxable to a participant as a result of the granting or exercise of a purchase right until a sale or other disposition of the acquired shares. The taxation upon such sale or other
disposition will depend upon the holding period of the acquired shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the shares are sold or otherwise disposed of more than two years after the beginning of
the offering period and more than one year after the shares are transferred to the participant, then the lesser of the following will be treated as ordinary income: (i)&nbsp;the excess of the fair market value of the shares at the time of such sale
or other disposition over the purchase price; or (ii)&nbsp;the excess of the fair market value of the shares as of the beginning of the offering period over the purchase price (determined as of the beginning of the offering period). Any further gain
or any loss will be taxed as a long-term capital gain or loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the shares are sold or otherwise disposed of before the expiration of either of the holding
periods described above, then the excess of the fair market value of the shares on the purchase date over the purchase price will be treated as ordinary income at the time of such sale or other disposition. The balance of any gain will be treated as
capital gain. Even if the shares are later sold or otherwise disposed of for less than their fair market value on the purchase date, the same amount of ordinary income is attributed to the participant, and a capital loss is recognized equal to the
difference between the sales price and the fair market value of the shares on such purchase date. Any capital gain or loss will be short-term or long-term, depending on how long the shares have been held. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </I>A participant will be taxed on amounts withheld for the purchase of shares of the combined
company&#8217;s common stock as if such amounts were actually received. Under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, a participant will recognize ordinary income equal to the excess, if any, of the fair market value of the
underlying stock on the date of exercise of the purchase right over the purchase price. If the participant is employed by the combined company or one of its affiliates, that income will be subject to withholding taxes. The participant&#8217;s tax
basis in those shares will be equal to their fair market value on the date of exercise of the purchase right, and the participant&#8217;s capital gain holding period for those shares will begin on the day after they are transferred to the
participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax Consequences to the Combined Company </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are no U.S. federal income tax consequences to the combined company by reason of the grant or exercise of rights under the 2026 ESPP. The combined company is
entitled to a deduction to the extent amounts are taxed as ordinary income to a participant for shares sold or otherwise disposed of before the expiration of the holding periods described above (subject to the requirement of reasonableness, the
deduction limits under Section&nbsp;162(m) of the Code and the satisfaction of tax reporting obligations). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>New Plan Benefits </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Participation in the 2026 ESPP is voluntary and each eligible employee will make his or her own decision regarding whether and to what extent to participate in the 2026
ESPP. Therefore, Rallybio cannot currently determine the benefits or number of shares subject to purchase rights and a new plan benefits table is thus not provided. In addition, Rallybio cannot determine the benefits or number of shares subject to
awards that would have been received by any service provider of Rallybio if the 2026 ESPP had been in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration with the SEC </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the 2026 ESPP is approved by Rallybio stockholders and becomes effective, the combined company intends to file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> registering the shares reserved for issuance under the 2026 ESPP as soon as reasonably practicable after the combined company becomes eligible to use such form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Required Vote </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The affirmative vote of a majority of the total votes cast by
the holders of Rallybio Common Stock entitled to vote at the Rallybio annual meeting, assuming a quorum is present, is required to approve the 2026 ESPP Proposal. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be
treated as shares present for purposes of determining the presence of a quorum for the transaction of business at the Rallybio annual meeting, but will not be counted as votes cast and will have no effect on the outcome of the vote on the 2026 ESPP
Proposal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2026 ESPP Proposal is conditioned on the consummation of the Merger. If the Merger is not consummated, the 2026 ESPP Proposal will have no effect,
even if approved by Rallybio&#8217;s stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is <B><U>not</U></B> conditioned upon the approval of the 2026 ESPP Proposal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards
&#8220;FOR&#8221; the approval of the 2026 ESPP Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE RALLYBIO BOARD UNANIMOUSLY RECOMMENDS THAT YOU </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>VOTE &#8220;FOR&#8221; THE 2026 ESPP PROPOSAL </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_20"></A>PROPOSAL NO. 9&#8212;THE ADJOURNMENT PROPOSAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Rallybio fails to receive a sufficient number of votes to
approve the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Name Change Proposal and/or the Authorized Share Increase Proposal, Rallybio may propose to adjourn the Rallybio annual meeting, for a period of not more than 60 days,
for the purpose of soliciting additional proxies to approve the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Name Change Proposal and/or the Authorized Share Increase Proposal. Rallybio currently does not intend to propose
adjournment at the Rallybio annual meeting if there are sufficient votes to approve the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Name Change Proposal and/or the Authorized Share Increase Proposal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a quorum is not present at the Rallybio annual meeting, under Rallybio&#8217;s bylaws, the chairperson of the Rallybio annual meeting will have the power to adjourn
the Rallybio annual meeting until a quorum is present or represented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The affirmative vote of a majority of shares of Rallybio Common Stock present in person (by virtual attendance) or represented by proxy at the Rallybio annual meeting
and entitled to vote on the matter is required to approve the Adjournment Proposal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger is <B><U>not</U></B><B></B>&nbsp;conditioned upon the approval of
the Adjournment Proposal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by
properly executed proxy cards &#8220;<B>FOR</B>&#8221; the approval of the Adjournment Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE RALLYBIO BOARD UNANIMOUSLY RECOMMENDS A VOTE
&#8220;FOR&#8221; </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE ADJOURNMENT PROPOSAL, IF NECESSARY </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_21"></A>RALLYBIO&#8217;S BUSINESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Rallybio,&#8221; the &#8220;Company&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Rallybio and its subsidiaries. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with
a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Our lead program, RLYB116, is a differentiated complement component 5 (&#8220;C5&#8221;) inhibitor with the potential to treat diseases of
complement dysregulation. In addition, RLYB332, a long-acting <FONT STYLE="white-space:nowrap">matriptase-2</FONT> <FONT STYLE="white-space:nowrap">(&#8220;MTP-2&#8221;)</FONT> antibody for the treatment of diseases of iron overload, is currently in
preclinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Developments </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;1, 2026, we
entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) with Candid Therapeutics, Inc., a Delaware corporation (&#8220;Candid&#8221;), a clinical-stage biotechnology company advancing a leading portfolio
of <FONT STYLE="white-space:nowrap">T-cell</FONT> engager (&#8220;TCE&#8221;) therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rallybio (&#8220;Merger Sub&#8221;). Upon the
terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio. The Merger is intended to qualify as a <FONT
STYLE="white-space:nowrap">tax-free</FONT> reorganization for U.S. federal income tax purposes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution and delivery of the Merger
Agreement, certain investors entered into the Subscription Agreement with Candid, pursuant to which such investors have agreed to purchase, immediately prior to the Merger, shares of Candid Common Stock representing an aggregate commitment of
approximately $505.5&nbsp;million in the Concurrent Financing. The shares of Candid Common Stock that are issued in the Concurrent Financing will be or will have the right to be, respectively, converted into shares of Rallybio Common Stock in the
Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions of the Merger Agreement, at the Effective Time (the &#8220;Effective Time&#8221;), (a) each then-outstanding share of
common stock or preferred stock of Candid (each such share, a &#8220;Candid Share&#8221;) (excluding any share described in clauses (b)&nbsp;or (c) below and Candid Capital Stock held by stockholders who have exercised and perfected appraisal rights
for such shares) will be converted into the right to receive a number of shares of Rallybio Common Stock, par value $0.0001 per share (&#8220;Rallybio Common Stock&#8221;), equal to the Exchange Ratio as set forth in the Merger Agreement (the
&#8220;Exchange Ratio&#8221;), (b)&nbsp;each Candid Share issued in the Concurrent Financing will be converted into the right to receive a number of shares of Rallybio Common Stock equal to the Concurrent Financing Exchange Ratio, (c)&nbsp;any
Candid Capital Stock held as treasury shares or held or owned by Rallybio, Merger Sub or any subsidiary of Rallybio or Candid immediately prior to the Effective Time will be canceled and shall cease to exist, and no consideration shall be delivered
in exchange therefor. Each then-outstanding option to purchase Candid Capital Stock will be converted into an option to purchase Rallybio Common Stock, based on the Exchange Ratio and subject to adjustment as set forth in the Merger Agreement. </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the Closing, on a pro forma basis and based
upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, pre-Merger equityholders of Candid (other than investors in the Concurrent Financing) are expected to own approximately 57.55% of the combined
company, pre-Merger equityholders of Rallybio are expected to own approximately 3.65% of the combined company and the investors in the Concurrent Financing are expected to own approximately 38.80% of the combined company (assuming proceeds from the
Concurrent Financing of $505.5 million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i)&nbsp;a valuation for Rallybio of $47.5 million (assuming Rallybio Net Cash
of $37.5 million as of the Closing), (ii)&nbsp;a fixed valuation for Candid of $750.0 million, and (iii)&nbsp;the relative capitalization of Rallybio and Candid. The percentage of the combined company that each party&#8217;s equityholders will own
following the Closing is subject to certain adjustments, including the amount of the final Rallybio Net Cash at the Closing. Rallybio Net Cash as calculated under the Merger Agreement makes certain </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
adjustments to the value of Rallybio&#8217;s Cash and Cash Equivalents (as defined in the Merger Agreement), and was equal to approximately $39.47&nbsp;million as of December&nbsp;31, 2025. The
adjustments are described in the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; Based on its Cash and Cash Equivalents and other balance sheet line items as of December&nbsp;31, 2025 and
current estimates of the other elements of Rallybio Net Cash (including projected adjustments to Rallybio&#8217;s Cash and Cash Equivalents), Rallybio calculates that it had Rallybio Net Cash of approximately $35.81&nbsp;million as of April&nbsp;15,
2026. Rallybio expects to continue to incur losses in future periods primarily related to the proposed Merger and, as a result, available Cash and Cash Equivalents will continue to decrease. For a description of the calculation of Rallybio Net Cash
as set forth in the Merger Agreement, please see the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior to the Effective Time, Rallybio and a rights agent are expected to enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;),
pursuant to which holders of record of certain Rallybio securities as of the close of business on the last business day prior to the day on which the Effective Time occurs will receive one contingent value right (each, a &#8220;CVR&#8221;) for each
outstanding share of Rallybio Common Stock, prefunded warrant, Rallybio restricted stock unit or In the Money Parent Option (as defined in the CVR Agreement) held as of such date. Pursuant to the CVR Agreement, each CVR holder will be entitled to
receive their pro rata share of (i)&nbsp;all of the net proceeds (including cash the value of stock to the extent listed on a national exchange, at the time of disposition), if any, received by Rallybio as a result of payments made to Rallybio of
any upfront, milestone, royalty and other payments received under any disposition agreement related to Rallybio&#8217;s <FONT STYLE="white-space:nowrap">pre-Merger</FONT> assets (the &#8220;Legacy Assets&#8221;), and (ii)&nbsp;any cash proceeds
received from Recursion under the Membership Interest Purchase Agreement, dated July&nbsp;8, 2025, by and among Recursion, Exscientia Ventures I, Inc., Rallybio Corporation and Rallybio IPB, LLC. For a period of one year after the Closing Date,
Rallybio will use commercially reasonable efforts to effect the disposition of the Legacy Assets. Such net proceeds will be subject to certain permitted deductions, including for applicable tax payments, certain expenses incurred or other
liabilities borne by Rallybio or its affiliates in respect of the Legacy Assets, and losses incurred by Rallybio or its affiliates due to a third-party proceeding in connection with such disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the proposed Merger with Candid the programs in
Rallybio&#8217;s pipeline that are illustrated in the chart below will be subject to the CVR described above. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g109079g01g01.jpg" ALT="LOGO" STYLE="width:6.30555in;height:2.01241in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>C5: Complement component 5; ABD: Albumin-binding domain; PTR: Platelet Transfusion Refractoriness; APS: Antiphospholipid Syndrome
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of Disorders Due to Complement Dysregulation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
complement system plays a central role in innate immunity, as well as shaping adaptive immune response. Dysregulation of the complement pathway has been implicated in the pathogenesis of a growing number of diseases, making it an attractive target
for therapeutic intervention. Antibody inhibitors of C5 have been successfully developed to treat diseases caused by complement pathway dysregulation, including paroxysmal nocturnal hemoglobinuria (&#8220;PNH&#8221;), atypical hemolytic uremic
syndrome (&#8220;aHUS&#8221;), refractory generalized myasthenia gravis </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
(&#8220;gMG&#8221;) and relapsing neuromyelitis optica spectrum disorder (&#8220;NMOSD&#8221;). Despite the approval of antibody-based C5 inhibitors for patients with these diseases, we believe
there remains a significant need in the market for safe, effective, patient-friendly, and accessible therapies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team has a track record of success in
designing, developing, and securing marketing approval for C5 complement inhibitors, including Soliris and Ultomiris, for patients around the world with severe and rare complement-mediated diseases. Our most advanced product candidate in this
therapeutic area is RLYB116, an innovative, once-weekly, small volume, subcutaneously injected inhibitor of C5, which is a central component of the terminal complement pathway. RLYB116 is an Affibody molecule attached to an albumin binding domain
(&#8220;ABD&#8221;) that has the potential to drive the rapid, complete, and sustained inhibition of C5 with a subcutaneous (&#8220;SC&#8221;) injection. We have completed two Phase 1 clinical trials in healthy participants that included the study
of RLYB116 as both a single ascending dose (&#8220;SAD&#8221;) and a multiple ascending dose (&#8220;MAD&#8221;).&#8195; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the first Phase 1 clinical trial, we
completed manufacturing process enhancements that were designed to improve the tolerability of RLYB116. In 2025, we completed the confirmatory Phase 1 clinical trial evaluating the pharmacokinetic (&#8220;PK&#8221;) / pharmacodynamic
(&#8220;PD&#8221;) properties of RLYB116. The confirmatory trial achieved its two key objectives including: a significant improvement in the tolerability of RLYB116 and demonstration of complete and sustained inhibition of terminal complement. These
results support the study of RLYB116 as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutic for multiple complement mediated diseases. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hematological Disorders </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2022, we obtained worldwide exclusive
rights to RLYB331, a preclinical, monoclonal antibody that is designed to inhibit <FONT STYLE="white-space:nowrap">MTP-2.</FONT> The inhibition of <FONT STYLE="white-space:nowrap">MTP-2</FONT> significantly increases levels of hepcidin, decreases
iron load and treats ineffective erythropoiesis. In 2024, we <FONT STYLE="white-space:nowrap">re-engineered</FONT> RLYB331 to extend its half-life. In the fourth quarter of 2024 we presented preclinical data at the annual meeting of the American
Society of Hematology (&#8220;ASH&#8221;) for RLYB332, the long-acting version of RLYB331, including favorable PD data, that support RLYB332 as a long-acting, potentially
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapy for the treatment of diseases of iron overload. We believe RLYB332 has the potential to address a significant unmet need for patients with severe
anemia with ineffective red blood cell production or erythropoiesis and iron overload, such as polycythemia vera, beta thalassemia and a subset of myelodysplastic syndromes (&#8220;MDS&#8221;), amongst others. Currently these patients are
underserved by the existing standard of care. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Artificial Intelligence Drug Discovery Collaboration </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, we formed a joint venture with Exscientia Limited (&#8220;Exscientia&#8221;), an Oxford, <FONT STYLE="white-space:nowrap">UK-based</FONT> artificial
intelligence (&#8220;AI&#8221;) and machine learning drug discovery company with a proprietary chemical design platform to discover novel small molecule drug candidates. Exscientia was acquired by Recursion in 2024. In July 2025, we entered into the
ENPP1 Purchase Agreement with Recursion Exscientia Ventures I, Inc., an indirect wholly-owned subsidiary of Recursion (&#8220;Buyer&#8221;) and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio Corporation to sell our interest in REV102, an
Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (&#8220;ENPP1&#8221;) inhibitor in preclinical development for the treatment of patients with hypophosphatasia (&#8220;HPP&#8221;), to Buyer (a subsidiary of our joint venture partner Recursion)
(the &#8220;JV Sale&#8221;). In connection with the JV Sale, we received a total of $20.0&nbsp;million in the third quarter of 2025 including $7.5&nbsp;million from an upfront payment and $12.5&nbsp;million from a milestone payment related to the
initiation of additional preclinical studies. We are eligible to receive a $5.0&nbsp;million milestone payment in connection with the initiation of dosing in a Phase 1 clinical study, as defined in the ENPP1 Purchase Agreement and low single-digit
royalties on all future net sales by Recursion of products comprising or incorporating certain compounds developed by REV-I. We may also be eligible to receive certain payments in the event of Recursion&#8217;s sale of the REV102 program. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>AbCellera Collaboration </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2022, we entered into a
strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera Biologic&#8217;s (&#8220;AbCellera&#8221;) antibody discovery engine
with Rallybio&#8217;s clinical and commercial expertise in rare diseases to identify optimal clinical candidates with a goal of delivering therapies to patients. We and AbCellera intended that the collaboration would
<FONT STYLE="white-space:nowrap">co-develop</FONT> up to five rare disease therapeutic targets, which will be chosen together by both companies with the first program focused on addressing the significant unmet therapeutic needs of patients with
rare metabolic diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2025, the
Company made a decision to evaluate strategic alternatives, with a goal of enhancing long term shareholder value that culminated with the signing of the Merger Agreement with Candid, a clinical-stage biotechnology company advancing a leading
portfolio of TCE therapeutics for autoimmune diseases on March&nbsp;1, 2026. In connection with the planned Merger, we have started to take steps to wind down our general and administrative operations that will not be needed after the close of the
Merger. We are continuing to move forward with limited research and development operations with a goal of advancing our programs in the near term to maximize the potential value of the CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>RLYB116 for the treatment of disorders due to
complement dysregulation </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB116 is an inhibitor of complement component C5, a component of the complement pathway which plays a central role in innate
immunity as well as shaping adaptive immune response. Dysregulation of the complement pathway has been implicated in the pathogenesis of a growing number of diseases, making it an attractive target for therapeutic intervention. Antibody inhibitors
of C5 have been successfully developed to treat diseases caused by immune dysfunction, including PNH, aHUS, refractory gMG and relapsing NMOSD. RLYB116 includes an Affibody molecule, which is an antibody mimetic protein that has a much smaller
molecular weight than a traditional antibody and may be easier and less costly to produce. In contrast to most <FONT STYLE="white-space:nowrap">C5-targeted</FONT> antibody therapeutics that are administered intravenously or via daily injection,
RLYB116 has the potential to be administered via an autoinjector as a small volume, once-weekly SC injection. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We view RLYB116 as a potential <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pipeline-in-a-product</FONT></FONT></FONT> for many disease including platelet transfusion refractoriness (&#8220;PTR&#8221;) and antiphospholipid syndrome
(&#8220;APS&#8221;). We believe RLYB116 can address significant unmet needs for patients with these diseases by providing a potential treatment that is more accessible and patient-friendly than existing marketed products, including by reducing the
frequency and improving the route of administration. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on our team&#8217;s experience studying and developing therapies targeting the complement system, we
believe there are five important attributes that could support clinical and commercial success in the treatment of a broad range of patients suffering from complement-mediated diseases. These include a mechanism of action targeting terminal
complement, the ability to produce rapid, complete and sustained inhibition of C5, a safety profile consistent with C5 antibodies currently approved for therapeutic use, the ability to self-administer the drug less frequently (e.g. once per week) in
an easy to use autoinjector, and pricing flexibility to treat a broad range of complement-mediated diseases. Based on the data generated to date and the manufacturing process enhancements completed in 2024, we believe RLYB116 has the potential to
demonstrate these attributes as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutic, and if so, could have a life-transforming impact on patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The complement system </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The complement system includes over 30
proteins in plasma and on cell surfaces that support the body&#8217;s adaptive or antibody-based immune system in the destruction of pathogenic bacteria. Complement proteins circulate in the blood in an inactive form prior to activation in response
to infection. Activation occurs through a pathway of proteolytic cleavage events initiated by pathogen recognition and resulting in pathogen destruction. Three complement pathways that converge on C5 are known and are referred to as the classical,
lectin and alternative pathways. In the classical pathway, antibodies bind to antigens, which in turn trigger a protease cascade that activates complement protein C3 and then complement protein C5. Activation of C5 convertase generates C5b which can
initiate formation of membrane pores and subsequent lysis of cells. The binding of C5b to host cells is normally prevented by the presence of specific glycoproteins on the cell surface. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Immune platelet transfusion refractoriness (PTR) disease background </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">PTR is a condition in which a patient shows poor platelet counts after a platelet transfusion due to an immune-mediated process. It can result from antibodies directed
against donor platelet antigens&#8212;especially human leukocyte antigen (&#8220;HLA&#8221;) class I antigens, or human platelet antigens (&#8220;HPAs&#8221;). These antibodies rapidly clear transfused platelets from the circulation, leading to
transfusion failure. Immune PTR typically develops after prior antigen exposure, such as through previous transfusions. It is diagnosed by consistently low post-transfusion platelet count in the absence of
<FONT STYLE="white-space:nowrap">non-immune</FONT> causes like sepsis or splenomegaly. We estimated that there are more than 25,000 cases annually in the United States and other major markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current treatments for PTR and their limitations </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Management of PTR includes using <FONT STYLE="white-space:nowrap">HLA-matched,</FONT> crossmatched, or <FONT STYLE="white-space:nowrap">HPA-matched</FONT> platelets, or
attempting to address the underlying immune sensitization. Platelet matching, the current standard of care is expensive, challenging and is often not an option in local settings not directly connected to a major blood center. Controlling the immune
response is often expensive and is accompanied by a variety of undesirable side effects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential benefits of our approach </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe PTR represents an attractive development opportunity for RLYB116 for several reasons. First, there are data from at least one investigator initiated trial
showing C5 blockade has a positive impact on post-transfusion platelet counts, providing a sound biological rationale for a <FONT STYLE="white-space:nowrap">C5-targeted</FONT> intervention. Second, PTR offers the opportunity for early clinical
validation using objective endpoints, including impact on post-transfusion platelet counts. And third&#8212;and most importantly&#8212;we believe that RLYB116 could potentially provide transformative therapeutic impact for unserved and underserved
patients with PTR globally. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>APS disease background </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">APS is a
potentially life-threatening, rare autoimmune disorder in which an individual&#8217;s immune system mistakenly creates antiphospholipid antibodies that can lead to the formation of blood clots. Blood clots can occur in the legs, lungs, brain, and
other organs, such as the kidneys and spleen. The clots can lead to a heart attack or a stroke. During pregnancy, women with APS are also at increased risk of miscarriage. APS can occur on its own but can also occur secondary to other autoimmune
diseases such as systemic lupus erythematosus. APS affects three to five times as many women as men and is most often diagnosed in people between the ages of 30 and 50. It is estimated that there are &gt;130,000 people in the US and &gt;120,000 in
Europe who suffer from APS. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current treatments for APS and their limitations </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, there is no cure for APS. However, medicines including blood thinners such as warfarin or heparin can help prevent health problems caused by the disease. The
goals of treatment are to prevent blood clots from forming and to keep existing clots from increasing in size. However, direct oral anticoagulants are generally less effective in preventing recurrent thromboembolic events, most notably strokes. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential benefits of our approach </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe APS is an attractive
indication to pursue as part of a comprehensive development strategy for two reasons. First, there is significant unmet need in patients with APS given the lack of currently available treatment alternatives and the rapid time to generate initial <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data. Second, we believe that RLYB116 has the potential to be an effective treatment for this patient population given published data from prior
investigational studies using commercially available complement inhibitors not approved in this therapeutic indication. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The RLYB116 solution: </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB116 is an engineered protein that includes an Affibody molecule and an antibody binding domain (&#8220;ABD&#8221;). We acquired rights to RLYB116 from Swedish
Orphan Biovitrum AB (Publ) (&#8220;Sobi&#8221;). RLYB116 was designed for optimal C5 binding, increased stability, as well as a long half-life in serum. Potential benefits of RLYB116 include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Subcutaneous administration</B><B>.</B> The low molecular weight allows for a higher concentration of active molecules
than antibodies<B> </B>in an equivalent volume. This likely enables the delivery of RLYB116 in a patient friendly format such as an autoinjector. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Efficiency of manufacturing. </B>RLYB116 is expressed in E. coli, providing for a more streamlined and potentially
lower cost manufacturing process compared to antibodies or other biologics expressed in mammalian cell culture, which typically require larger scale and longer manufacturing times. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Less frequent dosing</B><B>.</B> Linkage of the Affibody domain to an ABD may lengthen the dosing interval of<B>
</B>RLYB116 by extending the biological half-life and offer potential dosing benefits to patients. Based on the data generated to date, we believe that RLYB116 will be administered once-weekly. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Potentially lower risk of treatment conversion</B><B>.</B> Due to 1:1 binding to C5, there is an expected lack of risk
for drug-target-drug<B> </B>complex formation when switching from treatment with an antibody. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Favorable stability. </B>The Affibody platform provides the possibility of delivering highly stable and soluble
therapeutic agents that<B> </B>allow for high-concentration <FONT STYLE="white-space:nowrap">low-volume</FONT> products. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Affibody Scaffold and RLYB116 Structure </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g109079g01g05.jpg" ALT="LOGO" STYLE="width:2.67708in;height:2.42708in;">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development of RLYB116 </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have completed two Phase 1 clinical trials in healthy participants that included the study of RLYB116 as a SAD and a MAD. After the first Phase 1 clinical trial, we
completed manufacturing process enhancements that were designed to improve the tolerability of RLYB116 and enable us to increase the dose. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2025, we completed
the confirmatory (second) Phase 1 clinical trial evaluating the PK /PD properties of RLYB116 in healthy volunteers. The trial was a single-blind MAD study evaluating a <FONT STYLE="white-space:nowrap">4-week</FONT> treatment duration and a <FONT
STYLE="white-space:nowrap">10-week</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> period. There were eight participants in each of 2 cohorts, six of whom received RLYB116 and two of whom received placebo. The trial is summarized below.
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g109079g06g01.jpg" ALT="LOGO" STYLE="width:6.30555in;height:0.614239in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trial achieved its two key objectives including: a significant improvement in the tolerability of RLYB116 and demonstration of
complete and sustained inhibition of terminal complement. We believe the results, which are summarized in the three graphs below, support the study of RLYB116 as a potential
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutic for multiple complement mediated diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Serum
RLYB116 Concentration </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g109079g06g02.jpg" ALT="LOGO" STYLE="width:4.5in;height:2.5in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The PK profile of RLYB116 is highly predictable with low intersubject variability, rapid absorption and long terminal
elimination rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RLYB116 to C5 Ratio </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g109079g06g03.jpg" ALT="LOGO" STYLE="width:4.51042in;height:2.5in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB116 levels significantly exceed C5 within 12 hours of the first dose and are maintained at ratios of greater than 2:1 with a
once-weekly, subcutaneously administered dose of 300mg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Hemolytic Activity </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g109079g07g07.jpg" ALT="LOGO" STYLE="width:4.50939in;height:2.4739in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Most importantly, we observed complete and sustained inhibition of hemolysis observed in subjects who received the 300mg dose. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on market research conducted to date, we believe that an effective, once-weekly, well-tolerated therapy that can be rapidly self-administered with an autoinjector
would be an attractive alternative for patients suffering from a wide array of complement mediated diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>RLYB332 for the treatment of severe anemia with
ineffective erythropoiesis and iron overload </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2022, we obtained worldwide exclusive rights to RLYB331, a preclinical antibody designed to inhibit <FONT
STYLE="white-space:nowrap">MTP-2.</FONT> The inhibition of <FONT STYLE="white-space:nowrap">MTP-2</FONT> significantly increases levels of hepcidin, decreases iron load and treats ineffective erythropoiesis. We believe this molecule has the
potential to address a significant unmet need for patients with severe anemias with ineffective erythropoiesis and iron overload, including beta thalassemia and a subset of lower risk MDS. Currently these patients are underserved by the existing
standard of care. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2024, we completed <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies that demonstrated favorable
tolerability, dose-dependent PK, and sustained PD effects with RLYB332, a long-acting version of RLYB331. These findings, which were presented in a poster at the 66th annual meeting of ASH, support the continued development of RLYB332 as a
potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutic for treating diseases of iron overload. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>AbCellera Collaboration </U></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We entered into a strategic alliance with
AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration combines AbCellera&#8217;s antibody discovery engine with Rallybio&#8217;s clinical and commercial
expertise in rare diseases to identify optimal clinical candidates with a goal of delivering therapies to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. There are many public and private
biopharmaceutical companies, universities, government agencies and other research organizations actively engaged in the research and development of products that may be like our product candidates or address similar markets. In addition, the number
of companies seeking to develop and commercialize products and therapies competing with our product candidates is likely to increase. However, we seek to build our portfolio with key differentiating attributes to provide a competitive advantage in
the markets we target. The success of our product candidates, if approved, is likely to be a result of their efficacy, safety, convenience, price, the level of biosimilar or generic competition and/or the availability of reimbursement from
government and other third-party payors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our competitors may have significantly greater name recognition and financial, manufacturing, marketing, product
development, technical, commercial infrastructure, and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of
our competitors. These competitors also compete with us in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage
companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual
Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends, in part, on our ability to obtain, maintain, defend, and enforce patent rights and other intellectual property rights that
protect our business, preserve the confidentiality of our trade secrets, and operate without infringing the valid and enforceable intellectual property rights of others. In addition to our efforts to protect our product candidates and methods of
using them, we also seek to secure or acquire patent rights regarding other products and methods that are important to the general development of commercial products. We utilize a multi-layered approach that includes acquiring intellectual property
rights through purchase or exclusive license, filing and prosecuting U.S. and foreign patent applications directed to our own innovations, and developing and protecting proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> to maintain our
competitive position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ongoing efforts to secure patent rights that protect our business constitute a key component of our business strategy. We also strive to
protect as trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how,</FONT> certain aspects of our programs and technological innovations that are commercially valuable but are not amenable to or appropriate for patent protection. We
achieve this, in part, through the use of confidentiality agreements with our employees, consultants, scientific advisors, collaborators, licensors, and contractors, and by striving to maintain physical security of our premises and digital security
of our electronic information and technology systems. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding our commitment to protecting our intellectual property rights, we, like other pharmaceutical
and biopharmaceutical companies, are subject to several sources of uncertainty that can affect those rights. For example, we cannot be certain that any patents that we currently own or <FONT STYLE="white-space:nowrap">in-license,</FONT> or that we
may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future, will not be challenged, held to be invalid and/or unenforceable, have the scope of their claims narrowed, or be circumvented by others. Nor can we be certain that such
patents will successfully protect our products or our business from competition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, with respect to patent applications that are currently pending, or that may be pending in the future, we
cannot be certain that such patent applications will result in the issuance of granted patents, or of patent claims with the desired claim scope. In order to secure an issued patent, an invention claimed in a patent application must meet certain
legal requirements for patentability, which differ between countries based on each country&#8217;s particular patent laws. In addition, because of the significant amount of time required for clinical development and regulatory review of product
candidates, we cannot be certain that any of our product candidates will be commercialized while there is significant patent term remaining on patents relating to those products. The term of a patent depends upon the legal requirements for
determination of patent term in the country in which that patent is granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment (&#8220;PTA&#8221;) which compensates a patentee for
administrative delays by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) in examining and granting the patent. Likewise, a patent&#8217;s term may be shortened if it is terminally disclaimed over an earlier-expiring patent with a common
owner or inventor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term of a U.S. patent relating to an approved drug product may also be extended to compensate the patentee for delays due to the regulatory
approval process. Such a patent term extension (&#8220;PTE&#8221;) cannot exceed five years, and cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Furthermore, the term can be extended for
only one patent applicable to each regulatory review period and only those claims covering the approved product, or a method for using it or manufacturing it, may be extended. In the future, if any of our product candidates receive approval by the
FDA we expect to apply for PTE on any issued patents covering those products, depending upon the length of the clinical studies for each product and other factors. There can be no assurance that we will benefit from any PTE or favorable adjustments
to the terms of any patents we currently own or <FONT STYLE="white-space:nowrap">in-license</FONT> or that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to and separate from patent exclusivity, the FDA may also grant marketing exclusivity of varying lengths in connection with the approval of a New Chemical
Entity (5 years), Biologic (12 years), or Orphan Drug indication (7 years). Marketing exclusivity may also be granted for new clinical studies (3 years) and pediatric studies (6 months) on approved drugs. Depending on the length of the regulatory
approval process and the ability to make use of the procedures for obtaining PTE, any FDA exclusivity period may in part or in whole overlap with any patent exclusivity to which we are entitled. We intend to pursue relevant marketing exclusivities
in the US and in foreign countries in which any candidate product is approved. However, we cannot be certain that any such exclusivities will be granted or, if granted, will insulate our commercial product(s) from competition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to trade secrets, while we have confidence in the protective measures that we employ, such measures can be breached, and we may not have adequate remedies
for any such breach. We also cannot be certain that any of our activities will not be subject to the intellectual property rights of others. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;1,
2026, we owned two patent families relating to the current product candidates in our complement program, RLYB114 and RLYB116, and certain aspects of their use that were acquired from Sobi. These two patent families currently include five granted
U.S. patents and one pending U.S. patent application, with granted patents and/or pending patent applications in more than 25 additional countries worldwide. In the United States, Australia, Canada the European Patent Convention contracting states,
and Japan, applications in both patent families have been granted and are scheduled to expire between 2033 and 2034, excluding any PTA or PTE. In addition, we filed and own a family of patent applications directed to dosing and administration of
RLYB116 that consists of pending patent applications in Australia, Canada, Europe, Japan, the United States and 22 additional countries. Patents issuing in this patent family will have an expiration date in November 2042, excluding any PTA or PTE
that may be awarded. We also filed and own nine pending provisional patent applications directed to methods of treatment of various <FONT STYLE="white-space:nowrap">C5-related</FONT> conditions by administration of RLYB116. We have also <FONT
STYLE="white-space:nowrap">non-exclusively</FONT> <FONT STYLE="white-space:nowrap">in-licensed</FONT> certain patent rights relating to our current product candidates from Affibody, including patent rights relating to the Affibody molecule
technology and Albumod albumin binding molecule technology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;1, 2026, we exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Kymab
Limited certain patent rights to the current product candidate in our iron overload program, RLYB332, as well as <FONT STYLE="white-space:nowrap">back-up</FONT> compounds. Under the exclusive license, we are managing prosecution of a patent family
relating to RLYB332 and the <FONT STYLE="white-space:nowrap">back-up</FONT> compounds. The patent family </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
currently includes pending patent applications in the United States and in more than 20 other countries/regions, including Australia, Brazil, Canada, China, Eurasia, Europe, India, Japan, Mexico,
and Saudi Arabia. Patents have been granted in Eurasia, Japan, and Malaysia, and are scheduled to expire in November 2040. In addition, we filed and own a pending International (PCT) patent application family directed to use of RLYB332 for treating
pathologies of beta-thalassemia. Further, we have <FONT STYLE="white-space:nowrap">non-exclusively</FONT> <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Kymab Limited certain patent rights relating to the development, manufacture, and use
of RLYB332 and the <FONT STYLE="white-space:nowrap">back-up</FONT> compounds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Product License Agreement with Affibody AB </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2019, our
subsidiary IPC Research, LLC (&#8220;IPC Research&#8221;) and Sobi entered into a Contract Assignment Agreement pursuant to which Sobi assigned to, and IPC Research assumed, all obligations in a certain Product License Agreement (&#8220;PLA&#8221;)
as amended, between Sobi and Affibody AB (&#8220;Affibody&#8221;), dated March&nbsp;9, 2012, as amended on January&nbsp;1, 2018 and December&nbsp;22, 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the PLA, we obtained a license to the Affibody platform technology and a particular ABD, in order to further develop and commercialize certain Affibody
ligands, which we are now developing as RLYB116 and RLYB114. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the PLA, Affibody grants us (1)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
right under certain patents to use the Affibody ligands alone or as a fusion protein and (2)&nbsp;an exclusive right to use the Affibody ligands alone or as a fusion protein, in each case, for human therapeutic use. Affibody also grants us
(a)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right under certain patents to use the ABD in combination with the Affibody ligands as a fusion protein and (b)&nbsp;an exclusive right to use the ABD solely in combination with the
Affibody ligands as a fusion protein, in each case, for human therapeutic use. Affibody grants us a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under applicable <FONT STYLE="white-space:nowrap">know-how</FONT> needed to practice
the rights and licenses granted under the PLA. All licenses to us are sublicensable, provided that each sublicense is consistent with the terms and conditions of the PLA. Under the PLA, Affibody has an exclusive right under any product patents,
which are a category of certain patents that we own, to use the specific Affibody ligands outside of human therapeutics and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right under <FONT STYLE="white-space:nowrap">know-how</FONT> needed
to practice the Affibody ligands outside of human therapeutics. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the PLA, Affibody is the exclusive owner of, and controls prosecution, maintenance, and
defense of intellectual property covering, platform technology. We are the exclusive owner of, and control prosecution, maintenance, and defense of intellectual property covering, product technology. Affibody agrees to disclose to us any improvement
to the Affibody technology that it deems commercially reasonable for us to practice and grants us an option to license any such improvement. We have the first right to enforce product patents against a third-party infringer and Affibody retains the
first right to enforce any other licensed patent. We agree to not provide or make available any Affibody Ligand to a third-party on a standalone basis except for research purposes or to commercialize a licensed product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We agree to use commercially reasonable efforts to develop and commercialize a licensed product. We also will pay Affibody certain regulatory milestones up to an
aggregate amount of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>7.5&nbsp;million and (a)&nbsp;a <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalty on annual net sales of products if such products are covered by a valid claim
of a product patent or a platform patent or <FONT STYLE="white-space:nowrap">(b)&nbsp;low-single-digit</FONT> royalties on annual net sales of products that are not covered by any such valid claim. Our obligation to pay royalties expires on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis on the later of (a)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of a patent covering a licensed product or (b)&nbsp;the 10th anniversary following first commercial sale of such product in such country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The PLA will terminate when we are no longer obligated to pay royalties to Affibody. Either party may terminate the PLA upon material breach of the PLA by the other,
subject to a cure period, or immediately in the case of the other party&#8217;s insolvency, bankruptcy or a similar event. Affibody may terminate the PLA immediately if we or any of our affiliates or third party transferees commences any proceeding
challenging the validity of the licensed patents or any of Affibody&#8217;s other patents or challenging the confidentiality or substance of the licensed <FONT STYLE="white-space:nowrap">know-how</FONT> or licensed technology. We may terminate the
PLA for convenience upon 90 days prior written notice and upon payment of any amounts due to Affibody through the effective date of such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Affibody terminates the PLA or if we terminate the PLA for convenience, (a)&nbsp;all rights and licenses granted
under the PLA will terminate, (b)&nbsp;at Affibody&#8217;s request, we must transfer all rights to the product technology free of charge to Affibody and (c)&nbsp;we must return or destroy all of Affibody&#8217;s confidential information.
Furthermore, if we terminate for convenience, we must grant Affibody an exclusive, royalty free perpetual right to use all regulatory filings, approvals and data provided to regulatory authorities in support of such filings or approvals that relate
to the licensed product. However, if we terminate the PLA as a result of Affibody&#8217;s material breach of the PLA or its insolvency or bankruptcy, we will retain our license and rights under the PLA, provided that we will remain bound by certain
obligations under the PLA with respect milestone payments, royalties (subject to a reduction in rate, in the case of material breach), audits and indemnity. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Product License Agreement with Sanofi </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2022, through our
subsidiary, Rallybio IPE, LLC (&#8220;Rallybio IPE&#8221;), we entered into a License Agreement with Kymab Limited (&#8220;Sanofi&#8221;, and such agreement the &#8220;Sanofi License Agreement&#8221;). Under the Sanofi License Agreement, Sanofi
provides Rallybio IPE with worldwide exclusive rights to Sanofi&#8217;s KY1066, which is now referred to as RLYB331. Under the terms of the Sanofi License Agreement, Rallybio has an exclusive license to certain Sanofi patents to develop, manufacture
and commercialize RLYB331 and Rallybio agrees to use commercially reasonable efforts to develop and commercialize a licensed product in at least one indication in the field in each of several major markets, as described in the Sanofi License
Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We paid Sanofi an upfront cash payment of $3.0&nbsp;million. In addition, Rallybio has agreed to pay Sanofi up to an aggregate of $43.0&nbsp;million in
development and regulatory milestones and up to an aggregate of $150.0&nbsp;million in commercial milestones for a product in its first indication, plus tiered
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> double digit percentages of such milestone amounts for up to three additional indications, and mid to high single digit royalties on net sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Sanofi License Agreement contains other customary license terms including sublicensing, development, regulatory, manufacturing, commercialization, milestones,
royalties, intellectual property, and termination. The Sanofi License Agreement will expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis at the end of the applicable royalty term. Either party may terminate the Sanofi License Agreement upon material breach of the Sanofi License Agreement by the other, subject to a cure
period. Rallybio may terminate the Sanofi License Agreement for convenience upon 90 days prior written notice to Sanofi. Sanofi may terminate the Sanofi License Agreement immediately in the case of Rallybio&#8217;s insolvency, bankruptcy or a
similar event, or if Rallybio or its affiliates participates in any proceeding challenging the validity of the licensed patents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Sanofi License Agreement is
terminated in its entirety, among other things (a)&nbsp;all rights and licenses granted by Sanofi under the License Agreement (including any sublicenses) will terminate and (b)&nbsp;if Sanofi has an interest in developing, manufacturing and
commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shall negotiate an arrangement to provide Sanofi rights to the patents, <FONT STYLE="white-space:nowrap">know-how,</FONT> materials and other properties
controlled by Rallybio applicable to any of the licensed product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Asset Purchase Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Asset Transfer Agreement with Swedish Orphan Biovitrum AB (Publ) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
March 2019, through IPC Research, we entered into an agreement with Sobi, pursuant to which we acquired the right, title and interest in assets related to certain C5 inhibitor compounds. We are currently developing the assets acquired from Sobi as
RLYB116 and RLYB114. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We paid Sobi an upfront purchase price of $5.0&nbsp;million and we are obligated to pay Sobi an aggregate amount of up to $51.0&nbsp;million
upon achievement of certain development milestones and an aggregate amount of up to $65.0&nbsp;million upon achievement of certain sales milestones. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also will
pay Sobi tiered, low single-digit royalties on annual net sales to third parties for products containing any compound transferred under the agreement as an active ingredient. Our obligation to pay royalties expires, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, on the later of (a)&nbsp;the 10th anniversary
following first commercial sale of such product in such country and (b)&nbsp;the expiration date in such country of the last to expire of any issued patent included in the patent rights acquired from Sobi that includes at least one valid claim
covering the sale of such product in such country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are obligated to use commercially reasonable efforts to research, develop and exploit at least one product that
contains a compound transferred under the agreement as an active ingredient in each of the United States, European Union (&#8220;EU&#8221;) and Japan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If, prior to
the commercial launch in the United States of the first product containing the compounds, we decide to divest our rights in the assets acquired from Sobi or to terminate all research, development and commercialization activities in respect of the
acquired compounds, we must notify Sobi and negotiate in good faith with Sobi a possible business transaction relating to the assets. This right of negotiation will not apply to a transaction to sell all or substantially all of the assets of IPC
Research or an affiliate of IPC Research, a pledge of the assets as collateral or a sale or transfer of the assets to an affiliate of IPC Research that agrees to be bound by the right of negotiation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Joint Venture Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, we entered into a partnership with
Recursion (as successor in interest to Exscientia) and created <FONT STYLE="white-space:nowrap">REV-I,</FONT> which was jointly owned by Recursion and one of our wholly-owned subsidiaries, each a Member and collectively the Members. The joint
venture was formed to initiate early-stage drug discovery of orally available small molecules targeting ENPP1 for the treatment of HPP, and thereafter for the future research, development, manufacture, sale and exploitation of any company-owned
technology and compounds, including any resulting compound identified by the steering committee of the joint venture. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2025, we entered into a ENPP1
Purchase Agreement with Recursion Exscientia Ventures I, Inc., an indirect wholly-owned subsidiary of Buyer and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio Corporation to sell our interest in REV102, ENPP1 inhibitor in preclinical
development for the treatment of patients with HPP, to Buyer (a subsidiary of our joint venture partner Recursion) (the &#8220;JV Sale&#8221;). In connection with the JV Sale, we received a total of $20.0&nbsp;million in the third quarter of 2025
including $7.5&nbsp;million from an upfront payment and $12.5&nbsp;million from a milestone payment related to the initiation of additional preclinical studies. We are eligible to receive a $5.0&nbsp;million milestone payment in connection with the
initiation of dosing in a Phase 1 clinical study, as defined in the ENPP1 Purchase Agreement and low single-digit royalties on all future net sales by Recursion of products comprising or incorporating certain compounds developed by <FONT
STYLE="white-space:nowrap">REV-I.</FONT> We may also be eligible to receive certain payments in the event of Recursion&#8217;s sale of the REV102 program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>AbCellera Collaboration Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2022, the Company entered
into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration combined AbCellera&#8217;s antibody discovery engine with Rallybio&#8217;s clinical
and commercial expertise in rare diseases to identify optimal clinical candidates and ultimately deliver therapies to patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the agreement,
AbCellera and Rallybio were planning to <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five rare disease therapeutic targets, which will be chosen together by both companies. The collaboration was designed to allow Rallybio to add product
candidates to its existing pipeline and provide the option for AbCellera to conduct process development and clinical manufacturing activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Collaboration
Agreement with Johnson&nbsp;&amp; Johnson </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2024, through Rallybio IPA, we entered into a collaboration agreement (the &#8220;J&amp;J Collaboration
Agreement&#8221;) with Johnson&nbsp;&amp; Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. (&#8220;J&amp;J&#8221;). Under the J&amp;J Collaboration Agreement, the Company and J&amp;J planned to advance therapeutic
solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia (&#8220;FNAIT&#8221;). The Company shared certain aggregated, anonymized data with J&amp;J, collected from the Company&#8217;s FNAIT natural history study
and the Company&#8217;s Phase 2 FNAIT clinical trial. The Company also agreed to disseminate information to its FNAIT study sites related to J&amp;J&#8217;s and its affiliates&#8217; research and development of complementary therapeutic approaches
aimed at reducing the risk of FNAIT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the J&amp;J Collaboration Agreement, J&amp;J made an upfront payment of $0.5&nbsp;million. We were
also eligible to receive additional payments upon certain triggers related to both companies&#8217; FNAIT studies, however, in connection with our decision in April 2025 to discontinue development of RLYB212, we do not expect any payments regarding
the achievement of certain enrollment-related events. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The J&amp;J Collaboration Agreement expires in April 2026. The Company may terminate the agreement upon
J&amp;J&#8217;s material breach, the Company&#8217;s decision to discontinue an FNAIT study, or during a certain part of the term if the Company determines for any reason that termination of the agreement is in the best interests of the Company.
J&amp;J may terminate the agreement upon the Company&#8217;s material, uncured breach, upon the Company&#8217;s decision to discontinue an FNAIT study, documented failure of the Company to conduct its FNAIT studies in accordance with applicable law
and J&amp;J&#8217;s decision to discontinue its FNAIT studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not own or operate, and currently have no plans to establish, any internal manufacturing facilities. We currently rely and expect to continue to rely on
third-party contract manufacturer organizations (&#8220;CMOs&#8221;) for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial production of any product candidates that are approved. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely on multiple CMOs for all of our preclinical and clinical supply requirements, including drug substances and drug products, and label and packaging for
our preclinical research and clinical trials. We believe that we will be able to contract with other CMOs to manufacture drug substances if our existing sources of drug substances were no longer available to us or with sufficient capacity, but there
is no assurance that the drug substance capacity would be available from other CMOs on acceptable terms, on the timeframe that our business would require, or at all. We do not currently have supply commitments or other arrangements in place with our
existing CMOs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have any current contractual relationships for the manufacture of commercial supplies of any of our product candidates if they are
approved by the regulatory authorities, and we intend to enter into agreements with a CMO and plans for one or more <FONT STYLE="white-space:nowrap">back-up</FONT> manufacturers for the commercial production of our product candidates as they near
phase 3 clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any products to be used in clinical trials and any approved product that we may commercialize will need to be manufactured in facilities,
and by processes, that comply with the FDA&#8217;s current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements and comparable requirements of the regulatory agencies of other jurisdictions in which we are seeking approval. We currently
employ internal resources to manage our CMOs. We believe that RLYB116 and RLYB332 can be manufactured through reliable and reproducible biologic and chemical processes from readily available starting materials. We believe that our manufacturing
processes are amenable to <FONT STYLE="white-space:nowrap">scale-up</FONT> and will not require unusual or expensive equipment. We expect to continue to develop, on our own or with our collaborators, product candidates that can be produced
cost-effectively at contract manufacturing facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research, development, testing, manufacture, quality control, packaging, labeling, storage, record-keeping, distribution, import, export, promotion, advertising,
marketing, sale, pricing and reimbursement of drug and biologic products are extensively regulated by governmental authorities in the United States and other countries. The processes for obtaining regulatory approvals in the United States and in
foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory requirements, both <FONT STYLE="white-space:nowrap">pre-approval</FONT> and post-approval, require the expenditure of
substantial time and financial resources. The regulatory requirements applicable to drug and biological product development, approval and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted
by the agencies in ways that may have a significant impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Government Regulation of Drug and Biological Products </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, (the &#8220;FDCA&#8221;), and in the case of biologics, also under
the Public Health Service Act (the &#8220;PHSA&#8221;), and their implementing regulations. Failure to comply with the applicable U.S. requirements may result in FDA refusal to approve pending New Drug Applications (&#8220;NDAs&#8221;) or Biologics
License Applications (&#8220;BLAs&#8221;) or delays in development and may subject an applicant to administrative or judicial sanctions, such as issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions and/or civil or criminal prosecution brought by the FDA and the DOJ or other governmental entities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA must approve our product candidates for therapeutic indications before they may be marketed in the United States. For drug products, the FDA must approve an
NDA, and for biologic products, the FDA must approve a BLA. An applicant seeking approval to market and distribute a new drug or biologic in the United States generally must satisfactorily complete each of the following steps: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of preclinical laboratory tests and animal studies according to Good Laboratory Practice (&#8220;GLP&#8221;)
regulations or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacture and testing of the therapeutic or biologic moiety and its respective product formulation according to cGMP
regulations or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee representing each clinical
trial site before each clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good
clinical practices (&#8220;GCPs&#8221;) and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparation and submission to the FDA of an NDA or BLA requesting marketing approval for one or more proposed indications,
including payment of application user fees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">review of the NDA or BLA by an FDA advisory committee, where applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug or
biologic and its respective finished product is produced; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the
clinical data submitted in support of the NDA or BLA; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA review and approval of the NDA or BLA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preclinical Studies and IND </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before testing any drug or biological product
candidate in humans, the product candidate must undergo rigorous preclinical testing. The preclinical development stage generally involves laboratory evaluations of drug chemistry/biology, formulation, and stability, as well as in vitro and animal
studies to assess safety and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety and toxicology studies. The sponsor
must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin.
An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case,
the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Certain long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may initiate or continue after an
IND for an investigational product candidate is submitted to the FDA and human clinical trials have been initiated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Human Clinical Trials in Support of an NDA or BLA </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials involve the administration of an investigational product candidate to healthy volunteers or patients with the disease to be treated under the
supervision of qualified investigators. Clinical trials are conducted under protocols detailing the objectives of the study, inclusion and exclusion criteria, dosing procedures and the parameters to be used in monitoring the safety and effectiveness
criteria to be evaluated. Each protocol, as well as any subsequent amendments, must be submitted to the FDA as part of the IND. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An IRB representing each
institution that is participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must thereafter conduct a continuing review of the trial. The IRB will consider,
among other things, clinical trial design, patient informed consent, ethical factors and the safety of human subjects. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to
clinical trial subjects or their legal representatives and must operate in compliance with FDA regulations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials must also comply with extensive GCP
standards intended to ensure protection of human subjects and the quality and integrity of the study data, including requirements for obtaining subjects&#8217; informed consent. Additionally, some clinical trials are overseen by an independent group
of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group may recommend continuation of the trial as planned, changes in trial conduct or cessation of the trial at designated
checkpoints based on access to certain data from the study. The FDA may at any time while clinical trials are ongoing impose a partial or complete clinical hold based on concerns for patient safety and/or noncompliance with regulatory requirements.
This order issued by the FDA would cause suspension of an ongoing trial until all outstanding concerns have been adequately addressed, and the FDA has notified the company that investigations may proceed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Human clinical trials to evaluate therapeutic indications to support NDAs and BLAs for marketing approval are typically conducted in three sequential phases that may
overlap or be combined: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1: The product candidate is initially introduced into human subjects, who are commonly healthy volunteers, and
tested for safety, dosage tolerance, absorption, metabolism, distribution, and excretion, and if possible, to gain early evidence for effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2: Clinical trials are conducted in a limited patient population with a specified disease or condition to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3: Clinical trials are undertaken with an expanded patient population to further evaluate dosage, and to provide
substantial evidence of clinical efficacy and safety in an expanded patient population, often at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product candidate and
provide, if appropriate, an adequate basis for product labeling. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be
conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, to document a clinical benefit in the case of drugs or biologics approved under
FDA&#8217;s accelerated approval regulations and to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval
of an NDA or BLA. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for the product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate
approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol, GCP or other IRB requirements or if the drug has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the development of a new drug or biological product, sponsors have the opportunity to meet with the FDA at certain points, including prior to submission of an
IND, at the end of phase 2 and before submission of an NDA or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
BLA. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and must also develop additional
information about the physical characteristics of the drug or biological product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of
consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, potency and purity of the final drug or biological product. For biological
products in particular, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined in order to help ensure safety, purity and potency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Marketing Application Submission and FDA Review </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful
completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#8217;s chemistry, manufacturing, controls (&#8220;CMC&#8221;) and proposed labeling, are
submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a
number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality to establish the safety and efficacy of the investigational product to the satisfaction of
the FDA. The fee required for the submission of an NDA or BLA under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) is substantial (for example, for fiscal year 2025 this application fee is approximately $4.3 million), and the sponsor of an
approved NDA or BLA is also subject to an annual program fee, currently more than $403,000 per program. These fees are typically adjusted annually, but exemptions and waivers may be available under certain circumstances. No user fee is required for
orphan drug product applications, except when an application also includes an indication for a <FONT STYLE="white-space:nowrap">non-rare</FONT> disease or condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA conducts a preliminary review of all NDAs and BLAs within 60 days of receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the
submission whether an application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the application must be resubmitted with the additional
information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review of the application.
Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant and six months from the filing date for an
application with priority review. The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by
the FDA following the original submission. Despite these review goals, it is not uncommon for FDA review of an NDA or BLA to extend beyond the PDUFA goal date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before approving an NDA or BLA, the FDA will typically conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the
therapeutic/biologic to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities comply with cGMP requirements and are
adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with GCP requirements and the integrity of the clinical data
submitted to the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the FDA may refer any NDA or BLA, including applications for novel product candidates which present difficult questions of
safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts, including
clinicians and other scientific experts. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. The FDA also may require submission of a Risk Evaluation and
Mitigation Strategy (&#8220;REMS&#8221;), if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug or biological product. If the FDA concludes a REMS is needed, the
sponsor of the NDA or BLA must submit a proposed REMS and the FDA will not approve the NDA or BLA without a REMS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Pediatric Research Equity Act of 2003 (&#8220;PREA&#8221;), an NDA or BLA or certain supplements thereto
must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the
product is safe and effective, unless this requirement is waived, deferred or inapplicable. Sponsors must submit a pediatric study plan to FDA outlining the proposed pediatric study or studies they plan to conduct, including study objectives and
design, any deferral or waiver requests and other information required by regulation. The FDA must then review the information submitted, consult with the sponsor and agree upon a final plan. In general, PREA requirements do not apply to drugs or
biologics for indications granted orphan drug designation by the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA reviews an NDA or BLA to determine, among other things, whether a product is safe and
effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. The approval process is lengthy and often difficult, and the FDA may refuse to approve
an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. After evaluating the application and all related information, the FDA may issue either an approval letter or a
Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete, and
the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If a CRL is
issued, the applicant may either resubmit the NDA or BLA addressing all of the deficiencies identified in the letter or withdraw the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of
the NDA or BLA, the FDA will issue an approval letter. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product receives regulatory approval from the FDA, the approval is limited to the conditions of use
(e.g., patient population, indication) described in the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be
included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after
commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or
limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling
claims, are subject to further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulation of Combination Products </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain products may be comprised of components, such as drug or biologic components and device components that would normally be regulated under different types of
regulations, and frequently by different centers at the FDA. These products are known as combination products. We expect to rely on a delivery system, such as <FONT STYLE="white-space:nowrap">pre-filled</FONT> syringes, <FONT
STYLE="white-space:nowrap">pen-injectors</FONT> and/or autoinjectors to deliver certain of our product candidates. Although we have not yet selected the delivery system to use for administration of such product candidates, including RLYB116, we
expect that, if approved, any such product candidate would be regulated as a combination product, because it is composed of both a drug or biological product and a delivery system &#8220;device.&#8221; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination
product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA center for combination products, although the lead center may consult with other centers within the FDA. The determination of which
center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible
for review of the drug product would have primary jurisdiction for the combination product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A combination product involving a novel drug or biological product and
delivery system generally would have a drug or biologic primary mode of action. A combination product with a drug or biologic primary mode of action would be reviewed and approved pursuant to the drug or biologic approval processes. In reviewing the
NDA or BLA for such a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
product, however, the FDA review division reviewing the application could consult with their counterparts in the device center to ensure that the device component of the combination product met
applicable requirements regarding safety, effectiveness, durability and performance. Approval may require the performance of certain clinical studies, such as clinical usability or human factors studies to demonstrate the safety and/or effectiveness
of the device component of the combination product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similar considerations apply to regulation of drugs combined with delivery systems outside the United States,
including in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Expedited Programs for Serious Conditions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA
is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track
designation, breakthrough therapy designation, priority review designation and accelerated approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To be eligible for a fast track designation, the FDA must
determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a
therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for earlier and more frequent interactions with the FDA review team to expedite development and review of
the product. The FDA also may review sections of the NDA or BLA for a fast track product on a rolling basis before the complete application is submitted if the sponsor and the FDA agree on a schedule for the submission of the application sections
and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA. Fast track designation may be rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, a new drug or biological product may be eligible for Breakthrough Therapy designation if it is intended, alone or in combination with one or more other
drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient development
program beginning as early as Phase 1 and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. Breakthrough designation may
be rescinded by the FDA if the designation is no longer supported. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may designate a product for priority review if it is a drug or biologic that treats a
serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the proposed drug or biologic qualifies for priority review. A priority review designation is intended to direct overall attention and
resources to the evaluation of such applications and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months for an original BLA or NDA from the date of filing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or
approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finally, the FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic
advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition
when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#8220;IMM&#8221;) and that is reasonably likely to predict an effect on IMM or other clinical
benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. For drugs granted accelerated approval, FDA generally requires sponsors to conduct, in a diligent manner,
additional post-approval confirmatory studies to verify and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
describe the product&#8217;s clinical benefit. Failure to conduct required post-approval studies with due diligence, failure to confirm a clinical benefit during the post-approval studies, or
dissemination of false or misleading promotional materials would allow the FDA to withdraw the product approval on an expedited basis. All promotional materials for product candidates approved under accelerated approval are subject to prior review
by the FDA unless FDA informs the applicant otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Post-Approval Requirements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, governing, among other
things, monitoring and recordkeeping activities, reporting of adverse experiences with the product and product problems to the FDA, product sampling and distribution, manufacturing and promotion and advertising. Although physicians may prescribe
legally available products for unapproved uses or patient populations (i.e., <FONT STYLE="white-space:nowrap">&#8220;off-label</FONT> uses&#8221;), manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the
laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant
liability. The current presidential administration announced in September 2025 that it intends to prioritize enforcement of pharmaceutical advertising requirements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to
submit and obtain FDA approval of a new NDA/BLA or an NDA/BLA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials. The FDA may also place other conditions on approvals
including the requirement for a REMS to assure the safe use of the product, which may require substantial commitment of resources post-approval to ensure compliance. A REMS could include medication guides, physician communication plans or elements
to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of
products. Product approvals may be withdrawn for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards or if problems occur following initial marketing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FDA regulations require that drug and biological products be manufactured in specific approved facilities and in accordance with cGMP. The cGMP regulations include
requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution,
laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and satisfy the FDA or comparable foreign regulatory authorities&#8217; satisfaction
before any product is approved and our commercial products can be manufactured. In addition, for any of our product candidates that include a device delivery system, the device component will be subject to aspects of the Quality System Regulation
(&#8220;QSR&#8221;) applicable to medical devices. Manufacturers of drug-device combination products may either opt to comply with all quality regulations governing each component of the product separately, or may take a &#8220;streamlined
approach&#8221; to cGMP that allows the manufacturer to demonstrate compliance with the drug cGMP along with compliance with several specific provisions from the device QSR&#8212;namely, management responsibility, design controls, purchasing
controls, corrective and preventive action, installation, and servicing, as applicable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely, and expect to continue to rely, on third parties for the
production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations, including requirements for quality control and quality assurance, the maintenance of records
and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with
the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the
area of production and quality control to maintain cGMP compliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once an approval of a drug/biologic product is granted, the FDA may withdraw the approval if compliance with
regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or
with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information, imposition of post-market clinical trials requirement to assess new safety
risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other
safety information about a product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">mandated modification of promotional materials and labeling and issuance of corrective information; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, warning letters, untitled letters or other enforcement-related letters or clinical holds on post-approval clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal of the FDA to approve pending NDAs/BLAs or supplements to approved NDAs/BLAs, or suspension or revocation of
product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil or criminal penalties; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated
modification of promotional materials and labeling and the issuance of corrective information. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the distribution of prescription
pharmaceutical products is subject to the Prescription Drug Marketing Act, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the
states. Additionally, the Drug Supply Chain Security Act imposes requirements related to identifying and tracing certain prescription drugs distributed in the United States, including most biological products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Patent Term Restoration and Hatch-Waxman Marketing Exclusivity </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending upon the timing, duration and specifics of FDA approval for our product candidates, some of our U.S. patents may be eligible for limited PTE under the Drug
Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch Waxman Amendments permit restoration of the patent term up to five years as compensation for patent term lost during the FDA
regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date, and only those claims covering such approved drug product, a method for
using it or a method for manufacturing it may be extended. The patent-term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date of an NDA or BLA plus
the time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent. The
USPTO, in consultation with the FDA, reviews and approves the application for any PTE or restoration. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory exclusivity provisions under the FDCA also can
delay the submission or the approval of certain applications. The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to gain approval of an NDA
for a new chemical entity. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or a 505(b)(2) NDA submitted by another company for another version of such drug. However, an
application may be submitted after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
FDCA also provides three years of exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to
be essential to the approval of the application. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original
active agent for other conditions of use. Three-year exclusivity will not delay </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate
and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, both drugs and biologics can obtain pediatric exclusivity in
the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or
patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#8220;Written Request&#8221; for such a study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Biosimilars and Reference Product Exclusivity for Biological Products </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
March 2010, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) was enacted in the United States and included the Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;). The BPCIA amended the PHSA to create
an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. To date, the FDA has approved a number of biosimilars. The
FDA approved the first interchangeable biosimilar product in 2021 and has since approved others. The FDA has also issued several guidance documents outlining its approach to reviewing and approving biosimilars and interchangeable biosimilars. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the BPCIA, a manufacturer may submit an application that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological
product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety,
purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product and (for
products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference
biologic. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biosimilar applicant must demonstrate that the product is biosimilar based on data from analytical studies showing that the biosimilar product is highly similar to
the reference product, data from animal studies (including toxicity) and data from one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In
addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards
designed to assure product safety, purity, and potency. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of
the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. The FDA will not accept an application for a biosimilar or interchangeable product
based on the reference biological product until four years after the date of first licensure of the reference product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The BPCIA is complex and only beginning to
be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact
the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulation Outside of the United States </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in the
United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval from the
comparable regulatory authorities of foreign countries or economic areas, such as the EU, before we may commence clinical trials or market products in those countries or areas. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until recently, the EMA and the European Commission (&#8220;EC&#8221;) were responsible for approving new medicines
for supply in Northern Ireland according to the Northern Ireland Protocol. From January&nbsp;1, 2025, in accordance with the &#8220;Windsor Framework,&#8221; all new medicines for the UK market, including Northern Ireland, will be authorized by the
MHRA and UK packaging must carry a clearly legible &#8216;UK only&#8217; to be allowed onto the UK market. The International Recognition Procedure (&#8220;IRP&#8221;) provides the framework for the MHRA to take into account assessments of medicinal
products conducted by trusted regulatory authorities in Australia, Canada, Switzerland, Singapore, Japan, the United States and the EU when assessing applications for marketing authorization. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With the exception of the EU EEA applying harmonized regulatory rules for medicinal products, the approval process and requirements governing the conduct of clinical
trials, product licensing, and pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and
jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in
one country or jurisdiction may negatively impact the regulatory process in others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Union Drug Development, Review and Approval </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, our product candidates will be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing
authorization (&#8220;MA&#8221;) is granted by a competent regulatory agency. Similar to the United States, the various phases of preclinical and clinical research in the EU are subject to significant regulatory controls. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, clinical trials are primarily regulated by the CTR. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The CTR requires
sponsors to submit one clinical trial authorization (&#8220;CTA&#8221;) application via the Clinical Trials Information System, which will then be reviewed by the competent regulatory agency selected by the sponsor as the reporting Member State to
lead the validation and evaluation of the application. If successful, the resulting CTA would cover all EU Member States concerned by the application. However, a concerned Member State may in limited circumstances declare an <FONT
STYLE="white-space:nowrap">&#8220;opt-out&#8221;</FONT> from an approval and prevent the clinical trial from being conducted in such Member State. In addition to a CTA, sponsors of clinical trials conducted in the EU must also obtain a positive
opinion on the clinical trial from a research ethics committee in each Member State where the trial will be conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Combination Products </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Product candidates that incorporate a medical device for the administration of the medicinal product, and which are intended to be commercialized as a single integral
product used exclusively in the given combination, will be regulated by Directive 2001/83/EC or Regulation (EC) 726/2004 as a medicinal product. However, the medical device component must satisfy the general safety and performance requirements under
applicable EU law governing general medical devices. Proof of such must be included in an application for MA for the combination product. In particular, to the extent the device component has already been conformity assessed and a European
Conformity (&#8220;CE&#8221;) mark affixed, the certificate of conformity issued by the Notified Body must be provided in the MA application dossier. Where the medical device component has not already been CE marked, the MA application dossier must
include an opinion issued by a notified body on the conformity of the device component against the relevant general safety and performance requirements set out in Annex I of Regulation (EU) 2017/745. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">EU regulatory regime contemplates that MAs can be granted either centrally or nationally, albeit through mutual recognition or decentralized procedure, depending on the
type of product and the therapeutic indications for which approval is being sought. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Centralized Procedure </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The centralized procedure is compulsory for: medicinal products produced by biotechnology; orphan medicinal products; advanced-therapy medicinal products such as
gene-therapies; and medicinal products containing new active substances and which are indicated for the treatment of HIV, AIDS and immune dysfunctions, cancer, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
neurodegenerative diseases, diabetes, autoimmune and other immune dysfunctions, and viral diseases. The centralized procedure is optional for other medicines containing a new active substance,
which constitute a significant therapeutic, scientific or technical innovation, or which are in the interest of public health in the EU. Under the centralized procedure, a single MA application is submitted to the EMA where it will be evaluated by
its advisory committee, the Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;). Under the centralized procedure, the maximum timeframe for the evaluation of a MA application by the EMA is 210 days, excluding clock stops.
Clock-stops allow the applicant the necessary time to provide additional information in response to questions raised by the CHMP. The clock-stops considerably extend the time taken by the CHMP to complete the evaluation of a MA application. The EMA
will then provide the EC with an opinion on whether the medicinal product should be approved. Ordinarily, within 67 days of receipt of a positive scientific opinion from the EMA, the EC will adopt single MA an implementing decision on granting a
centralized marketing authorization. A centralized MA is valid for all EU member states and, by extension (after taking the corresponding national implementing measures), in Norway, Iceland and Liechtenstein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>National Procedure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The purely national procedure results in a MA in a
single EU Member State. This route is available for products not falling within the mandatory scope of the centralized procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Decentralized Procedure
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The decentralized procedure allows national MA applications in respect of medicinal products not authorized in the EU/European Economic Area
(&#8220;EEA&#8221;) to be submitted simultaneously in multiple EU member states. This is in contrast to the mutual recognition procedure, which applies if the product has been authorized in at least one EU member state on a national basis, and the
applicant seeks approval progressively of the same medicinal product in one or more EU member state(s). Both the decentralized and mutual recognition procedures provide for approval by one or more &#8220;concerned&#8221; member state(s) based on an
assessment of an application performed by one &#8220;reference&#8221; member state. Under the decentralized procedure, an applicant submits an application, accompanied by a dossier, containing the requisite scientific data, and related materials to
the reference member state and concerned member state(s). The reference member state prepares a draft assessment and drafts of the related materials within 120 days of the receipt of a valid application. Within 90 days of receiving the reference
member state&#8217;s positive assessment report, each concerned member state must approve the assessment report and related materials, unless they identify a potential serious risk to public health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Mutual Recognition Procedure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the mutual recognition procedure, the
concerned member state(s) have a <FONT STYLE="white-space:nowrap">90-day</FONT> period to recognize the MA in the reference member state. The decentralized procedure contemplates a single clock-stop at day 105 for applicants to address questions
raised by the reference member state and concerned member states, which may extend the process for completing the assessment procedure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In either case, if there is
a disagreement between member states during the assessment of the submitted data based on concerns about serious risks to public health, the Coordination Group for Mutual Recognition and Decentralized Procedures will consider the matter and seek to
reach a conclusion within 60 days. If this is not possible, the reference member state can escalate the issue to the EMA for arbitration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conditional Marketing
Authorization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In specific circumstances, Regulation (EC) No 726/2004 (as amended) enables applicants to obtain a conditional MA prior to obtaining the
comprehensive clinical data required for an application for a full MA. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1)&nbsp;the product candidate is intended for
the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases; (2)&nbsp;the drug candidate is intended to meet unmet medical needs of patients; (3)&nbsp;a MA may be granted prior to submission of comprehensive
clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4)&nbsp;the risk-benefit balance of the product
candidate is positive, and (5)&nbsp;it is likely that the applicant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
will be in a position to provide the required comprehensive clinical trial data. A conditional MA requires specific obligations to be fulfilled by the MA holder, including obligations with
respect to the completion of ongoing or new studies and with respect to the collection of pharmacovigilance data. Conditional MAs are valid for one year, and can be renewed annually, if the risk-benefit balance remains positive, and after a
satisfactory <FONT STYLE="white-space:nowrap">re-assessment</FONT> of benefit: risk balance and progress in fulfilling the specific obligations. Failure to submit the required comprehensive data may result in regulatory action against the
conditional marketing authorization, including the possibility of its revocation. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional MA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Pediatric Studies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EEA, companies developing a new medicinal product
must agree upon a pediatric investigation plan (&#8220;PIP&#8221;), with the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;) and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies. The PIP sets out the
timing and measures proposed for the generation of data to support a pediatric indication of the drug for which a MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are
sufficient data to demonstrate the efficacy and safety of the product in adults or other age groups not covered by the agreed PIP. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO in circumstances where the
medicinal product or the product class is likely to be ineffective or unsafe in part or all of the pediatric population; or the disease or condition occurs only in adult populations, or the specific medicinal product does not represent a significant
therapeutic benefit over existing treatments in pediatric patients. Products that are granted a MA with the results of the pediatric clinical trials conducted in accordance with the PIP (even where such results are negative) are eligible for a six
month extension to their supplementary protection certificate. In the case of orphan medicinal products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of the orphan market exclusivity may be available. This pediatric reward is subject
to the condition that the results are provided in respect of all studies in compliance with the agreed PIP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Union Regulatory Data Exclusivity </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, new products containing a new active substance are considered as &#8220;reference medicinal products,&#8221; and accordingly qualify for eight years of data
exclusivity and an additional two years of marketing exclusivity upon granting of a MA. The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the
reference medicinal product when applying for a generic or biosimilar MA in the EU. The marketing exclusivity period prevents a successful generic or biosimilar MA applicant from commercializing its product in the EU until ten years have elapsed
from the initial authorization of the reference medicinal product in the EU. The <FONT STYLE="white-space:nowrap">ten-year</FONT> market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten
years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Union Orphan Designation and Exclusivity </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The criteria for
designating an orphan medicinal product in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if it is intended for the diagnosis, prevention or
treatment of a life- threatening or chronically debilitating condition, which either (a)&nbsp;affects not more than five in 10,000 persons in the EU when the application is made, or (b), without the benefits derived from orphan status, would not
generate sufficient return in the EU to justify investment. In each case, there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized in the EU, or if such a method exists, the product will be of
significant benefit to those affected by the condition. The term &#8216;significant benefit&#8217; is defined in Regulation (EC) 847/2000 to mean a clinically relevant advantage or a major contribution to patient care. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan medicinal products are upon grant of a MA, entitled to ten years of market exclusivity for the approved therapeutic indication. During this <FONT
STYLE="white-space:nowrap">ten-year</FONT> market exclusivity period, the EMA or the competent authorities of the Member States of the EEA, cannot accept an application for a MA for a similar medicinal product for the same indication. A similar
medicinal product is defined as a medicinal product containing a similar active substance or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The application for orphan designation must be submitted before the
application for MA. The applicant will receive a fee reduction for the MA application if the orphan designation has been granted, but not if the designation is still pending at the time the MA is submitted. Orphan designation does not convey any
advantage in, or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">ten-year</FONT> market exclusivity in
the EU may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market
exclusivity. Additionally, MA may be granted to a similar product for the same indication at any time if: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically
superior; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the applicant consents to a second orphan medicinal product application; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the applicant cannot supply enough of the orphan medicinal product. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An equivalent regime is reflected in domestic law in the UK. Under the UK regime, however, orphan designations are not granted and instead a decision is made at the
point of MA grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB212 has been granted orphan drug designation by the EMA for the prevention of FNAIT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Priority Medicines Designation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Developers of innovative medicinal product
can apply to the EMA for access to the Priority Medicines (&#8220;PRIME&#8221;) program. A medicinal product will be accepted onto the PRIME scheme if the EMA determines that the available preliminary data demonstrate the medicinal product&#8217;s
potential to address an unmet medical need and bring a major therapeutic advantage to patients. As part of the program, EMA provides early and enhanced dialogue and support to optimize the development of eligible medicines and speed up their
evaluation, aiming to bring promising treatments to patients sooner. Rallybio anticipates that it will request PRIME designation for certain of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Periods of Authorization and Renewals </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, an initial MA is valid
for five years and may be renewed on the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the MA holder must provide
the EMA or the competent authority with a consolidated version of the file in respect of the medicinal product&#8217;s quality, safety and efficacy, including all variations introduced since the MA was granted, at least nine months before the MA
ceases to be valid. Once renewed, the MA is generally valid for an unlimited period, unless the EC or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the sunset clause, any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or
on the market of the authorizing member state (in the case of the national, decentralized and mutual recognition procedures) within three years after the MA is granted will cease to be valid. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EU is currently revising its general pharmaceutical legislation, known as the &#8216;Pharma Package&#8217;. This initiative is designed to ensure fair access to
safe, effective, and affordable medicines throughout the EU. It also aims to boost the competitiveness of the pharmaceutical industry by reducing regulatory burdens and enhancing supply chain security to better prevent and manage shortages. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The legislative process began with the European Commission&#8217;s proposal in April 2023, followed by the development of positions by the European Parliament and the
Council. Trilogue negotiations concluded with a political agreement in December 2025. The agreed text now awaits formal adoption by both the Parliament and Council, after which it will be published in the Official Journal of the EU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key measures include a new exclusivity framework, enhanced incentives for orphan drugs and antibiotics, an expanded
Bolar exemption, and a shortened regulatory assessment timeframe. The reforms also introduce stricter controls on product availability and supply shortages. It is anticipated that the new EU pharmaceutical legislation will be fully applicable in
2028, following a <FONT STYLE="white-space:nowrap">two-year</FONT> transition period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, in December 2025, the EC proposed the Biotech Act. This
legislation is intended to strengthen the competitiveness of the biotechnology sector and facilitate the development and timely market entry of biotechnology innovations, while maintaining high standards for the protection of human health. The
Biotech Act introduces a <FONT STYLE="white-space:nowrap">12-month</FONT> extension to the Supplementary Protection Certificate (&#8220;SPC&#8221;) for advanced therapy medicinal products such as gene and cell therapies, and innovative biotech
medicines. This extension aims to incentivize <FONT STYLE="white-space:nowrap">EU-based</FONT> manufacturing and R&amp;D by rewarding novel, highly effective medicines that conduct clinical trials across multiple EU Member States, addressing the
time lost in regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Brexit and the Regulatory Framework in the United Kingdom </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The UK formally left the EU on January&nbsp;31, 2020, and after the expiry of the transition period on December&nbsp;31, 2020, became a &#8220;third country&#8221; for
the purposes of EU law. At present, the regulatory regime in the UK broadly aligns with EU regulations. However, it is possible that the regime may diverge in the future. It remains to be seen how Brexit will impact regulatory requirements for
product candidates and products in the UK in the long-term. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EU and the UK concluded a trade and cooperation agreement (&#8220;TCA&#8221;), which was applied
provisionally from January&nbsp;1, 2021 and entered into force on May&nbsp;1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of the outcomes of GMP inspections and GMP documents. However,
the TCA does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To be used or sold in the UK, a medicinal product must have a valid
MA granted through the national application process. National applications are governed by the Human Medicines Regulations (SI&nbsp;2012/1916). Applications are made electronically through the MHRA Submissions Portal. The MHRA operates fixed
submission and assessment timetables for innovative medicines applications to facilitate consultation with its statutory advisory committee, the Commission on Human Medicines (&#8220;CHM&#8221;). The MHRA assessment procedure for a MA application
involves an initial evaluation, including orphan designation if applicable, and consultation with expert advisory groups as needed. By Day 90, applicants receive a consolidated request for information (&#8220;RFI&#8221;), which pauses the review
clock until a complete response is submitted electronically. Responses are assessed by Day 150, with further RFIs issued for minor issues or a CHM letter for major objections. Each subsequent RFI requires a complete response within three months, and
the clock is restarted upon submission. Applicants may make written or oral representations to the CHM if major objections remain. Final compliance checks are conducted once all issues are resolved, and the MHRA issues a grant or refusal letter
specifying any conditions and the MA expiry date. The entire assessment process is designed to be completed within 210 calendar days, excluding any procedural clock-stops for additional information or representations. The innovative medicines
timetable allows for a positive decision within 150 <FONT STYLE="white-space:nowrap">clock-on</FONT> days if all issues are resolved following one round of questions. Where there are outstanding issues at Day 150, we will come to a final decision as
soon as possible and within 210 <FONT STYLE="white-space:nowrap">clock-on</FONT> days. The innovative medicines timetable allows for a positive decision within 150 <FONT STYLE="white-space:nowrap">clock-on</FONT> days if all issues are resolved
following one round of questions. Where there are outstanding issues at Day 150, we will come to a final decision as soon as possible and within 210 <FONT STYLE="white-space:nowrap">clock-on</FONT> days. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the MHRA <FONT STYLE="white-space:nowrap">150-day</FONT> accelerated review is a specialized, fast-track national MA procedure designed for innovative
medicines, new active substances, and biosimilars, aiming for a decision in 150 <FONT STYLE="white-space:nowrap">&#8220;clock-on&#8221;</FONT> days rather than the standard 210. It requires high-quality applications, typically involving one round of
questions and a <FONT STYLE="white-space:nowrap">60-day</FONT> cool-down period for responses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;30, 2023, the MHRA published detailed guidance on its
recently announced new IRP for MAAs. The IRP applies from January&nbsp;1, 2024, and replaces existing EU decision reliance procedure. to apply for authorizations from seven international regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among
others). The IRP allows the MHRA to take into account the assessment and decision-making of the &#8216;Reference Regulators&#8221; to perform a targeted assessment of IRP applications but retain the authority to reject applications if the evidence
provided is considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
insufficiently robust. There exist two recognition timetables for new IRP MAAs: IRP Route A (60 days) and IRP Route B (110 days), both starting from validation. Eligibility is determined via an
applicant-completed form six weeks before submission. Recognition A applies to applications with Reference Regulator approval within the past two years, with no clock stop, but may revert to Recognition B if major objections arise. IRP Route B
covers Reference Regulator approvals within the past ten years (or exceptionally older) and applies if specific criteria, such as conditional approvals, manufacturing changes, or <FONT STYLE="white-space:nowrap">UK-specific</FONT> requirements, are
met. IRP Route B allows for consultation with the CHM and aligns with CHM dates for new active substances. Applications not eligible for either timetable may be submitted as full national applications if MHRA requirements are met. IRP can be used
for post-authorization measures including line extensions, variations, and renewal application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rest of the World Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with current good clinical practice requirements and the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to comply with applicable foreign regulatory
requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Coverage, Pricing and Reimbursement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of any biopharmaceutical
products, if and when approved by the FDA or analogous authorities outside the United States, will depend in significant part on the availability of third-party coverage and reimbursement for the products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, third-party payors include government healthcare programs, such as Medicare and Medicaid, private health insurers, managed care plans and other
organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services, including biopharmaceutical products. Significant uncertainty exists regarding coverage and
reimbursement for newly approved healthcare products. Seeking coverage and reimbursement is time consuming and expensive. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our
products, which would be in addition to the studies required to obtain FDA regulatory approvals. Third-party payors may take into account clinical practice guidelines in determining coverage and there may be significant delays before our products
are addressed by such guidelines and we cannot predict what position such guidelines would take with respect to our products if and when addressed. Coverage and reimbursement varies across third-party payors. Third-party payors may limit coverage to
specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication, or utilize other mechanisms to manage utilization (such as requiring prior authorization for coverage for a
product for use in a particular patient). Limits on coverage may impact demand for our products. Even if coverage is obtained, third-party reimbursement may not be adequate to allow us to sell our products on a competitive and profitable basis. As a
result, we may not be able to maintain price levels high enough to realize an appropriate return on investment in product development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in some foreign
countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Some countries provide that drug products may be marketed only after a
reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of our product candidate to currently available therapies (so called health technology assessment
(&#8220;HTA&#8221;) in order to obtain reimbursement or pricing approval). For example, subject to the requirements set out in Directive 89/105/EEC relating to the transparency of measures regulating the pricing of medicinal products for human use
and their inclusion in the scope of national health insurance systems, EU Member States have the legal competence to set national measures of an economic nature on the marketing of medicinal products in order to control public health expenditure on
such products. Accordingly, EU Member States can restrict the range of medicinal products for which their national health insurance systems </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
provide reimbursement and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product, or it may instead adopt a system of
direct or indirect controls on the profitability of the company placing the medicinal product on the market. Other EU Member States allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue
guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our
products. Historically, products launched in the EU do not follow price structures of the United States and generally tend to be significantly lower. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulation
(EU) 2021/2282 on health technology assessment (the &#8220;HTA Regulation&#8221;) entered into force on January&nbsp;11, 2022 and will apply from January&nbsp;12, 2025. Given the increasing use of HTA to guide market access in EU member states, the
HTA Regulation seeks to achieve three legislative objectives: to promote convergence in HTA tools, procedures and methodologies; to ensure efficient use of resources and strengthen the quality of HTA across the EU and to improve business
predictability. From January&nbsp;15, 2025, all new oncology medicines and advanced therapy medicinal products (i.e. gene and cell therapies and tissue engineered products) will be assessed at EU level through the Joint Clinical Assessment procedure
(&#8220;JCA&#8221;), which forms part of an HTA and evaluates the relative clinical effectiveness of a new health technology against one or more other health technologies. Importantly, the outcomes of JCAs are not binding on national HTA bodies
which may draw their own conclusions on the clinical added value of a new technology. From January&nbsp;13, 2028, all new orphan medicinal products will be subject to JCA. From January&nbsp;13, 2030, all new medicines will come under the scope of
the HTA Regulation. The HTA Regulation established the Coordination Group on HTA (the &#8220;HTACG&#8221;) consisting of representatives of EU member states, mainly from HTA authorities or bodies. The HTACG&#8217;s remit is to coordinate and adopt
the joint HTA work carried out by its subgroups within the scope of the HTA Regulation and to adopt methodological and procedural guidance documents for joint work, including JCAs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to
the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic, and regulatory developments may
further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel import or distribution (arbitrage between <FONT
STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other U.S. Health Care Laws and Regulations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States,
biopharmaceutical manufacturers and their products are subject to extensive regulation at the federal and state level, such as laws intended to prevent fraud and abuse in the healthcare industry, which may constrain their business operations. These
laws, some of which will apply only if and when we have an approved product, include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from
knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting,
receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and
Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) which, in addition to
privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products
prior to approval or for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal laws that require pharmaceutical manufacturers to calculate, report and certify certain complex product prices to
the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal Open Payments (or federal &#8220;sunshine&#8221; law), which requires pharmaceutical and medical device companies
to monitor and report certain financial interactions with certain healthcare providers to the Centers for Medicare&nbsp;&amp; Medicaid Services within the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) for <FONT
STYLE="white-space:nowrap">re-disclosure</FONT> to the public, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring
pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or report information related to payments to health care providers, marketing
expenditures or drug prices; state or local laws requiring the registration of pharmaceutical sales representatives; state laws regulating the manufacture and distribution of biopharmaceutical products; and state laws governing privacy, security and
breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">laws and regulations prohibiting bribery and corruption, such as the U.S. Foreign Corrupt Practices Act of 1977, as
amended (the &#8220;FCPA&#8221;) which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value
to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ensuring compliance is time consuming and costly. Violations of the laws may be subject to criminal and/or civil sanctions, including, in some instances, exclusion from
participation in federal and state health care programs, which could adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similar healthcare laws and regulations exist in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare
providers and laws governing the privacy and security of personal information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Health Care Reform in the United States and Potential Changes to Health Care Laws
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Health care reform has been a significant trend in the U.S. health care industry and elsewhere. In particular, government authorities and other third-party
payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services. Health care reform, specifically reform addressing pricing and payment for drugs, has been an ongoing focus and
is likely to continue under the current presidential administration. A number of healthcare reforms involving drugs have been successfully implemented, including reforms related to Medicare payment for drugs and manufacturer rebate obligations under
the Medicaid Drug Rebate Program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There has been heightened governmental scrutiny in recent years over the manner in which manufacturers set prices for their
marketed products, which has resulted in proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing and reform government program reimbursement methodologies for pharmaceutical and
biologic products. At the state level, individual states are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. These measures could reduce the ultimate
demand for our products, once approved, or put pressure on our product pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative or executive action, either in the United States or abroad. We expect that additional federal and state health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments
will pay for health care products and services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For a more detailed discussion of health care reform in the U.S., see &#8220;<I>Risk Factors&#8212;Risks Related to
Rallybio&#8212;Risks Related to Healthcare Laws and Other Legal Compliance Matters</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Data Privacy Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>U.S. Privacy Law </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are numerous U.S. federal and state laws and
regulations related to the privacy and security of personal information, including laws requiring the safeguarding of personal information, laws requiring notification to governmental authorities and data subjects as well as remediation in the event
of a data breach, and laws that afford individuals numerous rights with respect to their personal information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been several developments in recent years
with respect to U.S. state data privacy laws. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act (collectively, &#8220;CCPA&#8221;) imposes many requirements for the collection, processing, and
sharing of personal information of California residents. The CCPA contains significant penalties for companies that violate its requirements and provides California residents a private right of action, including the ability to seek statutory
damages, in the event of a breach involving their personal information. Several states have proposed or passed comprehensive privacy laws, including several laws imposing obligations similar to those of the CCPA. In addition, several states have
proposed or enacted health-focused consumer privacy laws, such as Washington state&#8217;s My Health, My Data Act, which took effect in March 2024, and imposes obligations related to the collection and sharing of certain health-related information
that is not subject to HIPAA and that does not fall within certain other exceptions in the law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also of note, in June 2024, the Protecting Americans&#8217; Data
from Foreign Adversaries Act of 2024 took effect. This law prohibits data brokers from making available certain personally identifiable sensitive data of U.S. individuals to &#8220;foreign adversary&#8221; countries, such as the People&#8217;s
Republic of China (the &#8220;PRC&#8221;), and entities controlled by such countries. Additionally, in January 2025, the DOJ published a final rule implementing President Biden&#8217;s Executive Order 14117, &#8220;Preventing Access to
Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern,&#8221; which became effective in April 2025. This final rule prohibits certain data brokerage transactions and transactions involving
certain bulk human &#8216;omic data and biospecimens from which such data can be derived with restricted persons and jurisdictions, such as the PRC, and &#8220;covered persons&#8221; that have certain ties to such restricted jurisdictions. The final
rule also places restrictions on certain vendor, employment and investment agreements with such jurisdictions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General Data Protection Regulation </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many countries outside of the United States maintain rigorous laws governing the privacy and security of personal information. For example, the collection, use,
disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is subject to the General Data Protection
Regulation (&#8220;GDPR&#8221;), which became effective on May&nbsp;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, and it imposes heightened requirements on companies that
process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before processing such data and imposing strict rules regarding the
transfer of personal data to countries outside the EEA, including the United States. The GDPR permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million, or 4% of annual global revenues, whichever is greater, and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory
authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes
place in the U.K. and includes parallel obligations to those set forth by GDPR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, we employed 14 full-time employees. Of our full-time employees, 7 employees are engaged in new product sourcing through business
development, research, manufacturing, product development and clinical development, and 7 are engaged in executive, finance, human resources, legal and other administrative functions. None of our employees are represented by a labor union or covered
by a collective bargaining agreement. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio was founded in 2018. Rallybio Holdings, LLC (&#8220;Rallybio Holdings&#8221;) was formed in Delaware in March 2018 and Rallybio IPD, LLC was formed in Delaware
in May 2020. On June&nbsp;30, 2021, Rallybio IPD, LLC was converted into a Delaware corporation and changed its name to Rallybio Corporation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our principal
executive offices are located at 234 Church Street, New Haven, CT 06510 and our telephone number is (203) <FONT STYLE="white-space:nowrap">859-3820.</FONT> Our corporate website address is https://www.rallybio.com. Information contained on or
accessible through our website is not incorporated by reference into this report and you should not consider information contained on or accessible through our website to be part of this report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Available Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Internet address is https://www.rallybio.com. Our
website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this proxy statement/prospectus. Our Annual Report on Form 10-K, Quarterly
Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to
Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) are available through the &#8220;Investors&#8221; portion of our website free of charge as soon as reasonably practicable after we
electronically file such material with, or furnish it to, the SEC. In addition, our filings with the SEC may be accessed through the SEC&#8217;s Interactive Data Electronic Applications system at https://www.sec.gov. All statements made in any of
our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or
documents unless we are required to do so by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_22"></A>CANDID&#8217;S BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Candid,&#8221; the &#8220;Company&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Candid and its subsidiary. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a global clinical-stage biotechnology company focused on building the leading portfolio of TCE therapeutics to treat autoimmune diseases, which affect an
estimated <FONT STYLE="white-space:nowrap">5-10%</FONT> of the global population. Despite available treatments, many patients experience persistent disease activity, progressive organ damage, and lifelong dependence on immunosuppressive therapies
that provide incomplete disease control and cause significant adverse events. Cizutamig, which targets <FONT STYLE="white-space:nowrap">B-cell</FONT> maturation antigen (&#8220;BCMA&#8221;), is our lead clinical-stage TCE program and is advancing
into global Phase 2 studies in generalized myasthenia gravis (&#8220;gMG&#8221;) and systemic autoimmune rheumatic diseases-interstitial lung disease <FONT STYLE="white-space:nowrap">(&#8220;SARD-ILD&#8221;).</FONT> TCEs harness a patient&#8217;s
own T cells to deplete pathogenic <FONT STYLE="white-space:nowrap">B-cells,</FONT> with the potential to deliver either deep depletion of <FONT STYLE="white-space:nowrap">B-cells,</FONT> which could provide durable disease remission (&#8220;immune
reset&#8221;), or partial depletion of <FONT STYLE="white-space:nowrap">B-cells,</FONT> which could provide for controlled, sustained disease management (&#8220;immune dimming&#8221;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have built a diversified pipeline of four TCE programs in development targeting distinct <FONT STYLE="white-space:nowrap">B-cell</FONT> antigens&#8212;BCMA, CD20,
and CD19. Our most advanced clinical stage program, cizutamig, is a BCMA TCE in-licensed from EpimAb Biotherapeutics that is being investigated in multiple Phase 1 dose-escalation trials in patients with gMG and systemic lupus erythematosus
(&#8220;SLE&#8221;) as well as investigator-initiated trials (&#8220;IITs&#8221;) in <FONT STYLE="white-space:nowrap">SARD-ILD,</FONT> systemic sclerosis (&#8220;SSc&#8221;), and other diseases outside the United States. Biopsies obtained post
treatment with cizutamig show deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion, including plasma cells, in bone marrow and lymph nodes. In Phase 1 dose escalation studies in patients with gMG, we have seen clinical improvements with
standardized physician and patient disease activity indices. In compassionate use via NPU studies in patients with <FONT STYLE="white-space:nowrap">SARD-ILD,</FONT> we have seen improvements in lung function as measured by increases in force vital
capacity (&#8220;FVC&#8221;). In patients with autoimmune disease treated with cizutamig, a favorable tolerability profile has been observed, with low rates of adverse events related to cytokine release and no deaths or dose-limiting adverse events
in Phase 1 dose escalation studies, compassionate use via NPU, and IITs. We plan to initiate global Phase 2 clinical trials in gMG and <FONT STYLE="white-space:nowrap">SARD-ILD</FONT> by the middle of 2026, which are designed to evaluate whether the
clinical effects observed in earlier studies can be confirmed in larger, randomized, controlled settings. In gMG, we plan to conduct a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study comparing
cizutamig to VYVGART<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a neonatal Fc receptor (&#8220;FcRn&#8221;) antagonist therapy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our second
clinical-stage program, CND261, is a CD20 TCE in-licensed from Genor Biopharma that is being investigated in Phase 1 dose-escalation studies in patients with rheumatoid arthritis (&#8220;RA&#8221;), SLE, as well as an IIT in ANCA-associated
vasculitis outside the United States. CND261 was engineered with the goal of achieving deeper <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion than approved CD20-targeted monoclonal antibodies (&#8220;mAbs&#8221;) such as Rituxan<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or GAZYVA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Lymph node biopsies post treatment with CND261 in patients with autoimmune disease shows deep depletion of CD20 positive <FONT
STYLE="white-space:nowrap">B-cells.</FONT> In patients with autoimmune disease treated with CND261, a favorable tolerability profile has been observed, with low rates of adverse events related to cytokine release and no deaths or dose-limiting
adverse events in Phase 1 dose escalation studies, compassionate use via NPU, and IITs. Beyond these two clinical programs, we have built a pipeline of next-generation trispecific TCEs, each designed to target two different antigens expressed on <FONT
STYLE="white-space:nowrap">B-cells.</FONT> CND319 is a TCE in-licensed from WuXi Biologics that targets CD19 and CD20 for <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion. In <FONT STYLE="white-space:nowrap">non-human</FONT> primate studies,
single doses of CND319 show deep tissue <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion with minimal cytokine release. We expect to initiate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT>
studies for CND319 in the middle of 2026. CND460 is a TCE that targets CD19 and BCMA and is currently undergoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials planned for the first half of 2027. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Approach: Why
TCEs Can Be a Transformative Treatment for Autoimmune Diseases </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">B-cell</FONT> dysregulation drives autoimmune disease
pathology, making these cells an attractive therapeutic target. TCEs engage a patient&#8217;s own T cells via CD3 binding to kill pathogenic <FONT STYLE="white-space:nowrap">B-cells,</FONT> which can include the terminally differentiated plasma
cells, potentially achieving either immune reset or immune dimming. In clinical data with our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
TCE drug candidates generated through a combination of Phase 1 dose escalation studies, IITs and via compassionate use via NPU treatment, as well as third party data with other TCE drug
candidates, strong signs of clinical improvement were observed in patients, even those who have failed multiple therapies. These observations are based on studies or compassionate use via NPU cases that were not placebo-controlled or statistically
powered, and involved a small number of patients, and the results may not be reproduced in future, larger or randomized controlled clinical trials. Our TCE drug candidates have the potential to be differentiated from marketed TCEs based on an
improved safety and tolerability profile. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe TCEs represent a significant step forward versus existing antibody and cell therapy-based approaches.
Compared to mAbs, TCEs deliver deeper <FONT STYLE="white-space:nowrap">B-cell</FONT> killing in tissues through <FONT STYLE="white-space:nowrap">T-cell</FONT> engagement which has been shown to translate to improved clinical responses. Compared to <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapy, which has also shown deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in tissues, TCEs offer the following several advantages: no need for leukapheresis, no lymphodepleting chemotherapy,
more scalable manufacturing, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> availability with the potential for outpatient administration. In clinical trials and real-world use to date, TCEs appear
to have an improved safety and tolerability profile as compared to <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies. TCEs have the potential to combine the potency needed to achieve deep <FONT STYLE="white-space:nowrap">B-cell</FONT>
depletion with the practical attributes required for broad patient access. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are evaluating cizutamig in clinical trials and IITs using a range of dosing
regimens designed to achieve both immune reset and immune dimming. Immune reset offers the potential advantage of a &#8220;one and done&#8221; approach in which a single treatment cycle can lead to deep <FONT STYLE="white-space:nowrap">B-cell</FONT>
depletion, which in turn could provide for durable disease remission. Immune dimming refers to partial <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion which offers the potential advantage of disease control and minimization of deep immune
suppression which could be associated with higher rates of infection and other health complications. Immune dimming would likely require intermittent chronic dosing at lower target doses. TCEs can be developed for both the immune reset and immune
dimming profiles based on different dosing regimens which we believe is a unique property of TCEs as compared to other <FONT STYLE="white-space:nowrap">B-cell</FONT> depleting modalities. For more information on certain health complications that can
result from B-cell depletion, including treatment with cizutamig, please see &#8220;<I>Risk Factors&#8212;Risks Related to Candid&#8212; Cizutamig&#8217;s mechanism of action results in deep and prolonged B-cell depletion, including memory B-cells,
which may lead to hypogammaglobulinemia, loss of vaccine-mediated immunity, and increased infection risk that could limit its clinical utility or require complex patient management strategies</I>.&#8221; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical development strategy is focused on: (1)&nbsp;efficiently generating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical data across multiple autoimmune diseases (2)&nbsp;using clinical data to prioritize indications for further investment into mid to later stage
clinical trials and (3)&nbsp;maintaining regulatory alignment and operational flexibility. To date, we have generated clinical data in China, Europe, and Australia through investigational new drug (&#8220;IND&#8221;) studies, IITs, and compassionate
use via NPU. As we advance cizutamig into global Phase 2 studies, we plan to engage with key regulatory agencies, including but not limited to the FDA, EMA, and NMPA, to align on study design, endpoints, and registrational pathways. To date, Candid
has not received approval from the FDA to initiate clinical trials in the United States and will require IND clearance prior to initiating any clinical trials in the United States. We believe speed, disciplined execution, and data-driven
decision-making are core strengths of our team, and we continuously evaluate emerging clinical data to advance high-potential programs and indications while deprioritizing those that do not meet our clinical or commercial thresholds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have
built a portfolio of four TCE programs at various stages of development. Our current pipeline is summarized in the table below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g30g30.jpg" ALT="LOGO" STYLE="width:6.31944in;height:2.70833in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cizutamig &#8211; A bispecific TCE Antibody Targeting BCMA expressing <FONT STYLE="white-space:nowrap">B-cells</FONT> and CD3
expressing <FONT STYLE="white-space:nowrap">T-cells</FONT> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cizutamig is a bispecific TCE antibody purposefully designed to bind BCMA which is expressed on <FONT
STYLE="white-space:nowrap">B-cells</FONT> including plasmablasts and plasma cells, with a lower affinity to CD3 on T cells to minimize cytokine release. Plasma cells are the primary source of pathogenic autoantibodies in autoimmune diseases. Unlike
FcRn antagonists such as VYVGART<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, which indirectly reduce autoantibodies by accelerating their clearance without eliminating the plasma cells producing them, cizutamig directly targets and
depletes plasma cells, potentially achieving deeper and more durable reductions in pathogenic autoantibodies. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of February 2, 2026, we have dosed 47
autoimmune patients with cizutamig intravenously across multiple ongoing Phase 1 clinical trials, IITs and through compassionate use via NPU and at a range of dosing regimens spanning immune dimming and immune reset. Evaluation was done in patients
with gMG, SARD-ILD, SLE, SSc, RA, and other autoimmune diseases with cytokine release syndrome (&#8220;CRS&#8221;) occurring in 13% of patients (11% Grade 1 and 2% Grade 2), and no cases of immune effector cell-associated neurotoxicity syndrome
(&#8220;ICANS&#8221;), deaths, or dose limiting adverse events. In biopsies obtained post treatment with cizutamig from patients dosed in the NPU pathway, we have observed deep <FONT STYLE="white-space:nowrap">B-cell</FONT> and plasma cell depletion
in bone marrow and lymph nodes were observed. In Phase 1 dose escalation studies in patients with gMG, clinical improvements were seen using standardized physician and patient disease activity indices. In compassionate use via NPU studies in
patients with <FONT STYLE="white-space:nowrap">SARD-ILD,</FONT> improvements in lung function as measured by increases in FVC and diffusing capacity of the lungs for carbon monoxide (&#8220;DLCO&#8221;). Three Phase 2 studies evaluating cizutamig in
patients with gMG are being planned: (1)&nbsp;a global placebo-controlled low dose-ranging study expected to start in the middle of 2026, (2) a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study
comparing cizutamig to VYVGART<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> expected to start in the middle of 2026 in China and (3)&nbsp;an immune reset study for cizutamig in the United States and/or Europe expected to start in the
first half of 2027. For <FONT STYLE="white-space:nowrap">SARD-ILD,</FONT> we are planning a global Phase 2 study comparing cizutamig to standard of care which is expected to start in the middle of 2026. These Phase 2 studies are designed to evaluate
whether the clinical effects observed in earlier studies can be confirmed in larger, randomized, controlled settings. To date, Candid has not received approval from the FDA to initiate clinical trials in the United States and will require IND
clearance prior to initiating any clinical trials in the United States. Candid has not previously submitted an IND to the FDA for autoimmune indications. All Phase 2 studies will have cizutamig administered intravenously with plans to transition to
subcutaneous dosing in later clinical studies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to licensing cizutamig from EpimAb Biotherapeutics, cizutamig had been evaluated in patients with multiple
myeloma (&#8220;MM&#8221;), where a 62% objective response rate was observed in 13 patients with MM treated at <FONT STYLE="white-space:nowrap">60-200</FONT> mg doses with a manageable safety and tolerability profile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CND261 &#8211; A bispecific TCE Antibody targeting CD20-expressing B-cells and
<FONT STYLE="white-space:nowrap">CD3-expressing</FONT> T Cells </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CND261 is a bispecific TCE antibody designed to bind CD20 on B-cells and CD3 on T cells. By
engaging with T cells, CND261 is engineered with the goal of achieving deeper <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in tissues compared to CD20-targeted mAbs such as
Rituxan<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or GAZYVA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. As of February&nbsp;2, 2026, 26 autoimmune patients with RA, SLE, or ANCA vasculitis have been dosed with CND261.
CRS was observed in 19% of patients (all Grade 1) and no cases of ICANS, deaths, or dose limiting adverse events were observed as of February 2, 2026. In biopsies optioned post treatment deep CD20-positive
<FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in lymph nodes was observed in patients treated with CND261 as of February 2, 2026. We are continuing clinical evaluation to characterize optimal dosing regimens and clinical activity across
different autoimmune diseases. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CND319 &#8211; A trispecific TCE Antibody Targeting CD19- and/or CD20-expressing B-cells and CD3 expressing T&nbsp;Cells
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CND319 is a trispecific TCE antibody designed to bind CD19 or CD20 on B-cells while engaging CD3 on T cells. Dual targeting of CD19 and CD20 could more
thoroughly address B-cell subsets as CD19 or CD20 expression levels can vary, potentially allowing for more complete and durable depletion than single-target approaches. In <FONT STYLE="white-space:nowrap">non-human</FONT> primate
(&#8220;NHP&#8221;) studies, CND319 demonstrated deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in the spleen, bone marrow, and lymph nodes at single administered doses with minimal cytokine release. We expect to initiate <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> studies by the middle of 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CND460 &#8211; A trispecific TCE
Antibody Targeting BCMA or CD19 expressing <FONT STYLE="white-space:nowrap">B-cells</FONT> and CD3 expressing T cells </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CND460 is a trispecific TCE antibody
designed to bind to BCMA and/or CD19 on B-cells or plasma cells, and CD3 on T cells. This dual-target strategy can address a potential limitation of CD19 or CD20-targeted therapies, which deplete <FONT STYLE="white-space:nowrap">B-cells</FONT> but
leave long-lived plasma cells intact which can continue autoantibody production. By achieving redundant and deep <FONT STYLE="white-space:nowrap">B-cells</FONT> and plasma cells depletion in a single molecule, CND460 has the potential to achieve
more profound and durable disease control. CND460 is currently undergoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, including NHP studies, with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials planned for first half of 2027. CND460 is being developed in collaboration with a third-party development partner. We have the right to formally
nominate CND460 as a development candidate upon the conclusion of IND-enabling studies, which have not yet been completed and for which no clinical data has been generated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to our development programs, we continue to have an active discovery effort to identify novel TCEs which can address various immunology and inflammatory
diseases. We are collaborating with several research partners to leverage their antibody engineering and other expertise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pharmaceutical market for autoimmune diseases features several classes of drugs, each generating significant revenue and addressing diverse patient needs. Drugs
targeting autoimmune diseases generated approximately </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">$105&nbsp;billion of revenue globally in 2023. Several antibody-based drugs, such as Dupixent<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Humira<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Rituxan<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,
GAZYVA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Stelara<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and others are approved and widely prescribed to treat various autoimmune diseases. Humira<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a mAb drug against tumor necrosis factor (&#8220;TNF&#8221;) that is approved for treatment of nine autoimmune diseases. Humira<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in
addition to other <FONT STYLE="white-space:nowrap">anti-TNF</FONT> drugs and drugs against other protein targets have been broadly adopted commercially for the treatment of autoimmune diseases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While Humira<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and other drugs for autoimmune diseases have been widely commercialized, they largely provide
symptomatic relief and disease progression occurs in the majority of patients. Furthermore, currently approved therapies require chronic administration, which may result in increased risk of infections, cancer, and other morbidities over time.
Therefore, we believe there are significant opportunities for new approaches, such as TCEs for <FONT STYLE="white-space:nowrap">B-cell</FONT> and plasma cell depletion, to be developed to address the unmet medical need. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Executive Team and Investors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team is led by entrepreneurial executives who have a track record of advancing programs into and through development. Each executive has deep experience in their
respective function and collectively share the vision to build the leading TCE company for autoimmune diseases. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Ken Song, M.D., Chairman, President and Chief Executive Officer</B><B>.</B> Ken is a career entrepreneur with direct
experience in healthcare investing and patient care. Ken has successfully led several life science companies in a diversity of areas. Most recently he led RayzeBio, a radiopharmaceutical company, from concept to Phase 3 in just over 3 years with the
eventual sale of the company in February 2024 to Bristol Myers Squibb (&#8220;BMS&#8221;). Ken also <FONT STYLE="white-space:nowrap">previously&nbsp;co-founded&nbsp;and</FONT> served as chairman of Ablaze Pharmaceuticals, <FONT
STYLE="white-space:nowrap">co-founded&nbsp;and</FONT> served as Chief Executive Officer of Ariosa Diagnostics (acquired by Roche), Chief Executive Officer of Metacrine, and Executive Chairman of Omniome (acquired by Pacific Biosciences).
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Tim Lu, M.D., Ph.D., Chief Medical and Scientific Officer.</B>&nbsp;Tim is a physician scientist entrepreneur with a
focus on developing innovative therapies for autoimmune disease. Prior to joining Candid, Tim was the Chief Medical Officer of DICE Therapeutics where he was responsible for developing and executing the clinical development of their lead molecule in
autoimmune diseases, which ultimately led to the company&#8217;s acquisition by Eli Lilly in 2023. Prior to DICE Therapeutics, Tim was senior medical director at Genentech where he oversaw the clinical development of small and large molecule drugs
for autoimmune diseases. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Arvind Kush, Chief Financial and Business Officer.</B><B></B>&nbsp;Arvind has extensive experience in capital raising
and mergers and acquisitions (&#8220;M&amp;A&#8221;). As Chief Financial Officer at RayzeBio, Arvind helped the company raise significant private financing as well as an initial public offering followed by the acquisition by BMS.&nbsp;Before joining
RayzeBio, Arvind executed numerous capital markets and M&amp;A transactions as an investment banker with Bank of America Securities. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Bernie Huyghe, Ph.D., Chief Technology Officer. </B>Bernie has extensive experience in overseeing chemistry,
manufacturing and controls (&#8220;CMC&#8221;) in drug development and commercial launch preparations of biologics and other biological drug products. Bernie has thorough knowledge of good manufacturing practices (&#8220;GMP&#8221;) and prior to
Candid was overseeing the GMP production and CMC efforts of two antibody therapeutics at Viridian Therapeutics. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are focused and driven to develop a portfolio of TCE antibody drug candidates for <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion with a goal of becoming
the first company to commercially launch this class of drugs for autoimmune diseases, assuming successful clinical development and approval. Key components of our strategy include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Initiate multiple Phase 2 studies for cizutamig in 2026 and demonstrate superiority of cizutamig over existing
therapies where applicable. </B>In 2026, we plan to initiate multiple Phase 2 studies with cizutamig in gMG and <FONT STYLE="white-space:nowrap">SARD-ILD</FONT> to further evaluate dosing, safety, and clinical activity. Clinical data observed to
date suggest the potential for meaningful differentiation from currently approved therapies across multiple indications. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Leverage our global infrastructure to aggressively advance a portfolio of TCE drug candidates into clinical development
for multiple autoimmune diseases</B>. We believe that clinical data generated from our ongoing and planned trials with each drug candidate will best guide further development into later stages of clinical development. To accelerate this process, we
are leveraging our global clinical infrastructure, inclusive of a clinical team in China, to conduct trials across multiple indications in parallel, enabling us to generate data more efficiently and inform development decisions across our portfolio
on an expedited timeline. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Evaluate immune reset and immune dimming profiles to cater to patient needs in specific autoimmune
diseases.</B><B></B>&nbsp;In our clinical trials, we are evaluating both immune reset and immune dimming dosing strategies. We believe the depth and durability of clinical benefit and overall tolerability correlates to the degree of cell depletion
and can be tailored for specific indications. We expect the administered dose and dosing frequency will also vary depending on the degree of <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion desired. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Conduct parallel clinical trials to identify the most suitable indications and optimal dosing strategy of cizutamig,
CND261, CND319 and CND460. </B>We are conducting multiple clinical trials for each of the drug </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
candidates in several autoimmune indications with the goal of allowing us to tap into a broader pool of patients for initial clinical evaluation. We believe this data driven approach provides the
highest likelihood of success for each of the programs. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Purposefully invest capital in activities to pursue further clinical data generation. </B>We plan to deploy capital in
those strategic aspects of the business key to our growth. We believe clinical data will best inform and guide us on how to prioritize further clinical development and indication prioritization. During development, we will look to balance investment
amount and time to reach our planned milestones. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Background of Autoimmune Diseases </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Autoimmune disease occurs when the immune system ends up attacking normal cells and tissues leading to inflammation and damage. Autoimmune diseases affect an estimated
300&#8211;500&nbsp;million people worldwide and account for more than $100&nbsp;billion in annual direct healthcare spending in the United States alone. Despite the availability of numerous drugs, the majority of autoimmune patients experience
incomplete disease control with chronic symptoms and progressive organ damage. The scale of unmet need creates a substantial opportunity for disease-modifying therapies capable of delivering durable remission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 1: U.S. and global prevalence of select autoimmune diseases </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g01g98.jpg" ALT="LOGO" STYLE="width:6.30556in;height:2.73646in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The autoimmune market features several large classes of drugs, each generating significant revenue and addressing diverse patient
needs. Several antibody-based drugs, such as Dupixent<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Humira<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Rituxan<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,
GAZYVA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Stelara<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and others are approved and widely prescribed to treat various autoimmune diseases. Humira<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a mAb drug against TNF approved to treat nine autoimmune diseases. As of 2023, it was the most commercially successful pharmaceutical product ever with approximately $220&nbsp;billion in total
cumulative sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While several drugs for autoimmune diseases have been widely commercialized, they largely provide symptomatic relief and disease progression
occurs in the majority of patients. These therapies provide incremental improvements but share several fundamental challenges: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Incomplete mechanistic reach limiting efficacy: Many therapies reduce inflammation or deplete subsets of <FONT
STYLE="white-space:nowrap">B-cells</FONT> but do not eliminate plasmablasts and plasma cells, which are major producers of pathogenic autoantibodies, the root cause of several autoimmune indications. Some therapies also have limited depletion of <FONT
STYLE="white-space:nowrap">B-cells</FONT> in tissues. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Lack of durability: Most autoimmune patients require chronic therapy, often lifelong, resulting in high cumulative
treatment costs, real-world adherence challenges and persistent risk of flare or progression </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Safety and tolerability constraints: Most approved therapies require chronic immunosuppression, which increases infection
risk, steroid dependence and reduces quality of life. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of <FONT STYLE="white-space:nowrap">B-Cell</FONT> Depletion in Autoimmune Diseases </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">B-cell</FONT> Overview </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">B-cells</FONT> are one type of immune system cells that have several functions. They can release cytokines, serve as antigen presentation cells to modulate other immune cells, such as T cells, and terminally differentiate
into plasma cells and produce antibodies that target and neutralize pathogens. However, in autoimmune diseases, <FONT STYLE="white-space:nowrap">B-cells</FONT> can malfunction and mistakenly produce antibodies against the body&#8217;s own cells and
tissues. In addition, <FONT STYLE="white-space:nowrap">B-cells</FONT> can misguide immune response driven by complex interactions between <FONT STYLE="white-space:nowrap">B-cells</FONT> and other immune cells, resulting in a chronic,
self-perpetuating cycle of immune activation and tissue destruction. Abnormalities in <FONT STYLE="white-space:nowrap">B-cell</FONT> regulation can cause or exacerbate autoimmunity, making them an attractive target for therapeutic interventions.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">B-cells</FONT> originate from bone marrow stem cells and undergo further transition and development in the bone marrow and
peripheral blood. BCMA is expressed broadly from <FONT STYLE="white-space:nowrap">pre-B</FONT> cells to the most mature <FONT STYLE="white-space:nowrap">B-cells</FONT> which are termed plasma cells, the cell types responsible for producing
antibodies. BCMA expression is higher on plasmablasts and plasma cells as compared to other <FONT STYLE="white-space:nowrap">B-cell</FONT> subtypes. Other cell surface proteins such as CD19 and CD20 are expressed in earlier stages of <FONT
STYLE="white-space:nowrap">B-cell</FONT> development. Clinical experience with drugs targeting BCMA have shown deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion of all subtypes and not just plasmablasts and plasma cells. The depth of
depletion of <FONT STYLE="white-space:nowrap">B-cell</FONT> subset populations may vary depending on which cell surface protein of <FONT STYLE="white-space:nowrap">B-cells</FONT> are targeted and this could lead to differential clinical effects
across autoimmune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 2: Expression of BCMA, CD20 and CD19 in <FONT STYLE="white-space:nowrap">B-cell</FONT> subtypes. Black arrows
note expression of specific surface proteins. </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g34g34.jpg" ALT="LOGO" STYLE="width:6.3167in;height:2.01377in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">BCMA is also expressed on activated plasmacytoid dendritic cells, key producers of type I interferons that contribute to inflammatory
signaling and support autoreactive <FONT STYLE="white-space:nowrap">B-cell</FONT> survival in autoimmune diseases. Together, these findings support BCMA as a relevant therapeutic target with the potential to disrupt autoantibody production,
inflammatory amplification, and pathogenic <FONT STYLE="white-space:nowrap">B-cell</FONT> activity, providing a strong mechanistic rationale for BCMA-targeted therapies in autoimmune indications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A study published by Dr.&nbsp;Joseph DeRisi and colleagues at the University of California, San Francisco, highlights the differential effects of targeting <FONT
STYLE="white-space:nowrap">B-cells</FONT> expressing various cell surface protein markers. Using a high throughput assay, it was found that all individuals, regardless of disease state, possess a distinct and complex set of autoreactive antibodies.
This unique immunological fingerprint, or &#8220;autoreactome,&#8221; was stable over years. Analyzing blood samples from cancer patients at baseline and after treatment with <FONT STYLE="white-space:nowrap">B-cell</FONT> depleting therapies
targeting CD20 (mAb), CD19 <FONT STYLE="white-space:nowrap">(CAR-T)</FONT> or BCMA <FONT STYLE="white-space:nowrap">(CAR-T),</FONT> showed that targeting BCMA was the only approach to have a statistically significant reduction in the autoreactome.
We believe this data highlights the importance of targeting BCMA to maximize clinical benefit in patients with autoantibody driven autoimmune diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 3: Changes in autoreactome of cancer patients treated with therapies targeting CD20
(rituximab mAb), CD19 <FONT STYLE="white-space:nowrap">(CAR-T),</FONT> and BCMA <FONT STYLE="white-space:nowrap">(CAR-T)</FONT> </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00s35.jpg" ALT="LOGO" STYLE="width:6.30557in;height:3.08439in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Early clinical experience in patients with gMG highlights the potential difference in targeting BCMA or CD19. Using <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapy, one published study showed that BCMA <FONT STYLE="white-space:nowrap">CAR-T</FONT> completely reduced autoantibodies associated with relapsed and refractory gMG in two patients and showed a near
complete remission of disease based on the Quantitative Myasthenia Gravis (&#8220;QMG&#8221;) score, a disease activity index for gMG. In a separate published case report, CD19 <FONT STYLE="white-space:nowrap">CAR-T</FONT> reduced autoantibodies by
71% and showed an improvement but not remission of disease as measured by the QMG score. FcRn antagonist drugs approved to treat gMG work by reducing autoantibody IgG levels indirectly by binding to FcRn which then precludes it from binding to
circulating IgG which in turn leads to faster elimination of IgG. These FcRn targeting drugs reduce IgG autoantibodies by approximately 57% but do not have any effect on other Ig antibody classes such as IgM, which can also contribute to disease
pathology. FcRn antagonist drugs are administered chronically and are associated with long term immunosuppression. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Different modalities for deep <FONT
STYLE="white-space:nowrap">B-dell</FONT> depletion and the advantages of TCE antibodies </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TCEs are typically antibody drugs that work by redirecting the
body&#8217;s own T cells to recognize and kill cells expressing a cell surface protein target of interest. Conventional <FONT STYLE="white-space:nowrap">B-cell</FONT> targeted mAbs such as
Rituxan<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or GAZYVA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> bind to <FONT STYLE="white-space:nowrap">B-cells</FONT> of interest but do not recruit <FONT
STYLE="white-space:nowrap">T-cells.</FONT> TCEs directly engage with <FONT STYLE="white-space:nowrap">T-cells</FONT> via the CD3 binding of the TCE and in turn, the <FONT STYLE="white-space:nowrap">T-cells</FONT> are able to kill the target cell. We
believe a TCE approach will lead to deeper <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion than mAbs which can translate to better clinical response. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TCEs
are able to mimic the immune-engaging mechanism of <FONT STYLE="white-space:nowrap">CAR-T</FONT> by binding a cell surface protein of interest on a target cell (e.g. BCMA on <FONT STYLE="white-space:nowrap">B-cells)</FONT> and the CD3 protein on <FONT
STYLE="white-space:nowrap">T-cells.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 4: Illustrative example showing mechanism of <FONT STYLE="white-space:nowrap">CAR-T</FONT>
and TCE Mechanism of Action of <FONT STYLE="white-space:nowrap">CAR-T</FONT> and Bispecific Antibody </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g01g99.jpg" ALT="LOGO" STYLE="width:6.30557in;height:1.8035in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Various modalities are being developed to achieve deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion, including autologous
and allogeneic <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies, <FONT STYLE="white-space:nowrap">NK-based</FONT> approaches, in vivo CAR platforms, myeloid engagers, mRNA-based TCE, and TCE antibodies. These approaches differ across several
key attributes, including depth of tissue depletion, predictability of pharmacologic effect, potential for prolonged lymphodepletion, scalability of manufacturing, and route of administration. Autologous and allogeneic
<FONT STYLE="white-space:nowrap">CAR-based</FONT> therapies have demonstrated the ability to achieve deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion but involve individualized or complex manufacturing processes and are typically
administered intravenously. Emerging modalities, including <FONT STYLE="white-space:nowrap">NK-</FONT> and mRNA-based approaches, remain under clinical evaluation with respect to durability, pharmacologic control, and scalability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TCE antibodies are designed as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> biologics and may offer a differentiated
profile, including the potential for deep <FONT STYLE="white-space:nowrap">B-cell</FONT> tissue depletion with titratable dosing and subcutaneous administration. TCEs allow for more predictable pharmacokinetics and treatment modulation. While each
modality presents potential advantages and limitations, we believe TCE antibodies represent a preferred clinically and commercially viable approach for achieving controlled, deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in autoimmune
diseases, subject to continued clinical validation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Initial clinical experience of TCEs in autoimmune disease </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical benefit of using TCEs to treat autoimmune diseases was initially published in the first half of 2024 by the FAU Erlangen group led by Dr.&nbsp;Georg Schett,
the pioneer who used <FONT STYLE="white-space:nowrap">CAR-T</FONT> for autoimmune diseases, and Dr.&nbsp;Ricardo Grieshaber-Bouyer. In this clinical case report series, six patients with RA who had failed a median of seven prior therapies were
treated <FONT STYLE="white-space:nowrap">off-label</FONT> with continuous intravenous infusion of Blincyto<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a CD19 targeting TCE currently approved to treat leukemia. In this study, lower and
fewer doses of CD19 TCE as compared to the leukemia approved dose were used to treat patients. All patients with RA showed clinical improvement following treatment as well as peripheral <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion but
incomplete <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in lymph nodes. Radiographic imaging using ultrasound and <FONT STYLE="white-space:nowrap">PET-CT</FONT> showed visual reductions in inflammation. As depicted in Figure 5, the
number of tender and swollen joints decreased from a median of 9 and 9 down to 0.5 and 1.0, respectively, at 12 weeks <FONT STYLE="white-space:nowrap">follow-up.</FONT> Patients also reported feeling better as measured by a global disease assessment
scale, which improved from 60 to 10. There were no cases of ICANS and no cases of high grade CRS. Longer term <FONT STYLE="white-space:nowrap">follow-up</FONT> showed most of the patients had rebound in their clinical improvement, which we believe
may have been to suboptimal dosing with incomplete <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in lymph nodes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 5: Effect of CD19 TCE therapy on tender joint count, swollen joint count and patient global
disease activity in RA patients </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g90t38.jpg" ALT="LOGO" STYLE="width:4.84706in;height:2.26471in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the clinical experience of using TCEs in patients with RA, the FAU Erlangen group published their clinical experience using
Tecvayli<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a BCMA TCE approved for MM, in four patients with different autoimmune diseases (SSc, Sj&ouml;gren&#8217;s syndrome, inflammatory myositis, and RA). The BCMA TCE was administered as
2 <FONT STYLE="white-space:nowrap">step-up</FONT> doses and the 3rd full dose within the first week of treatment followed by one additional full dose 4 weeks or 12 weeks later. Disease activity in all four patients improved with evidence of deep <FONT
STYLE="white-space:nowrap">B-cell</FONT> depletion and reductions in circulating IgG, IgA, and IgM antibody levels. There were no cases of ICANS and two cases of CRS, one Grade 1 and one Grade&nbsp;2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 6: Tecyalyi<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> BCMA TCE therapy decreases B-cells and IgG in peripheral blood in
patients with autoimmune disease </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00t37.jpg" ALT="LOGO" STYLE="width:5.95928in;height:2.28959in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Longer term <FONT STYLE="white-space:nowrap">follow-up</FONT> from FAU Erlangen in ten patients treated with Tecvayli<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> were published in late 2025. The majority of patients achieved rapid clinical responses with disease free remission, and some patients showing durable response beyond one year. Of the five
patients who had interstitial lung disease (&#8220;ILD&#8221;), four of them had improvements in lung diffusion capacity. Treatment with Tecvayli<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> was associated with eight cases of CRS of
which four cases were Grade 2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 7: Tecvayli<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> shows durable disease
remission <FONT STYLE="white-space:nowrap">off-therapy</FONT> in autoimmune diseases </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00s38.jpg" ALT="LOGO" STYLE="width:6.24138in;height:3.0431in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Another case series of five SSc patients treated with Tecvayli<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> was reported
in Nature Medicine this year by a physician group in Dusseldorf. Of the three SSc patients with ILD who had <FONT STYLE="white-space:nowrap">follow-up</FONT> to at least 6 months, two patients showed objective disease improvement as measured by
increase in FVC. The patient who did not show improvement in their ILD had developed pulmonary carcinoma as well as pulmonary hypertension which complicated the interpretation of treatment efficacy. All five patients treated with Tecvayli<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> experienced CRS, with three patients having Grade 2 and one patient having a Grade 3 event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cizutamig
&#8211; A bispecific TCE Antibody Targeting BCMA-expressing <FONT STYLE="white-space:nowrap">B-cells</FONT> and <FONT STYLE="white-space:nowrap">CD3-expressing</FONT> <FONT STYLE="white-space:nowrap">T-cells</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Overview </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cizutamig is a bispecific TCE antibody purposefully designed
to deplete BCMA-expressing <FONT STYLE="white-space:nowrap">B-cell</FONT> populations, including plasmablasts and plasma cells, while also mitigating the release of cytokines. In patients with autoimmune disease as well as MM, low rates of CRS with
no ICANS and clinical signs of improvement have been observed. As of February&nbsp;2, 2026, cizutamig has been administered in 47 patients across multiple autoimmune indications, using a range of dosing regimens spanning immune dimming to immune
reset. Immune reset offers the potential advantage of a &#8220;one and done&#8221; approach in which a single treatment cycle can lead to deep B-cell depletion, which in turn could provide for durable disease remission. Immune dimming refers to
partial B-cell depletion which offers the potential advantage of disease control and minimization of deep immune suppression which could be associated with higher rates of infection. Immune dimming would likely require intermittent chronic dosing at
lower target doses. Many of the treated patients had advanced, refractory disease and had exhausted approved therapies as well as investigational options. In this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> population, patients treated with cizutamig experienced meaningful improvements in disease activity, and several patients have discontinued other
autoimmune therapies and remain clinically stable or continue to improve at last <FONT STYLE="white-space:nowrap">follow-up.</FONT> </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Deep <FONT
STYLE="white-space:nowrap">B-cell</FONT> depletion in tissues supportive of immune reset profile </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tissue biopsy data from autoimmune disease patients
treated with cizutamig provide mechanistic evidence consistent with an immune reset profile, and this finding has been observed consistently across four patients with different autoimmune diseases under our NPU program. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In lymph node biopsies taken after the third weekly dose in the first treated patient&#8212;a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">40-year-old</FONT></FONT> with refractory RA&#8212;we observed deep depletion of B-cells including plasma cells in the lymph node, with marked reductions in CD19+, CD20+, and CD138+
cells relative to baseline as determined by immunohistochemistry (&#8220;IHC&#8221;). Bone marrow assessments corroborated these findings, showing near-complete elimination of CD19+ B-cells and CD138+ plasma cells. Peripheral <FONT
STYLE="white-space:nowrap">B-cell</FONT> reconstitution was observed at approximately four months post-treatment, with returning <FONT STYLE="white-space:nowrap">B-cells</FONT> displaying a na&iuml;ve phenotype (CD27-negative, <FONT
STYLE="white-space:nowrap">IgD-positive),</FONT> consistent with a reset of the pathogenic <FONT STYLE="white-space:nowrap">B-cell</FONT> compartment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Bone marrow and/or lymph node biopsies were subsequently obtained through the NPU pathway in three additional
patients across different autoimmune indications, and deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion consistent with the immune reset profile was demonstrated. In two patients with SSc biopsied at 8 weeks (after 5 doses), bone marrow
flow cytometry showed plasma cell reductions of greater than 99% and 98%, and mature <FONT STYLE="white-space:nowrap">B-cell</FONT> reductions of 96% and 97%, respectively. Lymph node biopsies were not obtained from these two patients. In a patient
with dermatomyositis biopsied at 7 weeks (after 5 doses), we observed 100% reductions in <FONT STYLE="white-space:nowrap">B-cells</FONT> including plasma cells in lymph node IHC. A bone marrow biopsy was not obtained from this patient No CRS or
ICANS was reported in any of the patients. The breadth and consistency of these findings across distinct autoimmune diseases support the potential of cizutamig to induce deep, compartment-wide <FONT STYLE="white-space:nowrap">B-cell,</FONT>
including plasma cell, depletion as a mechanism for potential durable disease remission. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety profile of cizutamig in autoimmune patients </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of February&nbsp;2, 2026, 47 patients with various autoimmune diseases have been dosed intravenously with cizutamig in
<FONT STYLE="white-space:nowrap">IND-sponsored</FONT> studies, IITs, and compassionate use via NPU. Additionally, 16 healthy volunteers have been dosed as of February 2, 2026 in an ongoing Phase 1 clinical trial comparing intravenous and
subcutaneous formulations of cizutamig. Of the 47 patients, 29 were dosed pursuant to an IIT or NPU program. Safety data as of the February&nbsp;2, 2026 cut off is presented on an aggregated basis and has been generated through ongoing Phase 1
clinical trials, IITs and compassionate use via NPU. The data generated via IITs and NPU is highly informative for Candid&#8217;s future clinical development but should not be viewed as representative of how the drug candidate will perform in
Candid&#8217;s clinical trials and may not be able to be used to establish safety or efficacy for regulatory approval. For information on the limitations of results from IITs and our NPU program, see the section titled &#8220;<I>Risk
Factors&#8212;Risks Related to Candid</I><I>&#8212;</I><I>Results of any patient who receives Candid&#8217;s drug candidate in an IIT, compassionate use </I><I>via NPU </I><I>program or expanded access program should not be viewed as representative
of how the drug candidate will perform in Candid&#8217;s clinical trials and may not be able to be used to establish safety or efficacy for regulatory approval</I>.&#8221; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A favorable safety profile has been observed in clinical studies of cizutamig to date. Among the 47 patients with autoimmune disease, 13% experienced CRS of any grade:
11% Grade 1 and 2% Grade 2. The sole case of Grade 2 CRS was a transient, asymptomatic hypotensive event lasting less than 30 minutes and responsive to IV fluids. No CRS events were observed in healthy volunteers. No ICANS have been reported across
any subjects treated with cizutamig. An analysis of serum cytokines (Interferon gamma, <FONT STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">TNF-alpha)</FONT> shows that the first dose of cizutamig serves as a priming dose
given a subsequent higher dose of cizutamig administered one week later did not induce a higher level of cytokines. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Treatment emergent adverse events
(&#8220;TEAEs&#8221;) have been manageable, with more than 92% of patients experiencing only Grade 1 or 2 events. The most frequently observed drug-related TEAEs were hypogammaglobulinemia (39% of patients), which was effectively mitigated with
intravenous IG (&#8220;IVIG&#8221;) therapy, and decreased lymphocyte count (23% of patients), consistent with expected T cell margination. Infections were generally mild, with upper respiratory tract infections occurring in 13% of patients. As of
February 2, 2026, three treatment-related serious adverse events were reported&#8212;one case of pneumonia and two cases of <FONT STYLE="white-space:nowrap">COVID-19&#8212;all</FONT> of which were treated and resolved without sequelae. Treatment
with cizutamig can result in depletion of B cells and plasma cells leading to loss of protective immunity requiring IVIG and/or revaccination and increased risk of infection which may require additional monitoring and treatment. These potential
infectious complications may require additional treatment and monitoring which could limit the use of cizutamig. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, no deaths, suspected unexpected serious
adverse reactions, or dose-limiting adverse events have been reported in patients treated with cizutamig. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cizutamig for gMG </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are conducting an ongoing multi-center Phase 1 dose-escalation study of cizutamig in patients with refractory gMG in China. The study is designed to evaluate the
safety, tolerability, pharmacokinetics, and clinical activity of cizutamig administered intravenously on a weekly schedule using a step-up dosing approach. The primary endpoints of the Phase 1 trial are safety and tolerability, and the determination
of the recommended Phase 2 dose. Secondary and exploratory endpoints include pharmacokinetic parameters, B-cell counts, and clinical disease activity measures - QMG and MG-ADL. The trial is not designed or powered to demonstrate statistically
significant efficacy, and the clinical observations described below should be interpreted in that context. As of February&nbsp;2, 2026, nine patients have been dosed across three cohorts. All nine patients had failed multiple prior therapies,
including steroids, pyridostigmine, immunosuppressants, biologics (including FcRn antagonists in 56% and rituximab, or Rituxan<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, in 11%), and acute interventions (high-dose IVIG or
plasmapheresis in 56%). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 8: Clinical response in gMG after treatment with cizutamig </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00v01.jpg" ALT="LOGO" STYLE="width:6.33101in;height:2.88051in;">
 </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Robust and consistent clinical activity was observed in patients treated with cizutamig across validated disease activity
measures&#8212;QMG and <FONT STYLE="white-space:nowrap">MG-ADL,</FONT> which are physician and patient reported scores, respectively. In Dose Group 1 (n=3, evaluated at 16 weeks), patients achieved an average reduction of 19.3 points in QMG score
(range: <FONT STYLE="white-space:nowrap">-7,</FONT> <FONT STYLE="white-space:nowrap">-29)</FONT> and 6.7 points in <FONT STYLE="white-space:nowrap">MG-ADL</FONT> score (range: <FONT STYLE="white-space:nowrap">-4,</FONT> <FONT
STYLE="white-space:nowrap">-8).</FONT> In Dose Group 2 (n=3, evaluated at 4 weeks and therefore unlikely to represent maximum benefit), patients achieved an average reduction of 9.3 points in QMG score (range:
<FONT STYLE="white-space:nowrap">-7,</FONT> <FONT STYLE="white-space:nowrap">-11)</FONT> and 7.3 points in <FONT STYLE="white-space:nowrap">MG-ADL</FONT> score (range: <FONT STYLE="white-space:nowrap">-6,</FONT>
<FONT STYLE="white-space:nowrap">-9).</FONT> Dose Group 3 had been enrolled for less than 2 weeks at the time of data cut, with insufficient <FONT STYLE="white-space:nowrap">follow-up</FONT> to assess clinical endpoints. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical responses were observed as early as 2 weeks post-treatment and were sustained through the observation period across both evaluable dose groups. All patients
with at least 4 weeks of <FONT STYLE="white-space:nowrap">follow-up</FONT> exceeded the established thresholds for clinically meaningful improvement&#8212;a reduction of <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>3 points in QMG score
and <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>2 points in <FONT STYLE="white-space:nowrap">MG-ADL</FONT> score. The magnitude of improvement observed substantially exceeded these thresholds, with average QMG reductions of 19.3 and 9.3
points in Dose Groups 1 and 2, respectively. As Dose Group 2 had improvement measured at 4 weeks, we believe deeper responses would be seen with longer <FONT STYLE="white-space:nowrap">follow-up</FONT> which is ongoing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The consistency of response across a heavily pretreated, refractory population, the rapid onset of clinical benefit, and the durability of effect through 16 weeks of <FONT
STYLE="white-space:nowrap">follow-up</FONT> support the potential for cizutamig to deliver meaningful clinical benefit in this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> disease. We plan to
share initial clinical data from all dose groups for cizutamig in the Phase 1 clinical trial in patients with refractory gMG in early 2027. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to conduct
three separate Phase 2 studies in patients with gMG. The first study is expected to initiate in the middle of 2026 in China and will evaluate cizutamig using immune dimming and immune reset dosing regimens versus VYVGART<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, an approved FcRn antagonist therapy. The primary endpoints for this study will measure change from baseline in QMG and <FONT STYLE="white-space:nowrap">MG-ADL.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A second Phase 2 study in gMG is also planned to begin in the middle of 2026 as a global, placebo-controlled trial. This study will evaluate multiple low doses of
cizutamig as monotherapy compared to placebo, with the same primary endpoints of change in QMG and <FONT STYLE="white-space:nowrap">MG-ADL</FONT> scores. The dose-ranging design of this study is intended to identify optimal dosing regimens including
an immune dimming dose regimen that balance efficacy with safety and tolerability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A third Phase 2 study in gMG is expected to initiate in the first half of 2027
in the United States and/or Europe. This study will evaluate cizutamig at an immune reset dose regimen, with efficacy assessed through changes in QMG and <FONT STYLE="white-space:nowrap">MG-ADL</FONT> scores. This study is designed to generate
clinical data in Western patient populations that may support future regulatory submissions in these markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Background of MG </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MG is a
chronic autoimmune disease marked by varying degrees of muscle weakness and fatigue afflicting approximately 128,000 and 1.4&nbsp;million people in the U.S. and globally, respectively. MG is generally classified into ocular MG, which only affects
the eye, and gMG which has more systemic involvement and accounts for 85% of MG cases. Either MG condition arises when the immune system produces autoantibodies that attack the communication between nerves and muscles, primarily targeting
acetylcholine receptors at the neuromuscular junction. In some cases, antibodies may also target other proteins, such as muscle-specific kinase. This disruption impairs the transmission of nerve impulses, leading to muscle weakness. While symptoms
can be transient and may spontaneously remit in the early stages, they typically become more persistent as the disease progresses, with symptom-free intervals becoming less frequent. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Current therapeutic strategies for MG include steroids, immunosuppressants, and agents that block the complement pathway or inhibit FcRn. FcRn antagonist drugs work by
reducing IgG levels indirectly by binding to FcRn which then precludes it from binding to circulating IgG which in turn leads to faster elimination of IgG. These treatments do not have any known effect on IgM antibodies which can also contribute to
disease pathology. FcRn antagonist drugs are administered chronically and are associated with long term immunosuppression. VYVGART<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, an FcRn antagonist therapy developed and commercialized by
Argenx, is approved to treat MG and eclipsed $1&nbsp;billion in annual sales in its second full year of commercialization. TCE drugs that target BCMA can deplete <FONT STYLE="white-space:nowrap">B-cells</FONT> including plasmablasts and plasma cells
which are responsible for producing IgG and IgM antibodies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cizutamig for <FONT STYLE="white-space:nowrap">SARD-ILD</FONT> </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have provided compassionate use via NPU treatment outside of an IND-sponsored study to patients with <FONT STYLE="white-space:nowrap">SARD-ILD</FONT> having SSc as
their primary rheumatological disease. Two patients with advanced, treatment-refractory <FONT STYLE="white-space:nowrap">SARD-ILD</FONT> were treated with cizutamig and followed for over six months. In both patients, clinical and radiographic
improvement following treatment were observed and the patients were able to discontinue therapies for SSc. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The first patient (Patient 1) experienced rapidly progressive SSc over approximately six months with multi-organ
involvement and had previously been treated with methotrexate, corticosteroids, and cyclophosphamide. High-resolution computed tomography (&#8220;HRCT&#8221;) showed improvement in ground glass opacities and pulmonary function tests
(&#8220;PFTs&#8221;) showed an increase in FVC as well as gas exchange as measured by DLCO. The patient also was able to improve their <FONT STYLE="white-space:nowrap">6-minute</FONT> walk test (&#8220;6MWT&#8221;). </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The second patient (Patient 2) had chronic, progressive SSc with an extensive history of prior therapies, including
methotrexate, cyclosporine, mycophenolate mofetil, tocilizumab, upadacitinib, nintedanib, sildenafil, and bosentan. HRCT showed improvement in ground glass opacities as well as reticular pattern changes. The patient also showed improvements in both
FVC and DLCO as measured by PFTs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 9: Clinical improvements in ILD following treatment with cizutamig </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00v02.jpg" ALT="LOGO" STYLE="width:6.30557in;height:2.70032in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The above two cases, obtained in a compassionate use via NPU setting that is not placebo controlled or powered to
demonstrate statistical significance, illustrate early radiographic and functional improvements in patients with severe, treatment-refractory <FONT STYLE="white-space:nowrap">SARD-ILD,</FONT> including individuals with extensive prior therapy and
advanced disease. Although the data may not be replicated in future, larger, randomized controlled clinical trials, the findings suggest potential disease-modifying activity. Improvements in lung function as measured by PFTs is also consistent with
published case series of patients treated with Tecvayli<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to initiate a global Phase 2 study
in the middle of 2026 evaluating cizutamig in patients with <FONT STYLE="white-space:nowrap">SARD-ILD.</FONT> This global study will compare cizutamig at an immune reset dose regimen to standard of care therapy. The primary endpoint will measure
change from baseline in FVC, a clinical endpoint that has been used for approval of other ILD drugs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Background on
<FONT STYLE="white-space:nowrap">SARD-ILD</FONT> </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">SARD-ILD</FONT> encompasses progressive pulmonary complications that occur in
patients with systemic autoimmune rheumatic diseases, including SSc, RA, idiopathic inflammatory myopathies, Sj&ouml;gren&#8217;s syndrome, and SLE. ILD represents one of the most serious and life-threatening manifestations of these autoimmune
conditions, characterized by inflammation and progressive fibrosis of the lung interstitium, leading to impaired gas exchange, declining lung function, and respiratory failure. The prevalence of ILD varies significantly across different diseases
with <FONT STYLE="white-space:nowrap">40-75%,</FONT> <FONT STYLE="white-space:nowrap">40-50%,</FONT> <FONT STYLE="white-space:nowrap">10-20%,</FONT> and <FONT STYLE="white-space:nowrap">3-10%</FONT> of patients with SSc, idiopathic myopathy,
Sj&ouml;gren&#8217;s syndrome, and SLE, respectively having concomitant ILD. <FONT STYLE="white-space:nowrap">B-cells</FONT> and plasma cells are believed to play a central role in disease pathogenesis through production of autoantibodies, secretion
of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> and <FONT STYLE="white-space:nowrap">pro-fibrotic</FONT> cytokines, and aberrant immune cell activation. The progressive nature of <FONT STYLE="white-space:nowrap">SARD-ILD</FONT>
significantly impacts quality of life and carries substantial mortality risk in several patient populations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Current treatment options for <FONT
STYLE="white-space:nowrap">SARD-ILD</FONT> remain extremely limited. For <FONT STYLE="white-space:nowrap">SSc-associated</FONT> ILD specifically, three therapies have received regulatory approval:
Ofev<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, an oral antifibrotic agent approved by the FDA in 2019; Actemra<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, an <FONT STYLE="white-space:nowrap">IL-6</FONT> inhibitor
approved by the FDA in 2021; and mycophenolate mofetil, an immunosuppressive agent widely used based on clinical trial evidence and guideline recommendations. These approved therapies have demonstrated the ability to slow decline in lung function as
measured by FVC but do not reverse disease progression in many patients, and are often limited by significant adverse effects including infections, gastrointestinal toxicity, and liver enzyme elevations. For other forms of <FONT
STYLE="white-space:nowrap">SARD-ILD,</FONT> including <FONT STYLE="white-space:nowrap">RA-ILD</FONT> and inflammatory myopathy-associated ILD, there are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapies with specific
labeled indications, and treatment relies on <FONT STYLE="white-space:nowrap">off-label</FONT> use of immunosuppressive agents including corticosteroids, cyclophosphamide, azathioprine, and rituximab. Despite available therapies, many patients
continue to experience disease progression, and mortality rates remain unacceptably high. Given the central role of B-cells and plasma cells in <FONT STYLE="white-space:nowrap">SARD-ILD</FONT> pathogenesis and the limitations of current therapies,
novel treatments that achieve deep B-cell and plasma cell depletion, such as BCMA-targeted therapies, represent a promising therapeutic approach for this patient population with significant unmet medical need. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Additional clinical studies in autoimmune disease patients currently being explored with</I><B><I> </I></B><I>cizutamig </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beyond gMG and <FONT STYLE="white-space:nowrap">SARD-ILD,</FONT> we are pursuing a broad exploratory program with cizutamig across additional autoimmune diseases
through a combination of <FONT STYLE="white-space:nowrap">IND-enabled</FONT> studies, IITs, and compassionate use via NPU. This multi-indication strategy reflects both the mechanistic versatility of BCMA-targeted
<FONT STYLE="white-space:nowrap">B-cell,</FONT> including plasma cell, depletion across autoimmune diseases and our ability to leverage a global clinical infrastructure to generate data in parallel across geographies. Current diseases in which we
are or plan to treat patients include a Phase 1 study in SLE, a Phase 1 study in thyroid eye disease (&#8220;TED&#8221;) and Graves&#8217; disease, a Phase 1 study in <FONT STYLE="white-space:nowrap">IgE-mediated</FONT> allergy, as well as IIT
studies in ulcerative colitis, IgA nephropathy (&#8220;IgAN&#8221;), RA, SSc, and Sj&ouml;gren&#8217;s syndrome. Compassionate use via NPU has been provided to patients with some of the aforementioned diseases as well as in autoimmune hepatitis,
idiopathic inflammatory myopathies, and transplant alloantibodies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In our ongoing Phase 1 multi-center dose escalation study of cizutamig in patients with SLE in
China, we have seen clinical improvements in disease activity as measured by the SLE Disease Activity Index 2000 <FONT STYLE="white-space:nowrap">(&#8220;SLEDAI-2K&#8221;).</FONT> The primary endpoints of this study are safety and tolerability, with
clinical activity assessed using the SLEDAI-2K as a secondary endpoint. In addition, complement C3 and C4 levels increase with treatment which can be low during SLE disease flare activity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 10: Clinical improvement and complement level changes in SLE following treatment with
cizutamig </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00v03.jpg" ALT="LOGO" STYLE="width:6.30554in;height:2.42856in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These exploratory studies serve a dual purpose: they allow us to characterize the safety profile of cizutamig across distinct disease
contexts while simultaneously providing early evidence of clinical activity to inform indication prioritization. Given the breadth of autoimmune diseases that may be amenable to deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion, this
parallel, indication-agnostic approach is designed to efficiently identify the opportunities where cizutamig has the greatest potential for clinical impact and to direct resources toward the most promising indications for later-stage development.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also seen consistent reductions in disease associated autoantibodies in patients who have been treated with cizutamig. These reductions in autoantibodies
are likely the result of the plasma cell depletion from treatment. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 11: Reduction of autoantibodies in various autoimmune diseases
following cizutamig treatment* </B></P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00v04.jpg" ALT="LOGO" STYLE="width:6.05789in;height:3.22632in;">
 </P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>*As of February 2, 2026</I> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Background on SLE </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">SLE is a complex autoimmune disease-causing widespread
inflammation and damage. Some patients with SLE also have lupus nephritis which is a disease affecting the kidneys. Approximately 204,000 and 3&nbsp;million people in U.S. and globally, respectively have SLE. Various autoantibodies are associated
with SLE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Treatment options for SLE focus on managing symptoms and preventing flares, as there is currently no cure for the
disease. Patients may be prescribed nonsteroidal anti-inflammatory drugs for pain relief, corticosteroids to reduce inflammation, and immunosuppressive medications to decrease immune system activity. Antimalarial drugs, such as hydroxychloroquine,
are also commonly used to manage skin and joint symptoms. GAZYVA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (obinutuzumab), a CD20 mAb, has shown clinical efficacy in patients with SLE and an ongoing clinical trial of LUNSUMIO<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (mosunetuzumab), a CD20 TCE, in SLE is underway. <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion with <FONT STYLE="white-space:nowrap">CAR-T</FONT> and TCE have also shown clinical
response in patients with SLE who have failed multiple lines of therapy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cizutamig healthy volunteer study for evaluation of subcutaneous formulation </I></P>
 <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical data in patients to date have been with cizutamig administered intravenously. We have developed a subcutaneous formulation of cizutamig and are currently
evaluating its safety, tolerability, and pharmacokinetics in a Phase 1 healthy volunteer study in Australia, with an intent to enroll 24 healthy volunteers. The Phase 1 healthy volunteer study was designed to study the safety, tolerability and
absolute bioavailability of subcutaneous dosing of cizutamig. As of February&nbsp;2, 2026, 16 healthy volunteers have been dosed, comparing intravenous to subcutaneous dosing. Preliminary data indicate that the subcutaneous formulation has been well
tolerated to date, with no CRS or serious adverse events reported. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to complete the healthy volunteer study in the first half of 2026. Subject to
favorable results from this study and regulatory approval, we plan to begin evaluation of the subcutaneous formulation of cizutamig in patients with autoimmune disease in the second half of 2026. The subcutaneous formulation, if successful, may
offer potential advantages in terms of patient convenience, treatment adherence, and broader clinical applicability compared to intravenous administration. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cizutamig antibody design and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cizutamig was purposefully designed to have high affinity binding to BCMA and lower affinity binding to CD3, with each antibody molecule capable of binding two BCMA
proteins and two CD3 proteins. Several published studies have shown that cytokine release due to CD3 binding can be reduced with lower CD3 affinity while preserving target cell killing by <FONT STYLE="white-space:nowrap">T-cells.</FONT> The Fc
portion of cizutamig is a human IgG1 sequence with specific mutations introduced to inhibit Fc binding to both Fc<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>Rs and complement component C1q, to
enable reduction of antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;) and complement-dependent cytotoxicity (&#8220;CDC&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 12: Structure of cizutamig showing two binding sites for BCMA on <FONT STYLE="white-space:nowrap">B-cells</FONT> and two binding sites for CD3
on <FONT STYLE="white-space:nowrap">T-cells</FONT> </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00z43.jpg" ALT="LOGO" STYLE="width:3.62245in;height:2.05102in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In vitro studies were performed in cell-based assays comparing cizutamig to teclistamab, or Tecvayli<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. In these studies, cizutamig showed comparable cytotoxicity to teclistamab while also demonstrating lower cytokine release both in terms of maximal levels as well as potency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">317 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 13: In vitro data showing improved therapeutic index of cizutamig as compared to teclistamab
</B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00z44.jpg" ALT="LOGO" STYLE="width:6.0439in;height:2.80976in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further <FONT STYLE="white-space:nowrap">pre-clinical</FONT> characterization was conducted in NHP studies and showed that cizutamig
dosing led to <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion as well as IgG, IgA, and IgM antibody reductions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Completed Phase 1 clinical trial in
patients with MM </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to licensing cizutamig from EpimAb Biotherapeutics, EpimAb Biotherapeutics completed a Phase 1 clinical trial in patients with
refractory MM in China and Australia. Clinical data as of the September&nbsp;23, 2024 final data <FONT STYLE="white-space:nowrap">cut-off</FONT> are summarized below. The median patient age was 65 years old with patients having had a median of 3
prior lines of therapy (range 2 to 6) and 55% having had prior transplantation. Cizutamig was administered once weekly by intravenous infusion, with flat dose levels ranging from of 0.2 to 300 mg. <FONT STYLE="white-space:nowrap">Step-up</FONT>
dosing was applied to all dose levels of 2 mg and above prior to the first dosing cycle. A total of 40 patients had received at least 1 dose of cizutamig. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
objective response rate (&#8220;ORR&#8221;) for the 40 patients treated across all cizutamig doses was 38%. Of the 18 evaluable patients who received 60 mg and above, the ORR was 67%, and in the 13 evaluable patients who received 60 mg to 200 mg,
the ORR was 62%. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CRS of any grade was observed in 25% of all patients treated, with Grade 1 and Grade 2 observed in 17.5&nbsp;% and 7.5&nbsp;%, respectively.
No cases of Grade 3 or higher CRS were observed. For the 13 patients who received 60 mg to 200 mg, CRS of any grade was seen in 31% with 8% being Grade 2. All of the CRS events in this subgroup were at the 200 mg dose as no CRS occurred in patients
receiving 60 mg or 120 mg. No cases of ICANS were reported of all patients treated. Treatment-related serious adverse events of 5% incidence or higher were pneumonia and CRS, which were seen in 10% and 7.5% of patients, respectively. There were 4
treatment emergent deaths, but none were considered to be treatment-related. As we have focused our resources on autoimmune indications, we do not intend to advance cizutamig further in MM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CND261 &#8211; A bispecific TCE antibody targeting CD20-expressing <FONT STYLE="white-space:nowrap">B-cells</FONT> and
<FONT STYLE="white-space:nowrap">CD3-expressing</FONT> T Cells </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Overview </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CND261 is a bispecific TCE antibody designed to deplete CD20 expressing <FONT STYLE="white-space:nowrap">B-cells,</FONT> while minimizing the release of cytokines. CD20
targeting with approved mAbs such as Rituxan<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and GAZYVA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> have already demonstrated clinical efficacy and commercial adoption in
multiple autoimmune diseases. We believe the addition of a CD3 binding effector function can lead to deeper <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion and in turn potentially demonstrate superior clinical outcomes for patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in tissues supportive of immune reset profile </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We obtained lymph node biopsy data from four autoimmune patients treated with CND261 providing preliminary evidence of tissue
<FONT STYLE="white-space:nowrap">B-cell</FONT> depletion as determined by IHC. In two NPU patients with RA, post-treatment lymph node </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">318 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
biopsies were obtained without available baseline comparators. In the first RA patient, a biopsy obtained at 8&nbsp;weeks&#8212;the only biopsy available for this patient&#8212;showed no evidence
of <FONT STYLE="white-space:nowrap">B-cell</FONT> reduction in the lymph nodes. Serum analysis showed anti-drug antibody (&#8220;ADA&#8221;) formation with confirmed lowering of drug exposure which we believe was likely a main contributing factor to
lack of <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion. In the second RA patient, a biopsy at 6&nbsp;weeks demonstrated full depletion of both CD19+ and CD20+ B-cells. In two IIT patients with SLE, lymph node biopsies at 4 weeks showed
100% depletion of CD20+ B-cells in both cases, with some residual CD19+ B-cells remaining, consistent with the selectivity of CD20-targeted depletion of CND261. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While these data are preliminary and based on a small number of patients without paired baseline biopsies in the RA cohort, the findings provide early directional
evidence that CND261 can achieve meaningful tissue B-cell depletion in some patients. The ADA observation in one RA patient highlights the importance of ongoing pharmacokinetic and immunogenicity monitoring and the potential need for exploration of
dosing strategies to mitigate ADA formation and any negative effects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Safety profile of CND261 in patients with autoimmune disease </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of February&nbsp;2, 2026, 26 autoimmune patients have been treated with CND261 across <FONT STYLE="white-space:nowrap">IND-enabled</FONT> studies, IITs, and
compassionate use via NPU. In patients with autoimmune disease treated with CND261, a favorable tolerability profile has been observed, with CRS observed in 19% of patients, all of which were Grade 1. No Grade 2 or higher CRS events were reported,
and no cases of ICANS were observed in any patient treated with CND261. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When combined with the pharmacodynamic biopsy findings described above, the emerging
profile of CND261&#8212;deep tissue CD20+ B-cell depletion with CRS limited to <FONT STYLE="white-space:nowrap">low-grade</FONT> and no ICANS&#8212;is encouraging for continued development in autoimmune indications. These data are early and based on
a limited patient population, and a more complete characterization of the clinical profile will emerge as the program advances. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Evaluation of CND261 in patients
with autoimmune disease </I></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are evaluating CND261 in a Phase 1 dose escalation study in up to 47 patients with refractory RA and a dose escalation IIT in up
to 19 patients with SLE. These studies are designed to evaluate safety and tolerability profile of CND261, and the determination of the recommended Phase 2 dose. Secondary and exploratory endpoints include pharmacokinetic parameters, B-cell counts,
and clinical disease activity measures. CND261 has also been provided for compassionate use via NPU in 2 patients with ANCA vasculitis and 2 patients with RA. As of February 2, 2026, 13 patients have been dosed in the Phase 1 study and 9 patients
have been dosed in the IIT study. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Completed Phase 1 clinical trial in patients with lymphoma </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to licensing CND261 from Genor BioPharma, Genor BioPharma completed a Phase 1 clinical trial in patients with refractory lymphoma in China and Australia. Clinical
data as of the January&nbsp;30, 2024 final data <FONT STYLE="white-space:nowrap">cut-off</FONT> is summarized below. The median patient age was 60 years old with patients having had a median of 3 prior lines of therapy (range 1 to 10) and 99% having
had prior treatment with rituximab. CND261 was administered by intravenous infusion once weekly for up to the first two cycles followed by every three weeks at flat dose levels of 1, 3, 10, 30, 50, 100, 200 and 300 mg.
<FONT STYLE="white-space:nowrap">Step-up</FONT> dosing was applied to 30 mg doses and above for the first dosing cycle. A total of 93 <FONT STYLE="white-space:nowrap">non-Hodgkins</FONT> lymphoma (&#8220;NHL&#8221;) patients had received at least 1
dose of CND261. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">NHL patients with both follicular lymphoma (&#8220;FL&#8221;) and diffuse large <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma
(&#8220;DLBCL&#8221;) were enrolled. Of the 51 efficacy evaluable DLBCL patients, doses of 3 to 300 mg were administered with an observed ORR of 51%. Of the 20 efficacy evaluable FL patients, doses of 10 to 300 mg were administered with an observed
ORR of 90%. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CRS of any grade was noted in 19.4% of the 93 patients who had received at least 1 dose, with 12.9% Grade 1, 5.4% Grade 2, and 1.1% Grade 5. The
single case of Grade 5 CRS occurred in a patient receiving 300 mg of CND261 who was diagnosed late and discharged prematurely from the clinical trial site without appropriate treatment. For DLBCL, there were 60 patients who had received 200 mg of
CND261 or less. Among these patients, CRS of any grade was observed in 19% of patients, with 2% being Grade 2 or higher. No cases of ICANS were reported of all patients treated. Treatment-related serious adverse events of 5% incidence or higher was
pneumonia which was seen in 6.5% of patients. There were 6 treatment emergent deaths of which 2 were deemed to be treatment-related due to one case of Grade 5 CRS for a patient receiving 300 mg of CND261 and one case of pneumonia <FONT
STYLE="white-space:nowrap">co-infected</FONT> with multiple viruses. As we have focused our resources on autoimmune indications, we do not plan to further develop CND261 for lymphoma. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">319 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>CND261 Ab design and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CND261 is a bispecific TCE antibody that binds to CD20 on <FONT STYLE="white-space:nowrap">B-cells</FONT> and CD3 on <FONT STYLE="white-space:nowrap">T-cells.</FONT>
CND261has been engineered to have tight binding to one CD20 protein and lower affinity binding to one CD3 protein. The effector portion of the Fc region has been kept intact which allows for ADCC as well as CDC mechanisms for cytotoxicity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 14: Structure of CND261 showing one binding site each for CD20 and CD3 </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00v05.jpg" ALT="LOGO" STYLE="width:1.69369in;height:2.00901in;">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In vitro studies were performed in cell-based assays comparing CND261 to odronextamab, a CD20 TCE that has progressed through
Phase 3 clinical trials for oncology indications. In these studies, comparable cytotoxicity to odronextamab was observed along with lower cytokine release both in terms of maximal levels as well as potency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 15: In vitro data showing improved therapeutic index of CND261 as compared to odronextamab </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00v06.jpg" ALT="LOGO" STYLE="width:4.085in;height:2.18in;">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00v07.jpg" ALT="LOGO" STYLE="width:6.00502in;height:1.41206in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given the limited cross reactivity of CND261 to NHP CD3, assessment of <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in
NHP cannot be reliably assessed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CND319 &#8211; A trispecific TCE Antibody Targeting CD19 or CD20-expressing <FONT STYLE="white-space:nowrap">B-cells</FONT> and
<FONT STYLE="white-space:nowrap">CD3-expressing</FONT> T Cells </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CND319 is a trispecific TCE that can bind to CD19 or CD20 on
<FONT STYLE="white-space:nowrap">B-cells.</FONT> By targeting both CD19 and CD20, CND319 increases the likelihood of engaging heterogeneous pathogenic <FONT STYLE="white-space:nowrap">B-cell</FONT> populations compared with single-target
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">320 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approaches. The optimized architecture positions CD19 and CD20 binding domains on the <FONT STYLE="white-space:nowrap">B-cell</FONT> side and a tuned CD3 binding domain on the <FONT
STYLE="white-space:nowrap">T-cell</FONT> side to promote stable immune synapse formation and <FONT STYLE="white-space:nowrap">T-cell&#8211;mediated</FONT> cytotoxicity. An <FONT STYLE="white-space:nowrap">Fc-silenced</FONT> IgG4 backbone and a CD3
domain with fast on/fast off kinetics are designed to preserve cytotoxic activity while limiting excessive <FONT STYLE="white-space:nowrap">T-cell</FONT> activation and cytokine release, supporting a differentiated therapeutic approach for
antibody-mediated autoimmune indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 16: Structure of CND319 showing the binding to CD19, CD20 and CD3 </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00v08.jpg" ALT="LOGO" STYLE="width:4.93274in;height:1.78924in;">
 </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In preclinical studies of CND319, potent and selective <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion was observed. In
tissue distribution studies conducted in NHPs, a single dose of CND319 resulted in near-complete depletion of CD20-positive <FONT STYLE="white-space:nowrap">B-cells</FONT> in the spleen, bone marrow, and lymph nodes seven days post-administration. <FONT
STYLE="white-space:nowrap">B-cell</FONT> depletion was observed across all tested dose levels (0.5 mg/kg, 1.5 mg/kg, 5 mg/kg, and 15 mg/kg), with depletion exceeding 95% in target tissues at doses of 1.5 mg/kg and higher. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, a favorable safety profile in these preclinical studies of CND319 was observed. Serum cytokine analysis conducted across the dose range showed minimal
cytokine release, with levels of key inflammatory cytokines including <FONT STYLE="white-space:nowrap">IL-4,</FONT> <FONT STYLE="white-space:nowrap">IL-5,</FONT> <FONT STYLE="white-space:nowrap">IL-10,</FONT>
<FONT STYLE="white-space:nowrap">IL-13,</FONT> and TNF remaining below the lower limits of quantification across all dose groups and time points evaluated. This lack of significant cytokine elevation suggests that CND319 may have the potential for
minimal CRS in clinical development. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These preclinical findings support the continued development of CND319 as a potentially differentiated <FONT
STYLE="white-space:nowrap">B-cell</FONT> depleting therapy with potent efficacy combined with an improved safety profile. The demonstration of robust <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion without significant cytokine release in
NHPs provides important <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data as we advance CND319 toward clinical evaluation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 17: CND319 shows deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion and low cytokine release in NHPs </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g00v09.jpg" ALT="LOGO" STYLE="width:6.25789in;height:3.12105in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">321 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities for CND319, including CMC
development, as well as required nonclinical studies to support initial clinical evaluation. These efforts are focused on establishing a scalable manufacturing process and generating the data necessary to support regulatory submissions. Subject to
completion of these activities and regulatory clearance, we plan to initiate a Phase 1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical study in the middle of 2026 to evaluate the safety,
tolerability, and pharmacologic profile of CND319. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CND460 &#8211; A trispecific TCE Antibody Targeting BCMA or CD19 expressing
<FONT STYLE="white-space:nowrap">B-cells</FONT> and CD3 expressing T cells </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CND460 is a trispecific TCE antibody designed to bind to BCMA and/or CD19 on
B-cells or plasma cells, and CD3 on T cells. This dual-target strategy can address a potential limitation of CD19 or CD20-targeted therapies, which deplete <FONT STYLE="white-space:nowrap">B-cells</FONT> but leave long-lived plasma cells intact
which can continue autoantibody production. By achieving redundant and deep <FONT STYLE="white-space:nowrap">B-cells</FONT> and plasma cells in a single molecule, CND460 has the potential to achieve more profound and durable disease control. CND460
is currently undergoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, including NHP studies, with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials planned for first half of 2027.
CND460 is being developed in collaboration with a third-party development partner. We have the right to formally nominate CND460 as a development candidate upon the conclusion of IND-enabling studies, which have not yet been completed and for which
no clinical data has been generated. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Clinical Development Strategy and Disease Prioritization </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, Candid has pursued an innovative and comprehensive regulatory strategy designed to accelerate clinical development while generating robust safety
and efficacy data across multiple geographies and patient populations. Our approach has been to leverage all available regulatory pathways to rapidly advance our product candidates and address significant unmet medical needs in autoimmune diseases.
</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With our initial IND submission for CND261, the FDA requested additional preclinical in vitro studies to understand the potency of cizutamig with autoimmune
patient T cells to establish a sub-MABEL/sub-therapeutic starting dose. Given this feedback, we did not feel that a Phase 1 study in autoimmune patients with active disease would be operationally feasible if we had started at sub-MABEL dosing. As a
result, we pivoted towards generating data ex-US including China and EEU. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To execute this strategy, we are leveraging our global clinical infrastructure to conduct
trials across multiple indications in parallel, enabling us to generate data more efficiently and inform development decisions across our portfolio on an expedited timeline. We established a clinical team in China to access the country&#8217;s deep
clinical expertise and large, concentrated patient populations with limited treatment options. Through this presence, we have successfully generated clinical data in multiple patients utilizing both the IND and IIT pathway in China. The primary
endpoints of these studies were safety and tolerability of the drug candidates in a given indication. Additionally, we have explored B-cell depletion, biomarker data and other disease specific efficacy benchmarks as secondary endpoints. These
pathways have enabled us to conduct clinical studies efficiently while building important relationships with leading physicians and clinical researchers in the region. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In parallel, we have provided our drug candidates as part of compassionate use under NPU in Europe to treat patients with highly refractory autoimmune diseases who had
exhausted available therapeutic options. This approach has allowed us to gather critical real-world evidence in severely ill patient populations while providing potential therapeutic benefit to individuals with few or no remaining treatment
alternatives. The compassionate use via NPU experience has been particularly valuable in informing our understanding of the clinical profile for cizutamig and CND261 in advanced disease settings. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through these multi-jurisdictional regulatory approaches, we have rapidly generated clinical data for both cizutamig and CND261 across various dose levels and
administration schedules. Our clinical experience to date has provided us with important insights into optimal dosing strategies for cizutamig, including appropriate immune reset doses to achieve sustained therapeutic effect while maintaining
favorable tolerability. As of February&nbsp;2, 2026, we have established a safety database comprising 47 patients treated with cizutamig and 26 patients with CND261 across various autoimmune indications, which we believe represents one of the most
comprehensive datasets for TCEs in autoimmune disease. Additionally, as of February 2, 2026, we have dosed 16 healthy volunteers in Australia with our subcutaneous formulation of cizutamig, expanding our understanding of alternative delivery
methods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">322 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe this diversified regulatory strategy has provided Candid with several important advantages, including
accelerated clinical timelines, a robust and geographically diverse safety database, access to diverse patient populations and disease presentations, and valuable dose-finding and optimization data that will inform our future pivotal trials. As we
advance toward later-stage clinical development, we intend to continue leveraging appropriate regulatory pathways in multiple jurisdictions while pursuing traditional regulatory approval routes in major markets including the United States and
Europe. With respect to the United States, to date we have not received approval from the FDA to initiate clinical trials and have not previously submitted an IND to the FDA for cizutamig in autoimmune indications. We have had limited interactions
with the FDA. In prior interactions, the FDA informed us that our existing Phase 1 oncology data for cizutamig would not support an IND filing and the proposed Phase 1 clinical trial for cizutamig in autoimmune diseases without further preclinical
testing, due to potential differences in T-cell responses between oncology and autoimmune patients. As a result of this feedback, we have prioritized generating clinical data outside the United States while conducting additional preclinical work
intended to support a future U.S. IND submission. We believe that the autoimmune clinical data being generated globally across multiple indications will ultimately support IND clearance in the United States; however, there can be no assurance that
the FDA will accept this data or that it will not require additional preclinical studies or modifications to proposed study designs, which could delay or prevent us from conducting clinical trials in the United States. Our regulatory strategy is
designed to maximize the speed and efficiency of our clinical programs while maintaining the highest standards of patient safety and data quality necessary for regulatory approval. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Disease indications of interest </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical development strategy is
focused on pursuing cizutamig and our other TCE drug candidates in autoimmune diseases that represent multibillion-dollar market opportunities. We are targeting two categories of indications: established commercial markets with validated therapeutic
need, and high unmet need indications where current treatment options are inadequate or nonexistent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the established commercial market category, we are pursuing
or planning to pursue clinical development in gMG, TED, Graves&#8217; disease, ulcerative colitis, IgAN, <FONT STYLE="white-space:nowrap">IgE-mediated</FONT> allergy, and RA. These indications represent large, validated markets with existing
approved therapies, but where significant unmet medical needs persist, including patients who are refractory to current treatment options, those who experience intolerable side effects, or those requiring more convenient administration or improved
efficacy. The collective market opportunity for therapies in these established indications represents billions of dollars in annual global sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the high unmet
need category, we are focusing on indications where current treatment options are severely limited or where no approved therapies exist. These include ILD, SSc, Sj&ouml;gren&#8217;s disease, and SLE. Additionally, we see clinical rationale and
market expansion opportunities in autoimmune hepatitis, ANCA vasculitis, idiopathic inflammatory myopathies, and transplant alloantibodies. These indications are characterized by serious, progressive, and often life-threatening disease courses, with
many patients experiencing inadequate responses to available immunosuppressive therapies or suffering significant treatment-related adverse events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">323 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 18: Current autoimmune diseases of interest for Candid&#8217;s clinical development of TCEs
</B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g49g49.jpg" ALT="LOGO" STYLE="width:6.31945in;height:3.085in;">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that TCEs can become the next major drug class to treat autoimmune diseases and that clinical data will guide the most
appropriate indications in which <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion can have the most significant impact. Our strategy of pursuing both established markets and high unmet need indications is designed to maximize the commercial
potential of our product candidates while addressing the most serious unmet medical needs in autoimmune disease. The breadth of our target indications reflects the central role that plasma cells and autoantibodies play in autoimmune disease
pathogenesis and the potential applicability of cizutamig&#8217;s unique mechanism across a wide range of antibody-mediated autoimmune conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Target
Product Profile for TCEs&#8212;Immune Reset and Immune Dimming </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We see an opportunity for our programs to be developed with different target product profiles
(&#8220;TPPs&#8221;) which are not mutually exclusive. At the core of each TPP, is the depth of desired <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion, which we believe correlates to depth and durability of clinical benefit as well as the
need for interim management of increased infection risk due to immunosuppression. We believe TCEs have now shown the same level of deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion and clinical response seen with <FONT
STYLE="white-space:nowrap">CAR-T</FONT> in autoimmune patients. We refer to this TPP as an &#8220;immune reset&#8221;. The goal with immune reset is to provide one cycle of therapy for durable benefit lasting years. As the immune system is
resetting, prophylaxis with intravenous immunoglobulins and antibiotics to prevent serious infections is likely needed. In contrast to &#8220;immune reset&#8221;, one can also target partial <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion
with the aim of demonstrating clinical improvement over existing standard of care in autoimmune diseases. We refer to this TPP as &#8220;immune dimming&#8221;. As only partial <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion is targeted,
underlying <FONT STYLE="white-space:nowrap">pre-existing</FONT> immunity could be preserved resulting in minimal to no infection risk. With immune dimming, we expect intermittent dosing of TCEs is needed to maintain clinical benefit. With cizutamig,
Candid&#8217;s lead program, we have dosed patients with both immune reset and immune dimming dosing regimens and observed initial promising clinical results to continue further studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">324 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 19: Potential to Pursue Both Immune Reset and Immune Dimming with TCEs </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g01g50.jpg" ALT="LOGO" STYLE="width:6.3357in;height:2.56242in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Discovery Programs </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have ongoing
discovery effort to identify novel TCEs which can address various immunology and inflammatory diseases. We are collaborating with several research partners to leverage their antibody engineering and other discovery expertise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing and Supply </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not own or operate, and currently have no
plans to establish, any manufacturing facilities. We rely on third-party contract development and manufacturing organizations (&#8220;CDMOs&#8221;) for the supply of our drug candidates for use in our preclinical studies and clinical trials. We have
made significant investments in CMC activities to support the development of our product candidates and to establish robust, scalable manufacturing processes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have engaged multiple third-party CDMOs for biologics development and manufacturing services and are continuously evaluating additional CDMOs to further diversify and strengthen our supply chain. This multi-sourcing strategy is designed to mitigate
supply chain risk and deliver continuity of drug supply as our programs advance through clinical development. We expect to have sufficient drug supply for our product candidates to conduct our planned clinical trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A key component of our CMC investment has been the development of subcutaneous formulations for our lead product candidates. We have successfully developed subcutaneous
formulations for cizutamig, CND261, and CND319. We plan to incorporate subcutaneous formulations into our clinical development programs for our product candidates as data from ongoing studies become available. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our CMC development efforts have focused on establishing robust, scalable manufacturing processes that can support both clinical development and potential commercial
production. This includes optimization of cell line development, upstream and downstream processing, formulation development, and analytical methods to deliver product quality, consistency, and stability. We have invested in process characterization
and comparability studies to support manufacturing transfers between CDMOs and to enable regulatory filings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of our drug candidates receives marketing
approval, we intend to rely on third-party CDMOs for commercial manufacturing. As our drug candidates advance through development, we expect to enter into longer-term commercial supply agreements to fulfill and secure our production needs. We will
seek to establish relationships with multiple qualified manufacturers to provide redundancy and supply chain resilience for commercial production. Our manufacturing strategy is designed to deliver adequate supply to meet anticipated commercial
demand while maintaining flexibility to respond to market dynamics and potential supply chain disruptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">325 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sales and Marketing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given
our stage of development, we have not yet established a commercial organization or distribution capabilities. We intend to build a commercial infrastructure to support sales of any of our approved future drugs. We expect to manage sales, marketing
and distribution through internal resources and third-party relationships. In addition, we plan to opportunistically explore commercialization partnerships, particularly with entities that have strong capabilities in geographies outside the United
States. As our current and future drug candidates progress through clinical development, our commercial plans may change. Clinical data, the size of the development programs, the size of our target markets, the size of the requisite commercial
infrastructure and manufacturing needs may all influence our commercialization strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease etiology, intense competition and
a strong emphasis on intellectual property. We face substantial competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies
and public and private research institutions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our competition for <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion includes mAbs, bispecifics which include
TCEs, IgG degraders, and various forms of cell therapy from several pharmaceutical and biotechnology companies, including AbbVie Inc., Amgen, Argenx, Artiva Biotherapeutics, Inc., Biohaven Ltd., Bristol-Myers Squibb Company, Cabaletta Bio, Inc.,
Cartesian Therapeutics, Inc, Cullinan Therapeutics, Inc., Fate Therapeutics, Inc., GSK plc, Immunovant, Inc., Johnson&nbsp;&amp; Johnson, Kyverna Therapuetics, Inc., Merck&nbsp;&amp; Co., Inc., Otsuka Pharmaceutical, Pfizer, Inc., Roche Holding AG,
among others. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and
expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We could see a reduction or elimination in our commercial opportunity if our competitors develop and
commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or with a more favorable label than our drug candidates. Our competitors also may obtain FDA or other
regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the
success of all of our drug candidates, if approved, are likely to be efficacy, safety, convenience, price, availability of the relevant isotope, the effectiveness of imaging diagnostics, the level of generic competition and the availability of
reimbursement from government and other third-party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business, including seeking, maintaining
and defending patent rights, whether developed internally or licensed from third parties. Our intellectual property strategy includes seeking to protect our proprietary position by, amongst other methods, striving to obtain issued patents by filing
and prosecuting patent applications in the United States and in jurisdictions outside of the United States, directed to our proprietary technology, inventions, improvements, and drug candidates that are important to the development and
implementation of our business. We also rely on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our proprietary technology and drug candidates, continued innovation, and
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain our proprietary position in the field of immunotherapy. We also plan to rely on data exclusivity, market exclusivity and patent term extensions
when </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">326 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements; to preserve
the confidentiality of our trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> to obtain and maintain licenses to use intellectual property owned by third parties; to defend and enforce our proprietary rights, including any patents
that we may own in the future; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
February&nbsp;26, 2026, we own one U.S. provisional patent application that discloses treatment of certain indications by cizutamig and one U.S. provisional patent application that discloses cizutamig dosing strategies. We have exclusively <FONT
STYLE="white-space:nowrap">in-licensed</FONT> 12 foreign patent applications that were filed in Europe, Australia, Brazil, Israel, India, Japan, South Korea, Mexico, New Zealand, Russia, and South Africa that disclose cizutamig sequences and have <FONT
STYLE="white-space:nowrap">non-exclusively</FONT> <FONT STYLE="white-space:nowrap">in-licensed</FONT> one U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application, ten foreign patent applications that were filed in Europe,
Australia, Brazil, Canada, Israel, India, South Korea, Mexico, New Zealand, and South Africa, and two foreign patents that were granted in Japan and Russia that disclose cizutamig <FONT STYLE="white-space:nowrap">anti-CD3</FONT> antibody sequences,
and two U.S. patents, two foreign patent applications that were filed in Europe and Japan, and 23 foreign patents that were granted in Australia, Canada, Israel, India, Japan, South Korea, Mexico, New Zealand, Russia, South Africa, Hong Kong, and
Europe with rights in Germany, France, United Kingdom, Belgium, Switzerland, Denmark, Spain, Ireland, Italy, Luxembourg, and Netherlands that disclose cizutamig antibody formats. All of the exclusively and
<FONT STYLE="white-space:nowrap">non-exclusively</FONT> <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications related to cizutamig are licensed from EpimAb Biotherapeutics, Inc, and are licensed worldwide except for
China, Taiwan, Hong Kong, and Macau. Absent any patent term extension, patent term adjustments, and terminal disclaimers, the Candid-owned and EpimAb <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patents that issue from these
pending applications are expected to expire between 2034 and 2047. We own one U.S. provisional patent application, one pending patent application filed under the Patent Cooperation Treaty (&#8220;PCT&#8221;), and two foreign patent applications that
were filed in Taiwan and Argentina that disclose treatment of certain indications by CND261. We have exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> one U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application,
two U.S. patents, one foreign patent application that was filed in Europe, four foreign patents that were granted in Europe, Japan, and South Korea that disclose CND261 sequences, and one PCT patent application and one U.S. provisional patent
application that disclose CND261 sequences and formulations, and one U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application and one foreign patent application that was filed in Europe that disclose heterodimerization
mutations used in CND261, and one U.S. patent and one foreign patent application that was filed in Europe that disclose CND261 back up sequences. All of the <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications related
to CND261 are licensed from Genor Biopharma Co. Ltd and are licensed worldwide except for China, Taiwan, Hong Kong, and Macau. Absent any patent term extension, patent term adjustments, and terminal disclaimers, the Candid-owned and Genor <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patents that issue from these pending applications are expected to expire between 2038 and 2045. We own one U.S. provisional patent application, one PCT patent application, and two foreign
patent applications that were filed in Taiwan and Argentina that disclose treatment of certain indications by CND319. We have exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> one PCT patent application, and two foreign patent
applications that were filed in Taiwan and Argentina that disclose CND319 sequences, and one PCT patent application that discloses treatment of certain indications by CND319. We have <FONT STYLE="white-space:nowrap">non-exclusively</FONT> <FONT
STYLE="white-space:nowrap">in-licensed</FONT> two U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, one U.S. patent, one PCT patent application, 30 foreign patent applications that were filed in Europe, Australia,
Brazil, Canada, China, Israel, India, Japan, South Korea, Mexico, New Zealand, Philippines, Singapore, Thailand, Hong Kong, Malaysia, Indonesia, Morocco and with the Eurasian Patent Organization, and 13 foreign patents that were granted in Macau,
Australia, China, Israel, Japan, South Korea, South Africa, Taiwan, Malaysia, Saudi Arabia, and with the Eurasian Patent Organization that disclose antibody formats and platform sequences used in CND319, and one U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application, three U.S. patents, 15 foreign patent applications that were filed in Europe, Australia, Brazil, Canada, China, Israel, India, South Korea, Mexico, Philippines, Singapore,
Thailand, Hong Kong, and Indonesia, and 15 foreign patents that were granted in Macau, Australia, China, Japan, South Korea, New Zealand, South Africa, Taiwan, Malaysia, Saudi Arabia, and with the Eurasian Patent Organization that disclose CND319 <FONT
STYLE="white-space:nowrap">anti-CD3</FONT> antibody sequences, and one U.S. patent, 12 foreign patent applications that were filed in Europe, Brazil, Canada, China, Israel, India, South Korea, Mexico, Singapore, and Hong Kong, and 12 foreign patents
that were granted in Macau, Australia, China, Israel, Japan, South Korea, Russia, Taiwan, and Indonesia that disclose CND319 anti-CD19 antibody sequences. All of the <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications
related to CND319 are licensed from WuXi Biologics together with its Affiliates and are licensed worldwide. Absent any patent term extension, patent term adjustments, and terminal disclaimers, the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">327 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Candid-owned and WuXi Biologics <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patents that issue from these pending applications are expected to expire between 2038 and 2046. In
addition, we own, two PCT patent applications and two U.S. provisional patent applications that disclose aspects of our technology related to other antibody compositions and methods. Absent any patent term extension, patent term adjustments, and
terminal disclaimers, patents that issue from these pending applications are expected to expire in 2046. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to our drug candidates and processes, we
intend to develop and commercialize in the normal course of business, and we intend to pursue patent protection directed to, when possible, compositions, methods of use, methods of making, dosing and formulations. We may also pursue patent
protection with respect to manufacturing, therapeutic development processes and technologies, and therapeutic delivery technologies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Issued patents can provide
protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications
filed in the United States can provide exclusionary rights for 20 years from the earliest effective filing date excluding U.S. provisional applications. In addition, in certain instances, the term of an issued U.S. patent that is directed to or
claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and
the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction but typically is also 20 years
from the earliest effective filing date excluding U.S. provisional applications. However, the actual protection afforded by a patent varies on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT>
basis, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-to-country</FONT></FONT> and depends upon many factors, including the type of patent, the scope of its claims, the availability of regulatory-related extensions,
the availability of legal remedies in a particular country, and the validity and enforceability of the patent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent positions of companies like ours are
generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of immunotherapy has emerged in the United States. The relevant patent laws and their
interpretation outside of the United States are also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or drug candidates and enforce the
patent rights that we have licensed or may license and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our
intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. With respect to company-owned or licensed intellectual property that we currently have or may
have in the future, we cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we or our licensors may file in the future, nor can we be sure that any patents
that may be granted to us or our licensors in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even the issued patents that we license do not guarantee us the right to
practice our technology in relation to the commercialization of our products. Patents and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third
parties may have blocking patents that could be used to prevent us from commercializing our drug candidates and practicing our proprietary technology, and the issued patents that we <FONT STYLE="white-space:nowrap">in-licensed</FONT> or may <FONT
STYLE="white-space:nowrap">in-license</FONT> and those that may issue in the future may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent
protection that otherwise may exist for our drug candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore,
our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents that we may own or that we exclusively <FONT STYLE="white-space:nowrap">in-licensed.</FONT> For these reasons,
we may face competition with respect to our drug candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular drug candidate can be
commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. A comprehensive discussion on risks relating to
our intellectual property is provided under the section of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">328 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
this proxy statement/prospectus titled &#8220;<I>Risk Factors&#8212;Risks Related to Candid&#8212;Risks Related to Candid&#8217;s Intellectual Property</I>.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License and Collaboration Agreements </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License and Collaboration
Agreement with Shanghai EpimAb Biotherapeutics Co., Ltd. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, we entered into a license and collaboration agreement (the &#8220;EpimAb License
Agreement&#8221;) with Shanghai EpimAb Biotherapeutics Co., Ltd. (&#8220;EpimAb&#8221;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the EpimAb License Agreement, we received a royalty-bearing,
sublicensable license, under certain <FONT STYLE="white-space:nowrap">know-how</FONT> and patent rights controlled by EpimAb relating to BCMA/CD3 bispecific antibodies, to research, develop, manufacture, use, sell, offer for sale, import and
otherwise commercialize cizutamig and certain derivatives of cizutamig that are also BCMA/CD3 bispecific antibodies, and products containing cizutamig or such derivatives (&#8220;CND106 Licensed Products&#8221;) everywhere in the world except for
Greater China (which includes Hong Kong, Macau and Taiwan) (the &#8220;Cizutamig Licensed Territory&#8221;) for the diagnosis, treatment or prevention of all human and <FONT STYLE="white-space:nowrap">non-human</FONT> diseases (the &#8220;Cizutamig
Field&#8221;). Our license is exclusive with respect to certain licensed patents and claims of certain other licensed patents that specifically cover any BCMA/CD3 bispecific antibody as a whole or that cover certain binding sequences and licensed <FONT
STYLE="white-space:nowrap">know-how</FONT> that is related to such licensed patents or licensed patent claims; it is <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to all other licensed patent claims and licensed <FONT
STYLE="white-space:nowrap">know-how.</FONT> We also have a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license from EpimAb (a)&nbsp;to manufacture cizutamig and Cizutamig Licensed Products in Greater China (including Hong Kong, Macau and
Taiwan) (the &#8220;EpimAb Territory&#8221;) solely for use in the Cizutamig Licensed Territory and (b)&nbsp;to research and develop CND106 Licensed Products in the CND106 Field in the EpimAb Territory solely for the purpose of obtaining regulatory
approval of CND106 Licensed Products in the Cizutamig Licensed Territory. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are responsible, at our cost, for the development, manufacture and commercialization
of CND106 Licensed Products in the CND106 Field in the CND106 Licensed Territory. We are obligated to use commercially reasonable efforts to develop at least one CND106 Licensed Product in the CND106 Field in the CND106 Licensed Territory; provided,
however, that this obligation will expire upon achievement of a certain development milestone, or upon our election to make a certain milestone payment early. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">EpimAb received total upfront cash consideration of $30.0&nbsp;million under the EpimAb License Agreement. In addition, we also issued to EpimAb&#8217;s parent company
and its shareholders a total of 30.0&nbsp;million shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock. We are obligated to pay EpimAb up to $95.0&nbsp;million in development and regulatory milestone payments,
up to $480.0&nbsp;million in commercial milestone payments and tiered single-digit royalties on net sales of CND106 Licensed Products. The royalty payments are subject to reduction under certain customary circumstances. On a CND106 Licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Cizutamig</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, our obligation to pay
EpimAb royalties commences on the first commercial sale of such CND106 Licensed Product in the applicable country until the latest to occur of (a)&nbsp;the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim within the licensed patents covering such CND106 Licensed Product in the applicable country, (b)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> regulatory exclusivity for such CND106 Licensed Product in the applicable country and (c) 12 years after the first commercial sale of such CND106 Licensed
Product in the applicable country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EpimAb License Agreement will remain in effect on a Cizutamig Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-CND106</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until expiration of all royalty payment obligations, unless it
is earlier terminated. Following expiration of the EpimAb License Agreement, the licenses granted to us become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable and fully <FONT STYLE="white-space:nowrap">paid-up.</FONT>
We may terminate the EpimAb License Agreement for convenience upon advance written notice to EpimAb. Either party may terminate the EpimAb License Agreement for the other party&#8217;s uncured material breach; provided, however, that this
termination right will not be available to either party after achievement of a certain development milestone, or upon our election to make a certain milestone payment early. Either party may terminate the EpimAb License Agreement in connection with
the insolvency of the other party. EpimAb may terminate the EpimAb License Agreement if we challenge a licensed patent, subject to a specified notice and cure period. Upon termination of the EpimAb License Agreement, we are subject to certain
post-termination obligations to enable EpimAb to be able to exploit Cizutamig Licensed Products in the Cizutamig Field on a worldwide basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">329 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License Agreement with Genor Biopharma Co. Ltd. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We entered into a license agreement with Genor Biopharma Co. Ltd. (&#8220;Genor&#8221;) in August 2024 and an amendment to this agreement in March 2025 (the
&#8220;Genor License Agreement&#8221;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Genor License Agreement, we received an exclusive, royalty-bearing, sublicensable license under certain <FONT
STYLE="white-space:nowrap">know-how</FONT> and patent rights controlled by Genor (including certain intellectual property <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Genor) relating to bispecific antibodies and heteromultimeric proteins
(&#8220;Licensed IP&#8221;) to develop, use, manufacture, commercialize and otherwise exploit CND261 (formerly known as GB261), certain derivatives of CND261 that are also CD20xCD3 bispecific antibodies, and products containing CND261 or such
derivatives (&#8220;CND261 Licensed Products&#8221;) everywhere in the world except for Mainland China, Hong Kong, Macau and Taiwan (the &#8220;CND261 Licensed Territory&#8221;) for the diagnosis, treatment or prevention of disease in humans and
animals (the &#8220;CND261 Field&#8221;). We also received a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under the Licensed IP in Mainland China, Hong Kong, Macau and Taiwan (the &#8220;Genor Territory&#8221;) to
manufacture CND261 Licensed Products in the Genor Territory and to conduct <FONT STYLE="white-space:nowrap">non-clinical</FONT> and certain clinical development of CND261 Licensed Products in the Genor Territory in the CND261 Field, solely for the
purposes of supporting exploitation of CND261 Licensed Products in the CND261 Field in the CND261 Licensed Territory. In addition, we have a right of first negotiation if Genor decides to commence negotiations with one or more third parties to grant
a license to develop, use, manufacture, commercialize or otherwise exploit CND261 Licensed Products in the CND261 Field in the Genor Territory. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are responsible,
at our cost, for the development, manufacture and commercialization of CND261 Licensed Products in the CND261 Field in the CND261 Licensed Territory. We are obligated to use commercially reasonable efforts to develop and obtain regulatory approval
for at least one CND261 Licensed Product in the CND261 Field in the United States and in at least one of Canada, the United Kingdom, France, Germany, Spain or Italy (&#8220;Major Market Countries&#8221;). We are also obligated to use commercially
reasonable efforts to commercialize at least one CND261 Licensed Product in the United States or any Major Market Country in which regulatory approval has been obtained for such product. We are also obligated to use commercially reasonable efforts
to conduct IIT(s) and Phase I clinical trial(s) of a CND261 Licensed Product in the Genor Territory for the indication of autoimmune and inflammatory diseases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Genor received total upfront cash consideration of $16.0&nbsp;million and received an additional $4.5 million and $2.0&nbsp;million upon the achievement of milestones
specified in and pursuant to the Genor License Agreement during the year ended December 31, 2025 and the period from May 1, 2024 (inception) to December 31, 2024, respectively. In addition, we issued an aggregate of 12,499,997 shares of our common
stock to an affiliate of Genor pursuant to a stock purchase agreement. We are also obligated to pay Genor up to $138.5&nbsp;million in development and regulatory milestone payments, up to $300.0&nbsp;million in commercial milestone payments, tiered
mid single-digit to low teen percentage royalties on net sales of CND261 Licensed Products, and mid single-digit to low double-digit percentage of income that we receive from our sublicensees if we sublicense our rights to CND261 Licensed Products.
The royalty payments are subject to reduction under certain customary circumstances. On a CND261 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CND261</FONT></FONT> Licensed Product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, our obligation to pay Genor royalties commences on the first commercial sale of such CND261 Licensed Product in the applicable country until the
latest to occur of (a)&nbsp;the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim within the patents licensed to us by Genor covering such CND261 Licensed Product in the applicable country,
(b)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> regulatory exclusivity for such CND261 Licensed Product in the applicable country and (c)&nbsp;ten years after the first
commercial sale of such CND261 Licensed Product in the applicable country. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Genor License Agreement will remain in effect on a CND261 Licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CND261</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until expiration of all royalty
payment obligations, unless it is earlier terminated. Following expiration of the Genor License Agreement, the licenses granted to us become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable and fully <FONT
STYLE="white-space:nowrap">paid-up.</FONT> Either party may terminate the Genor License Agreement for the other party&#8217;s uncured material breach or insolvency, subject to certain notice and cure periods. Genor may terminate the Genor License
Agreement if we challenge any of the patents licensed to us, subject to a specified notice and cure period. We may terminate the Genor License Agreement in its entirety, or on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> or CND261 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CND261</FONT></FONT> Licensed Product basis for
convenience upon advance written notice to Genor. Upon termination of the Genor License Agreement, we are subject to certain post-termination obligations to enable Genor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">330 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to be able to exploit the CND261 Licensed Products on a worldwide basis, or if the Genor License Agreement is not terminated in its entirety, in the applicable terminated countries. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License Agreement with WuXi Biologics </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2025, we entered
into a license agreement (the &#8220;WuXi License Agreement&#8221;) with WuXi Biologics (Shanghai) Co., Ltd. (&#8220;WuXi Biologics&#8221;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the WuXi License
Agreement, we received an exclusive, royalty-bearing license, with the right to grant sublicenses, under certain <FONT STYLE="white-space:nowrap">know-how</FONT> and patent rights controlled by WuXi Biologics, to develop, have developed,
manufacture, have manufactured, sell, offer for sale, have sold, import and have imported, export and have exported, and otherwise commercialize CND319, certain other CD19xCD20xCD3 trispecific antibodies, and products containing CND319 or such
CD19xCD20xCD3 trispecific antibodies (&#8220;CND319 Licensed Products&#8221;) for all human and <FONT STYLE="white-space:nowrap">non-human</FONT> use, including for all research, diagnostic and therapeutic purposes (the &#8220;CND319 Field&#8221;),
throughout the world. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are responsible, at our cost, for the global development, manufacture and commercialization of CND319 Licensed Products in the CND319
Field. Until completion of the first Phase I clinical trial of a CND319 Licensed Product, we are obligated to use commercially reasonable efforts to develop a CND319 Licensed Product in the CND319 Field. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">WuXi Biologics received total upfront cash consideration of $25.0&nbsp;million. We are also obligated to pay WuXi Biologics up to $150.0&nbsp;million in development and
regulatory milestone payments, up to $750.0&nbsp;million in commercial milestone payments, and tiered low to mid single-digit percentage royalties on annual net sales of each CND319 Licensed Product. The royalty payments are subject to reduction
under certain customary circumstances. On a CND319 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CND319</FONT></FONT> Licensed Product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, our obligation to pay WuXi Biologics royalties commences on the first commercial sale of such CND319 Licensed Product in the applicable country
and continues until the last to occur of (a) 12 years after the first commercial sale of such CND319 Licensed Product in the applicable country, (b)&nbsp;the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim within certain patents licensed to us by WuXi Biologics covering the composition of matter of such CND319 Licensed Product in a trispecific
format in the applicable country, and (c)&nbsp;expiration of regulatory exclusivity for such CND319 Licensed Product in the applicable country. In addition, if we sublicense our rights to CND319 Products, we are obligated to pay to WuXi Biologics a
percentage of certain income that we receive from our sublicensees; such percentage will be between a high single-digit to low double-digit, depending upon when the sublicense is granted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The WuXi License Agreement will remain in effect on a CND319 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CND319</FONT></FONT>
Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until expiration of all royalty payment obligations for such CND319 Licensed Product in the applicable country, unless it
is earlier terminated. Following expiration of the WuXi License Agreement, the license granted to us becomes fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> perpetual, and irrevocable. We may terminate the WuXi License Agreement in its
entirety, or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, for convenience upon advance written notice to WuXi Biologics. Either party may terminate the WuXi License Agreement for the
other party&#8217;s uncured material breach or insolvency, subject to certain notice and cure periods. WuXi Biologics may terminate the WuXi License Agreement if we or our sublicensees challenge any of the patents licensed to us, subject to a
specified notice and cure period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Government authorities in the United States, at the federal, state and local levels, and in other countries extensively regulate, among other things, the research,
development, testing, manufacturing, quality control, approval, licensure, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological
products such as those we are developing. Our drug candidates must be approved or licensed by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory authorities before they may be legally marketed
in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant
aspects of regulation in the European Union (&#8220;EU&#8221;) are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent
compliance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">331 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulation of Biological Products in the United States </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United
States, the FDA regulates biological products under the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;) and their implementing regulations. The process of obtaining regulatory approvals
and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during
the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an
approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement
or civil or criminal penalties. The process required by the FDA before a biological product may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of nonclinical laboratory tests and certain nonclinical animal studies according to good laboratory practices
(&#8220;GLPs&#8221;) and other applicable requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin and must be updated
annually; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approval by an independent Institutional Review Board (&#8220;IRB&#8221;) or ethics committee representing each clinical
site before the trial is commenced; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly
referred to as good clinical practices (&#8220;GCPs&#8221;), and any additional requirements for the protection of human research patients and their health information, to establish the safety, purity and potency of the proposed biological product
for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparation of and submission to the FDA of a biologics license application (&#8220;BLA&#8221;) requesting approval for
one or more proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections of the
manufacturing facility or facilities where the proposed biological product is produced to assess compliance with current good manufacturing practices (&#8220;cGMPs&#8221;), to assure that the facilities, methods and controls are adequate to preserve
the drug candidate&#8217;s identity, strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential FDA audits of the nonclinical studies and clinical trial sites that generated the data in support of the BLA;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">payment of user fees under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), unless exempted; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA review and approval of the BLA. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nonclinical Studies and Investigational New Drug Application </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before
testing any biological drug candidate in humans, the drug candidate must undergo rigorous preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation,
as well as animal studies to assess the potential safety and activity of the drug candidate. The conduct of preclinical tests must comply with federal regulations and requirements, including GLPs for certain studies. The clinical trial sponsor must
submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND, which is a request for authorization
from the FDA to administer an investigational biological product to humans in clinical trials. Some preclinical testing may continue even after the IND is submitted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises
concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that <FONT STYLE="white-space:nowrap">30-day</FONT> time period. In such a case, the IND sponsor and the FDA must resolve any outstanding
concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological drug candidate at any time before or during clinical trials due to safety concerns or <FONT STYLE="white-space:nowrap">non-compliance.</FONT> If the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">332 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
FDA imposes a clinical hold, trials may not initiate or resume under the IND without FDA authorization and then only under terms authorized by the FDA. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Trials in Support of a BLA </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials involve the
administration of the biological drug candidate to human subjects under the supervision of qualified investigators in accordance with GCPs, which include, among other things, the requirement that all research subjects provide their informed consent
for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be
used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Further,
each clinical trial must be reviewed and approved by an independent IRB or ethics committee at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial
participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent
that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical
study sponsor, known as a data safety monitoring board (&#8220;DSMB&#8221;), which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical
trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are also requirements
governing the reporting of ongoing clinical studies and clinical study results to public registries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Human clinical trials are typically conducted in three
sequential phases that may overlap or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1. The biological drug candidate is initially introduced into healthy human subjects and tested for safety. In the
case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. These trials are designed
to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the biological drug candidate in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2. The biological drug candidate is evaluated in a limited patient population to identify possible adverse effects
and safety risks, to preliminarily evaluate the efficacy of the drug candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency and safety of the
biological drug candidate in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product
labeling. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are
used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During all phases of clinical development, regulatory authorities require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial
investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, and the investigators for serious and unexpected adverse events, any
findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the
protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or
life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Phase 1, Phase 2 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">333 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its DSMB may suspend or terminate a clinical trial at any time on
various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted
in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with
clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be
precisely defined. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of
the final biological product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the
biological drug candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Submission, Review and Approval of a BLA to FDA </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA
submission must include results of product development, including results from laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an
annual program fee for biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on
BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Within 60 days
following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the
time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is
accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its
intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. Under the PDUFA guidelines
that are currently in effect, the FDA has a goal to complete a standard review of an original BLA within ten months after the filing date, or, if the application qualifies for priority review, within six months after the filing date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee,
typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the biological product approval process, the FDA also will determine
whether a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), is necessary to assure the safe use of the biological product. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable
patients to have continued access to such medicines by managing their safe use and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other
risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">334 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not
approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, before approving a BLA, the FDA may also inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial
requirements and GCP requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the FDA evaluates a BLA and conducts any inspections of manufacturing facilities where the investigational product and/or
its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A CRL
indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL typically describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified
may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the CRL may include recommended actions that the applicant might take to place a resubmitted application in a condition
for approval. If a CRL is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could
restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution,
prescribing, or dispensing in the form of a risk management plan or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials or studies designed to further assess the biological product, as well as
testing and surveillance programs to monitor the safety of approved products that have been commercialized and may limit further marketing of the product based on the results of these post-marketing studies. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pediatric Trials </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Pediatric Research Equity Act
(&#8220;PREA&#8221;), as amended, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for
each pediatric subpopulation for which the product is safe and effective. The FDCA requires that a sponsor of a biological product or drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of
administration submit an initial pediatric study plan (&#8220;PSP&#8221;) to the FDA not later than 60 days after the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or as may be agreed between
the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for
not including such detailed information and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. Generally, development program
candidates designated as orphan drugs are exempt from the above requirements. FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be
considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may, on its own
initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. The FDA may send a <FONT
STYLE="white-space:nowrap">non-compliance</FONT> letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expedited Development and Review Programs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA has a fast track
program that is intended to expedite or facilitate the process for reviewing drug candidates that meet certain criteria. Specifically, drug candidates are eligible for fast track designation if they are intended to treat a serious or
life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being
studied. The sponsor of a fast track drug candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA or BLA is submitted, the application may be eligible for priority
review with respect to a fast track drug candidate, the FDA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">335 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the
FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A drug candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its
development and review. A drug candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the drug candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more
intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any drug candidate, submitted to the FDA for approval, including a drug with a fast track or breakthrough designation, may also be eligible for other types of FDA
programs intended to expedite development and review, such as priority review. A BLA for a drug candidate is eligible for priority review if the drug candidate is designed to treat a serious condition, and if approved would provide a significant
improvement in the treatment, diagnosis or prevention of a disease compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority review in an effort
to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of original BLAs under its current PDUFA review goals. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, depending on the design of the applicable clinical studies, a product may be eligible for accelerated approval. In particular, products studied for their
safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical
benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the
severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform
adequate and well-controlled confirmatory clinical studies and may require such confirmatory studies to be underway prior to granting any accelerated approval. Biologics receiving accelerated approval may be subject to expedited withdrawal
procedures if the sponsor fails to conduct the required confirmatory trials in a timely manner or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval <FONT
STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may submit sections of the BLA for review on a
rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. The breakthrough
therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same product if relevant criteria are met. If a product is designated as breakthrough therapy, FDA will expedite the
development and review of such product. Fast Track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan Drug Designation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant
orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the
United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation
must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any
advantage in, or shorten the duration of, the regulatory review or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">336 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which
it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the &#8220;same biologic,&#8221; as defined by the FDA, for the same
indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same
disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan
designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the
product to meet the needs of patients with the rare disease or condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. Patent Term Extension and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, a patent claiming a new biological product, its method of use or its method of manufacture may be eligible for a limited patent term extension
under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. The extension period is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time
between the effective date of the IND and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date, except that the review period is reduced by any time during which the applicant failed to
exercise due diligence. Patent term extension cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible
for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection
with one of the approvals. The United States Patent and Trademark Office (&#8220;USPTO&#8221;) reviews and approves the application for any patent term extension in consultation with the FDA. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Biosimilars and Exclusivity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Biologics Price Competition and
Innovation Act (&#8220;BPCIA&#8221;) amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars, as well as interchangeable biosimilars. A biosimilar is a biological product that is
highly similar to an already <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> biological product, called the &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically
meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the FDA must find that the
biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biosimilar product and the reference product may be switched without increasing safety risks or
risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product may rely in part on the
FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The
FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version
of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA
also created certain exclusivity periods for biosimilars approved as interchangeable products, which may be substituted by pharmacies for the reference product, subject to state pharmacy law. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pediatric Exclusivity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pediatric exclusivity is another type of <FONT
STYLE="white-space:nowrap">non-patent</FONT> exclusivity in the U.S. and, if granted for a biologic, provides for the attachment of an additional six months of marketing protection to the term of any existing patent term or <FONT
STYLE="white-space:nowrap">non-patent</FONT> regulatory exclusivity for all formulations, dosage forms and indications of the biologic, including orphan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">337 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
exclusivity and reference produce exclusivity. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a
&#8220;written request&#8221; from the FDA for such data, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining. The data do not need to show the product to be effective in the pediatric
population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of <FONT STYLE="white-space:nowrap">FDA-requested</FONT> pediatric trials are submitted to and
accepted by the FDA within the statutory time limits, any existing period of <FONT STYLE="white-space:nowrap">non-patent</FONT> regulatory exclusivity or patent protection covering the product is extended by six months. As applied to patent terms,
pediatric exclusivity is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application relying on the BLA sponsor&#8217;s data. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-Approval Regulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If regulatory approval for a product or new
indication for an existing product is obtained, the sponsor will be required to comply with all generally applicable post-approval regulatory requirements as well as any specific post-approval requirements that the FDA may impose as part of the
approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with advertising and promotional labeling requirements and
record-keeping requirements. Manufacturers and certain of their subcontractors must register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for
compliance with ongoing regulatory requirements, including cGMP regulations. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort to maintain compliance with cGMP regulations and other regulatory
requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if
problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a
REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of
product licenses; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product recall, seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings
or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of the product from the market; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription biological products placed on the market. This regulation includes, among
other things, standards and regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational
activities and promotional activities involving the internet and social media. Promotional claims about a product&#8217;s safety or effectiveness are prohibited before it is approved. After approval, a product generally may be promoted for uses or
patient populations consistent with the product&#8217;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe products for uses that are not approved by the FDA (sometimes called <FONT
STYLE="white-space:nowrap">&#8220;off-label</FONT> use&#8221;) because the FDA does not regulate the practice of medicine. However, FDA regulations restrict manufacturers&#8217; communications about <FONT STYLE="white-space:nowrap">off-label</FONT>
uses. Promotional materials for approved biological products generally must be submitted to the FDA in conjunction with their first use. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other U.S.
Healthcare Laws and Compliance Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, our activities are potentially subject to regulation by various federal, state and local
authorities in addition to the FDA, including but not limited to, the Centers for Medicare&nbsp;&amp; Medicaid Services (&#8220;CMS&#8221;), other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">338 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
divisions of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), for example, the Office of Inspector General, the U.S. Department of Justice (&#8220;DOJ&#8221;) and individual
U.S. Attorney offices within the DOJ, and state and local governments. For example, our business practices, including our research and any future sales, marketing and scientific/educational grant programs may be required to comply with federal
anti-kickback and fraud and abuse laws, the false claims laws, the data privacy and security provisions of the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;), federal transparency requirements and similar state laws, each
as amended. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or
receiving any remuneration, including any kickback, bribe or rebate, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for, either the referral of an individual for, or the purchasing, leasing, ordering or
arranging for the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The
federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Additionally, a person or entity does not need to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Rather, if &#8220;one purpose&#8221; of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. There are a
number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that involve
remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable
statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti- Kickback Statute. Instead, the legality of the arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe
harbor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have knowingly
presented or caused to be presented a false or fraudulent claim to, among others, a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal civil False Claims Act (&#8220;FCA&#8221;) prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a
false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government in order to avoid, decrease or
conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the federal
government. Pharmaceutical and other healthcare companies are being investigated or, in the past, have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers
would bill federal programs for the product. In addition, pharmaceutical and other healthcare companies also have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and
thus <FONT STYLE="white-space:nowrap">non-reimbursable</FONT> uses. Moreover, a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud or to
obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully
falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to
the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. For example, HIPAA, as
amended by the Health Information Technology for Economic and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">339 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their implementing regulations, imposes requirements on certain types of individuals and entities, including covered entities, for example,
certain healthcare providers, health plans and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity and their
subcontractors that use, disclose, access, or otherwise process individually identifiable protected health information, relating to the privacy, security and transmission of individually identifiable health information. In addition, state laws
govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Physician Payments Sunshine Act and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for
which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, annually report information to CMS related to certain payments or other transfers of value made or distributed to
physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioners (physician assistants, nurse practitioners, clinical nurse specialists,
certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to
report annually certain ownership and investment interests held by physicians and their immediate family members. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also, many states have similar fraud and abuse
statutes or regulations similar to the aforementioned federal laws that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. In order to manufacture or distribute
products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship
products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution,
including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states and local jurisdictions have enacted legislation requiring
pharmaceutical and biotechnology companies to establish marketing compliance programs and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government,
file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities
from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and
state consumer protection and unfair competition laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our operations are found to be in violation of any of the federal and state healthcare laws described
above or any other governmental regulations that apply to us, we may be subject to significant penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from
participation in government programs, such as Medicare and Medicaid, injunctions, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become
subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations, any of which could adversely
affect our ability to operate our business and our results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Data Privacy and Security Laws </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and
share (collectively, &#8220;process&#8221;) personal data (including health- related information) and other sensitive information, including proprietary and confidential business information and information we collect about trial participants in
connection with clinical trials (collectively, &#8220;sensitive information&#8221;). Accordingly, we are subject to numerous state, federal and foreign laws and regulations; contractual obligations; industry standards; policies and other obligations
related to data privacy and security. For example, in the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws govern the
processing of sensitive information and these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">340 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
laws are increasingly stringent and reflect the evolving regulatory frameworks related to personal data processing that increase our compliance obligations and exposure for any actual or
perceived noncompliance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, certain foreign laws also govern the privacy, security and processing of sensitive information and apply to our operations.
For example, China has enacted the Personal Information Protection Law (the &#8220;PIPL&#8221;), Data Security Law (the &#8220;DSL&#8221;), the Cybersecurity Law (the &#8220;CSL&#8221;) and other implementing regulations to govern data privacy and
security. The PIPL took effect on November&nbsp;1, 2021 and creates a comprehensive data protection framework that applies to the processing of personal information both in China and outside of China where such processing is for purposes of
providing products and services to, or analyzing and evaluating the behavior of, individuals in China. Under the PIPL, entities conducting cross-border transfers of personal information are required to meet certain conditions, including satisfaction
of the security assessments conducted by competent government authority, signing and filing of standard contracts or obtaining certifications from qualified institutions, and fulfillment of notice and consent requirements. The DSL came into effect
on September&nbsp;1, 2021 and mandates entities processing &#8220;important data&#8221; to comply with specific data security obligations. The CSL, enacted in November 2016 and revised on October&nbsp;28, 2025, with the amendment taking effect on
January&nbsp;1, 2026, requires network operators to follow the principles of legality, legitimacy, and necessity when collecting and using personal information, to publicly disclose rules governing such collection and use, to clearly specify the
purpose, method, and the scope of the collection and use, and to obtain the consent of the individuals whose personal information is collected and used. Further, certain industry-specific Chinese laws and regulations apply to the collection and
processing of trial participants&#8217; data and human genetic resources, such as China&#8217;s Biosecurity Law and Regulations on the Administration of Human Genetic Resources. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Data privacy and security laws, regulations and other obligations are constantly evolving, may conflict with each other, increase our compliance efforts and can result
in investigations, proceedings, actions or other adverse consequences including those that involve significant civil and/or criminal penalties and restrictions on data processing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Coverage, Pricing and Reimbursement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Significant uncertainty exists
as to the coverage and reimbursement status of any drug candidates for which we obtain regulatory approval. In the United States and certain markets in other countries, sales of any products for which we receive regulatory approval for commercial
sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. No uniform policy for coverage and reimbursement exists in the United States, and coverage and
reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United
States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be
separate from the process for setting the price of a product or from establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a
formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the
cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of
our products, in addition to the costs required to obtain the FDA approvals. Our drug candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to
enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, any companion diagnostic test that we develop will be required to obtain coverage and reimbursement separate and
apart from the coverage and reimbursement we seek for our drug candidates, if approved. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, the United States government and foreign governments have
continued implementing cost-containment measures. For example, HHS imposes rebates on many Medicare Part B and Medicare Part D products to penalize price increases that outpace inflation on an annual basis. HHS has also been empowered to negotiate
the price of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">341 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
certain single-source biologics that have been on the market for at least eleven (11)&nbsp;years covered under Medicare as part of the Medicare Drug Price Negotiation Program. Each year up to
twenty (20)&nbsp;products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare
program on a per unit basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The marketability of any drug candidates for which we receive regulatory approval for commercial sale may suffer if the government and
third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and
third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may
be implemented in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare Reform </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United
States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug candidates, restrict
or regulate post-approval activities, and affect the ability to profitably sell drug candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting
changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly
affected by major legislative initiatives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation
Act (the &#8220;Affordable Care Act&#8221;) has substantially changed healthcare financing and delivery by both governmental and private insurers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since its
enactment, there have been executive, judicial and political challenges to certain aspects of the Affordable Care Act. For example, on July&nbsp;4, 2025, the One Big Beautiful Bill Act (the &#8220;OBBBA&#8221;) was signed into law, which narrowed
access to Affordable Care Act marketplace exchange enrollment and declined to extend the Affordable Care Act enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce
the number of Americans with health insurance. The OBBBA also is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting
provider taxes used to fund the program. Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired Affordable Care Act subsidies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted, including aggregate reductions to Medicare payments to providers,
which went into effect beginning on April&nbsp;1, 2013, and, due to subsequent legislative amendments to the statute will stay in effect through 2032, unless additional Congressional action is taken. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The current administration is pursuing policies to reduce regulations and expenditures across government agencies including at HHS, the FDA, CMS and related agencies.
These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. For example, the current administration has announced
agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> platform (TrumpRx) U.S. patients and Medicaid
programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-patient</FONT></FONT>
discounts and repatriation of foreign revenues. Other recent actions, for example, include (1)&nbsp;directing agencies to reduce agency workforce and cut programs; (2)&nbsp;directing HHS and other agencies to lower prescription drug costs through a
variety of initiatives; (3)&nbsp;imposing tariffs on imported pharmaceutical products; and (4)&nbsp;as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to
increase enforcement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> pharmaceutical advertising. Additionally, the current administration recently called on Congress to enact &#8220;The Great
Healthcare Plan,&#8221; to codify and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">342 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
pharmaceutical drugs available for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> purchase, and enact restrictions on pharmacy benefit manager
payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and
compliance risks. In June 2024, the U.S. Supreme Court&#8217;s Loper Bright decision greatly reduced judicial deference to regulatory agencies, which could increase successful legal challenges to federal regulations affecting our operations.
Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additional state and federal healthcare reform measures likely will be adopted in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Foreign Corrupt Practices Act </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Foreign Corrupt Practices Act
(&#8220;FCPA&#8221;), prohibits any U.S. individual, business, or its representatives and agents, from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or
candidate for the purpose of influencing any act or decision of a foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to
comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of
internal accounting controls for international operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Regulation </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the
Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by,
our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable
environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Europe / Rest of World Government Regulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to
regulations in the United States, we will be subject to a variety of regulations in other jurisdictions. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior
to the commencement of human clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements
governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the
ethical principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or our potential collaborators fail to comply with applicable foreign regulatory
requirements, we may be subject to, among other things, fines, suspension, variation or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Trials in the EU </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly to the United States, the
various phases of <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research in the EU are subject to significant regulatory controls. In the EU, clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014
(&#8220;CTR&#8221;), which entered into application on January&nbsp;31, 2022 repealing and replacing the CTD. The CTR foresaw a three-year transition period that ended on January&nbsp;31, 2025. Since this date, all new or ongoing trials are subject
to the provisions of the CTR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">343 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting
procedures, improve the supervision of clinical trials and increase transparency. Specifically, the Regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the
&#8220;EU portal&#8221;, the Clinical Trials Information System (&#8220;CTIS&#8221;); a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized
procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Part I assessment is led by the competent
authorities of a reference EU Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent
authorities of all concerned EU Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States
retain the power to authorize the conduct of clinical trials on their territory. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In all cases, clinical trials must be conducted in accordance with GCP and the
applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Medicines used in clinical trials, must be manufactured in accordance with the guidelines on cGMP and in a GMP licensed facility,
which can be subject to GMP inspections. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>EU Review and Approval Process of Medicinal Products </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, medicinal products can only be commercialized after a related marketing authorization (&#8220;MA&#8221;) has been granted. To obtain an MA for a product in
the EU, an applicant must submit a Marketing Authorization Application (&#8220;MAA&#8221;) either under a centralized procedure administered by the European Medicines Agency (&#8220;EMA&#8221;), or one of the procedures administered by the competent
authorities of EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EU. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The centralized procedure provides for the grant of a single MA by the European Commission that is valid throughout the EEA (which is comprised of the 27 EU Member
States plus Norway, Iceland and Liechtenstein). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i)&nbsp;medicinal products derived from biotechnological processes,
(ii)&nbsp;products designated as orphan medicinal products, (iii)&nbsp;advanced therapy medicinal products (&#8220;ATMPs&#8221;) and (iv)&nbsp;products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative
diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in
the interest of patients, authorization through the centralized procedure is optional on related approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the centralized procedure, the EMA&#8217;s
Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) conducts the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or
extensions to an existing MA. The maximum timeframe for the evaluation of an MAA under the centralized procedure is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in
response to questions of the CHMP. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and, in
particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the standard time
limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unlike the centralized authorization
procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the
application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application.
The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment
report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">344 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures&#8212; Human (&#8220;CMDh&#8221;) for review. If the CMDh fails to reach a consensus,
the matter escalates to the European Commission whose decision is binding on all EU Member States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The mutual recognition procedure allows companies that have a
medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the
acceptance by the competent authorities of the EU Member States of the MA of a medicinal product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member
State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An MA has, in principle, an initial validity
of five years. The MA may be renewed after five years on the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was
granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the Common Technical Document providing
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the
MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide on justified grounds relating to pharmacovigilance, to proceed with one further five-year renewal period for the MA. Once subsequently
definitively renewed, the MA shall be valid for an unlimited period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any authorization which is not followed by the actual placing of the medicinal product on the
EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> sunset clause). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Accelerated and Alternative Marketing Authorization Mechanisms </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Innovative
products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines (&#8220;PRIME&#8221;) scheme, which provides
incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target
conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the
potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of drug candidates with PRIME designation, including but not limited to, early and proactive regulatory
dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. A dedicated contact and rapporteur from the EMA&#8217;s
Committee for Human Medicinal Products, or CHMP, are appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. A <FONT STYLE="white-space:nowrap">kick-off</FONT> meeting initiates these
relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support
under the PRIME scheme may be withdrawn. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not
yet available. The European Commission may grant a conditional MA for a medicinal product if it is demonstrated that all of the following criteria are met: (i)&nbsp;the benefit-risk balance of the medicinal product is positive; (ii)&nbsp;it is
likely that the applicant will be able to provide comprehensive data post-authorization; (iii)&nbsp;the medicinal product fulfils an unmet medical need; and (iv)&nbsp;the benefit of the immediate availability to patients of the medicinal product is
greater than the risk inherent in the fact that additional data are still required. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must
be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA
and approved by the European Commission, the MA will cease to be renewed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An MA may also be granted &#8220;under exceptional circumstances&#8221; where the
applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">345 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge
at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal
products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for
authorization in exceptional circumstances is not subsequently required to provide the missing data. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although the MA &#8220;under exceptional circumstances&#8221;
is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA will be withdrawn if the risk-benefit ratio is no longer favorable. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pediatric Development in the EU </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, Regulation (EC)
No.&nbsp;1901/2006 provides that all MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan (&#8220;PIP&#8221;), agreed with the EMA&#8217;s
Pediatric Committee (&#8220;PDCO&#8221;). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to
implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO
when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent
a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a <FONT
STYLE="white-space:nowrap">six-month</FONT> extension to the Supplementary Protection Certificate (&#8220;SPC&#8221;), if any is in effect at the time of authorization or, in the case of orphan medicinal products, a
<FONT STYLE="white-space:nowrap">two-year</FONT> extension of orphan market exclusivity. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Manufacturing Regulation in the EU </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to an MA, various other requirements apply to the manufacturing and placing on the EU market of medicinal products. The manufacturing of medicinal products
in the EU requires a manufacturing authorization and import of medicinal products into the EU requires a manufacturing authorization allowing for import. The manufacturing authorization holder must comply with various requirements set out in the
applicable EU laws, regulations and guidance, including EU cGMP standards. Similarly, the distribution of medicinal products within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to
hold appropriate authorizations for distribution granted by the competent authorities of EU Member States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MA holders and/or manufacturing and import
authorization, or MA holders and/or distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with the EU or EU Member States&#8217; requirements applicable to the manufacturing of medicinal products. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Data and Market Exclusivity in the EU </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EU provides opportunities
for data and market exclusivity related to MAs. Upon receiving an MA, innovative medicinal products are generally entitled to receive eight years of data exclusivity and ten years of market exclusivity. Data exclusivity, if granted, prevents
regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar MAA
can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial MA of
the reference product in the EU. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the MA holder
obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no
guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity and products may not qualify for data exclusivity. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the
definition of a generic medicinal product. For such products, the results </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">346 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of appropriate preclinical or clinical trials must be provided in support of an application for MA. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for
different types of biological product. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan Designation in the EU </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, Regulation (EC) No.&nbsp;141/2000, as implemented by Regulation (EC) No.&nbsp;847/2000 provides that a medicinal product can be designated as an orphan
medicinal product by the European Commission if its sponsor can establish that: (i)&nbsp;the product is intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (ii)&nbsp;either (a) such
conditions affect not more than five in 10,000 persons in the EU when the application is made, or (b)&nbsp;the product without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary
investment in developing the medicinal product; and (iii)&nbsp;there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will
be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulation (EC) No.&nbsp;847/2000 sets out further provisions for implementation of the criteria for
designation of a medicinal product as an orphan medicinal product. An application for the designation of a medicinal product as an orphan medicinal product must be submitted at any stage of development of the medicinal product but before filing of
an MAA. An MA for an orphan medicinal product may only include indications designated as orphan. For <FONT STYLE="white-space:nowrap">non-orphan</FONT> indications treated with the same active pharmaceutical ingredient, a separate MA has to be
sought. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan medicinal product designation entitles an applicant to incentives such fee reductions or fee waivers, protocol assistance and access to the
centralized MA procedure. Upon grant of an MA, orphan medicinal products are entitled to a <FONT STYLE="white-space:nowrap">ten-year</FONT> period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept
another MAA or accept an application to extend for a similar product and the European Commission cannot grant a MA for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal
products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage
in, or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The period of market exclusivity may, however, be reduced to six years if, at the end
of the fifth year, it is established that the product no longer meets the criteria on the basis of which it received orphan medicinal product destination, including where it can be demonstrated on the basis of available evidence that the original
orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, an MA may be granted to a similar medicinal product with
the same orphan indication during the <FONT STYLE="white-space:nowrap">ten-year</FONT> period if: (i)&nbsp;if the applicant consents to a second original orphan medicinal product application, (ii)&nbsp;if the manufacturer of the original orphan
medicinal product is unable to supply sufficient quantities; or (iii)&nbsp;if the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior to the original orphan medicinal product.
A company may voluntarily remove a product from the register of orphan products. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-authorization Requirements in the EU </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory requirements applicable to
the manufacturing, marketing, promotion and sale of medicinal products. Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission
and/or the competent regulatory authorities of the individual EU Member States. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for
oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (&#8220;PSURs&#8221;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All new MAAs must include a risk management plan describing the risk management system that the company will put in place and documenting measures to prevent or
minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring,
more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">347 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pricing, Coverage and Reimbursement in the EU </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, pricing and reimbursement schemes vary widely from country to country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, some EU Member States may restrict the range of products for which their national health insurance systems provide reimbursement. Other countries may
control the prices of medicinal products for human use or allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Such pricing negotiations with
governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, EU Member States often require the completion of additional health technology assessments that compare the cost- effectiveness of a particular product
candidate to currently available therapies. This Health Technology Assessment (&#8220;HTA&#8221;) process is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use
of a given medicinal product in the national healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal
products by the competent authorities of individual EU Member States. At the EU level, on January&nbsp;12, 2025, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA Regulation&#8221;), entered into application through a phased
implementation. The Regulation initially applies to new active substances for oncology and ATMPs. It will be expanded to orphan medicinal products in January 2028, and to all centrally authorized medicinal products as of 2030. Select high-risk
medical devices also came into scope in 2026. The HTA Regulation is intended to boost cooperation among Member States in assessing health technologies, including new medicinal products. The Regulation establishes a framework for <FONT
STYLE="white-space:nowrap">EU-level</FONT> joint clinical assessments, joint scientific consultations, and the early identification of emerging health technologies. The Regulation permits EU Member States to use common tools, methodologies, and
procedures and requires them to rely on <FONT STYLE="white-space:nowrap">EU-level</FONT> joint clinical assessment reports for the clinical components of their national HTA evaluations. Individual EU Member States will continue to be responsible for
assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Compliance Requirements in the EU </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, the advertising
and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair
commercial practices. General requirements for advertising and promotion of medicinal products, such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising of prescription medicinal products
are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to
medicinal products comply with the product&#8217;s Summary of Product Characteristic (&#8220;SmPC&#8221;), which may require approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information
to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered <FONT STYLE="white-space:nowrap">off-label</FONT> and is prohibited in the EU. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Much like the Anti-Kickback Statute prohibition in the United States, as described below, the provision of benefits or advantages to physicians and other health care
professionals to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. Interactions between pharmaceutical companies and health care professionals are
governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these
requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. Infringement of related laws could result in substantial fines and imprisonment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments made to physicians and other health care professionals in certain EU Member States must be publicly disclosed. Moreover, agreements with health care
professionals may require prior notification or approval by the health care professional&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. Failure to comply with
these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">348 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our principal
executive offices are located in San Diego, California, where we lease 8,355 square feet of office space pursuant to a lease agreement that expires in September 2028 with an option to extend the lease for an additional two years. We also lease 5,748
square feet of office space in Shanghai, China pursuant to a lease agreement that expires in January 2029. We believe our existing facilities meet our current needs. We will need additional space in the future as we continue to build our
development, commercial and support teams. We believe we can find suitable additional space in the future on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and Human
Capital Resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had 48 employees, 40 of whom were primarily engaged in research and development activities. None of our
employees are represented by a labor union or party to a collective bargaining agreement. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our human
capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate
selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are not currently a party to any legal proceedings. From time to time, we may, however, in the ordinary course of business face various claims brought by
third parties, and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our products. Any of these
claims could subject us to costly litigation, and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid
claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our business, financial condition, results of operations
and prospects. Additionally, any such claims, whether or not successful, could damage our reputation and business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">349 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_23"></A>RALLYBIO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The
following discussion and analysis of Rallybio&#8217;s financial condition and results of operations should be read together with Rallybio&#8217;s consolidated financial statements for the years ended December&nbsp;31, 2025 and 2024, and the related
notes appearing elsewhere in this proxy statement/prospectus. This discussion and other parts of this proxy statement/prospectus contain forward-looking statements that involve risks and uncertainties, such as statements regarding Rallybio&#8217;s
plans, objectives, expectations, intentions and projections. Rallybio&#8217;s actual results could differ materially from those described in or implied by these forward-looking statements. Factors that could cause or contribute to such differences
include, but are not limited to, those discussed in the &#8220;Risk Factors&#8221; section of this proxy statement/prospectus. </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unless otherwise indicated or
the context otherwise requires, references in this section to &#8220;Rallybio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Rallybio and its subsidiaries. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company comprised of
experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Our lead program, RLYB116, is
a differentiated complement C5 inhibitor with the potential to treat diseases of complement dysregulation. In addition, RLYB332, a long-acting <FONT STYLE="white-space:nowrap">MTP-2</FONT> antibody for the treatment of diseases of iron overload is
currently in preclinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Developments </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
March&nbsp;1, 2026, we entered into the Merger Agreement with Candid, a clinical-stage biotechnology company advancing a leading portfolio of TCE therapeutics for autoimmune diseases, and Merger Sub, a wholly owned subsidiary of Rallybio. Upon the
terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio (the &#8220;Merger&#8221; and, together with
all of the other Contemplated Transactions. The Merger is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution and delivery of the Merger Agreement, certain investors entered into a Subscription Agreement with Candid, pursuant to which such
investors have agreed to purchase, immediately prior to the Merger, shares of Candid Common Stock representing an aggregate commitment of approximately $505.5 million in the Concurrent Financing. The shares of Candid Common Stock that are issued in
the Concurrent Financing will be or will have the right to be, respectively, converted into shares of Rallybio Common Stock in the Merger. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and
conditions of the Merger Agreement, at the Effective Time, (a)&nbsp;each then-outstanding share of common stock or preferred stock of Candid (each such share, a &#8220;Candid Share&#8221;) (excluding any share described in clauses (b)&nbsp;or (c)
below and Candid Capital Stock held by stockholders who have exercised and perfected appraisal rights for such shares) will be converted into the right to receive a number of shares of Rallybio Common Stock, calculated in accordance with the
Exchange Ratio as set forth in the Merger Agreement, (b)&nbsp;each Candid Share issued in the Concurrent Financing will be converted into the right to receive a number of shares of Rallybio Common Stock calculated in accordance with the Merger
Agreement, (c)&nbsp;any Candid Capital Stock held as treasury shares or held or owned by Rallybio, Merger Sub or any subsidiary of Rallybio or Candid immediately prior to the Effective Time will be canceled and shall cease to exist, and no
consideration shall be delivered in exchange therefor. Each then-outstanding option to purchase Candid Capital Stock will be converted into an option to purchase Rallybio Common Stock, subject to adjustment as set forth in the Merger Agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the Closing, on a pro forma basis and based upon
the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, pre-Merger equityholders of Candid (other than investors in the Concurrent Financing) are expected to own approximately 57.55% of the combined
company, pre-Merger equityholders of Rallybio are expected to own approximately 3.65% of the combined company and the investors in the Concurrent Financing are expected to own approximately 38.80% of the combined company (assuming proceeds
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">350 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
from the Concurrent Financing of $505.5&nbsp;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i) a
valuation for Rallybio of $47.5&nbsp;million (assuming Rallybio Net Cash of $37.5&nbsp;million as of the Closing), (ii) a fixed valuation for Candid of $750.0&nbsp;million, and (iii) the relative capitalization of Rallybio and Candid. The percentage
of the combined company that each party&#8217;s equityholders will own following the Closing is subject to certain adjustments, including the amount of the final Rallybio Net Cash at the Closing. Rallybio Net Cash as calculated under the Merger
Agreement makes certain adjustments to the value of Rallybio&#8217;s Cash and Cash Equivalents (as defined in the Merger Agreement), and was equal to approximately $39.47&nbsp;million as of December&nbsp;31, 2025. The adjustments are described in
the section titled &#8220;<I>The Merger Agreement</I>&#8212;<I>Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; Based on its Cash and Cash Equivalents and other balance sheet line items as of December&nbsp;31, 2025 and current estimates of the
other elements of Rallybio Net Cash (including projected adjustments to Rallybio&#8217;s Cash and Cash Equivalents), Rallybio calculates that it had Rallybio Net Cash of approximately $35.81&nbsp;million as of April&nbsp;15, 2026. Rallybio expects
to continue to incur losses in future periods primarily related to the proposed Merger and, as a result, available Cash and Cash Equivalents will continue to decrease. For a description of the calculation of Rallybio Net Cash as set forth in the
Merger Agreement, please see the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior to
the Effective Time, Rallybio and a rights agent are expected to enter into a CVR Agreement, pursuant to which holders of record of certain Rallybio securities as of the close of business on the last business day prior to the day on which the
Effective Time occurs will receive one CVR for each outstanding share of Rallybio Common Stock, prefunded warrant, Rallybio restricted stock unit or In the Money Parent Option (as defined in the CVR Agreement) held as of such date. Pursuant to the
CVR Agreement, each CVR holder will be entitled to receive their pro rata share of (i)&nbsp;all of the net proceeds (including cash the value of stock to the extent listed on a national exchange, at the time of disposition), if any, received by
Rallybio as a result of payments made to Rallybio of any upfront, milestone, royalty and other payments received under any disposition agreement related to Rallybio&#8217;s Legacy Assets, and (ii)&nbsp;any cash proceeds received from Recursion under
the Membership Interest Purchase Agreement, dated July&nbsp;8, 2025, by and among Recursion, Exscientia Ventures I, Inc., Rallybio Corporation and Rallybio IPB, LLC. For a period of one year after the Closing Date, Rallybio will use commercially
reasonable efforts to effect the disposition of the Legacy Assets. Such net proceeds will be subject to certain permitted deductions, including for applicable tax payments, certain expenses incurred or other liabilities borne by Rallybio or its
affiliates in respect of the Legacy Assets, and losses incurred by Rallybio or its affiliates due to a third-party proceeding in connection with such disposition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We completed a confirmatory PK and PD study of RLYB116 in healthy volunteers in 2025 and reported data in the first quarter of 2026. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2025, we entered into a Membership Interest Purchase Agreement (the &#8220;ENPP1 Purchase Agreement&#8221;) with Recursion Exscientia Ventures I, Inc., an
indirect wholly-owned subsidiary of Recursion (&#8220;Buyer&#8221;) and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio Corporation to sell our interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients
with HPP, to Buyer (a subsidiary of our joint venture partner Recursion) (the &#8220;JV Sale&#8221;). In connection with the JV Sale, we received a total of $20.0&nbsp;million in the third quarter of 2025 including $7.5&nbsp;million from an upfront
payment and $12.5&nbsp;million from a milestone payment related to the initiation of additional preclinical studies. We are eligible to receive a $5.0&nbsp;million milestone payment in connection with the initiation of dosing in a Phase 1 clinical
study, as defined in the ENPP1 Purchase Agreement and low single-digit royalties on all future net sales by Recursion of products comprising or incorporating certain compounds developed by <FONT STYLE="white-space:nowrap">REV-I.</FONT> We may also
be eligible to receive certain payments in the event of Recursion&#8217;s sale of the REV102 program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2025, we announced the discontinuation of our
RLYB212 program for the prevention of FNAIT based on PK data from the Phase 2 clinical trial that demonstrated an inability of the RLYB212 dose regimen to achieve predicted target concentrations, as well as the minimum target concentration required
for efficacy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><U>Complement Dysregulation</U> </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB116 is an
innovative, once-weekly, small volume, subcutaneously injected inhibitor of C5 in development for the treatment of patients with complement-related diseases. We have completed two Phase 1 clinical trials in healthy participants that included the
study of RLYB116 as both a SAD and a MAD. After the first Phase 1 clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">351 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
trial, we completed manufacturing process enhancements that were designed to improve the tolerability of RLYB116. In 2025, we completed the confirmatory Phase 1 clinical trial evaluating the
PK/PD properties of RLYB116. The confirmatory trial achieved its two key objectives including: a significant improvement in the tolerability of RLYB116 and demonstration of complete and sustained inhibition of terminal complement. These results
support the study of RLYB116 as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutic for multiple complement mediated diseases. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><U>Hematological Disorders</U> </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2022, we obtained worldwide exclusive
rights to RLYB331, a preclinical, monoclonal antibody that is designed to inhibit <FONT STYLE="white-space:nowrap">MTP-2.</FONT> The inhibition of <FONT STYLE="white-space:nowrap">MTP-2</FONT> significantly increases levels of hepcidin, decreases
iron load and treats ineffective erythropoiesis. In 2024, we <FONT STYLE="white-space:nowrap">re-engineered</FONT> RLYB331 to extend its half-life and completed <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies that demonstrated favorable
tolerability, dose-dependent PK, and sustained PD effects with RLYB332, a long-acting version of RLYB331. These findings, which were presented in a poster at the 66th annual meeting of the ASH, support the continued development of RLYB332 as a
potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutic for treating diseases of iron overload. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
December 2022, we entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration combined AbCellera Biologics Inc.&#8217;s
(&#8220;AbCellera&#8217;s&#8221;) antibody discovery engine with our clinical and commercial expertise in rare diseases to identify optimal clinical candidates with a goal of delivering therapies to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since inception, we have devoted substantially all of our
resources to raising capital, organizing and staffing the Company, business planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio,
developing and progressing our product candidates, preparing for and conducting clinical trials and establishing arrangements with third parties for the manufacture of our product candidates and component materials, including activities relating to
our preclinical development and manufacturing activities for each of our programs. We do not have any product candidates approved for sale and have not generated any revenue from product sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have funded our operations primarily through equity financings. From our inception and prior to our initial public offering (&#8220;IPO&#8221;),
we received proceeds of approximately $182.5&nbsp;million from equity financings. In August 2021, we closed our IPO and issued and sold 891,250 shares of common stock, inclusive of 116,250 shares sold pursuant to the full exercise of the
underwriters&#8217; option to purchase additional shares, at a public offering price of $104.00 per share. We received net proceeds of approximately $83.0&nbsp;million, after deducting underwriting discounts and commissions and other offering costs.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2022, we completed a <FONT STYLE="white-space:nowrap">follow-on</FONT> offering of approximately $54.8&nbsp;million pursuant to which we issued 725,456
shares of common stock, inclusive of 100,456 shares of common stock sold pursuant to the partial exercise of the underwriters&#8217; option to purchase additional shares at a price of $48.00 per share and to certain investors in lieu of common
stock, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase up to an aggregate of 416,673 shares of common stock at a price of $47.9992, which represents the per share public offering price for the shares less the $0.0008 per
share exercise price for each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. The net proceeds from the November 2022 <FONT STYLE="white-space:nowrap">follow-on</FONT> offering were approximately $50.8&nbsp;million, after deducting
underwriting discounts and commissions and other offering costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2024, we entered into a securities purchase agreement (the &#8220;JJDC Securities
Purchase Agreement&#8221;) with Johnson&nbsp;&amp; Johnson Innovation&#8212;JJDC, Inc. (&#8220;JJDC&#8221;), pursuant to which we sold to JJDC, in an unregistered offering, 454,545 shares of our common stock at a price of $14.56 per share, which
represented a 10% premium on our closing stock price on April&nbsp;9, 2024, for aggregate gross proceeds of approximately $6.6&nbsp;million, before deducting offering expenses. We agreed, among other things, to file with the SEC a registration
statement covering the resale of the shares, which we filed on May&nbsp;10, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">352 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2025, we announced that we had entered into the ENPP1 Purchase Agreement to sell our interest in REV102, an
ENPP1 inhibitor in preclinical development for the treatment of patients with HPP, to Buyer (a subsidiary of our joint venture partner Recursion). In connection with the JV Sale, we received a total of $20.0&nbsp;million in the third quarter of 2025
including $7.5&nbsp;million from an upfront payment and $12.5&nbsp;million from a milestone payment related to the initiation of additional preclinical studies. We are eligible to receive a $5.0&nbsp;million milestone cash payment in connection with
the initiation of dosing in a Phase 1 clinical study, as defined in the ENPP1 Purchase Agreement and low single-digit royalties on all future net sales by Recursion of products comprising or incorporating certain compounds developed by <FONT
STYLE="white-space:nowrap">REV-I.</FONT> We may also be eligible to receive certain payments in the event of Recursion&#8217;s sale of the REV102 program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
December&nbsp;31, 2025, we had cash, cash equivalents and marketable securities of $54.7&nbsp;million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital
expenditure requirements into 2028, although we anticipate that the proposed merger with Candid will be completed in 2026. See &#8220;&#8212;<I>Liquidity and Capital Resources</I>.&#8221; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred significant operating losses since inception, including net losses of $9.0&nbsp;million and $57.8&nbsp;million for the years ended December&nbsp;31,
2025 and 2024, respectively. Our loss for the year ended December&nbsp;31, 2025 included a $23.0&nbsp;million gain in connection with the JV Sale in 2025. As of December&nbsp;31, 2025, we had an accumulated deficit of $302.0&nbsp;million. These
losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We have not commercialized any products and have never generated revenue
from the commercialization of any product. If we are unable to complete the proposed transaction with Candid, we may need to raise additional capital. There can be no assurances, however, that additional funding will be available on terms acceptable
to us, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have any product candidates approved for sale and have not generated any revenue from product sales. In April 2024, we entered into a <FONT
STYLE="white-space:nowrap">two-year</FONT> collaboration agreement (the &#8220;J&amp;J Collaboration Agreement&#8221;) with Johnson&nbsp;&amp; Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. (&#8220;J&amp;J&#8221;). Our
collaboration and license revenue to date is related to data collection and data submission performance obligations pursuant to the <FONT STYLE="white-space:nowrap">two-year</FONT> J&amp;J Collaboration Agreement to facilitate the advancement of
research into products to address unmet needs relating to FNAIT. Pursuant to the J&amp;J Collaboration Agreement, we received an upfront payment of $0.5&nbsp;million from J&amp;J for the information dissemination and data provision services under
the agreement. We were also eligible to receive additional payments upon certain triggers related to the companies&#8217; FNAIT studies, however, in connection with our decision in April 2025 to discontinue development of RLYB212, we do not expect
payments regarding the achievement of certain enrollment-related events. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We determined there were performance obligations as follows: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(1) Data collection and submission revenue &#8211; derived from Rallybio&#8217;s ongoing management of the studies including the maintenance of a minimum site
footprint, the license to utilize, and timely, semi-annual submission of the anonymized data, in the required formats. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(2) Dissemination of J&amp;J
materials&nbsp;&amp; participant revenue &#8211; derived from Rallybio&#8217;s dissemination of content, information or materials related to the <FONT STYLE="white-space:nowrap">J&amp;J-Sponsored</FONT> Studies that are developed by J&amp;J and are
provided by Rallybio for the purpose of disseminating such content, information, or materials to staff at Rallybio study sites to provide to potential eligible participants regarding J&amp;J&#8217;s independent study. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2024, we also entered into the JJDC Securities Purchase Agreement. Under the terms of the JJDC Securities Purchase Agreement, JJDC made an equity investment
purchasing 454,545 shares of common stock with a par value of $0.0001 per share for a share purchase price of $14.56 per share which includes a 10% premium for an aggregate purchase price of $6.6&nbsp;million. The JJDC Securities Purchase Agreement
contains provisions related to the registration of the shares and the restriction on the sale or transfer of the shares for a period of time. We determined the J&amp;J Collaboration Agreement and JJDC Securities Purchase Agreement represented
combined agreements. In accordance with Accounting Standards Codification 606, <I>Revenue Recognition</I> and Accounting Standards </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">353 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Codification Topic 820, <I>Fair Value Measurement</I>, total consideration of $1.2&nbsp;million for the shares of common stock from the JJDC Securities Purchase Agreement, which represents the
premium of $0.7&nbsp;million and discount for lack of marketability of $0.5&nbsp;million, has been allocated to revenue and will be recognized over the two year expected performance period. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses consist of costs incurred in connection with our research and development activities, including our drug discovery efforts and the
development of our product candidates. We expense research and development costs as incurred, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">external research and development expenses incurred under agreements with third parties, such as contract research
organizations (&#8220;CROs&#8221;) as well as investigative sites and consultants that conduct our clinical trials and other scientific development services; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to manufacturing material for our clinical trials, including expenses related to the manufacturing <FONT
STYLE="white-space:nowrap">scale-up</FONT> and fees paid to contract manufacturing organizations (&#8220;CMOs&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">employee-related expenses, including salaries, bonuses, benefits, share-based compensation and other related costs for
those employees involved in research and development efforts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs of outside consultants, including their fees, and related travel expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expenses to acquire technologies, such as intellectual property, to be used in research and development including <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development (&#8220;IPR&amp;D&#8221;) that has no alternative future use at the time of asset acquisitions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to compliance with quality and regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">facilities, depreciation and other indirect costs allocated to employees and activities supporting our research and
development efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Costs for certain activities are recognized based on an evaluation of the progress to completion of each specific contract
using information and data provided to us by our vendors and analyzing the progress of our research studies or other services performed. Significant judgments and estimates are made in determining the expenses incurred at the end of any reporting
period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our direct, external research and development expenses consist primarily of fees paid to outside consultants, CROs, CMOs and research laboratories in
connection with our process development, manufacturing and clinical development activities. Our direct external research and development expenses also include fees incurred under license and intellectual property purchase agreements. We track these
external research and development costs on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not
allocate employee costs, facility costs, including depreciation, or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources and
third-party consultants primarily to conduct our research and development activities as well as for managing our process development, manufacturing and clinical development activities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The successful development of any product candidate is highly uncertain. If we are unable to complete the proposed transaction with Candid, we will need to raise
substantial additional capital in the future to fund the future development of our current programs. We intend to focus our near term research and development efforts on completing the ongoing activities and preparing our programs for a potential
transaction or sale. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and
administrative expenses consist primarily of salaries, benefits and share-based compensation for our personnel in executive, legal, business development, finance and accounting, and other administrative functions. General and administrative expenses
also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, tax and consulting services, insurance costs, travel expenses and direct and allocated facility costs not otherwise
included in research and development expenses. We expect our general and administrative expenses to increase in the short term in connection with activities to support the completion of the potential transaction with Candid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">354 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Total Other Income, Net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total other income, net, includes interest income earned on cash, cash equivalents and marketable securities, and income and expense items, including income related to
the proceeds from the JV Sale. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Loss on Investment in Joint Venture </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
recognize the <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of losses in the joint venture with Recursion (as successor in interest to Exscientia) on the consolidated statements of operations and comprehensive loss within the loss on
investment in joint venture line item, with a corresponding change to the joint venture investment asset on the consolidated balance sheets for equity method investments for which we do not have a controlling interest in. In July 2025, we sold our
interest in REV102 to Recursion. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the years ended December&nbsp;31, 2025 and 2024 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,064</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before equity in losses of joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Collaboration and license revenue was $0.9&nbsp;million for
the year ended December&nbsp;31, 2025, compared to $0.6&nbsp;million for the year ended December&nbsp;31, 2024. The increase of $0.2&nbsp;million in 2025 as compared to 2024 was due to our entrance into the J&amp;J Collaboration Agreement in the
second quarter of 2024 and the recognition of revenue related to the collaboration performance obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">355 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our
research and development costs for each of the periods presented: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Direct research and development by program</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB212</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB116</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other program candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Other unallocated research and development costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel expenses (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were $19.6&nbsp;million for the year ended December&nbsp;31, 2025, compared to $41.5&nbsp;million for the year ended December&nbsp;31,
2024. The decrease of $21.9&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $15.0&nbsp;million decrease in costs related to the development of RLYB212, primarily related to a decrease in clinical
development costs, manufacturing costs and other related development costs as a result of our discontinuation of the FNAIT program in April 2025; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $1.1&nbsp;million decrease in costs related to the development of RLYB116, primarily related to a decrease in
manufacturing costs; which were partially offset by an increase in clinical development costs and other related development costs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $1.9&nbsp;million decrease in costs related to the development of other program candidates, primarily related to RLYB332
manufacturing costs and other related development costs; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $3.7&nbsp;million decrease in payroll and personnel-related expenses, primarily due to lower ongoing headcount during
the year ended December&nbsp;31, 2025 as compared to the same period in 2024; offset by an increase in personnel-related expenses due to the severance expense recognized in the second quarter of 2025 in connection with the workforce reduction,
effective May&nbsp;2, 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $14.3&nbsp;million for the year ended December&nbsp;31, 2025, compared to $19.6&nbsp;million for the year ended
December&nbsp;31, 2024. The decrease of $5.3&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $4.7&nbsp;million decrease in personnel-related expenses, primarily related to lower ongoing headcount during the year
ended December&nbsp;31, 2025 as compared to the same period in 2024; offset by an increase in personnel-related expenses due to severance expense recognized in the second quarter of 2025 in connection with the workforce reduction, effective
May&nbsp;2, 2025; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $0.6&nbsp;million decrease primarily related to professional fees and other related general and administrative expenses;
offset by an increase in legal fees. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Total Other Income, Net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total other income, net, for the year ended December&nbsp;31, 2025 was $25.0&nbsp;million compared to $5.0&nbsp;million for the year ended December&nbsp;31, 2024. The
increase in total other income of $20.0&nbsp;million was primarily related to an increase in other income related to the JV Sale; offset by a decrease in interest income from marketable securities due to a lower excess cash balance. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Loss on Investment in Joint Venture </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture for
the year ended December&nbsp;31, 2025 was $0.9&nbsp;million compared to $2.2&nbsp;million for the year ended December&nbsp;31, 2024. The change was primarily due to the sale of our interest in REV102 in July 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">356 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;6, 2026, we executed a reverse
stock split of our issued and outstanding common stock, par value $0.0001, at a ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-8</FONT></FONT> with a record date of December&nbsp;30, 2025 (the &#8220;Reverse Stock
Split&#8221;). All common stock, per share and related information included below have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have funded our operations primarily through equity financings. From our inception and prior to our IPO, we received proceeds of approximately
$182.5&nbsp;million from equity financings. In August 2021, we closed our IPO and issued and sold 891,250 shares of common stock, inclusive of 116,250 shares sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional
shares, at a public offering price of $104.00 per share. We received net proceeds of approximately $83.0&nbsp;million, after deducting underwriting discounts and commissions and other offering costs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2022, we filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#8220;Shelf&#8221;) with the SEC in relation to the
registration and potential future issuance of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $300.0&nbsp;million. The Shelf was declared effective on August&nbsp;15,
2022. Pursuant to General Instruction I.B.6 to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (&#8220;Instruction I.B.6&#8221;), a company with a public float of less than $75.0&nbsp;million measured at certain time periods may not issue
securities under registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> in excess of <FONT STYLE="white-space:nowrap">one-third</FONT> of its public float in a <FONT STYLE="white-space:nowrap">12-month</FONT> period. We are
subject to the limitations of Instruction I.B.6, which may limit the amount of funds we can raise using the Shelf or any other registration statement on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> In connection with the Shelf, we also
simultaneously entered into a Sales Agreement with TD Securities (USA) LLC (f/k/a Cowen and Company, LLC) (&#8220;TD Cowen&#8221;), which was amended on March&nbsp;13, 2025 (as amended, the &#8220;Sales Agreement&#8221;). In accordance with the
terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $9.55&nbsp;million from time to time at prices through TD Cowen acting as our agent. Pursuant to the Sales Agreement, sales of
our common stock, if any, will be made in sales deemed to be &#8220;at the market offerings&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Under the Sales Agreement,
TD Cowen will be entitled to compensation equal to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. As of December&nbsp;31, 2025, we had not sold any shares of common stock pursuant to the Sales Agreement.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2022, we completed a <FONT STYLE="white-space:nowrap">follow-on</FONT> offering of approximately $54.8&nbsp;million consisting of 725,456 shares of
common stock, inclusive of 100,456 shares of common stock sold pursuant to the partial exercise of the underwriters&#8217; option to purchase additional shares at the price of $48.00 per share, and to certain investors in lieu of common stock, <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase up to an aggregate of 416,673 shares of common stock at a price of $47.9992, which represents the per share public offering price for the shares less the $0.0008 per share exercise
price for each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. The net proceeds from the November 2022 <FONT STYLE="white-space:nowrap">follow-on</FONT> offering were approximately $50.8&nbsp;million, after deducting underwriting
discounts and commissions and other offering costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2024, we entered into the JJDC Securities Purchase Agreement, pursuant to which we sold to JJDC in an
unregistered offering, 454,545 shares of our common stock at a price of $14.56 per share, which represented a 10% premium on our closing stock price on April&nbsp;9, 2024, for aggregate gross proceeds of approximately $6.6&nbsp;million, before
deducting offering expenses. We agreed, among other things, to file with the SEC a registration statement covering the resale of the shares within 120 days following the closing of the offering. We filed this registration statement on May&nbsp;10,
2024. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2025, we announced that we had entered into the ENPP1 Purchase Agreement to sell our interest in REV102, an ENPP1 inhibitor in preclinical
development for the treatment of patients with HPP, to Buyer (a subsidiary of our joint venture partner, Recursion). In the third quarter of 2025, we received a total of $20.0&nbsp;million in connection with the JV Sale, including $7.5&nbsp;million
from an upfront payment and $12.5&nbsp;million from a milestone payment related to the initiation of additional preclinical studies. We are eligible to receive a $5.0&nbsp;million milestone cash payment in connection with the initiation of dosing in
a Phase 1 clinical study, as defined in the ENPP1 Purchase Agreement and low single-digit royalties on all future net sales by Recursion of products comprising or incorporating certain compounds developed by
<FONT STYLE="white-space:nowrap">REV-I.</FONT> We may also be eligible to receive certain payments in the event of Recursion&#8217;s sale of the REV102 program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">357 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had $54.7&nbsp;million of cash, cash equivalents and marketable securities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Uses of Liquidity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently have no ongoing material financing
commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years. See &#8220;<I>&#8212;Contractual Obligations</I>&#8221;<I></I>. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that our existing cash, cash
equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months of the filing of this proxy statement/prospectus and we anticipate that the proposed merger with
Candid will be completed in 2026. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the numerous risks and uncertainties, length of time and scope of activities associated with research, development and
commercialization of pharmaceutical product candidates, we are unable to estimate the actual amount of funds we will require for development, approval and any approved marketing and commercialization activities. Our future capital requirements will
depend primarily on our ability to complete the proposed transaction with Candid. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not complete the proposed transaction with Candid and until such time,
if ever, as we generate significant revenue from product sales, we expect to finance our operations through the sale of equity, debt financings, marketing and distribution arrangements and collaborations, strategic alliances and licensing
arrangements or other sources. We currently have no credit facility or committed sources of capital. Any future sales of equity will result in dilution to our existing stockholders. If we raise additional funds through debt financing, we may be
subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and we may need to dedicate a substantial additional portion of any operating
cash flows to the payment of principal and interest on such indebtedness. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to
relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be
required to delay, limit, reduce or terminate product candidate development or future commercialization efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our cash flows for each of the periods presented: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,813</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2025, net cash
used in operating activities was $29.8&nbsp;million as compared to $49.3&nbsp;million for the year ended December&nbsp;31, 2024. The decrease in net cash used in operating activities was primarily related to a decrease in research and development
and general and administrative activities and changes in working capital. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by investing activities was $47.3&nbsp;million for the year ended December&nbsp;31, 2025 as compared to $33.5&nbsp;million for the year ended
December&nbsp;31, 2024. The increase of $13.8&nbsp;million in net cash provided by investing activities was primarily related to proceeds of $46.5&nbsp;million from maturities of highly-rated debt securities, in addition to an increase of
$18.5&nbsp;million primarily related to the $20.0&nbsp;million in proceeds from the JV Sale, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">358 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
partially offset by purchases of highly-rated debt securities of $17.7&nbsp;million during the year ended December&nbsp;31, 2025, as compared to proceeds from maturities of highly-rated debt
securities of $84.4&nbsp;million, partially offset by purchases of highly-rated debt securities of $48.9&nbsp;million during the year ended December&nbsp;31, 2024. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the year
ended December&nbsp;31, 2025 was $16&nbsp;thousand, representing proceeds from the issuance of common stock under the stock purchase plan. Net cash provided by financing activities for the year ended December&nbsp;31, 2024 was $5.2&nbsp;million,
primarily representing proceeds from the issuance of common stock pursuant to the JJDC Securities Purchase Agreement, after deducting offering costs and accounting for the total consideration allocation related to the J&amp;J Collaboration Agreement
of $1.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table
summarizes our contractual obligations as of December&nbsp;31, 2025: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENTS DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN<BR>1 YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MORE&nbsp;THAN<BR>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The contractual obligation amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms,
including fixed or minimum services to be used, fixed, minimum or variable price provisions and the approximate timing of the actions under the contracts. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Purchase and Other Obligations </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We enter contracts in the normal course of
business with CROs and other third-party vendors for clinical trials and testing and manufacturing services. Aside from those included in the table above, most contracts do not contain minimum purchase commitments and are cancellable by us upon
written notice. Payments that may be due upon cancellation consist of payments for services provided or expenses incurred. These payments are not included in the table above as the amount and timing of such payments are not known. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may incur contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable under agreements we have entered into with
various third-party entities pursuant to which we have acquired or <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. Due to the uncertainty of the achievement and timing of the events that require payment under these
agreements, the amounts to be paid by us are not fixed or determinable at this time and have not been included in the table above. See &#8220;<I>Rallybio&#8217;s Business&#8212;License Agreements</I>&#8221; and &#8220;<I>Rallybio&#8217;s
Business&#8212;Asset Purchase Agreements</I>&#8221; included elsewhere in this proxy statement/prospectus for a description of these agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical
Accounting Estimates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of
America. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent
assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under
different assumptions or conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are described in more detail in Note 2 &#8220;Summary of Significant Accounting
Policies Basis of Presentation and Principles of Consolidation&#8221; to our consolidated financial statements included elsewhere in this proxy statement/prospectus, we believe that the following accounting policies are those most critical to the
judgments and estimates used in the preparation of our consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">359 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the process of preparing our consolidated financial statements, we are required to estimate our research and development expenses that are incurred as of
each reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and with vendors to identify services that have been performed on our behalf and estimating the level of service performed
and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones
are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if
necessary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes
and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in
which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the
level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance accordingly.
<FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received
rather than when the payment is made. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we do not expect our estimates to be materially different from amounts incurred, if our estimates of the status and
timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We account for share-based compensation in
accordance with the Accounting Standards Codification 718, <I>Compensation&#8212;Stock Compensation</I>. Generally, share-based compensation is measured at the grant date for all equity-based awards made to employees based on the fair value of the
awards and is recognized over the requisite service period, which is generally the vesting period. Share-based compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition
is probable. We have elected to recognize the actual forfeitures by reducing the share-based compensation in the same period as the forfeitures occur. We classify share-based compensation in the consolidated statements of operations and
comprehensive loss in the same manner in which the award recipients&#8217; payroll costs are classified. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Black-Scholes option-pricing model uses as inputs the
fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our common stock options, the risk-free interest rate for a period that approximates the expected term of our common stock options,
and our expected dividend yield. See Note 2 &#8220;Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation&#8221; of our consolidated financial statements for additional information on the assumptions
utilized in the Black-Scholes option-pricing model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company and Smaller Reporting Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an EGC under the JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions
and reduced reporting requirements under the JOBS Act, for EGCs include presentation of only two years of audited financial statements in a registration statement for an IPO, an exemption from the requirement to provide an auditor&#8217;s report on
internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm
rotation, and less extensive disclosure about our executive compensation arrangements. Additionally, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This
allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">360 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new
or revised standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii)&nbsp;no longer qualify as an EGC. We may choose to early adopt any new or revised
accounting standards whenever such early adoption is permitted for private companies. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is
less than $700.0&nbsp;million and our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&nbsp;the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an EGC, we may continue to rely on exemptions from certain disclosure requirements that are available
to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025 and 2024, we did not have any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in Item&nbsp;303(a)(4)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recently Issued Accounting Pronouncements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A description of recently issued
accounting pronouncements that may potentially impact our financial position, results of operations and footnote disclosures is disclosed in Note 2 &#8220;Summary of Significant Accounting Policies Basis of Presentation and Principles of
Consolidation&#8221; to our consolidated financial statements for the year ended December&nbsp;31, 2025 appearing elsewhere in this proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">361 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_24"></A>CANDID&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should
read the following discussion and analysis of Candid&#8217;s financial condition and results of operations together with the consolidated financial statements and related notes included elsewhere in this proxy statement/prospectus. Some of the
information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to Candid&#8217;s plans and strategy for its business and related financing, includes forward-looking
statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section titled &#8220;Risk Factors,&#8221; Candid&#8217;s actual results could differ materially from the results described in or
implied by the forward looking statements contained in the following discussion and analysis. You should carefully read the section titled &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results
to differ materially from Candid&#8217;s forward-looking statements. Please also see the section titled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is a global clinical-stage biotechnology company focused on
building the leading portfolio of TCE therapeutics to treat autoimmune diseases, which affect an estimated 5-10% of the global population. Despite available treatments, many patients experience persistent disease activity, progressive organ damage,
and lifelong dependence on immunosuppressive therapies that provide incomplete disease control and cause significant adverse events. Cizutamig, which targets BCMA, is Candid&#8217;s lead clinical-stage TCE program and is advancing into global
Phase&nbsp;2 studies in gMG and SARD-ILD. TCEs harness a patient&#8217;s own T cells to deplete pathogenic B-cells, with the potential to deliver either deep depletion of B-cells, which could provide durable disease remission (&#8220;immune
reset&#8221;), or partial depletion of B-cells, which could provide for controlled, sustained disease management (&#8220;immune dimming&#8221;). </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has
built a diversified pipeline of four TCE programs in development targeting distinct B-cell antigens&#8212;BCMA, CD20, and CD19. Candid&#8217;s most advanced clinical stage program, cizutamig, is a BCMA TCE in-licensed from EpimAb Biotherapeutics
that is being investigated in multiple Phase&nbsp;1 dose-escalation trials in patients with gMG and SLE as well as in IITs in SARD-ILD, SSc, and other diseases outside the United States. Biopsies obtained post treatment with cizutamig show deep
B-cell depletion, including in plasma cells, bone marrow and lymph nodes. In Phase 1 dose-escalation clinical studies in patients with gMG, Candid has seen clinical improvements with standardized physician and patient disease activity indices. In
compassionate use via NPU clinical studies in patients with SARD-ILD, Candid has seen improvements in lung function as measured by increases in FVC. In patients with autoimmune disease treated with cizutamig, a favorable tolerability profile has
been observed,&nbsp;with low rates of adverse events related to cytokine release and no deaths or dose-limiting adverse events in Phase 1 dose escalation studies, compassionate use via NPU and IITs. Candid plans to initiate global Phase 2 clinical
trials in gMG and SARD-ILD by the middle of 2026, which are designed to evaluate whether the clinical effects observed in earlier studies can be confirmed in larger, randomized, controlled settings. In gMG, Candid plans to conduct a head-to-head
study comparing cizutamig to VYVGART<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a FcRn antagonist therapy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s second clinical-stage
program, CND261, is a CD20 TCE in-licensed from Genor Biopharma that is being investigated in Phase 1 dose-escalation studies in patients with RA, SLE, as well as an IIT in ANCA-associated vasculitis outside the United States. CND261 was engineered
with the goal of achieving deeper B-cell depletion than approved CD20-targeted mAbs such as Rituxan<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or GAZYVA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Lymph node biopsies
post treatment with CND261 in patients with autoimmune disease shows deep depletion of CD20 positive B-cells. In patients with autoimmune disease treated with CND261, a favorable tolerability profile has been observed, with low rates of adverse
events related to cytokine release and no deaths or dose-limiting adverse events in Phase 1 dose escalation studies, compassionate use via NPU and IITs. Beyond these two clinical programs, Candid has built a pipeline of <FONT
STYLE="white-space:nowrap">next-generation</FONT> trispecific TCEs, each designed to target two different antigens expressed on B-cells. CND319 is a TCE in-licensed from WuXi Biologics that targets CD19 and CD20 for B-cell depletion. In non-human
primate studies, single doses of CND319 show deep tissue B-cell depletion with minimal cytokine release. Candid expects to initiate first-in-human studies for CND319 in the middle of 2026. CND460 is a TCE that targets CD19 and BCMA and is currently
undergoing IND-enabling studies with first-in-human trials planned for the first half of 2027. CND460 is being developed in collaboration with a third-party development partner. Candid has the right to formally nominate CND460 as a development
candidate upon the conclusion of those studies, which have not yet been completed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">362 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since its incorporation in May 2024, Candid has devoted substantially all of its resources and efforts to organizing
and staffing its company, business planning, raising capital, identifying assets, engaging in strategic transactions and licensing arrangements, establishing and protecting its intellectual property portfolio preparing for and conducting its planned
preclinical studies and clinical trials, advancing arrangements with third parties for the manufacture of its drug candidates and component materials, and providing general and administrative support for these operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;19, 2024, Candid entered into an agreement and plan of merger and reorganization (the &#8220;2024 Merger Agreement&#8221;) with Vignette Bio, Inc.
(&#8220;Vignette&#8221;) and TRC 2004, Inc. (&#8220;TRC&#8221;, and together with Vignette, &#8220;Predecessors&#8221;). Upon the consummation of the merger pursuant to the 2024 Merger Agreement (the &#8220;2024 Merger&#8221;), Vignette and TRC
became wholly owned subsidiaries of Candid. In December 2024, Vignette and TRC were merged with and into Candid. As more fully described in Note 5 to Candid&#8217;s consolidated financial statements included elsewhere in this proxy
statement/prospectus, the total consideration transferred by Candid in the 2024 Merger primarily consisted of 105,000,000&nbsp;shares of Candid&#8217;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, 89,999,985 shares
of Candid&#8217;s Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock and 69,999,985 shares of Candid&#8217;s common stock with an aggregate fair value of $271.1&nbsp;million (including transaction costs). In exchange for
the consideration given, Candid received $116.9&nbsp;million of cash, other working capital of $0.8&nbsp;million and <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (&#8220;IPR&amp;D&#8221;) with a fair value of
$153.4&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;22, 2025, Candid established Shanghai Tandi Biotechnology Co., Ltd. (&#8220;Tandi&#8221;), a Shanghai Limited Liability
Company, as a wholly owned foreign subsidiary located in Shanghai, China, formed for the primary purpose of conducting clinical trials in China. Candid&#8217;s consolidated financial statements, included elsewhere in this proxy statement/prospectus,
include the accounts of Candid for all periods presented, and the accounts of Vignette and TRC from August&nbsp;19, 2024 through December&nbsp;27, 2024, and the accounts of Tandi from formation through December&nbsp;31, 2025. All intercompany
balances were eliminated in consolidation. The financial statements of the Predecessors, for the period from January&nbsp;1, 2024 through August&nbsp;19, 2024 (the 2024 Merger date), are included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;1, 2026, Rallybio entered into the Merger Agreement with Candid and Merger Sub. Upon the terms and subject to the satisfaction of the conditions described
in the Merger Agreement, Merger Sub will be merged with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio. The Merger is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization for U.S.
federal income tax purposes. In connection with the Merger, Rallybio will change its name to &#8220;Candid Therapeutics, Inc.&#8221; Candid following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company is
expected to be led by Candid&#8217;s management team and will focus on advancing a leading portfolio of TCE therapeutics for autoimmune diseases. Concurrently with entering into the Merger Agreement, Candid entered into the Subscription Agreement
with the Investors. Pursuant to the Subscription Agreement, Candid agreed to sell, and the Investors agreed to purchase, immediately prior to the Effective Time, shares of Candid Common Stock for an aggregate purchase price of $505.5&nbsp;million.
Shares of Candid Common Stock issued pursuant to the Concurrent Financing will be converted into shares of Rallybio Common Stock in accordance with the Merger Agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since its inception, Candid has funded its operations primarily through the issuance of shares of its convertible preferred stock, the issuance of shares of its capital
stock in connection with the 2024 Merger, and interest income on its investment portfolio. To date, in addition to the net cash it received in the 2024 Merger, Candid has received gross proceeds of approximately $206.2&nbsp;million from the sale of
shares of its convertible preferred stock (including cash proceeds from convertible debt converted in the financing). As of December&nbsp;31, 2025, Candid had cash and cash equivalents and short-term investments of $223.3&nbsp;million. Based on its
current operating plan, Candid estimates that its existing cash, cash equivalents and short-term investments as of the date of this proxy statement/prospectus, together with the estimated net proceeds from the Merger and the Concurrent Financing,
will be sufficient to fund its operating expenses and capital expenditures through 2030. However, Candid&#8217;s forecast of the period of time through which its financial resources will be adequate to support its operations is a forward-looking
statement that involves risks and uncertainties, and actual results could differ materially. Candid has based this estimate on assumptions that may prove to be wrong, and Candid could use its capital resources sooner than it currently expects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">363 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has incurred net losses since its inception. Candid&#8217;s net losses for the year ended December&nbsp;31,
2025 and the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024 were $92.2&nbsp;million and $174.3&nbsp;million respectively. Of such net losses, $31.3&nbsp;million and $162.0&nbsp;million, respectively, related to acquired
IPR&amp;D. As of December&nbsp;31, 2025, Candid had an accumulated deficit of $266.5&nbsp;million. Candid&#8217;s operating results may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing and level of expense related
to current or future development of its clinical and preclinical trials and its expenditures on other research and development and other activities. Excluding Candid&#8217;s acquired IPR&amp;D, Candid expects its expenses and operating losses will
increase substantially as cizutamig and CND261 and any other future drug candidates advance through preclinical and clinical trials, as Candid expands its clinical, regulatory, quality and manufacturing capabilities, hires additional personnel,
protects its intellectual property, and as Candid incurs significant commercialization expenses for marketing, sales, manufacturing and distribution, in anticipation of receiving marketing approval for one or more of its drug candidates, which it
may not receive. Furthermore, upon the Closing, Candid expects to incur additional costs associated with operating as a public company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid does not have any
drug candidates approved for sale and has not generated any revenue from drug sales. Candid does not expect to generate any revenues from drug sales unless and until it successfully completes development and obtains regulatory approval for one or
more drug candidates, which will not be for at least a number of years, if ever. Accordingly, until such time as Candid can generate significant revenue from sales of its drug candidates, if ever, Candid expects to finance its cash needs through
public or private equity or debt financings, or other sources, potentially including collaborations and other strategic arrangements with third parties. However, Candid may be unable to raise additional funds or enter into such other arrangements
when needed on favorable terms or at all. Candid&#8217;s failure to raise capital or enter into such other arrangements when needed would have a negative impact on its financial condition and could force it to delay, limit, reduce or terminate
clinical trials, research and development programs or other operations, or lead it to grant rights to third parties to develop and market drug candidates that it would otherwise prefer to develop and market itself. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid does not own or operate, and currently has no plans to establish, any manufacturing facilities. Candid has engaged, and currently relies on third party CDMOs,
for the supply of its drug candidates for use in its ongoing and planned preclinical studies and planned clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid relies on third party CDMOs for
biologics development and manufacturing services. Candid is evaluating third party CDMOs to further diversify and strengthen its supply chain. Additionally, Candid is establishing processes to help enable it to scale up production for late-stage
clinical trials as well as commercial use. Candid is also developing subcutaneous formulations for both of cizutamig and CND261. Candid expects to start evaluation of the subcutaneous formulation for cizutamig in clinical development in the second
half of 2026. If any of its drug candidates receive marketing approval, Candid intends to rely on third-party CDMOs for commercial manufacturing. As its drug candidates advance through development, Candid expects to enter into longer-term commercial
supply agreements to fulfill and secure its production needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License and Collaboration Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the 2024 Merger, Candid assumed certain license and collaboration agreements with EpimAb relating to cizutamig and with Genor relating to CND261. In
January 2025, Candid and WuXi Biologics entered into a license agreement relating to certain <FONT STYLE="white-space:nowrap">tri-specific</FONT> antibodies. As its drug candidates progress through development and toward commercialization, Candid
will need to make milestone payments to the licensors from whom it has <FONT STYLE="white-space:nowrap">in-licensed</FONT> its drug candidates. See the section titled &#8220;&#8212;<I>Contractual Obligations and Commitments</I>&#8221; below,
&#8220;<I>Candid&#8217;s Business&#8212;License and Collaboration Agreements</I>&#8221; and the notes to Candid&#8217;s consolidated financial statements included elsewhere in this proxy statement/prospectus for additional information on these
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Financial Operations Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The descriptions below reflect the composition of the operating expenses for Candid and the Predecessors. Not all listed expenses are applicable to each
entity. See &#8220;<I>&#8212;Results of Operations</I><I> for Candid</I>&#8221; below for descriptions of the operating expenses by period applicable to each of Candid, Vignette and TRC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">364 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating expenses consist of (i)&nbsp;research and development expenses,
<FONT STYLE="white-space:nowrap">(ii)&nbsp;in-process</FONT> research and development, and (iii)&nbsp;general and administrative expenses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and
Development </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses primarily consist of external and internal expenses related primarily to the discovery and development of its
drug candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. IPR&amp;D
expenses, which represent a significant portion of operating expenses, are classified separately from research and development expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development
expenses include: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">External: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">external research and development expenses incurred under agreements with CROs, investigative sites, consultants and other
third parties to perform research services, and conduct and support preclinical studies, toxicology and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">laboratory supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to manufacturing drug candidates for preclinical studies and clinical trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Internal: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">personnel and related expenses, including salaries, bonuses, payroll taxes and employee benefits for personnel involved in
research and development efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">facilities and other expenses, including direct and allocated expenses for rent, maintenance of facilities, insurance,
equipment, depreciation and other supplies and services. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid does not track its internal research and development expenses on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis because these expenses are deployed across multiple programs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid anticipates that its research and development expenses will increase substantially for the foreseeable future as it continues the development of cizutamig,
CND261, CND319 and CND460, as well as the discovery of and development of new drug candidates. Candid cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and
clinical trials of cizutamig, CND261, CND319 and CND460, its current development candidates, or any future drug candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical and clinical development
timelines, the probability of success and development costs can differ materially from expectations. Candid anticipates that it will make determinations as to which drug candidates and indications to pursue and how much funding to direct to each
drug candidate and indication on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments, and its ongoing assessments as to each drug candidate&#8217;s commercial potential.
In addition, Candid cannot forecast which drug candidates, if any, may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect its development plans and capital
requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s development costs may vary significantly based on factors such as:<B> </B> </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">per patient trial costs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of indications Candid pursues for its drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and scope of preclinical and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">365 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the choice of comparator arms in the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential alterations in the clinical development plan, including if additional safety monitoring is requested by
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the phase of development of a drug candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing, receipt and terms of approvals from applicable regulatory authorities, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efficacy and safety profile of a drug candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of manufacturing; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which Candid establishes additional collaboration, license or other arrangements. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A change in the outcome of any of these variables with respect to the development of Candid&#8217;s drug candidates may
significantly impact the costs and timing associated with the development of those candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Intangible assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as
IPR&amp;D. Acquired IPR&amp;D that has no alternative future use is expensed immediately. IPR&amp;D is related to assets acquired by the Predecessors in connection with certain license and collaboration agreements, assets acquired in the 2024 Merger
and subsequent milestone payments made in connection with the license and collaboration agreements assumed in the 2024 Merger, and assets acquired in connection with certain early-stage research licenses entered into subsequent to the 2024 Merger.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses
primarily consist of personnel and related expenses, including salaries, bonuses, payroll taxes and employee benefits, for personnel in executive, finance and other administrative functions. Other significant costs include legal fees relating to
intellectual property and corporate matters, professional fees for accounting and consulting services, insurance and facilities and related costs. Candid anticipates that its general and administrative expenses will increase substantially for the
foreseeable future to support its continued research and development activities and, if any of its drug candidates receive marketing approval, commercialization activities. Candid also anticipates increased expenses related to accounting, audit,
legal, regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT> services, costs associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations and other
costs associated with operating as a public company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Income (Expense), Net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other income (expense), net consists of (i)&nbsp;interest income, (ii)&nbsp;interest expense, (iii)&nbsp;change in fair value of convertible promissory
note&#8212;related party, and (iv)&nbsp;other expense&#8212;related party. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Interest Income </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest income primarily consists of interest income from cash and cash equivalents and short-term investments. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Interest Expense </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest expense primarily consists of interest expense
related to promissory notes Candid issued in June 2024 that were settled or repaid in August 2024. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Change in Fair Value of Convertible Promissory Note-Related
Party </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The change in fair value of convertible promissory note&#8212;related party represents the change in fair value of a convertible promissory note, for
which Candid elected the fair value option, between the June 2024 issuance date and August 2024 settlement in connection with its Series B convertible preferred stock financing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Expense&#8212;Related Party (Applicable to TRC Only) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other
expense&#8212;related party consists of discounts on Candid Common Stock issuances to related party investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">366 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations for Candid </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Year Ended December&nbsp;31, 2025 and the Period from May&nbsp;1, 2024 (Inception) to December&nbsp;31, 2024 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes Candid&#8217;s results of operations for the periods indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD FROM<BR>MAY&nbsp;1, 2024<BR>(INCEPTION)&nbsp;TO<BR>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development (includes related party amounts
of $0 and $153,502, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8211;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of convertible promissory note&#8212;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8211;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8211;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(92,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes Candid&#8217;s research and development expenses for the periods indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD FROM<BR>MAY&nbsp;1, 2024<BR>(INCEPTION)&nbsp;TO<BR>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">External expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cizutamig</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">CND261</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preclinical and indirect program expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total external expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Internal expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel and related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Facilities and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total internal expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">367 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were $62.2&nbsp;million and $14.1&nbsp;million for the year ended December&nbsp;31, 2025 and the period from May&nbsp;1, 2024
(inception) to December&nbsp;31, 2024, respectively. The increase of $48.1&nbsp;million was primarily driven by an increase in external expenses of $35.3&nbsp;million and an increase in internal expenses of $12.8&nbsp;million. The increase of
$35.3&nbsp;million in external expenses was primarily driven by an increase of $6.6&nbsp;million related to the clinical development of cizutamig for autoantibody driven autoimmune diseases, $9.8&nbsp;million related to the clinical development of
CND261 for autoimmune diseases, and $18.9&nbsp;million in preclinical and indirect program expenses, including increases in the manufacturing of drug candidates for Candid&#8217;s preclinical programs, toxicology, third-party research activities and
laboratory supplies. The increase of $12.8&nbsp;million in internal expenses was primarily driven by an $8.8&nbsp;million increase in personnel and related expenses, an increase of $2.1&nbsp;million in stock-based compensation and an increase of
$1.9&nbsp;million in facilities and other expenses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development expenses were $31.3&nbsp;million and $162.0&nbsp;million for the year ended
December&nbsp;31, 2025 and the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024, respectively. <FONT STYLE="white-space:nowrap">In-process</FONT> research and development expenses primarily consisted of the costs to acquire rights
to IPR&amp;D assets received in connection with Candid&#8217;s: (i)&nbsp;2024 Merger with Vignette and TRC, (ii)&nbsp;license agreement with WuXi Biologics, (iii)&nbsp;various early-stage research licenses, and (iv)&nbsp;milestone payments related
to various license and collaboration agreements, as these assets had not yet reached technological feasibility and had no alternative future use. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and
Administrative </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $8.7&nbsp;million and $3.1&nbsp;million for the year ended December&nbsp;31, 2025 and the period from
May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024, respectively. The increase of $5.6&nbsp;million was due primarily to $2.6&nbsp;million of consulting and professional services including legal fees relating to intellectual property and
corporate matters, audit and tax fees, and other consulting services, $2.3&nbsp;million of personnel and related expenses, $0.6&nbsp;million of stock-based compensation, and $0.1&nbsp;million of other general and administrative expenses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Income (Expense), Net </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other income (expense), net was
$10.0&nbsp;million and $4.9&nbsp;million for the year ended December&nbsp;31, 2025 and the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024, respectively. In 2025, other income (expense), net primarily consisted of
$10.0&nbsp;million of interest income on Candid&#8217;s cash, cash equivalents and short-term investments. In 2024, other income (expense), net primarily consisted of $5.1&nbsp;million of interest income on Candid&#8217;s cash and cash equivalents,
partially offset by a $0.2&nbsp;million change in the fair value of a convertible promissory note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations for Vignette </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Period from January&nbsp;1, 2024 to August&nbsp;19, 2024 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
following table summarizes results of operations for Vignette for the period indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD&nbsp;FROM<BR>JANUARY&nbsp;1,<BR>2024&nbsp;TO<BR>AUGUST&nbsp;19,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(60,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">368 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses consisted of various consulting services during the period. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development expenses were $60.0&nbsp;million for the period from January&nbsp;1, 2024 to August&nbsp;19,
2024, which consisted of $30.0&nbsp;million of cash consideration, and $30.0&nbsp;million in common stock as consideration paid to acquire IPR&amp;D assets received in connection with a license and collaboration agreement, as these assets had not
yet reached technological feasibility and had no alternative future use. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $0.6&nbsp;million for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024 which consisted primarily of consulting and
professional services including legal fees relating to intellectual property and corporate matters, and other consulting services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations for TRC
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Period from January&nbsp;1, 2024 to August&nbsp;19, 2024 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes TRC&#8217;s results of operations for the period indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD&nbsp;FROM<BR>JANUARY&nbsp;1,<BR>2024&nbsp;TO<BR>AUGUST&nbsp;19,<BR>2024 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative (includes related party amount of $910)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,991</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense&#8212;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expense&#8212;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were
$0.1&nbsp;million for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024 and consisted primarily of expenses related to the preclinical development of CND261 (formerly known as GB261). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development expenses were $23.5&nbsp;million for the period from January&nbsp;1, 2024 to August&nbsp;19,
2024, which consisted of $16.0&nbsp;million of cash consideration and $7.5&nbsp;million in common stock as consideration paid to acquire IPR&amp;D assets received in connection with a license agreement, as these assets had not yet reached
technological feasibility and had no alternative future use. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $1.4&nbsp;million for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024 which consisted primarily of consulting and
professional services including legal fees relating to intellectual property and corporate matters, and other consulting services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">369 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other income (expense), net of $14.5&nbsp;million for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024 consisted primarily of $14.5&nbsp;million of other
expense&#8212;related party in connection with the issuance of common stock to related party investors at a discount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sources of Liquidity for Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since Candid&#8217;s inception, it
has funded its operations primarily through the issuance of shares of its convertible preferred stock, the issuance of shares of its capital stock in connection with the 2024 Merger, and interest income on its investment portfolio. To date, in
addition to the net cash it received in the 2024 Merger and interest income, Candid has received gross proceeds of approximately $206.2&nbsp;million from the sale of shares of its convertible preferred stock (including cash proceeds from convertible
debt converted in the financing). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has incurred net losses and negative cash flows from operations since its inception and anticipates it will continue to
incur net losses for the foreseeable future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash Flows for Candid </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes Candid&#8217;s net cash flow activity for the periods indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD FROM<BR>MAY&nbsp;1, 2024<BR>(INCEPTION)&nbsp;TO<BR>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(56,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,516</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities for the year
ended December&nbsp;31, 2025 was $56.6&nbsp;million as compared to $9.3&nbsp;million for the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024. The net cash used in operating activities for the year ended December&nbsp;31, 2025 was
primarily due to Candid&#8217;s net loss of $92.2&nbsp;million and $5.3&nbsp;million of net accretion of discounts on investments, offset in part by $31.3&nbsp;million of adjustments related to acquired IPR&amp;D and related milestone payments,
$3.1&nbsp;million of stock-based compensation, $1.6&nbsp;million related to the <FONT STYLE="white-space:nowrap">write-off</FONT> of deferred offering costs and a $4.9&nbsp;million change in operating assets and liabilities in support of the growth
in Candid&#8217;s operations. The net cash used in operating activities for the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024 was primarily due to Candid&#8217;s net loss of $174.3&nbsp;million and $1.2&nbsp;million of net
accretion of discounts on investments, offset in part by $162.0&nbsp;million of adjustments related to acquired IPR&amp;D and related milestone payments, $0.4&nbsp;million of stock-based compensation, $0.2&nbsp;million of change in fair value of a
convertible promissory note and a $3.6&nbsp;million change in operating assets and liabilities, primarily driven by the net increase in operating liabilities in support of the growth in Candid&#8217;s operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by investing activities for the year
ended December&nbsp;31, 2025 was $2.0&nbsp;million as compared to net cash used in investing activities of $120.9&nbsp;million for the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024. The net cash provided by investing activities
for the year ended December&nbsp;31, 2025 was primarily due to net maturity of investment securities of $33.3&nbsp;million, offset in part by $31.3&nbsp;million of cash paid for IPR&amp;D. The net cash used in investing activities for the period
from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024 was primarily due to the purchase of $228.7&nbsp;million of investment securities, $8.5&nbsp;million of cash paid for IPR&amp;D, and $0.2&nbsp;million for the purchase of property and
equipment, offset in part by the $116.5&nbsp;million of net cash Candid acquired in the 2024 Merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">370 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net
cash provided by financing activities for the year ended December&nbsp;31, 2025 was $17,000 as compared to $205.6&nbsp;million for the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024. The net cash provided by financing activities
for the year ended December&nbsp;31, 2025 was primarily due to $0.1&nbsp;million of proceeds from the exercise of common stock options, offset in part by the payment of $0.1&nbsp;million of initial public offering costs. The net cash provided by
financing activities for the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024 was primarily due to $205.5&nbsp;million of net proceeds from the sale of shares of Candid&#8217;s convertible preferred stock, $0.4&nbsp;million of
proceeds from the exercise of common stock options, and $0.2&nbsp;million of proceeds from the issuance of a convertible promissory note, offset in part by the payment of $0.5&nbsp;million of initial public offering costs. Candid also issued and
repaid a $3.0&nbsp;million promissory note during the period. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash Flows for Vignette </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes Vignette&#8217;s net cash flow activity for the period indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD&nbsp;FROM<BR>JANUARY&nbsp;1,<BR>2024 TO<BR>AUGUST&nbsp;19,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities for the period
from January&nbsp;1, 2024 to August&nbsp;19, 2024 of $1.4&nbsp;million was primarily due to Vignette&#8217;s net loss of $60.6&nbsp;million and a $0.7&nbsp;million change in operating assets and liabilities, partially offset by $60.0&nbsp;million of
adjustments related to the IPR&amp;D Vignette acquired in connection with a license and collaboration agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024 of $30.0&nbsp;million was due to the $30.0&nbsp;million cash
payment in connection with a license and collaboration agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing Activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024 of $74.8&nbsp;million was primarily due to $74.6&nbsp;million
of net proceeds from the sale of shares of Vignette&#8217;s convertible preferred stock and $0.3&nbsp;million of proceeds from the issuance of debt. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash
Flows for TRC </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes TRC&#8217;s net cash flow activity for the period indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD&nbsp;FROM<BR>JANUARY&nbsp;1,<BR>2024&nbsp;TO<BR>AUGUST&nbsp;19,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,485</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">371 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net
cash used in operating activities for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024 of $1.5&nbsp;million was primarily due to TRC&#8217;s net loss of $39.5&nbsp;million, partially offset by $23.5&nbsp;million of adjustments related to
the IPR&amp;D TRC acquired in connection with a license and collaboration agreement and the $14.5&nbsp;million discount on common stock issuances to related party investors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities for the period
from January&nbsp;1, 2024 to August&nbsp;19, 2024 of $16.0&nbsp;million was due to the $16.0&nbsp;million cash payment in connection with a license and collaboration agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the
period from January&nbsp;1, 2024 to August&nbsp;19, 2024 of $90.9&nbsp;million was primarily due to $89.6&nbsp;million of net proceeds from the sale of shares of TRC&#8217;s convertible preferred stock, $1.0&nbsp;million of net proceeds from the
sale of shares of common stock and $0.3&nbsp;million of proceeds from the issuance of debt. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, Candid had cash, cash equivalents and short-term investments of $223.3&nbsp;million. Based on its current operating plan, Candid estimates
that its existing cash, cash equivalents and short-term investments as of the date of this proxy statement/prospectus, together with the estimated net proceeds from the 2024 Merger and the Concurrent Financing, will be sufficient to fund
Candid&#8217;s operating expenses and capital expenditures through 2030. However, Candid&#8217;s forecast of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement that
involves risks and uncertainties, and actual results could differ materially. Candid has based this estimate on assumptions that may prove to be wrong, and Candid could use its capital resources sooner than it currently expects, requiring it to seek
additional funds sooner than planned. Candid may also decide to raise capital opportunistically. Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress and costs to conduct these trials is
uncertain. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s future capital requirements will depend on many factors, including but not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number, scope, rate of progress and costs of its planned clinical trials for cizutamig, CND261, CND319, CND460 and
drug discovery and preclinical development activities for any future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and scope of clinical programs it decides to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope and costs of manufacturing development for any of its current or future drug candidates, including commercial
manufacturing at scale, if any drug candidate receives marketing approval, including as a result of inflation or any supply chain issues; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with hiring additional personnel and consultants as its business grows, including additional research
and development personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost, timing and outcome of regulatory review of cizutamig, CND261, CND319, CND460 and any future drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property
rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of any milestone and royalty payments to its existing or future suppliers, collaborators or licensors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with enhancing its operational systems and being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which it acquires or <FONT STYLE="white-space:nowrap">in-licenses</FONT> other drug candidates and
technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with commercializing cizutamig, CND261, CND319, CND460 or any future drug candidates, if they receive
marketing approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as Candid can generate substantial revenue to support its cost structure, Candid expects to finance
its cash needs through public or private equity or debt financings, or other sources, potentially including collaborations and other strategic arrangements with third parties. To the extent that Candid raises additional capital
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">372 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
through the sale of equity or convertible debt securities, the ownership interest of its stockholders could be diluted, and the terms of these securities may include liquidation or other
preferences that adversely affect the rights of Candid&#8217;s common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting Candid&#8217;s ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Candid raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its
technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to it and/or may reduce the value of its common stock. If Candid is unable to raise additional funds through equity or
debt financings on acceptable terms when needed, it may be required to delay, limit, reduce or terminate its drug development or future commercialization efforts or grant rights to develop and market cizutamig, CND261, CND319, CND460 or any future
drug candidates even if it would otherwise prefer to develop and market such drug candidates ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s operating lease obligations relate to its office space for its headquarters located in San Diego, California, as well as office space in Shanghai, China.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under its license and collaboration agreements, Candid has payment obligations that are contingent upon future events, such as the achievement of specified
development, regulatory and commercial milestones, and Candid is required to make royalty payments in connection with the sales of products developed under those agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although Candid could be required to make substantial milestone payments under its license and collaboration agreements as of December&nbsp;31, 2025, it is unable to
estimate the timing or likelihood of achieving the milestones or making future product sales. For additional details regarding these agreements, see the section titled &#8220;<I>Candid&#8217;s Business&#8212;License and Collaboration
Agreements.</I>&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has entered into, or may enter into in the future, contracts in the normal course of business with clinical trial sites and clinical
supply manufacturers and with vendors for preclinical studies and clinical trials, research supplies and other services and drugs for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are
cancelable contracts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For additional information regarding Candid&#8217;s contractual obligations and commitments, see Note 4 and Note&nbsp;6 to Candid&#8217;s
consolidated financial statements included elsewhere in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid did not have, during the periods presented, and does not currently have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as
defined in the rules and regulations of the Securities and Exchange Commission. The Predecessors did not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements during the period presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Estimates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This management&#8217;s
discussion and analysis of financial condition and results of operations is based on the financial statements of Candid, Vignette and TRC, which have been prepared in accordance with U.S. generally accepted accounting principles
(&#8220;GAAP&#8221;). The preparation of these consolidated financial statements requires estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the
consolidated financial statements. On an ongoing basis, evaluations of estimates and judgments are performed, including those related to accrued research and development expenses and various fair value measurements. The estimates are based on
historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that
are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While Candid&#8217;s
significant accounting policies are described in more detail in Note 2 to its consolidated financial statements appearing elsewhere in this proxy statement/prospectus, Candid believes the following accounting policies and estimates to be most
critical to the preparation of its consolidated financial statements. The significant accounting policies of the Predecessors are described in more detail in Note 1 to their financial statements appearing elsewhere in this proxy
statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">373 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The critical accounting policies and estimates of Vignette and TRC are substantially the same as those of Candid,
except as noted below related to the valuation of capital stock. The Predecessors had no material accrued research and development expenses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accrued research
and development expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the process of preparing Candid&#8217;s consolidated financial statements, Candid is required to estimate its accrued
expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with its personnel to identify services that have been performed on its behalf and estimating the level of service performed
and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of the actual cost. Candid makes estimates of its accrued expenses as of each balance sheet date based on facts and circumstances known to it at
that time. Candid periodically confirms the accuracy of its estimates with the service providers and, if necessary, makes adjustments. The significant estimates in its accrued research and development expenses includes the costs incurred for
services performed by its vendors in connection with research and development activities for which Candid has not yet been invoiced. Candid bases its expenses related to research and development activities on its estimates of the services received
and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven
payment flows. There may be instances in which payments made to its vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, Candid estimates the time period
over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, Candid adjusts the accrual or prepaid expense
accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although Candid does not expect its estimates to be materially different from amounts actually incurred, if its estimates of the status and timing of services performed
differ from the actual status and timing of services performed, it could result in Candid reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between Candid&#8217;s estimates of
such expenses and the amounts actually incurred. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Business Combinations and Asset Acquisitions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions, with a cost accumulation model used
to determine the cost of the acquisition. For an asset acquisition, the fair value of acquisition consideration is allocated to the identifiable assets acquired and liabilities assumed at cost on a relative fair value basis. If a single asset is
acquired, the entire cost is attributed to the acquired asset. In addition, for such asset acquisitions, no goodwill is recognized, acquisition-related costs are capitalized, and any associated contingent consideration is recorded when the
underlying contingencies have been resolved. Common stock and preferred stock issued as consideration in an acquisition of assets are measured based on the acquisition date fair value of the equity interests. Intangible assets that are acquired in
an asset acquisition for use in research and development activities that have an alternative future use are capitalized as IPR&amp;D. Acquired IPR&amp;D that has no alternative future use is expensed immediately. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-based Compensation Expense </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid measures its stock-based
awards based on the estimated grant date fair value of the awards. For stock-based awards with only service conditions, compensation expense is recognized over the requisite service period using the straight-line method. For stock-based awards that
include performance conditions, compensation expense is not recognized until the performance condition is probable to occur. Candid estimates the fair value of restricted common stock based on the fair value of the underlying common stock and the
fair value of stock options using the Black-Scholes option pricing model and recognizes forfeitures of stock-based awards as they occur. Estimating the fair value of equity awards as of the grant date using valuation models, such as the
Black-Scholes option pricing model, is affected by assumptions regarding a number of variables, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the fair
value of the underlying common stock on the date of grant. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. See Note 8 to Candid&#8217;s consolidated
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">374 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
financial statements included elsewhere in this proxy statement/prospectus for information concerning certain of the specific assumptions Candid used in applying the Black-Scholes option pricing
model to determine the estimated fair value of its stock options granted for the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024 and the year ended December&nbsp;31, 2025. As of December&nbsp;31, 2025, the total unrecognized
stock-based compensation expense for outstanding performance-based options was $4.3&nbsp;million. As of December&nbsp;31, 2025, total unrecognized stock-based compensation expense (excluding performance-based options) was $6.1&nbsp;million, which is
expected to be recognized over a remaining weighted-average period of approximately 2.6 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither Vignette nor TRC had stock-based compensation expense during
the periods presented for those entities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value of Capital Stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the capital stock issued in the transactions described below was determined using methodologies, approaches and assumptions consistent with the
American Institute of Certified Public Accountants Accounting and Valuation Guide: <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I> (the Practice Aid). The Practice Aid prescribes several valuation approaches for
setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its capital stock. The cost approach establishes the value of an enterprise based on the cost
of reproducing or replacing the property less depreciation and functional or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective
of our company&#8217;s future operations, discounting to the present value with an appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a
substitute asset with the same characteristics. Each valuation methodology was considered in each of the following valuations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>TRC </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July and August 2024, TRC issued common stock in connection with a license agreement and various sales of common stock. After considering TRC&#8217;s Series A
preferred stock financing with new and existing investors in August 2024, and the potential of a merger and acquisition (&#8220;M&amp;A&#8221;) transaction, TRC concluded a hybrid method utilizing both M&amp;A and alternative exit scenarios was most
appropriate. The hybrid method is useful when certain discrete future outcomes can be predicted, but also accounts for uncertainty regarding the timing or likelihood of specific alternative exit events. The equity value in the M&amp;A scenario was
determined using the fully diluted backsolve method, which assumes the undiscounted fair value of all shares the company are equal to the most recent round of financing on a fully diluted basis. The equity value in the alternative exit scenario was
determined using the backsolve method that considers the rights and preferences of each class of equity and solving for the total market value of invested capital that is consistent with a recent transaction in the company&#8217;s own securities.
The equity value in the alternative exit scenario was allocated using the option pricing method, whereby shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each
equity class. The values of the preferred and common stock are inferred by analyzing these options. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Candid </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, in connection with the 2024 Merger described above, Candid issued capital stock as consideration in the transaction. After considering Candid&#8217;s
Series B preferred stock financing in August 2024 with new investors, and a potential initial public offering (&#8220;IPO&#8221;), Candid concluded a hybrid method utilizing both IPO and alternative exit scenarios was most appropriate. The hybrid
method is useful when certain discrete future outcomes can be predicted, but also accounts for uncertainty regarding the timing or likelihood of specific alternative exit events. The equity value in the IPO scenario was determined using the fully
diluted backsolve method, which assumes that all shares in Candid are equal to the most recent round of financing on a fully diluted basis. The equity value in the alternative exit scenario was determined using the backsolve method that considers
the rights and preferences of each class of equity and solving for the total market value of invested capital that is consistent with a recent transaction in Candid&#8217;s own securities, considering the rights and preferences of each class of
equity. The equity value in the alternative exit scenario was allocated using the option pricing method, whereby shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of
each equity class. The values of the preferred and common stock are inferred by analyzing these options. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Determination of the fair value of common stock
underlying stock-based awards </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is required to estimate the fair value of the common stock underlying its stock-based awards when performing fair value
calculations. The fair value of the common stock underlying its stock-based awards was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">375 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
determined on each grant date by its board of directors, taking into account input from management and independent third-party valuation analyses. All options to purchase shares of its common
stock are intended to be granted with an exercise price per share no less than the fair value per share of its common stock underlying those options on the date of grant, based on the information known to it on the date of grant. In the absence of a
public trading market for its common stock, on each grant date Candid developed an estimate of the fair value of its common stock in order to determine an exercise price for the option grants. As noted above, Candid&#8217;s determinations of the
fair value of its common stock were made using methodologies, approaches and assumptions consistent with the Practice Aid. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to considering the results
of independent third-party valuations, our board of directors considered various objective and subjective factors, along with input from management, to determine the fair value of our common stock as of each grant date, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prices of Candid&#8217;s convertible preferred stock sold to investors in arm&#8217;s length transactions and the
rights, preferences and privileges of our convertible preferred stock relative to those of Candid&#8217;s common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s stage of development and business strategy and the material risks related to its business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress of Candid&#8217;s research and development programs, including the status of preclinical studies and clinical
trials for Candid&#8217;s drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s results of operations and financial position, including its levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed
mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the lack of marketability of Candid&#8217;s common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the likelihood of achieving a liquidity event for the holders of Candid&#8217;s common stock, such as an initial public
offering or a sale of the company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">trends and developments in Candid&#8217;s industry; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">external market conditions affecting the life sciences and biotechnology industry sectors; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the economy in general. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the common stock underlying Candid&#8217;s stock-based awards for options granted or modified from October&nbsp;2, 2024 (Candid&#8217;s first option
grant date) through May&nbsp;4, 2025 was determined utilizing the model described above in connection with the 2024 Merger. To determine the fair value of the common stock underlying its stock-based awards for options granted or modified from
May&nbsp;5, 2025 through December&nbsp;31, 2025, Candid continued to use a hybrid method utilizing both IPO and alternative exit scenarios. The methods used to determine the equity value in both the IPO scenario and alternative exit scenario were
updated to reflect the time elapsed since its last sale of equity securities to third-party investors. As a result, the equity value in the IPO scenario was updated to use the guideline public company method, and the equity value in the alternative
exit scenario was updated to use an adjusted enterprise value. To determine the adjusted enterprise value, the equity value used in the previous backsolve model was modified to reflect subsequent changes in the market environment and return on
productive expenses since the equity financing that was the basis for the previous backsolve model. The equity value in the IPO scenario continued to be allocated to each class of shares using the fully-diluted shares outstanding and the equity
value in the alternative exit scenario continued to be allocated using the option pricing method. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On May&nbsp;5, 2025, Candid repriced 5,595,000 options to
purchase shares of its common stock to lower the exercise price. The modification resulted in an increase of $0.3&nbsp;million in the fair value of the repriced stock options. There were no vested options at the modification date and, as such, the
incremental fair value will be recognized over the remaining requisite service period of the awards. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Retrospective reassessment of the fair value of our common
stock for financial reporting purposes </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the preparation of the consolidated financial statements necessary for inclusion in this proxy
statement/prospectus, Candid reassessed for financial reporting purposes, on a retrospective basis, the fair value of its common stock for each stock option granted or modified. For purposes of this reassessment, Candid evaluated its original
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">376 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
inputs and the methodologies used to determine its enterprise value, the methods it used to allocate enterprise value and the timing of those valuations. Candid utilized the reassessed fair
values to determine the stock-based compensation expense which is recorded in its consolidated financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are significant judgments and estimates
inherent in the determination of the fair value of capital stock. These judgments and estimates include assumptions regarding future operating performance, the time to complete an initial public offering or other liquidity event and the
determination of the appropriate valuation methods. If Candid had made different assumptions, its stock-based compensation expense, net loss and net loss per common share could have been significantly different. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the completion of the Merger, the fair value of the Combined Company&#8217;s common stock will be based on the closing price as reported on the date of grant
on the primary stock exchange on which the Combined Company&#8217;s common stock is traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See Note 2 to Candid&#8217;s consolidated financial statements appearing elsewhere in this proxy statement/prospectus for information about recent account
pronouncements, the timing of their adoption, and its assessment, if any, of their potential impact on Candid&#8217;s financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest
Rate Risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s cash, cash equivalents and short-term investments consist of cash held in readily available checking and money market funds, as
well as high-quality U.S. treasury securities and corporate debt securities. The primary objectives of Candid&#8217;s investment activities are to preserve principal, provide liquidity and maximize income without significantly increasing risk.
Candid&#8217;s primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates. However, due to the nature of the cash, cash equivalents, and short-term investments,
Candid does not believe that a hypothetical 10% change in interest rates during any of the period presented would have had a material effect on Candid&#8217;s consolidated financial statements included elsewhere in this proxy statement/prospectus.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Effects of Inflation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Inflation generally affects Candid by
increasing its cost of labor and research and development costs. Candid does not believe that inflation had a material effect on its business, results of operations, or financial condition, or on its consolidated financial statements included
elsewhere in this proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">377 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_25"></A>MANAGEMENT FOLLOWING THE MERGER </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information, as of February&nbsp;28, 2026, regarding the expected directors and executive officers of the combined company immediately
following the Closing. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"><B>Position(s)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ken Song, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Chairman of the Board of Directors</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tim Lu, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer and Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arvind Kush</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer and Chief Business Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bernie Huyghe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Technology Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Angie You, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dan Puckett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Michael Rome, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Aaron Royston, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ken Song, M.D.</I></B> has served as
Candid&#8217;s President and Chief Executive Officer and Chairman of the Candid Board since May 2024. Since March 2024, Dr.&nbsp;Song has also served as the Executive Chairman of the board of directors of Averto Medical, Inc., a privately-held
medical technology company, since March 2024, and a member of the board of directors of Perceptive Capital Solutions Corp since May 2024, a publicly traded special purpose acquisition company. Previously, Dr.&nbsp;Song served as the President, Chief
Executive Officer and member of the board of directors of RayzeBio, Inc., a publicly traded biotechnology company until its acquisition by Bristol-Myers Squibb, from July 2020 until February 2024. Dr.&nbsp;Song is also the <FONT
STYLE="white-space:nowrap">co-founder</FONT> and has served as the Chairman of the board of directors of Ablaze Pharmaceuticals Inc., a privately-held clinical-stage pharmaceutical company, since April 2021. From September 2016 until June 2020,
Dr.&nbsp;Song served as President, Chief Executive Officer and as a member of the board of directors of Metacrine, Inc., a publicly traded clinical-stage biopharmaceutical company, and from April 2010 until April 2016, Dr.&nbsp;Song served as Chief
Executive Officer of Ariosa Diagnostics, a privately-held diagnostics company that he <FONT STYLE="white-space:nowrap">co-founded,</FONT> which was subsequently acquired by Roche. Dr.&nbsp;Song served as Executive Chairman of the board of directors
of Omniome, Inc., a privately-held biotechnology company, from April 2017 until September 2021, which was subsequently acquired by Pacific Biosciences. Dr.&nbsp;Song served as a venture capitalist at Venrock from 2007 until 2010 and a consultant at
McKinsey&nbsp;&amp; Company, a management consulting company, from 2000 until 2002. Dr.&nbsp;Song received a B.S. in Biology from Massachusetts Institute of Technology and an M.D. from University of California, San Francisco. Dr.&nbsp;Song trained
in internal medicine at the University of California, San Francisco, specialized in gastroenterology and hepatology at the University of Washington and was a scientific research fellow at the Fred Hutchinson Cancer Center. We believe that
Dr.&nbsp;Song&#8217;s experience in the biotechnology industry, including his executive experience and his medical training, qualifies him to serve on the combined company&#8217;s board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Tim Lu, M.D., Ph.D.</I></B> has served as Candid&#8217;s Chief Medical Officer and Chief Scientific Officer since July 2024. Previously, Dr.&nbsp;Lu served as the
Chief Medical Officer at DICE Therapeutics, Inc., a publicly traded biopharmaceutical company until its acquisition by Eli Lilly and Company, from August 2020 until August 2023, and served as Vice President at Eli Lilly from August 2023 until July
2024. Prior to DICE Therapeutics, from October 2012 until July 2020, Dr.&nbsp;Lu held roles of increasing responsibility in clinical development at Genentech, Inc., a commercial-stage biotechnology company, including serving as Senior Medical
Director and the Therapeutic Area Lead for inflammatory bowel disease. Prior to Genentech, Dr.&nbsp;Lu was an Assistant Professor of Medicine in the Department of Gastroenterology at the University of California, San Francisco. Dr.&nbsp;Lu received
a B.S. in Biology from Yale University and an M.D., Ph.D. degree from the University of Texas Southwestern Medical Center. Dr.&nbsp;Lu trained in internal medicine and completed a gastroenterology fellowship at the University of California, San
Francisco. Dr.&nbsp;Lu is a board-certified Gastroenterologist. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">378 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Arvind Kush</I></B> has served as Candid&#8217;s Chief Financial Officer and Chief Business Officer since July
2024. Since October 2024, Mr.&nbsp;Kush has also served as a member of the board of directors at Inhibikase Therapeutics, Inc, a publicly traded biotechnology company focused on neurodegeneration. Previously, Mr.&nbsp;Kush served as Chief Financial
Officer of RayzeBio, from November 2021 until June 2024. Prior to RayzeBio, Mr.&nbsp;Kush served as Managing Director in the Healthcare Group in the Global Corporate Investment Banking Division at BofA Securities, a multinational investment bank and
financial services company, from February 2018 until November 2021, advising biopharmaceutical companies on strategic and financing transactions. From July 2008 until January 2018, Mr.&nbsp;Kush served in roles of increasing responsibility in the
healthcare investment banking team at BofA Securities and its predecessor companies, serving most recently as a Director in the Healthcare Group in the Global Corporate Investment Banking Division. From January 2004 until June 2006, Mr.&nbsp;Kush
served as Software Engineer at Caritor India Pvt. Ltd. (now NTT Data Services). Mr.&nbsp;Kush received a Bachelor in Engineering in Computer Science from Visvesvaraya Technological University in India and an M.B.A. from the Goizueta Business School
at Emory University. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Bernie Huyghe, Ph.D.</I></B> has served as Candid&#8217;s Chief Technology Officer since July 2024. Since January 2020, Dr.&nbsp;Huyghe
has served as a consultant at his consulting company, Huyghe Consulting, LLC. Previously, Dr.&nbsp;Huyghe served as Senior Vice President of Technical Operations at Viridian Therapeutics, Inc., a publicly traded biotechnology company focused on
autoimmune and rare diseases, from January 2021 until June 2024. Prior to that, Dr.&nbsp;Huyghe was Vice President in Manufacturing at Nucleus Biologics, LLC, a private biotechnology company in cell and gene therapy, from May 2020 until December
2020. From May 2018 until October 2019, Dr.&nbsp;Huyghe served as Senior Director in External Supply at Allogene Therapeutics, Inc., a clinical-stage public company focused on cancer and autoimmune disease. Dr.&nbsp;Huyghe holds a B.S. in Chemistry
from the University of Florida and a Ph.D. in Biophysical Chemistry from the University of California, Berkeley. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Angie
You, Ph.D.</I></B> has served as a member of the Candid Board since October 2024 and as Candid&#8217;s Lead Independent Director since November 2024. Dr.&nbsp;You has served as the Chief Executive Officer and a member of the board of directors of
Architect Therapeutics, LLC, a biotechnology company, since March 2023, and as a senior advisor to Frasier Healthcare, an investment firm, since February 2022. From April 2022 to May 2023, Dr.&nbsp;You served as advisor to Casdin Capital, LLC, a
life sciences investment firm. From December 2018 to January 2022, Dr.&nbsp;You served as Chief Executive Officer and a member of the board of directors of Amunix Pharmaceuticals, Inc., an immuno-oncology company (acquired by Sanofi S.A.). From
September 2014 to December 2018, Dr.&nbsp;You served as Chief Business&nbsp;&amp; Strategy Officer and Head of Commercial at Sierra Oncology, Inc., where she helped the company through a successful initial public offering and led the company&#8217;s
strategic and transactional business and commercial efforts. Dr.&nbsp;You has served as a member of the board of directors of ORIC Pharmaceuticals, a publicly traded biotechnology company, since November 2021. From April 2022 to February 2024,
Dr.&nbsp;You served on the board of directors of RayzeBio. Dr.&nbsp;You holds an A.B. in Chemistry from Harvard College and a Ph.D. in Biochemistry from Harvard University. We believe Dr.&nbsp;You&#8217;s public company leadership and drug
development and commercial strategy expertise in the biotechnology industry qualify her to serve on the combined company&#8217;s board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dan
Puckett</I></B> has served as a member of the Candid Board since October 2024. From April 2016 until February 2024, Mr.&nbsp;Puckett served as the Chief Financial Officer of Shockwave Medical, Inc., a publicly traded medical device company. Prior to
Shockwave Medical, from June 2015 to April 2016, Mr.&nbsp;Puckett served as Chief Financial Officer for Counsyl, Inc., a DNA testing and genetic counseling company. From September 2011 to June 2015, Mr.&nbsp;Puckett served as Chief Financial Officer
for Ariosa Diagnostics, Inc., a molecular diagnostics company (acquired by Roche). Prior to Ariosa Diagnostics, Mr.&nbsp;Puckett served as Executive Director, Operations at Cerexa, Inc., a Forest Laboratories, Inc. subsidiary, from April 2009 to
September 2011. Prior to Cerexa, Mr.&nbsp;Puckett held senior finance and operations positions at Affymetrix, Inc. and AOL, Inc. Mr.&nbsp;Puckett has served on the board of directors of Averto Medical, Inc. since March 2024 and PROCEPT BioRobotics
Corporation since March 2026. Mr.&nbsp;Puckett received a B.A. in Accounting from Washington State University and an M.B.A. from the University of San Francisco. We believe Mr.&nbsp;Puckett&#8217;s executive and financial experience qualifies him to
serve on the combined company&#8217;s board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">379 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Michael Rome, Ph.D.</I></B> has served as a member of the Candid Board since August 2024. Dr.&nbsp;Rome has
served in various roles at Foresite Capital Management, a healthcare and life sciences investment firm, since 2016, including serving as Managing Director since May 2020. Prior to that, he served as an Analyst at DAFNA Capital Management LLC, a
healthcare hedge fund, from September 2015 to July 2016. Dr.&nbsp;Rome also worked in early-stage drug development as a Senior Scientist for Vault Pharma, an academic <FONT STYLE="white-space:nowrap">start-up</FONT> out of the California NanoSystems
Institute at UCLA, from April 2014 to September 2015. Dr.&nbsp;Rome currently serves on the board of directors of multiple private biotechnology companies, including Remix Therapeutics, Inc., RayThera, Inc. and Khartis Therapeutics, Inc.
Dr.&nbsp;Rome previously served on the board of directors of Kinnate Biopharma Inc., a publicly traded company (acquired by XOMA Corporation), from June 2016 until April 2024, FS Development Corp. (now Disc Medicine, Inc.), a publicly traded special
purpose acquisition company from July 2020 to February 2021, FS Development Corp. II (now Padres Biosciences, Inc.), a publicly traded special purpose acquisition company, from August 2020 to December 2021 and Theseus Pharmaceuticals, Inc., a
publicly traded company (acquired by Concentra Biosciences, LLC), from January 2021 to February 2024. Dr.&nbsp;Rome received a B.S. in Molecular, Cellular and Developmental Biology from University of California, Los Angeles and a Ph.D. in
Biochemistry, Biophysics and Molecular Biology from the California Institute of Technology. We believe Dr.&nbsp;Rome&#8217;s extensive experience investing in diverse biotechnology companies and depth of knowledge and substantial experience as a
research scientist qualify him to serve on the combined company&#8217;s board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Aaron Royston, M.D.</I></B> has served as a member of the Candid
Board since August 2024. Dr.&nbsp;Royston has served in various roles at venBio Partners, a life sciences investment firm, since March 2015, including most recently as Managing Partner since April 2020. Prior to that, Dr.&nbsp;Royston served as a
Senior Associate at Vivo Capital, a global life sciences investment firm, from July 2014 until November 2015. Previously, Dr.&nbsp;Royston served as a Consultant at Bain&nbsp;&amp; Company, Inc., a management consulting company, from July 2013 until
July 2014, where he advised biotechnology companies on a broad range of strategic and operational issues. From July 2007 until July 2008, Dr.&nbsp;Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been
published in medical journals and presented at conferences. Dr.&nbsp;Royston previously served on the board of directors of RayzeBio, from August 2020 until December 2023, Ventyx Biosciences, Inc., a publicly traded biotechnology, from February 2021
until January 2023, Akero Therapeutics, Inc., a publicly traded biotechnology company, from June 2018 until August 2019, and VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.), a publicly traded biotechnology company, from June 2017 until
August 2019. Dr.&nbsp;Royston also currently serves on the boards of directors of multiple private biotechnology companies. Dr.&nbsp;Royston received a B.S. in Biological Sciences from Duke University, an M.D. from the University of Pennsylvania and
an M.B.A. from the Wharton School of the University of Pennsylvania. We believe that Dr.&nbsp;Royston&#8217;s extensive clinical and biotechnology industry experience qualifies him to serve on the combined company&#8217;s board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Jeffrey Tong, Ph.D.</I></B> has served as a member of the Candid Board since August 2024. Dr.&nbsp;Tong is a Partner at Third Rock Ventures, a healthcare
investment firm, which he joined in May 2016. Earlier in his career, Dr.&nbsp;Tong served as Executive Chairman of the board of directors of Delinia, Inc. (acquired by Celgene Corporation), a privately-held biotechnology company, and President and
Chief Executive Officer of Nora Therapeutics, Inc., a privately held biotechnology company. He also served as a member of the management team at Infinity Pharmaceuticals, Inc and was a member of the healthcare practice at McKinsey and Company.
Dr.&nbsp;Tong is currently serving as chairman of the board of Septerna (Nasdaq: SEPN) and has been a board member since 2019.&nbsp;He previously served as a member of the board of directors of Maze Therapeutics (Nasdaq: MAZE) from November 2018 to
January 2025, Rapport Therapeutics, Inc (Nasdaq: RAPP) from December 2022 to November 2024, Nurix Therapeutics, Inc (Nasdaq: NRIX) from February 2018 to May 2022, and serves on the boards of multiple private companies. Dr.&nbsp;Tong received an A.B.
in Biochemical Sciences from Harvard College, an A.M. in Chemistry and Ph.D. in Chemistry from Harvard University, and an M.M.S. in Medicine from Harvard Medical School. We believe that Dr.&nbsp;Tong&#8217;s significant experience building and
leading successful biotechnology companies and his scientific expertise qualify him to serve on the combined company&#8217;s board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Family
Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are no family relationships among any of Candid&#8217;s current directors and executive officers, and there are no family relationships
among any of the combined company&#8217;s proposed directors and executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">380 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Composition of the Board of Directors Following the Merger </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board is divided into three classes, which staggered structure will remain in place following the Closing. Each class has a three-year term, with one class
elected at each annual meeting. Vacancies on the combined company board of directors and newly-created directorships shall be filled exclusively pursuant to a vote of a majority of the directors then in office, even if less than a quorum, or by a
sole remaining director, except that any vacancy created by the removal of a director by the stockholders for cause shall be filled, in addition to any other vote otherwise required by law, only by vote of a majority of the outstanding shares of
common stock. No decrease in the number of directors constituting the combined company board of directors shall shorten the term of any incumbent director. A director elected to fill a vacancy shall be elected for the unexpired term of his or her
predecessor in office and a director chosen to fill a position resulting from an increase in the number of directors shall hold office until the next election of the class for which such director shall have been chosen, subject to the election and
qualification of his or her successor and to his or her earlier death, resignation or removal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Merger Agreement, each of the directors and officers
of Rallybio shall resign immediately prior to the Effective Time. Following the completion of the Merger, Candid anticipates that the combined company board of directors will consist of six directors, all of whom will be designated by Candid. Candid
currently expects that all of its current directors will continue to serve as directors on the combined company board of directors following the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Independence of the Board of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Nasdaq Rule&nbsp;5605 requires a
majority of a listed company&#8217;s board of directors to be comprised of independent directors. In addition, Nasdaq requires that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and
corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act. Under Rule&nbsp;5605(a)(2), a director
will only qualify as an &#8220;independent director&#8221; if, in the opinion of the company, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.
In order to be considered independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the
board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or
any of its subsidiaries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each individual expected to serve on the combined company board of directors upon the completion of the Merger, other than Ken Song, M.D.,
will qualify as an independent director under the Nasdaq listing standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid expects that the combined company board will maintain the flexibility to determine whether the roles of Chair of the combined company board and Chief Executive
Officer should be combined or separated, based on what it believes is in the best interests of the combined company at a given point in time. Candid believes that this flexibility is in the best interest of the combined company and that a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-size-fits-all</FONT></FONT></FONT> approach to corporate governance, with a mandated independent Chair, would not result in better governance or
oversight. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At this time, the Candid believes that Ken Song, M.D., Candid&#8217;s current President and Chief Executive Officer and the expected President and Chief
Executive Officer of the combined company, is best situated to serve as Chair of the combined company board of directors. Dr.&nbsp;Song is highly knowledgeable and has longstanding experience with respect to Candid&#8217;s business, operations and
industry and is expected to have an ongoing executive responsibility for the combined company. Dr.&nbsp;Song is well positioned to identify strategic priorities and lead the combined company&#8217;s consideration and analysis of such priorities. In
addition, Dr.&nbsp;Song offers a robust understanding of risks facing Candid and risks that the combined company will face. In Candid&#8217;s view, this enables the combined company board of directors to better understand the combined company and
work with management to enhance stockholder value. In addition, the Candid believes that this structure will enable the combined company to better fulfill its risk oversight responsibilities and enhances the ability of the President and Chief
Executive Officer to effectively communicate the combined company board of director&#8217;s view to management. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid expects that
&#8195;&#8195;&#8195;&#8195;&#8195; will be appointed as the lead independent director of the combined company to help reinforce the independence of the combined company board of directors as a whole. The position of lead </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">381 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
independent director is expected to be structured to serve as an effective balance to a combined Chief Executive Officer/Chair of the combined company board of directors: the lead independent
director will be empowered to, among other duties and responsibilities, preside over board meetings in the absence of the Chair, act as liaison between the Chair and the independent directors, preside over meetings of the independent directors, and
consult with the Chair in planning and setting schedules and agendas for board meetings to be held during the year. As a result, Candid believes that the lead independent director will help ensure the effective independent functioning of the
combined company board of directors in its oversight responsibilities. In addition, Candid believes that the lead independent director will be better positioned to build a consensus among directors and to serve as a conduit between the other
independent directors and the Chair of the combined company board of directors, for example, by facilitating the inclusion on meeting agendas of matters of concern to the independent directors. In light of Dr.&nbsp;Song&#8217;s extensive history
with and knowledge of Candid, and because the combined company board of directors&#8217; lead independent director will be empowered to play a significant role in the combined company board of directors&#8217; leadership and in reinforcing the
independence of the combined company board of directors, Candid believes that it will be advantageous for the combined company to combine the positions of Chief Executive Officer and Chair of the combined company board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of the Board in Risk Oversight </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The audit committee of the combined
company board of directors is expected to be primarily responsible for overseeing the risk management processes on behalf of its board of directors. Candid expects that the audit committee of the combined company board of directors will receive
reports from management periodically regarding the assessment of risks of the combined company. In addition, the audit committee will be expected to report regularly to the combined company board of directors, which will also consider its risk
profile. The audit committee and the combined company board of directors will focus on the most significant risks the combined company faces and its general risk management strategies. While the combined company board of directors will oversee the
combined company&#8217;s risk management, management will be responsible for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> risk management processes. The combined company board of directors will expect
management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
activities and to effectively implement risk management strategies adopted by the audit committee and the combined company board of directors. Candid believe this division of responsibilities will be the most effective approach for addressing the
risks the combined company faces and that the combined company board of directors&#8217; leadership structure, which also emphasizes the independence of the combined company board of directors in its oversight of its business and affairs, supports
this approach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Committees of the Board of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit
Committee </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the completion of the Merger, the members of the combined company&#8217;s audit committee are expected to be &#8195;&#8195;&#8195;,
&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;. &#8195;&#8195;&#8195; is expected to serve as the chair of the combined company&#8217;s audit committee. All members of the audit committee will meet the requirements for financial literacy under the
applicable rules and regulations of the SEC and Nasdaq and Mr.&nbsp;Puckett will qualify as an audit committee financial expert as defined under the applicable rules of the SEC and have the requisite financial sophistication as defined under the
applicable rules and regulations of Nasdaq. Under the rules of the SEC, members of the audit committee must also meet heightened independence standards. Each proposed member of the audit committee will be independent under the applicable rules of
the SEC and Nasdaq. The audit committee will operate under a written charter that will satisfy the applicable standards of the SEC and Nasdaq. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio audit
committee&#8217;s responsibilities include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appointing, approving the compensation of, and evaluating the qualifications, performance and independence of, our
independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the work of Rallybio&#8217;s independent registered public accounting firm, including through the receipt and
consideration of reports from such firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and permitted
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by Rallybio &#8216;s independent registered public accounting firm; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">382 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and Rallybio&#8217;s independent registered public accounting firm our annual and
quarterly financial statements and related disclosures, including earnings releases; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discussing with Rallybio&#8217;s independent registered public accounting firm critical audit matters and related
disclosures; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and Rallybio&#8217;s independent registered public accounting firm any material
issues regarding accounting principles and financial statement presentations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing disclosures about any significant deficiencies or material weaknesses in Rallybio&#8217;s internal controls,
including disclosures in Rallybio&#8217;s annual and quarterly reports; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">coordinating the Rallybio Board&#8217;s oversight of Rallybio&#8217;s internal control over financial reporting,
disclosure controls and procedures, code of business conduct and ethics, procedures for complaints and legal and regulatory matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discussing Rallybio&#8217;s risk management policies with management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing policies regarding hiring employees from Rallybio&#8217;s independent registered public accounting firm and
procedures for the receipt and retention of accounting related complaints and concerns; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">meeting independently with Rallybio&#8217;s independent registered public accounting firm and management;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving any related person transactions, in accordance with Rallybio policy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing our guidelines and policies governing risk assessment and risk management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the integrity of our information technology systems, process and data; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing the audit committee report required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the audit committee&#8217;s charter; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, at least annually, an evaluation of the performance of the audit committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The audit committee of the combined company is generally expected to retain these duties and responsibilities following the completion of the Merger. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the
consummation of the Merger, the members of the nominating and corporate governance committee are expected to be &#8195;&#8195;&#8195;, &#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;. &#8195;&#8195;&#8195; is expected be the chair of the Nominating
and Corporate Governance Committee. The composition the nominating and corporate governance committee will meet the requirements for independence under, and the functioning of such nominating and corporate governance committee will comply with, any
applicable requirements of the rules and regulations of Nasdaq and the SEC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Nominating and Corporate Governance Committee&#8217;s responsibilities
include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying individuals qualified to become members of Rallybio&#8217;s Board&#8217;s consistent with criteria approved by
the Rallybio Board and receiving nominations for such qualified individuals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to Rallybio&#8217;s Board the persons to be nominated for election as directors and to each committee of the
Rallybio Board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">considering and, if appropriate, establishing a policy under which Rallybio&#8217;s stockholders may recommend a candidate
to the Nominating and Corporate Governance Committee for consideration for nomination as a director; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and recommending committee slates on an annual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to Rallybio&#8217;s Board qualified candidates to fill vacancies on Rallybio&#8217;s Board;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing and recommending to Rallybio&#8217;s Board a set of corporate governance principles applicable to us and
reviewing the principles on at least an annual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to Rallybio&#8217;s Board with respect to our board leadership structure and board
committee structure; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing Rallybio&#8217;s policies and program with respect to significant issues of corporate public responsibility;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">making recommendations to Rallybio&#8217;s Board processes for annual evaluations of the performance of our Board of
Directors and committees of Rallybio&#8217;s Board; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">383 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the process for annual evaluations of Rallybio&#8217;s Board and committees of Rallybio&#8217;s Board;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and reporting to Rallybio&#8217;s Board any actual or potential conflicts of interest of members of
Rallybio&#8217;s Board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">providing new director orientation and continuing education for existing directors on a periodic basis;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing plans for director succession; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the Nominating and Corporate Governance Committee&#8217;s
charter; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and overseeing Rallybio&#8217;s initiatives regarding environmental, social and governance matters, including
related risks and opportunities, and Rallybio&#8217;s public disclosure with respect to such matters; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, on an annual basis, an evaluation of the performance of the Nominating and Corporate Governance Committee.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The nominating and corporate governance committee of the combined company is generally expected to retain these duties and responsibilities
following completion of the Merger. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the consummation of the Merger, the members of the compensation committee are expected to be &#8195;&#8195;&#8195;&#8194;&#8195;,
&#8195;&#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;&#8195;. &#8195;&#8195;&#8195;&#8195;&#8195; is expected to be the chair of the compensation committee. Each proposed member of the combined company&#8217;s compensation committee
will be independent under the listing standards of Nasdaq, a <FONT STYLE="white-space:nowrap">&#8220;non-employee</FONT> director&#8221; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and an
&#8220;outside director&#8221; as defined in Section&nbsp;162(m) of the Code. The composition of the compensation committee will comply with the applicable requirements of the rules and regulations of Nasdaq and the SEC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Compensation Committee&#8217;s responsibilities include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing Rallybio&#8217;s overall management compensation strategy, including base salary, incentive compensation and
equity-based grants; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving corporate goals and objectives relevant to the compensation of Rallybio&#8217;s chief executive
officer and other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to Rallybio&#8217;s Board the compensation of our chief executive officer and other executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to Rallybio&#8217;s Board with respect to
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and administering Rallybio&#8217;s cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, considering and selecting, to the extent determined to be advisable, a peer group of appropriate companies for
purposes of benchmarking and analysis of compensation for Rallybio&#8217;s executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to Rallybio&#8217;s Board any stock ownership guidelines for our executive officers and <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">retaining, appointing or obtaining advice of a compensation consultant, legal counsel or other advisor and determining the
compensation and independence of such consultant or advisor; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing, if required, the compensation committee report on executive compensation for inclusion in Rallybio&#8217;s
annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our annual proxy statement in accordance with SEC proxy and disclosure rules; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">monitoring Rallybio&#8217;s compliance with the requirements of Sarbanes-Oxley relating to loans to directors and
officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing Rallybio&#8217;s compliance with applicable SEC rules regarding stockholder approval of certain executive
compensation matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving all employment contracts and other compensation, severance and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">change-in-control</FONT></FONT> arrangements for Rallybio&#8217;s executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing and periodically reviewing policies and procedures with respect to perquisites as they relate to our
executive officers; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">384 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing the risks associated with Rallybio&#8217;s compensation policies and practices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing and presenting to Rallybio&#8217;s management&#8217;s plans for succession to senior management positions based
on guidelines developed and recommended by the Compensation Committee to the full Rallybio Board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing Rallybio&#8217;s strategies, initiatives and programs with respect to Rallybio&#8217;s management of human
capital resources; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the Compensation Committee&#8217;s charter; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, on an annual basis, an evaluation of the performance of the Compensation Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation committee of the combined company is generally expected to retain these duties and responsibilities following completion of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each member of
the compensation committee following the Closing will be a <FONT STYLE="white-space:nowrap">&#8220;non-employee&#8221;</FONT> director within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of the rules promulgated under the
Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">None of the proposed members of the compensation committee is a
current or former officer or employee of the Rallybio. During the last completed fiscal year, none of the proposed combined company executive officers served on the board of directors or compensation committee of any other company that has an
executive officer serving on the Rallybio Board or compensation committee or the proposed combined company board of directors or proposed compensation committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company will maintain a
code of business conduct and ethics that applies to all directors, officers and employees, including the combined company&#8217;s principal executive officer, principal financial officer, principal accounting officer or controller, or person
performing similar functions. A copy of the code will be available on the Corporate Governance section of the combined company&#8217;s website, www.candidrx.com, upon the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio and Candid expect to terminate
Rallybio&#8217;s Non-Employee Director Compensation Policy immediately prior to the Closing. The combined company board of directors will adopt a new non-employee director compensation policy following the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">385 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_26"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>OF THE COMBINED COMPANY </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the compensation
arrangements, including employment, termination of employment and change in control arrangements, with Rallybio&#8217;s and Candid&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<I>Management
Following the Merger</I>,&#8221; &#8220;<I>Rallybio Executive Officer and Director Compensation and Corporate Governance</I>&#8221; and &#8220;<I>Candid Executive Officer and Director Compensation</I>&#8221;, the following is a description of each
transaction involving Rallybio since January&nbsp;1, 2023, each transaction involving Candid since May&nbsp;1, 2024 (inception) and each current proposed transaction in which: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">either Rallybio or Candid has been or is to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Rallybio&#8217;s or
Candid&#8217;s total assets at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years, as applicable; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any of Rallybio&#8217;s, Candid&#8217;s or the expected combined company&#8217;s directors, executive officers or holders
of more than 5% the outstanding shares of Rallybio Capital Stock, Candid Capital Stock, or combined company&#8217;s common stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material
interest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rallybio Related Party Transactions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Certain Relationships and Transactions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than the compensation
agreements and other arrangements described under &#8220;<I>Rallybio Executive Officer and Director Compensation and Corporate Governance</I>&#8221; in this proxy statement/prospectus and the transactions described below, since January&nbsp;1, 2023,
there has not been and there is not currently proposed, any transaction or series of similar transactions to which Rallybio was, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of
Rallybio&#8217;s total assets amounts at December&nbsp;31, 2025 and 2024) and in which any director, executive officer, holder of five percent or more of any class of Rallybio&#8217;s capital stock or any member of the immediate family of, or
entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director and Officer Indemnification and
Insurance </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio has agreed to indemnify each of its directors and executive officers against certain liabilities, costs and expenses, and has purchased
directors&#8217; and officers&#8217; liability insurance. Rallybio also maintains a general liability insurance policy which covers certain liabilities of directors and officers arising out of claims based on acts or omissions in their capacities as
directors or officers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreements Related to the Merger </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Support Agreements </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution of the Merger Agreement,
certain stockholders of Rallybio holding approximately 24.8% of the outstanding shares of Rallybio Common Stock entered into support agreements with Rallybio and to vote all of their shares of Rallybio Common Stock in favor of (a)&nbsp;the Nasdaq
Stock Issuance Proposal, (b)&nbsp;the Reverse Stock Split Proposal, (c)&nbsp;the Name Change Proposal, (d)&nbsp;the Authorized Share Proposal, (e)&nbsp;the 2026 Plan Proposal and (f)&nbsp;the 2026 ESPP Proposal. For additional information regarding
the support agreements, see the section titled &#8220;<I>Agreements Related to the Merger</I>&#8212;<I>Support Agreements.</I>&#8221; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indemnification
Agreements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with Rallybio&#8217;s initial public offering in August 2021, Rallybio entered into agreements to indemnify its directors and
executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or
proceeding, including any action by or in our right, on account of any services undertaken by such person on our behalf or that person&#8217;s status as a member of our Board of Directors to the maximum extent allowed under Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">386 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Candid Related Party Transactions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreements Related to the Merger </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Support Agreements </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of Candid holding approximately 66.14% of the outstanding shares
Candid Capital Stock as of March&nbsp;1, 2026 entered into support agreements with Candid in favor of Rallybio, providing among other things, that such officers, directors and stockholders (x)&nbsp;will vote all of their shares of Candid Capital
Stock, among other things: (i)&nbsp;in favor of adopting the Merger Agreement and approving the Merger, the other Contemplated Transactions, the Candid Stockholder Matters and the other actions contemplated by the Merger Agreement, (ii)&nbsp;against
any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii)&nbsp;against any acquisition proposal involving a third party and (y)&nbsp;will not solicit or negotiate alternative acquisition proposal or
inquiries in their capacities as stockholders of Candid. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of Candid holding approximately 66.21% of the outstanding shares
of Candid Capital Stock as of March&nbsp;1, 2026 entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, pursuant to which, subject to specified exceptions, such persons accepted certain restrictions on transfers of the shares of
Rallybio Common Stock beneficially held by such persons or such persons&#8217; family members (other than shares received as a result of the conversion of shares received in the Concurrent Financing) for
<FONT STYLE="white-space:nowrap">the&nbsp;180-day&nbsp;period</FONT> following the Effective Time. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Concurrent Financing </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with entering into the Merger Agreement, Candid entered into the Subscription Agreement with the Investors, pursuant to which, and subject to the terms and
conditions therein, Candid agreed to sell, and the Investors agreed to purchase, immediately prior to the Effective Time, shares of Candid Common Stock for an aggregate purchase price of $505.5&nbsp;million. Shares of Candid Common Stock issued
pursuant to the Concurrent Financing will be converted into shares of Rallybio Common Stock in accordance with the Merger Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid and Rallybio have also
agreed to enter into the Registration Rights Agreement with the Investors at the closing of the Concurrent Financing. Pursuant to the Registration Rights Agreement, the combined company will prepare and file a resale registration statement with the
SEC within 30 calendar days following the closing of the Concurrent Financing. The combined company will use its commercially reasonable efforts to cause such registration statement to become effective as promptly as practicable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined company will also agree to, among other things, indemnify the Investors, their members, stockholders, directors, officers, partners, employees, managers,
agents, representatives and advisors under the registration statement from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to the
combined company&#8217;s obligations under the Registration Rights Agreement. Candid currently anticipates that &#8195;&#8195;&#8195;shares of Rallybio Common Stock will have registration rights pursuant to the Registration Rights Agreement
following the Closing. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes subscriptions of shares of Candid Common Stock by holders of more than 5% of the outstanding shares of
Candid Capital Stock (at the time of such transaction), expected holders of more than 5% of the outstanding shares of the combined company&#8217;s common stock immediately following the closing of the Contemplated Transactions and entities
affiliated with members of Candid&#8217;s and the expected combined company&#8217;s board of directors. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF STOCKHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Venrock<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with FMR LLC <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">venBio Global Strategic Fund IV, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Foresite Capital Fund VI LP<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares to be purchased in the Concurrent Financing by Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III, L.P. and VHCP
<FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC (collectively, &#8220;Venrock&#8221;). Following the closing of the Contemplated Transactions, Venrock is expected to beneficially own more than 5% of the outstanding shares of
the combined company&#8217;s common stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">387 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares to be purchased in the Concurrent Financing by certain subsidiaries and affiliates of FMR LLC and other companies whose shares are beneficially owned, or may be beneficially owned by FMR LLC.
Following the closing of the Contemplated Transactions, FMR LLC is expected to beneficially own more than 5% of the outstanding shares of the combined company&#8217;s common stock. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Royston, a member of the Candid Board and who is expected to serve on the board of directors of the combined company, is a managing partner at venBio Global Strategic Fund IV, L.P. (&#8220;venBio&#8221;).
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At the time of signing the Subscription Agreement, Foresite Capital Fund VI LP together with Foresite Labs Affiliates 2024, LLC, Foresite Labs Fund I, L.P., Labs <FONT STYLE="white-space:nowrap">Co-Invest</FONT> LLC and
Foresite Therapeutics 2024, LLC (collectively &#8220;Foresite Capital&#8221;) beneficially owned more than 5% of the outstanding shares of Candid Capital Stock. Following the closing of the Contemplated Transactions, Foresite Capital is expected to
beneficially own more than 5% of the outstanding shares of the combined company&#8217;s common stock. Dr.&nbsp;Rome, a member of the Candid Board and who is expected to serve on the board of directors of the combined company, is a managing director
at Foresite Capital. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Promissory Notes </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Convertible Note Financing </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2024, Candid issued and sold a
convertible promissory note to the Song 2016 Children&#8217;s Trust dated October&nbsp;14, 2016 (the &#8220;Song Children&#8217;s Trust&#8221;) in the principal amount of $0.2&nbsp;million (the &#8220;Song Note&#8221;). Dr.&nbsp;Song, Candid&#8217;s
President and Chief Executive Officer and Chairman of the Candid Board, is a trustee of the Song Children&#8217;s Trust, and may be deemed to beneficially own the shares held by the Song Children&#8217;s Trust. The convertible promissory note
accrued interest at a rate of 5% per annum, and subsequently converted at a 50% discount to the Series B purchase price in connection with the Series B Financing (as defined below). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Foresite Promissory Note </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2024, Candid issued and sold a promissory
note to Foresite Capital Fund VI LP, in the principal amount of $3.0&nbsp;million. The promissory note accrued interest at a rate of 5.12% and was subsequently repaid in accordance with its terms on August&nbsp;19, 2024, following the closing of the
2024 Merger described below. Foresite Capital beneficially owned more than 5% of the outstanding shares of Candid Capital Stock at the time of repayment of the promissory note. In addition, Dr.&nbsp;Rome, a member of the Candid Board, is a managing
director at Foresite Capital. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series B Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, pursuant to a Series B preferred stock purchase agreement, Candid issued and sold in two closings an aggregate of 171,666,659 shares of its Series B
convertible preferred stock at a purchase price of $1.20 per share and received gross proceeds of approximately $206.0&nbsp;million (the &#8220;Series B Financing&#8221;). In connection with the Series B Financing, Candid issued an additional
339,105 shares of Candid&#8217;s Series B convertible preferred stock upon the conversion and extinguishment of the Song Note. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes
purchases of shares of Candid&#8217;s Series B convertible preferred stock by holders of more than 5% of the outstanding shares of Candid Capital Stock (as a result of such transaction) and entities affiliated with members of the Candid Board or who
became affiliates of members of the Candid Board as a result of such transaction. The initial closing of the Series B Financing occurred immediately prior to the closing of the 2024 Merger described below. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF STOCKHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B<BR>PREFERRED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Venrock<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,833,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,999,999.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">venBio Global Strategic Fund IV, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,583,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,499,999.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fairmount Healthcare Fund II L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,583,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,499,999.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">TCG Crossover Fund II, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,583,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,499,999.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with OrbiMed<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,416,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,499,999.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Boxer Capital, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,416,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,499,999.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redmile Biopharma Investments III, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,416,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,499,999.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Song 2016 Children&#8217;s Trust dated October&nbsp;14,
2016<SUP STYLE="font-size:75%; vertical-align:top">(4) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 203,463.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III, L.P. and VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC. As a result
of the Series B Financing, Venrock became a holder of more than 5% of the outstanding shares of Candid Capital Stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">388 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by venBio Global Strategic Fund IV, L.P. Dr.&nbsp;Royston, a managing partner at venBio, became a member of the Candid Board as a result of the Series B Financing. As a result of the Series
B Financing, venBio became a holder of more than 5% of the outstanding shares of Candid Capital Stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments IX, LP (collectively, &#8220;OrbiMed&#8221;). As a result of the Series B Financing, OrbiMed became a holder of more than
5% of the outstanding shares of Candid Capital Stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents shares of Series B convertible preferred stock issued to the Song Children&#8217;s Trust, upon conversion of the Song Note. See &#8220;<I>Certain Relationships and Related Party Transactions of the Combined
Company&#8212;Candid Related Party Transactions&#8212;Promissory Notes&#8212;Convertible Note Financing</I>&#8221; for further information. Dr.&nbsp;Song, Candid&#8217;s President and Chief Executive Officer and Chairman of the Candid Board, is a
trustee of the Song Children&#8217;s Trust. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2024 Merger Transactions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, Candid entered into an Agreement and Plan of Merger and Reorganization (the &#8220;2024 Merger Agreement&#8221;), by and among Candid, Candid BCMA
Merger Sub, Inc. (&#8220;BCMA Merger Sub&#8221;), Candid CD20 Merger Sub, Inc., (&#8220;CD20 Merger Sub&#8221;), Vignette Bio and TRC. Pursuant to the 2024 Merger Agreement, BCMA Merger Sub was merged with and into Vignette Bio, with Vignette Bio
surviving as a wholly owned subsidiary of Candid, and CD20 Merger Sub was merged with and into TRC, with TRC surviving as a wholly owned subsidiary of Candid. The foregoing merger transactions are referred to in this proxy statement/prospectus as
the &#8220;2024 Merger.&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the time of the 2024 Merger, each of Dr.&nbsp;Rome and Dr.&nbsp;Song, Candid&#8217;s President and Chief Executive Officer and
Chairman of the Candid Board, was a member of the board of directors of Vignette Bio, and Dr.&nbsp;Tong was a member of the board of directors of TRC. As a result of the 2024 Merger, Dr.&nbsp;Rome and Dr.&nbsp;Tong became members of the Candid
Board. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective upon the completion of the 2024 Merger, (i)&nbsp;each issued and outstanding share of common stock of Vignette Bio was cancelled and exchanged for
one share of Candid Common Stock, (ii)&nbsp;each issued and outstanding share of Series A convertible preferred stock of Vignette Bio was cancelled and exchanged for one share of Candid Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible
preferred stock, (iii)&nbsp;each issued and outstanding share of common stock of TRC was cancelled and exchanged for 4.25 shares of Candid Common Stock, and (iv)&nbsp;each issued and outstanding share of Series A convertible preferred stock of TRC
was cancelled and exchanged for 4.25 shares of Candid Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table
summarizes the number of shares of Candid Common Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock received in connection with the
2024 Merger by entities who became holders of more than 5% of the outstanding shares of Candid Capital Stock and affiliates of members of the Candid Board as a result of such transaction. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF STOCKHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES <FONT STYLE="white-space:nowrap">A-1</FONT><BR>PREFERRED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES <FONT STYLE="white-space:nowrap">A-2</FONT><BR>PREFERRED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Foresite Capital<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,175,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,987,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,999,997.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Third Rock
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,950,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,000,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,000,003.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares issued to Foresite Capital Fund VI, L.P., Foresite Labs Affiliates 2024, LLC, Foresite Labs Fund I, L.P., Labs <FONT STYLE="white-space:nowrap">Co-Invest</FONT> LLC and Foresite Therapeutics 2024,
LLC. Dr.&nbsp;Rome, a managing director at Foresite Capital, became a member of the Candid Board as a result of the 2024 Merger. As a result of the 2024 Merger, Foresite Capital a holder of more than 5% of the outstanding shares of Candid Capital
Stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares issued to Third Rock Ventures V, L.P. and Third Rock Ventures VI, L.P. (collectively, &#8220;Third Rock Ventures&#8221;). Dr.&nbsp;Tong, a partner at Third Rock Ventures, became a member of the Candid
Board as a result of the 2024 Merger. As a result of the 2024 Merger, Third Rock Ventures became a holder of more than 5% of the outstanding shares of Candid Capital Stock. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Investor Agreements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid is party to an investors&#8217; rights
agreement, voting agreement and right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement containing registration rights, information rights, voting rights and rights of first refusal and
<FONT STYLE="white-space:nowrap">co-sale,</FONT> among other things, with certain of its stockholders, including holders of more than 5% of the outstanding shares of Candid Capital Stock, and entities with which certain of Candid&#8217;s officers
and directors are affiliated. The foregoing agreements will terminate at or prior to the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">389 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s amended and restated certificate of incorporation contains provisions limiting the liability of directors and officers of Candid, and Candid&#8217;s
bylaws, as amended, provide that Candid will indemnify each of its directors and executive officers (as defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> promulgated under the Exchange Act) to the fullest extent not prohibited by the DGCL
or any other applicable law. Candid&#8217;s amended and restated certificate of incorporation also provides the Candid Board with discretion to indemnify its directors, officers and agents (and any other persons to which the DGCL permits Candid to
provide indemnification) pursuant to Candid&#8217;s bylaws, as amended, agreements, vote of Candid&#8217;s stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145
of the DGCL. In addition, Candid&#8217;s bylaws, as amended, provide that Candid has the power to indemnify its other officers, employees and other agents as set forth in the DGCL or any other applicable law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has entered, and the combined company will enter, into separate indemnification agreements with each of its directors and executive officers. The Candid
indemnification agreements provide, and the combined company indemnification agreements will provide, that Candid, or the combined company, as applicable, will indemnify each of their respective directors and officers against any and all expenses
incurred by that director or officer because of his or her status as one of Candid&#8217;s or the combined company&#8217;s, as applicable, directors and/or officers or while serving in such capacity, is or was service or has agreed to serve as a
director, officer, employee or agent of another entity, to the fullest extent permitted by the DGCL, Candid&#8217;s or the combined company&#8217;s amended and restated certificate of incorporation and amended and restated bylaws. In addition, the
Candid indemnification agreements provide, and the combined company indemnification agreements will provide, that, to the fullest extent permitted by the DGCL, Candid or the combined company, as applicable, will advance all expenses incurred by
their respective directors and officers in connection with a legal proceeding involving his or her status as a director or executive officer or while serving in such capacity, is or was service or has agreed to serve as a director, officer, employee
or agent of another entity. The terms of the combined company indemnification agreements are qualified in their entirety by reference to the actual text of the indemnification agreement, a form of which is filed as an exhibit to this proxy
statement/prospectus. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Policies and Procedures for Transactions with Related Persons </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the Closing, combined company plans to adopt a new written related-person transactions policy that sets forth its policies and procedures regarding the
identification, review, consideration and oversight of &#8220;related-person transactions.&#8221; For purposes of the combined company&#8217;s policy only, a &#8220;related-person transaction&#8221; will be a transaction, arrangement or relationship
(or any series of similar transactions, arrangements or relationships) in which the combined company and any &#8220;related person&#8221; are participants involving an amount that exceeds the lesser of $120,000 and 1% of the average of the combined
company&#8217;s total assets at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years. Transactions involving compensation for services provided to the combined company as an employee, consultant or director will
not be considered related-person transactions under this policy. A related person will be any executive officer, director, nominee to become a director or a holder of more than five percent of the combined company&#8217;s common stock, including any
of their immediate family members and affiliates, including entities owned or controlled by such persons. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the policy, it is expected that where a transaction
has been identified as a related-person transaction, management will need to present information regarding the proposed related-person transaction to the combined company&#8217;s audit committee (or, where review by the combined company&#8217;s
audit committee would be inappropriate, to another independent body of the combined company&#8217;s board of directors) for review. The presentation will need to include a description of, among other things, all of the parties thereto, the direct
and indirect interests of the related persons, the purpose of the transaction, the material facts, the benefits of the transaction to the combined company and whether any alternative transactions are available, an assessment of whether the terms are
comparable to the terms available from unrelated third parties and management&#8217;s recommendation. To identify related-person transactions in advance, the combined company will rely on information supplied by its executive officers, directors and
certain significant stockholders. In considering related-person transactions, the combined company&#8217;s audit committee or another independent body of the combined company&#8217;s board of directors will take into account the relevant available
facts and circumstances including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risks, costs and benefits to the combined company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">390 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the impact on a director&#8217;s independence in the event the related person is a director, immediate family member of a
director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms of the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms available to or from, as the case may be, unrelated third parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event a director has an interest in the proposed transaction, the director will need to recuse himself or herself from the deliberations and approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies for Approval of Related Party Transactions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board has
adopted a written related person transaction policy setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount
involved exceeds the lesser of (i) $120,000 or (ii)&nbsp;one percent of the average of Rallybio&#8217;s total assets at year end for the last two completed fiscal years, in any fiscal year and a related person had, has or will have a direct or
indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of
a related person. In reviewing and approving any such transactions, the audit committee is tasked with considering all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that
could be obtained in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">391 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_27"></A>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Introduction </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;1, 2026, Rallybio, Merger Sub, and Candid
entered into the Merger Agreement, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Candid, with Candid surviving as a wholly owned subsidiary of
Rallybio. The Merger is expected to close in the second quarter of 2026 following the effectiveness of this registration statement, receipt of approval by the stockholders of each of Rallybio and Candid and the satisfaction or waiver of the other
conditions to the Merger. Upon completion of the Merger, the business of Candid will continue as the business of the combined company. After the completion of the Merger, Rallybio expects to change its corporate name from &#8220;Rallybio
Corporation&#8221; to &#8220;Candid Therapeutics, Inc.&#8221; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions of the Merger Agreement, at the Effective Time: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each outstanding share of Candid Capital Stock (other than the shares issued in the Concurrent Financing) will be
converted into the right to receive a number of shares of Rallybio Common Stock equal to the Exchange Ratio. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each outstanding share of Candid Common Stock issued in the Concurrent Financing will be converted into the right to
receive a number of shares of Rallybio Common Stock equal to the Concurrent Financing Exchange Ratio. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each outstanding share of Candid Common Stock that is unvested or subject to a repurchase option or a risk of forfeiture,
will be exchanged for the number of shares of Rallybio Common Stock based on the Exchange Ratio, and will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each outstanding and unexercised stock option to purchase Candid Common Stock will be assumed by Rallybio and will be
converted into an option to purchase the number of shares of Rallybio Common Stock with an exercise price, both of which are based on the Exchange Ratio, and will to the same extent otherwise remain unchanged as to the term, exercisability, vesting
schedule and other provisions of such stock options. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Merger, Candid entered into the Subscription Agreement with the
Investors, and Rallybio expects to enter into the Rallybio CVR Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of the Exchange Ratio and the Concurrent Financing Exchange Ratio is assumed to be
0.0716 shares of Rallybio Common Stock for each share of Candid Capital Stock upon the Closing and is subject to the assumptions set forth below. Under the expected Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger
Agreement, immediately after the Closing, pre-Merger equityholders of Candid (other than investors in the Concurrent Financing) are expected to own approximately 57.55% of the combined company, pre-Merger equityholders of Rallybio are expected to
own approximately 3.65% of the combined company, and the Investors are expected to own approximately 38.80% of the combined company (assuming proceeds from the Concurrent Financing of $505.5&nbsp;million), in each case, calculated on a fully diluted
basis using the treasury stock method, and subject to certain assumptions, including (i)&nbsp;a valuation for Rallybio of $47.5&nbsp;million (assuming Rallybio Net Cash of $37.5&nbsp;million as of the Closing), (ii)&nbsp;a fixed valuation for Candid
of $750.0&nbsp;million and (iii)&nbsp;the relative capitalization of Rallybio and Candid. In addition, a proposed reverse stock split at a ratio of 1-for-2.5 has been assumed as discussed below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio will ask its stockholders to approve an amendment to its amended and restated certificate of incorporation to effect the reverse stock split. Upon the
effectiveness of the amendment to its amended and restated certificate of incorporation effecting the reverse stock split, the outstanding shares of Rallybio Common Stock will be reduced by a ratio to be agreed upon by Rallybio and Candid. For
purposes of the unaudited pro forma condensed combined financial information a reverse stock split of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-2.5</FONT></FONT> has been assumed, and any references herein to the
proposed reverse stock split shall account for such assumption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">392 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be
accounted for as a reverse recapitalization under GAAP, as well as the Concurrent Financing and assumes the proposed reverse stock split at a ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-2.5.</FONT></FONT> For
further details related to the accounting for the Merger see Notes 1 and 3 below. All share amounts have been adjusted to reflect the estimated Exchange Ratio of 0.0716 shares of Rallybio Common Stock for each share of Candid Capital Stock, unless
otherwise stated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma condensed combined balance sheet assumes that the Merger took place on December&nbsp;31, 2025, and combines the
historical balance sheets of Rallybio and Candid as of such date. The unaudited pro forma condensed combined statements of operations for the year ended December&nbsp;31, 2025 assume that the Merger took place as of January&nbsp;1, 2025, and
combines the historical results of Rallybio and Candid for the year ended December&nbsp;31, 2025. The unaudited pro forma condensed combined financial information was prepared pursuant to the rules and regulations of
<FONT STYLE="white-space:nowrap">Rule&nbsp;8-05&nbsp;and</FONT> Article 11 of SEC <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-X.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro
forma condensed combined financial information, including the notes thereto, should be read in conjunction with the separate historical financial statements of Rallybio and Candid, and their respective management&#8217;s discussion and analysis of
financial condition and results of operations included elsewhere in this proxy statement/prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma condensed combined financial
information is based on the assumptions and adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are
performed including but not limited to changes in Rallybio&#8217;s assets and liabilities, additional financing, additional direct and incremental offering costs and the final reverse stock split. Adjustments have been made solely for the purpose of
providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting expected to be completed after the Closing may occur, and these differences could have a material impact
on the accompanying unaudited pro forma condensed combined financial information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma condensed combined financial information does not give
effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined
financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had Rallybio and Candid been a combined organization during the
specified period. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but
not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">393 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>As of December&nbsp;31, 2025 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><I>(in
thousands, except per share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RALLYBIO</B><br><B>(HISTORICAL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CANDID</B><br><B>(HISTORICAL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PROPOSED<BR>REVERSE<BR>STOCK<BR>SPLIT<BR>ADJUSTMENT<BR>(NOTE 5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00px solid #000000"><B>NOTES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TRANSACTION</B><br><B>ACCOUNTING</B><br><B>ADJUSTMENTS</B><br><B>(NOTE 5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NOTES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA</B><br><B>COMBINED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>A</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">539,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">492,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>B</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">61,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">227,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#8212;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">487,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">776,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#8212;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#8212;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Other assets, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">231,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">487,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 781,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">3,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">14,219</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#8212;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>C</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">27,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">7,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>D</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">15,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#8212;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">9,739</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">29,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Operating leases liabilities,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>C</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">17,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#8212;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">10,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">31,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Convertible preferred stock, $0.0001 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(427,735</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>E</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Stockholders&#8217; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Common stock, $0.0001 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom"><B>J</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>B</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>E</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>G</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom"><B>J</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>B</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,017,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,573</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>D</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>E</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(310,934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>F</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>G</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>H</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>I</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>F</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(301,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(266,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#8212;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(5,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>A</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(268,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>C</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>F</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>H</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>I</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total stockholders&#8217; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(213,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">904,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">749,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">231,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">487,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">781,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the unaudited pro forma condensed combined financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">394 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>For the Year Ended December&nbsp;31, 2025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><I>(in thousands, except per share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RALLYBIO</B><br><B>(HISTORICAL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CANDID</B><br><B>(HISTORICAL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PROPOSED<BR>REVERSE<BR>STOCK SPLIT<BR>ADJUSTMENT<BR>(NOTE 5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NOTES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TRANSACTION</B><br><B>ACCOUNTING</B><br><B>ADJUSTMENTS</B><br><B>(NOTE 5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NOTES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO FORMA</B><br><B>COMBINED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>AA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>BB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>AA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>BB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>CC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>DD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,064</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145,943</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gain on sale of joint venture and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before equity in losses of joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(92,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(111,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average common shares outstanding &#8211; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>EE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>EE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common share &#8211; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>EE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the unaudited pro forma condensed combined financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">395 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 1&#8212;Description of the Transaction </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;1, 2026,
Rallybio, Merger Sub and Candid entered into the Merger Agreement, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Candid, with Candid surviving as
a wholly owned subsidiary of Rallybio. Subject to the terms and conditions of the Merger Agreement, at the Effective Time: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each outstanding share of Candid Capital Stock (other than the shares issued in the Concurrent Financing) will be
converted into the right to receive a number of shares of Rallybio Common Stock equal to the Exchange Ratio. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each outstanding share of Candid Common Stock issued in the Concurrent Financing will be converted into the right to
receive a number of shares of Rallybio Common Stock equal to the Concurrent Financing Exchange Ratio. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each outstanding share of Candid Common Stock that is unvested or subject to a repurchase option or a risk of forfeiture,
will be exchanged for the number of shares of Rallybio Common Stock based on the Exchange Ratio, and will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each outstanding and unexercised stock option to purchase Candid Common Stock will be assumed by Rallybio and will be
converted into an option to purchase the number of shares of Rallybio Common Stock with an exercise price, both of which are based on the Exchange Ratio, and will to the same extent otherwise remain unchanged as to the term, exercisability, vesting
schedule and other provisions of such stock options. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Merger, Rallybio equity awards are expected to be accelerated and
fully vested prior to the Closing, after giving effect to the proposed reverse stock split of Rallybio Common Stock at an assumed ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-2.5</FONT></FONT> to be implemented
prior to the Closing. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anticipated Concurrent Financing </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with the execution and delivery of the Merger Agreement, Candid and the Investors executed the Subscription Agreement, pursuant to which the Investors agreed
to purchase shares of Candid Common Stock immediately prior to the Closing, for aggregate gross cash proceeds of $505.5&nbsp;million before estimated expenses, subject to no less than $450.0&nbsp;million in aggregate gross cash proceeds.
Approximately 360.7&nbsp;million shares of Candid Common Stock before giving effect to the Exchange Ratio, at an estimated purchase price of $1.40 per share are expected to be issued immediately prior to or concurrent with the Closing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the pro forma number of shares of common stock of the combined company expected to be outstanding immediately upon the consummation of
the Merger on a fully diluted basis using the treasury stock method, assuming (i)&nbsp;a valuation for Rallybio of $47.5&nbsp;million (assuming Rallybio Net Cash of $37.5&nbsp;million as of the Closing), (ii) a fixed valuation for Candid of
$750.0&nbsp;million, (iii)&nbsp;the relative capitalization of Rallybio and Candid, (iv)&nbsp;the anticipated proceeds from the Concurrent Financing of $505.5&nbsp;million and (v)&nbsp;a proposed reverse stock split of Rallybio Common Stock at an
assumed ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-2.5</FONT></FONT> to be implemented prior to the Closing: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON</B><br><B>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OWNERSHIP</B><br><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Candid stockholders and optionholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,327,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rallybio stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,427,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.65</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Concurrent Financing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,836,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total shares of common stock of the combined company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>66,590,897</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Consummation of the Merger is subject to certain closing conditions, including but not limited to, approval by Rallybio stockholders,
approval by Candid stockholders, Nasdaq&#8217;s approval of the listing of the shares of Rallybio Common Stock to be issued in connection with the Merger, the Concurrent Financing with cash proceeds of at least $200.0&nbsp;million, and the
effectiveness of the registration statement of which this proxy statement/prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">396 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The employment agreements for Rallybio employees include entitlement to change in control payments for certain
executives and severance for certain <FONT STYLE="white-space:nowrap">non-executives,</FONT> which is expected to be treated as <FONT STYLE="white-space:nowrap">pre-Merger</FONT> compensation expense of Rallybio and reflected as a reduction in cash
of Rallybio. Prior to the Closing, Rallybio also has or expects to (i)&nbsp;discontinue its research and development activities, and (ii)&nbsp;close out and terminate all contracts related to Rallybio&#8217;s clinical trials. To the extent such
severance costs and any other termination costs are not settled in cash by Rallybio prior to Closing, they will be assumed by the combined company at Closing and adjusted through Rallybio&#8217;s valuation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contingent Value Rights Agreement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended
December&nbsp;31, 2025, Rallybio sold Rallybio&#8217;s REV102 to Recursion in July 2025. In connection with the sale, Rallybio recorded contract assets related to potential future proceeds from the sale in the amount of $3.0&nbsp;million,
representing the Legacy Assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior to the Closing, Rallybio expects to enter into the Rallybio CVR Agreement, pursuant to which holders of Rallybio
Common Stock, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, restricted stock units and in the money stock options will receive one Rallybio CVR for each outstanding share, or share underlying such pre-funded warrant or equity award
held. Each Rallybio CVR holder will be entitled to receive on a pro rata basis a share of all of the net proceeds, if any, received by Rallybio from (i)&nbsp;upfront, milestone, or royalty fees under any disposition agreements related to the Legacy
Assets, and (ii)&nbsp;all of the cash proceeds, if any, received from Recursion related to the sale of Rallybio&#8217;s REV102 in July 2025. The combined company will use commercially reasonable efforts to effect the disposition of the Legacy Assets
for a period of one year after the Closing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company concluded that the Rallybio CVRs represent financial instruments and anticipates that they will be
accounted for at fair value. Accordingly, the Rallybio CVRs will be remeasured, with changes in fair value, if any, reflected in the consolidated statements of operations and comprehensive loss, as of each reporting period date. The estimated fair
value of the Rallybio CVR liability was determined using the discounted cash flow method to estimate future cash flows associated with the Legacy Assets and those arising from the sale of REV102, including the expected milestone and royalty
payments. The fair value of the Rallybio CVR liability arising from the sale of REV102 is estimated to be equal to the book value of the related contract asset of $3.0&nbsp;million. The fair value of the CVR liability related to any remaining Legacy
Assets is immaterial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the Merger, such Rallybio CVR liabilities represent an obligation because they are expected to be issued to <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Rallybio equityholders, and the combined company will not be entitled to any proceeds (other than reimbursement for any reasonable disposition costs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 2&#8212;Basis of Pro Forma Presentation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma
condensed combined financial information has been prepared in accordance with Article&nbsp;11 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-X</FONT> and depicts the proposed reverse stock split and accounting for the Merger
(&#8220;Transaction Accounting Adjustments&#8221;). The unaudited pro forma condensed combined balance sheet as of December&nbsp;31, 2025 assumes that the proposed reverse stock split and Merger had been approved or consummated on December&nbsp;31,
2025. The unaudited pro forma condensed combined statement of operations for the year ended December&nbsp;31, 2025 assumes that the proposed reverse stock split and Merger took place as of January&nbsp;1, 2025, and combines the historical results of
Rallybio and Candid for the year ended December&nbsp;31, 2025. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma condensed combined financial information is based on the assumptions and
adjustments that are described in the accompanying notes. The pro forma adjustments are subject to further revision as additional information becomes available and additional analyses are performed, including but not limited to changes in
Rallybio&#8217;s assets and liabilities, additional financing, additional direct and incremental offering costs and the final reverse stock split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined
financial information. There will be differences between the pro forma adjustments and the final accounting expected to be completed after the Closing, and such differences could be material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 3&#8212;Accounting for the Merger </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma condensed
combined financial information gives effect to the Merger, which is expected to be accounted for under GAAP as an <FONT STYLE="white-space:nowrap">in-substance</FONT> reverse recapitalization of Candid. The treatment as an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">397 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">in-substance</FONT> reverse recapitalization is based on the assessment that as a result of Rallybio&#8217;s discontinuation of its research and development
activities and settlement of its other remaining operating assets and liabilities, immediately prior to the Closing, Rallybio is expected to have nominal operations and nominal assets, apart from cash and cash equivalents and marketable securities.
Under a reverse recapitalization, Candid is considered to effect a financing transaction in exchange for issuing equity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio is not considered to be the
accounting acquirer in the Merger based on the following considerations: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid stockholders will own a majority of the voting rights of the combined company. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid will designate all initial members of the board of directors of the combined company. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Candid&#8217;s executive management team will become the executive management team of the combined company.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The combined company will be renamed &#8220;Candid Therapeutics, Inc.&#8221; and its headquarters will be Candid&#8217;s
current headquarters, in San Diego, California. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As the transaction is a reverse recapitalization, Candid&#8217;s assets and liabilities will be
carried into the books of Rallybio at their <FONT STYLE="white-space:nowrap">pre-combination</FONT> carrying amounts. Candid&#8217;s historical equity carrying values will become the equity of the combined company, with the number of shares
outstanding and the common stock aggregate par value adjusted for the effects of the exchange of Candid Capital Stock for Rallybio&#8217;s Common Stock. For periods prior to the Closing, the historical financial statements of Candid will become the
historical financial statements of the combined company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assets and liabilities of Rallybio will be adjusted upon completion of the Merger to their fair
values, which are expected to approximate their carrying values. No goodwill is recognized. The adjusted values of cash and cash equivalents, marketable securities and nominal other net assets acquired will be recorded as an adjustment to the <FONT
STYLE="white-space:nowrap">post-Merger</FONT> equity of the combined company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to the related Rallybio CVRs asset and liability, Management&#8217;s
preliminary conclusion is that (i)&nbsp;there is no value associated with the Rallybio CVRs related to any potential future disposition of any Legacy Assets as the likelihood of any payments received in connection with the Legacy Assets following
the Closing is remote and (ii)&nbsp;the value associated with the Rallybio CVRs related to the disposition of the Legacy Assets in July 2025, has been recorded within prepaid and other current assets and other assets, noncurrent with a corresponding
obligation recorded within accrued expenses and other current liabilities and other liabilities, noncurrent in the pro forma condensed combined balance sheet as of December&nbsp;31, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 4&#8212;Shares of Rallybio Common Stock Issued to Candid Stockholders upon the Closing of the Merger </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At Closing, all outstanding shares of Candid Capital Stock will be exchanged for shares of Rallybio Common Stock based on the preliminary estimated Exchange Ratio of
0.0716 shares of Rallybio Common Stock for each share of Candid Capital Stock and preliminary estimated Concurrent Financing Exchange Ratio of 0.0716 (rounded) shares of Rallybio Common Stock for each share of Candid Common Stock issued in the
Concurrent Financing, in each case, determined in accordance with the terms of the Merger Agreement and after giving effect to the proposed reverse stock split at an assumed ratio of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-2.5.</FONT></FONT> The estimated number of shares of Rallybio Common Stock that Rallybio expects to issue to Candid&#8217;s stockholders assumes Rallybio Net Cash at Closing is
$37.5&nbsp;million, and is determined as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shares of Candid common stock issued<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,521,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shares of Candid convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total Candid shares prior to Closing, <FONT STYLE="white-space:nowrap">pre-Exchange</FONT> Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508,527,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Concurrent Financing, <FONT STYLE="white-space:nowrap">pre-Concurrent</FONT> Financing Exchange
Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,658,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total Candid shares and Concurrent Financing prior to Closing,
<FONT STYLE="white-space:nowrap">pre-Exchange</FONT> Ratio and Concurrent Financing Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">869,186,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Estimated Exchange Ratio and Concurrent Financing Exchange Ratio (rounded)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Estimated shares expected to be issued to existing Candid stockholders and investors participating in
Candid Concurrent Financing upon Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,246,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> Includes 141,472,337 shares of Candid Common Stock issued as of December&nbsp;31,
2025, and 49,479 shares of Candid Common Stock issued after December&nbsp;31, 2025 to February&nbsp;28, 2026. Also includes shares of Candid&#8217;s restricted common stock subject to vesting conditions that are legally issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">398 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 5&#8212;Pro Forma Adjustments </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Merger based on preliminary estimates that could
change materially as additional information is obtained. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adjustments to the historical consolidated financial statements of Rallybio to conform to the accounting
policies of Candid are not expected to be significant.</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pro Forma Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The adjustments included in the unaudited pro forma condensed combined balance sheet as of December&nbsp;31, 2025, were as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect preliminary estimated incremental compensation expense of $5.4&nbsp;million related to severance and change
in control payments resulting from <FONT STYLE="white-space:nowrap">pre-existing</FONT> employment agreements or severance plan arrangements that will be incurred upon the Closing as a reduction to cash and cash equivalents and a corresponding
increase to accumulated deficit. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect the anticipated proceeds in cash and cash equivalents and a corresponding increase to additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital from the Concurrent Financing of $505.5&nbsp;million effected immediately prior to or at the Closing, net of estimated transaction costs in the amount of $12.6&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect the liability related to the Rallybio CVR that is payable to the
<FONT STYLE="white-space:nowrap">pre-Closing</FONT> Rallybio stockholders, and therefore is an obligation upon the Closing. The current and noncurrent liability in the aggregate amount of $3.0&nbsp;million is reflected with a corresponding increase
to accumulated deficit. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect the preliminary estimated Merger-related transaction costs in the amount of $7.6&nbsp;million, not reflected
in the historical financial statements, that are expected to be incurred by Candid in connection with the Merger. These costs include advisory, legal, consulting and accounting and other professional fees that are direct and incremental and treated
as a cost of raising equity since the Merger is accounted for as a reverse recapitalization, equivalent to the issuance of equity for the net assets of Rallybio. The $7.6&nbsp;million is recognized as a liability and a corresponding reduction of the
net proceeds received in additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect the conversion of Candid&#8217;s convertible preferred stock into Rallybio Common Stock in an aggregate
amount of $427.7&nbsp;million, recorded to common stock for the par value and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital of the combined company for the excess over the par value. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect derecognition of Rallybio&#8217;s historical accumulated deficit, and the recapitalization of Candid as
additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL">The pro forma adjustments recorded to Rallybio&#8217;s
accumulated deficit as of December&nbsp;31, 2025, were determined as follows (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s historical accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">301,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Compensation expense related to Rallybio in connection with the Merger (Note A)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Recognition of liability related to CVR assets (Note C)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s incremental stock-based compensation for acceleration of unvested awards
(Note&nbsp;H)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total adjustments to derecognize Rallybio&#8217;s historical accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">310,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">399 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL">The pro forma adjustments recorded to Rallybio&#8217;s additional paid-in capital as of December 31,
2025, were determined as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(359,932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rallybio historical net assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Compensation expense related to Rallybio in connection with the Merger (Note A)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Recognition of liability related to CVR assets (Note C)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s incremental stock-based compensation for acceleration of unvested awards
(Note&nbsp;H)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Par value adjustment to historical Rallybio for proposed reverse stock split (Note J)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total adjustments to derecognize Rallybio&#8217;s historical additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(310,934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(G)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To adjust the par value of common stock of the combined company expected to be outstanding at the Closing.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(H)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect incremental stock-based compensation in the amount of $0.6&nbsp;million, not reflected in the historical
financial statements, expected to be recognized on Closing related to the acceleration of Rallybio&#8217;s equity awards in accumulated deficit and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(I)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect stock-based compensation in the amount of $1.7&nbsp;million, not reflected in the historical financial
statements, expected to be recognized on Closing related to a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> for Candid&#8217;s equity awards with both service and liquidity performance based vesting conditions in accumulated deficit
and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(J)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To adjust the par value of Rallybio after giving effect to the proposed reverse stock split at an assumed ratio of
1-for-2.5. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pro Forma Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The adjustments included in the unaudited pro forma condensed combined statement for the year ended December&nbsp;31, 2025, were as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(AA)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect the recognition of $1.7&nbsp;million in research and development expense and in general and administrative
expense for stock-based compensation expected to be recognized on Closing related to a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> for Candid&#8217;s equity awards with both service and liquidity performance based vesting conditions.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(BB)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect the recognition of $0.6&nbsp;million estimated incremental stock-based compensation in research and
development expense and in general and administrative expense, not reflected in the historical financial statements, due to the acceleration of Rallybio&#8217;s equity awards. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(CC)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect the recognition of $3.0&nbsp;million in general and administrative expense for the liability related to the
Rallybio CVRs that are expected to remain with <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Rallybio stockholders upon the Closing. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(DD)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect the recognition of $5.4&nbsp;million for estimated incremental compensation expense in general and
administrative expense related to severance and change in control payments resulting from <FONT STYLE="white-space:nowrap">pre-existing</FONT> employment agreements or severance plan arrangements that are expected to be incurred upon the Closing.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">400 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(EE)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">The pro forma basic and diluted net loss per common share have been adjusted to reflect the pro forma net loss for the
year ended December&nbsp;31, 2025. In addition, the number of shares used to calculate the pro forma basic and diluted net loss per common share has been adjusted to reflect the estimated total number of shares of common stock of the combined
company that would be outstanding as of the date of the Closing, including the shares to be issued in the Concurrent Financing, as if they have been outstanding for the entirety of the period presented. For the year ended December&nbsp;31, 2025, the
pro forma weighted average common shares outstanding and pro forma net loss per common share, basic and diluted, were calculated as follows: </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(111,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rallybio weighted average common shares<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,629,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rallybio weighted average common shares (restricted common stock subject to acceleration on
Closing)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,928,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Reverse stock split</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rallybio subtotal<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP><SUP
STYLE="font-size:75%; vertical-align:top">(a)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,371,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Candid weighted average shares<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,521,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Candid weighted average shares of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Candid weighted average Concurrent Financing common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,658,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Candid pro forma weighted average common shares outstanding &#8211; basic and diluted, <FONT
STYLE="white-space:nowrap">pre-Exchange</FONT> Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">869,186,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Estimated Exchange Ratio and Concurrent Financing Exchange Ratio (rounded)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Candid subtotal<SUP STYLE="font-size:75%; vertical-align:top">(b)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,246,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted average common shares outstanding &#8211; basic and diluted, post-Exchange Ratio<SUP
STYLE="font-size:75%; vertical-align:top">(a) + (b)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,618,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per common share &#8211; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">From Rallybio&#8217;s historical audited financial statements as of and for the year ended December&nbsp;31, 2025. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Rallybio weighted average common shares after giving effect to the proposed reverse stock split at an assumed ratio of 1-for-2.5. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 141,472,337 shares of Candid Common Stock issued as of December 31, 2025, and 49,479 shares of Candid Common Stock issued after December 31, 2025 to February 28, 2026. Also includes shares of Candid&#8217;s
restricted common stock subject to vesting conditions that are legally issued. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">401 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_28"></A>DESCRIPTION OF RALLYBIO CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following description of Rallybio Capital Stock and provisions of Rallybio&#8217;s amended and restated certificate of incorporation and Rallybio&#8217;s bylaws
are summaries and are qualified by reference to such charter and bylaws and applicable provisions of the DGCL. Copies of Rallybio&#8217;s amended and restated certificate of incorporation and Rallybio&#8217;s bylaws are filed as exhibits to the
registration statement of which this proxy statement/prospectus is a part.</I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s authorized capital stock consists of 200,000,000 shares of Rallybio Common Stock, with a par value of $0.0001 per share, and 50,000,000 shares of
preferred stock, with a par value of $0.0001 per share. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of Rallybio Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting
rights. An election of directors by Rallybio&#8217;s stockholders shall be determined, in an uncontested election, by a majority of the votes cast by the stockholders entitled to vote on the election and, in a contested election, by a plurality of
the votes cast by the stockholders entitled to vote on the election. Holders of Rallybio Common Stock are entitled to receive proportionately any dividends as may be declared by the Rallybio Board, subject to any preferential dividend rights of any
series of preferred stock that Rallybio may designate and issue in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of our liquidation or dissolution, the holders of Rallybio Common Stock
are entitled to receive an amount of Rallybio&#8217;s net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of Rallybio
Common Stock have no preemptive, subscription, redemption or conversion rights. Outstanding shares of Rallybio Common Stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of Rallybio Common Stock
are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that Rallybio may designate and issue in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preferred Stock </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of Rallybio&#8217;s amended and
restated certificate of incorporation, the Rallybio Board is authorized to direct Rallybio to issue shares of preferred stock in one or more series without stockholder approval. The Rallybio Board has the discretion to determine the rights,
preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The purpose of authorizing the Rallybio Board to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder
vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third-party to
acquire, or could discourage a third-party from seeking to acquire, a majority of Rallybio&#8217;s outstanding voting stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pre-Funded Warrants </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of February 27, 2026, Rallybio had pre-funded warrants outstanding to purchase 416,673 shares of Rallybio Common Stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each pre-funded warrant entitles the registered holder to purchase one share of Rallybio Common Stock at an exercise price of $0.0008 per share of Rallybio Common
Stock. The exercise price of the pre-funded warrants and the number of shares of Rallybio Common Stock issuable upon exercise of the pre-funded warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting Rallybio Common Stock, as well as upon any distribution of assets, including cash, stock or other property, to Rallybio&#8217;s stockholders. The pre-funded warrants
have no expiration date and are exercisable, at the option of each holder, in whole or in part, by delivering notice and payment of the exercise price or by means of cashless exercise as further described in the pre-funded warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">402 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any
portion of any such warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, any other persons acting as a group together with the holder or any
of the holder&#8217;s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with the holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act) would exceed 9.99% of the number
of shares of Rallybio Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of such pre-funded warrant, which percentage may be increased or decreased at the
holder&#8217;s election upon 61 days&#8217; notice to us subject to the terms of such pre-funded warrants, provided that such percentage may in no event exceed 19.99%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the consummation of a fundamental transaction (as described in the pre-funded warrants), the pre-funded warrants will automatically be converted into the right of
the holder of such pre-funded warrant to receive the same kind and amount of securities, cash or other property that such holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction,
without regard to any limitations on exercise contained in the pre-funded warrants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to applicable laws, the pre-funded warrants may be offered for sale,
sold, transferred or assigned without Rallybio&#8217;s consent. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-takeover Effects of Rallybio&#8217;s Amended and Restated Certificate of Incorporation,
Amended and Restated Bylaws and the DGCL </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated certificate of incorporation and amended and restated bylaws contain certain
provisions that are intended to enhance the likelihood of continuity and stability in the composition of the Rallybio Board, but which may have the effect of delaying, deferring or preventing a future takeover or change in control of Rallybio unless
such takeover or change in control is approved by the Rallybio Board. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These provisions include: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Classified board.</I> Rallybio&#8217;s amended and restated certificate of incorporation provides that the Rallybio Board is divided into three classes of directors,
with the classes as nearly equal in number as possible. As a result, approximately one-third of the Rallybio Board will be elected each year. The classification of directors will have the effect of making it more difficult for stockholders to change
the composition of the Rallybio Board. Rallybio&#8217;s amended and restated certificate of incorporation also provides that, subject to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number
of directors will be fixed exclusively pursuant to a resolution adopted by the Rallybio Board. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Action by written consent; special meetings of stockholders.</I>
Rallybio&#8217;s amended and restated certificate of incorporation provides that stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in lieu of a meeting. Rallybio&#8217;s
amended and restated certificate of incorporation and Rallybio&#8217;s amended and restated bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted by a
majority of the Rallybio Board. Except as described above, stockholders will not be permitted to call a special meeting or to require the Rallybio Board to call a special meeting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Removal of directors.</I> Rallybio&#8217;s amended and restated certificate of incorporation provides that Rallybio&#8217;s directors may be removed only for cause
by the affirmative vote of at least 75% of the voting power of our outstanding shares of capital stock, voting together as a single class. This requirement of a supermajority vote to remove directors could enable a minority of Rallybio&#8217;s
stockholders to prevent a change in the composition of the Rallybio Board. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Advance notice procedures.</I> Rallybio&#8217;s amended and restated bylaws establish
an advance notice procedure for stockholder proposals to be brought before an annual meeting of Rallybio&#8217;s stockholders, including proposed nominations of persons for election to the Rallybio Board. Stockholders at an annual meeting will only
be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Rallybio Board or by a stockholder who was a stockholder of record on the record date for the meeting, who is
entitled to vote at the meeting and who has given Rallybio&#8217;s Secretary timely written notice, in proper form, of the stockholder&#8217;s intention to bring that business before the meeting. Although Rallybio&#8217;s amended
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">403 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and restated bylaws do not give the Rallybio Board the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or
annual meeting, Rallybio&#8217;s amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a
solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of Rallybio. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Supermajority approval requirements.</I> The
DGCL generally provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless either a corporation&#8217;s certificate of
incorporation or bylaws requires a greater percentage. Rallybio&#8217;s amended and restated certificate of incorporation and Rallybio&#8217;s amended and restated bylaws provide that the affirmative vote of holders of at least 75% of the total
votes eligible to be cast in the election of directors will be required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to Rallybio&#8217;s amended and restated certificate of
incorporation and Rallybio&#8217;s amended and restated bylaws could enable a minority of our stockholders to exercise veto power over any such amendments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized but unissued shares.</I> Rallybio&#8217;s authorized but unissued shares of Rallybio Common Stock and preferred stock are available for future issuance
without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized
but unissued shares of Rallybio Common Stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of Rallybio Common Stock by means of a proxy contest, tender offer, merger or otherwise. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Exclusive forum.</I> Rallybio&#8217;s amended and restated certificate of incorporation provides that, subject to limited exceptions, the state or federal courts
within the State of Delaware will be exclusive forums for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of Rallybio&#8217;s directors, officers or other
employees to Rallybio or Rallybio&#8217;s stockholders, (3) any action asserting a claim against Rallybio arising pursuant to any provision of the DGCL, Rallybio&#8217;s amended and restated certificate of incorporation or Rallybio&#8217;s amended
and restated bylaws, (4) any action to interpret, apply, enforce or determine the validity of Rallybio&#8217;s amended and restated certificate of incorporation or Rallybio&#8217;s amended and restated bylaws or (5) any other action asserting a
claim against Rallybio that is governed by the internal affairs doctrine; provided that, the exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Exchange Act or to any claim for which the federal
courts have exclusive jurisdiction. Rallybio&#8217;s amended and restated certificate of incorporation also provides that, unless Rallybio consents in writing to the selection of an alternative forum, the U.S. federal district courts shall be the
exclusive forum for the resolution of any claims arising under the Securities Act. Although Rallybio believes these provisions benefit Rallybio by providing increased consistency in the application of Delaware and certain federal securities law,
these provisions may have the effect of discouraging lawsuits against Rallybio&#8217;s directors and officers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Section 203 of the DGCL </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio is subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a
&#8220;business combination&#8217;&#8217; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed
manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who,
together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s voting stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: before
the stockholder became interested, the corporation&#8217;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction
which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the
voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">404 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
instances; or at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special
meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#8217;
amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Transfer Agent and Registrar</B> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The transfer agent and registrar for Rallybio
Common Stock is Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">405 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_29"></A>COMPARISON OF RIGHTS OF HOLDERS OF RALLYBIO CAPITAL STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>AND CANDID CAPITAL STOCK </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid and Rallybio are both incorporated under the laws of the State of Delaware. The rights of Candid stockholders and Rallybio stockholders are generally governed by
the DGCL. Upon completion of the Merger, Candid stockholders will become Rallybio stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of the combined company and the amended and restated certificate of
incorporation of the combined company, as amended. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The material differences between the current rights of Candid stockholders under Candid&#8217;s amended and
restated certificate of incorporation and bylaws and their rights as Rallybio stockholders, after the Merger, under Rallybio&#8217;s amended and restated certificate of incorporation and its amended and restated bylaws, both as will be in effect
immediately following the completion of the Merger without giving effect to the increase of the authorized shares, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference
to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for
a more complete understanding of the differences between being a stockholder of Candid or Rallybio before the Merger and being a Rallybio stockholder following the completion of the Merger. For more information on how to obtain these documents, see
the section titled &#8220;<I>Where You Can Find More Information</I>&#8221; of this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Authorized Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s amended and restated certificate of
incorporation authorizes the issuance of up to 974,000,000 shares of Candid Common Stock, $0.0001 par value per share, and 367,005,749 shares of Candid Preferred Stock, $0.0001 par value per share, of which 105,000,000 shares are designated as
&#8220;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock,&#8221; 89,999,985 shares are designated as &#8220;Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock,&#8221; and 172,005,764 shares are designated as
&#8220;Series B Preferred Stock.&#8221; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s authorized capital stock consists of 200,000,000 shares of common stock, $0.0001 par value per share, and 50,000,000 shares of preferred stock, $0.0001
par value per share. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement contemplates an amendment to Rallybio&#8217;s amended and restated certificate of incorporation in connection with the
Closing to implement the reverse stock split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conversion Rights, Liquidation Preferences, and Protective Provisions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amended and restated certificate of incorporation of
Candid provides that each holder of shares of Candid Preferred Stock shall, subject to certain conditions, have the right to convert such shares into shares of Candid Common Stock at any time in accordance with the amended and restated certificate
of incorporation of Candid. Each share of Candid Preferred Stock is convertible into 1.00 share of Candid Common Stock. The applicable conversion rates of each series of Candid Preferred Stock are subject to further adjustment if Candid issues
additional shares of Candid Common Stock or options or other securities convertible into shares of Candid Common Stock at a price per share below the applicable conversion price of a series of Candid Preferred Stock, subject to certain customary
exceptions. The current conversion prices of the Candid Preferred Stock are: $1.00 per share of Candid Series A-1 convertible preferred stock, $1.00 per share of Candid Series A-2 convertible preferred stock, and $1.20 per share of Candid Series B
convertible preferred stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amended and restated certificate of incorporation of Candid provides that at any time when at least 73,401,150 shares of Candid
Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to Candid Preferred Stock) are outstanding, Candid shall
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">406 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
not, either directly or indirectly by amendment, merger, consolidation, amendment, transfer, continuance, recapitalization, reclassification, waiver, statutory conversion, or otherwise, effect
any of the following acts or transactions, subject to certain exceptions, without the written consent or affirmative vote of a majority of the outstanding shares of Candid Preferred Stock, voting together as a single class on an as-converted to
Candid Common Stock basis (which majority shall include (i)&nbsp;the holders of a majority of the outstanding shares of Candid Series B convertible preferred stock, exclusively and as a separate class on an as-converted to Candid Common Stock basis
and (ii)&nbsp;the holders of a majority of the outstanding shares of Candid Series A convertible preferred stock, together as a single class on an as-converted to Candid Common Stock basis): (a) liquidate, dissolve or
<FONT STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of Candid or effect any Deemed Liquidation Event (as defined below) or any other merger, consolidation, statutory conversion, transfer, domestication or continuance;
(b)<B></B>&nbsp;amend, alter or repeal any provision of the amended and restated certificate of incorporation or bylaws, as amended, of Candid; (c)&nbsp;create or issue or obligate itself to issue shares of, or reclassify, any Candid Capital Stock
unless the same ranks junior to the Candid Preferred Stock with respect to its special rights, powers and preferences; (d)&nbsp;increase or decrease the authorized number of shares of Candid Common Stock, Candid Preferred Stock, or any additional
class or series of Candid Capital Stock; (e)<B></B>&nbsp;sell, issue, sponsor, create or distribute, or cause or permit any of its subsidiaries to sell, issue, sponsor, create or distribute, any digital tokens, cryptocurrency or other
blockchain-based assets (collectively, &#8220;Tokens&#8221;), including through a <FONT STYLE="white-space:nowrap">pre-sale,</FONT> initial coin offering, token distribution event or crowdfunding, or through the issuance of any instrument
convertible into or exchangeable for Tokens; (f)<B></B>&nbsp;purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of Candid Capital Stock other than
(i)&nbsp;redemptions of or dividends or distributions on Candid Preferred Stock as expressly authorized therein, (ii)&nbsp;dividends or other distributions payable on the Candid Common Stock solely in the form of additional shares of Candid Common
Stock, and (iii)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for Candid or any subsidiary in connection with the cessation of such employment or service at no greater than
the original purchase price thereof; (g)<B></B>&nbsp;unless the aggregate indebtedness of Candid and its subsidiaries for borrowed money following such action would not exceed $500,000, other than equipment leases, bank lines of credit or trade
payable incurred in the ordinary course of business, create, or issue, any debt security, create any lien or security interest (except for purchase money liens or statutory liens of landlords, mechanics, materialmen, workmen, warehousemen and other
similar persons arising or incurred in the ordinary course of business), or incur other indebtedness for borrowed money, including but not limited to obligations and contingent obligations under guarantees, or permit any subsidiary to take such
action with respect to any debt security lien, security interest or other indebtedness for borrowed money; (h)&nbsp;create, or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one or more other subsidiaries)
by Candid, or permit any subsidiary to create, or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of Candid, or
permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary; (i)&nbsp;increase
or decrease the authorized number of directors constituting the Candid Board, change the number of votes entitled to be cast by any director or directors on any matter, or adopt any provision inconsistent with granting each director one vote on each
matter presented to the Candid Board; (j)&nbsp;increase the number of shares authorized for issuance under any equity or <FONT STYLE="white-space:nowrap">equity-linked</FONT> compensation plan; (k)&nbsp;enter into any sale of control, exclusive
license or any transaction in which all or substantially all of the assets of Candid are sold; or (l)&nbsp;enter into any agreement by Candid or its stockholders regarding a transaction or series of related transactions by merger, consolidation,
share exchange or otherwise of Candid with a publicly traded &#8220;special purpose acquisition company&#8221; or subsidiary thereof. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amended and restated
certificate of incorporation of Candid provides that a &#8220;Deemed Liquidation Event,&#8221; is (a)&nbsp;a merger, consolidation, statutory conversion, transfer, domestication, or continuance in which (i)&nbsp;Candid is a constituent party or
(ii)&nbsp;a subsidiary of Candid is a constituent party and Candid issues shares of Candid Capital Stock pursuant to such merger, consolidation, statutory conversion, transfer, domestication, or continuance, except any such merger, consolidation,
statutory conversion, transfer, domestication, or continuance involving Candid or a subsidiary in which the shares of Candid Capital Stock outstanding immediately prior to such merger, consolidation, statutory conversion, transfer, domestication, or
continuance continue to represent, or are converted into or exchanged for shares of capital stock or other equity interests that represent, immediately following such merger, consolidation, statutory conversion, transfer, domestication, or
continuance, a majority, by voting power, of the capital stock or other equity interests of (1)&nbsp;the surviving or resulting corporation or entity; or (2)&nbsp;if the surviving or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">407 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
resulting corporation or entity is a wholly owned subsidiary of another corporation or entity immediately following such merger, consolidation, statutory conversion, transfer, domestication, or
continuance, the parent corporation or entity of such surviving or resulting corporation or entity; or (b)&nbsp;(i) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by
Candid or any subsidiary of Candid of all or substantially all the assets of Candid and its subsidiaries taken as a whole, or (ii)&nbsp;the sale, lease, transfer, exclusive license or other disposition (whether by merger, consolidation, statutory
conversion, domestication, continuance or otherwise, and whether in a single transaction or series of related transactions) of one or more subsidiaries of Candid if substantially all of the assets of Candid and its subsidiaries taken as a whole are
held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of Candid. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any voluntary or involuntary liquidation, dissolution, winding up of Candid or a Deemed Liquidation Event, the holders the holders of shares of each
series of Candid Preferred Stock are entitled to certain preferential payments out of the assets of Candid available for distribution to Candid&#8217;s stockholders, and, in the case of a Deemed Liquidation Event, payable to Candid stockholders or
received by Candid in a Deemed Liquidation Event (net of certain retained liabilities and expenses), on a pari passu basis based on their respective liquidation amounts, and before any payment shall be made to the holders of Candid Common Stock by
reason of their ownership thereof, an amount per share of each such series of Candid Preferred Stock equal to the greater of (i)&nbsp;the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per
share as would have been payable had all shares of such series of Candid Preferred Stock been converted into Candid Common Stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. After payment in full of all
liquidation amounts required to be paid to the holders of shares of Candid Preferred Stock, the remaining assets of Candid available for distribution to Candid&#8217;s stockholders, and, in the case of a Deemed Liquidation Event, payable to Candid
stockholders or received by Candid in a Deemed Liquidation Event (net of certain retained liabilities and expenses), shall be distributed among the holders of Candid Common Stock, pro rata based on the number of shares of Candid Common Stock held by
each such holder. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of Rallybio Common Stock
have no preemptive rights to subscribe for any shares of any class of Rallybio stock nor conversion rights to convert their common stock into or exchange their common stock for shares of any other class or classes or of any other series of the same
class of Rallybio&#8217;s capital stock. The rights, preferences and privileges of the holders of Rallybio Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of Rallybio preferred stock
that it may designate in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the dissolution, liquidation or winding up of the affairs of Rallybio, whether voluntary or involuntary, after payment or
provision for payment of the debts and liabilities of Rallybio and of the preferential and other amounts, if any, to which the holders of preferred stock shall be entitled, holders of Common Stock shall be entitled to receive all assets of Rallybio
available for distribution to its stockholders, ratably in proportion to the number of shares held by each such stockholder. A merger or consolidation of Rallybio with or into any other corporation or other entity or a sale or conveyance of all or
any part of the Rallybio&#8217;s assets, in any such case that does not in fact result in the liquidation of Rallybio and the distribution of assets to its stockholders, shall not be deemed to be a voluntary or involuntary liquidation or dissolution
or winding up of the Corporation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Board is authorized, subject to limitations prescribed by Delaware law, to issue up to 50,000,000 shares of
preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to determine or alter for each such series, such voting powers, full or limited, or no voting powers and such designation,
preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof. The Rallybio Board can also increase or decrease the number of shares of any series, but not below the number of
shares of that series then outstanding, without any further vote or action by the company&#8217;s stockholders. The Rallybio Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring or preventing a change of control of Rallybio or other corporate action and may adversely affect the market price of Rallybio&#8217;s common stock and the voting and other rights of the holders of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">408 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Number of Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s bylaws, as amended, provide that
Candid&#8217;s authorized number of directors shall be fixed from time to time by the Candid Board. The Candid Board currently has six members. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated certificate of incorporation and amended and restated bylaws provide that, subject to any special rights of the
holders of any series of preferred stock to elect directors, Rallybio&#8217;s authorized number of directors shall be determined from time to time by resolution of the Rallybio Board. The Rallybio Board currently has ten members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stockholder Nominations and Proposals </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s bylaws, as amended, provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as
directors at a meeting of stockholders must provide written notice on a timely basis to Candid&#8217;s secretary, which notice must contain certain information in order to be properly given, and must comply with certain solicitation requirements.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated bylaws provide
that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide written notice on a timely basis and also specify requirements as to the
form and content of a stockholder&#8217;s notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Classification of Board of Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s amended and restated certificate of
incorporation and bylaws, as amended, do not provide for the division of the Candid Board into staggered classes. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated certificate of incorporation provides that the directors shall be divided into three classes, with each class having a three-year
term expiring on a staggered basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Election of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s amended and restated certificate of incorporation provides that (i)&nbsp;the holders of record of the shares of Candid Series A-1
convertible preferred stock shall be entitled to elect one director to the Candid Board; (ii)&nbsp;the holders of record of the shares of Candid Series A-2 convertible preferred stock shall be entitled to elect one director to the Candid Board;
(iii)&nbsp;the holders of record of the shares of Candid Series B convertible preferred stock shall be entitled to elect one director to the Candid Board; in each case of (i)-(iii), subject to certain outstanding share requirements applicable to
such series of Candid Preferred Stock; (iv)&nbsp;the holders of record of the shares of Candid Common Stock shall be entitled to elect one director to the Candid Board; and (v)&nbsp;the holders of record of the shares of Candid Common Stock and of
any other class or series of voting stock (including Candid Preferred Stock), voting together as a single class on an as-converted to Candid Common Stock basis, shall be entitled to elect the balance of the total number of directors of Candid (the <FONT
STYLE="white-space:nowrap">&#8220;At-Large</FONT> Directors&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than any directors elected by the separate vote of the holders of any class or series of preferred stock, the Rallybio Board is divided into three classes,
designated as Class I, Class II and Class III. Directors are assigned to each class in accordance with a resolution or resolutions adopted by the Rallybio Board. Each director will serve for a term expiring at the annual meeting of stockholders to
be held in the third year following the year of their election; provided that each director initially assigned to Class I will serve for a term expiring at Rallybio&#8217;s first annual meeting of stockholders held following the filing of
Rallybio&#8217;s amended and restated certificate of incorporation; each director initially assigned to Class II will serve for a term expiring at Rallybio&#8217;s second annual meeting of stockholders
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">409 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
following the filing Rallybio&#8217;s amended and restated certificate of incorporation; and each director initially assigned to Class serve for a term expiring at Rallybio&#8217;s third annual
meeting of stockholders following the filing Rallybio&#8217;s amended and restated certificate of incorporation. The term of each director will continue until his or her successor is duly elected and qualified or until his or her earlier death,
resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Removal of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s bylaws, as amended, provide that, subject to any limitations imposed by applicable law and unless otherwise provided in Candid&#8217;s amended and
restated certificate of incorporation, any director may be removed from office at any time, with or without cause, by the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of Candid Capital Stock
entitled to vote generally at an election of directors. If Candid is subject to Section&nbsp;2115(b) of the California General Corporation Law (the &#8220;CGCL&#8221;), the Candid Board or any individual director may be removed from office at any
time without cause in accordance with the CGCL. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s amended and restated certificate of incorporation provides that if the holders of any class or
series of any Candid Capital Stock are entitled to elect one or more directors by the provisions of Candid&#8217;s amended and restated certificate of incorporation, such director(s) may removed without cause by, and only by, the affirmative vote of
the holders of a majority of the shares of the class or series of Candid Capital Stock entitled to elect such director. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated certificate of incorporation provides that, except as may otherwise be provided by the DGCL and subject to the special rights of
the holders of any series of preferred stock to elect directors, any individual Rallybio director may be removed only for cause and requires a stockholder vote by the holders of at least a 75% of the voting power of the then outstanding voting
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Vacancies on the Board of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s bylaws, as amended, provide that, unless otherwise provided in Candid&#8217;s amended and restated certificate of incorporation, and subject to the
rights of the holders of any series of Candid Preferred Stock, vacancies on the Candid Board may be filled by the affirmative vote of a majority of the directors then in office, even though less than a quorum, or by the sole remaining director;
provided that, if the holders of any class or series of any Candid Capital Stock are entitled to elect one or more directors by the provisions of Candid&#8217;s amended and restated certificate of incorporation, vacancies will be filled by a
majority of the directors elected by such class or series, or by the sole remaining director so elected, unless the Candid Board determines by resolution that any such vacancies or newly created directorships must be filled by stockholders.
Candid&#8217;s amended and restated certificate of incorporation provides that if the holders of any class or series of any Candid Capital Stock who have a right to elect a director pursuant to the provisions of Candid&#8217;s amended and restated
certificate of incorporation fail to elect such director, then such directorship shall remain vacant until such time as such holders fill such directorship, except that a vacancy in any <FONT STYLE="white-space:nowrap">At-Large</FONT> Director seat
can be filled by either (a)&nbsp;the stockholders entitled to elect the <FONT STYLE="white-space:nowrap">At-Large</FONT> Directors or (b)&nbsp;all of the director(s) then seated. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated certificate of
incorporation and amended and restated bylaws provide that, subject to any limitations imposed by the DGCL, any vacancies on the Rallybio Board and any newly created directorships, shall be filled only by the affirmative vote of a majority of the
directors then in office, even if less than a quorum or by the sole remaining director. However, any vacancy created by the removal of a director by the stockholders for cause shall be filled only by the affirmative vote of a majority of the
outstanding shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Voting Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s amended and restated certificate of incorporation provides that every stockholder shall be entitled to (i)&nbsp;one vote for each share of
Candid Common Stock and (i)&nbsp;such number of votes equal to the whole number of shares of Candid Common Stock into which shares of Candid Preferred Stock held by such stockholder are convertible, in each case, held by them as of the record date
for such meeting. Except as provided by law or the other provisions of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">410 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Candid&#8217;s amended and restated certificate of incorporation, holders of Candid Preferred Stock vote together with the holders of Candid Common Stock as a single class and on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> to Candid Common Stock basis. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rallybio Common Stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stockholder Action by Written Consent </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s bylaws, as amended, provide that any action required by statute to be taken at any annual or special meeting of the stockholders, or any action that may
be taken at any annual or special meeting of the stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents setting forth the action so taken, will be signed by the holders of outstanding stock
having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated certificate of
incorporation and its amended and restated bylaws do not provide for the right of stockholders to act by written consent without a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice of
Stockholder Meeting </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s bylaws, as
amended, provide that except as otherwise provided by statute, its amended and restated certificate of incorporation, or the bylaws, as amended, notice of each meeting of stockholders will be given not less than ten nor more than 60 days before the
date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if
any, by which stockholders and proxyholders may be deemed to be present in person and vote at any such meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notice to stockholders may be given in writing
directed to the stockholder&#8217;s mailing address (or by electronic transmission directed to the stockholder&#8217;s electronic mail address) as it appears on the records of the corporation and will be given (1)&nbsp;if mailed, when the notice is
deposited in the U.S. mail, postage prepaid; (2)&nbsp;if delivered by courier service, the earlier of when the notice is received or left at such stockholder&#8217;s address; or (3)&nbsp;if given by electronic mail, when directed to such
stockholder&#8217;s electronic mail address unless the stockholder has notified Candid in writing or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited by the DGCL. Notice of the time,
place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof or by electronic transmission by such person, either before or after such meeting, and will be waived by any
stockholder by such stockholder&#8217;s attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the
transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting will be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated bylaws provide that
written notice of a meeting of the stockholders shall be given not less than 10 nor more than 60&nbsp;days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and
time, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If mailed, notice is deemed given when deposited in the U.S. mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it appears on
Rallybio&#8217;s records. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after
such meeting, and will be waived by any stockholder by his or her attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">411 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder
so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Special
Stockholder Meetings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s bylaws, as
amended, provide that a special meeting of the stockholders may be called at any time for any purpose or purposes, by (i)&nbsp;the chair of the Candid Board, (ii)&nbsp;Candid&#8217;s Chief Executive Officer, (iii)&nbsp;the Candid Board pursuant to a
resolution adopted by directors representing a quorum of the directors then serving on the Candid Board or (iv)&nbsp;the holders of shares entitled to cast not less than 20% of the voting power of all then-outstanding shares of Candid Capital Stock,
and will be held at such place, on such date, and at such time as the Candid Board will fix; provided that, if Candid is subject to Section&nbsp;2115(b) of the CGCL, stockholders holding 5% or more of Candid&#8217;s outstanding shares will have the
right to call a special meeting. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s
amended and restated certificate or incorporation and amended and restated bylaws provide that, subject to the special rights of the holders of any series of preferred stock, a special meeting of stockholders may be called by the chairperson of the
Rallybio Board, Rallybio&#8217;s Chief Executive Officer, Rallybio&#8217;s President (in the absence of the Chief Executive Officer) or the Rallybio Board pursuant to a resolution adopted by a majority of the total number of directors which Rallybio
would have if there were no vacancies. The Rallybio Board shall determine the date, time and place, if any, of such special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Restrictions
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s bylaws, as amended, generally
restricts transfers of or encumbrances on shares of Candid Capital Stock (or any interest therein) and certain swap, short-sale and other derivative transactions involving such Candid Capital Stock, without first obtaining the approval of the Candid
Board, subject to certain limited exceptions, and any such transactions are subject to a right of first refusal in favor of Candid. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares of Rallybio capital stock are transferable in the manner prescribed by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid has entered into separate indemnification agreements with certain of its directors and executive officers, in addition to the indemnification provided for in
Candid&#8217;s amended and restated certificate of incorporation and bylaws, as amended. The indemnification agreements and Candid&#8217;s amended restated certificate of incorporation and bylaws, as amended, that will be in effect upon the Closing
require the combined company to indemnify its directors, executive officers and agents to the fullest extent permitted by Candid&#8217;s amended and restated certificate of incorporation, bylaws, as amended, and indemnification agreements. See the
section titled &#8220;<I>Certain Relationships and Related Party Transactions of the Combined Company&#8212;Candid Related Party Transactions&#8212;Indemnification Agreements</I>&#8221; for more information on these arrangements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated certificate of
incorporation provides that to the fullest extent permitted by law, Rallybio is authorized to provide indemnification of (and advancement of expenses to) directors, officers, who is made a party to any proceeding, against all liability and loss
suffered, including expenses, judgments, fines, and settlement amounts. Rallybio is also authorized to provide indemnification of (an advancement of expenses to) employees and agents of Rallybio (and any other persons to which applicable law permits
Rallybio to provide indemnification). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio has entered into separate indemnification agreements with each of its directors and executive officers, in addition
to the indemnification provided for in Rallybio&#8217;s amended and restated certificate of incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">412 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Amendment of Certificate of Incorporation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Candid Board and stockholders may amend, alter, change or
repeal any provision of Candid&#8217;s amended and restated certificate of incorporation in a manner prescribed by statue; provided that (i)&nbsp;any such amendment may be subject to the protective provisions described above, (ii)&nbsp;any repeal or
modification of the provisions of Candid&#8217;s amended and restated certificate of incorporation applicable to the limitation of liability of a director or officer of Candid or the indemnification of such directors, officers or agents shall not
(a)&nbsp;adversely affect any right or protection of persons existing at the time of such amendment, repeal, modification or elimination; or (b)&nbsp;increase the liability of such person with respect to any acts or omissions of such person
occurring prior to such amendment, repeal, modification or elimination, (iii)&nbsp;the affirmative vote of the Requisite holders is required to amend, repeal or adopt any provisions inconsistent with the provisions that renounce Candid&#8217;s
interest or expectancy in certain excluded opportunities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding any other provisions in Rallybio&#8217;s amended and restated certificate of incorporation or any provision of law which might otherwise permit a lesser
percentage, but in addition to any other vote required by law or by Rallybio&#8217;s amended and restated certificate of incorporation, the affirmative vote of the holders of at least 75% of the voting power of all of the then outstanding shares of
common stock of Rallybio entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles IV (Capitalization), V (Board of Directors), VI (Indemnification), paragraphs
(a)&nbsp;and (b) of VII (Written Consent and Special Meetings) and VIII (Amendments) of Rallybio&#8217;s amended and restated certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Amendment of Bylaws </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Candid&#8217;s amended and restated certificate of incorporation and bylaws, as amended, the Candid Board is expressly empowered to adopt, amend or repeal the
bylaws, as amended, of Candid. The stockholders also have power to adopt, amend or repeal the bylaws, as amended, of Candid; provided, however, that, in addition to any vote of the holders of any class or series of Candid Capital Stock required by
law or by the amended and restated certificate of incorporation, such action by stockholders requires the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of Candid Capital Stock entitled to vote
generally in the election of directors, voting together as a single class. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated certificate of incorporation and amended and restated bylaws provide that the Rallybio Board is expressly empowered to adopt,
alter, amend or repeal Rallybio&#8217;s amended and restated bylaws. Rallybio&#8217;s amended and restated certificate of incorporation also provides that the Rallybio stockholders shall also have power to adopt, amend or repeal Rallybio&#8217;s
amended and restated bylaws;<I>&nbsp;provided</I>,<I>&nbsp;however</I>, that, such action by stockholders shall require the affirmative vote of the holders of at least 75% of the voting power of all of the then-outstanding shares of Rallybio Common
Stock entitled to vote with respect thereto, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Forum Selection </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Candid </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid&#8217;s amended and restated certificate of
incorporation provides that unless Candid consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring
(i)&nbsp;any derivative action or proceeding brought on behalf of Candid, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Candid to Candid or Candid&#8217;s stockholders,
(iii)&nbsp;any action asserting a claim against Candid, its directors, officers or employees arising pursuant to any provision of the DGCL or Candid&#8217;s amended and restated certificate of incorporation or bylaws, as amended, or (iv)&nbsp;any
action asserting a claim against Candid, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of Candid, except for, as to each of (i)&nbsp;through (iv) above, any claim as
to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten
days following such determination), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">413 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rallybio </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio&#8217;s amended and restated certificate of
incorporation and amended and restated bylaws provide that, unless Rallybio consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of
Delaware dismisses a Covered Claim (as defined below) for lack of subject matter jurisdiction, any other state or federal court in the State of Delaware that does have subject matter jurisdiction) shall be the sole and exclusive forum for
(A)&nbsp;any derivative claim brought on Rallybio&#8217;s behalf; (B)&nbsp;any claim asserting a breach of a fiduciary duty owed to Rallybio or Rallybio&#8217;s stockowners owed by any current or former director, officer or other employee or
stockholder of Rallybio; (C)&nbsp;any claim against Rallybio arising pursuant to any provision of the DGCL, Rallybio&#8217;s amended and restated certificate of incorporation or amended and restated bylaws (as each may be amended from time to time);
(D)&nbsp;any claim to interpret, apply, enforce or determine the validity of Rallybio&#8217;s amended and restated certificate of incorporation or amended and restated bylaws; or (E)&nbsp;any claim against Rallybio governed by the internal affairs
doctrine (each of items (A)&nbsp;through (D), a &#8220;Covered Claim&#8221;). Notwithstanding the foregoing, these forum selection provisions do not apply to claims or causes of action brought to enforce a duty or liability created by the Securities
Act or the Exchange Act, or any other claim for which the federal courts of the United States have exclusive jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">414 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_30"></A>SECURITIES ACT RESTRICTIONS ON RESALE OF COMBINED COMPANY COMMON STOCK
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Rule 144, a person who has beneficially owned restricted combined company common stock for at least six months would be entitled to sell their
securities provided that (i)&nbsp;such person is not deemed to have been an affiliate of the combined company at the time of, or at any time during the three months preceding, a sale and (ii)&nbsp;combined company is subject to the Exchange Act
periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&nbsp;13 or 15(d) of the Exchange Act during the 12&nbsp;months (or such shorter period as combined company was required to
file reports) preceding the sale. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Persons who have beneficially owned restricted combined company common stock shares for at least six months but who are
affiliates of combined company at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of
securities that does not exceed the greater of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1% of the total number of combined company common stock then outstanding; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the average weekly reported trading volume of the combined company common stock during the four calendar weeks preceding
the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales by affiliates of combined company under Rule 144 are also limited by manner of
sale provisions and notice requirements and to the availability of current public information about the combined company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Restrictions on the Use of
Rule&nbsp;144 by Shell Companies or Former Shell Companies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rule&nbsp;144 is not available for the resale of securities initially issued by shell companies
(other than business combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule&nbsp;144 also includes an important exception to this prohibition if the following conditions are met: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the issuer of the securities that was formerly a shell company has ceased to be a shell company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the issuer of the securities is subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Exchange Act;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during
the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form <FONT STYLE="white-space:nowrap">8-K</FONT> reports; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting
its status as an entity that is not a shell company. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that following the consummation of the Merger, the combined company will no
longer be a shell company, and so, once the conditions set forth in the exceptions listed above are satisfied, Rule 144 will become available for the resale of the above noted restricted securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">415 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_31"></A>PRINCIPAL STOCKHOLDERS OF RALLYBIO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;6, 2026, Rallybio had 5,289,675&nbsp;shares of Rallybio Common Stock issued and outstanding. The table below shows certain information about the
beneficial ownership of Rallybio Common Stock, as of March&nbsp;6, 2026, by: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of Rallybio&#8217;s directors, </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of Rallybio&#8217;s named executive officers, and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all of Rallybio&#8217;s directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with SEC rules, Rallybio has included in the column &#8220;Number of Shares Beneficially Owned&#8221; all shares of Rallybio Common Stock over which the
person has sole or shared voting or investment power as of March&nbsp;6, 2026, and all shares of Rallybio Common Stock that the person has the right to acquire within 60 days after March&nbsp;6, 2026 through the exercise of any stock options. All
shares that a person has a right to acquire within 60 days of March&nbsp;6, 2026 are deemed outstanding for the purpose of computing the percentage beneficially owned by the person, but are not deemed outstanding for the purpose of computing the
percentage beneficially owned by any other person. Unless otherwise indicated, each person has the sole power (or shares the power with a spouse) to invest and vote the shares of Rallybio Common Stock listed opposite the person&#8217;s name. Where
applicable, ownership is subject to community property laws. Our inclusion of shares in this table as beneficially owned is not an admission of beneficial ownership of those shares by the person listed in the table. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Beneficial Owner</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of <BR>Shares <BR>Beneficially&nbsp;<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percentage <BR>of Shares <BR>Beneficially&nbsp;<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FMR LLC<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Viking Global Investors
LP<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">527,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Johnson&nbsp;&amp;
Johnson<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with 5AM Ventures<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with New Leaf Venture
Partners<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with TPG Inc.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Pivotal bioVenture
Partners<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau, M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Wendy K. Chung, M.D., Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Robert Hopfner, R.Ph., Ph.D., M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(7)(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald Hunt, M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(5)(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Hui Liu, Ph.D., M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Christine A. Nash, M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos<SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jonathan I. Lieber, M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All executive officers and directors as a group (12
persons)<SUP STYLE="font-size:75%; vertical-align:top">(19)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent of outstanding Rallybio Common Stock. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on information contained in a Schedule&nbsp;13G/A filed with the SEC on March&nbsp;6, 2026 reporting beneficial ownership of FMR LLC and Abigail P. Johnson. FMR LLC reports sole voting power over
561,798&nbsp;shares and sole dispositive power over 561,798&nbsp;shares. Ms.&nbsp;Johnson reports sole dispositive power over 561,798&nbsp;shares. The address of FMR LLC is 245 Summer Street, Boston, Massachusetts 02210. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">416 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(2).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based solely on information contained in a Schedule 13G/A filed with the SEC on February&nbsp;17, 2026 reporting beneficial ownership of Viking Global Investors LP, Viking Global Opportunities Rallybio GP LLC, Viking
Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP, and O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (together
with Viking Global Investors LP, Viking Global Opportunities Rallybio GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments
<FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the &#8220;Viking Reporting Persons&#8221;). The Viking Reporting Persons report shared voting and dispositive power over
527,871&nbsp;shares. Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP acquired warrants with the right to purchase 416,673&nbsp;shares. However, the terms of the warrants provide that no holder
of warrants shall have the right to exercise any portion of the warrants to the extent that, after giving effect to such issuance after exercise, such holder of warrants (together with its affiliates, any &#8220;group&#8221; or any other persons
whose beneficial ownership could be aggregated with the holders) would beneficially own more than 9.99% of the number of shares immediately following exercise (the &#8220;Blocker&#8221;). Any holder of warrants, upon notice to the Issuer, may
increase or decrease the Blocker, subject to a maximum of 19.99%, but any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Issuer. Accordingly, the amount of shares reported as beneficially
owned by the Reporting Persons set forth herein excludes shares that the Reporting Persons do not currently have the right to purchase upon exercise of the warrants held directly by Viking Global Opportunities Illiquid Investments <FONT
STYLE="white-space:nowrap">Sub-Master</FONT> LP due to the Blocker. The address of each of the Viking Reporting Persons is 600 Washington Boulevard, Floor 11, Stamford, CT 06901. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(3).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on information contained in a Schedule 13G filed with the SEC on July&nbsp;30, 2024 reporting beneficial ownership of Johnson&nbsp;&amp; Johnson (&#8220;J&amp;J&#8221;) and Johnson&nbsp;&amp; Johnson Innovation,
Inc. (&#8220;J&amp;J Innovation&#8221; and, together with J&amp;J, the &#8220;J&amp;J Reporting Persons&#8221;). J&amp;J Innovation is a wholly owned subsidiary of J&amp;J. The 454,545&nbsp;shares reported as beneficially owned herein are directly
beneficially owned by J&amp;J Innovation. J&amp;J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by J&amp;J Innovation. The J&amp;J Reporting Persons report shared voting and dispositive power over
the securities that are directly beneficially owned by J&amp;J Innovation. The address of J&amp;J is One Johnson&nbsp;&amp; Johnson Plaza, New Brunswick, NJ 08901. The address of J&amp;J Innovation is 410 George Street, New Brunswick, NJ 08901.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(4).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on information contained in a Form 4 filed with the SEC on February&nbsp;27, 2026, reporting beneficial ownership of 5AM Opportunities I, L.P. (&#8220;Opportunities I&#8221;), 5AM Opportunities I (GP), LLC
(&#8220;Opportunities GP&#8221;), 5AM Partners V, LLC (&#8220;Partners V&#8221;), 5AM Ventures V, L.P. (&#8220;Ventures V&#8221;), Andrew J. Schwab and Scott M. Rocklage (collectively, the &#8220;5AM Reporting Persons&#8221;) and a Form 4 filed with
the SEC on March&nbsp;9, 2023 reporting beneficial ownership of Partners V, Ventures V, Andrew J. Schwab and Scott M. Rocklage. Opportunities I is the beneficial owner of 156,469&nbsp;shares and Ventures V is the beneficial owner of
135,319&nbsp;shares. Opportunities GP is the general partner of Opportunities I and may be deemed to have sole voting and dispositive power over the shares held by Opportunities I. Mr.&nbsp;Schwab and Dr.&nbsp;Parmar are each a Managing Member of
Opportunities GP and may be deemed to have shared voting and dispositive power over the shares held by Opportunities I. Partners V is the general partner of Ventures V and may be deemed to have sole voting and dispositive power over the shares held
by Ventures V. Each of Mr.&nbsp;Schwab, Dr.&nbsp;Parmar and Dr.&nbsp;Rocklage is a Managing Member of Partners V and may be deemed to have shared voting and dispositive power over the shares held by Ventures V. Dr.&nbsp;Parmar, a member of our Board
of Directors until October 2024, is a Managing Member at Opportunities GP and Partners V, and may be deemed to have shared voting and dispositive power over all shares held by the 5AM Reporting Persons. Mr.&nbsp;Schwab, Dr.&nbsp;Parmar,
Dr.&nbsp;Rocklage, Partners V and Opportunities GP disclaims beneficial ownership over the shares held by Ventures V and Opportunities I, as applicable. The address of each of the 5AM Reporting Persons is 501 2nd Street, Suite 350, San Francisco,
California 94107. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(5).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on information contained in a Schedule 13G/A filed with the SEC on February&nbsp;6, 2023 reporting beneficial ownership of New Leaf Ventures III, L.P.
<FONT STYLE="white-space:nowrap">(&#8220;NLV-III&#8221;),</FONT> New Leaf Venture Associates III, L.P. <FONT STYLE="white-space:nowrap">(&#8220;NLVA-III&#8221;),</FONT> New Leaf Venture Management III, L.L.C.
<FONT STYLE="white-space:nowrap">(&#8220;NLVM-III&#8221;),</FONT> New Leaf Biopharma Opportunities II, L.P. (&#8220;NL <FONT STYLE="white-space:nowrap">BPO-II&#8221;),</FONT> New Leaf BPO Associates II, L.P. (&#8220;NL
<FONT STYLE="white-space:nowrap">BPOA-II&#8221;)</FONT> and New Leaf BPO Management II, L.L.C. (&#8220;NL <FONT STYLE="white-space:nowrap">BPOM-II&#8221;),</FONT> and Mr.&nbsp;Hunt and Vijay Lathi (together with
<FONT STYLE="white-space:nowrap">NLV-III,</FONT> <FONT STYLE="white-space:nowrap">NLVA-III,</FONT> <FONT STYLE="white-space:nowrap">NKVM-III,</FONT> NL <FONT STYLE="white-space:nowrap">BPO-II,</FONT> NL
<FONT STYLE="white-space:nowrap">BPOA-II,</FONT> NL <FONT STYLE="white-space:nowrap">BPOM-II</FONT> and Mr.&nbsp;Hunt, the &#8220;New Leaf Reporting Persons&#8221;). Each of <FONT STYLE="white-space:nowrap">NLV-III,</FONT> <FONT
STYLE="white-space:nowrap">NLVA-III</FONT> and <FONT STYLE="white-space:nowrap">NLVM-III</FONT> report shared voting and dispositive power over 268,469&nbsp;shares. Each of NL <FONT STYLE="white-space:nowrap">BPO-II,</FONT> NL <FONT
STYLE="white-space:nowrap">BPOA-II</FONT> and NL <FONT STYLE="white-space:nowrap">BPOM-II</FONT> report shared voting and dispositive power over 144,231&nbsp;shares. Each of Mr.&nbsp;Hunt and Mr.&nbsp;Lathi report shared voting and dispositive power
over 412,700&nbsp;shares. Mr.&nbsp;Hunt, a member of our Board of Directors, is a Managing Director at New Leaf Venture Partners, and may be deemed to have shared voting and dispositive power over all shares held by the New Leaf Reporting Persons.
The address of each of <FONT STYLE="white-space:nowrap">NLV-III,</FONT> <FONT STYLE="white-space:nowrap">NLVA-III,</FONT> <FONT STYLE="white-space:nowrap">NLVM-III,</FONT> NL <FONT STYLE="white-space:nowrap">BPO-II,</FONT> NL <FONT
STYLE="white-space:nowrap">BPOA-II,</FONT> NL <FONT STYLE="white-space:nowrap">BPOM-II,</FONT> Mr.&nbsp;Hunt and Mr.&nbsp;Lathi is 156 Fifth Avenue, Suite 820, New York, NY 10010. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(6).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on information contained in a Schedule 13D/A filed with the SEC on March&nbsp;3, 2026 reporting beneficial ownership of TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried (collectively, the
&#8220;TPG Reporting Persons&#8221;). The TPG Reporting Persons report shared voting and dispositive power over 378,551&nbsp;shares. The address of each of the TPG Reporting Persons is c/o&nbsp;TPG Inc., 301 Commerce Street, Suite 3300, Fort Worth,
Texas 76102. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(7).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Based on information contained in a Schedule 13D/A filed with the SEC on February&nbsp;12, 2024 reporting beneficial
ownership of Nan Fung Group Holdings Limited (&#8220;NFGHL&#8221;), NF Investment Holdings Limited (&#8220;NFIHL&#8221;), Nan Fung Life Sciences Holdings Limited (&#8220;Nan Fung Life Sciences&#8221;), Pivotal bioVenture Partners Fund I, L.P.
(&#8220;Pivotal&#8221;), Pivotal bioVenture Partners Fund I G.P., L.P. (&#8220;Pivotal GP&#8221;), Pivotal bioVenture Partners Fund I U.G.P. Ltd. (the &#8220;Ultimate General Partner&#8221;), Pivotal Partners Ltd (&#8220;Pivotal Partners&#8221;),
and Pivotal Life Sciences Holdings Limited (&#8220;Pivotal Life Sciences,&#8221; and together with Pivotal, Pivotal GP, Ultimate General Partner and Pivotal Partners, the &#8220;Pivotal Entities,&#8221; and together with NFGHL, NFIHL, Nan Fung Life
Sciences, Pivotal, Pivotal GP, the Ultimate General Partner and Pivotal Partners, the &#8220;Pivotal Reporting Persons&#8221;). The Pivotal Reporting Persons report shared voting and dispositive power over 300,580&nbsp;shares. Dr.&nbsp;Hopfner, a
member of our Board of Directors, is a General Partner at Pivotal bioVenture Partners, and may be deemed to have shared voting and dispositive power over all shares held by the Pivotal
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">417 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Reporting Persons. The address of each of the Pivotal Entities is 501 Second Street, Suite 200, San Francisco, CA 94107. The address of NFGHL is 23rd Floor, Nan Fung Tower, 88 Connaught Road
Central and 173 Des Voeux Road Central, Central, Hong Kong. The address of NFIHL is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(8).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 80,112&nbsp;shares issuable to Dr.&nbsp;Uden upon the exercise of options held directly by Dr.&nbsp;Uden that are exercisable within 60&nbsp;days following March 6, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(9).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 7,358&nbsp;shares issuable to Ms.&nbsp;Boudreau upon the exercise of options held directly by Ms.&nbsp;Boudreau that are exercisable within 60 days following March 6, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(10).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 8,151&nbsp;shares issuable to Dr.&nbsp;Chung upon the exercise of options held directly by Dr.&nbsp;Chung that are exercisable within 60&nbsp;days following March 6, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(11).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 17,334&nbsp;shares issuable to Dr.&nbsp;Hopfner upon the exercise of options held directly by Dr.&nbsp;Hopfner that are exercisable within 60 days following March 6, 2026. See also Footnote&nbsp;7
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(12).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 24,958&nbsp;shares issuable to Mr.&nbsp;Hunt upon the exercise of options held directly by Mr.&nbsp;Hunt that are exercisable within 60&nbsp;days following March 6, 2026. See also Footnote&nbsp;5.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(13).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 17,399&nbsp;shares issuable to Dr.&nbsp;Liu upon the exercise of options held directly by Dr.&nbsp;Liu that are exercisable within 60 days following March 6, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(14).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;37,251&nbsp;shares held directly by Dr.&nbsp;Mackay, (ii)&nbsp;54,562&nbsp;shares held directly by a limited liability company, of which Dr.&nbsp;Mackay is the managing member, and
(iii)&nbsp;78,452&nbsp;shares issuable to Dr.&nbsp;Mackay upon the exercise of options held directly by Dr.&nbsp;Mackay that are exercisable within 60 days following March 6, 2026. Dr.&nbsp;Mackay has sole voting and dispositive power over such
shares, and is deemed to be the beneficial owner of such shares. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(15).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 7,638&nbsp;shares issuable to Ms.&nbsp;Nash upon the exercise of options held directly by Ms.&nbsp;Nash that are exercisable within 60&nbsp;days following March 6, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(16).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 8,029&nbsp;shares issuable to Ms.&nbsp;Soteropoulos upon the exercise of options held directly by Ms.&nbsp;Soteropoulos that are exercisable within 60 days following March 6, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(17).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 39,077&nbsp;shares issuable to Mr.&nbsp;Lieber upon the exercise of options held directly by Mr.&nbsp;Lieber that are exercisable within 60 days following March 6, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(18).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 54,288&nbsp;shares issuable to Dr.&nbsp;Ryder upon the exercise of options held directly by Dr.&nbsp;Ryder that are exercisable within 60&nbsp;days following March 6, 2026. Dr. Ryder separated from Rallybio on
March&nbsp;31, 2026 </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(19).</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The beneficial ownership of all directors and executive officers. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">418 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_32"></A>PRINCIPAL STOCKHOLDERS OF CANDID </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information regarding beneficial ownership of the Candid Capital Stock as of February&nbsp;28, 2026, by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person, or group of affiliated persons, known by Candid to beneficially own more than 5% of the outstanding shares of
Candid Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of Candid&#8217;s directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of Candid&#8217;s named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all of Candid&#8217;s current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The percentage of beneficial ownership prior to the Merger and the Concurrent Financing in the table below is based on 508,527,565 shares of Candid Common Stock
outstanding as of February&nbsp;28, 2026 and assumes the conversion of all outstanding shares of Candid&#8217;s convertible preferred stock into 367,005,749 shares of Candid Common Stock as of February&nbsp;28, 2026. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess
sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of Candid Common Stock issuable pursuant to the exercise of stock options that are either immediately exercisable or exercisable
on or before April&nbsp;29, 2026, which is 60 days after February&nbsp;28, 2026. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that
person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, Candid believes based on information provided to Candid, the persons or entities identified in
this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise noted below, the address for each person or entity listed in the table is c/o Candid Therapeutics, Inc., 11622 El Camino Real, Suite 150, San Diego,
CA 92130. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME AND ADDRESS OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES<BR>BENEFICIALLY<BR>OWNED (#)<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE&nbsp;OF<BR>SHARES<BR>BENEFICIALLY<BR>OWNED&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Greater than 5% Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Third Rock
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,950,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Foresite Capital<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,174,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Song Beneficiary Trust U/T/A November&nbsp;6,
2024<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,060,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Named Executive Officers, Other Officers, and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ken Song, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,339,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tim Lu, M.D., Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,765,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arvind Kush<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,832,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dan Puckett<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,838,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Michael Rome, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Aaron Royston, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Angie You, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,838,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All current executive officers and directors as a group (9 persons)<SUP
STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,213,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1%. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Consists of (i) 5,887,002 shares of Candid Common Stock and 14,999,996 shares of Candid Common Stock issuable upon
conversion of Candid Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, in each case, held by Third Rock Ventures V, L.P. (&#8220;TRV V&#8221;), and (ii)&nbsp;15,062,998 shares of Candid Common Stock and 38,000,006
shares of Candid Common Stock issuable upon conversion of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">419 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Candid Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, in each case, held by Third Rock Ventures VI, L.P. (&#8220;TRV VI&#8221;). The sole general partner of TRV V
is Third Rock Ventures GP V, L.P. (&#8220;TRV GP V LLC&#8221;). The sole general partner of TRV GP V is TRV GP V, LLC (&#8220;TRV GP V LLC&#8221;). The sole general partner of TRV VI is Third Rock Ventures GP VI, L.P. (&#8220;TRV GP VI&#8221;). The
sole general partner of TRV GP VI is TRV GP VI, LLC (&#8220;TRV GP VI LLC&#8221;). Abbie Celniker, Ph.D., Robert Tepper, M.D., Reid Huber, Ph.D., Jeffrey Tong, Ph.D., Kevin Gillis, Neil Exter and Cary Pfeffer, M.D. are the managing members of TRV GP
V and TRV GP VI and collectively make voting and investment decisions with respect to shares held by TRV V and TRV VI. David Kaufman is also a managing member of TRV GP VI and contributes to voting decisions with respect to shares held by TRV VI.
Dr.&nbsp;Tong is a member of the Candid Board. The principal address for the entities and individuals named in this paragraph is 201 Brookline Avenue, Suite 1401, Boston, Massachusetts 02215. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 30,151,909 shares of Candid Common Stock issuable upon conversion of Candid Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 19,199,999 shares of Candid Common Stock
issuable upon conversion of Candid Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, in each case, held by Foresite Capital Fund VI LP (&#8220; Fund VI&#8221;), (ii) 2,835,591 shares of Candid Common Stock issuable upon
conversion of Candid Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 2,799,997 shares of Candid Common Stock issuable upon conversion of Candid Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible
preferred stock, in each case, held by Foresite Labs Fund I, L.P. ( &#8220;Labs Fund&#8221;), (iii) 10,631,250 shares of Candid Common Stock held by Foresite Labs Affiliates 2024, LLC (&#8220;Labs Affiliates&#8221;), (iv) 3,543,750 shares of Candid
Common Stock held by Foresite Therapeutics 2024, LLC (&#8220;Foresite Therapeutics&#8221;), and (v) 12,500 shares of Candid Common Stock issuable upon conversion of Candid Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred
stock held by Labs <FONT STYLE="white-space:nowrap">Co-Invest</FONT> VI LLC <FONT STYLE="white-space:nowrap">(&#8220;Co-Invest&#8221;).</FONT> Foresite Capital Management VI, LLC (&#8220;FCM VI&#8221;) is the general partner of Fund VI and the
managing member of <FONT STYLE="white-space:nowrap">Co-Invest</FONT> and may be deemed to have sole voting and dispositive power over the shares held by Fund VI and <FONT STYLE="white-space:nowrap">Co-Invest,</FONT> Foresite Labs Management I, LLC
(&#8220;FLM I&#8221;) is the general partner of Labs Fund and may be deemed to have sole and dispositive power over the shares held by Labs Fund, Foresite Labs, LLC (&#8220;Labs LLC&#8221;) is the managing member of Labs Affiliates and may be deemed
to have sole and dispositive power over the shares held by Labs Affiliates, Foresite Capital Management, LLC (&#8220;FCM&#8221;) is the managing member of Foresite Therapeutics and may be deemed to have sole and dispositive power over the shares
held by Foresite Therapeutics. James B. Tananbaum, M.D. is the managing member of FCM, FCM VI, and FLM I and may be deemed to have sole voting and dispositive power over the shares held by Fund VI, <FONT STYLE="white-space:nowrap">Co-Invest,</FONT>
Labs Fund and Foresite Therapeutics. Dr.&nbsp;Tananbaum is also a manager of Labs LLC and may be deemed to share voting and dispositive power over the shares held by Labs Affiliates. Each entity and Dr.&nbsp;Tananbaum disclaims beneficial ownership
of these shares except to the extent of their respective pecuniary interests therein. The business address of Dr.&nbsp;Tananbaum and each of the entities listed above is 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(3)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 33,060,000 shares of Candid Common Stock held The Song Beneficiary Trust U/T/A November&nbsp;6, 2024 (the &#8220;Song Beneficiary Trust&#8221;), 17,218,750 of which are restricted shares subject to
Candid&#8217;s right of repurchase within 60 days after February&nbsp;28, 2026. Argos Trust Company is the trustee of the Song Beneficiary Trust (the &#8220;Song Trustee&#8221;). Each of Elizabeth Warren, Abbi Kirchner, Richard Kuehnle, and Ashley
Blake are members of the Trust Committee of the Song Trustee and may be deemed to share voting and dispositive power over the shares held by the Song Beneficiary Trust. Dr.&nbsp;Song, Yu Linda Song and their children are beneficiaries of the Song
Beneficiary Trust. The address of the Song Trustee is 101 W. 69th Street, Ste 201, RM ARTC&nbsp;222, Sioux Falls, SD 57108. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(4)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 10,000,000 shares of Candid Common Stock issuable upon exercise of options held by The Song Family Trust, dated October&nbsp;14, 2016 (the &#8220;Song Family Trust&#8221;), all of which will be unvested
but exercisable by Dr.&nbsp;Song within 60 days of February&nbsp;28, 2026, and (ii) 339,105 shares of Candid Common Stock issuable upon conversion of Candid Series B convertible preferred stock held by the Song 2016 Children&#8217;s Trust dated
October&nbsp;14, 2016 (the &#8220;Song Children&#8217;s Trust&#8221;). Dr.&nbsp;Song and Yu Linda Song are trustees of the Song Family Trust and the Song Children&#8217;s Trust, and may be deemed to beneficially own the shares held by the Song
Family Trust and the Song Children&#8217;s Trust. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(5)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 9,565,360 shares of Candid Common Stock held by Dr.&nbsp;Lu, 5,181,274 of which are restricted shares subject to Candid&#8217;s right of repurchase within 60 days of February&nbsp;28, 2026, and (ii)
1,200,000 shares of Candid Common Stock issuable upon exercise of options, all of which will be unvested but exercisable by Dr.&nbsp;Lu within 60 days of February&nbsp;28, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(6)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 3,526,400 shares of Candid Common Stock held Mr.&nbsp;Kush, 1,836,704 of which are restricted shares subject to Candid&#8217;s right of repurchase within 60 days after February&nbsp;28, 2026, (ii)
1,653,000 shares of Candid Common Stock held by The Smilee Green Trust Dated August&nbsp;13, 2024 (&#8220;Trust I&#8221;), 860,938 of which are restricted shares subject to Candid&#8217;s right of repurchase within 60 days after February&nbsp;28,
2026, (iii) 1,653,000 shares of Candid Common Stock held by The City Park Trust Dated August&nbsp;13, 2024 (&#8220;Trust II&#8221;), 860,938 of which are restricted shares subject to Candid&#8217;s right of repurchase within 60 days after
February&nbsp;28, 2026, and (iv) 1,000,000 shares of Candid Common Stock issuable upon exercise of options, all of which will be unvested but exercisable by Mr.&nbsp;Kush within 60 days of February&nbsp;28, 2026. Mr.&nbsp;Kush and Maya Venkataramani
are trustees of each of Trust I and Trust II, and may be deemed to beneficially own the shares held by Trust I and Trust II. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(7)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,638,750 shares of Candid Common Stock issuable upon exercise of options, 819,375 of which will be unvested but exercisable by Mr.&nbsp;Puckett within 60 days of February&nbsp;28, 2026, and (ii) 200,000
shares of Candid Common Stock issuable upon exercise of options, all of which will be unvested but exercisable by Mr.&nbsp;Puckett within 60 days of February&nbsp;28, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(8)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,638,750 shares of Candid Common Stock held by Dr.&nbsp;You, 819,375 of which are restricted shares subject to Candid&#8217;s right of repurchase within 60 days of February&nbsp;28, 2026, and (ii)
200,000 shares of Candid Common Stock issuable upon exercise of options, all of which will be unvested but exercisable by Dr.&nbsp;You within 60 days of February&nbsp;28, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(9)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;the shares described in notes (4)&nbsp;through (8) above, and (ii) 4,099,440 shares of Candid Common Stock held by Dr.&nbsp;Huyghe, 2,220,530 of which are restricted shares subject to Candid&#8217;s
right of repurchase within 60 days of February&nbsp;28, 2026, and 500,000 shares of Candid Common Stock issuable upon exercise of options, all of which will be unvested but exercisable by Dr.&nbsp;Huyghe within 60 days of February&nbsp;28, 2026.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">420 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_33"></A>PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information regarding beneficial ownership of the combined company&#8217;s capital stock immediately after consummation of the Merger
and the Concurrent Financing, assuming the consummation of the Merger occurred as of February&nbsp;28, 2026, by: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person, or group of affiliated persons, expected by Rallybio and Candid to become the beneficial owners of more than
5% of the combined company&#8217;s outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person expected to be a director of the combined company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person expected to be a named executive officer of the combined company; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all of the combined company&#8217;s expected executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table lists applicable percentage ownership based on 64,362,557 shares of combined company common stock expected to be outstanding immediately following the
consummation of the Merger, is based on Rallybio&#8217;s and Candid&#8217;s capitalization as of February&nbsp;28, 2026, and assumes (i)&nbsp;no exercise of outstanding options to purchase shares of Candid Common Stock, outstanding options to
purchase Rallybio Common Stock or outstanding Rallybio <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants prior to the Closing, (ii)&nbsp;Rallybio Net Cash of $37.5&nbsp;million as of the Closing, (iii)&nbsp;an estimated Exchange Ratio of
0.0716, (iv)&nbsp;an assumed Concurrent Financing Exchange Ratio of 0.0716 per share (v)&nbsp;a Concurrent Financing of $505.5&nbsp;million, (vi)&nbsp;a reverse stock split of Rallybio Common Stock of
<FONT STYLE="white-space:nowrap">1-for-2.5</FONT> and (vii)&nbsp;the Closing on February&nbsp;28, 2026. Immediately after the Closing, under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, <FONT
STYLE="white-space:nowrap">pre-Merger&nbsp;equityholders</FONT> of Candid (other than Investors in the Concurrent Financing) are expected to own approximately 57.55% of the combined company,
<FONT STYLE="white-space:nowrap">pre-Merger&nbsp;equityholders</FONT> of Rallybio are expected to own approximately 3.65% of the combined company and the Investors in the Concurrent Financing are expected to own approximately 38.80% of the combined
company (assuming a Concurrent Financing of $505.5&nbsp;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (a)&nbsp;a valuation for Rallybio of
$47.5&nbsp;million (assuming Rallybio Net Cash of $37.5&nbsp;million as of the Closing), (b) a fixed valuation for Candid of $750.0&nbsp;million, and (c)&nbsp;the relative capitalization of Rallybio and Candid. The percentage of the combined company
that each party&#8217;s equity holders will own following the Closing is subject to certain adjustments as described in the Merger Agreement, including the amount of the final Rallybio Net Cash at Closing. Rallybio Net Cash as calculated under the
Merger Agreement makes certain adjustments to the value of Rallybio&#8217;s Cash and Cash Equivalents (as defined in the Merger Agreement), and was equal to approximately $39.47&nbsp;million as of December&nbsp;31, 2025. The adjustments are
described in the section titled &#8220;<I>The Merger Agreement&#8212;Calculation of Rallybio&#8217;s Net Cash</I>.&#8221; Based on its Cash and Cash Equivalents and other balance sheet line items as of December&nbsp;31, 2025 and current estimates of
the other elements of Rallybio Net Cash (including projected adjustments to Rallybio&#8217;s Cash and Cash Equivalents), Rallybio calculates that it had Rallybio Net Cash of approximately $35.81&nbsp;million as of April 15, 2026. Rallybio expects to
continue to incur losses in future periods primarily related to the proposed Merger and, as a result, available Cash and Cash Equivalents will continue to decrease. For a description of the calculation of Rallybio Net Cash as set forth in the Merger
Agreement, please see the section titled. There can be no assurances any of these assumptions will be accurate at the Closing. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beneficial ownership is
determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules
include shares of common stock issuable pursuant to the exercise of stock options or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that are either immediately exercisable or exercisable on or before April&nbsp;29, 2026, which is 60
days after February&nbsp;28, 2026. These securities are deemed to be outstanding and beneficially owned by the person holding those options or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for the purpose of computing the percentage
ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, Rallybio and Candid believe based on information provided to Rallybio and
Candid, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">421 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise noted below, the address for each person or entity listed in the table is c/o Candid
Therapeutics, Inc., 11622 El Camino Real, Suite 150, San Diego, CA 92130. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME AND ADDRESS OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES<BR>BENEFICIALLY<BR>OWNED (#)<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE<BR>OF SHARES<BR>BENEFICIALLY<BR>OWNED (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Third Rock
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,294,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Foresite Capital<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,668,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Venrock<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,047,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FMR LLC<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,620,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Named Executive Officers, Other Officers, and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ken Song, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tim Lu, M.D., Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">770,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arvind Kush<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">560,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dan Puckett<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Michael Rome, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Aaron Royston, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Angie You, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All current executive officers and directors as a group (9 persons)<SUP
STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,664,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1%. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,495,509 shares of combined company common stock held by Third Rock Ventures V, L.P. (&#8220;TRV V&#8221;), and (ii)&nbsp;3,799,311 shares of combined company common stock held by Third Rock Ventures
VI, L.P. (&#8220;TRV VI&#8221;). The sole general partner of&nbsp;TRV V is Third Rock Ventures GP V, L.P. (&#8220;TRV GP V LLC&#8221;). The sole general partner of TRV GP V is TRV GP V, LLC (&#8220;TRV&nbsp;GP&nbsp;V&nbsp;LLC&#8221;). The sole
general partner of TRV VI is Third Rock Ventures GP VI, L.P. (&#8220;TRV GP VI&#8221;). The sole general partner of TRV GP VI is TRV GP VI, LLC (&#8220;TRV GP VI LLC&#8221;). Abbie Celniker, Ph.D., Robert Tepper, M.D., Reid Huber, Ph.D., Jeffrey
Tong, Ph.D., Kevin Gillis, Neil Exter and Cary Pfeffer, M.D. are the managing members of TRV GP V and TRV GP VI and collectively make voting and investment decisions with respect to shares held by TRV V and TRV VI. David Kaufman is also a managing
member of TRV GP VI and contributes to voting decisions with respect to shares held by TRV VI. Dr.&nbsp;Tong is a member of the Candid Board. The principal address for the entities and individuals named in this paragraph is 201 Brookline Avenue,
Suite 1401, Boston, Massachusetts 02215. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 4,249,125 shares of combined company common stock held by Foresite Capital Fund VI LP (&#8220;Fund VI&#8221;), (ii)&nbsp;403,508&nbsp;shares of combined company common stock held by Foresite Labs Fund I,
L.P. (&#8220;Labs Fund&#8221;), (iii) 761,198 shares of combined company common stock held by Foresite Labs Affiliates 2024, LLC (&#8220;Labs Affiliates&#8221;), (iv) 253,733 shares of combined company common stock held by Foresite Therapeutics
2024, LLC (&#8220;Foresite Therapeutics&#8221;), and (v) 895 shares of combined company common stock held by Labs <FONT STYLE="white-space:nowrap">Co-Invest</FONT> VI LLC <FONT STYLE="white-space:nowrap">(&#8220;Co-Invest&#8221;).</FONT> Foresite
Capital Management VI, LLC (&#8220;FCM VI&#8221;) is the general partner of Fund VI and the managing member of <FONT STYLE="white-space:nowrap">Co-Invest</FONT> and may be deemed to have sole voting and dispositive power over the shares held by Fund
VI and <FONT STYLE="white-space:nowrap">Co-Invest,</FONT> Foresite Labs Management I, LLC (&#8220;FLM I&#8221;) is the general partner of Labs Fund and may be deemed to have sole and dispositive power over the shares held by Labs Fund, Foresite
Labs, LLC (&#8220;Labs LLC&#8221;) is the managing member of Labs Affiliates and may be deemed to have sole and dispositive power over the shares held by Labs Affiliates, Foresite Capital Management, LLC (&#8220;FCM&#8221;) is the managing member of
Foresite Therapeutics and may be deemed to have sole and dispositive power over the shares held by Foresite Therapeutics. James B. Tananbaum, M.D. is the managing member of FCM, FCM VI, and FLM I and may be deemed to have sole voting and dispositive
power over the shares held by Fund VI, <FONT STYLE="white-space:nowrap">Co-Invest,</FONT> Labs Fund and Foresite Therapeutics. Dr.&nbsp;Tananbaum is also a manager of Labs LLC and may be deemed to share voting and dispositive power over the shares
held by Labs Affiliates. Each entity and Dr.&nbsp;Tananbaum disclaims beneficial ownership of these shares except to the extent of their respective pecuniary interests therein. The business address of Dr.&nbsp;Tananbaum and each of the entities
listed above is 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 3,332,745 shares of combined company common stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCP&nbsp;EG&#8221;), (ii) 649,519 shares of combined company common stock held by Venrock
Healthcare Capital Partners III, L.P. (&#8220;VHCP&nbsp;III&#8221;) and (iii) 64,861 shares of combined company common stock held by VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC.
<FONT STYLE="white-space:nowrap">(&#8220;VHCP&nbsp;Co-Investment&#8221;).</FONT> VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCP EG. VHCP Management III, LLC (&#8220;VHCPM&#8221;) is the sole general partner of
VHCP III and the sole manager of VHCP <FONT STYLE="white-space:nowrap">Co-Investment.</FONT> Dr.&nbsp;Bong Koh and Nimish Shah are the voting members of VHCPM and VHCPM EG. The principal business address of Venrock is 7 Bryant Park, 23rd Floor,
New&nbsp;York, NY 10018, United States. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">422 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 3,602,751 shares of combined company common stock beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies. Abigail P.
Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC,
representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the
majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act
of 1940, to form a controlling group with respect to FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 716,000 shares of combined company common stock issuable upon exercise of options held by The Song Family Trust, dated October&nbsp;14, 2016 (the &#8220;Song Family Trust&#8221;), all of which will be
unvested but exercisable by Dr.&nbsp;Song within 60 days of February&nbsp;28, 2026, and (ii) 24,280 shares of combined company common stock held by the Song 2016 Children&#8217;s Trust dated October&nbsp;14, 2016 (the &#8220;Song Children&#8217;s
Trust&#8221;). Dr.&nbsp;Song and Yu Linda Song are trustees of the Song Family Trust and the Song Children&#8217;s Trust, and may be deemed to beneficially own the shares held by the Song Family Trust and the Song Children&#8217;s Trust. Does not
include 2,367,096 shares of combined company common stock held The Song Beneficiary Trust U/T/A November&nbsp;6, 2024 (the &#8220;Song Beneficiary Trust&#8221;), 1,232,863 of which are restricted shares subject to the combined company&#8217;s right
of repurchase within 60&nbsp;days after February&nbsp;28, 2026. Dr.&nbsp;Song, Yu Linda Song and their children are beneficiaries of the Song Beneficiary Trust but voting and dispositive power over the shares held by the Song Beneficiary Trust is
held by an independent third-party trustee. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 684,880 shares of combined common stock held by Dr.&nbsp;Lu, 370,979 of which are restricted shares subject to the combined company&#8217;s right of repurchase within 60 days of February&nbsp;28, 2026,
and (ii) 85,920 shares of combined company common stock issuable upon exercise of options, all of which will be unvested but exercisable by Dr.&nbsp;Lu within 60 days of February&nbsp;28, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 252,490 shares of combined company common stock held Mr.&nbsp;Kush, 131,508 of which are restricted shares subject to Candid&#8217;s right of repurchase within 60 days after February&nbsp;28, 2026, (ii)
118,355 shares of combined company common stock held by The Smilee Green Trust Dated August&nbsp;13, 2024 (&#8220;Trust I&#8221;), 61,643 of which are restricted shares subject to the combined company&#8217;s right of repurchase within 60 days after
February&nbsp;28, 2026, (iii) 118,355 shares of combined company common stock held by The City Park Trust Dated August&nbsp;13, 2024 (&#8220;Trust II&#8221;), 61,643 of which are restricted shares subject to the combined company&#8217;s right of
repurchase within 60 days after February&nbsp;28, 2026, and (iv) 71,600 shares of combined company common stock issuable upon exercise of options, all of which will be unvested but exercisable by Mr.&nbsp;Kush within 60 days of February&nbsp;28,
2026. Mr.&nbsp;Kush and Maya Venkataramani are trustees of each of Trust I and Trust II, and may be deemed to beneficially own the shares held by Trust I and Trust II. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 117,335 shares of combined company common stock issuable upon exercise of options, 58,667 of which will be unvested but exercisable by Mr.&nbsp;Puckett within 60 days of February&nbsp;28, 2026, and (ii)
14,320 shares of combined company common stock issuable upon exercise of options, all of which will be unvested but exercisable by Mr.&nbsp;Puckett within 60 days of February&nbsp;28, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 117,335 shares of combined company common stock held by Dr.&nbsp;You, 58,667 of which are restricted shares subject to the combined company&#8217;s right of repurchase within 60 days of February&nbsp;28,
2026, and (ii) 14,320 shares of combined company common stock issuable upon exercise of options, all of which will be unvested but exercisable by Dr.&nbsp;You within 60&nbsp;days of February&nbsp;28, 2026. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;the shares described in notes (5)&nbsp;through (9) above, and (ii) 293,520 shares of combined company common stock held by Dr.&nbsp;Huyghe, 158,990 of which are restricted shares subject to the
combined company&#8217;s right of repurchase within 60 days of February&nbsp;28, 2026, and 35,800 shares of common stock issuable upon exercise of options, all of which will be unvested but exercisable by Dr.&nbsp;Huyghe within 60 days of
February&nbsp;28, 2026. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">423 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_34"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts, will pass upon the validity of Rallybio&#8217;s Common Stock offered by this proxy statement/prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_35"></A>EXPERTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements
of Rallybio Corporation as of December&nbsp;31, 2025 and 2024, and for each of the two years in the period ended December&nbsp;31, 2025, included in this proxy statement/prospectus, have been audited by Deloitte &amp; Touche LLP, an independent
registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements of Candid Therapeutics, Inc. as of December 31, 2025 and 2024, and for the year ended December 31, 2025 and period from May 1, 2024 (inception)
to December 31, 2024, included in this proxy statement/prospectus, have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon
the report of such firm given their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements of Vignette Bio, Inc. for the period from January 1,
2024 through August 19, 2024, included in this proxy statement/prospectus, have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in
reliance upon the report of such firm given their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements of TRC 2004, Inc. for the period from
January 1, 2024 through August 19, 2024, included in this proxy statement/prospectus, have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included
in reliance upon the report of such firm given their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_36"></A>WHERE YOU CAN
FIND MORE INFORMATION </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio is subject to the informational requirements of the Exchange Act and in accordance therewith, files annual, quarterly and
current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains Rallybio&#8217;s filings as well as reports, proxy and information statements, and other information issuers file
electronically with the SEC at www.sec.gov. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio also makes available free of charge on or through its website at www.rallybio.com, its Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after Rallybio electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Rallybio are inactive textual
references and except as specifically incorporated by reference into this proxy statement/prospectus, information on or accessible from those websites is not part of this proxy statement/prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio has filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this proxy statement/prospectus is a part, under
the Securities Act to register the shares of Rallybio Common Stock to be issued to Candid stockholders in the Merger. This proxy statement/prospectus is a part of that registration statement and constitutes a prospectus of Rallybio, as well as a
proxy statement of Rallybio for its annual meeting. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about Rallybio and Rallybio Common Stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio has supplied all information contained in this proxy statement/prospectus relating to Rallybio and Candid has supplied all information contained in this proxy
statement/prospectus relating to Candid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">424 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you would like to request documents from Rallybio or Candid, please send a request in writing or by telephone to
either Rallybio or Candid at the following addresses: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Rallybio Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">234 Church Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">New Haven, CT 06510</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Attn: Jonathan Lieber</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Email:
jlieber@rallybio.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Candid Therapeutics, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">11622 El Camino Real, Suite 150</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">San Diego, CA
92130</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Attn: Jeff Woodley</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Email:
legal@candidrx.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rallybio stockholders may submit a written request for a copy of Rallybio&#8217;s most recently filed Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> to the above address or email address, which will be provided without charge.</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you are a Rallybio stockholder and would
like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger, including the procedures for voting your shares, you should contact Rallybio&#8217;s proxy solicitor, Georgeson, at the following
address, telephone number or email address: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">51 West 52<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Street, 6<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">New York NY 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Call Toll Free: (866) 539-7406 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Email:
rallybio@georgeson.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">425 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_37"></A>STOCKHOLDER PROPOSALS AND NOMINATIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Requirements for Stockholder Proposals to be Considered for Inclusion in our Proxy Materials.</I>&nbsp;To be considered for inclusion in next year&#8217;s proxy
statement, stockholder proposals must be received by Rallybio&#8217;s (or, if following the Closing, the combined company&#8217;s) Secretary at Rallybio&#8217;s (or, if following the Closing, the combined company&#8217;s) principal executive offices
no later than the close of business on &#8195;&#8195;&#8195;&#8195;&#8195;, which is 120 days prior to the date that is one year from this year&#8217;s mailing date of &#8195;&#8195;&#8195;&#8195;&#8195;, 2026. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Requirements for Stockholder Proposals or Director Nominations to be Brought Before an Annual Meeting.</I>&nbsp;Rallybio&#8217;s bylaws provide that, for stockholder
nominations to the Rallybio Board or other proposals to be considered at an annual meeting, the stockholder must have given timely notice thereof in writing to the Secretary at Rallybio Corporation, 234 Church Street, Suite 1020, New Haven, CT
06510. The Nominating and Corporate Governance Committee does not have a written policy regarding stockholder nominations, but has determined that it is the practice of the committee to consider candidates proposed by stockholders if made in
accordance with our bylaws. To be timely for the 2027 annual meeting, although not included in the proxy statement, the stockholder&#8217;s notice must be delivered to or mailed and received by Rallybio (or, if following the Closing, the combined
company) not earlier than the close of business on the 120th day nor later than the close of business on the 90th day prior to the anniversary date of the prior year&#8217;s annual meeting, except that if the annual meeting is set for a date that is
not within 30 days before or after such anniversary date, Rallybio (or, if following the Closing, the combined company) must receive the notice not later than the close of business on the tenth day following the day on which Rallybio (or, if
following the Closing, the combined company) first provides notice or public disclosure of the date of the meeting. Assuming the date of the 2026 annual meeting is not so advanced or delayed, stockholders who wish to make a proposal at the 2027
annual meeting must notify Rallybio (or, if following the Closing, the combined company) no earlier than &#8195;&#8195;&#8195;&#8195;&#8195; and no later than &#8195;&#8195;&#8195;&#8195;&#8195;. Such notice must provide the information required by
Rallybio&#8217;s bylaws with respect to each matter the stockholder proposes to bring before the 2027 annual meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any stockholder who intends to solicit
proxies in support of a director nominee other than the Rallybio&#8217;s (or, if following the Closing, the combined company&#8217;s) nominees must also comply with Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contacting the Rallybio Board </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stockholders wishing to communicate with the
Rallybio Board may do so by writing to the Rallybio Board or to the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Rallybio Board as a group, at: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Rallybio Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">234 Church Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">New Haven, CT 06510 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Attention: Secretary </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The communication must prominently display the legend &#8220;BOARD COMMUNICATION&#8221; in order to indicate to the Secretary that it is a communication for Rallybio
Board. Upon receiving such a communication, the Secretary will promptly forward the communication to the relevant individual or group to which it is addressed. Certain items that are unrelated to the Rallybio Board&#8217;s duties and
responsibilities may be excluded, such as spam, junk mail and mass mailings, resumes and other forms of job inquiries, surveys and business solicitations or advertisements. The Secretary will not forward any communication determined in his good
faith belief to be frivolous, unduly hostile, threatening, illegal or similarly unsuitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Householding of Proxy Statement/Prospectus </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">SEC rules concerning the delivery of annual disclosure documents allow Rallybio or your broker to send a single Notice of Proxy Materials or, if applicable, a single
set of our proxy materials to any household at which two or more of our stockholders reside, if Rallybio or your broker believes that the stockholders are members of the same family, unless Rallybio or your broker has received contrary instructions
from one or more of the stockholders. This practice, referred to as &#8220;householding,&#8221; benefits both you and Rallybio. It reduces the volume of duplicate information received at your household and helps to reduce our expenses. The rule
applies to Rallybio&#8217;s Notices of Proxy Materials, annual reports, proxy statements and information statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">426 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio will undertake to deliver promptly, upon written or oral request, a separate copy to a stockholder at a
shared address to which a single copy of the Notice of Proxy Materials or proxy materials was delivered. You may make a written or oral request by sending a notification to Rallybio&#8217;s Secretary at the address or telephone number above,
providing your name, your shared address, and the address to which Rallybio should direct the additional copy of the Notice of Proxy Materials or proxy materials. Multiple stockholders sharing an address who have received one copy of a mailing and
would prefer Rallybio to mail each stockholder a separate copy of future mailings should contact us at our principal executive offices. Additionally, if current stockholders with a shared address received multiple copies of a mailing and would
prefer Rallybio to mail one copy of future mailings to stockholders at the shared address, notification of that request may also be made through Rallybio&#8217;s principal executive offices. Stockholders who participate in householding will continue
to have access to and utilize separate proxy voting instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of the date of this proxy statement, the Rallybio Board does not intend to present any matters other than those described herein at the Rallybio annual meeting and
is unaware of any matters to be presented by&nbsp;other parties. If other matters are properly brought before the meeting for action by the stockholders, proxies will be voted in accordance with the recommendation of the Rallybio Board or, in the
absence of such a recommendation, in accordance with the judgment of the proxy holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">427 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_38"></A><A NAME="index"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Rallybio Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INDEX TO CONSOLIDATED
FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_1">Report of Independent Registered Public Accounting Firm (PCAOB ID
No.&nbsp;34)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_3">Consolidated Statements of&nbsp;Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_4">Consolidated Statements&nbsp;of&nbsp;Changes in Stockholders&#8217;
Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_7">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_8">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_9">Consolidated Statements of&nbsp;Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_10">Consolidated Statements&nbsp;of&nbsp;
Convertible Preferred Stock and Stockholders&#8217; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_11">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_12">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_13">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-60</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_14">Statement of&nbsp;Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-61</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_15">Statement&nbsp;of&nbsp;Convertible Preferred Stock and Stockholders&#8217;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-62</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_16">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-63</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_17">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-64</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_18">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-70</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_19">Statement of&nbsp;Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-71</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_20">Statement&nbsp;of&nbsp;Convertible Preferred Stock and Stockholders&#8217;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-72</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_21">Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-73</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin109079_22">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-74</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_1"></A><A NAME="toc109079_39"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the stockholders and the Board of Directors of Rallybio Corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying
consolidated balance sheets of Rallybio Corporation and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and
cash flows, for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles
generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an
opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audits included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ Deloitte &amp; Touche LLP </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Hartford, Connecticut </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">March 16, 2026 </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#8217;s auditor since 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_2"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other assets, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities and stockholders&#8217; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Deferred revenue, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Stockholders&#8217; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.0001 par value per share; 200,000,000 shares authorized as of December&nbsp;31, 2025 and
2024; and 5,283,321 and 5,188,743 shares issued and outstanding as of December&nbsp;31, 2025 and 2024, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Preferred stock, $0.0001 par value per share; 50,000,000 shares authorized as of December&nbsp;31, 2025 and
2024; no shares issued or outstanding as of December&nbsp;31, 2025 and 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(301,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(293,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#8217; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total liabilities and stockholders&#8217; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the consolidated financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_3"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR THE YEAR ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,064</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Gain on sale of joint venture and other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Loss before equity in losses of joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,629,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,443,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other comprehensive (loss) gain:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net unrealized (loss) gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other comprehensive (loss) gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the consolidated financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_4"></A>Consolidated Statements of Changes in Stockholders&#8217; Equity </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share amounts) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>COMMON</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ADDITIONAL</B><br><B><FONT STYLE="white-space:nowrap">PAID-IN</FONT></B><br><B>CAPITAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ACCUMULATED</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ACCUMULATED<BR>OTHER</B><br><B>COMPREHENSIVE</B><br><B>GAIN (LOSS)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>STOCKHOLDERS&#8217;</B><br><B>EQUITY</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,728,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">341,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(235,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock from a securities purchase agreement, net of offering costs of $268</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock under the stock purchase plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock under the stock award plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Forfeiture of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other comprehensive gain</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,188,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">354,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(293,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock under the stock purchase plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock under the stock award plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,283,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">359,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(301,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the consolidated financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_5"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR THE YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows Used in Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net accretion of discounts/premiums on debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(573</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Gain on sale of joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,350</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses, operating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accrued expenses and operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,813</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows Provided by Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from sale of common stock received from sale of joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows Provided by Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from the issuance of common stock from a securities purchase agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from the issuance of common stock under the stock purchase plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Payments of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#8212;beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#8212;end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the consolidated financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. BUSINESS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Corporation and subsidiaries (&#8220;Rallybio&#8221;,
the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221;, or &#8220;us&#8221;) is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with
a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The Company&#8217;s lead program, RLYB116, is a differentiated complement component 5 (&#8220;C5&#8221;) inhibitor with the potential to
treat diseases of complement dysregulation. In addition, RLYB332, a long-acting <FONT STYLE="white-space:nowrap">matriptase-2</FONT> <FONT STYLE="white-space:nowrap">(&#8220;MTP-2&#8221;)</FONT> antibody for the treatment of diseases of iron
overload is currently in preclinical development. In 2025, the Company completed a confirmatory pharmacokinetic (&#8220;PK&#8221;) and pharmacodynamic (&#8220;PD&#8221;) study of RLYB116 in healthy volunteers and reported data in the first quarter
of 2026. In April 2025, the Company announced the discontinuation of its RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (&#8220;FNAIT&#8221;) based on PK data from the Phase 2 clinical trial that demonstrated an
inability of the RLYB212 dose regimen to achieve predicted target concentrations, as well as the minimum target concentration required for efficacy. In July 2025, the Company entered into a definitive agreement to sell its interest in REV102, an
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (&#8220;ENPP1&#8221;) inhibitor in preclinical development for the treatment of patients with hypophosphatasia (&#8220;HPP&#8221;), to a subsidiary of its joint venture partner Recursion
Pharmaceuticals, Inc. (&#8220;Recursion&#8221;) (the &#8220;JV Sale&#8221;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;1, 2026, Rallybio entered into an Agreement and Plan of Merger and
Reorganization (the &#8220;Merger Agreement&#8221;) with Candid Therapeutics, Inc., a Delaware corporation (&#8220;Candid&#8221;), a clinical-stage biotechnology company advancing a leading portfolio of <FONT STYLE="white-space:nowrap">T-cell</FONT>
engager (&#8220;TCE&#8221;) therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Rallybio (&#8220;Merger Sub&#8221;). Upon the terms and subject to the satisfaction of the
conditions described in the Merger Agreement, Merger Sub will be merged with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio (the &#8220;Merger&#8221; and, together with all of the other transactions contemplated by
the Merger, the &#8220;Contemplated Transactions&#8221;). The Merger is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution and delivery of the Merger Agreement, certain investors entered into a subscription agreement with Candid, pursuant to which such
investors have agreed to purchase, immediately prior to the Merger, shares of Candid common stock representing an aggregate commitment of approximately $505.5 million in the concurrent financing (the &#8220;Concurrent Financing&#8221;). The shares
of Candid common stock that are issued in the Concurrent Financing will be or will have the right to be, respectively, converted into shares of Rallybio common stock, par value $0.0001 per share (&#8220;Rallybio Common Stock&#8221;), in the Merger.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), (a) each then-outstanding
share of common stock or preferred stock of Candid (each such share, a &#8220;Candid Share&#8221;) (excluding any share described in clauses (b)&nbsp;or (c) below and Candid Shares held by stockholders who have exercised and perfected appraisal
rights for such shares) will be converted into the right to receive a number of shares of Rallybio Common Stock calculated in accordance with the Exchange Ratio as set forth in the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b) each Candid
Share issued in the Concurrent Financing will be converted into the right to receive a number of shares of Rallybio Common Stock calculated in accordance with the Concurrent Financing Exchange Ratio as set forth in the Merger Agreement (the
&#8220;Concurrent Financing Exchange Ratio&#8221;), (c)&nbsp;any Candid Shares held as treasury shares or held or owned by Rallybio, Merger Sub or any subsidiary of Rallybio or Candid immediately prior to the Effective Time will be canceled and
shall cease to exist, and no consideration shall be delivered in exchange therefor. Each then-outstanding option to purchase Candid Shares will be converted into an option to purchase Rallybio Common Stock, subject to adjustment as set forth in the
Merger Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the Closing, on a pro forma
basis and based upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Candid (other than investors in the Concurrent Financing) are
expected to own approximately 57.55% of the combined company, <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio are expected to own approximately 3.65% of the combined company and the Investors in the Concurrent Financing
are expected to own approximately 38.80% of the combined company (assuming proceeds from the Concurrent Financing of $505.5&nbsp;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain
assumptions, including (i)&nbsp;a valuation for Rallybio of $47.5&nbsp;million (assuming Rallybio has net cash (&#8220;Rallybio Net Cash&#8221;) of $37.5&nbsp;million as of the closing of the Merger (the &#8220;Closing&#8221; and such date, the
&#8220;Closing Date&#8221;)), (ii) a fixed valuation for Candid of $750.0&nbsp;million, and (iii)&nbsp;the relative capitalization of Rallybio and Candid. The percentage of the combined company that each party&#8217;s equity holders will own
following the Closing is subject to certain adjustments as described in the Merger Agreement, including the amount of the final Rallybio Net Cash at Closing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior to the Effective Time, Rallybio and a rights agent are expected to enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;),
pursuant to which holders of record of certain Rallybio securities as of the close of business on the last business day prior to the day on which the Effective Time occurs will receive one contingent value right (each, a &#8220;CVR&#8221;) for each
outstanding share of Rallybio Common Stock, prefunded warrant, Rallybio restricted stock unit or In the Money Parent Option (as defined in the CVR Agreement) held as of such date. Pursuant to the CVR Agreement, each CVR holder will be entitled to
receive their pro rata share of (i)&nbsp;all of the net proceeds (including cash the value of stock to the extent listed on a national exchange, at the time of disposition), if any, received by Rallybio as a result of payments made to Rallybio of
any upfront, milestone, royalty and other payments received under any disposition agreement related to Rallybio&#8217;s <FONT STYLE="white-space:nowrap">pre-Merger</FONT> assets (the &#8220;Legacy Assets&#8221;), and (ii)&nbsp;all of the cash
proceeds, if any, received from Recursion under the Membership Interest Purchase Agreement, dated July&nbsp;8, 2025, by and among Recursion, Exscientia Ventures I, Inc., Rallybio Corporation and Rallybio IPB, LLC. For a period of one year after the
Closing Date, Rallybio will use commercially reasonable efforts to effect the disposition of the Legacy Assets. Such net proceeds will be subject to certain permitted deductions, including for applicable tax payments, certain expenses incurred or
other liabilities borne by Rallybio or its affiliates in respect of the Legacy Assets, and losses incurred by Rallybio or its affiliates due to a third-party proceeding in connection with such disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Basis of Presentation&#8212;</B>The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles
generally accepted in the United States (&#8220;GAAP&#8221;), and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP
as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the opinion of the Company, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation
of the financial position and results of operations for the reported periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative
to certain estimates or to identify matters that require additional disclosure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;6, 2026, the Company executed a reverse stock split of its issued
and outstanding common stock, par value $0.0001, at a ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-8</FONT></FONT> with a record date of December&nbsp;30, 2025 (the &#8220;Reverse Stock Split&#8221;). All common
share, per share and related information included in the accompanying financial statements and footnote disclosures have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. See Note&nbsp;14, &#8220;Subsequent
Events&#8221; for additional details. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Principles of Consolidation</B>&#8212;The consolidated financial statements include the accounts of the Company and its
wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Use of Estimates</B>&#8212;The preparation of the
Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
in the consolidated financial statements. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements are appropriate, actual results
could differ from those estimates. The most significant estimates are those used in the determination of the fair value of its common units and incentive units awarded to employees prior to the Company&#8217;s initial public offering
(&#8220;IPO&#8221;), for purposes of recording share-based incentive compensation, the fair value of stock options, as well as contracted research and development expenses incurred. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Liquidity and Ability to Continue as a Going Concern</B>&#8212;The accompanying consolidated financial statements have been prepared assuming that the Company will
continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are
issued. Since its inception, the Company has incurred net losses and negative cash flows from operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the years ended December&nbsp;31, 2025 and 2024,
the Company incurred a net loss of $9.0&nbsp;million and $57.8&nbsp;million, respectively. The loss for the year ended December&nbsp;31, 2025 included a $23.0&nbsp;million gain in connection with the JV Sale in 2025. In addition, as of
December&nbsp;31, 2025, the Company had an accumulated deficit of $302.0&nbsp;million. The Company expects to continue to generate operating losses and negative cash flows in the foreseeable future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company had cash, cash equivalents and marketable securities of $54.7&nbsp;million as of December&nbsp;31, 2025. The Company currently expects that its cash, cash
equivalents and marketable securities will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date these consolidated financial statements are issued. However, the Company does not anticipate that
its current cash, cash equivalents and marketable securities as of December&nbsp;31, 2025 will be sufficient to fund any of its product candidates through regulatory approval, and it will need to raise substantial additional capital to complete the
development and commercialization of its product candidates, if approved. Rallybio may satisfy its future cash needs through the sale of equity securities, debt financings, corporate collaborations or license agreements, working capital lines of
credit, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Collaboration
Arrangements</B>&#8212;The Company considers the nature and contractual terms of an arrangement to assess whether an arrangement involves a joint operating activity that expose two or more parties to significant risks and rewards dependent on the
commercial success of the activity. If the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts for such arrangement as a collaborative arrangement
under ASC 808, <I>Collaborative Arrangements </I>(&#8220;ASC 808&#8221;). ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition matters subjected to other authoritative guidance,
in certain cases by analogy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For arrangements determined to be within the scope of ASC 808 for certain research and development activities where a collaborative
partner is not a customer following the guidance of ASC 606, <I>Revenue Recognition </I>(&#8220;ASC 606&#8221;), the Company accounts for payments due to a collaboration partner as research and development expense and for payments owed to us from
our collaboration partner for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. The Company classifies payments owed or receivables recorded as other current liabilities and other
current assets, respectively, in the Company&#8217;s consolidated balance sheets. See Note 3, &#8220;Collaboration and License Agreements&#8221; for additional details. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Asset Acquisitions</B>&#8212;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted
for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable
assets. If this screen criteria is met, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs,
which would meet the definition of a business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset
acquisition, the cost allocated to acquire <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (&#8220;IPR&amp;D&#8221;) with no alternative future use is charged to research and development expense at the acquisition date.
See Note 3, &#8220;Collaboration and License Agreements&#8221; for additional details. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Variable Interest Entity</B>&#8212;The Company evaluates its ownership,
contractual, and other interests in entities to determine if it has any variable interest in a variable interest entity (&#8220;VIE&#8221;). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available
historical information, among other factors. If the Company determines that an entity in which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its
consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i)&nbsp;has the power to make decisions that most significantly affect the economic performance of the VIE; and
(ii)&nbsp;has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the
Company&#8217;s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The Company evaluated its investment in RE Ventures I, LLC, a limited liability company <FONT
STYLE="white-space:nowrap">(&#8220;REV-I&#8221;),</FONT> defined in Note 9, and concluded that it represented a VIE and the Company was not deemed the primary beneficiary. If the Company is not deemed to be the primary beneficiary in a VIE, the
Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP. See Note 9, &#8220;Investment in Joint Venture&#8221; for additional details. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Equity Method Investments</B>&#8212;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323,
<I>Investments&#8212;Equity Method and Joint Ventures </I>(&#8220;ASC 323&#8221;). The Company recognizes its <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of income and losses in &#8220;loss on investment in joint venture&#8221; on the
consolidated statements of operations and comprehensive loss, with a corresponding change to the investment in joint venture asset on the consolidated balance sheets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Financial Instruments</B>&#8212;The Company&#8217;s principal financial instruments are comprised of cash, cash equivalents, available for sale marketable
securities, accounts payable and accrued liabilities. The carrying value of all financial instruments approximates fair value. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Concentrations of Credit
Risk</B>&#8212;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company invests its excess cash in money market funds
and marketable securities in government insured financial institutions that are subject to minimal credit and market risk. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at
financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Cash and Cash
Equivalents</B>&#8212;The Company classifies amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market funds, with original maturities of three months or less at the time of purchase as cash and cash
equivalents. The carrying amounts reported on the consolidated balance sheets represent the fair values of cash and cash equivalents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Marketable
Securities</B>&#8212;We invest our excess cash balances in highly rated United States (&#8220;U.S.&#8221;) government-backed debt securities and treasuries. We classify our marketable securities as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> and accordingly, record such securities at fair value. Debt securities with original maturities of greater than 90 days are classified as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities and debt securities with original maturities of less than 90 days from the date of purchase are classified as cash equivalents. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unrealized gains and losses on our marketable debt securities that are deemed temporary are included in accumulated other comprehensive gain (loss) as a separate
component of stockholders&#8217; equity. If any adjustment to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
fair value reflects a significant decline in the value of the security, we evaluate the extent to which the decline is determined to be other-than-temporary and would mark the security to market
through a charge to our consolidated statements of operations and comprehensive loss. Credit losses are identified when we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. In the event of a credit
loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive gain (loss). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Property and Equipment</B>&#8212;Property and equipment are recorded at cost and consist of computer and other equipment, capitalized software, furniture and
fixtures and leasehold improvements. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, or for leasehold improvements, over the remaining term of the lease, if shorter. The estimated useful life
for each major asset classification are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Asset Classification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Useful&nbsp;Life</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Computer and other equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">lesser&nbsp;of&nbsp;lease&nbsp;life&nbsp;or&nbsp;useful&nbsp;life</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or
disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Impairment of Long-Lived Assets</B>&#8212;When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The
Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value. No such impairments were recorded during the years ended December&nbsp;31, 2025 or 2024. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Leases</B>&#8212;At the inception of an arrangement, we determine if an arrangement is, or contains, a lease based on the facts and circumstances present in that
arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease we (i)&nbsp;identify lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components,
(ii)&nbsp;determine the consideration in the contract, (iii)&nbsp;determine whether the lease is an operating or financing lease; and iv) recognize lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
(&#8220;ROU&#8221;) assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of fixed, or in substance fixed, lease payments over the expected lease term. When the interest rate implicit in
lease contracts is not readily determinable we use our incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized
basis, over a similar term, an amount equal to the lease payments in a similar economic environment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have elected to combine lease components with <FONT
STYLE="white-space:nowrap">non-lease</FONT> components on our office real estate asset class. Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis. Variable
lease expenses that are not considered fixed, or in substance fixed, are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our consolidated statements of operations and
comprehensive loss. Some leases include options to extend or terminate the lease and the Company includes these options in the recognition of the Company&#8217;s ROU assets and lease liabilities when it is reasonably certain that the Company will
exercise such options. We have elected the short-term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with an original term of 12 months or less. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Income Taxes</B>&#8212;The Company uses the asset and liability method of accounting for income taxes, as set forth in ASC&nbsp;740, <I>Accounting for Income
Taxes</I> (&#8220;ASC 740&#8221;). Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates for the years and jurisdictions in which the temporary differences are
expected to be recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company evaluates whether deferred tax
assets are more likely than not of being realized in determining whether a valuation allowance is necessary. In making such a determination, the Company considers all available positive and negative evidence, including the future reversals of
existing taxable temporary differences, projected future taxable income exclusive of reversing temporary differences and carryforwards, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies, taxable income in prior carryback years if
permitted under tax law, and the results from prior years. If the Company determines it is more likely than not, that all or a portion of a deferred tax asset will not be realized a valuation allowance is recorded with a charge to income tax
expense. Alternatively, if the Company determines that all or a portion of a deferred tax asset previously not meeting the more likely than not threshold will be realized, the Company reduces its valuation allowance and recognizes a benefit in
income tax expense. As of December&nbsp;31, 2025 and 2024, the Company determined that it is more likely than not that deferred taxes will not be realized and as a result recorded a full valuation allowance against its deferred tax assets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company files a consolidated U.S. federal income tax return and has elected to include all subsidiaries owned more than 80%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes and measure uncertain tax benefits in accordance with ASC 740 based on a <FONT STYLE="white-space:nowrap">two-step</FONT> process in which
(1)&nbsp;the Company determines whether it is more likely than not that the tax position will be sustained based on the technical merits of the position, and (2)&nbsp;for those tax positions that meet the
<FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, the Company recognizes the largest amount of tax benefit that is more than fifty percent likely to be realized upon ultimate settlement with the related tax
authority. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions, if any, in income tax expense. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Research and
Development Expenses</B>&#8212;Research and development expenses are comprised of costs incurred in performing research and development activities including personnel salaries, benefits, and share-based compensation; external research and
development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; the cost of developing and manufacturing clinical study materials, program regulatory
costs, expenses associated with obligations under asset acquisitions, license agreements and other direct and indirect costs. Costs incurred in connection with research and development activities are expensed as incurred. Costs are considered
incurred based on an evaluation of the progress to completion of each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. Depending upon the timing of invoicing by the service
providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These prepaid expenses or accrued expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved,
and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Stock Warrants</B>&#8212;The Company
accounts for stock warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance included in ASC 480, <I>Distinguishing Liabilities from
Equity </I>(&#8220;ASC 480&#8221;) and ASC 815,<I> Derivatives and Hedging</I> (&#8220;ASC&nbsp;815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the
definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment, which requires the use of professional judgment, is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Warrants that meet all of the criteria for equity classification are required to be recorded as a component of additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the
date of issuance and remeasured each balance sheet date thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Share-Based Compensation</B>&#8212;The Company accounts for share-based compensation in accordance with ASC 718,
<I>Compensation&#8212;Stock Compensation </I>(&#8220;ASC 718&#8221;). Generally, share-based compensation is measured at the grant date for all equity-based awards made to employees based on the fair value of the awards and is recognized over the
requisite service period, which is generally the vesting period. Share-based compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition is probable. The Company has
elected to recognize the actual forfeitures by reducing the share-based compensation in the same period as the forfeitures occur. The Company classifies share-based compensation in its consolidated statements of operations and comprehensive loss in
the same manner in which the award recipients&#8217; payroll costs are classified. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company estimates the fair value of options granted using the Black-Scholes
option pricing model (&#8220;Black-Scholes&#8221;) for stock option grants. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards. Black-Scholes requires inputs based on certain subjective
assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. Due to the lack of a public market for the Company&#8217;s common stock and lack of company-specific
historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company and in 2024, the Company
began to include its historical volatility rate in the computation. The historical volatility is calculated based on a period of time corresponding with expected term assumption. The Company uses the simplified method to calculate the expected term
for options granted where the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury
securities with a maturity date corresponding with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common
stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Fair Value Measurements</B>&#8212;ASC Topic 820, <I>Fair Value Measurement</I> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for
instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in
pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the
assets or liabilities and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction
between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level 2&#8212;Inputs other than Level&nbsp;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and
yield curves. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level 3&#8212;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level&nbsp;3 inputs
include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more
judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level&nbsp;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest
level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining fair value, the Company utilizes valuation techniques that maximize the use of
observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Future Milestone and Royalty Assets </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the JV Sale, the Company received consideration including an estimated $3.0&nbsp;million in future contingent milestones and royalty payments, which are
recognized as a contingent consideration asset within prepaid expenses and other current assets on the consolidated balance sheets. The fair value of this contingent consideration was determined using a model that incorporates significant
unobservable inputs based on Company estimates, external data, and management&#8217;s judgment and forecasts. Key assumptions in the model include the discount rate, the timing of expected cash flows, the probability of achieving the milestone and
royalty payments, and projected future net revenues. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company periodically reviews the carrying value of the Contingent Consideration when impairment indicators
arise and records an impairment loss if the carrying amount materially exceeds the reassessed fair value. Increases in the carrying value are recognized only when contingent gains are realized. Since the contingent payments are tied to Phase 1
clinical study milestones and future royalty payments, the Company believes the likelihood of timely payment by Recursion is remote. See Note 9, &#8220;Investment in Joint Venture&#8221; for additional details. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Segment Information</B>&#8212;Operating segments are defined as components of an enterprise for which discrete financial information is regularly reviewed by the
chief operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources and in assessing operating performance. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance,
and making operating decisions. All tangible assets of the Company are held in the U.S. See Note 12, &#8220;Segments&#8221; for additional details. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Basic and
Diluted Net Loss Per Share</B>&#8212;The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities.
Basic shares outstanding includes the weighted-average effect of the Company&#8217;s <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our common stock requiring little consideration upon exercise. Unvested restricted
common shares as of December&nbsp;31, 2025 and 2024 are not considered participating securities and as such are excluded from the weighted-average number of shares used for calculating basic and diluted net loss per share. Diluted net loss per share
is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially dilutive securities
include restricted common shares and stock options. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities
would be anti-dilutive. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Revenue Recognition</B>&#8212;The Company recognizes revenue in accordance with the provisions of ASC Topic 606, <I>Revenue from
Contracts with Customers</I> (&#8220;ASC 606&#8221;). The Company recognizes revenue when the Company&#8217;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive
in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the
performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when or as the Company satisfies a
performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may
include the following types of promised goods or services: (i)&nbsp;grants of licenses and related transfer of <FONT STYLE="white-space:nowrap">know-how,</FONT> (ii)&nbsp;performance of research and development services, and (iii)&nbsp;participation
on joint research and/or development committees. They also may include options to obtain further research and development services and licenses to the Company&#8217;s intellectual property. The payment terms of these agreements may include
nonrefundable upfront fees, payments based upon the achievement of certain milestones, and additional payments based on product sales derived from the collaboration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company exercises judgment in assessing those promised goods and services that are distinct and thus
representative of performance obligations. To the extent the Company identifies multiple performance obligations in a contract or group of contracts signed together, the Company must develop assumptions that require judgment to determine the
estimated standalone selling price for each performance obligation in order to allocate the transaction price among the identified performance obligations. The transaction is allocated on a relative standalone selling price basis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of
variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable
consideration is subsequently resolved. These estimates are reassessed at each reporting period as required. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company then recognizes revenue in the amount of
the transaction price that is allocated to the respective performance obligations when or as the performance obligations are satisfied. For performance obligations satisfied over time, the Company estimates the efforts needed to complete the
performance obligations and recognizes revenue over the satisfaction of the performance obligations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Restructuring</B>&#8212;The Company accounts for
restructuring charges in accordance with ASC Subtopic <FONT STYLE="white-space:nowrap">420-10,</FONT> <I>Exit or Disposal Cost Obligations</I>. The charges related to the workforce reductions are cash-based expenditures related primarily to
severance and benefit payments, with such amounts reflected in the Company&#8217;s consolidated statements of operations and other comprehensive loss. See Note 13, &#8220;Restructuring&#8221; for additional details. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Recently Adopted Accounting Pronouncements</B>&#8212;In December 2023, the FASB issued, ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> Income Taxes (Topic
740): <I>Improvements to Income Tax Disclosures</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2023-09&#8221;)</FONT> which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements.
The ASU is effective for public business entities for fiscal years beginning on or after December&nbsp;15, 2024 with early adoption permitted. The amendments in ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> were early adopted by the Company on
a prospective basis. There was no material impact to the Company&#8217;s financial statements as a result of adopting ASU <FONT STYLE="white-space:nowrap">2023-09.</FONT> See Note 8, &#8220;Income Taxes&#8221; for additional detail. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2025, the FASB issued ASU <FONT STYLE="white-space:nowrap">2025-03,</FONT> Business Combinations (Topic 805) and Consolidation (Topic 810):<I> Determining the
Accounting Acquirer in the Acquisition of a Variable Interest Entity</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2025-03&#8221;),</FONT> which revises current guidance for determining the accounting acquirer for a transaction effected primarily
by exchanging equity interests in which the legal acquiree is a variable interest entity that meets the definition of a business. The amendments require that an entity consider the same factors that are currently required for determining which
entity is the accounting acquirer in other acquisition transactions. The Company early adopted this ASU on a prospective basis as of October&nbsp;1, 2025. There was no material impact to the Company&#8217;s financial statements as a result of
adopting ASU <FONT STYLE="white-space:nowrap">2025-03.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Recently Issued Accounting Pronouncements</B>&#8212;In November 2024, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2024-03,</FONT> Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40):</FONT> <I>Disaggregation of Income Statement Expenses (</I>&#8220;ASU <FONT
STYLE="white-space:nowrap">2024-03&#8221;).</FONT> This ASU requires public entities to disclose additional transparency on certain costs and expenses. ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> is effective for annual periods beginning
after December&nbsp;15, 2026, and interim reporting periods beginning after December&nbsp;15, 2027. Early adoption is permitted. The Company has chosen not to early adopt this standard and is currently evaluating the potential impact of adopting
this standard on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. COLLABORATION AND LICENSE AGREEMENTS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Johnson&nbsp;&amp; Johnson Collaboration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2024, the Company
entered into a <FONT STYLE="white-space:nowrap">two-year</FONT> collaboration agreement (the &#8220;J&amp;J Collaboration Agreement&#8221;) with Johnson&nbsp;&amp; Johnson, through its wholly owned subsidiary, Momenta Pharmaceuticals, Inc.
(&#8220;J&amp;J&#8221;) to facilitate the advancement of research into products to address unmet needs relating to FNAIT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2025, the Company announced that RLYB212 Phase 2 PK results did not achieve target concentrations, including
the minimum target concentration required for efficacy, and that the Company would discontinue its RLYB212 program for the prevention of FNAIT. The Company will continue to follow any previously screened Phase&nbsp;2 participant who was also
eligible to enroll in the multinational FNAIT natural history study, in accordance with the study&#8217;s protocol. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the J&amp;J Collaboration
Agreement, the Company received an upfront payment of $0.5&nbsp;million from J&amp;J for the information dissemination and data provision services under the agreement. The J&amp;J Collaboration Agreement provides that the Company is eligible for
payments upon the achievement of certain screening-related events, however, the Company has discontinued screening and enrollment in both the FNAIT natural history study and the RLYB212 Phase 2 clinical trial. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company evaluated the agreement and determined it was within the scope of ASC 606. The Company determined there were performance obligations as follows: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">(1) Data collection&nbsp;&amp; submission revenue &#8211; derived from Rallybio&#8217;s ongoing management of the studies including the maintenance of a
minimum site footprint, the license to utilize, and timely, semi-annual submission of the anonymized data, in the required formats. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">(2)
Dissemination of J&amp;J materials&nbsp;&amp; participant revenue &#8211; derived from Rallybio&#8217;s dissemination of content, information or materials related to the <FONT STYLE="white-space:nowrap">J&amp;J-Sponsored</FONT> Studies that are
developed by J&amp;J and are provided by Rallybio for the purpose of disseminating such content, information, or materials to staff at Rallybio study sites to provide to potential eligible participants regarding J&amp;J&#8217;s independent study.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2024, the Company also entered into a securities purchase agreement (the &#8220;JJDC Securities Purchase Agreement&#8221;) with Johnson&nbsp;&amp; Johnson
Innovation &#8211; JJDC, Inc. (&#8220;JJDC&#8221;). Under the terms of the JJDC Securities Purchase Agreement, JJDC made an equity investment purchasing 454,545 shares of common stock with a par value of $0.0001 per share for a share purchase price
of $14.56 per share which includes a 10% premium for an aggregate purchase price of $6.6&nbsp;million. The JJDC Securities Purchase Agreement contains provisions related to the registration of the shares and the restriction on the sale or transfer
of the shares for a period of time. The Company determined the J&amp;J Collaboration Agreement and the JJDC Securities Purchase Agreement represented combined agreements. In accordance with ASC 606 and ASC 820, total consideration of
$1.2&nbsp;million for the shares of common stock from the JJDC Securities Purchase Agreement, which represents the premium of $0.7&nbsp;million and discount for lack of marketability of $0.5&nbsp;million, has been allocated to revenue and will be
recognized over the two year expected performance period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company valued the common stock issued to JJDC, in connection with the JJDC Securities Purchase
Agreement at fair value. The resulting fair value of $5.4&nbsp;million was determined by applying the discount due to lack of marketability during the registration and <FONT STYLE="white-space:nowrap">lock-up</FONT> period to the public trading
price of the common stock, which is a Level&nbsp;1 input, on the date of sale. The Company determined the value of the lack of marketability during the registration and <FONT STYLE="white-space:nowrap">lock-up</FONT> period by utilizing put option
models, which are considered Level&nbsp;3 inputs. Such option models included the Company&#8217;s historical volatility of 113.2% and the risk-free rate of 5.28% based on U.S. Treasury bond rates, as key inputs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognized $0.8&nbsp;million and $0.6&nbsp;million, respectively, in revenue during the years ended December&nbsp;31, 2025 and 2024, related to data
collection and data submission with the identified performance obligations, and the premium and discount allocated to revenue from the sale of the common stock to JJDC. The remaining revenue is included in deferred revenue on the Company&#8217;s
consolidated balance sheets as of December&nbsp;31, 2025, and will be recognized as the performance obligations are satisfied. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company determined that the
J&amp;J Collaboration Agreement is not in the scope of ASC 808, <I>Collaborative Arrangements</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Asset Acquisition </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2022, we obtained worldwide exclusive rights to RLYB331, with Kymab Limited (&#8220;Sanofi&#8221;) a preclinical antibody. In 2024, we <FONT
STYLE="white-space:nowrap">re-engineered</FONT> RLYB331 to extend its half-life and renamed the program RLYB332. We believe RLYB332 has the potential to address a significant unmet need for patients with severe anemias with ineffective
erythropoiesis and iron overload, including beta thalassemia and a subset of lower risk myelodysplastic syndromes (&#8220;MDS&#8221;). Under the terms of the license agreement, we made an upfront payment to Sanofi of $3.0&nbsp;million in the second
quarter of 2022 for the exclusive license to KY1066. We could also be required to pay up to an aggregate of $43.0&nbsp;million in development and regulatory milestones and up to an aggregate of $150.0&nbsp;million in commercial milestones for a
product in its first indication, plus tiered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> double digit percentages of such milestone amounts for up to three additional indications, and mid to high single
digit royalties on net sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The license was accounted for as an asset acquisition as substantially all of the fair value of the asset acquired was concentrated
in a single asset and thus the acquisition was deemed not to be a business combination. The acquired license rights represent an IPR&amp;D asset that was determined to have no alternative future use. Accordingly, the Company recorded an IPR&amp;D
charge of $3.1&nbsp;million to research and development expense, including transaction costs associated with this asset acquisition of $0.1&nbsp;million, in the consolidated statements of operations and comprehensive loss for the year ended
December&nbsp;31, 2022. The Company did not record an IPR&amp;D charge for the years ending December&nbsp;31, 2025 and 2024 and did not achieve any milestones related to the terms of the license agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>AbCellera Collaboration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2022, the Company entered into a
multi-year, multi-target collaboration with AbCellera Biologics (&#8220;AbCellera&#8221;) to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Under the terms of the agreement, AbCellera and Rallybio will <FONT
STYLE="white-space:nowrap">co-develop</FONT> and share the development costs of up to five rare disease therapeutic targets, which will be chosen together by both companies. At the point one party in the collaboration
<FONT STYLE="white-space:nowrap">opts-out</FONT> of future <FONT STYLE="white-space:nowrap">co-development</FONT> cost sharing, that party will be entitled to a share of future profit sharing from commercialization of the collaboration target,
dependent on the proportion of their <FONT STYLE="white-space:nowrap">co-development</FONT> contributions compared to the total development costs of a target as defined within the agreement. The agreement also has defined profit sharing floors that
correspond to the stage of development at the time a collaboration party <FONT STYLE="white-space:nowrap">opts-out</FONT> of <FONT STYLE="white-space:nowrap">co-developing</FONT> a target. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company concluded that the agreement with AbCellera will be accounted under the scope of ASC 808 as both parties will actively participate in joint operating
activities and are exposed to significant risks and rewards that depend on the commercial success of those activities. Under ASC 808, certain transactions between collaborative arrangement participants should follow the accounting for revenue under
ASC 606 when the collaborative arrangement participant is a customer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company determined that <FONT STYLE="white-space:nowrap">co-development</FONT>
arrangement as defined in our agreement with AbCellera does not meet the definition of a customer as defined by ASC 606. As a result, these activities will be accounted for as research and development costs. Payments due because of the <FONT
STYLE="white-space:nowrap">co-development</FONT> will be recorded as research and development expense in the period such expenses are incurred and for payments owed to us from our collaboration partner for the reimbursement of research and
development costs will be recorded as a contra-research and development expense in the period such expenses are incurred. Costs related to the AbCellera collaboration were $0.4&nbsp;million for the year ended December&nbsp;31, 2024. There were no
costs related to the AbCellera collaboration for the year ended December&nbsp;31, 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. MARKETABLE SECURITIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of our marketable securities by type of security as of
December&nbsp;31, 2025 and 2024 was as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value<BR>Hierarchy<BR>Level</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Holding&nbsp;Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Holding<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">U.S. government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value<BR>Hierarchy<BR>Level</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Holding&nbsp;Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Holding<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">U.S. government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair values of marketable securities by classification on the consolidated balance sheets as of December&nbsp;31, 2025 and 2024 was
as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair values of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities as
of December&nbsp;31, 2025 and 2024, by contractual maturity, are summarized as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Due in one year or less</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Due after one year through two years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate fair value of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt
securities in an unrealized loss position as of December&nbsp;31, 2025 and 2024 was $0.7&nbsp;million and $10.4&nbsp;million, respectively. As of December&nbsp;31, 2025 and 2024, we did not have any investments in a continuous unrealized loss
position for more than twelve months. As of December&nbsp;31, 2025, the Company believes that the cost basis of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities is recoverable. No
allowance for credit losses was recorded as of December&nbsp;31, 2025 and 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. LEASES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has
an operating lease for approximately four thousand five hundred square feet of corporate office space. The weighted-average remaining lease term as of December&nbsp;31, 2025 was 1 year, 9 months. The weighted-average discount rate utilized on our
operating lease liabilities as of December&nbsp;31, 2025 was 9.00%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating leases are included in operating lease ROU assets, operating lease liabilities, and
operating lease liabilities, noncurrent in our consolidated balance sheets as of December&nbsp;31, 2025 and 2024. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the presentation
of the Company&#8217;s operating lease as presented on the consolidated balance sheets: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><I>Assets:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><I>Liabilities:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future minimum lease payments from December&nbsp;31, 2025 until the expiration of the operating lease are as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Less: imputed discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Carrying value of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company incurred $0.2&nbsp;million in operating lease rent expense for both years ended December&nbsp;31, 2025 and 2024. Lease
payments made were $0.2&nbsp;million and $0.3&nbsp;million for the years ended December&nbsp;31, 2025 and 2024, respectively, with such amounts reflected on the consolidated statements of cash flows in operating activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. BALANCE SHEET COMPONENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Property and Equipment&#8212;
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment consisted of the following as of December&nbsp;31, 2025 and 2024: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Computer and other equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total property and equipment&#8212;net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation expense totaled $0.1&nbsp;million for both years ended December&nbsp;31, 2025 and 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Prepaid Expenses and Other Assets&#8212; </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets consisted of the following as of December&nbsp;31, 2025 and 2024: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other prepaids</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accrued Expenses&#8212; </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued
expenses consisted of the following as of December&nbsp;31, 2025 and 2024: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Compensation and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. STOCKHOLDERS&#8217; EQUITY </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common
Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2024, the Company entered into the JJDC Securities Purchase Agreement, pursuant to which the Company sold to JJDC, in an unregistered
offering, 454,545 shares of its common stock, at a price of $14.56 per share, which represents a 10% premium on the Company&#8217;s closing stock price on April&nbsp;9, 2024, for aggregate gross proceeds of approximately $6.6&nbsp;million, before
deducting offering expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company had 200,000,000 shares of common stock authorized as of December&nbsp;31, 2025 and 2024, of which 5,283,321 and 5,188,743
shares were issued and outstanding as of December&nbsp;31, 2025 and 2024, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company had 50,000,000 shares of preferred stock authorized as of December&nbsp;31, 2025 and 2024, of which no shares were outstanding as of December&nbsp;31, 2025
and 2024. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the November 2022 <FONT STYLE="white-space:nowrap">follow-on</FONT> offering, the Company entered into an agreement with certain investors for <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu of common stock to purchase up to an aggregate of 416,673 shares of common stock at a price of $47.9992, which represents the per share public offering price at the November 2022 <FONT
STYLE="white-space:nowrap">follow-on</FONT> offering for common stock less a $0.0008 per share exercise price for each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company may not effect the exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, and a holder will not be entitled to exercise any portion of
any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would exceed 9.99% of the number
of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#8217;s election upon 61 days&#8217; notice to the Company subject to the terms of such <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, provided that such percentage may in no event exceed 19.99%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#8217;s <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant is a freestanding instrument that does not meet the definition of a liability pursuant to ASC 480 and does not meet the definition of a derivative pursuant to ASC 815. The <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
is indexed to the Company&#8217;s common stock and meets all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant was classified as equity and accounted for as a component of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital at the time of issuance. All of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants related to our November 2022 <FONT STYLE="white-space:nowrap">follow-on</FONT> offering remain outstanding and unexercised as of December&nbsp;31, 2025. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Share-based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Share-based compensation is comprised of
the Company&#8217;s stock options, restricted stock awards, restricted stock units and shares issued pursuant to the employee stock purchase plan, and is classified in the consolidated statements of operations and comprehensive loss for the years
ended December&nbsp;31, 2025 and 2024 and was as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8194;2025&#8194;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8194;2024&#8194;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2021,
the board of directors adopted the Rallybio Corporation 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan initially reserved 680,043 shares of the Company&#8217;s common stock that have been issued in respect of outstanding
equity awards granted prior to the registrant&#8217;s IPO and for future issuances of shares to employees, directors and consultants in the form of stock options, SARs, restricted and unrestricted stock and stock units, performance awards and other
awards that are convertible into or otherwise based on the Company&#8217;s common stock. Dividend equivalents may also be provided in connection with awards under the 2021 Plan. The share pool will automatically increase on January 1st of each year
until 2031 by the lesser, of (i)&nbsp;five percent of the number of shares of the Company&#8217;s common stock outstanding as of such date and (ii)&nbsp;the number of shares of the Company&#8217;s common stock determined by the board of directors on
or prior to such date. On January&nbsp;1, 2025 and January&nbsp;1, 2024, the 2021 Plan share pool was automatically increased by 259,438 and 236,434 shares, respectively. As of December&nbsp;31, 2025, the total number of shares of the
Company&#8217;s common stock that were issuable under the 2021 Plan was 1,257,573 shares, of which 590,690 shares remained available for future issuance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
following table summarizes stock option activity for the year ended December&nbsp;31, 2025: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Stock Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Option&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Contractual<BR>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Outstanding stock options at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">529,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">628,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Exercisable stock options at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the
estimated fair value of the Company&#8217;s common stock. Stock options outstanding with an exercise price below the closing price as of December&nbsp;31, 2025 had an intrinsic value of approximately $89&nbsp;thousand based on a common stock fair
value of $5.49 per share, which was the closing price of the Company&#8217;s common stock on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
December&nbsp;31, 2025. Stock options outstanding and exercisable with an exercise price above the closing price as of December&nbsp;31, 2025 are considered to have no intrinsic value. Using the
Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the years ended December&nbsp;31, 2025 and 2024 was $4.92 per share and $11.78 per share, respectively. As of December&nbsp;31, 2025,
there was unrecognized share-based compensation expense related to nonvested stock options of $2.8&nbsp;million, which the Company expects to recognize over a weighted-average period of approximately 1.9 years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the stock options granted during the years ended December&nbsp;31, 2025 and 2024 was determined using the Black-Scholes option pricing model with the
following assumptions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">91.88%&nbsp;-&nbsp;119.61%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">89.41%&nbsp;-&nbsp;94.48%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.27 - 6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.50 - 6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.03% - 4.39%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.93% - 4.35%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.38 - $7.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.88 - $19.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A summary of the status of the Company&#8217;s nonvested restricted common stock awards at December&nbsp;31, 2025 and changes during the
year ended December&nbsp;31, 2025 was as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Restricted Stock Awards</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value<BR>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Nonvested restricted common stock awards at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Nonvested restricted common stock awards at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, there was no unrecognized share-based compensation expense related to nonvested restricted common stock
awards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A summary of the status of the Company&#8217;s nonvested restricted common stock units at December&nbsp;31, 2025 and changes during the year ended
December&nbsp;31, 2025 was as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Restricted Stock Units</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value<BR>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Nonvested restricted common stock units at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Nonvested restricted common stock units at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, there was unrecognized share-based compensation expense related to nonvested restricted common stock units
of $0.3&nbsp;million, which the Company expects to recognize over a weighted-average period of approximately 2.4 years. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Employee Stock Purchase Plan
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Company&#8217;s IPO, the board of directors adopted the Rallybio Corporation 2021 Employee Stock Purchase Plan (the &#8220;2021
ESPP&#8221;), which initially reserved 36,415 shares of the Company&#8217;s common stock for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
future issuances under this plan. The share pool will automatically increase on January 1st of each year from 2022 to 2031 by the lesser of (i)&nbsp;one percent of the number of shares of the
Company&#8217;s common stock outstanding as of such date (ii) 72,831 shares of the Company&#8217;s common stock, and (iii)&nbsp;the number of shares of the Company&#8217;s common stock determined by the board of directors on or prior to such date.
The 2021 ESPP share pool did not increase on January&nbsp;1, 2025 or January&nbsp;1, 2024. As of December&nbsp;31, 2025, the total number of shares of the Company&#8217;s common stock available for future issuance under the 2021 ESPP was 94,281
shares. During the years ended December&nbsp;31, 2025 and 2024, the Company issued 7,258 and 7,603 shares, respectively, of the Company&#8217;s common stock under the 2021 ESPP. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 ESPP allows eligible participants to purchase shares of the Company&#8217;s common stock through authorized payroll deductions. The purchase price of the
shares will not be less than 85% of the lower of the fair market value the Company&#8217;s common stock on the first day of an offering or on the date of the purchase. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2025 and 2024, the total share-based compensation for the 2021 ESPP was $16&nbsp;thousand and $0.1&nbsp;million, respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. INCOME TAXES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes income (loss) before
income taxes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company had no income tax expense (benefit) as of December&nbsp;31, 2025 and 2024. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#8217;s effective tax rate for the period ended December&nbsp;31, 2025 was 0.0%. For the period ended December&nbsp;31, 2025, the primary drivers of the
variance from the statutory rate were state taxes, research&nbsp;&amp; development tax credits, stock based compensation, and valuation allowance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is
a reconciliation from the Company&#8217;s statutory rate to the effective tax rate reported in the financial statements: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Statutory federal income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Tax credits (federal):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Orphan drug credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24.5</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> or
<FONT STYLE="white-space:nowrap">non-taxable</FONT> items:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#8217;s effective income tax rates are different from the federal statutory tax rates in 2024
predominantly due to the valuation allowance, tax credits, and state taxes. A reconciliation of the effect of applying the federal statutory rate to the net loss and effective income tax rate are as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">U.S. federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">State income taxes, net of federal income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The tax effect of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their
respective tax bases that give rise to deferred tax assets and liabilities are as follows at December&nbsp;31, 2025 and 2024: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Section&nbsp;174 capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100,451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company&#8217;s federal and state post-apportioned carryforwards are approximately $183.3&nbsp;million
and $181.6&nbsp;million, respectively. Of the federal amount, $183.3&nbsp;million will have an indefinite carryforward period. Of the state post-apportioned amount, $181.6&nbsp;million have a limited carryforward period and will begin to expire in
2038. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company&#8217;s federal and state carryforwards are approximately $25.0&nbsp;million and $0.9&nbsp;million, respectively.
All tax credits have a limited carryforward period and will begin to expire in 2038. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After weighing all available positive and negative evidence, the Company has
recorded a valuation allowance of approximately $100.5 million and $98.0 million as of December 31, 2025 and 2024, respectively. The Company increased the valuation allowance by $2.5 million and $19.7 million for the years ended December 31, 2025
and 2024, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to income tax in multiple jurisdictions, including federal, states, and city jurisdictions. The Company has federal,
state, and city income tax returns that are open to examination from 2022, 2023, and 2024 forward, respectively. In addition, the utilization of tax carryforwards, from periods prior to those previously mentioned may also be audited by the taxing
authorities once utilized. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result, the Company continuously monitors its current and prior filing positions in order to determine if any unrecognized tax
positions need to be recorded. The analysis involves considerable judgement and is based on the best information available. As of December&nbsp;31, 2025 the Company has no unrecognized tax benefits. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has not accrued any interest expense or penalties related to the unrecognized tax benefits for the period ended December&nbsp;31, 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has made no income tax payments and received no income tax refunds during the periods ended
December&nbsp;31, 2025 and 2024. All payments made to taxing authorities were for <FONT STYLE="white-space:nowrap">non-income</FONT> based tax liabilities and are outside the scope of ASC 740. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The One Big Beautiful Bill Act (the &#8220;OBBBA&#8221;) was enacted on July&nbsp;4, 2025. The Company has evaluated whether the OBBBA has a material impact on its 2025
financial statements. The only provision of the OBBBA that impacts the Company&#8217;s income tax accounting under Accounting Standards Codification 740 is the new Internal Revenue Code of 1986, as amended, Section&nbsp;174A (&#8220;Section
174A&#8221;), which permanently allows taxpayers to fully expense domestic research or experimental (&#8220;R&amp;E&#8221;) expenditures paid or incurred in taxable years beginning after December&nbsp;31, 2024. The requirement to capitalize foreign
expenses under Internal Revenue Code Section&nbsp;174 over 15 years has not changed. On August&nbsp;28, 2025, the Internal Revenue Service released procedural guidance (Rev. Proc. <FONT STYLE="white-space:nowrap">20;/.25-28)</FONT> for implementing
Section&nbsp;174A and related elections for domestic R&amp;E. Transition rules provide taxpayers with options to account for any remaining unamortized domestic R&amp;E expenditures paid or incurred in taxable years beginning after December&nbsp;31,
2021, and before January&nbsp;1, 2025. Taxpayers may continue to amortize such unamortized amounts over the remaining five-year period; alternatively, they may elect to deduct any remaining unamortized domestic R&amp;E expenditures either entirely
in the first tax year beginning after December&nbsp;31, 2024, or ratably over two taxable years (e.g., 2025 or ratably in 2025 and 2026). The company has decided it will elect to continue to amortize previously capitalized and unamortized domestic
R&amp;E expenditures over the remaining five-year period. As of December&nbsp;31, 2024, the company had approximately $41.4&nbsp;million of remaining unamortized domestic research and development expenditures, representing approximately
$11.4&nbsp;million of its gross deferred tax assets. As of December&nbsp;31, 2025, the company had approximately $25.5&nbsp;million of remaining unamortized domestic research and development expenditures, representing approximately $7.0&nbsp;million
of its gross deferred tax assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards
may be subject to an annual limitation under Section&nbsp;382 and Section&nbsp;383 of the Code, and corresponding provisions of state law, due to ownership changes that may have occurred previously or that could occur in the future. These ownership
changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income and tax liabilities. In general, an ownership change, as defined by Section&nbsp;382 of the Code, results from transactions increasing the
ownership of certain stockholders or public groups in the stock of a corporation by more than 5% over a three-year period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company completed a Section&nbsp;382
study and concluded that it underwent an ownership change as defined by the Code during the year ended December&nbsp;31, 2021. The Company does not currently believe that the annual limitation will result in the expiration of any net operating
losses or research and development tax credit carryforwards before utilization. Additional ownership changes which may have occurred after December&nbsp;31, 2021 and any future ownership changes may limit our ability to utilize remaining tax
attributes. Any carryforwards that will expire prior to utilization as a result of such additional limitations will be removed from deferred tax assets, with a corresponding reduction of the valuation allowance. Due to the existence of the valuation
allowance, limitations created by future ownership changes, if any, will not impact the Company&#8217;s effective tax rate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ASC 740 addresses the determination of
whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that
the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has no material uncertain tax positions that qualify for either recognition or disclosure in consolidated
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. INVESTMENT IN JOINT VENTURE </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2025, the
Company entered into the ENPP1 Purchase Agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with HPP, to Buyer (a subsidiary of its joint venture partner Recursion). In connection
with the JV Sale, the Company received compensation in the form of Recursion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
common stock (which is a <FONT STYLE="white-space:nowrap">non-cash</FONT> investing activity). The Company subsequently sold the Recursion common stock for cash proceeds of $20.0&nbsp;million in
the third quarter of 2025 which included $7.5&nbsp;million from an upfront payment and $12.5&nbsp;million from a milestone payment related to the initiation of additional preclinical studies. The Company is eligible to receive a $5.0&nbsp;million
milestone cash payment in connection with the initiation of dosing in a Phase 1 clinical study, as defined in the ENPP1 Purchase Agreement and low single-digit royalties on all future net sales by Recursion of products comprising or incorporating
certain compounds developed by <FONT STYLE="white-space:nowrap">REV-I.</FONT> The Company may also be eligible to receive certain payments in the event of Recursion&#8217;s sale of the REV102 program. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company evaluated the JV Sale under ASC 860, <I>Transfers and Servicing of Financial Assets</I> (&#8220;ASC 860&#8221;). Based on the Company&#8217;s evaluation of
the JV Sale under ASC 860, the Company recognized a gain from the sale of its equity interests in REV102 of $22.4&nbsp;million, based on the excess of the total net consideration allocated to the sale of the Company&#8217;s equity interests (based
on relative fair value) of $23.0&nbsp;million over the carrying value of the equity interests sold of $0.6&nbsp;million. The total net consideration of $23.0&nbsp;million included cash received of $20.0&nbsp;million, plus an estimated
$3.0&nbsp;million representing the fair value of the future milestone payments and future royalties (which is a <FONT STYLE="white-space:nowrap">non-cash</FONT> investing activity). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The contingent consideration was initially measured at fair value using a probability based present value model of the risk-adjusted estimated cash flows, with a
discount rate of 15.4%. This valuation model relied on significant unobservable inputs (level 3 inputs) based on management&#8217;s estimates, which were informed by external data, judgment, and forecasts. Key assumptions included the probability of
achieving the milestone and royalties, timing of cash flows, discount rate, and forecasted net revenues. The fair value of the contingent consideration is a <FONT STYLE="white-space:nowrap">non-recurring</FONT> fair value measurement and is recorded
as other assets and other assets, <FONT STYLE="white-space:nowrap">non-current</FONT> on the Company&#8217;s consolidated balance sheets and as gain on sale of joint venture and other income within the Company&#8217;s consolidated statements of
operations and comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the JV Sale, the Company, through one of its wholly owned subsidiaries, had a 50% interest of the joint venture entity,
<FONT STYLE="white-space:nowrap">REV-I.</FONT> For the years ended December&nbsp;31, 2025 and 2024 the Company funded $1.5&nbsp;million and $2.0&nbsp;million, respectively, associated with the Company&#8217;s commitment and its share of <FONT
STYLE="white-space:nowrap">REV-I</FONT> development costs. The Company did not provide any additional financial support outside of capital contributions to <FONT STYLE="white-space:nowrap">REV-I</FONT> during the years ended December&nbsp;31, 2025
and 2024. However, in connection with the joint venture, the Company provided certain scientific and finance and accounting related support which was reimbursed by <FONT STYLE="white-space:nowrap">REV-I</FONT> to the Company and included in other
income on the consolidated statements of operations and comprehensive loss. For the years ended December&nbsp;31, 2025 and 2024, the Company recorded $0.3&nbsp;million and $0.7&nbsp;million, respectively, related to such support. Prior to the JV
Sale, the Company held a 50% interest in the joint venture and based on management&#8217;s analysis, the Company was not the primary beneficiary of <FONT STYLE="white-space:nowrap">REV-I</FONT> and accordingly, the entity was not consolidated in the
Company&#8217;s consolidated financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2025 and 2024, the Company recorded its allocable share of <FONT
STYLE="white-space:nowrap">REV-I&#8217;s</FONT> losses, which totaled $0.9&nbsp;million and $2.2&nbsp;million, respectively, as a loss on investment in joint venture in the consolidated statements of operations and comprehensive loss. After
recognition of its share of losses for the period, the carrying value and maximum exposure to risk of the <FONT STYLE="white-space:nowrap">REV-I</FONT> investment there was no carrying value remaining on the
<FONT STYLE="white-space:nowrap">REV-I</FONT> investment as of December&nbsp;31, 2025 or 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Purchase Commitments</B>&#8212;The Company enters contracts in the normal course of business with contract research organizations (&#8220;CROs&#8221;) and other
third-party vendors for clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments that may be due upon cancellation consist
of payments for services provided or expenses incurred prior to cancellation. As of December&nbsp;31, 2025 and 2024 there were no amounts accrued related to termination charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. NET LOSS PER COMMON SHARE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted loss per common share were calculated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR THE YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Weighted-average number of common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,629,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,443,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic net loss per share of common stock is based on the weighted-average number of shares of common stock outstanding during the
period. <FONT STYLE="white-space:nowrap">Pre-funded</FONT> warrants to purchase 416,673 shares of common stock that were issued in connection with the November 2022 <FONT STYLE="white-space:nowrap">follow-on</FONT> offering were included in the
weighted-average number of common shares outstanding for the years ended December&nbsp;31, 2025 and 2024, respectively. The weighted-average number of common shares outstanding diluted for the years ended December&nbsp;31, 2025 and 2024 both exclude
approximately $0.7&nbsp;million stock options and nonvested restricted stock awards and units, which were not dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. SEGMENTS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company defines its segments on the basis of the way in which internally reported financial information is regularly reviewed by the CODM to analyze financial
performance, make decisions, and allocate resources. The Company&#8217;s CODM consists of its Chief Executive Officer, Chief Financial Officer and Chief Medical Officer. The Company manages its operations as a single operating and reportable segment
and the measure of segment profit or loss is net loss. The CODM uses net loss in the budget and forecasting process and considers <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">budget-to-actual</FONT></FONT> variances on a
quarterly basis when making decisions about the allocation of operating and capital resources. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the information about reported
segment revenues and significant segment expenses presented on the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December&nbsp;31, 2025 and 2024: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR THE YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">RLYB212</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">RLYB116</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other program candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Personnel (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">General and administrative, excluding personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">General and administrative, personnel (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other segment items*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Segment net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Other segment items includes total other income, net and gain and loss on investment in joint venture. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. RESTRUCTURING </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
May&nbsp;2, 2025, the Company approved a workforce reduction to focus resources on the Company&#8217;s lead program, RLYB116 and its preclinical development programs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of this effort, the Company eliminated approximately 40% of its positions. As a result of these actions, the Company incurred charges of approximately
$1.7&nbsp;million of which $1.2&nbsp;million was included in research and development expenses and $0.5&nbsp;million was included in general and administrative expenses, with such amounts reflected in the consolidated statements of operations and
comprehensive loss. The charges related to the workforce reduction were cash-based expenditures related primarily to severance and benefit payments. The Company recognized all such charges during the second quarter of 2025, with such amounts
reflected in the consolidated statements of operations and comprehensive loss. The accrued restructuring liability is included in accrued expenses in the consolidated balance sheets as of December&nbsp;31, 2025. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February, 2024, the Company announced a prioritization of its portfolio and a workforce reduction to focus resources primarily on the continued development of
RLYB212. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of this effort, the Company eliminated approximately 45% of its positions. As a result of these actions, the Company incurred charges of
approximately $3.3&nbsp;million of which $2.0&nbsp;million was included in research and development expenses and $1.3&nbsp;million was included in general and administrative expenses, with such amounts reflected in the consolidated statements of
operations and comprehensive loss. The charges related to the workforce reduction are cash-based expenditures related primarily to severance and benefit payments. The Company recognized all such charges in the first quarter of 2024, with such
amounts reflected in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Substantially all restructuring payments are expected to be completed by
August 2026. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the restructuring accrued expense activity as of December&nbsp;31, 2025: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Beginning accrued severance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Severance incurred during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Severance paid and adjustments made during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Ending accrued severance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. SUBSEQUENT EVENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Share Price and
Reverse Split </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;24, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) Listing
Qualifications Department notifying the Company that the closing bid price of the Company&#8217;s shares of common stock was below the minimum closing bid price of $1.00 per share during the prior 30 consecutive business days (the
&#8220;Notice&#8221;), as required for continued listing on the Nasdaq. Pursuant to Nasdaq&#8217;s Listing Rules, the Company had until August&nbsp;25, 2025 (the &#8220;Initial Compliance Date&#8221;) to regain compliance with the minimum closing
bid price requirement. As of the Initial Compliance Date, the Company had not regained compliance with the minimum closing bid price requirement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
August&nbsp;26, 2025, Nasdaq notified the Company that it had approved the Company&#8217;s application to transfer its listing to the Nasdaq Capital Market and that the Company is eligible for an additional 180 calendar day period, or until
February&nbsp;23, 2026 (the &#8220;Second Compliance Date&#8221;), to regain compliance with the minimum closing bid price requirement. At the opening of business on August&nbsp;29, 2025, the Company&#8217;s common stock was transferred to the
Nasdaq Capital Market, which operates in substantially the same manner as the Nasdaq Global Select Market, where it will continue to trade under the symbol &#8220;RLYB.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;26, 2026, the Company&#8217;s stockholders approved a proposal to amend its Amended and Restated
Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company&#8217;s issued and outstanding common stock, par value $0.0001 at a
ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-8.</FONT></FONT> Pursuant to the Certificate of Amendment, the Reverse Stock Split became effective at 12:01 a.m., Eastern Time, on February&nbsp;6, 2026 and began
trading on a post-split basis under CUSIP number 75120L 209. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All common share, per share and related information included in the accompanying financial statements
and footnote disclosures have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;24, 2026, Rallybio received a
letter from Nasdaq notifying the Company it had regained compliance with the Nasdaq&#8217;s Listing Rules and that it complies with the requirements for continued listing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Proposed Merger with Candid Therapeutics </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;1, 2026,
Rallybio entered into the Merger Agreement with Candid, a clinical-stage biotechnology company advancing a leading portfolio of TCE therapeutics for autoimmune diseases, and the Merger Sub. Upon the terms and subject to the satisfaction of the
conditions described in the Merger Agreement, Merger Sub will be merged with and into Candid, with Candid surviving as a wholly owned subsidiary of the Merger. The Merger is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-free</FONT>
reorganization for U.S. federal income tax purposes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions of the Merger Agreement, at the Effective Time, (a)&nbsp;each
then-outstanding share of common stock or preferred stock of Candid Share (excluding any share described in clauses (b)&nbsp;or (c) below and Candid Shares held by stockholders who have exercised and perfected appraisal rights for such shares) will
be converted into the right to receive a number of shares of Rallybio Common Stock, par value $0.0001 per share, calculated in accordance with the Exchange Ratio, (b)&nbsp;each Candid Share issued in the Concurrent Financing will be converted into
the right to receive a number of shares of Rallybio Common Stock calculated in accordance with the Concurrent Financing Exchange Ratio, (c)&nbsp;any Candid Shares held as treasury shares or held or owned by Rallybio, Merger Sub or any subsidiary of
Rallybio or Candid immediately prior to the Effective Time will be canceled and shall cease to exist, and no consideration shall be delivered in exchange therefor. Each then-outstanding option to purchase Candid Shares will be converted into an
option to purchase Rallybio Common Stock, subject to adjustment as set forth in the Merger Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrently with the execution and delivery of the Merger
Agreement, certain investors entered into a subscription agreement with Candid, pursuant to which such investors have agreed to purchase, immediately prior to the Merger, shares of Candid common stock representing an aggregate commitment of
approximately $505.5 million in the Concurrent Financing. The shares of Candid common stock that are issued in the Concurrent Financing will be or will have the right to be, respectively, converted into shares of Rallybio common stock in the Merger.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the Closing, on a pro forma basis and based
upon the number of shares of Rallybio Common Stock expected to be issued in connection with the Merger, <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Candid (other than investors in the Concurrent Financing) are expected to own
approximately 57.55% of the combined company, <FONT STYLE="white-space:nowrap">pre-Merger</FONT> equityholders of Rallybio are expected to own approximately 3.65% of the combined company and the Investors in the Concurrent Financing are expected to
own approximately 38.80% of the combined company (assuming proceeds from the Concurrent Financing of $505.5&nbsp;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions,
including (i)&nbsp;a valuation for Rallybio of $47.5&nbsp;million (assuming Rallybio has net cash (&#8220;Rallybio Net Cash&#8221;) of $37.5&nbsp;million as of the closing of the Merger (the &#8220;Closing&#8221; and such date, the &#8220;Closing
Date&#8221;)), (ii)&nbsp;a fixed valuation for Candid of $750.0&nbsp;million, and (iii)&nbsp;the relative capitalization of Rallybio and Candid. The percentage of the combined company that each party&#8217;s equity holders will own following the
Closing is subject to certain adjustments as described in the Merger Agreement, including the amount of the final Rallybio Net Cash at Closing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior
to the Effective Time, Rallybio and a rights agent are expected to enter into the CVR Agreement, pursuant to which holders of record of certain Rallybio securities as of the close of business on the last business day
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
prior to the day on which the Effective Time occurs will receive one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of Rallybio Common Stock, prefunded warrant,
Rallybio restricted stock unit or In the Money Parent Option (as defined in the CVR Agreement) held as of such date. Pursuant to the CVR Agreement, each CVR holder will be entitled to receive their pro rata share of (i)&nbsp;all of the net proceeds
(including cash the value of stock to the extent listed on a national exchange, at the time of disposition), if any, received by Rallybio as a result of payments made to Rallybio of any upfront, milestone, royalty and other payments received under
any disposition agreement related to Rallybio&#8217;s Legacy Assets, and (ii)&nbsp;all of the cash proceeds, if any, received from Recursion under the Membership Interest Purchase Agreement, dated July&nbsp;8, 2025, by and among Recursion,
Exscientia Ventures I, Inc., Rallybio Corporation and Rallybio IPB, LLC. For a period of one year after the Closing Date, Rallybio will use commercially reasonable efforts to effect the disposition of the Legacy Assets. Such net proceeds will be
subject to certain permitted deductions, including for applicable tax payments, certain expenses incurred or other liabilities borne by Rallybio or its affiliates in respect of the Legacy Assets, and losses incurred by Rallybio or its affiliates due
to a third-party proceeding in connection with such disposition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_7"></A><A NAME="toc109079_40"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the stockholders and the Board of Directors of Candid Therapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying
consolidated balance sheets of Candid Therapeutics, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December&nbsp;31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and
stockholders&#8217; deficit, and cash flows, for the year ended December&nbsp;31, 2025, and the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024, and the related notes (collectively referred to as the &#8220;financial
statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2025 and 2024, and the results of its operations and its cash flows for the year
ended December&nbsp;31, 2025, and period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements are the responsibility of the
Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">March 16, 2026 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">San Diego, California </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#8217;s auditor since 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_8"></A>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands,
except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">231,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities, Convertible Preferred Stock and Stockholders&#8217; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies (Note 4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Convertible preferred stock, $0.0001 par value; authorized shares &#8211; 367,005,749 at December&nbsp;31,
2025 and 2024; issued and outstanding shares &#8211; 367,005,749 at December&nbsp;31, 2025 and 2024; liquidation preference &#8211; $401,407 at December&nbsp;31, 2025 and 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Stockholders&#8217; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.0001 par value; authorized shares &#8211; 574,000,000 at December&nbsp;31, 2025 and 2024;
issued shares &#8211; 141,472,337 and 146,066,635 at December&nbsp;31, 2025 and 2024, respectively; outstanding shares &#8211; 99,375,112 and 71,091,026 at December&nbsp;31, 2025 and 2024, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(266,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(213,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">231,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_9"></A>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>May&nbsp;1, 2024<BR>(inception) to<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development (includes related party amounts
of $0 and $153,502, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Change in fair value of convertible promissory note &#8211; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(92,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Unrealized gain (loss) on investment securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(91,451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Weighted-average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,696,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,300,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_10"></A>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#8217;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance at May&nbsp;1, 2024 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series <FONT
STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock in connection with asset acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,999,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,499,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series B convertible preferred stock for cash, net of $805 of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,666,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Conversion of convertible promissory note with related party into Series B convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Vesting of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Unrealized loss on investment securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">427,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,091,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(125,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Exercise of vested common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Vesting of early exercised stock options and founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,057,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Unrealized gain (loss) on investment securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">427,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,375,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(266,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(213,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_11"></A>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in
thousands) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>May&nbsp;1, 2024<BR>(inception) to<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(92,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development (includes related party amount of
$0 and $153,502, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Write-off</FONT> of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Change in fair value of convertible promissory note &#8211; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion of discounts on investments, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accounts payable, accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets and liabilities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash paid for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash acquired in connection with asset acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Purchases of investment securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(228,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Maturities of investment securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from issuance of convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from issuance of promissory note&#8212;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Repayment of promissory note&#8212;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from issuance of convertible promissory note&#8212;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Payment of initial public offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,516</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Supplemental disclosure of noncash investing and financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset and
operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Conversion of convertible promissory note with related party into Series B convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock and convertible preferred stock in connection with asset acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">270,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock as issuance costs in connection with issuance of Series B convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Unpaid initial public offering costs in accounts payable, accrued expenses and other current
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_12"></A>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Organization
and Basis of Presentation </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Description of Business </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candid
Therapeutics, Inc. (including its subsidiaries, the &#8220;Company&#8221;) was incorporated in the State of Delaware on May&nbsp;1, 2024 and is based in San Diego, California. The Company is a global clinical-stage biotechnology company focused on
building the leading portfolio of T cell engager therapeutics to treat autoimmune diseases. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Forward Stock Split </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;19, 2024, the Company effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">55.1-for-1</FONT></FONT> forward split of shares of
the Company&#8217;s common stock (the &#8220;Forward Stock Split&#8221;). The par value of the common stock was not adjusted as a result of the Forward Stock Split. The accompanying financial statements and notes to the financial statements give
retroactive effect to the Forward Stock Split for the periods presented. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;19, 2024, the Company entered into an agreement and plan of merger and reorganization (the &#8220;2024 Merger&#8221;) (See Note 5) whereby Vignette Bio,
Inc. (&#8220;Vignette&#8221;) and TRC 2004, Inc. (&#8220;TRC&#8221;) became wholly owned subsidiaries of Candid Therapeutics, Inc. until Vignette and TRC were merged into Candid Therapeutics, Inc. on December&nbsp;27, 2024. On January&nbsp;22, 2025,
Candid Therapeutics, Inc. established Shanghai Tandi Biotechnology Co., Ltd. (&#8220;Tandi&#8221;), a Shanghai Limited Liability Company, as a wholly owned foreign subsidiary located in Shanghai, China, formed for the primary purpose of conducting
clinical trials in China. The consolidated financial statements include the accounts of Candid Therapeutics, Inc. for the periods presented, the accounts of Vignette and TRC from August&nbsp;19, 2024 through December&nbsp;27, 2024, and the accounts
of Tandi from formation through December&nbsp;31, 2025. All intercompany balances were eliminated in consolidation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transactions with Related Parties
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the time of the 2024 Merger, Ken Song, M.D., the Company&#8217;s President and Chief Executive Officer, was a member of the board of directors of
Vignette. In addition, each of Vignette and TRC had a board member in common with the Company. As a result, the 2024 Merger and related <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (&#8220;IPR&amp;D&#8221;) expense of
$153.5&nbsp;million are related party transactions (See Note 5). In June 2024, the Company issued a $0.2&nbsp;million convertible promissory note (the &#8220;Song Note&#8221;) to a trust for which Ken Song, M.D. is a trustee (See Note 7) and issued
a $3.0&nbsp;million promissory note (the &#8220;Foresite Note&#8221;) to Foresite Capital Fund VI, L.P., who, along with its affiliates (together &#8220;Foresite&#8221;), were principal owners of the Company at the time of repayment of the Foresite
Note (See Note 7). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity and Capital Resources </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From its
inception to December&nbsp;31, 2025, the Company has devoted substantially all its resources and efforts to organizing and staffing the Company, business planning, raising capital, identifying assets, engaging in strategic transactions and licensing
agreements, establishing and protecting its intellectual property portfolio, preparing for and conducting its ongoing and planned preclinical studies and preparing for and conducting its ongoing and planned clinical trials, advancing arrangements
with third parties for the manufacture of its drug candidates and component materials, and providing general and administrative support for these operations. The Company has incurred net losses since inception and had an accumulated deficit of
$266.5&nbsp;million as of December&nbsp;31, 2025. From inception to December&nbsp;31, 2025, the Company has funded its operations primarily with the net proceeds from the issuance of shares of its convertible preferred stock, the issuance of its
capital stock in connection with the 2024 Merger and income from investment securities. The Company expects to incur substantial operating losses for the foreseeable future and will need to obtain additional financing in order to initiate and
complete clinical trials and launch and commercialize any drug candidates for which it receives regulatory approval. The Company plans to finance its cash needs through public or private equity or debt financings or other sources. If the Company is
not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could
materially harm the Company&#8217;s business, financial condition, results of operations and prospects. There can be no assurance that such financing will be available or will be at terms acceptable to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company had cash and cash equivalents and short-term investments of
$223.3&nbsp;million which it believes will be sufficient to fund its planned operations for a period of at least 12 months from the date of issuance of these consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of Estimates
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#8217;s financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The
preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s
consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accruals for research and development expenses, stock-based compensation and the
determination of the fair value of the Company&#8217;s common and preferred stock (See &#8220;Fair Value Measurements&#8221; below). These estimates and assumptions are based on current facts, historical experience and various other factors believed
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may
differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accounting guidance defines fair value,
establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or <FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. Fair value is
defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be
determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs
used in measuring fair value as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&#8201;1:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Observable inputs such as quoted prices in active markets. </P></TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&#8201;2:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.
</P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&#8201;3:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own
assumptions. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The carrying value of the Company&#8217;s financial instruments, including cash, restricted cash, prepaid and other current assets,
accounts payable and accrued expenses and other current liabilities are considered to be representative of their respective fair values due to the short-term nature of those instruments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial assets measured at fair value on a recurring basis consist of marketable securities. The fair value of marketable securities is based upon market prices
quoted on the last day of the fiscal period or other observable market inputs. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs,
including reported trades, broker/dealer quotes, bids and/or offers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025 and 2024, the Company had no financial liabilities measured at
fair value on a recurring basis. None of the Company&#8217;s <FONT STYLE="white-space:nowrap">non-financial</FONT> assets or liabilities are recorded at fair value on a <FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. No transfers
between levels have occurred during the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis (in
thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>Reporting Date Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;Total&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets<BR>for Identical<BR>Assets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs</B><br><B>&#8195;(Level&nbsp;2)&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total assets measured at fair value on a recurring basis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2024:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total assets measured at fair value on a recurring basis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">273,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">229,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As further described in Note 7, the Company issued the Song Note in June 2024. The Company elected the fair value option for the Song
Note. The initial fair value was estimated using probability-weighted scenarios considering the possibility of conversion upon a qualified financing event, repayment at maturity, and a dissolution scenario. Outstanding principal and interest on the
Song Note was converted into 339,105 shares of the Company&#8217;s Series B convertible preferred stock on August&nbsp;19, 2024, which had a fair value of $0.4&nbsp;million at the time of conversion. As a result, during 2024, the Company recognized
a change in fair value of convertible promissory note&#8212;related party of $0.2&nbsp;million in the consolidated statements of operations and comprehensive loss related to the change in fair value from the issuance date to its settlement in August
2024. The fair value of the Song Note upon settlement was based on the fair value of the Series B convertible preferred stock issued to the noteholder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August
2024, in connection with the 2024 Merger described in Note 5, the Company issued capital stock as consideration in the transaction. The Company estimated the fair value of its capital stock using methodologies, approaches and assumptions consistent
with the American Institute of Certified Public Accountants Accounting and Valuation Guide: <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I> (the &#8220;Practice Aid&#8221;). The Practice Aid prescribes several
valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its capital stock. After giving consideration to its Series B
preferred stock financing in August 2024 with new investors, and a potential initial public offering (&#8220;IPO&#8221;), the Company concluded a hybrid method utilizing both IPO and alternative exit scenarios was most appropriate. The hybrid method
is useful when certain discrete future outcomes can be predicted, but also accounts for uncertainty regarding the timing or likelihood of specific alternative exit events. The equity value in the IPO scenario was determined using the fully diluted
backsolve method, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
assumes that all shares in the Company are equal to the most recent round of financing on a fully diluted basis. The equity value in the alternative exit scenario was determined using the
backsolve method that considers the rights and preferences of each class of equity and solving for the total market value of invested capital that is consistent with a recent transaction in the Company&#8217;s own securities. The equity value in the
alternative exit scenario was allocated using the option pricing method, whereby shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values
of the preferred and common stock are inferred by analyzing these options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are significant judgments, assumptions and estimates inherent in the determination
of the fair value of the Company&#8217;s capital stock. These include determination of a valuation method and selection of the possible outcomes available to the Company, including the determination of timing and expected future investment returns
for such scenarios. The related judgments, assumptions and estimates are highly interrelated and changes in any one assumption could necessitate changes in another. In particular, any changes in the probability of a particular outcome would require
a related change to the probability of another outcome. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table provides a reconciliation of all liabilities measured at fair value using Level&nbsp;3
significant unobservable inputs (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible<BR>Promissory<BR>Note&#8212;Related<BR>Party</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Balance at May&nbsp;1, 2024 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Issuance of convertible promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Settlement of convertible promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company had no liabilities measured at fair value using Level&nbsp;3 significant unobservable inputs during the year ended
December&nbsp;31, 2025. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash, Cash Equivalents and Restricted Cash </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents
include cash in readily available checking accounts and money market funds. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company had no restricted cash. As of
December&nbsp;31, 2024, restricted cash consisted of a money market account held as collateral in connection with the Company&#8217;s corporate credit cards. Cash, cash equivalents and restricted cash presented in the accompanying consolidated
statements of cash flows consisted of the following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Restricted cash included in prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Marketable Securities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company&#8217;s marketable securities primarily consist of money market funds, corporate debt securities and U.S. treasury securities classified within cash and cash equivalents and short-term investments depending on their maturity at the time of
purchase. Short-term investments are marketable securities with maturities greater than three </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
months from the date of purchase. The Company classifies marketable securities as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale,</FONT></FONT> as the sale
of such investments may be required prior to maturity to implement management strategies, and therefore has classified all marketable securities with maturity dates beyond three months at the date of purchase as current assets in the accompanying
consolidated balance sheets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Marketable securities classified as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
securities are carried in the accompanying consolidated balance sheets at fair value with the unrealized gains and losses, net of tax, if any, included in accumulated other comprehensive loss as a component of stockholders&#8217; deficit until
realized. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in interest income as an adjustment to yield over the life of the instrument.
Interest income is recognized in the accompanying consolidated statements of operations and comprehensive loss when earned. Realized gains and losses from the sale of marketable securities are determined on a specific identification basis and
included in interest income in the accompanying consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables summarize <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maturity</B><br><B>in Years</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1&nbsp;year&nbsp;or&nbsp;less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2&nbsp;years&nbsp;or&nbsp;less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">203,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maturity</B><br><B>in Years</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2&nbsp;years&nbsp;or&nbsp;less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">273,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">273,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amortized cost and estimated fair value in the tables above excludes $1.0&nbsp;million of accrued interest receivable included in
prepaid expenses and other current assets in the accompanying consolidated balance sheets as of each December&nbsp;31, 2025 and 2024. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that it will be required
to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities that do not meet the aforementioned criteria, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the severity of the impairment, any
changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income
through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive loss in the accompanying consolidated statements of operations and comprehensive loss. For the year
ended December&nbsp;31, 2025 and the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024, the Company did not recognize any impairment or realized gains or losses on sales of investments, and the Company did not record an allowance
for, or recognize, any expected credit losses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company had no
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities in a gross unrealized loss position. As of December&nbsp;31, 2024, the Company had <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities with a fair market value of $118.6&nbsp;million in a gross unrealized loss position of $0.2&nbsp;million. None of these securities had been in a continuous loss position for
greater than 12 months. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Concentrations of Credit Risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments. The Company maintains deposits in federally insured financial institutions in
excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which
those deposits are held. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is
subject to a number of risks similar to other biopharmaceutical companies, including but not limited to, dependency on the clinical and commercial success of its drug candidates, ability to obtain regulatory approval of its drug candidates,
uncertainty of broad adoption of its approved drugs, if any, by physicians and patients, manufacturing, the need to obtain adequate additional funding, significant competition, and protection of its intellectual property portfolio. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Property and Equipment, Net </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment are stated at
cost less accumulated depreciation. Depreciation and amortization are calculated using the straight-line method over the estimated useful life of the related assets, generally three to five years. Leasehold improvements are amortized over the
shorter of the estimated useful life of the assets or the remaining lease term. Repairs and maintenance costs are charged to expense as incurred. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leases
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified
asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. Lease terms are determined at the commencement date by considering whether renewal options and
termination options are reasonably assured of exercise. For its long-term operating leases, the Company recognizes a lease liability and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
(&#8220;ROU&#8221;) asset on its consolidated balance sheets and recognizes lease expense on a straight-line basis over the lease term. The lease liability is determined as the present value of future lease payments using the discount rate implicit
in the lease or, if the implicit rate is not readily determinable, an estimate of the Company&#8217;s incremental borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. The Company aggregates all
lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components for each class of underlying assets into a single lease component and variable charges for common area maintenance and other variable costs are recognized as expense as incurred.
The Company has elected to not recognize a lease liability or ROU asset in connection with short-term operating leases and recognizes lease expense for short-term operating leases on a straight-line basis over the lease term. The Company did not
have any financing leases from inception to December&nbsp;31, 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company reviews long-lived assets, such as property and equipment, for impairment whenever events or changes in circumstances indicate the carrying amount of an
asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered
to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Fair value would be assessed using discounted cash flows or other appropriate measures of fair
value. The Company has not recognized any impairment losses for the period from inception to December&nbsp;31, 2025. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2025 and 2024, the Company incurred deferred offering costs consisting of legal, accounting and other fees and costs directly attributable to its planned IPO.
During the year ended December&nbsp;31, 2025, the Company expensed $1.6&nbsp;million of previously deferred IPO costs, included as a component of general and administrative expense. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Business Combinations and Asset Acquisitions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with
Accounting Standards Codification (&#8220;ASC&#8221;) 805, <I>Business Combinations</I> (&#8220;ASC 805&#8221;), upon an acquisition, the Company performs an initial test to determine whether substantially all of the fair value of the gross assets
transferred is concentrated in a single identifiable asset or a group of similar identifiable assets, such that the acquisition would represent an asset acquisition rather than a business combination. If that test indicates that the set of assets
and activities is a business, the Company then performs a second test to evaluate whether the assets and activities transferred include inputs and substantive processes that together, significantly contribute to the ability to create outputs, which
would constitute a business. If the result of the second test suggests that the acquired assets and activities constitute a business, the Company accounts for the transaction as a business combination. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For transactions accounted for as business combinations, the Company allocates the fair value of acquisition consideration to the identifiable assets acquired and
liabilities assumed based on their estimated fair values. The excess of the fair value of acquisition consideration over the fair value of acquired identifiable assets and liabilities assumed is recognized as goodwill. During the measurement period
of a business combination, which is not to exceed one year, if new information is obtained about facts and circumstances that existed as of the acquisition date, changes in the estimated fair values of the net assets recorded may change the amount
of the purchase price allocable to the excess over the fair value of assets acquired. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings. Acquisition-related costs in a business combination are
expensed as incurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions, with a
cost accumulation model used to determine the cost of the acquisition. For an asset acquisition, the fair value of acquisition consideration is allocated to the identifiable assets acquired and liabilities assumed at cost on a relative fair value
basis. If a single asset is acquired, the entire cost is attributed to the acquired asset. In addition, for such asset acquisitions, no goodwill is recognized, acquisition-related costs are capitalized, and any associated contingent consideration is
recorded when the underlying contingencies have been resolved. Common stock and convertible preferred stock issued as consideration in an acquisition of assets are measured based on the acquisition date fair value of the equity interests. Intangible
assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as IPR&amp;D. Acquired IPR&amp;D that has no alternative future use is expensed immediately. Cash
payments for the acquisition of IPR&amp;D are reported as cash outflows for investing activities in the statements of cash flows. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Preferred Stock
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has classified its convertible preferred stock outside of stockholders&#8217; deficit on the accompanying consolidated balance sheets in
accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Company&#8217;s control, including liquidation, sale or transfer of the Company. For convertible preferred stock issued in exchange for cash proceeds, the Company records the convertible
preferred stock at the issuance price, net of related issuance costs, discounts, and proceeds allocated to other instruments issued together with the convertible preferred stock. The Company subsequently measures convertible preferred stock that is
currently redeemable or probable of becoming redeemable in the future by accreting changes in the redemption value using the interest method from the date of issuance to the earliest date the redemption feature can be exercised. As of
December&nbsp;31, 2025 and 2024, no classes of convertible preferred stock were redeemable or probable of becoming redeemable. See Note 8 for further information. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Term Debt </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-convertible</FONT>
term debt instruments are initially recognized at cash proceeds received, net of issuance costs, and are subsequently measured at amortized cost using the effective interest method. Interest expense is recognized based on the effective interest rate
of the respective instruments in the consolidated statements of operations and comprehensive loss over the term of the debt. See Note 7. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Debt
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has elected the fair value option for accounting for its convertible debt instruments pursuant to ASC 825, <I>Financial Instruments</I>. Under
the fair value option, convertible debt is initially recognized at fair value, with issuance costs expensed as incurred. Subsequent changes in the fair value of the convertible debt are recognized in other comprehensive income (loss) or nonoperating
income (loss) depending on whether the change is related to instrument specific credit risk or base market risk, respectively. See Note 7. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and
Development Costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All costs of research and development are expensed in the period incurred. Research and development costs primarily consist of salaries
and related expenses for personnel, stock-based compensation, outside service providers, facilities costs, fees paid to consultants and other professional services, external research and development costs incurred under agreements with contract
research, development and manufacturing organizations, supplies used in research and development and facilities, depreciation and other allocated expenses. Payments made prior to the receipt of goods or services to be used in research and
development are capitalized until the related goods are delivered or services performed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has entered into various research and development contracts
with research organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are presented in the
accompanying consolidated balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual
results could differ from the Company&#8217;s estimates. Historically, there have been no material differences between the Company&#8217;s estimates and the amounts actually incurred. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent Costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Costs related to filing and pursuing patent
applications are recorded as general and administrative expenses and expensed as incurred since recoverability of such expenditures is uncertain. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based
Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company measures its stock-based awards based on the estimated grant date fair value of the awards. For stock-based awards with only
service conditions, compensation expense is recognized over the requisite service period using the straight-line method. For stock-based awards that include performance conditions, compensation expense is not recognized until the performance
condition is probable to occur. The Company estimates the fair value of restricted common stock based on the fair value of the underlying common stock and the fair value of stock options using the Black-Scholes option pricing model. The Company
accounts for forfeitures of stock-based awards as they occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial
statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in
which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a
determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies,
and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset
valuation allowance, which would reduce the provision for income taxes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company records uncertain tax positions on the basis of a <FONT
STYLE="white-space:nowrap">two-step</FONT> process whereby (i)&nbsp;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii)&nbsp;for those tax
positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with
the related tax authority. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Comprehensive
loss is defined as a change in equity during a period from transactions and other events and circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. The only component of other comprehensive loss is unrealized losses on
investment securities. Comprehensive losses have been reflected in the consolidated statements of operations and comprehensive loss and as a separate component in the consolidated statements of convertible preferred stock and stockholders&#8217;
deficit. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Segment Reporting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating segments are identified as
components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The
Company operates and manages its business as a single operating segment and reportable segment, which is engaged in the research and development of novel therapies for autoimmune diseases. The Company&#8217;s CODM is its President and Chief
Executive Officer and the CODM reviews financial information on a consolidated basis for purposes of allocating resources and evaluating financial performance. See Note 10 for additional information. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net Loss Per Share </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic net loss per share is computed by dividing
the net loss by the weighted-average number of the Company&#8217;s common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has excluded 56,011,955 and 70,624,729 weighted-average unvested
shares from the weighted-average number of common shares outstanding for the year ended December&nbsp;31, 2025 and the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024, respectively. Diluted net loss per share is computed by
dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and
<FONT STYLE="white-space:nowrap">if-converted</FONT> methods. Dilutive common stock equivalents are comprised of convertible preferred stock, unvested restricted common stock subject to repurchase and options outstanding under the Company&#8217;s
equity incentive plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would
be anti-dilutive, were as follows (in common stock equivalent shares): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Convertible preferred stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,791,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,033,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,097,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,975,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,894,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468,015,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recent Accounting Pronouncements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2023-09,</FONT> <I>Income Taxes (Topics 740): Improvements to Income Tax Disclosures</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2023-09&#8221;),</FONT> which
requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. The Company early adopted this standard prospectively for the period ended December&nbsp;31, 2025. The
adoption impacted the Company&#8217;s income tax disclosures only and did not otherwise impact the Company&#8217;s consolidated financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November
2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2024-03,</FONT> <I>Income Statement - Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40):</FONT> Disaggregation of
Income Statement Expenses</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2024-03&#8221;)</FONT> which requires disaggregated disclosure of income statement expenses for public business entities. The ASU does not change the expense
captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. Entities are required to apply
the guidance prospectively and may apply it retrospectively. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2024-03</FONT> is effective for fiscal years beginning after December&nbsp;15, 2026, and interim periods within fiscal years beginning after
December&nbsp;15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2024-03</FONT> on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2025, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2025-03,</FONT> <I>Business Combinations (Topic 805) and Consolidation (Topic 810):
Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2025-03&#8221;),</FONT> which revises current guidance for determining the accounting acquirer for a
transaction effected primarily by exchanging equity interests in which the legal acquiree is a variable interest entity that meets the definition of a business. The amendments require that an entity consider the same factors that are currently
required for determining which entity is the accounting acquirer in other acquisition transactions. The Company is currently evaluating the impact of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2025-03</FONT> and intends to adopt this ASU on a
prospective basis as of January&nbsp;1, 2026. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if
adopted, would have a material effect on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Balance Sheet Details </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment, net consisted of the following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Office and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8201;167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8201;200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognized depreciation expense of $0.1&nbsp;million and $19,000, respectively, for the year ended December&nbsp;31, 2025
and the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other long-term assets consisted of the following (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Deferred IPO costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8199;1,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8199;3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">License fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Commitments and Contingencies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2024, the Company entered into a
noncancelable operating lease for office space for its headquarters in San Diego, California. The lease commenced in July 2024 and expires in September 2028, with a Company option to extend the lease for an additional two years. The option to extend
was not considered in the determination of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset or lease liability as the Company did not consider it reasonably certain that it would exercise such
option. The lease requires a security deposit and has certain rent escalations and additional charges for common area maintenance and other costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2025,
the Company entered into a noncancelable operating lease for office space in Shanghai, China. The lease commenced in March 2025 and expires in April 2028. The lease requires a security deposit and has certain rent escalations and additional charges
for common area maintenance and other costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information related to the Company&#8217;s operating leases is as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>May&nbsp;1, 2024<BR>(inception) to<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Variable lease expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash paid for amounts included in the measurement of the lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future minimum noncancelable operating lease payments and information related to the lease liabilities as of December&nbsp;31, 2025 were
as follows (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Years ending December 31:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Less: amount representing interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Less: current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025 and 2024, the Company&#8217;s weighted-average discount rate was 8.0%. As of December&nbsp;31, 2025 and
2024, the Company&#8217;s weighted-average remaining term was 2.6 years and 3.8 years, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contingencies </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is
probable that future expenditures will be made and such expenditures can be reasonably estimated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Merger with Related Parties </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;19, 2024, the Company, TRC and Vignette (TRC and Vignette together the &#8220;Acquirees&#8221;) executed an Agreement and Plan of Merger and
Reorganization (the &#8220;2024 Merger Agreement&#8221;), pursuant to which the Company acquired each of the Acquirees (the &#8220;Acquisitions&#8221;). The total consideration transferred in the Acquisitions consisted entirely of shares of the
Company as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">TRC: 89,999,985 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock and 54,999,985
shares of common stock, with an aggregate fair value of $140.5&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Vignette: 105,000,000 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and
15,000,000 shares of common stock, with an aggregate fair value of $130.0&nbsp;million. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounted for the Acquisitions as asset
acquisitions. The Company incurred transaction costs of $0.7&nbsp;million related to the Acquisitions, $0.3&nbsp;million of which was settled in shares of the Company&#8217;s common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The consideration paid and allocation to the net assets acquired were as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TRC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vignette</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Consideration paid:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total consideration paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net assets acquired:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net working capital (excluding cash)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total net assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The consideration allocated to IPR&amp;D was expensed in the Company&#8217;s consolidated statement of operations and comprehensive loss
for the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024 as the acquired IPR&amp;D has no alternative future use. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the Acquisitions,
the Company became party to certain license and collaboration agreements previously entered into by the Acquirees that may require future payments to the intellectual property owners upon the achievement of certain development, regulatory, and
commercial milestone events. Any potential future milestone payments will be accrued when the related contingency is resolved, and the milestone consideration becomes payable. Refer to Note 6 for further disclosure and information regarding the
license and collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. License and Collaboration Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License and Collaboration Agreement with Shanghai EpimAb Biotherapeutics Co., Ltd. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, in connection with the 2024 Merger, the Company became party to a license and collaboration agreement (the &#8220;EpimAb License Agreement&#8221;) with
Shanghai EpimAb Biotherapeutics Co., Ltd. (&#8220;EpimAb&#8221;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the EpimAb License Agreement, the Company has a royalty-bearing, sublicensable license,
under certain <FONT STYLE="white-space:nowrap">know-how</FONT> and patent rights controlled by EpimAb relating to BCMA/CD3 <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, to research, develop, manufacture, use, sell, offer for sale,
import and otherwise commercialize cizutamig and certain derivatives of cizutamig that are also BCMAxCD3 bispecific antibodies, and products containing cizutamig or such derivatives (&#8220;Cizutamig Licensed Products&#8221;) everywhere in the world
except for Greater China (which includes Hong Kong, Macau and Taiwan) (the &#8220;Cizutamig Licensed Territory&#8221;) for the diagnosis, treatment or prevention of all human and <FONT STYLE="white-space:nowrap">non-human</FONT> diseases (the
&#8220;Cizutamig Field&#8221;). The Company&#8217;s license is exclusive with respect to certain licensed patents and claims of certain other licensed patents that specifically cover any BCMAxCD3 bispecific antibody as a whole or that cover certain
binding sequences and licensed <FONT STYLE="white-space:nowrap">know-how</FONT> that is related to such licensed patents or licensed patent claims; it is <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to all other licensed patent
claims and licensed <FONT STYLE="white-space:nowrap">know-how.</FONT> The Company also has a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license from EpimAb (a)&nbsp;to manufacture cizutamig and Cizutamig Licensed Products in Greater China
(including Hong Kong, Macau and Taiwan) (the &#8220;EpimAb Territory&#8221;) solely for use in the Cizutamig Licensed Territory and (b)&nbsp;to research and develop Cizutamig Licensed Products in the Cizutamig Field in the EpimAb Territory solely
for the purpose of obtaining regulatory approval of Cizutamig Licensed Products in the Cizutamig Licensed Territory. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is responsible, at its own cost,
for the development, manufacture and commercialization of Cizutamig Licensed Products in the Cizutamig Field in the Cizutamig Licensed Territory. The Company is obligated to use commercially reasonable efforts to develop at least one Cizutamig
Licensed Product in the Cizutamig Field in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Cizutamig Licensed Territory; provided, however, that this obligation will expire upon achievement of a certain development milestone, or upon the Company&#8217;s election to make a certain
milestone payment early. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is obligated to pay EpimAb up to $95.0&nbsp;million in development and regulatory milestone payments, up to
$480.0&nbsp;million in commercial milestone payments, and tiered single-digit royalties on net sales of Cizutamig Licensed Products, none of which were due and payable as of December&nbsp;31, 2025. The royalty payments are subject to reduction under
certain customary circumstances. On a Cizutamig Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Cizutamig</FONT></FONT> Licensed Product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the Company&#8217;s obligation to pay EpimAb royalties commences on the first commercial sale of such Cizutamig Licensed Product in the
applicable country until the latest to occur of (a)&nbsp;the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim within the licensed patents covering such Cizutamig Licensed Product in the
applicable country, (b)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> regulatory exclusivity for such Cizutamig Licensed Product in the applicable country and
(c)&nbsp;twelve (12) years after the first commercial sale of such Cizutamig Licensed Product in the applicable country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EpimAb License Agreement will remain
in effect on a Cizutamig Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Cizutamig</FONT></FONT> Licensed Product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until expiration of all royalty payment obligations, unless it is earlier terminated. Following expiration of the EpimAb License Agreement, the
licenses granted to the Company become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable and fully <FONT STYLE="white-space:nowrap">paid-up.</FONT> The Company may terminate the EpimAb License Agreement for convenience
upon advance written notice to EpimAb. Either party may terminate the EpimAb License Agreement for the other party&#8217;s uncured material breach; provided, however, that this termination right will not be available to either party after
achievement of a certain development milestone, or upon the Company&#8217;s election to make a certain milestone payment early. Either party may terminate the EpimAb License Agreement in connection with the insolvency of the other party. EpimAb may
terminate the EpimAb License Agreement if the Company challenges a licensed patent, subject to a specified notice and cure period. Upon termination of the EpimAb License Agreement, the Company is subject to certain post-termination obligations to
enable EpimAb to be able to exploit Cizutamig Licensed Products in the Cizutamig Field on a worldwide basis. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License Agreement with Genor Biopharma Co. Ltd.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, in connection with the 2024 Merger, and as amended in March 2025, the Company became party to a license agreement (the &#8220;Genor License
Agreement&#8221;) with Genor Biopharma Co Ltd. (&#8220;Genor&#8221;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Genor License Agreement, the Company has an exclusive, royalty-bearing,
sublicensable license under certain <FONT STYLE="white-space:nowrap">know-how</FONT> and patent rights controlled by Genor (including certain intellectual property <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Genor) relating to bispecific
antibodies and heteromultimeric proteins (&#8220;Licensed IP&#8221;) to develop, use, manufacture, commercialize and otherwise exploit CND261 (formerly known as GB261), certain derivatives of CND261 that are also CD20xCD3 bispecific antibodies, and
products containing CND261 or such derivatives (&#8220;CND261 Licensed Products&#8221;) everywhere in the world except for Mainland China, Hong Kong, Macau and Taiwan (the &#8220;CND261 Licensed Territory&#8221;) for the diagnosis, treatment or
prevention of disease in humans and animals (the &#8220;CND261 Field&#8221;). The Company also received a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under the Licensed IP in Mainland China, Hong Kong, Macau and
Taiwan (the &#8220;Genor Territory&#8221;) to manufacture CND261 Licensed Products in the Genor Territory and to conduct <FONT STYLE="white-space:nowrap">non-clinical</FONT> and certain clinical development of CND261 Licensed Products in the Genor
Territory in the CND261 Field, solely for the purposes of supporting exploitation of CND261 Licensed Products in the CND261 Field in the CND261 Licensed Territory. In addition, the Company has a right of first negotiation if Genor decides to
commence negotiations with one or more third parties to grant a license to develop, use, manufacture, commercialize or otherwise exploit CND261 Licensed Products in the CND261 Field in the Genor Territory. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is responsible, at its own cost, for the development, manufacture and commercialization of CND261 Licensed Products in the CND261 Field in the CND261
Licensed Territory. The Company is obligated to use commercially reasonable efforts to develop and obtain regulatory approval for at least one CND261 Licensed Product in the CND261 Field in the United States and in at least one of Canada, the United
Kingdom, France, Germany, Spain or Italy (&#8220;Major Market Countries). The Company is also obligated to use commercially reasonable efforts to commercialize at least one CND261 Licensed Product in the United States or any Major Market Country, in
which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
regulatory approval has been obtained for such product. The Company is also obligated to use commercially reasonable efforts to conduct investigator-initiated trial(s) and Phase I clinical
trial(s) of a CND261 Licensed Product in the Genor Territory for the indication of autoimmune and inflammatory diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2025 and 2024, the Company paid
Genor $4.5&nbsp;million and $2.0&nbsp;million, respectively, upon achievement of certain milestones specified in the Genor License Agreement, and expensed such amounts as IPR&amp;D as there is no alterative future use for the Licensed IP. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company is also obligated to pay Genor up to $138.5&nbsp;million in development and regulatory milestone payments, up to
$300.0&nbsp;million in commercial milestone payments, tiered mid single-digit to low double-digit percentage royalties on net sales of CND261 Licensed Products, and mid single-digit to low double-digit percentage of income that the Company receives
from its sublicensees if the Company sublicense its rights to CND261 Licensed Products, none of which were due and payable as of December&nbsp;31, 2025. The royalty payments are subject to reduction under certain customary circumstances. On a CND261
Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CND261</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the
Company&#8217;s obligation to pay Genor royalties commences on the first commercial sale of such CND261 Licensed Product in the applicable country until the latest to occur of (a)&nbsp;the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim within the patents licensed to the Company by Genor covering such CND261 Licensed Product in the applicable country, (b)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">last-to-expire</FONT></FONT> regulatory exclusivity for such CND261 Licensed Product in the applicable country and (c)&nbsp;ten (10) years after the first commercial sale of such CND261 Licensed Product in the applicable
country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Genor License Agreement will remain in effect on a CND261 Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-</FONT></FONT> CND261 Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until expiration of all
royalty payment obligations, unless it is earlier terminated. Following expiration of the Genor License Agreement, the licenses granted to the Company become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable and fully <FONT
STYLE="white-space:nowrap">paid-up.</FONT> Either party may terminate the Genor License Agreement for the other party&#8217;s uncured material breach or insolvency, subject to certain notice and cure periods. Genor may terminate the Genor License
Agreement if the Company challenges any of the patents licensed to it, subject to a specified notice and cure period. The Company may terminate the Genor License Agreement in its entirety, or on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> or CND261 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CND261</FONT></FONT> Licensed Product basis for convenience upon advance written notice to
Genor. Upon termination of the Genor License Agreement, the Company is subject to certain post-termination obligations to enable Genor to be able to exploit the CND261 Licensed Products on a worldwide basis, or if the Genor License Agreement is not
terminated in its entirety, in the applicable terminated countries. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License Agreement with WuXi Biologics (Shanghai) Co., Ltd. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2025, the Company entered into a license agreement (the &#8220;WuXi Biologics License Agreement&#8221;) with WuXi Biologics (Shanghai) Co., Ltd. (&#8220;WuXi
Biologics&#8221;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the WuXi Biologics License Agreement, the Company received an exclusive, royalty-bearing license, with the right to grant sublicenses,
under certain <FONT STYLE="white-space:nowrap">know-how</FONT> and patent rights controlled by WuXi Biologics, to develop, have developed, manufacture, have manufactured, sell, offer for sale, have sold, import and have imported, export and have
exported, and otherwise commercialize CND319, certain other CD19xCD20xCD3 trispecific antibodies, and products containing CND319 or such CD19xCD20xCD3 trispecific antibodies (&#8220;CND319 Licensed Products&#8221;) for all human and <FONT
STYLE="white-space:nowrap">non-human</FONT> use, including for all research, diagnostic and therapeutic purposes (the &#8220;CND319 Field&#8221;), throughout the world. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is responsible, at its cost, for the global development, manufacture and commercialization of CND319 Licensed Products in the CND319 Field. Until completion
of the first Phase I clinical trial of a CND319 Licensed Product, the Company is obligated to use commercially reasonable efforts to develop a CND319 Licensed Product in the CND319 Field. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company paid WuXi Biologics total upfront cash consideration of $25.0&nbsp;million, incurred $1.5&nbsp;million of <FONT STYLE="white-space:nowrap">non-income</FONT>
taxes, and expensed such amounts as IPR&amp;D as there is no alterative future use for the CND319 Licensed Products. As of December&nbsp;31, 2025, the Company is also obligated to pay WuXi Biologics up to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
$150.0&nbsp;million in development and regulatory milestone payments, up to $750.0&nbsp;million in commercial milestone payments, and tiered low to mid single-digit percentage royalties on annual
net sales of each CND319 Licensed Product. The royalty payments are subject to reduction under certain customary circumstances. On a CND319 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CND319</FONT></FONT>
Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the Company&#8217;s obligation to pay WuXi Biologics royalties commences on the first commercial sale of such CND319
Licensed Product in the applicable country and continues until the last to occur of (a)&nbsp;twelve (12) years after the first commercial sale of such CND319 Licensed Product in the applicable country, (b)&nbsp;the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim within certain patents licensed to the Company by WuXi Biologics covering the composition of matter of such CND319 Licensed Product in a trispecific format in the applicable
country, and (c)&nbsp;expiration of regulatory exclusivity for such CND319 Licensed Product in the applicable country. In addition, if the Company sublicenses its rights to CND319 Products, it is obligated to pay to WuXi Biologics a percentage of
certain income that it receives from its sublicensees; such percentage will be between a high single-digit to low double-digit, depending upon when the sublicense is granted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The WuXi Biologics License Agreement will remain in effect on a CND319 Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CND319</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until expiration of all
royalty payment obligations for such CND319 Licensed Product in the applicable country, unless it is earlier terminated. Following expiration of the WuXi Biologics License Agreement, the license granted to the Company becomes fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> perpetual, and irrevocable. The Company may terminate the WuXi Biologics License Agreement in its entirety, or on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, for convenience upon advance written notice to WuXi Biologics. Either party may terminate the WuXi Biologics License Agreement for the other
party&#8217;s uncured material breach or insolvency, subject to certain notice and cure periods. WuXi Biologics may terminate the WuXi Biologics License Agreement if the Company or its sublicensees challenge any of the patents licensed to it,
subject to a specified notice and cure period. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Agreements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the fourth quarter of 2024, the Company entered into four early-stage research licenses that were determined to be asset acquisitions and recognized
$0.3&nbsp;million and $6.5&nbsp;million during 2025 and 2024, respectively, of IPR&amp;D expense related to these agreements. Upon the Company&#8217;s nomination of an exclusive development candidate under each agreement, the Company will be
obligated to pay customary development, regulatory, commercial and/or royalty payments upon achievement to the respective licensor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Debt </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Promissory Note with a Related Party </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;1,
2024, the Company issued the Song Note for proceeds of $0.2&nbsp;million, with an interest rate of 5.0% per annum. The Song Note had an original maturity date of June&nbsp;1, 2025. Upon a qualified financing event (as defined in the promissory
note), the Song Note would automatically convert into shares issued in that financing event at a 50% discount to the issuance price of the shares. Outstanding principal and interest on the Song Note were converted into 339,105 shares of the
Company&#8217;s Series B convertible preferred stock on August&nbsp;19, 2024. See Note 2 for further information regarding the fair value at settlement of the Song Note. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Promissory Note with a Related Party </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;21, 2024, the
Company issued the Foresite Note, which was a $3.0&nbsp;million promissory note, with an interest rate of 5.12% per annum. The unpaid principal and any accrued and unpaid interest were originally due and payable in full on the earlier of
(i)&nbsp;the fifth business day following the closing of an equity financing with total proceeds to the Company of not less than $100.0&nbsp;million, or (ii)&nbsp;December&nbsp;31, 2024. For the period from May&nbsp;1, 2024 (inception) to
December&nbsp;31, 2024, the Company recognized $23,000 of interest expense related to the promissory note. The principal and accrued and unpaid interest of the note was fully repaid in cash in August 2024 at which time Foresite was a related party.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Convertible Preferred Stock and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025 and 2024,
the Company&#8217;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock (&#8220;Series <FONT STYLE="white-space:nowrap">A-1&#8221;),</FONT> Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock
(&#8220;Series <FONT STYLE="white-space:nowrap">A-2&#8221;</FONT> and together with the Series <FONT STYLE="white-space:nowrap">A-1,</FONT> &#8220;Series A&#8221;) and Series B convertible preferred stock (&#8220;Series B&#8221; and together with
Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series <FONT STYLE="white-space:nowrap">A-2,</FONT> &#8220;Series Preferred&#8221;) consisted of the following (in thousands, except share and per share amounts): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Issued<BR>and</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common</B><br><B>Stock</B><br><B>Issuable on<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Original Issue<BR>Price&nbsp;Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,999,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,999,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,999,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,005,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,005,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,005,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">401,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">427,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, pursuant to a Series B preferred stock purchase agreement, the Company issued in two closings an aggregate of
172,005,764 shares of its Series B, of which (i) 171,666,659 shares of Series B were issued at a purchase price of $1.20 per share for gross proceeds of approximately $206.0&nbsp;million, and (ii) 339,105 shares of Series B were issued upon the
settlement of the Song Note with a fair value of $0.4&nbsp;million. The Company incurred $0.8&nbsp;million of issuance costs in connection with the Series B preferred stock financing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Description of Securities </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividends </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of then outstanding shares of Series Preferred, in preference to the holders of common stock, are entitled to receive, only when, as and if declared by the
board of directors, out of funds that are legally available therefor, <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends of 8% of the applicable original issue price per share. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Liquidation Preferences </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon any voluntary or involuntary liquidation,
dissolution or winding up of the Company, or upon the occurrence of a deemed liquidation event, the holders of then outstanding shares of Series Preferred are entitled to receive a liquidation preference at an amount per share equal to the greater
of (i)&nbsp;the applicable original issue price, plus any dividends declared but unpaid, if any and (ii)&nbsp;such amount per share as would have been payable had all shares of Series Preferred converted to common stock pursuant to the conversion
terms of the Series Preferred. If upon any such liquidation, dissolution or winding up of the Company or deemed liquidation event, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of
shares of Series Preferred the full amount to which they are entitled, the holders of shares of Series Preferred shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would
otherwise be payable. Liquidation payments to the holders of Series Preferred have priority and are made in preference to any payments to the holders of common stock. After full payment of the liquidation preference to the holders of the Series
Preferred, the remaining assets, if any, will be distributed ratably to the holders of common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Conversion </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of Series Preferred is convertible into one share of common stock, at the option of the holder, subject to certain anti-dilution adjustments. Each share of
Series Preferred is automatically converted into one share of common stock, subject to certain anti-dilution adjustments, upon the earliest to occur of, (a)&nbsp;immediately prior to the closing of the sale of shares of common stock to the public in
a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50.0&nbsp;million of gross proceeds to the Company and in connection with such
offering the common stock is listed for trading on the Nasdaq Stock Market, the New York Stock Exchange or another exchange or marketplace approved by the board of directors, and (b)&nbsp;the vote of the holders of a majority of the outstanding
shares of Series Preferred, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
voting together as a single class on an as converted to common stock basis (which majority shall include (i)&nbsp;the holders of a majority of the shares of outstanding Series B, exclusively and
as a separate class on an as converted to common stock basis and (ii)&nbsp;the holders of a majority of the outstanding shares of Series A, together as a single class on an as converted to common stock basis) (the &#8220;Requisite Holders&#8221;).
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Voting Rights </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each holder of outstanding shares of Series Preferred is
entitled to cast one vote for each share of common stock into which their shares of Series Preferred would convert and to vote as one class with the common stockholders on all matters presented to the stockholders of the Company except as provided
in the Company&#8217;s certificate of incorporation or by law. Certain matters require the vote of the Requisite Holders, which matters include material changes to the Company&#8217;s corporate structure, capitalization and the incurrence of certain
corporate obligations, among other matters. In addition, holders of each of Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series <FONT STYLE="white-space:nowrap">A-2,</FONT> Series B and common stock are entitled to separately elect certain
members of the Company&#8217;s board of directors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common Stock Issuances </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May and June 2024, the Company issued an aggregate of 73,227,900 shares of its common stock to certain founders and consultants at a price of $0.0000018 per share,
the then-current fair value of the Company&#8217;s common stock. Of these shares, 25,687,620 were issued under the 2024 Plan (defined and described below). At issuance, all such shares were subject to a repurchase option by the Company, under which
25% of the shares will be released from the repurchase option on the first anniversary of the respective issuance date, and 1/48th of the shares will vest and be released from the repurchase option on a monthly basis thereafter, subject to continued
services to the Company as of the date of such release. As of December&nbsp;31, 2025 and 2024, 41,065,557 shares and 73,227,900&nbsp;shares, respectively, were unvested and subject to repurchase by the Company at the lower of the issuance price or
the then-current fair market value per share. As of December&nbsp;31, 2025 and 2024, the repurchase liability related to the unvested shares was immaterial. For accounting purposes, unvested shares of common stock are not considered outstanding
until they vest. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2025, in connection with certain separation agreements, the Company repurchased 5,031,798 founder shares at their original issuance
price. The vesting of 979,612 founder shares was modified such that 706,408&nbsp;shares were immediately vested and 273,204 shares became subject to vesting over a 12 month period. The incremental fair value of vested shares at the modification date
of $0.6&nbsp;million was recognized at the modification date and the remaining incremental fair value of $0.2&nbsp;million will be recognized over the remaining requisite service period of the awards (generally the vesting period) on a straight-line
basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;19, 2024, the Company issued an aggregate of 69,999,985 shares of its common stock to certain stockholders of the Acquirees in the 2024
Merger (See Note 5). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;19, 2024, the Company issued 1,000,000 shares of common stock, at a fair value of $0.6&nbsp;million, to reimburse an investor
for expenses incurred related to their investments in the Company and the 2024 Merger. The fair value of the common shares was derived from the same model that was used to derive the fair value of the 2024 Merger consideration (See Note 5) and
$0.3&nbsp;million of the fair value was allocated to the 2024 Merger and $0.3&nbsp;million to the Company&#8217;s Series B preferred stock financing. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Equity
Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2024, the Company adopted the Candid Therapeutics, Inc. Equity Incentive Plan (as amended, the &#8220;2024 Plan&#8221;), which
provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other awards to its employees, members of its board of directors and consultants. As
of December&nbsp;31, 2025 and 2024, there were 60,711,153 shares authorized for issuance under the 2024 Plan, of which 3,988,040 shares and 7,151,033 shares, respectively, remained available for future issuance. Recipients of incentive stock options
are eligible to purchase shares of the Company&#8217;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2024 Plan is 10 years
and, in general, the awards vest at various </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
periods up to four years from the vesting commencement date, and may include performance conditions. The 2024 Plan allows for the early exercise of stock options, which may be subject to
repurchase by the Company at the lower of (i)&nbsp;the fair market value of the common stock at the repurchase date or (ii)&nbsp;the original exercise price. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
summary of the Company&#8217;s unvested shares and unvested stock liability, including unvested common stock issued to founders, is as follows (in thousands, expect share data): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Unvested<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unvested<BR>Stock<BR>Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Balance at May&nbsp;1, 2024 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Unvested common stock issued to founders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,227,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Early exercised common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,838,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Vested shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,975,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Early exercised common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Repurchase of common stock issued to founders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,031,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Vested shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,057,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,097,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A summary of the Company&#8217;s stock option activity is as follows (in thousands, except share and per share data): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Outstanding<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining<BR>Contractual Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,033,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,647,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(437,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,452,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2025
<B><I><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,791,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Vested and expected to vest at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,963,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Exercisable at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,198,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></I></B><B><I></I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><B><I></I></B>On May&nbsp;5, 2025, the Company modified certain outstanding stock option awards by reducing the exercise
price from $0.70 per share to $0.35 per share. The modification affected 5,595,000 stock options and resulted in incremental compensation cost of approximately $0.3&nbsp;million, representing the excess fair value of the modified awards over the
fair value of the original awards immediately before the modification. As none of the modified awards were vested as of the modification date, the incremental compensation cost will be recognized as stock-based compensation over the remaining
requisite service period of the awards. The impact of the modification is reflected in the weighted-average exercise price of the stock options outstanding as of December&nbsp;31, 2025. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>May&nbsp;1, 2024<BR>(inception) to<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Risk-free interest rate. </I>The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero
coupon U.S. Treasury notes with maturities similar to the expected term of the awards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected volatility. </I>Since the Company is not yet a public company
and does not have a trading history for its common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in
the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected term. </I>The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise
behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected dividend yield. </I>The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention
to pay cash dividends and, therefore, used an expected dividend yield of zero. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense recognized for all equity awards has been reported
in the accompanying consolidated statements of operations and comprehensive loss as follows (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>May&nbsp;1, 2024<BR>(inception) to<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total fair value of shares vested during the year ended December&nbsp;31, 2025 and the period from May&nbsp;1, 2024 (inception) to
December&nbsp;31, 2024 was $2.2&nbsp;million and $0.1&nbsp;million, respectively. The weighted-average grant date fair value per share of option grants for the year ended December&nbsp;31, 2025 and the period from May&nbsp;1, 2024 (inception) to
December&nbsp;31, 2024 was $0.28 and $0.56, respectively. As of December&nbsp;31, 2025 and 2024, the outstanding options included 17,827,500 and 17,325,000 performance-based options, respectively, for which the achievement of the performance-based
vesting conditions were determined to not be probable. In May 2025, the Company cancelled options to purchase 16,675,000 shares of the Company&#8217;s common stock with performance-based vesting and reissued 16,720,000 options in substitution
therefor. The modification was made to: (i)&nbsp;reduce the exercise price from $0.70 per share to $0.35 per share, which represented the fair market value of the Company&#8217;s common stock as determined by its board of directors on the
modification date, and (ii)&nbsp;modify the performance-based vesting conditions. The performance-based options were not considered probable of vesting as of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the modification date and, as such, the original grant date fair value was replaced with the modification date fair value. The aggregate unrecognized stock-based compensation expense for
outstanding performance-based options at December&nbsp;31, 2025 and 2024 was $4.3&nbsp;million and $9.5&nbsp;million, respectively. As of December&nbsp;31, 2025 and 2024, total unrecognized stock-based compensation expense (excluding
performance-based options) was $6.1&nbsp;million and $5.7&nbsp;million, respectively, which is expected to be recognized over a remaining weighted-average period of approximately 2.6 years and 3.4 years, respectively. The total intrinsic value of
stock options exercised during the year ended December&nbsp;31, 2025 and the period from May&nbsp;1, 2024 (inception) to December&nbsp;31, 2024 was $0.1&nbsp;million and $0.9&nbsp;million, respectively. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common Stock Reserved for Future Issuance </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Common stock reserved for
future issuance consists of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Conversion of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,005,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Common stock options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,791,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,033,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Shares available for issuance under the 2024 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,988,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,151,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,784,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,190,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The components of the
Company&#8217;s pretax net loss are as follows (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>May&nbsp;1, 2024<BR>(inception) to<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(92,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Pretax net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(92,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company&#8217;s income tax
expense, applying ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2023-09</FONT> prospectively, is as follows (in thousands, except percentages):&#8195; </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B><br><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Income tax expense (benefit) at the U.S. federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">State and local taxes, net of federal income tax effect
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Foreign tax effects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Changes in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Nontaxable or nondeductible items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Changes in unrecognized tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The state that contributes to the majority (greater than 50%) of the tax effect in this category relates to California for
the year ended December&nbsp;31, 2025. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the
Company&#8217;s income tax expense, prior to the adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2023-09,</FONT> is as follows (in thousands):&#8195; </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>May&nbsp;1, 2024<BR>(inception) to<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Tax computed at the U.S. federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The components of the Company&#8217;s net deferred tax assets (liabilities) are as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Unrealized losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accruals and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Intangibles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Capitalized research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total deferred tax assets, net of allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Unrealized gains</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use-assets</FONT></FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with FASB ASC 740, <I>Income Taxes</I>, the Company evaluated the realizability of its gross federal and state deferred
income tax assets. Deferred income tax assets are required to be reduced by a valuation allowance if it is more likely than not that some or all of the deferred income tax assets will not be realized. As a result of the cumulative losses, the
Company has established a valuation allowance against all of its U.S. federal and state deferred tax assets that will not be realized through the reversal of taxable temporary differences. The valuation allowance as of December&nbsp;31, 2025 and
2024 was $34.4&nbsp;million and $14.7&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards
of $24.9&nbsp;million and $53.7&nbsp;million, respectively. The entire amount of the federal NOLs carry forward indefinitely; however, these attributes were generated after 2017 which can generally be used to offset up to 80.0% of future taxable
income. The $53.7&nbsp;million of the state NOLs begin to expire in 2045 unless utilized. As of December&nbsp;31, 2025, the Company had federal research and development (&#8220;R&amp;D&#8221;) credits of $1.1&nbsp;million, which begin to expire in
2045 and state R&amp;D credits of $0.7&nbsp;million, which carry forward indefinitely. The Company recognizes the impact of a tax position in the consolidated financial statements if that position is more likely than not of being sustained on a tax
return upon examination by the relevant taxing authority, based on the technical merits of the position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the activity related to the
Company&#8217;s gross unrecognized tax benefits (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>May&nbsp;1, 2024<BR>(inception) to<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Increases related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Increases related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company had gross unrecognized tax benefits of $5.0&nbsp;million, none of which would affect the
effective tax rate if recognized given the Company&#8217;s valuation allowance position. The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. The Company&#8217;s policy is to recognize the
interest expense and/or penalties related to income tax matters as a component of income tax expense. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company had no accrual for interest or penalties on its
consolidated balance sheets at December&nbsp;31, 2025 and 2024 and has not recognized interest and/or penalties in its statements of operations and comprehensive loss for the year ended December&nbsp;31, 2025 or the period ended December&nbsp;31,
2024. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended (&#8220;Section&nbsp;382&#8221;), the Company&#8217;s ability to utilize net
operating loss carryforwards or other tax attributes such as research tax credits, in any taxable year, may be limited if the Company experiences, or has experienced, an &#8220;ownership change.&#8221; A Section&nbsp;382 &#8220;ownership
change&#8221; generally occurs if one or more stockholders or groups of stockholders, who own at least 5% of the Company&#8217;s stock, increase their ownership by more than 50 percentage points over their lowest ownership percentage within a
rolling three-year period. Similar rules may apply under state tax laws. The Company has not completed a Section&nbsp;382 study as of December&nbsp;31, 2025. The Company may have experienced one or more Section&nbsp;382 &#8220;ownership
changes&#8221; or may experience one or more in the future. If so, the Company may not be able to utilize a material portion of its net operating loss carryforwards and tax credits, even if the Company achieves profitability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to taxation in the United States, China, and various state jurisdictions. Due to the presence of net operating loss carryforwards, all income tax
years remain open for examination by U.S. federal and various state taxing authorities. The Company began filing in China in 2025. The Company has not been notified that it is under examination in any jurisdiction. As of December&nbsp;31, 2025, the
Company has not paid a material amount of income tax in any jurisdiction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in
the United States. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act of 2017, modifications to the international tax framework and the restoration of favorable tax
treatment for certain business provisions. This new legislation has multiple effective dates, with certain provisions becoming effective in 2025 and others implemented through 2027. The Company has reflected the effect of OBBBA within the provision
for income taxes and the deferred taxes as of December&nbsp;31, 2025.&#8195; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Candid Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Segment Reporting </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
order to allocate resources, the Company&#8217;s CODM regularly reviews scientific data from clinical and preclinical studies, forecasted cash balances, and monitors budgeted to actual expenditures for clinical and preclinical programs and other
projected operational expenses. The CODM assesses performance for the segment based on net loss, which is reported on the consolidated statement of operations and comprehensive loss. Significant segment expenses provided to the CODM are the same as
presented on the consolidated statements of operations and comprehensive loss as research and development, in-process research and development, general and administrative expenses, and other income (expense), net. The measure of segment assets is
reported on the consolidated balance sheets as total assets. No revenue has been generated since inception and substantially all assets are held in the United States. The accounting policies of this segment are the same as those described in the
summary of significant accounting policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information related to the Company&#8217;s operating segment is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B><br><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from<BR>May&nbsp;1,&nbsp;2024<BR>(inception)&nbsp;to<BR>December&nbsp;31,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">In-process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">162,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(92,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Subsequent Events </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has
completed an evaluation of all subsequent events through March 16, 2026, the date the consolidated financial statements were issued, to ensure these consolidated financial statements include appropriate disclosure of events both recognized in the
consolidated financial statements and events that occurred but were not recognized in the consolidated financial statements. The Company has concluded that no subsequent event has occurred that requires disclosure except as noted below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March 1, 2026, the Company, Rallybio Corporation (&#8220;Rallybio&#8221;) and Farmington Merger Sub, Inc., a wholly owned subsidiary of Rallybio (&#8220;Merger
Sub&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will
merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Rallybio (the &#8220;Merger&#8221;). In addition, on March 1, 2026, the Company entered into a subscription agreement (the &#8220;Subscription
Agreement&#8221;) with certain investors, pursuant to which the Company has agreed to sell, and such investors have agreed to purchase, shares of the Company common stock for an aggregate purchase price of $505.5 million, immediately prior to the
closing of the Merger (the &#8220;Concurrent Financing&#8221;). The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the closing of the Merger as well as certain other conditions. The
Merger is expected to close in the second quarter of 2026 following the effectiveness of the required registration statement, receipt of approval by the stockholders of each of Rallybio and the Company, and the satisfaction or waiver of the other
conditions to the Merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_13"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the stockholders and the Board of Directors of Candid Therapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying
statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit, and cash flows of Vignette Bio, Inc. (the &#8220;Company&#8221;) for the period from January&nbsp;1, 2024 through August&nbsp;19, 2024, and
the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the Company&#8217;s results of its operations and its cash flows for the
period from January&nbsp;1, 2024 through August&nbsp;19, 2024, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements are the responsibility of the
Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to
perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit included performing procedures to assess the
risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in
the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">March
16, 2026 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">San Diego, California </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#8217;s auditor
since 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_14"></A>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statement of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>January&nbsp;1,<BR>2024 to<BR>August&nbsp;19,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development (includes related party amount of $18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">General and administrative (includes related party amount of $68)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(60,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Weighted-average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,048,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_15"></A>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#8217;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock to founders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,175,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series A convertible preferred stock to licensor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series A convertible preferred stock for cash, net of $163 of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,737,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Settlement of SAFE with related parties into Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance at August&nbsp;19, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,175,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(60,619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(60,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B></B><I>See accompanying notes.</I><B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_16"></A>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statement of Cash Flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from</B><br><B>January&nbsp;1,<BR>2024 to<BR>August&nbsp;19,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(60,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets (includes related party amount of $(668))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accounts payable and accrued expenses (includes related party amount of $5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash paid for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of Series A convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuances of common stock to founders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of SAFE with related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Supplemental disclosure of noncash investing and financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Conversion of SAFE with related parties into Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Issuance of Series A convertible preferred stock to acquire in-process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B></B><I>See accompanying notes. </I><B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_17"></A>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Organization and Summary
of Significant Accounting Policies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Organization </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Vignette
Bio, Inc. (the &#8220;Company&#8221; and formerly <FONT STYLE="white-space:nowrap">FL2024-005,</FONT> Inc.) was incorporated in the state of Delaware in December 2023. Prior to the merger transaction in August 2024 described below, the Company was a
biotechnology company focused on identifying therapies to treat autoimmune diseases. On August&nbsp;19, 2024, the Company, TRC 2004, Inc. (&#8220;TRC&#8221;) and Candid Therapeutics, Inc. (&#8220;Candid&#8221;) executed an Agreement and Plan of
Merger and Reorganization (the &#8220;2024 Merger Agreement&#8221;), pursuant to which both TRC and the Company became wholly owned subsidiaries of Candid (the &#8220;2024 Merger&#8221;). Effective upon the completion of the 2024 Merger,
(i)&nbsp;each issued and outstanding share of common stock of the Company was cancelled and exchanged for one share of Candid common stock, and (ii)&nbsp;each issued and outstanding share of Series A of the Company was cancelled and exchanged for
one share of Candid Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From its inception through August&nbsp;19, 2024, the Company has devoted substantially all its resources and efforts to raising capital and acquiring the technology
that led to the 2024 Merger. The Company has incurred net losses and negative cash flows from operations since inception and had an accumulated deficit as of August&nbsp;19, 2024. Since inception through August&nbsp;19, 2024, the Company has funded
its operations primarily with the net proceeds from the issuance of its convertible preferred stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#8217;s financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of the
Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be
reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may
differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accounting guidance defines fair value,
establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or <FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. Fair value is
defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be
determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs
used in measuring fair value as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&#8201;1:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Observable inputs such as quoted prices in active markets. </P></TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&#8201;2:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.
</P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&#8201;3:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own
assumptions. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As further described in Note 2, the Company entered into SAFE agreements (as defined and described below) in June 2024 with certain
related parties. The Company elected the fair value option for the SAFE agreements. There was no material difference between the cash proceeds received at issuance in June 2024, the fair value at issuance, and the fair value at settlement in July
2024. Accordingly, no change in fair value was recognized in the statement of operations and comprehensive loss during 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company
considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. The Company had no cash equivalents for the period presented. Cash includes cash in readily available checking accounts
and money market accounts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company has classified its convertible preferred stock outside of stockholders&#8217; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon
certain change in control events outside of the Company&#8217;s control, including liquidation, sale or transfer of the Company. For convertible preferred stock issued in exchange for cash proceeds, the Company records the convertible preferred
stock at the issuance price, net of related issuance costs, discounts, and proceeds allocated to other instruments issued together with the convertible preferred stock. The Company subsequently measures convertible preferred stock that is currently
redeemable or probable of becoming redeemable in the future by accreting changes in the redemption value using the interest method from the date of issuance to the earliest date the redemption feature can be exercised. As of August&nbsp;19, 2024, no
convertible preferred stock was redeemable or probable of becoming redeemable. See Note 4 for further information. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Business Combinations and Asset
Acquisitions </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 805, <I>Business Combinations</I> (&#8220;ASC 805&#8221;), upon an
acquisition, the Company performs an initial test to determine whether substantially all of the fair value of the gross assets transferred is concentrated in a single identifiable asset or a group of similar identifiable assets, such that the
acquisition would represent an asset acquisition rather than a business combination. If that test indicates that the set of assets and activities is a business, the Company then performs a second test to evaluate whether the assets and activities
transferred include inputs and substantive processes that together, significantly contribute to the ability to create outputs, which would constitute a business. If the result of the second test suggests that the acquired assets and activities
constitute a business, the Company accounts for the transaction as a business combination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For transactions accounted for as business combinations, the Company
allocates the fair value of acquisition consideration to the identifiable assets acquired and liabilities assumed based on their estimated fair values. The excess of the fair value of acquisition consideration over the fair value of acquired
identifiable assets and liabilities assumed is recognized as goodwill. During the measurement period of a business combination, which is not to exceed one year, if new information is obtained about facts and circumstances that existed as of the
acquisition date, changes in the estimated fair values of the net assets recorded may change the amount of the purchase price allocable to the excess over the fair value of assets acquired. Upon the conclusion of the measurement period, any
subsequent adjustments are recorded to earnings. Acquisition-related costs in a business combination are expensed as incurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Acquisitions of assets or a group of
assets that do not meet the definition of a business are accounted for as asset acquisitions, with a cost accumulation model used to determine the cost of the acquisition. For an asset acquisition, the fair value of acquisition consideration is
allocated to the identifiable assets acquired and liabilities assumed at cost on a relative fair value basis. If a single asset is acquired, the entire cost is attributed to the acquired asset. In addition, for such asset acquisitions, no goodwill
is recognized, acquisition-related costs are capitalized, and any associated contingent consideration is recorded when the underlying contingencies have been resolved. Common stock and convertible preferred stock issued as consideration in an
acquisition of assets are measured based on the acquisition date fair value of the equity interests. Intangible assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are
capitalized as <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (&#8220;IPR&amp;D&#8221;). Acquired IPR&amp;D that has no alternative future use is expensed immediately. Cash payments for the acquisition of IPR&amp;D are
reported as cash outflows for investing activities in the statement of cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.
Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences
are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a
determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies,
and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset
valuation allowance, which would reduce the provision for income taxes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company records uncertain tax positions on the basis of a <FONT
STYLE="white-space:nowrap">two-step</FONT> process whereby (1)&nbsp;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&nbsp;for those tax
positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with
the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Comprehensive loss is defined as a change in
equity during a period from transactions and other events and circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. The Company&#8217;s comprehensive loss was the same as its reported net loss for the period presented. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Segment Reporting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating segments are identified as components of
an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating
decision-maker view the Company&#8217;s operations and manage its business in one operating segment. Significant operating expenses include research and development, <FONT STYLE="white-space:nowrap">in-process</FONT> research and development, and
general and administrative expenses, which are each separately presented on the Company&#8217;s statement of operations and comprehensive loss. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net Loss Per
Share </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic net loss per share is computed by dividing the net loss by the weighted-average number of the Company&#8217;s common shares outstanding for the
period, without consideration for potentially dilutive securities. The Company has excluded 352,047 weighted-average unvested shares from the weighted-average number of common shares outstanding for the period from January&nbsp;1, 2024 to
August&nbsp;19, 2024. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined
using the treasury-stock and <FONT STYLE="white-space:nowrap">if-converted</FONT> methods. Potentially dilutive common stock equivalents are comprised of convertible preferred stock. For the period presented, there is no difference in the number of
shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Related Party
Transactions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>SAFE Agreements with Related Parties </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June
2024, the Company entered into three Simple Agreement for Future Equity (&#8220;SAFE&#8221;) agreements with a principal owner (or its affiliates) (&#8220;Foresite&#8221;) of the Company under which it received aggregate proceeds of
$0.3&nbsp;million (the &#8220;Purchase Amount&#8221;). The Purchase Amount was converted in July 2024 into an aggregate of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
262,500 shares of Series A convertible preferred stock (&#8220;Series A&#8221;) with a fair value of $0.3&nbsp;million in connection with the Company&#8217;s Series A preferred stock financing
(see Note 4). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Consulting Services Provided by Related Party </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
May 2024, the Company entered into a services agreement with Foresite. For the period from December&nbsp;19, 2023 (inception) to December&nbsp;31, 2023, prior to entering into the services agreement, the Company recognized $3,000 of expenses for
services provided by Foresite. The Company recognized $0.1&nbsp;million of expenses associated with the services agreement for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Payments on Behalf of Related Party </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2024, the Company paid
$0.7&nbsp;million for certain research and development expenses on behalf of Candid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. License Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License and Collaboration Agreement with Shanghai EpimAb Biotherapeutics Co., Ltd. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, the Company entered into a license and collaboration agreement (the &#8220;EpimAb License Agreement&#8221;) with Shanghai EpimAb Biotherapeutics Co.,
Ltd. (&#8220;EpimAb&#8221;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the EpimAb License Agreement, the Company has a royalty-bearing, sublicensable license, under certain <FONT
STYLE="white-space:nowrap">know-how</FONT> and patent rights controlled by EpimAb relating to BCMA/CD3 <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, to research, develop, manufacture, use, sell, offer for sale, import and otherwise
commercialize EMB06 and certain derivatives of EMB06 that are also BCMAxCD3 bispecific antibodies, and products containing EMB06 or such derivatives (&#8220;EMB06 Licensed Products&#8221;) everywhere in the world except for Greater China (which
includes Hong Kong, Macau and Taiwan) (the &#8220;EMB06 Licensed Territory&#8221;) for the diagnosis, treatment or prevention of all human and <FONT STYLE="white-space:nowrap">non-human</FONT> diseases (the &#8220;EMB06 Field&#8221;). The
Company&#8217;s license is exclusive with respect to certain licensed patents and claims of certain other licensed patents that specifically cover any BCMAxCD3 bispecific antibody as a whole or that cover certain binding sequences and licensed <FONT
STYLE="white-space:nowrap">know-how</FONT> that is related to such licensed patents or licensed patent claims; it is <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to all other licensed patent claims and licensed <FONT
STYLE="white-space:nowrap">know-how.</FONT> The Company also has a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license from EpimAb (a)&nbsp;to manufacture EMB06 and EMB06 Licensed Products in Greater China (including Hong Kong, Macau and
Taiwan) (the &#8220;EpimAb Territory&#8221;) solely for use in the EMB06 Licensed Territory and (b)&nbsp;to research and develop EMB06 Licensed Products in the EMB06 Field in the EpimAb Territory solely for the purpose of obtaining regulatory
approval of EMB06 Licensed Products in the EMB06 Licensed Territory. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is responsible, at its own cost, for the development, manufacture and
commercialization of EMB06 Licensed Products in the EMB06 Field in the EMB06 Licensed Territory. The Company is obligated to use commercially reasonable efforts to develop at least one EMB06 Licensed Product in the EMB06 Field in the EMB06 Licensed
Territory; provided, however, that this obligation will expire upon achievement of a certain development milestone, or upon the Company&#8217;s election to make a certain milestone payment early. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, as partial consideration for the license, the Company paid EpimAb total upfront cash consideration of $30.0&nbsp;million and issued 30,000,000 shares of
its Series A with a fair value of $30.0&nbsp;million and expensed such amounts as IPR&amp;D as there is no alterative future use for the licensed technology. The Company is obligated to pay EpimAb up to $95.0&nbsp;million in development and
regulatory milestone payments, up to $480.0&nbsp;million in commercial milestone payments, and tiered single-digit royalties on net sales of EMB06 Licensed Products, none of which were due and payable as of August&nbsp;19, 2024. The royalty payments
are subject to reduction under certain customary circumstances. On a EMB06 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-EMB06</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the Company&#8217;s obligation to pay EpimAb royalties commences on the first commercial sale of such EMB06 Licensed Product in the applicable country until the latest to occur of
(a)&nbsp;the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim within the licensed patents covering such EMB06 Licensed Product in the applicable country, (b)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> regulatory exclusivity for such EMB06 Licensed Product in the applicable country and (c)&nbsp;twelve (12) years after the first commercial sale of such EMB06
Licensed Product in the applicable country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EpimAb License Agreement will remain in effect on a EMB06 Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-EMB06</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until expiration of all royalty payment obligations, unless it is
earlier terminated. Following expiration of the EpimAb License Agreement, the licenses granted to the Company become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable and fully
<FONT STYLE="white-space:nowrap">paid-up.</FONT> The Company may terminate the EpimAb License Agreement for convenience upon advance written notice to EpimAb. Either party may terminate the EpimAb License Agreement for the other party&#8217;s
uncured material breach; provided, however, that this termination right will not be available to either party after achievement of a certain development milestone, or upon the Company&#8217;s election to make a certain milestone payment early.
Either party may terminate the EpimAb License Agreement in connection with the insolvency of the other party. EpimAb may terminate the EpimAb License Agreement if the Company challenges a licensed patent, subject to a specified notice and cure
period. Upon termination of the EpimAb License Agreement, the Company is subject to certain post-termination obligations to enable EpimAb to be able to exploit EMB06 Licensed Products in the EMB06 Field on a worldwide basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Convertible Preferred Stock and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July and August 2024, pursuant to a
Series A preferred stock purchase agreement with new and existing investors to the Company, the Company issued an aggregate of 105,000,000 shares of Series A in multiple closings at a purchase price of $1.00 per share. In connection with the Series
A preferred stock financing the Company issued: (i) 74,737,500 shares of Series A for gross cash proceeds of $74.7&nbsp;million, (ii) 30,000,000 shares of Series A in connection with the EpimAb License Agreement and (iii) 262,500 shares of Series A
upon the settlement of the SAFE agreements described above. The Company incurred $0.2&nbsp;million of issuance costs in connection with the Series A financing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Description of Securities </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividends </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of Series A, in preference to the holders of common stock, are entitled to receive, but only out of funds that are legally available therefor, cash dividends at
the annual per share rate of $0.08. After payment of any preferential preferred stock dividends described above, if any additional dividends are paid or set aside, such dividends shall be paid to the holders of common stock and the holders of Series
A as if the shares of Series A had converted to common stock. Such dividends are noncumulative and are payable only when, as and if declared by the Company&#8217;s board of directors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Liquidation Preferences </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon any liquidation, dissolution or winding up of
the Company, the holders of Series A are entitled to receive a liquidation preference at the per share rate of $1.00, plus all declared and unpaid dividends. Liquidation payments to the holders of Series A have priority and are made in preference to
any payments to the holders of common stock. After full payment of the liquidation preference to the holders of the Series A, the remaining assets, if any, will be distributed ratably to the holders of common stock. The Series A would be deemed
converted to common stock in the event such conversion would result in a liquidation payment greater than its liquidation preference. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Conversion </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares of Series A are convertible into an equal number of shares of common stock, at the option of the holder, subject to certain anti-dilution adjustments. Each
share of Series A is automatically converted into common stock upon, (a)&nbsp;the closing of the sale of shares of common stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under the
Securities Act of 1933, as amended, resulting in at least $50.0&nbsp;million of gross proceeds to the Company and certain other conditions, or (b)&nbsp;the vote of the holders of at least a majority of the outstanding shares of Series A, voting
together as a single class on an as converted to common stock basis. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Voting Rights </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holder of each share of Series A is entitled to one vote for each share of common stock into which it would convert and has protective voting provisions related to
certain matters including material changes to the corporate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vignette Bio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
structure, capitalization and the incurrence of certain corporate obligations, among other issues. In addition, the Series A is entitled to elect certain members of the board of directors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common Stock Issuances </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2024, the Company issued an aggregate
of 15,000,000 shares of its common stock to certain founders at a price of $0.0001 per share, the then-current fair value of the Company&#8217;s common stock. At issuance, 825,000 of such shares were subject to a repurchase option by the Company,
under which 25% of the shares will be released from the repurchase option on May&nbsp;1, 2025, and 1/48th of the shares will vest and be released from the repurchase option on a monthly basis thereafter, subject to continued services to the Company
as of the date of such release. As of August&nbsp;19, 2024, 825,000 shares were unvested and subject to repurchase by the Company and the repurchase liability related to the unvested shares was immaterial. For accounting purposes, unvested shares of
common stock are not considered outstanding until they vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Income Taxes </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#8217;s pretax net loss for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024 was generated solely in the United States. A reconciliation of the
income tax expense computed at the U.S. federal statutory income tax rate to the Company&#8217;s income tax expense is as follows (in thousands):&#8195; </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>January&nbsp;1,&nbsp;2024<BR>to August&nbsp;19,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Tax computed at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,729</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> license consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to taxation in the United States and various state jurisdictions. The Company has not been notified that it is
under examination in any jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Subsequent Events </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company has completed an evaluation of all subsequent events through March 16, 2026, the date the financial statements were issued, to ensure these financial statements include appropriate disclosure of events both recognized in the financial
statements and events that occurred but were not recognized in the financial statements. The Company has concluded that no subsequent event has occurred that requires disclosure except as described in Note 1 above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_18"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the stockholders and the Board of Directors of Candid Therapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying
statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit, and cash flows of TRC 2004, Inc. (the &#8220;Company&#8221;) for the period from January&nbsp;1, 2024 through August&nbsp;19, 2024, and the
related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the Company&#8217;s results of its operations and its cash flows for the period
from January&nbsp;1, 2024 through August&nbsp;19, 2024, in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for
Opinion </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audit in accordance with
the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">March 16, 2026 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">San Diego, California </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#8217;s auditor since 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_19"></A>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statement of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>January&nbsp;1,<BR>2024 to<BR>August&nbsp;19,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">General and administrative (includes related party amount of $910)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,991</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Interest expense &#8211; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Other expense &#8211; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Weighted-average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,673,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_20"></A>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Promissory<BR>Note<BR>Receivable&nbsp;for<BR>Common&nbsp;Stock<BR>&#8211;&nbsp;Related&nbsp;Party</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#8217;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Collection of promissory notes receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock to related party investors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock to licensor, net of $18 of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,111,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock to licensor in connection with anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,830,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series A convertible preferred stock for cash, net of $109 of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,117,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Conversion of convertible promissory note into Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Balance at August&nbsp;19, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,176,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,941,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B></B><I>See accompanying notes.</I><B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_21"></A>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statement of Cash Flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>January&nbsp;1,<BR>2024 to<BR>August&nbsp;19,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Discount on common stock issuances to related party investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Noncash interest expense &#8211; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accounts payable (includes related party amount of $(10))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,485</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash paid for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of Series A convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuances of common stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of convertible promissory notes &#8211; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Proceeds from collection of promissory notes receivable related to common stock issuances &#8211; related
party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Net increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Supplemental disclosure of noncash investing and financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Conversion of convertible promissory notes and accrued interest into Series A convertible preferred stock
&#8211; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Issuance of common stock to acquire in-process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin109079_22"></A>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Organization and Summary
of Significant Accounting Policies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Organization </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TRC 2004,
Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware in September 2020. Prior to the merger transaction in August 2024 described below, the Company was a biotechnology company focused on identifying therapies to treat
autoimmune diseases. On August&nbsp;19, 2024, the Company, Vignette Bio, Inc. (&#8220;Vignette&#8221;) and Candid Therapeutics, Inc. (&#8220;Candid&#8221;) executed an Agreement and Plan of Merger and Reorganization (the &#8220;2024 Merger
Agreement&#8221;), pursuant to which both Vignette and the Company became wholly-owned subsidiaries of Candid (the &#8220;2024 Merger&#8221;). Effective upon the completion of the 2024 Merger, (i)&nbsp;each issued and outstanding share of common
stock of the Company was cancelled and exchanged for 4.25 shares of Candid common stock, and (ii)&nbsp;each issued and outstanding share of Series A convertible preferred stock of the Company was cancelled and exchanged for 4.25 shares of Candid
Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From its inception through August&nbsp;19, 2024, the Company has devoted substantially all its resources and efforts to raising capital and acquiring the technology
that led to the 2024 Merger. The Company has incurred net losses and negative cash flows from operations since inception and had an accumulated deficit as of August&nbsp;19, 2024. Since inception through August&nbsp;19, 2024, the Company has funded
its operations primarily with the net proceeds from the issuance of its convertible preferred stock, the issuance of common stock and convertible promissory notes. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#8217;s financial statements are
prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts. The most
significant estimates in the Company&#8217;s financial statements relate to the determination of the fair value of the Company&#8217;s common stock (See &#8220;Fair Value Measurements&#8221; below). These estimates and assumptions are based on
current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of
expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future
results of operations will be affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability
category measured at fair value on either a recurring or <FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for
considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&#8201;1:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Observable inputs such as quoted prices in active markets. </P></TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&#8201;2:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.
</P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&#8201;3:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own
assumptions. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July and August 2024, the Company issued common stock in connection with a license agreement (see Note 3) and various sales of
common stock (see Note 4). The Company estimated the fair value of its common stock using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide: <I>Valuation
of Privately Held Company Equity Securities Issued as Compensation</I> (the &#8220;Practice Aid&#8221;). The Practice Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches,
and various methodologies for allocating the value of an enterprise to its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
capital stock. After considering its Series A preferred stock financing with new and existing investors in August 2024, and the potential of a merger and acquisition (&#8220;M&amp;A&#8221;)
transaction, the Company concluded a hybrid method utilizing both M&amp;A and alternative exit scenarios was most appropriate. The hybrid method is useful when certain discrete future outcomes can be predicted, but also accounts for uncertainty
regarding the timing or likelihood of specific alternative exit events. The equity value in the M&amp;A scenario was determined using the fully diluted backsolve method, which assumes the undiscounted fair value of all shares in the Company are
equal to the most recent round of financing on a fully diluted basis. The equity value in the alternative exit scenario was determined using the backsolve method that considers the rights and preferences of each class of equity and solving for the
total market value of invested capital that is consistent with a recent transaction in the Company&#8217;s own securities. The equity value in the alternative exit scenario was allocated using the option pricing method, whereby shares are valued by
creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are significant judgments, assumptions and estimates inherent in the determination of the fair value of the Company&#8217;s capital stock. These include
determination of a valuation method and selection of the possible outcomes available to the Company, including the determination of timing and expected future investment returns for such scenarios. The related judgments, assumptions and estimates
are highly interrelated and changes in any one assumption could necessitate changes in another. In particular, any changes in the probability of a particular outcome would require a related change to the probability of another outcome. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company considers all highly liquid investments with
original maturities of three months or less when purchased to be cash equivalents. The Company had no cash equivalents for the period presented. Cash includes cash in readily available checking accounts and money market accounts. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has classified its
convertible preferred stock outside of stockholders&#8217; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events
outside of the Company&#8217;s control, including liquidation, sale or transfer of the Company. For convertible preferred stock issued in exchange for cash proceeds, the Company records the convertible preferred stock at the issuance price, net of
related issuance costs, discounts, and proceeds allocated to other instruments issued together with the convertible preferred stock. The Company subsequently measures convertible preferred stock that is currently redeemable or probable of becoming
redeemable in the future by accreting changes in the redemption value using the interest method from the date of issuance to the earliest date the redemption feature can be exercised. As of August&nbsp;19, 2024, no convertible preferred stock was
redeemable or probable of becoming redeemable. See Note 4 for further information. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Business Combinations and Asset Acquisitions </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 805, <I>Business Combinations</I> (&#8220;ASC 805&#8221;), upon an acquisition, the Company
performs an initial test to determine whether substantially all of the fair value of the gross assets transferred is concentrated in a single identifiable asset or a group of similar identifiable assets, such that the acquisition would represent an
asset acquisition rather than a business combination. If that test indicates that the set of assets and activities is a business, the Company then performs a second test to evaluate whether the assets and activities transferred include inputs and
substantive processes that together, significantly contribute to the ability to create outputs, which would constitute a business. If the result of the second test suggests that the acquired assets and activities constitute a business, the Company
accounts for the transaction as a business combination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For transactions accounted for as business combinations, the Company allocates the fair value of
acquisition consideration to the identifiable assets acquired and liabilities assumed based on their estimated fair values. The excess of the fair value of acquisition consideration over the fair value of acquired identifiable assets and liabilities
assumed is recognized as goodwill. During the measurement period of a business combination, which is not to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
exceed one year, if new information is obtained about facts and circumstances that existed as of the acquisition date, changes in the estimated fair values of the net assets recorded may change
the amount of the purchase price allocable to the excess over the fair value of assets acquired. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings. Acquisition-related costs in a business combination
are expensed as incurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions, with a
cost accumulation model used to determine the cost of the acquisition. For an asset acquisition, the fair value of acquisition consideration is allocated to the identifiable assets acquired and liabilities assumed at cost on a relative fair value
basis. If a single asset is acquired, the entire cost is attributed to the acquired asset. In addition, for such asset acquisitions, no goodwill is recognized, acquisition-related costs are capitalized, and any associated contingent consideration is
recorded when the underlying contingencies have been resolved. Common stock and convertible preferred stock issued as consideration in an acquisition of assets are measured based on the acquisition date fair value of the equity interests. Intangible
assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as <FONT STYLE="white-space:nowrap">in-process</FONT> research and development
(&#8220;IPR&amp;D&#8221;). Acquired IPR&amp;D that has no alternative future use is expensed immediately. Cash payments for the acquisition of IPR&amp;D are reported as cash outflows for investing activities in the statement of cash flows. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for income taxes under the asset
and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and
liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a
change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes net
deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of
existing taxable temporary differences, projected future taxable income, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies, and results of recent operations. If management determines that the Company would be able to realize its
deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company records uncertain tax positions on the basis of a <FONT STYLE="white-space:nowrap">two-step</FONT> process whereby (1)&nbsp;management determines whether it
is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&nbsp;for those tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition
threshold, management recognizes the largest amount of tax benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized
tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from
<FONT STYLE="white-space:nowrap">non-owner</FONT> sources. The Company&#8217;s comprehensive loss was the same as its reported net loss for the period presented. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Segment Reporting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating segments are identified as components of
an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating
decision-maker view the Company&#8217;s operations and manage its business in one operating segment. Significant operating expenses include research and development, <FONT STYLE="white-space:nowrap">in-process</FONT> research and development, and
general and administrative expenses, which are each separately presented on the Company&#8217;s statement of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic net loss per share is computed by dividing the net loss by the weighted-average number of the Company&#8217;s common shares outstanding for the period, without
consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding
for the period determined using the treasury-stock and <FONT STYLE="white-space:nowrap">if-converted</FONT> methods. Potentially dilutive common stock equivalents are comprised of convertible preferred stock. For the period presented, there is no
difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Related Party Transactions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Promissory Notes with Related Parties
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;28, 2024, the Company issued two convertible promissory notes (the &#8220;Two River Notes&#8221;) to affiliates of Two River, LLC (&#8220;Two
River&#8221;), a principal owner of the Company. The principal amount of the Two River Notes was $0.3&nbsp;million with an interest rate of 5.0% per annum. For the period from January&nbsp;1, 2024 to August&nbsp;19, 2024, the Company recognized
$1,000 of interest expense related to the Two River Notes. Outstanding principal and interest on the Two River Notes was converted into 59,130 shares of Series A convertible preferred stock in connection with the Company&#8217;s Series A preferred
stock financing (see Note 4). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Consulting Services Provided by Related Party </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2024, the Company entered into a letter agreement with Two River related to consulting services provided to the Company by Two River. During the period from
January&nbsp;1, 2024 to August&nbsp;19, 2024, the Company recognized $0.9&nbsp;million of general and administrative expense associated with the letter agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common Stock Issued to Related Parties </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2024, the Company
issued common stock to certain related party investors (see Note 4). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. License Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License Agreement with Genor Biopharma Co Ltd. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, the
Company entered into a license agreement (the &#8220;Genor License Agreement&#8221;) with Genor Biopharma Co Ltd. (&#8220;Genor&#8221;). Under the Genor License Agreement, the Company has an exclusive, royalty-bearing, sublicensable license under
certain <FONT STYLE="white-space:nowrap">know-how</FONT> and patent rights controlled by Genor (including certain intellectual property <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Genor) relating to bispecific antibodies and
heteromultimeric proteins (&#8220;Licensed IP&#8221;) to develop, use, manufacture, commercialize and otherwise exploit GB261, certain derivatives of GB261 that are also CD20xCD3 bispecific antibodies, and products containing GB261 or such
derivatives (&#8220;GB261 Licensed Products&#8221;) everywhere in the world except for Mainland China, Hong Kong, Macau and Taiwan (the &#8220;GB261 Licensed Territory&#8221;) for the diagnosis, treatment or prevention of disease in humans and
animals (the &#8220;GB261 Field&#8221;). The Company also received a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under the Licensed IP in Mainland China, Hong Kong, Macau and Taiwan (the &#8220;Genor
Territory&#8221;) to manufacture GB261 Licensed Products in the Genor Territory and to conduct <FONT STYLE="white-space:nowrap">non-clinical</FONT> and certain clinical development of GB261 Licensed Products in the Genor Territory in the GB261
Field, solely for the purposes of supporting exploitation of GB261 Licensed Products in the GB261 Field in the GB261 Licensed Territory. In addition, the Company has a right of first negotiation if Genor decides to commence negotiations with one or
more third parties to grant a license to develop, use, manufacture, commercialize or otherwise exploit GB261 Licensed Products in the GB261 Field in the Genor Territory. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is responsible, at its own cost, for the development, manufacture and commercialization of GB261 Licensed Products in the GB261 Field in the GB261 Licensed
Territory. The Company is obligated to use commercially reasonable efforts to develop and obtain regulatory approval for at least one GB261 Licensed Product in the GB261 Field in the United States and in at least one of Canada, the United Kingdom,
France, Germany, Spain or Italy (&#8220;Major Market Countries). The Company is also obligated to use commercially reasonable efforts to commercialize at least one GB261 Licensed Product in the United States or any Major Market Country, in which
regulatory approval has been obtained for such product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024, the Company paid Genor total upfront cash consideration of $16.0&nbsp;million. In addition, in August
2024, the Company issued an aggregate of 2,941,176 shares of its common stock to an affiliate of Genor pursuant to a stock purchase agreement containing certain anti-dilution rights. Under the terms of the stock purchase agreement, the purchaser
paid $1.0&nbsp;million for 1,111,111 shares of the Company&#8217;s common stock and was issued an additional 1,830,065 shares of the Company&#8217;s common stock based on its anti-dilution rights. The Company determined that the aggregate fair value
of the consideration paid to under the Genor License Agreement was $23.5&nbsp;million and consisted of: (i)&nbsp;the $16.0&nbsp;million of upfront cash consideration, (ii)&nbsp;the $2.2&nbsp;million discount on the sale of common stock to an
affiliate of Genor and (iii)&nbsp;the $5.3&nbsp;million fair value of shares of common stock issued in connection with anti-dilution rights, and expensed such amount as IPR&amp;D as there is no alterative future use for the Licensed IP. The Company
is also obligated to pay Genor up to $145.0&nbsp;million in upfront and development and regulatory milestone payments, up to $300.0&nbsp;million in commercial milestone payments, tiered mid single-digit to low double-digit percentage royalties on
net sales of GB261 Licensed Products, and mid single-digit to low double-digit percentage of income that the Company receives from its sublicensees if the Company sublicense its rights to GB261 Licensed Products, none of which were due and payable
as of August&nbsp;19, 2024. The royalty payments are subject to reduction under certain customary circumstances. On a GB261 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-GB261</FONT></FONT> Licensed Product
and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the Company&#8217;s obligation to pay Genor royalties commences on the first commercial sale of such GB261 Licensed Product in the
applicable country until the latest to occur of (a)&nbsp;the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim within the patents licensed to the Company by Genor covering such GB261 Licensed
Product in the applicable country, (b)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> regulatory exclusivity for such GB261 Licensed Product in the applicable country and
(c)&nbsp;ten (10) years after the first commercial sale of such GB261 Licensed Product in the applicable country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Genor License Agreement will remain in effect
on a GB261 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-</FONT></FONT> GB261 Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until
expiration of all royalty payment obligations, unless it is earlier terminated. Following expiration of the Genor License Agreement, the licenses granted to the Company become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual,
irrevocable and fully <FONT STYLE="white-space:nowrap">paid-up.</FONT> Either party may terminate the Genor License Agreement for the other party&#8217;s uncured material breach or insolvency, subject to certain notice and cure periods. Genor may
terminate the Genor License Agreement if the Company challenges any of the patents licensed to it, subject to a specified notice and cure period. The Company may terminate the Genor License Agreement in its entirety, or on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> or GB261 Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-GB261</FONT></FONT> Licensed Product basis for convenience
upon advance written notice to Genor. Upon termination of the Genor License Agreement, the Company is subject to certain post-termination obligations to enable Genor to be able to exploit the GB261 Licensed Products on a worldwide basis, or if the
Genor License Agreement is not terminated in its entirety, in the applicable terminated countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Convertible Preferred Stock and Stockholders&#8217;
Deficit </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2024,
pursuant to a Series A preferred stock purchase agreement, the Company issued in two closings an aggregate of 21,117,340 shares of its Series A convertible preferred stock (&#8220;Series A&#8221;) at a purchase price of $4.25 per share, and received
gross cash proceeds of approximately $89.7&nbsp;million. As described above, the Company issued an additional 59,130 shares of Series A convertible preferred stock upon the settlement of convertible promissory notes with a fair value of
$0.3&nbsp;million. The Company incurred $0.1&nbsp;million of issuance costs in connection with the Series A financing. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Description of Securities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividends </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of Series A, in preference to the holders of common
stock, are entitled to receive, but only out of funds that are legally available therefor, cash dividends at the annual per share rate of $0.34. After payment of any preferential preferred stock dividends described above, if any additional dividends
are paid or set aside, such dividends shall be paid to the holders of common stock and the holders of Series A as if the shares of Series A had converted to common stock. Such dividends are noncumulative and are payable only when, as and if declared
by the Company&#8217;s board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TRC 2004, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements&#8201;-&#8201;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Liquidation Preferences </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon any liquidation, dissolution or winding up of the Company, the holders of Series A are entitled to receive a liquidation preference at the per share rate of $4.25,
plus all declared and unpaid dividends. Liquidation payments to the holders of Series A have priority and are made in preference to any payments to the holders of common stock. After full payment of the liquidation preference to the holders of the
Series A, the remaining assets, if any, will be distributed ratably to the holders of common stock. The Series A would be deemed converted to common stock in the event such conversion would result in a liquidation payment greater than its
liquidation preference. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Conversion </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares of Series A are
convertible into an equal number of shares of common stock, at the option of the holder, subject to certain anti-dilution adjustments. Each share of Series A is automatically converted into common stock upon, (a)&nbsp;the closing of the sale of
shares of common stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50.0&nbsp;million of gross proceeds to the
Company, after deducting the underwriting discounts and commissions, and certain other conditions, or (b)&nbsp;the vote of the holders of at least 60% of the outstanding shares of Series A, voting together as a single class on an as converted to
common stock basis. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Voting Rights </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holder of each share of Series A
is entitled to one vote for each share of common stock into which it would convert and has protective voting provisions related to certain matters including material changes to the corporate structure, capitalization and the incurrence of certain
corporate obligations, among other issues. In addition, the Series A is entitled to elect certain members of the board of directors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common Stock Issuances
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2024, the Company issued 5,000,000 shares of common stock to related party investors for cash proceeds of $5,000. The Company concluded the
issuance date fair value of the common stock was $14.5&nbsp;million and recognized the $14.5&nbsp;million discount as other income (expense) in the accompanying statement of operations and comprehensive loss. No other goods or services were
exchanged in this transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#8217;s
pretax net loss for the period from January&nbsp;1, 2024 to August&nbsp;19, 2024 was generated solely in the United States. A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company&#8217;s
income tax expense is as follows (in thousands):&#8195; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from<BR>January&nbsp;1,&nbsp;2024<BR>to August&nbsp;19,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Tax computed at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> stock charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to taxation in the United States and various state jurisdictions. The Company has not been notified that it is
under examination in any jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Subsequent Events </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company has completed an evaluation of all subsequent events through March 16, 2026, the date the financial statements were issued, to ensure these financial statements include appropriate disclosure of events both recognized in the financial
statements and events that occurred but were not recognized in the financial statements. The Company has concluded that no subsequent event has occurred that requires disclosure except as described in Note 1 above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>STRICTLY CONFIDENTIAL </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>EXECUTION VERSION </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc109079_45"></A>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND REORGANIZATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">among:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FARMINGTON MERGER SUB, INC., </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CANDID THERAPEUTICS, INC., </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as
of March&nbsp;1, 2026 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annextoc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_1">DESCRIPTION OF TRANSACTION </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_2">The Merger</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_3">Effects of the Merger</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_4">Closing; Effective Time</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_5">Certificate of Incorporation and Bylaws; Directors and Officers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_6">Conversion of Shares</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_7">Calculation of Parent Net Cash</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_8">Contingent Value Right</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_9">Closing of the Company&#8217;s Transfer Books</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_10">Surrender of Certificates</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_11">Appraisal Rights</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_12">Further Action</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_13">Withholding</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section 2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_14">REPRESENTATIONS AND WARRANTIES OF THE COMPANY </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="white-space:nowrap">A-8</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_15">Organization, Standing and Power</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_16">Capital Stock</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_17">Subsidiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_18">Authority</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_19">No Conflict; Consents and Approvals</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_20">Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_21">No Undisclosed Liabilities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_22">Absence of Certain Changes or Events</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_23">Litigation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_24">Compliance with Laws</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_25">Health Care Regulatory Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-13</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_26">Benefit Plans</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_27">Labor and Employment Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-16</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_28">Environmental Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-17</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_29">Taxes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-18</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_30">Contracts</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-20</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_31">Insurance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_32">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_33">Intellectual Property</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-22</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_34">State Takeover Statutes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-23</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_35">No Rights Plan</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-23</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_36">Related Party Transactions</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-23</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_37">Certain Payments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-24</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_38">Brokers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-24</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_39">Concurrent Financing Compliance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-24</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_40">No Other Representations or Warranties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-24</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section 3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_48">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-24</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_41">Organization, Standing and Power</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-25</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_42">Capital Stock</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-25</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_43">Subsidiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-26</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_44">Authority</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-27</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_45">No Conflict; Consents and Approvals</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-27</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_46">SEC Reports; Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-28</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_47">No Undisclosed Liabilities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-30</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_49">Absence of Certain Changes or Events</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-30</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_50">Litigation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-31</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_51">Compliance with Laws</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-32</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_52">Health Care Regulatory Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-32</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_53">Benefit Plans</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-33</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_54">Labor and Employment Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-35</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_55">Environmental Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-36</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_56">Taxes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-36</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_57">Contracts</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-38</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_58">Insurance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-39</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_59">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-40</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_60">Intellectual Property</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-40</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_61">Related Party Transactions</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-42</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_62">Certain Payments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-42</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_63">Brokers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-42</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_64">Opinion of Financial Advisor</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-42</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_65">Merger Sub</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-42</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_66">State Takeover Statutes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-42</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_67">No Other Representations or Warranties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-42</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section 4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_68">CERTAIN COVENANTS OF THE PARTIES </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-43</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_69">Operation of Parent&#8217;s Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-43</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_70">Operation of the Company&#8217;s Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-45</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_71">Access and Investigation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-47</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_72">Parent Non-Solicitation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-47</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_73">Company Non-Solicitation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-48</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_74">Notification of Certain Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-49</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_75">Potentially Transferable Assets</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-50</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section 5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_76">ADDITIONAL AGREEMENTS OF THE PARTIES </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-50</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_77">Registration Statement; Proxy Statement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-50</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_78">Company Information Statement; Stockholder Written Consent</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-52</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_79">Parent Stockholders&#8217; Meeting</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-54</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_80">Regulatory Approvals</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-56</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_81">Company Options</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-57</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_82">Indemnification of Officers and Directors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-58</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_83">Additional Agreements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-60</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_84">Public Announcement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-60</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_85">Listing</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-60</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_86">Tax Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-61</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_87">Directors and Officers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-62</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_88">Termination of Certain Agreements and Rights</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-62</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_89">Section 16 Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-62</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_90">Cooperation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-62</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_91">Allocation Certificate; Parent Outstanding Shares Certificate</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-63</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_92">Company Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-63</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_93">Takeover Statutes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-63</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_94">Stockholder Litigation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-63</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_95">Equity Plans</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-64</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_96">Parent SEC Documents</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-64</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_97">Parent Options and RSUs</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-64</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_98">Parent Operations Wind-Down</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-64</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_99">Concurrent Financing</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-64</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section 6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_100">CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_101">No Restraints</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_102">Stockholder Approval</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_103">Parent Charter Amendment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_104">Listing</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_105">Subscription Agreement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_106">Effectiveness of Registration Statement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_107">Parent Net Cash Determination</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-66</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_108">HSR Act</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-66</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section 7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_109">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-66</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_110">Accuracy of Representations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-66</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_111">Performance of Covenants</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-66</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_112">Documents</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-66</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_113">FIRPTA Certificate</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-66</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_114">No Company Material Adverse Effect</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-67</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_115">Termination of Investor Agreements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-67</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_116">Company Lock-Up Agreements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-67</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section 8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_117">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-67</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_118">Accuracy of Representations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-67</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_119">Performance of Covenants</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-67</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_120">Documents</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-67</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_121">No Parent Material Adverse Effect</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-68</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_122">Parent Net Cash and Minimum Cash Amount</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-68</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section 9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_123">TERMINATION </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-68</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_124">Termination</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-68</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_125">Effect of Termination</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-70</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_126">Expenses; Termination Fees</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-70</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section 10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><A HREF="#annexatoc109079_127">MISCELLANEOUS PROVISIONS </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-72</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_128">Non-Survival of Representations and Warranties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-72</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_129">Amendment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-72</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_130">Waiver</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-73</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_131">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-73</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_132">Applicable Law; Jurisdiction; WAIVER OF JURY TRIAL</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-73</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_133">Attorneys&#8217; Fees</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-73</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_134">Assignability</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-73</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_135">Notices</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-73</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_136">Cooperation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-74</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_137">Severability</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-74</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_138">Other Remedies; Specific Performance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-75</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_139">No Third Party Beneficiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-75</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_140">Construction</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-75</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexatoc109079_141">Defined Terms Defined Elsewhere</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">A-76</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibits:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#annexatoc109079_142">Certain Definitions</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Exhibit&nbsp;B-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#annexatoc109079_143">Form of Company Stockholder Support Agreement</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">B-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#annexatoc109079_144">Form of Parent Stockholder Support Agreement</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#annexatoc109079_145">Form of Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#annexatoc109079_146">Form of CVR Agreement</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Schedules:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company Signatories</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exchange Ratio</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule&nbsp;5.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Directors and Officers</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</B> (this&nbsp;&#8220;<B><I>Agreement</I></B>&#8221;) is made and entered into as of
March&nbsp;1, 2026, by and among <B>RALLYBIO CORPORATION</B>, a&nbsp;Delaware corporation (&#8220;<B><I>Parent</I></B>&#8221;), <B>FARMINGTON MERGER SUB, INC.</B>, a Delaware corporation and wholly-owned subsidiary of Parent (&#8220;<B><I>Merger
Sub</I></B>&#8221;), and <B>CANDID THERAPEUTICS, INC.</B>, a Delaware corporation (the&nbsp;&#8220;<B><I>Company</I></B>&#8221;). Certain capitalized terms used in this Agreement are defined in <B>Exhibit A</B>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Parent and
the Company intend to effect a merger of Merger Sub with and into the Company (the &#8220;<B><I>Merger</I></B>&#8221;) in accordance with this Agreement and the DGCL. Upon consummation of the Merger, Merger Sub will cease to exist and the Company
will become a wholly-owned subsidiary of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. The Parties intend that the Merger qualify as a &#8220;reorganization&#8221; within
the meaning of Section&nbsp;368(a) of the Code, and by executing this Agreement, the Parties hereby adopt a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations
<FONT STYLE="white-space:nowrap">Sections&nbsp;1.368-2(g)</FONT> <FONT STYLE="white-space:nowrap">and&nbsp;1.368-3(a).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. The
Parent Board has unanimously (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii)&nbsp;authorized, approved and declared advisable this Agreement and the
Contemplated Transactions, including the issuance of shares of Parent Common Stock to the stockholders of the Company pursuant to the terms of this Agreement, the change of control of Parent and other actions contemplated by this Agreement, and
(iii)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Parent Stockholder Matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. The Merger Sub Board has unanimously (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable, and in the best
interests of Merger Sub and its sole stockholder, (ii)&nbsp;authorized, approved and declared advisable this Agreement and the Contemplated Transactions, and (iii)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth
in this Agreement, that Parent, as the sole stockholder of Merger Sub, votes to adopt this Agreement and thereby approve the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. The Company Board has unanimously (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable and in the best interests
of the Company and its stockholders, (ii)&nbsp;authorized, approved and declared advisable this Agreement and the Contemplated Transactions, and (iii)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this
Agreement, that the stockholders of the Company vote to approve the Company Stockholder Matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. Concurrently with the execution and
delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, (a)&nbsp;the Company Signatories (solely in their capacity as stockholders of the Company), which represent the Required Company
Stockholder Vote, are executing support agreements in favor of Parent in substantially the form attached hereto as <B>Exhibit <FONT STYLE="white-space:nowrap">B-1</FONT></B> (the &#8220;<B><I>Company Stockholder Support Agreement</I></B>&#8221;),
and (b)&nbsp;the officers, directors and stockholders of the Company listed in <U>Section</U><U></U><U>&nbsp;A</U><U><FONT STYLE="white-space:nowrap">-1</FONT></U> of the Company Disclosure Schedule (the &#8220;<B><I>Company Lock</I></B><B><I><FONT
STYLE="white-space:nowrap">-Up</FONT> Signatories</I></B>&#8221;) (solely in their capacity as stockholders of the Company) are executing <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements in substantially the form attached hereto as
<B>Exhibit C </B>(the &#8220;<B><I>Company Lock</I></B><B><I><FONT STYLE="white-space:nowrap">-Up</FONT> Agreement</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G.
Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, the officers, directors and certain stockholders of Parent listed in
<U>Section</U><U></U><U>&nbsp;A</U><U><FONT STYLE="white-space:nowrap">-1</FONT></U> of the Parent Disclosure Schedule (solely in their capacity as stockholders of Parent) are executing support agreements in favor of the Company in substantially the
form attached hereto as <B>Exhibit <FONT STYLE="white-space:nowrap">B-2</FONT></B> (the &#8220;<B><I>Parent Stockholder Support Agreement</I></B>&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">H. It is expected that, subject to <U>Section</U><U></U><U>&nbsp;4.5</U>, within seven
(7)&nbsp;Business Days after the Registration Statement is declared effective by the SEC, stockholders of the Company holding no less than the Required Company Stockholder Vote will execute and deliver an action by written consent in a form to be
mutually agreed by Parent and the Company (each, a &#8220;<B><I>Company Stockholder Written Consent</I></B>&#8221; and collectively, the &#8220;<B><I>Company Stockholder Written Consents</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I. Concurrently with the execution and delivery of this Agreement, certain investors have executed a Subscription Agreement by and among the
Company and the Persons named therein (representing an aggregate commitment no less than the Concurrent Investment Amount), pursuant to which such Persons have agreed to purchase the number of shares of Company Common Stock set forth therein
immediately prior to the Effective Time in connection with the Concurrent Financing (the &#8220;<B><I>Subscription Agreement</I></B><I>&#8221;</I>). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties,
intending to be legally bound, agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_1"></A><B>Section</B><B></B><B>&nbsp;1.</B> <U>DESCRIPTION OF
TRANSACTION</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_2"></A>1.1 <U>The Merger</U>. Upon the terms and subject to the conditions set forth in this
Agreement, at the Effective Time, Merger Sub shall be merged with and into the Company, and the separate existence of Merger Sub shall cease. The Company will continue as the surviving corporation in the Merger (the &#8220;<B><I>Surviving
Corporation</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_3"></A>1.2 <U>Effects of the Merger</U>. The Merger shall have the effects set
forth in this Agreement, the Certificate of Merger and in the applicable provisions of the DGCL. As a result of the Merger, the Company will become a wholly-owned subsidiary of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_4"></A>1.3 <U>Closing; Effective Time</U>. Unless this Agreement is earlier terminated pursuant to the provisions of
<U>Section</U><U></U><U>&nbsp;9.1</U>, the consummation of the Merger (the &#8220;<B><I>Closing</I></B>&#8221;) shall take place remotely on the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) Business Day following the
satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in <U>Sections</U> <U>6</U>, <U>7</U> and <U>8</U> (other than those conditions that by their nature are to be satisfied at or immediately prior to the Closing,
but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the
&#8220;<B><I>Closing Date</I></B>.&#8221; At the Closing, the Parties shall cause the Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger,
satisfying the applicable requirements of the DGCL and in a form reasonably acceptable to Parent and the Company (the &#8220;<B><I>Certificate of Merger</I></B>&#8221;). The Merger shall become effective at the time of the filing of such Certificate
of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as
the &#8220;<B><I>Effective</I></B> <B><I>Time</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_5"></A>1.4 <U>Certificate of Incorporation and
Bylaws; Directors and Officers</U>. At the Effective Time: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the certificate of incorporation of the Surviving Corporation shall be
amended and restated in its entirety to read identically to the certificate of incorporation of Merger Sub as in effect immediately prior to the Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation;
<I>provided</I>, <I>however</I>, that at or immediately prior to the Effective Time, the Surviving Corporation shall file an amendment to its certificate of incorporation to change the name of the Surviving Corporation to Candid Operating Company,
Inc., or such other name as shall be mutually agreed upon by Parent and the Company prior to filing such amendment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the certificate
of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Effective Time, until thereafter amended as provided by the DGCL and such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certificate of incorporation; <I>provided, however,</I> that at or immediately prior to the Effective Time, Parent shall file an amendment to its certificate of incorporation (the
&#8220;<B><I>Parent</I></B> <B><I>Charter Amendment</I></B>&#8221;) to (i)&nbsp;change the name of Parent to &#8220;Candid Therapeutics, Inc.&#8221;; (ii)&nbsp;effect the Nasdaq Reverse Split (the &#8220;<B><I>Reverse Stock Split
Proposal</I></B>&#8221;); (iii)&nbsp;subject to the approval of the Authorized Share Increase Proposal, effect the Authorized Share Increase; and (iv)&nbsp;make such other changes as shall be mutually agreed upon by Parent and the Company prior to
filing such amendment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the bylaws of the Surviving Corporation shall be amended and restated in their entirety to read identically
to the bylaws of Merger Sub as in effect immediately prior to the Effective Time (except that the name of the Surviving Corporation in such bylaws shall reflect the name identified in <U>Section</U><U></U><U>&nbsp;1.4(a))</U>, until thereafter
amended as provided by the DGCL and such bylaws; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) the Parties shall act in compliance with <U>Section</U><U></U><U>&nbsp;5.11</U>
(including, to the extent necessary, procuring the resignation or removal of any directors or officers of Parent immediately prior to the Effective Time) so that, as of the Effective Time, the directors and officers of Parent, each to hold office in
accordance with the certificate of incorporation and bylaws of Parent, shall consist of the Persons set forth in <U>Section</U><U></U><U>&nbsp;5.11</U> after giving effect to the provisions of <U>Section</U><U></U><U>&nbsp;5.11</U>, or such other
Persons as shall be designated by the Company in its sole discretion; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) the directors and officers of the Surviving Corporation,
each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Corporation, shall be the directors and officers of Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_6"></A>1.5 <U>Conversion of Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any
stockholder of the Company or Parent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) any shares of Company Capital Stock held as treasury stock by the Company or held or owned by
Parent, Merger Sub or any Subsidiary of Parent or the Company immediately prior to the Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) subject to <U>Section</U><U></U><U>&nbsp;1.5(c)</U>, each share of Company Capital Stock outstanding immediately prior to the Effective
Time (excluding shares of Company Capital Stock to be canceled pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)(i)</U>, shares of Company Common Stock issued in the Concurrent Financing to be converted pursuant to
<U>Section</U><U></U><U>&nbsp;1.5(a)(iii)</U> and Dissenting Shares), shall be automatically converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) subject to <U>Section</U><U></U><U>&nbsp;1.5(c)</U>, the Company Common Stock issued in the Concurrent Financing shall be converted
solely into the right to receive a number of shares of Parent Common Stock equal to the amount of Concurrent Financing Merger Shares multiplied by the percentage of the Concurrent Financing Proceeds represented by the applicable stockholder&#8217;s
investment in the Concurrent Financing, as set forth on the Allocation Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If any shares of Company Capital Stock
outstanding immediately prior to the Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of
Parent Common Stock issued in exchange for such shares of Company Capital Stock at the Effective Time will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Common Stock shall
accordingly be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any
such restricted stock purchase agreement or other agreement in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No fractional shares of Parent Common Stock shall be issued in connection with the
Merger, and no certificates or scrip for any such fractional shares shall be issued. Any holder of Company Capital Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (after aggregating all fractional shares
of Parent Common Stock issuable to such holder) shall receive from Parent, in lieu of such fractional share: (i)&nbsp;one share of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Capital
Stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii)&nbsp;no shares of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Capital Stock would otherwise be entitled to
is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) All Company Options outstanding
immediately prior to the Effective Time under the Company Benefit Plan shall be treated in accordance with <U>Section</U><U></U><U>&nbsp;5.5(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Each share of common stock, $0.0001 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time
shall be converted into and exchanged for one validly-issued, fully-paid and nonassessable share of common stock, $0.0001 par value per share, of the Surviving Corporation. Each stock certificate or book-entry share of Merger Sub evidencing
ownership of any such shares shall, as of the Effective Time, evidence ownership of such shares of common stock of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) If, between the time of calculating the Exchange Ratio and the Effective Time, the outstanding shares of Company Capital Stock or Parent
Common Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent
such split has not been previously taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the
extent necessary to provide the holders of Company Capital Stock, Parent Common Stock and Company Options with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization,
split (including the Nasdaq Reverse Split), combination or exchange of shares or other like change; <I>provided, however</I>, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital
Stock or Parent Common Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_7"></A>1.6 <U>Calculation of Parent Net Cash</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) For the purposes of this Agreement, the &#8220;<B><I>Anticipated Closing
Date</I></B>&#8221; shall be the date, as agreed upon by Parent and the Company at least fifteen (15)&nbsp;calendar days prior to the Parent Stockholders&#8217; Meeting, to be the anticipated date for Closing. At least five (5)&nbsp;Business Days
prior to the Parent Stockholders&#8217; Meeting, Parent shall deliver to the Company a schedule (the &#8220;<B><I>Net Cash Schedule</I></B>&#8221;) setting forth Parent&#8217;s estimated calculation of Parent Net Cash, including each component
thereof (the &#8220;<B><I>Net Cash Calculation</I></B>&#8221;) as of the Anticipated Closing Date prepared and certified by Parent&#8217;s Chief Financial Officer (or if there is no Chief Financial Officer, the principal accounting officer of
Parent). Parent shall make available to the Company the work papers and <FONT STYLE="white-space:nowrap">back-up</FONT> materials used or useful in preparing the Net Cash Schedule (including, with respect to Transaction Expenses, estimated final
invoices and current accounts receivable from each advisor to Parent) and, as reasonably requested by the Company, Parent&#8217;s accountants and counsel at reasonable times and upon reasonable notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Within three (3)&nbsp;Business Days after delivery of the Net Cash Schedule (the &#8220;<B><I>Response Date</I></B>&#8221;), the Company
will have the right to dispute any part of the Net Cash Schedule by delivering a written notice to that effect to Parent (a &#8220;<B><I>Dispute Notice</I></B>&#8221;). Any Dispute Notice shall identify in reasonable detail the nature of any
proposed revisions to the Net Cash Calculation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If on or prior to the Response Date, the Company (i)&nbsp;notifies Parent in writing
that it has no objections to the Net Cash Calculation or (ii)&nbsp;fails to deliver a Dispute Notice as provided in <U>Section</U><U></U><U>&nbsp;1.6(b)</U> then the Net Cash Calculation as set forth in the Net Cash Schedule shall be deemed to have
been finally determined for purposes of this Agreement and to represent Parent Net Cash as of the Anticipated Closing Date for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) If the Company delivers a Dispute Notice on or prior to the Response Date, then Representatives of both Parties shall promptly meet and
attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which agreed upon Parent Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to
represent Parent Net Cash as of the Anticipated Closing Date for purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) If Parent and the Company are unable to
negotiate an agreed-upon determination of Parent Net Cash as of the Anticipated Closing Date pursuant to <U>Section</U><U></U><U>&nbsp;1.6(d)</U> within three (3)&nbsp;calendar days after delivery of the Dispute Notice (or such other period as
Parent and the Company may mutually agree upon), then Parent and the Company shall jointly select an independent auditor of recognized national standing (the &#8220;<B><I>Accounting Firm</I></B>&#8221;) to resolve any remaining disagreements as to
the Net Cash Calculation. Parent shall promptly deliver to the Accounting Firm the work papers and <FONT STYLE="white-space:nowrap">back-up</FONT> materials used in preparing the Net Cash Schedule, and Parent and the Company shall use commercially
reasonable efforts to cause the Accounting Firm to make its determination within ten (10)&nbsp;calendar days of accepting its selection. The Company and Parent shall be afforded the opportunity to present to the Accounting Firm any material related
to the unresolved disputes and to discuss the issues with the Accounting Firm; <I>provided, however</I>, that no such presentation or discussion shall occur without the presence of a Representative of each of the Company and Parent. The
determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Parent Net Cash made by the Accounting Firm shall be final and binding upon the Parties and shall be
deemed to have been finally determined for purposes of this Agreement and to represent Parent Net Cash as of the Anticipated Closing Date for purposes of this Agreement, and the Parties shall delay the Closing until the resolution of the matters
described in this <U>Section</U><U></U><U>&nbsp;1.6(e)</U>. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of Parent Net Cash that was unsuccessfully
disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of Parent Net Cash. If this <U>Section</U><U></U><U>&nbsp;1.6(e)</U> applies as to the determination of Parent Net Cash as of the Anticipated
Closing Date described in <U>Section</U><U></U><U>&nbsp;1.6(a)</U>, upon resolution of the matter in accordance with this <U>Section</U><U></U><U>&nbsp;1.6(e)</U>, the Parties shall not be required to determine Parent Net Cash again even though the
Closing Date may occur later than the Anticipated Closing Date, except that either Party may request a <FONT STYLE="white-space:nowrap">re-determination</FONT> of Parent Net Cash if the Closing Date is more than five (5)&nbsp;Business Days after the
Anticipated Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_8"></A>1.7 <U>Contingent Value Right</U>. Prior to the Effective Time, Parent shall
declare a distribution (the &#8220;<B><I><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Distribution</I></B>&#8221;) to holders of (a)&nbsp;Parent Common Stock, <FONT STYLE="white-space:nowrap">(b)&nbsp;Pre-Funded</FONT> Warrants
(c)&nbsp;Parent restricted stock units and (d)&nbsp;In the Money Parent Options of one contingent value right (each, a &#8220;<B><I>CVR</I></B>&#8221;) for each outstanding (i)&nbsp;share of Parent Common Stock,
<FONT STYLE="white-space:nowrap">(ii)&nbsp;Pre-Funded</FONT> Warrant, (iii)&nbsp;Parent restricted stock units and (iv)&nbsp;In the Money Parent Option held by such holder<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>as of the close of
business on the record date described below, each representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the Contingent Value
Rights Agreement in the form attached hereto as <B>Exhibit D</B>, to be entered into between Parent and Computershare Trust Company, N.A. (the &#8220;<B><I>Rights Agent</I></B>&#8221;), with such revisions thereto requested by the Rights Agent that
are not, individually or in the aggregate, materially detrimental to the holders of CVRs and reasonably acceptable to the Company and Parent (the &#8220;<B><I>CVR Agreement</I></B>&#8221;). The record date for the
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Distribution shall be the last Business Day prior to the day on which the Effective Time occurs; <I>provided</I> that the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Distribution may be
conditioned upon the occurrence of the Effective Time. In connection with the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Distribution, Parent shall cause the CVR Agreement to be duly authorized, executed and delivered by Parent and the
Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_9"></A>1.8 <U>Closing of the Company</U><U>&#8217;</U><U>s Transfer Books</U>. At the Effective
Time: (a)&nbsp;all shares of Company Capital Stock outstanding immediately prior to the Effective Time shall be treated in accordance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;1.5(a)</U>, and all holders of certificates or book-entry shares representing shares of Company Capital Stock that were outstanding immediately prior to the
Effective Time shall cease to have any rights as stockholders of the Company; and (b)&nbsp;the stock transfer books of the Company shall be closed with respect to all shares of Company Capital Stock outstanding immediately prior to the Effective
Time. No further transfer of any such shares of Company Capital Stock shall be made on such stock transfer books after the Effective Time. If, after the Effective Time, a valid certificate previously representing any shares of Company Capital Stock
outstanding immediately prior to the Effective Time (a &#8220;<B><I>Company Stock Certificate</I></B>&#8221;) is presented to the Exchange Agent or to the Surviving Corporation, such Company Stock Certificate shall be canceled and shall be exchanged
as provided in <U>Sections</U><U>&nbsp;1.5</U> and <U>1.9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_10"></A>1.9 <U>Surrender of Certificates</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Prior to the Closing Date, Parent and the Company shall enter into an exchange agent agreement with Computershare Trust Company,
N.A. (the &#8220;<B><I>Exchange Agent</I></B>&#8221;), in a form reasonably acceptable to the Company. At the Effective Time, Parent shall deposit with the Exchange Agent: (i)&nbsp;evidence of book-entry shares representing the Parent Common Stock
issuable pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)</U>; and (ii)&nbsp;cash sufficient to make payments in lieu of fractional shares in accordance with <U>Section</U><U></U><U>&nbsp;1.5(c)</U>. The Parent Common Stock and cash amounts so
deposited with the Exchange Agent, together with any dividends or distributions received by the Exchange Agent with respect to such shares, are referred to collectively as the &#8220;<B><I>Exchange Fund</I></B>.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the Effective Time, the Parties shall cause the Exchange Agent to deliver to the Persons who were record holders of shares
of Company Capital Stock that were converted into the right to receive the Merger Consideration instructions for effecting the surrender of any Company Stock Certificates, or uncertificated shares of Company Capital Stock, in exchange for shares of
Parent Common Stock. Upon surrender of a Company Stock Certificate or other reasonable evidence of the ownership of uncertificated Company Capital Stock to the Exchange Agent for exchange, together with such other documents as may be reasonably
required by the Exchange Agent or Parent (including a properly completed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or the appropriate version of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8,</FONT> as applicable): (A)&nbsp;the
holder of such Company Capital Stock shall be entitled to receive in exchange therefor book-entry shares representing the Merger Consideration (in a number of whole shares of Parent Common Stock) that such holder has the right to receive pursuant to
the provisions of <U>Section</U><U></U><U>&nbsp;1.5(a)</U> (and cash in lieu of any fractional share of Parent Common Stock pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;1.5(c)</U>); and (B)&nbsp;such Company Stock Certificate so
surrendered shall be canceled. Until surrendered as contemplated by this <U>Section</U><U></U><U>&nbsp;1.9(b)</U>, each Company Stock Certificate shall be deemed, from and after the Effective Time, to represent only the right to receive book-entry
shares of Parent Common Stock representing the Merger Consideration (and cash in lieu of any fractional share of Parent Common Stock). If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a
condition precedent to the delivery of any shares of Parent Common Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate and post a bond
indemnifying Parent against any claim suffered by Parent related to the lost, stolen or destroyed Company Stock Certificate as Parent may reasonably request. In the event of a transfer of ownership of a Company Stock Certificate that is not
registered in the transfer records of the Company, payment of the Merger Consideration may be made to a Person other than the Person in whose name such Company Stock Certificate so surrendered is registered if such Company Stock Certificate shall be
properly endorsed or otherwise be in proper form for transfer and the Person requesting such payment shall pay any transfer or other Taxes required by reason of the transfer or establish to the reasonable satisfaction of Parent that such Taxes have
been paid or are not applicable. The Merger Consideration and any dividends or other distributions as are payable pursuant to <U>Section</U><U></U><U>&nbsp;1.9(c)</U> shall be deemed to have been in full satisfaction of all rights pertaining to
Company Capital Stock formerly represented by such Company Stock Certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No dividends or other distributions declared or made
with respect to Parent Common Stock with a record date on or after the Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Common Stock that such holder has the right to
receive in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger until such holder surrenders such Company Stock Certificate or provides an affidavit of loss, theft or destruction in lieu thereof in accordance with this
<U>Section</U><U></U><U>&nbsp;1.9</U> together with such other documents as may be reasonably required by the Exchange Agent or Parent (at which time (or, if later, on the applicable payment date) such holder shall be entitled, subject to the effect
of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Any
portion of the Exchange Fund that remains undistributed to holders of Company Capital Stock as of the date that is one (1)&nbsp;year after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates who
have not theretofore surrendered their Company Stock Certificates in accordance with this <U>Section</U><U></U><U>&nbsp;1.9</U> shall thereafter look only to Parent for satisfaction of their claims for Parent Common Stock, cash in lieu of fractional
shares of Parent Common Stock and any dividends or distributions with respect to shares of Parent Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) No Party to this
Agreement shall be liable to any holder of any Company Capital Stock or to any other Person with respect to any shares of Parent Common Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public
official pursuant to any applicable abandoned property Law, escheat Law or similar Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_11"></A>1.10
<U>Appraisal Rights</U><U>.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock
that are outstanding immediately prior to the Effective Time and which are held by stockholders who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the DGCL (collectively, the
&#8220;<B><I>Dissenting Shares</I></B>&#8221;) shall not be converted into or represent the right to receive the Merger Consideration described in <U>Section</U><U></U><U>&nbsp;1.5</U> attributable to such Dissenting Shares. Such stockholders shall
be entitled to receive payment of the appraised value of such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders fail to perfect or effectively withdraw or otherwise lose their appraisal
rights under the DGCL. All Dissenting Shares held by stockholders who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Capital Stock under the DGCL (whether occurring before,
at or after the Effective Time) shall thereupon be deemed to be converted into and to have become exchangeable for, as of the Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Dissenting Shares
upon their surrender in the manner provided in <U>Sections</U><U>&nbsp;1.5</U> and <U>1.9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company shall give Parent prompt
written notice of any demands by dissenting stockholders received by the Company, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with such demands,
and Parent shall have the right to participate in all negotiations and proceedings with respect to such demands. The Company shall not, except with Parent&#8217;s prior written consent (which consent shall not be unreasonably withheld, conditioned
or delayed), make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_12"></A>1.11 <U>Further Action</U>. If, at any time after the Effective Time, any further action is determined by the
Surviving Corporation to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and property of the Company, then the officers and
directors of the Surviving Corporation shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of Merger Sub, in the name of the Surviving Corporation and otherwise) to take
such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_13"></A>1.12 <U>Withholding</U>. The Parties and the Exchange Agent shall be entitled to deduct and
withhold from the consideration otherwise payable pursuant to this Agreement to any holder of Company Capital Stock or any other Person such amounts as such Party or the Exchange Agent reasonably determines it is required to deduct
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and withhold under the Code or any other Law with respect to the making of such payment. To the extent that amounts are so deducted and withheld and paid to the appropriate Governmental Body,
such deducted and withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding were made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_14"></A><B>Section</B><B></B><B>&nbsp;2.</B> <U>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except as set forth in the corresponding section or subsection of the disclosure letter delivered by the Company to Parent (the
&#8220;<B><I>Company Disclosure </I></B><B><I>Schedule</I></B>&#8221;) (it being agreed that (i)&nbsp;the disclosure of any information in a particular section or subsection of the Company Disclosure Schedule shall be deemed disclosure of such
information with respect to any other section or subsection of this Agreement to which the relevance of such information is readily apparent on its face and (ii)&nbsp;where applicable, references to the Company in this
<U>Section</U><U></U><U>&nbsp;2</U> shall include the Company&#8217;s Subsidiaries), the Company represents and warrants to Parent and Merger Sub as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_15"></A>2.1 <U>Organization, Standing and Power</U><U>.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company (i)&nbsp;is a corporation duly incorporated, validly existing and in good standing under the Laws of Delaware, (ii)&nbsp;has
all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&nbsp;is duly qualified or licensed to do business and is in good standing in each
jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in
good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company has previously made available to Parent true and complete copies of the Company&#8217;s Amended and Restated Certificate of
Incorporation (the &#8220;<B><I>Company Charter</I></B>&#8221;) and Bylaws (the &#8220;<B><I>Company Bylaws</I></B>&#8221;), in each case as amended to the date of this Agreement, and each as so delivered is in full force and effect. The Company is
not in violation in any material respects of any provision of the Company Charter or Company Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_16"></A>2.2
<U>Capital Stock</U><U>.</U><U> </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of the Company as of the date of this Agreement consists of (i)
574,000,000 shares of Company Common Stock, 141,521,816 of which have been issued and are outstanding as of the date hereof, and (ii) 367,005,749 shares of Company Preferred Stock, of which 105,000,000 shares are designated as Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, all of which are issued and outstanding, 89,999,985 shares are designated as Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, all of which are issued and outstanding, and
172,005,764 shares are designated as Company Series B Preferred Stock, all of which are issued and outstanding as of the date hereof. As of the date hereof, no shares of Company Common Stock were held by the Company in its treasury. All outstanding
shares of capital stock of the Company are, and all shares reserved for issuance will be, when issued, duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights. The Company does not have outstanding any
bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, securities having the right to vote) with the stockholders of the Company on any matter. Except as set forth above in
this <U>Section</U><U></U><U>&nbsp;2.2(a)</U>, as of the date hereof, there are no outstanding (A)&nbsp;shares of capital stock or other voting securities or equity interests of the Company, (B)&nbsp;securities of the Company convertible into or
exchangeable or exercisable for shares of capital stock of the Company or other voting securities or equity interests of the Company, (C)&nbsp;stock appreciation rights, &#8220;phantom&#8221; stock rights, performance units, interests in or rights
to the ownership or earnings of the Company or other equity equivalent or equity-based awards or rights, (D)&nbsp;subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from the Company, or obligations of the
Company to issue, any shares of capital stock of the Company, voting securities, equity interests or securities convertible into or exchangeable or exercisable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for capital stock or other voting securities or equity interests of the Company or rights or interests described in the preceding clause (C), or (E)&nbsp;obligations of the Company to repurchase,
redeem or otherwise acquire any such securities or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such securities. There are no stockholder agreements, voting trusts or other agreements or understandings to
which the Company is a party or of which the Company has knowledge with respect to the holding, voting, registration, redemption, repurchase or disposition of, or that restrict the transfer of, any capital stock or other voting securities or equity
interests of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Section 2.2(b)</U> of the Company Disclosure Schedule sets forth a true and complete list, as of the
date hereof, of all holders of rights to purchase or receive shares of Company Common Stock or similar rights (collectively, &#8220;<B><I>Company Stock Awards</I></B>&#8221;), indicating as applicable, with respect to each Company Stock Award then
outstanding, the type of award (e.g., incentive stock option, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock option, restricted stock unit, etc.), the number of shares of Company Common Stock subject to such Company Stock Award, the
name of the plan under which such Company Stock Award was granted, the date of grant, exercise or purchase price, vesting schedule, payment schedule (if different from the vesting schedule) and expiration thereof. Each Company Option was granted
with a per share exercise price that was not less than the fair market value of a share of Company Common Stock on the date such Company Option was granted and is exempt from the requirements of Section&nbsp;409A of the Code. The Company has made
available to Parent a true and complete copy of the forms of all award agreements evidencing outstanding Company Stock Awards. The Company does not sponsor, maintain or administer any employee or director stock option, stock purchase or equity
compensation plan or arrangement other than the Company Benefit Plans. As of the date hereof, the Company is under no obligation to issue shares of Company Common Stock pursuant to any employee or director stock option, stock purchase or equity
compensation plan or arrangement, other than in connection with the exercise of outstanding Company Stock Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_17"></A>2.3 <U>Subsidiaries</U>. <U>Section</U><U></U><U>&nbsp;2.3</U> of the Company Disclosure Schedule sets forth a true and complete list of each Subsidiary of the Company, including its jurisdiction of incorporation or formation. Each of the
Company&#8217;s Subsidiaries (a)&nbsp;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization, (b)&nbsp;has all requisite corporate or similar power and authority to own, lease and
operate its properties and to carry on its business as now being conducted and (c)&nbsp;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or
operation of its properties makes such qualification or licensing necessary, except in the case of clause (c), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not
reasonably be expected to have a Company Material Adverse Effect. All outstanding shares of capital stock and other voting securities or equity interests of each such Subsidiary are owned, directly or indirectly, by the Company, free and clear of
all Encumbrances other than Permitted Encumbrances of the Company and its Subsidiaries. Except for the capital stock of, or other equity or voting interests in, its Subsidiaries, the Company does not own, directly or indirectly, any equity,
membership interest, partnership interest, joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current or prospective obligation
to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement or other investment in any Person. Neither the Company nor any of its Subsidiaries has, at any time, been a general partner of, or has
otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_18"></A>2.4 <U>Authority.</U><U> </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has all necessary corporate power and authority to execute, deliver and perform its
obligations under this Agreement and, subject to the receipt of the Required Company Stockholder Vote, to consummate the Contemplated Transactions. The execution, delivery and performance of this Agreement by the Company and the consummation by the
Company of the Contemplated Transactions have been duly authorized by all necessary corporate action on the part of the Company and no other corporate proceedings on the part of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company are necessary to approve this Agreement or to consummate the Merger and the other Contemplated Transactions, subject, in the case of the consummation of the Merger, to the receipt of
the Required Company Stockholder Vote. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Parent and Merger Sub, constitutes a valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms (subject to the Enforceability Exceptions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company Board,
by unanimous written consent duly adopted resolutions (i)&nbsp;determining that the terms of this Agreement, the Merger and the other Contemplated Transactions are fair to and in the best interests of the Company&#8217;s stockholders,
(ii)&nbsp;approving and declaring advisable this Agreement and the Contemplated Transactions, including the Merger, (iii)&nbsp;directing that this Agreement be submitted to the stockholders of the Company for adoption, and (iv)&nbsp;resolving to
recommend that the Company&#8217;s stockholders vote in favor of the adoption of this Agreement and the Contemplated Transactions, including the Merger, which resolutions have not been subsequently rescinded, modified or withdrawn in any way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The affirmative vote (or written consent) of the holders of a majority of the outstanding shares of (i)&nbsp;Company Preferred Stock,
voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Company Common Stock basis (which majority shall include (A)&nbsp;the holders of a majority of the outstanding shares of Company Series B Preferred
Stock, exclusively and as a separate class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Company Common Stock basis and (B)&nbsp;the holders of a majority of the outstanding shares of Company Series A Preferred Stock, together as a
single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Company Common Stock basis), (ii) Company Common Stock, voting together as a single class, and (iii)&nbsp;Company Capital Stock, voting as a single class on an as converted
to Company Common Stock basis (the &#8220;<B><I>Required</I></B> <B><I>Company Stockholder Vote</I></B>&#8221;) and the Investor Agreement Termination Consent, are the only votes of the holders of any class or series of the Company Capital Stock or
other Company securities required in connection with the consummation of the Merger and the other Contemplated Transactions (except with respect to the Concurrent Financing). Other than the Required Company Stockholder Vote and the Investor
Agreement Termination Consent (and except with respect to the Concurrent Financing), no vote of the holders of any class or series of the Company&#8217;s capital stock or other securities is required in connection with the consummation of any of the
Contemplated Transactions to be consummated by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_19"></A>2.5 <U>No Conflict; Consents and
Approvals</U><U>.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to obtaining the Required Company Stockholder Vote, the execution, delivery and performance of this
Agreement by the Company does not, and the consummation of the Merger and the other Contemplated Transactions and compliance by the Company with the provisions hereof will not, contravene, conflict with, or result in any violation or breach of, or
default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any
pledge, claim, lien, charge, option, right of first refusal, encumbrance or security interest of any kind or nature whatsoever (including any limitation on voting, sale, transfer or other disposition or exercise of any other attribute of ownership)
(collectively, &#8220;<B><I>Encumbrances</I></B>&#8221;) in or upon any of the properties, assets or rights of the Company under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any
consent, waiver or approval of any Person pursuant to, any provision of (i)&nbsp;the Company Charter or Company Bylaws, (ii)&nbsp;any Company Material Contract to which the Company is a party or by which the Company or any of its properties or
assets may be bound or (iii)&nbsp;subject to the governmental filings and other matters referred to in <U>Section</U><U></U><U>&nbsp;2.5(b)</U>, any material Law applicable to the Company or by which the Company or any of its properties or assets
may be bound, except as, in the case of clauses (ii)&nbsp;and (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental Body is
required by or with respect to the Company in connection with the execution, delivery and performance of this Agreement by the Company or the consummation by the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Merger and the other Contemplated Transactions or compliance with the provisions hereof, except for (i)&nbsp;the filing with the SEC of such reports under Section&nbsp;13(a) or 15(d) of
the Exchange Act, as may be required in connection with this Agreement and the Contemplated Transactions, (ii)&nbsp;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and
any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws or Nasdaq, (iii)&nbsp;the filing of the Certificate of Merger with the Delaware Secretary of State as required by the DGCL, (iv)&nbsp;as may be required under
applicable Antitrust Laws and (v)&nbsp;such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made, individual or in the aggregate, have not had and would not
reasonably be expected to have a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_20"></A>2.6 <U>Financial
Statements</U><U>.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has made available to Parent true and complete copies of (i)&nbsp;the audited financial
statements of the Company as of December&nbsp;31, 2024 and (ii)&nbsp;the unaudited financial statements of the Company as of September&nbsp;30, 2025 (the &#8220;<B><I>Company Financial Statements</I></B>&#8221;). The Company Financial Statements
(i)&nbsp;are correct and complete in all material respects and have been prepared in accordance with the books and records of the Company, (ii)&nbsp;have been prepared in accordance with GAAP (except for, in the case of unaudited statements, the
absence of related notes) and (iii)&nbsp;fairly present, in all material respects, the financial position, of the Company as at the dates thereof and the Company&#8217;s respective consolidated results of operations and cash flows for the periods
then ended, except as otherwise noted therein and subject, in the case of any unaudited financial statements, to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments that will not, individually or in the aggregate, be
material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The books of account and financial records of the Company are maintained in accordance with sound accounting practice.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company maintains a system of internal accounting controls consistent with the practices of similarly situated private companies
designed to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation of the financial
statements of the Company in conformity with GAAP and to maintain accountability of the Company&#8217;s assets, (iii)&nbsp;access to the Company&#8217;s assets is permitted only in accordance with management&#8217;s general or specific
authorization, and (iv)&nbsp;the recorded accountability for the Company&#8217;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences. The Company maintains internal control
over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Since the Company&#8217;s inception, the Company has not identified (i)&nbsp;any significant deficiency or material weakness in the
design or operation of the system of internal accounting controls utilized by the Company, (ii)&nbsp;any fraud, whether or not material, that involves the Company, the Company&#8217;s management, other employees or advisors who have a role in the
preparation of financial statements or the internal accounting controls utilized by the Company or (iii)&nbsp;any claim or allegation regarding any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_21"></A>2.7 <U>No Undisclosed Liabilities</U>. As of the date hereof, the Company does not have any liabilities or
obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet under GAAP, except (a)&nbsp;to the extent
accrued or reserved against in the balance sheet of the Company as of September&nbsp;30, 2025 (the &#8220;<B><I>Company Balance Sheet</I></B>&#8221;), (b) for liabilities and obligations incurred by the Company in the Ordinary Course of Business
since the date of the Company Balance Sheet, (c)&nbsp;liabilities and obligations related to the performance of obligations of the Company under Company Material Contracts, (d)&nbsp;liabilities and obligations incurred in connection with the
Contemplated Transactions and (e)&nbsp;liabilities and obligations that are not material to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_22"></A>2.8 <U>Absence of Certain Changes or Events</U>. From the
date of the Company Balance Sheet to the date hereof, except in connection with the execution of this Agreement and the consummation of the Contemplated Transactions, (x)&nbsp;the Company has conducted its business only in the Ordinary Course of
Business; (y)&nbsp;there has not been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or would reasonably be expected to have a Company Material Adverse Effect; and
(z)&nbsp;the Company has not: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) (i) declared, set aside or paid any dividends on, or made any other distributions (whether in cash,
stock or property) in respect of, any of its capital stock or other equity interests, (ii)&nbsp;purchased, redeemed or otherwise acquired shares of capital stock or other equity interests of the Company or any options, warrants, or rights to acquire
any such shares or other equity interests, or (iii)&nbsp;split, combined, reclassified or otherwise amended the terms of any of its capital stock or other equity interests or issued or authorized the issuance of any other securities in respect of,
in lieu of or in substitution for shares of its capital stock or other equity interests; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) amended or otherwise changed, or authorized
or proposed to amend or otherwise change, its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or similar organizational documents) except as required to give effect to the Contemplated Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) adopted or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization or
effected or been a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated
Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) entered into any material transaction in connection with the Contemplated Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) acquired any material asset or sold, leased or otherwise irrevocably disposed of any of its material assets or properties, or granted any
Encumbrance (other than Permitted Encumbrances) with respect to such assets or properties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) sold, assigned, transferred, licensed,
sublicensed or otherwise disposed of any material Intellectual Property owned or purported to be owned by, assigned to, or exclusively licensed by, the Company, except for the grant of <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses
to such Intellectual Property in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) changed its financial or Tax accounting methods, principles or
practices, except insofar as may have been required by a change in GAAP or applicable Law, or revalued any of its material assets; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) agreed, resolved or committed to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_23"></A>2.9 <U>Litigation</U>. As of the date hereof, there is no Legal Proceeding (or basis therefor) pending or, to
the knowledge of the Company, threatened against the Company, its properties or assets, or any present or former officer, director or employee of the Company in such individual&#8217;s capacity as such, other than any Legal Proceeding that
(a)&nbsp;does not involve an amount in controversy in excess of $1,000,000 and (b)&nbsp;does not seek material injunctive or other nonmonetary relief. Neither the Company nor any of its properties or assets is subject to any outstanding judgment,
order, injunction, rule or decree of any Governmental Body. There is no Legal Proceeding pending or, to the knowledge of the Company, threatened seeking to prevent, hinder, modify, delay or challenge the Merger or any of the other Contemplated
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_24"></A>2.10 <U>Compliance with Laws</U>. The Company is, and since July&nbsp;1, 2024 has been, in
compliance in all material respects with all Laws applicable to its businesses, operations, properties or assets. The Company has not received, since July&nbsp;1, 2024, a notice or other written communication alleging or relating to a possible
material violation of any Law applicable to its businesses, operations, properties, assets or Company Products (as defined below). The Company has in effect all material permits, licenses, variances, exemptions, applications,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approvals, clearances, authorizations, registrations, formulary listings, consents, operating certificates, franchises, orders and approvals (collectively, &#8220;<B><I>Permits</I></B>&#8221;) of
all Governmental Bodies necessary for it to own, lease or operate its properties and assets and to carry on its businesses and operations as now conducted, and there has occurred no material violation of, material default (with or without notice or
lapse of time or both) or other event that would give others any right of revocation, non-renewal, adverse modification or cancellation of, with or without notice or lapse of time or both, any such Permit, nor would any such revocation, <FONT
STYLE="white-space:nowrap">non-renewal,</FONT> adverse modification or cancellation result from the consummation of the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_25"></A>2.11 <U>Health Care Regulatory Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company, and to the knowledge of the Company, each of its directors, officers, employees, agents (while acting in such capacity),
contract manufacturers, contract research organizations and clinical investigators is, and since July&nbsp;1, 2024 has been, in material compliance with all health care Laws to the extent applicable to the Company or any of its product candidates or
activities, including, but not limited to the following: (i)&nbsp;the Federal Food, Drug&nbsp;&amp; Cosmetic Act; (ii)&nbsp;the Public Health Service Act (42 U.S.C. &#167; 201 et seq.); (iii) fraud and abuse Laws such as the federal Anti-Kickback
Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b));</FONT> the civil monetary penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a);</FONT> the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.); the
administrative False Claims Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a));</FONT> the Criminal Health Care Fraud Statute (18 U.S.C. &#167; 1347); (iv) the exclusion laws (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7);</FONT> and (v)&nbsp;any Laws regulating the ownership, testing, research, development, manufacture, quality, safety, accreditation, packaging, storage, use, distribution, labeling, promotion, sale, offer
for sale, import, export or disposal of pharmaceutical products, including licensure required for any such activities (&#8220;<B><I>Health Care Laws</I></B>&#8221;). The Company has not engaged in any voluntary disclosure or self-disclosure to any
Governmental Body concerning any alleged, potential or actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any applicable Health Care Laws, and to the Company&#8217;s knowledge no such self-disclosure to any Governmental Body is
warranted. To the knowledge of the Company, there are no other facts or circumstances that reasonably would be expected to give rise to any material liability under any Health Care Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company is not party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar
agreements with or imposed by any Governmental Body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) All applications, notifications, submissions, information and reports submitted
in connection with any and all requests for a Permit from the U.S. Food and Drug Administration (&#8220;<B><I>FDA</I></B>&#8221;) or other Governmental Body relating to products that are regulated as drugs, biologics, or other medical products under
Health Care Laws, including the drug and biological candidates, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed and/or distributed by the Company (&#8220;<B><I>Company Products</I></B>&#8221;),
including, without limitation, investigational new drug applications, when submitted to the FDA or other Governmental Body were true, complete and correct in all material respects as of the date of submission and any necessary or required updates,
changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Body. The Company does not have knowledge of any facts or circumstances that would be reasonably likely
to lead to the revocation, suspension, limitation, or cancellation of a material Permit required under Health Care Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) All
preclinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of the Company have been since July&nbsp;1, 2024, and if still pending are being, conducted in material compliance with research protocols and all
applicable Health Care Laws. To the Company&#8217;s knowledge, no clinical trial conducted by or on behalf of the Company has been conducted using any clinical investigators who have been disqualified, debarred or excluded from healthcare programs.
Since July&nbsp;1, 2024, no clinical trial conducted by or on behalf of the Company has been terminated or suspended prior to completion, and no clinical investigator who has participated or is participating in, or institutional review board that
has or has had jurisdiction over, a clinical trial conducted by or on behalf of the Company has placed a partial or full clinical hold order on, or otherwise terminated, delayed or suspended, such a clinical trial at a clinical research site based
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on an actual or alleged lack of safety or efficacy of any Company Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All manufacturing operations conducted by or, to the knowledge of the Company, for the benefit of the Company have been and are being
conducted in material compliance with all Permits and all applicable Health Care Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Company has not received any written
communication from any Governmental Body that relates to an alleged material violation of any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import
detention or refusal, FDA Warning Letter or Untitled Letter, or any similar action by a Governmental Body relating to any Health Care Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the
Company Products required or requested by a Governmental Body, or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company Products, or any adverse experiences relating to the Company Products
that have been reported to FDA or another Governmental Body (&#8220;<B><I>Company Safety Notices</I></B>&#8221;), and, to the knowledge of the Company, there are no facts or circumstances that reasonably would be expected to give rise to a Company
Safety Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Neither the Company, nor, to the knowledge of the Company, any officer, employee or agent of the Company has made an
untrue statement of a material fact or fraudulent or misleading statement to a Governmental Body, failed to disclose a material fact required to be disclosed to a Governmental Body, or committed an act, made a statement, or failed to make a
statement that would reasonably be expected to provide a basis for the FDA to invoke its policy respecting the &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191
(September 10, 1991) and any amendments thereto (the &#8220;<B><I>FDA Ethics Policy</I></B>&#8221;). Neither the Company, nor, to the knowledge of the Company, any officer, employee or agent of the Company is or has been under investigation
resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Body by
the Company have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices has not had and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Neither the Company nor, to the knowledge of the Company, any officer, employee, or agent of the Company has been convicted of any crime
or engaged in any conduct that has resulted, or would reasonably be expected to result, in listing on the General Services Administrative System for Award Management or other published list of parties excluded from federal procurement programs and <FONT
STYLE="white-space:nowrap">non-procurement</FONT> programs or in debarment under applicable Law or, including, without limitation, 21 U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7,</FONT> or any
other statutory provision or similar law applicable in other jurisdictions in which the Company Products are sold or intended to be sold. Neither the Company nor, to the knowledge of the Company, any officer, employee or agent of the Company, has
been excluded from participation in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section&nbsp;1128 of the
Social Security Act of 1935, or any similar Health Care Law or program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) The Company is not, and has not been, a &#8220;business
associate,&#8221; &#8220;covered entity,&#8221; or &#8220;subcontractor&#8221; under Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167; 17921 et seq.) (&#8220;<B><I>HIPAA</I></B>&#8221; ) as those terms are defined in 42 C.F.R.
&#167; 160.103 and, since July&nbsp;1, 2024, has been in material compliance with any Privacy Laws applicable to health information, including HIPAA, in the Company&#8217;s possession to the extent applicable to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_26"></A>2.12 <U>Benefit Plans</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section 2.12(a)</U> of the Company Disclosure Schedule contains a true and complete list of each material Company Benefit Plan (other
than (i)&nbsp;form equity award agreements and awards made pursuant to such form(s), (ii) offer letters, employment agreements or contracts that may be terminated by the Company without notice and do not contain any severance, change in control,
retention bonus, or vesting acceleration provisions, and (iii)&nbsp;consultant contracts or arrangements that may be terminated by the Company with no more than 30 days&#8217; notice without penalty). For purposes of this Agreement,
&#8220;<B><I>Company Benefit Plan</I></B>&#8221; means each &#8220;employee benefit plan&#8221; (within the meaning of section 3(3) of ERISA, whether or not subject to ERISA), and each stock purchase, stock option, phantom stock or other
equity-based plan or award, severance, employment, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control,</FONT></FONT> fringe benefit, bonus, incentive, deferred compensation, supplemental retirement, health, life, or
disability insurance, dependent care and each other employee benefit and compensation plan, agreement, program, policy or other arrangement, whether or not subject to ERISA, whether formal or informal, written or oral, legally binding or not, under
which any current or former employee, director or individual consultant of the Company (or any of their dependents) has any present or future right to compensation or benefits or the Company sponsors or maintains, is making contributions to or has
any present or future liability or obligation (contingent or otherwise) or with respect to which it is otherwise bound. The Company has provided or made available to Parent a current, accurate and complete copy of each material Company Benefit Plan,
or if such Company Benefit Plan is not in written form, a written summary of all of the material terms of such Company Benefit Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
Neither the Company nor any member of its Controlled Group (defined as any organization which is, or was at the applicable time, a member of a controlled, affiliated or otherwise related group of entities within the meaning of Code
Section&nbsp;414(b), (c), (m) or (o)) has ever sponsored, maintained, contributed to or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&nbsp;a &#8220;multiemployer plan&#8221; (within the
meaning of ERISA section 3(37)), (ii) an &#8220;employee pension benefit plan,&#8221; within the meaning of Section&nbsp;3(2) of ERISA (&#8220;<B><I>Pension Plan</I></B>&#8221;) that is subject to Title IV of ERISA or Section&nbsp;412 of the Code,
or (iii)&nbsp;a Pension Plan which is a &#8220;multiple employer plan&#8221; as defined in Section&nbsp;413 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) With
respect to the Company Benefit Plans: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) each Company Benefit Plan complies in all material respects with its terms and with the
applicable provisions of ERISA and the Code and all other applicable legal requirements; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) each Company Benefit Plan intended to be
qualified under Section&nbsp;401(a) of the Code is so qualified and has received a favorable determination, advisory and/or opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of the Company
since the date of such letter that would reasonably be expected to result in the loss of the sponsor&#8217;s ability to rely upon such letter or of the qualified status of such Company Benefit Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) there is no material Legal Proceeding (including any investigation, audit or other administrative proceeding) by the Department of
Labor, the Pension Benefit Guaranty Corporation (the &#8220;<B><I>PBGC</I></B>&#8221;), the IRS or any other Governmental Body or by any plan participant or beneficiary pending, or to the knowledge of the Company, threatened, relating to the Company
Benefit Plans (other than routine claims for benefits); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) none of the Company Benefit Plans currently provides or represents any
liability to provide post-termination or retiree welfare benefits to any person for any reason, except as may be required by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;601 et seq. of ERISA and Section&nbsp;4980B(b) of the Code or other applicable similar law regarding health care coverage continuation (collectively,
&#8220;<B><I>COBRA</I></B>&#8221;), and none of the Company or any members of its Controlled Group has any liability to provide post-termination or retiree welfare benefits to any person or ever represented, promised or contracted to any employee or
former employee of the Company (either individually or to Company employees as a group) or any other person that such employee(s) or other person would be provided with post-termination or retiree welfare benefits, except to the extent required by
statute or except with respect to a contractual obligation to reimburse any premiums such person may pay in order to obtain health coverage under COBRA; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) each Company Benefit Plan is subject exclusively to United States Law; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) the execution and delivery of this Agreement and the consummation of the Merger will not, either alone or in combination with any other
event, (A)&nbsp;entitle any current or former employee, officer, director or individual consultant of the Company to severance pay or any other termination payment or other compensation or benefits (B)&nbsp;accelerate the time of payment or vesting,
or increase the amount of or otherwise enhance any benefit due to any such employee, officer, director or consultant or (C)&nbsp;result in a requirement to fund or set aside assets with respect to any Company Benefit Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company is not a party to any agreement, Contract, arrangement or plan (including any Company Benefit Plan) that may reasonably be
expected to result, separately or in the aggregate, in connection with the Contemplated Transactions (either alone or in combination with any other events), in the payment of any &#8220;parachute payments&#8221; within the meaning of
Section&nbsp;280G of the Code. There is no agreement, plan or other arrangement to which the Company is a party or by which the Company is otherwise bound to compensate any person in respect of Taxes or other liabilities incurred with respect to
Section&nbsp;409A or 4999 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_27"></A>2.13 <U>Labor and Employment Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company is and, since July&nbsp;1, 2024, has been, in compliance in all material respects with all applicable Laws relating to labor
and employment, including those relating to employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits,
<FONT STYLE="white-space:nowrap">non-discrimination</FONT> in employment, workers&#8217; compensation, unemployment compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, and continuation
coverage with respect to group health plans. Since July&nbsp;1, 2024, there has not been, and as of the date of this Agreement there is not pending or, to the knowledge of the Company, threatened, any labor dispute, work stoppage, labor strike or
lockout against the Company by employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No employee of the Company is covered by an effective or pending collective bargaining
agreement or similar labor agreement. To the knowledge of the Company, there has not been any activity on behalf of any labor union, labor organization or similar employee group to organize any employees of the Company. There are no (i)&nbsp;unfair
labor practice charges or complaints against the Company pending before the National Labor Relations Board or any other labor relations tribunal or authority and, to the knowledge of the Company, no such representations, claims or petitions are
threatened, (ii)&nbsp;representation claims or petitions pending before the National Labor Relations Board or any other labor relations tribunal or authority or (iii)&nbsp;grievances or pending arbitration proceedings against the Company that arose
out of or under any collective bargaining agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) To the knowledge of the Company, as of the date hereof, no current officer of
the Company intends to, terminate his or her employment relationship with the Company in connection with or as a result of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Since the Company&#8217;s inception, (i)&nbsp;the Company has not effectuated a &#8220;plant closing&#8221; (as defined in the Worker
Adjustment Retraining and Notification Act of 1988 (the &#8220;<B><I>WARN Act</I></B>&#8221;)) affecting any site </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of employment or one or more facilities or operating units within any site of employment or facility, (ii)&nbsp;there has not occurred a &#8220;mass layoff&#8221; (as defined in the WARN Act) in
connection with the Company affecting any site of employment or one or more facilities or operating units within any site of employment or facility and (iii)&nbsp;the Company has not engaged in layoffs or employment terminations sufficient in number
to trigger application of any similar state, local or foreign law. The Company currently properly classifies and since its inception has classified its employees as exempt or nonexempt in accordance with applicable overtime laws, and no person
treated as an independent contractor or consultant by the Company since its inception should have been classified as an employee under applicable Law, except where such action would not, individually or in the aggregate, result in the Company
incurring a material liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) With respect to any current or former employee, officer, consultant or other service provider of the
Company, there are no Legal Proceedings against the Company pending, or to the Company&#8217;s knowledge, threatened to be brought or filed, in connection with the employment or engagement of any current or former employee, officer, consultant or
other service provider of the Company, including, without limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay, employment classification or any other employment-related matter arising under applicable
Laws, except where such action would not, individually or in the aggregate, result in the Company incurring a material liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)
Except with respect to any Company Benefit Plan (which subject is addressed in <U>Section</U><U></U><U>&nbsp;2.12</U> above), the execution of this Agreement and the consummation of the transactions set forth in or contemplated by this Agreement
will not result in any breach or violation of, or cause any payment to be made under, any applicable Laws respecting labor and employment or any collective bargaining agreement to which the Company is a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Since July&nbsp;1, 2024, (i) no allegations of workplace sexual harassment, discrimination or other material misconduct have been made,
initiated, filed or, to the knowledge of the Company, threatened against the Company or any of its respective current or former directors, officers or senior-level management employees, (ii)&nbsp;to the knowledge of the Company, no incidents of any
such workplace sexual harassment, discrimination or other material misconduct have occurred, and (iii)&nbsp;the Company has not entered into any settlement agreement related to allegations of sexual harassment, discrimination or other material
misconduct by any of its directors, officers or employees described in clause (i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_28"></A>2.14 <U>Environmental
Matters</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company
Material Adverse Effect, (i)&nbsp;the Company has conducted its businesses in compliance with all, and has not violated any, applicable Environmental Laws; (ii)&nbsp;the Company has obtained all Permits of all Governmental Bodies and any other
Person that are required under any Environmental Law; (iii)&nbsp;there has been no release of any Hazardous Substance by the Company or any other Person in any manner that has given or would reasonably be expected to give rise to any remedial or
investigative obligation, corrective action requirement or liability of the Company under applicable Environmental Laws; (iv)&nbsp;the Company has not received any claims, notices, demand letters or requests for information (except for such claims,
notices, demand letters or requests for information the subject matter of which has been resolved prior to the date of this Agreement) from any federal, state, local, foreign or provincial Governmental Body or any other Person asserting that the
Company is in violation of, or liable under, any Environmental Law; (v)&nbsp;no Hazardous Substance has been disposed of, arranged to be disposed of, released or transported in violation of any applicable Environmental Law, or in a manner that has
given rise to, or that would reasonably be expected to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties or facilities owned or operated by the Company or as a result of any
operations or activities of the Company at any location and, to the knowledge of the Company, Hazardous Substances are not otherwise present at or about any such properties or facilities in amount or condition that has resulted in or would
reasonably be expected to result in liability to the Company under any Environmental Law; and (vi)&nbsp;neither the Company nor any of its respective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
properties or facilities are subject to, or are threatened to become subject to, any liabilities relating to any suit, settlement, court order, administrative order, regulatory requirement,
judgment or claim asserted or arising under any Environmental Law or any agreement relating to environmental liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) As used
herein, &#8220;<B><I>Environmental Law</I></B>&#8221; means any Law relating to (i)&nbsp;the protection, preservation or restoration of the environment (including air, surface water, groundwater, drinking water supply, surface and subsurface soils
and strata, wetlands, plant and animal life or any other natural resource) or (ii)&nbsp;the exposure to, or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling, production, release or disposal of
Hazardous Substances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) As used herein, &#8220;<B><I>Hazardous Substance</I></B>&#8221; means any substance listed, defined,
designated, classified or regulated as a waste, pollutant or contaminant or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental Law, including but not limited to petroleum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_29"></A>2.15 <U>Taxes</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company and each of its Subsidiaries has (i)&nbsp;timely filed all income and other material Tax Returns required to be filed by or
on behalf of it (taking into account any applicable extensions thereof) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&nbsp;timely paid in full (or caused to be timely paid in full) all material Taxes
that are due and payable, whether or not such Taxes were shown as due on such Tax Returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All material Taxes not yet due and
payable by the Company or any of its Subsidiaries as of the date of the Company Balance Sheet have been, in all material respects, properly accrued in accordance with GAAP on the Company Balance Sheet, and such Company Balance Sheet reflects an
adequate reserve (in accordance with GAAP) for all material Taxes accrued but unpaid by the Company and each of its Subsidiaries through the date of the Company Balance Sheet. Since the date of the Company Balance Sheet, neither the Company nor any
of its Subsidiaries has incurred, individually or in the aggregate, any liability for Taxes outside the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)
Neither the Company nor any of its Subsidiaries has executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any material amount of Tax, in each case that has not since expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) No material audits or other investigations, proceedings, claims, assessments or examinations by any Governmental Body (each, a
&#8220;<B><I>Tax Action</I></B>&#8221;) with respect to Taxes or any Tax Return of the Company or any of its Subsidiaries are presently in progress or have been asserted, threatened or proposed in writing, other than any such assertion, threat or
proposal that has been settled or withdrawn. No deficiencies or claims for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing against the Company or any of its Subsidiaries by a Governmental Body, other than any
such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The Company and each
of its Subsidiaries have timely withheld or deducted all material Taxes required to have been withheld or deducted from payments made (or deemed made) to their employees, independent contractors, creditors, shareholders and other third parties and,
to the extent required, such material Taxes have been timely paid to the relevant Governmental Body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of
its Subsidiaries has engaged in a &#8220;listed transaction&#8221; as set forth in Treasury Regulations <FONT STYLE="white-space:nowrap">&#167;1.6011-4(b).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Neither the Company nor any of its Subsidiaries (i)&nbsp;is a party to or bound by, nor has any liability pursuant to, any Tax sharing,
allocation, indemnification or similar agreement or obligation, other than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any such agreement or obligation which is a customary commercial agreement or obligation entered into in the Ordinary Course of Business with vendors, lessors, lenders or the like the primary
purpose of which is not Taxes (each, an &#8220;<B><I>Ordinary Course Agreement</I></B>&#8221;); (ii) is or has ever been a member of a group (other than a group the common parent of which is the Company) filing a consolidated, combined, affiliated,
unitary or similar income Tax Return; (iii)&nbsp;has any liability for the Taxes of any Person (other than the Company and its Subsidiaries) pursuant to Treasury Regulations &#167; <FONT STYLE="white-space:nowrap">1.1502-6</FONT> (or any similar
provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law) as a transferee or successor, by Contract (other than Ordinary Course Agreements) or otherwise by operation of Law; and (iv)&nbsp;is or has ever been treated as a
resident for any income Tax purpose, or as subject to Tax by virtue of having a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) No private-letter rulings, technical advice memoranda, or similar material agreements or rulings related to Taxes have been requested in
writing, entered into or issued by any taxing authority with respect to the Company or any of its Subsidiaries which rulings remain in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Neither the Company nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item
of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&nbsp;a change in method of accounting requested or initiated, or use of improper method of accounting, on or prior to the
Closing Date, (ii)&nbsp;a &#8220;closing agreement&#8221; as described in Section&nbsp;7121 of the Code (or any similar provision of state, local or foreign Tax Law) executed on or prior to the Closing Date, (iii)&nbsp;an installment sale or
open-transaction disposition made on or prior to the Closing Date, (iv)&nbsp;any deferred intercompany gain or excess-loss account described in Treasury Regulations under Section&nbsp;1502 of the Code (or any corresponding or similar provision of
state, local or foreign income Tax Law), (v) an election under Section&nbsp;965 of the Code, or (vi)&nbsp;the application of Section&nbsp;951 or 951A of the Code with respect to income earned or recognized or payments received prior to the Closing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) There are no Encumbrances for Taxes upon any of the assets of the Company or any of its Subsidiaries other than Encumbrances
described in clause (i)&nbsp;of the definition of Permitted Encumbrances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Neither the Company nor any of its Subsidiaries has
distributed stock of another Person or has had its stock distributed by another Person, in a transaction (or series of transactions) that was purported or intended to be governed in whole or in part by Section&nbsp;355 or 361 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) Neither the Company nor any of its Subsidiaries has been a United States real property holding corporation, as defined in
Section&nbsp;897(c)(2) of the Code, during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) No material
claim has been made in writing by any Governmental Body in a jurisdiction where the Company or any of its Subsidiaries has not paid a specific Tax or filed a specific Tax Return that the Company or any of its Subsidiaries is or may be required to
pay such Tax or file such Tax Return by such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) <U>Section 2.15(n)</U> of the Company Disclosure Schedule sets forth the
entity classification of the Company and each of its Subsidiaries for U.S. federal income tax purposes. Neither the Company nor any of its Subsidiaries has made an election or taken any other action to change its federal and state income tax
classification from such classification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) To the Company&#8217;s knowledge, the Company has not been, is not, and immediately prior
to the Effective Time will not be, treated as an &#8220;investment company&#8221; within the meaning of Section&nbsp;368(a)(2)(F) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) Neither the Company nor any of its Subsidiaries has taken any action (or agreed to take any action) nor does it know of any fact or
circumstance that would reasonably be expected to prevent or impede the Merger from qualifying for the Intended Tax Treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_30"></A>2.16 <U>Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section 2.16(a)</U> of the Company Disclosure Schedule lists the following Contracts (other than Company Benefit Plans and Excepted
Contracts)&nbsp;(a) to which the Company is a party; (b)&nbsp;by which the Company or any Intellectual Property owned or purported to be owned by, assigned to, or exclusively licensed by, the Company or any other asset of the Company is or may
become bound or under which the Company has, or may become subject to, any obligation; or (c)&nbsp;under which the Company has or may acquire any right or interest, in effect as of the date of this Agreement (all such Contracts, &#8220;<B><I>Company
Material Contracts</I></B>&#8221;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) each Contract relating to the disposition or acquisition of material assets or any ownership
interest in any entity, except as contemplated hereby, in each case, involving payments in excess of $1,000,000 after the date of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) each Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or
instruments relating to the borrowing of money or extension of credit in excess of $1,000,000 or creating any material Encumbrances with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) each Contract requiring payment by or to the Company after the date of this Agreement in excess of $1,000,000 in the aggregate in
the current calendar year or any future calendar year pursuant to its express terms relating to: (A)&nbsp;any agreement under which a third party is granted rights related to the sale or distribution of any Company Product (identifying any that
contain exclusivity provisions); (B) any agreement (other than a Company Benefit Plan) involving provision of services with respect to any <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development activities of the Company;
(C)&nbsp;any dealer, distributor, joint marketing, alliance, joint venture, cooperation, or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any
agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company; or (D)&nbsp;any Contract under which any third party provides any services relating
to the manufacture (in whole or in part) of any Company Product, in each case, except for Contracts entered into in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) each Company <FONT STYLE="white-space:nowrap">In-bound</FONT> License; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) each Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> License; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) each Contract requiring the payment of any royalty, dividend or similar arrangement based on the revenues or profits of the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii) any other Contract that is not terminable at will (with no explicit termination penalty ) by the Company and which involves
payment or receipt by the Company after the date of this Agreement under any such Contract of more than $1,000,000 in the aggregate, or obligations after the date of this Agreement in excess of $1,000,000 in the aggregate; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(viii) other than any Contract identified in <U>Section</U><U></U><U>&nbsp;2.16(a)(i)</U>-(vii), each Contract that would constitute a
&#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act), with respect to the Company (assuming the Company was subject to the requirements of the
Exchange Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) (i) Each Company Material Contract is valid and binding on the Company and to the knowledge of the Company, each
other party thereto, and is in full force and effect and enforceable in accordance with its terms; (ii)&nbsp;the Company, and, to the knowledge of the Company, each other party thereto, has performed all material obligations required to be performed
by it under each Company Material Contract; and (iii)&nbsp;there is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
no material default under any Company Material Contract by the Company or, to the knowledge of the Company, any other party thereto, and no event or condition has occurred that constitutes, or,
after notice or lapse of time or both, would constitute, a material default on the part of the Company or, to the knowledge of the Company, any other party thereto under any such Company Material Contract, nor has the Company received written notice
of any such material default, event or condition. The Company has made available to Parent true and complete copies of all Company Material Contracts, including all amendments thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_31"></A>2.17 <U>Insurance</U>. The Company is covered by valid and currently effective insurance policies issued in
favor of the Company that are customary and adequate for companies of similar size in the industries and locations in which the Company operates. <U>Section</U><U></U><U>&nbsp;2.17</U> of the Company Disclosure Schedule sets forth, as of the date
hereof, a true and complete list of all material insurance policies issued in favor of the Company, or pursuant to which the Company is a named insured or otherwise a beneficiary, as well as any historic incurrence-based policies still in force.
With respect to each such insurance policy, (a)&nbsp;such policy is in full force and effect and all premiums due thereon have been paid, (b)&nbsp;the Company is not in breach or default, and has not taken any action or failed to take any action
which (with or without notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any such policy and (c)&nbsp;to the knowledge of the Company, no insurer issuing any such policy has
been declared insolvent or placed in receivership, conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor, to the knowledge of the Company, will any such cancellation or
termination result from the consummation of the Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_32"></A>2.18 <U>Properties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has good and valid title to, or in the case of leased property and leased tangible assets, a valid leasehold interest in, all
of its real properties and tangible assets that are necessary for the Company to conduct its business as currently conducted, free and clear of all Encumbrances other than (i)&nbsp;Encumbrances for current Taxes and assessments not yet past due or
the amount or validity of which is being contested in good faith by appropriate proceedings, (ii)&nbsp;minor liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the
value of the assets or properties subject thereto or materially impair the operations of the Company; (iii)&nbsp;statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements; (iv)&nbsp;deposits or pledges
made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by Law; (v)&nbsp;mechanics&#8217;, workmen&#8217;s, repairmen&#8217;s, warehousemen&#8217;s and carriers&#8217;
Encumbrances arising in the Ordinary Course of Business, <FONT STYLE="white-space:nowrap">(vi)&nbsp;non-exclusive</FONT> licenses of rights to Intellectual Property granted in the Ordinary Course of Business, which do not (in any case or in the
aggregate) materially detract from the value of the rights to Intellectual Property subject thereto, and (vii)&nbsp;any such matters of record, Encumbrances and other imperfections of title that do not, individually or in the aggregate, materially
impair the continued ownership, use and operation of the assets to which they relate in the business of the Company as currently conducted (&#8220;<B><I>Permitted Encumbrances</I></B>&#8221;). Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse Effect on the Company, the tangible personal property currently used in the operation of the business of the Company is in good working order (reasonable wear and tear
excepted). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company has complied with the terms of all leases to which it is a party, and all such leases are in full force and
effect, except for any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. The Company enjoys peaceful and
undisturbed possession under all such leases, except for any such failure to do so that, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Section 2.18(c)</U> of the Company Disclosure Schedule sets forth a true and complete list of (i)&nbsp;all real property owned by the
Company and (ii)&nbsp;all real property leased for the benefit of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) This <U>Section</U><U></U><U>&nbsp;2.18</U> does not relate to intellectual property,
which is the subject of <U>Section</U><U></U><U>&nbsp;2.19</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_33"></A>2.19 <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section 2.19(a)</U> of the Company Disclosure Schedule sets forth a true and complete list of all (i)&nbsp;material patents and patent
applications; (ii)&nbsp;material trademark registrations and applications; and (iii)&nbsp;material copyright registrations and applications, in each case owned by the Company (collectively, &#8220;<B><I>Company Registered IP</I></B>&#8221;), and a
true and complete list of all domain names owned or exclusively licensed by the Company. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect (A)&nbsp;all of the
Company Registered IP is subsisting and, in the case of any Company Registered IP that is registered or issued and to the knowledge of the Company, valid and enforceable, (B)&nbsp;no Company Registered IP is involved in any interference, reissue,
derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of the Company, no such action is threatened with respect to any of the Company Registered IP and (C)&nbsp;the Company owns exclusively, free and clear
of any and all Encumbrances (other than Permitted Encumbrances), all Company Owned IP, including all Intellectual Property created on behalf of the Company by its employees or independent contractors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Section 2.19(b)</U> of the Company Disclosure Schedule accurately identifies all Contracts pursuant to which any material Intellectual
Property is licensed to the Company by any third party or any third party has granted to the Company a covenant not to sue with respect to any material Intellectual Property (other than (i)&nbsp;any
<FONT STYLE="white-space:nowrap">non-customized</FONT> software that (A)&nbsp;is so licensed solely in executable or object code form pursuant to a nonexclusive, <FONT STYLE="white-space:nowrap">internal-use</FONT> software license and other
Intellectual Property associated with such software and (B)&nbsp;is not incorporated into any of the Company&#8217;s products, (ii)&nbsp;any Intellectual Property licensed on a nonexclusive basis where the license is incidental to the primary
purpose of the relevant Contract or the provision of services to the Company, (iii)&nbsp;any material transfer agreements, research agreements, clinical trial agreements, services agreements, <FONT STYLE="white-space:nowrap">non-disclosure</FONT>
agreements or confidentiality agreements, or off <FONT STYLE="white-space:nowrap">the-shelf</FONT> software licenses or generally-available patent license agreements and (iv)&nbsp;agreements between Company and its employees in Company&#8217;s
standard form thereof) (each a &#8220;<B><I>Company <FONT STYLE="white-space:nowrap">In-bound</FONT> License</I></B>,&#8221; and the underlying Intellectual Property, the &#8220;<B><I>Company Licensed IP</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Section 2.19(c)</U> of the Company Disclosure Schedule accurately identifies each Contract pursuant to which any Person has been
granted any license or covenant not to sue under, any Company Owned IP or Company Licensed IP (other than (i)&nbsp;any material transfer agreements, research agreements, clinical trial agreements, services agreements,
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements or confidentiality agreements and (ii)&nbsp;any Company Owned IP or Company Licensed IP nonexclusively licensed in the Ordinary Course of Business and that does not grant any
commercial rights to any Company Product) (each a &#8220;<B><I>Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> License</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) To the knowledge of Company, the Company Owned IP and the Company Licensed IP constitutes all Intellectual Property necessary for Company
to conduct its business as currently conducted; provided, however, that the foregoing representation is not a representation with respect to <FONT STYLE="white-space:nowrap">non-infringement</FONT> of Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The Company has taken commercially reasonable measures to maintain the confidentiality of all information that constitutes or constitute
a material trade secret of the Company, including requiring all Persons having access thereto to execute written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements or assume other binding obligations to maintain confidentiality of
such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company
Material Adverse Effect, (i)&nbsp;to the knowledge of the Company, the conduct of the businesses of the Company, including the manufacture, marketing, offering for sale, sale, importation, use or intended use (as currently contemplated) or other
disposal of any product as currently sold or under development by the Company, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Intellectual Property of any Person, (ii)&nbsp;the Company has not received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may
be occurring or has or may have occurred and (iii)&nbsp;to the knowledge of the Company, no Person is infringing, misappropriating, or diluting in any material respect any Company Registered IP or Company Licensed IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect,
(i)&nbsp;the Company has taken commercially reasonable steps to protect the confidentiality and security of the computer and information technology systems owned, licensed and used by the Company (the &#8220;<B><I>IT Systems</I></B>&#8221;) and the
information and transactions stored or contained therein or transmitted thereby, (ii)&nbsp;to the knowledge of the Company, since July&nbsp;1, 2024, there has been no unauthorized use, loss, access, transmittal, modification or corruption of any
such IT Systems and (iii)&nbsp;since July&nbsp;1, 2024, there have been no material failures, crashes, viruses, or security breaches (including any unauthorized access to any personally identifiable information) affecting the IT Systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect,
(i)&nbsp;to the knowledge of the Company, the Company has at all times since July&nbsp;1, 2024, complied in all material respects with all applicable Laws governing privacy, data protection, and the collection, retention, protection, and use of
Personal Information (collectively, &#8220;<B><I>Privacy Laws</I></B>&#8221;) collected, used, or held for use by the Company, (ii)&nbsp;since July&nbsp;1, 2024, no claims have been received by the Company or, to the knowledge of the Company,
threatened in writing against the Company alleging the Company violated any applicable Privacy Laws, (iii)&nbsp;neither the Company&#8217;s performance of this Agreement nor the Company&#8217;s consummation of the Contemplated Transactions will
breach or otherwise violate any applicable Privacy Laws and (iv)&nbsp;the Company has taken commercially reasonable steps to protect the Personal Information collected, used or held for use by the Company against unauthorized loss, access, use,
modification, disclosure or other misuse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) To the knowledge of the Company, no government funding, facilities or resources of a
university, college, other educational institution or research center or funding from third parties was used in the development of the Company Owned IP or, to the knowledge of the Company, Company Licensed IP exclusively licensed to the Company, and
no Governmental Body, university, college, other educational institution or research center has, to the knowledge of the Company, any claim or right in or to such Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) The execution, delivery and performance by the Company of this Agreement, and the consummation of the Contemplated Transactions, will not
result in the loss of, or give rise to any right of any third party to terminate or modify any of the Company&#8217;s rights or obligations under any Company <FONT STYLE="white-space:nowrap">In-bound</FONT> License or Company <FONT
STYLE="white-space:nowrap">Out-bound</FONT> License. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_34"></A>2.20 <U>State Takeover Statutes</U>. As of the date
hereof and at all times on or prior to the Effective Time, the Company Board has taken all actions so that the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL are, and will be, inapplicable to the
execution, delivery and performance of this Agreement and the timely consummation of the Merger and the other Contemplated Transactions and will not restrict, impair or delay the ability of Parent or Merger Sub, after the Effective Time, to vote or
otherwise exercise all rights as a stockholder of the Company. No other Takeover Statute or any similar anti-takeover provision in the Company Charter or Company Bylaws is, or at the Effective Time will be, applicable to this Agreement, the Merger
or any of the other Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_35"></A>2.21 <U>No Rights Plan</U>. There is no stockholder
rights plan, &#8220;poison pill&#8221; anti-takeover plan or other similar device in effect to which the Company is a party or is otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_36"></A>2.22 <U>Related Party Transactions</U>. Since July&nbsp;1, 2024 through the date of this Agreement, there
have been no transactions, agreements, arrangements or understandings between the Company, on the one hand, and the affiliates of the Company, on the other hand, that would be required to be disclosed under Item 404 of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act (assuming the Company was subject to the requirements of the Exchange Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_37"></A>2.23 <U>Certain Payments</U>. Neither the Company nor any of its respective directors, officers, employees
or, to the Company&#8217;s knowledge, agents or any other Person acting on its behalf has, directly or indirectly, made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other
payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of the Foreign Corrupt Practices Act of 1977, the UK Bribery Act of 2010 or any other anti-bribery or anti-corruption Law (collectively, the
&#8220;<B><I>Anti-Bribery Laws</I></B>&#8221;). The Company is not, nor has it been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_38"></A>2.24 <U>Brokers</U>. No broker, investment banker, financial advisor or other Person, other than as set forth
on <U>Section</U><U></U><U>&nbsp;2.24</U> of the Company Disclosure Schedule, the fees and expenses of which will be paid by the Company or, following the Effective Time, Parent, is entitled to any broker&#8217;s, finder&#8217;s, financial
advisor&#8217;s or other similar fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company or any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_39"></A>2.25 <U>Concurrent Financing Compliance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has delivered to Parent true, correct and complete copies of all definitive agreements related to the Concurrent Financing,
including the Subscription Agreement, pursuant to which the Purchasers (as defined in the Subscription Agreement) party thereto (collectively, the &#8220;<B><I>Purchasers</I></B>&#8221;) have agreed, subject to the terms and conditions set forth
therein, to purchase the number of shares of Company Common Stock set forth therein in connection with the Contemplated Transactions. The Subscription Agreement has not been amended or modified prior to the date of this Agreement and as of the date
hereof, no such amendment or modification is contemplated (other than amendments or modifications that are permitted by <U>Section</U><U></U><U>&nbsp;5.23</U>), and as of the date hereof, the respective obligations and commitments contained in the
Subscription Agreement have not been withdrawn or rescinded in any respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) As of the date hereof, the Subscription Agreement is in
full force and effect and is the legal, valid, binding and enforceable obligation of the Company, and, to the knowledge of the Company, each of the Purchasers. There are no conditions precedent or other contingencies related to the funding of the
full amount of the Concurrent Financing, other than as expressly set forth in the Subscription Agreement. As of the date hereof, no event has occurred which, with or without notice, lapse of time or both, would reasonably be expected to constitute a
default or breach on the part of the Company or, to the knowledge of the Company, any Purchaser under the Subscription Agreement. As of the date hereof, the Company has no reason to believe that any of the conditions to the Concurrent Financing as
contemplated by the Subscription Agreement will not be satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_40"></A>2.26 <U>No Other Representations or
Warranties</U>. Except for the representations and warranties contained in <U>Section</U><U></U><U>&nbsp;3</U>, the Company acknowledges and agrees that none of Parent, Merger Sub or any other Person on behalf of Parent or Merger Sub makes any other
express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of Parent, its Subsidiaries or any other Person on behalf of Parent or Merger Sub makes any representation or
warranty with respect to any projections or forecasts delivered or made available to the Company or any of its Representatives of future revenues, results of operations (or any component thereof), cash flows or financial condition (or any component
thereof) of Parent (including any such projections or forecasts made available to the Company and Representatives in certain &#8220;data rooms&#8221; or management presentations in expectation of the Contemplated Transactions), and the Company has
not relied on any such information or any representation or warranty not set forth in <U>Section</U><U></U><U>&nbsp;
3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_48"></A><B>Section</B><B></B><B>&nbsp;3.</B> <U>REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER
SUB</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except (a)&nbsp;as disclosed in the Parent SEC Documents at least three Business Days prior to the date of this Agreement and
that is reasonably apparent on the face of such disclosure to be applicable to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representation and warranty set forth herein (other than any disclosures contained or referenced therein under the captions &#8220;Risk Factors,&#8221; &#8220;Forward-Looking Statements,&#8221;
&#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; and any other disclosures contained or referenced therein of information, factors, or risks that are predictive, cautionary, or forward-looking in nature); or (b)&nbsp;as set
forth in the corresponding section or subsection of the disclosure schedule delivered by Parent to the Company immediately prior to the execution of this Agreement (the &#8220;<B><I>Parent Disclosure </I></B><B><I>Schedule</I></B>&#8221;) (it being
agreed that (i)&nbsp;the disclosure of any information in a particular section or subsection of the Parent Disclosure Schedule shall be deemed disclosure of such information with respect to any other section or subsection of this Agreement to which
the relevance of such information is readily apparent on its face and (ii)&nbsp;where applicable, references to Parent in this <U>Section</U><U></U><U>&nbsp;3</U> shall include Parent&#8217;s Subsidiaries), each of Parent and the Merger Sub
represents and warrants to the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_41"></A>3.1 <U>Organization, Standing and Power</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent and Merger Sub is a corporation duly incorporated, validly existing and in good standing under the Laws of Delaware. Each
of Parent and Merger Sub (i)&nbsp;has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (ii)&nbsp;is duly qualified or licensed to do business and is in good
standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (ii), where the failure to be so qualified or
licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. Since the date of its incorporation, Merger Sub has not engaged in any activities other than
activities incident to its formation or in connection with or as contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent has previously made
available to the Company true and complete copies of the Certificate of Incorporation and Bylaws (or comparable organizational documents) of each of Parent and Merger Sub, and the Certificate of Incorporation and Bylaws (or comparable organizational
documents) of each other Subsidiary of Parent, in each case, as amended to the date of this Agreement, and each as so delivered is in full force and effect. None of Parent or Merger Sub is in violation in any material respects of any provision of
its respective Certificate of Incorporation or Bylaws (or comparable organizational documents). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_42"></A>3.2
<U>Capital Stock</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Parent consists of (i) 200,000,000 shares of Parent Common Stock and (ii)
50,000,000 shares of Parent Preferred Stock. As of the close of business on the Reference Date, (i) 5,289,675 shares of Parent Common Stock (excluding treasury shares) were issued and outstanding, (ii)&nbsp;no shares of Parent Common Stock were held
by Parent in its treasury, (iii)&nbsp;no shares of Parent Preferred Stock were issued and outstanding, (iv) 1,515,385 shares of Parent Common Stock were reserved for issuance pursuant to Parent&#8217;s 2021 Equity Incentive Plan (of which (x)
647,955 shares were subject to outstanding options to purchase shares of Parent Common Stock, (y)&nbsp;no shares were subject to outstanding restricted stock awards of Parent and (z) 33,099 shares were subject to outstanding restricted stock units
of Parent), (v) 94,281 shares of Parent Common Stock were reserved for issuance pursuant to Parent&#8217;s 2021 Employee Stock Purchase Plan and (vi) 416,673 shares of Parent Common Stock were reserved for issuance upon the exercise of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. Except as set forth above in this <U>Section</U><U></U><U>&nbsp;3.2(a)</U>, neither Parent nor any of its Subsidiaries has outstanding any bonds, debentures, notes or other obligations having
the right to vote (or convertible into, or exchangeable or exercisable for, securities having the right to vote) with the stockholders of Parent or such Subsidiary on any matter. Except as set forth above in this
<U>Section</U><U></U><U>&nbsp;3.2(a)</U> and except for changes since the close of business on the Reference Date resulting from the exercise of any options as described above, as of the Reference Date, there are no outstanding (A)&nbsp;shares of
capital stock or other voting securities or equity interests of Parent, (B)&nbsp;securities of Parent or any of its Subsidiaries convertible into or exchangeable or exercisable for shares of capital stock of Parent or other voting securities or
equity interests of Parent or its Subsidiaries, (C)&nbsp;stock appreciation rights, &#8220;phantom&#8221; stock rights, performance units, interests in or rights to the ownership or earnings of Parent or its Subsidiaries or other equity-equivalent
or equity-based awards or rights, (D)&nbsp;subscriptions, options, warrants, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
calls, commitments, Contracts or other rights to acquire from Parent or its Subsidiaries, or obligations of Parent or any of its Subsidiaries to issue, any shares of capital stock of Parent or
any of its Subsidiaries, voting securities, equity interests or securities convertible into or exchangeable or exercisable for capital stock or other voting securities or equity interests of Parent or its Subsidiaries or rights or interests
described in the preceding clause (C), or (E)&nbsp;obligations of Parent or any of its Subsidiaries to repurchase, redeem or otherwise acquire any such securities or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or
sold, any such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Section 3.2(b)</U> of the Parent Disclosure Schedule sets forth a true and complete list, as of the
date hereof, of all holders of rights to purchase or receive shares of Parent Common Stock or similar rights (collectively, &#8220;<B><I>Parent Stock Awards</I></B>&#8221; ), indicating as applicable, with respect to each Parent Stock Award then
outstanding, the type of award (e.g., incentive stock option, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock option, restricted stock unit, etc.), the number of shares of Parent Common Stock subject to such Parent Stock Award, the name
of the plan under which such Parent Stock Award was granted, the date of grant, exercise or purchase price, vesting schedule, payment schedule (if different from the vesting schedule) and expiration thereof. Parent has made available to the Company
a true and complete copy of the forms of all award agreements evidencing outstanding Parent Stock Awards. Parent does not sponsor, maintain or administer any employee or director stock option, stock purchase or equity compensation plan or
arrangement other than the Parent Benefit Plans. Parent is under no obligation to issue shares of Parent Common Stock pursuant to any employee or director stock option, stock purchase or equity compensation plan or arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The authorized capital stock of Merger Sub consists of 1,000 shares of common stock, par value $0.001 per share, of which 100 shares are
issued and outstanding, all of which shares are beneficially owned by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The shares of Parent Common Stock to be issued
pursuant to the Merger will be duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) To the knowledge of Parent as of the date of this Agreement and as of the Closing, no &#8220;bad actor&#8221; disqualifying event
described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a &#8220;<B><I>Disqualifying Event</I></B>&#8221;) is applicable to Parent or, to Parent&#8217;s knowledge, any Covered Person, except for a Disqualifying Event as to which Rule <FONT
STYLE="white-space:nowrap">506(d)(2)(ii-iv)</FONT> or (d)(3) of the Securities Act is applicable. &#8220;<B><I>Covered Person</I></B>&#8221; means, with respect to Parent as an &#8220;issuer&#8221; for purposes of Rule 506 promulgated under the
Securities Act, any person listed in the first paragraph of Rule 506(d)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_43"></A>3.3 <U>Subsidiaries</U>.
<U>Section</U><U></U><U>&nbsp;3.3</U> of the Parent Disclosure Schedule sets forth a true and complete list of each Subsidiary of Parent, including its jurisdiction of incorporation or formation. Each of Parent&#8217;s Subsidiaries (a)&nbsp;is an
entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization, (b)&nbsp;has all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its
business as now being conducted and (c)&nbsp;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such
qualification or licensing necessary, except in the case of clause (c), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent
Material Adverse Effect. All outstanding shares of capital stock and other voting securities or equity interests of each such Subsidiary are owned, directly or indirectly, by Parent, free and clear of all Encumbrances other than Permitted
Encumbrances of Parent and its Subsidiaries. Except for the capital stock of, or other equity or voting interests in, its Subsidiaries, Parent does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture
interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any
loan, capital contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person. Neither Parent nor any of its Subsidiaries has, at any time, been a general partner of, or has otherwise
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_44"></A>3.4 <U>Authority</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent and Merger Sub has all necessary corporate power and authority to execute, deliver and perform its obligations under this
Agreement and, subject to the receipt of the Required Parent Stockholder Vote, to consummate the Merger and the other Contemplated Transactions. The execution, delivery and performance of this Agreement by Parent and Merger Sub and the consummation
by Parent and Merger Sub of the Merger and the other Contemplated Transactions have been duly authorized by all necessary corporate action on the part of Parent and Merger Sub and no other corporate proceedings on the part of Parent or Merger Sub
are necessary to approve this Agreement or to consummate the Merger and the other Contemplated Transactions subject to (i)&nbsp;with respect to Parent, receipt of the Required Parent Stockholder Vote and (ii)&nbsp;with respect to Merger Sub, the
adoption of this Agreement by Parent in its capacity as sole stockholder of Merger Sub. This Agreement has been duly executed and delivered by Parent and Merger Sub and, assuming the due authorization, execution and delivery by the Company,
constitutes a valid and binding obligation of each of Parent and Merger Sub, enforceable against each of Parent and Merger Sub in accordance with its terms (subject to the Enforceability Exceptions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Parent Board, at a meeting duly called and held at which all directors of Parent were present, duly adopted resolutions
(i)&nbsp;determining that the terms of this Agreement, the Merger and the other Contemplated Transactions and thereby are fair to, advisable and in the best interests of Parent and its stockholders, (ii)&nbsp;approving and declaring advisable this
Agreement and the Contemplated Transactions, including the Merger and the issuance of shares of Parent Common Stock to the stockholders of the Company pursuant to the terms of this Agreement, and (iii)&nbsp;determining to recommend, upon the terms
and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Parent Stockholder Matters, which resolutions have not been subsequently rescinded, modified or withdrawn in any way. The Merger Sub Board
(by unanimous written consent) has: (x)&nbsp;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Merger Sub and its sole stockholder, (y)&nbsp;deemed advisable and approved this Agreement and the
Contemplated Transactions and (z)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub vote to adopt this Agreement and thereby approve the Contemplated
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The affirmative vote of a majority of the votes cast is the only vote of the holders of any class or series of Parent
Capital Stock necessary to approve the Parent Stockholder Matters (the &#8220;<B><I>Required Parent Stockholder Vote</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_45"></A>3.5 <U>No Conflict; Consents and Approvals</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to obtaining the Required Parent Stockholder Vote, the execution,
delivery and performance of this Agreement by each of Parent and Merger Sub does not, and the consummation of the Merger and the other Contemplated Transactions and compliance by each of Parent and Merger Sub with the provisions hereof will not,
contravene, conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any
obligation or to the loss of a benefit under, or result in the creation of any Encumbrance in or upon any of the properties, assets or rights of Parent or Merger Sub under, or give rise to any increased, additional, accelerated or guaranteed rights
or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&nbsp;the Certificate of Incorporation or Bylaws of Parent or Merger Sub and (ii)&nbsp;any Parent Material Contract to which Parent or
Merger Sub is a party by which Parent, Merger Sub or any of their respective properties or assets may be bound, or (iii)&nbsp;subject to the governmental filings and other matters referred to in <U>Section</U><U></U><U>&nbsp;3.5(b)</U>, any material
Law or any rule or regulation of Nasdaq applicable to Parent or Merger Sub or by which Parent, Merger Sub or any of their respective properties or assets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be bound, except as, in the case of clauses (ii)&nbsp;and (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental
Body is required by or with respect to Parent or Merger Sub in connection with the execution, delivery and performance of this Agreement by Parent or Merger Sub or the consummation by Parent or Merger Sub of the Merger and the other Contemplated
Transactions or compliance with the provisions hereof, except for (i)&nbsp;the filing with the SEC of such reports under Section&nbsp;13(a) or 15(d) of the Exchange Act, as may be required in connection with this Agreement and the Contemplated
Transactions, (ii)&nbsp;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws
or Nasdaq, (iii)&nbsp;the filing of the Certificate of Merger with the Delaware Secretary of State as required by the DGCL, (iv)&nbsp;as may be required under applicable Antitrust Laws and (v)&nbsp;such other consents, approvals, orders,
authorizations, registrations, declarations, filings or notices, the failure of which to be obtained or made, individual or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Parent Board and the Merger Sub board have taken and will take all actions necessary to ensure that the restrictions applicable to
business combinations contained in Section&nbsp;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or
similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_46"></A>3.6 <U>SEC Reports; Financial Statements</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent has filed with or furnished to the SEC on a timely basis true and complete
copies of all forms, reports, schedules, statements and other documents required to be filed with or furnished to the SEC by Parent since January&nbsp;1, 2023 (all such documents, together with all exhibits and schedules to the foregoing materials
and all information incorporated therein by reference, the &#8220;<B><I>Parent SEC Documents</I></B>&#8221;). As of their respective filing dates (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such
filing), the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act, as the case may be, including, in each case, the rules and regulations
promulgated thereunder, and none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. The certifications and statements required by (i)&nbsp;Rule <FONT STYLE="white-space:nowrap">13a-14</FONT> under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section 906 of the
Sarbanes-Oxley Act) relating to the Parent SEC Documents (collectively, the &#8220;<B><I>Certifications</I></B>&#8221;) are accurate and complete and comply as to form and content with all applicable Laws. As used in this
<U>Section</U><U></U><U>&nbsp;3.6</U>, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC
Documents (i)&nbsp;were prepared in a manner consistent with the books and records of Parent and its Subsidiary, (ii)&nbsp;were prepared in accordance with GAAP (except, in the case of unaudited statements, as permitted by Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> of the SEC) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto), (iii) complied as to form in all material respects with applicable accounting
requirements and the published rules and regulations of the SEC with respect thereto and (iv)&nbsp;fairly present in all material respects the consolidated financial position of Parent and its Subsidiaries as of the dates thereof and their
respective consolidated results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments that were not, or are
not expected to be, material in amount), all in accordance with GAAP and the applicable rules and regulations promulgated by the SEC. Since January&nbsp;1, 2023, Parent has not made any change in the accounting practices or policies applied in the
preparation of its financial statements, except as required by GAAP, SEC rule </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or policy or applicable Law. The books and records of Parent and its Subsidiaries have been, and are being, maintained in all material respects in accordance with GAAP (to the extent applicable)
and any other applicable legal and accounting requirements and reflect only actual transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent has established and
maintains disclosure controls and procedures (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> under the Exchange Act). Such disclosure controls and procedures are designed
to ensure that information relating to Parent, including its consolidated Subsidiaries, required to be disclosed in Parent&#8217;s periodic and current reports under the Exchange Act, is made known to Parent&#8217;s chief executive officer and its
chief financial officer by others within those entities to allow timely decisions regarding required disclosures as required under the Exchange Act. The chief executive officer and chief financial officer of Parent have evaluated the effectiveness
of Parent&#8217;s disclosure controls and procedures and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> or any amendment thereto, its conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by such report or amendment based on such evaluation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Parent and its Subsidiaries have established and maintain a system of internal control over financial reporting (as defined in Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> under the Exchange Act) which is effective in providing reasonable assurance regarding the reliability of Parent&#8217;s financial reporting and the
preparation of Parent&#8217;s financial statements for external purposes in accordance with GAAP. Parent has disclosed, based on its most recent evaluation of Parent&#8217;s internal control over financial reporting prior to the date hereof, to
Parent&#8217;s auditors and audit committee (i)&nbsp;any significant deficiencies and material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting which are reasonably likely to adversely affect
Parent&#8217;s ability to record, process, summarize and report financial information and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s internal control over
financial reporting. A true, correct and complete summary of any such disclosures made by management to Parent&#8217;s auditors and audit committee is set forth as <U>Section</U><U></U><U>&nbsp;3.6(d)</U> of Parent Disclosure Schedule.
Parent&#8217;s internal control over financial reporting is effective at the reasonable assurance level and Parent has not identified any material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Since January&nbsp;1, 2023 through the date of this Agreement, (i)&nbsp;neither Parent nor any of its Subsidiaries nor, to the
knowledge of Parent, any director, officer, employee, auditor, accountant or representative of the Parent or any of its Subsidiaries has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim,
whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of Parent or any of its Subsidiaries or their respective internal accounting controls, including any material complaint, allegation,
assertion or claim that Parent or any of its Subsidiaries has engaged in questionable accounting or auditing practices and (ii)&nbsp;no attorney representing Parent or any of its Subsidiaries, whether or not employed by Parent or any of its
Subsidiaries, has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation by Parent or any of its Subsidiaries or any of their respective officers, directors, employees or agents to the Parent
Board or any committee thereof or to any director or officer of Parent or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) As of the date of this Agreement,
there are no outstanding or unresolved comments in the comment letters received from the SEC staff with respect to the Parent SEC Documents. To the knowledge of Parent, as of the date of this Agreement, none of the Parent SEC Documents is subject to
ongoing review or outstanding SEC comment or investigation. As of the date of this Agreement, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the
delisting or maintenance of listing of the Parent Common Stock on Nasdaq that has not previously been disclosed in the Parent SEC Documents.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Neither Parent nor any of its Subsidiaries is a party to, or has any commitment to become a party to, any joint venture, <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet partnership or any similar Contract (including any Contract or arrangement relating to any transaction or relationship between or among Parent and any of its Subsidiaries, on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the one hand, and any unconsolidated Affiliate, including any structured finance, special-purpose or limited-purpose entity or Person, on the other hand, or any &#8220;off balance sheet
arrangements&#8221; (as defined in Item 303(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Exchange Act)), where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction
involving, or material liabilities of, Parent or any of its Subsidiaries in Parent&#8217;s or such Subsidiary&#8217;s published financial statements or other Parent SEC Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Parent is in compliance in all material respects with (i)&nbsp;the provisions of the Sarbanes-Oxley Act and (ii)&nbsp;the rules and
regulations of Nasdaq, in each case, that are applicable to Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) No Subsidiary of Parent is required to file any form, report,
schedule, statement or other document with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Parent has not been and is not currently a &#8220;shell company&#8221; as
defined under <FONT STYLE="white-space:nowrap">Section&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Parent is, and since its first date of
listing on Nasdaq has been, in compliance in all material respects with the applicable current listing and governance rules and regulations of Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) Parent&#8217;s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i)&nbsp;a registered public
accounting firm (as defined in Section&nbsp;2(a)(12) of the Sarbanes-Oxley Act), (ii)&nbsp;to the knowledge of Parent, &#8220;independent&#8221; with respect to Parent within the meaning of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT>
under the Exchange Act and (iii)&nbsp;to the knowledge of Parent, in compliance with subsections (g)&nbsp;through (l)&nbsp;of Section&nbsp;10A of the Exchange Act and the rules&nbsp;and regulations promulgated by the SEC and the Public Company
Accounting Oversight Board thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_47"></A>3.7 <U>No Undisclosed Liabilities</U>. As of the date hereof,
neither Parent nor any of its Subsidiaries has any liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected
on a balance sheet under GAAP, except (a)&nbsp;to the extent accrued or reserved against in the audited consolidated balance sheet of Parent and its Subsidiaries as at December&nbsp;31, 2024 included in the Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed by Parent with the SEC on March&nbsp;13, 2025 (without giving effect to any amendment thereto filed on or after the date hereof)&nbsp;(b) for liabilities and obligations incurred by Parent or its
Subsidiaries in the Ordinary Course of Business since the date of the Parent Balance Sheet, (c)&nbsp;liabilities and obligations related to the performance of obligations of Parent under Parent Material Contracts, (d)&nbsp;liabilities and
obligations incurred in connection with the Contemplated Transactions and (e)&nbsp;liabilities and obligations that are not material to Parent and its Subsidiaries, taken as a whole. Parent has no outstanding or accrued financial liability of any
kind arising from or in connection with the Contracts set forth on <U>Section</U><U></U><U>&nbsp;5.12(b)</U> of the Parent Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_49"></A>3.8 <U>Absence of Certain Changes or Events</U>. From September&nbsp;30, 2025 to the date hereof, except in
connection with the execution of this Agreement and the consummation of the Contemplated Transactions, (x)&nbsp;Parent and its Subsidiaries have conducted their business only in the Ordinary Course of Business; (y)&nbsp;there has not been any
change, event or development or prospective change, event or development that, individually or in the aggregate, has had or would reasonably be expected to have a Parent Material Adverse Effect; and (z)&nbsp;neither Parent nor any of its
Subsidiaries have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) (i) declared, set aside or paid any dividends on, or made any other distributions (whether in cash, stock or
property) in respect of, any of its capital stock or other equity interests, except for dividends by a wholly-owned Subsidiary of Parent to its parent, (ii)&nbsp;purchased, redeemed or otherwise acquired shares of capital stock or other equity
interests of Parent or its Subsidiary or any options, warrants, or rights to acquire any such shares or other equity interests, or (iii)&nbsp;split, combined, reclassified or otherwise amended the terms of any of its capital stock or other equity
interests or issued or authorized the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) amended or otherwise changed, or authorized or proposed to amend or otherwise change,
its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or similar organizational documents) except as required to give effect to Contemplated Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) adopted or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization or
effected or been a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated
Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) formed any Subsidiary or acquired any equity interest or other interest in any other entity or entered into a joint
venture with any other entity; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) (i) lent money to any Person (other than advances of reasonable business expenses to cover employees
and service providers in the Ordinary Course of Business), (ii) incurred or guaranteed any indebtedness for borrowed money, or (iii)&nbsp;guaranteed any debt securities of others; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Other than as required by applicable Law or the terms of any Parent Benefit Plan as in effect on the date of this Agreement:
(A)&nbsp;adopted, terminated, established or entered into any Parent Benefit Plan; (B)&nbsp;caused or permitted any Parent Benefit Plan to be amended in any material respect; (C)&nbsp;paid any material bonus or distributed any profit-sharing account
balances or similar payment to, or increased the amount of the wages, salary, commissions, benefits or other compensation or remuneration payable to, any of its directors, officers, employees, consultants or independent contractors; (D)&nbsp;awarded
any new or increased or amended any existing severance, retention or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> benefits offered to any current, former or new employees, directors, consultants
or other Persons or (E)&nbsp;hired, terminated or gave notice of termination (other than for cause) to, any officer, employee, consultant or independent contractor; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) entered into any material transaction in connection with the Contemplated Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) acquired any material asset or sold, leased or otherwise irrevocably disposed of any of its material assets or properties, or granted any
Encumbrance (other than Permitted Encumbrances) with respect to such assets or properties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) engaged in, or taken active steps to
prepare for, manufacturing or commercial operations with respect to any product or product candidate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) sold, assigned, transferred,
licensed, sublicensed or otherwise disposed of any material Intellectual Property owned or purported to be owned by, assigned to, or exclusively licensed by, Parent or its Subsidiaries, except for the grant of
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to such Intellectual Property in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k)
other than as required by Law or GAAP, taken any action to change accounting policies or procedures; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) changed its financial or Tax
accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable Law, or revalued any of its material assets; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) agreed, resolved or committed to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_50"></A>3.9 <U>Litigation</U>. As of the date hereof, there is no Legal Proceeding (or basis therefor) pending or, to
the knowledge of Parent, threatened against Parent or any of its Subsidiaries, any of their respective properties or assets, or any present or former officer, director or employee of Parent or any of its Subsidiaries in such individual&#8217;s
capacity as such. Neither Parent nor any of its Subsidiaries nor any of their respective properties or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets is subject to any outstanding judgment, order, injunction, rule or decree of any Governmental Body. There is no Legal Proceeding pending or, to the knowledge of Parent, threatened seeking
to prevent, hinder, modify, delay or challenge the Merger or any of the other Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_51"></A>3.10 <U>Compliance with Laws</U>. Parent and each of its Subsidiaries are, and since January&nbsp;1, 2023
have been, in compliance in all material respects with all Laws applicable to their businesses, operations, properties or assets. None of Parent or any of its Subsidiaries has received, since January&nbsp;1, 2023, a notice or other written
communication alleging or relating to a possible material violation of any Law applicable to their businesses, operations, properties, assets or Parent Products (as defined below). Parent and each of its Subsidiaries have in effect all material
Permits of all Governmental Bodies necessary for them to own, lease or operate their properties and assets and to carry on their businesses and operations as now conducted, and there has occurred no material violation of, material default (with or
without notice or lapse of time or both) or other event that would give others any right of revocation, <FONT STYLE="white-space:nowrap">non-renewal,</FONT> adverse modification or cancellation of, with or without notice or lapse of time or both,
any such Permit, nor would any such revocation, <FONT STYLE="white-space:nowrap">non-renewal,</FONT> adverse modification or cancellation result from the consummation of the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_52"></A>3.11 <U>Health Care Regulatory Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent and, to the knowledge of Parent, each of its directors, officers, employees, agents (while acting in such capacity), contract
manufacturers, contract research organizations and clinical investigators is and, since January&nbsp;1, 2023 has been, in material compliance with all Health Care Laws to the extent applicable to Parent or any of its products or activities. Parent
has not engaged in any voluntary disclosure or self-disclosure to any Governmental Body concerning any alleged, potential or actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any applicable Health Care Laws, and to the
Parent&#8217;s knowledge no such self-disclosure to any Governmental Body is warranted. To the knowledge of Parent, there are no other facts or circumstances that reasonably would be expected to give rise to any material liability under any Health
Care Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent is not party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or
similar agreements with or imposed by any Governmental Body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) All applications, notifications, submissions, information, claims and
reports submitted in connection with any and all requests for a Permit from the FDA or other Governmental Body relating to products that are regulated as drugs, biologics, or other medical products under Health Care Laws, including the drug and
biological candidates, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed and/or distributed by Parent or any of its Subsidiaries (&#8220;<B><I>Parent Products</I></B>&#8221;), including, without
limitation, investigational new drug applications, when submitted to the FDA or other Governmental Body were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections
or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Body. Parent does not have knowledge of any facts or circumstances that would be reasonably likely to lead to the
revocation, suspension, limitation, or cancellation of a material Permit required under Health Care Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) All preclinical studies
and clinical trials conducted by or, to the knowledge of Parent, on behalf of Parent have been since January&nbsp;1, 2023, and if still pending are being, conducted in material compliance with research protocols and all applicable Health Care Laws.
To Parent&#8217;s knowledge, no clinical trial conducted by or on behalf of Parent has been conducted using any clinical investigators who have been disqualified, debarred or excluded from healthcare programs. Since January&nbsp;1, 2023, no clinical
trial conducted by or on behalf of Parent or its Subsidiaries have been terminated or suspended prior to completion, and no clinical investigator who has participated or is participating in, or institutional review board that has or has had
jurisdiction over, a clinical trial conducted by or on behalf of Parent has placed a partial or full clinical hold order on, or otherwise terminated, delayed or suspended, such a clinical trial at a clinical research site based on an actual or
alleged lack of safety or efficacy of any Parent Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All manufacturing operations conducted by or, to the knowledge of Parent, for the
benefit of Parent have been and are being conducted in material compliance with all Permits and all applicable Health Care Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)
Parent has not received from any Governmental Body any written communication that relates to an alleged material violation of any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing,
enforcement, investigation, arbitration, import detention or refusal, FDA Warning Letter or Untitled Letter, or any similar action by a Governmental Body relating to any Health Care Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the
Parent Products required or requested by a Governmental Body, or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Parent Products, or any adverse experiences relating to the Parent Products that
have been reported to FDA or another Governmental Body (&#8220;<B><I>Parent Safety Notices</I></B>&#8221;), and, to the knowledge of Parent, there are no facts or circumstances that reasonably would be expected to give rise to a Parent Safety
Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Neither Parent, nor, to the knowledge of Parent, any officer, employee or agent of Parent has made an untrue statement of a
material fact or fraudulent or misleading statement to a Governmental Body, failed to disclose a material fact required to be disclosed to a Governmental Body, or committed an act, made a statement, or failed to make a statement that would
reasonably be expected to provide a basis for the FDA to invoke its FDA Ethics Policy. Neither the Parent, nor, to the knowledge of the Parent, any officer, employee or agent of the Parent is or has been under investigation resulting from any
allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Body by
Parent have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices has not had and would not reasonably be expected to have, individually or in the aggregate, a
Parent Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Neither Parent nor, to the knowledge of Parent, any officer, employee or agent of Parent has been convicted of any crime or engaged in
any conduct that has resulted, or would reasonably be expected to result, in listing on the General Services Administrative System for Award Management or other published list of parties excluded from federal procurement programs and <FONT
STYLE="white-space:nowrap">non-procurement</FONT> programs or in debarment under applicable Law, or including, without limitation, 21 U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7,</FONT> or any
other statutory provision or similar law applicable in other jurisdictions in which the Parent Products are sold or intended to be sold. Neither Parent nor, to the knowledge of Parent, any officer, employee or agent of Parent, has been excluded from
participation in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section&nbsp;1128 of the Social Security Act of
1935 , or any similar Health Care Law or program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Parent is not, and has not been, a &#8220;business associate,&#8221;
&#8220;covered entity,&#8221; or &#8220;subcontractor&#8221; under HIPAA as those terms are defined in 42 C.F.R. &#167; 160.103 and, since January&nbsp;1, 2023, has been in material compliance with any Privacy Laws applicable to health information,
including HIPAA, in Parent&#8217;s possession to the extent applicable to Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_53"></A>3.12 <U>Benefit
Plans</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section 3.12(a)</U> of the Parent Disclosure Schedule contains a true and complete list of each Parent Benefit Plan
(other than form equity award agreements and awards made pursuant to such form(s), which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
form(s) shall have been provided to the Company). For purposes of this Agreement, &#8220;<B><I>Parent Benefit Plan</I></B>&#8221; means each &#8220;employee benefit plan&#8221; (within the
meaning of section 3(3) of ERISA, whether or not subject to ERISA), and each stock purchase, stock option, phantom stock or other equity-based plan or award, severance, employment,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control,</FONT></FONT> fringe benefit, bonus, incentive, deferred compensation, supplemental retirement, health, life, or disability insurance, dependent care and each other
employee benefit and compensation plan, agreement, program, policy or other arrangement, whether or not subject to ERISA, whether formal or informal, written or oral, legally binding or not, under which any current or former employee, director or
individual consultant of Parent or its Subsidiaries (or any of their dependents) has any present or future right to compensation or benefits or Parent or any of its Subsidiaries sponsors or maintains, is making contributions to or has any present or
future liability or obligation (contingent or otherwise) or with respect to which it is otherwise bound. Parent has provided or made available to the Company a current, accurate and complete copy of each Parent Benefit Plan, or if such Parent
Benefit Plan is not in written form, a written summary of all of the material terms of such Parent Benefit Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Neither Parent, its
Subsidiaries or any member of their Controlled Group (defined as any organization which is, or was at the applicable time, a member of a controlled, affiliated or otherwise related group of entities within the meaning of Code Section&nbsp;414(b),
(c), (m) or (o)) has ever sponsored, maintained, contributed to or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&nbsp;a &#8220;multiemployer plan&#8221; (within the meaning of ERISA section
3(37)), (ii) a Pension Plan that is subject to Title IV of ERISA or Section&nbsp;412 of the Code, or (iii)&nbsp;a Pension Plan which is a &#8220;multiple employer plan&#8221; as defined in Section&nbsp;413 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) With respect to the Parent Benefit Plans: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) each Parent Benefit Plan complies in all material respects with its terms and with the applicable provisions of ERISA and the Code and all
other applicable legal requirements; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) each Parent Benefit Plan intended to be qualified under Section&nbsp;401(a) of the Code has
received a favorable determination, advisory and/or opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of the Parent since the date of such letter that would reasonably be expected to result
in the loss of the sponsor&#8217;s ability to rely upon such letter or of the qualified status of such Parent Benefit Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) there
is no material Legal Proceeding (including any investigation, audit or other administrative proceeding) by the Department of Labor, the PBGC, the IRS or any other Governmental Body or by any plan participant or beneficiary pending, or to the
knowledge of Parent, threatened, relating to the Parent Benefit Plans (other than routine claims for benefits); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) none of the Parent
Benefit Plans currently provides or represents any liability to provide post-termination or retiree welfare benefits to any person for any reason, except as may be required by COBRA, and none of Parent, its Subsidiaries or any members of its
Controlled Group has any liability to provide post-termination or retiree welfare benefits to any person or ever represented, promised or contracted to any employee or former employee of Parent (either individually or to Parent employees as a group)
or any other person that such employee(s) or other person would be provided with post-termination or retiree welfare benefits, except to the extent required by statute or except with respect to a contractual obligation to reimburse any premiums such
person may pay in order to obtain health coverage under COBRA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) each Parent Benefit Plan is subject exclusively to United States Law;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) the execution and delivery of this Agreement and the consummation of the Merger will not, either alone or in combination with
any other event, (A)&nbsp;entitle any current or former employee, officer, director or individual consultant of Parent or any Subsidiary to severance pay or any other termination payment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other compensation or benefits (B)&nbsp;accelerate the time of payment or vesting, or increase the amount of or otherwise enhance any benefit due to any such employee, officer, director or
consultant (C)&nbsp;result in a requirement to fund or set aside assets with respect to any Parent Benefit Plan or (D)&nbsp;restrict any rights of Parent to amend or terminate any Parent Benefit Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Neither Parent nor any Subsidiary is a party to any agreement, Contract, arrangement or plan (including any Parent Benefit Plan) that may
reasonably be expected to result, separately or in the aggregate, in connection with the Contemplated Transactions (either alone or in combination with any other events), in the payment of any &#8220;parachute payments&#8221; within the meaning of
Section&nbsp;280G of the Code. There is no agreement, plan or other arrangement to which any of Parent or any Subsidiary is a party or by which any of them is otherwise bound to compensate any person in respect of Taxes or other liabilities incurred
with respect to Section&nbsp;409A or 4999 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_54"></A>3.13 <U>Labor and Employment Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent and its Subsidiaries are and since January&nbsp;1, 2023, have been in compliance in all material respects with all applicable Laws
relating to labor and employment, including those relating to employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits,
<FONT STYLE="white-space:nowrap">non-discrimination</FONT> in employment, workers&#8217; compensation, unemployment compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, information privacy
and security, and continuation coverage with respect to group health plans. During the preceding three years, there has not been, and as of the date of this Agreement there is not pending or, to the knowledge of Parent, threatened, any labor
dispute, work stoppage, labor strike or lockout against Parent or any of its Subsidiaries by employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No employee of Parent or any
of its Subsidiaries is covered by an effective or pending collective bargaining agreement or similar labor agreement. To the knowledge of Parent, there has not been any activity on behalf of any labor union, labor organization or similar employee
group to organize any employees of Parent or any of its Subsidiaries. There are no (i)&nbsp;unfair labor practice charges or complaints against Parent or any of its Subsidiaries pending before the National Labor Relations Board or any other labor
relations tribunal or authority and, to the knowledge of Parent, no such representations, claims or petitions are threatened, (ii)&nbsp;representation claims or petitions pending before the National Labor Relations Board or any other labor relations
tribunal or authority or (iii)&nbsp;grievances or pending arbitration proceedings against Parent or any of its Subsidiaries that arose out of or under any collective bargaining agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) During the preceding three years, (i)&nbsp;neither Parent nor any Subsidiary has effectuated a &#8220;plant closing&#8221; (as defined in
the WARN Act) affecting any site of employment or one or more facilities or operating units within any site of employment or facility, (ii)&nbsp;there has not occurred a &#8220;mass layoff&#8221; (as defined in the WARN Act) in connection with
Parent or any Subsidiary affecting any site of employment or one or more facilities or operating units within any site of employment or facility and (iii)&nbsp;neither Parent nor any Subsidiary has engaged in layoffs or employment terminations
sufficient in number to trigger application of any similar state, local or foreign law. The Parent and its Subsidiaries currently properly classify and for the past three (3)&nbsp;years have classified its and their employees as exempt or nonexempt
in accordance with applicable overtime laws, and no person treated as an independent contractor or consultant by Parent or any Subsidiary within the past three (3)&nbsp;years should have been classified as an employee under applicable Law, except
where such action would not, individually or in the aggregate, result in Parent incurring a material liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) With respect to any
current or former employee, officer, consultant or other service provider of Parent, there are no Legal Proceedings against Parent or any of its Subsidiaries pending, or to Parent&#8217;s knowledge, threatened to be brought or filed, in connection
with the employment or engagement of any current or former employee, officer, consultant or other service provider of Parent, including, without limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay,
employment classification or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other employment-related matter arising under applicable Laws, except where such action would not, individually or in the aggregate, result in Parent incurring a material liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Except with respect to any Parent Benefit Plan (which subject is addressed in <U>Section</U><U></U><U>&nbsp;3.12</U> above), the
execution of this Agreement and the consummation of the transactions set forth in or contemplated by this Agreement will not result in any breach or violation of, or cause any payment to be made under, any applicable Laws respecting labor and
employment or any collective bargaining agreement to which Parent or any of its Subsidiaries is a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Since January&nbsp;1, 2023,
(i) no allegations of workplace sexual harassment, discrimination or other material misconduct have been made, initiated, filed or, to the knowledge of Parent, threatened against Parent, any of its Subsidiaries or any of their respective current or
former directors, officers or senior-level management employees, (ii)&nbsp;to the knowledge of Parent, no incidents of any such workplace sexual harassment, discrimination or other material misconduct have occurred, and (iii)&nbsp;Parent has not
entered into any settlement agreement related to allegations of sexual harassment, discrimination or other material misconduct by any of its directors, officers or employees described in clause (i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_55"></A>3.14 <U>Environmental Matters</U>. Except as, individually or in the aggregate, has not had and would not
reasonably be expected to have a Parent Material Adverse Effect, (i)&nbsp;Parent and each of its Subsidiaries have conducted their respective businesses in compliance with all, and have not violated any, applicable Environmental Laws;
(ii)&nbsp;Parent and its Subsidiaries have obtained all Permits of all Governmental Bodies and any other Person that are required under any Environmental Law; (iii)&nbsp;there has been no release of any Hazardous Substance by Parent or any of its
Subsidiaries or any other Person in any manner that has given or would reasonably be expected to give rise to any remedial or investigative obligation, corrective action requirement or liability of Parent or any of its Subsidiaries under applicable
Environmental Laws; (iv)&nbsp;neither Parent nor any of its Subsidiaries has received any claims, notices, demand letters or requests for information (except for such claims, notices, demand letters or requests for information the subject matter of
which has been resolved prior to the date of this Agreement) from any federal, state, local, foreign or provincial Governmental Body or any other Person asserting that Parent or any of its Subsidiaries is in violation of, or liable under, any
Environmental Law; (v)&nbsp;no Hazardous Substance has been disposed of, arranged to be disposed of, released or transported in violation of any applicable Environmental Law, or in a manner that has given rise to, or that would reasonably be
expected to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties or facilities owned or operated by Parent or any of its Subsidiaries or as a result of any operations or
activities of Parent or any of its Subsidiaries at any location and, to the knowledge of Parent, Hazardous Substances are not otherwise present at or about any such properties or facilities in amount or condition that has resulted in or would
reasonably be expected to result in liability to Parent or any of its Subsidiaries under any Environmental Law; and (vi)&nbsp;neither Parent, its Subsidiaries nor any of their respective properties or facilities are subject to, or are threatened to
become subject to, any liabilities relating to any suit, settlement, court order, administrative order, regulatory requirement, judgment or claim asserted or arising under any Environmental Law or any agreement relating to environmental liabilities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_56"></A>3.15 <U>Taxes</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent and each of its Subsidiaries has (i)&nbsp;timely filed all income and other material Tax Returns required to be filed by or on
behalf of them (taking into account any applicable extensions thereof) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&nbsp;timely paid in full (or caused to be timely paid in full) all material Taxes that
are due and payable, whether or not such Taxes were shown as due on such Tax Returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All material Taxes not yet due and payable by
Parent or any of its Subsidiaries as of the date of the Parent Balance Sheet have been, in all material respects, properly accrued in accordance with GAAP on the financial statements (including the related notes and schedules thereto) included (or
incorporated by reference) in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Parent SEC Documents, and such financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents reflect an adequate
reserve (in accordance with GAAP) for all material Taxes accrued but unpaid by Parent and each of its Subsidiaries through the date of such financial statements. Since the date of the Parent Balance Sheet, neither Parent nor any of its Subsidiaries
has incurred, individually or in the aggregate, any liability for Taxes outside the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Neither Parent nor
any of its Subsidiaries has executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any material amount of Tax, in each case that has not since expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) No material Tax Actions with respect to Taxes or any Tax Return of Parent or any of its Subsidiaries are presently in progress or have
been asserted, threatened or proposed in writing, other than any such assertion, threat or proposal that has been settled or withdrawn. No deficiencies or claims for a material amount of Taxes have been claimed, proposed, assessed or asserted in
writing against Parent or any of its Subsidiaries by a Governmental Body, other than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Parent and each of its Subsidiaries have timely withheld or deducted all material Taxes required to have been withheld or deducted from
payments made (or deemed made) to their employees, independent contractors, creditors, shareholders and other third parties and, to the extent required, such material Taxes have been timely paid to the relevant Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Neither Parent nor any of its Subsidiaries has engaged in a &#8220;listed transaction&#8221; as set forth in Treasury Regulations &#167; <FONT
STYLE="white-space:nowrap">1.6011-4(b).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Neither Parent nor any of its Subsidiaries (i)&nbsp;is a party to or bound by, nor
has any liability pursuant to, any Tax sharing, allocation, indemnification or similar agreement or obligation other than any Ordinary Course Agreement; (ii)&nbsp;is or has ever been a member of a group (other than a group the common parent of which
is Parent) filing a consolidated, combined, affiliated, unitary or similar income Tax Return; (iii)&nbsp;has any liability for the Taxes of any Person (other than Parent and its Subsidiaries) pursuant to Treasury Regulations &#167; <FONT
STYLE="white-space:nowrap">1.1502-6</FONT> (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law) as a transferee or successor, by Contract (other than Ordinary Course Agreements), or otherwise by
operation of Law; and (iv)&nbsp;is or has ever been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of having a permanent establishment, an office or fixed place of business, in any country other than the country in
which it was or is organized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) No private-letter rulings, technical advice memoranda, or similar material agreements or rulings
related to Taxes have been requested in writing, entered into or issued by any taxing authority with respect to Parent or any of its Subsidiaries which rulings remain in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Neither Parent nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of
deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&nbsp;a change in method of accounting requested or initiated, or use of improper method of accounting, on or prior to the
Closing Date, (ii)&nbsp;a &#8220;closing agreement&#8221; as described in Section&nbsp;7121 of the Code (or any similar provision of state, local or foreign Tax Law) executed on or prior to the Closing Date, (iii)&nbsp;an installment sale or
open-transaction disposition made on or prior to the Closing Date, (iv)&nbsp;any deferred intercompany gain or excess-loss account described in Treasury Regulations under Section&nbsp;1502 of the Code (or any corresponding or similar provision of
state, local or foreign income Tax Law), (v) an election under Section&nbsp;965 of the Code, or (vi)&nbsp;the application of Section&nbsp;951 or 951A of the Code with respect to income earned or recognized or payments received prior to the Closing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) There are no Encumbrances for Taxes upon any of the assets of Parent or any of its Subsidiaries other than Encumbrances described in
clause (i)&nbsp;of the definition of Permitted Encumbrances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Neither Parent nor any of its Subsidiaries has distributed stock of another Person or
has had its stock distributed by another Person, in a transaction (or series of transactions) that was purported or intended to be governed in whole or in part by Section&nbsp;355 or 361 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) Neither Parent nor any of its Subsidiaries has been a United States real property holding corporation, as defined in
Section&nbsp;897(c)(2) of the Code, during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) No material
claim has been made in writing by any Governmental Body in a jurisdiction where Parent or any of its Subsidiaries has not paid a specific Tax or filed a specific Tax Return that Parent or any of its Subsidiaries is or may be required to pay such Tax
or file such Tax Return by such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) <U>Section 3.15(n)</U> of the Parent Disclosure Schedule sets forth the entity
classification of Parent and each of its Subsidiaries for U.S. federal income tax purposes. Neither Parent nor any of its Subsidiaries has made an election or taken any other action to change its federal and state income tax classification from such
classification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) To Parent&#8217;s knowledge, neither Parent nor any of its Subsidiaries has been, is, or immediately prior to the
Effective Time will be, treated as an &#8220;investment company&#8221; within the meaning of Section&nbsp;368(a)(2)(F) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p)
Neither Parent nor any of its Subsidiaries has taken any action (or agreed to take any action) nor does it know of any fact or circumstance that would reasonably be expected to prevent or impede the Merger from qualifying for the Intended Tax
Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_57"></A>3.16 <U>Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section 3.16(a)</U> of the Parent Disclosure Schedule lists the following Contracts (other than Parent Benefit Plans)&nbsp;(a) to
which Parent or any of its Subsidiaries is a party; (b)&nbsp;by which Parent or its Subsidiaries or any Intellectual Property owned or purported to be owned by, assigned to, or exclusively licensed by, Parent or its Subsidiaries or any other asset
of Parent or its Subsidiaries are or may become bound or under which Parent or its Subsidiaries have, or may become subject to, any obligation; or (c)&nbsp;under which Parent or its Subsidiaries have or may acquire any right or interest, in effect
as of the date of this Agreement (all such Contracts, &#8220;<B><I>Parent Material Contracts</I></B>&#8221;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) each Contract relating
to the disposition or acquisition of material assets or any ownership interest in any entity, except as contemplated hereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) each
Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit or creating any material Encumbrances with respect to
any assets of Parent or its Subsidiaries or any loans or debt obligations with officers or directors of Parent or its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) each Contract requiring payment by or to Parent or its Subsidiaries after the date of this Agreement in excess of $125,000 in the
aggregate in the current calendar year or any future calendar year pursuant to its express terms relating to: (A)&nbsp;any agreement under which a third party is granted rights related to the sale or distribution of any product of Parent or its
Subsidiaries (identifying any that contain exclusivity provisions); (B) any agreement (other than a Parent Benefit Plan) involving provision of services with respect to any <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development
activities of Parent or its Subsidiaries; (C)&nbsp;any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Parent or its Subsidiaries have continuing obligations
to develop or market any product, technology or service, or any agreement pursuant to which Parent or its Subsidiaries have continuing obligations to develop any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Intellectual Property that will not be owned, in whole or in part, by Parent or its Subsidiaries; or (D)&nbsp;any Contract under which any third party provides any services relating to the
manufacture (in whole or in part) of any product of Parent or its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) each Contract containing (A)&nbsp;a covenant
limiting the freedom of Parent or any Subsidiary to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Parent&#8217;s products or services, (B)&nbsp;any most-favored pricing
arrangement, (C)&nbsp;any exclusivity provision, (D)&nbsp;any agreement to purchase minimum quantity of goods or services or (E)&nbsp;any <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provision; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) each Parent <FONT STYLE="white-space:nowrap">In-bound</FONT> License; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) each Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> License; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii) each Contract requiring the payment of any royalty, dividend or similar arrangement based on the revenues or profits of Parent or its
Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(viii) each Contract, offer letter, employment agreement, consulting or independent contractor agreement with any
employee, independent contractor, consultant or other natural person service provider that (A)&nbsp;is not immediately terminable at will by the Parent or its Subsidiaries without notice, severance or other cost or payment, except as required under
applicable Law, or (B)&nbsp;provides for retention payments, change of control payments, severance, accelerated vesting, or any similar payment or benefit that may or will become due as a result of the Merger; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ix) any other Contract that is not terminable at will (with no penalty or payment or requirement for more than 30 days&#8217; prior notice,
except as required by applicable law) by Parent or its Subsidiaries and which involves payment or receipt by Parent or its Subsidiaries after the date of this Agreement under any such Contract of more than $125,000 in the aggregate, or obligations
after the date of this Agreement in excess of $125,000 in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in the Parent SEC Documents publicly
available prior to the date of this Agreement, neither Parent nor any of its Subsidiaries is a party to or is bound by any &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, excluding, however, any Parent Benefit Plans). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) (i) Each Parent
Material Contract is valid and binding on Parent and any of its Subsidiaries to the extent such Subsidiary is a party thereto, as applicable, and to the knowledge of Parent, each other party thereto, and is in full force and effect and enforceable
in accordance with its terms; (ii)&nbsp;Parent and each of its Subsidiaries, and, to the knowledge of Parent, each other party thereto, has performed all material obligations required to be performed by themselves under each Parent Material
Contract; and (iii)&nbsp;there is no material default under any Parent Material Contract by Parent or any of its Subsidiaries or, to the knowledge of Parent, any other party thereto, and no event or condition has occurred that constitutes, or, after
notice or lapse of time or both, would constitute, a material default on the part of Parent or any of its Subsidiaries or, to the knowledge of Parent, any other party thereto under any such Parent Material Contract, nor has Parent or any of its
Subsidiaries received written notice of any such material default, event or condition. Parent has made available to the Company true and complete copies of all Parent Material Contracts, including all amendments there. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_58"></A>3.17 <U>Insurance</U>. Each of Parent and its Subsidiaries is covered by valid and currently effective
insurance policies issued in favor of Parent or one or more of its Subsidiaries that are customary and adequate for companies of similar size in the industries and locations in which Parent operates. <U>Section</U><U></U><U>&nbsp;3.17</U> of the
Parent Disclosure Schedule sets forth, as of the date hereof, a true and complete list of all material insurance policies issued in favor of Parent or any of its Subsidiaries, or pursuant to which Parent or any of its Subsidiaries is a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
named insured or otherwise a beneficiary, as well as any historic incurrence-based policies still in force. With respect to each such insurance policy, (a)&nbsp;such policy is in full force and
effect and all premiums due thereon have been paid, (b)&nbsp;neither Parent nor any of its Subsidiaries is in breach or default, and has not taken any action or failed to take any action which (with or without notice or lapse of time, or both) would
constitute such a breach or default, or would permit termination or modification of, any such policy and (c)&nbsp;to the knowledge of Parent, no insurer issuing any such policy has been declared insolvent or placed in receivership, conservatorship
or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor, to the knowledge of Parent, will any such cancellation or termination result from the consummation of the Contemplated Transactions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_59"></A>3.18 <U>Properties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent or one of its Subsidiaries has good and valid title to, or in the case of leased property and leased tangible assets, a valid
leasehold interest in, all of its real properties and tangible assets that are necessary for Parent and its Subsidiaries to conduct their respective businesses as currently conducted, free and clear of all Encumbrances other than Permitted
Encumbrances. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, the tangible personal property currently used in the operation of the business of Parent and its
Subsidiaries is in good working order (reasonable wear and tear excepted). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each of Parent and its Subsidiaries has complied with the
terms of all leases to which it is a party, and all such leases are in full force and effect, except for any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not had and would not reasonably be
expected to have a Parent Material Adverse Effect. Each of Parent and its Subsidiaries enjoys peaceful and undisturbed possession under all such leases, except for any such failure to do so that, individually or in the aggregate, has not had and
would not reasonably be expected to have a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Section 3.18(c)</U> of the Parent Disclosure Schedule
sets forth a true and complete list of (i)&nbsp;all real property owned by Parent or any of its Subsidiaries and (ii)&nbsp;all real property leased for the benefit of Parent or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) This <U>Section</U><U></U><U>&nbsp;3.18</U> does not relate to intellectual property, which is the subject of
<U>Section</U><U></U><U>&nbsp;3.19</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_60"></A>3.19 <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section 3.19(a)</U> of the Parent Disclosure Schedule sets forth a true and complete list of all (i)&nbsp;material patents and patent
applications; (ii)&nbsp;material trademark registrations and applications; and (iii)&nbsp;material copyright registrations and applications, in each case not related solely to RLYB212 and owned by Parent and its Subsidiaries (collectively,
&#8220;<B><I>Parent Registered IP</I></B>&#8221;)and a true and complete list of all domain names owned or exclusively licensed by Parent and its Subsidiaries. Except as, individually or in the aggregate, has not had and would not reasonably be
expected to have a Parent Material Adverse Effect (A)&nbsp;all of the Parent Registered IP is subsisting and, in the case of any Parent Registered IP that is registered or issued and to the knowledge of Parent, valid and enforceable, (B)&nbsp;no
Parent Registered IP is involved in any interference, reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of Parent, no such action is threatened with respect to any of the Parent Registered IP
and (C)&nbsp;Parent or its Subsidiaries own exclusively, free and clear of any and all Encumbrances (other than Permitted Encumbrances), all Parent Owned IP, including all Intellectual Property created on behalf of Parent or its Subsidiaries by its
employees or independent contractors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Section 3.19(b)</U> of the Parent Disclosure Schedule accurately identifies all Contracts
pursuant to which any material Intellectual Property is licensed to Parent or its Subsidiaries (other than (i)&nbsp;any <FONT STYLE="white-space:nowrap">non-customized</FONT> software that (A)&nbsp;is so licensed solely in executable or object code
form pursuant to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nonexclusive, <FONT STYLE="white-space:nowrap">internal-use</FONT> software license and other Intellectual Property associated with such software and (B)&nbsp;is not incorporated into any of
Parent&#8217;s or its Subsidiaries&#8217; products, (ii)&nbsp;any Intellectual Property licensed on a nonexclusive basis where the license is incidental to the primary purpose of the relevant Contract or the provision of services to Parent,
(iii)&nbsp;any material transfer agreements, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, research agreements, clinical trial agreements, services agreements,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software licenses and generally-available patent license agreements and (iv)&nbsp;agreements between Parent and any of its Subsidiaries and their employees
in Parent&#8217;s standard form thereof) (each a &#8220;<B><I>Parent <FONT STYLE="white-space:nowrap">In-bound</FONT> License</I></B>&#8221;, and the underlying Intellectual Property, the &#8220;<B><I>Parent Licensed IP</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Section 3.19(c)</U> of the Parent Disclosure Schedule accurately identifies each Contract pursuant to which any Person has been
granted any license or covenant not to sue under any Parent Owned IP or Parent Licensed IP (other than (i)&nbsp;any material transfer agreements, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, research agreements, clinical trial
agreements and services agreements and (ii)&nbsp;any Parent Owned IP or Parent Licensed IP nonexclusively licensed in the Ordinary Course of Business and that does not grant any commercial rights to any product of Parent or its Subsidiaries) (each a
&#8220;<B><I>Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> License</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) To the knowledge of Parent, the
Parent Owned IP and the Parent Licensed IP constitutes all Intellectual Property necessary for Parent and its Subsidiaries to conduct their business as currently conducted; provided, however, that the foregoing representation is not a representation
with respect to <FONT STYLE="white-space:nowrap">non-infringement</FONT> of Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Parent and its Subsidiaries have
taken commercially reasonable measures to maintain the confidentiality of all information that constitutes a material trade secret of Parent or its Subsidiaries, including requiring all Persons having access thereto to execute written <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreements or other binding obligations to maintain confidentiality of such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect,
(i)&nbsp;to the knowledge of Parent, the conduct of the businesses of Parent and its Subsidiaries, including the manufacture, marketing, offering for sale, sale, importation, use or intended use (as currently contemplated) or other disposal of any
product as currently sold or under development by Parent or its Subsidiaries, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual Property of any Person, (ii)&nbsp;neither Parent nor any
of its Subsidiaries has received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred and (iii)&nbsp;to the knowledge of Parent, no Person is
infringing, misappropriating, or diluting in any material respect any Parent Registered IP or Parent Licensed IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Except as,
individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&nbsp;Parent and its Subsidiaries have taken commercially reasonable steps to protect the confidentiality and security of
the computer and information technology systems owned, licensed and used by Parent and its Subsidiaries (the &#8220;<B><I>Parent IT Systems</I></B>&#8221;) and the information and transactions stored or contained therein or transmitted thereby,
(ii)&nbsp;to the knowledge of Parent, since January&nbsp;1, 2023, there has been no unauthorized or improper use, loss, access, transmittal, modification or corruption of any such Parent IT Systems, and (iii)&nbsp;since January&nbsp;1, 2023, there
have been no material failures, crashes, viruses, or security breaches (including any unauthorized access to any personally identifiable information), affecting the Parent IT Systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect,
(i)&nbsp;to the knowledge of Parent, Parent and its Subsidiaries have at all times since January&nbsp;1, 2023, complied in all material respects with all applicable Privacy Laws, (ii)&nbsp;since January&nbsp;1, 2023, no claims have been received by
Parent or, to the knowledge of Parent, threatened in writing against Parent alleging Parent a violated any applicable Privacy Law, (iii)&nbsp;neither Parent&#8217;s performance of this Agreement nor Parent&#8217;s consummation of the Contemplated
Transactions will breach or otherwise violate any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Privacy Laws and (iv)&nbsp;Parent and its Subsidiaries have taken commercially reasonable steps to protect the Personal Information collected, used or held for use by Parent or its
subsidiaries against unauthorized loss, access, use, modification, disclosure or other misuse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) To the knowledge of Parent, no
government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in the development of the Parent Owned IP or, to the knowledge of Parent, Parent Licensed
IP exclusively licensed to Parent, and no Governmental Body, university, college, other educational institution or research center has, to the knowledge of Parent, any claim or right in or to the Parent Owned IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) The execution, delivery and performance by Parent of this Agreement, and the consummation of the Contemplated Transactions, will not
result in the loss of, or give rise to any right of any third party to terminate or modify any of Parent&#8217;s or any Subsidiaries&#8217; rights or obligations under any Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> License or Parent <FONT
STYLE="white-space:nowrap">In-bound</FONT> License. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_61"></A>3.20 <U>Related Party Transactions</U>. Since
January&nbsp;1, 2023 through the date of this Agreement, there have been no transactions, agreements, arrangements or understandings between Parent or any of its Subsidiaries, on the one hand, and the affiliates of Parent, on the other hand (other
than Parent&#8217;s Subsidiaries), that would be required to be disclosed under Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act and that have not been so disclosed in the Parent SEC Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_62"></A>3.21 <U>Certain Payments</U>. Neither Parent nor any of its Subsidiaries (nor, to the knowledge of Parent,
any of their respective directors, executives, representatives, agents or employees) has, directly or indirectly, made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other payments,
in the form of cash, gifts, or otherwise, or taken any other action, in violation of the Anti-Bribery Laws. Parent is not, nor has it been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of
Anti-Bribery Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_63"></A>3.22 <U>Brokers</U>. No broker, investment banker, financial advisor or other Person,
other than Evercore Group, L.L.C. and Citizens JMP Securities, LLC, the fees and expenses of which will be paid by Parent, is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection
with the Contemplated Transactions based upon arrangements made by or on behalf of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_64"></A>3.23
<U>Opinion of Financial Advisor</U>. The Parent Board has received the opinion of Citizens JMP Securities, LLC, dated the date of this Agreement, to the effect that, as of such date and based upon and subject to the qualifications, limitations,
assumptions and other matters set forth therein, the Exchange Ratio is fair, from a financial point of view, to Parent, a signed true and complete copy of which opinion has been or will promptly be provided to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_65"></A>3.24 <U>Merger Sub</U>. Merger Sub was formed solely for the purpose of engaging in the Merger and the other
Contemplated Transactions and has engaged in no business other than in connection with the Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_66"></A>3.25 <U>State Takeover Statutes</U>. No Takeover Statute or any similar anti-takeover provision in the Certificate of Incorporation or Bylaws of Parent applicable to Parent is, or at the Effective Time will be, applicable to this Agreement, the
Merger, or any of the other Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_67"></A>3.26 <U>No Other Representations or
Warranties</U>. Except for the representations and warranties contained in <U>Section</U><U></U><U>&nbsp;2</U>, each of Parent and Merger Sub acknowledges and agrees that none of the Company or any other Person on behalf of the Company makes any
other express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of the Company or any other Person on behalf of the Company or any of its Subsidiaries makes any
representation or warranty with respect to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
projections or forecasts delivered or made available to Parent, Merger Sub or any of their respective Subsidiaries or Representatives of future revenues, results of operations (or any component
thereof), cash flows or financial condition (or any component thereof) of the Company (including any such projections or forecasts made available to Parent, Merger Sub or any of their respective Subsidiaries or Representatives in certain &#8220;data
rooms&#8221; or management presentations in expectation of the Contemplated Transactions), and none of Parent or Merger Sub has relied on any such information or any representation or warranty not set forth in <U>Section</U><U></U><U>&nbsp;2</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_68"></A><B>Section</B><B></B><B>&nbsp;4.</B> <U>CERTAIN COVENANTS OF THE PARTIES</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_69"></A>4.1 <U>Operation of Parent</U><U>&#8217;</U><U>s Business</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except (i)&nbsp;as set forth on <U>Section</U><U></U><U>&nbsp;4.1(a)</U> of the Parent Disclosure Schedule, (ii)&nbsp;as expressly
permitted by or required in accordance with this Agreement, including in connection with the Asset Dispositions pursuant to <U>Section</U><U></U><U>&nbsp;4.7</U>, (iii) as required by applicable Law, or (iv)&nbsp;as may be consented to in writing by
the Company (which consent shall not be unreasonably withheld, conditioned or delayed), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;9</U> and the Effective Time (the &#8220;<B><I><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period</I></B>&#8221;), each of Parent and its Subsidiaries shall (A)&nbsp;conduct its business and operations in the
Ordinary Course of Business and in compliance in all material respects with all applicable Laws and the requirements of all Contracts that constitute Parent Material Contracts, and (B)&nbsp;continue to pay material outstanding accounts payable and
other material current liabilities (including payroll) in the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except (i)&nbsp;as expressly permitted by
this Agreement, (ii)&nbsp;as set forth on <U>Section</U><U></U><U>&nbsp;4.1(b)</U> of the Parent Disclosure Schedule, (iii)&nbsp;as required by applicable Law, (iv)&nbsp;in connection with the Asset Dispositions pursuant to
<U>Section</U><U></U><U>&nbsp;4.7</U> or the winding down of Parent&#8217;s <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> CMC and clinical activities (including the termination of ongoing contractual obligations related to parent&#8217;s
current products or product candidates) pursuant to <U>Section</U><U></U><U>&nbsp;5.22</U>, or (v)&nbsp;with the prior written consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), at all times during the
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, Parent shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase,
redeem or otherwise reacquire any shares of its capital stock or other securities (except repurchases from terminated employees, directors or consultants of Parent or in connection with the payment of the exercise price or withholding Taxes incurred
upon the exercise, settlement or vesting of any award or purchase rights granted under any Parent equity incentive plan in accordance with the terms of such award in effect on the date of this Agreement); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A)&nbsp;any capital
stock or other security of Parent or any of its Subsidiaries (except for shares of Parent Common Stock issued upon the valid exercise or settlement of Parent Stock Awards); (B)&nbsp;any option, warrant or right to acquire any capital stock or any
other security; or (C)&nbsp;any instrument convertible into or exchangeable for any capital stock or other security of Parent or any of its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) amend the terms of any outstanding Parent Options; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries&#8217; certificate
of incorporation and bylaws (or comparable organizational documents), or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or
similar transaction except, for the avoidance of doubt, the Contemplated Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) form any Subsidiary or acquire any equity
interest or other interest in any other Entity or enter into a joint venture with any other Entity; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) (A) lend money to any Person (except for the advancement of reasonable and customary
expenses to employees, directors and consultants in the Ordinary Course of Business), (B)&nbsp;incur or guarantee any indebtedness for borrowed money, (C)&nbsp;guarantee any debt securities of others, (D)&nbsp;other than the incurrence or payment of
Transaction Expenses, make any capital expenditure in excess of $50,000, or (E)&nbsp;forgive any loans to any Persons, including Parent&#8217;s employees, officers, directors or Affiliates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii) other than as required by applicable Law or the terms of any Parent Benefit Plan as in effect on the date of this Agreement:
(A)&nbsp;adopt, terminate, establish or enter into any Parent Benefit Plan or any plan or agreement that would be a Parent Benefit Plan if in effect on the date hereof; (B)&nbsp;cause or permit any Parent Benefit Plan to be amended; (C)&nbsp;pay any
bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, fringe benefits, commissions, bonus or other compensation or benefits payable to any of its directors, officers, consultants, independent
contractors or employees; (D)&nbsp;hire any officer, employee, consultant or independent contractor; (E)&nbsp;modify the terms of any severance, retention or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> benefits offered to any current, former or new employees, directors or consultants (other than acceleration of Parent Stock Awards as contemplated by
this Agreement), or (F)&nbsp;grant any new, or modify any existing, severance, retention benefits, change in control award, or similar compensation or benefit to any Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(viii) recognize any labor union or labor organization; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ix) acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its material assets or properties, or grant any
Encumbrance with respect to such material assets or properties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(x) sell, assign, transfer, license, sublicense or otherwise dispose of
any Parent Owned IP or any Parent <FONT STYLE="white-space:nowrap">In-bound</FONT> License; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xi) make, change or revoke any material Tax
election, fail to pay any income or other material Tax as such Tax becomes due and payable (taking into account extensions of time to file any Tax Return granted in the Ordinary Course of Business of not more than seven (7)&nbsp;months), file any
amendment making any material change to any Tax Return, settle or compromise any income or other material Tax liability or submit any voluntary disclosure application, enter into any Tax allocation, sharing, indemnification or other similar
agreement or arrangement (other than customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), request or consent to any extension or waiver of any limitation period with
respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than seven (7)&nbsp;months), or adopt or change any
material accounting method in respect of Taxes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xii) enter into, materially amend or terminate any Parent Material Contract or Contract
that would be deemed a Parent Material Contract if entered into prior to the date hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xiii) other than as required by Law or GAAP,
take any action to change accounting policies or procedures; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xiv) initiate or settle any Legal Proceeding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xv) (A) fail to maintain any material insurance policies in full force and effect prior to the renewal period of any such material insurance
policies or (B)&nbsp;fail to exercise renewal rights for any such material insurance policies following the applicable expiration or acquire substantially similar insurance policies; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xvi) enter into or amend a Contract that would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the
consummation of the Contemplated Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xvii) enter into a new line of business or start to conduct a line of business; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xviii) agree, resolve or commit to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of
Parent prior to the Effective Time. Prior to the Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_70"></A>4.2 <U>Operation of the Company</U><U>&#8217;</U><U>s Business</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except (i)&nbsp;as set forth on <U>Schedule</U><U></U><U>&nbsp;4.2(a)</U> of the Company Disclosure Schedule, (ii)&nbsp;as expressly
permitted by or required in accordance this Agreement including in connection with the Concurrent Financing pursuant to <U>Section</U><U></U><U>&nbsp;5.23</U>, (iii)&nbsp;as required by applicable Law, or (iv)&nbsp;as may be consented to in writing
by Parent (which consent shall not be unreasonably withheld, conditioned or delayed), during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, the Company shall (A)&nbsp;conduct its business and operations in the Ordinary Course of
Business and in compliance in all material respects with all applicable Laws and the requirements of all Contracts that constitute Company Material Contracts, and (B)&nbsp;continue to pay material outstanding accounts payable and other material
current liabilities (including payroll) in the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except (i)&nbsp;as expressly permitted by this
Agreement, (ii)&nbsp;as set forth on <U>Schedule</U><U></U><U>&nbsp;4.2(b)</U> of the Company Disclosure Schedule, (iii)&nbsp;as required by applicable Law (iv)&nbsp;in connection with the Concurrent Financing pursuant to
<U>Section</U><U></U><U>&nbsp;5.23</U>, or (v)&nbsp;with the prior written consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed), at all times during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) declare, accrue, set
aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except repurchases from terminated employees,
directors or consultants of the Company or in connection with the payment of the exercise price or withholding Taxes incurred upon the exercise, settlement or vesting of any award granted under the Company Benefit Plan in accordance with the terms
of such award in effect on the date of this Agreement); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) sell, issue, grant, pledge or otherwise dispose of or encumber or authorize
any of the foregoing with respect to: (A)&nbsp;any capital stock or other security of the Company or any of its Subsidiaries (except for shares of Company Common Stock issued upon the valid exercise of Company Options); (B) any option, warrant or
right to acquire any capital stock or any other security, other than stock options or restricted stock unit awards granted to employees and service providers in the Ordinary Course of Business which are included in the calculation of the Company
Outstanding Shares; or (C)&nbsp;any instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) except as required to give effect to anything in contemplation of the Closing (including in connection with the Concurrent Financing),
amend any of its or its Subsidiaries Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar
transaction except, for the avoidance of doubt, the Contemplated Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) form any Subsidiary or acquire any equity interest
or other interest in any other Entity or enter into a joint venture with any other Entity; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) (A) lend money to any Person (except for
the advancement of reasonable and customary expenses to employees, directors and consultants in the Ordinary Course of Business), (B)&nbsp;incur or guarantee any indebtedness for borrowed money, (C)&nbsp;guarantee any debt securities of others,
(D)&nbsp;other than the incurrence or payment of Transaction Expenses, make any capital expenditure in excess of $1,500,000 of the budgeted capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenditure amounts set forth in the Company operating budget delivered to Parent concurrently with the execution of this Agreement (the &#8220;<B><I>Company Budget</I></B>&#8221;) or
(E)&nbsp;forgive any loans to any Persons, including the Company&#8217;s employees, officers, directors or Affiliates; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) recognize
any labor union or labor organization; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii) acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its
material assets or properties, or grant any Encumbrance with respect to such material assets or properties, except in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(viii) dispose of any of its material assets or properties, except in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ix) sell, assign, transfer, license, sublicense or otherwise dispose of any material Company Owned IP or any material Company Licensed IP,
in each case other than pursuant to <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses in the Ordinary Course of Business, the abandonment and refiling of patent applications or
<FONT STYLE="white-space:nowrap">co-commercialization</FONT> or partnership transaction, in each case, in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(x) make, change or revoke any material Tax election, fail to pay any income or other material Tax as such Tax becomes due and payable
(taking into account extensions of time to file any Tax Return granted in the Ordinary Course of Business of not more than seven (7)&nbsp;months), file any amendment making any material change to any Tax Return, settle or compromise any income or
other material Tax liability or submit any voluntary disclosure application, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the Ordinary
Course of Business the principal subject matter of which is not Taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an
extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than seven (7)&nbsp;months), or adopt or change any material accounting method in respect of Taxes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xi) enter into, materially amend or terminate any Company Material Contract or Contract that would be deemed a Company Material Contract if
entered into prior to the date hereof, except in the Ordinary Course of Business;<B><I> </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xii) except as otherwise consistent
with the Company Budget and the incurrence or payment of any Transaction Expenses or other costs or expenses arising as a result of this Agreement and the Contemplated Transactions, make any expenditures or discharge or satisfy any liabilities, in
each case, in amounts that exceed the aggregate amount anticipated in the Company Budget by $1,500,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xiii) other than as required by
Law or GAAP, take any action to change accounting policies or procedures; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xiv) initiate or settle any Legal Proceeding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xv) (A) fail to maintain any material insurance policies in full force and effect prior to the renewal period of any such material insurance
policies or (B)&nbsp;fail to use commercially reasonable efforts to renew any such material insurance policies following the applicable expiration or acquire substantially similar insurance policies; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xvi) enter into or amend a Contract that would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the
consummation of the Contemplated Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xvii) enter into a new line of business or start to conduct a line of business; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xviii) agree, resolve or commit to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the
Company prior to the Effective Time. Prior to the Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_71"></A>4.3 <U>Access and Investigation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this
Agreement, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s
Representatives to: (a)&nbsp;provide the other Party and such other Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property and assets and to all existing books,
records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries; (b)&nbsp;provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax
Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other
Party may reasonably request; (c)&nbsp;permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party
responsible for such Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may reasonably deem necessary or appropriate; and (d)&nbsp;make available to the other Party copies of
unaudited financial statements, material operating and financial reports prepared for senior management or the board of directors of such Party, and any material notice, report or other document filed with or sent to or received from any
Governmental Body in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this <U>Section</U><U></U><U>&nbsp;4.3</U> shall be conducted in such manner as not to interfere unreasonably
with the conduct of the business of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing, any Party may restrict the foregoing access to
the extent that any Law applicable to such Party requires such Party to restrict or prohibit access to any such properties or information or may redact any of the foregoing documents or reports to the extent necessary to preserve the attorney-client
privilege under any circumstances in which such privilege may be jeopardized by such access or the disclosure of such document or report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_72"></A>4.4 <U>Parent <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent agrees that, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, neither it nor any of its Subsidiaries shall,
nor shall it or any of its Subsidiaries, authorize any of their respective Representatives to, directly or indirectly, other than relating to communicating, discussing, negotiating or consummating the Asset Dispositions: (i)&nbsp;solicit, initiate
or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or
Acquisition Inquiry; (ii)&nbsp;furnish any <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Parent or any of its Subsidiaries to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;
(iii)&nbsp;engage in discussions (other than to inform any Person of the existence of the provisions in this <U>Section</U><U></U><U>&nbsp;4.4</U>) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry;
(iv)&nbsp;approve, endorse or recommend any Acquisition Proposal (subject to <U>Section</U><U></U><U>&nbsp;5.3</U>); (v) execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction
(other than a confidentiality agreement permitted under this <U>Section</U><U></U><U>&nbsp;4.4(a)</U>); or (vi)&nbsp;publicly propose to do any of the foregoing;<I> provided</I>, <I>however</I>, that, notwithstanding anything contained in this
<U>Section</U><U></U><U>&nbsp;4.4</U> and subject to compliance with this <U>Section</U><U></U><U>&nbsp;4.4</U>, prior to obtaining the Required Parent Stockholder Vote, Parent and its Subsidiaries may furnish
<FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Parent or any of its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a <I>bona fide</I> Acquisition Proposal by such Person,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the Parent Board determines in good faith, after consultation with Parent&#8217;s outside financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a
Superior Offer (and is not withdrawn) if: (A)&nbsp;none of Parent, any of its Subsidiaries or any of their respective Representatives shall have breached this <U>Section</U><U></U><U>&nbsp;4.4</U> in any material respect, (B)&nbsp;the Parent Board
concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would be inconsistent with the fiduciary duties of the Parent Board under applicable Law; (C)&nbsp;Parent receives from such Person an
executed confidentiality agreement containing provisions (including nondisclosure provisions, use restrictions, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions, no hire and &#8220;standstill&#8221; provisions), in the aggregate,
at least as favorable to Parent as those contained in the Confidentiality Agreement; and (D)&nbsp;substantially contemporaneously with furnishing any such <FONT STYLE="white-space:nowrap">non-public</FONT> information to such Person, Parent gives
the Company notice of Parent&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person and furnishes such <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Company (to the extent such
information has not been previously furnished by Parent to the Company). Without limiting the generality of the foregoing, Parent acknowledges and agrees that, in the event any Representative of Parent or any of its Subsidiaries (whether or not such
Representative is purporting to act on behalf of Parent or any of its Subsidiaries) takes any action that, if taken by Parent or any of its Subsidiaries, would constitute a breach of this <U>Section</U><U></U><U>&nbsp;4.4</U>, the taking of such
action by such Representative shall be deemed to constitute a breach of this <U>Section</U><U></U><U>&nbsp;4.4</U> by Parent for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If Parent, any of its Subsidiaries or any of their respective Representatives receives an Acquisition Proposal or Acquisition Inquiry at
any time during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, then Parent shall promptly (and in no event later than one (1)&nbsp;Business Day after Parent becomes aware of such Acquisition Proposal or Acquisition Inquiry)
(i)&nbsp;advise the Company orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry), (ii)&nbsp;in the case of a written
Acquisition Proposal or Acquisition Inquiry, furnish any written documentation and correspondence to or from Parent, any of its Subsidiaries or any of their respective Representatives, including any subsequent modifications or amendments, and
(iii)&nbsp;in the case of an oral Acquisition Proposal or Acquisition Inquiry, provide a written summary of the terms thereof. Parent shall keep the Company reasonably and promptly informed with respect to the status and material terms of any such
Acquisition Proposal or Acquisition Inquiry, any material modification, amendment or proposed material modification thereto (including any revision in the amount, form or mix of consideration) and of all verbal or written communications related
thereto, together with copies of new written documentation and correspondence to or from Parent, any of its Subsidiaries or any of their respective Representatives as well as written summaries of any material oral communications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that
relate to any Acquisition Proposal or Acquisition Inquiry (other than any Asset Disposition) that has not already been terminated as of the date of this Agreement, immediately terminate access to any
<FONT STYLE="white-space:nowrap">non-public</FONT> information of Parent provided to such Person via an electronic or physical data room and within three (3)&nbsp;Business Days after the date of this Agreement, request the destruction or return of
any <FONT STYLE="white-space:nowrap">non-public</FONT> information of Parent or any of its Subsidiaries provided to such Person as soon as practicable after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_73"></A>4.5 <U>Company <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees that, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, neither it nor any of its Subsidiaries
shall nor shall it or any of its Subsidiaries authorize any of their respective Representatives to, directly or indirectly: (i)&nbsp;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement
of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)&nbsp;furnish any <FONT STYLE="white-space:nowrap">non-public</FONT> information
regarding the Company or any of its Subsidiaries to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii)&nbsp;engage in discussions (other than to inform any Person of the existence of the provisions
in this <U>Section</U><U></U><U>&nbsp;4.5</U>) or negotiations with any Person with respect to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Acquisition Proposal or Acquisition Inquiry; (iv)&nbsp;approve, endorse or recommend any Acquisition Proposal; (v)&nbsp;execute or enter into any letter of intent or any Contract contemplating or
otherwise relating to any Acquisition Transaction; or (vi)&nbsp;publicly propose to do any of the foregoing;<I> provided</I>, <I>however</I>, that, notwithstanding anything contained in this <U>Section</U><U></U><U>&nbsp;4.5</U> and subject to
compliance with this <U>Section</U><U></U><U>&nbsp;4.5</U>, prior to obtaining the Required Company Stockholder Vote, the Company and its Subsidiaries may solicit any Acquisition Proposal and furnish
<FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of its Subsidiaries to, and enter into discussions or negotiations with, any Person, including any Person not making such Acquisition Proposal, following
receipt of a <I>bona fide</I> Acquisition Proposal by any Person, which the Company Board has determined in good faith, after consultation with the Company&#8217;s outside financial advisors and outside legal counsel, constitutes, or is reasonably
likely to result in, a Superior Offer if: (A)&nbsp;none of the Company, any of its Subsidiaries or any of their respective Representatives shall have breached this <U>Section</U><U></U><U>&nbsp;4.5</U> in any material respect, (B)&nbsp;the Company
Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would be inconsistent with the fiduciary duties of the Company Board under applicable Law; and (C)&nbsp;the Company receives from such
Person an executed confidentiality agreement containing provisions, in the aggregate, at least as favorable to the Company as those contained in the Confidentiality Agreement<I>. </I>Without limiting the generality of the foregoing, the Company
acknowledges and agrees that, in the event any Representative of the Company or any of its Subsidiaries (whether or not such Representative is purporting to act on behalf of the Company or any of its Subsidiaries) takes any action that, if taken by
the Company or any of its Subsidiaries, would constitute a breach of this <U>Section</U><U></U><U>&nbsp;4.5</U>, the taking of such action by such Representative shall be deemed to constitute a breach of this <U>Section</U><U></U><U>&nbsp;4.5</U> by
the Company for purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If the Company or any of its Subsidiaries or any of their respective Representatives
receives an Acquisition Proposal at any time during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, then the Company shall promptly (and in no event later than one (1)&nbsp;Business Day after the Company becomes aware of such
Acquisition Proposal) (i)&nbsp;advise Parent orally and in writing of such Acquisition Proposal (including the identity of the Person making or submitting such Acquisition Proposal), (ii)&nbsp;in the case of a written Acquisition Proposal, furnish
any written documentation and correspondence to or from the Company, any of its Subsidiaries or any of their respective Representatives, including any subsequent modifications or amendments, and (iii)&nbsp;in the case of an oral Acquisition
Proposal, provide a written summary of the terms thereof. The Company shall keep Parent reasonably and promptly informed with respect to the status and material terms of any such Acquisition Proposal, any material modification, amendment or proposed
material modification thereto (including any revision in the amount, form or mix of consideration) and of all verbal or written communications related thereto, together with copies of new written documentation and correspondence to or from the
Company or any of its Subsidiaries or any of their respective Representatives as well as written summaries of any material oral communications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company shall immediately cease any existing discussions, negotiations and communications with any Person that relate to any
Acquisition Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement, immediately terminate access to any <FONT STYLE="white-space:nowrap">non-public</FONT> information of the Company provided to such
Person via an electronic or physical data room. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_74"></A>4.6 <U>Notification of Certain Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, the Company shall promptly (and in no event later than two
(2)&nbsp;Business Days after the Company becomes aware of the same) notify Parent (and, if in writing, furnish copies of any relevant documents) if any of the following occurs: (i)&nbsp;any notice or other communication is received from any Person
alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions; (ii)&nbsp;any Legal Proceeding against or involving or otherwise affecting the Company or any of its Subsidiaries is commenced,
or, to the knowledge of the Company, threatened against the Company or any of its Subsidiaries or, to the knowledge of the Company, any director or officer of the Company or any of its Subsidiaries; (iii)&nbsp;the Company or any of its Subsidiaries
becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv)&nbsp;the failure of the Company to comply with any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covenant or obligation of the Company; in each case of clauses&nbsp;(i) through (iv), that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in
<U>Sections</U><U>&nbsp;6</U> or <U>7</U>, as applicable, impossible or materially less likely. No notification given to Parent pursuant to this <U>Section</U><U></U><U>&nbsp;4.6(a)</U> shall change, limit or otherwise affect any of the
representations, warranties, covenants or obligations of the Company or any of its Subsidiaries contained in this Agreement or the Company Disclosure Schedule for purposes of <U>Sections</U><U>&nbsp;6</U> and <U>7</U>, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, Parent shall promptly (and in no event later than two
(2)&nbsp;Business Days after Parent becomes aware of the same) notify the Company (and, if in writing, furnish copies of any relevant documents) if any of the following occurs: (i)&nbsp;any notice or other communication is received from any Person
alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions; (ii)&nbsp;any Legal Proceeding against or involving or otherwise affecting Parent or any of its Subsidiaries is commenced, or, to
the knowledge of Parent, threatened against Parent or any of its Subsidiaries or, to the knowledge of Parent, any director or officer of Parent or any of its Subsidiaries; (iii)&nbsp;Parent becomes aware of any inaccuracy in any representation or
warranty made by it in this Agreement; or (iv)&nbsp;the failure of Parent to comply with any covenant or obligation of Parent or Merger Sub; in each case of clauses&nbsp;(i) through (iv), that could reasonably be expected to make the timely
satisfaction of any of the conditions set forth in <U>Sections</U><U>&nbsp;6</U> or <U>8</U>, as applicable, impossible or materially less likely. No notification given to the Company pursuant to this <U>Section</U><U></U><U>&nbsp;4.6(b)</U> shall
change, limit or otherwise affect any of the representations, warranties, covenants or obligations of Parent or any of its Subsidiaries contained in this Agreement or the Parent Disclosure Schedule for purposes of <U>Sections</U><U>&nbsp;6</U> and
<U>8</U>, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_75"></A>4.7 <U>Potentially Transferable Assets</U>. Prior to the Closing, Parent will
use reasonable best efforts to sell, transfer, license, assign or otherwise divest the Potentially Transferable Assets to one or more third parties in one or a series of transactions immediately following the Closing<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>(each an &#8220;<B><I>Asset Disposition</I></B>&#8221; and collectively, the &#8220;<B><I>Asset Dispositions</I></B>&#8221;). Subject to the provisions of this <U>Section</U><U></U><U>&nbsp;4.7</U>
and the CVR Agreement, Parent may, in contemplation of the Asset Dispositions, (a)&nbsp;establish one or more Subsidiaries to hold the Potentially Transferable Assets, (b)&nbsp;transfer to any such Subsidiary any or all of the Potentially
Transferable Assets and the liabilities and obligations related thereto and (c)&nbsp;take such other steps that are reasonably necessary to prepare for the Asset Dispositions. For clarity, if Parent transfers the Potentially Transferable Assets to
one or more Subsidiaries, the terms of this <U>Section</U><U></U><U>&nbsp;4.7</U> shall apply to such Subsidiaries in addition to Parent. Each Party further acknowledges that Parent may not be successful in completing the Asset Dispositions.
Notwithstanding the foregoing, any such Asset Disposition shall require, to the extent consistent with applicable Laws, the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed) if such Asset Disposition
would create any <FONT STYLE="white-space:nowrap">post-disposition</FONT> liabilities or indemnity obligations for Parent following the Closing; <I>provided</I>, <I>however</I>, that the prior written consent of the Company shall not be required in
connection with any Asset Disposition if Parent agrees that the maximum aggregate dollar value of any post-disposition liabilities or indemnity obligation shall be considered as a reduction to Parent Net Cash as set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_76"></A><B>Section</B><B></B><B>&nbsp;5.</B> <U>ADDITIONAL AGREEMENTS OF THE PARTIES</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_77"></A>5.1 <U>Registration Statement; Proxy Statement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable after the date of this Agreement, the Parties shall prepare, and Parent shall cause to be filed with the SEC,
the Registration Statement, in which the Proxy Statement will be included as a part. Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will not, at
the time that the Proxy Statement or any amendments or supplements thereto are filed with the SEC, at the time the Proxy Statement or any amendments or supplements thereto are first mailed to Parent&#8217;s stockholders and at the time of the Parent
Stockholder&#8217;s Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
were made, not misleading. The Company covenants and agrees that the information provided by or on behalf of the Company or its Representatives to Parent for inclusion in the Registration
Statement (including the Company Audited Financial Statements or the Company Interim Financial Statements, as the case may be) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary in order to make such information not misleading. Parent makes no covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy
included therewith), if any, based on information provided by or on behalf of the Company or any of its Representatives for inclusion therein, and the Company makes no covenant, representation or warranty with respect to statements made in the
Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, other than with respect to the information provided by or on behalf of the Company, or any of its Representatives for inclusion
therein. The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to
any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC; provided that any such filings shall be subject to the consent of the Company (not to be unreasonably withheld, conditioned or delayed). Parent shall
provide the Company with copies of any written comments, and shall inform the Company of any oral comments, that Parent receives from the SEC or its staff with respect to the Registration Statement promptly after the receipt of such comments. Parent
shall use commercially reasonable efforts to respond promptly to any comments of the SEC or its staff and to have the Registration Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC;
provided that any such response shall be subject to the consent of the Company (not to be unreasonably withheld, conditioned or delayed). Each of the Parties shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to
Parent&#8217;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. Each Party shall promptly furnish to the other Party all information concerning such Party and such Party&#8217;s
Affiliates and such Party&#8217;s stockholders that may be required or reasonably requested in connection with any action contemplated by this <U>Section</U><U></U><U>&nbsp;5.1</U>. If Parent, Merger Sub or the Company become aware of any event or
information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, as the case may be, then such Party, as the case may be, shall promptly inform
the other Parties thereof and shall cooperate with such other Parties in filing such amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to Parent&#8217;s stockholders. The Company and Parent shall each
use commercially reasonable efforts to cause the Registration Statement and the Proxy Statement to comply with the applicable rules and regulations promulgated by the SEC and applicable federal and state securities Laws requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Parties shall reasonably cooperate with each other and provide, and require their respective Representatives to provide, the other
Party and its Representatives, with all true, correct and complete information regarding such Party or its Subsidiaries that is required by Law to be included in the Registration Statement and the Proxy Statement or reasonably requested by the other
Party to be included in the Registration Statement and the Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If, in connection with the preparation and filing of the
Registration Statement, the SEC requests or requires that a tax opinion be prepared and submitted regarding the Intended Tax Treatment (a &#8220;<B><I>Tax Opinion</I></B>&#8221;) (i) each of Parent and the Company shall deliver to Cooley LLP and
Ropes&nbsp;&amp; Gray LLP, respectively, customary tax representation letters satisfactory to its counsel, dated and executed as of the date the Registration Statement that shall have been declared effective by the SEC and such other date(s) as
determined reasonably necessary by such counsel in connection with the preparation and filing of the Registration Statement, which counsel shall be entitled to rely upon in rendering its Tax Opinion, and (ii)&nbsp;the Company and Parent shall each
use its reasonable best efforts to cause Cooley LLP and Ropes&nbsp;&amp; Gray LLP to furnish a Tax Opinion with respect to the Intended Tax Treatment.&nbsp;For the avoidance of doubt, in no event shall any such Tax Opinion be a condition to the
Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_78"></A>5.2 <U>Company Information Statement; Stockholder Written
Consent</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Promptly after the Registration Statement shall have been declared effective under the Securities Act, and in any event
no later than three (3)&nbsp;Business Days thereafter, the Company shall prepare, with the cooperation of Parent, and cause to be delivered to its stockholders an information statement, which shall include a copy of the Proxy Statement (the
&#8220;<B><I>Information Statement</I></B>&#8221;), to solicit the approval by written consent from the Company Signatories, including the Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to
Section&nbsp;228 of the DGCL, for purposes of: (i)&nbsp;adopting and approving this Agreement and the Contemplated Transactions, (ii)&nbsp;acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights
to demand appraisal for its shares of Company Capital Stock pursuant to Section&nbsp;262 of the DGCL, a true and correct copy of which will be attached thereto, and that such stockholder has received and read a copy of Section&nbsp;262 of the DGCL,
and (iii)&nbsp;acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares of Company Capital Stock in connection with the Merger and thereby waives any rights to receive payment of the fair
value of its shares of Company Capital Stock under the DGCL (collectively, the &#8220;<B><I>Company Stockholder Matters</I></B>&#8221;). Under no circumstances shall the Company assert that any approval or consent other than the Required Company
Stockholder Vote is necessary for its stockholders or otherwise to approve this Agreement and the Contemplated Transactions. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this
<U>Section</U><U></U><U>&nbsp;5.2(a)</U> shall be subject to Parent&#8217;s advance review and reasonable approval. The Parties shall reasonably cooperate with each other and provide, and require their respective Representatives to provide, the
other Party and its Representatives with all true, correct and complete information regarding such Party or its Subsidiaries that is required by applicable Law to be included in the Information Statement or reasonably requested by the other Party to
be included in the Information Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company covenants and agrees that the Information Statement, including any pro forma
financial statements included therein (and the letter to stockholders and form of Company Stockholder Written Consent included therewith), will not, at the time that the Information Statement or any amendment or supplement thereto is first mailed,
distributed or otherwise made available to the stockholders of the Company, at the time of receipt of the Required Company Stockholder Vote and at the Effective Time, contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, the Company makes no covenant, representation or
warranty with respect to statements made in the Information Statement (and the letter to the stockholders and form of Company Stockholder Written Consent included therewith), if any, based on information furnished in writing by Parent or any of its
Representatives specifically for inclusion therein. Each of the Parties shall use commercially reasonable efforts to cause the Information Statement to comply with the applicable rules and regulations promulgated by the SEC and applicable federal
and state securities Laws requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Promptly following receipt of the Required Company Stockholder Vote, the Company shall
prepare and deliver a notice (the &#8220;<B><I>Stockholder Notice</I></B>&#8221;) to every stockholder of the Company that did not execute the Company Stockholder Written Consent. The Stockholder Notice shall (i)&nbsp;be a statement to the effect
that the Company Board determined that the Merger is advisable in accordance with Section&nbsp;251(b) of the DGCL and in the best interests of the stockholders of the Company and authorized, approved and adopted this Agreement, the Merger and the
other Contemplated Transactions, (ii)&nbsp;provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and
the other Contemplated Transactions in accordance with Section&nbsp;228(e) of the DGCL and the Organizational Documents of the Company, and (iii)&nbsp;include a description of the appraisal rights of the Company&#8217;s stockholders available under
the DGCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this
<U>Section</U><U></U><U>&nbsp;5.2(c)</U> shall be subject to Parent&#8217;s advance review and reasonable approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company agrees that: (i)&nbsp;the Company Board shall recommend that the
Company&#8217;s stockholders vote to approve the Company Stockholder Matters and shall use reasonable best efforts to solicit such approval from the Company&#8217;s stockholders within the time set forth in <U>Section</U><U></U><U>&nbsp;5.2(a)</U>
(the recommendation of the Company Board that the Company&#8217;s stockholders vote to adopt and approve the Company Stockholder Matters being referred to as the &#8220;<B><I>Company Board Recommendation</I></B>&#8221;); and (ii) (1)&nbsp;the
Company Board Recommendation shall not be withdrawn or modified, (2)&nbsp;the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation and (3)&nbsp;no resolution by the Company Board or any committee thereof to
withdraw or modify the Company Board Recommendation or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing
clause&nbsp;(ii), if taken, shall constitute, in each case, a &#8220;<B><I>Company </I></B><B><I>Board Adverse Recommendation Change</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything to the contrary contained in this Agreement, and subject to compliance with
<U>Section</U><U></U><U>&nbsp;4.5</U> and this <U>Section</U><U></U><U>&nbsp;5.2(e)</U>, if at any time prior to the approval of the Company Stockholder Matters: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) If the Company has received a <I>bona fide</I> Acquisition Proposal (which Acquisition Proposal did not arise out of a material breach of
<U>Section</U><U></U><U>&nbsp;4.5</U>) from any Person that has not been withdrawn and after consultation with outside legal counsel, the Company Board shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer, the
Company Board may make a Company Board Adverse Recommendation Change if and only if: (A)&nbsp;the Company Board determines in good faith, after consultation with the Company&#8217;s outside legal counsel and financial advisor, that the failure to do
so would be inconsistent with the fiduciary duties of the Company Board to the Company&#8217;s stockholders under applicable Law; (B)&nbsp;the Company shall have given Parent prior written notice of its intention to consider making a Company Board
Adverse Recommendation Change at least four (4)&nbsp;Business Days prior to making any such Company Board Adverse Recommendation Change (a &#8220;<B><I>Company </I></B><B><I>De</I></B><B><I>termination Notice</I></B>&#8221;; and such period the
&#8220;<B><I>Company Notice Period</I></B>&#8221;) (which notice shall not constitute a Company Board Adverse Recommendation Change); and (C) (1)&nbsp;the Company shall have provided to Parent a description in reasonable detail of the reasons for
such Company Board Adverse Recommendation Change the identity of the party making the Acquisition Proposal, a summary of the material terms and conditions of the Acquisition Proposal and written copies of any relevant proposed transaction documents
(including with respect to financing arrangements), in accordance with <U>Section</U><U></U><U>&nbsp;4.5(b)</U>, (2)&nbsp;the Company shall have given Parent the three (3)&nbsp;Business Days after the Company Determination Notice to propose
revisions to the terms of this Agreement or make another proposal and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions
or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals made by Parent, if any, after consultation with outside legal counsel, the Company Board shall have determined, in good
faith, that such Acquisition Proposal is a Superior Offer and that the failure to make the Company Board Adverse Recommendation Change would be inconsistent with the fiduciary duties of the Company Board to the Company&#8217;s stockholders under
applicable Law; <I>provided </I>during any Company Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with
Parent in good faith (to the extent Parent desires to negotiate) to enable Parent to propose in writing an offer binding on Parent to effect such adjustments to the terms and conditions of this Agreement so that the applicable Acquisition Proposal
ceases to constitute a Superior Offer. For the avoidance of doubt, the provisions of this <U>Section</U><U></U><U>&nbsp;5.2(e)(</U><U>i</U><U>)</U> shall also apply to any material change to the facts and circumstances relating to such Acquisition
Proposal or any amendment to such Acquisition Proposal (including any revision in the amount, form or mix of consideration), and require a new Company Determination Notice and the Company shall be required to provide Parent with notice of such
material change or amendment, except that the references to four (4)&nbsp;Business Days shall be deemed to be two (2)&nbsp;Business Days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) Other than in connection with an Acquisition Proposal, the Company Board may make a Company Board Adverse Recommendation Change in
response to a Company Change in Circumstance, if and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
only if: (A)&nbsp;the Company Board determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary
duties of the Company Board to the Company&#8217;s stockholders under applicable Law; (B)&nbsp;the Company shall have given Parent a Company Determination Notice at least four (4)&nbsp;Business Days prior to making any such Company Board Adverse
Recommendation Change; and (C) (1)&nbsp;the Company shall have specified the Company Change in Circumstance in reasonable detail, including the material facts and circumstances related to the applicable Company Change in Circumstance, (2)&nbsp;the
Company shall have given Parent the three (3)&nbsp;Business Days after the Company Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to
negotiate in good faith with Parent (to the extent Parent desires to do so) with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals
made by Parent, if any, after consultation with outside legal counsel, the Company Board shall have determined, in good faith, that the failure to make the Company Board Adverse Recommendation Change in response to such Company Change in
Circumstance would be inconsistent with the fiduciary duties of the Company Board to the Company&#8217;s stockholders under applicable Law. For the avoidance of doubt, the provisions of this <U>5.2(e)(ii)</U> shall also apply to any material change
to the facts and circumstances relating to such Company Change in Circumstance, and require a new Company Determination Notice and the Company shall be required to provide Parent with notice of such material change, except that the references to
four (4)&nbsp;Business Days shall be deemed to be two (2)&nbsp;Business Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Unless this Agreement is otherwise terminated pursuant
to <U>Section</U><U></U><U>&nbsp;9.1</U>, the Company&#8217;s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with <U>Section</U><U></U><U>&nbsp;5.2(a)</U> and
<U>Section</U><U></U><U>&nbsp;5.2(d)</U> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or by any Company Board Adverse Recommendation
Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_79"></A>5.3 <U>Parent Stockholders</U><U>&#8217;</U><U> Meeting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Promptly after the Registration Statement has been declared effective by the SEC under the Securities Act, Parent shall take all action
necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock for the purpose of seeking approval of (the &#8220;<B><I>Parent Stockholders</I></B><B><I>&#8217;</I></B><B><I> Meeting</I></B>&#8221;):
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) (A) the issuance of Parent Common Stock or other securities of Parent that represent (or are convertible into) more than twenty
percent (20%) of the shares of Parent Common Stock outstanding immediately prior to the Merger to the holders of Company Capital Stock and Company Options in connection with the Contemplated Transactions pursuant to the Nasdaq rules and (B)&nbsp;the
change of control of Parent resulting from the Merger pursuant to the Nasdaq rules; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) the approval of the Parent Charter Amendment to
(A)&nbsp;change the name of Parent to &#8220;Candid Therapeutics, Inc.&#8221;, (B)&nbsp;effect the Nasdaq Reverse Split and (C)&nbsp;effect the Authorized Share Increase (the matters contemplated by
<U>Section</U><U></U><U>&nbsp;5.3(a)(</U><U>i</U><U>)</U> and <U>Section</U><U></U><U>&nbsp;5.3(a)(ii)(A)</U> and <U>(B)</U>, the &#8220;<B><I>Parent Stockholder Matters</I></B>,&#8221; and the matter contemplated by
<U>Section</U><U></U><U>&nbsp;5.3(a)(ii)(C)</U>, the &#8220;<B><I>Authorized Share Increase Proposal</I></B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) the Equity
Plan Proposals; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) any other proposals the Parties deem necessary to consummate the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Parent Stockholders&#8217; Meeting shall be held as promptly as practicable after the Registration Statement is declared effective
under the Securities Act and, in any event, no later than forty-five (45)&nbsp;calendar days after the effective date of the Registration Statement. Parent shall take reasonable measures to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ensure that all proxies solicited in connection with the Parent Stockholders&#8217; Meeting are solicited in compliance with all applicable Laws. Notwithstanding anything to the contrary
contained herein, if on the date of the Parent Stockholders&#8217; Meeting, or a date preceding the date on which the Parent Stockholders&#8217; Meeting is scheduled, Parent reasonably believes that (i)&nbsp;it will not receive proxies sufficient to
obtain the Required Parent Stockholder Vote or the approval of the Authorized Share Increase Proposal, whether or not a quorum would be present, or (ii)&nbsp;it will not have sufficient shares of Parent Common Stock represented (whether in person or
by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholders&#8217; Meeting, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholders&#8217; Meeting as
long as the date of the Parent Stockholders&#8217; Meeting is not postponed or adjourned more than an aggregate of thirty (30)&nbsp;calendar days in connection with any postponements or adjournments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent agrees that, subject to <U>Section</U><U></U><U>&nbsp;5.3(d)</U>: (i)&nbsp;the Parent Board shall recommend that the holders of
Parent Common Stock vote to approve the Parent Stockholder Matters, the Authorized Share Increase Proposal and the Equity Plan Proposals and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in
<U>Section</U><U></U><U>&nbsp;5.3(b)</U> above; (ii)&nbsp;the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s stockholders vote to approve the Parent Stockholder Matters, the Authorized
Share Increase Proposal and the Equity Plan Proposals (the recommendation of the Parent Board with respect to the Parent Stockholder Matters being referred to as the &#8220;<B><I>Parent Board Recommendation</I></B>&#8221;); and (iii) (1)&nbsp;the
Parent Board Recommendation shall not be withheld, amended, withdrawn or modified, (2)&nbsp;the Parent Board shall not publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation, (3)&nbsp;no resolution by the Parent
Board or any committee thereof to withdraw or modify the Parent Board Recommendation or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed, and (4)&nbsp;the
Parent Board shall not publicly announce an intention or resolution to effect any of the foregoing (the actions set forth in the foregoing clause&nbsp;(iii), if taken, shall constitute, in each case, a &#8220;<B><I>Parent Board Adverse
Recommendation Change</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary contained in this Agreement, and subject to
compliance with <U>Section</U><U></U><U>&nbsp;4.4</U> and this <U>Section</U><U></U><U>&nbsp;5.3(d)</U>, if at any time prior to the approval of the Parent Stockholder Matters at the Parent Stockholders&#8217; Meeting by the Required Parent
Stockholder Vote: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) If Parent has received a <I>bona fide</I> Acquisition Proposal (which Acquisition Proposal did not arise out of a
material breach of <U>Section</U><U></U><U>&nbsp;4.4</U>) from any Person that has not been withdrawn and after consultation with outside legal counsel, the Parent Board shall have determined, in good faith, that such Acquisition Proposal is a
Superior Offer, the Parent Board may make a Parent Board Adverse Recommendation Change if and only if: (A)&nbsp;the Parent Board determines in good faith, after consultation with Parent&#8217;s outside legal counsel and financial advisor, that the
failure to do so would be inconsistent with the fiduciary duties of the Parent Board to Parent&#8217;s stockholders under applicable Law; (B)&nbsp;Parent shall have given the Company prior written notice of its intention to consider making a Parent
Board Adverse Recommendation Change at least four (4)&nbsp;Business Days prior to making any such Parent Board Adverse Recommendation Change (a &#8220;<B><I>Determination Notice</I></B>&#8221;; and such period the &#8220;<B><I>Parent Notice
Period</I></B>&#8221;) (which notice shall not constitute a Parent Board Adverse Recommendation Change); and (C) (1)&nbsp;Parent shall have provided to the Company a description in reasonable detail of the reasons for such Parent Board Adverse
Recommendation Change, the identity of the party making the Acquisition Proposal, a summary of the material terms and conditions of the Acquisition Proposal and written copies of any relevant proposed transaction documents (including with respect to
financing arrangements), in accordance with <U>Section</U><U></U><U>&nbsp;4.4(b)</U>, (2)&nbsp;Parent shall have given the Company the three (3)&nbsp;Business Days after the Determination Notice to propose revisions to the terms of this Agreement or
make another proposal and shall have made its Representatives reasonably available to negotiate in good faith with the Company (to the extent the Company desires to negotiate) with respect to such proposed revisions or other proposal, if any, and
(3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals made by the Company, if any, after consultation with outside legal counsel, the Parent Board shall have determined, in good faith, that such
Acquisition Proposal is a Superior Offer and that the failure to make the Parent Board Adverse Recommendation Change would be inconsistent with the fiduciary duties of the Parent Board to Parent&#8217;s stockholders under
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Law; <I>provided </I>during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and
cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to enable the Company to propose in writing an offer binding on the Company to effect such adjustments to the terms and
conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer. For the avoidance of doubt, the provisions of this <U>Section</U><U></U><U>&nbsp;5.3(d)(i)</U> shall also apply to any material change to
the facts and circumstances relating to such Acquisition Proposal or any amendment to such Acquisition Proposal (including any revision in the amount, form or mix of consideration), and require a new Determination Notice and Parent shall be required
to provide the Company with notice of such material change or amendment, except that the references to four (4)&nbsp;Business Days shall be deemed to be two (2)&nbsp;Business Days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) Other than in connection with an Acquisition Proposal, the Parent Board may make a Parent Board Adverse Recommendation Change in
response to a Parent Change in Circumstance, if and only if: (A)&nbsp;the Parent Board determines in good faith, after consultation with Parent&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary duties
of the Parent Board to Parent&#8217;s stockholders under applicable Law; (B)&nbsp;Parent shall have given the Company a Determination Notice at least four (4)&nbsp;Business Days prior to making any such Parent Board Adverse Recommendation Change;
and (C) (1)&nbsp;Parent shall have specified the Parent Change in Circumstance in reasonable detail, including the material facts and circumstances related to the applicable Parent Change in Circumstance, (2)&nbsp;Parent shall have given the Company
the three (3)&nbsp;Business Days after the Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with the Company
(to the extent the Company desires to do so) with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals made by the Company, if any, after
consultation with outside legal counsel, the Parent Board shall have determined, in good faith, that the failure to make the Parent Board Adverse Recommendation Change in response to such Parent Change in Circumstance would be inconsistent with the
fiduciary duties of the Parent Board to Parent&#8217;s stockholders under applicable Law. For the avoidance of doubt, the provisions of this <U>Section</U><U></U><U>&nbsp;5.3(d)(ii)</U> shall also apply to any material change to the facts and
circumstances relating to such Parent Change in Circumstance, and require a new Determination Notice and Parent shall be required to provide the Company with notice of such material change, except that the references to four (4)&nbsp;Business Days
shall be deemed to be two (2)&nbsp;Business Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Nothing contained in this Agreement shall prohibit Parent or the Parent Board from
(i)&nbsp;complying with <FONT STYLE="white-space:nowrap">Rules&nbsp;14d-9</FONT> and <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> promulgated under the Exchange Act, (ii)&nbsp;issuing a &#8220;stop, look and listen&#8221; communication or
similar communication of the type contemplated by <FONT STYLE="white-space:nowrap">Section&nbsp;14d-9(f)</FONT> under the Exchange Act or (iii)&nbsp;otherwise making any disclosure to Parent&#8217;s stockholders; <I>provided however</I>, that, in
the case of the foregoing clause&nbsp;(iii), the Parent Board determines in good faith, after consultation with its outside legal counsel, that failure to make such disclosure would be inconsistent with applicable Law, including its fiduciary duties
under applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Unless this Agreement is otherwise terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1</U>,
Parent&#8217;s obligation to call, give notice of and hold the Parent Stockholders&#8217; Meeting in accordance with <U>Section</U><U></U><U>&nbsp;5.3(b)</U> shall not be limited or otherwise affected by the commencement, disclosure, announcement or
submission of any Acquisition Proposal or by any Parent Board Adverse Recommendation Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_80"></A>5.4
<U>Regulatory Approvals</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding the generality of <U>Section</U><U></U><U>&nbsp;5.7</U>, each Party shall, (i)&nbsp;as
promptly as practicable, but in any event within ten (10)&nbsp;Business Days following the date of this Agreement, make or cause to be made any filings required by each of them or any of their respective Affiliates under the HSR Act and
(ii)&nbsp;use reasonable best efforts to file or otherwise submit as promptly as practicable all applications, notices, reports and other documents required to be filed by such Party with or otherwise submitted by such Party to any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Governmental Body with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent and the Company shall consult and cooperate with one another, and consider in good faith the views of one another, in connection
with, and provide to the other in advance (to the extent legally permissible), any analyses, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by or on behalf of any party hereto in connection with proceedings
under or relating to the Antitrust Laws. Without limiting the foregoing, the Parties agree (i)&nbsp;to give each other reasonable advance notice of all meetings or substantive communications with any Governmental Body relating to any Antitrust Laws,
(ii)&nbsp;to give each other an opportunity to participate in each of such meetings, (iii)&nbsp;to the extent practicable, to give each other reasonable advance notice of all substantive oral communications with any Governmental Body relating to any
Antitrust Laws, (iv)&nbsp;if any Governmental Body initiates a substantive oral communication regarding any Antitrust Laws, to promptly notify the other party of the substance of such communication, (v)&nbsp;to provide each other with a reasonable
advance opportunity to review and comment upon all written communications (including any analyses, presentations, memoranda, briefs, arguments, opinions and proposals) with a Governmental Body regarding any Antitrust Laws and (vi)&nbsp;to provide
each other with copies of all written communications from any Governmental Body relating to any Antitrust Laws. Any such disclosures or provision of copies by one party to the other may be made on an outside counsel basis if appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Each Party shall bear its own expenses and costs incurred by such Party in connection with any filings and submissions pursuant to
Antitrust Laws, except that the Company shall pay the fees related to any filing made pursuant to <U>Section</U><U></U><U>&nbsp;5.4(a)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) In the event that any Legal Proceeding is instituted (or threatened to be instituted) by a Governmental Body challenging the Merger, each
of Parent, Merger Sub and the Company shall cooperate in all respects with each other and shall use reasonable best efforts to contest and resist any such Legal Proceeding and to have vacated, lifted, reversed or overturned any decree, judgment,
injunction or other order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation of the Merger; <I>provided,</I> <I>however</I>, that the Company may, in its sole discretion, determine
to settle such challenge provided that the terms of such settlement do not prevent or unreasonably delay consummation of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)
Neither Party shall, and each Party shall cause its Subsidiaries and Affiliates not to, acquire or agree to acquire any rights, interests, assets, business, Person or division thereof (whether through acquisition, license, joint venture,
collaboration or otherwise), or take any other actions, if such acquisition or action would reasonably be expected to (i)&nbsp;prevent, materially delay, or adversely affect in any material respect the ability of the Parties to consummate the any of
the Contemplated Transactions, or (ii)&nbsp;result in any Party being required to obtain any clearance, consent, approval, waiver, waiting period expiration or termination, <FONT STYLE="white-space:nowrap">non-action</FONT> or other authorization
under any Laws with respect to any of the Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_81"></A>5.5 <U>Company Options</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, each Company Option that is outstanding and unexercised immediately prior to the Effective Time under the
Company&#8217;s 2024 Equity Incentive Plan, as may be amended from time to time, (the &#8220;<B><I>Company EIP</I></B>&#8221;), whether or not vested, shall be converted into and become an option to purchase Parent Common Stock, and Parent shall
assume the Company EIP and each such Company Option in accordance with the terms (as in effect as of the date of this Agreement) of the Company EIP and the terms of the stock option agreement by which such Company Option is evidenced (but with
changes to such documents as Parent in good faith determines are appropriate to reflect the substitution of the Company Options by Parent to purchase shares of Parent Common Stock). All rights with respect to Company Common Stock under Company
Options assumed by Parent shall thereupon be converted into rights with respect to Parent Common Stock. Accordingly, from and after the Effective Time: (i) each Company Option assumed by Parent may be exercised solely for shares of Parent Common
Stock; (ii)&nbsp;the number of shares of Parent Common Stock subject to each Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Option assumed by Parent shall be determined by multiplying (A)&nbsp;the number of shares of Company Common Stock that were subject to such Company Option, as in effect immediately prior to the
Effective Time, by (B)&nbsp;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Parent Common Stock; (iii)&nbsp;the per share exercise price for the Parent Common Stock issuable upon exercise of each
Company Option assumed by Parent shall be determined by dividing (A)&nbsp;the per share exercise price of Company Common Stock subject to such Company Option, as in effect immediately prior to the Effective Time, by (B)&nbsp;the Exchange Ratio, and
rounding the resulting exercise price up to the nearest whole cent; and (iv)&nbsp;any restriction on the exercise of any Company Option assumed by Parent shall continue in full force and effect and the term, exercisability, vesting schedule and
other provisions of such Company Option shall otherwise remain unchanged; <I>provided, however</I>, that: (A)&nbsp;to the extent provided under the terms of the respective grant agreements governing the Company Options and the Company EIP, Parent
may amend the terms of the Company Options and the Company EIP, in accordance with the terms thereof to reflect Parent&#8217;s substitution of the Company Options with options to purchase Parent Common Stock (such as by making any change in control
or similar definition relate to Parent and having any provision that provides for the adjustment of Company Options upon the occurrence of certain corporate events relate to corporate events that relate to Parent or Parent Common Stock); and
(B)&nbsp;the Parent Board or a committee thereof shall succeed to the authority and responsibility of the Company Board or any committee thereof with respect to each Company Option assumed by Parent. Each Company Option so assumed by Parent is
intended to qualify following the Effective Time as an incentive stock option as defined in Section&nbsp;422 of the Code to the extent permitted under Section&nbsp;422 of the Code and to the extent such Company Option qualified as an incentive stock
option prior to the Effective Time, and, further, the assumption of such Company Option pursuant to this <U>Section</U><U></U><U>&nbsp;5.5(a)</U> shall be effected in a manner that satisfies the requirements of Sections 409A and 424(a) of the Code
and the Treasury Regulations promulgated thereunder, and this <U>Section</U><U></U><U>&nbsp;5.5(a)</U> will be construed consistent with this intent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent shall file with the SEC, as soon as reasonably practicable after the Effective Time, a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> (or any successor form), if available for use by Parent, relating to the shares of Parent Common Stock that are either (i)&nbsp;issuable with respect to Company Options assumed by Parent in accordance
with <U>Section</U><U></U><U>&nbsp;5.5(a)</U> or (ii)&nbsp;reserved for future grants under the Company EIP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Prior to the Effective
Time, the Company shall take all actions that may be necessary (under the Company EIP and otherwise) to effectuate the provisions of this <U>Section</U><U></U><U>&nbsp;5.5</U> and to ensure that, from and after the Effective Time, holders of Company
Options have no rights with respect thereto other than those specifically provided in this <U>Section</U><U></U><U>&nbsp;
5.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_82"></A>5.6 <U>Indemnification of Officers and Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) From the Effective Time through the sixth (6<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the date on which the
Effective Time occurs, each of Parent and the Surviving Corporation, jointly and severally, shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a
director, officer, fiduciary or agent of Parent or any of its Subsidiaries or the Company, respectively (the &#8220;<B><I>D&amp;O Indemnified Parties</I></B>&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable
fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to
the fact that the D&amp;O Indemnified Party is or was a director, officer, fiduciary or agent of Parent or of the Company or their respective Subsidiaries, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the
fullest extent permitted by Parent&#8217;s Organizational Documents or the Company&#8217;s Organizational Documents, as applicable, or pursuant to indemnification agreements made available to the Company, as applicable. Each D&amp;O Indemnified
Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Corporation, jointly and severally, upon receipt by Parent or the Surviving
Corporation from the D&amp;O Indemnified Party of a request therefor; <I>provided</I> that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is
ultimately determined that such person is not entitled to indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The provisions of the Organizational Documents of Parent or any of its Subsidiaries
with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Parent or any of its Subsidiaries that are set forth in the Organizational Documents of Parent or any of its Subsidiaries as of
the date of this Agreement shall not be amended, modified or repealed for a period of six (6)&nbsp;years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time,
were officers or directors of Parent or any of its Subsidiaries. The Organizational Documents of the Surviving Corporation shall contain, and Parent shall cause the Organizational Documents of the Surviving Corporation to so contain, provisions no
less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those set forth in the Organizational Documents of the Company as of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) From and after the Effective Time, (i)&nbsp;the Surviving Corporation shall fulfill and honor in all respects the obligations of the
Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Organizational Documents of the Company and pursuant to any indemnification agreements between the Company and
such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii)&nbsp;Parent shall fulfill and honor in all respects the obligations of Parent or any of its Subsidiaries to its
D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Organizational Documents of Parent or any of its Subsidiaries and pursuant to any indemnification agreements between Parent or
any of its Subsidiaries and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) From and after the Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an
effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase, prior to the Effective Time, a six
(6)-year prepaid &#8220;tail policy&#8221; for the <FONT STYLE="white-space:nowrap">non-cancellable</FONT> extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s and any of its Subsidiaries&#8217; existing
directors&#8217; and officers&#8217; insurance policies and Parent&#8217;s existing fiduciary liability insurance policies (if any), in each case, for a claims reporting or discovery period of at least six (6)&nbsp;years from and after the Effective
Time with respect to any claim related to any period of time at or prior to the Effective Time. During the term of the &#8220;tail&#8221; policy, Parent shall not take any action following the Effective Time to cause such &#8220;tail&#8221; policy
to be cancelled or any provision therein to be amended or waived in any manner that would adversely affect in any material respect the rights of its or any of its Subsidiaries&#8217; former and current officers and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) From and after the Effective Time, Parent shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by the
persons referred to in this <U>Section</U><U></U><U>&nbsp;5.6</U> in connection with their successful enforcement of the rights provided to such persons in this <U>Section</U><U></U><U>&nbsp;5.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) All rights to exculpation, indemnification and advancement of expenses for acts or omissions occurring at or prior to the Effective Time,
whether asserted or claimed prior to, at or after the Closing, now existing in favor of the current or former directors, officers or employees, as the case may be, of Parent or the Company or any of their respective Subsidiaries as provided in their
respective Organizational Documents or in any agreement shall survive the Merger and shall continue in full force and effect. The provisions of this <U>Section</U><U></U><U>&nbsp;5.6</U> are intended to be in addition to the rights otherwise
available to the current and former officers and directors of Parent and the Company and any of their respective Subsidiaries by Law, charter, statute, bylaw or Contract, and shall operate for the benefit of, and shall be enforceable by, each of the
D&amp;O Indemnified Parties, their heirs and their representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) From and after the Effective Time, in the event Parent or the
Surviving Corporation or any of their respective successors or assigns (i)&nbsp;consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or
(ii)&nbsp;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the successors and assigns of Parent or the Surviving Corporation, as the case may be, shall succeed to the obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.6</U>. Parent shall cause
the Surviving Corporation to perform all of the obligations of the Surviving Corporation under this <U>Section</U><U></U><U>&nbsp;5.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) The obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.6</U> shall not be terminated, amended or otherwise modified in any
manner that adversely affects any D&amp;O Indemnified Party, or any person who is a beneficiary under the policies referred to in this <U>Section</U><U></U><U>&nbsp;5.6</U> and their heirs and representatives, without the prior written consent of
such affected D&amp;O Indemnified Party or such other beneficiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_83"></A>5.7 <U>Additional Agreements</U>. The
Parties shall, subject to <U>Section</U><U></U><U>&nbsp;4.5</U>, (a) use commercially reasonable efforts to cause to be taken all actions necessary to consummate the Contemplated Transactions and (b)&nbsp;reasonably cooperate with the other Parties
and provide the other Parties with such assistance as may be reasonably requested for the purpose of facilitating the performance by each Party of its respective obligations under this Agreement and to enable the Surviving Corporation to continue to
meet its obligations under this Agreement following the Closing. Without limiting the generality of the foregoing, each Party shall use reasonable best efforts to: (i)&nbsp;make all filings and other submissions (if any) and give all notices (if
any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii)&nbsp;obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in
connection with the Contemplated Transactions with respect to Contracts set forth in <U>Section</U><U></U><U>&nbsp;5.7</U> of the Company Disclosure Schedule to remain in full force and effect, (iii)&nbsp;lift any injunction prohibiting, or any
other legal bar to, the Contemplated Transactions and (iv)&nbsp;
satisfy the conditions precedent to the consummation of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_84"></A>5.8 <U>Public Announcement</U>. The
initial press release relating to this Agreement shall be a joint press release issued by the Company and Parent and thereafter Parent and the Company shall consult with each other before issuing any further press release(s) or otherwise making any
public statement or making any announcement to Parent Associates or Company Associates (to the extent not previously issued or made in accordance with this Agreement) with respect to the Contemplated Transactions and shall not issue any such press
release, public statement or announcement to Parent Associates or Company Associates without the other Party&#8217;s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing:
(a)&nbsp;each Party may, without such consultation or prior written consent, make any public statement in response to questions from the press, analysts, investors or those attending industry conferences, make internal announcements to employees and
make disclosures in Parent SEC Documents, so long as such statements are consistent with and do not disclose material information not previously disclosed in previous press releases, public disclosures or public statements made jointly by the
Parties (or individually, if approved by the other Party); (b)&nbsp;a Party may, without the prior written consent of the other Party but subject to giving advance notice to the other Party of, and consulting with the other Party regarding, the text
of such press release, announcement or statement, issue any such press release or make any such public announcement or statement which Parent shall have determined in good faith, upon the advice of legal counsel, is required by any applicable Law;
and (c)&nbsp;Parent need not consult with the Company in connection with such portion of any press release, public statement or filing to be issued or made pursuant to <U>Section</U><U></U><U>&nbsp;5.3(e)</U> or with respect to any Acquisition
Proposal or Parent Board Adverse Recommendation Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_85"></A>5.9 <U>Listing</U>. Parent shall use its
commercially reasonable efforts, (a)&nbsp;to maintain its existing listing on Nasdaq until the Closing Date and to obtain approval of the listing of the combined company on Nasdaq; (b)&nbsp;without derogating from the generality of the requirements
of the foregoing clause (a)&nbsp;and to the extent required by the rules and regulations of Nasdaq, to prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the
Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance), (c) to effect the Nasdaq Reverse Split, and (d)&nbsp;to the extent required by Nasdaq Marketplace Rule 5110, to file an initial
listing application for the Parent Common Stock on Nasdaq (the &#8220;<B><I>Nasdaq Listing Application</I></B>&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the Effective Time. The Parties will use
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations and will reasonably promptly inform the other Party of all verbal or written
communications between Nasdaq and such Party or its representatives. The Company agrees to pay all Nasdaq fees associated with the Nasdaq Listing Application. The Company will cooperate with Parent as reasonably requested by Parent with respect to
the Nasdaq Listing Application and promptly furnish to Parent all information concerning the Company and its stockholders that may be required or reasonably requested in connection with any action contemplated by this
<U>Section</U><U></U><U>&nbsp;5.9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_86"></A>5.10 <U>Tax Matters</U><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) For U.S. federal income Tax purposes, (i)&nbsp;the Parties intend that the Merger qualify as a &#8220;reorganization&#8221; within the
meaning of Section&nbsp;368(a) of the Code (the &#8220;<B><I>Intended Tax Treatment</I></B>&#8221;), and (ii)&nbsp;this Agreement is intended to be, and is hereby adopted as, a &#8220;plan of reorganization&#8221; for purposes of Section&nbsp;354
and 361 of the Code and Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a),</FONT> to which Parent, Merger Sub and the Company are parties under Section&nbsp;368(b) of the
Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Parties shall use their respective reasonable best efforts to cause the Merger to qualify, and will not take (or knowingly
fail to take) any action or cause (or knowingly fail to cause) any action to be taken which action would reasonably be expected to prevent the Merger from qualifying, for the Intended Tax Treatment. The Parties shall use commercially reasonable
efforts to operate the Surviving Corporation so as to meet the &#8220;continuity of business enterprise&#8221; requirement and any other requirements pursuant to Section&nbsp;368(a)(2)(E) of the Code. The Parties shall not file any U.S. federal,
state or local Tax Return in a manner that is inconsistent with the treatment of the Merger as a &#8220;reorganization&#8221; within the meaning of Section&nbsp;368(a) of the Code for U.S. federal, state and other relevant Tax purposes, unless
otherwise required by a &#8220;determination&#8221; within the meaning of Section&nbsp;1313(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) At least ten
(10)&nbsp;Business Days prior to Closing, Parent will provide the Company with its determinations regarding the applicability of Section&nbsp;280G of the Code and reasonable supporting calculations to any employee, officer, director or other service
provider of Parent or any of its Subsidiaries that, in connection with the Contemplated Transactions (i)&nbsp;may receive the payment of any &#8220;parachute payment&#8221; within the meaning of Section&nbsp;280G of the Code or (ii)&nbsp;may receive
a benefit in the form of accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Each Party shall reasonably cooperate and shall cause its respective Affiliates to reasonably cooperate with each other Party and its
agents, including accounting firms and legal counsel, in connection with any Tax Proceeding or the preparation of any Tax Return of the Company or any of its Subsidiaries. Such cooperation shall include each Party making such information and
documents in its possession relating to the Company or any of its Subsidiaries reasonably necessary in connection with any Tax Proceeding or such preparation available to the other Party. The Parties shall retain all Tax Returns, schedules, and work
papers, and all material records and other documents relating thereto, until the expiration of the applicable statute of limitations (including, to the extent noticed by any Party, any extensions thereof) of the Tax period to which such Tax Returns
and other documents and information relate. Each of the Parties shall also make available to the other Party, as reasonably requested and available on a mutually convenient basis, personnel responsible for preparing, maintaining, and interpreting
information and documents relevant to Taxes to provide reasonable explanation of any documents or information provided hereunder. Any information or documents provided under this Agreement shall be kept confidential by the Party receiving such
information or documents, except as may otherwise be necessary in connection with the filing of Tax Returns or in connection with a Tax Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Fifty percent (50%) of any transfer Taxes shall be borne and paid by each of Parent and the Company if and when due. Each of Parent and
the Company shall, at its own expense, timely file any Tax Return or other documents with respect to such Taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Parent and its Subsidiaries shall timely file 2025 U.S. federal, state, and foreign
income Tax extensions for their applicable Tax Returns. Neither Parent nor any of its Subsidiaries shall file income Tax Returns or any other income Tax related forms (including but not limited to change in accounting method forms) prior to the
close of the Merger unless required to meet due dates required by applicable Law (for which a valid extension cannot be made). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_87"></A>5.11 <U>Directors and Officers</U>. The Parties shall take all necessary action so that immediately after the Effective Time, (a)&nbsp;the Parent Board comprises seven (7)&nbsp;members (provided that the total number of directors to comprise the
Parent Board immediately after the Effective Time may be changed by the Company at any time prior to the Closing by written notice to Parent), with each member designated by the Company, (b)&nbsp;the Persons listed on <U>Schedule</U><U> 5.11</U>
under the heading &#8220;Officers&#8221; are elected or appointed, as applicable, to the positions of officers of Parent, as set forth therein, to serve in such positions effective as of the Effective Time until successors are duly appointed and
qualified in accordance with applicable Law and (c)&nbsp;the Persons listed on <U>Schedule</U><U> 5.11</U> under the heading &#8220;Directors&#8221; are elected or appointed, as applicable, to the positions of directors of Parent, as set forth
therein, and to the classes of such director positions as set forth therein, to serve in such positions effective as of the Effective Time until successors are duly appointed and qualified in accordance with applicable Law. If any Person listed on
<U>Schedule</U><U> 5.11</U> under the heading &#8220;Officers&#8221; is unable or unwilling to serve as an officer of Parent, as set forth therein, as of the Effective Time, the Company shall designate a successor in its sole discretion. If any
Person listed on <U>Schedule</U><U> 5.11</U> is unable or unwilling to serve as a director of Parent, as set forth therein, as of the Effective Time, the Company shall designate a successor in its sole discretion. The Persons listed on
<U>Schedule</U><U> 5.11</U> under the heading &#8220;Directors&#8221; shall be the Company&#8217;s designees pursuant to clause&nbsp;(c) of this <U>Section</U><U></U><U>&nbsp;5.11</U> (which initial list may include vacancies and be supplemented or
changed by the Company at any time prior to the Closing by written notice to Parent to include different board designees who are reasonably acceptable to Parent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_88"></A>5.12 <U>Termination of Certain Agreements and Rights</U>. The Company shall cause the Investor Agreements set
forth on <U>Section</U><U></U><U>&nbsp;5.12</U> of the Company Disclosure Schedule to be terminated immediately prior to the Effective Time, without any liability being imposed on the part of Parent or the Surviving Corporation. Parent shall use
reasonable best efforts to cause the Contracts set forth on <U>Section</U><U></U><U>&nbsp;5.12(a)</U> of the Parent Disclosure Schedule to be terminated immediately prior to the Effective Time, without any liability being imposed on the part of
Parent or the Surviving Corporation. During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, Parent shall not initiate any research, development or discovery programs (including the nomination of new targets) under the Contracts set
forth on <U>Section</U><U></U><U>&nbsp;5.12(b)</U> of the Parent Disclosure Schedule. Parent shall use commercially reasonable efforts to prepay any costs or expenses to maintain any Legacy Asset (as defined in the CVR Agreement) through the
Disposition Period (as defined in the CVR Agreement) under the Contracts set forth on <U>Section</U><U></U><U>&nbsp;5.12(c)</U> of the Parent Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_89"></A>5.13 <U>Section 16 Matters</U>. Prior to the Effective Time, Parent and the Company shall take all such steps
as may be required (to the extent permitted under applicable Laws) to cause any acquisitions of Parent Common Stock, restricted stock awards to acquire Parent Common Stock and any options to purchase Parent Common Stock in connection with the
Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section&nbsp;16(a) of the Exchange Act with respect to Parent, to be exempt under Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. At least ten (10)&nbsp;days prior to the Closing Date, the Company shall furnish the following information to Parent for each individual who, immediately after the
Effective Time, will become subject to the reporting requirements of Section&nbsp;16(a) of the Exchange Act with respect to Parent: (a)&nbsp;the number of shares of Company Capital Stock owned by such individual and expected to be exchanged for
shares of Parent Common Stock pursuant to the Merger, and (b)&nbsp;the number of other derivative securities (if any) with respect to Company Capital Stock owned by such individual and expected to be converted into shares of Parent Common Stock,
restricted stock awards to acquire Parent Common Stock or derivative securities with respect to Parent Common Stock in connection with the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_90"></A>5.14 <U>Cooperation</U>. Each Party shall cooperate reasonably with the other Party and shall provide the
other Party with such assistance as may be reasonably requested for the purpose of facilitating the performance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by each Party of its respective obligations under this Agreement and to enable the combined entity to continue to meet its obligations following the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_91"></A>5.15 <U>Allocation Certificate; Parent Outstanding Shares Certificate</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company will prepare and deliver to Parent at least ten (10)&nbsp;Business Days prior to the Closing Date a certificate signed by the
Chief Financial Officer of the Company in a form reasonably acceptable to Parent setting forth (as of immediately prior to the Effective Time)&nbsp;(i) each holder of Company Capital Stock and Company Options, (ii)&nbsp;such holder&#8217;s name and
address; (iii)&nbsp;the number and type of Company Capital Stock held or underlying the Company Options as of the immediately prior to the Effective Time for each such holder; (iv)&nbsp;the number of shares of Parent Common Stock to be issued to
such holder, or to underlie any Parent Stock Award to be issued to such holder, pursuant to this Agreement in respect of the Company Capital Stock or Company Options held by such holder as of immediately prior to the Effective Time; and
(v)&nbsp;each investor in the Concurrent Financing, the total investment to be made by such investor in the Concurrent Financing, the percentage of the Concurrent Financing Proceeds represented by such stockholder&#8217;s investment in the
Concurrent Financing, and the number of shares of Company Common Stock to be issued to such holder pursuant to this Agreement (the &#8220;<B><I>Allocation Certificate</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent will prepare and deliver to the Company at least ten (10)&nbsp;Business Days prior to the Closing Date a certificate signed by the
Chief Financial Officer of Parent in a form reasonably acceptable to the Company, setting forth, as of immediately prior to the Effective Time (i)&nbsp;the number of shares of Parent Common Stock and (ii)&nbsp;the number of shares of Parent Common
Stock held or underlying the Parent Stock Awards (including whether such Parent Stock Awards are In the Money Parent Options) or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, in each case as of the Effective Time for such holder (the
&#8220;<B><I>Parent Outstanding Shares Certificate</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_92"></A>5.16 <U>Company Financial
Statements</U>. To the extent required, the Company will (i)&nbsp;furnish to Parent audited financial statements for the fiscal year ended 2025 for inclusion in the Proxy Statement and the Registration Statement (the &#8220;<B><I>Company 2025
Audited Financial Statements</I></B>&#8221; and, collectively with the audited financial statements of the Company as of December&nbsp;31, 2024, the &#8220;<B><I>Company Audited Financial Statements</I></B>&#8221;) and (ii)&nbsp;use commercially
reasonable efforts to, no later than May&nbsp;14, 2026, furnish to Parent unaudited interim financial statements for each interim period completed prior to the Closing that would be required to be included in the Registration Statement or any
periodic report due prior to the Closing if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;<B><I>Company 2026 Interim Financial Statements</I></B>&#8221; and collectively with
the Company 2025 Interim Financial Statements, the &#8220;<B><I>Company Interim Financial Statements</I></B>&#8221;). Each of the Company 2025 Audited Financial Statements and the Company 2026 Interim Financial Statements will be suitable for
inclusion in the Proxy Statement and the Registration Statement and prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on that basis will present
fairly, in all material respects, the consolidated financial position and the results of operations, changes in stockholders&#8217; equity, and cash flows of the Company as of the dates of and for the periods referred to in the Company 2025 Audited
Financial Statements or the Company 2026 Interim Financial Statements, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_93"></A>5.17
<U>Takeover Statutes</U>. If any Takeover Statute is or may become applicable to the Contemplated Transactions, each of the Company, the Company Board, Parent and the Parent Board, as applicable, shall grant such approvals and take such actions as
are necessary so that the Contemplated Transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such Takeover Statute on the Contemplated
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_94"></A>5.18 <U>Stockholder Litigation</U>. Until the earlier of the termination of this Agreement
in accordance with its terms or the Effective Time, Parent shall (a)&nbsp;promptly advise the Company in writing of any stockholder litigation or investigation against it or its directors relating to this Agreement, the Merger or the Contemplated
Transactions and keep the Company fully informed regarding such stockholder litigation and (b)&nbsp;give the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company the opportunity to participate in the defense or settlement of any stockholder litigation or investigation relating to this Agreement or any of the Contemplated Transactions, and not
settle any such litigation or investigation without the Company&#8217;s written consent, which will not be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_95"></A>5.19 <U>Equity Plans</U>. Prior to or as of the Effective Time, the Parent Board shall approve, adopt and
submit for approval by the stockholders of Parent, and recommend and use commercially reasonable efforts to cause the stockholders of Parent to approve, (a)&nbsp;the 2026 Equity Incentive Plan in a form to be mutually agreed by Parent and the
Company (the &#8220;<B><I>2026 Plan</I></B>&#8221;) which will provide for new awards for a number of shares of Parent Common Stock not exceeding 15% of the Parent Common Stock issued and expected to be outstanding immediately after the Effective
Time, as mutually agreed upon by Parent and the Company, and subject to approval by the Parent Board (for avoidance of doubt, such number of shares shall be in addition to the number of shares of Parent Common Stock subject to outstanding Parent
Stock Awards or subject to Company Options assumed by Parent as contemplated by <U>Section</U><U></U><U>&nbsp;5.5</U>), and which may include an annual increase pursuant to an &#8220;evergreen&#8221; provision to provide for optional annual
increases of up to 5% of the total number of fully diluted shares of capital stock of Parent as of the day prior to such increase; and (b)&nbsp;the 2026 Employee Stock Purchase Plan (the &#8220;<B><I>2026 ESPP</I></B>&#8221;), in a form to be
mutually agreed by Parent and the Company with a total pool of shares of Parent Common Stock not exceeding 1% of the Parent Common Stock issued and expected to be outstanding immediately after the Effective Time, and may include an annual increase
pursuant to an &#8220;evergreen&#8221; provision providing for an annual increase of up to 1% of the total number of fully diluted shares of capital stock of Parent outstanding as of the day prior to such increase ((a) and (b), collectively, the
&#8220;<B><I>Equity Plan Proposals</I></B>&#8221;). Subject to the approval of the 2026 Plan by the stockholders of Parent, Parent shall file with the SEC, promptly after the Effective Time, a registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> (or any successor form), if available for use by Parent, relating to the shares of Parent Common Stock issuable with respect to the 2026 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_96"></A>5.20 <U>Parent SEC Documents</U>. From the date of this Agreement until the Effective Time, Parent shall use
commercially reasonable efforts to timely file with the SEC all Parent SEC Documents. As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each Parent SEC Document filed by Parent with the
SEC shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_97"></A>5.21 <U>Parent Options and RSUs</U>. Before the Effective Time, Parent shall take all actions necessary to provide that all Parent Stock Awards shall be fully vested as of the Effective Time and that no option to purchase Parent Common Stock
shall be exercised later than ninety (90)&nbsp;
days following the termination of service of the holder of such option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_98"></A>5.22 <U>Parent Operations
Wind-Down</U>. During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, Parent and its Subsidiaries shall, except as the Company shall otherwise consent in writing, wind-down all preclinical, CMC and clinical activities as promptly as
practicable after the date hereof, with any liabilities with respect thereto to be reflected on the Net Cash Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_99"></A>5.23 <U>Concurrent Financing</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions of this Agreement, the Company shall use reasonable best
efforts to obtain the Concurrent Financing on the terms and conditions described in the Subscription Agreement and satisfy the conditions to the Concurrent Financing as described in the Subscription Agreement and shall not permit any termination,
amendment or modification to be made to, or any waiver of any provision under, or any replacement of, the Subscription Agreement if such termination, amendment, modification, waiver or replacement (i)&nbsp;reduces the aggregate amount of the
Concurrent Financing below the Concurrent Investment Amount or (ii)&nbsp;imposes new or additional conditions or otherwise expands, amends or modifies any of the conditions to the receipt of the Concurrent Financing, or otherwise expands, amends or
modifies any other provision of the Subscription Agreement, in a manner that would reasonably be expected to (x)&nbsp;delay or prevent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Closing or the consummation of the Merger or (y)adversely impact the ability of the Company to enforce its rights against other parties to the Subscription Agreement. The Company shall
promptly deliver to Parent copies of any such termination, amendment, modification, waiver or replacement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company shall use
reasonable best efforts (i)&nbsp;to maintain in effect the Subscription Agreement, (ii)&nbsp;to enforce its rights under the Subscription Agreement and (iii)&nbsp;to comply with its obligations under the Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company shall give Parent prompt notice (i)&nbsp;of any material breach or default by any party to the Subscription Agreement or
definitive agreements related to the Concurrent Financing of which the Company becomes aware, (ii)&nbsp;of the receipt of any written notice or other written communication from any Purchaser with respect to any (x)&nbsp;actual material breach,
default, termination or repudiation by any party to the Subscription Agreement or definitive agreements related to the Concurrent Financing of any provisions of the Subscription Agreement or definitive agreements related to the Concurrent Financing
or (y)&nbsp;material dispute or disagreement relating to the Concurrent Financing with respect to the obligation to fund the Concurrent Financing at or substantially simultaneously with the Closing, and (iii)&nbsp;if at any time for any reason the
Company believes in good faith that it will not be able to obtain all or any portion of the Concurrent Investment Amount on the terms and conditions, in the manner or from the sources contemplated by the Subscription Agreement or definitive
agreements related to the Concurrent Financing. The Company shall promptly provide information reasonably requested by Parent relating to the circumstances referred to in clauses (i), (ii) or (iii)&nbsp;of the immediately preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_100"></A><B>Section</B><B></B><B>&nbsp;6.</B> <U>CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are
subject to the satisfaction (or, to the extent permitted by applicable Law, written waiver by each of the Parties) of each of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_101"></A>6.1 <U>No Restraints</U>. No temporary restraining order, preliminary or permanent injunction or other order
preventing the consummation of the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Body of competent jurisdiction and remain in effect and there shall not be any Law which has the effect
of making the consummation of the Contemplated Transactions illegal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_102"></A>6.2 <U>Stockholder Approval</U>.
(a)&nbsp;Parent shall have obtained the Required Parent Stockholder Vote and (b)&nbsp;the Company shall have obtained the Required Company Stockholder Vote and such Required Company Stockholder Vote shall remain in full force and effect and shall
not have been revoked. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_103"></A>6.3 <U>Parent Charter Amendment</U>. The Parent Charter Amendment shall have
been duly filed with the Secretary of State of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_104"></A>6.4 <U>Listing</U>. (a)&nbsp;The
existing shares of Parent Common Stock shall have been continually listed on Nasdaq as of and from the date of this Agreement through the Closing Date and (b)&nbsp;the shares of Parent Common Stock to be issued in the Merger pursuant to this
Agreement shall have been approved for listing (subject to official notice of issuance) on Nasdaq as of the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_105"></A>6.5 <U>Subscription Agreement</U>. The Subscription Agreement shall be in full force and effect and cash proceeds of not less than the Concurrent Investment Amount shall have been received by the Company, or will be received by the Company
substantially simultaneously with the Closing, in connection with the consummation of the transactions contemplated by the Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_106"></A>6.6 <U>Effectiveness of Registration Statement</U>. The Registration Statement shall have become effective
in accordance with the provisions of the Securities Act and shall not be subject to any stop order or proceeding (or threatened proceeding by the SEC) seeking a stop order with respect to the Registration Statement that has not been withdrawn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_107"></A>6.7 <U>Parent Net Cash Determination</U>. Parent Net Cash
shall have been finally determined in accordance with <U>Section</U><U></U><U>&nbsp;1.6.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_108"></A>6.8 <U>HSR
Act</U>. All waiting periods (and extensions thereof) applicable to the Merger under the HSR Act shall have expired or otherwise been terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_109"></A><B>Section</B><B></B><B>&nbsp;7.</B> <U>ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER
SUB</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of Parent and Merger Sub to effect the Merger and otherwise consummate the Contemplated Transactions to be
consummated at the Closing are subject to the satisfaction (or, to the extent permitted by applicable Law, written waiver by Parent) of each of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_110"></A>7.1 <U>Accuracy of Representations</U>. (i)&nbsp;The representation and warranty of the Company set forth in
clause (y)&nbsp;of <U>Section</U><U></U><U>&nbsp;2.8</U> shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct in all respects on and as of the Closing Date with the same force and effect as
if made on and as of such date; (ii)&nbsp;the Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct in all material respects on and as of the
Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true
and correct in all material respects as of such date); and (iii)&nbsp;the representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations and clause (y)&nbsp;of
<U>Section</U><U></U><U>&nbsp;2.8)</U> shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except
(a)&nbsp;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse
Effect or other materiality qualifications), or (b)&nbsp;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth
in the preceding clause&nbsp;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Schedule made or
purported to have been made after the date of this Agreement shall be disregarded). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_111"></A>7.2 <U>Performance
of Covenants</U>. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_112"></A>7.3 <U>Documents</U>. Parent shall have received the following documents, each of which shall be in full
force and effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying
(i)&nbsp;that the conditions set forth in <U>Sections</U><U>&nbsp;7.1</U>, <U>7.2</U>, <U>7.5</U> and <U>7.6</U> have been duly satisfied and (ii)&nbsp;that the information set forth in the Allocation Certificate delivered by the Company in
accordance with <U>Section</U><U></U><U>&nbsp;5.15</U> is true and accurate in all respects as of the Closing Date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the
Allocation Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_113"></A>7.4 <U>FIRPTA Certificate</U>. Parent shall have received (i)&nbsp;an original
signed statement from the Company that the Company is not, and has not been at any time during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code, a &#8220;United States real property holding corporation,&#8221; as defined
in Section&nbsp;897(c)(2) of the Code, conforming to the requirements of Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.1445-2(c)(3)</FONT> and <FONT STYLE="white-space:nowrap">1.897-2(h),</FONT> and (ii)&nbsp;an original signed
notice to be delivered to the IRS in accordance with the provisions of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h)(2),</FONT> together with written authorization for Parent to deliver such notice
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the IRS on behalf of the Company following the Closing, each dated as of the Closing Date, duly executed by an authorized officer of the Company, and in form and substance reasonably
acceptable to Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_114"></A>7.5 <U>No Company Material Adverse Effect</U>. Since the date of this Agreement,
there shall not have occurred any Company Material Adverse Effect that is continuing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_115"></A>7.6
<U>Termination of Investor Agreements</U>. The Investor Agreements set forth on <U>Section</U><U></U><U>&nbsp;5.12</U> of the Company Disclosure Schedule shall have been terminated (or will be terminated as of the Closing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_116"></A>7.7 <U>Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U>. Parent shall have received
the Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements duly executed by each of the Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Signatories and each executive officer and director of the Company who is elected or
appointed, as applicable, as an executive officer and director of Parent as of immediately following the Closing, each of which shall be in full force and effect as of immediately following the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_117"></A><B>Section</B><B></B><B>&nbsp;8.</B> <U>ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligation of the Company to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the
Closing is subject to the satisfaction (or, to the extent permitted by applicable Law, written waiver by the Company) of each of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_118"></A>8.1 <U>Accuracy of Representations</U>. (i)&nbsp;The representations and warranties of Parent and Merger Sub
set forth in clause (y)&nbsp;of <U>Section</U><U></U><U>&nbsp;3.8 </U>shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct in all respects on and as of the Closing Date with the same force
and effect as if made on and as of such date; (ii)&nbsp;the Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct in all material respects on and
as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall
be true and correct in all material respects as of such date); and (iii)&nbsp;the representations and warranties of Parent and Merger Sub contained in this Agreement (other than the Parent Fundamental Representations and in clause (y)&nbsp;of
<U>Section</U><U></U><U>&nbsp;3.8</U>) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except
(a)&nbsp;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect
or other materiality qualifications), or (b)&nbsp;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the
preceding clause&nbsp;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Schedule made or purported to
have been made after the date of this Agreement shall be disregarded). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_119"></A>8.2 <U>Performance of
Covenants</U>. Parent and Merger Sub shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the Effective
Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_120"></A>8.3 <U>Documents</U>. The Company shall have received the following documents, each of which
shall be in full force and effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) a certificate executed by the Chief Executive Officer or Chief Financial Officer of Parent
certifying that the conditions set forth in <U>Sections</U><U>&nbsp;8.1</U>, <U>8.2</U> and <U>8.4</U> have been duly satisfied; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the
Parent Outstanding Shares Certificate; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the Parent Closing Financial Certificate, a draft of which shall have been provided at
least five (5)&nbsp;Business Days prior to the Closing, which certificate shall be accompanied by such supporting documentation, information and calculations as are reasonably requested by the Company to verify and determine the information
contained therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) a written resignation, in a form reasonably satisfactory to the Company, dated as of the Closing Date and
effective as of the Effective Time, executed by each of the directors of Parent who are not to continue as directors of Parent after the Effective Time pursuant to <U>Section</U><U></U><U>&nbsp;5.11</U> hereof; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) the executed CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_121"></A>8.4 <U>No Parent Material Adverse Effect</U>. Since the date of this Agreement, there shall not have
occurred any Parent Material Adverse Effect that is continuing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_122"></A>8.5 <U>Parent Net Cash</U><U> and
Minimum Cash Amount</U>. Parent Net Cash determined in accordance with <U>Section</U><U></U><U>&nbsp;1.6</U> shall be greater than or equal to $0. Parent&#8217;s Cash and Cash Equivalents as of the Anticipated Closing Date determined in accordance
with <U>Section</U><U></U><U>&nbsp;1.6</U> shall be greater than or equal to $1,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_123"></A><B>Section</B><B></B><B>&nbsp;9.</B> <U>TERMINATION</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_124"></A>9.1 <U>Termination</U>. This Agreement may be terminated prior to the Effective Time (whether before or
after approval of the Company Stockholder Matters by the Company&#8217;s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent&#8217;s stockholders, unless otherwise specified below): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of Parent and the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) by either Parent or the Company if the Contemplated Transactions shall not have been consummated by September&nbsp;1, 2026 (subject to
possible extension as provided in this <U>Section</U><U></U><U>&nbsp;9.1(b)</U>, the &#8220;<B><I>End Date</I></B>&#8221;); <I>provided</I>, <I>however</I>, that the right to terminate this Agreement under this
<U>Section</U><U></U><U>&nbsp;9.1(b)</U> shall not be available to the Company, on the one hand, or to Parent, on the other hand, if such Party&#8217;s action or failure to act has been a principal cause of the failure of the Contemplated
Transactions to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement, <I>provided</I>, <I>further</I>, <I>however</I>, that, in the event that (i)&nbsp;the SEC has not declared the Registration
Statement effective under the Securities Act or (ii)&nbsp;the waiting periods (and extensions thereof) applicable to the Merger under the HSR Act have not expired or otherwise been terminated by the date which is thirty (30)&nbsp;calendar days prior
to the End Date, then either Parent or the Company shall be entitled to extend the End Date for an additional sixty (60)&nbsp;calendar days by written notice to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) by either Parent or the Company if a court of competent jurisdiction or other Governmental Body shall have issued a final and
nonappealable order, decree or ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions; <I>provided</I>, <I>however</I>, that the right to terminate
this Agreement under this <U>Section</U><U></U><U>&nbsp;9.1(c)</U> shall not be available to the Company, on the one hand, or to Parent, on the other hand, if such Party&#8217;s action or failure to act has been a principal cause of the failure of
any such Governmental Body issuing any such order, decree or ruling or taking any such other action; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) by Parent if, subject to
<U>Section</U><U></U><U>&nbsp;4.5</U>, the Company Stockholder Written Consent executed by each Company Signatory shall not have been obtained within seven (7)&nbsp;Business Days of the Registration Statement becoming effective in accordance with
the provisions of the Securities Act; <I>provided</I>,<I> however</I>, that once the Company Stockholder Written Consent has been obtained, Parent may not terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;9.1(d)</U>; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) by either Parent or the Company if (i)&nbsp;the Parent Stockholders&#8217; Meeting
(including any adjournments and postponements thereof) shall have been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii)&nbsp;the Parent Stockholder Matters shall not have
been approved at the Parent Stockholders&#8217; Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; <I>provided, however</I>, that the right to terminate this Agreement under this
<U>Section</U><U></U><U>&nbsp;9.1(e)</U> shall not be available to Parent where the failure to obtain the Required Parent Stockholder Vote shall have been caused by the action or failure to act of Parent and such action or failure to act constitutes
a material breach by Parent of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) by the Company (at any time prior to the approval of the Parent Stockholder Matters
by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) by Parent (at any time prior to the
Required Company Stockholder Vote being obtained) if a Company Triggering Event shall have occurred; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) by the Company (at any time
prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote and following compliance in all material respects with all of the requirements set forth in <U>Section</U><U></U><U>&nbsp;5.2(e)(</U><U>i</U><U>)</U>)
concurrently with entering into a Permitted Alternative Agreement and after having paid to Parent the Parent Termination Fee pursuant to <U>Section</U><U></U><U>&nbsp;9.3(c)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Sub
or if any representation or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in <U>Section</U><U></U><U>&nbsp;8.1</U> or <U>Section</U><U></U><U>&nbsp;8.2</U> would not be satisfied as
of the time of such breach or as of the time such representation or warranty shall have become inaccurate; <I>provided</I> that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement;
<I>provided</I>, <I>further</I>, that if such inaccuracy in Parent&#8217;s or Merger Sub&#8217;s representations and warranties or breach by Parent or Merger Sub is curable by the End Date by Parent or Merger Sub, then this Agreement shall not
terminate pursuant to this <U>Section</U><U></U><U>&nbsp;9.1(</U><U>i</U><U>)</U> as a result of such particular breach or inaccuracy until the earlier of (i)&nbsp;the End Date and (ii)&nbsp;the expiration of a thirty (30)&nbsp;calendar day period
commencing upon delivery of written notice from the Company to Parent of such breach or inaccuracy and its intention to terminate pursuant to this <U>Section</U><U></U><U>&nbsp;9.1(</U><U>i</U><U>)</U> (it being understood that this Agreement shall
not terminate pursuant to this <U>Section</U><U></U><U>&nbsp;9.1(</U><U>i</U><U>)</U> as a result of such particular breach or inaccuracy if such breach by Parent or Merger Sub is cured prior to such termination becoming effective); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any
representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in <U>Section</U><U></U><U>&nbsp;7.1</U> or <U>Section</U><U></U><U>&nbsp;7.2</U> would not be satisfied as of the time of
such breach or as of the time such representation or warranty shall have become inaccurate; <I>provided</I> that neither Parent nor Merger Sub is then in material breach of any representation, warranty, covenant or agreement under this Agreement;
<I>provided</I>, <I>further</I>, that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the End Date by the Company then this Agreement shall not terminate pursuant to this
<U>Section</U><U></U><U>&nbsp;9.1(j)</U> as a result of such particular breach or inaccuracy until the earlier of (i)&nbsp;the End Date and (ii)&nbsp;the expiration of a thirty (30)&nbsp;calendar day period commencing upon delivery of written notice
from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <U>Section</U><U></U><U>&nbsp;9.1(j)</U> (it being understood that this Agreement shall not terminate pursuant to this
<U>Section</U><U></U><U>&nbsp;9.1(j)</U> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Party desiring to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;9.1</U>, shall give the other Party written notice of such
termination, specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_125"></A>9.2 <U>Effect of Termination</U>. In the event of the
termination of this Agreement as provided in <U>Section</U><U></U><U>&nbsp;9.1</U>, this Agreement shall be of no further force or effect; <I>provided</I>, <I>however</I>, that (a)&nbsp;this <U>Section</U><U></U><U>&nbsp;9.2</U>,
<U>Section</U><U></U><U>&nbsp;5.8</U>, <U>Section</U><U></U><U>&nbsp;9.3</U>, <U>Section</U><U></U><U>&nbsp;10</U> and the definitions of the defined terms in such Sections (including the definitions of such defined terms set forth in <B>Exhibit
A</B>) shall survive the termination of this Agreement and shall remain in full force and effect following such termination, and (b)&nbsp;the termination of this Agreement and the provisions of <U>Section</U><U></U><U>&nbsp;9.3</U> shall not relieve
any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_126"></A>9.3 <U>Expenses; Termination Fees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as set forth in this <U>Section</U><U></U><U>&nbsp;9.3</U>, <U>Section</U><U></U><U>&nbsp;1.6(e),</U>
<U>Section</U><U></U><U>&nbsp;5.4</U>, <U>Section</U><U></U><U>&nbsp;5.9</U> and <U>Section</U><U></U><U>&nbsp;5.10(e)</U>, the Transaction Expenses shall be paid by the Party incurring such expenses, whether or not the Merger is consummated;
<I>provided</I> that the Company shall bear 60% of all fees and expenses incurred in relation to (i)&nbsp;the printing and filing with the SEC of the Registration Statement and Proxy Statement and any amendments and supplements thereto and paid to a
financial printer or the SEC, and (ii)&nbsp;the proxy solicitation firm engaged in connection with the Parent Stockholders&#8217; Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) (A)&nbsp;this
Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1(b)</U>, <U>Section</U><U></U><U>&nbsp;9.1(e)</U> or <U>Section</U><U></U><U>&nbsp;9.1(</U><U>i</U><U>)</U>, (B)&nbsp;an Acquisition Proposal with respect to Parent shall have been
publicly announced, disclosed or otherwise communicated to Parent or the Parent Board at any time after the date of this Agreement but prior to the termination of this Agreement (which shall not have been withdrawn) and (C)&nbsp;within twelve
(12)&nbsp;months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction in respect of the Acquisition Proposal referred to in clause&nbsp;(B) or
in respect of any other Acquisition Proposal; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) this Agreement is terminated by the Company pursuant to
<U>Section</U><U></U><U>&nbsp;9.1(f)</U> (or, at the time this Agreement is terminated, the Company had the right to terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;9.1(f)</U>); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then Parent shall pay to the Company a nonrefundable fee in an amount equal to $1,425,000 (the &#8220;<B><I>Company Termination Fee</I></B>&#8221;), in the
case of <U>Section</U><U></U><U>&nbsp;9.3(b)(i)</U>, upon the consummation of such Subsequent Transaction or, in the case of <U>Section</U><U></U><U>&nbsp;9.3(b)(ii)</U>, concurrently with the termination of this Agreement plus any amount payable to
the Company pursuant to <U>Section</U><U></U><U>&nbsp;9.3(f)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) (A)&nbsp;this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1(b)</U>, <U>Section</U><U></U><U>&nbsp;9.1(d)</U>, or
<U>Section</U><U></U><U>&nbsp;9.1(j)</U>, (B)&nbsp;an Acquisition Proposal with respect to the Company shall have been publicly announced, disclosed or otherwise communicated to the Company or the Company Board at any time after the date of this
Agreement but prior to obtaining the Required Company Stockholder Vote (which shall not have been withdrawn, (1)&nbsp;in the case of a termination pursuant to <U>Section</U><U></U><U>&nbsp;9.1(b)</U> or <U>Section</U><U></U><U>&nbsp;9.1(j)</U>, at
the time the Required Company Stockholder Vote is obtained and (2)&nbsp;in the case of a termination pursuant to <U>Section</U><U></U><U>&nbsp;9.1(d)</U>, at the time of such termination) and (C)&nbsp;within twelve (12)&nbsp;months after the date of
such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction in respect of the Acquisition Proposal referred to in clause&nbsp;(B) or in respect of any other
Acquisition Proposal; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) this Agreement is terminated by Parent pursuant to <U>Section</U><U></U><U>&nbsp;9.1(g)</U> (or, at the time
this Agreement is terminated, Parent had the right to terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;9.1(g)</U>); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1(h)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then (A)&nbsp;the Company shall pay to Parent an amount equal to $50,000,000 (the &#8220;<B><I>Parent Termination Fee</I></B>&#8221;), in the case of
<U>Section</U><U></U><U>&nbsp;9.3(c)(i)</U> in the event this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1(d)</U> or <U>Section</U><U></U><U>&nbsp;9.1(j)</U>, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon the consummation of such Subsequent Transaction or, in the case of <U>Section</U><U></U><U>&nbsp;9.3(c)(ii)</U> and <U>Section</U><U></U><U>&nbsp;9.3(c)(iii)</U>, concurrently with the
termination of this Agreement, plus any amount payable to Parent pursuant to <U>Section</U><U></U><U>&nbsp;9.3(f)</U> and (B)&nbsp;the Company shall pay to Parent an amount equal to $10,000,000 in the case of
<U>Section</U><U></U><U>&nbsp;9.3(c)(i)</U> in the event this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1(b)</U>, upon the consummation of such Subsequent Transaction, plus any amount payable to Parent pursuant to
<U>Section</U><U></U><U>&nbsp;9.3(f)</U> (the &#8220;<B><I>Parent Termination Fee</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) (i)&nbsp;If this Agreement is
terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1(e)</U>, <U>Section</U><U></U><U>&nbsp;9.1(f)</U> or <U>Section</U><U></U><U>&nbsp;9.1(</U><U>i</U><U>)</U> or (ii)&nbsp;in the event of the failure of the Company to consummate the
transactions to be contemplated at the Closing solely as a result of a Parent Material Adverse Effect as set forth in <U>Section</U><U></U><U>&nbsp;8.4</U> (provided, that at such time all of the other conditions precedent to Parent&#8217;s
obligation to close set forth in <U>Section</U><U></U><U>&nbsp;6</U> and <U>Section</U><U></U><U>&nbsp;7</U> have been satisfied by the Company, are capable of being satisfied by the Company or have been waived by Parent), then Parent shall
reimburse the Company for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses incurred by the Company in connection with this Agreement and the Contemplated Transactions
(such expenses, collectively, the &#8220;<B><I>Third Party Expenses</I></B>&#8221;), up to a maximum of $500,000, by wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds within ten (10)&nbsp;Business Days following the date on
which the Company submits to Parent true and correct copies of reasonable documentation supporting such Third Party Expenses; <I>provided</I>, <I>however</I>, that such Third Party Expenses shall not include any amounts for financial advisors to the
Company except for reasonably documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses otherwise reimbursable by the Company to such financial advisors pursuant to the terms of the
Company&#8217;s engagement letter or similar arrangement with such financial advisors. For the avoidance of doubt, to the extent any Third Party Expenses are paid, such amounts shall be credited against any Company Termination Fee which becomes
payable thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) (i) If this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;9.1(d)</U>,
<U>Section</U><U></U><U>&nbsp;9.1(g)</U> or <U>Section</U><U></U><U>&nbsp;9.1(j)</U> or (ii)&nbsp;in the event of the failure of Parent to consummate the transactions to be consummated to the Closing solely as a result of a Company Material Adverse
Effect as set forth in <U>Section</U><U></U><U>&nbsp;7.5</U> provided, that at such time all of the other conditions precedent to the Company&#8217;s obligation to close set forth in <U>Section</U><U></U><U>&nbsp;6</U> and
<U>Section</U><U></U><U>&nbsp;8</U> have been satisfied by Parent are capable of being satisfied by Parent or have been waived by the Company, the Company shall reimburse Parent for all Third Party Expenses incurred by Parent up to a maximum of
$500,000, by wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds within ten (10)&nbsp;Business Days following the date on which Parent submits to the Company true and correct copies of reasonable documentation supporting such
Third Party Expenses; <I>provided</I>, <I>however</I>, that such Third Party Expenses shall not include any amounts for financial advisors to Parent except for reasonably documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses otherwise reimbursable by Parent to such financial advisors pursuant to the terms of Parent&#8217;s engagement letter or similar arrangement with
such financial advisors. For the avoidance of doubt, to the extent any Third Party Expenses are paid, such amounts shall be credited against any Parent Termination Fee which becomes payable thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Any Company Termination Fee or Parent Termination Fee due under this <U>Section</U><U></U><U>&nbsp;9.3</U> shall be paid by wire transfer
of same day funds. If a Party fails to pay when due any amount payable by it under this <U>Section</U><U></U><U>&nbsp;9.3</U>, then (i)&nbsp;such Party shall reimburse the other Party for reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including reasonable and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and disbursements of counsel) incurred in
connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this <U>Section</U><U></U><U>&nbsp;9.3</U>, and (ii)&nbsp;such Party shall pay to the other Party interest on such overdue amount (for
the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as
published in <I>The Wall Street Journal</I> or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent (3%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The Parties agree that, (i)&nbsp;subject to <U>Section</U><U></U><U>&nbsp;9.2</U>, payment of the Company Termination Fee shall, in the
circumstances in which it is owed in accordance with the terms of this Agreement, constitute the sole and exclusive remedy of the Company following the termination of this Agreement under the circumstances described in
<U>Section</U><U></U><U>&nbsp;9.3(b)</U>, it being understood that in no event shall Parent be required to pay the amounts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payable pursuant to this <U>Section</U><U></U><U>&nbsp;9.3</U> on more than one occasion and (ii)&nbsp;following payment of the Company Termination Fee (x)&nbsp;Parent shall have no further
liability to the Company in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by Parent giving rise to such termination, or the failure of the Contemplated Transactions to be consummated,
(y)&nbsp;neither the Company nor any of its Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against Parent or Merger Sub or seek to obtain any recovery, judgment or damages of any kind against such Parties (or
any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Parties) in connection with or arising out of this Agreement or the termination thereof, any breach by any such Parties
giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (z)&nbsp;the Company and its Affiliates shall be precluded from any other remedy against Parent, Merger Sub and their respective Affiliates, at law
or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated; <I>provided</I>,
<I>however</I>, that nothing in this <U>Section</U><U></U><U>&nbsp;9.3(g)</U> shall limit the rights of Parent and Merger Sub under <U>Section</U><U></U><U>&nbsp;10.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) The Parties agree that, (i)&nbsp;subject to <U>Section</U><U></U><U>&nbsp;9.2</U>, payment of the Parent Termination Fee shall, in the
circumstances in which it is owed in accordance with the terms of this Agreement, constitute the sole and exclusive remedy of Parent following the termination of this Agreement under the circumstances described in
<U>Section</U><U></U><U>&nbsp;9.3(c)</U>, it being understood that in no event shall the Company be required to pay the amounts payable pursuant to this <U>Section</U><U></U><U>&nbsp;9.3</U> on more than one occasion and (ii)&nbsp;following payment
of the Parent Termination Fee (x)&nbsp;the Company shall have no further liability to Parent in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the Company giving rise to such termination,
or the failure of the Contemplated Transactions to be consummated, (y)&nbsp;neither Parent nor any of its Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against the Company or seek to obtain any recovery,
judgment or damages of any kind against the Company (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of the Company) in connection with or arising out of this Agreement or the
termination thereof, any breach by the Company giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (z)&nbsp;Parent and its Affiliates shall be precluded from any other remedy against the Company and
its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be
consummated; <I>provided</I>, <I>however</I>, that nothing in this <U>Section</U><U></U><U>&nbsp;9.3(h)</U> shall limit the rights of the Company under <U>Section</U><U></U><U>&nbsp;10.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each of the Parties acknowledges that (i)&nbsp;the agreements contained in this <U>Section</U><U></U><U>&nbsp;9.3</U> are an integral
part of the Contemplated Transactions, (ii)&nbsp;without these agreements, the Parties would not enter into this Agreement and (iii)&nbsp;any amount payable pursuant to this <U>Section</U><U></U><U>&nbsp;9.3</U> is not a penalty, but rather is
liquidated damages in a reasonable amount that will compensate the applicable Party in the circumstances in which such amount is payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_127"></A><B>Section</B><B></B><B>&nbsp;10.</B> <U>MISCELLANEOUS PROVISIONS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_128"></A>10.1 <U><FONT STYLE="white-space:nowrap">Non-Survival</FONT> of Representations and Warranties</U>. The
representations, warranties and covenants of the Company, Parent and Merger Sub contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the Effective Time, and only the covenants that by
their terms survive the Effective Time and this <U>Section</U><U></U><U>&nbsp;
10</U> shall survive the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_129"></A>10.2 <U>Amendment</U>. This Agreement may be amended with the
approval of the Company, Merger Sub and Parent at any time (whether before or after obtaining the Required Company Stockholder Vote or before or after obtaining the Required Parent Stockholder Vote); <I>provided</I>, <I>however</I>, that after any
such approval of this Agreement by a Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an
instrument in writing signed on behalf of each of the Company, Merger Sub and Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_130"></A>10.3 <U>Waiver</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of
any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude
any other or further exercise thereof or of any other power, right, privilege or remedy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No Party shall be deemed to have waived any
claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on
behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_131"></A>10.4 <U>Entire Agreement; Counterparts; Exchanges by Electronic Transmission</U>. This Agreement, the
Company Disclosure Schedule, the Parent Disclosure Schedule and the other agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of
the Parties with respect to the subject matter hereof and thereof; <I>provided</I>, <I>however</I>, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms. This Agreement may
be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by electronic
transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_132"></A>10.5 <U>Applicable Law; Jurisdiction; WAIVER OF JURY TRIAL</U>. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable
principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a)&nbsp;irrevocably and unconditionally consents and
submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent
that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (b)&nbsp;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause&nbsp;(a)
of this <U>Section</U><U></U><U>&nbsp;10.5</U>; (c)&nbsp;waives any objection to laying venue in any such action or proceeding in such courts; (d)&nbsp;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over
any Party; (e)&nbsp;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <U>Section</U><U></U><U>&nbsp;10.8</U> of this Agreement; and (f)&nbsp;IRREVOCABLY AND
UNCONDITIONALLY WAIVES THE RIGHT TO TRIAL BY JURY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_133"></A>10.6 <U>Attorneys</U><U>&#8217;</U><U> Fees</U>. In
any action at law or suit in equity to enforce this Agreement or the rights of any of the Parties, the prevailing Party in such action or suit (as determined by a court of competent jurisdiction) shall be entitled to recover its reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> attorneys&#8217; fees and all other reasonable costs and expenses incurred in such action or suit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_134"></A>10.7 <U>Assignability</U>. This Agreement shall be binding upon, and shall be enforceable by and inure
solely to the benefit of, the Parties and their respective successors and permitted assigns; <I>provided</I>, <I>however</I>, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such
Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_135"></A>10.8 <U>Notices</U>. All notices and other communications hereunder shall be in writing and
shall be deemed to have been duly delivered and received hereunder (a)&nbsp;one (1) Business Day after being sent for next Business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&nbsp;upon delivery in the case of delivery by hand, or (c)&nbsp;on the date delivered in the place of
delivery if sent by email (provided that no bounceback or similar &#8220;undeliverable&#8221; message is received by such sender) prior to 5:00 p.m. Eastern Time, otherwise on the next succeeding Business Day, in each case to the intended recipient
as set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to Parent or Merger Sub: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Rallybio Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">234
Church Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New Haven, CT 06510 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Jonathan Lieber </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy to
(which shall not constitute notice): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Ropes&nbsp;&amp; Gray LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Prudential Tower </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">800 Boylston
Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston, MA 02199 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Zachary Blume; Tyler Silvey </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***]; [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to the
Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Candid Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">11622 El Camino Real, Suite 150 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:
[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a
copy to (which shall not constitute notice): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">10265 Science Center Dr. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San
Diego, CA 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Rama Padmanabhan; Lindsey O&#8217;Crump; Carlos Ramirez </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***]; [***]; [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_136"></A>10.9 <U>Cooperation</U>. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the
other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_137"></A>10.10 <U>Severability</U>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or
the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or
unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and
enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in
the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or
unenforceable term or provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_138"></A>10.11 <U>Other Remedies; Specific Performance</U>. Except
as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any
one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not perform the
provisions of this Agreement (including failing to take such actions as are required of it hereunder to consummate this Agreement) in accordance with their specified terms or otherwise breaches such provisions. Accordingly, the Parties acknowledge
and agree that the Parties shall be entitled to an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any
state thereof having jurisdiction, in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on
the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. Any Party seeking an injunction or injunctions to prevent breaches of this
Agreement shall not be required to provide any bond, surety or other security in connection with any such order or injunction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_139"></A>10.12 <U>No Third Party Beneficiaries</U>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights
pursuant to <U>Section</U><U></U><U>&nbsp;5.6</U>) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_140"></A>10.13 <U>Construction</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) References to &#8220;cash,&#8221; &#8220;dollars&#8221; or &#8220;$&#8221; are to U.S. dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Parties have participated jointly in the negotiating and drafting of this Agreement and agree that any rule of construction to the
effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the
authorship of any provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) As used in this Agreement, the words &#8220;include&#8221; and
&#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) As used in this Agreement, the word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject
extends and does not simply mean &#8220;if.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) As used in this Agreement, the word &#8220;or&#8221; shall not be exclusive
(<I>i.e.</I>, &#8220;or&#8221; shall be deemed to mean &#8220;and/or&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Except as otherwise indicated, all references in this
Agreement to &#8220;Sections,&#8221; &#8220;Exhibits&#8221; and &#8220;Schedules&#8221; are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Any reference to legislation or to any provision of any legislation shall include any modification, amendment, <FONT
STYLE="white-space:nowrap">re-enactment</FONT> thereof, any legislative provision substituted therefore and all rules, regulations, and statutory instruments issued or related to such legislations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The bold-faced headings and table of contents contained in this Agreement are for
convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) The Parties agree that each of the Company Disclosure Schedule and the Parent Disclosure Schedule shall be arranged in sections and
subsections corresponding to the numbered and lettered sections and subsections contained in this Agreement. The disclosures in any section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule shall qualify other
sections and subsections in this Agreement to the extent it is readily apparent on its face from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Each of &#8220;delivered&#8221; or &#8220;made available&#8221; means, with respect to any documentation, that prior to 11:59 p.m.
Eastern Time on the date that is two (2)&nbsp;calendar days prior to the date of this Agreement (i)&nbsp;a copy of such material has been posted to and made available by a Party to the other Party and its Representatives in the electronic data room
maintained by such disclosing Party or (ii)&nbsp;such material is disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly made available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval
system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Saturday,
Sunday, or any date on which banks in New York, New York are authorized or obligated by Law to be closed, the Party having such privilege or duty may exercise such privilege or discharge such duty on the next succeeding day which is a regular
Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) Unless otherwise indicated, (i)&nbsp;when calculating the period of time before which, within which or following which
any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period will be excluded; (ii)&nbsp;if the last day of such period is not a Business Day, then the period in question will end on
the next Business Day; (iii)&nbsp;if any action (other than any action described in <U>Section</U><U></U><U>&nbsp;5.4</U>) must be taken on or by a day that is not a Business Day, then such action may be validly taken on or by the next day that is a
Business Day; (iv)&nbsp;the measure of a period of one month or year for purposes of this Agreement will be the day of the following month or year corresponding to the starting date; and (v)&nbsp;if no corresponding date exists, then the end date of
such period being measured will be the next actual day of the following month or year (for example, one month following February&nbsp;18 is March&nbsp;18 and one month following March&nbsp;31 is May 1). References to &#8220;from&#8221; or
&#8220;through&#8221; any date mean, unless otherwise specified, from and including or through and including such date, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><A NAME="annexatoc109079_141"></A>10.14 <U>Defined Terms Defined Elsewhere</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2026 ESPP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2026 Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accounting Firm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.6(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Allocation Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.15(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anti-Bribery Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.23</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anticipated Closing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Asset Disposition(s)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certifications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.3</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COBRA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.12(c)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company 2025 Audited Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.16</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company 2026 Interim Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.16</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Audited Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.16</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Balance Sheet</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Benefit Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.12(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Board Adverse Recommendation Change</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Board Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Budget</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(b)(v)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Charter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Determination Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(e)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Disclosure Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company EIP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company <FONT STYLE="white-space:nowrap">In-bound</FONT> License</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.19(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Interim Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.16</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Licensed IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.19(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Signatories</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.16(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Notice Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(e)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> License</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.19(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Products</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.11(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Registered IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.19(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Safety Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.11(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Stock Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Stock Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Required Company Stockholder Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Stockholder Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Stockholder Support Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Stockholder Written Consent(s)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Termination Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.3(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Covered Person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.2(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Determination Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.3(d)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dispute Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.6(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Disqualifying Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.2(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dissenting Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.10(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">D&amp;O Indemnified Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Encumbrances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">End Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Environmental Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.14(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equity Plan Proposals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.9(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.9(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.11(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDA Ethics Policy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.11(h)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hazardous Substance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.14(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Health Care Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.11(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HIPAA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.11(k)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Information Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Intended Tax Treatment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.10(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IT Systems</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.19(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nasdaq Listing Application</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Net Cash Calculation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Net Cash Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ordinary Course Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.15(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Benefit Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.12(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Board Adverse Recommendation Change</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Board Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Charter Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Disclosure Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent <FONT STYLE="white-space:nowrap">In-bound</FONT> License</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.19(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent IT Systems</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.19(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Licensed IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.19(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.16(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Notice Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.3(d)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> License</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.19(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Outstanding Shares Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.15(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Products</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.11(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Registered IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.19(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Safety Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.11(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent SEC Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Stock Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Stockholder Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.3(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Stockholders&#8217; Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Stockholder Support Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Termination Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PBGC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.12(c)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pension Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.12(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Permitted Encumbrances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.18(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Distribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Privacy Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.19(h)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Purchasers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.25(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Required Company Stockholder Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Required Parent Stockholder Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Response Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.6(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Reverse Stock Split Proposal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rights Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stockholder Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subscription Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tax Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.15(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tax Opinion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Third Party Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.3(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WARN Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.13(d)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature pages follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Parties have caused this Agreement to be executed as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RALLYBIO CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Jonathan I. Lieber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan I. Lieber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer and Treasurer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FARMINGTON MERGER SUB, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Jonathan I. Lieber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan I. Lieber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Secretary</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Agreement and Plan of Merger and Reorganization</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Parties have caused this Agreement to be executed as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CANDID THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Kenneth Song, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kenneth Song, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Agreement and Plan of Merger and Reorganization</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexatoc109079_142"></A>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>For purposes of this Agreement (including this Exhibit A): </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Acquisition Inquiry</I></B>&#8221; means, with respect to a Party, an inquiry, indication of interest or request for information
(other than an inquiry, indication of interest or request for information made or submitted by the Company or any of its Affiliates, on the one hand, or Parent or any of its Affiliates, on the other hand, to the other Party) that could reasonably be
expected to lead to an Acquisition Proposal; <I>provided, however</I>, that the term &#8220;<B><I>Acquisition Inquiry</I></B>&#8221; shall not include the Merger or the other Contemplated Transactions or any transactions related to the Asset
Dispositions or Concurrent Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Acquisition Proposal</I></B>&#8221; means, with respect to a Party, any offer or
proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other
Party) contemplating or otherwise relating to any Acquisition Transaction with such Party, other than the Asset Dispositions and the Concurrent Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Acquisition Transaction</I></B>&#8221; means any transaction or series of related transactions (other than the Asset Dispositions
and the Concurrent Financing) involving: any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other
similar transaction: (i)&nbsp;in which a Party is a constituent entity; (ii)&nbsp;in which a Person or &#8220;group&#8221; (as defined in the Exchange Act) of Persons directly or indirectly acquires beneficial or record ownership of securities
representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries; or (iii)&nbsp;in which a Party or any of its Subsidiaries issues securities representing more than 20% of the
outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or (y)&nbsp;any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or
account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Affiliate</I></B>&#8221; means, with respect to a Person, any other Person that directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with, such Person. The term &#8220;<B><I>control</I></B>&#8221; (including the corollary terms &#8220;<B><I>controlled by</I></B>&#8221; and &#8220;<B><I>under common control
with</I></B>&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by Contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Agreement</I></B>&#8221; means the Agreement and Plan of Merger and Reorganization to which this <B>Exhibit A</B> is attached, as
it may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Antitrust Laws</I></B>&#8221; means the HSR Act or any other applicable U.S. or foreign
competition, antitrust, merger control or investment Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Authorized Share Increase</I></B>&#8221; means an increase in the
number of authorized shares of Parent Capital Stock that Parent is authorized to issue to a number determined by the Company in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Business Day</I></B>&#8221; means any day other than a Saturday, Sunday or other day on which banks in New York, New York are
authorized or obligated by Law to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Cash and Cash Equivalents</I></B>&#8221; means cash, currency, and cash
equivalents as determined in accordance with GAAP, including (a)&nbsp;all cash and cash equivalents in deposit accounts or other similar accounts, (b)&nbsp;marketable securities with maturities of three (3)&nbsp;months or less, (c)&nbsp;checks,
money orders, and other negotiable instruments, (d)&nbsp;cash in transit. Cash and Cash Equivalents shall be net of the amount of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding checks or other payment obligations that have been issued but not yet cleared, and (e)&nbsp;prepaid expenses, including those set forth on <U>Schedule A</U> of the Parent Disclosure
Schedule. For the avoidance of doubt, &#8220;Cash and Cash Equivalents&#8221; excludes any restricted cash, escrowed amounts, or amounts held as collateral for obligations, including letters of credit and performance bonds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Code</I></B>&#8221; means the Internal Revenue Code of 1986. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Associate</I></B>&#8221; means any current or former employee, independent contractor, officer or director of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Board</I></B>&#8221; means the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Capital Stock</I></B>&#8221; means the Company Common Stock and the Company Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Change in Circumstance</I></B>&#8221; means a change in circumstances (other than any such event, development or change
to the extent related to (A)&nbsp;any Acquisition Proposal, Acquisition Inquiry or the consequences thereof, or (B)&nbsp;the fact, in and of itself, that the Company meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or
other financial performance or results of operations) that affects the business, assets or operations of the Company or any of its Subsidiaries that occurs or arises after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Common Stock</I></B>&#8221; means the Common Stock, $0.0001 par value per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Fundamental Representations</I></B>&#8221; means the representations and warranties of the Company set forth in
<U>Sections</U><U>&nbsp;2.1(a)</U> (<I><U>Organization, Standing and Power</U></I>), <U>2.2</U> (<I><U>Capital Stock</U></I><I>)</I>, <U>2.3</U> (<I><U>Subsidiaries</U></I>) <U>2.4</U> (<I><U>Authority</U></I>) and <U>2.24</U>
(<I><U>Brokers</U></I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Material Adverse Effect</I></B>&#8221; means any Effect that, considered together with all
other Effects, has or would reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of the Company, taken as a whole; <I>provided</I>, <I>however</I>,
that any Effect, individually or together with other Effects, arising or resulting from the following shall not be taken into account in determining whether there has been a Company Material Adverse Effect: (a)&nbsp;general business, political, or
economic conditions generally affecting the industry in which the Company operates, including with respect to the imposition of, or adjustments to, tariffs or other trade restrictions; (b)&nbsp;acts of war, the outbreak or escalation of armed
hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics and related or associated epidemics, disease outbreaks or quarantine restrictions; (c)&nbsp;changes in financial,
banking or securities markets; (d)&nbsp;any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP); (e)&nbsp;the announcement of this Agreement or the pendency of
the Contemplated Transactions; (f)&nbsp;resulting from the taking of any action expressly required to be taken by this Agreement; or (g)&nbsp;continued losses from operations or decreases in cash balances of the Company; except, with respect to
clauses&nbsp;(a) through (d), to the extent such Effect disproportionately affects the Company, taken as a whole, relative to other similarly situated companies in the industries in which the Company operates, in which case, such Effect shall be
taken into account to the extent of such disproportionate effect on the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Option</I></B>&#8221; means any
option or other right to purchase shares of Company Capital Stock issued by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Owned IP</I></B>&#8221;
means all Intellectual Property owned by the Company or any of its Subsidiaries in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Preferred
Stock</I></B>&#8221; means the Company Series A Preferred Stock and the Company Series B Preferred Stock, collectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Series A Preferred Stock</I></B>&#8221; means the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, par value $0.0001 per share, and the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, par value $0.0001 per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Series B Preferred Stock</I></B>&#8221; means the Series B Preferred Stock, par value $0.0001 per share, of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Signatories</I></B>&#8221; means the officers, directors and stockholders of the Company set forth on
<B>Schedule</B><B></B><B>&nbsp;A</B> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Triggering Event</I></B>&#8221; shall be deemed to have occurred if:
(a)&nbsp;the Company Board shall have made a Company Board Adverse Recommendation Change; (b)&nbsp;the Company Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal; or (c)&nbsp;following the
date of this Agreement, the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Concurrent Financing</I></B>&#8221; means an acquisition of shares of Company Common Stock to be consummated immediately prior to
the Effective Time pursuant to the Subscription Agreement with aggregate gross cash proceeds of at least the Concurrent Investment Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Concurrent Financing Allocation Percentag</I></B><B>e</B>&#8221; means the quotient (rounded to four decimal places) determined
by <I>dividing</I> (A)&nbsp;the Concurrent Financing Proceeds <I>by</I> (B)&nbsp;the Aggregate Valuation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Concurrent
Financing Merger Shares</I></B>&#8221; means, subject to <U>Section</U><U></U><U>&nbsp;1.5(f)</U>, the product determined by <I>multiplying</I> (i)&nbsp;the Post-Closing Parent Shares <I>by </I>(ii)&nbsp;the Concurrent Financing Allocation
Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Concurrent Financing Proceeds</I></B>&#8221; means the proceeds resulting from the Concurrent Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Concurrent Investment Amount</I></B>&#8221; means $200,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Confidentiality Agreement</I></B>&#8221; means the Mutual Confidential Disclosure Agreement, dated as of February&nbsp;2, 2026,
by and between the Company and Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Consent</I></B>&#8221; means any approval, consent, ratification, permission, waiver
or authorization (including any Permits). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Contemplated Transactions</I></B>&#8221; means the Merger and the other
transactions and actions contemplated by this Agreement, including the Nasdaq Reverse Split, the Parent Charter Amendment, the Concurrent Financing and the Asset Dispositions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Contract</I></B>&#8221; means, with respect to any Person, any agreement, contract, subcontract, lease (whether for real or
personal property), mortgage, license, sublicense or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>DGCL</I></B>&#8221; means the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Effect</I></B>&#8221; means any effect, change, event, circumstance or development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Enforceability Exceptions</I></B>&#8221; means the (a)&nbsp;Laws of general application relating to bankruptcy, insolvency and
the relief of debtors; and (b)&nbsp;rules of law governing specific performance, injunctive relief and other equitable remedies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Entity</I></B>&#8221; means any corporation (including any <FONT
STYLE="white-space:nowrap">non-profit</FONT> corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited
liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>ERISA</I></B>&#8221; means the Employee Retirement Income Security Act of 1974. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Excepted Contracts</I></B>&#8221; means (a)&nbsp;shrink-wrap, click wrap and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> Contracts for commercially available software or services, (b)&nbsp;Contracts that have expired on their own terms or were terminated prior to the date hereof that do not have any continuing
obligations, rights or interests (other than obligations to maintain confidentiality or indemnification provided in the Ordinary Course of Business), (c) any materials transfer agreements, sponsored research agreements, services agreements or other
similar Contracts entered into in the Ordinary Course of Business, (d)&nbsp;Contracts with clinical trial sites, subcontractors and/or vendors, in each case, entered into in the Ordinary Course of Business and where any license granted thereunder by
the Company or Parent, as applicable, is incidental to the primary purpose of such Contract, (e)&nbsp;Contracts containing an inbound license granted to the Company or Parent, as applicable, to use third party Intellectual Property, where such
license is not material to the Company or Parent, as applicable, taken as a whole, (f)&nbsp;nondisclosure agreements entered into (x)&nbsp;in the Ordinary Course of Business or (y)&nbsp;in connection with discussions, negotiations and transactions
related to this Agreement or any transactions that were evaluated and/or pursued as an alternative to the transactions contemplated hereby, and (g)&nbsp;any Contract for the purchase of services, consumables, materials, equipment or supplies that is
entered into the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Exchange Act</I></B>&#8221;<I> </I>means the Securities Exchange Act of 1934.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Exchange Ratio</I></B>&#8221; means, subject to <U>Section</U><U></U><U>&nbsp;1.5(f)</U>, the following ratio (rounded to
four decimal places): the quotient obtained by <I>dividing</I> (a)&nbsp;the Company Merger Shares by (b)&nbsp;the Company Outstanding Shares, in which:<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Aggregate Valuation</I></B>&#8221; means the sum of (i)&nbsp;the Company Valuation, <I>plus</I>
(ii)&nbsp;the Parent Valuation <I>plus </I>(iii)&nbsp;the Concurrent Financing Proceeds. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Company Allocation Percentage</I></B>&#8221; means the Company Valuation <I>divided by</I> the
Aggregate Valuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Company Merger Shares</I></B>&#8221; the product determined by <I>multiplying </I>(a)&nbsp;the
Post-Closing Parent Shares <I>by</I> (b)&nbsp;the Company Allocation Percentage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Company Valuation</I></B>&#8221; means $750,000,000. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Company Outstanding Shares</I></B>&#8221; means the total number of shares of Company Capital Stock
outstanding immediately prior to the Effective Time (excluding any shares of Company Common Stock issued in the Concurrent Financing), expressed on a <FONT STYLE="white-space:nowrap">fully-diluted</FONT> and
<FONT STYLE="white-space:nowrap">as-converted</FONT> to Company Common Stock basis and using the treasury stock method, but assuming, without limitation or duplication, (i)&nbsp;the exercise of all Company Options outstanding as of immediately prior
to the Effective Time, and (ii)&nbsp;the issuance of shares of Company Capital Stock in respect of all other outstanding options, restricted stock awards, restricted stock units, warrants or rights to receive such shares, whether conditional or
unconditional and including any outstanding options, warrants, restricted stock awards, restricted stock units or rights triggered by or associated with the consummation of the Merger (but excluding any shares of Company Capital Stock reserved for
issuance other than with respect to outstanding Company Options as of immediately prior to the Effective Time). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Parent Allocation Percentage</I></B>&#8221; means the Parent Valuation <I>divided by</I> the
Aggregate Valuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Parent Equity Value</I></B>&#8221; means $10,000,000. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Parent Outstanding Shares</I></B>&#8221; means, subject to <U>Section</U><U></U><U>&nbsp;1.5(f)</U>
(that addresses, among other things, the possibility to effect the Nasdaq Reverse Split) and the immediately following sentence, the total number of shares of Parent Common Stock outstanding immediately prior to the Effective Time, expressed on a <FONT
STYLE="white-space:nowrap">fully-diluted</FONT> basis and using the treasury stock method (and shall include, for the avoidance of doubt, all In the Money Parent Options), but assuming, without limitation or duplication, the issuance of shares of
Parent Common Stock in respect of all Parent Stock Awards, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, and other outstanding options, warrants or rights to receive such shares, in each case, outstanding as of immediately prior to
the Effective Time (assuming cashless exercise), whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or associated with the consummation of the Merger (but excluding any shares of Parent Common
Stock reserved for issuance other than with respect to outstanding Parent Stock Awards as of immediately prior to the Effective Time and as set forth above). For the avoidance of doubt, no Out of the Money Parent Options shall be included in the
total number of shares of Parent Common Stock outstanding for purposes of determining the Parent Outstanding Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Parent Target Net Cash</I></B>&#8221; means $37,500,000. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Parent Valuation</I></B>&#8221; means (i)&nbsp;if Parent Net Cash is greater than Parent Target Net
Cash, the sum of (w)&nbsp;Parent Equity Value <I>plus</I> (x)&nbsp;Parent Target Net Cash <I>plus</I> (y)&nbsp;the amount by which Parent Net Cash exceeds Parent Target Net Cash, (ii)&nbsp;if Parent Net Cash is equal to Parent Target Net Cash, the
sum of (x)&nbsp;Parent Equity Value <I>plus</I> (y)&nbsp;Parent Target Net Cash, or (iii)&nbsp;if Parent Net Cash is less than Parent Target Net Cash, the sum of (w)&nbsp;Parent Equity Value <I>plus</I> (x)&nbsp;Parent Target Net Cash <I>minus</I>
(y)&nbsp;the amount by which Parent Target Net Cash exceeds Parent Net Cash. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B><I>Post-Closing Parent Shares</I></B>&#8221; means the quotient obtained by <I>dividing </I>the Parent
Outstanding Shares <I>by</I> the Parent Allocation Percentage. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Set forth on <U>Schedule I</U> is an illustrative
example of Exchange Ratio calculations as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>GAAP</I></B>&#8221; means generally accepted
accounting principles and practices in effect from time to time within the United States applied consistently throughout the period involved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Governmental Body</I></B>&#8221; means any: (a)&nbsp;nation, state, commonwealth, province, territory, county, municipality,
district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or <FONT STYLE="white-space:nowrap">quasi-governmental</FONT> authority of any nature (including any
governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority);
or <FONT STYLE="white-space:nowrap">(d)&nbsp;self-regulatory</FONT> organization (including Nasdaq). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>HSR Act</I></B>&#8221;
means the Hart-Scott-Rodino Antitrust Improvements Act of 1976. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Intellectual Property</I></B>&#8221; means all intellectual
property rights of any kind or nature in any jurisdiction throughout the world, including all of the following: (i)&nbsp;trademarks or service marks (whether registered or unregistered), trade names, domain names, social media user names, social
media addresses, logos, slogans, and trade dress, including applications to register any of the foregoing, together with the goodwill symbolized by any of the foregoing; (ii)&nbsp;patents, utility models and any similar or equivalent statutory
rights with respect to the protection of inventions, and all applications for any of the foregoing, together with all <FONT STYLE="white-space:nowrap">re-issuances,</FONT> continuations, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisionals, revisions, extensions and reexaminations thereof; (iii)&nbsp;copyrights (registered and unregistered) and applications for registration; (iv)&nbsp;trade secrets and
customer lists, in each case to the extent any of the foregoing derive economic value (actual or potential) from not being generally known to other Persons who can obtain economic value from their disclosure or use, and other confidential
information (&#8220;<B><I>Confidential Information</I></B>&#8221;); and (v)&nbsp;any other proprietary or intellectual property rights of any kind or nature, to the extent protected by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>In the Money Parent Options</I></B>&#8221; shall mean any Parent Options with
an exercise price less than or equal to the Parent Closing Price (subject to adjustment to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization
or other similar transaction with respect to Parent Common Stock). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Investor Agreement</I></B>&#8221; shall mean any
stockholders agreements, voting agreements, registration rights agreements, <FONT STYLE="white-space:nowrap">co-sale</FONT> agreements and any other similar Contracts between the Company and any holders of any share of Company Capital Stock,
including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director designation rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Investor Agreement Termination Consent</I></B>&#8221; shall mean the consent required to terminate the Investor Agreements set
forth on <U>Section</U><U></U><U>&nbsp;5.12</U> of the Company Disclosure Schedule in accordance with <U>Section</U><U></U><U>&nbsp;5.12</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>IRS</I></B>&#8221; means the U.S. Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>knowledge</I></B>&#8221; of any party means (i)&nbsp;the actual knowledge of any executive officer of such party or (ii)&nbsp;any
fact or matter which any such officer of such party would be expected to discover or otherwise become aware of in the course of conducting a reasonably comprehensive investigation, consistent with such officer&#8217;s title and responsibilities,
concerning the existence of the relevant matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Law</I></B>&#8221; means any federal, state, national, foreign, material
local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by
or under the authority of any Governmental Body (including under the authority of Nasdaq or the Financial Industry Regulatory Authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Legal Proceeding</I></B>&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal,
administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or
arbitration panel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Merger Consideration</I></B>&#8221; means, on a per share basis, the number of shares of Parent Common
Stock issuable in exchange for each share of Company Capital Stock, as applicable, in accordance with <U>Section</U><U></U><U>&nbsp;1.5(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Merger Sub Board</I></B>&#8221; means the board of directors of Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Nasdaq</I></B>&#8221; means the Nasdaq Stock Market, including the Nasdaq Capital Market or such other Nasdaq market on which
shares of Parent Common Stock are then listed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Nasdaq Reverse Split</I></B>&#8221; means a reverse stock split of all
outstanding shares of Parent Common Stock at a reverse stock split ratio mutually agreed to by Parent and the Company that is effected by Parent for the purpose of maintaining compliance with Nasdaq listing standards or for the combined company to
meet the initial listing standards of Nasdaq or otherwise if deemed advisable by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Ordinary Course of
Business</I></B>&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its and its Subsidiaries&#8217; normal operations and consistent with its and its Subsidiaries&#8217; past practices and the
Ordinary Course of Business of Parent shall also include actions required to effect the Asset Dispositions or effect the winding down of Parent&#8217;s prior research and development activities (including the termination of ongoing contractual
obligations relating to Parent&#8217;s current products or product candidates). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Organizational Documents</I></B>&#8221;
means, with respect to any Person (other than an individual), (a) the certificate or articles of association or incorporation or organization or limited partnership or limited liability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or
organization of such Person and (b)&nbsp;all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Out of the Money Parent Options</I></B>&#8221; shall mean Parent Options with an exercise price greater than the Parent Closing
Price (subject to adjustment to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to Parent Common
Stock). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Associate</I></B>&#8221; means any current or former employee, independent contractor, officer or director of
Parent or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Balance Sheet</I></B>&#8221; means the unaudited balance sheet of Parent as of
September&nbsp;30, 2025 included in Parent&#8217;s Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarterly period ended September&nbsp;30, 2025, as filed with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Board</I></B>&#8221; means the board of directors of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Capital Stock</I></B>&#8221; means the Parent Common Stock and the Parent Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Change in Circumstance</I></B>&#8221; means a change in circumstances (other than any such event, development or change to
the extent related to (A)&nbsp;any Acquisition Proposal, Acquisition Inquiry or the consequences thereof, or (B)&nbsp;the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other
financial performance or results of operations) that affects the business, assets or operations of Parent or any of its Subsidiaries that occurs or arises after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Closing Financial Certificate</I></B>&#8221; means a certificate executed by the Chief Financial Officer of Parent, on
behalf of Parent and not in his or her personal capacity, certifying Parent Net Cash as of the Anticipated Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Closing Price</I></B>&#8221; means the price per share in an amount equal to (a)&nbsp;the Parent Valuation divided by
(b)&nbsp;the Parent Outstanding Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Common Stock</I></B>&#8221; means the Common Stock, $0.0001 par value per
share, of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Fundamental Representations</I></B>&#8221; means the representations and warranties of Parent and
Merger Sub set forth in <U>Sections</U> <U>3.1(a)</U> (<I><U>Organization, Standing and Power</U></I>), <U>3.2(a) </U>and <U>(b)</U> (<I><U>Capital Stock</U></I>), <U>3.4</U> (<I><U>Authority</U></I>) and <U>3.22</U> (<I><U>Brokers</U></I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Material Adverse Effect</I></B>&#8221; means any Effect that, considered together with all other Effects, has or would
reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Parent or its Subsidiaries, taken as a whole; <I>provided</I>, <I>however</I>, that any
Effect, individually or together with other Effects, arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a)&nbsp;general business, political or economic
conditions generally affecting the industry in which Parent or any of its Subsidiaries operate, including with respect to the imposition of, or adjustments to, tariffs or other trade restrictions; (b)&nbsp;acts of war, the outbreak or escalation of
armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics and related or associated epidemics, disease outbreaks or quarantine restrictions; (c)&nbsp;changes in
financial, banking or securities markets; (d)&nbsp;any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(or interpretations of any Law or GAAP); (e)&nbsp;any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to
any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition); (f)&nbsp;the failure
of Parent to meet internal or analysts&#8217; expectations or projections or the results of operations of Parent (it being understood, however, that any Effect causing or contributing to the failure of Parent to meet internal or analysts&#8217;
expectations or projections or the results of operations of Parent may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition); (g)&nbsp;any changes
in or affecting clinical trial programs or studies conducted by or on behalf of Parent or its Subsidiaries, including any adverse data, event or outcome arising out of or related to any such programs or studies; (h)&nbsp;the announcement of this
Agreement or the pendency of the Contemplated Transactions; (i)&nbsp;the Asset Dispositions; (j)&nbsp;any reduction in the amount of Parent&#8217;s Cash and Cash Equivalents as a result of expenditures made by Parent related to wind down activities
of Parent associated with the termination of its research and development activities (including the termination of ongoing contractual obligations relating to Parent current products or product candidates); or (k)&nbsp;the taking of any action
expressly required to be taken by this Agreement; except, with respect to clauses&nbsp;(a) through (d), to the extent disproportionately affecting Parent and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the
industries in which Parent and its Subsidiaries operate, in which case, such Effect shall be taken into account to the extent of such disproportionate effect on Parent and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Net Cash</I></B>&#8221; means, without duplication, (a)&nbsp;Parent&#8217;s Cash and Cash Equivalents as of the
Anticipated Closing Date, <I>minus</I> (b)&nbsp;Parent&#8217;s accounts payable, accrued expenses (including Parent&#8217;s unpaid Transaction Expenses, the costs of any tail policy associated with any directors&#8217; and officers&#8217; insurance
policy to be bound at the Closing, and 40% of all fees and expenses incurred in relation to (i)&nbsp;the printing and filing with the SEC of the Registration Statement and Proxy Statement and any amendments and supplements thereto and paid to a
financial printer or the SEC, and (ii)&nbsp;the proxy solicitation firm engaged in connection with the Parent Stockholders&#8217; Meeting), lease termination costs, notice payments, fines or other payments to be made by Parent in order to terminate
any existing agreements to which Parent is a party, and any other estimated expenses associated with the wind-down of Parent&#8217;s prior research and development activities at or after Closing, actual and estimated costs and expenses incurred in
connection with the Asset Dispositions and other bona fide current and long-term liabilities (with any such liabilities, to the extent not required to be set forth in a balance sheet prepared in accordance with GAAP, to be resolved by Parent and the
Company in good faith), <I>minus</I> (c)&nbsp;any severance or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> or payments (including associated payroll taxes) that become payable by Parent to any
director, officer, employee or consultant of Parent or any of its Subsidiaries or other Person in connection with the consummation of the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Option</I></B>&#8221; means any option or other right to purchase shares of Parent Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Owned IP</I></B>&#8221; means all Intellectual Property owned by Parent or any of its Subsidiaries in whole or in part.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Preferred Stock</I></B>&#8221; means the Preferred Stock, $0.0001 par value per share, of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Personal Information</I></B>&#8221; means any information that alone or in combination with other information can be used to
identify an individual. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Triggering Event</I></B>&#8221; shall be deemed to have occurred if: (a)&nbsp;Parent shall
have failed to include in the Proxy Statement the Parent Board Recommendation or shall have made a Parent Board Adverse Recommendation Change; (b)&nbsp;the Parent Board or any committee thereof shall have publicly approved, endorsed or recommended
any Acquisition Proposal; (c)&nbsp;following the date of this Agreement, Parent shall have entered into any letter of intent or similar document or Contract relating to any Acquisition Proposal (other than a confidentiality agreement permitted
pursuant to <U>Section</U><U></U><U>&nbsp;4.4</U>) in violation of the terms of this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(d)&nbsp;Parent or any director or officer of Parent shall have willfully and intentionally breached the provisions set forth in <U>Section</U><U></U><U>&nbsp;4.4</U> or
<U>Section</U><U></U><U>&nbsp;5.3</U>; or (e)&nbsp;the Parent Board shall have failed to publicly reaffirm the Parent Board Recommendation within ten (10)&nbsp;Business Days after the Company so requests in writing, <I>provided</I>, that the Company
may only make such request once every thirty (30)&nbsp;days unless there has been a publicly disclosed change regarding an Acquisition Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Party</I></B>&#8221; or &#8220;<B><I>Parties</I></B>&#8221; means, each of or collectively, as applicable, the Company, Merger
Sub and Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Permitted Alternative Agreement</I></B>&#8221; means a definitive agreement that contemplates or otherwise
relates to an Acquisition Transaction that constitutes a Superior Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Person</I></B>&#8221; means any individual, Entity
or Governmental Body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Potentially Transferable Assets</I></B><I>&#8221; </I>means all assets, technology and Intellectual
Property of Parent as they existed at any time prior to the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</I></B><I>&#8221; </I>means each of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase shares of Parent Common Stock issued by Parent on November&nbsp;15, 2022 to the holders thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Proxy Statement</I></B>&#8221; means the definitive proxy statement/prospectus to be sent to Parent&#8217;s stockholders in
connection with the Parent Stockholders&#8217; Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Reference Date</I></B>&#8221; means February&nbsp;26, 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Registration Statement</I></B>&#8221; means the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT>
(or any other applicable form under the Securities Act to register Parent Common Stock) to be filed with the SEC by Parent registering the public offering and sale of Parent Common Stock to some or all holders of Company Capital Stock in the Merger,
including all shares of Parent Common Stock to be issued in exchange for all shares of Company Capital Stock in the Merger, as such registration statement may be amended prior to the time it is declared effective by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Representatives</I></B>&#8221; means, with respect to a Person, such Person&#8217;s directors, officers, employees, agents,
attorneys, accountants, investment bankers, advisors and representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Sarbanes-Oxley Act</I></B>&#8221; means the
Sarbanes-Oxley Act of 2002. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>SEC</I></B>&#8221; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Securities Act</I></B>&#8221; means the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Subsequent Transaction</I></B>&#8221; means any Acquisition Transaction (with all references to 20% in the definition of
Acquisition Transaction being treated as references to greater than 50% for these purposes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Subsidiary</I></B>&#8221;
means, with respect to a Person, an Entity that such Person directly or indirectly owns or purports to own, beneficially or of record, (a)&nbsp;an amount of voting securities or other interests in such Entity that is sufficient to enable such Person
to elect at least a majority of the members of such Entity&#8217;s board of directors or other governing body, or (b)&nbsp;at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Superior Offer</I></B>&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the
definition of Acquisition Transaction being treated as references to greater than 50% for these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes) that: (a)&nbsp;was not obtained or made as a result of a breach of (or in violation of) this Agreement; and (b)&nbsp;is on terms and conditions that the Parent Board or the Company
Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the Company or Parent, as applicable, to
amend the terms of this Agreement, and following consultation with its outside legal counsel and outside financial advisors, are more favorable, from a financial point of view, to Parent&#8217;s stockholders or the Company&#8217;s stockholders, as
applicable, than the terms of the Contemplated Transactions and is not subject to any financing condition (and if financing is required, such financing is then fully committed to the third party). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Takeover Statute</I></B>&#8221; means any &#8220;fair price,&#8221; &#8220;moratorium,&#8221; &#8220;control share
acquisition&#8221; or other similar anti-takeover Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Tax</I></B>&#8221; means all U.S. federal, state, local, foreign and
other net income, gross income, gross receipts, sales, use, stock, ad valorem, transfer, transaction, franchise, profits, gains, registration, license, wages, lease, service, service use, employee and other withholding, social security,
unemployment, welfare, disability, payroll, employment, excise, severance, stamp, occupation, workers&#8217; compensation, premium, real property, personal property, windfall profits, net worth, capital, value-added, alternative or <FONT
STYLE="white-space:nowrap">add-on</FONT> minimum, customs duties, estimated, escheat, unclaimed property and other taxes, fees, assessments, charges or levies of any kind whatsoever in the nature of tax (whether imposed directly or through
withholding and including taxes of any third party in respect of which a Person may have a duty to collect or withhold and remit and any amounts resulting from the failure to file any Tax Return), whether disputed or not, together with any interest
and any penalties, additions to tax or additional amounts with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>&#8220;Tax Proceeding&#8221;</I></B> means any
proposed audit, assessment, examination, claim or other controversy or proceeding relating to an amount of Taxes of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Tax Return</I></B>&#8221; means any return, declaration, report, election, claim for refund, information return, or statement
filed or supplied or required to be filed or supplied to any Governmental Body with respect to Taxes, including any schedule, attachment or supplement thereto, and including any amendment thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Transaction Expenses</I></B>&#8221; means, with respect to each Party, all fees and expenses incurred by such Party at or prior
to the Effective Time in connection with the Contemplated Transactions and this Agreement, including (a)&nbsp;any fees and expenses of legal counsel and accountants and the maximum amount of fees and expenses payable to financial advisors,
investment bankers, brokers, consultants, and other advisors of such Party; (b)&nbsp;fees paid to the SEC in connection with filing the Registration Statement, the Proxy Statement, and any amendments and supplements thereto, with the SEC;
(c)&nbsp;any fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and Registration Statement and any amendments and supplements thereto; (d)&nbsp;any fees and expenses payable to Nasdaq; and (e)&nbsp;any
fees and expenses of the Rights Agent and the Exchange Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Treasury Regulations</I></B>&#8221; means the U.S. Treasury
regulations promulgated under the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexatoc109079_143"></A>EXHIBIT <FONT STYLE="white-space:nowrap">B-1</FONT>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(see attached) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit <FONT
STYLE="white-space:nowrap">B-1-1</FONT> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexatoc109079_144"></A>EXHIBIT <FONT STYLE="white-space:nowrap">B-2</FONT>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(see attached) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit <FONT
STYLE="white-space:nowrap">B-2-1</FONT> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexatoc109079_145"></A>EXHIBIT C </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF COMPANY <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(see attached) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexatoc109079_146"></A>EXHIBIT D </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF CVR AGREEMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(see
attached) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex B </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109079g51c65.jpg" ALT="LOGO" STYLE="width:1.9588in;height:0.333333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;
1, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc109079_46"></A>PERSONAL AND CONFIDENTIAL </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rallybio Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">234 Church Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Haven, Connecticut 06510 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Board of Directors of Rallybio Corporation: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You
have requested our opinion as to the fairness, from a financial point of view, to Rallybio Corporation, a Delaware corporation (&#8220;<B>Parent</B>&#8221;), of the Exchange Ratio (as defined in the Agreement) proposed to be paid by Parent pursuant
to the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;<B>Agreement</B>&#8221;) to be entered into by and among Parent, Farmington Merger Sub, Inc., a Delaware corporation (&#8220;<B>Merger Sub</B>&#8221;), and Candid
Therapeutics, Inc., a Delaware corporation (the &#8220;<B>Company</B>&#8221;), which provides, among other things, for the merger of Company with and into Merger Sub with the Company as the surviving entity (the&nbsp;&#8220;<B>Merger</B>&#8221;), as
a result of which the Company will become a wholly-owned subsidiary of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Agreement, (a)&nbsp;each outstanding share of common stock
of the Company, par value $0.0001 per share (the&nbsp;&#8220;<B>Company Common Stock</B>&#8221;) other than (i)&nbsp;shares of Company Common Stock held in treasury, (ii)&nbsp;Dissenting Shares (as defined in the Agreement), and (iii)&nbsp;shares of
Company Common Stock owned by Parent or Merger Sub or any stockholder thereof and (iv)&nbsp;shares of Company Common Stock to be issued in the Concurrent Financing (as defined in the Agreement) will be converted into the right to receive a number of
shares of common stock of Parent, par value $0.0001 per share (the &#8220;<B>Parent Common Stock</B>&#8221;), equal to the Exchange Ratio (as defined in the Agreement); (b) the aggregate number of shares of Company Common Stock issued in the
Concurrent Financing will be converted into the Concurrent Financing Merger Shares (as defined in the Agreement), which will be allocated <I>pro rata</I> in accordance with each stockholder&#8217;s investment therein ((a) and (b)&nbsp;together,
the&nbsp;&#8220;<B>Merger</B> <B>Consideration</B>&#8221;); and (c)&nbsp;holders of Parent Common Stock prior to the consummation of the Merger will receive contingent value rights relating to the net proceeds received from any disposition or
commercialization of certain legacy assets of the Parent (the &#8220;<B>Parent Legacy Assets</B>&#8221;) occurring within a specified disposition period (the &#8220;<B>Parent CVRs</B>&#8221;). The terms and conditions of the Merger are more fully
set forth in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the opinion set forth herein, we have: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed certain publicly available financial statements and certain other business and financial information
relating to Parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed the historical trading prices and trading activity for the Parent Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed certain financial and operating data concerning the Company prepared by the management of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed (i)&nbsp;publicly available market capitalization data regarding companies in the biotechnology
industry that we believed to be comparable in certain respects to Company; and (ii)&nbsp;publicly available financial terms of certain initial public offerings involving companies in the biotechnology industry that we believed to be comparable in
certain respects to the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">participated in discussions with members of the senior management of the Parent and the Company and their
respective advisors and representatives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed the Agreement draft, dated as of February&nbsp;27, 2026, and certain related documents; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">performed such other analysis and considered such other factors as we deemed appropriate.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conducting our review and arriving at our opinion, we have assumed and relied, without independent
verification, upon the accuracy and completeness of all information and data that was publicly available or furnished to or otherwise reviewed by or discussed with us. We have further relied upon the assurance of the management of Parent and Company
that they are not aware of any facts or circumstances that would make such information inaccurate or misleading. As you are aware, neither Parent&#8217;s nor Company&#8217;s management provided us with, and we did not otherwise have access to,
financial forecasts regarding Parent&#8217;s or Company&#8217;s businesses. Accordingly, we did not perform either discounted cash flow analyses with respect to Parent or Company. In addition, with your consent, we have not made any independent
evaluation or appraisal of any of the assets or liabilities (contingent, derivative, <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> or otherwise) of Parent or Company, nor have we been furnished with any such evaluation or appraisal, and
we have not been asked to conduct, and did not conduct, a physical inspection of the properties or assets of Parent or Company. We have been advised that, given that Parent&#8217;s assets and liabilities are comprised of cash (net of liabilities)
and the Parent Legacy Assets (which currently are contemplated to be disposed) and that Parent is not expected to have any continuing business operations on a standalone basis other than those incidental to Parent&#8217;s status as a publicly traded
company, the management of Parent has not prepared financial forecasts relating to Parent. Accordingly, we have not performed a financial analysis of Parent, Parent Legacy Assets or Parent CVRs, and we have not ascribed any value to the Parent
Legacy Assets or Parent CVRs. We have assumed the value of Parent as directed by you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of rendering our opinion, we have assumed that the
representations and warranties of each party contained in the Agreement are true and correct, that each party will perform all of the covenants and agreements required to be performed by it under the Agreement and that all conditions to the
consummation of the Merger will be satisfied without waiver thereof. We have assumed that the final form of the Agreement will not vary materially from the last draft Agreement reviewed by us and that the Merger will be consummated substantially on
the terms described in such draft, without any amendment or waiver of material terms or conditions. We have also assumed that all necessary governmental, regulatory and other consents and approvals contemplated by the Agreement will be obtained and
that in the course of obtaining those consents and approvals no costs or restrictions will be imposed or waivers made that would have an adverse effect on the contemplated benefits of the Merger. We have relied on the assessments of the
Company&#8217;s management as to, among other things, the Company&#8217;s product pipeline, future products, technology and intellectual property, including the viability of and risks associated therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not legal, tax or regulatory advisors and have relied upon, without independent verification, the assessment of the Parent and the Company and their
legal, tax or regulatory advisors with respect to legal, tax or regulatory matters. We are not in the business of appraising tangible assets and have not made any independent valuation or appraisal of any or all of the assets or liabilities
(including any contingent, derivative or <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> assets or liabilities) of the Parent or the Company, nor have we been furnished with any such valuations or appraisals. In addition, we have not
evaluated the solvency of any party to the Agreement under any state or federal laws relating to bankruptcy, insolvency or similar matters. Our opinion is necessarily based on financial, economic, market and other conditions as in effect on, and the
information made available to us as of, the date hereof. Events occurring after the date hereof may affect this opinion and the assumptions used in preparing it, and we do not assume any obligation to update, revise or reaffirm this opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were not requested to consider, and our opinion does not address, the Parent&#8217;s underlying business decision to enter into the Agreement and pursue
the Merger, or the relative merits of the Merger as compared to any alternative business strategies that might exist for the Parent or the effect of any other transaction in which the Parent might engage. We were not requested to consider, and our
opinion does not address, the <FONT STYLE="white-space:nowrap">non-financial</FONT> terms of the Agreement or the Merger, including, without limitation, the structure or form of the Merger, nor were we asked to address the terms of any related
transactions to be entered into by the parties, including, without limitation, the CVRs and the Concurrent Financing, or the fairness of the Merger or any other term or aspect of the Merger to, or any consideration to be received in connection
therewith by, or the impact of the Merger on, the holders of any class of securities, creditors or other constituencies of Parent or any other party. This opinion is limited to and addresses only the fairness, from a financial point of view, as of
the date hereof, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parent of the Exchange Ratio to be paid by Parent pursuant to the terms of the Agreement. Furthermore, we express no opinion with respect to the amount or nature of any compensation to be paid to
any officers, directors or employees of any party to the Merger, or any class of such persons, relative to the Merger Consideration or otherwise, or with respect to the fairness of any such compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, as part of our investment banking business, are customarily engaged in the valuation of businesses and their securities in connection with mergers and
acquisitions, negotiated underwritings, competitive biddings, secondary distributions of securities, private placements and valuations for estate, corporate and other purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as financial advisor to the Parent in connection with the Merger and will receive a fee for providing this opinion, no portion of which is
contingent upon the completion of the Merger. In addition, the Parent has agreed to indemnify us against certain liabilities arising out of our engagement. We have not otherwise had a material relationship with, nor otherwise received fees from, the
Parent or any other party to the Merger during the two years preceding the date hereof, other than our provision of ordinary course equity research coverage of Parent during this period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with applicable legal and regulatory requirements, we have adopted policies and procedures to establish and maintain the independence of our
research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Parent or the proposed Merger and other participants in the Merger
that differ from the views of our investment banking personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of our trading, brokerage, investment management and financing
activities, we or our affiliates may at any time hold long or short positions, and may trade or otherwise effect transactions, for our own account or the accounts of customers, in debt or equity securities of parties to the Merger or other companies
or any currency that may be involved in the Merger. In the future, we may maintain other relationships with, and provide advisory and other services to the Company, Parent and their respective affiliates, and may receive fees for providing such
services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is given at the request of, and is intended for the benefit and use of, the Board of Directors of the Parent in connection with
its consideration of the Merger, and it is not intended to be and does not constitute a recommendation to any shareholder of the Parent as to how such shareholder should vote or act on any matter relating to the Merger. This opinion shall not be
used for any other purpose, and may not be disseminated, reproduced, quoted from or referred to at any time, without our prior written approval; <I>provided,</I> that this opinion may be included in its entirety in any proxy statement, information
statement or solicitation/recommendation statement on Schedule <FONT STYLE="white-space:nowrap">14d-9</FONT> required to be delivered to the Parent&#8217;s stockholders in connection with the Merger, and provided further that we shall have a
reasonable opportunity to review, comment on and approve any summary of or reference to this opinion contained in such statements in advance of any such delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of this opinion was approved by our fairness opinion review committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion on the date hereof that the Exchange Ratio to be paid by Parent pursuant to the terms of the
Agreement is fair, from a financial point of view, to Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Citizens JMP Securities, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">CITIZENS JMP SECURITIES, LLC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc109079_47"></A>SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SUPPORT AGREEMENT (<SMALL>THIS</SMALL> &#8220;A<SMALL>GREEMENT</SMALL>&#8221;)</B> is made as of March&nbsp;1, 2026, by and between<B>
</B><B>C<SMALL>ANDID</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (&#8220;<B><I>Company</I></B>&#8221;), and the Person set forth on <U>Schedule</U><U></U><U>&nbsp;A</U> hereto (the
&#8220;<B><I>Stockholder</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as of the date hereof, the Stockholder is the holder of the number of shares of
common stock, par value $0.0001 per share (&#8220;<B><I>Common Stock</I></B>&#8221;) and preferred stock, par value $0.0001 per share (&#8220;<B><I>Preferred Stock</I></B>&#8221; and collectively with the Common Stock, the &#8220;<B><I>Parent
Shares</I></B>&#8221;), of<B> </B><B>R<SMALL>ALLYBIO</SMALL> C<SMALL>ORPORATION</SMALL></B><SMALL></SMALL>, a Delaware corporation (the &#8220;<B><I>Parent</I></B>&#8221;), set forth opposite the Stockholder&#8217;s name on
<U>Schedule</U><U></U><U>&nbsp;A</U> (all Parent Shares owned by the Stockholder, or hereafter issued to or otherwise acquired, whether beneficially or of record, or owned by the Stockholder prior to the termination of this Agreement, as well as
shares set forth on <U>Schedule</U><U></U><U>&nbsp;A</U>, being referred to herein as the &#8220;<B><I>Subject Shares</I></B>&#8221;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company, Parent and <B>F<SMALL>ARMINGTON</SMALL> </B><B>M<SMALL>ERGER</SMALL>
S<SMALL>UB</SMALL></B><SMALL><B></B></SMALL><B>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;<B><I>Merger Sub</I></B>&#8221;), propose to enter into an Agreement and Plan of Merger and
Reorganization, dated as of the date hereof (the &#8220;<B><I>Merger Agreement</I></B>&#8221;), which provides, among other things, for the merger of Merger Sub with and into the Company, with the Company continuing as the surviving company (the
&#8220;<B><I>Merger</I></B>&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement (capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger
Agreement); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as a condition to its willingness to enter into the Merger Agreement, Parent has required that the
Stockholder, and as an inducement and in consideration therefor, the Stockholder (in the Stockholder&#8217;s capacity as a holder of the Subject Shares) has agreed to, enter into this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth
below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING
AGREEMENT; GRANT OF PROXY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder hereby covenants and agrees that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1. <B><U>Voting of Subject Shares</U></B>. From and after the date hereof, at every meeting of the holders of Parent Shares (the
&#8220;<B><I>Parent Stockholders</I></B>&#8221;), however called, and at every adjournment or postponement thereof (or pursuant to a written consent if the Parent Stockholders act by written consent in lieu of a meeting), the Stockholder shall, or
shall cause the holder of record on any applicable record date to, be present (in person or by proxy) and to vote or cause to be voted the Subject Shares (a)&nbsp;in favor of approving the Contemplated Transactions, including the Parent Stockholder
Matters, the Authorized Share Increase Proposal and the other actions contemplated by the Merger Agreement, (b)&nbsp;against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the
Merger, and (c)&nbsp;against any Acquisition Proposal. Except as permitted under clauses (A)&nbsp;through (K) of <U>Section</U><U></U><U>&nbsp;1.2</U> below, the Stockholder shall retain at all times the right to vote the Subject Shares in the
Stockholder&#8217;s sole discretion and without any other limitation on those matters other than those set forth in this <U>Section</U><U></U><U>&nbsp;1.1</U> that are at any time or from time to time presented for consideration to the Parent
Stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2. <B><U>No Inconsistent Arrangements</U></B>. Except as provided hereunder or under the
Merger Agreement, prior to the Effective Time, the Stockholder shall not, directly or indirectly, (a)&nbsp;create any Encumbrance other than restrictions imposed by Law or pursuant to this Agreement on any Subject Shares; (b)&nbsp;transfer, sell,
assign, gift or otherwise dispose of (collectively, &#8220;<B><I>Transfer</I></B>&#8221;), or enter into any contract with respect to any Transfer of, the Subject Shares or any interest therein; (c)&nbsp;grant or permit the grant of any proxy, power
of attorney or other authorization in or with respect to the Subject Shares; (d)&nbsp;deposit or permit the deposit of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject Shares; or
(e)&nbsp;take any action that, to the knowledge of the Stockholder, would make any representation or warranty of the Stockholder herein untrue or incorrect in any material respect or have the effect of preventing the Stockholder from performing the
Stockholder&#8217;s obligations hereunder. Any action taken in violation of the foregoing sentence shall be null and void <I>ab initio</I>. Notwithstanding the foregoing, the Stockholder may (A)&nbsp;Transfer the Subject Shares as a <I>bona fide
</I>charitable contribution, gift or donation; (B)&nbsp;Transfer the Subject Shares to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder; (C)&nbsp;Transfer the Subject Shares by will, other
testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder; (D)&nbsp;Transfer the Subject Shares to stockholders, direct or indirect affiliates (within the
meaning set forth in Rule&nbsp;405 under the Securities Act), current or former partners (general or limited), members or managers of the Stockholder, as applicable, or to the estates of any such stockholders, affiliates, partners, members or
managers, or to another corporation, partnership, limited liability company or other business entity that controls, is controlled by or is under common control with the Stockholder; (E)&nbsp;make Transfers that occur by operation of law pursuant to
a qualified domestic relations order or in connection with a divorce settlement; (F)&nbsp;make Transfers not involving a change in beneficial ownership; (G)&nbsp;if the Stockholder is a trust, Transfer Subject Shares to any beneficiary of the
Stockholder or the estate of any such beneficiary; (H)&nbsp;exercise an option to purchase Parent Shares or settle an equity award (including a net or cashless exercise of such option); (I) Transfer Parent Shares to the Parent to cover tax
withholding obligations of the Stockholder in connection with the vesting, settlement or exercise of any options or other equity awards, as applicable, <I><U>provided</U></I> that in each case, the underlying Parent Shares shall continue to be
subject to the restrictions on transfer set forth in this Agreement; (J)&nbsp;establish a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Parent Shares; and (K)&nbsp;Transfer
Parent Shares to the Parent pursuant to arrangements under which the Parent has the option to repurchase such Parent Shares; <I><U>provided</U></I> that, with respect to clauses (A)&nbsp;through (G) above, the transferee agrees in writing to be
bound by the terms and conditions of this Agreement and either the Stockholder or the transferee provides Company with a copy of such agreement promptly upon consummation of any such Transfer; <I><U>provided</U></I>, <I><U>further</U></I> that with
respect to clauses (A)&nbsp;through (C) and (E)&nbsp;through (G) above, no filing under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such Transfer (other than filings made in respect
of involuntary Transfers); <I><U>provided</U></I> that reasonable notice shall be provided to Company prior to any such filing and that the underlying Parent Shares shall continue to be subject to the restrictions on Transfer set forth in this
Agreement. For purposes of this Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3. <B><U>Documentation and Information</U></B>. The Stockholder shall permit and hereby authorizes the Company and Parent to publish and
disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that the Company or Parent reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions,
the Stockholder&#8217;s identity and ownership of the Subject Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. The Parent is an intended third-party beneficiary of this
<U>Section</U><U></U><U>&nbsp;1.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4. <B><U>Irrevocable Proxy</U></B><B>. </B>The Stockholder hereby revokes (or agrees to cause to
be revoked) any proxies that the Stockholder has heretofore granted with respect to the Subject Shares. The Stockholder hereby irrevocably appoints Company as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and proxy for and on behalf of the Stockholder, for and in the name, place and stead of the Stockholder, to: (a)&nbsp;attend any and all meetings of the
Parent Stockholders, (b)&nbsp;vote, express consent or dissent or issue instructions to the record holder to vote the Subject Shares in accordance with the provisions of <U>Section</U><U></U><U>&nbsp;1.1</U> at any and all meetings of the Parent
Stockholders or in connection with any action </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sought to be taken by written consent of the Parent Stockholders without a meeting and (c)&nbsp;grant or withhold, or issue instructions to the record holder to grant or withhold, consistent with
the provisions of <U>Section</U><U></U><U>&nbsp;1.1</U>, all written consents with respect to the Subject Shares at any and all meetings of the Parent Stockholders or in connection with any action sought to be taken by written consent of the Parent
Stockholders without a meeting. Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. The foregoing proxy shall be deemed to be a proxy coupled with an interest, is irrevocable
(and as such shall survive and not be affected by the death, incapacity, mental illness or insanity of the Stockholder, as applicable) until the termination of this Agreement and shall not be terminated by operation of law or upon the occurrence of
any other event other than the termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;4.2</U>. The Stockholder authorizes such attorney and proxy to substitute any other Person to act hereunder, to revoke any substitution and to
file this proxy and any substitution or revocation with the Secretary of the Parent. The Stockholder hereby affirms that the proxy set forth in this <U>Section</U><U></U><U>&nbsp;1.4</U> is given in connection with and granted in consideration of
and as an inducement to the Company to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <U>Section</U><U></U><U>&nbsp;1.1</U>. The proxy set forth in this
<U>Section</U><U></U><U>&nbsp;1.4</U> is executed and intended to be irrevocable, subject, however, to its automatic termination upon the termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;4.2</U>. With respect to any Subject
Shares that are owned beneficially by the Stockholder but are not held of record by the Stockholder (other than shares beneficially owned by the Stockholder that are held in the name of a bank, broker or nominee), the Stockholder shall take all
action necessary to cause the record holder of such Subject Shares to grant the irrevocable proxy and take all other actions provided for in this <U>Section</U><U></U><U>&nbsp;1.4</U> with respect to such Subject Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5. <B><U>No Ownership Interest</U></B>. Nothing contained in this Agreement will be deemed to vest in Company any direct or indirect
ownership or incidents of ownership of or with respect to the Subject Shares. All rights, ownership and economic benefits of and relating to the Subject Shares will remain and belong to the Stockholder, and Company will have no authority to manage,
direct, superintend, restrict, regulate, govern or administer any of the policies or operations of the Parent or exercise any power or authority to direct the Stockholder in the voting of any of the Subject Shares, except as otherwise expressly
provided herein with respect to the Subject Shares and except as otherwise expressly provided in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6.
<B><U>Waivers</U></B>. In connection with the Contemplated Transactions, the Stockholder hereby expressly&nbsp;agrees that the Stockholder will not bring, commence, institute, maintain, prosecute, participate in or voluntarily aid any action, claim,
suit or cause of action, in law or in equity, in any court or before any Governmental Body, which (a)&nbsp;challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (b)&nbsp;alleges that the execution and
delivery of this Agreement by the Stockholder, or the approval of the Merger Agreement by Parent Board, breaches any fiduciary duty of the Parent Board or any member thereof; <I><U>provided</U></I><I> </I>that the Stockholder may defend against,
contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7. <B><U>No Solicitation of Transactions</U></B>. The Stockholder hereby agrees that, during the
<FONT STYLE="white-space:nowrap">Pre-</FONT> Closing Period, the Stockholder shall not, directly or indirectly: (a)&nbsp;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any
Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (b)&nbsp;furnish any <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding
the Parent to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (c)&nbsp;engage in discussions (other than to inform any Person of the existence of the provisions in this
<U>Section</U><U></U><U>&nbsp;1.7</U>) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (d)&nbsp;approve, endorse or recommend any Acquisition Proposal; (e)&nbsp;execute or enter into any letter of
intent or any Contract contemplating or otherwise relating to any Acquisition Transaction; or (f)&nbsp;publicly propose to do any of the foregoing; provided, however, that the foregoing restrictions in this <U>Section</U><U></U><U>&nbsp;1.7</U>
shall only apply to the Stockholder in the Stockholder&#8217;s capacity as a holder of Parent Shares and not, for the avoidance of doubt, in the Stockholder&#8217;s capacity as a director or officer (if applicable) of the Parent, whose activities
with respect to any Acquisition Proposal or Acquisition Inquiry shall be governed by the Merger </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement. The Stockholder hereby represents and warrants that the Stockholder has read Section&nbsp;4.4 (Parent <FONT STYLE="white-space:nowrap">Non-Solicitation)</FONT> of the Merger Agreement
and agrees not to engage in any actions prohibited thereby. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder represents and warrants to Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1. <B><U>Organization; Authorization; Binding Agreement</U></B>. The Stockholder, if not a natural person, is duly incorporated or organized,
as applicable, validly existing and in good standing under the laws of its jurisdiction of incorporation or organization. The Stockholder has full legal capacity and power, right and authority to execute and deliver this Agreement and to perform the
Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by the Stockholder, and constitutes a legal, valid and binding obligation of the
Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2.
<B><U>Ownership of Subject Shares; Total Shares</U></B>. The Stockholder is the record or beneficial owner of the Subject Shares and has good and marketable title to the Subject Shares free and clear of any Encumbrances (including any restriction on
the right to vote or otherwise transfer the Subject Shares), except (a)&nbsp;as provided hereunder, (b)&nbsp;pursuant to any applicable restrictions on transfer under the Securities Act, (c)&nbsp;subject to any risk of forfeiture or repurchase
rights of the Parent with respect to any Parent Shares granted to the Stockholder under an employee benefit plan of Parent and (d)&nbsp;as provided in the certificate of incorporation or bylaws of the Parent. The Subject Shares listed on
<U>Schedule</U><U></U><U>&nbsp;A</U> opposite the Stockholder&#8217;s name constitute all of the Parent Shares owned by the Stockholder as of the date hereof. Except pursuant to the Parent&#8217;s certificate of incorporation, bylaws and the right
of the Parent to purchase or acquire any Parent Shares pursuant to an employee benefit plan of the Parent, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Subject Shares. For purposes of this
Agreement &#8220;<B><I>Beneficial Ownership</I></B>&#8221; shall be interpreted as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT> under the Exchange Act; <I><U>provided</U></I> that for purposes of determining Beneficial
Ownership, a Person shall be deemed to be the Beneficial Owner of any securities that may be acquired by such Person pursuant to any Contract or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise (irrespective
of whether the right to acquire such securities is exercisable immediately or only after the passage of time, including the passage of time in excess of 60&nbsp;days, the satisfaction of any conditions, the occurrence of any event or any combination
of the foregoing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3. <B><U>Voting Power</U></B>. The Stockholder has full voting power, with respect to the Subject Shares, and full
power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to agree to all of the matters set forth in this Agreement, in each case, with respect to all of the Subject Shares. None of the
Subject Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of the Subject Shares, except as provided hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4. <B><U>Reliance</U></B>. The Stockholder has had the opportunity to review the Merger Agreement, and this Agreement with counsel of the
Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the transactions contemplated by the Merger Agreement. The Stockholder understands that it must rely
solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving
Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the transactions contemplated by the Merger Agreement. The Stockholder understands and acknowledges that the Company, Parent and
Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5. <B><U>Absence of Litigation</U></B>. With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or
proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stockholder or any of the Stockholder&#8217;s properties or assets (including the Subject Shares) that could reasonably be expected to prevent, delay or impair the ability of the Stockholder to
perform the Stockholder&#8217;s obligations hereunder or to consummate the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6. <B><U><FONT
STYLE="white-space:nowrap">Non-Contravention</FONT></U></B>. The execution and delivery of this Agreement by the Stockholder and the performance of the transactions contemplated by this Agreement by the Stockholder does not and will not violate,
conflict with, or result in a breach of: (a)&nbsp;the organizational documents of such Stockholder, (b)&nbsp;any applicable Law or any injunction, judgment, order, decree, ruling, charge, or other restriction of any Governmental Body to which the
Stockholder is subject, or (c)&nbsp;any Contract to which the Stockholder is a party or is bound or to which the Subject Shares are subject, such that it could reasonably be expected to prevent, delay or impair the ability of the Stockholder to
perform the Stockholder&#8217;s obligations hereunder or to consummate the transactions contemplated hereby. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Company represents and warrants to the Stockholder that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1. <B><U>Organization; Authorization</U></B>. Company is a corporation duly incorporated, validly existing and in good standing under the
laws of the State of Delaware. The consummation of the transactions contemplated hereby is within Company&#8217;s corporate powers and has been duly authorized by all necessary corporate actions on the part of Company. Company has full power and
authority to execute, deliver and perform this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2. <B><U>Binding Agreement</U></B>. This Agreement has been duly authorized,
executed and delivered by Company and constitutes a valid and binding obligation of Company enforceable against Company in accordance with its terms, subject to the Enforceability Exceptions. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1.
<B><U>Notices</U></B>. All notices, requests and other communications to either party hereunder shall be in writing (including electronic mail) and shall be given, (a)&nbsp;if to Company, in accordance with the provisions of the Merger Agreement and
(b)&nbsp;if to the Stockholder, to the Stockholder&#8217;s address or electronic mail address set forth on a signature page hereto, or to such other address or electronic mail address as the Stockholder may hereafter specify in writing to Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2. <B><U>Termination</U></B>. This Agreement shall terminate automatically, without any notice or other action by any Person, upon the
earlier of (a)&nbsp;the termination of the Merger Agreement in accordance with its terms, (b)&nbsp;the Effective Time, and (c)&nbsp;the amendment of the Merger Agreement, without the prior written consent of the Stockholder, in a manner that affects
the economics or material terms of the Merger Agreement in a manner that is adverse to the Stockholder. Upon termination of this Agreement, neither party shall have any further obligations or liabilities under this Agreement;
<I><U>provided</U></I><I>, </I><I><U>however</U></I><I>, </I>that (i)&nbsp;nothing set forth in this <U>Section</U><U></U><U>&nbsp;4.2</U> shall relieve either party from liability for any breach of this Agreement prior to termination hereof, and
(ii)&nbsp;the provisions of this <U>Article</U><U></U><U>&nbsp;IV</U> shall survive any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3.
<B><U>Confidentiality</U></B>. Except to the extent required by applicable Law, the Stockholder shall hold <FONT STYLE="white-space:nowrap">any&nbsp;non-public&nbsp;information</FONT> regarding this Agreement, the Merger Agreement and the Merger in
strict confidence and shall not divulge any such information to any third person until Company has publicly disclosed its entry into the Merger Agreement and this Agreement;<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I>, that the
Stockholder may disclose such information (a)&nbsp;to its attorneys, accountants, consultants, trustees, beneficiaries and other representatives </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(<I><U>provided</U></I>&nbsp;such representatives are subject to confidentiality obligations at least as restrictive as those contained herein), and (b)&nbsp;to any Affiliate, partner, member,
stockholder, parent or subsidiary of the Stockholder,<I><U>&nbsp;provided</U></I>&nbsp;in each case that the Stockholder informs the Person receiving the information that such information is confidential and such Person agrees in writing to abide by
the terms of this<U>&nbsp;Section</U><U></U><U>&nbsp;4.3</U>. Neither the Stockholder nor any of its Affiliates (other than the Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press
release or other public announcement with respect to this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by
applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable. The Parent is an intended third-party beneficiary of this
<U>Section</U><U></U><U>&nbsp;4.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4. <B><U>Amendments and Waivers</U></B>. Any provision of this Agreement may be amended or
waived if such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this Agreement, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by either party in
exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5. <B><U>Binding Effect; Benefit; Assignment</U></B>. The provisions of this Agreement shall be binding upon and shall inure to the benefit
of the parties hereto and their respective successors and assigns. Except as set forth in Section&nbsp;1.3 and Section&nbsp;4.3, no provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities
hereunder upon any Person other than the parties hereto and their respective successors and assigns. Neither party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other
party hereto, except that Company may transfer or assign its rights and obligations under this Agreement, in whole or from time to time in part, to one or more of its Affiliates at any time; <I><U>provided</U></I> that such transfer or assignment
shall not relieve Company of any of its obligations hereunder; <I><U>provided however</U></I> that the Stockholder may transfer the Parent Shares to stockholders, direct or indirect affiliates (within the meaning set forth in Rule 405 under the
Securities Act), current or former partners (general or limited), members or managers of the Stockholder, so long as the transferee agrees in writing to be bound by the terms and conditions of this Agreement and either the Stockholder or the
transferee provides Company with a copy of such Agreement promptly upon consummation of any such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6. <B><U>Governing Law;
Jurisdiction</U></B>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or
proceeding between any of the parties hereto arising out of or relating to this Agreement, each party hereto: (a)&nbsp;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State
of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the
State of Delaware (the &#8220;<B><I>Delaware Courts</I></B>&#8221;); (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&nbsp;of this
<U>Section</U><U></U><U>&nbsp;4.6</U>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d)&nbsp;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party
hereto; (e)&nbsp;agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <U>Section</U><U></U><U>&nbsp;4.1</U> of this Agreement; and (f)&nbsp;irrevocably and
unconditionally waives the right to trial by jury. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7. <B><U>Counterparts</U></B>. This Agreement may be executed in several
counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission
in .PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8. <B><U>Entire Agreement</U></B>. This Agreement constitutes the entire agreement and
supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9. <B><U>Severability</U></B>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction
shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of
a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination will have the power to limit such term or provision, to delete
specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be
valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or
provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10. <B><U>Specific Performance</U></B>. Any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not
exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage would occur in
the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent
breaches of this Agreement and to enforce specifically the terms and provisions hereof in any Delaware Court, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties hereto waives any bond,
surety or other security that might be required of any other party with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11. <B><U>Construction</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party
shall not be applied in the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> As used in this Agreement, the words
&#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; &#8220;Articles,&#8221; and
&#8220;Schedules&#8221; are intended to refer to Sections or Articles of this Agreement and Schedules to this Agreement, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this
Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.12. <B><U>Further
Assurances</U></B>. Each of the parties hereto will execute and deliver, or cause to be executed and delivered, all further documents and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to
do, or cause to be done, all things necessary under applicable Law to perform their respective obligations as expressly set forth under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.13. <B><U>No Legal Actions.</U></B><B> </B>Each Stockholder will not in its capacity as a
Stockholder of Parent bring, commence, institute, maintain, prosecute or voluntarily aid any Legal Proceeding which (i)&nbsp;challenges the validity or seeks to enjoin the operation of any provision of this Agreement or (ii)&nbsp;alleges that the
execution and delivery of this Agreement by such Stockholder, either alone or together with the other voting agreements and proxies to be delivered in connection with the execution of the Merger Agreement, or the approval of the Merger Agreement and
the Contemplated Transactions by the Parent Board, constitutes a breach of any fiduciary duty of the Parent Board or any member thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.14. <B><U>Voluntary Execution of Agreement</U></B>. This Agreement is executed voluntarily and without any duress or undue influence on the
part or behalf of the parties. Each of the parties hereby acknowledges, represents and warrants that (i)&nbsp;it has read and fully understood the Merger Agreement, this Agreement and the implications and consequences thereof; (ii)&nbsp;it has been
represented in the preparation, negotiation, and execution of this Agreement by legal counsel of its own choice, or it has made a voluntary and informed decision to decline to seek such counsel; and (iii)&nbsp;it is fully aware of the legal and
binding effect of this Agreement. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any
statements or representations made by Parent, the Company or any of their respective agents or representatives. The Stockholder understands that such Stockholder (and not Parent, or the Company) shall be responsible for such Stockholder&#8217;s tax
liability that may arise as a result of the Contemplated Transactions. The Stockholder understands and acknowledges that Parent, the Company and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution,
delivery and performance of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.15. <B><U>Fees and Expenses</U></B>. Except as otherwise specifically provided herein, the
Merger Agreement or any other agreement contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.16. <B><U>Capacity as Stockholder</U></B>. The Stockholder signs this Agreement solely in the Stockholder&#8217;s capacity as a holder of
Parent Shares, and not in the Stockholder&#8217;s capacity as a director, officer or employee of the Parent or in the Stockholder&#8217;s capacity as a trustee or fiduciary of any employee benefit plan or trust. Notwithstanding anything herein to
the contrary, nothing herein shall in any way restrict a director or officer of the Parent in the exercise of his or her fiduciary duties as a director or officer of the Parent or in his or her capacity as a trustee or fiduciary of any employee
benefit plan or trust or prevent or be construed to create any obligation on the part of any director or officer of the Parent or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such
director, officer, trustee or fiduciary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.17. <B><U>No Agreement Until Executed</U></B>. Irrespective of negotiations among the parties
or the exchanging of drafts of this Agreement, this Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&nbsp;the Parent Board has approved, for
purposes of any applicable anti-takeover laws and regulations, and any applicable provision of the Parent&#8217;s organizational documents, the Merger, (b)&nbsp;the Merger Agreement is executed by all parties thereto, and (c)&nbsp;this Agreement is
executed by all parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(SIGNATURE PAGE FOLLOWS) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>ANDID</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Support Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>STOCKHOLDER</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Print Name of Stockholder)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Name and Title of Signatory, if Signing on Behalf of an Entity)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address for Notices:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Parent Support Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule&nbsp;A </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Name of Stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">No.&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#149;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc109079_48"></A>SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SUPPORT AGREEMENT (<SMALL>THIS</SMALL> &#8220;A<SMALL>GREEMENT</SMALL>&#8221;)</B> is made as of March&nbsp;1, 2026, by and between<B>
</B><B>R<SMALL>ALLYBIO</SMALL> C<SMALL>ORPORATION</SMALL></B><SMALL></SMALL>, a Delaware corporation (&#8220;<B><I>Parent</I></B>&#8221;), and the [Person] set forth on <U>Schedule</U><U></U><U>&nbsp;A</U> hereto (the
&#8220;<B><I>Stockholder</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as of the date hereof, the Stockholder is the holder of the number of shares of
common stock, par value $0.0001 per share (&#8220;<B><I>Common Stock</I></B>&#8221;) and preferred stock, par value $0.0001 per share (&#8220;<B><I>Preferred Stock</I></B>&#8221; and collectively with the Common Stock, the &#8220;<B><I>Company
Shares</I></B>&#8221;), of<B> </B><B>C<SMALL>ANDID</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), set forth opposite the Stockholder&#8217;s name on
<U>Schedule</U><U></U><U>&nbsp;A</U> (all Company Shares owned by the Stockholder, or hereafter issued to or otherwise acquired, whether beneficially or of record, or owned by the Stockholder prior to the termination of this Agreement, as well as
shares set forth on <U>Schedule</U><U></U><U>&nbsp;A</U>, being referred to herein as the &#8220;<B><I>Subject Shares</I></B>&#8221;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company, Parent and Farmington Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent
(&#8220;<B><I>Merger Sub</I></B>&#8221;), propose to enter into an Agreement and Plan of Merger and Reorganization, dated as of the date hereof (the &#8220;<B><I>Merger Agreement</I></B>&#8221;), which provides, among other things, for the merger of
Merger Sub with and into the Company, with the Company continuing as the surviving company (the &#8220;<B><I>Merger</I></B>&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement (capitalized terms used but not
otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as a
condition to its willingness to enter into the Merger Agreement, Parent has required that the Stockholder, and as an inducement and in consideration therefor, the Stockholder (in the Stockholder&#8217;s capacity as a holder of the Subject Shares)
has agreed to, enter into this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing and the respective representations,
warranties, covenants and agreements set forth below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING
AGREEMENT; GRANT OF PROXY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder hereby covenants and agrees that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1. <B><U>Voting of Subject Shares</U></B>. From and after the date hereof, at every meeting of the holders of Company Shares (the
&#8220;<B><I>Company Stockholders</I></B>&#8221;), however called, and at every adjournment or postponement thereof (or pursuant to a written consent if the Company Stockholders act by written consent in lieu of a meeting), the Stockholder shall, or
shall cause the holder of record on any applicable record date to, be present (in person or by proxy) and to vote or cause to be voted the Subject Shares (a)&nbsp;in favor of adopting the Merger Agreement and approving the Merger, the other
Contemplated Transactions, the Company Stockholder Matters, and the other actions contemplated by the Merger Agreement, (b)&nbsp;against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation
of the Merger, and (c)&nbsp;against any Acquisition Proposal. Except as permitted under clauses (A)&nbsp;through (K) of <U>Section</U><U></U><U>&nbsp;1.2</U> below, the Stockholder shall retain at all times the right to vote the Subject Shares in
the Stockholder&#8217;s sole discretion and without any other limitation on those matters other than those set forth in this <U>Section</U><U></U><U>&nbsp;1.1</U> that are at any time or from time to time presented for consideration to the Company
Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2. <B><U>No Inconsistent Arrangements</U></B>. Except as provided hereunder or under the Merger Agreement, prior to the
Effective Time, the Stockholder shall not, directly or indirectly, (a)&nbsp;create any Encumbrance other than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrictions imposed by Law or pursuant to this Agreement on any Subject Shares; (b)&nbsp;transfer, sell, assign, gift or otherwise dispose of (collectively,
&#8220;<B><I>Transfer</I></B>&#8221;), or enter into any contract with respect to any Transfer of, the Subject Shares or any interest therein; (c)&nbsp;grant or permit the grant of any proxy, power of attorney or other authorization in or with
respect to the Subject Shares; (d)&nbsp;deposit or permit the deposit of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject Shares; or (e)&nbsp;take any action that, to the knowledge of
the Stockholder, would make any representation or warranty of the Stockholder herein untrue or incorrect in any material respect or have the effect of preventing the Stockholder from performing the Stockholder&#8217;s obligations hereunder. Any
action taken in violation of the foregoing sentence shall be null and void <I>ab initio</I>. Notwithstanding the foregoing, the Stockholder may (A)&nbsp;Transfer the Subject Shares as a <I>bona fide </I>charitable contribution, gift or donation;
(B)&nbsp;Transfer the Subject Shares to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder; (C)&nbsp;Transfer the Subject Shares by will, other testamentary document or intestate succession to
the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder; (D)&nbsp;Transfer the Subject Shares to stockholders, direct or indirect affiliates (within the meaning set forth in Rule&nbsp;405 under the
Securities Act), current or former partners (general or limited), members or managers of the Stockholder, as applicable, or to the estates of any such stockholders, affiliates, partners, members or managers, or to another corporation, partnership,
limited liability company or other business entity that controls, is controlled by or is under common control with the Stockholder; (E)&nbsp;make Transfers that occur by operation of law pursuant to a qualified domestic relations order or in
connection with a divorce settlement; (F)&nbsp;make Transfers not involving a change in beneficial ownership; (G)&nbsp;if the Stockholder is a trust, Transfer Subject Shares to any beneficiary of the Stockholder or the estate of any such
beneficiary; (H)&nbsp;exercise an option to purchase Company Shares or settle an equity award (including a net or cashless exercise of such option ); (I) Transfer Company Shares to the Company to cover tax withholding obligations of the Stockholder
in connection with the vesting, settlement or exercise of any options, or other equity awards, as applicable, <I><U>provided</U></I> that in each case, the underlying Company Shares shall continue to be subject to the restrictions on transfer set
forth in this Agreement; (J)&nbsp;establish a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Company Shares; and (K)&nbsp;Transfer Company Shares to the Company pursuant to
arrangements under which the Company has the option to repurchase such Company Shares; <I><U>provided</U></I> that, with respect to clauses (A)&nbsp;through (G) above, the transferee agrees in writing to be bound by the terms and conditions of this
Agreement and either the Stockholder or the transferee provides Parent with a copy of such agreement promptly upon consummation of any such Transfer; <I><U>provided</U></I>, <I><U>further</U></I> that with respect to clauses (A)&nbsp;through (C) and
(E)&nbsp;through (G) above, no filing under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such Transfer (other than filings made in respect of involuntary Transfers);
<I><U>provided</U></I> that reasonable notice shall be provided to Parent prior to any such filing and that the underlying Company Shares shall continue to be subject to the restrictions on Transfer set forth in this Agreement. For purposes of this
Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3. <B><U>Documentation and Information</U></B>. The Stockholder shall permit and hereby authorizes the Company and Parent to publish and
disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that the Company or Parent reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions,
the Stockholder&#8217;s identity and ownership of the Subject Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. The Company is an intended third-party beneficiary of this
<U>Section</U><U></U><U>&nbsp;1.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4. <B><U>Irrevocable Proxy</U></B><B>. </B>The Stockholder hereby revokes (or agrees to cause to
be revoked) any proxies that the Stockholder has heretofore granted with respect to the Subject Shares. The Stockholder hereby irrevocably appoints Parent as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and proxy for and on behalf of the Stockholder, for and in the name, place and stead of the Stockholder, to: (a)&nbsp;attend any and all meetings of the
Company Stockholders, (b)&nbsp;vote, express consent or dissent or issue instructions to the record holder to vote the Subject Shares in accordance with the provisions of <U>Section</U><U></U><U>&nbsp;1.1</U> at any and all meetings of the Company
Stockholders or in connection with any action sought to be taken by written consent of the Company Stockholders without a meeting and (c)&nbsp;grant or withhold, or issue instructions to the record holder to grant or withhold, consistent with the
provisions of <U>Section</U><U></U><U>&nbsp;1.1</U>, all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written consents with respect to the Subject Shares at any and all meetings of the Company Stockholders or in connection with any action sought to be taken by written consent of the Company
Stockholders without a meeting. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. The foregoing proxy shall be deemed to be a proxy coupled with an interest, is irrevocable
(and as such shall survive and not be affected by the death, incapacity, mental illness or insanity of the Stockholder, as applicable) until the termination of this Agreement and shall not be terminated by operation of law or upon the occurrence of
any other event other than the termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;4.2</U>. The Stockholder authorizes such attorney and proxy to substitute any other Person to act hereunder, to revoke any substitution and to
file this proxy and any substitution or revocation with the Secretary of the Company. The Stockholder hereby affirms that the proxy set forth in this <U>Section</U><U></U><U>&nbsp;1.4</U> is given in connection with and granted in consideration of
and as an inducement to Parent, the Company to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <U>Section</U><U></U><U>&nbsp;1.1</U>. The proxy set forth in this
<U>Section</U><U></U><U>&nbsp;1.4</U> is executed and intended to be irrevocable, subject, however, to its automatic termination upon the termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;4.2</U>. With respect to any Subject
Shares that are owned beneficially by the Stockholder but are not held of record by the Stockholder (other than shares beneficially owned by the Stockholder that are held in the name of a bank, broker or nominee), the Stockholder shall take all
action necessary to cause the record holder of such Subject Shares to grant the irrevocable proxy and take all other actions provided for in this <U>Section</U><U></U><U>&nbsp;1.4</U> with respect to such Subject Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5. <B><U>No Ownership Interest</U></B>. Nothing contained in this Agreement will be deemed to vest in Parent any direct or indirect
ownership or incidents of ownership of or with respect to the Subject Shares. All rights, ownership and economic benefits of and relating to the Subject Shares will remain and belong to the Stockholder, and Parent will have no authority to manage,
direct, superintend, restrict, regulate, govern or administer any of the policies or operations of the Company or exercise any power or authority to direct the Stockholder in the voting of any of the Subject Shares, except as otherwise expressly
provided herein with respect to the Subject Shares and except as otherwise expressly provided in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6. <B><U>No
Exercise of Appraisal Rights; Waivers</U></B>. In connection with the Contemplated Transactions, the Stockholder hereby expressly (a)&nbsp;waives, to the extent permitted under applicable Law, any and all rights under Section&nbsp;262 of the
Delaware General Corporation Law, a copy of which is attached hereto as Appendix I, with respect to any Subject Shares and any and all rights under any other applicable Law granting the Stockholder the right to have any Subject Shares appraised in
connection with the Contemplated Transactions or to otherwise dissent from the Contemplated Transactions, (b)&nbsp;agrees that the Stockholder will not, under any circumstances in connection with the Contemplated Transactions, exercise any
dissenters&#8217; or appraisal rights in respect of any Subject Shares, and (c)&nbsp;agrees that the Stockholder will not bring, commence, institute, maintain, prosecute, participate in or voluntarily aid any action, claim, suit or cause of action,
in law or in equity, in any court or before any Governmental Body, which (i)&nbsp;challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii)&nbsp;alleges that the execution and delivery of this Agreement
by the Stockholder, or the approval of the Merger Agreement by Company Board, breaches any fiduciary duty of the Company Board or any member thereof; <I><U>provided</U></I><I> </I>that the Stockholder may defend against, contest or settle any such
action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7. <B><U>No Solicitation of Transactions</U></B>. The Stockholder hereby agrees that, during the Pre Closing Period, the Stockholder shall
not, directly or indirectly: (a)&nbsp;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be
expected to lead to an Acquisition Proposal or Acquisition Inquiry; (b)&nbsp;furnish any <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company to any Person in connection with or in response to an Acquisition Proposal
or Acquisition Inquiry; (c)&nbsp;engage in discussions (other than to inform any Person of the existence of the provisions in this <U>Section</U><U></U><U>&nbsp;1.7</U>) or negotiations with any Person with respect to any Acquisition Proposal or
Acquisition Inquiry; (d)&nbsp;approve, endorse or recommend any Acquisition Proposal; (e)&nbsp;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or (f)&nbsp;publicly propose to do any of the foregoing; provided, however, that the foregoing restrictions in this <U>Section 1.7</U> shall only apply to the Stockholder in the
Stockholder&#8217;s capacity as a holder of Company Shares and not, for the avoidance of doubt, in the Stockholder&#8217;s capacity as a director or officer (if applicable) of the Company, whose activities with respect to any Acquisition Proposal or
Acquisition Inquiry shall be governed by the Merger Agreement. The Stockholder hereby represents and warrants that the Stockholder has read Section&nbsp;4.5 (Company <FONT STYLE="white-space:nowrap">Non-Solicitation)</FONT> of the Merger Agreement
and agrees not to engage in any actions prohibited thereby. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder represents and warrants to Parent that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1. <B><U>Organization; Authorization; Binding Agreement</U></B>. The Stockholder, if not a natural person, is duly incorporated or organized,
as applicable, validly existing and in good standing under the laws of its jurisdiction of incorporation or organization. The Stockholder has full legal capacity and power, right and authority to execute and deliver this Agreement and to perform the
Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by the Stockholder, and constitutes a legal, valid and binding obligation of the
Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2.
<B><U>Ownership of Subject Shares; Total Shares</U></B>. The Stockholder is the record or beneficial owner of the Subject Shares and has good and marketable title to the Subject Shares free and clear of any Encumbrances (including any restriction on
the right to vote or otherwise transfer the Subject Shares), except (a)&nbsp;as provided hereunder, (b)&nbsp;pursuant to any applicable restrictions on transfer under the Securities Act, (c)&nbsp;subject to any risk of forfeiture or repurchase
rights of the Company with respect to any Company Shares granted to the Stockholder under an employee benefit plan of Company and (d)&nbsp;as provided in the certificate of incorporation or bylaws of the Company or that certain Investors&#8217;
Rights Agreement, dated as of August&nbsp;19, 2024, by and among the Company and certain stockholders of the Company, that certain Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, dated August&nbsp;19, 2024, by
and among the Company and certain stockholders of the Company, and that certain Voting Agreement, dated as of August&nbsp;19, 2024, by and among the Company and certain stockholders of the Company (the &#8220;<B><I>Voting Agreement</I></B>&#8221;).
The Subject Shares listed on <U>Schedule</U><U></U><U>&nbsp;A</U> opposite the Stockholder&#8217;s name constitute all of the Company Shares owned by the Stockholder as of the date hereof. Except pursuant to the Company&#8217;s certificate of
incorporation, bylaws and the right of the Company to purchase or acquire any Company Shares pursuant to an employee benefit plan of the Company, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the
Subject Shares. For purposes of this Agreement &#8220;<B><I>Beneficial Ownership</I></B>&#8221; shall be interpreted as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT> under the Exchange Act; <I><U>provided</U></I> that for
purposes of determining Beneficial Ownership, a Person shall be deemed to be the Beneficial Owner of any securities that may be acquired by such Person pursuant to any Contract or upon the exercise of conversion rights, exchange rights, warrants or
options, or otherwise (irrespective of whether the right to acquire such securities is exercisable immediately or only after the passage of time, including the passage of time in excess of 60&nbsp;days, the satisfaction of any conditions, the
occurrence of any event or any combination of the foregoing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3. <B><U>Voting Power</U></B>. The Stockholder has full voting power,
with respect to the Subject Shares, and full power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to agree to all of the matters set forth in this Agreement, in each case, with respect to
all of the Subject Shares. None of the Subject Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of the Subject Shares, except as provided in the Voting Agreement and as provided hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4. <B><U>Reliance</U></B>. The Stockholder has had the opportunity to review the Merger Agreement, including the provisions relating to
the payment and allocation of the consideration to be paid to the Company Stockholders, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the
transactions contemplated by the Merger Agreement. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives.
The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the transactions contemplated by
the Merger Agreement. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5. <B><U>Absence of Litigation</U></B>. With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or
proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Subject Shares) that could reasonably be expected to prevent, delay or
impair the ability of the Stockholder to perform the Stockholder&#8217;s obligations hereunder or to consummate the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6. <B><U><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></U></B>. The execution and delivery of this Agreement by the Stockholder
and the performance of the transactions contemplated by this Agreement by the Stockholder does not and will not violate, conflict with, or result in a breach of: (a)&nbsp;the organizational documents of such Stockholder, (b)&nbsp;any applicable Law
or any injunction, judgment, order, decree, ruling, charge, or other restriction of any Governmental Body to which the Stockholder is subject, or (c)&nbsp;any Contract to which the Stockholder is a party or is bound or to which the Subject Shares
are subject, such that it could reasonably be expected to prevent, delay or impair the ability of the Stockholder to perform the Stockholder&#8217;s obligations hereunder or to consummate the transactions contemplated hereby. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF PARENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parent represents and warrants to the Stockholder that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1. <B><U>Organization; Authorization</U></B>. Parent is a corporation duly incorporated, validly existing and in good standing under the laws
of the State of Delaware. The consummation of the transactions contemplated hereby is within Parent&#8217;s corporate powers and has been duly authorized by all necessary corporate actions on the part of Parent. Parent has full power and authority
to execute, deliver and perform this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2. <B><U>Binding Agreement</U></B>. This Agreement has been duly authorized, executed
and delivered by Parent and constitutes a valid and binding obligation of Parent enforceable against Parent in accordance with its terms, subject to the Enforceability Exceptions. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1.
<B><U>Notices</U></B>. All notices, requests and other communications to either party hereunder shall be in writing (including electronic mail) and shall be given, (a)&nbsp;if to Parent, in accordance with the provisions of the Merger Agreement and
(b)&nbsp;if to the Stockholder, to the Stockholder&#8217;s address or electronic mail address set forth on a signature page hereto, or to such other address or electronic mail address as the Stockholder may hereafter specify in writing to Parent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2. <B><U>Termination</U></B>. This Agreement shall terminate automatically, without any notice or other action by any Person, upon the
earlier of (a)&nbsp;the termination of the Merger Agreement in accordance with its terms, (b)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Effective Time, and (c)&nbsp;the amendment of the Merger Agreement, without the prior written consent of the Stockholder, in a manner that affects the economics or material terms of the Merger
Agreement in a manner that is adverse to the Stockholder. Upon termination of this Agreement, neither party shall have any further obligations or liabilities under this Agreement; <I><U>provided</U></I><I>, </I><I><U>however</U></I><I>, </I>that
(i)&nbsp;nothing set forth in this <U>Section</U><U></U><U>&nbsp;4.2</U> shall relieve either party from liability for any breach of this Agreement prior to termination hereof, and (ii)&nbsp;the provisions of this
<U>Article</U><U></U><U>&nbsp;IV</U> shall survive any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3. <B><U>Confidentiality</U></B>. Except to the
extent required by applicable Law, the Stockholder shall hold <FONT STYLE="white-space:nowrap">any&nbsp;non-public&nbsp;information</FONT> regarding this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any
such information to any third person until Parent has publicly disclosed its entry into the Merger Agreement and this Agreement;<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I>, that the Stockholder may disclose such information (a)&nbsp;to
its attorneys, accountants, consultants, trustees, beneficiaries and other representatives (<I><U>provided</U></I>&nbsp;such representatives are subject to confidentiality obligations at least as restrictive as those contained herein), and
(b)&nbsp;to any Affiliate, partner, member, stockholder, parent or subsidiary of the Stockholder,<I><U>&nbsp;provided</U></I>&nbsp;in each case that the Stockholder informs the Person receiving the information that such information is confidential
and such Person agrees in writing to abide by the terms of this<U>&nbsp;Section</U><U></U><U>&nbsp;4.3</U>. Neither the Stockholder nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall
issue or cause the publication of any press release or other public announcement with respect to this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the
Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable. The Company is an intended third-party
beneficiary of this <U>Section</U><U></U><U>&nbsp;4.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4. <B><U>Amendments and Waivers</U></B>. Any provision of this Agreement may
be amended or waived if such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this Agreement, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by
either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or
privilege. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5. <B><U>Binding Effect; Benefit; Assignment</U></B>. The provisions of this Agreement shall be binding upon and shall inure
to the benefit of the parties hereto and their respective successors and assigns. Except as set forth in Section&nbsp;1.3 and Section&nbsp;4.3, no provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or
liabilities hereunder upon any Person other than the parties hereto and their respective successors and assigns. Neither party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of
the other party hereto, except that Parent may transfer or assign its rights and obligations under this Agreement, in whole or from time to time in part, to one or more of its Affiliates at any time; <I><U>provided</U></I> that such transfer or
assignment shall not relieve Parent of any of its obligations hereunder; <I><U>provided however</U></I> that the Stockholder may transfer the Company Shares to stockholders, direct or indirect affiliates (within the meaning set forth in Rule 405
under the Securities Act), current or former partners (general or limited), members or managers of the Stockholder, so long as the transferee agrees in writing to be bound by the terms and conditions of this Agreement and either the Stockholder or
the transferee provides Parent with a copy of such Agreement promptly upon consummation of any such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6. <B><U>Governing Law;
Jurisdiction</U></B>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or
proceeding between any of the parties hereto arising out of or relating to this Agreement, each party hereto: (a)&nbsp;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State
of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the
State of Delaware (the &#8220;<B><I>Delaware Courts</I></B>&#8221;); (b) agrees that all claims in respect of such action or proceeding shall be heard and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determined exclusively in accordance with clause (a)&nbsp;of this <U>Section</U><U></U><U>&nbsp;4.6</U>; (c) waives any objection to laying venue in any such action or proceeding in such courts;
(d)&nbsp;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party hereto; (e)&nbsp;agrees that service of process upon such party in any such action or proceeding shall be effective if notice is
given in accordance with <U>Section</U><U></U><U>&nbsp;4.1</U> of this Agreement; and (f)&nbsp;irrevocably and unconditionally waives the right to trial by jury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7. <B><U>Counterparts</U></B>. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of
which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission in .PDF format shall be sufficient to bind the parties to the terms
and conditions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8. <B><U>Entire Agreement</U></B>. This Agreement constitutes the entire agreement and supersedes all
prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9. <B><U>Severability</U></B>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction
shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of
a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination will have the power to limit such term or provision, to delete
specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be
valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or
provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10. <B><U>Specific Performance</U></B>. Any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not
exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage would occur in
the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent
breaches of this Agreement and to enforce specifically the terms and provisions hereof in any Delaware Court, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties hereto waives any bond,
surety or other security that might be required of any other party with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11. <B><U>Construction</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party
shall not be applied in the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> As used in this Agreement, the words
&#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; &#8220;Articles,&#8221; and
&#8220;Schedules&#8221; are intended to refer to Sections or Articles of this Agreement and Schedules to this Agreement, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The bold-faced headings contained in this Agreement are for convenience of
reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.12. <B><U>Further Assurances</U></B>. Each of the parties hereto will execute and deliver, or cause to be executed and delivered, all
further documents and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable Law to perform their respective obligations as
expressly set forth under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.13. <B><U>No Legal Actions.</U></B><B> </B>Each Stockholder will not in its capacity as a
Stockholder of the Company bring, commence, institute, maintain, prosecute or voluntarily aid any Legal Proceeding which (i)&nbsp;challenges the validity or seeks to enjoin the operation of any provision of this Agreement or (ii)&nbsp;alleges that
the execution and delivery of this Agreement by such Stockholder, either alone or together with the other voting agreements and proxies to be delivered in connection with the execution of the Merger Agreement, or the approval of the Merger Agreement
and the Contemplated Transactions by the Company Board, constitutes a breach of any fiduciary duty of the Company Board or any member thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.14. <B><U>Voluntary Execution of Agreement</U></B>. This Agreement is executed voluntarily and without any duress or undue influence on the
part or behalf of the parties. Each of the parties hereby acknowledges, represents and warrants that (i)&nbsp;it has read and fully understood the Merger Agreement, including the provisions relating to the payment and allocation of the consideration
to be paid to Stockholders of the Company as well as holders of Company Options, this Agreement and the implications and consequences thereof; (ii)&nbsp;it has been represented in the preparation, negotiation, and execution of this Agreement by
legal counsel of its own choice, or it has made a voluntary and informed decision to decline to seek such counsel; and (iii)&nbsp;it is fully aware of the legal and binding effect of this Agreement. The Stockholder has had an opportunity to review
with its own tax advisors the tax consequences of the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective
agents or representatives. The Stockholder understands that such Stockholder (and not Parent, or the Company) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Contemplated Transactions. The
Stockholder understands and acknowledges that Parent, the Company and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.15. <B><U>Fees and Expenses</U></B>. Except as otherwise specifically provided herein, the Merger Agreement or any other agreement
contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.16. <B><U>Capacity as Stockholder</U></B>. The Stockholder signs this Agreement solely in the Stockholder&#8217;s capacity as a holder of
Company Shares, and not in the Stockholder&#8217;s capacity as a director, officer or employee of the Company or in the Stockholder&#8217;s capacity as a trustee or fiduciary of any employee benefit plan or trust. Notwithstanding anything herein to
the contrary, nothing herein shall in any way restrict a director or officer of the Company in the exercise of his or her fiduciary duties as a director or officer of the Company or in his or her capacity as a trustee or fiduciary of any employee
benefit plan or trust or prevent or be construed to create any obligation on the part of any director or officer of the Company or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such
director, officer, trustee or fiduciary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.17. <B><U>No Agreement Until Executed</U></B>. Irrespective of negotiations among the parties
or the exchanging of drafts of this Agreement, this Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&nbsp;the Company Board has approved, for
purposes of any applicable anti-takeover laws and regulations, and any applicable provision of the Company&#8217;s organizational documents, the Merger, (b)&nbsp;the Merger Agreement is executed by all parties thereto, and (c)&nbsp;this Agreement is
executed by all parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(SIGNATURE PAGE FOLLOWS) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>R<SMALL>ALLYBIO</SMALL> C<SMALL>ORPORATION</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Support Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>STOCKHOLDER</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Print Name of Stockholder)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Name and Title of Signatory, if Signing on Behalf of an Entity)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address for Notices:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Company Support Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule&nbsp;A </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Name of Stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">No.&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#149;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#167; 262. Appraisal rights [For application of this section, see &#167; 17; 82 Del. Laws, c. 45, &#167; 23; 82 Del. Laws, c. 256, &#167; 24; and 83 Del.
Laws, c. 377, &#167;&nbsp;22]. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Any stockholder of a corporation of this State who holds shares of stock on the date of the making
of a demand pursuant to subsection (d)&nbsp;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, or conversion, who has otherwise complied with subsection
(d)&nbsp;of this section and who has neither voted in favor of the merger, consolidation or conversion nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value
of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&nbsp;and (c) of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words
&#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares,
or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee
on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Appraisal rights shall be available for the shares of any class or series of stock of a constituent or converting corporation in a merger,
consolidation or conversion to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g) of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264 or &#167; 266 of
this title (other than, in each case and solely with respect to a domesticated corporation, a merger, consolidation or conversion authorized pursuant to and in accordance with the provisions of &#167; 388 of this title): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">(1) Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which
stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent
pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for conversion (or, in the case of a merger pursuant to &#167; 251(h) of this title, as of immediately prior to the execution of
the agreement of merger), were either: (i)&nbsp;listed on a national securities exchange or (ii)&nbsp;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the
constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f) of this title. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">(2) Notwithstanding paragraph (b)(1) of this section, appraisal rights under this section shall be available for the shares of any class or
series of stock of a constituent or converting corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, pursuant to &#167;&#8201;251,
&#167;&#8201;252, &#167;&#8201;254, &#167;&#8201;255, &#167;&#8201;256, &#167;&#8201;257, &#167;&#8201;258, &#167;&#8201;263, &#167;&#8201;264 or &#167;&#8201;266 of this title to accept for such stock anything except: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity if such entity is a
corporation as a result of the conversion, or depository receipts in respect thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">b. Shares of stock of any other corporation, or
depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation or conversion will be either listed on a national securities exchange
or held of record by more than 2,000 holders; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c. Cash in lieu of fractional shares or fractional depository receipts described in the
foregoing paragraphs (b)(2)a. and b. of this section; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">d. Any combination of the shares of stock, depository receipts and cash in lieu
of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">(3) In the event all of the stock of a subsidiary Delaware corporation party to a merger
effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">(4) [Repealed.] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) Any
corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or
consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title. If the certificate of incorporation contains
such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&nbsp;of this section, shall apply as nearly as is practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) Appraisal rights shall be perfected as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">(1) If a proposed merger, consolidation or conversion for which appraisal rights are provided under this section is to be submitted for
approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance
with &#167; 255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&nbsp;or (c) of this section that appraisal rights are available for any or all of the shares of the constituent corporations
or the converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information
directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such
stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation or conversion, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the
corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the
stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation or conversion shall not constitute such a demand. A stockholder electing to take such
action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger, consolidation or conversion, the surviving, resulting or converted entity shall notify each stockholder of each constituent or
converting corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation or conversion, and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section, of the
date that the merger, consolidation or conversion has become effective; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">(2) If the merger, consolidation or conversion was approved
pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent or converting corporation before the effective date of the merger, consolidation or conversion, or the surviving, resulting or converted entity
within 10 days after such effective date, shall notify each stockholder of any class or series of stock of such constituent or converting corporation who is entitled to appraisal rights of the approval of the merger, consolidation or conversion and
that appraisal rights are available for any or all shares of such class or series of stock of such constituent or converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or
the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may
be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation or conversion, shall, also notify such stockholders of the effective date of the merger, consolidation or
conversion. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, within the later of the consummation of the offer
contemplated by &#167; 251(h) of this title and 20 days after the date of giving such notice, demand in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">
writing from the surviving or resulting entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an
information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand
the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation or conversion, either (i)&nbsp;each such constituent corporation or the converting corporation shall send a
second notice before the effective date of the merger, consolidation or conversion notifying each of the holders of any class or series of stock of such constituent or converting corporation that are entitled to appraisal rights of the effective
date of the merger, consolidation or conversion or (ii)&nbsp;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second
notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h) of this
title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection
and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such
notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting corporation may
fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation or conversion, the record date shall be such
effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding subsection (a)&nbsp;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s
name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1) or (2)&nbsp;of this section, as applicable; provided that (i)&nbsp;such beneficial owner continuously owns such shares through
the effective date of the merger, consolidation or conversion and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&nbsp;of this section and (ii)&nbsp;the demand made by such beneficial owner
reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and
correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by
subsection (f)&nbsp;of this section. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e) Within 120 days after the effective date of the merger, consolidation or conversion, the
surviving, resulting or converted entity, or any person who has complied with subsections (a)&nbsp;and (d) of this section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the
Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger, consolidation or conversion, any person entitled to
appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or
conversion. Within 120 days after the effective date of the merger, consolidation or conversion, any person who has complied with the requirements of subsections (a)&nbsp;and (d) of this section hereof, upon request given in writing (or by
electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth
the aggregate number of shares not voted in favor of the merger, consolidation or conversion (or, in the case of a merger approved pursuant to &#167; 251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in
&#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
offer referred to in &#167; 251(h)(2) of this title)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial
owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3) of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for
purposes of such aggregate number). Such statement shall be given to the person within 10 days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10 days after expiration of
the period for delivery of demands for appraisal under subsection (d)&nbsp;of this section hereof, whichever is later. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f) Upon the filing
of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20 days after such service file in the office of the Register in Chancery in
which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the
petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the
hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by
the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g) At the hearing on such petition, the
Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates
to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If
immediately before the merger, consolidation or conversion the shares of the class or series of stock of the constituent or converting corporation as to which appraisal rights are available were listed on a national securities exchange, the Court
shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&nbsp;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for
appraisal, (2)&nbsp;the value of the consideration provided in the merger, consolidation or conversion for such total number of shares exceeds $1&nbsp;million, or (3)&nbsp;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(h) After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the
rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or
expectation of the merger, consolidation or conversion, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the
Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation or conversion through the date of payment of the judgment shall be compounded
quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the
judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein
only upon the sum of (1)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&nbsp;interest theretofore accrued, unless paid at that time. Upon application by the surviving,
resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any
person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&nbsp;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to
appraisal rights under this section. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) The Court shall direct the payment of the fair value of the shares, together with
interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other
decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(j) The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances.
Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&nbsp;of this section who participated in the proceeding and incurred expenses in connection therewith, the
Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not
dismissed pursuant to subsection (k)&nbsp;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&nbsp;of this section. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(k) From and after the effective date of the merger, consolidation or conversion, no person who has demanded appraisal rights with respect to
some or all of such person&#8217;s shares as provided in subsection (d)&nbsp;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other
distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation or conversion); provided, however, that if no petition for an appraisal is filed within the time provided in subsection
(e)&nbsp;of this section, or if a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in
respect of some or all of such person&#8217;s shares in accordance with subsection (e)&nbsp;of this section, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, no
appraisal proceeding in the Court of Chancery shall be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including without limitation, a reservation of
jurisdiction for any application to the Court made under subsection (j)&nbsp;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a
named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion within 60 days after the effective date of the merger, consolidation or conversion, as set forth in
subsection (e)&nbsp;of this section. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(<I>l</I>) The shares or other equity interests of the surviving, resulting or converted entity to
which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity
interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc109079_49"></A><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;1, 2026 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned (the &#8220;<B><I>Stockholder</I></B>&#8221;) understands that: (i)<B>&nbsp;R<SMALL>ALLYBIO</SMALL>
C<SMALL>ORPORATION</SMALL></B><SMALL></SMALL>., a Delaware corporation (&#8220;<B><I>Parent</I></B>&#8221;), has entered into an Agreement and Plan of Merger and Reorganization, dated as of March&nbsp;1, 2026 (the &#8220;<B><I>Merger
Agreement</I></B>&#8221;), with<B> C<SMALL>ANDID</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B>,<B> </B>a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), and Farmington Merger Sub, Inc., a Delaware corporation and
wholly-owned subsidiary of Parent (&#8220;<B><I>Merger Sub</I></B>&#8221;), pursuant to which at the effective time (the &#8220;<B><I>Effective Time</I></B>&#8221;), Merger Sub will be merged with and into the Company (the
&#8220;<B><I>Merger</I></B>&#8221;) and the separate corporate existence of Merger Sub shall cease and the Company will continue as the surviving corporation; and (ii)&nbsp;in connection with the Merger, the stockholders of the Company will receive
shares of common stock, par value $0.0001 per share, of Parent (&#8220;<B><I>Parent Common Stock</I></B>&#8221;). Annex A sets forth definitions for certain capitalized terms used in this agreement that are not defined in the body of this agreement.
Those definitions are a part of this agreement. Other capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a material inducement to the willingness of each of the parties to enter into the Merger Agreement and to consummate the Contemplated
Transactions, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Stockholder hereby agrees that the Stockholder will not, subject to the exceptions set forth in this letter agreement,
during the period commencing upon the Effective Time and ending on the date that is 180 days after the Effective Time (the &#8220;<B><I>Restricted Period</I></B>&#8221;), (a) Sell or Offer to Sell, any shares of Parent Common Stock or any securities
convertible into or exercisable or exchangeable for Parent Common Stock, including without limitation, Parent Common Stock or such other securities which may be deemed to be beneficially owned by the Stockholder or such Stockholder&#8217;s Family
Member, in accordance with the rules and regulations of the U.S. Securities and Exchange Commission and securities of Parent which may be issued upon exercise or settlement of a stock option or other equity award (collectively,
&#8220;<B><I>Shares</I></B>&#8221;), (b) enter into any Swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares, regardless of whether any such transaction described
in clause (a)&nbsp;or (b) above is to be settled by delivery of Parent Common Stock or such other securities, in cash or otherwise, (c)&nbsp;make any demand for or exercise any right with respect to the registration of any shares of Parent Common
Stock or any security convertible into or exercisable or exchangeable for Parent Common Stock, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to such
registration or (d)&nbsp;publicly announce any intention to do any of the foregoing, in each case other than: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) transfers of Shares as
<I>bona fide </I>charitable contributions, gifts or donations; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) transfers or dispositions of Shares to any Family Member or any trust
for the direct or indirect benefit of the Stockholder and/or the Family Member of the Stockholder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) transfers or dispositions of
Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the Immediate family of the Stockholder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) transfers of Shares to stockholders, direct or indirect Affiliates, current or former partners (general or limited), members or managers
of the Stockholder, as applicable, or to the estates of any such stockholders, Affiliates, partners, members or managers, or to another corporation, partnership, limited liability company or other business entity that controls, is controlled by or
is under common control with the Stockholder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) transfers that occur by operation of law pursuant to a court order or settlement
agreement related to the distribution of assets in connection with the dissolution of a marriage or civil union; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) transfers or
dispositions not involving a change in beneficial ownership; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) if the Stockholder is a trust, transfers or dispositions to any beneficiary of the
Stockholder or the estate of any such beneficiary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) transfers pursuant to a bona fide third party tender offer, merger,
consolidation or other similar transaction made to all holders of the Parent&#8217;s capital stock involving a change of control of the Parent, <I><U>provided</U></I> that in the event that such tender offer, merger, consolidation or other such
transaction is not completed, the Shares shall remain subject to the restrictions contained in this letter agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) transfers of
Parent Common Stock, if any, issued in connection with the Concurrent Financing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>provided</U></I>, that in each case of clauses (i)-(vii), (a)
other than with respect to clauses (i), (iii), (iv), (v) and (vii), no filing by any party (including any donor, donee, transferor or transferee, distributor or distributee) under the Exchange Act or other public announcement shall be required or
shall be made voluntarily in connection with such transfer or distribution (other than filings made in respect of involuntary transfers or dispositions or a filing on a Form 5 made after the expiration of the Restricted Period), (b) other than with
respect to clause (iv), any such transfer or distribution shall not involve a disposition for value, and (c)&nbsp;the transferee or donee agrees in writing to be bound by the terms and conditions of this letter agreement and either the Stockholder
or the transferee or donee provides Parent with a copy of such agreement promptly upon consummation of any such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding
the restrictions imposed by this letter agreement, the Stockholder may (a)&nbsp;exercise or settle an option to purchase Shares or other equity award (including a net or cashless exercise of such option) and <I><U>provided</U></I>
<I><U>further</U></I>, that the underlying Shares shall continue to be subject to the restrictions on transfer set forth in this letter agreement, (b)&nbsp;transfer Shares to Parent to cover tax withholding obligations of the Stockholder in
connection with the vesting, settlement or exercise of such options or other equity awards, as applicable, (c)&nbsp;establish a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (&#8220;<B><I><FONT
STYLE="white-space:nowrap">10b5-1</FONT> Plan</I></B>&#8221;) for the transfer of Shares, <I><U>provided</U></I> that such plan does not provide for any transfers of Shares during the Restricted Period and, <I><U>provided</U></I><I>
</I><I><U>further,</U></I> that, no filing under the Exchange Act or other public announcement shall be made voluntarily in connection with the establishment of such a plan, (d)&nbsp;transfer Shares to Parent pursuant to arrangements under which
Parent has the option to repurchase such Shares, or (e)&nbsp;transfer or dispose of Shares acquired on the open market following the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any attempted transfer in violation of this letter agreement will be of no effect and null and void, regardless of whether the purported
transferee has any actual or constructive knowledge of the transfer restrictions set forth in this letter agreement, and will not be recorded on the share register of Parent. To ensure compliance with the restrictions referred to herein, the
Stockholder agrees that Parent and any duly appointed transfer agent may issue appropriate &#8220;stop transfer&#8221; certificates or instructions. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be
placed upon any certificate(s) or other documents or instruments evidencing ownership of the Shares: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder hereby represents and warrants that the Stockholder has full power and authority to enter into this letter agreement. All
authority conferred or agreed to be conferred and any obligations of the Stockholder under this letter agreement will be binding upon the successors, assigns, heirs or personal representatives of the Stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any holder of Parent&#8217;s securities that is subject to a substantially similar agreement entered into by such holder,
other than the Stockholder, is granted a release or waiver of the foregoing restrictions by Parent with respect to any shares of Parent Common Stock for value other than as permitted by this or a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially similar agreement entered into by such holder, the same percentage of shares of Parent Common Stock held by the Stockholder shall be immediately and fully released on the same terms
from any remaining restrictions set forth herein (the &#8220;<B><I><FONT STYLE="white-space:nowrap">Pro-Rata</FONT> Release</I></B>&#8221;); <I><U>provided</U></I>, <I><U>however</U></I>, that such <FONT STYLE="white-space:nowrap">Pro-Rata</FONT>
Release shall not be applied unless and until permission has been granted by Parent, to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders&#8217; shares of Parent Common Stock in an
aggregate amount in excess of 1% of the number of shares of Parent Common Stock outstanding immediately following the Effective Time; <I><U>provided</U></I><I> </I><I><U>further</U></I> that if the Stockholder is an executive officer or director of
Parent and such release or waiver was conducted solely for the purpose of meeting Nasdaq&#8217;s initial listing standards, then such Stockholder shall not be entitled to such <FONT STYLE="white-space:nowrap">Pro-Rata</FONT> Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the release of any Shares from this letter agreement, Parent will cooperate with the Stockholder to facilitate the timely preparation and
delivery of certificates or the establishment of book entry positions at the Parent&#8217;s transfer agent representing the Shares without the restrictive legend above and the withdrawal of any stop transfer instructions at the Parent&#8217;s
transfer agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder understands that each of Parent and the Company is relying upon this letter agreement in proceeding
toward consummation of the Merger. The Stockholder further understands that this letter agreement is irrevocable and is binding upon the Stockholder&#8217;s heirs, legal representatives, successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter agreement and any claim, controversy or dispute arising under or related to this letter agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Stockholder understands that if the Merger Agreement is terminated in accordance with its terms, the Stockholder will be released from all obligations under this letter agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents that the undersigned has full power, capacity and authority to enter into this agreement. This letter
agreement may be executed by electronic (i.e., PDF) transmission, which is deemed an original. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Print&nbsp;Name&nbsp;of Stockholder:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>Signature (for individuals):</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>Signature (for entities):</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> L<SMALL>OCK</SMALL><FONT STYLE="white-space:nowrap">-</FONT><SMALL>UP</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Defined Terms </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Used in <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the agreement to which this Annex A is attached and of which it is made a part: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B>Affiliate</B>&#8221; shall have the meaning set forth in Rule 405 under the Securities Act.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B>Call Equivalent Position</B>&#8221;<B> </B>shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B>Exchange Act</B>&#8221;<B> </B>shall mean the Securities Exchange Act of 1934, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B>Family Member</B>&#8221; shall mean the spouse of the undersigned, an immediate family member of the
undersigned or an immediate family member of the undersigned&#8217;s spouse, in each case living in the undersigned&#8217;s household or whose principal residence is the undersigned&#8217;s household (regardless of whether such spouse or family
member may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). &#8220;<B>Immediate family member</B>&#8221; as used above shall have the meaning
set forth in Rule <FONT STYLE="white-space:nowrap">16a-1(e)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B>Immediate Family</B>&#8221; shall mean any relationship by blood, marriage or adoption, not more remote
than first cousin. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Put Equivalent Position</B>&#8221; shall have the meaning set forth in Rule
<FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B>Securities Act</B>&#8221; shall mean the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B>Sell or Offer to Sell</B>&#8221; shall mean to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, offer to sell, contract to sell or lend, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call
Equivalent Position, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pledge, hypothecate or grant any security interest in, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other way transfer or dispose of, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">in each case whether effected directly or indirectly. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;<B>Swap</B>&#8221; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole
or in part, the economic risk of ownership of Shares, regardless of whether any such transaction is to be settled in securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc109079_50"></A>CONTINGENT VALUE RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> C<SMALL>ONTINGENT</SMALL> V<SMALL>ALUE</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this
&#8220;<B><I>Agreement</I></B>&#8221;), dated as of [&#149;] (the &#8220;<B><I>Effective Date</I></B>&#8221;), is entered into by and between Rallybio Corporation, a Delaware corporation (&#8220;<B><I>Rallybio</I></B>&#8221;), and [&#149;], a
[&#149;], as Rights Agent (as defined herein). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>A.</B> Rallybio, Farmington Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Rallybio (&#8220;<B><I>Merger
Sub</I></B>&#8221;) and Candid Therapeutics, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), have entered into an Agreement and Plan of Merger and Reorganization, dated as of March&nbsp;1, 2026 (as it may be amended,
supplemented or otherwise modified from time to time pursuant to the terms thereof, the &#8220;<B><I>Merger Agreement</I></B>&#8221;), pursuant to which Merger Sub will merge with and into the Company (the &#8220;<B><I>Merger</I></B>&#8221;), with
the Company surviving the Merger as a wholly owned Subsidiary of Rallybio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>B.</B> Pursuant to the Merger Agreement, and in accordance
with the terms and conditions thereof, Rallybio has agreed to provide to the Holders (as defined herein) certain contingent value rights as hereinafter described. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>C.</B> The parties to this Agreement have done all things reasonably necessary to make the contingent value rights, when issued hereunder,
the valid obligations of Rallybio and to make this Agreement a valid and binding agreement of Rallybio, in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the premises and the consummation of the transactions
referred to above, it is mutually covenanted and agreed, for the proportionate benefit of all Holders, as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>
<B>Definitions</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Merger Agreement.
The following terms have the meanings ascribed to them as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Acting Holders</I></B>&#8221; means, at any time, the
registered Holders of more than 40% of the total number of CVRs outstanding at such time, as set forth on the CVR Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Affiliate</I></B>&#8221; of any particular Person means any other Person controlling, controlled by or under common control with
such particular Person. For the purposes of this definition, &#8220;controlling,&#8221; &#8220;controlled&#8221; and &#8220;control&#8221; mean the possession, directly or indirectly, of the power to direct the management and policies of a Person
whether through the ownership of voting securities, contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Assignee</I></B>&#8221; has the meaning set forth
in <U>Section</U><U></U><U>&nbsp;6.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Business Day</I></B>&#8221; means any day other than a Saturday, Sunday or other
day on which banks in New York, New York are authorized or obligated by Law to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>CVR</I></B>&#8221; means a
contingent contractual right of Holders to receive the CVR Payments pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>CVR Payment</I></B>&#8221; means a cash payment equal to 100% of the Net
Proceeds actually received by Rallybio during a CVR Payment Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>CVR Payment Period</I></B>&#8221; means an annual period
(or portion thereof) beginning on the Effective Date and ending on December&nbsp;31 of any given calendar year during the CVR Term; <I>provided</I>, that if the last CVR Payment Period would end subsequent to the expiration of the CVR Term, such CVR
Payment Period will end on the Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>CVR Register</I></B>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>CVR Term</I></B>&#8221; means the period beginning on the Closing and ending on
December&nbsp;31, 2030. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Disposition</I></B>&#8221; means the sale, license, transfer or other disposition to a third party
of any Legacy Asset by Rallybio or its Affiliates, including any sale or disposition of equity securities in any Subsidiary established by Rallybio to hold any right, title or interest in any Legacy Asset, in each case, during the Disposition
Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Disposition Agreement</I></B>&#8221; means a definitive written agreement providing for the Disposition of all or
any portion of the Legacy Assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Disposition Period</I></B>&#8221; means the period beginning on the Effective Date and
ending on the date that is one year thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Gross Proceeds</I></B>&#8221; means, without duplication, the sum of all
consideration that is received by Rallybio during the CVR Term with respect to (i)&nbsp;any upfront, milestone, royalty and other payments received under a Disposition Agreement and (ii)&nbsp;any Recursion Milestone Amounts; <I>provided</I>, that,
for the avoidance of doubt, Gross Proceeds shall not include any amounts that are Incidental Benefits. Equity securities shall only constitute Gross Proceeds to the extent they are listed and traded on a national stock exchange, and shall have such
value as quoted on such national securities exchange at the time of disposition of such equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Holder</I></B>&#8221; means, at the relevant time, a Person in whose name one or more CVRs are registered in the CVR Register.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Holder Representative</I></B>&#8221; means Stephen Uden, M.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Incidental Benefits</I></B>&#8221; means any amounts paid to, received or realized by Rallybio that are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Tax attributes, Tax refunds, Tax credits, Tax deductions or other Tax benefits (including utilization of net operating losses, basis
increases, amortization or depreciation deductions, or reductions in Tax liability); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) profit-share, revenue-share, or similar
participation payments; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) reimbursements or payments for research, development, clinical, regulatory, manufacturing, commercialization,
patent or other costs or services; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits of any nature or <FONT
STYLE="white-space:nowrap">non-cash</FONT> consideration (other than equity securities listed and traded on a national stock exchange); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) other ancillary, indirect or incidental benefits, rights or value received in connection with or arising out of the Disposition Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Law</I></B>&#8221; means any federal, state, national, foreign, material local or municipal or other law, statute,
constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any governmental authority (including under the authority of Nasdaq or the
Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Legacy Assets</I></B>&#8221; means Rallybio&#8217;s rights, assets, technology and
intellectual property that were in existence immediately prior to the execution of the Merger Agreement and were used or generated prior to such execution in one or more of Rallybio&#8217;s research and development programs. For clarity, the Legacy
Assets shall not include any asset, technology or intellectual property owned or controlled by the Company or its Subsidiaries prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Liability</I></B>&#8221; means any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of
any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Loss</I></B>&#8221; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;3.2(g)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Membership Interest Purchase Agreement</I></B>&#8221; means the
Membership Interest Purchase Agreement, dated as of July&nbsp;8, 2025, by and among Rallybio, Recursion Pharmaceuticals, Inc. and the other parties thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Net Proceeds</I></B>&#8221; means, for any CVR Payment Period, Gross Proceeds minus Permitted Deductions. For clarity, to the
extent Permitted Deductions exceed Gross Proceeds for any CVR Payment Period, any excess Permitted Deductions shall be applied against Gross Proceeds in subsequent CVR Payment Periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Notice</I></B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Officer&#8217;s Certificate</I></B>&#8221; means a certificate signed by the chief executive officer and the chief financial
officer of Rallybio, in their respective official capacities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Permitted Deductions</I></B>&#8221; means the sum of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any applicable Tax (including any applicable value added or sales taxes) imposed on Gross Proceeds or otherwise payable by Rallybio or any
of its Affiliates (regardless of whether the due date for such Taxes arises during or after the Disposition Period), including, without duplication, any income or other similar Taxes payable by Rallybio or any of its Affiliates that would not have
been incurred by Rallybio or any of its Affiliates but for the Gross Proceeds, and any applicable Tax imposed on or otherwise payable in connection with making any CVR Payment or the issuance of any CVR (including, without limitation, (i)&nbsp;the
employer portion of any employment, payroll, or other similar Taxes in respect of CVR Payments made in respect of Parent In the Money Stock Options granted to employees or Parent restricted stock units and (ii)&nbsp;any withholding Taxes (including
interest and penalties) relating to the issuance of a CVR or any CVR Payment); <I>provided</I> that, for purposes of calculating income Taxes payable by Rallybio or any of its Affiliates in respect of the Gross Proceeds, such income Taxes shall be
calculated without taking into account any net operating losses or other Tax attributes generated by Rallybio or any of its Affiliates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any reasonable and documented expenses incurred by Rallybio or any of its Affiliates to preserve or ready the Legacy Assets for sale or in
respect of its performance of this Agreement following the Effective Date or in respect of its performance of any Contract in connection with any Legacy Asset (in each case, to the extent such expenses are not included in the determination of the
Net Cash of Rallybio in accordance with the Merger Agreement), including any damages, liabilities arising under any Contract or Disposition Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any reasonable and documented expenses incurred or accrued by Rallybio or any of its Affiliates in connection with the negotiation, entry
into and closing of any Disposition Agreement or the Disposition of any Legacy Asset; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any Losses incurred by Rallybio or any of its Affiliates arising out of any third-party
claims, demands, actions, or other proceedings relating to or in connection with any Disposition, including indemnification obligations as set forth in a claims notice received by Rallybio or any of its Affiliates pursuant to any Disposition
Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any Liabilities borne by Rallybio or any of its Affiliates pursuant to Contracts related to Legacy Assets, including costs
arising from the termination thereof (in each case only to the extent not included in the calculation of Parent Net Cash); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) any
amounts payable to the Rights Agent in connection with the distribution of any CVR Payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Permitted
Transfer</I></B>&#8221; means a transfer of CVRs (i)&nbsp;upon death of a Holder by will or intestacy, (ii)&nbsp;pursuant to a court order, (iii)&nbsp;by operation of law (including by consolidation or merger) or without consideration in connection
with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity, (iv)&nbsp;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if
applicable, through an intermediary, or (v)&nbsp;as provided in <U>Section</U><U></U><U>&nbsp;2.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Person</I></B>&#8221;
means any individual, corporation, partnership, joint venture, estate, trust, company, firm, limited liability company, firm, society or other enterprise, association, organization, or any other entity not specifically listed herein, including any
governmental authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Pro Rata Share</I></B>&#8221; means, with respect to any Holder, the quotient obtained by dividing
(i)&nbsp;the aggregate number of CVRs held by such Holder by (ii)&nbsp;the aggregate number of outstanding CVRs held by all Holders, in each case, as reflected in the CVR Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Recursion Milestone Amounts</I></B>&#8221; means the aggregate cash payment amounts received by Rallybio from Recursion
Pharmaceuticals, Inc. pursuant to Section&nbsp;1.1(c) of the Membership Interest Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Rights
Agent</I></B>&#8221; means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent shall have been appointed pursuant to <U>Article 3</U> of this Agreement, and thereafter &#8220;<B><I>Rights
Agent</I></B>&#8221; will mean such successor Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Securities Act</I></B>&#8221; means the Securities Act of 1933,
as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Payment Statement</I></B>&#8221; means, for a given CVR Payment Period during the CVR Term, a written statement
of Rallybio, signed on behalf of Rallybio, setting forth in reasonable detail the calculation of the applicable CVR Payment for such CVR Payment Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An entity shall be deemed to be a &#8220;<B><I>Subsidiary</I></B>&#8221; of a Person if such Person directly or indirectly owns or purports to
own, beneficially or of record, (a)&nbsp;an amount of voting securities or other interests in such entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other
governing body, or (b)&nbsp;at least 50% of the outstanding equity, voting, beneficial or financial interests in such entity. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENT VALUE RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Holders of CVRs; Appointment of Rights Agent</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The CVRs represent the contractual rights of Holders to receive contingent cash payment of the aggregate CVR Payments from Rallybio
pursuant to this Agreement. The initial Holders shall be the holders of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(i)&nbsp;Parent Common Stock, <FONT STYLE="white-space:nowrap">(ii)&nbsp;Pre-Funded</FONT> Warrants, (iii)&nbsp;Parent restricted stock units and (iv)&nbsp;In the Money Parent Options as of the
close of business on the last Business Day prior to the day on which the Effective Time occurs (the &#8220;<B><I>Record Date&#8221;</I></B>). One CVR will be issued with respect to each (w)&nbsp;share of Parent Common Stock, <FONT
STYLE="white-space:nowrap">(x)&nbsp;Pre-Funded</FONT> Warrant, (y)&nbsp;Parent restricted stock unit and (z)&nbsp;In the Money Parent Option that is outstanding as of the close of business on the Record Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Rallybio hereby appoints the Rights Agent to act as rights agent for Rallybio in accordance with the express terms and conditions
set forth in this Agreement, and the Rights Agent hereby accepts such appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>No Certificate; Registration;
Registration of Transfer; Change of Address</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Holders&#8217; rights and obligations in respect of the CVRs derive solely
from this Agreement. The CVRs will not be evidenced by a certificate or other instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Rights Agent will create and
maintain a register (the &#8220;<B><I>CVR Register</I></B>&#8221;) for the purposes of (i)&nbsp;identifying the Holders of CVRs, (ii)&nbsp;determining the Holders&#8217; entitlement to CVRs and (iii)&nbsp;registering the CVRs and Permitted Transfers
thereof. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from Rallybio. Except for the obligations to the Rights Agent and the Holder Representative set forth herein, neither
Rallybio nor its Subsidiaries will have any responsibility or liability whatsoever to any Person other than the Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
Subject to the restrictions on transferability set forth in <U>Section</U><U></U><U>&nbsp;2.6</U>, every request made to transfer CVRs must be in writing and accompanied by a written instrument of transfer reasonably acceptable to the Rights Agent,
together with the signature guarantee of a guarantor institution which is a participant in a signature guarantee program approved by the Securities Transfer Association (a &#8220;signature guarantee&#8221;) and other requested documentation in a
form reasonably satisfactory to the Rights Agent, duly executed and properly completed, as applicable, by the Holder or Holders thereof, or by the duly appointed legal representative, personal representative or survivor of such Holder or Holders,
setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination in accordance with its own internal procedures, that the transfer
instrument is in proper form and otherwise complies on its face with the other terms and conditions of this Agreement (including the provisions in <U>Section</U><U></U><U>&nbsp;2.6</U>), register the transfer of the applicable CVRs in the CVR
Register. All transfers of CVRs registered in the CVR Register will be the valid obligations of Rallybio, evidencing the same right, and entitling the transferee to the same benefits and rights under this Agreement, as those held by the transferor.
Rallybio and the Rights Agent may each require payment by the applicable Holder of a sum sufficient to cover any stamp or other Tax or governmental charge that is imposed in connection with any such registration of transfer (or evidence from the
applicable Holder that such Taxes and charges are not applicable). No transfer of CVRs shall be valid until registered in the CVR Register and unless such transfer would not violate the Securities Act. Any putative transfer not duly registered in
the CVR Register or in violation of the Securities Act shall be void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> A Holder may make a written request to the Rights Agent
to change such Holder&#8217;s address of record in the CVR Register. Such written request must be duly executed by such Holder. Upon receipt of such written notice, the Rights Agent shall promptly record the change of address in the CVR Register.
The Acting Holders may, without duplication, make a written request to the Rights Agent for a list containing the names, addresses and number of CVRs of the Holders that are registered in the CVR Register. Upon receipt of such written request from
the Acting Holders, the Rights Agent shall promptly deliver a copy of such list to the Acting Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Payment
Procedures</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> No later than forty-five (45)&nbsp;days following the end of each CVR Payment Period during the CVR Term,
Rallybio shall deliver to the Rights Agent a Payment Statement for such CVR Payment Period. Concurrent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the delivery of each Payment Statement, on the terms and conditions of this Agreement, Rallybio shall pay the Rights Agent in U.S. dollars an amount equal to the CVR Payment for the
applicable CVR Payment Period; provided, however, that in the event that the aggregate CVR Payment on any Payment Statement shall be less than $1,000,000, no Payment Amount shall be due and instead such CVR Payment shall be added to subsequent CVR
Payments until: (i)&nbsp;the aggregate CVR Payments shall be at least $1,000,000 or (ii)&nbsp;the final CVR Payment Period. Rallybio will cause an amount equal to such CVR Payment to be transferred by wire transfer of immediately available funds to
an account designated in writing by the Rights Agent (for further distribution to the Holders in accordance with the terms hereof) not less than ten (10)&nbsp;Business Days prior to the date of the applicable payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Upon receipt of the wire transfer referred to in <U>Section</U><U></U><U>&nbsp;2.3(a)</U>, the Rights Agent will promptly (and in
any event within ten (10)&nbsp;Business Days) pay, by check mailed, first-class postage prepaid, to the address of each Holder set forth in the CVR Register at such time or by other method of delivery as specified by the applicable Holder in writing
to the Rights Agent, an amount in cash equal to such Holder&#8217;s Pro Rata Share of the applicable CVR Payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> With respect
to any Net Proceeds that are paid to Rallybio or its Affiliate, Rallybio shall have no further liability in respect of the respective CVR Payment upon delivery of the relevant funds to the Rights Agent in accordance with
<U>Section</U><U></U><U>&nbsp;2.3(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Rallybio and the Rights Agent will be entitled to deduct and withhold, or cause to
be deducted and withheld, from any amounts required to be paid or distributed under this Agreement (including any issuance of a CVR pursuant to this Agreement or any CVR Payment payable pursuant to this Agreement), such amounts as Rallybio or the
Rights Agent reasonably determines it is required to deduct and withhold with respect to the making of such payment or distribution (including in respect of the distribution of CVRs) under any provision of applicable Law relating to Taxes. To the
extent that amounts are so deducted and withheld pursuant to this paragraph (d), such deducted and withheld amounts will be treated for all purposes of this Agreement as having been paid or distributed to the Holder in respect of which such
deduction and withholding were made. The Rights Agent will solicit from each Holder a properly completed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or the appropriate version of IRS Form <FONT STYLE="white-space:nowrap">W-8,</FONT> as
applicable, at or prior to any distribution or other payment to such Holder under this Agreement. If Rallybio or the Rights Agent fails to withhold any Tax required to be withheld pursuant to any issuance of a CVR or CVR Payment, Rallybio and the
Rights Agent will be entitled to deduct and withhold, or cause to be deducted and withheld, such Taxes (including any interest and penalties) from subsequent payments with respect to the applicable CVR or, at Rallybio&#8217;s option, the Holder of
such applicable CVR shall promptly pay such Tax to Rallybio upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Any portion of a CVR Payment that remains
undistributed to the Holders on the date that is six months after the Rights Agent&#8217;s receipt of the applicable Payment Statement (including by means of uncashed checks or invalid addresses on the CVR Register) will be delivered by the Rights
Agent to Rallybio or a Person nominated in writing by Rallybio (with written notice thereof from Rallybio to the Rights Agent), and any Holder will thereafter look only to Rallybio for payment of such CVR Payment (which shall be without interest).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> If any CVR Payment (or portion thereof) remains unclaimed by a Holder on the date that is one year after the Rights
Agent&#8217;s receipt of the applicable Payment Statement or the CVR Payment (or immediately prior to such earlier date on which such CVR Payment would otherwise escheat to or become the property of any governmental authority), then: (i)&nbsp;such
CVR Payment (or portion thereof) will, to the extent permitted by applicable Law, become the property of Rallybio and will be transferred to Rallybio or a Person nominated in writing by Rallybio (with written notice thereof from Rallybio to the
Rights Agent), free and clear of all claims or interest of any Person previously entitled thereto, and no consideration or compensation shall be payable therefor, and (ii)&nbsp;the CVRs to which such payment relate shall be deemed abandoned in
accordance with <U>Section</U><U></U><U>&nbsp;2.5</U> and shall no longer be deemed outstanding for any purpose (including for purposes of calculating each Holder&#8217;s Pro Rata Share). Neither Rallybio nor the Rights Agent will be liable to any
Person in respect of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CVR Payment delivered to a public official pursuant to any applicable abandoned property, escheat or similar legal requirement under applicable Law. In addition to and not in limitation of any
other indemnity obligation herein, Rallybio agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to
Rallybio or a public official. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>No Voting, Dividends or Interest; No Equity or Ownership Interest</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> CVRs will not represent any equity or ownership interest in Rallybio or any of its Affiliates. The sole right of the Holders to
receive property hereunder is the right to receive CVR Payments, if any, in accordance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The CVRs and the
possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors outside of Rallybio&#8217;s control, and there is no assurance that Holders will receive any payments under this Agreement or in
connection with the CVRs. It is highly possible that there will not be any CVR Payments. Neither Rallybio nor its Affiliates owe, by virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the
parties hereto intend solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. This <U>Section</U><U></U><U>&nbsp;2.4(c)</U> is an essential and material term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B>Ability to Abandon CVR</B>. A Holder may at any time, at such Holder&#8217;s option or upon the failure to claim payment under
<U>Section</U><U></U><U>&nbsp;2.3(f)</U>, abandon all of such Holder&#8217;s remaining rights represented by CVRs by transferring such CVR to Rallybio or a Person nominated in writing by Rallybio (with written notice thereof from Rallybio to the
Rights Agent) without consideration in compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by Rallybio of such transfer and cancellation. No such notice to the Rights Agent shall be
required in the case of abandonment due to the failure to claim payment under <U>Section</U><U></U><U>&nbsp;2.3(f)</U>. Nothing in this Agreement is intended to prohibit Rallybio or its Affiliates from offering to acquire or acquiring CVRs, in
private transactions or otherwise, for consideration in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B>
<B><FONT STYLE="white-space:nowrap">Non-transferable</FONT></B>. The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer.
The CVRs will not be listed on any quotation system or traded on any securities exchange. Any purported transfer of a CVR other than through a Permitted Transfer shall be null and void <I>ab initio</I>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE RIGHTS
AGENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Certain Duties and Responsibilities</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the
extent such liability arises as a result of the willful misconduct, bad faith, fraud or gross negligence of the Rights Agent (in each case as determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of court of competent
jurisdiction). Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special, punitive, indirect, incidental or consequential loss or damages of any kind whatsoever (including, without limitation, lost profits),
even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Rights Agent will not have any duty or responsibility in the case of the
receipt of any written demand from any Holder with respect to any action or default by any Person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings
at law or otherwise or to make any demand upon Rallybio. All rights of action under this Agreement may be enforced (but shall not be required to be enforced) by the Rights Agent, any claim, action, suit, audit, investigation or proceeding instituted
by the Rights Agent will be brought in its name as the Rights Agent and any recovery in connection therewith will be for the proportionate benefit of all the Holders, as their respective rights or interests may appear on the CVR Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Certain Rights of Rights Agent</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no
implied covenants or obligations will be read into this Agreement against the Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Rights Agent may rely and will
be protected by Rallybio in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in the absence of bad faith
to be genuine and to have been signed or presented by or on behalf of Rallybio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Whenever the Rights Agent deems it desirable
that a matter be proved or established prior to taking or omitting any action hereunder, the Rights Agent may (i)&nbsp;rely upon an Officer&#8217;s Certificate and (ii), in the absence of bad faith, gross negligence, fraud or willful misconduct on
its part, incur no liability and be held harmless by Rallybio for or in respect of any action taken or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer&#8217;s Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The Rights Agent may engage and consult with counsel of its selection, and the written advice or opinion of such counsel will, in
the absence of bad faith, gross negligence, fraud or willful misconduct on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken or not taken by the Rights Agent in reliance thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Any permissive rights of the Rights Agent hereunder will not be construed as a duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> Rallybio agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any
loss, liability, damage, judgment, fine, penalty, cost or expense (each, a &#8220;<B><I>Loss</I></B>&#8221;) suffered or incurred by the Rights Agent and arising out of or in connection with the Rights Agent&#8217;s performance of its obligations
under this Agreement, including the reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of or in connection in connection with the execution, acceptance,
administration, exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the
extent such Loss has been determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision of a court of competent jurisdiction to have resulted from the Rights Agent&#8217;s gross negligence, bad faith, fraud or willful
misconduct; provided that this <U>Section</U><U></U><U>&nbsp;3.2(g)</U> shall not apply to (i)&nbsp;income, receipt, franchise or similar Taxes, (ii)&nbsp;any Taxes imposed due to the Rights Agent&#8217;s connection with the jurisdiction imposing
such Taxes (other than any connection caused solely by this Agreement or the Rights Agent performing, enforcing or receiving payments under this Agreement), or (iii)&nbsp;any Taxes imposed due to the failure of the Rights Agent to provide any form,
document or certificate that would have reduced or eliminated the amount of withholding taxes (&#8220;<B><I>Excluded Taxes</I></B>&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> In addition to the indemnification provided under
<U>Section</U><U></U><U>&nbsp;3.2(g)</U>, Rallybio agrees (i)&nbsp;to pay the fees of the Rights Agent in connection with the Rights Agent&#8217;s performance of its obligations hereunder, as agreed upon in writing by the Rights Agent and Rallybio
on or prior to the date of this Agreement, and (ii)&nbsp;to reimburse the Rights Agent for all reasonable and properly documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including all
stamp and transfer Taxes (excluding any Excluded Taxes) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement, except that Rallybio will have no obligation to pay the fees of the Rights
Agent or reimburse the Rights Agent in connection with any lawsuit initiated by the Rights Agent on behalf of itself or the Holders, except in the case of any suit enforcing the provisions of <U>Section</U><U></U><U>&nbsp;2.3(a)</U> or
<U>Section</U><U></U><U>&nbsp;3.2(g)</U>, if Rallybio is found by a court of competent jurisdiction to be liable to the Rights Agent or the Holders, as applicable in such suit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial
liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> The Rights Agent will not be deemed to have knowledge of any event of which it was supposed to receive notice hereunder but
has not received written notice of such event, and the Rights Agent will not incur any liability for failing to take action in connection therewith, in each case, unless and until it has received such notice in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> Subject to applicable Law, (i)&nbsp;the Rights Agent and any shareholder, affiliate, director, officer or employee of the Rights
Agent may buy, sell or deal in any securities of Rallybio or become peculiarly interested in any transaction in which Rallybio may be interested, or contract with or lend money to Rallybio or otherwise act as fully and freely as though it were not
the Rights Agent under this Agreement, and (ii)&nbsp;nothing herein will preclude the Rights Agent from acting in any other capacity for Rallybio or for any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either
itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to Rallybio resulting from any such act, default,
neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction) in the selection and continued
employment thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> Rallybio shall perform, acknowledge and deliver or cause to be performed, acknowledged and delivered all
such further and other acts, documents, instruments and assurances as may be reasonably required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement
(except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by Rallybio only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> The Rights Agent shall act hereunder solely as agent for Rallybio and shall not assume any obligations or relationship of agency or
trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by Rallybio, including, without
limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Rallybio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (a)&nbsp;any guaranty of
signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
program in addition to, or in substitution for, the foregoing; or (b)&nbsp;any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have
been altered, changed, amended or repealed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> The Rights Agent shall not be liable or responsible for any failure of Rallybio to
comply with any of its obligations relating to any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable regulation or law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> The obligations of Rallybio under this <U>Section</U><U></U><U>&nbsp;3.2</U> shall survive the expiration of the CVRs and the
termination of this Agreement and the resignation, replacement or removal of the Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Resignation and Removal;
Appointment of Successor</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Rights Agent may resign at any time by written notice to Rallybio. Any such resignation
notice shall specify the date on which such resignation will take effect (which shall be at least thirty (30)&nbsp;days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of
(x)&nbsp;the date so specified and (y)&nbsp;the appointment of a successor Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Rallybio will have the right to
remove the Rights Agent at any time by written notice to the Rights Agent, specifying the date on which such removal will take effect. Such notice will be given at least thirty (30)&nbsp;days prior to the date so specified (or, if earlier, the
appointment of the successor Rights Agent). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If the Rights Agent resigns, is removed or becomes incapable of acting, Rallybio
will promptly appoint a qualified successor Rights Agent. Notwithstanding the foregoing, if Rallybio fails to make such appointment within a period of thirty (30)&nbsp;days after giving notice of such removal or after it has been notified in writing
of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed
will, upon its acceptance of such appointment in accordance with this <U>Section</U><U></U><U>&nbsp;3.3(c)</U> and <U>Section</U><U></U><U>&nbsp;3.4</U>, become the Rights Agent for all purposes hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Rallybio will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a successor
Rights Agent in accordance with <U>Section</U><U></U><U>&nbsp;6.2</U>. Each notice will include the name and address of the successor Rights Agent. If Rallybio fails to send such notice within ten (10)&nbsp;Business Days after acceptance of
appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Rallybio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;3.3</U>, unless consented to in writing by the
Acting Holders, Rallybio will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> The Rights Agent will reasonably cooperate with Rallybio and any successor Rights Agent in connection with the transition of the
duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent; but such predecessor Rights Agent shall not be required to make
any additional expenditure or assume any additional liability in connection with the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Acceptance of Appointment
by Successor</B>. Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to Rallybio and to the resigning or removed Rights Agent an instrument accepting such appointment and a
counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the Rights Agent; <I>provided</I>, that upon the request of Rallybio or
the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>
<B>Efforts</B>. During the Disposition Period, Rallybio shall use commercially reasonable efforts to effect the Disposition of the Legacy Assets, if any, pursuant to one or more Disposition Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>List of Holders</B>. Rallybio will furnish or cause to be furnished to the Rights Agent, in such form as Rallybio receives from
its transfer agent (or other agent performing similar services for Rallybio), the names and addresses of the Holders within thirty (30)&nbsp;days following the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Prohibited Actions</B>. Unless approved by the Holder Representative, Rallybio shall not grant any lien, security interest,
pledge or similar interest in: (a)&nbsp;any CVR Payments, or (b)&nbsp;any Legacy Assets during the Disposition Period, other than (i)&nbsp;pursuant to the terms of a Disposition Agreement or (ii)&nbsp;any such interest generally granted with respect
to all assets of Rallybio and not specific to any of the Legacy&nbsp;Assets, and which do not prohibit the ability of Rallybio to complete a Disposition and, in connection therewith, to deliver title to the Legacy&nbsp;Assets to the purchaser
thereof, free and clear of such interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B>Audit Rights</B>. Until the Termination Date and for a period of one year
thereafter, Rallybio shall keep, and shall require its Affiliates to keep, complete and accurate books and records that may be necessary for the purpose of calculating the CVR Payments payable under this Agreement. At the request of the Acting
Holders, the Holder Representative shall have the right to appoint an independent accounting firm to perform, on behalf of all Holders, an inspection of such books and records for the sole purpose of determining the CVR Payments payable hereunder,
subject to the prior execution and delivery of a reasonable confidentiality agreement by such accounting firm. Upon at least ten (10)&nbsp;Business Days&#8217; prior written notice from the Holder Representative, such audit shall be conducted during
regular business hours in such a manner as to not unnecessarily interfere with Rallybio&#8217;s normal business activities. Such audit shall not be performed more frequently than once per calendar year. If the audit reveals an overpayment, Rallybio
shall be entitled to withhold such amount from future payments of CVR Payments. If the audit reveals an underpayment, Rallybio shall promptly (and in any event within thirty (30)&nbsp;days) remit such amount to the Rights Agent for distribution to
the Holders. Rallybio shall pay the audit costs if the audit reveals an underpayment; otherwise, the Acting Holders requesting the audit shall bear such audit expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Amendments Without Consent of Holders or Rights Agent</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Rallybio, at any time and from time to time, may enter into one or more amendments to this Agreement for any of the following
purposes, without the consent of any of the Holders or the Rights Agent (subject to <U>Section</U><U></U><U>&nbsp;5.3</U>), <I>provided</I>, that if any such amendment(s) (individually or the aggregate) impairs or adversely affects the rights of the
Holders hereunder, such amendment shall also require the prior written consent of the Holders in accordance with <U>Section</U><U></U><U>&nbsp;5.2</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of the
covenants and obligations of the Rights Agent herein in accordance with the provisions hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> to evidence the succession of
another Person to Rallybio and the assumption of any such successor of the covenants of Rallybio outlined herein in a transaction contemplated by <U>Section</U><U></U><U>&nbsp;6.6</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> to add to the covenants of Rallybio such further covenants, restrictions, conditions or provisions for the protection and
benefit of the Holders; <I>provided</I>, that in each case, such provisions shall not adversely affect the interests of the Holders; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> to cure any ambiguity, to correct or supplement any provision in this Agreement
that may be defective or inconsistent with any other provision in this Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement;<I> provided</I>, that in each case, such provisions shall not
adversely affect the interests of the Holders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> as may be necessary to ensure that CVRs are not subject to registration under
the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations made thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> as may be necessary to ensure that Rallybio is not required to produce a prospectus or an admission document in order to comply
with applicable Law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> to cancel CVRs (i)&nbsp;in the event that any Holder has abandoned its rights in accordance with
<U>Section</U><U></U><U>&nbsp;2.5</U> or (ii)&nbsp;following a transfer of such CVRs to Rallybio or its Affiliates in accordance with <U>Section</U><U></U><U>&nbsp;2.2</U> and <U>Section</U><U></U><U>&nbsp;2.6</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> as may be necessary to ensure that Rallybio complies with applicable Law; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> to effect any other amendment to this Agreement that would provide any additional rights or benefits to the Holders or that does
not adversely affect the legal rights under this Agreement of any such Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Promptly after the execution by Rallybio of any
amendment pursuant to this <U>Section</U><U></U><U>&nbsp;5.1</U>, Rallybio will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <U>Section</U><U></U><U>&nbsp;6.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Amendments with Consent of Holders</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In addition to any amendments to this Agreement that may be made by Rallybio without the consent of any Holder or the Rights Agent
pursuant to <U>Section</U><U></U><U>&nbsp;5.1</U>, with the consent of the Acting Holders, Rallybio and the Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions of
this Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Promptly after the
execution by Rallybio and the Rights Agent of any amendment pursuant to the provisions of this <U>Section</U><U></U><U>&nbsp;5.2</U>, Rallybio will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such
amendment in accordance with <U>Section</U><U></U><U>&nbsp;6.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>Effect of Amendments</B>. Upon the execution of any
amendment under this <U>Article</U><U></U><U>&nbsp;5</U>, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a
certificate from an appropriate officer of Rallybio which states that the proposed supplement or amendment is in compliance with the terms of this <U>Article</U><U></U><U>&nbsp;5</U>, the Rights Agent shall execute such supplement or amendment.
Notwithstanding anything in this Agreement to the contrary, the Rights Agent shall not be required to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or
immunities under this Agreement. No supplement, amendment or other modification to this Agreement shall be effective unless duly executed by the Rights Agent. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B>Notices to Rights Agent and to </B><B>Rallybio</B>. All notices, requests and other communications (each, a
&#8220;<B><I>Notice</I></B>&#8221;) to any party hereunder shall be in writing and delivered personally, by FedEx or other internationally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized overnight courier service or, except with respect to any Notice from any Holder, by email. Such Notice shall be deemed given (a)&nbsp;on the date of delivery, if delivered in person or
by <FONT STYLE="white-space:nowrap">e-mail</FONT> (upon confirmation of receipt) prior to 5:00 p.m. in the time zone of the receiving party or on the next Business Day, if delivered after 5:00 p.m. in the time zone of the receiving party or
(b)&nbsp;on the first Business Day following the date of dispatch, if delivered by FedEx or by other internationally recognized overnight courier service (upon proof of delivery), addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to the Rights Agent, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[&#149;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[&#149;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[&#149;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Attention: [&#149;]
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [&#149;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to Rallybio, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[&#149;]
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[&#149;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[&#149;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Attention: [&#149;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> [&#149;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as such party may hereafter specify for the purpose by notice to the other
parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Notice to Holders</B>. All Notices required to be given to the Holders will be given (unless otherwise
herein expressly provided) in writing and mailed, first-class postage prepaid, to each Holder at such Holder&#8217;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the
sending of such Notice, if any, and will be deemed given on the date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder will
affect the sufficiency of such Notice with respect to other Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B>Entire Agreement</B>. As between Rallybio and the
Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and
understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B> <B>Successor Substituted</B>. Upon any consolidation of or merger by Rallybio with or into any other Person, or any conveyance,
transfer or lease of substantially all of the properties and assets of Rallybio to any Person, the surviving Person or acquiring Person (as applicable) shall succeed to, and be substituted for, and may exercise every right and power of, and shall
assume all of the obligations of Rallybio under this Agreement with the same effect as if such Person had been named as Rallybio herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5</B> <B>Merger or Consolidation or Change of Name of Rights Agent</B>. Any Person into which the Rights Agent or any successor Rights
Agent may be merged or with which it may be consolidated, or Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other
shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties
hereto, <I>provided</I>, that such Person would be eligible for appointment as a successor Rights Agent under the provisions of <U>Section</U><U></U><U>&nbsp;3.3</U>. The purchase of all or substantially all of the Rights Agent&#8217;s assets
employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this <U>Section</U><U></U><U>&nbsp;6.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6</B> <B>Successors and Assigns</B>. This Agreement will be binding upon, and will be enforceable by and inure solely to the benefit of,
the Holders, Rallybio and the Rights Agent and their respective successors and assigns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Except for assignments to its Affiliates and as provided in <U>Section</U><U></U><U>&nbsp;6.5</U>, the Rights Agent may not assign this Agreement without Rallybio&#8217;s prior written consent.
Subject to <U>Section</U><U></U><U>&nbsp;5.1(a)(ii)</U> and <U>Section</U><U></U><U>&nbsp;6.4</U> hereof, Rallybio may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations
hereunder to one or more of its Affiliates or to any Person with whom Rallybio is merged or consolidated, or any entity resulting from any merger or consolidation to which Rallybio shall be a party (each, an &#8220;<B><I>Assignee</I></B>&#8221;);
<I>provided</I>, <I>however</I>, that in connection with any assignment to an Assignee, Rallybio shall agree to remain liable for the performance by Rallybio of its obligations hereunder (to the extent Rallybio exists following such assignment).
Rallybio or an Assignee may not otherwise assign this Agreement without the prior consent of the Acting Holders (such consent not to be unreasonably withheld, conditioned or delayed). Any attempted assignment of this Agreement in violation of this
<U>Section</U><U></U><U>&nbsp;6.6</U> will be void <I>ab initio</I> and of no effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7</B> <B>Benefits of Agreement; Action by
Acting Holders</B>. Nothing in this Agreement, express or implied, will give to any Person (other than Rallybio, the Rights Agent, the Holder Representative, the Holders and their respective permitted successors and assigns hereunder) any benefit or
any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of Rallybio, the Rights Agent, the Holders and their permitted
successors and assigns. The Holders are intended third-party beneficiaries under this Agreement, but will have no rights hereunder except as are expressly set forth herein. Except for the rights of the Rights Agent set forth herein, the Acting
Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to the performance of this Agreement by Rallybio, and no
individual Holder or other group of Holders will be entitled to exercise such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8</B> <B>Governing Law</B>. This Agreement and
the CVRs will be governed by, and construed in accordance with, the Laws of the State of Delaware, (without giving effect to any rule or principle that would result in application of the law of any other jurisdiction) and for all purposes shall be
governed by and construed in accordance with the laws of such State applicable to contracts to be made and performed entirely within such State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.9</B> <B>Jurisdiction</B>. In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement or
any of the transactions contemplated hereby, each of the parties hereto: (a)&nbsp;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware, or, if under applicable
Law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the District of Delaware (and appellate courts thereof); (b) agrees that all claims in respect of such action or proceeding shall be heard and
determined exclusively in accordance with clause (a)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.9</U>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d)&nbsp;waives any objection that such courts are an
inconvenient forum or do not have jurisdiction over any party; and (e)&nbsp;agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with
<U>Section</U><U></U><U>&nbsp;6.1</U> or <U>Section</U><U></U><U>&nbsp;6.2</U> of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.10</B> <B>Waiver of Jury
Trial</B>. Each of the parties hereto hereby irrevocably waives any and all right to trial by jury in any legal proceeding arising out of or related to this Agreement or the transactions contemplated hereby. Each party certifies and acknowledges
that (i)&nbsp;no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver, (ii)&nbsp;each party understands and
has considered the implication of this waiver, (iii)&nbsp;each party makes this waiver voluntarily, and (iv)&nbsp;each party has been induced to enter into this agreement by, among other things, the mutual waivers and certifications in this
<U>Section</U><U></U><U>&nbsp;6.10</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.11</B> <B>Severability Clause</B>. In the event that any provision of this Agreement, or the
application of any such provision to any Person or set of circumstances, is for any reason determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or
circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in
a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible; <I>provided</I>, <I>however</I>, that if an excluded provision shall affect the rights,
immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to Rallybio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.12</B> <B>Counterparts; Effectiveness</B>. This Agreement may be signed in any number of counterparts, each of which will be deemed an
original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document
format (.pdf), each of which shall be deemed an original. This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart
hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.13</B> <B>Termination</B>. This Agreement will automatically terminate and be of no further force or effect and, except as provided in
<U>Section</U><U></U><U>&nbsp;3.2</U>, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or compensation therefor upon the earliest to occur of: (a)&nbsp;the expiration of the CVR Term,
(b)&nbsp;the expiration of all payment obligations to Rallybio under the Disposition Agreements and/or the Membership Interest Purchase Agreement, and (c)&nbsp;the delivery of a written notice of termination duly executed by Rallybio and the Holder
Representative (such date, the &#8220;<B><I>Termination Date</I></B>&#8221;). The termination of this Agreement will not affect or limit the right of Holders to receive the CVR Payments under <U>Section</U><U></U><U>&nbsp;2.3(a)</U> to the extent
earned prior to the termination of this Agreement, and the provisions applicable thereto will survive the expiration or termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.14</B> <B>Force Majeure</B>. Notwithstanding anything to the contrary contained herein, none of the Rights Agent, Rallybio or any of its
Subsidiaries (except as it relates to the obligations of Rallybio under <U>Article 3</U>) will be liable for any delays or failures in performance resulting from acts beyond its reasonable control including acts of God, terrorist acts, shortage of
supply, breakdowns or malfunctions, interruptions or malfunctions of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war or civil unrest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.15</B> <B>Construction</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed
to be terms of limitation, but rather will be deemed to be followed by the words &#8220;without limitation.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The
headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States, unless
otherwise specified. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by
the parties and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page Follows </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, each
of the parties has caused this Agreement to be executed as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>R<SMALL>ALLYBIO</SMALL> C<SMALL>ORPORATION</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#149;]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ONTINGENT</SMALL> V<SMALL>ALUE</SMALL> R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="a1"></A>Annex G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc109079_51"></A>SUBSCRIPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS SUBSCRIPTION AGREEMENT</B> (this &#8220;<B><I>Agreement</I></B>&#8221;) is made and entered into as of March&nbsp;1, 2026 (the
&#8220;<B><I>Effective Date</I></B>&#8221;) by and among Candid Therapeutics, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), and each of the purchasers listed on the signature pages hereto, severally and not jointly (each a
&#8220;<B><I>Purchaser</I></B>&#8221; and together the &#8220;<B><I>Purchasers</I></B>&#8221;). Certain terms used and not otherwise defined in the text of this Agreement are defined in <U>Section</U><U></U><U>&nbsp;7</U> hereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Company is party to that certain Agreement and Plan of Merger and Reorganization by and among the Company, Farmington Merger Sub, Inc., a Delaware corporation (&#8220;<B><I>Merger Sub</I></B>&#8221;), and Rallybio Corporation, a Delaware corporation
(&#8220;<B><I>Parent</I></B>&#8221;), dated on or about the date hereof (the &#8220;<B><I>Merger Agreement</I></B>&#8221;), pursuant to which the Company will merge with and into Merger Sub and become a wholly-owned subsidiary of Parent (the
&#8220;<B><I>Merger</I></B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to sell to the Purchasers, and the Purchasers, severally and not
jointly, desire to purchase from the Company, an aggregate amount equal to $505,508,000 of shares of the Company&#8217;s Common Stock, par value $0.0001 per share (the &#8220;<B><I>Common Stock</I></B>&#8221;) in accordance with the terms and
provisions of this Agreement, immediately prior to, but subject to, the closing of the Merger; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and each
Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section&nbsp;4(a)(2) of the 1933 Act and Rule 506 of Regulation D promulgated under the 1933 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties and covenants herein contained, the parties
hereto hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Authorization of Securities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.01 The Company has authorized the sale and issuance of shares of Common Stock on the terms and subject to the conditions set forth in this
Agreement. The shares of Common Stock sold hereunder at the Closing (as defined below) shall be referred to as the &#8220;<B><I>Shares</I></B>&#8221; or<B><I> </I></B>&#8220;<B><I>Securities</I></B>&#8221;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Sale and Purchase of the Securities. </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.01 Upon the terms and subject to the conditions contained herein, the Company agrees to sell and issue to each Purchaser, and each Purchaser
agrees, severally and not jointly, to purchase from the Company, at a closing to take place remotely via exchange of executed documents (the &#8220;<B><I>Closing</I></B>&#8221; and the date of the Closing, the &#8220;<B><I>Closing
Date</I></B>&#8221;) to occur immediately prior to the Effective Time (as such term is defined in the Merger Agreement), that number of Shares (the &#8220;<B><I>Closing Shares</I></B>&#8221;) equal to (rounded down to the nearest whole
Share)&nbsp;(i) the aggregate commitment amount set forth under the heading &#8220;<B><I>Commitment Amount</I></B>&#8221; and opposite such Purchaser&#8217;s name on the Schedule of Purchasers set forth on <U>Schedule I</U> (the
&#8220;<B><I>Commitment Amount</I></B>&#8221;) divided by (ii)&nbsp;the Purchase Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.02 At or prior to the Closing, each Purchaser
will pay the aggregate subscription amount equal to the product of (A)&nbsp;the aggregate Closing Shares purchased under <U>Section</U><U></U><U>&nbsp;2.01</U>, multiplied by (B)&nbsp;the Purchase Price (the &#8220;<B><I>Subscription
Amount</I></B>&#8221;) by wire transfer of immediately available funds (a &#8220;<B><I>Wire</I></B>&#8221;) in accordance with wire instructions provided by the Company to the Purchasers at least five (5)&nbsp;Business Days prior to the Closing (the
&#8220;<B><I>Wire Instructions Notice</I></B>&#8221;); provided, for the avoidance of doubt, that no Purchaser shall be required to fund prior to the date on which the conditions to the Purchaser&#8217;s obligations set forth in
<U>Section</U><U></U><U>&nbsp;6.01</U> below are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
satisfied (other than those conditions which, by their nature, are to be satisfied at the closing of the transactions contemplated by the Merger Agreement and the Closing). If so requested by the
Company in the Wire Instructions Notice and agreed by the applicable Purchaser, the Subscription Amount of each Purchaser shall be paid into an escrow fund or trust account designated by the Company in writing (the &#8220;<B><I>Escrow
Account</I></B>&#8221;) to be released to the Company only upon satisfaction of each of the closing conditions set forth in <U>Section</U><U></U><U>&nbsp;6</U> below. In the event the Closing does not occur within three (3)&nbsp;Business Days of the
Closing Date specified in the Wire Instructions Notice, unless otherwise agreed by the Company and such Purchaser, the Company shall, or shall cause the escrow agent for the Escrow Account to, promptly (but not later than two (2)&nbsp;Business Days
thereafter) return the aggregate Purchase Price to such Purchaser by wire transfer of U.S. dollars in immediately available funds to the account specified by such Purchaser. On the Closing Date, the Company will deliver, against payment by each
Purchaser of its Subscription Amount, the Closing Shares in book-entry form, free and clear of all restrictive and other legends (except as expressly provided in <U>Section</U><U></U><U>&nbsp;3.10</U> hereof), and shall provide evidence of such
issuance from the Company&#8217;s transfer agent as of the Closing Date to each Purchaser. Notwithstanding anything to the contrary in this Agreement, (i)&nbsp;each Purchaser acknowledges that, as may be agreed among the Company and one or more
Purchasers, such Purchasers may not be required to fund their respective Subscription Amounts until such Purchasers receive evidence of the issuance of the Closing Shares to such Purchaser (or its nominee in accordance with its delivery
instructions) in form and substance reasonably acceptable to such Purchaser and such Purchasers shall not be required to fund their respective Subscription Amounts into the Escrow Account and (ii)&nbsp;the Schedule of Purchasers may be amended by
the Company and the affected Purchaser up to three (3)&nbsp;Business Days prior to the Closing, without the consent of the other parties hereto, to reflect the Subscription Amount paid by each Purchaser at the Closing and the actual number of Shares
purchased by each Purchaser at the Closing, provided that the Company shall provide to Purchasers such updated Schedule of Purchasers. For the avoidance of doubt, an amendment to this Agreement after the Effective Date allowing for the sale of
additional Securities (&#8220;<B><I>Additional Securities</I></B>&#8221;) to one or more Persons (whether or not an existing Purchaser) shall only require the approval of the Company and the Purchaser Majority; <U>provided</U> that the price paid
for such Additional Securities is equal to or greater than the Purchase Price. Subsequent to Closing, upon request of a Purchaser, the Company shall use commercially reasonable efforts to deliver, or cause to be delivered, to Purchaser within two
(2)&nbsp;Business Days of such request a book-entry statement of account from Parent&#8217;s transfer agent reflecting the issuance of shares of Parent Common Stock (as defined in the Merger Agreement) received in the Merger in exchange for the
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Representations and Warranties of the Purchasers</U>. Each Purchaser, severally and not jointly, represents and
warrants to the Company that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.01 <U>Organization</U>. The Purchaser is duly organized, validly existing and in good standing under the
laws of the jurisdiction of its organization and has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.02 <U>Validity</U>. The execution, delivery and performance of this Agreement and the consummation by the Purchaser of the transactions
contemplated hereby have been duly authorized by all necessary corporate, partnership, limited liability or similar actions, as applicable, on the part of such Purchaser. This Agreement has been duly executed and delivered by the Purchaser and,
assuming that this Agreement constitutes the valid and binding obligation of the Company, constitutes a valid and binding obligation of the Purchaser, enforceable against it in accordance with its terms, except as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors&#8217; rights generally, and as limited by laws relating to the availability of specific performance,
injunctive relief, or other equitable remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.03 <U>No Conflicts</U>. The execution, delivery and performance of this Agreement by
the Purchaser, the purchase of the Securities in accordance with their terms and the consummation by the Purchaser of the other transactions contemplated hereby will not conflict with or result in any violation of, breach or default by such
Purchaser (with or without notice or lapse of time, or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
benefit under (i)&nbsp;any provision of the organizational documents of the Purchaser, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or
partnership or operating agreement, as may be applicable or (ii)&nbsp;any agreement or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule or regulations, applicable to such Purchaser
or its respective properties or assets, except, in the case of clause (ii), as would not, individually or in the aggregate, be reasonably expected to materially delay or hinder the ability of the Purchaser to perform its obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.04 <U>Brokers</U>. There is no broker, investment banker, financial advisor, finder or other person which has been retained
by the Purchaser who is entitled to any fee or commission for which the Company will be liable in connection with the execution of this Agreement and the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.05 <U>Investment Representations and Warranties</U>. The Purchaser hereby represents and warrants that, it (i)&nbsp;as of the date of this
Agreement is a &#8220;qualified institutional buyer&#8221; (as defined in Rule 144A under the 1933 Act) or an institutional &#8220;accredited investor&#8221; as that term is defined in Rule 501(a) under Regulation D promulgated pursuant to the 1933
Act; or (ii)&nbsp;if an individual, is an &#8220;accredited investor&#8221; as that term is defined in Rule 501(a) of Regulation D of the 1933 Act and has such knowledge and experience in financial and business matters as to be able to protect its
own interests in connection with an investment in the Securities. The Purchaser further represents and warrants that (x)&nbsp;it is capable of evaluating the merits and risk of such investment, and (y)&nbsp;that it has not been organized for the
purpose of acquiring the Securities and is an &#8220;institutional account&#8221; as defined by FINRA Rule 4512(c). The Purchaser understands and agrees that the offering and sale of the Securities has not been registered under the 1933 Act or any
applicable state securities laws and is being made in reliance upon federal and state exemptions for transactions not involving a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy
of the Purchaser&#8217;s representations as expressed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.06 <U>Acquisition for Own Account</U>. The Purchaser is acquiring the
Securities for its own account for investment and not with a view towards distribution in a manner which would violate the 1933 Act or any applicable state or other securities laws. The Purchaser has not been formed for the specific purpose of
acquiring the Securities, to the extent such fact is required for the purposes of qualifying as an accredited investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.07 <U>No
General Solicitation</U>. The Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over
television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement. The purchase of the Securities by the Purchaser has not been solicited by or through anyone other than the Company or, on the
Company&#8217;s behalf, by Jefferies LLC, BofA Securities, Inc., TD Securities (USA), LLC, or Cantor Fitzgerald&nbsp;&amp; Co. (collectively, the &#8220;<B><I>Placement Agents</I></B>&#8221;), who have been engaged as joint placement agents for the
offering of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.08 <U>Ability to Protect Its Own Interests and Bear Economic Risks</U>. The Purchaser is a sophisticated
institutional investor, has the capacity to protect its own interests in connection with the transactions contemplated by this Agreement, and has sufficient knowledge and experience in investing in investments similar to the Securities to properly
evaluate the merits and risks of the investment in the Securities. The Purchaser is able to bear the economic and other risks of an investment in the Securities including but not limited to loss of the Purchaser&#8217;s entire investment therein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.09 <U>Disqualification Event</U>. To the extent the Purchaser is one of the covered persons identified in Rule 506(d)(1), the Purchaser
represents that no disqualifying event described in Rule <FONT STYLE="white-space:nowrap">506(d)(1)(i-viii)</FONT> of the 1933 Act (a &#8220;<B><I>Disqualification Event</I></B>&#8221;) is applicable to the Purchaser or any of its Rule 506(d)
Related Parties (as defined below), except, if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii)&nbsp;or (d)(3) is applicable. The Purchaser hereby agrees that it shall notify the Company promptly in writing in the
event a Disqualification Event becomes applicable to the Purchaser or any of its Rule 506(d) Related Parties, except, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii)&nbsp;or (d)(3) is applicable. For purposes of this Section, &#8220;<B><I>Rule 506(d) Related Party</I></B>&#8221;
means a person or entity that is a beneficial owner of the Purchaser&#8217;s securities for purposes of Rule 506(d) of the 1933 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10
<U>Restricted Securities</U>. Such Purchaser acknowledges and agrees that the Securities are being offered in a transaction not involving any public offering within the meaning of the 1933 Act, and such Purchaser understands that the Securities have
not been registered under the 1933 Act, by reason of their issuance by the Company in a transaction exempt from the registration requirements of the 1933 Act, and that the Securities must continue to be held and may not be offered, resold,
transferred, pledged or otherwise disposed of by such Purchaser unless a subsequent disposition thereof is registered under the 1933 Act or is exempt from such registration and in each case in accordance with any applicable securities laws of any
state of the United States. Such Purchaser understands that the exemptions from registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the 1933 Act depend on the satisfaction of various conditions including,
but not limited to, the time and manner of sale, the holding period and on requirements relating to the Company which are outside of such Purchaser&#8217;s control and which the Company may not be able to satisfy, and that, if applicable, Rule 144
may afford the basis for sales only in limited amounts. Such Purchaser acknowledges and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of the Securities. Such
Purchaser acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of the Securities or made any findings or determination as to the fairness of this investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Purchaser understands that any certificates or book entry notations evidencing the Securities may bear one or more legends in
substantially the following form and substance: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I)&nbsp;SUCH SECURITIES HAVE BEEN REGISTERED
FOR SALE PURSUANT TO THE SECURITIES ACT, (II)&nbsp;SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION
UNDER THE SECURITIES ACT, OR (IV)&nbsp;THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).
NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Securities may contain a legend regarding affiliate status of the Purchaser, if applicable, provided that the Company will
notify the Purchaser in advance of Closing if such legend is to be placed on its Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.11 <U>Review and Advisors</U>. The
Purchaser has had the opportunity to review with the Purchaser&#8217;s own tax advisors the U.S. federal, state and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of its purchase of the Securities set forth opposite such
Purchaser&#8217;s name on the Schedule of Purchasers and the transactions contemplated by this Agreement. The Purchaser is relying solely on the Purchaser&#8217;s own determination as to tax consequences, and on the Purchaser&#8217;s own sources of
information and advisors with respect to all tax matters, and not on any statements or representations of the Company (other than the representations and warranties in this Agreement), the Placement Agents or any of their respective agents, and
understands that the Purchaser (and not the Company) shall be responsible for the Purchaser&#8217;s own tax liability that may arise as a result of the transactions contemplated by this Agreement. Based on such information as the Purchaser deemed
appropriate and without reliance upon the Placement Agents, the Purchaser has independently made its own analysis and decision to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase the Securities. The Purchaser has (i)&nbsp;had the opportunity to ask questions of and receive answers directly with respect to its purchase of Securities, and (ii)&nbsp;conducted and
completed its own independent due diligence with respect to the purchase of Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.12 <U>Residency</U>. Such Purchaser&#8217;s
residence (if an individual) or offices in which its investment decision with respect to the Securities was made (if an entity) are located at the address immediately below such Purchaser&#8217;s name on the Schedule of Purchasers, or as otherwise
noted on the Schedule of Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.13 <U>Disclosure of Information</U>. The Purchaser has had an opportunity to discuss the
Company&#8217;s business, management, financial affairs and the terms and conditions of the offering of the Securities and the terms of the Merger with the Company&#8217;s management. The foregoing, however, does not limit or modify the
representations and warranties of the Company in <U>Section</U><U></U><U>&nbsp;4</U> of this Agreement or the right of the Purchasers to rely thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Representations and Warranties by the Company</U>. The Company represents and warrants to the Purchasers as of the date of this
Agreement and as of the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date) that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.01 <U>Organization and Good Standing</U>. The Company is a corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware, has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and is qualified to do business in each jurisdiction in which the character of its properties or
the nature of its business requires such qualification, except where such failure to be in good standing or to have such power and authority or to so qualify would not reasonably be expected to have a Material Adverse Effect. Each of the
Company&#8217;s subsidiaries is (i)&nbsp;duly incorporated and validly existing and in good standing under the laws of the jurisdiction of its incorporation and has the requisite power and authority to carry on its business as now conducted and to
own or lease its properties and (ii)&nbsp;qualified to do business as a foreign corporation and in good standing in each jurisdiction in which such qualification is required, except in each case as would not reasonably be expected to have a Material
Adverse Effect. &#8220;<B><I>Material Adverse Effect</I></B>&#8221; means any change, condition, event, circumstance, occurrence, result, state of facts or development that has or would reasonably be expected to have a materially adverse effect on
(a)&nbsp;the business, condition (financial or otherwise), assets, operations, results of operations, stockholders&#8217; equity or financial performance of the Company and its subsidiaries, taken as a whole or (b)&nbsp;the Company&#8217;s ability
to consummate the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.02 <U>Subsidiaries</U>. Except for Shanghai Tandi Biopharmaceutical Technology Co.,
Ltd, a wholly-owned subsidiary, the Company does not have any subsidiaries and does not otherwise own any shares of capital stock or any interest in any other Person. The Company does not control directly or indirectly or have any direct or indirect
equity participation or similar interest in any corporation, partnership, limited liability company, joint venture, trust or other business association or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.03 <U>Validity; Valid Issuance of Securities</U>. The Company has all requisite corporate power and authority to enter into this Agreement
and to consummate the transactions contemplated by this Agreement, subject only to (i)&nbsp;the adoption of the Merger Agreement in accordance with the terms thereof by the Company&#8217;s stockholders under the Delaware General Corporation Law and
the Company&#8217;s certificate of incorporation and (ii)&nbsp;the filing of an amendment to the Company&#8217;s certificate of incorporation. The execution, delivery and performance of this Agreement and the consummation of the transactions
contemplated by this Agreement by the Company have been duly authorized by all necessary corporate action on the part of the Company. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution
and delivery by each Purchaser, this Agreement constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors&#8217; rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief, or other
equitable remedies. The Securities are duly authorized and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and free and clear of any
liens or other restrictions, other than restrictions on transfer under applicable state and federal securities or such restrictions as the Purchaser has agreed to in writing with the Company, and will not have been issued in violation of or subject
to any preemptive or similar rights created under the Company&#8217;s certificate of incorporation, as amended by the certificate of amendment to be filed immediately prior to the Closing, or bylaws or the Delaware General Corporation Law. All of
the issued and outstanding shares of capital stock of the Company have been issued in compliance in all material respects with applicable federal and state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.04 <U>Governmental Consents and Filings</U>. Assuming the accuracy of the representations made by the Purchasers in
<U>Section</U><U></U><U>&nbsp;3</U> hereof and except as set forth in the Merger Agreement and the filing of the certificate of amendment to the Company&#8217;s certificate of incorporation, no material consent, approval, order or authorization of,
or registration, qualification, designation, declaration or filing with, any Governmental Entity (as defined below) is required on the part of the Company in connection with the consummation of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.05 <U>Absence of Violations, Defaults and Conflicts</U>. Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its
charter, bylaws or similar organizational document, (ii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement,
note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound or to which any of the properties or assets of the Company or any subsidiary is subject (collectively,
&#8220;<B><I>Agreements and Instruments</I></B>&#8221;), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (iii)&nbsp;in violation of any law, statute, rule, regulation, judgment, order,
writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or
operations (each, a &#8220;<B><I>Governmental Entity</I></B>&#8221;), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and the performance of this Agreement and the
consummation of the transactions contemplated herein (including the issuance and sale of the Securities) and compliance by the Company with its obligations hereunder do not and will not, whether with or without the giving of notice or passage of
time or both, (1)&nbsp;conflict with or constitute a breach of, or default under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or any subsidiary pursuant to, the Agreements
and Instruments, (2)&nbsp;result in any violation of the provisions of the certificate of incorporation, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document of the Company or any of its subsidiaries or (3)&nbsp;result
in any violation of any applicable law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except in the case of clauses (1)&nbsp;and (3), for such violations as would not, singly or in the aggregate, have or
reasonably be expected to have a Material Adverse Effect, or materially affect the validity of the Securities or the legal authority of the Company to perform its obligations hereunder and timely comply in all material respects with the terms of
this Agreement or the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.06 <U>Absence of Proceedings</U>. There is no action, suit, proceeding or, to the knowledge of
the Company, inquiry or investigation, before or brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which would have or reasonably be expected
to have a Material Adverse Effect or materially affect the validity of the Securities or the legal authority of the Company to perform its obligations hereunder and timely comply in all material respects with the terms of this Agreement or the
Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.07 <U>Possession of Licenses and Permits</U>. The Company and its subsidiaries possess such permits, licenses,
approvals, consents and other authorizations (collectively, &#8220;<B><I>Governmental Licenses</I></B>&#8221;) issued by the appropriate Governmental Entities necessary to conduct the business now operated by them, except where the failure so to
possess would not, singly or in the aggregate, have or reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries are in compliance with the terms and conditions of all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Governmental Licenses, except where the failure to comply would not, singly or in the aggregate, have or reasonably be expected to have a Material Adverse Effect. All of the Governmental Licenses
are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, have or reasonably be expected to
have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an
unfavorable decision, ruling or finding, would have or reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.08 <U>Payment of
Taxes.</U> The Company and its subsidiaries have filed all federal, state and foreign income tax returns and other tax returns required to have been filed under applicable law (or extensions have been duly obtained) and have paid all taxes required
to have been paid by them, except for those which are being contested in good faith and except where failure to file such tax returns or pay such taxes would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. No assessment in connection with U.S. federal income tax returns has been made against the Company that has not been paid or otherwise resolved in full. The Company and its subsidiaries have filed all tax returns that are required to have
been filed by them through the date hereof or have timely requested extensions thereof pursuant to applicable law except insofar as the failure to file such returns would not have or reasonably be expected to have a Material Adverse Effect, and have
paid all taxes due pursuant to such returns or all taxes due and payable pursuant to any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves
have been established by the Company or its subsidiaries and except where the failure to pay such taxes would not have or reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.09 <U>Insurance</U>. The Company and the subsidiaries carry or are entitled to the benefits of insurance, with what the Company reasonably
believes to be financially sound and reputable insurers, in such amounts and covering such risks as is customary for similarly situated companies and is adequate for the conduct of their respective businesses and the value of their respective
properties and assets, and all such insurance is in full force and effect. The Company has no reason to believe that it or any of the subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or
(ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not have or reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.10 <U>Investment Company Act</U>. The Company is not required, and upon the issuance and sale of the Securities will not be required, to
register as an &#8220;<B><I>investment company</I></B>&#8221; under the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.11 <U>Regulatory
Matters</U>. Except as would not, singly or in the aggregate, have or reasonably be expected to have a Material Adverse Effect: (i)&nbsp;neither the Company nor any of its subsidiaries has received any FDA Form 483, notice of adverse finding,
warning letter or other correspondence or written notice from the U.S. Food and Drug Administration (&#8220;<B><I>FDA</I></B>&#8221;) or any other Governmental Entity alleging or asserting noncompliance with any Applicable Laws (as defined in clause
(ii)&nbsp;below) or Authorizations (as defined in clause (iii)&nbsp;below); (ii) the Company and each of its subsidiaries is and has been in compliance with statutes, laws, ordinances, rules and regulations applicable to the Company and its
subsidiaries for the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the
Company, including without limitation, the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167; 301, et seq., similar laws of other Governmental Entities and the regulations promulgated pursuant to such laws (collectively, &#8220;<B><I>Applicable
Laws</I></B>&#8221;); (iii) the Company and each of its subsidiaries possesses all licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws and/or to carry on
its businesses as now conducted (&#8220;<B><I>Authorizations</I></B>&#8221;) and such Authorizations are valid and in full force and effect and the Company is not in violation of any term of any such Authorizations; (iv)&nbsp;neither the Company nor
any of its subsidiaries has received notice of any ongoing claim, action, suit, proceeding, hearing, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any product, operation or activity is in violation of any Applicable Laws or
Authorizations or has any knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, nor, to the Company&#8217;s knowledge, has there been any
noncompliance with or violation of any Applicable Laws by the Company or any of its subsidiaries that could reasonably be expected to require the issuance of any such communication or result in an investigation, corrective action, or enforcement
action by FDA or similar Governmental Entity; (v)&nbsp;neither the Company nor any of its subsidiaries has received notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any
Authorizations or has any knowledge that any such Governmental Entity is threatening or is considering such action; and (vi)&nbsp;the Company and each of its subsidiaries has filed, obtained, maintained or submitted all reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments were complete, correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.12 <U>Compliance With Laws</U>. The Company and its subsidiaries have complied with, are not in violation of, and have not received any
written notice alleging any violation with respect to, any applicable provisions of any statute, law or regulation with respect to the conduct of its respective business, or the ownership or operation of its respective properties or assets, except
for such violation that would not, singly or in the aggregate, result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.13 <U>Financial Statements</U>. The
Company has made available to each Purchaser its consolidated unaudited financial statements (including balance sheet, income statement and statement of cash flows) as of and for the fiscal year ended December&nbsp;31, 2024 and its unaudited
financial statements (including balance sheet, income statement and statement of cash flows) as of September&nbsp;30, 2025 (the &#8220;<B><I>Balance Sheet Date</I></B>&#8221;) and for the nine-month period ended on the Balance Sheet Date
(collectively, the &#8220;<B><I>Financial Statements</I></B>&#8221;). The Financial Statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;<B><I>GAAP</I></B>&#8221;) applied on a consistent
basis throughout the periods indicated, except that the unaudited Financial Statements may not contain all footnotes and other presentation items required by GAAP. The Financial Statements fairly present in all material respects the financial
condition of the Company and its subsidiaries as of the dates, and for the periods, indicated therein, subject in the case of the unaudited Financial Statements to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments. Since the
Balance Sheet Date, the Company has not incurred any liabilities or obligations, contingent or otherwise, that would be, individually or in the aggregate, material to the Company, other than (a)&nbsp;liabilities incurred in the ordinary course of
business; (b)&nbsp;obligations under contracts and commitments incurred in the ordinary course of business; (c)&nbsp;liabilities for transaction expenses incurred in connection with the transactions contemplated by this Agreement and the Merger
Agreement; and (d)&nbsp;liabilities and obligations of a type or nature not required under GAAP to be reflected in the Financial Statements. The Company maintains and will continue to maintain a standard system of accounting established and
administered to provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements of the Company in conformity with GAAP. Since the Balance Sheet Date, there has been no material change to any
material contract or arrangement by which the Company or any of its subsidiaries is bound or to which any of their respective properties or assets is subject, nor any other event or condition of any character that, in each case, has had or would
reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.14 <U>Information Provided</U>. The information to be supplied by or on
behalf of the Company for inclusion or incorporation by reference in the Registration Statement (as defined in the Merger Agreement) or supplied by or on behalf of the Company for inclusion in any filing pursuant to Rule 165 and Rule 425 under the
1933 Act or Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the 1934 Act, including the Company Presentation (each a &#8220;<B><I>Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> Filing</I></B>&#8221;), shall not, at the time the
Registration Statement or any such Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> Filing is filed with the Commission, at any time it is amended or supplemented or at the time the Registration Statement is declared effective by the
Commission, as applicable, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The information to be supplied by or on behalf of the Company for inclusion in the Registration Statement to be sent to the stockholders of Parent in connection with the meeting of Parent&#8217;s
stockholders (the &#8220;<B><I>Public Company Meeting</I></B>&#8221;), shall not, on the date the proxy statement/prospectus included in the Registration Statement is first mailed to stockholders of Parent, at the time of the Public Company Meeting
or at the Effective Time, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material fact, or omit to state any material fact necessary in order to
make the statements made in the Registration Statement not false or misleading; or omit to state any material fact necessary to correct any statement in any earlier communication with respect to the solicitation of proxies for the Public Company
Meeting that has become false or misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.15 <U>No Additional Agreements</U>. The Company does not have any agreement or
understanding with any Purchaser with respect to the transactions contemplated by this Agreement other than as specified in this Agreement. For the avoidance of doubt, the Company has not entered into any other securities purchase agreement, side
letter or other agreement with any other Person on or around the date hereof, that includes terms and conditions that are more favorable to such Person than to any Purchaser hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.16 <U>Private Placement</U>. None of the Company, its subsidiaries or any person acting on its or their behalf, has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security under any circumstances that would require registration under the 1933 Act of the Securities being sold pursuant to this Agreement. Assuming the accuracy of the
representations and warranties of the Purchasers contained in <U>Section</U><U></U><U>&nbsp;3</U> hereof, the issuance and sale of the Securities is exempt from registration under the 1933 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.17 <U>No Disqualification Events</U>. No Disqualification Event is applicable to the Company or, to the Company&#8217;s knowledge, any
Company Covered Person (as defined below), except for a Disqualification Event as to which Rule 506(d)(2)(ii)&nbsp;(iv) or (d)(3) is applicable. &#8220;<B><I>Company Covered Person</I></B>&#8221; means, with respect to the Company as an
&#8220;<B><I>issuer</I></B>&#8221; for purposes of Rule 506 promulgated under the 1933 Act, any person listed in the first paragraph of Rule 506(d)(1). The Company is not aware of any Person (other than any Company Covered Person) that has been or
will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of the Securities pursuant to this Agreement. The Company has complied, to the extent applicable, with its disclosure obligations under
Rule 506(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.18 <U>No General Solicitation</U>. Neither the Company nor, to the Company&#8217;s knowledge, any person acting on behalf
of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.19 <U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3</U> hereof, none of the Company, its subsidiaries or, to the Company&#8217;s knowledge, any of its or
their Affiliates or any Person acting on its or their behalf has, directly or indirectly, at any time within the past six months, made any offers or sales of any Company security or solicited any offers to buy any security under circumstances that
would (i)&nbsp;eliminate the availability of the exemption from registration under Regulation D under the 1933 Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii)&nbsp;cause the offering of the
Securities pursuant to this Agreement to be integrated with prior offerings by the Company for purposes of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations of any
National Exchange on which any of the securities of the Company are listed or designated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.20 <U>No Covered Foreign
Person</U>.&nbsp;Neither the Company nor any of its subsidiaries is a &#8220;covered foreign person,&#8221; as that term is defined in 31 C.F.R. &#167; 850.209. The consummation of the transactions contemplated by this Agreement will not result in
the establishment of a covered foreign person or the engagement by a &#8220;person of a country of concern,&#8221; as defined in 31 C.F.R. &#167; 850.221, in a covered activity, as that term is defined in 31 C.F.R. &#167; 850.208. Neither the
Company nor any of its subsidiaries currently engage, or have plans to engage, directly or indirectly, in a covered activity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.21 <U>Brokers</U>. Other than the Placement Agents, there is no broker, investment banker,
financial advisor, finder or other person which has been retained by or is authorized to act on behalf of the Company that is entitled to any fee or commission in connection with the execution of this Agreement and the consummation of the
transactions contemplated hereby (excluding the Merger). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.22 <U>Additional Representations and Warranties</U>. The Company&#8217;s
representations and warranties set forth in the Merger Agreement in <U>Section</U><U></U><U>&nbsp;2.2</U> (Capital Stock), <U>2.12</U> (Benefit Plans),<U> 2.13</U> (Labor and Employment Matters), <U>2.14</U> (Environmental Matters), <U>2.16</U>
(Contracts), <U>2.18</U> (Properties), <U>2.19</U> (Intellectual Property), and <U>2.22</U> (Related Party Transactions) are hereby incorporated by reference and made by the Company, as qualified by the disclosures in the Company Disclosure Schedule
(as defined in the Merger Agreement). As of the Effective Date, to the knowledge of the Company, the representations and warranties of Parent in the Merger Agreement and in any certificate or other writing delivered by Parent pursuant thereto are
true and correct as though given in accordance with <U>Section</U><U></U><U>&nbsp;9.1</U> of the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.23 <U>Reliance by
Purchasers</U>. The Company acknowledges that each Purchaser will rely upon the truth and accuracy of, and the Company&#8217;s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Company set forth
in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.24 <U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U>. The Company shall not consent or agree to
amend, alter, waive or otherwise modify the terms of any of the Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements (as defined in the Merger Agreement) without the consent of the Placement Agents and the Purchaser Majority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.25 <U>Anti-Bribery and Anti-Money Laundering Laws; Sanctions</U>. Each of the Company, its subsidiaries and, to the knowledge of the
Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A)&nbsp;anti-bribery laws, including but not
limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business
Transactions, signed December&nbsp;17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope, (B)&nbsp;anti-money laundering laws,
including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot
Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with
which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses
issued thereunder, or (C)&nbsp;except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, any laws with respect to import and export control and economic sanctions, including the U.S. Export
Administration Regulations, the U.S. International Traffic in Arms Regulations, and economic sanctions regulations and executive orders administered by the U.S. Department of the Treasury Office of Foreign Asset Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.26 <U>Clinical Data and Regulatory Compliance</U>. Except as would not reasonably be expected to result in a Material Adverse Effect:
(i)&nbsp;the preclinical tests and clinical trials, and other studies used to support regulatory approval (collectively, &#8220;<B><I>studies</I></B>&#8221;) being conducted by the Company that are described in, or the results of which are referred
to in, the Company Presentation were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific
research procedures; (ii)&nbsp;each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its Subsidiaries have no knowledge of any
other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Company Presentation; (iii)&nbsp;the Company and its Subsidiaries have made or will make all such filings and
obtained all such approvals as may be required by the FDA or from any other U.S. federal, state or local government or foreign government or Drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulatory Agency, or Institutional Review Board, each having jurisdiction over biopharmaceutical products (collectively, the &#8220;<B><I>Regulatory Agencies</I></B>&#8221;) for the conduct of
its business as described in the Company Presentation; (iv)&nbsp;neither the Company nor any of its Subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination or suspension of or imposing any
clinical hold on any clinical trials that are described or referred to in the Company Presentation; and (v)&nbsp;the Company and its Subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules,
regulations and policies of the Regulatory Agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.27 <U>Parent Reps</U>. As of the Effective Date and as of the Closing Date, to the
knowledge of the Company, the representations and warranties of Parent contained in Section&nbsp;3 of the Merger Agreement and in any certificate or other writing delivered by Parent pursuant thereto are true and correct as though given in
accordance with Section&nbsp;8.1 of the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Covenants. </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.01 <U>Further Assurances</U>. At or prior to Closing, each party agrees to cooperate and generally do such reasonable acts and things in
good faith as may be necessary to timely satisfy each of the conditions to be satisfied by it as provided in <U>Section</U><U></U><U>&nbsp;6</U> of this Agreement and effectuate the intents and purposes of this Agreement subject to the terms and
conditions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.02 <U>Disclosure of Transactions and Other Material Information</U>. The Company shall or shall cause Parent to, on
or before 9:00 a.m., New York City time, on the Business Day immediately following the Effective Date (or if this Agreement is executed between midnight and 9:00 a.m., New York City time, on any Business Day, no later than 9:01 a.m. on the Effective
Date), issue one or more press releases and/or file with the Commission a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (collectively, the &#8220;<B><I>Disclosure Document</I></B>&#8221; and the actual issuance or acceptance (as
applicable) of the filing of such press releases or Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> the &#8220;<B><I>Disclosure Time</I></B>&#8221;) disclosing all material terms of the transactions contemplated hereby and by the
Merger Agreement and any other material nonpublic information that the Company, Parent or their respective officers, directors, employees, agents or any other person acting at the direction of the Company or Parent has provided to the Purchasers in
connection with the transactions contemplated by this Agreement and by the Merger Agreement prior to the filing of the Disclosure Document. To the extent any Purchaser is named therein in accordance with the terms of this Agreement, the Company
shall provide such Purchaser with a reasonable opportunity to review and provide comments on the draft of such Disclosure Document. The Company represents and warrants that, from and after the Disclosure Time, no Purchaser shall be in possession of
any material, nonpublic information received from the Company, Parent or their respective officers, directors, employees, agents or other person acting at their direction. In addition, effective upon the Disclosure Time, the Company acknowledges and
agrees that any and all confidentiality or similar obligations under any agreement relating to the subject matter hereof, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors,
affiliates, employees or agents, including, without limitation, the Placement Agents, on the one hand, and any Purchaser or any of their respective affiliates, on the other hand, shall terminate and be of no further force or effect. The Company
understands and confirms that each of the Purchasers will rely on the foregoing representations in effecting transactions in securities of the Company. The Company shall not, and shall cause its officers, directors, employees and agents and Parent
not to, publicly disclose the name of any Purchaser or any affiliate or investment adviser of any Purchaser, or include the name of any Purchaser or any affiliate or investment adviser of any Purchaser without the prior written consent (including by
<FONT STYLE="white-space:nowrap">e-mail)</FONT> of such Purchaser (i)&nbsp;in any press release, marketing materials or any other public announcement, or (ii)&nbsp;in any filing with the Commission or any regulatory agency or trading market, except
(A)&nbsp;as required by the federal securities laws, rules or regulations, (B)&nbsp;to the extent such disclosure is required by other laws, rules or regulations, at the request of the staff of the Commission or regulatory agency or under
regulations of any national securities exchange on which Parent&#8217;s securities are listed for trading or (C)&nbsp;to the extent such disclosure contains only information previously approved in accordance with this
<U>Section</U><U></U><U>&nbsp;5.02</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.03 <U>Concurrent Financing Restructuring</U>. In the event the structure of the Concurrent
Financing (as defined in the Merger Agreement) either violates applicable Law (as defined in the Merger Agreement) or materially and adversely affects Parent&#8217;s ability to cause the Registration Statement to become effective in a timely manner,
and in any event 60 days prior to the End Date (as defined in, and as may be extended in accordance with, the Merger Agreement), then the Company and Purchasers shall cooperate and use commercially reasonable efforts to cause the Concurrent
Financing to be amended, modified and/or restructured such that such investment occurs as a direct acquisition of shares of Parent Common Stock (as defined in the Merger Agreement) substantially contemporaneously with the Closing in a manner which
preserves to the extent possible, the amount of funds ultimately received by Parent and its subsidiaries, and the number of share of Parent Common Stock ultimately held by each Purchaser in respect of such amounts as though the Concurrent Financing
and the Merger pursuant to the Merger Agreement have been consummated according to their respective terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.04 <U>Expenses</U>. The
Company and each Purchaser is liable for, and will pay, its own expenses incurred in connection with the negotiation, preparation, execution and delivery of this Agreement, including, without limitation, attorneys&#8217; and consultants&#8217; fees
and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.05 <U>Form <FONT STYLE="white-space:nowrap">S-4</FONT></U>. From the date hereof until the Closing Date, the Company
shall use commercially reasonable efforts to ensure the Registration Statement will register the issuance of the shares of Parent Common Stock to be issued, subject to and in accordance with the terms of the Merger Agreement, by virtue of the
Contemplated Transactions (as defined in the Merger Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.06 <U>Blue Sky Laws</U>. The Company, on or before the Closing Date,
shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities for sale to each Purchaser at the Closing pursuant to this Agreement under applicable securities or
&#8220;blue sky&#8221; laws of the states of the United States (or to obtain an exemption from such qualification). The Company shall make all filings and reports relating to the offer and sale of the Securities required under applicable securities
or &#8220;blue sky&#8221; laws of the states of the United States following the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.07 <U>No Amendment or Waiver of Merger
Agreement Terms</U>. The Company shall not amend, modify or waive (or approve an amendment, modification or a waiver requested by Parent of, or fail to contest an action regarding a breach of) any provision of the Merger Agreement in a manner that
would reasonably be expected to materially and adversely affect the benefits that the Purchaser would reasonably expect to receive pursuant to this Agreement without the consent of each Purchaser, it being agreed that any amendment or modification
to the definitions of &#8220;<B><I>Company Valuation</I></B>,&#8221; &#8220;<B><I>Company Outstanding Shares</I></B>,&#8221; &#8220;<B><I>Concurrent Financing Merger Shares</I></B>,&#8221; &#8220;<B><I>Concurrent Financing Allocation
Percentage</I></B>,&#8221; &#8220;<B><I>Concurrent Investment Amount</I></B>&#8221; and &#8220;<B><I>Concurrent Financing Proceeds</I></B>&#8221; shall be deemed materially adverse to the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.08 <U>Equal Treatment of Purchasers</U>. No consideration shall be offered or paid to any Purchaser to amend or consent to a waiver or
modification of any provision of this Agreement unless the same consideration is also offered to all of the Purchasers. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated
separately by each Purchaser and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of shares of Common Stock or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.09 <U>Legend Removal</U>. The restrictive legends described in <U>Section</U><U></U><U>&nbsp;3.10</U> shall promptly be removed in
accordance with applicable securities laws and, if applicable, the relevant provisions of the Registration Rights Agreement following the closing of the Merger. The shares of Parent Common Stock to be received in the Merger in exchange for the
Shares will be issued in book-entry form, free and clear of any liens or other restrictions whatsoever and without restrictive legends in accordance with applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10 <U>Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless each Purchaser and its Affiliates, and their respective directors, officers, trustees,
general partners, members, stockholders, partners, managers, employees, investment advisers and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other
title) and each Person who controls such Purchaser (within the meaning of Section&nbsp;15 of the 1933 Act and Section&nbsp;20 of the 1934 Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (collectively, the &#8220;<B><I>Indemnified Persons</I></B>&#8221;), from and against any and
all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements and other documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs
of enforcement thereof) to which such Indemnified Person may become subject (i)&nbsp;as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under this Agreement or
(ii)&nbsp;as a result of or arising out of any action, claim or proceeding, pending or threatened, against an Indemnified Person in any capacity by any third party (including a stockholder of the Company or Parent), whether directly or in a
derivative capacity, who is not an Affiliate of the Indemnified Person, with respect to the transactions contemplated by this Agreement, the Merger Agreement or the Registration Rights Agreement, and will reimburse any such Indemnified Person for
all such amounts as they are incurred by such Indemnified Person, except to the extent such amounts have been finally judicially determined to have resulted from such Person&#8217;s fraud or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Any person entitled to indemnification hereunder shall (i)&nbsp;give prompt written notice to the indemnifying party of any claim with
respect to which it seeks indemnification and (ii)&nbsp;permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder
shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a)&nbsp;the indemnifying party has agreed in writing to pay
such fees or expenses, (b)&nbsp;the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c)&nbsp;in the reasonable judgment of any such person, based upon written
advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate
counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice
as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation.
It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No
indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such judgment or settlement
(i)&nbsp;imposes no liability or obligation on, (ii)&nbsp;includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified
party in respect of such claim or litigation in favor of, and (iii)&nbsp;does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with
the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11 <U>Withholding Taxes</U>. Each Purchaser agrees to furnish the Company with any information, representations and forms as shall
reasonably be requested by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Conditions of Closing. </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.01 <U>Conditions of the Purchasers&#8217; Obligations at the Closing</U>. The obligations of each Purchaser under
<U>Section</U><U></U><U>&nbsp;2</U> hereof are subject to the fulfillment, at or prior to the Closing, of all of the following conditions, unless otherwise waived by such Purchaser solely as to itself. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of the Company contained in this Agreement shall be true and
correct in all respects on the Effective Date, and shall be true and correct in all material respects on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of the Closing Date
(except (i)&nbsp;the representations and warranties of the Company set forth in Sections <U>4.01</U>, <U>4.03</U>, <U>4.05</U> and <U>4.21</U> of this Agreement (collectively, the &#8220;<B><I>Fundamental Representations</I></B>&#8221;) shall be
true and correct in all respects on the Effective Date and on and as of the Closing Date with the same effect as though such Fundamental Representations had been made on and as of the Closing Date, (ii)&nbsp;to the extent expressly made as of an
earlier date in which case as of such earlier date and (iii)&nbsp;representations and warranties that are qualified as to materiality or Material Adverse Effect, which representations and warranties shall be true in all respects). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance</U>. The Company shall have performed and complied in all material respects with all covenants, agreements, obligations
and conditions contained in this Agreement that are required to be performed or complied with by it on or prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)
<U>Compliance Certificate</U>. The Chief Executive Officer of the Company shall have delivered to the Purchasers at the Closing Date a certificate, in form and substance reasonably acceptable to the Purchasers, certifying that the conditions
specified in <U>Sections 6.01(a)</U>, <U>6.01(b)</U>, <U>6.01(f)</U>, <U>6.01(i)</U>, <U>6.01(j)</U> and <U>6.01(k)</U> of this Agreement have been fulfilled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Qualification under Securities Laws</U>. All registrations, qualifications, permits and approvals, if any, required under applicable
securities laws shall have been obtained for the lawful execution, delivery and performance of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Secretary&#8217;s
Certificate</U>. The Secretary of the Company shall have delivered to the Purchasers at the Closing a certificate, in form and substance reasonably acceptable to the Purchasers (such consent not to be unreasonably withheld, conditioned or delayed),
certifying (i)&nbsp;the certificate of incorporation and bylaws of the Company, (ii)&nbsp;authorization of the Board of Directors of the Company approving this Agreement and the transactions contemplated under this Agreement (including the Merger
Agreement) and (iii)&nbsp;as to a certificate evidencing the good standing of the Company in Delaware issued by the Secretary of State of Delaware and in the State of California, issued by the Secretary of the State of California, each issued as of
a date within five Business Days of the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) <U>Merger</U>. All conditions to the closing of the Merger shall have been
satisfied or waived (other than the Closing hereunder and other than those conditions which, by their nature, are to be satisfied at the closing of the transactions contemplated by the Merger Agreement), and the closing of the Merger shall be set to
occur substantially concurrently with the Closing hereunder. The Merger Agreement or any provision thereof shall not have been amended, modified or waived in contravention of Section&nbsp;5.07 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) <U>No Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any Governmental Entity of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) <U>Registration Rights Agreement</U>. The Company shall have delivered the fully executed Registration Rights Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Registration Statement; Proxy Statement/Prospectus</U>. The Registration Statement shall have become effective under the 1933 Act and
no stop order suspending the effectiveness of the Registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Statement shall have been issued and no proceeding for that purpose, and no similar proceeding with respect to the Registration Statement shall have been initiated or threatened in writing by the
Commission or its staff. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) <U>Nasdaq</U>. Parent shall have submitted with Nasdaq an Initial Listing Application in respect of the
Parent Common Stock to be issued in the Contemplated Transactions, which shall have been approved by Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) <U>No Material Adverse
Effect</U>. Since the date of this Agreement, there shall not have occurred any Material Adverse Effect that is continuing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l)
<U>Minimum Financing Amount</U>. The Company shall receive at Closing aggregate proceeds from the purchase of Securities pursuant to this Agreement of not less than $450,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) <U>Opinion of Company Counsel</U>. The Placement Agents and the Purchasers shall have received from Cooley LLP, counsel for the Company,
an opinion, dated as of the Closing Date, in the form agreed between the Company and the Placement Agents and the Purchaser Majority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) <U>Consents</U>. Any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and
sale of the Shares, including the approval of the stockholders of Parent in connection with the Public Company Meeting, shall have been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.02 <U>Conditions of the Company&#8217;s Obligations</U>. The obligations of the Company under <U>Section</U><U></U><U>&nbsp;2</U> hereof are
subject to the fulfillment, at or prior to the Closing, of all of the following conditions, any of which may be waived in whole or in part by the Company in its absolute discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of the Purchasers contained in this Agreement shall be true and
correct as of the Effective Date and true and correct in all material respects on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of the Closing Date (except (i)&nbsp;to the
extent expressly made as of an earlier date in which case shall be as of such earlier date and (ii)&nbsp;representations and warranties that are qualified as to materiality, which representations and warranties shall be true in all respects, except
as would not, in the aggregate, materially and adversely affect the Purchasers&#8217; ability to consummate the transactions contemplated hereby). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance</U>. Each Purchaser shall have performed and complied in all material respects with all covenants, agreements, obligations
and conditions contained in this Agreement that are required to be performed or complied with by it on or prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)
<U>Qualification under Securities Laws</U>. All registrations, qualifications, permits and approvals, if any, required under applicable securities laws shall have been obtained for the lawful execution, delivery and performance of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Merger</U>. All conditions to the closing of the Merger shall have been satisfied or waived (other than the Closing hereunder and
other than those conditions which, by their nature, are to be satisfied at the closing of the transactions contemplated by the Merger Agreement), and the closing of the Merger shall be set to occur substantially concurrently with the Closing
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Payment</U>. Except as may be agreed to among the Company and one or more Purchasers in accordance with
<U>Section</U><U></U><U>&nbsp;2.02</U>, the Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for the number of Securities being purchased by each Purchaser at the Closing
as set forth on the Schedule of Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) <U>Injunction</U>. The purchase of and payment for the Securities by each Purchaser
shall not be prohibited or enjoined by any law or governmental or court order or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Definitions</U>. Unless the context otherwise requires, the terms defined in
this <U>Section</U><U></U><U>&nbsp;7</U> shall have the meanings specified for all purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>1933
Act</I></B>&#8221; means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>1934 Act</I></B>&#8221; means the Securities Exchange Act
of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Affiliate</I></B>&#8221; shall have the meaning ascribed to such term in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the General Rules and Regulations under the 1934 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Business Day</I></B>&#8221;
means any day other than Saturday, Sunday or other day on which commercial banks in the City of New York are authorized or required by law to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Presentation</I></B>&#8221; means that certain Investor Presentation, dated February 2026, as provided to the Purchaser
prior to the Effective Date and filed by Parent on Form <FONT STYLE="white-space:nowrap">8-K</FONT> on or around the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Commission</I></B>&#8221; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Effective Time</I></B>&#8221; has the meaning ascribed to it in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>National Exchange</I></B>&#8221; means the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, or
the New York Stock Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Person</I></B>&#8221; means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Purchase Price</I></B>&#8221; means an amount equal to (i)&nbsp;the Company Valuation (as defined in the Merger Agreement), (ii)
divided by the number of Company Outstanding Shares (as defined in the Merger Agreement but excluding the Securities being issued hereunder) as of immediately prior to the closing of offering of the Securities hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Purchaser Majority</I></B>&#8221; means, prior to the Closing, the Purchasers committed to purchase at least a majority the
Securities, provided that such majority includes each Purchaser who has committed to purchase (together with its affiliates and affiliated funds) at least $25&nbsp;million of Securities and, following the Closing, the Purchasers who hold at least a
majority of the Securities (including any Parent Common Stock issued in exchange therefore) still held by the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Registration Rights Agreement</I></B>&#8221; means the Registration Rights Agreement, in the form attached hereto as <U>Exhibit
A</U>, to be entered into at the Closing among the Company and each Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Rule 144</I></B>&#8221; means Rule 144
promulgated by the Commission pursuant to the 1933 Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Miscellaneous. </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.01 <U>Waivers and Amendments</U>. Neither this Agreement, nor any provision hereof, may be changed, waived, amended or modified orally or by
course of dealing, but only by an instrument in writing executed by the Company and the Purchaser Majority, provided that, (a)&nbsp;if any, change, waiver, amendment, modification disproportionately and adversely impacts a Purchaser (or group of
Purchasers), the consent of such disproportionately impacted Purchaser (or each Purchaser in such group of Purchasers) shall be required and (b)&nbsp;the consent of each Purchaser shall be required for any change in the Purchase Price, any change in
the type of security to be issued to Purchasers at Closing, or the amendment or waiver of this <U>Section</U><U></U><U>&nbsp;8.01</U>, <U>Section</U><U></U><U>&nbsp;8.13</U> or of any of the closing conditions set forth in <U>Sections 6.01(a)</U>,
<U>6.01(f)</U>, <U>6.01(i)</U>, <U>6.01(j)</U>, or <U>6.01(k)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notwithstanding the foregoing or anything else herein to the contrary, no amendment, modification, alteration, change or waiver of this <U>Section</U><U></U><U>&nbsp;8.01</U> shall be valid
without the prior written consent of the Placement Agents, which consent may be granted or withheld in the sole discretion of the Placement Agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.02 <U>Notices</U>. All notices, requests, consents, and other communications under this Agreement shall be in writing and shall be deemed
delivered (a)&nbsp;when delivered, if delivered personally, (b)&nbsp;four (4) Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid, (c)&nbsp;one (1) Business Day after being sent via a reputable
nationwide overnight courier service guaranteeing next Business Day delivery, or (d)&nbsp;upon delivery, in the case of email, in each case to the intended recipient as set forth below, with respect to the Company, and to the addresses set forth on
the Schedule of Purchasers with respect to the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">if to the Company: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Candid Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11622 El Camino Real, Suite 150 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute
notice): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10265 Science Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Charlie Kim; Carlos Ramirez </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: ckim@cooley.com; cramirez@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or at such other
address as the Company or each Purchaser may specify by written notice to the other parties hereto in accordance with this <U>Section</U><U></U><U>&nbsp;8.02</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.03 <U>Consent to Electronic Notice</U>. From the date hereof until the Closing Date, each Purchaser consents to the delivery of any
stockholder notice pursuant to Section&nbsp;232 of the Delaware General Corporation Law, as amended or superseded from time to time, at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth below the Purchaser&#8217;s name on the
signature page or Schedule I, as updated from time to time by notice to the Company. To the extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been
revoked until a new or corrected <FONT STYLE="white-space:nowrap">e-mail</FONT> address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other
parties of any change in its <FONT STYLE="white-space:nowrap">e-mail</FONT> address, and that failure to do so shall not affect the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.04 <U>Severability</U>. If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or
regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable
manner, and the remainder of this Agreement shall remain binding upon the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.05 <U>Governing Law; Submission to
Jurisdiction; Venue; Waiver of Trial by Jury</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed by, and construed in accordance with, the laws of
the State of New York without regard to choice of laws or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that mandatory principles of Delaware law may apply. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company and each of the Purchasers hereby irrevocably and unconditionally: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) submits for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated
hereby, to the general jurisdiction of any state court or United States Federal court sitting in the Borough of Manhattan, City of New York in the State of New York; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) consents that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to
the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same to the extent permitted by applicable law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified
mail (or any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in <U>Section</U><U></U><U>&nbsp;8.02</U> or at such other address of which the other party shall have been notified
pursuant thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by
law or shall limit the right to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing clause (i)&nbsp;are not available despite the intentions of the parties
hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) agrees that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of
any jurisdiction to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified herein or as otherwise permitted by law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) agrees that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal
process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement, to the extent permitted by law; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii) irrevocably and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.06 <U>Assignment</U>. None of the parties may assign its rights or obligations under this Agreement or designate another person (i)&nbsp;to
perform all or part of its obligations under this Agreement or (ii)&nbsp;to have all or part of its rights and benefits under this Agreement, in each case without the prior written consent of (x)&nbsp;the Company, in the case of a Purchaser, and
(y)&nbsp;the Purchasers, in the case of the Company, provided that a Purchaser may, without the prior consent of the Company, assign its rights to purchase the Securities hereunder to any of its Affiliates or to any other investment funds or
accounts managed or advised by the investment manager who acts on behalf of such Purchaser (provided each such assignee agrees to be bound by the terms of this Agreement and makes the same representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;3</U>). In the event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and be bound by the provisions of this Agreement by executing a writing agreeing to be bound
by and subject to the provisions of this Agreement and shall deliver an executed counterpart signature page to this Agreement and, notwithstanding such assumption or agreement to be bound hereby by an assignee, no such assignment shall relieve any
party assigning any interest hereunder from its obligations or liability pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.07 <U>Confidential
Information</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each Purchaser covenants that until such time as the transactions contemplated by this Agreement and any material <FONT
STYLE="white-space:nowrap">non-public</FONT> information provided to such Purchaser are publicly disclosed by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company in accordance with Section&nbsp;5.02 (or earlier termination of this Agreement), such Purchaser will maintain the confidentiality of all disclosures made to it in connection with this
transaction (including the existence and terms of this transaction), other than to such Purchaser&#8217;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the
performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company may request from the Purchasers such reasonable and customary additional information as the Company may deem necessary to
evaluate the eligibility of a Purchaser to acquire the Securities, and such Purchaser shall promptly provide such information as may reasonably be requested to the extent readily available; provided, that the Company agrees to keep any such
information provided by such Purchaser confidential, except (i)&nbsp;as required by the federal securities laws, rules or regulations and (ii)&nbsp;to the extent such disclosure is required by other laws, rules or regulations, at the request of the
staff of the SEC or regulatory agency or under the regulations of Nasdaq. The Purchaser acknowledges that the Company (or Parent) may file a copy of this Agreement and the Registration Rights Agreement with the SEC as exhibits to a periodic report,
current report or a registration statement of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.08 <U>Reliance by and Exculpation of Placement Agents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each Purchaser agrees for the express benefit of each Placement Agent, its affiliates and its representatives that (i)&nbsp;it is not
relying upon, and has not relied upon, any statement, representation or warranty made by the Placement Agents, any of their respective affiliates or any of their or their respective representatives, in making its investment or decision to invest in
the Company, (ii)&nbsp;the Placement Agents are acting solely as placement agents in connection with the transactions contemplated hereby and are not acting as underwriters, initial purchasers, dealers or in any other such capacity and are not and
shall not be construed as a fiduciary for such Purchaser, (iii)&nbsp;the Placement Agents, their respective affiliates and representatives have not made, and will not make any representations or warranties with respect to the Company or the offer
and sale of the Securities or any other matter concerning the Company or the transactions contemplated hereby, and the Purchaser will not rely on any statements made by the Placement Agents, orally or in writing, to the contrary, (iv)&nbsp;the
Purchaser will be responsible for conducting its own due diligence investigation with respect to the Company and the offer and sale of the Securities, (v)&nbsp;the Purchaser will be purchasing Securities based on the results of its own due diligence
investigation of the Company and the Placement Agents and each of their respective directors, officers, employees, representatives, and controlling persons have made no independent investigation with respect to the Company, the Securities, or the
accuracy, completeness, or adequacy of any information supplied to the Purchaser by the Company, (vi)&nbsp;the Purchaser has negotiated the offer and sale of the Securities directly with the Company, and the Placement Agents will not be responsible
for the ultimate success of any such investment and (vii)&nbsp;the decision to invest in the Company will involve a significant degree of risk, including a risk of total loss of such investment. Each Purchaser further represents and warrants to the
Placement Agents that it, including any fund or funds that it manages or advises that participates in the offer and sale of the Securities, is permitted under its constitutive documents (including, without limitation, all limited partnership
agreements, charters, bylaws, limited liability company agreements, all applicable side letters with investors, and similar documents) to make investments of the type contemplated by this Agreement. This <U>Section</U><U></U><U>&nbsp;8.08</U> shall
survive any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company agrees and acknowledges that the Placement Agents may rely on its
representations, warranties, agreements and covenants contained in this Agreement and each Purchaser agrees that the Placement Agents may rely on such Purchaser&#8217;s representations and warranties contained in this Agreement as if such
representations and warranties, as applicable, were made directly to the Placement Agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Neither the Placement Agents nor any of
their respective affiliates or representatives (1)&nbsp;shall be liable for any improper payment made in accordance with the information provided by the Company; (2)&nbsp;makes any representation or warranty, or has any responsibilities as to the
validity, enforceability, accuracy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement or in connection with any of the transactions
contemplated herein; or (3)&nbsp;shall be liable (x)&nbsp;for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or powers conferred upon it by this
Agreement or (y)&nbsp;for anything which any of them may do or refrain from doing in connection with this Agreement, except in each case for such party&#8217;s own gross negligence or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company agrees that the Placement Agents, their respective affiliates and representatives shall be entitled to (1)&nbsp;rely on, and
shall be protected in acting upon, any certificate, instrument, opinion, notice, letter or any other document or security delivered to any Purchaser by or on behalf of the Company, and (2)&nbsp;be indemnified by the Company for acting as the
Placement Agents hereunder pursuant to the indemnification provisions set forth in the applicable letter agreement between the Company and the Placement Agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.09 <U>Third Parties</U>. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this
Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director,
officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to
this Agreement or the transactions contemplated hereby, except as expressly set forth in this Agreement. Notwithstanding the foregoing, (i)&nbsp;the Placement Agents are intended third-party beneficiaries of the representations and warranties of the
each Purchaser and the Company set forth in <U>Section</U><U></U><U>&nbsp;3</U>, <U>Section</U><U></U><U>&nbsp;4</U> and <U>Section</U><U></U><U>&nbsp;6.01(c)</U> and <U>Section</U><U></U><U>&nbsp;8.08</U> respectively, of this Agreement and
(ii)&nbsp;the Indemnified Persons are intended third-party beneficiaries of <U>Section</U><U></U><U>&nbsp;5.10</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.10 <U>Independent
Nature of Purchasers</U><U>&#8217;</U><U> Obligations and Right</U><U>.</U> The obligations of each Purchaser under this Agreement are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any
way for the performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein, and no action taken by any Purchaser pursuant hereto, shall be deemed to constitute the Purchasers as, and the Company acknowledges
that the Purchasers do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group (including a &#8220;group&#8221; within
the meaning of Section&nbsp;13(d)(3) of the 1934 Act), and the Company will not assert any such claim with respect to such obligations or the transactions contemplated by this Agreement, and the Company acknowledges that the Purchasers are not
acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement and the Company acknowledges that, to its knowledge, the Purchasers are not acting in concert or as a group with respect to such
obligations or the transactions contemplated by this Agreement. It is expressly understood that each provision contained in this Agreement is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively
and not between and among the Purchasers. The Company acknowledges and each Purchaser confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each
Purchaser also acknowledges that Cooley LLP has not rendered legal advice to such Purchaser. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement,
and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. The Company has elected to provide all Purchasers with the same terms for the convenience of the Company and not because it
was required or requested to do so by any Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.11 <U>Headings</U>. The titles, subtitles and headings in this Agreement are for
convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.12 <U>Counterparts</U>. This
Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that
a facsimile or pdf signature including any electronic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and
effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.13 <U>Entire
Agreement</U>. This Agreement and the other agreements contemplated hereby (including all schedules and exhibits hereto and thereto), constitute the entire agreement between the parties hereto respecting the subject matter of this Agreement and
supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter of this Agreement, whether written or oral. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.14 <U>Survival</U>. The covenants, representations and warranties made by each party hereto contained in this Agreement shall survive the
Closing and the delivery of the Securities in accordance with their respective terms. Each Purchaser shall be responsible only for its own representations, warranties, agreements and covenants hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.15 <U>Contract Interpretation</U><U>.</U> This Agreement is the joint product of each Purchaser and the Company and each provision of this
Agreement has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.16 <U>Arm&#8217;s Length Negotiations</U>. For the avoidance of doubt, the parties acknowledge and confirm that the terms and conditions of
the Securities were determined as a result of <FONT STYLE="white-space:nowrap">arm&#8217;s-length</FONT> negotiations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.17
<U>Termination</U>. This Agreement shall terminate and be void and of no further force and effect, and all obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the
earlier to occur of (a)&nbsp;such date and time that the Merger Agreement is terminated in accordance with its terms, (b)&nbsp;upon the mutual written agreement of the Company and the Purchaser (provided that such termination shall not otherwise
apply to the other Purchasers), (c) by the Company, if any of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6.02</U> shall have become incapable of fulfillment and shall not have been waived by the Company, (d)&nbsp;by a Purchaser, if
any of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6.01</U> shall have become incapable of fulfillment and shall not have been waived by such Purchaser or (e)&nbsp;the Closing has not occurred by the six month anniversary of the
Effective Date (or the 8 month anniversary of the Effective Date if the End Date is automatically extended per the terms of the Merger Agreement). The Company shall notify each Purchaser of any termination of the Merger Agreement as promptly as
practicable after the termination thereof. Upon the termination hereof in accordance with this <U>Section</U><U></U><U>&nbsp;8.17</U>, any amounts paid by a Purchaser to the Company in connection with the transactions contemplated herein shall
promptly (and in any event within one Business Day) be returned in full to such Purchaser by wire transfer of immediately available funds to the account specified by such Purchaser, without any deduction for or on account of any tax withholding,
charges or <FONT STYLE="white-space:nowrap">set-off.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature pages follow </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly
executed as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CANDID&nbsp;THERAPEUTICS,&nbsp;INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to
Subscription Agreement</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly
executed as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to
Subscription Agreement</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="a2"></A>Annex H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc109079_52"></A>FORM OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS REGISTRATION RIGHTS AGREEMENT</B> (this &#8220;<B><I>Agreement</I></B>&#8221;), dated as of [&#149;], 2026, is entered into by and
among Candid Therapeutics, Inc., a Delaware corporation, Rallybio Corporation, a Delaware corporation (the &#8220;<B><I>Parent</I></B>&#8221;), and the several investors signatory hereto (individually as a &#8220;<B><I>Purchaser</I></B>&#8221; and
collectively together with their respective permitted assigns, the &#8220;<B><I>Purchasers</I></B>&#8221;). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Subscription Agreement by
and among the Company and the Purchasers, dated as of March&nbsp;1, 2026 (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<B><I>Subscription Agreement</I></B>&#8221;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHEREAS: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Upon the
terms and subject to the conditions of the Subscription Agreement, the Company has agreed to issue to the Purchasers, and the Purchasers have agreed to purchase, severally and not jointly, an aggregate of up to $505,508,000 of shares (the
&#8220;<B><I>Shares</I></B>&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<B><I>Common Stock</I></B>&#8221;), pursuant to the Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. The Company is party to that certain Agreement and Plan of Merger and Reorganization by and among the Company, Farmington Merger Sub, Inc.,
and Parent, dated as of March&nbsp;1, 2026 (the &#8220;<B><I>Merger Agreement</I></B>&#8221;), pursuant to which the Company will become a wholly-owned subsidiary of Parent (the &#8220;<B><I>Merger</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. Following the Effective Time (as defined in the Merger Agreement), Parent will change its name to Candid Therapeutics, Inc.
(&#8220;<B><I>TopCo</I></B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. To induce the Purchasers to enter into the Subscription Agreement, the Company has agreed to
provide certain registration rights under the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the &#8220;<B><I>1933 Act</I></B>&#8221;), and applicable state
securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the promises and the mutual covenants contained herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Purchasers hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>1. DEFINITIONS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
purposes of this Agreement, the following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#8220;<B><I>Company</I></B>&#8221; means Candid
Therapeutics, Inc. for all periods prior to the Effective Time (as defined in the Merger Agreement) and TopCo for all periods following the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#8220;<B><I>Filing Deadline</I></B>&#8221; means, with respect to the Initial Registration Statement required hereunder, the 30th
calendar day following the Closing Date and, with respect to any New Registration Statements or other Registration Statement filed hereunder, the 21st calendar day following the later of (i)&nbsp;date on which the Company is permitted by SEC
Guidance to file such New Registration Statement related to the Registrable Securities and (ii)&nbsp;the date on which the Company becomes aware of the necessity of filing such New Registration Statement related to the Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#8220;<B><I>Person</I></B>&#8221; means any individual or entity including but not limited to any corporation, limited liability company,
association, partnership, organization, business, individual, governmental or political subdivision thereof or a governmental agency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#8220;<B><I>Register</I></B>,&#8221; &#8220;<B><I>Registered</I></B>,&#8221; and
&#8220;<B><I>Registration</I></B>&#8221; refer to a registration effected by preparing and filing one or more registration statements of the Company in compliance with the 1933 Act and providing for offering securities on a continuous basis, and the
declaration or ordering of effectiveness of such registration statement(s) by the U.S. Securities and Exchange Commission (the &#8220;<B><I>SEC</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#8220;<B><I>Registrable Securities</I></B>&#8221; means (i)&nbsp;all shares of TopCo common stock issued to the Purchasers at the closing
of the Merger and (ii)&nbsp;any TopCo common stock issued or issuable with respect to the foregoing as a result of any stock split or subdivision, stock dividend, recapitalization, exchange or similar event. Registrable Securities shall cease to be
Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) upon the earliest to occur of (A)&nbsp;the date on which the Purchasers shall
have resold all the Registrable Securities covered by the Registration Statement, (B)&nbsp;such Registrable Securities have been previously sold in accordance with Rule 144, (C) such securities become eligible for resale without volume or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule
144, (D) with respect to Registrable Securities held by a Purchaser that is not an affiliate of the Company, upon exchange of such Registrable Securities for unrestricted shares under an effective registration statement on Form <FONT
STYLE="white-space:nowrap">S-4,</FONT> if available and assuming any applicable legends (if any) are removed from such Registrable Securities in accordance with this Agreement, or if unavailable, another appropriate form filed with the SEC, and
(E)&nbsp;five (5) years after the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#8220;<B><I>Registration Expenses</I></B>&#8221; means all registration
and filing fee expenses incurred by the Company in effecting any registration pursuant to this Agreement, including (i)&nbsp;all registration, qualification, and filing fees, printing expenses, and any other fees and expenses associated with filings
required to be made with the SEC, the Financial Industry Regulatory Authority, Inc. or any other regulatory authority, (ii)&nbsp;all fees and expenses in connection with compliance with or clearing the Registrable Securities for sale under any
securities or &#8220;Blue Sky&#8221; laws, (iii)&nbsp;all printing, duplicating, word processing, messenger, telephone, facsimile and delivery expenses, and (iv)&nbsp;all fees and disbursements of counsel for the Company and of all independent
certified public accountants of the Company (including the expenses of any special audit and cold comfort letters required by or incident to such performance); provided that in no event shall the Company be responsible for any underwriting, broker
or similar fees or commissions of any Purchaser or, except to the extent provided for in the Subscription Agreement, any legal fees or other costs of the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#8220;<B><I>Registration Statement</I></B>&#8221; means any registration statement of the Company filed with, or to be filed with, the
SEC under the 1933 Act, that Registers Registrable Securities, including the related preliminary or final prospectus, amendments and supplements to such registration statement, including <FONT STYLE="white-space:nowrap">pre-</FONT> and
post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws. &#8220;<B><I>Registration Statement</I></B>&#8221; shall also
include a New Registration Statement, as amended when each became effective, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a prospectus subsequently filed with the SEC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#8220;<B><I>Required Purchasers</I></B>&#8221; means the Purchasers holding a majority of the Registrable Securities outstanding
from time to time, provided that such majority includes each Purchaser who initially purchased (together with its affiliates and affiliated funds) at least $25&nbsp;million of Closing Shares (as defined in the Subscription Agreement) pursuant to the
Subscription Agreement and continues to hold such number of Closing Shares at the relevant time, provided further that such Closing Shares are Registrable Securities at the relevant time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#8220;<B><I>SEC Guidance</I></B>&#8221; means (i)&nbsp;any publicly-available written or oral guidance of the SEC staff, or any comments,
requirements or requests of the SEC staff (whether or not publicly-available); provided, that any such oral guidance, comments, requirements or requests are reduced to writing by the SEC (and shared with the Purchasers upon request if not
publicly-available) and (ii)&nbsp;the 1933 Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#8220;<B><I>Selling Expenses</I></B>&#8221; means all underwriting discounts and
selling commissions applicable to the sale of Registrable Securities and all similar fees and commissions relating to a Purchaser&#8217;s disposition of its Registrable Securities, including any legal fees or other costs of such Purchaser. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2. REGISTRATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Mandatory Registration</U>. The Company shall, as promptly as reasonably practicable and in any event no later than the Filing Deadline, prepare and file with the SEC an initial Registration Statement (the &#8220;<B><I>Initial Registration
Statement</I></B>&#8221;) covering the resale of all of the Registrable Securities. Before filing any Registration Statement, the Company shall furnish to the Purchasers a copy of the Registration Statement. The Purchasers and their respective
counsel shall have at least three (3)&nbsp;Business Days prior to the anticipated filing date of a Registration Statement to review and comment upon such Registration Statement and any amendment or supplement to such Registration Statement and any
related prospectus (including any documents incorporated by reference therein), prior to its filing with the SEC. Subject to any SEC comments, such Registration Statement shall include the plan of distribution substantially in the form attached
hereto as <U>Exhibit A</U>. The Company shall (a)&nbsp;consider in good faith any comments as the Purchaser or its counsel may reasonably propose to such document prior to being so filed with the SEC, and (b)&nbsp;not file any Registration Statement
or related prospectus or any amendment or supplement thereto containing information regarding the Purchaser to which such Purchaser reasonably (x)&nbsp;objects or (y)&nbsp;believes contains untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, unless such information is required (in the good faith opinion of the Company) to
comply with any applicable law or regulation or SEC Guidance. Each Purchaser shall furnish all information with respect to such Purchaser reasonably requested by the Company and as shall be reasonably required in connection with any registration
referred to in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Effectiveness</U>. The Company shall use commercially reasonable efforts to have the Initial
Registration Statement and any amendment declared effective by the SEC at the earliest possible date but no later than the earlier of (a)&nbsp;the seventy-fifth (75th) calendar day following the initial filing date of the Initial Registration
Statement if the SEC notifies the Company that it will &#8220;review&#8221; the Initial Registration Statement and (b)&nbsp;the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC
that the Initial Registration Statement will not be &#8220;reviewed&#8221; or will not be subject to further review (the &#8220;<B><I>Effectiveness Deadline</I></B>&#8221;). The Company shall notify the Purchaser by
<FONT STYLE="white-space:nowrap">e-mail</FONT> as promptly as practicable, and in any event, within twenty-four (24)&nbsp;hours, after the Registration Statement is declared effective or is supplemented and shall provide the Purchaser with copies of
any related prospectus to be used in connection with the sale or other disposition of the securities covered thereby. The Company shall use commercially reasonable efforts to keep the Initial Registration Statement continuously effective pursuant to
Rule 415 promulgated under the 1933 Act and available for the resale by the Purchasers of all of the Registrable Securities covered thereby at all times until the earliest to occur of the following events: (i)&nbsp;the date on which the Purchasers
shall have resold all the Registrable Securities covered thereby; (ii)&nbsp;the date on which the Registrable Securities may be resold by the Purchasers without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations by reason of Rule 144, and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 under the 1933 Act or any other
rule of similar effect and (iii)&nbsp;five (5) years after the date of this Agreement (the &#8220;<B><I>Registration Period</I></B>&#8221;). The Initial Registration Statement (including any amendments or supplements thereto and prospectuses
contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not
misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Sufficient Number of Shares Registered</U>. In the event the number of shares available under the Initial Registration
Statement at any time is insufficient to cover the Registrable Securities, the Company shall, to the extent necessary and permissible, amend the Initial Registration Statement or file a new registration statement (together with any prospectuses or
prospectus supplements thereunder, a &#8220;<B><I>New Registration Statement</I></B>&#8221;), so as to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cover all of such Registrable Securities as soon as reasonably practicable, but in any event not later than the Filing Deadline. The Company shall use its commercially reasonable efforts to have
such amendment and/or New Registration Statement become effective as soon as reasonably practicable following the filing thereof but no later than the earlier of the (i)&nbsp;seventy-fifth (75th) calendar day following the initial filing date of the
New Registration Statement if the SEC notifies the Company that it will &#8220;review&#8221; the New Registration Statement and (ii)&nbsp;the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is
earlier) by the SEC that the New Registration Statement will not be &#8220;reviewed&#8221; or will not be subject to further review (the earlier of such dates, the &#8220;<B><I>New Registration</I></B><I> </I><B><I>Effectiveness
Deadline</I></B>&#8221;). The provisions of <U>Sections 2(a)</U> and <U>2(b)</U> shall apply to the New Registration Statement, except as modified hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Allowable Delays</U>. On no more than two (2)&nbsp;occasions in any twelve (12)-month period for not more than thirty
(30)&nbsp;consecutive days or for a total of not more than sixty (60)&nbsp;days, the Company may delay the effectiveness of the Initial Registration Statement or any other Registration Statement, or suspend the use of any prospectus included in any
Registration Statement, in the event that the Company&#8217;s Board of Directors reasonably determines, in good faith and upon advice of legal counsel, that such delay or suspension is necessary to (A)&nbsp;delay the disclosure by the Company in the
Registration Statement of material <FONT STYLE="white-space:nowrap">non-public</FONT> information that the Company has a bona fide business purpose for preserving as confidential and the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> of
which at the time is not, in the good faith opinion of the Company&#8217;s Board of Directors, in the best interests of the Company, or (B)&nbsp;amend or supplement the affected Registration Statement or the related prospectus so that such
Registration Statement or prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus in light of the
circumstances under which they were made, not misleading (an &#8220;<B><I>Allowed Delay</I></B>&#8221;); <U>provided</U>, that the Company shall promptly (a)&nbsp;notify each Purchaser in writing (email being sufficient) of the commencement of an
Allowed Delay, but shall not (without the prior written consent of a Purchaser) disclose to such Purchaser any material <FONT STYLE="white-space:nowrap">non-public</FONT> information giving rise to an Allowed Delay, (b)&nbsp;advise the Purchasers in
writing to cease all sales under the applicable Registration Statement until the end of the Allowed Delay and (c)&nbsp;use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable. Each Purchaser may deliver written
notice (an &#8220;<B><I><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice</I></B>&#8221;) to the Company requesting that such Purchaser not receive notices from the Company otherwise required by this Section&nbsp;2(d); provided, however, that
such Purchaser may later revoke any such <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice in writing, which shall be effective five (5)&nbsp;Business Days after the receipt thereof. Following receipt of an
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice from a Purchaser (unless subsequently revoked), the Company shall not deliver any notices pursuant to this Section&nbsp;2(d) to such Purchaser and such Purchaser shall no longer be entitled to
the rights associated with any such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Rule 415; Cutback</U>. If at any time the SEC takes the position that the offering of
some or all of the Registrable Securities in any Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the 1933 Act (provided, however, the Company shall be obligated to use
commercially reasonable efforts to advocate with the SEC for the registration of all of the Registrable Securities) or requires any Purchaser to be named as an &#8220;underwriter,&#8221; the Company shall (i)&nbsp;promptly notify each holder of
Registrable Securities thereof and (ii)&nbsp;make commercially reasonable efforts to persuade the SEC that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering &#8220;by or on behalf of the
issuer&#8221; as defined in Rule 415 and that none of the Purchasers is an &#8220;underwriter.&#8221; Each Purchaser shall have the right to have its legal counsel, at such Purchaser&#8217;s expense, to review and oversee any registration or matters
pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U>, including to comment on any written submission made to the SEC with respect thereto. In the event that, despite the Company&#8217;s commercially reasonable efforts and compliance with the
terms of this <U>Section</U><U></U><U>&nbsp;2(e)</U>, the SEC refuses to alter its position, the Company shall (i)&nbsp;remove from such Registration Statement such portion of the Registrable Securities and/or (ii)&nbsp;agree to such restrictions
and limitations on the registration and resale of the Registrable Securities as the SEC may require to assure the Company&#8217;s compliance with the requirements of Rule 415 (collectively, the &#8220;<B><I>SEC Restrictions</I></B>&#8221;);
<U>provided</U>, <U>however</U>, that the Company shall not name any Purchaser as an &#8220;underwriter&#8221; in such Registration Statement without the prior written consent of such Purchaser (<U>provided</U> that, in the event a Purchaser
withholds such consent, the Company shall have no obligation hereunder to include any Registrable Securities of such Purchaser </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in any Registration Statement covering the resale thereof until such time as the SEC no longer requires such Purchaser to be named as an &#8220;underwriter&#8221; in such Registration Statement
or such Purchaser otherwise consents in writing to being so named). Any <FONT STYLE="white-space:nowrap">cut-back</FONT> imposed on the Purchasers pursuant to this Section&nbsp;2(e) shall be applied first to any of the Registrable Securities of a
Purchaser that the SEC has indicated cannot be included or must be limited in the number of Registrable Securities that can be included, and thereafter shall be allocated among the Purchasers on a pro rata basis, unless the SEC Restrictions
otherwise require or provides otherwise, or a Purchaser otherwise agrees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Each Registration Statement filed hereunder shall be on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> (except if the Company is not then eligible to register for resale the Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in which case such registration shall be on another
form in accordance with the provisions of this Section&nbsp;2(f)). If Form <FONT STYLE="white-space:nowrap">S-3</FONT> is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i)&nbsp;register the
resale of the Registrable Securities on another appropriate form and (ii)&nbsp;undertake to register the Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3</FONT> as soon as such form is available, <U>provided</U> that the Company
shall use commercially reasonable efforts maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> covering the Registrable Securities has
been declared effective by the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>3. RELATED COMPANY OBLIGATIONS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Registration Statement and whenever any Registrable Securities are to be Registered pursuant to Section&nbsp;2, including
on the Initial Registration Statement or on any New Registration Statement, the Company shall use its commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition
thereof and, pursuant thereto, the Company shall have the following obligations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notifications</U>. The Company will promptly
notify the Purchasers of the time when any subsequent amendment to the Initial Registration Statement or any New Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or where
a receipt has been issued therefor or any subsequent supplement to a prospectus has been filed and of any request by the SEC for any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus or for
additional information regarding the Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Amendments</U>. The Company will prepare and file with the SEC any amendments,
post-effective amendments or supplements to the Initial Registration Statement, any New Registration Statement or any related prospectus, as applicable, that, (a)&nbsp;as may be necessary to keep such Registration Statement effective for the
Registration Period and to comply with the provisions of the 1933 Act and the 1934 Act with respect to the distribution of all of the Registrable Securities covered thereby, or (b)&nbsp;in the reasonable opinion of a Purchaser and the Company, as
may be necessary or advisable in connection with any acquisition or sale of Registrable Securities by the Purchasers at least (1)&nbsp;Business Day prior to filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Purchaser Review</U>. The Company will not file any amendment or supplement to the Registration Statement, any New Registration
Statement or any prospectus, other than documents incorporated by reference, relating to any Purchaser, the Registrable Securities or the transactions contemplated hereby unless (A)&nbsp;the Purchaser and its counsel shall have been advised and
afforded the opportunity to review and comment thereon at least three (3)&nbsp;Business Days prior to filing with the SEC and (B)&nbsp;the Company shall have given good faith consideration to any comments thereon received from the Purchaser or its
counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Copies Available</U>. The Company will furnish to any Purchaser whose Registrable Securities are included in any
Registration Statement and its counsel copies of the Initial Registration Statement, any prospectus thereunder (including all documents incorporated by reference therein), any prospectus supplement thereunder, any New Registration Statement and all
amendments to the Initial Registration Statement or any New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with or furnished to the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company to the SEC or the staff of the SEC,
and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment) and such
other documents as Purchaser may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Purchaser that are covered by such Registration Statement, in each case as soon as reasonably practicable upon
such Purchaser&#8217;s request and in such quantities as such Purchaser may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall not be required to furnish any document to the Purchaser to the extent such
document is available on EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Notification of Stop Orders; Material Changes</U>. The Company shall use commercially reasonable
efforts to (i)&nbsp;prevent the issuance of any stop order or other suspension of effectiveness and, (ii)&nbsp;if such order is issued, obtain the withdrawal of any such order as soon as practicable. The Company shall advise the Purchasers promptly
(but in no event later than 24 hours) and shall confirm such advice in writing, in each case: (1)&nbsp;of the Company&#8217;s receipt of notice of any request by the SEC or any other federal or state governmental authority for amendment of or a
supplement to the Registration Statement or any prospectus or for any additional information; (2)&nbsp;of the Company&#8217;s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order
suspending the effectiveness of the Initial Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, or any New Registration Statement, or of the Company&#8217;s receipt of any notification of the
suspension of qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose; and (3)&nbsp;of the Company becoming aware of the happening of any
event, which makes any statement of a material fact made in any Registration Statement or any prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement or any prospectus
in order to state a material fact required by the 1933 Act to be stated therein or necessary in order to make the statements then made therein (in the case of any prospectus, in light of the circumstances under which they were made) not misleading,
or of the necessity to amend any Registration Statement or any prospectus to comply with the 1933 Act or any other law. The Company shall not be required to disclose to the Purchasers (and shall not so disclose to any Purchaser without such
Purchaser&#8217;s prior written consent) the substance of specific reasons of any of the events set forth in clauses (1)&nbsp;through (3) of the immediately preceding sentence and shall not provide any material
<FONT STYLE="white-space:nowrap">non-public</FONT> information to the Purchasers in such notice (each, a &#8220;<B><I>Suspension Event</I></B>&#8221;), but rather, shall only be required to disclose that the event has occurred. If at any time the
SEC, or any other federal or state governmental authority shall issue any stop order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, the Company shall use
its commercially reasonable efforts to obtain the withdrawal of such order at the earliest practicable time. The Company shall furnish to any Purchaser, upon request, without charge, a copy of any correspondence from the SEC or the staff of the SEC,
or any other federal or state governmental authority to the Company or its representatives relating to the Initial Registration Statement, any New Registration Statement or any prospectus, or prospectus supplement as the case may be. In the event of
a Suspension Event set forth in clause (3)&nbsp;of the second sentence of this Section&nbsp;3(e), the Company will use its commercially reasonable efforts to publicly disclose such event as soon as reasonably practicable, or otherwise resolve the
matter such that sales under Registration Statements may resume. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Confirmation of Effectiveness</U>. If reasonably requested by a
Purchaser at any time in respect of any Registration Statement, the Company shall deliver to such Purchaser a written confirmation (email being sufficient) from Company&#8217;s counsel of whether or not the effectiveness of such Registration
Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Listing</U>. The Company shall use commercially reasonable efforts to cause all Registrable Securities covered by a Registration
Statement to be listed on the Nasdaq Stock Market and any other National Exchange upon which the Registrable Securities are then listed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Compliance</U>. The Company shall otherwise use commercially reasonable efforts to
comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934 Act, including, without limitation, Rule 172 under the 1933 Act, file any final prospectus, including any supplement or amendment thereof, with the SEC
pursuant to Rule 424 under the 1933 Act, promptly inform the Purchaser in writing if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Purchaser is required
to deliver a prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make available to its
security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of at least twelve (12)&nbsp;months, beginning after the effective date of each Registration
Statement, which earnings statement shall satisfy the provisions of Section&nbsp;11(a) of the 1933 Act, including Rule 158 promulgated thereunder (for the purpose of this <U>Section</U><U></U><U>&nbsp;3(h)</U>, &#8220;<B><I>Availability
Date</I></B>&#8221; means the forty-fifth (45<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day following the end of the fourth (4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) fiscal quarter that includes the effective date of
such Registration Statement, except that, if such fourth (4th) fiscal quarter is the last quarter of the Company&#8217;s fiscal year, &#8220;<B><I>Availability Date</I></B>&#8221; means the ninetieth
(90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day after the end of such fourth (4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) fiscal quarter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U><FONT STYLE="white-space:nowrap">Blue-Sky</FONT></U>. The Company shall use commercially reasonable efforts to register or qualify or
cooperate with a Purchaser and its counsel in connection with the registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested by such Purchaser;
<U>provided</U>, <U>however</U>, that the Company shall not be required in connection therewith or as a condition thereto to (i)&nbsp;qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this
<U>Section</U><U></U><U>&nbsp;3(i)</U>, (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this <U>Section</U><U></U><U>&nbsp;3(i)</U>, or (iii)&nbsp;file a general consent to service of
process in any such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Rule 144</U>. With a view to making available to the Purchasers the benefits of Rule 144 (or its
successor rule) and any other rule or regulation of the SEC that may at any time permit the Purchasers to sell shares of TopCo common stock to the public without registration, for so long as any Registrable Securities are outstanding, the Company
covenants and agrees to use commercially reasonable efforts to: (i)&nbsp;make and keep adequate current public information available, as those terms are understood and defined in Rule 144; (ii) file with the SEC in a timely manner all reports and
other documents required of the Company under the 1934 Act; and (iii)&nbsp;furnish electronically to each Purchaser upon request, as long as such Purchaser owns any Registrable Securities, (A)&nbsp;a written statement by the Company that it has
complied with the reporting requirements of the 1934 Act, (B)&nbsp;a copy of or electronic access to the Company&#8217;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> and (C)&nbsp;such other information as may be reasonably requested in order to avail such Purchaser of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without
registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Cooperation</U>. The Company shall cooperate with the holders of the Registrable Securities to facilitate the timely
preparation and delivery of certificates or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and representing such number of shares of Common
Stock and registered in such names as the holders of the Registrable Securities may reasonably request in accordance with the provisions of the Subscription Agreement, and the Company may satisfy its obligations hereunder without issuing physical
stock certificates through the use of The Depository Trust Company&#8217;s Direct Registration System. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Removal of Restrictive
Legends</U>.&nbsp;Without limiting Section&nbsp;5.09 of the Subscription Agreement, the Company shall use commercially reasonable efforts to cause the Company&#8217;s transfer agent to remove any restrictive legend from any Registrable Securities,
as promptly as practicable following effectiveness of the applicable Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>4. OBLIGATIONS OF THE PURCHASERS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Purchaser Information</U>. Each Purchaser shall provide a completed Investor Questionnaire in the form attached hereto as Exhibit B or
such other form of questionnaire or information reasonably required by the Company in connection with the registration of the Registrable Securities within three (3)&nbsp;Business Days of request by the Company and no later than the end of the third
(3rd) Business Day following the date on which such Purchaser receives draft materials in accordance with Section&nbsp;2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<U>Suspension of Sales</U>. Each Purchaser, severally and not jointly with any other Purchaser, agrees that, upon receipt of any notice from the Company of the existence of an Allowed Delay or Suspension Event, the Purchaser will promptly
discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Purchaser&#8217;s receipt of a notice from the Company confirming the resolution of such Allowed Delay or
Suspension Event and that such dispositions may again be made; provided, for the avoidance of doubt, that the foregoing shall not limit the right of a Purchaser to sell or otherwise dispose of the Registrable Securities pursuant to Rule 144 or any
other exemption from the registration requirements of the 1933 Act or to settle a transaction pursuant to a Registration Statement as to which a contract for such sale was entered into prior to such Purchaser&#8217;s receipt of the notice from the
Company of the existence of the Allowed Delay or Suspension Event. The Company shall cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of a Purchaser in accordance with any sale of Registrable Securities pursuant
to a Registration Statement with respect to which such Purchaser has entered into a contract for sale prior to such Purchaser&#8217;s receipt of the notice from the Company of the existence of the Allowed Delay or Suspension Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Purchaser Cooperation</U>. Each Purchaser, severally and not jointly with any other Purchaser, agrees to cooperate with the Company as
reasonably requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement or New Registration Statement hereunder, unless such Purchaser has notified the Company in writing of
its election to exclude all of its Registrable Securities from such Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>5. EXPENSES OF REGISTRATION. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling
Expenses relating to securities registered on behalf of a Purchaser shall be borne by such Purchaser. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>6. INDEMNIFICATION. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Purchaser, each Person,
if any, who controls each Purchaser, the members, shareholders, directors, officers, partners, employees, members, managers, agents, representatives and advisors of each Purchaser and each Person, if any, who controls each Purchaser within the
meaning of the 1933 Act or the 1934 Act (each, an &#8220;<B><I>Indemnified Person</I></B>&#8221;), against any losses, obligation, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges and costs (including, without
limitation, court costs and costs of preparation, reasonable and documented attorneys&#8217; fees, amounts paid in settlement (with the prior consent of the Company, such consent not to be unreasonably withheld, conditioned or delayed) or reasonable
and documented expenses (collectively, &#8220;<B><I>Indemnified Damages</I></B>&#8221;)) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by
or before any court or governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (&#8220;<B><I>Claims</I></B>&#8221;), to which any of
them may become subject insofar as such Claims arise out of or are based upon: (i)&nbsp;any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement or (ii)&nbsp;any
violation or alleged violation by the Company or any of its Subsidiaries of the 1933 Act, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1934 Act or any other state securities or other &#8220;blue sky&#8221; laws of any jurisdiction in which Registrable Securities are offered or any rule or regulation promulgated thereunder
applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration of the Registrable Securities (the matters in the foregoing clauses (i)&nbsp;and (ii) being, collectively,
&#8220;<B><I>Violations</I></B>&#8221;). The Company shall reimburse each Indemnified Person promptly as such Indemnified Damages are incurred and are due and payable in connection with investigating or defending any such Claim. Notwithstanding
anything to the contrary contained herein, the indemnification agreement contained in this <U>Section</U><U></U><U>&nbsp;6(a)</U>: (A) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in
reliance upon and in conformity with information furnished in writing to the Company by the Purchaser or such Indemnified Person specifically for use in such Registration Statement and was reviewed and approved in writing by such Purchaser or such
Indemnified Person expressly for use in connection with the preparation of any Registration Statement; (B)&nbsp;with respect to any superseded prospectus, shall not inure to the benefit of any such Person from whom the Person asserting any such
Claim purchased the Registrable Securities that are the subject thereof (or to the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised
prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a Violation; (C)&nbsp;shall not be available to the
extent such Claim is based on a failure of the Indemnified Person to deliver, or cause to be delivered, if required the prospectus to the Persons asserting an untrue statement or omission or alleged untrue statement or omission at or prior to the
written confirmation of the sale of Registrable Securities; and (D)&nbsp;shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be
unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the
Purchaser pursuant to Section&nbsp;8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with the Initial Registration Statement, any New Registration Statement or any
prospectus, each Purchaser, severally and not jointly, agree to indemnify, hold harmless and defend, the Company, each of its directors and officers who signed the Initial Registration Statement or signs any New Registration Statement, and each
Person, if any, who controls the Company within the meaning of the 1933 Act or the 1934 Act (each, an &#8220;<B><I>Indemnified Party</I></B>&#8221;), against any losses, claims, damages, liabilities and expense (including reasonable attorney fees)
resulting from (i)&nbsp;any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement or (ii)&nbsp;any Violation or alleged Violation by the Purchaser of its obligations
under this Agreement, in each case to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with information about the relevant Purchaser furnished in writing by such Purchaser to the Company expressly for
use in connection with the preparation of the Registration Statement, any New Registration Statement, any prospectus or any such amendment thereof or supplement thereto. In no event shall the liability of a Purchaser be greater in amount than the
dollar amount of the proceeds (net of all expense paid by such Purchaser in connection with any claim relating to this Section&nbsp;6 and the amount of any damages such Purchaser has otherwise been required to pay by reason of such untrue statement
or omission) received by such Purchaser upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification obligation. Such indemnity shall remain in full force and effect regardless of any
investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by a Purchaser pursuant to Section&nbsp;8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an Indemnified Person or Indemnified Party under this Section&nbsp;6 of notice of the commencement of any action
or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section&nbsp;6, deliver to
the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly
noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be, and upon such notice, the indemnifying party shall not be liable
to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indemnified Person or the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense thereof;
provided, however, that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel with the
reasonable fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying
party would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party or Indemnified Person shall
cooperate with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or
Indemnified Person which relates to such action or claim. The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised as to the status of the defense or any settlement negotiations with respect thereto. No
indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No
indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise unless such judgment or settlement (i)&nbsp;imposes no liability or
obligation on, (ii)&nbsp;includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the Indemnified Party or Indemnified Person in
respect to or arising out of such claim or litigation in favor of, and (iii)&nbsp;does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the Indemnified Party or Indemnified Person.
Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which
indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person or
Indemnified Party under this Section&nbsp;6, except to the extent that the indemnifying party is prejudiced in its ability to defend such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The indemnification required by this Section&nbsp;6 shall be made by periodic payments of the amount thereof during the course of the
investigation or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment pursuant to this Section&nbsp;6 which person is later determined to not be entitled to such payment shall return such
payment (including reimbursement of expenses) to the person making it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The indemnity agreements contained herein shall be in addition
to (i)&nbsp;any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii)&nbsp;any liabilities the indemnifying party may be subject to pursuant to the law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7. CONTRIBUTION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the
extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section&nbsp;6 to the
fullest extent permitted by law; <U>provided</U>, <U>however</U>, that: (i)&nbsp;no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the 1933 Act) shall be entitled to contribution
from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii)&nbsp;contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all expenses paid by
such holder in connection with any claim relating to this Section&nbsp;7 and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by
such seller from the sale of such Registrable Securities giving rise to such contribution obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8. ASSIGNMENT OF REGISTRATION RIGHTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall not assign this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the prior
written consent of the Purchasers holding a majority of the Registrable Securities then outstanding (voting together as a single class); <U>provided</U>, <U>however</U>, that in any transaction, whether by merger, reorganization, restructuring,
consolidation, financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by
virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term &#8220;<B><I>Company</I></B>&#8221; shall be deemed to refer to such Person and the term &#8220;<B><I>Registrable Securities</I></B>&#8221;
shall be deemed to include the securities received by the Purchaser in connection with such transaction unless such securities are otherwise freely tradable by the Purchaser after giving effect to such transaction, and the prior written consent of
the Purchasers holding a majority of the Registrable Securities then outstanding shall not be required for such transaction. No Purchaser may assign its rights under this Agreement, other than to an affiliate of such Purchaser or to any other
investment funds or accounts managed or advised by the investment manager who acts on behalf of the Purchaser, without the prior written consent of the Company. The provisions of this Agreement shall be binding upon and inure to the benefit of the
Purchaser and its successors and permitted assigns. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>9. AMENDMENTS AND WAIVERS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of this Agreement, including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a
written instrument executed by (i)&nbsp;the Company and (ii)&nbsp;the Required Purchasers, <U>provided </U>that (i)&nbsp;any party may give a waiver as to itself, (ii)&nbsp;any amendment, modification, supplement or waiver that disproportionately
and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser or each Purchaser, as
applicable, and (iii)&nbsp;any amendments to <U>Section</U><U></U><U>&nbsp;6</U> or to the definitions of &#8220;<B><I>Filing Deadline</I></B>,&#8221; &#8220;<B><I>Effectiveness Deadline</I></B>,&#8221; &#8220;<B><I>New Registration Effectiveness
Deadline</I></B>&#8221; or &#8220;<B><I>Registration Period</I></B>&#8221; shall require the written consent of each Purchaser. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that
relates exclusively to the rights of one or more Purchasers and that does not adversely directly or indirectly affect the rights of other Purchasers may be given by Purchasers holding a majority of the Registrable Securities to which such waiver or
consent relates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>10. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notices</U>. All notices, requests, consents, and other communications under this Agreement shall be in writing and shall be deemed
delivered (a)&nbsp;when delivered, if delivered personally, (b)&nbsp;four (4) Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid, (c)&nbsp;one (1) Business Day after being sent via a reputable
nationwide overnight courier service guaranteeing next Business Day delivery, or (d)&nbsp;when delivered, in the case of email, in each case to the intended recipient as set forth below, with respect to the Company, and to the addresses set forth in
Schedule I to the Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">if to the Company: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Candid Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11622 El Camino Real, Suite 150 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute
notice): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10265 Science Center Drive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Charlie Kim; Carlos Ramirez </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: Ckim@cooley.com;
cramirez@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or at such other address as the Company or each Purchaser may specify by written notice to the other parties hereto in accordance
with this <U>Section</U><U></U><U>&nbsp;8.02</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>No Waiver</U>. No failure or delay on the part of either party hereto in the
exercise of any power, right or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude any other or further exercise thereof or of any other right,
power or privilege. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</U>. The provisions of
Section&nbsp;8.05 of the Subscription Agreement are incorporated by reference herein <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Entire
Agreement</U>. This Agreement, the Subscription Agreement and any other agreement contemplated hereby or thereby (including all schedules and exhibits hereto and thereto) constitute the entire agreement between the parties hereto respecting the
subject matter hereof and thereof and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter hereof and thereof, whether written or oral. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Headings</U>. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or
affect the interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Counterparts</U>. This Agreement may be executed in two or more identical
counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any
electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original,
not a facsimile or pdf (or other electronic reproduction of a) signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Further Assurances</U>. Each party shall do and perform,
or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Contract
Interpretation</U>. This Agreement is the joint product of each Purchaser and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any
party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>No Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their
respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person except as expressly provided in this Agreement. Except as set forth in Sections 6, 7 and 8, nothing in this
Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Severability</U>. If any part or provision of this Agreement is held unenforceable or in conflict with
the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid
and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U><FONT STYLE="white-space:nowrap">Non-Recourse</FONT></U>. Notwithstanding anything
that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or
future director, officer, employee, stockholder, general or limited partner or member of any Purchaser or of any affiliates or assignees thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of
any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future director, officer, employee,
stockholder, general or limited partner or member of any Purchaser or of any affiliates or assignees thereof, as such for any obligation of any Purchaser under this Agreement or any documents or instruments delivered in connection with this
Agreement for any claim based on, in respect of or by reason of such obligations or their creation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Specific Performance</U>. In
addition to any and all other remedies that may be available at law in the event of any breach of this Agreement, each Purchaser shall be entitled to seek specific performance of the agreements and obligations of the Company hereunder and to such
other injunction or equitable relief as may be granted by a court of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <U>Cumulative Remedies</U>. The remedies
provided herein are cumulative and not exclusive of any remedies provided by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Registration Rights Agreement to be
duly executed as of date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CANDID THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Registration Rights Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Registration Rights Agreement to be
duly executed as of date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PARENT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RALLYBIO CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Registration Rights Agreement to be
duly executed as of date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[NAME]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLAN OF DISTRIBUTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling
stockholders, which as used herein includes donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of common stock or interests in shares of common
stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or
interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices
related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any
one or more of the following methods when disposing of shares or interests therein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions to members, partners, stockholders or other equityholders of the selling stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales and settlement of short sales entered into after the effective date of the registration statement of
which this prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act, amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the
shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling stockholders for purposes of this prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of our common stock or interests therein, the selling stockholders may enter
into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our
common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other
transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares
such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and,
together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act,
provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be
&#8220;underwriters&#8221; within the meaning of Section&nbsp;2(a)(11) of the Securities Act (it being understood that the selling stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering). Any
discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &#8220;underwriters&#8221; within the meaning of
Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required, the
shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a
particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or
licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market
and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for
the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including
liabilities arising under the Securities Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the
Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed with the selling
stockholders to use commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i)&nbsp;the date on which the selling
stockholders shall have resold or otherwise disposed of all the shares covered by this prospectus and (ii)&nbsp;the date on which the shares covered by this prospectus no longer constitute &#8220;Registrable Securities&#8221; as such term is defined
in the Registration Rights Agreement, such that they may be resold by the selling stockholders without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT>
limitations and without current public information pursuant to Rule 144 under the Securities Act or any other rule of similar effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc109079_53"></A><A NAME="annxi"></A>ANNEX I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RALLYBIO CORPORATION, a corporation organized and existing under the laws of the State of
Delaware, hereby certifies as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;The name of the corporation is Rallybio Corporation (the
&#8220;<U>Corporation</U>&#8221;). The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on June&nbsp;30, 2021 (the &#8220;<U>Certificate of Incorporation</U>&#8221;). The
Certificate of Incorporation was amended on July&nbsp;12, 2021. The Certificate of Incorporation, as amended, was amended and restated on August&nbsp;2, 2021 (the &#8220;<U>Restated Certificate</U>&#8221;). The Restated Certificate was further
amended on February 6, 2026. This Certificate of Amendment (the &#8220;<U>Amendment</U>&#8221;) amends certain provisions of the Restated Certificate, and has been duly adopted in accordance with the provisions of Section&nbsp;242 of the General
Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;The Board of Directors of the Corporation has duly adopted a resolution, pursuant to
Section&nbsp;242 of the General Corporation Law of the State of Delaware, setting forth the following amendment to the Restated Certificate, and declaring the Amendment to be advisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;This Amendment was duly adopted by the vote of the stockholders holding the requisite number of shares of outstanding stock of the
Corporation entitled to vote thereon in accordance with the provisions of Sections 216 and 242 of the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;The Restated Certificate is hereby amended by adding the following Article&nbsp;XI &#8212; REVERSE STOCK SPLIT: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI &#8212; REVERSE STOCK SPLIT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of 12:01 A.M. (Eastern Time) on &#8195;&#8195;&#8195;&#8195; , 2026 (the &#8220;<U>Effective Time</U>&#8221;), each issued and outstanding
share of the Corporation&#8217;s Common Stock (including each share of treasury stock, collectively, the &#8220;<U><FONT STYLE="white-space:nowrap">Pre-Split</FONT> Stock</U>&#8221;) shall automatically and without any action on the part of the
holder thereof be reclassified as and reduced to &#8195;&#8195;&#8195;&#8195; of a share of Common Stock (such reduction of shares designated as the &#8220;<U>Reverse Stock Split</U>&#8221;). The par value of the Corporation&#8217;s Common Stock
following the Reverse Stock Split shall remain $0.0001 per share. Each holder of a certificate or certificates of <FONT STYLE="white-space:nowrap">Pre-Split</FONT> Stock shall be entitled to receive, upon surrender of such certificates to the
Corporation&#8217;s transfer agent for cancellation, a new certificate or certificates for a number of shares equal to such holder&#8217;s <FONT STYLE="white-space:nowrap">Pre-Split</FONT> Stock divided by &#8195;&#8195;&#8195;&#8195;, with any
fraction resulting from such division rounded down to the nearest whole number (in each case, such fraction, if any, being a &#8220;<U>Fractional Share</U>&#8221;). No Fractional Shares will be issued for
<FONT STYLE="white-space:nowrap">Pre-Split</FONT> Stock in connection with the Reverse Stock Split. Each holder of <FONT STYLE="white-space:nowrap">Pre-Split</FONT> Stock at the Effective Time who would otherwise be entitled to a Fractional Share
shall, in lieu thereof, receive a cash payment equal to x) the Fractional Share multiplied by y) the closing price of the Company&#8217;s Common Stock as reported on The Nasdaq Capital Market or other principal market of the Common Stock on the
first business day immediately preceding the date of the Effective Time.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;This Amendment shall be effective as of
&#8195;&#8195;&#8195;&#8195; , 2026 in accordance with the provisions of Section&nbsp;103(d) of the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;Except as set forth in this Amendment, the Restated Certificate remains in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has duly executed this Amendment in the name of and on behalf of the Corporation on this
&#8195;&#8195;&#8195;&#8195; day of &#8195;&#8195;&#8195;&#8195; , 2026. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RALLYBIO CORPORATION</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Stephen Uden, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc109079_53a"></A><A NAME="annxj"></A>ANNEX J </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND
RESTATED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Pursuant to Section&nbsp;242 and Section&nbsp;103 </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>of the General Corporation Law of the State of Delaware </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rallybio Corporation (the &#8220;<B>Corporation</B>&#8221;), a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the &#8220;<B>DGCL</B>&#8221;), does hereby certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors of the Corporation, acting in accordance with Section&nbsp;242 of the DGCL, duly adopted
resolutions declaring advisable the amendments to the Certificate of Incorporation of the Corporation filed with the Secretary of State on&#8195;&#8195;&#8195;&#8195;, 2026 (the &#8220;<B>Certificate of Incorporation</B>&#8221;) set forth in
paragraphs 2 and 3 of this Certificate of Amendment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article I of the Certificate of Incorporation is hereby deleted in its entirety and replaced by the following
Article I in lieu thereof: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8220;The name of this corporation is <B>Candid Therapeutics, Inc.</B> (the
&#8220;<B>Corporation</B>&#8221;).&#8221; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All references in the Certificate of Incorporation to &#8220;Rallybio Corporation&#8221; are hereby replaced
with &#8220;Candid Therapeutics, Inc.&#8221; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In witness whereof, the undersigned duly authorized officer of the
Corporation has executed this Certificate of Amendment on &#8195;&#8195;&#8195;&#8195;&#8195;, 2026. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Stephen Uden, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc109079_54"></A><A NAME="annxk"></A>ANNEX K </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND
RESTATED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned, being an officer of Rallybio Corporation (the&nbsp;&#8220;Corporation&#8221;), a corporation organized and existing under and by
virtue of the provisions of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;), hereby certifies, pursuant to Section&nbsp;242 and Section&nbsp;103 of the DGCL, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The name of the Corporation is Rallybio Corporation. The Corporation&#8217;s original Certificate of
Incorporation was filed with the Secretary of State of the State of Delaware on June&nbsp;30, 2021 (the &#8220;Certificate of Incorporation&#8221;). The Certificate of Incorporation was amended on July&nbsp;12, 2021. The Certificate of
Incorporation, as amended, was amended and restated on August&nbsp;2, 2021 (the &#8220;Restated Certificate&#8221;). The Restated Certificate was further amended on February 6, 2026. This Certificate of Amendment (the &#8220;Amendment&#8221;) amends
certain provisions of the Restated Certificate, and has been duly adopted in accordance with the provisions of Section&nbsp;242 of the General Corporation Law of the State of Delaware. The name of this corporation is Rallybio Corporation, and this
corporation was originally incorporated pursuant to the DGCL on January&nbsp;1, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors of the Corporation has duly adopted a resolution, pursuant to Section&nbsp;242 of the
General Corporation Law of the State of Delaware, setting forth the following amendment to the Restated Certificate, and declaring the Amendment to be advisable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The first sentence of section (a)&nbsp;of Article Fourth of the Certificate of Incorporation of the Corporation
is hereby amended in its entirety to read as follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The total number of shares of stock which the Corporation shall
have authority to issue is &#8195;&#8195;&#8195;&#8195; shares, consisting of &#8195;&#8195;&#8195;&#8195; shares of Common Stock, par value $0.0001 per share (&#8220;Common Stock&#8221;) and &#8195;&#8195;&#8195;&#8195; shares of Preferred Stock,
par value $0.0001 per share (&#8220;Preferred Stock&#8221;). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The foregoing amendment has been consented to and authorized by the stockholders of the Corporation by written
consent given in accordance with the provisions of Section&nbsp;228 of the DGCL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The foregoing amendment was duly adopted by a majority of the directors of the Corporation in accordance with
the provisions of Section&nbsp;141 and Section&nbsp;242 of the DGCL. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this certificate has been
executed by a duly authorized officer of this corporation on this&#8195;&#8195;&#8195;&#8195;day of&#8195;&#8195;&#8195;&#8195;, 2026. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Stephen Uden, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc109079_55"></A><A NAME="ii109079_1a"></A><A NAME="b1"></A>Annex L </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ANDID</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>2026 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
[&#8195;&#8195;&#8195;], 2026 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
[&#8195;&#8195;&#8195;], 2026 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>ENERAL</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Successor to and Continuation of Prior Plan.</B> The Plan is the successor to and continuation of the Prior Plan. As of the
Effective Date, (i)&nbsp;no additional awards may be granted under the Prior Plan; (ii)&nbsp;any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii)&nbsp;all outstanding awards granted under the
Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan
will be subject to the terms of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Plan Purpose.</B> The Company, by means of the Plan, seeks to secure and retain
the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to
benefit from increases in value of the Common Stock through the granting of Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Available Awards.</B> The Plan provides
for the grant of the following Awards: (i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options; (iii)&nbsp;SARs; (iv) Restricted Stock Awards; (v)&nbsp;RSU Awards; (vi)&nbsp;Performance Awards; and (vii)&nbsp;Other Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Adoption Date; Effective Date. </B>The Plan will come into existence on the Adoption Date, but no Award may be granted prior to
the Effective Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Share Reserve. </B>Subject to adjustment in accordance with Section&nbsp;2(c) and any adjustments as
necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed [&#8195;&#8195;&#8195;] shares, which is the sum of: (i)&nbsp;[&#8195;&#8195;&#8195;]<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> new shares, plus (ii)&nbsp;up to [&#8195;&#8195;&#8195;] Returning Shares, as such shares become available from time to time. In addition, subject to any adjustments as necessary to implement any
Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on January&nbsp;1 of each year for a period of ten years commencing on January&nbsp;1, 2027 and ending on (and including) January&nbsp;1, 2036,
in an amount equal to five percent (5%) of the total number of Fully Diluted Shares on December&nbsp;31 of the preceding year; provided, however, that the Board may act prior to January 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of a
given year to provide that the increase for such year will be a lesser number of shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Aggregate
Incentive Stock Option Limit.</B> Notwithstanding anything to the contrary in Section&nbsp;2(a) and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may
be issued pursuant to the exercise of Incentive Stock Options is [&#8195;&#8195;&#8195;]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> shares.
</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: To be equal to the product of (i)&nbsp;fifteen percent (15%), multiplied by (ii)&nbsp;the total
number of shares of our common stock outstanding plus all shares of our common stock issuable upon conversion or exercise of outstanding securities and rights, including (without limitation) preferred stock on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, equity awards, warrants (including <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), and any convertible indebtedness or similar instruments, whether or not then vested or
exercisable, determined on the effective date of the Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: To be equal to the number of new shares multiplied by 3. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Share Reserve Operation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Limit Applies to Common Stock Issued Pursuant to Awards. </B>For clarity, the Share Reserve is a limit on the number of shares
of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue
shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section&nbsp;303A.08, NYSE American Company Guide
Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</B> The following actions do not
result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1)&nbsp;the expiration or termination of any portion of an Award without the
shares covered by such portion of the Award having been issued; (2)&nbsp;the settlement of any portion of an Award in cash (<I>i.e.</I>, the Participant receives cash rather than Common Stock); (3) the withholding of shares that would otherwise be
issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4)&nbsp;the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Reversion of Previously Issued Shares of Common Stock to Share Reserve.</B> The following shares of Common Stock previously
issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1)&nbsp;any shares that are forfeited back to or repurchased by
the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2)&nbsp;any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3)&nbsp;any
shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>LIGIBILITY</SMALL> <SMALL>AND</SMALL> L<SMALL>IMITATIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Eligible Award Recipients.</B> Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive
Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Specific Award Limitations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Limitations on Incentive Stock Option Recipients.</B> Incentive Stock Options may be granted only to Employees of the Company or
a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Incentive Stock Option $100,000 Limitation.</B> To the extent that the aggregate Fair Market Value (determined at the time of
grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit
established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such
rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</B> A Ten Percent Stockholder may not be granted
an Incentive Stock Option unless (1)&nbsp;the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (2)&nbsp;the Option is not exercisable after the expiration of five years from the date of
grant of such Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Limitations on Nonstatutory Stock Options and SARs.</B> Nonstatutory Stock Options and SARs may not
be granted to Employees, Directors and Consultants unless the stock underlying such Awards is treated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as &#8220;service recipient stock&#8221; under Section&nbsp;409A or unless such Awards otherwise comply with the requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Aggregate Incentive Stock Option Limit.</B> The aggregate maximum number of shares of Common Stock that may be issued pursuant
to the exercise of Incentive Stock Options is the number of shares specified in Section&nbsp;2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit. </B>The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
with respect to any calendar year, including Awards granted and cash fees paid by the Company to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed (1) $750,000 in total value or (2)&nbsp;in the event such <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director is first appointed or elected to the Board during such calendar year, $1,000,000 in total value, in each case, calculating the value of any equity awards based on the grant date fair value of
such equity awards for financial reporting purposes.&nbsp;The limitations in this Section&nbsp;3(d) shall apply commencing with the first calendar year that begins following the Effective Date. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL>
R<SMALL>IGHTS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option and SAR will have such terms and conditions as determined by the Board. Each
Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated or if an Option designated as an Incentive Stock Option fails to qualify
as an Incentive Stock Option, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents.
The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise)
to the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Term.</B> Subject to Section&nbsp;3(b) regarding Ten Percent
Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Exercise or Strike Price.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, the exercise or strike price of
each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on
the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A
and, if applicable, 424(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Exercise Procedure and Payment of Exercise Price for Options.</B> In order to
exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that
do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise price of an Option
may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> by cash or check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> pursuant to a &#8220;cashless exercise&#8221; program developed under Regulation T as promulgated by the U.S. Federal Reserve
Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> by delivery to the Company (either by actual delivery or attestation) of shares
of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&nbsp;at
the time of exercise the Common Stock is publicly traded, (2)&nbsp;any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&nbsp;such delivery would not
violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4)&nbsp;any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5)&nbsp;such shares have been held by the
Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> if the
Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value
on the date of exercise that does not exceed the exercise price, provided that (1)&nbsp;such shares used to pay the exercise price will not be exercisable thereafter and (2)&nbsp;any remaining balance of the exercise price not satisfied by such net
exercise is paid by the Participant in cash or other permitted form of payment; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> in any other form of consideration that may
be acceptable to the Board and permissible under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Exercise Procedure and Payment of Appreciation
Distribution for SARs</B><B>.</B> In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise
of a SAR will not be greater than an amount equal to the excess of (i)&nbsp;the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being
exercised under such SAR, over (ii)&nbsp;the strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment,
as determined by the Board and specified in the SAR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Transferability.</B> Options and SARs may not be transferred
to third party financial institutions for value. The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the
transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and <I>provided, further</I>, that if an Option is an Incentive Stock Option, such
Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Restrictions on Transfer.</B> An
Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an
Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#8217;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under
Section&nbsp;671 of the Code and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Domestic Relations Orders.</B> Notwithstanding the foregoing, subject to the execution of transfer documentation in a format
acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Vesting.</B> The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as
determined by the Board. Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the
Participant&#8217;s Continuous Service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Termination of Continuous Service for Cause.</B> Except as explicitly
otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Options and SARs will terminate
and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous
Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</B> Subject to
Section&nbsp;4(i), if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if
applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its
maximum term (as set forth in Section&nbsp;4(a)): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> three months following the date of such termination if such termination is a
termination without Cause (other than any termination due to the Participant&#8217;s Disability or death); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> 12 months
following the date of such termination if such termination is due to the Participant&#8217;s Disability; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> 18 months following
the date of such termination if such termination is due to the Participant&#8217;s death; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> 18 months following the date of
the Participant&#8217;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i)&nbsp;or (ii) above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or,
if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock
subject to the terminated Award, or any consideration in respect of the terminated Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Restrictions on Exercise;
Extension of Exercisability. </B>A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other
written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination
Exercise Period: (i)&nbsp;the exercise of the Participant&#8217;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii)&nbsp;the immediate sale of any shares
of Common Stock issued upon such exercise would violate the Company&#8217;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would
otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to
the maximum permitted number of extensions; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section&nbsp;4(a)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B><B>.</B> No Option or SAR, whether or not vested, granted to an
Employee who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the U.S. Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the
date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the U.S. Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Award in the event of (i)&nbsp;such Participant&#8217;s death or Disability, (ii)&nbsp;a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii)&nbsp;a Change in
Control, or (iv)&nbsp;such Participant&#8217;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#8217;s then current employment
policies and guidelines). This Section&nbsp;4(j) is intended to operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be exempt from
his or her regular rate of pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Whole Shares.</B> Options and SARs may be exercised only with respect to whole shares of
Common Stock or their equivalents. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL>
S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Restricted Stock Awards and
RSU Awards.</B> Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of
the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Form
of Award.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> Restricted Stock Awards: To the extent consistent with the Company&#8217;s Bylaws, at the Board&#8217;s
election, shares of Common Stock subject to a Restricted Stock Award may be (A)&nbsp;held in book entry form subject to the Company&#8217;s instructions until such shares become vested or any other restrictions lapse, or (B)&nbsp;evidenced by a
certificate, which certificate will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares
subject to a Restricted Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> RSU Awards: An RSU Award represents a Participant&#8217;s right to be issued on a future
date the number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#8217;s unfunded
obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Award Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind
or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are
actually issued in settlement of a vested RSU Award). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Consideration.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> Restricted Stock Awards: A Restricted Stock Award may be granted in consideration for (A)&nbsp;cash or check, bank draft or money
order payable to the Company, (B)&nbsp;services to the Company or an Affiliate, or (C)&nbsp;any other form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> RSU Awards: Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in consideration for the
Participant&#8217;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any
shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#8217;s services to the Company or an Affiliate) upon the
issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Vesting. </B>The Board may impose such restrictions on or conditions to the
vesting of a Restricted Stock Award or RSU Award as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and
RSU Awards will cease upon termination of the Participant&#8217;s Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Termination of Continuous
Service.</B> Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason, (1)&nbsp;the Company may
receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the
Restricted Stock Award Agreement and the Participant will have no further right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award, or any consideration in respect of the Restricted
Stock Award and (2)&nbsp;any portion of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant
to the RSU Award, or any consideration in respect of the RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B>Dividends and Dividend Equivalents. </B>Dividends or
dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> <B>Settlement of RSU Awards.</B> An RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination
thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the
vesting of the RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Performance Awards.</B> With respect to any Performance Award, the length of any Performance
Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Other Awards.</B> Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock,
including the appreciation in value thereof may be granted either alone or in addition to Awards provided for under Section&nbsp;4 and the preceding provisions of this Section&nbsp;5. Subject to the provisions of the Plan, the Board will have sole
and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all
other terms and conditions of such Other Awards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Capitalization Adjustments</B><B>.</B> In the event of a Capitalization Adjustment, the Board shall appropriately and
proportionately adjust: (i)&nbsp;the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to Section&nbsp;2(a); (ii) the class(es) and
maximum number of shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;2(b); and (iii)&nbsp;the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock
subject to outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created
in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding
provisions of this Section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Dissolution or Liquidation.</B> Except as otherwise provided in the Award
Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of
repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired
by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to
repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Corporate Transaction. </B>The following provisions will apply to Awards in the event of a Corporate Transaction, except as set
forth in Section&nbsp;11, unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of
grant of an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Awards May Be Assumed.</B> In the event of a Corporate Transaction, any surviving corporation or
acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not
limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards
may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or
continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume, continue or substitute the Awards held by some, but not all Participants. The terms of any assumption, continuation or
substitution will be set by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Awards Held by Current Participants.</B> In the event of a Corporate Transaction in
which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed,
continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;<B><I>Current Participants</I></B>&#8221;), the vesting of
such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will<B> </B>be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the
effectiveness of the Corporate Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not
exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate
Transaction). With respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and that have multiple vesting levels depending on the level of performance,
unless otherwise provided in the Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction in which the Awards are not assumed, continued or substituted in
accordance with Section&nbsp;6(c)(i). With respect to the vesting of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and are settled in the form of a cash payment, such cash payment
will be made no later than 30 days following the occurrence of the Corporate Transaction or such later date as required to comply with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Awards Held by Persons other than Current Participants.</B> In the event of a Corporate Transaction in which the surviving
corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or
substituted and that are held by persons other than Current </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held
by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Payment for Awards in Lieu of Exercise.</B> Notwithstanding the foregoing, in the event an Award will terminate if not
exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board,
equal in value, at the effective time, to the excess, if any, of (1)&nbsp;the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award),
over (2)&nbsp;any exercise price payable by such holder in connection with such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Appointment of Stockholder
Representative.</B> As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company,
including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#8217;s behalf with respect to any escrow, indemnities and any contingent consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>No Restriction on Right to Undertake Transactions.</B> The grant of any Award under the Plan and the issuance of shares pursuant
to any Award does not affect or restrict in any way the right or power of the Company, the Board or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital
structure or its business, any Change in Control, any Corporate Transaction, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference
stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its
assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DMINISTRATION</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Administration by Board.</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan
to a Committee or Committees, as provided in subsection (c)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Powers of Board.</B> The Board will have the power,
subject to, and within the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine from time to time (1)&nbsp;which
of the persons eligible under the Plan will be granted Awards; (2)&nbsp;when and how each Award will be granted; (3)&nbsp;what type or combination of types of Award will be granted; (4)&nbsp;the provisions of each Award granted (which need not be
identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5)&nbsp;the number of shares of Common Stock or cash equivalent with respect to which an Award
will be granted to each such person; (6)&nbsp;the Fair Market Value applicable to an Award; and (7)&nbsp;the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including
the amount of cash payment or other property that may be earned and the timing of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To construe and interpret the Plan
and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a
manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To settle all
controversies regarding the Plan and Awards granted under it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To accelerate the time at which an Award may first be exercised or the time
during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation
of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock
or the share price of the Common Stock, including any Corporate Transaction, for reasons of administrative convenience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To
suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> To amend the Plan in any respect the Board deems necessary or advisable; provided, however<I>,</I> that stockholder approval will
be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1)&nbsp;the Company
requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To submit any
amendment to the Plan for stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> To approve forms of Award Agreements for use under the Plan and to amend the
terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board
discretion; <I>provided however</I>, that, a Participant&#8217;s rights under any Award will not be Materially Impaired by any such amendment unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant
consents in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to
promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xi)</B> To adopt
such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or
Consultants who are <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or
facilitate compliance with the laws of the relevant <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xii)</B> To
effect, at any time and from time to time, subject to the consent of any Participant whose Award is Materially Impaired by such action, (1)&nbsp;the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2)&nbsp;the
cancellation of any outstanding Option or SAR and the grant in substitution therefor of (A)&nbsp;a new Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a
different number of shares of Common Stock, (B)&nbsp;cash and/or (C)&nbsp;other valuable consideration (as determined by the Board); or (3)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Delegation to Committee.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> <B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in
this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the
authority to concurrently administer the Plan with the Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain
the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance.</B> To the extent an Award is intended to qualify for the
exemption from Section&nbsp;16(b) of the Exchange Act that is available under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors, as determined under Rule <FONT STYLE="white-space:nowrap">16b-3(b)(3)</FONT> of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by
the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Effect
of Board</B><B>&#8217;</B><B>s Decision.</B> All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Delegation to Other Person or Body.</B> The Board or any Committee may delegate to one or more persons or bodies the
authority to do one or more of the following to the extent permitted by Applicable Law: (i)&nbsp;designate recipients, other than Officers, of Awards, provided that no person or body may be delegated authority to grant an Award to themself;
(ii)&nbsp;determine the number of shares subject to such Awards; and (iii)&nbsp;determine the terms of such Awards; provided, however, that the Board or Committee action regarding such delegation will fix the terms of such delegation in accordance
with Applicable Law, including without limitation Sections 152 and 157 of the Delaware General Corporation Law. Unless provided otherwise in the Board or Committee action regarding such delegation, each Award granted pursuant to this section will be
granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, with any modifications necessary to incorporate or reflect the terms of such Award. Notwithstanding anything to the contrary herein,
neither the Board nor any Committee may delegate to any person or body (who is not a Director or that is not comprised solely of Directors, respectively) the authority to determine the Fair Market Value. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Withholding Authorization.</B> As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding
from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate arrangements to satisfy the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items withholding obligations, if any, of the Company and/or an
Affiliate that arise in connection with the grant, vesting, exercise or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no
obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B>Satisfaction of Withholding Obligation.</B> To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items withholding obligation relating
to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the
Participant in connection with the Award; (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to the Participant; (v)&nbsp;by allowing a Participant to effectuate a
&#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the U.S. Federal Reserve Board; or (vi)&nbsp;by such other method as may be set forth in the Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>No Obligation to Notify or Minimize Taxes; No Liability to Claims. </B>Except
as required by Applicable Law, the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such
holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be
liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i)&nbsp;agrees to not make any claim against the Company, or any of
its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii)&nbsp;acknowledges that such Participant was advised to consult with his or her own personal tax, financial and
other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from
Section&nbsp;409A only if the exercise or strike price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the U.S. Internal Revenue Service and there is no other impermissible deferral
of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or
Affiliates in the event that the U.S. Internal Revenue Service asserts that such exercise price or strike price is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the U.S. Internal
Revenue Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Withholding Indemnification. </B>The Company and/or its Affiliate may withhold or account for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items by considering statutory or other withholding rates, including minimum or maximum rates applicable in a Participant&#8217;s jurisdiction. In the event of overwithholding, the Participant may
receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock) or, if not refunded, the Participant may seek a refund from the local tax authorities. In the event of under-withholding, the Participant
may be required to pay any additional <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items directly to the applicable tax authority or to the Company and/or its Affiliate. As a condition to accepting an Award under the Plan, in the event that
the amount of the Company&#8217;s and/or its Affiliate&#8217;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the
Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. Further, if the obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items is satisfied by withholding in
shares of Common Stock, for tax purposes, the Participant will be deemed to have been issued the full number of shares subject to the Award, notwithstanding that a number of the shares is held back solely for the purpose of paying the <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Source of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock,
including shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Use of Proceeds from Sales of Common Stock.
</B>Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Corporate Action Constituting Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board,
regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes)
documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the
Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Stockholder Rights.</B> No Participant will be deemed to be the holder of, or
to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and
(ii)&nbsp;the issuance of the Common Stock subject to such Award is reflected in the records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>No Employment
or Other Service Rights.</B> Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or
an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will (unless otherwise required under Applicable Law) and without regard to any future vesting opportunity
that a Participant may have with respect to any Award (i)&nbsp;the employment of an Employee with or without notice and with or without Cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the
Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the U.S. state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or
commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the
Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Change in
Time Commitment.</B> In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee
of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted
by Applicable Law, to (i)&nbsp;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in
lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or
extended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Execution of Additional Documents.</B> As a condition to accepting an Award under the Plan, the Participant
agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#8217;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or
other regulatory requirements, in each case at the Plan Administrator&#8217;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Electronic Delivery and
Participation.</B> Any reference herein or in an Award Agreement to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or
posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate
in the Plan through any <FONT STYLE="white-space:nowrap">on-line</FONT> electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g.,
a stock certificate or electronic entry evidencing such shares) shall be determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Clawback/Recovery.</B>
All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the
Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and
permissible under Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the
occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#8217;s right to voluntarily terminate employment upon a &#8220;resignation for good reason,&#8221; or for a
&#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Securities Law
Compliance. </B>A Participant will not be issued any shares in respect of an Award unless either (i)&nbsp;the shares are registered under the Securities Act or (ii)&nbsp;the Company has determined that such issuance would be exempt from the
registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material
compliance with Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Transfer or Assignment of Awards; Issued Shares.</B> Except as expressly provided in the
Plan or the form of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of a Restricted Stock Award and similar awards,
after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the
terms of the Trading Policy and Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B>Effect on Other Employee Benefit Plans. </B>The value of any Award granted
under the Plan, as determined upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#8217;s benefits under any employee benefit plan sponsored by
the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B>Deferrals.</B> To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of
Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made
in accordance with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B>Section 409A. </B>Unless otherwise expressly provided for in an
Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A, and, to the extent not so exempt, in compliance with
the requirements of Section&nbsp;409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A, the Award Agreement evidencing such Award will incorporate the terms and conditions
necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement.
Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#8220;deferred
compensation&#8221; under Section&nbsp;409A is a &#8220;specified employee&#8221; for purposes of Section&nbsp;409A, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in
Section&nbsp;409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the
date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the
balance paid thereafter on the original schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B>Choice of Law</B><B>. </B>This Plan and any controversy arising out of or
relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of
Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be necessary, having
jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under
the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the
authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting
of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable
Law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DDITIONAL</SMALL> R<SMALL>ULES</SMALL> <SMALL>FOR</SMALL> A<SMALL>WARDS</SMALL>
S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> S<SMALL>ECTION</SMALL>&nbsp;409A. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Application. </B>Unless the
provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Subject to <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangements.</B> To the extent a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award is subject to Section&nbsp;409A due to application of a
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, the following provisions of this subsection (b)&nbsp;apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award vests in the ordinary course during the Participant&#8217;s
Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, in no event will the shares
be issued in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award any later than the later of: (i)&nbsp;December 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the calendar year that includes the applicable vesting
date; or (ii)&nbsp;the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day that follows the applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If vesting of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with the Participant&#8217;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award as of the date of grant, then the shares will be earlier issued in settlement of such <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Participant&#8217;s Separation from Service in accordance with the terms of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, but in no event later than the 60<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> day that follows the date of the Participant&#8217;s Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations
contained in Section&nbsp;409A applicable to &#8220;specified employees,&#8221; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such
Participant&#8217;s Separation from Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such <FONT STYLE="white-space:nowrap">six-month</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> If vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with a Participant&#8217;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are not a part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award on the date of grant, then such acceleration of vesting of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during
the Participant&#8217;s Continuous Service, notwithstanding the vesting acceleration of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or
pursuant to a fixed schedule, as provided under U.S. Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(a)(4).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for Employees and
Consultants.</B> The provisions of this subsection (c)&nbsp;shall apply and shall supersede anything to the contrary set forth in the Plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to the permitted treatment of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction if the Participant was either an Employee or
Consultant upon the applicable date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Vested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The following provisions shall apply to any Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> If the Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or
substitute the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Upon the Section&nbsp;409A Change in Control the settlement of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will automatically be accelerated and
the shares will be immediately issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market
Value of the shares that would otherwise be issued to the Participant upon the Section&nbsp;409A Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> If the
Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. The shares to be issued in respect of
the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not
occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be
issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The following provisions shall apply to any Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless otherwise determined by the Board pursuant to subsection (e)&nbsp;of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Unless otherwise determined by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will remain subject to the same vesting and forfeiture restrictions that were
applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the Acquiring Entity on the same schedule
that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each
applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> If the Acquiring Entity will not assume, substitute or continue any Unvested
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in
respect of such forfeited Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section&nbsp;409A, the Board may in its discretion
determine to elect to accelerate the vesting and settlement of the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares
that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be forfeited
without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards in connection with the Corporate Transaction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> The foregoing treatment shall apply with respect to all Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards
upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section&nbsp;409A Change in Control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a
Corporate Transaction for <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors.</B> The following provisions of this subsection (d)&nbsp;shall apply and shall supersede anything to the contrary that may be set forth in the Plan with
respect to the permitted treatment of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award in connection with a Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or
substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Upon the Section&nbsp;409A Change in Control the vesting and settlement of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will automatically be
accelerated and the shares will be immediately issued to the Participant in respect of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash
settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&nbsp;409A Change in Control pursuant to the preceding provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If the Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume,
continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Unless otherwise determined by the Board, the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will remain subject to the same vesting and
forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award shall be issued to the Participant by the
Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may
instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value made on the date
of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> If the RSU Award is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award, then the
provisions in this Section&nbsp;11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT>
Award: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Any exercise by the Board of discretion to accelerate the vesting of a
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless earlier issuance of the
shares upon the applicable vesting dates would be in compliance with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The Company
explicitly reserves the right to earlier settle any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award to the extent permitted and in compliance with the requirements of Section&nbsp;409A, including pursuant to any of the exemptions available
in U.S. Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(j)(4)(ix).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To the extent the
terms of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the
Change in Control or Corporate Transaction event triggering settlement must also constitute a Section&nbsp;409A Change in Control. To the extent the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provide that it will be settled
upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the termination event triggering settlement must also constitute a Separation From
Service. However, if at the time the shares would otherwise be issued to a Participant in connection with a &#8220;separation from service&#8221; such Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable
to &#8220;specified employees,&#8221; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#8217;s Separation From Service, or, if earlier,
the date of the Participant&#8217;s death that occurs within such six month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> The provisions in this subsection
(e)&nbsp;for delivery of the shares in respect of the settlement of an RSU Award that is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award are intended to comply with the requirements of Section&nbsp;409A so that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the delivery of the shares to the Participant in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will not trigger the additional tax imposed under Section&nbsp;409A, and
any ambiguities herein will be so interpreted. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>EVERABILITY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such
unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid
shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth
anniversary of the earlier of: (i)&nbsp;the Adoption Date; or (ii)&nbsp;the date the Plan is approved by the Company&#8217;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#8220;<B><I>Acquiring Entity</I></B>&#8221; means the surviving or acquiring corporation (or its parent company) in connection
with a Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#8220;<B><I>Adoption Date</I></B>&#8221; means the date the Plan is first approved by the Board
or Compensation Committee, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#8220;<B><I>Affiliate</I></B>&#8221; means, at the time of determination, any
&#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is
determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#8220;<B><I>Applicable Law</I></B>&#8221; means the Code and any applicable U.S
and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities, exchange, control, tax, federal, state, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule,
listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable
self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#8220;<B><I>Award</I></B>&#8221; means any right to receive Common Stock, cash or other property granted under the Plan (including
an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#8220;<B><I>Award Agreement</I></B>&#8221; means a written or electronic agreement between the Company and a Participant
evidencing the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided, including
through electronic means, to a Participant along with the Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#8220;<B><I>Board</I></B>&#8221; means the Board of
Directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final
and binding on all Participants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <I>&#8220;</I><B><I>Capitalization Adjustment</I></B>&#8221; means any change
that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate
structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the
conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B>
&#8220;<B><I>Cause</I></B>&#8221;<B><I> </I></B>has the meaning ascribed to such term in any written agreement between a Participant and the Company or any Affiliate of the Company defining such term and, in the absence of such agreement, such term
means, with respect to a Participant, the occurrence of any of the following events: (i)&nbsp;the Participant&#8217;s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers,
suppliers, vendors or other third parties with which such entity does business; (ii)&nbsp;the Participant&#8217;s commission of (A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or in each case the
equivalent in any relevant jurisdiction; (iii)&nbsp;the Participant&#8217;s failure to perform the Participant&#8217;s assigned duties and responsibilities to the reasonable satisfaction of the Company or any Affiliate of the Company which failure
continues, in the reasonable judgment of the Company, after written notice given to the Participant by the Company or any Affiliate of the Company; (iv)&nbsp;the Participant&#8217;s gross negligence, willful misconduct or insubordination with
respect to the Company or any Affiliate of the Company; or (v)&nbsp;the Participant&#8217;s material violation of any provision of any agreement(s) between the Participant and the Company or any Affiliate of the Company relating to noncompetition,
nonsolicitation, nondisclosure and/or assignment of inventions. The determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are
executive officers of the Company and by the Company&#8217;s Chief Executive Officer with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of a Participant was
terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or any Affiliate of the Company or such Participant for any other
purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#8220;<B><I>Change in Control</I></B>&#8221; or &#8220;<B><I>Change of Control</I></B>&#8221; means the occurrence,
in a single transaction or in a series of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Exchange Act
Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar
transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the
Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company
through the issuance of equity securities, or (C)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#8220;<I>Subject Person</I>&#8221;) exceeds the designated percentage threshold of the outstanding voting securities
as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition
of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and,
immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(A)&nbsp;outstanding voting securities representing more than 50% of the combined outstanding voting power of the Acquiring Entity in such merger, consolidation or similar transaction or
(B)&nbsp;more than 50% of the combined outstanding voting power of the parent of the Acquiring Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding
voting securities of the Company immediately prior to such transaction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> there is consummated a sale, lease, exclusive
license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and
its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the
Company immediately prior to such sale, lease, license or other disposition; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> individuals who, on the Adoption Date, are
members of the Board (the &#8220;<B><I>Incumbent Board</I></B>&#8221;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new
Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets,
merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate
and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement,
the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also
constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#8220;<B><I>Code</I></B>&#8221; means the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#8220;<B><I>Committee</I></B>&#8221; means the Compensation Committee and any other committee of one or
more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>
&#8220;<B><I>Common Stock</I></B>&#8221; means the common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#8220;<B><I>Company</I></B>&#8221; means
Candid Therapeutics, Inc., a Delaware corporation, and any successor corporation thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#8220;<B><I>Compensation
Committee</I></B>&#8221; means the Compensation Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#8220;<B><I>Consultant</I></B>&#8221; means any
person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is
compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is
treated as a Consultant under this Plan only if a Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such
person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#8220;<B><I>Continuous Service</I></B>&#8221; means that the Participant&#8217;s service with the Company or an
Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is
no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; provided, however<I>,</I> that<I> </I>if the Entity for which a Participant is rendering
services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from
an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by Applicable Law, the Board or the chief executive officer of the Company, in that
party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Company or an Affiliate, including sick leave, military leave or any other personal
leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided
in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by Applicable Law. In addition, to the extent required for exemption from or
compliance with Section&nbsp;409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#8220;separation from
service&#8221; as defined under U.S. Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> (without regard to any alternative definition thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#8220;<B><I>Corporate Transaction</I></B>&#8221; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other disposition of all or substantially all, as
determined by the Board, of the consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or other disposition of at
least 50% of the outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the
Company is not the surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is
the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property,
whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the
term Corporate Transaction shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Corporate Transaction (or any analogous term) in an
individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any
analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the
transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#8220;<B><I>determine</I></B>&#8221; or &#8220;<B><I>determined</I></B>&#8221;<B><I> </I></B>means as determined by the Board or
the Committee (or its designee) in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#8220;<B><I>Director</I></B>&#8221; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#8220;<B><I>Disability</I></B>&#8221; means, with respect to a Participant, such Participant is unable to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Section&nbsp;22(e)(3) of the Code, and will be determined by the
Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#8220;<B><I>Effective
Date</I></B>&#8221; means the effective date of this Plan, which is [&#8195;&#8195;&#8195;], 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B>
&#8220;<B><I>Employee</I></B>&#8221; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for
purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#8220;<B><I>Employer</I></B>&#8221; means the Company or the Affiliate that employs the Participant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#8220;<B><I>Entity</I></B>&#8221; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#8220;<B><I>Exchange Act</I></B>&#8221; means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#8220;<B><I>Exchange Act Person</I></B>&#8221;<B><I> </I></B>means any natural person, Entity or
&#8220;group&#8221; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of
the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a
registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company, or (v)&nbsp;any natural person,
Entity or &#8220;group&#8221; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined
voting power of the Company&#8217;s then outstanding securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#8220;<B><I>Fair Market Value</I></B>&#8221; means, as of
any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be
the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing selling price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In the absence of such markets for the
Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#8220;<B><I>Fully Diluted Shares</I></B>&#8221; means, as of any date, all of the common stock of the Company outstanding plus
all shares of common stock of the Company issuable upon conversion or exercise of outstanding securities and rights, including (without limitation) preferred stock on an as-converted basis, equity awards, warrants (including pre-funded warrants),
and any convertible indebtedness or similar instruments, whether or not then vested or currently exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B>
&#8220;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#8221; means any: (i)&nbsp;nation, state, commonwealth, canton, province, territory, county, municipality, district or other jurisdiction of any nature; (ii)&nbsp;U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;federal,</FONT> state, local, municipal, or other government; (iii)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity
and any court or other tribunal, and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority; or&nbsp;(iv)&nbsp;self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and
the Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#8220;<B><I>Grant Notice</I></B>&#8221; means the notice provided to a
Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment
right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B>
&#8220;<B><I>Incentive Stock Option</I></B>&#8221; means an option granted pursuant to Section&nbsp;4 of the Plan that is intended to be, and qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section&nbsp;422 of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#8220;<B><I>Materially Impair</I></B>&#8221;<B><I> </I></B>means any amendment to the terms of the Award that materially
adversely affects the Participant&#8217;s rights under the Award. A Participant&#8217;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the
amendment, taken as a whole, does not materially impair the Participant&#8217;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#8217;s rights under the Award:
(i)&nbsp;imposition of reasonable restrictions on the minimum number of shares subject to an Option or SAR that may be exercised; (ii)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the
Code; (iii)&nbsp;to change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (iv)&nbsp;to clarify the
manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section&nbsp;409A; or (v)&nbsp;to comply with other Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#8221;<B> </B>means a Director who either
(i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a
Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#8220;<B><I>Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT></I></B>&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged in a
business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K;</FONT> or (ii)&nbsp;is otherwise considered a <FONT STYLE="white-space:nowrap">&#8220;non-employee</FONT>
director&#8221; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#8220;<B><I><FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#8221;<B><I> </I></B>means any Award that is subject to, and not exempt from, Section&nbsp;409A, including as the result of (i)&nbsp;a deferral of the issuance of the shares subject to the
Award which is elected by the Participant or imposed by the Company, or (ii)&nbsp;the terms of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award</I></B>&#8221; means a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award granted to a Participant who was a Director but not an Employee on the applicable grant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk) &#8220;</B><B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement</I></B><B>&#8221; </B>means a severance
arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#8217;s termination of employment or separation
from service (as such term is defined in Section&nbsp;409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder))<B> (&#8220;</B><B><I>Separation from </I></B><B></B><B><I>Service</I></B><B>&#8221;) </B>and such
severance benefit does not satisfy the requirements for an exemption from application of Section&nbsp;409A provided under U.S. Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT>
<FONT STYLE="white-space:nowrap">1.409A-1(b)(9)</FONT> or otherwise.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> &#8220;<B><I>Nonstatutory Stock
Option</I></B>&#8221; means any option granted pursuant to Section&nbsp;4 of the Plan that does not qualify as an Incentive Stock Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> &#8220;<B><I>Officer</I></B>&#8221; means a person who is an officer of the
Company within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> &#8220;<B><I>Option</I></B>&#8221; means an Incentive
Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B>
&#8220;<B><I>Option Agreement</I></B>&#8221; means a written or electronic agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and
the agreement containing the written summary of the general terms and conditions applicable to the Option and which is provided including through electronic means, to a Participant along with the Grant Notice. Each Option Agreement will be subject
to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> &#8220;<B><I>Optionholder</I></B>&#8221; means a person to whom an Option is granted
pursuant to the Plan or, if applicable, such other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#8220;<B><I>Other
Award</I></B>&#8221; means an award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of
the Fair Market Value at the time of grant) that is not an Incentive Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>rr</B><B>)</B> &#8220;<B><I>Other Award Agreement</I></B>&#8221;<B><I> </I></B>means a written or electronic agreement between the
Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> &#8220;<B><I>Own,</I></B>&#8221;<B><I> </I></B>&#8220;<B><I>Owned,</I></B>&#8221;<B><I> </I></B>&#8220;<B><I>Owner,</I></B>&#8221;
or<B><I> </I></B>&#8220;<B><I>Ownership</I></B>&#8221;<B> </B>means that a person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities
if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> &#8220;<B><I>Participant</I></B>&#8221; means an Employee, Director or Consultant to whom an Award is granted pursuant to the
Plan or, if applicable, such other person who holds an outstanding Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> &#8220;<B><I>Performance Award</I></B>&#8221; means
an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of
Section&nbsp;5(b) pursuant to such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment
of Performance Awards. Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> &#8220;<B><I>Performance Criteria</I></B>&#8221; means one or more criteria that the Board will select for purposes of
establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: earnings (including
earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; relative stockholder return; return on equity or average
stockholder&#8217;s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes;
<FONT STYLE="white-space:nowrap">pre-tax</FONT> profit; operating cash flow; sales, annual recurring revenue or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working
capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#8217; equity; capital expenditures; debt levels; operating
profit or net operating profit; workforce diversity; growth of net income or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operating income; billings; financing; regulatory milestones; stockholder liquidity; corporate governance and compliance; intellectual property; personnel matters; progress of internal research;
progress of partnered programs; partner satisfaction; budget management; partner or collaborator achievements; internal controls, including those related to the U.S. Sarbanes-Oxley Act of 2002; investor relations, analysts and communication;
implementation or completion of projects or processes; employee retention; number of users, including unique users; strategic partnerships or transactions (including <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT
STYLE="white-space:nowrap">out-licensing</FONT> of intellectual property); establishing relationships with respect to the marketing, distribution and sale of the Company&#8217;s products; supply chain achievements;
<FONT STYLE="white-space:nowrap">co-development,</FONT> <FONT STYLE="white-space:nowrap">co-marketing,</FONT> profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and
other measures of performance selected by the Board or Committee whether or not listed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> &#8220;<B><I>Performance
Goals</I></B>&#8221; means, for a Performance Period, one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more
business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board
(i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method
of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to
generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as
determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels
during the balance of a Performance Period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of Common Stock by reason of any stock dividend or split, stock repurchase, reorganization,
recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends;
(9)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&#8217;s bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be
expensed under generally accepted accounting principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board may
establish or provide for other adjustment items in the Award Agreement at the time the Award is granted or in such other document setting forth the Performance Goals at the time the Performance Goals are established. In addition, the Board retains
the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement
of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> &#8220;<B><I>Performance Period</I></B>&#8221; means the period of time selected by the Board over which the attainment of one or
more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy)</B> &#8220;<B><I>Plan</I></B>&#8221; means this Candid Therapeutics, Inc. 2026 Equity Incentive Plan, as amended from time to time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz)</B> &#8220;<B><I>Plan Administrator</I></B>&#8221; means the person, persons, and/or third-party administrator designated by the
Company to administer the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Plan and the Company&#8217;s other equity incentive programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa)</B> &#8220;<B><I>Post-Termination Exercise Period</I></B>&#8221; means the period
following termination of a Participant&#8217;s Continuous Service within which an Option or SAR is exercisable, as specified in Section&nbsp;4(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>bbb</B><B>)</B> &#8220;<B><I>Prior Plan</I></B>&#8221; means the Rallybio Corporation 2021 Equity Incentive Plan, as amended from
time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ccc)</B> &#8220;<B><I>Prospectus</I></B>&#8221; means the document containing the Plan information specified in
Section&nbsp;10(a) of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ddd)</B> &#8220;<B><I>Restricted Stock Award</I></B>&#8221; or
&#8220;<B><I>RSA</I></B>&#8221; means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(eee)</B> &#8220;<B><I>Restricted Stock Award Agreement</I></B>&#8221; means a written or electronic agreement between the Company and a
holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary
of the general terms and conditions applicable to the Restricted Stock Award and which is provided including by electronic means, to a Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and
conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(fff)</B> &#8220;<B><I>Returning Shares</I></B>&#8221; means shares subject to outstanding stock awards
granted under the Prior Plan and that following the Effective Date:&nbsp;(A)&nbsp;are not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been
issued;&nbsp;(B)&nbsp;are not issued because such stock award or any portion thereof is settled in cash;&nbsp;(C)&nbsp;are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the
vesting of such shares; (D)&nbsp;are withheld or reacquired to satisfy the exercise, strike or purchase price; or&nbsp;(E)&nbsp;are withheld or reacquired to satisfy a tax withholding obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ggg)</B> &#8220;<B><I>RSU Award</I></B>&#8221; or &#8220;<B><I>RSU</I></B>&#8221;<B><I> </I></B>means an Award of restricted stock units
representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>hhh</B><B>)</B> &#8220;<B><I>RSU Award Agreement</I></B>&#8221;<B><I> </I></B>means a written or electronic agreement between the
Company and a holder of an RSU Award evidencing the terms and conditions of an RSU Award grant. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions
applicable to the RSU Award and which is provided including by electronic means, to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> &#8220;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#8221; means Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jjj)</B> &#8220;<B><I>Rule 405</I></B>&#8221; means Rule 405 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kkk)</B> &#8220;<B><I>SAR Agreement</I></B>&#8221; means a written or electronic agreement between the Company and a holder of a SAR
evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided, including
by electronic means, to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(lll)</B> &#8220;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#8221; means Section&nbsp;409A of the Code and the regulations
and other guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mmm)</B> &#8220;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A Change in Control</I></B>&#8221;
means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#8217;s assets, as provided in Section&nbsp;409A(a)(2)(A)(v) of the Code and U.S. Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nnn)</B> &#8220;<B><I>Securities Act</I></B>&#8221; means the U.S. Securities Act of
1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ooo)</B> &#8220;<B><I>Share Reserve</I></B>&#8221; means the number of shares available for issuance under the Plan
as set forth in Section&nbsp;2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ppp)</B> &#8220;<B><I>Stock Appreciation Right</I></B>&#8221; or
&#8220;<B><I>SAR</I></B>&#8221;<B><I> </I></B>means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qqq)</B> &#8220;<B><I>Subsidiary</I></B>&#8221; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting
power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rrr)</B> &#8220;<B><I><FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#8221; means any income tax, social insurance, payroll tax, fringe benefit tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items arising out of or in
relation to a Participant&#8217;s participation in the Plan and legally applicable or deemed applicable to the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(sss)</B>
&#8220;<B><I>Ten Percent Stockholder</I></B>&#8221; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or
any Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ttt)</B> &#8220;<B><I>Trading Policy</I></B>&#8221; means the Company&#8217;s policy permitting certain individuals to
sell Company shares only during certain &#8220;window&#8221; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uuu)</B> &#8220;<B><I>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#8221; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vvv)</B> &#8220;<B><I>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#8221; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><A NAME="toc109079_56"></A><A NAME="ii109079_2a"></A><A NAME="b2"></A><B>Annex M</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ANDID</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2026 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
[&#8195;&#8195;&#8195;], 2026 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
[&#8195;&#8195;&#8195;], 2026 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to
purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to
Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Plan includes two components: a
423 Component and a <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Company intends (but makes no undertaking or representation to maintain) the 423 Component to qualify as an Employee Stock Purchase Plan. The provisions of the 423
Component, accordingly, will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. In addition, this Plan authorizes grants of Purchase Rights under the <FONT STYLE="white-space:nowrap">Non-423</FONT>
Component that do not meet the requirements of an Employee Stock Purchase Plan. Except as otherwise provided in the Plan or determined by the Board, the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component will operate and be administered in
the same manner as the 423 Component. In addition, the Company may make separate Offerings which vary in terms (provided that such terms are not inconsistent with the provisions of the Plan or the requirements of an Employee Stock Purchase Plan to
the extent the Offering is made under the 423 Component), and the Company will designate which Designated Company is participating in each separate Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Company, by means of the Plan, seeks to retain the services of Eligible Employees, to secure and retain the services of new
Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DMINISTRATION</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as
provided in Section&nbsp;2(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will have the power, subject to, and within the limitations of, the express
provisions of the Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine how and when Purchase Rights will be granted and the provisions of each Offering (which
need not be identical). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To designate from time to time (A)&nbsp;which Related Corporations will be eligible to participate in
the Plan as Designated 423 Companies, (B)&nbsp;which Related Corporations or Affiliates will be eligible to participate in the Plan as Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Companies, (C)&nbsp;which Affiliates or Related
Corporations may be excluded from participation in the Plan, and (D)&nbsp;which Designated Companies will participate in each separate Offering (to the extent that the Company makes separate Offerings). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its
administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To settle all controversies regarding the Plan and Purchase Rights granted under
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To amend the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of
the Company, its Related Corporations and Affiliates, and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan with respect to the 423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To adopt such rules, procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit
or facilitate participation in the Plan by Employees who are <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals or employed or located outside the United States. Without limiting the generality of, and consistent with, the foregoing, the
Board specifically is authorized to adopt rules, procedures, and <FONT STYLE="white-space:nowrap">sub-plans</FONT> regarding, without limitation, eligibility to participate in the Plan, the definition of eligible &#8220;earnings,&#8221; handling and
making of Contributions, establishment of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures
and handling of share issuances, any of which may vary according to applicable requirements, and which, if applicable to a Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Company, do not have to comply with the requirements of
Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board may delegate some or all of the administration of the Plan to a Committee or
Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan and any applicable Offering Document to the Board will thereafter be to the Committee or subcommittee), subject,
however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Further, to the extent not prohibited by Applicable Law, the Board or Committee may, from time to time, delegate some
or all of its authority under the Plan to one or more officers of the Company or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the
delegation. The Board may retain the authority to concurrently administer the Plan with the Committee (or its delegate) and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated
administration of the Plan to a Committee (or a delegate of the Committee), the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> All determinations, interpretations and constructions made by the Board will not be subject to review by any person and will be
final, binding and conclusive on all persons. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> S<SMALL>UBJECT</SMALL>
<SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the provisions of Section&nbsp;11(a)
relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed <B>[&#8195;&#8195;&#8195;]</B><SUP STYLE="font-size:75%; vertical-align:top">1</SUP><B> </B>shares of Common
Stock, plus the number of shares of Common Stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on January&nbsp;1,&nbsp;2027 and ending on (and including) January&nbsp;1, 2036, in an amount equal
to the lesser of (x)&nbsp;one percent (1%) of the total number of Fully Diluted Shares on December 31st of the preceding calendar year, and (y)<B>&nbsp;[&#8195;&#8195;&#8195;]</B><SUP STYLE="font-size:75%; vertical-align:top">2</SUP><B> </B>shares
of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> increase in
</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: To be equal to 1% of the total number of shares of our common stock outstanding plus all shares of
our common stock issuable upon conversion or exercise of outstanding securities and rights, including (without limitation) preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, equity awards, warrants (including <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants), and any convertible indebtedness or similar instruments, whether or not then vested or exercisable, determined on the effective date of the Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: To be equal to the initial limit, multiplied by 3. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to
the preceding sentence. For the avoidance of doubt, up to the maximum number of shares of Common Stock reserved under this Section&nbsp;3(a) may be used to satisfy purchases of Common Stock under the 423 Component and any remaining portion of such
maximum number of shares may be used to satisfy purchases of Common Stock under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The stock purchasable under the
Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>;
O<SMALL>FFERING</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board may from time to time grant or provide for the grant of Purchase
Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will
deem appropriate, and with respect to the 423 Component, will comply with the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an
Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference
in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5
through 8, inclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant has more than one Purchase Right outstanding under the Plan, unless such Participant
otherwise indicates in forms delivered to the Company or a third party designated by the Company (each, a &#8220;<B><I>Company Designee</I></B>&#8221;): (i) each form will apply to all of such Participant&#8217;s Purchase Rights under the Plan, and
(ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher
exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the
first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i)&nbsp;that Offering will terminate immediately as of that first
Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>LIGIBILITY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b),
to Employees of a Related Corporation or an Affiliate. Except as provided in Section&nbsp;5(b) or as required by Applicable Law, an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in
the employ of the Company, the Related Corporation or the Affiliate, as the case may be, for such continuous period preceding such Offering Date as the Board may (unless prohibited by Applicable Law) require, but in no event will the required period
of continuous employment be equal to or greater than two years. In addition, the Board may provide (unless prohibited by Applicable Law) that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date,
such Employee&#8217;s customary employment with the Company, the Related Corporation or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Affiliate is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section&nbsp;423 of the Code with respect to
the 423 Component. The Board may also exclude (unless prohibited by Applicable Law) from participation in the Plan or any Offering Employees who are &#8220;highly compensated employees&#8221; (within the meaning of Section&nbsp;423(b)(4)(D) of the
Code) of the Company, a Related Corporation or an Affiliate, or a subset of such highly compensated employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may
provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs
thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that
Offering, as described herein, except that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the date on which such Purchase Right is granted will be the &#8220;Offering
Date&#8221; of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>
the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of
the Offering, the individual will not receive any Purchase Right under that Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Employee will be eligible for the
grant of any Purchase Rights under the 423 Component if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the
Company or of any Related Corporation. For purposes of this Section&nbsp;5(c), the rules of Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all
outstanding Purchase Rights and options will be treated as stock owned by such Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> As specified by
Section&nbsp;423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights under the 423 Component only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any
Related Corporations, do not permit such Eligible Employee&#8217;s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which, when aggregated, exceeds U.S. $25,000 of Fair Market Value of such stock (determined at
the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Officers of the Company and any Designated Company, if they are otherwise Eligible Employees, will be eligible to participate in
Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by Applicable Law) provide in an Offering that Employees who are highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will
not be eligible to participate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Notwithstanding anything in this Section&nbsp;5 to the contrary, in the case of an Offering
under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Eligible Employee (or group of Eligible Employees) may be excluded from participation in the Plan or an Offering if the Board has determined, in its sole discretion, that
participation of such Eligible Employee(s) is not advisable or practical for any reason. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be
granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage of earnings (as such concept is defined in the Offering Document) or with a maximum dollar amount, but in either case as so
specified by the Board in the Offering Document, during the period that begins on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be
exercised and shares of Common Stock will be purchased in accordance with such Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In connection with each Offering made
under the Plan, the Board may specify (i)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii)&nbsp;a maximum aggregate number of shares of Common Stock that may be
purchased by all Participants pursuant to such Offering and/or (iii)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of
Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&#8217;s accumulated
Contributions) allocation of the shares of Common Stock (rounded down to the nearest whole share) available will be made in as nearly a uniform manner as will be practicable and equitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be specified by the Board prior to
commencement of an Offering and will not be less than the lesser of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> an amount equal to 85% of the Fair Market Value of the
shares of Common Stock on the Offering Date; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock
on the applicable Purchase Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> An Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the
means of making Contributions by completing and delivering to the Company or a Company Designee, within the time specified in the Offering, an enrollment form provided by the Company or a Company Designee. The enrollment form will specify the amount
of Contributions not to exceed the maximum amount specified by the Board. Each Participant&#8217;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the
Company except where Applicable Law requires that Contributions be held separately or deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first practicable payroll occurring on or after the
Offering Date (or, in the case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the
Offering, a Participant may thereafter reduce (including to zero) or increase such Participant&#8217;s Contributions. If payroll deductions are impermissible or problematic under Applicable Law or if specifically provided in the Offering and to the
extent permitted by Section&nbsp;423 of the Code with respect to the 423 Component, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through payment by cash, check or wire transfer prior
to a Purchase Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> During an Offering, a Participant may cease making Contributions and withdraw from the Offering by
delivering to the Company or a Company Designee a withdrawal form provided by the Company or a Company Designee. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#8217;s Purchase Right
in that Offering will immediately terminate and the Company will distribute as soon as practicable to such Participant all of such Participant&#8217;s accumulated but unused Contributions and such Participant&#8217;s Purchase Right in that Offering
shall thereupon terminate. A Participant&#8217;s withdrawal from that Offering will have no effect upon such Participant&#8217;s eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new
enrollment form to participate in subsequent Offerings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Purchase Rights granted pursuant to any Offering under the Plan will terminate
immediately if the Participant either (i)&nbsp;is no longer an Employee for any reason or for no reason or (ii)&nbsp;is otherwise no longer eligible to participate. The Company will distribute as soon as practicable to such individual all of such
individual&#8217;s accumulated but unused Contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Unless otherwise determined by the Board, a Participant whose
employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between the Company and a Designated Company or between Designated Companies will not be treated as having terminated employment for
purposes of participating in the Plan or an Offering; however, if a Participant transfers from an Offering under the 423 Component to an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the
Participant&#8217;s Purchase Right will be qualified under the 423 Component only to the extent such exercise complies with Section&nbsp;423 of the Code. If a Participant transfers from an Offering under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the Purchase Right will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component for the remainder of the Offering. The Board may establish different and additional rules governing transfers between separate Offerings within the 423 Component and between Offerings under
the 423 Component and Offerings under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> During a
Participant&#8217;s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company and valid
under Applicable Law, by a beneficiary designation as described in Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Unless otherwise specified in the Offering
or required by Applicable Law, the Company will have no obligation to pay interest on Contributions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Purchase Date, each Participant&#8217;s accumulated Contributions will be applied to the purchase
of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in
the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in a
Participant&#8217;s account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be
held in such Participant&#8217;s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such next Offering, in which case such amount
will be distributed to such Participant after the final Purchase Date without interest (unless the payment of interest is otherwise required by Applicable Law). If the amount of Contributions remaining in a Participant&#8217;s account after the
purchase of shares of Common Stock is at least equal to the amount required to purchase one (1)&nbsp;whole share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be distributed in full to such Participant
after the final Purchase Date of such Offering without interest (unless otherwise required by Applicable Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Purchase
Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all
applicable U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state and other securities, exchange control and other laws applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is
not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and, subject to Section&nbsp;423 of the Code with respect to the 423 Component, the Purchase Date will be delayed until the shares of Common Stock are subject to
such an effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 27 months from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all Applicable
Laws, as determined by the Company in its sole discretion, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest (unless the payment of interest is otherwise
required by Applicable Law). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state
or other regulatory commission, agency or other Governmental Body having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its
sole discretion, that doing so is not practical or would cause the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary
for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell
Common Stock upon exercise of such Purchase Rights. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any
shares of Common Stock and/or Contributions from the Participant&#8217;s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the
Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock
and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common
Stock and/or Contributions, without interest (unless the payment of interest is otherwise required by Applicable Law), to the Participant&#8217;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then
to such other person as the Company may designate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTIONS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the
event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii) the class(es) and maximum number of
securities by which the share reserve is to increase automatically each year pursuant to Section&nbsp;3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and
(iv)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event of a Corporate Transaction, then: (i)&nbsp;any surviving corporation or acquiring corporation (or the surviving or
acquiring corporation&#8217;s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for
outstanding Purchase Rights, or (ii)&nbsp;if any surviving or acquiring corporation (or its parent company)<B> </B>does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the
Participants&#8217; accumulated Contributions will be used to purchase shares of Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by the Board) prior to the Corporate Transaction under
the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>MENDMENT</SMALL>, T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL>
<SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board may amend the Plan at any time in any
respect the Board deems necessary or advisable. However, except as provided in Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required
by Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan
while the Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Any benefits, privileges, entitlements and obligations under any
outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such Purchase
Rights were granted, (ii)&nbsp;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and other
interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii)&nbsp;as
necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#8217;s consent if such amendment is necessary to ensure that the Purchase Right
and/or the Plan complies with the requirements of Section&nbsp;423 of the Code with respect to the 423 Component or with respect to other Applicable Laws. Notwithstanding anything in the Plan or any Offering Document to the contrary, the Board will
be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit Contributions in excess of the amount designated by a Participant in order to adjust for mistakes in the
Company&#8217;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for
each Participant properly correspond with amounts withheld from the Participant&#8217;s Contributions; (iv)&nbsp;amend any outstanding Purchase Rights or clarify any ambiguities regarding the terms of any Offering to enable the Purchase Rights to
qualify under and/or comply with Section&nbsp;423 of the Code with respect to the 423 Component; and (v)&nbsp;establish other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan. The
actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase Rights granted under each Offering. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tax Qualification; Tax Withholding. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Although the Company may endeavor to (i)&nbsp;qualify a Purchase Right for special tax treatment under the laws of the United States
or jurisdictions outside of the United States or (ii)&nbsp;avoid adverse tax treatment, the Company makes no representation to that effect and expressly disavows any covenant to maintain special or to avoid unfavorable tax treatment, notwithstanding
anything to the contrary in this Plan.&nbsp;The Company will be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Each Participant will make arrangements, satisfactory to the Company and any applicable Related Corporation or Affiliate, to enable
the Company, the Related Corporation or the Affiliate to fulfill any withholding obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. Without limitation to the foregoing, in the Company&#8217;s sole discretion and subject to
Applicable Law, such withholding obligation may be satisfied in whole or in part by (i)&nbsp;withholding from the Participant&#8217;s salary or any other cash payment due to the Participant from the Company, a Related Corporation or an Affiliate;
(ii)&nbsp;withholding from the proceeds of the sale of shares of Common Stock acquired under the Plan, either through a voluntary sale or a mandatory sale arranged by the Company; or (iii)&nbsp;any other method deemed acceptable by the Board. The
Company shall not be required to issue any shares of Common Stock under the Plan until such obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The 423
Component is exempt from the application of Section&nbsp;409A of the Code, and any ambiguities herein shall be interpreted to so be exempt from Section&nbsp;409A of the Code. The <FONT STYLE="white-space:nowrap">Non-423</FONT> Component is intended
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be exempt from the application of Section&nbsp;409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent.
In furtherance of the foregoing and notwithstanding any provision in the Plan to the contrary, if the Committee determines that an option granted under the Plan may be subject to Section&nbsp;409A of the Code or that any provision in the Plan would
cause an option under the Plan to be subject to Section&nbsp;409A, the Committee may amend the terms of the Plan and/or of an outstanding option granted under the Plan, or take such other action the Committee determines is necessary or appropriate,
in each case, without the Participant&#8217;s consent, to exempt any outstanding option or future option that may be granted under the Plan from or to allow any such options to comply with Section&nbsp;409A of the Code, but only to the extent any
such amendments or action by the Committee would not violate Section&nbsp;409A of the Code. Notwithstanding the foregoing, the Company shall have no liability to a Participant or any other party if the option under the Plan that is intended to be
exempt from or compliant with Section&nbsp;409A of the Code is not so exempt or compliant or for any action taken by the Committee with respect thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will become effective immediately prior to and contingent upon the Effective Date. No Purchase Rights will
be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section&nbsp;12(a) above, materially amended) by
the Board. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common
Stock subject to Purchase Rights unless and until the Participant&#8217;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at
will nature of a Participant&#8217;s employment or amend a Participant&#8217;s employment or service contract, as applicable, or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ or
service of the Company, a Related Corporation or an Affiliate, or on the part of the Company, a Related Corporation or an Affiliate to continue the employment or service of a Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state&#8217;s conflict of
laws rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> If any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not
affect the other provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> If any provision of the Plan does not comply with Applicable Law, such provision shall be construed in such a manner as to comply
with Applicable Law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#8220;<B><I>423 Component</I></B>&#8221; means the part of the Plan, which excludes the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, pursuant to which Purchase Rights that satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#8220;<B><I>Affiliate</I></B>&#8221; means any entity, other than a Related
Corporation, whether now or subsequently established, which is at the time of determination, a &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may
determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#8220;<B><I>Applicable Law</I></B>&#8221; means the Code and any applicable U.S. and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities, exchange control, tax, federal, state, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing
rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of the New York Stock Exchange,
Nasdaq Stock Market or the Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#8220;<B><I>Board</I></B>&#8221;<I> </I>means the Board
of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#8220;<B><I>Capitalization Adjustment</I></B>&#8221; means any change that is made in, or other
events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or
other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#8220;<B><I>Code</I></B>&#8221;<I> </I>means
the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>
&#8220;<B><I>Committee</I></B>&#8221;<I> </I>means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#8220;<B><I>Common Stock</I></B>&#8221; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#8220;<B><I>Company</I></B>&#8221; means Candid Therapeutics, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>&#8220;Contributions</I></B>&#8221; means the payroll deductions, contributions made by Participants in case payroll
deductions are impermissible or problematic under Applicable Law and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional
payments into the Participant&#8217;s account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions or other
contributions and, with respect to the 423 Component, to the extent permitted by Section&nbsp;423. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#8220;<B><I>Corporate
Transaction</I></B>&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the
consolidated assets of the Company and its subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or other disposition of more than 50% of the outstanding
securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the Company is not the surviving
corporation; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is
the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property,
whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#8220;<B><I>Designated 423 Company</I></B>&#8221; means any Related
Corporation selected by the Board as participating in the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#8220;<B><I>Designated Company</I></B>&#8221;<B>
</B>means any Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Company or Designated 423 Company, provided, however, that at any given time, a Related Corporation participating in the 423 Component shall not be a Related Corporation
participating in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#8220;<B><I>Designated <FONT
STYLE="white-space:nowrap">Non-423</FONT> Company</I></B>&#8221; means any Related Corporation or Affiliate selected by the Board as participating in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#8220;<B><I>Director</I></B>&#8221;<I> </I>means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#8220;<B><I>Effective Date</I></B>&#8221; means the effective date of this Plan, which is [&#8195;&#8195;&#8195;], 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#8220;<B><I>Eligible Employee</I></B>&#8221;<I> </I>means an Employee who meets the requirements set forth in the document(s)
governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#8220;<B><I>Employee</I></B>&#8221;<I> </I>means any person, including an Officer or Director, who is &#8220;employed&#8221; for
purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation or solely with respect to the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Affiliate. However, service solely as a Director, or payment of a fee
for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B>
&#8220;<B><I>Employee Stock Purchase Plan</I></B>&#8221;<I> </I>means a plan that grants Purchase Rights intended to be options issued under an &#8220;employee stock purchase plan,&#8221; as that term is defined in Section&nbsp;423(b) of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#8220;<B><I>Exchange Act</I></B>&#8221;<I> </I>means the U.S. Securities Exchange Act of 1934, as amended and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#8220;<B><I>Fair Market Value</I></B>&#8221; means, as of any date, the value of the
Common Stock determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any
established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the <B><U>closing sales price</U></B> for such stock as quoted on such exchange or market (or the exchange or market with the
greatest volume of trading in the Common Stock) <B><U>on the date of determination</U></B>, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on
the date of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in
compliance with Applicable Laws and regulations and, to the extent applicable as determined in the sole discretion of the Board, in a manner that complies with Sections 409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#8220;<B><I>Fully Diluted Shares</I></B>&#8221; means, as of any date, all of the common stock of the Company outstanding plus all
shares of common stock of the Company issuable upon conversion or exercise of outstanding securities and rights, including (without limitation) preferred stock on an as-converted basis, equity awards, warrants (including pre-funded warrants), and
any convertible indebtedness or similar instruments, whether or not then vested or currently exercisable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#8220;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#8221; means any:
(i)&nbsp;nation, state, commonwealth, canton, province, territory, county, municipality, district or other jurisdiction of any nature; (ii)&nbsp;U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state, local, municipal or other
government; (iii)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund,
foundation, center, organization, unit, body or entity and any court or other tribunal, and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority; or (iv)&nbsp;self-regulatory organization (including the
New York Stock Exchange, the Nasdaq Stock Market and the Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#8220;<B><I><FONT
STYLE="white-space:nowrap">Non-423</FONT> Component</I></B>&#8221; means the part of the Plan, which excludes the 423 Component, pursuant to which Purchase Rights that are not intended to satisfy the requirements for an Employee Stock Purchase Plan
may be granted to Eligible Employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#8220;<B><I>Offering</I></B>&#8221;<I> </I>means the grant to Eligible Employees of
Purchase Rights, with the exercise of those Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#8220;<B><I>Offering Document</I></B>&#8221;
approved by the Board for that Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#8220;<B><I>Offering Date</I></B>&#8221; means a date selected by the Board for an
Offering to commence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#8220;<B><I>Officer</I></B>&#8221;<B> </B>means<B> </B>a person who is an officer of the Company or a
Related Corporation within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#8220;<B><I>Participant</I></B>&#8221;<I>
</I>means an Eligible Employee who holds an outstanding Purchase Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#8220;<B><I>Plan</I></B>&#8221;<I> </I>means this
Candid Therapeutics, Inc. 2026 Employee Stock Purchase Plan, as amended from time to time, including both the 423 Component and the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#8220;<B><I>Purchase Date</I></B>&#8221;<I> </I>means one or more dates during an Offering selected by the Board on which
Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#8220;<B><I>Purchase Period</I></B>&#8221; means a period of time specified within an Offering, generally beginning on the
Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#8220;<B><I>Purchase Right</I></B>&#8221;<I> </I>means an option to purchase shares of Common Stock granted pursuant to the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#8220;<B><I>Related Corporation</I></B>&#8221;<I> </I>means any &#8220;parent corporation&#8221; or &#8220;subsidiary
corporation&#8221; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#8220;<B><I>Securities Act</I></B>&#8221;<I> </I>means the U.S. Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#8221; means any income tax, social insurance,
payroll tax, fringe benefit tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items arising out of or in relation to a Participant&#8217;s participation in the Plan, including, but not limited to, the exercise of a
Purchase Right and the receipt of shares of Common Stock or the sale or other disposition of shares of Common Stock acquired under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#8220;<B><I>Trading Day</I></B>&#8221;<B> </B>means any day on which the exchange(s) or market(s) on which shares of Common Stock
are listed, including but not limited to the New York Stock Exchange, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc109079_57"></A>Annex N </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:11pt">


<IMG SRC="g109079g20k00.jpg" ALT="LOGO" STYLE="width:0.368557in;height:0.657425in;">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:14pt; font-size:6pt; font-family:Times New Roman"><I>RALLYBIO CORPORATION </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:14pt; font-size:6pt; font-family:Times New Roman"><I>234 CHURCH STREET </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:14pt; font-size:6pt; font-family:Times New Roman"><I>NEW HAVEN, CT 06510 </I></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:10pt">


<IMG SRC="g109079g10k00.jpg" ALT="LOGO" STYLE="width:2.29142in;height:0.58in;">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><B>VOTE BY INTERNET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><I></I><B><U></U></B><I>Before The Meeting </I>- Go to <U><B>www.proxyvote.com</B></U> <B>or scan the QR Barcode above </B> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time
&#8195;&#8195;&#8195;&#8195;&#8195;, 2026. Have your proxy card in hand when you access the website and follow the instructions to obtain your records and to create an electronic voting instruction form. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><I></I><B><U></U></B><I>During The Meeting </I>- Go to <B><U>www.virtualshareholdermeeting.com/RLYB2026</U></B> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and
follow the instructions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><B>VOTE BY PHONE -
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-690-6903</FONT></FONT></FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">Use any
touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time &#8195;&#8195;&#8195;&#8195;&#8195;, 2026. Have your proxy card in hand when you call and then follow the instructions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><B>VOTE BY MAIL</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">Mark, sign and date your proxy card and
return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">TO VOTE, MARK BLOCKS BELOW IN BLUE OR
BLACK INK AS FOLLOWS: </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="right" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px dashed #000000;">V89690-[TBD] &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; KEEP THIS PORTION FOR YOUR RECORDS &#8201;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">DETACH AND RETURN THIS PORTION ONLY &#8201; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 2.00pt;border-radius:10pt; background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:3%; font-size:7pt; font-family:Times New Roman"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="89%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="9"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"> &#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" COLSPAN="3"><B>The Board of Directors recommends you vote FOR the</B><B><BR></B><B>following proposals and FOR each of the nominees:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Abstain</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="font-size:7pt">1.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:7pt">To approve the issuance of shares of Rallybio Common Stock to the securityholders of Candid, pursuant to the terms of the Merger Agreement, which will (a) represent more than 20% of the shares of
Rallybio Common Stock outstanding immediately prior to the Merger and (b) result in the change of control of Rallybio, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="font-size:7pt">2.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:7pt">To approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to effect a reverse stock split of Rallybio&#8217;s issued and outstanding common stock at a ratio in the
range from 1-for-2 to 1-for-3, inclusive, with the final ratio to be mutually agreed to by Rallybio.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="font-size:7pt">3.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:7pt">To approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to change the name of Rallybio to &#8220;Candid Therapeutics, Inc.&#8221;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="font-size:7pt">4.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:7pt">To approve an amendment to Rallybio&#8217;s amended and restated certificate of incorporation to increase the number of authorized shares of Rallybio Common Stock from 200,000,000 shares to 500,000,000
shares.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD></TR>
</TABLE></DIV> </DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="23"></TD>
<TD HEIGHT="23" COLSPAN="2"></TD>
<TD HEIGHT="23" COLSPAN="2" STYLE="BORDER-TOP:2.50pt solid #000000; BORDER-RIGHT:2.50pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="23" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:2.50pt solid #000000;"><FONT STYLE="font-size:10pt">&#8195;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:7pt">5.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.43em; margin-right:8.57em; font-size:7pt; font-family:Times New Roman">To elect three Class II directors, each for a three-year term and until their successors are
duly elected and qualified or until their earlier death, resignation or removal.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Nominees:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Abstain</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; margin-right:0.71em; font-size:7pt; font-family:Times New Roman">5a. Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; margin-right:0.71em; font-size:7pt; font-family:Times New Roman">5b. Lucian Iancovici</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; margin-right:0.71em; font-size:7pt; font-family:Times New Roman">5c. Christine A. Nash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman">6.&#8194;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; margin-right:0.71em; font-size:7pt; font-family:Times New Roman">To ratify the selection of Deloitte
&amp; Touche LLP independent registered public accounting firm for Rallybio for the fiscal year ending December 31, 2026.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman">7.&#8194;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; margin-right:0.71em; font-size:7pt; font-family:Times New Roman">To approve the 2026 Plan, which will
become effective on the date immediately following the consummation of the Merger and is contingent on the completion of the Merger.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman">8.&#8194;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; margin-right:0.71em; font-size:7pt; font-family:Times New Roman">To approve the 2026 ESPP, which will
become effective on the date immediately following the consummation of the Merger and is contingent on the completion of the Merger.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman">9.&#8194;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; margin-right:0.71em; font-size:7pt; font-family:Times New Roman">To approve an adjournment of the
Rallybio annual meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1, Proposal 2, Proposal 3 and/or Proposal 4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9">Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must
sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="font-size:12pt">&#8195;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:2.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:2.00pt solid #000000;"><FONT STYLE="font-size:12pt">&#8195;&#8195;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:2.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:2.00pt solid #000000;"><FONT STYLE="font-size:12pt">&#8195;&#8195;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:2.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:2.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:2.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:2.00pt solid #000000;"><FONT STYLE="font-size:12pt">&#8195;&#8195;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="3"></TD>
<TD HEIGHT="3" COLSPAN="2"></TD>
<TD HEIGHT="3" COLSPAN="2"></TD>
<TD HEIGHT="3" COLSPAN="2"></TD>
<TD HEIGHT="3" COLSPAN="2"></TD>
<TD HEIGHT="3" COLSPAN="2"></TD>
<TD HEIGHT="3" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:4pt ;">Signature [PLEASE SIGN WITHIN BOX]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:4pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.71em; font-size:7pt; font-family:Times New Roman">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:4pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.86em; font-size:7pt; font-family:Times New Roman">Signature (Joint Owners)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:4pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.71em; font-size:7pt; font-family:Times New Roman">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> </div>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The Proxy Statement and Prospectus are available at www.proxyvote.com. </P>
<P STYLE="font-size:172pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1px; ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px dashed #000000;"><FONT STYLE="font-size:7pt">&#8195;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">V89691-[TBD]&#8195;&#8195; </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 2.50pt;border-radius:10pt; background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:14pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL MEETING
OF STOCKHOLDERS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;&#8195;, 2026 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; margin-right:3%; font-size:10pt; font-family:Times New Roman">The stockholders hereby appoint Stephen Uden and Jonathan Lieber, or either of them, as proxies, each with the power to
appoint his substitute, and hereby authorizes them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of Common Stock of Rallybio Corporation that the stockholders are entitled to vote at the Annual Meeting
of Stockholders to be held at &#8195;&#8195;, Eastern Time on &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, virtually at www.virtualshareholdermeeting.com/RLYB2026, and any adjournment or postponement thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; margin-right:3%; font-size:10pt; font-family:Times New Roman"><B>THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE STOCKHOLDERS. IF NO SUCH DIRECTIONS ARE MADE, THIS
PROXY WILL BE VOTED IN ACCORDANCE WITH THE RECOMMENDATION OF THE BOARD OF DIRECTORS OF RALLYBIO CORPORATION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; margin-right:3%; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR VOTE IS VERY IMPORTANT. PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD PROMPTLY USING THE ENCLOSED
REPLY ENVELOPE OR SUBMIT YOUR PROXY OVER THE INTERNET OR BY TELEPHONE BY FOLLOWING THE INSTRUCTIONS SET FORTH ON THE ENCLOSED PROXY CARD. </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; padding-bottom:14pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINUED AND TO BE SIGNED ON REVERSE SIDE</B> </P></div>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc109079_57a"></A>ANNEX O </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 262 OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL CORPORATION LAW OF THE STATE OF DELAWARE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPRAISAL RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Any stockholder of a corporations of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&nbsp;of
this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has otherwise complied with subsection (d)&nbsp;of this
section and who has neither voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of
Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&nbsp;and (c) of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in
a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an
interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in
voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Appraisal rights shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing
corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g) of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256,
&#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title (other than, in each case and solely with respect to a converted or domesticated corporation, a merger, consolidation, conversion, transfer, domestication or
continuance authorized pursuant to and in accordance with the provisions of &#167; 265 or &#167; 388 of this title): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Provided, however, that no
appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the
meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for the conversion,
transfer, domestication or continuance (or, in the case of a merger pursuant to &#167; 251(h) of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&nbsp;listed on a national securities exchange or
(ii)&nbsp;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote
of the stockholders of the surviving corporation as provided in &#167; 251(f) of this title. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Notwithstanding paragraph (b)(1) of this section,
appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation if the holders thereof are required by the terms of an
agreement of merger or consolidation, or by the terms of a resolution providing for conversion, transfer, domestication or continuance, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263,
&#167; 264, &#167; 266 or &#167; 390 of this title to accept for such stock anything except: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a. Shares of stock of the corporation surviving or resulting
from such merger or consolidation, or of the converted entity or the entity resulting from a transfer, domestication or continuance if such entity is a corporation as a result of the conversion, transfer, domestication or continuance, or depository
receipts in respect thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository
receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation, conversion, transfer, domestication or continuance will be either listed on a national securities exchange or held of record by more than 2,000
holders; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">O-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs
(b)(2)a. and b. of this section; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional
depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) In the event all of the stock of a subsidiary Delaware
corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) [Repealed.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Any corporation may provide in its
certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the
corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title or a transfer, domestication or continuance effected pursuant to &#167; 390
of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&nbsp;of this section, shall apply as nearly as is practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Appraisal rights shall be perfected as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) If a
proposed merger, consolidation, conversion, transfer, domestication or continuance for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior
to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c) of this title) with respect to shares for which appraisal rights
are available pursuant to subsection (b)&nbsp;or (c) of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting, transferring, domesticating or continuing corporation, and shall
include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly
available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to
the corporation, before the taking of the vote on the merger, consolidation, conversion, transfer, domestication or continuance, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the
corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the
stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation, conversion, transfer, domestication or continuance shall not constitute such a
demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger, consolidation, conversion, transfer, domestication or continuance, the surviving,
resulting or converted entity shall notify each stockholder of each constituent or converting, transferring, domesticating or continuing corporation who has complied with this subsection and has not voted in favor of or consented to the merger,
consolidation, conversion, transfer, domestication or continuance, and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section, of the date that the merger, consolidation or conversion has become effective; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) If the merger, consolidation, conversion, transfer, domestication or continuance was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167;
267 of this title, then either a constituent, converting, transferring, domesticating or continuing corporation before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, or the surviving, resulting
or converted entity within 10 days after such effective date, shall notify each stockholder of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation who is entitled to appraisal rights of
the approval of the merger, consolidation, conversion, transfer, domestication or continuance and that appraisal rights are available for any or all shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">O-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of
the constituent corporations or the converting, transferring, domesticating or continuing corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic
resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation, conversion, transfer,
domestication or continuance, shall, also notify such stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance. Any stockholder entitled to appraisal rights may, within 20 days after the
date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, within the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days after the date of giving such notice,
demand in writing from the surviving, resulting or converted entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if
any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s
shares. If such notice did not notify stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, either (i)&nbsp;each such constituent corporation or the converting, transferring,
domesticating or continuing corporation shall send a second notice before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance notifying each of the holders of any class or series of stock of such
constituent, converting, transferring, domesticating or continuing corporation that are entitled to appraisal rights of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance or (ii)&nbsp;the surviving,
resulting or converted entity shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or,
in the case of a merger approved pursuant to &#167; 251(h) of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days following the sending of the first notice, such second notice
need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3) of
this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence
of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting, transferring, domesticating or continuing corporation may fix, in advance, a record date
that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the record date shall
be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding subsection (a)&nbsp;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in
writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1) or (2)&nbsp;of this section, as applicable; provided that (i)&nbsp;such beneficial owner continuously owns such shares through the effective date
of the merger, consolidation, conversion, transfer, domestication or continuance and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&nbsp;of this section and (ii)&nbsp;the demand made by
such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary
evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified
list required by subsection (f)&nbsp;of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) Within 120 days after the effective date of the merger, consolidation, conversion, transfer,
domestication or continuance, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&nbsp;and (d) of this section and who is otherwise entitled to appraisal rights, may commence an appraisal
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">O-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days
after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have
the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance. Within 120 days after the effective date of the merger, consolidation,
conversion, transfer, domestication or continuance, any person who has complied with the requirements of subsections (a)&nbsp;and (d) of this section, upon request given in writing (or by electronic transmission directed to an information processing
system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the
merger, consolidation, conversion, transfer, domestication or continuance (or, in the case of a merger approved pursuant to &#167; 251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d.
of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2) of this title)), and, in either case, with respect to which demands for appraisal have been
received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3) of this section, the record holder of such shares shall not be
considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10 days after such person&#8217;s request for such a statement is received by the surviving, resulting
or converted entity or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d)&nbsp;of this section, whichever is later. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon
such entity, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their
shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The
Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at
the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal
rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the
appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation, conversion, transfer, domestication or continuance the shares of
the class or series of stock of the constituent, converting, transferring, domesticating or continuing corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as
to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&nbsp;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&nbsp;the value of
the consideration provided in the merger, consolidation, conversion, transfer, domestication or continuance for such total number of shares exceeds $1&nbsp;million, or (3)&nbsp;the merger was approved pursuant to &#167; 253 or &#167; 267 of this
title. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of
the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation
of the merger, consolidation, conversion, transfer, domestication or continuance, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all
relevant factors. Unless the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">O-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation, conversion, transfer,
domestication or continuance through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between
the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to
appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and
(2)&nbsp;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to
trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&nbsp;of this section may
participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The
Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and
conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j) The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application
of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&nbsp;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order
all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to
subsection (k)&nbsp;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&nbsp;of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(k)
Subject to the remainder of this subsection, from and after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, no person who has demanded appraisal rights with respect to some or all of such
person&#8217;s shares as provided in subsection (d) of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to
stockholders of record at a date which is prior to the effective date of the merger, consolidation, conversion, transfer, domestication or continuance). If a person who has made a demand for an appraisal in accordance with this section shall deliver
to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&nbsp;of this section, either within 60 days
after such effective date or thereafter with the written approval of the corporation, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, an appraisal proceeding in the
Court of Chancery shall not be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including without limitation, a reservation of jurisdiction for any
application to the Court made under subsection (j)&nbsp;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to
withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance within 60 days after the effective date of the merger, consolidation, conversion,
transfer, domestication or continuance, as set forth in subsection (e)&nbsp;of this section. If a petition for an appraisal is not filed within the time provided in subsection (e)&nbsp;of this section, the right to appraisal with respect to all
shares shall cease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">O-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(l) The shares or other equity interests of the surviving, resulting or converted entity to which the shares
of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the
surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">O-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc109079_41"></A>INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><A NAME="toc109079_42"></A>Item&#8201;20. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted by Section&nbsp;102(b)(7) of the DGCL, Rallybio&#8217;s amended and restated certificate of incorporation includes a provision to eliminate the personal
liability of Rallybio&#8217;s directors for monetary damages for breach of their fiduciary duties as directors, subject to certain exceptions. In addition, Rallybio&#8217;s amended and restated certificate of incorporation and amended and restated
bylaws provide that Rallybio required to indemnify its officers and directors under certain circumstances, including those circumstances in which indemnification would otherwise be discretionary, and Rallybio is required to advance expenses to its
officers and directors as incurred in connection with proceedings against them for which they may be indemnified, in each case except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of
fiduciary duty. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;145(a) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to
be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was
a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person
reasonably believed to be in or not opposed to the best interest of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or
proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be
in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful. indemnification shall be made with respect to any claim, issue or
matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery (the &#8220;Court of Chancery&#8221;) or the court in which such action or suit was brought
shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other
court shall deem proper. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio has entered into indemnification agreements with its directors and certain of its officers. These indemnification agreements
provide broader indemnity rights than those provided under the DGCL and Rallybio&#8217;s amended and restated certificate of incorporation. These indemnification agreements are not intended to deny or otherwise limit third-party or derivative suits
against Rallybio or its directors or officers, but to the extent a director or officer were entitled to indemnity or contribution under the indemnification agreement, the financial burden of a third-party suit would be borne by Rallybio, and
Rallybio would not benefit from derivative recoveries against the director or officer. Such recoveries would accrue to Rallybio&#8217;s benefit but would be offset by Rallybio&#8217;s obligations to the director or officer under the indemnification
agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio maintains directors&#8217; and officers&#8217; liability insurance for the benefit of its directors and officers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Merger Agreement provides that, subject to certain limitations as set forth in the Merger Agreement, from the Effective Time through the sixth anniversary of the
date on which the Effective Time occurs, Rallybio and the Surviving Corporation will indemnify each person who is, has been at any time prior to the date of the Merger Agreement, or who becomes prior to the Effective Time, a director, officer,
fiduciary or agent of Rallybio or Candid or their respective subsidiaries. The Merger Agreement also provides that the provisions relating to the indemnification, advancement of expenses and exculpation of present and former directors and officers
of Rallybio or any of its subsidiaries set forth in the organizational documents of Rallybio or any of its subsidiaries will not be amended, modified or repealed for a period of six&nbsp;years from the Effective Time in any manner that would
adversely affect the rights of individuals who, at or prior to the Effective Time, were officers or directors of Rallybio or any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
subsidiaries, unless required by applicable law. After Closing, the organizational documents of the surviving corporation will contain provisions at least as favorable as the provisions relating
to the indemnification, advancement of expenses and exculpation of present and former directors and officers presently set forth in Rallybio&#8217;s organizational documents as of the date of the Merger Agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From and after the Effective Time, (i)&nbsp;the Surviving Corporation shall fulfill and honor in all respects the obligations of the Candid to each person who is or has
served as a director or officer of Candid as of immediately prior to the Closing pursuant to any indemnification provisions under Candid&#8217;s amended and restated certificate of incorporation and bylaws and pursuant to any indemnification
agreements between Candid and such directors and officers, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii)&nbsp;Rallybio shall fulfill and honor in all respects the obligations of Rallybio or any of
its subsidiaries to each person who is or has served as a director or officer of Rallybio as of immediately prior to the Closing pursuant to any indemnification provisions under Rallybio&#8217;s amended and restated certificate of incorporation and
amended and restated bylaws or any of its subsidiaries and pursuant to any indemnification agreements between Rallybio or any of its subsidiaries and such directors and officers, with respect to claims arising out of matters occurring at or prior to
the Effective Time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From the Effective Time through the sixth (6th) anniversary of the date on which the Effective Time occurs, Rallybio shall maintain
directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for companies similarly situated to Rallybio. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From and after the Effective Time, Rallybio shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by indemnified persons in connection
with their successful enforcement of the rights provided to such persons in the Merger Agreement. The director and officer indemnification provisions of the Merger Agreement are intended to be in addition to the rights otherwise available to the
current and former officers and directors of Rallybio and Candid by law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of such indemnified persons, their heirs and their
representatives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event Rallybio or the Surviving Corporation or any of their respective successors or assigns (i)&nbsp;consolidates with or merges into any
other person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii)&nbsp;transfers all or substantially all of its properties and assets to any person, then, and in each such case, proper
provision shall be made so that the successors and assigns of Rallybio or the Surviving Corporation, as the case may be, shall succeed to the indemnification obligations set forth in the Merger Agreement. Rallybio shall cause the Surviving
Corporation to perform all of the director and officer indemnification obligations of the Surviving Corporation under the Merger Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>In the event
Rallybio or the Surviving Corporation or any of their respective successors or assigns (i)&nbsp;consolidates with or merges into any other person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or
(ii)&nbsp;transfers all or substantially all of its properties and assets to any person, then, and in each such case, proper provision shall be made so that the successors and assigns of Rallybio or the Surviving Corporation, as the case may be,
shall succeed to the indemnification obligations set forth in the Merger Agreement. Rallybio shall cause the Surviving Corporation to perform all of the director and officer indemnification obligations of the Surviving Corporation under the Merger
Agreement. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><A NAME="toc109079_43"></A>Item&#8201;21. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Exhibit Index </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
list of exhibits filed with this registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> is set forth on the Exhibit&nbsp;Index and is incorporated herein by reference. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Financial Statements </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements filed with this registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> are set forth on the Financial Statement Index and
is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><A NAME="toc109079_44"></A>Item&#8201;22. Undertakings. </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">The registrant hereby undertakes: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration
statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with
the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration
Fee&#8221; table in the effective registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain
unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant
to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the
registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in
the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the
initial distribution of the securities, if a primary offering of securities of the undersigned registrant is deemed to occur pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser,
and if the securities are deemed to be offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such
purchaser: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed
pursuant to Rule 424; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or
referred to by the undersigned registrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">The portion of any other free writing prospectus relating to the offering containing material information about the
undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual
report pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in this
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part
of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration
form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other Items of the applicable form. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">That every prospectus (i)&nbsp;that is filed pursuant to paragraph (g)(1) of Item 512 of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> or (ii)&nbsp;that purports to meet the requirements of section 10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment
to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To respond to requests for information that is incorporated by reference into the prospectus pursuant to Items 4, 10(b),
11, or 13 of this form, within one business day of receipt of such request, and to send the incorporated documents by first-class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective
date of the registration statement through the date of responding to the request. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">j.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">To supply by means of a post-effective amendment all information concerning a transaction, and the company being
acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">k.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">2.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex21.htm">Form of Plan of Liquidation and Dissolution (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Registration Statement on Form
 <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22,&nbsp;2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">2.2+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429dex21.htm">Agreement and Plan of Merger and Reorganization among Rallybio Corporation, Farmington Merger Sub, Inc. and Candid Therapeutics, Inc., dated
 as of March&nbsp;1, 2026 (incorporated by reference to Exhibit&nbsp;2.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-40693), filed with the SEC on March&nbsp;2,&nbsp;2026) (included as Annex A to the proxy statement/prospectus)</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521233263/d211041dex31.htm">Amended and Restated Certificate of Incorporation of Rallybio Corporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s
 Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40693),</FONT> filed with the SEC on August&nbsp;2, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000173941026000010/rlyb-20260126xex.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Rallybio Corporation (incorporated by reference to
Exhibit 3.1 to the Company&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-40693),</FONT> filed with the SEC on January&nbsp;26, 2026). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">3.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521233263/d211041dex32.htm">Amended and Restated Bylaws of Rallybio Corporation (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form
 <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40693),</FONT> filed with the SEC on August&nbsp;2, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex41.htm">Specimen stock certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement
 on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">4.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312522284569/d407423dex41.htm">Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current
 Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40693),</FONT> filed with the SEC on November&nbsp;14, 2022) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">4.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000173941024000115/rlyb-20240630xex41.htm">Registration Rights Agreement, dated April&nbsp;10, 2024, by and between Rallybio Corporation and Johnson&nbsp;
&amp; Johnson Innovation - JJDC, Inc. (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-40693),</FONT> filed with the SEC on August&nbsp;8, 2024). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">5.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Opinion of Ropes&nbsp;&amp; Gray LLP, counsel of Rallybio Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.1#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex101.htm">Asset Purchase Agreement, by and between Rallybio IPA, LLC and Prophylix AS, dated June&nbsp;
28, 2019 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;
333-257655),</FONT> filed with the SEC on July&nbsp;2, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.2#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex102.htm">Asset Transfer Agreement, by and between Swedish Orphan Biovitrum AB (PUBL) and IPC Research, LLC, dated March&nbsp;
15, 2019 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> filed with the SEC on July&nbsp;
2, 2021).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.3#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex103.htm">Product License Agreement, by and between Affibody AB and Swedish Orphan Biovitrum AB (PUBL), dated March&nbsp;
9, 2012, and assigned to IPC Research, LLC on March&nbsp;
15, 2019 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> filed with the SEC on July&nbsp;
2, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.4#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex104.htm">Amendment No.&nbsp;1 to Product License Agreement, by and between Affibody AB and Swedish Orphan Biovitrum AB (PUBL), dated January&nbsp;
1, 2018, and assigned to IPC Research, LLC on March&nbsp;15, 2019 (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> <FONT STYLE="white-space:nowrap">(File&nbsp;
No.&nbsp;333-257655),</FONT> filed with the SEC on July&nbsp;2, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.5#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471dex105.htm">Amendment No.&nbsp;2 to Product License Agreement, by and between Affibody AB and IPC Research, LLC, dated December&nbsp;
22, 2020 (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> filed with the SEC on July&nbsp;
2, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.6#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000095017022015571/rlyb-ex10_1.htm">License Agreement, by and between Rallybio IPE, LLC and Kymab Limited, dated as of May&nbsp;
5, 2022 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-40693),</FONT> filed with the SEC on August&nbsp;
8, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.7&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex107.htm">Form of Indemnification Agreement, between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit
10.7 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1012.htm">Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement
 on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22, 2021). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.9&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1013.htm">Form of <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option Award Agreement under the Rallybio Corporation 2021 Equity Incentive
 Plan (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on
July&nbsp;22, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.10&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1014.htm"><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option Award Agreement for <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors
 under the Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1015.htm">Form of Incentive Stock Option Award Agreement under the Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit
 10.15 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.12&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1016.htm">Form of Restricted Stock Unit Award Agreement under the Rallybio Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit
 10.16 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.13&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1017.htm">Form of Restricted Stock Unit Award Agreement for <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors under the Rallybio Corporation
 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.17 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended,
filed with the SEC on July&nbsp;22,&nbsp;2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.14&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1018.htm">Rallybio Corporation 2021 Cash Incentive Plan (incorporated by reference to Exhibit 10.18 to the Company&#8217;s Registration Statement on
Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.15&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1019.htm">Rallybio Corporation 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.19 to the Company&#8217;s Registration Statement
 on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.16&#134;***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#b1">Proposed 2026 Equity Incentive Plan of Candid Therapeutics, Inc. (included as Annex L to the proxy statement/prospectus and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.17&#134;***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#b2">Proposed 2026 Employee Stock Purchase Plan of Candid Therapeutics, Inc. (included as Annex&nbsp;M to the proxy statement/prospectus and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.18&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000173941023000007/rlyb-20230630xex101.htm">Second Amended and Restated Employment Agreement, by and between Rallybio, LLC, Rallybio Corporation and Stephen Uden, dated August&nbsp;1,
 2023 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40693),</FONT> filed with the SEC on August&nbsp;8,
2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.19&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429dex106.htm">Amendment to Second Amended and Restated Employment Agreement, effective as of March&nbsp;
1, 2026, between Rallybio Corporation and Stephen Uden (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-40693),</FONT> filed with the SEC on March&nbsp;1, 2026). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.20&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000095017023006264/rlyb-ex10_24.htm">Employment Agreement between Rallybio Corporation and Jonathan I. Lieber, dated as of February&nbsp;
1, 2023 (incorporated by reference to Exhibit 10.24 to the Company&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-40693),</FONT> filed with the SEC on March&nbsp;
6, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.21&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429dex107.htm">Amendment to Employment Agreement, effective as of March&nbsp;
1, 2026, between Rallybio Corporation and Jonathan Lieber (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-40693),</FONT> filed with the SEC on March&nbsp;1, 2026). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.22&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000173941025000093/rlyb-20250625xex101.htm">Employment Agreement, by and between Rallybio, LLC, Rallybio Corporation and Steven Ryder, dated as of June&nbsp;
25, 2025 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40693),</FONT> filed with the SEC on June&nbsp;
27, 2025). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.23&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429dex108.htm">Amendment to Employment Agreement, effective as of March&nbsp;
1, 2026, between Rallybio Corporation and Steven Ryder (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-40693),</FONT> filed with the SEC on March&nbsp;1, 2026). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.24&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521221832/d99471dex1023.htm">Form of Equity Adjusted Notice (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655),</FONT> as amended, filed with the SEC on July&nbsp;22, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312522215079/d307857dex12.htm">Sales Agreement, dated as of August&nbsp;
8, 2022, between Rallybio Corporation and TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (incorporated by reference to Exhibit 1.2 to the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File
 <FONT STYLE="white-space:nowrap">No.&nbsp;333-266668),</FONT> filed with the SEC on August&nbsp;8, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000173941025000041/rlyb-20250313xex11.htm">Amendment No.&nbsp;1 to Sales Agreement, dated March&nbsp;
13, 2025, by and between Rallybio Corporation and TD Securities (USA) LLC (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40693),
</FONT> filed with the SEC on March&nbsp;13, 2025). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.27#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000173941025000132/rlyb-20250930xex101.htm">Membership Interest Purchase Agreement, dated July&nbsp;
8, 2025, by and among Recursion Pharmaceuticals, Inc., Exscientia Ventures I, Inc., Rallybio Corporation and Rallybio IPB, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q
</FONT> <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-40693),</FONT> filed with the SEC on November&nbsp;6, 2025). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.28***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1028.htm">Form of Indemnification Agreement, by and between Candid Therapeutics, Inc. and each of its directors and executive officers.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.29***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1029.htm">Candid Therapeutics, Inc. 2024 Equity Incentive Plan, as amended, and Forms of Restricted Stock Award Grant Notice, Stock Option Grant
 Notice, Early Exercise Stock Purchase Agreement, Option Agreement and Notice of Exercise thereunder. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.30***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1030.htm">Form of Common Stock Purchase Agreement, by and between Candid Therapeutics, Inc. and Purchaser. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.31***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1031.htm">Offer Letter Agreement, dated July&nbsp;1, 2024, by and between Candid Therapeutics, Inc. and Ken Song, M.D. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.32***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1032.htm">Offer Letter Agreement, dated July&nbsp;12, 2024, by and between Candid Therapeutics, Inc. and Bernie&nbsp;Huyghe, Ph.D.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.33***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1033.htm">Offer Letter Agreement, dated July&nbsp;17, 2024, by and between Candid Therapeutics, Inc. and Tim Lu, M.D., Ph.D. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.34***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1034.htm">Offer Letter Agreement, dated July&nbsp;23, 2024, by and between Candid Therapeutics, Inc. and Arvind&nbsp;Kush. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.35***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1035.htm">License Agreement, dated August&nbsp;
2, 2024, by and between Candid Therapeutics, Inc. (as successor in interest to TRC 2004, Inc.) and Genor Biopharma Co Ltd., as amended. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.36***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1036.htm">License and Collaboration Agreement, dated August&nbsp;
5, 2024, by and between the Registrant (as successor in interest to FL2024-005, Inc.) and Shanghai EpimAb Biotherapeutics Co., Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.37***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1037.htm">Office Lease Agreement, dated June&nbsp;27, 2024, by and between the Registrant and Pacific North Court Holdings, L.P.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.38***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dex1038.htm">License Agreement, dated January&nbsp;2, 2025, by and between Candid Therapeutics, Inc. and Wuxi&nbsp;
Biologics (Shanghai) Co., Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.39***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#a1">Form of Subscription Agreement, dated March 1, 2026, by and among Candid Therapeutics, Inc. and the Purchasers party thereto (included as Annex G to the proxy statement/prospectus). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">10.40***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#a2">Form of Registration Rights Agreement, by and among Candid Therapeutics, Inc. and the Purchasers party thereto (included as Annex H to the proxy statement/prospectus). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000173941024000035/rlyb-20231223xex211.htm">Subsidiaries of Registrant (incorporated by reference to Exhibit 21.1 to the Company&#8217;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40693),</FONT> filed with the SEC on March&nbsp;12, 2024). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d109079dex231.htm">Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm of Rallybio Corporation. </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d109079dex232.htm">Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm of Candid Therapeutics, Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">23.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d109079dex233.htm">Consent of Deloitte &amp; Touche LLP, independent registered public accounting firm of Vignette Bio, Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">23.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d109079dex234.htm">Consent of Deloitte &amp; Touche LLP, independent registered public accounting firm of TRC 2004, Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">23.5**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consent of Ropes &amp; Gray LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">99.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d109079dex991.htm">Consent of Citizens JMP Securities, LLC.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">99.2***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079ds4.htm#annxi">Proposed form of Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Rallybio Corporation to Provide
 for the Reverse Stock Split (included as Annex I to the proxy statement/prospectus). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">99.3***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079ds4.htm#annxj">Proposed form of Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Rallybio Corporation to Provide
 for the Name Change (included as Annex J to the proxy statement/prospectus).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">99.4***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079ds4.htm#annxk">Proposed form of Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Rallybio Corporation to Provide
 for the Authorized Share Increase (included as Annex K to the proxy statement/prospectus). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">101.INS***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">101.SCH***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inline XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">101.CAL***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inline XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">101.DEF***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inline XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">101.LAB***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inline XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">101.PRE***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inline XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">107***</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312526108699/d109079dexfilingfees.htm">Filing Fee Table </A></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Filed herewith. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">**</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">***</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">#</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been redacted because they are both not material and the registrant customarily and actually treats such information as private or confidential. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">+</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The annexes, schedules and/or certain exhibits to this agreement have been omitted pursuant to Item 601(b)(2) or Item 601(a)(5) of Regulation S-K. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of New Haven, Connecticut, on April&nbsp;24, 2026. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt"><B>RALLYBIO CORPORATION</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Stephen Uden</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Stephen Uden and
Jonathan I. Lieber, and each of them individually, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, with full powers of substitution and resubstitution, for him
or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments and any related registration statements filed pursuant to Rule 462 and
otherwise), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent and full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as
fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, or any substitute or
resubstitute, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration
statement has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Stephen Uden</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Chief Executive Officer, President and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Stephen Uden, M.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Jonathan I. Lieber</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Chief Financial Officer and Treasurer <I>(Principal Accounting and Financial Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Jonathan I. Lieber</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Martin W. Mackay, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Helen M. Boudreau</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Wendy K Chung, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Robert Hopfner, R.Ph., Ph.D., MBA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Ronald M. Hunt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Lucian Iancovici, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Hui Liu, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Christine A. Nash, MBA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;24, 2026</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">Paula Soteropoulos</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">/s/ Stephen Uden</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom">Attorney-in-Fact</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d109079dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement No. 333-294361 on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of our report dated March&nbsp;16,
2026, relating to the financial statements of Rallybio Corporation. We also consent to the reference to us under the heading &#8220;Experts&#8221; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford, Connecticut </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;24, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>d109079dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement No.&nbsp;333-294361 on Form&nbsp;S-4 of our report dated March&nbsp;16, 2026, relating to the financial
statements of Candid Therapeutics, Inc. We also consent to the reference to us under the heading &#8220;Experts&#8221; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;24, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>4
<FILENAME>d109079dex233.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;23.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement No.&nbsp;333-294361&nbsp;on Form&nbsp;S-4 of our report dated March&nbsp;16, 2026, relating to the
financial statements of Vignette Bio, Inc. We also consent to the reference to us under the heading &#8220;Experts&#8221; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;24, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.4
<SEQUENCE>5
<FILENAME>d109079dex234.htm
<DESCRIPTION>EX-23.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement No.&nbsp;333-294361 on Form&nbsp;S-4 of our report dated March&nbsp;16, 2026, relating to the financial
statements of TRC 2004, Inc. We also consent to the reference to us under the heading &#8220;Experts&#8221; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte
&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;24, 2026
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>d109079dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF CITIZENS JMP SECURITIES, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
hereby consent to the use of our opinion letter, dated March 1, 2026, to the Board of Directors of Rallybio Corporation, included as Annex B to the proxy statement / prospectus which forms a part of the Registration Statement on Form&nbsp;S-4 of
Rallybio Corporation, to be filed on the date hereof, and to the references to such opinion in such proxy statement / prospectus under the captions: &#8220;Prospectus Summary &#8211; Opinion of Citizens JMP Securities, LLC,&#8221; &#8220;The Merger
&#8211; Background of the Merger&#8221; and &#8220;The Merger &#8211; Opinion of Opinion of Citizens JMP Securities, LLC (Rallybio&#8217;s Financial Advisor).&#8220; In giving such consent, we do not admit that we come within the category of persons
whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder, nor do we thereby admit that we are experts with respect to any part of such
Registration Statement within the meaning of the term &#8220;expert&#8221; as used in the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder. Additionally, such consent does not
cover any amendments to the Registration Statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:55%; text-indent:-2%">


<IMG SRC="g109079sig.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">New York, New York </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">April&nbsp;24, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g109079g00d17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00d17.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1AN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &%$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ-25ZM54RS3@\!WG*W?G+:/UJ_T..?!CKCF8A]'"\3EOEK6UNB])H:M>2?\
MUNZ\')'ZHWF[7SW=>B/U2GI\%OB!\&V'K[I3#>;M?/=UZ(_5&\W:^>[KT1^J
M4\#;!NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]
M$?JE/ VP;I3#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YNU\]W7HC]4;S=KY
M[NO1'ZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5&\
MW:^>[KT1^J4\#;!NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/
MU1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YNU\]W
M7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U3ZFAJUJJ)[MW7HC]4IQ];\)/
M&-D&Z7YU3 %-OMNL'NK7^UD@U]T[37SU$7DRXS>UT-6M%5/=NZ[/!'ZIYT_\
M0S_LO_$TJ[_A.\9(K"[I2_>;M?/=UZ(_5&\W:^>[KT1^J4\%VPFZ4PWF[7SW
M=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YN
MU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3
M#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L
M&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5&\W:^>[KT1^J4
M\#;!NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]$
M?JE/ VP;I3#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YJU\]W7HC]4TJAT?4
ML^E"LL3KK<$I8:994D34UE75C7DR_24_0J<)+K3\O%S^Q+_!$2:PL6E]WF[7
MSW=>B/U1O-VOGNZ]$?JE/!=L)NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4P
MWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!
MNE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/
M VP;I3#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YNU\]W7HC]4;S=KY[NO1'
MZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5&\W:^>[
MKT1^J4\#;!NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U1O-V
MOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5.R#0S:WRM;[MW5,_!'ZI2SNI/\0SQB:Q
MHL6E^;-$F J?$J7A*NZ5\24TNJU(]7;L3AS0W[>;M?/=UZ(_5/'['G@Q)^O_
M *(5LE:Q,+-IU3#>;M?/=UZ(_5&\W:^>[KT1^J4\%VPSNE,-YNU\]W7HC]4;
MS=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(
M_5&\W:^>[KT1^J4\#;!NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW
M=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YN
MU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3
M#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L
M&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I2Z70Y;&1/<E[NN:)GP1^J:7HIT
M>4N)+9=JBLNMPB=!7.@:D>IM1&-7-<TX=I^@I_\ #R_5)G['_P#-^_?M5W\M
MA)K&L+%ITDWF[7SW=>B/U1O-VOGNZ]$?JE/!=L)NE,-YNU\]W7HC]4;S=KY[
MNO1'ZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5&\W
M:^>[KT1^J4\#;!NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U
M1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YNU\]W7
MHC]4;S=KY[NO1'ZI3P-L&Z4PWF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?
M/=UZ(_5&\W:^>[KT1^J4\#;!NE,-YNU\]W7HC]4;S=KY[NO1'ZI3P-L&Z4PW
MF[7SW=>B/U1O-VOGNZ]$?JE/ VP;I3#>;M?/=UZ(_5,!C[1?0V3!]QN5->+E
M)+!J9-?J9+F[+B0MQJ.EWY-KU_Z?\9+5B(:K:=7Y3M;ZN:@B>ZOJ$56IL3+D
M\1ZLJKZ?4?=U'GLG^60_53\$/:>I7A\<UC^+P+\5FBTQN=655]/J/NZAE5?3
MZC[NH[0:Y?%[6>;S>Z75E5?3ZC[NH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[N
MH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[NH957T^H^[J.T#E\7M.;S>Z75E5?3
MZC[NH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[NH957T^H^[J.T#E\7M.;S>Z75
ME5?3ZC[NH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[NH957T^H^[J.T#E\7M.;S
M>Z75E5?3ZC[NH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[NH957T^H^[J.T#E\7
MM.;S>Z75E5?3ZC[NH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[NH957T^H^[J.T
M#E\7M.;S>Z75E5?3ZC[NH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[NH957T^H^
M[J.T#E\7M.;S>Z75E5?3ZC[NH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[NH957
MT^H^[J.T#E\7M.;S>Z75E5?3ZC[NH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[N
MH957T^H^[J.T#E\7M.;S>Z75E5?3ZC[NH9562_\ 7U'W=1VA>!?$.7Q>TYO-
M[I:+<ZJK2OG1:J5>VX5R!U73_,)_K \:\1%IA^BQS,TB9_#:\.?Y>GUC*&+P
MY_EZ?6,H>U@^W5^<XG[UOV  ZN                           /CO@KXC
M'6/XN?\ 6._B4R+O@KXC'6/XN?\ 6._B4Y6\]?[=Z?;O_3)  ZN
M                                  !RMWYRVC]:O]#B<K=^<MH_6K_0
MX<3]J?\ >KZN"^_7_>C]DI\%OB 3X+?$#S7N
M      ?6_"3QGP^M^$GC E"?^(9_V7_B:5=_PG>,E"?^(9_V7_B:5=_PG>,D
M$O@ *                             #ZG"2ZT_+Q<_L2_P $144X276G
MY>+G]B7^"(DK"H  J                              =U)_B&>,Z3NI/
M\0SQDGLL(]['G@Q)^O\ Z(5LDGL>>#$GZ_\ HA6R5[%NX #2
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MNK\[Q/WK?L !U<      !]1KG? 8]WU6YC4D[C+Y"@? ./)45%Y%X0
M  BHO N8        'QWP5\1CK'\7/^L=_$ID7?!7Q&.L?Q<_ZQW\2G*WGK_;
MO3[=_P"F2 !U<                                           #E;O
MSEM'ZU?Z'$Y6[\Y;1^M7^APXG[4_[U?5P7WZ_P"]'[)3X+?$ GP6^('FO<
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MC)/981[V//!B3]?_ $0K9)/8\\&)/U_]$*V2O8MW  :0
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M_6K_ $.)RMWYRVC]:O\ 0X<3]J?]ZOJX+[]?]Z/V2GP6^(!/@M\0/->X
M                         !];\)/&?#ZWX2>,"4)_XAG_ &7_ (FE7?\
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MSP8D_7_T0K9)/8\\&)/U_P#1"MDKV+=P &D
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M-(=4ZVQK)5OD>R-.155R9\"\I[K[><7X4N4-1=:A)&RIKZB,:B;<]F>J(O\
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M>'/\O3ZQE#V<'VZOSO$_>M^P&1P]:*B^WBGM](B++,J\*Y;$157[D4O=5AS
M^C^UTZ8@BCJ9Y,LUFB;)FJIQ=KP=JHR9HI,1WE</#SEB;:Z1'K+\YY@_1MKM
MF ,>TU11V6FAIZEJ*N<,#8W)^_5\*$-QC8)L-XEJK3(NN^-R(S)<\T<U')R<
M3D)CS1>9KII)FX:<58O$ZQ/K#" W"WZ-,67"DCJ:6VZT,C4<U==NU%3-./PF
M$Q#AZZ8<J607FFW"1Z9M3-%SX4XE\"G2,E9G2)<[8KUC=:LQ#% V*GP3B"IL
MC+O!1:]O>BN;)K-VHF?A\"GN?HSQ9'0K6/MN5.D>ZJ[7;\'+//AY"?4I'J1A
MR3VK+3P<TBD6=8$:N[(_4U?#GD;9O98N?0^V66Q5B5NLBZ[>#I+-ZU[SHE:6
MOY8U:@<V12/:KF1O<U.%R-54Z2VXJPS;*+0[!7);J>*X9/UI4C:C^"3+:B9\
M2'@T=5EP71O71TV'XZJ!89,ZEK6;$[?-5S<B[-O%Q''F-:[HCUT?3RDQ?9,^
MFJ/ ]]CL]??KFM#:8-VJ7*JZN:)EEFO'XE-_PCHWO=NQ+1RXCM35MSE5KD>K
M7-5<EXLU.M\E:=Y<,>&^3RQT_*8@JOL@++;K+<[:RUT<%*Q\6;DBC1F:YKR(
M:C8L XEOM&E7;+>LD"KDCE>U/ZDIEK:D7GHM\%ZY)QQ&LQ^&L SV),(7S#4;
M)+S1K"Q_P5UD7C1.)?"A5]$.C9M1:IZG$EO8Y)EUJ=SD8[-JHF2[47PDOFI2
MN[5<7#WR7V::2A0-HQUA&YX9K99:ZEW"CD?E"N:+FG[CC8<!XDOU&E5:Z!98
M%X'*]J<:IR^!37U*[=VO1CZ5]VS3JUD&;Q'A6]8;=&EYI%@U]K5UD7\%,(:B
M8M&L,VK-9TM&CX[X*^(QUC^+G_6._B4R+O@KXC'6/XN?]8[^)3G;SU_MUI]N
M_P#3)  ZN ;WH5OL-AQJQ]4B[G4MW-%SX%R5/ZFB!,T5%15147-%3B4S>L7K
M-9]6\=YQVB\>B[Z<L$7.[W."[V>)*F-S$8YJ.1%3AV[5\)@M&>BNKN%?+-B6
MGW"C8U=5NNU=9<VY<"\BJ8##^E3$EDI&T\4L53&Q,F^V5>]43+++X2<AW7K2
MWB6ZT;Z=SX*9KN%U/NC'=.NI\L4S5K].-/V^V<G#6O\ 5G77\,W8Z&U6S3C2
M4=D?K4T2-15\*ZB_U4X>R$M=8N,V7!(%]IHR-NZ9[,]B$PM]PJK?<XKA33/;
M5QO1Z2:RYJJ+GM5-O$;=B/2;>\0V1;7<(Z3<%5JJ]K7ZZJU45-JN7DY#?TKU
MR1:.O31B,^.^*U+=-9UC12-*GR'V?[#3?A$9BW)_^$*K[)U$3OF/+I>L,4]B
MJXZ9*.")D+7,:Y'Y-U<LU5RI^BG$>F'21>8L,OL38J3VFZ/<U<K7:V7CULON
M.7+WVQ'SJ^CF\?U)M\:-L]C8B)?JW+YKCC9_E]J_UO\ ['&A8,Q=<,)54L]L
M9 ]\B*B[JURI]RH?*;%MPI\5R8A8R#V\]VLK5:[4X%3@SSX^4ZVQ6F]K?F'S
MTSTC'2L]XG56-)DS*?3-A^654:QJ)FJ_4>AU^R$PY<;I<[=74$"U,#8MS5&J
MG#FY24XPQ57XKN,==<6PQSQHB-W%%1-GC538K'I:Q)::)E,UU/4L8F2.J$>]
MW\:&(PWIMM7O#K;B<63?2W:9UU>:]Z.+W9L*+=JZNW.!$<OM97<&2.7+X7'J
M\G&4K!UJMV'=&D&(&4,E?621(JQJJ.3->#8J+P9DDQAC>\XL1K;G*UL+5SW*
M)7(Q=F7 KE_^*>[">DJ_8:MWM&D=#/3)\%M0CW:J;=B9.3+A-7QY;TZ]]6,6
M;!CO.V)TT[]UMT47BZWJ&NJ:^U4]!2.C_)+'&UCG>!43;P<IHNB1R)I3O**J
M(JY[%7PQFMP:7\2Q5<\Z>U7-E;J[DJ2:C=O"B:^Q34:*_P!;18A=>:9Z1UCG
M(Y=7-&\6S8N?$G&8KP]OY>FKI?BZ?PZS.DMMTY6ZJBQU6U<D+DIW-8B/XE_)
MMZE-2P?^==K_ %J?BAG<7:1;OBFW)1W**D;&BHNM$QR.X^5R\IJENJI*"N@J
MX$:LL+M9J.X#OCK:,>VW=\F2U)S;ZSTUU?H7V05[N5GM](^V53Z=7/1'*U53
M/AY%(3<L37BZQ1P72NDGIVO1^JYSE3/)4SVKX5,IC3'=TQ?3QPW2.F8R-<TW
M%KD7[W*:HNU#.##LI$6CJWQ/$3DR3-)G1^E\=T\F)=%#76C\ME'\%%RSU45%
MX?$:[['_  [<K/)<KE<6+2TJ-:FHY4VY(_-=B^%";X0T@7O"T"P4$K)8,\TC
MF5[FIXD1R<ID,0Z5L17N@DHYG04T3TR<M/KL54_>]3C]#)%9QQVE]$<3BFT9
MK:[HCLH.C&XTS]+&*7-E:K:B1VYJO'^4>OX&BX[P-?)\=5K8:99$JYM:.763
MM4X.4T*AJZFAJF5-)/)%4-7-)&N5%SX.%"C0Z:L311(S<Z%ZI^D]DBK_ !G2
M<5Z6W4Z]-'*,^/+39EZ:3KT8K$&"[EA"[V%]UKTJ-WJ8U1FMGJ9.3PJ5?3%:
M:R[X#M26V+=W-A;FC53CW/J()B*_7#$-P=67.=TDBKFU-951G!P9JN7 ;98]
M+&(K/:XJ"#VM+%&W4:Z5'N<B<6U'H+X\D[;=Y@QYL,;Z=8K/]JYHOM%;9]&<
M\%QBW*95<[4S1=BHWD\1*M$5)B*2]7&JPS-$U\6R2*3+)R=JO JIX#K9I=Q(
ME-/#)[6E;+GFLB/<J(O$G;\!JN&L27+#ER?6VR962/V/;FY&NVIPHBIR(9KA
MOI?7366K\1BUIMUTJ_0F$\6Q8HNLUFN]D=#6-C57S*Q,EXMBY<BIQD0TJV>F
MLN,*B"B?K0N1'99YZJ\)GI=,^(Y(GM;!;HWN:J;HR.1')^_7)U6U4]=5RU57
M*^6>155SG*JK]YK!AM2TSVC\,\3Q%<E(K$ZS^>SH !]3X0Y6[\Y;1^M7^AQ.
M5N_.6T?K5_H<.)^U/^]7U<%]^O\ O1^R4^"WQ )\%OB!YKW TG3)^9<OC_\
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M/^L=_$ID7?!7Q&.L?Q<_ZQW\2F[>>O\ ;E3[=_Z9( '5P
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M1]3A)=:?EXN?V)?X(BHIPDNM/R\7/[$O\$1)6%0 !4
M            [J3_ !#/&=)W4G^(9XR3V6$>]CSP8D_7_P!$*V23V//!B3]?
M_1"MDKV+=P &D                             '"?_#R_5)G['_\W[]^
MU7?RV%,G_P /+]4F?L?_ ,W[]^U7?RV$GO"QVE3P 5
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M[\Y;1^M7^AQ.5N_.6T?K5_H<.)^U/^]7U<%]^O\ O1^R4^"WQ )\%OB!YKW
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MEXN?V)?X(BHIPDNM/R\7/[$O\$1)6%0 !4
M    [J3_ !#/&=)W4G^(9XR3V6$>]CSP8D_7_P!$*V23V//!B3]?_1"MDKV+
M=P &D                             '"?_#R_5)G['_\W[]^U7?RV%,G
M_P /+]4F?L?_ ,W[]^U7?RV$GO"QVE3P 5
M    -1TN_)M>O_3_ (S;C4=+OR;7K_T_XS-NRU[ORK9/\LA^JGX(>T\5D_RR
M'ZJ?@A[3V:>6'YN_GG]@ -,&U.!53Q'W-5X55?&I\ !,TX%5/$N0557A<Y?&
MH 'U%5.!RIXE/GC557E4 #[F[YSE3DS"*J<#E3Q*?  V\JY\N8S5>%RKXUS
M 'W-5X7.7QJ?  /N;N#6=ER9GP ?<U3@<Y/$I\_>N?* !]S5>%SE\:GQ%5.!
MSD\2@ -J\*JOC4<' JHO@  ^YN7A>Y?&I\  ^YKQN<J<BJ?$S3X*JGB7( !M
M7A<Y?&HVIP*J>)0 'C557E4^YJO"YR^-3X "9I\%53Q+D%S7X3G+XU  >+8O
M@&;EX7.5/"H     O OB 7@7Q :!=/\ ,)_K 73_ #"?ZP/!OYI?J<7DK^H;
M7AS_ "]/K&4,7AS_ "]/K&4/9P?;J_.\3]ZW[  =7
M        'QWP5\1CK'\7/^L=_$ID7?!7Q&.L?Q<_ZQW\2G*WGK_;O3[=_P"F
M2 !U<                                           #E;OSEM'ZU?Z
M'$Y6[\Y;1^M7^APXG[4_[U?5P7WZ_P"]'[)3X+?$ GP6^('FO<
M                    ^M^$GC/A];\)/&!*$_\ $,_[+_Q-*N_X3O&2A/\
MQ#/^R_\ $TJ[_A.\9()?  4                             'U.$EUI^
M7BY_8E_@B*BG"2ZT_+Q<_L2_P1$E85  %0
M   #NI/\0SQG2=U)_B&>,D]EA'O8\\&)/U_]$*V23V//!B3]?_1"MDKV+=P
M&D                             '"?\ P\OU29^Q_P#S?OW[5=_+84R?
M_#R_5)G['_\ -^_?M5W\MA)[PL=I4\ %0
M  #4=+OR;7K_ -/^,VXU'2[\FUZ_]/\ C,V[+7N_*MD_RR'ZJ?@A[3Q63_+(
M?JI^"'M/9IY8?F[^>?V  TP
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M(QRK64&2)R2=1KF"=%N)KY'7K0U-&U*>H?$_71^UR/>U>#PM4Q/%XYM$NE>
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M]6YY*H/+M,3:9A[F.LUK$2_8OL8_DXB_6N_%2M$E]C'\G$7ZUWXJ5HPV
M                         .$_Q,GU5)=H&^)Q)^T)OY\Q49_B9/JJ2[0-
M\3B3]H3?SY@*H                                             $<
MT_\ ^;X._73_ (Q%C(YI_P#\WP=^NG_&("Q1_ ;XCZ?(_@-\1]
M
M
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MJ,_Q,GU5)=H&^)Q)^T)OY\P%4
M          ".:?\ _-\'?KI_QB+&1S3_ /YO@[]=/^,0%BC^ WQ'T^1_ ;XC
MZ
M
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MF>;5V[/]*$_M^&8+YCW$K;C'4Q-1R+%-&J(J=N_/)51>(#E"R&GTNL996L9
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MG(B'(         <9/BW^)3D<9/BW^)0/P+I:^4?$'VE?P0#2U\H^(/M*_@@
M_47L8_DXB_6N_%2M$E]C'\G$7ZUWXJ5H
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M? R\QKZ2GJ ?H$'Y^]\#+S&OI*>H/? R\QKZ2GJ ?H$'Y^]\#+S&OI*>H/?
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MI*>H%]D#+ELL:Y_:D]0#] @T'1QI*M^,(UB<Q*2N;PQ.?K9\/ N29\!OP
M
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M^^U]54@DFW+7S^#K;,\O!R ; "1XKQ==;I@BGN5!2>UXGU"-<_=TS14>J(G
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M2TU,RR4Z-5.U17*N62+LV(WB,%9<-XWLK7VRA?![GJ[M9U>F;4X/G9\7(5T
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MR,)8\)VJS5T]91T[?;,KM99%:F:</!DGA4#,4--'1T<--"F4<3$8U.1$.X
M     $(]E1_AL.^.H_XB[D(]E1_AL.^.H_X@(
M
M     #U6NOJ;77PUE%*^*>)VLBM<J9^!<C]4Z*=(5+BJVQP5#]2YQ(B2,5%[
M;@VY\'+QGY,/3;*^IME=%5T,KHYXUS1S5R _=H)YHJTBTN+J3VO.NYW*-N;V
M99(NWA3:O*A0P
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M?X;#OCJ/^("
M                                          #U6JX55JKXJR@E6.>-
M45%R1>!<^/Q'ZHT5Z1Z3%E&E/5/9%<XT[:-<DUMJY9?N1.D_)I[+1<JJT7"*
MLH971S1N1R9+EGDN>2] '[J!/=%VD6CQ70L@J)(X;C&U$=&KOA>%,T3D4H0
M
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MNQ%;9JZL@2&%TF4.2YZS<DV\"<>8&U
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MKMRV^ VR)Z21,>W@<B*G[P.0  X3_$R?54EV@;XG$G[0F_GS%1G^)D^JI+M
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M_#8=\=1_Q 0
M                                           ?%5$3-2R:&M&$EUEC
MO%[8K*1BHZ*)4^&J.7P?Z?O []!FC^LFKH[Y5RRT\#4_)M8Y$U]BIMR7Q'Z,
M.$$3((611-1K&(C41.)$.8
M                                           T33?\G%R^M%_&AO9H
MFF_Y.+E]:+^- 0]NB;\P++]EB_EM-N-1T3?F!9?LL7\MIMP   #%8HDGAL59
M)2T\53(V-5W&5$5K]G J*94 0.NFM/M>.>PSU%#?72)K4<2JUFMFNS8U$RSR
MX^,SV-FU5(F%;S7L<[<(VNJ%1<\E5C$7E5=JE;2*-':R-36Y3DYJ.:J.3-%
MD>.JYDUSL>):=JRVYN6:IL5-CN7;QIQ'EQ9B6'$5]P\^AA>M/'5QKNJKL5<U
MV9*B*674;JZNJFKR!(V-1$1J(B 2NY5;L):0);K<(<[?5Q-8V5.)48U.!,UY
M>+B/*R\)?=)MOJ8(7-IMS<C7JOPNT7B*^]C7IDY$5#BZ/\FJ1HB.R5$7D C.
MD-*NQXAKH:!JNCO$:;$=EJOUE<JIMY&(5C#EJCLMFIK?#DK(45$7++/-57^I
MK-!A&X28J;=[U715+(45(8FYKJ\*;<T_U*;N
M         .,GQ;_$IR.,GQ;_ !*!^!=+7RCX@^TK^" :6OE'Q!]I7\$ 'ZB]
MC'\G$7ZUWXJ5HDOL8_DXB_6N_%2M   !I>E>I='AR.FC<J.JYVP*G*UR.S_
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MPJZJGI(MTJYXH8_G2.1J=*G<:/I3MC*BRS5;YI6K$Q$1C7N1J]MR(N7&;PG
M@           "$>RH_PV'?'4?\1=R$>RH_PV'?'4?\0$
M
M              1%541$S5=B(6+0]HODNTL5UOD+FT:+FR)[?A_?X>0#CH:T
M837:J9=K_3OCHF9.BB>U4UU14\6S8I^DX8F0Q-CB8C&-3)$1-B""&.GB;%!&
MV.-O UJ9(AS
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M8^M4.&H6,6ES6HEIVY-R[5<ERR3@1>,KJ<          XR?%O\2G(XR?%O\
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M\/CX\E/T=3014T#(:>-L<3$R:UJ9(B'8
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M+-,SZ         !QD^+?XE.1QD^+?XE _ NEKY1\0?:5_! -+7RCX@^TK^"
M#]1>QC^3B+]:[\5*T27V,?R<1?K7?BI6@
M  #A/\3)]527:!OB<2?M";^?,5&?XF3ZJDNT#?$XD_:$W\^8"J
M   /FJF>>29^(^Y)R  $1$X$/FJW//53/Q'T #YJMSSR3/Q'T #XC43@1$_<
M?0 1$1-A\U6YYZJ9^(^@ ?$:U%S1J9^(^@ ?$:B<"(G[CZ
M 1S3_P#YO@[]=/\ C$6,CFG_ /S?!WZZ?\8@+%'\!OB/I\C^ WQ'T
M
M
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MS5<^%>!.("L@                            !QD^+?XE.1QD^+?XE _
MNEKY1\0?:5_! -+7RCX@^TK^" #]1>QC^3B+]:[\5*T27V,?R<1?K7?BI6@
M                            #A/\3)]527:!OB<2?M";^?,5&?XF3ZJD
MNT#?$XD_:$W\^8"J
M !'-/_\ F^#OUT_XQ%C(YI__ ,WP=^NG_&("Q1_ ;XCZ?(_@-\1]
M
M
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MK14W>[4+[#99+/51.59Y6R1HUWB1JY\3NDM( ^-3)J(JYJ?0
M                '&3XM_B4Y'&3XM_B4#\"Z6OE'Q!]I7\$ TM?*/B#[2OX
M( ++H0TI6/#."HJ&OBK5F1ZN58X=9.%>/,H&_IACN-R]'_N8_P!C=:K=6:.X
MGU5OHYI$E<FM)"UR\*\:H53L?LW-%O\ 1F=0$[W],,=QN7H_]QOZ88[C<O1_
M[E$['[-S1;_1F=0['[-S1;_1F=0$[W],,=QN7H_]QOZ88[C<O1_[E$['[-S1
M;_1F=0['[-S1;_1F=0$[W],,=QN7H_\ <;^F&.XW+T?^Y1.Q^S<T6_T9G4.Q
M^S<T6_T9G4!.]_3#'<;EZ/\ W&_IACN-R]'_ +E$['[-S1;_ $9G4.Q^S<T6
M_P!&9U 3O?TPQW&Y>C_W&_IACN-R]'_N43L?LW-%O]&9U#L?LW-%O]&9U 3O
M?TPQW&Y>C_W&_IACN-R]'_N43L?LW-%O]&9U#L?LW-%O]&9U 3O?TPQW&Y>C
M_P!QOZ88[C<O1_[E$['[-S1;_1F=0['[-S1;_1F=0$[W],,=QN7H_P#<;^F&
M.XW+T?\ N43L?LW-%O\ 1F=0['[-S1;_ $9G4!.]_3#'<;EZ/_<;^F&.XW+T
M?^Y1.Q^S<T6_T9G4.Q^S<T6_T9G4!.]_3#'<;EZ/_<;^F&.XW+T?^Y1.Q^S<
MT6_T9G4.Q^S<T6_T9G4!.]_3#'<;EZ/_ '&_IACN-R]'_N43L?LW-%O]&9U#
ML?LW-%O]&9U 3F33GAAT;DW&XKFF7^'_ +FCZ*M*EBL,%X]MQ5JK4UDLK=2'
M/8LLCDX^1R%\EL-G;&]4M%OS1%7_  S.HFFA"UVZJ@Q#[8MU%+J7"9&Z\#5R
M3=Y=B9IX$ ]._IACN-R]'_N-_3#'<;EZ/_<HG8_9N:+?Z,SJ'8_9N:+?Z,SJ
M G>_IACN-R]'_N-_3#'<;EZ/_<HG8_9N:+?Z,SJ'8_9N:+?Z,SJ G>_IACN-
MR]'_ +C?TPQW&Y>C_P!RB=C]FYHM_HS.H=C]FYHM_HS.H"=[^F&.XW+T?^XW
M],,=QN7H_P#<HG8_9N:+?Z,SJ'8_9N:+?Z,SJ G>_IACN-R]'_N-_3#'<;EZ
M/_<HG8_9N:+?Z,SJ'8_9N:+?Z,SJ G>_IACN-R]'_N-_3#'<;EZ/_<HG8_9N
M:+?Z,SJ'8_9N:+?Z,SJ G>_IACN-R]'_ +C?TPQW&Y>C_P!RB=C]FYHM_HS.
MH=C]FYHM_HS.H"=[^F&.XW+T?^XW],,=QN7H_P#<HG8_9N:+?Z,SJ'8_9N:+
M?Z,SJ G>_IACN-R]'_N-_3#'<;EZ/_<HG8_9N:+?Z,SJ'8_9N:+?Z,SJ G>_
MIACN-R]'_N-_3#'<;EZ/_<HG8_9N:+?Z,SJ'8_9N:+?Z,SJ G>_IACN-R]'_
M +C?TPQW&Y>C_P!RB=C]FYHM_HS.H=C]FYHM_HS.H"=[^F&.XW+T?^XW],,=
MQN7H_P#<HG8_9N:+?Z,SJ'8_9N:+?Z,SJ G>_IACN-R]'_N-_3#'<;EZ/_<H
MG8_9N:+?Z,SJ'8_9N:+?Z,SJ G>_IACN-R]'_N-_3#'<;EZ/_<HG8_9N:+?Z
M,SJ'8_9N:+?Z,SJ G>_IACN-R]'_ +C?TPQW&Y>C_P!RB=C]FYHM_HS.H=C]
MFYHM_HS.H"=[^F&.XW+T?^XW],,=QN7H_P#<HG8_9N:+?Z,SJ'8_9N:+?Z,S
MJ G>_IACN-R]'_N-_3#'<;EZ/_<HG8_9N:+?Z,SJ'8_9N:+?Z,SJ G>_IACN
M-R]'_N:!I-TBV?%=[PNRW,JVK!-)K++%J_"6/+C_ -*GZ#['[-S1;_1F=1)-
M.EMH:*\81]IT-+ KIIM;<X6MSR6++/) +9'\6WQ'(^1_ ;XCZ
M
M
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M-%O]&9U 3O?TPQW&Y>C_ -QOZ88[C<O1_P"Y1.Q^S<T6_P!&9U#L?LW-%O\
M1F=0$[W],,=QN7H_]QOZ88[C<O1_[E$['[-S1;_1F=0['[-S1;_1F=0$[W],
M,=QN7H_]QOZ88[C<O1_[E$['[-S1;_1F=0['[-S1;_1F=0$[W],,=QN7H_\
M<^/TYX85CDW&Y;4^C_W*+V/V;FBW^C,ZCY)8+.D;E]R;?P+_ /TS.H#\#:0[
MQ377&MXKJ9LC89YU>U'-R7++C![]*T446D2_,BBCC8VI5$:UJ(B;$X$ 'ZD]
MC'\G$7ZUWXJ5HDOL8_DXB_6N_%2M                              '"
M?XF3ZJDNT#?$XD_:$W\^8J,_Q,GU5)=H&^)Q)^T)OY\P%4
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M:
M                           #1--_R<7+ZT7\:&]FB:;_ ).+E]:+^- 0
M]NB;\P++]EB_EM-N-1T3?F!9?LL7\MIMP
M                      XR?%O\2G(XR?%O\2@?@72U\H^(/M*_@@&EKY1\
M0?:5_! !^HO8Q_)Q%^M=^*E:)+[&/Y.(OUKOQ4K0
M         !PG^)D^JI+M WQ.)/VA-_/F*C/\3)]527:!OB<2?M";^?,!5
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M29-A^>.WW-ZR4#ER1SG*NI]R\@'ZB!T4573UU.V>DE9+$[@<U<SO
M
M                :)IO^3BY?6B_C0WLT33?\G%R^M%_&@(>W1-^8%E^RQ?R
MVFW&HZ)OS LOV6+^6TVX
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MR)-$R1J*B.3-,SF      "$>RH_PV'?'4?\ $7<A'LJ/\-AWQU'_ ! 0
M
M                         ^'T 5/1!I+GP]5LMUU>LM!(J-:YRN56+FGA
M\?$?IZEGCJH&30.UHWIFBGX-5,T*MH@TDS8?J66ZZ/=)0R*C6JJIVBJY?"GS
M@/U"#IHJJ&LIHZBG>CXGHBHJ+F=P
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M$1)J9S-97M357)-B_,RX.,\,-3>[Y74D-'A]EI8QZ++++3)M3AV:S/ O250
M<8FZD;6YYY)EGED<@       0CV5'^&P[XZC_B+N0CV5'^&P[XZC_B @
M
M                           !%R7-.$&2P_9:V_7**CM\+Y'O<B*J?HHJ
MY9[0*CH/QQ=H+DVU/AJ*VE?L35;GN?#R)G]_$?I,TK1O@2APG;F*D3'USVIN
MDJM3-%Y./E4W4
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ML^\W8   .$_Q,GU5)=H&^)Q)^T)OY\Q49_B9/JJ2[0-\3B3]H3?SY@*H
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M>RH_PV'?'4?\1=R$>RH_PV'?'4?\0$
M
M,CA^RUE^N,=%01.?(]<E5$543H10&'[-5WVY1T5!&Y\CU1%5.+:B?U/U?HWP
M'0X2H$5K$?6O3\I(O#PJNS9X3EHVP)2X/M^JW5DK'IE)(F?+P)T)Q&Z
M
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M;K99\#N3B4\N'L57&#$4=HN\M)6+,U59-22*]$R15R7-$ H@
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M0-8U&35BHFO-J\/#P<G"IN8
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M+PHO!TE>=!$]B,=%&YB<#5:BH?6Q1MRU8V)EP9)P <P
M                 .,GQ;_$IR.,GQ;_ !*!^!=+7RCX@^TK^" :6OE'Q!]I
M7\$ 'ZB]C'\G$7ZUWXJ5HDOL8_DXB_6N_%2M
M      '"?XF3ZJDNT#?$XD_:$W\^8J,_Q,GU5)=H&^)Q)^T)OY\P%4
M                                       ".:?_ /-\'?KI_P 8BQD<
MT_\ ^;X._73_ (Q 6*/X#?$?3Y'\!OB/H
M
M
M                           -$TW_ "<7+ZT7\:&]FB:;_DXN7UHOXT!#
MVZ)OS LOV6+^6TVXU'1-^8%E^RQ?RVFW
M                     #C)\6_Q*<CC)\6_Q*!^!=+7RCX@^TK^" :6OE'Q
M!]I7\$ 'ZB]C'\G$7ZUWXJ5HDOL8_DXB_6N_%2M
M         '"?XF3ZJDNT#?$XD_:$W\^8J,_Q,GU5)=H&^)Q)^T)OY\P%4
M                                          ".:?\ _-\'?KI_QB+&
M1S3_ /YO@[]=/^,0%BC^ WQ'T^1_ ;XCZ
M
M
M                           #1--_R<7+ZT7\:&]FB:;_ ).+E]:+^- 0
M]NB;\P++]EB_EM-N-1T3?F!9?LL7\MIMP
M                      XR?%O\2G(XR?%O\2@?@72U\H^(/M*_@@&EKY1\
M0?:5_! !>_8_X\PQ8\!QTMVO$%-4;HY=1S7*N6:\B%+WUL$]\--Y#_5)]['?
M"=CNF (YZ^W0S3;HY-9V>?"OA*?V 88YHI^EW6!X=];!/?#3>0_U1OK8)[X:
M;R'^J>[L PQS13]+NL=@&&.:*?I=U@>'?6P3WPTWD/\ 5&^M@GOAIO(?ZI[N
MP##'-%/TNZQV 88YHI^EW6!X=];!/?#3>0_U1OK8)[X:;R'^J>[L PQS13]+
MNL=@&&.:*?I=U@>'?6P3WPTWD/\ 5&^M@GOAIO(?ZI[NP##'-%/TNZQV 88Y
MHI^EW6!X=];!/?#3>0_U1OK8)[X:;R'^J>[L PQS13]+NL=@&&.:*?I=U@>'
M?6P3WPTWD/\ 5&^M@GOAIO(?ZI[NP##'-%/TNZQV 88YHI^EW6!X=];!/?#3
M>0_U1OK8)[X:;R'^J>[L PQS13]+NL=@&&.:*?I=U@>'?6P3WPTWD/\ 5&^M
M@GOAIO(?ZI[NP##'-%/TNZQV 88YHI^EW6!X=];!/?#3>0_U1OK8)[X:;R'^
MJ>[L PQS13]+NL=@&&.:*?I=U@>'?6P3WPTWD/\ 5&^M@GOAIO(?ZI[NP##'
M-%/TNZQV 88YHI^EW6!X=];!/?#3>0_U1OK8)[X:;R'^J>[L PQS13]+NL=@
M&&.:*?I=U@8Z72K@ET3T3$--FJ+^@_U2>:',?87M,-]2X7F"#=JZ5\>LUW;-
M6:5478G(J=)49L X92)ZI:*?@7C=UDYT+82L=PAO_MRW0R[E72L9K9[$2:5$
M3AY$0#>]];!/?#3>0_U1OK8)[X:;R'^J>[L PQS13]+NL=@&&.:*?I=U@>'?
M6P3WPTWD/]4;ZV">^&F\A_JGN[ ,,<T4_2[K'8!ACFBGZ7=8'AWUL$]\--Y#
M_5&^M@GOAIO(?ZI[NP##'-%/TNZQV 88YHI^EW6!X=];!/?#3>0_U1OK8)[X
M:;R'^J>[L PQS13]+NL=@&&.:*?I=U@>'?6P3WPTWD/]4;ZV">^&F\A_JGN[
M ,,<T4_2[K'8!ACFBGZ7=8'AWUL$]\--Y#_5&^M@GOAIO(?ZI[NP##'-%/TN
MZQV 88YHI^EW6!X=];!/?#3>0_U1OK8)[X:;R'^J>[L PQS13]+NL=@&&.:*
M?I=U@>'?6P3WPTWD/]4;ZV">^&F\A_JGN[ ,,<T4_2[K'8!ACFBGZ7=8'AWU
ML$]\--Y#_5&^M@GOAIO(?ZI[NP##'-%/TNZQV 88YHI^EW6!X=];!/?#3>0_
MU1OK8)[X:;R'^J>[L PQS13]+NL=@&&.:*?I=U@>'?6P3WPTWD/]4;ZV">^&
MF\A_JGN[ ,,<T4_2[K'8!ACFBGZ7=8'AWUL$]\--Y#_5&^M@GOAIO(?ZI[NP
M##'-%/TNZQV 88YHI^EW6!X=];!/?#3>0_U1OK8)[X:;R'^J>[L PQS13]+N
ML=@&&.:*?I=U@>'?6P3WPTWD/]4;ZV">^&F\A_JGN[ ,,<T4_2[K'8!ACFBG
MZ7=8'AWUL$]\--Y#_5&^M@GOAIO(?ZI[NP##'-%/TNZQV 88YHI^EW6!X=];
M!/?#3>0_U1OK8)[X:;R'^J>[L PQS13]+NL=@&&.:*?I=U@>'?6P3WPTWD/]
M4;ZV">^&F\A_JGN[ ,,<T4_2[K'8!ACFBGZ7=8'AWUL$]\--Y#_5)CI@QGA[
M$%YPHVS72&J=#-+KHQKDU<UCRX4\"E<[ ,,<T4_2[K);IHPW:+/><).MM#%3
MK)--K*W/;DL67"OA4"\1_%M\1R/D?P&^(^@
M
M
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MWD/]4]W8!ACFBGZ7=8[ ,,<T4_2[K \.^M@GOAIO(?ZHWUL$]\--Y#_5/=V
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MH&^)Q)^T)OY\Q49_B9/JJ2[0-\3B3]H3?SY@*H
M                       $<T__ .;X._73_C$6,B?LD:MM#4X5J7-5[8I)
MW*U%RSVQ 6N/X#?$?2'I[(&@1$3W$F](_P"P^^^"H.9)O2/^T"W@B'O@J#F2
M;TC_ +1[X*@YDF](_P"T"W@B'O@J#F2;TC_M'O@J#F2;TC_M MX(A[X*@YDF
M](_[1[X*@YDF](_[0+>"(>^"H.9)O2/^T>^"H.9)O2/^T"W@B'O@J#F2;TC_
M +1[X*@YDF](_P"T"W@B'O@J#F2;TC_M'O@J#F2;TC_M MX(A[X*@YDF](_[
M1[X*@YDF](_[0+>"(>^"H.9)O2/^T>^"H.9)O2/^T"W@B'O@J#F2;TC_ +1[
MX*@YDF](_P"T"W@B'O@J#F2;TC_M'O@J#F2;TC_M MX(A[X*@YDF](_[1[X*
M@YDF](_[0+>"(>^"H.9)O2/^T>^"H.9)O2/^T"W@B'O@J#F2;TC_ +1[X*@Y
MDF](_P"T"W@B'O@J#F2;TC_M'O@J#F2;TC_M MX(A[X*@YDF](_[1[X*@YDF
M](_[0+>"(>^"H.9)O2/^T>^"H.9)O2/^T"W@B'O@J#F2;TC_ +1[X*@YDF](
M_P"T"W@B'O@J#F2;TC_M'O@J#F2;TC_M MX(BGL@K>JHBV29$SX?;'_:4[!N
M++?BJVLJJ&1J/5,W19JJMZ40#8
M
M                             -$TW_)Q<OK1?QH;V:)IO^3BY?6B_C0$
M/;HF_,"R_98OY;3;C4=$WY@67[+%_+:;<
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MKMBKLR<N? !M8       !"/94?X;#OCJ/^(NY"/94?X;#OCJ/^("
M                                            ;'@C%E;A2ZLJJ1RK
M'P/9FN2IDJ<J<IK@ _:V"L4T>*K0RMHW(CN![.-J[.M#8#\48+Q77X4N;*JB
MD<L6?;Q<3DS3J0_6^"\54&*K4RKH9$UES1T:N36:J*J;415 V
M
M                                                  T33?\ )Q<O
MK1?QH;V:)IO^3BY?6B_C0$/;HF_,"R_98OY;3;C4=$WY@67[+%_+:;<
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M/9M\*(!DP  !KF-L2IAFBI:A:=9]WFW+).+M57/[C88W:[$<J99IP <@
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MAL.^.H_XB[D(]E1_AL.^.H_X@(
M                    &QX(Q;7X5N<<])*_<-9-TBSV.3-%7A1>0UP ?M3!
M>*Z'%%M944DC4D1$UX]9%5%_^(IL1^+,$XMK\*W-E123/2%51)(]9<E3Q?O4
M_6F#<44.)[5%544K7/5J:[.-JY(JI]X&?
M
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MKP7%9Y'U;H;A%77JHC=K/;(U53M5V(C5\/(!X(J2IQY?[JE=530VNWR.AC9
MJ-UU1SDSVHO(WD,OHLND\MNN%-63+)'0SK"Q[^'51&]9KN%+_#A:DO5%<&3>
MWEJ7NCC5J(Z1%=EFB*J*O&I\M]+<**PPVEL;V7*[OW67M%_)M5J<**FS:WD
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MR$>RH_PV'?'4?\0$
M            !\+#H P]?7W9+C3S/IK<B+KHN:))FW9Q>%%,7HFT<SXDK6U=
MPBDCH(U1V:HYNOP\"Y>#E/U%;Z."@HXJ:E9J0Q-1C4SSV(F7] /0
M
M                                                 &B:;_DXN7UH
MOXT-[-$TW_)Q<OK1?QH"'MT3?F!9?LL7\MIMQJ.B;\P++]EB_EM-N
M.EE53OD6-D\3GI^BCT5>@P]RQ5;;?>J:V5$N51.JHBHK<FY)GMV[ ,\#K2>)
M=7*5BZWP>V3;XCD^1C%1'O:U5V)FN68'('7-/%"U'32LC1>-SD0U2;%<K,=Q
M6..*)].^+=-U155?@JOBX@-O!B;5[I>Z==[=FIWTFLNX-C=FYJ;,M;9XS(/J
MZ>.7<WSQ-D^:KT1>@#N!\<YK6JYSD1J<:KL.N&I@G54AFCD5.'5<BY =H
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M;_\ U"KJZNXR99^/5R^\#.34=-.[6GIH9'<KV(J_>?8*2G@7."GAC7_0Q$_
MZ*BZT=/4P4\TVK+/GN::JKK9)GPY9<![0//-14L[]>:F@D?\Y\:*OWGV"BI8
M'Z\%-!&_YS(T1?N.\ =$E%2R2;I)30ND^<Z-%7I.Q8HU>CUC8KT3)'9;4.8
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M6*DUV_E7)\/\HG%DBIQIM-HQC=:**_246*+9&ZW.8BPU38D>]-FW@15X=7B
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M(
M
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MT\$5.S4A8C&\B'&HI(*G+=XVORX,SN '"&)D+$9$U&M3B0Y@
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M
M
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M1<IIN!?#$!8X_@-\1]/D?P&^(^@
M
M
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M_P#S?!WZZ?\ &("PQIE&WQ'(^1_ ;XCZ
M
M
M                          #0M.;=?1K=&YJF:QIFGUT-]-$TW_)Q<OK1
M?QH!-<!Z&H+IA*V5CK_=&.E@C>K62,R3-B+\SPF>WBJ?OANWG&>H;SHF_,"R
M_98OY;3;@(QO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=O.,]0;Q5/WPW;
MSC/4+. (QO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=O.,]0;Q5/WPW;SC
M/4+. (QO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=O.,]0;Q5/WPW;SC/4
M+. (QO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=O.,]0;Q5/WPW;SC/4+.
M (QO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=O.,]0;Q5/WPW;SC/4+. (
MQO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO
M%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4
M_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?
M#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=O.,]0;Q5/WPW;SC/4+. (QO%4_?#=
MO.,]0^.T%TZ-<O9#=MB=T9ZA:#C)\6_Q*!_/''UF;:<8W:A;4RS)!,K-T>J*
MKMB;5V(#*:6OE'Q!]I7\$ 'ZB]C'\G$7ZUWXJ5HDOL8_DXB_6N_%2M
M                        '"?XF3ZJDNT#?$XD_:$W\^8J,_Q,GU5)=H&^
M)Q)^T)OY\P%4                                             ".:
M?_\ -\'?KI_QB+&1S3__ )O@[]=/^,0%BC^ WQ'T^1_ ;XCZ
M
M
M                                          #1--_R<7+ZT7\:&]FB
M:;_DXN7UHOXT!#VZ)OS LOV6+^6TVXU'1-^8%E^RQ?RVFW
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MD    !PG^)D^JI+M WQ.)/VA-_/F*C/\3)]527:!OB<2?M";^?,!5
M            !QDD9&W6D>UC>5RY(?6N:]J.8J.:O J+FB@?0
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M$SSXTXC=
M
M         !HFF_Y.+E]:+^-#>S1--_R<7+ZT7\: A[=$WY@67[+%_+:;<:CH
MF_,"R_98OY;3;@
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M\1=R$>RH_P -AWQU'_$!
M              &2P]?*_#]P966V=\3VKFK6NR1WCZ$/UCHXQW18NMK7M<D5
M6W-'Q.=MX?W> _'AE,-WVMP_<HJRWS.C>UR*J(JHCD147)>@#]Q TW1SC>CQ
M7;6JU[6UC&INC.GJ-R
M
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MF:(]^6:[4X<ECY0*/65M-10I+5SQPQK^D]V2'"@N5%<$5:&JAG1.'<W9Y?\
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MAV4M1#50-FII&RQ.^"]JYHI)K?14>*\<79N(94='2NU(Z=9-SV:K5SV*B_\
M\3NP/,RT:1;C8[7,DUKR:YJ([7U%U%<J9[5X57CX@*N]S6-5SU1&IQJ?32JF
MXSWC'5+0T;M:@H=9:K+C<J.1$S3D5J<:&Z@<)_B9/JJ2[0-\3B3]H3?SYBHS
M_$R?54EV@;XG$G[0F_GS 50       &,Q+15-QL=91T4K(IIXW1H]RY(F:*G
M(IX,"X;3#-F]J*]))G.5\CT7/655SY$Y5-B &E8WP?47N[6^Y6VHCIZNES17
M/<J9HJ*G(O*IY,4X(KZF^+=L.5[*.KD3*7='9([:J\35\!0 !-*?1[<5Q%:;
MO6W-L\],]'S(YVQ<G(O:]HG$G&9K'F$);^^EK+=4)3W*E571/>N3<UU>'8OS
M3<0!J5;A6>]X8AH<05#9:^-$5)XEV([9M3-/!R&OR8(Q-70MH;K>H9+9P.;&
MY==4_>S(IH U3%.$TN6$VV6W/9 QCLVJY51$V.\"\;CRWK!U17X1MMH941ME
MI=SUGJY<EU<L^+P<ANH P%VL4E;A%;.R5K9%C8S75=G:N1>3P<AQPU8);3A*
M*TRRL?*R-6*]JYIM_<GX&P@#3<*82J+-A"NM$T\;Y:ADK4>U55$U];+B3YW(
M9/"-BDLF'4MTLK9'YO76:N:;?W(9\ :E@C"T^'ZNY2SSLD2JF?*U&JJY(Y<]
MNQ#Y8\*SV[&=TO3YV.BJ];58BKFF:M7;L_T\IMP GF(,$75^();IARXQTDDR
M(DJ2.7)<D1-F35Y#JH-'U=!BZ@O=1<4J'Q,5)D>[:JZN7:Y-39FJ\)2 !K%;
MAN:HQS2WU)F)##3I"L>:YJJ*_;EE_J3C.C&6%9[]=K35PSQQMHY4>Y'*J*Y$
MSX-B\IMP U/%V$4O/M6KHYUIKG2[8I<\DS3++/8O&C3#T^#;[7UM,_$UUBJ*
M>G=K,9 Y<UX]N;.5$*( /C6HQJ-:F2)L1#Z       "$>RH_PV'?'4?\1=R$
M>RH_PV'?'4?\0$
M          !D\.WRLP_<HZV@DU9&JF:99YH?K'1OCBCQ=:XW,>UM:QJ;K'L1
M<\DS7+-=F>9^.T155$1%55X$0M^@S1[7+6Q7RO=+31(BK''DJ:^;?#Q=L!^A
MP
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MFV@           (1[*C_  V'?'4?\1=R$>RH_P -AWQU'_$!
M                                           (BJJ(B9JNQ$0^*N2%
MFT-:,9+G)#>+U&B4K7:T<:JU=94<G"F2[-B@-#VC&6XSLNEXCU:5N2L8Y/A+
MMZD/T=!#'!"R*%J,C8B-1$3)$1!!#'!$V*%C61M3)&M3)$.8
M
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M.'J"EK*OVNU&M5'2KV^QWPN7@,AI.J*B&]X;9!430LDK(VO2-ZM1R9KL7+A
MH+Y&,3-[VM3E5<C6IL5LCQE'84IU=KQ[HDR/V?!5>#+P<IJ-3#6XPQK5V^2N
MJJ6VT;&*C:>56.<KF-7;PIPHO%QGAM=LFM.EN&EGJI*EJ0=HZ1RN<B:CLLU4
M"G6R6Y/N5:VMCC;2M<J0*UR*JILRS1-J<?"9)TT37:KI&([D5R9DRM=XJJ"[
MXPJ5FEE;3S.W..1RN:WMF)L3/9PFDTEWI[A;/;M=5WM;N]JJQ8JG*-')FC=B
M[<MB<8'Z&541,U5$3E.#)8Y,]1[79<BYDJK*_$=?H_IYD;*R5LGY=62Y/6-'
M+FJ+K<.JAX<)U5.^]T:V*[5R/<B^V*>ME<_-=5>#)$3E^X"S
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MNYY<.WB J%+40U=.R>FD;)$_X+F\"[<CM-+T15+JG!U.KM;M7/1,T_UN-T
M       X3_$R?54EV@;XG$G[0F_GS%1G^)D^JI+M WQ.)/VA-_/F J@
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M4\38V\C4.X           !"/94?X;#OCJ/\ B+N0CV4Z*M/AQ$157.HX/_2
M@ .>X3]PF\A1N$_T>;R% X Y[A/]'F\A1N$_T>;R% X Y[A/]'F\A1N$_P!'
MF\A0. .>X3_1YO(4;A/]'F\A0. .>X3_ $>;R%&X3_1YO(4#@#GN$_T>;R%&
MX3_1YO(4#@#GN$_T>;R%&X3_ $>;R% X Y[A/]'F\A1N$_T>;R% X Y[A/\
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MO<:-I6KG'&O"[++BRX-J\9^D(HVQ1M9&U&M38B(<:>&.GA;%"Q&1MV(B'8
M
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M\H^(/M*_@@&EKY1\0?:5_! !^HO8Q_)Q%^M=^*E:)+[&/Y.(OUKOQ4K0
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M!OB<2?M";^?,!5
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M9G49, 8Q,/V9%S2TV_/[,SJ,A#%'#&D<,;(XV[$:Q,D3]QS
M
M                                                   #1--_R<7+
MZT7\:&]FB:;_ ).+E]:+^- 0]NB;\P++]EB_EM-N-1T3?F!9?LL7\MIMP
M                                              XR?%O\2G(XR?%O
M\2@?@72U\H^(/M*_@@&EKY1\0?:5_! !^HO8Q_)Q%^M=^*E:)+[&/Y.(OUKO
MQ4K0                             !PG^)D^JI+M WQ.)/VA-_/F*C/\
M3)]527:!OB<2?M";^?,!5
M       CFG__ #?!WZZ?\8BQD<T__P";X._73_C$!8H_@-\1]/D?P&^(^@
M
M
M                                                    T33?\G%R
M^M%_&AO9HFF_Y.+E]:+^- 0]NB;\P++]EB_EM-N-1T3?F!9?LL7\MIMP
M                                             XR?%O\ $IR.,GQ;
M_$H'X%TM?*/B#[2OX(!I:^4?$'VE?P0 ?I_V,TC&:.(D<]B+NKN%4Y5*SN\7
M=6>4A$;%H5O5FH&TM%BVKAB1<]6*16IT:ID-ZS$G?I<?/+U 5[=XNZL\I!N\
M7=6>4A(=ZS$G?I<?/+U#>LQ)WZ7'SR]0%>W>+NK/*0;O%W5GE(2'>LQ)WZ7'
MSR]0WK,2=^EQ\\O4!7MWB[JSRD&[Q=U9Y2$AWK,2=^EQ\\O4-ZS$G?I<?/+U
M 5[=XNZL\I!N\7=6>4A(=ZS$G?I<?/+U#>LQ)WZ7'SR]0%>W>+NK/*0;O%W5
MGE(2'>LQ)WZ7'SR]0WK,2=^EQ\\O4!7MWB[JSRD&[Q=U9Y2$AWK,2=^EQ\\O
M4-ZS$G?I<?/+U 5[=XNZL\I!N\7=6>4A(=ZS$G?I<?/+U#>LQ)WZ7'SR]0%>
MW>+NK/*0;O%W5GE(2'>LQ)WZ7'SR]0WK,2=^EQ\\O4!7MWB[JSRD&[Q=U9Y2
M$AWK,2=^EQ\\O4-ZS$G?I<?/+U 5[=XNZL\I!N\7=6>4A(=ZS$G?I<?/+U#>
MLQ)WZ7'SR]0%>W>+NK/*0;O%W5GE(2'>LQ)WZ7'SR]0WK,2=^EQ\\O4!6YIH
MEAD1)6?!7])"8:"9&-AQ'K/8F=PFX7)W>8\:Z*\1JBHN,[AE^N7U3'V?0O>[
M6R9*;%U9$LLCI';G(J9JKE7->U\*@6[=XNZL\I!N\7=6>4A(=ZS$G?I<?/+U
M#>LQ)WZ7'SR]0%>W>+NK/*0;O%W5GE(2'>LQ)WZ7'SR]0WK,2=^EQ\\O4!7M
MWB[JSRD&[Q=U9Y2$AWK,2=^EQ\\O4-ZS$G?I<?/+U 5[=XNZL\I!N\7=6>4A
M(=ZS$G?I<?/+U#>LQ)WZ7'SR]0%>W>+NK/*0;O%W5GE(2'>LQ)WZ7'SR]0WK
M,2=^EQ\\O4!7MWB[JSRD&[Q=U9Y2$AWK,2=^EQ\\O4-ZS$G?I<?/+U 5[=XN
MZL\I!N\7=6>4A(=ZS$G?I<?/+U#>LQ)WZ7'SR]0%>W>+NK/*0;O%W5GE(2'>
MLQ)WZ7'SR]0WK,2=^EQ\\O4!7MWB[JSRD&[Q=U9Y2$AWK,2=^EQ\\O4-ZS$G
M?I<?/+U 5[=XNZL\I!N\7=6>4A(=ZS$G?I<?/+U#>LQ)WZ7'SR]0%>W>+NK/
M*0;O%W5GE(2'>LQ)WZ7'SR]0WK,2=^EQ\\O4!7MWB[JSRD&[Q=U9Y2$AWK,2
M=^EQ\\O4-ZS$G?I<?/+U 5[=XNZL\I!N\7=6>4A(=ZS$G?I<?/+U#>LQ)WZ7
M'SR]0%>W>+NK/*0;O%W5GE(2'>LQ)WZ7'SR]0WK,2=^EQ\\O4!7MWB[JSRD&
M[Q=U9Y2$AWK,2=^EQ\\O4-ZS$G?I<?/+U 5[=XNZL\I!N\7=6>4A(=ZS$G?I
M<?/+U#>LQ)WZ7'SR]0%>W>+NK/*0;O%W5GE(2'>LQ)WZ7'SR]0WK,2=^EQ\\
MO4!7MWB[JSRD([I]D8Z[X/U7M7*:;/)?#$=F]9B3OTN/GEZC&WC0G>;I+2OJ
M\65<JTZJK%DD55;GEP=KX$ M[)HD8B+*S@^<A]W>+NK/*0D.]7B/OTN'GE]4
M;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N
M\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)
M#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9
MB3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W
M5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[U
MF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[
M]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y
M2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3
MOTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X
M^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W
M>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+
MCYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GE
MZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[
MJSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>
M7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"
MO;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\
MI"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZA
MO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[
MQ=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D
M.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF
M)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=
M6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O6
M8D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3O
MTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE
M(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF).
M_2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+C
MYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=
MXNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN
M/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7
MJ KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+N
MK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY
M>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*
M]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSR
MD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&
M]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O
M%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0
M[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68
MD[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U
M9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9
MB3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._
M2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4
M@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[
M]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/
MGEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-W
MB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X
M^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>
MH"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZ
ML\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GE
MZAO68D[]+CYY>H"O;O%W5GE(:+IMEC=HYN2-D8JZT? Y/GH:WO68D[]+CYY>
MH\MTT/7VXT,M+4XOK98WY9M?*JIL7/YH&]Z)Y8VX LJ.D8B^U8N%R=S:;;N\
M7=6>4A&;=H@O]#10TU/C"N9'&U&HULJHB(B9?-/1O68D[]+CYY>H"O;O%W5G
ME(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)
M._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+
MCYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#
M=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OT
MN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>
M7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+
MNK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JSRD)#O68D[]+CY
MY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J&]9B3OTN/GEZ@
M*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;O%W5GE(-WB[JS
MRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"0[UF)._2X^>7J
M&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO68D[]+CYY>H"O;
MO%W5GE(-WB[JSRD)#O68D[]+CYY>H;UF)._2X^>7J KV[Q=U9Y2#=XNZL\I"
M0[UF)._2X^>7J&]9B3OTN/GEZ@*]N\7=6>4@W>+NK/*0D.]9B3OTN/GEZAO6
M8D[]+CYY>H"O;O%W5GE(<9)XMS=^59P+^DA(]ZS$G?I<?/+U!=%>(U3+LTN/
MGE]4#\RZ651=(V(,E14]LKP>) 66Z^QIK;A<)ZN;$:ODE=K*Y^:N7QKJ@#]+
M@  #KW>+==RW1FZ?-UDSZ#L
M
M
M
M
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M2ZS>V7L?.YW;(U-75RV<'!Q<9Y)ZI(+;>(L/5LTMJ2-561RY*UV:<&Q.++B
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M
M
M
M
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MJYJ[?O.^S7NAO"/]HRZRL^$U=BI^XQN,;]-974.XMCU9I=1RO<C41-5R_P!
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MRU$3%<UCTRULO_X@;"#'V&X)<[9#4[$<Y%UD1>!454_H9
M
M
M
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MQLIYK8QL=!"R-J-:C=B(>D
M
M
M
+            _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g109079g00s35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00s35.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1JT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &I<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*/_  !$( YT'9 ,!(@ "$0$#$0'_Q  =  $  @(# 0$
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MQ08H8@#+%!BAB ,L4&*&( RQ08H8@#+%!BAB ,L4&*&( RQ08H8@#+%!BAB
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MH,4,0!EB@Q0Q &6*#%#$ 98H,4,0!EB@Q0Q &6*#%#$ 98H,4,0!EB@,3)-
M           :[?VV)K$N_-64_P =JINX;O$I&F0_*5:-\;;KZ6N1<R%8T;BY
M%TM>NXU/HF[Y7]IM3QM])!FI2VU6QRHNA*!:G%!BAB ,L4&*&( RQ08H8@#+
M%!BAB ,L4&*&( RQ08H8@#+%!BAB ,L4&*&( RQ08H8@#+%!BAB ,L4&*&(
MRQ08H8@#+%!BAB ,L4&*&( RQ08H8@#+%!BAB ,L4&*&( RQ08H8@#+%!BAB
M ,L4&*&( RQ08H8@#+%!BAB ,L4&*&( RQ08H8@#+%!BAB ,L4&*&( RQ08H
M8@#+%!BAB ,L4&*&( RQ08H8@#+%!BAB ,L4&*&( RQ08H8@#+%!BAB ,@
M          $!:JGYIHN)>G&;5J>=I,7)3IO-5U5/S31<2].,VK4\[28N2G3>
M#TE$
M   #YH3%= 'TXYYHX&9\ST:W?4B#+'E1ENZ]MFV&V.6OD7-7'X6&YHQ3?0T:
MPKNWKO2U*NW+3J*:)^SF1O>S^J[Q8K,_ LC3VC1U*X05#'KXCME>:O)I60L5
MUEVY7LD3Z=0]?0>3=N_%Z+EWF@H+Q*DUG29V,CVNQV&*[2J[[D0LUF/D6<!C
M&]LD:/8J*U=U#(Q                   #ZW2?#ZW2!]           XJKY
M._B.4XJKY._B J'=_O[0<E_\N6_*@7?[^T')?_+EOR0L@ *@
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M?209J4MM5L<J+H2DYY7]IM3QM])!FI2VU6QRHNA*!:<
MUN_MZJ:Z=@S5]2K<Y&N[&U5PQ<C55$_@!LBX(F*K@AU'VG11R]C?4,1^]B56
MJ+Y7LO\ 6E-[EF6CH$>K6K&CFKFX[&RCMYR>0[\=RZQ\>?/;5>M0NSBE0_#'
M_P#Z;J8+WC<--\]*3J96D8YKVYS%147>/I4BKK;X7-E2HI*Z2LIVKLI(KW[&
M/C=O(6!R37O6^%VV54R-;5,1O96MW%7'J-=J32=2SI>MXW5NP ,68
M                                                        #(
M <=1/%3Q.DGD9&QNESE1$_B:M=2_MDWFM&IH[,61SX$:KG+F*U<<="HY=X#;
M0>;;MM4-AT3JJT9V11M15^$]K<>+%4-1L3*O=^U;4;0Q+-$][D8U\JQM8Y57
M!,%SUQT@2 #P[U7EHKMV8E=79[H%7!%CS5Q^"KMU430AV+M6W37@LR.NHD>D
M,B(Y,[#'91%W%7? ]0  0%JJ?FFBXEZ<9M6IYVDQ<E.F\U754_--%Q+TXS:M
M3SM)BY*=-X/240
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M;\D+( "H
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MIN)B5KNY8,64/*A7S.[.VD;)(BOC7#_K(NG!R:'F-DLM&E]KN*F/;JSMG_\
MFH_6/O=K=SPU9WG4?K&FID0N\B(BUEJ8_;L]0:R-W>&6IS[/4,6#<V7SNZ]R
M-;;-GJJ[GNJ/UCW8I&31I)$Y'L70YJXHI&461.[T<C7I66IBG_UV>H2104K*
M&D931.<YC,<%<N*[*X_U [           &2:#$R30           &DY7]IM3
MQM])!FI2VU6QRHNA*3GE?VFU/&WTD&:E+;5;'*BZ$H%IP
M"O&J@JI*FMLFR&.<C9IXT5$7<<UZ?_-@L.5TU3<+Z2W;&M3-58HZB+%<-C81
MR_\ S9+'SY2?CPYKIV3%9-B4T,;$1ZQL5RX;*KFHF]XCV3S[ KXK1LBEGA<U
MR+$S'!4V%S47?\9Z![-=:\/$MN9\NO6TT=53212M1R.:J;*8G1R"UG:B^%N6
M.Y5[&]Z.8W>S6_\ OO'I3R-BB>]ZHB-15Q53R,B=(MKY0K:M-F/88G9N*:%Q
M;]Z;F^<O5ZXPZ^BWRE8<#=4'GO1
M                               9  "&,I%1>RV[6FLFR(9J>C1&HL^$
MC47%K5THBII133=3!"Z"W[5CD=G/1L>*_>XLI4-1(7KAN%=-3AMKMGDQ^EQ%
M=[*_:,]XLH=G78CD<VG7-5Z(JX.SD72FSO;Q[64"XEFV'<J.T+-IXX*R@9[I
M66-B-<JLC5=*)CI0UN\K/<>J"L^23XBMB7%?^\E7*W*U,G-K:/TE'*C?OB<!
M'64"UG6UD=HZB155[51JJJXJN$#NL]W)W>6DNWDQHJB=R22N9&UD+%17N=V)
M%1$3%,?BX&E6Y"Z+(?#CBBK(JIYNIJ63MMHP6E853;JK+8[YH(HF2.5S&N5S
M51<-SX*.*+17/MR:WK/2JEHYJ5KL%:V6-6*J*B+H53WSAH^P^YHUI4:D*M3,
MS=&&X<P1 6JI^::+B7IQFU:GG:3%R4Z;S5=53\TT7$O3C-JU/.TF+DITW@])
M1
M^.1'-5JZ%3!3Z ( RUY.ZYMH,M^[C7+4-<KGLB:[.79Q_9;CN;YX]U,I]121
M,I;R6=6PR,3!7OB5-_=<Y"RSD1S51R8HNE%/#M*Z-W[2575UD4<SETJ^)%4R
MK::_ B6T,JECP1K[FBJ9Y-Q&-:[T.-'HVWBRFWGIZ>>BJZ6R4SE<LL<C6?$V
M-**GQF%A*;)Y=2G7%EA6?CO]@:;#0V?1T$>90TT4#-Z-N"?_ #9+-YE-.2DI
MXZ6G;#"U&L;H1$P.8 P4                   ^MTGP^MT@?0
M.*J^3OXCE.*J^3OX@*AW?[^T')?_ "Y;\J!=_O[0<E_\N6_)"R  J
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MHJ8ILXHBFXV;=JQ;,5%H+,I8%3=CC1#UM!KODM>=RV8\=<<:J^@ P;
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M2].,VK4\[28N2G3>:KJJ?FFBXEZ<9M6IYVDQ<E.F\'I*(
M
M            !];I/A];I ^@     (CRK94$L"OI+,LO.=52R-8YZ+AFHJ+O
MM5-*&T7GMRKH<FK+6@>J5:T39L[8^,L2NQT8:0-T!H&1^\=;>*P7U-I2*^1'
MX8KAHS&+N(F^IOS7M<N#7(O$!].*J^3OXCE.*J^3OX@*AW?[^T')?_+EORH%
MW^_M!R7_ ,N6_)"R  J
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MG/*_M-J>-OI(,U*6VJV.5%T)0+3@
M                                                         #(
M           ! 6JI^::+B7IQFU:GG:3%R4Z;S5=53\TT7$O3C-JU/.TF+DIT
MW@])1                                        .E:5ITEF1]DK9>Q
ML7=S57T(=TB#5'J[N::C55,<Y-CB0#>Y[\7?@J602UZ-E?AFIV.39QT?LGO4
M]3#4P)- _.B5,47!2%Z&XUDNR5^ZY&2+5>YEDS^R.TYJ>,ZV1_W5:%RK>L]D
MRHYLD[(UPQPP1B(!*%7?R[M'7.HZBO1M0U<U6]BD79QPW&X:3WJ&NIZ^G;-2
M2=DC<B*BX*GI*M45O4UA5=?9-XK&DJ,ZHD7W0E5F?!5<W'!$7>5=),61Y]WW
MP5#[!F=GOV7Q.<]V9L)L8N^X"3
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MB*BH=W^_M!R7_P N6_*@7?[^T')?_+EOR0L@ *@
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M299(HY%17L:Y4T8H99K<U6X)FX88 :KDSM9UJW2L]TR83QPL;(F./PLU,=S
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M7IQFU:GG:3%R4Z;S5=53\TT7$O3C-JU/.TF+DITW@])1
M                        (PRZV+:%LV%'%9=++42(KL6L3%="$GGS!-X#
M2*.S*QN3#W"Z!Z5?N7,[%ALXYJ;!I>3:ZEK176O!0UE--235$DZQJ]N&.=FX
M+Z2:Q@B:$ KU1U-ZK%I*VRG7=J*M5D>V.9(6KBW#-1=G9W,?O/?R+7/M2S[7
MM"V+7ADIGU+G.2)S5;ABK5XMPF;-;CBK6X\0T: /H
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M2.QA]T) WXN9F8[_ (RRXP3Z*8\0$>Y&KJU5VK!S:]7)-*J/5JHJ9N+6IA_
MD,                  15JC^]_4\E>FPE4BK5'][^IY*]-@'FZF':B[E/Z1
M,Y#&IAVHNY3^D3.                    R308F2:            TG*_M-
MJ>-OI(,U*6VJV.5%T)2<\K^TVIXV^D@S4I;:K8Y470E M.
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MS94:F&<JHF"N7=XS< @                                  ,@
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M?)W\0%0[O]_:#DO_ )<M^5 N_P!_:#DO_ERWY(60 %0
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M]_4\E>FPE4BK5'][^IY*]-@'FZF':B[E/Z1,Y#&IAVHNY3^D3.
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M>9#;]DSR)'%:%*]ZZ$;,Q5])Z8                        &0
M    " M53\TT7$O3C-JU/.TF+DITWFJZJGYIHN)>G&;5J>=I,7)3IO!Z2B
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MK:'@T7D':VAX-%Y /S_[7WU^JMOR3#M??7ZJV_),?H!VMH>#1>0=K:'@T7D
M_/\ [7WU^JMOR3#M??7ZJV_),?H!VMH>#1>0=K:'@T7D _/_ +7WU^JMOR3'
M:LVS[Y^[8<^.VLW.3'%)B^W:VAX-%Y#ZEFT2+BE-'CQ ?;.SDH8<_'.PV<>,
M[)\383!#Z$                      ^MTGP^MT@?0          .*J^3OX
MCE.*J^3OX@*AW?[^T')?_+EORH%W^_M!R7_RY;\D+( "H
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M^28=K[Z_56WY)C] .UM#P:+R#M;0\&B\@'Y_]K[Z_56WY)AVOOK]5;?DF/T
M[6T/!HO(.UM#P:+R ?G_ -K[Z_56WY)AVOOK]5;?DF/T [6T/!HO(.UM#P:+
MR ?G_P!K[Z_56WY)AVOOK]5;?DF/T [6T/!HO(.UM#P:+R ?G_VOOK]5;?DF
M':^^OU5M^28_0#M;0\&B\@[6T/!HO(!^?_:^^OU5M^28=K[Z_56WY)C] .UM
M#P:+R#M;0\&B\@%.,CM%>N.]\#J^.U4@1'8]E27#1XRZ1UXZ&DB7.C@C:[?1
M#L! BK5'][^IY*]-A*I%6J/[W]3R5Z; /-U,.U%W*?TB9R&-3#M1=RG](F<
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MPD.#\>R)+F_$=OEXV?$0X&6?1QN1S*>-')NHAV0@
M   #(            ! 6JI^::+B7IQFU:GG:3%R4Z;S5=53\TT7$O3C-JU/.
MTF+DITW@])1
M                                       /K=)\/K=('T
M#BJOD[^(Y3BJOD[^("H=W^_M!R7_ ,N6_*@7?[^T')?_ "Y;\D+( "H
M        ,))&1,5\CD:U-*JIJ-MY2+MV-(Z.KJW]D;N,C5V_O<1&>7Z^%<^T
M(;L60["2I1N=L)H=GM72GB3=.*X&1ZSH*6.NMQBSU,J)(K554V5S5_9=OXEB
M-K$;;O!EHNM)+FOGJ&IC@B^YW]1MU@WLL>W6HMG52.\3DS5_B:I6W N[5TO8
M)*!,U&YJ?I'[&PJ?2\9#E^\G51<VOBMF[KE;"V1%5-C817?YE5="#BO%:L'A
M7(MA+=NQ05^.+Y8FN=L;JGND8@
M     !%6J/[W]3R5Z;"52*M4?WOZGDKTV >;J8=J+N4_I$SD,:F':B[E/Z1,
MX                   #)-!B9)H           #2<K^TVIXV^D@S4I;:K8Y
M470E)SRO[3:GC;Z2#-2EMJMCE1="4"TX
M
M  R             0%JJ?FFBXEZ<9M6IYVDQ<E.F\U754_--%Q+TXS:M3SM)
MBY*=-X/240
M                                     #ZW2?#ZW2!]           X
MJKY._B.4XJKY._B J'=_O[0<E_\ +EORH%W^_M!R7_RY;\D+( "H
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M%6J/[W]3R5Z;"52*M4?WOZGDKTV >;J8=J+N4_I$SD,:F':B[E/Z1,X
M              #)-!B9)H           #2<K^TVIXV^D@S4I;:K8Y470E)S
MRO[3:GC;Z2#-2EMJMCE1="4"TX
M                                                        R
M          0%JJ?FFBXEZ<9M6IYVDQ<E.F\U754_--%Q+TXS:M3SM)BY*=-X
M/240
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M/[W]3R5Z;"52*M4?WOZGDKTV >;J8=J+N4_I$SD,:F':B[E/Z1,X
M           #)-!B9)H           #2<K^TVIXV^D@S4I;:K8Y470E)SRO[
M3:GC;Z2#-2EMJMCE1="4"TX
M                                                     R
M       0%JJ?FFBXEZ<9M6IYVDQ<E.F\U754_--%Q+TXS:M3SM)BY*=-X/24
M0
M                            #ZW2?#ZW2!]           XJKY._B.4X
MJKY._B J'=_O[0<E_P#+EORH%W^_M!R7_P N6_)"R  J
M":2H^J [Z]F<O_E+<)I*<ZIJ=T.4&GDA7](U'88;_9% L[+?.[UD4T45H6S0
M02M;@L<E0QKD^Y5.M!E,NC+)F);MG-7QU4?65%;8]IVZ]:RU:NH<Z3X6#I7+
MACRD4Y9;G(C<89Y4<FCX?_L;HZ>\QO3AO_1P4MQF5X:2IAK(&S4LK)H7?%>Q
MV*+LX:4XCF*E9,LI]J71M%EF6]-))0Z&OE>]V;L.<NRYR(FRY-PM;9]7#7T<
M553/:^*1,4<U45-[<-4QJ=2[*VB\<J_#L  C(
M            BK5'][^IY*]-A*I%6J/[W]3R5Z; /-U,.U%W*?TB9R&-3#M1
M=RG](F<                   !DF@Q,DT           !I.5_:;4\;?209J
M4MM5L<J+H2DYY7]IM3QM])!FI2VU6QRHNA*!:<
M
M        9             ("U5/S31<2].,VK4\[28N2G3>:KJJ?FFBXEZ<9
MM6IYVDQ<E.F\'I*(
M                                           !];I/A];I ^@
M     <55\G?Q'*<55\G?Q 5#N_W]H.2_^7+?E0+O]_:#DO\ Y<M^2%D !4
M              <-9+V"BJ)D_P"G&YWD15*292JQ]X\I52L_Q(I7M1/^['=Q
M+M5T?9J&IB32^-S?*BH4AO\ 4S[%RF5C)4P;),]4QY6!E37*-M6?E&.W'Y;9
M$U&1M:U,$1,$,CXQ45J*FA3Z>N^+:Y?*S(ZFA69$1)&_M)ACI1">-37>6HMJ
MZ7N>K<KG4R8(JJJZ9)-]5WB#+X5K*:S'-Q3.7<^]":=2[8TU!=*2HJ&*U9T3
M-Q\4DO6>?U6N7A])_)FTX9W\>DV  YGJ@
M       $5:H_O?U/)7IL)5(JU1_>_J>2O38!YNIAVHNY3^D3.0QJ8=J+N4_I
M$S@                   ,DT&)DF@           -)RO[3:GC;Z2#-2EMJM
MCE1="4G/*_M-J>-OI(,U*6VJV.5%T)0+3@
M
M   #(            ! 6JI^::+B7IQFU:GG:3%R4Z;S5=53\TT7$O3C-JU/.
MTF+DITW@])1                    BK+-E*BNK3)0T2YUH2HF";*8(N>W3
M@J:4 D.T+<LVS\?=E9#&J;BN0Z%+?.P*I^9%:4*NWE7 K=8=S+QW^7MC:U4^
M.GD7%$^ [8T[Z+NJ>U7Y$98(5ELVL<V=B8I@QJ;/WN+J5TLG3U$50Q'PR,>U
M=UJXG*5<N-?"W;EWIBLF\3W.I5SD15<BZ&KN-1=U4+1J1
M                                               /K=)\/K=('T
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M1I'&W-8FA$,C3-IM.Y=M*5QUBM8\  (S
M       (JU1_>_J>2O382J15JC^]_4\E>FP#S=3#M1=RG](F<AC4P[47<I_2
M)G                    9)H,3)-            :3E?VFU/&WTD&:E+;5;
M'*BZ$I.>5_:;4\;?209J4MM5L<J+H2@6G
M
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M47!4W,=WC(CAU/=VXY6OS,<U<?UDGKDM6'9=/8UFQ45&W-BC1$1,57<1-WB
M[X                                                       !];
MI/A];I ^@          <55\G?Q'*<55\G?Q 5#N_W]H.2_\ ERWY4"[_ ']H
M.2_^7+?DA9  5                !-)4?5 =]>S/M/^4MPFDJ/J@.^O9GVG
M_*!:^SOD,')0[)UK.^0P<E#L@
M     "*M4?WOZGDKTV$JD5:H_O?U/)7IL \W4P[47<I_2)G(8U,.U%W*?TB9
MP                   &2:#$R30           &DY7]IM3QM])!FI2VU6QR
MHNA*3GE?VFU/&WTD&:E+;5;'*BZ$H%IP
M
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MCI*=L$#<V-N."<:XGRDHZ>CC2.FA9&U/HM1/0<Y$
M                                          ^MTGP^MT@?0
M   .*J^3OXCE.*J^3OX@*AW?[^T')?\ RY;\J!=_O[0<E_\ +EOR0L@ *@
M              FDJ/J@.^O9GVG_ "EN$TE1]4!WU[,^T_Y0+7V=\A@Y*'9.
MM9WR&#DH=D                                         15JC^]_4\
ME>FPE4BK5'][^IY*]-@'FZF':B[E/Z1,Y#&IAVHNY3^D3.
M      R308F2:            TG*_M-J>-OI(,U*6VJV.5%T)2<\K^TVIXV^
MD@S4I;:K8Y470E M.
M                                               ,@
M $!:JGYIHN)>G&;5J>=I,7)3IO-5U5/S31<2].,VK4\[28N2G3>#TE$
M             #2LLNT"T?LW_EO-U-*RR[0+1^S?^6\"/-2=M3G^V7H,)X('
MU)VU.?[9>@PG@
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M\J/L4KVQUS$17,<K4795VYG*NA"? D8
M           BK5'][^IY*]-A*I%6J/[W]3R5Z; /-U,.U%W*?TB9R&-3#M1=
MRG](F<                   !DF@Q,DT           !I.5_:;4\;?209J4
MMM5L<J+H2DYY7]IM3QM])!FI2VU6QRHNA*!:<
M
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MED=3Z6Y[E5$^ Y^QH32Y"6I-3:TH/C7(]J.;LHI],0
M                                         ^MTGP^MT@?0
M  .*J^3OXCE.*J^3OX@*AW?[^T')?_+EORH%W^_M!R7_ ,N6_)"R  J
M         :9E:MV2P+G5E13NS958]J+BJ*GZ-Z[B^(W,C;+Y1/J[B578T55:
MCG>2*0#4\C5C4U18CK>K8636A6S+-V61J.<B.:QVE=G3LZ3>*WY2W_YNFL9%
M)4EN!0M33!FPN3QI&SK-GKOE*<?]3=7X6'<JJ6"MIG0543)8W)LM>U%3^) -
M[J-<G=]Z:LL9SJ>GG<K7,9\!NAJ)L-P^DI81FA" \NT[;1O+9U# N=(DCEP3
M_P#5J2WP+04<WNBF9*G[6/I.<ZEE1K#01,=I3'TJ=LU(
M                     !%6J/[W]3R5Z;"52*M4?WOZGDKTV >;J8=J+N4_
MI$SD,:F':B[E/Z1,X                   #)-!B9)H           #2<K^
MTVIXV^D@S4I;:K8Y470E)SRO[3:GC;Z2#-2EMJMCE1="4"TX
M
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MFZ-):U3&R*69ST5K,<$S7*F[Q&SD>Y!.]A9G+E_,<2$$
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M/_VC>6M:QJ-8F#4T(29F0T'T @
M   !%6J/[W]3R5Z;"52*M4?WOZGDKTV >;J8=J+N4_I$SD,:F':B[E/Z1,X
M                  #)-!B9)H           #2<K^TVIXV^D@S4I;:K8Y47
M0E)SRO[3:GC;Z2#-2EMJMCE1="4"TX                     #R[;MZS;$
MIG36A5,B:FYLJN[N)CO$,WCR^+!7OBL.R'5T#5_6]D?'C]RL GH$%7?R_4\T
MR,MNS74+-U^=))N+O,XB9;%MBAMJC956;.V:%R8HJ(J;JIH79W% ]
M                                                         &0
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M6/S##Q.Z<1/I 6JQ^88>)W3B!"1\@G>QLSER_F.)"(]R"=[&S.7+^8XD(
M                                           'UND^'UND#Z
M    !Q57R=_$<IQ57R=_$!4.[_?V@Y+_ .7+?E0+O]_:#DO_ )<M^2%D !4
M               $TE1]4!WU[,^T_P"4MPFDJ/J@.^O9GVG_ "@6OL[Y#!R4
M.R=:SOD,')0[(                                         BK5'][
M^IY*]-A*I%6J/[W]3R5Z; /-U,.U%W*?TB9R&-3#M1=RG](F<
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ML:6HMRG6&1LCFIBK-"9N'Q>-0)"
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MXG=.($)'R"=[&S.7+^8XD(CW()WL;,Y<OYCB0@
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M<5^ 'M \JS+PV5:;\RBKH)7[S78GJ@                #)-!B9)H
M     #2<K^TVIXV^D@S4I;:K8Y470E)SRO[3:GC;Z2#-2EMJMCE1="4"TX
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M#,
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MGT@+58_,,/$[IQ A(^03O8V9RY?S'$A$>Y!.]C9G+E_,<2$
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M44R/ N'7+:%T[.J'*JN=$W%5XCWS               R308F2:
M  TG*_M-J>-OI(,U*6VJV.5%T)2<\K^TVIXV^D@S4I;:K8Y470E M.
M            !U;5^:JW[!_14[1U;5^:JW[!_14"I>1[OY6CRI^FA;N2&.1?
MAQL=QM12HF1[OY6CRI^FA;Y=*@8MC8SXC&MXDP,@
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MM)BY*=-X/243H6[\SU?(.^="W?F>KY %4]3=MXK_ +3_ )%+7J50U-VWBO\
MM/\ D4M>H4  0                             " M5C\PP\3NG$3Z0%J
ML?F&'B=TX@0D?()WL;,Y<OYCB0B/<@G>QLSER_F.)"
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MT/=$F)N36M8U&L:C6IH1#7?);).[2V8\5,4:K B(U,&HB)O(?0#!L
M   !R0?K$*V9*N_C:O\ X_Y+BR<'ZQ"MF2KOXVK_ ./^2X"S8
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M\*M/<F@[6W6L^F5,',B:BHN_@>X<-)/!44[)*61DD*I\%S%14P^XYC
M         R308F2:            TG*_M-J>-OI(,U*6VJV.5%T)2<\K^TVI
MXV^D@S4I;:K8Y470E M.                  !U;5^:JW[!_14[1U;5^:JW
M[!_14"I>1[OY6CRI^FA;Y=*E0<CW?RM'E3]-"WRZ5
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M"U6/S##Q.Z<0(2/D$[V-F<N7\QQ(1'N03O8V9RY?S'$A
M                               ^MTGP^MT@?0          .*J^3OXC
ME.*J^3OX@*AW?[^T')?_ "Y;\J!=_O[0<E_\N6_)"R)I*_ZK'YBIOM4Z+BP"
M:2O^JQ^8J;[5.BXJ)#R0=[^@^[H--Q-.R0=[^@^[H--Q
M                 Y(/UB%;,E7?QM7_ ,?\EQ9.#]8A6S)5W\;5_P#'_)<!
M9L      .O75D-#2OJ*E52)B8JJ)B!V 1V_+'<]DKHUK9LYNPJ) ]?Z'S7DN
M?PR?S=_4!(H(ZUY+G\,G\W?U#7DN?PR?S=_4!(H(ZUY+G\,G\W?U#7DN?PR?
MS=_4!(H(ZUY+G\,G\W?U#7DN?PR?S=_4!(H(ZUY+G\,G\W?U#7DN?PR?S=_4
M!(H(ZUY+G\,G\W?U#7DN?PR?S=_4!YFJ%O'+9-V4HJ*5S*FJ1416K@J9KXU]
M"D<V'=:@LZRTDDIHY*E_PE>Y-G3_ .YY666^=EWDO99RV;,^2G:LF*NC5NEC
M-]-]JFU6Q;%%1T#'32YK<U-Q?$=O25CS:7#UEK>*P^,:WL21-:B-78P/&O9<
MZ@K[,EDIZ>..I8U7(YK=G' \.:_M.DN%# ^9R+NXM_H<T&45['?^MH'1Q[JH
M]7;'W-.F;X[1J7+6F2L[AZ60FUJA+0K[%M![I$B5<Q'+C@B.:U/0;EE*N906
MC9$]734T<59$BO21K=G81R^E2+\E]J4]7E-J*F!5;'(U-A472LN.[QD_6O74
M\=E5SI78-6%Z:/\ *IQ1$:F'JUF9C<M.U-MZ*NI95V':$SY'TKWHQ7+C\%J,
M3^JD\%0,E-Z[+N_E)M2JKYGQTSNR(BMC5VRKF;W$I/6O)<_AD_F[^HYF:101
MUKR7/X9/YN_J&O)<_AD_F[^H"101UKR7/X9/YN_J&O)<_AD_F[^H"101UKR7
M/X9/YN_J&O)<_AD_F[^H"101UKR7/X9/YN_J/K,L=SWRLC2MFSGN1J(L#]*_
M<!(@.K9M=!:-%%54KE=#*U'M54PQ14Q0[0 R308F2:            TG*_M-
MJ>-OI(,U*6VJV.5%T)2<\K^TVIXV^D@S4I;:K8Y470E M.
M    !T[8>UEDUJO5$3L#]E>2IW"#LNU[ZN69MV[O.5:N1$65=A$1,Y[')LIA
MO;H$,7&O#27?RO6E7U;OT.?,W%$QTO3>XBR=C97+NVC4+%V=S'*NQC&J$$W7
MR1LEF[-;,Z.E?\)S<S=7#'91W&>Y;N1ZBDASK)F2"5NSAF*N/E<;.U;3'G"S
M-)50UD22TTC7L7=13F*H7/O=;F3.U&TENYTMG+BF+5;L8(N&AJKI<FZ6CLBT
M:>UK/BK*-V=!*F+5PPW53^AA,:\2R=P $
M        ".<NUJS65<NH?3O<QSLW91?_ *K.LD8CW+A8TULW,J(Z=N<YN;L?
M_K&+_0#@R/V73V?<JD=%$ULKW29SD397X;L#=C1<CMM4MHW/I86/_3QN?G-7
M8_;=@;T90VP*U'M5KDQ:NE%*[92[-CL'*?8-;9[4@62MIL_,V,[&5RKCY"P\
MDC(HW22.1K6[*JI7;*!:C+SY3[#H[.QD2&LIU>NA$1)51?224LLI9<JSV922
MKIDB:Y?O0[1UK,A6GLVEA73'$UB_<AV2-8               #(  #P;]M<^
MZ-IM9\98]CRH>\<55#'44[XIDQC<F"H!!,<%G5N2BTXJ3!9V/E5WQM.*;YUH
M*NAJ,F4;E5$JZ.=SHU^%\9L>QXM)[U!8EU;JVM:?NJV&-BK$V8%BEV%SE5=G
M%378\FEG5%XJ:>DMYJV?+.V7W.E._P"'B['#.5V*8IL!4WW.J75=VZ"63XRP
MQX_@0]DZ]G4L='10T\*81QL:U.)$P_H=@(  " M53\TT7$O3C-JU/.TF+DIT
MWFJZJGYIHN)>G&;5J>=I,7)3IO!Z2B="W?F>KY!WSS[P*K;%K%1,5['H JKJ
M;MO%?]I_R*6OP4HK<"\5KV!>6MFL6F=/*LBXHCF)^VOTD4E)<J]^_!$O.P>H
M%68S5&:I6?76OWX(EYV#U!KK7[\$2\[!Z@19C-49JE9]=:_?@B7G8/4&NM?O
MP1+SL'J 68S5&:I6?76OWX(EYV#U!KK7[\$2\[!Z@%F,U1FJ5GUUK]^")>=@
M]0:ZU^_!$O.P>H!9C-49JE9]=:_?@B7G8/4&NM?OP1+SL'J 66D7L<;GNT-3
M%2J65&VZZ^N4"2Q:=ZI1TTSH7-P:N*ME<W'91%T.WSTJO*I?J2DG8^R94:Z-
MR*O98=A,.0>%D;EDK;W6G6U;/_5R/F>]JJFPJN:JZ-C294CE.DF=0EBZ%TZ&
MP+-BBCB19</A.Q<F*\6*[Q[T])!/&Z.6/%JI@J8J=;W3/]'^*#W3/]'T';&H
M\-&T3Y0;KI=FT([?L=.QYBKG(FS\;!NERKOKN%E+O6K#;ED06A2_JI<[#3N.
M5NZB;Q#V45[YKIU;96_!Q9TT(UR?Y1+WV3=Z*DLV@DGI6*[-<DD2:7.5=+57
M2JG+EK$3X;J3N%O,U1FJ5GUUK]^")>=@]0:ZU^_!$O.P>H:F2S&:HS5*SZZU
M^_!$O.P>H-=:_?@B7G8/4 LQFJ,U2L^NM?OP1+SL'J#76OWX(EYV#U +,9JC
M-4K/KK7[\$2\[!Z@UUK]^")>=@]0"S&:I .JQ14L&''>=TXCQ==:_?@B7G8/
M4- RN7SO)>&S6QVW1/IV)C@JOC=^TSZ+4WD"K09!.]C9G+E_,<2$1WD 55R7
M68JZ>R3?F.)$"                                              ?
M6Z3X?6Z0/H          '%5?)W\1RG%5?)W\0%0[O]_:#DO_ )<M^5 N_P!_
M:#DO_ERWY(61-)7_ %6/S%3?:IT7%@$TE?\ 58_,5-]JG1<5$AY(.]_0?=T&
MFXFG9(.]_0?=T&FX@                                <D'ZQ"MF2KO
MXVK_ ./^2XLG!^L0K9DJ[^-J_P#C_DN LV     &MY0MJ=?]F[HJ;(:WE"VJ
M5WV;NBH%6L@-VK+O!>BUF6M3).UBIFHKW-_97Z*H3OK974\&MYV7UB(-3#MK
MMG[NBI9$X\MIBSIQQ'%INME=3P:WG9?6&ME=3P:WG9?6-R!KY3^MG&&FZV5U
M/!K>=E]8:V5U/!K>=E]8W(#E/Z<8:;K974\&MYV7UAK974\&MYV7UC<@.4_I
MQAINME=3P:WG9?6&ME=3P:WG9?6-R Y3^G&&FZV5U/!K>=E]8:V5U/!K>=E]
M8W(#E/Z<80[E4R9V/#=>:KL6C2*J@38P>]V.+VI^T[#1B0)2RU5\+9C@G7!D
M7P5387<^[Z)<R\"9UC52*F=L-V/^Y"K&3*DC?7USVX)*CTV/O<>AT&\EN$SX
M<'73&.G./EO5E632V;3-CIV8*B;*XK_53FJ5C<Q6N3.Q3#2?5@FQ5-DR]Q8I
MBKMGB/HHU$:A\SYF=RT2UJ)EW;P6=;-,F;'V=G9>)%5RZ<?0>Y?^_P#%;=GT
MMEV&W/FG8Q'JCM#E1S5^,U-]-TZF4JF5MVI5<[1G*FQNYJF[Y!;E6:EW(+5J
M($?4.5JHY7.W61NW\-/B/%ZZT8K>/;WOY\SEIJ?3FR79*K);=R.IMVD2:LF^
M&N+W-TM3Z+\-.)N&ME=3P:WG9?6-Q:U&M1K4P:FA#Z>1-YF=[>M%8B---ULK
MJ>#6\[+ZPULKJ>#6\[+ZQN0)RG]7C#3=;*ZG@UO.R^L-;*ZG@UO.R^L;D!RG
M].,--ULKJ>#6\[+ZPULKJ>#6\[+ZQN0'*?TXPTU,F5U/!K>=E]8AG+M=.QK!
MK[+?95*D+EFBQ5'O7]M^^J[R%F$TD!ZI/Y99/VT/3>;,5IFS"\1Q3CDNVCV1
M^ZQ=!IM9JF2[:/9'[K%T&FUG8Y0R308F2:            TG*_M-J>-OI(,U
M*6VJV.5%T)2<\K^TVIXV^D@S4I;:K8Y470E M.  (FOUEILZZ5KK05-,DCT1
M%Q[*YNE/$Q36_?(V3P%.?=_:(\RHT4-?EILZGJ&YT3YHD<F*[*8>(GNER:79
M=1TSEL]F*Q-5?TDF]R@-']\C9/ 4Y]W]H>^1LG@*<^[^T;[K978\'LYR3UAK
M978\'LYR3U@-"]\C9/ 4Y]W]H>^1LG@*<^[^T;[K978\'LYR3UAK978\'LYR
M3U@-"]\C9/ 4Y]W]H>^1LG@*<^[^T;[K978\'LYR3UAK978\'LYR3U@-"]\C
M9/ 4Y]W]H>^1LG@*<^[^T;[K978\'LYR3UAK978\'LYR3U@-"]\C9/ 4Y]W]
MH>^1LG@*<^[^T;[K978\'LYR3UAK978\'LYR3U@(]J]4?9;Z2=L5$B2.8Y&K
MV=VPN&Q_TS3,E-L-MV^-KVL]NS,^9R;.C.<UV\F_O$XU.3"[4E-,QEGL1[V*
MUJY\FPN'*(:NO017.RCVE9]6SL$$KYEAQ55Q:LF:W?7]DSQ_:&-OA),,V94*
M]="G;]WMWOXG,V")R9S4Q:NRBGWW/'O'8TM&RLQPU]T*E[V_#C5B-7%=U[36
MLEF7"BNO=6GLRLIDE?"W!%[*K?VG+H1B[^^>GEEMZCI+!DL^%Z.GE5JJW93#
M![5WC9,D.36R9+E44UL4#754C55V+W)H>[>=AHP.7-]FW''AU_?(V3P%.?=_
M:'OD;)X"G/N_M&^ZV5V/![.<D]8:V5V/![.<D]8U,VA>^1LG@*<^[^T/?(V3
MP%.?=_:-]ULKL>#V<Y)ZPULKL>#V<Y)ZP&A>^1LG@*<^[^T/?(V3P%.?=_:-
M]ULKL>#V<Y)ZPULKL>#V<Y)ZP&A>^1LG@*<^[^T/?(V3P%.?=_:-]ULKL>#V
M<Y)ZPULKL>#V<Y)ZP&A>^1LG@*<^[^T/?)61NT*<^[^T;[K978\'LYR3UCP;
M^Y.[N4MT;0F@H6MD8C,%SW[&+VI](#8\F>46DOU#-)1P]C2-41?AJ[3G;[4^
MB;V5OU)#49!:;4T(]GIE+(                       ^*B.:J.3%%/H JQ
M?JZ-X+B7JEM:[^<M&[-5,$8FAJ8_&55TJNX>U9.7OL-.V&U+.S:AB8.<M1I7
M[H\"Q,T$4[%9,QKVKN*:]6W&N_5R*^:@8KETKGO3T*%B=*[WJRA7@OZ]+,L"
MF=!32KFNPD8_'2B_&:U=U-TE3(ODU;=BF]WVC\.OE3.78PPQS';CE32BDB63
M=^R[)1/<-(R->-5]*J>J#8  @               #(  #QKY5#Z6[%H3Q?'9
M'BGE0]DZ%OP15-CU4-2]K(7MP<YRX(B8@5YK;H4K<GMI6Q-+))5N?(Y%[([8
MV471]YZM=93'Y-*"TXY'LJ:6;LC5SEV<V/%$-2M6BO73V7:%F61336G9DTC\
MV2GB5Z(JKLICY#T;M6=?"W([.L2OLNKH[/BJ&/D?+ K45NPU=GB50JP=SJE]
M7=R@EE^.L+,?PH>R=:S*1M#9]/3,T11M9Y$1/Z'9"   @+54_--%Q+TXS:M3
MSM)BY*=-YJNJI^::+B7IQFU:GG:3%R4Z;P>DHG0MWYGJ^0=\Z%N_,]7R *I:
MG%C'WWKT>QKD[)^TF/\ U%+6+3T_U$7X$*J:F[;Q7_:?\BEKU"N+W/3_ %$7
MX$'N>G^HB_ AR@(XO<]/]1%^!![GI_J(OP(<H XO<]/]1%^!![GI_J(OP(<H
M XO<]/\ 41?@0>YZ?ZB+\"'* .+W/3_41?@0>YZ?ZB+\"'* .O/1T\L$L:P1
M8/:K?B)NE4+SPU5P<I]75RQJVDJIY)$5,,,UTR_T:6W-6O[<^BO99CH*EB)*
MB?!?H7%$=A_%2Q.IV?+6K"M>DMF@CJJ1Z.:],<,-!Z"YK4578(B$+5UP;X73
MJW]I&35-.BXHUD;W_P#S0<$D&42UD]SNLRK@:[85SJ=R'1&:->6KMR]W*O>2
M&J@[16>[LE5*J8HB?1<CMWQ$WW(NW!=V[=+9KHHGNBS\79N..+W.W>,B[)?D
MEFL^T8[4MURR5"(OP79VZU4T*G$3F:+VY3MLK&H<7N>G^HB_ @]ST_U$7X$.
M4&*N+W/3_41?@0>YZ?ZB+\"'* .+W/3_ %$7X$'N>G^HB_ AR@#B]ST_U$7X
M$'N>G^HB_ AR@#B]ST_U$7X$($U5\4;+"AS(V-V'?%:B?MQ%@" M5C\PP\3N
MG$%2/D$[V%F<N7\QQ(1'N03O8V9RY?S'$A!
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M)3DS2[<RU]>[LE8[!=G'87X*[OC1253R.JSSFOM['2X(P4X@ .9T@
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M_F--D-;RC[2;3XH_S&@A$&I+_56IRV>F4L>5PU)?ZJU.6STRECP
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MO  Q        ')!^L0K9DJ[^-J_^/^2XLG!^L0K9DJ[^-J_^/^2X"S8
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M39#6\H^TFT^*/\QH(1!J2_U5J<MGIE+'E<-27^JM3EL],I8\
M                                    #(  #P[\1OENI:3(L<]8]C#C
M0]P\&\%Y+&LVGG9:55"W-;BZ-7MSE^Y5 TW)!;]C-L.:F[)3T]0R=Z/1RL8J
M[.G3B998K8LV:[S*6*:">IED5D36.:Y4<K'(B["XZ30:VZ-WK7J);1L&\3+.
M[(Y<8\^-F*XXXZ?&8T%W+%N_74UIVW>%;5[%*UT<#'LD57-7%-A%\2I]X5.E
MS8Y8KM6>V=79Z0QZ<?H(>T=2R:F*KLZGG@:YD3XVJQKDP5$5$5#MA   0%JJ
M?FFBXEZ<9M6IYVDQ<E.F\U754_--%Q+TXS:M3SM)BY*=-X/243H6[\SU?(.^
M="W?F>KY %4]3=MXK_M/^12UZE4-3=MXK_M/^12UZA0 !
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M+LI_D<G]2"<F>466XU5:M%'03UD2U+U3L;%<C=A$PV.(PM&F,PM\" /? R^
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MGQ1_F-!"(-27^JM3EL],I8\KAJ2_U5J<MGIE+'@
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M$T)/.B<6?$6G72I5C4O;;[<_>*C\R(M.NE3OAQR'UND^'UNDJ/H
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MZS=KJ9-K%N^J/CIXWRZ<Y6X;_C\9NX,IO:?&TBD0^(B-:B(F")N'T Q9
M          FD@/5)_++)^VAZ;R?$TD!ZI/Y99/VT/3>;,7V89/JG')=M'LC]
MUBZ#3:S5,EVT>R/W6+H--K.UR!DF@Q,DT           !I.5_:;4\;?209J4
MMM5L<J+H2DYY7]IM3QM])!FI2VU6QRHNA*!:<  5(RA=_2R_MX?06FHOD%+]
MBST%6<H7?TLO[>'T%IJ+Y!2_8L] '*
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M/5\@"J>INV\5_P!I_P BEKU*H:F[;Q7_ &G_ "*6O4*  (
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M3XH_S&@A$&I+_56IRV>F4L>5PU)?ZJU.6STRECP
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M3H6[\SU?(.^="W?F>KY %4]3=MXK_M/^12UZE4-3=MXK_M/^12UZA0 !
M                          ("U6/S##Q.Z<1/I 6JQ^88>)W3B!"1\@G>
MQLSER_F.)"(]R"=[&S.7+^8XD(    32 FD"K>J9[X5@\A?S">K+^;J?D$"Z
MIGOA6#R%_,)ZLOYNI^0<V?TWX?;M  YV\
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M8=M=L_=T5+(X'%E^SJQ?4 P&!K; # 8  ,!@  P&  # 8  ,!@  P&  # 8
M ,!@  P&  # 8  ,!@ 320'JD_EED_;0]-Y/B)LD!ZI3Y99/VT/3>;,7V89/
MJG')=M'LC]UBZ#3:S5,EVT>R/W6+H--K.UR!DF@Q,DT           !I.5_:
M;4\;?209J4MM5L<J+H2DYY7]IM3QM])!FI2VU6QRHNA*!:<  5(RA=_2R_MX
M?06FHOD%+]BST%6<H7?TLO[>'T%IJ+Y!2_8L] '*
M            :WE'VDVGQ1_F--D-;RC[2;3XH_S&@A$&I+_56IRV>F4L>5PU
M)?ZJU.6STRECP
M ,@            $!:JGYIHN)>G&;5J>=I,7)3IO-5U5/S31<2].,VK4\[28
MN2G3>#TE$Z%N_,]7R#OG0MWYGJ^0!5/4W;>*_P"T_P"12UZE4-3=MXK_ +3_
M )%+7J%  $                              @+58_,,/$[IQ$^D!:K'Y
MAAXG=.($)'R"=[&S.7+^8XD(CW()WL;,Y<OYCB0@   !-(":0*MZIGOA6#R%
M_,)ZLOYNI^00+JF>^%8/(7\PGJR_FZGY!S9_3?A]NT #G;P
M                /*O9M7M3]VEZ#CU3RKV;5[4_=I>@XL?*(-U+VV^W/WBH
M_,B+3KI4JQJ7MM]N?O%1^9$6G72IWPXY#ZW2?#ZW25'T          #BJOD[
M^(Y3BJOD[^("H=W^_M!R7_RY;\J!=_O[0<E_\N6_)"R)I*_ZK'YBIOM4Z+BP
M":2O^JQ^8J;[5.BXJ)#R0=[^@^[H--Q-.R0=[^@^[H--Q           #SKQ
M6@VRK"K:URHG8HG.3'?1"J=VZ>>_64"KK:YSGP0S.P1<<,&RHOC30Y2RV4ZF
MEJ[CVG'3XYZ1N78QT9J[Q7S(/50TUL6I339J3]DE;LX8XY\:<>DSQQ$V\I;Q
M":*2GCI*>."!J-CC1&HB)AH.5R(YJM<B*BI@N)]784X:N=E+2R3RJC6,:JJJ
MKAN':T((REV;-=2]4-KT"K%'*]57-Q1-EV&Y@6;N9;D-LW=I:MTL:2.1<[%R
M?25-_P 15:_5XJZ_DZTM'3,BI878-E5CME$7%-E%5#M638]YZ2B9%3WBK8(T
MT,BK)6II7<0T=B^2=TCP6ZG'C\7GRMXU4<F+7(O$?2L5)?V^%TF(M2J6E3MT
MND=-*[RJY$TN_@3%DSRCV??:D_1)V"K;AG1.5J+LJ[0F<JZ&XFF^.U)U:&W'
MDKDC=)VWL &#,       !R0?K$*V9*N_C:O_ (_Y+BR<'ZQ"MF2KOXVK_P"/
M^2X"S8     :QE(D['=&N<J*OP')L<E39S6LHB(ZZ=<BHBIF.T\E0*9Y,[^K
M<RW+1J$A=)V543!&HN&QANJA)'O@G\"DYMOK'A:GR[]EVW>:UX[5HJ:I8S#-
M26%KT3X*_212>M;JZG@.S?,XO5.;)-8MYAOI%M>)1#[X)_ I.;;ZP]\$_@4G
M-M]8E[6ZNIX"LWS.+U1K=74\!6;YG%ZIARI^,^-OU$/O@G\"DYMOK#WP3^!2
M<VWUB7M;JZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<
MVWUB7M;JZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<V
MWUB7M;JZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<VW
MUB7M;JZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<VWU
MB7M;JZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<VWUB
M7M;JZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<VWUB7
MM;JZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<VWUB7M
M;JZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<VWUB7M;
MJZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<VWUB7M;J
MZG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$/O@G\"DYMOK#WP3^!2<VWUB7M;JZ
MG@*S?,XO5&MU=3P%9OF<7JCE3\.-OU$7O@G\"DYMOK&AY1,HW=A66?G0/CS)
MH]+430Y5WU^D693)U=3'YBLWS.+U2%\O5V[(L6LLOM79]+38S18]BA8S'X;_
M **)O(9XYK-O$,+1;7F5A<D\G9;BV0J(J?\ IHM/(:;>:GDL:C;CV1@B)_Z6
M+1R&FV'2T!DF@Q,DT           !I.5_:;4\;?209J4MM5L<J+H2DYY7]IM
M3QM])!FI2VU6QRHNA*!:<  5(RA=_2R_MX?06FHOD%+]BST%6<H7?TLO[>'T
M%IJ+Y!2_8L] '*                #%[V,3%[VM3QK@8Q3PRX]BFB?AIS7(
MH'(             &MY1]I-I\4?YC39#6\H^TFT^*/\ ,:"$0:DO]5:G+9Z9
M2QY7#4E_JK4Y;/3*6/
M       R             0%JJ?FFBXEZ<9M6IYVDQ<E.F\U754_--%Q+TXS:
MM3SM)BY*=-X/243H6[\SU?(.^="W?F>KY %4]3=MXK_M/^12UZE4-3=MXK_M
M/^12UZA0 !                              ("U6/S##Q.Z<1/I 6JQ^
M88>)W3B!"1\@G>QLSER_F.)"(]R"=[&S.7+^8XD(    32 FD"K>J9[X5@\A
M?S">K+^;J?D$"ZIGOA6#R%_,)ZLOYNI^0<V?TWX?;M  YV\
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M"4"TX  J1E"[^EE_;P^@M-1?(*7[%GH*LY0N_I9?V\/H+347R"E^Q9Z .4
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M^8TV0UO*/M)M/BC_ #&@A$&I+_56IRV>F4L>5PU)?ZJU.6STRECP
M                                        ,@            $!:JGY
MIHN)>G&;5J>=I,7)3IO-5U5/S31<2].,VK4\[28N2G3>#TE$Z%N_,]7R#OG0
MMWYGJ^0!5/4W;>*_[3_D4M>I5#4W;>*_[3_D4M>H4  0
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M/W=%2R)6[4P[:[9^[HJ61.++]G5B^H #6V
M    FD@/5)_++)^VAZ;R?$TD!ZI/Y99/VT/3>;,7V89/JG')=M'LC]UBZ#3:
MS5,EVT>R/W6+H--K.UR!DF@Q,DT           !I.5_:;4\;?209J4MM5L<J
M+H2DYY7]IM3QM])!FI2VU6QRHNA*!:<  4ZRM6G!9.6*BKJK.[##)$]V:F*X
M(A*]-J@+HQTL#')6YS(VM7] NE$(KRJ4$%HY9Z"EJF(^&66)KD7=144FVER.
MW/?24[W67"KG1M<OQ]*IR@KR??!W0WJWF%ZQ[X.Z&]6\PO6>UK-W/\%P_P"O
MUAK-W/\ !</^OU@/%]\'=#>K>87K'O@[H;U;S"]9[6LW<_P7#_K]8:S=S_!<
M/^OU@/%]\'=#>K>87K'O@[H;U;S"]9[6LW<_P7#_ *_6&LW<_P %P_Z_6 \7
MWP=T-ZMYA>L>^#NAO5O,+UGM:S=S_!</^OUAK-W/\%P_Z_6 \7WP=T,%P2MQ
M^P4TNY%NT=[LHE9:S4>L3(4S,]N"IA(BIZ23M9NYZ[':N'_7ZQ&5+9]#<#*6
MZA;&D='51L8S#'2Y^]L[B&5/E)2X^MB5%1,=&&@X*21%G>J;N)V&4\$L;9&(
MBL>B.1>,X9X>PKGQIL'2P>)E$LZ&T[M5+)415:BN15\2*5PM2U9I;"L^QV/5
M(XU:U4W%V?\ W)SRIWLI[(N_)$J_^HE3!&X+H5')IP*_6HZGI[.LFM23.GEP
M=(W-787.WS5?6U]3I+=W*"*S+$C8QJ(Y43%4XU/0I*ED<:H[''B/,N_7=M;-
MA='L)AL^5>H]IM)&B8*F*GM5UQC3YN^^4[^6+JN![5:]%5J[F!HV3F_E)<.]
M%5#7++[D=F;#&X[ZKL?>;Y[EA395J8&D9-;I4=\[Z5,E; V6E;F8HOWHNZB[
MAQ==KC#O_F[YS^)975!W0WJWF%/GO@[H;U;S"]9[6LW<],$[5PZ/\_K#6;N?
MX+A_U^L>8]AXOO@[H;U;S"]8]\'=#>K>87K/:UF[G^"X?]?K#6;N?X+A_P!?
MK >+[X.Z&]6\PO6/?!W0WJWF%ZSVM9NY_@N'_7ZPUF[G^"X?]?K >+[X.Z&]
M6\PO6>/?#+G=6U+M5M%3)5]FE1F;G0*B;#T7^AN6LW<_P7#_ *_6/$OODGNI
M076KJJFLV%DT:,S7)G;&+VI]+Q@:UJ27HZ&TE30Y[%3RRED2MVI)8C8;31$T
M/9AY92R(0                                               !D
M           @+54_--%Q+TXS:M3SM)BY*=-YJNJI^::+B7IQFU:GG:3%R4Z;
MP>DHG0MWYGJ^0=\Z%N_,]7R *IZF[;Q7_:?\BEKU*H:F[;Q7_:?\BEKU"@ "
M                              0%JL?F&'B=TXB?2 M5C\PP\3NG$"$C
MY!.]C9G+E_,<2$1[D$[V-F<N7\QQ(0    FD!-(%6]4SWPK!Y"_F$]67\W4_
M((%U3/?"L'D+^83U9?S=3\@YL_IOP^W: !SMX
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MJE=]F[HJ!7+4P[:[9^[HJ61*W:F';7;/W=%2R)Q9?LZL7U  :VP
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MTRECRN&I+_56IRV>F4L>
M        !D             @+54_--%Q+TXS:M3SM)BY*=-YJNJI^::+B7IQ
MFU:GG:3%R4Z;P>DHG0MWYGJ^0=\Z%N_,]7R *IZF[;Q7_:?\BEKU*H:F[;Q7
M_:?\BEKU"@ "                              0%JL?F&'B=TXB?2 M5
MC\PP\3NG$"$CY!.]C9G+E_,<2$1[D$[V-F<N7\QQ(0    FD!-(%6]4SWPK!
MY"_F$]67\W4_((%U3/?"L'D+^83U9?S=3\@YL_IOP^W: !SMX
M                  'E7LVKVI^[2]!QZIY5[-J]J?NTO0<6/E$&ZE[;?;G[
MQ4?F1%IUTJ58U+VV^W/WBH_,B+3KI4[X<<A];I/A];I*CZ          !Q57
MR=_$<IQ57R=_$!4.[_?V@Y+_ .7+?E0+O]_:#DO_ )<M^2%D !4
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M<Z*&9V=- N8OW-;UDE$#ZEW/?16C(N/8W3/PWOBQD\'B9(U:7I4G=0 &#,
M   $TD!ZI/Y99/VT/3>3XFD@/5)_++)^VAZ;S9B^S#)]4XY+MH]D?NL70:;6
M:IDNVCV1^ZQ=!IM9VN0,DT&)DF@           -)RO[3:GC;Z2#-2EMJMCE1
M="4G/*_M-J>-OI(,U*6VJV.5%T)0+3@ "I&4+OZ67]O#Z"TU%\@I?L6>@JSE
M"[^EE_;P^@M-1?(*7[%GH Y0          !Q5$\5-$LD[T8Q-*J:K:&4.[]%
M/V*2N@5VCXX&W@\*QKUV1:^"4=9"]Z_LH['>ZSW4V414T*
M   -;RC[2;3XH_S&FR&MY1]I-I\4?YC00B#4E_JK4Y;/3*6/*X:DO]5:G+9Z
M92QX                                                &0
M      " M53\TT7$O3C-JU/.TF+DITWFJZJGYIHN)>G&;5J>=I,7)3IO!Z2B
M="W?F>KY!WSH6[\SU?( JGJ;MO%?]I_R*6O4JAJ;MO%?]I_R*6O4*  (
M                         ! 6JQ^88>)W3B)]("U6/S##Q.Z<0(2/D$[V
M-F<N7\QQ(1'N03O8V9RY?S'$A    ":0$T@5;U3/?"L'D+^83U9?S=3\@@75
M,]\*P>0OYA/5E_-U/R#FS^F_#[=H '.W@
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M"*KIW(Z*3'-5%1="JFYQ':(RU/5H35V3RC2=RN6-JX*N*KLRR>/Q$FG&^G
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MN2>(*Z6I+_56IRV>F4L>5NU(S^R4UI/1%1'/9IXY2R(0
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M#=2]MOMS]XJ/S(BTZZ5*L:E[;?;G[Q4?F1%IUTJ=\..0^MTGP^MTE1]
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MS:_Y914\W+C1WI.^ /(H[M6+1S)+2V;21R(N*.;"U%]!ZZ;"8)L(FX $  %
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M_CB]4T]J6WN0M""KVN'E%X-/^.+U1KAY1>#3_CB]4=J3N0M""KVN'E%X-/\
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MQO#'(]J.8J*U=U##>V<1ID
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M:JNZJ[O&>H>9DOSG;MI7C&G'V&+ZO^([#%]7_$Y 8,W'V&+ZO^([#%]7_$Y
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M?)W\0%0[O]_:#DO_ )<M^5 N_P!_:#DO_ERWY(60 %0              FP
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MG.1J(J^[<,?]LES)-E 9?ZRI:MM'[D5CW,S.R]DT9N[FI](Q8M\
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M]\*P>0OYA/5E_-U/R"!=4SWPK!Y"_F$]67\W4_(.;/Z;\/MV@ <[>
M   #[CXD\A\50                 !Y5[-J]J?NTO0<>J>5>S:O:G[M+T'%
MCY1!NI>VWVY^\5'YD1:==*E6-2]MOMS]XJ/S(BTZZ5.^''(?6Z3X?6Z2H^@
M      8   <55\G?Q'*<55\G?Q 5#N_W]H.2_P#ERWY4"[_?V@Y+_P"7+?DA
M9  5
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M8XZ<.I#TP8L0
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M         #BJVO=2RMB7!ZM5$4JK:MP,I<MH3/BM:U$8N&"-EGPT)XRUY\P
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MDO\ Y<M^5 N_W]H.2_\ ERWY(60 %0
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MP5$5/&>?46+9E1)GSV?22.WW0M5?XH>@ .M34%'2IA3TL$?(C1/0AV0
M                                                         #(
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MI55_C'ODP7-N%8EU84;9],WLFSC(YK<[=W41-\VL
M":0$T@5;U3/?"L'D+^83U9?S=3\@@75,]\*P>0OYA/5E_-U/R#FS^F_#[=H
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M^7+?E0+O]_:#DO\ Y<M^2%D !4
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MJV.5%T)2<\K^TVIXV^D@S4I;:K8Y470E M.
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MWFJZJGYIHN)>G&;5J>=I,7)3IO!Z2B
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M.2_^7+?DA9  5
M               (IU1Z(MP*A53'!JX?C82L19JB]H-1R5Z; *J45CT]+=U;
M1CJWQU:*[-8U$V530==J7@K6825,G8U3=>AYMU85JZU,]<6L?C_$D'<PWC;C
MWKY>1_0ZSLVBM8B9:Q84-IW>M:&U(/AS0O;)LNPV47'^A93)CEFH[76.S[95
M8:S8:FPY<5^"FGC52$D7 \"\=.D3XJV+8EB<UZ+Q*JBU->8:^C_I6O>*9(^5
M\XI&RQM?&N+')BBF9'V0NVI+:R?T,TSL9&(UB['^5J_U)!-3VP
M   ,DT&)DF@           -)RO[3:GC;Z2#-2EMJMCE1="4G/*_M-J>-OI(,
MU*6VJV.5%T)0+3@
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MJ?FFBXEZ<9M6IYVDQ<E.F\'I*(
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M"HNAR[A9FCIV4E+%3Q)@R-J,3B0YMS#<!&(             'UND^'UND#Z
M         !Q57R=_$<IQ57R=_$!4.[_?V@Y+_P"7+?E0+O\ ?V@Y+_Y<M^2%
MD !4
M      BS5%[0:CDKTV$IE9M4U?QM4L=WK,^%BU>R/1=_,<FPK?$NZ#>D"W)G
MCCJ7M>N"J[^IO"31KH<:0V[L]+2I5QNQ5OPL,/\ W/3I+6II(T;(J->FPNRO
M4;J[KXE\]UV*,]N[B\Q[;.U4=H/)O-*UM"K%7X3MA$^Y3IOMB&E:KF.1RX;"
M?_$-FR8W*M&^EXH*RHC<E%&]'X[&XYKMQ470X6O&M,>AZ&]KQ>WB(3UJ:Z*:
MFR?P/F:K<]R.1/%F,):.G9%#'9EFT]'"F#(F(U-.YQG<-+Z,
M #)-!B9)H           #2<K^TVIXV^D@S4I;:K8Y470E)SRO[3:GC;Z2#-2
MEMJMCE1="4"TX
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M/>2*\.6&S[09'V)LE1&B-SL[34([3@GTB[L/ZIG$=E8U#EM\LP 9(R
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M5\G?Q 5#N_W]H.2_^7+?E0+O]_:#DO\ Y<M^2%D !4
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M70E)SRO[3:GC;Z2#-2EMJMCE1="4"TX
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M_P &3_CB'<O?'_!D_P".(MK@F\GD&";R>0<(.4JE=R]\?\&3_CB"W7OC@O\
M^YD_XXBVN";R>08)O)Y!P@Y2J%<W)O>UM_J&TJVP9Z6FCF8]RJYF"(DJ.W%W
ML2WD:81M3>0^X)O)Y#Z91X8@  R             0%JJ?FFBXEZ<9M6IYVDQ
M<E.F\U754_--%Q+TXS:M3SM)BY*=-X/240
M                                     0_E=R5=T<R6E8JLI[0;CBYN
M**[%6I^RF.A%-2L6V[YW6B2"W+&M&L@9_P!6.F>J;*JNEW&B%C3CJ((:B-65
M$,<K%TM>U')_$L3H01+E(M*K8K+*N[:TDJZ,*?.]"\9U;KW-O'>R]-/:5[()
MH:&G<CFP31O8JZ<=A45-XGBFLFSJ5V=34-+$[?9"UOH0[NY@B(B"9F1QT\,=
M/!'#"U&QL:C41$PV$V#D (                !];I/A];I ^@
M<55\G?Q'*<55\G?Q 5#N_P!_:#DO_ERWY4"[_?V@Y+_Y<M^2%D !4
M                                                       A?++D
MC2\TK;1L7L<%<U%1<$5,?BHFPUN\BDT "F,UV[W6$BMK;&M">)O_ %(Z9^;A
MQJAPPMMZL=V.BL&TI'KL?!IU7#R%T)X(:B-65$,<C%V%1[45/XG7I;+L^E=G
M4U#31.WV1-;Z$-D9;1&G#;^?@M;E,*VY,<E]NUUYJ6U+QT[X*:GD9*V*:-[5
MV'(NA4PT*I9N&-D,+(HT1K&-1K43<1#/<P1$0&$SOS+LI2M(XUCP  C(
M         #)-!B9)H           #2<K^TVIXV^D@S4I;:K8Y470E)SRO[3:
MGC;Z2#-2EMJMCE1="4"TX
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MIN^B^4E+$$M:;>9E:TK2-5AUJ*@HZ%B,HJ2"!J;D4:-]">)#L@&+(
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M_>7Q%9-8V^7"Z?SCV23<B>3ZW;HUU3+;,\<C)%:K49)G:&O3>3?0"8P $
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M?$_'!R.1<=G#?\0-#N-<ZU;'NM0T%;*QU1"C\]4?BFR]RILX;RH B2P
M                       '#5U4-)"LM3(V.--E5<N!YG=18WA"#\:&K9;W
M.2YE4C'*U58],?\ M4TRP<CM/7V'9U8^K<CZBGCF7]&FES47Z7C F:BM>@K7
M9M+512.WD<F)WRM5O7;M3)U>FQJNEK9'T,U5#$]N#6I\)ZJNZJZ&(3I#>FSH
MJ:D2JGS)I(&RJF:J["IQ ;"#QK(O-9EK5$D-%.LDD>.<F8Y-'&GC.I:M];$L
MNK]S5E4K)<<,$C<OH0#9 =6S;0IK1IVS4DF?&NRBX*GI.T
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M8$HTJG^XTC8Q&YJX9_9L-[> G('QCD>QKFZ%3%#Z
M                            !Y=3>"RZ698IZV%DB:6JY,3C9>:QWN1K
M:^!57_.A J76[K<IEI4\\[F,8UZI\%%T2X;Z;YL%K9%TI[/J)J*N>V:-CGMP
MC1-E$54_:W\ )O@FCGC;)"]KV+LHJ+BBF9%^12UY8KM6A16K,Y\MG5<D&>J8
M_!8QF]]YMU5?.Q:5C'2U2HCE1$_1N797[@-B!T*JUJ.EHFU<\N;"Y,47!5_@
M>39-]K$M6I6"CJU?(FXL;D]* ;* FR
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ML%5$W,UW4;!<"VZ:UKOT2PS+)*V!B28M5/A(QN/I V8
M                              !5P3%3R9KQV3#(Z.6N@:]-**]#TY_U
M+^(K5=.Y:7PO/;*U%0YB1R2X?!1=$F&^F^!8."\-E3O1D5= YR[F>AZC'->U
M',<CFKLHJ*5YOKDLJKOV/-:5DUSTEIVND5$8U-AK5=NKXD-JR'WV=:%TYUMB
M9<^CJ/<BN5%7%6L;O)Q@2Z#7)+ZV)'6,I75:]F?H3L;M_#>.>VKTV58T<;Z^
MH6-)/BX,<['R(![@/*L2\%G6U'GV?/V1/&U6[^_Q'J@
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MNR!9D1/V<YR.W/$!-2+BF*: =&PJN.MLBDJ(G9S'Q-<BX88XHBG>
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MW6MWZ1;17&JP=GK@B?M+AL)L:,#UBH
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M6F@P26FA;$Y,['9:QB+N>,HD$ !
M            !A/^I?Q%=LGMJVY9]Z+;2Q;,;6HKY<5=.R/#])_F^XL3/^I?
MQ$.Y$$5+R6]BF"9\WYB <MY9[]7DLR6SF6.RECF:Z-[TJ87[#D5J["X;YIMY
M[D2W-R82TTLJNJZRN9/)BB?!>Z-45-A532A9(B[5 HJW4@P3'_U4?H>!IEP\
MDEG2W<IK;M"=SJGL39\,U4V<U'8;#L-/B-1DKKOU]Z;1=>5%DA@?F0,_2)@B
MIL[+-GREA<G\79;AT,2ILOI&-\K$(SL:\M/<&]5MT-LQ805$J.B>KL,4:WQ(
MJ[I%1A76O27<MZ.TKE_$3.SHEQW4S4V9$7?4MY9%6M=9T-0J8*]%7#[U0@RU
M,HMHWDO#!072BS8ESLYZ9KTV$Q3XR>)2>J1KV4[&RKB]-*X8%'*  @
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MKH:B;O$>H>-<ZU(;8NY05<'Q'PL73C^RB_U/9*@
M                          #@JZ2"KB6.IC;(Q=*.0Y8HVQ1,CC:C6,1&
MM1-Q$T&0 '0EL>@EK&U<E-&ZH30]4V=./I.^ "HBHJ+LHIX=;=.Q:V99:BAB
M<]5Q5<,,3W !TK.LJBLYF;14\<2?Y4.Z
M      ,98VRQN9(B.:Y,%1=TR '3H+,HZ!7+20,B5VG-3#$[@ 'QS4<F#D14
M\9XM3=6QJF;LLM!"K]_# ]L <5/30TT?8X(VL9O-3 \VT;MV3:,J25=%%(]-
MW ]< =.S[+HK.;FT=/'$G^5#"NL>@KIHY:JFCDDC<CFN5-E%30=\ ?(V-C8U
MC$P:U,$3Q'T
M#J0V=20U+JB*!C9G;"N1-E=G$[8 '%4T\53"Z*=B/C=L*BG'0T--01K'20MB
M8NXU,#L@#IVA9E':#,VLIXY4_P S<3S::Z%ATTW98K/B1^XJIB>\ #41J8(F
M"                                   =.T;+H[1:UM;3LF1NC.3$[@
MXZ>".GB;'"Q&,30B;AR  =2T;.I+1A6*L@9*Q=QR?_-XZEGW=LJSW9U+1Q,=
MOX;)ZP X:ND@JX'0U,39(W)@K7(>/2W1L2FE[)%01(]%Q153$]X =:IH*:II
M%IIH6.@5N:K%38PPP.M95AV?96=[@IF0YRXKF_=U(>D
M                                "IBF"G5H[/I:.1[Z:%D;GXYRM33B
M=H #KUM%3UT:1U4396(N.#DQV3L #CIX8Z>)L<+48QJ8(B;AYUJW?LRU'(ZN
MI(Y7)NJFR>J /*LR[UEV8[.HJ.*-V^B;/_S9/5
M              #I2V712UB5<E.QU0B8(]4V<#N@ #SK3L2SK3^74L<J[ZIL
M[G4AZ( \^S;&H+-3"CIHXO&B;)RU]G4E>S-JX(Y4_P R8G; 'D6?=JR:";LM
M+11,DQQSL#N6A9U):$/8JR!DL>\Y/%A_4[8 X**D@H:9D%+&D<3$1$:FYN'.
M
M    ?%>U-+D3[SYV1GTV^4#(!%14V%/F<F.&*8@?0      ^*J)I5$ ^@(N.
M@       'Q'(JX(J8[Q]
M                                                  'QSVM^,YJ<
M:@?0?&N1WQ51>(*Y$TJB<8'T&/9&?3;Y3)%1="X@ !BF.&*8@ #XKFHN"N3'
MC ^@
M                                  #XKD32J)QJ?$D8NA[?*!D!IT
M#'LC,<,]N/&9  ?,YN.&<F/&?0 /BJB:51#Z !\5R)I5$/H
M
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MRN>YKD557'0]4_H;"$
M                                           &@97;\=QUC=D@S754
MF&8U<?I(FXJ+NFK7+N]>>\]F=L+:MVUJ%TB(YD=/4N:F[CL.1=Y#6=4F][[:
MLZ.55[#L\7QT)[NRUC+"HTC1,W,V,.-0J%KR+?:XUIPRT51:=M4;L45LDDLZ
MI\%-QN&ZY?(;%E7M:TWT=@MHJJKLZ2K?,U_8GNB=\'-P_P#GC)4JDI\U%J>Q
MX;F?A_4BW+2K5M*[>:J*G99M'):$=N*X=KR4\<C+U6YBYB+LUB[W$>"RMO-<
MN]MGTUJUM16V9631P))/,^3!579WDT(3+0?(J?[-OH(XRXX-H[OO1$STM%JH
MOCS7 ;-?B]<=VK#6M[&Z5[VKV-C6YV*YJJFPB^(BVXU]+PW@RB1):+9Z2ADA
M:^*'](QKFK,W!V:Y<-"JA,$5F4=K611-M&FBJ$;&QR)(U'8+F^/C4T*T*:&D
MRNV;#31,BB90QHUK4P1$2HP0#8LJEZ9+KW<DJ*;-6H<N:S''=1V\J+I0T*Y]
MF7HO'=F2VJJW;2IZA[>S1PQU3T9@K<[#!=G2;?EJL":V[JR>Y6YTT2H]$XD<
MO]2.[@Y2.U%SI+*KZ69*V!G8$;V)RZ&88Z=\*V?(]?JT+3M:NL.VW(ZHI<$1
MZN<YSMA57%7+Q$OE6<BE14U64NT*F=JM=+BN&SL?!+3!
M
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M7:\C5=4.E2-'8+AG,7?\9R9";>99-ZZVR$EQIW/7-V=C!&K]Q%66 !4
M
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M.5W]3W1H 0
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M7''.Q7?QWP(IR&W4K.V%7>"U6]C?48+'%IS45%1=G[B;C&.-L3$8Q,&IH0R
M
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M&B@;#3,1D;=#4.<
M
M
M
M
M
M
M
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M\::>-#=\M6T>?[5G]3GR,=[>Q?LG=-P&Z,QS4SM)]
M
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MQ.0";H)$F@CE;\5[4<GWH8U<3IJ:6)KLUSVJU%WL4,H(VPPQQ,^*QJ-3B0S
MAC*)=ZUK!L.JM2&U(US7I@WL:[J^,RN7=:UK>NY0VD^UHV+41H_-6-=@VG+9
MM"K.6STG;R0][ZQ?W=O]0-CL.BDL^S8:::5)7LQQ>B88XJJ_U.\
M
M
M
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M%^R=TW'!EJVCS_:L_J<^1CO;V+]D[IN W4
M                                                           (
MRRU7>J:ZBH;7LR-TE99\[)5:B*OP&(]R[")OX;I)I\>QLC',D:CF.3!6N3%%
M0"/[BY1K'M&RH8+2K(J.T86(R:*=R-57(FRJ)BJX<9A?W*-9EG68Z*QZR&LM
M%[D:R*%R/797!=C%%.U>+)==^VZI:AZ5-%*NRJT2LBQV<?HJ<EW<F=@6'4),
MQL];(FAU;F2JG^E ."QZVU;/R=R5]N(K*YS$1S'9WP55ZMT*NQL*FZ:QDTR=
M0U=A1VK:-?:L%?5IC)[GJ59CFN<U-S'1ANDJ6[9,%M65-9]4Z2."56JJQ*C7
M?!<CDPQ1=U#M45-'1TS(($S8V8X)]^($77]N!2T=W:FT*:T;6J*RE1%B2HJ<
M]J9SFHNQAO'?OK:D%K9*;0J:9Z/9[G<Q51=U-A20+1HXJ^CEI:C'L4F".PT[
M"X_T-:I;A67379J;";45SJ*?/SE?(U7IG+BN"YN'\ /#R16'9-5<NGEJK+H9
MI%D>BODIV.73OJAKN4"G[C+YV-:-DH^FH9YHXYHH_@QK\)SE^"F":$0E>[5A
MTMWK*99]"^5\#'*Y%E5%=L\2(=&^ET+/O=2006E)4Q-AD[(QU.]&NQP5-*HN
M^!SU]G0WFL.C[)55E,R1K)T?2R]C<N+=&.SL?"]!U;$N?3636>Z(K3M>H=FY
MN9452O;I1=&'B/;LJBCLVSJ:BA?(^*GC;$UTBXN5&HB)BN_L': T/+9M"K.6
MSTG;R0][ZQ?W=O\ 4]R\]@TMX[)DLZO?,R"1455B<B.V.-%,[NV/3V#8]-9M
M$Z5T%.Q&,6545RIXU1$ ](
&    ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g109079g00s38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00s38.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1[24&AO=&]S:&]P(#,N,  X0DE-! 0
M    'K4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 # 0$!              $"! 4#!@?_Q  T$0$  0,!!P(& 00#  ,!
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MGVL;V%]%SC%-9V91:5,RN"*;0INJS4-\&'R$KR;V/((86DM&N:R[]4J7(52
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M>CYN(36&:M'AF%%IKGL<"TM<6D$'JWK1)_93B>%/QIBA,GI;E7E[H<NYK .
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MF7\GV&_ZNE_\MJV9 1$0$1$!$1 1$0$1$!$1 5G)E)#?MU5Y6\I(UL@H&=S
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MKJA#2]FDR&T.9%Q_K3_\&K;>=#BU>/I7:%2:<8\&/ GG/Y5SKL8PC\7>"O\
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MU;,M9V9Z;/<-_P!72_\ EM6S("(B B(@(B("(B B(@(B("-W(C=R#B7TK_\
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M"(B B(@(B("(B M*VS?R8XB_H_\ U!;JM*VS_P F.(?Z/_U!!]^S+79]AO\
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MP6J8PV@8=P6\0*].Q($9S&Q0!!?$]4DM'U0>MI0;F""+JDQ&C>598XY ()S
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MWGBN75:,VD[7Z;/Q@2T5&4?$RZ^JTPSI]P7:]&W9O3/M_P#L.'ZSF+,1[_\
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M4Z,4_P!B_P Y3GJ/<Z=7[-"1;^,+T^W\4_SE.B]/]D_SE.>H]SIM?LT!%O\
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M+T_V3_.4Z+T_V3_.4YZCW.FU^S0$6_\ 1>G^R?YRG1>G^R?YRG/4>YTVOV:
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MMT('K'K4^M:^NO4@%]P(L@@ EWK&X"DV)L- %-CUFZ@CJ .O6@N#<B-%@ B
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MGP&1#M5Q2TEH.7EHG_\ %6KLQ#BW9GBJ#!Q/,U&HT1KHAYY.3KGYH8#F,<6
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M3>Q&\@]17/9/Z/>$9:8A1V3U=<]K@ZSIIA&A_F(.,XHQ3"Q)MFI\24?RE/\
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ME;9_Y,<0_P!'_P"H(/OV9?R?8;_JZ7_RVK9EK.S+^3[#?]72_P#EM6S("(B
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MYIUUL1XW4PSSE]B*VYPM=IS#P5#2XG-G!_5ZT%]%;#BYPT(5Q 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M:TK;/_)CB'^C_P#4%N6=W8*TK;*\G9EB$%MO]''_ !!!DMF7\GV&_P"KI?\
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MGRDG*PV,A0(3(7J-#0[*T"Y ^Q?>06C1!X FL'UN=FH\67D'O9RCA<.;OO\
M:K70/$/Z-B>=GS7H3"V&ZK-24Q$EY7.SG#A?E&C73B5F>B-:[D?BL^:YU6U7
M(G$42ZE&S6IB)FN/N\Q= \0_HV)YV?-.@>(?T;$\[/FO3O1&M=R/Q6?-.B-:
M[D?BL^:QYNYX2RY6UYQ]WF/H'B']&Q/.SYIT#Q!^C8GF9\UZ<Z(UKN1^*SYI
MT3K7<S\5GS4YRYX2L;+:\X^[S'T#Q!^C8GF9\TZ!X@_1L3S,^:].=$ZUW,_%
M9\TZ)UKN9^*SYISESPDY2UYQ]WF/H'B#]&Q/,SYJ.@6(3NIL3SL^:].]$ZUW
M,_%9\T&$ZWU25_\ U6?-2=MNQ\+<S]%C9+/SN1'U>8^@>(1_^[8GG9\U8F<.
M5VA!L]&E8L!C' 9P]H^[0KU)T2K?<?VK/FOBJF!:I491TO,2#7,)!LYT-VOV
M$J4;==FK$VYCZ)<V.S%,S3<B?JVK9;M-IF-*>&/>R5J69Y,L'.><C2-<V4#K
M70.4RZO'JG07XKR9-[(L=T2:,UAN%.0RUNI@3D.!IO.Z(. 5#:AM-,(LY*HG
M@351H?.NI;N;T=W)N6IB>SJGTAL=-HE);2I%Y?.3)? CPV1',+&OAZ$Z6._<
MN?;$:+%D:9$J48&TTRQ) URO<-]]=R85V78MQ/.MJV*N=EH+7L$>99,<H6FV
M4W>3N"ZU)86J$G!$"!3V0H+=T-CF-:-;G0'Q6_LVY$YFJ'/VJ*YC=B'P$YG%
MP^H=R+*='JIF/^BV'4.4;8?BIZ.U3NO[1OS72XU$?Y1]W#KV6],_"?LQ5^I%
ME>CM4 OS7]HWYIT?J?=?VC?FG&H\H^Z4[+>TG[,4BRO1^I]U_:-^:='ZGW7]
MHWYJ\>WY1]UY6[I/V8I%E>C]3[K^T;\TZ/U/NO[1OS3CV_*/N<K=TG[,4BRO
M1^I]U_:-^:='ZGW7]HWYIQ[?E'W.5NZ3]F*197H_4^Z_M&_-.C]3[K^T;\TX
M]ORC[G*W=)^S%(LKT?J?=?VC?FG1^I]U_:-^:<>WY1]SE;ND_9BD65Z/U/NO
M[1OS3H_4^Z_M&_-./;\H^YRMW2?LQ2+*]'ZGW7]HWYIT?J?=?VC?FG'M^4?<
MY6[I/V8I%E>C]3[K^T;\TZ/U/NO[1OS3CV_*/N<K=TG[,4BRO1^I]U_:-^:=
M'ZGW7]HWYIQ[?E'W.5NZ3]F*197H_4^Z_M&_-.C]3[K^T;\TX]ORC[G*W=)^
MS%(LKT?J?=?VC?FG1^I]U_:-^:<>WY1]SE;ND_9BK)997H_4^Z_WV_-.C]3[
MK_?;\U.-1Y1]SE;ND_9BK)997H_4^Z_WV_-.C]3[K_?;\TXU'E'W.5NZ3]F*
MLEEE>C]3[K_?;\TZ/U/NO]]OS3C4>4?<Y6[I/V8JR665Z/U/NO\ ?;\TZ/U/
MNO\ ?;\TXU'E'W.5NZ3]F*LBRO1^I]U_OM^:='ZGW7^^WYIQJ/*/N<K=TG[,
M4BRO1^I]U_OM^:='ZGW7^^WYIQJ/*/N<K=TG[,4BRO1^I]U_OM^:='ZGW7^^
MWYIQJ/*/N<K=TG[,59++*]'ZGW7^^WYIT?J?=?[[?FG&H\H^YRMW2?LQ5DLL
MKT?J?=?[[?FG1^I]U_OM^:<:CRC[G*W=)^S%62RRO1^I]U_OM^:='ZGW7^^W
MYIQJ/*/N<K=TG[,59++*]'ZGW7^^WYIT?J?=?[[?FG&H\H^YRMW2?LQ5DLLK
MT?J?=?[[?FG1^I]U_OM^:<:CRC[G*W=)^S%62RRO1^I]U_OM^:='ZGW7^^WY
MIQJ/*/N<K=TG[,59++*]'ZGW7^^WYIT?J?=?[[?FG&H\H^YRMW2?LQ5DLLKT
M?J?=?[[?FG1^I]U_OM^:<:CRC[G*W=)^S%62RRO1^I]U_OM^:='ZGW7^^WYI
MQJ/*/N<K=TG[,59++*]'ZGW7^^WYIT?J?=?[[?FG&H\H^YRMW2?LQ5DLLKT?
MJ?=?[[?FG1^I]U_OM^:<:CRC[G*W=)^S%60#197H_4^Z_P!]OS4C#]3M_JO]
M]OS3C4>4?<Y6[I/V8JR665Z/U/NO]]OS3H_4^Z_WV_-./;U3E;ND_9BK)997
MH_4^Z_WV_-2W#]3OI*_WV_-./;UC[G+7OE$_9B S,"&[U\%>IC:Q2GR;@+EP
M.K;[ELS</55MR)37_>-^:EN'JHPYFRI)X<HWYJ57;4QC>C[O6U:OQ.9B?LT7
M81CZF4FFOP_69EL"8YQ%BM+\SC8Y0- ".KBO0!N(=S[EY>QML:Q'$GW5&@2\
M41[ 9(,6%"XDF^8>"P,*/M4D((EIDU6)%!OF?5[G7_U%P[M%,5?W0^CM3,T]
MWI+:3B"6P[A&<F9F(&B,Q\"$\W%WF&XBU@==%YFV3TV;K%9FJU/9RUP8]D1Y
M#S$+'6M>]_S5]TI@O:/C"?ALK(J/HQKFQ.3B5%D5@((:3E,3@7=7'BNP47 \
MY1*?#DY229D9?UVEC";DGJ/BMC9MS.9JAK[5%4T;M,+=P;NW.=O;V52LGT>J
M8-Q+$D[QRC?FI&'JGW7]HWYKJQ>MQ']T?=Q>5N3/P_#%A%E>CM4[K^T;\U/1
MZI]U_OM^:<>WY1]V%6R7=)^S$HLMT>J?=?[[?FG1ZI]U_OM^:<>CRC[L>4NZ
M3]F)19;H]4^Z_P!]OS4='JGW7^^WYIQZ/*/N<I=TG[,59++*]'ZGW7^^WYIT
M?J?=?[[?FG&H\H^YRMW2?LQ5DLLKT?J?=?[[?FG1^I]U_OM^:<:CRC[G*W=)
M^S%62RRO1^I]U_OM^:='ZGW7^^WYIQJ/*/N<K=TG[,59++*]'ZGW7^^WYIT?
MJ?=?[[?FG&H\H^YRMW2?LQ5DLLKT?J?=?[[?FG1^I]U_OM^:<:CRC[G*W=)^
MS%62RRO1^I]U_OM^:='ZGW7^^WYIQJ/*/N<K=TG[,59++*]'ZGW7^^WYIT?J
M?=?[[?FG&H\H^YRMW2?LQ5DLLKT?J?=?[[?FG1^I]U_OM^:<:CRC[G*W=)^S
M%62RRO1^I]U_OM^:='ZGW7^^WYIQJ/*/N<K=TG[,59++*]'ZGW7^^WYIT?J?
M=?[[?FG&H\H^YRMW2?LQ5DLLKT?J?=?[[?FG1^I]U_OM^:<:CRC[G*W=)^S%
M64V64Z/U/NO]]OS4]'ZGW7^^WYIQJ-8^YRMW2?LQ5DLLKT?J?=?[[?FG1^I]
MU_OM^:<>WJG*W=)^S%64$:%9;H_4^Z_WV_-.C]3ZI7^^WYIQ[>L?<Y:[\HG[
M,0UI+V\.M:WM$HSJYAB:@2XO%)8!8 G1X/6M\9A^J-WRNG^\;\U3T>J;'6$I
MG8=2"]MK^]8UW+548WH^[WLV[],YF)^SCGT?MHL##49U$K[^1DGQHL=TS$>Y
MV4Y&@-R@'K;O\5ZKRBV=OK'<O-6.-B]3J,7G5&EN1BAK6\E!,*&#J23?,-=5
MKC(^U.088$9E3>\^M=U7!/\ F+BW**8G^Z'T-JJ:H[O2V,\5TO"U+?&JDRR$
MYUVPPX.U<6DC<#P7G;9"^H8XVJU:N1H<1\*)!A1 7Q.4MD,-F\V/YO!?!)[-
M-HV,XL.)7(U4YB'#6+4&1@"#;ZIB<"5Z5V?X&I^"Z/!DY$0HL9C7-=-<@V'$
MB O+K$CA<#?U!8/1S''&QV:QAM$J-1G)A\M3W18<2&3";$;$LUH(MF%MQZET
MW!^!Z'AJ5EX4A3I%LU" #YF'+-AOB$$D$V^:VHL.4:FX5#H;G.:=66.I'6@D
M7Y1W %7/[2!M@.M3;P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P
M""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[
M2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE
M-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O )
M;P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""
M/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?
MVE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O
M );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P
M""/[2?VE-O );P""/[2?VE-O );P""/[2?VE-O );P""/[2TK;(1^3+$.E_]
M''_$%NUO +2]LMALQQ#<#_5Q_P 00??LU-]GN&[#_P#=TO\ Y;5LH&[5:ULT
MUV>X<M^CI?\ RPMF&Y 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 0[D0[D(0U0[
M<5+5#MQ0:;LS8TT*9T_VI_\ @U;;D;P'N6J[,A>A3/\ 2W_X-6W95CBD_J6\
MC> ]RG(U5Y4LF[29J6\C>"<FSA^"N6"90F[2N:EODV</P3DV</P5S*$RA3=I
M-ZI;Y-G#\%2Z$WJ"O90E@K%,1\$G,]I6Q#%MRAT-H%R![E>4/'JJ;N9[K\/@
M^:XRD$ WTL59ATR3%QS*6MQY-OR7U6:?651)#B%E.[2D552IA0F0888QC6-&
MYK18*"T$JXTAP3*+I3CXPDQ,J!#;UW4A@ZE7E0:*S412HR Z%.29Q*K&]56"
M9,96N29Q*<DSB5=L$L$R86N29Q*<DSB5=L$L$R86N29Q*<DSB5=L$L$R86N2
M9Q*<DSB5=L$L$R86N29Q*<DSB5=L$L$R86N29Q*<DSB5=L$L$R86N29Q*<DS
MB5=L$L$R86N29Q*<DSB5=L$L$R86N29Q*CDF^*O6"BR9,+7)-\4Y)OBKUDLF
M8,+/)-\4Y)OBKUDLF8,+/),XE3R3.)5W*$RA3>,+/)-XE.2;XJ]E"90F\861
M";Q*GD6\2KN4)97>3=6N1;Q*<BWB5=LEDWH-U:Y%O$IR3.)5VR90F]!NK7),
MXE.29Q*NY0F4)O0;JUR3.)3DF<2KN4)E";T&ZM<BWB4Y%O$J[9+)O0;JUR+>
M)3D6\2KMDLF]!NK7(MXE.1;Q*NV2R;T&ZM<BWB4Y%O$J[9+)O0;JUR+>)3D6
M\2KMDLF]!NK7(MXE.1;Q*NV2R;T&ZM<BWB4Y%O$J[9+)O0;JUR+>)3D6\2KM
MDLF]!NK7(MXE.1;Q*NV2R;T&ZM<BWB4Y%O$J[9+)O0;JUR+>)3D6\2KMDLF]
M!NK7(MXE.29Q*NV2R;QNK?),XE.29Q*N62R;R[JWR3.)49&,&:YT5VRI>P.:
M0F<IA;#V'K_!5 -.XJD06CK*J#0%/@L1,J- _P ++Y_1LI$<7/E)=QMO,-I7
MV@:7*$D;@+*3$2OP6)>!"@C+#A0X?\UH"NEC7=93* =YNIO8:)33$? ^*@P6
M\2J1#;?>5<"FPN%9E-U AMMO*CDV<2KM@%%DS@PM\FSB4Y-G$JY9+)DPM\FS
MB4Y-AZRKED 3)A;Y%O$IR+>)5VR65WH3=6N1;Q*<BWB5=LEDWH-U:Y%O$IR+
M>)5VR63>@W5KD6\2G(MXE7;)9-Z#=6N1;Q*<BWB5=LEDWH-U:Y%O$IR+>)5V
MR63>@W5KD6\2G(MXE7;)9-Z#=6N1;Q*<BWB5=LEDWH-U:Y%O$IR+>)5VR63>
M@W5KD6\2G(MXE7;)9-Z#=6N1;Q*<BWB5=LEDWH-U:Y%O$IR3.)5VR90F\;JU
MR3.)3DF<2KN4)E";QNK7),XE1R;&ZW*O90J7-&4IO1*[JV,AZT#&<2@8!Q50
M:$S@W9E9T+M-RM<PE'.O$E8#O$PP3_@OLLV]B@LXVZMZDQ$K';XDK"AP862$
MQK&WW-%@KJAELNFY2K'8$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 6E;9_Y,<0_P!'_P"H+=5I6V?^3'$/]'_Z
M@@^_9E_)]AO^KI?_ "VK9EK.S+^3[#?]72_^6U;,@(B("(B B(@(B("(B B(
M@(B("(B A1"D"%*A2$E(%2[<54J7;BHRAJ&S+_N*9_I;_P#!JVZZY5@/&=/D
M:3,PHS9@NYR\^JP'J'CX+9/R@4OLS7PQ\UJ3MMJF<34V(V.[,9BEN04W6E_E
M IG9F?ACYI^4"F=F9^&/FISUKR7DKWC+<[I=:9^4"F=F9^&/FGY0*9V9GX8^
M:<]:\CDKWC+<[J;K2_R@4SLS/PQ\T_*!3.S,_#'S3GK7D<E>\9;HJ'$76G?E
M IO9F?ACYI^4&EC>V:^&/FD[?9\H6-AO_*F6WY@ 4#KMLM/_ "@4HCZLU\,?
M-.G]* ^K-?#'S6/.V<YWX.1OQVW);@"!HI-K+3NG]*.]LU\,?-.G]+[,U\,?
M-93MUB<?U+.PWX_PEN32 %.8+3!M I79FOACYJ?R@TKLS7PQ\U.?V6/C7!R&
MT_*B6YY@EPM,_*#2NILU\,?-/R@TOLS7PQ\TZALOG!R&U>$MRN$S!:;^4&E]
M;9KX8^:?E!I79FOACYJ]0V7S@Y#:O"6Y9@F8+3?R@TKLS7PQ\T_*#2NS-?#'
MS3J&R^<'(;5X2W+,$S!:;^4&E=F:^&/FGY0:5V9KX8^:=0V7S@Y#:O"6Y9@F
M8+3?R@TKLS7PQ\T_*#2NS-?#'S3J&R^<'(;5X2W+,$S!:;^4&E=F:^&/FGY0
M:5V9KX8^:=0V7S@Y#:O"6Y9@F8+3?R@TKLS7PQ\T_*#2NS-?#'S3J&R^<'(;
M5X2W+,$S!:;^4&E=F:^&/FGY0:5V9KX8^:=0V7S@Y#:O"6Y9@F8+3?R@TKLS
M7PQ\T_*#2NS-?#'S3J&R^<'(;5X2W+,$S!:;^4&E=F:^&/FGY0:5V9KX8^:G
M4-E\X.0VKPEN68*DV<=-ZT_\H-*[,U\,?-0-H%+ULV9^&/FG/[+/^<'(;5X2
MW(DC1RM%[0;:ZK4F[0*476R35_\ =CYJS/;3J')0G/C.CC*+D9&W_P")>U&U
M6JO[*LO.K9+U/]],PWAG%"77ZK+ET/;5A:)&#+SN8G?R;;?\2V"5QY1YZ&'0
M(D5P/4 V_'BMJBW5<^$-6NJ+?QEMS7>MJJ\PWK61BZFC\V9\@^:GI?3;?5F/
M(/FL^6KG_&7CS-NGM-4-D+PIY0+6NEU-[,QY!\U'2ZF]B9\@^:1LU<?XRG-6
MO*&RM>%5G"U@8NIW8F/(/FIZ7T[LS'D'S3EKGC*\U:C_ "ALV<)G"UGI?3NS
M,>0?-.E].[,QY!\TY:YXR<W:\H;-G"9PM9Z7T[LS'D'S3I=3NS,>0?-.6N>,
MG-VO*&S9PF<+6>EU/[$QY!\TZ74_L3'D'S3EKGC*<W:\H;-G"9PM9Z74_L3'
MD'S3I=3^Q,>0?-.6N>,G-VO*&S9PF<+6>EU/[$QY!\TZ74_L3'D'S3EKGC)S
M=KRALV<)G"UGI=3^Q,>0?-.EU/[$QY!\TY:YXR<W:\H;-G"9PM9Z74_L3'D'
MS3I=3^Q,>0?-.6N>,G-VO*&S9PF<+6>EU/[$QY!\TZ74_L3'D'S3EKGC)S=K
MRALV<)G"UGI=3^Q,>0?-.EU/[$QY!\TY:YXR<W:\H;-G"9PM9Z74_L3'D'S3
MI=3^Q,>0?-.6N>,G-VO*&S9PF<+6>EU/[$QY!\TZ74_L3'D'S3EKGC)S=KRA
MLV<)G"UGI=3^Q,>0?-.EU/[$QY!\TY:YXR<W:\H;-G"9PM9Z74_L3'D'S3I=
M3^Q,>0?-.6N>,G-VO*&S9PF<+6>EU/[$QY!\TZ74_L3'D'S3EKGC)S=KRALV
M<)G"UGI=3^Q,>0?-.EU/[$QY!\TY:YXR<W:\H;-G"9PM9Z74_L3'D'S3I=3^
MQ,>0?-.6N>,G-VO*&S9PF<+6>EU/[$QY!\TZ74_L3'D'S3EKGC)S=KRALV<)
MG"UGI=3^Q,>0?-.EU/[,QY!\TY:YXRO-VO*&RYPF<+6NEU/[,QY!\TZ74_LS
M'D'S3EKGC)S=KRALV<)G:M9Z74_L3'D'S3I=3^Q,>0?-.6N>,IS=KRALV=J9
MVK6>EU/[$QY!\TZ74_L3'D'S3EKGC)S=KRALV=J9PM9Z74_L3'D'S3I=3^Q,
M>0?-.6N>,KS=KRALV<)G"UGI=3^Q,>0?-.EU/[$QY!\TY:YXRG-VO*&S9PF<
M+6>EU/[$QY!\TZ74_L3'D'S3EKGC)S=KRALV<)G"UGI=3^Q,>0?-.EU/[$QY
M!\TY:YXR<W:\H;-G"9PM9Z74_L3'D'S3I=3^Q,>0?-.6N>,G-VO*&S9PF<+6
M>EU/[$QY!\TZ74_L3'D'S3EKGC)S=KRALV<)G"UGI=3^Q,>0?-.EU/[$QY!\
MTY:YXR<W:\H;-G"9PM9Z74_L3'D'S3I=3^Q,>0?-.6N>,G-VO*&S9PF<+6>E
MU/[$QY!\TZ74_L3'D'S3EKGC)S=KRALV<)G"UGI=3^Q,>0?-.EU/[$QY!\TY
M:YXR<W:\H;-G"9PM9Z74_L3'D'S3I=3^Q,>0?-.6N>,G-VO*&S9PF<+6>EU/
M[$QY!\TZ74_L3'D'S3EKGC)S=KRALV<)G"UGI=3^Q,>0?-.EU/[$QY!\TY:Y
MXR<W:\H;-G"9PM9Z74_L3'D'S3I=3^Q,>0?-.6N>,G-VO*&S9PF<+6>EU/[$
MQY!\TZ74_L3'D'S3EKGC)S=KRALV<)G"UGI=3^Q,>0?-.EU/[$QY!\TY:YXR
M<W:\H;-G"9PM9Z74_L3'D'S3I=3^Q,>0?-.6N>,G-VO*&S9PF<+6>EU/[$QY
M!\TZ74_L3'D'S3EKGC)S=KRALV=J9VK6>EU.[$QY!\TZ74[L3'D'S5Y:YXR<
MU:\H;-G:F=JUGI=3NQ,>0?-.EU.[$QY!\TY:YXR<U:\H;-G"9PM9Z74_L3'D
M'S3I=3^Q,>0?-.6N>,G-VO*&S9PF<+6>EU/[$QY!\TZ6T[L3'D'S4Y:YXR<W
M:\H;+G%E&=O$K6NEM.[$QY!\TZ6T[L3'D'S5C9KGC)S=KRALH>/%2'M\5K/2
MVG=B8\@^:=+J=V9CR#YIRUSQDYJUY0V?,.)4.((M<K6>EU.[$QY!\TZ7T\;F
MS%_Y@^:G+7/&3FK7E#877(UW>"AH<1ZF[Q6O'&M.8TN?RS&\7- _YK 3^U[#
M4G$R1'S3G:?48T_]2QFFJCM5#TIKMU]Z9=#:[,TW.JI)B:!MK?G7X+0Z3M2P
MW5)S) BQV1'$"\4-:-]NTMYEXT&.WE($1D1K^MK@0O.<2]OA'9];/JBRE0P6
M:%*J"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B M*VS_P F.(?Z
M/_U!;JM*VS_R8XA_H_\ U!!]^S+^3[#?]72_^6U;,M9V9?R?8;_JZ7_RVK9D
M!$1 1$0$1$!$1 1$04O)M9NA5+7FVNI\%5$-AIO5MPR,)9J[P043,Y!EH)BS
M$6'"8-+O<&Z_>N6S&W6APH_)0:-B*< %S%E91D1GO$1/I+19R!@.!$IH<8QG
MH;7969SERQ+Z>Y?!]'^8PY"P48<&;E)>(^-%:842:&8M.7J)N@W3!VTNA8IC
M/@RG.)2,UN;+.!D,G4#0!QXK::E4(--E8DQ.1&LA,:7&Y N +FU[+S?M0P;'
MP]CBGU'"M+G'P(DQ AQ.1AQ(UF#5Q)-["XWK?MO\Y,OP9*1)>6CED5\1L1@9
M<M;D<#?@@NSVW:@RLQ$APZ)B6;8S_P :5DV1(=N.;E-RV;!6T6C8NY1LB8\K
M&:&D09S)#>2Z^@:''71:ML2?0/R;TF49.2;)F9@.@QH#ID<H;O<,N6]P3?\
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M\,++W2Z;U>IP[>C$>@)+NT'X83T!)=V@_#"R]TNF]7J<.WHQ'H"2[M!^&$]
M27=H/PPLO=+IO5ZG#MZ,1Z DN[0?AA/0$EW:#\,++W2Z;U>IP[>C$>@)+NT'
MX83T!)=V@_#"R]TNF]7J<.WHQ'H"2[M!^&$] 27=H/PPLO=+IO5ZG#MZ,1Z
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M-0%-@-P"BJ(8WG==5HB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M!.4"&55DLJ>4"<H$,JK)94\H$Y0(9562RIY0)R@0RJLEE3R@3E AE59+*GE
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M.)4<"C1K_1:0]A_?=\TZ+2'L/[[OFM@]9/63B5' HT:]T6D/8#SN^:=%Y'V
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ME?J\$]7@J+#M*0/UDQ!E5ZO!/5X*,OZR9?UE,0N4^KP3U>"C+^LF7]9,095
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M_L!\0K6D3E+9U*MLO2R/[ ?$*=+(_L!\0K6D3E+9U*MLO2R/[ ?$*D8MC;C
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MLF$UV\;E(8++&?1[,Z_=Z4^K7Z?AC[.2' ]6N;NE;?SS\DZ#U7M2OG/R76P
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M/@;-Y2]=]):7W^5^,U.DM+[_ "GQFKR)^59OZ);_ .Y_^"?E6;^B6_\ N?\
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MK[$,2_160DY:G2[9>2@L@0&WLQ@L!<W*^FX/U2M5V<XEAXIPO+5.$6N,0ON
M20,KRWK^Q;.'%U[, ^Q)8?\ ;7MHLO"FL%5N'&L;R487(OO85P'9/_ OK$N'
M7APC":T>'KKKNV?%<C0<)3\M'C,$Q-RL>'":[-<N#.JP\0N3;)(;C(S4W%;8
MS+840>/UOFMW9-Z*NS0VV:=R<N@.A^J'>"H"J>XN#;;@J0NO3G/>7SEVJ(^$
M"XEMWG'BH-E@289@PW$WZ\SEVT+D^VRD&-(NJ+&Y@T0X5[#M'YKPVNB9I^+<
M]/KC?[QH]#;-*5 HN%(,M*$.#G&(0&Y=X"VTWO=OK!<KV XLEZYA9DM%C@U%
ML5_\&2YSL@#=;E=4B/M_% .7$JBJ)^+Z2B(F%N=@-G)"9EG^HV-#=#=I?0@C
M_FO*,2EPL-;;*O3))P=!AMEV@AN7ZS83CI]I7I7&%=E*!AV;G)R9$*\-[89-
M_6?D<0-/L7EK \]&Q1M%J-6B@ET2%#<279OJY&[SKU+UV:FJ:X[O#:YB+4]W
M9[ZJ-ZE%WL3$?%\IF=[XI 2RA%G#%-DLH1$39%"G5#N(FJ:H9D2R:J$,RFR6
M4(@FR64(@FR64(@FR64(@FR64(@FR64(@FR64(@FR64(@FR64(@FR64(@FR6
M4(@(A12:HAE$9P+ 8JPM)XADG\NU@B>JT1LF8M -[?\ YQ6?7-MIN,WTQWH^
MF.SQ7PVO.5[F$'.01^"\+LQ,8AO[)1/$F9ER052H8:FG2\C/1N0N7EC7902=
M+_@%N.R^F09W//S,017V=#R.;>UBTWNK]#V;Q9BF/G:W%C09GE"&PWM:^[;
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M=#\1OS3H[5^Z'XC?FND62R<_=TC]^J=,LZS^/].<=':MW/\ :-^:=':MW/\
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M^6%\UW/(U,C>"<G_ ,I_?HQZA7XQ^?\ ;AGY/IK]!2ONA?-5P<"3\"('P*-
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MC#]4N?\ 13;^>WYJD8=JKB;2A^(WYKI)8WB52YN47;K]JVNHU1HTJ_2[=?\
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M.9IP]>0JG*.=83<N?LB-^:^OG$'+<16'QS!>0J_LEQOA. V9EYV7GS;-R<E
M?$=O M;)XK[,%8XG)>;ATG%;9B!&N0'3$)L!H:UO7>QW@K"S9BY.-YZW*YHI
MS$9>JW3C =(K/>%3SUGM6>\+DL")#C,$2$YKV$7#FFX5Q;_3X^57X<J/5-8_
M+JW/6>U9[PIYZSVK/>%RA$Z?_P OP=4C3\NK\]9[5GO"<]9[5GO"Y0I"=/\
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M;KMSJ%69A"5C4B%,00]T03+1"S$0\AO?0V'BN91,;X[P-5948NG*A.2DQ%9
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MDG2&H=X=Y6_)8_D#P*<@>!3AV](.)=UED.D-0[P[RM^2=(:AWAWE;\EC^0/
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MOBFOBNE^@I'NL'R!/04CW6#Y G4/8Z5.KFFOBFOBNE^@I'NL'R!/04CW6#Y
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M8V_$O"/29U<RU35=,]!2/=H/D"CT%(]V@^0+/J$:+TJ=7--4U72_04CW6#Y
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MK<:T$G_7OV,3]U#C7#X)O/[O_)B?NJQV8_%L6B:+71C6@$7$_I_N8G[J#&M
M)MS_ /8Q/W5<F&Q:)HM=.-: -\_^QB?NITUH&G^G[_\ R8G[J9@PV+1-%KHQ
MK0";"?\ V,3]U.FM [_^QB?NIDPV+1-%KO37#_?_ -C$_=3IKA_O_P"QB?NI
MDPV+1-%KO37#_?\ ]C$_=3IKA_O_ .QB?NIDPV+1-%KPQI0#_MW[&)^ZHZ:T
M"Y'/]1_Y,3]U,P8;%IP"?<%KHQKA\_[?^QB?NITUP_W_ /8Q/W4R8;%]P3[@
MM>&-* 1?G_[&)^ZG37#_ '_]C$_=3)AL/W!%KW32@6OS_3_<Q/W5'3;#_?\
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MW!:[TUP_W_\ 8Q/W4Z:X?[_^QB?NID;%]P3[@M=Z:X?[_P#L8G[J=-</]_\
MV,3]U,C8ON"?<%KPQI0#_M_[&)^ZHZ:X?[_^QB?NID;%]P3[@M>&-* =T_\
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MKA\[I_\ 8Q/W4Z:X?O;G_P"QB?NIDPV'[@GW!:\<:X?'^W_L8G[JCIKA_O\
M^QB?NIDPV+[@GW!:[TUP_P!__8Q/W4Z:X?[_ /L8G[J9&Q?<$^X+7>FN'^__
M +&)^ZI&-</G_;_V,3]U,C8?N"?<%KO37#_?_P!C$_=4C&M +;B?T_W,3]U,
MF&P_<$^X+7NFN'[_ .O_ +&)^ZAQI0!OG_V,3]U,F&P_<$^X+7CC7#X-C/\
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MK8T6N=-J!W_]C$_=08VH'?\ ]C$_=0;&BUWIK0-/]/W_ /DQ/W4.-: /]O\
MV,3]U!L2+7>FM M?G_[&)^ZG36@=_P#V,3]U!L2+7>FU [_^QB?NITVH'?\
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MNO14<<I L>*XUL;,C3(467G?X&H"'%+XCWY6EA</5 )W_<@M8/IL:@UBJ3U
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M7X[Z-2J19A-1E6Q'D-TNTM=H;Z;N"Q^TJI0:U0\/Q">7J4:5SM+"/4<0PNS
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MQT]7BMZV05R-.2D2G3 ;GE868EK; W<=VOBM,P%5(=&HM8I$R'LCP*?&+;@
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M5Z>R3=+F<R#.UL.Q+N1=>YM]JXYM)DI64VH5J4E9:# E8=2CL9!APPUC6AY
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M'-;9KB;!IT0<1V:YCMIP[EN *G!T'5J%ZVVNUBC4J0@.K]-D9Z&8<0@3;,X
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MF(T2,1SB$UH+G$V'J:#58N#]'F8,E$,Q,U)\P' ,8Z<AEN73]7[4&F_19/\
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M@(B("(B B(@(B("(B B(@(B("(B J54J=$#103874Z*B)H-_W*87LD$N%PX
M*'.-[ W^Q6,[1ZF87&JEL9C";D!9;K#>A=N[@?<EW<#[E1SF'VA[TYS#[0]Z
M=]$S&JOUO%/6\51SF'VQ[TYS#[8]Z=]#,:JPZS'7<+J7F[?5<%9N"=-0=57#
MUTM9,,HJ7AOLI5+?MNJ@HJGK5:I(U52 B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B""0!JF8$7;JHB EN@NL?59QU-H]1G
MRS,9:7B1N2O8'*TG?XV0?=RFH&76^HON5Q>5XGTI9H9"S"L W._GQU_N*]_^
MJ:;_ /\ %('_ +X_N(/42H,2Q(+=>K7>O,'_ .J:;_\ \4@?^^/[BM-^E+-$
MQ"["L 6._GQT_N(/4H>+>MHA?8BXTXK$88J;JWAJC5;D1#,_)P9HP@ZX;G8'
M6OUVOO61=>&TN?JW@>I!B,0XPH6'&WKU1@R.@<.4N;@D@'0<05KS=LF 3OQ+
M)#[G_NK9ZQA^C5N':LTN1G;@ <Y@-B: W U'$E>>/I$88H5&A0_1%'ITH2Z#
M?F\LR'O<Z^X(.PP]L> 7NR])I+-PL_\ =6WT:LR-:D!.TJ89,RCB0(K+V)&A
MWK MV=X+MF&%:$'7WB0A7_X5EW0J;A^DEL&# ITC")>608>5@WDZ-"#)PHK8
MHNW4<55GM?3[/%:!*;6L$3$TV4EJY!$<N R-@11O.GYOBMUEYJ!-RS9F6C<I
M"=<M-B+V-NOQ"#ZFN-O6&56)N=@RD")'F'AD&&,SWG<T<5J5=VEX1P]/.E*Y
M6X<K-7R\DZ%$=8V!WAI&XA6YS$]$Q1A&MQ*#/LFX<&7O$+6.;;,#;ZP&^Q09
MFA8SH%>G)B5I%3@S4>7?R<5C+W:[734>!5,CCC#L_7'4:2JL"-5&O?#,NW-F
MS,OF&ZVF4^Y<&^CB#TWQ27"S14#8_%77*)4\!1L8OEZ1 I;<0B-%:Z+"D\D7
ME '<IZ^4:D!US?75!O[3?J5)><UFBXXK2:SM3P919ETK4Z]#EY@$C*8,4[C8
M[FGK"^[#N.,.XFBB'AZJLFXIOZK8;V[A<_6 XA!M.:S;D64<H"/5U/!><-HN
MU21A8P<:;B:99)-@-:8<-T5C ^YOI;>N[3F(Z5(4L5.9FVLD2[D^5RNM>Q.X
M"_44&:S\%-[B[=5S8;:-GW+9!B:"7GJYO&U_N+8Y;&-"F*.^KP*DTR AOB%X
M8\ -9?,;6OU'J0;+GW::E2YUB!Q7/(^US \&4EYN-B&$V%%N89Y&+ZUCK^:K
MTMM5P9/RL>- KT/DX;<SGB#%]4:Z_5\$&]F)J0!<A!$!!MJ1O"T>A[3\'5FI
M0*;3*[#F)Y[Q"8P08@+W?:6VZEMT]-R]/DX\W.1!!@0A=[[$VUMU(/KSZ@6U
M*M1YN%+PC$F'B&P&URN>SNV/ ,![X4;$T*'$:2">0C7:0=1]5?=,XHH^)<-1
MXU$GFS,-D1K"]K'-UT/6!U$(,]A[%M$Q$8GH2H09QD)YAO=#OZKQ8D:CQ'O6
M:Y07L!ZW!>5_H_8MHF%Y2K/K]2;)PC48QS.8]V]K /J@\"NV4K:S@FK3I@4^
MN08L;*76$&*#8?:WQ0;XZ(&MN\6ZE(=<VMKUA618"SSG;U$\5I.UW&-.PSA>
MH<O4C)3T6#$@P',#P[E3#<66+1H= ;H-[=$LX-:,QOKX*3$:' $ZG<O-7T>=
MH[9F.V2Q+B*;CSD1@AL$S$B12Y[HMFBYOU$+KM9VGX-HL_'DJI7(4&:@FSVN
M@Q"6FU]X:>HA!O(=K8Z*20-ZPLIB"F3&'6UZ#-MB4E\+EA,Y76R<;6O^"U-V
MV7 $*9B0(N)87+!V7*8$;0^1!T(QF!X82,YW#BJ@20;MLL73*K(U:7AS5.B-
MCPG-#F1 TC0BXWB^H6N5O:A@^BQS JE>AR\47N#!BFUC8[FGK0;N'@_5U0/!
M*TW#NTK"5?F^;T6L0IJ+8G*V%$;NW[VA<,VJ[2HLKM*@/I.(9V'213@U\.%%
MB,A\KRC[G+QM;6R#U+G]W%,^ERM.FMHF%I*ALK$>L,]&OC\V$8PHEN4L3:V6
M^X<%\,YM8P3)1!+S6((3(EP!>#%-R=P^J@W\/!!OH1O"HY9MP&^L;Z^"T>H;
M4\%TUF:>KL*$XFUC!BFYWVT:LCA;'&&\5.>R@5&',QF-#G-9#>VP)L-7-'6@
MVK.>""(#<#ZPZEA,0X@I>')7G5;GQ*P;$YG-<ZUM^X%:[2MJV":O-ME:=7H4
M69<X- ;!B@D_>T(-]S?AO\%28H_-&98ZI5>1IE(?5)Z9$&0AL#WQBTD92; V
M OUA:G.;6,"P(;71<0PH0<T.!$"+J..C4&_"( /7]5"]V6X9<\+K7J)C"@UV
MGQ)ZF3T.9E(3A#?%$-PLZP-K$7ZPO.&TW:F9G:/)Q\.XJGH=$A27)1VP(L6'
M#Y8/B7NW2YL6:VX<$'K#E1:[M!NNIS6&HL5@L*UZF8DI?/J+-MG95KS"+@US
M1G !/U@.(]Z8JQ/2,+R4*;K\ZV3@1(H@M<YCG7>02!ZH/4T^Y!GLUQIJK4Q,
M,@0(D:(0V'#:7O)_-:-25HE0VNX)D'6F*["8;V_B8NFE^IJR4/$U(Q)A*H3-
M#GFSDN^4C.$0,<VX <#]8 [Q9!DZ'BRBUZ:F):CS\*;CRX!BL9>[ =U[A9AL
M7,7@#UF]5UYBV+8EI6%\48JFJY.ME)=T"'D<YKG9K7)^J"NP4?:W@BKS<.5I
MU>@Q)R(X-#&P8H+B=PN6@(-^#S;ZNO!!$%[=?!8VH5F1IM+?4IZ8$*3AMSNB
M%I(MQL!?K6F';/L^AQW,?B.#RES<<WC:'A]1!T8O%[#ZW!08EAH+NX+%X?K]
M,Q%*<[HDPR:EQ8<HUKFVN+C> =Q"UFM;5L%4.?=*U6NPI>;;>\,P8IW$@ZAI
M&\%!O+XEF^H,SN%U5GX!:OAC'.'<3/Y.A5&'-Q22 &PWMW"Y^L!U%?=B/$5*
MP]3&SM9G6R<HZ*(0BEKG7<03:S03N!]R#-AU[V&BAC\VA%G<%HE)VMX(J\T)
M:FUZ%&BG4-$&*.NW6T=9"WIELQ&\\4%:(B B(@(B(*(F[56K9AENKL3<K;/K
M+"J%B6I;0)Z/)TD/E8CX3N5:+L=;J*YZ:]5#_M\QYRMXVF?]RC_?,_P*YHOF
MO4=HN6KF[3/;N^@],V:W>C^J&1]-U3O\QYR@KM4&G/YCSE8X*-;KDSMUV)^/
M\.STZS,XQ_+)>FZH;_Z?,><J&URJ-<#Z0F+#>,YU6/"@[BD;=6QZ=:B?@R8K
M]4N3S^8MPSE=BP]$?&I<E$B.+GN@L<2=Y):%PD?57<\+_P#<TC_N(?\ PA?0
M>DW9NYWG!]6L4V9B*&81$7><5KV)L9T+#+?^VJC!E#IH^_7>VX'@L"-L> 22
M!B:2N!>UG_NKD_TK "^$UNKB^!?[+N70MG>!L)S.&8<><PS18T8Q7M+XDE#<
M;7XD(-EH6TS"-=G.:4FN2TS-9<W),#KVN!?4<2/>LE6<742BSDM*5:?@RLS,
MQ!!@PWWN]YM9HL.NX]ZY)M5PA3L+5.A5?#LI+4LS-6EI5XDH#8-V$$D$MM<$
ML!LL1](2)#E\<84C18EV,JT!SB1]4#)<H/14.8;$:',L[CX*O.-+=:YRS:U@
M6F_Z).U^#"F6:/:8$4G74;F\"MKH&(J3B*2=-46=;,R^4$1&L<VP-Q>Q /44
M&<S\-;;_  3/8BXL.*T2M;5,%T*<,G5*]#@S+'.AO88,4G,TV(N&GK7V8:VA
MX5Q/-"4HU7AS4P\V:QL*(.HN_.:.H%!MKHMANUZA?>J\UK7%AQ6M8HQ;1,+,
M:ZOU!LHUPS-<YCG:7M^:#UK"4_:[@>H1Q#DL00H[M;MY&*-WVM0= :ZYW:<5
M&<7TU5B7B-.5V<EKAF'B"M&J6US M-G'2\[B&%!C 7+>0BG_  :@WXQ;6-M"
M;74YSFMETXK&TJIR54D6SE/F!,2CR6->&D"XT.A7W,80 3$)X H+KGV.[0;_
M  4"("+M]8+7L4XMHF&83(U>J#9.&YV7UF.=?2]O5!ZEA:5M9P14YL2]/KL&
M)$+FM:UL&*,Q.X:M0;U$CLAMS.(#1O/!8*FXTP_4JK'ILE4X,:=@Q3 B0FWN
MUX)!&[P*P^TC%M+H^$)N-&G1+Q9F7B&5<&NN\MM>Q TWA:#L&K&&ZC-U"(PR
ML2JQXT-XBF">4+R'$G,1O.NMT'=2ZU]->H<4:\.O;JWJT1G:YN<AVX'K6)KN
M(Z5AZ!RU9G&RD(6NXL<Z]S:_J@]:#-.?8V NIS7W"X6C4C:G@RK1G0:=7(4Q
M&!/JB#%&[?O:MS!O"!AN):=<R"Z(@+,PW7LJKKGD?:_@2!,&6B8@@PW@7MR$
M7]U5XPVA8?IF&8D\ZL\DR-F@P8@9$!,3*ZP%A<;D&_<H!F)T#1>ZPDMB^A35
M=F*- J,%]4E\HBRXOF9FM:^EM;CWKS]]'S:+R\TV6Q5B6<C3$6'R;(4U$BQL
MT0Q0&B^HU!76)G%&SVD8CJL:.^FRU9@,:^;BMDW<J &@@N>&:V%NLH.CW&E^
MM1?4Z?9XK7\-8IH^)I8S5%GFS4!H#@YK'-N#>WU@.!5O$F+Z-AIT'T[/ME#'
M!,$.8YV<"U_J@VWCWH-B,36P%^*J+@&W)L%K-2QG0:;1(-8GI]D&0BPA'9%+
M'D.8;6-@+]8ZE@I#:[@6HS+(<IB.%%>=.2$"* 3:_6U!T%KR3JVPXW4AP.[5
M?/+13'@MB#U8;P'-(.\'<5)S-%FCU]]O!!]&;BL)B+%5(PU*PIC$$["D(,6*
M(+'1+D.>02!H.#3[EK=8VKX)I<SR-2Q##EHN4'(8,4Z7.NC? KD/TC,9T'%F
M#:5T?J+)W+5H+B6L>VP$.*#]8#B/>@[W&QMAV Z&V-5(##$>(; 0[UG'<-RV
M(.N 1JN4X=J&#H-#I[:\R0=.F,0PQI7E'%^8Y=<IUM;5;=B'&=!PR2^NU-LE
MK8L+'N TO^:#U:H-H<;64%]BN>RNV3 ,W'9!@8D@Q(D0AK&\A&WG^PMP%6D1
M2#5>< TX,Y0QLIMEXVM=!DLV_3[/%&N)O=MESJ;VSX E)A\*/B2"R)#)#F<A
M&T/D6TX?Q!3,521FZ!4.<RX N]C7-M<7'U@.I!G&NN;)G%_!:GB/'>&<+16P
MJ_5V2<3+>SH3W7%[7]4'K6/I>U7!E5=R--KD*/&<39H@Q1>PN=[>"#>^4URD
M>OP4L=F%P%C:M5)&E2!J$_'$& TAO*%I._=N%UI\CMAP+-QN1E,0PHCSK80(
MHZ_%J#H9=8ZC3BH#P=VI5ML1CV&('YF+3:WM-P?1)Q\G5*W"E9II#7,,&(2"
M1<:AMMQ!0;MF-SIN0/T.FY8:@8@IE>DV1J/.B:A.%Q$#7-S"Y'6!UK+L-A9V
M]!6UUQN4JD$7L.I5("(B B(@(B("(B B(@(B("M\5<5KBL:L_(2XV%U;?ZS+
M^*N.^JJ3_%K.)PDPT+$U0FH%9C,@QXC&AK=&NMU+%&JSKM\S&\R^S%__ '[&
M_FM_P6%"Z]JS;JHIG'QA\_M&T7*:ZHSVB7V^DYWO,7S)Z3G>\Q?,OC1>W+V]
M&KSE3Z_24[WJ+YD])3O>HOF7R(G+V]#G*F?PQ49R)5H4&/,Q8K7YCZSMU@5O
MT$YF^*YOA8?]ORWV._X2NE2P&4_:N3M-,47,4_##N[%7-RC,HANL"+=:NAVE
M[*V!:^BJ!NM?YMZ,X57N+K7L38VH&%V-=7ZE!D0YXACE+[R"0-!P!*V$;EYU
M^D=!AQ\08=@QV-C0XE:E&/AO%VO:6D$$'>"$'2V[9MGY) Q/)>&C]?[JR=$V
MD83K<TV6I=;EIB8>YK&L8'7+G&P&HZU\TAL\P=%EF/?@^@M.IOS&$>L_JKAN
MWO#L# F):!5L.1&R G9ESN;R<,0&LY/D[ %N_4D[M+H/24?$=+@5%DA%FX;9
MQ[LC81O<NX;EE0XEM[+S%2L0-%5PK6:W-OAP^5,68BQ'.>; BY/65UANV7 )
MBN@#$D+E+Y0.0C?N(.C%P 49]-VO!?-)S4*<DY:9EWB)+1X;8L.)J+M<+@V.
MNH*TZM[5,%4.;,M5<00Y>.+C*8,4[C8[FGK"#>.5!U:+CK*DO(=;+I;>M:PO
MC;#N)G%M#J4.:L2"&PWMN0+_ )P'40IQ'C:@88.7$%09)G0^LQ[M][?5!X%!
MLCH@:ZSM%2(ISD.9E'4;[RM/H>TC"E>CF7I%6A3D8-+["%$:; @?G-'$+9:A
M/2U/E3,5&*(,)FI<03:P)ZO %!]V;34:\%3RK0_*[0G0>*T(;7<#S%0$A!Q!
M",TYS6-8(,6Y+K6%\MNL+=)*+"FI2'&@D16.OEB6WZ^*#[ =3?J5/*;]-RI;
M< @>L>OP6"Q1BVAX69"?7Y]DDV('.:7,<ZX;:_U0>(0;!GTN18<59F9N%*P'
M1X[PR SZSSN'4M.P_M/P?B&=$G2:Y#F8[G9&L$&(+G4];0.I8;;KBZET+!\[
M(1:D96HS4)CY=C6O#G 1&W((%AH#UH-NH.-\/U^<B2E'J<";F6.<QT-E[@MW
M[PMB+K=6O!>??HP35#C251APHL")6(LVY['\B>4RY&YO6M]O6N_OS'1HO^L@
MJ,0*2[UB +K1W;4,&<],CZ=A":#>4+.1B7RWMV;+ZI+'N&)^FMJ$I6FODW$M
M$40H@N1O%B+]2#;PX$7ZE2(FNHL.H\5SD;9]GXB"$,2P2^_U>0C?N+<J'5Y"
MMRS)NFS(CRT0$L<&D#0V.A ZP4&5+CP4AX()ONWK2<0[3,(8>J<61K%<ARTU
M!<&Q(;H41UC8'J:1N*R>&,98?Q2(CJ#463;8>7-EAO;]:]OK <"@V Q0"+CU
M>*D1!]W%:?4MH>%9"HS%.G:O#AS4%YAQ&&%$.1PWC1ME11-I&$JQ4A3:;68<
MS.%YAMAB%$!N 21<MMN!0;FZ(&N XJ<QS !NG%6&D,87O.=O$]2T:H;7L$4^
M,^7FZ_"A1@3=I@Q3:QMU-\$'0;ZV5'*W%V-S?>L9A^N4ZOR;IFC38FH >6&(
M&N;9P -M0#N(]ZUW\IF$#&,*'6H0BAN8L$*)NX_50;OG'W<5#HF7>-^Y:'2=
MJ^"JM,"6IU>A1H^_((,4:7 OJWB0MEQ#6Z;A^4YW69P0)=Q(#G-<X @$]0/4
M"@S >-+Z'@A> -5S24VS;/XD6S,3PHD1U@UAEXV_R+=96OTV>HPJDM,-B2.0
MQ.5RD -%];$7ZD&6#K@FVBEKK[Q9<ZG]KV!J?,/A3>(X<.*PD.AF!%-CPT:M
MCPOB^AXJ@F/A^HMG&0[!V5CVZD7'U@$&QH@W"^A1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%$4D-TWW6%Q<''!U=<X>MS"
M/I_Z;EF8_P!4?:ODJ$BRHT^<D8[WMAS$%\%Q8=0' @V\=4'YL?6;JT CJ"HS
M1.R/>O7Q^C)A/E'.?5:\+Z6$6#__  U'_P"F/"7Z7K_Q8/\ _#0>0LT3LCWJ
MK<V]AF/5Q7KO_P#3'A+]+U_XL'_^&@^C)A+.TLJU>)&\&+!__AH.I;,@[\FV
M$SN_[)E-W5_ L6R:/:3>]C:QW+XJ+2H-'HE/I4O$BN@2<O#EF.>1F+6-#038
M6O8#J7UPB;D6&AL/%!6T6825Y\^E"RT"%8GZ\#_B<O0'U&ESB;WW+S[]*2)_
MH\%IT=GESI_.<@]"-!M_" -^Q>;_ *0^)ZZS%S*%27/R"++N:QL9S.4+FD9'
M>L!8DZKTAE??4:+B>WW!\S&?*XAI+'19R!.08CP][6MR,:XG@3J!I=!I4_AK
M:-%IS96%LUP_*QO6 FX$67;&N;V.81+Z=7V!7HDQCK VSZ++8AAQY>-&EH\.
M'$=.\H]KO6-VECS8C,#=9*M;9XM<H$K2J<9<8BFWOEX\)D.(P0@^[6.8\FU]
M6]9LMDHNS>=FMEDS*UJ;J$U7GR<RP0H\RV*UL0YPRSC>UP6ZW08#Z/N'I'$=
M.F*KB:$RKS+VPWET^QLP6D.>-"\$Z@#W!;Q4\!2-&D,0U&E3DU+PHS3%,I!R
MPX-A>S<H ]47.BY3LPQA!V4S\Y0L9O;*-88<-N5CHSCJ7.N67&YX6P46:F<9
M3F+ZQ!GYST/+1!'E&PXI8V)">7D9F.\&C2P08KZ.CW=.,3@@:U Z?%7Q8 @&
M-MWGX;8T1CW5&=(+38C2+N7W_1Q#.G6*A<W=479?VJQF!)6'/[=ZC*"/&A9Z
MC.W?#.5S;"*=#]R#Z*A$K.#L13<#$.#J)4Y2;C1(\.:J+8<Q$:S,0T-]8D [
M[6ZU\6'*[AR8Q@R+,U6+AL<BX<E2X+X;>O6S6G4[ON"W+#^/,/89G*O);0(K
M7Q>>/YJ8TNZ9)A V&MG6U&[1:=C 2.U'%4.%L\E99T'FX:7PH0E79FEQ=]:W
M46H-@VFT&C,QNQD&F2(@NDX;])9@#B;^L1;>5N&U>#A*$Z'"Q'B2?I$O#B0X
MG-I:$]T(D V!:UA&HO=:SMFC,H=?@5&I'DY-DI!@%X]8Y]=+#7JWK!;8'O=M
M 9B"*!&PVYL"%>+ZPSC4_P 'OW ZV07J[BG!4:0F(6%:%0)Z6<QP9./IO)Q1
MZIN1=K2"#N6IX&GYB+2<62AF(KI6'1YAS(1><C"1O W ZGWKI&(MI6"9VCQI
M#!4A2X]0BM<PPWTTP@UCFD9@;-%\Q;[UR7"T\VEQL7R55#8$V:1%86,!< 7-
M!&HOU$(.Q?1XP71Y[9[3I^JR4M47QX;B&3<!D5L.T5X]7,#:]A=:'B"B2D/;
MM!I<M#9*TZ/48<)TM 8&0BTANF0"UM3I;K78OHW&VR6@ENH=#B6O_OHBYAB$
M _21D+DW]+0M/(@VS:Q0Z;AJ;P_&HLA*2,S#;$/*RT%L)[W#+9Q<T WU.OBM
M@QO%I$W@6EOQ-B*HTF'%I\-T1TMG=REPTESK W-^/%?+MZTC4@OT.6-E][%I
MFVNG5&-0L&U" W-3I6F-,R#$ :;M9:[;ZH+4YB;9_#IK(&%Z?1JZ8;6LC3$[
M3"V)G%MY<QMR1J3Q7R[*IMQ;/-/\! ?,O<(4/1@T%K!9^4VG8 E\.RLG0Y*F
M1J^V##:Z#%IA#'/  >2[*+G1VMUK&SZ<B0*S,2U2@P8$W-18DQ!A0A=IAD;^
MNVXZ('T<L+4^NS%4CU6##F&-G8[! C0VQ(9LUA#K.!UU6\[<\'4>E8:9/T23
MEZ7-&8APRZ1@,@G+E=<7: =;#W+DFQ;&C,'UJ?FJB]L.EF/&#G97//*'+;U6
M_9P6V[5-I;=H$%M"P=R,W!:]DQG?#?"?ZH(=JX@6]8=2#K&P6K3E:V<2<Y4X
MCXTRZ+%!=$>7FP>0-225]^U>ET^<P35XD_(RLQ%ARL:(QT:"UY:\0G6<"1H1
MQ60V<X=Z+X8@4LAP$-[W>L03ZSK[QHIVC02_ ]>#=?\ 0)BU_P#=.0<*^B_2
MZ;,2T6--2,I$CLEB]D5\%KGM<(IL02+@CBMQP;AVE5?:CCHU61E9UD)\J6-F
M8#(@;=AO;,#:]@N>_1MQ32*/$=2JA,/9.1X/-X;1#<Z[WQ?5%P+#>-5U?9DU
MK=I6/P22"Z5U._ZCD',=KU9K8QO2<+X4@AD!D>)+0J? B\A!C7R68YN8,MOW
MZ:E?? H>T%LES>)LDPG$BM:&\Y>98Q7'M%W*;UG-N^$)R!6*/BBA0R]TBZ-,
MS#W1&MRGU,O G<=RJD]NU"E<)"7?.AV)(,%K.0=+Q2PQ>L%W_.Z#*;,J3B"D
MX5Q$W&T.+16Q8['03+QVQ.19P9D<[* ;"W!:? J^S&COGH;*LW$E7B1G/9"J
MU/?%L;^LT.=#L /6._>L_"IU=JFRG%<:)&CNG*JZ%-2PYQHUKG-=9I)]46.Z
MZU'9;C7 V&9"=E<8P93TFV/ZKGR!CNL&AI]8-/6#UH-+QIB ^EX4Q19*5HI$
M+*!36<@'>L=3EMJ18?<%L.URFR+-JU-@-DY9LN^B0XCF"$T OY2)J1;?XK";
M6*\:W';5(-/D)6DPF""(DM"Y,DYG$7;>^XCJ68VP5>2&T6FU.)%(DFT>' +P
MTWSYWFUM^Y!N_P!*20E:?@"0@4^4@2L U."<D"&&-N61;FPZU>.$J.S9I!FW
MRDO-3>>+_#QH#'1-,]O6(OI866.^D9B"GXDV<R$]28SHTL*K"AYBPL]8,B7T
M/VK<H@<=DL&P%L\;7[HB#7OH]83IE7P#3ZK7)6#4YB89&!$["9& +8SV@C,"
M;V: M8 ]"?2!B25* D)-T_*0S EOX)A:>3)&5MA;4Z>*Z1]&4'\DM$MKZLQO
M_I$1<VKX/_ZE".KTE)W]T-!D-H]8Q+5-H\:ET2DRU8AR<T!S6:B@0W@AOJN#
MW $%?#7<.[1ZE+/AR>S7#]&C $-F*=%EX,0$_G9A$WC_ )K=]HT&!@[&%-Q*
M]SFR4S-\I.1'#-DAL#=6ANI_%:[C_:J<8B!0]GL<1XDXUT&)%+8D"(QQMERN
M): =':ZH,G-2&):7L,K\OBZ'%AS+):"UG*3 C'1S;ZASNM?/]'["-(JN')Z-
M5Y.7GW&,PM,U!9%R L!RMS V'@LOB"AS5"V"U&'49N<F:C&DH+I@3,;E<CPY
MMPT\+^)7T?1M(9A.<<XG+RD/-X?P80:%L??%EMJ8I#'N]&19B9<Z7O\ P9RL
M?;U-VF4=74%AMLU%IDGM?IDI*T^3EI2)3.5?"@P&M8Y_*1O6+0+$Z#7P"R^R
MHENV^ !JPQILW/\ ,B+X_I!Y*3M8IE0G'N;+LI;6D_6U,6,!H->M!Z;HU-E*
M7)M@4^3EY*$3G,*7AMAM)(&MFZ7T"Y']+-HB;/Z46FQ-7A"XW_Q49=1PGB&1
MQ+3.>TF*8T!KC"+BPM]8 $Z'[0N4_2V+OR;TISO5?Z8A  ;OXF,@RNR3 ]"C
MX*DIJI2$K4YB+RK7.G)=D4_QC@#=PWV%EA83CA_'.,Z;383&2#9(,9+-&2%"
M#H;22UHL!<DG0=96%V6[79'"^&8%*Q7%A2SH#8A8608D1Q>YY< 2+BUBL[@J
M9&(ZUB_%(:Q]/J-.(EWVL"6-##ZIU&K3O0:KL-PU(UW&V(G5)@F(4!D)X@16
M-?#=KJ"' Z&RS?TA*#3*!1Y*=H=,DJ7-0^5<V))0&07.(#;7+0#I_P U3]&\
M6QKBW,2+P8.GWE9CZ45^BLIE -F1M_V-0?'4IFA1]F&!YO&N)JE3(3I O<R"
M(D5LW<0\W* -=FL;6OVBL+7\0X'=39.5PG1Z'5()@-;&G8]-Y.,'"UC=S&DD
MC4GQ6 K'*TG#>R^KU=C(M(@2L2)$9%_A&%N6&-6=8N1HMKGMIF$)RALEL)R%
M+C5")";F8^GF& _0D V&E@>M!A_H]3TY.UVIR(FYB! B5"-DA0HA#6M#"0 +
MV %MRLU.8K&$<3SLE7\%T*IP9F/%F84W460YB*(9<0T YC8>K>W$E8G8[4I2
M#C6;D:Q&?(S,_.QX[!*@^J,CCZI%[#0BW!;W0=HF%,.&J2>/IC/.NG(CY1T:
M6?,N,MH&G-8VU#M-/LU0:9AFMX<FL5PGS%7C8=?R3AR-,A/AM(U];U6G4[OL
M 7W;1Z_B6O;1_1E&ID"IPF23(_,8T6T$$.(+\KW!N;4"^^Q7RXS$KM.Q1!EM
MG\E*\D98 Q(,(2K\S7.<X7=;J+5O.UFG1,,8W9C&%";"D8DM#IY<+9<UR\^J
MWUKV;OW(-3KN%MHU2A-9(;-J!1XS'!_*TZ-+P7G0Z7$3=<@_: NT[&9/$E/P
M;+RF,H<451CXA>Z-,".\@O.6[@YU]/%<BVC;5HF,(LM2L!S/*,Y9CW16B)+Q
M+$%I%R1I=P7;=F-&J5!PM I]7BQX\RQSW&)'C<J\W<2+N^Q!MB(B B(@(B(*
M(GU50W1]NNRKB D6"MML3FZ]RPJ^,+$-&VF7]# ?^:S_  *YL0>I=,VE"(*$
M'96G^&:-?L*YG;Q7RWJM&;OW?3^CU8B5(S=:J4 (21U!<+$1/=WYF9G$)NH/
MU2H#CP"$G*Z_W)13%4E<S2#4:+N>%]*/(@[^0A_\(7#&9PW1H*[GA?\ [GD<
MV_D(?_"%]3Z/;W<OEO6:]Z89A$1?0."\T_2JORT,#>70-?O<MZV=83BSN&X<
M85VKPARCQDAQ[-T.]:)]*I_^DPFCZV:7/XN78]EX'1"%J1_#/W?:@Q\ULW@S
M=0@3$]7:O.0X$5D:' F(H?##V[B 1H=^OB5R_P"D9!$SC'"LL_U&QZK!A%S=
MX!#!?\5Z.)).@&7J/6O.^W\'\H.#'O%FFLR]K?\ IH.DMV?8=EL*S7+4J1G)
M@R\2\S,2L-\6]G6.8MO<?\@N5;-(C96J[2J9'J,U(4F79+L;%@.<#*L+8A<Z
M&T;CUZ!>A)LYL/3A( :8$2WN*\JB2FYJL[4O1KGDLA0N5&?*/XM]OMW%!N5.
MKVR^F2519"GI?$M:( A"K4U\5SH@O?UW0]YZS?6RT UIPVE4.8ILM I+'<X<
M84@WD6.NQUKAO#J6YX"VAX!HE!E9"LR\B:S"@0X3R^G&(3%:+.N\--]>NZTC
M&&((<SCFFUN<E922HTL8YA1)6$6YX;P0PN;J;ZMZM+H.I;592NR HF(I2DR]
M>I\&3;SB%48C'PLS] "QS@3]8$:;[+GF)L4TB:DVLGZ+2,..(:3&IDKD>#?B
MT'?N70IK$U)HE8PW4IR?F)C#3Y+E)L3#71&M<YEF 0[:BY;U&RQ.TG:'@3$.
M'8U.PU DH]3>YCF!U/,/U0ZY]8M'5XH(VC8R%(V9-.&*Y/3K.7A?Z;$?%9%:
M2-6 Z'+N]ZP^%:7CR:H[7C9KARK O/\ I4X^7?$/A=T2]@MJE=E54F]C,2@S
M$K>?C5 3C3RL,NY,@6 <= /!8W"VUZ'A#"HI=5= 96V1W$P3"B/;R9W',#:^
MG%!F-AF'-H5%Q/,.Q7(196C\T>V'",\R+#$4O800QL1UC8.UM_BN\_6!UL1K
M8+B6P&F8FB3T7$&)(\SR$>6B2XA&:Y2$'![+$-N2#9IU^U=N&C?5U:>LH.+R
MTFS$VV_$],K YU(2,*!'AR\8")#!+(=_5=<"]SN'6LKM5P/09?!-7J5*D)6E
M3-/DXT=D21EV07%P9<$EH!T(T^U:SBRMOV>[6JKB*<;#;2ZDZ!+Q(KP7D,:R
M&7$-:;W :=]UB-IVTZEXXDY>C8'G8DW%G1$EIB&^'$@@9P&L S6&OK;[H+>R
MV>Z3[+L20ZVQE0,A*0Q BS0Y5[<W*7(+KVOE&[@%O.P:E4^#*S\2%(2D.*UT
M(MB-@M#AH[6]E\F#<'.PGL?JHFFN9.3,D.5:7-< 6YMQ;_.68V&MO3:CPO"U
M^YR#IMA<Y=>)7&MIDQ@R7Q#*SF+<33TM"A0G,YF8,2+!?=QL7-#' D'=]B[(
M'!QM#U(T*\NU9T'"&U2'4,<M;%IC^7>UDPWG+,KBX-]07Z[?8@T_:OB"GQ6P
MYG"\K)TV$QC6"+(03+E_K'UC8 W(M==#^D%C*L4J@R,"F3DQ*.="@1#$@1WP
MW&^<$7!' +1]M-=D<3R3)S#<E),I$)K(,2)"@<B1$S$VRFW46ZV71,8T>1VL
M[.(<[A%\2;C2\S#E7EP$&Q8W,X>N ?SP@V79QL]H<]A*&^=D):8CNB/'.(LO
M#?$WZ#,1?1?8[9G2\.X4F)>9CQJS#APHA8*BUD7*X@D.%QH1J >!*YOA':]*
MT3"+*548S(-3$1Y+&PHCK!U[',#;\5M6R7#5<AX$F)JN3L_,1GRTPTB--\J+
MYC;>3U!!J?T7J5(3<*+,3E.DXT=DL][7Q(+7.8X1=' D7!%MZMMIL*M[;L=T
MN*QKVS$&#!;< D%T-@TOH#JOG^C?BBF42=?2JA',.<BP# :P0W.NY\4%HN!;
MK"SN%@7?2.Q8T ;Y77K^K#0?#LOJ\3 NTJMX8FC:5=,R\O"$0EV46<38-T'U
MPOIJD"-M!VONEGQ(D6FT>=,)[0[U0U_%K]_U.H+Y_I*4)U KE(K]*+^=1HD:
M/'+G "[!#R[K$[SUK=_HZT::EJ//5^K0&")61!F83[A][9[GK(WC>@TK&4SB
M*)B^4HN'J))U:4I[XDJV3F8C6PHH&X.:YP;N%^&B^7$&%]HM5DG0)/9EAVE.
M+0.<2$66A1&F][@B)O.[["5O6T@0,(8[HV)7N<REM,68G7D7RWT%FMU.KO%8
M':#M=AXME64/9],"/&G88#HA9$@1&/:[-9KB6@>JTH.C;%Z9B>F8:F8.,8<9
MDV(XY%L69$?^#R-&A#G6%[Z*C;I6YS#^!'S]->YLP)F&S,UY:;&]]005F-FM
M#G*)01"J,U-S,:.6Q7.F(W*EI+!< \+A4[4<-OQ1AAU-@-+WF,R)8.:W=?K.
MB#GVP_!E%J.&HT_6Y6!5IDS+X8=/P&1R&Y6$ %P)TN?>5IWTD<*TVB2=/F:9
M!ARK'3L&'S>!#;#AB[8A+K- UT"N[)=I,KL[E8]#QK$9*PG1'S+7MAOC/N[*
MUHNVXMZKNI:?MLQH<7QY.+*O:Z0$Q"L6M<WUP'C<X^/!!LV(&$OI#89.L]#'
M"VIU65VF81QC*XTJ5;I]*%>I$(PXSH-0F8;H+8;(;2\Y'/!_-((MJ+K$XBAB
MU(A%[A>=AC,#KJ2LQBF<JV -IDS/STU,3.&YJ- @QA-QC&:V"&L,0B&#OL'=
M1OP*#5*EBN1FZ;R=4PKAZANRD&8D)1HB0_$%MS<;PHQCB>9AX9P?3<+56<GN
M=\I"?"B17PVQ!ZM@;V!WG>M]Q;M/V:U6ASLE1VRL:I3,)\*7:ZFN:#$(LW4M
M%M;:W6IU7 57FL&TC$$E*,#I&$Z9RMB,:QN[JO?JZD'TTBCX]%)A%NRG"L^V
M(P%LS,F6=$B#M$F)>Y\5D-F^%]I5.V@R,[4J+Z(H;XT2)'EI6>A\@UI8[*.3
M;$-P"0 +:+)8=VWT.C8/;(5*::VNRL%D,0>;Q7,+QO!<-/Q5O9/#Q/BW&SL3
MS<>.RE0II\2%"A3)$)\-[7%MX9<3UC3J093$U8V?TK$$P*_465&KNBQ',DI^
M2?'ACUB'-!R$ -.8@7ZEQC:=B&!'AOFZ-3*?1S#:UC'4Z%R%QG/K:6-R#;[%
MU*1Q3A+">)<1P<<PY=TQ,U./&EWQ9,S#FPLQ%FD-.47!T7.-L-<Z3R$6<I%.
MI\*DPFLA.B0(/).S9[C0G@6]2#KVU##&)L2TJ!&P^Z;CD0(3#*MFFPX3B"27
M$.<!>Q&OV+F5:Q5*LD(;:OA:@4**8H_A9&5:'VL>MM_$_<%G\856?Q!068IP
M94)MU-E6PY&(!&=!9RHU=ZA()-GMUW>Y9>M;7,"SM),*2E*9-51S[<E&IKLH
M98C,"1OO;KZT"MXJD:)LOEHN$<2U*MLC3KH/.IQT5L35CR1<AIT("T[!,AM
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MF\H+WLZVNO7JOI5$%@A06,#G.#6AMW;S;BJT!$1 1$0$1$!$1 1$0$1$!$1
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MJHAR\!H:1+P6@]88 5]@8!>W6@8!??J@M6!LRP+-UB$9#8QYR-#=>H65X-
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M-5]G"\X3HS5?9PO.%TFR63G[GL=+LZRT/#U!FY.LP9B,UH# Z]G [P0MXAD
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M1I-B7 V;IKUH-;VA3,6!A:8B2SPV*(C '6!_.7&M@LE Q9*347$#><Q1-1F
MAQA^JW+8>K;B5V#:8 ,)S 8+$O8;_P!I>;]CF.*EA>#-0I'!U7KK>=1G<I),
M<X7-A;1AU%OQ0=JQ_@J4I]!BS.&PV0G89S9WN=$]4 DBSB1U!:]]'''%7Q)
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M$W,^U5C\U$01%^NQ3$^HB(*(/UEYU^ECOE?]PS_,<B(.]T'_ %"G_P!&A_\
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:U#^]$0?2B(@(B("(B B(@(B("(B B(@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g109079g00t37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00t37.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1?V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %]D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(3$3010B,E%A!4)Q(X&A,S12D;'!<B0U8M'A_]H # ,!  (1 Q$ /P#JD
M                G(!.0
M
M
M
M
M                 %'+A"J<BCTWFJB+CTECX'4YX5\^/X6]P%^"Q\#J/.$_
MLM[AX'4><)_9;W 7P+'P.H\X3^RWN'@=1YPG]EO<!? L? ZCSA/[+>X>!U'G
M"?V6]P%\"Q\#J/.$_LM[AX'4><)_9;W 7P+'P.H\X3^RWN'@=1YPG]EO<!?
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M"?V6]P%\"Q\#J/.$_LM[AX'4><)_9;W 7P+'P.H\X3^RWN'@=1YPG]EO<!?
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M*GB?$Q4DF?*O:Y$3\#U
M
M
M
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MDE),CVF5+S6:SJ45M%N\ *(5(2
M                                          %
M
M
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MZ%*\G<QQ;7G=MQM;CUBF3-%/IF)G^&^:07_],&9^2;^"$;[%?%UE6OYJBO\
MQ)(T@G_Z7L_PF_@A&NQ15^&]4BIXN7Y]HZ*]_P!1SQ_^+FIV_3:3^7EM+OU5
M=];QVZ6=\4"O5J^,N/*P;;3[%*2KH'RTE>CY5153QEYF2VK[,&WN=:VT2(VJ
M3*X1..>?410]VO=*N\66I6-G4CWG#Q[8HX\8K_+;WG[NO+&2<OJ5G==>&[[-
M++JK3.J/!9M^2BWDRO2*O#)TK$Y58F>"G.^R_:[+<*^.@O,2-J'.1-Y5X\5]
M)T+33-FB1[%14]!Z.6+=%>KOV\_=R8IKZEM1J?L]2J% ASNE4
M
M   "B\"I10+&2[T,3W,DG1KFKNJFZO!?J/GW[MWSE/9=W%^GJXE>KD!C_?NW
M?.4]EW</?NW?.4]EW<9' 7 &.]^[=\Y3V7=P]^[=\Y3V7=QD.&!]" 8_W[MW
MSE/9=W#W[MWSE/9=W&13!3MR@&/]^[=\Y3V7=P]^[=\Y3V7=QD.W@5P!CO?N
MW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4
M]EW</?NW?.4]EW<9!?0@3U 8_P!^[=\Y3V7=P]^[=\Y3V7=QD<# &.]^[=\Y
M3V7=P]^[=\Y3V7=QD5]10#'^_=N^<I[+NX>_=N^<I[+NXR.!@#'>_=N^<I[+
MNX>_=N^<I[+NXR./447AV 8_W[MWSE/9=W#W[MWSE/9=W&0^@JG+D!CO?NW?
M.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]E
MW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?
MNW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.
M4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW
M<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9'
MP!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO
M?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?
M.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]E
MW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?
MNW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.
M4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW
M<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9'
MP!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO
M?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?
M.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]E
MW</?NW?.4]EW<9' P!CO?NW?.4]EW</?NW?.4]EW<9' P!CO?NW?.4]EW</?
MRW?.4]EW<9' P
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MUJIM36HG!#KFU:X:X:>(<\5M?-;/D\R(G,JG,%4,F\
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M5QUG1$+M^-KNU$4#[
M                                       #(R  R"B\T*@
M  "J"CEQU@-Y"BR-_O)]9$>UC:>S350MNHT;)5N3&$7BBXS^9&#-H6KH,5TL
M$W@R^-Q:N,&>/)%^_BOW3>.CMYG[.K$=E!DB[9?M,IM3L2"96LJ6(F\U5PN<
MXZR1J^MAHZ5T\TC6QIQ5<FN:OHQN_AGBO&7M7RNMY.O@-].U/K.=]8;7ZNKN
MCJ&P1K(J*J;S,KUF(MNU*_V*O9[^0R="]>*O:J80IAMZFNKMOQOW7R[QSJ.\
MQYTZ@RG453B:_I+45)J"WQU-*]B[R<D=GJ,^WD:6K-)U*E+Q>-U5 !5<
M                           !3=XKD8*@"F%[1N\"H HB#'I*@"F./,(A
M4 4QQ*(W"<^)] #Y1G$;O%>)] "F[P&[PQDJ /E&^DKCTE0!3' ;O#!4 ?.[
MP*X])4 !@
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M48Q&IP1$P@%0
M                                    %%YH5*+S0J            \J
ME%6%^[Y6ZN#U/*ID;%&Z1_DM3*E;ZZ9VF/+E36$+:?;,LM]9FD61NZLGD^2A
M--RK=)NTRY%?0*Q8^#45.PAK;+42:OUBMOLL.98W(U7L3CR0Q=1LCU2RTI+X
M74N5&YZ/>,8GKX-:6C41[_?OY+:CF3:)[_;[*[/*:H?M-J9+4Q[:'I%5%9Y.
M,DM;<[U4VS2R002JR1[4XD>;%[U'IZ\OM%XB:VI\G?>G%5R;)[I%RRVVGDC7
M,:M-/U&(]'!CK.Z]HW]T<#<\K+>T:M]GU[GO2M%-0.KZV!L\[W9WGIE>1OFU
M+25LN&FZAR4D;96-7=<B84QGN?T1-+1+U\/P0WK6:9L-5R\E33]:C47BO[?'
MX9_I<SN+3YF>Z =@M\J**_S6I\JK"QRX1?H3\CIN-<MR<@[*$>FT:HW<XWU_
M$Z=U575]OTY)/:HG2U;6^*U$SDZ<T]>+'DGS,,Z5C'FR8X\;;&#G=VO=HZ*N
M+1,J)_\ +:8:HVRZRIKJVUS6UZ5KN358F>63F=#J$'.J:^VCJG[(F^R:5^'V
MT?S1-]DWN Z)!SM\/MH_FB;[)O</A]M'\T3?9-[@.B0<[?#[:/YHF^R;W#X?
M;1_-$WV3>X#HD'.WP^VC^:)OLF]P^'VT?S1-]DWN Z)!SM\/MH_FB;[)O</A
M]M'\T3?9-[@.B0<[?#[:/YHF^R;W#X?;1_-$WV3>X#HD'.WP^VC^:)OLF]P^
M'VT?S1-]DWN Z)!SM\/MH_FB;[)O</A]M'\T3?9-[@.B0<[?#[:/YHF^R;W#
MX?;1_-$WV3>X#HD'.WP^VC^:)OLF]P^'VT?S1-]DWN Z)!SM\/MH_FB;[)O<
M/A]M'\T3?9-[@.B0<[?#[:/YHF^R;W#X?;1_-$WV3>X#HD'.WP^VC^:)OLF]
MP^'VT?S1-]DWN Z)!SM\/MH_FB;[)O</A]M'\T3?9-[@.B0<[?#[:/YHF^R;
MW#X?;1_-$WV3>X#HD'.WP^VC^:)OLF]P^'VT?S1-]DWN Z)!SM\/MH_FB;[)
MO</A]M'\T3?9-[@.B0<[?#[:/YHF^R;W#X?;1_-$WV3>X#HD'.WP^VC^:)OL
MF]P^'VT?S1-]DWN Z)!SM\/MH_FB;[)O</A]M'\T3?9-[@.B0<[?#[:/YHF^
MR;W#X?;1_-$WV3>X#HD'.WP^VC^:)OLF]P^'VT?S1-]DWN Z)!SM\/MH_FB;
M[)O</A]M'\T3?9-[@.B0<[?#[:/YHF^R;W#X?;1_-$WV3>X#HD'.WP^VC^:)
MOLF]P^'VT?S1-]DWN Z)!SM\/MH_FB;[)O</A]M'\T3?9-[@.B0<[?#[:/YH
MF^R;W#X?;1_-$WV3>X#HD'.WP^VC^:)OLF]P^'VT?S1-]DWN Z)!SM\/MH_F
MB;[)O</A]M'\T3?9-[@.B0<[?#[:/YHF^R;W#X?;1_-$WV3>X#HD'.WP^VC^
M:)OLF]P^'VT?S1-]DWN Z)!SM\/MH_FB;[)O</A]M'\T3?9-[@.B0<[?#[:/
MYHF^R;W#X?;1_-$WV3>X#HD'.WP^VC^:)OLF]QB)-LVL:>\1VNHM[VU;EQNJ
MQ,_AZ0.H 8;2-76UMFAGN<:QU+D3>:J8ZC,@
M                      HJ9ZLE0!BY[#:YY%DFM].^1>M6(7U/3Q4[$9!$
MV-G8U,'L *>LJ     !/6  ">@
M
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MH(ODV>R@Z"+Y-GLH>@ \^@B^39[*#H(ODV>RAZ #SZ"+Y-GLH.@B^39[*'H
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MEYJN"^
M             "B\T*E%YH5            44J47F!\21M>BH]K7)V*F2T2U
M439>E2FBW^W<0OE CM.X-]M/EC6M3#6HB)V(?7/@$PA4#PGIX9V[LL37)_S-
M13QI[?34_P#4PQL]340O ([>">_D:B(F$*IR*%4 '.NL?W]T?J9_(=%'.NL?
MW]T?J9_(!T2SR4]14HSR4]14 !U%$Y 5 3UCCV@ "B9 J
M
M  =IS?J_]^])_'^;3I#M.;]7_OWI/X_S:!T>SR4]14HSR4]14
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MC9!IVNCCX1LJGX;V<&DE5WZC/_AN_!2-]@_["KO\T[\&@2@@
M            ZP -/VM0R3Z!ND4#%?(Y&HC4Z_'0U_9)H^UQ:8HZBKM=.VL3
M*JYT;5=S7KP2>YJ.:J*B*G8H:F$PB(GJ B_;E1S3V.WQT<&]N5#>#4QA,*;1
M71/70D<:-7I/!6ICKSNFSN8CN;44;J*F%1,=@$%62AK&[+;S"^!R2JO!J]?E
M&S:7IIV;(70.C5LO0KXJ]?BH2<D;<*FZB(OH&ZW&[XN.S $7[+::HAV9UD4T
M3F2*]^&K_ TU[0E!<V;/-4Q4S'PU;II%C7.%\A.1.2,:U,(U-T-:QJ*B(F%
MY/JZ)U;8(Z1+;))=HYD=)/(B*JX7MYDFZYAGJ]D=-%# YTS71HK,=:/)@2&/
MBO1L^HKN,W=U4;CJX :]I2!/@110U3<-\'1'H[J(GV6:<CGVD76XQJKZ>G<]
MC47DG%"6M<0UU18)Z:UHJ3RX:BMSP3/H+?9SIQ=/61L,Z[U6_+I'JG%550-J
M:G$J
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MUW\RG+FQ^G;3?'?KC;=@$!DT
M                                       [3F_5_P"_>D_C_-ITAVG-
M^K_W[TG\?YM Z/9Y*>HJ49Y*>HJ
M     .L-Y#K#>0           ,#  #"#  #   8"@*!;UWZC/_AN_!2-]@_[
M"KO\T[\&DD5WZC/_ (;OP4C?8/\ L*N_S3OP:!*
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MS454]('N@"
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M*Z
M                 .TYOU?^_>D_C_-ITAVG-^K_ -^])_'^;0.CV>2GJ*E&
M>2GJ*@                                     #K#>0ZPWD
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M5[T=O85RXSDWJ&-L,;8V)AC4P@'HG+B @
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MYSX._P!S>MDNJF:@T] DLN]6,RCT5>/ B9F?*8U':&^@ A(
M
M ':<WZO_ '[TG\?YM.D.TYOU?^_>D_C_ #:!T>SR4]14HSR4]14
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M1Z:8U1;=1TRS6V;>QC+7<%3Z ,Z@"
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M@!N=LKH;A11U%._>8],HI=MY$';#M424[GV&XO=X0USMW*Y)Q0
M
M     ':<WZO_ '[TG\?YM.D.TYOU?^_>D_C_ #:!T>SR4]14HSR4]14
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MMS/%%7D5O6+1VEIBM-)W,)0ZN 3D8NT7FGKXD5CL/[%,IGJ.2=QV=D3$]U0
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M&<T12:C9-)-J-[%56IAK'*J(N0-T3D G(
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M8
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MB*[&%53*J!7 QP" "F B8ZRH 8*8*@!@(F  "
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M@IA.P@40^F\A@$@<ZZQ_?W1^IG\AT4<ZZQ_?W1^IG\@'1+/)3U%2C/)3U%0
M       /GGS3@0CMPTFZ*6._T+7(^!6J[=3/:GYDX%C>[?'=+;-23)EDB84#
M3-D6KFZBLC4E>U)XD1JMSQX<"047*<#F&C6IV=;0E:[>;;Y7JW*IP7BB\SI.
MUUL=?115,#D6.1J.3 %V G(
M                                 #M.;]7_ +]Z3^/\VG2':<WZO_?O
M2?Q_FT#H]GDIZBI1GDIZBH
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MR(KJ^=J.E>[GGF8;9GI>97OU#?,NN%9E[6+P1B*N>7U$E-3F!3'C*I]#
M
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M6=QR+CCVDUT<'@\+69SC@;WBG1$UGO[J5Z^N8GP]L'TA3!5#)J       R
M  YUUC^_NC]3/Y#HHYUUC^_NC]3/Y .B6>2GJ*E&>2GJ*@        "BE2B^
MCF!'.V32*:@L2RPM5)X%Z1%3T(IK^PG5[JE)K)6N1LE*W=;O)A>"X)CFC26)
M['<G)A4.<-H=HJ-&:TANEO:Y*:63QU3EU*!TDB\"J&%TI>8+Y:(:JF>CD5$S
M@S28XX
M                ':<WZO\ W[TG\?YM.D.TYOU?^_>D_C_-H'1[/)3U%2C/
M)3U%0                                     !UAO(=8;R
M           % 4"WKOU&?_#=^"D;[!_V%7?YIWX-)(KOU&?_  W?@I&^P?\
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M\E,\,]1C*&^6RX4[YJ*M@FC8F7*UW(TBQ[3*"LU;<+94U<$<,*N:QZKY2HN
M)(Z1F]N[S=[LSQ/K/$AJ@NTD6V"M2HK-VB2-RHCE\7GP)2ME]MESD<R@K8)W
MM7BC'95 ,IGT%,^LU2U7&\2Z@J8*IC$HFNPQ>&>:F9N=]MEKX7"MAA5>I[L
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M:(]V=9%616<\<_R)&V7ZGBU!88E23-1&U$>BKQ_[X ;H"B<>LJ
M                                                         #M.
M;]7_ +]Z3^/\VG2':<WZO_?O2?Q_FT#H]GDIZBI1GDIZBH
M                        ZPWD.L-Y                    "@*!;UWZ
MC/\ X;OP4C?8/^PJ[_-._!I)%=^HS_X;OP4C?8/^PJ[_ #3OP:!*
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M.R1BY:Y$4]B)-A>K??*VOMU8Y4JXGHW"KGAC_8EL              #( #(
M                                                 =IS?J_]^])_
M'^;3I#M.;]7_ +]Z3^/\V@='L\E/45*,\E/45
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MU'25:(CG;LB]1FHY&R-RQV4,IK,>6L6B?#TR @(6 ,
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M>^6VYPK7*O7ZO435HS5=+J.@9+$YK95:BN8BY)QY:Y(W4TV4%,\^TJ:(
M                                         #M.;]7_ +]Z3^/\VG2'
M:<WZO_?O2?Q_FT#H]GDIZBI1GDIZBH
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MY*^;3%7+(W<>ZI<JL[.#23:U$2BG5."[CE^Y2-]A"_\ @5?_ )IWX- E!
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M]2OW;6#5%UI2=3%,U9[HRYTW31)A,B:S$;(O69U$LB G% 57
M %C?9VTUGK)WMWFQQ.<K>W"&BZ5U*VMTQ=ZRCIVT[J='KA.M43F;EJU<::NG
M^7?_ "J1-L[>U=":DQU-DROT 8NQ:MUCJFAKVT#O!VT[W+TZ.=Q1%7T^@V+3
M%_N^I=$W6GDFW*ZD<L;I<JN]A<%-BSF+L_NSD_ORHOIXJ6FR)Z>]>J/1-)_,
M!K&SJTZ@2BN53X=FA1'))'Q\9<^LVC9Q47&#9Y5>\D6_4NJ%PN<;J94N=GST
M^!UZXY3+OYC4;1?*ZT;.$][T5&352MDE3*;J<>X#.5]YU3H^KH)[M<DJV5;]
MQ8=Y<MY>E>TS6UW6UUTU=K5%:H^E\)=A6*J]J=Y$6J::WMJK34TMRFKIEF19
M,KXK>1)VTZ9LNN-+N;Q1[T5/::!AM0ZNU?I*IHJ^XOZ6&K>C&TRN7AQ3TEU>
M=2ZMM4MOO=9+T=!4S-C\'WE[4])D=N[F^^.FD<F<U343VFGOMY<U-,67L\)9
MC'K0#-;2M65EGT53W2W\9Y&M=NY5.:IP^\TBX:GUBVQ4^HWO6"E8U'N@WG>.
MG+M,QM2>B;.+-Z>B_F:7NTER-V1TN%1$Z"+EZV@:U5:KU?<]/,U%3KX)1PMW
MW1[R^.B+CM-^L^I;G>=GD-TMU.DE?(B-1F5^E3#W5R-V&0JF$1:-/Q-?MM[K
M[)L2I:JU-59ED:U5X^*BYSR ]':AU/I6]6]UZK4JHZU53H-Y?$Z^TP6O[=?:
MC:3!X#7K'.]BNC7CP3/K-8N3:5]ZLE=%7RU<\GCS97*,<J95/K)"UW<HK5K^
MUU]2N*;H>#\\% VO4^IZ[2ECHJ&1?"KK,Q$RJKSQC/UFN5-UUAI=(KQ>*CPB
M@<J;\2N7Q4^L]-J<,E95674E)$Z2GA;E6IV912NT'6UOU#I9;3:G)/65+=Q6
M-7BW**GY@7.TS:!64%GM598U15JGHF,KQXXP86MO>LK,^DO-RJ%2WRO:U8MY
MV$X^LQFL[3)9+5I.EJE<LOA3%<BIR\="9M9VJ*ZZ1J(943#(>D:N.2HF?R U
M*^ZPKJV]6&CLKT1M1NNG5%7@F,DH0(Y(6(]<N1$RI!NP:RSR7:Y7"L?TD<;U
M9%PX)C@3KA *IRX@                    **41.951] &.OUQ2UVN>J<G"
M-BN(%N?N@XZ2NEAZ!%1CE;Y/^YT!<Z*.X4<E/.BJR1-U<$;U>Q73E3422OCE
MWGKE?'_V,JQ>+S,^&L33T]>Z/O\ B,B^03V%[RG_ !%1\?Z.GLKWF[3[%=*4
M['/GWV-3FJR(GY&JW'2&S^CJ.A2;>=G']:B_D7BT3;ICRSU,1,^RT7W1<>.$
M">S_ +F\;-]JL>K*Q84CW53'48CXL=%)#%)/)N)(G#,J)G[C=]&Z L=A>E1:
MLKGKW\F^+HC<WAAEZK1'IRWMBY1%P?1\M[$/HR;0%%*E% HB8134]H.E&:IM
M3J5SE1%ZS;.OK*E+TB^NKV36TUG<-'V;Z*;I*WI3,?O83FOK-QJH&5$3HI&Y
M8O,]43B5^\TRVG-,S?W4QTC']*#M=[%XKE5NJK9,Z&1<KP7TF#TUL,J/#FS7
MBJDDC8Y%W>W[CHQ&\>*%4]"*4P1Z/TK9?ZGEC;)9Z:TTC(*9B-1J8,FWD4PN
M<KQ/I.1>;3:=RK6L5C4!SKK']_='ZF?R'11SKK']_='ZF?R$+.B6>2GJ*E&>
M2GJ*@%Y*<^[<+A='79E,Y'1T''QD;Z>TZ"(QVW7*V46G7MK&(^547=1.9$QN
M-)AA=&^]%KLS'P/9O.1-YRN3L,U[Y6^OB=#)(Q[7<%RY#G_3,-UK562-RMHU
M7Q6JG49NMH+I% ]::1=[!PSP+3N=NNG'M:O4N+Q+[PZNC?8I457/159G/6=*
MZ:JIZRS4\U2B),Y/&.,*&BNMPOR1,?NU2+P<I*UKUS?]&21TUV@6H8G-4C5>
M"^E#LQ4FE>F7+:)B=2Z.14[2J&AZ4VE6F]HC9)&4\B_V7KC\5-WIZB*H9OPR
M,>WJ5JY+JO4  "BE2BKA4 @OW4S$=8*)'<4ROXH:[IFQVJ;3E&^6D1SU:F5R
M;)[J3]@T7K7\4,5I3'P9HOX4.WAQ$[B8<O)F8B-*_!ZS?-$^LJFGK-NO_H:<
M&KCB7Y5OD29_NJ=W3'V<F[--V!01T^U.M; W=8B2</H0ZH.6]A#57:I78[)/
MP0ZD/&O]4O3I],  *K R#RGFC@8KI9$8WM5< >F>)97J>2GM=3+3XZ9C%5J+
MVFK:IVB6FR,<C9XYY43.ZQ47\"*[MM"OFKYY**R4SH4?XB.6->OZ2!@HZB2_
MZZ5+Y*B(V7",5<=I,M'3PTM,R*E:B1HG#"D/KLFU(D;KK4RJM2W])A%3\#/:
M/U<ZC>MNOGZ)\64WG)@\[EX;;ZH6JWRZTU-4T$K*Y&K'CK7&"(M*U=;;=9K#
M8E?+3*YR*B)G"9/G:IKVH\6EMC=^%SD19$:J\./62QL6LUK98H:^+$E7*U%?
MEV<9QG@6X>&U?FDF4ET[G.@8Y_!ZM3/K/4IRY%3T%0
M                           [3F_5_P"_>D_C_-ITAVG-^K_W[TG\?YM
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M?J,_^&[\%(WV#_L*N_S3OP:217?J,_\ AN_!2-]@_P"PJ[_-._!H$H
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MO2?Q_FTZ0[3F_5_[]Z3^/\V@='L\E/45*,\E/45
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M;QP0%;JVX[.9J>W7&"&HM+W(UDFZCE3DG/GR)YI)6SP,DC\AR90@>Z<@$
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MVU8VOM^^VAE=E^YE$PBY(2Z:12J+DPFE;_3:@MK*NE5%1?29M
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M"@;QL2FJ)M#4CJI7J[AC>YXPF#?BSM-O@M=#%24D;8XHT1$1J8X(F"\
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M[QDKU5\*G.NL?W]T?J9_(=%'.NL?W]T?J9_(57=$L\E/45*,\E/45
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M;3I#M.;]7_OWI/X_S:!T>SR4]14HSR4]14
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M5NS/6CJ.L1? *F7Q5?E,(O Z0ME?#<**.HIWHYCT1> %V @
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M]7_OWI/X_P VG2':<WZO_?O2?Q_FT#H]GDIZBI1GDIZBH
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M41$1.I"FE]_92EIXZ6!L,#&L8Q,(B)U'LT*$5$0A*N.(   9&0 &?0
M                           *+S0J47FA4           !14R5 'FL+.*
MJQJKZ4'01]<;/J/0$:'DD$:<F-3U(?:(J+SX'T"1YRPLE:J2-1R+VH>4-'%
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MWI/X_P V@='L\E/45*,\E/45
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MAVG-^K_W[TG\?YM Z/9Y*>HJ49Y*>HJ
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M@ ,C( #(5<(  R4R!4!%R              "B\T*E%YH5
M          '.NL?W]T?J9_(=%'.NL?W]T?J9_(!T2SR4]14HSR4]14
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MC<WS7;PA%148J[I)-GJVUE&R1%XJB9.7C\J,UIK]E*WW*_0! =BX
M     HO-"I1>:%0                *'C53QT\+I97;K4YJIZYYD0[>=42V
MJTK34SD263L5<G-R,TXJZCS/:&N''ZEOP^=4;9J"V52TU"D<[VY1?&4KI/;+
M0W.L935JQ02N5$1%<II^QG9O2W>C=<KPDDDLBHJ;V.S/8-M.SJDLM"ETM2R,
M?&BKA,=OH0Z;:X=XKGG>^T_ASTF>5N</;7C\NBJ6=E3"DD*HYB]9[-Y$/;!-
M4R7:S,IZAR.>Q=W/'/)"86XP:YL7I6Z5,&7U:[]_=4YUUC^_NC]3/Y#HE5^H
MYVUC^_NC]3/Y#)LZ)9Y*>HJ49G=3AU%>/8 ',IQQR&> 'Q/*R")TDCD1B<U4
M\Z6JAJ6JL+VN1.Q34-K5T][](UK(WHVHD9B-.M5(XV"ZOJ)ZN>CNB[CU?AN\
MJ]GI(W$2CJC>D^H BHK45..2B^HD?0''L''L"0#CV#CV  HX]@SZ !3J*Y]!
M:W*KCHJ*:HF5&LC:JJJ@><MSI(YTB?,U).S)>1N:]$<WBBG)6L=7W"3:!'-1
MN<ZC;*F53.,9.E=$7B*\62GEB>CE1N'87K(B8E&XGPV(%.*E>/82D X]@X]@
M #CV#CV %+2Z4K:VWSTSN4K%:77'L'/F!R9J^.?1NKWQSQJVB>_/2+PX*9ZA
MN=)7Q-DI9&N14XX4FW6>C;;JBC=%6L\?'!R(F?O0YIVCVB71=4M/;'.D9E$1
M.OCZBT6UY=_'Y?1'39LMRN]+;X7.FD1')P3B833VDZO:#62/5'QL;E62(G?Z
MSVV<:8=J^9B7&1S5PKE:BIG[SI735@H[%0,IJ.-$1K415PB*I$VVKR.5ZL=-
M?"#'Z$U-I1>DI:RHJD;P1/0GJ4]:#:9JNV2+%<+6JQ)_:<CCH9S4<F'-14])
M8U]IHJV%8YX(U1>O=0AQ(\LFU^SRJC;G+%3O7AY1O=FU%;;PS?M]5'*G+**:
M5>=CMAN**Y%EC?U;N[W&F7C9OJ2S*B:8GE5B<<_^RH!/Z<N8P<Y4FIM8:;E3
MWYBEE:SGO([O-ILVVZBJ)F4]72]%(BX<JJO<!F]K>A(M0VN:II6JVMC;O,5J
M)G)I>R36]59ZU-.7U$:Z++&R/547AR_$ERU:LM%SIU='6TZ/5OD*],G(>V.Y
MU'QF5:VQZ9;)XJL7GXJ =J5-93P4O3S2M;%CRE7@8JV:CLM95.BHZF%TOH5#
MER@O6K;Q11T]0^1(&HB=?>>T%JO%MD\)H99>E)Z717C9+1O3KI"K4[3BN^;3
M]:6J=(Y)%:SEQWN\Z?V17FKONCJ6MK^,[LY_[4C3":S$ZENCFHYJHO(UR^:,
ML]XC>E32LWU3"/1$RGW&R<PB>@B$(!ONR*X6UTE=9JZ7]'XR1M3G]2F/M>T+
M4^F9DI;G0N=3,7"R/WDX'1RHBYRB?28N]6*AN](^"JA8J.3&4:F21J^EMIUC
MO,,37544=2O!6;W)3>89631M?$[>8Y,HJ*0OJ;8U!%OU-@EF;4*N41,<_J0U
MRDO.K-GU0UU[CDFHD\5$<B_1R4#H[[RCW(U%5W!.U3F;:IMKJUMU*MB1L,SN
M+DRN?R-/M>OM:7>+H^D<K7\<IO=Y.EJ5F\ZAU35:PLM+5>#SUL39?[JN0SE/
M/'40MDB<CV+R5#D273URJGI45,TO3IZ3SOFL=8Z:HT;!))T3>W/>3IK;C7K'
M5+L-?J*M(#]SAKB\ZIFJV79^\C%7"\>Q.U2?$]15@J!Q[!Q[  ''L''L 'SU
MKQX'UQ["QO4[J:UU4T>-]K%5,@7F2SN-SI;;"Z6LE9$Q$SERX..ZG:OJZ:\U
MD5-)O,CD5J(BN[5])E8[AJC4<'_B,DB0JF%Y]Y,0TQX[9)U5U79[Q1W>!9:"
M9DK,XRU3(IQXG(C)M2Z:IG):9)'1)QXY_)2NSW:EJBNUO2V^N>O1.=NN:N]W
MD:,F*V/ZG7;0?$2JL;5QS1%/OCV!F=IS?J_]^])_'^;3H_/!>!SAJ_\ ?O2?
MQ_FT#H]GDIZBI1G)/45                                      '6&
M\AUAO(           !K&T:JEH]'W*:G>L<K8E5')U*;.6=TI::NH9:>M1%AD
M;NNSU@<^[-+!4:CBCN$NJ)_">E55IT<B\G+PY^@D':G?*FRV6@L]'(JU59NP
M=(J^,GI-6V@:5H]&I!=[!4.BF25%Z+>3QLKCJ]93:-)+-)HR[564:]T;GJO)
M%P!9U]GNFSM*"]I<9ZI)W-;-'+Y**Y%7J7T&4UC>Z_6%\HK):)U@@>Q'S21K
MQ3@9';O7PSZ*HX89&/?/+&YJ-7*\EY&J:"B?9-H<3;@[<Z:#Q.DX=A(OWTUP
MV9:CHFOKYZR@JE5%69>2_03M"])8FO1>"IDAS;W/!5SV:AA>UU0LBKAJY5#)
M27[75))X/2Z=9-!&B(V3#N*?60)-KOU&H_PW?@I&^P?]A5^?G3OP:6E3J7:!
MX+,CM,,W=QV>#NSUGM[GQ\C],5<E0W<E=4NWF]BX:!O.M&5<FFJ]E J^$K$[
M=W4X\EY$*[.Z'3UP@DHM3.5EX5ZIF541>:XQE.PGJYUT-OI7SU*XB:G%2)=>
M?!.\6JHN='5Q17*)-Z/HW(CE<GHY@9!+O-HF_4-G9&UUIJ'HD4SE[4SSY<U4
MS,^L:J77,=GHH8Y*5K=Z23BJIP1?5UF@)#77S98EPKT=X5;U5\+G)C>3>5$Y
M^@S.P.BJ:J@J;M<VJLTV=U5[,JGX(2/NZ[0+Y<-35UHTS2P22TCU:_?555<+
MCM0R>J+AJ"HV=U<L].R*MPB/;QY>CB8/6VF[5+=JZX6:\LMUT:Y72IOM3>7/
M+J/?36H*W46S.[+7,7I8$2-'(B^/Z?N(%GL8NFHH;<^2Z1Q)9XVYZ7CGEZR[
MK-H&HZUU376*W136JF=A[UWE7''T]A;Z/KXJO9S6V^CE:ZM2/R&KE>1J&A=.
MOK-.U$,^J5MZJY6R4[U:B\O2OK E:HVA-DT'-?:..-TD64<Q7+C*)DU&#:=J
M.Z65MUMMLC\$CRLKG;W4O''T'C>].4VFMDE?3TE<M;$YSG+*N.*X]'J,[2QQ
M0;$OT36(CH)%543TJ!C8MIU^O=K=66*VQK'!GIG/WE3ASX\#.+JVBOF@V72Z
M0MPDBL>Q%X(J.P6N@HHH]C<SXVM17ME55^E34+<K?B=?Q1?Z8_/M@2I6:KH;
M#HJBKF(B,EC1((U7FJ\D-=M>IM9UDT-0MKB;;YE147#L[J_3V&OZYIIY=":3
MJHV.?3P+&Z1&IE,8).LFJ[)+:*)65E.B]&QO1[Z91<<L 9ZD@B9'TZ0M9+(U
M%?A.*D57#:%>[G?I[?I>E@E6G<K7M>JJJX5?2G82]&]CXT>BHK53**0EKRS6
MVDJ*J[V"[,H[A!E7PHY$5ZY^A0)%K-2NLVE4N=[8V*9&\6>G!I]!JK65PDCJ
MJ6V1>]\CN#E1V=WZS ZLK;EJG9?35[H7(Z)_Z1&HOC)AJY_$D72>JK([3U&B
M5=.Q[&(U8U<B.1<=A(TBZ[\FV6V.F;B18&Y3_J>;-JW65PCNZ6C3=*RHK41%
M=O97'7U&NW:5DFVNW/:J;JP(J>T\UFZ6NK?M0KW3W=UJ1Z(L<CL(B^*G6I D
M31^NZNKJ:ZV7RGCI[I2QJ]6(JIGAE.?H4P-AVE7V_766DM]NC5(IE8]_C*B-
M3K*:=T;2TE?<[HE]]\JU87(Y6JU4QNXZBYV%PLEL%Z?&B=*ZID8CDY@7E^UW
M=)KHZTZ9I8ZFNAX3YRJ-7KY>DO-(:ZJJBZ2VG4%.RGKHVY\7.'+GT^LU/9U4
MQ:;V@:BBOBI"Z>5RQRS<$7QL\U/N[SQW_:E3.M#NDCIW*LLD?%%3@G,D7U9M
M!OEVOU5;M,4L$CJ=RM<CU557CCM0V:.Z5S]*5TNJ:5L+HT\EN41>'IR:EJ[3
M-IEKJJOLE[9;:^-5<]F^U-Y>SJZRWL&HZZ^Z OL%T:BOI41K9>/C\%[@-J@U
M70V39[-=J"-.AC<NZU5YKA"TTCJ?55UJ*:HGHH5MLSD5)&([*)]9XZ%I+?6[
M+I8+LY&TCI%WE7'#Q6FK45=-H_5%MI++<4N-MJI&IT:.1VYQQU$"?FKE$SS/
MO!YPNWXV.5,*J(IZ !@ "FZA7  !4*80J +:KHH*IBMF8CD4U"[:5<U72T3W
M)CCNX-W3@41.9G;'6WEKCRVQSN$;T=SK[3-NSHJL1?[63;+5J&EK41'.1C^S
M)D*VW4U8UR2L15[<&H732TT#EEHG.7KQP3!E%;X_'>'3UX\_GM+<YH(ZF/CA
M47DJ&%J:*6E?OQY5OH-=M]\K;;)N5#5<Q.'C9-KMMZHZ]NZKVH]4XHJF.7#C
MY'?Q:#IR8.\=ZE'<MYNY)A%Q@QM5IAE=4/GDE<N]U<#*5MM:]%? O$LX*J:C
M>K7IGUG+:\XYC'R(W'W4M@IF^;'_ -+!='0(O]8[[C[CT=%&]KV2OWD7*<BY
MEK)7S(_*X[#+4ERC?%^D5$<A.&_&R7F-:8WX?1$3I=TL214[8U7*HF.)\RT<
M$J+OQM7Z"W?<X6YPY%+:2\<5W&M5#MOR\%8[R5P7MXA\U6FZ*H1?%W<]B(86
MKT;&W*P2JGKP91]QG>OBM5#XS63K_:.+)GPY/%-RM\%_R[-7GLE=1*O1S</1
M_P"YY0W*Y43_ !E>Y$_O9-P;;*B3^LR>[;)&Y/'7/U&-<6>T[I684MQL=8[7
M:W!K.H8N[-"S[RZ;JULRJBM1GTF9=IRC<U<QHJ]O Q-5I*G?GHYE9Z.!T3BY
M73K;&)O2>W=],N?A*^+.GUEY%0SSIE),H:U5Z=J:7C!+E$_YD+-M;<*-V%DX
M)Z3EC',3_6B737E9/%:MDN_1VV+QWHLB]1KZWF1'>*Q,%G554M7)OS*JJ>"\
MOS-HX^/S$/4Q1;IW9L]IJDKG;BJC9.PS"15=.OBY5#1()703ME9G>:N3-2:I
MJG1HU(VIA,9XE9P8ZQU1,Q+GY.2V+OK<-GBN<T?"1J%U%=X%7#W(U?2I'S[A
M6U;O$7ZCUCMUTJ?(:[ZBN/D9ZSJO>'!;/BM':LQ*1'7*D1,K.Q/I+"IOENPJ
M/>UR&G_!FY*F9-_Z%*?!^1.$KWICT&]^?EIYKIE6N3).JP]KS4VBHRZ)5:_L
M3_V,'#5OII%6FE<U/0;!26:E:_$SE,[26FT\L;R^DWXW/RWGO,:4OP\L=YC3
M6XM55C84C1&N5$QG*EN^]5]2_=8Y45>S)N-;IR@J8\0IN+CFF#5ZRP5MNE62
MF:Y[6\47!W9<%<\;BVF%HR5\O&.BO%0J^/)A>TM+G15-'A*EZJKNHRU%J>II
MHW13QIO8PBJBH8.LJI:R=\LSM[*Y3T')?]*F8G5MRBUHB.WE:\,<C:]#W)8I
MG4SU3QURF35L(?3)'P.62)V'IR4K@_3,N*_7M6N3IG:9F\4!BM,3R5%HCDE=
MEZ]?T(94]"8UV=M9W&P $)          !1>:%2B\T*@                >
M;W8:JG,/ND*MWOY2Q9\7'YG3Z^2IS)[I&B>EYI)L>*B+Q^DX\G^YQ;\;=.'Z
M,FOM*9]D\38M*TZ-3^RW\$+;;'"V71]9E,^*O$N=DT[9]+0*Q<HB-_ M-L]2
MRGT?6*]>"M4Z/UG]_P#+E_1O&)$?N<*AS;O4Q(OB[Z_D='W:YTUIH75=9)N0
MM3*JISE[FRG6:YU%0U/%WU_!#HB_6>FOELDHJQ'+"_@J(N#NY7[/XAR\;Z\F
MO'5+5%VLZ6RJ>'LX>ON(1U5K:S5.V2EN44R+2M1N7]7!N.PE==B&F,K^BF^U
M<538AI7=5/!Y%7M613E=;*MVLZ6W4_I[.7I[BOQLZ5^?L^_N,2FP_3&/ZJ7[
M5P^(_3'R<OVK@,K\;.E?G[/O[@FUG2RIPKV9^GN,3\1^F,?U<OVKC7-=;+-+
M6&RRU:MD:].#?TCER#QW>>JM10:TU'016Z3?I(W>/CDJ93N,#K&C73=\HJNV
ML5L:*CGJB>DNME>GF4#9*R)'=$_R=Y<]1N&J;<EQLM3&C=Z56*C?6<DW^9PV
MR?/MF;;M5T\R@@2LK&,F1J;R<2X^-G2J9_IS/O[B$MGNBK)<+Q+17U\GA"NP
MU-]4_ E?XD-+KC]%,O\ _E<=43$QV=L3N-LO\;.E?G[/O[A\;.E?G[/O[C$_
M$?ICY.7[5P^(_3'R<OVKB4LM\;.E?G[/O[A\;.E?G[/O[C$_$?ICY.7[5P^(
M_3'R<OVK@,M\;.E?G[/O[BGQLZ6^?L^_N,5\1^F/DY?M7%/B/TQGC%-]JX#+
M)M:TM\_9]_<:GM&VEVVZ626WV6H;++,W=\7.2^K=BVEJ:EEFD;*UK&J[/2N(
M@L>DZ.;62K:=]:>"3#MYRKR5>TK:W3&Y5O;IKMN.G]*Q3Z2J9ZAG]+<Q5:JI
MQ*;,-8Q:1JZFBO,FY"KEPKL^@D**-L43(VHFZC43!$FU;33)[@RND:K:7+4=
MNKCT'-CO\SDQ9-6[IF7:QI9,?T]GW]Q7XV=*_/V??W&EZ,V3:4O-CIZMJ2N5
MR<<2NYF>^(_3'R<OVKCK=K+?&SI7Y^S[^X?&SI7Y^S[^XQ/Q'Z8^3E^U</B/
MTQ\G+]JX#+?&SI7Y^S[^X?&SI7Y^S[^XQ/Q'Z8^3E^U</B/TQ\G+]JX#+?&S
MI;Y^S[^XI\;.EL_K[/O[C$_$?ICY.7[5P^(_3&/ZN7[5P&0K-J^G'4DR4M:Q
M\VXNZG'GCU$56")^K=554]P:KZ5=Y6JO+T%GM+T+8[3<H:*RK(E4JIE.D5>.
M?2;]HBTK;+%#'(W$V,JO689;]M.;/?7:&J1/?HW6#:IJJVA3*+V<4)2CVM:8
M5B*^N8BJG%.//ZC4M>6;WWLSXVM\9%155.'::OLPV?:;OR3PUG2^$1*N4Z1R
M<E)Q6W&DX+[C25_C:TM\^9]_</C9TM\_8OU]QB?B/TNN4Z.;[5Q7XC],?)R_
M:N-G0ROQLZ6\X,^_N";6-*_/X_O[C%?$?ICY.7[5P^(_3'R<OVK@+FKVC:)K
M$7PJ>GDSVHO<:W=+GLYKV2+&^&*5R<',3'Y&;^(_3'R<OVKBGQ'Z8^3F^U<!
M$]XMVGH'OJK??Y&XXHQ'&@4E*RY:G=(R19D1WE+U\#I==B.F$:N8YOM7$":F
MAI-*;0);?0YZ%KU1$7CU9)CRUP1$WC:0:*)E/3,;&F.'8>V\J9ZSSI)&STS)
M(W;V4Y'HB*O!#1[T3]FF[2;;"ZS^%*Q%<WN4DC9'M)T];-'4U-6538Y6JN47
M/<1SM)KV-M"TV\F\N4X^I3==EFR.PW?2=/5UC9'3/5<[LBHA2SR>;KKC21?C
M9TMC]?9]_<5^-G2OS]GW]QB?B/TQ\E+]JX?$?ICY.7[5Q5Q,K\;.EOG\?W]P
M^-G2WS^/[^XQ7Q'Z8^3E^U</B/TQ\G+]JX#*_&SI;Y_']_<65RVC:)ND715T
M\$S,\G(J_D6_Q'Z8^3E^U<4^(_3'R<OVK@(0VRPZ:N513NTY,U<KQ:WJ^XSF
MBK:VAM<>\U%>K4XJGH/+;EHRSZ'BHZBW(Y)'+C#G*X]M'7)EPMD;LX<C4X?0
M6J]#@]._RSV\N57B65YHH[A;YF2M1V&*J</07VZO7S+:YU3*.AF?(NZJL5$^
MHO+TYC<3M@]A.I[7I2Z7"*Z/; BJN,^I";DVLZ6^?L^_N()V-:,MNM+K72W7
M><UJ^+N.5OX$P)L/TQQ_13?:N,GS]_JEE_C9TK\_9]_</C9TK\_9]_<8GXC]
M,?)R_:N'Q'Z8^3E^U<%&6^-G2OS]GW]P^-G2OS]GW]QB?B/TQ\G+]JX?$?IC
MY.7[5P&6^-G2OS]GW]Q97?:II>>VU$3:UCG.8J(G'N+;XC],?)R_:N+2Z;%=
M,P4$\B,E16-SQE4#GW2=K95ZDJZJ-=Z%TF\G8J<25V-;&Q&QINM1.2$3Z1ND
M=#J.IH845(6R;O'CVDLMW7-1T:[R<%-*O9X?3T=AS4D:K'<6NYF@;M+IW:!2
MUTJ(V%JM55-_SN-WW<&MYFA545-J;7%/;GNS Y6HNZN%$IYFO3[NA*?:SI;H
M6[U<Q%PF4X]QZ?&SI7Y^S[^XPT&P_3/0LS'*JX3_ -5Q]_$?ICY.7[5QF\5E
M?C9TKA?Z>S[^X@W4FL[/5;8Z2OBF1:9'<7IG'-I+OQ'Z8^3E^U<?3-B.EFJU
M>@DWD7*+TB@2-:+A3W.C;4TCMZ%R)A4+TQ]BM5/9K>RCI$5(F)P15S_WR,@
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M>-KFYW),HJ?0:V_7-CHZB6!;'<G.8Y6;R1*J+A<=I.LLJ]6"OMMEWZCN4O\
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M+DD4K6.CZ3HU3#D]& ,H"-)-K-%')(Q;1=%W'*WA#P7"FWZ5O\6HK:E7%!/
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MZF:H)4FI(WIR5J%P>=-"V")(V)AJ<CT#(
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M>7$J           #
M    '6&\AUAO(                    4!0+>N_49_\-WX*1OL'_85=_FG?
M@TDBN_49_P##=^"D;[!_V%7?YIWX- E
M
M   H %/453@@ !.                *+S0J47FA4
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M+[G=/_AEN5ROC?B:\2ELF*^6_;[0QY5_3RTQTG<3Y2XG(^CYSQ4^B(:  )
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MTI2=Q$@ (6                                     #K#>0ZPWD
M              &0 4 "WKOU&?\ PW?@I&^P?]A5W^:=^#22*[]1G_PW?@I&
M^P?]A5W^:=^#0)0
M
M      !1>:%2B\T*@                          !3K(XVXIG1]1]/X*2
M-UD<;<G?_!U1Z_R4XN?_ *7]X_\ +IX?^M5 .R/:#2Z2FG2J8U6^E53K)53W
M0-I6)SFPQJJ=6^I%^Q[0%'JR:?PV16HG+&.M268M@=B8JXJ)/93N/2Y,7F(W
MYU#AQ37U+Z\;E%\^I(]INOK<UJ)#%$_BB=?'/6=$Z@I$HM%54+5X-@7\#G[:
M'H9-FMPIKQ:I'JUCLKG';Z"8Z&^+?MG4]0_&^Z!>7\)Q9NB?TZT8HU%9G?\
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MU&'^!"\0L[8BI0Q(O/=0O$Y&MO,LL?TP  JN
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MZ?OM#?Z+PJV3)+"O6B*@&5 3T@   *+S0J47FA4
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M6,,1JN]RRT;$9&UO8B(>J<CYW3Z3D4:Q&@
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M9\ 8#X'6#"_^%TWLF4MUMI;;!T-#"R&)/[+4PA=@      HO-"I1>:%0
M                       #@,# %/4"H HG,>H(5(@40J, D4'U%1@;! ,
M      # * 5          % A4(!3UAO J         !1R93B5*+R 808[>8
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M!O('6    HO-"I1>:%0
M          &/NUVHK5$DE?.R%B\$5SL&0-6UWHZEU;1,IJN5T;6JBY1N>6?2
MG:!]?#K3OG*'VT'P[T[YRA]M.\C_ .(2S]5;)C_#_P#R'Q"6?Y[)]FO^H"0/
MAWIWSE#[:=X^'>G?.4/MIWD?_$)9_GLGV:_ZA\0EG^>R?9K_ *@) ^'6G?.4
M/MIWCX=:=\Y0^VG>1_\ $)9_GLGV:_ZA\0EG^>R?9K_J D#X=:=\Y0^VG>/A
MWIWSE#[:=Y'_ ,0EG^>R?9K_ *A\0EG^>R?9K_J D#X=Z=\Y0^VG>/AWIWSE
M#[:=Y'_Q"6?Y[)]FO^H?$)9_GLGV:_Z@) ^'>G?.4/MIWCX=Z=\Y0^VG>1_\
M0EG^>R?9K_J'Q"6?Y[)]FO\ J D#X=Z=\Y0^VG>/AWIWSE#[:=Y'_P 0EG^>
MR?9K_J'Q"6?Y[)]FO^H"0/AWIWSE#[:=X^'>G?.4/MIWD?\ Q"6?Y[)]FO\
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MV,3@JIC_ +Y 98
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MV)J.5$QQP9!.6, 50    !1>:%2B\T*@
M                         #B.( #B.( #B.( #B.( #B.( #B.( #B.(
M#B.( #B.( #B.( #B.( #B.( #B.( #B.( #B.( #B.( #B.( #B.( #B.(
M#B.( !                                                   ZPW
MD.L-Y
M
M                      47FA4HO-"H
M     'RKL+Z"N5 J"F?4$7U 5!3/9C(WN?;V 5!3)4       !5  IGBI7(
M%,C*XY<0*@ID9 J"F1D"H*9[ BY J"F>(1<JH%0"F0*@IDJBY  %,@5 3)15
M5 *@ID9 J"F>T;WHR!4%$7ZBO$ "F?K"+Q4"H   HJX"KP5>H"H*9YE0
M                                                         !UA
MO(=8;R
M
M                       HO-"I1>:%0
M     +"^7&"T6FLN%4Y&04T:RO<[DB)Q.86>Z=NBW)&+:*/P7I,*_+L[N>?,
MEKW2=V;;-EETC23=EJ_T#6_WD7@OXH<B5&B*Z'9_%JC=_H[YUB5,\DPS"X].
M\OU =_V6OBNEKI:ZG<U\4\:2-5O+BA<5E0REI)JB5<1Q,5[O4B94AOW+.J_?
MS1#[?/(KJFWR='A?[NZF/S,CM[VA_ ZUK1)1OG6O@='OM3R<HY,\T[ (TO\
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M<QO'';Q<3YH[55JU=:FW"S3]+"N,HJ8<U53.%0#/HJ+R!1O!5*@
M                                       .L-Y#K#>0
M                                    %,]GK- VK;3K?L[IJ:2MI)JR
M6H=AL4+T1V./'CZC?T^@YHUC!'M$]T'365Z]);K? BR]291CG)][D0":MF>M
MZ/7FG4NU##)3MWW1NAD7+VJBXXX+/:7M(M>@Z>G\.CEJ:VH<C8J:'RGYSQ1<
M8ZB)]@M9)I/:A?\ 1U6Y6PRJ^:G:O'BJ-=_*BFN^Z;IK\W:!9EJ*VE?#(K/
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MZN1.VP_6\VMM(LK*]J)7PR.BEW4PBJF%SP]8$CIR
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MR-Y]QG^U+S_@_FTS$5B6Q^Y9F;*U$EJ6LJ'>E'2(K?N5#$>XU_:EXZOT/YM
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MU@:\GN<M89_6Z/U=.[_2=);(--5ND]#T%IN;V/J8-_>5CE<G%[EYJB=II/\
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MCRJYX9:F>H"9F]>2H0
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MC;NLD;Z;>W'QIQ5%QP7ZOO/C1.S:W:2T]<+-0U-3)25B/1R2+Y.\W"X^HWL
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MU,<RH        /G&5YH!] HB8*\>T !Q[1Q[0 ''M''M  <>T<>T
M                                                   *83!4IU%0
M                   8     ,#     !A  &$[!@       8  #"=B#
M ,  !@80 !@  ,      P    #                        "@*
M                                WD B8
M
M           G6
M                       4ZBH
M                                                           %
,             ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g109079g00v01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00v01.jpg
M_]C_X  02D9)1@ ! 0$ Q #$  #_[1KV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &MD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MY;[X6'_WMGG.;Z?%%9F(=XM7FF\1-O-V& #&?0@
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M C8<\E1&L7/6JZ^V4F15/0V?H'5_ZA)_#C+6,G-6*Y)B&[IK3?%6UNH ").
M
M
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M97[P[# !@/J@
M       %9=$1[WJ_O<7F<<P'3_1$>]ZO[W%YG',!KZ'^7^;![1_G?D  ML\
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M/Y-?L  A6
M
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M4[EOOA8?_>V><XR?)/V28?YE?O#L, & ^J
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MY-?L  A6
M
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MHJ99L@:U>="O0<SBI,[S#JN?)6-HM++N5QK+E4.GN%5-4RJN>E*]7*G>S,0
MDB-D<SOSD  >           $IW+??"P_^]L\Y%B4[EOOA8?_ 'MGG.,GR3]D
MF'^97[P[# !@/J@
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M^@=7_J$G\.,M8P]1_-L^FTG\FOV  0K
M
M
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M_&UEJZVS54--#4M?)(Y$R:B<*ZSIX'EM;>8F-H=5[-QUF+;SR  4FB
M                                                  @&[=9Z^]X)
MZ4M-+)55/3,;][CVY)I9K]IS_P!CC%_(%9S)Z3K\%G%JK8J\,0IY]%3/;BM,
MN0.QQB_D"LYD](['&+^0*SF3TG7X)?'W](0?#,?K+D#L<8OY K.9/2.QQB_D
M"LYD])U^!X^_I!\,Q^LN0.QQB_D"LYD](['&+^0*SF3TG7X'C[^D'PS'ZRY
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MZW"++<;%@^II;O224E0ZM?(C)-JM5D:(O.B\Q8H!4O>;VFT^;0QXXQTBD>0
M#AV
M
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M@ZO6KE&E\H@&R!K>KUJY1I?*(.KUJY1I?*(!L@:WJ]:N4:7RB#J]:N4:7RB
M;(&MZO6KE&E\H@ZO6KE&E\H@&R!K>KUJY1I?*(.KUJY1I?*(!L@:WJ]:N4:7
MRB#J]:N4:7RB ;(&MZO6KE&E\H@ZO6KE&E\H@&R!K>KUJY1I?*(.KUJY1I?*
M(!L@:WJ]:N4:7RB#J]:N4:7RB ;(&MZO6KE&E\H@ZO6KE&E\H@&R!K>KUJY1
MI?*(.KUJY1I?*(!L@8M'<:.M<YM)50S*W:C'(N1E
M
M
M
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M6IJE>]JR*U$541[D38B)L1#*W:_>XN_@G?=4C_0S^]U%X1_\1X%L@
M
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M* ,6GKHIZN>F8J[Y#EI:N-$7\4,HU5OH98+S7U+\M[FT='+;J:U/P VH
M
M                  !=@"[ .?,#_K%7GY\__,Z#.?,#?K%7GY\__,Z#
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MA7VY56W%TSZ;1?)0)^T[/)JY+J3["S3.SXNZO-5S%?O*\0 "%(
M
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M?!EI*NQ<T1?Q,PUM#;WT]VK:ISD5L^CDB<&2(GX ;(
M
M     NP!=@'/F!OUBKS\^?\ YG09SY@;]8J\_/G_ .9T&        !H<;X>3
M$U@GMKIEA216KIIP9.1>+N&'<,'4]?@N"P3S2(V&)L;96KDJ*UN2+J)4 *JM
MNY5.ZXTDM]O$M=34BHL42Y<"YZ\FIW2S+@B-MM2B;$B<B<QDF/<O<ZJ\$[S
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M"<@
M                   (-NU^]Q=_!.^ZI'^AG][J+PC_ .(\D&[7[W%W\$[[
MJD?Z&?WNHO"/_B/ MD                                  "L^B+]["
MO^>GW7%F%9]$7[V%?\]/NN#VO56]#_8J?P;?,>YX4/\ 8J?P;?,>YD/TFO2
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M0^KM=+/)[>2-'+WU RP
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M+4;FO=U$3W,+]55C'T-4CY$C3-LJZ\DRV+J[G'PE@&1EQ3BM-9:&.\7KQ0
MC=@
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M9(7IK13-1$1$1-2(2Q._.%"U9K.T]0 'KP
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M4MFHFT]*Q$7:YW"Y39 %2UIM.\K$1$1M  #QZ
M                                                   "#;M?O<7?
MP3ONJ1_H9_>ZB\(_^(\D&[7[W%W\$[[JD?Z&?WNHO"/_ (CP+9
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ML  D5
M                       "[ %V <^8&_6*O/SY_P#F=!G/F!OUBKS\^?\
MYG08           #'N7N=5>"=YC(,>Y>YU5X)WF HWH8_=#%/A&>=Y?10O0Q
M^Z&*?",\[R^@!BPUT4U;-2MSWR),W:N]Z3*-91T,D-YK*IRIO<J(C?L] &S
M
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M=/6>4))<L4P26>2W6RWMHHI':3U1R+FNKB1.(BH!':TVZKV'!3#$Q2.J0,Q
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MU-?GEW]2EC$>"V]-I\EOM+'%,\S7I;G'Y@ )E
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M8YMM=)PLTG;-FK1T. "V@
M                                          !!MVOWN+OX)WW5(_T,
M_O=1>$?_ !'D@W:_>XN_@G?=4C_0S^]U%X1_\1X%L@
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MW=GXJ>>Y]<EN%AC21V<D*[VO>1$*]/P9)KZ\VGF_CZ2F3SIRG[>23  L,P
M
M                NP!=@'/F!OUBKS\^?_F=!G/F!OUBKS\^?_F=!@
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MON55+)"KM!C'YZ]2+G]OV%@EO'?O*\6S4P9N^QQDB-MP ':8
M                                                         0;=
MK][B[^"=]U2/]#/[W47A'_Q'D@W:_>XN_@G?=4C_ $,_O=1>$?\ Q'@6R
M                               !6W1!^]O5^$;YG%DE;=$'[V]7X1OF
M<!/;-[D4/@(_NH9AAV;W(H? 1_=0S                    JG#WZP6*_W.
MG_AL+6*IP]^L%BO]SI_X;"U@                   JW=Y_L>%?]<I?O*6?
M!^8C^:GF*PW>?['A7_7*7[REGP?F(_FIY@/L                  8=Y]QZ
M[P$GW5(%T/GO=M_U"M_\F0GMY]QZ[P$GW5(%T/GO=M_U"M_\F0"R0
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M1EFNPY[B4GS/Q4V)JUYQ#XK+$1>T1Z@ .D8
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M)<V2-TD,@THVVY/HZ[;1P]  'KT
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MWK^5@[5V:YJI)R>EHM6)AG:C%;%EM2W6)  =(0
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MUAQM6V:551LBJC<UR3-$5<_L+;(M-;?'M/6.2KV=DF^"(MUKRG\@ $Z\
M
M     (-NU^]Q=_!.^ZI'^AG][J+PC_XCR0;M?O<7?P3ONJ1_H9_>ZB\(_P#B
M/ MD  #$NU!%=+;4T-0KVPSL5CE8N3D1>+,RP!A4EMAIK2ENC=(L"1K'FJII
M9+GW.Z:9,%VWJ;;:+?:K>:!4=$NFW27+1]MVNOVJ<1)@!J[A9*:ON]ON,SY4
MGH4>D:-5$:NDK57-,O\ *G"(K)31XBDO+7R]-R0=+JU530T<T79EGGVJ<)M
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M/1SU3BS1$U&\         %4X>_6"Q7^YT_\ #86L53A[]8+%?[G3_P -A:P
M       &NO\ :*>^6U]%6.E;"]<U6-41?M13.@B;!!'$S-6L:C4SVY(F1]@
M       "K=WG^QX5_P!<I?O*6?!^8C^:GF*PW>?['A7_ %RE^\I9\'YB/YJ>
M8#[       !BU-NI*FIAJ)Z>.2>%<XWN36U=6SF0C$> :6&Y55=27F]4U14K
MG(L,[$1=FKVG<0F( P+-;G6VG=$ZOK:U7.STZMZ/<G<141-1G@      &'>?
M<>N\!)]U2!=#Y[W;?]0K?_)D)[>?<>N\!)]U2!=#Y[W;?]0K?_)D LD
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M3'GRG[Q_=G@ L,L
M                      +L 78!SY@;]8J\_/G_ .9T&<^8&_6*O/SY_P#F
M=!@           ,>Y>YU5X)WF,@Q[E[G57@G>8"C>AC]T,4^$9YWE]%"]#'[
MH8I\(SSO+Z &DMSWKB.XL5RJU&IDG%J:;L^&MC21RM1--=O&!]@
M"I=T:%;3C:V72/M6/T4<O=S=G]BEK4TK9Z:*9BYMD8CT7N*F9$-U>V=/88EF
M8F<M,J/;]+D1?L,G<TN?5+"U+I+G) U(G?0F2>8K8_P9;5]>;.P?P=5?'Y6_
M%'])2H %EH@
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M-/G&\?>%Q@^8GMEB9(Q<VN1'(O<4^BPS
M                                        NP!=@'/F!OUBKS\^?_F=
M!G/F!OUBKS\^?_F=!@    *SQGNTX4PM=5MM34K4UC5T7L@R<C%XE5,\E LP
M$1L.Z%8;UB">R4]2C+E$Q)%BD5&JY%1JZL]OMD)< !7.Z-ND,PXR>EH:2>2O
M:J(CWQJD::\MN62\)M*S&"VS<]@O]9&CYY*=KTC1<D<]69Y;.,"9&/<O<ZJ\
M$[S%24.Z/B&AKK=+B*VQQ6RO<B1O:[)6(JY:^U[BELU[D?;*AS=BQ.7[ */Z
M&/W0Q3X1GG>7T4+T,?NABGPC/.\OH :2W:?7'<-+2T-%,L]FQINSX:Z)97-:
MK-\3VR(J9_2!]@         #&N5.E5;ZB!R9I)&K<OH*RW**I;;?;K9I]3UE
MT6I\W3S+6*>QC&[#^Z)25\2*R*HD1SE35GFJ:7WBKJ/PS7)Z,W7?PK8]1[9V
MG[3R7"#X@D;-!'*S6U[4<G>4^RTT@
M                                     !!MVOWN+OX)WW5(_P!#/[W4
M7A'_ ,1Y(-VOWN+OX)WW5(_T,_O=1>$?_$>!;(
M            %;=$)[VU7X1OF<625MT0?O;U?A&^9P$VLU'3K:*'."/\PS]G
M_*AF=)TW]Q'XIY6;W(H? 1_=0S /#I.F_N(_%'2=-_<1^*>X \.DZ;^XC\4=
M)TW]Q'XI[@#PZ3IO[B/Q1TG3?W$?BGN /#I.F_N(_%'2=-_<1^*>X \.DZ;^
MXC\4=)TW]Q'XI[@#PZ3IO[B/Q1TG3?W$?BGN /#I.F_N(_%'2=-_<1^*>X J
M3#]-"N[_ (I8L3-!*.GR3+5^;:6ITG3?W$?BE88>_6"Q7^YT_P##86L!X=)T
MW]Q'XHZ3IO[B/Q3W 'ATG3?W$?BCI.F_N(_%/< >'2=-_<1^*.DZ;^XC\4]P
M!X=)TW]Q'XHZ3IO[B/Q3W 'ATG3?W$?BCI.F_N(_%/< >'2=-_<1^*.DZ;^X
MC\4]P!X=)TW]Q'XHZ3IO[B/Q3W %4;N]- RCPMH1,3.^4J+DG!I*69!1TV\1
M_D(_:I^SW"N-WG^QX5_URE^\I9\'YB/YJ>8#SZ3IO[B/Q1TG3?W$?BGN /#I
M.F_N(_%'2=-_<1^*>X \.DZ;^XC\4=)TW]Q'XI[@#PZ3IO[B/Q1TG3?W$?BG
MN /#I.F_N(_%'2=-_<1^*>X \.DZ;^XC\4=)TW]Q'XI[@#PZ3IO[B/Q1TG3?
MW$?BGN -9>:.G2T5V4$?YA_[/^52$]#VB)N=,1-B5];_ .3(3V\^X]=X"3[J
MD"Z'SWNV_P"H5O\ Y,@%D@  J9HJ+L4Y@W6MS7&-!B:]7'!J.J+?>D5:J&-F
MDY557:LLEX^#(Z?78I0F-MQS$%\Q1<+E28I;2P5$KGLA614T$557+VJ@1G<U
MW/,;7O$F'ZG&,;J:UV)&+3PRQZ#M2MU)DUN?M=JJIU"B9(B)L0Y(HL+7[ FZ
MUA:DO=_=4TE74M6-T<BN1RH]G:N143X1UNW8@   #\?[1>\?I^/]HO> Y^Z&
MO])\1]Y?O-.@CGWH:_TGQ'WE^\TZ" P[U4RT=GKJFFB?-/# ^2.-B9J]R-54
M1$XU5#G+#F)J6Y7!*G&&&+W=KU#*]S6LI7:+$1_:]JU41<DT4UH6WNC8KFML
MK;;0:IGM59'JGM47+++[2MZ>HGH9HZRGD5LZKGI9)Q_T+>GTW?5FTS](5+ZJ
M(M-:QOMU-T"X7>_XPBIKA8\0KA2")KDIJ2D=G,__ #*U6N1-:\*["VMSBNI*
MFRK#;K%6V6F@=H-@JH5C5=2:]>M>^,%XHAN]L5U<Z..JC=HO14V]U"0I<:)-
MD\:%6*S/DGQY:Y*Q:LLJ1[8XW/>J-:U%557@0U%EOEOO$E3#2*BNB7)R*B:^
MZ1_=$Q'%3VI:2DD1\U0BM56_LMX?.5UAB[OLMVCJFYJSVLB<;<\_P+N'1SDQ
MS:>ODBR:C@O%8Z)A>Z.;"5^CN%$B])R*B*U-FS9KSXLRQ;?615U)'44[M*-Z
M9H:^OGMEVMSX99XW1R)S$*PK=78>O#[95RI)2O=VKTUHG=^Q#*BEL-]MN4_L
MWK7KKL/%,_Q*1^L?WAO=UF[7*S8(KZFR0SRUJHC&[S'IN8BKDKLE1<\D7/Z"
MM]R2\6B"HBD9A^_5=ZFR2IN,],]6HY5S7:Y4:G>1-A,=TW$3'4[+?12H[33.
M143@X$\Y%L"WI;1>&::ITM-DQZ9;->TU*:.;8IOYL&VHBM^'R1VV5E9=+]57
M3'F&\37)S7_]+21T3TBB35K[56H[8NU%VEP8DA2^X-CK(:26ED:U)&0S1Z#V
M:TS14X-69,&HQS4<U&JB]P_)HVRPOC<G:N:K5*%Z\59K*]@RSAR5R1Y2CV K
MFE?8H6.?I2PM1CD[B:D\Q)"M,.2NL.,ZFAD7*"9ZHWO9KH_@661X+<5=IZPM
M=HX8QYN*ORVYQ^8 "90
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M9;
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MD^!RZ"*O=7/\"I\F7Z2U/_(T?UQS^TIV "PRP
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M/LK4Y:1>M>4_6%D@U.%[LMYM:53H][72T='//@3TFV)JS%HWA1R8[8[32W6
M 'K@  %17-.MW=1BG3M*>J>F:]]45Q;K51S45-BZRM]V>WJ^W4MQB;V\#]%5
M1./_ .B9X5KVW.PTE4U<])F2_0JI^!6P_@R6I^;.TG\+/DP^7S1^?7]VU !9
M:(
M        (-NU^]Q=_!.^ZI'^AG][J'PC_P"(\D&[7[W%W\$[[JD?Z&?WNH?"
M/_B/ MD    !JYK'2RW^&\2.E6JACWIC=)-!$UZ\LMO;+PGU?K+2WNC2GK$>
MB->U[7QJB.:K7(Y,ER7A:AL@!H+WA.W7FJMU37+.Z:A7-CD<G;[-3M6O/13B
M,N^6*BO5''3UC':,;D=&YF2.8J(J(J+EJ76IM#QJ:NFI5C2IJ(85D=H,WQZ-
MTG<29[5U; -);,)TM%<HZ^6LN%;4Q)HQOJY4DT$[FI,MJ\YFVNQ4EMEN+X%D
M<M=,Z:5'JBII.VY:MAM !$^L2W?]1&VKN+:6=SGOI6S(D6;E7/M='NFCQU;&
M6VAL5' E1%;::HTWU46N6),G[,DS_:X$+&ED9$W2E>UC<\LW+DF9](N:9IL
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MY;<I_-)XW(]C7(N:*F9^D>P+<NJ-CCTU_*Q*K'$A)*6XJQ,*N;%.')..WD
MZ1
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M!NK\5+(*>M[UPSNERTZZH*ER-S[BY+YT*N;\%ZW_ "9NK_A9\>;RZ3^?1<(
M+32
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MG14>Q4:Y4_[ES^Q":6:N9<;;#5,RR>F>6>PKX?PS.-J:_;-CIJ8\XVG[PS
M6&6
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MGO$5F-^;J^CS9\%K8XZ?O](CSE(=P^B@Q!N9S4$\#624=2^%)FI^<<C6=O\
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M9:>1<D5?V<F_CF6"=8K\=(L[TN7OL-;^L  )$X
M                                         "#;M?O<7?P3ONJ1_H9_
M>ZA\(_\ B/)!NU^]Q=_!.^ZI'^AG][J'PC_XCP+9        -?=+12W*:EEJ
M&KOM-(DL3VY(J.3/TFP       <B.:J*F:+J5#QHZ2"BIVP4D3(H6[&-3)$/
M8       PKM;*>ZT[(*QJNB:]'Z*;%5,]2]S69H -1&HB)L34        5MT
M0?O;U?A&^9Q9)6W1!^]O5^$;YG 3VS>Y%#X"/[J&88=F]R*'P$?W4,P 8MTM
M]/<Z*6EJV:<4B9=U%XT[IE #XAC;#"R-F>BQJ-3/B0^P /F6-LL;XY&HYCT5
MKFKL5%X#XI::&D@;#31MCB;L:U,D0]0      8,]KII[G!7S-5\\+5;'GL;F
MJ+GW]1G    !5.'OU@L5_N=/_#86L53A[]8+%?[G3_PV%K   !K[5:*6UOJ7
M4;7-2=VFYO BZ]G.IL  !X145/%52U,<+&SR(B/>B:W(F>6?.I[@      P[
MO;:>ZT;J6K1SH7+VS4_:[B]PR88FPPQQ1IDQC4:U.)$/L   !5N[S_8\*_ZY
M2_>4L^#\Q'\U/,5AN\_V/"O^N4OWE+/@_,1_-3S ?8
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M?8LFFGSC>/O"QP?C'(]J.;K14S0_2PRP
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M*9E;3_AFV/T9VA_AWR8)\IWC[2R  66B
M                                    @V[7[W%W\$[[JD?Z&?WNH?"/
M_B/)!NU^]Q=_!.^ZI'^AG][J'PC_ .(\"V0
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M/8KS;I9&QQUD#GN7)$1Z:U(L.2)K&\\UO7Z6U,TS2)X9YQ^;8  G9P
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MY!?\&6MO7DR<W\+54R>5N4_UA;( ++1
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MKY6M7F53\M"0MME,E+.Z>!&)H2.=I*Y.ZII+[@ZPW*IEK[E21OER[9[D3\4
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MURE^\I9\'YB/YJ>8K#=Y_L>%?]<I?O*6?!^8C^:GF ^P
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M52EKTWBJ:F2YY9*2]-::C7I>+QO5\+GT^3!;AR1L  [0
M                                         78 NP#GS WZQ5Y^?/\
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M4GF):38[<58LEPY(RXZWCS@ !VE
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M6&L74MQ1(*M>EZQ,D5K]6:GE,W/AORE[GT/X>]T\\5?WC[I0 BYIFFP$[.
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M7)-'K1%]L@TMHVFGH^;T6.^'CT]XYTF8_)[@(J*F:*BH"TN@
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MM/\ 99@(]AG%%)>6(S22.JX8UU9][62$GK:+1O#-RX;X;33)&T@ .D0
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M22$(W,Z6@2B=/"[2K%7)^:ZVZO\ [)N:>&9M2)L^3U],>//:N.-H@ !*I@
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M(V,->&D1#\][KNIFGH  D
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M^ZAF&'9O<BA\!']U#,   ",UEMJ:7&E-=:./3AJ8EIJE$X-:*C^\B,1/I),
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ML+T>QR9HJ'H:":8VY2  /
M            ",[I5R?:,#W>NA<YDD,6;7-3-47-"3$>Q\RXOPM6I9J:GJJW
M11605#4<R37L7-40"HMS"ML<]VM238HO+KF]JN2"IC1L<JZ*YY+O:><OXHFL
MGNVZ!>,-4S,,R6J.@FW^>H<]J[WDF>BW4W;EEJSVE[)L @V[7[W%W\$[[JD?
MZ&?WNH?"/_B/)!NU^]Q=_!.^ZI'^AG][J+PC_P"(\"V0
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M3-%J)%1<E)MUN67DJA\BWT&=0T5-;Z9*>AIXJ>!%54CB:C6HJKFJY)W0/<
M5;N_X N6/L.4M+:*AD4]/(LF@_8_N9YG/5OM>(=S*EK*>]X%@N<4C'LZ<6FT
M]#-JMS1ZQKW]IVN><\$-1&K)XF2L7:U[45 .8^A;QW9;>E;9*Z1:>X5U4F\Q
MJB(BJKW=KP?"0Z@(;5;FF%I[[27AMKCBN%-*V9DL;W-[9%S3M47+@XB9)J0
M  !^/]HO>/T_'^T7O <_=#7^D^(^\OWFG01S[T-?Z3XC[R_>:=! # H[ATQ<
MJNDWO+>,NVSVYHB_B9Y@TEO;3W&JJD>JNGRS3BR1$_ #.           Q;I1
M17&@GI9VHZ.5N2HJ9]Y><R@>3&_)Y,1,;2I_!E?-A7%]19:QSNE9)%9'I+DB
M:UT51%X]1<&W80#=4L*3T#;M1MT:NE5'*J9YN3-/,;K<_OJ7RP0O>OY>)$9)
MLVIJS^PK8=\=IQ3^3.TDSI\EM-;IUK]O3\DE(GC[#C;O;W30-3IJ)O%[9,]G
MVJ2PC.Z#=YK1AZ:2F8KI']II(F:-S7:2YN'@GBZ-7'DG%,WCRB=_K&W/]E4X
M0Q3+A66MA=&LK'N1-!79:*IGGP=TM?"F,+??V-8R1L57DFE$YR9KWN,Y[<Y7
MN5SES<JYJO&9%KJYJ"O@J:9RMEC>CD5.XIE8=3;%R\GRFG[7OCF,45C@W_/:
M9]?HZA(=BS E!>6K-2HVDK$UH^-FI>^B9<YI*:[XMKXFOIXWMC<FI=Z3)?\
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MJXVN7]ESDS\Y)7-2W25?+H=1B^>DMN#YC>V1J.8Y'-7A0^B14
M        !^.<UJ9N5$3NF-+<:.+/?*F)N7&Y#R9B'45FW2&4#33XFM,.>=;"
M[+X+T])K9\=VF-%T5E?\W17\3B<M(ZRGIH\]_EI+>W:ZTEJI]]K)6L3@3-,U
M[R$&H;CAN3&TE_WV:.ND@Z6S?J9HJK.[E^PA&<5WI;W<EF9II U,F-=EJYOH
M-,4[ZN>+\/1OZ?L/'.*)S3/%/[+FO.&Z"_W.T72:1RR6^7?H58[4JY.3_DI(
M%V$0W,ZJ6>QN9*Y7)$]6M5>+:2]=A=QVXZQ9\]J<,X,ML<^3GS WZQ5Y^?/_
M ,SH,Y\P-^L5>?GS_P#,Z#.T   *NW;=U5NYQ2TB,M_3E35H[0SET$;E_P!J
MYE(W/%.Z?CNP7"[T=7U.M%/"Z9Z4\SHW:"(N:9MRSU(=+8[P%8<;TC(;]2;\
MZ-%WIZ/<U69\62I]I1V*>AYNU!3U/6;?I&T[VJCJ:HD<B*W+VJ(C5S ^.ALW
M/&71U'C.Y72HJ*R-^DR-^:ZT<J9JY7:_:\7"=.G+^XC7XWP7B6@PI>;7(VU3
M2:"2NA5K4S7/-'*B*NU=IU  (WNAWB6Q82KZZF<C9V1N2-5^%HKEYB2$-W6)
M;;%A*;JW!52T+GHCTIT3234NO6J=WA AV%[GBZZU%&Y,06J1'JCGT[9&K)H\
M66>9;%R<C;;4(]R(N].VKW#G7$L5AI*VP28)G?TY(YN;6RJ]=J^V3277L+PQ
M?A^GQ!8DCKGS,WIBR9QO<Q<]%>)4 JKH8_=#%/A&>=Y?10?0OM1E9B=B;&OC
M1,^^\OP >,=-%'423,8B2O\ ;.RUK_[D>QIK?/(_$5PB<]5C:U,F\6IH&Y*^
MW5*18UH+E&G;0O[94[[<OQ+!--B^A2OP]6Q*F:I&Y[>^B*J$VGOP9(E'EKQ4
MF%9[F56D&-JEF>3:B)>=5:I<ISSAN9:#%U!,Y5_.(UWT?_1T,FM"K7'W62^/
MTG]O)G]EVG@O2?*9#QK*>&JII(:EK71.:J.1R:LCV,"_U$=+9:V:;/0;$[/+
M;L4[MRCFU8MP_BF=ME17IS;7<:VDM=6Y]*_M7(U=7>VF+8;I+9[BRJAS7),G
M-SRTDXOL-7'4LJ7R/8JY*Y5R7;M/M5R368O'SWA]SI_#ZK3Q>)BU;1U]?NOF
MS72FNU(VHI7HJ+J5N>MJ]TSBK=R*Y0R5]92II;XJ:35SU*G/W"TC6PY.\I%G
MQ&6V"U[>'MQ5WZ@ )7" [HEO?35-/>:5%1T:HCU:G=77]N1,+%7MN5KIZIJI
MF]B*[)=BY:T/NZTC*ZWST\B9M>W[=J$*W.ZY]%75EFJ5UQO70S[BKG^!7_EY
M/I/]6K'_ ,K2?_;'_2?[+  !893\<U'-5KD145,E12EMT?#+[)<>J-"S_HIG
M*KVM;DC%SV=[6748MTH(+E0S4M4Q'1R-5J]SND.?#&6NWFKZC#.2(FD[6CG$
M^DJLP/BQ]N<R&I<LE%(J)FKOS:_^K]A;4$K)X62Q.1S')FBHN>91%PMKL,WU
M]OKLW4-0O:/3]G7J7-<MF>LF&%+W-8Z[J;<7*ZE?VT4B[$1<EVKEJUJ5M/EF
MGX+M/3YH[5Q3>(VS4^:/7ZPLH!%14S1<T!?5
M                           >%?5,HJ.6IE]I&W24I^]8IN5?5/='4RP0
MHO:LC>J:OH+)QM/!'A^JCGE1CI&JC4SUJI2^K-<BAJ[S$Q6)?2]AZ:EJ6RVC
M>4MPIBVMI:^*&MF?/3R.T55[E56YZMJ_06PQR/:CFKFBIFBE#V6EDK+I30PH
MJN5Z+JXDUKYB]::/>:>.///1:B$FDM:8F)5^W,.+'>LTC:9ZH5NU^]Q=_!.^
MZI'^AG][J+PC_P"(\D&[7[W%W\$[[JD?Z&?WNHO"/_B/+;"6R
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M3TEO;XNT\/B]-U\X_P!X_P!T^ 1<TS38"VS@
M                    JHB9JN2 #08GQ+36:%6Y[Y5.1="-$SU]TU&*\7K!
M*ZAM+=\J5U*],U1-? >>%\)ODE;<KVY9JA^3T8[7EPZRO;+-IX,;3PZ.F*D9
MM5RCRCSG_A@6JR5^**Q+A>'*RE76UB:L^#\"4U>$+141L:M/HZ*9(K57,W[6
MHUJ-:B(B:D1#].JX:Q'/FBS=H9;VB:3PQ'2(\FLL]BH+2B])PHUR[7*N:FS
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MB'!*W6Z2U;:S>]/]G>\\OM)H%U(>7QUO&UEK3ZG)IK<6*=I5SV.'\H)Y+_\
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M?)<=YI/!?\I?1Y\--33Q.GC_ /E'I]8^B9@ L,L
M                 # O-VIK12+/5OR3)=%J;7+W#R9B(WEU2EKVBM8WF674
M3Q4\3I9Y&QQM3-7.7)$*^OF)*R^5+K=862:&?;2L5=:?1L,5TMVQG6.;"Y8;
M>BY:]29?0FW:3RQV6DL],D=-&B/_ &GKK52OQ6S<J\JM6,>+01Q9?Q9/3RC[
MM9A?"E/:6)-4:,]8[:]S=G>VDF )ZTBD;59N;-?/;CR3O( #I$  "#;M?O<7
M?P3ONJ1_H9_>ZB\(_P#B/)!NU^]Q=_!.^ZI'^AG][J+PC_XCP+9
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MY-BY(NK,\<'VNLAQ'9I8V3PPPM>E2U+6ZE:[\FY&Z3L\GZ^/\2TP
M                 /Q_M%[Q^GX_VB]X#G[H:_TGQ'WE^\TZ".?>AK_2?$?>
M7[S3H( :BVUDTU[N-.]V<46CHIELS:U?Q-N>,5+#%42SQL1)),M)W'P?@![
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M01.C7/))512>4\\51$DD$C9&+L5JYDM,E;]%+4Z3)IYVO'+RGREZ  D5@
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M+]?ZM[4Z:F6GB-/T\X]/^$H !89@
M JHB*JJB(G"I"L3XOWM_25F3?ZEVI7-S7+O'%[Q2-Y3Z?39-1;AI'_#;XDQ+
M2V:%R*N^5*^UC;K(C:K)7XIK>G[L[0I=+2:W8JHJYY)]AL<-8.<Z5*^]N62=
MRZ6@N2Z^Z3IK4:U&M3)$3)$(8I;+SORCT7[9\6BB::?G;SM_9YTE-%24[(8&
MZ,;$R1#U +/1E3,S.\@ #P     0;=K][B[^"=]U2/\ 0S^]U%X1_P#$>2#=
MK][B[^"=]U2/]#/[W47A'_Q'@6R
M
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M0V'?LD7016O7/7\T"PP53N55U%77F9:3&,]WDC;DZEEC8U4U>V[55_\ 4+6
M                   %V +L Y\P-^L5>?GS_P#,Z#.?,#?K%7GY\_\ S.@P
M           &/<O<ZJ\$[S&08]R]SJKP3O,!1O0Q^Z&*?",\[R^BA>AC]T,4
M^$9YWE] #S9-$Z5T;7M61OMFHNM#T-;1T,L-YJZIRMWN5$1J(NO@] &R
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M'7OPSNC5-!(F4%6_)J<';+FGV*6Z=:>_%7:>L<EW099OBX;=:\I_( !.N@
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M_H9_>ZB\(_\ B/ MD
M
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MAAD<U$>QSLLG<.WNG6GU%<D;;;)])K\&HF:XXVV]4@!A=5K?\=IO*(.JUO\
MCM-Y1"QQ1ZKO'7U9H,+JM;_CM-Y1!U6M_P =IO*(.*/4XZ^K-!A=5K?\=IO*
M(.JUO^.TWE$'%'J<=?5FF)<K?3W&F?!51H]KD5-?!W3YZK6_X[3>40=5K?\
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M"]K6-[7ITNS6U47@-RNP#GS WZQ5Y^?/_P SH,Y\P-^L5>?GS_\ ,Z#
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M$VHIG(O YO"U3W'DF?PVZPNZO2Q2(S8>=)_;Z2V  )E
M    \ZB>*FB=+/(UC&IFJN4/8B9Y0]"&8KQ<RF5U#;,Y:MVK238W^IK;WB6L
MOD[K=88W*Q?;2)J54^G++:;_  KA6"SM2>;\K6+M<N62=XKS><D\./IZM3'I
ML>DK&74\Y\J_W:C"N$I7U"7&]*DDCNV2->[KU\Y/&M1C4:U,D1,D0_02X\<8
MXVA2U.JR:FW%?]/0 !VK@            "#;M?O<7?P3ONJ1_H9_>ZB\(_\
MB/)!NU^]Q=_!.^ZI'^AG][J+PC_XCP+9
M
M                        (QND.H4PC7)=72MHW(U'NB:Y53MDXM>TDYXU
ME+#64TE/51MEAD3)S')FBH!SG?*6S6I^&*G!EPDDK)I6Z38Y55RZV9(J9YIW
ME+TOECCQ!9H*>LGJ851&O5T$KHW9Y+PHN?"8UJP'AVUUZ5E';HVSHNDU557(
MU<\]2+L),[VB]X#GSH9F)'B+$+$551K53-5S7VS3H0Y]Z&O])\1]Y?O-.@@!
MI[;230WRXSO;E%+HZ*\>36I^"FX,6GKHIZN>F9GOL.6E]*(OX@90
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M-[GUV2[X:IY5<KI8_P G)G\+;^*$D-"EHM6+0WL62,E(O7I( #IV
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M^K;V*R4EGI]"FC:CU]L_+6OTFT -"(BL;0^7O>V2TVO.\R  ]<
M      (-NU^]Q=_!.^ZI'^AG][J+PC_XCR0;M?O<7?P3ONJ1_H9_>ZB\(_\
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M/@RS7CS1%_$#-
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M<ZI;T])"V!%UZ#ES5/I:650TL5%2QT\#=&.-J-1#W QX:X_E-5KLNJV[R>4
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MQEVV>W-$7\0,\
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MI/EV%_%?CKQ/F-7I_#Y9Q[[[.?,#?K%7GY\__,Z#.?,#?K%7GY\__,Z#)%8
M          Q[E[G57@G>8R#'N7N=5>"=Y@*-Z&/W0Q3X1GG>7T4+T,?NABGP
MC/.\OH :VCKI)KS5TKD3>XD16KS>DV1BPT,4-;-5-SWR5,G?9Z ,H
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M"=5[?WA80*]Z_JKDQWC+Z!U_57)CO&7T#Q./U/A.J]O[PL(%>]?U5R8[QE]
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M1?Q V0
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M[H&&:J_.LT%UB?<FKDL*,=GGEGMRR*[PMB"2FW/<3TT;E2HIJ*6:%$^:Y5_
MT>([#;J;H=V7"&-K*V-'5#9T7MM-9')GS*J$N&_'2++6CS=_AKD=$@UN&IY*
MFPT,T_YQ\:*XV1*L@             1W&V'6X@M;HD71G9KC5>,D0.;5B\36
M7L2Y@J;=4071]O>S_J6R[UH\:YY%V;G.%>H='TQ4*BU4S45<E]JBZ\C<U&&K
M?47V*[2QJM5'LUZL]62_8;HJX-+&.TVG\F9V?H/"7O?UY1]@ %QI
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MFKF)R>2#;M?O<7?P3ONJ1_H9_>ZB\(_^(\D&[7[W%W\$[[JD?Z&?WNHO"/\
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M &)34$<%;453%7?)\M+Z$1/P,LU5OKI9[S7TS\M[AT='Z6M7\0-J
M
M               78 NP#GS WZQ5Y^?/_P SH,Y\P-^L5>?GS_\ ,Z#
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M;M?O<7?P3ONJ1_H9_>ZB\(_^(\D&[7[W%W\$[[JD?Z&?WNHO"/\ XCR=FK9
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M]YY5\H0;=K][B[^"=]U2/]#/[W47A'_Q'D@W:_>XN_@G?=4C_0S^]U%X1_\
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MJ6H1F]O=ED[;GYR< ")6ZVUD>Z+=:]\#DHY8&-9+JR<J-8F7V*2T
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M^I>8 HSV/E'RW4^+_4>Q\H^6ZGQ?ZEY@"C/8^4?+=3XO]1['RCY;J?%_J7F
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MI$+3N98:MES;7T]*]9FNTFH]45K5SSU9)W )7:VJRW4S7>V2-N?,901,DR0
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MB;-#)%(F;'M5KD[BID:S#N'Z##]/-#;(UC9*]9'(N6M555XNZH&V
M        *QW?K@E'A)D*P-EZ8DWO2=^QJ5<_L+.,"]VBBO="^CN,*2P.X%X
M.?Z:CDPSC+#,T]>VZ[\W1:U55=[S1R:M2'1Y#<.;FV'K!<&UM%3R.J&YZ+I%
M1='5EJR1.,F0                &IQ53PS8?N3IH8Y'-I95:KFHJIVB[" [
MAJPMP76K4Z.\)/)I9[,M-Q:%5 RIIIJ>9,XY6*QR<:*F2^<TULPI:[;9ZBV4
MD3F4DZJKVYIFN:JJ\'= IVYW1VZ#.MIM#H+7AR!W;ND315ZIKX$=_EX2[\/T
ME-0V>DI:%VE3Q1HUCN-$(?V(L)Y9=)OYV^@FMHMU/:;=!143="GA:C6(O B
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M6T=&Y9=!RIDKT5JIFFDG$I&MQNMNCL>79'T;&ME_M.2?FM3=G;=Q.,"^
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M5@.LJZ17HZ)DDL2+J5DC4<W7].8$S!I\'U[KEAJ@JY,M)[%1<NXJI^!N
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MH01)HM3//[3+
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MHT1&,1&HB'V        !56*_?[PK_I<W\9A:I56*_?[PK_I<W\9A:H
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ML2JK57C34GF-P
M          !&,=076JHXH+4UV3G9O5NW+)=7F*RM5!7RW)8Z)CEJHETERVH7
MH1+#V'EM]^J:O?VO5R*CF)P;%*F;!QWB6WH.T8P8+TF(^GUGZI+;G3.H8'5;
M=&=6)IIQ+PF0 6XY,69WG=$=T"FNM73116Y-*G5%WU$VK]A7F':6X2UZ26IB
MNGB[9<N+9^)=T[%DA>Q-JID1C"&&7V.KGE?+I[XQ6_:B_@5,N";Y(EMZ+M&N
M'37QS$;QT^OKNDM(Z5U-&Z=J-E5O;(G IZ@%MB3.\[@ #P
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M45!T/^&L3X/HZ^S7Y&OMS'HZE>B:T]MGP_-X"WP
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MJ@JKL&88^,7/RC/4'8,PQ\8N?E&>H!:H*J[!F&/C%S\HSU!V#,,?&+GY1GJ
M6J"JNP9ACXQ<_*,]0=@S#'QBY^49Z@#%?O\ >%?]+F_C,+5*$I,%6S!^[CAV
M"V/J)&36Z61RSN1514E8FK)$+[              !B4]%!#6SU$>>^RY:>OB
M1$_!#(GF9!!)+*Y&QL:KG*JY9(A ,-8THZS%%; Z1S8Y7(V+2=JS[5//F<6O
M6LQ$SU19,^/',5O.TST6$ #M* P[M<(+702U=2Y$CC:J[<LS0X4QI18@JYJ>
M)JQ/9K325.V3/@YSF;UB>&9YHK9L=;QCM/.4J !TE
M
M                 #46Z@EI[W<:IZ)O<ZHK5S[C4_ VYJ[?=6U=VKJ--'_I
MU1$5'9YZD7\0;MH   "ZMIY0U,,SG-BE8]R;4:Y%!N]0
M
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MJX-?>*F33\62+,C4]G=[J:Y>>WG]/1*(-/>F[[EI\.1]@%QL
M
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MC6HUJ-:F2)L0_2\W(^H  ]
M                                                          "K
M>B.][]G[XS[DA:15O1'>]^S]\9]R0"T(OS3/FH?1\Q?FF?-0^@
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M:>IN]P > #YDD9&Q7R.1K4VJJY'Q35$-3'IT\C)&9Y9M7,]V\S=Z@ \
M
M                          ##IJ^*HKJFE9GIP*B.U=Q%_$S#!I+<VGN-
M55M<JNJ%153+9J1/P S@
M
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MOWN^Z6)K0 &<M@
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M9+9(R1$+C36#\C:C&(U-B'Z9RV
M                                                           !
M5O1'>]^S]\9]R0M(JWHCO>_9^^,^Y(!:$7YIGS4/H^8OS3/FH?0
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M$5-)RHB?"8[;P*!8@(-CJKZG55HQ#22:<;9$ADR74Z-4<NSOY$Y
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M5%MKJU%GCCHDSGCDB5LC.^U=:<8&]!$V8_LKVQR9U;::1=%M2Z!4ASXM/VO
MO"9EMQ;;J^YQ4$;*N*>9%=$L\#HVR(B*JJU5]MJ1=@$@!$;-B*FBAO-35W)]
M3%35;XE18%8K%1RHD;>V727@3++/B/:FQA#5W>EM]-0UC9)DTU6IC=#DS5FY
M$5.VVH!*
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M=-"JLWR3-KM+4N2M5-2Z^,]WG;9YM'5O@ >/0
M
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M51T6:9(Q4X4RR^T\WYNHK&V^[; (#UR
M                                                           @
MVZ=#*K[-5)$^2FIYE6;1;I9(JMR5>939S7RTW!TL% C:F=U+(J31-1S8TT?:
MJY-BKQ=Q>(DKFM>W)S4<G$J9GQ'!%'GO<3&Y[=%J)F!5ENO[[#N9VZ&!R1UM
M3/41QO>J(V/.:5=)<T75J^TR:^"VIN:W.@LU73UU8K&R3+!)IN<N^-5576O!
MDA9+J:!S4:Z&-6IL16ID@93P1Y[W#&W/4N343,"K<17JAN4.%X*&9L[XYXED
MWM4<C.V;J7+8NHW5;40V_=19/72QT\,],V.-\CM%'.R5,D5>'6G.3=M+3M]K
M!$G#J8A]20Q2*BR1L>K=BN:BY 5++='ROO:/O$=N5SU;T@D$;I)DX%15R=K3
M)?I,6C:DFYM@9)$TT6XOS1R9Y_GRXEI:=7Z:P1*[C5B9GTD$2,:Q(F:+5S:F
MBF2+W (C<(HW;IEN5S&JJ4JY9ILU2$2NR956/434G2L:Y?\ =,6ZL;5<CE:F
MFFQV6L^5@B57*L;%TDR=VJ=MWP*JN<E3%<,-R6Y]7%4LM;4<^BIDJI,M&/4L
M:ZD39K[W&2?<YEHHH*NCB?5+7K(LM2E5#O,BNR:F:LS7+5HDCGMK'U3:F%RQ
M3M;O;7-1-3=6K[$/B@L\%'525355]7+JDF7:]-6K+9P)S'F[K:-NK9  ]<@
M
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M8XJ]T6V8@Q1465T-'3/@1M*Z3-4<]KN%J:]1;H
M
M
M
M
M
M
M
M
M
M
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MN;QM7,^B+X!?3MI;C34]*^CDAJW-DIUD21L;M%NIJHB)H[-7?)0
M
M
M
M
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M<Y<D3-7+K78AG
M
M
M
<                                 !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g109079g00v02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00v02.jpg
M_]C_X  02D9)1@ ! 0$ SP#/  #_[1Q<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '#\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7_[D^R)J_B!OK_\ <G*KV.?;W?1:I>R^=?LB:OX@;Z__ '*GV1-7?[P-]?\
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M>Z6KOTQ#?UK7BK<31-3#@;E478ICPBO*S_7[%OT@^@*( W4OY6+>[W%?SQ]
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M-S_L#I550*J(\BITJJ#I0=9P:XPVG_,6=L5A8.X=[*<?\"RR%]);_)#ZFCQ
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MN61AW)+E/#JV&KI<-+)XCJ8><<;%= 11JG<T4[*-V"JB*%A$1 1$0$1$!$1
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MB%6VMC='4T[@#J&QN#:]_*M)5XG2/R4*1L[34<^':+B]K@W4,W3=1-Z?_/\
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M5.=.<_OE$<95$YPF-#B5+'E3%*8S,$\DA+&EVY&ZR*K&*1N!84ULS7RPD%[
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M0;X72?H6?0%\;25#JC,-.X&XYYOTA?96$_>NC_0L_P H092(B B(@(B("(B
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M,[Z5R7$1_H%1^C/T+K/]'-P&0&_IG?2O3^G>[U/IOBIU4<$5!P1>F]=Z1$1
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M; *9D \4'+^3ICQG7,;G,(!<-R+=#%2MUY0SU58M512/PJN;<R1C46N\H_\
M45U&P5"!N;;H.85%4W.N:L-?AD4W<%'X\DTC=/C"^PZ>D+79VD<<]M%.^KBE
MCB #Z%C9'G8;.#B NOVX]2@$N!X[A&9ZW$L'BIZN&KMKCD=I<VW4?24&#D6N
MPFEQM\50[$#B]2-I:V)K"X=0TN(Z"KO)PUXS5F,N:\ SFVH6!W*S(L#QG&\Q
M4F(XY'34T-*/$CC=K+COO?TJ>!MFAHX!!R_'*:++^=I\7Q2C;4X=5,TEW-B3
M0;GH*R<+Q2+&<>C&7,/@911B\LSZ9C/0-K\5TBP50 . 0<PQS%Z)N(U-)G'#
M :<&\,T;+EPWZ18JSR?15+*W%I\%CE;A+F_:&3.)N=KVO<\;KJEA?@JV0<>Q
M#%<!KJ6:+,^%R0XPS4&\RPC4>@@M(OOUJL%+7P\F-8VL;*6NDO UYU.#-:[!
M9+#J00+"L+&*<FL-(]H#G4P#=5]CH49Y/(*S%\R4TE="X185$Z/Q^EQ+]QZ'
MA=C  X!+!!S#,D#<#SR<:Q.A;4X741<T\Z!)S;K[&Q\E^"NT&+18WF.CBRUA
MU.RA9<U%0^F8S3L38;7ZO6NE6%K67AHV(Z$&/6-E?2RMI7".8BS7$7L>A<ZP
MG/$F#T\E%G..J[X1O/CLA:6.8;6X6\O0NH 611W3$X<GRS$[&^4&HQW"Z-]-
MAG-!FIX#"\^)^"/S2LO#LYU> R5-%F^.IEE#[QSQQ-+7-/186^A=,TCJ32%.
M(1W<@CD;FG/-#B&!T4D%+3M//2O:&:_0#O\ ]ED876^XC'\4CQ6FF%'4RF2&
M6(:Q:YX[WZ0NKZ0FG;I003+&-XICV8ZBH@$D>!-;:-LD;02[;?KZ^E;_ #?A
MC\6R]644.DR21NTW.U[&RW98/*O#(RV0ESK@G8=2)\N<8+GBDPO"6X?BD%6R
MNA!9S;8P0>JQ!\JS.3W 9VX?B517Q<V<0<7!AM<-=JX^ARZ!9+#J1#A>$4U>
M_,--EMT;S1P3\\XD;. %^/H4QY2L$E<</Q&DIA.RC<"^(@'Q!;H/F70[;6Z$
ML.I!RZLS+A&(-AI\MX5%)7O>T#72,:&BXO<D=5UZSBR49DRYSD=G-V>&MV:=
M(^9=/L$L$'@7 XKV."61 1$0$1$!$1 1$0$1$!8&,G3A<_F6>M=CNV%5/YJ#
MG<\CG @+S!+S8LY5:1:ZTM=B,<50&.<!OUH)1!-JX*Z]WBFX6JPVH;)&"T@^
ME9\LUV<4&#5%IN -U@@'4;!94K@7%6M8;P"#S<-%BLRBE(-@L,@.-S8KU&_0
MX$(-[8FQ5T@%BQZ20RM"R"X$6"#RVP-E[/#R+Q;RI<\$%#:^RKIN%738<$;Y
MT%NVDJ]&>M>' 7X[JC;M.Y07G'BK8%W*O'<(-D'D@\ JVL%37I*]%P*#P' '
M=5O?@%5L8))53XJ"V >E5<3;Q574%0D(/-^M4DO97 T.7A^J_!!XCXE7>I4V
M'19-2#WT+RS>Z Z@O+;M)W05#3<JY;9>"3?95)(:@7#;W6LKY;N(:LJ>8!A!
M6K>\.<;H,=P)-UZC%R 5<U *Y2Q\X_8;(-A2M:UEUD0?[0VRMZ-$=EYIWD3-
MMUH.DC@$1O (@*S5[4LWYA^A7E9JA>EEN?P"@Y2+.X#SJLLC8J9U@EM#B!P*
MP\8E$&'RN.VR"!XMB9.*Z;FVH_2IWERK8Z!FZXUB6(AV).-]]1Z?*NC9&J1/
M&T'?=!T./2]NRM2$,)NJM\1C=)6-627:=T%B>4%]P;!7XW-+;ZMUJ7A[G$"Z
M],#V#<E!N62=15S2XW(6LHY':[$DK=1NNS=!:A+A>Z]-<\.X;*Z&WV"HV]RW
MI04$C'.LY6IW .\7@KG<IN7%6987-O;=!ZV<W8[JA#MK="QOMC3L"KK)77L;
MH*/JN;)#E:=5ZN"]S4QD(-EY[B-MC9!XD.IIL5@N<X/V*SG4[F[7*\]Q$F]O
MF06J=KGGK6QIH6MV>E'&R/WUE?>T%UVE![=3M(\4+R]KHVV"OM?S;+E8XEYQ
MY)X(/48=:Y"]ZMMN*IS@X JA(O<%!Z9)IXJLDEQLK&H$V0NL4%UQ.FZM<[T*
M_&\%GC%6C$#<M0-=Q95 V5DM<T\%=B:Z]R4'MI(NO43GEV_!>'DCWJN,E &^
MR YKG$BRQY0Z-C@2K_/DR;<%BUDVJZ#!D#3>ZK3Q.<X%HV6/XSI#N;+;4K6L
M9XS@$$=SE4FGPR3<W-EP3%Y7OJW/()W)76>4G%XF1F%KA>XZ5RR1\<K7$D;H
M,3"ZLSXO1,(_WK?I7V[A'WKH_P!"SZ OC/*N&BIQZF,8OID;T+[.PUNF@IF_
MBQM'S(,A$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'AXM<KY:S.?\
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MVHG,0F.&M4SF(<.P?*>>9<+I9(,&I71.8"TF>UPLOW'Y^Z,%I?V@+Z%R@?\
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MI*EVIX<;CB3_ !01F!K6\K!TM ^T[V]*Z(M*W+].,P]]]3^Z-&BU]K;]JW2
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M$;EPI^'RQ7X:A]*Z+2_[/'^:/H4>S  ]\8M8ZA]*D5.+01C_ (0@]HB("(B
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M; #=8\5=3.?I;/&7=0=NM/G2:H9@%2:;4UVG<CC9<X;)114M+)AU03B;G>,
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MQ6UR)AN+8-+5457"PT9>Y[)!>^[K]7E*T%7DC$7YM)B [T22B9XN>(-^%K=
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M=WG6YS>BJ(G'?V>^4J(2X#(#,&'4TAI_"\8;*'U-6ZLK\$9+1.H61RL)D>"
MZUNM2C,&%8IC> 0RRM9'6Q.#S%T$W6LJZ7%\PNHJ6HHVTL<3P7O/';JXJM49
MEAQ--55R9C,9Q[>>_P#265F#X>*U^*UEN<8S3J>=@W?M*T&2XC59RQ+$J:$Q
M4#H^;8;;/(L+CU%8^<N_M77MI(J=TF&ML7Z#8OW)MYM@MYDVJKN?;238;W)3
M,C)#O+<;<?.IQW\-LQ<O13C$4SG^9_\ B7(B*[TA$1 1$0:_,7WBQ#] _P"@
MJ"\@W]4)O[P_Z5.LQ?>+$/T#_H*@O(-_5";^\/\ I0=*'!$'!$!$1 1$0$0E
M4N+(*HJ:A:Z:AUH*HJ:AUJMP@(J:@JW" B7"7" BIJ"K<7L@(@(*7" B7%KI
M<(")<)<("*EQ>RJ-T!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 *QJUP932$\++)6OQPEN%U!Z0U!@1%CV:F%:C&(
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M0D_EX_\ ,%^DF7_O'A_]WC_RA!GHB("(B B(@(B((3RAYTDRD:,1T K#4EP
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M.#>I9.<:J)^=Z?OS)*,#?#JB+'$-+B!>^X75I(V2-TO:'-ZBO$E/%(T!\;7
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M];?JIX!<L?CU'K;]5.5)SZ&)]D_0_$[OUB?9/T/Q.[]8LOP"Y9_'J/6WZJ>
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MC7,IR";;<5!<2S37U\SBUU@3T$H.Q8KFS#J")]WM+@#L++F>8.4F1\DD=(7
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M,.,&3$&U=0YK><:P !I] 'D6PQ'(\<N(S5>'UTU$Z8WD;'L'&_'9;7+&7*;
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MX'6#_P!)[%9ER-GA[?O-5^R4$_&<67N)%:FSC<_=-O0N>MR!GJ^V#UGLE'Y
MST?_ */6>R4$JQ3-;YV%K);>I1FJKY93XU1\ZQQR=YX)WP>K]DJKN3G.Y_\
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MMD^0<% ?"!6?)C$O9=]5/"!6?)C$O9=]5.92<JK9/4"@7A K/DQB7LN^JGA
MK/DQB7LN^JFNDY56R?710'P@5GR8Q+V7?53P@5GR8Q+V7?5372<JK9/D4!\(
M%9\F,2]EWU4\(%9\F,2]EWU4UTG*JV3Y% ?"!6?)C$O9=]5/"!6?)C$O9=]5
M-=)RJMD^10'P@5GR8Q+V7?53P@5GR8Q+V7?5372<JK9/D/%0'P@5GR8Q+V7?
M53P@58&^6<2]EWU4YE)RJMF'B']MM%_R]W^>-=);Q7$ZO'\1?RBTV-^Y[$!
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M.DQ%,VFIF&9T)DD#I+ ';8;;]*V\N8A'E,8PR+439HCOTF31QMUE!O\ 1%J
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M'C- ZCFEEBB>Z[C&0"1OMN.&ZVJ6%[H(]3Y:@CHNY7U51+$V1D@#].Q:X.'
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MLU/20N=)IIH'P-W%]+FZ3Z;!;JPM94#0$$;I\JTL,CW/J)Y2Z T_C:=F$@]
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MZ<135'MM_P"T8Y$),(:R>DHZ9D=? W1/( +O(-E ^4BNRY58KW/A>'QPU@J
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M4LD3Q9S"6GR64\)33RYW4^H3,W,3X2^DS_C%/E./+U-:. -YL/9LXW=?JO\
M.NO<F3:K+F0ZJNQ^601O;S@;*3<#<]/7<+1\D_)I&88L9QJ,N?[^&'4+><V]
M*R^47!\W9CE?1T\44.%QFS&-+07#HOXWD5+DT55Z*>T-K5-RBCFUYF?9P:L>
MV6HD>!XKG$A6;W6174DE#5RT\P^V1FQ6.N^F(Q&GP\JK,U3EB8I_L,B^RN2S
M^H&"?W9GT!?&N*?[#(OLKDL_J!@G]V9] 7G<?^=['TK\DI:."(."+SWJB(B
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M[XO%)"B?*JTMRTP$"W/-W]:ECFV82TV41Y4WEV6(P>(F;?YUS\3.+<Q+*_\
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MIR;?QC[')HVC[-*[*.#AKG"@CMYRK5/E3!CJU4,9\ERI%&UP-R00O3VM=[P
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MYCXO"R[/RNZW8?'";^^/T+E5#A+J@#CI'1UH+\,3>9\7<'<!23"<,9/2">8
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ML/.H]4![ 6=*D4<.C9PM<+"Q*G:Z(D&Q 0:*JH8:ZBDHZQH?'(-@>M?+6?\
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MV.CB%9CFD)(V#AY4'N-KFQZWB[NI>6ZWDD#@KK97](N5C2/<UQ\:PZ=T%NK
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M5R(?;'.!NQRRG!K66!L%;I':F.T@ CH5IY%RYYOY%*(E21C2"&NLU>H &,<
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MT>*S9@RMBN$LH1!7P-YL0,X&Q' DGR]*RJ?)N+X>UT&%YADIZ.YT1&(NTB_
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MV2USU((ERHX<S$,GU;GNT.I_MT9.UG $?Q6OY(J:>;!ZG&*[>KKY2XN/2T
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MD3_^98CO_N_^ND7+)2""O3PQNXMOQ7HNE<=6GAT+&K:B*-S=;;.*]..SX/\
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MQ&/VF44\51$1/?S/]IKE*=]-EW'9(W /;*X@^EZMX=638OD:MDQ!_.N$A&X
MM8M4%H\QUU-155+$6<U4.+GW:+W-^U>:/,%=287)01.:('DEP+;G?R^A*>(B
MG'\%'%4Q$4]^T.FT==381E##WPTT\S"T:N8 )ON2HYR@U\6(8932NPRJIY+
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MQ R5D@>+D[W0;*LS3C.+PM$P+"XWM8]JR:'$)*N TDT>MXZE;EIY'XK>E:#
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MMZ?_ '!OTL74CQ]*Y;)_;T_^X-^EBZD>/I051$0$1$!4<+M*JJ.-FE!X%P%
M,S8E72YE;0TM8VEB#'.<XFW5Y5/QPNH'BE)A%9FN9M7*YD[6<+D ^HJ)<O%Z
MM,13/NW.5XJEFLU>(,JP1MI=>RU6>LQ34D#Z;#@#5!I<2.#6CI/K"U6&RG#<
MVRP87(^>D$!>6WOXWC=?F"TLN(3C#<5GK:*8U52UWCFWB#>W3YEG-6(<5WBO
M].:*>WG^G5,OS/J,$I)I3=[V7)\JV4))X\5'<BUO=F7J?[4Z/FSH\;IV!O\
M.I''[X[+2)[/2LU:K=,Y]EQ$12U$1$!$1!K\Q?>+$/T#_H*@O(-_5";^\/\
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MJANJ.1I:X>0[+6U^7:"NPB/#)XR:5G!HMUWZENR+I8=2"(1Y P2(-YMDXMP
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M5.__ "@_)ZG]MWU5U%$'+N__ "@_)ZG]MWU4[_\ *#\GJ?VW?57440<N[_\
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M)ZG]MWU5TUNP *]BW0H'+^__ "@_)ZG]MWU4[_\ *#\GJ?VW?57440<N[_\
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M>>PW6PL%X=QL@ULF!X3)-STN%T+YN/..IV%WKLL?,V#]]L'-#"Z.&-Y%_$!
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M=:#73X!A%1.Z:?":"69VY?)3L))ZR2%IN4?#9JS)5=1893E\CM 9%$WJ<#L
MI8T@W5;!!&< R]AYP'"^^&%4;JN*FB:\RT[2\.# ""2+J0L:QC T-#&C@&BP
M7J^^UCT*DCV1L+Y'!K1N238!!KI\#PF>H,TV%T$DY-S(^G87'TD76<8(G1&+
M0SFR-);86(ZK=20S1SL#X9&R,/!P-QZU< !'F06::E@IH1%2P1PQ#@QC0UOJ
M"\P4%)3B3N>E@BYSW^B,#5Y[#=93>&Z:1U(,:FHJ:B:6TE/! T[EL; T$^A4
MAHZ:&:2:&GA9,_=[VL <[SGI6794TCJ0:ZKPC#*U^NMP^DJ']<T#7GYPO4U
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MWBQ#] _Z"H+R#?U0F_O#_I0=*'!$'!$!$1 1$0:O,F-TV7\+DKZULKX8^(B
M+OG(48J.5#!(@QS8:^6)P!YV.-I:+]!.I7>6+^H]9M<7'\4J*:GBY-3'%$&M
M-,UUO*2"@\UG*;@=.T.BCK*MFG4YU.QK@SSW<%LILZX9'@$&,-;42TDK] YM
MH):;VWWZ_*M-R<0L\'S/%%C">CR%:W)&&MQ/).*4;_>/EDMMTAP(^A!T.7%:
M:/"78B7$TXCYW;C:UUJCG'"VX",6E,L5.XV:UX >[AP%[=/6N;U&,RS9/I,O
MN([KY[N5S;>,&@EJV69Z-M)F/*U%(T"D9$+WX:K/[ @DE%RD8/45,44L%=2\
M[[Q]1&UK7>8AQ6^Q[,-!@E$*FND(:?>M;8N=YKE86:GX%!0P''8V.@U 1W:X
M[^A0_-!;-GG 6/;:BT7COL/PK<?0@D>&\H>$UE;'3205U&Z3WCJF-K6N\UG%
M9^9<WX;EV6F9B FM.;-<QH+1Y[D+2<KL5/[EG/>UHG8\&(]-[.4=SBT35^4>
M[0'!VC67&W2$$H9RD8.^I9%)!70L>;-EE8T,=YCJ6%RKXE/1T=!+354T##,W
M4Z*0MNW4WC;R+-Y4X*4Y-J=3&^(!S>]K;'@HQGIIFRCEL5 NYPBU ]=VH)%#
MRF8,Q\$+X:XM=I9S^ANB_GU7^92[$<6H\/PUU?4S-;3-;KU]8MT*,Y\IHO<-
M.T,;I;&VPX644SZ:AV3,LQQ/#(G-A#G.%P/>6)02FGY2,(EGBCEIL0IHY7:6
M331M:PGSZBMQF/-6'Y?91OKN=,=4[2Q\8! X;FY&VX4/Q_ L?GP"1F)X_01T
M.AI>X4CMA<6_"\RP\\P1G!<ET[Y!4Q_:V&2UN< $8U6\O%!(6<IN"NJH83!7
MM9*X,9,Z-O-DGRZOX*58KB]'A>&/KZN4-IFB^KK4<Y2*>-V1:IQ8-<7-%IMP
M.MH^A1W-YYRAR9%4G_0GEG/$["VEEK_.@WU)RD83//$R2EQ"FCE=I9--&UK"
M>JX<5[Y3JR:'+$510U$L+GSL ?&\M)!!Z0O?*/%3.R36EX 8UK2TGKN+644Q
MB29W)9A;J@6=SD5M75I-D'0J_&:3!<';68A(6Q@6ZW./4+K1T_*1A4DT;)J3
M$::.0V;-/$UK#Z=15G/M;2T^%8=%-2"KJ9)6\Q'JL-5]B5%N4*7,9RJ'8BVA
M@I=;+,8WQQL;;ZC]"#?\HF<)<+DI(J&"LWE:72L8"U[;\ ;\=E(L'S125.$.
MKJB&JHXHVC6:E@:3YK$J-9W-\ P D[]T1W]H)RLB893HQ 0QA<S6XC;WI0;*
M/E)PATC=5+B#('.#14.C:(_7J_@IA2U,55 R:G>'QO%VN'2N:5F!X_/EHMK,
M=P]F'NBW_P!%=LVW7JZE+LC0"FR[2PMJQ5M8"&RAND'QCT(/.9,Z89EZOIZ3
M$1.'SM+FN8T%HM;C<CK6LI.4W YZHP2LK*;8D23L:UKO,0XK69TB9-RE9<;(
MT.%CQ_/:O'*Y#&:K 1H'^T6^8H-Q#REX)+7LIN;K&->[2V=S&B,[]>J_S*38
MMC%'A6'OK*V71 T WZ[\+*'\K<$;,LQ!C W1(-('1L5K^4PN=[FHY'?Z*^1G
M.7X<-K^FR#<T_*7@TLD39:>OIHI" V::-K6&_ W#CLL/E5S0[#<$DIZ&.M$\
MS8RVJA T-!> ?&O>]@>CI"VW*#!2^XJO#FQ\VR \WY/%-K**XJZ23D7I'5%^
M>+HKDC?_ &@?P0;S(6)TM'EJ>MK*C$PQC6NFDQ!]][&Y;=QV]70KD?*5A#W1
MEU+B$<#W:6U#XFB/UZOX+1<JCI&\FN%-@(&IT(>2-M/-NO=7\6P+,$^7I65V
M/X?W YGC.%*38>2SD&QY3,TOPG+X?AL=2Z6=G.1U$306 6Z3>X5:#,U+C&5Z
MPXG18A'%%"3.7L:TO!O[TAWD\BU&9*9E/R01PQ5+:MD<=A,&Z0X>-T+?8J6G
MDWG<-[TSOXH-)F.M@I^3.GJ,NOJZ: O CU2$2 >->Y!Z_*NBT.HTD1<2;L!N
M>/#K7)<1_L:HA<6+OXO76*.2,8?"XO:UO-M\8G;@@RV\%5>8W![ X$$'@1TK
MT@(B("(B B(@(B("(B B(@(B("(B B(@(B(*$ \5Y Z.A>U3I0>'M-O%MZ5J
M,<:[FV  6Z5N25J\8JFT]/*YUMF$[^9!PGE?S,Z*9N&TKB+6O;TKE/=&F0:G
M%SCT%;C/>*.K,QU<A8" X@646JYP7-<UOCH-H^JDE:>< 8/(L)L!E+G-)._%
M5L*AD8F<;[7LNF8ZS!*3)L#*+2ZK=$";'>^E!S-PL=+>'3=>BZ1C; @M7BCB
M=)+>4VN5GBC#9P'NNQ!E85 ^6:,L!:X':RZI!E3$,6P.82_='1V:XD]BYQ0U
MO<KVB.,D-(-U]!9'S%3XK@#HWO:PM99!\Z4/)!B-1--"^LI XFP!>Z_^53W
M>3-^5\O3]V3!\C@?>DGK/2%"L=&,T>?(Y::63N0R;V;MQ*^DL*Q+#\3PZ"&H
ME8YV@ MOO=!\^8;7QX=B+&RL$D.L7!'E79AEK!<TX!'+%$&/<WBUH\H7-.5S
M!Z>BQ'52-+6NZO.M-D[-^(Y?JFQL)=#TM(0;#,O)Y78&^:> <Y3"YZ>'J4#A
M9#-)-W47 MX-LOH[ <ZT&/QNIJIT;7N%B"5"<^9"II3)4X;?62"0W@@Y)2U;
MS4\U$VS0; CBI5E^GBQC%8:&NNUG'7YMUA,I(\-;HD9]N;L;JV)Y(FOJ&N#7
M@;(.CY]CPREP*"AP^</ECV<=K\++D-3(UK'1^569*NHDG,A>7%QW5YU/SL9D
MFV)06'!W-;.'K1_-FGTAOC=:K% 'N(8;V"L$N#M!&R#.[J?%2- T^4KS35[X
MWELS06N.U]]EBQ1.+RT'4P\5<JHXR]K"[;K0;2HHF-C;41LUM=O8#@E/5%SP
MUHU#J/0K^#SF#[6XAT1:LR.FCTR3,'!!+.3K#*/$<0::MP:UNX:%]#X<*84[
M88+:6"RXER68,6@ULNHZKV76('" :HKDNXH,ZK+9*C3T#J5N:*Y#6M%NOI7F
MG>UQ<7;./2O1<6W(=N@PI'RLD+ #I'2O8LS3)8$=*]AI>QP<X _2K4!LUS9M
MFCYT'M[FN\9OBM*U=5(U[G1$^:ZNUDLKXR(F[#@M= X/>>?;9X0>XQ%H<)2[
MQ>I2O+9!H!:^GHNHG3P"69S'&UU,L%B$-$U@X60;!$&P1 1$0$1$&OE<&S.;
M;<G=(HM,EP-K*]-#=X?U<5;>;F[#XUMD%6R'G+ 7;P*UN(CF)21:Q%]EL8(W
MNWD/J6'B</.R%O3H/\4'RURQ3<YC\QO^$1NH 6211M\8EI\JFG*O!;,]1&^^
MSBH>[2YHCN=*#RTMD-KV*N:70.:[<@J[W/"&MYDW<.*QII9IWADA  .R#,[O
MG>"QI :K#YI'7#GN-]N*M2 QD!OOCP51'('^.$&SHC'!1/ON\]?G7G#WDRN/
M"PVLL)C><<&](6QEC%%"'$^,]!1M1)2<\T.U!_6JT@%;22,<=QP"PXF22/V\
M;4MM &4C1:PD=:_D0:_F(H@&O-GG@%[<R6E&_P"%N O&.TW^F4DSW$QW&K3Y
MRMMBX@?)"*77HYIM[GIL@TKH0;:>)W(1S(@_?9UEFRP\S%SK3>3@0L%L<4[W
MOD):0@LM):7$"X\J] F39VS>BRMAW1'<E9M'3FH9IX.05TLBC#'$N)X+&G!C
M/C#9;/#8>ZL0CHG#3)<6<KF9,-J,-J.;DMT;E!A8?)*&.<2 PC:RL&4LE>#M
M?=*:H+?M;O>+V6PSN+AN6H,2>)[VAS67:>)6QPM\086NMS@X!2*FEH&9;E&D
M<]I_@H4YC#=PU!]]B$&Q!DGJ"VWC773>2W*[ZG%8:F<#1&Z]_0N<X0Q]3I9"
MQQEN!=?3?)YA,E%@3;@\X=R@D?!NAA(#=@KL9.H:@-/252%I:=3^A>Y'MCC=
MJ(L1L$%)I!$?$/ON%E9=&0T7%P>*MQQM:-3KDG@LB>I$=,;#=!CU<H8S0T[+
M1S/C<XC>_2KM7,7#6#XU^"M-:TB0R-TDCB@V.7><.(M:3=@!LIH%#<L!SJS?
MW@!W4R0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%0C>ZJB"ENM>='K7M$'G254
M"W!51 1$0$1$%JI^X2_FGZ%R_D']]F__ )O4?]:1=/J]Z>6WXI7S]R;X!F;$
M\1S9+@>9#AD Q6H!C$(=<\[)TH/H=%R_W'9\^73OV8=J>X[/GRZ=^S#M0=01
M<O\ <=GSY=._9AVI[CL^?+IW[,.U!U!%R_W'9\^73OV8=J>X[/GRZ=^S#M0=
M01<O]QV?/ET[]F':GN.SY\NG?LP[4'4$7+_<=GSY=._9AVI[CL^?+IW[,.U!
MU!%R_P!QV?/ET[]F':GN.SY\NG?LP[4'4$7+_<=GSY=._9AVI[CL^?+IW[,.
MU!U!%R_W'9\^73OV8=J>X[/GRZ=^S#M0=01<O]QV?/ET[]F':GN.SY\NG?LP
M[4'4%S;E](/)U+;X93?]4*Q[CL^=.>''_P#IAVJ$\KV6\W4>2Y)L3S8ZMINZ
M8!S1@#=S(+&]^@[H.]X1]ZZ3]$WZ%EKD^'90ST^@IW1YX<UAC:0WN8;"WG61
M[CL^?+IW[,.U!U!%R_W'9\^73OV8=J>X[/GRZ=^S#M0=01<O]QV?/ET[]F':
MGN.SY\NG?LP[4'4%0C>X7,/<=GSY=._9AVI[CL^?+IW[,.U!T[2;'@FDVZ%S
M'W'9\^73OV8=J>X[/GRZ=^S#M0=/()7D-(X67,O<=GSY=._9AVI[CL^?+IW[
M,.U!TVSM[D+TT6;8KF'N.SY\NG?LP[4]QV?/ET[]F':@Z@BY?[CL^?+IW[,.
MU/<=GSY=._9AVH.H(N7^X[/GRZ=^S#M3W'9\^73OV8=J#J"\WL>!7,?<=GSY
M=._9AVKR,G9[%_\ QR[]F':@\R$>'E^__P!/;]+%U(G=?.3\N9L\+3J7W5.[
MX=QAW=7,?@W;M;U>I3X9/SWL/=P[]F':@ZBBY?[CL^?+EW[,.U/<=GSY=._9
MAVH.H(N7^X[/GRZ=^S#M3W'9\^73OV8=J#J"'@N7^X[/GRZ=^S#M3W'9\^73
MOV8=J#IP#NDA5L;;KF'N.SY\NG?LP[4]QV?/ET[]F':@Z<0[H(7GFR;ZK7Z%
MS/W'9\^73OV8=J>X[/GRZ=^S#M0=-TOV (LO0%ES#W'9\^73OV8=J>X[/GRZ
M=^S#M0=01<O]QV?/ET[]F':GN.SY\NG?LP[4'4$7+_<=GSY=._9AVI[CL^?+
MIW[,.U!U!%R_W'9\^73OV8=J>X[/GRZ=^S#M0= S%]XL0_0/^@J"\@QOE":W
MPA_TK6XSE#/,>$UCY<[.DC;$XN;W.!<6X<5E_P!'J.6+)+F5$O/2"=]W6M?<
MH.H7 V14O;ILB#TB(@(B(-+FW!&9BP:;#9)GPMDL=;1<CBO4N#LDP 8292&<
MT(]=M]NGYEMG#>_2J;'9!I<O8$S",!;AC)G2,:S0'D;KQEO!8LMX=-&*@RQN
M>Z1SGBUKE;XMVXJQ7T4-?224M6P202"SF'@=[H.59=PZEQ7E-Q*NIFL?34[R
M>)L7$WN!YP5T',N7:3'J=K*D%DK/N<K"0YGFLLS",(HL'I^9P^G;#%^*U9_S
M((/3Y$YR>%V+8O5XA% 0613&S1;S<?2MUF++5)C5/&QY,,T5N:FCN',\RWIV
M(ZNE+GH00F'(YFJ8G8UBU5B<,6[89=A?K-K7_P"ZT?*K21U.8, I;F-CGAOB
M&Q&_19=2;;<66#78-0XA4T]15T[9)8#JC<>+2@B<N0GUCV-Q/&JRLI&GQ:=Y
ML/6-ST\5M\SY8AQN"DA,[H&4[VN:UC0>!!M\RDFGJ5=.QZ4&IQS"&XK@TF'O
ME=&Q[0TN N=E9JLO4=9EZ'"*P<[%%$V-KSL00+ [=.RW>D]::>-R@@WN%JIV
M,IZ['JVIP]A%Z9]@' '@7#<CSE;3'LJ08J,+:R5U/#A[@8V-&UA:P_PA273?
MCNJVZD&IQ_"QC.!SX>Z0QME#?' N19P/#T*QB.7:3$L"BPNM!D;$QK62>]<T
M@6U"RWA"H./#B@@[<ASSF.+%,<K:VA8X.[GDL&FW"Y&Y]*WN/9=I,6P(84;Q
M0-#=!9^ 0+"RWMMM]TT^I!#JW)8KL'IZ.KQ"HEJ('ZXJD@![3Z%KZ_D^EQ*A
M-/B>.5E58C07  ,MY!L?2N@:;G<JNG:UT$>QS+,.*X+#0RS/88;&.5O%KAP*
MLTF6"[")</Q>NEQ*-U@TRM +;<+6LI/;UII-MSN@@?N"G?$VFEQVN?AP.],;
M6(ZK\;6\JF.'44&'T<=+2L#(HQ8-"RM'% U!'L5RU'B&8Z#%GSO8^DX1@;.W
M!_@J9IRW'C\U$^6=\7<LG."S0;J0AEE4-.YZ4&CS7@+,PX?W+),Z(!P=J:+K
MWC.7Z3&,*;15C=6D ,>"0YI%MP1YEN-K^5!<GCP005N0I9^;@Q+&ZVLH8S;N
M=^S7#J)&YV\JWV/Y>AQ? '84UW<\-V%I8/>Z7AUK>A;W3ZU4- MY$&IJ\%HJ
M[!&X771BH@9&V,@[$V%K[<"HQ[@ZET HY\>KI,.'&G-@"+\-7'YU/+6Z53AP
M0:BLR]1567N\YB#:(1B, $BUA:ZU&&Y0GI\'J\,J,8J:F":/FV![6_:QOP/$
M\>E2[K(Z>*$@@]*",QY0I/<HW IY'30L&S^!O<F^WG*T^8<(GP[)DF'FMK:N
MH<0V&1ATN!X ;$;<%/AOLA8@U64*:HI,O44-8]SIVQC47$DK<+R#;95!N@JB
M(@(B("(B B(@(B("(B B(@(B("(B B(@(J.-DO< V0>7; J%YTGD9AU5QOH=
M8^A324@,-]E#,Q1=T4=7%?5=IMZB@^3<:?*<7J'.-[O*L$ RQL+ XN/%;/--
M++3XG4Q%I%GD\%CX52QR.:\O/.-WMUH+1TPU(B=TA7"]S9'-YQSF] )-@K52
MP]UNUM((X$A>.:=JULN>M!?BBU-<6N.KSKVQTK8]R252..S0]CN/%)'@-]]P
M09<56YD);Z]EF83F:LPTO;!(]K'"Q 6D9*]KO%W:>A;&.ADG@<_\$"Z#?4&:
M^<+FU48D)X$M&RW63)JFKQZ,PSN#"?>W\H4%HF-C+M U'I6]R-/#18ZR5\NF
M[N!\X0=.Y8,.!PQD^D<XQM[^E<9:V21X+2+CB5WKE JX:S+CFL<'%T9Z5\_5
M+GP/='&_I07@Z6CJS5P2N:YN]@5TK(>=(ZJU+BCW.<ZX%[+DG=4@(:\7 *OL
M8>=;4-.@MX(.WYPR3#58;-B5&&\-73YUR:@I":F2*K%XQ=2'"^4#$*:@%"\Z
MHB W?J6%B=1W=&YT5FD[FW2@B6)0,BJG\Q[RYV"\.E+0&R7WV 64^FE@>Z20
M?:_*LBJH))Z(5#6V:T[%!JZ;7'*^_3P5RHHY'3L;&+EW%>P[:[A9P6\RU-3]
MT!U41QXW0:*AB=!)(R9HXGZ5FU='3R1!T=KA7L=IV#%)'Q2!S'$D +$,4L;"
M6L.@(,JBCC8P7Z-E)\,935U534;!;G7@$]>X6@H&!],\OV)X+IG)3EQD@-=.
MTDL<-(L@Z!A%%'A-#!3Q-&POLMTV/Q-0Z58DC:2 .A7R[FV@%POT!!;GD;"P
M;&YZ4I[OB+G'S*ZXA[-,EK]2M2->+!F[0@O11$W<\\%@UTH>XB]@%6JJG6L-
MCTK53U+2_3Q/2@K---&V[7W;U*W?G3SA!NJQS%LM@-35>8R262P&G?;9!:YU
MU-!+5R;1Q-))6?R;8_W_ ,.JYVDEC)2UI/5<C^"YCRXYK[Q9>FPYDC>>F;8V
M._&RWO\ 1=<7Y +W'<R7O_ZG(.R(B("(B B(@QIIFQN(-R2K3CXI<P#S+W/9
M@+R-UY9(R^EI\<H+T&[+]/4L'$7<W*'=!%E=;SK7.+AYE9Q*,RT[2[8@W0?.
M/+?AC8<2=5-%B\WNN61L(:76NOI/E5P&3%L%D=$PN>SJ%U\ZMAEI9S#(+%!@
M%SAJ(NTW7J5H&ESG;VZ%==&7RN8>)*R:G")6T8D>YH \J#'IV/GN]D1?IZ>I
M'SET@(&PXA;S+N8Z?!L-J*22(2/E%@?3=1V1T@<^0-V<;H,F*FGFU2TK39NY
M)5QD%350ZY22&G>ZR:.NDCHG,B;[[BL45,T<;HP;!R#V)F4K28MW!6R]\KFR
MR2<=[+%F^UMWWNJ"%[G,=;Q.A!(,"8RNK8X)QKCU6WZ%T'/.2V46 TV(X?I
MT"^YZKJ#9>F@H:.43$"H.[0LK$L[5\F%=[G.NP';Z$$;BG<'N,Q);U+'F'VS
MG(]F'B%0D/E+C[X]"OB+[7J<;>1!F4-#SD!GC#="<YW-,'QVMP5(JGN6F=#$
M;ZN(6M+7N#B76%[[H,J226.M%3%(6O:;@A4Q7%ZG$I :J0G2+7*LM<=)#@=^
M!6-(PDZ7H/3WVCL-PO=/=KM7 %6C$^%H\4Z5E7:^$'I""]SKC&YA!L5?PZ@;
M4^)[T]:Q]>IK6]:VF#4L\SC'""9"=MD$SY-,.B?F".G,37D. N1Y5]*4S8Z2
ME<QK0+#H"YMR095DP^(UU:PME(!%Q;K70L7F$-!*?PG#B@P*BL:T/=T*U"Q\
MP$TANT'8+740=,PAX)WXK<@MIV G9@Z$ /:TDN'B@;+45%2YTE]](/!9%34<
M]JL+,6NW+CTM0'ATLSBUMFV5(FNJ9 W42&\?,JQ.>U^@7U'@.M:;/.-LRSE^
M5X<T5<K2&B^Z#*PS,S#G"GPJE) %]7#JNNJ#@ODOD?QAV)\I,3Y#=QU$^I?6
MC>" B(@(B("(B B(@(B("(B BC6/9WP/ JTTF)53HIP-6D,)V]"MX3GW+^*U
M#8*2N;SKN >"R_K02E%ILQ9EPW+T,4N*S.B9*2&V:3<CS>=;6"9D\$<L>['M
M#@?(1=!<1:+'LV8/@1 Q*K;&X_@C=WJ"LX)G7 \:E$5!6M=(>#7>*3ZT$C1:
M_%\9H<(IC/B%1'#&.&IPN?,.E:"AY1LMUM0V&"N\<FPUL+1ZR@EZ+PR5KV!S
M"'-.X(.Q6NQC'J#"#$*Z70Z5VEC0"23Y@@VB*.U^<\&H:MM-4U);,;7 :2!?
M<7/0MEB&,4>'T+:NIE#876TD;WOU=:#8(L&HQ2FI\.[NE+Q3Z=1.@W \W%5P
MK$Z7%:)E50R<Y"_@;609J(#=$%JI^X2?FGZ%R_D'XYN_YO4?]:1=0JON$GYI
M^A<OY!^.;O\ F]1_UI$'541$!$1 1$0$14+K<>""J*.5^=,&HJDP33O<]ILX
MQQE[6^<C8+9C&*$X=W?W1'W):_.:MNI!L$49HL\8)65+((ZB1KGFS721.8UW
MF)V4E:0X7'!!5$1 1$0$1$!<WY?O[.I?[Y3?]4+I"YOR_?V=2_WRF_ZH03W"
M/O72?HF_0LM8F$?>ND_1-^A9: B(@(B("(J%UC:R"J+QKWW!6LJ\P4-+B$='
M/*&SR>];?BBLU13WEMD6IQO'J/!XVNJG[N-FM;NX^@+S@N8:+%RYM*\A[=RQ
M_BN'H*91S*-6C/=N$7D/O?;@O0-Q=%Q$1 1$0%Y W"]*@XH.6R?V]/\ [@WZ
M6+J)X^E<ND_MZ?\ W!OTL74CQ]*"J(B B(@(B'8("*@=?HLO$LS8XW/>0&M%
MR;H+B+4X)C]%C,<SZ*34(G:7=5]NGTK7U6=<+IJB2&1SR^,V=H:7 ><@6"99
M<ZW$15GM*3(L>CJXZNECGA(='(+@@W5YKKN(LC2)S&8>D1$2(B("(B#7YB^\
M6(?H'_05!>0;^J$W]X?]*G68OO%B'Z!_T%07D&_JA-_>'_2@Z4."(."("(B
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MROU4SPUT8W\JP>Z'0PE@'C'B4%M\C74SG2;/"PKL>W5HW7HW=J#07./0C6R
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MFGZ%R_D'XYN_YO4?]:1!U5$1 1$0$1$ \"K;B'-+7<"%<Z%8F:71/:QQ#B+
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M>"^+?Z/9_P#B%3-/'2[Z%]I-X("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MR^5>*W)]+5X%2X6^5XB@>'M=;<[WZT&-FN%@Y/I6M8-+::_^$K6S$>"J0_\
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M-F.V*# EHXXHB2Z[NM6*&L=!4 ,X#BMA)&QK3K=Q6!+2:'F5AVZD$NI)FU$
M.VZO:6@%IX*,876Z'$7.RN28C.9>!T70:G.V0Z7&FNEA;IFMT'RKC^-Y2Q3
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MM_._BY?$T7OE]L_T6/[/6_G?Q<@[*B(@(B("(B"&XS5.DQ$Q!WBAY&WG5IE
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M7BD#W2VZPH:_(>/T\I#('D#HV[5]+13:W!S=QU%4J.9>0[0W5YD'S:,IXU*
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MJ)XEB4N)U'.5,SG'JN@VN9,WU5474F&@0T;; $ [_.M!S3C3F:0F_$DI(""
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M+>"^+OZ/-O=_3M M=KOH7VBW@$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M1O$@#FD$=%E<6NP8WI&W6Q0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
C1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g109079g00v03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00v03.jpg
M_]C_X  02D9)1@ ! 0$ MP"W  #_[1CL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &,\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%"\FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M*"@H*"@H*"@H*/_  !$( MD'9 ,!(@ "$0$#$0'_Q  <  $  @(# 0
M        !@<$!0(#" '_Q !8$  ! P,!! ,'#P@) P0" 04  0(#! 41!@<2
M(3$305$4(E5A<9'1"!46%S(W4G.!DI.AL;+!(S-"5G)TL](U-CA4E,+3X? D
M4V)#@J+Q)31CXB8H1(3_Q  : 0$  P$! 0               @,$!0$&_\0
M.!$!  (! @,%!@4$ P$  P$   $" P01$B$Q!1-!46$4(C)2<9$C@:&QP3-"
MT>$D4_!B!C1#8__:  P# 0 "$0,1 #\ ]4@
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M-J7\,KAO#*X7'>*!Z=M451!;X8ZV;IZAK</DX=\OR(AE
M
M   &+<KC1VRF6HN%1'3PHN%>]<)_S@8-HU/9+Q*L5KN=-52)S;&[*H>;=3]W
M[4]N=3IYU;+!9Z)&N5C5X;J(S>Y87F]>LW^J-A=RLMPMUQV>UW0U$,C72QRR
M/1%PJ+U[V>*=G6!Z+!4>O-J\FC_6RRQ6]UTU)-&UDD$3N"/W6]?/BKDZC"TE
MMHJ9=44]@UC89[+65*HD*O7*.RB\\HG_ (^<"Z04AJ+;A56_5];IZWZ=EKZN
M+>2+HGJJOQO9X8X<&Y-5;/5!5]:E501Z4JI+] KD6E8JJB(WB[*XRF$1W5U
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M4\2*OE151?K13=
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M49GJ=N.1%^LJWU+5_FK+%>+)52.DDM53T;5=V*Y_#_X@7@
M                                                       JK:OL
MCAUC<8+O:ZYULO,2Y6=B*[?PC43])$3&ZG41&AV%7NZ7.DEUEJ9]PI*5Z/9!
MT?!V%1<<%3L0]!@"F-JVQB36-SM55;;KZW-H(4BC:D>\J(B-1,+G_P 31V_8
M?JBFKJ:>37%9(R*1KU8K%[Y$7./='H, 47M#V(5^I]6LOE'J!U%.R%L2*V++
MLIO97.\G/>-7%L*U4V1KG:[K51%Y;B_S'H@ 4EM*V+UVK-50WJBOKJ":*/=:
MK8MY47>5<YSXS6VGU/DL]UAJM6:CGN\,3D<D$C'(B^+*/X=9?X JC:5LHDUG
MJ"T5#K@VGM=#NHM(D64<B+E>.47K4D^I=GUCO&FJVULM])!)/ Z)LS84RQ5:
MJ([AC[28 "B8=A]<W9Y6:6??=^!\S)87+"GY-$<]53&>O?3KZBV-%6!-/:7M
M]IDD;4.I8TCZ16XS\AO@!5&VK995;1)+<D%V[A@I=Y>C2)'(Y5W>/-/@D6L6
MQ'4UJJ:-8]:3I34[VKT+8$1%:F.'NNQ#T  *LJ]ELM1M<H]9^N*(R!BM6GZ/
MGE'ISS_Y]G4=&U[8[3ZXN%/<[?6>MMSC1&NG8Q55S4WO_)$SWW/F6T -9IJD
MK:"RTU-=*ONRKC;NOFW4;OKVX3@;,
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M5E%104T2(D<+$8W"8X(AW@
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M@T5I>GM<#ND>G?RR8QO/7BOUJH$J
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M=X7D^D3_ %!["=IWA>3Z1/\ 4/0  \_^PG:=X7D^D3_4'L)VG>%Y/I$_U#T
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M=&>%V_1/] ]MW1GA=OT3_0/:DT=X(@^8WT#VI-'>"(/F-] #VW=&>%V_1/\
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M-<U=UW%%1 )MIK45#J"SP7*ADS3S9W<HJ<EPO-$[ 0+8C[W%L\LGWW "U0
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M14PJ ;5J;K41.2'TXQ*JQM5>>#D
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M4PCL<4.TTU8R9=14KF(O0HSON/#](W(
M       #IK5Q23*BX7<7[ 2[.D9\-OG/J/:JX1R*OE/.E36U/=$G_42<_A&[
MT'5U#M44;732.:JKE%7Q'.IVA%K17A<RG:46M%>'JO$ '1=,
M                         "';7_>[OG[M)]QQ,2';7_>[OG[M)]QP$;V(
M^]Q;/+)]]P&Q'WN+9Y9/ON %J@  :+5&F:347<7=DDC.Y)DF9N8XJBHO'*>(
MWH BNKM$T&I*:C94/DAFI$Q%-'C>3EVHOP4.>B]&4.EDJ'TTDL]14*BR32XW
MEQGL1.U23@"D/5*>[TS^\K]Z,N&Q?T/1_%H4]ZI3W>F?WE?O1EPV+^AZ/XM
M,XZ:M8$@<M5N]$G-7<CN(EM,MRUNFIGMWU?"J/1&]?5^($FH*NGKJ2.HHY6R
MP2)EKV\E0Z*6[4-5<*BAIZF.2KI_SL2+Q9RY^=/.5;;M5>Q38G9ZR-JNGF8L
M,*]37KOJBKQY=Z1[8=5VFAVBWREI[@RIFJ(M[I=Y%Z1RK'Z<?(!Z!
M
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M-NO*>B6#):\3Q.8 ,Z\
M                                      !1.WK^O.D?CE^UI><'YEGD
M*,V]?UYTC\<OVM+S@_,L\@',                  4)H/W^+I\5_D:7V4)H
M/W^+I\5_D:7V 7@AB6^M;6=-NM5.BD=&N?$N#+7BAB6^A91]-N.5W2R.D7/4
MJKD#+
M                           %:^J#][NI_:7[CS<;'O>ZM'DD_BN-/ZH/
MWNZG]I?N/-QL>][JT>23^*X"9             !1%[_M%47["?<0O<HB]_VB
MJ+]A/N(!>X  P)[@L5U@H]Q%21N]O=G/T&>8LM#%)71U;L]+&F$^OTF4
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MN%OAJ8ERV1N3/7-?)DO&2>?\,^F]RUL<]>OY,L %K8
M
M  HG;U_7G2/QR_:TO.#\RSR%&;>OZ\Z1^.7[6EYP?F6>0#F
M     *$T'[_%T^*_R-+[*$T'[_%T^*_R-+[ +R4UEDJY:KNOIG9Z.9[&\.I'
M*B&S.J".*/?Z%&IERJ[=[>L#M
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M\.OT64#IHJAE52QS1.1S'IG*'<:HG=KB=^8
M                                                      "B=O7]
M>=(_'+]K2\X/S+/(49MZ_KSI'XY?M:7G!^99Y .8                  H3
M0?O\73XK_(TOLH30?O\ %T^*_P C2^P"\E-38&2L[LZ;>XSR*W>7JWEP;8Z*
M6JBJ>DZ%V]T;E8[@O!47"@=X
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M=\_=I/N.)B0[:_[W=\_=I/N. C>Q'WN+9Y9/ON V(^]Q;/+)]]P M4
M %(>J4]WIG]Y7[T9<-B_H>C^+0I[U2GN],_O*_>C+AL7]#T?Q: 9QJ=3TTU7
M:I(J=JND54PAMC%N-;%04SIY\[B=@&1$BI&U%YHAK=36IEXM$]*],N5%5GB=
MA43[39M7>:BIR4^GEJQ:-I>6K%HVE MF-TD2*:T5:XF@<NXB\\95?Q)Z5GJN
M)VGM94MVA3%/,YJ28[."+]A9-/*V:%DC%RUR(J&?33,1..>M?V9M+:8B<5NM
M?V\', &EJ
M                          %$[>OZ\Z1^.7[6EYP?F6>0HS;U_7G2/QR_
M:TO.#\RSR <P                 !0F@_?XNGQ7^1I?90F@_?XNGQ7^1I?8
M!>**:^TT3J/NG?<B])*Z1/E55-@O!%,&UURUG=&6[O12NC\N%P!G
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M?-WU./;9KTV;OZ<>VP "]H
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MIJ*S/#?E*VFIK,\-XX9]4N!\C>V1B.8Y'-7DJ'TT-(
M                *U]4'[W=3^TOW'FXV/>]U:/))_%<:?U0?O=U/[2_<>;C
M8][W5H\DG\5P$R        (SJO15JU++'+71XFCX(]O/'828 1BIT/9I['36
MIU.B4D#TD:U/A)GC_P#)3=5MMIZRUS6^9J+3RQ+"Y/\ Q5,?89H P;':J:S6
MZ.BHF[L$>51/*N2EKW_:*HOV$^XA>Y1%[_M%47["?<0"]P !CR4<4E7'4N;^
M58F$7S^DR#2UCY4U'2-:KNB5G'L_2-T              "/Z\J^X],5CTYO:
MK$^5%]!("!;5ZA74%-0L]U-(U?DPY"G46X<=I4:FW!BM+:;-J7N;2].Y?=2J
MYR_.4E)A62G2EM-)"G)L:?7Q,TEBKPTBJ>*O!2*^4  +%@
M                    !&:[15JK:J2HEC[]ZY4DP(VI6_*T;H7QUO&UHW16
MGT+:()XY61KO,<CDX=:$I8U&M1J<D3!]!Y3'6GPQL4QTQ_#&P ":8
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MQR/8CFJBM5,HJ=:$=''!2:>,2AH8X*3C\8E] !K;0
M                                                       41MZ_
MKSI'XY?M:7I!^99Y"B]O7]>=(_'+]K2](/S+/(!S              0'6^TB
MBT]4)24T?=-:C]U[%X(U,+U_(3R-V_&UW+*9 Y K>Y[0KDR_5]NL]C?<$I'(
MUSX]Y>I%ZD7M)S8:RIK[5#4UM*ZDJ'YWH7(J*W"JB<^/),@4GH/W^+I\5_D:
M7V4)H3W^+I\5_D:7V .N%T3M[H7-7"JCMU>OK.Q>2FKL5-+3]U],U6[\[W-S
MV*Y50#:                %>;4I5J*FWVUO_J/:]4^<A896UR__ ".T^GA3
MOF4R(JX^3TF;5<Z</G.S+J_@X?.8A85OB2&B@C:F$:Q$.%SHHKA0S4LR99(U
M6^3**F?K,I$PB(#1M&VS3PQMLK?1-?)8K[4V*N54BWOR*JF.M5Z^W>0L@A&T
MBS/FIXKG0M=W53.WUW4SE$PN?DW3=:.O3+S:&2(Y.FC1&2)UHO\ Q%,V"9QV
MG#/Y?1EP3..TX9_+Z?Z;T &IK #1WO5-KM+%Z>IC?+_VV.1SO-DC:]:1O:4;
M7K2-[3LWAHK]JFVV=B]/,DDO_;C<U7>;)$);KJ34[ECM]*^DI%_3<S"*GE5#
M=V'0M%1.2>N>^JJ>URKA./E,_?7R<L4?G+-W]\O+%'+SEIGW746JE6&WP+14
M3^"R2,7"IR7CA?&;BPZ#HJ)[:BO<ZJJD7>5RN5$1?.3".-D;=V-J-;V(F#D2
MKIXWXKSQ2E731OQ9)XI]?\.,4;(F(V-J-:B81$.0,:KKZ2C:JU53#"B?#>C?
MM+]XAHWB'5>;I3VBA?55:NZ)F,[N,\51.M4[2.>V+9>RI^:W^8TVT+4]LK[1
M)14<Z32N5.+<*G!R+S3R*5B<S4ZVU+[8]IARM5KK4OPXYB8>@-/ZAHKZV1:'
MI.\YH]$\78J]IN"L]CO*L^7_ "EF&W3Y)R8XM9OTV2<N.+VZBHBIA4RA'K]I
M&VWA%=+&L<W5(Q53'R9P2$%MJ5O&UHW6WI6\;6C=63K=J/23E?;Y.[:/FK$9
MO.QS7/>\.OK-Y8->4-<](*YJT=3G"I(J-;]:DQ5$5,*F4(_?M)VZ\-<Z2/HY
ML<)&*J8^1%,_<WQ_TIY>4LO<9,7]*>7E+?12,E8CXG->Q4RBM7**<BL'6_4>
MDY5?;E?64*+E6[N\N/,N#?V+75#6*D-P5*.J3@YLB[J9\JX)4U$;\-XVE.FI
MK,\.2.&?5, <8I&2QH^)[7L5,HYJY13D:&D
M    5KZH/WNZG]I?N/-QL>][JT>23^*XT_J@_>[J?VE^X\W&Q[WNK1Y)/XK@
M)D             %$7O^T51?L)]Q"]RB+W_:*HOV$^X@%[@ #J?-"VH;$YS4
ME<F4153*_P#,'::JJHYI+]35+43HF,PJ_.])M0              5OJ=?7+:
M';Z/FR'=5WGS^)9!6ND/_P KKNNKUXL:S"+U9PPRZGGPT\Y9-5SX:><K)8W=
M8UJ<D3!] -36                 !51$557")S50 -<Z^VIJJBW&D14_P#Y
MF^DYT]WMU3*D4%=322+R:V5JJOR9(\=?-'CKYLX $D@
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MDSE43ZT,F3\++&3PGE+'D_"RQD\)Y3_"S@ :VP
M                                                    %$;>OZ\Z
M1^.7[6EZ0?F6>0HO;U_7G2/QR_:TO2#\RSR <P            %2[>Z.EAM%
M!41T\+)WU6'2-8B.=WC^:\RQJJ\T%L[DAKJF.&2H[V-KG(BN7"KP\RG9>K-0
M7F&.*Y4[)XV.WVHY,X7"IGZSC<K';[E-32UM,R62G7>B5R9W5PJ?BH%*WBEL
M[*C4=PI-3U%)<6(LG0*Y85<Y&IA,;R;W5U%C:#FN6H-G\"U\\M/62MD;TV[W
MR=\Y$7'#JP;&Y:&T]<:U:JJMT+IEXN5&HB.\O#B2"EIXJ6!D-/&R*)B8:QB8
M1/D \_[,*5]'MKN$$M0^H>V)<R/3"N[Q#T*4)H/W^+I\5_D:7V 7@ABT-:RK
MZ;H\_DWNC7RHN#*7BBF%;*'N+NC+][I972<N65R!F@               .5$
M157DA6VSY%N6J;A<Y.*;NXB^/O"<:AJNX[-5SYPK&90C&R6FZ.P/G<G?2R*N
M?%R_ RY?>RTKY;RR9?>S4KY;RG  -36XRQMEB?'(B.8]%:J+UHI5K*A-&ZR=
M"DG_ $-0J.>W/!O/'WBU"F-JG]9U^+:8M;/!6,D=8EAUT\%(R1UB5F)JNRJJ
M8N$''_S3TG5=]76JW4^^M5%,]4RUD;D<J^8HAJ9<B=JEM:0T71+1TU=7_P#5
M22,1Z-?Q1N4Y87)3AU67/,UK$*<&KS9YFM8AKY+QJ74LBQVRGDI*1>4BHJ9^
M543Q&ZLV@Z2!Z3W21];4+SZ15PGUKDE\,4--$C(61Q1IU-1&HA@7*^VZW,WJ
MFI8GB:N5^HTQ@K7WLL[SZM,:>M??RSO/KT;"&&.%B,AC8QJ=34PAS(#7;1(7
M*K+9135#NI4RGX&$SV7W[BV1:.'Q*C5_ ]G54Z4C?Z/9U=.F..+Z)Y77FW4+
M56JK(&*GZ*R)GS9(Q<=H%&Q7,MD$E9)R1&HN,_(BG10[/FO>DEXKI:MW6BN=
MZ5)3;]/VN@:B4]% BI^DK$5?/@\_'OY5_67F^HOY5C[RA*7'6%Z7%-3.HX5Z
MW-QP7QJB&52Z$J*M4DO5SJ)57BK-Y<?:3]K4:B(U$1$ZD/I[&FK/.\S+V-+6
M>>29M]42K=!VJ2VNIJ:/H9%Q^5QO+P5.U?$:7VL(O[^_Z/\ W+'![;2XK=:O
M;:3#;G-4<TCIAFGDFW)W3+)GFW&.7C\1(P"ZE*TCAKT74I7'7AKT  23   <
MB.14<B*B\T4CU[TC:[KESX&PS<^DC3=7/R8)""-J5O&UHW1O2MXVM&ZMI;=J
M33,BOMLTM=1MX(QW?+CR<3;637=)4NZ"Z,6BJ.6'\$^O'C)FJ(J85,H:*]:5
MM=U15EIF,EZGL3=7ZC/W-\?/%/+REF[F^/GBGEY2W4,T<[$?#(R1B\G-7*',
MK2>T:CTRY9+;5/JZ1..XY>7BPJKXC:V+7M+4O2"Y1/I:C_RSA?J0]KJ8WX<D
M<,O:ZF-^')'#*;'743,IX))I7(V-C5<Y5[$/L,T<S$?$]KVKUM7)I]9+C3U8
MB/1BK&[FN,]ZO OM;:LRVXJQDO%?-$KCM G2I<VC@;T35PBJO/ZB1Z3U1%>D
M=%*U(JEOZ.<YYE0$FV>PRR:AB?%E&,1=Y4\A@Q9[S>-Y?2:KL_!7!,UC:8CJ
MMX '1?,                   K7U0?O=U/[2_<>;C8][W5H\DG\5QI_5!^]
MW4_M+]QYN-CWO=6CR2?Q7 3(             *(O?]HJB_83[B%[E$7O^T51
M?L)]Q +W  &%-7MBN4-(K<ND;E%\_H,TPIJ!LMRAK%=AT;=U$\_I,T
M        P[Q4I1VRIJ%5$Z-F\0[9)3*EKJ*MZ=_+(N%7LY?@;#:;6K2:;D:U
M519EW.'D7T&PT11]PZ;I(E3#L.5?G*99][/$>4?NR3[^HB/EC]V] !J:P
M             Z:Y<4<ZYQWB_88MXO%'::=TM7,UN$SNHN57Y" UM^O6J9GT
MUCB?!2+WJO5<9Z^? HRYZTY=9\E&7/7'[O6?*%>5$C^GD[]W/M-WH)[EU319
M<[W2]?B,UVS^][R]Y&OCWTX_6;;2>C+K;[[3552QB11KE51R+^)Q\6#+&2)F
ML]7$Q:?+&2)FL]5IH #OOH@
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MDO>TU2]SH\]29=CEY$+-(:>\WISZQRE7ILDWI[W6.4@ +V@
M              %=;4M;773#Z.*W6E98IIV1OJWO3<8BYX;N47/H.S66J+LR
M_P!HT[IY*=M?71=,^:9KG-C8BHBKA'(OZ2+S L$$(V=:HK[O6WFT7N.%MSM3
MHVR/A14;(C]Y6JB*JXX-3KZR;@
M      41MZ_KSI'XY?M:7I!^99Y"B]O7]>=(_'+]K2](/S+/(!S
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M[2_<>;C8][W5H\DG\5QI_5!^]W4_M+]QYN-CWO=6CR2?Q7 3(
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M8H&(R-O)$.PE33Q$\5YWE+'IHB>/)/%81,)A.0 -#2
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M -B/YJ'9%#'%GHV-;GL3!1AT/=7B_$SX.S^ZO%^+?9S !T'2
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MM"^*\'NQ&P #UZ      .I:F%%PLC<^4^LGB>[=9(U5[$/-X>;P[  >O0
M        8M1<*2GSTU1&S':IJ:G5]G@546I1ZI\#"_B1F]8ZRMI@R7^&LRD!
MH+_JFAL[^BEWY)\9W6(BX\N50U<^OJ-55M)35$KOV4])7%SJ)*NNFFF14>YR
MKA>I#-FU,1'N.GHNS+7MOGC:%JV/6-!=)T@Q)%,Y<-1Z(B+YE4DI05 Y[:VG
M6-5WTD;C'E+VMZO=04ZR^[6-JN\N"6GRSDB>)7VEHZ::8FG27> #2Y8
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MEKUWO37+']T1]^@ "YA
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MI?8!>2F);Z-E)TW1NWNDD<]?$JJJF6O)34V!LK>[.F1Z9J)%;O(O+>7& -L
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MYM/QSCL5,(32CI8:.!D-.Q&1M3"(AW)PY G3'%>?BHS:B^7:L\HCI  ";.
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M>&,,[QTEN[R==28O\<=/6/)8@.,;VR1M>Q4<UR914ZSD:7+
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M+)$141R(N%.8
M             !1&WK^O.D?CE^UI>D'YEGD*+V]?UYTC\<OVM+T@_,L\@',
M      '":&.>-T<T;)(W<VO3*+\A0^V363=+:@I[)IG2UNK:QT*SR+W.Q=UJ
M(J\MQ>IKB[+]=J:R6N>OKG*VGA3>>J(JX3Y"A]2I:->:RMFH](ZDI(YNA=3U
M$$BI&JL<Q6_IN:J\'NX8 C&G=HNHZN\6-*C3-JI*2OEQ'4I31HG!-Y<.W$PN
M%3KZSU<>9;=LKUL[4-!02U;'Z8HJQ]13SM<S*-7DB)OYQAC/.>FD3"
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M;R*6.5N8I&/3M:N3F0.73M\M*[]IN,T[$_\ 3>N$^MQ]I=8UU$_HKU;WL_\
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M4R0K2=9)8;K+9J]ZI&JYB<Y>'''+ZRC^E?TG]W1__:P__=/UC_2?  O<X
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MO=F.Z>B;TN.6]CC]9DG10U<5;2QU%.[>C>B.1<8.\R3&W*5W4
M                                                  41MZ_KSI'X
MY?M:7I!^99Y"B]O7]>=(_'+]K2](/S+/(!S       !B7:EHZVWSP7*..2D>
MU4D;(B*U4QXSS3M#T[LJLTDDM!=:BVW-N58E(V3&<]6XSR]9Z,U39VWZQU5N
MDD=&R=JM5S5PJ(J*GXD#TIL-T;84CD?0)75#<*KZI&R<<=7>@4ALIUEKN35=
M-16NMK;E9^EW5=5N>O>87&-]4ZD0]@'114=-0P)#1P1P1)P1D;<(AW@
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M_M%47["?<0"]P !KZBO6*[P4>[E)&[V?/Z#8&-)10R5L=4[/2L3"<>'7Z3)
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MQ\AIQZZ:TF+<Y56T\3;ET?-,VEMFM45*CU>Y.+E7MQQ-J 8+6FT[RT1&T;0
M \>@
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MDU%#)65+58^1-UK5[."Y^TFP!;2D4KPPQ:C/;/DG);Q  34@
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M??=NTNF]GK-=]]P &EJ"'[2*A6VZ"D;SJ'X\SF^DF! =4KW?K.VTB<6Q]_\
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MK15&-U5ZN7'ZE,\_A6XO"71I_P O%W<_'7IZQY+% 145,IR!H<X
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MO"?W2G_D:;?^ZG[?Z38 %[G@
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MC.KAC:D/HM=>+YIVZ1R^P "UD
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M:2W5"JDU/R1>:IG_ ')B>X[\=8E7J,,X<DTD !-2
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M3R(S?;2QLZ-5Y<4B3K3MZP/4M,]LD#'QIABIP0[#JI98YJ=DD&.C<F6X.T
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MM<F45.M#D6L@
M             HC;U_7G2/QR_:TO2#\RSR%%[>OZ\Z1^.7[6EZ0?F6>0#F
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MQ9 F$Z^.,?Y2?D)V;P*_UPK7)QFDRB_^YQ-BG!'N[^;;VA/XO!'2L1  "YA
M                          (-K;2KY9?76SN6*M9A5:U,;R<>SY"<@KR8
MZY*\-E>7%7+7ALB^B]2LN]/W/4IT5=%E'L5>>.OZT)05_K73D]+4^O5CWF5#
M,*^-G#*<>/!4[$X&]T;J2*]T>Y(J1UD:8DC7.>?D\A5BR36>ZR=?#U4X<LUM
MW63KX3YI& #2U        !QD8V1CF/1%:Y,*B]9R %=U+9=(ZCZ=F74%4["I
MR1O+/VJ6#3RLGA9+&J*UR(J*8-_M<5UMTM/*B;V%5BXY+A<$7T1=7T4U1:;F
M_<=$OY-SUYIQ]"&>OX5N'PET<G_*P]Y_?7KZQYIR#2W#4]HH47IZV/>3J;EW
MV(I'*W:$QSE9:J"6J=U.3>1/K:2OGQTZRY%]1BIULGITS55/ GY:>)G[3D0K
MKN[6%Z3$%*E+$O7O(U4_^2'?3Z"K:M=^[W:H>J\V95?\RE?M%K?TZ3/UY*O:
M+W_ITF?KR5]?:F22[U;HYY%8K^"H]<'&R33>N]'^6E_.M_34W%?HF[QUDS*:
MC<^%'=ZY7MXIYSG:=(7J*YTLDE$K6,D17+OMX)YSD=UEX]YK/5QNYR\>\UGJ
MNN/W#?(A#]K_ +W=\_=I/N.)@Q,-1%["'[7_ 'N[Y^[2?<<?0OI$;V(^]Q;/
M+)]]P&Q'WN+9Y9/ON $2]4#I;2;KHRY774;K-5SL6.5C(W2=,W*KQ1B*O-.O
ML-;H.SZ)U'JZRK9]2NEI;7WU/;GPO9O/W][.7-1.;EX8ZR+:OU+HN^;8(;E>
MZWN^PNCPU>C=NL7?Y*U6YQC/).LR+G5:)JMK6E$V>K'3O2HCZ5\43HV>ZY85
MJ+GD!ZU1,(B)R!\9[E,\>!]   "D/5*>[TS^\K]Z,N&Q?T/1_%H4]ZI3W>F?
MWE?O1EPV+^AZ/XM ,XQ;G0QW"E=!*JHU>PRC5:FJY:.UR30.W7HJ<0-HU-UJ
M(G4?3C$JK&U5YJAR TNM/ZL7'XA_W5*!/2-=215M)+35"9BE:K7)XE3!%JC9
M]9U@E2&.1)%:NZJJG/'#J.?K-+?-:)JYVMTM\]HFO@AFR;^LC_BU^Q3>;2(E
MHKW;+BS@KG[KE\2;J?B8FSF&"W:IKZ*H;BI8JMC=VHF]^&"2;3Z/NG3KI&IW
M\+T<GG3T%>*G_%F/&%6*D^R3'C$_L^:_26KTW'- BJQ6H]R)V*K<%5%RZ/G9
M<]+4B2HCVI$R-R*G/#4,*;0EJDGWV],QJKE6M<B)]A=DPSEVO7Q?7=E]I8\6
M'AO]4*TA;[I5R2NM<[Z=$14<].2\N'-/$2?UDU-X4?Y__P"HE]LMU-;*9(*2
M-&1HN?*IEEM-/$5VF5>?M*U[S-:QMZQ""^LFIO"C_P#G_N(U6T5TT]<F)W2Z
M)U2NZLK>"+Q3GA2WR/:XM:7&RR.:B=+ BR-7R-4\R8(X=Z[[PEI>T+3DBMXC
MAGTAI66;4KV(YMU>J*F4X_\ ]1]]9-3>%'^?_P#J-OH6Z+<;.C9%S-"NZ[SK
MC["1DJ8JVB)B9^ZO+J\N*\TM6.7I"F]7T%SI*B);I,^=51=UZ]7+QKXC0-3+
MD1.>4+VNULIKI2N@JV(YJIP7K3R$9GT#0)2R) ^7I^;7.<G#ZBC)I;;[U='2
M]K8XI%<D;3Z=$CT\U[+)1-D7+DA8B^9#8$$TI?)K?6+9[PNZ^/O6.Y\O)Y"=
MFO%:+5Y.+JL-L62>+QYP  L9@
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MN?)Q*<)'I&QUMT69])4=SM;P5V<97L^LP8LV3B\WT>LT.GC%O\.WBM[IH_\
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M0?O=U/[2_<>;C8][W5H\DG\5QI_5!^]W4_M+]QYN-CWO=6CR2?Q7&UN3(
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MW#>_WYDP)TO%XWAGS8+8;<-@ $U(
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M&^C8V-B,8B(U$PB(<@1K6*](3R9;Y/CG< !)6
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MEXR5G3WZ3T])_P!IJ#5Z;NL=WMD=0U>_QAZ=B_\ %-H6Q,6C>&*])I::VZP
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M3*\C%MUQH[E"LMOJH:F)%5JOB>CDSRYIY ,H
M              /CW-8QSWJC6M3*JO)$ ^@Q+9<J*Z0OEMU5#4Q,<K'.B>CD
M1R+A4RG698%$;>OZ\Z1^.7[6EZ0?F6>0HO;U_7G2/QR_:TO2#\RSR <P
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MU55>"F6=3QSPQRW=2G9488[V\[[<]D\T785H8%K:SOZVHQ(JKGO<Y7&/E)0
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M           #A++'$F9'M8G_ )+@Y,>U[=YCD<G:@>[>+Z  \
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MZRHC;U_7G2/QR_:TO2#\RSR%%[>OZ\Z1^.7[6EZ0?F6>0]>N8
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M=3^VO\-YN-CWO=6CR2?Q7&G]4'[W=3^VO\-YN-CWO=6CR2?Q7 3(
M     *(O?]HJB_83[B%[E$7O^T51?L)]Q +W,*\6R"ZT3Z:I;EJ\E[%,T'DQ
M$QM*5;328M7K"H=0Z6JK2U[F(^:!.*O1O),]9.-"T])3Z=;-38WI$5TCO'_S
M!MKH^GG:^@FXOE9E$QY?00C35>ZV6B[T,SL/I^_3/CW4,TUKBO$^&SHWU%\^
MEO-IYQ.\_0V<)W9J*YW!W%'(K$7YA8Y!MDE-N6&6=WNI)57..K#?0;[5&H*>
MQT:O>J/G7@R-%XKS]!/14M:D1'67!TONX8M/CS;LANU.L[FT[T:+ATK]WY,*
MBD0L^MJ^FNKIJR1TM-(Y-YF?<IE.*<.PV&T*NCOE99Z2B>CVRO3.%SC*HG'S
ME^OP7PXYW\>2.HSQ;#;AZMGLIM204$M;(S#Y%1&*J=2912?&)::1E#;X*>-J
M-1C4RB=O699*T[SRZ-.&G=TBH "*Q!]IDSGQ4=$Q>,C]Y43K3CZ"8T,"4U)%
M"U,(QJ-0A5R__*:^I8/=1P,<CDYIGOR>%./G:UF[4^YAQXO3?[@ +F%K=1W!
M;9:*BI;[MK5W?+A2FJRZ5M74/FEJ9=YRYX/5$0N;4%O]<[5/2HJ(Y[5W57MP
M4K4T4T%;+3;CGR1KA=Q,F'5\6\>3Z#L:,<UMO\7\);HS5CJ1SX+K.JP8[QSN
M:<^LEOLRLO\ >D^KTD7T5I-9U=4W6'\DJ=Y&Y./62WV*6;^Y,)X>]X/\J-;.
MC[Z=]]_3;9HM3ZSI_6]8[3.CIG\-Y,=[Q3\,E?+<*Q9>E6JFW\YSOJ6-J?1U
M+);W/M<+8YV<<)^EQ3\,E=+;JQ)NB6EFW\XQN*49^\XO>=#LZ=-W<]W^>_5/
M=*:R@;0=%=Y\2L7".7'%.'^YN_9E9?[TGU>DU.E-'T[;?TEU@;),]<HB_HIP
M_P!S=^Q2S?W-AIQ]]PQT<O43HN\MU_+;9U>S*R_WI/J](]F5E_O2?5Z3M]BE
MF_N;![%+-_<V$_Q?13OH_*WZ.KV967^])]7I'LRLO]Z3ZO2=OL4LW]S8/8I9
MO[FP?B^AOH_*WZ.KV967^])]7I'LRLO]Z3ZO2=OL4LW]S8/8I9O[FP?B^AOH
M_*WZ.KV967^])]7I.$NL[.D;E94HKD3@G#GYS(]BEF_N;#C)I*T.C<C:1B.5
M."]AY^+Z$3H_*WZ*NN]\K;E5/EDJ)&M7W+&NPB)\AMM$W^KIKI%3S3/DIY55
M%1ZYPO;]1J[U8:VV5;XG0O>Q/<O8U514_P"(;?1&GJFHN<=341.C@BRO?(J*
MJ_\ %,-.\[SU=_-.G]GGIP[<EK)Q3("<$P#JOD0
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MU1434MJDDIW*V1%3"H;8ZZAL+HU2H:QT?6CT14^L#E$JK&U5YX.03&.'(
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M)M%Z4?I^69\E2DN_U(W&/K,>ETN6F6+6CDQ:729<>6+6CDE@ .R[8
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M6T;3'^5$;>OZ\Z1^.7[6EZ0?F6>0HO;U_7G2/QR_:TO2#\RSR&EH<P
M           !0F@_?XNGQ7^1I?90F@_?XNGQ7^1I?8%5;1+E/+>'TG2.2")$
MPU%X+_S!%&2NCD8^-RM>W&%1<*2+:.^--2/1JM]RF53MP1F148B<>:&&^FSV
MM.U9YOH])K='&&LS:(FO7^4NDN=PU6ZCM<"O;&UC4G?GW2XXY\Q95HMT%KHH
MZ:F8UK6HB*J)S7&,KYC2Z!M]-262*:!4=+.UKWNX915:G DQT[Y/=BD<HC]W
MS7*UYR1X_L  J2           (+M-MCYJ>.NCQB)$:Y/%Q4G1!]?U;ZNHIK/
M3.7?E<CG87RICZT*<^W!.[;V=-HSQ-?#K]%;1Q22N1L<;W*O+"*I/;+HB26W
MQRSU,D$STRK6JO#BN.2^0F5IM%)14D#&4T/2,;[OHTWL^4V15BTL1SMS;-5V
MM>_NXN2"NT9<8_\ ]>]3IXLN_F(5J6BJZ&XK#7S/GDQP>Y57*><N\U-_L-)>
MHD;4MW9&YW7M1,IRZ\>(]R::)K[J&E[3M2_XO./I"DFHJJB)SSP)W;+AJ6CM
M\+8X$?"C$W,XSCJ-U:M"T-%4MFED?,K5RUKL8^PEK6HUJ(U$1$X(B$,.GM7G
M,[+]9VGBOM6M>*/5 FZKO$/_ .Q;9'?L_P#T=K==O9^?M<[?E7^4G*HB\T0Z
MGTT#_=PQ.\K$4O[N\=+,/M&GGXL7VF43CU]0K^=IYH_D5?P,N'6UHD]U*]OE
M8INI+502)W]%2KY8F^@Q)M-VF7W5% GDB:GX#;+'C!QZ2>M9C\W&+4UJE7#:
ME/E3!F176BE3+*F+Y7(:>715HDRO1.:O_CNI^!ARZ!MZYZ*:H8O[2>@;Y8\(
M.#23TM,?DEC:J!WN9HE\CD.:/8O)S5\BD)=H-6_F+I4L_P#<IUKI&\0K^0O5
M0J?M._F'>9/&I[/IYZ9?O$IM5U,5)3/GF<C8V)E5(;+M"I&SJUE*]T:+C>WL
M?+C!H]36^^45N=W=5RSTRXWLO5>M,?I+UX(>9LNHO$[1&SI:/LS#>DVM/%]%
M[6>YT]UI$J*5V6KP5%YHIG%;[*UF[JJD3/0;JKXLY0L@UX;S>G%+D:S!&#--
M*SR  6,H                                     K7U0?O=U/[:_P -
MYN-CWO=6CR2?Q7&G]4'[W=3^VO\ #>;C8][W5H\DG\5P$R             "
MB+W_ &BJ+]A/N(7N41>_[15%^PGW$ O<  :VIH'RWFGJT<FY&W=5,>7TE=[2
M*62ANTDD"[K*J--['6N5]"%C5%P6*[04>YE)&[V]V<_00W:O4,8E#$J-WU=O
M9Z^OT&;51$XYW:=+>L7X,GPV]V?S2/0M-W+IBC8J856JJ^=2![2;3607-]=*
M]TM-)A&JJ^YX<OJ4L+2%:VML5/(W"*B*CD3J7)%M;5<MZO4%BHURS*/E<U>7
M-/Q0Z'9\\,QP]-F#/A[JO=3UCDK(DNSRE[LU-%GBD+>DX]6'(IDWVQVVR4\[
MVU;:F=WY-L>/<*K>:_*AM-C])F6NJU3L:B^?T%O:.HXJTQUZ6G](YL'#/>UI
M/_MEF@ QNJ'R1=UCG=B9/IK-2U?<5EJ9LX5$1$^543\3R9VC=/'6;VBL>**Z
M&1:W4-TKW<4WE1JKY?\ <GI$]FU(L%C=*Y.^F?O_ "*UI+"K!&U(:=?:+9YB
M.D<OL  N8V'>*M*&V5%0JXZ-BJGEP179[0I,E7<JAJ/=4/RU7)G"(KD]!V[1
MJM>XX;?$OY6H>G!.>.*$BL%(E#:*6!J8W697RKQ_$H^/)]&^/P=+OXWG](_V
MST3"83D "]@#CT4>]O;C=[MQQ.0              .+V,>F'M:Y/&F3ZUJ-3
M#41$[$/H                                      *(O%/+37&>.=%1
MZ.YKUG"V025-?!% BJ]STQCJ+DO&GZ"ZJCJJ)$>GZ;41%\^#Y9].V^TN5]-$
MBR+PWWHBJGRX,'LD\77D^BCMBG==/>;6)%;$U%YHA$-K_O=WS]VD^XXF)#MK
M_O=WS]VD^XXWOG4;V(^]Q;/+)]]P&Q'WN+9Y9/ON %J@       I#U2GN],_
MO*_>C+AL7]#T?Q:%/>J4]WIG]Y7[T9<-B_H>C^+0#.-1JJ"6HM,C*=JN>JIP
M13;F-<*R*AIUFG548G8!WQ(J1M1>>#D?&JCFHJ<E/H        &!>K73W:AD
MIJIB.:[DN$56KVIDKZT7&KT7=/6VYJLEO=Q9(N>&?_I>HM U6H[)37R@=3U*
M+GFUR+A47S+VJ9\V*;>_3XH9LV&;>_3E:/\ VS903,GB;)$Y',<F45#F5IIN
MZU6EKFMIO2XI%X12XSA>'U<^HLF-[9&(]BHYJIE%0GARQDCU\4\.:,L>4QUA
MR !:N   -3>-/T%U8J5$+4>O_J-:F]Y\&V!Y-8F-I3I>V.>*L[2KR6VWO3,F
M_;9'U5+S5CG+A/DRGB-U8M8TM<Y(JQO<L_8[/$E)HKYI>@NK5<^-8YNJ1BX7
M[%*>[M3X)_)MC4XL_+41S\X_EO&N1R9:J*G:A]*[2/46F79:J5=$WFG/'V$D
MLFJZ"Y8C<]8:CK8],<25<L3.UN4J\NCM6./'/%7SC^4@.,L;)8W1R-1S')A4
M5,Y.351R9:J*GB!:Q]%>7:WU.E;DEPMN^ZB>[,L><(G'L3'PE)I9;I!=J)E1
M3N1<HF\WX*]AEU,$=3 ^&9N]&],*A7U7356C[NM52(KK9*[+V\\)R\7:9YB<
M,[Q\/[.E68UM.&W]2.D^?I]5B@Q;97P7*D944S]YCDSXT,HOB=^<.=:LUG:>
MH #UX            :N\7^WVF)7U<[47J:G%5/+6BL;R\M:*QO,MH:*_:HM]
MGC=TLJ/FQPC;G*_41"IU#?M2S.AL,"P4O)97)AW8O7X^PVU@T'2T[TJ;LYU5
M5YRN7(K?L13-WU\G+%'YST9)SWR\L,?G/1II+AJ#5TJQ4,;Z.@5=USVN5%PO
M;QX]?42+3^AZ"VJDU3_U=2O%72HCDS\J$JAB9#&V.)J-8U,(B=1S)4T\1/%>
M=Y3IIJQ/%>>*7QK4:U&M1$:G!$0^@&AI           !PEE9$Q7R.1K4YJI%
M+SK2GA<L%K:M349QP;EJ?6A"UZTCFNPX,F:=J0E-1414\:OFD:QJ<U52'776
MCGRK3V6#NE_+?5%Q^!AP6"\WZ1);W,L4'5&U<+CS+VDRM-GHK7'N4<2-[7+S
M4KWODZ<H:^#3Z;XYX[>4=$1H-*UUVD2IU!4RHG_91V<>=5\9,[?;J6WQ(RDA
MCC3M:U$5?,98)TQUIT9\VJR9N5IY>4=  %C,  "B-O7]>=(_'+]K2](/S+/(
M47MZ_KSI'XY?M:7I!^99Y .8                  H30?O\73XK_(TOIR;S
M53*IE,90H70?O\73XK_(TOL"G-=Z>J;?<)JS+YJ>9ZNWUXJW*YQ]9&Z>&:MG
MCAA8KY%X(B'H&LIHJNF?#.Q'QN3BBD9T=9*.BJ*R:*)4D;,^-JKU(CE1/J.C
MCUVU-K1SAEMI][<NC,T59)++:TBFE>^1Z[[FJO!JX3@GF)  8+VF\S:6FL16
M-H  1>@          ZJJ=E-3OFD7#&)E2"Z(II+M=ZB]565_19GCQ[WCQ\BF
M7M%N$B0PVVE7,U1S3Q<?02.P6UMJMD5*WFW.5[>)1/OY-O"'0K_Q]--O[K\O
MR;$ %[G@               .BMI8JVEDIZAJ.C>F%14R0J79W"LZK'5O;$JY
MW53CCS$\!7?'6_Q0T8=5EP1,8YVW:^R6FFM%&D%*WAS5RHF57QX3Q&P )Q$1
M&T*;6F\S:T\P 'J(                                     K7U0?O=
MU/[:_P -YN-CWO=6CR2?Q7&G]4'[W=3^VO\ #>;C8][W5H\DG\5P$R
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MKUUH[R,<=*QL  N8@
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M  "UD        41MZ_KSI'XY?M:7I!^99Y"B]O7]>=(_'+]K2](/S+/(!S
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MHG2KES\=IN2&*LUKSZRMUF6,F3:OPQR@ !:R@
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M^G@\C3VR<\T[^G@PK9:Z.VPI%1P,C:G9Q^TS0#3$1$;0U1$1&T  /7H
M '745$-.S?J)8XF]KW(U/K#V(WY0[ 8U+7TE4JI35,$JIU,D1WV*8EXOM#:H
ME=4S,WT_]-KDWE^3)Y-HB-]TJX[VMPQ'-M#2WS4M!:6+TLB22_\ ;C5%=YLD
M8DO5\U"]8K73.IJ9W_J/8N%^7'C-K9-&4U(])ZY[JFH[55<)]93WEK\L<?FV
MQIL>#GJ)Y^4=?]-.^JOFJ9%92M?1T2_I.1414Y<\>4D%BTE1VY4EF_ZBH^&[
M/ D4<;8VHV-J-:G4B'(]KAB)WMSE#)K+37@QQPU]/YE\:B-3#41$\1] +F(
M            41MZ_KSI'XY?M:7I!^99Y"B]O7]>=(_'+]K2](/S+/(!S
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MSU\$*.]KEO%8Z.A72Y-'AOEM'.>4>F_5-0 :W&
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M,NEK.U*9L4XZ1SEW@ VN&
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MY$<U%X*A=J<B6FOQ5GS5]JX9Q9*QX;<OR  :7+
M                                        AVU_WN[Y^[2?<<3$AVU_
MWN[Y^[2?<<!&]B/O<6SRR??<!L1][BV>63[[@!:H       *0]4I[O3/[ROW
MHRX;%_0]'\6A3WJE/=Z9_>5^]&7#8OZ'H_BT SC%N5;'04KIYL[B=AE&#>:#
MUQH7TZ.W<]8&:U=YJ*G6?3XQNZU$[#Z
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M1.I,9,LMQTX8WGK+)J<_>SPUY5CI  "QE
M                                             5KZH/WNZG]M?X;S
M<;'O>ZM'DD_BN-/ZH/WNZG]M?X;S<;'O>ZM'DD_BN F0             41>
M_P"T51?L)]Q"]RB+W_:*HOV$^X@%[D3VBWF:TVA'4<W1U#G)CMQE"6%?[6K<
MR2W1UK4<LL:HW"<>&?\ <JS3MCM._A+/JIM7#::]5?5=WKJ]DDU552ODY>[7
MEY_&3/8_W/FK5Z,[ISP54XXX<OK*XW'X5=U>'B+!V36MLU3-6R[[70NPU.74
MGI.;I<MLN6L9)G:(<G2WM?-7=:A$M<ZC?:8VTU(N*F1-[>[$X^@EI6NU&C5M
M9!5(Y,*U&*GCXK^!T<]IK29J^L[.QTR9XK?HT-/JF[PSI)W9*_CE6N<JHOR9
M)#9+76ZJ>VNNM2YU(BY;%O<%PN%X9X<B",8][D:QJJY5PB8+DT3;I+=8X63I
MB1R*JIV<55/J4R:>)R6VMSAV>T;4TV/BQQ$6GDV]%1T]%"D5+$R)B=36HF2$
MZRTC/65:UEN1JJY._9P3_G63T&V^.MXX9<#!JLF"_>5GFJFR:+N$U9&ZLC;%
M UR*[OD7/BYEI4T+*>".&),,8U&HGB0[ >8\5<?1/5:S)J9B;^#XYJ.:J*F4
M4J^_Z)K8JN22@:V2!RY1,HF[XN*EH@]R8JY(VEYI=7DTMIFGBKK26C:B.L95
M7)K6MC7+691<J6* ,>.,<;0CJ=3?4VXK@ +&<
M                                      "';7_>[OG[M)]QQ,2';7_>
M[OG[M)]QP$;V(^]Q;/+)]]P&Q'WN+9Y9/ON %J@       I#U2GN],_O*_>C
M+AL7]#T?Q:%/>J4]WIG]Y7[T9<-B_H>C^+0#.-=?ZY]OMSYXFM<Y%Y.Y&Q.B
MMI8JR!8IV[S%Z@.V-=YC57K0Y!J(B(B<D
M                                                         41M
MZ_KSI'XY?M:7I!^99Y"B]O7]>=(_'+]K2](/S+/(!S
M%":#]_BZ?%?Y&E]E":#]_BZ?%?Y&E]@%Y*:VRT<E)W5TF/RDSWIY%<JFR7@B
MF%;*[NWI^]W>BE='Y<+@#-/C^+')XCZ0[6.H71/2V6[OZJ5,*J?H\5]!"]XI
M&\KL&&V:_#575[BZ"ZU,>]O8=S3KX'"UTDM=7100-57N7JZBS[!I"DI:!6U\
M;9YWKERN1%QRX)P\1O+=:J*WY[DIXXU7FK6X4QUTLS.\N[D[7I2LTI&\QRW9
M5,Q8Z>-BKE6M1#L -[YR9W
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M,1%,T OB(CHP6M-NL@ /40
M                                  AVU_WN[Y^[2?<<3$AVU_WN[Y^[
M2?<<!&]B/O<6SRR??<!L1][BV>63[[@!:H       *0]4I[O3/[ROWHRX;%_
M0]'\6A3WJE/=Z9_>5^]&7#8OZ'H_BT SC3ZJEEAM$CH'*U^4XH;@ZJF:*")7
MSO1C$YJH'.+\VW/8<@BHJ93D
M                                                HC;U_7G2/QR_
M:TO2#\RSR%%[>OZ\Z1^.7[6EZ0?F6>0#F                  *$T'[_%T^
M*_R-+[*$T'[_ !=/BO\ (TOL O%#%H:*.CZ7HU5>D>Z1<]JKDP=07^DLL2+4
M*KI'>Y8W"K]I$HM>*V&H1\;W2O55B[U,(BKP1>)7;+6O66C'I,N7::QU2#6.
MH4M<*4]-WU9*F&ICEQ\OE.G1FG5HF+75_?5LJ[^<^YRGV\S#T98I99G7>ZIO
M3RKOQIRPBIG/UJ3<A2LWGCM^31GR5P4G!BGZSY^GT  7N>
M
M   *U]4'[W=3^VO\-YN-CWO=6CR2?Q7&G]4'[W=3^VO\-YN-CWO=6CR2?Q7
M3(             *(O?]HJB_83[B%[E$7O\ M%47["?<0"]P#IK*J&CIWS5#
MT9&WFJA[$3,[0Z9J!DMQBJU<N_&W=1.KK])IM:WSULH^@@7-7,F&)CEX_J4T
M]7KR+NU'4[9%I6IA45J95>/C\APTG2.U!=IKS6IEC';L;>6.'^Y1?)Q>[3K+
MH8-+./?+GCE7]9\FYT18?6NCZ>I3_JY<[RYY)PX?42< MI6*1M#'FRVS7F]N
ML@ )*@
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MV-J+S1#D?&+O-1>T^@
M                                        !1&WK^O.D?CE^UI>D'YE
MGD*+V]?UYTC\<OVM+T@_,L\@',                  4)H/W^+I\5_D:7V4
M)H/W^+I\5_D:7V!46T-9O9%*DN=S";G9R(SQ+JU%I^EO4*),F[*WW,B(N?M3
ML(S9-$1+4/DKG.<R-ZM:Q6JF\B*N%YF#)IKS:9A]#INU,-,5:VCG$?\ ONDV
MC^E]C]'TV<]&W&>S=0W)QBC;%&UD;4:QJ81$ZD.1NK&T;.#DOQWFWF  ]0
M
M               %:^J#][NI_;7^&\W&Q[WNK1Y)/XKC3^J#][NI_;7^&\W&
MQ[WNK1Y)/XK@)D             %$7O^T51?L)]Q"]RB+W_:*HOV$^X@%[D-
MVH.E;9XDC54C5_?X\J8)D8UQH8+A2OIZEB/C=VD,E>*LUA?ILL8<M<DQRA0J
M9QA.18.RITN*QO'H>?BSP,>HT,YER;3Q3.6!_'?Z->]Y\.?B)S8K13V>CZ"F
M3FN7.XY5?/XC+AP6K:)EU];VAARX;4IUG_V[8@ VN"
M                                                           !
M#MK_ +W=\_=I/N.)B0[:_P"]W?/W:3[C@(WL1][BV>63[[@-B/O<6SRR??<
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M>AP4+[(-KG@:#YS/2/9!M<\#0?.9Z0+Z!0OL@VN>!H/G,](]D&USP-!\YGI
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M#G"I[IW'FO+/(M<"GK=L.HJ6YTM9-=ZNH6G>CT:_/-/E+@:B-:B)R0^@
M                  UFH[U26&U2UU>_=A9A.OBJ\$3@BD0T/K:U7"[/H8K:
MMLGJE=.W>1?RV<N5WN4Y\_E.C;NC_8I J?FDJ(]_R;[2/7-\<VM-()0JBR)2
M-5=WX/0ICZ@+J  &FU1>;9:+;))>)&)"Y,;CFJN]XL(B]AA[/;S1WS34%3;:
M1M)2HJM9"U>#?J3M[#MUO:Z&XV*J=74L4ZQLWF*]J+NKVIYU\Y&=@G]0*?\
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M.>]<-5RHY%X)SYM7J O-CD>QKFKEKDRB]J'TZZ:-(J>*-JY:QJ-1?$B'8
M           8]QKJ>W4DE562I%!&F7.7JXX(K8=4VK6U1<[8RF;-20>Z<_*M
MD1')CO5:G7A247.BIKA12TU;"R>!Z=\QZ91<<4X>5$*JV7TS*766K*>CC;%'
M&Y[6,:F$1-YO! -M6[4*"@K)*6AMTU30TR[DE1$CMUB]F$8N>KEVEB4L[*FG
M9-$JK&],HJHJ?:>9;-%=J31]WNE)<FPQ4\Z(^E=G$BJC4RJ=?-/,>B=)5CKA
MIR@JWQMC=+'O*UJ81.*@;8          # N=GMUU1J7*AIJK=]STL:.QYS/
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MXGO7DUJN\QYTU!J^/4>IIH]025$=FII7-C@@X+(B.7"KG*=G9R/1IPZ)GP4
MUFE*JCK-/T<ULC6*C<S\FQ4QA#;!$1$PG!       :75]%7U]CE@M,C(ZM7-
M5JOSNJB*BJBXZE0J;9Q2WN#:A<FU3J=',:K:C<1=U4[]&[O'M+S/B-1%543B
MH'T                ^/SNKN^ZZCZ /+-P;1(R]LU#%.[4;W)W.J*BI[A-W
MCQ\76>A]!I7-TI0)=?\ ]O==O\<\-Y<?5@W;X(GR)(YB*].2G8
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MF^OKXYG5#T1%5KF\D3'8;;3&F[?INFD@MC7MCD5%=O*B]O8B=IN0
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MSULLE<V>9RN<K)&IS5?_ !\9*--V.ET_;6T-$Z5T+7*Y%E<BKQ\B(;0
M            :2@TS04.H:N\P=+W95-W9,JF[C*+P3'B3K-)>]FMDNMPFJWK
M4P/G_.MA>UK7^5-U2; #%M=!3VRABHZ*-(Z>/.ZU.K*JJ_6JF4
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MJ(O'BO:;$UNG+O2WVRT=QH9&/@GB:]-U<XRU%Q]9L@
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M1$WO,B(!G@
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M57+A$.$53!+$LL4T3XTYO:]%1/E [0=5/54]2CEIIXID:N%Z-Z.QYCM
M                 !U14\4,DCXV(U\BY<J=9V/<C&.>Y<-:F54B6E=817N_
M7.WHB-[G>K8G;R?E$17)P3'8GC/)MMR\U63+CI:M;3SGHEP /5H=5/3Q4S%;
M Q&-5<JB'RLJ(Z2EDGF<C8V)E54C6@M61ZEIJA7(C)HWJB,WD55;A..,)UJ>
M<6T\/FIMEQUR5I:?>GHE8 /5P
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MGN%TCGGKZQL$MHCA8KH8U5>_5Z)G"[J?HI[KGVW*U<M153"J@'T
M        ^.<C6JY>"(F5 UMNLE';[C65M,Q6SU:JZ5=Y5RN<]:FS(?IK64-W
MU%<+;P:D+E2)RN3O\*O),=B>,F [R<GO3.ZC37Q7IOAZ;S]_$ .NIGCIH'S3
M.1L;$RY5ZD"_HP+)9*.S=T=PL5G3NWWY<JY7Y5\9LR):'U;'J.:NA5$9) [#
M4WD57-[<83Q$M'>3D]Z9W4::V*V.)P_"  +P
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M8MG[DNL5>YS:FG:]\.ZJ(N\W*=?5E2PB6+?ACB:.S^]]GK&:.<?^@ !8V@
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M[;[[>FW^=UGQO22-KV\G(BH<@U$:B(U$1$Y(@-3Z$
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MM5V>Y1U%P;2UT[Y$66KF<US]W/)N<JF$1.2]1;J9PF>8
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M2TVM1C4:U$:U."(B81"G3UF*N;V)AMCP<4VWB?#R\'T &AV@
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MJM:B?@98![').L16-H  'H
M
M!A45KHZ*JJ:BEIXHIJAV]*]K$17KE5RJHG'BJ\S+E>V*-SWKAK455(GIC5*7
M.^5U'(Y$8CEZ#@O?(BK^"(1FT1,1*W'I;9JVR1&_"EP )*A4RBHO)3#M=LH[
M7"^*@IXH(W.WE;&Q&HJXQG@GB,P#9Y-8F=_$  >@
M
M              %5$157D@&%1VNCHZNHJJ:GBCGJ%S*]K$17KG/%43*F::.T
M:AI[C=:RBC5-Z!51%^%Q5/P-X1K,3').^"<$\%HV\?N  D@PK;:Z.V]-W#3Q
M0]*[>?N,1N\O:N$,T 1&SRM8K&T  #T
M                                                           (
M;M*O'<5K[CB<J33XSXF\?Q0F17&O]-U4JUEWDJ(UCB:FZS*YQGER\95FF8I.
MSH=EUQSJ*][.T?O/@V>S.\K6VYU%*J=+3IWJ8YM[?.I-"M]"::JXNX[M#4QM
MCE3+F97*MSQ3EXBR!AF>'F][4KBC46G%/*?TGQ  6N<
M
M                           BVT*OFI;0D-*F99U5/(B8S]I5=GDJJ2XL
MFID5)(G=]CJ3DI?JHB\T(EI*U5=%J&_5%5 K(:B971.7])-]R_8J&;+CFUXG
M=W.S]?3!I[TFL<O7KO.W[)-0U"55'!.B*U)&(_"]64R=X!I<2=IGD  /
M
M                                 T.M+MZTV621J_E7]ZQ,>-,_4IOC
M&K:"EKD:E7"V5&\M[J(VB9C:%N"U*9(MDC>(479;C+;[M#6,7+VNRN>O/#\2
M^*.HCJZ:.>!V]&],M7M(!I.U4DVJ[_%/3,=#'(J1M7DG?J6!3PQT\+8H6(R-
MJ81J=13IZS6)=;MK/CRWK$1M,1'VF-W8 #0X@
M
M          &'>*!ESML]'*]6,E3"N3FG'/X&8#R8WY)5M-)BU>L,2T4++9;8
M*.-RO9"W=1R\UXF6 >Q&W(M:;3-IZR  (@
M
M                JHB*JKA$.FGJH*G?[GFCEW%W7;CD7=7L4#N
M.BGK*:I>]E//%*YBX<C'(JM\H'>
M
M  #XC6HJJB(BKS7!]
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MZ/.>\[Y>*(OG\9NME5IK8Z^Z5UPAK&1.E5*9:S?Z3<YIG>X\EZ^O(%E
M
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MD[AGH*B33CIUC>UK']WOG5BY3+DCPN,*G5R+Q@DZ2)C\*U7-1RM7FF0;.8
M
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M(I)HFR.8BYW55,JAE&/;7POM]*ZESW.Z)JQYY[N.'U&0
M
M     /CVM>QS'HCFN3"HO)4/H B,VSVPRSR/Z"5C)7;[XF2JUCESGW*<.9L5
MTK:^[Z"K2!624,:Q0;CL(UJM5JICR*IO0!#EV=6-:J6H:E;'-(N7.BJ7LSY<
M*9UVT=:[JE,ZLCD6>G:C(Y6R*UR(F>&>?Z2DC $=L>C[58[I+<+;$^.IECZ)
M[G/5R*W*+R\J(<+=HNSV^6M=2PR-CK(W131*]58Y%QGO>2<B2@"')LYL'0=
ML50L".WFL6=V&KSX(;:335ODNE+<7L>M92LW(G;RX1.'5U\D-V -%#I:W0W:
MIN<<;TK*ENY*[?7"IA47AU<U,9-$V=M'64K89.@JY.EF3I%RKMY7<%ZN*DF
M%<ZNTP^2NM;J1E1!#1PI#%+!,K9,-141-Y.*</M4S](T%VHJI\M8^K9$K41D
M$]4M0KDX\=Y5X?[$W4$.&=^J[O*\.W#S_,3EQY@ FI
M
M                          %3*87D=<L,<K-R1J.;V*G([ 'L3,=&M99J
M.-N88(HY$55:YC$;A?D,^%BL8B*N5ZU.8/(B(>S:9C:0 'J(
M
M                          .,C$>QS'<E3"FBI--PQU<DDBIT*KE(F)NM
M=G.=Y$X.^4WX/)K$]4ZWFN^SC%&R*-L<36L8U$:UK4PB(G4B'( ]0
M
(       !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g109079g00v04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00v04.jpg
M_]C_X  02D9)1@ ! 0$ O@"^  #_[1Q24&AO=&]S:&]P(#,N,  X0DE-! 0
M    '#4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME-+P""138H*SX25C@[3"\2=#1Z+3)D1%9%:$XO(8_\0 &@$!  (# 0
M          $$ @,%!O_$ #D1 0 " @$# P$&! 8" @(#   ! @,1!!(A,043
M05$4(C)A<9$S4H&A%2-"L='P!L'A\21B0W*"_]H # ,!  (1 Q$ /P#ZI
M                                     +9/B7%L^*QU 8.K:G9Z18UK
MW4J\:%I22<ZDDVEEX7+CS:(W'I.V.Z]=M_B3_A/#IJ7_ (:ZSU=[3_S8'R<6
M^/QZY8W,N=S.;;CVB*Q#ZX],[8W/X]M_B3_A"Z3MCL8\_;?XD_X3Y'XI-M\
MWX>.,X+/V'']95/\3RQ\0^N/3.V.7_YVW^)/^$>F=L=G\>V_Q)_PGR.LOEQ#
MRI8Y^$1P:>=RG_$\GTC^[ZY],_8[V>M_B3_A'IG;'>SMO\2?\)\CYPNU]2*-
M\&R?L%/.Y1_B>7Z0^N?3/V.2?^WK?XD_X3TL>D+9;4+^C:6>LT:ES6DH4X*$
M\R;Y+D?(<>?B)%T;Q_\ KW0<-K^N4_K&%N%2M9G<L\?J.2]XKJ'V+%91=U""
MPL<,%6<S\H=G\U0 2
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MLYSKJKD @
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M>SJQH6G?L]/ZJ*W)X\8=:^5WA<JW(ZNJ([-@ "HO@
M
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M^DC>4^&6TNMDCZ-OR\T']LI_26\N^B5+!_$J^QHI%W!%(E4<!ZI4
M
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MZOK%/K*]0PL X3TZL>0"Y
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MT_JHJ\[O%5_TN/O6U^38  YKL
M
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M/HV_+S0?VRG])GD_ARUX/XE?U?9$2J*1*HX+U0
M                                                 #F'](C\@)?M
M-/[3YC:SPRTFN?8?3G](C\@)?M-/[3YC.MPOX;A>H_Q8_1M-F-;NM UFAJ-F
M]RI3?&*?":['V\CICZ5=#E?K4*NREO/4EB7FK%/?<EP3SNY^<X_V@WWPUR=Y
M5,6>^*-5=#T'I*KV6V-UKE_;SNE6HNC&DI[O<TY1?#.?U?G-A?\ 2#LM>4ZL
MI[&VO=ZG.HXTW)>_N9.5CJ(^SUWU,HY62L:EU/2.DG1Z&S6G:1JVSD-1C9PW
M5.LX26>/%*47@C.V^T>CZY3MXZ1H-'2YTWF4J:@MY<>'>Q1$WS'4*X*TG<%^
M3;)7IE3QDYZ$OSG:+_Q?\F9!R<="?YSM%_XW^34)Y'\.3C=LU?U?6?44*]10
MX3TT*KD N0
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M\++;ZC[:V=_$>G_LU+ZJ,.?.XJQ]+[39L0 <UV
M
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M[BL"6 ,KM!J;@ 9
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MN ,KM&>( #(7'D
M                   #65A\@ -"]CMG&_Q%I?[I3\A7T';.>P.E_NE/R&]3
M3Y,&75/U8]%?HT"V-V;]@=+_ '2GY"[T'[.8_$.E_NE/R&]&2.J?J=%?HT*V
M-V;7_P"!TOQ^9*?D'H.V<]@M+_=*?D-\&TN;'5/U.BOT:!;&;-KEH.E_NE/R
M%?0=LWP_V#I?#_\ 4I^0WPRNU$]4_4Z*_1H5L;LXI9\XM,S^RT_(;RG3C2A&
M%.*C"*PHI821=E=H(F9GRF*Q7P  A(
M
M               ^7 IG/+F!CW]Y;V%O4N;NK"E0@LRG.2BE[[-?L_M%IFOT
M9U-(O:-S"$MUNE.,\? WVG,OZ2&N5:&AVNB6%1J[OZJ3C'B]W$GG'CBB&=$\
M:_1OTA^AV\K.%M?4U-.?++?:_:@?3"?7G@6\FV<ZZ6ND"XV'CILZ%G&YC<5-
MR2;:?*7)8\!#[[I@VATC4K6MK6SZMM&NWBG5EO)\GVQ76NT#M]S<T+1;UQ7I
M4D^"[I-1SXLF#KFT&FZ)0IU-1NJ5"G4:C"4IQ66VDN;7:?/?](;7]8GM-H<;
M*C55A)*I0<)27=GE\'CQ(EG2%KSI[#Z#=;2Z!3JW=2M3BZ$ZDXJ'&''ACM^8
M#M-M5A<4(5J4HSIU$I1G%Y37:>CPN'$UFS]Q1GHEA.FH483HQE&GO>I6.2(5
MTI])/H3J6>GZ9;*^U:\RJ5%/F\Q[,_K=@$SUG:#3M&G;QU&ZI4)5Y[E.,IQ3
MD\I=;7:C:4Y1J0C.#3C)*2>>:/EGI+VCUS5]2V9MMI-'EIMTKNG*+Q+=DG.&
M>+2ZL?"=,VWZ2+W0+[2=!T*SHW.HW%"+S6GN1BL1Z\/M ZWGGR6/"135=O\
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M8C1:Y/&'P^.SZ"Z%]IX[3;%VE=S4JU&*IU%UYPG]H$\!3//)4
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MC7KZ=5C4C<TVFY**SS7M4=(V#U3SZV2TR_SF56BMY^%<'] &^
M                                                    !1M(ME)8
M>\U''-LN>#4;4T;FYT"\I6$FKJ26YCGZI9^;(&CU?I+V5TR\E:7.KVJJIX;C
M7IX3^,232-5LM7LU<Z;=4;FD^&_3FI+EGJ;[4?*&PFH[)Z);7>E=(FC5H:DZ
MCWKBM&;ER2ZVL<4SL?0[I.A:#::IJ&@[1N_TRHW5=&4XM45A/'JGU8 ZUG'/
M+?@,34]0MM-LZEU?5J=*C3692G)127OG&M0Z6MHM2U*]6QV@>>&G6<G&I6[[
MB\]6(OP=9F[1[4RVMZ&-8O:UG5L[FG!0JTIP:W7O1Y9]\#J^D:E:ZK84KRPK
M0K6U59C.$E)/WT6:OJ]AHUOYHU.ZHVU%O"E5FHKYVB%]!,HPZ+]$WG&/W-8R
M_ B4[2;/:7M19*TU>DKBC&3>%-QQ[Z:[ -='I#V6DWNZ[IKSU^:J?\1M[K:#
M2K32XZC=7]I2LI1WHU9UHQC+'8V\,^=-L-A]GK[I$TW9C9?3G24*D97E6-6<
M]V*<6^;?5O&TZ1K.C<=(>R.QSW_.BE4C&5)2>)_>LYXY_2?P@=TT/:32=>A.
M6D:A:7:CZI4JT9M? V;B/7V'SG7L:&PW3CIEAH*=K8WJIPJ45)M/,J2;XY[7
M\)]&0XKAR J
M                                  !27#M J"U9QQ9580%0
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M4>&<LN7(ISXLJN0                    "W'/'#P@7 I%8*@
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M,XR!<"G!,J            %&LOPE%G.'@"X   6\"X
M    H_G--M5/4:6@W,]&497J2W/C+/4^K)N@!\YZ-TF[+ZKH=:UZ1K*,-6IM
MQJ1G3C!O@NM.+YY-3T+:7<:GJ.U%;1*%:WT6M3J0I1J)X;QF..?4X]9]$7^R
M^C:A6[K>6%.I4[<M?0S86EG;65%4;6E&E37)(#YRZ)MM=,Z/K?6])VHWK>^C
M7E*,'%?=%A+K:ZTR5ZYM0]K>A_7M06E>=]OA*EGAW5;R[[EV8^$ZMJ&S^EZE
M7C6O+.G5JQY2XKZ#+G8VT[3S)*C%V^-W<7+ '%=E=D+C;+H8T"TL]4J:=.FM
M[NE-9SZGAS\!,>CW8ZYV#T;57>:O6U%SAW12J+&[NJ3[7VD]M;:E:6\*-O!0
MI1X**+Y4XSIRA-;T9<&@.)] =O#5=>VHV@KXG6E>2A"4GQ45*HOH2,#IGHSV
M>Z3-G=JJ].IYVTJOW:I&.5#'<N/'A^BSNEC86]C"<;6BJ:F\M+M*WME;WUO*
MWNZ*JTI+#3ZP/GJVOZ72)TUZ?JFA1J5=/L8TYU*KCPX2I-\L_JL^CHK"P8&E
MZ79:73<+*WA13[,\3/76P*@                          "G!A\,+.&!4
M%JYXXY[2Y<@
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MQT+Q=TJ?P%<])3_1T%?\2I_ =&X]J '.?_$IO.[H/B[I4_@*_P#B4N4-!?\
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M3]XN7(HN94
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MU:H$^14HBH
M " ]+?X%IG[5'Z43X@/2W^!:9^U1^E 3BT_!:/N<?H*UFU1J.+P\%+3\%H^Y
MQ^@]&LIIK.>8&GV=JU:MJ^[2;DI?:S%VGMZE%TM1ME]UI/OE'K6'_H;VE1IT
M4U3BHKP%:D%.DXXWHRYID3&VS%D]NW4\K&YA=VL*U+C":R9$>TC6CSEIE_6T
M^L\0F]ZG_/PDD4L<'S,:3N.Z<U.BW;Q\+T5+4WUX]XJC-J$UDJ47,J
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M5IB<=^J/$M<_=G?PF"]4T7'C3K1EC#66>RXHL1.VQ7(P4ZRJ)!
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M%4\FA97+D N0)
M            4ZB [0_G3T#W&?U:I/NH@.T/YT] ]QG]6J!/D5*(J
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M\677N,OH9DF-J7XLNO<9?0P(=T2?BC4/VRI]A.B"]$GXHU#]LJ?83H
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M4L+ 7S'9=)>N0"Y D
M        (3TO_D=6]T7U9$V(3TO_ )'5O=%]60$LTO\  *'M491BZ7^ 4/:H
MR@           \-0_ +GW*7T,A'1%^ :E[O+_,J$WU#\ N?<I?0R$=$7X!J7
MN\O\RH!/,_2:"\K5EM);TX3E&DX]\NI\4;_/>GG*G1[HI3C!U.IO&4#Y7KU3
MR^!&MJ_ZK=V=]%8=.6'\#)/U> UFT%MYJTRM3:SV&S%.KPT\BO5CG\N[-MZB
MJTHSYY1ZYQU&EV3NE6TNG!O[K3S&2]__ +&[7$QO7IF89X[==(LK'B@ 8PS
M                                                         !3J
M(#M#^=/0/<9_5JD^ZB [0_G3T#W&?U:H$^14HBH !\BBX("H*%'R'<7 \XY+
MEX"!<"CP5)@  !K-H];T_9W1[G5-9N/,UA;[O=*NY*>[O245PBF^;2Y=9?H6
MJ6>M:7;ZAIE;N]G<052E447'>3Y<&DU[Z(-_2*>.A_:!^X?Y],P_Z->H.^Z-
M:,92R[:M*@EV)1AY3+7;;'J[Z=5!0JN1BR                        "F
M[PP5 $3Z0-"N];H64+-0;I55.6\TN":?V&EVHV8UAZT]0T94ZG=Z7<JT:DDL
M9364\_WF=%EXLEO+PX YE=;$ZGIMGIU;1Y4ZU[1A*-6$VE&6]%)]?5Q/.>PF
MIVNF6E>RE2GJ=*NZ\X/"B\M/&<^ ZE]'@'+@@(IL)H5UI<+^YU3<\V7U3NDH
M1PU#C+@G[YH^E+3K*WM]-K6]K0IUI74<S4$F^*ZSH^%)\5XNT@72U^ Z7^U1
M^E 3FS6+6CA+U$?H*U_O$WU[KY"T_!:/N<?H/3@EQQCK T^S,ZDK2?==[.]^
MD_"S;];+*>XH_<=W=_NEZXH#$O["E?6LZ-QB49=J(94Z/*$7*4+N6ZGE1<,X
M^<GDL\^HHN/+D86Q5M.Y6,'+RX(F,<ZA']E*T+>G4T^=-4ZM)YPN&\N'$D#Q
M)+AGQFAVALJRW=0L8XNJ7#A^FGPX_"S9Z5>POK2-6FUG&)+L?8*QT_=,T>Y_
MFQ\^?U9E/+><\#T/.GE/"]2>AFK@
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M(8\FX^]Y@K??GRSXO,4\8*E(-.*QR*F]D
M                        0GI?_(ZM[HOJR)L0GI?_ ".K>Z+ZL@)9I?X!
M0]JC*,72_P  H>U1E           !X:A^ 7/N4OH9!^B/\7ZE[O+_,J$XU#\
M N?<I?0R$=$7X!J7N\O\RH!/'S781Z]E5]$UNMZIW+=Y+..:)#SB><E2=1*6
MYW7JSC('HLK+?(MG'?6[))IEZ*9P^8$5T+-GM!>VC?>2BYQZE^BB4QX(BVTM
M-V>I6U_#@MY1D_A\A*4T\<3=F[ZO]57C?=ZL<_$_[KUR 0-*T
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M_/IG)?Z-M?SGVOA9R?XTLZ=5+WJC_P"DV5C=9:;3J\/J/J""!K;@
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M?9*1>L[AOF^..KM$7A\9%4DHM,HE%M<'P++CO0
M                               ,;4OQ9=>XR^AF28VI?BRZ]QE]# AW
M1)^*-0_;*GV$Z(+T2?BC4/VRI]A.@           I^B<Z_\ 5FG^SOZ9'1?T
M3G7_ *LT_P!G?UI =%9J-HXU'9_<M[>RO4^-&W[3SJR@HONCBE_>> :66K_J
MU/*[[=6<^(A>U]J[/6[+4*2Q"<MVICES7/X2;\.#BUCP&IVIM5=Z553YP6^O
M>X_85>53JQ]OAOX^2<=XEM:<E4HQE%\&DTRY/#2?')JMEKM7>BVSZX04'XTL
M&VW>^1OQVZZQ9JO7IF87@ S8A8\8?!91>6<\H".;<:C:66D5'=454W^$?'A^
M0XM5O[NI757S1456'&#WFW$[YK>E6^JV4[:XCF,N"?8<4U;9F_T[4?,U.E.I
MO>HJ*+:2\)QN?2_5U1X<WG4R3,35T;8#:CSUI>9+AMW,$VYYRF33+RB']'.F
M6=KIBK48_=Y-J;?-$QBN3.CQ9O.*)OY7<'5[<=2J?$N7(HBJ-\-H "0
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M]S-6?YNW[>$MCR 7(&E:
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MUGS#V!C4;JG5DXTZL9-<TGD]U+/#K)CNB8TN!:F^MC/P!"X!/*
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M\>/(US&IF);:6BU8M"\%N6TBXAD
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MV I'"EQYLJD^OD7' VO7(!<N
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M&XLY.5)\.)AAY-,LS&^\,:9:W[0V2QC)0HF^KD7%CPV" 0)
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M8/*!6*PC5"P
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M2VVHQMZ$8)N276SJTFTQ]YX;/7'6VL<[>X+8=>.1<9M+F_\ 2*_,_M!_P/\
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MC<*Y&]VCD&LF23(R$N' H@*YXE<EO7D-I$BN7V!/M*1>2H%0
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M=NWWU";A[V$;I^]C_16B.C/_ /VC_9(3T7(MY+B7+D:(60 $@
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M4O%O17VG=M/N8WEE1N(>IJQ4E[YCECNRX\_=TR  :E@
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MM.C86!A 1G8O0:NB6]W4O:\:UW=3[K6E!8CG+?!<^LTO2RWYATQ\OZU#Z4=
MPB =+?X'IG[5#Z4!-K1_U2CC]1?0:G:V_J6>C5ITN#PUGWF;>U7]5HOJW(_0
M8VKV5*^L:M"O][<7EXY&-HF:]FS#-:WB;^'#:E3?GOIM3SG/A.H]'6HU[[3.
MYW''<;Q)>/\ U(K2V-N+JJ_,]92H.6-['+YR4;.);.S>G74%%2XQK<E+^?L*
MF*MZ7ZK>'H>?EX^7CQCPSN8^&^UO2X:M92MJLY1B_P!4C'I=6G!>:;EQ\$H^
M0G*>>*:Q])2.<OCP,\O#PYIZKUW+S^//?'&JSJ&LT;2*>F:=YCC.=2#>>^_[
M> CVH;^R=S*XH8EIU5[TX/\ 0EVK'O=I.(I8.:=*EOJ4^YSHN4K**[Z$?'X_
M$89ZQAP_<CQX_)5Y%YBLW^7KI?2'&XUKN%:G"%I)M1J)//7A_1U$_MZ\+BFI
MTI;T7Q3/FV*2;:6'D[%T92NWI,E=5MZ&>\BWEI8\96X7+O>W1?NJ<3DVRVFM
MTVCR>2KYHLBWXRN>1UG07@                    +<98_2QU%4@(&EVCT6
MGK-EW*I+=J1>8OL?$A]ML!<>:4KBO'N">>]YLZ0UE<2L>1JMAI:>J5O#SLV&
MO12>S%M+>-I0A1I+O(K"R9745Q@HT;(B(\*LS,SN5L7P>>8DY8[U(N7%,(F$
M:[(EMCLP]94:UNVJ\5C&4D^/A\9'M(V$O%=PJ7K4*47EJ,E_J=.>,%(]9IMA
MI:VU_%ZEGQ8_:B>SPIVL*=.%)13A%862LK2BUQIH]\!+'6;=0H]4_5A^8+>:
M[ZC$\Y:18RYVT'[QL,X*IKL&H3%K1\M5+0--GZJU@>;V<TI<%9T^/@-UU%N,
MOL&HEE[MX^42U_96SK6%6.G6\:=REPQPZO"<S=A=TJKI=P?=.6#O&%GD62I4
M][/<XY[<&B_'K>=NAQ/5<O&K-9C:-;"Z.].TY.YABK/CS3X>\2CDUP> HQ2X
M)(;K_6-M*12-0H9LULUYO;Y:;6-G-/U2:G=0EO\ ;%KR&3I&D6NEPW+.GNI\
MV^;-C@K$F*Q$[T3FO->B9[*@ R:@QM2_%EU[C+Z&9)C:E^++KW&7T,"'=$GX
MHU#]LJ?83H@O1)^*-0_;*GV$Z TVU&L3T32JU]3LZEVJ?.%.2B_G/GW7*FR.
MUNTTM1O-HM;T;4)14.X*E)J/5ZKN37SG?ML]:KZ#H-UJ%K8SOJU*+<:$)8<O
M?.)ZETJWNJ4MS5>C:O=0?-5)QEPZ_P!$#H'1;LK9Z-4J75CM!>:K"HN$:]2+
MQX<**9TE<CD70QJ&RNKW-U<:+I$=&U.'>UK-1PX\_P"ZEU9]\Z[%80     !
M3]$YTOSLT_V=_6D=%_1.=?\ JS3_ &=_6D!T4UVNVM6[M.YT$G--/#\:\AL3
M'O;F%I3=6KZG@OG I&AFU5*KEY@HR^ BUK4EL]K4Z$E_4KJ3<&^.Z_>\:)?"
M2G34T^$EDUFT&F0U"QE!\)Q[Z+2XIKB:,V/<=5?,,;1.MPVD6FE)+/A/.K35
M6G.G/U,DT_$S2;*ZC.O;.VN6U<6[[G)-\6EP3]_!O7EI/K789X[1DC<)K;<;
MA![NS=K<3M'E-/NMO+PKBU\+1*=!NU>V,7)_=(=[->%</L,?:&R=S;*K27W>
MD]Z+7-X_[(TFD7DK6\I58O=H7$E"JNJ,\X\IA$=-M0Z4ZSXM_,)HL)X7,O/*
M+364\L]$\O!O<Y4%(YXY*@           #  %KQDNP"-Z'FX]:R:W7=*M]7L
M9V]W#*?)KFN9M7R+<<")K$]I)C<:<!UK9Z]TN_C:NFY1J/%*64\^!G2-AMD%
MI$5<WL<W;SAIIJ*\!,*EK1JSC*I2A)QY-H]L=G IX>%7%?K5<7#ICO-EX +R
MT                             !">E_\CJWNB^K(FQ">E_\ (ZM[HOJR
M E>F?@%'VJ,I<>9BZ9^ 4/:F5GCCJ U6TCA7T>[H>JE.&-Q346_A/F_934-3
MV=TUZ?+8*C>1A/[G5[K!-\%S[_QG<MN=F=&UFK;U-3U2OIMQ3X4JM&XC1EU]
M;1$H:3M#IDG+0MO;>[DN5#4*G=^'C[I% 3S8*\JWVSU&M6TQ:9-R:\S*2DEP
M76F_Y1)(YZ^PTNR575ZNCTY;0PHPOMYY5'&[C"[)/KSUFYAXWCP@7     /#
M4/P"Y]RE]#(1T1?@&I>[R_S*A-]0_ +GW*7T,A'1%^ :E[O+_,J 3QOFT:6[
MLJ\]?HW481="*PV^:Y&Z:SO)&)._I4[V%K+U<EE 9:7!\>#+BG:^PJ   %DO
M5<>1KM8M_-.FUZ+7?-</A_T-A.+>7O81">D&^U73W3N+&INV^,3X<N+\/B-N
M"DWO%8GNK<O+7#AM>T=OEO-E+MU]-A2E]\H_<W[R1NE%)G#+7:35;.=5V]>,
M7-[W#/'P\R<; :EJ^KU*E:]K-T(O"Y\>'C+?)X-\43>9[.=P?5<>:8PQ$[_]
M)YP"BM[(6,%6<]VI5BL9*E(E0
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M0A!2>&^.Y'P/KZSZ0/G"M=[0]*>V>C5GH572+"QEF<Z[<I/@^U1\!]'@
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M<!'D          ><<  !3B5 %L4\/>&&N1< &.!3OBH MC''(JT5 %FX-TO
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MLGG%M-M\4^1:FW/F:X;WME%<HMX? 50%0414 !@
M                      !3J(#M#^=/0/<9_5JD^ZB [0_G3T#W&?U:H$^1
M4HBH!K*+4L%P(%,%N>."X+Q$[-*8#17)3(%J3RST+2X   .;_P!(K\SVT'_
M_P"8IGCT6?FZV=_8J?T'M_2*_,]M!_P/^8IGCT6?FZV=_8J?T%C%X5<_E*'S
M.2;5UO.7IPT'5'WD*]NZ&\NMXDO^HZVSD'3_ $I4*^S&I4N$K>Z:G)=CE!>4
MV6\--)U+Z"CQR^HN:X&-IES&[TZWN8>IK4XU%XFLF4N13^70\P(  <<Z/MM*
M=A=;2SVDU6XG2IW2C0C5G.JTLSSB/%I<%\QT;0]HM,VDM;AZ+>*INK=;W7!P
M;Z\/#.3]%&E:?J.U.T$M0LZ-RH5I;D:L%+]*7;XC-Z%J<:&U>MTJ6%2C%M12
MPN:Z@)'T:W5+N^J;VT574E"K+>555(*ECJS/AP\!LKKI'V:H=T3O:LW%[K<;
M>HTO\2C@Y[T;JE5M=K85YNG3DZV])1RXK[35[.6>H7>RUQ96U#270NGA7->O
M3C52R^.&\Y FFU&V%WK&P%[J6FT[K3'&JH4ZD:K3FNMIK'7P]XSMG>D+1++9
M[3J>LZG.=ZZ>:DI0G5><OG))\34;5:4]$Z(%8JYC<SI/#G&2<5F3?>\7CGVF
M'#0-+CT'SO\ S#;^;/,W=.[]S3GO;^,YQGD!UMZO8QTM:A.Y@K1Q4NZM\,$?
MH])&S%6M&E#4)9D\*3H5%%_XL8.9:M4N9=#M@H5:CI]TBJG%^HQR?@S@PZFS
M%GZ$+>^NMH[.A9R2:A3L]Z<'E=2GG/+J [AKNTNE:'0MZ^I72IT:[Q3G&+FI
M<NN*?:BW0MJ-)UVZN;?2[KN]6W6:BW))+CCFUA\NHY)TA4TM@MF(0NYW=+E&
MK*#I[T<0YQ;9U38G2-/T[1K2M8V="C5KV]-U*D(*,IO"?%]8$A  'E7C)TYJ
MG+=DUP>.LXSJFR_2?6U*O.SVE=.WE+O(]S6$L>Z':GG/+@.OK XUL_LQTEVV
MK6U34]I'6M%+OX=S7%<?]XSLQ1+CG/#LP5      ! .ES\"TS]JA]*)^0#I<
M_ M,_:H?2@)Q:?@M'VD?H-1M5HT=7TVI2[G"=5KO6TN#X]IM[1?U6C[1?075
M)*,6WGAQX&O)CC)6:3X/,=W#-0V7U:&JQM/,TI-\I+U./'RZR9;.:;>;)0E4
MN+:-:E/U52"3E'X,OJ)KIUW3OZ?=8P2<7CCS,V4(RX.*:\*X%*.!6MNNMIW\
M-6'!3'>;Q'EI[FA:;0:;*GOQG!]:XX9!7L#?*M+%1;G;PX_.;O;&RJ:7:U+W
M3*\K?]:G!X7TX^8@_H@U5M-ZA5\3*G*Y]<-^G-3O]7<X63-CI/LV[?FZ1LA.
M%C;2TZ5-4[B#SN\M]=J_GJ).WSP^1!='H7.J;/4[ZG4;OJ<L0GUM<.'SLE&B
MZC&^H/?CN7%/A.#?%,ZG&R1:D3'RJ<FLWF<D=^_=LH2S'F$O?*K&>2QVEW!&
M]3:O7=)MM6LZE&YIQFVN];7+^<$%T#8"5'5IU;[%2WA/,(M+EE^'CU'3$_ '
MP7 T9.-CR6BUH[M5\-+VBTQX8ZM*'<U25.+A%<(M<$<_V]V.C.%2^TVFH3BG
M*I&*7??SQ.D8X>$LJ14UAI-/FFLIDYL%<M>F4Y,5<E9K+YZTW3+J^J25*A4D
MJ?JUC&$=HV-\Q0TN%*P:W5PDNM/+SGYS;V]C:V\INC;TH.7JFHKB1S5])N-/
MN//#1DU+_P RA%84U]&>'85,/&GB_?\ +1@XT<>-QW2M/"?@+GR;1I-+UVUN
M+.56M4C1G3^^0J2Q*+\3/?2-<L=54W95H3<><=Y9^ NQEI.HB?*U%HEM8\BI
M2+6"N5VFU(                                          !C:E^++K
MW&7T,R3&U+\677N,OH8$.Z)/Q1J'[94^PG1!>B3\4:A^V5/L)T!!^F'2+_6M
MB+^STJAW6[DLPCE+>?'M.%ZOI/2=JD]#=SLU;SCI;BZ2E5IM2W7'FFO[J/JI
M975\X:?# '/.C35=M+ZXJPVMTBC84(+%/N<XRZO CHL>"+</JY%T>0 MZ\ES
MY,MX]?+LP!R[;*YUS1]3H7,=7J8JU53IT.YN-/=PVVY;V,Y77VGCM-K.L7NJ
M:K.PU"=I0TVG&:A#+51MQ7--?K>'D9^T.RNTNJW%6UG?T:FGU)J:G*E'>I\,
M87'/SHLU[8C5I7UP]%N(0M+N"A751)M)-/AE]L4!*]/VBI^A6VU:]C4<:D-Y
MJE3E-\\<DLD(T#6K;6^E%5[-5E35%K[K2E3?.75))]9TC2=,I6.DT+&.)0HQ
MW,M<'QSR(11IPI=+$%3IPIIT'PCPSQD!T=\C7ZU9RO;=4X/CGL\*-@^1BZA>
M1LJ7=))M9QP\8'M;T^YV\(/G&*7P'HN"X%E*HITHS2]4D\,NSPX$#"U73Z&H
MVM2A<P4XS6.)S6IT?7%M<W%Q&HG0I/NE.FXI\LO',ZMCB6R7!J2RFL%?-QJ9
MN\^6N^&F2=VAI]EM0I7FGPC"*ISI=[*"X8ZN7O&'MW95KK0ZO<$VXIR:76ED
MQ-0530M:A=TH-6E=J%5)82?##^DEE.<*]&,HN,H26>U-#'/76<=O,-W&S3BO
M%OF' MR4'C=:EV-<3H.S.SUW3TE7-*4[:\WLQX\)+CP:RO ;W:72;7S'.O;V
MU)5X=]E01MM-K1N[.E5IR6[C&%UX>#'%@Z;=Y=SF>J6SXHZ(UORPM(UCNDG;
M7R5"[CP:?Z7A1M'<6].HH2K0C-]3DDS1[9T:5/2:ETZ?W>'J91X-<'UG)I7E
MS.<JD[FK*ICA)U'P)R9IQ3KRT<7TZ.;$WK.G>\XZ^':7)K'!D,Z.M3K7UA4H
MW$YSE3>-Z4LOJ\I,*>&BQ6W5&W.Y&"<&2<<_#UZBD>7$)X$>1DTJ@97:,H
M                          &5VC( !//(               A/2_^1U;W
M1?5D38A/2_\ D=6]T7U9 2O3/P"A[5&4^:,;2_P"A[5&2N0'#.FRKI4-O=EU
MM(Z3TI2;J*M%2@^$^:?!G.]'MMA=3Z0-4\\-5HVNSE-*5*SIO<HU)82SNII?
M-U'TUM)LIHVT<J;UK3Z-VJ?&/=(YQS\K-(^BK8W/#0;3APSN(#?[+5M(KZ-1
MEL[YG6GKA#S/%*/P+WC<QX-K/SF!HNDV>BV4;/3+:%O:QY0@L+^>",^"7'[0
M*@#*[4  &0/#4/P"Y]RE]#(1T1?@&I>[R_S*A-]0_ +GW*7T,A'1%^ :E[O+
M_,J 3S'!>,U-SITZNM4KO*W(+'+Q>0V^>"\>#7UM2A2U*%FXMRFLY0&PZN',
MJ4_G!4   *,HTLYZRO6Q'PHCN+=U=84>]X%WO%J3SUH"S=XO'/K-'K&@4KB4
MKBSS0O$\]TAPR_#RR;[=>>ORE&FT\Y^ RK::3NK"^.N2.FT;1K3=<JVE5V>M
MI4G'$85>J?5[W5U]9)*<H3BITVG%K*>>HQ+VPH7E*5.XHP:[7'+\9$;^\N]E
M*F^^ZW>GODFVMQ>/CV_,;8I&:=4\JULMN+&\G>OU^GZIYP:X"/!'/8])-JHO
M^I5./^\__P 3:[/;90UB^5K1LJL7C,I[SDDLKGP\)G?AYJ5ZK5[0PQ^I\7+:
M*4ON9_*4OSG."I2+XM=@ZBLOJ@HFL\RH  9
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M8F-P]')(MEEI./(1RUEK#["JY)/@(2O
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MEXF9QC:E^++KW&7T,"&=$$8PT6^A!8C&[FDG[Q/""]$GXHU#]LJ?83H
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M,S]K)_+/[-?VC#_/'[PW +*33@G%Y3XIEW(UMRH+6WV#/;P N!Y9>\\#,EU
M>H+8/)<                      4ZB [0_G3T#W&?U:I/NH@.T/YT] ]QG
M]6J!/D5*(J!27!%%Q1< &"F$5*,@@PAUEJ;SQ7OE?G J5*/GXBI,   .;_TB
MOS/;0?\  _YBF>/19^;K9W]BI_0>W](K\SVT'_ _YBF>/19^;K9W]BI_06,7
MA5S^4H8ZO &57+P&U6<<VID]'Z>-G-3Y*YC*APZ^]W?^L^ASY]Z=[?N.I;)Z
MG'U-I=[TGXZE+R'>=,N%=Z=;7"Y5:<:B]]9*^7SM;X\]M,I I'K*FI86M93[
M#GFL=&-O>:U4U#3M3K:<JB6_3I0<E+"6>.]X#HH @>R?1[;[.;3UM6MKZI4A
M4I.GW"<.6=W,M]R;?&/+PGGM%T;6NI:I4O\ 3[ZKI=Q4^^3I)RWOADEU(Z
M(CL5L5:;,U*]>-:=U>55NRKU$TVN'#&6NI&DO.C)RO*L]+UVYT^C4>9484^Z
M+X92SV'20!%MG=B],T30Z^F4J?=*5=YJ-Y3D\+POL1%JG1-32J4;/7+FULIO
M+MHTW*.?&Y9ZD=2 &IV;T6VT#2Z-A91Q2@N,N/?2QC/%OL1M8KBRH
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M>XR^AF28VI?BRZ]QE]# AW1)^*-0_;*GV$Z(+T2?BC4/VRI]A.@
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MDL$,Z7/R,J^Z+ZLB:)$+Z7?R-K>Z+ZLC*$I;I?X!0]JC*,72_P  H>U1E$@
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M.2\:BW]A@_T=+[S3T;6=*;S5MYSIR79B32^@TY8[+'&GO+J$7DJ(\@:%L
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M/>(=ZC/)<\]IX6=7?MH3D^+YGMR? MPX,QJ=+LOEUB&<<7D"/("H  8&  &
M                             /D!U 4RP4SV#.>*("3?4>&I?BRZ]QE]
M#/?/8>&I?BRZ]QE]#)$.Z)/Q1J'[94^PG1!>B3\4:A^V5/L)T       !D!U
ME$GAY?$U]_K-A97="VN;B$*]9[M.#YR?\HQ=5VGTC2[R%K?WE.C7GRA)/+^
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M&>N7OFHN-0JPUJE:14>YR67V]0&W2YHN+4\Y6."+@
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M.;M-27<;N+QQY2\*?+M-YG*X8\IE%MM5\<TG4KH+!<64^OM+R6
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M<^9@:1>4[ZRA7I<^4EV,SUX"W2T6CJCY:IC7:5RY +D#)
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M*9*CE7]&R\=?HYI6]1_=K:M.G)=F)-+Z#JI3M&I="L[@ !#(
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M1:LTG4J[W'D5*8*FQB                                        #
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MGHLT#V:T[]ZI^4>BS0/9K3OWJGY0-V#2>BS0/9K3OWJGY1Z+- ]FM._>J?E
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M3L[[$VOQ$6/8K9WAC2;5I_W%@DHPL8 P]*TZTTRV\SV%"G0H)Y4(+",P)8Y
M           +7RQGWS4:GLYI.J5U5OK"WKU(\%.<4VN?E-SA# $;]!.SG)Z5
M:\/[B(]MQL'I]QI6[I.DV_=U*+>[''#>CGYLG1<(Y[MMKNKK:&AI6AW,;:?<
MY5)U)1C)<%)XXI_JM>^!M].V'T&%E;QK:3;=T5.*EF.>..)D^@G9WV)M?B(K
ML)K-76]!IW%RON\).G4?##DL9:PNTD($$VNV%TFKH5S#3-)M_-;C]SW88>3V
MV>V%T6GI%I"^TFW\TJE'NC<<]]CB9FW^L:CI.D5IZ5:U*U9P;[HEWM/'6^#_
M )1E[$WUSJ.S-C<WM3?N*D<SEA+C[P'GZ"=G?8FU^(C US8;0ZFD7L+32;;S
M2Z,^YXAQWL/&/?)B:':[SXE9QAH=2G1J2>)5IX?<UURPTT\<P(_L=L)I=+9R
MSAJFDT'>IS[IOQX^KECYL&\]!.SOL3:_$1INCG7-2U"XU&SU.NKSS*TE=0C%
M1GG.?4I+P>\3L".^@G9WV)M?B(>@G9WV)M?B(D0 COH)V=]B;7XB+9[$[.[D
ML:3;9Q^HB1YXM<CPO;JG:6M2O6DHTX++;8'-]BM@K6C=ZI/5]*HN#K/N._#/
M>\.65XR6QV)V>:XZ3:Y]HB,;$[5ZEK6U]]1K[U/3U!NC3E%9Y\'G&?G.DPSA
MYY@1[T$[.^Q-K\1#T$[.^Q-K\1$B $=]!.SOL3:_$0]!.SOL3:_$1(@!'?03
ML[[$VOQ$/03L[[$VOQ$2( 1WT$[.^Q-K\1#T$[.^Q-K\1$B $=]!.SOL3:_$
M13T$[/>Q%K\1$C?(M7%^ #FNUFP%E6U329:;I-!48U?N^ZL+=Q+G[^"3^@G9
MW=_%%KPY9@0C;?:_6-/V@K6]&_C9TZ:^YT7"$N[/AUR65U\NPZAI=Q4NK&E7
MKT^YU)KC#.<<0-3Z"=G?8FU^(AZ"=G?8FU^(B1 ".^@G9WV)M?B(>@G9WV)M
M?B(D0 COH)V=]B;7XB'H)V=]B;7XB)$ ([Z"=G?8FU^(AZ"=G?8FU^(B1 ".
M^@G9WV)M?B(H]B=GL<-(M7_@1(RDO FP(EJNP^ARTZX5MI-MW5TWNX@N9J-A
M=A-/M]GZ$=8TFW=YO3WNZ1XXWY8Y^#!2XVFUI[=6>GSH3M-.G/=6]%/NG&/;
M'/;R9C[;:MM/H]:M?1O:%O9PE&%*UW82=9[N>#<<]3Y 2N.Q.SS7'2;7WJ:*
M^@G9WV)M?B(V^E5YW-C0K5H2A4G!-Q:Y&6!'?03L[[$VOQ$/03L[[$VOQ$2(
M 1WT$[.^Q-K\1#T$[.^Q-K\1$B $=]!.SOL3:_$0]!.SOL3:_$1(@!'?03L[
M[$VOQ$/03L[[$VOQ$2( 1KT$[.K>?G3:X\,$1BKL'8^CB-6.DT?.ON./4][O
M=[_J2/;_ %C4=(T6O/2+2=:NH2DZF.%/"SGDU_V(Q?[:7NG[$6%U5K1\WWE1
MTE6DHI0;;6<8P\<.H"6>@G9[OO\ 9%K\1%8[&;/0E"4=(M=Z+S][1KNCK5;[
M4;:MYOU.AJ&ZUW\%"+CX,11,UB2R!;3BH+=CA+L747C"            6S2:
M:DLKECM(_5V,V?J5)U)Z7:RJ3>]-N"RR1#" C7H*V>2[[2K7&?U$1._V M9;
M;VM>CI5#SLC#O\1X9[WP>,Z=.6[3E)K.%R1R>]VJU[S7=ZI0NXK2;:XC0=KN
M0;DNM[V[G]%_"!-WL5L\V\Z3:M]7W-)%WH)V=]B;7XB-W;U.ZT*53EO14L/J
MRCW COH)V=]B;7XB'H)V=]B;7XB)$ (WZ"=G<O\ V3:I>&FB)[4[!VM3:'2:
MFG:52\Q1;[NHQX<GS^8Z<WWV/F.;[7[4ZW:;46%G:4)VMC.6)5913[KSY9CX
MN3 DKV)V=QQTBUS[1%RV)V=X_P"R;7XB)#%]7OE8]8$>]!.SOL3:_$0]!.SO
ML3:_$1(@!&Y;$;.-8>DVN/:(B^V6P-E5J:<](TFCNQKQ[LHQ_1WHY^;)TN7C
M.?[<W>TMG5N+RRU"A8Z=;QWU'=A-U6EG'?1X9QCGU@;NEL1L^J4%+2+7.ZL]
MX7K8G9WV)M?B(S-E[ZOJ6@6EW=0W*U6";7V]1M8\\9 C_H)V=]B;7XB'H)V=
M]B;7XB)$ ([Z"=G?8FU^(AZ"=G?8FU^(B1 ".^@G9WV)M?B(>@G9WV)M?B(D
M0 COH)V=]B;7XB'H)V=]B;7XB)$ ([Z"=G?8FU^(C2[7[!Z56T"ZAI>DV_FM
MI;F['#]4NSP9)X1G;C:%:'I565NG.^G%]QIQPVWPR\>#.>0&'H.PVB0T6PC>
M:3;>:50@JF8Y>]NK/SFP]!.SOL3:_$1Y]'FI7>K;,VUWJ4]^ZDWOO"6'V827
M(DP$=]!.SOL3:_$0]!.SOL3:_$1(@!'?03L[[$VOQ$/03L[[$VOQ$2( 1WT$
M[.^Q-K\1#T$[.^Q-K\1$B $=]!.SOL3:_$0]!.SOL3:_$1(@!'?03L[[$VOQ
M$/03L[[$VOQ$2( 1WT$[.^Q-K\1#T$[.^Q-K\1$B $=]!.SOL3:_$0]!.SOL
M3:_$1(@!'?03L[[$VOQ$/03L[[$VOQ$2( 1WT$[.^Q-K\1#T$[.^Q-K\1$B
M$=]!.SOL3:_$0]!.SOL3:_$1(@!'?03LZO\ \3:_$1;Z"MG5%I:3:>'O$2.2
MRG@PM6KU;73KFO;PWZL(YC'M8'/=F-@;2GM!JD]1TNCYBEGN*E'AS7^I*UL3
ML]^EI5KX.\1"=@-J]6U':*C;7>I1OZ=6+E5I*G"/<'XXK+ZN>.9UG/$".>@G
M9U?_ (FVW7_<1E:;LQHVFW*N+'3K:C6CP4XQ2:7\LW>$,("WCC@TRY<BF$5
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MQZ+/S=;._L5/Z#V_I$_F>V@_X'_,4SQZ+/S=;._L5/Z"QB\*N?RE# 8-JL
M)<ZZ>;%WNP-9TXMU:%:-5-+DDFW]!T/HROUJ&PNBUXR4L6M.#?AC%)_0:;;6
MSC>[)ZO2DM[^JU6EX=R6#7?T<KUW'1Q:V\WFK;5*M.7@^Z2Q]!IRQV;\$]W4
MD @:%L                          !\N#P1O;G0JVNZ%.WM7"-Q"7=*>^
MVDVD^>/&20 038S0=5I:]<:QK<*%.K*EW&,*4F_U>/%+]4G75Q*@#PN*3J4*
MD8\)-8(ST;Z'>:%I-Q0OU34YU=^.XV^&$NM+L): !!^DRPV@U.TIVFAQHNA/
M[]OR:<EG..$7CD3@ 1O8:UOK'2:=M?6-O9JDMV,:-24\X2XMR29)   Z@ +>
M7'! -L]@:FL75UJ%G?U*5U.G*$:;@G%YC@Z" (YL+H]UHFSMO8WM;NM2&<M+
MEF3?VDC          #*[0:_5]5L='M)W>IW-*VMEA.=26%SPOG: R[B'=:,X
MIX<HN.>S*.3+8S6O-_F9T+7N*NW75YW26_N[ZEC&[CDOG)_J&U>B:=I5'4[[
M4[:C8U\.G7E-*$LXQA^^B^[VGT6TTNAJ=QJ-O3LJRBZ=:4UN3WL8P_\ $OA
MW-".Y1A#>WG&*6>TO/&VK1N:$*U*494JD%.$H\5)-93/2*Y=0%V1E=IY5JD*
M-*=6H]V$(N4F^22YLP=$US3M;HSJZ5=T;JE"6[*5.6\DTVOI3^ #9@MBO&RX
M   !22RL=14 0W;_ $"]UGS#YAW'W&IO2WVTDO>3-'M_HFT>L;04*EO;VU?2
MZ"RJ,ZDHN;R^;4?:]?4=. &OT.-RK"CYLH4[>LHI.G3DY17#DFTC8
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MYXU;&SN[*FDJ%*56<5%X66\1[=[MYG4P!CV#JNUINXA&G5:[Z,7E(R
M       U6TME6U#0[ZUMVNZ5J,X1SRRXM+/PD)O=B]0N=C]/M?N'FZRK.O&+
MD]V6&VER\74=+ $&V'V?U*SU2ZU/58T:-6K&,52HMM<(I9XI=A.5R
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M3;QU&HN]H-*M-7H:5<WM&G?UTW3H2DE*7+DO?1M(YSU 7@
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M*\ +8<BY%5=@ !(
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MX6%.M2M:5.ZK=UK)=]+M9DFNT&%Y2TNWI:G*E.[A'%25'.X\<L9X\C8@
M
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MCP[6NSD!UA-9>.PN7(L3;SAYRB^*2BDN0
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MC%)GH\%42A<@N87((A(
M              "UI,+@5YEO'CAA"Y%2V*:SEY+B$@     "C? )DP*ELEDK
MD 5
M              ^0%KXE%\Q<BUM<@*I\>)<6)\5DO(   4:X%(KB(\BJ)%06
MYYERY
M               !\BF.!7J* (K X=H? HVNP"X $          4;$"J!1,+
MF2*17%EQ1%0
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M7!E5R*KK*=91ATUP
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MM<OCW6/TGW%1^]1\1S^7CKCF.F'4]/RWR5GKG:X %-T0
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MY;Y8K:VX?32XI%SYE4E@,Y+O"YE2D2H
M
M                   P&!3J9Q3^DU^*M&]WG]4[7U,XI_2:_%6C>[S^J;^-
M_%A6Y?\ !L^?DLDQZ)+*VU+;[3;6_H4;BA/NN]"M34UP@WUD/BL\,$YZ%)KT
MQM+S+&55>$N7W.1U\OX+?H\_Q]>[7?U=5MZ>SU?:VMH4MBJ%."<EYK\RP4.&
M>/J3E&L;-T'TB+2-*BJEM.O%SC!II1<N^]Y9.HT-N[R?23<:#=JC"QE.5*,X
M+=J9>4N.3PV.V5I:+TA[0:C=U9RHV5)55*:X-5-Z3\;6Z4<=IQ[W]'4R5C+,
M1'U>?25LGHWH/NO..PM:=WIL8=VG1IQC)I+,F\+L3.!K/@/I39?5ME=5OM<T
MW3[ZYN+C5(S56%:+W5PDN&5_>/GO:"QGIFLWMG4AN.E5:2\'-?,T;N)>=365
M;FTC<7CY:_&#[;V?_$EA^SP^@^),Y/MO9_\ $EA^SP^@U<__ $RW>E>+-@NL
MIUE5UE.LYT.PJ
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M]UC]*/N*E][CXC1S^TPM^E?ALN !SW6
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M4B5)
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M>$<_G3':(=7TRLQU3+,BWAA<PEP*I<2@ZJH
M                                            'R 8%N3Y.Z;?SGZW
MXZ7^3 ^L>74?,/3!L_K-_P!(VL7%EI&HW%";I;M2E;3G&6*4$\-+#XHN<*8B
M\[^CG^I5FV*(CZ_\N9M>%KQ&7IVHWNF7$J^G7=Q:5W'<=2A4E3EN\.&4\XX(
MSWLIM$O_ ,#JW[G4_A'H5VB]@-6_<ZG\)U)M68U+BUK>.\1+76=_>6-QW>RN
M[BVKXQW2C4<)8\:>3*O-H-8O;>="[U;4*]&;S*%2XG*+\:;/?T*;1?\ \?U;
M]SJ?PCT*;1?_ ,?U;]SJ?PD3-)G<IB,E8U&V#IVIW^F3G/3[VYM936).C5E!
MM>'#,:M4G5JRJUIRG4D\RE)Y;?:S;^A/:+/X@U;]SJ?PCT*;1-_B#5OW.I_"
M3ND3N)1TW\3$M=IOX?:^ZQ^D^X:?WN/B/C:PV5VAC>VSEH.JJ*J1;;LZG#CX
MC[)I?>XYYX.=SIB;1J75]+B8K:)A< "@ZH
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MKV\X1;S'"RUCJ,\T].*8F=RJ8OO\B+5KTQ_WR^B6W@KGF,%>HY#O$>141Y
M
M                                              !;)<2X 40*X"0%
M$4;\8QC/7DX_METPU-"VLN="M-)K7EQ2Y=RC*3?%]23[! [!U<@N/B.*V'3?
MW'4K>WU[1+O3J5::@JM:G.*RWCKBEUHDW2;TD4MCM.TZ[A;NYC>O[GC/'EV)
M_K(#HGOE5R.'T>F769[F[LGJ#C/#4NXU,8?7G<.R:+=SOM+MKJK2E2G5AO.$
MEAQ\ &8^0BE@K@)80%"HP,$  "0
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ML^^EV =JZBJY'C;5Z=S1A5HS4Z<UF,HO*:/9<@
M                                                4*C %K+>$EQR
M8FLZG::-I]:]U"M&C;TEF4I-)?.<9N.FZ\O*M26@;/W=[94WQKTZ<VOFBUV
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M1;%ZVMH=G+/4XTW35Q%RW>>.^:^PWI (! D
M
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M#N&D:?2K17=84*<9+')J*-BEA
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MI4:<'F%*G%]L8I 8&SEE/3-$LK.M)2G0IJ#DNMFT0
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MT?PTY<7[>1.B(=%.GW.E["Z99W]+N5S3IM3B\_K2?VDO
M
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MT#LF?&$>5"3=*.7QQR/5<@
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M(@G2Q^+]._:Z?UX@3>AQIQSV(]%P/.W^]1]JCT
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MTXS6<GO!M^(L1,3W:Y7  R
M                      ^: ?- 0+9?\X^T7M8?6J$\?JD0/9?\X^T7M8?6
MJ$\?JD"%0   *9?' %043;YK!1-O/#D!<"U2ZGS&7V8[ *QZ_&<\Z3OQKH'N
M_P!DCH><9R<\Z3?QMH"SQ[O_ -,@.B%CDHQ;;2BN;9=G@S&U"+E95HQCEN/
M#WHSA.&:;3CVHO-;L]3G2TRG"HL27-&R
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MB/:R:^)8?AMJ/$I.N?@+BV*X%>LLLURY +D
M                                   +D03I8_%^G?M=/Z\2=KD03I8_
M%^G?M=/Z\0)O;_>H^U1Z'G;_ 'J/M4>@
M                       ".=(GY':G[C/ZK)&1OI$_(_4_<9_58%.CG\DK
M+_%]9DC7!<R-]'?Y)V7^+ZS)#CO\X MA6ISJRA&2;7-%MU&G.C45:*4&N^-7
MI=O5IZU>5:B:I27#YC/U-_U&NO!]IC?73,IK/=%=GMHK&TIU[:I<+N5*;[DW
MGEP\';DDVDZK:ZC.HK6JI[O%\SA<XQ=1YQN[SZB=]%&%7N\M8W>"^ \[P/4K
MVR5Q6\2OYN-6M9LZ6"WAU<AGL/1[<]<"U+OLEQ(
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MWB**\TSPU"+G:58167*.$!ZT*D*L%.F\Q?6>AKM!HRH:;1IU%B45R]XV(
M
M  UVT?XCO?<F;$UVT?XCO?<F!'.A_P#(:R]M4_S9DT(7T/\ Y#67MJG^;,F@
M      +)+>WHM)IKK+P!IUL[I"K*NM/ME44M_>W.*?/)D5M)L*]Q"YJ6M*=:
M*6[-QXKL-@ +7PCR]XYOLO\ G3UW+_0AP_PG27UG-MF/SI:Y[2G]4#I.#RK5
M:=/'=)*.7PR>J-1M%;U+BG1C2CO-5(R$#:+DL<B):ZEI&MV^H4^%.:[E5QRQ
MSS_[42ZGG<CU82R8&NV4+_3JMO*.=XTYJ[KN/,,+UW'9F4IJ4%-/*DLGHWP(
M[LA>2K:?YFK/%Q0;A)?/]#1(NKCS,Z6ZHB659W&UT>0"Y S2
M                                               N1!.EC\7Z=^UT
M_KQ)VN1!.EC\7Z=^UT_KQ F]O]ZC[5'H>=O]ZC[5'H
M                                  CG2)^1^I^XS^JR1D;Z1/R/U/W&
M?U6!;T=\-DK+_%]9FVUFXE::;<5J;Q.,6T_>-3T=_DE8_P"+ZS/+;W4ZUAI5
M7N=+NE.:PWV<&1-+7CIIYEC?+7#6;W\0A2VTU;=QO1Q)M9X^4ENQ.J7&N6EQ
M&\DI=7#WCE;JI4X)/+;Y=A*^CK6U97<K2<4J,^=1]1S,'I?/PWZ\_P""/U_X
M1;U?A9=8\4_>G]/^4F>P%AE_=JG%Y+H;/3V>E*ZTRHYK].$NM?S@DBU&T]<T
ML^W0JW-&XMJO<ZL)XCG$9)F7V3C5[X];_5;][);\?A&H[?:?#,:M.I&HN<>+
M^PVNA;26NLU94[>,HN/;U_,<<N^%Y5>%ER)CT7X>H5]U_P \3E</U//DS5QV
MGM_1:S\;'2DVAT^+RR\LCZI+)>>G<T
M                          #YH!\T! ME_P X^T7M8?6J$\?JD0/9?\X^
MT7M8?6J$\?JD"%0  *-<>94 6;BSGAGP!THRQO)/'(O %CIJ6-[CCD'336)<
M5X2\ 6[O9C!SSI.3\]=!QA+N_P!DCHD>OQG/.D[\:Z![O]D@.AX\);.:A'>D
M^!>8UY!U+2K&*RW'" ]+>I&M!3@TXM<#U-=H%&=OIM.G53WTN.38@
M                                                         #7;
M1_B.]]R9L37;1_B.]]R8$<Z'_P AK+VU3_-F30A?0_\ D-9>VJ?YLR:
M      !1]9S;9C\Z6N^TI_5.DOK.;;,?G2USVE/ZH'24SQN;FG0W>Z/&\\(]
M^HC^U52$*5%RG&"4T^/8*QN=0-\GO+P%.?-&'8:C:W=/%M6A.22SAF:L-OP$
M3$[U,)0V^;T;:55XY5O<K=ECAB3Z_@B3'GQ1J-I[%7^F588^Z0>]%]:>'Y2N
MR]^]0TV-2;7=(\)KL9HQ_<O-?B?'_MJK]VVFY7(!<N +#8
M                                             N1!.EC\7Z=^UT_K
MQ)VN1!.EC\7Z=^UT_KQ F]O]ZC[5'H>=O]ZC[5'H
M                                C?2+^1^J>XS^JR2$;Z1?R/U3W&?U
M6$3X6]'?Y)67^+ZS-OJME3O[&K0J1C)237%9-/T=_DC9?XOK,V^JW4[/3Z]>
MG%2E"+DD^!'7T1UQ\%JQ>.F?EPK6-/JZ9J-6AN-N$^]X<UCD3S8W2K1Z%<NK
M!>:)<X36)PX_#_W(CJ&I3O+Z%W4@G44L[N3?Z?J%U7A<:C",(-?<YTT^#7#B
MO@1NOZUAY]8XM9^],./@]'MZ?EMRIC=8G_LHI.=13EBK5X=DF3GHO3K5KV-6
M;FG'&)//6C!M=D:5Y;JO2OX)2ZGCRFYV%MJ>D:E=4*U6$JDH][AKCQ1Y+B<+
MD8N16<D3K;U63D8LF*>F6^J[*:5.4Y.VAOOKP:[9JRMM*U6ZM5!0FY;\'VI\
M,?,2V;:>6^78B/;3T94:MOJ-!-RH/ODES3X?:=G-@I366D=X5*WM,364BAPP
MB]/PGA;5H5Z,*T'F$TFF>N4NTNQ,3'9JUKRO0*)E24  )
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M/>E=RD_5S*Y"*+P\2\T+D4"*@$ @2
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M[?[U'VJ/0\[?[U'VJ/0
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M.3,.)ZGN\8-&7C:K[FW4HKPE<<2G)"+SS.ZI0N !(
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M=-Q:6&\]OD,</.PYK=%)[LKX,E(W:&\!;O=I5/+\!<:50.HH!4%,\2H
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MZ?UXD[7(@G2Q^+]._:Z?UX@3>W^]1]JCT/.W^]1]JCT
M                                   1SI$_([4_<9_59(R.=(GY':G[
MC/ZK MZ.?R2LO\7UF21<5QZR-='/Y)67^+ZS)*N"X@8="]A7NJM&+[ZGS,;7
MK&%[83A*2BX\5)]1986,Z&J7-:?J:BX?-Y#+U/*T^M)<.'VFO)6+5F+,J3JR
M.:?K^GW.F]SOZL%6AWCSCB6[&W4;FUO;6B][N;Q%]6,(Y=-IU).+?JNTE71O
M>*VU>K2RTJB\GD.+P/5,N>T<:T1J6_D<6E/\[?>&/>;)ZNJU:KW&,H9SA9S]
M!O.CS2[FC*K6E&*IRX?,=!DMZ#B^OF:#9N7F>]OK%K"A/?CXGP^PSKZ;CX^>
MMH^6<Y[7I-42OMB+^MJ%S7A.FHU9N2Y];\1[Z+HMYLS>J\N5W6B\I[BY=7VG
M1FF^3YGG4A&I2E"<5)8XIFZ/2L5)ZZ>6'VJ]HZ9\/&WOK>YHPJ0JQW9+*XF1
M3K4IR485(M]B.+:]7J6VM7=*E7J0IQG+=2?!<6;+8*YN9Z]2A5K5)Q?)-FC'
MZM,Y8PS'SIMMQ(BO5MUT '<40
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MJ\G&?#B;:FU)*4>*?86*9*WC=98368\KEZKF7EB6&NLO,H0  D
M                      #7;1_B.]]R9L37;1_B.]]R8$<Z'_R&LO;5/\V9
M-"%]#_Y#67MJG^;,F@      +)K>34N7TEY;PSV@<RU#3+73^DO3:EK3<9UG
M4E-MMY;CX?&:7:J-K9:_J=[8Z@X:OW1+N$H)J2WI<L^0[!4LK>I<PN)T8RK0
M]3-\T8EQHFG7%TKFM:0E63RI/.6!K+G3[O7MEK*,KF5G<5*%.4Y1BFTVDWP(
M7T<:?4TKI UBUK7#N9QA#OVL/U+\IUB$5&.(K"26$CG&S'YTM<]I3^J!THQ+
MZ\IVG<W4SWTE%&6:S6K*I=JBJ>.]FI,@8NU5-5='G.">:;WE\#-G8UE<V<*B
M:::YKX"E_1573ZE.2SF.#6[)5G4TE4Y>JIR:?PMFSSC_ $2W@07-E>LP0\+J
MC&M2G3EAJ1&MCZSM*E?2ZW"=*6:>>N'5]#)5CB1#::$],U:UU.BL07>U,<>'
M'RE;-NLUR1\?^V%NWWDNR7H\:%2-2FIQ>4^)ZQ>5DL1/T9J@ D
M              "CY%2C60"Y&LV@NU9Z77K2DDXHV2X$6VPE*ZKVFGPX]VGO
M37@P_P#0U99Z:RPO.JLW8VU\SZ3"<D^Z5LSEGQX^PWQX65)4;>G36,16#W,L
M=>FL0RK&HT  S2                   N1!.EC\7Z=^UT_KQ)VN1!.EC\7Z
M=^UT_KQ F]O]ZC[5'H>=O]ZC[5'H
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MQ":.NJ*Y!0J2
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M[]KI_7B3M<B"=+'XOT[]KI_7B!-[?[U'VJ/0\[?[U'VJ/0
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M4N'4LIT9_?*,W%^++Q]!O(O@R<-^ND6E%HU;2Y<BI:N*X%QM8@
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M><VT^[-I4+N.4UR4N//YC1D^Y>+PPMVG:7IER/./"..HJI9-^V:]=8"!(
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M;V../?/FS9G9&RGIUE6I](=Q36[%]R4GWK[.1](Z125'3+2G&LZ^Y2BNZO\
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MJ^U2WMJM&,54DEE9ZWXSE8O4,5+SCF?E9M@M-8LZ'XRXLYEZ.O"J
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M]Z+\)[4WF+X8/5Q,3WAREQ:EX,%P)%LD$ECK*@&E>H(H5
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M.[TZ:A!17J4L$:T*WI6>TEW0IPC!.#DDEX8DIX/'@)Y.3KF/HT*QXH!> %=
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MVN1!.EC\7Z=^UT_KQ F]O]ZC[5'H>=O]ZC[5'H
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MN4,E&\)\"B>\@+FT@FGR+<<"L>0%0       4:>? ,%0!19"6>94 !Q  8
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M^G?M=/Z\0)O;_>H^U1Z'G;_>H^U1Z
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MWES#@G+AOKJP;V+7:C9CO&2-PQM$U[+UR 3&5VFUB 9
M                         /F@'S0$"V7_ #C[1>UA]:H3Q^J1 ]E_SC[1
M>UA]:H3Q^J0(8NIJCYWW/FI)V_<INHGR<<//S'S##5NCJOM#4I5MDZ<;!UW3
MG>N/>J3EAM_<O'UGTEM7"4MFM5A!2E*5K544N>=QGR94VAMX]'EYL]5T"]=^
M[RI-U5;RRXN4NO=\/:!U;8S:'9VTVXM](V$T"A.VG.*K:A3I;NZLK/'<7:^O
MJ.YP]2<-Z'-L- MX:9H6E[/W5I<3A"G4JRH269/";<MQ=;?6=SCR      *1
MZ_&<\Z3OQKH'N_\ TR.AQZ_&<\Z3OQKH'N__ $R Z%SXHQ[VX\S6\ZKX;L<\
M3(7 YYTF[1*UIPL;6K]UDLRW9<N/7\#)A7Y.>O'QSDLMV<VPK7FTM6VNY1C2
ME*48<_#@E&U.DT]7TVI"2S.*S%]C_E'#:5S*E<1N*<VJD);V4SMVQVLT]8T:
ME.+WJD8J,UG+SCK,ZVFD]5?,.7P.77EQ?#D[[\?HX]9Z;<7&JQL%%NLJFY/M
MPGS^DF^UNRUS/3[96<(JG;4VYI)9;277GP,F5MH-K0U>>H0IP56?/O?'Y3:R
MA&4)Q:S%\TR]G]0M>]9K\,>-Z)CIBO2_SV_I\/G5+=DXX>\GC&?A)QL)*KH]
M]&-Y",+>NMZ-3'D\9M*^Q47M)*LH)VC[[=4>&>LQ]I9+0K>O0KP56WJQ?<GU
MTWCJYOFRQR^57/3HQS^;G<7@7X-IS9.T5G_O[MAJ&VD:&T5*SI3@[=\'/LY>
M5DVIS4J>]%Y36<GSC)R=251RDY/K;XG8.CK7?/'3.X5Y?=Z6>$I<6LOJ^ Y%
MJSKPZ/IOJ<Y\ML>3Y\)?%+FS6Z[;4KC3JSK++BLQ>.*9LY2C%8DXK/++P8M_
M2E6LJM*GARDN!6S5ZL=H_)Z"G:T.*TM;U)*/]=K>_-^4FG1[K$VKA:C=-O/#
M?DWV$>6QFJQ6>YKP$HV+V8J6E.NM5I1E*3X97B/-<''R:YHGX=+-;%./M*80
MO[2:[VXI/_$CTA7H2XJK!_XC6SV=T^7*FX^U>#RELW07WNM6AXIR\IZ&;9H_
MT[<[5?JR=3TNVOUW18C7CZFI#A)>^:F&LW.D1G2U:#E1APC67Z7P9,E[/UX)
M]RU&O'P9EY33[2Z3>TM)N95;QU:<8Y:DO*RGGG+CB<E*ZG^FOZMU(I:>FTLI
M;;Z8V\RP_??V&\T'6+?5Z4YVSX0:3Y^'P> X;3PXK&.")?L7KOG1:7&;2M6C
M)IMP3:7/L3[2CQ/5\ELG3E\?U6,O#K6OW?+JXY>,B]IM?1N(Y5K4\2;;^@S(
M;26S7W6E6I^.#\AVZ<O#?\-O]U*<5H\PWF6%GL-/3VAT^7_G8\:P9-/5["HL
MJZI^_)(VQEI/B6/3+/></!1-XXGC&\MIKO;BD_%-%55IR3W:D6O S+KK]4:G
MZ/9/PALA5WMY:6UU5H.A4;@\9XK[#,T#;"WU:_\ ,M*C.,L9RW_H5*\_CS;V
MXMW_ *MLX+Q&YA*P 76D   #*[0  RNU%,KM1&Q4#()                %
MO-AI#&,^$)81 81K]HOQ%>^Y,S\/CX3 VB6-"O?<F!'>A_\ (:R]M4_S9DT(
M7T/_ )#67MJG^;,FA(A72[7T.UV/N*^TUK"ZLH27W.2SO2XX2X/P]1Q79:ZZ
M-;Z%P]<V:H:1.E'?A&M33[HLI<%W->'X#HW]).%26PL73MZMPHUXR<*<7)OA
M+J1R#:O:K0MH]M=&O[S9R^>E6M)QK4H6TXJ?J\<H=LEU=0';.A?7Z.MZ==>=
M>AQTK2*,\4%&.[W3@N.-V/5CJZCI4.OK(5T:;5Z=M)85HZ1IE73[>A+=W)4G
M3[.2W5VDVBL9\/$"H22?  #RE;49U8U9TH2J1]3*44VO$SSJZ?9UJ\:]6UH3
MK1Y3E!.2]\R0!;C&<<#F^R^%TIZYA)=Y#ZITE]9S;9C\Z6N>TI_5 Z4:[6+Y
MV4:6(YWY*+?C-@8FHV4+U0C-XW6I 9--MPB^62-S7F3:R#Y0KPQQ[>'D))'U
M.%U+!'-KI1H3MKI2BIT99Y\>3,J_1NX_>TU^K/VDH=VT:XCC+QDR-'K>:-.H
MU<YWHY#N+>XL\=VI/?CRWDS6['56].J49OC1ENX?B)C\$_DUS$^)2%<@/$#!
MB%LLY+BV2XYX@:W7[RK9:3<5Z%)U*D8\$<#U.^KW][5N+IN523>4^</ ?1<H
MJ<)1G'*?--<&<UVSV(J5[OS7I<-USEW\(PX<?Y9S.?AO>(FOCZ*7-PVR5W7X
M:'8C:6\TNM*WW9U[>6,KB]WGRYG2);5Z?&@YUJSIX6>^A+GV<CSV0V8M](L(
M=UI4ZE:<4YN<.*>.7'QFRU70[/4+2I1G;T8J<6DU37 RP8L^/'Y_HSP8\M,>
MIGNY%M1M1=ZI?YHU94Z%*68.$FL\O(3/83;&G>T/,^HSC2JQ7!M\^) MH]G+
MS1K]TNY5*E"<L4VHO#Y>4F&Q&Q+[DKO58=\UWL&L-<>93P6S^[_NI\?W_>G<
M?JGRU:Q?#S53^$C^U^UEOIEF_,M6G4KRX1BF;![,:?EON;]YD3VVV,B[=76G
M*3J0YPXO*+_(MGBDZA?RSDC',U\HSH&V%]8ZEW>ZJ2JTY\)0E)M)>#GV'8]+
MU"WU&UC7MJBG%]AP32=*N]3OE:T*4E57"2<?4KP_,=OV8T:&BZ;"VA)RZWXR
MOZ??+:9BWA6X-\MHGJ\-TEVE.0WO 5?$ZKH*@ D     %LD5Z@4D\)O/! 1?
M;6X=2E;65)YE6JQC)=>'P^TD=E1C1M*5**PHQ2PB,6JCJ6UM6HUO4K>GA=:W
MN]?V$M@L(KX?O6M;^G[-=.\S97'#  +#8                        +D0
M3I8_%^G?M=/Z\2=KD03I8_%^G?M=/Z\0)O;_ 'J/M4>AYV_WJ/M4>@
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MM>WXCP[#;MNC!RYRBF>L3RM\QI4U)<HH](<F>KKX<N5P ,D
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MVN1!.EC\7Z=^UT_KQ F]O]ZC[5'H>=O]ZC[5'H
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M=/Z\2=KD03I8_%^G?M=/Z\0)O;_>H^U1Z'G;_>H^U1Z
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M)IK/47+EP(WL)7J7&@4ZE6>_-OF_$B21Y(Z>')[M(O'RK7KT6FH #:Q
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MVNG]>).UR()TL?B_3OVNG]>($WM_O4?:H]#SM_O4?:H]
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M5";[RFN]6/$;A9:XF/0M*5&O.O!8E-<3)?8D!7!1Q3YHJ *;JQC <4UAK@5
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M5XU;BI*6?!EX^DDBBLHQ]-ME:V-"C'@H12Q[QDXSQ&*O32(DK&HTJDD #8R
M                        !D B"=+'XOT[]KI_7B3M$#Z6/Q?IW[73^O$@
M3BW^]1]JCT/.W^]1]JCT)
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M9UJLGQC%OYC3;&TINC=WL_5755S7BRVOI*^7[UHHPMWF(2:+RBI2/(J6&8
M                 "><C(V !3..8%04R^I%')KJR!67PGGOQ<FM]9[,D;V]
MUFKI.EJ5!Q56H]U-\?YY'+H:WJ%*JZ\:[<GSSR-^+C3EKU;3IWAKDT0;I8_%
M^F_M5/Z\21;+ZD]3TFG<224N4L+AG"\I'.E=YT_3NSS73^O$T3'3.I-)Q;_>
MH^U1Z'G;_>H^U1Z!
M       !'.D3\CM3]QG]5DC(YTB?D=J?N,_JL"WHY_)*R_Q?69).KB1KHZ_)
M*S_Q?69).6$@-+I5>M4UJ\IS?>17#YC==?'L/*E0IPK3J0QORYGMUX[ *@
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MA1U*TC<VSS3?7AHS5AEBMHM'5$]F$Q,=EQ3!0?"2A<@47+@.)(J $L
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MMII%U1H5:B[I4>.3X+#\ANZ52-6$9TWF+ZQ$+]<E+3-:SWA[%46LN7(AL
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M>^Y,ZOIT7C!'N>?S5^1T^Y/2CO0_^0UE[:I_FS)H0OH?_(:R]M4_S9DT+S0
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MG;_>H^U1Z!
M !'.D3\CM3]QG]5DC(YTB?D=J?N,_JL"SHZ_)*R_Q?69)7U$:Z.OR2L\_P![
MZS))CJ7(#2:35K3UF\A.3=./+/O&\6=WPGE"G2C4DZ:2G+FT>O@7:!4
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M#%OYRC8UG!M22X&462494VIXW6!@:!4G5TZE*LVY]9LCSH0A3@HT\;O5@]
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M<3VA=DJF6]3*P>1"50  ZBQ1>\VWE%X MW>#*I-+&2H
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M.EC\7Z=^UT_KQ F]O]ZC[5'H>=O]ZC[5'H
M                          CG2)^1VI^XS^JR1D;Z1'_]'ZI[C/ZK IT<
M_DE9?XOK,DD>7A(UT=/_ .D;/_%]9DEQCB!HM(G6EK-[W5R[FEWJ;X=1O%PX
M^ \X4Z4:DI1QO/G@]%P7$"X%&T$UA 5 R     9&0         &2B::X 5
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MR1I'+M2UHZ90/9?\X^T7M8?6J$\?JD0/9?\ ./M%[6G]:H3QOOD=A45
M     %(]?C.>=)WXUT#W?[)'0\X3?A.>=)WXUT!?[_\ Z9 =$,6^7]3JXSG=
MX8,K/462]2U)+'A P-GI3GIE)U=YR_O<S9'G24(Q2AC=2ZB_* J N(  903R
M +$\YX%Y8LIM 52X<2B7')5+)5)@42XY^8K@8*X"(6R@I)Y2^ UU[I-G=1<:
MMO2E)_I;JR;,MP][(1-8MY12KL]>V>9:=?U%'FJ;;:^DI#:"\TZE):I9U-V"
MXUL\/H)7N\VU\Y#ND+S;7T_S+8474[IPD\9QR,H5,U/8I-\?GZ>7.M>U^O?:
M^[VE4FJ5.7W/ONK/4=>V7U6GJNE6]:,DY;J4EO9><'&_0UJS6';M)86>/'YB
M7]'M#5-+U"=&YMY*VFT\\>'/P!QO3<W(IGF<E9U9T\JBR$L\BY<S%Z94
M  "::          -I#(         #)1-/D!4        !M+/@*9 J:[:/\1W
MON3-@I++1KMHW_L*^\%)@1WH?_(:R]M4_P V9-"%]$/#8>R3_6J?YDR:
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M>5O)=Q@_[J/4
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M0".>F1L[ZYJ_)LHND?9[C_6*K_X;))YS:;ZPM?DH^0M\YM-WG):?:]GWJ/D
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M4H65LIQY-4HIKY@,FWXTH<,/'(]5R*;JR5
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MUE9UG%3[4L(G<7E9ZNHBFPVSM;1:-U6NYJI>W=1U*DEX4N'PHE<.3_G %0
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M&E=5*DY2J-KU,GGL[,GKT=Z'K.A496^HU*$Z"2XQQO2EQXMX3 G,>7$"/(
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MM:]<6<;"O"-M2>].G)XWGQ\'A1Z0V-JZO84'M#**O:#<:7<7NQC''8L+KEU
M>_1->W5[LU4=_6C5NH5Y1DUXHDT77P(GT>;+RV9L+BC.K*I*I5<\MYZEY"6I
MY\8                                                        !
MK*:&$ !11P^T)<%EY*@"CBGE]8W<YSQ*@"F[VO)4  4W5C!4 4QSR\C!4
M      4QQ>&$L%0    QM0O:=A9U[FMGN5&#G+'/!DF+?T5<65Q1EQ4Z<HX[
M<IH"/:;M]HNH;/76M4*LU8VTG"HY)936/#X>TMT3I!T+6=F;K7;*M.5A;)NH
MVEE?/CYSYJU/49Z)4VFV,A+%6]U",J<4LXBZF.?B16M<2V%T_7]B6WW6^5O&
MFN?Z4E+B_&!]5[,ZY9[1:11U/393=I668.267\#9LT^/TX/G+:S:*ZV<L]D]
MD=/KNTI2M:<J]6,5*2?<Z;_2SUMGKH?25K6D;/Z_2OM^X5O#-I<2A!9;4^>,
M=D>H#Z)X\<)D=TC;+2M4VCOM#M*DY7UFDZL6EA92?;X3@VR6VNO6^KZ%=^;:
ME_"_K05S1[G!;BG-9QA+DF^LC^T6V5SLMTJ;4/3J;5W>0ITXU6DU2S2CWSSV
M974P/KM2SR+B-[!6U:WV=MI7-XKRM46_*LDDGEMXY+ERY=1)    HXY7$;J*
M@ UG.>0       *;JX#=6<]94 ,<0       42QXRN.8 %N[X>!51X<7DJ "
M6.O(               !1+GX2H HHI>(;O//%%0!3=QR#7PE0!3!5+   HXY
MR5 %&O",<>94       ICB^)4 444L]KZQN]C*@   !H=K]JM.V4L(7FK2G&
MA*:AF"3XM/M:[#?'/^G32//CHYU6C#[["G*I#QJ,O*!L]K>D'0ME;2RN=6KS
MC2NY*-)P2>>#?6UV,KKVWFBZ+8V%W>UI]QOI*%'<2;DWG'-K]5GS3!SZ5H6&
MGTIO=TJSJ5IM\.^5117+P3-ALCJJVOVIV/T>LMZ&EMNLN6'&K+L\$T!]7PDI
M*..M9*<4D_A9\O:GT@ZUKFOZS.WU"=G"PENVU*-*#WWPYY3[6;+:?I0UR\T'
M0K.4I6%[>MJYJ;D'P6^UC.5^BNH#Z*U"\I6%E6NJ^52I1WI&NV4VEL-J-*CJ
M.E2G*VD\)R2SR3ZF^TXWL?M)J=W:;0:/?U:EW9TZ.];W,H1CQRLIXQV=G60/
MH?VMO=2JZ+LI85?,-MW5SK59Q3[HXT_4KF_T5V ?7"DVN6/&7'E2CW*FDV\+
M@V^L]5P   !@INKCV,J **.,<>15+       !1Q3Y\ACCG)4 44>''B^TJN"
M[0      "C7(*)4 44<>,JEA                  ,>$HXIE0!3"QQ&ZLYZ
MRH I@8*@"BCA\ HXY%0 &$ !2,<%0       4W>.4RH ICCGK*@   !1/Y^1
M';G;+2[;:NVV>K3G'4+B#G!86ZTM[/7G]!]1(,;K>.LX9_2!DM VHV;VGBMU
M6KE3J27'A)3CR_Q@=(GTA:%3VN]#<ZT_/+#>[A;O#/AS^B^HR;;;+2[C:NOL
M_2G-ZA12<UA8X[WAS^B^H^7[Z-256ZZ1H2;@[]TX/^XW'JY?ILF>QFN]RM]O
M=O:=-N;J+S.^KC.HDVO\: ^C\KB4QPX>)GS#LUMQK]&YTG5E?5+VI>U8NYM^
MY02A"37+@GP4G\!D[3[=ZGKNUFITJ%].QM]-BNXTXTX-SF][@\I]<%\('>MJ
M-J],V7I6TM4G*$:\U3AC'-M+K:[4;NWK1KT:=6GZFI%3CGK3XGS)TA[27FJ]
M%VCZGJ]&2NK2[AOQ:2[HHU5C&.U1\',EW0;M'J>VFK76H7=TJ-I;0IPI6>ZE
M)+#CQ>/[G;U@=Q   HEC@N14 444O&-WX2H +@     #', "F.',8^ J "0Z
MP    #  %,9YE<  4P^'$JEC/A
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MRD^<8N3ECDNTE8
M                              #%U*TC>V=>VJ>HJQ<'[X '-^BKHGM]
MA;C4JGFIW#O(N+>>2;3QR78-@NBBALMMCJ&N*Y=7S0FH0_4RX^#^[\X &NU3
MH@N:>LZA=[.ZJK&E?/[O"2R^KEWK[$;':/HII:GI&ETK6\G0U'3\]SN98XYW
MN?#^\^H #,V:V O;&SU1:MJ:NKN]CN[\4E&*X<N]7A-'0Z&:-MLK86%O=[FH
MV=>->G=1Y\DFN78GU=8 '6;.G5I6=.%Q/NU9);TNU]IDKP@
M
M   (=TJ;%4MN]F*FDU*O<92E&4:GZN))]C[,  :>ET6VD.C1;)]WS!8?=<\Y
M+=X\O[JZCVV4Z-++1^CROLQ<U.[TZ\<5*F>;X8ZNU  :+9_HJU/3KVRHW&M*
M>DV4]ZC1C%9W4UB+>[V)'MM!T5753:"\U39S5(V,KV.+B$UG//EWK_6D !EZ
MST7>>6R^E:3/4)N5I6A6J5)8^Z-34FN$>7#!E:7T<+1MMZ6NZ1=^9J<J<:=Q
M;KU,THQ7#AX'U]8 '10
;                                !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g109079g00v05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00v05.jpg
M_]C_X  02D9)1@ ! 0$ W@#>  #_[1WZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '=T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M /_A0NQH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B
M96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX
M.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D
M;V)E(%A-4"!#;W)E(#DN,2UC,# R(#<Y+F(W8S8T8V,L(#(P,C0O,#<O,38M
M,#<Z-3DZ-# @(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @
M(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @
M(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SID8STB
M:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @
M(" @(" @(" @>&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&9X
M+S$N,R\B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B"B @(" @(" @
M(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O
M(CX*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C8M,#,M,3!4,30Z-3<Z
M,#<K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T
M941A=&4^,C R-BTP,RTQ,%0Q,SHU-CHQ.2LP-3HS,#PO>&UP.D-R96%T941A
M=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C8M,#,M,3!4,30Z
M-3<Z,#<K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z
M0W)E871O<E1O;VP^06-R;V)A="!01$9-86ME<B R-2!F;W(@5V]R9#PO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B
M93ID;V-I9#IP:&]T;W-H;W Z-&5D-#4X,S4M8V4U-2UA,31A+6%A,#4M961A
M-C0Q-#DX-3<S/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M26YS=&%N8V5)1#YX;7 N:6ED.F(Y-#8W,S8Y+3EC930M,&,T92TX8V%B+3 W
M,F4X8S5E,# S.#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.G-U8FIE8W0^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/C4W/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!-33IS=6)J96-T/@H@(" @(" @(" \>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI
M8V%T:6]N+W!D9B!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HP.#4P,#=F-"TT9C R+6$Q-# M.#$P,BTR83$S,3-D861F
M9#(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C8M,#,M,3!4,30Z-38Z,S8K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<" R-BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M-V9D,S(V9&8M-&4S-2TQ8S0R+6)A-S,M.30X8F1D.#5D830U/"]S=$5V=#II
M;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V
M+3 S+3$P5#$T.C4W.C W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @
M,C8N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A
M<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E
M<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@
M:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z8CDT-C<S-CDM.6-E-"TP8S1E+3AC86(M
M,#<R93AC-64P,#,X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 S+3$P5#$T.C4W.C W*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @,C8N," H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C1A
M.3-C8V1A+3ED-C4M-#AB82UA,F4V+6,P.6,S9C(P9F-E8SPO>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C=F9#,R-F1F+31E,S4M,6,T,BUB83<S+3DT
M.&)D9#@U9&$T-3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T
M4F5F.F1O8W5M96YT240^>&UP+F1I9#HP.#4P,#=F-"TT9C R+6$Q-# M.#$P
M,BTR83$S,3-D861F9#(\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HT83DS8V-D82TY9#8U
M+30X8F$M83)E-BUC,#EC,V8R,&9C96,\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @
M/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^061O8F4@4$1&($QI8G)A<GD@,C4N,2XQ.3(\+W!D9CI0
M<F]D=6-E<CX*(" @(" @(" @/'!D9G@Z4V]U<F-E36]D:69I960^1#HR,#(V
M,#,Q,# W,S(R-#PO<&1F>#I3;W5R8V5-;V1I9FEE9#X*(" @(" @(" @/'!D
M9G@Z0V]M<&%N>3Y2;W!E<R F86UP.R!'<F%Y($Q,4#PO<&1F>#I#;VUP86YY
M/@H@(" @(" @(" \<&1F>#I$3T-81$]#240^,38X,34Q.3 R7S$S/"]P9&9X
M.D1/0UA$3T-)1#X*(" @(" @(" @/'!D9G@Z4D=-871T97(^,3$V.#<U+3 P
M,3<\+W!D9G@Z4D=-871T97(^"B @(" @(" @(#QP9&9X.D1O8UA&;W)M870^
M1&5F875L=$9O<FUA=#PO<&1F>#I$;V-81F]R;6%T/@H@(" @(" @(" \<&1F
M>#I$;V-83&]C871I;VX^179E<GE086=E/"]P9&9X.D1O8UA,;V-A=&EO;CX*
M(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O
M;&]R36]D93X*(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/
M<FEE;G1A=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I;VX^,C(R+S$\
M+W1I9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N
M/C(R,B\Q/"]T:69F.EE297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI297-O
M;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@(" @(" @(" \
M97AI9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF.D-O;&]R4W!A8V4^"B @(" @
M(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXS-S8\+V5X:68Z4&EX96Q81&EM
M96YS:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$:6UE;G-I;VX^-#0V/"]E
M>&EF.E!I>&5L641I;65N<VEO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  8$!08%
M! 8&!08'!P8("A *"@D)"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G
M*2HI&1\M,"TH,"4H*2C_VP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" );
M ?P# 2(  A$! Q$!_\0 '  !  (" P$               8' 04#! @"_\0
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ME=3A#IJ2Y7&>]W-IY3Y[>8;#=9NHY?QXZGMVX./ONTRTO1TFA](>4U7*)NR
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M'Q\4]VR(H$8UU9C7T/E-.#Y5%@@CJ5V]'W.'6&E9;97X%73CD#3Z1P<=ZW9
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MRVULKH>@SC8*Q0L@GQ*C29=>(B^E],-MCW5%5(Z6H<<Y?OA2&MJXZ*DEGG<
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MK=5LN%%%41$$.&ZDO$33T=WLU1$YC2_D/*2.A50:$NK[3<IK+<"?.?B/F/\
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M5V?--%9J!Q,TA <6E-HK76FDJ-9ZT=*X.=00/RT'<+T59*%E'1PQ,:&AK0,
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MT6MO=3+JK5<=MI<FFB>&N/4*^=)66*UVRG@C#?,: 2!C=4M4M;NA@$4+6@
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M@C#(P!T72M=(VG@C:T8#6@>Y;+V*B@B(@(B("(B B(@(B("(B B(@(B("(B
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M(V-C;RQ@-9X+[C]/V*9-13++N0_2?K+9]K\BO0+_ -2[^%>?M)^LMGVOR*]
MO_4G^%9\O;TN+X1YMN_K4JOXODI8_!+AX[*)W?UJU7O^2E;_ $EZG2_U1CY_
MG5<ZBHJNQZB%TI8S)"XY> ,KN3Z_BFI71P4\WE3ARC,9QE3B6-LK"V5K7M\"
MNFVU4+9.9M.WF7;7Z<][\5%M VJJ;5SW.N;R23#8>\Y4PKOV.7W+F: UH:T
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MZ3+_ ,C_ '74N-AN%FI_*K+6R![?])<5%Z/*3Q4SGQM>F*>-L;!R]/%=@=%
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M]1'=:FVSO[1D0P'#WJ:UP'D<GL5HBS7A]?1U]"Y?:CX%7B.BH[Z.GH7+[4?
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M_LS)!*?.QOA2*HUO;S1R&+G=,6X#.7O7:6^JIV_I\Z.O+*N:2BF@[.LB'G$
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%$1$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g109079g00v06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00v06.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1H<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &?\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"C_P  1" *.!,H# 2(  A$! Q$!_\0 '0 !  $% 0$!
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MR0R,@7&4B\D.;/0.6%T[@3SUP5+=/OU+@
M
M
M                                           (2>7A,F0G\+IW \_5
M-1MM.H3K7510A!9ZF#</.)5MN_7[NQM:<^6C'/,TL?2:[XM3W=K6X[C3=/M\
M62PN=+#[+Q<L>)X'L7K"I9[SU"C7G)3C#F?5>0'3FN:E2TC3JMW7ZPIQ;Z>I
M&FJ_LA=(IW%2D[6JW"371+P?RC.N-%Y"TV5=3E+&8R2^8Y>X<RV;&UKUMPSO
M'5E*I_5Q;Z\[_P #\ .C.'G%BRWCK-/3[:WJ4Y3YL-I>$7+S?D>EO_B/8;2F
MK>:=>\ETC2BDVWX+JT8YPELMFN]5]MJYK3N8*6(5'_A>>G*O!FJM;KSU[V1%
M&TN<2H4[VDN5>3J_\@-@4>/]C1NH6^I65:WJU'[U24?M&Y]*O:6HVT;JVJ*5
M*71',WLA]E6EOJE.^MHRA*G'HDUCM\1N#@GJ,)\.Z5S<32C"I++?R8@;'A+J
M^J*N7K,&GQ/VS1JU:<[^FIPDXM=?/XB'NJ;7;PK^E\TOJ SU315OIT,&L.(^
MW[V[A;T+VG*I-XBEGZC-J<N:GE>*R@)Q><Y*E(>)4
M                    #*  90R@    90  #*    !E        #( !
M    90
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M=.WXWU'9%GEVU!]ER1^@Y0W_ "SQRLW_ (DO\QUC9K_5Z7R%] %X
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M=]0TZRJW5RVJ5-9>#5VP.+"W9O>XTBWI8MZ>5EI9SA/P^,#;A*/8BNI)=
M
M                                                4:*@"+7K(OF\
M\HN# %OER@W)+"^<N8 %K&7EK. DN=M+!=P +:4GGWQ&%/KDO "/8K'N5P .
M1M^_AQLOEK^8ZTM/O:E\A?0<E[]_#C9?+7\QUI:?>U+Y"^@"Z
M                             <_^RPF_N!9X73TB_B= /L: ]EC_ -06
M?^\7\P&,>QQV3HFY=!N:NK6OI*D9X3Z>7Q&W_<=VEC[Q_>OJ-:>Q:UG3M/T"
MZC?7M"A)SZ*I44?#ULWI_I7H6$ONK9_MX?6!BRX.[0_N_P#>OJ/0T3AKMO1;
MR-U86?)5BTT\KP_0>TMU:%%/_P [6?[>/UEZQUW3-2JNG8WM"O*/=4ZD98^9
M@>@FTL1>#%.*&M+1MH7U>4N66$E^EI&782Z(T;[)[4I1T>VTRBY>DN)1Z)^M
MO^ %O@#MVG?Z1J6H7?OH7=6I%Q\XR7_,S.?"#:=2HY3L<MO+>5]1Z/"/3/N7
MLG3:/(HRJ485'A8ZN*,SQZ@-/;]X7[7TW:M_<VEERU:=/*>5Y_$<^>Q]T+3]
M=W&K;4J/I*,FER_.==\4%_T)U3_=?Q.5O8O?]KJ?RH_Q Z.?!W:#DW]S_P!Z
M^H][;&R=%VU5<])M_12?C_X1DTA@"D>G3/B7,D$NO8E("CZLPOB-O:PVCIM6
M5Q-.YJ0EZ..'W\.QD.X=7M]"TFXU"\EBE2CGOU9RO;66I\:=XNZHU:L=+MJF
M<3F^5IMM>KP UAQ#M=4U*I6W'J5!PHWE22I-M=5EX\?4=C<!\^Y[IJ?A!_YF
M:?\ 95Z;0T/9.WM.M*4:<:,E%N$4LOEZOH;AX#_@^TS_ ';_ ,S V#.:A%RD
M\17=GGQUK3Y5G2C=4W4SC&1N*WK7>CWEO;3<*U2FXPDGC#P_$YLT;AIO:WWM
M.\N-1NY6?I5)1]L3:QGRR!U%)9BVNYB^]M[Z9M&Q=74:J](T^6#3Z_,9-#WL
M81EEOE2;-<<3.&T=[:E;U;FMR6U/O'/1]<]L@: W[Q$W%OQW=II%K.&G<S><
MX375>+)^Q4A4I<0:M*KTG!24EZ\(Z%N]G:1MK9=Q2L;&T52-/'I50BI=GXX-
M#>QM_"QJ/3^U+_*@.O(]R1&/<D
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MC'BO$U=P)W=>:!K5SP_W;7J*^MI/VI5KR:])!1[+F\/>2\6>7N'_ /53I/\
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MK2T^]J7R%]!R7OW\.-E\M?S'6EI][4OD+Z +H
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M#.8?8W?A8U'Y<O\ +$#KR/<D1CW)
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M-^.3JZK3A6I3IU(J4)Q<9)^*?<TMH' VEH?%&>ZK"_A3M)5I5O:BCVS/FQV
MAQI6>)FS,>;_ )C==:K"C2E4JR481692?@C67&/AG>[[N],N=.U=:96L^T\9
M;[^I^9AJX#Z]?M4MP;UO+RS;]_3AA<R_3 "FAZI;;O\ 9(75YH\W4MM-H*E5
MJ/LY+IT_4?D;(W_Q+TG:5U2TZ4:UYK%=I4;2@DY-M-]<M'H["V)H^QM&GI^@
MTZD%->_JU&G.3Z]7A)>+\#3USP UU;IO-<L-UQM[RO)M5%!\T5TZ=O4@,TX;
M;6W#=[INMW;U]%3O9Q]%:VL>]"GA]'[U+^W+S-3;SVVKCV0[TW4[ZK9VNIRY
MN:D\.HG)>]SW726.GF; T/A/O2QUFTN[K?-2XH49\TZ3B_?KR[&:\3^'%COO
M3;:%S7JV]_:9E;W%-I.,^F&\I^,4!J;CQLC2.'VTK'<&TXUK#4Z-S&EZ55ZD
M_2)QFWE3DUW2^8Z"VW=U;[0K*YN7FM5IJ4NB77]!I_3."FJ7NI6;WGN6IJVG
M6?6C0BL9EX<V8^3EVP;PITXTJ<84XJ,(K"2\ -.W_P#^HNC_ .YP^A&Y#";C
M9-2KQ+ANGVW%4XT8TO08Z],=?W&;
M         <C;]_#C9?+7\QUI:?>U+Y"^@Y+W[^'&R^6OYCK2T^]J7R%] %T
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ME-89B^U^'FC;;U6IJ&GTVKBIG+>?K S"/<D42P5
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M\.-E\M?S'6EI][4OD+Z#DO?OX<;+Y:_F.M+3[VI?(7T 70
M
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M[^'&R^6OYCK2T^]J7R%] %T                     &0^Q$"0*1*@
M         911]B@$@0YL,G%Y0                               (\S
MD4YD44O,KS("JZ@)Y
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M;]-3_*P_60]-3_*P_60%P%OTU/\ *P_60]-3_*P_60%P%OTU/\K#]9#TU/\
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MT>(&C554OHROH+^RVOM$>Q'Q:!Z'N8[BQ_US7_:/ZA[F&XO[YN/VDOJ/>CQ
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MTJM6O(N-2$FNN/5]9LFGAQ]Z<%ZSCMQEI$[3 ! $H]B)*/8
M      *-#!4 $&LH ""BX]%V+=2G&=.<*D(RC+HXM91?+4U[YY[ :<W[M.AM
M;6*.Z=*7))UHQJ4Z<.5=>K>5\7D9[M'==MN.=2G;RAZ2BES)34GX?66>*%>V
MM=D:C4N_?Q]'+D]4N5X..MB[^O\ ;FZ77I59RMJM7$TL=L8_@@.\H)I/+)I'
ME[>U&&J:3;WE)MQJ13>3U$P*@
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M\GI[.?-MRSE+NX]<GL_H+5I;4[:A&E0BH4X]DB]@O/GL^:F9GO*@[%<#!"%
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M4F<DW^)=M)B([OL\!X$5--X3)+L<\I$278BB2[$@
M    6YKN7"W./,^^ .?/9.Z]7K:4]&L:-6=3F4GR>/O?^9R]/2]2ITW4J6-6
M%-=7)M?6?H=J&VM)U"MZ6]L:%:IVYIP3^E'B[AV-H5QHEW;PTVV@Y0Z25*.5
MUSY :O\ 8JZU<U=$NK&^C4Y_3-PD^V.5?4= 1CAK+ZFF/8]SH.TU2WE;1HUJ
M-U*,982;BDO5\9N>.&\MYP!<!3)5/(
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M\A?0<F[]_#E9/_&OYCK2T^]J7R%] %TMX?.7 !;Y<YR$L%P8([I1I_!)! E
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M
M              @:HXJ<2+G:FMV5C;T>:->K"#;ECX32\O6;7?8QK<&TM,UZ
MZHW&HT8SJT9J46\^#S_ #5'%+?5IHFGZ?J%QI]O<U:L>:2FD\=_-/R,)H^R2
MK4::C2L*=.G^+"2C]$3<^]*>S(RI6&NV[E*"2CA=.WRD5TWAKL>^MU4M["C.
M+?=\WU@:KT+V0]QJ-_2M?:C_ *1I-^E[=?DG2FGUW<65"KCK4IQE\ZR89;\+
M-K6US"M;Z?2A.+SE.7UF<4J4:,(0IK$(Q44OB O+HR2ZD24>P
M  !R-OW\.-E\M?S'6EI][4OD+Z#DO?OX<;+Y:_F.M+3[VI?(7T 70
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M6'A_&9]3SS2ZY7@!?75 I'L5         $7/KC!(CS+($@%U
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M;?OX<;+Y:_F.M+3[VI?(7T')>_?PXV7RU_,=:6GWM2^0OH N@
M                                  P  *.*?<J (JG%/H522*@&C!1Q
M314 6W%=B#Y<_$7FLD'#J!;Q!]XIB5*GRO,$3Y&BN&UU(U"8F7GW=A:WE-TZ
MM../485K&QH1EZ72YRC4SEY:[_,;$4$D^BRR/H\=DAIMCRVI&MM?6>J:[H]2
M%&_I2KT(I).#_P"9ZM?7=,U6WJVER_13JQY<23Z/YC)YT(5/AP37DT>1J6V[
M"[C+EM:5.H_]I&"RA&ZSLFU+^8:_X>ZA:[5UB[T&^NHTZ2GS4)--J3>5X?$C
M;$*CG24HR4D^TEXFHMY<,[BZJJ_MKFK.M;?TD6\Y>'GS]0V3Q+IJI+1K]3=>
MV?)*367WP:WCE'*$_M]QNC<-*3RTV7'GP/+TO5[*]I.="M%_I1Z2FFLHPIWA
MC:LU[6A--X*ID(O)7/7!=7:N22[$5U*II 5 RAE  $\@
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M0OH N@
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M]P-V/N':5_7C<SEZ%TW'K%=>J?D;_H\WHES?"\2:3\6PEU[@30
M                                                %IX:EAY+I;Y>
MDL@:=XL\2=-VM<^BO](I7O+C+E54?#/C%FNO=]VRH]=J6V?_ 'J/_P#S-Z[L
MV;H>X*CGJD:3EYRSY&,/A%M&2Z*C\S U[I/'#;U]=TJ-':=%3;24E<Q?_P#3
M.D=,K*XL;>K&')&=.,E'RRNQS'OS:>A[(W9H]S:\M2A4E.4X06>SACO\;.FM
M)G"KIMI.GTC*C"27J<4!]Q*/8B2CV              .1M^_AQLOEK^8ZTM/
MO:E\A?0<E[]_#C9?+7\QUI:?>U+Y"^@"Z
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MZK)]:D\XDBSGM6:^5]%"W&1-/(5VJ231$H@E,!=@
M  "C[E0!%(EA  1:&"0
M                  "CD6ZF'"2EXHD^QA_$+>MGL_2IW-Y*//UY8MKJ!I_C
MM4W%1O*OW#A4DGC'*TO[/K9IIWG$""RH5OUH_:.C>'O$C3][7EVKRTMI4J79
MRIQ?DO+UFO=\<8;"SOYVVD:7I\HP2RY4(/KE_P"$#"=J;>W7N/<=J]4M*M2G
M":S)SCTRUGQ]1VCH]N[;3[>C)>^A3C'YD:&X1\7M-U2]5I?6EK;5YN"C*G3C
M#SSX?$="4Y1G&+AU4DI)^H"Z2CV(DH]@             #D;?OX<;+Y:_F.M
M+3[VI?(7T')>_?PXV7RU_,=:6GWM2^0OH N@
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M!47/XQ;ZK]!M$O/MA^:>'N1FF22+,'&2]ZT7(O'B&>M+B!%->9+(0 9
M
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M?>U+Y"^@Y+W[^'&R^6OYCK2T^]J7R%] %T
M                                          @(370@E@NLB5FNTM6\
M5MO+^CUZTI_ZQ:2YGAOKTS_ S/9VM6^L:/;UZ%13DH\LTO"6>QZ5W;QNH3HU
M<NE+N:*T.578G$J=K*;^YMQ+*=3OEKU8\O(Z*5]VNH\PAO\ IOKCP(SAGFZ]
M'T*PDI16&NW<JNIA_"6#;KV-;ZM!RC+EGYY9B6D\,:L+O->LW37;_P 8-SR6
M40Y?,R_;TF=R]##ZIGPTG'6>SR=NZ1#2K948]4E@]2G27++)<C#';)7EZYR;
M1$1&G!DM.2W*W=\=S:4[FA*C4BI0DL=3$;[:TM.J2N=&DX57U<4\Y^?)G*;7
M8BW[[."%ZY9IX8?I.Y_1U/0:I3]!)=Y/Q,GH75.O'FHS53XB-Y84+N+56FNO
MBC!-6L:^V[_VW:2G4MV^JEU^C!*T1&66QH/*3[%R)CFV=>HZI&*BTIXZQ9D7
M,DF\]@SOCFDZE+Q)Q[%F,\]2:EUP%$P4R,@5!1,J
M
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MEI][4OD+Z#DO?OX<;+Y:_F.M+3[VI?(7T 70
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MWKWA[/-T'=%N#RNY5].S)9PJL\Q=+<7A#G"-:7 04LDT\@
M
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MFX/^UX,[CLTO:]'R4(_0!?
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MO&7GP-KQ2>'XFN._.NWB]9TMNDRSCM/A< !=R@
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M$O-*YM4A[6KPRW""37=^LW#=6E&\H2HW$>:#\#&Y</\ 0I5)2]#6R^KQ*/U
M<^<'<ZYQKGJ%M#%HYU??>KT,OK+>][26T^.M#6;Q-6;NJ4\KRC4S_$Z;T/;F
MGZ*Y/3Z<XR;SF37U%S6= L-84?;U.<FOQ6OJ YEXT<2K76[BG;Z5%U(U%C+2
M[X^,W=P-TYZ=L.A1J1]]*JV_U8_4>M3V!H<)<WHJK:?C)?49/;V\+>G&G234
M(]@+"TJSE.3E;P;;]9/[DV*_]6A^\^I/#)IY Y$WQ2A2XY64*<5&/,NB_P"(
MZSMNE&CCMR+Z#D_B _\ TYV37XR_G.L;1?ZO1^0OH O@
M                                                       %)=BI
M278"#2/ WG84=1V[J%"NLKT$VGY=#WSR]RR_\Q:A''>A/Z"U/[H@F=0Y]X=<
M2([9G<:9>)3MJ;?+)]UU1G<>,>D9;ST_1]9S]<J*OZZ];R0][B70^@MZ?COW
M</O]].KMC[WM-URJPL_[!F/7P9S_ .QN2]N7V/'ZV;^@E%,\3JL<8LDTAVUG
M<;7(MX)(A$FCGA( "0P,( "/BR,DVNA)]V4:Z 6G3;[GC:_HU#4Z4H5(^_\
M"1[V'@MU*?-T$QN-)BTUGE'ES[OW:UWI4W6AF=+FSU\C$*=2*52I%O"\#JB]
MLJ=U1]'668X\#7^[=BVU6+NK13YH=7'*Z_N.++TG+O$OK/3_ %_C2,.6/_7E
M<$M+J4YUKRHL)R>/F_YFWX?"9ANR]1IJU]K2CZ*K%XY9=V9A"6>7/0Z,5.%=
M/ ]1S3FSSDE>RQEE,^01JX4DV5()]28
M                                           $3YKRSM[NFX7-&%6/
ME.*?TGUX13E60/'H[=TJG-5*=C;QFO%4HK^!ZD(<D,+MX(N<J'*@(0@^[[EQ
M+"     4DLE0!;4.I-1PBH CRL<K) "/*RB)C" B5CW*X02P!R-OW\.-E\M?
MS'6EI][4OD+Z#DO?OX<;+Y:_F.M+3[VI?(7T 70
M                                                  "DNQ4I+L!
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M-0HWMO&O0?-%K."5+8YJ]%)$BQ3J=GGHR]S(0R5!1LIEDB0
M
M                   #D;?OX<;+Y:_F.M+3[VI?(7T')>_?PXV7RU_,=:6G
MWM2^0OH N@
M                       "F"/)U)@"VX]&044^\47GV*$<8'FZSIEKJNGU
M+*^IJ=&?@_/_ ,,TKKM'7.'6LJOIDJUQHSDLJ;4E'*\EA]_4;ZFHM>^/AU'3
M;6_M:E&\HQJTYK#RC3'DBGGP//VOKUKKVE4[NUJQG^.DFN7YSV8U%**<7GP-
M3:KM[5=E5ZM[M.%S7L*GOZMI",IM]?5VZ>H]S9>^K/5(^UM0BM+O(M9HW$\2
M;SY/#$X^TVH-@*6$74^A\_,N7FC)3B_%%Q/*,]BZ",&2$ ,E$&@*Y1'Q"1+
M[D(E&^A5H)(F!'J^Y%XQ@G/HBU%Y(T0^/4+.C>4^6O2C4CZS"+VUN=M:@J]K
M*<K.3;E%M-17AA+J;$Y3Y[NQI7=*5*O%2BPWQ9./:7GZ'J]MJ%!.E43GXQP^
MYZZDUW,-U'0IZ1.=[H_/SQ]\Z4<O/CX%W1-UQK_T>I8M:V<8J/E;^?!,+6Q<
M_P J,QC)-%<EBC.,X*4&I+S1>330<VIA<0"        #[ ,H(B5B!4
M
M             '(V_?PXV7RU_,=:6GWM2^0OH.2]^_AQLOEK^8ZTM/O:E\A?
M0!=
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M/3UE8O/<"96)0K$"H
M                                    .1M^_AQLOEK^8ZTM/O:E\A?0
M<E[]_#C9?+7\QUI:?>U+Y"^@"Z
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MXCK33U_JE!_X$</7=/7#:(JZ<=^4;?3X$H=BG@5CV9Y\+J@ D
M
M      '(V_?PXV7RU_,=:6GWM2^0OH.2]^_AQLOEK^8ZTM/O:E\A?0!=
M
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MJHZF>4*4Q6QSJR_T*Q[,AAYSDE3[,Y6B0
M                                                    .1M^_AQL
MOEK^8ZTM/O:E\A?0<E[]_#C9?+7\QUI:?>U+Y"^@"Z
M
M            *8&"H I@JNP    4:&"H I@)8*@        "DL>)\E6>)XCD
M^J18]&N9O(1._AI/C%>Q]O4J,%RR>>J^,U[RSQ%2EUQW-H<5-OUJ]S[<CS<M
M-9Z?&:JJU%U:YN9/&,,\GJ/SOK3]$]%]J^#7TVAPFUZ;N9V=1MJ$7CYU]9N6
MEB<$_/J:4X3:!4=6=]/FCSQ?3]*^HW31][""7@L'?@I-8?(^K^W[\^W]KW:)
M6F\IX(RZHK26(LW>5W3
M                                      !R-OW\.-E\M?S'6EI][4OD
M+Z#DO?OX<;+Y:_F.M+3[VI?(7T 70
M
M                    1D0E@G(M.#R-;1,Z?/>6E*[I2IUXQE%K#YHY,76P
M=)]LNJZ5++><>C1F*@\"4?)%?;KY;XNJRXXU2=/DL+"A94E3H4X0BECWL4C[
M(I",2:[,LRM:;3N5,$H]BA6(0J
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MH"J2*X0$2L2N$$L
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M[Y)X<XON\>#/OVQLC?NXM+IZA;7?]%))K$XKPSXL#L%= <JQX7<16LJYD_\
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M<K^Y;Q%_.7^UA]H>Y;Q%_.7^UA]H#J@'*_N6\1?SE_M8?:'N6\1?SE_M8?:
MZH!RO[EO$7\Y?[6'VA[EO$7\Y?[6'V@.J <K^Y;Q%_.7^UA]H>Y;Q%_.7^UA
M]H#J@'*_N6\1?SE_M8?:*>Y9Q%_.I?M8?: ZI?8AXXSU.6)\+N(D(2D[J6$L
M_P!;#[1ANW=3W'I>^86.H7F90FX-)^4DO,#MN/8J6+'/M.BV\MPB_P!Q?
M
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MJ'^[C]!>+-C]YT%Y4X_07@
M                                     %'V*@")6/8KA!=       6G
M++:4<X+K>#&>(.KST+:E]?46E.$>CSCNTOX@?/NG7=!L9TH:W6HOWWO4TY8>
M5Y'MZ3<VMY9T:]A.$[5KWG+X+/D<A["TO5>*NLZBM2U&ZIT:,ISIN$Y/\9KQ
M7DC)N$>^=1T'B35V=<U)5K&F_1J=23SC,7GK\8'4]-IQZ$B%'#IYBTT_(F
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MGBF_'U>HW-PWW-4W1H4KJYIJG7IS]'-+MGN!EF,DUV(I^1)=@
M
M         (29KOCU-PX:ZGCNXK_,C8LC%.)FERUC9U_:0ZRE'*_0T_X :+]B
M'%\MW-^--9^:1@]&O&E[(J[FNG+4>?G@7.$.]8</-7U>AJ].489G"GZ\<R7\
M#U.%6V;O=W%6ZW-125E*7/[[Q68K^ '75@T[2DX]FB^6K5<M&,?Q>A=
M !&2RR1&7<#G;CGQ!NYZJ]MZ-0E[:B\.2?FO^9K3@CH^I:?Q4HQU1M7$Z3>6
M\_C?4=?QT#3GJ<KZ5K!W3_VC[_\ CH<^:))>[S2SEXI/Z)@;EXK7BTS8FIUY
M2?2GA8^)FH_8^;5LM<TG4;Z_I*K*I.7*Y-OO-FR>/]-U.&.I\K[0,;]B[4SL
MNI'IF,GV^5(#6NW:<=M<>9Z?#,:<JK22?3X#^HZ'WQN^AM2BZMQ2])E-]_\
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MX)W_ +<E&EJ-7VFY<V'*.?H-Q;5T6CH.C6^GV^7&C%1R_'IC^ 'M1[%2,42
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M6,W.=6?I)MX[XQX 9/%Y+B[$,%0) I'N5
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MH]>F.[;_ (F0<J*Q[="H%OD>7EER&8K#>0 *Y&"A)=@"6
M
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M0$AEE$\^#*.6%V; G%]2I!262:Z@,#   IR+R*@"DDL%,DF4P 75=2N E@
M       !A  4PNOK#@GW14 444ECP'*L%0!1))817"  80P@ &$
M
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M>.5-I_\ Y/?CV.9O8EZO5<+NPJM-*3BOT2:.EDWA 3
M
M
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M6)12EX+S]:/9T"[WAN;8FK6>O4JTZO3T<73A'LX_BI>L"'L7L^FU%>;GA_\
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MMG3K74"2[
M
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MO(NM>] J@(]@
M
M                                       $7W"[DL#      !1]RA+
MP@(8)1\2H                      *21'!, %V   B2&$!$$L(80$0NY+"
M&    $20P@*1[E1@
D                                             ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g109079g00v07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00v07.jpg
M_]C_X  02D9)1@ ! 0$ QP#'  #_[1804&AO=&]S:&]P(#,N,  X0DE-! 0
M    %?,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZYUNH[OI:N=V=90U!='$\X/(0T[ _P Y2;Q$N[+)H^\5DL@BY*=X8XNQEY!
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M)*N0$18V^W:ELEKJ+C<9>SI*=A?(_/0 9_0@R2*,AQPT+W78?-]:I]O'0O\
M&[?:/K02<BTK2_$C3FJ*F6GLE=[HEA89'@8V;[5Z:9XBZ;U+<IJ"TW!DU7'G
M,9< 3CKC=!N*(.FRU:ZZXL=JU+36*MK.2Y5+@V.+'4G&._TA!M*+!:IU+;=+
M6P5][J##2N>(P[TD$_0"M.^WAH4=;NWVCZT$G(HSAXVZ(EG9''=@Y\C@QK1C
M<DX\5(M-,VH@CFC)+)&A[?4=P@]T1$!$1 18V_W:DLEMFK[C,(:6(#F<3XG
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M9)+CGT-/<>J\.*E;>-*\)II*:Y2&Y4XB8:HL;YQYF@G!&/F6I\,(QK7B_?\
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M:N-QNU09)#6/:P<K1R-Y6'&P])7VS<*K!1WBYZBG9-5W";+VNF<TMC/*!YH
M!Z#Q[UJ_DD$G0]PS_CS_ ,QB"2^(U-=9M-U$UBK#3UM,.W8, ]H6@GE.0>JL
MX;ZNAUAIV&NC:8YF^9/&[JQX<6]WCRY6V$ YR,J -#2OTGQ]O=BB<?L;7,$C
M [KSXC\/YSNY!T KDP$0$1$!$1 1$04<-BHJXFZEU(RY2632U''VC8.VFJIC
MAH&VPP#OYP[AT*E5W18O4 _Y%K.@'9GZ4$?< ZR>;AM#/63/FF#"YSW').&A
M0C23U&J=<ZE95ZQJ+/ RND; WFV(,C\#H>F IDX!$?:K82TO(8_+?$<@V44Z
MEU-P[.F]36\6CW'?W&6-O,QSG.E/. 00,?"^E!NW$*[U>D.'%IL5'=9ZNMK7
MEHKFX/,TF0YR?D'3N6%A==N%/$^UVU]WJ;G0W&+S_=#LX/GC;^B%K5QL%W@X
M-Z:NMP#NRH9WG&02&%TQZ#?O"SVIKS2\3>+EADTFY]9!10 S/P6!N\I_" \0
M@]*R]WGB?Q(N.F(KC-;J*VU-0QLD) +N5SP.G\P>U931FLZ[3>C-8VVMJGU5
M?9NV["5^"7 %^,^P+5M.UT?#;C/?[KJ;F@H*RIJ712@<^<ODQLW)_"'=WK(6
M*R/U;IGB!J"WQN='7=L*8$@<X^Z=QW'=U08*EL6J*O0L&LX-0U7;N>9'1<YQ
MR\Q;TQCN72VG]24LNDK1<[E.R U4#'\SSC<C_>N;J'B9::3@Y3:6?SONK"8>
MR#';9D+LYQCO\5/-LT/;;[P_L5KU%2"9M-3L'(3T< /J"#8_?19AS?\ *M/L
M,XS_ +E]=IN]%<NU]P5+*AL9P7-\?^"M"EX):& <?L0.8CQ'U+4?);IHJ1^J
MJ: $0PUI:P'N'*Q!/RH[HC4=W(.<>#'[_NK?\S)^?&J<1-_*5TS\7/T3*S@J
M[/'S5N#D]E)^?&K^())\I?3/*,XIS]$R#)<=-+55AO5%K_3@;'/0O#JN-N?N
MK>8'IC'XV>BQW'/4]-J[@?:[K2G[]5LYVGJUP9*"-O2"N@[E20UU%44E2P/I
MYXW1R-\6N!!'L*XIXRZ?N.@:^MLL3?\ W?N$PJJ8G?S@TC&W3'.X;A!U=6[\
M+9L_XF5SAP?X<:EU/I)M;9]1&WTW:N9V7:.;N,;[-*Z+JI.;A5,YI_YF?I6H
M>2B_FX8M&=_=+R1\C4&N1\%=:L>''6.0.[MG_P!A2MK?2LVIK;0VR:H<RA9*
M'5 CD<U\@#7# (P>\=XZ+=,!6.:"2"@B/2M;4Z*L&JK;<*A\[+:Y\M*]YR[L
MG -8-_Y0/M5/)]M5:^V5^I;R7NK;O+VK&N<?,CRXC;IT>/8O7B)1S7'7EOM$
M,>8KI!$)WY^"V*1\NWKY<=_52G3P1T\$4,+>6*-H8QH[F@8"#U[ES_HN8WSR
MB[S5S^<;?$8HP[N&).G](KH ]% EMI_>QY2DD,F&P7BG=,T^G$NW^J@EGB2/
M_P!.M3__ -94_P"R<N6^%EWXF46F!%HRC,UL$KL.$3''/,<]6GOSWKJ/B4<<
M/-3X_BZH_P!FY1]Y*_+]K; /]_?W?RW(-*EJ.-]]C?0R!M'&_8R.A8T =>HC
MSW*2^"7#F70UOJY;C4,J;I7.#YWM)(&.[<#O)[E*!:#W*N$''M[TY<=3>4!?
M+=9KH;?4]F7B;/+L.4$9 /B/8MRJ.".MI8GL]^8.1CE,S\'_ %%K4FK+9H[R
MC;Y=KN][*40F++6EVYY#W _BE28_RBM%",D5%02.X0R;_P"J@U;@_-)PWUL_
M2&HJ2-U=7NYXZ^-Q<) ,XW=@]1X=ZR_E$[:WX??&S^>Q:K8[K6\6>,UNO5OH
MG06JU@9D=MT+B,Y.^=N@6T^401[]^'V3C%6<[?RV(,3KQTVBN.UGO4664-RB
M#9L="[E(Q_JA;7Y0-6;E)IW3%&XF6X5;'2M'^#:]AR?D#EF^.6G8KYP\J9@T
MFLH>2>!P[G @?02HYX%7*KUYK]VI*]CN6W43*=I.P+R'AQ^<(/+7M(RAXW:(
MI8QAL$M/$,?R1"/T+[?*]BD^QECF)(IVU #O#/*__>O/BD0/*"TCOG]E19]L
M*E+C%H]^N=%5%J@<!4!XFA.0// <T9SW><4&WVHL=;X#'CDY1@KZL;Y7-6@.
M-KM)T/V!U]2R05-(>1LK&DDCTXSGOZ+,:G\HFR/MTT.F(IZNYS-+(<QO#6N.
MS200,[GQ03G!6TU1+)'!*R5[#A[6G=JA33]N.KN/MROA<'T5E8::(GO)#NG]
M:OGX1Z>K](Z;U!K;4@[.XUL3I>3(/*PN!WQGKR@]5M'DW6]]/P\975#?N]PG
M=4N/K#6_^5!H7E4PU4VI=%0V^1L=8^H<R![NC7ET0:>A[\=R^:ITOQKH[:ZI
MCU%13M8PN;%$P%^ ,]#"!\ZRGE)D>_\ X=CIBX-_VD*Z"HQ^Q83_ "&_0@X]
MTO:]2\3KK)9=5:I93OB?YU%( R1V/ -9@]?%=1QV6DT_HFIMMMC#*:GI'L:
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M"\M>\(K5JFO-PBFEHZTGSY(R!S#'3=I\ @BZX025>F.)U32. IS61AN-@<&
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M:CU:V*G>W+&> 03)#PAT/!(R2*PQ->QP<#V\IP0<_C+>((XX(8XHF@,8T-8
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MM3*2ICB=)',V>4EI:,]"['<HAX=:EXKT6C;?3Z8L=%4VJ,/$,LCAS.R]Q/\
M?1WD]RS]94\;-54,]MJ;11T4$S>1\D<C00#UZRGZ$%.!U]K:OAQKVS5DSY8K
M72R1PN=CH6RC&>OX 5WD[:"TUJ?2E;57RUQU,[:IS0YTKV[9/XI"WG2>@FZ$
MX1WZEE>7U]102NJ79&"X1NV'J+BH2X5:%UCJ.R555I>_MM]*VH<UT9\<G=!.
M.KN#VAVZ>KY(K4RCDCA=(V9L\I+2!D'=WB%\'DQ72NK-*U-+63OJ(*29T<$C
MN]H<0/F 4?Z@X.<1:FWR&XZ@BN4$8YW4Y('/C?&Y'@I.\G[5%NN5B?8J2B;0
M5EJ BJ81WO!+21U&Y:3U01/QSL'OAXQ7:BCWG;;>UB'B\,CQ]*G#@;?Q?>'U
MN>YQ-33<T,V?Q@X_H(6B5^WE3M;W&C;]$2]>#P]ZO%35.EY!R0S'W5!G\(D,
M!^@H-QX]78T.AIZ.&3EK+A(REB ZGG<&GYG*(_)RM/V%XKW:@^$Z*@',[^4>
M0GYUL6I)I]8^4#;;6PYM]F':R8[I 7'O]+ O/A:,^4)JKO'8OQ[6H+N.NI+S
M?=5V_0>FY3!45+0^:0''3F.,@$C8!;-I/@7I:W6U@OE&+G<'??9WSRC)QOT<
M/3W+4Z4\OE4RB78.CRS/\S_\KHG /0H.?N)W!J*UTYO?#QDM!<J8\_912/=S
MX',,<Q.=VC8^*DWA1<+Y7Z-HW:HIY*>Z-!9('M +L..#@;= %N,CVPL+WO#6
M#=Q/0+R%33]@9F2-="W?F:X$((@N<;=6\?:&.+SJ2P4I=,'=#([M6[?TVJ/.
M*MNI;GY1UHH*^%LU+.Z!CV$D9!> >GK4A^3O3S5S-1:FJ1Y]QK"(SXL#8\?/
ME1AQLCNTG'FABL#VLNKQ"*<Y P_FVZGQP@G?[3NA._3\/Y1-_:4/>4+P_LNC
M+72ZBTPQ]MJXY0P-CD>[FWQ^$3X_,O>\P\<+7;Y:Q]5VD<0R\-EC)QZN=8'A
M]IFZ<8KA#<-5WWW31TI(=2-\V08&>\$=7()IM%RJ+SP"GK:YQ=4R6-Y>YP&7
M'W/DG;Q4?^3[P^TQJ30PKKU:V5-29I!SF61O21X[G#P"F'5%MIK1POO-OH&=
MG2T]IGBC;X-;"X#Y@N;N$E!Q,J=-A^C:ED=I[5^&F1@.>=V>KAWY[D$]2<&M
M"R1N8;%%OWBHFV_UE$?"42:.XXUVE;?4.FM4ID!;G(9RM>1U_FA8#5NJ>+.G
M*R&BU!7OH6SNY6U',U[>_P#%<? J7^"/#*#2\4E[K:MM?=*P<W;M/F@$8VV[
M\GO08CC_ *XKV5U+HG3;I&76N>UCI6X\T.P ,[G?F\.Y971G O35%:XG:AI!
M<[G(.::9\\HR3ZG#H,#HH\U*PQ>5/;.W.(S-!R9\>9BZE&-_2@@#BEP:IJ"W
MF]</8WT%TI<$1Q2O=S[]W,3W$K>-+U5XK>#\QU)!)%<6T$D<@D !.&$9./'J
MI#D>QG,]Q#<#))Z86&U3/%+I&[OAD8]ON63=IR/@E!%_DI;Z+NGQY_Z5-S1@
M*$?)1_<7=,'_ )\_]*F\=$!6N.#UPJD[K3N*6LH=%:7FN4F'U!/9P1G.'/()
M&?1MXH-4XP:DK:ZJBT=IQQ%QK6\T\PQB"(9.>\YRW'3O6I^2G1?8ZYZNHNT[
M44\S(^<]78<\96T<+:"W66TU]WO-UI);]<PY]0[MFGE&!AH_H@]3U6K^3K=*
M6FU)K,U-9!'VU6.3F>//)<_H@EGB/KFVZ$M4-?=F5+X9)!&! UI.<$][AX+.
M6RYQ7*UPW"FYS!*WG:UP .%2[V:W7VF9#=:2&K@!#VM?N,^/SK[Z2GBI8&0T
M[!'$P8:T= @@+6.K-7:ZDNUDTU1OM5NI1*VHK9P!SM:#L,!W4 ^'5>ODE1.A
MLVH(97<\D<S&N=^,>>;=3;J( :>N>!_S67\PJ%_)5_:FIOC0_P!I,@FB]VJC
MO-MFH;A V:GE&'-</H46\"+Y5037;2%VE,M9:IB(GGOBY6X]/7F4Q$=,* ;V
M[[#>5!9O<^S+A1.[4?C'EG^H()^;T55:WJ1W!7("(B B(@+RG9VD;XR2 X8S
MX+U5,!!HW#O0%'HIER;23R3>[93*_GQ@9QZ/0M>O7!REDNU37V&\7&T25CLU
M(II.02;_ ,D#Q/7*EKE&ZK@(-#IN&EDCT?+IZ8324\Y+I93R]H]YSEQ/+U\X
M]0M8M? ^VT]93>[;M<:RAHSS4U-)("V,[]Q&.\] .JF/ 5"T$80:'K[0,>IJ
MNGN%+7U%MN5.WLV3T[N4\I[LC?O/?WKY]$\++5II]5522S5U?5-+9YJ@M>7A
MP/-U&=\GJ5(A:"G*,H(>O/!2CJ:NK9;+M6V^UUK@ZHHX7\D;SC?S0 /'J#U4
MHV6V06FWP45*T-@B;@; +(!H"J0"@L'3JN?- ?PF]5CN]QCZ(5T+@+GK0/\
M"<U7\2'T0H.A&]5<K1LKAT0$1$!$1!SQQV_?GT+ZC]+EFO*O_>^@^,,_/8O;
MBQH^\WSB?I6Z6ZG[2BH0>V?OYO7T>E9+R@],W75>CHZ*R0]O4-E:\MW[G-/<
M#X(-RX<G&@=-_P#];3?[)JV$G9W<N:[54<;+7;:6@I*>E%/2Q-@C!I@2&M
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MJ"X1F6@J(V;N=&YK?605ROIG27%#1M[O55IRCBC%?,7.,D1?D!SB.K?Y10=
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M92Q5=++3U#>>*08</0@ASAW1NUCQ.K]= .^QU.TTE$7?AC!)(SOC[J?#HIK
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MJ8]*JB"G*K2P-)<!NKT0:IQ$CO-5IJIH]/PMDJJL& O<<=FUP(+_ )%Z</\
M2U/I+3E-;:8><T$R/SGG<7%Q^=Q6S<@[QE W'>3ZT#"JB("(B B(@(B("(B
MB(@(B("(B B(@\ZC[R[U*#?)E_;^L?CY_,8IRJ/O+O4H-\F7]OZQ^/G\QB"=
MD1$!$1 1$0$1$!$1!3"8540$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M8V5<J-  !G955,JA*=Q<BIE,J15%3*90514RF4%45,IE!5%3*J-P@(B("(B
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M_+I/K7UVW3%';Y>TAJ+@]W7$M6]X]A*B>D9Q7-Z*UK=NJN&RA B(@(B("(B
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M@P QO+]"^L ]ZOW'5.JR\^4+ P;83X/095^%7"2+6G(5R=R80$1%((B("(B
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M*'.+K=9W2[.MNFY#16R.#M9:DMV>=MLX_E>/<@E.V76CNE**FW5,51 >CXW
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M@N8W&SL ;K$5_#*UUEAM]MDN%V+K=)VM'5.J 9H#YI :[EV:.1NP\$&D:,U
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M>;E)YBYN<9QOU[EM%ZNT%[UAPON5"7^Y:N2LD9S;'!I7=<$H)-1$0$1$!$1
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MH-\F7]OZQ^/G\QBG*H^\N]2@WR9?V_K'X^?S&()V1$0$1$!$1 1$0$1$!$1
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M'+;2\4X98;5.VQQQ"1LG;28$@YB-^;/7'>L1JK1FK](Z\KK[H6B=4LJX^R<
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M: ", 8..BU_0>FH=,V%M'#CM7N[69V2>:0M )W_FA;$%:]HF=1XA*XC"N'1
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M?0L\L#H3]QUF^+L^A9Y 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MVRCBH*..GIV\L;!@ ]5][ K&-ZKT:,(P[_55,(B B(@(B("(B B(@(B("(B
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MP[E\%RXH:DNVM:_3VDK?1EU%'VKY:AKG9 Y<]'M[W+VX<V2\ZIU.W6NHG-%
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M*VMC< D]4AKDF*QT1_=<!LKFJC5<C$1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M)^XZS?%V?0L\@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@*A0E6EV>BB10NQOG [U'-=3C6>L*>2*7FL]KPYS<[22Y.WI
MQYI63XAWZ6DHOL;97QRWRJ(9#"[? [R=QCH>]9?2&FZ33-H%%1\Y:7F61[R"
M7/( )V \ M(^2.KZI9B.,- P &] !W+U5S<%OB%7 5$*-Z%#U551W1!1%0*U
MS@"1GIN@LE=AS=O-[RM4N=:R]W,6F'F=3QGGG>W8 #;&>O?\R^_4ES= ^&BI
M-ZNI/*PC\$9W/SKZM/V>&U12")I[60\TCSU<[O/SJ-_1K3Y(ZI9"EAC@B;'$
MWE8P8 7T@#"L WR>J]!T4PR ,(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB N>=!?PG-5_$A]$*Z&7/.@OX3FJ_B0^B%!T,$0(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B*F4%,IDH?0O)SR"0-SX*)%E3,V!CGS/
M#6-!<YQV 'K4=6:WU&JM8G4;Y7,ME*YT,$).6R%K@"_'^@<;=Z]==78WZO;I
M2TSEM4\AU;(P_>8P>_'B X=W1;M8;=#;+934< ')$P-R!\+T_+U6L?)7?UD?
M>QGFXPK\;950,#"'HLJBBIG&=TS@+Y+C7T]OI)*BK?R1-ZDJ4Q&WM*[8N)PT
M#<Y6H7*OFOM5/;;4^2,#S9)VD@ ;C8[>!7H^IK-2R,^QSW06W'G2=[^_ ]&,
M=ZV2W4-/1PAE/$U@P,D#!/K\5$-JZQQN?+Y;/:X[?2QP,\Z5@\^0CSG'KN>]
M90,!.X0-WR%Z *6,S-IW*W 5S57 0#"($1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1!YU'WEWJ4&^3+^W]8_'S^8Q3E4?>7>I0;Y,O[?UC\?
M/YC$$[(B("(B B(@(B("(B B(@(B("(B B(@(B("(B K3G*J3@*T% )7C/*R
M-I,CPUN.I.,)43"!CY)'!L3&ESB>X 9)6HSU'OJJ.SH)B;=&</D8[',>F,CY
M?8H:4KN>[TLXEOMS;<)XG1TL&1$QW]\V.^#Z_F6U@8:X =.BLIX60M:R)H:Q
MO0!>SM@?2$1:W4QUTKFVZV5-9*"6PL+NJU7A)9ZJV:?GJ+@\NJJZ<U#N;JT%
MK6X_U5X\2:Z>HK;9IRC!Y[B[[J0?@Q[@D_*0M\AC:UK0UH: , #H%;O3'K[J
M/H8T8SNK@,*C3D*JK (B*01$0$1$!$1 1$0$1$!$1 1$0$16N=CH@J3X+7-;
M:II=*V=]=6-=*0X-9!'DOD."<  $GH>Y6ZNU=0:6BIS<'/=45;BRF@C +Y7#
M P!G?=S?:M=TGI^YW.\U-]U:Z.5KQ^PZ-[<B ;;D$?"V/=^$4%^@]-3NNLNJ
MM0@B]U0Y6Q$AS:=F/@MZXW+NA[U(C6C V\%8UK=B O0=$%,#*<H540$1$!$1
M 1$0$1$!$1 1$0$1$!$1 4*^5A^]NWXW']*FI0KY6'[V[?C<?TH),T)^XZS?
M%V?0L\L#H3]QUF^+L^A9Y 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!%3*M<YW<@JY8?4%YH]/VV:ON$O)#'UR>O?@+[*FJ$
M,,TDDC6MB87N/@ ,D_,H[H.WUY?FU513GWO48<&13-R*B0.QS8Z$#SQWJ:5W
M.Y\"[1.E9:W4+]7W.:45%0PB*GD.1$"1TSTZ'PZJ36CS059#&QD8:QH#1T "
M]!L,=R6O-YVE5O155H.%7)4(.].Y6.SW%6\Q.WT(+N; )6)OUVAMM$^61KGN
MR&M8T[N.5Y7N],MP; UKIJR3X$+>I]*^*R66H-1[LNKNUE=YP8XDM;GT'90U
MI2-;LOTY03RR.N5P:!438<(R<]F.N!X=5LK!C*MC8 .@'J5X"F%+6ZE6C/57
M*C55%1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%SSH+^$YJOXD/HA70R
MYYT%_"<U7\2'T0H.A@BIE,H*HJ93*"J*F4R@JBIE,H*HJ950<H"(B B*A*"J
M*@.55 1$0$1$!$1 1$/1 14RF4%45,IE!5%3*J@HXJS=7.7D]V#A5M;IC:81
MQQ0XAUFC*ZEAIZ2.I;,S/G9ZY/I'@M(DXX70AV;73M)&,MSD?ZRL\I&4"\VP
M@<SA%\%O7J>Y1$[M&@_<I7.\>4Y7N\/AXLF*+7CNY,E[1.H=5\,[33LL<%WD
M DN-RB9-/-WDD9Q\Y]JW)AP_E[@M?X=Y]XMA)!'["BV/=YH6PAPYAMNO&RQ/
M7/\ +JK.X>G-YJ\W/<.FXQT7QW"YTU"PF>9@=C9F=S\BP%+<[M>>T;!2FA@S
M@22@\Q'H&RKI>M)MW92[7N*BC#>;GJ"<-C;N2?!8ZWVJ>Y3>Z;SS$'X,!(PW
MV+[[+I^GMKY*C>6KEW?*[J5F&DG8@)I;KBG:JRFIV0Q]G'&&,'0!?0  $8,!
M7 (R_4;WJJ 81 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1!YU'WEWJ4&^3+^W]8_'S^8Q3E4?>7>I0;Y,O[?UC\?/YC$$[(B$X0$5 <
MJJ B(@(B("(B B(@(B("(B B(@(B(*..%;S>E7.Z+YI'\K\8V0>CGD GJ%Y&
M7E:7.. -R5#^NM=U\=SDHZ#LF1,;DG.Y/M7EI34MQU16LL=<]L<+VAQDCSDX
MR<=?0L/?K-NE['_"YXP?$6_#Y_LWFXU]1?+DR@I(N:W<Q%1.-@1MYOCOYPZ+
M9;=;X*"G;#1Q-BB'<%2WTL='314],,,C:&Y\?25]S0&[9W*VT\JUXGM7PH06
MMVZKYJ^LBI:2:>H>&111N>]Y[F@9)]B^AS^48.PSWJ.]77YEYO;-(V]CY#*1
M[ME:"6Q1YPYN>F2.;V*U:]4J/;0(-]OMUU%)Y]+*1%1%VQ#6@-=_K,*D'EQE
M?'9Z""VV^&CI6!D,+>5H"^_IT2UNJ11G>KD!RB@$1$!$1 1$0$1$!$1 1%3(
M0514SGHF0@JJ95H>2L7>;[;K-$9+G6009!+6O> YV.H ZGNZ>*#*%Q&Y(PM(
MUGK)EO9-;K4YM3?96@4\# 3N3U)Z; $]>Y8BDU#J'65344ELHWV:WMW%;,TE
MTK1MYHV(ZYSOT6S:/T=0:8AE%+SR5,\ADEGD(+WD@#<X] 08C0VDIXXF776'
M)57Z0@N<3YL7?AH&W4_,%(#&M#0 -AT5,=V%>WH@8"(B B(@(B("(B B(@(B
M("(B B(@(B("(B H5\K#][=OQN/Z5-2A7RL/WMV_&X_I029H3]QUF^+L^A9Y
M8'0G[CK-\79]"SR BIE,H*HB("(B B(@(J$IE!5%0'Q3*"J*F54;A 1$0$1$
M!$0E 14RF4%45,H#E!5$1 1#T5,H*IW*F4)V4; $JJL:4<_E4B]6Y*M[79"[
M""KCA?/4SMIX7R22-8UHR7.Z#=?+>;K2VND=4UTS(HFCJXXSZ!XJ/HH[CQ%B
MECJ&2V[3HD#3&YI$E1C#@<GH,XZCN*M2FXW/A*MPJ)=>ZA-OHW2-L%*_]DS,
M\WM7Y^"._'FGVJ2:"BAH::*"F8&1QM#0 O*UV^"V4,%'11-B@@8(V-:.X# ^
MA?>'>A1:V_ECQ" (J9&-T!SG 4"A)!7E).R-I=(\- VR>BI+(6!SG !H\3A0
MSQ4U#+-4.H:=[#'D$EIWZ+.]XI6;.SA<.W,R>W7LF'W5'*QQCGC..IRL#>;W
M.1[ELS1453MCR]&>DY4'Z2JZA]?!1-GD$$[\/:,KH2S6Z"W4D<=/&&Y R>\J
MF'-[L;TZ.?Z?_P =?IO.Y>%BL<-*145#.TKG#SY'$GY/#P6<Y1X*C,A>K1@+
M=YDS,K6 ;J["(B!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1%3F](051,ID
M("YYT%_"<U7\2'T0KH9<\Z"_A.:K^)#Z(4'0B*N!XJTE Y@F<]%8' ^"KG'=
ML@O&,;HO,.).ZOR$%45,A,A!5 <*@W5>Y!4'Q5<KSRF0 4%^>JH2O/F'=N?!
M4YP1DN 1+U!\%7)5D??S*XHA7)3)5N4R$%V2F2K0<JJ"H/BJY"M5I("#TR%0
MG969"MYL=1@H/1%;S;^*KE!5%:2?0J<Q]&% ]-DSZ5Y9.=MQZ%C+M>;=:V%U
MPK&0 ?C?[DB)GPG4LIS=07 D+5-8ZNAL,E)2Q0FJN-6_LX(0< NR .8]PR1O
M@K6;MK6Z7OFI]*0-IH2<.KZG :!G\$9)Z>([U]UFI;!:@*JHD-=>'#,T_G$O
M?WX&S1OGH M8I%?QIFEICLQE5:XK<RIU!K"*.MN$IRR''.R)H&S1G^;GIWK#
MT>MK+[J#:C3M$V-QQD1,./\ 566XA"X7VTN=2451'$T' =R^!]*B^&TW"IE%
M/34DCI3CS7;#KXKS\^?/[GRSV?2^F>F\3+@F^>T;3_'J2VTD,$,+B&N8.RBC
M  QW #*&JO%S8]M/3"D@?L)7N/-CT#'Z5?IO3])14%-VD&:@1MYB23@X6QQ,
M:UN&C"ZJ[\O!R3BI:8Q]V"LVFHJ1O-62.K)LYYY_./R9)PLZ8^7&!T7L&C&R
MJ K,+6FWE:T;)A7850,(JHT;%5 PB("(3A6E^^PR@N16AV54'*"J(B B(@(B
M("(3@*TNQTZ^""Y%:'9ZC"N0$1$!$1 1$0$1$!$1 1$0$1$!$5"<(*HJ!P/>
MJH/.H^].4&>3*?V=K'X^?S&*<ZC[TY05Y,W[>UA\?/YC$$\%RM)*ID)G;9!4
M.P5<'9[U\YW.ZN! VRGD_E[93*L!R,A$%^4RK#T5N?0Y0/7*97D'#P*N!079
M3F]*M)V7RUE5'20235+VQQ,:7.<<[ =2G\)?9S(7CQ6FNXAZ8#L?9FFV.#YK
M_J65LNH+7?&N=:JUE4UIPXQ@X'M"M-+Q&]&F=#E4'*\?@CO5IR?%5C]4:>_,
M%0.ST7F,*QTK(&E\CN5OB5.S4O<N(*!^5BGWJ@[0--2P.)Q@ GZ%\];>Q$S%
M/333//3E _24B=K12=Z9QQZ]%KMYU#!25S:&)AEJW]&CN_XRL<*>_P!TJ>:J
ME924)ZQ,^&1Z=C]*S4%JHZ2![X(<2<N[W$DE1,3/:&G3%.\]T$ZNIZ2.\O?+
M74XJ\8=%MM\JV#A#2T$=_P"W-?'+4RM/)"W&V ?3Z?!0W>GN-[KC)EQYC@Y6
MS\(:N.DUQ;Y9WLC8P29<XG8<A7HSZ/BKC]V/.G1D]>SY,?PW],]G4K"(W.!.
M#UPA<''FR2 L-'JFRS2N93UK)I0/@M:[?Y<86O7^_P!^NH=1Z4M[X9LX=4U.
M QH\1@DYSCN\5P12;.*-1&H?=J[4LE%7PV*V1":\U[2Z%LAPUC=\N)W[FN[E
M]^CM.MLMM#JKLYKG,3)45'+YSGG<[]<9S[59I;2='9WBJ=S5-Q>,2U,A)+O5
MW#Y %LX :IM:(CIJ*M& /%551N%14A #A5R50(<>*D5!RJ%V^R\:NHBI::2>
M9X9%&,N<>X+4M!<0K+K1]6VTRNYZ=W*YKQ@D>/J0;J.B*UKMMNBJ"@JBM+L'
MT(YV-T%R'HJ<R^>JK(:9I,TK&CTG"#Z 4)\%@I]5V6#/;7&!@]9/T+SH]7V.
MKG[.GN#'R> 8_P"I!G^;JM;@U;0U&KJC3L7:&MAC;*\X&.4EWI_DE8K6^O*'
M3EGK*F5D^&-PV0-&.8].I]*XSI]<WJFU:Z_MJB^N+^8N>!@C)(! [MR@_01I
M('0K4-:\0++I(QQ7"8OJ)3YD4>"X]>[/H*U'1%LNNLK73W6]:EFJ*:=@>*:F
M:UK&$]Q/*'?.MZMVB[#0R-DAM['3#I)(]SS\Y*##17C4>I;8Y]FM[+;32C$=
M14R$2@>/)RXZ>E6:5X>QTA?4:EJW7ZL+@YCJQG,V/<D\K22!W=/ +?8X61L#
M(VAK1T [EZ<OIQL@\XX61L:V-C6- P T8 'H5X5X&RIA!4=$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1"<#* >FR#/>L5?[W06.WOJ[M5,IH!^&[./F7EIO4=
MJU! ^6S5T57&PX<YF1CVA!FE"OE8?O<,^-Q_2IJRH5\J\YX<-^-Q_2@DO0O[
MCK/\7;]"SG,5@]#?N-M'Q=JS#G !V>X907=H%7F6@WCB/;*"LGI&1R2U$(W
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MHX(N1\DDIQN7%06I6OBVUMTU!06R,NK)0P>L+%TFI)[D>:S4CYH3_?''#?:
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MQFJ(ZVJE-GJ:@P0LY1@9<X-/CWA=0Q.:]H<S=I&0?6@]0<JJM:KLH"*@.55
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MR9+S??F7'C^(.K7YYKS7#U1R?6OF;KS5K7$.N]:]I\8Y/K79WO<L??9[:?\
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MLQ_S>B_(Y?[2Z<&FK+_%%N_)6?4J^]JR_P 46[\E9]2#F'[>VL_\!1_D<O\
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ME:BT.>6=H6D$''1P=^A!H/!GASI:[:!L]RK[3%+6.:'N>YSMSZLX4K-TM8@
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MV;/Q6^Q><+6Q,;&P8:P!H'H"]&OR<80>;Z>-SLEH]B]&,#0 .B!V>Y7("(B
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ML;[M:W_RKTUOHR;4.J]/7:*I[-EKDYW,Q\+J@WB/.^YW\>Y>H& K&;C(Z*]
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M;M5:%JIZFUUNF)X:*>WM+&12#+"T\V>H/XW@@^_A'>JR^Z-@J[C*V6I:\L)
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MCP"JB("(B"F%CK[;&7:US44KBUD@P2.JR2IA!J>B](4VFM(ML&>WI\$.SWY
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MVZGU-4U=4:VGJ'X;VCN5WG.'3./F7MP\;[NL7%J^1?M2N]T.B/>0.W^L+/\
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M_7Q'SJ<N&'%"GUN:R!](ZWUE-ASXGG.!OO\ ,5%_DIW.VPR7ZBG(95F9\H)
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M$1$ C*IA$0,)A$04+<XW7E)14LC^:2GB>[\9S 2B(/5C&L&&@ =P'<KD1 3
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F,(B"J(B"F%5$04PJC9$0$1$!$1 1$0$1$!$1 1$0$1$!$1!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g109079g00v08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00v08.jpg
M_]C_X  02D9)1@ ! 0$ WP#?  #_[1FJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &8T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MLO#Q8H*D)34X0U-U)D5C9(,G1$:SPH3_Q  ; 0$  P$! 0$
M 0(#! 4&!__$ #P1  (" 00 ! 0#! D$ P$    ! @,1!!(A,04305$4(C)A
M(W&1!A:!L14S-5)38G+!X4*AT? T0_&2_]H # ,!  (1 Q$ /P#ZI1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $7!/)"@VK^H%-8ZL4T;&RRXR1GL@)TNN<959Q]6: ,Q+%A^.P=^Y1G
M4G4FLNK71V_^YX ,%S7')0%WB5NUQRW#>YSV6--<J6."29THV1C+L%?.-;J^
MNBI?98:F1S)L!Y+CSRO9M6^6@;&R1S-_T@#]+E 7A;=86ROJWPLD#'-. 2>"
MI#!,R5N8W!P]0<KY?<0^M93M]S&,_%2^Q:CK=/S-8W:ZFX'<H"]@BP[16"NM
MU/4M Q+&U_'Q&5F Y0!$1 $0_F7&[T0'*+C)XR%R@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 %X54ABIWO:,[1N7OY*,Z_O4-DT]432O#7;'!H)[G!0'S_ -0KG4ZE
MJY7/=Q%]%H';"AS*Z1K6MX#V=UU@NM099&M&9)3@971MIJW2.WXW'E 2*CN\
M3J!SGN'F._FHY;WOEO+C&"8]V3PNAI9:6)K9A@;E*+:REIZ<%H!<X9SE 2.F
MU#1TUL= ^%K7[<;B>ZT1@=>G2F-FYF.X\EJM3 .H7&/.XCR7IHS4/LU*^FD(
M!(QR.4!IJA]18+@^-O,9//"SVZCA#XW'ZRLRX2T\PE=4#/.05J7VUM:]CHF
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MT1^I?3P\U:?96'J%YU']YD_H%>B\ZC^\R?T"JECY[^Y]&=#2<_\ ];-^D*T
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 %#^K?\0[G_HU,%#^K?\ $.Y_Z-3'LB71\FV;
M_ 8_F[_F*W-K,'M\ JO[QN]_//"T]E_P%G_F_25<.B+%8(=+FY7]I<^>0PL:
M&!V/0\H^PNC?0R=._ CW2PAV!N_$_N7<OZ<\XE@_W'[EY3=/-/M='&ZIF:=G
MM!)8,;/M47USIJSPV1]UT_4&2.)S8WC&.<X4$FBZANLS[N/P=+74@8.0S'*B
MA^@5R?B3E<'Z!0$V^YX_CW</Z(_4OIX>:^8?N>/X]W#^B/U+Z>'FK3[*P]0O
M.H_O,G] KT7G4?WF3^@54L?/GW/G\1Y/]=F_4K0?]%5?]SY_$>3_ %V;]2M!
M_P!%?C/CO]HW?F>I1_5HZ%P:PN)P %5T_6:TB2:6&W7*:@A?X<DS(V9W>6!O
MSA6?*7"!Y8T/=CAI\U\D75M+$ZXFA%UL]Y94%OL4#BZ)_H2_(Y[\87I?LWX=
MI]:K//CG&/\ WW_B4OL<,8+<U?>J.JZF:/DAN-TB;4QQ/9#"XMAD!E=C>-P\
M^#P>,=UC])[W.-::Y=<ZZH?24@8_$LCGMC:"XD@$\<#R4>NT=QEZB=.9;I3;
M*OV6G\9K6@-:?&?Z?#"XLU+/1ZJU]8IJ>45EYI9(J4@>XYQ:X#)\N7!>]=I*
MGIG1%KZ5[=*?+_0YXRENR3;^&>TEQJ!;[D;4U_ANJO#;P[Y;^W(6TU5U2LVG
M:NABGCJJAM7 *ACX&!P(+G- Y<.<M*H:E-+1:?DL]T;?'7=DNP43)2*9V<8S
M[W!Y]%(;K:*B@U1T_I)*+P'0Q0ET1=O\/-3(?I?(Y^M39X%X?"2>WCGU[26<
M_P#YQR2KIO@M?2'5&U7^]2VHTU71U08Z1K:A@ +0W<>SCY9*U=;UKLL%;.VG
MH;E44E.=LL\<3< _#+E'K_035W76JIXVG=/;9H6/<.-SJ=X&3]:T&C=2LT-I
MR[:8N]GGJ+HZIRV%T37PRY#<;B3]G!\EA7X/HK(JVNO<W&+V[L8SV\EG;-<,
MMN\]3K%0V>WUT!J*PW#_  :*%@WN.2WG) &""#SY+C2G4BV7JJK*2>.IH:VF
MC,DL<[0!M R2""<\<JJ==6JX0Q:7OU;;'6JAA88ZB"UD1F .D>06!N,$@@\=
MR?K7GI6W1:BU;73V*EN55$RDG;[9<)CXA+H', +<G/) [J/Z$T$M-*:^_.5P
MT^L]$*Z>Y(ENINKENKK3>*:U4]R:P,=$RL:P- <#WR'9 /EPI1T,JZBNZ:VJ
M:LGEGF<Z;=)*\O<?QK^Y/*J&P:D-BT%>M(55JJ#=\O8T,8"QWO%Q+CGR&<<'
ML%;/0)KV=,+0)&EKMTW!_P!,]<WCFBJT?A[A5#"WK#SG*P^?XEJ9N4^2Q).R
MUNI?XMW'_0._0ME)V6MU+_%NX_Z!WZ%\AIOZ^/YK^9U3^EG;[G;_ !2V/_1J
MR%6_W.W^*6Q_Z-60OW4\@(B( B(@"(B (B( B(@"(B (B( B(@"(B \I#MRX
M^05!W2\T%?KV9]SD_N:!I8"[D9R?V*\[LR66WSQT^/&<WW>5!=%:#910U$MY
MACDGE?NY:"NK33A4I2D0R$=*[K!0ZTKJ2F>?9*B0N;CMW/DN]?;7WSJ;44)G
M?' XDNP?+)4LU1H.7[_4=PL<;8_#&'@<>?P7O:-)5\&NWW>;;X)!\_FNEWUY
M=B?+7_<A(A]AM@L_406F&9[J6=CMV3\QV6+:-,44_4F>C>[\6W#QQY[BI])I
M.M/4&&\>Z*9C2"?7DK6ZBT=>F:NCNUD<PM>T!^?=QAQ/ZT5\>E+M!HUFIO[D
MZH6V",D1-9'@#^F5)JCJ#X-R]C^]E2[#@-^!A>-TTG<:S6EON;MA9"U@><^C
MLJP32P\%T3"<CDM6%MD&H\9X)2*1OD@GZJ4#ZL8C<QI =SCNKM:6&%NT#;CA
M0?J#HAU^?'64,G@UD6 WW>^,^?UK2V>P:R-3##75(CIF'Z0>3D?)39LOKBU+
M&"#6SG_^=47'&6\_^1;;KJ(A86AV#(2-OK](+&U)H:^2:G%SM<C=[6MPXG'(
M&%ZTF@+M=KG!4ZDJRYD1!V ;@?M*V4J]T+-WTH8-[:&W5_3^W-MIV57@M#22
M56<)JK9U"II-4!TDKG>X2=P^K*M+5EHO3*>G&G) T0M#0PD@'R\E$K;H*^7>
M_P %?J.9K1$00![^?M5:+()2DVL//YAHM2N>V2RS2,'#H<CUQA4%H^JOE/?;
MN+' )"9G[LNQ_+*^@IZ;-L?31_\ T_#;]F%"NG6E*RQ7.YSU8:&SO+F$?%Q*
MQT]L85SSRPUR:S5+Z>IME$[5#W,G]W,+.<G!4%H9XJ+7=!]Z1-3PR9!;]'(Q
M\%8_4G2%?>:RFN%K<U]1"1^+=V[$+0T^A;[-?Z"XUOACPL[FCRX6]5E:AR_1
MDM&KU7;!=^I45,Z0L8]A)<$N-J_ [7-##;ZB3PIAEP[*0:KT1=ZS4AN-MD:S
M8/=)7&G=%WNLU VXZDD&8N& '=G[5=71VI[N$NB$BV6?17*X8,#'DAR%Y*Y+
M')SA!\T6NNEYHK8 :R8,4@V!'#L]E\\=:M%U=-62W>F?OIR!D'U&59VI-=T<
M-M<ZUR>+.[@>6%4VI=07>^1FFFD)8[RR?VJ<%'8HE<6FN(F/M3<;> I7:JSQ
M@61#<'<*)5L,U/.Z"1GO+>Z$CGAK"68?AV<$X4%MR9OMD<+7.?[KAS@^2C5Z
MN#7R.\-QRWT6WU4ZHK)"R-@:]W&05H8+/4TL;S5-^.4)-+1U8DN@%62YA[;N
M5+PV,1-CC(VN'DHD8!4UQA ]_/!6WMT,MNJ6^T.+H_CY("2/M<1MV_Q"< >[
MA=*2IW4HI&19.>"MA3ZABD#8:.F;)@8/./U+FBJYF5CGMI!N/EG]R PIXJJU
M2M:\NV/&2T%)JVKG\-NZ1T8^B"X\+*K*]SZESZUO/DWOA>EFN4=-(Z5T8<-W
M /&4!"=666J$WWP\,"/S'JMW8IHY(8@^-N#W&%,+S<J>[49IH:;D_'./S*--
MIVTM6()3X8[]D!GZFH8_O=$:=[Q&?I,\APM9:;G#04Y8QH+_ "RI2ZKIY;<V
MDBQ+GN<<A0VX6UQF(B&2#WP@,>]72>5F^5YQV:,K8:?=3P\S-,U2X>X,9P5J
M[589[E=6P2.);N [?%67TLI*&@U344E8QKG$#87#L4!;6B#4NL$/M@Q)SC)S
MPI NK&AK,  #X+L@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@.HSYE<_6N/T*&ZLZE:9TK<_O?>:\15FP2&(#)#3V*K]
MT23,%/K59#K?H<C/WT/^S^]<_P -^AORK_P_O5B.2S/K3ZU6?\-^AORK_P /
M[T_AOT-^5?\ A_>@Y+,^M/K59_PWZ&_*O_#^]/X;]#?E7_A_>@Y+,^M/K59_
MPWZ&_*O_  _O3^&_0WY5_P"']Z#DLSZT^M5G_#?H;\J_\/[T_AOT-^5?^']Z
M#DLSZT^M5G_#?H;\J_\ #^]/X;]#?E7_ (?WH.2S/K3ZU6?\-^AORK_P_O3^
M&_0WY5_X?WH.2S/K3ZU6?\-^AORK_P /[T_AOT-^5?\ A_>@Y+,\NZX'S59_
MPWZ'Q_[U_P"']ZX'6[0X_P#S4G/_ (?WJ,$\EF^?==@JR;UNT.3_ .\_KV_O
M5@66Y4MXME/<*"42TM2P21O'FT]D7V(,U$12 B(@"(B *']6_P"(=S_T:F"A
M_5O^(=S_ -&ICV1+H^3;-_@#/_-^DJ[=&T-'JC25)0250IZBEJ/%QMSD#_NJ
M3LO^ L_\WZ2MI2NE$P\%Q#G>Z,>:/L+HNZ]7^TTFJX:"JEW4@H_!>YH\\Y6/
M46RPU.E:ZUV6K=XKCXI);GL<X6#8] 6JBMD5TU15F,R<AIQCT"VL>E]+WMSX
M]/7%\57M('A8&?L4$E'2,+)'-/\ )X[KH?H%;74EGGLEVGHJD9>P]_4>JU1^
M@4!-ON>/X]W#^B/U+Z>'FOF'[GC^/=P_HC]2^GAYJT^RL/4+SJ/[S)_0*]%X
MU+@V&0G@;'*I8^??N??XBR_Z[-^D*T 3YC*HOI#KO3^FM+34%YK13U0JI7EA
M'D2%-QU>T9^56?9^]?E/C/A>LMU]MD*FTW['HU6044FR>'S&U#SW;E0/^%W1
MN?\ WJS[%S_"[HS\JL^S]Z\V/A&OCU5+]"_FU^Y.\G^:N=QQC'"@?\+NC/RJ
MS[/WI_"[HS\JL^S]Z?T1XA_AR'FU^Y._/.T9[+D.([!0/^%W1GY59]G[T_A=
MT9^56?9^]3_1/B'^'(>;7[D[R?1,G.<<J"?PNZ,_*K/L_>G\+NC/RJS[/WJ%
MX3X@NJY#S:_<G?K[O=!P,!HPH)_"[HS\JL^S]Z?PNZ,_*K/L_>G]$:_&/+EC
M\AYM?N3O)SG'/9 ,^6%!/X7=&?E5GV?O7!ZNZ-/:ZM^S]Z/PGQ"2PZY#S:_<
MGP;D<E:O5(Q8*_!X\%WZ%%!U<T?S_P"UF_9^]8-^ZJZ2JK-60P7,.EDB<UK0
M.YQ\UKI_!]:K8MU-<KT(E;!Q:R3S[G<8Z2V,?_IJR%7/W/0+>D]CSYQY5C+]
MC/,"(B (B( B(@"(B (B( B(@"(B (B( B(@. %UQYXRNZ*, Z;<^2Y 79$P
M#KCA".,8RNR)@'7;SG'P3[<>B[(F = .>R8/IE=T3 .F,GLN0,=EV1, ZX)*
MX+?>[+NBD'3!RFT_)=T48!U YP4QD8*[(F =,$_+R1H[^J[GL5XRS,A;OE<&
MCXICD9/5O;A.%CMK(7,W"0 ?$KF"IAF)#'@D?%3@'NJ@UE;)ZO6KHYY'>SNC
M!:/+N5;CGAK2XD;1W.54.J+G'7ZN#8)PR)K0TOS\5,3.WZ>"OKG;*ZQSR.?&
M70'C)7>URLEA)SS\3R%NM67"&:L;0QR^+%W+E&9*-\$IDICM9Y_%:8.1-F'>
MZ=WM3Y'\C;PHO07*KHZF7P&Y.?(J75E>(Z-Y/O2X(PH,9I:6XF67=MD=G"JS
M>K+)0+K*^$231X((.5GNOT=:R*!S6Y/&0>Z6R6CK+341SN]XM]T+4PTE/!5L
M,8Y]50WSZ'-\MKH9V5=*",<GA8\U='-1D2?WS"D;9/:('0[N!ZJ(W2-L-:YG
M;)X0M@V&G+_#:6/WL!?SR?BMO2ZSIXY#+[N7>1*UFGK)#52CVD@-<#W"S:G2
ML%3-*RFC!;$,Y'_7Q0@P*_4$556>*WD$\X*WOC4LU QX.'@#LH--1M@KS"UN
M .ZD[( V@B# 1CS0$MTQ*R%CGU&&@\MSYJ(ZZGD?7.J87G8W*L'2]-%>J.(5
M #61 -^> HKU#AAEG%#;H27Y(P.<H#3Z(U.(WN9(P%Q 'O%2F*5K;D'5(#8W
ME5O56BLM1B,T+HI3V)!"VE%-6UP'CNPUO8H":RU-+37.1U$\$<>\"M!2W&:*
MZMJ&R?C 0<Y^*Q)VOC'A4QR\]RK3TCTECF9#57&IW@G<6#X("V=-5;JRRT\L
MOTG#GXK:K'HZ>*DI60P#:QG 60@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@.O9?/NI*>&J^Z:GCFB;(T65IPX9YR%]!
MJ@+M_P#%!4__ &1OZ0O+\9;CX?<U_=9I5S-$Y-FMP&/8J?\ V N/O+;O\BI_
M]@+8.^E]2X7XX]3:W]3_ %9ZBBO8P/O+;O\ (J?_ & GWEMW^14_^P%GHH^(
MM_OO]63M7L8'WEMW^14_^P$^\MN_R*G_ -@+/1/B+?[[_5C:O8U_WFMW^1T_
M^P%S]Y;=C_ J?_8"V.6[>2%':S7&F:*JDIJJ]V^*=AVO8Z=H+3\>>%O5\3<\
M5N3_ "R5>U=FP^\UN_R.G_V N?O+;L9]BI_]@+K47RU4UI^^<]=3,M^ ?:'2
M ,P3@<]N_"U]/KK2U1(R&GOUMDED(:UC:AI+B?(#*O&O6268[GC\R,P-D++;
MB,BBIS_Y GWEMW^14_\ L!94]?2T=')4U51%!3,&YTCW - ]25@674%HO3Y!
M:+E25KF?3$$H?CYX54M3*.].6%^8^4]?O+;O\BI_]@(++;CVHJ<_^0+8GZ*Z
MQ\'NL?/M_OO]2VU>Q@?>6W?Y%3_[ 3[RV[_(J?\ V L\]RBK\1;_ 'W^K)VK
MV,#[RV[_ "*G_P!@+D66V_Y'3_[ 6<%SYJ?B+?[[_5D;5[$%ZJVNBAZ?7Y\5
M+"QS:5Q:X,&05/>BO^*O2_.?[@BY_P#*H?U;_P 7.H/]4<I?T3_Q4Z6_U"+_
M )0OT;]C)RLTMCD\_-_LCAU2PU@FR(B^Q.4(B( B(@"A_5O^(=S_ -&I@H?U
M;_B'<_\ 1J8]D2Z/DZS#-"SYN_YBM]8"T7JDW_1$C3RM#9>:%G_F_25L(WN8
M\.:<.:00C["Z+@ZAVJKO&J+92N=)'220-#7M' .#Y*)&QUECUS'04+Y9I(W-
M)<T8." >WR4MTGK^KBM40N5I?6,A!#:AKNW/R6E_A#CI-65EUBHB]\K-K0Y_
MT> /3X*"3SZW;#J=@ ]\1-W'U.%71^@5LK]=:B\W*:LJC[[R3COA:T_0* FW
MW/'\>[A_1'ZE]/#S7S#]SQ_'NX?T1^I?3P\U:?96'J#V74@D'/YEV15+&JDL
M-L>][W6^F<YW<F,<K@:?M7;[VTO^["VR)^8-3^#UJ_)U+_NPGX/6K\FTO^["
MVR(#4_@]:OR;2_[L)^#UJ_)M+_NPMLB U/X/6K\FTO\ NPGX/6K\FTO^["VR
M(#4_@]:OR;2_[L)^#UJ_)M+_ +L+;(@-3^#UJ_)M+_NPGX/6K\FTO^["VR(#
M4_@]:OR;2_[L)^#]J_)M+_NPMLB U'X/VK/%LI?GX87;[P6KM][J;G_],+:H
MHQ[@\Z:%E/ V*)C61L&&M:, !>B(I 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!%P#D+!K[K343MLKLNQG#>2BYX!GHM?;;O27 D0/]X?
MR7<%9^>"3V0'*)E,H B+@GX(#E"L:IK8:?\ OK@#Z96&;OO!\"![OBA#DD;3
M/Q"B6K*L^WTL#.<D[AE9U74W'PGO]R.,#G(Y4&TYNOERJY:J;+HY'-;CYJ\4
M8V6+&$2*X&!K0''D^0*U=R?X<4;J1Q8<\\96[IK724THED<7D>1*V>RDF:2Y
MC0!\5?".>*EG.2L=2W:Y4U*8Z:<EKN#PHAX$C6;MWON.2IWK*)LT[_86AS8Q
MD@<J#FHE#]KHR/7A52P3EOC)Y1THR0XY>1W6)'6QT\SHISD!;1CBYQ./)1QT
M37W4AX/.%9A(Q+KFMGS2#!^*UU?;IJSPHC&0X<$X5FOTVU]D%?0O:XQGWF <
M\*/W$N\!LL9 ='W"KCC)=3V\(B%-:Y;?-NR2/,8655!S&-EC>"[T6RCNGC1R
M"9@[8SV6L8UQ>_< 6NXX*HTC:M[NSK/=W00M9'$?$(Y/EE:,MG?6-J:@Y][.
M MA6;(89&L=EV[D$]EA^*R,#>[OYIAFV?0EMHO%,',+FY:!C!*D%DK!'27";
MAK2TXR?B%4,-7X-<][,.9N/GW4SH[I!46Z2-SPPD9 RH(-+!6,GO$PEXRX_I
M4JN4DC+?%'%R"H_8K2ZMN[7%IV<GMW4MFMD]1<7QT["61#&!R@1S8Z^:GHVT
MVW:X^9.%(+/3"W7ZBK*I\4A<X-(SZ\_J6-;8J&ICD972>$]G'?"U]502^POK
MHI2Z*)XV_G1\ E'W0K@^CMAIXN3N)=Y=@J6CDK)"UF_#?,-Y5V5%\I*SI[XE
M\@=-X9VQ[7;3R#^Q:30MQTTV@GDK*&1DS!N!DD'O=_@JRG&+PV4E9&+VM\G?
MI;H:>]/]KK';*9N."T@NY7T+20,IH6Q1YVM]53NB>HCGUS:=].V*A)#1CRY]
M5<<<@>T/:,@]BHA9&?TL5V1L^EGJBX+L>2QY*V".38^5@<>PW!7R7,G*946N
MFI@*T4E!A\G\IW<!;BS5YK8"78WMX.%"DGP0I)O"-BB90%22$1$ 1$0!$1 $
M3*X!SY(#E$RF?@@")E,H B9YPF4 1<9Y3<@.474.7)/P0'*+C/P3=\"@.47&
M4!0'*)E,H B Y1 $7&5R#E $1<9Y[(#E$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 <*@+M_\4%3_P#9&_I"O]4!=O\ XH*G
M_P"R-_2%Y7C?]GW_ .EFE/\ 6(LAWTOJ7"Y/T_J7"_%SU@B(H 1!RN,_! 0W
MK!=)[+T_NE72NVS.8(01W;O.W(^65#.F/3C3]RT/25MTHQ5U=P8Z5TS_ *3"
M>/=^S/S*M/5%FAU!8:VV5)(CJ(RS(_DDC@_4JBM%AZE:5HI[-:3;ZJB<YW@S
M29W1M(QQ@\8[\Y7UOA5N_0RT]-BKLW9;;QE?G_L<ML?FSC*-?K/1,NC.D^IJ
M=MR954U14PRQQB+:6'Q6#GDYX 6QI^GNGJ[I&*\T+(ZYE!)4>T,X<7,!=_\
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M1$52P1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:6./5=_\"-RE+:BQ#])<^:Y+>2<KCS7AX-2)=6_\7.H/]4<I?T3_ ,5.EO\
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M3XZ.&R+2R2.HT_1&U">VESW[<N:.X4!KXGB20;'MVG R%/;#=V.DG\%P##D
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M6T34G/M'C:FJ2EEDDTM3MJ[Y31R$;0X$@^:DW42^SLK#;:5SHH(0,[3C.?\
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M;="VVMH79DA#=IW<Y"T[-"Z?8\O%OB+B<Y+03G[%)A\T0'2"%D$38XFAK&C
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M#.X9DD(&YQPN?5ZI0^2/9MI]-E[F>N@=(46D[1'2TL;?$Q^,D Y<?7*D[0$
M^*Y;](KQF\O+/32PL(8"Y1$)"(B )A$0#"$91"@/"KIH:NG?#4,;)&X8+7#*
M^<>JG3RHTO6_?O3HW4DCB9H0<;1WX'VKZ4*\:JGCJ8713-:]CAAP<,@H^5M?
M12RM36&?*EJND%S@;)"3G'O-(P<K8$< '.[S"RNJ73VJTK7S7O3OOT;G%TD/
M;:22>,+3V>Z17*F#XG<X!(]%X6JTKJ>Y='C7T.IY]"W='V_3UTMGOTS9*EF-
MP+1GMY+PEJ](T51MEH)FR,//XMO[5 [5<)[95BHIGD/!!+<X!4DN%;3:GNE
MP0[)Y/<D</FJJV.Q))9_(WA:I12@EDW59[7K ,IZ&(06V,CWG^[QW\EK[QH4
M04;IJ&J;.Z,$R-/DMEK&\?>6DCL]J&QQ;AY P?3A>VEJ6:RZ=KZZYR.)J(SM
M:3GR*TVPG+9+E^K]C64(RDTUE^OV*OQMR,8]5H+]:/:B*FE<8ZQ@RUXX/'Q4
MAG=OD>YGF5X2RLIXG/<<-;R2N2JR4);H]GG*3K>8DVZ/=2S4[+%J)QCKF9\-
MYYWCRR5;EVM\%SHGQ5#06N'!]%\H::TY7:YU3$ZUM,-+3O#I*@'!&.<+Z%U-
M?V::LL=##(9:QK W<[T]5[\[$JMUJ[/9A9FMRL*QU/:FVJZ2T[) ]@Y;A23I
MA>IH+JR@)+H9..3VX)X4+EDFJZISW9DDD/F<Y*M/IWI04@BKZQH,Y&Y@/\GR
M_0O&TZE*W,#@T\7*W=#HL9O8+L%U;PT+L%] >N@B(@"(B (B( 2!W("X!![$
M%:J^6IURC:!5RT^WSC)&5@VJP5-!5MD^^4\L/FQY+L_G0$D11;6]-J:>F8[2
MUPIZ29@]YLL'B;_S\+4:,N&L_OC[/J:GA?%_]6)FP?H0%@(M->M16^SSPQ5\
MOAOF^B21A9U%605D0DII62COEIR@,M%P/FN4 1$0!$1 %U\SVX79=3W4 U6H
MH*=UNEDG8"0,AP'.5X6*K,=@AEKG!@+ <O/P35>?8HV ]W\K7ZRM[*C3$A:9
M&F)FYH:?@M(K.,@@ N]EI]2S5\WAN=&YVW:!EW*YU/U<I8HWP24SQ3O[2?%5
M99G137F,59_%EY#\E2_J-8K(;5MM,;G-;@O)DSW^"]6S2U1E&+[9DIEBT%^H
MKQINBGI)&E\<8:<'GL%7G2^C%SZCU-9+_P#+.1]KE']./N=ATG57"V;7Q,?M
M<QS-Q QZK(Z/W:2>:<T50R*LJ'8&X< X_>D:XUJQ09/U'T+IW JZW9@,W#@?
M6J/Z[25,FLJ'PV./@,WL ]=Q_8MS=-5:QT@V02T4=3&[WA*QF!^A: =0:/4M
M6V:YTWL]?"-K7$@@_#''FL-)7.,O,2RB9--8(Q3U+KIJ!D%9.6SO+0=Q[#*M
MG3UNGI62U=N,^_'T\8!Q\5"K7:Z6^7J"LI+<ZGEWM89M^YIY],?%7Y':#3Z?
MFHX#B1\;AGXD=U.KO32X$4?/VLGON-]HH'')WM#OK*M?6U2VR].Q TX)8& ?
M,Y57T-#6U&NX8:I@$D;QDXP, K=];;O++5TEEC!#6L:\GU[K>4-TZZUTN2J?
MJ5W9+Q66VK>ZWN_&2Y!Y\CPLBEO\%N,LKH?&K'2;G2/\CGE8%ILM5/<7Q4S\
M5&P[1C.>,K6W.F,#S3U0=[2"0\=N<KT=L)2P4RT679]2'55U8^JC(H:2(AQ:
M>/HD?I5F]-WVBII)Q01M\2,G)VC/GYJD=+U\5%IFX4=&UD3Y6?C'$!Q=SZ^2
MF_0RYBBH[@]\)?EW)#EY>IT^(2:6,/@TB^>36:SLTE;U'\"J/XF60'+O3 6J
MZTBGMU514-#M+(-H.T<'#0M]J74@N&NX&F$-B8_:1QG& O6*R6VZ:IKI;E ^
M>C+BUOXS&WG"VC*4%&4O1$-96$:.P:UTW6%E/?;?&'LBVMD:T$<8]0H'?;J*
M>Y5#K,X^S$G:.W&5*NH/2BNM5P\:RM,]!(<M :2YN?+*Q=+](KY>6/>ZI92Q
M-\G1DG/YEC"R$?GA+^!R65RF\21![3?Y(YWBH;P3WRI#>-14\%"V*D <7#)*
MU^J=$5NG[DZEJ>7\D2!I /*Q;;9)'./CM=(?(-"ZZKI2[9R6U1CZ&F=5OGF)
MJ. 3PLV.".K+8N"#VVA;>LL3X<.EI9@SX@C"V-B9;:.0231^[QR7=BB3DFUR
M':HX1FVK3E888V45,_MWQW4OTEIJNK:\-N'XN&)P(;GG.5M=.7"[7"BD?:J5
MKXHOY9'?\RPOPTK+?5/;749;-YC./U+\^\4\7\7NA.G8HQZ[Y/6T^CI34LY)
MQ76FH@B_$5 V@=BM591,Z63;MWCODJ+W355WN V08AC*U$-ZK*"J9LDQ(X@'
MXKY:/AULJW%XR_\ WD]#>L_*BUC:VS%TLIQ+CN%S1>/ YT;\NC'FM:+Q-!2Q
M.F&?$'?LMI25)E@#R/=(7@VPNA'\3E'0L/H]9J6"=["\?%9=NJ(K56-<6^Z_
MCY+PHYHI)P!SA=;Q4-;"X1M]\=N5IX?J;=-<K(OF/I^96<$X\>I.J.HCJ(1)
M$>"O?Y+1Z1'_ +)8X'+G?2^"W6..>Z_6]/-VUQE-<M9.!K#P>@[(N&]ERN@J
M%UX/9=D\D!BUD$<].^.9H<PCEN,Y7Q;JV)E+J&M9&P,9XAPW&,<E?;)'?*^3
M>K%*)M95A?3F%K7.Q@?2]X\KFU"XR8:A<9*_! =Z'R*[OJ7'W' O*]J,4_MF
MR8.<WTSA2#[Q4LD[7PL>P''<Y7)*:CV>;9;"'U&%8;4;K74U "(73.#=Q^)P
MKUTAH.R:(::B\U<,LK\!N\!58+2V&M'A3%LD6"'!9EXEJ[M%'+<JQ\W@D8;G
M"BO4PCWR*=95!/CDM[7>L:'3>GS5V<0RRNRUH;Q^A4K?NIUYO=K=;JZFC<)O
M=W[R2,K+N-ULDUL%"()'R<G)D[%0N.,SUP;"W#6'R6GGN:]C26LW+K@Q)6RT
M<S7O:<=UG-EJ:JG=)3QDM:.<>2SYZ9U4QS9N7#@+VM,3X&/A@+LNX(6+GQGU
M.25D6NN3!M%8V=WASM^CP05(VT1JJ9QA $;1V6@J+;[/.XC(>3DY6PVR06PO
MBF<V0]QY=UG/#::,LIR4UP8D5>Z@?-3.'!/ 4ZTC74LU R+ADI)Y5:W#/XN=
MK@^7S7O9ZRI^^L A!Y=R,+LPI1R>LX[HY+LNMI(H ^.M< >XRO;2E)04U,3*
M&%Y[N(&2O2>VBHLT,;"]DDC1R3G"B,]/=+!6M9/,)J7/D,+-&?1/JPTN'/B)
M:\=L+7W>D-59Y)H7N=/M[+8:?92W"E+MW.,]UNF14T%(XNQP/,J8IEHQ;Y93
MGL6II((XF!S(B_OD]N5=&A;$ZWT,$T\YFE+!DGR4&EO\LE];;:)GB!SP'$<A
MH5NVN'P:*-CA@AHS\UT:?'/!O0DS,;C'"Y7#>RY/Q74=06-5U,-'3NGJ96Q0
ML'O.=V"P[]>J.QT#ZJND C'89^E\ L"$T&L]/DSQ2-I)O+=@GCU0&HL6N_O[
MJ T=LI9)*-AP^H_DYY[*6/M5&^M-6^!AJ.P>6@E:%U7I_15&( &P1XX (R<<
M+WLNLK1=I"REJ 7]P"1G]*C*(RB1M''&,#R7=1"IU]8J>>2&2H_&,." 1Q^=
M;2SW^WW=N:*=K\>6X9^Q,H91NT4<U!JVU6-_AUT^V3C@$?M7KI_4=MOS'.H)
MVO+>XR,IGG RLX-\BBMZUK:+15>!5S?C/1I''YUM;)>J.\T_C4,S7QGC (R$
M4DQN3-JBZA:C4&H:"Q0B6X2AC7$ <A,^Y/1N46NLMUI;O1LJ:*021.[$+8A2
MN0N0BX. "2<!8]95-IJ.2IP9&L&<-[E 9*Z/<&@D[0/4JJ7:RU5?[B(=.VH4
ME*Q^))IO?W#Y;>//S5CU% :^U-IJ]SM[VC>Z,[><<H#F6\6YDC6.JX=Y. W=
MR5WNMRI[71NJ:MX9"T9RHQ1=-[#25#*AK:F29IR'.E)Y4JJZ*"KI3!51B6(C
M!:X90$7I>HECJ:ID$<SB]QP!A3*-P>QKAV(R%IH-,VB"5LD5%$'CL0.RW+6A
MK0!V" Y1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1<=EU['GL@.Z+%J*ZGIVET\T<;?5SL+35>M-/TP(FNE-QY>(%.&1E$C106
M7JCI>(^]6EWRV_M6,[J[I9IQ[3*?D&_VDVLC<BPT4"@ZJ:7E[5CF_P!+:/UK
M;T6N-/U?$5TIL^CI $VL;D29%C4];35#=T,\;V^H(7N""..5'YECLBZ@#*Y"
M Y7!7.5U.-P/F@.E1*V&%\CW - R2J=UUJEUPF?34SBVF:>2#](A23JI<:FG
MHXZ>'<V.0C>1Y]S^H*L*!D4U8QE0=L;G>\5ZNATZ4?,D>=JKFY;(F9I^S3WB
MK$433L[N..RNS3EFI[11-BA:-^ '.QR5TTO;;?0V^/[VX+" 2[.5N?CA<VKU
M3M>U='1IZ%4LOLZSQLEA='*-S'#!!\U\^]5NFM19Z]^H-+L+F.<73P-& !WR
M,?$+Z&[A=7QMEC<R0 M(P0?-<L)NM[HFTX*:PSY3L-YAN=/WVSM #V'R*VYX
MRIAU(Z30%L]XTKFFNFXR/8<ELG<\#R.55UDO4LLKZ.[L\"O8<.#A@$_)>]I]
M5&U8]3R;J'!_8WY:2/@N=V#YY^:.&>!@M7266.)CI)7!K6C))748?;T.7$,:
M2XXQR?DHV]U?JV[,LM@:XAQQ)(,\+0:HOMTN%'4NM5-+[!'EKY&C/'Q*G_W-
M.OK+2OFM%PI64U?,]NVHW#\9P>#VQ^?NO-U>KPMD.SMT^F<OFD7=TWT31:.L
MS*>!@=5/P^64M&7.QA2_/&3W7 >US&O;@@C.0NCG-8Q[GD!HY)/HO'DW+EGI
M))'L#E<A1NTZNLMTKI:.CJXW5,;MI87#O\.5(&$>13 33/1%PB$G*($0!$1
M$*(@&>%P%RB \9XF3QOBE8U[#W!&05\X=4NG-9IFO=>=.1.DHG$F:)HQMR?@
MOI5>4T;)8RR0!S#P04:333Z924%-89\I66Z172FRUP#V\%OF%N+=5/HJN&HA
M&)(SGYJ2]1^E+:&.:\:1#HJH$ND@.2'GX>GGY*M[%>A6%T%4PPU<9VO8_CE>
M+J=(ZGOAU_(\B[3RK>Y%S-U=9IC'555*TU;!W+0>5%]5ZFJ+V\,'XNG9PUK3
MW4='/=8MPK8*&!TLI]T#U7/*ZRU;"LM3.:PCUFE9!&]\IVM:,Y6IL-FK^H5Z
M924;716QK@)91Y@=_P!*VN@=)7'7]<^6X!U-9&''8YD]1E6O<Z^V:#M3;3IR
M%C9!R.0<$^9^Q=]%$=,O-N[.FJCRX[K#(J);7T^T^VW6QC!-C . "2?7"JZL
MJ)J^L=/.2Z20X(SE=JNIJ;K6F28F69Y' ]59^AM#PQ1PUUQ:3,,EK<=ES2G9
MK;"DMVJGMC])B]/-(.867"X,P_.6,(^PJSFMVMQY(&X &.!V7<?$+UJ*8U1Q
M$]*NM5+".OD%V"+@_'A;&AV1>1E8WNX?:L*KO=MH@355L$7])X"89&4;)%%9
M]>Z=B<<W6G=C^:\']:QOX2M-;PT5S7$^A;^U3@91,T7A2S1U,#)83N8X @_!
M%!)[I@<\=T1   $PB(#1:ETQ;=10EEQIV2. PUSADA:_1VD8],SU'LU0]\#Q
M[L9[-^04MQSE<80$-JNH%KHM1BT7 FGF."USW !V>RET<C96-?&[<UW((*TV
MJ-+V[4-(8JZ++@,->.X7E8;;#I/3QB?.Z6" .<7$8XR2@)&BU-@U!;[Y3NEM
MT[) TX< X$C[%M@<H B(@"X/FN5X5<G@PR2>@R@('UAOALNGV2L=MF+_ '3G
MX%5G1]6JPV^2"K8)FO;CEW[E;;[%!JFE=)=1OC+G;&^G.%7?5;1MBL6G'STH
MVS$EK<'SP5Z.CE3A53664>2F:BXQNJ)7M.,N)[_%=[)5SNJZB(RY:\;B">"M
M!X;Y)_"8''GG(6VEB@;4Q.@DP6MP?FO>E"/1D6AHZJ Z;W>-Y!)>>"?@H1IS
M1]\H(/OM1QO$+?>RUIRMAI>$W"S5,.]S 7\@#NK=M\5+06JD@J9MU/(P,;CN
M#\OK"\VV:T\I2BLMEXK)@:%ZDT]6P6O4#0"[#0YY&/SK4=2-#6^OJ#561L3"
MU@>[;SNY/;'R58ZAH64NIZFBJ:@,$I)CW#'F5G::U=/IJZ,BK7>-3 C.#Y94
M0K3;MT[_ ($O[FUTGK.KTW<(:"[ASJ6.0.#>V.1Z_)7NS7U*;=]\132^P!N3
M(""!]:T%PLFF>HUI]IIWQLGVG&' D$?#*K._0345M@M%?*Z.WQO&XX^D,\KG
MLV:EYQA^I*;1()=1_?HW*^4+!#'!]%Y/)(^*BEINS]3WPU=;*V26*/ :3G.,
M_M4_TQ=M*4=@?25$S!3N/T-XR>1\5A:"N-A=JNJIXGQ0PN)='N<!D8 _2KPD
MXQDU%_F.R+V6[4MHUD*ZK(C9'S@G&/=[*(:JOL%VU!65+0-KWDCS5@:\T<&:
MEK:EDS'0.C$C6CN3CR4'EL51-&V2")VT. <<'@97;394_P 3/H9M,[:?J::2
MT5[9P!-M]PGYJV.DM W\$JRJCG<QV><>?=4A5T38K@(6O]YS@,>JOS3[JJTZ
M/MU%#38$^,N/F>3Z++722A\K[:+)99&(=*U]1?I[K/EU,7$@X.5/.GEF@,]6
MVH<7NWF3GL07''Z0NU'>IJ.&6AGIY&/=P2X8;]2\K"V;[[24E*\M8[WWOQQS
MS^M>=9;9..&\8+I8+&K*B*EI7.D<&@# "P-,M)I99,%N]^1GS6MABM@JA'+*
MZ:7/!XQE2F)H# &\-''9<3X+>II=0Z:MU[VNK86O<WS(72@TE9Z+:8**(.'G
MA;\MR,(!@*=\L8R1M6<FMN=DHKA2N@G@8YKACD=E0FI^D52V\#PZN**BD?V(
M/KY+Z+)(/(^M?/6L[O4735;X7R'P(CV'S/[%A?KI:2MR3-M/HHZJ>TN?3%GI
M=/6*.GIMNR-N2X?RE2^IKE'>K[-6.:T1M]T9]%ESZX=:[<ZW-D+MXV@^BKW4
M53)3P1NIG>ZXX./->%K-8];&*CQGL]C1Z*-+?FHG[:?[X4P]FA#,?RL*)&D$
M>H8FSR!S&O!/VK;V/4,QM0C9&XO(P<+3U+'-\5TT;B]W;C"\73*R$Y1EPO0V
MU&D3A^&N2>:IJ8!;:9L$C2XN&-I[+:T=TI*2AC943,:2T=W#E4Y3>T[MAR3G
MC([*0V"!HJQ[7+OR?-<NH\/@JMDI92R_N8TZ"3[):^\/I:QTE(6O83W!67;[
MJ:^I:Q_$SW8 RHG4R-IJMP8W,>?)>%17R13,F@]U[3D'"K#25RDFU_$[9Z!.
MG;'L^A[) VCH(HRX;W#)^:V#3GO]J^:I;_<3-'-)(X[>1PI91=4*B.@9 (MT
MT?#G9[K[#3^)4QCL:PD>1=X;;!\<EV#('J%SY9"K_2G42CN>R&JS%/V.2,*;
M2UT$,+II'M$8&<Y7IUW0L68LX+*9UO$D90SCE<'LHD_7-O,YC9O<,XW9&%)X
M)FU$#)(^6N (*5WUVO$'D3JG!9DNSV/JH_?=*6N]RB2MIV/>/,MY6^)XXY7;
MG'=:-)KDR:4EAE.:MZ,4-6?:;-MIYV]V[>'*KZ^&JL=P]BN\+HBTX#B, _:O
MK+U5!?=&5+'5UNIVL]_+B3Z]ERWTQG'<<6KTT)QW/T(W4-9%**F%PFA?W \E
MH[A4M87O;PPC@!;""*>BH6/\GC!REQME-4VM[FS-:YHSA>1!J+Y/#CS(AEK$
M4M8\R''HLZC<VFK2('##EKJ>VN-0]S"2&^BSJ1K!70D#.UPS]J[98>3JLP^G
MDV]%%)-.Y[LEK5F4DT-+5[W9&"O:-YBJ'FG:7AS3D#RX*U<Y<7N)[YYX7-]>
M4SCR8>H;FR6IVP%Q<3W)2DJ9IZ7P]A)/"UEWVFI9X7#ULVS"AM)EW'Q]O"VP
ME%)'2Z_EBO4U3GLIJ[9,?/D%6MT^M%NGIQ5N#3+DX*I>C#[G7EU2"-T@ )\^
M5] :=H:6TVJG'B-[9QE;O,8X/2?RQ2,W45[CM(87N.UN, %1.^ZM%WHGQP4\
MCG<8<I94VMESIY)YF_BQVW+#L,EMA<*?,>[)[."JF437J5[8M37:T5'A-:]S
M7>6%O*[6]=5@TYC<T#Z65N.HPH:84\@<R'<0,Y^!5>2S1.G.QX<,]\K.4VW@
MPOM<>(HMKH]76ADU2^K=&RN?@@NQZ_\ 97)!/#,/Q4C7#X%?(]/4P"4/:]N6
MCD \JS>E]UE?>FAC7QTY;@EW /([%;T:AY4,'3IM4Y/RVB\0?(+G/*\XWY9E
M59>;[<-1:TBM%D<YM-1OWSR 9'<#''UKT#TC=ZKT7/J._P!--757_LV#WO!Q
MD$Y'[%,PQE)1AD30UD;< #T"]HFED;6N.YPXSA<3L$C"T]B%#Z'H?/\ 8Z-N
MN.H-:^X@OIX7G##R,9/[%9_X#6B@>ZLI*=L<L<;@"!CR58--3T_UW4U513R/
MHYGD[FM.,9*G]#U#I;Y4FCH*:=[71NR\MX'"RCA?490Q_P!1!NFUBH;UJ>],
MKH&2!DF!N&?5<ZFM8T3KFURVQVR"H>W<QO'\K"PM%ZF@TOJ6\/K8I/QDF0 W
MYK.EFK-?:UH*B*EFBHZ9PRYS3C@DK-9V_<R2>W[EAW[2MGN,<MWN,3'/?$'%
MSO+W5672>F?%J6ZU5""VA@CDY\B=O_99G5_551%<&Z>IV2-@C:ULK@,YR.?S
M+>]/;W9FT+K+;XY!/+&_)([G"T[D7DTY<&DT#:*74]\N]5<XVRNRYK01G& %
MWZ52?>?7MVM;'8IFDD#/ X:5A:7OC=%7RZ4]QBE'B9<P@8SD#U63TYL$NH[Q
M=KI4-?##.2UKBT]L *BRGP46>$B\8ZN&1VUDC7.] 52W4=CM5:QCL\;@8HF.
M>[SY#3^LJ86W15+I=\UTBJ'RNC8[@CU"KG2]CO.HKW7W:BJ/9]SG-!<.XRM)
MMX-+,XX)+T3KGT%37V*<G?3O(;DXXSZ?6K@W8:3\%\U5\5ST)K'VRH#JF2;N
M6 \E6UTXK;]=7U%QNS?"HYL.@B.<M"FO..2U><<FMU+=]2WJ]SVFQTTM+3Q.
M+7U+@<'RXX4ZTW03V^U0TU;4&IF &Y[CW*V;&@9P #YKL!@!:&@:T-  & %R
MB(!A ,(B (.$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 =0L>O@-32RPM>Z,N& YO<+)QPN".Y/DA&.#YGOVB;VZYSPW2_32
M1;SM;SR,GXK&@Z9VECMTQEE<>Y+E>>M+;O#*E@R1P[A1$0\=LKJK:P<DU),B
M--HNT0# I _XN"]1I*T#GV*/Y;5*_!^"Y\(^@5^#/GW(;-HFT3<^R,'P:,+5
MU?3:TR.WP>+')\"K&\$>874PIP.2L_P1O=&PMME^GB\PTY/ZUGVK66N]-_B9
M@VMI6'+G.803^E3IT7'E]B\G0\=LA5VIDJ4EZGEIKKI;ZB84]\HI*&0':7OD
M&#]1 5J66_V^\4PGH*B.1I[ ."INZV.CN32VL@$@QA0^31-79ZF2LTU6.IIF
MG<&_%5=*]#2-[Z9]3M.?/NN3S]2^?--]7KK8IX*'5U)(Z+.SVG&/KR5=FFM0
MV_45 VLM=1'-"[OM>'%I]#A82BT=,9I]'?4%G@O%#)!.T<C@XY!RJ/U!9Y[-
M7O@FY:#EK@,9"^@VG)X6FU)8X+S1212-&_NUV.RZM)J72]LNCGU%"L65V5IH
M;5$EMD%+4DFE=VY[%6_3SLGA:^,Y:X9R%\]WBV3VNNDIYVN&WL2,9"F&@=5N
MHY&4-8[,/9KB<877J],K(^96<VFU#@]DRV?3*[X7E%(U[&N:00>0NX=E>/\
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M""SNN64E#F635\=>IK9JFG92^"X D<#E>%%%3MR][  ?BO:[4L%- 7>(W?\
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M2./<[SV\K6$XOEHZJ[(^O)MGZ@DO$E.Z4NJ8X0"YC._'"U>I*XSW6=ULB?%
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MN3E,(82-=666WUDF^II8Y'^I632TL5+&&0,#&#LT+WY]5RFU=A(Z/8V1I:\
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MBK,#;$UPW/\ JSE4E:K1=M53B24&EH?+(.3A22RZ=K+Y</OOJF5TT[CEL3>
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M0/$LI!A=M/./3A5Y;ZN3V&2C92[Y7G&=N7!?4/2JRT[-)TOM=-$9QSES 2.
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MY\UE:7TO/0U\E96S-DF=W\_-3'PB7>\00N6Q@=N$6EK4MV M-!2W)'#(P-V
M,E5[<-'5IO,U=1SACG.)&/+)RK%P<<'E"T\X/*O;3&U)2]"]E4;%AD%L>D)8
MKHVMN$_BR-.1G*F[&[2NVTXY(RN0WMGR4UU1K6(H5U1K6$=D1%J:!$1 $1$
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M57M9+:RUV^*F@ ;M')QW7-H*):J[SK.CIU^HCHJ?AZNV;&-H:P-:,- P NX
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#?J_[J+:-IS3Z?HH\8(B&?FH7U#OM9<!:*&HDWQM>3R?Z/[%9-"T1P1M9PW
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M8 <?%87ZF5N<<)DJ*1P  N=H'DF.5SA<R). !Y+E,(I /98%[J_8[165(_\
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M]KL>A7JQDI<Q?!+37#/1%P'@HUP.<>2L0<HB( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"'L4760X:4!B3G@K6U![K/F/NE:VH/=72,V8-0>2M;4G@K/G/)*
MUM2>ZUB92-?,>%K:GZ)SZK/G. 5JJ^3PX97N/N@$K6)A(CW2^,U75NOE&"(F
MCZO>"^CAV7SQ]SS$^JUIJ2N(S%V:3_3*^AP,97-:_F.NE?*$1%F:A$1 $1$
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M! /PX^* VF@JZGK=,T+J69LC&,VD@YY]%(EHM(:7H-+4#J.V-+87/+\'R/\
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M=:O;_P"$FS&%T4,.UGA"I:7L!\-O?!;GS\UY6BAK'=2+355]WH!5$_WJCIB
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M$1 $1$ 75QY\OK79<'GT0%3ZANM5?^I5'9K?(X4]$&2S.9VSNY!^H!6LWA@
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M3:]7%EKME363'+8F[L+6Z,OYU%:Q6^ 8FN)#<^8!(S^9 2!HQPN5P%R@"(B
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M8QN 5]I1,]L=EV7!RN5<J$1$ 1$0!$1 $1$ 1$0!,(B #A$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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'$ 1$0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g109079g00v09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00v09.jpg
M_]C_X  02D9)1@ ! 0$ O@"^  #_[1@04&AO=&]S:&]P(#,N,  X0DE-! 0
M    %_,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*/_  !$( Z@'50,!(@ "$0$#$0'_Q  =  $  @(# 0$
M        !@<%" (#! $)_\0 81   0," @0#$ \&! 0$! 4%  $" P0%!A$'
M$B$Q$T%5%!46(C5187%TD9.4L;+1T@@7&#(T-U)35G)S@9*ATR,V0E3!X3-D
ML^(D8G7"0X*B\"4X18,F8Z/#\2=$5V6$_\0 &@$!  ,! 0$
M  $" P0%!O_$ #D1 0 " 0($!0,# P,# P4    ! A$#$Q(A,5$$%$%2814R
MD2)Q@04S\$*QT2.AP23A\31#8G*"_]H # ,!  (1 Q$ /P#:D
M
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M:JHJR*F>2]939@T+T9?&-A;_ *I3?ZK3?0Y]:L5F,-]*TS$Y  8-0
M
M                                                     U/]EC\8
MMN_Z5'_K3&V!J?[+'XQ;=_TJ/_6F-M#[F6K]JE@ =CE
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MW4  #5_V7'[SV+N-WGJ4,7S[+C]Y[%W&[SU*&.[2^R''J?=( #10
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MIO\ 5:;Z'+XCK#IT.D@ .=L
M
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MFIK!?&U-3#"KI=B2/1N>QG7->G>^=VSX"T5Q,SW5FV8B  %E0
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MK)LUERXT*FT]WM+QI"K&0R,?1TC8XH%:N:9<&W/L;T7<5R"T:<1;B1-YF,
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M]O5P;*V65E96OG@:FJ]%<U%3)'9Y)GGN52G@373X9ZDWR  T9@
MDNC+XQL+?]4IO]5IOH:%Z,OC&PM_U2F_U6F^AR^(ZPZ=#I( #G;
M
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M^)2^J.@_$OT=O/B4OJF_@'F)[&Q'=H'T'XE^CMY\2E]4=!^)?H[>?$I?5-_
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M_1V\^)2^J;^ >8GL;$=V@?0?B7Z.WGQ*7U1T'XE^CMY\2E]4W\ \Q/8V([M
M^@_$OT=O/B4OJCH/Q+]';SXE+ZIOX!YB>QL1W:!]!^)?H[>?$I?5'0?B7Z.W
MGQ*7U3?P#S$]C8CNT#Z#\2_1V\^)2^J.@_$OT=O/B4OJF_@'F)[&Q'=I)HZP
MKB"FQ_AJ>HL-UBACN5.]\CZ.1K6M25JJJJJ;$3KF[8!G>_&TI3@  9K@
M
M
M
M
M
M
M
M
M
M                                   C%TT@82M5;)1W+$EJI:J-<GQ2
MU+6N:O915,G8<0V?$%/)/8[G25\,:Y/?3RH]&KV53M*!E 1[HVPSSWYU\_K;
MSRU]3F;AV\)K9Y9:N>>9(4VIFFX
M
M
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M7:SW1HJKUU ]X
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MZKF+Z0,@"JM M*VWTM]H(G.=!35:QQZV]$1SD_H6J
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M(
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M$]C)\55+W3-YQEJZ=:US#33O-IQ*U0 <[<
M             !QD8R1NK(UKF]9R9D)TE:-;1CZV0T-QFJ*2..1)$=2(QKE5
M$<F2YM79TQ. !$<<Z/[+C*Q0VNZQO;'"J.BEA5&O8J(J9ILRW*O$8O1YHFL>
M";C-<*2>LKJ^5NJM15O:YR)LV)JHB<180 @NF_XK[]]DWSVDHPSU H/LD(OI
MO^*^_?9-\]I*,,]0*#[) ,D
M                     *WTUZ/JW']%9(;?64U*Z@K4J7K.CLG)EEDF2+M.
M6DO1MT8V&W4\5>^CN- NM#,QV3<\TSSV+LR0L8 46S0_B>_WJU56/\3Q7*EM
MK^$@BIVZJY]=<V]=&]XNRL:C+?.UJ9-2)R(GW*>@Z*_X#4_9N\B@5SH8^%8H
M[N=Y[RS2LM#'PK%'=SO/>6:
M                   !UR012+G)$QR]=S44YL8UC=5C4:G61,CZ .O@(=?7
MX*/7^5JIF=@ %3:#OAN(NZ/ZN+9*FT'?#<1=T?U<6R
M
M        :+Z8OC0Q-W:\AQ,=,7QH8F[M>0X]&O2'#;K( "4       ;@66Q:
M,7V>@=4VZRK.L$:R*Z+:KM5,\_O*7OPKUKQ-/P;R^US@;@.&Z'+7P66>MP*;
MC 5MAT7MI9%9;K(CT39E$9QKQ/HOLSW:<@V"T!85P?>;+<I[['23U;*IS&LG
M5$1K,FY99IUU4J72706JVXQN-+8I>$HHY%1F6Y.QN0UB^9X6<UQ&47 !94
M                      -Q/8R?%52]TS><:=FXGL9/BJI>Z9O.,=?[6NC]
MRU0 <;J                                             $%TW_%??
MOLF^>TE&&>H%!]DA%]-_Q7W[[)OGM)1AGJ!0?9(!D@
M                                           Z*_X#4_9N\BG>=%?\
M!J?LW>10*YT,?"L4=W.\]Y9I66ACX5BCNYWGO+-
M                                         *FT'?#<1=T?U<6R5-H.
M^&XB[H_JXMD
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MXT[-Q/8R?%52]TS><8Z_VM='[EJ@ XW4
M                 (+IO^*^_?9-\]I*,,]0*#[)"+Z;_BOOWV3?/:2C#/4"
M@^R0#)
M       !T5_P&I^S=Y%.\Z*_X#4_9N\B@5SH8^%8H[N=Y[RS2LM#'PK%'=SO
M/>6:
M !'L>XKH\&X9J[Q7IKLA;TL2.R61VY&IOX\C!Z-=)-+C3"-7?WT+[=3TROUV
M/EX1<FHJJN:(G6 GH*,]T1;N>B-YPUG.99^!YY\(NI[[5SU=3/\ ,NVBJ8JV
MC@JJ=VM#,QLC%ZZ*F: 59H.^&XB[H_JXMDJ;0=\-Q%W1_5Q;(
M
M              !HOIB^-#$W=KR'$QTQ?&AB;NUY#CT:](<-NL@ )0
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MBJI>Z9O.-.S<3V,GQ54O=,WG&.O]K71^Y:H .-U
M            .+)&/5R,>URM7)41<\E[)R       /CG-8U7.5&M3>JKDB&'
M9BO#SZSF1E^M+JK/+@4K(U?GUM76S S(//6UM+04SJBNJ8*:G;OEFD1C4^]=
MAT6J]6N[M<ZTW*BKFM]\M-.R5$[>JJ@133?\5]^^R;Y[2489Z@4'V2$7TW_%
M??OLF^>TE&&>H%!]D@&2
M           '175M+04SJBOJ8::G;[Z6:1&-3MJNPQ=QQ;A^W5,$%=>K=!+-
M[QLE2QJJG7VKN S8/C'M>Q'L<CFJF:*BYHI]      !T5_P&I^S=Y%.\Z*_X
M#4_9N\B@5SH8^%8H[N=Y[RS2LM#'PK%'=SO/>6:
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MA<A4V@[X;B+NC^KBV0
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M*JE[IF\XT[-Q/8R?%52]TS><8Z_VM='[EJ@ XW4
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MIN#=+(KE_B5J*JY:FS,"[0       5-H.^&XB[H_JXMDJ;0=\-Q%W1_5Q;(
M                                                    !%-(F!+5
MCJU-HKNQ4X-56.1OOFJO_P#"$9T<:%;!@FY<WT[WU=6B](^1N6KVD55[!:(
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MM)1AGJ!0?9(1?3?\5]^^R;Y[2489Z@4'V2 9(
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MK%'=SO/>6:57H)JX*]N(ZJCE;-3RUCG,D:N:.17.7-"U
M                                 !6^E+&U+A>OI8:G#<UX66)'H]D.
MOJ;7)EN7K?F60=<T43T5TL;'Y)_$U% H/VX+;_\ X^JO%$]4S>AW$N)<2XMN
MD\]LDM6&F1_L*=]*V/-^LNU'(Q%7I5;Q\1%?;%Q/=L:VMUN@HZ/#=96S4435
M@8Y\KF1:^:JK=GOF[EXB=:+L6WV?%=UPQBRGACKJ=G-$,L+4:U\>LK4V(U.-
MCEW 6J       "IM!WPW$7=']7%LE3:#OAN(NZ/ZN+9
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MR;Y[2489Z@4'V2 9(
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M!\$5,_$L-.Q(XF5KD:U-R)K/+2*RT,?"L4=W.\]Y9H
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MV2IM!WPW$7=']7%L@
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M$RRX"+U2! 36)ZP1,QT9._WZY8@JVU-XJG5,Z-U4<K6MV?<B&, )Z(
M  #<3V,GQ54O=,WG&G9N)[&3XJJ7NF;SC'7^UKH_<M4 '&Z@
M                !5'LB\-UU[PC#6VQG"U-KD2H;"BY:_3LS[R(JF L7LD<
M,R6J-;O#64]>QB),Q&-R<]$VZO3;L\]Y>RHBIDNXC=RP1AFXU3JNNM%-+.KM
M97NS3;GOV*!36"KQ4:5M+\&(J&EEIK#:87Q(^3)'N<Y'(FQ%7K(;$GFMU)24
M5,V"ACCCA8F2-9N0](           073?\5]^^R;Y[2489Z@4'V2$7TW_%??
MOLF^>TE&&>H%!]D@&2
M      .,L;98GQR)K,>BM<G70Y #66)<9:%KW=5I;8RZX;JY>$:]%3-G\77:
MN]SN\=>(,6XUTOT+L/62QLH+?.N=14R*FQB9HJ+TSMF:IN3/8ALK)64G-"4\
MDL:RK_ N\CDFD#"-->>=3[U1QW'8G 9+K;41>MEN5 ,KA&RQX>PW06J%<V4T
M>KGGQJJJOYJIESXUR.:CFKFBIFBGT      '17_ :G[-WD4[SHK_ (#4_9N\
MB@5SH8^%8H[N=Y[RS2LM#'PK%'=SO/>6:
M                      *ATZX-OMTJK5B3!Z(^]VSI6QJJ9N8J.1<D79GT
MZ[^(MXZZFHBIH72U$C8XV[W. UU]OC%#6)12831+LO2HQ%35S_'VR4Z#L'W^
MGO=WQ=C)C(KI<55&0(O^$U5UN+9O<Y-ZECWW$^'K#0LKKQ7TM+3/VME>FQ>\
MAZL.XAM6(Z+FNQUT5939ZO"1YY9Y(O'V%3O@90^/=JL<[)5R3/).,^@"H:Z\
M633'!B#"L$]QM=5:YEBF<K69N5KW)L]]LS8O9R4JG##WTF$-)&$*6)D[+/.Y
MB5#%76D1%G15=GLSZ3B3C4N7&&A7#F)+U-=%J+A;JR9565]$]K>$5=^>LU>S
MWS/X'T=V+!]HK+?;8I)6UK=6JEG5%?,F2ITV2(G\3MR<8%.K>*3W*>OK9(L2
MT^67\>:M\I8NC>VWN/0W9:6UU,--<EC5[9)DS:C5<Y4W(O$J<1B_<]X3Y]K7
M\T7+@%FX9:'A&<!GGGEEJZV7WENTL$=+3100-1D43$8QJ<2(F2(!3_L>HZN)
M+ZRX2LEJDGZ=[-R],[L(7(5-H.^&XB[H_JXMD
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MA>:[%U98+_;Z>FJ*>)DJ/@55:]'*]-F:_P#)UBP2E-%+J^ZZ1KS=JJL@KX^
MCBX>G:J1YHLFQ-;;_%^9=8                &B^F+XT,3=VO(<3'3%\:&)
MN[7D./1KTAPVZR  E   !Z+?15%QK8:2BB=-4S/1D;&[W.5<D0\Y;NBR@9AC
M"5UQS7M1)&1\%;<]J.E773-43;L<Q.L1:<0FL9E"Z+1]B>MN=5;J6U.DK*9&
MK+&DT::J.3--JNRW*9+VHL<<@R>,1>N1V#$]WIJ^IK*6NEAGJ':TCF<986BB
MHQ1BS$+&U-YJF6NG_:U4FLWWB*F:;M^2]8K,VCFM$1/)!L3X)Q#A>"*:_6U]
M''*[58KI&.S7;\E5ZRD=+!TQXXDQ=?N#A5$MM&O!TZ9*BKL3-5SX\\^L1[!&
M$[EC"\MMUJ8U7ZJOD>YR(UC=V:YJF>U4V)UR8F<9LB8YXA'S,7/#5WMEHHKI
M7T3X:"LVP2N<WI]_$BYIN7>A8E5H0N#89>=UZH*^KC3/F:-%8Y>QF[)/S,G[
M(Y\K+EA_#M(U%C@IT5&\>OK/3?NW*1QQ,Q$)X)B)F5( M5NAJKI:>!U^OE#:
MJF7=!(QTKD^]F:<1'\3:/:_#N)Z*T7"IA1E6B+%5(F;%155$V)MXOS)B]9Z(
MX9A"@2''6%ZC"&(9K35SQSR1IGPD:*B*F:IQ]HRDFCVOAP=17ZHJ88EKI6QT
MU*J*KY456IK9IL1.FX\MQ/%'5&)0H%M2:%YZ:6"EN.(J"DN$K45*9T3W*BKQ
M:S<V_F5]BW#M=A>^5%KN;$;/$N:*U45'-7<Y,E7>FTB+1/1,UF.K# ]-NHI[
MC6PTE'&LD\ST8QN:)FJKDF\M!-#$\+Z:GN>(:"BKYT35IGQ/>J*N6S6;FWC3
MC)FT1U1%9GHJ8D.&\%X@Q+!)-9+;)511KDYZ/8Q$_$J=8R%RP#7VO&D6'KE/
M#3ND>UK:E>F9DY&KK9)FNYR%\X@P?-9-&5NP_;<0P4+XWOG?,Z-R\,BJY<DR
M39[Y"EM3&,+5IG.6K]PM]5;ZR:EK(5CGA7*1N:.U=F>]-AY39RPZ,*"@T>75
MM;=:*HK;DJMCKW1OU8U5JIDB99\7Y%-6?1U<;SBJML]KJ(*B*DVRUGO&(WI=
MN3E1?XD)KJ1.2:3"$ M>70Q6STM2^RWNANE33IFZGC8Z-W%QOR3C0AV!,'U>
M+[^EJI)8X)/XGR)FC>+B)B\3S1PRC(+&Q1HJK,.6&KN5PNE(BPY:D#4572HJ
MHF:9;$WKOZQ7),3$]$3$QU  2@   W$]C)\55+W3-YQIV;B>QD^*JE[IF\XQ
MU_M:Z/W+5 !QNH                             55[(;%-RP[A:G@LDR
MT];<94@9.F^-==FW//K*J%.7.S8[I[W;<"XAQ''54=V76?)&]V;41-=6YJF_
MI<MREY::M'];C^TT--;KA!0S4TBR))*U7;<VJF67U2KJG0-CNJN,%?48XI9*
MR#/@Y5B?FW-,MFSK*!SP5AZ?19IBMUDMU?+46>Y4[WOC>]'*KFM=EGDB)QH;
M*%$8-T.XJMN-:"^XBQ33W1*5KVHS@W([IDRV*7N       >>XUM/;J*:LK9$
MBIH6Z\CU15U4Z^2;2EI/9'6".O5KK57I;4EX-:_^#MZN6MQ+Q<0%X@A6/=)%
MEP;AVGNU8Z2=E2Y&4\437:TBJCEV;-GO5WF,T<:6K7C2[5%J2BJ;;<X6ZZT\
M_3*K=FU%1,N/K@>[3?\ %??OLF^>TE&&>H%!]DA%]-_Q7W[[)OGM)1AGJ!0?
M9(!D@                                               #HKI7044
M\S$171L<Y,]V:(=YUU$+9Z>2%ZJC9&JU53?DH&E]'AVW7;#F*<9W"]U4.):1
M\DU*V.5J(JL5Z(BHK57^%N6U#)R8.P>_0++=W31NQ(R.697JY-=RI*]J)NZV
M7>+-JO8Q8.J*F6=]TQ CY7J]42>'+-5S^:.KW+F#.5,1>'A_2 LG0_52UNC:
MQ5%0[6E?"[->T]R)^2$P,5A6QTV&K!1VBADFDIJ5JM8Z945ZHJJNU41$X^L9
M4      '17_ :G[-WD4[SHK_ (#4_9N\B@5SH8^%8H[N=Y[RS2LM#'PK%'=S
MO/>6:                                                 -?O9!T
ML6(M(F%,+W6M=26>JC=-*]CM54<C951<U14_@:FXV!*\TG:)+%I$KJ6JO57<
MX)*>-(FI221M14S<NW68[;TR@43AC!F%$TG5EBN5REK</4,:24S:B5KD555[
M51<FHFY$W(A,="M%06#3-B.V6"5'VJ6GX1K47-&_M'HF62)Q-:>_W+F#.5,1
M>'A_2)?HTT-V#1[=I[A9JVZSS2Q\&YM7)&YJ)V-5C5X^N!90       *FT'?
M#<1=T?U<6R5-H.^&XB[H_JXMD
M                    AFD32':<!LI9+VDJ1U*N1CF-5VU,L]R+UT,#A/3;
MAG%%\IK5:UG?53KDU%C<B)MRSS5J=<"T0"$XRTBVK#5[MMHDUYJ^LG9"D;6.
MR:CE1,U7++C3CXP)L"$XKQP^SWBCM5OMDEQKZB+ADC;(V/)N>6]RHG&G&2/#
MM?5W&VLJ+A0.H)W;X72->J;>NU50#)JB*F2[CJ@IXH,^!C:S/?D<)*VFC>C'
MSL:Y5RR53E%502R.CCE8Y[=Z(H'<<9&-D:K7M1S5XE.E*ZE616)/'KIO3,AN
M--(,&&KC-3.IG3M@@CFD<G\.O(K$3OY=\";PPQP,U(F(QO60YG1!5Q2M;T[4
M<K=96Y[D/D5;32O5D<['.1<LD7C ]                -%],7QH8F[M>0XF
M.F+XT,3=VO(<>C7I#AMUD !*   "[=-$K;-HXP78J5J-@FA?42)_S=(Y//4I
M(N;3P]U?A; U?%T\"TDD:O;N16I$W+_TKWBEONA>O2526JWU-UN$%%0Q.EJ)
MG(QC$XU4N+'U?!H]P1!@ZTJU;C5Q\)<)D]]TV:ZBY?\ *Y.ON(1HPQ=;\&UU
M5<*BVOK+@L>I3/UD1L2YHN:HJ;]B;B+WRYU%YN]5<*V5\L]0_6<Y[E5>LB9K
MUDR3[A,3,\^B(F(CY>$NW #I;%H.Q'=J"34K9Y48DC=CHTV;,_\ RE)%@:-M
M($.&:"NM5ZMR72S5?3/IG9>^V;>FS3+8O%QDWB9CD4G$\WGT,T557Z1K/S.D
MF39]:5[/X4R7:OWDSKZ.OQKIQN:4E4E/'0/?(DZ)GP<:<>_KKQ=<[</Z8L.X
M>NDDUEPDRDIGQZJI'P;9%=GQN1$V;MA L 8ZJ,+XIFNU1%S8VJ8L=2Q=[VKM
MV*O91"F+3,SA:,1$1E+\65F!KK>GU%357V_W!ZHU'0U'!Y[=R(Z)5R3:I[/9
M#5D5#B7#EF@:Y(:"GCE1SW9JF;W)DN7U3P4VDK"5JN,598L'MIID<JN>_@W.
M:BHJ=(J-35__ )(CCV^U./\ %T]RH:"HR>B,9$B:ZL3654S5.V*UG*9F,2MK
M&6#W8QTCV"ZO=G:JBBCFJ)$1,FHUCWYKGQ*N2;N,A^D#$E?>\<Q0X5@<Z@L?
M[*GBB7I4:U5S=Q;T1.\37'6)9L':(+38I%9%?IZ.&![47-\3$1N:*J<62.3>
M4KH_Q=5X.O:5U(B/8YJLEB7<]JHJ9*GWJ12)F,EIB)PM6*X8/TFW2F?=UJ+)
MBG/4:Z)<VR2)MS5-1>--B:W&5MI56\4^*9[=?:M:J6CRBC>O&Q$R:N]=Z(A,
M&Z2<&07%]TI<&N;=%<LK7N=&K&O7;GJZO77KE9XJOE3B._5=TK53AJAZNR3B
M3/8A:D3$_"+3&$NT+8>JKK>JNXP5RT%-;(TFGJ$3-6MVKQ+GN8N[,D?_ .!K
MQC2DX.2^W>YU5;$SAFU*-3-7HFLJ.BSU4SW9[B(:+L=-P;47&.JHDK;=<(TC
MJ(-F;D1'(FU=FYRDKM&E'"]BO$%98\(MIVM<KGN=P:R[]S7(B9)O_(BT3F2L
MQAW:8Y&7W2];,.-8O 4TM/3(Y5S5R2,BS[QX_9*5[),84EL8N?.ZF8S+K:S&
M*1NDQM3^V=T5U]#)/&V=L[84>FLBMU=7:O6U3"8XOZXGQ-679T;H^'U>E<N:
MHB-1-_W$UK,3'P3;,2L[2DL5AT185PXU5UY$6KV[U17R+_WF:PHVQ6/07'4W
M9*AM/=9DBJ'4CM1ZK^TRS75=LR;UNL1"_:3+-?\ !L5NNV'N&O$%*ZF@K<V9
M1[\E1%3-,MG&8G .D*.Q6RHM%^MZ7:S2],E._)=1W736S1-BNXN,KPSPIXHR
MG.C:Y8*L=_6NPQ3WJHJV1JCF/J$5JMS3?^R3CRXSMT$\$EWQ5BC52*EBC5C&
MK_"Y%:N_[R*U^DRTV^SU%)@FQ+9ZBH35DJ7*U9%;GGDCFHBIM1.\8;#N.X;1
MHZO>'$HY755RE5ZU*/1$:BHU,LM^]OYB:S,21:(E"ZZLJ:^JDJ:V9\\\BYND
M>N:N7LGG -F0     &XGL9/BJI>Z9O.-.S<3V,GQ54O=,WG&.O\ :UT?N6J
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MXMDJ;0=\-Q%W1_5Q;(
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MQA0,  =]%155=-P-#335,N6MJ0QJ]V77R0#H!]>US'*U[5:Y-BHJ9*A\
M2G ^.+E@Q]2^TP4$CZA$1SJF'A%3+=EM3(C$<;Y7HR-KGO7<UJ9JIVUM%54,
MW UU--3399ZDT:L=EU\E(F(GE*8G'.'LQ'?*[$-VGN5UF=-4RJJJJJJHU,U7
M),U7)$SW&, )0   #U06^LGII*B"DJ)*>/W\K(W*UO;5$R3<IY0       =]
M'1U5=+P5%335$OR(F*]>\@'0#ZYJM54<BHJ;T4^       W$]C)\55+W3-YQ
MIV;B>QD^*JE[IF\XQU_M:Z/W+5 !QNH
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M17_ :G[-WD4"N=#'PK%'=SO/>6:5EH8^%8H[N=Y[RS0
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M=\-Q%W1_5Q;)4>@F1DM5B!\3VO8M1L<U<T7:[C+<
M
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M/60 $H   -Q/8R?%52]TS><:=FXGL9/BJI>Z9O.,=?[6NC]RU0 <;J
M                       %7>R%Q36X=P:E/:9'0W"XO2"&5N]BZ[$7\G*A
M#[%['6V55I@J,25]557:6-'R2.=(BL>J9KGT^W)<R4^R$PG>\56>U,PY%')5
M4LRR].N2(N;%3B7Y)$.:]/G_ /J?%V^J!\T?TEUT9:78\*U-QGK;'<872PN>
MJY1JU'*C4157_EVYH;$&N^&,,Z2KKI(M-\QM%1NAHV2,1T+=3+-N6Y$-B
M         @NF_P"*^_?9-\]I*,,]0*#[)"+Z;_BOOWV3?/:2C#/4"@^R0#)
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M\!J?LW>10*YT,?"L4=W.\]Y9I66ACX5BCNYWGO+-
M                             %#:?J2IQ5C["F#&SOBHZYKII$1RHCE:
MV5<E1%3/WB%\E.Z<=&\N*[G0WMF(VV)M#"D?#JFKJ],[;KZS<L]?("3MT2X*
M;;UHVV&DX-6ZNNK$5_XLLRNM"%#-A#2MB?"T,[Y+4K5GIHU<N473N;QJN:Y1
MHA'4T,WA;0VZII1G6V.8DB5?#.X)6JN2+K\+ED3?0CHREPU>ZB_NQ.V_1U,*
M1I*WIL]ZYZ^N[/WV?W@76?'N1C'.<N2(F:GT*B*BHJ9HH&J^F'2M#B;$K\*4
MMQDM5E@G=%75:;5DU5R<U$V+EFU4W[<R8V9N%K]HKNF&, U"3STE,CYE2)4=
M*_4=MWYYN5J]<N&3#5BED=)+9;8^1ZJYSG4L:JJKO55R/3;[1;;<YZV^WT=*
MK\M98(6LULNODFW>H&J2X\B]I?H&6EK%Q3K\RK2<"[6R5RMZW6-@<$X/IX]&
M5HL-WB<YC84?(S-6*CG9N5.OLUE)3SDM7-?-7.RAYJSUN&YG9KY]?6RS,@!3
MWL?J.&@=?J:E:K865&345<_XG%PE3:#OAN(NZ/ZN+9
M
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MGQ54O=,WG&G9N)[&3XJJ7NF;SC'7^UKH_<M4 '&Z@
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M[]]DWSVDHPSU H/LD R0
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M@.LYOAQ!5\%+#PM8KN#E:K7-S<Y<E1=J%KE8Z%T1*K$Z(F2<W.\]Y9P
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M$7=']7%LE3:#OAN(NZ/ZN+9
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M!^AG.BV\GT?@&^@<Z+;R?1^ ;Z!YCX-CY?GF#]#.=%MY/H_ -] YT6WD^C\
MWT#S'P;'R_/,'Z&<Z+;R?1^ ;Z!SHMO)]'X!OH'F/@V/E^>8/T,YT6WD^C\
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MT'IIX(J>/@Z>*.*--NJQJ-3O(9ZFKQQC"]-/AG.78 #%J
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MLF^>TE&&>H%!]D@&2
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MQ\*Q1W<[SWEF@
M  "/8UMEYN5NCZ'+FENN$3]=KW-1S7<2H[-KN+/B \F,L?6;"=73TEQ=/+63
MMUF04[6N>K=NW)539L7O'+!F/+-BVHJ:>VNFCJZ;_$@G:C7HG7R15V9[/N4I
M2]W.^U./J2HND]%8<1,IVTG_ !K$YDJ6M5[D5BN:KL\W.XDW(6=@#!=XH,2U
M&(\37&CJ:^6F;3,91-U8FL1SG)_ W-<WNVKGQ 6.       "IM!WPW$7=']7
M%LE3:#OAN(NZ/ZN+9
M
M
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MOOWV3?/:2C#/4"@^R0#)
M          #77&U_?6Z0K[;L38RJ,+4%$L?,;&1L<DR+&U7+M1=RK^8T<X8F
MQO::^X4]WFCN5'4-;17MC6HZ=FJN:*W+5R1VS=_ AL#6T%-6ZG-422:N[-53
M+O'?%&R*-&1IJM3<@'@P]!7TUFI8;Q/'45[&JDLL:YH[:N2[DXLN(R(
M  .BO^ U/V;O(IWG17_ :G[-WD4"N=#'PK%'=SO/>6:5EH8^%8H[N=Y[RS0
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MB;F@>30=\-Q%W1_5Q;)37L>*YER;?*N-CXVR3YHU^6:=,[K%R@
M
M
M                                                   $%TW_ !7W
M[[)OGM)1AGJ!0?9(1?3?\5]^^R;Y[2489Z@4'V2 9(
M                                           .BO\ @-3]F[R*=YT5
M_P !J?LW>10*YT,?"L4=W.\]Y9I66ACX5BCNYWGO+-
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MFXJ/V/FD9^-;+)!5P-BJJ97(JL:J-5$U>RORBW0
M
M
M                                   (+IO^*^_?9-\]I*,,]0*#[)"+
MZ;_BOOWV3?/:2C#/4"@^R0#)
M                         !T5_P !J?LW>13O.BO^ U/V;O(H%<Z&/A6*
M.[G>>\LTK+0Q\*Q1W<[SWEF@
M                         %3:#OAN(NZ/ZN+9*FT'?#<1=T?U<6R (9I7
MPG:\586GANT3G)#E)&]BHCFKNXT7KJ3,Q>*?W?K?J?U0"-Z)L%6C"%@:RT1R
M:TRJY[Y%17.5<NLB?)0G!C,-=1J?M?U,F
M
M
M                             !!=-_Q7W[[)OGM)1AGJ!0?9(1?3?\5]
M^^R;Y[2489Z@4'V2 9(
M                    .BO^ U/V;O(IWG17_ :G[-WD4"N=#'PK%'=SO/>6
M:5EH8^%8H[N=Y[RS0
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MD  2S
M
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M(F:\9"R6 K71_IBP_C.HJ8Z9[:-L"-5SZF1&(N>>[61,]Q-NB*R\L6[QEGI
MR@*_Q_I5L.#::FJ)YHJV*97-SII4>K<LM^KGOS_(].!=)=BQ;:G5\-3!1Q([
M51M3,C'+M5-RY=8";@\5)=[;6S<%1W"CJ)<L]2*9KW9=?)%/:
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ME;Z04'B47I M8%=X<H-(D5WA??+S1ST"9Z\;*6-JKLV;47/>6(
M
M
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M$<K*E[45<MJY(I98 B6&='UBPW<TK[7'4MJ$8K,Y*ASTR7?L4EH
M                   "J/9#X'KL8X:HI+.SA;A;9^'BBV]/FK45-G81>(M<
M :QS6C&&E#%>%VW[#=99;=9UUI9*EKTX1^6>;<VIO5C>^;.(B(B(B9(G$@
M  >=]#2/G29]+ Z9-J2+&BN3[ST     .$T,4[-2>-DC/DO:BI^9S 3$XYP\
M\%%2T[]:"F@B=UV1HU?R/0 .A,S/.7344E/4*BU%/#*J;E>Q'9=\^P4T%.BI
M3PQ1(N]&,1N?>.T$8A/%.,9Y/-3T--3U$L\,+&2RKF]R)DKNV<Y:2GE=K2T\
M+W==S$53N!/128B>KXQC8VHV-K6M3<C4R0^@!+H6BI5?KK30*_//6X-,SO1,
MDR3< ,HB(CH'Q&-:JJC415WJB'T!(%V[P /C6M8F36HU.PF1]
M                  >>X4<-?0U%)4M1\,\;HWIUT5%1?*>@ 40OL=J3GBJ=
M$E9SC6?AN=?!+J>^SRUM?\\B\*"DBH:&GI*9NK#!&V-B=9$3)#O
M        '!(8DE65(V<(J9*_53-?O/KF-=[YK5[:'( ?&M1J9-1$3L(?0 .*
MQL5<U8U5[*')$1$R1,D  #(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M
M
M
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M^QQLO4V+MO\ /<>T(>3F'_.5OA?[#F'_ #E;X7^QZP!Y.8?\Y6^%_L?.8O\
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M,DV$D(U@K=<^ZG>1"2A(
M
M
M                                                         83%
MTU;%:]6VHJU#WM38[57+63/)>UF!FP0)ETJ:I(**"JFBDC9.Z5SG*KM9B9HF
M:Y9IGF<(+Q<+A%6SI4N@YWL:Y&I_XJY*JY[OD]G>!,K_ ++%<>YI/-4A=!<*
M-M)$BU<"*B;461/297$]\GI[ Q&T$M3S72*KW,1<F9MVYY(O7.^V84L<M!3R
M/M5&KWL1RJL+<\U^X#%<\:+^;I_"-](YXT7\W3^$;Z3/="%AY)HO -] Z$+#
MR31> ;Z A@>>-%_-T_A&^DZJBJMU3"^&>HI9(W;%:Y[5121]"%AY)HO -] Z
M$+#R31> ;Z E$J:&S4T21PS4S6H[7SX1N:KEEM/E)!9*2J=44\E(R5>-'LR;
MVNL2[H0L/)-%X!OH'0A8>2:+P#?0!%I^=$ZR\-+2.X7+7S>U<\ES3\S%WZW6
M^X(BTU=0P2*YSGN<C7ZRNWKO0GO0A8>2:+P#?0.A"P\DT7@&^@"$V>@LUNMK
M:1*BEDS1J/<KF],J;?*AT7JVVVNBRI*RAIWJJJY7(UR.^[--I/>A"P\DT7@&
M^@="%AY)HO -] $0L#;?:+:RDCKJ=^2JYSM=J9N7?LS,CSQHOYNG\(WTF>Z$
M+#R31> ;Z!T(6'DFB\ WT 8'GC1?S=/X1OI'/&B_FZ?PC?29[H0L/)-%X!OH
M'0A8>2:+P#?0$(U77"B6AJ$2KI\U8O\ XB>DE5CVX<BR^2[SE/#<<)V)E!4.
M;:J-'(Q514A;Z#WV=-7#\:-V(B.1/Q*$H?:*^D9;XVOJH&N1S\T61$5.G4]G
M/&B_FZ?PC?2>^PX7LM1:XI9[9222.5ZN<Z%JJO3+V#W]"%AY)HO -] &!YXT
M7\W3^$;Z1SQHOYNG\(WTF>Z$+#R31> ;Z!T(6'DFB\ WT!# \\:+^;I_"-])
MY7.M+F2M6>F1)7Z[\I&IF[9M_)"4="%AY)HO -] Z$+#R31> ;Z E$8X+)'6
MK5LDI$F55=GKLR15WKVSNF=:9I9)))J1SY$1KE5[=J)N)1T(6'DFB\ WT#H0
ML/)-%X!OH @MZH;;74^I35E#!)DU%<Y&O143<F6:=D^V*W6BUT4D*U=++)*K
MG2/UFIFKL\]F>[:I.>A"P\DT7@&^@="%AY)HO -] $&NM!:ZJG<VDJJ&GF74
MS>NJY%1N[9FAV89IK?8Z!U.ROII'/<KW.1S6HJJJKNS[)->A"P\DT7@&^@="
M%AY)HO -] &!YXT7\W3^$;Z1SQHOYNG\(WTF>Z$+#R31> ;Z!T(6'DFB\ WT
M!# \\:+^;I_"-](YXT7\W3^$;Z3/="%AY)HO -] Z$+!R31> ;Z &"U1V&*-
M45%16+M3MJ1.T5M+%3O9+4PL>CMK7/1%382_",;8L.TK(VHUC6JB(FY-JF(P
M[ANT5M!P]7;Z6:9[NF>^)JJOWJ@2\O/&B_FZ?PC?2.>-%_-T_A&^DSW0A8>2
M:+P#?0.A"P\DT7@&^@(8'GC1?S=/X1OI'/&B_FZ?PC?29[H0L/)-%X!OH'0A
M8>2:+P#?0!%K@MIN$;65<],]&KFB\(W-.T?6NM+:-M*V:D2!,NDUVY;"4="%
MAY)HO -] Z$+#R31> ;Z E%52SN;(U9:3)^IK=.W;J^][Q@*>PVY+HE557*B
MDB8KU9&U&M]\N:YKFN>XLGH0L/)-%X!OH'0A8>2:+P#?0!%9DLTSG++)1N5R
M(BJKF+N3)# TUCH(KU%6ON=&L<+T?'&U&M5%1<TS7,LCH0L/)-%X!OH'0A8>
M2:+P#?0!@>>-%_-T_A&^D<\:+^;I_"-])GNA"P\DT7@&^@="%AY)HO -] 0P
M//&B_FZ?PC?2.>-%_-T_A&^DSW0A8>2:+P#?0.A"P\DT7@&^@# MN-%G\,I_
M"-])F,"/;)9YG,<CFK.N2HN:+TK3NZ$;#R31> ;Z!@^GBI;?4PT[&QQ,G<C6
MM3)$35:$HQ3UE-#<;LV:HA8[FQ^QST1=R'IYXT7\W3^$;Z3VVG#]JN%5=9JV
M@IIY>;'IK21M<NY.-4,CT(6'DFB\ WT 8'GC1?S=/X1OI'/&B_FZ?PC?29[H
M0L/)-%X!OH'0A8>2:+P#?0$,#SQHOYNG\(WTG1-/;)IHI9:BE=)%GJ*KVKEG
MO)+T(6'DFB\ WT#H0L/)-%X!OH"41I8+)35;JF&2E;*JJN>NS)JKORZV9W3.
MM,SY'R34CG29:ZJ]NW+8A*.A"P\DT7@&^@="%AY)HO -] $&O-';ZV!6TM;1
M02JYKE<[5>BZJ9)LS062VV:V6Y:5:FEE5[7-D<KFIK(JJJIE]Y.>A"P\DT7@
M&^@="%AY)HO -] $$O=!;JYJ.I:RAIY]='.<Y&N1V2*F[--N[:>O#L=OLMKC
MHXZZG?JJJJ[7:F:JJKNS)AT(6'DFB\ WT#H0L/)-%X!OH P//&B_FZ?PC?2.
M>-%_-T_A&^DSW0A8>2:+P#?0.A"P\DT7@&^@(8'GC1?S=/X1OI"7&B_FZ?PC
M?29[H0L/)-%X!OH'0A8>2:+P#?0!X<%5=.K;DJ5$2HM4[)==-NQ"2\UT_P#,
M1?C0K&@ME+%B:]4\,21P1N35C9TK4VKN1-AE^=M-\EWX@E-^:Z?^8B_&AVL>
MU[=9CD<WKHN9 UMU-DO2N_$9W!&:6F=NLY4;4R-367/)$78@$@
M
M
M
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M:9@P^&?@U9W0[S6@<<,^^NO=K_(TS1A<,^^NO=K_ "-,T
M    %;TO[WW[ZR><IES$4O[WW[ZR><IEPA\7<IDL$]3*GNN7RF-7<IDL$]3*
MGNN7R@A(  $@
M
M
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MW0[S6F8,/AGX-6=T.\UH''#/OKKW:_R-,T87#/OKKW:_R-,T
M       %;TO[WW[ZR><IES$4O[WW[ZR><IEPA\7<IDL$]3*GNN7RF-7<IDL$
M]3*GNN7R@A(  $@
M
M
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M86Z@T_U5\JG#"'4=G;4YX6Z@T_U5\JG#"'4=G;4#-
M8?#/P:L[H=YK3,&'PS\&K.Z'>:T#CAGWUU[M?Y&F:,+AGWUU[M?Y&F:
M              "MZ7][[]]9/.4XUV)K90U+Z>IF5LK-Z(B>DY4O[WW[ZR><
MIB,5X=FJ'\U44]1PLDC4<UC&JB(KDSWIUE4"1V^O@N-+P]*[6B7-$4SF">IE
M3W7+Y2(83@GI:2KIYW/<V*HE9&Y[415:CE1-W8)?@GJ94]UR^4"0
M
M
M
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MH=YK3,&'PS\&K.Z'>:T#CAGWUU[M?Y&F:,+AGWUU[M?Y&F:
M      "MZ3][[]]9/.4A&,JVVNOD]%#4/BK5_P 261,HX]J\:9KGL7BZQ-87
MMCQ9B![UR:U455^]3"U-^M]ROM$MJEDK9:=7:\,2:N>LF6W6RW9*N_B RV#H
M8*>PPQTU<ZN:F><RIEK.X^)"78)ZF5/=<OE,6S_"3-NJJIFK>LO6,I@GJ94]
MUR^4"0
M
M
M                                       !C,06E+Q1<S/J9H&:R.58
ME1%7)47C1>L9,*J(BJJY(@$?EPVDM-!&^NJN$A:Z-LB.;K:KMBINZR9'R7"M
M,JHD%140L<B-E:QR92HFS;L[??,\Z:-K4<Z1B-7<JJF2ATT;5:CI&(KMR*J;
M0/%=8VPX?K(F)DQE*]K>TC5.ZU=3J?ZB'"]]1;AW/)YJG.U=3J?ZB >H
M              >6Z=3JG[-3QVCJ SM.\Y3V73J=4_9J>.T=0&=IWG*!SPSU
M%I^V_P ]QDS&89ZBT_;?Y[C)@                  !B,+=0:?ZJ^53AA#J
M.SMJ<\+=0:?ZJ^53AA#J.SMJ!F@                  ,/AGX-6=T.\UIF#
M#X9^#5G=#O-:!QPS[ZZ]VO\ (TS1A<,^^NO=K_(TS0
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MP:9]LXWM,K)7HF[F>3S5.5K5$MU-FJ;6(!ZP BHN>2IL    !FF>6:9]8
M  &:9Y9IGU@     #RW3J=4_9J>.T=0&=IWG*>RZ*BVZJ1%3-(US[QX[1U 9
MVG><H'/#/46G[;_/<9,@=;B>2P6F@9%3+-PFLJKGL3IW;-QFHKQ=JN)KJ6SN
M:UR9ZSIF^1<CFGQ6G%IISF8[1,J\49PD0*_MJXLCOLSYHUEBRVQK*W5^Y-;8
M2%+[4PKE7VR6#LH]'^:BE=/QE;1FT37]XDBV6?!BX+];IER2=6KUGQN;Y40[
MI;M012,8^KB1S_>IGGF;QK:<QF+1^4YA[@?$<U=RHOWGTT2   !FF>6:9]8
M    &:9Y9IGU@,1A;J#3_57RJ<,(=1V=M3GA;J#3_57RJ=>$51MF8KE1$S7>
M!FP#%IB"V+<N8.:V<T[>ER7B[.67%UR8K,]%+ZE*8XIQEE <6O8[WKFKVE.1
M"X JHF]40     /BJB*B*J9J!]     ##X9^#5G=#O-:9C-,\LTSZQA\,_!J
MSNAWFM XX9]]=>[7^1IFC"8:5$==E5<DYM?Y&GMN=S@H(\WKK2N]Y&U%57=Y
M%)B,]"(ST=[ZN%E4RG=(B3/3-K>OQG>0A^';E<;I'=IJWF2I3_#ARUM1-NS-
M%V[U,SS?=*%V5=2)/"FQ9XU1/OU<U4O-(])7FD>DL\#PT5VHZM/V<R([C:]%
M:OYHA[=9,L\TRZY28F.JLQ,=7T $(    543+-43,     &:(J)FF:@5O2_O
M??OK)YRF7,12_O??OK)YRF7"'Q=RF2P3U,J>ZY?*8U=RF2P3U,J>ZY?*"$@
M 2                %"^R?^$X=^I/Y6%]%"^R?^$X=^I/Y6&>K]LN3QO]FW
M\?[J- !R/!              ')K7.SU6JN6_)-QQ  ')6.1J.5JHU=RY;% X
M@                           <M5VIK:JZN>6>6P#B
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MB?MEU1X.E\QIWS,-10>V]4#[7=*FBD5%?"[554/$9//F,3B0
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M*GNN7RD>6Z1Y+_P]7X!WH)#@A'<Z)7.8]FO42/1'M5JY*NS8H$@
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M*      ;2^Q]^+BF[HE\XU:-I?8^_%Q3=T2^<:Z/W.[^G_W?X6. #J>V
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M;2DF>>V=K?RS.J\:3L*X;M:1VB6&K<BY,BI5:J<:[51=B&KH+[L^D.GS]O\
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MJ<[5U.I_J(=5W>V2PUKV*BM=3/<B]=%:IVVKJ=3_ %$ ]0
M    \MTZG5/V:GCM'4!G:=YRGLNG4ZI^S4\=HZ@,[3O.4#GAGJ+3]M_GN,F8
MS#/46G[;_/<9,                   ,1A;J#3_ %5\JG#"'4=G;4YX6Z@T
M_P!5?*IPPAU'9VU S0                  &'PS\&K.Z'>:TS!A\,_!JSNA
MWFM XX9]]=>[7^1IFC"X9]]=>[7^1IF@                   K>E_>^_?6
M3SE,N8BE_>^_?63SE,N$/B[E,E@GJ94]UR^4QJ[E,E@GJ94]UR^4$)   D
M              *%]D_\)P[]2?RL+Z*%]D_\)P[]2?RL,]7[9<GC?[-OX_W4
M: #D>"         'OYSW+G8ZX\P57,#51%J."=P:*N67399<:=] 1$ST>
M            /?;[/<KC#+-;Z"JJ8HO\1\,3GHWMJB; 1$ST> 'ML]KK+Q7,
MI+=3R3U#\\F,:JKL3/B[1TUU)/0UDU+5QNBGB=JO8Y,E:O65 G$XRZ  $ !V
MTT$E34100,5\LKT8QJ)FKG*N2(@'VFJ9Z5RNIIY87+O6-ZM7\CY/435#]>HE
MDE?\I[E<OYGKO5FK[+4MI[G2RT\JM1R-D:K55/O,>$SF.4@ "      !Z:"A
MJKA4)!0T\U3,NZ.)BN<OW(>BZV.ZVA&+=;=64:/][P\+F:W:S0)X9QEC@ $
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MQJT;2^Q]^+BF[HE\XUT?N=W]/_N_PL< '4]L
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M9/.4RX0^+N4R6">IE3W7+Y3&KN4R6">IE3W7+Y00D  "0
M H7V3_PG#OU)_*POHH7V3_PG#OU)_*PSU?MER>-_LV_C_=1H .1X(
M 72[_P"7JN^VA\Z$I8NEW_R]5WVT/G0EZ>KI\-_K_:526:UUEYKXZ.W0/GJ)
M-S6IGV54G?M-XCR5.:+9PJ)GP7#.U^]J$AT&P-H,,7Z\Q[:E$X)J[]7)-_\
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M.)C+%5E-+1U4M/4-5DL3E:YJ\2H=)SED=+(Z21=9[ES5>N<"CED
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MTCP5YB,S$3+6H$QTGX1Z$;\E-#+PU+*SA(W9[=ZIDO>(<4F,<G+>DTM-9Z@
M(5#:7V/OQ<4W=$OG&K1M+['WXN*;NB7SC71^YW?T_P#N_P +' !U/;
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MU5WJK?[H9VT+G;*94W+&BH=-UA9#A^KB:B:L=*]K<^LC%0[[5U.I_J(!Z@
M               !Y;IU.J?LU/':.H#.T[SE/9=.IU3]FIX[1U 9VG><H'/#
M/46G[;_/<9,QF&>HM/VW^>XR8                   8C"W4&G^JOE4X80Z
MCL[:G/"W4&G^JOE4X80ZCL[:@9H                  ##X9^#5G=#O-:9@
MP^&?@U9W0[S6@<<,^^NO=K_(TS1A<,^^NO=K_(TS0
M5O2_O??OK)YRF81JKN0Q%)^^%^^LGG*1.XV^ON]YN#Z&")60RK&JO<J*JHJ]
M8"PG(J(N9D<$]3*GNN7RD8PU1U%%:FPU;6-E15548JJGYDGP3U,J>ZY?*!(
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ME8^?6X=R*U(<OV;MB)M7IN/[D+4Q2M*VUO=72O9"U4Z5JY<(N:9-W+O7)/O
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M9^#5G=#O-:9@P^&?@U9W0[S6@<<,^^NO=K_(TS1A<,^^NO=K_(TS0
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M*@C54S36C<A?@LZ(\+JSSPI\$WAT?S38\BPQ#<J=\LC'/2I:U59L:KLLM_\
M"8K&^%*W"5V=15JI(W+-DS4R:_9GL[Z%>&8YLYTKQ$VF.4<D=!E,-6=]]O$%
MOBE;$^5R-1[DS1,U1/ZGOQ7A:;#N+%L4U3'-*BQIPK6JC>G1%39]XQRRKP6F
MO%Z(X"WO:2JF002SX@H(DE8CVH^-R<7]SJDT-/8QSNB6VKDF>6HXMMV;>5U>
MRI@=E3%P-1+%K([@WJW-./)<LSK*.<                  &\U%\#@^S;Y
M*+X'!]FWR [WU$='<  EIYI2^,/$'=;R+$ITI?&'B#NMY%CAMUE\SJ_?;]P
M$*     #8[1GA;"<%GM]UJ7TW-S%5_[25FQ4=L7+>8C3ICNBJ+<MAM%1PCE<
MBS/CSR1,EZ7/CS14W%$ OQ_IX8=<^+_Z>W6N  %'(
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M=0&=IWG*>RZ=3JG[-3QVCJ SM.\Y0.>&>HM/VW^>XR9C,,]1:?MO\]QDP
M                Q&%NH-/]5?*IPPAU'9VU.>%NH-/]5?*IPPAU'9VU S0
M                 &'PS\&K.Z'>:TS!A\,_!JSNAWFM XX9]]=>[7^1IFC"
MX9]]=>[7^1IF@                   K>E_>^_?63SE,N8BE_>^_?63SE,N
M$/B[E,E@GJ94]UR^4QJ[E,E@GJ94]UR^4$)   D                *%]D_
M\)P[]2?RL+Z*%]D_\)P[]2?RL,]7[9<GC?[-OX_W4: #D>"
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M:,K1?:QB<\&L8U7\;M;515_(G$3F8:SIZ>I%K4SF.?-1X *.5>'L<_@MX_\
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MU^Q5V;6JJ$U!:NG%9S#71\)31MQ5F0 &CJ
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MB*7][[]]9/.4RX0^+N4R6">IE3W7+Y3&KN4R6">IE3W7+Y00D  "0
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M-GQ)#AYMEJ^:%I(7LF_9/9JJNIE[Y$SW+N*Q (F<SE34U)U+3:0 $*
M             WFHO@<'V;?(!1? X/LV^0'>^HCH[@ $@
M
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M)Q^@="F'N0;3XG'Z!L3W/IMO<R=%\#@^S;Y =R(B(B(B(B;$1 =#UX
M
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MM\/_ +3+@#$<WW/DMOA_]HYON?);?#_[3+@#$<WW/DMOA_\ :.;[GR6WP_\
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MY\EM\/\ [1S?<^2V^'_VF7 $0;B^H=<*JC;:E66F7)_[;9OR^2=W1-6<D_\
MZR^J8"E_>^_?63SE,N!Z.B:LY)__ %E]4S%AN?/6B=.L*PN;(Z-S%7/)4W[<
MD(\NY3)8)ZF5/=<OE D
M
M
M                                                      >6Z5K+
M?0S5,FU&-S1J;W+Q)WP/5DF662#).L15N)JB>CI'TU(WFB9LKUCD<J:K69*O
MWY'SHJDGX1]%3-?#3-1U2KW9*W-,^ERSSW+OR SU\ZBW#N>3S5.=JZG4_P!1
M##XDQ!;*2R/YLJXJ=]73.6%DCLE=FW8B=]#+VE46VTRIM18T5 /6
M          /+=.IU3]FIX[1U 9VG><I[+IU.J?LU/':.H#.T[SE YX9ZBT_;
M?Y[C)F,PSU%I^V_SW&3                   #$86Z@T_U5\JG#"'4=G;4Y
MX6Z@T_U5\JG#"'4=G;4#-                   8?#/P:L[H=YK3,&'PS\&
MK.Z'>:T#CAGWUU[M?Y&F:,+AGWUU[M?Y&F:                   "MZ7][
M[]]9/.4RYB*7][[]]9/.4RX0^+N4R6">IE3W7+Y3&KN4R6">IE3W7+Y00D
M"0
M
M
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MJSNAWFM,P8?#/P:L[H=YK0..&??77NU_D:9HPN&??77NU_D:9H
M         *WI?WOOWUD\Y3+F(I?WOOWUD\Y3+A#XNY3)8)ZF5/=<OE,:NY3)
M8)ZF5/=<OE!"0  )
M
M
M                                               ,9B")\] Z.*H?
M"Y=O29:SLE38F>S;N^\R9Y+G;J>Y4_ U3=9N:*BIO147//\ (""4]?5UL,%$
M^KEA=&E2YSMFMTGO47BV9<1]AN%;<(ZRH?520K;V-5C6Y?M%R5=O;U4[Y*Y,
M,VZ2DCIUB758KE1<]JZWON^<JG#EOJ'PN?$J<$B(B(N_+++/O 8W$=TN$=@8
MM-;9:MM12*LKV991YMVJN:IUU,_:-MLIE5,E6--APO+498JYK4R:VF>B)V-5
M3LM74ZG^H@'J                  'ENG4ZI^S4\=HZ@,[3O.4]ETZG5/V:
MGCM'4!G:=YR@<\,]1:?MO\]QDS&89ZBT_;?Y[C)@                  !B
M,+=0:?ZJ^53AA#J.SMJ<\+=0:?ZJ^53AA#J.SMJ!F@"!QX@N_1TEN>QB4JN<
MB-ZZ(CLEW]@O33F^<>CG\1XFOA^'BB?U3C\IX "CH              P^&?@
MU9W0[S6F8,/AGX-6=T.\UH''#/OKKW:_R-,T87#/OKKW:_R-,T!Q5[4>C%<F
MLNY#D5U?I;G#C:&H:K$AAR1$XD:[-J9]\L5NU$5=Y>U.&(GNO:O#@ !10
M          5O2?O??OK)YRG.KQ!:J.=T-36LCE;O:K7;/R.-)^^%^^LGG*81
MMFJ+K<[E)/<*JG:R=S(V1JW)6HJ]=% E-'64]=3\-22I+$NQ'(BIY3,X)ZF5
M/=<OE,!:J%;?1) L\D^6:Z\F6?Y(AG\$]3*GNN7R@2
M
M
M
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M>RZ=3JG[-3QVCJ SM.\Y0.>&>HM/VW^>XR9C,,]1:?MO\]QDP
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MTJ)*[MJB'EJF\[+]'5)LIZK]G)UD7B[ZJ:3SS#2><S#/@ S9@
M "MZ3][[]]9/.4CV)+O4,O,-924+YX[=(Z)SN$:B*YW299+MXR0TO[WW[ZR>
M<ISJK!;:JLYJGIT=*NU=B9.7KKL [+-<4N=$LW!K%(USHWL5<]5R;%3ODAP3
MU,J>ZY?*8>EI8:.%T=-&V-BJKE1$RS5=ZF8P3U,J>ZY?*!(
M
M
M
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MNY3)8)ZF5/=<OE,:NY3)8)ZF5/=<OE!"0  )
M
M
M
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MNN7RF-7<IDL$]3*GNN7R@A(  $@
M
M
M
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M$QYV7;EQ?%6^DPMU9B2GO=OIJ:X22TLW^-*E(W)FU$V_=GQH6IK36<XACK^
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M<_5U<U7?LS4#(@
M
M
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M>#<J.?%K+JN<BYHN_9MRW=8#,IMW
M
M                                          .+Y&L<U'.1%<N2=DY
M
M
M           *?PO8[GB&AN%Q9?JFGK&SN;&J1M5&Y;$_]Y%P%;T6#<2T$%91
M4%XIH*&HD5^LC<Y&Y[][%0#G;<=UCL*VNL=2(^HGC5TLLKM6),G*F6:<>Q.(
MR&&\?4M[6TN93RQ17"-RQO=EDCT5W2[^LW,\%;H\?#46QUHGB2*CIW4Z1SN<
MB)F[6UDR1<UXMNS:1O$F$*JV8+MN&:*>6>ZI,LE-4,1,FKD[-79IULTW*!:.
M%KRE_M3:^.%\4,CEX/6WN;DFWR]XRYY;50PVRW04=,F4,+=5J=@]0
M
M
M                                              !PFA9,S5D3-#E&
MW4:B9J[+C4 #Z
M
M                          'Q6HJHJHF:<8 'T
M
M
>                                    '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g109079g00z43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00z43.jpg
M_]C_X  02D9)1@ ! 0$ 8@!B  #_[2!H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ($L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MI<2ZMZ_Z@I[DYU1;A;FRLAF]=@>! ,CRSR[Z2@WW[J>OSLEFA].%OD?&;_\
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M#Q&CG!QP@L:)@CC8P$D- &3[ER1$!5)U U=U*M5P,>E=(TURIO%D;XCV./J
MC:>'CORK;1!YY^Z)UM_T=T7]7)_Q4^Z)UM_T=T7]7)_Q5Z&1!YY^Z)UM_P!'
M=%_5R?\ %3[HG6W_ $=T7]7)_P 5>AD0>>?NB=;?]'=%_5R?\5/NB=;?]'=%
M_5R?\5>AD0>>?NB=;?\ 1W1?U<G_ !4^Z)UM_P!'=%_5R?\ %7H9$'GG[HG6
MW_1W1?U<G_%3[HG6W_1W1?U<G_%7H9$'GG[HG6W_ $=T7]7)_P 5/NB=;?\
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M\/\ V*M.J(K-3=0J[3='5U,0BBCJ<0O+CPP?BY'^=W5S46G[5#31M-MHBX-
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M)7U9U3644%#:+4RGEJ[O ]L3)&GUG<  '( [^:U-JT+7#2]+<)X'MOCF.=/
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M;)/:+&YK8JEK"UM3][Y8=QR1D^2E%U9JC2E-I2.VU5)%:J.G8VZQX#W2-8&
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M[=M#MVT@<_%7UTWL?VKLU),]A;,^G#7^MD=U]U]I-E_I9'Q1.DJB&- $@:,
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M2!^0UQ:6YP<'@_!9JFQ.[K*VBT;QP(B(]$1$!$1 1$0$1$!$1 1$0$1$!$1
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MPV,M <?8IFO 1$0$1$!$1 1$0$1:G4VH;=IJWMK;Q,Z&F=((@X,<_P!8@D#
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M22-S(T-/JN([#A:)\MZ7HB+P$1$'GKKD;M6ZFJZ&W7VXVMK?">'4TSV_B<C
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MP1D-<>,?%51J.["Y7!U3*YHRT-]4'''Q4_ZBW=ULHJ*UV^9T)I@^"7P'[0\
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MFL[2O:VBT;P(B+QZ(B("(B B(@(B("(B B(@(BT^HM04EEHW32OCD>"!X0D
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MP4S7364[*JEF@E:US)&%A#AD$$8Y"V8LDX[Q:&O+2,E)K+R70U8H*CQX-KV
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MOL8=,U^G[*Z*X"+=Z;*_[V_=P8F#^Y7LVDIF?(IX6_!@"YQPQQ#$<;&#_5:
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M]RN4%)&YK'S2MC#G=@2<+%B=(&[6M!/O5G=-[(ZUT5=>*]KXFPMCJF'<'-(
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M!$1 1$0$1$!$1 6NO]TBM%KJJJ9T>8H7RM:Z0,W;6DX!6Q5)];[ZZLN5DM%
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MU; Z:&9CXRUYXXSV5M+G.H:CU+=D>SHNGZ?TZ]\^XB(JU9"(B B(@(B("(B
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M5TSH:F2.3&8W%HP?85T9=O(<?573QY\N7G>/#F3M&.X*1@.<<?H650T$M8\
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M_?+'/B]:DU3+J%11REU<UQ\*25K0X=CAA']RA3AN>'GY(X*L33CHK]:H**L
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MZ:EL[<PQ%S7;SDAF/>H!:*&KN<S8J*,2,=GNX#D#/FI%I>X7!\\@GI*BXPO
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MWX<K+K;=!+2,:V:0UP=F2+/#1S[OAYK7IIM-/#'5^<GZ-?=+A2U3\1,D$.T
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MO2]K)-NI=S][A$S<[.<G'=>4+;5S4<_B4Q =@CD95E:-ZDU$$\=/=I08RYC
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M001D$+ZM'HBO%QTG9YR29'T4#W\8Y,8*WB]>"(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B#JJX144LT#CALK"P\9[C"HZOZ;UVF]7NO=D?5U;!"
M(A30P[&<CD\'W>Q7LB#%M1D-LI#.QS)?!9O:[N#M&05B7V\,M<+'88]Q=M+2
M[&.,K:J#=0:6=D3)\[XWR@!K1DCU2L,DVB/A;,<5F?BE :N;Q ><_/[UC9R/
M@N;F%IP?I77GD\'C]*X?),[_ !.[K-:1VR^HOC#N\D!W' !"1M;Y2L[SM'#N
M@B,K@WD ]CCNK M,)T_89)IAB:-^1&\;202 M=H>SQU+G2UC621B/<T$D8(*
MX:VNYJJQ]- YS8WQM[XQD'/]RM,6*-)3\1?Q:8VC]U3GR3JLWX:ORQ.\HS=*
MHU=?,]WJB65Q[YQDK)H[?1/@:Z6X,C<<Y! ]OQ6J()<X'D@]T .>>RK^^+6F
M]EAEI,5BF-NZ*DI*:8205S9G-.0!C]JV.H(J>HME,8I6>-G+PT#/;S45B)CY
MB.TKL%5-(=F\@^9([K=.>)JT3I;6OOOPZH8"7;6DN'M5IZ&M3Z:F,LK7#>V-
MS=S<>1[*'Z3M@JKLR![0YA:X\YQV5LTT8AIXHAC#&!HQ[AA6W3,$V_B7A6=7
MU,3M2L^78B(KM0"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@KSJ=HK[>11UE/(]DM*R1PBCBSXI.#@\^Y4==*&6W5TE-/&]L[,;HW-P1D9[
M?0O6C@' @]BHEJ/0]LNU2^K%)"*R0MWRN<[D 8QP?</H5EH]=Z,=MN%=J]%Z
MOQ4Y>;6L+WAK@6./8>U'-+"6@9(X*]%6_IU9(G!]9002R \.#W\#'Q7VX].K
M'-&_T2WP12.!]8O?W\O-3O\ FN/?;9!_Y7DV\S#SAM /K.VE<V/,9W-&2.0I
M-KC2TEAN$D4AC<UH;RS..1[U&,XQ[E98\M<L;U5N33VP3Y6]TJU=%&&4=>Z.
M".*G=A\DO<[QQCYRKC7D&.>:(DPO+7=L^Y>IM*W,W6WR3DN.V4L];'L!\OBN
M?ZA@FE^^.%_T[/WT[)Y;A$15JR%7O4G5U/;H#24TD4M2'EDD8EPY@+>Y"FMZ
MJ31VFJJ&D@Q,+N.Z\S:PKG5NH*ZH).9),DG'L"G:'3SEOO[0@:[4QAIM[M1-
M(7@[B7'_ #B<E=1.6CX+YG*VFG;1+>;C#2PEK3)*R,EP.!N..<+I)FF&-Y\.
M<K%\T[1Y:N(>MG.[W+L:=S@0P9'E[5>EAZ6T=+"T7**EJ) #ES7/&>>/8MG-
MTWLA8?!H(&/\CO?^U5E^HT[_ !PL\?3;]GGE1-ELU7=JSPZ6GFEY&\,9NV G
M&5Z&T+IJ.PVQL3\22A[CO?&&NP5WZ<TK;[(Y[Z:FC9*]H:YS2XYYSYJ0J!J]
M;.;X8X3]'HHP_%;D1$5>L!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0:?5%L^V=KEA;D/<6\AN3P<JK6VI\-=F5[V>#)QEN-V#_ ,E=2ANL
M+8UCV3P!K&AKWR=_6\_VJLU^F[X]2.86?3]3V3Z<\2T3JEPIV^!")9,\@=\*
M-7IK(ZQA9)QL' \^2LV:X.#S%1ET4C>2[@@CV?J6H>3.#-(=Q;Q[_P#WRJ++
MFBU.V.5]@Q36_=/#Y'ZNXX^4%V0.,0#AY+K!]7W>07!Q=VSZOL4+?LVF%CMW
M[Q*S[)=H[G:)J.4LCD<QL;&[LEW'D%!+_;W45QJ!ZQP[&",8X2QU[Z:X4\F7
M88\'C"FM^MT=SL\%;"UK9YI YSG$Y(P1Y? *ZV_&8:Y/^JJCC_1Y[4_Z;*X)
M)/(VGV(N3FDN&2N).%26F.(758F9W!\,KZUQ#P&C=E&')6YLMAJ*VH8&.8T;
M@#N!6ZF"]IB:1NPR9J4K,9)V3+054^2EDAV8,</ SWY5?Z[T#==9ZLI_2):^
MCH#3"-^(R^/+2YP)!(&<D*VM.6;[5L)<6%[F[26YYY]ZW2['35M7'$6Y<5J;
M5MEF:\,#3]O;:K';Z!KMWHM-'!OVX+MK0W./F6>B+>CB(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B(()=]%,]'D;1^D2$@'UGL'.?@%"[
MG;JJB>V*HBV!I+6>L"3CX'X*[UKKE:*6N;Z\,(=SZQB#CD^:JM1TO'DC>O*W
MTW5;TMME\PI&5Q8W;-ZK/:%EVRFEKZJ*!K,F1P:,$#/TJ;W/0C9(RYE4"<CU
M13Y_O699+ RUP/JI=KG0NWC=%M/ ]ODJ_'TRU+;+++U2DUWQ,2OJ7Z?L=/3Q
M!IGYCD;)SM')[C"KTEI=B$[F^];[5->^MN51Z[FQAV0-^1V4=#L-P&X/M"BZ
M[4=\^G'$>/\ PE:'3=L>I/,^9_JY#@G]*(.1GO[4'91*UB*I=M^Y\('99-!"
MZLF$+1D @<'![X\UC#+I&M X/G[%.=!VATM1))/3EC/##FR/BX=SY$K=H\,Y
M[Q3V:M9FC3XYNEFEK*+51!CO$#PXG#G ]_@MXB+L:4C'';5Q.2\Y+=UA$19L
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$6/<:D4=#
M45! =X4;GXSC. 3C*1&Y,[(AU3LYK[$YT0>Z0RLX#@!@9]J\]5<1AGE8>['%
MI^8J?:FZCSW.-S8J>6%I(.UM42./F"KZ:4S2OD=G+R7')SW71=-I>E9BSG>H
M9*WM':X,&2O0G1BI](TS5$XSZ8X<#_48O/8X4CTSJJKLD)@@?.&.D,A:R<L!
M) '8?!;==@G-3:&O19XPWWEZ?10/IOK Z@-1#-&8W01L]9\^\O)R/8/8NSJ%
MJ\6.%T,3 Z=KVY#9]CL$$]L97/QI[S?LCET'KT[.^>&UZ@5/H^E+IVR:=Q&0
MO,=3(99WR''K'/"E%\UK6W*FD@D?4^'(TM(=4N<,'W844 W$Y. KW0::<-?*
MAU^>,\^#>-V KTZ0:>DHZ26KG;(P3M@EC]9I#N"?+XA40!MD![A63HK7<]!4
M4-%)'+)$YT4675)#6 <=L=OV+W7Q>U-JO-!%*7WLOQ%BVRL97T;*B(M+'$CU
M7;AP<=UE+FYC:=I=)$[QO B(O'HB(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B L6YTHK+?4T[MV)8G1^J<'D$+*1>6B+1M+V)VG>%*7JT
M26FLDIXFN+6$ %[@3R,^2U4;=SQ_FJT]=6EU32-FIHRZ9TK<^''EV-I'./+L
MJODC,;PW=@D9QV7(:_!.GRS%>)=CT[-&HQ1-N8<7'UW-\@N)&5R(^GVKYW[*
M)3:9VLG7F8C>KZWU03Y>94ZT9=&2Q,I)G-;''$2"&G).?^:@A#L'OCS679)*
MF.L>8&3.&W'J9[9'L4C3:FV'+%*\(NIT]<V*;VY9^HK$ZVU;8W->,QAWK.:?
M,CR^"UU)0S3RB*!FYSB&XR!W5U7"VTU<"9H8G/P '/C#B!G*Z:*R4=*XN%/3
MEW!!$0!!"N;='Q]^]>%-7K-XQ^>4+M.AY)8P+BR>$\YV2,]O'M4]M]#'0Q%D
M3GD''RB%E(K'!I<>"/A5FHUF74?/(B(I**(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B NNHA940/BE&6/&",XX78B"I-7VDT-
MQF>T 4SGX8-V3V\U&W ;]H5]S01RC#VM/Q&5&;[I6&JBDDA=)XN  UH SRJ3
M5=,[IM>J^TG5>V(I=5.=N6M\^"OC3EQC\PMS<K#54CY'20O#6%Q!)'("TLD<
MFXN+, JBM@O6VVR]IJ<<UWW;&QTGI=QAB< 6N<0><>2N6T4[::W4\;!@-C#>
M^5%=#6-L;/29M[9&/RUIQ@C;_P U-AQV72]-TWI8XM/,N8ZIJO6R36.($1%9
MJL1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%J-5D
MBR5F/^HD^J5MUI]5_P "5G\Q)]4K/'\T,,GRR\KGNN*Y.."N(Y784X\.1M;>
M=A?0/7"^+Z,;@%E[,)Y67T4)^V=P^$7UBNOK.X_NFJ6^6V/ZJ[.BO\)5_P (
MOK%=76?\**G\F/ZJJL?C5S]OV6EYWTD??]U<^11O9?/(KXK3>%9M+ZLNU?X_
M3_SC?UK#67:O\>@_G&_K7EXWK+VENVSTIT\YTK3?E/\ K%211OIW^"M+^4_Z
MQ4D7(YXVR6C]9=;@G?'6?T@1$6IM$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$'QS0X8*J#4ML;1S"1HP&Q@_*SYE7 M#J>R,N5-*
MYI?XNP-:UN.><J#KM-Z]/',)_3]3Z&3SQ*G0'2Y+,8')R@(SX;?WS]"W4VGZ
MZ.J?":>0-:[:TY'*DNG]';@R6K\:-W((]4KG<6BR9[[1&VSH\NNQX*[S.^Z%
MT%'//4Q0N+")' =U9.G-+T]-&R69GK%F#AY]JD5)00TS UK0[  R6C/"RAQV
M5]ING4Q[3?S*@U/4;Y-XIX@1:K4>H+;IVWRUMWJV4U/$&ESW@D#+MH[#VE9-
MJN=)=:*"JH9FS0S1ME8YH(!:X9!Y]RLE8S$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!%7?4KJ/;-+A])Z:V.XL<PE
MCH'N&T@GN!C]*GU#,*BC@F!SOC:[.,=QE!W(B(,6JM]+5-(GA:_((Y]_=:<:
M4H#5.<ZGA,!'#.>#_P"\J1(M=L5+>9ALC+>OB)==/!'3LV0L#6^P+L1%LB-N
M&$SOYD1$1X(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#X]P
M8QSG' :,E1*[Z^M-LF\.21CSM#O5F9Y_.M]J'^ +G^:R_4*\=:*Z?TFM[_ R
MMBF>'->T^'*&?):3YH/8=BO-/>:<RTOR0&GY0/<9\ELE$^GFDJ?25ODIJ5DK
M&O;&T^)('GU00.WQ4L0%I]6?P)6?S$GU2MPM/JS^!*S^8D^J5GB^>&&3Y9>5
MGKXS!!X7U_F@SD!G<KL=]I<?MO#X" 3D)_E N3VO;ZSQ@%<<@R!>[^7FWA9G
M1/FY5_PB^L5U=9_PHJOR8_JKMZ)?PE</A%]8KJZS_A14_DQ_5592-M9/V_99
M7G_1Q]_W5QY%&D <C*>17UH<?D#/M5GX5GE\.,<!9=K'^&T_\XW]:Q2\CY2R
M;7S70$?]8W]:\GA['+TIT[_!2E_*?]8J2*-]._P4I?RG_6*DBY'4?FV^\NNT
M_P"57[0(B+2W"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@QWT=.]^]T32[.<^]=[6AHPT8"^HO(K$<0]FTSS(B+77ZZTUHHA/
M62^&QSM@.TNYP3Y? KUX\V_97:Q='.^QTL[C%444,IV.:6Y$SCSYY]0+N^Q<
MZ@U57)6VRZU$TT4$--!3M>6@,[MX^@+S3J"[SWJM;4U187MC$8V-P, D_P!Z
MW/3&\BS:MMDCWM9"ZLI_$):78:)!GM[LH]?HTBPK+=:.]6]E;;93+3/)#7EI
M;G!P>" >ZS4>"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@*/ZWOL-BL59-++&R3T:9\8=+L+BUN>/T*0+S']E3K=L9MEOH))X
MWL=5P3YC:0[Y X)^=!Y\UQJVNU-?9:^:>H9O:UNQU0Z3L,=UZQ^QSZ@?NBLD
M\%?(&SQU#((VRU7B.<-@[ _J7B=6/T0U0^PZQM$+I9&TTE:Q\C&,:[<.WFCU
M[_18EHKXKG;H*RG#Q%*,MWC![X_N66CP1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$&OU%^#]S_-9?J%>>OL>?PCI/RIO[->A=
M1?@_<_S67ZA7GK['G\(Z3\J;^S0>E41$!:;5G-DK.<?>)/JE;E:;5@_^"U?\
MS)]4K/%\\,,GRR\LLB?))X3&N<[&>!DJ>TM%0Z7I(9J^*FK'U#&RM9.QK2W
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M*5DA9L,FQH:<^2W9*]UNVS1CM%8WA)*J>UZBHI(Z6DHJ&I<0UK(@USR <DC
M![9^A1"E@]'O#8B[)9.&\C'9V%(],V&HHH?MU,8C3T[RQVUQ+N0!P,8_&"T
M>)=0R2>3JHN&?>]9X8YB)\0UY)XW>C.G?X*4OY3_ *Q4D4;Z=_@I2_E/^L5)
M%SFH_-M]Y=+I_P JOV@1$6EN$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0%2OV151J2LT_!1:>L5TJI(JYKC)1MD<7,\-^
M3AK>V2/T*ZD0?FU=-#ZIM5')5W33EXHZ6/&^6>CD8QN3@9)&.20%D473_6<\
M,%71:6OTD4C6RQ314,I#@>6N:0.W8@A>R_LD/XJKW_\ E_[=BF'3C^+W2_\
MLNE_LFH*V^QN.I*#3M):M16FZTIC;,\S5K9&DDR9 PX>P^U76B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@ZZ@O$+C$W<_R
M"\OZWZ'7/4&J+K<705Y;4U<T[=DL6W#WD\9\N5ZD1!XGU/T*K;);/2Y8:YK=
MX9E\D1'.?9\%MJ/['FX[89V07') >/OL2]%]8OP//YPS_P RF%O_ ,0IOYIO
MZD$;Z96>JL&C[;:JN-[32Q%N7N!=G<3R1QYJ5HB B(@(B("(B B(@(B("(B
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M,V&G;3"H>_8YP P#G R?-!N7/:P9<X-'O.%P;/$XX;*PGV!P5%4NK[[U&O\
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MG6B]:.U)14-JH[9/1RTPFDDJ(Y"YKM[A@8>.,-'DK*Z9:UI]8V"DJ3)#Z>Z
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ME' SS\L(/3XY[(M-HV[-OFF;=<FDD5,(DR6[>_N6Y0$1$!$1 1$0$1$!$1!
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MYP6Q#])7SK/43&_U%.9"8 (R&>_:J6,.^KF-_P#/"[G-_I(G;_/*MI) -P:
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M)>B]KJ;;5ZA=5!H$KXBW:[/8R?M"ENN-+TFJK5%15S7NC9,)@&/VG(:X=_\
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M$0$1$!$1 1$0$1$!$1!YWZD5K*#J[<II "WT:-O+L?B-5^15D#;>)_%C\-C
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M:VKUW<J^&GE;(^FF@)9* <EIS(1@_ J[[;116^CCIH&,:R,8&QH:.^>P64B
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MI*ZNM,;GZGJ< _)B[?DKMZ(EWVQKRXYRV+]977UF?(W5-5M=ZNV/C_=6FO\
M.3]OV;IW_!Q]_P!T%M5>;6_(B\7+@[DXPIAH[5 KJRXQ/HF 0P[@2_.?T*)6
M&WON#W,D<S)< -W"FFG+!#:I:N20PET\7AY:X_WK=FFG#3B[D9DU>ZIC,?H3
M1G_^IG^Y:VWDS71DF"W=,'8^)6^ETAZ/$Z424V&^0>[*T5#F.["+/#)PWCW.
M6W'-)B>UKO%M_+TCT[_!2E_*?]8J2*-]._P4I?RG_6*DBYG4?FV^\NFT_P"5
M7[0(B+2W"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B((%U7T8_5%O\>"IDBJ*6%XC
M;'%O<XG!XY!!X6CTG=-1Z<T[26C]SE?6^CL+/2'![2_))SC:?;[5;*(*ETSI
M"NN^NK;JV[>DT<E Q]***:(D2-+'X=N)&.93Y?BJV@     !P $1 11SJ'?_
M -S&D+A=A$9C3^'][$FPG=(UO?!Q\I1&ST-]O]JBU!!?:ZGAJ(A5LHVE[L C
M.P'<,^SM\R"R:Y]1'!FDC;))GY+O9]*AFA[OKJNK[@S5=@HK?2QU.RF?"\$R
M19/K'[X[GM[._9;C3]=6/T_%+6PU$<Y>X$3$AV,G'<*N>D>LZ_5M;JBCEEJ8
MG4M<::-[YS)M&7<@<8[=D$ZZB:QCTC1TD\KH6B>;PAXC7.\L_BJ7KS;]D98;
ME24-NGJ+Y45,4E7AD3@[##M/(]8JZ=.Z=NMMK(Y:[4%37QM+B8Y [#LC [N/
M8\H)2BIS4^L;M>=2QVFQ4M?"VFJWTE144LCGAF7AH>\-'&,./)]JQ=>WB_=-
M*'[:SU5RO\)D;3B$/?&,N!.[/K=MN.WF@NU%K=/W6.[T(J(MHQ@$->'8. >_
MSK9("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B(-?J+\'[G^:R_4*\]?8\_A'2?E3?V:]"ZB_!^
MY_FLOU"O/7V//X1TGY4W]F@]*HB("TNKF-?9*L.)!\&3']$K=+3ZL&;+5GV0
MR?5*SQ_-#"_RR\]TECJZO3;'4<+I)S(?5W- QGWK-&EC;[5425(F8Y\>]P+F
MG!QSV4=@O%;2^I!4SLC'XK9" NN>\7&>.2.:OJGL>,8=*2,+J+XK6LY6F2*U
M8DL6VH>UN3$/DN\RNN-K62AQ)X7-KB&@.)<?:5Q(];!^E;ZTVEA-]ZK-Z)D_
M;.X'R(CQ_2*V'4"E94:\JA.YS(O"9ZS?;M"P.B7\(UX_U8OUE<>L,TL&JZE\
M4CV^K&/5./Q56Q&^KF/T_983.VDC[_NT%/IF[UM6R2OHS$V-WJ%CV\M]IY*P
M-56FGH S;)(:@OQ(QV,-X^"Z'7^YN;ZM?5MP/*9RUU353U+RZIFDF<3G+W$\
MJ7&.TSY1/4B(8XCS(",E9UJSZ=",<"1OZUAG.[(.![%EVK_'H.>\C?UK?%-H
M:9OO+TIT[_!2E_*?]8J2*-]._P %*7\I_P!8J2+D]1^;;[RZO3_E5^T"(BTM
MPB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("*O>HW4=^DWO@MECFOUP8Y@=1TLWWT-<W.\M#7' X\O,+YT[ZD2:G
M,L=[L<VFZOQ&L@IZZ;#Z@$<E@<UI..W *#GU(ZAQ:.DH&ROIV^E5(IQXK'N^
MC:I5'?*2.U2W"LF;'3QOVN>&N(&< <=^Y5>=:]4V+3CK*;SI6BOIJJX0QF<L
M'@NQ\L98[GZ%B]7M75-JTK64UMTO554#O#>9*?.T.\0<<,// ^E!9FG]2VC4
M+JH6>L%2:5P;-ACF[2<X^4!GL>RVZ\D](NIU[L=7=VT>@[O<Q631F0P;_O&"
M[Y6(S[3[.R]*Z=U(*_3=/=;S2&R.E>YAIZQ^PL(<0,EP;W SV02%%0#_ +(.
MZO;-+0].+M6TL3BU\\$SW,:1Y$B$@>1^=6-TYZB4FLH/6@BM]:R)LDM(^I#Y
M(B3C:X8!!^(03E$1 1$0$1$!$1 1$017J?8*G4NBKE:J$,-34>%LWNVCU96N
M//P!5.2]0[OTTCM=GOTT3:2%XI6-@A$APPC//'D>ZO+5=UJ[1:YZNDIFSF,-
M.'' R7 ?WJ+7G4-CNVEJEE2VA==YJ21H@,>YS9G,(#02.^<(-Y8M246K-+0W
M:UF0TLLCFM,C-KLM)!X^94I]C+^$.L_]L'ZSU/.CEDKJ#0=)]L()::I$L@=
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/ B(@(B("(B B(@(B(/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g109079g00z44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g00z44.jpg
M_]C_X  02D9)1@ ! 0$ S0#-  #_[1C64&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" -+!Q4# 2(
M A$! Q$!_\0 '0 !  $% 0$!              <#! 4&" (!"?_$ %L0  $#
M P$$!04("PT( 00" P ! @,$!1$&!Q(A,1,B05&1"!1A<=$5&#)25H&AL187
M(S-"56)RDI/2-38W.%-S='64LK/!X20T0U2"HL+P8R4G1?$F@^)7A/_$ !H!
M 0 # 0$!               ! @,$!0;_Q  U$0$  @$"! 0$! 8" P$
M 0(#!!$2(3%1$Q1!4@5AD:$S<8'P%2(RP='A(U,T0K'Q_]H # ,!  (1 Q$
M/P#JD
M
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MRB\%55[$0"30
M
M
M
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M*^H;#/+*Q6-=VX144G%[&R,<R1J.8Y,*U4RBIW*:9+LRTS)<?/?-)&3;V_\
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MDR*V-DC5;O+EO%,^I4 F
M
M
M
M                                               >)HHYF*R:-DC%
MYM>F4/D%/# F((8XT_(:B?45       #XYJ.:K7(BM7FB]I] %"&CIH'[T-/
M#&[O8Q$4K@                    /CVM>U6O:CFKS14RA] %K[G46<^9TV
M>_HF^PN6-:QJ-8U&M3DB)A#Z
M
M
M
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MUU/<(YK>VD\V:UR*DN_O9S^2G<9URUM.T.W+\.U&&DY+QRCYPDL &CA
M
M
M
M
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MIE.0
M
M
M
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M)O+O/5KD7APY</I.N&HC6HU.2)@^1O9+&V2-S7L<B.:YJY147DJ*>@
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M
M
M
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M>Y+Q9MVM;T5QI7K!4Q+S:Y.2_.U6K\X0V,
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M/1T]G@8CFLPB(BJBN3T>!'=TN]#4[3M+U]@T]56)CWJQ7N;N)*FZ_L1RI_\
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MD7AGE\%"?B)ME6B;W%J:X:OUHD;+W5HC(X(W(YL+$14PBHJ\]Y>TED
M
M
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M &RT/2G15YOB3+6/^?=7V(;F
M                             !XGFB@C62>1D<:<W/<B(GSF"AUGIR:K
M2ECO-&Z=5PC=_M]?(#8 4I:B&*G=/)*QL+4WE>J\$3OR>:*KIZZF944<S)H7
M?!>Q<HH%<   #R^1D>.D>UN5PF\N,J!Z      "U2XT:W!:%*F+SQ&[RP[W6
MQPXX^= +H
M
M
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M=JBO=CK;=/P941.CSW93F879O=I:ZRNHZ_A<:!ZP3M7Q:OZ*M)9ML
M                                                 -.VL:CJ]+Z,
MJ;I;MWSB-[&IO(BIA5]**;1<J**X44M+/O='(B(NZN%X+G_(B';-HJEH]"54
MUMBJIJE)&(UC<O54SW(4O,Q$[.O1TQWRUB\^O39'GV]]4=T'Z#?V2=]D>I*S
M56C8+G<MWSA\KV+NHB)A%X<D0X_]P[M^*Z[^SO\ 8=%;%-%4M9H2GFN<55#4
MK+(BL=EBXSPX*<^&]YMS>U\2TVFIAWK$1S]$T@M;90Q6ZABI*?>Z*/.-Y<KQ
M55_S+HZWS<[;\G/6T:ON>O-KD>AZ*X5-%::5B25?0O5JR<$7CNX7'73AGL-O
MN>PK1TEFG@MUN\UN'1KT-6V1^^Q^.#LYSSP:533MTMY3]QFN;FPT]UIT;%*_
M@U>#.W_H4Z$K*RGHZ.:JJ961T\3%>]ZKP1$3*J$(HTE;[Y8-F=\HMH,KZVBI
MFO;&]LCG2OAWEYJN%[NWD?--:WM.F]FUDJM/62[5=MJ-](XHF=(]F%3X67>G
MO/M?M!H==;/-8.M=+4QP4<;XEEE1$;(J+C+>/+@6NQ_45MTOL&MMSO$K&011
MO5$5,J]<\$1.U57 %*Y^4!0VMD;[EIR]TK9%W6K+ C45?TC=*S:-04FH[#9I
MJ6J;57>)98\M3#$1'KAW'GU%(ZT+8+AM,U<W66IX>AL=.KO<VC<B-WDY;RIS
MY-SS[2MM3<V+;]H=SU1K.@>F5X)\&8"2MHFNJ'1%+13W"&>5*J=(&I$B+A51
M5RN53N(BVUZ[JZ#:3IZF@I;LM+3/21\464;4+AWP4SAW-.?<9/RJ9XDMVG8-
M]O2NKV.1N>.-U_'Z2MM<1$VG:!SC"N3.?5(!N&JMJEITW:K745U-6+77%B.@
MH6,19LJB+A6Y_*1#"6/;=0U%_IK5?+/<;1+5+B!]1&C6NX*J9ROH4QVU'4=)
M3;1;;;M/Z?ANNK$;F-\[E:R)%W,+\)J?%\".=L$FL77;2[M9-ME-FM:L5/2N
MR]OI7BO#GV@3?K_:Q9]$WRGMMS@JI))XU>Q86H[.,<$RJ<>)@+;M]L2UTM+?
M*"X6J1&;\?G#&MWT[.;N9@M;TT57Y0.B63L1[$AWL+WHC#YM\MU+4;3]$MEA
M:J/7<<F,91$E7ZT V6P[<;7<-2T=IK;5<;=Y\]K*26IC1J2*JHB?A>E._F7<
M%;IQ=NU13LIZI-0^9[SIE5>BW-UGY7=N]AKOE'P1QWG0$D;&M>VZ,1%1,8^Z
M1&-17IY2%Q5G%_N*Y4]?11 ;AJG;/;K5J">SVJV5UWJJ9?\ :/-6(Y(\*J+V
M\^"E[H+:[9]9ZADL]NIJR*IBA623IF(FZJ*B*U<*O'*FJ>2VE+)9M025*1^Z
M[KA)YRCOA(F5Q].\8[13*)GE/ZG2W;G1>;)O;G+>Q%GZ0.A0
M
M
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M[^[FFJ&O>F[+)&G2-^*_M0S0
M                  /CFM<F'(BIW*A] %/H(OY*/]%#VUK6IAJ(B=R(?0#<
M  &D[2]G-JUW21-K'.IJV!<PU<2==G/AE%1<<5[2/G[%]4UL*6ZZ;0KC46E>
MK)'T;\R-[6JO2]J$[@#3:39_;;=H*ITO:=VEAGB6-TR,RY55<JY4SQYKVFA7
MS81)<]&V+3[-32P0VQ7*KDI<I,JJBIEN^B)C'I)O $)4NQ_5M)3QP4NTJNA@
MC:C61LHU:C43DB(DQG=;[*%U39;4R>]S17NW(B17)L:[[E1<\4WD7M7M[24
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M!D0
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MILNH8.JZWU"-F5.V%[F;_P#VL4W:FF;44\4S%RR1J/3U*F3=XZH
M
M
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MCE]'1B]0 &34
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MN^PM=%0:CI=V1JIRJ&HB)ZNK$\VAYEHC?ET2@  @
M
M
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MX?2&LV_DXO65FG(]M/"<CVTW80]H>CRAZ*2TJ^H;"AKR&PH8Y?1T8O4 !DU
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MJX+A1V+S*-::IJT;&N5^Y,<J(C4X\D.E":WB_134:7)IYB,D;;@ +.<
M
M
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M/:'H\H>BDM*OJ&PH:\AL*&.7T=&+U  9-0
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MAR<<\."]QSG'HFGT3MQTO2TU;55:3,<Y75#D<J<.S"(=/$'[0?XP.C_YE_U
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MP #5YP
M
M                     #XYK7?":B^M#ST4?\FSP/8 \=%'_)L\!T4?\FSP
M/8 \=%'_ ";/ =%'_)L\#V /'11_R;/ =%'_ ";/ ]@#QT4?\FSP'11_R;/
M]@#QT4?\FSP'11_R;/ ]@#QT4?\ )L\!T4?\FSP/8 \=%'_)L\!T4?Q&^![
M'GHH_B-\!T4?Q&^!Z 'GHV?$;X#HV?$;X'H >>C9\1O@.C9\1O@>@!YZ-GQ&
M^ Z-GQ&^!Z 'G<9\5O@-QGQ6^!Z 'G<9\5O@?=QOQ6^!] 'S<;\5O@-QOQ4\
M#Z /FXWXJ> W&_%3P/H ^;K?BIX#=;\5/ ^@#YNM[D\!NM[D\#Z /FZG<@W4
M[D/H ^83N0^X3N0 !A.Y!A.Y  &$[D&$[@ &$[AA.X !A!@ !@
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M1&W1S6M:T[VG< !*H
M
M
M
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MRKH9V34[N3VKE"IYW3_RS/$LYYK,3LK@\131RYZ-[78[E/80
M
M
M
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M5,HJ<E0TP\J[2\[XE,6SS>O27T &KSP
M
M
M
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MLIIT94I\*GD5&R-];<F9+1.[*U9K.UH  %0
M
M
M
M                                                       !87VZ
MTUDM-1<:U7)3P(CGJU,KSQ_F<\U.M+5K3;II:ILKY'1PQN:[?8K>.#I.2-DK
M%9(QKV+S:Y,HI!FN::"FV_:0;3PQ1-6)^4C:C>ST 3J
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M>SVE[#+'/&DD,C)(W<G,7*+\X3-9CK#V  @
M
M
M
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M?1^V;'H*JVCS7Q6ZOI+=%;>B54=!C>W\MQ^$O9O 22
M
M
M
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M*)M9;JN"II7)E)8I$>WQ1<%I:-1VF[UU926RN@J:BD=N3,BD1RL7*IA<+Z%
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M>A4X%<
M
M
M
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M":2CM73=/.Z19II,8WGJC47^ZAN8
M
M
M
M                        #S(]L4;Y)'(UC$5SE7L1 /0-6LNO],WJ\NM5
MLNL4]>F]]R1CT7ASXJF#:0    M(KE12U[J**IB?5M;ONB:[*HG#BOBABFZR
ML+M2+84N#/=9.=/N.SRSSQCDG>!L -=IM:6"IU$^Q0W%CKJS.]!N/RF.?'&/
MI-B     8S45^MNG;<^OO-2VFI&*B+(K5=C*X3@B*O:!DP6%BO%#?;='7VJH
M2HI)/@R(BIGQ1%[2_  'F1[8V.?(Y&L:F555PB >@:+==K6B;75K35E]A;,C
MMU4;%(]$7ES:U4-HL%^ME_HFU=GK8JJ!W)S.?SHO% ,D              HU
M=5!1PNFJIHX8F\W/=A#[2U$553QST[TDAD3>:Y.2H!5    M&W*C?7+1,J8G
M52)O+$UV7(G'GX*!=@UVAUKI^NO\MEI;BR2YQ?#@1CT5.7:J8[4[38@
M "SN]RI+1;:BON,S8*2!BODD<BKA$3*\$X]A;Z9O]OU+:8KG9YUGHI%5&2;C
MF9PN%X.1%YH!E      &O4^L['4:HDT]#6[]VC15? D;^&,_A8W>Q>TV$  %
M5$157D@ &J4FT+3-927"II+FV:*@;OU*MBDRQ./'&[E>2\C+::U!;-2VN.XV
M6J;4TDG)Z-5O;CDJ(J<NX#*@
M
M
M
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M1%7K*O+O52,O*';N[;=)OJ$7H%GCPO\ U1Y-F\KIJNV<V=S$56-J&JJ]R;J
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ME,*CT_S,EY.UUFL&T[4VC9)'>9I++)3L5>JS=>N$1/3O%OY)?[[-5_\ ]?\
MY%OI*/?\JZX+2<8VH]7X_P"G/T@=4
M
M
M
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M"Z
M
M
M
M
M
M
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MJP<J>^8U5\C(/&7V#WS&JOD9!XR^P#JL'*GOF-5?(R#QE]@]\QJKY&0>,OL
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M/?,:J^1D'C+[ .JP<\[-MN^H=5:VM=EKM+PT=-5O<U\[5DRS#'.[4QS3!T,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                               %&LJH**EEJ:N5
MD-/$W>?(]<(U.]5+2UWRV7:*22VU]/51Q_#=$]'(WU@9$&O2ZUTU%(^.2^4#
M7L56N:LR914YH>H-9Z;GF9%#>Z!\CUPUK94554#/@Q5RU'9[95)37"Y4M-4*
MF4CDD1%5/495JHYJ*U<HO%%  Q<>H+3)<W6YEQIG5[55JP(]-]%[L&4
M
M
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M:K5:JHBJBHO<79CM.W:&]V:EN%.FZR>-KE;G.ZJIE4^8R(
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ME+3="S2^EJ6CK*IKF4K51TSW<%RY5Y_.1;2:<VE/I870W*)(E8BM3SIR83'
MO=M=PKJ#1]MH)I%Z>9Z=.]KUZR8=P\40#=8MH>FI9$8RO?A7;J/6GD1F?SMW
M'TEXNL;&E]99DK%=<'HBMC;$]R+EN\G61,<N/,US2U@MTVR:GAJH859-1+,Z
M1S$RQ7,RKL]Z=YH>Q>B?<=H-76S/=(VDA>C'NZV516L3C^:H$_@
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ME>F=Y>M]6$)N
M
M                0CMZI9Y[]:E@@ED1&-RK&*N.L[N)N $<;2X99-EU-''&
M]\G1Q=5K55?O:]A&^B]<7S2UF]SJ6S]+'TBR;TD$BKE41.Q4[CH\ :%L_P!0
MU.MZ*YQ7^V10Q0K&C6=&YJ/WM[/-5[D-ACTE88WM>RUTR.:J*BHG)3. "'=K
MNEKE'?J?4UCC669BM61$5,M5J)NKCYC6]3:CU#KNDIK.VT+$J2(YSD8K<JGI
M<N,'0P PFBK0^QZ:H:"5V98XV[_YV$S])FP
M                                              %5$3BN 4:R!*FF
MDA<YS$>U4WFKA4]*+WA,;;\VF;8;-7W[2;**TP><57G+).C1[6]5$=E>LJ)V
MH7VS*VU=GTE34=QBZ&IC7KLWD=C@G:BJA\33=S7,S[W*M5#PI51'(UK>6'IO
M=?ACNXC[&+A&F8+W4(^;A5*]'.1_I8F]U5\3/BM[77Y?#_VQ])_?^_JTG6VD
M[U<=I-/=:*BZ6WH^)5FZ5B)P:B+P5<]BDC:LL5-J*PSVZJ1%<YF\SBF6N3DO
MBAC_ +%*ERK3R7FL]SH^,+&O<DK7=ZOSQ1./# ^QR[*BU+[W)[I)U6/1BI$C
M.Y6;W%>*\<\\#BM[3P,'_;'TG]_G_=&FSG0E_L>LXZJMHMVAA5S5GZ9BHJ;R
M<<([/).XRVUW2=ZONL+96VFB\XI8Z=C'/25C<.21ZJF'*BKP5#=?L6K&8CBO
M-2E//QJVO5SE>O;N+O=3.7=_9W#[%:MV627JK6"'C2HCG(]J\\O=GK<U3LX8
M'%;VG@8/^W[3^_\ 7T;';FK%0T\,F$D9$U'-SR7!KFT;3$>K; M+'*UM1$[I
M(G93&>*<?F51]C=TQYS[N2I<G=5[T:[HMWN1F]S3CA<EK+HZY0U:K;+_ %,5
M+(S=ECFWI,KG*JWK)@B;V]JU=/@GE.6/I/[_ "_LU2"GUM#HINGH[0C>HM/Y
MUT\>[T:ICX^>2]Q8671^K=*33QV:-LSZR!&NG;(Q.B=OM55PJIG@BIR7F2)]
MBE2J^;+>*M+:SK1L1[NE1W?OYY)W8'V-W5<U#KW(M?'U87(U4C1G+#F[W67'
M'.4XD\5O:KX&#_M^T_O\_P"[8K3'/%;:6.LEZ6I9&ULK_C.QQ4NBRM%$^AHF
MQ35$E1*J[SY'JO6<O/"=B>@O2\.6T1$S$3O  "50
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MO%ZL\L8(C_CF=_GM^_T5P 7<X
M                                                        !YFD
M9#$^25R-8Q%<Y57"(@'H&C63:CIN\WY+51U+G3/>K(I%3J2*G-&NY+V<N]"G
M]M?2_P!D:V=:Q$E1_1]+E.CW\9W=[.,X WT
M                                                       %'SNG
M2J\V\XB\XQO=%OIOX[\<SP^X4<=6E*^KIVU*\HED1'K_ -.<@7(+:JN%'22,
MCJJNG@>]<-;)(UJN]2*O$5=PHZ-C'5=73P-?\%99&M1?5E0+D'QCFO:CF*CF
MKR5%RBGT
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MLC'_  7M=ZER!Z
M
M                      -=VB,J'Z)O#:+/G"P+NX]:9^C)L1\>U'L<UR(K
M7)A47M X\V7U]5:Y-'I'44U8^JG= M*D:)) N&)O*NZG?WKR+2:6C=LU=1HG
M_P#(O=M55NZO2?AXX]V,'4UKT!INUWMUVH;9!%6JY7;Z,:F%7FJ<!]@.F_=_
MW9]S*?S_ #O=)T;>>,9Y=P&$UCI#4UYNC:JUZA\P@Z-K5BW47K)S7X"FL:"D
MU%9MKT^GKS>%N%,E Z=.JU,.S'W-3XRDUD21?QD)_P"J7?7 !+8
M
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ME4XN7&,KX(1_Y3/[R;5_6T7^'*!+3%WFHO>F3Z>8OO3/S4/0
M                                                         !S]
MMZT[JV[W:MK8[?'6V"CH9NB9TB-5KE8F7XX*JINY3F:K9_=>U:/T-?+W021V
MVV5DK52/#G;KDJ$WMW\YR(=5/:U[',>B.:Y,*B]J%)U)3NI^@=#&L/Q%;P\
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MZLJ)G#HW.4G8A.P_P\ZF_G:3_!4";
M
M                                           B2+^,A/\ U2[ZX"6R
M)(OXR$_]4N^N "6P                                     *J)S5 1
M)MKN5NL<;:JHO;J.LE>QK(6R)G':N.?) );147DH-=T*E"ZS-GM=P\_II5WF
MR[Z.[$X<#8@ +.[7*FM=NJJRJE8V*FB=,_+D1<-157ZCG./RGH_LF=3R6QB6
MI)%9TB9W\9Y\_P#(#I@%.FF9401S1+ECTRBE0
M            !$GE,_O)M7];1?X<I+9$GE,_O)M7];1?X<H$LQ?>F?FH>CS%
M]Z9^:AZ
M                         !"=A_AYU-_.TG^"I-A"=A_AYU-_.TG^"H$V
M                                      !KVJM86G2[6.O$Z0,=R<[@
M@&P@PFE]3VW4L#YK3+TT3>;TY>)FP /C\HQVZF78X)Z30KGJN_45^@MGN=0K
M)4;[HLU+4X-5$XIGFN\@&_ HT3IWTL;JIC8YU3K-:N43YRL            &
M#U7JJTZ5IX)[W4.@CG<K&*V-S\JB9[$4UK[<.C/QE+_99/V2]<5[1O$,K9L=
M)VM:(E(((^^W#HS\92_V63]D?;AT9^,I?[+)^R6\')[91YG%[H^J001]]N'1
MGXRE_LLG[(^W#HS\92_V63]D>#D]LGF<7NCZI!!'WVX=&?C*7^RR?LC[<.C/
MQE+_ &63]D>#D]LGF<7NCZI!!'WVX=&?C*7^RR?LC[<.C/QE+_99/V1X.3VR
M>9Q>Z/JD$$??;AT9^,I?[+)^R/MPZ,_&4O\ 99/V1X.3VR>9Q>Z/JD$$??;A
MT9^,I?[+)^R?4VPZ,7_\E+_99/V1X.3VR>9Q>Z/JD &@)M>T<O*Y2_V:3]D]
M)M;T>O*XR_V:3V#P<GMD\QB]T?5OH-$3:QI%?_R,O]FD]AZ;M5TD[E<)/[/)
M["/!R>V3S&+W1]6\@TE-J6E%Y7"3^SR>P])M/TLO*OD_L\GL'@Y/;)YC%[H^
MK= ::FTS2Z\JZ3^SO]AZ3:1IE>5=)^H?[!X5_;*?'Q>Z/JW &HIM%TVO*MD_
M4/\ 8>DVA:<7E6O_ %#_ &#PK]I/'Q^Z/JVP&JIK_3R\JQ_ZE_L/2:\T^O*K
M?^I?[!X5^TGCX_='U;0#64US85Y5;_U+_8>DUO8EY5;_ -4_V$>%?L>-C]T-
MD!KJ:SLB\JI_ZIWL/2:PLR\JEWZIWL'AW[)\;'[H; # IJVSKRJ7?JW>P])J
MJTKRJ'?JW>P>'?L>+3W0S@,*FI[6O*=WZMWL/2:DMB\IW?JW>P>';L>+3O#,
M Q*:AMR\IG?H.]AZ2_6]>4SOT%'AV['BT[PR@,<EZH5Y2K^@IZ2[T:\I%_14
MC@MV3XE.Z_!8I=:1>4B_HJ>DN=*O_$7]%1P6['B5[KP%I[I4W\HOZ*CW1IOC
MK^BHX+=D\=>Z[!:^?T_QU_14^^?4_P =?!1PSV..O=<@MO/H/CKX*7#'(]B.
M:N47D1,3"8F)Z/H (2           1)%_&0G_JEWUP$MD21?QD)_ZI=]< $M
M@                                &,U!15-=0.CHZV2CD3CTD:\0,F"
M+M,W"KHF5-QOFH)I8Z:JE@;3955D1JX3J\54S+JS4.I%1*"-;70.YROSTB^K
MBF/ #;+C=**VQ[]=4QP-QGKK@X]\I*BN&H]8NNEICJ:FVJUC&NQU6NW6IPQW
MJBG5%KT9;:1R2U+75E1S62;#LKX&.UGIJZWB-:2WU,5-0Y:Y&(WDJ<>_O CO
M85IS7%BT<VD?)%3-E?TC.EZRL143L5J]Q(RZ6O-6N]<;Y(KEY]$FZGT(AL.G
MH+C!2N;=9FRR[W!6IV>*F4 TNHV?T=732P5M95SQRL5CT=(["HJ87M(D@\F2
MB9J=:N2X(ZU[^^D''>QGEGQ[3H\ >((F00LBC3#&)A$/8
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M[A#43I=(G[C%RN.CD3/TH!.T7WIGYJ'H\Q?>F?FH>@
M                                                  @ZW:@NC_*6
MJ+.^LD6VI2N>D&\N[GK=A.(         A.P_P\ZF_G:3_!4FPA.P_P /.IOY
MVD_P5 FP                                 ISS1T\3I)GM8QO-SEPB
M 5 6$=XMTCD:RMIU<O9TB&$NVL(8IUI;/ ^XU?:V)%5K?6[&$[ -J.5_+(=7
MOJ+1T4J+;\.16MY[W#&>'K[2<V6*^WI4DOE>ZCA5?]VIEPJ>MV51? NF[/\
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M,5[4XX6.1<?0A/Q$GE,_O)M7];1?X<H$LQ?>F?FH>CS%]Z9^:AZ
M                                \S(]8GI$J))A=U5Y9(\CNVIWZLDL
MR5U!OMB67.[V=7A\'\HWJ\+,VTUKJ5,SI"]8T_*W5Q])^?R5VJ?MDSRQI4>[
M25CMYJ)^%O<O5\X'Z%Q[VXF^J*[''!]*%O65U% M0B)*K$WD3O*X
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M:4HZ>AVX:DIZ.%D,+9:3#&\D^XJ!.8
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M"=A_AYU-_.TG^"I-A"=A_AYU-_.TG^"H$V
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M]ZO3+G;\655>]5RI(37(YJ*U45%[4 ^@
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M<D5%^"G8B^('2T7WIGYJ'H\Q?>F?FH>@
M   6-[NM)9;7/<+C*D-+ F7O7LXX OC$ZAO]'8Z9)*IV]*_A'"WB]Z^A.?81
MW;MN&G[Y-)0V+I)KD]>C@C>U41[EX(O''#YS<M.:<5DJW.]N\YN<O67>7+8O
MR6IZ/G QU'9[GJ:=M9J%SZ:B1<LH&JN%3GU^6?G3L(9\IS9?<*ZKAOED8Q:2
M*-&/@:W",PW&4Q^;])T^:3M#IM0W.CGMUHHZ62FE;CI)%PJ+C\Y/3V 8+R=M
M$5VBM%NIKJ[_ &JHF658^.&)A$Q]!*9B=-RW66C=[M4T-/,U<-;$O!4\5,L
M                       !Y>QLC5;(UKFKV*F4.8-7[5-,U%WKK97Z%@JY
M8'[CGM@;O]_/<RAU"<H6/5S=FNKM14NK;$ZKGJ:A9F5/1(_+5:W"?]H&(TIM
M%TEI[4K;M:]/W&DZ'*21,D<YJ(O>F$3O.L=+7ZCU)8Z:Z6V1'TT[<M7*+CBJ
M?Y')$%RJKS=M8ZGH+!T%GEI'1)"L:8>]R/W7(F>?J.@?)XM%99]F=OAN$;HY
M7JYZ,=S:BN4"2P       "$[#_#SJ;^=I/\ !4FPA.P_P\ZF_G:3_!4";
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MELVJ[53JJ0P1MIFJJXCPUN$QGFF$\"2@   $21?QD)_ZI=]<!+9$D7\9"?\
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M]H%EJ-0Z1N=JHYDAFJH7Q(]>29:J=R]YS[!L#U;!0+10ZBW*5<YC1_#BN?B
M2;Y.FH[KJ#1\WNVYTTU),L#:ERJO2HG#.5]7TDK'-FE-B.K+#6T?0:@W*.&9
MLCHFKP5$7C^ =(Q-5L3&N7*HB(J@>C6+GH/3ERO;;M6VNFEKD5%Z1T35551,
M)GAW(;. -:U!H?3U_KH*RZVRGGJ(<;KW1M5>"Y[4/NH-#Z?O\--'=+93S-IF
MHR+,;5W43DB93D;( *%!1T]!214M'$R&"--UC&(B(B>I"*_*9_>3:OZVB_PY
M26R)/*9_>3:OZVB_PY0)9B^],_-0]'F+[TS\U#T
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M]1H.S6X5UTVNZ@J[K0OH*M\U*CH'*F6XB<B<E7L]('0@
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M913)<@   $21?QD)_P"J7?7 2V1)%_&0G_JEWUP 2V
M      6EVKHK;;JBLG5$CA8KN*XRO8GSFN:^VA6'0T$3[Y/(U\JX9'&S><OI
MYH:Y2ZKH=ILU#2:?ED=;&N2:L<]NZJ;J[S6^+>SO V305#))'57RN:OG=Q=T
MC4<G%D65W$15_)5/ VT\Q1MBB9'&U&L8B-:B=B(>@
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MVB_PY26FN1S45JHJ+VH1+Y3/[R;5_6T7^'*!+,7WIGYJ'H\Q?>F?FH>@
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MFK8[.U56W4&)JI.Q[\)NL7O14<O@;NU$:B(U,(@
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M@        !"=A_AYU-_.TG^"I-A"=A_AYU-_.TG^"H$V
M        PVI-26[3L3);K.D,3LKO.Y)@U&\ZYH-16]EMTS4MJ*NN>D;71KG=
M:BY>OZ*.- \L%+M[@6I:!52AWGI4(B)E5X8[.[>-;\CRWUTUPKZZIC1U'"U6
M0N=S:_MQ\R@=/6:WPVJUTM#3I]S@C;&B]^$1,KZ>!>
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M4MDUK:;C710-IJ>9'O5KG9Q^B96M?BC;H]'3Z?2S@M;):.+GZ_1TJ #=Y
M                   Y/JM1W30VVC4UTBL5;6Q5#W,:K('JGPG<<HGI,7LR
MVAWC1M7>IG:8N$WNA4.G3_9W]7*-3'+\DDK7.UJHLFIZZWLTFM6V&16I-T35
MW\*O$U:O\H-EO<UM=I%D#G)E$?$U,H!.&RW6-3K*S35M7;)[<]C]Q(Y6*U5]
M/$W,C[8QK:/7.GIKA#;TH6,DW-Q&HB+Z>!((      (D\IG]Y-J_K:+_  Y2
M6R)/*9_>3:OZVB_PY0)9B^],_-0]'F+[TS\U#T
M'*C457*B(G-5/+'MD;O1N:YO>BY(-\JS5%YT]IBACLTKX(ZB7$LK,93@O#/_
M +R-1\DS6-^NMYN5ONE3+4V^.!9NDDX[CLIV_P#O,#I>ZW"GM=!-65DB,AB:
MKE55YX3.$[UX&M:4H)KG<I-272-63R)T=+"Y/O4:<,\>U5WE]2EGE^M-0*G%
M+%;Y<*B\JB1%]'8BM7M[>1O;&M8Q&L1$:B81$[ /H
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MP1#'Z-B?>;O6ZBJVY8YRPT;5_!C15153\[#5-T
M
M               'QV$:JKRQQ/H<B*U47DO #G+5--L;DU)='W:IQ<'5,BU"
M(SE)O+O?@=^3%^9;#O\ FE_5_P#^!+5SV-:0N-QJJVJMS'3U$CI9'8YN<N57
MQ4MOM&Z*_%C -EV8,L$>DJ=NDG[]J1R]&N,<>WL0VLQ.E[!0Z:M,=MM4214L
M:JK6IZ3+    (DB_C(3_ -4N^N ELB2+^,A/_5+OK@ EL
M    #'7^[066V35E2J[K$PUJ<WN7@B)ZUP@&#US=*A>ALEH=_P#4JQ<*YO\
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MPM@IDIH\<(D1$W? O36L;1L\S-;CR6MWD !+(
M!SYMJVWTVFJ^JL]DI(I;G'O,DF>BX8O+ARXYSVD9:)CTC?Z]-0;1]1)-5.<J
MI2HQ51$3@F>"F_4E#IO5.V34EMOULIT9 YSNE<B9<N\[T>@WC[5FSG_E*7Z0
M-TV?W;3MTLR?8D^)U#"J,Q&S=1%3YO0;,:[HC3]DT];I*?3L4<=,YV\Y&=YL
M0 !>"$+ZGVJ7^SUE37.L"LL--5,I7/DD1'R*Y."M3"IC.>T": 0QJ[:U<J:]
MUM-IZU><TUK@2IKGR/1JHWK91."\<,=W'R[;6[A73VRDTE;/.:J>B2NFZ5Z-
M1C<HBMX(O'+D F@B3RF?WDVK^MHO\.4VS1>NK=J#1E)J"=Z4<$J(CDD7X+L)
MPX>M"/O*&U#:KGI&UP6^NAGF2Z1.W6+QQT<O'Z4 FZ+[TS\U#T>8OO3/S4/0
M                     !8WBTT5YHG4ERIXZB!W-KVHJ&AOM-NCJ_L8TG31
MTL+E22NGA:B;K>>YE,)E<(GJ4V+5=_E@J&6>SMZ2[U"<%7X,+?CN\4[.TO\
M2UBBL=OZ)KNEJ'KO33N^%([TJO'L0#(6VB@MU%#2TK$9%$U&HB>A"Y
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MUF(B';H_AU,^.U[6Z=G<J+E,IR!X@^\Q_FH>S9Y(
M
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M:JZ_:GMULEHF,94S,C5R*G#+D3N])2<E:SM+KQ:++FQSEI'*$\  NY
M          %*>GBGQTT:/QRR4O<ZD_Y=A= "A#1T\+]Z*)K7=Z%<
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M5IJP4&G+<E#:XUCI][>PO?\ ^H94 F(V4M:;3O;J*B*F%Y'A(8T7*,0]@(
M
M                        B2+^,A/_ %2[ZX"6R)(OXR$_]4N^N "6P
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MJOT%:**.%FY#&R-GQ6IA#*F+AMQ.W5?$?,88Q<.VSV #9Y@
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M1,( ;1&SR+7M>=[2  E4
M                                                       !YD>V
M.-SWKAK4RJ]R$3V_;7;*K4,5&^CGCMTTRT\5:YO5<]$553O['=G829?()*FS
M5T$*XDDA>UJ^E44Y)AG\_P!(6+1]-33I?Z>[/DD;N?!;]U7>[^3D\0.PU<U%
MPKD3YR(XG-]\?.N\W'N2[CGTP&>UKHF\7V\K66_4M9;8=Q&]!$YR)E.W@Y#2
MY-B5W?>UNBZQKDK%CZ-945^]N\.&=_.."> $X=+'_*,_20=-%_*,_20AO[45
M_7GKFZ?IR?MFH[1M*:@TC!:%9JVXU"UM8VE7>D>FZBL>[/POR")6K$3UG9TC
MT\7\K'^DAA-5ZNL^E[8ZNNU9''$B[J(F7*JX5<83/<1P_9!>7\]9W+]-_P"V
M:7M+V(ZBDM#9K?>9[Q*Q^5@G5Z\,+Q3BOU=HWGLM-:^Y-VCMH&G]5T4E1;*Z
M/$:X>V3+%3Q1"[U!K&S6.VS5M76Q.CB3*HQ=Y5\#F_9KL*O];35$UYJWVAJK
MNMCC1R.=Z5Y&QZ@V"UM+:*B2BO-36SM3JP/1V'_2OU$3,[+XJ4M>(M+=X-N^
MDYIF1I+,BO7&58[V&J>4#K5UXT4^DTO-,LJRHLCHUW<LP[//YB/:+8]J>6JA
MCEM_11N<B.DW7=5._D27#L#FA14CU)5-1>:8=A?^XICM:W6'5K,&##,<-M_R
M0IY/]QU%9]9MJ(7/\WZ)Z2-J%<K'9:N."+SS@W74^U_53[K64J300P1ROCQ$
MU4RB*J=JD@4NQ.OI6JE/J:=B+W,=^T1Q:MEM9?=:W^SLN;$EM[T<Z9[%7I-]
M7^G\GZ2,G'M_*MH?*<4^/]_]),V=7"GN^G*:Y55JFK:V17(Y\CT5O!RIP15[
MD-[@NEZ<S<H;530M3EOJF/H<:'9-D-_MENCI:?6%73,:JJD<&^UJ97/!$>7W
MVL-2_+BY?I2?MEZQ.T;N;-DQQDMX=8VWY-DN]KU%>;;4T\U=!2](W&['RY_.
M0_2;![M'50R/KH-UKVN7#NQ%-\^U?J3Y;W+]*3]L?:OU)\M[E^E)^V1;'6W5
MIA^(9<$3&/:-_DWZTZ:M=%2P,=$R21C$:KGNSQ1#,QQT\2(D;8FHG<B$4?:O
MU)\M[E^E)^V/M7ZD^6]R_2D_;+Q&SCM>UN<REO?9\9OB-]GQF^)!FK="ZFL6
MFZ^YLUI<9'4T>^C5?)QXHGQSSHS1&IM0:9M]T?K2X1NJ8DD5B/D7&?\ K)53
MKOL^,WQ&^SXS?$B3[5^I/EO<OTI/VQ]J_4GRWN7Z4G[8$M[[/C-\1OL^,WQ(
MD^U?J3Y;W+]*3]L?:OU)\M[E^E)^V!+>^SXS?$;[/C-\2)/M7ZD^6]R_2D_;
M'VK]2?+>Y?I2?M@2WOL^,WQ&^SXS?$YSU-I[5%GUOINQ-UA<'LNJ2JZ19'Y9
MN+&GQ_\ Y/H-Q^U?J3Y;W+]*3]L"6]]GQF^(WV?&;XD2?:OU)\M[E^E)^V/M
M7ZD^6]R_2D_; EO?9\9OB-]GQF^)$GVK]2?+>Y?I2?MC[5^I/EO<OTI/VP);
MWV?&;XC?9\9OB1)]J_4GRWN7Z4G[9\79AJ1$5?LWN7Z4G[8$N;[/C-\1OL^,
MWQ.<]G.GM4:L;>EEUA<(?,*Y](F'O7>1K6+GX?Y1N/VK]2?+>Y?I2?M@2WOL
M^,WQ&^SXS?$B3[5^I/EO<OTI/VQ]J_4GRWN7Z4G[8$M[[/C-\1OL^,WQ(D^U
M?J3Y;W+]*3]L?:OU)\M[E^E)^V!+>^SXS?$;[/C-\2)/M7ZD^6]R_2D_;-7V
MAZ9U/H^Q,ND>L+A4*D[(UC<]Z(J+G\OT ="@M+.]TEIHWR.5SW0L557M7"%V
M                         -0UMM"L>CYX(+K,_IY4WDCC8YRHWCQ7"+W&
MWG/>L)[?1;=;G-J5T#:)]KQ3K4XW<YCX)O<,Y1WT@3Q9KG27BVP5UOE2:FF;
MO,>G:GSD8>4S^\FU?UM%_ARF)V.6[4-7L2H8;/6I0UKI-Z*25%7#,,]*=SBA
MJS9EK[4U!#27+4U+)%%.V=J=&_X2(Y$7X7Y2@3M%]Z9^:AZ(A32FTM$1$U52
MX3\A_P"V6%^L^TFSV>KN$FIZ:1E.S?5J,>F?^X";3XYS6-5SU1K4XJJKA$(*
MT=1[2-3Z8MUZAU+3PQUL22MC<UZJU,\OA'K5FD=ITNG:]C-2Q3*L2IT<;7HY
MW#DB[R@2W:]466Z5KZ2WW&&>I;SC;G/TF95<)DX-V5Z1UQ)KN!MK966^KC5R
MOJ)6O1K4PN<\N9TH[2NTM&JOV54W+XC_ -L#?9=:Z=AE=')=86O:N%14=P7P
M,W2U4%52LJ:>1KX'M1S7\D5%XY.';K8[RVYU*5%)4RS)(N](D:X<N>9--CTI
MM$J=#P-HK]'! ^D:D=.K7H]J;B8;G>Y]G(QQY)M,Q,/5UN@QZ>E;5MONF"DU
MCI^KN:VZGND#ZQ%QT:93Z<8/=YU;8K-4I!<[C%3S*F=UR.7A\R'$M@T+J^76
M+::FH*^FKTD7-4YKT:GIWL&R;3=*7RW:HCI+W6RW:NF9O,>U'*JIPX)E5[T+
M7OPQNY=)IHSWX)EU.W:#IR:-ZT=P2J>W\"*)ZJOT&H:RVPT]A2)KZ58'3? Z
M=%7Y\(OI(OV/Z.U5(VM?:)66M6KA5J879=RY<4+;:_LMUQ7UD%?62,O;U;N?
M<VNZB(O=UN\FEIM&^R-1IZX;S3BZ)MTU1NUE;HKK4WN2HI)4WDBIUW6M]'%,
M]Y<TFK-$V21]/#5P12QKNO7HWJN?7@C'9ILZV@633+8Z*[P6UDV7K2N:]59S
M]*?5VD5W;2FHDN53T]MK)Y-]=Z1L+L.7O*9,EJ](=.@T>+43/'?I^_5VI1U5
M+=*!D\#VRTTS<HO8Y/G(IIM@NDJ?5#;LUK]QCTD; KF[J.3CW>KM-?TOH7:%
M+I^C=2:F\Q@5G5IW->BL3/+X2%X_9MM'<N5UKCAC_B?MFD3,QT<E\>.MIKQ=
M/DEK4>H+=I:RK6UKT92Q;L:(SCCNX)ZC6+)M<TU=[G!0TL[^FF54;O,<B<$5
M>[T$5:NV7:[99I7UFH'7:)'(JTV'\>?'BY?J-$T%HF_W^IIZNS,6*+I%8E2K
M5PQ4;E>7H5.WM,K7O%MHAWZ;2Z7)AM>]N<;_ "^SLA]QI&?"J(T^<MI;];8O
MAU2?,UR_4A#K-F&MFKE=0TKE[U8[]HN(MGFNHO@7^A^>)R_^1MS>=_Q?-AMJ
M&UJ[V?5,M)8YH7TC6HJ*YCD7./2J&S[)]I-9>K'43WB%\]2R=6-Z%JXW=UJ_
MYJ:G>=AVI;S7.JZ^^42SN1$7$*XX?]1E=,[+];Z9I)*:SZCI(H7O614Z)R<<
M(G8[T(8UK?CY]'I9<VCG3Q6L?S<OWNDU=4S2)_LUJJ7+^5A/\S%ZBNU\JK%6
MLCM:,:L?-5X_0XU_[%=IGRJI?T'_ +9\72FTM4PNJ:54_FW_ +9KM/=YU<M:
MSO%7-]OH+HM?3(VGJT7I6X56NX<3KVVV"ZS6ZE2JO$VZL3.JW"8X)Z")M60:
M\TW=[!0RWB@E?=JE*=CVQ.3HUWF-S\+\M/ VQ-*[2^S55+C\Q_[9GCQ<#LUG
MQ*=1MM7;;]6]1:2I\?[3554R^E_^AA]5[+[)J)D#:A)8UBY.:Y,KSYY1>\U[
M[%=IGRJI?T'_ +8^Q7:9\JJ7]!_[9I-8GDXJZC+6>*MFP:(V8VC25S?6T+I7
MR.;N_=%14Y+Z$[S?41$Y<"(OL5VF?*JE_0?^V/L5VF?*JE_0?^V3$16-H5R9
M;Y;<5YWE+I\W4[D\"(_L5VF?*JE_0?\ MGS[%=IGRJIOT'_MDLTO)PY Y\T1
M)M%U6VZK!J*"#W/K'4;MYKUWE:UCL_"_+3P-F^Q7:9\JJ7]!_P"V!+H(B^Q7
M:9\JJ7]!_P"V/L5VF?*JE_0?^V!+H(B^Q7:9\JJ7]!_[8^Q7:9\JJ7]!_P"V
M!+H(B^Q7:9\JJ7]!_P"V8#5<NT#1SK157&_P5=/4U\%*Z-C7(N'O1/C*!/@*
M5(YSZ6%SURYS&JOKP50                     "RO=PCM-FKKA-][I8'SN
M]36JO^1"NF-KE]J+W9Y[U;H8+!>9WP4DK?A(K7N;E4WE^([L)@UC;9+OI.\V
MZ%<2U='+"Q?2YBHGUG.NG;#J"[U&D--5%FJZ1MAJI)JFKD8Y(W-61ZINKCND
M3P4#H.Y:OL=MK'TM;<8H9V?"8Y%RGT$$PZWL]LVRZ@N#ZA)*6:2F5CVM547=
MB5%[.\FF\[/=-7FX25URM=//52?">Z-JJOBACV;)M',D<]MGIT5?_C9[ M68
MB><;L9]N?3?\L[]!WL/GVZ--)SF<G_0[V&9^U;I+\44_ZMOL(WV]:%T_9=&T
MU3;;?'!,ZNCC5S&M15:K'KC@GH0KM/=?CI[?NW#[=&F_Y9WZ#O88S4&WC3]M
MMTDU/O33XPR/=5,K\^#9J;9?I)U/&Y;33Y5J+][;[#!ZZV(:<O\ 89*2W014
M%7G>CF;&G!<+P7&/03M/<XZ>W[M=T9Y0UMN3I(;S3^;3(JJQ6(JHY/F5?29Z
M\[:[+%:JI]O?OU;8U6)KF.PKNPUW9AY/%#I^JFJM1SPW%ZY;'&D?5:G?QSZ3
M?;ILETO5VZH@I[?#3S2,5K)4C;EB]_(B8G;JMCOCBT<5>2&8]O&H^D;OPT:,
MWDSU'<L_G&Y:TVY44&E:EUE<BW)\:MC5S78:Y47CV<EP6C/)W8DC5=?$<U%R
MJ>;<T_2)#39-I!:=(I+13OZNZKEC9GZC/'%^?$[]?ETL[>!$?>'-VS7;1?[9
MJJ.74-R=66V5')+&Y%7=X<%3'I1"AM UM4WC5-;6VJLJ64LCE5C4<K>&5[#H
MFV;$M%4%1),VULE<_LD:UR)\V#1Z?1%@?MRJ[-YA&EN;01RI"C4W4<J297&,
M=B$Y*3:-HEAHM733VFUJM=V=[0;U16#S-*J!O755DG55=]9&VU36-[K]0S0R
MWVI\V9P8R-51O->/!#K9-E6D$3]R*=?7&WV%*;9'HR96J^S4V4[HV?LEJUF(
MVW8Y\U,EYM6O5&>RC:&YF@*6&IIZ=]2UKV+/O(USDWW8SE<\L$.26:=T[G;\
M7%V?AI[3K/[5&CD1,66EX?\ Q,]AZ^U7I'\3T_ZMOL(OBB_5OI?B%]+$Q2L<
M_P _\M7TYJZ2GL5OIG7FV0=% QBHYKU5,-1.PR#M24TWW[5M(SOZ-KT^M#+?
M:IT=^)J7]4SV#[5&COQ+2_JF>PMPN:<]IG?:/HU34E-I+4= VFNVJIY4:]'X
M1W5RB*GQ/28W3&F=GM@O$-PAO?3OBSADBY:N4QV,0W"\[+=(0VJJD99J9'-C
M545(F>PTS89L^TU>= 4M7<;9!-4.>Y%>]C55?%!P5WWV6C69HKP1;DDV+6^E
M(4Q%<:5GYK53_(J?9]IG\;0>#O88[[5&COQ+2_JF>P?:HT=^):7]4SV%G,R"
MZ\TPJ\;I3K\R^P)KW3"<KK3IZD7V&/\ M4:._$M+^J9[!]JC1WXEI?U3/8!D
M?L^TS^-H/!WL'V?:9_&T'@[V&.^U1H[\2TOZIGL'VJ-'?B6E_5,]@&1^S[3/
MXV@^GV#[/M-?C:#P=["(]L&@M.VJ\:,BH;;#$RJN+8YD8QJ;[>DB3"X3N522
MF[*='*U%]Q:7E_),]@&2^S[3/XV@\'>P?9]IG\;0>#O88[[5&COQ+2_JF>P?
M:HT=^):7]4SV 9'[/M,_C:#P=[!]GVF?QM!X.]ACOM4:._$M+^J9[!]JC1WX
MEI?U3/8!D?L^TS^-H/!WL'V?::_&T'@[V&.^U1H[\2TOZIGL'VJ-'?B6E_5,
M]@&1^S[3/XV@^GV#[/M,_C:#P=["(=":#T[6[5=96^IML+Z2E5.AC<QJHSX'
M),>E23?M4:._$M+^J9[ ,C]GVF?QM!X.]@^S[3/XV@\'>PQWVJ-'?B6E_5,]
M@^U1H[\2TOZIGL R/V?:9_&T'@[V#[/M,_C:#P=[#'?:HT=^):7]4SV#[5&C
MOQ+2_JF>P#(_9]IG\;0>#O8/L^TS^-H/!WL,=]JC1WXEI?U3/8:KM1V;Z6MN
M@KU5T=IIXZB*F>YCVQM145&JJ+R EZDJ8JNFCJ*9Z20R)O-<G)4*IJ^R]$;L
M^L*)R\U:;0
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M:OJ*HOMGJKO2PML5YGE@I]U<*Q6;Z<\<<JST<R?0
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M2NCMJEMT_2VZ2GMKYWP/GE14Z56KA5;EO+YUY@3.>%BC7G&SP/8 (B(F$3"
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M(>R#="[3M15NI+*E_I866F^)+YJK%PK%8KD1%X<<I&[N)R
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MFR]OIVQI._<2-%<W=QGT9.MZ>3I86/QC>3. /8
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MG-<JY=P<G#A^4;T         -(LNB9;?M)NVIW5$;HZV)(TB15RWCZO\S=P
M      :+3:'DBVG5&J75$:Q2T_0]%E=[\+T?E=YO0 A&JV)U51?IF.NS/L9E
MK%K747'?WU1>W=SC*JOPB;D1$3"<$
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MM-=G.CJZB-T4SF\\JVGRO'TY*.U?2%MT'M TI)IQ)('3-;TF53BJ[Z*O!$[
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MA5 Z% ;R0
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MTC%;O)S3)K6SK1%%HJV3TU(]TT]1(LLT[\;SW+W_ $^(&V
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M6G15H; QKI57DDB*]4^E$.@"UI+;1T<TTU+3112S+F1[&X5Z^D"Z
M
M
M
M                                         6Z3O\Z=%T$FZB)B3ANJ
M7"                                                  "QJ:Z6&1
M6LHJB5$_"8B8^LO@!B_=.H_%E7X-]I>TLSYHT<^&2)?BOQDK@
+           __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g109079g01g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g01g01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[16*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %6T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M1J^R<J-^MUJO];2T4$D:1PQN39:BQ,5<;NM5.(3E<U[A?^]%Q[2? ]7Y0_\
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M)\#A,# PIZ+N[\KNO?:FX]I/@/*[KWVIN/:3X'"8&!A3T7=WY7=>^U-Q[2?
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MG;W2WZWTTG@ZE8(9(70IE$15;(C55,N:FY%X_4IP6\Z4U4U>D5!0%L*@
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M7<K-!26WE"N]);6,92L='L-:B(B9C:JXQNXJIR*IA<&Z9RBZ  *
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M<H  H                     !EH_\ 68_Z1B,M'_K4?VF:O0D/E\_?V_\
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M.*>*[Q+$^1[E18\L<W*(G'Z0USC:._\ ]1R/!2G6.(/0@ "@
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MD='#>!N  % 'YRI0(!7K"+]6_P"T;AN (O$#< '["G65* 53]("#< &0!R*
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MQZ-]8W_WB+\(?-BT9ZQO_O$7X1.@+MK[+(+^;%HSUC?_ 'B+\(?-BT9ZQO\
M[Q%^$3H!MK[+(,^;'HSUC?\ WB+\(?-CT9ZQO_O$7X1.8&VOL09\V/1GK&_^
M\1?A#YL>C/6-_P#>(OPB<P-M?99!GS8]&>L;_P"\1?A#YL>C/6-_]XB_")S
MVU]ED&?-CT;ZQO\ [Q%^$/FQZ-]8W_WB+\(G,#;7V609\V/1GK&_^\1?A#YL
M>C?6-_\ >(OPB<P-M?99!GS8]&>L;_[Q%^$4^;'HSUC?_>(OPB= 397V607\
MV/1GK&_^\1?A#YL>C/6-_P#>(OPB= 7;7V609\V/1GK&_P#O$7X0^;'HSUC?
M_>(OPB<P-M?8@SYL>C/6-_\ >(OPA\V/1GK&_P#O$7X1.8&VOL09\V/1GK&_
M^\1?A#YL>C/6-_\ >(OPB<P-M?8@SYL>C/6-_P#>(OPA\V/1GK&_^\1?A$Y@
M;:^Q!GS8]&>L;_[Q%^$/FQZ,]8W_ -XB_")S VU]B#/FQZ,]8W_WB+\(?-CT
M9ZQO_O$7X1.8&VOL09\V/1GK&_\ O$7X0^;'HSUC?_>(OPB<P-M?8@SYL>C/
M6-_]XB_"'S8]&>L;_P"\1?A$Y@;:^Q!GS8]&>L;_ .\1?A#YL>C/6-_]XB_"
M)S VU]B#/FQZ,]8W_P!XB_"+HOR9M'1R->EPOV47.^HB_")Q!-M?99$VKN0C
M3.J;LZX7"LN\<RL9'B":-K<,8UB<8UZ&H:3YL>C?6-_]XB_")T CR51^ED%_
M-CT9ZQO_ +Q%^$5^;'HWUC?_ 'B+\(G,#97V609\V/1OK&_^\1?A#YL>C?6-
M_P#>(OPB<P-E?99!GS8]&^L;_P"\1?A#YL>C/6-_]XB_")S!=M?99!GS8]&>
ML;_[Q%^$/FQZ,]8W_P!XB_")S VU]ED&?-CT9ZQO_O$7X0^;'HSUC?\ WB+\
M(G,#;7V609\V/1GK&_\ O$7X0^;'HSUC?_>(OPB<P-M?99!GS8]&>L;_ .\1
M?A#YL>C/6-_]XB_")S VU]ED&?-CT;ZQO_O$7X13YL>C/6-_]XB_")T!-M?9
M9!?S8M&>L;_[Q%^$/FQZ,]8W_P!XB_")T!=M?99!GS8]&>L;_P"\1?A#YL>C
M/6-_]XB_")S VU]B#/FQZ,]8W_WB+\(?-CT9ZQO_ +Q%^$3F!MK[$&?-CT9Z
MQO\ [Q%^$/FQZ,]8W_WB+\(G,#;7V(,^;'HSUC?_ 'B+\(?-CT9ZQO\ [Q%^
M$3F!MK[$&?-CT9ZQO_O$7X0^;'HSUC?_ 'B+\(G,#;7V(,^;'HSUC?\ WB+\
M(?-CT9ZQO_O$7X1.8&VOL09\V/1GK&_^\1?A#YL>C/6-_P#>(OPB<P-M?8@S
MYL>C/6-_]XB_"'S8]&>L;_[Q%^$3F!MK[$&?-CT9ZQO_ +Q%^$/FQZ,]8W_W
MB+\(G,#;7V(,^;'HSUC?_>(OPA\V/1GK&_\ O$7X1.8&VOL09\V/1GK&_P#O
M$7X0^;'HSUC?_>(OPB<P-M?8@SYL>C/6-_\ >(OPA\V/1GK&_P#O$7X1.8&V
MOL09\V/1GK&_^\1?A#YL>C/6-_\ >(OPB<P-M?8@SYL>C/6-_P#>(OPA\V/1
MGK&_^\1?A$Y@;:^Q!GS8]&>L;_[Q%^$/FQZ,]8W_ -XB_")S VU]ED5TG(;I
MNFTC5Z=9679:*ID21[UFC\(BY:NY?!X_@IT=9H/FQZ-]8W_WB+\(G,$CR51^
MED%_-CT9ZQO_ +Q%^$5^;'HSUC?_ 'B+\(G,%VU]ED&?-CT9ZQO_ +Q%^$/F
MQZ-]8W_WB+\(G,#;7V609\V/1OK&_P#O$7X0^;'HSUC?_>(OPB<P-M?8@SYL
M>C/6-_\ >(OPA\V/1GK&_P#O$7X1.8&VOLL@SYL>C/6-_P#>(OPA\V/1GK&_
M^\1?A$Y@;:^RR#/FQZ-]8W_WB+\(I\V/1GK&_P#O$7X1.@&VOL09\V/1OK&_
M^\1?A%/FQZ,]8W_WB+\(G0$V5=ED&?-CT9ZQO_O$7X0^;'HSUC?_ 'B+\(G,
M%VU]B#/FQZ,]8W_WB+\(?-CT9ZQO_O$7X1.8&VOLL@SYL>C/6-_]XB_"'S8]
M&>L;_P"\1?A$Y@;:^Q!GS8]&>L;_ .\1?A#YL>C/6-_]XB_")S VU]B#/FQZ
M,]8W_P!XB_"'S8]&>L;_ .\1?A$Y@;:^Q!GS8]&>L;_[Q%^$/FQZ,]8W_P!X
MB_")S VU]B#$_)CT;C_Q&_\ O$7X1N=*\@VF=,U\U705MX?)+3RTSFS31JW9
MD8K'+NC3?ARX):!)\E4_I9!TWY,^CI9I)%N%^17N5VZ>+<JK_5%GS8]&>L;_
M .\1?A$Z ;*NRR"_FQZ,]8W_ -XB_"'S8M&>L;_[Q%^$3H"[:^RR"_FQZ,]8
MW_WB+\(K\V/1GK&_^\1?A$Y@;:^RR#/FQZ,]8W_WB+\(?-CT9ZQO_O$7X1.8
M&VOLL@SYL>C/6-_]XB_"'S8]&^L;_P"\1?A$Y@;:^RR#/FQZ-]8W_P!XB_"'
MS8]&^L;_ .\1?A$Y@FROLL@SYL>C?6-_]XB_"'S8]&>L;_[Q%^$3F!LK[+(,
M^;'HSUC?_>(OPA\V/1GK&_\ O$7X1.8+MK[+(,^;'HSUC?\ WB+\(?-CT9ZQ
MO_O$7X1.8&VOLL@OYL>C/6-_]XB_"'S8]&>L;_[Q%^$3H!MK[+(,^;'HSUC?
M_>(OPA\V/1GK&_\ O$7X1.8&VOL09\V/1GK&_P#O$7X0^;'HSUC?_>(OPB<P
M-M?8@SYL>C/6-_\ >(OPA\V/1GK&_P#O$7X1.8&VOL07\V/1OK&_^\1?A!/R
M8]&^L;_[Q%^$3H";:^Q$^C^0C3.E;NEQM]9=Y)T9L(D\T;FHFTB]$:;\M3I-
M77_DVZ0K:ZHJI;A?4DGD=*Y&SQ817*JKC]R^LFP#95[N(,^;'HWUC?\ WB+\
M(?-CT;ZQO_O$7X1.8&VOLL@SYL>C/6-_]XB_"'S8]&>L;_[Q%^$3F!MK[+(,
M^;'HSUC?_>(OPA\V/1OK&_\ O$7X1.8+MK[+(,^;'HWUC?\ WB+\(?-CT9ZQ
MO_O$7X1.8&VOLL@SYL>C/6-_]XB_"'S8]&>L;_[Q%^$3F!MK[+(,^;'HSUC?
M_>(OPA\V/1GK&_\ O$7X1.8&VOLL@SYL>C/6-_\ >(OPA\V/1GK&_P#O$7X1
M.8&VOLL@SYL>C/6-_P#>(OPA\V/1GK&_^\1?A$Y@;:^Q!GS8]&>L;_[Q%^$/
MFQZ,]8W_ -XB_")S VU]B#/FQZ,]8W_WB+\(?-CT9ZQO_O$7X1.8&VOL09\V
M/1GK&_\ O$7X0^;'HSUC?_>(OPB<P-M?8@SYL>C/6-_]XB_"'S8]&>L;_P"\
M1?A$Y@;:^Q!GS8]&>L;_ .\1?A#YL>C/6-_]XB_")S VU]B"_FQZ-]8W_P!X
MB_"*I^3)HU'(OC"_+_\ [$7X1.8)LJ[+(KUSR':<UE?9;M=*R[1U,B(BMIYH
MVL3"8W(L:K^TY_YL>C?6-_\ >(OPB= (\E4<7+(+^;%HSUC?_>(OPA\V+1GK
M&_\ O$7X1.@+MK[+(+^;%HSUC?\ WB+\(K\V/1GK&_\ O$7X1.8&VOLL@SYL
M>C/6-_\ >(OPA\V/1GK&_P#O$7X1.8&VOLL@SYL>C?6-_P#>(OPA\V/1GK&_
M^\1?A$Y@;:^Q!GS8]&>L;_[Q%^$/FQZ,]8W_ -XB_")S VU]ED%_-CT9ZQO_
M +Q%^$5^;'HSUC?_ 'B+\(G,#;7V(,^;'HSUC?\ WB+\(?-CT9ZQO_O$7X1.
M8&VOL09\V/1GK&_^\1?A#YL>C/6-_P#>(OPB<P-M?8@SYL>C/6-_]XB_"'S8
M]&>L;_[Q%^$3F!MK[$&?-CT9ZQO_ +Q%^$/FQZ,]8W_WB+\(G,#;7V(,^;'H
MSUC?_>(OPA\V/1GK&_\ O$7X1.8&VOL09\V/1GK&_P#O$7X0^;'HSUC?_>(O
MPB<P-M?8@SYL>C/6-_\ >(OPA\V/1GK&_P#O$7X1.8&VOL0A3?DTZ/IZB*:.
MX7Y71O1Z(ZHBQE%SZ(W6L>0S36JZRBJ;C67>-])21T4:031M16,5<*N8UW^<
MOP)5!-E78@OYL>C?6-_]XB_"*_-CT9ZQO_O$7X1.8&VOLL@OYL6C/6-_]XB_
M"'S8]&>L;_[Q%^$3H"[:^RR#/FQZ,]8W_P!XB_"'S8]&^L;_ .\1?A$Y@;:^
MRR#/FQZ,]8W_ -XB_"'S8]&>L;_[Q%^$3F!MK[$&?-CT;ZQO_O$7X13YL>C/
M6-_]XB_")T VU]ED%_-CT9ZQO_O$7X0^;'HSUC?_ 'B+\(G0#;7V607\V/1G
MK&_^\1?A#YL>C/6-_P#>(OPB= -M?99!?S8]&>L;_P"\1?A%?FQZ,]8W_P!X
MB_")S VU]ED&?-CT9ZQO_O$7X0^;'HSUC?\ WB+\(G,#;7V(,^;'HSUC?_>(
MOPA\V/1GK&_^\1?A$Y@;:^Q!GS8]&>L;_P"\1?A#YL>C/6-_]XB_")S VU]B
M#/FQZ,]8W_WB+\(?-CT9ZQO_ +Q%^$3F!MK[$&?-CT9ZQO\ [Q%^$4^;'HSU
MC?\ WB+\(G0#;7V607\V/1GK&_\ O$7X0^;'HWUC?_>(OPB= 397V.4T7H6W
M:1T]3V:V3UDE+ Y[FNG>USUVG*Y<JC43BO4#JP8GGD       9    !D  ,C
M*=8    ,IUC(  93K
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M4ZT4J9:
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MWE] TSU?!&]Z8<YJ*J=6XS-X;CR6NLBN%!!5P+F.5J.:IZV[CR>I=E0
M                  !T@  "F0*H"B+OP5                  IE!E *@I
MM#:W<% J"BK]2C* 5!1%R5                                 #H Z
M,-9_JLW]%?[C\]F<#]":S_59OZ*_W'Y[,X'N_@^Y>?S^EZ<%,C3&G!3(T^D\
M<LC2].)8TO3B:ASED:9$,;3(A6%[2]I8TO:6'.5[>)E;Q,3>)E;Q-,2O0O0L
M0O0K,LB%Z%B%Z%ARED89&&-AD8:87M,C3&TR-#$KT+T+$+T*Q+*SI+V\"QG2
M7MX%AB5[2]O26-+V])J'.61.!D3@8TX&1.!88E>TO;P+&E[>!J'.5[3(W@8V
MF1O KFR-+V\"QI>W@5A<AD88T,C#7XYS[94XEZ%B<2]"*J "H
M                                          !5,MPYBX<BHJ%.@(I+
M77[/^DC:%U8KG1T->]J83S7KT[O\B16*CF[2+N7@I\Z)E,+THNXD;1&KG.1M
M%<'KE$PQV$1%QCCOX\3X?\W^#;_DH?IOZ7_5;_\ #YO:1D7?OXEW$L3"_:O
MN1>A>)\=^D7-*E&KQ*B
M                                        Z2U>G]I<4P@(03^52BK9
M+1C/TI=V/KC/36:)I]2<B=F\'38N$-NA?$YB+E7;+<YQQW9)CK[=17!B-KJ2
MGJ6MX)-&UZ)]F4^I#+#3Q0P,AAC9'"UNRUC41&HG4B=1UCRS%,4Q^2Q-$3-Y
M0I^39JA]=9JBPUDBK64:ND8UW%(O,3?_ /,Y2,M ZHH-'\I]?<KOSA*?P+XO
MW*/:7*[*IT_4?5]%9K;0S.FHK?24\SDV7/AA:QRIU*J)PW(8)=-621ZNDL]N
M>Y>+G4S%5?V&H\T953;VFOU#G=$\I5BUE5R4MGYUX2-$SX6+9Z%7K7J4B[\J
M%F+GIYRHN%>K<XXKE">J"S6RWO5]!;Z2F>O%T,+6*OZ$+Z^UT%P5BU]%35*Q
MKEGAHFOV5^K*;C-%<4591#4Q,Q9K=%L6/2MLW8Q U,<#YYY0[O36'ET2Y5VV
ME/!/%([8;M+A$C5=WYCZACB9&Q&1M:UB)A&HF$1/L/!66&TULRRUELH:B5>+
MY8&/<OYU0>/R8535,>R:;Q9\\\JO*%1Z_LS+-I:WUE3*^5KG.6!=IJHNY-V>
M)*>B8TT#R;027Q)FMB:R21J-R]JN1J;./J4[.EL-HI)-NEM=#"_^-'3L:OZ4
M0]E32P54+HJF)DT3N+)&HYJ_:BBKR1,11$<)33,3>9?(/+EK6U:UOE%5V59W
M10TS8GI*S97*.>O6O\9#Z/Y/]?6;6,4D5FYQFG:FWX:/93HX;USQ-XFE; G"
MR6SW6/X'KH+3;[=M>+Z&EI=KCX&)K,_H05^2*J8IMZ*:9B;H(Y;^4JQ7:Q5E
M@I%JO&$4R(Y'Q8;N1R+OS]:%WY/_ "@66W:=HM-SK5>,732/39BRS"KGCDFR
M;35DGE=)-9[=)(Y<JYU,Q57[5P74VG;-2RI+3VF@BD;P>RG8U4_.B%V1AA8Q
MG*[Y\Y4*"XZ2Y4Z;5+:226@R]WA&L5S4<_PB85<8X.0\7*AJEG*<^@MNDZ"J
MG<V1KU>Z%45%1'IT9W><A].5E#2UL?@ZRFAJ(^.Q*Q'I^A3ST5DM=#)MT5MH
MZ=_\:*!K%_8AJ//>(O',)ARP:3MSK5IR@HG9VHH\*B]"YS_U-NQ<Y& UJ)G!
MYYF9F[HJ!O"                         "Q5WKU_47E,$&IK;[245[MMK
MG\)SFO<]L.RW+<M8YZY7HW-4VY'VK/\ :;H?^OJ/_32GFUKJK4-#KRAL=BAA
ME954:2>>B?N;MMR;>5XIA$3&[B=,+RS$I*!$]_U+K'25XMU)4<WU"EP_<XD9
M$VC\'*JX:U5R_*?7N0]UTNNK=,OM]TO%?2UMLGFCAJ*1E*V)U.LCFM:GA$<[
M;V5=Q1J9V>C(PDRA)0([Y3-6W>Q5FF&6"&*J6Y2RL?$]4;MHC$5,.7AC.?KQ
M@U6J=0ZRT93TERN,U-=Z:5Z-DHXZ=L#HMRK]-%=M<.KI$>.9,HA+((POEXUC
M8K-\H[C4TB4L2[=1:4@:KHV)G/[NCESG"+N;_"^HW6J=3U='%IR:WNB;'<*J
MGCD141WFR/:BHGYE7>-<F4.U!SVN;M4V?2M;7T3FI41*S95S=I-[VHN[[%.6
MU?K*[VG0=JN]$V*6MJ&-<]BHB(]51.'5Q%/CFJUB:HA)0(RO%;KJUV-^H*FJ
MHT; U9I[.E.Q58QJ*JM2=';\XXHWIX;C>:EUDVW:=I:VABYQ55KFP4\:93]T
M=E$SN7=M=8PG\6[L01Q<Y]:V6U>-Y;I27%K$:^6WI1-@5K5^E^Z[:_13*_1W
MXZ,G<66XLNMHHKA#NBJX&3L3J1S45/[S,Q8B;M5JO5M%IN:EBJZ>MJ9JI^Q%
M%20K*YR[]V$^Q3P46O[;-<8**MHKK:WSJC(G7&E6G;(Y51$:U7+O<N>!I.4V
MIAI-8Z0GJIHX8FUK5<^1Z-:FY_%5X&/E+N5KOE+;+=:*B"X7.2LC6):5R3+%
MQ3;5S<[*(JMWJJ&XICA+NDNVM8;95312634$[8V[2S4] Z2+&,Y1W U]NY3*
M"X1++06/4E1'M;"OCMKW)E.*913IZR-T6G)V2;WMI'-=T[T8<IR*[]*5&=W_
M &V;_H2T6N-I>]<4-HK:6CEH+K45E1"DS8::E61[6JJIO1%RF]JE]FUI07&X
M-H9J:X6RI>W:C9<:=:=9-Z)AJ.7>N_H.2UK=J:R\J]LJJQM2^+Q>UNS3T[YG
M?Z23^"U%45]PAUUJVQI8F/:VTU3*JJDF8L,J(U?]'L/1'*U=I%SO3<FXN/%T
MNE9%7)<6-7?P+SG'+8                                .@#H PUG^J
MS?T5_N/SV9P/T)K/]5F_HK_<?GLS@>[^#[EY_/Z7IP4R-,:<%,C3Z3QRR-+T
MXEC2].)J'.61ID0QM,B%87M+VEC2]I8<Y7MXF5O$Q-XF5O$TQ*]"]"Q"]"LR
MR(7H6(7H6'*61AD88V&1AIA>TR-,;3(T,2O0O0L0O0K$LK.DO;P+&=)>W@6&
M)7M+V])8TO;TFH<Y9$X&1.!C3@9$X%AB5[2]O L:7MX&H<Y7M,C>!C:9&\"N
M;(TO;P+&E[>!6%R&1AC0R,-?CG/ME3B7H6)Q+T(JH *@
M                                    "  P1;S:PA<GTD<BJBINRA:5
M7>F!9:;>DC:&U;M8HK@]J/541KW*B9)#C<V2-'-<BM7@J'SLUSFN1S%5')P5
M%P2/H;5R/:VAN,C6[*88]?X2Y/A_SOX5O^3QOT_]*_JF7_#YI_ZE([/J*F.)
MR/8US%14<B*B]9?O/COT<*@MRN CE50+@
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MG+<HW:5V4XHK$QA>'$ZTS,0L  (H                             #H
MZ ,-9_JLW]%?[C\]F<#]":S_ %6;^BO]Q^>S.![OX/N7G\_I>G!3(TQIP4R-
M/I/'+(TO3B6-+TXFH<Y9&F1#&TR(5A>TO:6-+VEASE>WB96\3$WB96\33$KT
M+T+$+T*S+(A>A8A>A8<I9&&1AC89&&F%[3(TQM,C0Q*]"]"Q"]"L2RLZ2]O
ML9TE[>!88E>TO;TEC2]O2:ASED3@9$X&-.!D3@6&)7M+V\"QI>W@:ASE>TR-
MX&-ID;P*YLC2]O L:7MX%87(9&&-#(PU^.<^V5.)>A8G$O0BJ@ J
M                                                 R G$)\"K55K
MT5BJCF[T5-V\I@(9F(F+-?XSS*2-":M5^S15[E5Z-1L;E<N_!(B.VT\U>/2B
MGSHURL7+?I<47J)'T-JS::RWUJM1=^S(O3N_R4^)_/\ X-O^3Q_[?I_Z5_5<
MK>'S^_R4B(BYWKDN3CP+(L.:BY+TWJ?'?H^%P
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MU#$;4U"O<JS*F]5V554;E<KNZSIDW(4:G7T%QRGEJ  !0
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MAC0R,-?CG/ME3B7H6)Q+T(JH *@
M                       $X@$#"J."!%5,HG$(W*]*YW(B)Q4DRM-.7"N$
MW)C.>")TD@Z$THY\D=QKV]:-8N47A_F-"Z2\)LUU>BHN$5C%3<21%&D;=EN$
MZMV#XO\ /_G>_'0_3?TK^F3QY?-_J%T;-AJ(G O:A:WZN!<A\:'Z14
M
M           *8*]((+=D(U"X%++51"BM3>57B<Y>=;Z<LMR2@NEVIZ:L543P
M3\YRN,='UH(BXZ/<A1./$Y^^ZST_84IEO%T@I$J6J^+;SY[=V],)]:?I/1;M
M36>XU<-+0W"*>>:!E3&QN?.C<BJUW#@J(OZ!:4NW"8^TJB)LX7.[K/)!<:6>
MLFI89VOJ(DR^-.*;\'K3@J;]Q%50K@M:H52@J>;UEJ<5Z51-R%R;T4\B5]*E
MT;;EE;SU85G2+IV$<C5=^E40<H]FSNWC"8*(79(JQ$RO_4JB)_\ ITG+7'E
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MV32L,-9#S:23#^;],6Y$V5_1T&:HXY]K#M4X;@&\ 8:
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M%5 !4
M "J+OQP*!43&_A_UZB$*HGVKOW8Z20M":2\(C*ZXLRQR98S<N%1>/3U%-":4
M5SFU]>B+O16Q*F[C_D22R-L;4:QJ-1$W(G0?$_G?SK?\?C_]OT_]+_I=K>;R
MQ_U"L+&QL1C?HM1$1"[CQX%&+E7(G07+P/C>_;])'4&['U%J*W/$.^@43S53
M._(.?4,@
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MR;.$QC&%=T]1UJIG.=Y397KW]8B448U&M1$3")P*JQK\*]J+CAE.!54*H+K
M4V&[>WLMV\8VL;\%0!1C&L3#&HU.I$P55,\0 ,/-*;.>;PYZ]A#,
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M4XA2J;]R(JJJ[D1,J2]EBF*O7L3>J83"+N3ZSO=%Z1>Y4K;@QV,98Q47ZO\
M,OT-I)72LKK@U%9CS8]Z='^9)4<;8V(UB8:B80^+_._GQ_\ 'XWZ7^E_TJ9M
MYO/_ *@C:C$PB<$,B;RB#[#XL?7Z7_I<@*-STE2@
M
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M./9WL15:J[_M:=$C<<!@F4EE0-XWA0#>-X #>-X #>-X #>-X #>-X #>-X
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MZ[U1,E^-XQOSTBY*D:83CDN+6MPJJG27;P &\;P &\;P &\;P &\;P &\;P
M&\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P
M&\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P &\;P
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M%SF#TL?:0<Y@]+'VD!=E!BYS!Z6/M(.<P>EC[2 NR@Q<Y@]+'VD'.8/2Q]I
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M+G,'I8^T@YS!Z6/M("[*#%SF#TL?:0<Y@]+'VD!=E!BYS!Z6/M(.<P>EC[2
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MK0"H&4ZQE.L !E.M!E.L !E.L93K  93K090 !E.L93K  93K093K0 !E
M
M                                 ,@
M
M
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MT\C98(Y&_1>U')^<RMX*8:6)(:>.).#&(W]!F;TGE_>'6%0
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M\7?Q^3)Z04R5.<.H
M
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MX>D%$^TJ<G4 0
M
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M3.%P+27;0&NEN]OIWNBJ+A21R-W*U\S6JGZ5/8DL:Q+)X1G@\9V\[L?:165
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M$1$3"(B=!><KW]M0MD_T;CAUXJ=Q)_HW'#KQ4]'\?V\_G]"%2B%3TO.  (
M                                           !0J *?8>BCJGTLB.8
MN[I0P%-Q)B)]K$S'IV-#5,J8T<U4STIG@>E.)QU%5/I)$<Q<MZ4.GHZIE1$C
MF.1>L\?D\<P]?C\D519ZP4:5.;J
M
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MA<<MFC=,U'-@5%546/*91?HY^M$)':F_H+(6)%#&S.YK4:GYB]#G,W:B+*@
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MM9T\5$WN]T:JK<NW+U%P3@#QO8
M
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M\5/1_']O/Y_0A4HA4]+S@ "
M         4*E 'V*9((732;$:+E1!$Z:1&,3B=1;*%E+$B\7*F57!S\E>,.G
MCHRE2V4+*:--WG])[T0(A4\4S-4O9$6@ 0!0
M
M                                                 *+C>O2"U5Z>
ML6N.;Y1ZI:31]<YKME959!^L>UB_\QRG(PWQ.VX:=SE:=ZU";7%$<J)CJQYI
ML^4R3G-PT]:$5?\ ML[G_JE8_P#Z'BO57'ISE)97SN2.FN%,VG55W)ENTXZT
M\T8L?MW2ZXOK[1011434?<JZ1*:E8[./".1RMSPW>;UH<AR-VB*WU>H*ITKI
MW+*S$[][E3P:;65X[E3'YCW:91+FZKUM<HWL<L*QTD4J86.!%1R9^O:1W!<;
MSGZ1)K?R--5ZJVHKY)H)5Z<.?*U/V8+3'XE_UTU9RA2RU-6FG;!57NCILI+4
MP3,C:UR9VDP_"[L+^@W^F=44E^L,MSIFN:L"NCGA<N5BE:U%<Q5Z53.,IN,M
MDBIK/I:F5C6QP04K9'X^IF57]A'.FZE]+I'6MY152*LNDZPXZ8Y)&HUR?:CS
M.-+5VXH.5!;NBMT[8*JZU+%_=88IF,6-O\95=A%WX3=UG5Z1U-3:CL,=RA8L
M"*BK)$Y<K'A53>O3PR:SD[M-+IG0]'&R+P;DB22=W\)[L85R_7N0CZWI-1\C
M,4NULRWASJ>14XHB^$;_ -"XTS>"[LI^46>IFJGZ:T]57NWP;G5<,[(VY3Z2
M;+\+N5%3\QTNEM2TFHK(EQILL8U7,F8N]8GM3SFKUX7=N,UL93VK3T.RB,IX
M($>['U-RJ_WD,2U4]%R:ZEKX<HMPNZK$J>C=4-POYT>(IBKB"[NW\H=74NJ)
M=/Z:K+Q;XGK&M7%41QM5R=&R["\%:OYSS\H-VAOFC+0M(YW-[Q5-IDPO%'-?
MN7LG=V:ABM=JI:&#"14T38VHG#")@X[6"<^UWIR@:U?^SN;7[NC9=L__ '$I
MM?C\+MK>=1TNE[1;8)&+/5S,9!34S%V73/1$1&HO!-^$W]9KZ#7E2RZ4M)J3
M3U58VU2N;!)/,R5'N1-Z89GK3CUGBTLOC/E6U952INMR4\$.>*))$U7?M:7<
MIV*^[:?M-,J.JY9W2HQ.*-9LN5?T#&/1$MSK#6UMTI74$5U58X:IZM?-OQ%Y
MKE151$55RJ8W=9K[3KVKJ+Q145TTY5VN*L5&05$L['MD<O!,-W[T1R[^H\%1
M2P7[E?='40[<%MH6RM5W!9%<]BI^A3V:O1*[7VG*'.^F>VOQ]2;;,_VBTTT^
MK)=O=6ZH@T]' QM.^LN%2]&4])&Y&NE55PF%7<F_";^LYZ'E)DCN4-NNVGZJ
MW5\\C6Q02S,>KT54VG9;E/-RU?SF'26;ORFZFKIEWVQ\=-"U>ALD;7+^U#TW
MJNIKKRGV>U1JCWV^&:2I:O0KVQNC_N7B2*8]$RRZW:ERU=IBUJJHU\LSY,=*
M)$KD_:AW;?M(_MSO&'*Y<,(J1T-'&J+UN7;:J'?32,AC=)(Y&L;Q<O!"5?D+
M#G]9W:2CM[:6@<B7*M<D%/G.&N=G#EQC<BIUH<YR80OM=_U)9IY%>ZF=3OVU
MXO=(Q9'?H5RFEI-5U-7JB>^-TK?[A2HWP-%+30L<U8]VWE5<F_;:[@9=-WF:
MKY5_"3V>Y6EUQB<](ZYC6.D\'&C<IA5X?]4-4Q_;,0DU.HU=KZ@TQ=Z2AKXG
M[-1M(DJ+N:Y&Y:BIC^$N&_G,%CUY45=ZI[9>+!56B2H:BPNFF9)MJN=WFYQP
M7B:NV4%/>^5R[U]3#GQ7'$E.J\=IS7L?_<>F_1>,>5>T4Z)OH8F5>?M5[1%,
M>I+M5RC:IU#!JVUVJTV>N5D%7%5.?!4M8M7&F45G'Z*JJ)A>E#J+A?O":7;-
MJ/3KX4J9FTSJ&I>R7:VE5J9QE%3']YXF1+7\L$DRIM4]%;%AV5X)+X5CD7[<
M*7Z^D6KU#IFUJNY:R*M_52(O_41$3:(A8:WE/KZ.W6&RTSF-I*&22.;8:GFL
M;$^-VSA/JW'HBY1Y(IJ-]7IVJI;+5.Q!<73,6-[,9:]&)YR(N[<J9WENJ***
M^\IVG*:H:BPVQLTSFK_"5[$5OZ%87\L<S9[50V6-6\ZN,R,C1>/F.1Z_L:I8
MB*HB)CVE[.GU9J6BTS;VU-<_+Y7^"@BWYEDPJHU%QN7"+O7<:ZPZKN=?=64=
MUTS66F-\:O9/-41R(Y45$V<-7.=_[#546+GRL53ZI$<RAHU9"U>".\(U=I/K
MWJAU5Y;'55=!1^%:R=LK:I&JN]S6*F?[T,XQ%HE;M;J;6#+3<8K9;Z"6Z7>5
MJO;21/1CME,*J[3MW!<\3A[KJ5^KM4V"Q55NEMM7X6?G---(UZL:V/:8Y53<
MJ*YCDZ>!ON2-ZUZ7R\RK_P!HJJMT+U7JB<]C?V%MHJ8;]RJW">G5'16B%L3G
M+Z15E8Y$^S<:IC'GI+W=5IK4,5[GNL+8'P2V^K=2.:YV=I6HBY3'1YQZ([W%
M)J1UHCC<]S*=T\DN=S%1S41F.M4=G/U'%T-?!IO6^HUK<PTZTWC![EW(J+)L
M9_8;_0EJDIXZNZ5K=FON+TEE1/X./-1/T(BF)IMRL.M !AH
M                                                        62?0
M<<0=M+]!QQ!Z/ \_G]'  'IY>:\  ')P  <G  !R<  ')P  <G  !R<  ')P
M  <G  !R<  ')P  <G  !R<  ')P  <G  !R<  ')P  <G ,]0*= +J_4B%]
M/"Z65(V)E5$,+YI$C9O<IU-MH&4T?0K^DYU^3"+.OCHRFZELH64L><9>J;UZ
MC8)P*(A4\4S>7KB+18  4
M
M                                     +5XJO47#[2#GJW3K*K55!>Y
M:E=JB1Z10[.[SV;*[\GEUMHZBU:MM\8/<UE%,LR-1%\]53&-RI@ZK<HV364Q
M-X2S6:@M:7:Q5MM\-S=*F)T7A&MSLY3C@\E;INBK--/LM2BNIW1N9G>F%5%3
M.Y?K4WV K<C*5LCMN@+K40Q45WU9/<+-&K4YBM%'&BL;]%NVW#MV$WY.AO\
MIF"YZ:99*>5:.C8D36[+=O#8W-<U-ZY_@(F<G1X&/J&4I9KKS;DN5IJJ-9?
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M<B]9+4;6M8UJ<$W(6TU+#31)'30QPQIP;&U&HGYD,N!55EPL0J!O&\@ ;QO
M ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO
M ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO  ;QO
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M>-X #>-X #>-X #>-X #>-X #>-X #>-X #> "#)8O'BA=E  &4&4( &4&4
M 9090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!
ME  &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4
M9090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E
M  &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4  9
M090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E
M &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4  90
M90 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E  &4&4  9090 !E!E
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M=T?(#5?MW6^[1=TD\#9)C",/D!JOV[K?=HNZ/D!JOV[K?=HNZ2>!LDQA&'R
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M=T?(#5?MW6^[1=TD\#9)C",/D!JOV[K?=HNZ/D!JOV[K?=HNZ2>!LDQA&'R
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M-<+M)7U#5<KIWL:U79553<B8W)N!OP9RE<8  94
M
M
M
M
M
M                                            !T@  "F0"%2B*55<
M 4*A%SP  %"J  ,H     #( 8"+D    "@ $ R
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M15"X!. (T
M
M              !&UZ??+MRG5EEH-0U5JHJ>V152-IX(GJY[I'-7.VU>A$))
M(_HE_P#?A=O^!P?XSRTI+TMTEJ'/[^KMCJYI3;O_ /F5^26H?;N[>Z4OX9VG
M0$&1$.*326H>G7=V]TI?PROR1U![>7;W2E_#.S5>H(HRDM#C/DCJ#V\NWNE+
M^&/DCJ#V\NWNE+^&=HBH.@926AQ?R2U![=W;W2E_#'R1U![=W;W2E_#.T3@%
M&1:'%_)'4'MY=O=*7\,?)'4'MY=O=*7\,[/)7=GZQD6AQ?R2O_MY=O=*7\,?
M)'4'MY=O=*7\,[3=U#<,I+0XOY(Z@]O+M[I2_ACY(Z@]O+M[I2_AG:9&4$52
M6AQ?R1U![>7;W2E_#'R1U![=W;W2E_#.TR@R@O,06AQ?R1U![>7;W2E_#'R1
MU![>7;W2E_#.UW%/L%Y+0XOY(Z@]O+M[I2_ACY(Z@]O+M[I2_AG:9WX*[L"\
MEH<3\D=0>WEV]TI?PQ\D=0>WEV]TI?PSM=Q0F4EH<9\DM0=&N[M[I2_ACY):
MA]N[M[I2_AG:(,ERDM#B_DGJ'V[NWNE+^&4^26H?;N[>Z4OX9VV[J RDLXE-
M)ZA]N[M[I2_AE5TIJ%/_ .>[M[I2_AG;;BU> R+.)Y)+I<+KI::6[UCJVJBK
M:BG\,]C6JYK)%:F4:B)P3J.W;]$C[D43_NG6;_\ XK6?XSB06\%^T3[E85 !
M       !D "BJ$5< 5!1%*Y%P R4R2XJ"F1DHJ"BKO&0*@  !D"X HB]97(
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MRJNUG:7/#&"<8U\Q/L-5T6B$B;K@4*G.&@
M        62?Z-QQ"G;R)^YN.'4]'@]O/YO05*#!Z7G5!3 P$5!3 P!4%,# %
M04P, 5*#!4"B*J*BHJI]:&^M%RVT2&=</_@N7I-%T!%5%145<IP,5T15#=%<
MTNY8N6E31V>Y[2)!*J;2<%ZS=-<JIP/'73-$VE[*:HJCA<"B*H1=ZF6E0
M
M                                                           (
M^HO]N-V_X'!_C/)!(_H?]N5V_P"!P?XSS5/ZDN^3<B%KEPJX+\%JIE%,K^/G
M:Y<H'*#<]87.V:42FE92O<WP;XXD5$3:_A/5.AJG7<D'*'<[_<;C9]2Q,CN5
M$[9D<U6HW*914\U,;E:N_)%MLL5ZO_*;?:;3UX\5R^&>CWY<FTF9-V[ZD7])
M*FF^3ZFT18+U<KM7K/7U#,SU6UN3*\4RF<JJK^D]=<41PXQ54DKQU:]OP?C*
MA1_0WP[,_P!YZ)ZRFIVM6HJ(84<N&J]Z)E>I,GQ]?[-;(]/>.+7;[XZ5%\VX
M2U$:Q*N,[D1$=]9VG*55U5PY,-+5$TSG54E4W]U1=^=N5$7/YD,3X(XFZ[)3
M?JG5]OL5FJ:])J>J="F^)E0U%7^\IHK5]'JBQQW!JQ4RN1%= LR/<S*(N_AU
M]701!JKDLM-KY/:JZ+45TU9*R.5ROE14SC/\4S<E>E[50<G]9>*2>=U?51M1
M[7/16IA$X)C^<O275X\;W7.I."WBVM8USKC1HUW!5F:B+]F\];9HEB25LC'1
MX^GM)C'7D^5-&Z"AU%R:U]ZK:ZI\)1/V*>-LF&-PUB[TQ_.7I-G)JN[TO(53
M/AJ)/"NJDI5>BKM;#F2N7?GK1!/\>/43^LQY9M>8?1T5WMTLO@XKA2/?PV6S
M-55_-DS2UU)!(D<U5!'(J91KY$150^4(-)W+F-#<=+V&_LNBO1[JB:IB6-R(
M[H1,+T'4<I]'55^KM+TM3/+35<M,ULSF.PY%6--M,[_K0:(O:ZSY)CFSZ$2Y
M4*TZSI64RP(N%D25NRB]6<_6GZ35ZANE/)IRXR6^MBDDCA5=N"5%5OUY12*-
M>\F=9;-%TMITC+530I525$T,LB*Z7::Q$3@B;MG)Y.3^IL:6W4E'0455;[G#
M2.\/3RN:K<9;O1&IUXZ3-/CBUXE<YO9U'(;J%T^G*A]\NJR2^&5&K5U.7?3?
MNRY?L.TUO7W*'3$]5IF6F=69;X-TDD:,QT[W*C?VGSOI#D_I]0:'OMVK*NI1
M]&R6>GC8_#4<WPB[TQUH;BCKJBKY *N"KE\*M-/X-KG;UPDCDQ^;!JOQTS/$
MI%<ISTI=*KY,4%1J:>EAKGQM\*J31["OPF<*U5;QZE-LRZ6]T_@4KJ7PW\1)
MF[7Z,GS7K-%\B6DMAVRJN9A4_HL,'*3I6BTI8[9J.SW>K?=ZE[=MTLVTKMIK
MU54PB=*=8T1/Z;)?4RN:C557(B8SE>!@IZVEG25:>J@E2/Z:LD14;QX[]W!3
MRV9_/[+3/JF(OA8TVVJFY3YV@NC]"ZCUU8Y%5G/(G.A1>A5C>Y,?K$.5'CSF
M8B6JJ[1=]*05E-.USH*F&5&YVE8]'(WKS@Y3E!O%UCTT^HT;444U8V1&;3YH
MD8G6F7N1N=_60'H?4-9H^V7^"Y2*V2NHH:F%%Z/"Y55_.CC87FT>+/R?:5TG
M^EK)TJG*[K<C4_\ M.FB*9YEG9?TEC5'*+\D;+;)+I!'65]2]&2,BG:S915?
MYVY%3'FI^DUW+CJ*5O)@MQL=P?!,Z>']TI9\.;G.6[35(RY6;#1+IG3MU>Z9
M*B1R0.PY-G95TB\,<=R'0<IFE[;I?D4?3VF29\4E13RO\*]'+E<KT(G6IO71
M%INF4I?TA>J6735CYS<8'5<M%"YZ23HKW.6-,KO7*KG)TJ+G&%W'RSJ;0L>G
M]%V'5$%PJGW%T<,J(Z3+4:[P>&M3&[".7IZCZ-T74RUVE;14U#MJ66EC>]>M
M5:AQ\E$1%XENB9_6\*+N0K@M=P.3;@.13]ZE;_Q2L_QG$@H1_P B:?\ =2M_
MXI6?XSB0"U>R  $    %+?L_,!55QD)O0B?E\UA>=)6NW2V.J;3R3.>CU6-C
M\X5F-SD7^,IW.A+C47;1=CN%<_;JZFCBFE=A$RYS455PFXU-$Q3DD3S9OU7>
M""+QR@:BI^6VBT_#6M2TR5<<+H? L7<J[_.QM?M)DN=]M5KJ(*:X7*CI:FH5
M$BBFF:QTF5QYJ*N5W[MPJHFF8^I%43RVB)A"AH)=6Z>AJDIIK[;&5*KA(G53
M$<J]6,Y-RR=KXVR,<UT;DVD<B[E3KR8F)I]M1+,@7<:"IU?IZGJ^:U%\MD53
MG'@GU3$?^C.2 >3&OJIN6NM26HDD:L2>;MJJ<8N@[4>*:HF?5F9J?3B<<!2#
MM66>MJ.6J.L@OMNAB3P*K1R5C6RHB-9G]SXKG'[27+Q?K7:&M6ZW*BHT=P6H
MF;'G]*_69FBUK&3;(G6,&NM5ZMEW:K[3<*2MC;Q=3S-D1/T+]AANVH+3:'-2
MZW.BHMK>G.)VQY_2IB(F9LLS9M^A2C5R:&KO-ONFG+E/:;A2U36TTBH^GE:]
M$79=THOU$(?DW5U3-K+4,<\\DC,HNRYRKC>\Z4^/*F9Z2:K3$/H]$"&JNM^M
M5G3:NMSHZ)J[\U$S8_[U++7J2S7:18[7=J"L=QV8*AKU_8OUH<\9Z:NW"H#Q
M7"Y4=MIG5%QJX*6!.,DST8U/SJ>2TZDLUXD=':KO05DB;]BGG;(J?H46FUQN
M"B\#PW.Z45KA\-<:RFI(?X\\B,3]*GCM6J+%=IEBM=YMU9)QV(*ACU_0BC&2
M[=H#SU=5!1P.FJYXX8F\7R.1K4_.I&_*CJRSU^@[S'9KU0U-0D2HK::I:]R;
MEZERA:*)JE)FT)/1<Y*D._DS5$LVC'^'E?(J2.PKG*O\)>E282UT83B4S>+J
M@)P!E0               %"U5XEX((WY2ZCQ-J+2]_J%:V@HIY?#O=_ 1\+V
M-_M/1/SG;U-UHJ>VR7"HJ(XZ!C=ITSOHHF<9/374D%;3/@JHFR1/W*UQQ=%R
M5:3HZEDL-!4;;%RU'5L[F_G17X4W,Q,<HT^B*>5O)K=ZV5JM;612R-3IPFTA
MO^2%/^XM'_6S_P"*\ZB6C@FH9*.2-.;/8L;FIN\U=V-Q99K726>WLHK='X*G
M8KE:U7*[&555WKOXJI:J[Q*4THSM$$U3%KN*#95ZU<^RB_5*Y5_8AT/)7<Z-
M>3>V2^%:QE+"D<^?_*<F]6K]>%3])TUMLE!;JFLGHX59+5R.EF<KE5'.5555
MPJX3>J\#0UW)QIFNNC[A44,O.7NVW;%5*QJKU[*.1O["S7%26<AR75U-<;?K
M:JH9/"TTM6U6/3IQ Q/[T/3R5NMB\E*17UT?,*BKJ8'I(JHCMJ9[=G=UYP=_
M;M.VRW)<$HJ9(DKGI)4(CEPYR-1J;L[MR)PP8Z'2]HHM/3V."EV;;,DB/B61
MRJOA%57*CE7*?27@N[H$UQZ(AP=TI:C02VZIL5TFGM=14(B6Z;95B->YK4V,
M-1VY'YWN_@IQWYV%IGCMO*Q<::L=X)];2-=3[7"3]U?N3Z]RJ;BQ\G&FK)<H
M*^WT4[:F'/@W254LC6Y147S7.5."]1M-3:6M.IH8X;Q3.F;&NTU62OC<GYVJ
MBC*GTMFP6OI4N3;>L[$K'0K.D7\)8T<C5=]F51/SD-:+HYJWDDO\=.B+(WG#
MME>*HGA-R?62?IC1METS+-+:*:2*25-E[I)Y)5QNW)MN7'!#V6&P6ZP4CZ:U
MTZPP/<KG-5SGY5555^DJ]:DBO'T6>#0UTH[AI"WU%+*CH8(&Q2*O\![&HCD7
M[%0Y'1E70/N^K+_/)&RTK.M.L[E7956R*N?S[;?TF^K^3#2M?6255103^%>[
M:=L5DS$5<Y7S6N1#J:*VT=%;XZ*G@8RDC8C$8N_<B83.>*[DWJ,K>BR+;_0+
MH*T)>-+7.9+;X3;;;7[*PN;CZ+/-VL[NEQEU11U#N4VC\+>:RT1U5,YE//2H
MQ5>Y71HD:[;53*K_ '<3I+5R8Z6M5=#5T=#,D\+MMGA*N:1J+_1<Y4_8=%?K
M';[]1+272!9H57.YSF.3<J;E:J*G$N<08N%O^D*?;MZ:CUE=IH4J8Y(8I_ H
MCY&N143S8T7C@I9)/%W+/=H:Y[&R5U%&E,J?P]ESW*GVHU,G1V#D_P!.V"N2
MKMM)*VH1%1'2U,LJ(GV/<J&PU+I>T:DIV17>F=*UB[37,E=&Y%_I-5%$5Q'!
MBX#E)N]!4:WTK;(:ACJR*M262-/I-;X.5O\ >2TSZ"?8<K0Z$T_104D=/0N1
M*6HYU$YTSW.;)L*S.TJY5,*NY=W3Q.K;]%#-543$6*8L(5" Q#0 "@
M                         "R3_1N.'7BIW$G^C<<.O%3T?Q_;S^?T(5*(
M5/2\X  @             (N%SG'U]1O;1<T<B0SKYR;FNZS0A-RY1=YFNB*H
M;HKFEW2*B\"O2:.TW+;Q%.Y$=T+UFZ;OX'BJIFF>7LIJBJ%P ,M
M
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M_O5K?^*5G^,XD U5[(  9   "U>GH+BU>I> $$_E4[K+9\_QI?[XR2^2Q?\
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MQZ,E47] %^4&4+%X+C=T%-KAQ0#("Q/K+DX%%0
M 62?Z-QPZ\5.XD_T;CAUXJ>C^/[>?S^A"I1"IZ7G  $           !09 =(
M"&:DIWU,FPQ%^TDVAJ(R5HJ:2IF1L:+_ $NHZ^F8Z.-K7+M*B<3!0T;*:-&M
M1,ITX/6AX_)7E+U^.G&%0 <W0
M
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M%<@4V4QQ"-1"O0$ IL] 1N.DN %NRF\ILERE,X (U$*A-Y3@@^D+D ;O0%
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MC6\<;U4K04L=/"B-3?TJ>I-WV'D\GDRX>OQ^/$*@'&'4 !0
M
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MD3_>K6_\4K/\9Q(!'_(G^]6M_P"*5G^,XD U5[(  9      &   PG4  P
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M$9L(UJ,QC9QNP>**RVN&1)(K;1,>G!S8&(J?GP>\ ,
M        "R3_ $;CB#MY/H.3ZCAST>!Y_-Z"I08/3P\RH*8&!P<J@I@8'!RJ
M"F!@<'*H*8&!P<@&#-2T[ZF388F>M23,1"Q$R4E,^IDV6(N.E3JJ"E931(UJ
M;^E<"@I(Z:+9:GYSU'D\GDRX>OQ^/%5 $!R=0
M
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M5V$SO-VU,()(5 !%    R  &0
M
M                  '0"B[T HK?-V>CK-0MB@3^&_\ -CX&X";BTU3"33$M
M.EB@]))^SX%?$4'I)/V? VY7\Q=E3.%+3^(H/22?L^ \10>DD_9\#<?F'YAL
MJ,*6G\10>DD_9\!XB@]))^SX&X_,/S#9484M/XB@]))^SX#Q%!Z23]GP-Q^8
M?F&RHPI:?Q%!Z23]GP'B*#TDG[/@;C\P_,-E1A2TWB*#TDG[/@>^CHXZ5FS&
MB'I_,!-<S[6*(@3ZBI1-W J8:  4
M
M                                     "F *@HFXJ    % 2PJ44# %
MF2[**G J%3*%0:G45*-3!4*                ("@ J@*%4      "#):5(
M 'YQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP
M &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'
M  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL
M< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZ
MQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[
MK'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;
MNL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQ
MNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K
M&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;N
ML;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !N
MZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &
M[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'
M;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL< !NZQNZQP &[K&[K'  ;NL;NL<
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MGPQ1>D'*BGTI=-JOU-G[P)0 V?#$ !S:
M
M
M
M
M                                              !I]1ZBMFFZ'GEZ
MJ^;4RO1FVK'/WJBKC#45>A34P\H>F9K)/=X[IFWP.1KY5@E395<X\U6YZ%Z#
MB+__ .T.7VU4];OBHZ3PT"?ST>F%_M*=?RB:3EO]GJ&6EM+%<Y)(Y/"U#G(Q
M=CAG"+_<=,;>V8E[=-Z\T[J6KYM9;CSF9$RK? 2,Z%7BYJ)T*=/G'3O(GTMJ
MN_TFIUT3?H*!E<VE:VDJJ+;6-52)SLN5ZYX(W@WCD[K2%'>J"U31ZCK8JRL6
M=[V21+E$C7&RWZ*;^/02JBQ$W6:EUG8=,OC9>[@E,^1$5J>">_*+G^*U>I39
M6.\45\ML-PM<_AZ.7.Q)LN;G"JU=SD14WHO%"+="Q,N'+!JFJKFYJJ;,4;>&
MPU/!.3]JJ>_E$N=39;O:+-8'\PENU3%X>IC3+D9M(Q=G.4SA=V[H&'X72BKE
M1=Z_85RO^1#=3?KYIW4.H;')=JBXQ);7U-/4U+6>%B>V%[MVRB)QQQ1>!RK]
M4ZK@TG8KXZ_3NEJ94@?!LL\&Y%:Q$<OFYVLR*O'&Y#4>*9BZ9OH[*XZOM**N
M,[R'[1>K[9M?5%BN-UFN4+Z7PC%F1N6.V]G^"UO0G[3D+=J?5LO)W'J6:_S+
M-32^=$C6;,S$VU7:\W.?,1-RINR715:YFGI-16SQ_P").=8NFQX3P.P[Z.$7
M.<8X*G2;;.]=^\@]MU=Y5_&J-RYEGDGV7)TI"U?^AJ;;J77%VIVW.SQZ@J9)
M*EW[DL,/-$C5R81%1=O<BK^A/K$^$R?0JJJINR$7BBKO(66Z:DO.I]0445ZJ
M;=!0L\*QL36;2*LBMV5RU=R)CZSG$UAJF+25FU%)>IG/=7,IY*?99X.2/9>Y
M<^;G.6HFY>!(\,F;Z-SN09Z<[B"+WK&_WC5-?;;3X\8RDIHWL;:XH7*Z22%C
MT\)X1>&57AT'HN^I-7T]FTLRLDFMMPJZB>"=LC6HYS$V$:Y>*9PJKU9&J5R3
M<Y?KP4C?M;T<CD^HA:VU]YFU'J72U;?J^>..F26&J<V/PK,38Z&XX-QPZ5-C
M^3O0S1:0BJGW&JEAD;AM,_9\&S<W>F$ST8WKTDGQ3$3*17=+*YWKG 15Z5(K
MO-UO-]Y29M.6VZ36J"F@>YTE.C=I[]EKF_21R8W[]Q967&_7'7%'I5;O+0)2
MT[GSU5(C5DF78:K57;:J=>=R<=Q-<KDEA'<>H95>&X@6[:RU#;-,ZQHDN4DM
M9::N-E/7.:WPKF+4-9AVY&\,\$Z5+IKMJINI-/4+-03XO<"*]%1FS"[,BY9Y
MF>$:)OSQ4U'BDR3PCM_64157.%W=!!+-77^ALFLZ*:Z2U%5;8U?!5/:W;:O@
MFNZ$1.+NH>/]2VMFD+M5WN>HCN<S(JFD5K/!HBR-8BM\U%SA<KE>/U%GPS$7
ME,X3LCL<5"+OZ2'*>ZWW55VU3-27NKME+:]IE/! UFR]6*]%5^TUR[]E."FB
MEUWJ.KT[I:2GKDIZJ>JYO.YC4Q(B1YRN47IZB:9C@S?0"N7H0KM?H(<H-27;
M3^I]4VVMN51=8;;;I*V)U4UNTNSX/<NRC4Z5-+I:_P"M:^HM%=31Z@JH9JE$
MJ6S0PI2I%X3"JQ6KMY1O7TY+JDS3[E>@M<]&X1SD3/6I!K+UJ:[2:PDCOM51
MLL[4DBCB:S*Y63S79:NY-A.'6IH]75U?J73&B+C5W"H9/(](G["-1-OP;7+(
MF47SEVOLW<!3XIE<GT943LIX7RS.V8V)E5QG<<UIOE TUJ6XNH+'<^=52,61
M6> D9YJ*B*N7-1.*ITFTCM\\=B6B=62U<Z1['.*C&T]>MVRB)^A".>3^AU+H
M9M'8+PVU2VV5'L@FHW2.E21TF4VMI&ICSUX)T&*:+W)J2VF>LTVIM46?3%-'
M/?:WFL4BX:[P;WY5%3^*B]:'CT10W^@I*MFIJ^"MF=,YT+HE5=EBN541?-;T
M*GZ",N52[V>OY1+7;+]<8:>V4<,DDFVN$<Y['HB9PO!S6]0HHO*Y<)?J+];Z
M>Q.O,U2C;:V-)5FV7+YJ].,9_8:&Q\I6E+Y7LHK7=TFJ7_19S>5F=Z)Q<U$X
MJA%%GOD=RY -1T'./#.MT?-F8Z6)X/"I]65/'LW:GH-#7+4\="MFAK(F4RT*
MO697[;E1)$?AN,([@O4==%HF_=F,TP77E/TE:;A/0W"[^"JH<>$9S>5VSE,I
MO:U4X'3V:ZT=WH8ZRW3I/32)EKT:K<_F5$4A_DK1D_*1JYJMS$^.G3"]*+&X
M\G)_2W5U[UO;=.5,=(K9&NIWO7S6.65VWOPJ\$QP,U^.*9F"FJZ>4RG$YZZZ
MRL5KO=):*^X)%<:K_0P^#>NWOQQ1,)OZU-A8H:RGL]##=)F3U\<#&SRLX/>B
M><J;DW*N>A#YEU5>[9?*O4MVJ+I3PW"EF7F$#U5'/:C45-E,*B[U7I,T>/)J
M:K/I2[ZCM=GJ*""Y57@9:^5L%,W8<[;>Y<(FY%QO5..!:]16RZ7.OM]!5>%J
MZ!6I4Q[#DV%=G&]4POT5X9(>U?=F7J#DQN$*Y;+<Z9,]>S,C5_:U3QVFCNM3
MKGE!FM%UFMRTS62O=%L[3\>%5J><U4QN7JXFM/$IF^@\] SUD 4VO;[56/2<
MBUSV325#Z>J>UK?W96Q9ROY]^[!O*S5%XCY1]46YMPD;1TMK6>&)&MPQ_A8T
MSPSG#E_22?#,3,=&<)B15,%PJTHK?553FN>E/$Z56MXKLHJX3]! =3J#5D&D
M;%J)+],LE=4MA6G5K/!X5[F[_-S_  >OI-M;=2WVW:UKK/5W6:M@EH'5,3I&
MMS$_FZR*B81-VTJ8SG<B#3)FE#1>I8M4V?QA!3RT[$E=$K)<9RW[#?9XIG>0
M)/K'47R'H:N*Y/YY+<IJ=9'-;]!'-1$X="*IO;7?;II[E+GLMXO,]=;EH6U&
MU4HW]S59%;G+6IT-_:2?%)%23+_?;?I^VR5]YJ>;4C%PLFPYV-RKP:BKT*>Q
ME5')1I4Q*KXW1^$:J;MI,90A[EAU78]0\G=>VRW."L>Q^7)$J[O-=\4,%+<M
M0:7U-HVGJKQ-74-TB2-]-(C5:S.PUJIAK5W;72JEI\5XN9)&T;K"'5$MTBIZ
M6>G=05#J=RRX\]4<J93'V'3H[KR0/)K'4":6US5,N4BU%#=64]*Y6M_<V<Z1
MBM3=PV=QL*6^7ZU:OTQ#57BHK8+Q"DLL$C6;$;MEZX9AJ+CS4XJJB?'^F:6[
MU=J.S6^:NN4W@*2%JN?)LJ["(F5W(BKT',3<HEN2_6NW4L%151W!JNCJ6)LL
M;AR-WHN%XK^PB2\W'4&K-%:KN]1>)H:2-RM901HU(DB\$JJF]JNSG^=TFZM5
M^N=!<M#6ZBJWQ455#(Z:'"8>OA\;]V>"J:TVCGVF:=<_6-I=Y\_TE]U/<+'J
M:Y?*&L@6UUSXX8V-CP]GA')AV6KN1&IC"IQ7)L+UK6KDDTDRX7Z:R4%;;(:N
M6IB1NT][XU547:1R<43HZ3&F?4+FG%%WX4P5U7#144]55/\ !P0,=)(Y45=E
MJ)E5W?4APW(Y/=J[3/C"\W*JKN<NVX7S(Q$5F$WMV43=G)PUTNE_U9)K9L5W
MEHZ*V4RJVFB1J-DS#M*CLM5<+OX*B[Q3XYF;+-2:;%>:&^VUE?:JCP]&]RM;
M(C7-RJ+A=RHB\4-AE=^3YYT[?;G;^3O2=KM=2M)/<JR=KZEB(KF-;*U%V<Y3
M?MKQ13I&7F_:?UQ66"HN\UQIWT:312U*-VV.P]?X+6I_!3H4L^*8F8A(K3'O
M+5=]>\^=)]5:LH^3^TZG2^2S53YVPOII&M\#(U8U=EV&[6UGJ7&XZFRW^\67
M7-5:;Q>I:RB=0NJ$DJ$;F)VVQ/X+4W85>A1IJ,TQY.6L>LH+OJFZV2.DGCEH
M%1'3.5-A^]R;NG^"1+6:UNT%VL]5:Z_4<UOK+@E.KJ^*G2G>WPJ,=L*SSNM-
MYMI=77OY1:PA2O>D-'#$^GC1K<1JJOSC=]2%CPRF:;$7=E1GBBKNZR X-1ZD
MHM.Z5U#47RIJ%KI%9/2.:SP2M\&YR+N:BYSCIZ"5;90:BBUE65E;<8);$^)S
M8:5JKML>KFJB_13=A'=*\3%7CQ:BJ[T:IUE8]++"E^K^:>&^A^Y/?M=E%/!'
MRDZ5DM$MS9=<T42HCY$@EW97">;LYX_4</RS5+J/E#T74-I9ZIT<FTD-.B*]
M^)&;D151,K]I[>3[3]R^5>HM15U#+;8*Q&^!IYDQ(N$D1=I$RG2B[EZ3441C
M>4RF[H*3E:T95U#8*:];<K]R-YK,G_V%U;RKZ-HZJ:FJ+SL31.V7MYM,N%^U
M&8.5Y(T_]O:UW(G_ &V?A_34C9M9>J32.K5IH:*2R25BLJ5<K^<,78B7+4^C
MC<WCUJ;CQ1,S#,U2^I::HCJ862P/VXGIYKNLP7JZT=EMTM=<I_ TL*9>_95V
M$^Q$53A[59;E'8-.0Z/NK66V"5'SK4+YTL?A'*]J8:J9RN.C@7\MK7)R:W3:
MWN1K<G**;U1#>7#963E(TM?*UE):[LDU2]%<UBP2LRB(JKO<U$X(INK'J.V7
MU:M+35>'=2R+#-YCF[#T1%5-Z)GBG A*GM5TU;1Z&6FLU90TEJM[?"U=4U&M
MF3P"(BL5JNRBXW91%WC1MWALMAUE43UM51M\9R(BTB-69R[#-T:/\U5^TZ:8
MM>)9SL^@]K*9R6M>CD7#D7[%(.TWJ"^5&L;GIZLK;XR!]ND>U]RCA;/&]7,:
MCF[&6[LKQR:[DLGJM/Z#O5XCKZF18G3HVF<C5C5R*_#EW(N<IGCTF=/$SU_^
MF;Z"VL)OS]IJ[-J*UWFHK8+95^'DHI5@G38<W8>G%-Z)GBG AJP7O6]34VBX
M4L&H*RFG1[ZJ*LAA2FPYJ;/@U8NWA,JN_J;]9K;9J*HTS1:^JZ%%6I\;2M8N
M,X57L3K^LNFW!F^C-I<\"C'HY%V7(J)U+DAG3%5K&6]P0N^4SK;4P>"FGN,,
M#5@>KD\^/8ZD3^%GBNXP_DX6^5D=RJDN%0Z%';"TWF^#55<[SEW9RF%Z<;U,
MSX[1,S*Q5R[_ %!RD:6T_<'T5WNO-ZEB(KF<WE=C/#>UJH>[2VLK'JATJ6.O
MYTL29?\ N,C,)_\ ,U#EOR@DSR<3HJ+CG=/P_K$/!R@WRXZ?Y)K566BI6GJ>
M;TS4>B(O%&)T_:*:<HA;\I855W+P0KGZ]R<2*M1U]5IW3UOAN6H;U/<:V?:1
M:-D+I5\WZ#$<U$V=RKOWG-V+6%^;2:_I9JRY;=NHGU%*^XQQMJ(')$BIE&>;
MQ7/3T#5)DGG.>&5*_P!Y 46HM1T5MTA>9[Y53^-:AL$],YK/!HFVQJ*F&HN5
M155=_$V5WU'7T>OZBCU)>KK9+?-*YM%) R+P#D155-I7(KLJF$W)Q4:I3-)%
MZUI8;->H+1<KAX&XSQI*R)(GNRW+DSE&JB;VNZ>@Z%'*J;E($M=!43<O%3B[
MUFZF=(CT1F5;X5R(SZ/T>GK^LPT6M-0.Y'Z^[/NDSKE',C&SJUN439<N.&.@
MUIO:((K?06>I3E:O6<%/KNATPM'4+/5M>K:A%3839C5ZYZ>"8(VU-J6^TE39
M*BZW&ZVVP2QQLDKJ)D2^>]&><_;1<(CE7@G#.X\^NM?7.QZBLJ6:ZNK+=+2N
M3:<UJI.O@?->N$3?E4=NPF>CH%/BDS3WOZ5^T(JD'U=ZU#IVRZ7U!-?*JX<_
M_P!:I)VL\$FU&OT=EJ.W*J<5Z"^YW?45?J?6-)37VIHJ:VKX6G2%&;64;'YJ
M[35\WSU7KS@SKDS38JJG%3BJWE4T=15DM'4WG8J8GJQ[>;3+AV<8RC,&;DIO
M-7J#0=!<;@_;J9%E:]V,9V97-3]B(0;1U-YI:37K[?%0OM+ZM(ZSPJO\,C5D
MD3,:)YN[+E7/U%H\>4VDFJSZ;H*R&OH8*RDE22FG8V2-^%3+53*+A=_ K5U4
M=)3R5%0_8AC3:>Y4SA/S$%W"^RZ;TAI"U:8EKWMN<37OD@:QTZ-\$U41F?-S
MYN_/0JF66;5=5IS4L%V=>Z:WPPOFIZFNCB;,_P"BG@W;.6XXKNWYZ2QX3-*^
ME]7675$4LMAKN=,B=L/7P3V87_YD0WK57>?.E#<+WI[DGTS+:;Q4-FKK@V-$
MD1FS&U9)&JQ,-^BJIE<Y7*G::IN,]CIK30SW_453<:MBR(V@CIW3/X+A$>U$
MPF?MP)\4WM!%:5\KG"J%<C6JKEPB=) UEY0+Y2Z1U2M5-535=)5L@IGUC&I,
MQ'S)'AZ,\W*(O1TYXF[O%GOJ:!K:FOU)654$M$V1R/\ ![22*Y,HF&)YF,?7
MG)G5,>S)+R/143"HO3N*[6[IR0+:KG<])\C=KK**Y5,T]Q?S:%LR,V:57>$7
M:9A$Z69WYXF[N%QONDM2V&&6]U5TI;I&]',JT9F-46-,MV&M_CKQST"?':_)
MDEFKJ4IJ.>=45R1,<]43BN$5<&CT1J>+5=C;<Z>FFIHW.V=B945?HHO1_2(Y
MY/KGJ&^NU!65M]JD@H):AL,3$9OPKT1'>;P3"8POVFAJ-;ZE9HVPUD-R<ZKG
MK)8Y'2-3#VI$Q41<)UJJFM7$P34^A=I<=815Z2'K=J&[:>U?>[;7W.INU-34
M+JB%:EK-K:1[6[]E&IC&316346M;I%:KI;HM05/A:Q.<1NAAYFL*2*CMA47;
MX(B+GIS]1F/%)DG_ "J%-K])"4NI;K3ZZ;3ZMN]VL-+4N:M$R)D7-W[.-ICE
M<BNRN6INZU+[OJ>MIM=O@U!>[M9;1,Y4HIH&1<WD1-I4VE<BNWHB<$XJ@U2N
M2:TSO7C]1YKE7T]LMU375TJ14M.Q9)'JBKLM1,JN$WJ<[0T.H?EG+727."33
M[Z=6QTJ*NVDFWE'?1X;.[Z1SW+M>(*+2\-OFG;"E?,V"5R\$B=M(Y24T7JB"
M:N+NRL&J+3?[=)76BL2HI6(JND\&YN,*J+N<B+_!7]!H9.5?1L5=)1R7I$J6
M2^ <WFTV$?M;.,[&.)%W)O>K9;=4WVS6JNAJ:"MI&+"L:JJ(YD#MO*KC^$J]
M9KK8ROO.E-1V"VV2MJYI[J]><(UO@&HE1E<KM;641.KB=M$1/,\,Q7*>=2:U
ML.FGQ-O=P2F61$5J)$]^>/\ %:O4IM[77T]SH8JNBE\+3RY5K\*F<+C@N_H(
M4NVC]6Z2N5LO>G(:6[34M"RCDIWJY7.5'/551$1N[SDZ47B=)IZLJ]4Z3M-5
MH.9EI@CJD6HBGW*L:;>TU,;>]55J\3G5XXM>)6*DH9W*N304&LK'7WV6S4EP
M22YQJJ.A2-Z85,YWJF/X*]/09M47-;+I:Y5\LB))2TDDJ+UN:Q5_O0^:[1>K
M70WNP7^FND,EVDN%0^IC1<N1DRM:B8QC=M/SOZ.DE'CRBY-3ZMRJ]/V!7HU,
MO<B8(AU'?+S7<J+;+:[Q-26N>@CES"C=IJKMKM-RU=Z[*<>@Y6[W&ZW_ ));
M^ZYW6JDFMU8^%7M1B+*U(4=AV[AY_1C@6/%,DUI?U?K2GTU6VRFFI)ZAU=,R
M%KHE3#=IVSE<G41OVV-=P1R9(/N=PO&F;+I.&CO-9(VKKH8Y%D:S.PZ545NY
MJ;E0O6[:ENUWU7#!?9Z2"VTR31>"1FUM;$CD3>U=RJU,_473-KI%:6KWJ&V6
M.6DCNE6D#ZMZL@16.=MJG%-R+CBG$VN57.#YIO=\N.J--:/FJYL5\5=+2NFQ
MA7.;''E_VKE5X?F.UMVHKKIW55^M]QN=5=::EHEJ8EJ&LVD=X1&X\U&IC TS
M:%S3 CL\"BN4@5]ZU32Z$M&L'Z@J999:E%EH7-9X!8VJ_+4PW:W["?PNE38Z
MDU/=J/6,/CVXW*SV.H9"ZDGH61K%(Y6-5Z/5Z*N$54X=:_49GQ3!FFK.[BIJ
M=1ZBMFG*'GEYJTIJ=5QM[#G?L:BJ1O=;K>[ERCNLULOT]/:G6Z&=)HD9MY5D
MCD<W+53SME,Y3AP(^U9J*X7KDRNM->:A:JMHKA)3I.Y$3:8UL>,XQORJ]'2;
MI\,S,7_2:_;Z?:[;8CFKE%3**4VEZ/\ ]9$D5VO.EM?4-!<[M47*CK*!95CD
M1G[F[PC6Y;AK>C/'/$TK;UJ:XZ8NNJ8K_4TZ4\LCHJ)C6>"V8W2)A<M5V_P:
M9\[I7@8CPS/)G^)>KM36RCNB6N6I_P#:3HGRLIT8[+FM;M+OQCA]9Y=#ZKAU
M9:ZFMIJ::F;#4OIE9*J956XW[NC>13;+Q/=]?Z7NDN&U$MKED<K4_A\V157]
M)Y*C7&H8>36YW1MRD=6Q7J:F9(K6[HT5B(WAP3*FM7%DS_7T!-+X*)\BY5$3
M.$XG/Z(U7#JNWS54%--3)&]6*V7&5PJIT?8<)27._P"F^4ZUV>YWB:YTEQI-
MI8Y4;B.19,9;AK5X-7CGB<[1:YU!-I!J-N#TKJNXLI6SJUN8F.D>W*;L9X<4
M7@(\4S$RN2:EU%;$U"VQ\[3QHYBR)!L.WM1$55SC'!4Z2NI-0VS3= ZNO57S
M:E143;V'/WJJ)P:BKTH0_I:CKZ/EVI&W&XRW%76][FS38V\K$Q79V6HF-^$^
MI#L.5W35WO45LKK$Z%]7;I72)#*JHC]I-G=A%^OI0D^.TQ$_I%7#L--ZBMNI
M:!U;8ZI*FF1ZQ[:QN9YR(BXPY$7@J&V1<INXD#U6K+Q7Z2O=314S[+JR@D\)
M5QQM3#T\Q%1-I7=+DZN'Z?0_75UU#?H4L=>M/1T]MEJ)VL:F'2->B(F_/0HT
MS,9$5IO1V<]766S2MBB?(]V&,:KG+U(0#2ZAU0[1M'JF:^SX2Z,IG4K6LV)&
M>'V%1?-SP3H7I-G5WZ^ZJU7<+=272:VT5-0MF<VG1N7JZ)RX7:1V[+?JW*HC
MP\F:6[!?[;?Z2:IM%3SB&*58'NV'-P]$153SD3K0V>5X=)\T::OEVT[R1U]5
M0U7@JY+O,CG-1%1R[$?6AW.L+E?M,V^SVAEYGJ;G<Z^.%]9,C/W%CT>F&8:F
M]%:B[VKTB?#)%:7MK=QW*47/1DABIOU]TYJRX62>\5-PADMLM3#-4-9MQ/;&
MB[MEJ)C*]**<\_4VJW:3@OZ7Z=)%K5I? (UG@U3PC&97S<Y\[K$>&J3-]$(N
M[CO*YPI"U)J6]6/6U%1UUSGN%+7VYM8Z.5K?W*1?"*J,PC?-\U..5.<M>K-;
MWRB2[V>+4%1,Z5')3QPP\T5F.&57;XXZ1IF(O)F^C,KDN,42KX-NUN7"93ZS
M(AR;50!.D
M
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MU%Q=5JD<"JYNTK<IAN=R;/$G+ZBU>'YQ'DE)IBS@M.\GGB[4<=ZN5WJ+I-#
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MZ(6=/YRXRJJ (
M
-              /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g109079g01g05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g01g05.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[25$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )2<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             /_A/TMH='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC,# R(#<Y
M+C$V-#0X."P@,C R,"\P-R\Q,"TR,CHP-CHU,R @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&9X+S$N,R\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @
M("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@
M(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z
M<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O
M(CX*(" @(" @(" @/'!D9G@Z05!42U9%4CXQ,2XQ+C N,C(Q,SD@4')O(%!R
M;V1U8W1I;VXM,S(\+W!D9G@Z05!42U9%4CX*(" @(" @(" @/'AM<#I#<F5A
M=&5$871E/C(P,C8M,#,M,3!4,#4Z-3=:/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y4;V]L:VET(&AT=' Z+R]W=W<N86-T
M:79E<&1F+F-O;3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO
M9&EF>41A=&4^,C R-BTP,RTQ,%0Q-#HR-SHQ,RLP-3HS,#PO>&UP.DUO9&EF
M>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C8M,#,M,3!4
M,30Z,C<Z,3,K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^5&]O;&MI="!H='1P.B\O=W=W+F%C=&EV97!D9BYC;VT\
M+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F
M/"]D8SIF;W)M870^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI
M:60Z,6$S,S)B,C4M830S,"UC,31C+3DQ8C(M9F-B,S<V-S%C9F%D/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B
M93ID;V-I9#IP:&]T;W-H;W Z,#DX,6-F-#$M-#,S9BTR9C1F+6(W.#0M,V(S
M93-B9F%D8F,U/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.3DS,SDW9#0M.3@R-"UB8S1F
M+6$W.#(M961B,#9D-V9B,68Y/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HY.3,S.3=D-"TY.#(T+6)C-&8M83<X,BUE9&(P-F0W
M9F(Q9CD\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C8M,#,M,3!4,30Z,C4Z,C,K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z.&-C9F0Y9C<M964Q,2TT,30X+6%F.3$M96$P,61E9C8T93!B/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(V+3 S+3$P5#$T.C(W.C$S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T
M.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O
M;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,6$S,S)B,C4M830S,"UC,31C+3DQ
M8C(M9F-B,S<V-S%C9F%D/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 S+3$P5#$T.C(W.C$S*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M>&UP+FEI9#HX8V-F9#EF-RUE93$Q+30Q-#@M868Y,2UE83 Q9&5F-C1E,&(\
M+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N
M=$E$/GAM<"YD:60Z.3DS,SDW9#0M.3@R-"UB8S1F+6$W.#(M961B,#9D-V9B
M,68Y/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.3DS,SDW9#0M.3@R-"UB8S1F+6$W
M.#(M961B,#9D-V9B,68Y/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QP:&]T;W-H
M;W Z1&]C=6UE;G1!;F-E<W1O<G,^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/GAM<"YD:60Z.3DS,SDW9#0M.3@R-"UB
M8S1F+6$W.#(M961B,#9D-V9B,68Y/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D)A9SX*(" @(" @(" @/"]P:&]T;W-H;W Z1&]C=6UE;G1!;F-E<W1O
M<G,^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P &! 4&!00&!@4&!P<&
M" H0"@H)"0H4#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M
M*# E*"DH_]L 0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@"V ,C P$B  (1
M 0,1 ?_$ !P  0 !!0$!               & 0(#!0<$"/_$ $\0  $# P,"
M! 0#!00'!04( P$  @,$!1$&$B$Q00<3(E$4,F%Q(X&1%4)2H=$(,['!%B1B
M<I+A\#1#<X*B%U.#D[(E)F.CL\+2T_%$E/_$ !L! 0 # 0$! 0
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MEP\1L&6CG!R''*@_@C>Z;2FL+9:KTR"GW/EF-54N$;F Q.QU[9;CKW0;6[>
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$08G\@JV/J5<TY"H>%$DQJ57<K'(QKHWAS0>"LC.0J/=LZ]TJF9\-:RB:X<
M!H_)<OO^K+A022MW518TN'#L# *ZYSYF1TPN:^+EQH;=:96.>\2302X&TGD
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MFJYAR.1A7]D5IR%972I",[JWE7,[J-I7(B*4"(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B"P]"K6]^ZO+3@JC&$9SA/LC[K2<)T:3GLJNC)/96,
M:_U!Q&.@2%_LQXWA<_\ &FC-5IRH+&%Y92S=&Y[!=%9$6^RUU\MD=RH)Z>5C
M7[XW, )('/V5<D;]+\;)\=HF7QM;Z?R(6LDS&\9R",'JM_25LU,=T;WG!S\Q
M4DU[HF>V7>HEB%.RF)8UK0]Q(.P'N/H5"*:?<_:">N.B\>W>MY\?=^A_3\V&
M^.L6F/4))!JBOBX:V0C_ ,1RRR:MN73;*/KYKEH'.+1P>59,Z9L+I'/!:.%>
MV68AZ%^)AO&ZRSW6_7"I=ZI9P,GCS7+5P;WOS+(__P Q59'.(:YQR'+T0L:_
M@#E83EEIQL$4GTO+8O+<USFOR,>KG"K06BGJ7A@J<.P3M "PB/,A'8'E7P&:
M&N+Z9P8,8"K%]SN75FK$_P!/M[GZ:G:UPB%1(#W#%#;W%)0UTT$F]KF$ AW!
MZ970--7JOJ:ML3Z@N:90S!:W^BA/B5O@U'7RRG+3(T<?[@77CQS/F'S?*YG2
M=9/#60SG:?5W]UG;4<?/_-:CS1'P[/OPKO/;C/*337M&/EQ,>);=LH?Z=_7Z
MKJ7AO:7APF?&\M<R)X+F<>ZY)9VBIJV #TDD8/V*Z@-7,L]LI(:5T\<C8FQN
M+6-():T#NII2DS^ZVC/;+FQ6Z5W'Y=WLC(R1OVL'/5;QLE#C$L\ /0$D+Y2N
M7B??8X2*&Y31NR,$PQ_T6ID\2M4R%H-WD+CT_!C_ /XKHG-T\5\OF+_2YR9)
MM;;[)IOA3(?*J(WC'8@J$^)>EQ<Z&1U(V1SQ$0/*CR<Y^BXSHKQ+NM/*/VM7
MSS-V.'HACZY&.P[+O>GM3T]XI,Q>=G#0=[0.2,]BM:Y8RUU9CG^F9L,=]3I\
MXW&QW2T5,@=3UI;G:-\;AVRM735\^[9*US,GN2OJ&[V*EN8W3PM?EV[EQ';'
M9<HU5X>/8[SZ".FB8Q@!S([.=Q^A]UQY.+[FOERTOKQM$M,U3I:YS2\D!S?W
MOJOH5M+!+;7P%S=SC[#/4+YSM=-)9;O.*PM<-X:/+YZ'\EWFSW&.KE9/'O$
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MPO"JJ!50$1%$ B(I!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MT1,&P..<IY0!82X\+*<:6J_8M*W@1G_B*]55;*>IA<US">-OS$+8X:><A48
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MUHGO$I\IA;*5D0QM'[O0E;V-K0W@+GEOOE3:P(ZN.)AX;SD].O0J3VW4-+6
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MX'2@@. )[KU#.!D([(:2%/N#:*W*V4[W$2P,>[)&['?W6AJK'50YDHZH0 =
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MUBJ^NKI;E(6Q/=&&G/)RK(*#X?F1S7N'.<++30_#M_#!R1@Y6RI:22=P?*W
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ML\%JNK.)J8-/^^W^JK-:KB&.<ZGPP DG<WI^JZ]Q^64R\$$0?+GCHL_PS?\
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M&.RHJ=DTCLH6,=R6M)]\+5W>TTU=$YM3!#,TMQA\8=Q^:VH&%4D*.J8R3'I
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M_A56T;?8?\*V>T)M"C4#6BC!ZD'_ ,JJVB;[#_A6PVE5 ("G4#PMHF#H&_\
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ML,(>&\$YXY5XECDQLMNG@^#B=YC1D=%9<XXY:20N< [ &/S6DK:2JI6"..4
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MMU"ZKJHG6BCDFDCJ&AY,>7,R#GD#OZ1_);BVW:ZTMNI[=%3W%KFQ-I_,:'
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MD>&Y/W*B;0FE+8Y\H/X=Z6FLL>^ZL,=:V5SF-:\.:6%@&>/S4Y:UT)<X_O\
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M@B%41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M73QTP!?&.!_@JXYBD>6$>_,E13PS.)D!.3GJHE>=!45:"^GB.X-#1NE([_\
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M=$6M<3R3W7I16BL0K/EC\L_17!IPKD4HTMVJK1C*JB)$1$!$1 1$0$1$!$1
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M(]+>$5^$4Z1M5$10"(B B(@(B("(B B(@(B("'Z(J.SCTC)08VL!/*JYC<<
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MK7IQVEK3//+.R5M0(Y#E^#DD[L +VOTY8M+Z-GI75-2RX7>@/EQ2'=OD,9
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M]U4JPN/L@O1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MO1X5U#AH2]4$1!K9*IPB81P?2SOT[%!Z-2:HK;KJ6XVFR&LI9:*4B2>)QVR
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MPI#6V37#Z*I%31TPIY8W>81)'G:0<_O>R">Z)U%#JBRT]13M=!4/#W.#W O
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M9:WH.O92-NTO&WIW5TA(X'N@^:J3P O5+.VF@UI5QTS\N>QE,]K"<=2!)C/
M_DMMIOP)FL][96R7D3.;,R1SC1%I=M=DDG>>ONN_AI,H<WY!U6+$^]^XCRNP
M^B#ENK/#5]W\2XM4-N <R.D%/Y'P^_/S<[MWUZ86VNNE+C4W/3,]'?:FG@ML
MK7ST\8=MF:"P[' .  PTCD'J5.1&\-_U3#6_57-;% 1O!\R3YB.Y_P"B@RL:
MQ[,D-W?7JH=JG2;[U>[=7&K\L4F1L,6[=D^^>%,P&-&[!08?DM[(/'::=U'0
MQ4_)# ><8[DJ%4NAGTVIZ&OIJ_R*:%VZ2DCAVME//)P<=QV/13YQER6QD9"H
M[!<)3^Z@YQJW0%3<;E/66>YOM,TDA?*^FA+72#V<6N!/YK2M\/[W=J=T5;J*
MN^'><.CF8]S3CD9!?CKA=CBECE) SD=51P#';!\G4A!SJETN-):9O$+JAE5\
M51N9D1;,;6.'N<_,H#X>Z*N%3I"&XVV]3TI,CVBG@8[(]6">'#_!=UO%N_:-
M(^%[0Z-S'-QG'!&%XM(VFFT]:(Z&"/R]CG. #B[J<]2@@%I\.[I672CJ[KJ"
MJE@HYF2.@J8W.;*W(+F^I^,$#!X/52?7NC([_I]ENH9XZ6%LS9&LBAW-& [.
M&@CN5,XVB4.W\A4P('';PWH$$<U3IJ*]VD4Y?%!4MA\J.4Q!SVGW;R#^BYW3
MZ%U%2U#Z=FH[F(&#:W#9 W\AOPNRSQN?-'(S&&=5<YWFC8WYAR<H.9:<\+7V
MG5=OO,MV;4&EW>@T^"<M</FW''S+SW.MN-9K.II(G5D$%/4MP\.=M>,CH.F%
MU5QVPO<_LO#'9[>Z=U683YSSN<[>[D_;*#W%Q:_R\%W?<HKKC2+-10Q/CGCH
MJBF$CHYO)W.#CC#@<@@@MSE2X$.Y9U6-N9/,;+R!P$'&I-$:B=2BA&I;G)@[
M_B )"#]/G_S4TT]HT6ZPW&BK*QE;-6Q;/,DBY82T@\$G/53"/;!Z6\-1K69+
ML>KJ$'(JKPXN\4[V4.HZNFIQC9%#&]K6^^ '@=<E6T?A[?*JIC;<=15TU+G;
M)%/&]S'M]B"_&%V':]_JXY56S,E:6MS[((Q/I.)MCH[?#+$P4X(W,A !_('A
M7Z"L+M,V9]"Z7XDNF=+YGE[,9 &,9/M_-2)KHP2PYR%7#P[:#P4$'M>B9*/5
M%TNPKN*R8R^6(<;<N+L9SSU6TUSILZBL\])'4B%\A8=_E[R,'/3(4E827%KN
MW"M?B)^1P @XUXR6EI?H*UR/:YVXTPE<SY#^"W=C^?56_P"@M]H80RBU!7FG
M;PUD+) P9Y. 'XZY72=3Z=IM05MJJ981))02&5A+RW:26G.!U^4=5N:0LA8*
M9^=S><#I[_YH(3HC0<EBD?4W&O\ VG.7MDC?-#ZHL=0"22/R7NIM)F'7%RU"
M*H/^,A$7D"+EN P9W9Y^3V[J7/<X,=D\*T/$<+7]R<(.?:YT*ZZW""LLU<+8
M^&+8'4T."#D\Y:1@X.%'Z3P_U!45$;)]57'9"X.W/;(0_GIR]=C;$V-A;CTG
MJ%5C6G( ](Z(-3%9A':9;?*\3M>_>7.9D=N,?DH!2Z!N-LU%4UM->JAD%14B
M3R8XG,:&AQ.WAV".<=%U8EP:2T\+'YD<A .2YO\ B@A6OM%2ZA+ZBW5YME>[
M:/BH8B9=HZMW @X/W45BT'J&0-IY=47+:,1ESFR8<.F?G78)W/C!?GCHJ&6,
M;-V<N01&.EJ-(Z2HJ<S2W&=DI8Z09:YP<7.R>2>. M;X.ON,UON<ETDJWO\
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MM\*]>W#4VHJRWU53)((:8R^J&-HSN:.K1G]Y>7P(9'+05KBTY%>X?^EJ#L+
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MO@>T'RWD NYY6.!OESREYPQWRYZ+C]]K==V.CEO5TO='-0TH'F,AB87G)VC
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M#3G&"N$7D,_TMM5P /E25XG _>QYC7?;*E-]U?6W?54EAL4[Z:<1"8&>-FS
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M9.<M'0],N_5>6FTAJVOJB;MJ**HIB,^6]A'(Z'I]T&MUW2QVZ_Z49"\O<8^
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M.3@YR@/!:W#1^'V/=6R1^8]A'R#YC[*#C5TG_M-N%B,,IIX:9LHD\ST$D,/
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M@O).>4:'M. !A9$0>44H,SWNR,\]5F_$)PX#:LB(+-N?F[=%C?#F7<,K.B#
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M6L>R([W-#2[CG!^@4!=X=:CH6?"V.JM]/1MY8Q[W.(SR>2PGKE=:C>]VX.B
MQWPJ?#!\A>7N!/9!S.Q>&4+JJ.NU%%!4U--('QOBF>, <G@8!Y6_U;HB@U#9
MHJ&.!GE,E$H#Y7MQ@.'4<]U+GPMD! ><=#A6N,$<0B=.&[3USR@Y/)X>ZCK_
M ,*LJ[?)1N],C ]P)'W#/MW4_P!,Z:H]/6ZG93PAE0V,1O<U[G _;*WT4?DL
M+020><E&M;N)WY/L@UEYH1=;7/15 #W2[>Y P' ]OLM-;M'P4-%<(FQQ@54)
MC.)''.01WZ=5+,EW(:CR2T#"#1:#L3-.V,4$36M:)'/PUQ<.<=SRM==-*Q76
M]V^OD8QSJ";S6DO<"/4#P!P?E[J6M!9#R,'*NS@>D @]3[((G_HM%%JRIOS6
M,$LT0A+M[LXPT=.G[JV^H[:R]:=K:&1H=YL>SU.('ZA;1A]1R/1CJD3,!_?)
M00:?0L-9I"VV62.(QTCR\-,KP!DN[]3\RNU3H2&_44E&Z.(TLC&M>QTKVY(=
MGJ.>P4W+_46- )'98Y"2[+_0SN4'+#X;W6TTD$&F9:*E:!LD$DCGY:.@&6E;
MK2OA]!:[Q3WJXQ127.#<ULL<K\!I:6XV\#]X]E-CM']W)OSUYZ+*QHB;C<7.
M]B@AU?HSXF]15X;#M;4&?F1V?F#NBR:WT9'J."5T3(_.>6^J21S1@?92J,",
MOW.(\WIGM]OU5T4+(7[O,)^A00FQ:<N(TY=K572T\D-1&8-K7'&TM+<9P"MI
MIC2T%KL=+;98V&E@#MK&/<<$N)ZGGN5))3M>UK0-KNI59<MB C&XY0<I=X<W
M:@J!^P)J*FB<=T@DD<XD_FTK86+P^BH[A+77B.&:KE'K?%*_EV0<XX'9= FB
M;48+Y#'CCA7L&(Q&WU!O?W01>_:4;<M6T-YF;&Y]-!Y0)>X$#U]AQ^\I'44K
M9+0^D(&'0F+&>.6X7H8[+MOOW5SFCWZ((QH[2L-DI@T1L&'./I>X]?NI/"[)
M>T=&\*QQ)&1T62)N!GW07HB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@*QQ##TZHB"A!<<MX3#AU*(@QN!#R^3F,]!WRK^=[3E$05)+22
M3Z3T6,1ECPQA :>2$1!5WE]'-)(5#'+N_#>&L]D1!<TN'!/*$F-Y+CD?1$04
MBC<QK\D8/*L?3T[R3)'N=W*(@REKS(WU#9W"LCDC?-)&QI#F]2>B(@OA:Z,8
M>03G/"M:\.=)G/HY1$!K_B&Y9PWV*K\GH/5W PB(!:2W8#ZARKB[R\9_DB(,
M)<V)[IG [7\#'7_KA7//GL./DZ$%$061QL)+8F[7-ZE7@8D'F<E$0)&9+2[D
M#D?15E896$QD#/NB(*0O:]CBX$[.%='("<C.U$07EC#P6]50[(QP/IPB( 8&
M'<>RN:.I[%$04:S#-IPJQYY![(B"Y$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
.1 1$0$1$!$1 1$0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g109079g01g50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g01g50.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1944&AO=&]S:&]P(#,N,  X0DE-! 0
M    %C<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!!0Q4Z$A,U%Q@9&Q%31!83)R!2)"P4/_V@ , P$  A$#$0 _ .J0
M
M              ,2IKFP2JQ6*JXSE#+(:Z?SM?$AQ;F8B^'-J;H9/KHSWMWE
M'KHSWMWE(H'CF6GGCE*^NC/>W>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHSWMWE(
MH#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>NC/>W>4B@,RT8Y2OKHS
MWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>NC/>W>
M4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^N
MC/>W>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][
M=Y2* S+1CE*^NC/>W>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.4K
MZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHS
MWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>NC/>W>4B@,RT8Y
M2OKHSWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>N
MC/>W>4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1
MCE*^NC/>W>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1
MZZ,][=Y2* S+1CE*^NC/>W>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,
MM&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>NC/>W>4B@,RT8Y2OKHSWMW
ME'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>NC/>W>4B@
M,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>
MW>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2
M* S+1CE*^NC/>W>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.4KZZ,
M][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHSWMW
ME(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>NC/>W>4B@,RT8Y2OK
MHSWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*^NC/>W>4>NC/>
MW>4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.4KZZ,][=Y1ZZ,][=Y2* S+1CE*
M^NC/>W>4>NC/>W>4B@,RT8Y2OKHSWMWE'KHSWMWE(H#,M&.6Q02)-$UZ)A%Z
M#[,>W_S./Q?O,@HL]L/6.  #6@
M
M
M           0UT_G:^)"9(:Z?SM?$AYU?XN+?!A@ F>0
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M_P#F<?B_>9!99X0]XX  -:
M
M
M       !#73^=KXD)DAKI_.U\2'G5_BXM\&& "9Y
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MW=QA4WLKS]1;QSG;(_6G7<,%HJG31LFW6R-_*3"Y^K)T8<U(9:  >;D
M                                3MO_ )G'XOWF08]O_F<?B_>9!99X
M0]XX  -:
M
M                                                     !#73^=K
MXD)DAKI_.U\2'G5_BXM\&& "9Y
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M=53HZ%0L6F>^6GBDFB6&1S$<Z-5158JIQ153@N/ >@,F;R9O  <L
M                             $[;_P"9Q^+]YD&/;_YG'XOWF066>$/>
M.  #6@
M
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MNO$V#QHZF&LIF5%-(DD+TRUR=)7^NI9&:ZL+62/:U<91%5$7VQL1?V-B+UC
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M>9!CV_\ F<?B_>9!99X0]XX  -:
M
M
M            !#73^=KXD)DAKI_.U\2'G5_BXM\&& "9Y
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MF066>$/>.  #6@
M
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ME/$U>M&(A[ T%1%145,HO0?$<4<2*D;&L1>AJ8/L& ?,D;)&[LC&O;U.3)]
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M0!\10QQ)B*-C$_Y6H@DBCE1.5C8_"Y3>3.#[  ^(XHX][DXV,WERNZF,GV#
M                     3MO_F<?B_>9!CV_^9Q^+]YD%EGA#WC@  UH
M
M
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M16)>[#+14TT#XVRM57(BN:J)G.,<50S=CJHNELIS+(_[[C<-T7EW8WH '#
M                 3MO_F<?B_>9!CV_^9Q^+]YD%EGA#WC@  UH
M
M
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M^L]];Z8J[A<*2[661L=RIDW6YX;R<>G*?G*+^UE[8=2L8_3US:]$5O8TG/\
MHJ:OL>1$TMA.9)'_ 'W&-5T.M+U03TEP6EHXG,5%Y%R*LG#VN4=P1>;YR9V<
MV6LL=A2DN#&LE1[EPCD=PWE7G3QG/"S<<(;4 #AR                  "=
MM_\ ,X_%^\R#'M_\SC\7[S(++/"'O'  !K0
M
M
M                    (:Z?SM?$A,D-=/YVOB0\ZO\ %Q;X,, $SR
M
M                      #$NU(^NMTU-'4/IWR(B)*SG;QSP,L&C5-,Z+I[
M-7R5U15RU]:Y,-EF3BU./A7K-K $S?Q  &              A=3Z<I-04\;*
ME7,EB7>BE8JHYB^#"^(@O837XW/9-6\GS;O)IS>/.3=P=1:F&WH33.FZ/3\,
MB4N\^:5<RRO55<]?#E5)L R9O8  P                        3MO_F<?
MB_>9!CV_^9Q^+]YD%EGA#WC@  UH
M
M
M             $-=/YVOB0F2&NG\[7Q(>=7^+BWP88 )GD
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M:DOM)8+<^KK')P1=QF>+UZD^H@;5J336J*J)51J5;/:-G1$=\W%?":_M#_\
MR.O+%;955:=LC7N:O,Y%<W*?4+KY[2Z^6;17S6EZ:M3:[=34U(O%G9"=TJ?.
MJ'[#K.\6:OCIM66]L;)%W4GA]HB_7]I844;88F1QM1K&(C41.A$(W45CI+]1
M=C5S<L14<BIP5%,Q1^89?"3B>V6-LD;D<QR9:Y%RBH?1X4%*RBH:>EB55CAC
M;&W//A$P:_M$OTFG].OJ:?"3R/2)B\."JBKGZCF(OFZ&-G-/HM15LVO9[._D
MNQ&,5R8;W7Y73GP(0UFT==;A1QU]QOU;#5RIO[C%7=;U<,HG-CH([1S*Z/:7
M/'='MDJF1JUSV\SN#N/,=Q9CM=1"V@5_K"ZW&Y:FI]-V>9:=5;OU$K>=&KCF
M\65,:ZZ0NMHH)*ZV7ZLFJ8DWN3E55:[RJOV&8?&67+)!JFG]2R7;1DUTBCS5
M1,<CFI^>C<_O0T_2E*[5<$M57ZAJ8:Y[U3L>*16[G%<<$5!A\2Y;9JT::G2^
MUJJE/ZW*Y.0RJ*N,]63PT1%?*&NK*"[+)/1Q)F"H>GMN;AGIYUZ>@U^FK:I=
M>WN):F;DF*W=9RB[J=TO,@B.)$+0!7NUVJJZ6.S]@3R12NG5,,>K4<N6X1<=
M!^+HV[W&B2JJK_51UCV(YL<:JUC5QP3@J?8(L]E\R7+#!HVRZ^55QLM5%<'K
M)44DCF(Y>=6HB+Q\I%VB&MUK<[E/4W&HI*6GDY.**!RMX97G5%3P##XES?;I
M>;?:]U*ZJBB<Y<-:KDWE^8SVJCFHJ<R\2IJ>TQV[:'%;[B]]R@DCQ$Z=RJK%
M[GKSUELHB(B(G,ADQ<3%S] !RP
M             !.V_P#F<?B_>9!CV_\ F<?B_>9!99X0]XX  -:
M
M
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M(L\FW>]MA,^,XM1^7,OH '#
M           $[;_YG'XOWF08]O\ YG'XOWF066>$/>.  #6@
M
M
M                                 0UT_G:^)"9(:Z?SM?$AYU?XN+?!
MA@ F>0
M                               $?5V2U5DBR5=LH9Y%YW2T['*OSJA(
M T85%:K?0NS0T%)3+UPPM9]B&:   !@
M                   G;?\ S./Q?O,@Q[?_ #./Q?O,@LL\(>\<  &M
M
M
M                                          AKI_.U\2$R0UT_G:^)
M#SJ_Q<6^## !,\@
M
M                                   !.V_^9Q^+]YD&/;_YG'XOWF06
M6>$/>.  #6@
M
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M2?WIP[$G]Z<3P&5!@AXT37,I8VO3#D3BGSGL >D1=%SN  &@
M
M
M
M                                             '"TWX9_Z2G=)PM-
M^&?^DI]'_'_]>G_KY'^4_P"/7_QU]LK_ !!LOR:/[B&UFJ;*_P 0;+\FC^XA
MM9#4_G+Z='N[/D  X>@
M
M
M
M
M                            '"TWX9_Z2G=)PM-^&?\ I*?1_P ?_P!>
MG_KY'^4_X]?_ !U]LK_$&R_)H_N(;6:ILK_$&R_)H_N(;60U/YR^G1[NSY
M.'H
M
M
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MIN-3&=[J3P(7(3U*<T[6&5E&K9K6<=D !YO4
M
M
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M4 !*M
M
M                              #1]IFM*K1L--4,H4J*:5=U7_FNX\.=
M.I/*=6+,VYPPXMVXIV<5K@T;U4'\VT[^G4?9&:QZF_\ 'VH^02??C(?:=K]V
MMH[<UU(E/V(LB\.G>W?"OYI&;.=5KHZ_27%L"3J^!T.ZOA<U<\Z?FGU;-*U&
MSX/R^';K6)VK,B>SL=A@J[9[M-J]7WSL&&VMCC8Q9))/S6HJ)^=X4+1/EVZ=
MJG-UI]NE5LU8Q6>  #AZ
M
M                                                       % ^J8
M]T;7^J3[7F_;3->56C)J94H&U%+.F$D_-=U+Q3J4HG:5KEVLZFFE=3)!R+-W
M"=/%?"O67;)2M8HM_A\W;J]C!-._M;7ZFS\8;C^K9]CSHLY#V;ZR71MPJ:EM
M.DZRM1N%Z,9\*=9>FS7:'5:SN4\"6]L%/#&KW2^'*)CVR]?U#:Z5J;<V_P ,
MV"O8BQ%._M60 "%],
M
M                                         ('7%ABU%IJLH)43>>W+
M'8RK51<\/)@G@;9F;,WPYM68M1-F7#=PI):"MGI:EBLFA>K'M5,85%P>"<>8
MM[U0>ETM]XBO%*Q$@J\\IC/!Z+E57Q[QK.Q_3'LDU9"V9B.HZ;^6ERG!R(J=
MS\^3[=FM$T\Q^;M;/:BKE+NV):473VF4J*N/<KZM5=(CFX5J(Y41/G1$4L4_
M&M1K4:U,(G!#]/C6[<V[4VI?HZ5.*=B+$?@ !P[
M
M
M             !K&T?33-4Z7J:#=19T7E(%5/:O1%1%\BJ<>RQOBD='(US'M
M7"M<F%0[I.9-O>EO6;4B7&FC1M'7)O+A,(DF791/F1"_8:MTS8E\K_)4;XBK
M'XXJPC8Z1[6,:KGN5$1$3*JIUKLCTRW3>D:9DC42KJ$Y69<8SE55OU*A1>Q+
M3"Z@U7'43,WJ2@<R9^4_*RJM3_M4ZH:B-:C6HB(B81$.MMJ__.&?XVCQJSZ/
MT 'SGU@
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MXO6KZ,ST#V#:6^+UJ^C,] QT-,F7M6N/97_;[LO>FX^5GI';[LO>FX^5GI+
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M*B2)RM>UN45.@I;8]K&_WO5C*6ZW*6IIU8Y58YK43VKEZ$\!*M7H
M                 0^L*J:BTU<*FED6.>.-7,>G0H$P#E^UZTUW=)'1T%TJ
M9GM3*HB1ICRH9-7K37EDDCDN=9+NNX(V1&*B_L^(#I<&G[,M7^RZRNJ)HTBJ
MHG[DC6IP7@BY3BO6;@          -:VB7FIL.EJJOHMSEX^;>YN9?0!LH*WV
M/ZPN.JF5JW+DD6)<-W$5.KTED
M
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M4&T*S66[1VV9\DM6]Z,5C&KW*JN.*KP V\'S#(DL+)&\SVHY/G/H
M
M                    "B?50_V9_P 3_M%T6#W"MWR:/[J%+^JA_LS_ (G_
M &BZ+![A6[Y-']U"JIW-CU^45'[FIZ?"IO5-^X5E^4O^Z65H'\1=.?W;3?Y3
M2M?5-^X5E^4O^Z65H'\1=.?W;3?Y31;[BSYR4_N;?E#.OWN/5_H'/>P3\=X_
MU;ON..A+][CU?Z!SWL$_'>/]6[[CB5:G_5'?SNU_HN(VS:'U/J_3]--/6Q4U
M%'&B4\+N*.1$QT+PSA.?K)+U1W\[M?Z+BS]F_P")5J_4-^Q .>M*7;4=DNTM
MEL[\U,RK"D:KS+SY3BB9PA,:WV=WRS6MU\K[A'5O8K5DPF',551$X]/%>@_-
M+?TV4OREW^6I<&V+^CZY_P#1]] (G87?:N\:=GAK9.4=2*UC7+SJB[V$^I"G
M9GW!FTF1UE:CKARZ\BBKCCN\>E.C)9?J<?<F[?K(_P#S-,TM_3;2_*7?Y:@?
MNM]GM]M%K=?;C7QU4K5:LJ)[9BJJ)S]/%>@]](RZOUO;&VJEK4AH*9-R29>I
M>9%3/'F7F0MC;#_1_<_^C[Z&I>IQ]R;M^LC_ /,"MM26>[[.]0PJRK:Z9R<I
M'-&F$=S9X<_.I;&U>M6X[+4JW(C72[CE1/TT-8]4E[JV3]3)]Y"<UXQSMC,#
MFM<K6L8KE1.;^43G#'QZG/W(N?Z;/_(U?U0OXT4WZK]S39/4YS1);;I&LC.4
M1S%5N4SCNN)J>WNMIJO54;::>.58H]U^XY'87#>' -6EK#^B2K_4L_S&E,;.
M;3J"_0UMNLDS:>CDW>R955."<<93/'IYD+GUA_1)5_J6?YC35/4W?S>]>.+_
M ,P*_P!2V6[[.K_3N95M=,Y.4CFC3".QC/#GYU+^K]5LHM"^OSVMWEBWFLPN
M'.SC'U%8^J2]U+)^ID^\A,:DIY9]AU$L2.7DV(]V$SPRY/WH!I6F[-==I5?4
MU=UN38H(UPJN5.?GPU.*])Z5OKKLNU+2\A6LJJ*1<X3BCVHJ91<*G'"F/LNT
MK/J6"I92:EFM4L;N,$:*Y7)A.ZPCV_9T$OJW0%%;)J>/4&N7OD5'*QLM/OJU
M.&>"R\,\ Q?%KK8[A;J>KA<CF2L1R*GU_616O?Q0NGZE3VT93PTNF:"&FJ.R
M86,5&R[N[O=TO1E<>4\=>_BA=/U*AKG_ &1:FM^F+O4U-S>YL;V(U,-5>OJ1
M39MJ>T.U:DL++=:6R32NE1ZJK')A,.3I1.LUG9#IBW:HO%3375LKHHX]YO)O
MW5SQ-DVH;.*/35I;=;!+.Q(Y$:]CG*JM3"]UO9ZT3HZ0QMNQ/3]38-.5=;<F
M.B?,Y7HQ51<,1J+GA\YH>J]07776LELE#.V"B21T3$YD5J+Q<N5ZC>ME&I*G
M46B[A2UDCI:RG8]B/<Y7.<W<3"KT\ZJ4[8+4^LURZW2W1]IE=(]G9.%WFNX\
M/;-YUX<_2&MGU1H&MT;;FW:UW9LKXU3E$8J93@JY3P<"U-F>K)-2:3EJI]SL
MRFWF2(U%3*HF47BOA0TB_P"S.:WVR2HN^NJE*/F=RL+E:O!>&%EPO23VR&W6
MJS6RY24%W]=(%<JR.2#<W>#>'MG9_P#L"IX:R?6^J5BOUS[$AD<[&^BX9SJC
M4Y\?.3ZZ6U!I6]0RZ4J&W&%,/S'(S"\RX7BA*UVC-+ZSN=0_2]V;352Y>Z%(
MT>U57*\,.3"&H7JEU'LYNT,;;A,U'HJQ[DKD8]$QSM1<=(8OG6FIWZ>T@^Y.
MB1*I6HUD;^*;R\_,OC7G*7TKI>X[1'U-RNUT2*)KU:CGJF7.YU1/%P-VVMU$
MUXV94->C%;EZ22(G'"<4X_.:;LQT;4:FM$LE'JJ>VR1RJCJ6)JNX83#N$C>?
MCT= :^8:ZZ;,=6,IGU;:FWNQO8XM<S@J\R\Z9-BVQ:86YT*ZJCJF<DZ)CDB1
M/^1/00VJ="6ZW5K8+[KA[JE$RB2TV\J)PZY>'0;WKNGCIMD7(T\RSQ,C3=DW
M=W>3#N.,KCR@53LRT0_5<LLS*ML'8KT545,YPJ+^\Z=HXNQZ6&%5SR;$9GKP
MF"F/4X*G)W1,\<\W[)=@
M                                                           #
MGWU3GNO8_P!1)]Y#H(Y]]4Y[KV/]1)]Y"G8^]A%M_<3Z?+H"'\"S]%#Z/F'\
M"S]%#Z)EL        !SW</ZR[?E,7^G:="'/=P_K+M^4Q?Z=I5LO&UY2BVWA
M8_M#H0TG;'^(=?XOW.-V-)VQ_B'7^+]SB5:TGU.'M+IX_P"$T?;-^/E;XO\
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MMKY/Y-9DAF8G,YJKG*%R[&OQ#H?_ 'H0I[4?],2_*8_NH&M[]4<N=.6E?_\
M:7[BFH:4TAJ75^G(6)61TEJB3=B:[BCUPF5PBYZ$-N]4;^+5H^5+]Q39]C7X
MAT7_ +^2T"B+7<;[HO451;K?(G96]R&XOM7*JIA>?Q=/2;1JC9UJ2IL\M]NM
MPCGJ-WE'P+[9J<R<<XYL$1JW^E[_ !D/_B7_ *J_$ZL_4)^X"NO4^7ZLKX[A
M;:J59(Z=K9&*O.F>&/J-/NO].%)_>L7^<3/J;?=>]?J(_O*0UU_IPI/[UB_S
M@-_]49^)M!_>#/\ +D-"T;I/4FK]/LAAJXZ2T1.5&;W%'NPF>&<YQNF^^J,_
M$V@_O!G^7(2NP[\1(?UJ_=:&*>TY4W+0NOH:!\V6)4LBF1O,]F_A5\F?*6IM
MHU9662Q4L=K=R4U6Y,R<<M;AW-X>"%8;1_Z4W_*&?>+!VWRVU-(V^*L8Y:MV
MXL+FIS=R[G7JY^ :UO3.RWU_TW#>:NXR-J)V<HQ&JF$3'3P7PD7LBI:.IUP^
MW7>C@K)%5SF2/155CF(JY3CX$/VQRZBHK/'24.J;+#2/;P9)=&-<S/1C>X<Q
MOVR'2-!:IY;B^[4=RN+TX<A*V3<147*Y1RYSE?(!:3&HQC6M3#6IA$ZD/T
M
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MSLW7LAED<[AG'.Q.G'2>NOK=I"^7%;E9M24%'6N[IZ.>Y&N=G.]E$7"^(O<
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M$CP=&:<N-)<[3!/05<=7$U$C66-55%<B<><D@
M
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MC';S<81F>O&,_6!8].]9((WN3#G-153JRA]@
M
M     43ZJ'^S/^)_VBZ+![A6[Y-']U"E_50_V9_Q/^T718/<*W?)H_NH55.Y
ML>ORBH_<U/3X5-ZIOW"LORE_W2RM _B+IS^[:;_*:5KZIOW"LORE_P!TLK0/
MXBZ<_NVF_P IHM]Q9\Y*?W-ORA.@ E6@
M
M                                                       !S[ZI
MSW7L?ZB3[R'01S[ZISW7L?ZB3[R%.Q]["+;^XGT^70$/X%GZ*'T?,/X%GZ*'
MT3+8        #GNX?UEV_*8O].TZ$.>[A_67;\IB_P!.TJV7C:\I1;;PL?VA
MT( "5:
M
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M-;V>W*Y733D<UZIWP5C7*QR.145V$1<X7QJ;(
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MYSU\3>".T_9:*PVUE#;8N3@:N<95<KA$SQ\2$B
M        #GWU3GNO8_U$GWD.@CGWU3GNO8_U$GWD*=C[V$6W]Q/I\N@(?P+/
MT4/H^8?P+/T4/HF6P        '/=P_K+M^4Q?Z=IT(<]W#^LNWY3%_IVE6R\
M;7E*+;>%C^T.A#!O5IHKU0OH[E V:!_.U4YO"G4IG E6M<TUHJQZ<G?-:J/<
ME<F%>]RO5$SG@J\W,;&    %<;=D1VD&(O,L[4/FQ[,--5=FHIYX*I9)86N=
MBI>B*JIU9-LUAINGU1;&T55/+"Q'H_>CQGAXR5MU*VAH8*5CE<V%B,15YU1
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M$73G]VTW^4TK7U3?N%9?E+_NEE:!_$73G]VTW^4T6^XL^<E/[FWY0G0 2K0
M                         ?DC&R,<QZ(YCDPJ+TH8=KM5#:HY([;20TS)
M';[FQMPBKUF:                                      #"NUJH+Q2I
M3W2DAJH$<CT9*W>1')E,_6IFHB-1$1,(G!
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MPU54N9I6-PZ1?"O29H
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M\&3PGNUNIW[D]?21/_-?,UJ_6H&:#YBD9*Q'Q/:]B\SFKE%/H
M
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M>)]5==24:(M7500(O-RLB-SY0,@&-27"CK%5*2KIYU3WJ1KOL4R0
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MLQG*KSY4#8]N;ZV.DMSFK4I:TD_XE8%5%YG<^.@BIK1HR\6Q?8M7P4-W:J+
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MM"'^8,_5)]@%;["Z^J?:[A;JN9\W8DRHUSURJ)A$QXN!9Y5.Q#^>:@_7EK
M
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M,;_SFH[RE/[5;M3:LJ[9IVR3-JI'S(^1T:Y:WHXXX_E%OTS%CIXF+SM:B>1
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M:PU?;J2NMU#IZ&CK:V>5$>V-K5W6]?-X%+(I][D(^41$?NIO(G,BX ^P
M                                     !1/JH?[,_XG_:+HL'N%;ODT
M?W4*7]5#_9G_ !/^T718/<*W?)H_NH55.YL>ORBH_<U/3X5-ZIOW"LORE_W2
MRM _B+IS^[:;_*:5KZIOW"LORE_W2RM _B+IS^[:;_*:+?<6?.2G]S;\H3H
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MS:4LEFGY:V6Z*GEYMY%55^M2; &/7T--<*=T%;"V:%W.UQ T^@M,T\[9H;1
MV1JY1=YRX7RFS #%KK?2UU"^CJX6R4KV[CHUX(J8QC@?MLM]+:Z&*CH(6P4T
M>=R-N<)E<KS^%5,D 05VTC8;O.LUQML,\J_E*KD^Q3*LM@M=D8YMJHXZ9KN?
M=ROVDF (Z[V2W7A8%N=(RHY%V]'O*O<KU\%)!&-1B,1.Y1,8\!^@"-M%CMMG
M?.ZVTC*=TR[TBM55WE^=22
M                                                 !S[ZISW7L?Z
MB3[R'01S[ZISW7L?ZB3[R%.Q]["+;^XGT^70$/X%GZ*'T?,/X%GZ*'T3+8
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M#=='V"ZU:U-PMD,TZ\[U5R*OD4])M*V2>*CBEMT3F4C^4@3*]P[AQ3CX$)H
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MCJ4;S;V4^Q24 $+9]*V2S3<K;+?%3R?G-557ZU)H
M                        *)]5#_9G_$_[1=%@]PK=\FC^ZA2_JH?[,_XG
M_:+HL'N%;ODT?W4*JG<V/7Y14?N:GI\*F]4W[A67Y2_[I96@?Q%TY_=M-_E-
M*U]4W[A67Y2_[I96@?Q%TY_=M-_E-%ON+/G)3^YM^4)T $JT    *N$RO!
M-=NNMM.VJ98J^YQ12(N%:C'.^Q%/JT:RT_=YDBM]SBED7F:K7-^\B ;
M     ?#98WO<QDC'.;P5$5%5 /L         ^&2QO<K62,<Y.=$<BJ@'V
M        !^/<UC5<]R-:G.JKA$ _0?+'MD;O1N:YO6U<H?0          C:6
M^VVJO=5:*>J:^XTK$?-#NN16-7''.,?E)T]($D
M
M      <^^J<]U['^HD^\AT$<^^J<]U['^HD^\A3L?>PBV_N)]/ET!#^!9^BA
M]'S#^!9^BA]$RV         Y[N']9=ORF+_3M.A#GNX?UEV_*8O].TJV7C:\
MI1;;PL?VAT( "5:      (^]7F@LE*E3=*A*>!7(U'*U5X_,BF933QU-/'/
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M*?5FO=NO-$ZKMM2DU,UVXKU:YB(N$7\I$ZT D0?,;V2-WHW-<WK:N4/H
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M@F>DBJBP/5S415SCBB&X@
M                                            .??5.>Z]C_42?>0Z
M".??5.>Z]C_42?>0IV/O81;?W$^GRZ A_ L_10^CYA_ L_10^B9;
M <]W#^LNWY3%_IVG0ASW</ZR[?E,7^G:5;+QM>4HMMX6/[0Z$('6>IZ32MI6
MMK$5^5W61HN%>I/&I;2M)+JVR)312MBJ8W;T;G<WB7ZB5:B]#;4*#5-R6A=2
M.HJA456(Z3?W^*<.9"P2H=FNRVMT_?6W*[U%.YT2+R3(7*[CPXKE$Z,EO
M!7.W3\48_P!>TV&&Z)9M"4]P=$LR04C7[B.W=[#>LU[;I^*,?Z]IG7_^BF3Y
M"GW0(VFVJ-KJ"&6UV*LK:ER*LD$*N<D7'AER-5.)+Z,U[3ZBN$UOJ**6W7")
M-Y8)G*JXX=:)UGAL6I8(="4,L43&RR*_?>B<7=TO.IKU5&V#;K1\DB-Y:)5?
MCI[EWH0#7MJFH:Y^M[8WUKJ84H:M$B3>7_BMUZ8W>'3CP\Y;>D]05-YHZFHN
M-IFM*0JG"=W.G'*Y5$X)@K_;!^/.D?E<?WVE@;09Y:?1=Z? BJ_L25,IT)N.
MX@0%5M&?+7SP6"Q55VBA=NNGC<K&9Z>.ZJ<_A)'2>N::^W!]NJ:.:W7%J*J4
M\^<N3'.F43J7R&B[-:;62:1HY;"ZU)12J]S72OP]R[[D7>[A>G/29\>FM3SZ
M\MEWO-3:HI(6*Q6P2JCWMP_HW$SQ<H&RZNU_3Z:OD%OJJ-SV2L5ZS))C&,<-
MW'%>)EZ.U9/J.IJ&NLU70TT;=Z.>;*)+Q3F16IU_4:9KJ"*HVMZ>CGC;(S>:
MJM<F47NF%N,8V-B-C:C6IP1$3"(!6-JVMPW.W/DI++52UZ2JQM)$Y9%5J(B[
MRN1O#G7HZ#)MFU*F=634M]MD]GFCC61K9W*JO1$5<)EJ<>KKR1GJ=:2!=,5]
M6L3%J>S7Q\ICCN\G&N,_.OE/':730R[3=*)+$QZ25#4>CDRCD1\?!>OG DJW
M:E44T:U*:7N#K>B_SERN:F.O"LYC?;5=:6[VAE?1/26GD9O)XNI3#UC3Q.TG
M<85C;R7(JFZB81#4MB2JNAY$555$543P=R!D:(U)0U5CNE99-/,I'4[U1:>!
M4S*J(G4W]Q7&F]5W*EV@7*OCL=94S2M=FC:]=Z/*]/<K]AN>P3W-NORE?L0P
MM#?TRWW]"3[P'EM?U+7U&GH*=UFJJ5DBI(Z=7+AB\4W5[E.)LNR_4U?<*&@M
M]18ZJF@C@1$JWN56OPB\?:IU=?2?&W;\2O\ ]YOV*;+HQSF:(M;F)ES:1JHG
M6N (W4FNX;9<_6VV4$UVKT3,D5.J]QS<ZHBF';]H[?7.*BOMGJ;0^7@Q\SE<
MUR]6=U$ZS1=",U+5ZCU156!:!)DJU;,M4[#FY<_")W*\."DOK'3>L[[24\=W
MJ++&R*5'MD2547/'AE(TZU WS76JV:3H(*J6E6H;(]&*B2;F[Q1,\R]9KLVT
MZ22+E;3IVON$*,1SY(]Y&M7I1%W%1<&#MGB<FEK1'.Y'NY9K7+G*+W33?M)T
MT,&FK='#$QC%IV91K43/<IS@1ND=94NI;745-+ ]E33\)*979<U>/#F\'45"
M[55R3:@RY>LE6LZ(J)0;Z[R]RY,^U^?FZ#;-ES$@VAZEAB[F/*NW4YLY3TG@
MO]/<'Z#ON/ M#3MRGNMKCJJJAEH97<\$BY<WZD/2]W6ELUNEK:^1(X(TRJKT
M^!#.*K]4-431Z4I8HT5(WU+=YR?HOX 9%-M0J:O^5I-+7&:AS_.&JY4QUXW"
M&V?W&"Z[5+G64JJL4K%<F4PJ9WUPJ=?$MJUT=/1VZ&FIHFQP-8B(Q$X%6:-I
MXJ;;#>V01MC9ER[K4PG.\#=M9:SH=,\C%(QU36S+B.FBXN7R(O@\IKB[4*FE
MQ)=M+W"AHU7C.]7.1/'W"$7:&)==NMT;<8D>VFI4DB8[F:Y.2PJ%F:DHZ>ML
ME73U;6+ YG'>3@@'M!=*.>U^N,,['4>XLG*(O#!HS=I51623NLFFZRXTD;E:
ME0QZM1V%7F3<7J,'8I$Z[[-:VCJG.W'5$D#5SS-Y-F,?.IAVJWZST(V2DMM)
M%=;8CU=&R-%1^,]/<\Z^,#>M&ZPI-3-FCCBDIJR#\+3R9WF>5$ZT\I&T-ZMD
MFT>>V1V6&.O:Q56N14WG<'<.;/0O3TF%LVO%GNM^N3XK:^WWWD\U,;G*N6Y:
MG-G]'H(NU?TXU7ZIWV2 ;#J;:'2Z?U*EIJZ-[FK'RG+-DYUPG<HW&57B1-9M
M3GHD2:LTQ7P4*NPE1(KFIY%9X"/U#3Q5.VZ@9/&V1B1,=NN3*93=-WVET\4V
MA;M'(QJM2'APYN*<W4!.4MRI:FV,N$4S5I'LY1)%7"8ZS1^V/45<DSK)IVKN
M-'&Y6]D,>K4=CJ3=4\M#4\USV1LI628D=%NM55YD3"D%LXU[9]/Z;2VW-)(J
MF"16KN-14>J(B<,JG'@!*Z2U#?=6ZEDE9*RAH:.5K9:-V>45,\47BG4O1TEH
M%7[+**IJ]1WK4'(.@H:MZI"CTPKTRO''-T?66>[.ZN.?' "K*9WL@VQRK(W>
MI[3&L>[SHCN[3/U(;YJG45%IRW+55S^*KNQQ-]M([J1.?H-$V4Y?KO6TDV$G
M6H3>;^;W3R/VONK:K7.F:.D2+?WUY%)EPQ[U5N,\%^Q0)Q^TBX0P]D5.DKA%
M2=,JO<N$ZU3<-WL%XI+[;(JZWR;\$B>1<9POE-)GI-H<M.^&5]D=$YNZJ*_*
M8\V9>R2PUM@M%535U133;TJO:E/(KVMYNM$Z@-[-,U!KN.@N[K7:;=-=JZ-N
M])'"Y41B<.=41>M/*;F4Q0WBFT3M*O?KUE8ZF-',EC1%5,HQ<+G' #,N>MK]
M=KS1V2EHEL53.BN5]2Y5541%7N5[G\W!:=MCFBM]-'5R<I4,B:V1_P"<Y$XK
MY2I:^L;KO7MHJ+#%*M)1,S+4/;A$]OPRF>M/*7$ ([45T2S66JN#HEF2!J.W
M$=NYRJ)S_.2)K>T?\2;K^K;]] -8IMJB5U%#):K#65M2Y,R0Q.54CZLN1JIU
M^0]K9M5MT\-4EQHYJ"M@_P#TKU5SW+U(FZB_49>QBFAAT/1R1Q,;))Q<Y&\7
M<$YU-9DHJ:7;Q5-D@C<WD&/W7-14SNQ<<?.!)U.U.:CD8^OTQ7TU"YV$J9%<
MB>16%ALN%,^W)7I*WL56<IRBKPW>LU?:[!')L\NZO8BK%&CF>!=Y$^Q36;Q4
MS4^P&EEA<[E%I(&JJ+QPKVHOU*!(2;3I*B>9+%IVMNE/&Y6+/$YR-7"XX=PO
M43FC];T>HJB6D?!)0W&-,NIILH['#K1,\Z#9930T^B+9R$;6;\37NPG.JHBY
M-.UXQMLVLZ=J:!$CGJ&*LB-_+]LF5\B ;7K'7=/IB\4=%54CI&5#=Y94DQN\
M_1A<\Q"UNU&>F8ZH;IBX.MR*O_%.5S$W?SL*SFQQ([:=#'/M'TY',QKV+C+7
M)E%XN+&U330OTM<X%C9R78ST1J)P1-U0,"?5+9])-O5GHY+BV1%W88UP[G5%
MZ%ZNHJ#9KJNY6VZW9\%CJ[BL[DWF,>O\CQZ>Y4WW8>J^PV9F>Y9*]&IU)E2(
MV'>[NI/TV_:!Z;:*K>IM*5=0Q8$[(Y1['<[.,:JB^(SY-I51!2M?;],W"MHX
MF(BU";S&KA.*IW"Y,?;HQLDFF6/1',=5JU47I171EDVVGACM=/ R)C8>2:FX
MC4QS=0$9I?4=)J>Q.KJ'*)Q8]B\['8YO(J&C;'%<V]ZP5C=YR5&4;G&5WG\#
MRV&9BI;] U5Y)L[U1OAW6GOL8]W]7?*4^\\#:]'ZQCU#<+E0R4;J*JHI-Q8W
M2;ZO3*IO)P3AS>4]=<ZKBTK0T\SZ=:J6>5(F1-?NJJK\RFEZ@;[$MJM%<X^X
MH[JWD9=WF3VN<Y\2GK?&KJK:K1V]$5U%:X^4F3G3>[K"_P#<T"SJ.5\])#++
M$L,CV(YT:KG=5>C)!ZQU;0Z8IHW569:B95;#3L]M(O#@F,]:>4V(IJ]JM=MU
MIZ6K;RE/3\F^)KN*(JMC5?K FG[3ZNF1);CI2X4M'TSN5RHGC3<-\HKM2U]I
M]<:&1L].K%>BM7GPF<> ]Z^C@K:.2FJHFR0/3"L5.!5.PVHE=HR\4ZO5\,<L
MFXY?U;> $A'M:AF;.RGLM3/61R.C;3PO5[G854RN&\"P;+627"V4]5/3/I9)
M$55A?[9G%4X\$*VV&TL"K?IW0QK-V5A'JU%5.Z?S*6L!4VT[^D73/B3_ ,RS
M;Q<Z6T6Z>MKI6Q01-5SE5>?"9PG6O#F*RVG?TBZ9\2?^9D;?)9DL5OIXEQ'-
M/W65PF45N,^50,MFT>OJ&.GH=)W"HH\]S,CG)O)UHFX;+H[5=#JBEDDI-Z.:
M-<20O]LWRHG6AJUMIMH,=OIF4K[*V!(V[B(_'#'ZL_-G6FKM:M8W:ONTUO\
M^(@1JP4LBKNNRWCN[J(G!/K D[]M 917F2U6FUSW6MB_",B<K48N5X*NZO4H
ML6T&.LO,=KN]KJ+362\(FS*JH]<IP1=U.M"$ONEM0V/559?]+/AG2K57SPR)
MW2JJKP3@O7X#PI]3TU=JFU0ZSL,EON<+T[&GWE1-_*<>CAS*!NVL]74>F(8>
M7C?45,RXC@CSO.Y^I%ZE-=?M*JJ-\3[UIFMH*-[D1:ASU<C<]?<)@S-I&D*O
M4+J*OM%1'%<*1<LY7VKDX^!>OJ-7O&I[W3V]U)KC3KI[:]422HC543G\2=.
M+<HJF&MI(JFF>CX96H]CDZ45,GE=;C36N@EK*V5L4$29<YRF-I:6AFL-&^TI
MBB6-.315SA,<QHVWZ>6+2U#'&J[DU8UDB)TMW7+]J(!],VGU=2U9K9I2X5E)
M^3,USD1R=:)N&S:.UA0ZGCE;"UU/60JB2TTN4>Q>/6B9YEZ"3TY3Q4UBHH8(
MVLC;$U$:B<.8K2H8VU[=(64"(QM3 CIF-YE5<Y5?*H&L;0=0U5UUY:F5M@G6
M.DE<QM&]<]DIGH[GI\2\YM&I-2U;-#5+*?2=3;V3.W'-:JHD>,+O+W"<_,>6
MMOZ:-,_K6_8AOVT7\2KK^K;]Y *_V.:HN#+71VSUDJYJ=\JHM=O+N)G'1N]'
MC-WU;K6FL-5'104TMPN3^*4T&5<B=:X1<<Z>4C=AWX@T_P"M=]B&D6_U^KMJ
M=\FLJT?9K&87LIV,,3<3AW*]2 ;E'M)DIJN&._6"KM<,KMU)GN5[<]''=0VG
M4]_CLFGIKLV+LJ-C4>C6OW=Y,9Y\*:!JRQ:YO=EFI+I-96P*K5Y19516*CD7
M*+R?#F)36=-+1;'V4M1(R2:&CCC>]BY:YR,PJHO2@'Q%M1[,IHGVFP5M?*YN
M7LB5RM8O5O(U44E]$Z[I]2UE10RT<EON$+=YU/*[*XX=:)UH>FRJFA@T1;5A
MB8QSFN5RHW"JN\O.IJ"QMI]NKEA1&<K$F_A,9[EOH SMJR.M&H-/Z@IU5LK)
M>QY%3AW"KCG_ .M2RJ>5L]/%-&N62-1[?$J9*]VYX]BD>,;_ "S-WKSOM-UT
MUO+IRU;_ +;L2+/CW$ D0               43ZJ'^S/^)_VBZ+![A6[Y-']
MU"E_50_V9_Q/^T718/<*W?)H_NH55.YL>ORBH_<U/3X5-ZIOW"LORE_W2RM
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M:( UW0>GETW8(J.2599U57R/SE%555>!L0
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M376G=3S.F<Y&JY%X*J]2J:U2V?5>DM576HL5KBN-%7/1V\]Z(K$RO_,WB6X
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M+::FA@CSN1,1C<]2)@UFDTO,NMY]07"I9*K(^2I8V(J<FWNLYSS\'+S&U
M              43ZJ'^S/\ B?\ :+HL'N%;ODT?W4*7]5#_ &9_Q/\ M%T6
M#W"MWR:/[J%53N;'K\HJ/W-3T^%3>J;]PK+\I?\ =+*T#^(NG/[MIO\ *:5K
MZIOW"LORE_W2RM _B+IS^[:;_*:+?<6?.2G]S;\H3H )5H
M
M
M          <^^J<]U['^HD^\AT$<^^J<]U['^HD^\A3L?>PBV_N)]/ET!#^!
M9^BA]'S#^!9^BA]$RV         Y[N']9=ORF+_3M.A#GNX?UEV_*8O].TJV
M7C:\I1;;PL?VAT( "5:
M
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M))*F5VY'O+P3PKP\7 E6MQ!36S':A<KYJ!EMO$<3^61>3?&F[NKX4QU9+E
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MD.ZYK5SC+NGACH-M
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M^C8---J)Y)GU5QJ5WIIWXXKE5X<$ZSP?I"=VT%-1=E1<BC-WD=U=[F1.?FZ
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M!'/OJG/=>Q_J)/O(4['WL(MO[B?3Y= 0_@6?HH?1\P_@6?HH?1,M@
M .>[A_67;\IB_P!.TZ$.>[A_67;\IB_T[2K9>-KRE%MO"Q_:'0A"ZMTW1:GM
M3J&X(N[G>:]N<M7K)H$JUHFBMF=KTM<'5L<TM5485&.D3&YQ3F1%QT&]@
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M0:9HC2MRTO55-.RX0SV9[E=%"]J\I'Q7''@G3QX&Y@
M                                                !1/JH?[,_P")
M_P!HNBP>X5N^31_=0I?U4/\ 9G_$_P"T718/<*W?)H_NH55.YL>ORBH_<U/3
MX5-ZIOW"LORE_P!TLK0/XBZ<_NVF_P II6OJF_<*R_*7_=+*T#^(NG/[MIO\
MIHM]Q9\Y*?W-ORA.@ E6@
M                                             "+U!8+=?Z5(+I3,
MF8BY:JM3>:O@7' UKM86'/&2Y.9^8M4Y6^+!O( CK'9;?8Z1*:V4T4$?3N-1
M%=X55$XDB
M    #GWU3GNO8_U$GWD.@CGWU3GNO8_U$GWD*=C[V$6W]Q/I\N@(?P+/T4/H
M^8?P+/T4/HF6P        '/=P_K+M^4Q?Z=IT(<]W#^LNWY3%_IVE6R\;7E*
M+;>%C^T.A  2K0
M
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MIJRAI8ZEW),:Y5;NJYV$3CS(B(>VJ%U?H&."YR7UUUI'2I&Z.?.$545?SO\
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M'6Y[#JZ>HQS\E(C\>10,D&$^[VUDW)/N%&V7\Q9FHODR9F\U6[R*F[C.<\,
M?H,-+K;UC?(E?2+&Q=USN6;AJ]2KG@I]4EQHJQRMHZRFG5.=(I6NQY% R@0&
MO+H^S:3N-;$_<D9'NM=U*[@BIX>)A[+YJVHT90S72IEJ:F3+UDE7+E15RGU
M;6#"J+O;:>18ZBX4<3T_)?,UJ^15,J&:*>-'P2,D8O,YCD5/*@'V#'JZZDHT
M1:NJ@@1>;E9$;GRJ?E)<**L54I*RGG5.?DI6N^Q0,D'E4U$-+$LM3-'#&G.^
M1R-1/G4_:>>&IB26GECEC7F>QR.1?G0#T -1VEZE73]C5*5V;C4N2.G:B\<J
MO/A/!D#;@59L:O-WJ+E>[;J"LGJ*JF5B-Y5^\J<7HOBYBSJFH@I8EEJ9HX8T
MYWR.1J>50/4&%-=K="UCIJ^DC:],M5TS41R>#B9$-3!/#RT,T<D7Y['(K?*@
M'J"O-9;0$M6H[/;;7-0SLJI49/(YZ*D2*Y$XJBX3GZ3<IJRFK+5-)#<8&,1N
M'5$<K5:Q?'G" 2**B\RY!K6SZU3VBQ.AJ;LVZNDF65M0U<INJC4PG%>I5^<V
M4 "O-M=_JK)ING];:F2GK)ZAK$=&[#D;NN_>B&)2Z*U;)3L?+K.NC>J95N57
M'U@6<#4=)Z;O5IN#I[IJ*IN42MPD4BKA%Z^)L=5<Z"D?N5==2P/_ #996M7Z
MU RP>-+5T]6S?I:B&=O7&]')]1IFV"]U-ETH];?-)#6S/:V)\;L.3NDSCYE
MWD%5VW1^K*RV4M2NM*V-\\39-U5=W.\B+CG\)\:-U#?K9K=VF=05"5J/:JLG
M7.]G&<\Z\."@6N#'FKJ2&=L,U5!',Y,I&Z1$<J>!#Q]>+;RW)>N-'RN<;G+M
MWL^+(&< G'F   Q?7&BY:2'LRFY6--Y[.5;O-3K5,\.= ,H&'372@JI>2I:Z
MEFD_,CF:Y?(BG[4W2@I9-RJKJ6%_YLDS6KY%4#+!\Q2,FC;)$]KV.YG-7*+\
MY@:ANT%DL]37U3VM9$W*9Z55<(GE5 )$%':(U5?Y]=T<EXJ9^P+EONAIE?W#
M4=C=PG4F\A>( %7[/-0U5QU+?JRXW)R6R)W(Q,FE1(V.3=YL]/!2QZ2OHZS/
M8=73U&.?DI$?CR*!D@\YYXJ>-9*B6.*-.=SW(U/*IBP7>VU$B1P7&CE>OY+)
MVN7R(H&< 85VNE):J1\];411-:U7(CWHU78Z$SS@9H*6TQ7WG6==4U<FJ/6N
M))=R&EAF1JO1.E$SGH4M^IKJ.B1$JZR"'A_\TK6JOE4#*!C4E?1UF>PZNGGQ
MS\E(CL>13TJ:B&EB66IFCAC3G?(Y&IY5 ]08CKG0-=&UU=2HLGM$65O=>+CQ
M,L "J=I=VNM3K2S6&R7*>@=,N[,^)RIC.,*J?.?5RTEK*@HY*NDU=4U4L*;_
M ",BJB/1.?I^<"U :;LLU1-JC3B5%6U$J8G<F]6HN'81./VFY  # ?>K7')N
M/N5$U_YJSM1?)D#/!\Q2,E8CXGM>Q>*.:N44\JNLIJ-J.JZF&!J],KT:GU@>
MX,:DN%%6*J4=93SJG/R4K7?8I [2KO+9='7&JIY%CG6-T<;TX*URM7"IX<@;
M.#6-"5-1'H:@J;Q4R33[CWR32KERY>[&?FPAK6Q:ZW2^T]RN%RK)YHN5Y..-
M[LHW@U<I]8%F \YYHJ>)TM1*R*-O.][D:B?.IH=LV@1UFNZVUNJ*&.U0Q9;.
MZ1$5S^'Y2KA>D"P >:3PK!RR2Q\CC._O)NX\9B,O5K?(D;+E1.>JXW4G8J^3
M(&> BHJ(J+E%Z3#2ZV]8GRI7TBQL=NN?RS<(O4JYYP,P'@M;2I3MJ%J8$@<F
M4DY1-U4\?,1U;J:S4E+-427.D<R)JN<D<K7NX=2(JJ!, @M)ZE@U)#4S4L$T
M443D:CI&JW?STIE$,^6\VR*3DY;C1,D_-=.U%\F0,X'PR:-\7*LD8Z/&=]'(
MJ8Z\FA:JUZVWZGM-LML]#+%4N5)Y7/14CX]><)\X%@ QX*ZEGIUGAJH)(4X+
M(R1%:GSHN#P9>K6^3DV7*B=)G&ZD[57/BR!G@(J*B*BY1>D*N$RH'XY[6>V<
MC?&N#]*NY1=>:Z6+*NL5J7+L<TLG'"\?^CH++FGIJ*%%GFB@B:F$5[D:B>4#
MV!B4MSH*M^Y25U+._P#-CE:Y?J4RP !A5%VMU,]65%PI(GISMDF:U?(J@9H-
M1N^OK307".BIU?6U#E3*4[5>U$5<9WD14Z#;@        *)]5#_9G_$_[1=%
M@]PK=\FC^ZA2_JH?[,_XG_:+HL'N%;ODT?W4*JG<V/7Y14?N:GI\*F]4W[A6
M7Y2_[I96@?Q%TY_=M-_E-*U]4W[A67Y2_P"Z65H'\1=.?W;3?Y31;[BSYR4_
MN;?E#XU\RO?I*XMM"O[,6/N-S.]\V..3F/245Z?J.!MH[)2OWESN[V<87.<>
M#)UX>4=+!&_?C@B8_P#.:Q$4E6O4  #3MKEP2W:$N,F]A[T;&B9XKO.1%^TW
M$J;;W71I#9K>]^ZV:?,N>9&Y;Q^I0(O9]J2]V#2]+1TNC[C51\9$G8QZ(]'+
MG/M5X<2P-(:FNUZKY8+CIRKM<3(]])9T<B.7*)A,M3CQ^H^;3K+35':Z.F]=
MJ=.1A9'C#NAJ)U> F*/4MHK*.>JI:Z.6"#\(]$7#?*GA0#1-H\3M+ZGMVK*1
MJ\DG\E5M:G.U5QE>M>[4\;/;JS:%?&WFZI)#8Z>1%I:9Z+B5,\ZIP3\E.OG/
M&6FJ]J-?/*]5AT_2H]D#>997JBX=T_\ *2NR.ZOIDK=-5ZXJJ"561Y3V[,NX
M^1$ R-H]LK*V6VT;+C36NQL7_B'<OR3E1.&$1,93&>&35M86S0E%IRK?:+C2
M-N<*-6)8JI'2*[>3/#.5X9/&W3VZZ;0+Q[,YU_D78IXGN<UN$PB+W/@,3:5=
M-.3T,%NTY2(]9IFL=4,1=W.4[G*KG/-T=(%A:=NE3VJ5KKC(O+,M[G->Y>+D
M2+*+GI533-EFB(K[9I+G=IYUHZJ5[VTS'.8BJCW)EV%X]/1TFP[25]9=E4%
MG<S<E%3-8G.O!&J;;H.W^MFD;93<.$*/7'_-W7[P*EJK#+:]IL=CTM6ST5/5
M1;TN'*J,]LJ]/4U/*3FOM!6:TZ3J;A$^I]<841R5+YG*YS^OBO2IZ:%W+UM4
MO]TXK# W<ASU\,_>4S]N=4OL>H[8QV'U]0UB?,YO\0$OHVZSP;-J6XU[G.EB
MA<YRO7BJ(Y43BO@P5QLFT:Z_P55==*F5*)[\\C&]6K(O6JHO-S\#<MHLR6/9
M0RGB[CE864Z^%58JK]:&)LTU?8K7IJFMM?,M#64S,2ME:O=+G.4QGK AM:6"
MGT-J+3U=IYTM,VJJ4@DCWU5%Z%5?F<;!MUJG+8:*UQ.Q+75"-3Q(J(OWB&KZ
MM-H.T&VLMF7VFW_RCYE3";R;RY3QX:?>U.LB3:)IAERDY.@IIDD5SDX>VC5>
M;Q ;1K"\>P[9_ ^C:C9=QD,7@<J*JK]2FB:>CT3);6S:ENO9]SE3>DDEGRK?
M F7>/CX3:=M5*MYT)35%M_EH8*AL^6]+4:]OVJ>M%?-"SVEM;(E+&N[ET:M=
MO(O5XP(391=(X=9W6TVNK?4VAS>4AWG[Z,1%=A$7*]:>0PM62TS=I]7[,VU'
MK,L;4I$WEY-';K>O"?GFTZ"N<ER@O5PM]FI::"'>2B<F\CID[K&]Q\#?*>=C
MUC9M2T-12ZJBI::KB>K70JCN*(O.B\_5T@8M)I2G6^T%UT)7PLHV+_Q$<<^6
MN3CG@G#F5#>=8V%NI;!46Q]0^G;*K5Y1J95,+GFRA5VD(Z&#:Y'%I1\CK-R+
MEJ&Y56-=NR81,\<>U-^U'KRV6#4%':*R*I?45.YAT;45K=Y<)G*Y E-'V)NF
M[!3VME0ZH;#O?RCDPJY55YLKUDO+(V*-TDBHC&IE54_6N1S4<U<HJ912M=L.
MHI8*6&P6M7+<:Y4SNI[5F5_A B+2KMH.T)]<_+K+:W8A14RU[LKA4Z.AIE*Y
M+7MTD<QJ-CK*9L2-:F$SB/B?MGV014U!$CKW<()G-19&P[N[O=.,IDUW4>G6
MZ)UQIFJ97U58R6;,CI\91$<W@F -RVZUJP:4BI6N5%K)VQ*U%YTY_P!QNFFJ
M/ULT[;Z5[49R$#6.3&,80K7;9+R=RL%14H[L!LB*Y<<$7NB?U3M&LL%GJ$ME
M1V=4R1.1K(FKPX<ZYQPZ?F @=G4?KSM#U/<WY<R-5I=_IQG'!?\ I(-=)VBY
M;7ZRTPTZK14\23RHCU7>548J\?&]3<-A=(YNF:BXR(B/KYW2+\SG>DU[05YH
M*#:!J*IO%2VGJ9%6-F\B\6]SU?HH!*Z^DBT7I^GL>F&/IIKC.F%:Y55N<(J]
M?,W!)VK9?9DM;$NS):JOD8BS3OD<J[^.*IE>'')%;9(9:.[V2]K&LE)3/1LJ
M)QW>+N/_ '(;15[0]/0VAU;'7L>Y8U>R)&KO.=C.[X^@#6=E555T&K+UIN2I
MDGHZ5JRQ<HY55J9:N$S^F>4.;UMR61W=LM<*QJBIE$RDG\9F;(+753U=SU+7
MQK&^O<K8D7\S*)_X(0NQ^YTB:JO3Z^=([C5OW6L<B[SD1$7]R@2>T.X5U[UE
M;]*6V>6")Z))5/B<N58JIGFZDWB6K-EMA=;714L<L58C>YJ.4=O;W6O']YKU
MWJ6:5VOMN=TRE!61*QLR)G=5>OP)O(;!K7:#:J2QS):JMM57RINQ1QM7/%,Y
MX]'#ZP/'8U?:NZ:'J9ZU\DTM+.^%KE[ISD1C5^?BY2"V;6BBUI1UUWU),ZLJ
MUF5JPN>N(FHB+S9X<Z]'02FGK=6:,V5U>XYD-RE59\/7*(Y=UJIY&E;VJIL#
MZ-DMPM]]=62=U-)3[K6/7I7&\GV ;IH^W6Z':U7TUGB9+:X:94=E$>UDG#@B
M]''/D/V=:G:!KVJMKJB:&QT#45S(WJU)%X<%QCI=]1LNRZYZ:J*>:FT_!)3S
MLPLK)LK(J\>*KE?#T])JNB+G3Z0UI>Z"^N['Y=W*1RN3+5RC> $CK[0UKLNG
M9KI8DEH:VDW7M?&]>/=)S\?&3$>H9)MDTMSJW+V0M$Y-[/%ST8O'Y\$-M,U7
M37JA9IW3TB5=76O:U[F(N(T1R+T^!%/;:!:9+1LCCH*=KE?"QB2XX_D+O?6!
M)[$Z%:714-0]$1U6]\J]?ME3CY""U-_^:VRVBA9W45+#RCL\R.3?7]R$IIG7
M>G+;I"C9V:U98HU3D&M57JN5X=7UD)LJE?J#7E\O<\2Q;G"-CN=N=[*?6!D[
M9Y*IEQLW9B5'K"DJK4<BJIEN69WL?/C)CSZ9T[?[9%)H2LAIKJQ4<F[4;KT;
MQ]LB+UX)J#7<3M3W.R:HIJ:EIV.5L$BHY>4;E>?YMWFZS3-<0V2'4%KDT9)B
MY23)OLA5V%\>?F NZTQU,5N@97/1]2UN'N3F530=N]=-!I6.EA<K>RI$:Y4Z
MD5/26/'GDVYY\)DT?;!8*B]Z7<ZB3>J:5>5:WK1,*OV 3^B;;#:]+VVGIVM:
MWD6O7"8RKDROUJ33FHYJM<F45,*A7.B]I-FEL]-2W:=*&MIV)$]DC5X[O#*8
MSU&!KC:-2UU$ZU:4>^KKZE4:V6-O<LXY7G\"=72!8MMM-OLZ5$E%3Q4Z2=U(
MK41$7&>*_65=42.VA;1$IFY?8[4N7=+7N3"*B]&?;'MJ>ZUVE]#45D=.Z:_7
M%O)KT[JN1K7)]:X/S3VR)K+;%-47JOIZJ9J/E;!N[N5X]*9 ]-:M9:-K&G*Q
M.YAF;NOW4QC'#Y^8W;:)</6S1ETJD7&(T9G])R-_>5%M,T@ND(K==(KC6UO_
M !"19GW>Y56N7AA/ ;EMQKFR:<M]'$_>9<*AK.'2B.:O[@-:V<WW4%@TS'#0
M:1J*Z*15E[(:]R<HB\4YF+U]9[T\]?M2NG8%R>VVTU&[E9:+.])PX9Z%_*^L
MMS3E*E%8+92HF.1IHH\>)J)^XJ^+%NV\U/)(C&5<368Z^YC] %E5EYLMA2*E
MKKA1T7<Y9'-*UB[O'F1?$IZ6N_VF[2.CMERHZM[4RYL,K7JGD4\+UI>S7NI;
M472A943-8C$<KW)A,JN."IUJ?MDTU:+)+)):J)E.^1$1RHYRYQXU7K KO;O,
M^LELME8JYGF2;"=.$>G[RV8(F00MBB3=8U,(G45)7HMWVZQ0\7-ML;9%3H3+
M6?QF^:VU=0Z1HH:FXQSR-F?N,;"B*JK\ZH!L1^2/;&QSWN1K&IE55<(AB6:X
M17:U4EPID<D-3&V5B.Y\*F>)%[0*Y+=H^ZSJ[#D@>C/TL+@"I]GNG'ZOO=YN
ME5531T"RK$]L;E:Z541O!514X>@SMH6F:+1M1:+IIU9J67LA&R(DBJCTWFIQ
MX^%3VV/:JM%GL4E%=9EHZE9%D59&KA^>E,9_]0:IN;=?:NM5KLBK-04<J2SS
M(F&KQSCCQ_)^L";VP7-6;.(G.=_+5G)M5J<Z[S%R?&E-F]%';:.JOLT]7/$W
M?9&KG-9$G%<(W..M>;I,#:O&RMU'I.PPJBM?*C7HOY*(K43/S*6JZ)4HUB;S
M\GNIY, 5%;H9]HVL;@M=/,VR4#MQL#'JU).*XSC'@,G:'HJWZ?L3[QI]9:&L
MI%1Z+&]<.QQX\? 8FS"\4FE;I>+-?).Q9^75S'O3@_G3G3Q&1M*U3#J1D.FM
M.N[*EJI&MEE8G!B91.GP*OD F[SJ%[]D;[E4.5*B:G5C51>=_'^%2"V<;.Z>
MNTU3U%_EFGCF3>CIVO<UK$ZU1%PJ\_1U'AM@C6U:%LMAI45972,543G7N7Y3
MRJ;5IW7^FH[##O5J4RQ-W5AD:N\B]7 #6+51^P_:Q%:[7+*ENJXT<Z!SE5$7
MCCGZLGIM4U'R^IZ?3TEQ=;:%F'U4S7[JKE$5$YTZ'<V>@]-#,FU9M"KM3R1N
M2@ITY&F5_#>3+L+PZD1/*8VHFT5FVP5-PU!$CK97T[8V/>BJUCD;&F>'Z*@1
M]^AT RS3.LU8V&XQHCH96U'=9S^EE>&3<]*W^:JV33W"MD59H*.1N^Y>+E;'
MPX]*J1VJ[_I2W4.+/24E?<I%:D4*-=A<KQ5>;HR?6T:J?0[*XV24\5+5538T
M6GBSA%<B(Y$SU9 @-F.AH]161UPN]14+0U,KWMIF.<Q'*CW)E51>/3T=)([8
MH8X;=8M-VY.38Z9'-;S]RB/+!T+;_6S25LI>'")'\/\ F[K]Y6NK[A!VWK6Z
M\2)%1TJ*C7.1<=/5XP-DVRVR-NA'2T[<+0OC=&U$Z-]J?83%-J*GMNSNCNTS
MD5L=#&[&?;/Y-%W?'E#.U;3Q7;2-Q8Q4?&^G<]J]>$RGV%-Z,[)UE'9["YCF
MT%M=OU:\R/PJ8;Y$<!O.R>QS2.JM379'/KZ]5W.43BQB*B)S_HH;3KR]+8-*
MUUP;CE&-1K./Y3E1J+]9.01,AA9%&B-8Q$:B)U&B[:Z2>JT5.ZG:K^2>Q[FI
MTIOM] $-HS9_2WNT1W?53IZRMK42=-Z1R(QKN*8X]2IY#5[[IIM)M%M5@I*N
M6:@D?RJ12N5R0KA>'%5\?SE@:<V@:>@TI0++7-;-!3,8Z'=7>WFM1%1.CG0U
M?0=4[5.U:Y7:2)T44$&8F.YT7N$_>J@2VTZZ5UPU-;-*6J:2%U4U)9GQ*N]N
M97*<./,Q2379;8$MKH>3E=5[G"I61V]OXX.Y^OCC)KVJIDTSM;M]YN".];Y8
M58LB)G<5=]/_ "0VC4VT&R4EDJ)*&N9454D:MACC:N5<J83G\. ([8M<JNHI
M+S;:R9\Z6RIY"-[URJIEW2OB-,I7VQ=:W./7Z3(]Z_R"S.5(T3"<V5QUFU:"
MH+GIW0UTO#:9DESK%=5<@]5[KBY43AUHJ&3;=3Z8U=8(W:B;31529Y6%4<FX
MO@5./-X0/S3NEGV_5,5RTK7Q.T_(W$D39E>U7<>9.;I0UW7^HH;MK?UDK;FZ
M@L]*B.F<V3=Y5<)W/.G6O2>^R1C8]9WJ.R2226)BX:JJN[SOW<9X]1CL;;K#
MM0NC-31-[$JV[T,KT56Y7=X</&H&!JMNB(+)+/INM2"ZP[JQ.BFXN7>3*+A>
M/#)O$VKIZ791%>9%_P",=3L8CE7GD<U$WO*I%:JU!INB6"FT_;Z2XW&9Z(D>
M';J)UJN4ZC*VM4%2_9]3K'3LC6G6-TL,?,W"MRB>!,*!XZ/V=T=VM$5SU0L]
M97U:<KW4CD1B+Q3''JP:GJ33+:/:!:K!1U<LM!-(DB0R.5R0KCPJO6J_.6+8
M]H.G8]-T;I*]K98J=K5AW5WMYK<8YL=!J6B*MVJ]K=PNCXG1004Z.B8[G14Y
M-/#S\5 N<_'.1C5<Y41J)E57H0_2%UK6MH-)W>H<N%;2R[OZ6XN *[V2HZZ:
M[U)>G-5R<:;?7CS*S''Q,,_;W521V*VT3'N;'6U*1O1%QE$5%X^0R]AE$Z#1
MW9CVX6ME?)Y'N;^X^]M%DJ;KIZ"IHF[\U!*DZ,Z^*(!MNE:&*W:=MM- QK6L
MIXT7"8RNZF5)1414PJ90KW2.TJQ5%HIH;E5)15L,3621RM7BY$PJIC/#*$-K
MS:"RZTZV;1[Y*JLG5&K-&WN4;A<XSTYQT 6+1VJW6"@J.P((J6+"O=NHC4SC
MG^I"C]F]_NE#<+O=J#3M;=4K9,+)$URHU455QE$7CQ+'U0LVFMEE1'5SK-6-
MB1JR<^\[>3]Q$[)]0V"R:.IJ>JN4$4[UY5[%1V4543P> "6M.M;]6W*FII]'
MW"FBED:QTTB/1K$5>=>YZ#?R%MFJ;+=*I*:WW"*>=4RC&HN<>0F@      <^
M^J<]U['^HD^\AT$<^^J<]U['^HD^\A3L?>PBV_N)]/ET!#^!9^BA]'S#^!9^
MBA]$RV         Y[N']9=ORF+_3M.A#GNX?UEV_*8O].TJV7C:\I1;;PL?V
MAT(5QMT9<GZ4;ZV\KR2/S,D6<[OAQT<^2QS\>QKVJU[4<U>=%3*$JUS=L-CN
MBZOC=2\LE&C5Y?GW,93GZ,YP=)'G#3PPYY&*.///NM1#T   #3]K5Q2W:&N+
MD5>5D1K&(G2N\G[LF@[/=27RP:9IZ2ETA<:N)W\JDS&/1'Y1.*=RO42FWZX-
M;16NW[R-Y2=LCU7FW>Z3]QMELUAIBAM]/2LN]/NPQHQ,([H3Q ?ND=37:]5\
MD%QTY66N)K%<DLR.1%7*<.+4-:VE1.TQJ2WZLI&+R:+R54QOY:8=Q7_M\AOE
M%J.T5M'45=+7124].F97HBX;]7@4KAU-5[3[I+--F+3M+EL3>99GXY_^[KZ
M,FQ455K^^MO=U9)'9*9V:2F>BXEXY1RIS?F]9E[0;76W"]45/472EMVGH\)*
MSLCDW/;PRF$QPQE.<^-DUSGHZ:Y:;K$1:ZVN5L:+^6U$5$3_ +36-)R66YZD
MOE1K2H5:R*I5(8I7.:U&HKN9&]6$ ^]<6[1%#INHDL5RIFW2%,Q+!4HZ1R\>
M"X7)8=KN<S-FL=PN;UY=:15D=T[RY1/W%5[3[A8:^EIK5IBC156H15J6HNZO
M<NRU,KGG7JZ"P-K4C+3L[GH:;@Z58XHO.-5?J U+95HF._6>6Y7B>9U-42.<
ME,QRL1RY5<N5%X\_5UF+66*6T[3%LNEJV>@AJ(D23"J[<148JKS\^<>4MC0%
M VVZ.M$")ARTL3W_ *2L3/UFC:'5+SM;U#=7IO1Q0I"SP.3DT_\ %0/G7V@+
M-:=(5EQA?4)7TZ,5*E\KG.RKVITKX2>T]=)XMD:UU?([E8[<YS7N7B[$66\>
ME5,/;I5;NFZ6@1>-=4,BQUX<U?W'AM,?ZS[*Z*VLX3.AAID:G3AJ-7[0(/99
MH>.^65URN\\SJ*JD>]E,Q[FHY4>Y-YV%X\R]'2-2V>'0NL[--IY\L$-0N[)"
MKU5KO;=?B0V'9WK2P4.E:.BK*M*.>G:J/CE:N>+E7/#/7]9"05+MH.T2DJ:6
M-ZVBW(N7JF$?SX^\!.[<JIR6&BMK786X5#8\=>'M4]M<7I^C]G5'%28CJW01
MT[%3ANKN85WEP0.U>KB9M T\RX/Y.AAW9E>Y."+E>KQ(2&V:'UPT];;K1)V1
M24\J2.1OY3%XYQXD UZR0:%6W-??[HVON,J9DEDGRJ+U)EW#H)78]=6LU'>K
M1154E7:V.WZ9SG[VZG'IRO0B$M3WK0OK,RK=V*F&)EBM=O9ZCVV>7*:X6FYW
M.GLU-1L1')3;N<RX3*;V57KZ -1U7+3-VE3IK5M0MI5B)3\52+/#Q)XR<I]*
M0.O5#==!5\#*5O\ .&1S[S7<_0G#J,JQZQL^I*&II-60TM-60R.8^%4=A415
M3@O/T&MZ2BHX-JW):3D>ZU<GF9J*JL3@G-GCSX L[6VFV:ILDEN?5/ID>J+R
MC6[V,*B\V4SS'KHZP-TU8H;:RH?4)'_\CDQG@B<V5QS$7?-?6NSZFI;)415+
MZF?=P]C4W&JY51$7*YYTZC;@/B:6.")\LSVQQL3+G.7"(A46EF2:]UW-?*EC
MEM- JQT[')EJNQS=6>[R9^V*^SS=CZ9LZ[U=6.Q)C\EN.9?'E%/BV[((:6D:
MQ+[<87+Q<V+=W<^0#RL__P".VWUU.[N4K(G3=2+[=?WF;M[K-S2M/1196>IJ
M6HB=;=U^?W&I7"PIH[:58%;75-4E3(V/E)\9XN1,</&;!M$1+SM*T[:N>*%V
M_,G@56^D"2M^S"V>LZ>ODT]=4MC54<LCFM8F,X1N<)_]D=L41[TU);'RR24$
M,O)1(KE7"*KD7"^)$+$U+6-MVGZZH7FCB5/+P_>:;L+HUBTB^KE3^6JIG/5>
MM."I]J@:91:2M%XVL7*W10+ZVT\22JF\N7.[C/'QJXV7:?04&D]G<U%:HU@A
MJYTB5-[.55'+^XB]FEYMM#J[4DMXJFT];)5+%$UR+W3=Y4_<AG;8,W;4&G++
M%E_9+^61$Z<(Y/W@;G89[=I72EJIKK64U$C8T8BS/2/>5.?GZ20M^IK'<:E*
M>@N]#4SJF4CBG:YR_,BGW>]/VN^-C2ZTC:A(_:(KG)CR*AC6C25CL]8E5;;>
MR"H1JM1Z/<O!?&H%7;;*N2LU;:+;24TM7)$W?=#&F5<[CA$1/ ILGL_U'\1K
MI^R_^ B=.)Z_;:[K6?\ P4D**S/6B1I^]2X -.U#JFJMV@I[Q44;Z.L=&J,A
MDYV/5JXSE.LU_1>A:6\V>.Z:I6:NKJI5?B21RHQ,JB(B*O4B$QMGMT]RT)51
MTS5<^)[9E1/S6HJJ-+:^L,NGJ5U36QTTL4:,DC>U<M5.'1XL_.!@Z;T7=--Z
MS6:V5")IY[51T+YG*K>?F:OB;Q(3;C6RSWNP6VDIW5$L<G+K$U>,B93#>'Z)
MLFA-57+5%]KY8X498X\MA>Y,.<J8X>12!I<7O;A))+W<5OC=%N]2IOX^L#]N
M&T+4EHM>9]'3TL$;$8DSI';K,)P5<L\!);.+ M?7NU;<JV.LJZE%Y)(_:QIS
M="^!>@W35E.VJTW<H7-1Z/@>F%\1H^PJJ5VC:QJKPIIWM3P<$7]X$!J"@FU;
MM>=2PU+Z:.DBY-[V<53"OSCBF%7FR>^T[1%GL.EWW*AY>.X1O1$G=,Y7.7"K
MTKSY0SMCL?KAJ+4UZD3>Y>?#'=7%RK]IZ[=9GU%':+0SGK*E%QUXX?\ D!O6
MCIYZG3-OFJE59G1]TJ\_.I,&LZFU+0:,L-+45T4KHG*V)K(4155<9Z53J4FK
M-<(KM:J2X4Z.2&IC;*Q'<Z(J9X@9;G(QJN<J(U$RJKT(47HS3SM8:NO]PFJI
MH:-LJPO2-RM63&$QO(J<.Y^I"W=8U;:'2MWJ'.W5922JWPNW'80U;8?0NI]'
M-K'HB/K9'R*G3P>Y.(&E[0].T^E;]9GZ6DFI*RH=R:HCU7@N\F]S_P#N#;;C
MLXMBV.MJKU/45MR2!\CJE\CL-=NJN4;G@F2/U'NWO;39J-,K3TE.JR_I(DJI
M^XW#:;</6[1%VD1<+) ^%/&YJH! ;#*BIETW4Q5$LDL4,[F0N>JKW.\[K(C6
ME;)K76U'IJWOWK?3+RE4]O%N4WEPN.C@WYU/VW7EFB-D=#(Q?_R-1O\ )\,J
MKG/>Y%7P8,72&RB2HMC*^XW6MI*ZH[IS8-W@G4N4YP,O:920V75>B*BE:D<#
M*A(51J8W6-=$B>/@6!K&YI;M)U]>QZL5D.^Q47"_,5%M,T/[&K13W6*Z5U;R
M$S>$^[AN53J3P&Q;6;HU^S2V1P/WY:QT3-U.=4Y-V?K0",V7:$BO-B6XWF:9
M])52.D93,>YJ*N\J;SL+Q7@O0?5;;(]$[2[1%8I)(J.K;B2!7JK55=Y,\?F\
MAL&@M;:?H]+4E)55:4<U.U6OBE:N4XJO1GK(:R.?KG:8V\Q,?ZT6]BQL<O#>
M7NL+_P!R 9FVU]2RIL:SI4>L:2JM;R*KQ;EO/CP;QAS::TW?[9')HBLAIKJQ
M45NY/NNQTHJ(IL#M;QQZKKK)J6GIJ:D3\!*J*O*)T9Y^C!HVT"&Q0W:V2:+>
MK;L^9-]D*NW5;AV57/3S 7?9XZF&V4T=>]'U36(DCDYE=TFE;:J&AFTC/5UL
M:NF@:YL"[V$1SD7HZ>9"P"KMNLSYJ"TVEB_SVI3@G3A43_R QM'Z7LU@T71Z
MCJZ3?N%/&Z57JY<9WE1.'B5#QT%IGV:4LE^U5+/4K+(J10*]VXUN$7FSCI7H
MZ#=M7VJ2LV>UENI&XE?3-:U$ZT5%_<:[LQUI9X=)T=#7U+*2IHV)$]CVKQPB
M<>'S^0"&UA:(]":DL-=I^26""KJ.3FI]]=QR;S4YLXYG+T$MMTN&='4E-$B\
MO5S,5&I^;NNS]J$9>*U-H&O;736S,MJMDB3238PU5RBXZ^.X>^T1K;KM&TU:
M&I_(P.194\&6X^I0)O36S>AI6TM7=IYJZMB3+%5SFL9X$;E4Z_*6 &INM1$Y
MD3!C72H[$MM74^\POD\B*O[@*+N5XK)=KM=<;?:JFY=BHUB0PHKE:K4:BKP1
M>E/K);5NT*_26]U+/8*NS138:ZKF1W<IGJ5J?:>&R.^V>@J[[<+M710U%34*
MK-Y%SNY7/,GB)K:/KRQ5E@JK;;9$N%9.C6,:QBX:N\B\57'0G0!L>SZBM.F=
M&0/BKH'4KD2:2J<Y&M551,\<_O)-FLM-/>C67ZV.<JX1$J6<5\I#;/=-<EH&
MGME[AY1LN)'Q.<J8RB<.'B,^/0&F(Y&O9:8T>U45%Y1_!4_Z@(':YJ"LIJ6@
MM5EE='67!Z;LK'87<P[F5/#CB9$>RVQ>MBQ5$<L]:K.-0Z1V\KNA>?@0VUAK
MK/JC3-^6%7T-$O)N:G'\Y4^I#9KOM$L%)9Y:JGKF3R[O\E&QJ[SG<R >.@K7
M=M*VBZ1WRH;/20*LE,J2*]R1IO*N<\W#=X%<VZ\6?4U]KZ_6-T5M,U^Y!1<K
MNMPF$WL91.A>CI+*T[47;4>@JR2YQLCJ:VGD;$UO#N7-7=7ZT-(V9U.G:.AJ
M;9J&.**X4\KD7EFKW2;RKE,>- (RY7"Q635%FJ]%UBHDLR13T[)=YJHN4RJ9
MQT]70;=MRG=-262SL<N;C5(W"=.'-3_R/*CO5KN6M*2VZ9M-)4TB-WYJMR.3
M<5$<O#CX$Z.DP-HE;!%M5L*W.1(J.D<V5KW)P1=YB]'B W#7E4RQ[.*A&X8]
M*=L4:(F.ZQ_]*?&QVV>MNAJ+>X2S[TCTQS+O*GV(AKNWROY725O;3+FGFJFN
M61$X*FX_@6'IFKMM5:V)9JAL]+&JM1S<\_/T^,#[U'1TM=9:N&X,62FW%>]J
M.W<[O'G^8IS97HJS7]]\J+A2J^!E3NTS4>J;K=YW#P\R%MZTGDI]*75\+=Y_
M8STQXVJF32]B-UM3-,4U RJ8MS>][Y(U1=Y>Z7'@Z0,K:#:*J5ELMU-<:>V6
M*/C.YU1R;U]MP3FRG-TFL:NMFA:+3U2^TW*D2YQ)F-T54BR*[/CR>5NGMUTV
M@W;V:3JBP)B"%[G-:G!OYOC4Q=I-RT[4T,5JTY2(]T\S6NJ&(NZB[R<,JN<_
M-T@6%I>ZU4>RUMQKGN6>&E<_?5>.&IP7/B-&V7:&BO\ 99:RZU50M#-.Z1*9
MCE8CUYMY51>/D-DVC/2S;):>G9W"OABIU1.E5C7/V&VZ$H?6O1]NI51&K'&J
M^557]X%=W.EAN&OZ/2\]1)1V6DI\1P(]6\IC>QTIGVJ'EM2TW8K)3VYMHA;%
M=):AB1Q-7*R)O-SE.GG^L@K_ '6EN.KKF[4=-75:0O6.G=0(U-QJ*O2JHJDS
MHRZZ-I+U3I+17*.MD>UD,M<N4:Y5QPPY>G &P;2M02Z:T=04] C*6MJVL8YS
M41FXFXN5X=.<&O4-+L^2W<G<;FE96N3NZE\_=9\'=+CRDQMLI7-?9;NL2S4=
M-+B1K>/!45?W$A5WO0L%J=5L[%D7=[AB-=ER]0&!L7KUKV:CM"U,E5;Z61&0
M2.<JJL;E>G!<]34Z37+;I*SWC:Q=+='3N];*:'E%3>7+G]QGCXW.+'V8U,EP
ML\M?):Z>W,F=_)MBSES4YE7*KUFD[,+Q;J+5>HY;M4M@KI:E8XFN1>Z;G_Z0
M"4VF69]@T3'2:=AGBHN71U2D3G;VYE.E/$A&6RR:-U#8N3L=2RFO7))R:NFW
M9.5QPSQSSFUZBUH^RZNI[9=Z:".SU$>\E2J*JY[K"*GC:G1TFE[48]+.H65=
M@D:V]NE18^QU=EZJJ="\ +5T917"W:;HZ6\S)/71(Y'R([>RF\N[Q\6#'V@W
MA;)I2NK&.Q*UN(^.,N5?1DS],+4+I^WK6_SCD6[V?$:5MZ>YFC84;S/JFM=X
MMUP$ALCM:6?1,$LR)RM3FID<O/Q:G.OS%?U=^MVIM97'V2W1U-::*58HJ7E=
MU)<*J97BGYOAYRX[73H[345/$FZCJ=6-\&45"IM!OLEIO-\M>IXHXZE*E5B?
M*BX>F\[F5/F BM7UFFK0E'<-$UW)5S)D1\<4N4<S"YRB+UXZ"_J.;LFECF1N
M[OMSCJ*LN-[L]1J&DM6EK31W"1Z_RLCD<C6)Q\*> VF^Z]M=DU'2V2HBJ'5$
MZ-P^-J;C<JJ(BY7/.G4!GZ]N51:=)W*LHT7EXX7JU43VJ[J\?FP:7H?2=CN^
MEXKM>I.SJF;>?+-+(JHWNE3'%5QP1"9VQ72JMVEG-HWL3EG<G(F$5RL5.*(B
M\"K*6?2S(F<M;-0M3&7M:K48J]/Y8&W[&J6!U\O:TL39K6Q[D@E>Q'+G+>&]
MXO"6^:MH6ZV&JL#I-.Q\E20YWHN.\U41%7.57HQTGSHS75MU955D%!%41/IL
M9Y9J(CLYYL*O5T@;6       "B?50_V9_P 3_M%T6#W"MWR:/[J%+^JA_LS_
M (G_ &BZ+![A6[Y-']U"JIW-CU^45'[FIZ?"IO5-^X5E^4O^Z65H'\1=.?W;
M3?Y32M?5-^X5E^4O^Z65H'\1=.?W;3?Y31;[BSYR4_N;?E"= !*M   (J[Z=
MM%XE9)=;=35;V)AKI6;RHA*@#6_8)I;O#;_-(9<.E['!;YJ"&UTC*.9V_)"D
M:;KEZU3YB9 'C1TL%%31T])$R&"--UK&)A$3P&*EEMJ77US["@]<,8[(W>[Q
MC'.2  B+KIFRW:?EKE;*6JE_/E9E>H_7Z;L[XH(WVVF5D#M^)JLX,7K0E@!A
M72U4%U9&RXTD-2V-V\Q)&YW5ZT\B&9&QL<;6,1&L:B(B)T(A^@# MEGMUK65
M;=1PTRRKO/Y-N-Y>M?(?MRM%ON<M-)<*.&H?3.WX72-RL;N'%/(GD,X 5?MF
MI*NZ2V.T4U/-)32S(]ZL8JM;A%1,KS)S])O%PTU9KINNN5MIJEZ(G&1F5)@
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M>0Z".??5.>Z]C_42?>0IV/O81;?W$^GRZ A_ L_10^CYA_ L_10^B9;
M    <]W#^LNWY3%_IVG0ASW</ZR[?E,7^G:5;+QM>4HMMX6/[0Z$ !*M
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M<:FD;_\ .Q&HW'7A5R!8H(?2^HJ#4E!V5;I%5&KA['(J*Q>/!?(I,
M
M                                            Y]]4Y[KV/]1)]Y#H
M(Y]]4Y[KV/\ 42?>0IV/O81;?W$^GRZ A_ L_10^CYA_ L_10^B9;
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MS4])(NF]E,4J=PZ&G?/GQN5W[R.V!4*0Z6JJM[?Y2IJ7/1W_ "[K>'E0"S0
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M4T';=#G1$M0Q$Y:GFC>Q>KND]!M^G7K+8+9([VSJ6)R^-6(!(
M                                       "B?50_P!F?\3_ +1=%@]P
MK=\FC^ZA2_JH?[,_XG_:+HL'N%;ODT?W4*JG<V/7Y14?N:GI\*F]4W[A67Y2
M_P"Z65H'\1=.?W;3?Y32M?5-^X5E^4O^Z65H'\1=.?W;3?Y31;[BSYR4_N;?
ME"= !*M   -,VG5UF99DH+S)4/[)<FY3TSEY2145%3@B*N,^ W,K':59;M[*
MK7?K71+<&4S=QU.U%5>"KQQCP_4![6W5-?;+3#!;='53**"/@LDW)]RB<ZY9
MSKSJ1VPJ-]0E[NKV<BV6=6I&G,G!JY^HR+]=M97RR5L5#9);<SD7921JK))P
M]JUJI]>2;V:6>HL6A(XZJ"5M;(CWR1;O=([*HB8\6 -3TE14^I=JE]KZF%E1
M3T3]V+E&HY.=V%X]7.3^W">&+1,E/NHLTLC&QM_ZD3AY4&QFQUMMM-=5W:FE
MIJZJJ%5T<C<+NX3"^55,;:I:KE>]0:=I:*CJ)*)DZ+4RM9EC6[[%SY$4"4K)
M%L>RA72/Q)'1(J+S<53.#YV+T#J+0U,]Z86I<LWV)^XR]HUBJKKHJ6WVU-Z9
MC4W6\4WD1JICAXS"V<W"]+:GV^YV.:@2D@7DY'(J<H[/,B8\($%:'>O6VNNJ
M9&HYEOC6!$QE$5-]$7Q\#QU-1Q:HVPP6RI;R]-00I(]G.F%W%7/[1,[)[/7T
MEQU#<KM234\]=4;[4F;A<;SURG[1K5#;-6TFKKSJ2BH';_*<AR,[519HNMO!
M?S&^4"U-2,HZ?3-<RI8QM(V%4W<<$ZN'CP5CH2OFM.Q.X5*;S9-Z9&+U9:B(
MJ&3?*O6&LJ;UI6QRVFEE5.6FERF41<\.'@0W9VDJ9NB':?APC>Q^31Z]+]W&
M\OS\0(?8Q9XJ+2<5<]K75M:YTDLF.*]V[''Q8(';>QC;C8I(&HE;RR(U6IW6
M[AWS]1]:<N&K=(T"VB;3\]RA@5R0S0(JHJ*JKQX)UF58=-7G4&JH[]JF-M/#
M3HO8])E55%\/!/"!C[5W.NNL=/V%[E['>J3/;G@Y,NX+^P6<REI:2V]C)'&V
MDCCW%8J)N[J)CC\QH.TW3]TEO5LU#8X>R:FC1&.@3.7-RO-P7\Y3%NEYUI?[
M+704UBDM?_#OWEDRKY.Y7N6(K>=?FZ ,+8C11OOFH+I!$V.#E'4[<)CI:O#P
M=R>VBL7G:U?;BG&*C3DXG=:+O)_Y$]LHM%58M%-6NIIHZR5SY)(5;W>=YR)P
M\6%,38O8ZZW6NX5=XII::NJ:A<LD;A=W=;A?+D#3*:NNM?M)OEQH;6ETDM\Z
MP-1[L)%ASD:J91>/<_42VL9=6ZGLS[?4:<2-%<CFOY1%W5X\>;PF?46R_:.U
M=<KI9;>ZY4%R>LDL,>=Y'95<\W_,O2+BFK=:55-3/HJBQ6Z)Z22/<]S)'X14
MQP3P\V>@#9JG3U3=MG+;-52+#5/@:CG<^'-<COW&E6B]W_0= VVWRRNJ[9$F
MZE1!G",QC+L(O4;5M$LMXG2@N&GJB7EJ-R*ZGY1R)*W/-PSGG4B+IJ35%SM,
M]O72-2R:>-8G22-7DVY3&<X_<!LNSVEL:6^HN>GE=R5P?RLB.7F<BKE,8X<5
M4VLU79IIV;3>F8:2K>UU0Y5>]&\S5557'UFU
M
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M?Y31;[BSYR4_N;?E"= !*M
M
M                                              #GWU3GNO8_U$GW
MD.@CGWU3GNO8_P!1)]Y"G8^]A%M_<3Z?+H"'\"S]%#Z/F'\"S]%#Z)EL
M    !SW</ZR[?E,7^G:="'/=P_K+M^4Q?Z=I5LO&UY2BVWA8_M#H0 $JT
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M^4T6^XL^<E/[FWY0G0 2K0
M
M                                              Y]]4Y[KV/]1)]Y
M#H(Y]]4Y[KV/]1)]Y"G8^]A%M_<3Z?+H"'\"S]%#Z/F'\"S]%#Z)EL
M  !SW</ZR[?E,7^G:="'/=P_K+M^4Q?Z=I5LO&UY2BVWA8_M#H0 $JT
M
M
M                     %$^JA_LS_B?]HNBP>X5N^31_=0I?U4/]F?\3_M%
MT6#W"MWR:/[J%53N;'K\HJ/W-3T^%3>J;]PK+\I?]TLK0/XBZ<_NVF_RFE:^
MJ;]PK+\I?]TLK0/XBZ<_NVF_RFBWW%GSDI_<V_*$Z "5:
M
M
M         '/OJG/=>Q_J)/O(=!'/OJG/=>Q_J)/O(4['WL(MO[B?3Y= 0_@6
M?HH?1\P_@6?HH?1,M@        .>[A_67;\IB_T[3H0Y[N']9=ORF+_3M*ME
MXVO*46V\+']H="  E6@
M
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M(QMCSUX3 K38BQ9L69ONO-FLU)JVZENS=?<]P 2K0
M
M
M
M
L                                                       ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g109079g01g98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g01g98.jpg
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M=<B^/J1M7,1EZJ?U#/3_ ,T%D6.G_F@LB^QH_P#73_J'EJ_<B(BZ((B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MB1V_!':%SMN=K:LUSJ::XU/%'2LS'24^>44>>7]H]I/CY@%F*JM6O:F?B/\
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MWN[(V,;\-WB3D<CV 96Z=6-/3IW_ '*<=YES.BZFL^D]K]S[56,TU2&WUM.
M"Z)KHI(LYX7%A):YIQ_]0J4TOI%M-N_1:7U!")HXZ[J)V!Q:)&\R"",'!&#Z
M"M4Z\5;_ !M,$T[((BZSU%L[H2VW07NZ&.VV&F@ DIC.]K)).(\W.))QC #6
M\R?W^UFW&V^N-.22Z<IJ5C#F..LHG.:Z)X'Y0/;VCDX=A]:Y]NC][3LMN7'Z
M+>,TQ<)-9.TS$P/N0K#18_)XPXM)SX<LY\%TFS;G;C;JP0U.L##53/PQU15\
M;NL?CF&1-[O43XE=-36IHV^YE(IF7*"*\]V;!M[6Z'DU)H6>".>&>.)\4+W
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M[&53FGP(FD7&ZZPV5U)9*'9:EIJV\6ZGJ8HZD/BEJ6->W,DA&6DYY@CZ5O\
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M!Y)?YUR)+_.N1?$U?ZZO]R]=/ZAGI_YH+(K*T)M!6:ITO1WB&\P4T=1QXB=
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M\ NIER=NQ<(+KNA17"C?QTU5%231N\Q _>NL5821$1$$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M?F4L4>T5<-/7:W2W#2XI>HJ).*<PQB-W68'PQ@'BQCM4A1!$1 1$0$1$!$1
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MO#;KE;WVN:=P9#(9A+&YQ[ 3@%N>SL*L;5.H*#3%EGNEU>]E-%@'@;Q.<2<
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MU=60RL8 << <&MP3V\FXSWD%=G*/7+16G;E<J6X5MIIY*NE:UL+^;> -.6C
M(&!Z%(4)E#]T]65.C=,LNM)21U3A4QQ/9(2!PG.3D=AY 9\ZB='OWIB6DZRJ
MI;E!.!SB$;7Y/F=Q#]^%:]7305E-)3U<,<\$@X7QR-#FN'@0>14(J=H]$U$Y
ME=9&,<3DMCGD8WZ [ ]2'PYY='4;E[HRRVZC="RNJ&O<T<^JB;@%[CXX&3YS
MYU:?2EI97V.QU36DPPU$D;R!V%S01_A*MK3^GK1IZF,%EM]/1QN^%U;>;OTG
M=I]97KNENH[K0RT5RIHJFEE&'Q2-RTH;J4V;W/LU#IRQZ:JHJOVQ,_L9A8P%
MAXY"6N)SV>5SY*N]9NAI-ZZZ7544DM"VXA\K"">*#(X>7>.'')=#V?;+2-HN
M<5PH+.QE5$X/C<Z61X8X=A <XC*V6J-'6#5' ;Y;8:F1@PV3)8\#PXFD''F[
M$-U)[P:ST?<M+-M&E*>":>1[7F6GI>J;"QO,CFT'U!2OHO?[CW+^L7?91J:V
MK;K2EKHZJFH[- (ZEACF+RY[W-/:.(DD#T$+;Z<T_:]-T3Z2R4;*2G>\R.8T
MDY<0!G))/8!]"&[F'> RV;>6LK98R6MG@JF#LXVAK3R];2/4KMH-86?<ZS7Z
MR6853)7T+@7U$8:T%X('83V'"E&J-(V+5#(Q?;=%5.CY,>26O:/ .:0<>;.%
M^:5T?8M*MF%AM[*4S8$C^)SW.QV9+B3WH;N9=KM04FAM5UU-JJW%T#V]1,U\
M0>^![3R.#W=H./%6[<-U=NJ: OIZ9E9)CE'%;^$GUO "G6I=%:=U+()+U:J>
MHF QUPRR3'AQ-()^E:FW[4:+H9A+%8X9'@Y'7R/E']UQ(_<AO#/>];4-AT)0
M:C-#,:&=L);!'PAS&R $>;D.Y5ON/K#;;4^F:R<@2WIT)]CEM*^.=LF/)XGX
MP0#C.21A7=6VVAKK<Z@K*2":B<T,,#V LP.P8[.7<H;_ *(M$>R.N]I&YSGA
MZ^7A^CB0A7G18IJP2WZJP\4#FQQY/P72 D\O. ?^H+H!>:W4%);*..DM]-#3
M4T8PR*)@:T>H+THDB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MU+QGX+@WK&N [N)F<@=X"S;NUE?N#NW;]NZ"KDIK53\,E<Z,_"/#UCB?'#<
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M5SQ00,&7R2O#6M'B2>05 ]&N^W*U:CO^@+S.Z8VXO?3%QSP<#PQ[6Y_).6N
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M#97SP.XXPSF0&N_*R3DGT>&3.==:9I-7:6K[-7L86U$9$;W#)BDQY+QYP?\
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M#B:X9/+X+@1V'EY\]"7ZUQ:PT;-;YYYZ6&Y4[>*2 X>UIPX@9^CT%5+TP/\
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MUA_[;UJ=9RLU7THM.TML<)FVAL0J'LYAIB<^5V3YN(-]/);;I@_[F63^L/\
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MGL'R0[A8#YB]V?["O=<ISV^[;L[WWRLL%U]K8[. RFK.$NX QW WAP>UQXW
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M$1$$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0<X[V_\
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M$AKF\O#))/;X(CH1%0.G]2ZKVYW)MVDM975U[M%TX6TE=+GK&N<>%I).3\+
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MO=N<&5+6#A#P<\+P.X\B"/$>?"U&\.X]YH-2T&C-"Q,EU#6 &29S0[J [)
M/+.!Q$GD!Z>4.V0JJ=O2%UG';)HIK?4LJ9&.B<',<.O8X$$<B.9'K6;:LB\=
M)G6-=4#C?2-J6Q$_D\,C(A_TY'K0>J]:7WAT]:IKU!K%EQGIV&::C:.++1S(
M:'-P[EW8'F5C;+;@-W TJ:N>..&YTK^IJXF?!XL9#V^ </W@CN4_(!!!&05S
M'T?*CV@UQN-10\H:6*60,[OY&5P'[G()#JO7FK-9Z_JM(;:S0T<-%Q-J[B\
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MQD8*\^M-*7RMZ0^F;Y26Z:6TT\,8EJAC@86F3(//SCZ4%@;M_%AJK^KI_P#
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M4IW\K(Z+:34;Y' =9"V%OG+WM;C]ZJRFTIKK:+55QJ=%VP7W3M<[/L<'B<T
MDM!:#Q!S<D<0R".WP&2^VK<?=^KHJ"^6@::TY!*)9>/(<X]F<'RG'!..0'/F
M@G_1JHWTFT-H,C2UT[YIL'P,C@/W %6>O+:;?36FUTEOH8Q'2TL388F>#6C
M_@O4B"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#B'I#?'%J/\
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M=("JFB9)%H*\OC> YKFO)#@>P@]6ICMGN74:TNU513Z8N5H;#!UPFJ,EKO*
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M[C0T]90S,GI9V"2*5AR'M(R"$&=$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!%5VO=XK?IJ_/L
M-JM-??;Y'CCIJ5I 82,@$X))P0>0*C5+T@C07:*CUGI&Y6)DG9(]SG%H^46.
M8TD><9]""]D6.EGBJJ:*HII&RP2L$D<C#D.:1D$'P(61 1%6>[>[EOV]JJ.B
M-"^Y5]0PRNACE$?5,[ YQP>T@X&.XH+,11O;K54>M-(T5]AI7TC:DO'4N?QE
MI:\M// SV>"U^YFX]EV_H8I;H9)ZN?/44D&"^3':3GD&^<^K*":(J%EW]NE
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MN(R/I!47W-W9M&AJJ&W&GGN=ZF +**F." >SB=SQGN !/F06*BHAN_U5;*N
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M?[F^G8ZO9*R!DQ&7-86Y('ADXSZ @W=FWQN5%JBEL^O],26,53@V.?+@&9.
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M?;J6H:^0X#I0&28/I(QGSJO="[LU>WUOH=+;AZ?KJ#V&WJ(:N-F0Y@[,M['
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MCZ TKEG9FGD?L=N8]H/"Z$@?V8B3^XH0F_1,LT;M/WC4E4.MN5;5NAZY_-W
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M55^JZ[+YZAU+(_J>+F6M)',GO=W]@Y=MTZ3W>TCJJ^P6BSUL[ZZ<.,;'T[V
M\+2X\R,=@*D'N)TK^;-C^H1?A7IMVF+#;*IM3;;):Z2I:"&RT])'&\ \C@@
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MS$>A=P62YTMZM%'<K?():2JB;-$X=[2,_2BO':M462[7>MM=MN5/4W"B)%1
MQV71X/"<^@\EN5SIL7\?6X?Z=3_W(70]3/#2T\D]3+'#!&TO?)(X-:UH[22>
M0"(R(JSK-]- 4U8:<WITN#@R14TCV#UAO/U94[L%[MNH+;'<++6PUM&_D)(G
M9&? ]X/F/-!L46BN6K;);-24%@K:T17:O;QT\'5O/&.?/B P/@GM/<HQ?-Y]
M#6:XOH:F]-EG8[AD-/$^5K#YW-!!]64%B*!;C[D4NB+Q8;?4V^:K==9"QKXY
M T1X<UN3GM^%^Y2RP7NVZAMD=PLM;#64<GP98CD9[P1V@^8\U1'2?_WUV_\
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M)&2QN#FN:>>01VA<R[I[HVRX;DZ1K-.ZBJ?:>DDC-=U/71L $H+N)N!Q>3X
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M$QP4P<0US>(M8.78'<+GG';V=B*N2S[KZ(O%:RDH=14CJAYX6ME#XN(^ +P
M2INJ;W<VATU5Z(N538[336ZYT,#JB%],W@X^ $EC@.1R 1GMSA9-@=;/N.TE
M167B5TLMCZR*61QRY\;&![23^B>'^RB+"U1K#3^E8V.U!=J6A+QEC'NR]P\0
MT9<1ZEX--;CZ1U+6"DLM]I:BJ=\&%W%&]WZ(> 3ZE2FR&E(-S;S?=::VB]L
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M5[&WVRUP'555=*T/QDQOZN,M>/." 5EZ-6HJJSW*[;>Z@/5UM!*]]*''P/\
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MAS')]#'-*Z*-RHA;?;$U< H.KZWV1U@ZO@QGBXNS&.]%<\TXX.F+,(NQS?*
M_H039$F3I#Z]DD.9![+ SX>R6_<%^[-<6M-]]3ZQ@8XVVG#V0R$8XBX"-G_[
M-I/FY+S4%7%H'I07,W1XIZ"\!_#,\X9B;#P<^'6-+<]R#IA<N[/N=!N/NF*?
MDUE-6EN.XB8X71VI+[0:=L=5=KI4,AI*>,O+B?A<N36^)/8 J.Z+=FGN,.K-
M27",MCNLI@9G\KFYTA'FRYH]109^AXUHTI?W#X1K6@^CJQC^)5R:X:U^B[^U
M_P  V^H!]'5N5"]&.Y,TQJS4^CKQ(V"M=,#"'GAXWQES7 >)(+2/$ JTM]M4
M4FF]N;PV>=C:RNIWTE-%GRGN>"TD#P:"3GS>=!"^B 7>X2\ _!%R./\ TH\_
MY*]E5G1JL$UCVNHW53#'-<)7UI:X8(:[#6?2UH/K4SL6L]/WZ\5UJM%SBJKA
M0Y]D0M:X%F'<)YD8.#RY91%'[=DR]*?53I?A-94!N?,6 ?N72"YHO=5'H/I1
M-N5R<(+7=6 ]<[DT-D9P$D^ D;S\!S71-WN]!:+3/<[C5104,,?6/E<[EC'=
MXY[@.U%<\;5%T/20UYU'8(JT\O'KV'^*]/0Y -+JQY^&Z6GS]$GWE9.C)1SW
MK5FL-9SQ.CAK9GQ1<0[2^3K'CU#@'K6OV K(M$[J:KTE=7MIWU,G!3F0X#W1
MN=P ?I,?D>.$'1MX:U]HKFO^ Z!X.?#A*Y6V9DD9LAN;P9QU! ]<3@?W+H'=
MW5%)I70=VJJF=C*B6G?!2QD^5)*YI#0!WXSD^8%5UL/HV=^QUZIZAG!-J!DY
MB#N7D&/JV$^D@GT$(0V_14:T;5M+>UU=,3Z?)'\ %*=[VM=M/J</[/8A/K!!
M'[U6O1-U!!#:KOI:N>(+E3U3IV0R'A<YI :X >+2SF/^92/I.:HI+3MW56GK
MF&XW1S(HX0?*# X.<XCPPW'I*'VS]%XN.TE$'=@J9PWT<?WY5L*%;+6&;3>V
M=BM]6PQU0A,TK",%KI'%^#YQQ8]2FJ((B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B(.(>D-\<6H_TH?L(T3I#?'%J/\ 2A^PC1&H=)]&[XG+#Z9_
MMWK:ZPVXMFJ=76/4-;55D55:7,=%'$YH8_@?QCBRTGM\#V+5=&[XG+#Z9_MW
MJRT94?TJ[_66[2]KM%*_J*6[3NCJI^'/"QG">'UEV?'R5([/LUMX^ST@BM$%
M?'U0Q5^R'DS<OAY:X#GV\N2FNK-,VC5=I?;;_1LJZ4GB )(<QP['-<.8/,]B
MJ\]';3+7.;37?4$$#CSB94LX?\"*@MOMM!I3I(6FV;?5$AHI6AM=!'*9&,&'
M&1A.3D!H:[F3@JZ=#;:VO2.H[Q?*:JK:RX7,N,DE2YIX Y_&X##1VG';X!>G
M06W&F]#MD=8J(BJD;PR54[NLE</#/</,  I@B"AVYNWMKW!ME+27:6HIW4LI
MEBFIRT.&1@MY@\CR^@*8H@\MIHQ;K71T39I9Q30LA$LI!>_A &7$=YQS7S>;
M?%=K/76ZH<]L-9 ^G>YA <&O:6DC/?@KV(@BNVVB*'05@DM-LJ*FHA?.ZH<^
MH+2[B(:,<@!C#0M[>[71WJTU=MN<+9Z.JC,4L9[P?X'O![E[405]MKM19-O[
MG6UUHJ:^>:JCZDBI>TAC<YP.%H[P.WP4PU#8[=J*T3VR\TL=513C#XW_ +B#
MV@CN(YK8H@I(]'FU4\TGM3J6_4%*\Y,,<K<?2 /WY4TVZVPL.@YZFIM1JZBN
MJ&=7+4U4O$\MR#C   Y@'LRIRB#G'?.GAJ]_=!4U5$R:GF;3QR1O;Q->TU#P
M00>T$*17/HZ:<J:R5U#=;M0T$KN-U''(US!Y@2,_3E3G5&W5JU'K.RZEK:BL
MCK;46&*.)S1&[@>7CB!:3VGN(4S16AT5I*T:-LS;98:;J8,\;W./$^5WRG'O
M/_V%J-?;<VS6MULE?<JJL@EM4A?&V!S0'Y<UV'9:>]H[/.IJB(*%Z;V[ME@U
MU>=4TM5625MT#A)%(6]6SB<''APT'M:.TJ:(@A6Y&W-LU\^TNNM564YMTCWQ
M^QW-'%Q<.0<M/R!^]35$01C7NAK'KBVLH[]3%YC),,\;N&6(GMX7>?P.1R')
M5G%T<;+EL4^H;W+0M.13\; /IQC]RO-$&HTKINU:5L\=LL5(REI&'.!S<]W>
MYQ/,GSE49TFXV2Z^V_CE:U\;YBUS7#((,L>00NBE#-<[=6K65YLMRN51613V
MI_'$V!S0U_E-=AV6GO:.S"$(5>^CSIRMKYYK;<;G:Z:=W%)20/!C]#01R'F.
M58>@M$V70]I=06*G<P2$.FFD/%),[N+C_D, >"DJ((7N1MO8M?TT#;PV:*JI
M\B&JIW!LC >T<P01YB/1A1>Q;$V*DK8:F^7.Z7[J/YF&MES$S^SW^C./,K<1
M!$]M=#4&@+'/:[74551#+4.J'/J"TN#BUK<>2!RPT+'N3M[9MP+;!2WGKHY:
M=Q=!40. ?'GM',$$' R#X!3!$%=[9;4VW05QJ:^FN5?7U4T/L?-2X<+(^(.P
M !X@=Z]]#MS;*/<FLUI'55AN%3'P.A<YO5#R6MR/)SV-'>IJB#S72BCN-LJZ
M&=SFQ5,+X7EG: YI!QY^:CVVVB*#0-ADM5LJ*FHADG=4.?4%I=Q$-&.0 QAH
M4J1!!=\JFWTVU6HC=F\<#Z?JV,S@F4D"/'H=PGU%0_HJ::]J=!37>9G#4W:;
MC:2.?5,RUO[^,^@A3[<C0M#KZT4]MNM96T]-#,)\4KFMXW $#/$T^)4AL]NI
M[1:J.W4+."EI(FPQ-\&M&!_!!ZT1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%'M>:3H]::=ELURJ*JGIY'LD
M+Z9X:_+3D=H(QZE(404<[HU:5=\*[W\^F:+_ /=K?Z'V3L.C]24MZM]RO$]3
M3AX;'42L+#Q-+3D!@)Y'Q5I(@T&M=(V?65F=;;]3==!GC8]IX7Q.^4UW<?W>
M*JN+HX6,/$4VH+W)0!W$*;C8!]/#C]RO-$&ITMIRU:6L\5LL5(REI(^?"WF7
M./:YQ/,D^)4>W'VRT_KYD3[O'+#6PMX8ZNG<&R!O;PG((<,GL(Y<\8RINB"D
M[;T==/1UD,MWNUVN<,7P:>60,81X$@9QZ"%;TCJ"P61[^&*CMM! 7$-'"R*-
MC>X>  7N7DNUNI+O;IZ"Y0,J*.=O!+$_L</ H*)Z/MCJ-0:UU!N+60NIJ6MF
MF911'M=Q.RYWH '#YSQ>"N;6&EK3J^S26N^THGIG'B:0</C<.QS3W'FMG;Z*
MFMU#!1T$$=/2P,#(XHV\+6-'8 %Z$%%MZ-UC#^J.H+U[ XN+V/Q,_CPX_<K:
MTCIBTZ2LT=LL-*VGI6GB//+GN/:YQ/,GD%ND00_<7;JPZ]I8H[U#(RHA!$-5
M X-E8#VC)!!'F(*@%#T<[ VIB=<[U>*^FB/DT[WM8W'@2!G'HPKO1!YK904E
MKM]/0VZGCIJ2!@9%%&,-:T=P4%W'VCT[KJJ;75HJ**YM:&^RJ5P:YX'8'@@@
MX\>WSJPT04U8NCYINCN459>:^XWIT1!;%5/ C..SB &2/-G"N1C&QL:QC0UC
M1@- P /!?J("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B(*@U-L!IG4&H+A=ZJXWB*HK9G3R,BE
MCX0YQR<983CUK6^]ITI_^5K]_P"K%_\ NU>*((=H72%HVSTQ74])653Z!LCZ
MV::L>UQ9A@!^"   &9[%5NPUFGU/N#J#<:IA=3T-1-+'0QGM>7'!=Z T8\Y)
M\%?-TM]+=;?44-P@;/23L+)8G]CVGN*_;;04MLH(**W4\=-20-#(XHV\+6CP
M 0:O6>D[1K&S/ME^IA/3D\;' \+XW=SFN[CS^]50SHW6,/$3]07IU '<7L?B
M8/W\./W*]$0:?2>FK5I2S16NQ4K::D8>+ .7/<>USB>9)\5J=P]O;#KVBBAO
M<,@GASU-5 X-ECSV@$@@CS$$*7(@H^BZ.5@;41&Y7N\5U+$<MIW/:QN/#(&<
M>C"N6TVVCM%MIZ"V4\=-1T[ R**,8#0O6B"NMQMH=.:XK1<*OV10W0 --52.
M +P.SC!!!QX\CV<^2T.G^C]INAN<==>*VXWI\1!9%5/ CY=G$ ,D>;./,KC1
M!K-17>DTYI^NNE:0RDHH3(X#ED <FCSDX ]*IOHR:7JPZ\:VN<?427E[Q30_
M_P!LOXG.]!=@#S-SWA71?+/;[[;I*"\4D=71R$%\,G-KB#D9]87KIX8J:"."
MGC9%#$T,8Q@PUK0,  =PP@C>O]"6/75M927VG<XQ$NAGB=PRQ$]O">?(\L@@
MCD/!5K3='"Q"6-M;?;S5449RVG+VM'HSC^ "O)$'@L5GH+#:J>VVBECI:*G;
MPQQ,[!Y_.2>9)YE0_<C:C3NO)F55Q;/2W)C> 5=*X->X#L#@00X#Z?.I^B"F
M+-T>M.4UPBJKS<;G>!%CAAJ'AK#CN.!DCS9"N6&*.&)D4+&QQ,:&M8T8#0.P
M =P7TB"K]>;)Z;U9=GW5LE7:[G(>*2:C< )'?*<TCM\XQGO7FTAL5INPW>.Z
M5U16WFNB<'QFL<"QKAV.X0.9'G)'F5LH@(B("(B B(@(B("(B B(@(B("(B
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M!K2<\SCD3Z$1,$7-NW&V+=R-+0ZHU-JN]3W&K?(6BGG:! 6O+<'(//EG X<
MA75MUIVXZ7L,EMNMZFO)9.YT%1.#QMB(&&').<$.[^]!*%S5N+/J6_\ 2!.E
M;3JBY6>FFA9P&"9X9'B R'R&N&<D'Z5TJN=*S_C"I?U7_P"AN18;&HVLW*MT
M;I[-N35U=0WFV*I?*UKO-S<\?2%ZMJMU[O)JI^C-Q*9M+?&NZN&HX0SK'XSP
MN \G)',.;R/+S9O!<U]+*F%JU!I+4=%B.N#GL+QR.8G,>P^HN=^Y!=.Z.FJ[
M5NC:RT6NX^U]5,YCA-D@$-<"6G'/!6?;BP5FE]&6VSW*O-?5TS7!\_/GEQ<
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M_%Q;_P"LX_LI59VWG^X.F?ZLIOLFHK1;L1ZVJZ:VV_0+X:9]5(\5=;(0/8[
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MZ6O;I-Y4SGO\H]H#YG$_X0@^]4[7ZTTA9:B_:>UW=:ZLHF&>:"0O;UC6\W$
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M/+>$RL)(R0/R@00?4K=7-NU0]K^DWK"EBY13-JB6CLYRL>NDD01$0$1$!$1
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M_M'+X0[5OM]M+W/5V@)[78XF35IJ(I Q\@8"&DYYGEWH-OM+\6.E?ZMI_P#
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M(=M7H.CV_P!-"VTLSJFHE?UU34.;P]8_ '(=P & /O4Q1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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ML!P\MW6 \+>'P([O.$%H(B("(M%K+5=IT=:!<[]4/@I#*V$.;&YY+B"0, >
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MX@^4X'D.X\N7+FO3J/<:YVS>JRZ/@I:-UNK(F/DE>UW6@D/[#Q8_)'=XJTR
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MV"*WSTS&/BJZ8DPS@D@@<R,C&>WO[ JFM]LUOLA=+DZT6GW0:4J9.M/59+V
M=A. 2QP'(G!:<*WML=S+)N!33>UG6T]? T.FHY\<;1V<0(Y.;GEGZ0,HJ<(B
M(@B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("T.M-*6W6-G;;+T)G48F9,YD4G!QEN<
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MW5?2PF;68EIK.S,3'<P#&P8^B1Y=Z5T;)&R6-\<C6OC>"US7#((/:"N<=O\
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MB&6.>%DL+VR1/:',>PY#@>8(([0HE>=LM&W>WNI*G3EMCCQAKZ>!L+V^<.8
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M^MC/I RW/?E9M>1NW+Z05)I2JD?[16EO%-&QQ <0P/>?226LSW81=EAP;[:
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M2!^1+5. /]W!5DV&QVS3] VBLM#3T5*WGU<+ T$^)\3YSS6Q1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MLW1XT5;ZUE1/[97 ,.1#53MX#Z0QK2?IPK=@ACIX(X8(V10QM#&,8,-:!R
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M#\)Y].!Z  .Y5EKO:6^0:UDU?MO=(;?<YG%\]/*>%KG'X1!P00[M+7#&>>?
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M3CL03?H[6V2V[1V-LS2V2<25.#X/>XM/]WA*LA8Z:"*FIXH*>-L<,30QC&C
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M@XAZ0WQQ:C_2A^PC1.D-\<6H_P!*'["-$:ATGT;OB<L/IG^W>J_WY^/3;O\
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M1C@]@<.PC(7)'2 V_LF@['IB"S12.J)YIO9%5,[BDF(#,9[@.9Y =ZZTIO\
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MWF2I$1@E>3DN,;BS)\Y#0?6IRB"(B B(@(B("(B B(@(B("(B B(@(B("(B
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M+?+0W&EAJ:.5O"^&5@<TCT*L.D+0TULV.KJ"@B$-)3>QH8HP20UC96 #GS[
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MU?!C&.'LPN==A;536/?[6-KH X4E)2U$40<<D-%1%@9[U<%?NMHNCL!NQO\
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MGSJ_-,ZNTWJ"X5U%IZX4U9/2-:Z?V."6@.) P['"[L/82J:U[_Q5:4_41?\
MNH+\H+70V^CIJ2BI((*:F ;#&Q@ C &.7@N:V:<MVINE/>:.\P]?21'V083\
M%[FQ,P'>(R>SO74"YWTI_P 6FH?U#_LHT(63OC::.OVGO\4\$9;2TIG@PT?R
M;F<P6^'9CT$A0WHJ::MD&BO= *=K[K52R1.G?S+&-. UO@.\^/J"L'>'XKM4
M_P!7R_X2HOT7OBDHOZ3/_C0^D(WYI8K5O7H6ZT+&Q553-#UKF#'&6S- )\3A
MV/0 K\U'26BKM;_=%#1RVZ!PG?[,#3&PMYAQXN7+SJBND=\:&WGZ]OV[%L^E
MU)7,T/:V4Q>*%];BIX>PGA)8#YLY]8""25N^.WU"\TK;J9F,'!BGI9', \ <
M8(]"KKHUUE'4;LZT-DRVT5$<DU.SAX1P=>.#EW8#CR5E:6O6W%AT11U5#662
MGH&4[7.)+#,XXY\3?AE^>T8SE5KT=;C!=]YM9W*CB?%2U<,L\3'MX2&.G:6Y
M'=R(0=&76)LUKK(G_ ?"]I]!:0J'Z'<KCIW44))X&5<;QX9+,'_"%=6LZ]MK
MTC>ZYYP*>BFE^AA(51]$2WN@T)=*UX(]E5Y:WSM8QHS])=]""]$1$01$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$7CN]TH+/1.K+M6T]%2
M-(:Z:HD#& DX R>2"@>F)_L6E/UU1_"-=#4W^SQ?HC^"YBZ5&I;)?J333;)=
MZ"X.AEG,@IIVR< (9C.#RS@J_P"Q:RTU=IX**UW^UU=8]GDP053'O=@9. #G
MD 452.D^72UO@E^$62\.?U3<?N72"YJW6?)M]O\ 6C64T4CK56AHF>P9QY'5
M2-](;PN [U<-SW2T9061]S.H;?/$&<;(H)FOE><<FA@/%GT@8[\(*CV['%TI
M]5&+X+65'%CTL!_>G1<Y:ZUTV3^=XAG/ZU^?\E[^C-:JVZW_ %/KNXPF(7.1
M\5/G\KBDXY"/,"&C/F/@M%:;C'M3T@[T+WQ4]FO/&]DY!X6MD?QM=Z X%I\.
M:#IY<W]$@$WK6SV?S7' !_>EPK(W#W7TU8=*UM3;[U05UPDA<VD@I9VRN=(0
M0TGA)PT'F2?#Q6BZ+>EJBQ:%GN-?&Z*HN\HF:UPP>J:,,)].7'T$(+E7-^H.
M72[M1E^"6LX?J[O\U;%EW,LMWW K](4T-:VXT?&'2/C:(G%F.( \6>_O'<JJ
MZ1%-5:6W*TKKJG@?)21.CBGX1^4QQ/"3W<3'$#]$H0Z-7-\XXNF-#U7:UGE'
M_P#,2K>9NAHM]E%T]T=N%/P<? 9AUHY=G5_"XO-A5-L73U.M-V=1Z_F@?%;P
M7PTI>.9<X!H'I;&.?G<$&+8+EOIK\2?SO%59S_2AE=(+F.X5K=K>D=67.ZM?
M%9+T'N,X:2 V0ASCR^3(WF.W'/O5O:OW7TI8M.U%PI[U;ZZHZLFGIZ:=LCY7
MX\D8:<@9[2>Q!4.P[7/UYN8Z#X'53AN/$ROPMQT.BWW/:C ^%[*BSZ. X_S6
MRZ*^F:JBTS=+_=(W-FO4H,8>,%T3<^5_:<YWJ />HAM#>:?:K<W4NF-32BBH
MJMXZFIEY,\DN,;B>YKFN[>X@90=&ZK+1I>\E_P $4<V?1P.5,=#YKAHZ^./P
M#7@#T]6W/\0MUO9NCI^@T-<J&T7:CN%TN$+J:*.DE;+P->,.>XM) PTG'>3C
MSK<]'W2U1I7;:C@KHW15M9(ZMFC<,%A> &@^?A:W([CE!9"(B((B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B N<=L_^*/5_P"KJ?\ '&KSO.K=/62K%+>;Y;:&I+0\15%2R-W"<X."
M>SD5SMM]J2R4?2,U1=:J[4,-LG94"*JDG:V)^7L(PXG!S@_0BPZD1>"RWJV7
MRE=4V6X4E?3M>8W24TK9&AV <$@]N"/I46MFYEEN.X=7HZ"&M%RIN+BE=&T1
M.+1EP!XL]GF[D14]PY=,*D,OP2UO#]3/^:Z07.&_\-3I#=;3&N88'R40,<<Y
M:/RF$Y;GN+HS@?HE6Z=T-%BR^VGNCMQI^#CX!,.M[.SJ_A<7FPBJA@'%TQ9C
M%^2SROJ0_P#HFR'+I#:]$G\Y_K>,_P!);_\ 19]@J2JU=N;J;7]3 ^*BD<^&
MEXQVN<0 !X\+&@'SN6MOU6-K^D=+>KDQ[+)>6N<Z8-) ;(!QGE\F1H)';C'B
M@Z;7+NT+7.W&W4=!\'V-6AN/$S''^:N;5.ZVDK)I^>XQ7NWUTHC)@IZ:=LCY
M78Y# .1SQDGL4%Z+6FJJ*QWK4=VC(DO<@$8>,%T8+B7>ASG'^[YT'GZ'A;[E
M+\!\+V:W/HZL8_S5R:W+1HR_E_P1;ZC/HZMRYXV6O=/M;N#J32FJ9A14T\@Z
MFHFY,RTG@<3W!['9SV<@IYOGN?8:30UQMEFNE)<+I<HC2LCI)1+P,?R<YQ:2
M!Y)('?DCSH-=T0&N&A+PX_ -R./_ $H\_P"2O95YL)I>?2FVUOI*Z,Q5U2YU
M7/&1@L<_&&GSAH:#Y\KUZ,W,LNK=47:PVV&M95V[C,CYHVACPU_ 2TAQ/:1V
M@(BI]NN72GU4)?A%M1P_WF8_<ND%S1N',_;CI#T.JJJ.3VFN31UDC6Y !9U<
M@\Y&&OQYPKAO6Z>CK78Y;G[?V^J:&%T<-/.U\LAQR:& Y!/GQCO150[5M<_I
M(:],'8(JT<O'KV?YKT=#DCV'JP?EB6GS]$G_ -5[^B]9:VKJ=1ZUN<1C?=IG
M-@R/A O+Y'#S<6 /T2HWMO=J?:?>+4EBU$_V';+@[^1J'C#  XNB<3\DM<X$
M]Q[>PH.EKN6BTUI?\ 0/SZ.$KE;9IDG^A#<US<\)@('JC=G]RMS>#=/3UJT3
M<H;5=Z*ONE; ZGIXJ29LI:7@@O<6D@  D\^TKS;(Z$EH-FJNVW-AAJ;ZR:25
MKQSC;(S@:"/T0#CSH'14+3M6WA[173<7I\G_ "PI5O<6C:C4_'V>Q#].1C]Z
MI_HYZPH]&3WO1VKJB.UU,=698GU+N!G'@->PN/(?!:1W')]>[Z1&XEIK]*G2
M^FJV&Z7.YRQQO;1O$H8P.!QEN07.(: !XGS9"2=%YKAM)0EW8ZIG+?1Q_?E6
MPHMM=IU^E- V6SS8]D4\.9L<P)'$O>/4YQ"E*((B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B(.(>D-\<6H_TH?L(T3I#?'%J/]*'["-$:ATGT;OB
M<L/IG^W>M]JW;G2FK)C/?+-3S51&#4,)BD/I<T@GUY6AZ-WQ.6'TS_;O5EHR
M@.GMG]#V&M95T5CB?4QGB8^ID?-PGQ <2,^?"GR(@YRZ4$K-1:LTEI"WQ,?<
MY).-TF,F,2N#&CS#R2X^@+H*SV^"TVFCMU&WAIJ2%D$8\&M  _@M2[1>GW:L
M&IGVV-U\  %4Y[R1AO#R;GA'D\NQ2%!&=8:#TUK L=J&U0U4T;>!DP+F2-;G
M..)I!QS/+LYK5Z7VFT9IJO976NS1^S(SQ1RSR/F+#XM#B0#YP,J=(@^9(V2Q
MOCE:U\;P6N:X9!![00J]CV7T''=6W".Q,;,UXD#!/)U8<#GX'%C'F[/,K$1!
MAK:2GKZ26EK8(JBFE:6212M#FO'@0>15<U.QFW]14F8V1T9)R61U4K6_1Q<O
M4K,1!H]*Z1L.E*>2'3UKIZ%LF.-T8)>_'9Q..2?65CN6C;#<M3T6H:V@$MXH
MFAL%1UCQP@$D>2#@X+CVCO4@1!^.:'-+7#+2,$+0Z/T=8M'TU33Z<H11Q5#Q
M)(!(]_$X# ^$2M^B#1:OTE9=7T$-'J*B%93Q2"9C>L<S#L$9RT@]A*]UQL]!
M<;)-:*RG$ENEAZA\/$0"S&,9!S^]>]$&KTSI^VZ9L\-KLE,*:AB+BR/C<[!)
MR3EQ)[2O+JW1]AU=2L@U#;(:QL>>K<[+7LSV\+A@CZ5OD00'3NT&B+!7,K*&
MQQOJ6'B8^ID?-P'Q <2,^?&5/D1!X;S:+?>Z!]%=Z*GK:1_,Q3L#VY\>?8?.
MH [8K;]U1UOM(\#.> 5<W#]'$K-1!K[%9;;8+>RALM%!14C.8CA9PC/B?$^<
M\UBU+IRT:FMQH;]005M-G(;*.;3XM(YM/G!6U1!7-JV4T%;:UM5#8F2R-.6M
MJ)I)6#^RXD'U@J8ZBT_;-1626T7BE;/;I>'BA#BP>206X+2",$#L6U1!XK+:
MZ.RVJEMMLA$%%3,$<48<7<+1W9.2?6M1J_0NF]7M9[H;5!5R,'"R7FR1H\ ]
MI!QYLX4D1!7%LV2T#;YQ,RQ-G>#D"HGDD;_=+L'UA6!)14SZ!U"86"D=$83$
MT<+>#&.$ =@QRY+.B#2:1TI9M(6Z2AT]1BDI9)3,]G6.?EY &<N)/8!]"W:(
M@@6H]HM$Z@KI*ROLD;:J0\3Y*>1\/&>\D-(!/GQE;71^@=,Z0+GZ?M,--.\<
M+IR3)(1X<;B2!YAR4H1!XKS::"]VZ:@NU)#64<HP^*9O$T^'K\Z@#-C-OV57
M7BQD\\]6:J4L^CB5F(@P4%%36ZCAI*"GBIJ6%O!'%$T-:P>  6FTCHVPZ0;6
M#3M *,5;P^;$CW\1&<?")QC)[/%2!$$-U=MEI+5E6ZKO=GBEK' !U1&]T3W8
MY#B+2,\O'*^]'[;Z4TA4&IL5HBAJR"WKY'.ED /: 7$X]6%+T0%KM26F&^V"
MXVJJ_F:VG? X^'$",^D9RMBB"B^BY<9J&BU!HZY_R=PM-6YXC/R2>%P'F#FY
M_MA6/JW;C2>JYS/?+-3S51Y&HC+HI#Z7-()]>5N*?3EGIK_47NGMU-'=JAG5
MRU368>]O+D3W_!'T+:H(#IW:#1%@K65=#8XGU,9XF/J)'S<)[B XD ^?"G-7
M305E-)35<,4]/*WA?%*T.:\>!!Y$+*B"M:_8[0%94NG=8^J<XY+8:B1C?[H=
M@>I2[2ND[%I2E=3Z>ME/11OQQE@)>_'9Q..2?65O$0>6Z6ZCNU!-17.EAJJ2
M8<,D,S YKAYP57\>QNW\=9[(%CR0>+JW5,I9]'%^Y64B#!045-;Z.*DH*>*F
MI8F\,<43 UK!X #D%!]]M1/TWMG=ZB N%54M%'"6]H=)D$^IO$?4I^OQS0X8
M< 1X%!771^TR=,[9VUDT?!5UP]FS@C!R\#A!]# T>G*L9$0%$M6[<:3U9,9[
MY9J>:J/(U#"8I#Z7-()]>5+400'3VT&B+#6LJZ&QQ/J8SQ,?42/FX3W$!Q(S
MY\*?(B"%:LVNTAJJM=67BSQOK'?"GA>Z)[_TN$CB])RO=H_0.F='\3M/VF&F
MF>.%TY)DD(\.-Q)QYAR4G1!'Y]&V&?5T.IY: .OD+.!E3UC^0X2WX.>'L)'8
MI 0""" 0>1!1$%=WG9?0EVK'U,]B9#*\Y=[&E?"TG]%I 'J"W6DMO-*Z3GZ^
MPV:GIJG!;U[BZ20 ]H#G$D>I2I$$?U?HZQ:OBI8]14 K&4KS)$#(]G"3V_!(
MSV!2    #L')$0>"]V>W7VW24%XHH*VCD^%%,P.&?$>!\XYJ Q[%[?LJ1,+(
MYV#GJW54I9]'$K-1!YK;04EKH8J.W4T-+21#ACAA8&M:/, L5[M%OOEMFM]W
MI(:RCE&'Q2MR#X'S'SCF%[D05Y9]F-"6FXLK::Q,?,QW$P3S/E8T_HN)!]>5
M)J#25DM^IZ[45)0B.\5L?53U D<>-OD\N$GA'P&]@[EO408*^BIKA1RTE?3Q
M5-+,WADBE8'->/ @]JKJHV+V_GJ3,;(YF3DLCJI6M^CBY>I68B#2:6TI8M*T
MSX-/6RGH628XS&W+GX[.)QR3C)[3WK%7Z-L-?JJDU)5T DO-(T,AJ.L>.$#.
M/)!X3\(]H[U($0%'Z71MAI=65.IH* ,O=0S@DJ.L>>(8 ^#GA')H[E($0>2[
MVZEN]LJK=<8A-1U49BEC)(XFD8(R.8]2\NF-/6S2]HCM=CI12T,;G.;'QN?S
M)R3EQ)6U1!']1:-L.H[G;;C>: 5-9;G<=-(9'MX#D.[ 0#S //*VMUMM'=[?
M/0W.EBJJ.9O#)#*WB:X>A>M$%<4.R>@:.O;5QV%CWM/$V.:>22,']%SB#Z#E
M2FTZ1L=IU!77NW4#(+E6L$<\K7NPYHQ@!N>$?!'8!V+?(@J+I.W\VS;LVNG)
M-;>9VTT;&_"+ >)^!ZFM_M*;;9:<&E-"V>SD 300 S8[Y7>4_P#ZB5LKKIVT
M7:X4-=<[=3U570NXJ:65G$8CD'(]8!]2VJ B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B M5J;3UKU/:GVV^TC:NB>YKS&YSF\P<@Y:0?
MWK:H@KK_ $)[>_FY']9G_&MEIS:_1VG+O#=++98Z:OA#A'*)I7EN06GDYQ'8
M2%,T0:^_66VW^VR4%ZHH*VC?S,4K<C/<1X'SCFH)2[&Z IZL3ML9>0<ADE3*
MYGT%W/UJRT08J6FAI*:*GI(8X*>)H8R.-H:UH'8 !R 6IU7I2QZLHFTNH;;!
M6Q,.6%X(<P_\KA@CU%;M$%=V;9?0EIK654%C9+*P\3?9,SYF@_HN)!]84SU#
M=Z73]AKKK7.X*6BA=*_'> .P><\@/2MBOF2-DK',E8U['<BUPR"@I#H\Z6JZ
MNONNX5^CZNOO+WNIHL8#(G.XB[UD #S#/>KGNMNH[M034-SI8:NDF'#)#,P.
M:X>@KU- : &@ #D .Y$%9C8O;\577^T;NW/5FJEX/HXE8=LM]):Z&&BMM-#2
MTD(X8X86!K6CS +TH@U&I]-6?5%O]A7^WP5M.#Q-$@YL/BUPYM/G!4/MFR6@
MK=6-J8[$V9[3EK:B>25@_LN.#Z\JQT0?C&-C8UC&AK&C :!@ >"CNL-$:=UA
M'&W4-KAJW1C#)<EDC!X![2#CS9PI&B"!:;VBT3IZO96V^R1NJHSQ,DJ)'S<!
M\0'$@'SXRIZB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B((EJG;C2>JKD+A?[/'5U@C$76&61
MAX1G PUP'>5I_P#0GM[^;D?UF?\ &K%1!%Z"U:<VWTM<IK92,M]K@#ZR=K7N
M?Q$-&3EQ)R0T !5GT?=,U=SO-VW&OL755=V?)[#AQC@C<[)?Z\!H\P)[PKRD
M8R1CF2-:]CA@M<,@K]:T-:&M #0, #N0>6[VRAO%OFH;K20U='*,/BF:'-=Z
MC_%5\S8O;]E5U_M&X\\]6:J4L^CB5F(@\]NH:6VT4-';Z:&FI86\,<,3 UK1
MX !>'4NG+1J:WFAOUO@KJ;/$&R#FT^+2.;3YP5MD05O;=D= T%8VICL8E>TY
M:V>>21@_LEV#Z\JQHXV11MCB:UD;0&M:T8  [  OI$$:UAH73FL&1C4-KAJY
M(QADN2R1H\ ]I!QYLX6ITSM)HK3E>RMMMEC-7&>)DM1(^8L/BT.) /GQE3M$
M&AUWJ2GTEI*YWJJP6TL1+&$XXY#R8WUN("KGHY:*J;/::S4][:1>+X>MX",&
M.(GB&1W%Q/%CPX?.KBEBCF862L:]AY\+AD+Z0:W4-AM>HK<^@OE#!6TCCGJY
M6YP?$'M!\XYJ#T>QV@*6K;4-L?6%IR&2U$KV?W2[!]!RK*1!CIX8J:"."GC9
M%#&T-9&QH:UH'8 !V!:/5VC-/ZO@9%J*V0UG5_S<ARV1GH>T@@>;.%($00#3
M^SVA[%7,K**R1OJ8SQ,=42OF#3W$-<2,^?"GZ(@B6L-N=*ZOG$]^M,4]4!PB
M=CG1R8[@7-()]>5ATEMAI'2=6*NRV>)E8/@SRO=*]OZ)<3P^K"F:("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@XAZ0WQQ:C_2A^PC1.D-\
M<6H_TH?L(T1J'2?1N^)RP^F?[=ZLM5IT;OB<L/IG^W>K(EFBAQULC&9[.)P&
M49?:("",@Y"("+YDD9$WBE>UC?%QP%^L<U[0YC@YI["#D%!^HB("(B B(@(B
M("+PVR[VVZ.G;;+A1UCH'<,HIYFR&,^#L$X/(]J]R B+POO%MCNC+;)<:-MQ
M>.)M*Z9HE<.W(9G)^A![D1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$0D $DX 6#V;2__C,'_J!!G18/9M+_ /C,'_J!9FN:Y@<UP+2,
M@@\D'ZBP>S:7_P#&8/\ U OJ.I@E=PQ31O=X-<"4&5$1 18ZB>&FA=+4RQPQ
M-[7R.#0/65AH;C15X<:&LIJD-[>IE:_'IP4'J1%YZVNI*&,/KJJ"F8>0=-(&
M ^LE!Z$6&DJJ>LA$M)/%/$>Q\3PX?2%F0$7DKKG04#FBNKJ6F+NP32M9GZ2O
M1#+'/$V2&1DD;AEKF'(/H(0?:(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B+$VHA?.Z%DT
M;IFC+F!P+AZ0@RHB("(L4M1#%(R.6:-DC^3&N< 7>@=Z#*B(2 "2< ("+PP7
MBV5%1['I[C1RS]G5LG:YWT Y7N0$7Q-+'#$Z2:1D<;1ESGG 'I*\]#=*"O<Y
MM#74M2YO:(96OQ]!0>M$1 1%X8[Q;)*GV-'<:-]1G'5-G:79]&<H/<B+YD>R
M)CGR.:QC1DN<< !!](O'176WUTCHZ*OI*A[>UL,S7D>H%>Q 18JFH@I872U4
MT<,3>U\C@UH]96.AN%%7M<ZAJZ>I:WM,,K7@?04'I1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$'$/2&^.+4?Z4/V$:)TAOCBU'^E#]A&B-0
MZ3Z-WQ.6'TS_ &[U5_2>H'7G<_1UIZTL;61QTX/:&E\Y;G'T?0K0Z-WQ.6'T
MS_;O5?[\_'IMW^MIO^Z1&XZ+FH:E]IN^DKL]_L^S3G@8\Y(C)PYO]EX/]X*\
MUS?KH_Z-^D-:]1,_DK3?!PU)[&CBPR3/H/!)Z2KRUWJ&'2ND+K>I\$4D)<QI
M_+D/)C?6X@(.<M_*^IUOKJ[6RBF?[5:7M\L\W"?),H'E>OB+&>IRM3HP/)VC
MH.)Q(;43@9/8.,JO=#Z?FI.C_K;4EQR^XWV&68R.^$8VDX/K<7GSY"L#HO?%
M)1?TB?\ QH+.MUSH+DU[K=6TM6V,\+S!*V0-/@<$X7IED9%&^25[61L!<YSC
M@- [22N;]LQ_H\Z0-[TN_P#D[;=@33#L;WR1?0"]GI4^Z2FH_:';*LIXG\-5
M='BB9CMX3DO/HX01_:"(LR@KZ2XP=?;ZJ"J@R6]9!('MR.[(.%Y;Q?[/90TW
MBZT%!Q#+?9-0R/B]'$1E5A9W':7H_-J^J;[8LIQ.YKQVU$Q& 1_R\30?,U1;
M:':>@UE8QJW7TE5=:ZYN=)'&^=S & D!Q+2"2<' S@#')!?=HO5KO,3I+1<:
M.NC;\)U-.V0#T\).%[US#N_H5FU-1;-8:"GJ*)C*@0S4[I"]HR"1S/,L/"00
M2>T*Y=4ZEJJC9VMU'8PYE5-:_94/#S,9<S)/I:"3ZD$@N>J]/VNJ]BW.^VND
MJ?\ RIZN-CAZB<K:12PUE,)()6302-\E\;@0X'O!"YSV'T#H75^CC67A@NE^
MDDD-8V2I>V2+RCCR6N!P1@\7/))Y]RNS0.C;?H>U5%ML\M2^CEJ'5#63OXS'
MQ!HX6G Y>3GGSYH(SM!M_I[1E9>9=/WIUSDJ"R.5IE8_J0TN(:>'OYGM\%H^
MD3N%<-*VBW>Y2\4T->ZK,=0Q@BF>UH:3@M<#CGYE'NB9_P")ZY_7P_XIEH>E
M#H:RZ?@I[[;8IF5]SKY'5!=*7-)(+C@'LYHKHFAU59)**G?+>[7UCHVEW^M1
MCF1S[U"9=$:5O6ZU-J^GU"R:YL+'BC@J(W->YC.$'EY6, $CS+P4&P&AIJ&G
ME?2UW&^-KCBJ=VD*O*'2ULT=TG-/VJR,E91B/K )'EYRZ&3/,^A!U*2&@DD
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M7B;#M5I=K  #1,=R\3S/[R@HO76GZO8O5=HOVE:VKDLE7)U<]-,_.<<S&[
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M#N%D4#L<?,M:?#B=ASLD' &%ZMT=F*/1^G9=3:&K;C25ULQ,]IFR2P'FYK@
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M'+U5+1POQ@GF&CM PW!<<9)<%];K[8_Z,J*GU?H*X5U*ZDF:V>-\G%PAQP'
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MRG:'#(."02" W/(<B3C(6KOFKMU-L:BDK=8R4%\LDT@C>^%K1PGMP'!K2UV
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MM5;[A"V>DJ8S%+&X9#FD8*J+HF?%A/\ UE+_ ((U<LLC(8GRRO:R-C2YSG'
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M?]:W^J'%5S21CC/;_*.D>_Z2&_0I-L/N)9+Y8+3I"E;6-N=);N&1SX@(SP@
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M+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@>T6X?SDM_8-/\
MB3VBW#^<EO[!I_Q(B![1;A_.2W]@T_XD]HMP_G);^P:?\2(@>T6X?SDM_8-/
M^)/:+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@>T6X?SDM_8
M-/\ B3VBW#^<EO[!I_Q(B![1;A_.2W]@T_XD]HMP_G);^P:?\2(@>T6X?SDM
M_8-/^)/:+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@>T6X?S
MDM_8-/\ B3VBW#^<EO[!I_Q(B![1;A_.2W]@T_XD]HMP_G);^P:?\2(@>T6X
M?SDM_8-/^)/:+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@>T
M6X?SDM_8-/\ B3VBW#^<EO[!I_Q(B![1;A_.2W]@T_XD]HMP_G);^P:?\2(@
M>T6X?SDM_8-/^)/:+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2
M(@>T6X?SDM_8-/\ B3VBW#^<EO[!I_Q(B![1;A_.2W]@T_XD]HMP_G);^P:?
M\2(@>T6X?SDM_8-/^)/:+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I
M_P 2(@>T6X?SDM_8-/\ B3VBW#^<EO[!I_Q(B![1;A_.2W]@T_XD]HMP_G);
M^P:?\2(@>T6X?SDM_8-/^)/:+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<E
MO[!I_P 2(@>T6X?SDM_8-/\ B3VBW#^<EO[!I_Q(B![1;A_.2W]@T_XD]HMP
M_G);^P:?\2(@>T6X?SDM_8-/^)/:+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW
M#^<EO[!I_P 2(@>T6X?SDM_8-/\ B3VBW#^<EO[!I_Q(B![1;A_.2W]@T_XD
M]HMP_G);^P:?\2(@>T6X?SDM_8-/^)/:+</YR6_L&G_$B('M%N'\Y+?V#3_B
M3VBW#^<EO[!I_P 2(@>T6X?SDM_8-/\ B3VBW#^<EO[!I_Q(B![1;A_.2W]@
MT_XD]HMP_G);^P:?\2(@>T6X?SDM_8-/^)/:+</YR6_L&G_$B('M%N'\Y+?V
M#3_B3VBW#^<EO[!I_P 2(@>T6X?SDM_8-/\ B3VBW#^<EO[!I_Q(B![1;A_.
M2W]@T_XD]HMP_G);^P:?\2(@>T6X?SDM_8-/^)/:+</YR6_L&G_$B('M%N'\
MY+?V#3_B3VBW#^<EO[!I_P 2(@>T6X?SDM_8-/\ B3VBW#^<EO[!I_Q(B![1
M;A_.2W]@T_XD]HMP_G);^P:?\2(@>T6X?SDM_8-/^)/:+</YR6_L&G_$B('M
M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@>T6X?SDM_8-/\ B3VBW#^<EO[!I_Q(
MB![1;A_.2W]@T_XD]HMP_G);^P:?\2(@>T6X?SDM_8-/^)/:+</YR6_L&G_$
MB('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@>T6X?SDM_8-/\ B3VBW#^<EO[!
MI_Q(B![1;A_.2W]@T_XD]HMP_G);^P:?\2(@>T6X?SDM_8-/^)/:+</YR6_L
M&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@>T6X?SDM_8-/\ B3VBW#^<
MEO[!I_Q(B![1;A_.2W]@T_XD]HMP_G);^P:?\2(@>T6X?SDM_8-/^)/:+</Y
MR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@>T6X?SDM_8-/\ B3VB
MW#^<EO[!I_Q(B![1;A_.2W]@T_XD]HMP_G);^P:?\2(@>T6X?SDM_8-/^)/:
M+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@>T6X?SDM_8-/\
MB3VBW#^<EO[!I_Q(B![1;A_.2W]@T_XD]HMP_G);^P:?\2(@>T6X?SDM_8-/
M^)/:+</YR6_L&G_$B('M%N'\Y+?V#3_B3VBW#^<EO[!I_P 2(@@VHMBKCJ*\
=U-UO&LQ45]06F63VK:SBPT-')L@ Y =R(B+N_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g109079g01g99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g01g99.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1;"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %J4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@
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M2I5TI0HJY5?,?/B45]!(@
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MIQ2<H87H1>.CYL#V>#ILKFE>V="ZMI.="O3C5IR<7',9+*>'S7)^)W
M
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M%3MJD80@N?H-2DW\&+;Z^)>G9SHD[?8&KZU>_OA>QJ0J<_R(S?#T>.GJ//\
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M5NJ7#7N7%TV_S'%9Z/S7D!Z"IPC3@H06(KDD<@
M
M
M
M
M   !U75Q3M;:K7K-JE3BY2:6<)': /SW[8M6M]4[4+N]LU4G0HUYPE+NY+FJ
MTV^J\FCV=V,[HTO<>P]&6E5IU)6=I2M:RE2E#AJ0IP4EZ26<-]43H
M                                  #6[DN+JTT&_KV%/CN:="<H+B2P
MU%M/GRZX-D /+79GVH;HW10U';FNUZESJEU<]PLTZ<%3H-*,^<8)/&6^N7X'
MI/;>E0T/0;'3*4^\A:TE24L8SCU9?TFR
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                           !UUJ].C^Z2X?B,66KV,4W*NDE_-?V 9P-
M9]WM-_2E_8E]@6NZ;^DK^Q+[ -F#"6JV3?*NO[+^PRJ56%6.:<LH#F
M
M
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MK^I63X8U$EXIQ1O;#>:;4;N@E_/X_J2 F0,&PU6SODO>U93?BN%KZ49P
M
M
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M"V@5[I>Z[FVQ"Z7>P7+"Q'ZB7:7KEEJ#4:-3\:_R.%_3@#:
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M_FM &NT;6[#6*/>:?7[V/]"4?I2-B:4UFLZETZVBT;K.X  0D
M                                     !B:EJ%OI]'O+F?"O#DWGY""
MZUN6XOW*E;_BZ+Y<+P\_,!+-6W%:6":356JOR,M?/@ANH[COKYN%.;A3?Y.(
MOY\&):Z94J>E5]%>77)M[>VIT%BG''Q@:>AIU>L\U9..?/G]9L*&FT*?PH\3
M\\M?69P"-N,81BL))(Y            !QG3A-8E%-&%7TRC4^ N!^?-_69X
MT%6QN+9\5)MI>*Y&WT/=%Q9R[J\;JTNB7*/#Z^2YF08E[90N8^4O,)VG5A?V
M]_3X[:HIKQPGR,HJ7N[K3JRJTWPM=)<G\Q+-"W7"IPT;_,9]%/'7XD@)<#Y"
M2G!2B\Q:RF?0
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M)1IO"_G,RQAX]?%6">7S+>;Z=,^TW7')N-?ACX+@IO\ \)Q_"9KWZ1_W=/\
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MLQ7#/S-=1K7>DW*G2FXM/R3R$K7!H= W#1U&,:=5\%QTQUR_D-\
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MO/&_8HX7@<WD<&V..JG>';XGJE,T]&3[;?V6$ N:Y T'5
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MM4&OT;4Z.I6ZG3?I+JC8
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ME-YC)93 Y@
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M.)+'-9"5G PM)U&EJ5K&M1Y9ZKR9F@
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MJ%RJ-!_B8=,>.<?8<--LHT(*<N<W_B8^D6F?QU19\L_&;<   @
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M.5E.M)-/'HMR2SG&>BZ%SV=S2O+:G7H24J=2*DFO)K).AW  @
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MWN)N=E.LTT\>BW)+.<9Y)="YK.YI7EM3KT)*5.I%237DUDG0[@ 0
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MC]HBLS$3MU8?&N1Q.9Q:\CZ%^R?K$7K^Y9I[Q^']/C^30Y6+7WP^  ]RTP
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M([M;U&5[<-)_BXO$?6C6FWBQ],;GRT,V7KG4>  &9@
M   'V$G"2E%X:>27[?U974>YK/\ &I=?,AYRHU)4JBG!X:*7I%X9,>2:3M90
M-;HFHJ_M_2QWD?A?.;(TIB8G4NC6T6C<!H=RZ;WU+OZ*_&1ZKS-\?))2BT^C
M%;36=PB]8O&I9G8_N:,%]R+J7-Y=)XZ))M^!;9YFU6A4TK4XUJ#:B^<2_=G:
MY'7M&HW+PJW"N\BO!O/J]1I<_!$3]6OB76])Y4VK."_FOC]&\ !S79
M                       &FW5J*L--DD\5:B]#XFL_2031:'%5=672/3YT
M9>[[UWFK3IP>:=/'#\<5DRK6BJ%%07@!W  ( #KKUH48<51X0'88US>T:&5*
M7I>1J;K4JE7,8>C'Y3 ;;ZL)TV=75IO]SCP^W#,&K<U:OPY9^(Z02E]R_,'P
M ?1D^ #MI5ZE)^A+!G4M6JQ_=%Q>S"-8 ));7]&ORSB7D99$5RZ&9:ZA5H<G
MZ4?((TD0.BUN87$,P?/Q1WD( EE@%,D6FLQ2=3[$?FY+ED^GQ//M/I\;]9P\
MS%R;?OG>T^_M,?E^3K89I-?L!A/J :'&Y%^+EKFQSWJR6K%HU+@#E+FLG$^S
M>F>H8_4./&;'_./B7(R8YQVU( #H*   XU8*I3E!])+!IM.KRTO5Z=27P5++
M]ANS5:W1S!55USAA,+*MZJK4(5(])13.PC.QK_O[&5O-YJ0;?Q<D28
M                &)K'[T7W]1/]EF68FL?O1??U$_V6!YUJV=6^UB[I4%FI
MQR:7GS_Q)%LC=%?;NHNSOL^]74X:D>7H2RDWGGT2\#HVG_#>7]=_YD2=]H6S
M*>HT*M_8IJZA%R<5^4EQ-^*2YLL)Q8W=&^M:5Q;RXJ52*E%X:Y-9.\HS9.Z;
MC;FH2LKV.;=U.":;^ \I-YP^B3Y%V6%W2OK2E<6\E*E4BI1:\FLD3 [P 0
M            WA-OHBE.UO<;OM1^YEK)]U1:4_7-.7J\F6!VC;@6AZ)/@PZ]
M?--+R34N?3U%*Z%:3U"\G=7#;7%EOSER9U.!@C_FM[>'$]6Y4Z_=Z>9\_HV^
MWM.5K;JK-?C)K/LRC<'SH?3;M:;3N7,K6*QJ  $)"/;@U?NE*WMWZ?23QT]1
ME;@U%6ENZ<'^-FN7LZ$+G)SDY2>6S/AQ[^Z6MGRZ^VKXVV\OJ #::0
M               &?I&HSL:Z><TV_21@ B8B8U*:S-9W"Q[:O"XHQJ4GF,NA
MVD*V_J;LZSIU'^*F31--970TKTZ)='%DC)&WTZZ]*-:E*G-93.P%&1#:<[C;
MNLPK4)8X7B,NN5CG])Z&V]J]#6]+I7MM\"IGEY8;7U%,:[8>_;7T?W2/1_3]
M!W]E.Y9:5J+T^X:5M6RVW^3A-KP\RG+Q?7Q]<?BAG].Y'[MF^E;\-O\ *\@
M<1Z8   Q-6NE9:?6KO\ (2^=X^LRR&[]ODHTK6#YOBX_]UH",:=!W5XYU7Q>
M?R$@-?HU'N[?C?6?U-FP!(  @.,YQA%RD\)'3=75.VCF;Y^"-#=W<[B69/DN
MB!$-E=:K&.8T5Q/\[)J:MQ5JO,YMOY#J!*SZ?       #Z=E*M4I2S"33.H
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M\RSX-1>/G,XAVMT'8:K"O#DI2XU\6"\5C)2<<^ZG7.#)7-7V>F :79^J+5]
MM;IRS4E',^6,<W]ANC@6K-9FL^SUU+1>L6CQ( "JP
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MR8R=I[=/_EJ\N_?IT  ]PTP  #INJ?>V\X8ZH[@!K=IW+M-;A#.%4?=OY?\
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M=UL=IM7<QI\;QGS.)R?3V'$^D_LM3C?N49,%=6GM;YW#G\F;=>K  /3-<
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M"7"M/NZ4Y_FQ;*^U"O[YO*M7PD\DRW!7][Z=*2_*?#\J9!39P5[3+3Y-N\5
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M_M8/9L0#JNJO<T)5/+'TA#4ZS<\=14H/T5U]?0U9]DVVVSX2L
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MSG/V%K%2V[X]3CGS?T,$)"NB 1PK2X*4I>00C^IU>]N9>7+'R&&?6\MGPE8
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MSN.NXCQ4*L?.+7S""?"N)K$Y+UGP[KR'=W56'E+!TG0CPY,]I  2
M      #7ZGJ<;&45*FY\7D\&53KJ=JJW#A./%@KU1O2TTM$1/M+N!K=/U6-Y
M<2I1I.#CXMY-D36T6C<%J32=2  E4       !*=FK%"Y]<H_62,T>TZ7!9SE
M^?A_2;PT<GXI=+#&J0  HR-)NJ"=@Y>*Q]*)UV*57/2+N#Z0X,?&YD)W/'.D
MU7Y</[2)9V%3XK35HY^"Z7_C*<J-\:?U9N!.N9$?,+1 !Q'IP
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MFC<5Y5[6G*:C.7/+2ACGUZ$<>8C)6MHG\N\3_A;F5F<%[XYB(F>_:8F?ZK3
M!UGG B>^=V4-"MI4:>*EW./*&>B?$L]/-#?6ZZ.A6;ITI*5W4348I\X\I>ES
M]:*MT+2=0W?K$J]>4I4W/-2;7+JLKU=28@<=N:)=[KUJ5:HN&C.JYU9Q7+X2
M;77UEYZ-IM+2K"E:T')QA%1RWGHL''1=*MM)LJ=O:TXQ48I-^;22S\QGB9
M$   *K[;JS5&WHYY-1ECXY$7VW!0TZ+7Y6'\QO.W"?\ E]I#/_(Q>/\ 6D:G
M0EC3:'KA'Z#N<>-<>KRW,G?+LV  +,8  (MO%?C:#_F_61PE.[Z>:5*IY<OI
M(L;F'\+G9XU>0 &5B              '&<N&#EY+)KK#58WERZ,:3BUXMY*S
M:(G4K12;1,Q[-F#7ZGJ4;%P4J;GQ>3P9=M55>A"HEA26<"+1,Z)I,1U3X=H
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M.$G_ #HIG-)16(I)>2     ;+1(<5>4OS<,UIO\ 1J/!;\;ZR V  (5
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MNS0])M](L:=M;1248I.7BVDE]1]T72K;2;*G;VM.,5&*3:ZMI)9^8SQ,@ "
M       !0W:M0]Z;MA/IQKO?^\D9>GRX[&A+S@G\QG]M]LO?EK<XYJE&&?\
M6FS3;?J]YIM)?FQ4?F.]BGJP5EY3D5Z.5>/EL@ %0  8NHVZN;2I3?DVO;AE
M?U:;I59TY?"B\,LHB6Y[#NZOOBG'T)?"]K;,^"VIU+6Y%-QU0T  -II
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M/\20 EIM;H8DJJ\>IJ257%&->E*$O$C-:FZ51QDL-$P0ZP $@
M       &?I%#O*_&URCS,*$7.2C%9;)+8T%0H16.>.81+( !" PM7T^GJ5C5
MMJLI1C.+CF+P9H I+<NS[W2'*I34JUNN?&EC!&%F,N64T>D:E.%6#C4A&<7X
M2640C=.Q*%XIW&G)4JV,N/-\7L1:)$+VSN^\T:7!/-:@WSC)\_B;+6V_N&SU
MFA&5"I%5<9E3SEHHW4]-N=-KNE=TI4Y9Y<2QDZ[.[KV=55+:K.$D\\G@:'HX
M%<[4W[&HXV^K-1?157A(L*WKT[BE&I1FIPDLIHKH=@;267T!B:I75"TFV\-\
MD!K;>#O=8I4\9XI\/SEI6U/NK>E3_-@H_(B!;&M/?&HRN)+,81XD_7E%@A(
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MHC3Z70>HZS2@_@N6&_4$PG.T;-V>DQ4EB4Y<?Q-(W1QHP5*E""Z1BE\AR
M                   !B:Q^]%]_43_99EF)K'[T7W]1/]E@4EL;^'*_KO\
MS$65OK=M#0K65"E+BO:D7PQ7Y.5))OU913=IJ532M;N+FBDZBG)1SX/BS]1M
MMO:-?;PUB=>XE+N74XJD^JYR3:7/E\(MH?- T6_W=K$KBKET95..I-],<2RE
MY?"+OT?3*&E65.WMHI**2;\WA+ZCYHFEV^D6%*UMHI*$4G+Q;PE]1GD3(  @
M          !!NUZP]];7E5@OQE*HI-_S4I-E7;/K9I5:+?//%]"+XW+:J\T#
M4:#67.WJ*/MX6D>>M(;T[7:U"IR:DZ6'Y\2.QP+=6*U/AYWU:G1GKD^>R8@
MS-0   Z;JC&XMYTI=))H[@#6U?:G93LKF4)+T<OA?FC$)]JMA"^MW&7*2YQ?
MKYD'O+:I:UY4JJPUT?F;F/)U1^;GYL71.X\.D &5A
M   ^QBY227-OD?$LM)=23;>TAQ:N+A>'HQ96UHK&Y7QTF\ZAF[=TUVE%U*JQ
M4GX>74W(!HVM-IW+I5K%8U  "$A\;PF_(^F/?U50M*LY=$L".Y,ZC:*7$97^
MXE3I\^*HL>SED])6-M&TM:="'P8+E\I0O9=8/4-V6]2ISIT^+B_L2Q]!Z!-3
MU*_W5I'M#I^BX_\ ;MEGWD !S':                          ! ]]V#I
MW:NXKT:O7'AA11C:7<*M0P_A+K\I.-7L8W]C4H2ZR7)^7-?85E85)6EWPU5A
M>*?L8$A-9JUFZJ[RFN:ZKS-FN8"$1:P\,^&VU.PPW5I+VHU)*P
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MNF\%.5Y4CZ4LQ6?B>30PA+5=3IVT$W3SS?D6/:4(V]O"G!)**2Y!+M
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M$]6T.I;N52W3G3ZX7-I&WCRQ/:6EEP37O7PT@#33::PT#,UP
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MRIV]K3C%1BDVES;22S\QSTS3;;3J+IVM*,$WEO'-OEX_$9A,R  (
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MUMM^HMVWK4[BC"K2DI0DDTT5TEV
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MT5I=C2TVQI6MNL4Z:PC%S<OTL?TX\SY;7I>#ZV6<]O$>/U90 .,]&
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M->SB\V9NC7+^.HT*VGZC5JU8V\8-2A*<U+KTZ)("S
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M>%>'%!IG::2]L;S2*_XQ-+P?@_\ WDS+/4:=6*4WPS]?B#3/  0
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MS'V6;C>@;CI.K/%M7_%3ST2;3;^8],V]6%>A3K4WF%2*G%^::RBLPES !
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M?7-*5&IWL///QDFT#5H7-.-&J\58K"SXGN\6:G*Q1GQ>)<:DSCM].[=@ EG
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M1E&LU?0[O2ZSE34ITOSXIX\/M.NUU7\FLE[4#3;@XTZD:BS"2:]1R"
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M*PL)+Z#(./R>3;/;<^'I>%PZ\6G3'GWD !K-P
M                !T7=I1NZ4J=>"DGXXYHA6L;3JT&ZMBY5(_F)9:)X *GH
M7M>TDX58MXZI]3:V][1K=))2\LDOU/0K._B^.'!+S@DOJ(CJ6U;NUS.UDZJ\
M(P3R!D@T$+NZLY.%6+3\IKF9M#5:<\*HN%^;"--D#KA7I3^!4B_8SL
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M5;R7G'E'JO%>1-SG\OE]?^WC\?Y=GT[T^<7^]E_%/]@ '.=@
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MOZ=.%-8IQC%>I8 T.C[9MK-*=>*JU?7S7R-&_A",(\,(J,?)+!]
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M;L])Q>)CXU>FG]0 &!L@
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M_P"E%,R(4:</@4X1]D4@*ZM=M:C<M=XI4L_Z1,W^G[0MZ3S=R[QK\U\OH)2
M,6UTZUM8I4:%-->/"L_*=]>I3HT9SK2C"E%9DY=$CF:?=6EU]8TFK9V]:-+O
M8N,I-M<GY8 \X=H6KV^K[@K5;.A2HT8^C^+@HY:SE\B,%M7'8MJ4LNCJ%DFW
M^5*;_P#":F[[)->H<7!.A6PO^34N?S%]PA79+>S;<M3;^O47*HU:UI1A53?)
M1SE^/(YU^SC<E)XCIU6IRSZ,6:ZXV=N&U?X[2;J'/DW$#U9;U8UZ%.K3>83B
MI)^IG,KKL?UF[N-/GINI4JD+BAF2E)<N'DDNI8I1(     XU)QITY3J24816
M7)]$B!5(6&_JE[;U+I2M:?%35&%3$N.+QQ<O##-5VR[TAIUE4TBQG_E5:+C5
M?E"49+ESY/)2&BZU?:/?0NK.M*-2,N+#;P^>>:SS-[!QK6KU^)]F6E)F-I-O
MOL^U#;E>=2C3G<67.2J4XR:@LOJ\>"2(.>B-D]H^F;@MHV&M<%.Z:4/QD5P3
MY)82R_')J-_]ED;SO=1V]P\4DZCI-OTNKQ%)>S!L8^1-9Z,O:5XOKM91QN=M
M[DU+;]Y"O87-2*B\NFY-P?-=8YQX(UU_97%A<RM[NE*E5CUC)<^N/J,<VYB+
M1J63R],[![1+'<-&%&[J0M[[E'AG*,>.6$O16?%MD\3RLKH>,K*4Z=95:<YP
M</2S!X?+R+7[/^U-V7=V&M.4K=-0A5QSBLI)R;?EG)S<_#UWQL%L?PO8&-IM
M_;:E:QN+*M&K1ETE%Y73/UHR30UIB         #C4G&E3G4J24803E)OP2 Y
M$?W9NO3MMV52K=UH.LHMQHJ:4Y<GC"?K6"';\[4K+354LM(??W2?#.HDI02]
M)-=4\Y2*,UO4+K4KRI<W5:=1U9.:3DVHY;>.?M-S!Q)OWOVADICWY2'>V_=3
MW'<5(JM.A9*34*<&XYCF6%+#P^3(:WEY8!U*TBD:JV(B(\!DZ=8W.HW4+>SH
MSK59-)1A'+YO'UHD.S=DZIN6YI]Q1<+3B2G6FGP^&5E>.'DO+1]%T'L_T=UK
MN=-5>',IU,-RFHYQ%M+\WD8<O(BG:.\J6O$=FD[.=$U?:%A"MJ$Y5+>XE%2H
MI2S1REZ4D^2247DM*E4A6I1J4I*=.2S&2>4T>>NT/M-K:RYV>D\5*S3:<I+$
MI?"64T^F&3#L6WG"]L(Z/?5,75%?BY/Q@E%+QSG+9HYL-YK]2WEBM6==4K5J
MTH5J<J=6,9PDL-264RMM\;)24[W2:?5N4Z44WYODDN2Z%EAI---93.;FP4S5
MZ;-?)CKDC4O-=6G.E4E"I%QG%X:?)IF^VQN>\T6YABI.=ME*4&\\N73+PN2+
M%WCLVCJL97%FHT[I+IT4ES?1+KEHJ34;"XTZYE0NZ<J<TWU77GC/S'!RX<O$
MON/ZN;?'?!;<+SE6HZ]MJK.EB7?V[:CU<9./)>WF45J%M*SOJ]O--2I3<7GU
M&PV_N"\T:XC.C4<J>?2A++6/4LG5N&_HZE?SNJ4)0E4;E-/'5OP+<GD5Y%(M
M_%"V;+7+6)]X2WLFU)T[ZK8RGBG-2J<WX^BBUCS[MFZ=IK5K-/'%.,'[')'H
M&+4HIQ>4^:9T?3<G5CFOPVN);=-?#Z #HMH  &/?65O?6\Z%W2A5IR6,2BGC
MUK/B4UO?8-SIMQ4N](A.I;=>"";E'KZO47:?)14HM22:?5-&Q@Y%\$[KX:O*
MX>/DUU?S\O-^DZY4H35&\RTGC+ZKVY)/1K4ZT%.E)2CYIY)1O7L]H:IWEUIG
M#2NN<N%O$7U>$DBK+NSU;;=SPW5*=-9PN)/AE[#KX\F/D1NLZGX><S8,W$G5
MXW7Y2\&FT[7;>XBHUI=W4\6^29MX24XJ47E/Q$UFOE6MHMWAR !"P
M          8MW?V]JGWU2*EY>(B-^"9B.\LHU6JZQ1M(.,)*=7R37(TU_K=>
M\GW5G%J+\,<_I)#M;L[U'4JL+C4DZ%OG+C-M2E[.3+S%<4=62=,=/J9YZ,,;
M_-'M*TW5-S7O!1A4G'K*2BW&/_O!=FS]GV>WZ";A"K=->E4:SY],KER9NM(T
MJTTJVC0LZ2C&*QEI9?M?QF<<OD\RV7[:]JN_PO3J<?[[=[?( #2=(
M                 :SU,2YTZTN(XJ4*?M45GZ#+ $;N]HV57TJ4JD)>U8^@
MU5;9599=*YIX\FGDG( KBKMG4:>>'BGC\U,QYZ)JT%E4+A^Q,L\ 59]RM8_1
M;OY&/N5K'Z+=_(RTP!6$=#U62RZ-PO:F95+:VH5?AR</Z298H A%'957EWUS
M!K^:FC;6FT["BDYNI.?CEK'T$A &-;V-M0BE3H4UCQX5DR0
M       @&_-!X9._MH\G\-)=$DVV04O6YH4[BA.E6BI0FL-,J'<NDSTN_G!Q
M?=2YQECESSR/&>O>G?2O^\8X[3Y_5ZCTCF_4K]&\]X\?HU 7+H >;=M8FPM=
M5:DK&YDE."]!M]>B2)J499W%2TN*=:C)QG"2DL>HM_;VJ4]4L(5(R7>)<,EG
MGE)9?SGM?0O4?K4^ADG[H\?G#RWJW"^E;ZU/$MH #T3B@
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M^[+]TL33M.M=.H0I6E&G345C*BDW[<(RP#0F9GO+K1$1&H  0D
M
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MOXNHE*/Q)HEL4HI**22\$?0<V^2V2=VG;LX\5,5>FD:@ !1D
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M,@
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M<(M_0;<&"^?)?\5FSCXV+'^"L0X4Z-.DL4J<(+^;%(Y@&)G
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M;U8UZ%.K#G"I%27L:R<R&=ENL/4M"=*M-RK49<"3?/A2BEXDS*@
M                 ,.[TNQNOW>TH3><Y=.+?SH^VVF6-MCN+.W@U^5&E%/Y
MD98*]%=[TC4>0 %D@
M
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M0@U4C)Z7**API\\\\8R6%[F3=;UK9-/3;J4E=Z:H6SA4?I>C!9Y9R!<@
M
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M,B8$:[(]1]Z:[4HR?HUXJFEZW)%VGG38]5TMU:7CH[B"?RGHN+RD_,20  @
M
M
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MM>:946RNS+6]K=I6IZS:7FFK0[RI5J>]U*?>)R^#RX5'DO66^
M
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M+B/01!NS';-31[.=U>12N*RY+RCR:ZKKU)R1(  @
M
M
M                            5KV\ZA>:=M>QJZ?=W%K4E>*+G0J2@VN"
M?+*?3DBB_OGU_P#ES5/^UU/M+J]T1_!/3_UZ/]W,\_'7X=8G%WAL8X^UM_OG
MU_\ ES5/^UU/M/1]2ZN%V2.Z5>K[Z^XG>]]QOCX^XSQ<77.>>3RR>H*O\3#_
M .H?_3E.76(Z=1[HR1X>=OOGU_\ ES5/^UU/M-YL?<6M7&\=$HU]8U&K2G>4
MHSA.YG*,DYK*:;YHAAOM@?PWT']>H_MHVKTKTSV9)B-/6X ."U
M
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M[>I<Z4TIQI33S&$$EGAP_G1?.S=5IZUMC3;^G*,N^MZ<I.+SZ7"L^+\0-R
M   X5*5.ICO*<)XZ<23.7"N'APN'I@^@C4>4[:75]L:7JBEW]M"$GUG3A%2^
M7!'*G9;HC4G"O?*3Z9J1Q^R3T$[0JB\[*ZN7[RN::7AWM1_5 U-7LPUN%>,%
M6LI*3^$I3PO;Z!=H)V*AL.RJ]51>_P"ZM73SS[FI+./C@3'0M@Z1I%W&YI.O
M6JI=*SC**?FO11+0-@DDDDL)=$@ 0
M
M
M                    JOW1'\$]/_7H_P!W,\_'H'W1'\$]/_7H_P!W,\_'
M8X7_ !-G%^$/4%7^)A_]0_\ ISR^>H*O\3#_ .H?_3E.9_#^J,GL\OF^V!_#
M?0?UZC^VC0F^V!_#?0?UZC^VC;O^&62?#UN #S[3
M
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MRM[FK^Z5J5",)SYYYR2R^8&>
M
M
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MX .&U0
M
M
M
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MHR>SR^;[8'\-]!_7J/[:-";[8'\-]!_7J/[:-N_X99)\/6X //M,
M
M                                   !C:E>T-.L:MW=S5.A2692;226
M<=7R/.%37-X]L.OW%#:]U]R="M)<$[CCK6]2;RT^&4'*+Z+Y2V^W6K5H]EFO
MSMTW45&.$L_GQ\B-^Y;I4X]G/'&G"$Y7-7B:CAOF!&[SL?WKIMO[ZT?>.HW%
MW!<3IWFJ5YP;]24,DE[#.TC4]TU+K2=RVT+?5;1/+A2E"$UQ86.*3DWA>1<!
M@6NBZ7:74KFTTVRH7,N4JM*A&,W[6ED"*]L^Y8;9V'J5S&OW5U*D^XQ+ADY)
MKIS3\? I;L(W)N31-[STS=5]<W5/58TZEN[BK4FHJ;<N7&UCEY)FV[>+^ANK
MM"V]M3WQ&%K2J.=S/C27#./++YKK'Q1T]O2LM#I[6U[0KJVG<Z6TJBI5$\QA
M!)9X</YT!Z W'4E3T&^G2FXR5)M2B\-?&>4^RG:VX>T">I5I[PW!0[JO52C#
M5*L$DIX7+$CTE;:K3UKLYA?TIJ??6492:>?2X5E=7XGF?L/WIK&VWJM/2=M:
MMJRE7K9G9V,J\5^,\U) ;O?.@[T[)YVFOV>XKW5;*$G*K2O;ZO<)**\8XBL<
M_%GH[9.M+<.V-/U+"4J]&,II+EQ<*SCF_%^9YM[0=W:_O[5=.VYKM@]L:77G
MPSGJ=*=G4J*2YI.4I1?3R/2^U-,M]'V[I]C9N$J-*A"*E'#4O17/*2SGS VP
M
M
M                  'FKW25M;W>^]M4+Q1="=>:DI8Q^X^OD>E3S/[IFPAJ
MF]MN6=2M7H1JUIIU*$N&<<4<\GAXZ 32^[->SF>BR=>YL;5.G%RJPJV].4.G
MY7#R-'[EN>JQEK="O6NJVCT9<-K5KRG*,EWDT^&3]%^'0SJGN>-&NM-2^^O>
M-1U()\%748.#]J[KH:KLBUR^VCO6]V!JM.AW=/@5I.DI.4G/BF^)MI=&ND0-
M/J-WJ?;)VD5]%IW=U9;=LU&=9T*DJ4Y9BUU7%%^E%=46A3[$-GQL?>[MJKEC
M'?<-+O/[7 5E[EY^]M\;CM[JK'WPX1Q%RYOTY/Q]1Z< \Y[>VYNCL\[4HV>E
MO5M1VO7G!?C.]K1I+A<GC"C"/I/!K/=1Z9+6MV;<T^$W3G<7' I9X<?BUXX9
MZ)OMS:'8:E3T^^UC3[>_J/$+>K<0C4D\9Y1;R^7,HSMY:?:=LYKFO?J_NT!(
M/<[[SJWNGU=M:]*I3UFSXIXKOA<X.6(\/%+B?)>1K/= [GN=8NJ.SMN5\U:T
M?\MJPD^&$)+,?2@VT\Q?5'9VS;.U?3;NPWEL*SJUM9H</?6U"$FJL%#A2X::
M4I=<\Y'9V:;+OM.VEK&O[KH?_'[V.)*K%MTXJ68XXUQ)^D_%@8'N1J,K?1-0
MHSEQ3IU*D&\YRU5DB7>Z/W)]PNSVYH4>)W5_^)I*'7*:EYI]$^F2,>Y6_P S
MUG]8K?WTB+]J^\])U3M@TO3]8NJ4=$T^:K3XIQPW*FTT^)N+YX\$!B=F&G7'
M9IVCZ;:UZ]6-IK<*4FZDWC+BYOJHKQ]9ZNA)3BI1>4UE,\H]OV^MKZWI6D76
MV]2HO4=,<I0[NK3XO@QBEZ+SX/R/1'9KKU'<6S-+OJ%2-3-&,)-//I123\7X
M@9F\-QT-K:)<:I=V=]=T*$'.<+.DJD\+U-I?.=.V]XZ1N#;SUJSN(T[*.5-U
MIP3AC&>+$FEU\S>75O1N[>I0N:<*M&HN&<)Q4E)>33ZGB[>E:]V;N;5-J:)J
MUM+0=1CFO)W$FK;BDY-KAQ&'-)9:8'J;87:#IN]JU_#2+/4:=*SFZ<KBXI15
M*HT\-0E&3SY^QFL[<=YU=F[.K7%K%RO+B,Z=#EE*:65G$D_D-WV;:#IV@;4L
MK?2>"5*I"-:<X\/I3E%9>8I9*N]US3J2VQH=2$N&G3NIRJ/.%C@ Z.S/L<H:
MO81US>MW>WU_<YDJ52KWE*,7S6(U(-KKYF=VB]BEA3T2YO\ 9]:_L-5H4W*C
M&TJ*DI2\.5.&7\1;.SJM.MMK3IT9QG'N(+,7E?!1M+NYH6=M4N+NM3H4*:XI
MU*DE&,5YMOH!5?9M?:_<=FFHV^Z;6ZHWUNITU.O2J1<X*,4GF?-YY\RM.PC9
M&B;HO]PU-8M(5IQO;G#=.$G^ZX_*BR_[[7=)US;6IU-&U.SOX4Z<H3E;5HU%
M%KJGAOF5-[E[_.MR?KES_? ;'?/83I-?3JEUMBXO--U.DN*BZ%6-&&?7P4\_
M(<_<Y[PU+5*6J;?UZ;G?Z94E'O)<3XHIJ"YREE]'X(NBK.%.G*=1I02RV^AY
MS[#'[Z[7MVW-K-.UBG&7"^656EGIR D=_P!D-YKV^;_6]Z:K"II"6;>VH7,G
M&.)-KCC4@XXX7SPR']KFUMO;86EWFRKZI3UEW*C&A95X+*X9/G&FE)\TB_;B
M[T?==CJ.DV6L4JDG"=&O[QN(NK1_)?3/"T_-=2@.T;L_J=E]6CNS1[Z[UFC;
MU%*I3UFM[XX4DVW%1C''@NOBP/1>V95Y[>TR=Y_G$K:DYYSG/ LYSSSG)J-U
M;"T+=%["ZUBTC6JP@H)N$)<DV_RHOS9F[)URCN';5CJ%!**J4H<44L)2X4VD
MLOES-X!Y"M]F:++M_KZ*[2G]SU3IXI]W#'.MP].''3U'H"GM3;O9]I^HZ[IM
MG&E.A;R<W&G33<4T\<E'R7B5#:__ #/W/]72_ORZ>V*E4K=F>XH4,]X[.>,>
MP"DMB[>O>V7<>HZWN6\O*6C6EQ.C;V]"K*$9<,\KBC)2B\QGX,LW4^P[:ES8
M.C;4J]K64<0K4.[ISSC";DH9]9I/<H58/8U]1[V$JT+^IQQ4LM>C37,NT"A^
MP^ANW;>Y]1T+7*6I76DQ<W;75>-6IC\9&,5QRPL**;Y(A&X-+TW6/=&JUUI4
MG9RLTY=[PX_SAK\I-=&STQ:[GT*[U.>G6NLZ=6U"'PK:%Q"51<^'G%//7E[3
MS!NO;=#=7NB5IMS?:A8TYVB;JV-54JG^<275I^?EX("X_P &G9U__+?EM_\
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MZ #@M0
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M.W3<N[MZ:A'+ZO" S
M
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M6U]6HU>"I!OAC%3GUPHYPECF3GM"VC9[SVY<Z7>I)U(2C3J868-K&4VG@DH
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MU_\ X:M_Q%J[#UV\W%H$+_4M*O=*N'/A=O=T)49I83SPMMXYOY"0@
M
1                   __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g109079g06g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g06g01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1 \4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $!\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-QU9)01T,S'!E$]ELW\HVMBVXB\.&TY<UX*LF$!V1":"",CQ ,Y A(%@QB<
ML2( 3@# *( 3@#  @!. , " $X P ( 3@#  @!. , " $X P ( 3@#  @!.
M, " $X P ( 3@"I (H(Q 1UK0*EQF,Y"H@#4DL9CB3"80DNAS?C7TLLD9$:E
M5I4Q8'+$E2HX$JFT#-6%O2Z)0^TA5PI2:X#R8?:.<G#A(49@%2"I  !4
M  *D%2  "I!4@  J0          5  "I!4@  J05(  *D          %2  "
MI!4@
M
M
M                     !B,A@ D!!G0=?-9S+Y3>=L8I#%^,R;NJ\(RI7%[
M2!'9 ./!1L/&,I=A74N-J*I*+CPT'WJ0HDA(@A(A   "@
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M  $ ,DF)&"3&1F 5PB1BGTAD
M
M
M                                   #&HR&!EA 8K(SQ#5.S>XI#MGB
MPX7G./Z@VN2LHU3LYT-ZSOZYS^0$>OV/SK((0_T%?QF/3HQ#S&Q]_5^$^HK^
M,QZ=&("&18QD,2QC("   %
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M[!_55_&8]0GT@F"&98QD(2)$4
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M/ZNP?U5?QF/4)](>7V/_ .KL']57\9CU)8%!*59I$C%(R&6@  4
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M)2K)(R&*1D(T
M                <0!Q (&)C(8F$$M=;+GYE>^LW]X;"_YCCOVC^4@V7/S*
M]]9O[PV%_P QQW[1_*0VPV0GT2]@ GT2]@##3H[4_F5WZR?O%$K5_P!89G^U
M._QF+VVH_,KOUD_>*(VK_K#,_P!J=_C,>WPR.I( (![X0(*""$B )I=8A Q4
M9EQF0N02DDK,S,ZTIA'+E<:<#&HB$)2M22,J*Q81Q2(C*M:B$])7(DXGW5NZ
M1;-K\# MLO2F4JO:4I(UH49F1%3*.@MWLL1=I&VF?(X*';;)9%>+HJDHB+C/
MH&L2))XW2,3<I+%0_L'&=*N<Q!EM6P^RW%V=ES4*4% O(;0:2-ZZ,SJJO$8]
M [L]1!L7MN72M)5KP4K+_<:+*YI0Z$,#;26)1=0G#7Z,RV79;9->L_'^40[$
M(X=VI=%W5,)&7$8]:K9ZBKTY262JZ67I7*ZD?6-$W",I=0QH5<94#AK]&9;P
ML:N:VRM,[-G(6X8OK3]6E<&EUAQG7B':;.D[9E[UQ#N)4Y?6ZD=2P&A7@-)R
MJT\VE+:FI=&QS"#*Y^8B5ME3V$.),IG&S1TW9C&1,0HZ?EW5.8L!8S&>",KE
MNB4;.[[$&;<1+94X=T9U<2M1_>/)6SV4(J?/)44O@6$)2::L$HL%:UQC7*E$
MHZ)9*G0"B.F+[!J-"OT9;ELKLW1$KEJ(1Z!EKJ6VD-)-TEF> J91T%J]DY^=
MQI.(@X)I*74N%>B418"IE&M\!X+T2>F@G@H31)$:L0W&A3Z&Z(?9HBD23R)V
M ER^'=U62S/[QJ.9QOE45?B0@CPX$E@QF."EM5*J69'D,9I(BXZBQ2M?:$$F
M9F9F5*B1&/$ Z0 4  0H)(0)%B( ?>#(R>(S+B'P&;*S-W 9E@RCGJQVEQUJ
M3:LX;ML9P94]7G/]B'IL2$F7&0XEC+/Q,1(8A3*'#^<+"EOH+I':E(9B1DDF
MHA5,%+@Q\C7KF7Y/4T-33O/Z<N& Y^T,T]4B.P8;0S3U2([!CAL8V:GXRX G
M#D'.VAFGJ<1V#$;137U.)[!AL-FI^,N%AR 2KG"8YNT4U]3B>P8DI%-?48E7
M^0PV&S4_&77N*NUUP""*N =AM),RP'+X@O\ (8Q.1S2N"#B2_P AC45PS.GJ
M9_QG^' 4T@U$:VT'3*1#Y+8;-9*)*4X:\$J#M2DDTIA@HD_\IB#DDT]1B.P8
MU$VA)TKX_P 9=>MMMQ-%(2?300EEM'HH27V$.R3(YIZC$=@P.1S7B@8GL&)^
MK[7BOC_&?X==>D*42C(C,LI#(V4'C(O90<\I'-?4(GL&)*1S7U")[!B8M]D:
M5OPG^'7&RBYH22(O8/FF%:+&E)^TB':'(YKZA$]@Q)2.:^H1/8,:B+).E:9_
MPG^'6I:0DC(B(B]@P2PV2[HB*M:XAVAR.:>H1'8,"D<T]0B.P8O=.&WXS_#K
M76D.TNN+H$-P[2#X*2ZAV>TDS]1B.P8;23/U&([!C/=>&WXS_#@$=$TXAQ_)
M6KJII2?M(AV^T<T]1B.P8@I'-/4(CL&+$8]EC3U(F)VSV_9U;4.TVLU)2DCQ
MX"(<BHYI229^HQ'8,-HYIZC$=@QF:S9=NIG,UG^'"J%1S=HYIZC$=@PVCFGJ
M,1V#$XI-NI^,_P .%4*CG;1S7U&)[!AM'-?4(GL&'%*[;_C/\."1B5)(B'-*
M1S3U&([!@J2S0R_H41V3$XY@V7F/\9_AUQ&,C/@F.9M'-/48CL&,D229J41'
M!1%#P>@83I]TBFI[;9_AR+'W*ID^1'PC:I3[2&GMGV61,';=<2;2O)SAVDW9
MF6/#@%D;#2 X9PW8J')*C;,N&T5:W1<8Y=MK$2ZU</<Q#<(TY=).^+A4N'0J
MX,-,H]-+35^C\J\+-:9OVE1UXV3+@.5*F$?)*FR,C)>$N,6F\WR"54DS:&(C
MXREJ<'_S$>;M!YZA_=J?Q!Z:^)Q'>7U*Z<U[9RJVIRZ49^4.%[%&,3,E>D^L
MRZ3%IO-V@\]0_NU/X@>;M!E_C4/[M+\07J*KME5LUEQ/K+V&8E*TEC<-7M%H
M_-W@\]0_NTOQ \W>#SU#^[2_$#J*FV56U+16I.J3[!%V53.^J57*8M(KY/$$
M7^,PY_\ ;4_B"4_)W@S+!.8?W:7X@O44PDQ\*M$H^=6DLA'@$W::U)U14R&+
M2*^3S!E@.=0_NTOQ 3\GF!N3_P#.88_^VI^,9G7K+6WLJZ3B*'5TS/I'=61M
M,[9^8*B&#2X9J0='#.F Z\0L.CY/$%4__.(?W:7QB5?)V@^*<PY?]L+\08Y:
ML8EY=.SZ^<.E+DOE5V1XS2NO'TCP-OMDF)M5=D^S#-$I"4T:-7$9GQF-R>;K
M"GA.=L%_VTOQ!DGY.\$6.<PY_P#;4_B!&I2/9J%626FIU5@,QD:TGB=4FF0Q
M:8_D\P)_XQ#>[4_&(\WB"SS#>[4_&.G/45:OA4POK5[3,%.(--"7<])"TOF[
MP6>8;W8G\0/-W@L\P_NQ/X@1KU%6DJ06-U2O:"EI5C>5UBTI?)X@L\PWNU/Q
MB?-X@L\0WNU/QB=1457(TEB?67L,*HK53RE>TQ:CS>(+/$-[M3\8>;Q!9XAO
M=J?C#J*BK*G$F?!?6GV'0+I!GPG5*]HM-YO$%GB&]VI^,/-X@L\0WNU/QAU%
M15FZ;I2[$722]%]:?8=!:?S>8'/$-[M3\8'\GB!SQ#>[4_&'49,*L$:#])U2
MO:=0NDD1D3ZZ9*BTWF\06>8?W:G\0/-W@L\P_NQ/QASU%626W5)FO"0&X5T9
MD\HJY#,6F\W>"SQ#>[$_&'F[P6>8;W8GXPYZBK:'$)6:E.&NI4HK",;I)>B^
MLO88M-YO$%GF&]VI_$#S>(+/,-[M3^()S5%6;I!^D\I7M.HR<<0M))OID1%3
M +2>;Q!9YAO=J?Q \WB"SS#>[4_B"QKP*M$M)()*7ED19#&)K(O1>7[*F+3^
M;Q!9YAO=J?Q!*?D\P)'AG$,?_;4_&$Z]<#0.QW:K<G.(>8,H9><96M1)=(Z'
M=(-/%[1]=DFVCEL(Z#B(A#+1PY+(DM75#NC(\-?8-[*^3M"5JF=,%[):7X@R
M+Y.T&989S#G_ -M+\08C6J*N*<;-"3NL)XR&%VCE"TJ?D\01F9;<0^#_ /6I
M^,9>;M!YXA_=B?C'2/$Q!A5@G$<H3?$<H6F\W:#SQ#^[$_&(\W:#SS#^[$_&
M+U1A5F^(Y0F^(Y0M+YN\%GF']V)_$#S=X+/$/[L3\8=2859OB.4)NT<H6E\W
M:#SS#^[$_B!YNT'GF']V%^('4F%6;XCE!?$<H6F\W:#SS#^[$_B"?-V@\\P_
MNQ/X@D>),*L7Q/*"^)Y0M/YNT'GF']V)_$#S=H//,/[L3^(+U4&%6+XGE!?$
M\H6G\W:#SS#^[$_B!YNT'GF']V)_$#JH,*L7Q/*"^)Y0M/YNT'GF']V)_$#S
M=H//,/[L3^('50858OB>4%\3RA:?S=H//,/[L3^('F[0>>8?W8G\0.J@PJQ?
M$\H+XGE"T_F[0>>8?W8G\0/-V@\\P_NQ/X@=5!A5B^)Y07Q/*%I_-V@\\P_N
MQ/X@>;M!YYA_=B?Q ZJ#"K%\3R@OB>4+3^;M!YYA_=B?Q \W:#SS#^[$_B!U
M4&%6+XGE!?$\H6G\W:#SS#^[$_B!YNT'GF']V)_$#JH,*L7Q/*"^)Y0M/YNT
M'GF']V)_$#S=H//,/[L3^('50858OB>4%\3RA:?S=H//,/[L3^('F[0>>8?W
M8G\0.J@PJQ?$\H+XGE"T_F[0>>8?W8G\0/-V@\\P_NQ/X@=5!A5B^)Y07Q/*
M%I_-V@\\P_NQ/X@>;M!YYA_=B?Q ZJ#"K%\3R@OB>4+3^;M!YYA_=B?Q \W:
M#SS#^[$_B!U4&%6+XGE!?$\H6G\W:#SS#^[$_B!YNT'GF']V)_$#JH,*L7Q/
M*"^)Y0M/YNT'GF']V)_$#S=H//,/[L3^('50858OB>4%\3RA:?S=H//,/[L3
M^('F[0>>8?W8G\0.J@PJQ?$\H+XGE"T_F[0>>8?W8G\0/-V@\\P_NQ/X@=5!
MA5B^)Y07Q/*%I_-V@\\P_NQ/X@>;M!YYA_=B?Q ZJ#"K%\3R@OB>4+3^;M!Y
MYA_=B?Q \W:#SS#^[$_B!U4&%6+XGE!?$\H6G\W:#SS#^[$_B!YNT'GF']V)
M_$#JH,*L7Q/*"^)Y0M/YNT'GF']V)_$#S=H//,/[L3^('50858OB>4%\3RA:
M?S=H//,/[L3^('F[0>>8?W8G\0.J@PJQ?$\H+XGE"T_F[0>>8?W8G\0/-V@\
M\P_NQ/X@=5!A5B^)Y07Q/*%I_-V@\\P_NQ/X@>;M!YYA_=B?Q ZJ#"K%\3R@
MOB>4+3^;M!YYA_=B?Q \W:#SS#^[$_B!U4&%6+XGE!?$\H6G\W:#SS#^[$_B
M!YNT'GF']V)_$#JH,*L7Q/*"^)Y0M/YNT'GF']V)_$#S=H//,/[L3^('4P85
M8OB>4%\3RA:?S=H//,/[L3^('F[0>>8?W8G\0.I@PJQ?$\H"6WQJ%I_-V@\\
MP_NQ/X@CS=H+/,/[L3^('5085:)Q'*$W:#Q*%I#^3Q!4P3F&]VI^,9,_)Z@D
MGAF\,?\ VU/QB3XHPT[L$RV(BMD&!B&VU&PE#J5+*F [V>#]Y"Z,&5Q#,(_0
M21]0\?8#8Z@+))5>SA8EPW%+)Q,(ELRJDBI6IY/WCVK1G=&5[H1'0AY=34W*
MS)6,L@E!F:1BD^$K@C(NKH'/(FIY J>01_F#_, FIY J>01_F#_, FIY!@1G
M7"0R_P PQ--3]*@BP&K)A&I]G(R-ZSUT=/GG/Y!M8Z)+!A&J=G$KIVSV#^V<
M_D&X<[9^'KK J(K/0A$=>"K^,QZ4G#,ZT(><V/4EN?A*T]!7\9CU!7/%08RM
M8G E1Y!)+,^(AC@$\6 A6V5T%T,#J(*HL,Y?2Z,1=GD$$72%.D25RR)1Y ,S
M+B&!%CP@9'3TC"!-V>0AD2C/B'RH>49$1\HQ4C+Z5"IT&%/TQ!E@],Q%?0C,
M^(*GD'R(Z8U";HN6!#Z5,*F/G4N6%T7+ _Y?2IY NCR#YW1<H+HN4*?\L[H\
M@71Y!@5#^D(H?*,$[OI=*R!4\@^=#Y1B2+*L#N^AF=,0BZ/(,/\ .(H9_2,#
MN^I&85/(/F5:>D%#Y1@=WT(SR!=$/F5>4,BH!W97190NA&#H"J:<0BIJ)PCY
M5_2$5_3 ?:H#XU_3"OZ8+V?6IA4?*OZ8E)X<*@3#ZU+*(J6415.4@JG*0@FZ
MR!4QB=#Q'08T/E&*9?2IC!Q9I(\ QH?*,8J(Z83J+"3+-MPU$=2(0I9D0Q+%
M@*@G+4%B.S7>RPJZDKWUF_O&>PO^8X_]H_E(8[+1$4E>H1>DW]XG87.DBC_V
MC^4AJ?9QI%IOW;'2> @&)8B 8=\.GM1^97?K)^\41M7_ %AF?[4[_&8O=:C\
MRN_63]XHC:O^L,S_ &IW^,Q[?#,.I( (![D00D005$22@DB3B4FZKB =G9J#
M;CIY!,.E5"GVTGAI@-1$,S.%AQH64S&**L) Q3B?T&5*^XAC$P47"?TJ!B6\
M%>&TI/WBTDQ>ENQ[9]AV%:?)2GKSP>'@42E<9ER1JRW^R%9ZT4 LH2&F*8BB
M4I-Q"2*A*,SQ*/*./)EIJ>X09&9)H?2((R*I4,>^LQL73RT[2XF7Q$O0TI14
M)YQ9'A*I8DGQ#XSG8SG<ECVX>+?@%*<<N"O;BS*I&65)91J-7X'ACH?$8RN2
M(ALZ7;#-H9@@W6HF5DT:341*=61X,'('G(>P,VB)MY"T]!$Y<7=5+53^$7EA
M,/)I+H$F2:8ALV;[#-HY3!+BHN*E2FTD1T;=69X3IQH(>(@9#%1TXVM86R40
M;MYJI1DFZJ99,6#($:L&'3FJY30B.H(X2>&0VJ6P5:HI;Y=Y9)[S<&Y2_.75
M"Q_V?0/'P]D)C$S5V7(=A2?;;OIF:E7-,'1TD+&K$KAYHE&>!!W(R)MU2B)%
M7%GB)!5,;2AM@RTKCI-^5RF[/#6_.4_@'GXNR$ULA/X9$8]"+=NC6DVE*46
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M/G%P[+Z:7*D)7DQE4>'MP^U$J;<;<(Z-%@+VCGPT_3#2V70S5P:ELI0>$R/
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M+%ZO734I$?J=9,C91'PY+2DT7&&IX.,<V=)EQRZ%5#>3D]>JG<J(SK0AQ)_
MJ<B6VT7)'<4KARF/M V3B7":<6ZP:#(E4JJM.H2;1)R:6V,2[ZQE?(RNEUX/
M^YCU"+FG$.LE$N3!0R4$2:D5#H9Y1V*4X1YM28<-.)CX9F9%BH/FK"6,29#
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M.U)P2N-+_2N:@182=ECE4;HKFH=N&LL;I6=/9@LYZ]!%_J/ 8[\-G/7X+2/
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M8BL#/LVQNBN:A.X&?9MC=%<U"<%3=*SF_'9OUR!TCP$'LQV;I_3('2/ 5DW
MS[-L;HKFH25@9]FV-T5S4'#4W3"S);,-G"_OL#I'@(WXK,\<? %_J/ 5F.P<
M]+'+(T_]*YJ#<%.:895&G_IG-0<55F9GNLVC9ALSAI'P&D> RWX;->OP.D>
MK#N#G9^C*HY/^E<U"=P4]S9&Z*YJ#BJE;2L[OQ6:]?@=(\!![,-FJ_T^!TCP
M%8MP4]S9&Z*YJ#<%/<VQNBN:@C1HO)WPL[OPV:]?@=(\ +9ALUZ_ Z1X"L>X
M&>YMC=&<U!N!GN;(W17-0O#1BVI,+.;\-FO7X'2/ -^&S?K\#I'@*Q[@I[FV
M-T5S4&X*>YMC=%<U#/%5JMYE9O??LWZ_ Z1X 6S!9HO[_ Z1X"LNX*>YLC=%
M<U"#L#/<VQNBN:A8TJR3,PLYOPV:/^_P.D> )V8;-)_O\#I'@*Q%8&>YMC=%
M<U"=P,]/_#8W17-0O#0M?]<0LX>S%9H_[_ Z1X"$[,%FB_Q"!TCP%8RL#/<V
MQNBN:A.X&>YMC=%<U"\-";?KB%F]^&S1_P!_@=(\ +9ALT7]_@=(\!6/<#/<
MVQNBN:@.P4\I^;(W17-0<-"]IBRSN_'9L_[] Z1X"-^&S5?Z? Z1X"L96"GF
M;(W17-0;@IYFN-T5S4'#1-6\Q/99O?DLV7]^@=(\ /9BLV?]^@=(\!6/<#/,
MV1NBN:A)6"GA?X7&Z*YJ"-&BZM\5[+.)V8[-$5/+H'2/ 2>S!9LR_I\#I'@*
MQ;@IYFN-T5S4)*P4]+_#8W17-0S.E6&MV:96:+9>LWG"!TCP&6_#9LBIY? Z
M1X"LFX.>YLC=%<U"-P4]S9&Z*YJ#BK+&A>9F<K.;\-FO7X'2/ 1OP6:]?@=(
M\!6/<#/<VQNBN:@W!3W-L;HKFH(TJFM>8MV6>+9BLT>#R^!TCP#?ALUZ_ Z1
MX"L)6"GN;(W17-0;@I[FR-T9S4'#1;7E9[?ALUZ_ Z1X >S#9JG]/@=(\!6'
M<%/<V1NC.:@W!3W-D;HSFH.*K/)*SN_#9OU^!TCP#?ALWZ_ Z1X"L6X*>YLC
M=&<U!N"GN;(W1G-0<53DE9ES9ALW@I'0)_ZCP&;>S'9LDD7ED#I'@*QG8*>Y
MLC=%<U FPD^+_#([17-0O3UF,M;NV5GM^.S7KD#I'@)WY+->OP)?ZCP%8=P<
M^/\ PV-T5S4,2L%/"]*5QI_Z5S4)T\0DZDXRL_OR6:SA Z3X!OR69/\ Q&!T
MGP%8=P<ZS5':*YJ$;@YW7\U1VBN:@C0J4U9E: MF.S.<8'2/ -^.S.<('2/
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MK-^O0.D> K%N"GN;(W1G-0;@I[FV-T5S4'%5KD6=WX;->OP.D> ;\5FB_O\
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M2+C''4B(CLL3F7K4IX)8>( 2K 6 P'F=<   *      L(
M
M
M
M
M
M
-        ,BQ   /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g109079g06g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g06g02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1GH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &<L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                    _^$[WFAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-BXP+6,P,#(@-SDN,38T-#@X+" R,#(P+S W+S$P+3(R.C V.C4S
M(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP
M9&9X/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9G@O,2XS+R(*(" @(" @(" @
M(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @
M>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@
M(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&1F>#I!4%1+5D52/C$Q
M+C$N,"XR,C$S.2!0<F\@4')O9'5C=&EO;BTS,CPO<&1F>#I!4%1+5D52/@H@
M(" @(" @(" \>&UP.D-R96%T941A=&4^,C R-BTP,RTQ,%0P-3HU-UH\+WAM
M<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/E1O;VQK
M:70@:'1T<#HO+W=W=RYA8W1I=F5P9&8N8V]M/"]X;7 Z0W)E871O<E1O;VP^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(V+3 S+3$P5#$T.C0R.C V
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R-BTP,RTQ,%0Q-#HT,CHP-BLP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @(" @/'!D9CI0<F]D=6-E<CY4;V]L:VET(&AT=' Z+R]W
M=W<N86-T:79E<&1F+F-O;3PO<&1F.E!R;V1U8V5R/@H@(" @(" @(" \>&UP
M34TZ26YS=&%N8V5)1#YX;7 N:6ED.C8R,V,W8V(S+6$T96,M,# T,"TY,3,S
M+65D-&-A,C(S9C@P9#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM
M<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.F-B.#<Q.&$T
M+6)F,V4M,S$T8BUA831E+39E,C@S,6$V9#DW,SPO>&UP34TZ1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED
M.C@X8CAE9#@U+68P9F,M,3(T,RTX-6,V+38P.#1E8V1E-3)F.#PO>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.#AB.&5D.#4M9C!F
M8RTQ,C0S+3@U8S8M-C X-&5C9&4U,F8X/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 S+3$P5#$T.C0R
M.C V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE
M=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-C(S
M8S=C8C,M831E8RTP,#0P+3DQ,S,M960T8V$R,C-F.#!D/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 S
M+3$P5#$T.C0R.C V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N
M," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HX.&(X960X-2UF,&9C+3$R-#,M
M.#5C-BTV,#@T96-D934R9C@\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @
M(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.#AB.&5D.#4M9C!F8RTQ
M,C0S+3@U8S8M-C X-&5C9&4U,F8X/"]S=%)E9CID;V-U;65N=$E$/@H@(" @
M(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.#AB
M.&5D.#4M9C!F8RTQ,C0S+3@U8S8M-C X-&5C9&4U,F8X/"]S=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^
M"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@
M(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L
M;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*
M"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I
M*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( NX%1@,!(@ "$0$#$0'_
MQ  <  $  04! 0               @$#!08'! C_Q !;$  " 0," P4$!@4%
M# <%!P4  0(#!!$%(082,0<3(D%1,F%QD105%E2!T2-"H;'!,S128G(D0W-U
M@I*RL\+2X? ()28V4V.B%T1%@Y,U565TE*/Q)S=DA.+_Q  : 0$  P$! 0
M             0(#! 4&_\0 +1$!  (" @(" @$%  $% 0    $" Q$2(00Q
M$T$B43(%%"-A<8%"D;'!T?#_V@ , P$  A$#$0 _ /JD        HRK9!@37
M0$8LD
M
M
M                                               1?4B*SQ';U,!Q
MAK"TVUE3CGOIT^:/+/EEU\@-@1*/0Y16O]5I6E.^52^G"N\*FIS\/X_@=$T'
M5H:O;RKTHJ$8S<,*?-T2?\0,H"DI8(J>?U6!,%KGE%OPMY*Y<H=&F!<!&,MM
MV(O+?H!(                                    ^@ $<C($@174D
M
M
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M0
M                                                     */J4 D"
M)6/F!4                                                  0EOL
M^A8O+6E>494KB//"2PUEK]QZ&MRF -=^QNA]].K]#?/+J^]G^9L5/$5A# 2\
M: 5$V5BE%$F\%NIEQV C62JTYI>2?4U6SHRI\73EE?R?^RCU:[1NIRINWHN:
M7-S8\C%</]['B=JM#E?=O]R WB$\IY)1QU033B\"/0"H
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M7E;E0
M    %'GU*@"D2DY8"62,X-] /+6OH4JBIS4G)K.R+,M7H+;EJ9779?F:'VB]
MF-+BW7*6J3O+RC4IV\:"ITE'E>)2>=_/Q'(^,N"I<,W%E2E7N7"ZN/HZE4Q\
MUCS ^FI:I1E:.O!5$D\;I9_>>ZA+GI1GY22:.#VW89;5)JL]3U%2Z8Q'!VKA
M^Q6FZ9;6D9RFJ%&%+,NKY5C^ &2
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M2--MIY)
M       #0 $8LD4Y4.5 0FWGEB\-G$.W!58WV@NM/GBM2V7INCM\UM@X?VXK
MNKWA]QZRU)9S\4!V;3I][;*I#PK+6&>FC.,G))8:Z^\L::O[G4O/+/8GD
M                                                   %'TR5*/T
MBES-B7H,\K$NF0/-<V=*I3E*<(MI-K*-8TV$8\63C%)?H_X(V:M>4XPG";>6
MFEL:UI]-/BR<H].[_@@-O4<08IM^9&,GRO).#R@)
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M I%814
M          "%3J</[=_YWP[_ (R7[T=PJ=3A_;O_ #OAW_&2_>@.T:=_-%\6
M>J/F>73OYHOBSU1\P*@
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M/FI\J?+OU1>PAA 0Y5A;+816)-Y)X1%]0*8WR5>X $D\@I'H5
M                                                      A/J</[
M=_YWP[_C)?O1W&9P[MX_G?#O^,OXH#M&F_S3\6>M(\FF_P T_%GK70
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M?,#85+8KS&)N]9MK6TMKB<:KIW$>>"264L)[[^\OZ??TKZU5>BIJ#;6)+#V
M]_,4-7X<XTT[B"[N[>RIW4:EM55*;JPBDVVUMAO;9F1OM?M;&[G;5H5G4AC+
MC%-;K/K[P,N",9)XQYDF@*QZ%0E@
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M2CE9V$8Y661S)[-]2XLJ* D"-//*\D@
M                              %N;PWGH7"S<5%!;Q;W\AO0K)-KH4IY
MBWE;&B<9<>TM U.VHSM;RI&=/G:I8QU:]?<8&?;;I2DZ3TK4G.'7V/S*<TNL
MSBFL/8XCVVPI2OM"3F\K4?XHV+2.UBQU?7;6RI:9J-/O<K,U'&R;]?<:OVYW
M%.I5X:JTJ4HN>HIO;?R-*]JS3;M%@N2SQYY?4]\5X5\#Q:;*-2@I8PLOJ>JD
MI*4^:65Y>XA,5TN  "L>I4I'J5
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MDH] (M/F3\BD^?.R6"8
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M;BJ4J3C-.GUB\^2 VZ"S%Y)0QT12.>5Y6"L(XWR!(
M       "DO(J1GG; 3"B(XW)Q6Q'#]"85F".Q7(BNN45:]Q":J9$FW%C!2:?
M(\=0G[6JDG'&/,M.I+/D7>23ZQ?R(NG+/LOY"*J7]KT5F"?N*/PK**8ECHQ"
M,L[I_B5B):?2CJ27H7(^**;ZE''W!)^C)XJUWM7(R3Q[ACW#D=H9&2>/<,>X
M<CM#(R3Q[ACW#D=D/9*A= 2 !1@5!'<;@2!2)4       /H%T !@H^O0!AC#
M*@"F&5    "+Z@8W& !*/0C@DN@
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M;G\G4QTWF)-%BC7I5(*5.I"47T:>47E.+6TE\SSGG3&E044XMX4DW\2N5Z@
M,KU**2?1H"H                                  MM\LLRZD8IN4I0V
MSZDY846GU*4T!C==UFCHNG5;F[[QQI\N>[BF]VE_$Y)>=I>JU[ZO"PN7"DJD
ME%3H0VCG8Z3VCU:,.%+U5'%2S3Z_VT<WX5XXX=T^K<4M1J:=3<>6"=2.[:RG
MY 9?A'C#6+W6HVUW<QG3<)2PJ45O^".HV]5U:3;ZI(TO0^,.'=4U14]*K:?6
MK.#:5*.^%U\C=,R?(U#$7U: C5JJC34GGFSC8E<.%O2E5DGR167CJ3CRYP\.
M/JS0N/[NI]/M;!5)4Z5Q3?-.,FG'<#/5^)M.=65&<+A\G]5?F;!XL\K\SFEM
MIFBNPHT[C6G"M'VL]?/J;OP]8?5EI.BKBI<\U1SYZCW6R6/V?M R?=+.6B4L
M.&"+S(DW&G',I;>\#$7^CV]ZW.O#F=/+CXFO^>AA-(I0M>*)0I+"5-^>?)&S
MUKVV<9Q=:*>&C7]/5.7%,Y0GS?H_X(#;(9<7DK'T]"WSO&,$HK;FSU F".1D
M"0(QZD@
M
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MQRP<T1Q<^N*N-B--8FBJEL([,GVCVN%&4;!(+J2(KJ2
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M$P1S)KH2
M
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MUS;9_DYK^!EZ56G5IYIRRO@!++R\;(N$(9R\="8
M
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M@L? Y7V&Y4M4E#HZ=+_:.K;RCXN@4449-Q;D72"A%X>^Q,
M                M)YJ+PX(J+E4J*4LQ]'T+M.7-%MEN&)5*B T#M#UJRT/
M3;E6]E;*45!IPE&#WDEY(PNC<8Z15M%.MHUA6J*G&7BJ0;;Q_9ZFS<;<&V>L
M6=?OZ$I\R@MJKCTEDU/3^&>#[&,XU*%PJM%)3Q4F]X]?/W 7M"XFAJ?&JMK/
M18V=-T'+O*4LI873:*.KQD\4ERO#2R:1P@N&H:C&6F1KJZY98YN;&//J;Q5J
MJ,J<4_;Z 7TEC9+ (QREA]2N6 Y5Z(-^0RR$LMY DEDK*7*BD7MN1JIM/ %F
MO<TXTYJ;C'*?66,FL6$HRXKFXX?Z/R^"/=K=E<5W3=%1:CS9R_@8G0*<Z/$[
M57&53?3X(@;M&68O*P5A%9SL%)2B\"FFNO0"W'E46^529\]=J"E+BAX;A_=Z
MZ'T+3?*GS'SYVIRYN)OT?7Z>L@?0S<5-1PLLA*7,VN79?M*U$N=<O\IC8CXT
M\3QA[ :3QOP1=<25I5K+7:^F1<8QY*--R2QY[3CU.4\=<%ZGP[<Z70^UE[5=
MXY1SB4,8<5T[QY]H^CFXTUR0V?4Y'V[QB]4X7E+VU*JX_'-,#'<&< ZG4LZ=
MU+B6]J*2E'#IR?GZ\YVBTH*WM(4N\4IJ*7-C#;2ZFO\ 9PZKX2M'+&>:?^FS
M8W2?,I-;H"K;I03PYOH7BW!Y;B^J+@@  2
M
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M*ELS4[)YXLGE8_1_P1[-:KZE"K!6MQ&$&Y*2:6Z^1C-$[V?$K=Q)2EW;RU\
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M %6]VXK/P+A;IIJ33$9][%NGMC;<"X",.;?F9%.2EN]@+@
M
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M%F,(M06"!1IN;V\RY+#37F1IO*919[Q 7%LD
M
M                                                 %'U*E'U B6Z
MGB\*>ZW+A"47GFB\-A-7*NV:=5Z#?4U#,I6DDEZ[LY+V-TJUOJ]]*=)IRHI;
M_P!I'2^U^UU&[NZ4+>Y4*+MW&47G#\3]QSW1.$.)*%:I<V.J4:4:D=N5RSC/
M]D]#'>(P6AV5MJKJ?:+P1I'$6OTKS5-=K:=<1MXTE1@DTXJ4GS?M?R-9EV=<
M+0<8_:JK-TWOF"V,!4T3C76]>MYU->37+R?I'+RR_P"C[R'%G#^N</+3W<ZG
M2J3O*RHYIM]?5Y2.#%;\IC;AR7U.FP7O9SPM5J.\I\6U]DH\JBL>AV?AFTI6
MFDVM&WKNO3A0IPC-_K)1PG^)R.P[,N(ZD5_UM9=SOX'*?^Z=CT*WE9:=;VU1
MJ52C2A3E*/1M+#:(WNK6+?BR"3P,;%>8KDSX*;0;<5E+);KI\ZDO)%V4DENB
MF.\B\;?$O'28G4N9]KO#=[K^GVD+*G7G*%9S?=^G*T<@UO@K5=,T.X[ZVN51
M4HMRDEMF21]3*+S)/=(TOM5IN? &I.EB-3FI8D_\)$ZL/E?'J'1CS\>GSOPU
MP=JFKNZ5"TN)JE%/,$O//Y&Q:9IVK\%06I5K&KR1S#]+LO%\#HG8@G*.IQDT
MY1I4D_?[1O6N:#;ZUI3M:M*E*+FI8J9QL;V\^;3QGTUMGY2T;@GM,MM5FK:Y
M=K1J*=.EA3;>7L=-C.%6"E3GS)^:/E?C'A?4>%M:=U95Z=*E&O.LU1YLXA+*
MZHZ-V<]H#K:30^G2NJL^6;;ER_TWCS]#+)@YQNB)Q[[AX^Q^LJNK:A)X7)J+
M1WC*E!<NY\[=DVI6]#7:U#E?-<W^5C'F_,^A[?'ETP<]\/PSJ7/FIJ5[)5/!
M%%448I@BG@D                      6Y1BZBEE\RZ(@DXSFZFT7T9*#S-
M>7N(SGB;4HN2S@#2./.![?B:WKUH5+EUI1A!1IRC%;2SYHU>GP#H%I"WIW.H
M7T*M-*,XYB\-8RMH'0.T"O<67"MY6L:E2E5BX<KHMQDLS2>,'*]&X0U_B.I<
M5H\35J+VJ<LYSDUS9>.H'0.$],T+3M2C]!O[BK7498C46V'_ )*-RC)*25+Q
M1?M-^1SC@_L_U?1=:C=7NON\@H2BX/F\_BSI*Y8144EG&,H"K<82;3W-5XHU
MC4=$N*4K:WHSMN3GJ3J9;COCR:-I<.>/*GB7J6+_ $^C>TI0KPIU$UCQQY@-
M2K\:V-SIENY7%)7F<U*:ISQ'K_P\ST=EUA=V&@W$+^CW-9W,I*/,GF/)!9V;
M]&>M<)V'>2:H6?P5)&Q4>2$&H4U!9Z)8 K-<W7R*58*I3<)92]Q+.62>,>0&
MO7'#=I.=2K*M74LN6$UCU]#$Z5;PMN*90IN4DJ?G\$;E6<53FFTLIFJVD?\
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M&+';*Y9?Z3-D+1Z3/I-,.*<LE$2)0
M
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ME^LSJ-OB23E[6QS[A_784^)587>CQLY]TY]]5?*_AAQ7[SH<4I<DXM077;S
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M $Y&Q&L\"R_[(:=C;PR_TY&S'G5ZF8<4SVDB1%$BZ
M
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M&O\ ;TI1M-$Y)N*[VILOA$V/LGC%<))RC&3[^?5? #<Z2QS2726Y,1Z+&P
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MO;_KSK5XS*2)$42*J@
M
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MK)"7D2C[)"%0 2
M
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M_P#Q-+]J/)GE$]/.F->G:+#^:9][/9#9?$\EFUW'*O4],'U-(C4(B5P%$QD
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M
M
M!;CU+A;CU(%65CT*,K'H2F/2VWRMYWR1CXJO-CR)1]N6?4<SYVOU2%8]N?=J
MFN_0-'O*=.,U*=K72<6NO*SYI^E5*\G>5IN3J;8?7;;^!]6<4<(Z;KVUU.X]
MF<7W<TO:Z]4?-G:1H-EP[Q/>V-G*LZ5)TU'O))O>FI/HEYL]/P+1SU_IZ7AZ
MY?\ AYN%51J6U?O()R=39ORV.M=DFN3EJ5[IZ<^[MZ*Y=UCVO+YF"[,NSW3.
M(M&NZUW*[4HU>1=W4C%8Y4_-/U.H<)=GVD\-U*E:PG=NI4AR256HI+&<^20\
MK/2=U3ER1/3=H2;\SCW:_9?6%_HZ;C^AO^???S1UB[EW-*371+.YQ7B_57]=
M5(R</#<RY?"]]SQLF6M6.+#.3N';]-Q*@I;=6>G&&]S3^"]2G6T^%&IR*NYR
M?*D^AME&:ELGNNHIFBW3'+BFGM>3#"60M^AKMAI:K./+XX\RST)5%CV=B2]I
MKS**4GLTB82\6HZ39:I;1A?V].NEEXFOP.:]HO _#NE\%W]YIVDVMO>TY4^2
MM!/,4YQ3\_1OYG5FI)]-C4.UM8X#U%KIFE_K(DCGO91PGH&K1O7JFDV]U4A3
MIOFFGU?-E_L.LZ#PQHVDI2TS3J%MC..1/SZFA]A4I-ZIGIW=+'_J.K8S#?J!
M2;Y907ET+N%Z%ODBL;O)+FWQY@2PO087H4W(RJ*/M/ $P  #0*;[@52P4:R4
M:;*QR@/)6MZ=2K)5(*2]YH/%W9GIFL0S2M[2G-0Y4Y1;\\G1:LGEI%M4:<'E
M-Y1:+3'J5XO/IJW!G#L>%=+H45*G*,8.FE337ZV?,Q^E]H%IJ%[3H1MJE/GS
MO*<?)-_P-NOZ"N8J-7*@GE-'S+QSP%J.@7,;O1K.K5I4Z46Y5JL'B3DXM8RO
M)HVPXXR3JTM\5(M[=)[:J_?V6BU*<\1E4F\9]T3;.RA1EPNG'"??3_@?,^M<
M2W];3K"SK1H*M:IQG%1?A>%YYP^AUWL&U^G<6=.PJ5(*Y<ZL^11?3"\^AKE\
M::4WMIDQ:J[A%^7H5R>:TDVZF?4])Q.*T:DR5CU(DHH(2     0;QN_(C-XB
MG'S]"53QTI*)1+EIP3\@//?U:5*SG5KQARK&>=I>?J<AUSM.C9:C4M;+A2=V
MHUI4IU:-7;">.9X@]GNS?NTM5_LI?*VQSYIXS_;B:9P)?:#;T-1C.=573I15
M=8DUSXEG'XY SW!'%5IJU6,9:92LKEJ7AE43GA>[E3-X@W6>7X%'IGS.,Z3]
M#K=I2K:>Y-_1FDY9]-^IV:G&4J4.]Z<JZ 75AK"DL^IIW%'"EUJNIVM>&J5*
M+I0<=J;EY^O,;='N4W!9RBL9S;VP!Q[CWA/59Z;;4(:U=3C3JY6(2?D_+F.@
M<#V=S9Z95IW-Q5JS=9R4IIII<L=MW[C8*MO&NL5EE+?9E8/$7W?0"?)MEO)&
M?+4CRR2Q[R5-MYR4=-9SY 8ZMI5JN><Z-&3EE[P6Q@]/ITJ7%$E3A".*?ZJ2
M\D;1<SI\C4F]DT:O:1@^*I]WG'=_P1:NBG\FU++3W9267''-R^\E%-1>2$U%
MKQ]"J9]OF/M-U6[^W.FQC<5G'Z.ME4?]*9"O.=96$JD93??1?BW\S#=H;NI\
M::>[3E<E06,XZ\TSWO2>-+FTM9Z?2MI)-37-*"V_%GK1,1CAW5G\(?55*LJN
M_(O3)5/+EOL<FX"U/CRMQ396G$'T3ZKJ<[K=VH<VT)..,;^THG6:=/$I[;'E
M1,/.CM&H\1Y4OD<D[=)<VI<,QQAN55)^F],Z)J_$&G:-7:OJLX))/:#EU^!R
M+M;XGTO5M2T"I9UIS5O.HY9IM8RX8Z_ I)ITWL[DZ/!]I&2YFI3W?]MFB=MV
M(<1Z)*,5S]S)IKK[1L' W%FD+AJWH5:U3OHRFVE3ETYF8#MGG"?$&@UD_"J#
M:?NR6I-M[:4F89"K=:=;=GVC5M8LK:ZA.I)*-QRX4LSW\2>^#3^+*O#NH=GF
MKWNE:#IME*E*$$J$(-YYX9>5%>3-DX@T2EQ'V<:'1G!U%"NZF%+E_IK^)PW1
M]2E0X1U+2XR25:OS<O+UQR^?^2=>&DWB75BCG$NX]F'"6BZQPK9U*^F6"JSM
MHMSG;QDVWG?.#!<>=G,N%>%+[4K+5%%6_=M0I4.[RY5(QZJ6W4WCL6FI<,V=
M/SC;0_>ST]N$E#LLUOO/9_09_P#KTSGRU_*8<V6FI:+P7V<W6M:11O)\02_2
MT*5;DE2<^7FCG&><ZCP;PQ5T&TI4G?NO&#E^IRIY?Q9C.R",%PM:RCG$K*V?
M_H-XCO1S'U*0I"L_#NX\S70N4I<T$VL9\BW"4FGDNP]G<@5 !(
M
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MZ$I7DT^CR"--))X)
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M75+.7_S#3NT_A/5=6D_JZZMZ*=#E\;EUYF_*+-!LNROB*5).OJ&GSROZ4_\
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MI^3-MU'M*JT5?VU2ZJ8YIPPJ$?>C1]!XHJV7%U[K%"M*/?TG3YN[3;]GR?\
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MDVICBK+)EFR[!<JP2P1IU(U8\T,XZ;DC9SF"L?,%40L  (
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MU<1><J3+*K:F[NG_ '-7QCU?O-\L["SN:4:M.BU*2RW*3_,]\-+M4\RI+/\
M:?YG52MI<-\L5GIY-&E6EI]/O*<HR[I=?4U'B33-2KUI.A2N6G%>RGZG0X4E
M3@HTUA+8.FWUP7XV_3*,NG*/J/4ZD81<+I-==F;1PQI-U:<KK=\L9]I&WJA!
M;XW^)/EQT$4M^D_.USB#2:M];N$95$^22V6>IJE+@FO&3FZUQEK&.[_XG3>6
M7JBO++/58'Q3?J2N>:M#TOA"I0NJ=6=:MX99WA_Q-PI6RA;PHN6>3S:/=OC8
M@X/.=LEJ^/$,[YIEI[X.@M^_D_\ Y:_,N6_"=.,LNJ]L?WM&VI2_6:97E+1@
MK"?GMIX;2UIVT.5236<],$+FPHW34O"^7/ZJ9[I4DUNEDI3I\BEC&Y:<56<9
M+;>"GI=#EPX0?^0CTV]M2H95.,>N=HI'JC%);K<I&GOG8B,<)M>96W!3DU."
M:]Z(1HTNBIP_S4>E1?,\XP(TTO+<O%8A$7E8C0IJ3:A%?@79-/PI+<ER/+Q@
MBJ<E)/*P3QA$VF5M8;:Y%\@H8GGE_87HPPV_4.,^;JL$146JD<X?1(JDG'9E
MR4&UC;'F45)*.([$Z-+=.GUW#@LO<NPC*.<M%7!-Y9'&#4+5-<JQDJXXWSU)
MR@^;,<(2BW%+;);2ND%'/F([9)1A)+=HER[$:3I%PR$E$DDUYAPSU&C2Q*+<
MWA>$DVX]$7>5I86"*@_-HF2*PHFFMRCWZ$N[?JBJ@UZ$1&DS$+7*\DHY3W)J
M+\\%7 M/:L51SCH5B\H<C]Q51P1!,!0JXOR"B_-HDTH"6!@;-(HJ5P,$3(H"
MN!@;D4!7 P-R*$<D\$>1^X;3'2F4,KU'=OU13NWZH&Y6*E/O:D7GD4'G;]8F
MYMU.[QMC/,3=.6'AK/D1IT9I9DTY>HDY2XCQ/V=:G7O+Z[H:AJ.\ZE6-.$7A
MY;:74Y[?\%<0NO.*T_4*[6/&Z;;>Q]8RHSELVN5]2,;&@GEP\3\^9D0GE,OE
M"WX6XQLZ<NYT;5N7KM"2.W=D;U>A80HZK87-"4*&/TV<YYO>='[M<CCY,A1H
M1I2;22S[R90G'&-D5*QCA#!"0JA@(D  $                     "C :&
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MCGJ*X=+SG9&G2I6BYG-X]G<]>"S^CKMQG#9;[GHP;Q7BPM;DC@8)8&"55
M        *,J48!$HD42B!4
M
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M<,89( 1PQAD@!'#&&2 $<,-,D (I,K'8J
M
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MBLX)$:3O8
M
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M8PWN72U1YM^9-%T
M
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M'0J
M
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MG[:+I:@O$BZ:+2  (                         !DC9HP$AD(;-  )
M
M
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MLK'3Q2"W)D4]R194
M
M
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M=               !24E%98%06U)R>SV*N7+U F"D'E%0
M'T  BLOS&)>J D            ;P@ (2GA(<W@R!,$*<G+FSY$P
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MF4C/.S164N5/" DNF_4"+RDP      4Y5S9\RC@F\[D@ :R@
M!O"R^A#O,OP[DIO$)/&<+H6J;4XY2Y6!=E+"]Y%S\*:QDITV;YAM/PI8P Z+
MGJ;8]"DN6JERO."E.G)+%2?/[F5RDW&,<8 DUS4VI[? 9Y8I>7D$L/Q33]S$
MVM@"E)^2P54TT^5Y:+=3+IYC+!*G%0CEX;Z@3CGE\6S*A/*R
MHE@JUD ",8)/*R2            "CDD0E.6,P2:(U).$DFG+G>/@5A!QEO/,
M?0";<L+"1!>&;E/;.Q;E&I*?-&JU&+W7J2EFK'E3Y6M\@5E-YQ-))E)5732Z
M<GDRE!-4YNH^=I[9$&IRDIQ\*Z)@7U*+CE/8I*323CAY+-*IWMO)J#AOC!>C
M["SZ )2:@V26Z3(+Q1P5@^J] )      :RL  1[M>\DEA80 !+
M   !OGW$'-II/!1S<9O9M"K'F64P*QGF;7DB'--Q;:6"JQ"">,ME824MN7"
MIE2BL>74DN50Z[$8X4IK!6"S##>X%8R6)8Z^0YFH9DDF'B.$DLOS+:IR[]RE
M4S#'L@7.=R]C#*PEEX?M(@EU46HE8;2::W]?4"X                4;P5*
M->8%&RB7J52R4DL+(&'XDURUT:C&-:<HW%>,^X2CE.2]?Q:-,^T_$,*?TBNK
M56;V34=\_,EVI3D];X:I\K<9UI1?^=3-DU/3J'V?5'DIK$T^;D7JR$;9'1M4
MM=5MU4MY2E."2EF./%@R<'//BQ@T7LRJ2^CZE!Q;2KI)^FQO4'MC.6-&TLE
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MF6X1[ATZ5*DN3"3:6"_%14VT]_0$0DD5PB@"RN 414
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MO3K&-7VW2@ECUPCW'FMJ5.E*6)\V6L)^7P/2
M   %)YY7R]30^(^);C0-0A],J\M&O5<::C!2>$U^9ODFU%M++,7?Z7;:EE5^
M1N&7O%/ES\0-'[1=9L]6X7G"S<W7=6#\4<+"9>IZAJ.DZ9I,ZU2,:'<0D\13
M?*HK/[#8-.X8M+6]5=5G7ARM<DHIQ,W7M:%Q0='DA*/*X>RGRIK &KRXGL-1
MT^G*K*I*#EE>#&ZRC6.&+*O>\+<112BU*<E'?&V#;EPE;*\FXW$\8]A16%T,
M["C;VKA2@J<8O&4DEGX@:1P7K%AH]M2L+IU%7H4G&2C'*]K/7\3'\.NK<\7:
M=7MVOHT6XRSUSB7YHW+6.&[:_J2JJ;I<TD\PBO3![]*TVAI-I.,%&<N?G4I1
M2?1+^ &2E+.RZHK#;PRZD>\_1PEA>(E-8?/YKR F MTF !'EQ-R]21@]?UZR
MT>+E<W5O2?,HXJ5%'JL@9:/Z3+>^":;CMY%J%:A67-3K0:7]%F&U+BC3=.K2
MH5KVTC4@\-3JI->8&=A'E6&5P4BUCPRRBN0&"J293(6X$N5#E13'Q&/B DDE
ML(E,#FQZ 29&/M#G^!6/4"0  I+/*^7KC8M92IIUNN?(NR>(MK=I%M-2AS5/
M#\0/)K%Q4HZ9<5K>24H0RFT:EHG%T?K*XH:E5E)0AG$::ZY7I\3><PE%Q\,H
M>?FC!:SP]::G)\E14JG-S/NXK/3 &HWEQ#6>T+2:^GMNG"C*#YUC?%1_Q/'J
MSJ:!KES<UVH*XJXS'Q9P\G0-+T>WTZ+J4)*K.,LIN*STP7=3TVWU:G!5^6#@
MV_93>_Q T3BW6Z>OT:MG8SE+O8Q24X\NZES/?\"UJVB\3SL-!^K96ZA1I+FY
MG'IB&.J]S-STOARTM;JG6IU>]Y<]8K'1HS5*A3A*6)\V^T?3W <9X^GQG1X?
MJPKU[;N5.&R4.N?@=&X"G>ST6'TZ495.[I\N$OZ/N,MJ=M"_I2MJU.*BVGGE
MST/33I0A&E&EA*"2\*QT ]---17-U*E(]-RH
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M495.5*K54UAYVP;G0QRK/M>9947;RI4J-)<C24FE@]"2YWA[^@$@
M       !C<  42PRH I*.6O<4<?-=20 MPC-*7,TWY$HQQN_:\V2 # P  2
M                       #64T !"G%QZX))-9*@"#IJ4GS+*'=\T6JFY,
M6Y4VHI4\)(DX1:Q@D (\N%B.Q2,-L/&"8 @J44TXK!,
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MHOR*.DTTXX3ZR]Y> $>[BWEK+]2G=QBGRK#)@"D,J*YGEE0
M               A*FF\I+)3D?+C8N ",8*,7RK#9;J4Y\B[MI3SN_<7@!9A
M15*+5)*.=W\0Z+7BAA3?M/U+P M\M3O$^9<GFBLX;YCA/S)@"/*FO%N52P5
M                        $91RB*@^5].;R9< %N$)?WQIH2C4=*24ES^3
M+@ MQA+DCEKF\_>%32ELER>A< $>7]G0I)2<,9W)@",5+'B>Y512>?,J
M
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M;7L]I.4E)YEGKNCIM*4*%:-O"&.;Q973_G8O4_8_ I06(/X@7
M
9                              '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g109079g06g03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g06g03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1AP4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &%,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>\R0!$>A)$>@$@
M
M
M                                                      (7O,DB
M73;J4;:7,FY8\D!D(CT,4I^%2E+ESY-G-[C5-0UZLKW3Y7EO1IKNG3I3E).2
MR\[8W\2^X#IP-,X3U^=6M<6=VJBJ4%&#E5J;R>6NC-N3<98>6O4#*"G._P"B
MP]X]< 7!C;?-'KCS+1>9M9 L
M
M
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M53WZJ^'F;O!**Y<Y: D
M
M                                                         ?0C
MF D$<PR!(                                                  $
M**2V) %$DI-KJ>%J?"FCZC54[RU<Y**CGO9K;.?)_$]Y]60T!\&E:59Z72[N
MQI=W#E4<<SELOFST$O%GS(P6CU K*"Z_>([/;W?0M)+;+//UCOW9N-M2[R7,
MM@-9O*<Y<3:=)-8559_UC=DL2;-"T^5S3U>V5S1[MNJL9],F^1PVVF!8
M                         (;)(8"+)*Q+9 C+(R_4LT0UL!&66*HL
M      (8$@H2F!8%7U %@5 %@5 %@574L
M
M       1)I)YZ'S7-Q"BHMJ6[QL?4^AS[M*X"I<:4;:E<75S;*A6E53HI;Y6
M,/(&WU-5MZ=7DE&IGX)?Q)CJ5%27,I^)[;+^)^;N.^SY<':9<75O=7=>G2Y/
M%5PEXI)>7S-DX2[(:-66B:W[??<[=&\Y,1Y<^&>/D!WJG456"<,K/J%)I^)F
M&SH>STHIM[9ZGT0WR_0!SK/F6*REA[%@
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M83T:6U.X>5*4NC6.?/5/R Z'EC+/BTV\=W1YWRY27-A-8/LBU)[= +@
M
M                        ")9P\/#,<Z<GCEDD_/XF5]"DHIM/<#D7\H*;
MCPOJ";^K^IV_TT;_ ,$2?^2.B[[>PT,?^6C0/Y0$G'AS4,8_^#^VCH' R_Y)
M:._6QH?[- >ZE*4>I*7+%B/3!*6 ,<6G)Y1E#0
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MBU)WVI-+?'>LZOV7\57>NQC0NJ5RIQMW4=6K)OF?,EZ?$]67 NE/9JOC^\_
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M]3P^#[&M:6]Q*HDI57&77/DSWUS=)_J R
M
M    ^A#\B7T(?D!Q[^4%_P!'-0_\']M'0^!O^B.B_P#<:'^S1SS^4%_T<U#_
M ,']M'0^!O\ HCHO_<:'^S0'NQ+%8E@
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M<@:):4)6>LVU.I*5=RJK$Y+>.YOD%\=S3KA2>OV6.G>K]HW&.,_$"P
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M45A9\[VYNYCG[\'W+F4?'TP(I2CS0 K&*BXJ$>2*\DL(NWNVMPGL^8F*6,Q
ML
M                               !66V"Q6?D!R#^4$O^3FH?^#^VCH7
MZ_Y(Z+_W&A_LT<]_E _]'-0_\']M'0N"/^B6B_\ <:'^S0'NK8L5+(
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M7>D4*^E49T:,N;EC/JL2:?F_,#UE/.4\(EODCE;E(I2C)OJBU/#CA@9
M
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MTARR?,GG)HE"A7L]:LZ=Y65>4ZJPUY+)O5..'E;1\D!D
M   IC$VV7(;6=T!C4>9Y?D?'K%&=>U[NDG)I]%\F>AC9\NQ7'+N]\DE'#;C@
MC5:E1?YI=8QY2B8Y<#:M#&+.ZQT]Z)W5XE3;BL,*.8^+?8[3EL9TX;;\$:K"
MY53V2ZPECWHG7-#HU++2[.G.+4XT81DI>344>LHI1P4Y>JEOGI\#-SW]3U_I
M$&YKF:^X\KBJTG>Z97I48RE*5-QQ'KD]9+DCCR^!.T5NLY.<OK=MV;QTX'K/
M"&HTZLJBMKAY:6[6.AX,ZJ51*YEW36V%Z'Z0O:%*M!<U)/?.Z-5NN#=,N:BG
M[#;=,;Q/K<'FW''5?!\O_CKR9^V-<KT/1[N_NG.THU*E+:2E%K=9/T!:4E2I
M\BSAO.Y\.CZ19:=;PIV]K2IM1Y6X+!Z=-."Y9;R]3Q^3S?DNWT/"\7\./?UE
MBN5&N<:Z=6U'2ZU*WA.<I..%![[,V-)OJQ->#"ZGFQRT]MCA4N!=5YYM6EWN
M_P"E$+@;5>3#M;O/]J)W*,7YLM&"YFW@[?DK.G'N$>#=2L=8MJMQ;7,(1JJ3
M<I+&#KT(\M&,/-%Y;R6"RCA[G.Y;:D8ES1FE37-'S9SN[C"?%]YF34E664OF
MCHR3C-8?A\T>9+1;9W]6[=&DZE27-S8WR95K''?>1UR$ZD>6T5&/-4]'E_@8
M]<O-/N--T>E&XCWT:?+",>LI8CA=#<]1TZA?T94KBE"I)XWFO)/)XMMPI1IW
M?>W,+>K3IS4J,</P)/R_5]P&JZG3G0T7-]#NK7O%]8_7?8]G5]7A;6.G0@Z;
MIRH++:?3"-EU;2K;4+#V6=&E*GS*7));9/GJZ!;5+&="O1HU)]VX49-;4]L+
M]P'-N/J]O4X4L[BE43G.Y2:73&)_P.BZHG/ABM&'BD[=87KL?)#A.U5A3M[^
MA;W-*#;4,-I/+W_6_O/?5EFDJ;<'3QCE^ &M<"5*,G4H1J9N:=/ZRG_1W/(U
MZF]*X[T^]J9C9TJ*=2K/I'/.O+YHV_3]#C8:C<W5!4J<JRP^79_:?1?Z5;7U
M"=.\HTZTI)+,EG;.< ?(^)=+J6;J1O:3DH<T>N[P>7:\1:C<:+*_IVU":4N7
MH^7KCU(7""=?%-6\:*EM##]WT-FH:=:6UB[6G;TXT,\W=I;9R!K]7B"QN='O
MHU*U"-S[/)<D4_?<7M]YY_ %*M4J4JTH-4G":4ETZGHW'"5.=RJE&-O"G*;E
M..'XEGH>_I]E1T^UA2H4X04<XY%MN\@?4\.4<=$3E.;7D1'$HRY5AB&,X:W]
M0,@
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MQ7*N@74L!11</<6<]<DQB\\S]YE@
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MO5G_ %C<UG+?D:/*O"YUZRE2<91559<7G'B-WB\;>7J!8#(  9
M     &  &  38 C<C<J+%62!HB@;V+-%6GA[$VJ(O/4O'HRM---Y0DGG9,OU
M)=1<I%YDA'..C)2^!-KI? *[DE1((!%2,$/)&Y46  4
M
M                           #Z B?0ENH(_)95+8E/$6F]RHFK-T<)[1E
MS=MNA+_Y)?XUCW>TS7Z>G\/:-;0EXJ\NXEF.>L<'B=HL^[[;]!GR\V+);?\
MG%>US0>^T73KV=ZZ?-.56,''H^7.$\G;Q>*7DGM77B^N9\0:93TR_E0IJ2Q%
M/=YZGS6=Y*E=VM:LTE;U(SCA>C3_ ''GR=Q<TW6KRJKR<IMO];.@VO9A>7=G
MI]:C7N90NH0G*4;5M04DGG.=^I]W/DQPGKG7NF,DWMVGLTUZEJ_#-FXR;J2[
MQ^[CI-HVZ$W4C**^1I'9YPG+A?3[>G5O)U>[4UB=/D]Z3?JS=X23DG'&/-H^
M!GK=T\%B\,)<C]Y%UN8Y8C-S33SM@LFO4YQR6)1&0A2+(! J@
M                       K(^6_N(V-E<W53/=TJ<JDN59>$FV?5(\WB%TU
MH.I*O-0@[:KF3\ERO+ Y5JG:;<W-\Z>C5JE.ARII5:,,Y\_4R<.<:Z_>:S:4
M+N[ISI3K1@TJ45LWOT1YO!O%_#VCUXV-W6L)4$I3]HJQ\67Y=#=M,XXX3N]2
MMK6TN]-=S6J*%*,(^*4F]L;=0-\HSYZ$93WR3.,E[F%'S*TL>]^26CGDEE 1
M%I?VO,\W6=7M]+I2[]5'))2\*SLWCU/MN;NE:TXNK*,<O&YROAFC:7]E/5-:
MU.=M*C4=+NYOFBXX6&\_&3^X#IVEWU'4K:%2BI[Q4O$L=3[$UGEGO+X&H\-:
M/;PKU[JPU&K<4JV))+W4LO&#;ECEQ)X8$XGY-8/DU&WIW=%T*JSNGUP?2W&+
M7-+'I\1OSN264!I5*WI66M6E.G%KGJKSSYF[QW7+YHTZOB7$%E*3QBJOVC<4
M_$VNGJ!=)(%>8<P$I89)">20
M
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M37>K/^L;AX7-Y?B\T!+1"07/AKE1S3C;C+B;1KNI3T?3+&X2K.'UN?=QU]]
M=.2PR3@U?M;XGL)=SJ.F:91K27,H\LWF/KM-^C/JH]I7&E>K9N&BZ8[:M*/C
M7-GD>-_YST8';P>5P_>5[_3N_O:<*=7G<>6'3'WL]*.<236/0"X*26(;[#.Z
MP!<%4GS//0L
M
M                               B:RB2M3'+OZ@1TA(I+:FF1&49)RST
M/%XCUFVTNW52\JQIQFW&+<6\O'P&'\KJ-8X^SAG;)JDM-[1;"_BY<U&RCAQ2
MSO*HO/YF_P#9?QK#B6'LD8W"J6]&$IRJ**3\ML,_/VLUKB^NXW-Q",:L8**4
M>F,OX_$ZUV U;?VV]7/]9[/#F6.CYCZW+X^.'!NS=>KEP]<+8]CM[7+PY?Q7
M\W]3X?\ 31T'@BHJG"FCJEF/+94,Y\_JT<_[>I3_ ,FK]N*[CZG,O//.CH/
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M]36;6A;54H.,:6<-M//FS:%T M$DJ + B/0D
M"&(DM!= *R9\>I4/;M-O+;*CWE&=/+W6Z:/HF^ISNUXEXGJ:AKM*K;6JH6LY
MQM6DLR2<DL^+T2] --O:.M\&ZPZ-M?7%73XP3[BA%J/-+S/NX1TK5>(==M=1
MU.]J3A8UX5(PK1;>&\M+[C#?<=\?4KQTK2RT^5/E3\48Y_;/HX8XVXZOM;M+
M;4K*PA:U*\(5'",<J+>^/&P.S1Q3@E%87P+2S&2]#%#GG22:63,F^D]L@'%2
M65LPXX?-G+0@DI/!6&.99]_R0$[+=K.0VU+?<LF\OX$/=<T-V!2,'XY3ES><
M5Z$3J]W2YY/;.-S+"/*F_-]3YK^WI7E!T*SEU3\.P&J3JJMKEI*#]VJO/^L;
ME%)Q4L>)^9I%O94+#7+2%%R\=5/Q//F;SG#W JI-S7DCX;O2+&ZJ2G<6M*JV
M\YDO,^Z/,T^9;"<^6*40.$]K]C94.,;*%*VIPINRBW%+;//4.H<,:/I=3AW2
M)RL*+G[+2ES./GR+<YQVTJ/^5]G&7\X[*.%_IU#K'"TI1X6T6/D[.BO_ $(#
MTJ-"%*ER4%&G'.<(R2>$B'&*>V<GQZEJ=IIBA[96[M33:\+EG'7HOB!]D7S[
M,L\170\.GQ/HU1[7F?\ PI_P*QXIT9MQ]L\6=OJI_P  /<\4MU+!D/CL;NVO
M::E;5.=-9Z->?Q1]@
M
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MI3IP<'5G%Q<LRSG>4OEU-C6?5F.$>3PPZHS
M
M                                                       \C%4>
MWJ97T,53H$JM&64\K?)CK4_#4EGJGL6CC#:\BL^:5.;73#).[MK'J;?E&-:I
M?\9V%Q5G.5:,.52E+FEC$O/[6?IOA6/_ !%8\RR^XANU\#\O\/MSX[TRF_RD
M_P!F9^I]"7=Z19K_ +**_4?3_P"1G6.,>GFSZ<T[?%_R8U#T^I_;1OW V_"F
MC_\ <J'^S1H7;[_T7U#_ ,']M&_<!_\ 1/2/^XT/]FCYF,]8XY7VQCWXI>B)
MP(DF;WVQ$87HC#+*V;>YE9CCE_SWO^6"7'>KOX2Z<?[:.%Y7UO2N:&9S[YS<
M84.9QQ'U3-*[+^++O3[ZCIEW7KTZ=6<ZCE5N'%+P?T7_ &3]%W=O3N(5*:3;
M::>_JCA_&W9G>SUBG<Z);04845',Z_Y699Z_!H^GXO/AR<=XN1Z^+*7Z[+<U
M5<\*U:T*F5*SE+F3SS>!^?F<D[#JB]OI-12?+4Z'1-*C4TW@*G:ZEA5:.G\D
ME'?=0WZ'..PNK2K:E2J6^>3EJ+<\DPNLM?IYLI9MW2BUB>7ALAY3?C:13'5^
M:);7=IS]3E)N.<RTO.<G%M)[?K,2<Y+><H_:>55XJTZ%54U4J9Z?S;,=7BK2
M]UWE3G77ZMD[GT^=O?ISS!R<NC]2TFW%.+?V'D:7K-A?-4:,IN4Y82<6O(]:
M.8-K\GHBR[7>TPWCO(O%YRL=/,IA.>"\6NB\BB0
M  5D>9Q')QT+4)0;BXVU1\RVQX7N>F?+?T%=V-U;X3C5IRIR3VRFF@/SY+2*
M6H:5])5];JPK.?)R.>=E\6SVK;A^ST7B/AVK;:Y*[=2M"<J;DL93CML_B;-4
M[/9JCW-&E;QM<YY'5EU//X9X!UNCK="YURK9UZ5O7C.@H3>813W6T5GHNH'6
M+:IWM&,TE'/DC-$QQI=W34:>$D7<DEMU L"GB:V9;?/78"05=1+KDK.HH[O.
M +R>,+'4I+*;:64.;;?\KH?-?WD+&V=2KS832\*SU UBYFY<0V&8\J[U?M&Y
M-^6-O4T.G>0OM<LY4>9*-5)\RQYF]0EXG!]4!D?1F.I[J^9=E:GNKY@<3[;)
M<O&EBTLXL8[?Z=0V;6N)=2X:X.X=KZ3I4M2G6M(<\(\W@Q3BUT3ZY9K';:L\
M:V*7_48_MU#I_#]C;W7"VBJYI\Z5G1\VOR%Z <IJ=L/$$*+GJ/"WL-OG>K4E
M.,4_)9:,EAVL\17%Y;TK?A65:C4G&,JL74DHQ;Z]#W.W/2;"U[/[F=O;\DU6
MI;\TG^5\6>CV8:39U=+YY4$Y1I46GS/KROX@:[VU7]Q?]EEI>7=J[>M._BG2
M>=L*HO/Y&Y]F'_,$FEORT_V4:W_*$I1I\ T:,%B*OJ;Q_HS-B[,JD8Z!*6_+
M&-/*_P!$#<XM\J:66R4RE-]Y34Z6R?J62Y4^?=@7YB3$GRMM^Z^A=/,6H]0+
M +HL]0
M
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M=7FK+UBECKTV_6;PG+F?A;2\RRQCX%XXQ@Q)H523GS)EDL9^(44ELB44
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M%-OED^J-@3<H[K!AMZ%.BN[MX*GR[/!GSBHEY 76R0
M
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MT"!"*)
M
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MW$;.G64JSC*4*?1^\^GWG7R.+"X63ZUGQ^^.WZBU[>TIQ\E/]S.:_P FQ_\
M)S4/_P!0G_LX&[_2$=5X>LKRA*,N]DWX)\_1M=5\C1OY-^%P]?Q4D\ZA/?\
M\.!^?N-QMV^=99;*[,GNRYB>SVW,F?%C'VB"60B60C0D $_8  H
M
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M?_TX'+R^+URMTY<\U79HK+?P+<WAR4AM.1>.$L,\%CSK+=$$D""002NA0
M
M
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M=)M=,LNAB4C)'>([_9N) !0
M
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MCV,L/=1BE)9QYF6G[J-2VU?720 5
M
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M>S_\,")>*#CR[M8S^\\.[X?J7%U*M[<XY2\/)G]Y[WUFW+CE_<4;7?-2)?\
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M-2,(JO-R<LI[K,5T-]IK$$LY^)\E&C3IJ32>.KW/KHM.FG'H)=M;O[6 !0
M
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MR6'.75&2+4H*2\SHB^5ZC*]2@)*+Y7J"N"8K&2JD !
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MES*47+.?7J;+!)K=&NF)63 6"L<KWGDDBI)10M#S D
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MX5U2.K64JZ53*J.&9I9V2?E\SWD?"Y/;*_R>+)!:(2!F1S6 !5
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MM2](O^)QX.3CP[SFSAY,<+VXE9<=ZY<7$*MKIUI4J;I+Q)/;^T=VX>JZA?\
M#=&XKVT(7#M(3Y(O;F<,M=?4MIW &@VE2,Z>F6L5%O91?I@VBA:4[:A&E04:
M=.,5%17HNB+S<^&=_C-'+SRW^+\X\;6?$=QK]>;TN'(XPW4UZ?VCPI<-\05H
M/DTUMM?TX_Q/TY>Z19W,Y5*EO3E)XW:*QT:SIN/+;T_L1VP\^8R21?\ LS3F
M_9+H.K:?&C/4;-T(=S..>:+WY_@SZ>UOA#4.(:]K4LK:I5[JC*'@E%;MY\V=
M1MZ-.C1C&$$DNB1:/BB\_K.-\G+\GY9]<9S9[WI^9J?9EQ#A1>FU\+_M*?\
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MR3QSPDI)?#8SYP8M@>I5-9)ZD*.Z,>V7Z:9  =&0
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MX0KZ#Q+IFB3IRB[^*EAU(R;S)K9K9=#;+7LCN*EI2J0HUFI+/\_ ^WM;D_\
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M "C>[&26M^@Q\ (R"<? E("N!@M@8 16Q. E@ ,#  # P
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M0 "6
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MC":TQLA;&7!'(C43=0EL0D744ARDL(AO"P3#=!Q3$5RK8L$AH  E@
M      R,C P R,C P R,C P R,C P R,C P R,C P R,C P R,C P R,C P
M                 &0 &1D !D9  9"       ?0 "N6,LG(RP">Y(6?,
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MR99D4X[R>1EOHF7C%O9]"93C'9LQ^F9U]6I^XBQ%-IP370DL
M
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MFUH+EBD21'W230
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M3.8=N-A:4>%-3J4Z=&G-4J6%&"3_ )U'6'E+">_F<N[>(Q?"FIIKQ.E2W_\
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M61GAAIEU_:S5FTI%DB$2#0U@@D8(:0"< 2KI'D,$@6IH2 &1 &-ADC)-J)8
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M9<O0<KSDA1?JRR3Y2"DGXD@\+<F,>N0TW'&&.S2(P2?S+>&+\PT^:/4.&7U
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M-16%DORI^'FW1>'3I@$B.4<I8!4)8)
M                                       &LH "O*.4L (2PR0
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MD8]>[V7F7 %8I<SV\7FRT'E;@E
M
M                                            "'U D%0!6JVFFG@^
M6]A"O1:E%-96S,]QA1SYI/!HG&/&'T13J4:=6$;N#CF,J;:P]_D=./BO)=1R
MYN?'AQW7)>UF^<=4M[:WYW3G"<9\F\5XL;FH<)ZM]"ZY6J5(U)P[IP2@_5Q?
M[CV*NH4)1O:=S/%2YE)I*+WSG[AH6B6E[7=.:J-*#EM+'F??PXO7BN.1P?\
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M $Y!")       ! $C 0 @$D "402@
M
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MU7QC2BOW'V.&VP7A6_F7=&*G1ITUBG3A%>D8I%\? L""N"_*O1$%@&%Z#"]
M &%Z!)+H@ &%Z(  ,(87H     80    ,+T(Y5Z+[B0 PO087H@ &%Z(CEC_
M $5]Q( A12Z)$@ ,
M
M
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ML W*GM%-;IHO'J>3P_=U+FU^LDY.,8;OY'K1Z@25?4L5?4"P
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M]D]RD)/=2W+)*+<DNH%P       5G!36'DL !65-2ZY,=M;0MX\L')K.=S,
M           $9>22D\OH\8 ME\V/(KS[M/&?(K!2Y<.6_J5J3[N44X\SEYKR
M O%/+;7B]#R=1T>G=ZE:W4G4YZ/1)I+KG?8]7F;6V4_4)-)RYLX\@$:;[M0?
M1%N]AC.=OD1/-2FN67*RL7![."2^(%G522;]U]"[?DNIC23SG#BNB)I2YX\[
M6/F!D6?,%8O+98         /( #YE94U=NXYI\[6,9V/HC%1Z$@ EOD
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MYPW9UKN%6-27/E5&V]IR7G\@-@DU*+:\@I)0282C%-<RW)BECR8%P
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M@IIJHL/>;?[P/=E*DII/.3+%?T>A$'S)MQ2:);RO0"X
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M]2KB\X7N^A< 4C&:?58)Q+FZ[%@!10W><#E?,\XY/0N *N+SX=EYD\JQT)
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M/FDFO(R@"KBV]]X^@:>R70L *]VL[(APS)-^1< 0T1&+18 0UDE+
M                (:) %6GAX>Y$8OE\33EZEP!1Q>=@XKK^5ZEP^@%-^5IO
M<124=UN3AC# K24N5JH\O);#Z)[$I;D@446OD621(
M      B2RBLHMM8]WS1< 4Y'EK;E\D''R?N^:+A] ,?*GL]TNA'+EXEO'T+X
M8PP*\K>WY/3'P"I*.T4E'T+)%@*3@Y86W+YH0ARO&W)Y(N
M
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MATRUC9:;:6L%%1H484DH]$HK&WW'TA+"P
M
,             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g109079g07g07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g07g07.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1>N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %Y$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P     ! A$#!!(A,1-!%")1,C,C!6%Q@4*AL?_:  P# 0 "$0,1 #\ ^J0
M      4ET(DI="UWD.91YX\SZ+($P4+<J]&$DI5:<6^B<D@+H(Q:DLQ::]41
MJ5J=/^$J0A_6DD!=74D6:=2%3>G.,E_1>2\       ,KU
M
M
M
M         "CZHJ4?5 5*2*E) 8K7[ZMI]G&M;1A*;FHXFLK&'[_<<VL=8UBO
MQ9IL;NWMH4Y5TLQZXYOZQU:XHTJT.6O3C4CG.)+*R<\URG"AQQH2H4E&FYIR
MY5A>UY@;GK]_+2[.%U3Y7.=10?,FUT;\O@<[L+34^(*%34;NA"-:V?)!4Y)1
M:Z[IM^IL?:J[C[/4':.IGZ5'^#STY)^AE>&OH[TZYC0A34'/Q..,=%U Q'!O
M$%>M<W^G5%23L*+;2B\K#QN\X?W&&I7-SQI?4YQA"5EATISI^!IQS+'B?O7D
M6=*YH<6<3_1<YY)J7=^F?/!DNQR%-Z#5DN7G^E3QZ^Q$"&AZG=Z'K%2PJ0I1
MHRJQH4W)<TFE+'D^NYTA.37B2.:\9*$.(](='EYW>KO.7K[4>ITKFSMC %4D
MO/<-S_-2(R346\YVR8?4-7G:N25&<L8Z2Q^X#,153#4DB4,1Z]3 VNOJK<4J
M<J3BY22WG_Y&<QSQYE+&0"CR/8NK=$9O#Z9)+IZ
M
M
M
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MX1;SA>8%R7\+$F>:E5D^L&STIY60
M                    #R  CD9 D".20            &\%,@5!3)5/(
M
M
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MX6?,"66,LB )98RR( EEC+(@"66,LB )99(@B8
M
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MA*6^QZ*4N:G%KS1Y9-PDHQ6<GJIYY%GK@CR_:0 (H
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M-GEVP14W468/"]YC.))QIV?-4?+UY?>\&@V5O<W_  U5OJM'DDI\N(O;JOQ
MZMG$-^N"WSN:Q!X?JSE^E6E?4;>[5:FX*UIYAR_G;/K\BEOJ]>STSZ'.E35/
MFYN9YR!T]U<1DF_%Y,K3J-03FVV<OO=)T]ZAIE:A=U)U924G'&V<K;H="TJ#
MIZ;2A)8BF]_O8&FWVJ:SKES*&@7SM5"3I2[Y)9EG9[)['LX:U'4[2_KV6MW;
MNJU&'BE32Y6\IY6R\F>.\X=^BWGTS1'4O*E.3J.,L)<^<X\CV:5Q7J%M<5*/
M$%I0L:,(^":RW*7ILWY9 AK_ !)7N-0I:5I-6M;WES37=5)I<D7E]7N^B]#Q
MU9<3Z$J5?6-5IW%"K)1C&CNT^N^8KR*]F]NK*WDIMJ3N)2P_ZJ-]FH1YJBE[
M?4"WIU]3U*S=Q;QG&'-RXFDGE?#)JW%O$-:%2A::;4JT+B4Y4G-I8YMDGY[9
M]QLUG3HN:E"HW/?"-&X-4*O%_$*C+,H73RO3\I("L?M1IE#Z7J>JTZU!/E<:
M>[R^G6*-FTWB&C4L*E6K&M*5.FG)X6[Q\3+ZIW4K9QKSY(96Z-*X#C.IJ.O0
MY?R7TA)2]5F>X%FGQ96NN)[FA0JUXVT:2E&$HQV>(_B9CB75KFPU/38TZTXT
MJD%*<8I>+<\7$;5OJ-6-'QU%R[/TP9#BC3YW>FQN9*2[FWSMC'3('IU/5W2T
M6WNJ4JD93FEG"S^=^!C.RW6KO5]!N:VHUYUZT;J4(RDDL1Y8O&WQ9@Y7=.^T
M6WTVG)2KT9<\HKJEO]WYR/5&=/A34*-K.7@FN^;J=5G*\OZH&3M]7O*W$=]:
MQKS[NE/"BTL)9-V-'X.H]_Q#J5\L]U<1YHR71^)&\
M
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M-8?@]K\4:KJFG75E?/Z36=2DHKUQD[+)<W4P^OZ%0U:TE2K.JHMI^"23V^*
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MPE9.SX?T_F2[[N8J<L8;^)GR"6$EZ$P
M
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MHU(\F.[_ #O4]D?96.AWDT^!RY]^5JH *Y@                    "( "
M&  !1E #6XPO0HY)%.=#36XEA>A1I>@YT4YD9U%W#!3!7F13*+J&XE36<D\(
MA&2CDKS)C2;@XQ]$4PO)(IAA>'=C6C4220:7H4YTAS(NXGA1)+HD21%+<E@+
MZ56Y5)$<CF*S:G@)$82)DJQ'H4>W0JV4YXM>9(JL'GJ2;PB*E%= \214,YW
M2QL !3FQMC)4/V0"2PVDB#<N9]24'U*N20%6LX"27H1YEYE5'.Z KA>XIRCE
MQNRG,O("71$-\DHR;>Y("/58:R5CA)X213F3>"DDD!5O)51*013GW G@8(\P
MY@)8!'F)
M
M         &LD5''FR0 BH[MMY#@LY6Q( 0=->6S\VEU#IKRV7HD3 $)0S%;X
MP6L;[/Y'H?1EI));$\_1*C..4MWLBBIPE#%2$6O62)1YFWN8G6ZUY2A+Z-4C
M'=8RD_W"RZ-:KEO:EI="IQ!IMY04(RMX-I0@MVI9ZKH7N#./-25]/27H=6I0
MMZ+E&Y<I-3\2_HX_.?GY%SBJ3J5H.L\SY'O]YMW NB63TJVNY4?RU2FU*7/+
M?Q>F<>1QG=OP^CS8XX<;;^F%U+T?91:E_"Q1>1VF]>7S@ %
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M-C9$\FA\(TY7'%^LUYX=.:<H^3]I&]QZ@2
M
M                                   +<*L9MI)]<;@7 6XU8RK2II/,
M5G)/F6>H%00A5C*<HK.8E)UHQJ*#SEK(%Q]&6)>XN2FE'/7);BXR6R&S[53:
MB\+(@N;VX+[Q&,]]T8G6:EY3C+Z/6Y-U_P"NA=^#[:9Q92H+B#3Z4ZT8]YM_
MWC=-$MU1LJ4*4G."B\-?$XEVBRUC[1Z97HWL8QIQS)>;\7P.N=GUS7K\/V4[
MFHZDW3DV_7Q,Y3*;?1ZB7XVT/VT7%T+;:31<3RLG3>WS@
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M?%_O+>M\%T:LG6T2E;VMWLE4E*73S7F9GAW3M0L;:5._N*=63C%)P;VPM_)
M8#B.A6>O7%2%.4H.,4FEM[*-EU2$ZFBU*4:7,Y4,;+=;'KK65.K',X1<_-LO
MN'@4?S<8: Y%PWIMZ^+[ZE5H5HT(T6XR:V;S#_S,QVFV-U6U*G6M:522A;Q7
M@7GS2_$WV-E;TZTJU*DHU9+#EZK_ -)$JUK2N(M5X*;:QOZ 8+@JSJ6VDVM:
MI"2J5**4DUNC9(]2%*FJ5*-.FE&,5A+T+B6 *@
M
M                                     A6@IPQ)M+)&<U%Q@^C1<FLK
M&<%E1[QMO\W;<#P:[?W&G6<*EK2A5;FH^+TPW^XYII^ATM<LZVIW=2I2KVLN
M2$*>.62]^?B=#XHO:5K80[ZE*JE52PO@SGVDZ1K%?3KF5EJ'<45+$Z?*_$]M
M^@&R\(ZW5K_2M-J4Z<:.GT<PFL\TL;;F A.OQQ=1J]VE0QW4IT=L..9>?Q1D
MN&W0H+4*/(OIL+>4:]7.\WY[$.R*$9:!6E2Q3FKF:3_ZD0+?#^H5N&]6J6%W
M3A3I5:D;>C.>[GAX\O/='2$T^AS7C3DEQ!HB<<S5ZLR]7S1.D947L2D]CB\]
M-BDU3Y?%/!.67!X>^#7]4E=*4E2J22RNB)9=+ORT_CJHX:A;[+'(_P!9MO!T
MG/0[1I=8/]IFC<20KWE_;]XY+"Y?$O>;YPO3=MHEK'KB+6WQ9PDNWT>H\<;8
M4TTT78K"1;II8>2XNAZ,?3YH "@                     B  BA4   48T
M;'#.^2G=KU*Y&?>9W5U%.1+S"B5S[RF1NKVQ7 P4R5&Z:BG0JF4?O",[NUU%
M,%>1!%3=MTG;%.4<B*Y]X70Q,J:B,8)/.2:6"BSDJ;]IZ  ) 14H510'*4*Y
M <HY1D9 I@89( 1PP2*/J!0  $LE>4)X&0'*4Y<%<E4\@1PQAD@!2*W*@ !Y
M  1PQAD@!'!(
M
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MP,%0    HUN5 $<,89( 42]1@J *8*I8
M
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MQEMS>YG#[?4YKKC;,DN22+L%B"1;QRO'D78]#M/3YE  5
M
M
M
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MM)RY7X2[#V5D[3T^950 5
M
M
M                                      !1Q\299E*G.;BXO*?4NS2Q
MD1SRY0&*UW2+?5;.I0O*4*O/CVF\83SY'-]5[.M?HW$JW#]_86=#F<G%SGEQ
M71>P_>=:BN?=]#&ZMJ]GI#I_3:\:2J-J/,F\X^'Q YE#A3BZK1_UQ:<^>KE+
M_@,AH79S>_28U]<JV5W*-2,XM2GE;Y?YJZF=U?M!T:PS5=]1Y5A9E"?G]QG.
M'=?M-=MY5;2M"IRJ+\*:ZK*Z_ #(V5G"RMHT+:,:=*.<1719>2_S8VEODC&=
M3F?-%*/J5CX8RR!XM3T^C=T4G3BWS9WSZ,TS4N$:%M85KET:&*:SLY9ZG0*<
M?$Y>J-)XTU!WL?JRV49UKFGB,5E-[Y^'D!B.!;2]LK[5;BI7@[65!]S"/6&^
M5Y?O//H-&MQ1B>IS5S3YG3:J;9265T][-SL+2I9\*TJ4HM5H6SC.+\O":UV-
M5U3T6I;-KFE=3DEY^Q'\ /+85KKA_7?HJK<MK6KQHTJ=/?EBI8P\_$Z<TVMV
M<VXU=.7$ND*E+FFKWQKT\43I#7KL@>O*L&EL4K6].K#QP3R_,A47A;CN\&&U
M#4M2M7)6UI3J)8QS/_S*M]=S7>-+3O:].-'EB^1K?XF0X&TBM:QA7G.D^:DX
M^%O/M+W>XT_M,U'5(P@H65-N5"3QGSS\2]V1ZAJ%2I&G<VM.FHVTGL_/G7O.
M7;-OIR7DX;?XZXI>1<70L0;Y6FL,O0]E'36GS*J  @
M
M
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M\JS55
M
M
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M^='\#CN;?4X9O@RV[3GE]Y?AO%;8/-3?,^9]$>J/18.OT^5?8
M
M
M
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M+)Y?,MW:J "@
M
M
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M'BM7G./4]T>BSU.^-V^9E-94 !ID
M
M
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MG+MFWT^#?9=.[49QY7'.[/5#:*/+3C%1YL;H]4'F*9TT^=E_E50 $
M
M
M              #R*9*OHR(%<CF*%'T>0"J<RS##7J)U(P2YGB3Z(U#7.-K3
M1M25E*VJ3?(IYC));Y_ \T^/K*HH3^C5%R[X<X@;Q&4L>-8)FAKM%LZE3D5I
M67_7B;Q;U%6MZ=1+"G%2Q\4!<
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ME\FNZ@ *Y@
M
M                               ^C(DBF *$9Q4H2B^C6&3P.4#G^M]E
M^A:U?_2Z]6^[SE4/!5BEA?&)QGC3A/1-)XMT73XUKOENKUT'S23>.\A'9J/O
M/J)+$N:.R]#Y^[3(0GVA\,MQCF.IR?3_ *:F!O=#L>X>HSYE5U'[ZT?^$Z/:
MT8V]M2HT\\E."@L]<)8)IY>,%0
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MW3,*E*,6MWU1DX+$4LY+'@Y)K*Q4 &F
M
M                                                          6_
MS3Y_[2/Y0>&_[SE_FP/H#\T^?^TC^4'AO^\Y?YL /H&/M$R$?:)@
M                                     $6US)/J)13*M^+&"TMJDL[
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M"'=THPSG"QEECP\EWE:F #3
M
M                                                  +?YI\_]I'\
MH/#?]YR_S8'T!^:?/_:1_*#PW_><O\V 'T#'VB9"/M$P
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MFLZJ #3F
M
M                                  "W^:?/_:1_*#PW_><O\V!] ?FG
MS_VD?R@\-_WG+_-@!] Q]HF0C[1,
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MQYY9G=J@ TY
M
M                                      M_FGS_ -I'\H/#?]YR_P V
M!] ?FGS_ -I'\H/#?]YR_P V 'T#'VB9"/M$P
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MIY;^1ML?96V#3NSNC&CI]TJ2>75SN_<C<8YY5GJ7%SZG_;50 :<
M                     Z MU7A>+V1+F2_)] +@(1?+%.?5DH<V/'U J
M
M                                                "WY'S_VD?R@\
M-_WG+_-IGT#+VCY^[3?Y0>&?[SE_FTP/H&/M$R*]@DN@
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M:556<5"MG+7+'?=+;=_(\G9KC[$Z4ZN\^[><?UF;/0AW<&GZY N
M
M                                           A+VCY^[3?Y0>&?[SE
M_FTSZ!E[1\_=IO\ *#PS_><O\VF!]!+V"2Z$5[!)=
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M><A[<_X[:?[N_P!I@;QV9?[!Z/\ V;_;D;2:MV8_[!Z/_9O]N1M(
M
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MN3@/1UU_)O\ :D;7"7,LXP!4
M                                                  !*    >9"4
M\>0$\$)K<HJN?)D9U,+H/?@GA)+8-[,A'FDMG@14E[4LEF.DMV-E8K8MN:BV
ML-DJ<_#NC-ST3':[@HF6)2EE^/"/+<:A"A)QD\M>>48O+IUG'OT][P.=01C[
M:_C5<L;[^IA>*=0N*-!JVG4A)5$LQ],,Q\VVYQ>=,[<ZE0H0<ZM2,8)9;PSS
M4-=L*\G&G<1DTL^S+\#F]&IJFH0G0G=U<S?+F2Z&P\.Z!7H9=:O&<G##?*_4
MSNUKMD;%Q%7K4+2I.A%2:BNO]8T&N]8OJU5T[2+C%YRI8V^9U*I0I5:3A7@I
MI^3+,+"VIJ:I4(0YEAX,WCM:PY)/#D4*$ZES%77-!-;X9J<N'J=;4;Z<Y5.7
MO9.+36ZRSM%UPU%U^>+II)=.5FGZ]I?T.\I*G.$54G+F277=?B?/N%CZW%U6
M.2WH$J>D:+35*7-.,GM/WM^AU33KCO;>BWC>,7_@:5H_#_TJC"4I4W2>?"TS
M>;6@J5.$4EX4EM[CW=/A7AZO/')ZFLK(IQW*P6WN#VZ'MT^9(NKH"D/962I0
M        (57-)=W%-DRC>$!Y]0E5C:5?HT%.OCPQ?F<8U^^[0J.KWGU?PY;5
MK=5'RSE42S'U_A$=N>'%RQNCRW$:;HU7R+F<7E_<!\]T^..,:NK4]/H:-9SU
M.I%RIT.9^))-O?GQT3?7R.B=GFI<6U[JYCK6C6]LL0RX3SYOF_/?0TKA^"?;
MGHT7[#H5-O\ [54[M'NK><NZI<LIO#:\P+N4ZF);/!2CE<^-T,9CS>9R#C7M
M%NM#O*4:=M>S@Y3YN[>S46O<!V('SW;=L5U>74J5.UU"#4>;#DOP,]P5VBWN
MK\06EI6M[Z,*E7D;J/;I\ .S$X]"VI9BI+S\BZ #Z  69QYTT]DO-%BK:TYV
M[B_$L^9ZFN7/O+->M3M;=RJN.$_-X Y+VU.-IJ_"U.G2IKO)U%GEW]JG^)OW
M /\ LQ;9V\4_VF<\[;JE.[USA)TJD/#4J;)Y_.IG0^!$X\,6R;R^:?[3 V)$
MX]"%/=/))[ 5     0?-WBPO"4<5EXZDJDL19!/$5)^8'@UG2J&KV\[>Z=10
MFDGR/#V>37GP#HJYE*I=IO;^$7_";DUBJGY8,9JVI6NEPE5NJM+Q*3BI34>G
MID#!4>S[2$L<]WC^T7X&9T+1K;0HUH6KJ8JM9[QI],XZ+WFKW?:194:;C"@Y
M//6-:)GN'N)J.M4FZ5M)<G*F^92Z@9^*4WG/B*4YMO&W4I.7A\,>5DJC4(;1
MWQY 5<8QDY-XR0J<\YJ*7Y)^TR+K0I4E.XG&,7MXWC?[S3;GCM49+NM-N:T,
M;RIRRE\=@-US'')3>7#J1:IW$7&3>_H8[0M9M]4H*I",:51TU.<').4?<S&:
MWQ?;Z765*WLY7<W!27<33\VL;? #9HRC"/)3>>18>1',MV830N(;?5XO%-6]
M5*+E"<US9?DUZF=6R&]'VIA-,\U:]I6J:JS44O<V>B"W>6>+4[)75-J+BFVO
M+(]K]M9U:M3J<2:7*,L^)>7](N<<6=:XTZ#I0YLUD^J7YLCSW=A*AKVGRG54
M^62>,>\O\=:VK#2:3^C5)_EU'PO'YLC&7#MUZ'?R37]>3@&PN**G*K3Y4JF>
MJ?D;['H<[[-N)X:I3J05O.FW5Y?%+/YN3HBW1,.+LKKUO^VJHFNA!$UT.CR*
M/J4*OJ4 %8E"L0*@                    (OJ1)/J1 C*?*<C[<E*5_9\J
MS_H[_:9U&^U*PL,RO;NVH[J.*M6,=_O9R#MIO[6_O[25E?4)1C;M/NZJDL\S
M]&!T3LVJ2I\":1G"_)O]J1MB>>AHG9]K.EV? VD4[O4;)5(TVFJE>*>>:7JS
M=+.M3K4G*C5A5BGC,))K(%\
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MJU[CJ%..(I$PF4O[7;IUG^RIQ1()8(MG5Y$L#"*1Z%0&$$L
M     43&2@*BN61YGDJ1QN15<Y*I(B5R!SGM)X%CQ/.;G0=2+J0G_"\O2#1R
MWCS@BEH-Q0H6U%PC4I<[3J\V^<'TI*2BVVLKWG(^V^2CJMCXDO\ 1WY_TF-+
MW3^-<T;LMHZUP[8W$[64YS3DVJ_+YM';.%=*^I].J6_+R\U5SQS<WDE^XQW9
MO)+@K2I83S3>_P#UF;-3RD\Y&C:>7DCSO!7(,ZJ**;*\S"*K&#4](<S',P5V
M(ND>9CF94H65-*1DVUDN$5U)!8                  "C8RRH IEA/)4
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M:<I5%)1Y]^F +M7#>&>36%RZ3=J/G1E^H]/A2VFI/XGGUG_5-T_2C+]0'&>
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MO#>5:S=?FQ-?T<'<H]%G8S,YE?#KUG^RKL7E!HC%DLFGD52P@%N@
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MK-:E14,-N?[CL6GMNRHN77E61CE;[>GK,9J9?=>E$D11)&G@2CT CT
M    I)\JR5*265A@0[U>A53RNA1P2]0D1)M/.Q'GWZ$NB>?(HFI+9B;552R4
M<L$7%)$<Q\V4\)*6V2D9Y;6.A3F6'S,Q6K:O;V5/^%2EOUBWT,7)K'&UE9S4
M?+)K/%6N.PI)4Z=3FE&>\7YH\6B\3N]NZ=-SI.,L](-=$S8KFPIWT(2GS8:_
M->.IRMM=IC,?;F5FKW7ZV95YQC-9Q-9Z;&^</Z&K'Q2E"3;B\I8Z&6L-,H6D
M4H.>V>KR>E1\2P)A/LO))Z>.^TFUNYN=>C3G)M9<D<L[8Z<M/U"S5K+NXN@V
MU'S?,SL3V1R+MT_UA9_[N_VF6\6-]L3ERGJMIX#TVVO>#=+KWE&%:4X-MR6^
M>9FVVVGT;6#A0A"$6\X2\S7^S?\ V#T?^S?[4C;&Q.'#^,WDROV\\J"DL2PR
MD+:%/V8I,] .N.,GI._)@=>T;ZRA!5)0?)S./,LXR:1JO#M]:SE*WO%!+"2C
M%G4Y-KH44D_:9SRPENW7#J,Y-.:</W.HTKF,*UQ5FN>*Z&]J]^CV4*M5.67R
M]?C^![.[CNTWD\.KV*OK549*32FI;/'K^)-7%KNF=\K%CQ!0NY\J@X;XWDC*
M0N82Z-?,Y?<<(W-"7>4:%1M;[U(EJQ^M+"YJ0[B"26-VG^\S>3*+>/'Z=8<\
M22PRO,>.WN9?1IU;C$5%[M+R/!#7K%W-6F[A93QCDE^!K'.Z\N/QY9>F;C/F
MCG!52Z'EIU*52D^ZEE9]#T<TE&*73&YTF3/9E/:;FE+ E+E()1YLIL3JM-*.
M#7=&?7M)3VZ,FI%B52:CE)9+JZ%GDW$^89(HJAHW$LE.8H">17F',42&">17
MF*<WN&"F"P1EO)/T%1[;$E%9*5(I(J>6A]LZI1[.-=ITZ:C.5"+4EY>-%OL<
MY?LAI,9+,E9PR_4N=M*QP)K*_P"@C^VB'8ZL\+:9_N< GEOOGX=D3W:6X445
M"S8DEOC<KS%"A%'42?0*HF\8(N*R4C%)E1=R5R1*H:J[BN1DH4R35%<C)$ .
M\]Q3O5Z'F=6IWC6%C."[##]HI,I5U5$_(939%<JZ,BE%S>^Y-Q;/X=XLXP4=
M5)]&69I4WGT/'=:G;V^]2JH[X]ELSW+CQ9Y>F54M\%)32ZG@L-1M;R#J4:O/
MA\OLM?K7O-:XKU.^I3Y;6%.2<I+=>7S,W*NDP\ZK;*][3HK,FG]YYZ>ITJT^
M6,<M/'M)G-(VNJ:HORMO'#_FR2Z?>;!PIP]5L*M2=2E.+G*$MYI],^ASN>3M
M.+"3RRW%>I5K&CS4G4]M+P_!FDQO-1OY-1N*T$WR[^\ZC<6T*M/EGG&<[,4[
M*C!;.7S)V[]LS*8SPT?0.'=1E=2KO4%XH/9Q?JOP-XA91=.4*ZC43]4>JG!1
MBE'.">#ICQ8Z<LN2VL=3TBSA4<HV]--^X]D:7*_!B*+N CI,)&+G:CROS>0H
M)="8-3PRCRY6,E%2:?4FNI(NTLVBHX0Y%Z(D"*C&+7F5:;\RH MNFWYE>3WD
MP%W45$K@J B/*5Y2H":1Y?>,8)%&*J@ ,^31T&0#7DT9&2I3&P-*\PYB.!@@
MES#)1+<K@"G-[@Y[/8IC8I@"S%-0;9P'M&DO_:#PWMUU-_YL#Z!G.3BT\'S]
MVC=VN/\ AMS;7_*4G_\ MIFYK*7;/G'*2.S<2:H]/I3>)/#BMGZG#+BYGJ/:
M-PO4\4%3U"+?-YYJ1_ ZGV@7UK"E64JN'S0_-?X',:UVK'B31+W5&J-M1KJK
MSI9\"E%MX67T/#>3+'/4?2QX<;Q[O\?12V741>S?4TFU[2.#Y/F6L+GQNOH]
M7_A-QM.[=-NE)RB]SV;NMOG:\Z>F,ERHKS$%T!(J?,.8@5142R,E !5M/JCR
M:DJ4[9*K34X\RV?WGJ\F>/4/XLOZWXD\K'&NP-9N>(.\\6-1ER^Y;G<(XBL^
M1Q#L%VN=?_O%_O.VO>"+(EJK>'R^I"M/%O56.D7^HC'+DF4J/\G7_JO]14VX
M/H,O_CKHS_\ \>I_DU3OZ>Q\_:#)2[==&QT^CU/\FJ=\<N7!F^]1KU%USVZ'
MAU::EI=XNGY*7ZF>OF\&3'ZIB6E7R?1TI+_!FM+CY<@X(DJ/;5J<NO\ H&-O
M_M';'<IPQRO='#^ HTX]MVJ1R\+3_P#PCM<J4)R6['AC/<NE_O/R47AER3P\
M%GF5&FHI[+U$:LE%\^$CGEEV^VI+]KS>$,GGC*+<FG[S6.(>)96-24(SI)\J
M>\&_,EY))MUX^&YWPV=7$4ZG,]H^K,5J6ITZ-"5;',DTL)HY_?:GJFK/%*E2
MG#+>4L;/XLL47.VI?1[I*$\\V.OZCQY]1]/=Q]-,+O)Y];;GJ%"-1_P]1\C?
MYN6OQ-AT"XGID5"4G.*37AZ;O)K7:))75[PX[%]YW3ESYVQO#U^#,S;W-&CP
M[0^D3Y;CO'S1PVL99.//SX=>7XL\.W7EU&A656A&276*+M)[&O<+WL+B@TI)
M[Q2PGZ&P2S%>$]>%M?+SQDJM.6S)\Q3!0ZR,:2YBG/[BCZ$2Z9J4WB:V*2BI
M+.R)R68M$7%N*7H%8/B;7*>A6%6M4CS\JB\*:CUE@XMJW%+XNU.O:0NIV-*C
M5<9=Y7S&HI/&,;;;?XG9N+^'*.N:=6HRIN<I**2Y^7I+)I$.R#28/O5:5._?
MB;^D/',!>X$M]#X:I1J5KO2^_BY+O%*$)8?EG)OVD7U"_5:=O<TJ\$T\0J*:
M2>?0YU7[(M,O7_IUI-I_S;AHW#@SA2APU1KTK.DZ<)\BWJ<VT<I?K V5)<O@
MBHOW%,N+RT32QXG[194Y.7)4Z2> /)JNGPU&DH<]-/F4O$L^31A[ZTL-&T>Z
ME4M[:H\*6T(KS2,SJEU9:305Q=N482DH)I-[X;_<:!1UBWXEU&A14W4TV7@K
MKEY9>;V\_0"O"E*K5O=8NJ7-;4:M"4H;-+'HF7>R6UHW6BU:]Y"G5O(W,XPJ
MU8J4U'DCLF]\;OYLVJA3T[Z!5L=/Y_R%)Q2EG98PMV:=P)>4]%Q0U.3A5=24
MTHKFV<<>7O3 KQ%:1L.);"=NXT77O%S\BY7/Q+KCKU.FP3?F<MU2YCK_ !-:
M?17SPM+Q3W7+A.2^?0ZEF6=@)84(MM+;<Q.H:NK>4DJ<GC'21E98<6JGFCP5
M=-M;AOFC)Y_I-!*U>\O%>ZW8;->)+=Y\S8]0H*=E""2>)9Z?$P&K6MM::[IT
M:*DFVGNV]\FS]YW5",JCPGL9KKQ75\.4</:?6I:K0DXR:4G^:_1G6['*M*65
MA\J.1<,\<V%]KUI:4:\W4JS:2=)KR?F=@MI<U"$O5&<'JZN[QQ7421%(D='A
M2CT!2/0J         *2Z;%0^C MK.XB5YDLD.9<PA:GZD>G0(C+9O(OB))M7
M>7G@B^5=9Q^]F'U?6[>QIMSFU+ERO#GS-0O^*+FM5?T.K%QSYT_(\F?)IZ,.
M"UM_$=S4H6=5T7/FQ%KD>_M'/I4[_4[RI&4[E14OSN9K=G4';0K4W&LF\^C*
MV^GT:+;IQ:;]6=/;4SQDTP/#O#D+%PJ5%2DXM_\ R\/=&SQ2C%)+;&V"O*WM
M+H57HO(U(YY9;0>7T;1%YBB]A\NQ!PD^IUQCAEM&+;CEG).W+^/V?^[O]IG7
M%'?E75'(NW)KZ=9_[N_VF8L\GTW?LW_V#T?^S?[4C;#4^S2+GP)I'+_S;_:9
MM:DF61504R51I4*F=@FDMTBM3.-B&[ZDTF_*3DL842"VW>WQ+BPEMU(RBZFT
MO9)IN9(=U%KQ137O19E8VLI.4K:BV^K<$>QY\BG*GUZF.Q>]Y+RCWMG5I4TH
M<WHCG&J</7\+VO5HW%5)S;\,9'4-_/H4Y8M/WF,L*Z<?-V33DMO>ZK:2495+
MZ:6_M2.AZ/>5*UG2E5A435.+;F_<>RIIU"<6G%_,N_1U&VG3BMG#EZ^XSVV-
MWEF7T\T]3MZ=3$ITU\9H]%.ZH5,.-2F_A),T3B;0M0=24[*G#EPDLS1A+:[U
M*QJQ5=P6ZZ)/H9WDW.''+[=;<HN.4T_@3CDUGAW4*MW0CF2;PWTQYF=J7U&C
MA5)-/'H=>/+7MQY."RZCU;DH]"Q0N:=>*=-MKKT+G>Q6S9U^2./QV+@(J2:R
M5'=#6@(HIK."K:1993:H*1DF5<DBZ38B,R2:(U&L$65H?;3_ +"ZS_N\?VT1
M['/]EM,_W.'[B7;2_P#W%UC^PC^VB/8X_P#W6TS_ '.'[@NXW\#(R@;@$5YD
M.9%38BDNCP,KJ4YDXO'D5E#+]62BWCS$5E9*<R)W1)C:GN43"FB"DI)X,][<
MQ3;13)8K5H4HMS>R]QX7K-FI\KG+/]5F>^.DPM>MR_*/POKU)]Y".\JD5\7@
M\U]<.-IWE%^U3<EE>[8Y]J^I:K4K2A2E3QE/>*]#C<JWQ\&_+H-;5+:EUJTG
M_P!=%RG=4ZM"-6E*+4OYKR<VM-$U6]\5:%-IORDD;[H&F.TTVA2K1Q.,6GB6
M?-B=U:RPQP:9KNJZBJZA15[AP_-E+U9CZ-GJFH;U*UW%/Q>-29T^5G1<U+#V
M]Y>A"$4E'.Q9A6\.KF'TU_A'2JME;N->KSOO'+=-?FKU,W=:?0K<O/0I2:?5
MP3/5"*>_F33:?N.LQ\/-GR7+*Y/'1L:%*.(4*4?A!(N]VET2^Y%^>7[(WQL.
MT[ZMQ7JOF2PFML$DDUXNI&$8QR7M9N24(XVR2P1AGG?H3-1GVI@8*A]"B(*X
M8PP*+J2*8*Y0 #*&4 !3F17*  #( #*&4 !3F17* $9%6TB+F@>@!23#G$+L
M!3F16,T^C)LV;A=0YI=2G>1P-FTP1R,E3:0(Y&0;5*$.\BWC.XG-16_F1-HR
M:>V#Y_[2Z:EQ]PWXDO\ E*77^UIG?*3R^9]#@W:?"#X^X9:S_K*3_P#VTQP2
MV5K&;RVZEQ-PW]9*IBI27,X]89Z')N(;>-YQ#HNEU8Q@ZU;Z.I36V\HK./0[
M_P L'#F?0XGQ):2ONT/A>M;K-.VOLU&WC"[R/X,\?+CK+;W<?)>W39K/LNMZ
M-)9G93EOO]'1TNG%*GR0BH[8RE@C22Y,T^I-SA%J*SEGLQNX\.7B[3@N6*3>
M6O,J14EC<JM^A45*E!T0-*@CS(KD&E)]#RWW\57];\3TRDC#<3:Q9Z/I\:]]
M.4:;J*&8Q;W:;\O@3ND7'"VN6=@W\8X@_O&7[SM><01QSL7M*NGU-7G=)1C<
M7KJT\/.8M,Z_"<91370Q>6.F?%<?:4=D6;J:A;5I9ZP?ZB\YJ47@Q6O7$:-E
M++PW&2Z>XYWD3CX]W3CO"%'G[4]+OGCEA3J1RU_T4UU^\[O+$Z<91QTSL<!X
M:OZ5IJU"-635QXFL+*QRO_S.TZ1J-*I9TN:3S*G''A]Q,>77MZ.?I<L65I[P
MP>'58_\ )5\D\-TI8^3/71EE>XU_7-9M86MQ3YY<[A*/LOJ,NHDCEP\5MU'-
MN%*2L.U&_O:TXXE9\F7M_,\_N.U0<)PC.+CC"9PJ^JP>J5;A-YE%+/W(Z]I%
MS2NM.C*W;?)"*>5C?!RX^HW7?GX=5=O]3H6]64*DX;/&\TO(U"_XO=12A1IU
MDVMN6I[R[Q)P_J.H7$ZM"G"5.4DUF:7E@]MAPE:TJD95*4LI_P#.,[Y?\FEQ
M^/&>:]W"MY5NZ>:JJ[TT_&V_,GJ/#\+V[YYJDURI8E3R9:QM*5K%1HIK"QN\
M['MDGAXZFIQ2SVX9<NKO%B+/2K2SA&/T:@WA1RJ:70\.J\/4[FY=>"HPCRI8
M[LS\H-O,_N)\L90Q+H<_QY7.<N7VXOVH4OJ35.'J27.[J<TN1<N,.'SZFT\.
M:%]9Z#0JU94XN4I;5(9>S:,'VWQ_Y<X4G+K3J5''_M4S>^"6JW#-M5GO)RG^
MTSK^-,<>Z-SD_P"_EDM,TRG8PQ'N^J?ACCH>^J_"L>I'PO!2ITY8]4)CIQRR
M>B.Z*>8@]BIL@^A'!/R*%9J0 "@    "DWRK.,D)).47L3DDUN6X>),#PZWI
M:U6UC1E64%&:GGEYO)KU]YJ-OP%*VM:M.C?RA.3RI0H8:_[QOF)Q;PU@DU/F
M336 ,!P]H#TJ$G6O)5I3I\CYX8^_JSS:GPG3N:RK0NHTW&*CA4L^;]_O-EGB
M;Y9>0CX]O(#$:'H-#2U4G*5.K.HENZ:BTUG?S]3,QCMG)"4Z;?(T\QV1=@N6
M&X$$UG<LW-W2M\\S@L>LDB]%1DWD\&JZ>KB,N5++:ZL)6OZI=4[C7=/<>79I
M;//F;#.HG349)<J?F:M?6BM=<TY-;<R>SSYFU7$(RLX2BNK_ !,5OA]N,Z)H
MU&UXFL*M/NVXR;\--+R9VRQ_BE+^JCD&F3G'B*Q4WLV^GP9U^Q>;2DU_-1,/
M;V=3_AB]**E$5.CPJPZ%2D.A4      #)270CD">2-26(-]2F1A26&!82;WS
M[R2GGHL_ I*23:6<=#&ZEJ]MIL'*JJFS2\*SU^\YW/1,+61E*$/;JQBWT3>#
MQ:HYJVC.BY3S)>S]YH-[Q/=WUW3C:5,14FGSP2ZLWG09U;C3*"NFI2PV\;>;
M.?R]WAWQX^WS7/WIU]J=Q!3C<QC[+S"4D;7H7#\+:DN^Y92Y<>.ECS-BM;2C
M1RX1:WSU/0H1;>Q)Q]WETO-J:B$);]"[&7N+:2)1.TQCQ[74\HBENRG,UT))
M[&]+*+8KGW#;!1X(J$Y\NZADY!VV9EJ%FN5_Q=_M,ZU6J\LFO(X/VW\14X:M
M8).?\7?YJ_G,Z88]S<PVZQV:2<."-)7(]J;_ &F;.WGRP:'V1ZS"^X3T^E%S
MS"BWO%+\]F\4Y\T6S-FJEQTFB2>"(3(RK+<I@K'<J-LZ11)%"J!I4I@J (R7
MA9")<ET9!(-215%<96 D":7TMSI1QB6&O>CQ5],MJV,PHY_J)F1FE)%KE42=
MD2<F4]/+;6-.V]CE2QC:.#3^)](O:O-*A7N=HO:$9/S]S-YDGY"5-36&<^3!
MVXN>[MR<AH5M5TN34Z5[46.7=RC[S=>&]<JW;4:EK*&9M9E-OR^!GKC2+6X_
MAH-[YVDT1L]'L[1IT:<DT\^TV<IC8ZY<N->F=Q2A%.I5A#^M)(I2NZ%5XIW%
M.6?YLTS \3VUVZ6;>5-+F>,^F#2[:^U73VISJTL1](I]=O0OES[=^G64^597
MB*QFY=8X-$X?XLK7-SW->I*6)1CM32\\&[]]'DY]\=#6.5C&7'5_9%&L]&6Z
M=6-7.,[%SILCI,]N?:16/,C4Z$_B1J=#4J::)VT_["ZQ_81_;1#L>VX5TS_<
MX%SMI6.!=8Q_S$?VT0['DOLMIF?T.!6=5ON2F2>$4Y4%0FG..$\>\E'$8XE)
M?>5Y?3J0J1RMS/=I9CM<:4H[/Y$8>&,LGCKZA2M(XGS;/&RR0MM2HW,L04\Y
MQNC%Y&YQW^/;*IB._A^\\\[VVHQ;J7%%8W\4TC!\3:I7LX-49<K51+V4_)FD
M?2=6U/PQJTFGX=XI>_T.7=768>'2Z>L6<ZCC"XMV_=53//Q#>5;>SJ=S1G)X
MB_"VOSO@:MH7#U[WJJ5I47LF\2?K\#>ZU"E<TVIQ;73K@LEL7]<:Y77N-4O*
M]2,:5Y%<SZ.3ZL]^E\/7U6:E5K7,.OM4Y?B;];:5:TYRE&#RWGVF>R-%0?@V
M$PM:^63T\UI:8LZ-*<LN%.,6VNNV",M+M\MR[K/O@CT1E/GDLK&2<DI/<[S!
MYYS9?U"G:PA%J'+]R+L%RQ2]"4$TMAC?<LQB996HJ.?,KW>/,DEA%)-HTS,=
MD5A$D4I[Q>26"&@%?(H:0P1)KH1P0TK#J2*16"HB@ ?0!D9(9&0)E,$4R60&
M!@9&0(%4R**H"XF0?5A%=@* EL-@(J.=\E>7WC/H4RP$E[RVT3W926$\2Z^X
M""^)))+SR4Y$]T4E*,4\Y)HF-)+F>%M@N-)+9K/N+,*BDWW?7SR0<Y0>9/9>
MA=-3"K\<O/,L?$K+;I')85PI>NWN"JSZ1?\ @-+V5<EF75.*0BHO_P"8L_$\
M<]1BHS4^;;KA'BCJ]M"H]JGR_P#,U,;5^*LY)K&S1&$6FWNTSP65["ZC)T^;
M9XW1BM>XNM-#?)==]E2Y/!!/?&?43&VZ/CK8^;TAEE6G);IHYQ7[6M$H4)3Y
M;W*_Z&/_ !%=([4M.U.I4A0^E;8QS48KK]YKX\OX?%6]UH]SFZ<\1CMR/9/R
M_>?,_:+Q'2N^/=,G34,6&I3<U&KGI5CU]/99O7'_ &B7VD:E.S=9JV[N,W%4
M8MY;?G]R.$7E>-YK-Y?2RW6N)5L].LF^GWGLZ3IM[M>KINGW[?8&A:O'7='I
MW-",81FWCDGSK9M=30J%!6W$5"K7GM&YYESK'21H'!?:1<:7;TM*MJLXJ'-)
M+N8M;O/5_$W.\O/I5Q93RW.H^9MK&[P?*Z[C^/+_ -UWG3V73KUG<QKVD:E)
MIQ;>\7GS/5/#:>%E&J:!?PM='HPJ<V4Y=%[V>ZIQ':4VN\57/NBOQ..'+J/)
MS\%QWX9]2\*\&2BF_P":T8.QXCMKFO.$.]Q%9WBOQ+^MZJK*VJ3BY)QBG[*?
MF=9GN;<IA],KMYR*=Y'FVFG[LG,ZO&UU*O.$*KPGC>G$E:\3W\M5I4I55R-/
M*[M>C'>UV.ERJ14=\+WMGEGJ-I1;[RZH)KRE42/.Y5+C38SBUSNES9?JT:%J
M=EJE>[FE4H\N%U^'P'<=C>;GB"PBDHW-LV]MJT34^-M5L[S3(T9U;?:K&6]1
M/R?XF-K\.WE.,:LW2Q%<SQ)_@:MQW;UK70X7,'%.5:,?7RE^!Y.7ELRL>WIN
M'&K_  CKCM;QXI\]-5=WWF%^HW*KQ;64FZ-C.I'RY:KQ^HYUV4T8:SIVI3J+
MFG2K*";>/+W'1N'K&R=Y6MKBG)]W#.TGZK\3GC;D]?/QXR7P]VCZ]6OKJFW;
M3ITN;EE+G;2V\]C'\97$J[Q2JR2IRDWRRSM@V*GI%&PTROW$.6>>9>)OT.>Z
MKJU*C>7M"ZYVVW!<J\SU\?#:X=+CCEE6OV&IZ7<XIQNK.-Q)OEQ4BYX]WF;'
MIE&YC<6[A=5I4Y2CC#>,9^)S6UX<I6.H4[OD25-/I-M[IK]YT;AZ]G<2M:=N
M\*CR)\R\O_2-9]-9EI];J^+&87PZ?2IMZ>Z;K.,^;.?,YO>6%:M<5VJ]24(S
MES/#:2SY[G0+BMW>F.M^<I8S@TBUJW%.GJ3JRBXSRUA>6YF])<H^5TN/G)I5
M]K-&TUJMI:A3K5*45-RYUEY2?3'O.I<"74J-"5*M3:5:46G)XPL'*JFEV-3B
MJYOZU.3JSI*+:D_1>7W&_P"D7%R]0LZ<)1Y-EAKRP<L>CRQK76<>MNFQC&4%
MAK!9C/E>\2EBJO=)U'%K'E\244YL],X\H^1EC:N1J?T"7-WBV>/O(0:3<65F
ME23<=L'28Y.=_56<-X^+HQ42SE2^X<\'!9SEH\MS5=.+>2R6>W3#]W)NW6M!
M:YPIFK%+O*F?%T\5,W[@.4:G"=JZ4E-<T]XO/YS/GOM3XCJZOJ]KB;<K*K54
M<P2QXE\_9.F]AG$LKK3*&F5I2E.G"K4>()+V_7[SV<G'ECQ2UZ<^E^/#O=@S
M'NFXX;2\B%/>*;V^)"W4HJ2GC$GY%SERVET1Y7AL\IQ)$(O))&6HD4P5!J,U
M4 $4     4D\++(--/PK)<:36&4YO) 1Y.:.[:**&$\R9<6?,HUE@0QR+*WR
M5SA]-_0MSJ*,L;[,N^TLK9@1V3RDF_/W$HR;\B'L-\V_-Z$H^A**<J></<\]
M:\H6Z?TBK&FE_.+\O#G!CK_3U?1:FHO+3W;73X&>ZE8#4KBA>ZS92I58R47C
M,?B;-**^A4XIY2?7YFJWEA&SU>RA148\S3>&WY^\VA-_1H0?M+S-]LK7%/.V
MB*MH;UVSITM1HNO+/)!)9?4Z#9I*VIJ+S'E6'ZGSSIMC<OBG3[QU88HM_'H_
M<=[TR=1Z7:3<O:@C%UCZ>SJ<?TE9/*6SZAM+JR$IQ7B:8E'O(Q<=O/<LNWBT
MNQV17*(034?$\LJ:1+**97J19";?D(B[S+U',EYEN$'C+:(SDO0EJS_NNR:Q
MU(Y6.I",N98(PDL>XJS57.9>I9N;BE1I2E4J**7FS%ZMK%*R37)4SNLI+R-#
MU3B.[OZCMJ%:<%-+VHQQMN>7/FREU([8\-]_3I=2I&M:U)4)*<N1M8\WC8T#
M6=$U+4;RHIT[B%.6'E;K9&S<*.Y=K^6JJ7AAY>XV+E7IN68W/VU,IA?#6M X
M<I6*YIKGD^5^."\C880Y-E%1BNF%@N\LENFBDGA>+<3BF/VYY<MRHI))X>2.
M\F\%8\C_ #6')+HL'HQN,GAQN[[33AG&5DEF/JCS\C59;K&":PN;)=:/-3]K
M>.Z(]"E*6*3^)2HV\-/XC=:F&R=2,5XI81"52*6>;8Q>LZO;V%"4[BE4FDTO
M#CS^\Y?Q1VNV5G3E"A0OX2Y9+*A![KXR.F/#ER>G7'@VZO>75.,<\T>I\H=I
M>H1UG4;:I9S590I.+<'G#YF9JKVHZKJ=U-6=W<4J6%)1G2I[8V?D_,USB+3)
MZ/=T*;<,U8\_@;?G[SZ/3]+,?&5>[BX,;-6NC=B'$=IIE.5OJ%S3H<EORXG)
M]>?)W"TUO3JZQ2NZ4GG&$SY!^AWU&VIW=M7IT^^VZ9>/E[C+\/\ $/$=35Z#
MH:FH6WB4H.G'+?*]_9^!GGZ3'_*5.7I\9-[?74)QG!2A).+64T1=6"ZR1KO#
M%W<SX7MZ]S5[RK]%4W))=<=3BG$/:Q?Z?JW<?2+KN^12Q&G3\\G@QXKE=/'C
MQS*ZV^CZ52,L\LDRYS+&6]CYOTWMO5*6*ZOYYPMJ=/\ $ZMP+QQ;<1V=&4:5
MRG/G?Y2,5T;7DRY<&6*Y<-Q;US+U15/=KS-7U_C"PT.5'Z1;W,^\3:[M1VQC
MU?O/+IW'%GJ4N:VH75/*SXU'R>/4S./*S>F/CR_C<QE+J8JUUFC=2Y:<*D99
MPFTOQ/;&MGV\LS9IBXY3Z7IM.#P6DI8\RTKNFY)*,N5^1==522Y$TEZA+ADD
MDULRJ>4\/+1#O?RR3ST#33;B\9(SVV+L7X-]BWB+>5(1?+#Q;LI%)I\JP3RU
M-JN:CLL,A"+6<-LHVHR>=R\H26^5@L_[FM^UO=MIMHN*/=P;>^/4-Q6\EELA
M])A+PN,MS-TSXB4U&I#Q)/XH\-?3J%:#CW<-_P"@CWQ2:RO9\D0=2,)8:8[8
MZXY]K#6^A4*%9U()9<L^PEYE-=I7/T67T:G.<\K:)FY2CRII,@GS++W.7)CN
M:Q;QYK:Y='4-9LZTG7LJL8<V<RF^B9E=,XFJ5*KA4C%-1;]M^IN5WI5O=TY1
MJ4XO*:W;\S%TN%;*E7E-4*>ZQM*1RF&<^FOEVS=M<1JTE/*QA9*_2:,I."J1
M<EU1Y;ZD[:PJ_1\0Q!OU.<WNL:A:W]9JY:3PMHKT^!JYYX_37'QS-G^U^$KG
M@S5:5!.I4E0BHQ75^-'E[([FC3T&QM95(JYHVL(U*;ZQ?O,%?:]<:G0G2J5)
MRC-<K4HI>_R+G 4E::M?-K.:>%CXG/\ *RWZ\/1^%C,+E;Y=7G7A"+E*227F
M>6MJ]C17Y6ZIQ^+- U_6-1^FNWM[EP@XIX<5^!XZEGJ5VJ'/=4WSXSE>OW%_
M)VXS@Q^ZZ=:7]M=T^>WKPJ0SC,6:?Q-J5_3K<EM0G.+<UE2?KL9GA?2JEE8J
MG5E"6)-^%LRE72[>L\SI1;7O9WQG?&/UPOAS.5MJ^HQ_@;A9WVDWTV-JX9T6
MXM6IUY5E)34E&7F;1;65"VCX*:7ELV3;W\.S,7CU4O476HA<6D+FFE5IQSG.
M\4R%I8T**Q&E3ZY]A'IC*6/$\DHSBO)G7MQ<>_QI10C'I%+X(E2QC#23(2K1
MSNF)37.NO0U-1.[:NRF^9XR]BKV><[$9QY^5^FY67L&I8FH1E%YS@.,9-XE\
MBS&:YFL>>"\DH[F>["_;..TEX5CJ$\MYZE))M91"49./A:4O-C>/]:NUQ22D
MDWN5;6^2W&/B3ENR*ES3DO0;QOJF,J[3G!Q>&B::?1EF%-*+45@KAKS'DOM=
M;7J4SLWY(MQ?\[<I4EO%1VB^J]2S9JKJG%K*:P5RO4\E>XI4([PEC/D7'-.*
ME'*6,ETU,:OJ44^J*\R]3R2KQ@N::;SML4C<Q<MDQ(EPOT]I27LL\\KA*.V3
MRU=2A"#YE-_<BZ)AE?I[E)-XR5,<M2HODQ":E)XSM^)<JW,J2<Y-N'HD-+\=
M>QR2ZO!%U8)XYEDU&_X[TZVG5A5MKN4J;E'*4>J^\URZ[6-(H5)*=EJ#:QTC
M#_B.DX<[]-3BOVZEWD?4=Y'U-;T+B:TUBUE6H4:\(QQE32SNL^3-3XV[3;+A
MRM5A6H7LN2I&'Y.,'UCGS9)Q96ZT3C=.[R/\Y%5.+Z-'S=7[<5W4W36H)^3[
MNE^)G. NU&XUS4*E*52Z<5!22G3IK\Y+R.GXV>MK\4_KNSJ17621Y*VJ6=&3
MC4N*<6GC=FF]IVMWFCZ+=5[&O*E.$*;344]W42?7W' ;SCSB"YN:O_*,\J3Q
MFE#\!Q=/>3[=.+IYG[KZNAJ]E.6(75-OT3/4ZT%3[QR7)CFS[CY*X?X@XON-
M6@EK,.[Y7X73AUQ_5/I+3Z.I7'"E%SNH.O.RB^=K\YT^O3U,9\<QNMN>7'C+
MK;TWO%NBV565.YU*VISCC*E+U/!5[0^%Z3_*ZW91^,V<3XIX.XHOM8K2CJUD
MH-1VDGY)?T#'+LOUNXE!5[^PGY=9K_\ B>C'I^*S=R=\>GX[-[?2FC<2:7J\
M8RTV]H7,91<DZ;SE)XS\S \<<=V/#=>C3N*UO&4Z;FE4FUYX,7V8\'W6@V=!
M5:UO+EHRA^3<GUGGS1+CWL]I<25:5:ZA;U)4Z;@G.<UMG/D<>S"9:WX<IAA,
M];:Q>]MMO3?Y"-E4CGKWLC)<(=J='B"[IT:4;5RG*44H5&^D>8QEKV,Z8X<M
M2UM);?\ .U38N$.RS3.'KJG7M[6WA*$Y23A5J/K'E\S5G%)X=;CA/MFN*M>K
MZ=IMM7M[>-2552;7,UC".'ZAVG<0_3.1:1B#BM^^D?15QH]I>TE1NZ,:E.FL
M07,UCY&$CV=</59\]33:<GT_A:GXF<.3'&>F)G(X=8<><3W%]0C2T>I*$JD5
M)JK+9-G>.&KJ_NM I5;FUE2KN4LP;;:\3+EMP3H-E.,J&GP@TT]JDWTZ=69^
MTIT:>*-*'+%;I9&?+,IZ3+E?-?%VF<:W5_.-MINI1I.I47-"<NC>SZF 7!'&
MU1<T:&LY?DIO\3ZVJ6=.;SRKYLG1MH4UM%?,Z3JK/H_)O\<I[+.&M7T^E6GJ
MKO:<U53C&LV\KE^)<[1.![K7I<U&K=1?>J>*:S^;@ZLXI=$4P<OFR[NY/R+O
M>GS;9]B-W7I-7-_J5/+\X+I\S9N&.R1:-5G5E?WDTE%^."71Y]3MF"W<0<[>
MK&+2;BTOD:_(SI^17!.TB[MM:UYZ;1IT<UJ,&JD%F2PW+]QR6[M8VMY<4I2V
MIU)1;:Z8;1UC6. .(:G$U.^M=2L::C3Y5GFST:_F^\YQQ#PSJUCKD*-_>6U9
MWEQ*/@SCVL//A7\X]_!RS":E?4Z;/&>&7X"HPHW]*]C0A7H.,XJ<HK#?0]_%
MM]4L]8TA4V_RU1[<S6-X_B>_3N'KS3=/C9VU>C#D;:QEK=Y\T8S7=!U*MJ>E
MU;JZH5%2GE=5C=>[W'R^OQ^2[_\ +W?K)W-WX=5S?T(J<JL(X;V;?F;&^$;F
MO5@YU;F,/-XZ&%TNK]6Z!0J;]]S.+E'?*R_4ZMI]Y"O2QB7EU/D8\5]/F]7U
M65\:8+1>'?H#;=6I)..,R77<S][8PNJ<H3\UCID]/=RDMFE'R1*6552/=CQS
M3Y=Y<K6!I<,VT)RELV_6FCWT=+MH>-4J;:\^1'NCS*<^9Y3Z%*J:IM0>$7XX
M?)DHER1C%1271%7;P>[I1S_51*+S"'-NTBG>3[Y^+P8Z%[$W6(X@M:E73Z\;
M:FYS[N22BO/&QS76M*O)Z7"C?V]2E251-2DL[[G7:C>&J;QGJ<L[:]?JZ7H<
M84ISC55S!.48IK#C)^9G'HL>7/W[>WIN;*76FM\$5K6PHWM+2*T+N<JWBC';
M$L=-C:+6]=G7G=7^+9U5RXD_/T_P.$\.:Y<Z'=3G3JRCWU3O7R13W^\]NHZW
MQ+Q+>5:-GJD:5*#52,:M.*PL8\HOU/?/^E3"[WX?0Y<KE/+Z=MN(M,U;3*]Q
MI]Y0N*,'R2E!Y2EL\?XH^<.-+>YUCBS5U:5*RC1KRE^2;Z'6> ^$;_2>$K^U
M^D6_>5*[J*46VEX8+S7N--^P7$E/6]8NJ6J6,:=>3:6^<;]? ;XL<,;?+Q\.
M6/'E=5I'"NE5M9UVVT^O>W-+ON;HVWM%RZ9]QN7"U1\-<0U;2[J2<*MQ&WIS
MK/'-RS:ROFC5=&TG7+?C&TM=/OZ%'490E*G6:S&*Y)9ZQ?DFNGF;I_[-N++[
M4K*\OM8TZJZ5>-=^TGGF3?2'N.W+,)E[^GLZCJ^_]?I>[6J^O0U&I'2+2XKV
M7)#\I3FTN;?*V-'N^,]4MK*=K<6/=NM3=/FE4>5MAO\ Q/H9Z7&&G..K*-P^
M;?E;7P]#C5QP]0XDU2JK:G3IT[6LXSC5E)93EY8SZ%X,L<IK+U'EX<YC:YU'
M4KB-5W+JU&Y+EY7-X_\ 6QWRKQA:Z?PS]+HPMJE6C0C+#>-\+S./ZMH=*WXK
MNM(A""5&G&ILWR[I/X^9MW!EA2OJCTK5X*YIW$U!)-I*..C:PSIR\>%G='HY
MLYRS=>A]LUQ<48TOHEO!1WYE6EN3TKM9U.YU.WH/3:2C-X;567O-JI=E'#ZJ
MRQIU#DQLN^J?B9_3^S7AZA7A6AIU)2@]GWM3\3R7/CD\1\_D[)Z9:WU"O=Z!
M1NXTL5)TN=Q3Z;'!M9XXXDCJ<:-+3:LHN">56E[SZ/HVMK;6\;6G2Q2A'D44
MWT^9BGP-H-2NJT]/@Y)8SWD_Q.?'RS#?ASG)(^>X\4<62FL:7<^-^%=[+?\
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M6K>K=VUY"$:_,W4DL8Y3KO&=6_H:9;1L+=5IJIAI^2P_>;?&VH8?=4HPEY/
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M,#>.S'_8/1_[-_MR-I-6[,?]@]'_ +-_MR-I
M         H^I&KT1)]2-7H@-#[:O]A=8_P!WC^VB'8Y_LMIG^YP)]M7^PNL?
M[O']M$.QS_9;3/\ <X =   %8]2I2/4J
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M90            ^C  LO&=HEU/,2$FG(FUF(%$H^XD6U!IEQ=
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MA/\ *?<!:N*49SI\T8O?S1<C!07+%)+T2P1JY[RG\2Y+J!1$X]"")QZ
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M]"1&#3V7EL2           "+BF5Y7CJ5 %(IKJ\E0       4YO%@J4Y?'D
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MW-9PQ##Q.?+G+QU^\TF[UO7= H6M;6[FE4I5YJE!481;YNN^RV)<?77TJM]
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M36M0[4M2NK'PQG:)+GV>RIK]QTZG&OC\I*+?E@#T1Z I'/*N;J5
M%)1RNN"H C*/-YX*Q6(X*@"D(\JQU*@       CS>%O'0D0I^*+R!7F?*FED
MC4K1ITW.I*,$OYSP1J5.39>N"UJ%%5K.I&:RWC]8&I:KQG<TKN='3-(GJ,J=
M24)]Q4;Y4GA-XB\9,EP]Q%5U"[C;WUC*PN6F^YJ3?/A>>&DS1=)UVUT76]=Y
MU54^]G&/+%/>,I>K,MPE=U]>XIIZJY)T^ZE3\247LO1?$#HEU4IT:4JM2<8Q
M@G+,GA;&G4^.Z-;BNXT>G0I2A2I*JJ\:^>;:.V,>_P!?(O<6ZG4=6TL:$FOI
M+E2DG%8><+K]YI6FZ7;6''%U](@W<?1TI.,FUCP@=*UO7:6ET%+EA5K3IN<*
M7>8<WZ(UVVX]NY5)*ZT.I;4<>&K.JTI/T68_'Y&,XWG.?%W#5&FTJ$^6,T^K
M7,C,\7Z5&>C6M.T2C.-7+YI/&,,#<K6XIW--SI2C))XS%Y+QJG9O6N*VC7#N
MI1E-7#2:6-N6)M8                   /(MOVN7)<(<LN]YLKEQT IEFM=
MHEE/4.&71A&<I=[%XBLO;)LRA+,MUN1JT(5:7)52E'.< :+PWQ+:TM+N(7%2
MVA6I8C&$IX<L(Q_!=O4N^T/5-3<9*C7MGRM+P=::V?W&>N^!K*=U&I;T*,(9
MS-.<\MY,_I.D6^FTHJWIQA-1<6TV]LY\P/33DZM12Z);;'I+:I\C_)XC'S1<
M0                           "S+*;Y5S%XIRXSR[-@0CXJ7B\)HG'+BM
M7TC$^;Q2VS[T;VH2?M--&+U30J%_>V=>=.#5"67EO/5=/D!Y;2UC>Z/1IRDX
M)2<ME[V:5V;SM;>C<PU>E0H3=;,8UTDY+'7<ZC2M:5&DJ=&"C%=%DU[5>$[:
MX:G:TZ5.HEA.4I=0-.N7"ZXIU*&F1C*,<-=PO+"]"=G7I4>,+&>L2A"DJ<N9
MW#VQRSQG/O-WT#AJTTQRK.C3=W4CRU*D92\6_O\ N+>N<*V.J555G0INHH*"
M<I26V6_+X@:CV@7EA4J:5]2U+:JW6?/]':V6V,X.A:7&5.BHU'+FR_:ZFO:=
MP39V]9SK4:,TFG!*4ML,VFK2DTW2:C+R8%R$<.3]212":A%2>7C=E0
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M#MIIKCW=&"PFO#*3Z_$#+YYHQ;\T3BN59#CTQLD)1;CC.X$@
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MM>&*G/9@7^S?3ZFGZ-<4ZO>9E<.:YUAXY8_@;60HTH48<M./*B8
M
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MIK"68^K)TTEEI]>I:IMU89SA>C+E+;* F
M
M
M                                                       !2?L2
M^  %BI-T:2E'#;>-R[RJ34WU0 #V\I^1&#Y9J"Z/< "3@ES2WSU*1?>0\7^
M %.50V7277)6$%&32R  ]B6%Y^HJO$,^\ "F.6:P1N7RQBUYL "YC%1%(R;E
M)  4J14891<A[*^  %0
K                                                      ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g109079g10k00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g10k00.jpg
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M P$!              <(!08#! D" ?_$ %<0  $# @(%!0D)#0<"!04   $
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MQTMUMS]NFJ&[3>KJ*RB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M(B B(@(B("(B B(@@G6W\3;?YRM-U/O&&_? 1>URW+6W\3;?YRM-U/O&&_?
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MX:R.6J#FQ4T4F>S)(X[@<M^0 <?0MP54-;3%/=^)Z+#M/)G!;8^5G /&9XW
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MH[T\8@PM*VVXICFNM!&=AW*G9J8<MV6T?=9=#M_6%9W!F,[%C*@[JL%?'49
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M?Y*VBJ7K;>.=O\W/\D(F'5G\E%!\+)[5*:BS5G\E%!\+)[5*: B(@(B("(B
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MJRJIZ*EEJ:R>*GIXF[4DLKPQC!TDG< NE:+_ &>\OD99[M;Z]T0!>*6I9*6
M\"=DG)!DD18*#&6&*BHCIZ?$=EEGD<&,C971.<YQ.0  =F3GS(,ZB+&W>_V>
MS/C9>+M;Z!T@)8*JI9$7@<2-HC-!DD7#1U5/6TL531SQ5%/*W:CEB>'L>.D$
M;B%S("+#WS%%BL+FMO5YM] ]PS:RHJ&L<1U G,K]LN)[%?'%MFO-NKGCBVGJ
M6/<.T YH,NB(@(L'>L78=L=0*>\7RVT501GR4]2QC\NG9)SR64H*VEN-)'56
M^I@JJ:09LE@D#V.["-Q0=A$6%@Q9AV>N;107^T2UCG\FV!E9&Z0OSRV0T.SS
MZD&:1%AKABO#UNK)*2X7ZTTM5'EMPSUD;'MS&8S:79C<04&91?,DC(XW22/:
MV-HVBYQR '3FM9FTA8.AG,,F*;*V0'(CNV/<>LYY!!M"+@H:VEKZ9E105,-3
M3O\ <RPR![3V$;EC;CBK#ULK'TEROUII*J/+;AGK(XWMS&8S:7 C,$%!F46N
M_=SA/_5-B_W"'^I/NYPG_JBQ?[A#_4@V)%C+KB"S6@Q"[7>WT)F!='W34LBV
MP.<;1&?$+H?=SA/_ %38O]PA_J0;$BQMHO\ 9[RZ5MGNUOKW1 &04M2R4L!X
M9[).7 K)("UG2AY-\5?%=3]4Y;,M9TH>3?%7Q74_5.05RU0/'N\?%I^MC5LU
M4S5 \>[Q\6GZV-6S1:(B(@B(@+YED9%&Z25[61L!<YSCD !SDJ/=(^EW#>"&
MR033]WW8#=14S@7-/Z;N#/3OZBJT8GQSC;2Q=1;*.*=]/(? MM"#L 9\7GGR
MZ7'(=2+B:M)6L%9['RM%A1D=WN S:9R3W/&>T;W^C=UJ!;1AO%^EK$M3<(:8
M3RS/_M%:]@A@C[2!EGES#,J9-&NKK34G)5V.)FU4^YPM\#B(V_KOXN[!D.LJ
MP%!1TUOI(J6AIXJ:FB&S'%$P,:T=  W!!&VB;0[:L!2-KWU,U=>BPM=/F61L
M!XAK =XZW9^A2@B(B"=;?Q-M_G*TW4^\8;]\!%[7+<M;?Q-M_G*TW4^\8;]\
M!%[7(O%J$1$01$0$1$!$1 52];;QSM_FY_DK:*I>MMXYV_S<_P D(F'5G\E%
M!\+)[5*:BS5G\E%!\+)[5*: B(@U/2GA./&>![E:"&]TN9RM,X_Y9F[VGT\#
MU$JNNJYBJ2P8TJL-7$NB@N6;6L?NY.H9GD.K,9CM#5;95!UD<,SX1TB4^([5
MM0PW%XJHY&#+DZEA!=ZSLN[2>A%C<];C%O(T-NPM2R>'.15U8!_R D,:>TYG
M]D+-Z+,(?<QH&O5341[-PNMNGJYLQO##$[DV^AN_M<5"^$Z>MTP:9(ZBZL')
M32"IJVMSV8X(P!L#J.36]KLU;O'30W N(6M #1;:@ #F_!.05EU0O*'=?BI_
MUT2P&LBP/TSW9AX.;3#_ /2Q9_5"\H=U^*G_ %T2P&LDSE-,UW9GEM-IQG_^
M%B+U+XU9L,9?XQ>?E1?T+/771!04FB*[84M4U152%[JVEDJ-G:$X R&X 9'9
MV>QQ4>#5?JLO&J']Q/\ 6IQT782?@G!M'8I*QM8Z!\CN6;'L!VT\NX9GIZ41
M7W5/Q4ZV8GKL,UCBR&X-,L+7;MF=@WCTMS^2%S:V>+S6WNBPM1R9PT0%15!O
M/,X>"WT-.?[?4M<TXV:IT?Z767FTCDHJF5MRI7 ;A('9O;\H$Y=#@OS0C8JG
M2)I8EO-X'+04TIN-6XCP7/+LV,[-KFZ&D(?K/:I^+S;<15F&*UY;!<!RM.';
MMF=HWC]IH_X!?>MIBHU^(:##%(\NBH&B>H:WGF>/!':&G_FL#IZP]48"TI17
MNT9P05DHN%*]HW,F:[-[?E9'+H< N/0O::G2+IA==[LWE(H)G7.K.7@EVUFQ
MG9M$;NAI0_5F=#V%!@[ %LMCV!M8YG=%5TF5^]P/9N;^RL_BSQ6O/F4W\#EE
M%B\6>*UY\RF_@<B//_"U_N.&+Y2W:SSF&KIW;0/,X<[7#G:>!"M7<M/EDCT<
M1WJBV'7R;.%EN<[,QS ;R[_VQF#GS[AN.>4,:M=EH,0XTNMKNT#9Z*IM4K'L
M/PD61!YB#O!YBLY;=7N['2*^V5KG_<W"1,;@,@98\]S!T2<QZ./1F5#=PN=;
M>;Y)<;I.^HK*F8222OXN)/LY@.9>C"I+I_M]+:M*TU!;H&4])3P4L<43!D&M
M$;<@K.:<\4_<IHXN=5%)L5E2WN.FR._;>",QV-#G>A"JQZ0:JOTJ:7ZV"R#E
M][Z>C&>[DHFN.?82'._:6^:I.+#37&Y84K'D-GSJJ5KN:1HRD;Z0 ?V2M(T
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61$!$1 1$0$1$!$1 1$0$1$!$1!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g109079g20k00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g20k00.jpg
M_]C_X  02D9)1@ ! 0$!+0$M  #_[0\>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #P$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             /_A/WQH='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#DN,2UC,# R(#<Y
M+F8S-31E9F,L(#(P,C,O,3$O,#DM,3(Z-# Z,C<@(" @(" @("(^"B @(#QR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9G@](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&1F>"\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @
M(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O
M(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS
M.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP
M+R(*(" @(" @(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]T:69F+S$N,"\B"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N
M<RYA9&]B92YC;VTO97AI9B\Q+C O(CX*(" @(" @(" @/'!D9G@Z05!42U9%
M4CXQ,2XQ+C N,C(Q,SD@4')O(%!R;V1U8W1I;VXM,S(\+W!D9G@Z05!42U9%
M4CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C8M,#,M,3-4,#0Z,C4Z
M-3,M,#0Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T
M;W)4;V]L/E1O;VQK:70@:'1T<#HO+W=W=RYA8W1I=F5P9&8N8V]M/"]X;7 Z
M0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(V+3 S
M+3$S5#$W.C0V.C0T*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C R-BTP,RTQ,U0Q-SHT-CHT-"LP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'!D9CI0<F]D=6-E<CY4;V]L
M:VET(&AT=' Z+R]W=W<N86-T:79E<&1F+F-O;3PO<&1F.E!R;V1U8V5R/@H@
M(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^0G)I;VYE<RP@1G)A;FML:6X\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T
M;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T
M;W-H;W Z,3(W-S5D8C,M,S@T."TU-S1F+6$X-S0M,#,S,&0X,S%A8S<P/"]X
M;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C-D.69C8V%A+34Q,C0M-#(T82UB8F-C+3DU-S1C.&5C8S$S-3PO
M>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z8C1A,V,W,C(M93 Q,"TP
M-C0P+3EC93@M-C4W93=E-C0S8V9C/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HW8F$P960Y-RTS9C@W+6-F-#,M8C8S,BTT934X
M93,T.6,Q8F,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C8M,#,M,3-4,3<Z-#8Z-#0K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<" R-2XT("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA
M9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E
M<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS9#EF8V-A
M82TU,3(T+30R-&$M8F)C8RTY-3<T8SAE8V,Q,S4\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C8M,#,M,3-4
M,3<Z-#8Z-#0K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R-2XT("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R
M;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12
M968Z:6YS=&%N8V5)1#YX;7 N:6ED.C=B83!E9#DW+3-F.#<M8V8T,RUB-C,R
M+31E-3AE,S0Y8S%B8SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M/'-T4F5F.F1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.F(T83-C
M-S(R+64P,3 M,#8T,"TY8V4X+38U-V4W938T,V-F8SPO<W12968Z9&]C=6UE
M;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YA
M9&]B93ID;V-I9#IP:&]T;W-H;W Z8C1A,V,W,C(M93 Q,"TP-C0P+3EC93@M
M-C4W93=E-C0S8V9C/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QP:&]T;W-H;W Z
M0V]L;W)-;V1E/C$\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QT
M:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^"B @(" @(" @
M(#QT:69F.EA297-O;'5T:6]N/C,P,3$W-3$O,3 P,# \+W1I9F8Z6%)E<V]L
M=71I;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N/C,P,3$W-3$O,3 P
M,# \+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I
M;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF
M.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @
M/&5X:68Z4&EX96Q81&EM96YS:6]N/C$Q,3PO97AI9CI0:7AE;%A$:6UE;G-I
M;VX^"B @(" @(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXQ.3@\+V5X:68Z
M4&EX96Q91&EM96YS:6]N/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $, !@0%!@4$!@8%
M!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@+" C)B<I*BD9
M'RTP+2@P)2@I*/_   L( ,4 ;P$!$0#_Q  =   " @,! 0$
M" 8' 04) @0#_\0 2!   0,# 0,'" 0+!P4      0(#!  %!A$'(3$($A-!
M46%Q%"(R-G6!D;-2H;'!&",S0D-58H*4LM$5%D1RDL+A)"5SA*+_V@ ( 0$
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*[H*QH*S117__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g109079g30g30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g30g30.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1@ 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %^,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"C_P  1" ,L!V@# 2(  A$! Q$!_\0 '  ! 0 " P$!
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M.98+#_[O_P"[_A#)&-P_^[_^[_A#)'K6?;AX>T^[5]@ -&
M             !A[9^^;A_F;^5#,&'MG[YN'^9OY4,[G6G[_ !+:U_&OZ_,,
MP #1B                                           >>J_O:/^88>@
M\]5_>T?\PPRO>W4WV;W:?M]FT7^#@^;;^!W'31?X.#YMOX'<>6]\
M                       !,<0_#7AS^4J/QA*<3'$/PUX<_E*C\82G$A9
M 5                              )FWX>%^CG?@PIA,V_#POT<[\&$E8
M4P %0                               !,[)\.F)OY.E_(XIA,[)\.F)
MOY.E_(XIA(60 %0                             "::-/A$T@_/4WXS%
M+)IHT^$32#\]3?C,2>JQ\J6 "H                                ^/
ML1^_K%/TA-^H\\IZL1^_K%/TA-^H\\IZ>S>W#P]L]ZH !L^4
M                                   !Z\,>_P PQ_/-_*X##'O\PQ_/
M-_*X'C[9[LOT'Z?[,,%A_P#=_P#W?\(9(QN'_P!W_P#=_P (9(]2S[</&VGW
M:OL !HP                           ,/;/WS</\ ,W\J&8,/;/WS</\
M,W\J&=SK3]_B6UK^-?U^89@ &C$
M          \]5_>T?\PP]!YZK^]H_P"8897O;J;[-[M/V^S:+_!P?-M_ [CI
MHO\ !P?-M_ [CRWO@                               )CB'X:\.?RE1
M^,)3B8XA^&O#G\I4?C"4XD+( "H                             !,V_
M#POT<[\&%,)FWX>%^CG?@PDK"F  J
M )G9/ATQ-_)TOY'%,)G9/ATQ-_)TOY'%,)"R  J
M         331I\(FD'YZF_&8I9--&GPB:0?GJ;\9B3U6/E2P 5
M                      'Q]B/W]8I^D)OU'GE/5B/W]8I^D)OU'GE/3V;V
MX>'MGO5  -GR@        ,@ZRW-MO2O=05*42_\ OK&NIYS'B)B>BS$QU #T
M4-%4U]0D%%!)/,NYD;5<J_4"(R\X/17T53;ZAT%=!)3S-WLD:K53ZCS@F,
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M?RH9@P]L_?-P_P S?RH9W.M/W^);6OXU_7YAF  :,0
M                        #SU7][1_S##T'GJO[VC_ )AAE>]NIOLWNT_;
M[-HO\'!\VW\#N.FB_P '!\VW\#N/+>^
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M&L55SW]ALAW'-P        $S;\/"_1SOP84PF;?AX7Z.=^#"2L*8 "H
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M=81JL(7&.CK*B&=[VJY'19Y?>:XQNL]K4WJN15_9%^^FE^;=_P $J@_OX_\
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MC?%-YI&5-#:W+"],T621D:K]3E113=IFB*YY96NQ7%<VXC,QV:>#8\1X)O\
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M5R3F3/<FW<+-BJBO5T6_M-%=O1&9G^_AX0 ?6\\//5?WM'_,,/0>>J_O:/\
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MFN39E?$U6-X-^KLSS%49C!3.)9JB_P '!\VW\#N.,;$CC:QON6HB(<CIR
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M25EJ345,]M1&B^979BJNFG^4X2BW77_&,M$![[S:*ZRUKZ2YT[X)VKDK7?\
M"[E/ =1.><.9B8G$@ "/7ACW^88_GF_E<!ACW^88_GF_E<#Q]L]V7Z#]/]F&
M"P_^[_\ N_X0R1C</_N__N_X0R1ZEGVX>-M/NU?:J>QV;3KC-ZRZO#)&O!9[
M\]5V>7U'5[(7NA<<-X7A.![G;J9YZN]V>7W&DX1OLV',04ESI]KH7+FW/+-%
M145/,JEVN=VP)I$H*:6[W""AJ(DW33MB5JJB9IM5,T/GN9MWMYC,8?39Q=L3
M:B<3G*#X8I+S65ZQX?[K2JU<U6F<YJY>54,S:J2]4N/*-ESHJJOND4D4G!3/
M57+DYJMS5479NWE@LM9@+1[2U55;+I35M1(W=#4-E<N2+DB9*JIO)Y8L>TS]
M*DN(+C&K*:?^Q;MSU&ZS415^1$.HNU5ZIBGEAS-FBWIBJKGG_$*)C*BOESJ:
M&HJ\1P87U&_X=:MJ(ORY.;GYCAI^A8NCF@F>]D\S:F)G#MR7634?M1?*>#'E
MNP=B2[]^ZS%]+W.C$<^BCF:]SLD38WP]BJB+R;U.&FB_6.OT<T5'9[I15$C*
MF)4ACG:^1&HUZ9JB+GS><^:B)U48_P#3[+DQHN9_]]6PX5N<EFT$4MQ@:CI:
M:D?(Q%3EX1Q@M!6,;OB"\W*BNU0ZH8VG=.BNY%UF-R^]3JI;_9VZ G6YUUH4
MN'<;V=S+.WA<^$5<M7///(U7V/MTM]IQ/<9;I74U'$^B5C7U$K8T5VNQ<D55
MW[%+N\T7)F.>7.]Q<M1$\L0S&C^UTU1IKNZOB9JTLTKHV9;$WIN^L[M,..KU
M9\9Q4UOJG0TT4;7+&W<Y==Z+G]2(:S:\64]@TMU]T;(R:WRU,B/?&Y%1S5SR
M5%3DS5"@8SH\!XEKXKY5XAHFOCB36@94,5[T15=EEK;_  CNJ--R*JXS&'%$
MZK55-N<3EZM)UP?=M!L5PF1&R5,=-*Y$Y%5S5/#HW^ &^_R]=^FIQTF8AP[6
M:)$HK+<J-ZHD"14J3M65K4<FQ6YYYHF\\& ;[::70E>:"JN=%#7205B,IY)V
MMD<KF*C41JKFN?(9Q3.ZZ?\ )K-4;[.?^+-Z"8(J#1W6W.*-O=+DD<YV6U=3
M6RVFM:.,>WNOQ^^DKJETU+-(K$C=N;G(U$R^1#\T(8WMEOME38;W-'30OS6.
M61Z-8J*JZR*J[$WH9RR46 L,XE2Y17^CJIYY<FZE0Q6Q:SD=FJZR[$5-YU5&
M*J]49ST<VZM5%N:*L1'5@/9"L63&MH8V%TZNAR2-N]WA;D-QQ+!?[OAVD9/7
M184C8YJZ_=;6JJ(CDRS16Y9YYY>0TW2UB2UKI#L%SHJRFKZ:E1KY%IY6R)L=
MGEFF9L^.V84QS3T=2_&%'0)&U$="Z9BZR)K;VZZ9+MW^0G.*:,Q_HY37<Q/^
M,X_VRF-H%30O6I4U\5TEA@:J5;%1R/773PD7->?G,7H%O%?<<-7+NRIDE[G5
MS(M9RKJHC6Y?B=>)+YA=FA^OM=ENM(N5.UD,#ZAO#.\-%]SGGGO-6T#8JMEG
M;7VZ[5$5*RH57MFE>C6[41,E5?D)%$S9JY?+J;D1?HY_#"6^LK,5Z2*.AO-3
M)401U+]5KU541&YJB?<6?23;Y)X:&EH<4TV'8HMNHLB1*]-F2)X;=B9$@QK#
M9L+8HH;QAJ\4UP>^=99&P2-?J(JKFF:.7DV&\XCJ\(:2K513UM]I;160[TGE
M:BIGEFF2N;G\IW<C,TU1T^OPSLSBFNB>=7WU_P LEB&6SU>CJ:W7C$5JN5;!
M$JLE2HCUW*UNS9K*N:JGUGS06[%%PP;AC!Z6NTOH;O7O:K.'CU'Y;,E<JIGE
MOS1"(F^RQB)?-ME6:HCEF(##VS]\W#_,W\J&8,/;/WS</\S?RH:W.M/W^)86
MOXU_7YAF  :,0                                          #SU7]
M[1_S##T'GJO[VC_F&&5[VZF^S>[3]OLVB_P<'S;?P.XZ:+_!P?-M_ [CRWO@
M                       !XI;1;9IUGFM]'),NU9'0M5R_7EF>T ?C6HUJ
M(U$1$W(A^@   !,<0_#7AS^4J/QA*<3'$/PUX<_E*C\82G$A9  5 U/2?<)*
M#"59P"N;+(B-1[5R5OA-S^XVPQ.*[0E[L-70*J-=*U-5V6>2HJ+_ ,$GHL=4
MBP;5TU-97LFPI47-\KESJ$B5^SF1=1<O.9'1G!<J/&4J);JZCMM0LCM66-Z-
M:B(Y6HJJB)RG9A^NQ3A.EDMJ6&IK8D<JL?&QV2+NSS1JYIN,S@*WX@FODUTO
M3IX('*YS:>17)[K/9DN[+9R&<?#N?EI%1117#28^EGS6&2I1KT1<LT5R9H9?
M2W8+?:*:@DMT#8'*KD75Y=QRIK-<TTFI5K;JQ*7NE'<,L+M3+63;GED9[3';
M:VX45"V@HZBI<USM9(8U?ENWY#'*3/.&0N[XJC $:5]>M)'(W5=+DKE5,EV9
M9IG_ /@TJP5-II[/+34V'Y[QK+MJ6TRY_4NJN7G-JQ38:ZZZ/Z:DIHWMJ89$
ME6-R*CE1$<F67UH87"U?B>CL\5HH\/34\K57_P!7-&YC=JJNU%;Y><L]4CHZ
M]"$K^^5RBS<V+45VHO(NLU#7Z"VP772-)252*Z%\RHY.?P3:M$%JN-!=KC)<
M:&IID?&J(Z6)S$<NLF[-# ML^(:;&53<+?;JE'1R:['20NU';,M^61/B%^99
M#2WA^@M,-!5VZ%M.]7*BHQ,L\LLOQ/=C&J=5Z*J":17*]8HM97;U7P,U,3?X
ML48RK*6"JM%31P1.WR1N1NW>N:HG,;KC##<\^ X[90YR34T<;&HC?=ZJMS^Y
M"XSG!TQEQPA\&;_Y63\AJ>A/]]7/Y&__ ",G@JHOD=EJ[/6V>KAA93R-9*^)
MR:RZJY(F:;=R><Z=$-IN-ON]Q?74%53,>C=5TT3F(ONMV:#YA/B6L6:W0732
M%+352*L*RN5S47+--;<9'2W9Z*RU=NDMD*4ZO:[/4V;4W*>K"MFN<&D.2IFM
M]7'3*]R\*^%R-]TG+ED9/3-:Z^XR6Y;?15-4C&NUN!B<_+;RY(3'[97/-U:6
MX*J3"UIF8YRT[>#UTS_BU';3!7ZZV"LP?3T5NI&=\DRSU(,G)M7ERVF<TLO;
M'8;3 Z>1E2C6*E/J^Z1&JBYIGS^0\#4Q=14B5"VJW\&QJ+FE&W6R\PGJ1T;Y
MHVI:NCPI31U^NDF]K7[VMV;/)RFT&H:.<5/Q)03=TQ)'4PNR75W*F2;=VS>;
M>:4].3B>H "H$S;\/"_1SOP84PF;?AX7Z.=^#"2L*8 "H
M                 F=D^'3$W\G2_D<4PF=D^'3$W\G2_D<4PD+( "H
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MYN'^9OY4,[G6G[_$MK7\:_K\PS  -&(
M             !YZK^]H_P"88>@\]5_>T?\ ,,,KWMU-]F]VG[?9M%_@X/FV
M_@=QTT7^#@^;;^!W'EO?                                3'$/PUX<
M_E*C\82G$QQ#\->'/Y2H_&$IQ(60 %0                     :;I"P@_$
ML<$M-,D55#L;K;E3:8>6R8YJ+<M!/74'<ZIJJJ+X62+G\4I0)I7+6L"X7CPS
M;7Q<)PL\KM=[\LN1$R^XV4 L1A   "9M^'A?HYWX,*83-OP\+]'._!A)6%,
M!4                                3.R?#IB;^3I?R.*83.R?#IB;^3
MI?R.*82%D !4                              FFC3X1-(/SU-^,Q2R:
M:-/A$T@_/4WXS$GJL?*E@ J                                /C[$?
MOZQ3](3?J//*>K$?OZQ3](3?J//*>GLWMP\/;/>J  ;/E
M                                 >O#'O\ ,,?SS?RN PQ[_,,?SS?R
MN!X^V>[+]!^G^S#!8?\ W?\ ]W_"&2,;A_\ =_\ W?\ "&2/4L^W#QMI]VK[
M  :,                           ##VS]\W#_ #-_*AF##VS]\W#_ #-_
M*AG<ZT_?XEM:_C7]?F&8 !HQ
M       //5?WM'_,,/0>>J_O:/\ F&&5[VZF^S>[3]OLVB_P<'S;?P.XZ:+_
M  <'S;?P.X\M[X                               "8XA^&O#G\I4?C"
M4XF.(?AKPY_*5'XPE.)"R  J                              3-OP\+
M]'._!A3"9M^'A?HYWX,)*PI@ *@                               "9
MV3X=,3?R=+^1Q3"9V3X=,3?R=+^1Q3"0L@ *@
M      $TT:?")I!^>IOQF*6331I\(FD'YZF_&8D]5CY4L %0
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M7LA/>13?2$/X/*:3+V0GO(IOI"'\'@4:@_P-/\VW\#O.B@_P-/\ -M_ [P
M
M
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M 'G@CZ:C_1F #V,_P84_S[OR,*J2KV,_P84_S[OR,*J
M             "3Z/_ACQ[\]#_MH2L$GT?\ PQX]^>A_VT(%8
M                                  "9>R$]Y%-](0_@\II,O9">\BF^
MD(?P>!1J#_ T_P VW\#O.B@_P-/\VW\#O
M
M
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MDK9*V!'.U971<&B^&[/),UV9YFVG10TD-#2QT]*Q(X6)DUJ<AW@
M !*M-_[SP1]-1_HS :;_ -YX(^FH_P!&8 /8S_!A3_/N_(PJI*O8S_!A3_/N
M_(PJH                              )/H_^&/'OST/^VA*P2?1_\,>/
M?GH?]M"!6        "?8LTA/L>*(K:RC;+3,?&VIE5?"8CLES1.78J[S>;C5
M-HK?553TS;!$Z5?D:BK_ ,$9LSK7=\-XBJ[E5,2NN"R.A1R+FS5UFMW)\@%L
MAD;+$R1GN7M1R?(IR-0T67COMA.GUW*Z>G5T4B_(Y<ONR,3H:D?)37KA'N?E
M4IEK+GEL4"BF&H,1TE=B"LL\4<Z5-+'PCW.:FHJ:VKL7//?Y#2\+2/DTP8CB
M?(]8^Y79-5RY)X;#"X>P?;9](=UH'\-P--#PC,I'9Y\)EM7,"S@F>(&2WW&]
M+AIE1-!:X*?A)D8N3G.S?R[\O!:>/%-L=@.HM]SLE1/P+Y."GBD=K-5%5$1=
MNWE4"L T'29(RHH;5)-=V6VW2:SYFN1VO*G@JB-R1?+S;S0ZJOM5MN=KJ<+5
M56KNZ(VRI(Y7-<BO:G+Y,P+T"9:4'U-1<,+LI9W4\M141(U[5]RKGMR7[SPX
M_P +QX=L2WBBK*E;C%(CG2.?FCER5=V[D3D HF*<04N&K4ZX5T<\D*.1NK"U
M%=GDJ\JIS<Y[;DVJDM\R6Z1D=6YO]FZ3W*+Y=B_@3C35;H:G"%-<9==:B)&L
M;DY43)6JJ[/J,W7X=H\/83NJV]TR+)&BJKI%=RISJ![ZVXW;#^"YJZ[.IZNX
MT[45RQKDQV;D3F3D7F,KANXONUBHJ^2-L;YXT>K6KFB$^B>^30+&Y[E<]:=N
M:N7-5_MCCAO!,5SP=2UE=6U#JE8-:%6/U4C3>B9)Y<]^>\"J@F> <0U--AN\
MP5TKIY;9(Z-DF29JF63?O0Z,(X49BJT=^;[55+ZNK57M1C]5L:+M3)$RY^7F
M J8)S@:[5-LJ;_9ZV22H;;<W4[G99JQ$>N2_4U#'X2PXN,8ZJ]WNIJ5X69[8
M&,?JHUK7.;R?(@&TV_%4U5I"N6'74T;8:6)LC9D<NL[-C';4W?Q&VD>P9;5H
M]+M\H*F9]2C:9&J]RY*YJLC5$V9;D5$^HS.C6IFM=^O6'JU[G+!_;1.<N?@;
M,]ORO0"D G>B]9[M=+OB"HD<K*AW!PLSV(SP5W?*A1       3+V0GO(IOI"
M'\'E-)A[(EZ1X#@>N:HVOB79\CP*10?X&G^;;^!WD;IM/-@BIXHW6RZ*K&(U
M<FQ\B?YCLX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1
M=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U
M^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S
M'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'Z
MXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX
M_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+
M!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T
M7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=
M?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?L
MQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^
MN!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!
M8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8
M1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_
MC\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\
ML'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'
M1=U^S'ZXX_+!T7=?LQ^N!8 1_C\L'1=U^S'ZXX_+!T7=?LQ^N!8 :+@C2=9<
M6U;Z6D94TU0GN63M3-WR:JJ;T
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M2'P>Q_ST7Y7@?,(
M                                          .ZDJ9J.HCGIGK'*Q<V
MN3D/I[1)I(BQ/3,H;DYD=T8G)L21$1-O+Y?,?+9W4=5-154=13/6.:-=9KDW
MHH'W6"9:)-)$.)J:.@N3V1W1C<N7^TR3?\NQ5WE-
M
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M4VJ>EUAM;K>ZA=0P+1NDX58M7P5=GGGES[ -8Q4QO%?&FJG^%@_!IK6,8_\
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MRR3>JKGK9?65+17BJ?$]GD?4TZ1R0.1NLU,FN^1 -V   D^C_P"&/'OST/\
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M-Z+]8&3)9[)#X/8_YZ+\KRIDL]DA\'L?\]%^5X'S"
M
M           .^AJYZ&KBJ:61T<\3M9KVKDJ*?3VB7213XFI&4%RE;'=8VHWP
MLTX7)N_/GV+RGRT>B@K)Z"LBJJ.5\4\3D<U['*BHOU ?=()GHETCT^)J1M#<
M96QW2-&M367^]V;T\NS[RF
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M[)(Y7/S25-5N>29?]2'J@Q&RHQ5+9*>F=(Z&)9)9M?)&9*U,LLM_A(H&>
M                               $JTW_ +SP1]-1_HS :;_WG@CZ:C_1
MF #V,_P84_S[OR,*J2KV,_P84_S[OR,*J    '">5D$,DTKD9'&U7N<JY(B(
MF:J:Q[;42R72ZNI,J6FUTIUU_P#$*U'>38BJU-NW>!M0-!JL:7J@ME/<KEA^
M&*WR(CU?'5J]S6JF>:MU$Y$5=YL-^Q-1V>UPU4J.DEG1O P,VO>KDS1$3?R
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M'S"
M                                  !MFCW!=;B^ZLBA:YE&QR<-,K55
M$3F^78!Z=%F%[K?\0T\MM=+3PT\C'R5*(N34SSRSV<R\I]<4S'14\<;WZ[FM
M1JNY\DWF,PQ8*+#MKCHJ"-&M:B:SLMKE1-ZF7
M
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MP"4UL4D>%<(7'@7RTM')%)-JM5=5J/:JK]2(IZ])V*K5=L+QT]NF6>1TS'>
MFLC4V[U3<5+N>'@. X&/@<LN#U4U<N;(Z&VJWM:K6T%(C5VJB0MR_ #1\;1]
MZVV'$D;55*/49.C$VNC5,U553_*AZ=%M'++3UM]JVKP]R?KIK;T:FS+_ $H=
MV.+1?KZQ;92,I8K5(J(^57^&C<LE1&Y>5>7D-NH::.CI(J>%J-CC;JHB =X
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MO$[:F2JBM=DN2IERIF:PN!JAT'<LF(J]U#EJ\!P;$\'FUD36W>4#Q8KNM _
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MJL-:Z"OFI614\CW-C:W^TR;FFU=J;N3G,E855;';E555>YH\U7:J^"@'N
M        EGLD/@]C_GHORO*F2SV2'P>Q_P ]%^5X'S"
M
M            ;9H]P76XONC(8$1E*U<Y97+L1$Y-WR><!H]P578NNL<4+592
M-7.6947)$YOEY/K/J_#%@HL.VN*AM\:-8QJ(KN5RHB)G]PPSA^@P[;(J*W0M
M8QC417;U<N6]57Y#+
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M)5DL]FPQ%'0TZ1W%ST93N8Y==7Y+MW\Y1[6V=EO@;5O:^=&^$YNY>;[@/4
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MVTM'!3L57-BC;&BKO5$3(\]A;.RQVYM7GW2E-&DN>_7U4S^_,]P
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M^0^L<-6"AP[;(Z*W1(R-B;5Y7+SKYD,HC43<B)\A^@
M
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M1A+#=IOF*<6ONE(D[HZ]Z-59'-R\)W,J&\5-FM]FPU=(K93,@8M-)FB*JY^
MO*JYF?1$3<@ T31M\&W_ &S_ (N/!AW$,.&-%T=QG8Z1&U%0QK4Y7+-)ER^0
MI2(B)DB;#\U4RRR3("+8<Q197W-]YQ'<&5%<[;%$BIJ0IY$V;=B<_*6&VUL-
MPHHZJF=K129ZJ_(JI_P>C4;\5/,?J;-P           2K3?^\\$?34?Z,P&F
M_P#>>"/IJ/\ 1F #V,_P84_S[OR,*J2KV,_P84_S[OR,*J
M                "3Z/_ACQ[\]#_MH2L$GT?_#'CWYZ'_;0@5@
M                                    )E[(3WD4WTA#^#RFDR]D)[R*
M;Z0A_!X%&H/\#3_-M_ [SHH/\#3_ #;?P.\
M
M
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MD JH/+::I];;:>IEA="^5B.6-V]OD4]0
M !*M-_[SP1]-1_HS :;_ -YX(^FH_P!&8 /8S_!A3_/N_(PJI*O8S_!A3_/N
M_(PJH                              )/H_^&/'OST/^VA*P2?1_\,>/
M?GH?]M"!6                                              F7LA/
M>13?2$/X/*:3+V0GO(IOI"'\'@4:@_P-/\VW\#O.B@_P-/\ -M_ [P
M
M
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M<)14KXVN=GOUF-RW>4LX PN#(J^'#-O9=Y'R5J1)PBO7-V?E7E7RF:
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M&V>C,[ -=XX\#=/T77,]8<<>!NGZ+KF>L;%[2\-= VST9G8/:7AKH&V>C,[
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MZ"F5-W!M_ [SHH-E#3?-M_ [P
M
M
M                     ('H]QYAS#.+<>0WNYT]++)=I=5LDC6JN4LN>]?*
MAO?''@;I^BZYGK&L:*K!:+IBG'S[E;:.J>V[29.FA:]4SEFSWIY"D^TO#70-
ML]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V :
M[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V :[QQX&Z?
MHNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V :[QQX&Z?HNN9ZPX
MX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V :[QQX&Z?HNN9ZPXX\#=/T7
M7,]8V+VEX:Z!MGHS.P>TO#70-L]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+V
MEX:Z!MGHS.P>TO#70-L]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MG
MHS.P>TO#70-L]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO
M#70-L]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&
M9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V :[QQ
MX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V :[QQX&Z?HNN
M9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V :[QQX&Z?HNN9ZPXX\#
M=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]
M8V+VEX:Z!MGHS.P>TO#70-L]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:
MZ!MGHS.P>TO#70-L]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.
MP>TO#70-L]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70
M-L]&9V :[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V
M:[QQX&Z?HNN9ZPXX\#=/T77,]8V+VEX:Z!MGHS.P>TO#70-L]&9V 2'21CW#
MF)KY@V"RW2GJI8KO'*]&2-75:D4J9[%YW)YP932YA^T6N[X*DMULHZ5[[Q&Q
MSH86M54X*9<ER3R( ,I[&?X,*?Y]WY&%5)5[&?X,*?Y]WY&%5
M                   !)]'_ ,,>/?GH?]M"5@D^C_X8\>_/0_[:$"L
M                                        !,O9">\BF^D(?P>4TF7L
MA/>13?2$/X/ HU!_@:?YMOX'>=%!_@:?YMOX'>
M
M
M                                  !*]"_OET@?2S_U9BJ$KT+^^72!
M]+/_ %9BJ
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MYKSJ,UYU/P ?N:\ZC->=3\ '[FO.HS7G4_ !^YKSJ,UYU/P ?N:\ZC->=3\
M'[FO.HS7G4_ !^YKSJ,UYU/P ?N:\ZC->=3\ '[FO.HS7G4_ !^YKSJ,UYU/
MP ?N:\ZC->=3\ &]:-<?5F$ZQ(U5)*&1WAL=GL^3;Y$/JJS7.FN]!%5T4B21
M/3-%0^&S>]&./*K"MRCCED<ZWO7)[%S7+/E3;Y$ ^M@>*SW2EN]!%5T,K9(9
M&HY%0]H
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MEK:F:HEX3+7F>KW>Y;RJ!O      2?1_\,>/?GH?]M"5@D^C_P"&/'OST/\
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MO*F2SV2'P>Q_ST7Y7@?,(
M                                                   WS1ACVJPM
M<XHYY7OMSUR?&JJJ)LWHGF/J>S76DO%#'5T$S98GM1VQ=V:9Y+YSX<-^T6X^
MJ,*7)D4[W26^5R(]BN7)O)FB?^;@/K,'ALUUI+Q0QU=!,R6)Z(O@KGEFFY3W
M
M                       !*]"_OET@?2S_ -68JA*]"_OET@?2S_U9BJ
M:1C_ $@TV$*B"!]&^KFE;K:K7ZF2?+DILN&KO#?K)2W.F:K8JAJJB+O3)51?
MO0#)  #KJ)X:>-9*B6.)B?Q/<C4\ZG)DL;XDE8]KHU3-'HN:*G/F3#2K8;C4
MVVY7&JN;TH8%9P5)'FB*BO:F;MN2[^;D-KPM\'E%_(__ !4#8H)XJB-)*>5D
ML:[G,<CD\Z!:B%)T@6:/AE3-(]9-94Y\MY,M%N*;-;L'TM/6U\$4S5VM<Y$5
M-B'9176BNVEVDFM]1'/&E'*BN8N?(T"F/>UC5<]R-:B9JJKDB'6ZHA;#PSIH
MTA^.KDU?.8#2%37&KPQ40V=JOJG.;X*.U<V\J>8\5RPS57NQVJCFJ.X*>/4=
M4P1)MD1-[<T7+:F?(H&ST]QH:F34IZRFE?\ %CE:Y?,BG;45,%,S7J9HXF?&
MD<C4^\EN,;);\/5]E7#J+#=7U+6\%%DU7Q[<];51,]NKOYSKQ9<Z*YXV[@OD
M\L=NH85<L,:*Y99,VY(K=N>QSN0"J4M935:*M+4PS(F_@WH[+S'>33!T=E3%
M2SX<KI::/@526@F@=%KKG[IJ+EY.1>4VW#]^J+K<*VFGM531LIUR;++GE+NW
M;$Y_N S4\T5/$LE1*R*--[GN1J)]:G-CFO:CF.1S53-%1<T4TO3'\']?\Y!^
MJTZZS%K,,V7#<3Z.2J6MAU6ZCLE:K6MY,ESSU@-Y/'WTH^^?>_AT[LU=;@\E
MSRRS-4CQU/%=J2CNECGH8ZM^I%,Z761=V]-79O3SGIFOE,W'$]LAL\4ER93K
M(VIS:US_  ,T;GEFF>Q-X&W'BM]TH[A+414<[9)*=R-D1$5-55W$[T?7Z_5>
M);Y!-0R5$#:B)K]>L3*E:NMGDB^ZY\DRW&QX3O\ ;JV>^N@MD5!W%(ULTC$;
MG+FBKFN2)NR\H&W'745$-.Q'U$T<3%7+6>Y&IG]9I3,<5\U#)7TN')Y+<U?[
MY:A&JJ<Z-5N9B=)=T@O6 :"X4F? 3U#5;GY%5/\ @"G@&I7'&$C;U/;+-:I+
MG/3I_;*V7@VL7;LS5%3/9]X&V.<C6JYRHC43-57<AY*FYT5/0K62U,?<J99R
MM763;\AKM!B6._66]Q/IGTE92PO;- ]<U;X+DWY)S+YC7\+W&FM6B2GJZVB9
M70,U$6!^63LU:B;T5-F\"EP2LGACEB=K1R-1S5YT5,T.9IM\QI#8J>Q(RVOD
M9<(VK''$[+@T75R:B(FWW7)S'7#CBH9=Z*CN5CGHHZR1(H9G2ZR*JJB)FFKL
MW\H&U)<Z-;FMO2=O=B-5ZQY+GDF6W[T/8:O!>**3'LMJ2V1)6,IW2K69-UE1
M-3P=V?\ $G+R'DGQM+/<:FEL-GENC:?+A)6R\&U%5$7+-6JB[P-S!JMIQK15
MUAK+E+%)3K1KJS0NS5S5V9<F?*G)RF-EQW74]K2Z5>')X;:JI_;+4(KDS7)%
M5FKFFU4 W>6I@BD9'+-$R1_N6N<B*[Y$.TF.-:B.KQAA>H@=K12->YJY99IJ
MN*<      2K3?^\\$?34?Z,P&F_]YX(^FH_T9@ ]C/\ !A3_ #[OR,*J2KV,
M_P &%/\ /N_(PJH   #7L?TDM9A*YQP)F]()'9)O7)CMAL(<B.14<B*B[%1>
M4"2:"+M0P66JH*FHA@JHY-K)'HU7;5Y%^5#9,:8\M%AEBBDCAN$STSU(Y$<K
M?,B_^*8W$&B:@N-QEK*"OFMTDBZSD8Q79K]I#\L.B6WT%?'57"OFN,D:ZS==
MJMV_:4#QZ>)>'P!;9>"6+7KHUU%WI_9RFOXGPO4V^TVS%5CUTGBC;PS&-7G=
MF[-/E1"H8^PFS%UE@MSJMU(V*=LR/;'KYY-<W++-/C?<9:AM<=-9HK=([AHV
M,U%56Y:WU 0K1]=>_>EJGN"LU'3ND>K<\\E5CU,YI(<UFF*QN>J-:E+'FJKD
MB>'(;+AC1?38?Q0R[TUQ>]C'.5M.L662*U4RUM;R\QW8\T<,Q7>XKDMUDHWQ
MP-A1K(=;<YRYYZR?& S6,K[;*+#-R=-6T_AT\D;6I(U5<Y6JB(B9\ZFA>QZA
M?'!?ZR1JLIYG1:CG)DG@\)GM^M#TT^AJ'AF+77VIJX45%6-T:IG]>L;^W#]+
M3X9J++;U6EBEIG4[9&IFYN;5;K>54W[P-)QSCB:LJ)</X4A6MK)4=%-+'X21
MHO@KN1>??GLR,CA/!SL.X-N43W<-<*R![I%U=NLJ+DB;^<UZ+0MP,JRQ8DJ8
MY%WO;!DJ_7KFU8)P/-AJXRU,U\J;BU\:Q\'*U41,U1<_=+S?>!*]&>%K5B&H
MN,%WK9(I(Y5U:9K]76_ZM_)GEN,GHEEEMND&NM5)4.J*%L3LLG9M]TS;O5/(
M;=?]%-'<+G+6V^Y3VV25<W)&U7?_ "0S>!\#4.%$DDAD=4U<B*UTSTR547+9
MEFO,@'YI4C8S1[?-1K6YQ-5<DRS\-ICM"/O,;\Y_\&FU8JLZ7_#];:W3+ E2
MU&\(C=;5R5%W9IS'FP7AUN&+.E RI6I1':VNK-7D1-V:\P&>     "3Z/_AC
MQ[\]#_MH2L$GT?\ PQX]^>A_VT(%8       !PGD6*"21&N>K&J[5:F:KDFY
M"48?P1[9[G=+OB6*OII))E;#&JNB<C$S1-^W<B%: $DQ9@%F'^XKSAJ.OJJN
MEG8Y8-9TKG-3-5RRV\B<AE,;)<8<06"_T=KJZUE/$K)((HW:Z*JHNY$5>3FY
M2C@".8\KK]BBCMK8L-W"GIXJIKUUHWN?GJN3:W4143;O-MTK6RLK[/22V^!]
M1)25#9EBC:KG.3=L1/E-V &C7V&HQM@RJX.@J[?61RM6**JC<QRJU6NSR5$5
M47=GSF/HL57FDL;+?-A:ZOKHX^!UVQ2+&Y<LM;6U,BD@#1L+X?JK5@6YQU+'
M.N%9%-,]C455UG-5=5$Y5S54,?0VVN;H??1.HZE*S@')P"Q.X3/+=JY9E) &
MM8:IIX<"04\L,K)TI5:L;F*CD7)=F6_,\&BBCJJ'#;HJVFFIY.&D74E8K%R5
M[E1<E-T &@Z*Z"LHJK$:UE+44Z2U3'1K+&K-=-7>F:;4/S0[05E!:;@RNI*B
MF>ZHUFMFC5BJFJFU,T-_ &C8:H:N'21B*IFI9XZ:6-J1RNC5&/\ <[EW*<JV
MBJG:7**L;33K2-MZ,6=(UX-'9R[%=NSVIL\J&[@";XK6Y6;2!#?*2TU=RIG4
MJ0JVG8YRM5-?F:OQD,)BJ>^XDO\ ANJ7#U=34E/,J[8WN<W-69J]-5-5-G+Y
M>8L8 T#'U!656-,)3TU)430P/D662.-7-CS='EK*B9)N7?S'NTJT=36X;@BH
MJ>:HD2M@>K(F*]41';5R3D,K?,345HJ8J:2.IJ:J1%5(:6/A'HB9;53/RGLL
M=XI;U1]T4;G9(JM<QZ9/8J*J9.3D78!J./+#55M'9;A2TC:N:W*U[Z1[<^$;
MDBJF62[=F662F*K;A)60-@M&!E@K'*B<)4V_5C;]:QY<Q4P!UTT:Q0,8[554
M3;JMU4\QV        EGLD/@]C_GHORO*F2SV2'P>Q_ST7Y7@?,(
M
M                      ';3025,[(8&*^1ZHUK43-54#?=$V.:W#EVCI59
M+4T<[VM=$U554VY9HFWG/JNGE2:GBE1JM1[4=DJ9*F:<I(=#^C)+2UEUO+$=
M5.U711JB^#R[?N+$B9)DFX
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M7@?,(
M                                 !SAB?-*V.)JN>Y<D1.4#]IH)*F=
MD,+5=(]<FHG*I]%:(=%[+8R.ZWN-KZIR-?%&N?@YIGM\_P!Q^Z(=&,5MB@NU
MXC1]4YNLR-<_!S3E39SEB1$1$1$R1 "(B(B(F2)R
M
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MYG-UDA<]96(O.BY)N\H&_@X02)+#'(FY[4<GUG,
M              )5IO\ WG@CZ:C_ $9@--_[SP1]-1_HS ![&?X,*?Y]WY&%
M5)5[&?X,*?Y]WY&%5   #S7.H6EMM74-3-88GR(GR(J_\&DX-I5J<$7NHBS6
MJKW52JOE57ZJ?>;W50,J:::"7/@Y6*QV7,J9+^)A,%VV>TVV>CG;DQM1*Z->
M=CGJJ?=D!B=%]QHTPK'2\,QM12NEX9G*S*1V:K^)[K/B=MUQ!74U+&R2WTK=
MM4F[6R:N6_RKR<AZ[EA*PW.I6>OM=//,N][T7,R%-;**EH5HZ>GCCI5146-$
MV9*!INBZHBBL5=<:M[8TJZMS]9?(B-_^)X8JYF(=(C+C2N3O5:X=5T_\+GHJ
M[OJD0V9,!871VLEDI-;///57M,RZTT+K:^WK2QK1/3)T67@JG_B :;4W6MQE
M4OH;(JT]J:NK/5JFU_D;OW[-Z<JGEQ]:Z>RV:Q4]&Q(Z*&KCX15Y=K$15\R&
MQ>T#"W0=']E>TS;[71/M;;:ZFC6A:QL:0Y>"C4W)]R :3CJJ@O-ZL-IHWI*[
MATJ94;_"QCFNS_TJ>R@8S$>+Y)U1%MUF=P4+>1TN>3E_[5C;YS8;7ART6N.:
M.WT$-.R9-61&)[I/+YSVT%%34$' T<+88LU=JMW9KO T2T3PVK25>X[A(QKZ
MID;H7KRHB;43SH9G$6+(J*NH*"@8RKK*F=C%9OU&*N2N7:G.GG,W=[-;KQ&V
M.YTD52QNY'IN.JS8>M-E<YUJH8:57)DJQIO0#4*EW?+2Q3QS(C8[?1J[9\;-
MCO\ Y#25?(KC;5P_:)$J*^N5(W,9R,7/-?.B><V:YX0L%TK9*NX6JFJ*F3+6
MD>BYKDF2?<B'KM%BMEGS[V445-FF2ZB<G_B(!A*>[4<MYFPM61*D3855JO7+
MA$1R;-B_^9&#P&RDH,9WNEMCL[=%"K]^>J_7R5,UV[D0W>\V&UWI&)=:**J1
MGN>$3/(QURL_<%DDH<-TL=,LRHU58FQB;,UW\R9 8;1SG6WG$=T1N4<E9) Q
M>=J+K)^8WP\-CMD%GM=/14R>!$Q&YKO<J(B9KY=A[@   $GT?_#'CWYZ'_;0
ME8)/H_\ ACQ[\]#_ +:$"L           :[I%61,$7E8,^$[G75RWYFQ'":)
MDT3HY6HZ-R9*U>4#6< 1TGM(M_<[&K&L.W-/EWFF:&=1(<1<'EJ<(_++_*TV
M*/1C9XGO2&LN4<#US=3MD9P:_5J9_>9C#6$+=AUM:VWNJ-2J<KG->YJHW-$3
M)N2)S<N8&HZ.VT;L$8B;<I4AI'5\C9)%7+518XTS\YU4=HOEBL?"X?K:2ZV1
MT>O'%,U5<Z-4WYHB<AN]FPK;[5:JVW1+--35<KII$F5%7-6M3),D39X*&$;H
MTM;&NC@N-UAIU7^XCEC1GR9:F?W@:WB*OCN.B!DULIDHV\/&QT2*N3514UN5
M5R/?26C%4^%H6)7V5MODHVIX3),TC5G+LYC>Z2Q6^ELK;5% G<:,U-5>79EF
MOE-:XM;6C71QW"ZQTKE7_P!.R6/@\EWIEJ9Y?6!C8WT]@T4:E:Z"[Q(LD?\
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MI<-5"U5RG96U:+FQ6IDUOU*F?/RE1 )L38
M
M "5Z%_?+I ^EG_JS%4)7H7]\ND#Z6?\ JS%4    ?CTUF.3G3(_0!*[-?(<%
M7Z\T-Y8K&U,ZU$,GQT5K6[/LJ?N!+@ZXXQQ9601/BUZ9KHT?EFOA/R4J8 AU
MKK;/46J:2]R5%7?%U]>FUD:J.RYDRV9Y^8]]-1R5FA^1D$3D6.J?(K$WM1JJ
MJH6( 2^X8E;7:-VK9I7I)2M@@J5:B*K&99/W^1%-7Q'+A^2PIWJ2>NJUU5?/
MKYI&N6W--GX<A> !Y[=^[Z;YIOX'H
M     "5:;_WG@CZ:C_1F TW_ +SP1]-1_HS ![&?X,*?Y]WY&%5)5[&?X,*?
MY]WY&%5                              !)]'_PQX]^>A_VT)6"3Z/\
MX8\>_/0_[:$"L                                             !,
MO9">\BF^D(?P>4TF7LA/>13?2$/X/ HU!_@:?YMOX'>=%!_@:?YMOX'>
M
M
M                                                    !*]"_OET
M@?2S_P!68JA*]"_OET@?2S_U9BJ
M                  !*M-_[SP1]-1_HS :;_P!YX(^FH_T9@ ]C/\&%/\^[
M\C"JDJ]C/\&%/\^[\C"J@                              D^C_X8\>_
M/0_[:$K!)]'_ ,,>/?GH?]M"!6
M            F7LA/>13?2$/X/*:3+V0GO(IOI"'\'@4:@_P-/\ -M_ [SHH
M/\#3_-M_ [P
M
M
M       )7H7]\ND#Z6?^K,50E>A?WRZ0/I9_ZLQ5
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MJNV6N."H[NB9KHYR[%1VS:OD ME N=#3*F[@V_@=YT4&RAIOFV_@=X
M
M
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MH3;N  *J)O5 FW<      "3Z/_ACQ[\]#_MH2L$GT?\ PQX]^>A_VT(%8
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ME\)N[?YP,\
M
M               E>A?WRZ0/I9_ZLQ5"5Z%_?+I ^EG_ *LQ5
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MN:B ;&        2SV2'P>Q_ST7Y7E3)9[)#X/8_YZ+\KP/F$
M                                      #/8/Q-789N3*JADR;GX;5W
M.^]# @#[1P9BFAQ1:F5='(FON>S+)6KD; ?%N#L3UV&;I'4T4KFLUO#9FN3D
MVI_R?6."\54&*+7%4T<K5E5J:\>Y6KEM V$
M
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M;&QK&(C6HF2(B9'(      $L]DA\'L?\]%^5Y4R6>R0^#V/^>B_*\#YA
M                                                 #8,%XHK,+W>
M*KI)':B+X<>LJ(Y/D1?*:^ /M#!F*Z#%%LBJ:.5O"JU%DBSVM7+;_P FPGQ?
M@K%%9A>[Q5=*]RQHY->/65$<G_BJ?5^#,5T&*+9'4T<K.%U462+6S5J[>Q0-
MA
M
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MS4]F!+)6VC!:6VN8UM5J.35:Y%3:U$WG?@BRS6RP+27.&-9.'DDU=CTR5<T
M\UTQ!07[!N(W6U\SDAH9D?PD#X]\;LLM9$SW&F62PW:HP'%<H;]6TG P/DCA
MII7,9X.>Q41=N[[U*9?K=W1AV[4=##&V:II98F(U$:BN<Q43/ZU,98[-64F
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MLD/@]C_GHORO ^80
M           "MZ"+#?9;W'7TKY*:W,<U9%<Q5;(W-<T3DY%V^4PNB_1[5XHK
MHYZEBQVUBHYSE1?"3F3S'U'9[72VB@BI*&%D44;4:B-3+,#V@
M
M                                                E>A?WRZ0/I9_
MZLQ5"5Z%_?+I ^EG_JS%4       !C[_ '>EL5KEKZ[7[GC5K7:B9KFYR-3[
MU R .JCJ&5=+#419\'*Q'MSWY*=H  P&-+^_#MKAJV4[9UDJ(X-57:N6MGMW
M>0#/@Q4[KI+7V^2CX!*!S-:H1SO"S7+++9S9\J&5
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M(U$R1$Y#]  $GT?_  QX]^>A_P!M"5@D^C_X8\>_/0_[:$"L
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M9(?!['_/1?E>5,EGLD/@]C_GHORO ^80
M                         W_1=@"IQ5<8Y9VK';F+F]ZHY-;R(N7R<HT7
M8 J,5UK9ID6.@C=X;ES\+9R;/D/J:T6REM-!%24,21PQM1J(GD0#\L]LI;10
M14E#$V*&-J-1$Y<D/:
M
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MZ6/+5>O.F1ZSPV*WMM5GI*!CE>VGC2-'+RY'N
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MTCAC3)$/8
M
M             $KT+^^72!]+/_5F*H2O0O[Y=('TL_\ 5F*H
M                                       $JTW_ +SP1]-1_HS :;_W
MG@CZ:C_1F #V,_P84_S[OR,*J2GV-+VIHPIT5S47AW;U_P"AA5.$9\=OG Y
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M4'^!I_FV_@=X
M
M
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MX
M
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M7P?O4&]:;_WG@CZ:C_1F #V,_P &%/\ /N_(PJI*O8S_  84_P ^[\C"J@
M                            D^C_ .&/'OST/^VA*P2?1_\ #'CWYZ'_
M &T(%8                                             "9>R$]Y%-
M](0_@\II,O9">\BF^D(?P>!1J#_ T_S;?P.\Z*#_  -/\VW\#O
M
M
M                                               E>A?WRZ0/I9_Z
MLQ5"5Z%_?+I ^EG_ *LQ5
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MF*;I5WS7E9P:O3)<DULVIY>13WZ+7OP_I*N-B9+K0*]\2(NW-6YKGR?% N@
M    2?1_\,>/?GH?]M"5@D^C_P"&/'OST/\ MH0*P
M                          $P]D2](\!P/7-4;7Q+L^1Y3R6>R0^#V/\
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M#[1!@<'8FHL3VIE91/S7<]BIDK5R,\
M
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M?O%ML5JMCM:W6ZDI7<\42-_ "=:=FRMT?VU*ER/F[NCUE3E7@Y3LQ+A)N(<
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MMZ'>      "6>R0^#V/^>B_*\J9+/9(?!['_ #T7Y7@?,(
M                                      #8,%XIK<+W2.IHY%2/6\-G
M(Y,E3G3G/K+!V**'$]KBJJ.5%>K45[-RM7+:?%IL6",4UF%KQ%5TKU6-%\.-
M57)R;4W(J<X'V># 8.Q108GM<5512M616HKX]J*U<MN\SX
M
M                                              $KT+^^72!]+/\
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M.A5=>547)?"14Y4=S\ARJL.WW#,]/6V>Y5MSCX1K9::=SWJK=ZJBJJY;N;E
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M#X/8_P">B_*\J9+/9(?!['_/1?E>!\P@
M                           V/!&*JS"UWBJJ:1ZQ:R<)'K*B.3Y$7RGU
M?@[%-!B>V1U-%*Q9-5%?'GM:NWL4^+2MZ![+?I+Y'6TCY*>W-<U95>U=61N:
MYHFU$Y%V[=X'TL
M
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M'L?\]%^5Y4R6>R0^#V/^>B_*\#YA
M                      #?-&& :K%5RCDF8Z.WL7-[U:[)WD1<LN;E YZ,
M='U7BFOCFG8Z*W,5'.>K5R<FW8GF/J2RVJDLUOBHZ"%D44;4;X+43/RJ++:J
M2SV^&CH86QQ1M1J9)OR3E/<
M
M                       !*]"_OET@?2S_ -68JA*]"_OET@?2S_U9BJ
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M^Q32R24C63LI9'+MU?#3/- *8#7='E6ZNP?;IY':[E1[<^?5>YO_  ;$
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MJ            EGLD/@]C_GHORO*F2SV2'P>Q_ST7Y7@?,(
M                                      &^:,, U&+*U))$6.AC=D]_
M/]WE0#]T88 J<65S9946.@C=X;U14UMF>Q<OD/J:RVJDL]!%1T$38X8VHU,N
M7)#]LUKI;101TE#$D<+$R1$Y3V@
M
M                             !*]"_OET@?2S_U9BJ$KT+^^72!]+/\
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M5.3-/<EC &-PU35%'8:&GK9.$J8HD;(_G7G,D
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M(?H         D^C_ .&/'OST/^VA*P2?1_\ #'CWYZ'_ &T(%8
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MOI;92MIJ"!D$#=S&[D/4
M
M                          "5Z%_?+I ^EG_JS%4)7H7]\ND#Z6?^K,50
M                                                   )5IO_ 'G@
MCZ:C_1F TW_O/!'TU'^C, 'L9_@PI_GW?D854E7L9_@PI_GW?D854
M                       $GT?_  QX]^>A_P!M"5@D^C_X8\>_/0_[:$"L
M                                             !,O9">\BF^D(?P>
M4TF7LA/>13?2$/X/ HU!_@:?YMOX'>=%!_@:?YMOX'>
M
M
M                                       !*]"_OET@?2S_ -68JA*]
M"_OET@?2S_U9BJ
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MSL J@)7WOTL=,VGJ&=@[WZ6.F;3U#.P"J E?>_2QTS:>H9V#O?I8Z9M/4,[
M*H"5][]+'3-IZAG8.]^ECIFT]0SL J@)7WOTL=,VGJ&=@[WZ6.F;3U#.P"J
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M=KL %E
M
M
M
M
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M]1-)&Y^2^$U(Y%R\Z ;L
M
M
M
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M?W+/#42-3/4CD:J_B!Z@8^P76.\6V.KB8L:NV.C<NUB\RF0
M
M
M
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MNKGWF=\;EAS?J<*JHYNS/)>=#<ZB!WM2E1*=SZB:A1DNKX,CO[/+?EFJH9X
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MQN&Z.&@LU/!3MR8U%VKM5=J[UY3)
M
M
M
0                  '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g109079g34g34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g34g34.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[14*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %.T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M          #_X4: :'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP
M86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y
M9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM
M<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L(#(P,C O
M,#<O,3 M,C(Z,#8Z-3,@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @
M(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS
M+R(*(" @(" @(" @(" @>&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&9X+S$N,R\B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QX
M;7 Z36]D:69Y1&%T93XR,#(V+3 S+3$P5#$T.C0Y.C(Q*S U.C,P/"]X;7 Z
M36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C8M,#,M
M,3!4,3,Z-38Z,3DK,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#(V+3 S+3$P5#$T.C0Y.C(Q*S U.C,P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%C
M<F]B870@4$1&36%K97(@,C4@9F]R(%=O<F0\+WAM<#I#<F5A=&]R5&]O;#X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S
M:&]P.C4T,#9B93<X+6%D83<M.34T-"UA.#9C+6,U-V0Y,S<U93@S,CPO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#IC8V(S-&4X-"TY,S<T+3(Y-&4M8C=C-2TX-60W.&,X-&5A-C0\+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#HT83DS8V-D82TY9#8U+30X8F$M83)E-BUC,#EC,V8R,&9C
M96,\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.G-U8FIE8W0^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/C4W/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!-33IS=6)J96-T/@H@(" @(" @(" \>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI
M8V%T:6]N+W!D9B!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HX8V%A,S$X-"UB,# S+6-D-#,M.#@R8BTP-C@S,SDU9F)A
M-3,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C8M,#,M,3!4,30Z-#$Z,S4K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R
M=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!A
M<'!L:6-A=&EO;B]P9&8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C%C960U.61C+34V-30M83<T."UB
M8F-B+38R-&0Q86%F,C5A9#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R-BTP,RTQ,%0Q-#HT,3HS-2LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R
M=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO<&1F('1O(&%P<&QI8V%T:6]N
M+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CAB96,R,C@Y+38Q-F8M
M-V$T."TY,#8Y+3(P9#8V,&$V,61B-CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-BTP,RTQ,%0Q-#HT.3HP
M.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#IE,#0P83<W9"TT965F+3@X-&(M8C,T-RUA
M-C4W930V938Q,C$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C8M,#,M,3!4,30Z-#DZ,C$K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@
M:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IC8V(S
M-&4X-"TY,S<T+3(Y-&4M8C=C-2TX-60W.&,X-&5A-C0\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C8M,#,M
M,3!4,30Z-#DZ,C$K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E
M9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \
M<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.F4P-#!A-S=D+31E968M.#@T8BUB
M,S0W+6$V-3=E-#9E-C$R,3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HX8F5C,C(X.2TV,39F+3=A
M-#@M.3 V.2TR,&0V-C!A-C%D8C8\+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HT83DS8V-D
M82TY9#8U+30X8F$M83)E-BUC,#EC,V8R,&9C96,\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @
M(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @
M(" @(#QP9&8Z4')O9'5C97(^061O8F4@4&AO=&]S:&]P(&9O<B!7:6YD;W=S
M("TM($EM86=E($-O;G9E<G-I;VX@4&QU9RUI;CPO<&1F.E!R;V1U8V5R/@H@
M(" @(" @(" \<&1F>#I3;W5R8V5-;V1I9FEE9#Y$.C(P,C8P,S$P,#<S,C(T
M/"]P9&9X.E-O=7)C94UO9&EF:65D/@H@(" @(" @(" \<&1F>#I#;VUP86YY
M/E)O<&5S("9A;7 [($=R87D@3$Q0/"]P9&9X.D-O;7!A;GD^"B @(" @(" @
M(#QP9&9X.D1/0UA$3T-)1#XQ-C@Q-3$Y,#)?,3,\+W!D9G@Z1$]#6$1/0TE$
M/@H@(" @(" @(" \<&1F>#I21TUA='1E<CXQ,38X-S4M,# Q-SPO<&1F>#I2
M1TUA='1E<CX*(" @(" @(" @/'!D9G@Z1&]C6$9O<FUA=#Y$969A=6QT1F]R
M;6%T/"]P9&9X.D1O8UA&;W)M870^"B @(" @(" @(#QP9&9X.D1O8UA,;V-A
M=&EO;CY%=F5R>5!A9V4\+W!D9G@Z1&]C6$QO8V%T:6]N/@H@(" @(" @(" \
M<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7
M%!@8%Q06%AH=)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'
M"@@*$PH*$R@:%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*/_  !$( EP'9P,!(@ "$0$#$0'_Q  =  $  00#
M 0              !P$"! 8#!0@)_\0 5A   @$" P,%# 8'!0<# P,%  $"
M P0%!A$2(3$'&$%181,7(E-457&1DI/1TA0R@:.QTQ4C0E*AP? (,S9RX18D
M-$-BLO%S@J(E-<(F)S=C1$5TA/_$ !H! 0 # 0$!               ! P0"
M!0;_Q  J$0$  @(" @(!!0 " P$      0(#$00A$C$303(%%")182,S0G&!
MD?_:  P# 0 "$0,1 #\ ]4@       #I Z0
M
M
M    "CZ2&^6K%+RRS!A,+6NZ<9<4DGKNEUHF1])!W+O_ (DP?^NB0$SX7*4[
M*DY/5M&68>$?\#2]'\S,
M
M
M #I Z0
M
M                                   "CZ2#N7?_ !)@_P#71(G%])!W
M+O\ XDP?^NB0$S81_P #2]'\S,,/"/\ @:7H_F9@
M
M
M                     =('2
M
M                                                       4?20=
MR[_XDP?^NB1.+Z2#N7?_ !)@_P#71("9L(_X&EZ/YF88>$?\#2]'\S,
M
M
M                                    #I Z0
M
M
M          "CZ2#N7?\ Q)@_]=$B<7TD'<N_^),'_KHD!,V$?\#2]'\S,,/"
M/^!I>C^9F                                            U!PU*L*
M<.Z5&E'M%.M"K':A+:B^H#F!8GOT6_<<5*ZHU9[$*B<UQ0&0"W7BGT%RX
M      -1J-!H U T
M            >[>46CZ *@                  "FF_B&VNC<!4%JT?A)B+
M0%P                Z0.D
M
M                         6O=+I N3X@MX/BM'T%RX            !34
MJMX           4?20=R[_XDP?\ KHD3B^D@[EW_ ,28/_71("9L(_X&EZ/Y
MF88>$?\  TO1_,S       WV,ZS&L=L,&@IXA65*+X-_9\4=E+=P(1_M'T*E
MW:6-M3DX2E)[UZ8/^0$R6%[0Q"UC<VDU4HR6JDNDY:]>G;TIU:TE"G!:R;Z%
MQ(FY!L7G^CZV%7,])T&HPVM%KHHK^1VO+)C4Z&#5L,LV_I=S%I:<='%KA]J
MW3"<PX=BU6I3L;A5)TWH]/M^#.UVEKH]S('_ +/MG5L:]ZKJHY592VIZ_LOP
MV;IC?*/&WQ&I98585KVK!Z-P]+70GV 2(GNX-'%4N:5.:C4FHR?!,T#+7*3#
M$\3EAE]95+*]T\&-1\7IJMS2ZT:!RJYLQBAF"TIT[2M3A&<E%Z?6W_Y0/0:D
MGPX!/7AO-!Q+.\L%R[:7E]9U(UIO39X:[F^KL-@L<=A<Y=CBJI2C'8<]CU_
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M1^2A;.2+#3AH_P 0-N                '2!T@
M
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M<Y1U]:8$EX+0G;87;4:O]Y".CWF8<-G3E2MJ<)O645HV<P
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MA]?"LKV=G=0V:L$]5H^L#8P               !T@=(
M#7?H-0 *:HJFFM4  U0U0 #5#5  -4-4  3  !M+B-5H  ;T6\)I\  &HU0
M#5           -4  33"::U0 #5  !J@ !35:)E0 ":? HI)\&!4#4HI+5K7
M@!4#5:E-4!4%-I:/?P*MI  -5IKT           -4  U*:K5KJ J F@    #
M5:E-I:-]" J"BDGP*@ -4-=P !--;@FF  ;TXA-/@  U0U6FH #7<
M .D")<Q4:O\ M_;2A2G*.L=9:/3]DP\[T:T\^X6X4:DH)K5J+ZF2W.PMJE95
M9T(.JN$G%-^L5,.M:U>%:K0IRJP^K)P3: U+EAA*KDJYA2A*<MI/2*;?"1D9
M'A.&0**G"49*G4\%K1\9&T7-M3N:4J=S3A5IO]F44U_$K1HPI4NY4H0C22T4
M4M$!%_)93JT[S-$ZE*<(NYDUK'CX0Y"Z56E:8BJL)TWW5M;4=/V8DEVUC;VG
M=G0H4X]UEM3TBEJV+.SM;*,E:4:=+:>KV8)?@!%5S1K/EHI3=*;I)+P]EZ?W
M2.VY;:=2K@]DZ-.<WW;>HIO1:,WZ6'VLKM73HT_I"_;V%KU<=-2^[M*%Y!0N
MZ4*D4]4I13_$"+>5>5[3P?")4HU7;JJN[J"?U?"UUT[#J\P8MEF63I4K2SE4
MNW"">E.6NUNU)ENK*VN:+HW-"G4I/]F<%)'74,L8/24DL.M)1;X.C#=_ #4L
M@TJM3DPV%1E";@M(-:/38AT'4\DF(TU4NL.G2J0N&OVDUT?ZDK6MK1MJ/<:-
M*%.BMRC&*2]1A6^"6-K>?2:%M1I5G^U&"6OJ0$4X!B,,JYTQ#])4ZD85Y-QE
ML/KD^KM*9CQZEC6>;!65*K.$8[+EL/3C+L[26,1P+#[^<:EW:6\ZD?VG3BW_
M !12WP/#+:I&5*PM557":HQ3]>@$/9BI7#Y4[*4:-38BXZO9>G&!OW*?A-3$
M\LP5*G*IW)*<H+5M[XO^1M53#+.K=_29VM*5=;E-P3:^W0RY04X.,HIIK1Q>
M]- 0_EG$LKPPA1Q'#MBO36DE*$M>"-[R95PFXISJX/:*WATO9:;WOK^TS*V5
M<)JU'-V5%-O5I4XI/^!V=E8V]E3V+6WITH]4(I?@!DQX%0N  H^D@[EW_P 2
M8/\ UT2)Q?20=R[_ .),'_KHD!,V$?\  TO1_,S##PC_ (&EZ/YF8      !
MH@ &B&A24E%-R>B1C2Q&TB]'6BGZ&!E:(-)\464ZU.I%.$E),NVEU@5T0T74
M4E)1XO0Q?TC:=U[GW>.WU:,#+&BZD44DUJGJBJ:? !HNH#5'#]+H=U[GW1;?
M4!S:(:+J1P1O+>5?N*JIU/W=&<^NX  MZW                  4:W<"I27
M#B!3@TM>/04W(XKNHZ5"I4BEM16YL@K#<V9WQVM<3PBE3E2A+93E/3H77-=8
M$]\'O8UU>B1#6"9XQ_!L7M[/-M%1A7FH1E%[6_VG^\B8;>HJUO"I#A-*4?0P
M.3=P7$:Z<7Q.@SEF2VRSAKN;CZ[UV%LMZO1O3^!%M'&<_9BV[[!:,(V2D]-:
MFSJO1MKJ G'5+M973T$:Y SC>5[RKA>/P[G?TWIUZO=TZOM)'K3C!;4Y;*76
M!?IZT6.I%24=N.V^C7>64;FE7BW1FI:<=".,7QN[I<I-K8QG)4)+735Z?6EV
M]@$E.<=K3;BGU/34N2C+H3T(JS-CM[;<H5&SHU)J@W3U2DTM^SV]K)3H/6E!
MZ<8K4#D226Y)             */@TS#>'VKN%<*A'NR_:V=YF;^D;_L M2ZR
MRYH4KBBZ=>"G3EN:9RZ!K^ &):X=:6MO*C;T(0I2XQ2T3_K0ZYY4P-U'4>'4
M'-\7O1WFFO'4HEOWH#"LL-LK+_A;:E2Z-8[C&O<O83>U74N;&E4F^,M^O\#M
MVNI(:+H0&!88598?%JRMJ=%/=X*.6A8VUO5G5ITHJI-ZN26]_P!:F5OUX! 8
MM:PM[BLJU6C"=2*T3DMZ.2I;TJM/N=6DI0ZGP.;>$NML#'C:4(T948TH=Q:T
M<4M$=4LJ8&IN<<.H[6O'>=[IIPT*I=F@'7T,+L:%-TZ-K",)<5%:)F+6RU@U
M9MU,/HO7LT.YT?05T Z_#<)L<,3_ $?:TZ*?%Q+Y8=9SN5<.A3=>.]3TWF9H
M^A)!1W<-/0!U>)8+AN)S56_LZ=:4=R;7]=9PT<M8/3TC3P^C%Q>J>R=RD]-R
M*I:/I P[C#[2[MU0N*$)T8K11DMW];C MLKX-1J=TIV%&,M===#NVGV:#1_L
MZ) 8]>VI75*5"O"-2E):.+6XQ<-P7#L,G.5E:PHRD]6XZ[^/Q.QT:6[3["NF
M[0"L>" 6Y       :+J&BZ@  T74@ *;*ZD5T74@ *.*?%)E4DN"0 !K7B-
M  T74 !1Q3XI,JDEP20  -)\4@ ***7!(J !39BN"7J*Z  -$
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M4]?_ '2,Z&4LG?3:*=W.I633BG4;W^LP,5C&ERJ8=1A]2-/97:MJ8'#F[_\
ME"W]-+\($S6W]Q3_ ,J(8S?**Y4J";?&ET=D"9[?^YI]6R@.0
M
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M=6M>M ;Y@W_VFQ_]&'_:C-,/#(3HX=:TYKPX4XQ:^Q&8         -"Y8_\
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M?8W:Y3I594GW+=X7V(FC5:=APPMJ*J.HJ:4^LYM%IIH!5<
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MI+=T::='8CO()12BEN2T*[*VM=-Y5+0
M
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MDM--^XN314"QQW:::KMWE-B"FI**7H1R "QQU?!>D:;MRU]*+P!;H^*XEP
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MB\Q''\+JVT7*G![]/1("6,(_X"EZ/YF88F&)JPHQ:T:6C,M         -1Q
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MM%)G\7>V%*=&SI4ZDFYQBDV9'0$F7:)H\OW[>S$:]*@ )
M
M                        '2!T@                    */AQ KKZ0WH
M4B^)B7M_1LZ;=22;Z@,O:73N])QRN:,==:U--=<D:E<XQ=7<WW%-0,2<9S>L
MY23?'>!L]UC5O0UWRFTMVRDT=;4S#5E+6G![/:CJX4](OB^UE\8Q2T [BWS%
M3>ZM&:?9$[*VQ*WK+^\4?\S2-4V([]Q:Z2?!M?:!O%.M3GNA.,O0]3D;T-$A
M.O0?ZFHWIT'8V&.5:?@W,=>T#:M4$8UK=T+A:TYK7J.>*>NK N
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M.6GBME4TV+FG+T,:G^AG:A/7K..-6$UX$D_071?80+@43WE0
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M2 @<5&K&I!2A)2B^#1RZF;T  )                 =('2
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M -CF15%%N$>!G:50       :1RC9;ECU."AM;4>K0T>SY+9.O&5:4]%UZ/\
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MRZ5? JCC4M5VER;U>G X0N!373IU&KTX$BH*;WP %0       !T@=(
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MBM-W07/B58%LM\9>@UNHM+B:[38WQ:->Q&+A>)=#.\:NZT!KP1T%D]*0=*
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MZA?^YQ1&]I!UZ@GJ8>'7D+RTA7I;XS2?\-3+13,:7Q.XVKJ5+5O9<@0
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M1DT_VM#<\&L%94%%_6?%HYK*RI6M/9IQ6G6945IP8!+1M]95+1:
M    #  Q;NUA<4VGQ-?K49VU1J2;B^#9M.G4<-:C&K'2<4T=5MIQ:L2UR,]>
M!=M+K1EWF&23UMWX/2CKW&I3;C.FU%=++8F)5:FKF4H].I75'#&<?V6B[>'.
MX7Z]8318-0C<+]2UR*:@)VMT>I71Z:%'N^M)(HG4D]*4'+M0VC6R<MF#Z7U'
M88/:.4NZU4UIP+\/PYIJ=;?V';P@HK2.Y'$V^H74QZ[E6*W%V@6X%:T6X
M          &@ %-"UQ3AO6Y[B\M?#1;P-#S5EB;N9WMFN.^2W[_X&I4:JVI4
MZL90J1>FDEIJ31.*V-'O1K&9<KT\2I.=OI3KK@U]O;VFW!RM?QN\SE<"+;OC
M]M#WM:O<47V,K7P^_L)=SN:,Y)?M:'$JM+@WI+J/1B8M&XEXUZS3J\=N0=(3
MU0(1'2NI:]Q7AQ+9S@EX;T76-;/<;VKZ=Q7513<VDNMED:KEX-&FZS_Z3M<$
MRU>8G652[C*E07[+7^J(O>M([E9CQVR_QQQ_]=?A=E7Q>[5.A3DJ?3)IDJ81
M84\.M8TJ*Z%JWUE]C8T+.ELT*:CIU&:H[CRLV><G7T]WB\2,$;GVI%;R[0+<
M"AL%N             .@MTW%SX%.@@6Z::O7>='F3!XXK:2CK^L2W/['\3O2
MV6G0CNMIK.X<9,<7KXSZ0[=65UAM1TKJ#T7">CT*1:DO :DWU<"5[_#K>]H2
MC7AKJC0L;RK<6E=UL/UE2_<^U]OH/1P\JMOXV>-R.#:F[5].E>Y]'V%4VN#+
M'W>F_P!?;3AVO_P'5@GJYI+J-?\ Z>?'\>IA=Z651Q]VH_OH*M2_?1&I1NO]
MK_4.*;Z$6QJ3E_<495'V&998)B.*R6E*5"'3JO\ P1-XK&YE97%?)U6&"NZ5
MJBIVT'.3>FY:Z>HWK*N6E9I75QM.N]^CZ/X=IVV"X%:V%**V$ZB6]L[C1+1:
M\#S\_*F_\:^GK\3@QB_E?N2.NK3+M!$J8HZ>D:!+0 D        658*=.47P
M:T-*Q/DYPB_O9756,NZ2>KW(WA\#CFVX-IZ:'=,EL?=9TKOBIDZO&T,9YML-
MP&,;2P<7)O2:U6O2;]D.PM*6#TJ]O'PIK?)\2/<>R=B=WG#Z7-3G;2FFUINT
MU7:2]A-I"SPVE1@MG92W&ODVCXXB)W,L/%I:<MIF-1'IGQAHMY5QW"/U5J5,
M+TEFG48.(85;7L'&K'37I1V)27 F)FO<(M6+1JS1Z^2:*;=!O[?_  85SE>Y
MI0>Q):+JU^!(BWG78W=T[&UE4GP_U-%.3DF=;8[\+#K>FC8;EJK=5)1K/AU?
M^#9\(RM9V-3ND%)RZ=48.4,<M\2Q"XA3XI=?H[.TW),C+FR;\93Q^/BUY5AQ
M1IPI[H1V?07;"XZE_%A&=L6-:'2YEP2UQ2RFJZ:DE]9<>)WKXG%6AM4Y+K1-
M;36=PYO6+1,2@;!L.P_&<7J89>-1C%[,6M-^]+I])MD.2G#J56$Z2>YI[O\
MP:KB^7\4M,RPE8V]1IUHRE42Z-2<<-E/Z%151-3V5KJ>AR,UL>II;IY?$X]<
MDSYU[A9@UC&PLH4$WLP22U]&AFI:Z]17CKJ%N>AYT]O5B(B-0*.A5 !(
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MC33;C%)G(H[M6%IJNW>7<5N,K="D5H7%$5            4T*@"FSVE'O1<
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MI0C]2,5Z$<D%NUU*KY/DG:)''?Q95( Y0HT"H         #I Z0
M          #1:\  &B*-+J14 8=U9VUPGW6"?V(ZRXR_0:UI:Q;]'P.^TT>X
MIHWTL#5I9;KZ/8JZ+TG$LM77C?\ Y&WZ:<$4^P#4X9:N=7M5?6S+M<NQB_US
MVOZ]!L2[$-.T# ML+M+>6L(+7T+X&=LI+P4D5TZ]=>LIIIT:@7
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ML?[NC3UZ]E? [:$(P7@Q45U)%5'3M+EPWF>;3;\FNM*TC5857 !($.@
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M$1&A71=2                        &B   #7L8#1=0
M                &BZ@  U0U0            =1F'"H8MALK>HDV^#?H?Q-
M=RQD^I@]VJFVW'5[MK_0W?37B@M5Z#JMYK'C!"BT327$NCTZ#MT$>#W' J "
M0           =('2
M
M                               <-Q=4J"3JR44WHM2^G5A4BI1>J? "
M\%-I):O<6RDEQW("\&)1OK:M5E3I58RG'C%=!D=.@%X,.OB%K;UHTJU:,9OH
M9E*::U6]<4P+@                <-Q<TK=)U9*.IR4ZD:D-J#U0%P*.6FA
M1S2UUZ%JP+BC:Z3&HWUO7J2IT:L9SB]'%=!SZZ-Z@8&-V4KW#J]"$MESBU_
MT7*F0598O6N;UJI';<HIKKU[>U&_U[ZUH5^Y5JT8U'N47TF1'1Z-<&M465RV
MK7QA3?!6]XO;Z:QG'*UMCMBXQA&->/U9:>GM768^0<MU,#I356M*?1H_M[6;
MBTN/2<$[FA1DHU)QA.3W)](^6WCXR?!3S^2([<T5NW%Z+%QVDMQ<GKP*X7>R
M'27'#.O2HPE.K-1BNEF$L=PYO17,&_2('9@XZ->G7AMT9*<>M%ZEKT,"H
M                X+JZI6L5*O)0B^EG+"<9K6+UUWH"XM2WLKM+K+6][T X
MKFG&K3E"2UBUHT:Y2R?A]/$OIBI1V]=>'^IW6)XI:X91[I=U%!=3,;",PX=B
MFU]#N(SFGILZ[SJ+S6-0XMCK>=VAV-:A2J4'3J04J;6FRS5L$R58X9B$[M04
MJC::W?5_B;9Q>_BNHY--STXL5O:N]2BV*EYB9CTI36S'3H15G%6KT[>.U6FH
MQZV7PJPJ13AHT^&G2<:6.0%-KUE)344V^"XLD7 ZV6-V$9N$KB"DN@RK:\H7
M*UH34_0!D IM=A5;P
M                                                   .D#I
M
M
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M;2MF/#Z=N_\ >%5@]%Q^L_\ 0F;"HR6'6VWQ[G'CZ ,P
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M;?E3$KK$:#E=T^YM=&GH^(&P HI:O0J
M
M   =('2
M
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M#[%J2?A$91PJTA/=.-&"?J1E2IQE]:*?I0TT NB]=/05+8\2X
M !1@1[RN6-S=VUI]%I.:C-:Z?:8N:LKSQG)5"I&+5];04H1^V/\ )$D[*D])
M)-=J.JS3:75SA%>GAT^YUW'P?6@(PPC.V(8?@,<.N,.K2K4HJ&WHM-VB_>[#
MCY$Y5+C#,<G56E2HIK9?'ZNAQ5XYK^B2PN5!NMK_ 'O<]S7#CL]A(/)UEG]
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MX*,=>Q:?R,J%*,8Z4TH^@Y !;TI::]I<
M
M     =('2
M
M                       4TZAOTX;RH L=.+>KBM?07*/6RH IOUTTW%4
M &B  ):                H][X?:4:UXHN '&Z2EKK%:]>F\NBM.C1(N  ,
M "FG2^(2Z^DJ **.@>O5]I4 6N.I2,-EK2*]*1> *16B*@
M      #  IH&OB5 %BIK:<MF/JWER3TX%0!3?KPW#IW\"H H]>HKIV  4TZR
MBU>NJT+@!Q[&_79CZB])ZZZ_85
M
M      !T@=(
M
M
M
M
M                          !T@=(
M
M
M
M
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M1QC)[_M0'H@
M                                    !&>8.6O*F XO<X;?U+A7-O-P
MGL]STU3TZ9I]!UW."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%
MS@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+
M)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5X
MRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NO
MNOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\
MP<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'.
M"R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE
M>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+
MK[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z
M_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS
M)=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"70
M1%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<
MX+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R
M5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,
MNONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[
MK\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,
M'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@
MLE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7
MC+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ
M^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONO
MS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"
M701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$
M1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$7.
M"R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE
M>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+
MK[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z
M_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!
MS@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+
M)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5X
MRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NO
MNOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\
MP"701%S@LE>,NONOS!S@LE>,NONOS )=!$7."R5XRZ^Z_,'."R5XRZ^Z_, E
MT$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@LE>,NONOS!S@LE>,NONOS )=!$
M7."R5XRZ^Z_,'."R5XRZ^Z_, ET$1<X+)7C+K[K\P<X+)7C+K[K\P"701%S@
MLE>,NONOS!S@LE>,NONOS )=/&W]KG_'\/\ TH?]J)LYP62O&77W7YAYQ_M!
MYOPS..:X7^#2G*AW.,?#V==5%+H; BV$I0DI1;C)<&GHR2>3_EDS1E"I"$+R
MIB%FMW<+NK.HHK75[*<M$^/01J /<')SR[9=S3"%OB$OT;B.D5W*2G-3>FK:
M:CHN#XLEV,HS6L9*2ZT]3YA)Z$CY Y8<T9.5.A:W,+BPC+:=M6CK'HZM'T=8
M'O<$1\G?+KEO-*HVU[5>&XA+5-7#A"$GJ]%'PV^&GVLEJE4A6I0J4I*=.<5*
M,D]4T^# N          'F'E-JU*/*1?U+?5U8UJ;BE'75[$3-Q'.N<+K"OHD
MJ5U2M]A0U5JGJEV[!P\H52-'E2KU)RTIPN*,I/J2C$F2GGK+%/!Z<*^)V\]F
MC%2IRBWJ].' "/>0RM@MKB%2%Q5;Q:KX,5*#22W;D]=.*9T?+)<3KYXKTJFN
MQ"48Q3ZG&)T]A5^GY][O@]/N,:MU*5"$%HH)MM::<-QO/+OEZM&]HXS;TY2I
MM;-24>B6[3\ )7R=;TK7+6'PH04(NC"32ZW%:L[#$K"VQ*SJ6M]256A46DHO
M=KZB,>3;E'PN.!PL\<NE:UZ"4(RJ:M36FF[37AI_$<HG*7A\<)J6N 7KK7-5
M:=UHMQ=/CT[GT?Q W[!,L81@E:=7"[14*DEHVIR>OK9!O++%/E!3EHTX4TTS
M<^12MC>(_2+[%;V[K6R\&FJU:4U+7IWM]1IG+-KWP8Z:-[-+<!Q9TP6ME>XP
MO&\*<H*M!3VHK=&>LMV_7H1R64[SE(SI0G74H6E)0E*'UDE'9VEKNXZ-DSQP
M.SQ_*-I98C!NE*DM\=-J/:FT]&7Y2RAAF5;>O3PQ59=U>U*=9J4NGI20'GV]
MMJ=GRAW%M0BHTJ5S5IQ2Z$G)+\#U#6J1HTIU*CTC!:M]AYEQI?\ [GWVOEM;
M?_[I$U<K>,?HC)URX3<:EQK033T:UA)ZKU 1'@M2GFGE+^E7]6$*,)JI^LGH
MO <5V=1S<K5"A@V:K?$<'KTG&K'7]3)2V9:RUZ7T,Z[)&0,1S9:UKRVO*5I"
M#23J)MRU;3TT_P IGYIY+L4P+!ZV(5<0H7,*.FL:<9*6^273Z0)ZR[B,<6P:
MVO8Z:58M_P 6OY'8D4\@>,NYP>OAM6<G4H2E*"D]=(>#_.1*P
M
M            ?/KEN_\ Y/Q__P#V9_\ <S1C>>6[_P#D_'__ /9G_P!S-&
M
M
M
M                +J<YTIJ=.4H36]2B]&B1,A\L&:<I58QI7]6ZLTMF5"JX
MRU6FBTE*+:Z.!'*74;5DS(>/YNNXTL(L*M2'[531)1W=K ]=\G7+CE[-KC;W
M4HX;?R:2I3DW'J^NTETDKTYPJ04Z<HS@]ZE%ZID#\FO]GG"\$G3O,QU(W]W%
MIQII)TUO7&,HOJ)VMZ%*VH0HT(1ITH)1C&*227H0'(       ".<S<E5CCV,
MW6(U\1N:4[AIN$81:CI%+^1U:Y$<,W:XK>-+HV(DM #5LIY'PG+;[I;4^Z77
M!UY[I:;MW5T?Q-DNK>E=VU6WN8*I1JQ<)Q?!IK1HY0!&>,\CV"7]S*M;5ZUD
MGQA2BFOXC#.1[!K6M"5S<UKRFG_=U(I)^HDP <-G;4;.VIV]M!4Z--:1BNA&
MDYKY-K/,>.K$[B_N*-1**V(1BUN])O@ Q\/MHV=E1MH2<HTX[*;XLR.C0 ".
MKODKL+G,-?%GB%S&K5K3K."A'1.3;:_B=OGC)%#-LZ'TN^KT*='1QA3BFMI:
M[]_^9FW #J,J8%0RY@M'#K:<JD*3D]N2T;UDY?S,W%+*&(V%6UJMJ%1)-KL>
MO\C* &AY/Y-[;*^*_3K/$[JI)PV)0E"*4EJG_P#BC?
M
M       B7,W(5ES,&-W>)WE6LJ]S-SDE%::MZG5\W#*GCJ_LHFX 0CS<,J>.
MK^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ
M_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#
M*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PR
MIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"
M/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RA
MS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHF
MX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ
M_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO
M[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PR
MIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J
M>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0C
MS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<
MW#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N
M $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO
M[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^
MRB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J
M>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*G
MCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\
MW#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-
MPRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@
M!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^
MRAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_L
MHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*G
MCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-PRIXZO[*'-PRIX
MZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<,J>.K^RB;@!"/-
MPRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX 0CS<,J>.K^RAS<
M,J>.K^RB;@!"/-PRIXZO[*'-PRIXZO[*)N $(\W#*GCJ_LH<W#*GCJ_LHFX
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M1Z)]1.=A9V]A:T[:SIJE0IQ48P7!)+1?@<X
M
M
M
M
M                                           >8/[0.0\<SGRETJ.#
M6DJE+N<%.KNV8>!Q>_7H9Z?*:+771:]8$#<GG]G7!<)4+G,LEB-TO^7N[EP7
M&+CZ>DF_#,.L\+M8VV'6U*VH1X4Z45%+?KP^UF6$
M
M
M
M
M            ! W+QRFXSD+,]A^C90G:U(KNM*45X2T?!M/0[OD_Y><MYIJT
M[6[4L,O9O10JRVH]'[>B7215_;$_^_X=_D7X,\ZQ;3U3T: ^G-O7HW-)5;>K
M"K3?"4)*2?VHY#P5R?\ +'F?)TH4Z5Q]-LH_\BZE.44NG1*2T/2O)YR\9=S-
M3IT<2FL-OME:PGJU*6F_9TUW<>+ F %(M26JWHJ
M                                 #K\9QG#\&H*KB5W1H)Z[*J5(Q<M
M..B;6O%>LR[NO&VM:U>?U:4'-^A+4\SX[>8CG?.D[95JDX=VE"E3VO!A%<=%
MN7"($KU.6'+4)N.S?R2>FU&E%Q].NUP-CR[G3!<?:A97=.-9O2-*K.,9R]$=
M6V=#9<DF6J5I3IW%"K6J**4YJK**D]-[TUW$99PR;B.4LPT:^"2JRIR:G3E!
MZ.&FF[CJ]X'HJYK1M[>I6J:[%.+D]..B(\?+'EI-IT\1U7_]&/S&Q87>U[_)
M+K7<7&O]'<9Z\6U'>R ^3;!;/',S?1,2INI1?0GLOCUH"6Z'+#EJK55/8OX-
MO36=**7_ '&\81B]AB]NJV'7="XCHFU3J1DX]CT;T9H^+<DF7[BTJJQIU:%R
MT]F;J2DD]-V[4B? ,0Q+)6<(V\JU2-.%78G24M(S6^.TUO73J!Z>.BS3FK"\
MLVRK8G6WMI*E3<74?;LMK<8V=L3N[?*=Q>80_P!>X:TVEJ0+CF!YAN\&J8[C
MM:JZ*DHP[I-3VN/!;6JX=0$_Y1S=AV::=:>&1N$J6FUW6"C^#?4=MBF)6F%V
MLKB_N*5O26Y2J34=7HWHM7O>Y[B*O[/?_"7_ *(O^+.GY?L4N98Q:V$9R5LJ
M2GL:[MK:FMKU ;G4Y8,M4ZK@XWTM'IM1I1<?3KM&XX!CV'X]9JXPRYIU8M)N
M*G%RCJM=Z3>A'F7>3# KK*D*E>$ZMY4A)]V4VEKJ]-VO1N-'R/?7&5N4&KA\
M:[=JJ]6E.">BDHJ:77TI >CP
M      +:DU3ISG+ZL4V_07&/B'_ 7/\ Z4OP8$=WG+=DVTN:E"M>S52F])+6
MGQ]LX>_MDGRZ?KI_.>*<V_XDQ#_U6=2![L[^V2?+I^NG\X[^V2?+I^NG\YX3
M 'NSO[9)\NGZZ?SCO[9)\NGZZ?SGA, >[._MDGRZ?KI_.._MDGRZ?KI_.>$P
M![L[^V2?+I^NG\X[^V2?+I^NG\YX3 'NSO[9)\NGZZ?SCO[9)\NGZZ?SGA,
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M!3IR4HM:IIZHN
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MXKC>.1Q'&:-6A;*?=INM3E!U&]6M-RZ=. $YY9ISI8!80J_7C22?I-5Y:_\
M!57_ -6/X,WR*48I+@C0^6I:Y*J_^K'\&!KO]GMKZ'B"7'P?Q9WO*OD:IF>W
MIW6'N*OJ"2V9/12@MIZ+=QU:Z=#H?[/:7T3$=-WU=WVL[OE7N\UX93HWN6[F
MJK6*4:M*E;QJR3\)N3UB]%HD@-!P[!>4:C:QP^E"]MK=ZQVN[:0BF^R7;U&I
MV%I<6^=%9W53NUW"M4A4DGKM36UM/5]J9O3Y9+YX9.VJ8:G>R@X=T<]'J]=^
MFSZ-QQ\E.5;_ !;,-3'\4IU*5/NDJOZR#CW1S4M=-R6GA)[@)Y
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MRTT27%MO@D9X&-AMC;X;84;.RI1I6]&*A"$5HDD9(
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MOL1>
M
M
M
M  #R9_;$_P#O^'?Y%^#/.AZG_M-Y4QC-&:\+ML%L:US)Q2<H1;4=SXZ'-R=_
MV;+.W5.[S?<.XJ::JWH3\#H^LI0UZ^D#SCE7*.-9HO86V#64ZTVTFVU!+[9-
M(]&\G_\ 9JM*%.C=9MNZE6LUK*UIJ,5%Z<').2?^AZ!P' \.P"QC:81:T[6W
M7[$#L0.MP3 L,P.VC0PJQMK6$5I^JI1@WZ=$M3L@
M
M
M
M
M                              !KV;LXX/E*-M/'+EV]*N]F,^YRGOU2
M_93ZT!L(,3#<1M,2MJ=Q8W%.M2J14XN+Z&M5NXHRP                +73
M@YJ;A';7[6F\N
M
M
M
M
M        !Y\_MA?X7P__ #/_ +HGH,\^?VPO\+X?_F?_ '0 \VY+SYCV4+A5
M,'OJE*G^U2U\&78STKR??VC\+Q:M3M,RVWZ/KSDEW:+2I+TMRU_@>04%NWH#
MZ9X5B5GBMG"ZPZYIW-O/ZM2F]4S+/G;DOE S#E"[5?"+Z<4MSIU-)Q:]$M4N
M)Z0Y._[1N&XG"G;9IH_0[G92[K3\*,WUO<D@/00,7#L1L\2H*M875"YIO]JE
M44U_!F4
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MGF#6]+D^5#N6CN:52-3=OEJYZ?B0_EBI^A.5"4*"<:=&ZKTVET)*:2 ],@
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M [H
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MW,8PG'?JMG:[7ZR0.2KD_J8!5GB.*;KQZ;%-Z/N>YZ[]_6UN?0!)H
M                                                   TWE?P^YQ3
M(&)VEE2E5KU-C9BEJWX2/%7>LS=YGN/=R^!]!P!\^.]9F[S/<>[E\!WK,W>9
M[CW<O@?0< ?/CO69N\SW'NY? =ZS-WF>X]W+X'T' 'SX[UF;O,]Q[N7P'>LS
M=YGN/=R^!]!P!\^.]9F[S/<>[E\!WK,W>9[CW<O@?0< ?/CO69N\SW'NY? =
MZS-WF>X]W+X'T' 'SX[UF;O,]Q[N7P'>LS=YGN/=R^!]!P!\^.]9F[S/<>[E
M\!WK,W>9[CW<O@?0< ?/CO69N\SW'NY? =ZS-WF>X]W+X'T' 'SX[UF;O,]Q
M[N7P'>LS=YGN/=R^!]!P!\^.]9F[S/<>[E\!WK,W>9[CW<O@?0< ?/CO69N\
MSW'NY? =ZS-WF>X]W+X'T' 'SX[UF;O,]Q[N7P'>LS=YGN/=R^!]!P!\^.]9
MF[S/<>[E\!WK,W>9[CW<O@?0< ?/CO69N\SW'NY? =ZS-WF>X]W+X'T' 'SX
M[UF;O,]Q[N7P'>LS=YGN/=R^!]!P!\^.]9F[S/<>[E\!WK,W>9[CW<O@?0<
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M69N\SW'NY? ZG,.3<;R];1KXM95+>G)Z)SBUKZT?1T\^?VPO\+X?_F?_ '0
M\B   #M<MY?Q+,>(1LL'MI7%PVO!4DM/6T>B^3_^S3&5.C=YNO*L)<7:T=E-
M;N#;4DP//.7,L8QF*[A;X385Z\IM+;5.6PM6EODEHN)Z%Y/?[-,HU*5YFZ]A
M**TE]$IP>_C^VIKLZ#T/ES+.#Y<M8T,&P^VM8I:.5*E&#EZ=$M3N .IR]ES"
MLO6<+;";*E0IPX-+67!+B]_0CM@
M
M
M
M
M                                !Y\_MA?X7P__ #/_ +HGH,CWE7RY
MAF9:F%6F,4'7M]MO94Y1_:CU,#PUEW+>+YBNXV^#X?<W<V]-:5*4U'TZ)GHK
MD\_LUQ_5W6<;A27'Z/;S>CW\):Q37K/0F7LKX+EZVA1P?#;:VC%)*48+:X:;
MY<7P.Y ZC+67,+RU8JTP:UC;4$DME2E+7UM]9VX
L                                                       ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g109079g49g49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g49g49.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1<D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %P<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*/_  !$( YX': ,!(@ "$0$#$0'_Q  <  $  P # 0$
M        !08' P0( 0+_Q !:$  ! P,! P4(#P8$!0,#  L  0(#! 41!@<2
M(1,Q05%5%A<B89.4T=((%#(V-U)6<7-T@9&5L;(5<J&SP=,C-4)U,S1BDL*"
MHO D0\-35.$EH^+Q)D1%8__$ !H! 0 # 0$!               ! @,$!0;_
MQ  S$0$  @(! P0! P(& P$  P   0(#$3$$$B$4%4%1$S(S4G&!!31AL='P
M(D+A(Z'!\?_:  P# 0 "$0,1 #\ ]4@
M                             >'KM_FE;],_]2GN$\/7;_-*WZ9_ZE,,
MWP\O_$N*_P!W4 !SO*
M
M
M                                   'I+V-/O(N'^XO_E1&M&2^QI]Y
M%P_W%_\ *B-:.S'^F'T/2_LU  7=
M
M                  'AZ[?YI6_3/_4I[A/#UV_S2M^F?^I3#-\/+_Q+BO\
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M[&GWD7#_ '%_\J(UH[,?Z8?0]+^S4 !=T
M
M                       >'KM_FE;],_\ 4I[A/#UV_P TK?IG_J4PS?#R
M_P#$N*_W=0 '.\H             #U?L*^"^T?/-_.>>4#U?L*^"^T?/-_.>
M;8?U._\ P[]V?Z?\.YI75+*W4EUL=2]/;--NOC14XN:J97[E5"A:QV6NK]HM
M)4TK$_9M6])*E%=P8UJ,143ASKQ4H^L;Y4Z>VL5%QI'*CHGQ*]J(B[[$1JJW
M[<'I2T7BFN-A@ND<C?:\D>^KDYDQP7[E12\:OXGX==)KU&\=^:R@M4WRETK;
M[9;J?P9IY(Z:)B)E4:J[N]]A-WY572]Q5>=:.3]"GF_4VI7ZEVJT,R<*:"LC
MBA;U(CFHOWJF3T???>M</J<GZ%)K;NVTQ9ORS?7$/*6@T1=I-F14RBW&/]9Z
M1VKQ1IH*\*C&HO(/YD_Z7'F[07PE67_<H_UGI3:S[P;Q] _]+BF/]$N7H_V;
MO()[/T_%&NDZ)5C9GVLWH\1XP/:6G_>E1?5F_D1A^5?\.YL\L6/X4*/_ '9O
M\T]-;1O>#>_J,W\IQYELGPH4G^[-_FGIK:-[P;W]1F_E.)Q_IE?H_P!O(PK8
MAJ>TZ<J;BZ\RI&V5&[BJW/-D]*6VKAKZ*&JI5S!*W>8O6AX;/9N@?>?:OH&D
MX;?"?\/RS,33XAG^T?7^FZ[35TM])4-=5N9)$C4:GNMUR?FI&^QB8U]'J'>:
MUV)(.=,]#S$+Q_FU=]._]2FX>Q@_Y/4/TD'Y/*TM-K^66'-.;J(FW^JO>R.:
MUNJ*-&M1$Y)>9/W32M@'P=TGTDG\QQF_LD/?11_1+_XFD; /@[I/I)/YCBU/
MW):X?\W;_OT[E\32FF+Y->;W)&VOJD1K5?QPC4Z$^[G)6SW73NLJ">.B=#5P
MM3=ECQA41<IQ^?"GGG;E*^3:#6M>[*-9'CQ>"A*>QSJI(];R4S5_PI:9[G)X
MVXQ^:B+_ /EVZ37JO_V_%KQMT-L^C8M+WQDM U4H:M%>QN<[BIC*<W6J]9I'
ML<(V.TU6JYC5_P 1O.GC<=KV1,37:,;*ONFS,1/M4Z_L;O>S6_2-_-Q$5[<F
MD4QQCZK4<:4/V0K6MU>U&HB)N]"?]##=]G?O+M'U=OY&%>R']^#?W?\ P8;K
ML[]Y=H^KM_(G'^N5^G_S&1Y$O_\ GMR^LR?J4]/["?@PM/[TW\YYY@O_ /GM
MR^LR?J4]/["?@PM/[TW\YY7#^J7-T'[T_P!/_P"V"[8?A!NOSM_2ALGL>8V.
MT2JN8U5Y5W.G_4XQO;#\(-U^=OZ4-G]CO[R%^E=^IPQ_K6Z7_,V_NR+;HU&[
M3KLC41$W8>"?1,+WL9V:T=3;(+U?8.4>]V_!$Y>"(BKA53'B14XE+VTPI4;6
MKA"KMU)%IV9ZLQ,/1]H;[3TA1MB7C%0LPO6J1H36L3>=K8,5;Y[VM\3*$NFM
M-*:=J_:%14PQ2L1-YC6YW>K)^KQIO3NN;'RL;(Y&RL=R-1'P5JKPRGVIU=!Y
M1O4CI;O7/>N7+._]2FY^QDJYIK??*:1^8J=T/)MZM[E%4FM^Z>V86P]5^;)^
M.U?$L9UC89M-ZAK+74*CEA=X*HN<M7BWH3CA4/5&SN!DFA+4BL9EU,Q,JG_2
MAD'LE8&1Z@MDK?=21/WOLW40V39K[Q[/]79^E!CC5I@Z7'&//>L*]30Z,T!4
M3>WJF*.NJY'2N?+Q<O'.."8PF\6OD++JNR[S60U=#.U6HY$QE%X*>1-6323:
MFNKI7*YR54K<^)'K@]"^QY55T2B*O!'KC_O>*7W/;KPMTW4?DO./MB(83M%L
M3-.ZNK[?#PA:[?8F<X:[BB?<5HT7;[\)5=]##^A#.C&T:F8>7FK%<EHC[7[8
M[HUFK+^]:Q,V^CW'S-1<*[.<-YN9=U<\QZ*N%7I[1EKC]LI#24S41C&XSG'
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MR)D3$D]RS"JF41$YUWT_@4OV-?\ R%P^=/S(/V2DKW7RW1*[P&Q*J)U*O/\
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MI?V:@ +N@
M                                                          #P
M]=O\TK?IG_J4]PGAZ[?YI6_3/_4IAF^'E_XEQ7^[J  YWE
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MZ2]C3[R+A_N+_P"5$:T9+[&GWD7#_<7_ ,J(UH[,?Z8?0]+^S4 !=T
M
M                                            >'KM_FE;],_]2GN$
M\/7;_-*WZ9_ZE,,WP\O_ !+BO]W4 !SO*
M
M                                         :;LGVAT&C::JCKJ2JG6
M7F6'=X<?&J$9M7UE1ZRNE-54--40,B9NJDV,K]RJ44%NZ==K:<]YI^/X  58
MM#V0ZZHM$S71]?2U-0E6V-&\CN\-U79SE4ZQM:UU0ZTEH74%+4TZ09WN6W>.
M>K"J9X"W=.NUM^>_X_Q_  "K$
M                       'I+V-/O(N'^XO_E1&M&2^QI]Y%P_W%_\ *B-:
M.S'^F'T/2_LU  7=
M
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M%G\K+_;'>'U)VA9_*R_VSTD!^*IZ#"\V]X?4G:%G\K+_ &QWA]2=H6?RLO\
M;/20'XJGH,+S;WA]2=H6?RLO]L=X?4G:%G\K+_;/20'XJGH,+S;WA]2=H6?R
MLO\ ;'>'U)VA9_*R_P!L]) ?BJ>@PO-O>'U)VA9_*R_VQWA]2=H6?RLO]L])
M ?BJ>@PO-O>'U)VA9_*R_P!L=X?4G:%G\K+_ &STD!^*IZ#"\V]X?4G:%G\K
M+_;'>'U)VA9_*R_VSTD!^*IZ#"\V]X?4G:%G\K+_ &QWA]2=H6?RLO\ ;/20
M'XJGH,+S;WA]2=H6?RLO]L=X?4G:%G\K+_;/20'XJGH,+S;WA]2=H6?RLO\
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MS4TTTM4Z='4[G*U&JQC<+E$X^"I=P#2(U&H==*12L5CB  $K
M
M
M
M                   \J[=OA J/H6?U/2.BO>;8?J$'\MIYNV[?"!4?0L_J
M>D=%>\VP_4(/Y;3NZC]FCS.D_?R)D '"],
M
M
M
M
M                                             !Y5V[?"!4?0L_J>
MD=%>\VP_4(/Y;3S=MV^$"H^A9_4](Z*]YMA^H0?RVG=U'[-'F=)^_D3( .%Z
M8
M
M
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MPZW/+IZ?JJ]1OMCA^P 8.D
M
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M&_%3[CZ /FXWXJ?<-QOQ4^X^@#YN-^*GW#<;\5/N/H ^;C?BI]PW&_%3[CZ
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MMI^9ZQI?^7C_ '4.WJOT4_H\WH?W,G]?^7( #B>D
M
M
M    %;VD^\#4/U&7]*ED*WM)]X&H?J,OZ5+X_P!4,\OZ+?T8=[&SW]UG^WR?
MS(STJ>:O8V>_NL_V^3^9&>E3HZW]UR?X=^S_ '  <CO
M
M
M                       >2MIWPH7+ZVGYGK&E_P"7C_=0\G;3OA0N7UM/
MS/6-+_R\?[J';U7Z*?T>;T/[F3^O_+D !Q/2
M
M
M"M[2?>!J'ZC+^E2R%;VD^\#4/U&7]*E\?ZH9Y?T6_HP[V-GO[K/]OD_F1GI4
M\U>QL]_=9_M\G\R,]*G1UO[KD_P[]G^X #D=X
M
M
M                #R5M.^%"Y?6T_,]8TO\ R\?[J'D[:=\*%R^MI^9ZQI?^
M7C_=0[>J_13^CS>A_<R?U_Y<@ .)Z0
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M +JSL2Q>5E'?]U9V)8O*RF5 >CQ'N.;[:KW_ '5G8EB\K*._[JSL2Q>5E,J
M]'B/<<WVU7O^ZL[$L7E91W_=6=B6+RLIE0'H\1[CF^VJ]_W5G8EB\K*._P"Z
ML[$L7E93*@/1XCW'-]M5[_NK.Q+%Y64=_P!U9V)8O*RF5 >CQ'N.;[:KW_=6
M=B6+RLH[_NK.Q+%Y64RH#T>(]QS?;5>_[JSL2Q>5E'?]U9V)8O*RF5 >CQ'N
M.;[:KW_=6=B6+RLH[_NK.Q+%Y64RH#T>(]QS?;5>_P"ZL[$L7E91W_=6=B6+
MRLIE0'H\1[CF^VJ]_P!U9V)8O*RCO^ZL[$L7E93*@/1XCW'-]M5[_NK.Q+%Y
M64=_W5G8EB\K*94!Z/$>XYOMJO?]U9V)8O*RCO\ NK.Q+%Y64RH#T>(]QS?;
M5>_[JSL2Q>5E'?\ =6=B6+RLIE0'H\1[CF^VJ]_W5G8EB\K*._[JSL2Q>5E,
MJ ]'B/<<WVU7O^ZL[$L7E91W_=6=B6+RLIE0'H\1[CF^VJ]_W5G8EB\K*._[
MJSL2Q>5E,J ]'B/<<WVU7O\ NK.Q+%Y64=_W5G8EB\K*94!Z/$>XYOMJO?\
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MXD]T;UM'9;6]>$2#MVRW5ETJDIK=32U-0J92.)N\Y4^8[U?I:^6^2&.MM-9
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M<*B]"Y<9'MF^$*Y_.W\C&F:;99I].G)T\4PUR[\RI +!3:,U)54S:BGLE?)
MY-Y'MA545.O)#-I9W5?M5L+UJ-_D^31/"WLXQCKR;Q:)XERS2T<PX 6./0^I
MY(TD98;BYBIG>2!<$-<*"KMU0L%?3R4\R<[)&X41:)XDFEJ^9AU0:AL7T?55
MVIJ>IN]HGDM#X9%25[')&JXX<4)[;3H*=:ZV]RMCJ)(]U_*^UV.>B+X.,\_C
M,9ZBL7[&\=+><7Y?_P"&(@_<T3X)I(IF*R2-RM<UR85%3@J*?@W<P
M        "[;#/A@L7U>J_EH>MCR3L,^&"Q?5ZK^6AZV/&ZO]V?\ OP^BZ#]B
MO]_]P ',[           >4O9 _"[6?[=3?G(4 O_ +('X7:S_;J;\Y"@'L])
M^U'_ 'Y?.]?^_;^W^P #I<8
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M(GY;8.EMFB;1\/+()2\6"[69&+=K=4T:/7#>6C5N?O\ F(LVB8GS#GF)B=2
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MF]L72U55+#G&_(S"$&>GO9 ^\U/WU/,)3I\LY:=TM>JPQAOVQ( #9S
M                                  (_4'^35?[@&H/\FJ_W >7UWZX_
MH]O_  O]NW]33_\ DU)^X2!'Z?\ \FI/W"0/1Q?HC^CR<W[EOZR  NR
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MD#\+M9_MU-^<A0#V>D_:C_OR^=Z_]^W]O]@ '2XP
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M?L@?>:G[ZGF$]/>R!]YJ?OJ>83IZ+]MQ_P"(_O?V  =;@
M                         1^H/\FJ_P!P#4'^35?[@/+Z[]<?T>W_ (7^
MW;^II_\ R:D_<) C]/\ ^34G[A('HXOT1_1Y.;]RW]9  79
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M0H![/2?M1_WY?.]?^_;^W^P #I<8
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M_!RF, &N/'7'';5AFS6S6[K  +L@
M       $?J#_ ":K_< U!_DU7^X#R^N_7']'M_X7^W;^II__ ":D_<) C]/_
M .34G[A('HXOT1_1Y.;]RW]9  79
M
M                                                    +ML,^&"Q
M?5ZK^6AZV/).PSX8+%]7JOY:'K8\;J_W9_[\/HN@_8K_ '_W  <SL
M   !Y2]D#\+M9_MU-^<A0"_^R!^%VL_VZF_.0H![/2?M1_WY?.]?^_;^W^P
M#I<8
M
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M6@>Q)//JCUQWDM ]B2>?5'KFC@:@9QWDM ]B2>?5'KCO):![$D\^J/7-' U
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M@B=*K6\Z[J*N$^XB='ZC9J.BDGCIY8=Q<+OIP7BJ<./B&Q/@
M                                     "IW;X6="_0W'^7&::9E=OA9
MT+]#<?Y<9IIA?EM3@ !58          &9T_PRZJ_VR@_5.6LJE/\,NJO]LH/
MU3EK-Z<,;<@ +*@
M
M                                      *3MK^"K4WU1?S0#;7\%6IO
MJB_F@,LG+6G!L3^"K3/U1/S4NQ2=B?P5:9^J)^:EV-(X9SR  E
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MKO)TX(W*=0TY%14147*+Q0^GYB1J1,2/W"(B-XYX'Z+J
M                             "IW;X6="_0W'^7&::9E=OA9T+]#<?Y<
M9IIA?EM3@ !58          &9T_PRZJ_VR@_5.6LJE/\,NJO]LH/U3EK-Z<,
M;<@ +*@
M
M                              *3MK^"K4WU1?S0#;7\%6IOJB_F@,LG
M+6G!L3^"K3/U1/S4NQ2=B?P5:9^J)^:EV-(X9SR  E
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M;O=,C:U?G1#F +*@
M"IW;X6="_0W'^7&::9E=OA9T+]#<?Y<9IIA?EM3@ !58          &9T_PR
MZJ_VR@_5.6LJE/\ #+JK_;*#]4Y:S>G#&W( "RH
M
M
M  "D[:_@JU-]47\T VU_!5J;ZHOYH#+)RUIP;$_@JTS]43\U+L4G8G\%6F?J
MB?FI=C2.&<\@ )0
M   _$L4<S-V:-DC>IR90_,-/# BI!#''GXC43\CE
M        #\O8U[5:]J.:O.BIE#] #JK;J)5RM'39^B;Z#GBBCB;NQ,:QO4U,
M(?L
M     %3NWPLZ%^AN/\N,TTS*[?"SH7Z&X_RXS33"_+:G  "JP          ,
MSI_AEU5_ME!^J<M95*?X9=5?[90?JG+6;TX8VY  65
M
M
M      4G;7\%6IOJB_F@&VOX*M3?5%_- 99.6M.#8G\%6F?JB?FI=BD[$_@J
MTS]43\U+L:1PSGD !*
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MF^V!T;%7'5Q9GB3.A=52W>6HM]SBY*XTWN\JGA\5XXPF.C[Q$FEP !*
M                                           %3NWPLZ%^AN/\N,TT
MS*[?"SH7Z&X_RXS33"_+:G  "JP          ,SI_AEU5_ME!^J<M95*?X9=
M5?[90?JG+6;TX8VY  65
M
M                                            4G;7\%6IOJB_F@&V
MOX*M3?5%_- 99.6M.#8G\%6F?JB?FI=BD[$_@JTS]43\U+L:1PSGD !*
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MI_AEU5_ME!^J<M9O3AC;D !94
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M@EG&S0
M "D[:_@JU-]47\T VU_!5J;ZHOYH#+)RUIP;$_@JTS]43\U+L4G8G\%6F?JB
M?FI=C2.&<\@ )0
M
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M<5\2=:%I)A
M            J=V^%G0OT-Q_EQFFF97;X6="_0W'^7&::87Y;4X  56
M     !F=/\,NJO\ ;*#]4Y:RJ4_PRZJ_VR@_5.6LWIPQMR  LJ
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M6IOJB_F@,LG+6G!L3^"K3/U1/S4NQ2=B?P5:9^J)^:EV-(X9SR  E
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M5IJ'45FEN>H735+*AKH(GQM:KE1S5Q[K/'@!I0 +J
M                        J=V^%G0OT-Q_EQFFF97;X6="_0W'^7&::87Y
M;4X  56          !F=/\,NJO\ ;*#]4Y:RJ4_PRZJ_VR@_5.6LWIPQMR
MLJ
M                 %3*87F  Z;[7;Y';SZ&E<O6L+5_H<U/24]-_P O3PQ?
M1L1OY',
M            *3MK^"K4WU1?S0#;7\%6IOJB_F@,LG+6G!L3^"K3/U1/S4NQ
M2=B?P5:9^J)^:EV-(X9SR  E
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M?X9=5?[90?JG+6;TX8VY  65
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MI%7#&O8U<^-%<WBG$;--/!GMCU3=;??6VG5;6-?(BK'/A&M7&?$B8X*3FO\
M4,NGK1'-3,1\\\J11YZ%XK_0;C6S2S SI6Z_;2>V5JJ=7)Q6'DV<W_;DL&A-
M2IJ.UNED8D=1$[<D;X\(N?XB)V:<-INM\GU354M9;I8[<U%1DJIAOSHN[Q^\
MM90+)J.YU6T2YVJ:H1U#"YR,CY-J8QCIQDY-8ZFN<5_IK)8&L2JE8CED?A<+
MEW#"HJ=!$3X3I>P9E=KEK/3E.E?<9X*ND;PD:UC$QGASHWYC0K171W.VT]9#
M_P .9F^WYB8G:)AVP 2@
M  %)VU_!5J;ZHOYH!MK^"K4WU1?S0&63EK3@V)_!5IGZHGYJ78I.Q/X*M,_5
M$_-2[&D<,YY  2@
M                      '%+40Q2,CDE8Q[UPUKEPKOF.4
M    #CGFC@C62:1L;$YW.7"(?MCFO:CF*CFKS*@'T XYYXJ=F_/(R-F<9<N$
MR!R ^(J*B*BY13Z
M      %3NWPLZ%^AN/\ +C--,RNWPLZ%^AN/\N,TTPORVIP  JL
M #,Z?X9=5?[90?JG+652G^&757^V4'ZIRUF].&-N0 %E0
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M)*QV$PN>EOB+II&TNLEAIJ*5R.D8GA*G-DFO*)X3  +*@
M                           I.VOX*M3?5%_- -M?P5:F^J+^: RR<M:<
M&Q/X*M,_5$_-2[%)V)_!5IGZHGYJ78TCAG/( "4
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MQMY47"<R<>G)>281( "4
M     "IW;X6="_0W'^7&::9E=OA9T+]#<?Y<9IIA?EM3@ !58          &
M9T_PRZJ_VR@_5.6LJE/\,NJO]LH/U3EK-Z<,;<@ +*@
M                           #@KIWT]+)+%"Z9[4RD;>=QE]=%?-:7^A;
M5VJJMMN@<CW).QV,IE>=6IS\$-7!$QM,3I^(HV11MCC:C6-3"(G0A^P"4
M
M                              "D[:_@JU-]47\T VU_!5J;ZHOYH#+)
MRUIP;$_@JTS]43\U+L4G8G\%6F?JB?FI=C2.&<\@ )0
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MN7FRB+UKS9-6*OI71]-8YWU4LSJRN?SU#T5%^Y57Q%H)K&D3( "4
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M,_/DGB80
M            I.VOX*M3?5%_- -M?P5:F^J+^: RR<M:<&Q/X*M,_5$_-2[%
M)V)_!5IGZHGYJ78TCAG/( "4
M
M                                                *G=OA9T+]#<?
MY<9IIF5V^%G0OT-Q_EQFFF%^6U.  %5@          9G3_#+JK_;*#]4Y:RJ
M4_PRZJ_VR@_5.6LWIPQMR  LJ
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MJ_VR@_5.6LJE/\,NJO\ ;*#]4Y:S>G#&W( "RH
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MJJI_!2SGX@C;##'$SW+&HU/F1#]EXC2D@
M                    *G=OA9T+]#<?Y<9IIF5V^%G0OT-Q_EQFFF%^6U.
M %5@          9G3_#+JK_;*#]4Y:RJ4_PRZJ_VR@_5.6LWIPQMR  LJ
M
M       .*:HA@W>7ECCWEPW?<B97Q9.4
M                                            "D[:_@JU-]47\T V
MU_!5J;ZHOYH#+)RUIP;$_@JTS]43\U+L4G8G\%6F?JB?FI=C2.&<\@ )0
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M^V4'ZIRUE4I_AEU5_ME!^J<M9O3AC;D !94
M                    ",U+<_V/8ZNNW=Y86IA/&JHB?F29'Z@MK;O9ZJ@>
M[=29J)GJ5%14_BB AF^FK7?-8T\ERK+W5443GJC&0*J(O3S(Y,<Y\O<.H-$S
M054-SJ+C1N=AW+97'1TJO6AQ4"ZHT.CJ6*D6OH4<KT2-BJJ]'.B+CF0G+=M%
MM=PD2FO% ZE>O,V5-]OVY1,&<:_NOY_LM])>Z&2AHZBHJJ>G6I8U[&2RHU5R
MG,F><DRB;4;;'5:8BKJ)&*M$YDL?)IP5%<B<,=&%)W1MU;<M,4M6Y<N;'B3C
MGPD3*EXGSI77C:5?74C*MM*^J@;5.3>;"LB(]4X\4;G/0OW'YK+E0T2HE96T
MU.J\<2RM9^:F=:-1U\UW=+N[C%2J^.%5XY15=_1Q#6Y+=<];72/5$TC521R1
M-D?N-3BO6I'<GM:]1W*AK55*.MIJA4Y^2E:_\E(/7^H6V.Q5,E+54[+DU&.C
MA<YN^Y%>B*J-7BJ8ST=!7:K2+H+M1U^CJB)8VN_QV>V,MQU\,]9V=KUFHYM/
M5=V>QRUL+8XV.WN"-Y1.C_U*)F=21$;6#3&HZ*XVFWNGN-&M?-"USXDF;O;V
M,JF[G).3S101K)/(R.-.=SW(B)]JE)T-I*TMM%HNB0O]N.@9(KM]<;RMX\/M
M(75]8^_:VAL;ZGVK01I_BNW]W*IO?-U(-ZCR:\M#COMIE>C(KI0/>O\ I;4,
M5?S)%>"<3.;MHO3:T$JVZL9!5-;EC_;*+Q3[3O;+KU-==.S1U;E=/3.6+>5<
MY:C6\<]>54F)\ZDU]+9'=*"1DCHZZE>V/W:ME:J,^?CP/Q!>K742)'!<J*61
M?]+)VN7[D4Q[1=B6_P!]N5/+5214K'*][&*J;_%.'!4\1([1=*T.GZ.FKK.L
ML$J.POAJN?\ YDKW3K9VQO35*RY4-"J)6UM-3JJ91)96LRGVJ?NDK:6L9OT=
M3!4-ZXI$>G\"BV'1E/>:&*YWZHFJYZIB2(U'*UK$5,X1,^-2(TK"[3^TF2TT
MSWK1S([=:Y57")O*GZ2=R:A:];6BDN551OJ[ZEM6-?!8LB-W^/1ER%LB;R<;
M6Y5<)C*F5[9_\PL_[Z?F6[:)>Y;'IV6:F_YAZHQBKT>$F?X9&_,FN$S47FUT
MTBQU%RHHGIP5LD[6K]RJ=BDJZ:L8KZ2HAG8G#>B>CD_@9[I+0=#76>&NO+IJ
MBJJ&I(JJ]4W47'#\SM6S25QL.JHY[/*C[.],R1R2JBM7CP1..?\ 3Q&Y-0OY
M0]K-74TE)9UI:B:!7UC6N6-ZMWDPO!<%\,\VQ_\ )V3Z\W\E)MPBO+0)I8X8
MW23/9'&WBKGKA$^T_%+54]7%RM)/%/'S;\3T<GWH1>L_>Q</W$_4A"[)/>FS
MZ3_P:-^=&O&UKJZ^CHW,;5U=/ YZX:DLB-ROBRIRU,\-+"Z:IECAA9[I\CD:
MU/G53,=L/_/VCZ9GYJ6O:;[QKM^XW];1ODUPFI+K;XX(YY*^D9#(F62.F:C7
M)UHN>)^Z.XT5:J^TJRFJ,<_)2M?C[E,SV?:2@O=CAJ[Q-+-$U.3AA:Y6HUO/
MGG\:]!U-5VWN#O5%<[.^1*:15:L3G*J;RH[^F".Z=;3J.&MU55!21++53Q01
M)SOD>C4^]3]PRQSQ-E@D9)&Y,M>Q45%^94*=M4>V31LSV+EJN:J+]I,:']Z=
ML^B_JI._.D:\;2<]?1T]2RGGJZ>*=Z;S8WR(USDZT15RO,OW'-+(R&-TDKVQ
MQMYW.7")]IF&O_A+LGU5?SD.YMBJ:B*CHHD=(RD?*WE',RF>#N&?N([N4Z71
MM^L[G[C;K;U=U)4,S^9(M5'(BM5%1>E#.:?2VD[G:\6VI8V=4\!RU";Z+XTR
M630E#=;=9EIKVYCIF/Q&K7[W@83G7KSDF)E$Q"Q@ E
M                              "D[:_@JU-]47\T VU_!5J;ZHOYH#+)
MRUIP;$_@JTS]43\U+L4G8G\%6F?JB?FI=C2.&<\@ )0
M                                           <53/'34\D\SMV.-JN
M<O4B <H*%I+:$R^7IU!/1LI6JU>3DY7>WUWD1$QA.LOI$3OA,QH!6*35#I]<
MUFGEI4:VGB23E]_B[P6KC=Q_U=?0?=;ZG=IJ"FD92I4<M(D>%?NXSGCS+U#<
M&EF!^().5@CDQC?:CL=64/V2@      ?%5$15541$YU4_$,\4Z*L,K)$3G5C
MD7 '(
M           *G=OA9T+]#<?Y<9IIF5V^%G0OT-Q_EQFFF%^6U.  %5@
M     9G3_#+JK_;*#]4Y:RJ4_P ,NJO]LH/U3EK-Z<,;<@ +*@
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MM<N>?JZ"Y;3WK/L\KI-U6J](7;O/C_$:<5+H%K[A%57BZ5%R6-<M9(BM1/\
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MB_5%<L"\[5:N53Y]\L^G+%1V"A]K4+,(J[SW+SN7")G^ B/),^$J "RH
M                                           "D[:_@JU-]47\T VU
M_!5J;ZHOYH#+)RUIP;$_@JTS]43\U+L4G8G\%6F?JB?FI=C2.&<\@ )0
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M=M61R,<[&6HKG*?O9+2OJ'W*\U"*KZA^[&Y4_P!**J*F?L0G>](UK;1@ 65
M
M%3NWPLZ%^AN/\N,TTS*[?"SH7Z&X_P N,TTPORVIP  JL          #,Z?X
M9=5?[90?JG+652G^&757^V4'ZIRUF].&-N0 %E0
M                             16I;5-=[:ZEIZU]$]RHO*L;E4XHO6G4
M1&DM%PV&KEJYJM]=6/\ _NO;A4Y_&O6I; 1J.4[  2@
M       (S4UJ2]V.KMRS<@D[43E-W>W<*B\V4ZB3 $1I6S)8;/%0)/R^Y_KW
M-W/V94EP
M        I.VOX*M3?5%_- -M?P5:F^J+^: RR<M:<&Q/X*M,_5$_-2[%)V)_
M!5IGZHGYJ78TCAG/( "4
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M9076Y4,U'1TSD<R.5%X*W'#BB<^.HU9$PF$YB:QS),^-  +*@
M                                                 "IW;X6="_0W
M'^7&::9E=OA9T+]#<?Y<9IIA?EM3@ !58          &9T_PRZJ_VR@_5.6L
MJE/\,NJO]LH/U3EK-Z<,;<@ +*@
M
M                                                  *3MK^"K4WU
M1?S0#;7\%6IOJB_F@,LG+6G!L3^"K3/U1/S4NQ2=B?P5:9^J)^:EV-(X9SR
M E
M
M                          "IW;X6="_0W'^7&::9E=OA9T+]#<?Y<9II
MA?EM3@ !58          &9T_PRZJ_P!LH/U3EK*I3_#+JK_;*#]4Y:S>G#&W
M( "RH
M
M                            "D[:_@JU-]47\T VU_!5J;ZHOYH#+)RU
MIP;$_@JTS]43\U+L4G8G\%6F?JB?FI=C2.&<\@ )0
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M%:K5<U'*B]&4)B=HF'( "4
M  *G=OA9T+]#<?Y<9IIF5V^%G0OT-Q_EQFFF%^6U.  %5@          9G3_
M  RZJ_VR@_5.6LJE/\,NJO\ ;*#]4Y:S>G#&W( "RH
M
M
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M:V!47<=A$<J8QQ5?$2MG;J"KL=RAOT,+*J2)S(4C<U47+53H^P1S)*N;%/\
MEKQ],W\W'8NVF;7J*Y5%58;DE'<XG?XKXG*JYYDX(J8]R=W9E8+A8H+BVY1-
MC6:1KF8>CLHF]U?.AT*S2UYLM\J;GI>1DGME<O@>B-1/M5>/'/01$>$[\HFL
MJ-4Z+DBJ*ZK=76U'HU[G+E53/C553I-5I)DJ*6&9$PDC&OQ\Z9,YKK'JO4LL
M-/?DBI;>U[7/;&YKM["^)4\9H]-$D%/%"WBV-J,3[$P35$N0 %E0
M                               %3NWPLZ%^AN/\N,TTS*[?"SH7Z&X_
MRXS33"_+:G  "JP          ,SI_AEU5_ME!^J<M95*?X9=5?[90?JG+6;T
MX8VY  65
M
M                                4G;7\%6IOJB_F@&VOX*M3?5%_- 9
M9.6M.#8G\%6F?JB?FI=BD[$_@JTS]43\U+L:1PSGD !*
M
M
M        %3NWPLZ%^AN/\N,TTS*[?"SH7Z&X_P N,TTPORVIP  JL
M   #,Z?X9=5?[90?JG+652G^&757^V4'ZIRUF].&-N0 %E0
M
M
M          %)VU_!5J;ZHOYH!MK^"K4WU1?S0&63EK3@V)_!5IGZHGYJ78S?
M8Y?[/3;,=.0U-VM\,S*5$<R2I8US5RO!45>!<>Z:Q=MVSSN/TFD<,YY2X(CN
MFL7;=L\[C]([IK%VW;/.X_22A+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"([IK
M%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z:Q=M
MVSSN/TCNFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\
M[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"([IK%VW;/.X_
M2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN/TCN
MFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([IK%
MVW;/.X_2!+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=MV
MSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN/TCNFL7;=L\[
MC]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X_2
M!+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@2X
M(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"([
MIK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z:Q
M=MVSSN/TCNFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=
ML\[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"([IK%VW;/.
MX_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN/T
MCNFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([I
MK%VW;/.X_2!+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=
MMVSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN/TCNFL7;=L
M\[C]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X
M_2!+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@
M2X(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"
M([IK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z
M:Q=MVSSN/TCNFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7
M;=L\[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN/TCNFL7;=L\[C]($N"([IK%VW;
M/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C]([IK%VW;/.X_2!+@B.Z:Q=MVSSN
M/TCNFL7;=L\[C]($N"([IK%VW;/.X_2.Z:Q=MVSSN/T@2X(CNFL7;=L\[C](
M[IK%VW;/.X_2!%7;X6="_0W'^7&::9-/=*"X[6M$);ZZEJE9#<-_D)FOW<QL
MQG"\.8UDPORVIP  JL          #,Z?X9=5?[90?JG+64F>Y4-NVR:F6X5M
M-2H^V4&YR\K6;V'3YQE>/.A/]TUB[;MGG<?I-J<,;<I<$1W36+MNV>=Q^D=T
MUB[;MGG<?I+JI<$1W36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z1W36
M+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=TUB[;
MMGG<?I EP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9Y
MW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z1W36+MNV>=Q^
MD"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<?I E
MP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<$1
MW36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=TU
MB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8NV
M[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MNV>
M=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG<?
MI'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z1W
M36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=TUB
M[;MGG<?I EP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[
M9YW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z1W36+MNV>=
MQ^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<?I
M EP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<
M$1W36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=
MTUB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8
MNV[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MN
MV>=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG
M<?I'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z
M1W36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=T
MUB[;MGG<?I EP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8N
MV[9YW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<?I EP1'=-8NV[9YW'Z1W36+MNV
M>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0)<$1W36+MNV>=Q^D=TUB[;MGG<
M?I EP1'=-8NV[9YW'Z1W36+MNV>=Q^D"7!$=TUB[;MGG<?I'=-8NV[9YW'Z0
M(#;7\%6IOJB_F@(W;'?[/4[,=1PTUVM\TSZ54:R.I8YSERG!$1>(,LG+6G#1
MNX32/R6L/X?#ZH[A-(_):P_A\/JEC!FNKG<)I'Y+6'\/A]4=PFD?DM8?P^'U
M2Q@"N=PFD?DM8?P^'U1W":1^2UA_#X?5+& *YW":1^2UA_#X?5'<)I'Y+6'\
M/A]4L8 KG<)I'Y+6'\/A]4=PFD?DM8?P^'U2Q@"N=PFD?DM8?P^'U1W":1^2
MUA_#X?5+& *YW":1^2UA_#X?5'<)I'Y+6'\/A]4L8 KG<)I'Y+6'\/A]4=PF
MD?DM8?P^'U2Q@"N=PFD?DM8?P^'U1W":1^2UA_#X?5+& *YW":1^2UA_#X?5
M'<)I'Y+6'\/A]4L8 KG<)I'Y+6'\/A]4=PFD?DM8?P^'U2Q@"N=PFD?DM8?P
M^'U1W":1^2UA_#X?5+& *YW":1^2UA_#X?5'<)I'Y+6'\/A]4L8 KG<)I'Y+
M6'\/A]4=PFD?DM8?P^'U2Q@"N=PFD?DM8?P^'U1W":1^2UA_#X?5+& *YW":
M1^2UA_#X?5'<)I'Y+6'\/A]4L8 KG<)I'Y+6'\/A]4=PFD?DM8?P^'U2Q@"N
M=PFD?DM8?P^'U1W":1^2UA_#X?5+& *YW":1^2UA_#X?5'<)I'Y+6'\/A]4L
M8 KG<)I'Y+6'\/A]4=PFD?DM8?P^'U2Q@"N=PFD?DM8?P^'U1W":1^2UA_#X
M?5+& *YW":1^2UA_#X?5'<)I'Y+6'\/A]4L8 KG<)I'Y+6'\/A]4=PFD?DM8
M?P^'U2Q@"N=PFD?DM8?P^'U1W":1^2UA_#X?5+& *YW":1^2UA_#X?5'<)I'
MY+6'\/A]4L8 KG<)I'Y+6'\/A]4=PFD?DM8?P^'U2Q@"N=PFD?DM8?P^'U1W
M":1^2UA_#X?5+& *YW":1^2UA_#X?5'<)I'Y+6'\/A]4L8 KG<)I'Y+6'\/A
M]4=PFD?DM8?P^'U2Q@"N=PFD?DM8?P^'U1W":1^2UA_#X?5+& *YW":1^2UA
M_#X?5'<)I'Y+6'\/A]4L8 KG<)I'Y+6'\/A]4=PFD?DM8?P^'U2Q@"N=PFD?
MDM8?P^'U1W":1^2UA_#X?5+& *YW":1^2UA_#X?5'<)I'Y+6'\/A]4L8 KG<
M)I'Y+6'\/A]4=PFD?DM8?P^'U2Q@"N=PFD?DM8?P^'U1W":1^2UA_#X?5+&
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M$TC\EK#^'P^J.X32/R6L/X?#ZI8P!7.X32/R6L/X?#ZH[A-(_):P_A\/JEC
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M$TC\EK#^'P^J.X32/R6L/X?#ZI8P!7.X32/R6L/X?#ZH[A-(_):P_A\/JEC
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MK#^'P^J.X32/R6L/X?#ZI8P!7.X32/R6L/X?#ZH+&
M
M
M
M
M
M
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M3JWN'Y ;N"!T/?TU+IZ"X;B1O=X+VHN<.PBKT>,G@
M
M
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M(Q(S">([P
M
M
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MJ*2:%'JQ9&.9O-YVY3&4.4 573VA[79ZU]=A]57O<KEFF\)45<\V>*<_66H
M                              H.T#9]+JZOAG6ZI311<T:P;_S\=Y"X
MV2@;:[114#'(YM-"R+>1,;VZB)G'V'=
M
M
M
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M7@GV_P  +.
M
M
M
M                            !\<J-:JKS(?0!E#:2HUOK]T]9 ]EFMST
M1L4S%W97)A5RCN"HJHO1TE_[EM/]A6KS./T$P ,EV84D])>M46ODI((9G(L3
MN35K6IA>;H_U'3TI?:K1=7=+95VBIJ9)*A7LDC1<.RJJF51%ZT-F &/VV*\:
MAVG4\UYH_:S*.))XVXWFIAS%1,\V24VM,J*:_:9NK*62IIJ&97RLC3*^Z:J<
M./4II@ I=\A=KC9]*M/"^FDE:]T<4J<=YN\B)QQC)6[!KFJT_:H;5<;)5RU=
M,G)HZ/*M?CFXHU43H-8 &;Z'M5PGO-QU7?(N3FDBW88?=*C$_KP0X-E%/+'6
MZGNM9!(QTLR*S>8J+NHLB<,\>;!IX SC9312/NFHKC4Q2,?+5JD>^U47=17)
MT_8<&OZ>>[:_TY2MAD6"DD29[MQ5:OAQKA5YNLTX 5;:742TVBKDVEB<]\L+
MH$:QJJJ(YJIP1"NTD,]GV,2P,AD6>6EE;N(U=[,B.Z$^<TL 5/9=;G6S1U'!
M(U6R*KGKE,+Q7/\ 4K6B:>HN&TZ_W:HBD8V)&PL5[51%3=W>&?W#40!FVUME
M16U]@MD,4DD534LY16M56IB1J<>CIZ1M:L]9+9K34442S?L^1KGQ)_J1,+_X
MFD@#**_6]SN>F:FFM%DGCFCI7)*^7*(UJ-5%W4PF5ZL'=T)1SV[99<:J2-Z5
MDT%1,YNZJ.5?#5.'.:4 *%L9MTE'I=]1.QS)JF9[G-<W"IASL?F1U323W+;,
MU)(Y$IJ*-)&R*U=U5W8UPB\W0:< ,UUU0W"TZOH=34,+ZF&-NY/&Q<.1O@HN
M.O@B]!UKGK6Z:C@2VV"V5=)4S.1KIWJYG)IGBJ+A/'TFI@#IV:FEI+;3PU,S
MYIFL3?>]V55<<>)1-I4<MQU5I2ABBE="RKY29R-56X1\2\>CK-' $+JN3VEI
M.Y)"Q[E;2R1QM8BJN=Q43F*SLRLKV: J*>9KHJBL25';R85-[./S-  &1Z=U
M)7:)I)++<[345#(97K#+%EV\BN5>.$7K0F](S7R_ZDDO%5R]%:FINQ4JR+AW
M!4RK<^).CI-!."X),M!4I2Y6=8G)'A<>%A<<>CC@#%*"[W!NO;S?J2D6M@I%
M;33)O>$B*KD3'3_I4E=0Z@N6NH8[):K944L4KT]L339;NMSQQE$SPR679;IV
MOL5+<GW6)(JFKGY141Z.RF\Y<Y15^,7@#*-=:=GM=KTR^C@6II[4YCIXFI_Q
M,.8J\/'NKUG8N&N:^[66L@LUCGC<D#T<Z7*(UNZO!$5$ROS&G@#/]F=IFAV>
M2HK',KJMDV4<FZN55V[^H@MFESFL5WKK-66ZI]L3U3LS(B[GNG<<XQT]9KH
MS33C:BX[5KE<9H)&1P0)"Q7,5$7G3AGYCI;2&5=KUM:;T^DEJJ*-^4;%E514
MW.A$7'-U&L #,-H]TGOFD[?#34<[6U\K-YJL55:B/;S\.'/TDOJV&]4>G[3/
M9'.S11LY:%'*WE$3=X<%ZD7K+P ,FO\ K2.^V=U NGYYJV5BL1)8EW8W*F,H
MJMQS_D779U:JBSZ2H:.L7,S6[RIG.,\<?860
M
M
M
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M[N&.A/G0X[#K"S7R98:"I<LOQ)(W1K]S@+
M
M
M
M
M    'G_;3:+U4ZOEFAIJNHHG-9R/)M5Z-5&IG@G-Q/0  IVRFDN5'I"DCN_*
M)-AV&R.RYJ;[OZ8+B   "JB(JKS(!6M?ZCBTYIZIJ%>B5+F*V%O3O*BX7[S-
M]'W_ $Y;M+W-EPN"/NMPCD25SHG.7BCD1,XYL*G22RT53K?7KI*^GD;9+>Y$
M;%*Q=V54QG*.QE%5%Z.DO/<;IKL&V>;,] %7V'UR5&FYJ9CE<RFD=N\>"(Z1
MZ\$Z".T_"R_;5[U6RL;+2Q1^U\.3+<[C47\E.+9O[9L-RU53MI960MQ+"G).
M1J[J.7#>&.GH)K8]1314=UK:J%\<M75.?X;<+A'.3IX@1>C7=R&NZZQ54BLI
M*S=?3JN=U7JJ>"GVO/NC56[[6;]<\;\4#&Q(N,HU=QJ?9[@D]KMBGJJ&EO%K
M8Y;C;I.5:K$XJUN7?/SM0X-B%NJ::SUM;71RQSULB/=RB*BJJ.>G3Q C-G3&
MW#:+?:ZI1'SQR+&U7<51$3']$-<,EO-NO&C=7SWJST3JVVU*HLT351%1<)GI
MST+QP=N?:;7S1<G0::K/;3_!;OJY$:[HSEB(OW@:&K;?/6IE*62KC3*9W5>W
M^J=!F6UK5%++7TNGO;7(T[I46MD;E=UG@KCAS\'+P.2PT=UTY0774E]CEDNE
M0Q6P0-3E,+ARHG@[W4G4=O0&C:>MHYKSJ:CBJZZO<KUBJ8D?R2(YR(B9ST8^
MX"KZXO\ IN33UJI[)5M?-0RQ;K&PN8JHCD55RJ<.8VFUOY2VTC_C0L7^!1=H
MNC[0S25<^V6:CBJF,5S'04[4?P1>;"9+#L_J)JG2E$^I21LK6[BI(BHJ8X=(
M$!MKA;W,05B(O*4U2QR+U)SK^1^-8:A6FT7;:&ADWKE<Z>.&)K>?PVHU5\7N
MD)[:50.N.B[I%&USWLA?(UK4RJJC5PB%#V6V:MO5Q@NU\AEC9;FLBI8I6]28
MRB+S<6IT =B^6RTV#2-!9JV61U542)*^*G:[E)G=3L(O#PL<>L7.XLATO611
M:*9#3-I7)R[UB;C#5\+"HBJO3UG-M CJ[7KFWWKVA)6T;6XPQ,[BHK..$15Z
M%Z#HZ[U1>+_IN>&W62HBI7*C))'95R[R*F$:J(O7Q F=FE%4UFRZIA9(K7U<
M=0R%N?\ AJY7HF/O0KVE[C%H^F?:]5V!-Q9%S6<BDC7-55]TJ(N>"]9:9[9>
M+9LZH&V![TK((FS.C3P5<F-YR<Z?,1ETUJESL$E#5:>J9JU\2Q;CXW*B/5JI
MO95F.?Q@2%EIJ+3>EM07FT5K9J6IB=/ C<HV-6H]<(G1Q7^!Q;*K#25UGDO=
MTIXJNLKI7O5T[$>K4WG(B)GHQ@YM)Z5JN]K4VNN:L<]5#*C(EPO)*Y7[O3C_
M %(0VE]3W'2%N6RW6SU4SZ=[DBDC1SD>U554]RUR)T=(%L71<=/JV*\VN2*B
M:C=R2&*/=1Z<.K"='\2N7177?;+24J+OQVYO+)THU<1N_H3.A9[_ '>\5EUN
MS9J2A<U&04KGY;^]C/!>'5TE8KY*W2.TNONDMOGK:2K8C621M553P6]2*O3_
M   M^UVL6CT/7[CL.F3D<)T[R*F"MW=%LNQ>"!JHV6HA8B-1>*\HG_[2)U=<
M[YJJY6>F?:IJ6U5%5&B93?54WVHKG<V,>-"=VKVZKCLME92T\D]/1JQ)61IG
M*-5O0GS*!,PQ1Z=V8R-<Y&[U&YR83'A.C5?S(;2%)#1[(:RIK(HUD?3SSKRB
M(N53?<U>/3Q/QKRXU%TV>44='15#))Y61;B,<JM:G!<IA.LFM1VFH?LN6AH(
MG+,VB;EB<%7#.* 1^QRS4DFF?VA4TD$DM1.][5?&BJU$<N,+]J'6TR[]K[6;
MG7-:CHJ2!(."<&KQ3_Q.QLTOLL.G%MSK;4P344+E57M=ASD15X>#QYNA5./9
M%15:4^HZN:.6">LF\%7M5J\%DPJ9_> Z.J[?7V37TFH)K8MUMLC6INX1ZQX:
MB*J)Q5/NZ#NVN.PZMU#;[E:7MH+A1NS-3I&L;W<47"\$S[E?O/Q;-5WBPUEP
MH=2T%54QHY>1F:CI$<W*KCP4=T*TXM%4-3=-H4VH:>V.MUN1BLW%1&[ZJU4W
ML<%YTSS=(&K
M
M
M
M                                                      #@?64S
M*A('U$+9UYHU>B.7[.<YP              #@964SZAU.RHA=.WGC1Z*Y/LY
MSG    #@EK*:&9D,U1#'*_@UCGHCG?,G2<X
M                             !QU-1#2Q++4S1PQIP5\CD:B?:I^HWLE
MC;)&YKV.1'-<U<HJ+S*B@?H
M
M
M
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M);VL\SGK4S*UJNXKS*]N>DY-"U#KAM2KIVVQMLA2DW7TK7-<F<-XKN\.A?O
M[.LMH5(W4EEI[7<96TT50Y+ANPR)AJ.;PQCPN&]S9+7?-3TDNAKE=;542.8E
M/*V*56/C<C]UR(J;R(N<H4VV45'=-LMQ1*6!U'31)X",3=WE8WHQUHI+[7GP
MP:=I;-20LB6LJ&,:V-$:B(KL+A$^<#AT7K6VVK3D#=17B>6N>KGO5[9)E1%7
M*<6HN."]9H-JN5)=:-E5;YVS0/3+7)E/%S+Q3F*[1Z6LUITI*SVA3O5M,YSY
M)8FN>O@JJY7!4]E\LE!H[4-8BJVGC222'"X1$:Z7..H"UZ<I-/5VJ+G=;3/+
M+<(7<C4HJ.1K785,)E$SS+S*IW;OK.PVBH6"NKT;*G.V.)\F/^U%*'HJIDM6
MSS45\3+9*M9Y(GYXJY%DPO7SDSLIT[2.L"W&XT\556U;U>]\\:/5$RN,*J*O
M2!;;#J2TWY'K:JQLZLQO-5KF.3GZ'(B]!+E0H-%16[64E[MTT=/#(S<?2LCP
MU>")GAA,\%^\MX%1N=)IZ[:UI8:B>5;W1-Y=D34<B(W+5RJXQT-Z21KM76.A
MNDUNJZ]L59#'RCXU8[@W"+SXPO!4X<Y2MGJONNT*_P!U7+VPHV#>5<]:8X\?
M])&:3M%/JG:3?KC7Q^V(:21C-U^'-5<*B(J+S^X O]OUWIRX5\='2W#>J)%W
M6-=#(S>7FX*YJ(=;7^LZ+3EMJ(^65+B^)W(LY-ZIG'!=Y$PG.G253:I;Z2FO
MNF(;=2T]/525+$CY&-K%_P"(U.C!S[74;^R+-;I8(G5=7)$QTBM17Y1S45$7
M[0.CL^KYKI(ZNK-37*6HB8Z>2CW96QHU./.O@KS$]LGKKA=*N_UE=65$].Z?
M%.R217-8U'R)AJ+S<R?<2.HFT>G]"U$L5+!#*M)R.\R-&JJK&J<Z(=;9]'#9
M]FT4M;*E,UT4DLDV.*(JN=GAQ7"*!-7?6=AM-4ZGK:_=F;SMCB?)CY]U%.U8
M=1VJ^\I^RZM)ECQO-5CF.3.>AR(O09G8+A0T<E=-:M/2WQ9YG/6IF5K5=X2K
ME%>W..)^]$U+[AM6J*AEL;:XVTNZ^F8YJIG'!5W>'0H&C7;5%GM-='1W"M;#
M42(JM:K'+S8Z43"<Z'1AU]IN:N91LN7^.]^XU'02-15SCW2MQ_$H]304VJ-L
M=1%5-66BHV-<K>"HKMU."HO.F6KE#M[8K9;*6ST,%'10T]6^9C(7PL:Q6IO-
M1>9/F N=VUMI^U3\C6W%J2<Z\G&^1$^=6HJ$M:;G1W:C956Z=L\#^9R93^"\
M4*W;M+6>V:4E5]%!+(ZE6226:-KGJNXJKQQ\Y6-EKWT.D=15K,LIV-EDA5%P
MB(U95X=70!='ZWT\QU:UUQ:CJ-_)S-Y)^6NRJ81,>%Q1>;)^K1K.P799DH;@
MURPMWGI)&^-43C\9$SS%)V2Z<HKE%77VX4S*A]34R.CY5K7M]V[*X5,]1T[U
MI^BN>UME!31I3P-ITDF;3HC&N3"<%1$QA>.0+TW:!IIU:RD2Y?XSGHQN8)$:
MJYQ[K=Q_$LJSQ)3\NLC4AW=_?SPW<9SDS;:]:;70:)1E'0TL-1RL;(71Q-:_
MGQP5$^8D+Y545-LUM]+=*N2F6:BB8B1[V^]=Q$5J81>?./M DJC:%IF"5T;[
MBY7-7"JRGE>GWHU4)9NH;6ZT.NC*MKZ)K5<LC6N543]U$ST+T&<6ZZPT-G2&
MAT1[8IVQKO32.B:J\/=+EJ*?=DG"QZCK:J!GM17.E9 ]$<QFZZ553',!^:#:
M-33:[J99KA,VR-:C6,2&5R*NZJ9W43*<>M#2[A?+;;Z!E;6U3(:=[4>U7(N\
MY%QC#>?I3H,_V0VRDK'7^OJ*.GD9/5JL6]$U4:B/?P;E."<QU(88]7[3GLJF
MHZW6Q$:V#G9O87H7ASL3H NM%K_3=94MIX+BO*N7#4D@D8B_:YJ(6&LK(*.B
MFJZF5&4T3%D>_GPU$RJ\.?@G047:Q9;9'I&:>*CIJ>:%[5CDBB:UR+XE1/$A
M':DN4SMC-/)*N9Y8(H4XKEV41OV@6E-H&FEB@D;<MYLZ[L:)!(JJO#HW<ISI
MSDI8M06R^^V/V54\M[7=N2HL;F*U<JF/"1.I2N;.M(6R@TW;JB>D@J:N:&*=
M9)XFO<Q5:BX153*8S_ A=FSVVK66K*29<-DD2=%7ANIO2JH%^O-_MMFDIH[E
M4\D^I?R<348YZN=E$QAJ+UH24;VR1M>S.ZY$5,IC@IENGHY=8:_JKK4MWK;;
MI%93)SM<Y%5-Y$7QL1>8TJ[3+36NLG1<+%"]^>K#54"%=KG3K7UC%N+4?2/1
MDS>2?EKLJF$X<>+5YLGZM6M=/W5\K:*XM<Z)N\])(WQX3C\9$ZE*)L?T[1W-
MMROEPIHZA9ZE_)\LUKV^Z557"IXT.K?+%0W':_%;J>)((4C1\S8$1C7(C$7"
MHB8PO'(%^7:!IE*UM*MR_P 9SMQ/\"3=5<X]UNX_B2=WU%:[0M%^T*KDO;CM
MV!48YR/7ATHBX]TG/UE,VKV>TV_0DK*6AI(9VNC9"YD+6O\ =-3@J)\QTMH]
M&[O=:?K55>4HVT_#KRC,_I U1\C&1.D>Y$C:W>5W1CK(JV:EM-S;6OHZM'LH
MG;D[W,<QK5RJ<ZHB+[E>;)4]:7Z6+15JI*)<U]V@CAC1%7*(YK45?N=TJ5C4
MU"^R6'3>F8'JR:YO3VX]%P[>WH][*IS^Z=SY OTNT33$4JQON3MY%PJMIY7)
M]Z-P62@K::X4L=31S-FA>F6N;TH1--I:S4MH;1K;Z-6-BW'/6!F5X85W-S])
M0]F=6^AIM8P1R.]J4#I5@XKAJ(Z3FZN9.8"\2:UT_')7QON#4?0OY.=O)ORU
MV53")CPN*+S9.2QZOL=\J74]MKN4F:F58^)\:_\ N1,\Q1-DVG:2Z.N=^N,#
M:E:BKD=&DK6O;[IV5PJ+UH?G:+24EJUKIB:U1LIJB:1S)DA:C/!S'CF1.M0-
M0NERH[73+45]0R").EW3\R=)7X-H6FIIVQ,N#D<YVZBNII6M5?WE;@@-J%1:
MJFYVZFJG35=3 JR)1Q9P[*I[KP53H*]KF\NGTO4Q)HZ.@ARU&5&_%X&7)C#4
M3/5S :9JK4]NL=JY>JJE8M1$]:=S(W/1RHG#BU%QSISE/V7ZWAKX98KO<)I*
MZ:9W)1+#(Y$9T+O85.GK..^QMI=BM')5HR:H2D@2)7IES-_<3"*O]"TZ#LE%
M;=+6V5]-!RSJ=DKI%B3>3+$5>.,@5C4&HWP;3HJ:6Z34MKI8N4F:Q[MUR[J\
M%:G/Q0MUIUOI^[5R4=#<-^H7F8^%\>>"KP5S43H*)HBS4FHM=ZBN=QA2HA@J
M7L@:]$<QV'O3*HJ+T8P-IE%24^L]*16JFAIZCEG+)R+$8JMRS&<(G1O 7C7\
MEB?:64.I:A\--52-1FXURN<Y%3',B]*H2<4U!8[%3;\Z14-- QC'2<^XC41/
M'G&#/]J&]=-8Z<MD:;RQ/=.J)U9:O_B=3:K=5FU7;;3-"^6A@5)I(8T7_$3"
M+A4PJ*G#J N<6T/3$L[867)=]SMU%6GE1N?WE;@LSZB%E-[8=(U(=W?W\\,8
MSDR'45YM5?8*BAI-,\C(YB)&]E/A6JG-CP/$3MIM]SNVRU*)SI65B,:UJ.54
M7#6IPXJ!-NVA:9;*Z/\ :#U5J[JN2FE5N?WD;C^)8[?6TUPI65-%,V:!Z9:Y
MO28_IR^VZV6I-/ZHLD5!(D?(.J70H]KEQNY\%J\<].>DT/05E@LMH5E%6+4T
MD[N6B7F1J+QX)T<, 64
M
M
M
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MT:3H*2L7_';&U7)G.[X*</L+$
M
M
M
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M8G(Z-Z(YJITHH'[
M
M
M
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MU-/_ ,6&FCC?\Z-1%_(#O
M
M
M
M                                               "A6K3]T7:=77V
MNITCI5CY*%R2-7*;J)S9RG,7T
M
M
M                                                         /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g109079g51c65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g51c65.jpg
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MDI.RL\'1TA4S-%1B<L(6)#535H*4HN'B)D-$8X3Q_\0 &P$  @,! 0$
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M\=80KL(W4TU6#)3/S,%0!WLC?N(XA1M(R'YEM4[)(]:R43U<\K00V1[G '>
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MS&6>P$]*$<6FVMK2J9A4VI':1<_$%VI['9ZJY5C9'4].W6>(P"XC/+8"1TJ
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MS*A=(V%781Q&^A;(Z6ED8)8)';RPDC(]8((1@]+K3*UK#;GAKX$:@ED@F9+
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MCRQN"AZ[&#*\6S%=HK'G)D-5&YY_AU@#YLTC)6\E"K"3Y->IL)$12/H(1$0
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g109079g90t38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079g90t38.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1MF4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &TD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*/_  !$( J@%K@,!(@ "$0$#$0'_Q  =  $  @,! 0$!
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MP-$AR_O6)!=Z":0,BF:7'D!@K8 @C(Z*\IMQ2K@PH^*PB(IF@B(@"(B (B(
MB(@*5N7\YFS_ )&;^[*ZE2MR_G,V?\C-_=E=2 (B( B(@"(B (B( B(@"(B
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M3/9/J=<6XW#=^7H>W$SA5<]37KTVFNE1#B3>P-=\'KT]0^*CC>#VK&C#=37
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M &S%=:I3W17\(:/_ #G3_MF*ZT 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M%4=L8:PN!//O'L*W]/*V>)LD9RUW1:MR6KH9TJ#KA\GVB(N'0B(@"(B (B(
MB(@*5N7\YFS_ )&;^[*ZE2MR_G,V?\C-_=E=2 (B( B(@"(B (B( B(@"(B
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MR"OU 49]QV[?N_CO0KZ3T%@_>]SM^<@_%PMQJCC!;M.:LCTY-1UKZAG9M,C
MW8=S0?C ]_@K;43O'#G2MYO/OK<K2V>X9![4S2-Z  <@X#N'<@)/#4,EC:\'
M =TRO543QEN^L+/=[=#I5U6RF[;!;%3"48P[O+3Y*RM/:A91:7M\^J:V*EK)
M@_)J7-B+L.QT..[" EB+%I[A25-&VK@J(I*9S=S9&O!:1XYZ+55&LM.T\FR>
M]6^-_@ZI8#]* WZ+!MUWH+DP/H*R"H:>ACD#OH*SD 1$0!$1 $1$ 1$0!$1
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MK$YY+2\0-+76\&+WKOYI6L8UN!OYX#1W$>!6NXC:)U-=KS'-;+S4T\(9@M9
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MQK;6PW"CCJJ9VZ*3.#[#CZEDK!@(B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B =RH3B*7VGB52W.XY%L9R<YWK-R6
M- ]49/4CN5]K1:ITU2:BH9*>J)9N_#;S(YC[%.6J$XY8*VNGI_<W%IPGC?\
M,FOF?5HU#:ZNACDIZMKF ?%</I"J+CA>;==*JBH[<]D]8R>/< P@C+F$<R/
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MX\?R9W;\F[]1RX=))H'^(^G_ ,WT_P"S:MZM%H'^(^G_ ,WT_P"S:MZ@"(B
M(B( B(@"(B (B( B(@-+J^S&^6*MHVRRQNE@?&.S>6Y):1CD1XJ)<(M#'1C:
MP2U<\CYVM;LEG+PW!/0;CCJK%FW]D_L\;]IVY\>Y<^T]@UC'Q/EK-M.:%[CN
M]9V<8=C\'Q([T!T(B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M513LI#R!,9!SR^U 7LB_&'+0?$97Z@"(B (B( B(@"(B (B( B(@"(B (B(
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MI_\ -]/^S:MZ@"(B (B( B(@"(B (B( B(@"I[CEKRY:/?:C9(6;YY)&S.,
M>2 !CJ#XE7"M'K":AHK1+77($Q4^#@8SS('+)'B@//0%VJ+[H^V7*L_[141E
MS_5V\]Q'3Y%(% ^&_$*SZM9)3VADS! =N)&M'GW./BIX@"(B (B( B(@"(B
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M%OCJZH@EHG +L$] <'\(*S&.:]H<QP<TC((.05PX?J(B (B( B(@"(B (B(
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M$$9!4.O=DM&GZ.X7FBH(F5L5/(]CFL& X-)'+'D%,E\3Q-FADB>,L>TM/L*
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MW5<VF+,V2G##(\X]8'Q'@1XJ&?3&I5;Z%^SZG-*)HJ7A[IBB@#*N>G:_Y_\
MB690Z3TA33![9Z=Q_P"OQE75MX6W_4-,*RMO=UAD=U9#4 -_2TK,CX(75KP?
M?^]GVU+?\"];UJ?CY/'BT2QK1^4OVU"D;2L%#L[(#U=O3"S%&-!Z?FT_:*>E
MGJJBH=&S:73/#B>?L"DZYD24G3LU"ZW5!$18-A$1 $1$ 1$0!5]QX_DSNWY-
MWZCE8*K[CQ_)G=OR;OU'("2:!_B/I_\ -]/^S:MZM%H'^(^G_P WT_[-JWJ
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MY-WZCD!)- _Q'T_^;Z?]FU;U:+0/\1]/_F^G_9M6]0!?$TL<+-\TC(V],N<
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ML+MHR#G !/<@/Z  Y /BBU>F[Y07^V15EKG[:G>.3MCF],@\B >H*VB (B(
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M>YT%+/4L$K(CL:6D\P0.HY!=/4DPG@;(.CEY\D-#HA.&AT>J(BP8"(B (B(
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M7[NR<\FG'+%5M[>B]?[%J4>320;NNQN?F7JC1@ #H$1G4J5!$1<.A$1 $1$
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M<@))H'^(^G_S?3_LVK>K1:!_B/I_\WT_[-JWJ (B( O*>GBG $K [!R,KU1
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MT_\ F^G_ &;5O4!$>*$+YM,3MC// /\ O-5":4GCGH7F(8 <NIY6"2-S'='
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MN"VF+WI>HK9[G4;F2.W8P!OY#IR\EM-/\7X;MKUFGF4TS7.?(S<6' VM<?\
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M6.CD?,]I86NS@ '* Y.U?13TVI+K%1POA@;52@;G _AE3JANMYNE%LMTC()
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M6SH$C]P^G^?_ /;Z?]FU;[(\51]'PRUW1TD--3:XJHX(6".-@BB]5H& /@>
M7M]SOB!_3NK_ -5#_@0%U9'BF1XJE?N=\0/Z=U?^JA_P)]SOB!_3NK_U4/\
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M@@$_!]JJ"/AAK&JB='44-R#&G !I7C_A6MCX3:H[5W:6BXL8T$EQI9.[/XJ
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M6/[TT7_@,_LA9R(#!]Z:+_P&?V0OUEKHVD%L# 1Y!9J(#\: T8'1?J(@"(B
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MA=EI&?8N8=6-A=:9!4;=GF<+8:,UMK*TV"HHX-.W"N<\$,G;32';\+P;CO\
MT*/:,:B[1'/!1>QTLU[7' .2OTN#>I7+>EM6<3;9?*BKN-DN]92O<2V%U%(
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M&,-RKR[1*2HK+/*2H\=/VQEHM,%%$06Q XP,=3E;!$7G(A$1 $1$ 1$0!$1
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M$ 1$0!$1 $1$ 1%\32"*)SW= N2:BFV%N?KY&,^&]K?:<+X;4P..&S1N/@'
MJC[K<:[7^HWV^B>8*.F(BE>WD[+L'EU'0E?%_P"'59HZA?=;)<JBKGBP>SJ,
M!IR0#\$9Z.*S&=14\OAB_P#+?D=DGK>.&\E\/J7PBB7#G4@U#:72. $D;MK@
M/G4M5IP<):63QY%DCJ01$6#81$0!>;ZB%AP^:-I\W + U'7FVVBIJFM+C&W.
M!W\U2MJT=7:]J*RKNU9444<)'9B''/(.<Y!^*/G4U-RFXQ7"MG6XQ2<GSLB^
MXY8Y!F-[7#\4Y7TJ)T;<)M(ZW;IGMI*F G>V1_PL'/ACXJO9IR,JSBM,9Q>T
ME:)1FW*49*F@B(LE B(@"$XZHH+Q4U++8[/(RC#75<C"6!W3/-8G/0O5[(U&
M-\DU-5 #@SQ ^!>%Z,>UXRQP</$'*H.FX=QWBD%PK[[-!6O:)&Q1ENW)YD<V
MY4WX3QW>C@JZ2Y&-\3)L1O:226X'7E[56,;M2V:^7S).7$H[Q_SH6,B(LFPB
M(@"_'.#1EQ 'B2OU5KQ0FU!4#T.T10>C2';)(XN#FCRP,=P4LN3NU:5_L;A'
M4Z;HL=DL<F=DC'8ZX.4?-''^^2,;_6< J&X"U-6RNOT57*Z1\4L0^=I*R+G1
M5VOM65]!)+-24,-3) 7Q_"PTG!&<CN"MDC)34(*[5^R)*2J4I;4Z+PCGAD.(
MY8W?U7 KT7/LEEGX<ZCI&T==-64\PPX3XR#D=, *^Z"7MZ&GE/(OC:[YPBTS
MAK@[7'Q.:FIO')=+^![HB+AL(B( B(@"(B (B( B(@"(B (B( B(@"(B Q+M
MGT"?'7852GN>\^G3]K^^;#UZX]57I*P21N8>A&%2-;;+GH/5+KQ'":FV&,Q&
M*F]:7)(.<' QAI[UC'-8\S<N)*K]?W-9$YX'"/*:?RLM?5NWWCJ]V/WMW55K
M[G,N]Y3G.WLN7SA8U[X@S:LIA;[+9[O32.&Q[ZR)C&\\=[7N\#W>"GO#/2[M
M,6**EE<QTK6[26'(^@*F"+AWLY*KI+U]3&7(I1CB7-V_3_=DO1$7#H1$0!?C
MFM<,.:'#S&5^K"NU>VWTQE=%-+Y1 $_I(6)R4(N4N#L4Y.D:G5=[HM.VB>0"
M*-VTM:U@QS(..0"K[AG8Y;Q>ZS4-<UWW\!C<C'($GI\O@J]K-7FZZC;57ZQW
MN2E8X.#886%V1C'5_DKCT7Q$MEV=Z%166^4W9M'K5,$;6_HD/@M]EC+?*_S-
M<>2_N2SO_P"OB*Y]?V+#1$0H$1$ 1$0%!>Z-=5/J:"*EZD]X'XWBMC1\,&UU
MC97U4]3Z>(MXVSN:W('+D'8[@I#QFTQ6WNW4\UL[+MH9-Q#R1D8=TP#XK04?
M%$6^U>]=58[V^M##%OC@88\] <F0''R*.*EAE!?G3;7GOY#)%O+&;_+5?[_0
MV'!N]U[JRKM-T>'2PQ=H.0\0.H^U6TJIX0:?KH:ZJN]S:QCYXNS#03GJ#X?6
MK67IDY-1U_FI7[D<57+3^6W7L$1%@L$1$!CUC&]DYVT;O''-43[G@ UE0",C
M:5?%6"87 #*H_@;0UEKEJI:REFC 83C',IV=J.3(WQI_N:R[]F:7]4?NRYKA
M4T=K@=/((8N_. W*IBR25.OM;15A:XVR)PG9EN/6:1CK@^*C_%'5E7=-424D
MUHNK[5&UN.SB:7$]_5V.H"G6BN(UCBDI[90:?U%#O<&!\U/$&C)[R)#X^"SV
M:.N2S/\ _*_7^QGM'A3Q+K^9_HOU+9IXA#"R-HP&C"]%YT\HGB;(UKF@]SNJ
M]%MG%5;!$1<.A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MP1B1D+#'D=3DR9Q\BSN$.G;A'5UMWN36,,TVZ-N3N#<-Z\O$>*]6-R[R=?\
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M(@"(B (B( B(@"(B (B( B(@"^7QLD&'L:X>8ROI$!Y-IH&G+88@?)@"]41
M$1$ 1$0!?CFAPPX CS7ZB \/0Z;_ #>'^P%],IX8SED,;3Y- 7JB (B( B(@
M"(B $ C! (\UXFEIR<F"(GQV!>R(#\:UK1AK0!Y!?J(@"(B (B( OAL4;/@Q
ML;[!A?:(#Q=2T[CET$1/B6!&TM.TY;!$#XA@7LB  8Z(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B \GTT#SE\,;C
MXEH*^XXHXQB-C6C\487TB (B( B(@"(B ^)(8I/WR-C_ .LT%>?H=-_F\/\
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M-A);&QI/7 QE?#J6G<2701$GO+ O9$!XMI:=IRV"('Q# O8<AR1$ 1$0!$1
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M(B (B( B(@"(B (B( BP+[7.MMJJ:MD?:.B9N#?%1C0FNH]3U%= Z-D4E*6
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M6_0%FK:TPQQQ0X0:E+(\D^:KX!$19-A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M%65T!I+=2<XSU,NX$'((&,%H^==%P01PQ,C8T!K!@>2AGDI2V(YI*4MB%?=
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M= _=G_\ TM</]?&M5[G?AI-I>B]-NH_RJ0;@S'P3R_YJ\-C?BM^9 5)]V?\
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M@"(B (B( B(@/B:&*=A9-&R1AZM>T$'YUB,LUL8X.9;J)KASR(&@_0B(#.:
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g109079sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109079sig.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  D .$# 2(  A$! Q$!_\0
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M'+\,]8\,W_A1;R[N=1U#^S+K3M1UFX>WN5>&1Q(QD\TK(C1(WF!2Q7>#G(P
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M@#POQ!\3$\=>(/"W]F^$_%VEG3=12]DUO4?#=Y"(80K++"B>69':53Y9!4(
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M^&K2^O-;^%7CZZ\4:I)]KU2\L=(22%G PD,+-(C&*),1IN12<%B-SL3]&T4
M?+FK?&KQ/XV\8Q+K/P>\=6O@W1;I;B.V@L!)<:I=(8W@D=&VJL,39; <EI$1
MONQ_-L?$+XW7WB+3M*MC\,O'5EHR:K93ZO+?:1(,6B3!G*K;^<[[65&9-H#(
M&7/)KZ+HH \ID_:.\/WL ;0-#\7>)9&X'V'PQ?I".V3-+"D?!Z@,6_V37:>
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
